PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	van Gijn, SE; Wierenga, E; van den Tempel, N; Kok, YP; Heijink, AM; Spierings, DCJ; Foijer, F; van Vugt, MATM; Fehrmann, RSN				van Gijn, Stephanie E.; Wierenga, Elles; van den Tempel, Nathalie; Kok, Yannick P.; Heijink, Anne Margriet; Spierings, Diana C. J.; Foijer, Floris; van Vugt, Marcel A. T. M.; Fehrmann, Rudolf S. N.			TPX2/Aurora kinase A signaling as a potential therapeutic target in genomically unstable cancer cells	ONCOGENE			English	Article							EMBRYONIC CELLULAR PROLIFERATION; POLO-LIKE KINASE-1; AURORA-A KINASE; BREAST-CANCER; INVESTIGATIONAL AURORA; DNA-DAMAGE; PHASE-II; MLN8237 ALISERTIB; MAMMARY-TUMORS; INHIBITOR	Genomic instability is a hallmark feature of cancer cells, and can be caused by defective DNA repair, for instance due to inactivation of BRCA2. Paradoxically, loss of Brca2 in mice results in embryonic lethality, whereas cancer cells can tolerate BRCA2 loss. This holds true for multiple DNA repair genes, and suggests that cancer cells are molecularly "rewired" to cope with defective DNA repair and the resulting high levels of genomic instability. In this study, we aim to identify genes that genomically unstable cancer cells rely on for their survival. Using functional genomic mRNA (FGmRNA) profiling, 16,172 cancer samples were previously ranked based on their degree of genomic instability. We analyzed the top 250 genes that showed a positive correlation between FGmRNA levels and the degree of genomic instability, in a co-functionality network. Within this co-functionality network, a strong cluster of 11 cell cycle-related genes was identified, including TPX2. We then assessed the dependency on these 11 genes in the context of survival of genomically unstable cancer cells, induced by BRCA2 inactivation. Depletion of TPX2 or its associated kinase Aurora-A preferentially reduced cell viability in a panel of BRCA2-deficient cancer cells. In line with these findings, BRCA2-depleted and BRCA2-mutant human cell lines, or tumor cell lines derived from Brca2(-/-); p53(-/-) mice showed increased sensitivity to the Aurora-A kinase inhibitor alisertib, with delayed mitotic progression and frequent mitotic failure. Our findings reveal that BRCA2-deficient cancer cells show enhanced sensitivity to inactivation of TPX2 or its partner Aurora-A, which points at an actionable dependency of genomically unstable cancers.	[van Gijn, Stephanie E.; Wierenga, Elles; van den Tempel, Nathalie; Kok, Yannick P.; Heijink, Anne Margriet; van Vugt, Marcel A. T. M.; Fehrmann, Rudolf S. N.] Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, Groningen, Netherlands; [Heijink, Anne Margriet; Spierings, Diana C. J.; Foijer, Floris] Univ Groningen, Univ Med Ctr Groningen, European Res Inst Biol Ageing, Groningen, Netherlands	University of Groningen; University of Groningen	van Vugt, MATM; Fehrmann, RSN (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, Groningen, Netherlands.	m.vugt@umcg.nl; r.s.n.fehrmann@umcg.nl	Fehrmann, Rudolf/E-2551-2011	Fehrmann, Rudolf/0000-0002-7516-315X; Heijink, Anne Margriet/0000-0001-9229-0575; Kok, Yannick/0000-0001-7041-5496; Spierings, Diana/0000-0001-8403-474X; Foijer, Floris/0000-0003-0989-3127; van Gijn, Stephanie/0000-0003-2172-1731	Dutch Cancer Society [RUG 2011-5093, RUG 2012-5549, RUG 2013-5960]; Netherlands Organisation for Scientific Research [NWO-VIDI 917-13334, NWO-VENI 916-16025]; European Research Council (ERC-Consolidator grant "TENSION")	Dutch Cancer Society(KWF Kankerbestrijding); Netherlands Organisation for Scientific Research(Netherlands Organization for Scientific Research (NWO)); European Research Council (ERC-Consolidator grant "TENSION")	This work was financially supported by grants from the Dutch Cancer Society (RUG 2011-5093 to MATMvV, RUG 2012-5549 to FF, and RUG 2013-5960 to RSNF), the Netherlands Organisation for Scientific Research (NWO-VIDI 917-13334 to MATMvV and NWO-VENI 916-16025 to RSNF), and the European Research Council (ERC-Consolidator grant "TENSION" to MATMvV).	Adamson B, 2012, NAT CELL BIOL, V14, P318, DOI 10.1038/ncb2426; Aguilera A, 2008, NAT REV GENET, V9, P204, DOI 10.1038/nrg2268; Alcaraz-Sanabria A, 2017, MOL CANCER THER, V16, P2552, DOI 10.1158/1535-7163.MCT-17-0223; Ashworth A, 2011, CELL, V145, P30, DOI 10.1016/j.cell.2011.03.020; Bakker B, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0971-7; Barr PM, 2015, J CLIN ONCOL, V33, P2399, DOI 10.1200/JCO.2014.60.6327; Blanco I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120020; Borges DD, 2018, LEUKEMIA RES, V64, P61, DOI 10.1016/j.leukres.2017.11.013; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Buccitelli C, 2017, GENOME RES, V27, P501, DOI 10.1101/gr.212225.116; Caceres-Gorriti KY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091000; Carter SL, 2006, NAT GENET, V38, P1043, DOI 10.1038/ng1861; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Ciriello G, 2013, NAT GENET, V45, P1127, DOI 10.1038/ng.2762; Coleman RL, 2014, ANN ONCOL, V25, piv305; Crasta K, 2012, NATURE, V482, P53, DOI 10.1038/nature10802; Daniels MJ, 2004, SCIENCE, V306, P876, DOI 10.1126/science.1102574; Dauch D, 2016, NAT MED, V22, P744, DOI 10.1038/nm.4107; Davies H, 2017, NAT MED, V23, P517, DOI 10.1038/nm.4292; Dickson MA, 2016, ANN ONCOL, V27, P1855, DOI 10.1093/annonc/mdw281; Engebraaten O, 2013, AM J PATHOL, V183, P1064, DOI 10.1016/j.ajpath.2013.05.033; Ertych N, 2016, P NATL ACAD SCI USA, V113, P1817, DOI 10.1073/pnas.1525129113; Evers B, 2008, CLIN CANCER RES, V14, P3916, DOI 10.1158/1078-0432.CCR-07-4953; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Fehrmann RSN, 2015, NAT GENET, V47, P115, DOI 10.1038/ng.3173; Graff JN, 2016, CANCER-AM CANCER SOC, V122, P2524, DOI 10.1002/cncr.30073; Habermann JK, 2009, INT J CANCER, V124, P1552, DOI 10.1002/ijc.24017; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Heijink AM, 2015, P NATL ACAD SCI USA, V112, P15160, DOI 10.1073/pnas.1505283112; Huck JJ, 2014, MOL CANCER THER, V13, P2170, DOI 10.1158/1535-7163.MCT-14-0027; Janssen A, 2011, SCIENCE, V333, P1895, DOI 10.1126/science.1210214; Jasin M, 2013, COLD SPRING HARB PER, V5; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kufer TA, 2002, J CELL BIOL, V158, P617, DOI 10.1083/jcb.200204155; Liu X, 2007, P NATL ACAD SCI USA, V104, P12111, DOI 10.1073/pnas.0702969104; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Ma N, 2010, MOL BIOL CELL, V21, P979, DOI 10.1091/mbc.E09-07-0601; Macurek L, 2008, NATURE, V455, P119, DOI 10.1038/nature07185; Mankouri HW, 2013, EMBO J, V32, P2661, DOI 10.1038/emboj.2013.211; Matulonis UA, 2012, GYNECOL ONCOL, V127, P63, DOI 10.1016/j.ygyno.2012.06.040; Melichar B, 2015, LANCET ONCOL, V16, P395, DOI 10.1016/S1470-2045(15)70051-3; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Moynahan ME, 2010, NAT REV MOL CELL BIO, V11, P196, DOI 10.1038/nrm2851; Niu H, 2015, FRONT ONCOL, V5, P3052; Perez de Castro Ignacio, 2012, Genes Cancer, V3, P721, DOI 10.1177/1947601912473306; Rottenberg S, 2008, P NATL ACAD SCI USA, V105, P17079, DOI 10.1073/pnas.0806092105; Roy R, 2012, NAT REV CANCER, V12, DOI 10.1038/nrc3181-c3; Schoonen PM, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15981; Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933; Shigeishi H, 2009, INT J ONCOL, V34, P1565, DOI 10.3892/ijo_00000286; Slabicki M, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000408; Sloane DA, 2010, ACS CHEM BIOL, V5, P563, DOI 10.1021/cb100053q; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; Takahashi Y, 2015, ANN ONCOL, V26, P935, DOI 10.1093/annonc/mdv034; Tayyar Y, 2017, CRIT REV ONCOL HEMAT, V119, P59, DOI 10.1016/j.critrevonc.2017.09.006; Tomii C, 2017, WORLD J SURG ONCOL, V15, DOI 10.1186/s12957-016-1095-y; van den Bos H, 2016, GENOME BIOL, V17, P1758; van Vugt MATM, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000287; van Vugt MATM, 2004, MOL CELL, V15, P799, DOI 10.1016/j.molcel.2004.07.015; WEI P, 2013, J CLIN ONCOL S, V31; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Xu J, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-200	63	26	27	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2019	38	6					852	867		10.1038/s41388-018-0470-2	http://dx.doi.org/10.1038/s41388-018-0470-2			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK5LC	30177840	hybrid, Green Published, Green Accepted			2022-12-17	WOS:000458006300007
J	Chen, ST; Kuo, TC; Liao, YY; Lin, MC; Tien, YW; Huang, MC				Chen, Syue-Ting; Kuo, Ting-Chun; Liao, Ying-Yu; Lin, Mei-Chun; Tien, Yu-Wen; Huang, Min-Chuan			Silencing of MUC20 suppresses the malignant character of pancreatic ductal adenocarcinoma cells through inhibition of the HGF/MET pathway	ONCOGENE			English	Article							HEPATOCYTE GROWTH-FACTOR; PHASE-I; CANCER-CELLS; EXPRESSION; MET; FIBROBLASTS; ACTIVATION; PROGNOSIS; STROMA; PHENOTYPES	Mucins are heavily glycosylated proteins that play critical roles in the pathogenesis of tumour malignancies. Pancreatic ductal adenocarcinoma (PDAC) is characterised by the aberrant expression of mucins. However, the role of mucin (MUC) 20 in PDAC remains unclear. PDAC is usually surrounded by a dense fibrotic stroma consisting of an extracellular matrix and pancreatic stellate cells (PSCs). The stroma creates a nutrient-deprived, hypoxic, and acidic microenvironment, and promotes the malignant behaviours of PDAC cells. In this study, immunohistochemical staining demonstrated that high MUC20 expression correlated with poor progression-free survival and high local recurrence rate of PDAC patients (n = 61). The expression of MUC20 was induced by serum deprivation, hypoxia, and acidic pH in PDAC cells. MUC20 knockdown with siRNA decreased cell viability, as well as migration and invasion induced by PSCs in HPAC and HPAF-II cells. In intraperitoneal, subcutaneous, and orthotopic injection models, MUC20 knockdown decreased tumour growth in immunodeficient mice. Phospho-RTK array and western blot analysis indicated that MUC20 knockdown decreased HGF-mediated phosphorylation of MET in PDAC cells. Moreover, HGF-induced malignant phenotypes could be suppressed by MUC20 knockdown. Co-immunoprecipitation revealed the physical association of MUC20 and MET. These findings suggest that MUC20 knockdown suppresses the malignant phenotypes of PDAC cells at least partially through the inhibition of the HGF/MET pathway and that MUC20 could act as a potential therapeutic target.	[Chen, Syue-Ting; Liao, Ying-Yu; Huang, Min-Chuan] Natl Taiwan Univ, Grad Inst Anat & Cell Biol, Coll Med, Taipei, Taiwan; [Kuo, Ting-Chun; Tien, Yu-Wen] Natl Taiwan Univ Hosp, Dept Surg, Taipei, Taiwan; [Lin, Mei-Chun] Natl Taiwan Univ Hosp, Dept Otolaryngol, Hsinchu, Hsinchu, Taiwan; [Lin, Mei-Chun] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University	Huang, MC (corresponding author), Natl Taiwan Univ, Grad Inst Anat & Cell Biol, Coll Med, Taipei, Taiwan.; Tien, YW (corresponding author), Natl Taiwan Univ Hosp, Dept Surg, Taipei, Taiwan.	ywtien5106@ntu.edu.tw; mchuang@ntu.edu.tw		TIEN, YU-WEN/0000-0002-9126-2705; KUO, TING-CHUN/0000-0003-1960-1423; HUANG, MIN-CHUAN/0000-0002-0704-3447	National Taiwan University Hospital [106-N3608]; Translational Research Program of National Taiwan University Hospital; National Taiwan University College of Medicine [107C101-B2, NSC-83]; Ministry of Science and Technology, Taiwan [104-2320-B-002-068-MY3, 106-2321-B-002-034]	National Taiwan University Hospital(National Taiwan University); Translational Research Program of National Taiwan University Hospital; National Taiwan University College of Medicine(National Taiwan University); Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, TaiwanMinistry of Science, ICT & Future Planning, Republic of Korea)	This study was supported by National Taiwan University Hospital (106-N3608 to Dr. TCK), Translational Research Program of National Taiwan University Hospital and National Taiwan University College of Medicine (107C101-B2 and NSC-83 to Dr. MCH), and Ministry of Science and Technology, Taiwan (104-2320-B-002-068-MY3 to Dr. MCH and 106-2321-B-002-034 to Dr. YWT). In addition, we are grateful to Dr. WH Lee (Genomics Research Center, Academia Sinica, Taiwan) for providing human PDAC and PSC cell lines. We are grateful to Dr. SH Wang (Graduate Institute of Anatomy and Cell Biology, College of Medicine, National Taiwan University, Taiwan) for providing reagents and technical assistance during revision process.	Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Chauhan SC, 2012, MOL CANCER THER, V11, P24, DOI 10.1158/1535-7163.MCT-11-0598; Chen CH, 2016, GYNECOL ONCOL, V140, P131, DOI 10.1016/j.ygyno.2015.11.025; Chen CH, 2013, GYNECOL ONCOL, V128, P560, DOI 10.1016/j.ygyno.2012.12.012; Erkan M, 2012, NAT REV GASTRO HEPAT, V9, P454, DOI 10.1038/nrgastro.2012.115; Feig C, 2012, CLIN CANCER RES, V18, P4266, DOI 10.1158/1078-0432.CCR-11-3114; Garajova Ingrid, 2015, Transl Oncogenomics, V7, P13, DOI 10.4137/TOG.S30534; Gore J, 2014, CANCER CELL, V25, P711, DOI 10.1016/j.ccr.2014.05.026; Goydos JS, 1996, J SURG RES, V63, P298, DOI 10.1006/jsre.1996.0264; Gulec SA, 2011, CLIN CANCER RES, V17, P4091, DOI 10.1158/1078-0432.CCR-10-2579; Haridas D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026839; Higuchi T, 2004, MOL CELL BIOL, V24, P7456, DOI 10.1128/MCB.24.17.7456-7468.2004; Higuchi T, 2004, J BIOL CHEM, V279, P1968, DOI 10.1074/jbc.M304558200; Kaur S, 2013, NAT REV GASTRO HEPAT, V10, P607, DOI 10.1038/nrgastro.2013.120; Kitajima Y, 2008, CANCER SCI, V99, P1341, DOI 10.1111/j.1349-7006.2008.00828.x; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; Locker GY, 2006, J CLIN ONCOL, V24, P5313, DOI 10.1200/JCO.2006.08.2644; Maitra A, 2008, ANNU REV PATHOL-MECH, V3, P157, DOI 10.1146/annurev.pathmechdis.3.121806.154305; Mei L, 2016, J GASTROINTEST ONCOL, V7, P487, DOI 10.21037/jgo.2016.03.03; Molina V, 2012, TUMOR BIOL, V33, P799, DOI 10.1007/s13277-011-0297-8; Moniaux N, 2006, J BIOL CHEM, V281, P23676, DOI 10.1074/jbc.M600302200; Nielsen MFB, 2016, WORLD J GASTROENTERO, V22, P2678, DOI 10.3748/wjg.v22.i9.2678; Ozdemir BC, 2014, CANCER CELL, V25, P719, DOI 10.1016/j.ccr.2014.04.005; Patel MB, 2014, CARCINOGENESIS, V35, P1891, DOI 10.1093/carcin/bgu122; Paulson AS, 2013, GASTROENTEROLOGY, V144, P1316, DOI 10.1053/j.gastro.2013.01.078; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Pothula SP, 2016, BRIT J CANCER, V114, P269, DOI 10.1038/bjc.2015.478; Qian LW, 2003, CANCER LETT, V190, P105, DOI 10.1016/S0304-3835(02)00517-7; Ramanathan RK, 2005, CANCER IMMUNOL IMMUN, V54, P254, DOI 10.1007/s00262-004-0581-1; Rizwani W, 2015, CANCERS, V7, P1785, DOI 10.3390/cancers7030861; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Swartz MJ, 2002, AM J CLIN PATHOL, V117, P791; Takikita M, 2009, CANCER RES, V69, P2950, DOI 10.1158/0008-5472.CAN-08-3879; Tanaka S, 2016, ANN SURG ONCOL, V23, P197, DOI 10.1245/s10434-015-4463-x; Vincent A, 2011, LANCET, V378, P607, DOI 10.1016/S0140-6736(10)62307-0; Yamasaki H, 2004, INT J ONCOL, V24, P107; Yauch RL, 2012, CURR OPIN GENET DEV, V22, P45, DOI 10.1016/j.gde.2012.01.003	38	26	26	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 15	2018	37	46					6041	6053		10.1038/s41388-018-0403-0	http://dx.doi.org/10.1038/s41388-018-0403-0			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HA3SQ	29993037	hybrid, Green Published			2022-12-17	WOS:000450175900003
J	Ooki, A; Dinalankara, W; Marchionni, L; Tsay, JCJ; Goparaju, C; Maleki, Z; Rom, WN; Pass, HI; Hoque, MO				Ooki, Akira; Dinalankara, Wikum; Marchionni, Luigi; Tsay, Jun-Chieh J.; Goparaju, Chandra; Maleki, Zahra; Rom, William N.; Pass, Harvey, I; Hoque, Mohammad O.			Epigenetically regulated PAX6 drives cancer cells toward a stem-like state via GLI-SOX2 signaling axis in lung adenocarcinoma	ONCOGENE			English	Article							SELF-RENEWAL; SERUM DNA; SOX2; GENE; DIFFERENTIATION; METHYLATION; EXPRESSION; PATHWAYS; HEDGEHOG; INITIATION	It remains unclear whether PAX6 acts as a crucial transcription factor for lung cancer stem cell (CSC) traits. We demonstrate that PAX6 acts as an oncogene responsible for induction of cancer stemness properties in lung adenocarcinoma (LUAD). Mechanistically, PAX6 promotes GLI transcription, resulting in SOX2 upregulation directly by the binding of GLI to the proximal promoter region of the SOX2 gene. The overexpressed SOX2 enhances the expression of key pluripotent factors (OCT4 and NANOG) and suppresses differentiation lineage factors (HOPX and NKX2-1), driving cancer cells toward a stem-like state. In contrast, in the differentiated non-CSCs, PAX6 is transcriptionally silenced by its promoter methylation. In human lung cancer tissues, the positive linear correlations of PAX6 expression with GLI and SOX2 expression and its negative correlations with HOPX and NKX2-1 expression were observed. Therapeutically, the blockade of the PAX6-GLISOX2 signaling axis elicits a long-lasting therapeutic efficacy by limiting CSC expansion following chemotherapy. Furthermore, a methylation panel including the PAX6 gene yielded a sensitivity of 79.1% and specificity of 83.3% for cancer detection using serum DNA from stage IA LUAD. Our findings provide a rationale for targeting the PAX6-GLI-SOX2 signaling axis with chemotherapy as an effective therapeutic strategy and support the clinical utility of PAX6 gene promoter methylation as a biomarker for early lung cancer detection.	[Ooki, Akira; Hoque, Mohammad O.] Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21231 USA; [Dinalankara, Wikum; Marchionni, Luigi; Hoque, Mohammad O.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21231 USA; [Tsay, Jun-Chieh J.; Rom, William N.] NYU, Sch Med, Dept Med, Div Pulm Crit Care & Sleep Med, New York, NY 10016 USA; [Goparaju, Chandra; Pass, Harvey, I] New York Univ Med, Langone Med Ctr, Dept Cardiothorac Surg, Div Thorac Surg, New York, NY 10016 USA; [Maleki, Zahra] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21287 USA; [Hoque, Mohammad O.] Johns Hopkins Univ, Sch Med, Dept Urol, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins University; New York University; New York University; NYU Langone Medical Center; Johns Hopkins University; Johns Hopkins University	Hoque, MO (corresponding author), Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21231 USA.; Hoque, MO (corresponding author), Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21231 USA.; Hoque, MO (corresponding author), Johns Hopkins Univ, Sch Med, Dept Urol, Baltimore, MD 21287 USA.	mhoque1@jhmi.edu	Marchionni, Luigi/S-6774-2017	Marchionni, Luigi/0000-0002-7336-8071; Tsay, Jun-Chieh/0000-0002-2282-2510; Ooki, Akira/0000-0001-7618-5775; Rom, William/0000-0002-8793-7028; Pass, Harvey/0000-0003-3222-3471	Flight Attendant Medical Research Institute Clinical Innovative Award [103015]; NCI [R01CA206027]; SPORE in Cervical Cancer [P50 CA098252]; NATIONAL CANCER INSTITUTE [P50CA098252, R01CA206027] Funding Source: NIH RePORTER	Flight Attendant Medical Research Institute Clinical Innovative Award; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); SPORE in Cervical Cancer; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was funded by the Flight Attendant Medical Research Institute Clinical Innovative Award 103015 (M.O. Hoque), NCI R01CA206027 (M.O. Hoque), the Career Development award from SPORE in Cervical Cancer Grants P50 CA098252 (MOH).	Aberle DR, 2011, NEW ENGL J MED, V365, P395, DOI 10.1056/NEJMoa1102873; Asami M, 2011, DEVELOPMENT, V138, P5067, DOI 10.1242/dev.074591; Beck B, 2013, NAT REV CANCER, V13, P727, DOI 10.1038/nrc3597; Begum S, 2011, CLIN CANCER RES, V17, P4494, DOI 10.1158/1078-0432.CCR-10-3436; Belinsky SA, 2004, NAT REV CANCER, V4, P707, DOI 10.1038/nrc1432; Blanchon T, 2007, LUNG CANCER, V58, P50, DOI 10.1016/j.lungcan.2007.05.009; Bora-Singhal N, 2015, NEOPLASIA, V17, P538, DOI 10.1016/j.neo.2015.07.001; Boumahdi S, 2014, NATURE, V511, P246, DOI 10.1038/nature13305; Cheung WKC, 2013, CANCER CELL, V23, P725, DOI 10.1016/j.ccr.2013.04.009; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Coutinho P, 2011, GENOME RES, V21, P1349, DOI 10.1101/gr.124115.111; Eramo A, 2010, ONCOGENE, V29, P4625, DOI 10.1038/onc.2010.207; Greenberg AK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039403; Holland PWH, 2007, BMC BIOL, V5, DOI 10.1186/1741-7007-5-47; Hu B, 2016, CELL DIFFER INVASIVE, V167, pe18; Infante P, 2015, TRENDS PHARMACOL SCI, V36, P547, DOI 10.1016/j.tips.2015.05.006; Justilien V, 2015, CLIN CANCER RES, V21, P505, DOI 10.1158/1078-0432.CCR-14-0507; Kamachi Y, 2001, GENE DEV, V15, P1272, DOI 10.1101/gad.887101; Lang D, 2008, MOL CARCINOGEN, V47, P148, DOI 10.1002/mc.20375; Lang D, 2007, BIOCHEM PHARMACOL, V73, P1, DOI 10.1016/j.bcp.2006.06.024; Leon G, 2016, PHARMACOL THERAPEUT, V158, P71, DOI 10.1016/j.pharmthera.2015.12.001; Liu YP, 2013, CANCER RES, V73, P406, DOI 10.1158/0008-5472.CAN-12-1733; Maeda Y, 2007, PHYSIOL REV, V87, P219, DOI 10.1152/physrev.00028.2006; Marquardt T, 2001, CELL, V105, P43, DOI 10.1016/S0092-8674(01)00295-1; Mascarenhas JB, 2009, J BIOL CHEM, V284, P27524, DOI 10.1074/jbc.M109.047209; Masui S, 2007, NAT CELL BIOL, V9, P625, DOI 10.1038/ncb1589; Mayes DA, 2006, CANCER RES, V66, P9809, DOI 10.1158/0008-5472.CAN-05-3877; Nam HS, 2014, TUBERC RESPIR DIS, V76, P211, DOI 10.4046/trd.2014.76.5.211; Ooki A, 2010, ONCOGENE, V29, P3263, DOI 10.1038/onc.2010.76; Ooki A, 2018, CANCER RES, V78, P168, DOI 10.1158/0008-5472.CAN-17-0836; Ooki A, 2017, CLIN CANCER RES, V23, P7141, DOI 10.1158/1078-0432.CCR-17-1222; Osumi N, 2008, STEM CELLS, V26, P1663, DOI 10.1634/stemcells.2007-0884; Po A, 2017, ONCOGENE, V36, P4641, DOI 10.1038/onc.2017.91; Rauch TA, 2012, TUMOR BIOL, V33, P287, DOI 10.1007/s13277-011-0282-2; Reik W, 2007, NATURE, V447, P425, DOI 10.1038/nature05918; Sansom SN, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000511; Santini R, 2014, ONCOGENE, V33, P4697, DOI 10.1038/onc.2014.71; Shen Y, 2006, HUM MOL GENET, V15, P2623, DOI 10.1093/hmg/ddl188; Shiraishi M, 2002, ONCOGENE, V21, P3804, DOI 10.1038/sj.onc.1205454; Shyr CR, 2010, PROSTATE, V70, P190, DOI 10.1002/pros.21052; Stolzenburg S, 2012, NUCLEIC ACIDS RES, V40, P6725, DOI 10.1093/nar/gks360; Takebe N, 2015, NAT REV CLIN ONCOL, V12, P445, DOI 10.1038/nrclinonc.2015.61; Tammemagi MC, 2013, NEW ENGL J MED, V368, P728, DOI 10.1056/NEJMoa1211776; Watanabe H, 2013, CANCER CELL, V23, P707, DOI 10.1016/j.ccr.2013.05.013; Yamaoka T, 2000, DIABETOLOGIA, V43, P332, DOI 10.1007/s001250050051; Yin Z, 2006, AM J PHYSIOL-LUNG C, V291, pL191, DOI 10.1152/ajplung.00385.2005; Zhao XT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085738	47	26	26	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 8	2018	37	45					5967	5981		10.1038/s41388-018-0373-2	http://dx.doi.org/10.1038/s41388-018-0373-2			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GZ6PQ	29980786	Green Accepted			2022-12-17	WOS:000449562500005
J	Peng, MG; Wang, JJ; Zhang, DY; Jin, HL; Li, JX; Wu, XR; Huang, CS				Peng, Minggang; Wang, Jingjing; Zhang, Dongyun; Jin, Honglei; Li, Jingxia; Wu, Xue-Ru; Huang, Chuanshu			PHLPP2 stabilization by p27 mediates its inhibition of bladder cancer invasion by promoting autophagic degradation of MMP2 protein	ONCOGENE			English	Article							DOWN-REGULATION CONTRIBUTES; MATRIX METALLOPROTEINASES; PROGNOSTIC-SIGNIFICANCE; UP-REGULATION; IN-VITRO; CELL; EXPRESSION; P27(KIP1); AKT; ISORHAPONTIGENIN	Pleckstrin homology domain leucine-rich repeat protein phosphatase 2 (PHLPP2) is a tumor suppressor that catalyzes the dephosphorylation of the AGC kinases, while p27 acts as a tumor suppressor that regulates cell cycle, apoptosis, and cell motility. Our previous studies have identified that PHLPP2 participates in inhibition of transformation of human bronchial epithelial cells following lung carcinogen B[a] P/B[a] PDE exposure. However, nothing was known about the association of p27 with regulation of PHLPP2 expression and the role of PHLPP2 in bladder cancer (BC) invasion. In our current studies, we demonstrated that PHLPP2 inhibited BC invasion through promoting MMP2 degradation via p62-mediated autophagy; and p27 expression was able to stabilize PHLPP2 protein by inhibiting protein degradation of Hsp90, which could directly bind to PHLPP2 and protect it from degradation. More in-depth studies discovered that stabilization of Hsp90 by p27 was mediated by calpain1 proteolysis system, whereas p27 inhibited calpain1 gene transcription by attenuating Jak1/Stat1 cascade in human invasive BC cells. Collectively, we for the first time revealed PHLPP2 downregulation in BCs and its participating in promotion of BC invasion, as well as novel role of p27 and mechanisms underlying its regulation of PHLPP2 protein degradation through Hsp90-dependent manner. Our findings improve our understanding of p27 and PHLPP2 roles and their crosstalk in regulation of BC invasion, which further contributes to improve the current strategy for invasive bladder cancer therapy.	[Peng, Minggang; Wang, Jingjing; Zhang, Dongyun; Li, Jingxia; Huang, Chuanshu] NYU, Nelson Inst Environm Med, Sch Med, Tuxedo Pk, NY 10987 USA; [Peng, Minggang] Huazhong Univ Sci & Technol, Union Hosp, Dept Obstet & Gynecol, Tongji Med Coll, 1277 JieFang Ave, Wuhan 430022, Hubei, Peoples R China; [Jin, Honglei] Wenzhou Med Univ, Sch Lab Med & Life Sci, Wenzhou 325035, Zhejiang, Peoples R China; [Wu, Xue-Ru] NYU, Sch Med, Dept Urol, New York, NY 10016 USA; [Wu, Xue-Ru] NYU, Sch Med, Dept Pathol, New York, NY 10016 USA	New York University; Huazhong University of Science & Technology; Wenzhou Medical University; New York University; New York University	Huang, CS (corresponding author), NYU, Nelson Inst Environm Med, Sch Med, Tuxedo Pk, NY 10987 USA.	Chuanshu.huang@nyumc.org		Wu, Xue-Ru/0000-0001-6058-6291; Huang, Chuanshu/0000-0003-4133-5096	NIH/NCI [CA165980, CA177665, CA217923]; NIH/NIEHS [ES000260]; Natural Science Foundation of China [NSFC91773391]; Scientific Research Training Program for Young Talents (Union Hospital, Wuhan, China); NATIONAL CANCER INSTITUTE [P01CA165980, R01CA177665, R01CA217923] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000260] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH/NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Scientific Research Training Program for Young Talents (Union Hospital, Wuhan, China); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was partially supported by the grants of NIH/NCI CA165980, CA177665, and CA217923, and NIH/NIEHS ES000260, and by grants of the Natural Science Foundation of China NSFC91773391 and the Scientific Research Training Program for Young Talents (Union Hospital, Wuhan, China).	Au-Yeung Nancy, 2013, JAKSTAT, V2, pe23931, DOI 10.4161/jkst.23931; Averna M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116738; Brognard J, 2008, TRENDS ENDOCRIN MET, V19, P223, DOI 10.1016/j.tem.2008.04.001; Brognard J, 2007, MOL CELL, V25, P917, DOI 10.1016/j.molcel.2007.02.017; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Chou R, 2016, CANCER-AM CANCER SOC, V122, P842, DOI 10.1002/cncr.29843; Dikic I, 2010, CANCER RES, V70, P3431, DOI 10.1158/0008-5472.CAN-09-4027; Dong GJ, 2015, EUR J IMMUNOL, V45, P2377, DOI 10.1002/eji.201445349; Duran A, 2011, MOL CELL, V44, P134, DOI 10.1016/j.molcel.2011.06.038; Esposito V, 1997, CANCER RES, V57, P3381; Fang Y, 2013, MOL CANCER THER, V12, P1492, DOI 10.1158/1535-7163.MCT-12-0922; Gao T, 2008, J BIOL CHEM, V283, P6300, DOI 10.1074/jbc.M707319200; Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008; Huang HS, 2016, AUTOPHAGY, V12, P1687, DOI 10.1080/15548627.2016.1196313; Huang HS, 2015, CLIN CANCER RES, V21, P3783, DOI 10.1158/1078-0432.CCR-14-2829; Huang HS, 2014, ONCOTARGET, V5, P493, DOI 10.18632/oncotarget.1643; Ichimura Y, 2008, J BIOL CHEM, V283, P22847, DOI 10.1074/jbc.M802182200; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Jiang GS, 2016, CANCER PREV RES, V9, P567, DOI 10.1158/1940-6207.CAPR-15-0338; Jin HL, 2015, ONCOTARGET, V6, P522, DOI 10.18632/oncotarget.2680; Kamai T, 2000, BJU INT, V86, P14, DOI 10.1046/j.1464-410x.2000.00726.x; Kamai T, 2001, BRIT J CANCER, V84, P1242, DOI 10.1054/bjoc.2000.1736; Knowles MA, 2015, NAT REV CANCER, V15, P25, DOI 10.1038/nrc3817; Komatsu M, 2010, FEBS LETT, V584, P1374, DOI 10.1016/j.febslet.2010.02.017; Kumar B, 2010, CANCER RES, V70, P832, DOI 10.1158/0008-5472.CAN-09-2918; LEVI F, 1993, INT J CANCER, V55, P419, DOI 10.1002/ijc.2910550316; Lippai M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/832704; Liu JY, 2011, MOL CELL BIOL, V31, P4917, DOI 10.1128/MCB.05799-11; Liu JY, 2010, J BIOL CHEM, V285, P26058, DOI 10.1074/jbc.M110.100271; Liu T, 2015, GENET TEST MOL BIOMA, V19, P548, DOI 10.1089/gtmb.2015.0123; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Lovaas JD, 2013, PROSTATE, V73, P522, DOI 10.1002/pros.22592; Masciullo V, 1999, CANCER RES, V59, P3790; Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005; Park SL, 2015, ONCOL REP, V34, P1605, DOI 10.3892/or.2015.4119; Piechaczyk M, 2008, BIOCHEM SOC T, V36, P864, DOI 10.1042/BST0360864; Primdahl H, 2002, J CANCER RES CLIN, V128, P295, DOI 10.1007/s00432-002-0344-3; Puzio-Kuter AM, 2009, GENE DEV, V23, P675, DOI 10.1101/gad.1772909; Rabbani F, 2007, BJU INT, V100, P259, DOI 10.1111/j.1464-410X.2007.06927.x; Ren F, 2014, MOL CELL BIOCHEM, V385, P95, DOI 10.1007/s11010-013-1818-0; Rogov V, 2014, MOL CELL, V53, P167, DOI 10.1016/j.molcel.2013.12.014; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Sossey-Alaoui K, 2005, EXP CELL RES, V308, P135, DOI 10.1016/j.yexcr.2005.04.011; Stamenkovic I, 2000, SEMIN CANCER BIOL, V10, P415, DOI 10.1006/scbi.2000.0379; Steeg PS, 1997, NAT MED, V3, P152, DOI 10.1038/nm0297-152; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Storr SJ, 2011, NAT REV CANCER, V11, P364, DOI 10.1038/nrc3050; VANDERBURG MEL, 1988, GYNECOL ONCOL, V30, P307, DOI 10.1016/0090-8258(88)90244-2; von Reyn CR, 2012, J NEUROCHEM, V121, P793, DOI 10.1111/j.1471-4159.2012.07735.x; Wang Y, 2016, ONCOGENE, V35, P4080, DOI 10.1038/onc.2015.470; Wang Y, 2014, CELL REP, V6, P278, DOI 10.1016/j.celrep.2013.12.031; Xu JW, 2016, ONCOTARGET, V7, P34112, DOI 10.18632/oncotarget.8746; Yuen EY, 2007, J PHYSIOL-LONDON, V580, P241, DOI 10.1113/jphysiol.2006.122754; Zhang D, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.496; Zhang DY, 2014, J CELL SCI, V127, P2920, DOI 10.1242/jcs.148130; Zhang DY, 2010, CANCER RES, V70, P813, DOI 10.1158/0008-5472.CAN-09-0448; Zhou L, 2013, ACTA PHARMACOL SIN, V34, P651, DOI 10.1038/aps.2013.12	57	26	28	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 25	2018	37	43					5735	5748		10.1038/s41388-018-0374-1	http://dx.doi.org/10.1038/s41388-018-0374-1			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GY1KL	29930380	hybrid, Green Published			2022-12-17	WOS:000448288200003
J	Knickelbein, K; Tong, JS; Chen, DS; Wang, YJ; Misale, S; Bardelli, A; Yu, J; Zhang, L				Knickelbein, Kyle; Tong, Jingshan; Chen, Dongshi; Wang, Yi-Jun; Misale, Sandra; Bardelli, Alberto; Yu, Jian; Zhang, Lin			Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer	ONCOGENE			English	Article							NF-KAPPA-B; ACQUIRED-RESISTANCE; RAS ONCOGENES; APOPTOSIS; THERAPY; INHIBITION; MUTATIONS; CETUXIMAB; MEK; PANITUMUMAB	Intrinsic and acquired resistance to anti-EGFR antibody therapy, frequently mediated by a mutant or amplified KRAS oncogene, is a significant challenge in the treatment of colorectal cancer (CRC). However, the mechanism of KRAS-mediated therapeutic resistance is not well understood. In this study, we demonstrate that clinically used anti-EGFR antibodies, including cetuximab and panitumumab, induce killing of sensitive CRC cells through p73-dependent transcriptional activation of the pro-apoptotic Bcl-2 family protein PUMA. PUMA induction and p73 activation are abrogated in CRC cells with acquired resistance to anti-EGFR antibodies due to KRAS alterations. Inhibition of aurora kinases preferentially kills mutant KRAS CRC cells and overcomes KRAS-mediated resistance to anti-EGFR antibodies in vitro and in vivo by restoring PUMA induction. Our results suggest that PUMA plays a critical role in meditating the sensitivity of CRC cells to anti-EGFR antibodies, and that restoration of PUMA-mediated apoptosis is a promising approach to improve the efficacy of EGFR-targeted therapy.	[Knickelbein, Kyle; Tong, Jingshan; Chen, Dongshi; Wang, Yi-Jun; Yu, Jian; Zhang, Lin] UMPC Hillman Canc Ctr, Pittsburgh, PA 15213 USA; [Knickelbein, Kyle; Tong, Jingshan; Chen, Dongshi; Wang, Yi-Jun; Yu, Jian; Zhang, Lin] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15213 USA; [Misale, Sandra] Mem Sloan Kettering Canc, Program Mol Pharmacol, New York, NY 10065 USA; [Bardelli, Alberto] IRCCS, Candiolo Canc Inst FPO, I-10060 Candiolo, TO, Italy; [Bardelli, Alberto] IRCCS, Dept Oncol, I-10060 Candiolo, TO, Italy; [Yu, Jian] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Memorial Sloan Kettering Cancer Center; IRCCS Fondazione del Piemonte per l'Oncologia; IRCCS Fondazione del Piemonte per l'Oncologia; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Zhang, L (corresponding author), UMPC Hillman Canc Ctr, Pittsburgh, PA 15213 USA.; Zhang, L (corresponding author), Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15213 USA.	zhanglx@upmc.edu	Zhang, Lin/A-7389-2009; Yu, Jian/A-8301-2009; Wang, Yixuan/GZK-6559-2022; Wang, Yin/HCI-9352-2022; wang, yi/GVT-8516-2022; wang, yixuan/GXW-2866-2022; Wang, Yijun/GXW-1763-2022; BARDELLI, Alberto/J-9721-2018	Zhang, Lin/0000-0003-0018-3903; Yu, Jian/0000-0002-4021-1000; Tong, Jingshan/0000-0003-1640-5769; BARDELLI, Alberto/0000-0003-1647-5070	U.S. National Institute of Health [R01CA106348, R01CA172136, R01CA203028, R01CA217141, U19AI068021, R01CA215481]; Cotswold Foundation; Department of Pharmacology & Chemical Biology, University of Pittsburgh School of Medicine;  [P30CA047904]; NATIONAL CANCER INSTITUTE [R01CA172136, R01CA217141, P30CA047904, R01CA203028, R01CA106348, R01CA215481] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI068021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK085570] Funding Source: NIH RePORTER	U.S. National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cotswold Foundation; Department of Pharmacology & Chemical Biology, University of Pittsburgh School of Medicine; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors thank our lab members for critical reading. This work is supported by U.S. National Institute of Health grants (R01CA106348, R01CA172136, R01CA203028, and R01CA217141 to LZ; U19AI068021 and R01CA215481 to JY). KK was supported by a fellowship from the Cotswold Foundation and the Department of Pharmacology & Chemical Biology, University of Pittsburgh School of Medicine. This project used the UPMC Hillman Cancer Center shared facilities that were supported in part by award P30CA047904.	Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116; Banck MS, 2009, CLIN CANCER RES, V15, P7492, DOI 10.1158/1078-0432.CCR-09-0188; Bardelli A, 2010, J CLIN ONCOL, V28, P1254, DOI 10.1200/JCO.2009.24.6116; Bhola PD, 2016, MOL CELL, V61, P695, DOI 10.1016/j.molcel.2016.02.019; Brown MF, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.104; Chen DS, 2014, ONCOTARGET, V5, P8107, DOI 10.18632/oncotarget.2440; Chu E, 2012, CLIN COLORECTAL CANC, V11, P1, DOI 10.1016/j.clcc.2011.05.005; Conforti F, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.27; Corcoran RB, 2013, CANCER CELL, V23, P121, DOI 10.1016/j.ccr.2012.11.007; Cragg MS, 2008, J CLIN INVEST, V118, P3651, DOI 10.1172/JCI35437; Cragg MS, 2007, PLOS MED, V4, P1681, DOI 10.1371/journal.pmed.0040316; Del Poeta G, 2016, DRUG TODAY, V52, P249, DOI 10.1358/dot.2016.52.4.2470954; Diaz LA, 2012, NATURE, V486, P537, DOI 10.1038/nature11219; Dudgeon C, 2012, ONCOGENE, V31, P4848, DOI 10.1038/onc.2011.644; Giam M, 2008, ONCOGENE, V27, pS128, DOI 10.1038/onc.2009.50; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hata AN, 2014, CANCER RES, V74, P3146, DOI 10.1158/0008-5472.CAN-13-3728; Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; Kasper S, 2013, ONCOGENE, V32, P2873, DOI 10.1038/onc.2012.302; Knickelbein K, 2015, GENES DIS, V2, P4, DOI 10.1016/j.gendis.2014.10.002; Lee HJ, 2015, CELL RES, V25, P225, DOI 10.1038/cr.2015.8; Lievre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191; Lu Y, 2007, CANCER RES, V67, P8240, DOI 10.1158/0008-5472.CAN-07-0589; Luo J, 2009, CELL, V137, P835, DOI 10.1016/j.cell.2009.05.006; Martini M, 2012, NAT REV CLIN ONCOL, V9, P87, DOI 10.1038/nrclinonc.2011.164; Medico E, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8002; Meyerhardt JA, 2005, NEW ENGL J MED, V352, P476, DOI 10.1056/NEJMra040958; Ming L, 2006, J BIOL CHEM, V281, P16034, DOI 10.1074/jbc.M513587200; Misale S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9305; Misale S, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007947; Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156; Ostrem JM, 2013, NATURE, V503, P548, DOI 10.1038/nature12796; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Siravegna G, 2015, NAT MED, V21, P795, DOI 10.1038/nm.3870; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; Sun J, 2014, MOL CANCER THER, V13, P1298, DOI 10.1158/1535-7163.MCT-13-0846; Sun Q, 2009, ONCOGENE, V28, P2348, DOI 10.1038/onc.2009.108; Tsai KKC, 2003, CANCER RES, V63, P3418; Yu J, 2008, ONCOGENE, V27, pS71, DOI 10.1038/onc.2009.45; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Yun JY, 2009, SCIENCE, V325, P1555, DOI 10.1126/science.1174229; Zhang L, 2013, CURR COLORECT CANC R, V9, P331, DOI 10.1007/s11888-013-0188-z	44	26	26	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 16	2018	37	33					4599	4610		10.1038/s41388-018-0289-x	http://dx.doi.org/10.1038/s41388-018-0289-x			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GQ5OV	29755130	Green Accepted			2022-12-17	WOS:000441736700008
J	Vaniotis, G; Rayes, RF; Qi, S; Milette, S; Wang, N; Perrino, S; Bourdeau, F; Nystrom, H; He, Y; Lamarche-Vane, N; Brodt, P				Vaniotis, George; Rayes, Roni F.; Qi, Shu; Milette, Simon; Wang, Ni; Perrino, Stephanie; Bourdeau, France; Nystrom, Hanna; He, Yi; Lamarche-Vane, Nathalie; Brodt, Pnina			Collagen IV-conveyed signals can regulate chemokine production and promote liver metastasis	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; NF-KAPPA-B; COLON-CANCER; CARCINOMA-CELLS; PATHWAYS; MICROENVIRONMENT; EXPRESSION; CROSSTALK; INVASION; 3-KINASE/AKT	Liver metastases remain a major cause of death from gastrointestinal tract cancers as well as from other malignancies such as breast and lung carcinomas and melanoma. Understanding the underlying biology is essential for the design of effective targeted therapies. We previously reported that collagen IV alpha 1/alpha 2 overexpression in non-metastatic lung carcinoma (M27(colIV)) cells increased their metastatic ability, specifically to the liver and documented high collagen IV levels in surgical resections of liver metastases from diverse tumor types. Here, we aimed to elucidate the functional relevance of collagen IV to metastatic outgrowth in the liver. Gene expression profiling revealed in M27(colIV) cells significant increases in the expression of chemokines CCL5 (5.7-fold) and CCL7 (2.6-fold) relative to wild-type cells, and this was validated by qPCR and western blotting. Similarly, in human colon carcinoma KM12C and KM12SM cells with divergent liver-colonizing potentials, CCL7 and CCL5 production correlated with type IV collagen expression and the metastatic phenotype. CCL7 silencing by short hairpin RNA (shRNA) reduced experimental liver metastasis in both cell types, whereas CCL5 silencing reduced metastasis of M27(colIV) cells, implicating these cytokines in metastatic expansion in the liver. Subsequent functional analyses implicated both MEK/ERK and PI3K signaling upstream of CCL7 upregulation and identified CCL7 (but not CCL5) as a critical migration/invasion factor, acting via the chemokine receptor CCR3. Chemokine CCL5 was identified as a regulator of the T-cell immune response in the liver. Loss of CCL7 in KM12SM cells was also associated with altered E-cadherin and reduced vimentin and Snail expression, implicating it in epithelial-to-mesenchymal transition in these cells. Moreover, in clinical specimens of colon cancer liver metastases analyzed by immunohistochemistry, CCL5 and CCL7 levels paralleled those of collagen IV. The results identify the chemokines CCL5 and CCL7 as type IV collagen-regulated genes that promote liver metastasis by distinct and complementary mechanisms.	[Vaniotis, George; Rayes, Roni F.; Qi, Shu; Wang, Ni; Perrino, Stephanie; Bourdeau, France; Brodt, Pnina] McGill Univ, Ctr Hlth, Dept Surg, Res Inst, Montreal, PQ, Canada; [Milette, Simon; Brodt, Pnina] McGill Univ, Ctr Hlth, Med & Res Inst, Montreal, PQ, Canada; [Nystrom, Hanna] Umea Univ, Dept Surg, Dept Surg & Perioperat Sci, Umea, Sweden; [He, Yi; Lamarche-Vane, Nathalie] McGill Univ, Dept Anat & Cell Biol, Montreal, PQ, Canada; [He, Yi; Lamarche-Vane, Nathalie] McGill Univ, Ctr Hlth, Montreal, PQ, Canada; [He, Yi; Lamarche-Vane, Nathalie; Brodt, Pnina] McGill Univ, Ctr Hlth, Canc Res Program, Res Inst, Montreal, PQ, Canada; [Brodt, Pnina] McGill Univ, Ctr Hlth, Res Inst, Dept Oncol, Montreal, PQ, Canada	McGill University; McGill University; Umea University; McGill University; McGill University; McGill University; McGill University	Brodt, P (corresponding author), McGill Univ, Ctr Hlth, Dept Surg, Res Inst, Montreal, PQ, Canada.; Brodt, P (corresponding author), McGill Univ, Ctr Hlth, Med & Res Inst, Montreal, PQ, Canada.; Brodt, P (corresponding author), McGill Univ, Ctr Hlth, Canc Res Program, Res Inst, Montreal, PQ, Canada.; Brodt, P (corresponding author), McGill Univ, Ctr Hlth, Res Inst, Dept Oncol, Montreal, PQ, Canada.	pnina.brodt@mcgill.ca	Nystrom, Hanna/AAK-4743-2021	Rayes, Roni/0000-0001-7508-020X	Canadian Institute for Health Research [MOP 80201]; Quebec Ministere de l'Economie, de l'Innovation et des Exportations [PSR-SIIRI-843]; Swedish Research Council; Vasterbotten County Council; Henry R. Shibata fellowship from the Cedars Cancer Institute; MITACS	Canadian Institute for Health Research(Canadian Institutes of Health Research (CIHR)); Quebec Ministere de l'Economie, de l'Innovation et des Exportations; Swedish Research Council(Swedish Research CouncilEuropean Commission); Vasterbotten County Council; Henry R. Shibata fellowship from the Cedars Cancer Institute; MITACS	We thank Dr. Julia Burnier for the initial analysis of the microarray data, Ms. Anette Berglund for skillful technical assistance with immunohistochemistry, and the laboratory of Dr. Jean-Jacques Lebrun for help and advice. This work was supported mainly by grants MOP 80201 from the Canadian Institute for Health Research and a PSR-SIIRI-843 grant from the Quebec Ministere de l'Economie, de l'Innovation et des Exportations (to P.B.) and also by grants from the Swedish Research Council and Vasterbotten County Council (to H.N.). R.F.R. was supported by the Henry R. Shibata fellowship from the Cedars Cancer Institute. R.F.R. and G.V. were supported by MITACS internships.	Akram IG, 2016, TUMOR BIOL, V37, P2461, DOI 10.1007/s13277-015-4089-4; Bai D, 2009, INT J CANCER, V125, P2863, DOI 10.1002/ijc.24748; Brodt P, 2001, J BIOL CHEM, V276, P33608, DOI 10.1074/jbc.M102754200; Brodt P, 2016, CLIN CANCER RES, V22, P5971, DOI 10.1158/1078-0432.CCR-16-0460; Brunner PM, 2015, EXP DERMATOL, V24, P522, DOI 10.1111/exd.12709; Burnier JV, 2011, ONCOGENE, V30, P3766, DOI 10.1038/onc.2011.89; Cambien B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028842; Chang LY, 2012, CANCER RES, V72, P1092, DOI 10.1158/0008-5472.CAN-11-2493; Cho YB, 2012, ONCOL REP, V28, P689, DOI 10.3892/or.2012.1815; Eefsen RL, 2012, J ONCOL, V2012, DOI 10.1155/2012/907971; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Fidler IJ, 2008, LANCET ONCOL, V9, P808, DOI 10.1016/S1470-2045(08)70201-8; Frentzas S, 2016, NAT MED, V22, P1294, DOI 10.1038/nm.4197; Goos JACM, 2016, ONCOTARGET, V7, P2123, DOI 10.18632/oncotarget.6188; Guan XM, 2015, ACTA PHARM SIN B, V5, P402, DOI 10.1016/j.apsb.2015.07.005; Hauser AS, 2017, NAT REV DRUG DISCOV, V16, P829, DOI 10.1038/nrd.2017.178; Hirai H, 2014, CLIN EXP METASTAS, V31, P977, DOI 10.1007/s10585-014-9684-z; Hoyer Morten, 2011, Clin Epidemiol, V3 Suppl 1, P11, DOI 10.2147/CLEP.S20613; Ichikawa M, 2011, MOL CANCER RES, V9, P133, DOI 10.1158/1541-7786.MCR-10-0394; Jung DW, 2010, INT J CANCER, V127, P332, DOI 10.1002/ijc.25060; Kim SH, 2011, J ENDOCRINOL, V209, P139, DOI 10.1530/JOE-10-0377; KITADAI Y, 1995, AM J PATHOL, V147, P1238; Lee YS, 2016, ONCOTARGET, V7, P36842, DOI 10.18632/oncotarget.9209; Li S, 2015, GROWTH HORM IGF RES, V25, P253, DOI 10.1016/j.ghir.2015.07.008; Luo J, 2015, ONCOTARGET, V6, P27555, DOI 10.18632/oncotarget.4515; Yamada M, 2008, CLIN CANCER RES, V14, P2351, DOI 10.1158/1078-0432.CCR-07-4499; Moreno-Layseca P, 2014, MATRIX BIOL, V34, P144, DOI 10.1016/j.matbio.2013.10.011; MORIKAWA K, 1988, CANCER RES, V48, P6863; Mrowietz U, 1999, BRIT J CANCER, V79, P1025, DOI 10.1038/sj.bjc.6690164; Nystrom H, 2015, TUMOR BIOL, V36, P9839, DOI 10.1007/s13277-015-3729-z; PAGET S, 1989, CANCER METAST REV, V8, P98; Proudfoot AEI, 2015, CYTOKINE, V74, P259, DOI 10.1016/j.cyto.2015.02.011; Samani AA, 2004, CANCER RES, V64, P3380, DOI 10.1158/0008-5472.CAN-03-3780; Samani AA, 2007, ENDOCR REV, V28, P20, DOI 10.1210/er.2006-0001; Shen XJ, 2016, ONCOL LETT, V12, P3250, DOI 10.3892/ol.2016.5122; Soria G, 2008, CANCER LETT, V267, P271, DOI 10.1016/j.canlet.2008.03.018; Stormes KA, 2005, BREAST CANCER RES TR, V89, P209, DOI 10.1007/s10549-004-5328-3; Struyf S, 2001, EUR J IMMUNOL, V31, P2170, DOI 10.1002/1521-4141(200107)31:7<2170::AID-IMMU2170>3.0.CO;2-D; Su BX, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-206; Turdean S, 2012, ACTA MED MARISIENSIS, V58, P254; Van den Eynden GG, 2014, CLIN CANCER RES, V20, P5140, DOI 10.1158/1078-0432.CCR-14-0158; Van den Eynden GG, 2013, CANCER RES, V73, P2031, DOI 10.1158/0008-5472.CAN-12-3931; Vellinga TT, 2016, ONCOGENE, V35, P5263, DOI 10.1038/onc.2016.60; Yoshimura K, 2009, CANCER RES, V69, P7320, DOI 10.1158/0008-5472.CAN-09-0315; Zhang DL, 2004, J BIOL CHEM, V279, P19683, DOI 10.1074/jbc.M313145200; Zhang DL, 2003, ONCOGENE, V22, P974, DOI 10.1038/sj.onc.1206197	46	26	26	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2018	37	28					3790	3805		10.1038/s41388-018-0242-z	http://dx.doi.org/10.1038/s41388-018-0242-z			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GM8HR	29651051				2022-12-17	WOS:000438465600003
J	Yoo, KC; Suh, Y; An, Y; Lee, HJ; Jeong, YJ; Uddin, N; Cui, YH; Roh, TH; Shim, JK; Chang, JH; Park, JB; Kim, MJ; Kim, IG; Kang, SG; Lee, SJ				Yoo, Ki-Chun; Suh, Yongjoon; An, Yoojeong; Lee, Hae-June; Jeong, Ye Ji; Uddin, Nizam; Cui, Yan-Hong; Roh, Tae-Hoon; Shim, Jin-Kyoung; Chang, Jong Hee; Park, Jong Bae; Kim, Min-Jung; Kim, In-Gyu; Kang, Seok-Gu; Lee, Su-Jae			Proinvasive extracellular matrix remodeling in tumor microenvironment in response to radiation	ONCOGENE			English	Article							FACTOR-KAPPA-B; GLIOMA STEM-CELLS; HYALURONAN SYNTHESIS; BRAIN-TUMOR; GLIOBLASTOMA; ACTIVATION; CANCER; MIGRATION; INVASION; STABILIZATION	Ionizing radiation is widely used for patient with glioblastoma (GBM). However, the effect of radiation on patient survival is marginal and upon recurrence tumors frequently shift toward mesenchymal subtype adopting invasiveness. Here, we show that ionizing radiation affects biomechanical tension in GBM microenvironment and provides proinvasive extracellular signaling cue, hyaluronic acid (HA)-rich condition. In response to radiation, HA production was increased in GBM cells by HA synthase-2 (HAS2) that was transcriptionally upregulated by NF-kappa B. Notably, NF-kappa B was persistently activated by IL-1 alpha-feedback loop, making HA abundance in tumor microenvironment after radiation. Radiation-induced HA abundance causally has been linked to invasiveness of GBM cells by generating movement track as an extracellular matrix, and by acting as a signaling ligand for CD44 receptor, leading to SRC activation, which is sufficient for mesenchymal shift of GBM cells. Collectively, our findings provide an explanation for the frequent brain tumor relapse after radiotherapy, and potential therapeutic targets to block mesenchymal shift upon relapse.	[Yoo, Ki-Chun; Suh, Yongjoon; An, Yoojeong; Uddin, Nizam; Cui, Yan-Hong; Lee, Su-Jae] Hanyang Univ, Res Inst Nat Sci, Dept Life Sci, Seoul 04763, South Korea; [Lee, Hae-June; Jeong, Ye Ji] Korea Inst Radiol & Med Sci, Div Radiat Effect, Seoul 01812, South Korea; [Roh, Tae-Hoon; Shim, Jin-Kyoung; Chang, Jong Hee; Kang, Seok-Gu] Yonsei Univ, Severance Hosp, Brain Tumor Ctr, Dept Neurosurg,Coll Med, Seoul 03722, South Korea; [Park, Jong Bae] Natl Canc Ctr, Res Inst & Hosp, Specif Organs Canc Branch, Goyang 10408, South Korea; [Kim, Min-Jung] Korea Inst Radiol & Med Sci, Natl Radiat Emergency Med Ctr, Lab Radiat Exposure & Therapeut, Seoul 01812, South Korea; [Kim, In-Gyu] Korea Atom Energy Res Inst, Dept Radiat Biol, Environm Radiat Res Grp, Daejeon 34057, South Korea	Hanyang University; Korea Institute of Radiological & Medical Sciences; Yonsei University; Yonsei University Health System; National Cancer Center - Korea (NCC); Korea Institute of Radiological & Medical Sciences; Korea Atomic Energy Research Institute (KAERI)	Lee, SJ (corresponding author), Hanyang Univ, Res Inst Nat Sci, Dept Life Sci, Seoul 04763, South Korea.; Kang, SG (corresponding author), Yonsei Univ, Severance Hosp, Brain Tumor Ctr, Dept Neurosurg,Coll Med, Seoul 03722, South Korea.	seokgu9@gmail.com; sj0420@hanyang.ac.kr	Cui, Yanhong/ABB-1148-2021	Cui, Yanhong/0000-0002-4169-6521; Kang, Seok-Gu/0000-0001-5676-2037; Roh, Tae Hoon/0000-0002-1004-9364; Ud Din, Nizam/0000-0002-9845-3109; Chang, Jong Hee/0000-0003-1509-9800	National Research Foundation (NRF); Ministry of Science, ICT and Future Planning, Korean Government, through its National Nuclear Technology Program [NRF-2015M2A2A7A01044998, NRF-2016R1E1A1A01942075]	National Research Foundation (NRF); Ministry of Science, ICT and Future Planning, Korean Government, through its National Nuclear Technology Program	This work was supported by the National Research Foundation (NRF) and Ministry of Science, ICT and Future Planning, Korean Government, through its National Nuclear Technology Program (NRF-2015M2A2A7A01044998 and NRF-2016R1E1A1A01942075).	Bellail AC, 2004, INT J BIOCHEM CELL B, V36, P1046, DOI 10.1016/j.biocel.2004.01.013; Bhat KPL, 2013, CANCER CELL, V24, P331, DOI 10.1016/j.ccr.2013.08.001; Bohrer LR, 2014, CANCER RES, V74, P374, DOI 10.1158/0008-5472.CAN-13-2469; Bourguignon LYW, 2001, J BIOL CHEM, V276, P7327, DOI 10.1074/jbc.M006498200; Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712; Catton C, 2003, UROL CLIN N AM, V30, P751, DOI 10.1016/S0094-0143(03)00051-X; Colman H, 2010, NEURO-ONCOLOGY, V12, P49, DOI 10.1093/neuonc/nop007; de Groot J, 2009, J NEURO-ONCOL, V95, P151, DOI 10.1007/s11060-009-9916-2; Dirks PB, 2008, J CLIN ONCOL, V26, P2916, DOI 10.1200/JCO.2008.17.6792; Du JY, 2009, NAT BIOTECHNOL, V27, P77, DOI 10.1038/nbt.1513; Dunn GP, 2012, GENE DEV, V26, P756, DOI 10.1101/gad.187922.112; Entwistle J, 1996, J CELL BIOCHEM, V61, P569, DOI 10.1002/(SICI)1097-4644(19960616)61:4<569::AID-JCB10>3.0.CO;2-B; Freije WA, 2004, CANCER RES, V64, P6503, DOI 10.1158/0008-5472.CAN-04-0452; Gladson CL, 1999, J NEUROPATH EXP NEUR, V58, P1029, DOI 10.1097/00005072-199910000-00001; Hartupee J, 2008, J BIOL CHEM, V283, P15689, DOI 10.1074/jbc.M801346200; Hwang E, 2016, ONCOTARGET, V7, P4890, DOI 10.18632/oncotarget.6640; Hyc A, 2009, INT J MOL MED, V24, P579, DOI 10.3892/ijmm_00000268; Joseph JV, 2015, CANCER LETT, V359, P107, DOI 10.1016/j.canlet.2015.01.010; Kim MJ, 2011, J CELL SCI, V124, P3084, DOI 10.1242/jcs.080119; Kim YG, 2013, CHILD NERV SYST, V29, P549, DOI 10.1007/s00381-012-1988-1; Kim YH, 2014, CANCER LETT, V354, P132, DOI 10.1016/j.canlet.2014.07.048; Lal S, 2000, J NEUROSURG, V92, P326, DOI 10.3171/jns.2000.92.2.0326; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Mao P, 2013, P NATL ACAD SCI USA, V110, P8644, DOI 10.1073/pnas.1221478110; Nguyen DH, 2011, CANCER CELL, V19, P640, DOI 10.1016/j.ccr.2011.03.011; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Saavalainen K, 2007, J BIOL CHEM, V282, P11530, DOI 10.1074/jbc.M607871200; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Shankar A, 2014, CHIN J CANCER, V33, P148, DOI 10.5732/cjc.013.10095; Soeda A, 2009, ONCOGENE, V28, P3949, DOI 10.1038/onc.2009.252; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Sun ZW, 2002, SHOCK, V18, P99, DOI 10.1097/00024382-200208000-00001; Tammi RH, 2011, FEBS J, V278, P1419, DOI 10.1111/j.1742-4658.2011.08070.x; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Vigetti D, 2010, J BIOL CHEM, V285, P24639, DOI 10.1074/jbc.M110.134536; Yoshida Y, 2004, J BIOL CHEM, V279, P1768, DOI 10.1074/jbc.M311498200	36	26	27	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 14	2018	37	24					3317	3328		10.1038/s41388-018-0199-y	http://dx.doi.org/10.1038/s41388-018-0199-y			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GJ6XB	29559744				2022-12-17	WOS:000435526600010
J	Caja, L; Tzavlaki, K; Dadras, MS; Tan, EJ; Hatem, G; Maturi, NP; Moren, A; Wik, L; Watanabe, Y; Savary, K; Kamali-Moghaddan, M; Uhrbom, L; Heldin, CH; Moustakas, A				Caja, Laia; Tzavlaki, Kalliopi; Dadras, Mahsa S.; Tan, E-Jean; Hatem, Gad; Maturi, Naga P.; Moren, Anita; Wik, Lotta; Watanabe, Yukihide; Savary, Katia; Kamali-Moghaddan, Masood; Uhrbom, Lene; Heldin, Carl-Henrik; Moustakas, Aristidis			Snail regulates BMP and TGF beta pathways to control the differentiation status of glioma-initiating cells	ONCOGENE			English	Article							GROWTH-FACTOR-BETA; STEM-CELLS; MESENCHYMAL TRANSITION; SELF-RENEWAL; GLIOBLASTOMA; BONE; MAINTENANCE; INDUCTION; PROGNOSIS; INTERACTS	Glioblastoma multiforme is a brain malignancy characterized by high heterogeneity, invasiveness, and resistance to current therapies, attributes related to the occurrence of glioma stem cells (GSCs). Transforming growth factor beta (TGF beta) promotes self-renewal and bone morphogenetic protein (BMP) induces differentiation of GSCs. BMP7 induces the transcription factor Snail to promote astrocytic differentiation in GSCs and suppress tumor growth in vivo. We demonstrate that Snail represses stemness in GSCs. Snail interacts with SMAD signaling mediators, generates a positive feedback loop of BMP signaling and transcriptionally represses the TGFB1 gene, decreasing TGF beta 1 signaling activity. Exogenous TGF beta 1 counteracts Snail function in vitro, and in vivo promotes proliferation and re-expression of Nestin, confirming the importance of TGFB1 gene repression by Snail. In conclusion, novel insight highlights mechanisms whereby Snail differentially regulates the activity of the opposing BMP and TGF beta pathways, thus promoting an astrocytic fate switch and repressing stemness in GSCs.	[Caja, Laia; Tzavlaki, Kalliopi; Dadras, Mahsa S.; Hatem, Gad; Maturi, Naga P.; Moren, Anita; Heldin, Carl-Henrik; Moustakas, Aristidis] Uppsala Univ, Dept Med Biochem & Microbiol, Sci Life Lab, Biomed Ctr, Box 582, SE-75123 Uppsala, Sweden; [Caja, Laia; Tzavlaki, Kalliopi; Dadras, Mahsa S.; Hatem, Gad; Maturi, Naga P.; Moren, Anita; Watanabe, Yukihide; Savary, Katia; Heldin, Carl-Henrik; Moustakas, Aristidis] Uppsala Univ, Ludwig Canc Res, Sci Life Lab, Biomed Ctr, Box 595, SE-75124 Uppsala, Sweden; [Tan, E-Jean; Maturi, Naga P.; Uhrbom, Lene] Uppsala Univ, Dept Immunol Genet & Pathol, Sci Life Lab, Rudbeck Lab, SE-75185 Uppsala, Sweden; [Wik, Lotta; Kamali-Moghaddan, Masood] Uppsala Univ, Biomed Ctr, Dept Immunol Genet & Pathol, Sci Life Lab, Box 815, S-75108 Uppsala, Sweden; [Watanabe, Yukihide] Univ Tsukuba, Dept Expt Pathol, Fac Med, Tsukuba, Ibaraki, Japan; [Savary, Katia] Univ Reims, UMR CNRS MEDyC 7369, Reims, France	Uppsala University; Uppsala University; Uppsala University; Uppsala University; University of Tsukuba; Universite de Reims Champagne-Ardenne	Caja, L; Moustakas, A (corresponding author), Uppsala Univ, Dept Med Biochem & Microbiol, Sci Life Lab, Biomed Ctr, Box 582, SE-75123 Uppsala, Sweden.; Caja, L; Moustakas, A (corresponding author), Uppsala Univ, Ludwig Canc Res, Sci Life Lab, Biomed Ctr, Box 595, SE-75124 Uppsala, Sweden.	laja.caja@imbim.uu.se; aris.moustakas@imbim.uu.se	Tan, E-Jean/J-3425-2019; Caja, Laia/J-4618-2019	Tan, E-Jean/0000-0002-4631-174X; Caja, Laia/0000-0002-8786-8763; Maturi, Nagaprathyusha/0000-0002-7726-8617	Ludwig Cancer Research; Swedish Cancer Society [CAN 2012/438, CAN 2015/438, CAN 2012/1186]; Swedish Research Council [K2013-66X-14936-10-5, 2015-02757]; Lisa Erikssons minnesfond	Ludwig Cancer Research; Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Lisa Erikssons minnesfond	This work was supported by: Ludwig Cancer Research; Swedish Cancer Society (CAN 2012/438, CAN 2015/438 to ArM); and Swedish Research Council (K2013-66X-14936-10-5 to ArM, 2015-02757 to C-HH). LC was supported by postdoctoral fellowships from Lisa Erikssons minnesfond (2013) and Swedish Cancer Society (CAN 2012/1186).	Nieto MA, 2013, SCIENCE, V342, P708, DOI 10.1126/science.1234850; Assarsson E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095192; Bonavia R, 2011, CANCER RES, V71, P4055, DOI 10.1158/0008-5472.CAN-11-0153; Bruna A, 2007, CANCER CELL, V11, P147, DOI 10.1016/j.ccr.2006.11.023; Cahoy JD, 2008, J NEUROSCI, V28, P264, DOI 10.1523/JNEUROSCI.4178-07.2008; Caja L, 2015, FEBS LETT, V589, P1588, DOI 10.1016/j.febslet.2015.04.058; Caja L, 2012, CURR PHARM DESIGN, V18, P4072, DOI 10.2174/138161212802430459; Caren H, 2015, STEM CELL REP, V5, P829, DOI 10.1016/j.stemcr.2015.09.014; Chen J, 2012, NATURE, V488, P522, DOI 10.1038/nature11287; Dhasarathy A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026514; Doyle KP, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-62; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Ferletta M, 2011, INT J CANCER, V129, P45, DOI 10.1002/ijc.25647; Floratos A, 2010, BIOINFORMATICS, V26, P1779, DOI 10.1093/bioinformatics/btq282; Gonzalez-Gomez P, 2015, ONCOTARGET, V6, P10950, DOI 10.18632/oncotarget.3459; Haar CP, 2012, NEUROCHEM RES, V37, P1192, DOI 10.1007/s11064-011-0701-1; Herbertz S, 2015, DRUG DES DEV THER, V9, P4479, DOI 10.2147/DDDT.S86621; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Ikushima H, 2011, J BIOL CHEM, V286, P41434, DOI 10.1074/jbc.M111.300863; Kampf C, 2012, JOVE-J VIS EXP, DOI 10.3791/3620; Kobayashi A, 2011, J EXP MED, V208, P2641, DOI 10.1084/jem.20110840; Larssen P, 2017, MOL CELL PROTEOMICS, V16, P502, DOI [10.1074/mcp.A116.064725, 10.1074/mcp.M116.064725]; Mahabir R, 2014, NEURO-ONCOLOGY, V16, P671, DOI 10.1093/neuonc/not239; Marinescu VD, 2005, NUCLEIC ACIDS RES, V33, pD91, DOI 10.1093/nar/gki103; Ming GL, 2011, NEURON, V70, P687, DOI 10.1016/j.neuron.2011.05.001; Miyazono Kohei, 2002, Sci STKE, V2002, ppe40, DOI 10.1126/stke.2002.151.pe40; Nguyen DH, 2013, CANCERINCYTES, V2, DOI DOI 10.1038/PROTEX.2013.097; Penuelas S, 2009, CANCER CELL, V15, P315, DOI 10.1016/j.ccr.2009.02.011; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349; Sakaki-Yumoto M, 2013, BBA-GEN SUBJECTS, V1830, P2280, DOI 10.1016/j.bbagen.2012.08.008; Savary K, 2013, ONCOGENE, V32, P5409, DOI 10.1038/onc.2013.67; Schachtrup C, 2010, J NEUROSCI, V30, P5843, DOI 10.1523/JNEUROSCI.0137-10.2010; Tan EJ, 2015, NUCLEIC ACIDS RES, V43, P162, DOI 10.1093/nar/gku1293; Tate CM, 2012, CELL DEATH DIFFER, V19, P1644, DOI 10.1038/cdd.2012.44; Tchaicha JH, 2011, CANCER RES, V71, P6371, DOI 10.1158/0008-5472.CAN-11-0991; Grande MT, 2015, NAT MED, V21, P989, DOI 10.1038/nm.3901; Thuault S, 2008, J BIOL CHEM, V283, P33437, DOI 10.1074/jbc.M802016200; Villagrasa P, 2012, ONCOGENE, V31, P4022, DOI 10.1038/onc.2011.562; Vincent T, 2009, NAT CELL BIOL, V11, P943, DOI 10.1038/ncb1905; Watanabe Y, 2016, J BIOL CHEM, V291, P12706, DOI 10.1074/jbc.M116.729699; Whissell G, 2014, NAT CELL BIOL, V16, P695, DOI 10.1038/ncb2992; Yan K, 2014, GENE DEV, V28, P1085, DOI 10.1101/gad.235515.113; Yan K, 2013, CURR OPIN NEUROL, V26, P701, DOI 10.1097/WCO.0000000000000032; Yang HW, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-301	45	26	28	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	19					2515	2531		10.1038/s41388-018-0136-0	http://dx.doi.org/10.1038/s41388-018-0136-0			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GF3RN	29449696	Green Published, hybrid			2022-12-17	WOS:000431873400005
J	McKinnon, T; Venier, R; Yohe, M; Sindiri, S; Gryder, BE; Shern, JF; Kabaroff, L; Dickson, B; Schleicher, K; Chouinard-Pelletier, G; Menezes, S; Gupta, A; Zhang, XH; Guha, R; Ferrer, M; Thomas, CJ; Wei, YH; Davani, D; Guidos, CJ; Khan, J; Gladdy, RA				McKinnon, Timothy; Venier, Rosemarie; Yohe, Marielle; Sindiri, Sivasish; Gryder, Berkley E.; Shern, Jack F.; Kabaroff, Leah; Dickson, Brendan; Schleicher, Krista; Chouinard-Pelletier, Guillaume; Menezes, Serena; Gupta, Abha; Zhang, Xiaohu; Guha, Rajarashi; Ferrer, Marc; Thomas, Craig J.; Wei, Yuhong; Davani, Dariush; Guidos, Cynthia J.; Khan, Javed; Gladdy, Rebecca A.			Functional screening of FGFR4-driven tumorigenesis identifies PI3K/mTOR inhibition as a therapeutic strategy in rhabdomyosarcoma	ONCOGENE			English	Article							B-CELL LYMPHOMA; ALVEOLAR RHABDOMYOSARCOMA; EMBRYONAL RHABDOMYOSARCOMA; MUSCLE REGENERATION; FUSION GENE; MUTATIONS; CANCER; FGFR4; DIFFERENTIATION; PATHOGENESIS	Rhabdomyosarcoma (RMS) is the most common pediatric soft tissue sarcoma and outcomes have stagnated, highlighting a need for novel therapies. Genomic analysis of RMS has revealed that alterations in the receptor tyrosine kinase (RTK)/RAS/PI3K axis are common and that FGFR4 is frequently mutated or overexpressed. Although FGFR4 is a potentially druggable receptor tyrosine kinase, its functions in RMS are undefined. This study tested FGFR4-activating mutations and overexpression for the ability to generate RMS in mice. Murine tumor models were subsequently used to discover potential therapeutic targets and to test a dual PI3K/mTOR inhibitor in a preclinical setting. Specifically, we provide the first mechanistic evidence of differential potency in the most common human RMS mutations, V550E or N535K, compared to FGFR4(wt) overexpression as murine myoblasts expressing FGFR4(V550E) undergo higher rates of cellular transformation, engraftment into mice, and rapidly form sarcomas that highly resemble human RMS. Murine tumor cells overexpressing FGFR4(V550E) were tested in an in vitro dose-response drug screen along with human RMS cell lines. Compounds were grouped by target class, and potency was determined using average percentage of area under the dose-response curve (AUC). RMS cells were highly sensitive to PI3K/mTOR inhibitors, in particular, GSK2126458 (omipalisib) was a potent inhibitor of FGFR4V550E tumor-derived cell and human RMS cell viability. FGFR4(V550E)-overexpressing myoblasts and tumor cells had low nanomolar GSK2126458 EC50 values. Mass cytometry using mouse and human RMS cell lines validated GSK2126458 specificity at single-cell resolution, decreasing the abundance of phosphorylated Akt as well as decreasing phosphorylation of the downstream mTOR effectors 4ebp1, Eif4e, and S6. Moreover, PI3K/mTOR inhibition also robustly decreased the growth of RMS tumors in vivo. Thus, by developing a preclinical platform for testing novel therapies, we identified PI3K/mTOR inhibition as a promising new therapy for this devastating pediatric cancer.	[McKinnon, Timothy; Venier, Rosemarie; Kabaroff, Leah; Schleicher, Krista; Chouinard-Pelletier, Guillaume; Menezes, Serena; Gladdy, Rebecca A.] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada; [Yohe, Marielle; Sindiri, Sivasish; Gryder, Berkley E.; Shern, Jack F.; Khan, Javed] NCI, Genet Branch, Oncogen Sect, Ctr Canc Res, Gaithersburg, MD USA; [Gryder, Berkley E.] Mt Sinai Hosp, Dept Pathol, Toronto, ON, Canada; [Gupta, Abha] Hosp Sick Children, Div Hematol Oncol, Toronto, ON, Canada; [Zhang, Xiaohu; Guha, Rajarashi; Ferrer, Marc; Thomas, Craig J.] Natl Ctr Adv Translat Sci, Div Preclin Innovat, NIH, Bethesda, MD USA; [Wei, Yuhong; Davani, Dariush; Guidos, Cynthia J.] Hosp Sick Children, Dev & Stem Cell Biol, Toronto, ON, Canada; [Gladdy, Rebecca A.] Ontario Inst Canc Res, Toronto, ON, Canada; [Gladdy, Rebecca A.] Univ Toronto, Dept Surg, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); National Institutes of Health (NIH) - USA; NIH National Center for Advancing Translational Sciences (NCATS); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Ontario Institute for Cancer Research; University of Toronto; University Toronto Affiliates; University of Toronto	Gladdy, RA (corresponding author), Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada.; Gladdy, RA (corresponding author), Ontario Inst Canc Res, Toronto, ON, Canada.; Gladdy, RA (corresponding author), Univ Toronto, Dept Surg, Toronto, ON, Canada.	gladdy@lunenfeld.ca	Gladdy, Rebecca/A-2516-2013; Shern, Jack/V-4002-2019; Khan, Javed/AAG-3538-2019; Khan, Javed/P-9157-2014	Gladdy, Rebecca/0000-0003-4143-6620; Venier, Rosemarie/0000-0001-6063-7562; Thomas, Craig/0000-0001-9386-9001	Canadian Cancer Society Research Institute; Cancer Stem Cells Program of the Ontario Institute for Cancer Research; Ontario Institute for Cancer Research; NATIONAL CANCER INSTITUTE [ZIABC011002, ZIABC010806] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [ZIATR000047] Funding Source: NIH RePORTER	Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS)); Cancer Stem Cells Program of the Ontario Institute for Cancer Research; Ontario Institute for Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	CJG was supported by funding from the Canadian Cancer Society Research Institute and the Cancer Stem Cells Program of the Ontario Institute for Cancer Research; RAG was supported by a Clinical Investigator Award from Ontario Institute for Cancer Research.	Abraham J, 2014, GENE DEV, V28, P1578, DOI 10.1101/gad.238733.114; Barr FG, 1999, CANCER RES, V59, p1711S; Bendall SC, 2011, SCIENCE, V332, P687, DOI 10.1126/science.1198704; Campeau E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006529; Cao LA, 2010, CANCER RES, V70, P6497, DOI 10.1158/0008-5472.CAN-10-0582; Ceribelli M, 2014, P NATL ACAD SCI USA, V111, P11365, DOI 10.1073/pnas.1411701111; Chen L, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005075; Chmielecki J, 2017, CANCER RES, V77, P509, DOI 10.1158/0008-5472.CAN-16-1106; Crose LES, 2012, CLIN CANCER RES, V18, P3780, DOI 10.1158/1078-0432.CCR-10-3063; Dowling RJO, 2010, SCIENCE, V328, P1172, DOI 10.1126/science.1187532; Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Griner LAM, 2014, P NATL ACAD SCI USA, V111, P2349, DOI 10.1073/pnas.1311846111; Gryder BE, 2017, CANCER DISCOV, V7, P884, DOI 10.1158/2159-8290.CD-16-1297; Johnson RA, 2010, NATURE, V466, P632, DOI 10.1038/nature09173; Kashi VP, 2015, NAT REV CANCER, V15, P426, DOI 10.1038/nrc3961; Khan J, 2001, NAT MED, V7, P673, DOI 10.1038/89044; Kikuchi K, 2011, CURR TOP DEV BIOL, V96, P33, DOI 10.1016/B978-0-12-385940-2.00002-4; Knight SD, 2010, ACS MED CHEM LETT, V1, P39, DOI 10.1021/ml900028r; Lewin J, 2015, J CLIN ONCOL, V33, P3372, DOI 10.1200/JCO.2015.62.7380; Li S, 2013, PLOS ONE, V8; Linardic CM, 2008, CANCER LETT, V270, P10, DOI 10.1016/j.canlet.2008.03.035; Marics I, 2002, DEVELOPMENT, V129, P4559; McKinnon T, 2015, ONCOTARGET, V6, P14220, DOI 10.18632/oncotarget.3856; Ognjanovic S, 2009, CANCER-AM CANCER SOC, V115, P4218, DOI 10.1002/cncr.24465; Paulson V, 2011, GENE CHROMOSOME CANC, V50, P397, DOI 10.1002/gcc.20864; Perova T, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008661; Poschl J, 2014, ACTA NEUROPATHOL, V128, P123, DOI 10.1007/s00401-014-1297-8; RANDO TA, 1994, J CELL BIOL, V125, P1275, DOI 10.1083/jcb.125.6.1275; Seki M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8557; Shern JF, 2014, CANCER DISCOV, V4, P216, DOI 10.1158/2159-8290.CD-13-0639; Taylor JG, 2009, J CLIN INVEST, V119, P3395, DOI 10.1172/JCI39703; Tenente IM, 2017, ELIFE, V6, DOI 10.7554/eLife.19214; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Weigel BJ, 2016, J CLIN ONCOL, V34, P117, DOI 10.1200/JCO.2015.63.4048; Williamson D, 2010, J CLIN ONCOL, V28, P2151, DOI 10.1200/JCO.2009.26.3814; Zhao P, 2006, J BIOL CHEM, V281, P429, DOI 10.1074/jbc.M507440200; Zhao P, 2004, DEV DYNAM, V229, P380, DOI 10.1002/dvdy.10457	39	26	26	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	20					2630	2644		10.1038/s41388-017-0122-y	http://dx.doi.org/10.1038/s41388-017-0122-y			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GG2TH	29487419	Green Accepted			2022-12-17	WOS:000432545100002
J	Rauf, F; Festa, F; Park, JG; Magee, M; Eaton, S; Rinaldi, C; Betanzos, CM; Gonzalez-Malerva, L; LaBaer, J				Rauf, Femina; Festa, Fernanda; Park, Jin G.; Magee, Mitchell; Eaton, Seron; Rinaldi, Capria; Betanzos, Carlos Morales; Gonzalez-Malerva, Laura; LaBaer, Joshua			Ibrutinib inhibition of ERBB4 reduces cell growth in a WNT5A-dependent manner	ONCOGENE			English	Article							BREAST-CANCER CELLS; GASTROINTESTINAL STROMAL TUMORS; OVARIAN-CANCER; THERAPEUTIC TARGET; IMATINIB MESYLATE; CATENIN PATHWAY; BTK INHIBITOR; EXPRESSION; MALIGNANCIES; MUTATIONS	Alterations in ERBB family members have been associated with many tumor malignancies. EGFR and ERBB2 have been extensively explored in clinical oncology and several drugs currently target them therapeutically. However, the significance of ERBB4 as a potential therapeutic target remains mostly unexplored, even though ERBB4 is overexpressed or mutated in many solid tumors. Using a unique functional protein microarray platform, we found that ibrutinib inhibits ERBB4 activity in the same nM range as its canonical target, BTK. Cell-based assays revealed that ibrutinib treatment inhibited cell growth and decreased phosphorylation of ERBB4 and downstream targets MEK and ERK in cancer cell lines with high levels of endogenous ERBB4. In vivo, ibrutinib-responsive mouse xenograft tumors showed decreased tumor volumes with ibrutinib treatment. Interestingly, global gene expression comparisons between responsive and non-responsive cells identified a signature featuring the WNT pathway that predicts growth responsiveness to ibrutinib. Non-responsive ERBB4-expressing cell lines featured elevated activity of the WNT pathway, through the overexpression of WNT5A. Moreover, inhibition of WNT5A expression led to an ibrutinib response in non-responsive cell lines. Our data show that inhibiting ERBB4 reduces cell growth in cells that have low WNT5A expression and reveal a link between the ERBB4 and WNT pathways.	[Rauf, Femina; Festa, Fernanda; Park, Jin G.; Magee, Mitchell; Eaton, Seron; Rinaldi, Capria; Betanzos, Carlos Morales; Gonzalez-Malerva, Laura; LaBaer, Joshua] Arizona State Univ, Virginia G Piper Biodesign Ctr Personalized Diagn, Tempe, AZ 85281 USA	Arizona State University; Arizona State University-Tempe	LaBaer, J (corresponding author), Arizona State Univ, Virginia G Piper Biodesign Ctr Personalized Diagn, Tempe, AZ 85281 USA.	jlabaer@asu.edu		Festa, Fernanda/0000-0002-2822-823X				Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419; Anderson KS, 2011, J PROTEOME RES, V10, P85, DOI 10.1021/pr100686b; Arend RC, 2013, GYNECOL ONCOL, V131, P772, DOI 10.1016/j.ygyno.2013.09.034; Arteaga CL, 2014, CANCER CELL, V25, P282, DOI 10.1016/j.ccr.2014.02.025; Berglof A, 2015, SCAND J IMMUNOL, V82, P208, DOI 10.1111/sji.12333; Bian XF, 2017, J PROTEOME RES, V16, P195, DOI 10.1021/acs.jproteome.6b00354; Blanke CD, 2008, J CLIN ONCOL, V26, P620, DOI 10.1200/JCO.2007.13.4403; Carpenter G, 2003, EXP CELL RES, V284, P66, DOI 10.1016/S0014-4827(02)00100-3; Davies S, 2014, INT J GYNECOL PATHOL, V33, P402, DOI 10.1097/PGP.0000000000000081; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Gilmour LMR, 2001, CANCER RES, V61, P2169; Grabinski N, 2014, INVEST NEW DRUG, V32, P1096, DOI 10.1007/s10637-014-0141-2; Herman SEM, 2011, BLOOD, V117, P6287, DOI 10.1182/blood-2011-01-328484; Honigberg LA, 2010, P NATL ACAD SCI USA, V107, P13075, DOI 10.1073/pnas.1004594107; Junttila TT, 2005, CANCER RES, V65, P1384, DOI 10.1158/0008-5472.CAN-04-3150; Kim JY, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2195-3; Krejci P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035826; Kurppa KJ, 2016, ONCOGENE, V35, P1283, DOI 10.1038/onc.2015.185; Liu T, 2010, MOL CELL BIOCHEM, V340, P265, DOI 10.1007/s11010-010-0426-5; Masso-Valles D, 2015, CANCER RES, V75, P1675, DOI 10.1158/0008-5472.CAN-14-2852; Mendoza-Naranjo A, 2013, EMBO MOL MED, V5, P1087, DOI 10.1002/emmm.201202343; Nakata A, 2015, SCI REP-UK, V5, DOI 10.1038/srep13076; Niehrs C, 2012, NAT REV MOL CELL BIO, V13, P767, DOI 10.1038/nrm3470; Prickett TD, 2009, NAT GENET, V41, P1127, DOI 10.1038/ng.438; Rushworth SA, 2013, CELL SIGNAL, V25, P106, DOI 10.1016/j.cellsig.2012.09.008; Sagiv-Barfi I, 2015, P NATL ACAD SCI USA, V112, pE966, DOI 10.1073/pnas.1500712112; Smith MR, 2015, EXPERT OPIN PHARMACO, V16, P1879, DOI 10.1517/14656566.2015.1067302; Wang XH, 2016, MOL CANCER THER, V15, P2198, DOI 10.1158/1535-7163.MCT-15-0813; Williams CS, 2015, CARCINOGENESIS, V36, P710, DOI 10.1093/carcin/bgv049; Woyach JA, 2012, BLOOD, V120, P1175, DOI 10.1182/blood-2012-02-362624; Wu H, 2014, ACS CHEM BIOL, V9, P1086, DOI 10.1021/cb4008524	31	26	27	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	17					2237	2250		10.1038/s41388-017-0079-x	http://dx.doi.org/10.1038/s41388-017-0079-x			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GE3FW	29398709	Green Published, hybrid			2022-12-17	WOS:000431100200003
J	Herr, R; Halbach, S; Heizmann, M; Busch, H; Boerries, M; Brummer, T				Herr, Ricarda; Halbach, Sebastian; Heizmann, Miriam; Busch, Hauke; Boerries, Melanie; Brummer, Tilman			BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines	ONCOGENE			English	Article							MAMMARY EPITHELIAL-CELLS; ACQUIRED-RESISTANCE; MOLECULAR LANDSCAPE; FEEDBACK INHIBITION; PROGNOSTIC-FACTOR; GENE-EXPRESSION; MEK INHIBITORS; RAF INHIBITION; TUMOR-GROWTH; COLON-CANCER	BRAF mutations occur in similar to 10% of colorectal cancer (CRC) and are associated with poor prognosis. Inhibitors selective for the BRAF(V600E) oncoprotein, the most common BRAF mutant, elicit only poor response rates in BRAF-mutant CRC as single agents. This unresponsiveness was mechanistically attributed to the loss of negative feedbacks on the epidermal growth factor receptor (EGFR) and initiated clinical trials that combine BRAF (and MEK) inhibitors, either singly or in combination, with the anti-EGFR antibodies cetuximab or panitumumab. First results of these combinatorial studies demonstrated improved efficacy, however, the response rates still were heterogeneous. Here, we show that BRAF inhibition leads to the upregulation of a variety of receptor tyrosine kinases (RTKs) in CRC cell lines, including not only the EGFR, but also human epidermal growth factor receptor (HER) 2 and HER3. Importantly, combination of the BRAF inhibitors (BRAFi) vemurafenib (PLX4032), dabrafenib, or encorafenib with inhibitors dually targeting the EGFR and HER2 (such as lapatinib, canertinib, and afatinib) significantly reduced the metabolic activity and proliferative potential of CRC cells. This re-sensitization was also observed after genetic depletion of HER2 or HER3. Interestingly, BRAF inhibitors did not only upregulate RTKs, but also increased the abundance of the GRB2-associated binders (Gab) 1 and Gab2, two important amplifiers of RTK signaling. An allele-specific shRNA-mediated knockdown of BRAF(V600E) revealed that Gab2 upregulation was directly dependent on the loss of the oncoprotein and was not caused by an "off-target" effect of these kinase inhibitors. Furthermore, Gab2 and Gab2-mediated Shp2 signaling were shown to be functionally important in BRAFi resistance. These findings highlight potential new escape mechanisms to these targeted therapies and indicate that a broad suppression of RTK signaling might be beneficial and should be taken into account in future research addressing targeted therapy in BRAF-mutant CRC.	[Herr, Ricarda; Halbach, Sebastian; Heizmann, Miriam; Brummer, Tilman] Univ Freiburg, Inst Mol Med & Cell Res IMMZ, Signal Transduct Tumour Dev & Drug Resistance Grp, Fac Med, Freiburg, Germany; [Heizmann, Miriam] Univ Freiburg, Fac Biol, Freiburg, Germany; [Busch, Hauke; Boerries, Melanie] Univ Freiburg, Syst Biol Cellular Microenvironm, IMMZ, Fac Med, Freiburg, Germany; [Busch, Hauke] Univ Lubeck, Inst Expt Dermatol, Lubeck, Germany; [Busch, Hauke] Univ Lubeck, Inst Cardiogenet, Lubeck, Germany; [Boerries, Melanie; Brummer, Tilman] German Canc Res Ctr, German Canc Consortium DKTK Partner Site Freiburg, Partner Site Freiburg, Heidelberg, Germany; [Boerries, Melanie; Brummer, Tilman] Univ Freiburg, CCCF, Freiburg, Germany; [Brummer, Tilman] Univ Freiburg, Ctr Biol Signalling Studies BIOSS, Freiburg, Germany	University of Freiburg; University of Freiburg; University of Freiburg; University of Lubeck; University of Lubeck; Helmholtz Association; German Cancer Research Center (DKFZ); University of Freiburg; University of Freiburg	Herr, R; Brummer, T (corresponding author), Univ Freiburg, Inst Mol Med & Cell Res IMMZ, Signal Transduct Tumour Dev & Drug Resistance Grp, Fac Med, Freiburg, Germany.; Brummer, T (corresponding author), German Canc Res Ctr, German Canc Consortium DKTK Partner Site Freiburg, Partner Site Freiburg, Heidelberg, Germany.; Brummer, T (corresponding author), Univ Freiburg, CCCF, Freiburg, Germany.; Brummer, T (corresponding author), Univ Freiburg, Ctr Biol Signalling Studies BIOSS, Freiburg, Germany.	ricarda.herr@mol-med.uni-freiburg.de; tilman.brummer@zbsa.de	Brummer, Tilman/AAA-9428-2020; Halbach, Sebastian/G-4021-2012; Brummer, Tilman/B-6218-2016; Boerries, Melanie/AAM-2602-2021; Busch, Hauke/R-6452-2016	Brummer, Tilman/0000-0003-4387-7905; Halbach, Sebastian/0000-0002-6827-8178; Brummer, Tilman/0000-0003-4387-7905; Busch, Hauke/0000-0003-4763-4521; Griffin, Ricarda/0000-0003-1368-2832	German Research Foundation (DFG) [SFB 850]; Heisenberg professorship [EXC 294 BIOSS]; BMBF [e:Bio 0316184D]; e:Med research and funding concept, DeCaRe [FKZ 01ZX1409B]	German Research Foundation (DFG)(German Research Foundation (DFG)); Heisenberg professorship(German Research Foundation (DFG)); BMBF(Federal Ministry of Education & Research (BMBF)); e:Med research and funding concept, DeCaRe	We thank Martin Kohler for valuable discussions, Roland Rad for sharing MouseT1 cells, and Silke Kowar for expert technical assistance. This work was supported by the German Research Foundation (DFG) through SFB 850, projects B4 (TB) and Z1 (HB and MB), a Heisenberg professorship to TB, EXC 294 BIOSS and the BMBF through e:Bio 0316184D, and MB within the framework of the e:Med research and funding concept, DeCaRe (FKZ 01ZX1409B).	Abel EV, 2013, J CLIN INVEST, V123, P2155, DOI 10.1172/JCI65780; Abreu MTH, 2011, MOL BIOL CELL, V22, P105, DOI 10.1091/mbc.E10-03-0185; Ahronian LG, 2015, CANCER DISCOV, V5, P358, DOI 10.1158/2159-8290.CD-14-1518; Bai RP, 2015, INT J CANCER, V137, P2310, DOI 10.1002/ijc.29607; Batlle E, 2005, NATURE, V435, P1126, DOI 10.1038/nature03626; Bennett HL, 2008, ONCOGENE, V27, P2693, DOI 10.1038/sj.onc.1210928; Bentires-Alj M, 2006, NAT MED, V12, P114, DOI 10.1038/nm1341; Bier D, 2016, CHEMMEDCHEM, V11, P911, DOI 10.1002/cmdc.201500484; Boerries M, 2015, GENOM DATA, V4, P158, DOI 10.1016/j.gdata.2015.04.015; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Brummer T, 2006, J BIOL CHEM, V281, P626, DOI 10.1074/jbc.M509567200; Caenepeel S, 2017, ONCOTARGET, V8, P17795, DOI 10.18632/oncotarget.14855; Cagnol S, 2013, ONCOGENE, V32, P564, DOI 10.1038/onc.2012.88; Carraway KL, 2010, SEMIN CELL DEV BIOL, V21, P936, DOI 10.1016/j.semcdb.2010.09.006; Castellano E, 2013, CANCER CELL, V24, P617, DOI 10.1016/j.ccr.2013.09.012; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Chaussepied M, 2004, MOL CELL, V16, P831, DOI 10.1016/j.molcel.2004.11.003; Chernoff KA, 2009, CLIN CANCER RES, V15, P4288, DOI 10.1158/1078-0432.CCR-09-0280; Clarke CN, 2015, J GASTROINTEST ONCOL, V6, P660, DOI 10.3978/j.issn.2078-6891.2015.077; Connolly K, 2014, CURR ONCOL, V21, pE151, DOI 10.3747/co.21.1661; Corcoran RB, 2015, J CLIN ONCOL, V33, P4023, DOI 10.1200/JCO.2015.63.2471; Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341; Cortina C, 2007, NAT GENET, V39, P1376, DOI 10.1038/ng.2007.11; Daly RJ, 2002, ONCOGENE, V21, P5175, DOI 10.1038/sj.onc.1205522; Das Thakur M, 2013, NATURE, V494, P251, DOI 10.1038/nature11814; Di Nicolantonio F, 2008, J CLIN ONCOL, V26, P5705, DOI 10.1200/JCO.2008.18.0786; Ding CB, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0524-2; Ding CB, 2015, INT J CLIN EXP PATHO, V8, P2779; Duckworth C, 2016, ONCOGENE, V35, P4036, DOI 10.1038/onc.2015.472; Ellebaek S, 2016, INT J CANCER, V139, P2095, DOI 10.1002/ijc.30242; Fattore L, 2015, ONCOTARGET, V6, P24823, DOI 10.18632/oncotarget.4485; Fleuren EDG, 2016, NAT REV CANCER, V16, P83, DOI 10.1038/nrc.2015.18; Fleuren EDG, 2010, INT J CANCER, V127, P1486, DOI 10.1002/ijc.25172; Gala K, 2014, CLIN CANCER RES, V20, P1410, DOI 10.1158/1078-0432.CCR-13-1549; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Hafner C, 2004, CLIN CHEM, V50, P490, DOI 10.1373/clinchem.2003.026849; Halbach S, 2016, LEUKEMIA, V30, P1942, DOI 10.1038/leu.2016.92; Halbach S, 2016, CELL COMMUN SIGNAL, V14, DOI 10.1186/s12964-016-0129-y; Halbach S, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-30; Herr R, 2015, CANCER RES, V75, P216, DOI 10.1158/0008-5472.CAN-13-3686; Hoeben A, 2013, INT J CANCER, V132, P1042, DOI 10.1002/ijc.27763; Hong DS, 2016, CANCER DISCOV, V6, P1352, DOI 10.1158/2159-8290.CD-16-0050; Horst B, 2009, AM J PATHOL, V174, P1524, DOI 10.2353/ajpath.2009.080543; Hugo W, 2015, CELL, V162, P1271, DOI 10.1016/j.cell.2015.07.061; Jubb AM, 2005, CLIN CANCER RES, V11, P5181, DOI 10.1158/1078-0432.CCR-05-0143; Karaman MW, 2008, NAT BIOTECHNOL, V26, P127, DOI 10.1038/nbt1358; Kidger AM, 2016, SEMIN CELL DEV BIOL, V50, P125, DOI 10.1016/j.semcdb.2016.01.009; King AJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067583; Klijn C, 2015, NAT BIOTECHNOL, V33, P306, DOI 10.1038/nbt.3080; Klinger B, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2013.29; Kolch W, 2015, NAT REV CANCER, V15, P515, DOI 10.1038/nrc3983; Kopetz S, 2015, J CLIN ONCOL, V33, P4032, DOI 10.1200/JCO.2015.63.2497; Kugel CH, 2014, CANCER RES, V74, P4122, DOI 10.1158/0008-5472.CAN-14-0464; Little AS, 2013, ONCOGENE, V32, P1207, DOI 10.1038/onc.2012.160; Liu W, 2017, LEUKEMIA, V31, P1415, DOI 10.1038/leu.2016.326; Lynch DK, 2002, EMBO J, V21, P72, DOI 10.1093/emboj/21.1.72; Mao ML, 2013, CLIN CANCER RES, V19, P657, DOI 10.1158/1078-0432.CCR-11-1446; Matsumura T, 2014, ANN SURG ONCOL, V21, pS743, DOI 10.1245/s10434-014-3889-x; Medico E, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8002; Montero-Conde C, 2013, CANCER DISCOV, V3, P520, DOI 10.1158/2159-8290.CD-12-0531; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Norz D, 2015, CELL SIGNAL, V27, P2191, DOI 10.1016/j.cellsig.2015.07.016; Oddo D, 2016, CANCER RES, V76, P4504, DOI 10.1158/0008-5472.CAN-16-0396; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Ortiz-Padilla C, 2013, ONCOGENE, V32, P2696, DOI 10.1038/onc.2012.271; Peng SB, 2015, CANCER CELL, V28, P384, DOI 10.1016/j.ccell.2015.08.002; Prahallad A, 2015, CELL REP, V12, P1978, DOI 10.1016/j.celrep.2015.08.037; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Pratilas CA, 2009, P NATL ACAD SCI USA, V106, P4519, DOI 10.1073/pnas.0900780106; Rad R, 2013, CANCER CELL, V24, P15, DOI 10.1016/j.ccr.2013.05.014; Radic-Sarikas B, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03129-6; Roring M, 2012, EMBO J, V31, P2629, DOI 10.1038/emboj.2012.100; Schwarz LJ, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx065; Smith MP, 2016, CLIN CANCER RES, V22, P5966, DOI 10.1158/1078-0432.CCR-16-0954; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Sundar R, 2017, CANCER DISCOV, V7, P558, DOI 10.1158/2159-8290.CD-17-0087; Tran B, 2011, CANCER-AM CANCER SOC, V117, P4623, DOI 10.1002/cncr.26086; Vincent KM, 2017, ONCOTARGET, V8, P10498, DOI 10.18632/oncotarget.14443; Wang Y, 2012, ONCOGENE, V31, P2512, DOI 10.1038/onc.2011.435; Williams CB, 2015, ONCOTARGETS THER, V8, P3561, DOI 10.2147/OTT.S90766; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Wohrle FU, 2013, LEUKEMIA, V27, P118, DOI 10.1038/leu.2012.222; Wohrle FU, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-22; Wohrle FU, 2009, STRUCTURE, V17, P779, DOI 10.1016/j.str.2009.05.003; Wu XC, 2016, SCI REP-UK, V6, DOI 10.1038/srep19000; Xiang SH, 2017, BIOCHEM BIOPH RES CO, V484, P719, DOI 10.1016/j.bbrc.2017.01.095; Yaeger R, 2015, CLIN CANCER RES, V21, P1313, DOI 10.1158/1078-0432.CCR-14-2779; Yaeger R, 2014, CANCER-AM CANCER SOC, V120, P2316, DOI 10.1002/cncr.28729; Yang L, 2015, J BIOL CHEM, V290, P26627, DOI 10.1074/jbc.M115.667717; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhang ZF, 2010, CARCINOGENESIS, V31, P577, DOI 10.1093/carcin/bgq020	91	26	26	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	12					1576	1593		10.1038/s41388-017-0063-5	http://dx.doi.org/10.1038/s41388-017-0063-5			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GA8YC	29326440				2022-12-17	WOS:000428626700003
J	Ma, D; Chen, X; Zhang, PY; Zhang, H; Wei, LJ; Hu, S; Tang, JZ; Zhou, MT; Xie, C; Ou, R; Xu, Y; Tang, KF				Ma, D.; Chen, X.; Zhang, P-Y; Zhang, H.; Wei, L-J; Hu, S.; Tang, J-Z; Zhou, M-T; Xie, C.; Ou, R.; Xu, Y.; Tang, K-F			Upregulation of the ALDOA/DNA-PK/p53 pathway by dietary restriction suppresses tumor growth	ONCOGENE			English	Article							CANCER-CELL PROLIFERATION; DEPENDENT PROTEIN-KINASE; CATALYTIC SUBUNIT; MODEL ORGANISMS; DNA-DAMAGE; ALDOLASE; PHOSPHORYLATION; ACTIVATION; EXPRESSION; INTERACTS	Dietary restriction (DR) delays the incidence and decreases the growth of various types of tumors; however, the mechanisms responsible for DR-mediated antitumor effects have not been unequivocally identified. Here, we report that DR suppresses xenograft tumor growth by upregulating a novel signaling pathway. DR led to upregulated aldolase A (ALDOA) expression in xenograft tumors. ALDOA physically interacted with the catalytic subunit of DNA-dependent protein kinase (DNA-PK) and promoted DNA-PK activation. Activated DNA-PK phosphorylated p53 and increased its activity. Although ALDOA can function as an oncogene in cultured cells, it can also activate the tumor suppressor p53. Thus, ALDOA overexpression in the presence of p53 suppressed xenograft tumor growth; however, when p53 was suppressed, ALDOA overexpression promoted xenograft tumor growth. Moreover, we demonstrated that p53 suppression inhibited the antitumor effects of DR. Our results indicate that upregulation of the ALDOA/DNA-PK/p53 pathway is a mechanism accounting for the antitumor effects of DR.	[Ma, D.; Chen, X.; Zhang, P-Y; Zhang, H.; Wei, L-J; Tang, K-F] Wenzhou Med Univ, Affiliated Hosp 1, Digest Canc Ctr, Wenzhou 325015, Zhejiang, Peoples R China; [Ma, D.; Chen, X.; Zhang, P-Y; Zhang, H.; Wei, L-J; Xu, Y.; Tang, K-F] Wenzhou Med Univ, Affiliated Hosp 1, Inst Translat Med, Wenzhou, Peoples R China; [Hu, S.] Wenzhou Med Univ, Inst Genom Med, Wenzhou, Peoples R China; [Tang, J-Z] Third Mil Med Univ, Daping Hosp, Res Inst Surg, Chongqing, Peoples R China; [Zhou, M-T] Wenzhou Med Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Wenzhou, Peoples R China; [Xie, C.] Wenzhou Med Univ, Affiliated Hosp 1, Dept Radiat Oncol, Wenzhou, Zhejiang, Peoples R China; [Ou, R.] Wenzhou Med Univ, Affiliated Hosp 1, Dept Gynecol, Wenzhou, Peoples R China	Wenzhou Medical University; Wenzhou Medical University; Wenzhou Medical University; Army Medical University; Wenzhou Medical University; Wenzhou Medical University; Wenzhou Medical University	Tang, KF (corresponding author), Wenzhou Med Univ, Affiliated Hosp 1, Digest Canc Ctr, Wenzhou 325015, Zhejiang, Peoples R China.	tang_kaifu@wmu.edu.cn		Hu, Shanshan/0000-0003-4904-0583; Tang, Kai-Fu/0000-0002-2657-4163; Chen, Xiao/0000-0001-6155-6035; Zhou, Mengtao/0000-0002-2455-250X; Tang, Kai-Fu/0000-0002-6892-1207; Zhou, Meng-Tao/0000-0002-0613-1656	National Natural Science Foundation of China [81572780]; Zhejiang Provincial Natural Sciences Foundation [LZ16H160004]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Zhejiang Provincial Natural Sciences Foundation	We thank Bin Tan (Chongqing Medical University, Chongqing, China), as well as Guiling Li, Tongke Chen and Yixiang Han (Wenzhou Medical University, Wenzhou, China), for providing technical assistance. This work was supported by the National Natural Science Foundation of China (Grant No. 81572780) and the Zhejiang Provincial Natural Sciences Foundation (Grant No. LZ16H160004).	Anzo M, 2008, CANCER RES, V68, P3342, DOI 10.1158/0008-5472.CAN-07-3165; Buscaglia CA, 2006, J BIOL CHEM, V281, P1324, DOI 10.1074/jbc.M506346200; Caspi M, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-164; Concepcion J, 2009, COMB CHEM HIGH T SCR, V12, P791, DOI 10.2174/138620709789104915; Curry NL, 2013, CANCER DISCOV, V3, P908, DOI 10.1158/2159-8290.CD-12-0507; Ding Q, 2003, MOL CELL BIOL, V23, P5836, DOI 10.1128/MCB.23.16.5836-5848.2003; Du S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085804; Fontana L, 2015, CELL, V161, P106, DOI 10.1016/j.cell.2015.02.020; Goodwin JF, 2014, CANCER DISCOV, V4, P1126, DOI 10.1158/2159-8290.CD-14-0358; Hakvoort TBM, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.216986; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Kalaany NY, 2009, NATURE, V458, P725, DOI 10.1038/nature07782; Kao AW, 1999, J BIOL CHEM, V274, P17742, DOI 10.1074/jbc.274.25.17742; Kim JH, 2002, BIOCHEMISTRY-US, V41, P3414, DOI 10.1021/bi015700a; Kim K, 2012, ONCOGENE, V31, P4290, DOI 10.1038/onc.2011.605; Lee C, 2011, ONCOGENE, V30, P3305, DOI 10.1038/onc.2011.91; Lessa RC, 2013, HEAD NECK-J SCI SPEC, V35, P1475, DOI 10.1002/hed.23169; Lew CR, 2012, J BIOL CHEM, V287, P42554, DOI 10.1074/jbc.M112.405969; Lincet H, 2015, ONCOGENE, V34, P3751, DOI 10.1038/onc.2014.320; Longo VD, 2014, CELL METAB, V19, P181, DOI 10.1016/j.cmet.2013.12.008; Meynet O, 2014, TRENDS MOL MED, V20, P419, DOI 10.1016/j.molmed.2014.05.001; Moreschi C, 1909, Z IMMUNITATSFORSCH, V2, P651; PENHOET E, 1966, P NATL ACAD SCI USA, V56, P1275, DOI 10.1073/pnas.56.4.1275; POGSON CI, 1967, NATURE, V216, P156, DOI 10.1038/216156a0; Rous P, 1914, J EXP MED, V20, P433, DOI 10.1084/jem.20.5.433; SCHAPIRA F, 1966, ENZYMOL BIOL CLIN, V7, P98, DOI 10.1159/000457208; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SIBLEY JA, 1955, CANCER RES, V15, P306; Spindler SR, 2001, ANN NY ACAD SCI, V928, P296; Tang KF, 2008, J CELL BIOL, V182, P233, DOI 10.1083/jcb.200801169; TANNENBAUM A, 1953, CANCER RES, V13, P532; WEINDRUCH R, 1982, SCIENCE, V215, P1415, DOI 10.1126/science.7063854; Wu JM, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.289; Wu JM, 2012, CARCINOGENESIS, V33, P519, DOI 10.1093/carcin/bgr304; Zhang PY, 2016, NUCLEIC ACIDS RES, V44, P3629, DOI 10.1093/nar/gkv1504	36	26	27	4	21	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2018	37	8					1041	1048		10.1038/onc.2017.398	http://dx.doi.org/10.1038/onc.2017.398			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FX2QD	29084207				2022-12-17	WOS:000425905700007
J	D'Abronzo, LS; Bose, S; Crapuchettes, ME; Beggs, RE; Vinall, RL; Tepper, CG; Siddiqui, S; Mudryj, M; Melgoza, FU; Durbin-Johnson, BP; White, RWD; Ghosh, PM				D'Abronzo, L. S.; Bose, S.; Crapuchettes, M. E.; Beggs, R. E.; Vinall, R. L.; Tepper, C. G.; Siddiqui, S.; Mudryj, M.; Melgoza, F. U.; Durbin-Johnson, B. P.; White, R. W. deVere; Ghosh, P. M.			The androgen receptor is a negative regulator of eIF4E phosphorylation at S209: implications for the use of mTOR inhibitors in advanced prostate cancer	ONCOGENE			English	Article							INITIATION-FACTOR 4E; CELL-PROLIFERATION; MAMMALIAN TARGET; RAPAMYCIN; TRANSLATION; GROWTH; ACTIVATION; PROTEIN; BICALUTAMIDE; MNK1	The antiandrogen bicalutamide is widely used in the treatment of advanced prostate cancer (PCa) in many countries, but its effect on castration-resistant PCa (CRPC) is limited. We previously showed that resistance to bicalutamide results from activation of mechanistic target of rapamycin (mTOR). Interestingly, clinical trials testing combinations of the mTOR inhibitor RAD001 with bicalutamide were effective in bicalutamide-naive CRPC patients, but not in bicalutamide-pretreated ones. Here we investigate causes for their difference in response. Evaluation of CRPC cell lines identified resistant vs sensitive in vitro models, and revealed that increased eIF4E(S209) phosphorylation is associated with resistance to the combination. We confirmed using a human-derived tumor xenograft mouse model that bicalutamide pre-treatment is associated with an increase in eIF4E(S209) phosphorylation. Thus, AR suppressed eukaryotic initiation factor 4E (eIF4E) phosphorylation, while the use of antiandrogens relieved this suppression, thereby triggering its increase. Additional investigation in human prostatectomy samples showed that increased eIF4E phosphorylation strongly correlated with the cell proliferation marker Ki67. Small interfering RNA-mediated knockdown (k/d) of eIF4E-sensitized CRPC cells to RAD001+bicalutamide, whereas eIF4E overexpression induced resistance. Inhibition of eIF4E phosphorylation by treatment with CGP57380 (an inhibitor of mitogen-activated protein kinase-interacting serine-threonine kinases MAP kinase-interacting kinase 1 (Mnk1/2), the eIF4E upstream kinase) or inhibitors of extracellular signal-regulated kinase 1/2 (ERK1/2), the upstream kinase-regulating Mnk1/2, also sensitized CRPC cells to RAD001+ bicalutamide. Examination of downstream targets of eIF4E-mediated translation, including survivin, demonstrated that eIF4E(S209) phosphorylation increased cap-independent translation, whereas its inhibition restored cap-dependent translation, which could be inhibited by mTOR inhibitors. Thus, our results demonstrate that while combinations of AR and mTOR inhibitors were effective in suppressing tumor growth by inhibiting both AR-induced transcription and mTOR-induced cap-dependent translation, pre-treatment with AR antagonists including bicalutamide increased eIF4E phosphorylation that induced resistance to combinations of AR and mTOR inhibitors by inducing cap-independent translation. We conclude that this resistance can be overcome by inhibiting eIF4E phosphorylation with Mnk1/2 or ERK1/2 inhibitors.	[D'Abronzo, L. S.; Crapuchettes, M. E.; Beggs, R. E.; Siddiqui, S.; Melgoza, F. U.; Ghosh, P. M.] Univ Calif Davis, VA Northern Calif Hlth Care Syst, Sacramento, CA 95817 USA; [D'Abronzo, L. S.; Bose, S.; Vinall, R. L.; White, R. W. deVere; Ghosh, P. M.] Univ Calif Davis, Sch Med, Dept Urol, 4860 Y St,Suite 3500, Sacramento, CA 95817 USA; [Vinall, R. L.] Calif Northstate Univ, Coll Pharm, Elk Grove, CA USA; [Tepper, C. G.; Ghosh, P. M.] Univ Calif Davis, Dept Biochem & Mol Med, Sacramento, CA 95817 USA; [Mudryj, M.] Univ Calif Davis, Dept Med Microbiol & Immunol, Sacramento, CA 95817 USA; [Durbin-Johnson, B. P.] Univ Calif Davis, Div Biostat, Dept Publ Hlth, Sacramento, CA 95817 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis	Ghosh, PM (corresponding author), Univ Calif Davis, Sch Med, Dept Urol, 4860 Y St,Suite 3500, Sacramento, CA 95817 USA.	paghosh@ucdavis.edu	Tepper, Clifford G/H-6527-2011; Vinall, Ruth/L-7026-2019		Department of Veterans Affairs [I01BX000400]; National Institutes of Health [R01CA133209, R01CA185509]; NATIONAL CANCER INSTITUTE [R01CA133209, P30CA093373, R01CA185509] Funding Source: NIH RePORTER; Veterans Affairs [I01BX003458, I01BX000400] Funding Source: NIH RePORTER	Department of Veterans Affairs(US Department of Veterans Affairs); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Veterans Affairs(US Department of Veterans Affairs)	We thank Novartis Pharmaceuticals for the gift of RAD001. We also thank Stephanie Soares, Department of Urology, University of California Davis, School of Medicine (Sacramento, CA, USA), for the construction of the tissue microarrays used in this study, and Yu Wang, Department of Urology, for assistance with mice experiments. Human PSA-luciferase construct was kindly provided by Dr XuBao Shi, University of California Davis, Department of Urology. CWR-R1 cells were provided by Dr Elizabeth Wilson (University of North Carolina), pRNS1-1 cells were from Dr Johng Rhim, University of the Health Sciences (Bethesda, MD, USA), whereas PC-346C cells were from Dr WM van Weerden, Josephine Nefkens Institute (Erasmus MC, Rotterdam, Netherlands). We also thank Dr Xinbin Chen (UC Davis School of Veterinary Medicine) for the pRL-HCV-FL plasmid, and Maitreyee K Jathal and Thomas M Steele (UC Davis, Department of Urology) for samples of 22Rv1 xenograft tumors. This work was supported by a Biomedical Laboratory Research and Development (BLRD) Merit Award (I01BX000400, to PMG) from the Department of Veterans Affairs, and by Awards R01CA133209 (to PMG) and R01CA185509 (to PMG) from the National Institutes of Health.	Amato RJ, 2008, CLIN GENITOURIN CANC, V6, P97, DOI 10.3816/CGC.2008.n.015; Bianchini A, 2008, CARCINOGENESIS, V29, P2279, DOI 10.1093/carcin/bgn221; Canedo CS, 2010, AM J PHYSIOL-ENDOC M, V298, pE761, DOI 10.1152/ajpendo.00421.2009; Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008; Chamie K, 2008, AM J TRANSPLANT, V8, P2668, DOI 10.1111/j.1600-6143.2008.02430.x; Chen LQ, 2010, CANCER RES, V70, P5994, DOI 10.1158/0008-5472.CAN-09-4440; Chen MH, 2011, CANCER CELL, V20, P173, DOI 10.1016/j.ccr.2011.07.013; Chen RY, 2001, J BIOL CHEM, V276, P31858, DOI 10.1074/jbc.C100271200; Chow H, 2016, CANCER-AM CANCER SOC, V122, P1897, DOI 10.1002/cncr.29927; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Edlind MP, 2014, ASIAN J ANDROL, V16, P378, DOI 10.4103/1008-682X.122876; Fang Z, 2012, J BIOL CHEM, V287, P2090, DOI 10.1074/jbc.M111.323303; Furic L, 2010, P NATL ACAD SCI USA, V107, P14134, DOI 10.1073/pnas.1005320107; Ghosh PM, 2005, ENDOCR-RELAT CANCER, V12, P119, DOI 10.1677/erc.1.00835; Gingras AC, 2001, GENE DEV, V15, P2852; Goetz C, 2010, MOL THER, V18, P1937, DOI 10.1038/mt.2010.145; Graff JR, 2009, CANCER RES, V69, P3866, DOI 10.1158/0008-5472.CAN-08-3472; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Idris AI, 2012, METHODS MOL BIOL, V816, P545, DOI 10.1007/978-1-61779-415-5_34; Lachance PED, 2002, MOL CELL BIOL, V22, P1656, DOI 10.1128/MCB.22.6.1656-1663.2002; MacVicar GR, 2013, CURR OPIN ONCOL, V25, P252, DOI 10.1097/CCO.0b013e32835ff161; Mbatia HW, 2015, J MED CHEM, V58, P1900, DOI 10.1021/jm501792c; Mikhailova M, 2008, ADV EXP MED BIOL, V617, P397, DOI 10.1007/978-0-387-69080-3_38; Mooso Benjamin, 2010, Genes Cancer, V1, P927, DOI 10.1177/1947601910385450; Mooso BA, 2012, ENDOCR-RELAT CANCER, V19, P759, DOI 10.1530/ERC-12-0171; Nakabayashi M, 2012, BJU INT, V110, P1729, DOI 10.1111/j.1464-410X.2012.11456.x; R Core Team, 2020, R LANG ENV STAT COMP, DOI DOI 10.1002/ECY.3000; Ramamurthy VP, 2015, ONCOTARGET, V6, P3195, DOI 10.18632/oncotarget.3084; Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009; Schayowitz A, 2010, BRIT J CANCER, V103, P1001, DOI 10.1038/sj.bjc.6605882; Sekiyama N, 2015, P NATL ACAD SCI USA, V112, pE4036, DOI 10.1073/pnas.1512118112; Shi XB, 2007, PROSTATE, V67, P591, DOI 10.1002/pros.20544; Shi YJ, 2005, J BIOL CHEM, V280, P10964, DOI 10.1074/jbc.M407874200; Shveygert M, 2010, MOL CELL BIOL, V30, P5160, DOI 10.1128/MCB.00448-10; Sonenberg N, 2008, BIOCHEM CELL BIOL, V86, P178, DOI 10.1139/O08-034; Squillace RM, 2012, INT J ONCOL, V41, P425, DOI 10.3892/ijo.2012.1487; Stead RL, 2013, FEBS LETT, V587, P2623, DOI 10.1016/j.febslet.2013.06.045; Sun SY, 2005, CANCER RES, V65, P7052, DOI 10.1158/0008-5472.CAN-05-0917; Ueda T, 2004, MOL CELL BIOL, V24, P6539, DOI 10.1128/MCB.24.15.6539-6549.2004; Ueda T, 2010, P NATL ACAD SCI USA, V107, P13984, DOI 10.1073/pnas.1008136107; Wang XR, 2007, MOL CELL BIOL, V27, P7405, DOI 10.1128/MCB.00760-07; Wang Y, 2008, ONCOGENE, V27, P7106, DOI 10.1038/onc.2008.318; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Wen QY, 2016, ONCOTARGET, V7, P27787, DOI 10.18632/oncotarget.8497; Wendel HG, 2007, GENE DEV, V21, P3232, DOI 10.1101/gad.1604407; Wu Y, 2010, ANTICANCER RES, V30, P3895; Zhang WS, 2009, CANCER RES, V69, P7466, DOI 10.1158/0008-5472.CAN-08-4385; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	48	26	27	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	2017	36	46					6359	6373		10.1038/onc.2017.233	http://dx.doi.org/10.1038/onc.2017.233			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM9WN	28745319	Green Accepted, Green Submitted			2022-12-17	WOS:000415622900001
J	Xie, G; Liu, X; Zhang, Y; Li, W; Liu, S; Chen, Z; Xu, B; Yang, J; He, L; Zhang, Z; Jin, T; Yi, X; Sun, L; Shang, Y; Liang, J				Xie, G.; Liu, X.; Zhang, Y.; Li, W.; Liu, S.; Chen, Z.; Xu, B.; Yang, J.; He, L.; Zhang, Z.; Jin, T.; Yi, X.; Sun, L.; Shang, Y.; Liang, J.			UTX promotes hormonally responsive breast carcinogenesis through feed-forward transcription regulation with estrogen receptor	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; INTEGRATIVE GENOMICS VIEWER; H3K27ME3 DEMETHYLASE UTX; CANCER-CELLS; GENE-REGULATION; TUMOR MICROENVIRONMENT; ER-ALPHA; POLYCOMB; JMJD3; METHYLATION	UTX is implicated in embryonic development and lineage specification. However, how this X-linked histone demethylase contributes to the occurrence and progression of breast cancer remains to be clarified. Here we report that UTX is physically associated with estrogen receptor (ER) and functions in ER-regulated transcription. We showed that UTX coordinates with JHDM1D and CBP to direct H3K27 methylation-acetylation transition and to create a permissive chromatin state on ER targets. Genome-wide analysis of the transcriptional targets of UTX by ChIP-seq identified a set of genes such as chemokine receptor CXCR4 that are intimately involved in breast cancer tumorigenesis and metastasis. We demonstrated that UTX promotes the proliferation and migration of ER+ breast cancer cells. Interestingly, UTX itself is transactivated by ER, forming a feed-forward loop in the regulation of hormone response. Indeed, UTX is upregulated during ER+ breast cancer progression, and the expression level of UTX is positively correlated with that of CXCR4 and negatively correlated with the overall survival of ER+ breast cancer patients. Our study identified a feed-forward loop between UTX and ER in the regulation of hormonally responsive breast carcinogenesis, supporting the pursuit of UTX as an emerging therapeutic target for the intervention of certain ER+ breast cancer with specific epigenetic vulnerability.	[Xie, G.; Zhang, Y.; Li, W.; Liu, S.; Chen, Z.; Xu, B.; Yang, J.; He, L.; Zhang, Z.; Jin, T.; Yi, X.; Sun, L.; Shang, Y.; Liang, J.] Peking Univ, Dept Biochem & Mol Biol, Key Lab Carcinogenesis & Translat Res, Sch Basic Med Sci,Minist Educ,Hlth Sci Ctr, 38 Xueyuan Rd, Beijing 100191, Peoples R China; [Liu, X.; Shang, Y.] Tianjin Med Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Tianjin Key Lab Med Epigenet, Tianjin, Peoples R China; [Shang, Y.] Capital Med Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Beijing, Peoples R China	Peking University; Tianjin Medical University; Capital Medical University	Liang, J (corresponding author), Peking Univ, Dept Biochem & Mol Biol, Key Lab Carcinogenesis & Translat Res, Sch Basic Med Sci,Minist Educ,Hlth Sci Ctr, 38 Xueyuan Rd, Beijing 100191, Peoples R China.	liang_jing@bjmu.edu.cn	Chen, Zhe/AAA-3235-2020	Chen, Zhe/0000-0002-5303-9879; Xie, Guojia/0000-0002-8250-6157	Ministry of Science and Technology of China [2014CB542004]; National Natural Science Foundation of China [31371301, 81572771, 91219201, 81130048]	Ministry of Science and Technology of China(Ministry of Science and Technology, China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants (973 Program: 2014CB542004 to JL and YS) from the Ministry of Science and Technology of China, and grants (31371301 and 81572771 to JL and 91219201 and 81130048 to YS) from the National Natural Science Foundation of China.	Agger K, 2007, NATURE, V449, P731, DOI 10.1038/nature06145; Benyoucef A, 2016, GENE DEV, V30, P508, DOI 10.1101/gad.276790.115; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chen YC, 2015, HEPATOLOGY, V61, P1591, DOI 10.1002/hep.27665; Choi HJ, 2015, EMBO REP, V16, P1288, DOI 10.15252/embr.201540244; Cui YK, 2006, MOL ENDOCRINOL, V20, P2020, DOI 10.1210/me.2005-0063; De Santa F, 2007, CELL, V130, P1083, DOI 10.1016/j.cell.2007.08.019; Ezponda T, 2014, CLIN CANCER RES, V20, P5001, DOI 10.1158/1078-0432.CCR-13-2499; Guo F, 2016, ONCOGENE, V35, P816, DOI 10.1038/onc.2015.139; Harburg GC, 2011, J MAMMARY GLAND BIOL, V16, P257, DOI 10.1007/s10911-011-9225-1; Hart CD, 2015, NAT REV CLIN ONCOL, V12, P541, DOI 10.1038/nrclinonc.2015.99; Hong SH, 2007, P NATL ACAD SCI USA, V104, P18439, DOI 10.1073/pnas.0707292104; Ichinose H, 1997, GENE, V188, P95, DOI 10.1016/S0378-1119(96)00785-8; Jin QH, 2011, EMBO J, V30, P249, DOI 10.1038/emboj.2010.318; Ju BG, 2006, SCIENCE, V312, P1798, DOI 10.1126/science.1127196; Kim JH, 2014, CANCER RES, V74, P1705, DOI 10.1158/0008-5472.CAN-13-1896; Kim KH, 2016, NAT MED, V22, P128, DOI 10.1038/nm.4036; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Lan F, 2007, NATURE, V449, P689, DOI 10.1038/nature06192; Lavery DN, 2005, BIOCHEM J, V391, P449, DOI 10.1042/BJ20050872; Lee MG, 2007, SCIENCE, V318, P447, DOI 10.1126/science.1149042; Lee YH, 2014, TUMOR BIOL, V35, P7699, DOI 10.1007/s13277-014-2027-5; Liang J, 2013, ANNU REV PHYSIOL, V75, P225, DOI 10.1146/annurev-physiol-030212-183708; Liu T, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-8-r83; Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784; Mohammed H, 2013, CELL REP, V3, P342, DOI 10.1016/j.celrep.2013.01.010; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Ntziachristos P, 2014, NATURE, V514, P513, DOI 10.1038/nature13605; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Park UH, 2016, ONCOGENE, V35, P3742, DOI 10.1038/onc.2015.443; Ratajczak MZ, 2006, LEUKEMIA, V20, P1915, DOI 10.1038/sj.leu.2404357; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Rhodes LV, 2011, CANCER RES, V71, P603, DOI 10.1158/0008-5472.CAN-10-3185; Ringner M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017911; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Rocha-Viegas L, 2014, MOL CELL BIOL, V34, P3765, DOI 10.1128/MCB.00839-14; Scala S, 2015, CLIN CANCER RES, V21, P4278, DOI 10.1158/1078-0432.CCR-14-0914; Schuettengruber B, 2007, CELL, V128, P735, DOI 10.1016/j.cell.2007.02.009; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shi L, 2011, P NATL ACAD SCI USA, V108, P7541, DOI 10.1073/pnas.1017374108; Simons SS, 2013, MOL CELL ENDOCRINOL, V376, P81, DOI 10.1016/j.mce.2013.06.007; Smith E, 2014, NAT STRUCT MOL BIOL, V21, P210, DOI 10.1038/nsmb.2784; Smith MCP, 2004, CANCER RES, V64, P8604, DOI 10.1158/0008-5472.CAN-04-1844; Svotelis A, 2011, EMBO J, V30, P3947, DOI 10.1038/emboj.2011.284; Szasz AM, 2016, ONCOTARGET, V7, P49322, DOI 10.18632/oncotarget.10337; Teicher BA, 2010, CLIN CANCER RES, V16, P2927, DOI 10.1158/1078-0432.CCR-09-2329; Thorvaldsdottir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017; Tsukada YI, 2010, GENE DEV, V24, P432, DOI 10.1101/gad.1864410; Van der Meulen J, 2015, BLOOD, V125, P13, DOI 10.1182/blood-2014-05-577270; Van der Meulen J, 2014, EPIGENETICS-US, V9, P658, DOI 10.4161/epi.28298; van Haaften G, 2009, NAT GENET, V41, P521, DOI 10.1038/ng.349; Wade MA, 2015, NUCLEIC ACIDS RES, V43, P196, DOI 10.1093/nar/gku1298; Wang JK, 2010, GENE DEV, V24, P327, DOI 10.1101/gad.1882610; Wu HJ, 2005, NATURE, V438, P981, DOI 10.1038/nature04225; Xu C, 2015, DRUG DES DEV THER, V9, P4953, DOI 10.2147/DDDT.S84932; Yu YC, 2014, DNA CELL BIOL, V33, P543, DOI 10.1089/dna.2013.2289; Zhang H, 2004, GENE DEV, V18, P1753, DOI 10.1101/gad.1194704; Zhang H, 2006, EMBO J, V25, P4223, DOI 10.1038/sj.emboj.7601306; Zhang XHF, 2013, CLIN CANCER RES, V19, P6389, DOI 10.1158/1078-0432.CCR-13-0838; Zwart W, 2011, EMBO J, V30, P4764, DOI 10.1038/emboj.2011.368	62	26	27	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2017	36	39					5497	5511		10.1038/onc.2017.157	http://dx.doi.org/10.1038/onc.2017.157			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FI4RG	28534508				2022-12-17	WOS:000411960500006
J	Wald, JH; Hatakeyama, J; Printsev, I; Cuevas, A; Fry, WHD; Saldana, MJ; VanderVorst, K; Rowson-Hodel, A; Angelastro, JM; Sweeney, C; Carraway, KL				Wald, J. H.; Hatakeyama, J.; Printsev, I.; Cuevas, A.; Fry, W. H. D.; Saldana, M. J.; VanderVorst, K.; Rowson-Hodel, A.; Angelastro, J. M.; Sweeney, C.; Carraway, K. L., III			Suppression of planar cell polarity signaling and migration in glioblastoma by Nrdp1-mediated Dvl polyubiquitination	ONCOGENE			English	Article							E3 UBIQUITIN LIGASE; DISHEVELLED DEP DOMAIN; NEURAL-TUBE DEFECTS; CANCER CELLS; NRDP1; PROTEIN; MECHANISMS; INVASION; RECEPTOR; CATENIN	The lethality of the aggressive brain tumor glioblastoma multiforme (GBM) results in part from its strong propensity to invade surrounding normal brain tissue. Although oncogenic drivers such as epidermal growth factor receptor activation and Phosphatase and Tensin homolog inactivation are thought to promote the motility and invasiveness of GBM cells via phosphatidylinostitol 3-kinase activation, other unexplored mechanisms may also contribute to malignancy. Here we demonstrate that several components of the planar cell polarity (PCP) arm of non-canonical Wnt signaling including VANGL1, VANGL2 and FZD7 are transcriptionally upregulated in glioma and correlate with poorer patient outcome. Knockdown of the core PCP pathway component VANGL1 suppresses the motility of GBM cell lines, pointing to an important mechanistic role for this pathway in glioblastoma malignancy. We further observe that restoration of Nrdp1, a RING finger type E3 ubiquitin ligase whose suppression in GBM also correlates with poor prognosis, reduces GBM cell migration and invasiveness by suppressing PCP signaling. Our observations indicate that Nrdp1 physically interacts with the Vangl1 and Vangl2 proteins to mediate the K63-linked polyubiquitination of the Dishevelled, Egl-10 and Pleckstrin (DEP) domain of the Wnt pathway protein Dishevelled (Dvl). Ubiquitination hinders Dvl binding to phosphatidic acid, an interaction necessary for efficient Dvl recruitment to the plasma membrane upon Wnt stimulation of Fzd receptor and for the propagation of downstream signals. We conclude that the PCP pathway contributes significantly to the motility and hence the invasiveness of GBM cells, and that Nrdp1 acts as a negative regulator of PCP signaling by inhibiting Dvl through a novel polyubiquitination mechanism. We propose that the upregulation of core PCP components, together with the loss of the key negative regulator Nrdp1, act coordinately to promote GBM invasiveness and malignancy.	[Wald, J. H.; Hatakeyama, J.; Printsev, I.; Cuevas, A.; Fry, W. H. D.; Saldana, M. J.; VanderVorst, K.; Rowson-Hodel, A.; Sweeney, C.; Carraway, K. L., III] Univ Calif Davis, Sch Med, Dept Biochem & Mol Med, Sacramento, CA 95817 USA; [Wald, J. H.; Hatakeyama, J.; Printsev, I.; Cuevas, A.; Fry, W. H. D.; Saldana, M. J.; VanderVorst, K.; Rowson-Hodel, A.; Sweeney, C.; Carraway, K. L., III] Univ Calif Davis, Sch Med, UC Davis Comprehens Canc Ctr, Sacramento, CA 95817 USA; [Angelastro, J. M.] Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis	Carraway, KL (corresponding author), Univ Calif Davis, Sch Med, Dept Biochem & Mol Med, Res Bldg 3,Room 1100B,4645 2nd Ave, Sacramento, CA 95817 USA.	klcarraway@ucdavis.edu	Rowson-Hodel, Ashley/AAE-2619-2022	Rowson-Hodel, Ashley/0000-0003-0531-9929; Cuevas-Navarro, Antonio/0000-0001-6208-6944; Hatakeyama, Jason/0000-0001-8690-5107	NIH [CA123541, CA166412, CA118384, CA165758, CA165546]; DoD BCRP fellowship [W81XWH-10-1-0069]; NCI [P30CA093373]; NATIONAL CANCER INSTITUTE [R01CA166412, R01CA118384, F31CA165546, P30CA093373, F31CA165758, R01CA123541] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DoD BCRP fellowship; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	These studies were supported by NIH grants CA123541 (KLC), CA166412 (KLC) and CA118384 (CS), NIH fellowships CA165758 (JH) and CA165546 (IP), DoD BCRP fellowship W81XWH-10-1-0069 (JHW), and NCI P30CA093373 (Cancer Center Support Grant-FACS core). We thank Drs Paul Knoepfler, Madelon Maurice and Hiroaki Miki for kindly providing reagents and cell lines.	Anastas JN, 2012, ONCOGENE, V31, P3696, DOI 10.1038/onc.2011.528; Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419; Andersson U, 2004, ACTA NEUROPATHOL, V108, P135, DOI 10.1007/s00401-004-0875-6; Cao ZW, 2007, MOL CELL BIOL, V27, P2180, DOI 10.1128/MCB.01245-06; Chen LQ, 2010, CANCER RES, V70, P5994, DOI 10.1158/0008-5472.CAN-09-4440; Courbard JR, 2009, DEV BIOL, V333, P67, DOI 10.1016/j.ydbio.2009.06.024; de Groot REA, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004985; Diamonti AJ, 2002, P NATL ACAD SCI USA, V99, P2866, DOI 10.1073/pnas.052709799; Eke I, 2012, INT J RADIAT ONCOL, V84, pE515, DOI 10.1016/j.ijrobp.2012.06.012; Fry WHD, 2011, MOL CELL BIOL, V31, P3009, DOI 10.1128/MCB.05105-11; Funato Y, 2010, CURR BIOL, V20, P1945, DOI 10.1016/j.cub.2010.09.065; Gao B, 2011, DEV CELL, V20, P163, DOI 10.1016/j.devcel.2011.01.001; Gao C, 2010, CELL SIGNAL, V22, P717, DOI 10.1016/j.cellsig.2009.11.021; Gonzalez-Sancho JM, 2004, MOL CELL BIOL, V24, P4757, DOI 10.1128/MCB.24.11.4757-4768.2004; Haglund K, 2005, EMBO J, V24, P3353, DOI 10.1038/sj.emboj.7600808; Hatakeyama J, 2014, ENDOCR-RELAT CANCER, V21, pR345, DOI 10.1530/ERC-14-0141; Huang Z, 2010, PROTEIN CELL, V1, P638, DOI 10.1007/s13238-010-0078-y; Huse JT, 2013, ANNU REV MED, V64, P59, DOI 10.1146/annurev-med-100711-143028; Ingalla EQ, 2010, J BIOL CHEM, V285, P28691, DOI 10.1074/jbc.M110.127977; Jiang YS, 2015, TUMOR BIOL, V36, P1129, DOI 10.1007/s13277-014-2726-y; Kamino M, 2011, CANCER SCI, V102, P540, DOI 10.1111/j.1349-7006.2010.01815.x; Lee KH, 2015, ONCOTARGET, V6, P3240, DOI 10.18632/oncotarget.3087; Lewandowski KT, 2014, J CELL SCI, V127, P315, DOI 10.1242/jcs.129148; Luga V, 2012, CELL, V151, P1542, DOI 10.1016/j.cell.2012.11.024; Luk SK, 2012, EUR J CANCER, V48, P149, DOI 10.1016/j.ejca.2011.09.006; Montcouquiol M, 2006, J NEUROSCI, V26, P5265, DOI 10.1523/JNEUROSCI.4680-05.2006; Murdoch JN, 2001, HUM MOL GENET, V10, P2593, DOI 10.1093/hmg/10.22.2593; Ostrom QT, 2013, NEURO-ONCOLOGY, V15, P1, DOI 10.1093/neuonc/not151; Paw I, 2015, CANCER LETT, V362, P1, DOI 10.1016/j.canlet.2015.03.015; Pellegrin S, 2008, CURR PROTOC CELL BIO, V38, DOI DOI 10.1002/0471143030.CB1408S38; Peng Y, 2012, CURR TOP DEV BIOL, V101, P33, DOI 10.1016/B978-0-12-394592-1.00002-8; Printsev I, 2014, J BIOL CHEM, V289, P8570, DOI 10.1074/jbc.M113.527036; Qiu XB, 2004, EMBO J, V23, P800, DOI 10.1038/sj.emboj.7600075; Sewduth RN, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5832; Shi HL, 2015, J NEURO-ONCOL, V124, P357, DOI 10.1007/s11060-015-1851-9; Shi HL, 2014, IUBMB LIFE, V66, P704, DOI 10.1002/iub.1320; Simons M, 2009, NAT CELL BIOL, V11, P286, DOI 10.1038/ncb1836; Sun LX, 2006, CANCER CELL, V9, P287, DOI 10.1016/j.ccr.2006.03.003; Tauriello DVF, 2012, P NATL ACAD SCI USA, V109, pE812, DOI 10.1073/pnas.1114802109; Tauriello DVF, 2010, CELL CYCLE, V9, P3700, DOI 10.4161/cc.9.18.13204; Tauriello DVF, 2010, MOL CELL, V37, P607, DOI 10.1016/j.molcel.2010.01.035; Thakkar JP, 2014, CANCER EPIDEM BIOMAR, V23, P1985, DOI 10.1158/1055-9965.EPI-14-0275; Torban E, 2008, P NATL ACAD SCI USA, V105, P3449, DOI 10.1073/pnas.0712126105; Torban E, 2012, CURR TOP DEV BIOL, V101, P237, DOI 10.1016/B978-0-12-394592-1.00005-3; Trinh J., 2009, THESIS; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wong HC, 2000, NAT STRUCT BIOL, V7, P1178; Wu XL, 2004, MOL CELL BIOL, V24, P7748, DOI 10.1128/MCB.24.17.7748-7757.2004; Yen L, 2006, CANCER RES, V66, P11279, DOI 10.1158/0008-5472.CAN-06-2319	49	26	26	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	2017	36	36					5158	5167		10.1038/onc.2017.126	http://dx.doi.org/10.1038/onc.2017.126			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF9XD	28481871	Green Accepted, Green Submitted			2022-12-17	WOS:000409371100007
J	von Morgen, P; Burdova, K; Flower, TG; O'Reilly, NJ; Boulton, SJ; Smerdon, SJ; Macurek, L; Horejsi, Z				von Morgen, P.; Burdova, K.; Flower, T. G.; O'Reilly, N. J.; Boulton, S. J.; Smerdon, S. J.; Macurek, L.; Horejsi, Z.			MRE11 stability is regulated by CK2-dependent interaction with R2TP complex	ONCOGENE			English	Article							STRAND BREAK REPAIR; CLINICAL PRESENTATION; DNA; PHOSPHORYLATION; HSP90; PROTEIN; COCHAPERONE; CHAPERONE; MEDIATE; GENES	The MRN (MRE11-RAD50-NBS1) complex is essential for repair of DNA double-strand breaks and stalled replication forks. Mutations of the MRN complex subunit MRE11 cause the hereditary cancer-susceptibility disease ataxia-telangiectasia-like disorder (ATLD). Here we show that MRE11 directly interacts with PIH1D1, a subunit of heat-shock protein 90 cochaperone R2TP complex, which is required for the assembly of large protein complexes, such as RNA polymerase II, small nucleolar ribonucleoproteins and mammalian target of rapamycin complex 1. The MRE11-PIH1D1 interaction is dependent on casein kinase 2 (CK2) phosphorylation of two acidic sequences within the MRE11 C terminus containing serines 558/561 and 688/689. Conversely, the PIH1D1 phospho-binding domain PIH-N is required for association with MRE11 phosphorylated by CK2. Consistent with these findings, depletion of PIH1D1 resulted in MRE11 destabilization and affected DNA-damage repair processes dependent on MRE11. Additionally, mutations of serines 688/689, which abolish PIH1D1 binding, also resulted in decreased MRE11 stability. As depletion of R2TP frequently leads to instability of its substrates and as truncation mutation of MRE11 lacking serines 688/689 leads to decreased levels of the MRN complex both in ATLD patients and an ATLD mouse model, our results suggest that the MRN complex is a novel R2TP complex substrate and that their interaction is regulated by CK2 phosphorylation.	[von Morgen, P.; Burdova, K.; Macurek, L.; Horejsi, Z.] ASCR, Inst Mol Genet, Dept Canc Cell Biol, Videnska 1083, Prague 14200 4, Czech Republic; [von Morgen, P.] Charles Univ Prague, Fac Sci, Prague, Czech Republic; [Flower, T. G.; Smerdon, S. J.] Francis Crick Inst, Struct Biol DNA Damage Signalling Lab, London, England; [O'Reilly, N. J.] Francis Crick Inst, Peptide Chem, London, England; [Boulton, S. J.] Francis Crick Inst, DSB Repair Metab Lab, London, England; [Horejsi, Z.] Queen Mary Univ London, Barts Canc Inst, Ctr Mol Oncol, John Vane Ctr, Charterhouse Sq, London, England	Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; Charles University Prague; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; University of London; Queen Mary University London	Macurek, L (corresponding author), ASCR, Inst Mol Genet, Dept Canc Cell Biol, Videnska 1083, Prague 14200 4, Czech Republic.; Horejsi, Z (corresponding author), Queen Mary Univ London, Barts Canc Inst, Ctr Mol Oncol, John Vane Ctr, Charterhouse Sq, London, England.	libor.macurek@img.cas.cz; z.horejsi@qmul.ac.uk	Macurek, Libor/C-7865-2014; von Morgen, Patrick/P-6869-2019; Von Morgen, Patrick/M-7566-2017	Macurek, Libor/0000-0002-0987-1238; von Morgen, Patrick/0000-0002-0614-6292; Von Morgen, Patrick/0000-0002-0614-6292; O'Reilly, Nicola/0000-0002-4204-6491; Burdova, Kamila/0000-0003-4402-3688; Flower, Thomas/0000-0002-7890-6473; Smerdon, Stephen/0000-0001-5688-8465; Licenikova Horejsi, Zuzana/0000-0002-9943-1649	Czech Science Foundation [14-34264S]; Institutional grant of IMG [RVO 68378050]; Wellcome Trust [200462/Z/16/Z, FC001156, FC001048, WT104558]; Grant Agency of the Charles University [309015]; Francis Crick Institute - Cancer Research UK [FC001156, FC001048]; UK Medical Research Council [FC001156, FC001048]; European Research Council [ERC 268639]; Cancer Research UK [11581] Funding Source: researchfish; Medical Research Council [MC_U117584228, U117531954, 1254166] Funding Source: researchfish; The Francis Crick Institute [10267, 10156, 10048, 10013] Funding Source: researchfish; MRC [MC_U117584228] Funding Source: UKRI	Czech Science Foundation(Grant Agency of the Czech Republic); Institutional grant of IMG; Wellcome Trust(Wellcome TrustEuropean Commission); Grant Agency of the Charles University; Francis Crick Institute - Cancer Research UK; UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); European Research Council(European Research Council (ERC)European Commission); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); The Francis Crick Institute; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	All cell lines were from the Cell Services of the Friancis Crick Institute and were regularly tested for mycoplasma infection. This work was supported by the Czech Science Foundation (14-34264S), Institutional grant of IMG (RVO 68378050) and the Wellcome Trust (200462/Z/16/Z). PM was partially supported by the Grant Agency of the Charles University (309015). SJS, TF and SJB are supported by the Francis Crick Institute, which receives its core funding from Cancer Research UK (FC001156 and FC001048), the UK Medical Research Council (FC001156 and FC001048) and the Wellcome Trust (FC001156 and FC001048). SJB was also supported by Wellcome Trust (WT104558) and European Research Council (ERC 268639).	Aparicio T, 2016, J CELL BIOL, V212, P399, DOI 10.1083/jcb.201504005; Bartkova J, 2008, MOL ONCOL, V2, P296, DOI 10.1016/j.molonc.2008.09.007; Benbahouche NE, 2014, J BIOL CHEM, V289, P6236, DOI 10.1074/jbc.M113.499608; Bennardo N, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000683; Boulon S, 2010, MOL CELL, V39, P912, DOI 10.1016/j.molcel.2010.08.023; Buis J, 2012, NAT STRUCT MOL BIOL, V19, P246, DOI 10.1038/nsmb.2212; Cannavo E, 2014, NATURE, V514, P122, DOI 10.1038/nature13771; Chen C, 2013, P NATL ACAD SCI USA, V110, P20605, DOI 10.1073/pnas.1306328110; Chubb D, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11883; Danielsen JMR, 2009, J BIOL CHEM, V284, P4140, DOI 10.1074/jbc.M808174200; Dery U, 2008, MOL CELL BIOL, V28, P3058, DOI 10.1128/MCB.02025-07; Deshpande RA, 2016, MOL CELL, V64, P593, DOI 10.1016/j.molcel.2016.10.010; Gunn Amanda, 2012, Methods Mol Biol, V920, P379, DOI 10.1007/978-1-61779-998-3_27; Heikkinen K, 2006, CARCINOGENESIS, V27, P1593, DOI 10.1093/carcin/bgi360; Horejsi Z, 2014, CELL REP, V7, P19, DOI 10.1016/j.celrep.2014.03.013; Horejsi Z, 2010, MOL CELL, V39, P839, DOI 10.1016/j.molcel.2010.08.037; Kiianitsa K, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt171; Kijas AW, 2015, NUCLEIC ACIDS RES, V43, P8352, DOI 10.1093/nar/gkv754; Kim SG, 2013, MOL CELLS, V35, P463, DOI 10.1007/s10059-013-0138-2; Kleibl Z, 2016, BREAST, V28, P136, DOI 10.1016/j.breast.2016.05.006; Lamarche BJ, 2010, FEBS LETT, V584, P3682, DOI 10.1016/j.febslet.2010.07.029; Luo H, 2014, NUCLEIC ACIDS RES, V42, pD574, DOI 10.1093/nar/gkt1131; Machado-Pinilla R, 2012, RNA, V18, P1833, DOI 10.1261/rna.034942.112; Hoa NN, 2016, MOL CELL, V64, P1010, DOI 10.1016/j.molcel.2016.11.028; Pal M, 2014, STRUCTURE, V22, P805, DOI 10.1016/j.str.2014.04.001; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Rao F, 2014, MOL CELL, V54, P119, DOI 10.1016/j.molcel.2014.02.020; Regal JA, 2013, HUM MOL GENET, V22, P5146, DOI 10.1093/hmg/ddt368; Rosenbaum J, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003906; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Taylor AMR, 2004, DNA REPAIR, V3, P1219, DOI 10.1016/j.dnarep.2004.04.009; Theunissen JWF, 2003, MOL CELL, V12, P1511, DOI 10.1016/S1097-2765(03)00455-6; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Williams GJ, 2010, DNA REPAIR, V9, P1299, DOI 10.1016/j.dnarep.2010.10.001; Yu ZB, 2012, CELL RES, V22, P305, DOI 10.1038/cr.2011.128; Zhao RM, 2005, CELL, V120, P715, DOI 10.1016/j.cell.2004.12.024; Zhao RM, 2008, J CELL BIOL, V180, P563, DOI 10.1083/jcb.200709061	37	26	26	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 24	2017	36	34					4943	4950		10.1038/onc.2017.99	http://dx.doi.org/10.1038/onc.2017.99			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FE5EI	28436950	Green Published, Green Accepted, hybrid			2022-12-17	WOS:000408234400010
J	Yang, J; Liu, K; Yang, J; Jin, B; Chen, H; Zhan, X; Li, Z; Wang, L; Shen, X; Li, M; Yu, W; Mao, Z				Yang, J.; Liu, K.; Yang, J.; Jin, B.; Chen, H.; Zhan, X.; Li, Z.; Wang, L.; Shen, X.; Li, M.; Yu, W.; Mao, Z.			PIM1 induces cellular senescence through phosphorylation of UHRF1 at Ser311	ONCOGENE			English	Article							ONCOGENE-INDUCED SENESCENCE; HEMI-METHYLATED DNA; HUMAN-DIPLOID FIBROBLASTS; HISTONE H3 TAIL; STRUCTURAL BASIS; SRA DOMAIN; METHYLTRANSFERASE DNMT1; EPIGENETIC INHERITANCE; TRANSGENIC MICE; PROTEIN UHRF1	PIM1 is a proto-oncogene, encoding a serine/threonine protein kinase that regulates cell proliferation, survival, differentiation and apoptosis. Previous reports suggest that overexpression of PIM1 can induce cellular senescence. However, the molecular mechanism underlying this process is not fully understood. Here we report that UHRF1 is a novel substrate of PIM1 kinase, which could be phosphorylated at Ser311 and therefore promoted to degradation. Our data demonstrates that PIM1 destabilizes UHRF1, leading to DNA hypomethylation, which consequently results in genomic instability, increased p16 expression and subsequent induction of cellular senescence. Taken together, our results suggest that down-regulation of UHRF1 is an important mechanism of PIM1-mediated cellular senescence.	[Yang, J.; Liu, K.; Chen, H.; Zhan, X.; Li, Z.; Wang, L.; Shen, X.; Li, M.; Yu, W.; Mao, Z.] Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Sch Basic Med Sci, 38 Xueyuan Rd, Beijing 100083, Peoples R China; [Yang, J.] Qingdao Univ, Affiliated Hosp, Dept Cadre Hlth Care, Qingdao, Peoples R China; [Jin, B.] Peking Univ, Dept Clin Lab, Hosp 1, Beijing, Peoples R China	Peking University; Qingdao University; Peking University	Yu, W; Mao, Z (corresponding author), Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Sch Basic Med Sci, 38 Xueyuan Rd, Beijing 100083, Peoples R China.	yuwenhua@hsc.pku.edu.cn; zbmao@bjmu.edu.cn		, Jiong/0000-0001-9698-0338	National Basic Research Programs of China [2013CB530801]; Natural Science Foundation of China [81471406, 81541066]; National Natural Science Foundation of China [81471406, 81541066, 81641183]	National Basic Research Programs of China(National Basic Research Program of China); Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Basic Research Programs of China (Grant number 2013CB530801) and the Natural Science Foundation of China (Grant number 81471406 and Grant number 81541066). This work was supported by the National Basic Research Programs of China (Grant Number 2013CB530801) and the National Natural Science Foundation of China (Grant Number 81471406, 81641183 and 81541066).	Achour M, 2008, ONCOGENE, V27, P2187, DOI 10.1038/sj.onc.1210855; Acton D, 1992, Curr Top Microbiol Immunol, V182, P293; Arima Y, 2004, GENES CELLS, V9, P131, DOI 10.1111/j.1356-9597.2004.00710.x; Arita K, 2008, NATURE, V455, P818, DOI 10.1038/nature07249; Arita K, 2012, P NATL ACAD SCI USA, V109, P12950, DOI 10.1073/pnas.1203701109; Avvakumov GV, 2008, NATURE, V455, P822, DOI 10.1038/nature07273; Barradas M, 2009, GENE DEV, V23, P1177, DOI 10.1101/gad.511109; Bashtrykov P, 2014, J BIOL CHEM, V289, P4106, DOI 10.1074/jbc.M113.528893; Berkyurek AC, 2014, J BIOL CHEM, V289, P379, DOI 10.1074/jbc.M113.523209; Bonapace IM, 2002, J CELL BIOL, V157, P909, DOI 10.1083/jcb.200201025; Bostick M, 2007, SCIENCE, V317, P1760, DOI 10.1126/science.1147939; BREUER M, 1991, CANCER RES, V51, P958; Bronner C, 2007, PHARMACOL THERAPEUT, V115, P419, DOI 10.1016/j.pharmthera.2007.06.003; Bullock AN, 2005, J BIOL CHEM, V280, P41675, DOI 10.1074/jbc.M510711200; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Chen H, 2013, MOL CELL BIOL, V33, P1139, DOI 10.1128/MCB.01191-12; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Cheng JD, 2013, J BIOL CHEM, V288, P1329, DOI 10.1074/jbc.M112.415398; Chu J, 2012, MOL BIOL CELL, V23, P59, DOI 10.1091/mbc.E11-06-0487; Citterio E, 2004, MOL CELL BIOL, V24, P2526, DOI 10.1128/MCB.24.6.2526-2535.2004; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772; CUYPERS HT, 1984, CELL, V37, P141; Dhomen N, 2009, CANCER CELL, V15, P294, DOI 10.1016/j.ccr.2009.02.022; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Du JM, 2015, NAT REV MOL CELL BIO, V16, P519, DOI 10.1038/nrm4043; Du ZW, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001462; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Fang J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11197; Fang ZY, 2009, CELL IMMUNOL, V257, P80, DOI 10.1016/j.cellimm.2009.03.001; Feldman BJ, 1997, ONCOGENE, V15, P2735, DOI 10.1038/sj.onc.1201670; Fraga MF, 2007, TRENDS GENET, V23, P413, DOI 10.1016/j.tig.2007.05.008; Gelato KA, 2014, MOL CELL, V54, P905, DOI 10.1016/j.molcel.2014.04.004; Gorgoulis VG, 2010, CURR OPIN CELL BIOL, V22, P816, DOI 10.1016/j.ceb.2010.07.013; Grandori C, 2003, GENE DEV, V17, P1569, DOI 10.1101/gad.1100303; Gray-Schopfer VC, 2006, BRIT J CANCER, V95, P496, DOI 10.1038/sj.bjc.6603283; Harrison JS, 2016, ELIFE, V5, DOI 10.7554/eLife.17101; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Heyn H, 2012, P NATL ACAD SCI USA, V109, P10522, DOI 10.1073/pnas.1120658109; Hogan C, 2008, J BIOL CHEM, V283, P18012, DOI 10.1074/jbc.M709695200; HOLLIDAY R, 1986, EXP CELL RES, V166, P543, DOI 10.1016/0014-4827(86)90499-4; HOOVER D, 1991, J BIOL CHEM, V266, P14018; Hu LL, 2011, CELL RES, V21, P1374, DOI 10.1038/cr.2011.124; Jass JR, 2007, HISTOPATHOLOGY, V50, P113, DOI 10.1111/j.1365-2559.2006.02549.x; Jia YH, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.7; Jin B, 2014, AGING CELL, V13, P879, DOI 10.1111/acel.12249; Johansson A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067378; Karagianni P, 2008, MOL CELL BIOL, V28, P705, DOI 10.1128/MCB.01598-07; Katakura Y, 1999, BIOCHEM BIOPH RES CO, V255, P110, DOI 10.1006/bbrc.1999.0129; Kia SK, 2008, MOL CELL BIOL, V28, P3457, DOI 10.1128/MCB.02019-07; Klutstein M, 2016, CANCER RES, V76, P3446, DOI 10.1158/0008-5472.CAN-15-3278; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Leverson JD, 1998, MOL CELL, V2, P417, DOI 10.1016/S1097-2765(00)80141-0; Liu XL, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2562; McClay JL, 2014, HUM MOL GENET, V23, P1175, DOI 10.1093/hmg/ddt511; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Mikkers H, 2004, MOL CELL BIOL, V24, P6104, DOI 10.1128/MCB.24.13.6104-6115.2004; Miura M, 2001, EXP CELL RES, V263, P202, DOI 10.1006/excr.2000.5115; Mousli M, 2003, BRIT J CANCER, V89, P120, DOI 10.1038/sj.bjc.6601068; Mudbhary R, 2014, CANCER CELL, V25, P196, DOI 10.1016/j.ccr.2014.01.003; Nady N, 2011, J BIOL CHEM, V286, P24300, DOI 10.1074/jbc.M111.234104; Narlik-Grassow M, 2014, MED RES REV, V34, P136, DOI 10.1002/med.21284; Narlik-Grassow M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060277; Nawijn MC, 2011, NAT REV CANCER, V11, P23, DOI 10.1038/nrc2986; Nishiyama A, 2013, NATURE, V502, P249, DOI 10.1038/nature12488; O'Sullivan J, 2006, CANCER EPIDEM BIOMAR, V15, P573, DOI 10.1158/1055-9965.EPI-05-0542; Qian KC, 2005, J BIOL CHEM, V280, P6130, DOI 10.1074/jbc.M409123200; Qin WH, 2011, J CELL BIOCHEM, V112, P439, DOI 10.1002/jcb.22998; Ramesh V, 2016, GENE DEV, V30, P2199, DOI 10.1101/gad.284992.116; Reimann M, 2010, CANCER CELL, V17, P262, DOI 10.1016/j.ccr.2009.12.043; Rothbart SB, 2013, GENE DEV, V27, P1288, DOI 10.1101/gad.220467.113; Sadler KC, 2007, P NATL ACAD SCI USA, V104, P1570, DOI 10.1073/pnas.0610774104; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; Schmidt T, 1998, ONCOGENE, V17, P2661, DOI 10.1038/sj.onc.1202191; SELTEN G, 1986, CELL, V46, P603, DOI 10.1016/0092-8674(86)90886-X; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sharif J, 2007, NATURE, V450, P908, DOI 10.1038/nature06397; Shay KP, 2005, MOL CANCER RES, V3, P170; TANG ZQ, 1994, MECH AGEING DEV, V73, P57, DOI 10.1016/0047-6374(94)90038-8; Tauber M, 2015, NUCLEUS-PHILA, V6, P123, DOI 10.1080/19491034.2015.1026022; Tittle RK, 2011, DEV BIOL, V350, P50, DOI 10.1016/j.ydbio.2010.11.009; Trotzier MA, 2004, BIOCHEM BIOPH RES CO, V319, P590, DOI 10.1016/j.bbrc.2004.05.028; Tu ZG, 2011, DEV CELL, V21, P1077, DOI 10.1016/j.devcel.2011.10.010; Uemura T, 2000, CELL STRUCT FUNCT, V25, P149, DOI 10.1247/csf.25.149; Unoki M, 2004, ONCOGENE, V23, P7601, DOI 10.1038/sj.onc.1208053; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; Vogt M, 1998, CELL GROWTH DIFFER, V9, P139; von Meyenn F, 2016, MOL CELL, V62, P848, DOI 10.1016/j.molcel.2016.04.025; Wang CK, 2011, CELL RES, V21, P1379, DOI 10.1038/cr.2011.123; Wang Z, 2001, J Vet Sci, V2, P167; Wei S, 1999, CANCER RES, V59, P1539; WELLER EM, 1993, CELL PROLIFERAT, V26, P45, DOI 10.1111/j.1365-2184.1993.tb00005.x; Zemskova M, 2010, MOL CANCER RES, V8, P1126, DOI 10.1158/1541-7786.MCR-10-0174; Zhao JL, 2016, J SENSORS, V2016, DOI 10.1155/2016/3270916; Zhuo DX, 2010, J BIOL CHEM, V285, P31491, DOI 10.1074/jbc.M109.068387	98	26	27	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 24	2017	36	34					4828	4842		10.1038/onc.2017.96	http://dx.doi.org/10.1038/onc.2017.96			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FE5EI	28394343				2022-12-17	WOS:000408234400002
J	He, W; Wang, C; Mu, R; Liang, P; Huang, Z; Zhang, J; Dong, L				He, W.; Wang, C.; Mu, R.; Liang, P.; Huang, Z.; Zhang, J.; Dong, L.			MiR-21 is required for anti-tumor immune response in mice: an implication for its bi-directional roles	ONCOGENE			English	Article							MESENCHYMAL STEM-CELLS; VERSUS-HOST-DISEASE; KAPPA-B ACTIVATION; T-CELLS; CANCER-IMMUNOTHERAPY; SMALL MOLECULES; HEPATIC-INJURY; MOUSE MODEL; MICRORNA-21; PROMOTES	Here we show that miR-21, a microRNA known for its oncogenic activity, is also essential for mediating immune responses against tumor. Knockout of miR-21 in mice slowed the proliferation of both CD4(+) and CD8(+) cells, reduced their cytokine production and accelerated the grafted tumor growth. Further investigations indicated that miR-21 could activate CD4(+) and CD8(+) T cells via the PTEN/Akt pathway in response to stimulations. Taken together, these data suggest the key functions of miR-21 in mediating antitumor immune response and thereby uncover a bi-directional role of this traditionally known ` oncomiR' in tumorigenesis. Our study may provide new insights for the design of cancer therapies targeting microRNAs, with an emphasis on the dynamic and possibly unexpected role of these molecules.	[He, W.; Mu, R.; Liang, P.; Huang, Z.; Zhang, J.; Dong, L.] Nanjing Univ, NJU Adv Inst Life Sci NAILS, Sch Life Sci, State Key Lab Pharmaceut Biotechnol, 163 Xianlin Ave, Nanjing 210093, Jiangsu, Peoples R China; [Wang, C.] Univ Macau, Inst Chinese Med Sci, State Key Lab Qual Res Chinese Med, Taipa, Macao, Peoples R China; [Zhang, J.] Nanjing Univ, Jiangsu Prov Lab Nanotechnol, Nanjing, Jiangsu, Peoples R China	Nanjing University; University of Macau; Nanjing University	Zhang, J; Dong, L (corresponding author), Nanjing Univ, NJU Adv Inst Life Sci NAILS, Sch Life Sci, State Key Lab Pharmaceut Biotechnol, 163 Xianlin Ave, Nanjing 210093, Jiangsu, Peoples R China.	jfzhang@nju.edu.cn; leidong@nju.edu.cn	zhang, jiani/GVS-2052-2022; Wang, Chunming/I-3392-2013	Wang, Chunming/0000-0001-9185-9678	National Basic Research Program of China [2012CB517603]; National High Technology Research and Development Program of China [2014AA020707]; National Natural Science Foundation of China [31671031, 81673380, 31200695, 31400671, 51173076, 91129712, 81102489]; Program for New Century Excellent Talents in University [NCET-13-0272]; Nanjing University State Key Laboratory of Pharmaceutical Biotechnology Open Grant [02ZZYJ-201307]; University of Macau [MYRG2014-00069-ICMS-QRCM, MYRG2015-00160-ICMS-QRCM]; opening fund of the State Key Laboratory of Quality Research in Chinese Medicine, University of Macau [005]	National Basic Research Program of China(National Basic Research Program of China); National High Technology Research and Development Program of China(National High Technology Research and Development Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for New Century Excellent Talents in University(Program for New Century Excellent Talents in University (NCET)); Nanjing University State Key Laboratory of Pharmaceutical Biotechnology Open Grant; University of Macau; opening fund of the State Key Laboratory of Quality Research in Chinese Medicine, University of Macau	This project was funded by the National Basic Research Program of China (2012CB517603), the National High Technology Research and Development Program of China (2014AA020707), the National Natural Science Foundation of China (31671031, 81673380, 31200695, 31400671, 51173076, 91129712 and 81102489), the Program for New Century Excellent Talents in University (NCET-13-0272), Nanjing University State Key Laboratory of Pharmaceutical Biotechnology Open Grant (02ZZYJ-201307). CW acknowledges the funding supports from University of Macau (MYRG2014-00069-ICMS-QRCM, MYRG2015-00160-ICMS-QRCM) and the opening fund of the State Key Laboratory of Quality Research in Chinese Medicine, University of Macau (No. 005).	Adams JL, 2015, NAT REV DRUG DISCOV, V14, P603, DOI 10.1038/nrd4596; Barnes SE, 2015, J IMMUNOTHER CANCER, V3, DOI 10.1186/s40425-014-0045-x; Basseres DS, 2010, CANCER RES, V70, P3537, DOI 10.1158/0008-5472.CAN-09-4290; Blanco B, 2015, INT IMMUNOPHARMACOL, V28, P675, DOI 10.1016/j.intimp.2015.07.032; Chakraborty AK, 2014, NAT IMMUNOL, V15, P798, DOI 10.1038/ni.2940; Chen H, 2014, CANCER IMMUNOL RES, V2, P167, DOI 10.1158/2326-6066.CIR-13-0155; Coulie PG, 2014, NAT REV CANCER, V14, P135, DOI 10.1038/nrc3670; Dudda JC, 2013, IMMUNITY, V38, P742, DOI 10.1016/j.immuni.2012.12.006; Dunn GP, 2004, IMMUNITY, V21, P137, DOI 10.1016/j.immuni.2004.07.017; Echevarria-Vargas IM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097094; Gao SQ, 2015, ACTA BIOMATER, V25, P184, DOI 10.1016/j.actbio.2015.07.020; Garchow B, 2016, CLIN IMMUNOL, V162, P100, DOI 10.1016/j.clim.2015.11.010; Garchow BG, 2011, EMBO MOL MED, V3, P605, DOI 10.1002/emmm.201100171; Gubin MM, 2014, NATURE, V515, P577, DOI 10.1038/nature13988; Gupta SK, 2016, CARDIOVASC RES, V110, P215, DOI 10.1093/cvr/cvw030; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Ho WY, 2003, CANCER CELL, V3, P431, DOI 10.1016/S1535-6108(03)00113-2; Kim EH, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00020; Kim YJ, 2009, STEM CELLS, V27, P3093, DOI 10.1002/stem.235; Kosaka A, 2015, BIOCHEM BIOPH RES CO, V458, P549, DOI 10.1016/j.bbrc.2015.02.003; Lee DH, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.95; Lee KC, 2015, J HEPATOL, V63, P1405, DOI 10.1016/j.jhep.2015.07.035; Lei FY, 2011, CANCER RES, V71, P4742, DOI 10.1158/0008-5472.CAN-11-0359; Leone E, 2013, CLIN CANCER RES, V19, P2096, DOI 10.1158/1078-0432.CCR-12-3325; Liu G, 2010, J EXP MED, V207, P1589, DOI 10.1084/jem.20100035; Liu Juan, 2013, Cancer Biology Medicine, V10, P131, DOI 10.7497/j.issn.2095-3941.2013.03.002; Locke FL, 2013, J IMMUNOL, V191, P1677, DOI 10.4049/jimmunol.1202018; Ma XD, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8151; Ma XD, 2011, P NATL ACAD SCI USA, V108, P10144, DOI 10.1073/pnas.1103735108; Mahasa KJ, 2016, J THEOR BIOL, V404, P312, DOI 10.1016/j.jtbi.2016.06.012; Mellman I, 2011, NATURE, V480, P480, DOI 10.1038/nature10673; Meng YB, 2015, J ORTHOP RES, V33, P957, DOI 10.1002/jor.22884; Meylan E, 2009, NATURE, V462, P104, DOI 10.1038/nature08462; Murugaiyan G, 2015, J CLIN INVEST, V125, P1069, DOI 10.1172/JCI74347; Ni YX, 2014, NEURAL REGEN RES, V9, P828, DOI 10.4103/1673-5374.131599; Pan W, 2010, J IMMUNOL, V184, P6773, DOI 10.4049/jimmunol.0904060; Pfeffer SR, 2015, DRUG DEVELOP RES, V76, P270, DOI 10.1002/ddr.21257; Rosenberg SA, 2015, SCIENCE, V348, P62, DOI 10.1126/science.aaa4967; Si ML, 2007, ONCOGENE, V26, P2799, DOI 10.1038/sj.onc.1210083; Simpson-Abelson Michelle R, 2013, Cancer Immun, V13, P14; Song GS, 2010, HEPATOLOGY, V51, P1735, DOI 10.1002/hep.23547; Soond DR, 2012, J IMMUNOL, V188, P5935, DOI 10.4049/jimmunol.1102116; Spiotto MT, 2004, NAT MED, V10, P294, DOI 10.1038/nm999; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Teteloshvili Nato, 2015, Microrna, V4, P117; Thum T, 2008, NATURE, V456, P980, DOI 10.1038/nature07511; Tveita AA, 2015, CANCER RES, V75, P3268, DOI 10.1158/0008-5472.CAN-14-3640; Uzzo RG, 1999, J CLIN INVEST, V104, P769, DOI 10.1172/JCI6775; Wang T, 2012, AM J PATHOL, V181, P1911, DOI 10.1016/j.ajpath.2012.08.022; Wu HQ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001020; Wu YR, 2016, TUMOR BIOL, V37, P12061, DOI 10.1007/s13277-016-5074-2; Wu YH, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1611-4; Wu YX, 2015, BLOOD, V126, P1314, DOI 10.1182/blood-2015-02-627356; Xu WD, 2013, EXPERT OPIN THER TAR, V17, P659, DOI 10.1517/14728222.2013.773311; Yang JC, 2016, ADV IMMUNOL, V130, P279, DOI 10.1016/bs.ai.2015.12.006; Yung BC, 2016, MOL PHARMACEUT, V13, P653, DOI 10.1021/acs.molpharmaceut.5b00878; Zhan MM, 2016, DRUG DISCOV TODAY, V21, P1027, DOI 10.1016/j.drudis.2016.04.011; Zhang C, 2008, BIOMATERIALS, V29, P1233, DOI 10.1016/j.biomaterials.2007.11.029; Zhang N, 2011, IMMUNITY, V35, P161, DOI 10.1016/j.immuni.2011.07.010; Zhang ZP, 2013, J BIOL CHEM, V288, P37082, DOI 10.1074/jbc.M113.517953; Zhao T, 2014, INT J BIOL MACROMOL, V63, P114, DOI 10.1016/j.ijbiomac.2013.10.037	62	26	27	2	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2017	36	29					4212	4223		10.1038/onc.2017.62	http://dx.doi.org/10.1038/onc.2017.62			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB0LE	28346427				2022-12-17	WOS:000405835800012
J	He, Y; Northey, JJ; Pelletier, A; Kos, Z; Meunier, L; Haibe-Kains, B; Mes-Masson, AM; Cote, JF; Siegel, PM; Lamarche-Vane, N				He, Y.; Northey, J. J.; Pelletier, A.; Kos, Z.; Meunier, L.; Haibe-Kains, B.; Mes-Masson, A-M; Cote, J-F; Siegel, P. M.; Lamarche-Vane, N.			The Cdc42/Rac1 regulator CdGAP is a novel E-cadherin transcriptional co-repressor with Zeb2 in breast cancer	ONCOGENE			English	Article							SMAD-INTERACTING PROTEIN-1; GTPASE-ACTIVATING PROTEIN; ADAMS-OLIVER SYNDROME; OF-FUNCTION MUTATIONS; PHOSPHORYLATES CDGAP; CELL MOTILITY; EXPRESSION; GENE; ARHGAP31; RECEPTOR	The loss of E-cadherin causes dysfunction of the cell-cell junction machinery, which is an initial step in epithelial-to-mesenchymal transition (EMT), facilitating cancer cell invasion and the formation of metastases. A set of transcriptional repressors of E-cadherin (CDH1) gene expression, including Snail1, Snail2 and Zeb2 mediate E-cadherin downregulation in breast cancer. However, the molecular mechanisms underlying the control of E-cadherin expression in breast cancer progression remain largely unknown. Here, by using global gene expression approaches, we uncover a novel function for Cdc42 GTPase-activating protein (CdGAP) in the regulation of expression of genes involved in EMT. We found that CdGAP used its proline-rich domain to form a functional complex with Zeb2 to mediate the repression of E-cadherin expression in ErbB2-transformed breast cancer cells. Conversely, knockdown of CdGAP expression led to a decrease of the transcriptional repressors Snail1 and Zeb2, and this correlated with an increase in E-cadherin levels, restoration of cell-cell junctions, and epithelial-like morphological changes. In vivo, loss of CdGAP in ErbB2-transformed breast cancer cells impaired tumor growth and suppressed metastasis to lungs. Finally, CdGAP was highly expressed in basal-type breast cancer cells, and its strong expression correlated with poor prognosis in breast cancer patients. Together, these data support a previously unknown nuclear function for CdGAP where it cooperates in a GAP-independent manner with transcriptional repressors to function as a critical modulator of breast cancer through repression of E-cadherin transcription. Targeting Zeb2-CdGAP interactions may represent novel therapeutic opportunities for breast cancer treatment.	[He, Y.; Lamarche-Vane, N.] McGill Univ, Dept Anat & Cell Biol, McGill Univ Hlth Ctr, Canc Res Program,Res Inst, Montreal, PQ, Canada; [Northey, J. J.; Siegel, P. M.] McGill Univ, Goodman Canc Res Ctr, Montreal, PQ, Canada; [Pelletier, A.; Cote, J-F] Inst Rech Clin Montreal, Montreal, PQ, Canada; [Kos, Z.] Univ Ottawa, Dept Pathol & Lab Med, Ottawa, ON, Canada; [Meunier, L.; Mes-Masson, A-M] Ctr Hosp Univ Montreal, Ctr Rech, Montreal, PQ, Canada; [Haibe-Kains, B.] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada; [Haibe-Kains, B.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [Haibe-Kains, B.] Univ Toronto, Dept Comp Sci, Toronto, ON, Canada; [Northey, J. J.] Univ Calif San Francisco, Dept Surg, San Francisco, CA USA	McGill University; McGill University; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; University of Ottawa; Universite de Montreal; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Toronto; University of California System; University of California San Francisco	Lamarche-Vane, N (corresponding author), McGill Univ, Anat & Cell Biol, RI MUHC, 1001 Boul Decarie,Room E02-6230, Montreal, PQ H4A 3J1, Canada.	Nathalie.lamarche@mcgill.ca	Northey, Jason/AAX-6365-2021; Haibe-Kains, Benjamin/D-3702-2011	Northey, Jason/0000-0003-3115-2560; Mes-Masson, Anne-Marie/0000-0002-6498-266X; Haibe-Kains, Benjamin/0000-0002-7684-0079	FRSQ chercheur-national; William Dawson scholar; Canadian Institute for Health Research (CIHR) [MOP-119544, MOP-144425]; FRQS senior scholarship	FRSQ chercheur-national(Fonds de la Recherche en Sante du Quebec); William Dawson scholar; Canadian Institute for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); FRQS senior scholarship	We thank Dr Patricia Tonin for helpful discussions and Dr John J Bergeron for critically reading this manuscript. We are grateful to Dr Morag Park (McGill University) for providing the Zeb2 and E-cadherin-luc constructs. We thank Dr Torsten Nielsen for providing the human breast cancer TMA and the CdGAP IHC staining through the Genetic Pathology Evaluation Center (GPEC), ZF Dong for IHC staining of primary tumors, Dr Min Fu for assistance with confocal microscopy at the imaging platform of the RI-MUHC, Martin Primeau and Vilayphone Luangrath for affinity purification of the CdGAP antibodies. NL-V was a recipient of a FRSQ chercheur-national and a William Dawson scholar. Canadian Institute for Health Research (CIHR) MOP-119544 to NL-V and MOP-144425 to JFC. JFC is a recipient of a FRQS senior scholarship.	Azim HA, 2012, CLIN CANCER RES, V18, P1341, DOI 10.1158/1078-0432.CCR-11-2599; Barras D, 2014, CANCER METAST REV, V33, P87, DOI 10.1007/s10555-013-9458-0; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Caron C, 2016, SCI REP-UK, V6, DOI 10.1038/srep27485; Danek EI, 2007, J BIOL CHEM, V282, P3624, DOI 10.1074/jbc.M610073200; Desmedt C, 2007, CLIN CANCER RES, V13, P3207, DOI 10.1158/1078-0432.CCR-06-2765; Elloul S, 2005, CANCER-AM CANCER SOC, V103, P1631, DOI 10.1002/cncr.20946; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gonzalez DM, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005189; Haibe-Kains B, 2012, JNCI-J NATL CANCER I, V104, P311, DOI 10.1093/jnci/djr545; Hajra KM, 2002, CANCER RES, V62, P1613; Hassed SJ, 2012, AM J HUM GENET, V91, P391, DOI 10.1016/j.ajhg.2012.07.005; He Y, 2011, ONCOGENE, V30, P1032, DOI 10.1038/onc.2010.477; Holliday DL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2889; Hu QP, 2016, INT J CANCER, V138, P2804, DOI 10.1002/ijc.29982; Isrie M, 2014, AM J MED GENET A, V164, P1576, DOI 10.1002/ajmg.a.36486; Karimzadeh F, 2012, J BIOL CHEM, V287, P19610, DOI 10.1074/jbc.M112.344606; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Kim T, 2009, CANCER METAST REV, V28, P77, DOI 10.1007/s10555-008-9167-2; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Lahoz A, 2008, GENE DEV, V22, P1724, DOI 10.1101/gad.1691408; Lamarche-Vane N, 1998, J BIOL CHEM, V273, P29172, DOI 10.1074/jbc.273.44.29172; Laurin M, 2013, P NATL ACAD SCI USA, V110, P7434, DOI 10.1073/pnas.1213050110; Liu CL, 2002, AM J PATHOL, V161, P1557, DOI 10.1016/S0002-9440(10)64434-3; Long JY, 2005, J BIOL CHEM, V280, P35477, DOI 10.1074/jbc.M504477200; Makretsov N, 2003, HUM PATHOL, V34, P1001, DOI 10.1053/S0046-8177(03)00411-8; Meester JAN, 2015, AM J HUM GENET, V97, P475, DOI 10.1016/j.ajhg.2015.07.015; Metzger O, 2013, J CLIN ONCOL, V31, P3083, DOI 10.1200/JCO.2012.46.1574; Naji L, 2011, BIOCHEM BIOPH RES CO, V409, P96, DOI 10.1016/j.bbrc.2011.04.116; Northey JJ, 2008, MOL CELL BIOL, V28, P3162, DOI 10.1128/MCB.01734-07; Parker RL, 2002, AM J CLIN PATHOL, V117, P723; Sanchez-Tillo E, 2011, AM J CANCER RES, V1, P897; Shaheen R, 2013, AM J HUM GENET, V92, P598, DOI 10.1016/j.ajhg.2013.02.012; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Southgate L, 2015, CIRC-CARDIOVASC GENE, V8, P572, DOI 10.1161/CIRCGENETICS.115.001086; Southgate L, 2011, AM J HUM GENET, V88, P574, DOI 10.1016/j.ajhg.2011.04.013; Tabaries S, 2015, ONCOTARGET, V6, P9476, DOI 10.18632/oncotarget.3269; Tcherkezian J, 2005, MOL CELL BIOL, V25, P6314, DOI 10.1128/MCB.25.15.6314-6329.2005; Tcherkezian J, 2007, BIOL CELL, V99, P67, DOI 10.1042/BC20060086; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Wang CA, 2014, CANCER RES, V74, P7357, DOI 10.1158/0008-5472.CAN-14-0666; Wang JL, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5735; Wong TS, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/921564; Wu ZQ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4998	46	26	28	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2017	36	24					3490	3503		10.1038/onc.2016.492	http://dx.doi.org/10.1038/onc.2016.492			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EX6GL	28135249	Green Accepted			2022-12-17	WOS:000403340700012
J	Wu, MJ; Kim, MR; Chen, YS; Yang, JY; Chang, CJ				Wu, M-J; Kim, M. R.; Chen, Y-S; Yang, J-Y; Chang, C-J			Retinoic acid directs breast cancer cell state changes through regulation of TET2-PKC zeta pathway	ONCOGENE			English	Article							PROTEIN-KINASE-C; EPITHELIAL-MESENCHYMAL TRANSITION; STEM-CELL; PKC-ZETA; PROGRESSION; METASTASIS; TRIAL; FATE	The key molecular mechanism governing the cancer cell state (stem cell-like state vs differentiation state) to control the cancer stem cell (CSC) pool remains elusive. This study provides the first evidence showing that all-trans retinoic acid (ATRA) induces the interaction and chromatin recruitment of a novel RAR beta-TET2 complex to epigenetically activate a specific cohort of gene targets, including MiR-200c. TET2-activated miR-200c further targets and suppresses PKC zeta, a cell polarity protein that has a pivotal role in directing asymmetric division of mammalian stem cells to sustain the stem cell pool. Our data reveal that pharmacological concentration of ATRA effectively downregulates PKC zeta through activation of miR-200c, leading to a decrease of the stem cell-like populations from non-tumorigenic mammary epithelial cells and non-aggressive breast cancer cells. However, aggressive breast cancer cells that manifest TET2-miR-200c dysregulation sustain a CSC pool highly resistant to ATRA, where inhibition of PKC zeta directs the resistant CSCs to the luminal cell-like state and sensitization to tamoxifen, resulting in abrogation of mammary tumor growth and progression. Together, these findings elucidate a novel RAR beta-TET2-miR-200c-PKC zeta signaling pathway that directs cancer cell state changes and also provide previously unidentified therapeutic implications for PKC zeta inhibitors in diminishment of breast CSCs to eradicate breast cancer.	[Wu, M-J; Kim, M. R.; Chen, Y-S; Yang, J-Y; Chang, C-J] Purdue Univ, Dept Basic Med Sci, 625 Harrison St, W Lafayette, IN 47907 USA; [Wu, M-J; Kim, M. R.; Chen, Y-S; Yang, J-Y; Chang, C-J] Purdue Univ, Ctr Canc Res, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Chang, CJ (corresponding author), Purdue Univ, Dept Basic Med Sci, 625 Harrison St, W Lafayette, IN 47907 USA.	chunjuchang@purdue.edu	Wu, Meng-Ju/AAY-9406-2021; Wu, Meng-Ju/AAY-9410-2021	Wu, Meng-Ju/0000-0001-6847-7065; Chang, Chunju/0000-0003-2887-9603	Department of Defense Breast Cancer Breakthrough Award [W81XWH-15-1-0644]; V foundation for Cancer Research Grant [V2015-019];  [P30 CA023168]; NATIONAL CANCER INSTITUTE [P30CA023168] Funding Source: NIH RePORTER	Department of Defense Breast Cancer Breakthrough Award; V foundation for Cancer Research Grant; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the assistance of Dr Chao-Ching Chang as well as Dr Chi-Hong Chao with advice on animal and biochemical experiments, and Mr Chun-Chih Hsu with LC-MS/MS analysis. This study was supported by Department of Defense Breast Cancer Breakthrough Award (W81XWH-15-1-0644 to C-J Chang), V foundation for Cancer Research Grant (V2015-019 to C-J Chang), and P30 CA023168 to the Purdue University Center for Cancer Research in support of the use of facilities.	Antal CE, 2015, CELL, V160, P489, DOI 10.1016/j.cell.2015.01.001; Bryan M, 2011, INVEST NEW DRUG, V29, P1482, DOI 10.1007/s10637-010-9478-3; Castoria G, 2004, MOL CELL BIOL, V24, P7643, DOI 10.1128/MCB.24.17.7643-7653.2004; Chang CC, 2015, CANCER RES, V75, P2375, DOI 10.1158/0008-5472.CAN-14-3076; Chang CJ, 2011, NAT CELL BIOL, V13, P317, DOI 10.1038/ncb2173; Chao CH, 2014, J CLIN INVEST, V124, P3093, DOI 10.1172/JCI73351; Chen Q, 2013, NATURE, V493, P561, DOI 10.1038/nature11742; Cuzick J, 2011, LANCET ONCOL, V12, P496, DOI 10.1016/S1470-2045(11)70030-4; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; Garattini E, 2007, VITAM HORM, V75, P301, DOI 10.1016/S0083-6729(06)75012-9; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Ito S, 2010, NATURE, V466, P1129, DOI 10.1038/nature09303; Knoblich JA, 2010, NAT REV MOL CELL BIO, V11, P849, DOI 10.1038/nrm3010; Kumar BNP, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-273; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Martin-Belmonte F, 2012, NAT REV CANCER, V12, P23, DOI 10.1038/nrc3169; Paul A, 2015, SCI REP-UK, V5, DOI 10.1038/srep12520; Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Smith CA, 2007, EMBO J, V26, P468, DOI 10.1038/sj.emboj.7601495; Song SJ, 2013, CELL, V154, P311, DOI 10.1016/j.cell.2013.06.026; Sutton LM, 1997, CANCER CHEMOTH PHARM, V40, P335, DOI 10.1007/s002800050666; Tang XH, 2011, ANNU REV PATHOL-MECH, V6, P345, DOI 10.1146/annurev-pathol-011110-130303; Urtreger AJ, 2005, MOL CARCINOGEN, V42, P29, DOI 10.1002/mc.20066; Urtreger AJ, 2012, IUBMB LIFE, V64, P18, DOI 10.1002/iub.574; Veronesi U, 1999, J NATL CANCER I, V91, P1847, DOI 10.1093/jnci/91.21.1847; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Zhang F, 2010, CANCER RES, V70, P9360, DOI 10.1158/0008-5472.CAN-10-0207	32	26	27	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2017	36	22					3193	3206		10.1038/onc.2016.467	http://dx.doi.org/10.1038/onc.2016.467			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW6KA	28218902	hybrid, Green Published			2022-12-17	WOS:000402617900011
J	Zelenko, Z; Gallagher, EJ; Tobin-Hess, A; Belardi, V; Rostoker, R; Blank, J; Dina, Y; LeRoith, D				Zelenko, Z.; Gallagher, E. J.; Tobin-Hess, A.; Belardi, V.; Rostoker, R.; Blank, J.; Dina, Y.; LeRoith, D.			Silencing vimentin expression decreases pulmonary metastases in a pre-diabetic mouse model of mammary tumor progression	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; TYPE-2 DIABETES-MELLITUS; MICE LACKING VIMENTIN; BREAST-CANCER; IGF-I; INSULIN-RESISTANCE; CELL MIGRATION; INCREASED RISK; HYPERINSULINEMIA; INVASION	Increased breast cancer risk and mortality has been associated with obesity and type 2 diabetes (T2D). Hyperinsulinemia, a key factor in obesity, pre-diabetes and T2D, has been associated with decreased breast cancer survival. In this study, a mouse model of pre-diabetes (MKR mouse) was used to investigate the mechanisms through which endogenous hyperinsulinemia promotes mammary tumor metastases. The MKR mice developed larger primary tumors and greater number of pulmonary metastases compared with wild-type (WT) mice after injection with c-Myc/Vegf overexpressing MVT-1 cells. Analysis of the primary tumors showed significant increase in vimentin protein expression in the MKR mice compared with WT. We hypothesized that vimentin was an important mediator in the effect of hyperinsulinemia on breast cancer metastasis. Lentiviral short hairpin RNA knockdown of vimentin led to a significant decrease in invasion of the MVT-1 cells and abrogated the increase in cell invasion in response to insulin. In the pre-diabetic MKR mouse, vimentin knockdown led to a decrease in pulmonary metastases. In vitro, we found that insulin increased pAKT, prevented caspase 3 activation, and increased vimentin. Inhibiting the phosphatidylinositol 3 kinase/AKT pathway, using NVP-BKM120, increased active caspase 3 and decreased vimentin levels. This study is the first to show that vimentin has an important role in tumor metastasis in vivo in the setting of pre-diabetes and endogenous hyperinsulinemia. Vimentin targeting may be an important therapeutic strategy to reduce metastases in patients with obesity, pre-diabetes or T2D.	[Zelenko, Z.; Gallagher, E. J.; Tobin-Hess, A.; Belardi, V.; Blank, J.; Dina, Y.; LeRoith, D.] Icahn Sch Med Mt Sinai, Div Endocrinol Diabet & Bone Dis, One Gustave L Levy Pl,Box 1055, New York, NY 10029 USA; [Rostoker, R.; LeRoith, D.] CRIR, Haifa, Israel; [Rostoker, R.; LeRoith, D.] Technion, Fac Med, Diabet & Metab Clin Res Ctr Excellence, Haifa, Israel	Icahn School of Medicine at Mount Sinai; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	LeRoith, D (corresponding author), Icahn Sch Med Mt Sinai, Div Endocrinol Diabet & Bone Dis, One Gustave L Levy Pl,Box 1055, New York, NY 10029 USA.	Derek.LeRoith@mssm.edu			NCI grant [2R01CA128799-06A1]; American Diabetes grant [1-13-BS-108]; NIH/NCI [1K08CA190770]; NCI Supplement [R01CA171558-02S1]; NATIONAL CANCER INSTITUTE [K08CA190770, R01CA128799, R01CA171558] Funding Source: NIH RePORTER	NCI grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Diabetes grant; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI Supplement; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	NCI grant (grant 2R01CA128799-06A1) to DLR. American Diabetes grant 1-13-BS-108 to DLR. NIH/NCI 1K08CA190770 to EJG. NCI Supplement R01CA171558-02S1 to YD. Scuola di Specializzazione in Endocrinologia e Malattie del Metabolismo, University of Pisa to VB.	ADAMI HO, 1991, CANCER CAUSE CONTROL, V2, P307, DOI 10.1007/BF00051670; Beronja S, 2010, NAT MED, V16, P821, DOI 10.1038/nm.2167; Borowsky AD, 2005, CLIN EXP METASTAS, V22, P47, DOI 10.1007/s10585-005-2908-5; Cannata D, 2010, ENDOCRINOLOGY, V151, P5751, DOI 10.1210/en.2010-0792; Chari ST, 2005, GASTROENTEROLOGY, V129, P504, DOI 10.1053/j.gastro.2005.05.007; COLUCCIGUYON E, 1994, CELL, V79, P679, DOI 10.1016/0092-8674(94)90553-3; DeFronzo RA, 2004, MED CLIN N AM, V88, P787, DOI 10.1016/j.mcna.2004.04.013; Eckes B, 1998, J CELL SCI, V111, P1897; Eckes B, 2000, J CELL SCI, V113, P2455; Ferguson RD, 2013, ENDOCR-RELAT CANCER, V20, P391, DOI 10.1530/ERC-12-0333; Ferguson RD, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3089; Fernandez AM, 2001, GENE DEV, V15, P1926, DOI 10.1101/gad.908001; Fierz Y, 2010, DIABETES, V59, P686, DOI 10.2337/db09-1291; FRANKE WW, 1982, DIFFERENTIATION, V23, P43, DOI 10.1111/j.1432-0436.1982.tb01266.x; Gilles C, 1999, J CELL SCI, V112, P4615; Goodwin PJ, 2002, J CLIN ONCOL, V20, P42, DOI 10.1200/JCO.20.1.42; Haslam DW, 2005, LANCET, V366, P1197, DOI 10.1016/S0140-6736(05)67483-1; Hines IN, 2011, AM J PATHOL, V179, P2855, DOI 10.1016/j.ajpath.2011.08.014; Lawlor DA, 2004, CANCER CAUSE CONTROL, V15, P267, DOI 10.1023/B:CACO.0000024225.14618.a8; LeRoith D, 2006, INT J BIOCHEM CELL B, V38, P904, DOI 10.1016/j.biocel.2005.01.019; Lipscombe LL, 2008, BREAST CANCER RES TR, V109, P389, DOI 10.1007/s10549-007-9654-0; Los M, 2002, MOL BIOL CELL, V13, P978, DOI 10.1091/mbc.01-05-0272; Marshall J, 2011, METHODS MOL BIOL, V769, P97, DOI 10.1007/978-1-61779-207-6_8; McInroy L, 2007, BIOCHEM BIOPH RES CO, V360, P109, DOI 10.1016/j.bbrc.2007.06.036; Mendez MG, 2010, FASEB J, V24, P1838, DOI 10.1096/fj.09-151639; Moore CB, 2010, METHODS MOL BIOL, V629, P139, DOI 10.1007/978-1-60761-657-3_10; Novosyadlyy R, 2010, CANCER RES, V70, P741, DOI 10.1158/0008-5472.CAN-09-2141; Onitilo AA, 2012, CANCER CAUSE CONTROL, V23, P967, DOI 10.1007/s10552-012-9972-3; Ouchi N, 2011, NAT REV IMMUNOL, V11, P85, DOI 10.1038/nri2921; Pei XF, 2004, IN VITRO CELL DEV-AN, V40, P14; Redaniel MTM, 2012, CANCER CAUSE CONTROL, V23, P1785, DOI 10.1007/s10552-012-0057-0; Rostoker R, 2015, ENDOCR-RELAT CANCER, V22, P145, DOI 10.1530/ERC-14-0490; Samani AA, 2007, ENDOCR REV, V28, P20, DOI 10.1210/er.2006-0001; Satelli A, 2011, CELL MOL LIFE SCI, V68, P3033, DOI 10.1007/s00018-011-0735-1; Shen XC, 2015, J BIOL CHEM, V290, P11578, DOI 10.1074/jbc.M114.620237; Svegliati-Baroni G, 2011, GUT, V60, P108, DOI 10.1136/gut.2010.219741; Tezcan O, 2014, BIOMED PHARMACOTHER, V68, P357, DOI 10.1016/j.biopha.2014.01.006; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Vuoriluoto K, 2011, ONCOGENE, V30, P1436, DOI 10.1038/onc.2010.509; Wei JC, 2008, ANTICANCER RES, V28, P327; Yang Y, 2012, CANCER, V119, P1512; Yu Y, 2014, BRIT J CANCER, V110, P724, DOI 10.1038/bjc.2013.768; Zanders MMJ, 2013, MATURITAS, V74, P37, DOI 10.1016/j.maturitas.2012.10.007; Zhang PH, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-567; Zhu QS, 2011, ONCOGENE, V30, P457, DOI 10.1038/onc.2010.421	45	26	26	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 9	2017	36	10					1394	1403		10.1038/onc.2016.305	http://dx.doi.org/10.1038/onc.2016.305			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2TG	27568979	Green Accepted			2022-12-17	WOS:000395862500008
J	Queisser, A; Hagedorn, S; Wang, H; Schaefer, T; Konantz, M; Alavi, S; Deng, M; Vogel, W; Von Mssenhausen, A; Kristiansen, G; Duensing, S; Kirfel, J; Lengerke, C; Perner, S				Queisser, A.; Hagedorn, S.; Wang, H.; Schaefer, T.; Konantz, M.; Alavi, S.; Deng, M.; Vogel, W.; Von Mssenhausen, A.; Kristiansen, G.; Duensing, S.; Kirfel, J.; Lengerke, C.; Perner, S.			Ecotropic viral integration site 1, a novel oncogene in prostate cancer	ONCOGENE			English	Article							CELL-CYCLE PROGRESSION; STEM-LIKE CELL; EVI1; EXPRESSION; OVARIAN; ERG; AMPLIFICATION; ONCOPROTEIN; INHIBITOR; ZEBRAFISH	Prostate cancer (PCa) is the most commonly diagnosed non-cutaneous cancer in men in the western world. Mutations in tumor suppressor genes and in oncogenes are important for PCa progression, whereas the role of stem cell proteins in prostate carcinogenesis is insufficiently examined. This study investigates the role of the transcriptional regulator Ecotropic Viral Integration site 1 (EVI1), known as an essential modulator of hematopoietic and leukemic stem cell biology, in prostate carcinogenesis. We show that in healthy prostatic tissue, EVI1 expression is confined to the prostate stem cell compartment located at the basal layer, as identified by the stem cell marker CD44. Instead, in a PCa progression cohort comprising 219 samples from patients with primary PCa, lymph node and distant metastases, EVI1 protein was heterogeneously distributed within samples and high expression is associated with tumor progression (P<0.001), suggesting EVI1 induction as a driver event. Functionally, short hairpin RNAmediated knockdown of EVI1 inhibited proliferation, cell cycle progression, migratory capacity and anchorage-independent growth of human PCa cells, while enhancing their apoptosis sensitivity. Interestingly, modulation of EVI1 expression also strongly regulated stem cell properties (including expression of the stem cell marker SOX2) and in vivo tumor initiation capacity. Further emphasizing a functional correlation between EVI1 induction and tumor progression, upregulation of EVI1 expression was noted in experimentally derived docetaxel-resistant PCa cells. Importantly, knockdown of EVI1 in these cells restored sensitivity to docetaxel, in part by downregulating anti-apoptotic BCL2. Together, these data indicate EVI1 as a novel molecular regulator of PCa progression and therapy resistance that may control prostate carcinogenesis at the stem cell level.	[Queisser, A.; Hagedorn, S.; Alavi, S.; Von Mssenhausen, A.; Perner, S.] Univ Hosp Bonn, Sect Prostate Canc Res, Bonn, Germany; [Queisser, A.; Hagedorn, S.; Alavi, S.; Von Mssenhausen, A.; Kristiansen, G.; Kirfel, J.; Perner, S.] Univ Hosp Bonn, Inst Pathol, Bonn, Germany; [Queisser, A.; Hagedorn, S.; Alavi, S.; Von Mssenhausen, A.; Kristiansen, G.; Kirfel, J.; Perner, S.] Univ Hosp Bonn, Ctr Integrated Oncol Cologne Bonn, Bonn, Germany; [Wang, H.; Schaefer, T.; Konantz, M.; Lengerke, C.] Univ Basel Hosp, Dept Biomed, Hebelstr 20, CH-4031 Basel, Switzerland; [Vogel, W.; Perner, S.] Univ Med Ctr Schleswig Holstein, Campus Luebeck & Res Ctr Borstel, Leibniz Ctr Med & Biosci, Borstel, Germany; [Duensing, S.] Heidelberg Univ, Sch Med, Dept Urol, Sect Mol Urooncol, Heidelberg, Germany; Univ Basel Hosp, Dept Biomed, Hebelstrasse 20, CH-4031 Basel, Switzerland	University of Bonn; University of Bonn; University of Bonn; University of Basel; Forschungszentrum Borstel; University of Kiel; Schleswig Holstein University Hospital; Ruprecht Karls University Heidelberg; University of Basel	Lengerke, C (corresponding author), Univ Basel Hosp, Dept Biomed, Hebelstr 20, CH-4031 Basel, Switzerland.; Lengerke, C (corresponding author), Pathol Univ Hosp Luebeck, Leibniz Res Ctr Borstel, Inst Pathol, Ratzeburger Allee 160,Bldg 50, D-23538 Lubeck, Germany.	Claudia.Lengerke@unibas.ch; Sven.Perner@uksh.de	alavi, samin/Y-3285-2019; Lengerke, Claudia/AAV-8745-2021; , Anne/ABC-3403-2021	Lengerke, Claudia/0000-0001-5442-2805; , Anne/0000-0002-4727-782X; Schaefer, Thorsten/0000-0003-4867-8374; Konantz, Martina/0000-0002-4319-3119	German Research Foundation (Deutsche Forschungsgemeinschaft) [PE 1179/11-1]; Schweizer Nationalfonds [310030_149735]; Rudolf-Becker-Foundation; Wilhelm-Sander-Foundation [2011.077.2]; German Cancer Aid (Mildred-Scheel Doctoral Student Fellowship)	German Research Foundation (Deutsche Forschungsgemeinschaft)(German Research Foundation (DFG)); Schweizer Nationalfonds; Rudolf-Becker-Foundation; Wilhelm-Sander-Foundation; German Cancer Aid (Mildred-Scheel Doctoral Student Fellowship)	The study was supported by a grant from the German Research Foundation (Deutsche Forschungsgemeinschaft (PE 1179/11-1)) to SP, the Schweizer Nationalfonds to CL (310030_149735), the Rudolf-Becker-Foundation and the Wilhelm-Sander-Foundation (2011.077.2) to SP and the German Cancer Aid (Mildred-Scheel Doctoral Student Fellowship) to SH. We also acknowledge the TCGA Research Network for providing their cancer data sets.	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Aytekin M, 2005, GENE, V356, P160, DOI 10.1016/j.gene.2005.04.032; Baca SC, 2013, CELL, V153, P666, DOI 10.1016/j.cell.2013.03.021; Barbieri CE, 2012, NAT GENET, V44, P685, DOI 10.1038/ng.2279; Bard-Chapeau EA, 2012, P NATL ACAD SCI USA, V109, P2168, DOI 10.1073/pnas.1119229109; Bareiss PM, 2013, CANCER RES, V73, P5544, DOI 10.1158/0008-5472.CAN-12-4177; Beltran H, 2011, CANCER DISCOV, V1, P487, DOI 10.1158/2159-8290.CD-11-0130; Braun M, 2012, PROSTATE CANCER P D, V15, P165, DOI 10.1038/pcan.2011.67; Brooks DJ, 1996, BRIT J CANCER, V74, P1518, DOI 10.1038/bjc.1996.583; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen X, 2013, CELL CYCLE, V12, P579, DOI 10.4161/cc.23721; Choi J, 2007, DEV BIOL, V304, P735, DOI 10.1016/j.ydbio.2007.01.023; De Marzo AM, 2007, NAT REV CANCER, V7, P256, DOI 10.1038/nrc2090; Deng XY, 2013, MOL CARCINOGEN, V52, P255, DOI 10.1002/mc.21852; Dutta P, 2013, MOL ONCOL, V7, P647, DOI 10.1016/j.molonc.2013.02.008; Fan XL, 2012, UROL ONCOL-SEMIN ORI, V30, P314, DOI 10.1016/j.urolonc.2010.03.019; Gao D, 2014, CELL, V159, P176, DOI 10.1016/j.cell.2014.08.016; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Goyama S, 2010, INT J HEMATOL, V91, P753, DOI 10.1007/s12185-010-0618-5; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Haldi Maryann, 2006, Angiogenesis, V9, P139, DOI 10.1007/s10456-006-9040-2; Han L, 2013, ACTA PHARM SIN B, V3, P65, DOI 10.1016/j.apsb.2013.02.006; Hieronymus H, 2014, P NATL ACAD SCI USA, V111, P11139, DOI 10.1073/pnas.1411446111; KAIGHN ME, 1979, INVEST UROL, V17, P16; Kataoka K, 2012, CANCER SCI, V103, P1371, DOI 10.1111/j.1349-7006.2012.02303.x; Kerr CL, 2014, CURR OPIN ONCOL, V26, P328, DOI 10.1097/CCO.0000000000000080; Konantz M, 2013, LEUKEMIA, V27, P56, DOI 10.1038/leu.2012.211; Konantz M, 2012, ANN NY ACAD SCI, V1266, P124, DOI 10.1111/j.1749-6632.2012.06575.x; Kregel S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053701; Kumar A, 2016, NAT MED, V22, P369, DOI 10.1038/nm.4053; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Kustikova OS, 2013, LEUKEMIA, V27, P1127, DOI 10.1038/leu.2012.355; Li P, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-55; Liu Y, 2006, ONCOGENE, V25, P3565, DOI 10.1038/sj.onc.1209403; McGilvray R, 2007, FEBS J, V274, P3960, DOI 10.1111/j.1742-4658.2007.05928.x; Mosquera JM, 2007, J PATHOL, V212, P91, DOI 10.1002/path.2154; Mosquera JM, 2013, NEOPLASIA, V15, P1, DOI 10.1593/neo.121550; MUCENSKI ML, 1988, MOL CELL BIOL, V8, P301, DOI 10.1128/MCB.8.1.301; Nanjundan M, 2007, CANCER RES, V67, P3074, DOI 10.1158/0008-5472.CAN-06-2366; Nayak KB, 2013, INT J BIOCHEM CELL B, V45, P1568, DOI 10.1016/j.biocel.2013.04.032; Nwachukwu JC, 2009, CANCER RES, V69, P3140, DOI 10.1158/0008-5472.CAN-08-3738; Pardali K, 2005, J CELL PHYSIOL, V204, P260, DOI 10.1002/jcp.20304; Patel JB, 2011, ONCOGENE, V30, P1290, DOI 10.1038/onc.2010.510; PEDRALINOY G, 1980, NUCLEIC ACIDS RES, V8, P377, DOI 10.1093/nar/8.2.377; Perner S, 2006, CANCER RES, V66, P8337, DOI 10.1158/0008-5472.CAN-06-1482; Pflueger D, 2009, NEOPLASIA, V11, P804, DOI 10.1593/neo.09572; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Rosa-Ribeiro R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097080; Sattler HP, 2000, PROSTATE, V45, P207, DOI 10.1002/1097-0045(20001101)45:3<207::AID-PROS2>3.0.CO;2-H; Schaefer T, 2015, ONCOTARGET, V6, P43540, DOI 10.18632/oncotarget.6183; Scheble VJ, 2010, MODERN PATHOL, V23, P1061, DOI 10.1038/modpathol.2010.87; Schroeder A, 2014, CANCER RES, V74, P1227, DOI 10.1158/0008-5472.CAN-13-0594; Sethi S, 2013, AM J TRANSL RES, V5, P200; Shackelford D, 2006, CANCER RES, V66, P11360, DOI 10.1158/0008-5472.CAN-06-1774; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Souers AJ, 2013, NAT MED, V19, P202, DOI 10.1038/nm.3048; Tanaka M, 2014, ONCOGENE, V33, P2454, DOI 10.1038/onc.2013.204; Taneja SS, 2004, J BIOL CHEM, V279, P13944, DOI 10.1074/jbc.M306576200; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Tu SM, 2012, CLIN GENITOURIN CANC, V10, P69, DOI 10.1016/j.clgc.2012.01.002; van Doorn-Khosrovani SBV, 2003, BLOOD, V101, P837, DOI 10.1182/blood-2002-05-1459; Van Leenders GJLH, 2001, BJU INT, V88, P35, DOI 10.1046/j.1464-410X.2001.00117.x; Volkert S, 2014, CANCER GENET-NY, V207, P103, DOI 10.1016/j.cancergen.2014.02.010; Wang H, 2015, JOVE-J VIS EXP, V95; Wieser R, 2007, GENE, V396, P346, DOI 10.1016/j.gene.2007.04.012; Yu ZR, 2012, INT J BIOCHEM CELL B, V44, P2144, DOI 10.1016/j.biocel.2012.08.022; Zhang BB, 2014, TUMOR BIOL, V35, P11861, DOI 10.1007/s13277-014-2417-8	68	26	26	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	11					1573	1584		10.1038/onc.2016.325	http://dx.doi.org/10.1038/onc.2016.325			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EP5ZR	27617580				2022-12-17	WOS:000397458100011
J	Yang, G; Gong, Y; Wang, Q; Wang, L; Zhang, X				Yang, G.; Gong, Y.; Wang, Q.; Wang, L.; Zhang, X.			miR-100 antagonism triggers apoptosis by inhibiting ubiquitination-mediated p53 degradation	ONCOGENE			English	Article							MICRORNA EXPRESSION; TUMOR SUPPRESSION; PROTEIN LIGASE; PROTEASOME; BREAST; SIGNATURE; FAMILY; GENES; MDM2	During tumourigenesis, p53 functions as 'the guardian of the genome' because p53-dependent apoptosis strongly regulates the fate of cancer cells. Therefore, p53 regulation must be sensitive and accurate. p53 activity is regulated through its ubiquitination and deubiquitination. However, the role of microRNA in ubiquitin-mediated p53 degradation has not been previously studied. Our previous studies indicated that miR-100 is required for apoptosis. In the current study, the mechanism of p53 protein ubiquitination mediated by miR-100 was characterized. An analysis of primary tumour samples from gastric cancer patients showed a significant correlation between miR-100 upregulation and primary human gastric tumourigenesis and progression. The in vivo and in vitro data indicated that miR-100 antagonism specifically induced the apoptosis of poorly differentiated gastric cancer cells but not non-cancerous gastric cells, indicating that miR-100 has a crucial role in regulating the progression of gastric tumours. In the regulation of p53-dependent apoptosis, miR-100 antagonism inhibited ubiquitin-mediated p53 protein degradation by activating RNF144B, an E3 ubiquitination ligase. Consequently, the miR-100-RNF144B-pirh2-p53-dependent pathway was initiated. Our findings highlight a novel mechanism of ubiquitin-mediated p53 protein degradation in apoptosis.	[Yang, G.; Gong, Y.; Zhang, X.] Zhejiang Univ, Collaborat Innovat Ctr Deep Sea Biol, 388 Yuhangtang Rd, Hangzhou 310004, Zhejiang, Peoples R China; [Yang, G.; Gong, Y.; Zhang, X.] Zhejiang Univ, Coll Life Sci, 388 Yuhangtang Rd, Hangzhou 310004, Zhejiang, Peoples R China; [Wang, Q.; Wang, L.] Bengbu Med Coll, Affiliated Hosp 1, Dept Gastroenterol, Bengbu, Peoples R China	Zhejiang University; Zhejiang University; Bengbu Medical College	Zhang, X (corresponding author), Zhejiang Univ, Collaborat Innovat Ctr Deep Sea Biol, 388 Yuhangtang Rd, Hangzhou 310004, Zhejiang, Peoples R China.; Zhang, X (corresponding author), Zhejiang Univ, Coll Life Sci, 388 Yuhangtang Rd, Hangzhou 310004, Zhejiang, Peoples R China.	zxb0812@zju.edu.cn		Zhang, Xiaobo/0000-0003-4606-212X	National Natural Science Foundation of China [41276152, 31430089]; National Program on the Key Basic Research Project [2015CB755903]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Program on the Key Basic Research Project	This work was supported by the National Natural Science Foundation of China (41276152, 31430089) and the National Program on the Key Basic Research Project (2015CB755903).	Adams J, 2003, CANCER TREAT REV, V29, P3, DOI 10.1016/S0305-7372(03)00081-1; Allende-Vega N, 2010, SEMIN CANCER BIOL, V20, P29, DOI 10.1016/j.semcancer.2009.10.004; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Barboza JA, 2008, MOL CANCER RES, V6, P947, DOI 10.1158/1541-7786.MCR-07-2079; Bartel DP, 2004, NAT REV GENET, V5, P396, DOI 10.1038/nrg1328; Benard G, 2010, EMBO J, V29, P1458, DOI 10.1038/emboj.2010.39; Bernassola F, 2008, CANCER CELL, V14, P10, DOI 10.1016/j.ccr.2008.06.001; Cairo S, 2010, P NATL ACAD SCI USA, V107, P20471, DOI 10.1073/pnas.1009009107; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chen D, 2009, EMBO REP, V10, P166, DOI 10.1038/embor.2008.231; Christodoulou F, 2010, NATURE, V463, P1084, DOI 10.1038/nature08744; Conforti F, 2013, ONCOGENE, V32, P4758, DOI 10.1038/onc.2012.497; Deng YB, 2008, NAT REV CANCER, V8, P450, DOI 10.1038/nrc2393; Donehower LA, 2009, NAT REV CANCER, V9, P830, DOI 10.1038/nrc2731; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074; Feki A, 2004, CRIT REV ONCOL HEMAT, V52, P103, DOI 10.1016/j.critrevonc.2004.07.002; Gong Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep11650; Henson BJ, 2009, GENE CHROMOSOME CANC, V48, P569, DOI 10.1002/gcc.20666; Isaacson MK, 2009, CELL HOST MICROBE, V5, P559, DOI 10.1016/j.chom.2009.05.012; Laine A, 2007, ONCOGENE, V26, P1477, DOI 10.1038/sj.onc.1209924; Le MTN, 2009, GENE DEV, V23, P862, DOI 10.1101/gad.1767609; Lee EJ, 2007, INT J CANCER, V120, P1046, DOI 10.1002/ijc.22394; Leite KRM, 2011, UROL ONCOL-SEMIN ORI, V29, P265, DOI 10.1016/j.urolonc.2009.02.002; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Liu W, 2009, CHINESE MED J-PEKING, V122, P2405, DOI 10.3760/cma.j.issn.0366-6999.2009.20.002; Liu ZQ, 2007, DEV DYNAM, V236, P2889, DOI 10.1002/dvdy.21302; Medina-Ramirez CM, 2011, CANCER RES, V71, P7705, DOI 10.1158/0008-5472.CAN-11-2192; Mercer J, 2007, MUTAT RES-FUND MOL M, V621, P75, DOI 10.1016/j.mrfmmm.2007.02.011; Motegi A, 2009, CANCER LETT, V283, P1, DOI 10.1016/j.canlet.2008.12.030; Nam EJ, 2008, CLIN CANCER RES, V14, P2690, DOI 10.1158/1078-0432.CCR-07-1731; Pietsch EC, 2008, ONCOGENE, V27, P6507, DOI 10.1038/onc.2008.315; Ravid T, 2008, NAT REV MOL CELL BIO, V9, P679, DOI 10.1038/nrm2468; Shang F, 2011, FREE RADICAL BIO MED, V51, P5, DOI 10.1016/j.freeradbiomed.2011.03.031; Shi W, 2010, INT J CANCER, V126, P2036, DOI 10.1002/ijc.24880; Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312; Tsvetkov P, 2011, J BIOL CHEM, V286, P8839, DOI 10.1074/jbc.M110.193276; Wang XJ, 2011, CELL CYCLE, V10, P4225, DOI 10.4161/cc.10.24.18662; Wienholds E, 2005, SCIENCE, V309, P310, DOI 10.1126/science.1114519; Wong TS, 2008, CLIN CANCER RES, V14, P2588, DOI 10.1158/1078-0432.CCR-07-0666; Yang G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039015; Zuckerman V, 2009, J PATHOL, V219, P3, DOI 10.1002/path.2584	44	26	27	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2017	36	8					1023	1037		10.1038/onc.2016.270	http://dx.doi.org/10.1038/onc.2016.270			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EM5SA	27524417				2022-12-17	WOS:000395371500001
J	Garcia-Rendueles, AR; Rodrigues, JS; Garcia-Rendueles, MER; Suarez-Farina, M; Perez-Romero, S; Barreiro, F; Bernabeu, I; Rodriguez-Garcia, J; Fugazzola, L; Sakai, T; Liu, F; Cameselle-Teijeiro, J; Bravo, SB; Alvarez, CV				Garcia-Rendueles, A. R.; Rodrigues, J. S.; Garcia-Rendueles, M. E. R.; Suarez-Farina, M.; Perez-Romero, S.; Barreiro, F.; Bernabeu, I.; Rodriguez-Garcia, J.; Fugazzola, L.; Sakai, T.; Liu, F.; Cameselle-Teijeiro, J.; Bravo, S. B.; Alvarez, C. V.			Rewiring of the apoptotic TGF-beta-SMAD/NF kappa B pathway through an oncogenic function of p27 in human papillary thyroid cancer	ONCOGENE			English	Article							GROWTH-FACTOR-BETA; KINASE INHIBITOR P27(KIP1); CELL-CYCLE PROGRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; BREAST-CANCER; MESSENGER-RNA; CDK INHIBITOR; TRANSCRIPTIONAL ACTIVATION; DEPENDENT KINASES; TUMOR-SUPPRESSOR	Papillary thyroid carcinoma (PTC), the most frequent thyroid cancer, is characterized by low proliferation but no apoptosis, presenting frequent lymph-node metastasis. Papillary thyroid carcinoma overexpress transforming growth factor-beta (TGF-beta). In human cells, TGF-beta has two opposing actions: antitumoral through pro-apoptotic and cytostatic activities, and pro-tumoral promoting growth and metastasis. The switch converting TGF-beta from a tumor-suppressor to tumor-promoter has not been identified. In the current study, we have quantified a parallel upregulation of TGF-beta and nuclear p27, a CDK2 inhibitor, in samples from PTC. We established primary cultures from follicular epithelium in human homeostatic conditions (h7H medium). TGF-beta-dependent cytostasis occurred in normal and cancer cells through p15/CDKN2B induction. However, TGF-beta induced apoptosis in normal and benign but not in carcinoma cultures. In normal thyroid cells, TGF-beta/SMAD repressed the p27/CDKN1B gene, activating CDK2-dependent SMAD3 phosphorylation to induce p50 NF kappa B-dependent BAX upregulation and apoptosis. In thyroid cancer cells, oncogene activation prevented TGF-beta/SMAD-dependent p27 repression, and CDK2/SMAD3 phosphorylation, leading to p65 NF kappa B upregulation which repressed BAX, induced cyclin D1 and promoted TGF-beta-dependent growth. In PTC samples from patients, upregulation of TGF-beta, p27, p65 and cyclin D1 mRNA were significantly correlated, while the expression of the isoform BAX-beta, exclusively transcribed in apoptotic cells, was negatively correlated. Additionally, combined ERK and p65 NF kappa B inhibitors reduced p27 expression and potentiated apoptosis in thyroid cancer cells while not affecting survival in normal thyroid cells. Our results therefore suggest that the oncoprotein p27 reorganizes the effects of TGF-beta in thyroid cancer, explaining the slow proliferation but lack of apoptosis and metastatic behavior of PTC.	[Garcia-Rendueles, A. R.; Rodrigues, J. S.; Garcia-Rendueles, M. E. R.; Suarez-Farina, M.; Perez-Romero, S.; Alvarez, C. V.] USC, Ctr Invest Mol Med & Chron Dis CIMUS, Santiago De Compostela, Spain; [Garcia-Rendueles, A. R.; Rodrigues, J. S.; Garcia-Rendueles, M. E. R.; Suarez-Farina, M.; Perez-Romero, S.; Alvarez, C. V.] USC, Inst Invest Sanitarias IDIS, Grp Endocrine Neoplasia & Differentiat, Santiago De Compostela, Spain; [Barreiro, F.] Univ Hosp Santiago de Compostela CHUS, Dept Surg, Santiago De Compostela, Spain; [Barreiro, F.; Bernabeu, I.; Rodriguez-Garcia, J.; Cameselle-Teijeiro, J.] USC, Santiago De Compostela, Spain; [Bernabeu, I.] Univ Hosp Santiago de Compostela CHUS, Dept Endocrinol, Santiago De Compostela, Spain; [Rodriguez-Garcia, J.] Univ Hosp Santiago de Compostela CHUS, Dept Clin Biochem, Santiago De Compostela, Spain; [Fugazzola, L.] Fdn IRCCS Ca Granda Policlin, Endocrine Unit, Milan, Italy; [Fugazzola, L.] Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy; [Sakai, T.] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Targeting Canc Prevent, Kyoto, Japan; [Liu, F.] Rutgers State Univ, Rutgers Canc Inst New Jersey, Susan Lehman Cullman Lab Canc Res, Ctr Adv Biotechnol & Med,Ernest Mario Sch Pham, Piscataway, NJ USA; [Cameselle-Teijeiro, J.] Univ Hosp Santiago de Compostela CHUS, Dept Pathol, Santiago De Compostela, Spain; [Bravo, S. B.] Univ Hosp Santiago de Compostela CHUS, Dept Prote, Santiago De Compostela, Spain; [Garcia-Rendueles, M. E. R.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA	Universidade de Santiago de Compostela; Universidade de Santiago de Compostela; Complexo Hospitalario Universitario de Santiago de Compostela; Universidade de Santiago de Compostela; Complexo Hospitalario Universitario de Santiago de Compostela; Complexo Hospitalario Universitario de Santiago de Compostela; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; Kyoto Prefectural University of Medicine; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Complexo Hospitalario Universitario de Santiago de Compostela; Complexo Hospitalario Universitario de Santiago de Compostela; Memorial Sloan Kettering Cancer Center	Alvarez, CV (corresponding author), Univ Santiago de Compostela, Sch Med, Ctr Invest Mol Med & Chron Dis CIMUS, Endocrine Neoplasia & Differentiat Grp P0L5, Santiago De Compostela 15782, A Coruna, Spain.; Alvarez, CV (corresponding author), Univ Santiago de Compostela, Sch Med, Inst Biomed Res IDIS, Santiago De Compostela 15782, A Coruna, Spain.	clara.alvarez@usc.es	Bernabeu, Ignacio/P-2049-2014; Alvarez, Clara V/AAN-4173-2020; Lopez, Susana Belén Bravo/F-8487-2016; bernabeu, ignacio/GRJ-0401-2022; Fugazzola, laura/AAH-7803-2021; Rodriguez Garcia-Rendueles, Maria/B-6939-2019	Bernabeu, Ignacio/0000-0001-8421-7394; Lopez, Susana Belén Bravo/0000-0001-7615-3079; bernabeu, ignacio/0000-0001-8421-7394; Alvarez, Clara V/0000-0003-1500-4058; Perez, Sihara/0000-0003-1744-0208; R. Garcia-Rendueles, Angela/0000-0002-8675-377X; Rodriguez Garcia, Javier/0000-0002-5631-2981; Suarez, Maria del Carmen/0000-0002-8739-3550	MINECO-FEDER [BFU2013-46109-R]; Xunta de Galicia [R2014/050, 09CSA020208PR]; ISCIII-FEDER [PI12/00749]	MINECO-FEDER; Xunta de Galicia(Xunta de GaliciaEuropean Commission); ISCIII-FEDER	We thank Ana Senra (CIMUS; Spain); Jun Ninomiya-Tsuji, Kuni Matsumoto (Japan), Donald Kufe (Boston), Pura Munoz-Canoves (Barcelona), Celia Pombo and Juan Zalvide (Spain) for technical help, plasmids or materials, and Carlos Dieguez for helpful discussions. The manuscript was edited for English language by Pamela Lear (Oxford University). This project has been supported by grants from the MINECO-FEDER BFU2013-46109-R and Xunta de Galicia R2014/050 to CVA and 09CSA020208PR to SBB; and ISCIII-FEDER PI12/00749 to JC-T.	Adjei A, 2015, EXPLORING PATHWAY IN; Agrawal N, 2014, CELL, V159, P676, DOI 10.1016/j.cell.2014.09.050; Al-Maghrabi Jaudah, 2012, J Gastrointest Cancer, V43, P279, DOI 10.1007/s12029-011-9292-y; Alarcon C, 2009, CELL, V139, P757, DOI 10.1016/j.cell.2009.09.035; [Anonymous], 2016, J CLIN INVEST, DOI DOI 10.1172/JCI85271; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Besson A, 2007, GENE DEV, V21, P1731, DOI 10.1101/gad.1556607; Bravo SB, 2003, ONCOGENE, V22, P7819, DOI 10.1038/sj.onc.1207029; Bravo SB, 2013, J CLIN ENDOCR METAB, V98, P2431, DOI 10.1210/jc.2012-3812; Carneiro C, 1998, ONCOGENE, V16, P1455, DOI 10.1038/sj.onc.1201662; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Chacko BM, 2001, NAT STRUCT BIOL, V8, P248, DOI 10.1038/84995; Chassot AA, 2007, ONCOGENE, V26, P5772, DOI 10.1038/sj.onc.1210386; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng YB, 2015, ONCOTARGET, V6, P4180, DOI 10.18632/oncotarget.2907; Cianfrocca R, 2008, CELL DEATH DIFFER, V15, P354, DOI 10.1038/sj.cdd.4402264; Ciarallo S, 2002, MOL CELL BIOL, V22, P2993, DOI 10.1128/MCB.22.9.2993-3002.2002; Coleman J, 2001, BMC Mol Biol, V2, P12, DOI 10.1186/1471-2199-2-12; DARZYNKIEWICZ Z, 1980, P NATL ACAD SCI-BIOL, V77, P6696, DOI 10.1073/pnas.77.11.6696; Darzynkiewicz Z, 2015, ONCOTARGET, V6, P11735, DOI 10.18632/oncotarget.4149; De Marco C, 2015, ONCOTARGET, V6, P39634, DOI 10.18632/oncotarget.4022; Edwards BK, 2014, CANCER-AM CANCER SOC, V120, P1290, DOI 10.1002/cncr.28509; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; Foster David A, 2010, Genes Cancer, V1, P1124, DOI 10.1177/1947601910392989; Freudlsperger C, 2013, ONCOGENE, V32, P1549, DOI 10.1038/onc.2012.171; Fu NY, 2009, MOL CELL, V33, P15, DOI 10.1016/j.molcel.2008.11.025; GERDES J, 1984, J IMMUNOL, V133, P1710; Gingery A, 2008, EXP CELL RES, V314, P2725, DOI 10.1016/j.yexcr.2008.06.006; Gomis RR, 2006, CANCER CELL, V10, P203, DOI 10.1016/j.ccr.2006.07.019; Gomis RR, 2006, P NATL ACAD SCI USA, V103, P12747, DOI 10.1073/pnas.0605333103; Grimm T, 2005, BLOOD, V105, P3263, DOI 10.1182/blood-2004-07-2752; Hakem A, 1999, J EXP MED, V189, P957, DOI 10.1084/jem.189.6.957; Heldin CH, 2012, FEBS LETT, V586, P1959, DOI 10.1016/j.febslet.2012.02.037; Hiromura K, 1999, J CLIN INVEST, V103, P597, DOI 10.1172/JCI5461; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Jain MV, 2015, CELL CYCLE, V14, P2109, DOI 10.1080/15384101.2015.1041692; James MK, 2008, MOL CELL BIOL, V28, P498, DOI 10.1128/MCB.02171-06; Jang CW, 2002, NAT CELL BIOL, V4, P51, DOI 10.1038/ncb731; Landa I, 2010, ENDOCR-RELAT CANCER, V17, P317, DOI 10.1677/ERC-09-0016; Lannetti A, 2008, P NATL ACAD SCI USA, V105, P14058, DOI 10.1073/pnas.0710846105; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Lloyd RV, 1997, ENDOCR PATHOL, V8, P293, DOI 10.1007/BF02739931; Macias MJ, 2015, TRENDS BIOCHEM SCI, V40, P296, DOI 10.1016/j.tibs.2015.03.012; Maddika S, 2009, MOL CELL BIOL, V29, P1235, DOI 10.1128/MCB.00668-08; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; Matsuura I, 2005, BIOCHEMISTRY-US, V44, P12546, DOI 10.1021/bi050560g; Matsuura I, 2004, NATURE, V430, P226, DOI 10.1038/nature02650; MIYASHITA T, 1995, CELL, V80, P293; Motti ML, 2007, CELL CYCLE, V6, P2817, DOI 10.4161/cc.6.22.4883; Motti ML, 2005, AM J PATHOL, V166, P737, DOI 10.1016/S0002-9440(10)62295-X; Murata K, 2005, MOL CELL BIOL, V25, P4262, DOI 10.1128/MCB.25.10.4262-4271.2005; Pacifico F, 2004, J BIOL CHEM, V279, P54610, DOI 10.1074/jbc.M403492200; Palona I, 2006, ENDOCRINOLOGY, V147, P5699, DOI 10.1210/en.2006-0400; Park DS, 1997, J NEUROSCI, V17, P8975; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Philipp-Staheli J, 2001, EXP CELL RES, V264, P148, DOI 10.1006/excr.2000.5143; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; Qin HX, 2009, BMC SYST BIOL, V3, DOI 10.1186/1752-0509-3-73; Ramesh S, 2008, EMBO REP, V9, P990, DOI 10.1038/embor.2008.158; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Riesco-Eizaguirre G, 2009, CANCER RES, V69, P8317, DOI 10.1158/0008-5472.CAN-09-1248; Seoane J, 2004, CANCER BIOL THER, V3, P226, DOI 10.4161/cbt.3.2.717; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Solt LA, 2008, IMMUNOL RES, V42, P3, DOI 10.1007/s12026-008-8025-1; Sorrentino A, 2008, NAT CELL BIOL, V10, P1199, DOI 10.1038/ncb1780; Tachibana I, 1997, J CLIN INVEST, V99, P2365, DOI 10.1172/JCI119418; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Vidal A, 2002, J BIOL CHEM, V277, P16433, DOI 10.1074/jbc.M112090200; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Wang GN, 2005, BIOCHEM J, V386, P29, DOI 10.1042/BJ20041820; Wang GN, 2009, J BIOL CHEM, V284, P9663, DOI 10.1074/jbc.M809281200; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Wang J, 2008, CANCER RES, V68, P3152, DOI 10.1158/0008-5472.CAN-07-5348; Witzel II, 2010, BIOCHEM SOC T, V38, P217, DOI 10.1042/BST0380217; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamashita M, 2008, MOL CELL, V31, P918, DOI 10.1016/j.molcel.2008.09.002; Yang W, 2001, ONCOGENE, V20, P1688, DOI 10.1038/sj.onc.1204245; Zhang YE, 2009, CELL RES, V19, P128, DOI 10.1038/cr.2008.328; Zhao D, 2015, ONCOGENE, V34, P5447, DOI 10.1038/onc.2014.473	84	26	28	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 2	2017	36	5					652	666		10.1038/onc.2016.233	http://dx.doi.org/10.1038/onc.2016.233			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IS	27452523				2022-12-17	WOS:000394167700007
J	Gupta, A; Hossain, MM; Miller, N; Kerin, M; Callagy, G; Gupta, S				Gupta, A.; Hossain, M. M.; Miller, N.; Kerin, M.; Callagy, G.; Gupta, S.			NCOA3 coactivator is a transcriptional target of XBP1 and regulates PERK-eIF2 alpha-ATF4 signalling in breast cancer	ONCOGENE			English	Article							UNFOLDED PROTEIN RESPONSE; STEROID-RECEPTOR COACTIVATOR-3; ENDOPLASMIC-RETICULUM STRESS; CELL FATE DECISIONS; ER STRESS; TRANSLATIONAL REGULATION; MESSENGER-RNA; PERK; ACTIVATION; EXPRESSION	XBP1 is a multitasking transcription factor and a key component of the unfolded protein response (UPR). Despite the wealth of knowledge about the role of XBP1 in luminal/ER-positive breast cancer, not much is known about the effectors of XBP1 in this context. Here we show that NCOA3 is a transcriptional target of XBP1. We observed increased expression of NCOA3 during conditions of UPR and oestrogen (E2) stimulation. Further investigations revealed a role for the IRE1-XBP1 axis in the induction of NCOA3 during UPR and oestrogen signalling. We identify a novel role for NCOA3 in activation of PERK-ATF4 axis during UPR where knockdown of NCOA3 compromised the optimal activation of the PERK-ATF4 pathway. We found that NCOA3 is required for induction of XBP1 during E2 stimulation and uncover a positive feedback regulatory loop that maintains high levels of NCOA3 and XBP1 in breast cancer. Furthermore, upregulated NCOA3 was required for XBP1-mediated resistance to antihormonal agents. Increased expression of NCOA3 was associated with poor prognosis and higher levels of XBP1-S in breast cancer tissues. Our results uncover a novel steroid hormone-independent role for NCOA3 in UPR signalling. Further we identify a positive feedback regulatory loop consisting of XBP1 and NCOA3 that maintains high levels of NCOA3 and XBP1 expression in breast cancer tissues. Taken together our data identify XBP1-NCOA3 axis that regulates cell fate decisions in ER-positive breast cancer cells.	[Gupta, A.; Hossain, M. M.; Callagy, G.; Gupta, S.] Natl Univ Ireland, Lambe Inst Translat Res, Sch Med, Discipline Pathol, Galway, Ireland; [Miller, N.; Kerin, M.] Natl Univ Ireland, Inst Clin Sci, Sch Med, Discipline Surg, Galway, Ireland	Ollscoil na Gaillimhe-University of Galway; Ollscoil na Gaillimhe-University of Galway	Gupta, S (corresponding author), Natl Univ Ireland, Inst Clin Sci, Sch Med, Discipline Pathol, Galway H91 REW4, Ireland.	sanjeev.gupta@nuigalway.ie	Miller, Nicola/F-4009-2018; Gupta, Sanjeev/AAG-9749-2020; gupta, sanjeev/B-2824-2008	Miller, Nicola/0000-0002-5416-7047; Gupta, Sanjeev/0000-0002-4691-6853; gupta, sanjeev/0000-0002-4691-6853; Hossain, Muhammad Mosaraf/0000-0002-1308-1116; Gupta, Ananya/0000-0001-8920-0815; Kerin, Michael/0000-0003-4164-5561	Health Research Board [HRA_HSR/2010/24]; Breast Cancer campaign [2011PR26]; Breast Cancer Campaign [2011MayPR26] Funding Source: researchfish	Health Research Board; Breast Cancer campaign; Breast Cancer Campaign	This publication has emanated from research conducted with the financial support of Health Research Board (grant number HRA_HSR/2010/24) and Breast Cancer campaign (grant number 2011PR26).	Acosta-Alvear D, 2007, MOL CELL, V27, P53, DOI 10.1016/j.molcel.2007.06.011; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Axten JM, 2012, J MED CHEM, V55, P7193, DOI 10.1021/jm300713s; Binet F, 2015, CELL METAB, V22, P560, DOI 10.1016/j.cmet.2015.07.010; Blais JD, 2006, MOL CELL BIOL, V26, P9517, DOI 10.1128/MCB.01145-06; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; Cawley K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073870; Cawley K, 2011, METHOD ENZYMOL, V490, P31, DOI 10.1016/B978-0-12-385114-7.00002-7; Chen X, 2014, NATURE, V508, P103, DOI 10.1038/nature13119; Clarke R, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00140; Coste A, 2006, EMBO J, V25, P2453, DOI 10.1038/sj.emboj.7601106; Cross BCS, 2012, P NATL ACAD SCI USA, V109, pE869, DOI 10.1073/pnas.1115623109; Davies MPA, 2008, INT J CANCER, V123, P85, DOI 10.1002/ijc.23479; Ding LH, 2003, NUCLEIC ACIDS RES, V31, P5266, DOI 10.1093/nar/gkg731; Feng YX, 2014, CANCER DISCOV, V4, P702, DOI 10.1158/2159-8290.CD-13-0945; Gomez BP, 2007, FASEB J, V21, P4013, DOI 10.1096/fj.06-7990com; Gupta AK, 2015, SCI REP-UK, V5, DOI 10.1038/srep12522; Gupta A, 2015, METHODS MOL BIOL, V1292, P19, DOI 10.1007/978-1-4939-2522-3_2; Gupta S, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.74; Gupta S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008008; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Hetz C, 2012, NAT REV MOL CELL BIO, V13, P89, DOI 10.1038/nrm3270; Hetz C, 2011, PHYSIOL REV, V91, P1219, DOI 10.1152/physrev.00001.2011; Hu R, 2015, MOL CELL BIOL, V35, P379, DOI 10.1128/MCB.00847-14; Johnson AB, 2012, MOL CELL ENDOCRINOL, V348, P430, DOI 10.1016/j.mce.2011.04.021; Kakiuchi C, 2006, J NEUROCHEM, V97, P545, DOI 10.1111/j.1471-4159.2006.03772.x; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Lydon JP, 2011, ENDOCRINOLOGY, V152, P19, DOI 10.1210/en.2010-1012; Mujcic H, 2013, CLIN CANCER RES, V19, P6126, DOI 10.1158/1078-0432.CCR-13-0526; Murphy LC, 2000, CANCER RES, V60, P6266; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Nagelkerke A, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3373; Papandreou I, 2011, BLOOD, V117, P1311, DOI 10.1182/blood-2010-08-303099; Read D.E., 2012, ENDOPLASMIC RETICULU, P143, DOI [10.1007/978-94-007-4351-9_6, DOI 10.1007/978-94-007-4351-9_6]; Reineke EL, 2014, J BIOL CHEM, V289, P17721, DOI 10.1074/jbc.M113.539908; Romero-Ramirez L, 2004, CANCER RES, V64, P5943, DOI 10.1158/0008-5472.CAN-04-1606; Samali A, 2010, INT J CELL BIOL, V2010, DOI [10.1155/2010/830307, DOI 10.1155/2010/830307]; Sengupta S, 2010, HORM MOL BIOL CLIN I, V2, P235, DOI 10.1515/HMBCI.2010.025; Torres-Arzayus MI, 2004, CANCER CELL, V6, P263, DOI 10.1016/j.ccr.2004.06.027; Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038; Wang M, 2014, NAT REV CANCER, V14, P581, DOI 10.1038/nrc3800; Wijayaratne AL, 2001, J BIOL CHEM, V276, P35684, DOI 10.1074/jbc.M101097200; Wu RC, 2002, MOL CELL BIOL, V22, P3549, DOI 10.1128/MCB.22.10.3549-3561.2002; Xu JM, 2009, NAT REV CANCER, V9, P615, DOI 10.1038/nrc2695; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Zhang H, 2004, CANCER RES, V64, P7169, DOI 10.1158/0008-5472.CAN-04-1176; Zhao C, 2003, CANCER, V98, P18, DOI 10.1002/cncr.11482	48	26	30	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 10	2016	35	45					5860	5871		10.1038/onc.2016.121	http://dx.doi.org/10.1038/onc.2016.121			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EB7IR	27109102	hybrid, Green Published, Green Accepted			2022-12-17	WOS:000387560800005
J	Wu, J; Lu, M; Li, Y; Shang, YK; Wang, SJ; Meng, Y; Wang, Z; Li, ZS; Chen, H; Chen, ZN; Bian, H				Wu, J.; Lu, M.; Li, Y.; Shang, Y-K; Wang, S-J; Meng, Y.; Wang, Z.; Li, Z-S; Chen, H.; Chen, Z-N; Bian, H.			Regulation of a TGF-beta 1-CD147 self-sustaining network in the differentiation plasticity of hepatocellular carcinoma cells	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; GROWTH-FACTOR-BETA; TUMOR-INITIATING CELLS; CANCER STEM-CELLS; CELLULAR PLASTICITY; CLONAL EVOLUTION; EMT/MET DYNAMICS; PROMOTES; DEDIFFERENTIATION; METASTASIS	Cellular plasticity has an important role in the progression of hepatocellular carcinoma (HCC). In this study, the involvement of a TGF-beta 1-CD147 self-sustaining network in the regulation of the dedifferentiation progress was fully explored in HCC cell lines, hepatocyte-specific basigin/CD147-knockout mice and human HCC tissues. We demonstrated that TGF-beta 1 stimulation upregulated CD147 expression and mediated the dedifferentiation of HCC cells, whereas all-trans-retinoic acid induced the downregulation of CD147 and promoted differentiation in HCC cells. Overexpression of CD147 induced the dedifferentiation and enhanced the malignancy of HCC cells, and increased the transcriptional expression of TGF-beta 1 by activating beta-catenin. CD147-induced matrix metalloproteinase (MMP) production activated pro-TGF-beta 1. The activated TGF-beta 1 signaling subsequently repressed the HNF4a expression via Smad-Snail1 signaling and enhanced the dedifferentiation progress. Hepatocyte-specific basigin/CD147-knockout mice decreased the susceptibility to N-nitrosodiethylamine-induced tumorigenesis by suppressing TGF-beta 1-CD147 signaling and inhibiting dedifferentiation in hepatocytes during tumor progression. CD147 was positively correlated with TGF-beta 1 and negatively correlated with HNF4a in human HCC tissues. Positive CD147 staining and lower HNF4a levels in tumor tissues were significantly associated with poor survival of patients with HCC. The overexpression of HNF4a and Smad7 and the deletion of CD147 by lentiviral vectors jointly reprogrammed the expression profile of hepatocyte markers and attenuated malignant properties including proliferation, cell survival and tumor growth of HCC cells. Our results highlight the important role of the TGF-beta 1-CD147 self-sustaining network in driving HCC development by regulating differentiation plasticity, which provides a strong basis for further investigations of the differentiation therapy of HCC targeting TGF-beta 1 and CD147.	[Wu, J.; Lu, M.; Shang, Y-K; Wang, S-J; Meng, Y.; Chen, Z-N; Bian, H.] Fourth Mil Med Univ, Cell Engn Res Ctr, State Key Lab Canc Biol, Dept Cell Biol, 169,Changle West Rd, Xian 710032, Shaanxi, Peoples R China; [Li, Y.] PLA 323 Hosp, Dept Oncol, Xian, Peoples R China; [Wang, Z.; Li, Z-S] Fourth Mil Med Univ, Dept Pathol, Xian, Peoples R China; [Chen, H.] Peking Univ, Canc Hosp, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China	Air Force Military Medical University; Air Force Military Medical University; Peking University	Chen, ZN; Bian, H (corresponding author), Fourth Mil Med Univ, Cell Engn Res Ctr, State Key Lab Canc Biol, Dept Cell Biol, 169,Changle West Rd, Xian 710032, Shaanxi, Peoples R China.	znchen@fmmu.edu.cn; hjbian@fmmu.edu.cn		Chen, Zhi-Nan/0000-0001-5512-4623	National Natural Science Foundation of China [31401222, 31571434, 31401190, 81172144]; National Science and Technology Major Project [2012ZX10002-015, 2012AA020806, 2015CB553701]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Science and Technology Major Project	We thank professor Mien-Chie Hung (Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA) for providing pEGFP-Snail1, and we thank professor Ye-Guang Chen (School of Life Science, Tsinghua University) for providing pcDNA-Flag-Smad7. This work was supported by grants from the National Natural Science Foundation of China (No. 31401222, 31571434, 31401190 and 81172144) and the National Science and Technology Major Project (No. 2012ZX10002-015, 2012AA020806 and 2015CB553701).	Nieto MA, 2013, SCIENCE, V342, P708, DOI 10.1126/science.1234850; Ber S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030759; Bitting RL, 2014, CANCER METAST REV, V33, P441, DOI 10.1007/s10555-013-9483-z; Brabletz S, 2010, EMBO REP, V11, P670, DOI 10.1038/embor.2010.117; Chakrabarti R, 2012, NAT CELL BIOL, V14, P1212, DOI 10.1038/ncb2607; Chui MH, 2013, INT J CANCER, V132, P1487, DOI 10.1002/ijc.27745; Cicchini C, 2015, BBA-GENE REGUL MECH, V1849, P919, DOI 10.1016/j.bbagrm.2015.05.005; Cicchini C, 2015, LIVER INT, V35, P302, DOI 10.1111/liv.12577; Cozzolino AM, 2013, J HEPATOL, V58, P65, DOI 10.1016/j.jhep.2012.08.023; Derynck R, 2007, NAT CELL BIOL, V9, P1000, DOI 10.1038/ncb434; Dow LE, 2015, CELL, V161, P1539, DOI 10.1016/j.cell.2015.05.033; Erez N, 2013, NATURE, V500, P37, DOI 10.1038/nature12459; Frank NY, 2010, J CLIN INVEST, V120, P41, DOI 10.1172/JCI41004; Ghajar CM, 2013, NAT CELL BIOL, V15, P807, DOI 10.1038/ncb2767; Giannelli G, 2014, CANCER RES, V74, P1890, DOI 10.1158/0008-5472.CAN-14-0243; Giannelli G, 2011, BBA-REV CANCER, V1815, P214, DOI 10.1016/j.bbcan.2010.11.004; Godoy P, 2009, HEPATOLOGY, V49, P2031, DOI 10.1002/hep.22880; Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762; Grusch M, 2010, CURR CANCER DRUG TAR, V10, P849, DOI 10.2174/156800910793357943; Gumireddy K, 2009, NAT CELL BIOL, V11, P1297, DOI 10.1038/ncb1974; Janiszewska M, 2015, CELL STEM CELL, V16, P11, DOI 10.1016/j.stem.2014.12.011; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Khayati F, 2015, ONCOTARGET, V6, P9766, DOI 10.18632/oncotarget.2870; Kim SC, 2014, HEPATOLOGY, V59, P1750, DOI 10.1002/hep.26699; Kumar SM, 2012, ONCOGENE, V31, P4898, DOI 10.1038/onc.2011.656; Lazarevich N, 2004, HEPATOLOGY, V39, P1038, DOI 10.1002/hep.20155; Liu Y, 2015, ONCOGENE, V34, P5524, DOI 10.1038/onc.2015.7; Lu M, 2015, J MOL HISTOL, V46, P79, DOI 10.1007/s10735-014-9602-3; Makarova-Rusher OV, 2015, J HEPATOL, V62, P1420, DOI 10.1016/j.jhep.2015.02.038; Medema JP, 2013, NAT CELL BIOL, V15, P338, DOI 10.1038/ncb2717; Meyer C, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2012.204; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Pisco AO, 2015, BRIT J CANCER, V112, P1725, DOI 10.1038/bjc.2015.146; Salomao M, 2012, DIAGN HISTOPATHOL, V18, P37; Santangelo L, 2011, HEPATOLOGY, V53, P2063, DOI 10.1002/hep.24280; Sidhu SS, 2010, ONCOGENE, V29, P4145, DOI 10.1038/onc.2010.166; Sun BC, 2008, CELL CYCLE, V7, P934, DOI 10.4161/cc.7.7.5622; Suzuki T, 2002, J GASTROEN HEPATOL, V17, P994, DOI 10.1046/j.1440-1746.2002.02774.x; Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336; Tang J, 2012, CELL DEATH DIFFER, V19, P1779, DOI 10.1038/cdd.2012.60; Tschaharganeh DF, 2014, CELL, V158, P579, DOI 10.1016/j.cell.2014.05.051; Ulianich L, 2008, J CELL SCI, V121, P477, DOI 10.1242/jcs.017202; Varga J, 2014, FEBS LETT, V588, P2422, DOI 10.1016/j.febslet.2014.06.019; Walesky C, 2013, HEPATOLOGY, V57, P2480, DOI 10.1002/hep.26251; Wei Q, 2016, ONCOGENE, V35, P2655, DOI 10.1038/onc.2015.328; Wu J, 2011, ONCOGENE, V30, P4410, DOI 10.1038/onc.2011.149; Wu K, 2012, HEPATOLOGY, V56, P2255, DOI 10.1002/hep.26007; Yao H, 2014, INT J BIOL SCI, V10, P43, DOI 10.7150/ijbs.6818; Ye X, 2015, TRENDS CELL BIOL, V25, P675, DOI 10.1016/j.tcb.2015.07.012; Yin C, 2008, HEPATOLOGY, V48, P1528, DOI 10.1002/hep.22510; Zeng X, 2011, HEPATOLOGY, V54, P2036, DOI 10.1002/hep.24647; Zhang HX, 2013, STEM CELLS, V31, P433, DOI 10.1002/stem.1298; Zhang Y, 2013, J HEPATOL, V59, P1255, DOI 10.1016/j.jhep.2013.07.009; Zhao P, 2011, HEPATOLOGY, V54, P2012, DOI 10.1002/hep.24592; Zhu D, 2015, NAT MED, V21, P572, DOI 10.1038/nm.3867; Zulehner G, 2010, AM J PATHOL, V176, P472, DOI 10.2353/ajpath.2010.090300	56	26	26	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2016	35	42					5468	5479		10.1038/onc.2016.89	http://dx.doi.org/10.1038/onc.2016.89			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XO	27041581				2022-12-17	WOS:000386998200002
J	Wright, HJ; Arulmoli, J; Motazedi, M; Nelson, LJ; Heinemann, FS; Flanagan, LA; Razorenova, OV				Wright, H. J.; Arulmoli, J.; Motazedi, M.; Nelson, L. J.; Heinemann, F. S.; Flanagan, L. A.; Razorenova, O. V.			CDCP1 cleavage is necessary for homodimerization-induced migration of triple-negative breast cancer	ONCOGENE			English	Article							DOMAIN-CONTAINING PROTEIN-1; CUB-DOMAIN; CELL CARCINOMA; TYROSINE PHOSPHORYLATION; TARGET GENE; PKC-DELTA; SURVIVAL; SRC; ADHESION; IDENTIFICATION	Triple-negative breast cancer (TNBC) is a highly aggressive and metastatic form of breast cancer that lacks the estrogen, progesterone and HER2 receptors and is resistant to targeted and hormone therapies. TNBCs express high levels of the transmembrane glycoprotein, complement C1r/C1s, Uegf, Bmp1 (CUB)-domain containing protein 1 (CDCP1), which has been correlated with the aggressiveness and poor prognosis of multiple carcinomas. Full-length CDCP1 (flCDCP1) can be proteolytically cleaved, resulting in a cleaved membrane-bound isoform (cCDCP1). CDCP1 is phosphorylated by Src family kinases in its full-length and cleaved states, which is important for its pro-metastatic signaling. We observed that cCDCP1, compared with flCDCP1, induced a dramatic increase in phosphorylation of the migration-associated proteins: PKCd, ERK1/2 and p38 mitogen-activated protein kinase in HEK 293T. In addition, only cCDCP1 induced migration of HEK 293T cells and rescued migration of the TNBC cell lines expressing short hairpin RNA against CDCP1. Importantly, we found that only cCDCP1 is capable of dimerization, which can be blocked by expression of the extracellular portion of cCDCP1 (ECC), indicating that dimerization occurs through CDCP1's ectodomain. We found that ECC inhibited phosphorylation of PKCd and migration of TNBC cells in two-dimensional culture. Furthermore, ECC decreased cell invasiveness, inhibited proliferation and stimulated apoptosis of TNBC cells in three-dimensional culture, indicating that the cCDCP1 dimer is an important contributor to TNBC aggressiveness. These studies have important implications for the development of a therapeutic to block CDCP1 activity and TNBC metastasis.	[Wright, H. J.; Motazedi, M.; Nelson, L. J.; Razorenova, O. V.] Univ Calif Irvine, Dept Mol Biol & Biochem, 845 Hlth Sci Rd,Gross Hall,Room 3010, Irvine, CA 92697 USA; [Arulmoli, J.; Flanagan, L. A.] Univ Calif Irvine, Dept Biomed Engn, Irvine, CA USA; [Heinemann, F. S.] Hoag Mem Hosp, Dept Pathol, 301 Newport Blvd, Newport Beach, CA 92663 USA; [Flanagan, L. A.] Univ Calif Irvine, Dept Neurol, Irvine, CA 92717 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	Razorenova, OV (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, 845 Hlth Sci Rd,Gross Hall,Room 3010, Irvine, CA 92697 USA.	olgar@uci.edu		Motazedi, Maryam/0000-0002-9856-4933	NIH [F31CA196226]; NATIONAL CANCER INSTITUTE [T32CA121940, F31CA196226] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [TL1TR001415, UL1TR001414] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	This work was supported by NIH Award F31CA196226 to HJW. We thank Drs Alice Police and Erin Lin for providing primary TNBC tissue, Dr Peter Kaiser for MDA-MB-231 and MDA-MB-468 cell lines, Dr Dan Mercola for MDA-MB-453 cell line, Dr Xing Dai for MCF10A cell line, Dr Albert Koong for split-luciferase vectors, Dr Inder Verma for pVSVG and Delta R8.2 lentivirus packaging plasmids, Dr Jae-Won Soh for pHACE-PKC delta construct, Dr Sanford Shattil for pRC-CMV-Src construct, Dr Peter Chumakov for pLM-CMV lentiviral vector, Miranda Paley from Dr Jennifer Prescher lab and Linan Liu from Dr Weian Zhao's lab for help with IVIS Lumina Imager, and Dr David Fruman and Dr Hung Fan for critical reading of the manuscript.	Adams MN, 2015, ONCOGENE, V34, P1375, DOI 10.1038/onc.2014.88; Alajati A, 2015, CELL REP, V11, P564, DOI 10.1016/j.celrep.2015.03.044; Arora R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098370; Benes CH, 2012, ONCOGENE, V31, P653, DOI 10.1038/onc.2011.262; Benes CH, 2005, CELL, V121, P271, DOI 10.1016/j.cell.2005.02.019; Bhatt AS, 2005, ONCOGENE, V24, P5333, DOI 10.1038/sj.onc.1208582; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; Brown TA, 2004, J BIOL CHEM, V279, P14772, DOI 10.1074/jbc.M309678200; Casar B, 2014, ONCOGENE, V33, P255, DOI 10.1038/onc.2012.547; Casar B, 2012, ONCOGENE, V31, P3924, DOI 10.1038/onc.2011.555; Chaudary Naz, 2006, Breast Dis, V26, P55; Choi CYH, 2008, MOL IMAGING, V7, P139, DOI 10.2310/7290.2008.00017; Cvetkovic D, 2014, JOVE-J VIS EXP, DOI 10.3791/51341; Emerling BM, 2013, P NATL ACAD SCI USA, V110, P3483, DOI 10.1073/pnas.1222435110; Gandji LY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123472; Guiro K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118724; He Y, 2016, ONCOGENE, V35, P468, DOI 10.1038/onc.2015.101; He Y, 2010, J BIOL CHEM, V285, P26162, DOI 10.1074/jbc.M109.096453; Hooper JD, 2003, ONCOGENE, V22, P1783, DOI 10.1038/sj.onc.1206220; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; Kim KH, 2010, J LIPID RES, V51, P3425, DOI 10.1194/jlr.M007989; Kim S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119473; Kollmorgen G, 2013, MOL ONCOL, V7, P1142, DOI 10.1016/j.molonc.2013.08.009; Kollmorgen G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053050; Law ME, 2013, ONCOGENE, V32, P1316, DOI 10.1038/onc.2012.138; Lee HX, 2009, GENE DEV, V23, P2551, DOI 10.1101/gad.1839309; Leroy C, 2015, ONCOGENE, V34, P5593, DOI 10.1038/onc.2015.19; Lin CY, 2014, CANCER RES, V74, P5229, DOI 10.1158/0008-5472.CAN-13-2995; Liu H, 2011, P NATL ACAD SCI USA, V108, P1379, DOI 10.1073/pnas.1017228108; Maller O, 2013, J CELL SCI, V126, P4108, DOI 10.1242/jcs.121590; Mamat S, 2010, ONCOL REP, V23, P1221, DOI 10.3892/or_00000753; Metzger O, 2012, J CLIN ONCOL, V30, P1879, DOI 10.1200/JCO.2011.38.2010; Miroshnikova YA, 2011, PHYS BIOL, V8, DOI 10.1088/1478-3975/8/2/026013; Miyazawa Y, 2013, MOL CANCER RES, V11, P628, DOI 10.1158/1541-7786.MCR-12-0544; Miyazawa Y, 2010, CANCER RES, V70, P5136, DOI 10.1158/0008-5472.CAN-10-0220; Ng D, 2009, PLOS BIOL, V7, P278, DOI 10.1371/journal.pbio.1000041; Nieva C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046456; Qiu B, 2015, CANCER DISCOV, V5, P652, DOI 10.1158/2159-8290.CD-14-1507; Razorenova OV, 2014, MOL CELL BIOL, V34, P739, DOI 10.1128/MCB.00644-12; Razorenova OV, 2011, P NATL ACAD SCI USA, V108, P1931, DOI 10.1073/pnas.1011777108; Razorenova OV, 2005, GENE, V350, P89, DOI 10.1016/j.gene.2005.02.006; Romero A, 1996, FEBS LETT, V382, P15, DOI 10.1016/0014-5793(96)00133-0; Sandercock AM, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0415-0; Seidel J, 2011, BIOCHEM BIOPH RES CO, V414, P226, DOI 10.1016/j.bbrc.2011.09.062; Siva AC, 2008, CANCER RES, V68, P3759, DOI 10.1158/0008-5472.CAN-07-1657; Sowter HM, 2003, CANCER RES, V63, P6130; Spassov DS, 2011, MOL CELL BIOL, V31, P766, DOI 10.1128/MCB.00841-10; Tu YF, 2011, BBA-BIOENERGETICS, V1807, P1125, DOI 10.1016/j.bbabio.2011.04.015; Uekita T, 2008, AM J PATHOL, V172, P1729, DOI 10.2353/ajpath.2008.070981; Uekita T, 2007, MOL CELL BIOL, V27, P7649, DOI 10.1128/MCB.01246-07; Uekita T, 2014, MOL CANCER RES, V12, P1449, DOI 10.1158/1541-7786.MCR-13-0587; Uekita T, 2013, CANCER SCI, V104, P865, DOI 10.1111/cas.12154; Wortmann A, 2011, J BIOL CHEM, V286, P42303, DOI 10.1074/jbc.M111.227462; Zhau HYE, 2011, CLIN CANCER RES, V17, P2159, DOI 10.1158/1078-0432.CCR-10-2523	54	26	27	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2016	35	36					4762	4772		10.1038/onc.2016.7	http://dx.doi.org/10.1038/onc.2016.7			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0IS	26876198	Green Accepted, Green Submitted			2022-12-17	WOS:000383324700009
J	Taylor, MA; Wappett, M; Delpuech, O; Brown, H; Chresta, CM				Taylor, M. A.; Wappett, M.; Delpuech, O.; Brown, H.; Chresta, C. M.			Enhanced MAPK signaling drives ETS1-mediated induction of miR-29b leading to downregulation of TET1 and changes in epigenetic modifications in a subset of lung SCC	ONCOGENE			English	Article							SQUAMOUS-CELL CARCINOMA; GENE-EXPRESSION; CANCER; METHYLATION; GEFITINIB; SURVIVAL; PATHWAY; TARGET; PD-1; OVEREXPRESSION	Non-small-cell lung cancer is the leading cause of cancer death worldwide and is comprised of several histological subtypes, the two most common being adenocarcinoma (AC) and squamous cell carcinoma (SCC). Targeted therapies have successfully improved response rates in patients with AC tumors. However, the majority of SCC tumors lack specific targetable mutations, making development of new treatment paradigms for this disease challenging. In the present study, we used iterative non-negative matrix factorization, an unbiased clustering method, on mRNA expression data from the cancer genome atlas (TCGA) and a panel of 24 SCC cell lines to classify three disease segments within SCC. Analysis of gene set enrichment and drug sensitivity identified an immune-evasion subtype that showed increased sensitivity to nuclear factor-kappa B and mitogen-activated protein kinase (MAPK) inhibition, a replication-stress associated subtype that showed increased sensitivity to ataxia telangiectasia inhibition, and a neuroendocrine-associated subtype that showed increased sensitivity to phosphoinositide 3-kinase and fibroblast growth factor receptor inhibition. Additionally, each of these subtypes exhibited a unique microRNA expression profile. Focusing on the immuneevasion subtype, bioinformatic analysis of microRNA promoters revealed enrichment for binding sites for the MAPK-driven ETS1 transcription factor. Indeed, we found that knockdown of ETS1 led to upregulation of eight microRNAs and downregulation of miR-29b in the immune-evasion subtype. Mechanistically, we found that miR-29b targets the DNA-demethylating enzyme, TET1, for downregulation resulting in decreased 5-hmC epigenetic modifications. Moreover, inhibition of MAPK signaling by gefitinib led to decreased ETS1 and miR-29b expression with a corresponding increase in TET1 expression and increase in 5-hmC. Collectively, our work identifies three subtypes of lung SCC that differ in drug sensitivity and shows a novel mechanism of miR-29b regulation by MAPK-driven ETS1 expression which leads to downstream changes in TET1-mediated epigenetic modifications.	[Taylor, M. A.; Wappett, M.; Delpuech, O.; Chresta, C. M.] AstraZeneca, R&D Oncol iMed, Room 33F83-7 Mereside,Alderley Pk, Macclesfield SK10 4TG, Cheshire, England; [Brown, H.] AstraZeneca, Personalised Healthcare & Biomarkers, Alderley Pk, Macclesfield, Cheshire, England	AstraZeneca; AstraZeneca	Taylor, MA (corresponding author), AstraZeneca, R&D Oncol iMed, Room 33F83-7 Mereside,Alderley Pk, Macclesfield SK10 4TG, Cheshire, England.	molly.taylor@astrazeneca.com		Taylor, Molly/0000-0002-7885-8395	AstraZeneca Postdoc Programme	AstraZeneca Postdoc Programme(AstraZeneca)	We thank the Targets Biology group at AstraZeneca for critical comments of the manuscript, and Henry Brown and Hayley Campbell for their scientific expertise on fluidigm experiments. Funding was provided by the AstraZeneca Postdoc Programme.	Akbay EA, 2013, CANCER DISCOV, V3, P1355, DOI 10.1158/2159-8290.CD-13-0310; Azuma K, 2014, ANN ONCOL, V25, P1935, DOI 10.1093/annonc/mdu242; Bruzzese F, 2011, J CELL PHYSIOL, V226, P2378, DOI 10.1002/jcp.22574; Cross DAE, 2014, CANCER DISCOV, V4, P1046, DOI 10.1158/2159-8290.CD-14-0337; D'Incecco A, 2015, BRIT J CANCER, V112, P95, DOI 10.1038/bjc.2014.555; Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013; Del Prete A, 2011, BIOCHEM MEDICA, V21, P264; Devarajan K, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000029; Dhillon T, 2010, J THORAC ONCOL, V5, P314, DOI 10.1097/JTO.0b013e3181ce6604; Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104; Ficz G, 2014, GENOMICS, V104, P352, DOI 10.1016/j.ygeno.2014.08.017; Gaujoux R, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-367; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hayes DN, 2006, J CLIN ONCOL, V24, P5079, DOI 10.1200/JCO.2005.05.1748; Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714; Hsu SD, 2014, NUCLEIC ACIDS RES, V42, pD78, DOI 10.1093/nar/gkt1266; Huang Y, 2014, TRENDS GENET, V30, P464, DOI 10.1016/j.tig.2014.07.005; Jacobsen A, 2013, NAT STRUCT MOL BIOL, V20, P1325, DOI 10.1038/nsmb.2678; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Jin CL, 2014, NUCLEIC ACIDS RES, V42, P6956, DOI 10.1093/nar/gku372; Keir ME, 2008, ANNU REV IMMUNOL, V26, P677, DOI 10.1146/annurev.immunol.26.021607.090331; Lan MS, 2009, FASEB J, V23, P2024, DOI 10.1096/fj.08-125971; Lee ES, 2008, CLIN CANCER RES, V14, P7397, DOI 10.1158/1078-0432.CCR-07-4937; Li XY, 2013, ONCOL REP, V29, P1975, DOI 10.3892/or.2013.2298; Liao RG, 2012, LUNG CANCER MANAG, V1, P293, DOI 10.2217/LMT.12.40; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Lin YC, 2015, CLIN CANCER RES, V21, P428, DOI 10.1158/1078-0432.CCR-14-1150; Liu AH, 2009, INT J CLIN EXP PATHO, V2, P519; Liu SY, 2005, CELL PHYSIOL BIOCHEM, V16, P207, DOI 10.1159/000089846; Lopez-Romero P, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-64; Lou YF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097719; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Marinov M, 2009, CLIN CANCER RES, V15, P1277, DOI 10.1158/1078-0432.CCR-08-2166; Nana-Sinkam SP, 2013, CHEST S, V143, pe30S; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Ramirez-Valle F, 2008, J CELL BIOL, V181, P293, DOI 10.1083/jcb.200710215; Sajadian SO, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0133-x; Senbabaoglu Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep06207; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Taylor Molly A, 2014, Mol Cell Ther, V2, P1, DOI 10.1186/2052-8426-2-30; Vlachos IS, 2015, NUCLEIC ACIDS RES, V43, pD153, DOI 10.1093/nar/gku1215; Weber A. M., 2014, PHARMACOL THERAPEUT, V149, P124; Wilkerson MD, 2010, CLIN CANCER RES, V16, P4864, DOI 10.1158/1078-0432.CCR-10-0199; Williams K, 2011, NATURE, V473, P343, DOI 10.1038/nature10066; Wojtalla A, 2013, CLIN CANCER RES, V19, P96, DOI 10.1158/1078-0432.CCR-12-1138; Wu BK, 2014, CELL REP, V9, P1827, DOI 10.1016/j.celrep.2014.10.063; Xu YF, 2011, MOL CELL, V42, P451, DOI 10.1016/j.molcel.2011.04.005; Zhang ZF, 2010, CARCINOGENESIS, V31, P577, DOI 10.1093/carcin/bgq020	49	26	30	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	33					4345	4357		10.1038/onc.2015.499	http://dx.doi.org/10.1038/onc.2015.499			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3ZU	26776158	Green Published, hybrid			2022-12-17	WOS:000382152100006
J	Heinicke, U; Kupka, J; Fichter, I; Fulda, S				Heinicke, U.; Kupka, J.; Fichter, I.; Fulda, S.			Critical role of mitochondria-mediated apoptosis for JNJ-26481585-induced antitumor activity in rhabdomyosarcoma	ONCOGENE			English	Article							HISTONE DEACETYLASE INHIBITOR; QUISINOSTAT JNJ-26481585; CANCER; VORINOSTAT; LYMPHOMA; CHILDREN; CELLS; CHEMOTHERAPY; FREQUENCY; CASPASE-8	JNJ-26481585 is a second-generation histone deacetylase inhibitor with broad-range efficacy and improved pharmacodynamic properties. In the present study, we investigated the therapeutic potential of JNJ-26481585 and its molecular mechanisms of action in rhabdomyosarcoma (RMS). Here, we report that JNJ-26481585's anticancer activity critically depends on an intact mitochondrial pathway of apoptosis. JNJ-26481585 induces apoptosis and also inhibits long-term clonogenic survival of several RMS cell lines at nanomolar concentrations that cause histone acetylation. Importantly, JNJ-26481585 significantly suppresses tumor growth in vivo in two preclinical RMS models, that is, the chorioallantoic membrane model and a xenograft mouse model. Mechanistically, we identify activation of the mitochondrial pathway of apoptosis as a key event that is critically required for JNJ-26481585-mediated cell death. JNJ-26481585 upregulates expression levels of several BH3-only proteins including Bim, Puma and Noxa, which all contribute to JNJ-26481585-mediated apoptosis, as knockdown of Bim, Puma or Noxa significantly inhibits cell death. This shift toward proapoptotic Bcl-2 proteins promotes activation of Bax and Bak as a critical event, as genetic silencing of Bax or Bak protects against JNJ-26481585-induced apoptosis. Intriguingly, rescue experiments reveal that JNJ-26481585 triggers Bax/Bak activation independently of caspase activation and activates caspase-9 as the initiator caspase in the cascade, as Bcl-2 overexpression, but not the broad-range caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (zVAD.fmk) blocks JNJ-26481585-induced Bax/Bak activation and caspase-9 cleavage. In conclusion, JNJ-26481585 exerts potent antitumor activity against RMS in vitro and in vivo by engaging mitochondrial apoptosis before caspase activation and represents a promising therapeutic for further investigation in RMS.	[Heinicke, U.; Kupka, J.; Fulda, S.] Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, Komturstr 3a, D-60528 Frankfurt, Hesse, Germany; [Fichter, I.] Expt Pharmacol & Oncol GmbH, Berlin, Germany; [Fulda, S.] German Canc Consortium DKTK, Heidelberg, Germany; [Fulda, S.] German Canc Res Ctr, Heidelberg, Germany	Goethe University Frankfurt; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Fulda, S (corresponding author), Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, Komturstr 3a, D-60528 Frankfurt, Hesse, Germany.	simone.fulda@kgu.de		Fulda, Simone/0000-0002-0459-6417	BMBF; Deutsche Kinderkrebsstiftung	BMBF(Federal Ministry of Education & Research (BMBF)); Deutsche Kinderkrebsstiftung	We thank C. Hugenberg for expert secretarial assistance. This work has been partially supported by grants from the BMBF and the Deutsche Kinderkrebsstiftung (to SF).	Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220; Arts J, 2009, CLIN CANCER RES, V15, P6841, DOI 10.1158/1078-0432.CCR-09-0547; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Carol H, 2014, PEDIATR BLOOD CANCER, V61, P245, DOI 10.1002/pbc.24724; Chen X, 2013, CANCER CELL, V24, P710, DOI 10.1016/j.ccr.2013.11.002; Dagher R, 1999, Oncologist, V4, P34; Dantonello TM, 2009, J CLIN ONCOL, V27, P1446, DOI 10.1200/JCO.2007.15.0466; Deleu S, 2009, LEUKEMIA, V23, P1894, DOI 10.1038/leu.2009.121; Ellis L, 2009, MOL CANCER THER, V8, P1409, DOI 10.1158/1535-7163.MCT-08-0860; FELIX CA, 1992, CANCER RES, V52, P2243; Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608; Fulda S, 1997, CANCER RES, V57, P3823; Fulda S, 2010, NAT REV DRUG DISCOV, V9, P447, DOI 10.1038/nrd3137; Graab U, 2015, ONCOTARGET, V6, P8722, DOI 10.18632/oncotarget.2726; Hacker S, 2009, ONCOGENE, V28, P3097, DOI 10.1038/onc.2009.161; Halkidou K, 2004, PROSTATE, V59, P177, DOI 10.1002/pros.20022; Han ZY, 1997, J BIOL CHEM, V272, P13432, DOI 10.1074/jbc.272.20.13432; Happo L, 2012, J CELL SCI, V125, P1081, DOI 10.1242/jcs.090514; Hayes-Jordan A, 2009, CURR OPIN PEDIATR, V21, P373, DOI 10.1097/MOP.0b013e32832b4171; Heinicke U, 2014, CANCER LETT, V351, P50, DOI 10.1016/j.canlet.2014.04.021; Inoue S, 2007, LEUKEMIA, V21, P1773, DOI 10.1038/sj.leu.2404760; Labi V, 2008, J EXP MED, V205, P641, DOI 10.1084/jem.20071658; Matthews GM, 2012, ADV CANCER RES, V116, P165, DOI 10.1016/B978-0-12-394387-3.00005-7; MILLER RW, 1995, CANCER, V75, P395, DOI 10.1002/1097-0142(19950101)75:1+<395::AID-CNCR2820751321>3.0.CO;2-W; Sarosiek KA, 2013, MOL CELL, V51, P751, DOI 10.1016/j.molcel.2013.08.048; Stuhmer T, 2010, BRIT J HAEMATOL, V149, P529, DOI 10.1111/j.1365-2141.2010.08126.x; Stupack DG, 2006, NATURE, V439, P95, DOI 10.1038/nature04323; Taylor AC, 2000, MED PEDIATR ONCOL, V35, P96, DOI 10.1002/1096-911X(200008)35:2<96::AID-MPO2>3.0.CO;2-Z; Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312; Venugopal B, 2013, CLIN CANCER RES, V19, P4262, DOI 10.1158/1078-0432.CCR-13-0312; Vogler M, 2009, CANCER RES, V69, P2425, DOI 10.1158/0008-5472.CAN-08-2436; Wiegmans AP, 2011, CANCER RES, V71, P3603, DOI 10.1158/0008-5472.CAN-10-3289; Witt O, 2012, KLIN PADIATR, V224, P398, DOI 10.1055/s-0032-1323692; Workman P, 2010, BRIT J CANCER, V102, P1555, DOI 10.1038/sj.bjc.6605642; Xargay-Torrent S, 2011, CLIN CANCER RES, V17, P3956, DOI 10.1158/1078-0432.CCR-10-3412	35	26	26	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2016	35	28					3729	3741		10.1038/onc.2015.440	http://dx.doi.org/10.1038/onc.2015.440			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UQ	26616861				2022-12-17	WOS:000379622800011
J	Zhang, Q; Wei, T; Shim, K; Wright, K; Xu, K; Palka-Hamblin, HL; Jurkevich, A; Khare, S				Zhang, Q.; Wei, T.; Shim, K.; Wright, K.; Xu, K.; Palka-Hamblin, H. L.; Jurkevich, A.; Khare, S.			Atypical role of sprouty in colorectal cancer: sprouty repression inhibits epithelial-mesenchymal transition	ONCOGENE			English	Article							COLON-CANCER; CELL-MIGRATION; TARGET GENE; EXPRESSION; AKT2; MOUSE; DIFFERENTIATION; ESTABLISHMENT; METASTASIS; ANTAGONIST	Sprouty (SPRY) appears to act as a tumor suppressor in cancer, whereas we demonstrated that SPRY2 functions as a putative oncogene in colorectal cancer (CRC) (Oncogene, 2010, 29: 5241-5253). We investigated the mechanisms by which SPRY regulates epithelial-mesenchymal transition (EMT) in CRC. SPRY1 and SPRY2 mRNA transcripts were significantly upregulated in human CRC. Suppression of SPRY2 repressed AKT2 and EMT-inducing transcription factors and significantly increased E-cadherin expression. Concurrent downregulation of SPRY1 and SPRY2 also increased E-cadherin and suppressed mesenchymal markers in colon cancer cells. An inverse expression pattern between AKT2 and E-cadherin was established in a human CRC tissue microarray. SPRY2 negatively regulated miR-194-5p that interacts with AKT2 3' untranslated region. Mir-194 mimics increased E-cadherin expression and suppressed cancer cell migration and invasion. By confocal microscopy, we demonstrated redistribution of E-cadherin to plasma membrane in colon cancer cells transfected with miR-194. Spry1(-/-) and Spry2(-/-) double mutant mouse embryonic fibroblasts exhibited decreased cell migration while acquiring several epithelial markers. In CRC, SPRY drive EMT and may serve as a biomarker of poor prognosis.	[Zhang, Q.; Wei, T.; Xu, K.; Khare, S.] Univ Missouri, Dept Internal Med, Sect Gastroenterol & Hepatol, Columbia, MO 65212 USA; [Shim, K.; Wright, K.] Med Coll Wisconsin, Dept Pediat, Milwaukee, WI 53226 USA; [Palka-Hamblin, H. L.] Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL USA; [Jurkevich, A.] Univ Missouri, Mol Cytol Core, Columbia, MO 65212 USA; [Khare, S.] Harry S Truman Mem Vet Hosp, Columbia, MO 65201 USA	University of Missouri System; University of Missouri Columbia; Medical College of Wisconsin; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Missouri System; University of Missouri Columbia; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harry S. Truman Memorial Veterans' Hospital	Khare, S (corresponding author), Univ Missouri, Dept Internal Med, 1 Hosp Dr, Columbia, MO 65212 USA.	khares@health.missouri.edu		Jurkevich, Alexander/0000-0002-1161-0918; Wei, Tao/0000-0002-9510-5512	VA Merit Award [1171590]; RO3 Award [CA150081]; University of Missouri Research Board Award; School of Medicine Bridge Funding; RO1 Award [DC010387]; NATIONAL CANCER INSTITUTE [R03CA150081] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC010387] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000824] Funding Source: NIH RePORTER	VA Merit Award(US Department of Veterans Affairs); RO3 Award; University of Missouri Research Board Award; School of Medicine Bridge Funding; RO1 Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); Veterans Affairs(US Department of Veterans Affairs)	Thanks to Yuanxi Xu and Tammy Strawn for providing help in IHC data collection and analysis. Renilla luciferase control vector (pRL-null Vector) is a kind gift from Dr Guifa Xi at Northwestern University, Chicago, IL, USA. pmiR-GLO-AKT2-3'UTR and pmiR-GLO-AKT2-3'UTR mutant is a kind gift from Dr Jie Hong at School of Medicine, Shanghai Jiao Tong University, Shanghi, China. This work was supported by VA Merit Award (Project1171590), RO3 Award (CA150081), University of Missouri Research Board Award and School of Medicine Bridge Funding to SK and an RO1 Award (DC010387) to KS.	Acunzo M, 2013, P NATL ACAD SCI USA, V110, P8573, DOI 10.1073/pnas.1302107110; Agarwal E, 2013, CELL SIGNAL, V25, P1711, DOI 10.1016/j.cellsig.2013.03.025; Barad O, 2004, GENOME RES, V14, P2486, DOI 10.1101/gr.2845604; Barbachano A, 2010, ONCOGENE, V29, P4800, DOI 10.1038/onc.2010.225; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Basson MA, 2005, DEV CELL, V8, P229, DOI 10.1016/j.devcel.2004.12.004; Buchan JR, 2007, SCIENCE, V318, P1877, DOI 10.1126/science.1152623; Cheng GZ, 2007, CANCER RES, V67, P1979, DOI 10.1158/0008-5472.CAN-06-1479; Chi LJ, 2006, ENDOCRINOLOGY, V147, P3777, DOI 10.1210/en.2006-0299; Chiang YP, 2012, EXP THER MED, V3, P560, DOI 10.3892/etm.2011.436; Diaz-Lopez A, 2014, CANCER MANAG RES, V6, P205, DOI 10.2147/CMAR.S38156; Feng YH, 2011, CANCER BIOL THER, V11, P111, DOI 10.4161/cbt.11.1.13965; Grille Sylvia, 2004, Journal de la Societe de Biologie, V198, P375; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Hayashi S, 2002, DEV BIOL, V244, P305, DOI 10.1006/dbio.2002.0597; Hick AC, 2013, DEV BIOL, V381, P227, DOI 10.1016/j.ydbio.2013.04.022; Hino K, 2008, RNA, V14, P1433, DOI 10.1261/rna.810208; Hino Kimihiro, 2007, Nucleic Acids Symp Ser (Oxf), P415, DOI 10.1093/nass/nrm208; Holgren C, 2010, ONCOGENE, V29, P5241, DOI 10.1038/onc.2010.264; Khare S, 1999, AM J PHYSIOL-GASTR L, V276, pG1005; Khare S, 2006, AM J PHYSIOL-GASTR L, V291, pG1100, DOI 10.1152/ajpgi.00008.2006; Kroepil F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046665; Kumarswamy R, 2011, RNA BIOL, V8, P706, DOI 10.4161/rna.8.5.16154; Leeksma OC, 2002, EUR J BIOCHEM, V269, P2546, DOI 10.1046/j.1432-1033.2002.02921.x; Li XY, 2011, J CELL BIOL, V195, P729, DOI 10.1083/jcb.201105103; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Masoumi-Moghaddam S, 2014, CANCER METAST REV, V33, P695, DOI 10.1007/s10555-014-9497-1; Natalwala A, 2008, WORLD J GASTROENTERO, V14, P3792, DOI 10.3748/wjg.14.3792; Ordonez-Moran P, 2014, ONCOGENE, V33, P1975, DOI 10.1038/onc.2013.140; Pichiorri F, 2010, CANCER CELL, V18, P367, DOI 10.1016/j.ccr.2010.09.005; Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Rychahou PG, 2008, P NATL ACAD SCI USA, V105, P20315, DOI 10.1073/pnas.0810715105; Shim K, 2005, DEV CELL, V8, P553, DOI 10.1016/j.devcel.2005.02.009; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Tazawa H, 2011, EXPERT OPIN BIOL TH, V11, P145, DOI 10.1517/14712598.2011.542749; Tsanou E, 2008, ANTICANCER RES, V28, P3815; Villagrasa P, 2012, ONCOGENE, V31, P4022, DOI 10.1038/onc.2011.562; Watanabe T, 2011, EUR J CANCER, V47, P1946, DOI 10.1016/j.ejca.2011.03.029; Yamaguchi H, 2005, CURR OPIN CELL BIOL, V17, P559, DOI 10.1016/j.ceb.2005.08.002; Zhao HJ, 2014, THERANOSTICS, V4, P1193, DOI 10.7150/thno.8712	42	26	27	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2016	35	24					3151	3162		10.1038/onc.2015.365	http://dx.doi.org/10.1038/onc.2015.365			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO9GI	26434583	Green Published, Green Accepted, hybrid			2022-12-17	WOS:000378092700007
J	Patel, B; Patel, J; Cho, JH; Manne, S; Bonala, S; Henske, E; Roegiers, F; Markiewski, M; Karbowniczek, M				Patel, B.; Patel, J.; Cho, J-H; Manne, S.; Bonala, S.; Henske, E.; Roegiers, F.; Markiewski, M.; Karbowniczek, M.			Exosomes mediate the acquisition of the disease phenotypes by cells with normal genome in tuberous sclerosis complex	ONCOGENE			English	Article							RADIAL GLIAL-CELLS; RAPAMYCIN; NOTCH; TSC; ANGIOMYOLIPOMA; MECHANISMS; DIFFERENTIATION; PROGENITORS; ACTIVATION; GROWTH	Functions of extracellular vesicles including exosomes in the pathogenesis of tuberous sclerosis complex (TSC) have not yet been studied. We report that the extracellular vesicles such as exosomes derived from tuberous sclerosis 1 (Tsc1)-null cells transform phenotypes of neighboring wild-type cells in vivo in such manner that they become functionally similar to Tsc1-null cells. The loss of Tsc1 in the mouse neural tube increases the number of the wild-type neuronal progenitors, which is followed by the precocious and transient acceleration of neuronal differentiation of these cells. The mechanisms regulating these changes involve the exosomal delivery of exosomal shuttle Notch1 and Rheb esRNA and component of.-secretase complex presenilin 1 from Tsc1-null cells to wild-type cells leading to the activation of Notch and Rheb signaling in the recipient cells. The exosome-mediated mechanisms may also operate in the cells of angiomyolipoma (AML), which develops as a result of mutations in TSC1/TSC2 genes in TSC patients, because we observed the reactivation of mammalian target of rapamycin and Notch pathways, driven by the delivery of Rheb and Notch1 esRNA, in AML cells depleted of Rheb that were treated with the exosomes purified from AML cells with the constitutively high Rheb levels.	[Patel, B.; Patel, J.; Cho, J-H; Manne, S.; Bonala, S.; Markiewski, M.; Karbowniczek, M.] Texas Tech Univ Hlth Sci Ctr, Sch Pharm, Dept Immunotherapeut & Biotechnol, 1718 Pine St, Abilene, TX 79601 USA; [Henske, E.] Brigham & Womens Hosp, Dept Med, Div Pulm & Crit Care Med, 75 Francis St, Boston, MA 02115 USA; [Henske, E.] Harvard Univ, Sch Med, Boston, MA USA; [Roegiers, F.] Fox Chase Canc Ctr, Canc Biol Program, 7701 Burholme Ave, Philadelphia, PA 19111 USA	Texas Tech University System; Texas Tech University Health Science Center; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Fox Chase Cancer Center	Karbowniczek, M (corresponding author), Texas Tech Univ Hlth Sci Ctr, Sch Pharm, Dept Immunotherapeut & Biotechnol, 1718 Pine St, Abilene, TX 79601 USA.	Magdalena.karbowniczek@ttuhsc.edu			CPRIT [RP 120168]; DoD grant [BC 111038]	CPRIT; DoD grant	We thank Drs Maureen Murphy and Aristotelis Astreinidis for his invaluable comments. CPRIT grant RP 120168 to M Karbowniczek and the DoD grant BC 111038 to MM Markiewski.	Arbiser JL, 2002, AM J PATHOL, V161, P781, DOI 10.1016/S0002-9440(10)64237-X; Arbiser JL, 2001, AM J PATHOL, V159, P483, DOI 10.1016/S0002-9440(10)61720-8; Au KS, 1999, AM J HUM GENET, V65, P1790, DOI 10.1086/302648; Bakhti M, 2011, J BIOL CHEM, V286, P787, DOI 10.1074/jbc.M110.190009; Baonza A, 2001, DEVELOPMENT, V128, P3889; Baybis M, 2004, ANN NEUROL, V56, P478, DOI 10.1002/ana.20211; Bissler JJ, 2008, NEW ENGL J MED, V358, P140, DOI 10.1056/NEJMoa063564; Bonnet CS, 2009, HUM MOL GENET, V18, P2166, DOI 10.1093/hmg/ddp149; Brugarolas JB, 2003, CANCER CELL, V4, P147, DOI 10.1016/S1535-6108(03)00187-9; Cepeda C, 2010, EPILEPSIA, V51, P160, DOI 10.1111/j.1528-1167.2010.02633.x; Cheadle JP, 2000, HUM GENET, V107, P97, DOI 10.1007/s004390000348; Gan B, 2008, P NATL ACAD SCI USA, V105, P19384, DOI 10.1073/pnas.0810584105; Ge WH, 2002, J NEUROSCI RES, V69, P848, DOI 10.1002/jnr.10364; Govindarajan B, 2012, VASC CELL, V4, DOI 10.1186/2045-824X-4-11; Hall DJ, 2007, BMC BIOL, V5, DOI 10.1186/1741-7007-5-10; Hartman TR, 2009, HUM MOL GENET, V18, P151, DOI 10.1093/hmg/ddn325; HOCKFIELD S, 1985, J NEUROSCI, V5, P3310; Johnson MW, 1999, BRAIN PATHOL, V9, P45; Karbowniczek M, 2006, J BIOL CHEM, V281, P25447, DOI 10.1074/jbc.M605273200; Karbowniczek M, 2010, J CLIN INVEST, V120, P93, DOI 10.1172/JCI40221; Kenerson H, 2005, PEDIATR RES, V57, P67, DOI 10.1203/01.PDR.0000147727.78571.07; Kim J, 2003, NEURON, V38, P17, DOI 10.1016/S0896-6273(03)00163-6; Knox S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000375; Kornblum HI, 2007, STROKE, V38, P810, DOI 10.1161/01.STR.0000255757.12198.0f; Lasser C, 2012, JOVE-J VIS EXP, DOI 10.3791/3037; Lee C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050501; Lee PS, 2010, AM J RESP CELL MOL, V42, P227, DOI 10.1165/rcmb.2009-0050OC; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Ma DZ, 2010, J BIOL CHEM, V285, P8621, DOI 10.1074/jbc.M109.092353; Malatesta P, 2000, DEVELOPMENT, V127, P5253; Martynoga B, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008359; Marzesco AM, 2005, J CELL SCI, V118, P2849, DOI 10.1242/jcs.02439; Melo SA, 2014, CANCER CELL, V26, P707, DOI 10.1016/j.ccell.2014.09.005; Mineo M, 2012, ANGIOGENESIS, V15, P33, DOI 10.1007/s10456-011-9241-1; Mizuguchi M, 2000, ACTA NEUROPATHOL, V99, P503, DOI 10.1007/s004010051152; Neuman NA, 2011, EMBO MOL MED, V3, P189, DOI 10.1002/emmm.201100131; Niida Y, 2001, AM J HUM GENET, V69, P493, DOI 10.1086/321972; Noctor SC, 2001, NATURE, V409, P714, DOI 10.1038/35055553; Okamura Y, 2008, DEVELOPMENT, V135, P3555, DOI 10.1242/dev.022319; Palmini A, 2004, NEUROLOGY, V62, pS2, DOI 10.1212/01.WNL.0000114507.30388.7E; Pardal R, 2007, CELL, V131, P364, DOI 10.1016/j.cell.2007.07.043; Parker MA, 2005, EXP NEUROL, V194, P320, DOI 10.1016/j.expneurol.2005.04.018; Patch K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007574; Ramesh V, 2003, BIOCHEM SOC T, V31, P579, DOI 10.1042/bst0310579; Ratajczak J, 2006, LEUKEMIA, V20, P847, DOI 10.1038/sj.leu.2404132; Tian TA, 2010, J CELL BIOCHEM, V111, P488, DOI 10.1002/jcb.22733; Walker AS, 2010, NEURAL PLAST, V2010, DOI 10.1155/2010/894374; Weisman R, 2007, GENETICS, V175, P1153, DOI 10.1534/genetics.106.064170; Wilson C, 2006, CANCER RES, V66, P7934, DOI 10.1158/0008-5472.CAN-06-1740; Wong M, 2008, EPILEPSIA, V49, P8, DOI 10.1111/j.1528-1167.2007.01270.x; Yu J, 2004, AM J PHYSIOL-LUNG C, V286, pL694, DOI 10.1152/ajplung.00204.2003; Zhou XM, 2009, P NATL ACAD SCI USA, V106, P8923, DOI 10.1073/pnas.0903621106	52	26	26	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2016	35	23					3027	3036		10.1038/onc.2015.358	http://dx.doi.org/10.1038/onc.2015.358			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0NB	26434588				2022-12-17	WOS:000377474500008
J	Sotoca, AM; Prange, KHM; Reijnders, B; Mandoli, A; Nguyen, LN; Stunnenberg, HG; Martens, JHA				Sotoca, A. M.; Prange, K. H. M.; Reijnders, B.; Mandoli, A.; Nguyen, L. N.; Stunnenberg, H. G.; Martens, J. H. A.			The oncofusion protein FUS-ERG targets key hematopoietic regulators and modulates the all-trans retinoic acid signaling pathway in t(16;21) acute myeloid leukemia	ONCOGENE			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; GENOME-WIDE ANALYSIS; PML-RAR-ALPHA; TRANSCRIPTION FACTOR; PROSTATE-CANCER; BINDING-SITES; HISTONE DEACETYLASE; RECEPTOR-ALPHA; CD38 ANTIGEN; SELF-RENEWAL	The ETS transcription factor ERG has been implicated as a major regulator of both normal and aberrant hematopoiesis. In acute myeloid leukemias harboring t(16; 21), ERG function is deregulated due to a fusion with FUS/TLS resulting in the expression of a FUS-ERG oncofusion protein. How this oncofusion protein deregulates the normal ERG transcription program is unclear. Here, we show that FUS-ERG acts in the context of a heptad of proteins (ERG, FLI1, GATA2, LYL1, LMO2, RUNX1 and TAL1) central to proper expression of genes involved in maintaining a stem cell hematopoietic phenotype. Moreover, in t(16; 21) FUS-ERG co-occupies genomic regions bound by the nuclear receptor heterodimer RXR:RARA inhibiting target gene expression and interfering with hematopoietic differentiation. All-trans retinoic acid treatment of t(16; 21) cells as well as FUS-ERG knockdown alleviate the myeloid-differentiation block. Together, the results suggest that FUS-ERG acts as a transcriptional repressor of the retinoic acid signaling pathway.	[Sotoca, A. M.; Prange, K. H. M.; Reijnders, B.; Mandoli, A.; Nguyen, L. N.; Stunnenberg, H. G.; Martens, J. H. A.] Radboud Univ Nijmegen, Dept Mol Biol, Fac Sci, Nijmegen Ctr Mol Life Sci, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	Martens, JHA (corresponding author), Radboud Univ Nijmegen, Dept Mol Biol, Fac Sci, Nijmegen Ctr Mol Life Sci,FNWI, Geert Grootepl 28, NL-6500 HB Nijmegen, Netherlands.	j.martens@ncmls.ru.nl	Stunnenberg, Hendrik G./D-6875-2012; Nguyen, Luan/GYA-2927-2022; Martens, Joost/D-4966-2012	Stunnenberg, Hendrik G./0000-0002-0066-1576; Martens, Joost/0000-0003-2008-6537; Prange, Koen/0000-0002-9835-1735	EU [BLUEPRINT-282510]; Dutch Cancer Foundation [KWF KUN 2009-4527, KUN 2011-4937]; Netherlands Organization for Scientific Research (NWO-VIDI)	EU(European Commission); Dutch Cancer Foundation(KWF Kankerbestrijding); Netherlands Organization for Scientific Research (NWO-VIDI)(Netherlands Organization for Scientific Research (NWO))	This work was supported by the EU (BLUEPRINT-282510), the Dutch Cancer Foundation (KWF KUN 2009-4527 and KUN 2011-4937) and the Netherlands Organization for Scientific Research (NWO-VIDI to JHAM). Database accession: All ChIP-seq and RNA-seq data can be downloaded from the NCBI Gene Expression Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geo/) under accession number GSE60477.	Beck D, 2013, BLOOD, V122, pE12, DOI 10.1182/blood-2013-03-490425; Bock J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052872; Boersema PJ, 2009, NAT PROTOC, V4, P484, DOI 10.1038/nprot.2009.21; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; De Bellis F, 2014, CANCER RES, V74, P2328, DOI 10.1158/0008-5472.CAN-13-2568; Delva L, 2004, ONCOGENE, V23, P4389, DOI 10.1038/sj.onc.1207578; Denissov S, 2007, EMBO J, V26, P944, DOI 10.1038/sj.emboj.7601550; Diffner E, 2013, BLOOD, V121, P2289, DOI 10.1182/blood-2012-07-446120; DRACH J, 1993, BIOCHEM BIOPH RES CO, V195, P545, DOI 10.1006/bbrc.1993.2080; DRACH J, 1994, CANCER RES, V54, P1746; DUBOIS C, 1994, BLOOD, V83, P3264; Ebralidze AK, 2008, GENE DEV, V22, P2085, DOI 10.1101/gad.1654808; Goldberg L, 2013, BLOOD, V122, P2694, DOI 10.1182/blood-2013-01-477133; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Hallier M, 1998, J BIOL CHEM, V273, P4838, DOI 10.1074/jbc.273.9.4838; Hicks GG, 2000, NAT GENET, V24, P175, DOI 10.1038/72842; Kong XT, 1997, BLOOD, V90, P1192; Kryndushkin D, 2011, PROTEIN CELL, V2, P223, DOI 10.1007/s13238-011-1525-0; Lacadie SA, 2011, GENE DEV, V25, P289, DOI 10.1101/gad.2031511; Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Lian Z, 2001, BLOOD, V98, P513, DOI 10.1182/blood.V98.3.513; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu SJ, 2007, J PHARMACOL EXP THER, V321, P953, DOI 10.1124/jpet.106.118406; Loughran SJ, 2008, NAT IMMUNOL, V9, P810, DOI 10.1038/ni.1617; Martens JHA, 2012, BLOOD, V120, P4038, DOI 10.1182/blood-2012-05-429050; Martens JHA, 2010, CANCER CELL, V17, P173, DOI 10.1016/j.ccr.2009.12.042; Mills KI, 2000, BRIT J HAEMATOL, V108, P316; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; Ng AP, 2011, BLOOD, V118, P2454, DOI 10.1182/blood-2011-03-344739; Pereira DS, 1998, P NATL ACAD SCI USA, V95, P8239, DOI 10.1073/pnas.95.14.8239; Powers CA, 1998, MOL ENDOCRINOL, V12, P4, DOI 10.1210/mend.12.1.0043; PRASAD DDK, 1994, ONCOGENE, V9, P3717; Rapin N, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2014.22; Saeed S, 2011, BRIT J CANCER, V104, P554, DOI 10.1038/sj.bjc.6606095; Saeed S, 2012, BLOOD, V120, P3058, DOI 10.1182/blood-2011-10-386086; Salek-Ardakani S, 2009, CANCER RES, V69, P4665, DOI 10.1158/0008-5472.CAN-09-0075; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; Shikami M, 1999, BRIT J HAEMATOL, V105, P711, DOI 10.1046/j.1365-2141.1999.01384.x; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Sugawara T, 2010, EXP HEMATOL, V38, P696, DOI 10.1016/j.exphem.2010.04.006; Sun ZH, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1000614; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Walsby EJ, 2007, BRIT J HAEMATOL, V139, P94, DOI 10.1111/j.1365-2141.2007.06756.x; Wei GH, 2010, EMBO J, V29, P2147, DOI 10.1038/emboj.2010.106; Wilson NK, 2010, CELL STEM CELL, V7, P532, DOI 10.1016/j.stem.2010.07.016; Winnes M, 2007, ONCOL REP, V17, P1033; Yamamoto K, 1997, LEUKEMIA, V11, P599, DOI 10.1038/sj.leu.2400594; Yang L, 2000, MOL CELL BIOL, V20, P3345, DOI 10.1128/MCB.20.10.3345-3354.2000; Yu JD, 2010, CANCER CELL, V17, P443, DOI 10.1016/j.ccr.2010.03.018; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zinszner H, 1997, ONCOGENE, V14, P451, DOI 10.1038/sj.onc.1200854; Zinszner H, 1997, J CELL SCI, V110, P1741; Zou JH, 2005, MOL CELL BIOL, V25, P6235, DOI 10.1128/MCB.25.14.6235-6246.2005	54	26	29	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2016	35	15					1965	1976		10.1038/onc.2015.261	http://dx.doi.org/10.1038/onc.2015.261			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ2CC	26148230	hybrid, Green Published			2022-12-17	WOS:000374010300009
J	Wang, Y; Deng, O; Feng, Z; Du, Z; Xiong, X; Lai, J; Yang, X; Xu, M; Wang, H; Taylor, D; Yan, C; Chen, C; Difeo, A; Ma, Z; Zhang, J				Wang, Y.; Deng, O.; Feng, Z.; Du, Z.; Xiong, X.; Lai, J.; Yang, X.; Xu, M.; Wang, H.; Taylor, D.; Yan, C.; Chen, C.; Difeo, A.; Ma, Z.; Zhang, J.			RNF126 promotes homologous recombination via regulation of E2F1-mediated BRCA1 expression	ONCOGENE			English	Article							SPORADIC BREAST-CANCER; NUCLEOTIDE EXCISION-REPAIR; DNA-DAMAGE; OVARIAN-CANCER; DIFFERENTIAL REGULATION; REPLICATION ARREST; GENE-EXPRESSION; MESSENGER-RNA; FREQUENT LOSS; E2F1	RNF126 is an E3 ubiquitin ligase. The deletion of RNF126 gene was observed in a wide range of human cancers and is correlated with improved disease-free and overall survival. These data highlight the clinical relevance of RNF126 in tumorigenesis and cancer therapy. However, the specific functions of RNF126 remain largely unknown. Homologous recombination (HR)-mediated DNA double-strand break repair is important for tumor suppression and cancer therapy resistance. Here, we demonstrate that RNF126 facilitates HR by promoting the expression of BRCA1, in a manner independent of its E3 ligase activity but depending on E2F1, a well-known transcription factor of BRCA1 promoter. In support of this result, RNF126 promotes transactivation of BRCA1 promoter by directly binding to E2F1. Most importantly, an RNF126 mutant lacking 11 amino acids that is responsible for the interaction with E2F1 has a dominant-negative effect on BRCA1 expression and HR by suppressing E2F1-mediated transactivation of BRCA1 promoter and blocking the enrichment of E2F1 on BRCA1 promoter. Lastly, RNF126 depletion leads to the increased sensitivity to ionizing radiation and poly (ADP-ribose) polymerase inhibition. Collectively, our results suggest a novel role of RNF126 in promoting HR-mediated repair through positive regulation on BRCA1 expression by direct interaction with E2F1. This study not only offers novel insights into our current understanding of the biological functions of RNF126 but also provides a potential therapeutic target for cancer treatment.	[Wang, Y.; Deng, O.; Feng, Z.; Du, Z.; Xiong, X.; Lai, J.; Zhang, J.] Case Western Reserve Univ, Sch Med, Dept Radiat Oncol, 10900 Euclid Ave,BRB 323, Cleveland, OH 44106 USA; [Deng, O.; Yang, X.; Ma, Z.] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Breast Surg, 58 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China; [Lai, J.] Fujian Med Univ, Affiliated Hosp 2, Quanzhou, Fujian, Peoples R China; [Xu, M.; Taylor, D.] Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA; [Wang, H.] Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA; [Yan, C.] Georgia Regents Univ, GRU Canc Ctr, Augusta, GA USA; [Chen, C.] Chinese Acad Sci, Kunming Inst Zool, Key Lab Anim Models & Human Dis Mech, Kunming, Yunnan, Peoples R China; [Difeo, A.] Case Western Reserve Univ, Gen Med Sci, Cleveland, OH 44106 USA	Case Western Reserve University; Sun Yat Sen University; Fujian Medical University; Case Western Reserve University; University System of Maryland; University of Maryland Baltimore; University System of Georgia; Augusta University; Chinese Academy of Sciences; Kunming Institute of Zoology; Case Western Reserve University	Zhang, J (corresponding author), Case Western Reserve Univ, Sch Med, Dept Radiat Oncol, 10900 Euclid Ave,BRB 323, Cleveland, OH 44106 USA.; Ma, Z (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Breast Surg, 58 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China.	mazhefu@mail.sysu.edu.cn; Junran.zhang@case.edu	Du, Zhanwen/H-9903-2016	Deng, Ou/0000-0002-9933-1832; Yan, Chunhong/0000-0002-3974-7991; DiFeo, Analisa/0000-0001-8319-6763	National Cancer Institute [R01C A154625]; Department of Radiation Oncology, Case Western Reserve University School of Medicine; National Natural Science Foundation of China [31271503]; Guangdong Provincial Natural Science Foundation of China [S2012010008368]; Sun Yat-sen University; Radiation Resources Core Facility; Cytometry & Imaging Microscopy Core Facility of the Case Comprehensive Cancer Center [P30 CA43703]; NATIONAL CANCER INSTITUTE [DP2CA186571, R01CA139107, R01CA154625, P30CA043703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM107058] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Radiation Oncology, Case Western Reserve University School of Medicine; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Provincial Natural Science Foundation of China(National Natural Science Foundation of Guangdong Province); Sun Yat-sen University; Radiation Resources Core Facility; Cytometry & Imaging Microscopy Core Facility of the Case Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This study was supported by a grant (R01C A154625) from the National Cancer Institute and a startup fund from the Department of Radiation Oncology, Case Western Reserve University School of Medicine to JZ; National Natural Science Foundation of China grant (31271503), Guangdong Provincial Natural Science Foundation of China grant (S2012010008368) and a startup fund from Sun Yat-sen University to ZM. This research was also supported by Radiation Resources Core Facility and Cytometry & Imaging Microscopy Core Facility of the Case Comprehensive Cancer Center (P30 CA43703). We thank Daniel Li and Mehdi Haider for the technical support.	AMFO K, 1995, ONCOGENE, V11, P351; Andreassen PR, 2006, CARCINOGENESIS, V27, P883, DOI 10.1093/carcin/bgi319; Bindra RS, 2007, ONCOGENE, V26, P2048, DOI 10.1038/sj.onc.1210001; Bindra RS, 2005, CANCER RES, V65, P11597, DOI 10.1158/0008-5472.CAN-05-2119; Biswas AK, 2012, CANCER RES, V72, P13, DOI 10.1158/0008-5472.CAN-11-2196; Biswas AK, 2014, CANCER RES, V74, P3369, DOI 10.1158/0008-5472.CAN-13-3216; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen HH, 2011, RADIAT RES, V175, P214, DOI 10.1667/RR2323.1; Chen J, 2011, CELL CYCLE, V10, P1287, DOI 10.4161/cc.10.8.15341; De Siervi A, 2010, CANCER RES, V70, P532, DOI 10.1158/0008-5472.CAN-09-1477; Delker RK, 2013, P NATL ACAD SCI USA, V110, P1029, DOI 10.1073/pnas.1214538110; Evers B, 2006, ONCOGENE, V25, P5885, DOI 10.1038/sj.onc.1209871; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Feng ZH, 2012, NUCLEIC ACIDS RES, V40, P726, DOI 10.1093/nar/gkr748; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Guo RF, 2011, NUCLEIC ACIDS RES, V39, P1390, DOI 10.1093/nar/gkq983; Guo RF, 2010, J BIOL CHEM, V285, P19308, DOI 10.1074/jbc.M110.121939; Helleday T, 2010, CARCINOGENESIS, V31, P955, DOI 10.1093/carcin/bgq064; Iwanaga R, 2004, ONCOGENE, V23, P8581, DOI 10.1038/sj.onc.1207976; Johnson DG, 2006, CURR MOL MED, V6, P731; Litman R, 2005, CANCER CELL, V8, P255, DOI 10.1016/j.ccr.2005.08.004; Liu K, 2003, MOL CELL BIOL, V23, P3287, DOI 10.1128/MCB.23.9.3287-3304.2003; Moynahan ME, 2010, NAT REV MOL CELL BIO, V11, P196, DOI 10.1038/nrm2851; Mueller CR, 2003, BREAST CANCER RES, V5, P45, DOI 10.1186/bcr557; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Putzer BM, 2013, TRENDS MOL MED, V19, P89, DOI 10.1016/j.molmed.2012.10.009; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086; Russell PA, 2000, INT J CANCER, V87, P317, DOI 10.1002/1097-0215(20000801)87:3<317::AID-IJC2>3.0.CO;2-B; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Shi W, 2010, CARCINOGENESIS, V31, P994, DOI 10.1093/carcin/bgq035; Smith CJ, 2013, J CELL SCI, V126, P1366, DOI 10.1242/jcs.116129; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Stanelle J, 2002, NUCLEIC ACIDS RES, V30, P1859, DOI 10.1093/nar/30.8.1859; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Turner NC, 2007, ONCOGENE, V26, P2126, DOI 10.1038/sj.onc.1210014; Wang A, 2000, J BIOL CHEM, V275, P4532, DOI 10.1074/jbc.275.6.4532; Wang B, 2004, J BIOL CHEM, V279, P54140, DOI 10.1074/jbc.M410493200; Wang ZJ, 1999, BRIT J CANCER, V80, P70, DOI 10.1038/sj.bjc.6690323; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; Yanaihara N, 2003, INT J ONCOL, V23, P567; Yang SZ, 2008, EMBO REP, V9, P907, DOI 10.1038/embor.2008.128; Yang TL, 2004, GENE CHROMOSOME CANC, V41, P250, DOI 10.1002/gcc.20080; Zhang JR, 2005, NAT STRUCT MOL BIOL, V12, P902, DOI 10.1038/nsmb991; Zhang JR, 2013, CELL BIOSCI, V3, DOI 10.1186/2045-3701-3-11; Zheng WX, 2000, GYNECOL ONCOL, V76, P294, DOI 10.1006/gyno.1999.5664; Zhi X, 2013, CANCER RES, V73, P385, DOI 10.1158/0008-5472.CAN-12-0562; Zhuang J, 2006, CANCER RES, V66, P1401, DOI 10.1158/0008-5472.CAN-05-3278	49	26	26	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2016	35	11					1363	1372		10.1038/onc.2015.198	http://dx.doi.org/10.1038/onc.2015.198			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG6LQ	26234677	Green Accepted			2022-12-17	WOS:000372196400003
J	Pazarentzos, E; Giannikopoulos, P; Hrustanovic, G; St John, J; Olivas, VR; Gubens, MA; Balassanian, R; Weissman, J; Polkinghorn, W; Bivona, TG				Pazarentzos, E.; Giannikopoulos, P.; Hrustanovic, G.; St John, J.; Olivas, V. R.; Gubens, M. A.; Balassanian, R.; Weissman, J.; Polkinghorn, W.; Bivona, T. G.			Oncogenic activation of the PI3-kinase p110 beta isoform via the tumor-derived PIK3C beta(D1067V) kinase domain mutation	ONCOGENE			English	Article							LUNG-CANCER; ERLOTINIB RESISTANCE; PIK3CA MUTATIONS; PI3 KINASE; PTEN LOSS; GROWTH; INHIBITORS; PATHWAY; BRAF	Activation of the phosphoinositide 3-kinase (PI3K) pathway occurs widely in human cancers. Although somatic mutations in the PI3K pathway genes PIK3CA and PTEN are known to drive PI3K pathway activation and cancer growth, the significance of somatic mutations in other PI3K pathway genes is less clear. Here, we establish the signaling and oncogenic properties of a recurrent somatic mutation in the PI3K p110 beta isoform that resides within its kinase domain (PIK3C beta(D1067V)). We initially observed PIK3C beta(D1067V) by exome sequencing analysis of an EGFR-mutant non-small cell lung cancer (NSCLC) tumor biopsy from a patient with acquired erlotinib resistance. On the basis of this finding, we hypothesized that PIK3C beta(D1067V) might function as a novel tumor-promoting genetic alteration, and potentially an oncogene, in certain cancers. Consistent with this hypothesis, analysis of additional tumor exome data sets revealed the presence of PIK3C beta(D1067V) at low frequency in other patient tumor samples (including renal cell carcinoma, glioblastoma multiforme, head and neck squamous cell carcinoma, melanoma, thyroid carcinoma and endometrial carcinoma). Functional studies revealed that PIK3C beta(D1067V) promoted PI3K pathway signaling, enhanced cell growth in vitro, and was sufficient for tumor formation in vivo. Pharmacologic inhibition of PIK3C beta with TGX-221 (isoform-selective p110 beta inhibitor) specifically suppressed growth in patient-derived renal-cell carcinoma cells with endogenous PIK3C beta(D1067V) and in NIH-3T3 and human EGFR-mutant lung adenocarcinoma cells engineered to express this mutant PI3K. In the EGFR-mutant lung adenocarcinoma cells, expression of PIK3C beta(D1067V) also promoted erlotinib resistance. Our data establish a novel oncogenic form of PI3K, revealing the signaling and oncogenic properties of PIK3C beta(D1067V) and its potential therapeutic relevance in cancer. Our findings provide new insight into the genetic mechanisms underlying PI3K pathway activation in human tumors and indicate that PIK3C beta(D1067V) is a rational therapeutic target in certain cancers.	[Pazarentzos, E.; Hrustanovic, G.; Olivas, V. R.; Gubens, M. A.; Bivona, T. G.] Univ Calif San Francisco, Dept Med, Div Hematol & Oncol, San Francisco, CA 94158 USA; [Pazarentzos, E.; Hrustanovic, G.; Olivas, V. R.; Gubens, M. A.; Bivona, T. G.] Univ Calif San Francisco, Helen Diller Comprehens Canc Ctr, San Francisco, CA 94143 USA; [Giannikopoulos, P.; St John, J.; Polkinghorn, W.] Driver Grp, San Francisco, CA USA; [Balassanian, R.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; [Weissman, J.] Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA; [Weissman, J.] Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Bivona, TG (corresponding author), Univ Calif San Francisco, Dept Med, Div Hematol & Oncol, San Francisco, CA 94158 USA.	trever.bivona@ucsf.edu		Pazarentzos, Evangelos/0000-0002-5453-1646; Weissman, Jonathan/0000-0003-2445-670X	NIH; Howard Hughes Medical Institute; Doris Duke Charitable Foundation; American Lung Association; National Lung Cancer Partnership; Sidney Kimmel Foundation for Cancer Research; Searle Scholars Program	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Howard Hughes Medical Institute(Howard Hughes Medical Institute); Doris Duke Charitable Foundation(Doris Duke Charitable Foundation (DDCF)); American Lung Association; National Lung Cancer Partnership; Sidney Kimmel Foundation for Cancer Research; Searle Scholars Program	We acknowledge funding support (to TGB) from the following sources: NIH Director's New Innovator Award, Howard Hughes Medical Institute, Doris Duke Charitable Foundation, American Lung Association, National Lung Cancer Partnership, Sidney Kimmel Foundation for Cancer Research and Searle Scholars Program.	Bauer TM, 2015, PHARMACOL THERAPEUT, V146, P53, DOI 10.1016/j.pharmthera.2014.09.006; Boehm JS, 2007, CELL, V129, P1065, DOI 10.1016/j.cell.2007.03.052; Burger MT, 2011, ACS MED CHEM LETT, V2, P774, DOI 10.1021/ml200156t; Carracedo A, 2008, ONCOGENE, V27, P5527, DOI 10.1038/onc.2008.247; Chalhoub N, 2009, ANNU REV PATHOL-MECH, V4, P127, DOI 10.1146/annurev.pathol.4.110807.092311; Charles RP, 2014, MOL CANCER RES, V12, P979, DOI 10.1158/1541-7786.MCR-14-0158-T; Dbouk HA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063833; Deuker MM, 2015, CANCER DISCOV, V5, P143, DOI 10.1158/2159-8290.CD-14-0856; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Hollander MC, 2011, NAT REV CANCER, V11, P289, DOI 10.1038/nrc3037; Jackson SP, 2005, NAT MED, V11, P507, DOI 10.1038/nm1232; Janku F, 2011, MOL CANCER THER, V10, P558, DOI 10.1158/1535-7163.MCT-10-0994; Jia SD, 2008, NATURE, V454, P776, DOI 10.1038/nature07091; Kang SY, 2005, P NATL ACAD SCI USA, V102, P802, DOI 10.1073/pnas.0408864102; Karakas B, 2006, BRIT J CANCER, V94, P455, DOI 10.1038/sj.bjc.6602970; Kosaka T, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/165214; Lammers PE, 2014, J NATL COMPR CANC NE, V12, P6, DOI 10.6004/jnccn.2014.0002; Lin LP, 2014, P NATL ACAD SCI USA, V111, pE748, DOI 10.1073/pnas.1320956111; Ling YH, 2008, MOL PHARMACOL, V74, P793, DOI 10.1124/mol.107.044396; Oxnard GR, 2011, CLIN CANCER RES, V17, P5530, DOI 10.1158/1078-0432.CCR-10-2571; Porta C, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00064; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Schroeder MP, 2013, GENOME MED, V5, DOI 10.1186/gm413; Sos ML, 2009, CANCER RES, V69, P3256, DOI 10.1158/0008-5472.CAN-08-4055; Tang J, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00015; Vogt PK, 2007, TRENDS BIOCHEM SCI, V32, P342, DOI 10.1016/j.tibs.2007.05.005; Wu JY, 2011, CLIN CANCER RES, V17, P3812, DOI 10.1158/1078-0432.CCR-10-3408	27	26	26	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2016	35	9					1198	1205		10.1038/onc.2015.173	http://dx.doi.org/10.1038/onc.2015.173			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DF4WH	25982275	Bronze			2022-12-17	WOS:000371351700014
J	Bailly, A; Perrin, A; Malhab, LJB; Pion, E; Larance, M; Nagala, M; Smith, P; O'Donohue, MF; Gleizes, PE; Zomerdijk, J; Lamond, AI; Xirodimas, DP				Bailly, A.; Perrin, A.; Malhab, L. J. Bou; Pion, E.; Larance, M.; Nagala, M.; Smith, P.; O'Donohue, M-F; Gleizes, P-E; Zomerdijk, J.; Lamond, A. I.; Xirodimas, D. P.			The NEDD8 inhibitor MLN4924 increases the size of the nucleolus and activates p53 through the ribosomal-Mdm2 pathway	ONCOGENE			English	Article							CANCER-SPECIFIC ACTIVATION; RNA-POLYMERASE I; NEDD8-ACTIVATING ENZYME; PROTEIN NEDDYLATION; DNA-DAMAGE; MDM2; TRANSCRIPTION; REPLICATION; DISRUPTION; ACTINOMYCIN	The ubiquitin-like molecule NEDD8 is essential for viability, growth and development, and is a potential target for therapeutic intervention. We found that the small molecule inhibitor of NEDDylation, MLN4924, alters the morphology and increases the surface size of the nucleolus in human and germline cells of Caenorhabditis elegans in the absence of nucleolar fragmentation. SILAC proteomics and monitoring of rRNA production, processing and ribosome profiling shows that MLN4924 changes the composition of the nucleolar proteome but does not inhibit RNA Pol I transcription. Further analysis demonstrates that MLN4924 activates the p53 tumour suppressor through the RPL11/RPL5-Mdm2 pathway, with characteristics of nucleolar stress. The study identifies the nucleolus as a target of inhibitors of NEDDylation and provides a mechanism for p53 activation upon NEDD8 inhibition. It also indicates that targeting the nucleolar proteome without affecting nucleolar transcription initiates the required signalling events for the control of cell cycle regulators.	[Bailly, A.; Perrin, A.; Malhab, L. J. Bou; Pion, E.; Xirodimas, D. P.] CNRS, Ctr Rech Biochim Macromol, UMR 5237, Montpellier, France; [Larance, M.; Nagala, M.; Zomerdijk, J.; Lamond, A. I.] Univ Dundee, Coll Life Sci, Ctr Gene Regulat & Express, Dundee, Scotland; [Smith, P.] Millennium Pharmaceut Inc, Cambridge, MA USA; [O'Donohue, M-F; Gleizes, P-E] UMR CNRS 5099, Lab Biol Mol Eucaryote, Batiment IBCG, Toulouse, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; University of Dundee; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Xirodimas, DP (corresponding author), CRBM, 1919 Route Mende, F-34293 Montpellier, Langeudoc, France.	dimitris.xirodimas@crbm.cnrs.fr	Bailly, Aymeric P/AAA-3141-2021; Larance, Mark/AAG-8613-2019; Gleizes, Pierre-Emmanuel/ABB-9653-2021; Gleizes, Pierre-Emmanuel/H-3821-2014	Bailly, Aymeric P/0000-0002-0842-5631; Gleizes, Pierre-Emmanuel/0000-0003-0830-7341; Gleizes, Pierre-Emmanuel/0000-0003-0830-7341; Perrin, Aurelien/0000-0001-5895-3064; Larance, Mark/0000-0002-8579-2267; Xirodimas, Dimitris/0000-0001-9275-1140; Zomerdijk, Joost/0000-0003-1865-729X; O'Donohue, Marie-Francoise/0000-0002-1204-8285	ANR (National Agency for Research) postdoctoral fellowship awarded; ATIP/AVENIR; Marie Curie Career Integration (FP7) grants	ANR (National Agency for Research) postdoctoral fellowship awarded(French National Research Agency (ANR)); ATIP/AVENIR; Marie Curie Career Integration (FP7) grants	We are grateful to Dr Yanping Zhang for providing the wild- type and mutant Mdm2 C305F MEFs, the Montpellier RIO Imaging facility and Stefano Fumagalli for critical reading of the manuscript. AB and AP are supported by an ANR (National Agency for Research) postdoctoral fellowship awarded to AB. The project in DPX laboratory was supported by ATIP/AVENIR and Marie Curie Career Integration (FP7) grants.	Abidi N, 2015, ENDOCR-RELAT CANCER, V22, pT55, DOI 10.1530/ERC-14-0315; Andersen JS, 2005, NATURE, V433, P77, DOI 10.1038/nature03207; Andersen JS, 2002, CURR BIOL, V12, P1, DOI 10.1016/S0960-9822(01)00650-9; Baker NE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058266; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Blank JL, 2013, CANCER RES, V73, P225, DOI 10.1158/0008-5472.CAN-12-1729; Boulon S, 2010, MOL CELL, V40, P216, DOI 10.1016/j.molcel.2010.09.024; Brownell JE, 2010, MOL CELL, V37, P102, DOI 10.1016/j.molcel.2009.12.024; Bywater MJ, 2012, CANCER CELL, V22, P51, DOI 10.1016/j.ccr.2012.05.019; Chadha GS, 2010, MOL CELL, V37, P5, DOI 10.1016/j.molcel.2009.12.028; Chen DY, 2001, J CELL BIOL, V153, P169, DOI 10.1083/jcb.153.1.169; Dai MS, 2007, EMBO J, V26, P3332, DOI 10.1038/sj.emboj.7601776; Derenzini M, 2009, HISTOPATHOLOGY, V54, P753, DOI 10.1111/j.1365-2559.2008.03168.x; Donati G, 2013, CELL REP, V4, P87, DOI 10.1016/j.celrep.2013.05.045; Drygin D, 2014, DRUG DISCOV TODAY, V19, P259, DOI 10.1016/j.drudis.2013.08.012; Duda DM, 2011, CURR OPIN STRUC BIOL, V21, P257, DOI 10.1016/j.sbi.2011.01.003; Duncan K, 2012, FUTURE ONCOL, V8, P1461, DOI [10.2217/FON.12.131, 10.2217/fon.12.131]; Enchev RI, 2015, NAT REV MOL CELL BIO, V16, P30, DOI 10.1038/nrm3919; Fox AH, 2002, CURR BIOL, V12, P13, DOI 10.1016/S0960-9822(01)00632-7; Fuhrman LE, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000657; Fumagalli S, 2012, GENE DEV, V26, P1028, DOI 10.1101/gad.189951.112; Fumagalli S, 2009, NAT CELL BIOL, V11, P501, DOI 10.1038/ncb1858; Golomb L, 2014, FEBS LETT, V588, P2571, DOI 10.1016/j.febslet.2014.04.014; Greco A, 2009, REV MED VIROL, V19, P201, DOI 10.1002/rmv.614; Hannan RD, 2013, EXPERT OPIN THER TAR, V17, P873, DOI 10.1517/14728222.2013.818658; Harper JW, 2012, MOL CELL PROTEOMICS, V11, P1541, DOI 10.1074/mcp.R112.021154; Hernandez-Verdun D, 2006, HISTOCHEM CELL BIOL, V125, P127, DOI 10.1007/s00418-005-0046-4; Horn HF, 2008, ONCOGENE, V27, P5774, DOI 10.1038/onc.2008.189; James A, 2014, NUCLEUS-PHILA, V5, P402, DOI 10.4161/nucl.32235; Kressler D, 2010, BBA-MOL CELL RES, V1803, P673, DOI 10.1016/j.bbamcr.2009.10.009; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Lam YW, 2007, CURR BIOL, V17, P749, DOI 10.1016/j.cub.2007.03.064; Larance M, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.014407; Lee LW, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/601274; Lempiainen H, 2009, CURR OPIN CELL BIOL, V21, P855, DOI 10.1016/j.ceb.2009.09.002; Liakopoulos D, 1998, EMBO J, V17, P2208, DOI 10.1093/emboj/17.8.2208; Lin JJ, 2010, CANCER RES, V70, P10310, DOI 10.1158/0008-5472.CAN-10-2062; Lindstrom MS, 2007, MOL CELL BIOL, V27, P1056, DOI 10.1128/MCB.01307-06; Lindstrom MS, 2009, BIOCHEM BIOPH RES CO, V379, P167, DOI 10.1016/j.bbrc.2008.12.083; Liu G, 2010, ONCOGENE, V29, P2252, DOI 10.1038/onc.2009.494; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Macias E, 2010, CANCER CELL, V18, P231, DOI 10.1016/j.ccr.2010.08.007; Miotto B, 2010, MOL CELL, V37, P57, DOI 10.1016/j.molcel.2009.12.012; Montanaro L, 2008, AM J PATHOL, V173, P301, DOI 10.2353/ajpath.2008.070752; Olson MOJ, 2005, HISTOCHEM CELL BIOL, V123, P203, DOI 10.1007/s00418-005-0754-9; Osaka F, 1998, GENE DEV, V12, P2263, DOI 10.1101/gad.12.15.2263; PERRY RP, 1970, J CELL PHYSIOL, V76, P127, DOI 10.1002/jcp.1040760202; Pestov Dimitri G, 2008, Curr Protoc Cell Biol, VChapter 22, DOI 10.1002/0471143030.cb2211s39; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Robledo S, 2008, RNA, V14, P1918, DOI 10.1261/rna.1132008; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; Saville MK, 2004, J BIOL CHEM, V279, P42169, DOI 10.1074/jbc.M403362200; Shen XT, 1996, CELL, V86, P475, DOI 10.1016/S0092-8674(00)80120-8; SOBELL HM, 1985, P NATL ACAD SCI USA, V82, P5328, DOI 10.1073/pnas.82.16.5328; Soucy TA, 2009, NATURE, V458, P732, DOI 10.1038/nature07884; Sun XX, 2010, J BIOL CHEM, V285, P25812, DOI 10.1074/jbc.M109.098442; Sundqvist A, 2009, EMBO REP, V10, P1132, DOI 10.1038/embor.2009.178; Tatham MH, 2009, NAT PROTOC, V4, P1363, DOI 10.1038/nprot.2009.128; Teng T, 2013, MOL CELL BIOL, V33, P4660, DOI 10.1128/MCB.01174-13; Vlatkovic N, 2014, CELL MOL LIFE SCI, V71, P771, DOI 10.1007/s00018-013-1361-x; Wang M, 2011, EXPERT OPIN THER TAR, V15, P253, DOI 10.1517/14728222.2011.550877; Watson IR, 2011, CANCER CELL, V19, P168, DOI 10.1016/j.ccr.2011.01.002; White RJ, 2008, TRENDS GENET, V24, P622, DOI 10.1016/j.tig.2008.10.003; Xirodimas D, 2001, ONCOGENE, V20, P4972, DOI 10.1038/sj.onc.1204656; Xirodimas DP, 2008, EMBO REP, V9, P280, DOI 10.1038/embor.2008.10; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003	67	26	28	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2016	35	4					415	426		10.1038/onc.2015.104	http://dx.doi.org/10.1038/onc.2015.104			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC2OT	25867069	Green Submitted			2022-12-17	WOS:000369056700002
J	Park, Y; Kim, W; Lee, JM; Park, J; Cho, JK; Pang, K; Lee, J; Kim, D; Park, SW; Yang, KM; Kim, SJ				Park, Y.; Kim, W.; Lee, J-M; Park, J.; Cho, J. K.; Pang, K.; Lee, J.; Kim, D.; Park, S-W; Yang, K-M; Kim, S-J			Cytoplasmic DRAK1 overexpressed in head and neck cancers inhibits TGF-beta 1 tumor suppressor activity by binding to Smad3 to interrupt its complex formation with Smad4	ONCOGENE			English	Article							SQUAMOUS-CELL CARCINOMA; TGF-BETA; DAP-KINASE; DOWN-REGULATION; APOPTOSIS; PROTEIN; GENE; PATHWAYS; RECEPTOR	Head and neck squamous cell carcinoma (HNSCC) is an extremely aggressive cancer with a poor prognosis and low patient survival. Because chemotherapy for advanced HNSCC is often ineffective, discovering new therapeutic targets that are important for HNSCC development and progression and elucidating their molecular mechanisms are required. In the present study, we describe the role of DRAK1 (death-associated protein kinase-related apoptosis-inducing kinase 1) as a novel negative regulator of the transforming growth factor-beta (TGF-beta) tumor suppressor signaling pathway for the first time in human HNSCC cells. DRAK1 was significantly overexpressed in primary human HNSCCs and in HNSCC cell lines. Through gain-and loss-of-function experiments, we demonstrated that the DRAK1 expression level regulated TGF-beta 1-induced transcriptional activity and expression of the tumor suppressor gene p21Waf1/Cip1. DRAK1 depletion enhanced TGF-beta 1-induced growth inhibition in vitro and suppressed tumorigenicity in xenograft models in vivo. Mechanistically, DRAK1 was predominantly localized in the cytoplasm and bound to Smad3, thereby interrupting Smad3/Smad4 complex formation, which is the core process for the induction of tumor suppressor genes by TGF-beta 1. Thus, our findings suggest that cytoplasmic DRAK1 increases tumorigenic potential through inhibition of TGF-beta 1-mediated tumor suppressor activity in HNSCC cells and may be a potential therapeutic target for HNSCCs.	[Park, Y.; Kim, W.; Lee, J-M; Park, J.; Cho, J. K.; Pang, K.; Lee, J.; Kim, D.; Yang, K-M; Kim, S-J] CHA Univ, CHA Canc Inst, Seoul 135081, South Korea; [Kim, W.] CHA Univ, Coll Med, Seoul 135081, South Korea; [Lee, J-M; Park, J.] CHA Univ, Coll Pharm, Seoul 135081, South Korea; [Cho, J. K.; Pang, K.; Lee, J.; Kim, S-J] CHA Univ, Dept Biomed Sci, Seoul 135081, South Korea; [Park, S-W] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul, South Korea	Pochon Cha University; Pochon Cha University; Pochon Cha University; Pochon Cha University; Seoul National University (SNU)	Yang, KM (corresponding author), CHA Univ, CHA Canc Inst, Dept Biomed Sci, 605 Yeoksam 1 Dong, Seoul 135081, South Korea.	kmyang@cha.ac.kr; kimsj@cha.ac.kr			National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning [NRF-2012M3A9C4048735, NRF-2009-0081756, NRF-2014R1A1A1005186]	National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning	This research was supported by the Bio-Synergy Research Project (NRF-2012M3A9C4048735 to S-JK), Bio & Medical Technology Development Program (NRF-2009-0081756 to S-JK) and Basic Science Research Program (NRF-2014R1A1A1005186 to K-MY), through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning.	Bialik S, 2006, ANNU REV BIOCHEM, V75, P189, DOI 10.1146/annurev.biochem.75.103004.142615; Bornstein S, 2009, J CLIN INVEST, V119, P3408, DOI 10.1172/JCI38854; Forastiere A, 2001, NEW ENGL J MED, V345, P1890, DOI 10.1056/NEJMra001375; Hunter KD, 2005, NAT REV CANCER, V5, P127, DOI 10.1038/nrc1549; Inbal B, 1997, NATURE, V390, P180, DOI 10.1038/36599; Itoh S, 2007, CURR OPIN CELL BIOL, V19, P176, DOI 10.1016/j.ceb.2007.02.015; Jang CW, 2002, NAT CELL BIOL, V4, P51, DOI 10.1038/ncb731; Kang JM, 2012, ONCOGENE, V31, P5123, DOI 10.1038/onc.2012.18; Kim SJ, 2000, CYTOKINE GROWTH F R, V11, P159, DOI 10.1016/S1359-6101(99)00039-8; Kogel D, 2001, BIOESSAYS, V23, P352, DOI 10.1002/bies.1050; Koukourakis MI, 2006, J CLIN ONCOL, V24, P727, DOI 10.1200/JCO.2005.02.7474; Levy L, 2006, CYTOKINE GROWTH F R, V17, P41, DOI 10.1016/j.cytogfr.2005.09.009; Mao P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081803; Mao P, 2011, J BIOL CHEM, V286, P19381, DOI 10.1074/jbc.M111.218040; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Peng CH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023452; Pignon JP, 2009, RADIOTHER ONCOL, V92, P4, DOI 10.1016/j.radonc.2009.04.014; Pyeon D, 2007, CANCER RES, V67, P4605, DOI 10.1158/0008-5472.CAN-06-3619; Qiu W, 2007, CANCER LETT, V245, P163, DOI 10.1016/j.canlet.2006.01.003; Sanjo H, 1998, J BIOL CHEM, V273, P29066, DOI 10.1074/jbc.273.44.29066; Wang D, 1997, CARCINOGENESIS, V18, P2285, DOI 10.1093/carcin/18.11.2285; Watanabe Y, 2010, MOL CELL, V37, P123, DOI 10.1016/j.molcel.2009.10.028; Weber F, 2007, JAMA-J AM MED ASSOC, V297, P187, DOI 10.1001/jama.297.2.187; White RA, 2010, ONCOGENE, V29, P5437, DOI 10.1038/onc.2010.306; Worsham MJ, 2006, ARCH OTOLARYNGOL, V132, P409, DOI 10.1001/archotol.132.4.409; Worsham MJ, 2003, ARCH OTOLARYNGOL, V129; Yan XH, 2009, ACTA BIOCH BIOPH SIN, V41, P263, DOI 10.1093/abbs/gmp018; Yang KM, 2013, CANCER RES, V73, P6679, DOI 10.1158/0008-5472.CAN-13-0891; Yang KM, 2012, CELL REP, V2, P1286, DOI 10.1016/j.celrep.2012.09.028; Ye H, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-69	33	26	27	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2015	34	39					5037	5045		10.1038/onc.2014.423	http://dx.doi.org/10.1038/onc.2014.423			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR9RC	25531329				2022-12-17	WOS:000361693300004
J	Caruso, JA; Akli, S; Pageon, L; Hunt, KK; Keyomarsi, K				Caruso, J. A.; Akli, S.; Pageon, L.; Hunt, K. K.; Keyomarsi, K.			The serine protease inhibitor elafin maintains normal growth control by opposing the mitogenic effects of neutrophil elastase	ONCOGENE			English	Article							MAMMARY EPITHELIAL-CELLS; HUMAN BREAST-TUMORS; LEUKOCYTE ELASTASE; TRANSGENIC MICE; CATHEPSIN-G; CANCER; PROLIFERATION; EXPRESSION; LUNG; DIFFERENTIATION	The serine protease inhibitor, elafin, is a critical component of the epithelial barrier against neutrophil elastase (NE). Elafin is downregulated in the majority of breast cancer cell lines compared with normal human mammary epithelial cells (HMECs). Here, we evaluated the role of elafin and NE on proliferation and tumorigenesis. Elafin is induced in growth factor-deprived HMECs as they enter a quiescent (G0) state, suggesting that elafin is a counterbalance against the mitogenic effects of NE in G0 HMECs. Stable knockdown of elafin compromises the ability of HMECs to maintain G0 arrest during long-term growth factor deprivation; this effect can be reversed by re-expression of wild-type elafin but not elafin-M25G lacking protease inhibitory function. These results suggest that NE, which is largely contributed by activated neutrophils in the tumor microenvironment, may be negatively regulating the ability of elafin to arrest cells in G0. In fact when purified NE was added to elafin-knocked down HMECs, these cells demonstrated greater sensitivity to the growth-promoting effects of purified NE. Activation of ERK signaling, downstream of toll-like receptor 4, was essential to the mitogenic effect of NE on HMECs. These findings were next translated to patient samples. Immunohistochemical analysis of normal breast tissue revealed robust elafin expression in the mammary epithelium; however, elafin expression was dramatically downregulated in a significant proportion of human breast tumor specimens. The loss of elafin expression during breast cancer progression may promote tumor growth as a consequence of increased NE activity. To address the role of NE in mammary tumorigenesis, we next examined whether deregulated NE activity enhances mammary tumor growth. NE knockout in the C3(1) TAg mouse model of mammary tumorigenesis suppressed proliferation and reduced the kinetics of tumor growth. Overall, the imbalance between NE and its inhibitors, such as elafin, presents an important therapeutic target in breast cancer.	[Caruso, J. A.; Akli, S.; Hunt, K. K.; Keyomarsi, K.] Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; [Caruso, J. A.; Keyomarsi, K.] Univ Texas Houston, Grad Sch Biomed Sci, Houston, TX USA; [Pageon, L.] Univ Texas MD Anderson Canc Ctr, Dept Vet Med & Surg, Houston, TX 77030 USA; [Hunt, K. K.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Keyomarsi, K (corresponding author), Univ Texas MD Anderson Canc Ctr, Expt Radiat Oncol, 1515 Holcombe Blvd,Box 66, Houston, TX 77030 USA.	kkeyomar@mdanderson.org	Poubelle, Patrice E/G-6537-2013; Keyomarsi, Khandan/H-2716-2016	Keyomarsi, Khandan/0000-0002-5440-0849	National Institutes of Health through MD Anderson's Cancer Center Support Grant [CA016672];  [5R01CA087548-10];  [5R01CA15228]; NATIONAL CANCER INSTITUTE [R01CA152228, P30CA016672, R01CA087548] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000371] Funding Source: NIH RePORTER	National Institutes of Health through MD Anderson's Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	We thank Dr Elizabeth Mittendorf discussions during the course of this study; Dr Vimla Band for HMECs; Dr Eric Campeau and Dr Didier Trono for making plasmids available through the Addgene repository; Wendy Schober and Dr Jared Burks for assistance with flow cytometry and cellular imaging; and Stephanie Deming for editorial assistance with the manuscript. This work was supported by the National Institutes of Health through MD Anderson's Cancer Center Support Grant, CA016672 and grant 5R01CA087548-10 (to KK) 5R01CA15228.	Akli S, 2011, CANCER RES, V71, P3377, DOI 10.1158/0008-5472.CAN-10-4086; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; Belaaouaj A, 1998, NAT MED, V4, P615, DOI 10.1038/nm0598-615; Caruso JA, 2010, CANCER RES, V70, P7125, DOI 10.1158/0008-5472.CAN-10-1547; Cole KA, 2004, AM J PHYSIOL-CELL PH, V286, pC349, DOI 10.1152/ajpcell.00255.2003; Devaney JM, 2003, FEBS LETT, V544, P129, DOI 10.1016/S0014-5793(03)00482-4; DiCamillo SJ, 2002, J BIOL CHEM, V277, P18938, DOI 10.1074/jbc.M200243200; Doucet A, 2007, BIOCHEM J, V405, P455, DOI 10.1042/BJ20070020; Duncan JS, 2012, CELL, V149, P307, DOI 10.1016/j.cell.2012.02.053; Foekens JA, 2003, CANCER RES, V63, P337; Green JE, 2000, ONCOGENE, V19, P1020, DOI 10.1038/sj.onc.1203280; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Houghton AM, 2010, NAT MED, V16, P219, DOI 10.1038/nm.2084; Huang CD, 2004, LIFE SCI, V74, P2479, DOI 10.1016/j.lfs.2003.07.059; Hunt KK, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3374; Jiang Z, 2002, J CELL BIOL, V156, P185, DOI 10.1083/jcb.200106084; Kerrin A, 2013, THORAX, V68, P315, DOI 10.1136/thoraxjnl-2012-202536; KEYOMARSI K, 1991, CANCER RES, V51, P3602; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Korkmaz B, 2008, BIOCHIMIE, V90, P227, DOI 10.1016/j.biochi.2007.10.009; Korkmaz B, 2010, PHARMACOL REV, V62, P726, DOI 10.1124/pr.110.002733; MAINARDI CL, 1980, J BIOL CHEM, V255, P5435; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; Mittendorf EA, 2012, CANCER RES, V72, P3153, DOI 10.1158/0008-5472.CAN-11-4135; MOLNAR G, 1994, MOL CELL BIOL, V14, P5242, DOI 10.1128/MCB.14.8.5242; Motta JP, 2012, SCI TRANSL MED, V4; Ohta K, 2004, AM J PHYSIOL-HEART C, V287, pH286, DOI 10.1152/ajpheart.00479.2002; Porter DC, 2001, MOL CELL BIOL, V21, P6254, DOI 10.1128/MCB.21.18.6254-6269.2001; Ramachandran R, 2011, J BIOL CHEM, V286, P24638, DOI 10.1074/jbc.M110.201988; Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907; Rogalski C, 2002, J INVEST DERMATOL, V118, P49, DOI 10.1046/j.0022-202x.2001.01650.x; Shapiro SD, 2003, AM J PATHOL, V163, P2329, DOI 10.1016/S0002-9440(10)63589-4; Simpson AJ, 2001, J IMMUNOL, V167, P1778, DOI 10.4049/jimmunol.167.3.1778; Vandermeeren M, 2001, ARCH DERMATOL RES, V293, P343, DOI 10.1007/s004030100238; Wang ZX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004380; Westin U, 2002, MEDIAT INFLAMM, V11, P7, DOI 10.1080/09629350210304; WIEDOW O, 1990, J BIOL CHEM, V265, P14791; Yamamoto S, 1997, BRIT J CANCER, V76, P1081, DOI 10.1038/bjc.1997.511; Yang HA, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-92; Yang XC, 2010, INT J DERMATOL, V49, P1068, DOI 10.1111/j.1365-4632.2010.04500.x; Yokota T, 2007, CANCER RES, V67, P11272, DOI 10.1158/0008-5472.CAN-07-2322; Yu KS, 2011, BIOCHEM BIOPH RES CO, V408, P160, DOI 10.1016/j.bbrc.2011.04.001; Zaidi SHE, 1999, J CLIN INVEST, V103, P1211, DOI 10.1172/JCI5099; Zaidi SHE, 2002, CIRCULATION, V105, P516, DOI 10.1161/hc0402.102866; ZHANG M, 1995, CANCER RES, V55, P2537; Zwang YR, 2011, MOL CELL, V42, P524, DOI 10.1016/j.molcel.2011.04.017	46	26	27	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	27					3556	3567		10.1038/onc.2014.284	http://dx.doi.org/10.1038/onc.2014.284			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM1IQ	25195861	Green Accepted			2022-12-17	WOS:000357434900008
J	Shaukat, Z; Liu, D; Choo, A; Hussain, R; O'Keefe, L; Richards, R; Saint, R; Gregory, SL				Shaukat, Z.; Liu, D.; Choo, A.; Hussain, R.; O'Keefe, L.; Richards, R.; Saint, R.; Gregory, S. L.			Chromosomal instability causes sensitivity to metabolic stress	ONCOGENE			English	Article							TUMOR-SUPPRESSOR GENE; OXIDATIVE STRESS; CANCER-CELLS; PAS KINASE; ANEUPLOIDY; DROSOPHILA; GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; DNA; MITOCHONDRIA; DEHYDROGENASE	Chromosomal INstability (CIN), a hallmark of cancer, refers to cells with an increased rate of gain or loss of whole chromosomes or chromosome parts. CIN is linked to the progression of tumors with poor clinical outcomes such as drug resistance. CIN can give tumors the diversity to resist therapy, but it comes at the cost of significant stress to tumor cells. To tolerate this, cancer cells must modify their energy use to provide adaptation against genetic changes as well as to promote their survival and growth. In this study, we have demonstrated that CIN induction causes sensitivity to metabolic stress. We show that mild metabolic disruption that does not affect normal cells, can lead to high levels of oxidative stress and subsequent cell death in CIN cells because they are already managing elevated stress levels. Altered metabolism is a differential characteristic of cancer cells, so our identification of key regulators that can exploit these changes to cause cell death may provide cancer-specific potential drug targets, especially for advanced cancers that exhibit CIN.	[Shaukat, Z.; Liu, D.; Choo, A.; Hussain, R.; O'Keefe, L.; Richards, R.; Saint, R.; Gregory, S. L.] Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA 5006, Australia	University of Adelaide	Gregory, SL (corresponding author), Univ Adelaide, Sch Mol & Biomed Sci, N Terrace, Adelaide, SA 5006, Australia.	stephen.gregory@adelaide.edu.au	O'Keefe, Louise V/B-9856-2008; Saint, Robert/A-4190-2008; Gregory, Stephen L/B-9918-2008; Choo, Amanda/ABA-9721-2021; Richards, Robert/ABE-6423-2020	Saint, Robert/0000-0002-7989-6043; Gregory, Stephen L/0000-0002-0046-5815; Choo, Amanda/0000-0002-4510-3615				Baker DJ, 2009, CANCER CELL, V16, P475, DOI 10.1016/j.ccr.2009.10.023; Bauer G, 2012, ANTICANCER RES, V32, P2599; Beumer KJ, 2008, P NATL ACAD SCI USA, V105, P19821, DOI 10.1073/pnas.0810475105; Buffin E, 2007, NAT CELL BIOL, V9, P565, DOI 10.1038/ncb1570; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Carter SL, 2006, NAT GENET, V38, P1043, DOI 10.1038/ng1861; Cheung-Ong K, 2013, CHEM BIOL, V20, P648, DOI 10.1016/j.chembiol.2013.04.007; Clem B, 2008, MOL CANCER THER, V7, P110, DOI 10.1158/1535-7163.MCT-07-0482; Coe JP, 2002, FREE RADICAL BIO MED, V32, P187, DOI 10.1016/S0891-5849(01)00792-4; Crasta K, 2012, NATURE, V482, P53, DOI 10.1038/nature10802; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Fang J, 2007, J DRUG TARGET, V15, P475, DOI 10.1080/10611860701498286; Gogvadze V, 2008, TRENDS CELL BIOL, V18, P165, DOI 10.1016/j.tcb.2008.01.006; Gross S, 2010, J EXP MED, V207, P339, DOI 10.1084/jem.20092506; Hao HX, 2008, IUBMB LIFE, V60, P204, DOI 10.1002/iub.32; Hao HX, 2007, P NATL ACAD SCI USA, V104, P15466, DOI 10.1073/pnas.0705407104; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hockenbery DM, 2010, ENVIRON MOL MUTAGEN, V51, P476, DOI 10.1002/em.20552; Holen K, 2008, INVEST NEW DRUG, V26, P45, DOI 10.1007/s10637-007-9083-2; Howes RE, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001339; Iijima K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008498; Janssen A, 2011, SCIENCE, V333, P1895, DOI 10.1126/science.1210214; Jiralerspong S, 2009, J CLIN ONCOL, V27, P3297, DOI 10.1200/JCO.2009.19.6410; KAPLAN O, 1990, CANCER RES, V50, P544; KASAI H, 1984, NUCLEIC ACIDS RES, V12, P2137, DOI 10.1093/nar/12.4.2137; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Kuo WY, 2000, INT J CANCER, V85, P857, DOI 10.1002/(SICI)1097-0215(20000315)85:6<857::AID-IJC20>3.3.CO;2-L; Le A, 2010, P NATL ACAD SCI USA, V107, P2037, DOI 10.1073/pnas.0914433107; Liu JK, 1996, FASEB J, V10, P1532, DOI 10.1096/fasebj.10.13.8940299; Manganelli Genesia, 2013, Cardiovascular & Hematological Disorders - Drug Targets, V13, P73; MERTENS F, 1994, PEDIATR HEMAT ONCOL, V11, P361, DOI 10.3109/08880019409140536; Michelakis ED, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000677; Miwa S, 2003, FREE RADICAL BIO MED, V35, P938, DOI 10.1016/S0891-5849(03)00464-7; O'Keefe LV, 2011, HUM MOL GENET, V20, P497, DOI 10.1093/hmg/ddq495; Owusu-Ansah E, 2009, NATURE, V461, P537, DOI 10.1038/nature08313; Ozben T, 2007, J PHARM SCI-US, V96, P2181, DOI 10.1002/jps.20874; Pfau SJ, 2012, EMBO REP, V13, P515, DOI 10.1038/embor.2012.65; Puzio-Kuter Anna M, 2011, Genes Cancer, V2, P385, DOI 10.1177/1947601911409738; Radyuk SN, 2010, FREE RADICAL BIO MED, V49, P1892, DOI 10.1016/j.freeradbiomed.2010.09.014; Ren JG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012520; Reuter S, 2010, FREE RADICAL BIO MED, V49, P1603, DOI 10.1016/j.freeradbiomed.2010.09.006; Sajesh BV, 2013, GENETICS, V195, P757, DOI 10.1534/genetics.113.156836; Schlafli P, 2009, CELL MOL LIFE SCI, V66, P876, DOI 10.1007/s00018-009-8699-0; Shaukat Z, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047447; Sheltzer JM, 2012, P NATL ACAD SCI USA, V109, P12644, DOI 10.1073/pnas.1209227109; Sotgia F, 2013, ONCOTARGET, V4, P1309, DOI 10.18632/oncotarget.1182; Sotillo R, 2010, NATURE, V464, P436, DOI 10.1038/nature08803; Stanton RC, 2012, IUBMB LIFE, V64, P362, DOI 10.1002/iub.1017; Swanton C, 2009, P NATL ACAD SCI USA, V106, P8671, DOI 10.1073/pnas.0811835106; Tanaka T, 2006, CELL CYCLE, V5, P1940, DOI 10.4161/cc.5.17.3191; Terhzaz S, 2010, PHYSIOL GENOMICS, V41, P33, DOI 10.1152/physiolgenomics.00147.2009; Thompson SL, 2008, J CELL BIOL, V180, P665, DOI 10.1083/jcb.200712029; Torres EM, 2007, SCIENCE, V317, P916, DOI 10.1126/science.1142210; Wang JX, 2012, TUMOR BIOL, V33, P95, DOI 10.1007/s13277-011-0251-9; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Wassmann K, 2001, CURR OPIN GENET DEV, V11, P83, DOI 10.1016/S0959-437X(00)00161-1; Weaver BAA, 2007, CANCER RES, V67, P10103, DOI 10.1158/0008-5472.CAN-07-2266; Weaver BAA, 2006, CURR OPIN CELL BIOL, V18, P658, DOI 10.1016/j.ceb.2006.10.002; Williams BR, 2008, SCIENCE, V322, P703, DOI 10.1126/science.1160058; Wong HW-S, 2013, CELL CYCLE, V13, P1; Wu Defeng, 2005, Toxicol Appl Pharmacol, V207, P70, DOI 10.1016/j.taap.2005.01.057; Yun JY, 2009, SCIENCE, V325, P1555, DOI 10.1126/science.1174229; Yuneva M, 2007, J CELL BIOL, V178, P93, DOI 10.1083/jcb.200703099; Zhang CH, 2014, ANTI-CANCER AGENT ME, V14, P280, DOI 10.2174/18715206113136660337; Zhang JD, 2007, BBA-MOL BASIS DIS, V1772, P1175, DOI 10.1016/j.bbadis.2007.10.001	65	26	26	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	31					4044	4055		10.1038/onc.2014.344	http://dx.doi.org/10.1038/onc.2014.344			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN9PE	25347746				2022-12-17	WOS:000358780500003
J	Song, JH; An, N; Chatterjee, S; Kistner-Griffin, E; Mahajan, S; Mehrotra, S; Kraft, AS				Song, J. H.; An, N.; Chatterjee, S.; Kistner-Griffin, E.; Mahajan, S.; Mehrotra, S.; Kraft, A. S.			Deletion of Pim kinases elevates the cellular levels of reactive oxygen species and sensitizes to K-Ras-induced cell killing	ONCOGENE			English	Article							C-MYC; GLUTAMINE-METABOLISM; GENE-EXPRESSION; TRANSGENIC MICE; CANCER; KRAS; GROWTH; DETOXIFICATION; ONCOPROTEIN; COOPERATION	The Pim protein kinases contribute to transformation by enhancing the activity of oncogenic Myc and Ras, which drives significant metabolic changes during tumorigenesis. In this report, we demonstrate that mouse embryo fibroblasts (MEFs) lacking all three isoforms of Pim protein kinases, triple knockout (TKO), cannot tolerate the expression of activated K-Ras (K-Ras(G12V)) and undergo cell death. Transduction of K-Ras(G12V) into these cells markedly increased the level of cellular reactive oxygen species (ROS). The addition of N-acetyl cysteine attenuated ROS production and reversed the cytotoxic effects of K-Ras(G12V) in the TKO MEFs. The altered cellular redox state caused by the loss of Pim occurred as a result of lower levels of metabolic intermediates in the glycolytic and pentose phosphate pathways as well as abnormal mitochondrial oxidative phosphorylation. TKO MEFs exhibit reduced levels of superoxide dismutase (Sod), glutathione peroxidase 4 (Gpx4) and peroxiredoxin 3 (Prdx3) that render them susceptible to killing by K-Ras(G12V)-mediated ROS production. In contrast, the transduction of c-Myc into TKO cells can overcome the lack of Pim protein kinases by regulating cellular metabolism and Sod2. In the absence of the Pim kinases, c-Myc transduction permitted K-Ras(G12V)-induced cell growth by decreasing Ras-induced cellular ROS levels. These results demonstrate that the Pim protein kinases have an important role in regulating cellular redox, metabolism and K-Ras-stimulated cell growth.	[Song, J. H.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; [Song, J. H.; Chatterjee, S.; Kistner-Griffin, E.; Mahajan, S.; Mehrotra, S.; Kraft, A. S.] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA; [An, N.; Kraft, A. S.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; [Chatterjee, S.; Mehrotra, S.] Med Univ S Carolina, Dept Surg, Charleston, SC 29425 USA; [Kistner-Griffin, E.] Med Univ S Carolina, Dept Publ Hlth Sci, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina	Song, JH (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 86 Jonathan Lucas St, Charleston, SC 29425 USA.	songjin@musc.edu; kraft@musc.edu		SONG, JIN/0000-0002-0123-2909	Genomics Shared Resource at Hollings Cancer Center; Seahorse Biosciences Academic Core Facility, Medical University of South Carolina; NIH [P30-CA138313]; DOD [W81XWH-08-PCRP-IDA, R01 CA1732000]; American Cancer Society Institutional Research Grant; NATIONAL CANCER INSTITUTE [R01CA173200, P30CA138313] Funding Source: NIH RePORTER	Genomics Shared Resource at Hollings Cancer Center; Seahorse Biosciences Academic Core Facility, Medical University of South Carolina; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD(United States Department of Defense); American Cancer Society Institutional Research Grant(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by the Genomics Shared Resource at Hollings Cancer Center and Seahorse Biosciences Academic Core Facility, Medical University of South Carolina. We thank Dr Allen J Ebens at Genentech Inc. and Novartis Oncology for providing the Pim kinase inhibitors used in this study. This work was supported by the NIH P30-CA138313, DOD W81XWH-08-PCRP-IDA, R01 CA1732000, and American Cancer Society Institutional Research Grant awarded to the Hollings Cancer Center, Medical University of South Carolina.	Adam M, 2006, CANCER RES, V66, P3828, DOI 10.1158/0008-5472.CAN-05-2309; Agrawal S, 2008, LEUKEMIA, V22, P78, DOI 10.1038/sj.leu.2404988; Beharry Z, 2011, P NATL ACAD SCI USA, V108, P528, DOI 10.1073/pnas.1013214108; Bhalla K, 2011, CANCER RES, V71, P6888, DOI 10.1158/0008-5472.CAN-11-1011; Cai HJ, 2012, CANCER RES, V72, P4672, DOI 10.1158/0008-5472.CAN-12-0228; COMPERE SJ, 1989, P NATL ACAD SCI USA, V86, P2224, DOI 10.1073/pnas.86.7.2224; de Groof AJC, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-54; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; Diaz F, 2012, HUM MOL GENET, V21, P5066, DOI 10.1093/hmg/dds350; GAETANI GF, 1989, BLOOD, V73, P334; Gaglio D, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.56; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Garcia PD, 2014, CLIN CANCER RES, V20, P1834, DOI 10.1158/1078-0432.CCR-13-2062; Gomez-Duran A, 2012, BBA-MOL BASIS DIS, V1822, P1216, DOI 10.1016/j.bbadis.2012.04.014; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Kim KT, 2005, BLOOD, V105, P1759, DOI 10.1182/blood-2004-05-2006; Langley RJ, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005893; Li F, 2005, MOL CELL BIOL, V25, P6225, DOI 10.1128/MCB.25.14.6225-6234.2005; Liu W, 2012, P NATL ACAD SCI USA, V109, P8983, DOI 10.1073/pnas.1203244109; Lu J, 2013, BLOOD, V122, P1610, DOI 10.1182/blood-2013-01-481457; Menssen A, 2012, P NATL ACAD SCI USA, V109, pE187, DOI 10.1073/pnas.1105304109; Mikkers H, 2004, MOL CELL BIOL, V24, P6104, DOI 10.1128/MCB.24.13.6104-6115.2004; Mitsushita J, 2004, CANCER RES, V64, P3580, DOI 10.1158/0008-5472.CAN-03-3909; Osthus RC, 2000, J BIOL CHEM, V275, P21797, DOI 10.1074/jbc.C000023200; Peek CB, 2013, SCIENCE, V342, P591, DOI 10.1126/science.1243417; Pitkanen S, 1996, J CLIN INVEST, V98, P345, DOI 10.1172/JCI118798; Podsypanina K, 2008, P NATL ACAD SCI USA, V105, P5242, DOI 10.1073/pnas.0801197105; Santidrian AF, 2013, J CLIN INVEST, V123, P1068, DOI 10.1172/JCI64264; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; Son J, 2013, NATURE, V496, P101, DOI 10.1038/nature12040; Song JH, 2006, J NEUROSCI, V26, P3299, DOI 10.1523/JNEUROSCI.5572-05.2006; Song JH, 2012, CANCER RES, V72, P294, DOI 10.1158/0008-5472.CAN-11-3240; Soucek L, 2013, GENE DEV, V27, P504, DOI 10.1101/gad.205542.112; Telang S, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-77; Tran PT, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002125; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; Wang J, 2012, ONCOGENE, V31, P1794, DOI 10.1038/onc.2011.371; Wang JB, 2010, CANCER CELL, P18207; Wasik AM, 2013, SCI REP-UK, V3, DOI [10.1038/srep01400, 10.1038/srep02007]; Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107; Weiner J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040221; Yang WS, 2014, CELL, V156, P317, DOI 10.1016/j.cell.2013.12.010; Ying HQ, 2012, CELL, V149, P656, DOI 10.1016/j.cell.2012.01.058; Ziegler M, 2000, EUR J BIOCHEM, V267, P1550, DOI 10.1046/j.1432-1327.2000.01187.x	45	26	26	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	28					3728	3736		10.1038/onc.2014.306	http://dx.doi.org/10.1038/onc.2014.306			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM4TZ	25241892	Green Accepted			2022-12-17	WOS:000357679100010
J	Cai-McRae, X; Zhong, H; Karantza, V				Cai-McRae, X.; Zhong, H.; Karantza, V.			Sequestosome 1/p62 facilitates HER2-induced mammary tumorigenesis through multiple signaling pathways	ONCOGENE			English	Article							TRANSCRIPTION FACTOR NRF2; BINDING PROTEIN P62; BREAST-CANCER; BETA-CATENIN; TRASTUZUMAB RESISTANCE; IN-SITU; AUTOPHAGY; PTEN; KINASE; P62/SQSTM1	Previous studies have shown that increased levels of the adaptor protein Sequestosome 1/p62 are observed in human breast cancers and significantly correlate with HER2 overexpression. However, the role of p62 in the pathophysiology of HER2-induced mammary tumorigenesis has not yet been investigated. In this study, we report that p62 facilitates HER2-mediated cell survival in both two-dimensional and three-dimensional cell culture and that HER2-induced cellular transformation requires p62, as well as NRF2, which is known to become stabilized by its release from Kelch-like ECH-associated protein 1 (KEAP1) via p62-KEAP1 interaction. In agreement with these results, genetic ablation of p62 delays HER2-induced mammary tumorigenesis in tumor cell allografts in nude mice, and in MMTV-Neu transgenic mice. We also report that ablation of p62 impairs AKT and beta-catenin activation in association with PTEN (phosphatase and tensin homolog deleted on chromosome ten) accumulation, both in vitro and in vivo. Further in vivo studies suggest that loss of p62 also impairs NF-kappa B and NRF2 activation. Collectively, our results provide compelling evidence that p62 contributes to HER2-induced mammary tumorigenesis through multiple signaling pathways, including the PTEN/phosphoinositide-3-kinase/AKT axis, WNT/beta-catenin signaling, the NF-kappa B pathway and the NRF2-KEAP1 axis, and offer novel insights into the potential role of p62 in the regulation of the tumor suppressor PTEN.	[Cai-McRae, X.; Karantza, V.] Rutgers State Univ, New Brunswick, NJ 08903 USA; [Cai-McRae, X.; Zhong, H.; Karantza, V.] Rutgers State Univ, Rutgers Canc Inst New Jersey, Dept Med Med Oncol, New Brunswick, NJ 08903 USA; [Zhong, H.] Rutgers Robert Wood Johnson Med Sch, Dept Pathol & Lab Med, Piscataway, NJ USA; [Karantza, V.] Rutgers Robert Wood Johnson Med Sch, Dept Internal Med, Div Med Oncol, Piscataway, NJ USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Karantza, V (corresponding author), Rutgers State Univ, Rutgers Canc Inst New Jersey, Dept Med Med Oncol, 195 Little Albany St,Rm 3550, New Brunswick, NJ 08903 USA.	karantzav@gmail.com						Alimonti A, 2010, NAT GENET, V42, P454, DOI 10.1038/ng.556; Arias-Romero LE, 2013, CANCER RES, V73, P3671, DOI 10.1158/0008-5472.CAN-12-4453; Babu JR, 2005, J NEUROCHEM, V94, P192, DOI 10.1111/j.1471-4159.2005.03181.x; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002; Bose S, 2002, HUM PATHOL, V33, P405, DOI 10.1053/hupa.2002.124721; Chang MA, 2014, PROSTATE, V74, P149, DOI 10.1002/pros.22737; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Depowski PL, 2001, MODERN PATHOL, V14, P672, DOI 10.1038/modpathol.3880371; Duran A, 2008, CANCER CELL, V13, P343, DOI 10.1016/j.ccr.2008.02.001; Duran A, 2011, MOL CELL, V44, P134, DOI 10.1016/j.molcel.2011.06.038; Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Geetha T, 2012, J BIOL CHEM, V287, P29672, DOI 10.1074/jbc.M111.322404; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; Inami Y, 2011, J CELL BIOL, V193, P275, DOI 10.1083/jcb.201102031; Jain A, 2010, J BIOL CHEM, V285, P22576, DOI 10.1074/jbc.M110.118976; Joung I, 2005, BIOCHEM BIOPH RES CO, V334, P654, DOI 10.1016/j.bbrc.2005.06.138; Karantza-Wadsworth V, 2008, METHOD ENZYMOL, V446, P61, DOI 10.1016/S0076-6879(08)01604-2; Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707; Kim S, 2004, J BIOL CHEM, V279, P4285, DOI 10.1074/jbc.M308383200; Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035; Komatsu M, 2012, PHARMACOL RES, V66, P457, DOI 10.1016/j.phrs.2012.07.004; Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021; Korkaya H, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000121; Kuusisto E, 2001, NEUROREPORT, V12, P2085, DOI 10.1097/00001756-200107200-00009; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LIU E, 1992, ONCOGENE, V7, P1027; Lozy F, 2014, AUTOPHAGY, V10, P662, DOI 10.4161/auto.27867; Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048; MORTIMORE GE, 1977, NATURE, V270, P174, DOI 10.1038/270174a0; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Niehrs C, 2012, NAT REV MOL CELL BIO, V13, P767, DOI 10.1038/nrm3470; Ozes ON, 1999, NATURE, V401, P82; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Park K, 2006, HISTOPATHOLOGY, V48, P702, DOI 10.1111/j.1365-2559.2006.02403.x; Parkhitko A, 2011, P NATL ACAD SCI USA, V108, P12455, DOI 10.1073/pnas.1104361108; Perren A, 1999, AM J PATHOL, V155, P1253, DOI 10.1016/S0002-9440(10)65227-3; Petherick KJ, 2013, EMBO J, V32, P1903, DOI 10.1038/emboj.2013.123; Rolland P, 2007, ENDOCR-RELAT CANCER, V14, P73, DOI 10.1677/erc.1.01312; Salazar M, 2006, J BIOL CHEM, V281, P14841, DOI 10.1074/jbc.M513737200; Schade B, 2013, CANCER RES, V73, P4474, DOI 10.1158/0008-5472.CAN-12-3925; Seibenhener ML, 2004, MOL CELL BIOL, V24, P8055, DOI 10.1128/MCB.24.18.8055-8068.2004; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Thompson HGR, 2003, ONCOGENE, V22, P2322, DOI 10.1038/sj.onc.1206325; White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0	50	26	26	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 4	2015	34	23					2968	2977		10.1038/onc.2014.244	http://dx.doi.org/10.1038/onc.2014.244			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK3EX	25088198	Bronze			2022-12-17	WOS:000356100500003
J	Paul, BT; Blanchard, Z; Ridgway, M; ElShamy, WM				Paul, B. T.; Blanchard, Z.; Ridgway, M.; ElShamy, W. M.			BRCA1-IRIS inactivation sensitizes ovarian tumors to cisplatin	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; CYCLIN D1 EXPRESSION; PHOSPHATIDYLINOSITOL 3-KINASE; ANOIKIS RESISTANCE; CLINICAL ACTIVITY; GROWTH-FACTORS; CANCER; TRKB; OVEREXPRESSION; PROMOTES	Ovarian cancer is the first in mortalities among gynecologic cancers in the United States, often due to late diagnosis and/or acquired platinum-resistant recurrences. This study investigates whether BRCA1-IRIS is a novel treatment target for ovarian cancers and in platinum-resistant recurrences. Here we show that more than half of the ovarian cancer samples analyzed showed BRCA1-IRIS and survivin overexpression and lacked nuclear FOXO3a expression. Normal ovarian epithelial cells overexpressing BRCA1-IRIS formed metastasis in mice when injected in the peritoneal cavity, whereas aggressive ovarian cancer cell lines failed to form tumors or metastases in mice when BRCA1-IRIS was silenced in them. We show that BRCA1-IRIS activates two autocrine signaling loops, brain-derived neurotrophic factor/tyrosine kinase B receptor (BDNF/TrkB) and neuregulin 1 (NRG1)/ErbB2. These loops are involved in anoikis resistance and metastasis promotion. These loops operate in several ovarian cancer cell lines, and BRCA1-IRIS silencing or inactivation using a novel inhibitory peptide renders both non-functional and promoted cell death. In a mouse xenograft model, BRCA1-IRIS inactivation using this novel inhibitory peptide resulted in significant reduction in ovarian tumor growth. More importantly, this treatment sensitized ovarian tumors to low cisplatin concentrations. Taken together, these data strongly suggest that BRCA1-IRIS and/or BDNF/TrkB and NRG1/ErbB2 could serve as rational therapeutic targets for advanced ovarian cancers.	[Paul, B. T.; Blanchard, Z.; ElShamy, W. M.] Univ Mississippi, Med Ctr, Inst Canc, Jackson, MS 39216 USA; [Paul, B. T.; Blanchard, Z.; ElShamy, W. M.] Univ Mississippi, Med Ctr, Dept Biochem, Jackson, MS 39216 USA; [Ridgway, M.] Univ Mississippi, Med Ctr, Dept Obstet & Gynecol, Jackson, MS 39216 USA	University of Mississippi; University of Mississippi Medical Center; University of Mississippi; University of Mississippi Medical Center; University of Mississippi; University of Mississippi Medical Center	ElShamy, WM (corresponding author), Univ Mississippi, Med Ctr, Inst Canc, 2500 North State St,G651,G362, Jackson, MS 39216 USA.	welshamy@umc.edu	ElShamy, Wael M./L-1090-2018; ElShamy, Wael/AAF-2867-2019					Alcantara S, 1997, J NEUROSCI, V17, P3623; Auersperg N, 2013, GYNECOL ONCOL, V130, P246, DOI 10.1016/j.ygyno.2013.03.021; Banerjee S, 2009, ONCOLOGIST, V14, P706, DOI 10.1634/theoncologist.2009-0013; BIRLING MC, 1995, CURR OPIN CELL BIOL, V7, P878, DOI 10.1016/0955-0674(95)80073-5; Blank SV, 2010, GYNECOL ONCOL, V119, P451, DOI 10.1016/j.ygyno.2010.08.008; Brader S, 2004, TUMORI J, V90, P2, DOI 10.1177/030089160409000102; Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031; Chen LF, 2013, INT J GYNECOL CANCER, V23, P256, DOI 10.1097/IGC.0b013e31827ad2b8; Chock K, 2010, ONCOGENE, V29, P5274, DOI 10.1038/onc.2010.262; Chock KL, 2010, CANCER RES, V70, P8782, DOI 10.1158/0008-5472.CAN-10-1352; Choudhury KR, 2010, J HISTOCHEM CYTOCHEM, V58, P95, DOI 10.1369/jhc.2009.953554; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; ElShamy WM, 2004, NAT CELL BIOL, V6, P954, DOI 10.1038/ncb1171; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Felsher DW, 2008, APMIS, V116, P629, DOI 10.1111/j.1600-0463.2008.01037.x; Geiger TR, 2007, CANCER RES, V67, P6221, DOI 10.1158/0008-5472.CAN-07-0121; Gordon MS, 2006, J CLIN ONCOL, V24, P4324, DOI 10.1200/JCO.2005.05.4221; Hao L, 2007, INT J CANCER, V121, P39, DOI 10.1002/ijc.22597; Hondermarck H, 2012, CYTOKINE GROWTH F R, V23, P357, DOI 10.1016/j.cytogfr.2012.06.004; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Huang HJ, 2011, BBA-MOL CELL RES, V1813, P1961, DOI 10.1016/j.bbamcr.2011.01.007; Jiang L, 2013, ONCOL LETT, P51605; Jungbluth S, 1997, DEVELOPMENT, V124, P1877; Kim H, 2004, J BIOL CHEM, V279, P33538, DOI 10.1074/jbc.M404115200; Kupferman ME, 2010, ONCOGENE, V29, P2047, DOI 10.1038/onc.2009.486; Lafky JM, 2008, BBA-REV CANCER, V1785, P232, DOI 10.1016/j.bbcan.2008.01.001; Liguang Z., 2007, Experimental Oncology, V29, P121; Liu AX, 1998, CANCER RES, V58, P2973; Makhija S, 2010, J CLIN ONCOL, V28, P1215, DOI 10.1200/JCO.2009.22.3354; MASANA Y, 1993, J NEUROSCI RES, V35, P468, DOI 10.1002/jnr.490350503; Matheny RW, 2009, BIOCHEM BIOPH RES CO, V389, P117, DOI 10.1016/j.bbrc.2009.08.101; Matsuo K, 2010, EXPERT OPIN INV DRUG, V19, P1339, DOI 10.1517/13543784.2010.515585; McCormick F, 2011, J SURG ONCOL, V103, P464, DOI 10.1002/jso.21749; Monsalve M, 2011, CURR DRUG TARGETS, V12, P1322, DOI 10.2174/138945011796150307; Nakuci E, 2006, EXP CELL RES, V312, P3120, DOI 10.1016/j.yexcr.2006.06.021; OHANLAN KA, 1995, GYNECOL ONCOL, V59, P200; Okamura K, 2012, LUNG CANCER, V78, P100, DOI 10.1016/j.lungcan.2012.07.011; Page C, 2000, ANTICANCER RES, V20, P407; Pece S, 1999, J BIOL CHEM, V274, P19347, DOI 10.1074/jbc.274.27.19347; Ponnusamy MP, 2010, ONCOGENE, V29, P5741, DOI 10.1038/onc.2010.309; Puehringer D, 2013, NAT NEUROSCI, V16, P407, DOI 10.1038/nn.3333; Ricci A, 2010, GROWTH FACTORS, V28, P221, DOI 10.3109/08977191003677402; Santo EE, 2013, CANCER RES, V73, P2189, DOI 10.1158/0008-5472.CAN-12-3767; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; Sheng Q, 2010, CANCER CELL, V17, P298, DOI 10.1016/j.ccr.2009.12.047; Shimizu Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034102; Siwak DR, 2010, J ONCOL, V2010, DOI 10.1155/2010/568938; Smit MA, 2011, ONCOGENE, V30, P3735, DOI 10.1038/onc.2011.96; Smit MA, 2009, MOL CELL BIOL, V29, P3722, DOI 10.1128/MCB.01164-08; Tanner B, 2006, J CLIN ONCOL, V24, P4317, DOI 10.1200/JCO.2005.04.8397; Torti D, 2011, EMBO MOL MED, V3, P623, DOI 10.1002/emmm.201100176; Ween MP, 2011, INT J MOL SCI, V12, P1009, DOI 10.3390/ijms12021009; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Weng DH, 2009, CANCER LETT, V273, P257, DOI 10.1016/j.canlet.2008.08.027; Yang J, 2004, CELL; Yang JY, 2008, NAT CELL BIOL, V10, P138, DOI 10.1038/ncb1676; Yarden Y, 2001, EUR J CANCER, V37, pS3; Yu XH, 2008, CANCER SCI, V99, P543, DOI 10.1111/j.1349-7006.2007.00722.x; Yu YJ, 2010, APMIS, V118, P188, DOI 10.1111/j.1600-0463.2009.02577.x; Yue W, 2010, REGUL PEPTIDES, V180, P33; Zhang HY, 2009, EUR J OBSTET GYN R B, V146, P81, DOI 10.1016/j.ejogrb.2009.04.035; Zheng WP, 2011, TUMORI, V97, P756, DOI 10.1700/1018.11093	62	26	30	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 4	2015	34	23					3036	3052		10.1038/onc.2014.237	http://dx.doi.org/10.1038/onc.2014.237			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK3EX	25132263				2022-12-17	WOS:000356100500009
J	Krakowiak, MS; Noto, JM; Piazuelo, MB; Hardbower, DM; Romero-Gallo, J; Delgado, A; Chaturvedi, R; Correa, P; Wilson, KT; Peek, RM				Krakowiak, M. S.; Noto, J. M.; Piazuelo, M. B.; Hardbower, D. M.; Romero-Gallo, J.; Delgado, A.; Chaturvedi, R.; Correa, P.; Wilson, K. T.; Peek, R. M., Jr.			Matrix metalloproteinase 7 restrains Helicobacter pylori-induced gastric inflammation and premalignant lesions in the stomach by altering macrophage polarization	ONCOGENE			English	Article							EXPRESSION; ACTIVATION; MATRILYSIN; RESPONSES; CANCER; MMP-7; HOST	Helicobacter pylori is the strongest risk factor for the development of gastric cancer. Although the specific mechanisms by which this pathogen induces carcinogenesis have not been fully elucidated, high-expression interleukin (IL)-1 beta alleles are associated with increased gastric cancer risk among H. pylori-infected persons. In addition, loss of matrix metalloproteinase 7 (MMP7) increases mucosal inflammation in mouse models of epithelial injury, and we have shown that gastric inflammation is increased in H. pylori-infected MMP7(-/-) C57BL/6 mice. In this report, we define mechanisms that underpin such responses and extend these results into a genetic model of MMP7 deficiency and gastric cancer. Wild-type (WT) or MMP7(-/-) C57BL/6 mice were challenged with broth alone as an uninfected control or the H. pylori strain PMSS1. All H. pylori-challenged mice were successfully colonized. As expected, H. pylori-infected MMP7(-/-) C57BL/6 mice exhibited a significant increase in gastric inflammation compared with uninfected or infected WT C57BL/6 animals. Loss of MMP7 resulted in M1 macrophage polarization within H. pylori-infected stomachs, as assessed by Luminex technology and immunohistochemistry, and macrophages isolated from infected MMP7-deficient mice expressed significantly higher levels of the M1 macrophage marker IL-1 beta compared with macrophages isolated from WT mice. To extend these findings into a model of gastric cancer, hypergastrinemic WT INS-GAS or MMP7(-/-) INS-GAS mice were challenged with H. pylori strain PMSS1. Consistent with findings in the C57BL/6 model, H. pylori-infected MMP7-deficient INS-GAS mice exhibited a significant increase in gastric inflammation compared with either uninfected or infected WT INS-GAS mice. In addition, the incidence of gastric hyperplasia and dysplasia was significantly increased in H. pylori-infected MMP7(-/-) INS-GAS mice compared with infected WT INS-GAS mice, and loss of MMP7 promoted M1 macrophage polarization. These results suggest that MMP7 exerts a restrictive role on H. pylori-induced gastric injury and the development of premalignant lesions by suppressing M1 macrophage polarization.	[Krakowiak, M. S.; Wilson, K. T.; Peek, R. M., Jr.] Vanderbilt Univ, Dept Canc Biol, Med Ctr, Nashville, TN 37232 USA; [Noto, J. M.; Piazuelo, M. B.; Hardbower, D. M.; Romero-Gallo, J.; Delgado, A.; Chaturvedi, R.; Correa, P.; Wilson, K. T.; Peek, R. M., Jr.] Vanderbilt Univ, Div Gastroenterol, Dept Med, Med Ctr, Nashville, TN 37232 USA; [Hardbower, D. M.; Wilson, K. T.] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA; [Wilson, K. T.] Vet Affairs Tennessee Valley Healthcare Syst, Nashville, TN USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Peek, RM (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, 2215 Garland Ave,MRB 4 1030C, Nashville, TN 37232 USA.	richard.peek@vanderbilt.edu		Wilson, Keith/0000-0003-4421-1830	Department of Veterans Affairs [T32CA009592, F32CA153539, T32GM008554, K01AT007324, P01CA028842, R01DK053620, 1I01BX001453];  [R01DK058587];  [R01CA077955];  [P30DK058404];  [P01CA116087]; NATIONAL CANCER INSTITUTE [R01CA077955, F32CA153539, P01CA028842, T32CA009592, P01CA116087, R01CA190612] Funding Source: NIH RePORTER; NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE [K01AT007324] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [R01AT004821] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058587, P30DK058404, R01DK053620] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008554] Funding Source: NIH RePORTER; Veterans Affairs [I01BX001453] Funding Source: NIH RePORTER	Department of Veterans Affairs(US Department of Veterans Affairs); ; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Veterans Affairs(US Department of Veterans Affairs)	This study was supported by T32CA009592 (MSK), F32CA153539 (JMN), T32GM008554 (DMH), K01AT007324 (RC), P01CA028842 (KTW and PC), R01DK053620 and 1I01BX001453 from the Department of Veterans Affairs (KTW), R01DK058587, R01CA077955, P30DK058404 and P01CA116087 (RMP).	Barry DP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029046; Bray F, 2013, INT J CANCER, V132, P1133, DOI 10.1002/ijc.27711; Cassetta L, 2011, THESCIENTIFICWORLDJO, V11, P2391, DOI 10.1100/2011/213962; Chung WC, 2010, GASTRIC CANCER, V13, P162, DOI 10.1007/s10120-010-0552-5; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; El-Omar EM, 2000, NATURE, V404, P398, DOI 10.1038/35006081; Fox JG, 2003, GASTROENTEROLOGY, V124, P1879, DOI 10.1016/S0016-5085(03)00406-2; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Kassim SY, 2007, INFECT IMMUN, V75, P5640, DOI 10.1128/IAI.00799-07; Lifsted T, 1998, INT J CANCER, V77, P640, DOI 10.1002/(SICI)1097-0215(19980812)77:4<640::AID-IJC26>3.0.CO;2-8; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; MCDONNELL S, 1991, MOL CARCINOGEN, V4, P527, DOI 10.1002/mc.2940040617; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Noto JM, 2013, J CLIN INVEST, V123, P479, DOI 10.1172/JCI64373; Ogden SR, 2010, CANCER RES, V70, P30, DOI 10.1158/0008-5472.CAN-09-2899; Polk DB, 2010, NAT REV CANCER, V10, P403, DOI 10.1038/nrc2857; Quante M, 2013, GASTROENTEROLOGY, V145, P63, DOI 10.1053/j.gastro.2013.03.052; Schumacher MA, 2012, GASTROENTEROLOGY, V142, P1150, DOI 10.1053/j.gastro.2012.01.029; Senota A, 1998, CLIN EXP METASTAS, V16, P313; Sierra JC, 2013, AM J PHYSIOL-GASTR L, V305, pG196, DOI 10.1152/ajpgi.00495.2012; Weischenfeldt Joachim, 2008, CSH Protoc, V2008, DOI 10.1101/pdb.prot5080; Wilson CL, 1996, INT J BIOCHEM CELL B, V28, P123, DOI 10.1016/1357-2725(95)00121-2; Zhang Xia, 2008, Curr Protoc Immunol, VChapter 14, DOI 10.1002/0471142735.im1401s83	23	26	26	1	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 2	2015	34	14					1865	1871		10.1038/onc.2014.135	http://dx.doi.org/10.1038/onc.2014.135			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE9IQ	24837365	Green Accepted			2022-12-17	WOS:000352158000013
J	Zhao, Z; Wang, L; Xu, W				Zhao, Z.; Wang, L.; Xu, W.			IL-13R alpha 2 mediates PNR-induced migration and metastasis in ER alpha-negative breast cancer	ONCOGENE			English	Article							NUCLEAR RECEPTOR NR2E3; S-CONE SYNDROME; IL-13 RECEPTOR; INTERLEUKIN-13 RECEPTOR; PHOTORECEPTOR DEVELOPMENT; ROD PHOTORECEPTORS; MOLECULAR-CLONING; EXPRESSION; IDENTIFICATION; CHAIN	Emerging evidence has linked photoreceptor cell-specific nuclear receptor (PNR/NR2E3), an orphan nuclear hormone receptor, to human breast cancer. PNR was shown to be a transcriptional activator of estrogen receptor-alpha (ER alpha) in ER alpha-positive breast cancer cell lines and high-level expression of PNR correlates with favorable response of ER alpha-positive breast cancer patients to tamoxifen. Interestingly, gene expression microarray study shows that PNR regulates distinct genes from those regulated by ER alpha, suggesting that PNR could have ER alpha-independent functions. Herein, we investigated the function of PNR in ER alpha-negative breast cancer cells. Our results showed that PNR-induced cell migration and metastasis of ER alpha-negative breast cancer cells both in vitro and in vivo, and the effect was attributed to the upregulation of interleukin (IL)-13R alpha 2, a high-affinity receptor for IL-13 that regulates tumor growth, invasion and metastasis of various human cancers. Mechanistically, PNR activated transcription of IL-13R alpha 2 through direct recruitment to IL-13R alpha 2 promoter. Upon stimulation with IL-13, IL-13R alpha 2 increased the extracellular signal-regulated kinases 1 and 2 phosphorylation, which led to breast cancer migration and metastasis. The IL-13 triggered signal cascade was specific to IL-13R alpha 2, as the closely related IL-13R alpha 1 was not regulated by PNR. IL-13R alpha 2 is a novel tumor antigen that is overexpressed in a variety of solid tumor types. This study presents the first evidence that PNR could promote ERa-negative breast cancer metastasis through activation of IL-13R alpha 2-mediated signaling pathway.	[Zhao, Z.; Wang, L.; Xu, W.] Univ Wisconsin, Dept Oncol, McArdle Lab Canc Res, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Xu, W (corresponding author), Univ Wisconsin, Dept Oncol, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.	wxu@oncology.wisc.edu			DOD ERA of HOPE Scholar Award [W81XWYH-11-1-0237]; NATIONAL CANCER INSTITUTE [P30CA014520] Funding Source: NIH RePORTER	DOD ERA of HOPE Scholar Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This project was supported by DOD ERA of HOPE Scholar Award (W81XWYH-11-1-0237) to WX.	Aman MJ, 1996, J BIOL CHEM, V271, P29265, DOI 10.1074/jbc.271.46.29265; Barderas R, 2012, CANCER RES, V72, P2780, DOI 10.1158/0008-5472.CAN-11-4090; Caput D, 1996, J BIOL CHEM, V271, P16921, DOI 10.1074/jbc.271.28.16921; Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Cheng H, 2004, HUM MOL GENET, V13, P1563, DOI 10.1093/hmg/ddh173; Christofori G, 2007, NATURE, V446, P735, DOI 10.1038/446735a; Conzen SD, 2008, MOL ENDOCRINOL, V22, P2215, DOI 10.1210/me.2007-0421; Daines MO, 2006, J IMMUNOL, V176, P7495, DOI 10.4049/jimmunol.176.12.7495; David MD, 2003, ONCOGENE, V22, P3386, DOI 10.1038/sj.onc.1206352; De Monte L, 2011, J EXP MED, V208, P469, DOI 10.1084/jem.20101876; Donaldson DD, 1998, J IMMUNOL, V161, P2317; Fichtner-Feigl S, 2006, NAT MED, V12, P99, DOI 10.1038/nm1332; Fujisawa T, 2012, INT J CANCER, V131, P344, DOI 10.1002/ijc.26366; Fujisawa T, 2009, CANCER RES, V69, P8678, DOI 10.1158/0008-5472.CAN-09-2100; Gupta GP, 2007, NATURE, V446, P765, DOI 10.1038/nature05760; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Haider NB, 2000, NAT GENET, V24, P127, DOI 10.1038/72777; Hershey GKK, 2003, J ALLERGY CLIN IMMUN, V111, P677, DOI 10.1067/mai.2003.1333; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; Husain SR, 2003, J NEURO-ONCOL, V65, P37, DOI 10.1023/A:1026242432647; Jezequel P, 2013, DATABASE-OXFORD, DOI 10.1093/database/bas060; Joshi BH, 2009, IMMUNOTHERAPY-UK, V1, P321, DOI 10.2217/IMT.09.8; Kapitskaya M, 2006, ASSAY DRUG DEV TECHN, V4, P253, DOI 10.1089/adt.2006.4.253; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kawakami K, 2001, J EXP MED, V194, P1743, DOI 10.1084/jem.194.12.1743; Kobayashi M, 1999, P NATL ACAD SCI USA, V96, P4814, DOI 10.1073/pnas.96.9.4814; Mears AJ, 2001, NAT GENET, V29, P447, DOI 10.1038/ng774; Miloux B, 1997, FEBS LETT, V401, P163, DOI 10.1016/S0014-5793(96)01462-7; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; Mollema NJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017494; Murata T, 1997, BIOCHEM BIOPH RES CO, V238, P90, DOI 10.1006/bbrc.1997.7248; Muscat GEO, 2013, MOL ENDOCRINOL, V27, P350, DOI 10.1210/me.2012-1265; Noetzel E, 2012, ONCOGENE, V31, P2101, DOI 10.1038/onc.2011.403; O'Brien KMB, 2004, INVEST OPHTH VIS SCI, V45, P2807, DOI 10.1167/iovs.03-1317; Obiri NI, 1997, J IMMUNOL, V158, P756; Oh ECT, 2008, BRAIN RES, V1236, P16, DOI 10.1016/j.brainres.2008.01.028; Olkhanud PB, 2011, J IMMUNOL, V186, P5656, DOI 10.4049/jimmunol.1100463; PANKRATZ MJ, 1992, SCIENCE, V255, P986, DOI 10.1126/science.1546296; Park YY, 2012, EMBO MOL MED, V4, P52, DOI 10.1002/emmm.201100187; Pedroza-Gonzalez A, 2011, J EXP MED, V208, P479, DOI 10.1084/jem.20102131; Peng GH, 2005, HUM MOL GENET, V14, P747, DOI 10.1093/hmg/ddi070; Powell E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030993; Puri RK, 1996, BLOOD, V87, P4333, DOI 10.1182/blood.V87.10.4333.bloodjournal87104333; Qin Q, 2013, J OCUL PHARMACOL TH, V29, P298, DOI 10.1089/jop.2012.0135; Ring BZ, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-12-241; Roduit R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007379; Sharon D, 2003, ARCH OPHTHALMOL-CHIC, V121, P1316, DOI 10.1001/archopht.121.9.1316; Steeg PS, 2003, NAT REV CANCER, V3, P55, DOI 10.1038/nrc967; Takezawa S, 2007, EMBO J, V26, P764, DOI 10.1038/sj.emboj.7601548; Tan MHE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074359; Wang L, 2014, CANCER CELL, V25, P21, DOI 10.1016/j.ccr.2013.12.007; Wang L, 2013, NUCLEIC ACIDS RES, V41, P6870, DOI 10.1093/nar/gkt415; Wang L, 2009, MOL PHARMACOL, V76, P1238, DOI 10.1124/mol.109.059105; Webber AL, 2008, EXP EYE RES, V87, P35, DOI 10.1016/j.exer.2008.04.006; Wolkenberg SE, 2006, BIOORG MED CHEM LETT, V16, P5001, DOI 10.1016/j.bmcl.2006.07.056; Wu AH, 2003, NEURO-ONCOLOGY, V5, P179, DOI 10.1215/S1152851702000510; Yan CH, 2006, MOL CELL BIOL, V26, P6357, DOI 10.1128/MCB.00311-06; Zhao ZG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0052044, 10.1371/journal.pone.0061814, 10.1371/journal.pone.0080574]	60	26	27	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 19	2015	34	12					1596	1607		10.1038/onc.2014.53	http://dx.doi.org/10.1038/onc.2014.53			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CD9KI	24747967	Green Accepted			2022-12-17	WOS:000351416800012
J	Adams, MN; Harrington, BS; He, Y; Davies, CM; Wallace, SJ; Chetty, NP; Crandon, AJ; Oliveira, NB; Shannon, CM; Coward, JI; Lumley, J; Perrin, LC; Armes, JE; Hooper, JD				Adams, M. N.; Harrington, B. S.; He, Y.; Davies, C. M.; Wallace, S. J.; Chetty, N. P.; Crandon, A. J.; Oliveira, N. B.; Shannon, C. M.; Coward, J. I.; Lumley, J. W.; Perrin, L. C.; Armes, J. E.; Hooper, J. D.			EGF inhibits constitutive internalization and palmitoylation-dependent degradation of membrane-spanning procancer CDCP1 promoting its availability on the cell surface	ONCOGENE			English	Article							DOMAIN-CONTAINING PROTEIN-1; CUB-DOMAIN; PKC-DELTA; SRC; RESISTANCE; SURVIVAL; IDENTIFICATION; METASTASIS; INVASION	Many cancers are dependent on inappropriate activation of epidermal growth factor receptor (EGFR), and drugs targeting this receptor can improve patient survival, although benefits are generally short-lived. We reveal a novel mechanism linking EGFR and the membrane-spanning, cancer-promoting protein CDCP1 (CUB domain-containing protein 1). Under basal conditions, cell surface CDCP1 constitutively internalizes and undergoes palmitoylation-dependent degradation by a mechanism in which it is palmitoylated in at least one of its four cytoplasmic cysteines. This mechanism is functional in vivo as CDCP1 is elevated and palmitoylated in high-grade serous ovarian tumors. Interestingly, activation of the EGFR system with EGF inhibits proteasome-mediated, palmitoylation-dependent degradation of CDCP1, promoting recycling of CDCP1 to the cell surface where it is available to mediate its procancer effects. We also show that mechanisms inducing relocalization of CDCP1 to the cell surface, including disruption of its palmitoylation and EGF treatment, promote cell migration. Our data provide the first evidence that the EGFR system can function to increase the lifespan of a protein and also promote its recycling to the cell surface. This information may be useful for understanding mechanisms of resistance to EGFR therapies and assist in the design of treatments for EGFR-dependent cancers.	[Adams, M. N.; Harrington, B. S.; He, Y.; Davies, C. M.; Coward, J. I.; Armes, J. E.; Hooper, J. D.] Univ Queensland, Translat Res Inst, Mater Res Inst, Brisbane, Qld 4102, Australia; [Davies, C. M.; Wallace, S. J.; Chetty, N. P.; Crandon, A. J.; Oliveira, N. B.; Shannon, C. M.; Coward, J. I.; Perrin, L. C.; Armes, J. E.] Mater Hlth Serv, South Brisbane, Qld, Australia; [Lumley, J. W.] Wesley Hosp, Auchenflower, Qld, Australia	Mater Research; University of Queensland; Mater Health Services; Wesley Hospital	Hooper, JD (corresponding author), Univ Queensland, Translat Res Inst, Mater Res Inst, Canc Biol & Management, 37 Kent St, Brisbane, Qld 4102, Australia.	john.hooper@mater.uq.edu.au	Harrington, Brittney/Z-5941-2019; Coward, Jermaine/F-2903-2016; Harrington, Brittney/P-1687-2016; Hooper, John/C-1481-2016; Adams, Mark/AAE-1209-2021; Armes, Jane/D-6396-2012; Coward, Jermaine/C-1779-2012	Harrington, Brittney/0000-0001-7083-069X; Coward, Jermaine/0000-0002-2309-9379; Harrington, Brittney/0000-0001-7083-069X; Hooper, John/0000-0003-1054-8486; Adams, Mark/0000-0003-1906-5018; Armes, Jane/0000-0002-2215-0347; HE, Yaowu/0000-0002-7828-263X; Davies, Claire/0000-0001-8651-0914; Chetty, Naven/0000-0002-7158-7123; Perrin, Lewis/0000-0002-6119-8458	Cancer Council Queensland [614205, 1021827]; Wesley Research Institute [2008/06]; Australian Research Council Future Fellowship [FT120100917]	Cancer Council Queensland(Cancer Council Queensland); Wesley Research Institute; Australian Research Council Future Fellowship(Australian Research Council)	We thank Dr Jon Whitehead for helpful discussions. This work was supported by Cancer Council Queensland Grants 614205 and 1021827 and Wesley Research Institute Grant 2008/06 to JDH. MNA and BSH received Australian Post-Graduate Awards. JDH holds Australian Research Council Future Fellowship FT120100917.	Adams MN, 2012, N-S ARCH PHARMACOL, V385, P861, DOI 10.1007/s00210-012-0783-6; Adams MN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028018; Awakura Y, 2008, J CANCER RES CLIN, V134, P1363, DOI 10.1007/s00432-008-0412-4; Benes CH, 2005, CELL, V121, P271, DOI 10.1016/j.cell.2005.02.019; Blaskovic S, 2013, FEBS J, V280, P2766, DOI 10.1111/febs.12263; Casar B, 2014, ONCOGENE, V33, P255, DOI 10.1038/onc.2012.547; Casar B, 2012, ONCOGENE, V31, P3924, DOI 10.1038/onc.2011.555; Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704; Deryugina EI, 2009, MOL CANCER RES, V7, P1197, DOI 10.1158/1541-7786.MCR-09-0100; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; Dong Y, 2012, J BIOL CHEM, V287, P9792, DOI 10.1074/jbc.M111.335448; Emerling BM, 2013, P NATL ACAD SCI USA, V110, P3483, DOI 10.1073/pnas.1222435110; Fukuchi K, 2010, MOL PHARMACEUT, V7, P245, DOI 10.1021/mp900236t; Gao WC, 2013, GASTROENTEROLOGY, V145, P636, DOI 10.1053/j.gastro.2013.05.049; He Y, 2010, J BIOL CHEM, V285, P26162, DOI 10.1074/jbc.M109.096453; Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599; Hooper JD, 2003, ONCOGENE, V22, P1783, DOI 10.1038/sj.onc.1206220; Ikeda JI, 2009, CANCER SCI, V100, P429, DOI 10.1111/j.1349-7006.2008.01066.x; Joffre C, 2011, NAT CELL BIOL, V13, P827, DOI 10.1038/ncb2257; Kollmorgen G, 2013, MOL ONCOL, V7, P1142, DOI 10.1016/j.molonc.2013.08.009; Kulbe H, 2012, CANCER RES, V72, P66, DOI 10.1158/0008-5472.CAN-11-2178; Liu H, 2011, P NATL ACAD SCI USA, V108, P1379, DOI 10.1073/pnas.1017228108; Macdonald JL, 2005, J LIPID RES, V46, P1061, DOI 10.1194/jlr.D400041-JLR200; Miyazawa Y, 2013, MOL CANCER RES, V11, P628, DOI 10.1158/1541-7786.MCR-12-0544; Miyazawa Y, 2010, CANCER RES, V70, P5136, DOI 10.1158/0008-5472.CAN-10-0220; Morris DP, 2008, J BIOL CHEM, V283, P2973, DOI 10.1074/jbc.M705795200; Razorenova OV, 2011, P NATL ACAD SCI USA, V108, P1931, DOI 10.1073/pnas.1011777108; Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X; Sandilands E, 2008, TRENDS CELL BIOL, V18, P322, DOI 10.1016/j.tcb.2008.05.004; Siva AC, 2008, CANCER RES, V68, P3759, DOI 10.1158/0008-5472.CAN-07-1657; Uekita T, 2008, AM J PATHOL, V172, P1729, DOI 10.2353/ajpath.2008.070981; Uekita T, 2007, MOL CELL BIOL, V27, P7649, DOI 10.1128/MCB.01246-07; Uekita T, 2011, CANCER SCI, V102, P1943, DOI 10.1111/j.1349-7006.2011.02052.x; Wheeler DL, 2010, NAT REV CLIN ONCOL, V7, P493, DOI 10.1038/nrclinonc.2010.97; Wortmann A, 2011, J BIOL CHEM, V286, P42303, DOI 10.1074/jbc.M111.227462; Wortmann A, 2009, IUBMB LIFE, V61, P723, DOI 10.1002/iub.198; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	37	26	26	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 12	2015	34	11					1375	1383		10.1038/onc.2014.88	http://dx.doi.org/10.1038/onc.2014.88			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CD1AR	24681947				2022-12-17	WOS:000350806500004
J	Wang, Q; Shen, B; Chen, L; Zheng, P; Feng, H; Hao, Q; Liu, X; Liu, L; Xu, S; Chen, J; Teng, J				Wang, Q.; Shen, B.; Chen, L.; Zheng, P.; Feng, H.; Hao, Q.; Liu, X.; Liu, L.; Xu, S.; Chen, J.; Teng, J.			Extracellular calumenin suppresses ERK1/2 signaling and cell migration by protecting fibulin-1 from MMP-13-mediated proteolysis	ONCOGENE			English	Article							MATRIX METALLOPROTEINASES; MOLECULAR-CLONING; PROTEIN; EXPRESSION; CANCER; PROGRESSION; FIBRONECTIN; MECHANISM; CLEAVAGE; ADHESION	Extracellular proteins are vital for cell activities, such as cell migration. Calumenin is highly conserved among eukaryotes, but its functions are largely unclear. Here, we identify extracellular calumenin as a suppressor of cell migration and tumor metastasis. Calumenin binds to and stabilizes fibulin-1, leading to inactivation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) signaling. We further identify the minimal functional domain of calumenin (amino acids 74-138 and 214-280). Depletion of calumenin induces fibulin-1-and phospho-ERK1/2 (pERK1/2)-dependent promotion of cell migration. Consistently, in hepatocellular and pancreatic carcinoma, both calumenin and fibulin-1 are downregulated. Furthermore, we show that matrix metalloproteinase13 (MMP-13) proteolyzes fibulin-1 and that calumenin protects fibulin-1 from cleavage by MMP-13. Calumenin, together with fibulin-1, also interacts with fibronectin and depends on both syndecan-4 and a5a1-integrin to suppress ERK1/2 signaling and inhibit cell migration. Thus, extracellular calumenin regulates fibulin-1 to have crucial roles in ERK1/2 signaling and cell migration.	[Wang, Q.; Shen, B.; Chen, L.; Zheng, P.; Feng, H.; Hao, Q.; Liu, X.; Liu, L.; Xu, S.; Chen, J.; Teng, J.] Peking Univ, State Key Lab Biomembrane & Membrane Bioengn, Key Lab Cell Proliferat & Differentiat, Minist Educ,Coll Life Sci,Dept Cell Biol & Genet, Beijing 100871, Peoples R China; [Chen, J.] Peking Univ, Ctr Quantitat Biol, Beijing 100871, Peoples R China	Peking University; Peking University	Chen, J (corresponding author), Peking Univ, State Key Lab Biomembrane & Membrane Bioengn, Key Lab Cell Proliferat & Differentiat, Minist Educ,Coll Life Sci, 5 Yiheyuan Rd, Beijing 100871, Peoples R China.	chenjg@pku.edu.cn; junlinteng@pku.edu.cn		Wang, Qiao/0000-0001-6416-1733; Shen, Birong/0000-0002-1208-506X; Zheng, Pengli/0000-0002-3797-4023	National Natural Science Foundation of China [31271424]; Major State Basic Research Development Program of China (973 program) [2010CB833705]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Major State Basic Research Development Program of China (973 program)(National Basic Research Program of China)	We thank Dr W Scott Argraves at the Medical University of South Carolina for kindly providing anti-fibulin-1 antibody (3A11). The lentivirus system is a kind gift from Dr Jincai Luo at Peking University. We also thank Dr Li Yu and Dr Xiaofeng Wang at Tsinghua University, and Dr Zhengfan Jiang at Peking University for helpful discussion. We also thank Dr IC Bruce at Zhejiang University and Dr Xiaolei Su at the University of California, San Francisco, for reading the manuscript. This work was supported by the National Natural Science Foundation of China (31271424) and the Major State Basic Research Development Program of China (973 program) (2010CB833705).	Cooley MA, 2012, DEV DYNAM, V241, P303, DOI 10.1002/dvdy.23716; Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829; Ding SJ, 2004, PROTEOMICS, V4, P982, DOI 10.1002/pmic.200300653; Duncia JV, 1998, BIOORG MED CHEM LETT, V8, P2839, DOI 10.1016/S0960-894X(98)00522-8; Feng H, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.403; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Honore B, 2009, BIOESSAYS, V31, P262, DOI 10.1002/bies.200800186; Hseu MJ, 1999, FEBS LETT, V445, P440, DOI 10.1016/S0014-5793(99)00177-5; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; Hynes RO, 2009, SCIENCE, V326, P1216, DOI 10.1126/science.1176009; Jones CB, 2003, CARDIOVASC RES, V59, P812, DOI 10.1016/S0008-6363(03)00516-9; Julovi SM, 2011, J ORTHOP RES, V29, P258, DOI 10.1002/jor.21216; Kanda M, 2011, MOL CARCINOGEN, V50, P571, DOI 10.1002/mc.20735; Kapoor A, 2010, NATURE, V468, P1105, DOI 10.1038/nature09590; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Klein T, 2011, AMINO ACIDS, V41, P271, DOI 10.1007/s00726-010-0689-x; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; Labat-Robert J, 2012, PATHOL BIOL, V60, P15, DOI 10.1016/j.patbio.2011.10.003; Leeman MF, 2002, CRIT REV BIOCHEM MOL, V37, P149, DOI 10.1080/10409230290771483; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu J, 2009, CANCER CELL, V16, P195, DOI 10.1016/j.ccr.2009.08.010; Lu Y, 2011, P NATL ACAD SCI USA, V108, P2957, DOI 10.1073/pnas.1009395108; Martinez-Quiles N, 2004, MOL CELL BIOL, V24, P5269, DOI 10.1128/MCB.24.12.5269-5280.2004; Mendoza MC, 2011, MOL CELL, V41, P661, DOI 10.1016/j.molcel.2011.02.031; Mikula M, 2010, FUNCT INTEGR GENOMIC; Moll F, 2002, ONCOGENE, V21, P1097, DOI 10.1038/sj.onc.1205171; Morgan MR, 2007, NAT REV MOL CELL BIO, V8, P957, DOI 10.1038/nrm2289; Morgan MR, 2013, DEV CELL, V24, P472, DOI 10.1016/j.devcel.2013.01.027; Olin AI, 2001, J BIOL CHEM, V276, P1253, DOI 10.1074/jbc.M006783200; PAN TC, 1993, EUR J BIOCHEM, V215, P733, DOI 10.1111/j.1432-1033.1993.tb18086.x; Pupa SM, 2004, ONCOGENE, V23, P2153, DOI 10.1038/sj.onc.1207323; ROARK EF, 1995, J HISTOCHEM CYTOCHEM, V43, P401, DOI 10.1177/43.4.7534784; Roger P, 1998, AM J PATHOL, V153, P1579, DOI 10.1016/S0002-9440(10)65746-X; Shen CY, 2002, LUNG CANCER, V38, P235, DOI 10.1016/S0169-5002(02)00300-8; Teng JL, 2005, NAT CELL BIOL, V7, P474, DOI 10.1038/ncb1249; Turk BE, 2001, NAT BIOTECHNOL, V19, P661, DOI 10.1038/90273; Twal WO, 2001, J CELL SCI, V114, P4587; Vandenbroucke RE, 2013, EMBO MOL MED, V5, P1000, DOI 10.1002/emmm.201202100; Vizoso FJ, 2006, SCAND J GASTROENTERO, V41, P1050, DOI 10.1080/00365520600554667; Voisin SN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016352; Vorum H, 1999, EXP CELL RES, V248, P473, DOI 10.1006/excr.1999.4431; Vorum H, 1998, BBA-PROTEIN STRUCT M, V1386, P121, DOI 10.1016/S0167-4838(98)00089-2; Wang Q, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035344; Wang Qiao, 2012, Front Biosci (Elite Ed), V4, P998, DOI 10.2741/E435; Wang QA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013252; Wang QA, 2010, CELL RES, V20, P713, DOI 10.1038/cr.2010.47; Wang XF, 2009, P NATL ACAD SCI USA, V106, P21288, DOI 10.1073/pnas.0908151106; Williams SA, 2009, MOL BIOL CELL, V20, P1141, DOI 10.1091/mbc.E08-06-0621; Wu WG, 2002, CLIN EXP METASTAS, V19, P319, DOI 10.1023/A:1015515119300; Xie L, 2008, EXP BIOL MED, V233, P155, DOI 10.3181/0706-RM-167; Yabe D, 1998, GENOMICS, V49, P331, DOI 10.1006/geno.1998.5245; Yang M, 2000, P NATL ACAD SCI USA, V97, P1206, DOI 10.1073/pnas.97.3.1206; Zhang H, 2008, ACTA BIOCH BIOPH SIN, V40, P375, DOI 10.1111/j.1745-7270.2008.00420.x; Zhang XR, 2012, CARTILAGE, V3, P267, DOI 10.1177/1947603511435273; Zigrino P, 2009, J INVEST DERMATOL, V129, P2686, DOI 10.1038/jid.2009.130	55	26	29	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2015	34	8					1006	1018		10.1038/onc.2014.52	http://dx.doi.org/10.1038/onc.2014.52			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC1RT	24632605				2022-12-17	WOS:000350121300007
J	Hsu, TI; Lin, SC; Lu, PS; Chang, WC; Hung, CY; Yeh, YM; Su, WC; Liao, PC; Hung, JJ				Hsu, T-I; Lin, S-C; Lu, P-S; Chang, W-C; Hung, C-Y; Yeh, Y-M; Su, W-C; Liao, P-C; Hung, J-J			MMP7-mediated cleavage of nucleolin at Asp255 induces MMP9 expression to promote tumor malignancy	ONCOGENE			English	Article							PROSTATE-CANCER CELLS; LUNG-CANCER; GASTRIC-CARCINOMA; MATRILYSIN MMP-7; IN-VITRO; APOPTOSIS; PROTEINS; BINDING; PROGRESSION; TARGET	Nucleolin (NCL) participates in DNA transcription, ribosomal biogenesis and the regulation of RNA stability. However, the contribution of NCL to tumor development is still not clear. Herein,we found that NCL expression correlated with poor prognosis in lung cancer patients. Overexpressed NCL was predominantly cleaved to C-terminal truncated NCL (TNCL). In lung cancer formation, activation of the epidermal growth factor receptor pathway induced NCL expression, and also the expression of matrix metalloproteinase (MMP) 7, which then cleaved NCL at Asp255 to generate TNCL of 55 kDa. TNCL increased the expression of several oncogenes, including MMP9, anaplastic lymphoma kinase (ALK), HIF1a and CBLB, and decreased the expression of tumor suppressors including BRD4, PCM1, TFG and KLF6 by modulating mRNA stability through binding to the 3'-untranslated regions of their transcripts, thus ultimately enhancing metastasis activity. In conclusion, this study identified a novel role of the cleavage form of NCL generated by MMP7 in stabilizing MMP9 mRNA. We also provide a new insight that MMP7 not only cleaves the extracellular matrix to promote tumor invasion but also cleaves NCL, which augment oncogenesis. Blocking NCL cleavage may provide a useful new strategy for lung cancer therapy.	[Hsu, T-I; Lin, S-C; Lu, P-S; Chang, W-C; Hung, J-J] Natl Cheng Kung Univ, Coll Biosci & Biotechnol, Inst Bioinformat & Biosignal Transduct, Tainan 701, Taiwan; [Hsu, T-I; Chang, W-C; Hung, J-J] Natl Cheng Kung Univ, Ctr Infect Dis & Signal Transduct, Tainan 701, Taiwan; [Chang, W-C; Hung, C-Y; Hung, J-J] Natl Cheng Kung Univ, Inst Basic Med Sci, Tainan 701, Taiwan; [Chang, W-C; Hung, J-J] Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 701, Taiwan; [Chang, W-C; Hung, J-J] Taipei Med Univ, Coll Med, Grad Inst Med Sci, Taipei, Taiwan; [Yeh, Y-M; Su, W-C] Natl Cheng Kung Univ, Coll Med & Hosp, Dept Internal Med, Tainan 701, Taiwan; [Liao, P-C] Natl Cheng Kung Univ, Dept Environm & Occupat Hlth, Tainan 701, Taiwan	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; Taipei Medical University; National Cheng Kung University; National Cheng Kung University	Hung, JJ (corresponding author), Natl Cheng Kung Univ, Inst Bioinformat & Biosignal Transduct, Tainan 701, Taiwan.	petehung@mail.ncku.edu.tw	Hsu, Tsung-I/AAK-9942-2020; Ogunwobi, Olorunseun/F-3172-2010	Hsu, Tsung-I/0000-0002-7524-7740; Su, Wu-Chou/0000-0003-2953-4105	National Cheng-Kung University project of the Program for Promoting Acedemic Excellence and Developing World Class Research Centers [100-2320-B-038-032-MY3, NSC101-2321-B-006-004-MY3]; Food and Drug Administration, Ministry of Health and Welfare, Executive Yuan, Taiwan [DOH102-TD-TB-111-NSC101]; Tissue Bank, Research Center of Clinical Medicine, National Cheng-Kung University Hospital; Headquarters of University Advancement at the National Cheng-Kung University - Ministry of Education, Taiwan	National Cheng-Kung University project of the Program for Promoting Acedemic Excellence and Developing World Class Research Centers; Food and Drug Administration, Ministry of Health and Welfare, Executive Yuan, Taiwan; Tissue Bank, Research Center of Clinical Medicine, National Cheng-Kung University Hospital; Headquarters of University Advancement at the National Cheng-Kung University - Ministry of Education, Taiwan	This work was supported by the National Cheng-Kung University project of the Program for Promoting Academic Excellence and Developing World Class Research Centers, together with grants 100-2320-B-038-032-MY3 and NSC101-2321-B-006-004-MY3 obtained from the National Science Council, Taiwan. This work was also supported by the Food and Drug Administration, Ministry of Health and Welfare, Executive Yuan, Taiwan (Grants DOH102-TD-TB-111-NSC101). This research received funding from the Headquarters of University Advancement at the National Cheng-Kung University, which is sponsored by the Ministry of Education, Taiwan. We are grateful for the support from the Tissue Bank, Research Center of Clinical Medicine, National Cheng-Kung University Hospital.	Abdelmohsen K, 2011, NUCLEIC ACIDS RES, V39, P8513, DOI 10.1093/nar/gkr488; Adachi Y, 1999, GUT, V45, P252, DOI 10.1136/gut.45.2.252; Aihara R, 2005, BRIT J SURG, V92, P454, DOI 10.1002/bjs.4868; Bai RY, 2000, BLOOD, V96, P4319, DOI 10.1182/blood.V96.13.4319; Bouvet P, 1998, J BIOL CHEM, V273, P19025, DOI 10.1074/jbc.273.30.19025; Britschgi A, 2013, P NATL ACAD SCI USA, V110, pE1026, DOI 10.1073/pnas.1217072110; Camidge DR, 2012, NAT REV CLIN ONCOL, V9, P268, DOI 10.1038/nrclinonc.2012.43; Chang WC, 2012, J BIOMED SCI, V19, DOI 10.1186/1423-0127-19-94; Chiarle R, 2005, NAT MED, V11, P623, DOI 10.1038/nm1249; Curtin JF, 2004, J BIOL CHEM, V279, P17090, DOI 10.1074/jbc.M307629200; Davies G, 2001, CLIN CANCER RES, V7, P3289; Dozier S, 2006, Med Chem, V2, P523, DOI 10.2174/157340606778250261; FANG SH, 1993, EXP CELL RES, V208, P48, DOI 10.1006/excr.1993.1221; Feng Y, 2012, CANCER RES, V72, P6502, DOI 10.1158/0008-5472.CAN-12-1909; Herrero R, 2011, J CLIN INVEST, V121, P1174, DOI 10.1172/JCI43004; Hsu TI, 2012, ONCOGENE, V31, P3973, DOI 10.1038/onc.2011.568; Hsu TI, 2012, MOL PHARMACOL, V82, P1115, DOI 10.1124/mol.112.078485; Joo EJ, 2010, J CELL BIOCHEM, V110, P1272, DOI 10.1002/jcb.22643; Kito S, 2005, J ORAL PATHOL MED, V34, P478, DOI 10.1111/j.1600-0714.2005.00346.x; Kito S, 2003, BIOCHEM BIOPH RES CO, V300, P950, DOI 10.1016/S0006-291X(02)02942-X; Komiya T, 2010, ONCOGENE, V29, P1672, DOI 10.1038/onc.2009.453; Kryczka J, 2012, J BIOL CHEM, V287, P36556, DOI 10.1074/jbc.M112.384909; Leng L, 2003, J EXP MED, V197, P1467, DOI 10.1084/jem.20030286; McClelland M, 2009, AM J PATHOL, V174, P638, DOI 10.2353/ajpath.2009.080463; Mitsiades N, 2001, CANCER RES, V61, P577; Mongelard F, 2007, TRENDS CELL BIOL, V17, P80, DOI 10.1016/j.tcb.2006.11.010; Nishimura Y, 2013, BRIT J CANCER, V108, P1324, DOI 10.1038/bjc.2013.65; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; PASTERNACK MS, 1991, J BIOL CHEM, V266, P14703; Remy L, 2006, CANCER RES, V66, P11228, DOI 10.1158/0008-5472.CAN-06-1187; Roger B, 2003, CHROMOSOMA, V111, P399, DOI 10.1007/s00412-002-0221-5; Rosebeck S, 2011, SCIENCE, V331, P468, DOI 10.1126/science.1198946; Sengupta TK, 2004, J BIOL CHEM, V279, P10855, DOI 10.1074/jbc.M309111200; Serin G, 1996, BIOCHIMIE, V78, P530, DOI 10.1016/0300-9084(96)84759-6; Tripathi M, 2011, PROSTATE, V71, P184, DOI 10.1002/pros.21233; Tsunezumi J, 2009, J CELL BIOCHEM, V106, P693, DOI 10.1002/jcb.22062; vonBredow DC, 1997, EXP CELL RES, V236, P341, DOI 10.1006/excr.1997.3711; Wang S, 2010, NEOPLASIA, V12, P284, DOI 10.1593/neo.91610; WARRENER P, 1991, BIOCHEM BIOPH RES CO, V180, P716, DOI 10.1016/S0006-291X(05)81124-6; Williams H, 2010, CARDIOVASC RES, V87, P137, DOI 10.1093/cvr/cvq042; Yamamoto H, 2001, J CLIN ONCOL, V19, P1118, DOI 10.1200/JCO.2001.19.4.1118; Yamamoto K, 2010, J BIOL CHEM, V285, P28862, DOI 10.1074/jbc.M110.136994; Zhang X, 2013, ONCOGENE, V32, P2782, DOI 10.1038/onc.2012.289; Zou HY, 2007, CANCER RES, V67, P4408, DOI 10.1158/0008-5472.CAN-06-4443	44	26	26	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2015	34	7					826	837		10.1038/onc.2014.22	http://dx.doi.org/10.1038/onc.2014.22			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB2QF	24632608				2022-12-17	WOS:000349472000003
J	Yun, SM; Yoon, K; Lee, S; Kim, E; Kong, SH; Choe, J; Kang, JM; Han, TS; Kim, P; Choi, Y; Jho, S; Yoo, H; Bhak, J; Yang, HK; Kim, SJ				Yun, S. M.; Yoon, K.; Lee, S.; Kim, E.; Kong, S-H; Choe, J.; Kang, J. M.; Han, T-S; Kim, P.; Choi, Y.; Jho, S.; Yoo, H.; Bhak, J.; Yang, H-K; Kim, S-J			PPP1R1B-STARD3 chimeric fusion transcript in human gastric cancer promotes tumorigenesis through activation of PI3K/AKT signaling	ONCOGENE			English	Article						fusion transcript; gastric cancer; transcriptome sequencing	GENE FUSIONS; PROSTATE-CANCER; DARPP-32; PATHWAY; RNAS; REARRANGEMENTS; EXPRESSION; MUTATIONS; DOPAMINE; RECEPTOR	Fusion genes act as potent oncogenes, resulting from chromosomal rearrangements or abnormal transcription in many human cancers. Although multiple gastric cancer genomes have been sequenced, the driving recurrent gene fusions have not been well characterized. Here, we used paired-end transcriptome sequencing to identify novel gene fusions in 18 human gastric cancer cell lines and 18 pairs of primary human gastric cancer tissues and their adjacent normal tissues. Multiple samples revealed expression of PPP1R1B-STARD3 fusion transcript. The presence of PPP1R1B-STARD3 correlated with elevated levels of PPP1R1B mRNA. PPP1R1B-STARD3 fusion transcript was detected in 21.3% of primary human gastric cancers but not in adjacent matched normal gastric tissues. Based on reverse transcription PCR analysis of DNA, unlike other fusions described in gastric cancer, the PPP1R1B-STARD3 appears to be generated by RNA processing without chromosomal rearrangement. Overexpression of PPP1R1B-STARD3 in MKN-28 significantly increased cell proliferation and colony formation. This increased proliferation was mediated by activation of phosphatidylinositol-3-kinase (PI3K)/AKT signaling. Furthermore, expression of PPP1R1B-STARD3 fusion transcript enhanced the tumor growth of MKN-28 cells in athymic nude mice. These findings show that PPP1R1B-STARD3 fusion transcript has a key role in subsets of gastric cancers through the activation of PI3K/AKT signaling.	[Yun, S. M.; Yoon, K.; Kim, E.; Choe, J.; Kang, J. M.; Kim, P.; Choi, Y.; Yoo, H.; Kim, S-J] CHA Univ, CHA Canc Inst, Seoul 135081, South Korea; [Yun, S. M.; Kim, S-J] CHA Univ, Dept Biomed Sci, Coll Life Sci, Seoul 135081, South Korea; [Lee, S.; Jho, S.; Bhak, J.] Genome Res Fdn, Personal Genom Inst, Suwon, South Korea; [Lee, S.; Bhak, J.] TheragenEtex Inc, TheragenEtex Bio Inst, Suwon, South Korea; [Kong, S-H; Han, T-S; Yang, H-K] Seoul Natl Univ, Canc Res Inst, Seoul, South Korea; [Kong, S-H; Yang, H-K] Seoul Natl Univ, Coll Med, Dept Surg, Seoul, South Korea	Pochon Cha University; Pochon Cha University; Seoul National University (SNU); Seoul National University (SNU)	Kim, SJ (corresponding author), CHA Univ, CHA Canc Inst, 605 Yeoksam 1 Dong, Seoul 135081, South Korea.	kimsj@cha.ac.kr		Lee, Sunghoon/0000-0002-8916-2035; Lee, Sunghoon/0000-0002-6682-119X; Kang, Jin Muk/0000-0002-7949-9160	National Research Foundation of Korea (NRF) [2009-0081756, 2012M3A9C4048736]; TheragenEtex; Industrial Strategic Technology Development Program - Ministry of Knowledge Economy (MKE, Korea) [10040231]; Genome Research Foundation	National Research Foundation of Korea (NRF)(National Research Foundation of Korea); TheragenEtex; Industrial Strategic Technology Development Program - Ministry of Knowledge Economy (MKE, Korea); Genome Research Foundation	This work was supported in part by the National Research Foundation of Korea (NRF) grants (2009-0081756 and 2012M3A9C4048736 to S-JK). JB and SL were supported by TheragenEtex and Genome Research Foundation internal funds. JB was supported by the Industrial Strategic Technology Development Program (10040231) funded by the Ministry of Knowledge Economy (MKE, Korea).	Akiva P, 2006, GENOME RES, V16, P30, DOI 10.1101/gr.4137606; Beckler A, 2003, CANCER, V98, P1547, DOI 10.1002/cncr.11654; Belkhiri A, 2005, CANCER RES, V65, P6583, DOI 10.1158/0008-5472.CAN-05-1433; BRENE S, 1994, J NEUROSCI, V14, P985, DOI 10.1523/JNEUROSCI.14-03-00985.1994; Courtney KD, 2010, J CLIN ONCOL, V28, P1075, DOI 10.1200/JCO.2009.25.3641; Deng NT, 2012, GUT, V61, P673, DOI 10.1136/gutjnl-2011-301839; El-Rifai W, 2002, CANCER RES, V62, P4061; Fienberg AA, 1998, SCIENCE, V281, P838, DOI 10.1126/science.281.5378.838; Greengard P, 1999, NEURON, V23, P435, DOI 10.1016/S0896-6273(00)80798-9; Guggenheim DE, 2013, J SURG ONCOL, V107, P230, DOI 10.1002/jso.23262; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Hold GL, 2007, GASTROENTEROLOGY, V132, P905, DOI 10.1053/j.gastro.2006.12.026; Ito Kosei, 2012, Seikagaku, V84, P278; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Kannan K, 2011, P NATL ACAD SCI USA, V108, P9172, DOI 10.1073/pnas.1100489108; Katoh M, 2004, INT J ONCOL, V24, P757; Li H, 2008, SCIENCE, V321, P1357, DOI 10.1126/science.1156725; McPherson A, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1001138; Mitelman F, 2007, NAT REV CANCER, V7, P233, DOI 10.1038/nrc2091; Mukherjee K, 2010, SURGERY, V148, P354, DOI 10.1016/j.surg.2010.05.011; Palanisamy N, 2010, NAT MED, V16, P793, DOI 10.1038/nm.2166; Persson M, 2009, P NATL ACAD SCI USA, V106, P18740, DOI 10.1073/pnas.0909114106; Poulin F, 2003, J BIOL CHEM, V278, P52290, DOI 10.1074/jbc.M310761200; Prensner JR, 2009, CURR OPIN GENET DEV, V19, P82, DOI 10.1016/j.gde.2008.11.008; Robinson DR, 2011, NAT MED, V17, P1646, DOI 10.1038/nm.2580; Tao J, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001423; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Wang K, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-348; Wang XS, 2009, NAT BIOTECHNOL, V27, P1005, DOI 10.1038/nbt.1584; Wei JX, 2012, P NATL ACAD SCI USA, V109, pE2543, DOI 10.1073/pnas.1205664109; Yoon K, 2013, GENOME RES, V23, P1109, DOI 10.1101/gr.145706.112; Zayed A, 2007, LEUKEMIA LYMPHOMA, V48, P489, DOI 10.1080/10428190601136163; Zhu SM, 2011, GASTROENTEROLOGY, V141, P1738, DOI 10.1053/j.gastro.2011.06.070	35	26	26	0	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	2014	33	46					5341	5347		10.1038/onc.2013.472	http://dx.doi.org/10.1038/onc.2013.472			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MF	24276243				2022-12-17	WOS:000345120600004
J	Li, H; Huang, F; Fan, L; Jiang, Y; Wang, X; Li, J; Wang, Q; Pan, H; Sun, J; Cao, X; Wang, X				Li, H.; Huang, F.; Fan, L.; Jiang, Y.; Wang, X.; Li, J.; Wang, Q.; Pan, H.; Sun, J.; Cao, X.; Wang, X.			Phosphatidylethanolamine-binding protein 4 is associated with breast cancer metastasis through Src-mediated Akt tyrosine phosphorylation	ONCOGENE			English	Article						breast cancer metastasis; hPEBP4; Akt; Src	KINASE INHIBITOR PROTEIN; TRAIL-INDUCED APOPTOSIS; ALPHA-INDUCED APOPTOSIS; RAF KINASE; MESENCHYMAL TRANSITION; PATHWAY ACTIVATION; CELLS; EXPRESSION; PROSTATE; RESISTANCE	Metastasis is responsible for more than 90% of the mortality observed among patients with breast cancer. Human phosphatidylethanolamine-binding protein 4 (hPEBP4) is a novel member of the PEBP family and functions as an anti-apoptotic molecule. Here, we found that the metastatic MDA-MB-231 breast cancer cells expressed much higher levels of hPEBP4 than the nonmetastatic MCF-7 breast cancer cells and that the expression levels of hPEBP4 were positively correlated with the metastasis of clinical breast cancer. The hPEBP4 overexpression in the MDA-MB-231 cells significantly promoted cell invasion in vitro and increased the development of lymph node metastasis in vivo. Conversely, the silencing of hPEBP4 suppressed the cell-invasive ability both in vitro and in vivo. Further investigation showed that hPEBP4 promoted the expression or activity of the metastasis-related proteinases MMP (matrix metalloproteinase) 2, MMP9 and MMP13. This hPEBP4-potentiated cell invasion and MMP expression is due to an increase in Akt activation. Knockdown of Akt restored hPEBP4-induced breast tumor metastasis in the hPEBP4-MDA-MB-231 xenograft mouse model. Moreover, we found that hPEBP4 functioned as a scaffolding molecule and enhanced the association of Akt with Src to promote Akt tyrosine phosphorylation, a prerequisite for the full activation of Akt, in a phosphatidylethanolamine-binding domain-dependent manner. Given the present information about human breast cancer, these functional data from cell culture and animal studies suggest that, in human breast cancer hPEBP4 is a novel and clinically relevant metastasis accelerator gene and may be a new diagnostic marker and therapeutic target for breast cancer metastasis.	[Li, H.; Huang, F.; Fan, L.; Jiang, Y.; Wang, X.; Wang, Q.; Cao, X.; Wang, X.] Zhejiang Univ, Inst Immunol, Sch Med, Hangzhou 310058, Zhejiang, Peoples R China; [Li, J.; Pan, H.; Sun, J.] Zhejiang Univ, Sch Med, Hangzhou 310058, Zhejiang, Peoples R China	Zhejiang University; Zhejiang University	Wang, X (corresponding author), Zhejiang Univ, Inst Immunol, 388 Yuhang Tang Rd,Med Res Bldg B819, Hangzhou 310058, Zhejiang, Peoples R China.	wangxiaojian@cad.zju.edu.cn			National Basic Research Program of China (973) [2014CB542101, 2013CB530502]; National Natural Science Foundation of China [81282353, 81072437, 81000302]; Doctoral Fund of Ministry of Education of China [20120101110022]; Zhejiang Major Science and Technology Special Project [2009C13018, 2009C14015]; Research Fund of Science Base [J1103603]; Qianjiang Talent Program of Zhejiang Province [2012R10027]; Scientific Research Foundation of the Health Bureau of Zhejiang Province [WKJ2012-2-030]	National Basic Research Program of China (973)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Doctoral Fund of Ministry of Education of China(Ministry of Education, China); Zhejiang Major Science and Technology Special Project; Research Fund of Science Base; Qianjiang Talent Program of Zhejiang Province; Scientific Research Foundation of the Health Bureau of Zhejiang Province	This work was supported by grants from the National Basic Research Program of China (973) (2014CB542101, 2013CB530502), the National Natural Science Foundation of China (81282353, 81072437, 81000302), the Doctoral Fund of Ministry of Education of China (20120101110022), Zhejiang Major Science and Technology Special Project (2009C13018, 2009C14015), the Research Fund of Science Base (J1103603), Qianjiang Talent Program of Zhejiang Province (2012R10027) and Scientific Research Foundation of the Health Bureau of Zhejiang Province (WKJ2012-2-030).	Al Saleh S, 2011, INT J ONCOL, V38, P1197, DOI 10.3892/ijo.2011.942; Baritaki S, 2007, J IMMUNOL, V179, P5441, DOI 10.4049/jimmunol.179.8.5441; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Castaneda CA, 2010, CANCER METAST REV, V29, P751, DOI 10.1007/s10555-010-9261-0; Chatterjee D, 2004, J BIOL CHEM, V279, P17515, DOI 10.1074/jbc.M313816200; Chen RY, 2001, J BIOL CHEM, V276, P31858, DOI 10.1074/jbc.C100271200; Cheung LWT, 2006, CANCER RES, V66, P10902, DOI 10.1158/0008-5472.CAN-06-2217; Dangi-Garimella S, 2009, EMBO J, V28, P347, DOI 10.1038/emboj.2008.294; Fu Z, 2003, J NATL CANCER I, V95, P878, DOI 10.1093/jnci/95.12.878; Garcia R, 2009, EMBO REP, V10, P278, DOI 10.1038/embor.2009.4; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Hagan S, 2005, CLIN CANCER RES, V11, P7392, DOI 10.1158/1078-0432.CCR-05-0283; Jiang TY, 2003, J BIOL CHEM, V278, P15789, DOI 10.1074/jbc.M212525200; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Li HZ, 2007, J BIOL CHEM, V282, P4943, DOI 10.1074/jbc.M609494200; Li P, 2006, INT J MOL MED, V18, P505; Liu HB, 2010, J BIOL CHEM, V285, P21934, DOI 10.1074/jbc.M110.109876; Liu HY, 2012, TUMOR BIOL, V33, P267, DOI 10.1007/s13277-011-0279-x; Lopez-Knowles E, 2010, INT J CANCER, V126, P1121, DOI 10.1002/ijc.24831; Luan B, 2009, NATURE, V457, P1146, DOI 10.1038/nature07617; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Min CY, 2008, J CELL BIOCHEM, V104, P733, DOI 10.1002/jcb.21695; Odabaei G, 2004, ADV CANCER RES, V91, P169, DOI 10.1016/S0065-230X(04)91005-6; Prasad S, 2010, MOL CELL BIOCHEM, V336, P25, DOI 10.1007/s11010-009-0267-2; Qiao M, 2008, CELL CYCLE, V7, P2991, DOI 10.4161/cc.7.19.6784; Roskoski R, 2004, BIOCHEM BIOPH RES CO, V324, P1155, DOI 10.1016/j.bbrc.2004.09.171; Wang XJ, 2005, CLIN CANCER RES, V11, P7545, DOI 10.1158/1078-0432.CCR-05-0879; Wang XJ, 2004, J BIOL CHEM, V279, P45855, DOI 10.1074/jbc.M405147200; Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050; Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670; Yang WL, 2010, CELL CYCLE, V9, P486, DOI 10.4161/cc.9.3.10508; Yang WL, 2009, SCIENCE, V325, P1134, DOI 10.1126/science.1175065; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Yu GP, 2012, TUMOR BIOL, V33, P223, DOI 10.1007/s13277-011-0265-3; Yu GP, 2011, TUMOR BIOL, V32, P1257, DOI 10.1007/s13277-011-0230-1; Yu GP, 2013, TUMOR BIOL, V34, P91, DOI 10.1007/s13277-012-0514-0; Zhang YY, 2007, INT J MOL MED, V19, P55; Zheng Y, 2010, MOL CELL BIOL, V30, P4280, DOI 10.1128/MCB.00024-10; Zhu QS, 2011, ONCOGENE, V30, P457, DOI 10.1038/onc.2010.421	39	26	30	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	2014	33	37					4589	4598		10.1038/onc.2013.408	http://dx.doi.org/10.1038/onc.2013.408			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AP3UZ	24276246				2022-12-17	WOS:000342004800006
J	He, T; Haapa-Paananen, S; Kaminskyy, VO; Kohonen, P; Fey, V; Zhivotovsky, B; Kallioniemi, O; Perala, M				He, T.; Haapa-Paananen, S.; Kaminskyy, V. O.; Kohonen, P.; Fey, V.; Zhivotovsky, B.; Kallioniemi, O.; Perala, M.			Inhibition of the mitochondrial pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase by doxorubicin and brequinar sensitizes cancer cells to TRAIL-induced apoptosis	ONCOGENE			English	Article						doxorubicin; pyrimidine pathway; mitochondria; brequinar; DHODH; TRAIL	DEATH RECEPTORS; CASPASE-8 EXPRESSION; UP-REGULATION; C-FLIP; LIGAND; IDENTIFICATION; MODULATORS; COMPLEX; TARGETS; SODIUM	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising agent in selectively killing tumor cells. However, TRAIL monotherapy has not been successful as many cancer cells are resistant to TRAIL. Chemotherapeutic agents, such as doxorubicin have been shown to act synergistically with TRAIL, but the exact mechanisms of actions are poorly understood. In this study, we performed high-throughput small interfering RNA screening and genome-wide gene expression profiling on doxorubicin-treated U1690 cells to explore novel mechanisms underlying doxorubicin-TRAIL synergy. The screening and expression profiling results were integrated and dihydroorotate dehydrogenase (DHODH) was identified as a potential candidate. DHODH is the rate-limiting enzyme in the pyrimidine synthesis pathway, and its expression was downregulated by doxorubicin. We demonstrated that silencing of DHODH or inhibition of DHODH activity by brequinar dramatically increased the sensitivity of U1690 cells to TRAIL-induced apoptosis both in 2D and 3D cultures, and was accompanied by downregulation of c-FLIPL as well as by mitochondrial depolarization. In addition, uridine, an end product of the pyrimidine synthesis pathway was able to rescue the sensitization effects initiated by both brequinar and doxorubicin. Furthermore, several other cancer cell lines, LNCaP, MCF-7 and HT-29 were also shown to be sensitized to TRAIL by brequinar. Taken together, our findings have identified a novel protein target and its inhibitor, brequinar, as a potential agent in TRAIL-based combinatorial cancer therapy and highlighted for the first time the importance of mitochondrial DHODH enzyme and pyrimidine pathway in mediating TRAIL sensitization in cancer cells.	[He, T.; Haapa-Paananen, S.; Kohonen, P.; Fey, V.; Kallioniemi, O.; Perala, M.] VTT Tech Res Ctr Finland, FI-20521 Turku, Finland; [Kaminskyy, V. O.; Zhivotovsky, B.] Karolinska Inst, Inst Environm Med, Div Toxicol, S-10401 Stockholm, Sweden; [Kohonen, P.] Karolinska Inst, Inst Environm Med, Div Mol Toxicol, S-10401 Stockholm, Sweden; [Kallioniemi, O.] Univ Helsinki, FIMM Inst Mol Med Finland, Helsinki, Finland	VTT Technical Research Center Finland; Karolinska Institutet; Karolinska Institutet; University of Helsinki	He, T (corresponding author), VTT Tech Res Ctr Finland, Itainen Pitkakatu 4C,POB 106, FI-20521 Turku, Finland.	tao.he@vtt.fi	Kohonen, Pekka/F-9596-2011; Zhivotovsky, Boris/A-4346-2014; Kallioniemi, Olli P/H-5111-2011	Kohonen, Pekka/0000-0002-7845-3611; Zhivotovsky, Boris/0000-0002-2238-3482; Kallioniemi, Olli P/0000-0002-3231-0332; Kaminskyy, Vitaliy/0000-0002-8151-5270	EU-APOSYS [HEALTH-F4-2007-200767]; EU (CHEMORES) project; Swedish Research Foundation; Swedish Cancer Foundation; Swedish Childhood Cancer Foundation; Stockholm Cancer Foundation	EU-APOSYS(European CommissionEuropean Commission Joint Research Centre); EU (CHEMORES) project; Swedish Research Foundation; Swedish Cancer Foundation; Swedish Childhood Cancer Foundation(European Commission); Stockholm Cancer Foundation	We acknowledge Jouni Latoniitty and Rami Makela for robotic technical assistance, Ville Harma and Johannes Virtanen for advices and help in 3D experiments, Pirjo Kapyla for excellent technical support and Drs I Lavrik and P Krammer for antibodies. Finnish DNA Microarray Centre is acknowledged for performing TaqMan qRT-PCR and Illumina gene expression analysis. This work was supported by EU-APOSYS project (contract HEALTH-F4-2007-200767), EU (CHEMORES) project, the Swedish Research Foundation, the Swedish and Stockholm Cancer Foundations, and the Swedish Childhood Cancer Foundation.	Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Aza-Blanc P, 2003, MOL CELL, V12, P627, DOI 10.1016/S1097-2765(03)00348-4; Baumann P, 2009, MOL CANCER THER, V8, P366, DOI 10.1158/1535-7163.MCT-08-0664; Booth NL, 2009, CANCER IMMUNOL IMMUN, V58, P1229, DOI 10.1007/s00262-008-0637-8; Cleaveland ES, 1996, BIOCHEM BIOPH RES CO, V223, P654, DOI 10.1006/bbrc.1996.0950; Coussens MJ, 2011, JOVE-J VIS EXP, DOI 10.3791/3305; CRAMER DV, 1995, PEDIATR NEPHROL, V9, pS52, DOI 10.1007/BF00867685; Evans ME, 2005, AM J PHYSIOL-GASTR L, V289, pG388, DOI 10.1152/ajpgi.00072.2005; Falschlehner C, 2007, INT J BIOCHEM CELL B, V39, P1462, DOI 10.1016/j.biocel.2007.02.007; Finlay D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013375; Harma V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010431; Hopkins-Donaldson S, 2003, CELL DEATH DIFFER, V10, P356, DOI 10.1038/sj.cdd.4401157; Johnstone RW, 2008, NAT REV CANCER, V8, P782, DOI 10.1038/nrc2465; Kaminskyy VO, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.51; Kaminskyy VO, 2011, CARCINOGENESIS, V32, P1450, DOI 10.1093/carcin/bgr135; Kawasumi M, 2007, J INVEST DERMATOL, V127, P1577, DOI 10.1038/sj.jid.5700853; Kisim A, 2012, J CANCER RES CLIN, V138, P1155, DOI 10.1007/s00432-012-1187-1; Kojima Y, 2011, J BIOL CHEM, V286, P43383, DOI 10.1074/jbc.M111.309377; Koschny R, 2007, J MOL MED, V85, P923, DOI 10.1007/s00109-007-0194-1; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Lee SC, 2011, ANTICANCER RES, V31, P3385; Lee YJ, 2011, MOL MED REP, V4, P1255, DOI 10.3892/mmr.2011.558; Liu SP, 2000, STRUCT FOLD DES, V8, P25, DOI 10.1016/S0969-2126(00)00077-0; Loffler M, 2005, TRENDS MOL MED, V11, P430, DOI 10.1016/j.molmed.2005.07.003; Mahmood Z, 2010, EXP CELL RES, V316, P887, DOI 10.1016/j.yexcr.2009.12.011; MAROUN J, 1993, CANCER CHEMOTH PHARM, V32, P64, DOI 10.1007/BF00685878; Mellier G, 2010, MOL ASPECTS MED, V31, P93, DOI 10.1016/j.mam.2009.12.002; Merrill JE, 2009, J NEUROL, V256, P89, DOI 10.1007/s00415-009-0075-3; O'Donnell EF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040926; Ovcharenko D, 2007, CANCER RES, V67, P10782, DOI 10.1158/0008-5472.CAN-07-1484; Papenfuss K, 2008, J CELL MOL MED, V12, P2566, DOI 10.1111/j.1582-4934.2008.00514.x; PETERS GJ, 1990, BIOCHEM PHARMACOL, V39, P135, DOI 10.1016/0006-2952(90)90657-7; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Safa A. R., 2012, Experimental Oncology, V34, P176; Shawver LK, 1997, CLIN CANCER RES, V3, P1167; Shivapurkar N, 2002, ONCOGENE, V21, P8510, DOI 10.1038/sj.onc.1205941; Szliszka E, 2012, INT J ONCOL, V41, P818, DOI 10.3892/ijo.2012.1527; Tang XM, 2009, BIOL PHARM BULL, V32, P963, DOI 10.1248/bpb.32.963; Taylor DJ, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-470; Vaculova A, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-87; Vyas VK, 2011, MINI-REV MED CHEM, V11, P1039; White RM, 2011, NATURE, V471, P518, DOI 10.1038/nature09882; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yan SC, 2012, J CANCER RES CLIN, V138, P1279, DOI 10.1007/s00432-012-1204-4; Zhu H, 2012, INT J MOL MED, V30, P1087, DOI 10.3892/ijmm.2012.1105	46	26	27	2	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2014	33	27					3538	3549		10.1038/onc.2013.313	http://dx.doi.org/10.1038/onc.2013.313			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2FK	24013224				2022-12-17	WOS:000338941100006
J	Xu, Y; Swartz, KL; Siu, KT; Bhattacharyya, M; Minella, AC				Xu, Y.; Swartz, K. L.; Siu, K. T.; Bhattacharyya, M.; Minella, A. C.			Fbw7-dependent cyclin E regulation ensures terminal maturation of bone marrow erythroid cells by restraining oxidative metabolism	ONCOGENE			English	Article						cyclin E; Fbw7; erythropoiesis; reactive oxygen species; p53	TUMOR-SUPPRESSOR; TRANSCRIPTION FACTOR; HEMATOPOIETIC STEM; UBIQUITIN LIGASE; S-PHASE; EXPRESSION; DIFFERENTIATION; P53; PROMOTES; DAMAGE	The mechanisms that coordinate the final mitotic divisions of terminally differentiated bone marrow (BM) erythroid cells with components of their structural and functional maturation program remain largely undefined. We previously identified phenotypes resembling those found in early-stage myelodysplastic syndromes (MDS), including ineffective erythropoiesis, morphologic dysplasia and BM hyper-cellularity, in a knock-in mouse model in which cyclin E mutations were introduced at its two Cdc4 phosphodegrons (CPDs) to ablate Fbw7-dependent ubiquitination and degradation. Here, we have examined the physiologic consequences of cyclin E dysregulation in BM erythroid cells during terminal maturation in vivo. We found that cyclin E protein levels in BM erythroid cells are dynamically regulated in a CPD-dependent manner and that disruption of Fbw7-dependent cyclin E regulation impairs terminal erythroid cell maturation at a discrete stage before enucleation. At this stage of erythroid cell maturation, CPD phosphorylation of cyclin E regulates both cell-cycle arrest and survival. We also found that normal regulation of cyclin E restrains mitochondrial reactive oxygen species (ROS) accumulation and expression of genes that promote mitochondrial biogenesis and oxidative metabolism during terminal erythroid maturation. In the setting of dysregulated cyclin E expression, p53 is activated in BM erythroid cells as part of a DNA damage response-type pathway, which mitigates ineffective erythropoiesis, in contrast to the role of p53 induction in other models of dyserythropoiesis. Finally, cyclin E dysregulation and ROS accumulation induce histone H3 lysine 9 hyper-methylation and disrupt components of the normal terminal erythroid maturation gene expression program. Thus, ubiquitin-proteasome pathway control of G1-to-S-phase progression is intrinsically linked to regulation of metabolism and gene expression in terminally differentiating BM erythroid cells.	[Xu, Y.; Swartz, K. L.; Siu, K. T.; Bhattacharyya, M.; Minella, A. C.] Northwestern Univ, Dept Med, Div Hematol Oncol, Feinberg Sch Med, Chicago, IL 60611 USA; [Swartz, K. L.; Siu, K. T.] Northwestern Univ, Driskill Grad Program Life Sci, Feinberg Sch Med, Chicago, IL 60611 USA; [Minella, A. C.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center	Minella, AC (corresponding author), Northwestern Univ, Dept Med, Div Hematol Oncol, Feinberg Sch Med, 303 East Super St,Lurie 5-115, Chicago, IL 60611 USA.	a-minella@northwestern.edu		Minella, Alex/0000-0001-6693-3362	NIH [R01HL098608]; Leukemia Research Foundation; Sidney Kimmel Foundation for Cancer Research; American Cancer Society; American Society of Hematology; NATIONAL CANCER INSTITUTE [P30CA060553] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL098608] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Leukemia Research Foundation; Sidney Kimmel Foundation for Cancer Research; American Cancer Society(American Cancer Society); American Society of Hematology; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Dr Navdeep Chandel and Laura Sena (Northwestern University) for providing reagents as well as invaluable advice. We also thank Dr Amit Verma (Albert Einstein College of Medicine) for helpful discussions. This work was supported by NIH grant R01HL098608 and funding from the Leukemia Research Foundation, the Sidney Kimmel Foundation for Cancer Research, the American Cancer Society and the American Society of Hematology.	Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Balamurugan K, 2010, EMBO J, V29, P4106, DOI 10.1038/emboj.2010.280; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Blanchet E, 2011, NAT CELL BIOL, V13, P1146, DOI 10.1038/ncb2309; Chen K, 2009, P NATL ACAD SCI USA, V106, P17413, DOI 10.1073/pnas.0909296106; Dirlam A, 2007, MOL CELL BIOL, V27, P8713, DOI 10.1128/MCB.01118-07; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; Dutt S, 2011, BLOOD, V117, P2567, DOI 10.1182/blood-2010-07-295238; Figueroa ME, 2009, BLOOD, V114, P3448, DOI 10.1182/blood-2009-01-200519; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Ishikawa-Sekigami T, 2006, BLOOD, V107, P341, DOI 10.1182/blood-2005-05-1896; Jaako P, 2011, BLOOD, V118, P6087, DOI 10.1182/blood-2011-08-371963; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Kang YA, 2012, MOL CELL BIOL, V32, P226, DOI 10.1128/MCB.06166-11; Kelly DP, 2004, GENE DEV, V18, P357, DOI 10.1101/gad.1177604; Kinross KM, 2006, BLOOD, V108, P886, DOI 10.1182/blood-2005-09-008656; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Kossatz U, 2010, J CLIN INVEST, V120, P3820, DOI 10.1172/JCI41959; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231; Leung CG, 2007, J EXP MED, V204, P1603, DOI 10.1084/jem.20062395; Li FX, 2003, MOL CELL BIOL, V23, P3607, DOI 10.1128/MCB.23.10.3607-3622.2003; Li TY, 2012, CELL, V149, P1269, DOI 10.1016/j.cell.2012.04.026; Mavrakis KJ, 2011, NAT GENET, V43, P673, DOI 10.1038/ng.858; Minella AC, 2007, ONCOGENE, V26, P6948, DOI 10.1038/sj.onc.1210518; Minella AC, 2002, CURR BIOL, V12, P1817, DOI 10.1016/S0960-9822(02)01225-3; Minella AC, 2008, GENE DEV, V22, P1677, DOI 10.1101/gad.1650208; Onoyama I, 2007, J EXP MED, V204, P2875, DOI 10.1084/jem.20062299; Pop R, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000484; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Sablina AA, 2005, NAT MED, V11, P1306, DOI 10.1038/nm1320; Sandoval H, 2008, NATURE, V454, P232, DOI 10.1038/nature07006; Sankaran VG, 2008, GENE DEV, V22, P463, DOI 10.1101/gad.1627208; Santoni-Rugiu E, 2000, MOL CELL BIOL, V20, P3497, DOI 10.1128/MCB.20.10.3497-3509.2000; Santos Janine H, 2002, Methods Mol Biol, V197, P159, DOI 10.1385/1-59259-284-8:159; Schweers RL, 2007, P NATL ACAD SCI USA, V104, P19500, DOI 10.1073/pnas.0708818104; Singer JD, 1999, GENE DEV, V13, P2375, DOI 10.1101/gad.13.18.2375; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thompson BJ, 2007, J EXP MED, V204, P1825, DOI 10.1084/jem.20070872; Tothova Z, 2007, CELL, V128, P325, DOI 10.1016/j.cell.2007.01.003; Weiss MJ, 1997, MOL CELL BIOL, V17, P1642, DOI 10.1128/MCB.17.3.1642; Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290; Wilson A, 2008, CELL, V135, P1118, DOI 10.1016/j.cell.2008.10.048; Woo RA, 2004, GENE DEV, V18, P1317, DOI 10.1101/gad.1165204; Xu YF, 2010, J BIOL CHEM, V285, P34439, DOI 10.1074/jbc.M110.152306	44	26	26	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	2014	33	24					3161	3171		10.1038/onc.2013.289	http://dx.doi.org/10.1038/onc.2013.289			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK4QU	23873023	Green Accepted			2022-12-17	WOS:000338410000009
J	Drosten, M; Lechuga, CG; Barbacid, M				Drosten, M.; Lechuga, C. G.; Barbacid, M.			Ras signaling is essential for skin development	ONCOGENE			English	Article						Ras signaling; keratinocytes; senescence; epidermis; hair follicles	HAIR FOLLICLE DEVELOPMENT; K-RAS; EGF RECEPTOR; CELL-CYCLE; EPIDERMAL HOMEOSTASIS; TYROSINE KINASE; STEM-CELLS; ADULT MICE; H-RAS; N-RAS	Proliferation in the epidermis is a tightly controlled process. During skin development, epidermis formation and hair follicle morphogenesis crucially depend on the regulated balance between proliferation and differentiation. Here we deleted all three Ras loci (H-Ras, N-Ras and K-Ras) from keratinocytes in vitro as well as specifically from the epidermis in mice using a K5Cre strain. Upon Ras elimination, keratinocytes ceased proliferation and entered into senescence without any signs of apoptosis induction. Constitutive activation of the mitogen-activated protein kinase pathway was able to partially rescue the proliferative defects. In mice, Ras signaling was essential for proper development of the epidermis and hair follicles. Deletion of the three Ras loci during epidermis formation in mouse embryos caused a dramatic decrease in proliferation, resulting in a substantially thinner epidermis and delayed appearance of differentiation markers. We could not detect apoptotic or senescent cells in these embryos suggesting that loss of Ras protein expression only leads to severe hypoproliferation. These observations provide genetic evidence for an essential role of Ras proteins in the control of keratinocyte and epidermal proliferation.	[Drosten, M.; Lechuga, C. G.; Barbacid, M.] Spanish Natl Canc Res Ctr, CNIO, Mol Oncol Programme, Madrid 28029, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO)	Drosten, M (corresponding author), Spanish Natl Canc Res Ctr, Mol Oncol Programme, Melchor Fernandez Almagro 3, Madrid 28029, Spain.	mdrosten@cnio.es; mbarbacid@cnio.es		Drosten, Matthias/0000-0002-3205-456X	European Research Council [ERC-AG/250297-RAS AHEAD]; Spanish Ministry of Economy and Competitiveness [SAF2011-30173]; Autonomous Community of Madrid [S2011/BDM-2470/ONCOCYCLE]; EU-Framework Programme [LSHG-CT-2007-037665/CHEMORES, HEALTH-F2-2010-259770/LUNGTARGET, HEALTH-2010-260791/EUROCANPLATFORM]	European Research Council(European Research Council (ERC)European Commission); Spanish Ministry of Economy and Competitiveness(Spanish Government); Autonomous Community of Madrid; EU-Framework Programme	We thank the Histopatholoy and Confocal Microscopy Units at the CNIO for their help. This work was supported by grants from the European Research Council (ERC-AG/250297-RAS AHEAD), EU-Framework Programme (LSHG-CT-2007-037665/CHEMORES, HEALTH-F2-2010-259770/LUNGTARGET and HEALTH-2010-260791/EUROCANPLATFORM), Spanish Ministry of Economy and Competitiveness (SAF2011-30173) and Autonomous Community of Madrid (S2011/BDM-2470/ONCOCYCLE) to MB.	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Blanpain C, 2009, NAT REV MOL CELL BIO, V10, P207, DOI 10.1038/nrm2636; Buse P, 1999, J BIOL CHEM, V274, P7253, DOI 10.1074/jbc.274.11.7253; BYRNE C, 1994, DEVELOPMENT, V120, P2369; Candi E, 2008, CELL MOL LIFE SCI, V65, P3126, DOI 10.1007/s00018-008-8119-x; Candi E, 2005, NAT REV MOL CELL BIO, V6, P328, DOI 10.1038/nrm1619; Dajee M, 2002, ONCOGENE, V21, P1527, DOI 10.1038/sj.onc.1205287; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; Drosten M, 2010, EMBO J, V29, P1091, DOI 10.1038/emboj.2010.7; Dumesic PA, 2009, J CELL BIOL, V185, P409, DOI 10.1083/jcb.200804038; Esteban LM, 2001, MOL CELL BIOL, V21, P1444, DOI 10.1128/MCB.21.5.1444-1452.2001; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; Fuchs E, 2008, GENE DEV, V22, P976, DOI 10.1101/gad.1645908; Fuchs E, 2007, NATURE, V445, P834, DOI 10.1038/nature05659; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; Guerra C, 2011, CANCER CELL, V19, P728, DOI 10.1016/j.ccr.2011.05.011; He J, 2008, NAT STRUCT MOL BIOL, V15, P1169, DOI 10.1038/nsmb.1499; Itahana Koji, 2007, Methods Mol Biol, V371, P21; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Kern F, 2011, BRIT J CANCER, V104, P229, DOI 10.1038/sj.bjc.6606009; Keyes WM, 2005, GENE DEV, V19, P1986, DOI 10.1101/gad.342305; Khavari TA, 2007, CELL CYCLE, V6, P2928, DOI 10.4161/cc.6.23.4998; Kim WY, 2006, CELL, V127, P265, DOI 10.1016/j.cell.2006.10.003; Kolch W, 2010, NAT REV CANCER, V10, P618, DOI 10.1038/nrc2900; Koster MI, 2007, ANNU REV CELL DEV BI, V23, P93, DOI 10.1146/annurev.cellbio.23.090506.123357; Koster MI, 2009, ANN NY ACAD SCI, V1170, P7, DOI 10.1111/j.1749-6632.2009.04363.x; Lechler T, 2005, NATURE, V437, P275, DOI 10.1038/nature03922; Lee J, 2012, SEMIN CELL DEV BIOL, V23, P906, DOI 10.1016/j.semcdb.2012.08.003; Lichti U, 2008, NAT PROTOC, V3, P799, DOI 10.1038/nprot.2008.50; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Rojas AM, 2012, J CELL BIOL, V196, P189, DOI 10.1083/jcb.201103008; Millar SE, 2002, J INVEST DERMATOL, V118, P216, DOI 10.1046/j.0022-202x.2001.01670.x; Navas C, 2012, CANCER CELL, V22, P318, DOI 10.1016/j.ccr.2012.08.001; Paus R, 1999, J INVEST DERMATOL, V113, P523, DOI 10.1046/j.1523-1747.1999.00740.x; Petiot A, 2003, DEVELOPMENT, V130, P5493, DOI 10.1242/dev.00788; Potenza N, 2005, EMBO REP, V6, P432, DOI 10.1038/sj.embor.7400397; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Ramirez A, 2004, GENESIS, V39, P52, DOI 10.1002/gene.20025; Scholl FA, 2004, CANCER RES, V64, P6035, DOI 10.1158/0008-5472.CAN-04-0017; Scholl FA, 2007, DEV CELL, V12, P615, DOI 10.1016/j.devcel.2007.03.009; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; Simpson CL, 2011, NAT REV MOL CELL BIO, V12, P565, DOI 10.1038/nrm3175; Oskarsson T, 2006, GENE DEV, V20, P2024, DOI 10.1101/gad.381206; Stewart S, 2000, J BIOL CHEM, V275, P8854, DOI 10.1074/jbc.275.12.8854; Tarutani M, 2003, CANCER RES, V63, P319; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; TRIGG MJ, 1972, J ZOOL, V68, P165, DOI 10.1111/j.1469-7998.1972.tb01346.x; Truong AB, 2006, GENE DEV, V20, p[63, 8723]; Vitale-Cross L, 2004, CANCER RES, V64, P8804, DOI 10.1158/0008-5472.CAN-04-2623; Weinberg WC, 2002, CRIT REV ORAL BIOL M, V13, P453, DOI 10.1177/154411130201300603; Yuan JS, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-85	52	26	28	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2014	33	22					2857	2865		10.1038/onc.2013.254	http://dx.doi.org/10.1038/onc.2013.254			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EI	23831572				2022-12-17	WOS:000337231800005
J	Xu, W; Li, Y; Liu, C; Zhao, S				Xu, W.; Li, Y.; Liu, C.; Zhao, S.			Protein lysine acetylation guards metabolic homeostasis to fight against cancer	ONCOGENE			English	Review						acetylation; metabolic coordination; cancer metabolism	PYRUVATE-DEHYDROGENASE COMPLEX; LINKING HISTONE ACETYLATION; FATTY-ACID OXIDATION; GLYCOGEN-PHOSPHORYLASE; DEACETYLASE INHIBITORS; CALORIE RESTRICTION; FUMARATE HYDRATASE; RENAL-CANCER; DNA-BINDING; P53	Properly coordinated metabolism and maintained metabolite homeostasis are important because altered metabolite homeostasis has a causal role in many human diseases, including cancer. Metabolite homeostasis is maintained by fine-tuned coordination of metabolite generation and utilization. Metabolite deregulation has recently been shown to alter the signaling pathways and reprogram epigenetic factors associated with tumorigenesis. Protein lysine acetylation is emerging as a metabolism-coordinating mechanism. Mechanistic studies have shown that acetylation may have roles in nutrient adaptation and in maintaining metabolite homeostasis by exerting regulatory effects on metabolic enzymes, metabolic pathways and metabolic networks. Here we review recent progress in the determination of the role of acetylation regulation in metabolism coordination. In particular, we review links between deregulated acetylation in metabolic enzymes and tumorigenesis. We further hypothesize on applications of the mediation of acetylation to restore deregulated metabolism coordination and thus develop novel means of cancer treatment.	[Xu, W.; Li, Y.; Liu, C.; Zhao, S.] Fudan Univ, Sch Life Sci, Sate Key Lab Genet Engn, Shanghai 200032, Peoples R China; [Xu, W.; Zhao, S.] Fudan Univ, Inst Biomed Sci, Shanghai 200032, Peoples R China	Fudan University; Fudan University	Zhao, S (corresponding author), Fudan Univ, Sch Life Sci, Sate Key Lab Genet Engn, 713 Mingdao Bldg,131 Dongan Rd, Shanghai 200032, Peoples R China.	zhaosm@fudan.edu.cn			National 973 Programs of China [2012CB910300, 2012CB721102, 2013CB911204, 2013CB945400]; NSFC Foundation of China [31030042]; Shanghai Basic Research Fund [11JC1401100]	National 973 Programs of China(National Basic Research Program of China); NSFC Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Basic Research Fund	The work was supported by the National 973 Programs of China (Nos. 2012CB910300, 2012CB721102, 2013CB911204 and 2013CB945400), NSFC Foundation of China (31030042) and the Shanghai Basic Research Fund (11JC1401100).	Aksoy P, 2006, BIOCHEM BIOPH RES CO, V345, P1386, DOI 10.1016/j.bbrc.2006.05.042; Alam NA, 2003, HUM MOL GENET, V12, P1241, DOI 10.1093/hmg/ddg148; ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; Anderson KA, 2012, ESSAYS BIOCHEM, V52, P23, DOI [10.1042/bse0520023, 10.1042/BSE0520023]; Andreyev AI, 2005, BIOCHEMISTRY-MOSCOW+, V70, P200, DOI 10.1007/s10541-005-0102-7; Astuti D, 2001, AM J HUM GENET, V69, P49, DOI 10.1086/321282; Balakin KV, 2007, ANTI-CANCER AGENT ME, V7, P576, DOI 10.2174/187152007781668698; Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; Brooks CL, 2011, PROTEIN CELL, V2, P456, DOI 10.1007/s13238-011-1063-9; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Capello M, 2011, FEBS J, V278, P1064, DOI 10.1111/j.1742-4658.2011.08025.x; Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Christofk HR, 2008, NATURE, V452, P181, DOI 10.1038/nature06667; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Desvergne B, 2006, PHYSIOL REV, V86, P465, DOI 10.1152/physrev.00025.2005; DRAPIER JC, 1986, J CLIN INVEST, V78, P790, DOI 10.1172/JCI112642; Esteban MA, 2005, NAT MED, V11, P1047, DOI 10.1038/nm1005-1047; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Gorke B, 2008, NAT REV MICROBIOL, V6, P613, DOI 10.1038/nrmicro1932; Gray MW, 2001, GENOME BIOL, V2; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Gu W, 2004, NOVART FDN SYMP, V259, P23; Gu W, 2004, NOVART FDN SYMP, p[259, 53]; Gu Wei, 2004, Novartis Found Symp, V259, P197; Guarente L, 2011, CELL METAB, V14, P151, DOI 10.1016/j.cmet.2011.07.007; Hallows WC, 2006, P NATL ACAD SCI USA, V103, P10230, DOI 10.1073/pnas.0604392103; Hallows WC, 2011, MOL CELL, V41, P139, DOI 10.1016/j.molcel.2011.01.002; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hebert AS, 2013, MOL CELL, V49, P186, DOI 10.1016/j.molcel.2012.10.024; Heltweg B, 2006, CANCER RES, V66, P4368, DOI 10.1158/0008-5472.CAN-05-3617; Hirschey MD, 2010, NATURE, V464, P121, DOI 10.1038/nature08778; Hirschey MD, 2009, METHOD ENZYMOL, V457, P137, DOI 10.1016/S0076-6879(09)05008-3; Hodawadekar SC, 2007, ONCOGENE, V26, P5528, DOI 10.1038/sj.onc.1210619; Isaacs JS, 2005, CANCER CELL, V8, P143, DOI 10.1016/j.ccr.2005.06.017; Jiang WQ, 2011, MOL CELL, V43, P33, DOI 10.1016/j.molcel.2011.04.028; JOHNSON LN, 1992, FASEB J, V6, P2274, DOI 10.1096/fasebj.6.6.1544539; Kim J, 2009, MICROBIOL-SGM, V155, P2420, DOI 10.1099/mic.0.027060-0; Kim SC, 2006, MOL CELL, V23, P607, DOI 10.1016/j.molcel.2006.06.026; Koivunen P, 2012, NATURE, V483, P485, DOI 10.1038/nature10898; Kondoh H, 2005, CANCER RES, V65, P177; Kuhajda FP, 2000, NUTRITION, V16, P202, DOI 10.1016/S0899-9007(99)00266-X; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Lain S, 2008, CANCER CELL, V13, P454, DOI 10.1016/j.ccr.2008.03.004; Lara E, 2009, ONCOGENE, V28, P781, DOI 10.1038/onc.2008.436; Launonen V, 2001, P NATL ACAD SCI USA, V98, P3387, DOI 10.1073/pnas.051633798; LINN TC, 1969, P NATL ACAD SCI USA, V62, P234, DOI 10.1073/pnas.62.1.234; Liu J, 2012, ACTA BIOCH BIOPH SIN, V44, P629, DOI 10.1093/abbs/gms048; Liwer Stein JM, 1969, METHODS ENZYMOLOGY, V13; Lombard DB, 2007, MOL CELL BIOL, V27, P8807, DOI 10.1128/MCB.01636-07; Lombard David B, 2011, Handb Exp Pharmacol, V206, P163, DOI 10.1007/978-3-642-21631-2_8; Lu JY, 2011, CELL, V146, P968, DOI 10.1016/j.cell.2011.07.044; LUETHY MH, 1995, GENE, V164, P251, DOI 10.1016/0378-1119(95)00465-I; Lundby A, 2012, CELL REP, V2, P419, DOI 10.1016/j.celrep.2012.07.006; Luo JY, 2004, P NATL ACAD SCI USA, V101, P2259, DOI 10.1073/pnas.0308762101; Lv L, 2011, MOL CELL, V42, P719, DOI 10.1016/j.molcel.2011.04.025; MCKEEHAN WL, 1982, CELL BIOL INT REP, V6, P635, DOI 10.1016/0309-1651(82)90125-4; Melino Gerry, 2010, Nature, V466, P905, DOI 10.1038/466905d; Mizzen CA, 1998, CELL MOL LIFE SCI, V54, P6, DOI 10.1007/s000180050121; Mullighan CG, 2011, NATURE, V471, P235, DOI 10.1038/nature09727; Muraoka M, 1996, ONCOGENE, V12, P1565; Nakagawa T, 2009, CELL, V137, P560, DOI 10.1016/j.cell.2009.02.026; Niemann S, 2000, NAT GENET, V26, P268, DOI 10.1038/81551; Niinaka Y, 1998, CANCER RES, V58, P2667; Ota H, 2006, ONCOGENE, V25, P176, DOI 10.1038/sj.onc.1209049; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; POGO BGT, 1966, P NATL ACAD SCI USA, V55, P805, DOI 10.1073/pnas.55.4.805; Portnoy T, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-269; Schwer B, 2009, AGING CELL, V8, P604, DOI 10.1111/j.1474-9726.2009.00503.x; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Sen N, 2012, TRANSCR-AUSTIN, V3, P119, DOI 10.4161/trns.20094; Someya S, 2010, CELL, V143, P802, DOI 10.1016/j.cell.2010.10.002; Starai VJ, 2002, SCIENCE, V298, P2390, DOI 10.1126/science.1077650; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Tan JH, 2010, J HEMATOL ONCOL, V3, DOI 10.1186/1756-8722-3-5; Tan MJ, 2011, CELL, V146, P1015, DOI 10.1016/j.cell.2011.08.008; Tang Y, 2008, CELL, V133, P612, DOI 10.1016/j.cell.2008.03.025; Tang Y, 2006, MOL CELL, V24, P827, DOI 10.1016/j.molcel.2006.11.021; Tanner KG, 1999, J BIOL CHEM, V274, P18157, DOI 10.1074/jbc.274.26.18157; Timmermann S, 2001, CELL MOL LIFE SCI, V58, P728, DOI 10.1007/PL00000896; Tomlinson IPM, 2002, NAT GENET, V30, P406, DOI 10.1038/ng849; Wang QJ, 2010, SCIENCE, V327, P1004, DOI 10.1126/science.1179687; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Warburg O, 1924, BIOCHEM Z, V152, P319; Ward PS, 2010, CANCER CELL, V17, P225, DOI 10.1016/j.ccr.2010.01.020; Won KY, 2012, HUM PATHOL, V43, P221, DOI 10.1016/j.humpath.2011.04.021; Xekouki P, 2012, J CLIN ENDOCR METAB, V97, pE357, DOI 10.1210/jc.2011-1179; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Yang HY, 2007, CELL, V130, P1095, DOI 10.1016/j.cell.2007.07.035; Yang MH, 2012, P NATL ACAD SCI USA, V109, P10843, DOI 10.1073/pnas.1201487109; Yu W, 2009, J BIOL CHEM, V284, P13669, DOI 10.1074/jbc.M901921200; Zhang JM, 2009, MOL CELL PROTEOMICS, V8, P215, DOI 10.1074/mcp.M800187-MCP200; Zhang TF, 2012, CELL METAB, V15, P75, DOI 10.1016/j.cmet.2011.12.005; Zhao SM, 2010, CELL RES, V20, P1279, DOI 10.1038/cr.2010.160; Zhao SM, 2010, SCIENCE, V327, P1000, DOI 10.1126/science.1179689; Zhao SM, 2009, SCIENCE, V324, P261, DOI 10.1126/science.1170944; ZIELKE HR, 1984, FED PROC, V43, P121	102	26	29	1	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	2014	33	18					2279	2285		10.1038/onc.2013.163	http://dx.doi.org/10.1038/onc.2013.163			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AG5ID	23665675				2022-12-17	WOS:000335451800001
J	Daenen, LGM; Houthuijzen, JM; Cirkel, GA; Roodhart, JML; Shaked, Y; Voest, EE				Daenen, L. G. M.; Houthuijzen, J. M.; Cirkel, G. A.; Roodhart, J. M. L.; Shaked, Y.; Voest, E. E.			Treatment-induced host-mediated mechanisms reducing the efficacy of antitumor therapies	ONCOGENE			English	Review						host response; antitumor therapy; therapy resistance; microenvironment; host-tumor interactions	MESENCHYMAL STEM-CELLS; METRONOMIC ORAL CYCLOPHOSPHAMIDE; ENDOTHELIAL PROGENITOR CELLS; GROWTH-FACTOR RECEPTOR; TUMOR ANGIOGENESIS; BONE-MARROW; DRUG-RESISTANCE; SUPPRESSOR-CELLS; MULTIPLE-MYELOMA; CANCER PATIENTS	In addition to its direct effects on tumor cells, chemotherapy can rapidly activate various host processes that contribute to therapy resistance and tumor regrowth. The host response to chemotherapy consists of changes in numerous cell types and cytokines. Examples include the acute mobilization and tumor homing of pro-angiogenic bone marrow-derived cells, activation of cells in the tumor microenvironment to produce systemic or paracrine factors, and tissue-specific responses that provide a protective niche for tumor cells. All of these factors reduce chemotherapy efficacy, and blocking the host response at various levels may therefore significantly improve treatment outcome. However, before the combination of conventional chemotherapy with agents blocking specific aspects of the host response can be implemented into clinical practice, a better understanding of the molecular mechanisms behind the host response is required.	[Daenen, L. G. M.; Houthuijzen, J. M.; Cirkel, G. A.; Roodhart, J. M. L.; Voest, E. E.] Univ Med Ctr Utrecht, Dept Med Oncol, NL-3508 GA Utrecht, Netherlands; [Shaked, Y.] Technion Israel Inst Technol, Rappaport Fac Med, Dept Mol Pharmacol, Haifa, Israel	Utrecht University; Utrecht University Medical Center; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Voest, EE (corresponding author), Univ Med Ctr Utrecht, Dept Med Oncol, POB 85500,F02-126, NL-3508 GA Utrecht, Netherlands.	e.e.voest@umcutrecht.nl		Houthuijzen, Julia/0000-0003-0404-1961				Abdullah SE, 2012, CANCER-AM CANCER SOC, V118, P3455, DOI 10.1002/cncr.26540; Ahn GO, 2010, P NATL ACAD SCI USA, V107, P8363, DOI 10.1073/pnas.0911378107; Apetoh L, 2011, CURR MOL MED, V11, P365, DOI 10.2174/156652411795976574; Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622; Bertolini F, 2003, CANCER RES, V63, P4342; Bian ZY, 2009, ARCH MED RES, V40, P163, DOI 10.1016/j.arcmed.2009.01.002; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Bono A, 2010, CANCER BIOL THER, V10, P682, DOI 10.4161/cbt.10.7.12898; Bottini A, 2006, J CLIN ONCOL, V24, P3623, DOI 10.1200/JCO.2005.04.5773; Browder T, 2000, CANCER RES, V60, P1878; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; Bruchard M, 2013, NAT MED, V19, P57, DOI 10.1038/nm.2999; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; CARMEL RJ, 1977, CANCER RES, V37, P145; Cerniglia GJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006539; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Daenen LG, 2009, MOL CANCER THER, V8, P2872, DOI 10.1158/1535-7163.MCT-09-0583; Daenen LGM, 2011, CANCER RES, V71, P6976, DOI 10.1158/0008-5472.CAN-11-0627; Davis A J, 2000, Lancet Oncol, V1, P86, DOI 10.1016/S1470-2045(00)00019-X; De Palma M, 2005, CANCER CELL, V8, P211, DOI 10.1016/j.ccr.2005.08.002; Dellapasqua S, 2008, J CLIN ONCOL; DeNardo DG, 2011, CANCER DISCOV, V1, P54, DOI 10.1158/2159-8274.CD-10-0028; DePrimo SE, 2007, J TRANSL MED, V5, DOI 10.1186/1479-5876-5-32; Ebos JML, 2007, P NATL ACAD SCI USA, V104, P17069, DOI 10.1073/pnas.0708148104; Ebos JML, 2009, CLIN CANCER RES, V15, P5020, DOI 10.1158/1078-0432.CCR-09-0095; Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021; Egeblad M, 2010, DEV CELL, V18, P884, DOI 10.1016/j.devcel.2010.05.012; Emmenegger U, 2011, NEOPLASIA, V13, P40, DOI 10.1593/neo.101174; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; Farace F, 2007, ANN ONCOL, V18, P1421, DOI 10.1093/annonc/mdm367; Farmer P, 2009, NAT MED, V15, P68, DOI 10.1038/nm.1908; Frassanito MA, 2001, BLOOD, V97, P483, DOI 10.1182/blood.V97.2.483; Garcia AA, 2008, J CLIN ONCOL, V26, P76, DOI 10.1200/JCO.2007.12.1939; Giannoni E, 2010, CANCER RES, V70, P6945, DOI 10.1158/0008-5472.CAN-10-0785; Gilbert LA, 2010, CELL, V143, P355, DOI 10.1016/j.cell.2010.09.043; Gingis-Velitski S, 2011, CANCER RES, V71, P6986, DOI 10.1158/0008-5472.CAN-11-0629; Green SK, 1999, ANTI-CANCER DRUG DES, V14, P153; Hanahan D, 2000, J CLIN INVEST, V105, P1045, DOI 10.1172/JCI9872; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; HANNA N, 1981, J IMMUNOL, V127, P1754; Hartmann TN, 2005, ONCOGENE, V24, P4462, DOI 10.1038/sj.onc.1208621; Hazlehurst LA, 2001, BLOOD, V98, P1897, DOI 10.1182/blood.V98.6.1897; Hideshima T, 2007, NAT REV CANCER, V7, P585, DOI 10.1038/nrc2189; Jain RK, 2003, CANCER CELL, V3, P515, DOI 10.1016/S1535-6108(03)00138-7; Jin DK, 2006, NAT MED, V12, P557, DOI 10.1038/nm1400; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kato H, 2004, NEW ENGL J MED, V350, P1713, DOI 10.1056/NEJMoa032792; Kerbel RS, 2010, NAT MED, V16, P1084, DOI 10.1038/nm1010-1084; Kerbel RS, 2006, SCIENCE, V312, P1171, DOI 10.1126/science.1125950; Kerbel RS, 2004, NAT REV CANCER, V4, P423, DOI 10.1038/nrc1369; Kim JJ, 2005, NAT REV CANCER, V5, P516, DOI 10.1038/nrc1650; Kinzler KW, 1998, SCIENCE, V280, P1036, DOI 10.1126/science.280.5366.1036; Kitadai Y, 2006, AM J PATHOL, V169, P2054, DOI 10.2353/ajpath.2006.060653; Klement G, 2000, J CLIN INVEST, V105, pR15, DOI 10.1172/JCI8829; Klopp AH, 2007, CANCER RES, V67, P11687, DOI 10.1158/0008-5472.CAN-07-1406; Klopp AH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012180; KOBAYASHI H, 1993, P NATL ACAD SCI USA, V90, P3294, DOI 10.1073/pnas.90.8.3294; Kuilman T, 2009, NAT REV CANCER, V9, P81, DOI 10.1038/nrc2560; Langenberg MHG, 2010, CANCER BIOL THER, V9, P743, DOI 10.4161/cbt.9.9.11551; Le DT, 2012, CANCER RES, V72, P3439, DOI 10.1158/0008-5472.CAN-11-3912; Lewis CE, 2007, CANCER RES, V67, P8429, DOI 10.1158/0008-5472.CAN-07-1684; Li HJ, 2012, CANCER DISCOV, V2, P840, DOI 10.1158/2159-8290.CD-12-0101; Lindauer A, 2010, CLIN PHARMACOL THER, V87, P601, DOI 10.1038/clpt.2010.20; Loven D, 2013, DRUG DISCOV TODAY, V18, P193, DOI 10.1016/j.drudis.2012.07.015; Low JA, 2010, J CLIN ONCOL, V28, P5321, DOI 10.1200/JCO.2010.27.9943; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Madden JI, 2012, INFINITY REPORTS UPD; Martin FT, 2010, BREAST CANCER RES TR, V124, P317, DOI 10.1007/s10549-010-0734-1; Meads MB, 2008, CLIN CANCER RES, V14, P2519, DOI 10.1158/1078-0432.CCR-07-2223; Meads MB, 2009, NAT REV CANCER, V9, P665, DOI 10.1038/nrc2714; Neesse A, 2011, GUT, V60, P861, DOI 10.1136/gut.2010.226092; Nguyen DH, 2011, CANCER CELL, V19, P640, DOI 10.1016/j.ccr.2011.03.011; Norden-Zfoni A, 2007, CLIN CANCER RES, V13, P2643, DOI 10.1158/1078-0432.CCR-06-0919; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Penel N, 2012, CRIT REV ONCOL HEMAT, V82, P40, DOI 10.1016/j.critrevonc.2011.04.009; Pietras K, 2005, J CLIN ONCOL, V23, P939, DOI 10.1200/JCO.2005.07.093; Pietras K, 2008, PLOS MED, V5, P123, DOI 10.1371/journal.pmed.0050019; Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909; Roodhart JM, 2010, NEOPLASIA, V12, P87, DOI 10.1593/neo.91460; Roodhart JML, 2011, CANCER CELL, V20, P370, DOI 10.1016/j.ccr.2011.08.010; Roodhart JM, 2012, AACR ANN M; Samson DJ, 2004, J CLIN ONCOL, V22, P3618, DOI 10.1200/JCO.2004.04.077; Shaked Y, 2008, CANCER CELL, V14, P263, DOI 10.1016/j.ccr.2008.08.001; Shaked Y, 2006, SCIENCE, V313, P1785, DOI 10.1126/science.1127592; Shaked Y, 2009, CANCER RES, V69, P7524, DOI 10.1158/0008-5472.CAN-09-0381; Shojaei F, 2007, NAT BIOTECHNOL, V25, P911, DOI 10.1038/nbt1323; Shojaei F, 2009, P NATL ACAD SCI USA, V106, P6742, DOI 10.1073/pnas.0902280106; Shree T, 2011, GENE DEV, V25, P2465, DOI 10.1101/gad.180331.111; Sotgia F, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2892; Stupp R, 2007, J CLIN ONCOL, V25, P1637, DOI 10.1200/JCO.2006.09.8376; Sumida T, 2011, INT J CANCER, V128, P2050, DOI 10.1002/ijc.25812; Sun Y, 2012, NAT MED, V18, P1359, DOI 10.1038/nm.2890; Taylor M, 2012, CANCER DISCOV, V2, P434, DOI 10.1158/2159-8290.CD-11-0171; Tredan O, 2007, J NATL CANCER I, V99, P1441, DOI 10.1093/jnci/djm135; Vala IS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011222; Voloshin T, 2010, CANCER BIOL THER, V10, P686, DOI 10.4161/cbt.10.7.13240; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; Watanabe T, 2009, J CLIN ONCOL, V27, P1368, DOI 10.1200/JCO.2008.18.3939; Welford AF, 2011, J CLIN INVEST, V121, P1969, DOI 10.1172/JCI44562; Yamauchi K, 2008, CANCER RES, V68, P516, DOI 10.1158/0008-5472.CAN-07-3063; Yan XL, 2012, BREAST CANCER RES TR, V132, P153, DOI 10.1007/s10549-011-1577-0	103	26	27	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2014	33	11					1341	1347		10.1038/onc.2013.94	http://dx.doi.org/10.1038/onc.2013.94			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD0SD	23524584				2022-12-17	WOS:000332943500001
J	Sarris, M; Nikolaou, K; Talianidis, I				Sarris, M.; Nikolaou, K.; Talianidis, I.			Context-specific regulation of cancer epigenomes by histone and transcription factor methylation	ONCOGENE			English	Review						cancer epigenetics; lysine methylation; histones; transcription factors	TUMOR-SUPPRESSOR GENE; NF-KAPPA-B; DEMETHYLASE JMJD3 CONTRIBUTES; PARTIAL TANDEM DUPLICATION; CHRONIC MYELOID-LEUKEMIA; POLYCOMB-GROUP PROTEINS; LYSINE METHYLATION; BREAST-CANCER; CELL-PROLIFERATION; ANDROGEN-RECEPTOR	Altered expression or activity of histone lysine methylases and demethylases in cancer lead to aberrant chromatin modification patterns, which contribute to uncontrolled cell proliferation via cancer-specific deregulation of gene expression programs or the induction of genome instability. Several transcription factors that regulate growth-associated genes undergo lysine methylation, expanding the repertoire of regulatory targets modulated by histone-methylating enzymes during tumorigenesis. In certain specific tumor types or specific physiological conditions, these enzymes may trigger chromatin structure and/or transcription factor activity changes that result in opposite effects on cancer initiation or progression. The mechanisms of such context-specific dual functions and those involved in the crosstalk between factor and histone modifications are subject to extensive research, which is beginning to shed light into this novel level of complexity of cancer-related epigenetic pathways.	[Sarris, M.; Nikolaou, K.; Talianidis, I.] Biomed Sci Res Ctr Alexander Fleming, Vari 16672, Athens, Greece	Alexander Fleming Biomedical Sciences Research Center	Talianidis, I (corresponding author), Biomed Sci Res Ctr Alexander Fleming, 34 Alexander Fleming St, Vari 16672, Athens, Greece.	talianidis@fleming.gr	Talianidis, Iannis/F-7556-2016; Nikolaou, Kostas/AAB-3428-2020	Talianidis, Iannis/0000-0002-1209-3609; Nikolaou, Kostas/0000-0003-2390-9156; Nikolaou, Konstantin/0000-0003-2668-7325	European Research Council Advanced Investigator Grant [ERC-2011-AdG294464]; Greek Operational Program 'Education and Lifelong Learning' of the National Strategic Reference Framework (NSRF)-Research Funding Program: Thales [Thales 656]	European Research Council Advanced Investigator Grant(European Research Council (ERC)); Greek Operational Program 'Education and Lifelong Learning' of the National Strategic Reference Framework (NSRF)-Research Funding Program: Thales	Work in the author's lab is supported by European Research Council Advanced Investigator Grant (ERC-2011-AdG294464) and the Greek Operational Program 'Education and Lifelong Learning' of the National Strategic Reference Framework (NSRF)-Research Funding Program: Thales (Thales 656).	Abu-Farha M, 2008, MOL CELL PROTEOMICS, V7, P560, DOI 10.1074/mcp.M700271-MCP200; Agger K, 2009, GENE DEV, V23, P1171, DOI 10.1101/gad.510809; Albert M, 2010, SEMIN CELL DEV BIOL, V21, P209, DOI 10.1016/j.semcdb.2009.10.007; Anderton JA, 2011, ONCOGENE, V30, P2037, DOI 10.1038/onc.2010.579; Angrand PO, 2001, GENOMICS, V74, P79, DOI 10.1006/geno.2001.6524; Asangani IA, 2013, MOL CELL, V49, P80, DOI 10.1016/j.molcel.2012.10.008; Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180; Barradas M, 2009, GENE DEV, V23, P1177, DOI 10.1101/gad.511109; Beck DB, 2012, GENE DEV, V26, P2580, DOI 10.1101/gad.195636.112; Beke L, 2007, ONCOGENE, V26, P4590, DOI 10.1038/sj.onc.1210248; Berdasco M, 2009, P NATL ACAD SCI USA, V106, P21830, DOI 10.1073/pnas.0906831106; Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915; Bhaumik SR, 2007, NAT STRUCT MOL BIOL, V14, P1008, DOI 10.1038/nsmb1337; Bracken AP, 2007, GENE DEV, V21, P525, DOI 10.1101/gad.415507; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Brown MA, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-26; Calnan DR, 2012, AGING-US, V4, P462, DOI 10.18632/aging.100471; Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333; Carr SM, 2011, EMBO J, V30, P317, DOI 10.1038/emboj.2010.311; Ceol CJ, 2011, NATURE, V471, P513, DOI 10.1038/nature09806; Cerveira N, 2003, LEUKEMIA, V17, P2244, DOI 10.1038/sj.leu.2403104; Chadwick RB, 2000, P NATL ACAD SCI USA, V97, P2662, DOI 10.1073/pnas.040579497; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Cho HS, 2012, INT J CANCER, V131, pE179, DOI 10.1002/ijc.26501; Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117; Cloos PAC, 2006, NATURE, V442, P307, DOI 10.1038/nature04837; Cock-Rada AM, 2012, CANCER RES, V72, P810, DOI 10.1158/0008-5472.CAN-11-1052; Collett K, 2006, CLIN CANCER RES, V12, P1168, DOI 10.1158/1078-0432.CCR-05-1533; Courts C, 2008, J NEUROPATH EXP NEUR, V67, P720, DOI 10.1097/NEN.0b013e31817dd02d; Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672; Deng QD, 2004, ONCOGENE, V23, P4903, DOI 10.1038/sj.onc.1207615; Dietrich N, 2007, EMBO J, V26, P1637, DOI 10.1038/sj.emboj.7601632; Dorrance AM, 2008, BLOOD, V112, P2508, DOI 10.1182/blood-2008-01-134338; Dorrance AM, 2006, J CLIN INVEST, V116, P2707, DOI 10.1172/JCI25546; Douglas J, 2003, AM J HUM GENET, V72, P132, DOI 10.1086/345647; Du Y, 2001, CANCER RES, V61, P8094; Duns G, 2010, CANCER RES, V70, P4287, DOI 10.1158/0008-5472.CAN-10-0120; Ea CK, 2009, P NATL ACAD SCI USA, V106, P18972, DOI 10.1073/pnas.0910439106; Ehrbrecht A, 2006, J PATHOL, V208, P554, DOI 10.1002/path.1925; Ernst T, 2010, NAT GENET, V42, P722, DOI 10.1038/ng.621; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Esteve PO, 2011, NAT STRUCT MOL BIOL, V18, P42, DOI 10.1038/nsmb.1939; Esteve PO, 2009, P NATL ACAD SCI USA, V106, P5076, DOI 10.1073/pnas.0810362106; Frescas D, 2008, CELL CYCLE, V7, P3539, DOI 10.4161/cc.7.22.7062; Frescas D, 2007, NATURE, V450, P309, DOI 10.1038/nature06255; Fujii S, 2008, CANCER SCI, V99, P738, DOI 10.1111/j.1349-7006.2008.00743.x; Gaughan L, 2011, NUCLEIC ACIDS RES, V39, P1266, DOI 10.1093/nar/gkq861; Gonzalez ME, 2011, CANCER RES, V71, P2360, DOI 10.1158/0008-5472.CAN-10-1933; Hamamoto R, 2004, NAT CELL BIOL, V6, P731, DOI 10.1038/ncb1151; Hamamoto R, 2006, CANCER SCI, V97, P113, DOI 10.1111/j.1349-7006.2006.00146.x; Hayami S, 2011, INT J CANCER, V128, P574, DOI 10.1002/ijc.25349; He J, 2008, NAT STRUCT MOL BIOL, V15, P1169, DOI 10.1038/nsmb.1499; He LS, 1998, CANCER RES, V58, P4238; Hu LP, 2009, CANCER RES, V69, P4067, DOI 10.1158/0008-5472.CAN-08-4097; Huang J, 2007, NATURE, V449, P105, DOI 10.1038/nature06092; Huang J, 2006, NATURE, V444, P629, DOI 10.1038/nature05287; Huang J, 2010, J BIOL CHEM, V285, P9636, DOI 10.1074/jbc.M109.062588; Hudlebusch HR, 2011, CLIN CANCER RES, V17, P2919, DOI 10.1158/1078-0432.CCR-10-1302; Italiano A, 2006, CANCER GENET CYTOGEN, V167, P122, DOI 10.1016/j.cancergencyto.2006.01.004; Ivanov GS, 2007, MOL CELL BIOL, V27, P6756, DOI 10.1128/MCB.00460-07; Jaju RJ, 2001, BLOOD, V98, P1264, DOI 10.1182/blood.V98.4.1264; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jiang GL, 1999, INT J CANCER, V83, P541, DOI 10.1002/(SICI)1097-0215(19991112)83:4<541::AID-IJC17>3.0.CO;2-F; Kachirskaia I, 2008, J BIOL CHEM, V283, P34660, DOI 10.1074/jbc.M806020200; Kahl P, 2006, CANCER RES, V66, P11341, DOI 10.1158/0008-5472.CAN-06-1570; Kassambara A, 2009, BIOCHEM BIOPH RES CO, V379, P840, DOI 10.1016/j.bbrc.2008.12.093; Kauffman EC, 2011, MOL CARCINOGEN, V50, P931, DOI 10.1002/mc.20758; Kim H, 2009, J BIOL CHEM, V284, P19867, DOI 10.1074/jbc.M109.021485; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Ko S, 2011, MOL ENDOCRINOL, V25, P433, DOI 10.1210/me.2010-0482; Kolomietz E, 2003, LEUKEMIA, V17, P1313, DOI 10.1038/sj.leu.2402969; Komatsu S, 2009, CARCINOGENESIS, V30, P1139, DOI 10.1093/carcin/bgp116; Kondo Y, 2007, HEPATOL RES, V37, P974, DOI 10.1111/j.1872-034X.2007.00141.x; Kontaki H, 2010, CELL CYCLE, V9, P3836, DOI 10.4161/cc.9.19.13384; Kontaki H, 2010, MOL CELL, V39, P152, DOI 10.1016/j.molcel.2010.06.006; Kouskouti A, 2004, MOL CELL, V14, P175, DOI 10.1016/S1097-2765(04)00182-0; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Krajewski WA, 2010, MOL CELL BIOL, V30, P552, DOI 10.1128/MCB.00775-09; Krivtsov AV, 2008, CANCER CELL, V14, P355, DOI 10.1016/j.ccr.2008.10.001; Krivtsov AV, 2007, NAT REV CANCER, V7, P823, DOI 10.1038/nrc2253; Kurotaki N, 2002, NAT GENET, V30, P365, DOI 10.1038/ng863; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lee J, 2008, CANCER CELL, V13, P69, DOI 10.1016/j.ccr.2007.12.005; Lee JM, 2012, MOL CELL, V48, P572, DOI 10.1016/j.molcel.2012.09.004; Lee ST, 2011, MOL CELL, V43, P798, DOI 10.1016/j.molcel.2011.08.011; Levy D, 2011, NAT IMMUNOL, V12, P29, DOI 10.1038/ni.1968; Li Q, 2011, CANCER RES, V71, P6899, DOI 10.1158/0008-5472.CAN-11-1523; Li WJ, 2011, BIOCHEM BIOPH RES CO, V416, P372, DOI 10.1016/j.bbrc.2011.11.045; Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324; Lin YH, 2009, BLOOD, V114, P651, DOI 10.1182/blood-2009-03-209395; Lin YW, 2010, EMBO J, V29, P1803, DOI 10.1038/emboj.2010.63; Ling BMT, 2012, P NATL ACAD SCI USA, V109, P841, DOI 10.1073/pnas.1111628109; Liu C, 2007, CANCER RES, V67, P2626, DOI 10.1158/0008-5472.CAN-06-4126; Liu XY, 2011, P NATL ACAD SCI USA, V108, P1925, DOI 10.1073/pnas.1019619108; Lu PJ, 1999, J BIOL CHEM, V274, P15633, DOI 10.1074/jbc.274.22.15633; Lu T, 2010, P NATL ACAD SCI USA, V107, P46, DOI 10.1073/pnas.0912493107; Magerl C, 2010, HUM PATHOL, V41, P181, DOI 10.1016/j.humpath.2009.08.007; Malgeri U, 2000, CANCER RES, V60, P4058; Martinez-Garcia E, 2011, BLOOD, V117, P211, DOI 10.1182/blood-2010-07-298349; McCabe MT, 2012, P NATL ACAD SCI USA, V109, P2989, DOI 10.1073/pnas.1116418109; McLaughlin-Drubin ME, 2011, P NATL ACAD SCI USA, V108, P2130, DOI 10.1073/pnas.1009933108; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Morin RD, 2011, NATURE, V476, P298, DOI 10.1038/nature10351; Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518; Mueller D, 2007, BLOOD, V110, P4445, DOI 10.1182/blood-2007-05-090514; Munro S, 2010, ONCOGENE, V29, P2357, DOI 10.1038/onc.2009.511; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Nie K, 2008, AM J PATHOL, V173, P242, DOI 10.2353/ajpath.2008.080009; Nishikawa N, 2007, CANCER RES, V67, P9649, DOI 10.1158/0008-5472.CAN-06-4111; Nishioka K, 2002, MOL CELL, V9, P1201, DOI 10.1016/S1097-2765(02)00548-8; Niu X, 2012, ONCOGENE, V31, P776, DOI 10.1038/onc.2011.266; Northcott PA, 2009, NAT GENET, V41, P465, DOI 10.1038/ng.336; O'Carroll D, 2001, MOL CELL BIOL, V21, P4330, DOI 10.1128/MCB.21.13.4330-4336.2001; Oda H, 2010, MOL CELL, V40, P364, DOI 10.1016/j.molcel.2010.10.011; Oda H, 2009, MOL CELL BIOL, V29, P2278, DOI 10.1128/MCB.01768-08; Okada Y, 2005, CELL, V121, P167, DOI 10.1016/j.cell.2005.02.020; Okada Y, 2006, NAT CELL BIOL, V8, P1017, DOI 10.1038/ncb1464; Oshimo Y, 2004, INT J CANCER, V110, P212, DOI 10.1002/ijc.20090; Parsons DW, 2011, SCIENCE, V331, P435, DOI 10.1126/science.1198056; Pasqualucci L, 2006, J EXP MED, V203, P311, DOI 10.1084/jem.20052204; Pedersen MT, 2010, TRENDS CELL BIOL, V20, P662, DOI 10.1016/j.tcb.2010.08.011; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Pfau R, 2008, P NATL ACAD SCI USA, V105, P1907, DOI 10.1073/pnas.0711865105; Piao GH, 2008, HISTOL HISTOPATHOL, V23, P1171, DOI 10.14670/HH-23.1171; Pless O, 2008, J BIOL CHEM, V283, P26357, DOI 10.1074/jbc.M802132200; Pollock JA, 2012, ACS CHEM BIOL, V7, P1221, DOI 10.1021/cb300108c; Reid AG, 2004, LEUKEMIA, V18, P178, DOI 10.1038/sj.leu.2403162; Rice JC, 2002, GENE DEV, V16, P2225, DOI 10.1101/gad.1014902; Rosati R, 2002, BLOOD, V99, P3857, DOI 10.1182/blood.V99.10.3857; Rui LX, 2010, CANCER CELL, V18, P590, DOI 10.1016/j.ccr.2010.11.013; Saddic LA, 2010, J BIOL CHEM, V285, P37733, DOI 10.1074/jbc.M110.137612; Sampath SC, 2007, MOL CELL, V27, P596, DOI 10.1016/j.molcel.2007.06.026; Sander S, 2008, BLOOD, V112, P4202, DOI 10.1182/blood-2008-03-147645; Saramaki OR, 2006, GENE CHROMOSOME CANC, V45, P639, DOI 10.1002/gcc.20327; Schulte JH, 2009, CANCER RES, V69, P2065, DOI 10.1158/0008-5472.CAN-08-1735; Shi XB, 2007, MOL CELL, V27, P636, DOI 10.1016/j.molcel.2007.07.012; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Skawran B, 2008, MODERN PATHOL, V21, P505, DOI 10.1038/modpathol.3800998; Steele-Perkins G, 2001, GENE DEV, V15, P2250, DOI 10.1101/gad.870101; Subramanian K, 2008, MOL CELL, V30, P336, DOI 10.1016/j.molcel.2008.03.022; Takawa M, 2012, CANCER RES, V72, P3217, DOI 10.1158/0008-5472.CAN-11-3701; Tam W, 2006, BLOOD, V107, P4090, DOI 10.1182/blood-2005-09-3778; Tatton-Brown K, 2005, AM J HUM GENET, V77, P193, DOI 10.1086/432082; Tokumaru Y, 2003, ONCOGENE, V22, P6954, DOI 10.1038/sj.onc.1206403; Towbin BD, 2012, CELL, V150, P934, DOI 10.1016/j.cell.2012.06.051; Trojer P, 2007, MOL CELL, V28, P1, DOI 10.1016/j.molcel.2007.09.011; Tzatsos A, 2009, P NATL ACAD SCI USA, V106, P2641, DOI 10.1073/pnas.0813139106; van Haaften G, 2009, NAT GENET, V41, P521, DOI 10.1038/ng.349; van Kemenade FJ, 2001, BLOOD, V97, P3896, DOI 10.1182/blood.V97.12.3896; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395; Vermeulen M, 2007, CELL, V131, P58, DOI 10.1016/j.cell.2007.08.016; Wang J, 2009, NAT GENET, V41, P125, DOI 10.1038/ng.268; Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050; Watanabe Y, 2007, CLIN CANCER RES, V13, P4786, DOI 10.1158/1078-0432.CCR-07-0305; Weikert S, 2005, INT J MOL MED, V16, P349; Whitman SP, 2008, BLOOD, V112, P2013, DOI 10.1182/blood-2008-01-128595; Wissmann M, 2007, NAT CELL BIOL, V9, P347, DOI 10.1038/ncb1546; Wu SM, 2010, GENE DEV, V24, P2531, DOI 10.1101/gad.1984210; Xiang Y, 2007, P NATL ACAD SCI USA, V104, P19226, DOI 10.1073/pnas.0700735104; Xiang Y, 2007, CELL RES, V17, P850, DOI 10.1038/cr.2007.83; Xie Q, 2012, EMBO REP, V13, P371, DOI 10.1038/embor.2012.25; Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604; Yang F, 2012, EMBO J, V31, P110, DOI 10.1038/emboj.2011.364; Yang JB, 2010, P NATL ACAD SCI USA, V107, P21499, DOI 10.1073/pnas.1016147107; Yang LQ, 2011, CELL, V147, P773, DOI 10.1016/j.cell.2011.08.054; Yang XD, 2010, MOL CELL BIOL, V30, P2170, DOI 10.1128/MCB.01343-09; Yang XD, 2009, EMBO J, V28, P1055, DOI 10.1038/emboj.2009.55; Yu J, 2007, CANCER CELL, V12, P419, DOI 10.1016/j.ccr.2007.10.016; Zeng JP, 2010, GASTROENTEROLOGY, V138, P981, DOI 10.1053/j.gastro.2009.10.004; Zuber J, 2011, GENE DEV, V25, P1628, DOI 10.1101/gad.17269211	172	26	27	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2014	33	10					1207	1217		10.1038/onc.2013.87	http://dx.doi.org/10.1038/onc.2013.87			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AC6KI	23503463				2022-12-17	WOS:000332631100001
J	Fulda, S				Fulda, S.			Regulation of cell migration, invasion and metastasis by IAP proteins and their antagonists	ONCOGENE			English	Review						IAP proteins; Smac; migration; invasion	NF-KAPPA-B; X-LINKED INHIBITOR; ALPHA-DEPENDENT APOPTOSIS; C-RAF KINASE; TNF-ALPHA; CASPASE INHIBITION; MULTIPLE-MYELOMA; STRUCTURAL BASIS; INNATE IMMUNITY; THERAPEUTIC INTERVENTION	Inhibitor of apoptosis (IAP) proteins are a family comprised of a total of eight mammalian members that were initially described to act as endogenous inhibitors of caspases. In addition, extensive evidence has been accumulated over the last years showing that IAP proteins can regulate various signal transduction pathways, thereby exerting non-apoptotic functions beyond the inhibition of apoptosis. For example, IAP proteins have been implied in the control of cell motility, migration, invasion and metastasis. However, currently the question is controversially discussed whether or not they positively or negatively control these processes. As small-molecule inhibitors of IAP proteins have entered the stage of clinical evaluation as experimental cancer therapeutics, a better understanding of their various cellular effects will be critical for their rational use in the treatment of human diseases.	Goethe Univ Frankfurt, Inst Expt Canc Res, D-60528 Frankfurt, Hesse, Germany	Goethe University Frankfurt	Fulda, S (corresponding author), Goethe Univ Frankfurt, Inst Expt Canc Res, Komturstr 3a, D-60528 Frankfurt, Hesse, Germany.	simone.fulda@kgu.de		Fulda, Simone/0000-0002-0459-6417	Deutsche Forschungsgemeinschaft; Ministerium fur Bildung und Forschung [01GM0871, 01GM1104C]; European Community; Jose Carreras Stiftung	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Ministerium fur Bildung und Forschung; European Community(European Commission); Jose Carreras Stiftung	The expert secretarial assistance of C Hugenberg is greatly appreciated. This work has been partially supported by grants from the Deutsche Forschungsgemeinschaft, the Ministerium fur Bildung und Forschung (01GM0871, 01GM1104C), European Community and Jose Carreras Stiftung.	Ahn S, 2012, BIOCHEM BIOPH RES CO, V419, P419, DOI 10.1016/j.bbrc.2012.02.037; Ahn S, 2010, BIOCHEM BIOPH RES CO, V399, P256, DOI 10.1016/j.bbrc.2010.07.064; Annunziata CM, 2007, CANCER CELL, V12, P115, DOI 10.1016/j.ccr.2007.07.004; Asselin E, 2001, CANCER RES, V61, P1862; Bertrand MJM, 2008, MOL CELL, V30, P689, DOI 10.1016/j.molcel.2008.05.014; Bertrand MJM, 2009, IMMUNITY, V30, P789, DOI 10.1016/j.immuni.2009.04.011; Beug ST, 2012, TRENDS IMMUNOL, V33, P535, DOI 10.1016/j.it.2012.06.004; BIRNBAUM MJ, 1994, J VIROL, V68, P2521, DOI 10.1128/JVI.68.4.2521-2528.1994; Blankenship JW, 2009, BIOCHEM J, V417, P149, DOI 10.1042/BJ20081885; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Chen ZH, 1999, BIOCHEM BIOPH RES CO, V264, P847, DOI 10.1006/bbrc.1999.1585; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Csomos RA, 2009, BIOCHEM J, V420, P83, DOI 10.1042/BJ20082140; Damgaard RB, 2012, MOL CELL, V46, P746, DOI 10.1016/j.molcel.2012.04.014; Dejardin E, 2006, BIOCHEM PHARMACOL, V72, P1161, DOI 10.1016/j.bcp.2006.08.007; Demchenko YN, 2010, BLOOD, V115, P3541, DOI 10.1182/blood-2009-09-243535; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Dogan T, 2008, NAT CELL BIOL, V10, P1447, DOI 10.1038/ncb1804; Dueber EC, 2011, SCIENCE, V334, P376, DOI 10.1126/science.1207862; Dynek JN, 2010, EMBO J, V29, P4198, DOI 10.1038/emboj.2010.300; Eckelman BP, 2006, EMBO REP, V7, P988, DOI 10.1038/sj.embor.7400795; Fingas CD, 2010, HEPATOLOGY, V52, P550, DOI 10.1002/hep.23729; Fulda S, 2012, NAT REV DRUG DISCOV, V11, P109, DOI 10.1038/nrd3627; Garcia-Fernandez M, 2010, GENE DEV, V24, P2282, DOI 10.1101/gad.1970110; Geisbrecht ER, 2004, CELL, V118, P111, DOI 10.1016/j.cell.2004.06.020; Glinsky GV, 2006, CELL CYCLE, V5, P1208, DOI 10.4161/cc.5.11.2796; Grech AP, 2004, IMMUNITY, V21, P629, DOI 10.1016/j.immuni.2004.09.011; Gyrd-Hansen M, 2008, NAT CELL BIOL, V10, P1309, DOI 10.1038/ncb1789; Haas TL, 2009, MOL CELL, V36, P831, DOI 10.1016/j.molcel.2009.10.013; Hauser HP, 1998, J CELL BIOL, V141, P1415, DOI 10.1083/jcb.141.6.1415; He JQ, 2006, J EXP MED, V203, P2413, DOI 10.1084/jem.20061166; Heasman SJ, 2008, NAT REV MOL CELL BIO, V9, P690, DOI 10.1038/nrm2476; Hofer-Warbinek R, 2000, J BIOL CHEM, V275, P22064, DOI 10.1074/jbc.M910346199; Huang YH, 2001, CELL, V104, P781, DOI 10.1016/S0092-8674(02)02075-5; Jeyaprakash AA, 2007, CELL, V131, P271, DOI 10.1016/j.cell.2007.07.045; Keats JJ, 2007, CANCER CELL, V12, P131, DOI 10.1016/j.ccr.2007.07.003; Kim J, 2010, AM J PHYSIOL-HEART C, V299, pH300, DOI 10.1152/ajpheart.00180.2010; Krieg A, 2009, P NATL ACAD SCI USA, V106, P14524, DOI 10.1073/pnas.0907131106; Labbe K, 2011, IMMUNITY, V35, P897, DOI 10.1016/j.immuni.2011.10.016; Launay S, 2005, ONCOGENE, V24, P5137, DOI 10.1038/sj.onc.1208524; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Liu JY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035682; Liu JY, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.176982; Lopez J, 2011, MOL CELL, V42, P569, DOI 10.1016/j.molcel.2011.04.008; Lopez J, 2010, CURR OPIN CELL BIOL, V22, P872, DOI 10.1016/j.ceb.2010.08.025; Lu M, 2007, MOL CELL, V26, P689, DOI 10.1016/j.molcel.2007.05.006; Mahoney DJ, 2008, P NATL ACAD SCI USA, V105, P11778, DOI 10.1073/pnas.0711122105; Mao AP, 2010, J BIOL CHEM, V285, P9470, DOI 10.1074/jbc.M109.071043; Mehrotra S, 2010, CANCER CELL, V17, P53, DOI 10.1016/j.ccr.2009.11.021; Min CY, 2008, J CELL BIOCHEM, V104, P733, DOI 10.1002/jcb.21695; Mollereau B, 2013, CELL DEATH DIFFER, V20, P181, DOI 10.1038/cdd.2012.82; Ndubaku C, 2009, FUTURE MED CHEM, V1, P1509, DOI [10.4155/fmc.09.116, 10.4155/FMC.09.116]; Oberoi TK, 2012, EMBO J, V31, P14, DOI 10.1038/emboj.2011.423; Oberoi-Khanuja TK, 2012, J BIOL CHEM, V287, P28445, DOI 10.1074/jbc.M112.341297; Reffey SB, 2001, J BIOL CHEM, V276, P26542, DOI 10.1074/jbc.M100331200; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(01)00274-4; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Sanna MG, 2002, MOL CELL BIOL, V22, P1754, DOI 10.1128/MCB.22.6.1754-1766.2002; Scheidereit C, 2006, ONCOGENE, V25, P6685, DOI 10.1038/sj.onc.1209934; Schile AJ, 2008, GENE DEV, V22, P2256, DOI 10.1101/gad.1663108; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Shiozaki EN, 2003, MOL CELL, V11, P519, DOI 10.1016/S1097-2765(03)00054-6; Silke J, 2001, EMBO J, V20, P3114, DOI 10.1093/emboj/20.12.3114; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Tian S, 2006, INT J ONCOL, V29, P861; Tseng PH, 2010, NAT IMMUNOL, V11, P70, DOI 10.1038/ni.1819; Varfolomeev E, 2008, J BIOL CHEM, V283, P24295, DOI 10.1074/jbc.C800128200; Varfolomeev E, 2008, CELL CYCLE, V7, P1511, DOI 10.4161/cc.7.11.5959; Varfolomeev E, 2007, CELL, V131, P669, DOI 10.1016/j.cell.2007.10.030; Varfolomeev E, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2001878; Vaux DL, 2005, NAT REV MOL CELL BIO, V6, P287, DOI 10.1038/nrm1621; Vince JE, 2008, J CELL BIOL, V182, P171, DOI 10.1083/jcb.200801010; Vince JE, 2007, CELL, V131, P682, DOI 10.1016/j.cell.2007.10.037; Vince JE, 2012, IMMUNITY, V36, P215, DOI 10.1016/j.immuni.2012.01.012; Vucic D, 2005, BIOCHEM J, V385, P11, DOI 10.1042/BJ20041108; Vucic D, 2011, 13 INT TNF C AW JAP; Vucic D, 2011, NAT REV MOL CELL BIO, V12, P439, DOI 10.1038/nrm3143; Wilmanski JM, 2008, J LEUKOCYTE BIOL, V83, P13, DOI 10.1189/jlb.0607402; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Yu JX, 2012, J BIOL CHEM, V287, P13752, DOI 10.1074/jbc.M111.337469	80	26	27	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2014	33	6					671	676		10.1038/onc.2013.63	http://dx.doi.org/10.1038/onc.2013.63			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5IL	23474760				2022-12-17	WOS:000331129200001
J	Buchwald, M; Pietschmann, K; Brand, P; Gunther, A; Mahajan, NP; Heinzel, T; Kramer, OH				Buchwald, M.; Pietschmann, K.; Brand, P.; Guenther, A.; Mahajan, N. P.; Heinzel, T.; Kraemer, O. H.			SIAH ubiquitin ligases target the nonreceptor tyrosine kinase ACK1 for ubiquitinylation and proteasomal degradation	ONCOGENE			English	Article						ACK1; estrogen; proteasome; SIAH1; SIAH2; TNK2	BREAST-CANCER-CELLS; ANDROGEN RECEPTOR; DOWN-REGULATION; E3 LIGASE; STABILITY; PATHWAY; ACTIVATION; EXPRESSION; PROTEINS; PHOSPHORYLATION	Activated Cdc42-associated kinase 1 (ACK1) is a nonreceptor tyrosine kinase linked to cellular transformation. The aberrant regulation of ACK1 promotes tumor progression and metastasis. Therefore, ACK1 is regarded as a valid target in cancer therapy. Seven in absentia homolog (SIAH) ubiquitin ligases facilitate substrate ubiquitinylation that targets proteins to the proteasomal degradation pathway. Here we report that ACK1 and SIAH1 from Homo sapiens interact in a yeast two-hybrid screen. Protein-protein interaction studies and protein degradation analyses using deletion and point mutants of ACK1 verify that SIAH1 and the related SIAH2 interact with ACK1. The association between SIAHs and ACK1 depends on the integrity of a highly conserved SIAH-binding motif located in the far C-terminus of ACK1. Furthermore, we demonstrate that the interaction of ACK1 with SIAH1 and the induction of proteasomal degradation of ACK1 by SIAH1 are independent of ACK1's kinase activity. Chemical inhibitors blocking proteasomal activity corroborate that SIAH1 and SIAH2 destabilize the ACK1 protein by inducing its proteasomal turnover. This mechanism apparently differs from the lysosomal pathway targeting ACK1 after stimulation with the epidermal growth factor. Our data also show that ACK1, but not ACK1 mutants lacking the SIAH binding motif, has a discernable negative effect on SIAH levels. Additionally, knockdown approaches targeting the SIAH2 mRNA uncover specifically that the induction of SIAH2 expression, by hormonally-induced estrogen receptor (ER) activation, decreases the levels of ACK1 in luminal human breast cancer cells. Collectively, our data provide novel insights into the molecular mechanisms modulating ACK1 and they position SIAH ubiquitin ligases as negative regulators of ACK1 in transformed cells.	[Buchwald, M.; Pietschmann, K.; Brand, P.; Heinzel, T.; Kraemer, O. H.] Univ Jena, Ctr Mol Biomed, Inst Biochem & Biophys, D-07745 Jena, Germany; [Guenther, A.] Univ Giessen, Lung Ctr, Dept Internal Med 2, D-35390 Giessen, Germany; [Mahajan, N. P.] Univ S Florida, H Lee Moffitt Canc Ctr, Drug Discovery Dept, Tampa, FL 33682 USA	Friedrich Schiller University of Jena; Justus Liebig University Giessen; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Kramer, OH (corresponding author), Univ Jena, Ctr Mol Biomed, Inst Biochem & Biophys, Hans Knoll St 2, D-07745 Jena, Germany.	Oliver.Kraemer@uni-jena.de	Heinzel, Thorsten/B-1013-2015; Krämer, Oliver H/L-9266-2015	Krämer, Oliver H/0000-0003-3973-045X	German Cancer Aid [FKZ102362]; Wilhelm-Sander Foundation [2010.078.1]; NATIONAL CANCER INSTITUTE [R01CA135328] Funding Source: NIH RePORTER	German Cancer Aid(Deutsche Krebshilfe); Wilhelm-Sander Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank C. Kosan, M. Korfei and S. Scheiding for their discussions and their excellent help. We are grateful to M. Kogl, N. Varin-Blank, Z. Ronai, R. Marschalek, H. Bursen, A. Baniahmad, O. Werz and O. Huber for providing material. Grant support: German Cancer Aid (FKZ102362); Wilhelm-Sander Foundation (No. 2010.078.1).	Ahmed AU, 2008, JNCI-J NATL CANCER I, V100, P1606, DOI 10.1093/jnci/djn365; Buchwald M, 2010, LEUKEMIA, V24, P1412, DOI 10.1038/leu.2010.114; Bursen A, 2004, ONCOGENE, V23, P6237, DOI 10.1038/sj.onc.1207837; Calzado MA, 2009, NAT CELL BIOL, V11, P85, DOI 10.1038/ncb1816; Chan W, 2009, J BIOL CHEM, V284, P8185, DOI 10.1074/jbc.M806877200; Chua BT, 2010, MOL ONCOL, V4, P323, DOI 10.1016/j.molonc.2010.03.001; Depaux A, 2006, BIOCHEM BIOPH RES CO, V348, P857, DOI 10.1016/j.bbrc.2006.07.092; Frasor J, 2005, P NATL ACAD SCI USA, V102, P13153, DOI 10.1073/pnas.0502782102; Fukushima T, 2006, IMMUNITY, V24, P29, DOI 10.1016/j.immuni.2005.12.002; Habelhah H, 2002, EMBO J, V21, P5756, DOI 10.1093/emboj/cdf576; Holliday DL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2889; House CM, 2006, STRUCTURE, V14, P695, DOI 10.1016/j.str.2005.12.013; House CM, 2009, CANCER RES, V69, P8835, DOI 10.1158/0008-5472.CAN-09-1676; Howlin J, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2087; Jansen MPHM, 2009, BREAST CANCER RES TR, V116, P263, DOI 10.1007/s10549-008-0125-z; Khurana A, 2006, J BIOL CHEM, V281, P35316, DOI 10.1074/jbc.M606568200; Korzeniewski N, 2010, MOL BIOL CELL, V21, P3942, DOI 10.1091/mbc.E09-12-1049; Kramer OH, 2008, FASEB J, V22, P1369, DOI 10.1096/fj.06-8050com; Kramer OH, 2003, EMBO J, V22, P3411, DOI 10.1093/emboj/cdg315; Kramer OH, 2012, LEUKEMIA IN PRESS; Li C, 2004, ONCOGENE, V23, P9336, DOI 10.1038/sj.onc.1208114; Lin Qi, 2010, Bulletin of Botanical Research, V30, P4; Liu M, 2012, MOL CELL, V46, P325, DOI 10.1016/j.molcel.2012.03.007; Lu M, 2005, ONCOGENE, V24, P4362, DOI 10.1038/sj.onc.1208661; Mahajan K, 2012, AM J PATHOL, V180, P1386, DOI 10.1016/j.ajpath.2011.12.028; Mahajan K, 2010, PROSTATE, V70, P1274, DOI 10.1002/pros.21163; Mahajan K, 2010, J CELL PHYSIOL, V224, P327, DOI 10.1002/jcp.22162; Mahajan K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009646; Mahajan NP, 2005, CANCER RES, V65, P10514, DOI 10.1158/0008-5472.CAN-05-1127; Mahajan NP, 2007, P NATL ACAD SCI USA, V104, P8438, DOI 10.1073/pnas.0700420104; Metzger MB, 2012, J CELL SCI, V125, P531, DOI 10.1242/jcs.091777; Mogk A, 2007, TRENDS CELL BIOL, V17, P165, DOI 10.1016/j.tcb.2007.02.001; Nadeau RJ, 2007, J CELL BIOCHEM, V100, P151, DOI 10.1002/jcb.21040; Nagano Y, 2011, CELL CYCLE, V10, P2592, DOI 10.4161/cc.10.15.16912; Osborne CK, 2011, CLIN CANCER RES, V17, P1147, DOI 10.1158/1078-0432.CCR-10-1869; Pao-Chun L, 2009, J BIOL CHEM, V284, P34954, DOI 10.1074/jbc.M109.072660; Perissi V, 2008, MOL CELL, V29, P755, DOI 10.1016/j.molcel.2008.01.020; Pietschmann K, 2012, MOL CANC TH IN PRESS; Pietschmann K, 2012, INT J BIOCHEM CELL B, V44, P132, DOI 10.1016/j.biocel.2011.10.008; Prieto-Echagile V., 2011, J SIGNAL TRANSDUCT, V2011; Sarkar TR, 2012, MOL CELL BIOL, V32, P320, DOI 10.1128/MCB.05790-11; Stebbing J, 2012, ONCOGENE IN PRESS; Twomey E, 2010, EXP CELL RES, V316, P68, DOI 10.1016/j.yexcr.2009.09.001; van der Horst EH, 2005, P NATL ACAD SCI USA, V102, P15901, DOI 10.1073/pnas.0508014102; Venables JP, 2004, HUM MOL GENET, V13, P1525, DOI 10.1093/hmg/ddh165; Wen YY, 2010, MOL CARCINOGEN, V49, P440, DOI 10.1002/mc.20615; Wen YY, 2010, CANCER SCI, V101, P73, DOI 10.1111/j.1349-7006.2009.01339.x; Winter M, 2008, NAT CELL BIOL, V10, P812, DOI 10.1038/ncb1743; Wu HL, 2010, BIOCHEM BIOPH RES CO, V397, P391, DOI 10.1016/j.bbrc.2010.05.024; Xu ZH, 2006, J BIOL CHEM, V281, P303, DOI 10.1074/jbc.M509060200; Yokoyama N, 2003, J BIOL CHEM, V278, P47713, DOI 10.1074/jbc.M306716200; Yun S, 2008, J BIOL CHEM, V283, P1034, DOI 10.1074/jbc.M705874200; Zhao HL, 2010, BIOCHEM BIOPH RES CO, V399, P623, DOI 10.1016/j.bbrc.2010.07.127	53	26	29	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2013	32	41					4913	4920		10.1038/onc.2012.515	http://dx.doi.org/10.1038/onc.2012.515			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235KQ	23208506	Green Accepted			2022-12-17	WOS:000325717800007
J	Ray-David, H; Romeo, Y; Lavoie, G; Deleris, P; Tcherkezian, J; Galan, JA; Roux, PP				Ray-David, H.; Romeo, Y.; Lavoie, G.; Deleris, P.; Tcherkezian, J.; Galan, J. A.; Roux, P. P.			RSK promotes G2 DNA damage checkpoint silencing and participates in melanoma chemoresistance	ONCOGENE			English	Article						MAPK; RSK; Chk1; DNA damage; melanoma; chemoresistance	RIBOSOMAL S6 KINASE; SIGNAL-REGULATED KINASE; PROTEIN-KINASE; CHK1; PHOSPHORYLATION; RAS; INHIBITION; RESISTANCE; SURVIVAL; PATHWAY	The incidence of malignant melanoma is growing rapidly worldwide and there is still no effective therapy for metastatic disease. This type of cancer is highly resistant to conventional DNA-damaging chemotherapeutics, and intense research has been dedicated for understanding the molecular pathways underlying chemoresistance. The Ras/mitogen-activated protein kinase (MAPK) signalling pathway is often deregulated in melanoma, which frequently harbours activating mutations in NRAS or BRAF. Herein, we demonstrate that the MAPK-activated protein kinase RSK (p90 ribosomal S6 kinase) contributes to melanoma chemoresistance by altering their response to chemotherapeutic agents. We find that RSK phosphorylates checkpoint kinase 1 (Chk1) at an inhibitory site, Ser280, both in vitro and in vivo. Our results indicate that RSK is the predominant protein kinase operating downstream of mitogens and oncogenes of the Ras/MAPK pathway, and consistent with this, we find that RSK constitutively phosphorylates Chk1 in melanoma. We show that RSK inhibition increases Chk1 activity in response to DNA-damaging agents, suggesting that the Ras/MAPK pathway modulates Chk1 function and the response to DNA damage. Accordingly, we demonstrate that RSK promotes G2 DNA damage checkpoint silencing in a Chk1-dependent manner, and find that RSK inhibitors sensitize melanoma cells to DNA-damaging agents. Together, our results identify a novel link between the Ras/MAPK pathway and the DNA damage response, and suggest that RSK inhibitors may be used to modulate chemosensitivity, which is one of the major obstacles to melanoma treatment.	[Ray-David, H.; Romeo, Y.; Lavoie, G.; Deleris, P.; Tcherkezian, J.; Galan, J. A.; Roux, P. P.] Univ Montreal, Inst Res Immunol & Canc, Montreal, PQ H3C 3J7, Canada; [Roux, P. P.] Univ Montreal, Fac Med, Dept Pathol & Cell Biol, Montreal, PQ H3C 3J7, Canada	Universite de Montreal; Universite de Montreal	Roux, PP (corresponding author), Univ Montreal, Inst Res Immunol & Canc, POB 6128,Stn Ctr Ville, Montreal, PQ H3C 3J7, Canada.	philippe.roux@umontreal.ca	Roux, Philippe P./J-3996-2012; Romeo, Yves/AAC-1669-2021	Roux, Philippe P./0000-0002-5962-0250; Galan, Jacob/0000-0003-3304-0474	Canadian Cancer Society Research Institute [700878]; Cancer Research Society [DF121153]; Canadian Institutes of Health Research (CIHR)	Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS)); Cancer Research Society; Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR))	We thank all the members of our laboratory for their insightful discussions and comments on the manuscript and the data. This work was supported by grants from the Canadian Cancer Society Research Institute (700878) and the Cancer Research Society (DF121153) PP Roux holds a Canada Research Chair in Signal Transduction and Proteomics. JA Galan holds a postdoctoral fellowship from the Canadian Institutes of Health Research (CIHR). IRIC core facilities are supported by the FRSQ.	Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Cargnello M, 2011, MICROBIOL MOL BIOL R, V75, P50, DOI 10.1128/MMBR.00031-10; Caron E, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.68; Carriere A, 2008, CURR BIOL, V18, P1269, DOI 10.1016/j.cub.2008.07.078; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Chen Y, 2008, FRONT BIOSCI-LANDMRK, V13, P5016; Clark DE, 2005, CANCER RES, V65, P3108; Cohen MS, 2005, SCIENCE, V308, P1318, DOI 10.1126/science1108367; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dhomen N, 2007, CURR OPIN GENET DEV, V17, P31, DOI 10.1016/j.gde.2006.12.005; Eton O, 1998, J CLIN ONCOL, V16, P1103, DOI 10.1200/JCO.1998.16.3.1103; Fecher LA, 2008, CURR OPIN ONCOL, V20, P183, DOI 10.1097/CCO.0b013e3282f5271c; Flaherty KT, 2006, CLIN CANCER RES, V12, p2366S, DOI 10.1158/1078-0432.CCR-05-2505; Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384; Gogas HJ, 2007, CANCER-AM CANCER SOC, V109, P455, DOI 10.1002/cncr.22427; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Joseph EW, 2010, P NATL ACAD SCI USA, V107, P14903, DOI 10.1073/pnas.1008990107; Julien LA, 2010, MOL CELL BIOL, V30, P908, DOI 10.1128/MCB.00601-09; King FW, 2004, CELL CYCLE, V3, P634; Koberle B, 2010, BBA-REV CANCER, V1806, P172, DOI 10.1016/j.bbcan.2010.07.004; Li P, 2012, MOL BIOL CELL, V23, P1582, DOI 10.1091/mbc.E11-10-0883; Liu XS, 2010, PROTEIN CELL, V1, P999, DOI 10.1007/s13238-010-0131-x; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Mamely I, 2006, CURR BIOL, V16, P1950, DOI 10.1016/j.cub.2006.08.026; Markovic SN, 2007, MAYO CLIN PROC, V82, P490, DOI 10.4065/82.4.490; Meloche S, 2007, ONCOGENE, V26, P3227, DOI 10.1038/sj.onc.1210414; Michaloglou C, 2008, ONCOGENE, V27, P877, DOI 10.1038/sj.onc.1210704; Miller AJ, 2006, NEW ENGL J MED, V355, P51, DOI 10.1056/NEJMra052166; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Niida H, 2007, MOL CELL BIOL, V27, P2572, DOI 10.1128/MCB.01611-06; Old WM, 2009, MOL CELL, V34, P115, DOI 10.1016/j.molcel.2009.03.007; Peschiaroli A, 2006, MOL CELL, V23, P319, DOI 10.1016/j.molcel.2006.06.013; Puc J, 2005, CANCER CELL, V7, P193, DOI 10.1016/j.ccr.2005.01.009; Romeo Y, 2012, BIOCHEM J, V441, P553, DOI 10.1042/BJ20110289; Romeo Y, 2011, EXPERT OPIN THER TAR, V15, P5, DOI 10.1517/14728222.2010.531014; Roux PP, 2007, J BIOL CHEM, V282, P14056, DOI 10.1074/jbc.M700906200; Roux PP, 2003, MOL CELL BIOL, V23, P4796, DOI 10.1128/MCB.23.14.4796-4804.2003; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; Rubinfeld H, 2005, MOL BIOTECHNOL, V31, P151, DOI 10.1385/MB:31:2:151; Sapkota GP, 2007, BIOCHEM J, V401, P29, DOI 10.1042/BJ20061088; Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109; Shtivelman E, 2002, CURR BIOL, V12, P919, DOI 10.1016/S0960-9822(02)00843-6; Smith JA, 2005, CANCER RES, V65, P1027; Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; van de Weerdt BCM, 2006, CELL CYCLE, V5, P853, DOI 10.4161/cc.5.8.2692; Walker M, 2009, ONCOGENE, V28, P2314, DOI 10.1038/onc.2009.102; Yoon S, 2006, GROWTH FACTORS, V24, P21, DOI 10.1080/02699050500284218	49	26	29	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2013	32	38					4480	4489		10.1038/onc.2012.472	http://dx.doi.org/10.1038/onc.2012.472			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223SW	23108403				2022-12-17	WOS:000324831300003
J	Peyre, M; Stemmer-Rachamimov, A; Clermont-Taranchon, E; Quentin, S; El-Taraya, N; Walczak, C; Volk, A; Niwa-Kawakita, M; Karboul, N; Giovannini, M; Kalamarides, M				Peyre, M.; Stemmer-Rachamimov, A.; Clermont-Taranchon, E.; Quentin, S.; El-Taraya, N.; Walczak, C.; Volk, A.; Niwa-Kawakita, M.; Karboul, N.; Giovannini, M.; Kalamarides, M.			Meningioma progression in mice triggered by Nf2 and Cdkn2ab inactivation	ONCOGENE			English	Article						meningioma; adenovirus; NF2; CDKN2AB; mouse model	TUMOR-SUPPRESSOR; MALIGNANT PROGRESSION; DCE-MRI; P16(INK4A); GENE; SENESCENCE; BENIGN; RECURRENCE; P15(INK4B); REGRESSION	Aggressive variants of meningiomas (WHO grade II and III) represent up to 30% of those tumors that are among the most common primary central nervous system tumors in adults. Currently, there is no effective treatment for grade-II and -III meningiomas, the main treatment remaining surgical excision. Genetic studies have highlighted two main events associated with meningioma progression: an increase of chromosomal instability in tumors with NF2 inactivation and homozygous deletions or point mutations of the CDKN2AB locus. In this study we demonstrated that in mice, in addition to bi-allelic Nf2 inactivation, homozygous and heterozygous Adenovirus Cre-mediated Cdkn2ab deletions lead to increased meningioma frequency (72% and 50%, respectively) with a shorter latency (3.5 and 7.8 months, respectively) compared with control cohorts and induce grade II/III meningioma progression with an incidence of 34% and 28%, respectively. Moreover, Cdkn2ab inactivation in arachnoidal cells was associated with decreased senescence compared with Nf2(-/-) and wild-type arachnoidal cells in vitro. We have established three mouse meningioma cell lines and generated a syngenic orthotopic meningioma mouse model with 50-100% grade-II/III meningiomas after reimplantation. Comparative genomic hybridization of four meningiomas from Cdkn2ab homozygous mice and three cell cultures revealed the absence of unbalanced chromosomal segments in tumors and several chromosome imbalances in cell cultures. In addition, we were able to detect meningiomas by using bioluminescence and to evaluate tumor vascular permeability by dynamic magnetic resonance imaging. These results show that Nf2 and Cdkn2ab cooperate to promote meningioma progression in mice. The short latency of tumor development and the ability to derive grade II/III meningioma cell cultures are key aspects of this model to promote its use in pre-clinical drug testing.	[Peyre, M.; Kalamarides, M.] Hop Beaujon, AP HP, Dept Neurosurg, F-92110 Clichy, France; [Peyre, M.; Clermont-Taranchon, E.; Niwa-Kawakita, M.; Karboul, N.; Kalamarides, M.] Univ Paris 07, Paris, France; [Peyre, M.; Clermont-Taranchon, E.; Niwa-Kawakita, M.; Karboul, N.; Kalamarides, M.] Fdn Jean Dausset, Unite Inserm U674, Paris, France; [Stemmer-Rachamimov, A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neuropathol, Boston, MA USA; [Quentin, S.] Inst Univ Hematol, INSERM, U944, Paris, France; [El-Taraya, N.; Walczak, C.; Volk, A.] Univ Paris 11, INSERM, U759, F-91405 Orsay, France; [El-Taraya, N.; Walczak, C.; Volk, A.] Inst Curie, Ctr Rech, F-91405 Orsay, France; [Giovannini, M.] House Res Inst, Los Angeles, CA USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Foundation Jean Dausset-CEPH; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Harvard University; Harvard Medical School; Massachusetts General Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Saclay; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Kalamarides, M (corresponding author), Hop Beaujon, AP HP, Dept Neurosurg, 100 Blvd Gen Leclerc, F-92110 Clichy, France.	michel.kalamarides@bjn.aphp.fr	Volk, Andreas/A-8474-2019	Volk, Andreas/0000-0003-0915-5458; Kawakita, Michiko/0000-0002-9450-583X; Peyre, Matthieu/0000-0001-8470-9516	Association pour la Recherche sur le Cancer; Ligue Nationale contre le Cancer-comite Paris; Fondation Anber; Association Neurofibromatoses et Recklinghausen; Inserm	Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Ligue Nationale contre le Cancer-comite Paris; Fondation Anber; Association Neurofibromatoses et Recklinghausen; Inserm(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission)	We thank A Berns for Ink4ab<SUP>-/+</SUP> mutant mice, M Pla and staff of the Institut Universitaire d'Hematologie (IUH), Universite Paris 7, for mouse housing. We also thank J Calderaro and G Morcrette for their help in additional pathological analyses. This work was supported by Grants from the Association pour la Recherche sur le Cancer (subvention fixe and funding to MP), Ligue Nationale contre le Cancer-comite Paris, Fondation Anber, Association Neurofibromatoses et Recklinghausen (to ECT and NK) and Inserm.	Aghi MK, 2009, NEUROSURGERY, V64, P56, DOI 10.1227/01.NEU.0000330399.55586.63; Al-Mefty O, 2004, J NEUROSURG, V101, P210, DOI 10.3171/jns.2004.101.2.0210; Bostrom J, 2001, AM J PATHOL, V159, P661, DOI 10.1016/S0002-9440(10)61737-3; Buschges R, 2002, BRAIN PATHOL, V12, P145; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772; Evans DGR, 2006, J MED GENET, V43, P289, DOI 10.1136/jmg.2005.036319; Gaya A, 2008, BRIT J CANCER, V99, P321, DOI 10.1038/sj.bjc.6604426; Goutagny S, 2011, ANN ONCOL, V22, P990, DOI 10.1093/annonc/mdr012; Goutagny S, 2010, CLIN CANCER RES, V16, P4155, DOI 10.1158/1078-0432.CCR-10-0891; Hanft S, 2010, J NEURO-ONCOL, V99, P433, DOI 10.1007/s11060-010-0348-9; James MF, 2008, NEUROBIOL DIS, V29, P278, DOI 10.1016/j.nbd.2007.09.002; Jongsma J, 2008, CANCER CELL, V13, P261, DOI 10.1016/j.ccr.2008.01.030; Kalamarides M, 2002, GENE DEV, V16, P1060, DOI 10.1101/gad.226302; Kalamarides M, 2008, BRAIN PATHOL, V18, P62, DOI 10.1111/j.1750-3639.2007.00105.x; Kamijo T, 1999, CANCER RES, V59, P2217; Kim WY, 2006, CELL, V127, P265, DOI 10.1016/j.cell.2006.10.003; Korshunov A, 2003, INT J CANCER, V104, P728, DOI 10.1002/ijc.11013; Krimpenfort P, 2007, NATURE, V448, P943, DOI 10.1038/nature06084; Lamszus K, 2000, J NEUROPATH EXP NEUR, V59, P504, DOI 10.1093/jnen/59.6.504; Leone PE, 1999, ONCOGENE, V18, P2231, DOI 10.1038/sj.onc.1202531; Lopez-Gines C, 2004, CANCER GENET CYTOGEN, V148, P123, DOI 10.1016/S0165-4608(03)00279-6; Lou E, 2012, J NEURO-ONCOL, V109, P63, DOI 10.1007/s11060-012-0861-0; Louis DN, 2007, WHO CLASSIFICATION T; Loveless ME, 2012, NEOPLASIA, V14, P54, DOI 10.1593/neo.111478; Lyons SK, 2003, CANCER RES, V63, P7042; Menon AG, 1997, ONCOGENE, V14, P611, DOI 10.1038/sj.onc.1200853; Mihaila D, 2003, CLIN CANCER RES, V9, P4443; Morrison JP, 2007, TOXICOL PATHOL, V35, P838, DOI 10.1080/01926230701584130; Perry A, 2002, BRAIN PATHOL, V12, P183; Pistolesi S, 2004, NEUROPATH APPL NEURO, V30, P118, DOI 10.1046/j.0305-1846.2003.00516.x; Puchner MJA, 2010, ANN ONCOL, V21, P2445, DOI 10.1093/annonc/mdq634; Ragel BT, 2008, SURG NEUROL, V70, P295, DOI 10.1016/j.surneu.2007.06.031; Riemenschneider MJ, 2006, LANCET NEUROL, V5, P1045, DOI 10.1016/S1474-4422(06)70625-1; Romagosa C, 2011, ONCOGENE, V30, P2087, DOI 10.1038/onc.2010.614; RUTTLEDGE MH, 1994, NAT GENET, V6, P180, DOI 10.1038/ng0294-180; Sharpless NE, 2004, ONCOGENE, V23, P379, DOI 10.1038/sj.onc.1207074; Simon M, 2001, J NEURO-ONCOL, V55, P149, DOI 10.1023/A:1013863630293; Sotillo R, 2009, CANCER CELL, V16, P451, DOI 10.1016/j.ccr.2009.11.014; Vautier J, 2010, MAGN RESON MED, V64, P313, DOI 10.1002/mrm.22396; Weber RG, 1997, P NATL ACAD SCI USA, V94, P14719, DOI 10.1073/pnas.94.26.14719	41	26	26	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2013	32	36					4264	4272		10.1038/onc.2012.436	http://dx.doi.org/10.1038/onc.2012.436			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214WL	23045274				2022-12-17	WOS:000324168000008
J	Guo, L; Liew, HP; Camus, S; Goh, AM; Chee, LL; Lunny, DP; Lane, EB; Lane, DP				Guo, L.; Liew, H. P.; Camus, S.; Goh, A. M.; Chee, L. L.; Lunny, D. P.; Lane, E. B.; Lane, D. P.			Ionizing radiation induces a dramatic persistence of p53 protein accumulation and DNA damage signaling in mutant p53 zebrafish	ONCOGENE			English	Article						mutant; p53 protein; DNA damage; ionizing radiation; zebrafish; stability	SMALL-MOLECULE INHIBITORS; MDM2; GAIN; ACTIVATION; PATHWAY; INSTABILITY; EXPRESSION; LIGASE; DOMAIN; P63	Mutant p53 proteins accumulate to high levels in human tumors and in preneoplastic lesions in the skin and fallopian tube. However examination of tissues from mice and fish that are homozygous for mutant p53 surprisingly showed that the protein was present only at low levels except in the tumors that arose in these animals. The mutant protein did accumulate, however, following treatment with ionizing radiation in the same tissues in which the wild-type protein is induced. Here we study in detail the accumulation of mutant and wild-type p53 proteins following ionizing radiation in zebrafish embryos. We found that the mutant protein was induced by lower levels of radiation and reached higher levels than the wild-type protein. Morpholino knockdown of the zebrafish homologs of Mdm2 and Mdm4 caused dramatic accumulation of mutant p53 protein. The most remarkable results were observed by examining p53 protein levels over an extended time course. Mutant p53 protein increased and persisted for days after irradiation and this was accompanied by persistent elevation of phosphorylated H2AX (gamma H2AX), implying that the resolution of DNA damage signaling in these embryos is severely compromised by mutations in p53. Thus mutation in p53 results in an exaggerated and persistent damage response, which could in turn drive the process of cancer development as high levels of mutant p53 can act as an oncoprotein to drive invasion and metastasis.	[Guo, L.; Liew, H. P.; Camus, S.; Goh, A. M.; Chee, L. L.; Lane, D. P.] Inst Biomed Sci, Lab P53, Singapore 138648, Singapore; [Lunny, D. P.; Lane, E. B.] Inst Biomed Sci, Epithelial Biol Lab, Singapore 138648, Singapore		Lane, DP (corresponding author), Inst Biomed Sci, Lab P53, 8A Biomed Grove,Immunos 06-06, Singapore 138648, Singapore.	dplane@p53lab.a-star.edu.sg		Lane, David/0000-0003-0551-3545	Biomedical Research Council of Singapore	Biomedical Research Council of Singapore(Agency for Science Technology & Research (A*STAR))	We thank Dr Hwang Le-Ann from the Molecular Antibody Unit at the Institute of Molecular and Cell Biology for providing us the ZFp53-5.1 and ZFp53-9.1 antibodies. The zebrafish tp53<SUP>m214k</SUP> mutant line was generously provided by Professor A Thomas Look (Dana Farber Cancer Institute, Boston, MA, USA). Adult zebrafish was processed and sectioned by the Biopolis Shared Facility Histology Unit. All the adult zebrafish were maintained by zebrafish facility at the Institute of Molecular and Cell Biology. This work was supported by the Biomedical Research Council of Singapore.	BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARTEK J, 1991, ONCOGENE, V6, P1699; Berghmans S, 2005, P NATL ACAD SCI USA, V102, P407, DOI 10.1073/pnas.0406252102; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Ding K, 2006, J MED CHEM, V49, P3432, DOI 10.1021/jm051122a; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Flores ER, 2005, CANCER CELL, V7, P363, DOI 10.1016/j.ccr.2005.02.019; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Guo L, 2010, CELL CYCLE, V9, P1998, DOI 10.4161/cc.9.10.11732; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Huang L, 2011, P NATL ACAD SCI USA, V108, P12001, DOI 10.1073/pnas.1102309108; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; Iyappan S, 2010, J BIOL CHEM, V285, P33065, DOI 10.1074/jbc.M110.115113; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Lee KC, 2008, ONCOGENE, V27, P629, DOI 10.1038/sj.onc.1210695; Li Y, 2007, ONCOGENE, V26, P2220, DOI 10.1038/sj.onc.1210311; Linke K, 2008, CELL DEATH DIFFER, V15, P841, DOI 10.1038/sj.cdd.4402309; MELTZER PS, 1994, J NATL CANCER I, V86, P1265, DOI 10.1093/jnci/86.17.1265; Messner DJ, 2006, J CELL BIOCHEM, V99, P241, DOI 10.1002/jcb.20919; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Pant V, 2011, P NATL ACAD SCI USA, V108, P11995, DOI 10.1073/pnas.1102241108; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Plechanovova A, 2011, NAT STRUCT MOL BIOL, V18, P1052, DOI 10.1038/nsmb.2108; Robu ME, 2007, PLOS GENET, V3, P787, DOI 10.1371/journal.pgen.0030078; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Song H, 2007, NAT CELL BIOL, V9, P573, DOI 10.1038/ncb1571; Suh YA, 2011, CANCER RES, V71, P7168, DOI 10.1158/0008-5472.CAN-11-0459; Terzian T, 2008, GENE DEV, V22, P1337, DOI 10.1101/gad.1662908; van Leeuwen IMM, 2011, CELL CYCLE, V10, P1590, DOI 10.4161/cc.10.10.15519; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Walsh T, 2011, P NATL ACAD SCI USA, V108, P18032, DOI 10.1073/pnas.1115052108; Wang XJ, 2011, CELL CYCLE, V10, P4225, DOI 10.4161/cc.10.24.18662; Wang XJ, 2011, J BIOL CHEM, V286, P23725, DOI 10.1074/jbc.M110.213868; Xu J, 2011, NAT CHEM BIOL, V7, P285, DOI 10.1038/nchembio.546; Yang YL, 2005, CANCER CELL, V7, P547, DOI 10.1016/j.ccr.2005.04.029; Zeng ZQ, 2009, ZEBRAFISH, V6, P405, DOI 10.1089/zeb.2009.0611	39	26	27	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2013	32	34					4009	4016		10.1038/onc.2012.409	http://dx.doi.org/10.1038/onc.2012.409			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IC	23069659				2022-12-17	WOS:000323748100009
J	Granit, RZ; Gabai, Y; Hadar, T; Karamansha, Y; Liberman, L; Waldhorn, I; Gat-Viks, I; Regev, A; Maly, B; Darash-Yahana, M; Peretz, T; Ben-Porath, I				Granit, R. Z.; Gabai, Y.; Hadar, T.; Karamansha, Y.; Liberman, L.; Waldhorn, I.; Gat-Viks, I.; Regev, A.; Maly, B.; Darash-Yahana, M.; Peretz, T.; Ben-Porath, I.			EZH2 promotes a bi-lineage identity in basal-like breast cancer cells	ONCOGENE			English	Article						basal-like; breast cancer; differentiation; EZH2; Polycomb; GATA3	STEM-CELLS; POLYCOMB; GATA-3; MUTATION; FATE; DIFFERENTIATION; IDENTIFICATION; MORPHOGENESIS; PROGENITORS; POPULATION	The mechanisms regulating breast cancer differentiation state are poorly understood. Of particular interest are molecular regulators controlling the highly aggressive and poorly differentiated traits of basal-like breast carcinomas. Here we show that the Polycomb factor EZH2 maintains the differentiation state of basal-like breast cancer cells, and promotes the expression of progenitor-associated and basal-lineage genes. Specifically, EZH2 regulates the composition of basal-like breast cancer cell populations by promoting a 'bi-lineage' differentiation state, in which cells co-express basal- and luminal-lineage markers. We show that human basal-like breast cancers contain a subpopulation of bi-lineage cells, and that EZH2-deficient cells give rise to tumors with a decreased proportion of such cells. Bi-lineage cells express genes that are active in normal luminal progenitors, and possess increased colony-formation capacity, consistent with a primitive differentiation state. We found that GATA3, a driver of luminal differentiation, performs a function opposite to EZH2, acting to suppress bi-lineage identity and luminal-progenitor gene expression. GATA3 levels increase upon EZH2 silencing, mediating a decrease in bi-lineage cell numbers. Our findings reveal a novel role for EZH2 in controlling basal-like breast cancer differentiation state and intra-tumoral cell composition.	[Granit, R. Z.; Gabai, Y.; Hadar, T.; Karamansha, Y.; Liberman, L.; Waldhorn, I.; Ben-Porath, I.] Hebrew Univ Jerusalem, Hadassah Med Sch, Inst Med Res Israel Canada, Dept Dev Biol & Canc Res, IL-91120 Jerusalem, Israel; [Hadar, T.] Hadassah Med Ctr, Dept Surg, IL-91120 Jerusalem, Israel; [Gat-Viks, I.; Regev, A.] Broad Inst Harvard & MIT, Cambridge, MA USA; [Gat-Viks, I.; Regev, A.] MIT, Dept Biol, Cambridge, MA USA; [Maly, B.] Hadassah Med Ctr, Dept Pathol, IL-91120 Jerusalem, Israel; [Darash-Yahana, M.; Peretz, T.] Hadassah Med Ctr, Sharett Inst Oncol, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hadassah University Medical Center; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Massachusetts Institute of Technology (MIT); Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Hadassah University Medical Center	Ben-Porath, I (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Inst Med Res Israel Canada, Dept Dev Biol & Canc Res, IL-91120 Jerusalem, Israel.	ittaibp@mail.huji.ac.il		Granit, Roy Zvi/0000-0002-6487-2559	Israel Science Foundation [1560/07]; Israel Cancer Association; Israel Cancer Research Foundation; Joint Research Fund IMRIC-Hadassah	Israel Science Foundation(Israel Science Foundation); Israel Cancer Association; Israel Cancer Research Foundation; Joint Research Fund IMRIC-Hadassah	We thank Eli Pikarsky, Yuval Dor and Yehudit Bergman for critical reviewing of the manuscript, Marius Wernig for the Fip-EZH2 construct, Alex Roesch and Meenhard Herlyn for the pLU-JARID1Bp-GFP-Blast<SUP>R</SUP> construct and Sabine Werner for the CK14 promoter plasmid. We thank Norma E. Kidess-Bassir for histological support. This study was supported by the Israel Science Foundation (Grant 1560/07), the Israel Cancer Association, the Israel Cancer Research Foundation, and the Joint Research Fund IMRIC-Hadassah.	Alford SH, 2012, BREAST CANCER RES TR, V132, P429, DOI 10.1007/s10549-011-1591-2; Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530; Asselin-Labat ML, 2011, MOL CELL BIOL, V31, P4609, DOI 10.1128/MCB.05766-11; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bouras T, 2008, CELL STEM CELL, V3, P429, DOI 10.1016/j.stem.2008.08.001; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Chang CJ, 2011, CANCER CELL, V19, P86, DOI 10.1016/j.ccr.2010.10.035; Debnath J, 2005, NAT REV CANCER, V5, P675, DOI 10.1038/nrc1695; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Gonzalez ME, 2009, ONCOGENE, V28, P843, DOI 10.1038/onc.2008.433; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; Gusterson BA, 2005, BREAST CANCER RES, V7, P143, DOI 10.1186/bcr1041; Gusterson B, 2009, NAT REV CANCER, V9, P128, DOI 10.1038/nrc2571; Hock H, 2012, GENE DEV, V26, P751, DOI 10.1101/gad.191163.112; Keller PJ, 2012, P NATL ACAD SCI USA, V109, P2772, DOI 10.1073/pnas.1017626108; Kenny PA, 2007, MOL ONCOL, V1, P84, DOI 10.1016/j.molonc.2007.02.004; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Kouros-Mehr H, 2008, CANCER CELL, V13, P141, DOI 10.1016/j.ccr.2008.01.011; Kouros-Mehr H, 2006, CELL, V127, P1041, DOI 10.1016/j.cell.2006.09.048; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Livasy CA, 2006, MODERN PATHOL, V19, P264, DOI 10.1038/modpathol.3800528; Mehra R, 2005, CANCER RES, V65, P11259, DOI 10.1158/0008-5472.CAN-05-2495; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007; Pietersen AM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2214; Prat A, 2011, MOL ONCOL, V5, P5, DOI 10.1016/j.molonc.2010.11.003; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Proia TA, 2011, CELL STEM CELL, V8, P149, DOI 10.1016/j.stem.2010.12.007; Rakha EA, 2009, BREAST CANCER RES TR, V113, P411, DOI 10.1007/s10549-008-9952-1; Richter GHS, 2009, P NATL ACAD SCI USA, V106, P5324, DOI 10.1073/pnas.0810759106; Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002; Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991; Spike BT, 2012, CELL STEM CELL, V10, P183, DOI 10.1016/j.stem.2011.12.018; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Suva ML, 2009, CANCER RES, V69, P9211, DOI 10.1158/0008-5472.CAN-09-1622; Usary J, 2004, ONCOGENE, V23, P7669, DOI 10.1038/sj.onc.1207966; Van Keymeulen A, 2011, NATURE, V479, P189, DOI 10.1038/nature10573; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Visvader JE, 2009, GENE DEV, V23, P2563, DOI 10.1101/gad.1849509; Yu J, 2007, CANCER CELL, V12, P419, DOI 10.1016/j.ccr.2007.10.016; Zhang M, 2008, CANCER RES, V68, P4674, DOI 10.1158/0008-5472.CAN-07-6353; Zufferey R, 1998, J VIROL, V72, P9873, DOI 10.1128/JVI.72.12.9873-9880.1998	44	26	28	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2013	32	33					3886	3895		10.1038/onc.2012.390	http://dx.doi.org/10.1038/onc.2012.390			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202JH	22986524	Green Submitted			2022-12-17	WOS:000323210200011
J	Chen, DWC; Saha, V; Liu, JZ; Schwartz, JM; Krstic-Demonacos, M				Chen, D. W-C; Saha, V.; Liu, J-Z; Schwartz, J-M; Krstic-Demonacos, M.			Erg and AP-1 as determinants of glucocorticoid response in acute lymphoblastic leukemia	ONCOGENE			English	Article						glucocorticoid receptor; gene expression; systems biology; dynamic model	TRANSCRIPTION FACTOR ERG; FACTOR-KAPPA-B; GENE-EXPRESSION; C-JUN; INDUCED APOPTOSIS; TMPRSS2-ERG FUSION; BH3-ONLY PROTEINS; JNK PATHWAY; RECEPTOR; CELLS	Glucocorticoids (GCs) are among the most widely prescribed medications in clinical practice. The beneficial effects of GCs in acute lymphoblastic leukemia (ALL) are based on their ability to induce apoptosis, but the underlying transcriptional mechanisms remain poorly defined. Computational modeling has enormous potential in the understanding of biological processes such as apoptosis and the discovery of novel regulatory mechanisms. We here present an integrated analysis of gene expression kinetic profiles using microarrays from GC sensitive and resistant ALL cell lines and patients, including newly generated and previously published data sets available from the Gene Expression Omnibus. By applying time-series clustering analysis in the sensitive ALL CEM-C7-14 cells, we identified 358 differentially regulated genes that we classified into 15 kinetic profiles. We identified GC response element (GRE) sequences in 33 of the upregulated known or potential GC receptor (GR) targets. Comparative study of sensitive and resistant ALL showed distinct gene expression patterns and indicated unexpected similarities between sensitivity-restored and resistant ALL. We found that activator protein 1 (AP-1), Ets related gene (Erg) and GR pathways were differentially regulated in sensitive and resistant ALL. Erg protein levels were substantially higher in CEM-C1-15-resistant cells, c-Jun was significantly induced in sensitive cells, whereas c-Fos was expressed at low levels in both. c-Jun was recruited on the AP-1 site on the Bim promoter, whereas a transient Erg occupancy on the GR promoter was detected. Inhibition of Erg and activation of GR lead to increased apoptosis in both sensitive and resistant ALL. These novel findings significantly advance our understanding of GC sensitivity and can be used to improve therapy of leukemia.	[Chen, D. W-C; Schwartz, J-M; Krstic-Demonacos, M.] Univ Manchester, Fac Life Sci, Manchester M1 7DN, Lancs, England; [Saha, V.; Liu, J-Z] Univ Manchester, Sch Med, Manchester M1 7DN, Lancs, England; [Chen, D. W-C; Schwartz, J-M; Krstic-Demonacos, M.] Univ Manchester, Fac Life Sci, Manchester Inst Biotechnol, Manchester M1 7DN, Lancs, England	University of Manchester; University of Manchester; University of Manchester	Schwartz, JM (corresponding author), Univ Manchester, Fac Life Sci, Manchester Inst Biotechnol, Manchester M1 7DN, Lancs, England.	jean-marc.schwartz@manchester.ac.uk; m.k.demonacos@manchester.ac.uk	Schwartz, Jean-Marc/AAS-8274-2020	Schwartz, Jean-Marc/0000-0002-6472-0184; Saha, Vaskar/0000-0002-2916-9649				Al-Shahrour F, 2004, BIOINFORMATICS, V20, P578, DOI 10.1093/bioinformatics/btg455; Baldus CD, 2007, J CLIN ONCOL, V25, P3739, DOI 10.1200/JCO.2007.11.5253; Baldus CD, 2006, J CLIN ONCOL, V24, P4714, DOI 10.1200/JCO.2006.06.1580; Barrett TJ, 1996, BIOCHEMISTRY-US, V35, P9746, DOI 10.1021/bi960058j; Basuyaux JP, 1997, J BIOL CHEM, V272, P26188, DOI 10.1074/jbc.272.42.26188; Biddie SC, 2011, MOL CELL, V43, P145, DOI 10.1016/j.molcel.2011.06.016; Birdsey GM, 2008, BLOOD, V111, P3498, DOI 10.1182/blood-2007-08-105346; Biswas SC, 2007, J BIOL CHEM, V282, P29368, DOI 10.1074/jbc.M702634200; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Bruna A, 2003, EMBO J, V22, P6035, DOI 10.1093/emboj/cdg590; Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351; Cai JA, 2010, TRANSL ONCOL, V3, P195, DOI 10.1593/tlo.09328; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Chen DWC, 2010, PHARMACOGENOMICS, V11, P1545, DOI [10.2217/pgs.10.125, 10.2217/PGS.10.125]; Davies L, 2008, MOL ENDOCRINOL, V22, P1331, DOI 10.1210/me.2007-0360; De Bosscher K, 2003, ENDOCR REV, V24, P488, DOI 10.1210/er.2002-0006; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; Erkizan HV, 2009, NAT MED, V15, P750, DOI 10.1038/nm.1983; Erlacher M, 2005, BLOOD, V106, P4131, DOI 10.1182/blood-2005-04-1595; Ernst J, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-191; Ernst J, 2005, BIOINFORMATICS, V21, pI159, DOI 10.1093/bioinformatics/bti1022; Galon J, 2002, FASEB J, V16, P61, DOI 10.1096/fj.01-0245com; Geng CD, 2005, J BIOL CHEM, V280, P43264, DOI 10.1074/jbc.M508245200; Grice EA, 2010, P NATL ACAD SCI USA, V107, P14799, DOI 10.1073/pnas.1004204107; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hollenhorst PC, 2011, GENE DEV, V25, P2147, DOI 10.1101/gad.17546311; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Jaiswal AK, 2004, FREE RADICAL BIO MED, V36, P1199, DOI 10.1016/j.freeradbiomed.2004.02.074; Jin JY, 2003, J PHARMACOL EXP THER, V307, P93, DOI 10.1124/jpet.103.053256; Kettritz R, 2004, J BIOL CHEM, V279, P2657, DOI 10.1074/jbc.M309778200; Krstic MD, 1997, MOL CELL BIOL, V17, P3947, DOI 10.1128/MCB.17.7.3947; Leung KT, 2008, CARCINOGENESIS, V29, P544, DOI 10.1093/carcin/bgm294; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Li L, 2004, J BIOL CHEM, V279, P4058, DOI 10.1074/jbc.M310415200; Loffler M, 1999, ONCOGENE, V18, P4626, DOI 10.1038/sj.onc.1202820; Lynch JT, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-38; Martens JHA, 2011, INT J BIOCHEM CELL B, V43, P1413, DOI 10.1016/j.biocel.2011.05.014; Medh RD, 1998, CANCER RES, V58, P3684; Medh RD, 2001, ONCOGENE, V20, P4629, DOI 10.1038/sj.onc.1204680; Miller AL, 2007, CANCER CELL INT, V7, DOI 10.1186/1475-2867-7-18; MINER JN, 1992, GENE DEV, V6, P2491, DOI 10.1101/gad.6.12b.2491; Mitchell CD, 2005, BRIT J HAEMATOL, V129, P734, DOI 10.1111/j.1365-2141.2005.05509.x; Mittelstadt PR, 2001, J BIOL CHEM, V276, P29603, DOI 10.1074/jbc.M101522200; Pearce D, 1998, J BIOL CHEM, V273, P30081, DOI 10.1074/jbc.273.46.30081; Ploner C, 2008, LEUKEMIA, V22, P370, DOI 10.1038/sj.leu.2405039; Qi XM, 2002, J BIOL CHEM, V277, P25884, DOI 10.1074/jbc.M203039200; Rahim S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019343; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Schmidt D, 2009, METHODS, V48, P240, DOI 10.1016/j.ymeth.2009.03.001; Schmidt S, 2006, BLOOD, V107, P2061, DOI 10.1182/blood-2005-07-2853; Segal E, 2005, NAT GENET, V37, pS38, DOI 10.1038/ng1561; Segal E, 2004, NAT GENET, V36, P1090, DOI 10.1038/ng1434; Seth A, 2005, EUR J CANCER, V41, P2462, DOI 10.1016/j.ejca.2005.08.013; Sevilla L, 1999, MOL CELL BIOL, V19, P2624; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; So AYL, 2007, PLOS GENET, V3, P927, DOI 10.1371/journal.pgen.0030094; Sun C, 2008, ONCOGENE, V27, P5348, DOI 10.1038/onc.2008.183; Thoms JAI, 2011, BLOOD, V117, P7079, DOI 10.1182/blood-2010-12-317990; Tsuzuki S, 2011, BLOOD, V10, P1182; Verger A, 2001, J BIOL CHEM, V276, P17181, DOI 10.1074/jbc.M010208200; Wallace AD, 2001, J BIOL CHEM, V276, P42714, DOI 10.1074/jbc.M106033200; Wang ZQ, 2003, J BIOL CHEM, V278, P23861, DOI 10.1074/jbc.M301843200; Wen LP, 1997, AM J PHYSIOL-LUNG C, V273, pL921, DOI 10.1152/ajplung.1997.273.5.L921; White RJ, 2010, TRENDS GENET, V26, P214, DOI 10.1016/j.tig.2010.02.004; Xenaki G, 2008, ONCOGENE, V27, P5785, DOI 10.1038/onc.2008.192; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6; Yi HK, 1997, ONCOGENE, V14, P1259, DOI 10.1038/sj.onc.1201099; Zhao F, 2005, NUCLEIC ACIDS RES, V33, pD103, DOI 10.1093/nar/gki004; Zhou F, 1996, MOL ENDOCRINOL, V10, P306, DOI 10.1210/me.10.3.306; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	73	26	27	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2013	32	25					3039	3048		10.1038/onc.2012.321	http://dx.doi.org/10.1038/onc.2012.321			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	168KX	22869147				2022-12-17	WOS:000320705700004
J	Jones, KB; Su, L; Jin, H; Lenz, C; Randall, RL; Underhill, TM; Nielsen, TO; Sharma, S; Capecchi, MR				Jones, K. B.; Su, L.; Jin, H.; Lenz, C.; Randall, R. L.; Underhill, T. M.; Nielsen, T. O.; Sharma, S.; Capecchi, M. R.			SS18-SSX2 and the mitochondrial apoptosis pathway in mouse and human synovial sarcomas	ONCOGENE			English	Article						synovial sarcoma; apoptosis; chemotherapy; targeted therapy; mouse model	CELL LINE; BCL-2; EXPRESSION; PROTEIN; INHIBITOR; INSIGHTS; MODEL	Synovial sarcoma is a deadly malignancy with limited sensitivity to traditional cytotoxic chemotherapy. SS18-SSX fusion oncogene expression characterizes human synovial sarcomas and drives oncogenesis in a mouse model. Elevated expression of BCL2 is considered a consistent feature of the synovial sarcoma expression profile. Our objective was to evaluate the expression of apoptotic pathway members in synovial sarcomas and interrogate the impact of modulating SS18-SSX expression on this pathway. We show in human and murine synovial sarcoma cells that SS18-SSX increases BCL2 expression, but represses other anti-apoptotic genes, including MCL1 and BCL2A1. This repression is achieved by directly suppressing expression via binding through activating transcription factor 2 (ATF2) to the cyclic adenosine monophosphate (AMP) response element (CRE) in the promoters of these genes and recruiting TLE1/Groucho. The suppression of these two anti-apoptotic pathways silences the typical routes by which other tumors evade BH3-domain peptidomimetic pharmacotherapy. We show that mouse and human synovial sarcoma cells are sensitive in vitro to ABT-263, a BH3-peptidomimetic, much more than the other tested cancer cell lines. ABT-263 also enhances the sensitivity of these cells to doxorubicin, a traditional cytotoxic chemotherapy used for synovial sarcoma. We also demonstrate the capacity of ABT-263 to stunt synovial sarcomagenesis in vivo in a genetic mouse model. These data recommend pursuit of BH3-peptidomimetic pharmacotherapy in human synovial sarcomas.	[Jones, K. B.; Jin, H.; Randall, R. L.] Univ Utah, Dept Orthopaed, Salt Lake City, UT 84112 USA; [Jones, K. B.; Jin, H.; Lenz, C.; Randall, R. L.; Sharma, S.; Capecchi, M. R.] Univ Utah, Ctr Childrens Canc Res, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; [Jones, K. B.; Jin, H.; Lenz, C.; Capecchi, M. R.] Univ Utah, Howard Hughes Med Inst, Dept Human Genet, Salt Lake City, UT 84112 USA; [Su, L.; Underhill, T. M.; Nielsen, T. O.] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada; [Su, L.; Underhill, T. M.; Nielsen, T. O.] Univ British Columbia, Biomed Res Ctr, Vancouver, BC, Canada; [Sharma, S.] Univ Utah, Dept Med, Div Hematol Oncol, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; University of British Columbia; University of British Columbia; Utah System of Higher Education; University of Utah	Capecchi, MR (corresponding author), Univ Utah, Howard Hughes Med Inst, 15 North 2030 East Room 5440, Salt Lake City, UT 84112 USA.	mario.capecchi@genetics.utah.edu			Huntsman Cancer Foundation; National Cancer Institute (NIH) [K08CA138764]; Canadian Cancer Society Research Institute [018355]; Terry Fox Foundation; CIHR Institute of Cancer [TFF 105265]; NATIONAL CANCER INSTITUTE [K08CA138764] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021168] Funding Source: NIH RePORTER	Huntsman Cancer Foundation; National Cancer Institute (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS)); Terry Fox Foundation; CIHR Institute of Cancer(Canadian Institutes of Health Research (CIHR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We gratefully acknowledge the support of the Paul Nabil Bustany Fund for Synovial Sarcoma Research, the Huntsman Cancer Foundation, and career development support from National Cancer Institute (NIH) K08CA138764. This work was also supported by grants from the Canadian Cancer Society Research Institute (Grant no. 018355) and the Terry Fox Foundation and CIHR Institute of Cancer (TFF 105265). We thank Matt Hockin, PhD, at the University of Utah for producing the TATCre protein.	Gandhi L, 2011, J CLIN ONCOL, V29, P909, DOI 10.1200/JCO.2010.31.6208; Haldar M, 2007, CANCER CELL, V11, P375, DOI 10.1016/j.ccr.2007.01.016; Haldar M, 2009, CANCER RES, V69, P3657, DOI 10.1158/0008-5472.CAN-08-4127; Hirakawa N, 1996, HUM PATHOL, V27, P1060, DOI 10.1016/S0046-8177(96)90284-1; Joshi SK, 2002, GENESIS, V33, P48, DOI 10.1002/gene.10089; Joyner DE, 2006, J ORTHOP RES, V24, P474, DOI 10.1002/jor.20087; Kawai A, 2004, CANCER LETT, V204, P105, DOI 10.1016/j.canlet.2003.09.031; Knosel T, 2010, EUR J CANCER, V46, P1170, DOI 10.1016/j.ejca.2010.01.032; Ladanyi M, 2002, CANCER RES, V62, P135; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Liu TM, 2011, ARTHRITIS RHEUM-US, V63, P2711, DOI 10.1002/art.30430; Mancuso T, 2000, LAB INVEST, V80, P805, DOI 10.1038/labinvest.3780085; Nakayama R, 2007, MODERN PATHOL, V20, P749, DOI 10.1038/modpathol.3800794; Nakayama R, 2010, AM J SURG PATHOL, V34, P1599, DOI 10.1097/PAS.0b013e3181f7ce2c; Su L, 2010, ONCOGENE, V29, P4352, DOI 10.1038/onc.2010.204; Su L, 2012, CANCER CELL, V21, P333, DOI 10.1016/j.ccr.2012.01.010; Sun BC, 2006, EUR J CANCER PREV, V15, P258, DOI 10.1097/01.cej.0000198896.02185.68; Tahir SK, 2010, MOL CANCER THER, V9, P545, DOI 10.1158/1535-7163.MCT-09-0651; Tse C, 2008, CANCER RES, V68, P3421, DOI 10.1158/0008-5472.CAN-07-5836; Wilson WH, 2010, LANCET ONCOL, V11, P1149, DOI 10.1016/S1470-2045(10)70261-8; Yecies D, 2010, BLOOD, V115, P3304, DOI 10.1182/blood-2009-07-233304	21	26	26	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2013	32	18					2365	2371		10.1038/onc.2012.247	http://dx.doi.org/10.1038/onc.2012.247			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140VF	22797074	Green Accepted			2022-12-17	WOS:000318683600013
J	Li, A; Zhang, C; Gao, S; Chen, F; Yang, C; Luo, R; Xiao, H				Li, A.; Zhang, C.; Gao, S.; Chen, F.; Yang, C.; Luo, R.; Xiao, H.			TIP30 loss enhances cytoplasmic and nuclear EGFR signaling and promotes lung adenocarcinogenesis in mice	ONCOGENE			English	Article						TIP30; lung adenocarcinoma; EGFR signaling; tumor suppressor	EPIDERMAL-GROWTH-FACTOR; BRONCHIOALVEOLAR STEM-CELLS; FACTOR RECEPTOR; TARGETED THERAPIES; TUMOR-METASTASIS; MUTANT P53; C-MYC; K-RAS; CANCER; EXPRESSION	Lung adenocarcinoma, the most common type of human non-small cell lung cancer (NSCLC), frequently overexpresses epidermal growth factor receptor (EGFR). However, the mechanisms underlying EGFR overexpression are not completely understood. Recent studies have identified that decreased expression of TIP30 (30kDa HIV-1 Tat interacting protein) is associated with the metastasis of human NSCLCs, but a causative relationship between TIP30 deficiency and NSCLC development remains unclear. We show here that Tip30 deletion leads to spontaneous development of lung adenomas and adenocarcinomas in mice. Lung tumor development was preceded by aberrant expansion of bronchioalveolar stem/progenitor and alveolar type II (AT2) cells, and also increased expression of EGFR and its downstream signaling factors in the lung of Tip30(-/-) mice. Moreover, TIP30 knockdown in human lung adenocarcinoma cells resulted in prolonged EGFR activity in early endosomes, delayed EGFR degradation, increased EGFR nuclear localization, leading to upregulated pAKT and pERK1/2 expression. Importantly, in human lung adenocarcinomas, low TIP30 expression correlates with prolonged patient overall and post-progression survival times. Together, these results suggest that TIP30 functions as a tumor suppressor to inhibit EGFR cytoplasmic and nuclear signaling and suppress adenocarcinogenesis in the lung, and highlight the potential of therapeutic strategies aiming at inhibiting EGFR signaling for patients with low TIP30-expression lung adenocarcinoma.	[Li, A.; Zhang, C.; Gao, S.; Chen, F.; Yang, C.; Xiao, H.] Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA; [Li, A.; Chen, F.; Luo, R.] Southern Med Univ, Nanfang Hosp, Dept Oncol, Guangzhou 510515, Guangdong, Peoples R China; [Zhang, C.] Michigan State Univ, Genet Program, E Lansing, MI 48824 USA; [Gao, S.] Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA	Michigan State University; Southern Medical University - China; Michigan State University; Michigan State University	Luo, R (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Oncol, 1838 North Guangzhou Rd, Guangzhou 510515, Guangdong, Peoples R China.	luorc01@163.com; xiaoh@msu.edu	Zhang, Chengliang/E-6943-2016	Zhang, Chengliang/0000-0003-3798-4157; Zhang, Chengliang/0000-0001-6999-4670	NIDDK, NIH [RO1 DK066110-01, W81XWH-08-1-0377]; DOD [RO1 DK066110-01, W81XWH-08-1-0377]; Nanfang Hospital, China; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK066110] Funding Source: NIH RePORTER	NIDDK, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); DOD(United States Department of Defense); Nanfang Hospital, China; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We are grateful to Jill Pecha for backcrossing Tip30 knockout gene into Balb/c mice, Ying Qin and Zuguo Li for histological examination of preneoplastic lesions and tumors, Eran Andrechek and Inez Yuwanita for helping patient survival analysis, and Sandra Z Haslam for critical reading of the manuscript. This work was supported by grants RO1 DK066110-01 and W81XWH-08-1-0377 (to HX) from NIDDK, NIH and DOD. AL is partly supported by a fellowship from Nanfang Hospital, China.	Berger AH, 2010, NAT GENET, V42, P216, DOI 10.1038/ng.527; Besson A, 2007, GENE DEV, V21, P1731, DOI 10.1101/gad.1556607; Bitler BG, 2010, J CELL SCI, V123, P1716, DOI 10.1242/jcs.062661; Cappuzzo F, 2005, JNCI-J NATL CANCER I, V97, P643, DOI 10.1093/jnci/dji112; Chen V, 2010, CELL CYCLE, V9, P4941, DOI 10.4161/cc.9.24.14230; Chen X, 2006, DIGEST DIS SCI, V55, P2219; Ehrhardt A, 2001, BRIT J CANCER, V84, P813, DOI 10.1054/bjoc.2000.1676; Fisher GH, 2001, GENE DEV, V15, P3249, DOI 10.1101/gad.947701; Fong S, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-23; Gazdar AF, 2008, CANCER PREV RES, V1, P156, DOI 10.1158/1940-6207.CAPR-08-0080; Ito M, 2003, CANCER RES, V63, P8763; Jackson EL, 2005, CANCER RES, V65, P10280, DOI 10.1158/0008-5472.CAN-05-2193; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Ji HB, 2006, CANCER CELL, V9, P485, DOI 10.1016/j.ccr.2006.04.022; Jiang C, 2004, J BIOL CHEM, V279, P27781, DOI 10.1074/jbc.M401809200; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; King FW, 2004, MOL CELL BIOL, V24, P7091, DOI 10.1128/MCB.24.16.7091-7101.2004; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Morimoto M, 2009, DEV BIOL, V325, P171, DOI 10.1016/j.ydbio.2008.10.013; Nikitin AY, 2004, CANCER RES, V64, P2307, DOI 10.1158/0008-5472.CAN-03-3376; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2010, NAT REV CANCER, V10, P760, DOI 10.1038/nrc2947; Pecha J, 2007, ONCOGENE, V26, P7423, DOI 10.1038/sj.onc.1210548; Politi K, 2006, GENE DEV, V20, P1496, DOI 10.1101/gad.1417406; RUSCH V, 1993, CANCER RES, V53, P2379; Shedden K, 2008, NAT MED, V14, P822, DOI 10.1038/nm.1790; Shtivelman E, 1997, ONCOGENE, V14, P2167, DOI 10.1038/sj.onc.1201059; Sun S, 2007, J CLIN INVEST, V117, P2740, DOI 10.1172/JCI31809; Tchou-Wong KM, 2002, AM J RESP CELL MOL, V27, P186, DOI 10.1165/ajrcmb.27.2.4799; Tong X, 2009, AM J PATHOL, V174, P1931, DOI 10.2353/ajpath.2009.080846; Tsao MS, 2005, NEW ENGL J MED, V353, P133, DOI 10.1056/NEJMoa050736; Wang SC, 2006, NAT CELL BIOL, V8, P1359, DOI 10.1038/ncb1501; Xiao H, 2000, EMBO J, V19, P956, DOI 10.1093/emboj/19.5.956; Xiao H, 1998, P NATL ACAD SCI USA, V95, P2146, DOI 10.1073/pnas.95.5.2146; Yanagi S, 2007, J CLIN INVEST, V117, P2929, DOI 10.1172/JCI31854; Yang CH, 2008, J CLIN ONCOL, V26, P2745, DOI 10.1200/JCO.2007.15.6695; Zhang CL, 2011, J BIOL CHEM, V286, P9373, DOI 10.1074/jbc.M110.207720; Zhang CL, 2010, CANCER RES, V70, P10224, DOI 10.1158/0008-5472.CAN-10-3057; Zhao J, 2008, HEPATOLOGY, V48, P265, DOI 10.1002/hep.22280; Zhao J, 2007, HUM PATHOL, V38, P293, DOI 10.1016/j.humpath.2006.08.005	42	26	28	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2013	32	18					2273	2281		10.1038/onc.2012.253	http://dx.doi.org/10.1038/onc.2012.253			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140VF	22733137	Green Accepted			2022-12-17	WOS:000318683600004
J	Sun, Y; Cao, S; Yang, M; Wu, S; Wang, Z; Lin, X; Song, X; Liao, DJ				Sun, Y.; Cao, S.; Yang, M.; Wu, S.; Wang, Z.; Lin, X.; Song, X.; Liao, D. J.			Basic anatomy and tumor biology of the RPS6KA6 gene that encodes the p90 ribosomal S6 kinase-4	ONCOGENE			English	Article						PRS6KA6; RSK4; alternative splicing; breast cancer; pancreatic cancer	X-LINKED GENES; TRANSLATIONAL REGULATION; C-MYC; MESSENGER-RNA; BREAST-CANCER; CYCLIN D1; INDUCED SENESCENCE; PANCREATIC-CANCER; TRANSGENIC MOUSE; OVARIAN-CANCER	The RPS6KA6 gene encodes the p90 ribosomal S6 kinase-4 (RSK4) that is still largely uncharacterized. In this study we identified a new RSK4 transcription initiation site and several alternative splice sites with a 5'-RACE approach. The resulting mRNA variants encompass four possible first start codons. The first 15 nucleotides (nt) of exon 22 in mouse and the penultimate exon in both human (exon 21) and mouse (exon 24) RSK4 underwent alternative splicing, although the penultimate exon deleted variant appeared mainly in cell clines, but not in most normal tissues. Demethylation agent 5-azacytidine inhibited the deletion of the penultimate exon, whereas two indolocarbazole-derived inhibitors of cyclin-dependent kinase 4 or 6 induced deletion of the first 39 nt from exon 21 of human RSK4. In all human cancer cell lines studied, the 90-kDa wild-type RSK4 was sparse but, surprisingly, several isoforms at or smaller than 72 kDa were expressed as detected by seven different antibodies. On immunoblots, each of these smaller isoforms often appeared as a duplet or triplet and the levels of these isoforms varied greatly among different cell lines and culture conditions. Cyclin D1 inhibited RSK4 expression and serum starvation enhanced the inhibition, whereas c-Myc and RSK4 inhibited cyclin D1. The effects of RSK4 on cell growth, cell death and chemoresponse depended on the mRNA variant or the protein isoform expressed, on the specificity of the cell lines, as well as on the anchorage-dependent or -independent growth conditions and the in vivo situation. Moreover, we also observed that even a given cDNA might be expressed to multiple proteins; therefore, when using a cDNA, one needs to exclude this possibility before attribution of the biological results from the cDNA to the anticipated protein. Collectively, our results suggest that whether RSK4 is oncogenic or tumor suppressive depends on many factors. Oncogene (2013) 32, 1794-1810; doi: 10.1038/onc.2012.200; published online 21 May 2012	[Sun, Y.; Yang, M.; Wu, S.; Wang, Z.; Liao, D. J.] Univ Minnesota, Hormel Inst, Austin, MN 55912 USA; [Cao, S.] Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA; [Lin, X.] Chinese Acad Sci, Inst Oceanol, Qingdao, Peoples R China; [Song, X.] Shandong Canc Hosp & Inst, Shandong Prov Key Lab Radiat Oncol, Jinan, Peoples R China	University of Minnesota System; Roswell Park Cancer Institute; Chinese Academy of Sciences; Institute of Oceanology, CAS; Shandong First Medical University & Shandong Academy of Medical Sciences	Cao, S (corresponding author), Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA.	shousong.cao@roswellpark.org; djliao@hi.umn.edu		Lin, Xiukun/0000-0002-0306-4953	NIH [RO1 CA100864]; Pardee Foundation grant on pancreatic cancer; NATIONAL CANCER INSTITUTE [R01CA100864] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pardee Foundation grant on pancreatic cancer; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by a NIH grant RO1 CA100864 and a Pardee Foundation grant on pancreatic cancer to DJ Liao. We would like to thank Dr Fred Bogott from Austin Medical Center at Austin of Minnesota for his excellent English editing of the manuscript.	Anjum R, 2008, NAT REV MOL CELL BIO, V9, P747, DOI 10.1038/nrm2509; Arava Y, 2005, NUCLEIC ACIDS RES, V33, P2421, DOI 10.1093/nar/gki331; Bender C, 2012, INT J CANCER, V131, pE45, DOI 10.1002/ijc.26486; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Bignone PA, 2007, ONCOGENE, V26, P683, DOI 10.1038/sj.onc.1209827; Biliran H, 2005, CLIN CANCER RES, V11, P6075, DOI 10.1158/1078-0432.CCR-04-2419; Biliran H, 2007, CLIN CANCER RES, V13, P2811, DOI 10.1158/1078-0432.CCR-06-1844; Calvo SE, 2009, P NATL ACAD SCI USA, V106, P7507, DOI 10.1073/pnas.0810916106; Campbell MJ, 2002, IN VITRO CELL DEV-AN, V38, P326; Cao SS, 1999, CLIN CANCER RES, V5, P1925; Chatterjee S, 2009, BIOL CELL, V101, P251, DOI 10.1042/BC20080104; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; Dewdney SB, 2011, CLIN CANCER RES, V17, P2120, DOI 10.1158/1078-0432.CCR-10-2668; Dummler BA, 2005, J BIOL CHEM, V280, P13304, DOI 10.1074/jbc.M408194200; El-Kady Ayman, 2011, J Carcinog, V10, P24, DOI 10.4103/1477-3163.90437; Fitzgerald KD, 2009, BBA-GENE REGUL MECH, V1789, P518, DOI 10.1016/j.bbagrm.2009.07.004; Foster BA, 1997, CANCER RES, V57, P3325; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Gresner P, 2009, ACTA BIOCHIM POL, V56, P307; Hauge C, 2006, J CELL SCI, V119, P3021, DOI 10.1242/jcs.02950; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; Hinnebusch AG, 2005, ANNU REV MICROBIOL, V59, P407, DOI 10.1146/annurev.micro.59.031805.133833; Iacono M, 2005, GENE, V349, P97, DOI 10.1016/j.gene.2004.11.041; Ingolia NT, 2009, SCIENCE, V324, P218, DOI 10.1126/science.1168978; Ivanov IP, 2010, NUCLEIC ACIDS RES, V38, P353, DOI 10.1093/nar/gkp1037; Kohn M, 2003, GENE EXPR PATTERNS, V3, P173, DOI 10.1016/S1567-133X(03)00004-8; Kozak M, 2005, NUCLEIC ACIDS RES, V33, P6593, DOI 10.1093/nar/gki958; Kozak M, 2005, GENE, V361, P13, DOI 10.1016/j.gene.2005.06.037; Kozak M, 2008, GENE, V423, P108, DOI 10.1016/j.gene.2008.07.013; Kozak M, 2007, GENE, V403, P194, DOI 10.1016/j.gene.2007.08.017; Kozak M, 2007, J CELL BIOCHEM, V102, P280, DOI 10.1002/jcb.21464; Kozak M, 2006, GENE, V382, P1, DOI 10.1016/j.gene.2006.06.004; Le Quesne JPC, 2010, J PATHOL, V220, P140, DOI 10.1002/path.2627; Liao D. Joshua, 2007, Critical Reviews in Oncogenesis, V13, P93; Liao DJ, 2000, ENDOCR-RELAT CANCER, V7, P143, DOI 10.1677/erc.0.0070143; Liao DZJ, 1998, CARCINOGENESIS, V19, P2173, DOI 10.1093/carcin/19.12.2173; Liao DZJ, 2000, CARCINOGENESIS, V21, P2167, DOI 10.1093/carcin/21.12.2167; Liao JD, 2007, HISTOL HISTOPATHOL, V22, P661, DOI 10.14670/HH-22.661; Lin HC, 2001, CANCER LETT, V173, P63, DOI 10.1016/S0304-3835(01)00677-2; Lleonart ME, 2006, ONCOL REP, V16, P603; Lopez-Vicente L, 2011, CARCINOGENESIS, V32, P470, DOI 10.1093/carcin/bgr003; Lopez-Vicente L, 2009, CLIN CANCER RES, V15, P4546, DOI 10.1158/1078-0432.CCR-08-3159; Mercer TR, 2011, NUCLEIC ACIDS RES, V39, P2393, DOI 10.1093/nar/gkq1158; Myers AP, 2004, MOL CELL BIOL, V24, P4255, DOI 10.1128/MCB.24.10.4255-4266.2004; Niehof M, 2005, MOL PHARMACOL, V67, P604, DOI 10.1124/mol.104.008672; Nyiko T, 2009, PLANT MOL BIOL, V71, P367, DOI 10.1007/s11103-009-9528-4; Palazzo AF, 2012, BBA-GENE REGUL MECH, V1819, P566, DOI 10.1016/j.bbagrm.2011.12.012; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; Shatsky IN, 2010, MOL CELLS, V30, P285, DOI 10.1007/s10059-010-0149-1; Sumanasekera C, 2008, BIOCHEM SOC T, V36, P483, DOI 10.1042/BST0360483; Sun Y, 2012, J CANCER, V3, P93, DOI 10.7150/jca.4163; Sun Y, 2011, J CANCER, V2, P36, DOI 10.7150/jca.2.36; Szamecz B, 2008, GENE DEV, V22, P2414, DOI 10.1101/gad.480508; Tanner DR, 2009, J BIOL CHEM, V284, P34809, DOI 10.1074/jbc.M109.039040; Thakur A, 2005, BREAST CANCER RES TR, V93, P135, DOI 10.1007/s10549-005-4516-0; Thakur A, 2008, MOL CANCER, V7, DOI [10.1086/1476-4598-7-11, DOI 10.1086/1476-4598-7-11]; Thakur A, 2008, CLIN CANCER RES, V14, P4427, DOI 10.1158/1078-0432.CCR-08-0458; Thakur A, 2007, MOL CANCER RES, V5, P171, DOI 10.1158/1541-7786.MCR-06-0071; Vila-Perello M, 2010, CELL, V143, P191, DOI 10.1016/j.cell.2010.09.031; Wang CG, 2011, CELL CYCLE, V10, P57, DOI 10.4161/cc.10.1.14449; Wang Y, 2007, CANCER RES, V67, P3698, DOI 10.1158/0008-5472.CAN-06-4000; Wethmar K, 2010, BIOESSAYS, V32, P885, DOI 10.1002/bies.201000037; Yang M, 2011, J CANCER, V2, P386, DOI 10.7150/jca.2.386; Yntema HG, 1999, GENOMICS, V62, P332, DOI 10.1006/geno.1999.6004	64	26	26	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2013	32	14					1794	1810		10.1038/onc.2012.200	http://dx.doi.org/10.1038/onc.2012.200			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	118RQ	22614021	Green Accepted			2022-12-17	WOS:000317043900006
J	Liu, ZY; Wang, JY; Liu, HH; Ma, XM; Wang, CL; Zhang, XP; Tao, YQ; Lu, YC; Liao, JC; Hu, GH				Liu, Z. Y.; Wang, J. Y.; Liu, H. H.; Ma, X. M.; Wang, C. L.; Zhang, X. P.; Tao, Y. Q.; Lu, Y. C.; Liao, J. C.; Hu, G. H.			Retinoblastoma protein-interacting zinc-finger gene 1 (RIZ1) dysregulation in human malignant meningiomas	ONCOGENE			English	Article						retinoblastoma protein-interacting zinc-finger gene 1 (RIZ1); malignant; meningiomas; apoptosis; tumor suppressor gene	ANAPLASTIC MENINGIOMAS; BREAST-CANCER; PR DOMAIN; EXPRESSION; METHYLTRANSFERASE; PRODUCT	Retinoblastoma protein-interacting zinc-finger gene 1 (RIZ1) expression is often silenced in many types of human tumors. However, the relationship between RIZ1 expression and malignant meningiomas remains unclear. Here we have found for the first time that the expression of RIZ1 genes are associated with meningiomas progression through extensive analyses of Affymetrix GeneChip microarray data. Further validation methods for gene expression included quantitative PCR (qPCR), western blot and immunohistochemistry analysis, and these methods confirmed that RIZ1 is significantly downregulated in malignant meningioma tissues, as compared with benign meningiomas. In addition, malignant meningioma cells were stably transfected with ectogenic RIZ1 using Lentivirus-mediated transfection, and the transfections were followed by an in vitro 5-bromo-2-deoxyuridin incorporation assay, colony formation assay, cell cycle analysis, invasive analysis, apoptotic assay and western blot analysis. Our results demonstrate that the forced expression of RIZ1 in a malignant meningioma cell line inhibited cellular proliferation and arrested the cells in the G2/M phase of the cell cycle. We also confirmed that overexpression of RIZ1 may induce apoptosis of malignant meningioma cells. Furthermore, RIZ1 overexpression in malignant meningioma cells was associated with the downregulation of c-myc expression. These results from our study indicate that RIZ1 expression is significantly downregulated as the formation of meningiomas progressed, and suggest that RIZ1 may represent a promising candidate tumor suppressor gene that contributes to malignant meningiomas. Oncogene (2013) 32, 1216-1222; doi:10.1038/onc.2012.155; published online 21 May 2012	[Liu, Z. Y.; Wang, J. Y.; Wang, C. L.; Tao, Y. Q.; Lu, Y. C.; Hu, G. H.] Second Mil Med Univ, Shanghai Changzheng Hosp, Dept Neurosurg, Shanghai, Peoples R China; [Liu, H. H.; Liao, J. C.] Second Mil Med Univ, Shanghai Changzheng Hosp, Dept Otorhinolaryngol Head & Neck, Shanghai, Peoples R China; [Ma, X. M.] Second Mil Med Univ, Shanghai Changzheng Hosp, Dept Pathol, Shanghai, Peoples R China; [Wang, C. L.] Dept Neurosurg, Hefei, Anhui, Peoples R China; [Zhang, X. P.] Shanghai Jiao Tong Univ, Key Lab Stem Cell Biol, Inst Hlth Sci, Shanghai Inst Biol Sci,Chinese Acad Sci,Sch Med, Shanghai 200030, Peoples R China	Naval Medical University; Naval Medical University; Naval Medical University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University	Hu, GH (corresponding author), Second Mil Med Univ, Shanghai Changzheng Hosp, Dept Neurosurg, Shanghai, Peoples R China.	liaojc@public2.sta.net.cn; huguohan6504@sina.com			Shanghai Science and Technology Foundation of China [08431900400, 09411950900]; Shanghai Science and Technology Youth Fund of China [09ZR410000]; Natural Sciences Fund Project of Anhui Province, China [11040606M212]	Shanghai Science and Technology Foundation of China; Shanghai Science and Technology Youth Fund of China; Natural Sciences Fund Project of Anhui Province, China	The meningioma cell line IOMM-Lee and CH157-MN were kindly provided by Professor Randy Jensen and Dr David Gillespie (Utah State University, USA). The research was supported by Shanghai Science and Technology Foundation of China: 08431900400 (Guohan Hu), Shanghai Science and Technology Foundation of China: 09411950900 (Jianchun Liao), Shanghai Science and Technology Youth Fund of China: 09ZR410000 (Huanhai Liu) and Natural Sciences Fund Project of Anhui Province, China: No. 11040606M212 (Chunlin Wang).	BUYSE IM, 1995, P NATL ACAD SCI USA, V92, P4467, DOI 10.1073/pnas.92.10.4467; Carling T, 2004, MOL CELL BIOL, V24, P7032, DOI 10.1128/MCB.24.16.7032-7042.2004; Chadwick RB, 2000, P NATL ACAD SCI USA, V97, P2662, DOI 10.1073/pnas.040579497; Gazzerro P, 2006, EXP CELL RES, V312, P340, DOI 10.1016/j.yexcr.2005.11.002; GLAHOLM J, 1990, INT J RADIAT ONCOL, V18, P755, DOI 10.1016/0360-3016(90)90394-Y; GOLDSMITH BJ, 1994, J NEUROSURG, V80, P195, DOI 10.3171/jns.1994.80.2.0195; He LS, 1998, CANCER RES, V58, P4238; Huang S, 1998, J BIOL CHEM, V273, P15933, DOI 10.1074/jbc.273.26.15933; Jiang GL, 2001, CANCER RES, V61, P1796; Jiang GL, 1999, INT J CANCER, V83, P541, DOI 10.1002/(SICI)1097-0215(19991112)83:4<541::AID-IJC17>3.0.CO;2-F; Kim Y, 2004, CANCER RES, V64, P8980, DOI 10.1158/0008-5472.CAN-04-1926; LEE WH, 1990, NEUROSURGERY, V27, P389, DOI 10.1227/00006123-199009000-00008; Liu LM, 1997, J BIOL CHEM, V272, P2984, DOI 10.1074/jbc.272.5.2984; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Modha A, 2005, NEUROSURGERY, V57, P538, DOI 10.1227/01.NEU.0000170980.47582.A5; Perry A, 1999, CANCER, V85, P2046, DOI 10.1002/(SICI)1097-0142(19990501)85:9<2046::AID-CNCR23>3.0.CO;2-M; Piao Z, 2000, CANCER RES, V60, P4701; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Rossi V, 2009, J CELL PHYSIOL, V221, P771, DOI 10.1002/jcp.21920; Shadat NM, 2001, CANC INVEST, V28, P806; Steele-Perkins G, 2001, GENE DEV, V15, P2250, DOI 10.1101/gad.870101; Tao YQ, 2006, BIOFACTORS, V28, P203, DOI 10.1002/biof.5520280307; Wang JY, 2012, J NEURO-ONCOL, V106, P473, DOI 10.1007/s11060-011-0692-4; Ware ML, 2004, NEUROSURGERY, V54, P55, DOI 10.1227/01.NEU.0000097199.26412.2A; Weber RG, 1997, P NATL ACAD SCI USA, V94, P14719, DOI 10.1073/pnas.94.26.14719; Zhang X, 2002, J CLIN ENDOCR METAB, V87, P1262, DOI 10.1210/jc.87.3.1262; Zhang X, 2010, CANCER RES, V70, P2350, DOI 10.1158/0008-5472.CAN-09-3885	27	26	29	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2013	32	10					1216	1222		10.1038/onc.2012.155	http://dx.doi.org/10.1038/onc.2012.155			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OP	22614009				2022-12-17	WOS:000316454500002
J	Su, Y; Li, J; Witkiewicz, AK; Brennan, D; Neill, T; Talarico, J; Radice, GL				Su, Y.; Li, J.; Witkiewicz, A. K.; Brennan, D.; Neill, T.; Talarico, J.; Radice, G. L.			N-cadherin haploinsufficiency increases survival in a mouse model of pancreatic cancer	ONCOGENE			English	Article						cell adhesion; apoptosis; invasion; matrix metalloproteinase	CELL-MIGRATION; DUCTAL ADENOCARCINOMA; SIGNALING PATHWAY; HEDGEHOG; METASTASIS; GROWTH; INVASION; KI-RAS(G12V); ADHESION; MATRIX	Pancreatic ductal adenocarcinoma (PDA) is often detected at a late stage, hence the identification of new therapies that have potential to block tumor progression is critical for this lethal disease. N-cadherin upregulation has been observed in many cancers including PDA, however, a causal role for this cell adhesion receptor in disease progression has yet to be defined. The concomitant expression of oncogenic Kras(G12D) and mutant p53 (Trp53(R172H)) in the murine pancreas results in metastatic PDA that recapitulates the cognate features of human pancreatic cancer providing an excellent animal model to identify genes required for tumor progression. Here we determine the consequences of genetically manipulating N-cadherin expression in a mouse model of PDA. Remarkably, mice with reduced N-cadherin expression (that is, Ncad(-/+)) survived 25% longer (177 vs 142 days, P<0.05) than animals expressing two wild-type N-cadherin (Cdh2) alleles. The survival benefit is likely due to a cumulative effect of N-cadherin's role in different aspects of tumorigenesis including tumor-cell survival, growth, migration and invasion. Interestingly, reduced hedgehog signaling may contribute to the better prognosis for the Ncad(-/+) mice. Moreover, the matrix metalloproteinase MMP-7, associated with poor prognosis in PDA, was reduced in Ncad(-/+) tumors. Finally, Ncad(-/+) tumor cells exhibited decreased FGF-stimulated ERK1/2 activation consistent with N-cadherin's ability to promote FGFR signaling. These data support a critical role for N-cadherin in PDA and its potential prognostic value. Additionally, this study provides in vivo genetic evidence that the cell-surface protein N-cadherin represents a promising therapeutic target for the treatment of pancreatic cancer. Oncogene (2012) 31, 4484--4489; doi: 10.1038/onc.2011.574; published online 12 December 2011	[Su, Y.; Li, J.; Brennan, D.; Neill, T.; Talarico, J.; Radice, G. L.] Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Ctr Translat Med, Philadelphia, PA 19107 USA; [Witkiewicz, A. K.] Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Radice, GL (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Ctr Translat Med, Coll Bldg,Room 309,1025 Walnut St, Philadelphia, PA 19107 USA.	glenn.radice@jefferson.edu			Center for Molecular Studies in Digestive and Liver Disease [NIH P30DK050306]; University Research Foundation-University of Pennsylvania; NIH [R21 CA133609]; Pilot Research Award-Thomas Jefferson University; NATIONAL CANCER INSTITUTE [R21CA133609] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK050306] Funding Source: NIH RePORTER	Center for Molecular Studies in Digestive and Liver Disease; University Research Foundation-University of Pennsylvania; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pilot Research Award-Thomas Jefferson University; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Dr D Tuveson (Cancer Research UK, Cambridge) for the LSL-K-ras<SUP>G12D</SUP> and LSL-Trp53<SUP>R172H</SUP> mice and Dr A Lowy (UCSD) for the Pdx1/Cre mice. We are grateful to Han Du, Craig Riley, David Kurz, Leeanne Griffith and Andrew Ho for technical assistance. This work was supported by the Center for Molecular Studies in Digestive and Liver Disease (NIH P30DK050306) and University Research Foundation-University of Pennsylvania, NIH R21 CA133609, Pilot Research Award-Thomas Jefferson University (to GLR).	Agbunag C, 2004, CANCER RES, V64, P5659, DOI 10.1158/0008-5472.CAN-04-0807; Augustine CK, 2008, CANCER RES, V68, P3777, DOI 10.1158/0008-5472.CAN-07-5949; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Brembeck FH, 2003, CANCER RES, V63, P2005; Cavallaro U, 2001, NAT CELL BIOL, V3, P650, DOI 10.1038/35083041; Crawford HC, 2002, J CLIN INVEST, V109, P1437, DOI 10.1172/JCI200215051; Deramaudt TB, 2006, MOL CELL BIOL, V26, P4185, DOI 10.1128/MCB.01055-05; Fukuda A, 2011, CANCER CELL, V19, P441, DOI 10.1016/j.ccr.2011.03.002; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Hezel AF, 2006, GENE DEV, V20, P1218, DOI 10.1101/gad.1415606; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Hulit J, 2007, CANCER RES, V67, P3106, DOI 10.1158/0008-5472.CAN-06-3401; Johansson JK, 2010, GENESIS, V48, P374, DOI 10.1002/dvg.20628; Kang JS, 2003, P NATL ACAD SCI USA, V100, P3989, DOI 10.1073/pnas.0736565100; Karafin MS, 2010, INT J CLIN EXP PATHO, V3, P47; Kostetskii I, 2005, CIRC RES, V96, P346, DOI 10.1161/01.RES.0000156274.72390.2c; Lehembre F, 2008, EMBO J, V27, P2603, DOI 10.1038/emboj.2008.178; Luo Y, 2005, DEV DYNAM, V232, P336, DOI 10.1002/dvdy.20241; Morton JP, 2007, P NATL ACAD SCI USA, V104, P5103, DOI 10.1073/pnas.0701158104; Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631; Nomura S, 2008, BRIT J CANCER, V99, P305, DOI 10.1038/sj.bjc.6604473; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; Schreiber FS, 2004, GASTROENTEROLOGY, V127, P250, DOI 10.1053/j.gastro.2004.03.058; Shintani Y, 2008, INT J CANCER, V122, P71, DOI 10.1002/ijc.23027; Shintani Y, 2006, CANCER RES, V66, P11745, DOI 10.1158/0008-5472.CAN-06-2322; Suyama K, 2002, CANCER CELL, V2, P301, DOI 10.1016/S1535-6108(02)00150-2; Tanaka H, 2010, NAT MED, V16, P1414, DOI 10.1038/nm.2236; Tenzen T, 2006, DEV CELL, V10, P647, DOI 10.1016/j.devcel.2006.04.004; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; Wheelock MJ, 2008, J CELL SCI, V121, P727, DOI 10.1242/jcs.000455	31	26	26	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2012	31	41					4484	4489		10.1038/onc.2011.574	http://dx.doi.org/10.1038/onc.2011.574			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	018YR	22158044	Green Accepted			2022-12-17	WOS:000309704500006
J	Rusiniak, ME; Kunnev, D; Freeland, A; Cady, GK; Pruitt, SC				Rusiniak, M. E.; Kunnev, D.; Freeland, A.; Cady, G. K.; Pruitt, S. C.			Mcm2 deficiency results in short deletions allowing high resolution identification of genes contributing to lymphoblastic lymphoma	ONCOGENE			English	Article						DNA replication; licensing factor; dormant origins; lymphoblastic lymphoma; Mcm2	ACUTE MYELOID-LEUKEMIA; TRANSCRIPTION FACTORS; HUMAN-CELLS; REPLICATIVE STRESS; T-ALL; MUTATIONS; ORIGINS; CANCER; NOTCH1; CYCLE	Mini-chromosome maintenance (Mcm) proteins are part of the replication- licensing complex that is loaded onto chromatin during the G1-phase of the cell cycle and required for initiation of DNA replication in the subsequent S-phase. Mcm proteins are typically loaded in excess of the number of locations that are used during S-phase. Nonetheless, partial depletion of Mcm proteins leads to cancers and stem cell deficiencies. Mcm2 deficient mice, on a 129Sv genetic background, display a high rate of thymic lymphoblastic lymphoma. Here array comparative genomic hybridization is used to characterize the genetic damage accruing in these tumors. The predominant events are deletions averaging less than 0.5 Mbp, considerably shorter than observed in prior studies using alternative mouse lymphoma models or human tumors. Such deletions facilitate identification of specific genes and pathways responsible for the tumors. Mutations in many genes that have been implicated in human lymphomas are recapitulated in this mouse model. These features, and the fact that the mutation underlying the accelerated genetic damage does not target a specific gene or pathway a priori, are valuable features of this mouse model for identification of tumor suppressor genes. Genes affected in all tumors include Pten, Tcfe2a, Mbd3 and Setd1b. Notch1 and additional genes are affected in subsets of tumors. The high frequency of relatively short deletions is consistent with elevated recombination between nearby stalled replication forks in Mcm2-deficient mice. Oncogene (2012) 31, 4034-4044; doi:10.1038/onc.2011.566; published online 12 December 2011	[Rusiniak, M. E.; Kunnev, D.; Freeland, A.; Cady, G. K.; Pruitt, S. C.] Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Pruitt, SC (corresponding author), Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Elm & Carlton St, Buffalo, NY 14263 USA.	steven.pruitt@roswellpark.org			NIH-NCI; Ellison Medical Foundation; NYSTEM; NCI-CCS; NATIONAL CANCER INSTITUTE [R01CA130995] Funding Source: NIH RePORTER	NIH-NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Ellison Medical Foundation(Lawrence Ellison Foundation); NYSTEM; NCI-CCS; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from the NIH-NCI, the Ellison Medical Foundation and NYSTEM to SCP. Cost of animal maintenance and flow cytometry was supported in part by an NCI-CCS grant to RPCI.	Abeysinghe SS, 2003, HUM MUTAT, V22, P229, DOI 10.1002/humu.10254; Aftab S, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-226; Bai T, 2010, BMC DEV BIOL, V10, DOI 10.1186/1471-213X-10-7; Blow JJ, 2011, TRENDS BIOCHEM SCI, V36, P405, DOI 10.1016/j.tibs.2011.05.002; Blow JJ, 2005, NAT REV MOL CELL BIO, V6, P476, DOI 10.1038/nrm1663; Brackertz M, 2002, J BIOL CHEM, V277, P40958, DOI 10.1074/jbc.M207467200; Buckler JL, 2008, IMMUNOL REV, V224, P239, DOI 10.1111/j.1600-065X.2008.00650.x; Chuang CH, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001110; Collins-Underwood JR, 2010, LEUKEMIA, V24, P1676, DOI 10.1038/leu.2010.177; De Keersmaecker K, 2010, NAT MED, V16, P1321, DOI 10.1038/nm.2246; Ge XQ, 2007, GENE DEV, V21, P3331, DOI 10.1101/gad.457807; Ge XQ, 2010, J CELL BIOL, V191, P1285, DOI 10.1083/jcb.201007074; Hess JL, 2004, CRIT REV EUKAR GENE, V14, P235, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i4.10; Ibarra A, 2008, P NATL ACAD SCI USA, V105, P8956, DOI 10.1073/pnas.0803978105; Jeannet R, 2010, BLOOD, V116, P5443, DOI 10.1182/blood-2010-05-286658; Katzav S, 2009, INT J BIOCHEM CELL B, V41, P1245, DOI 10.1016/j.biocel.2008.11.006; Kim J, 2009, CELL, V137, P459, DOI 10.1016/j.cell.2009.02.027; Kuiper RP, 2007, LEUKEMIA, V21, P1258, DOI 10.1038/sj.leu.2404691; Kunnev D, 2010, ONCOGENE, V29, P3630, DOI 10.1038/onc.2010.125; LeBrun DP, 2003, FRONT BIOSCI, V8, pS206, DOI 10.2741/1030; Ley TJ, 2010, NEW ENGL J MED, V363, P2424, DOI 10.1056/NEJMoa1005143; Maser RS, 2007, NATURE, V447, P966, DOI 10.1038/nature05886; Meyer C, 2009, LEUKEMIA, V23, P1490, DOI 10.1038/leu.2009.33; Mullighan CG, 2007, NATURE, V446, P758, DOI 10.1038/nature05690; Nishiyama A, 2009, CELL STEM CELL, V5, P420, DOI 10.1016/j.stem.2009.07.012; Orr SJ, 2010, ONCOGENE, V29, P3803, DOI 10.1038/onc.2010.138; Palomero T, 2007, NAT MED, V13, P1203, DOI 10.1038/nm1636; Pruitt SC, 2007, STEM CELLS, V25, P3121, DOI 10.1634/stemcells.2007-0483; Ramirez J, 2009, EPIGENETICS-US, V4, P532, DOI 10.4161/epi.4.8.10108; Rebollo A, 2003, IMMUNOL CELL BIOL, V81, P171, DOI 10.1046/j.1440-1711.2003.01159.x; Remke M, 2009, BLOOD, V114, P1053, DOI 10.1182/blood-2008-10-186536; Santos J, 2010, CANCER GENET CYTOGEN, V197, P60, DOI 10.1016/j.cancergencyto.2009.10.010; Shima N, 2007, NAT GENET, V39, P93, DOI 10.1038/ng1936; Tefferi A, 2010, LEUKEMIA, V24, P1128, DOI 10.1038/leu.2010.69; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Williams RT, 2008, COLD SH Q B, V73, P461, DOI 10.1101/sqb.2008.73.039; Yang Q, 2008, J IMMUNOL, V181, P5885, DOI 10.4049/jimmunol.181.9.5885; Zani VJ, 1996, BLOOD, V87, P3124, DOI 10.1182/blood.V87.8.3124.bloodjournal8783124	38	26	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2012	31	36					4034	4044		10.1038/onc.2011.566	http://dx.doi.org/10.1038/onc.2011.566			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	004NQ	22158038	Green Accepted			2022-12-17	WOS:000308688800004
J	Yoshida, Y; Ninomiya, K; Hamada, H; Noda, M				Yoshida, Y.; Ninomiya, K.; Hamada, H.; Noda, M.			Involvement of the SKP2-p27(KIP1) pathway in suppression of cancer cell proliferation by RECK	ONCOGENE			English	Article						RECK; cell cycle; extracellular matrix; SKP2; p27; collagen	GENE-EXPRESSION SIGNATURE; REGULATOR RECK; IN-VIVO; PROTEIN; SKP2; INHIBITOR; P27; METALLOPROTEINASE; CLASSIFICATION; ACCUMULATION	The membrane-anchored matrix metalloproteinase-regulator RECK is often downregulated in cancers; in some cases, a significant correlation between the level of residual RECK in resected tumors and patient survival has been noted. Furthermore, restoration of RECK expression in certain cancer-derived cell lines results in reduced tumorigenicity. Here we report that acute RECK expression in colon carcinoma cells results in cell cycle-arrest accompanied by downregulation of a ubiquitin ligase component, S-phase kinase-associated protein 2 (SKP2), and upregulation of its substrate, p27(KIP1). Our data indicate that RECK-induced growth suppression is at least partially dependent on p27, and that RECK and type I collagen share similar effects on the SKP2-p27 pathway. Importantly, in patients with lung, colorectal and bladder cancers, the RECK/SKP2 ratio is high in normal tissues and lower in the cancer tissues. These findings reveal a novel molecular pathway linking cell-cycle progression to RECK downregulation, extracellular matrix degradation and SKP2 upregulation, and suggest that treatment regimens that induce RECK expression could be promising cancer therapies. Oncogene (2012) 31, 4128-4138; doi:10.1038/onc.2011.570; published online 12 December 2011	[Yoshida, Y.; Ninomiya, K.; Noda, M.] Kyoto Univ, Dept Mol Oncol, Grad Sch Med, Sakyo Ku, Kyoto 6068501, Japan; [Yoshida, Y.; Ninomiya, K.; Noda, M.] Kyoto Univ, Global COE Program, Grad Sch Med, Sakyo Ku, Kyoto 6068501, Japan; [Hamada, H.] Tokyo Univ Pharm & Life Sci, Dept Life Sci, Lab Oncol, Tokyo, Japan	Kyoto University; Kyoto University; Tokyo University of Pharmacy & Life Sciences	Noda, M (corresponding author), Kyoto Univ, Dept Mol Oncol, Grad Sch Med, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan.	mnoda@virus.kyoto-u.ac.jp			JSPS; MEXT	JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); MEXT(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank Chiaki Takahashi for the RECK cDNA, Mako Yamamoto for R1B2-6 cells, Hitoshi Kitayama and Tomoko Matsuzaki for discussions, David Alexander for critical reading of the manuscript, Hai-Ou Gu and Aiko Nishimoto for technical assistance and Aki Miyazaki for secretarial assistance. This work was supported by JSPS Grant-in-Aid for Creative Scientific Research and MEXT Grant-in-Aid on Priority Areas.	Bond M, 2008, CARDIOVASC RES, V80, P290, DOI 10.1093/cvr/cvn188; Caswell PT, 2009, NAT REV MOL CELL BIO, V10, P843, DOI 10.1038/nrm2799; Chandana EPS, 2010, BMC DEV BIOL, V10, DOI 10.1186/1471-213X-10-84; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dyrskjot L, 2004, CANCER RES, V64, P4040, DOI 10.1158/0008-5472.CAN-03-3620; Frescas D, 2008, NAT REV CANCER, V8, P438, DOI 10.1038/nrc2396; Freshney R.I., 1987, CULTURE ANIMAL CELLS, P117; Fu Y, 2007, J CELL BIOCHEM, V102, P704, DOI 10.1002/jcb.21323; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hatta M, 2009, CELL SIGNAL, V21, P1885, DOI 10.1016/j.cellsig.2009.08.005; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; Kondo S, 2007, J CELL SCI, V120, P849, DOI 10.1242/jcs.03388; Landi MT, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001651; LEIBOVITZ A, 1976, CANCER RES, V36, P4562; Lin HK, 2010, NATURE, V464, P374, DOI 10.1038/nature08815; Loayza-Puch F, 2010, ONCOGENE, V29, P2638, DOI 10.1038/onc.2010.23; Miki T, 2007, J BIOL CHEM, V282, P12341, DOI 10.1074/jbc.M610948200; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Morioka Y, 2009, ONCOGENE, V28, P1454, DOI 10.1038/onc.2008.486; Muraguchi T, 2007, NAT NEUROSCI, V10, P838, DOI 10.1038/nn1922; Murai R, 2010, ONCOTARGET, V1, P252; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; Noda M, 2003, CANCER METAST REV, V22, P167, DOI 10.1023/A:1023043315031; Noda M, 2007, CANCER SCI, V98, P1659, DOI 10.1111/j.1349-7006.2007.00588.x; Oh J, 2001, CELL, V107, P789, DOI 10.1016/S0092-8674(01)00597-9; Omura A, 2009, J BIOL CHEM, V284, P3461, DOI 10.1074/jbc.M806212200; Prifti E, 2008, BIOINFORMATICS, V24, P2636, DOI 10.1093/bioinformatics/btn492; RASHEED S, 1974, CANCER, V33, P1027, DOI 10.1002/1097-0142(197404)33:4<1027::AID-CNCR2820330419>3.0.CO;2-Z; Sabates-Beliver J, 2007, MOL CANCER RES, V5, P1263, DOI 10.1158/1541-7786.MCR-07-0267; Sasahara RM, 1999, BIOCHEM BIOPH RES CO, V264, P668, DOI 10.1006/bbrc.1999.1552; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Takahashi C, 1998, P NATL ACAD SCI USA, V95, P13221, DOI 10.1073/pnas.95.22.13221; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Yoshida Y, 1997, BIOCHEM BIOPH RES CO, V230, P426, DOI 10.1006/bbrc.1996.5975; Zhang H, 2003, HEPATOLOGY, V38, P305, DOI 10.1053/jhep.2003.50345; Zhu L, 2010, CELL RES, V20, P605, DOI 10.1038/cr.2010.71	40	26	27	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2012	31	37					4128	4138		10.1038/onc.2011.570	http://dx.doi.org/10.1038/onc.2011.570			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	004NR	22158033				2022-12-17	WOS:000308688900005
J	Lu, J; Hamze, Z; Bonnavion, R; Herath, N; Pouponnot, C; Assade, F; Fontaniere, S; Bertolino, P; Cordier-Bussat, M; Zhang, CX				Lu, J.; Hamze, Z.; Bonnavion, R.; Herath, N.; Pouponnot, C.; Assade, F.; Fontaniere, S.; Bertolino, P.; Cordier-Bussat, M.; Zhang, C. X.			Reexpression of oncoprotein MafB in proliferative beta-cells and Men1 insulinomas in mouse	ONCOGENE			English	Article						Maf; MafB; Men1; pancreatic beta-cells; proliferation; insulinoma	ENDOCRINE NEOPLASIA TYPE-1; MULTIPLE-MYELOMA; C-MAF; MICE; GENE; EXPRESSION; OVEREXPRESSION; REVEALS; TRANSLOCATION; SECRETION	MafB, a member of the large Maf transcription factor family, is essential for the embryonic and terminal differentiation of pancreatic alpha- and beta-cells. However, the role of MafB in the control of adult islet-cell proliferation remains unknown. Considering its oncogenic potential in several other tissues, we investigated the possible alteration of its expression in adult mouse beta-cells under different conditions of proliferation. We found that MafB, in general silenced in these cells, was reexpressed in similar to 30% of adaptive beta-cells both in gestational female mice and in mice fed with a high-fat diet. Importantly, reactivated MafB expression was also observed in the early beta-cell lesions and insulinomas that developed in beta-cell specific Men1 mutant mice, appearing in >80% of beta-cells in hyperplasic or dysplastic islets from the mutant mice > 4 months of age. Moreover, MafB expression could be induced by glucose stimulation in INS-1 rat insulinoma cells. The induction was further reinforced following Men1 knockdown by siRNA. Furthermore, MafB overexpression in cultured beta TC3 cells enhanced cell foci formation both in culture medium and on soft agar, accompanied with the increased expression of Cyclin B1 and D2. Conversely, MafB downregulation by siRNA transfection reduced BrdU incorporation in INS-1E cells. Taken together, our data reveal that Men1 inactivation leads to MafB reexpression in mouse beta-cells in vivo, and provides evidence that deregulated ectopic MafB expression may have a hitherto unknown role in adult beta-cell proliferation and Men1-related tumorigenesis. Oncogene (2012) 31, 3647-3654; doi:10.1038/onc.2011.538; published online 28 November 2011	[Zhang, C. X.] CNRS 5286, INSERM, U1052, Lyon Canc Res Ctr CRCL, F-69008 Lyon, France; [Lu, J.; Hamze, Z.; Bonnavion, R.; Assade, F.; Fontaniere, S.; Bertolino, P.; Cordier-Bussat, M.; Zhang, C. X.] CNRS, UMR5286, Lyon, France; [Lu, J.; Hamze, Z.; Bonnavion, R.; Assade, F.; Fontaniere, S.; Bertolino, P.; Cordier-Bussat, M.; Zhang, C. X.] Univ Lyon, Lyon, France; [Herath, N.; Pouponnot, C.] CNRS, UMR 3347, Inst Curie, INSERM,U1021, F-91405 Orsay, France; [Lu, J.; Zhang, C. X.] Ruijin Hosp, Sinofrench Life Sci & Genom Ctr, E Inst Shanghai, Shanghai, Peoples R China; [Lu, J.] Shanghai Jiao Tong Univ, Ruijin Hosp, Shanghai Clin Ctr Endocrine & Metab Dis, Shanghai 200030, Peoples R China	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; Centre de Recherche en cancerologie (CRCL); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Saclay; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Zhang, CX (corresponding author), CNRS 5286, INSERM, U1052, Lyon Canc Res Ctr CRCL, 28 Rue Laennec, F-69008 Lyon, France.	chang.zhang@lyon.unicancer.fr	ZHANG, Chang Xian/G-2905-2013; Bertolino, philippe/D-4072-2018; Cordier-Bussat, Martine/G-4019-2014; Bertolino, philippe/M-8977-2019	Bertolino, philippe/0000-0001-8064-8269; Bertolino, philippe/0000-0001-8064-8269; Zhang, Chang Xian/0000-0002-5443-8951; Bonnavion, Remy/0000-0002-7389-4282	Association pour la Recherche contre le Cancer (ARC), France; Ligue contre le Cancer du Rhone and de la Loire; MIRA program of Region Rhone-Alpes; National Science Foundation of China [NSFC30900700, 81170719, 30800537]; Science and Technology Commission of Shanghai Municipality [10140902900]; PhD-fellowship from ARC; Shanghai Pujiang Program [10PJ1408900]; Shanghai New Excellent Youth Program [XYQ2011009]	Association pour la Recherche contre le Cancer (ARC), France(Fondation ARC pour la Recherche sur le Cancer); Ligue contre le Cancer du Rhone and de la Loire; MIRA program of Region Rhone-Alpes(Region Auvergne-Rhone-Alpes); National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); PhD-fellowship from ARC(Australian Research Council); Shanghai Pujiang Program(Shanghai Pujiang Program); Shanghai New Excellent Youth Program	We are grateful to Denis Ressnikoff for expert assistance of confocal microscopy, Jean-Michel Vicat and Martin Donnadieu for the maintenance of the mouse colonies, Dr Fabienne Rajas for help in high fat diet experiments, Pr. Jacques Philippe for Arx antibody, Dr Pierre Maechler for providing INS-1E line to M Cordier-Bussat. This study was supported by the Association pour la Recherche contre le Cancer (ARC), France, the Ligue contre le Cancer du Rhone and de la Loire, the MIRA program of Region Rhone-Alpes, National Science Foundation of China (NSFC30900700, 81170719, 30800537), and Science and Technology Commission of Shanghai Municipality (10140902900). J Lu and Z Hamze were the recipients of PhD-fellowship from ARC. J Lu was also the recipient of Shanghai Pujiang Program (10PJ1408900) and Shanghai New Excellent Youth Program (XYQ2011009).	Artner I, 2006, DIABETES, V55, P297, DOI 10.2337/diabetes.55.02.06.db05-0946; Artner I, 2007, P NATL ACAD SCI USA, V104, P3853, DOI 10.1073/pnas.0700013104; Bertolino P, 2003, MOL ENDOCRINOL, V17, P1880, DOI 10.1210/me.2003-0154; Bertolino P, 2003, CANCER RES, V63, P4836; Chesi M, 1998, BLOOD, V91, P4457, DOI 10.1182/blood.V91.12.4457.412k48_4457_4463; Crabtree JS, 2003, MOL CELL BIOL, V23, P6075, DOI 10.1128/MCB.23.17.6075-6085.2003; Eychene A, 2008, NAT REV CANCER, V8, P683, DOI 10.1038/nrc2460; Fontaniere S, 2006, ENDOCR-RELAT CANCER, V13, P1223, DOI 10.1677/erc.1.01294; Fontaniere S, 2008, J ENDOCRINOL, V199, P287, DOI 10.1677/JOE-08-0289; Huang K, 2000, GENE, V242, P419, DOI 10.1016/S0378-1119(99)00500-4; Hurt EM, 2004, CANCER CELL, V5, P191, DOI 10.1016/S1535-6108(04)00019-4; Hussein N, 2007, EUR J CANCER, V43, P402, DOI 10.1016/j.ejca.2006.08.038; Karnik SK, 2007, SCIENCE, V318, P806, DOI 10.1126/science.1146812; Loffler KA, 2007, INT J CANCER, V120, P259, DOI 10.1002/ijc.22288; Lu JL, 2010, GASTROENTEROLOGY, V138, P1954, DOI 10.1053/j.gastro.2010.01.046; Merglen A, 2004, ENDOCRINOLOGY, V145, P667, DOI 10.1210/en.2003-1099; Morito N, 2006, CANCER RES, V66, P812, DOI 10.1158/0008-5472.CAN-05-2154; Morito N, 2011, CANCER RES, V71, P339, DOI 10.1158/0008-5472.CAN-10-1057; Mould AW, 2007, INT J CANCER, V121, P776, DOI 10.1002/ijc.22734; Nishimura W, 2008, DEV BIOL, V314, P443, DOI 10.1016/j.ydbio.2007.12.009; Nishimura W, 2006, DEV BIOL, V293, P526, DOI 10.1016/j.ydbio.2006.02.028; Nishizawa M, 2003, ONCOGENE, V22, P7882, DOI 10.1038/sj.onc.1206526; Pechhold S, 2009, NAT BIOTECHNOL, V27, P1038, DOI 10.1038/nbt.1579; Pouponnot C, 2006, ONCOGENE, V25, P1299, DOI 10.1038/sj.onc.1209171; Rocques N, 2007, MOL CELL, V28, P584, DOI 10.1016/j.molcel.2007.11.009; Schnepp RW, 2006, CANCER RES, V66, P5707, DOI 10.1158/0008-5472.CAN-05-4518; Teta M, 2007, DEV CELL, V12, P817, DOI 10.1016/j.devcel.2007.04.011; van Stralen E, 2009, EXP HEMATOL, V37, P78, DOI 10.1016/j.exphem.2008.08.006; Wang HY, 1997, P NATL ACAD SCI USA, V94, P4372, DOI 10.1073/pnas.94.9.4372; Xavier GD, 2010, BIOCHEM BIOPH RES CO, V402, P252, DOI 10.1016/j.bbrc.2010.10.010; Yang YM, 2010, J TAIWAN INST CHEM E, V41, P1, DOI 10.1016/j.jtice.2009.11.002; Yang YQ, 2007, MOL CELL ENDOCRINOL, V265, P34, DOI 10.1016/j.mce.2006.12.032; Zhang C, 2005, MOL CELL BIOL, V25, P4969, DOI 10.1128/MCB.25.12.4969-4976.2005	33	26	28	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2012	31	31					3647	3654		10.1038/onc.2011.538	http://dx.doi.org/10.1038/onc.2011.538			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985EG	22120711				2022-12-17	WOS:000307245600007
J	McDonnell, SRP; Hwang, SR; Basrur, V; Conlon, KP; Fermin, D; Wey, E; Murga-Zamalloa, C; Zeng, Z; Zu, Y; Elenitoba-Johnson, KSJ; Lim, MS				McDonnell, S. R. P.; Hwang, S. R.; Basrur, V.; Conlon, K. P.; Fermin, D.; Wey, E.; Murga-Zamalloa, C.; Zeng, Z.; Zu, Y.; Elenitoba-Johnson, K. S. J.; Lim, M. S.			NPM-ALK signals through glycogen synthase kinase 3 beta to promote oncogenesis	ONCOGENE			English	Article						NPM-ALK; GSK3; ALCL; oncogenesis	ANAPLASTIC LYMPHOMA KINASE; TYROSINE KINASE; APOPTOSIS; CELLS; PHOSPHORYLATION; INHIBITION; PROTEIN; CDC25A; INACTIVATION; CAL-101	Anaplastic large cell lymphoma (ALCL) is the most common type of pediatric peripheral T-cell lymphoma. In 70-80% of cases, the chromosomal aberration t(2;5)(p23;q35) results in the juxtaposition of anaplastic lymphoma kinase (ALK) with nucleophosmin (NPM) and the subsequent expression of the NPM-ALK fusion protein. NPM-ALK is a chimeric tyrosine kinase, which induces numerous signaling pathways that drive proliferation and abrogate apoptosis. However, the mechanisms that lead to activation of downstream growth regulatory molecules have not been completely elucidated. Using a mass spectrometry-based phosphoproteomic screen, we identified GSK3 beta as a signaling mediator of NPM-ALK. Using a selective inhibitor of ALK, we demonstrated that the tyrosine kinase activity of ALK regulates the serine-9 phosphorylation of GSK3 beta. Expression of NPM-ALK in 293T cells led to an increase of pS(9)-GSK3 beta (glycogen synthase kinase 3 beta) compared with kinase-defective K210R mutant NPM-ALK, but did not affect total GSK3 beta levels. Phosphorylation of pS(9)-GSK3 beta by NPM-ALK was mediated by the PI3K/AKT signaling pathway. ALK inhibition resulted in degradation of GSK3 beta substrates Mcl-1 and CDC25A, which was recovered upon chemical inhibition of the proteasome (MG132). Furthermore, the degradation of Mcl-1 was recoverable with inhibition of GSK3 beta. ALK inhibition also resulted in decreased cell viability, which was rescued by GSK3 beta inhibition. Furthermore, stable knockdown of GSK3 beta conferred resistance to the growth inhibitory effects of ALK inhibition using viability and colony formation assays. pS(9)-GSK3 beta and CDC25A were selectively expressed in neoplastic cells of ALK + ALCL tissue biopsies, and showed a significant correlation (P<0.001). Conversely, ALK-ALCL tissue biopsies did not show significant correlation of pS(9)-GSK3 beta and CDC25A expression (P<0.2). Our results demonstrate that NPM-ALK regulates the phosphorylation of S-9-GSK3 beta by PI3K/AKT. The subsequent inhibition of GSK3 beta activity results in accumulation of CDC25A and Mcl-1, which confers the advantage of growth and protection from apoptosis. These findings provide support for the role of GSK3 beta as a mediator of NPM-ALK oncogenesis. Oncogene (2012) 31, 3733-3740; doi:10.1038/onc.2011.542; published online 19 December 2011	[McDonnell, S. R. P.; Hwang, S. R.; Basrur, V.; Conlon, K. P.; Fermin, D.; Wey, E.; Murga-Zamalloa, C.; Elenitoba-Johnson, K. S. J.; Lim, M. S.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Zeng, Z.; Zu, Y.] Methodist Hosp, Dept Pathol, Houston, TX 77030 USA	University of Michigan System; University of Michigan; The Methodist Hospital System; The Methodist Hospital - Houston	Lim, MS (corresponding author), Biomed Sci Res Bldg,Room 2039,109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	meganlim@med.umich.edu	Murga-Zamalloa, Carlos/AAX-9387-2021	Murga-Zamalloa, Carlos/0000-0002-2238-5066; Hwang, Steven/0000-0002-6536-1291; Elenitoba-Johnson, Kojo/0000-0002-1082-1545; Lim, Megan/0000-0002-0415-2867	NIH [5R01CA140806-02, R01DE119249, R01CA136905]; NATIONAL CANCER INSTITUTE [R01CA136905, R01CA140806] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported in part by funding from the NIH (5R01CA140806-02) awarded to MS Lim, MD/PhD and (R01DE119249 and R01CA136905) KSJ Elenitoba-Johnson, MD. Mangeng Cheng, PhD of Cephalon, Inc provided the small molecule ALK inhibitor.	Amin HM, 2007, BLOOD, V110, P2259, DOI 10.1182/blood-2007-04-060715; Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; Boccalatte FE, 2009, BLOOD, V113, P2776, DOI 10.1182/blood-2008-06-161018; BOSTOCK CJ, 1971, EXP CELL RES, V68, P163, DOI 10.1016/0014-4827(71)90599-4; Boulares AH, 1999, J BIOL CHEM, V274, P22932, DOI 10.1074/jbc.274.33.22932; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Fernandez-Vidal A, 2009, CELL CYCLE, V8, P1373, DOI 10.4161/cc.8.9.8302; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Herman SEM, 2010, BLOOD, V116, P2078, DOI 10.1182/blood-2010-02-271171; Ito M, 2010, CANCER GENE THER, V17, P633, DOI 10.1038/cgt.2010.20; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Kang T, 2008, CANCER CELL, V13, P36, DOI 10.1016/j.ccr.2007.12.002; Lannutti BJ, 2011, BLOOD, V117, P591, DOI 10.1182/blood-2010-03-275305; Lim MS, 2009, BLOOD, V114, P1585, DOI 10.1182/blood-2009-02-204735; Marzec M, 2007, ONCOGENE, V26, P813, DOI 10.1038/sj.onc.1209843; Maurer U, 2006, MOL CELL, V21, P749, DOI 10.1016/j.molcel.2006.02.009; Meijer L, 2003, CHEM BIOL, V10, P1255, DOI 10.1016/j.chembiol.2003.11.010; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Ott GR, 2010, ACS MED CHEM LETT, V1, P493, DOI 10.1021/ml100158s; Palmer RH, 2009, BIOCHEM J, V420, P345, DOI 10.1042/BJ20090387; Ruchatz H, 2003, EXP HEMATOL, V31, P309, DOI 10.1016/S0301-472X(03)00007-9; Rush J, 2005, NAT BIOTECHNOL, V23, P94, DOI 10.1038/nbt1046; Slupianek A, 2001, CANCER RES, V61, P2194; van Noort M, 2002, J BIOL CHEM, V277, P17901, DOI 10.1074/jbc.M111635200; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Zamo A, 2002, ONCOGENE, V21, P1038, DOI 10.1038/sj.onc.1205152; Zhao Y, 2007, MOL CELL BIOL, V27, P4328, DOI 10.1128/MCB.00153-07	32	26	27	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2012	31	32					3733	3740		10.1038/onc.2011.542	http://dx.doi.org/10.1038/onc.2011.542			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	990TF	22179823	Green Accepted			2022-12-17	WOS:000307653800007
J	Sulzmaier, FJ; Valmiki, MKG; Nelson, DA; Caliva, MJ; Geerts, D; Matter, ML; White, EP; Ramos, JW				Sulzmaier, F. J.; Valmiki, M. K. G.; Nelson, D. A.; Caliva, M. J.; Geerts, D.; Matter, M. L.; White, E. P.; Ramos, J. W.			PEA-15 potentiates H-Ras-mediated epithelial cell transformation through phospholipase D	ONCOGENE			English	Article						PEA-15; PLD; cell cycle; H-Ras; cell transformation	PHOSPHATIDIC-ACID; CYCLIN D1/CDK4; CANCER-CELLS; PROTEIN; EXPRESSION; KINASE; SIGNAL; ACTIVATION; APOPTOSIS; RECEPTOR	The small GTPase H-Ras is a proto-oncogene that activates a variety of different pathways including the extracellular-signal-regulated kinase (ERK)/mitogen-activated protein kinase pathway. H-Ras is mutated in many human malignancies, and these mutations cause the protein to be constitutively active. Phosphoprotein enriched in astrocytes, 15 kDa (PEA-15) blocks ERK-dependent gene transcription and inhibits proliferation by sequestering ERK in the cytoplasm. We therefore investigated whether PEA-15 influences H-Ras-mediated transformation. We found that PEA-15 does not block H-Ras-activated proliferation when H-Ras is constitutively active. We show instead that in H-Ras-transformed mouse kidney epithelial cells, co-expression of PEA-15 resulted in enhanced soft agar colony growth and increased tumor growth in vivo. Overexpression of both H-Ras and PEA-15 resulted in accelerated G1/S cell cycle transition and increased activation of the ERK signaling pathway. PEA-15 mediated these effects through activation of its binding partner phospholipase D1 (PLD1). Inhibition of PLD1 or interference with PEA-15/PLD1 binding blocked PEA-15's ability to increase ERK activation. Our findings reveal a novel mechanism by which PEA-15 positively regulates Ras/ERK signaling and increases the proliferation of H-Ras-transformed epithelial cells through enhanced PLD1 expression and activation. Thus, our work provides a surprising mechanism by which PEA-15 augments H-Ras-driven transformation. These data reveal that PEA-15 not only suppresses ERK signaling and tumorigenesis but also alternatively enhances tumorigenesis in the context of active Ras. Oncogene (2012) 31, 3547-3560; doi:10.1038/onc.2011.514; published online 21 November 2011	[Sulzmaier, F. J.; Valmiki, M. K. G.; Caliva, M. J.; Ramos, J. W.] Univ Hawaii Manoa, Univ Hawaii Canc Ctr, Canc Biol Program, Honolulu, HI 96813 USA; [Sulzmaier, F. J.; Valmiki, M. K. G.; Ramos, J. W.] Univ Hawaii Manoa, Dept Mol Biosci & Bioengn, Honolulu, HI USA; [Nelson, D. A.; White, E. P.] Inst Canc Res, New Brunswick, NJ USA; [Caliva, M. J.; Matter, M. L.] Univ Hawaii Manoa, John A Burns Sch Med, Dept Cell & Mol Biol, Honolulu, HI USA; [Geerts, D.] Sophia Childrens Univ Hosp, Dept Pediat Oncol Hematol, Rotterdam, Netherlands	Cancer Research Center of Hawaii; University of Hawaii System; University of Hawaii Manoa; University of Hawaii System; University of Hawaii Manoa; University of Hawaii System; University of Hawaii Manoa; Erasmus University Rotterdam; Erasmus MC - Sophia Children's Hospital	Ramos, JW (corresponding author), Univ Hawaii Manoa, Univ Hawaii Canc Ctr, Canc Biol Program, Biosciences Bldg,Room 241C,651 Halo St, Honolulu, HI 96813 USA.	jramos@cc.hawaii.edu	Matter, Michelle/GSN-9703-2022; Ramos, Joe/G-4074-2010; White, Eileen/ABD-6745-2021; Gudur Valmiki, Mohana/H-2391-2017; Geerts, Dirk/K-8260-2015	Ramos, Joe/0000-0002-9708-2115; White, Eileen/0000-0003-2961-3065; Gudur Valmiki, Mohana/0000-0002-7313-9092; Geerts, Dirk/0000-0002-6386-8187; Matter, Michelle/0000-0002-5988-9663	National Institutes of Health National Cancer Institute [R01CA93849]; National Institute of General Medicine [R01GM088266]; Victoria S and Bradley Geist Foundation; NIH National Center for Reasearch Resources [RR016453]; National Institutes of Health [R37CA53370]; NATIONAL CANCER INSTITUTE [P30CA071789, R37CA053370, R01CA093849] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016453] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM088266] Funding Source: NIH RePORTER	National Institutes of Health National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute of General Medicine(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Victoria S and Bradley Geist Foundation; NIH National Center for Reasearch Resources; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Maarit Tiirikainen and the University of Hawaii Cancer Center Genomics Shared Resource laboratory for their assistance with the mRNA expression analysis. We also thank Anna Knapinska, Shirley Young-Robbins and Marci Takemoto for their excellent technical assistance. This work was supported by the National Institutes of Health National Cancer Institute (R01CA93849 to JWR) and National Institute of General Medicine (R01GM088266 to JWR) and the Victoria S and Bradley Geist Foundation (to JWR). MLM was supported by NIH National Center for Reasearch Resources Grant RR016453. DAN and EPW were supported by a grant from the National Institutes of Health (R37CA53370 to EPW).	Barrett T, 2009, NUCLEIC ACIDS RES, V37, pD885, DOI 10.1093/nar/gkn764; Bartholomeusz C, 2008, CANCER RES, V68, P9302, DOI 10.1158/0008-5472.CAN-08-2592; Buchanan FG, 2005, P NATL ACAD SCI USA, V102, P1638, DOI 10.1073/pnas.0406698102; Castaneda CA, 2010, CANCER METAST REV, V29, P751, DOI 10.1007/s10555-010-9261-0; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; Cordova-Alarcon E, 2005, ARCH MED RES, V36, P311, DOI 10.1016/j.arcmed.2005.04.001; Degenhardt K, 2006, CLIN CANCER RES, V12, P5298, DOI 10.1158/1078-0432.CCR-06-0439; Donaldson JG, 2009, BBA-MOL CELL BIOL L, V1791, P845, DOI 10.1016/j.bbalip.2009.05.011; Doti N, 2010, MOL BIOSYST, V6, P2039, DOI 10.1039/c005272h; Dunn KL, 2005, BIOCHEM CELL BIOL, V83, P1, DOI 10.1139/O04-121; Ferro E, 2010, CELL SIGNAL, V22, P1804, DOI 10.1016/j.cellsig.2010.05.010; Formisano P, 2005, ONCOGENE, V24, P7012, DOI 10.1038/sj.onc.1208871; Formstecher E, 2001, DEV CELL, V1, P239, DOI 10.1016/S1534-5807(01)00035-1; Frankel P, 1999, BIOCHEM BIOPH RES CO, V255, P502, DOI 10.1006/bbrc.1999.0234; Haling JR, 2010, MOL BIOL CELL, V21, P664, DOI 10.1091/mbc.E09-08-0659; Hancock JF, 2007, NAT CELL BIOL, V9, P615, DOI 10.1038/ncb0607-615; Joseph T, 2001, BIOCHEM BIOPH RES CO, V289, P1019, DOI 10.1006/bbrc.2001.6118; Joseph T, 2002, ONCOGENE, V21, P3651, DOI 10.1038/sj.onc.1205380; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lazarov M, 2002, NAT MED, V8, P1105, DOI 10.1038/nm779; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; LOVEC H, 1994, ONCOGENE, V9, P323; Lu ZM, 2000, MOL CELL BIOL, V20, P462, DOI 10.1128/MCB.20.2.462-467.2000; Macaluso M, 2002, J CELL PHYSIOL, V192, P125, DOI 10.1002/jcp.10109; Nandan MO, 2004, ONCOGENE, V23, P3404, DOI 10.1038/sj.onc.1207397; Noh DY, 2000, CANCER LETT, V161, P207, DOI 10.1016/S0304-3835(00)00612-1; Pastorino S, 2010, FASEB J, V24, P2818, DOI 10.1096/fj.09-144295; Radig K, 1998, PATHOL RES PRACT, V194, P157, DOI 10.1016/S0344-0338(98)80016-2; Ramos JW, 2008, INT J BIOCHEM CELL B, V40, P2707, DOI 10.1016/j.biocel.2008.04.009; Ramos JW, 2000, MOL BIOL CELL, V11, P2863, DOI 10.1091/mbc.11.9.2863; Renganathan H, 2005, BIOCHEM J, V390, P729, DOI 10.1042/BJ20050378; Revet I, 2008, EXP CELL RES, V314, P707, DOI 10.1016/j.yexcr.2007.12.008; Rizzo MA, 2000, J BIOL CHEM, V275, P23911, DOI 10.1074/jbc.M001553200; Sathyan KM, 2007, MODERN PATHOL, V20, P1141, DOI 10.1038/modpathol.3800948; Scott SA, 2009, NAT CHEM BIOL, V5, P108, DOI 10.1038/nchembio.140; Shi M, 2007, CANCER LETT, V258, P268, DOI 10.1016/j.canlet.2007.09.003; Streit M, 1999, AM J PATHOL, V155, P441, DOI 10.1016/S0002-9440(10)65140-1; Tan TT, 2005, CANCER CELL, V7, P227, DOI 10.1016/j.ccr.2005.02.008; Uchida H, 1999, ANTICANCER RES, V19, P671; Uchida N, 1997, J CANCER RES CLIN, V123, P280, DOI 10.1007/s004320050060; Vaidyanathan H, 2007, P NATL ACAD SCI USA, V104, P19837, DOI 10.1073/pnas.0704514104; Viparelli F, 2008, J BIOL CHEM, V283, P21769, DOI 10.1074/jbc.M803771200; WABER PG, 1993, CANCER, V72, P3732, DOI 10.1002/1097-0142(19931215)72:12<3732::AID-CNCR2820721228>3.0.CO;2-U; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Whitehurst AW, 2004, J BIOL CHEM, V279, P12840, DOI 10.1074/jbc.M310031200; Yang HZ, 2001, BBA-PROTEIN STRUCT M, V1547, P313, DOI 10.1016/S0167-4838(01)00202-3; Zeng X, 2010, ONCOGENE, V29, P5103, DOI 10.1038/onc.2010.253; Zhang Y, 2000, J BIOL CHEM, V275, P35224, DOI 10.1074/jbc.M003329200; Zhao C, 2007, NAT CELL BIOL, V9, P706, DOI 10.1038/ncb1594; Zhao YT, 2000, BIOCHEM BIOPH RES CO, V278, P140, DOI 10.1006/bbrc.2000.3719	50	26	28	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2012	31	30					3547	3560		10.1038/onc.2011.514	http://dx.doi.org/10.1038/onc.2011.514			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	979UA	22105357	Green Accepted			2022-12-17	WOS:000306844100007
J	Yu, D; Zhan, XH; Zhao, XF; Williams, MS; Carey, GB; Smith, E; Scott, D; Zhu, J; Guo, Y; Cherukuri, S; Civin, CI; Zhan, X				Yu, D.; Zhan, X. H.; Zhao, X. F.; Williams, M. S.; Carey, G. B.; Smith, E.; Scott, D.; Zhu, J.; Guo, Y.; Cherukuri, S.; Civin, C. I.; Zhan, X.			Mice deficient in MIM expression are predisposed to lymphomagenesis	ONCOGENE			English	Article						MIM; I-BAR; chemokine; B cells; lymphoma	MISSING-IN-METASTASIS; SUPPRESSOR 1 MTSS1; B-CELL LYMPHOMA; TUMOR-SUPPRESSOR; STRUCTURAL BASIS; DOWN-REGULATION; BLADDER-CANCER; SONIC HEDGEHOG; ACTIN; GENE	Missing in metastasis (MIM) is a member of newly emerged inverse Bin-Amphiphysin-Rvs (BAR) domain protein family and a putative metastasis suppressor. Although reduced MIM expression has been associated with bladder, breast and gastric cancers, evidence for the role of MIM in tumor progression remains scarce and controversial. Herein we characterized a MIM knockout mouse strain and observed that MIM-deficient mice often developed enlarged spleens. Autopsy and histological analysis revealed that nearly 78% of MIM(-/-) mice developed tumors with features similar to diffuse large B lymphoma during a period from 1 to 2 years. MIM(-/-) mice also exhibited abnormal distribution of B cells in lymphoid organs with decrease in the spleen but increase in the bone marrow and the peripheral blood. Furthermore, the bone marrow of MIM(-/-) mice contained a higher percentage of pre-B2 cells but fewer immature B-cells than wild-type mice. In response to CXCL13, a B-cell chemokine released from splenic stromal cells, MIM-deficient B-cells did not undergo chemotaxis or morphological changes in response to the chemokine and also did not internalize CXCR5, the receptor of CXCL13. Microarray analyses demonstrated that MIM is the only member of the I-BAR domain family that was highly expressed in human B cells. However, low or absent MIM expression was common in either primary B-cell malignancies or established B-cell acute lymphocytic leukemia or lymphomas. Thus, our data demonstrate for the first time an important role for MIM in B-cell development and suggest that predisposition of MIM-null mice to lymphomagenesis may involve aberrant interactions between B lineage cells and the lymphoid microenvironment. Oncogene (2012) 31, 3561-3568; doi:10.1038/onc.2011.509; published online 14 November 2011	[Yu, D.; Zhan, X. H.; Williams, M. S.; Carey, G. B.; Smith, E.; Zhan, X.] Univ Maryland, Sch Med, Ctr Vasc & Inflammatory Dis, Baltimore, MD 21201 USA; [Zhao, X. F.; Zhan, X.] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; [Williams, M. S.; Carey, G. B.] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA; [Scott, D.] Univ Hlth Sci, Res Dept Med Uniformed Serv, Bethesda, MD USA; [Zhu, J.] Nantong Univ, Affiliated Hosp, Dept Gen Surg, Nantong, Peoples R China; [Guo, Y.; Cherukuri, S.; Civin, C. I.] Univ Maryland, Sch Med, Dept Pediat & Physiol, Ctr Stem Cell Biol & Regenerat Med, Baltimore, MD 21201 USA; [Zhan, X.] Univ Maryland, Sch Med, Marlene Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Nantong University; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Zhan, X (corresponding author), Univ Maryland, Sch Med, Ctr Vasc & Inflammatory Dis, 800 W Baltimore St, Baltimore, MD 21201 USA.	xzhan@som.umaryland.edu			NATIONAL CANCER INSTITUTE [R01CA113809] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI070823] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA113809-05] Funding Source: Medline; NIAID NIH HHS [R01 AI070823] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bailey JM, 2007, J CELL BIOCHEM, V102, P829, DOI 10.1002/jcb.21509; Bodenstine TM, 2008, CANCER MICROENVIRON, V1, P1, DOI 10.1007/s12307-008-0001-8; Bompard G, 2005, J CELL SCI, V118, P5393, DOI 10.1242/jcs.02640; Callahan CA, 2004, GENE DEV, V18, P2724, DOI 10.1101/gad.1221804; CHANG Y, 1992, EMBO J, V11, P1891, DOI 10.1002/j.1460-2075.1992.tb05241.x; Dierks C, 2007, NAT MED, V13, P944, DOI 10.1038/nm1614; Egeblad M, 2010, DEV CELL, V18, P884, DOI 10.1016/j.devcel.2010.05.012; Frost A, 2009, CELL, V137, P191, DOI 10.1016/j.cell.2009.04.010; Gallop JL, 2005, BIOCHEM SOC SYMP, V72, P223, DOI 10.1042/bss0720223; Gribben JG, 2010, CURR OPIN ONCOL, V22, P424, DOI 10.1097/CCO.0b013e32833d5938; Karnoub Antoine E, 2006, Breast Dis, V26, P75; LeBien TW, 2008, BLOOD, V112, P1570, DOI 10.1182/blood-2008-02-078071; Lee SH, 2007, STRUCTURE, V15, P145, DOI 10.1016/j.str.2006.12.005; Lee YG, 2002, NEOPLASIA, V4, P291, DOI 10.1038/sj.neo.7900231; Liang HL, 2003, CANCER CELL, V4, P349, DOI 10.1016/S1535-6108(03)00268-X; Lin JX, 2005, ONCOGENE, V24, P2059, DOI 10.1038/sj.onc.1208412; Lindemann RK, 2008, CANCER RES, V68, P961, DOI 10.1158/0008-5472.CAN-07-5500; Lipp M, 2004, NAT IMMUNOL, V5, P12, DOI 10.1038/ni0104-12; Liu K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-428; Liu W, 2011, DEVELOPMENT, V138, P2035, DOI 10.1242/dev.058800; Loberg RD, 2005, INT J ONCOL, V26, P1699; Ma S, 2007, HUM PATHOL, V38, P1201, DOI 10.1016/j.humpath.2007.01.004; Mahadevan D, 2005, MOL CANCER THER, V4, P1867, DOI 10.1158/1535-7163.MCT-05-0146; Martensson IL, 2010, FEBS LETT, V584, P2572, DOI 10.1016/j.febslet.2010.04.057; Mattila PK, 2007, J CELL BIOL, V176, P953, DOI 10.1083/jcb.200609176; McAllister SS, 2010, J CLIN ONCOL, V28, P4022, DOI 10.1200/JCO.2010.28.4257; Middendorp S, 2009, BLOOD, V114, P2280, DOI 10.1182/blood-2009-03-208215; Millard TH, 2005, EMBO J, V24, P240, DOI 10.1038/sj.emboj.7600535; Morse HC, 2002, BLOOD, V100, P246, DOI 10.1182/blood.V100.1.246; Nixdorf S, 2004, CANCER LETT, V215, P209, DOI 10.1016/j.canlet.2004.05.002; Nowee ME, 2007, J PATHOL, V213, P46, DOI 10.1002/path.2217; Parr C, 2009, EUR J CANCER, V45, P1673, DOI 10.1016/j.ejca.2009.02.019; Quinones GA, 2010, CELL CYCLE, V9, P2522, DOI 10.4161/cc.9.13.12123; Rolink Antonius G, 2004, Methods Mol Biol, V271, P271; Saarikangas J, 2011, J CELL SCI, V124, P1245, DOI 10.1242/jcs.082610; Scita G, 2008, TRENDS CELL BIOL, V18, P52, DOI 10.1016/j.tcb.2007.12.002; Shaffer AL, 2002, NAT REV IMMUNOL, V2, P920, DOI 10.1038/nri953; Su Y, 2008, J IMMUNOL, V181, P1153, DOI 10.4049/jimmunol.181.2.1153; Wang D, 2011, J GASTROINTEST SURG, V15, P1205, DOI 10.1007/s11605-011-1546-2; Wang Y, 2007, CANCER INVEST, V25, P79, DOI 10.1080/07357900701205457; Woodings JA, 2003, BIOCHEM J, V371, P463, DOI 10.1042/BJ20021962; Xia S, 2010, DEVELOPMENT, V137, P1075, DOI 10.1242/dev.049437; Yu D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020845; Yu J, 2010, ONCOGENE, V29, P6464, DOI 10.1038/onc.2010.370	44	26	27	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2012	31	30					3561	3568		10.1038/onc.2011.509	http://dx.doi.org/10.1038/onc.2011.509			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	979UA	22081072	Green Accepted			2022-12-17	WOS:000306844100008
J	Fu, K; Ren, H; Wang, Y; Fei, E; Wang, H; Wang, G				Fu, K.; Ren, H.; Wang, Y.; Fei, E.; Wang, H.; Wang, G.			DJ-1 inhibits TRAIL-induced apoptosis by blocking pro-caspase-8 recruitment to FADD	ONCOGENE			English	Article						DJ-1; TRAIL; FADD; caspase-8; DISC; apoptosis	P53 TRANSCRIPTIONAL ACTIVITY; FAMILIAL PARKINSONS-DISEASE; CANCER-CELLS; ANDROGEN RECEPTOR; DEATH RECEPTORS; TNF-FAMILY; PROTEIN; IDENTIFICATION; EXPRESSION; REGULATOR	DJ-1 was initially identified as an oncogene product involved in human tumorigenesis in cooperation with Ras. Increased DJ-1 expression is associated with tumorigenesis in many cancers, whereas the loss of DJ-1 function is linked to an autosomal recessive form of Parkinson's disease (PD). It has been reported that DJ-1 protects cells from TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis. However, the mechanism by which DJ-1 is involved is still largely unknown. Here we show that DJ-1 inhibits TRAIL-induced apoptosis by blocking Fas-associated protein death domain (FADD)-mediated pro-caspase-8 activation. Wild-type DJ-1, but not the PD-associated mutant L166P, binds to FADD to inhibit the formation of the death-inducing signaling complex (DISC). DJ-1 competes with pro-caspase-8 to bind to FADD at the death effector domain, thereby repressing the recruitment and activation of pro-caspase-8 to the active form of caspase-8. Thus, our study suggests that DJ-1 protects against TRAIL-induced apoptosis through the regulation of DISC formation. Oncogene (2012) 31, 1311-1322; doi:10.1038/onc.2011.315; published online 25 July 2011	Univ Sci & Technol China, Chinese Acad Sci, Lab Mol Neuropathol, Dept Neurobiol,Key Lab Brain Funct & Dis, Hefei, Anhui, Peoples R China; Univ Sci & Technol China, Chinese Acad Sci, Sch Life Sci, Hefei, Anhui, Peoples R China	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS	Wang, G (corresponding author), Univ Sci & Technol China, Chinese Acad Sci, Lab Mol Neuropathol, Dept Neurobiol,Key Lab Brain Funct & Dis, 443 Huangshan Rd, Hefei 230027, Anhui, Peoples R China.	wghui@ustc.edu.cn	FEI, Erkang/AAI-9825-2021; Ren, Haigang/U-6034-2017; Wang, Guanghui/U-3979-2017	Ren, Haigang/0000-0001-8844-4754; Wang, Guanghui/0000-0001-8551-6468; FEI, Erkang/0000-0002-3581-9521	National Natural Sciences Foundation of China [30970921]; National High-tech Research and Development program of China 973 [2011CB5004102]	National Natural Sciences Foundation of China(National Natural Science Foundation of China (NSFC)); National High-tech Research and Development program of China 973	We grateful to Dr Juha Klefstrom (University of Helsinki, Finland) and Dr Xiaolu Yang (University of Pennsylvania) for the kind gifts of pC4M-Fv2E-caspase-8 and the pC4M-Fv2E-caspase-8 C-A mutant and Mian Wu (University of Science and Technology of China, China) for the pGBKT7- FADD plasmid. The ARGENT Regulated Homodimerization Kit was kindly provided by ARIAD Pharmaceuticals (www.ariad.com/regulationkits). This work was supported in part by the National Natural Sciences Foundation of China (No. 30970921) and the National High-tech Research and Development program of China 973-projects (2011CB5004102).	Agata N, 2008, CANCER RES, V68, P6136, DOI 10.1158/0008-5472.CAN-08-0464; Andres-Mateos E, 2007, P NATL ACAD SCI USA, V104, P14807, DOI 10.1073/pnas.0703219104; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; Bretaud S, 2007, J NEUROCHEM, V100, P1626, DOI 10.1111/j.1471-4159.2006.04291.x; Canet-Aviles RM, 2004, P NATL ACAD SCI USA, V101, P9103, DOI 10.1073/pnas.0402959101; Chang DW, 2003, EMBO J, V22, P4132, DOI 10.1093/emboj/cdg414; Clements CM, 2006, P NATL ACAD SCI USA, V103, P15091, DOI 10.1073/pnas.0607260103; Condorelli G, 1999, ONCOGENE, V18, P4409, DOI 10.1038/sj.onc.1202831; Davidson B, 2008, HUM PATHOL, V39, P87, DOI 10.1016/j.humpath.2007.05.014; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Fan J, 2008, FEBS LETT, V582, P1151, DOI 10.1016/j.febslet.2008.03.003; Fan J, 2008, J BIOL CHEM, V283, P4022, DOI 10.1074/jbc.M707176200; Foti R, 2010, J BIOL CHEM, V285, P18565, DOI 10.1074/jbc.M109.088294; Friedlander RM, 2003, NEW ENGL J MED, V348, P1365, DOI 10.1056/NEJMra022366; Giaime E, 2010, CELL DEATH DIFFER, V17, P158, DOI 10.1038/cdd.2009.116; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hod Y, 2004, J CELL BIOCHEM, V92, P1221, DOI 10.1002/jcb.20159; Johnstone RW, 2008, NAT REV CANCER, V8, P782, DOI 10.1038/nrc2465; Junn E, 2005, P NATL ACAD SCI USA, V102, P9691, DOI 10.1073/pnas.0409635102; Kim RH, 2005, CANCER CELL, V7, P263, DOI 10.1016/j.ccr.2005.02.010; Le Naour F, 2001, CLIN CANCER RES, V7, P3328; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Macedo MG, 2003, HUM MOL GENET, V12, P2807, DOI 10.1093/hmg/ddg304; MacKeigan JP, 2003, CANCER RES, V63, P6928; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Miller DW, 2003, J BIOL CHEM, V278, P36588, DOI 10.1074/jbc.M304272200; Mo JS, 2008, CELL DEATH DIFFER, V15, P1030, DOI 10.1038/cdd.2008.26; Moore DJ, 2003, J NEUROCHEM, V87, P1558, DOI 10.1111/j.1471-4159.2003.02265.x; Nagakubo D, 1997, BIOCHEM BIOPH RES CO, V231, P509, DOI 10.1006/bbrc.1997.6132; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nieminen AI, 2007, EMBO J, V26, P1055, DOI 10.1038/sj.emboj.7601551; Niki T, 2003, MOL CANCER RES, V1, P247; Oliver FJ, 1998, J BIOL CHEM, V273, P33533, DOI 10.1074/jbc.273.50.33533; Olzmann JA, 2004, J BIOL CHEM, V279, P8506, DOI 10.1074/jbc.M311017200; Pardo M, 2006, INT J CANCER, V119, P1014, DOI 10.1002/ijc.21942; Ren HG, 2010, CANCER LETT, V297, P101, DOI 10.1016/j.canlet.2010.05.001; Riedl SJ, 2004, NAT REV MOL CELL BIO, V5, P897, DOI 10.1038/nrm1496; Scaffidi C, 1999, CURR OPIN IMMUNOL, V11, P277, DOI 10.1016/S0952-7915(99)80045-4; Shinbo Y, 2006, CELL DEATH DIFFER, V13, P96, DOI 10.1038/sj.cdd.4401704; Sitaram RT, 2009, INT J CANCER, V125, P783, DOI 10.1002/ijc.24335; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Takahashi K, 2001, J BIOL CHEM, V276, P37556, DOI 10.1074/jbc.M101730200; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tillman JE, 2007, CANCER RES, V67, P4630, DOI 10.1158/0008-5472.CAN-06-4556; Vasseur S, 2009, P NATL ACAD SCI USA, V106, P1111, DOI 10.1073/pnas.0812745106; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Xu J, 2005, HUM MOL GENET, V14, P1231, DOI 10.1093/hmg/ddi134; Zhang HY, 2008, ENDOCR-RELAT CANCER, V15, P535, DOI 10.1677/ERC-07-0195	52	26	29	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	10					1311	1322		10.1038/onc.2011.315	http://dx.doi.org/10.1038/onc.2011.315			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906KS	21785459	Bronze			2022-12-17	WOS:000301344600010
J	Sala, G; Traini, S; D'Egidio, M; Vianale, G; Rossi, C; Piccolo, E; Lattanzio, R; Piantelli, M; Tinari, N; Natali, PG; Muraro, R; Iacobelli, S				Sala, G.; Traini, S.; D'Egidio, M.; Vianale, G.; Rossi, C.; Piccolo, E.; Lattanzio, R.; Piantelli, M.; Tinari, N.; Natali, P. G.; Muraro, R.; Iacobelli, S.		CINBO	An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling	ONCOGENE			English	Article						ErbB-3 receptor; ErbB-3/Akt pathway; monoclonal antibody; targeted therapy	RECEPTOR TYROSINE KINASES; BREAST-CANCER; PHOSPHOLIPASE C-GAMMA-1; MONOCLONAL-ANTIBODIES; LUNG-CANCER; CELL-LINES; EXPRESSION; HER3; RESISTANCE; CARCINOMAS	The ErbB receptors, such as ErbB-1 and ErbB-2, have been intensely pursued as targets for cancer therapeutics. Although initially efficacious in a subset of patients, drugs targeting these receptors led invariably to resistance, which is often associated with reactivation of the ErbB-3-PI3K-Akt signaling. This may be overcome by an ErbB-3 ligand that abrogates receptor-mediated signaling. Toward this end, we have generated a mouse monoclonal antibody, MP-RM-1, against the extracellular domain (ECD) of ErbB-3 receptor. Assessment of human tumor cell lines, as well as early passage tumor cells revealed that MP-RM-1 effectively inhibited both NRG-1 beta-dependent and -independent ErbB-3 activation. The antagonizing effect of MP-RM-1 was of non-competitive type, as binding of [I-125]-labeled NRG-1 beta to ErbB-3 was not influenced by the antibody. MP-RM-1 treatment led, in most instances, to decreased ErbB-3 expression. In addition, MP-RM-1 was able to inhibit the colony formation ability of tumor cells and tumor growth in two human tumor xenograft nude mouse models. Treatment with the antibody was associated with a decreased ErbB-3 and Akt phosphorylation and ErbB-3 expression in the excised tumor tissue. Collectively, these results indicate that MP-RM-1 has the potential to interfere with signaling by ErbB-3 and reinforce the notion that ErbB-3 could be a key target in cancer-drug design. Oncogene (2012) 31, 1275-1286; doi: 10.1038/onc.2011.322; published online 8 August 2011	[Sala, G.; Traini, S.; D'Egidio, M.; Vianale, G.; Rossi, C.; Piccolo, E.; Lattanzio, R.; Piantelli, M.; Tinari, N.; Muraro, R.; Iacobelli, S.] Univ Fdn G DAnnunzio, Dept Oncol & Expt Med, I-66100 Chieti, Italy; [Sala, G.; Traini, S.; D'Egidio, M.; Piccolo, E.; Piantelli, M.; Tinari, N.; Natali, P. G.; Muraro, R.; Iacobelli, S.] MediaPharma Srl, Chieti, Italy	G d'Annunzio University of Chieti-Pescara	Sala, G (corresponding author), Univ Fdn G DAnnunzio, Dept Oncol & Expt Med, Via Colle Ara 1, I-66100 Chieti, Italy.	g.sala@unich.it	Sala, Gianluca/C-2056-2017; Lattanzio, Rossano/K-1927-2018	Sala, Gianluca/0000-0002-4494-915X; Lattanzio, Rossano/0000-0001-9803-4476; Piantelli, Mauro/0000-0003-0154-482X; Traini, Sara/0000-0003-3233-4833; Tinari, Nicola/0000-0001-8449-5407	AIRC	AIRC(Fondazione AIRC per la ricerca sul cancro)	We thank Dr F Petronzelli (Sigma-Tau Pomezia, Italy) for the measurement of MP-RM-1 affinity by surface plasmonic resonance; Dr O Segatto, Dr S Anastasi and Dr M Sallese for advice and reagents, R La Sorda and MR Nicotra for the immunohistochemical analysis, Dr A Sala and Professor V De Laurenzi for discussion. PGN and MP partially supported by AIRC.	ALIMANDI M, 1995, ONCOGENE, V10, P1813; Anastasi S, 2005, ONCOGENE, V24, P4540, DOI 10.1038/sj.onc.1208658; Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656; Baulida J, 1996, J BIOL CHEM, V271, P5251; Bianchi S, 2006, J CELL PHYSIOL, V206, P702, DOI 10.1002/jcp.20535; Chen LQ, 2010, CANCER RES, V70, P5994, DOI 10.1158/0008-5472.CAN-09-4440; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIGIESI G, 1992, HYBRIDOMA, V11, P519, DOI 10.1089/hyb.1992.11.519; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Fiorini M, 2002, ONCOGENE, V21, P6530, DOI 10.1038/sj.onc.1205823; Franklin MC, 2004, CANCER CELL, V5, P317, DOI 10.1016/S1535-6108(04)00083-2; Giampaglia M, 2010, CANCER TREAT REV, V36, pS72, DOI 10.1016/S0305-7372(10)70024-4; Gschwind A, 2004, NAT REV CANCER, V4, P361, DOI 10.1038/nrc1360; Hynes Nancy E., 2007, V172, P45; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Ishikawa N, 2005, CANCER RES, V65, P9176, DOI 10.1158/0008-5472.CAN-05-1556; Karamouzis MV, 2007, INT J BIOCHEM CELL B, V39, P851, DOI 10.1016/j.biocel.2006.11.017; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; Lee-Hoeflich ST, 2008, CANCER RES, V68, P5878, DOI 10.1158/0008-5472.CAN-08-0380; Leonetti C, 1996, JNCI-J NATL CANCER I, V88, P419, DOI 10.1093/jnci/88.7.419; Liu BL, 2007, INT J CANCER, V120, P1874, DOI 10.1002/ijc.22423; Mendelsohn J, 2006, SEMIN ONCOL, V33, P369, DOI 10.1053/j.seminoncol.2006.04.003; MOTTOLESE M, 1988, EUR J CANCER CLIN ON, V24, P1277, DOI 10.1016/0277-5379(88)90215-5; NATALI PG, 1993, BRIT J CANCER, V68, P746, DOI 10.1038/bjc.1993.422; Piccolo E, 2002, ONCOGENE, V21, P6520, DOI 10.1038/sj.onc.1205821; Prewett M, 1998, CLIN CANCER RES, V4, P2957; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; REGECAMBRIN G, 1992, CANCER GENET CYTOGEN, V64, P170, DOI 10.1016/0165-4608(92)90350-H; Reschke M, 2008, CLIN CANCER RES, V14, P5188, DOI 10.1158/1078-0432.CCR-08-0186; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Sala G, 2008, CANCER RES, V68, P10187, DOI 10.1158/0008-5472.CAN-08-1181; Saxena R, 2010, MED RES REV; Schoeberl B, 2010, CANCER RES, V70, P2485, DOI 10.1158/0008-5472.CAN-09-3145; Schoeberl B, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000352; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; Shi FM, 2010, P NATL ACAD SCI USA, V107, P7692, DOI 10.1073/pnas.1002753107; Sithanandam G, 2005, ONCOGENE, V24, P1847, DOI 10.1038/sj.onc.1208381; SUNADA H, 1986, P NATL ACAD SCI USA, V83, P3825, DOI 10.1073/pnas.83.11.3825; Tanner B, 2006, J CLIN ONCOL, V24, P4317, DOI 10.1200/JCO.2005.04.8397; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; WEINSTEIN JN, 1992, CANCER RES, V52, pS2747; Witton CJ, 2003, J PATHOL, V200, P290, DOI 10.1002/path.1370; Wu WKK, 2009, ANTICANCER RES, V29, P229; Yi ES, 1997, MODERN PATHOL, V10, P142; Zhou BBS, 2006, CANCER CELL, V10, P39, DOI 10.1016/j.ccr.2006.05.024	48	26	33	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	10					1275	1286		10.1038/onc.2011.322	http://dx.doi.org/10.1038/onc.2011.322			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906KS	21822299				2022-12-17	WOS:000301344600007
J	Xu, PZ; Chen, ML; Jeon, SM; Peng, XD; Hay, N				Xu, P-Z; Chen, M-L; Jeon, S-M; Peng, X-D; Hay, N.			The effect Akt2 deletion on tumor development in Pten(+/-) mice	ONCOGENE			English	Article						Akt2; Pten; tumor development; hyperinsulinemia	INSULIN-RESISTANCE; PROSTATE-CANCER; CELL-MIGRATION; IN-VIVO; PTEN; DEFICIENCY; BREAST; SUPPRESSION; NEOPLASIA; GROWTH	The serine/threonine kinase Akt is frequently activated in human cancers and is considered an attractive therapeutic target. However, the relative contributions of the different Akt isoforms to tumorigenesis, and the effect of their deficiencies on cancer development are not well understood. We had previously shown that Akt1 deficiency is sufficient to markedly reduce the incidence of tumors in Pten(+/-) mice. Particularly, Akt1 deficiency inhibits endometrial carcinoma and prostate neoplasia in Pten(+/-) mice. Here, we analyzed the effect of Akt2 deficiency on the incidence of tumors in Pten(+/-) mice. Relative to Akt1, Akt2 deficiency had little-to-no effect on the incidence of prostate neoplasia, endometrial carcinoma, intestinal polyps and adrenal lesions in Pten(+/-) mice. However, Akt2 deficiency significantly decreased the incidence of thyroid tumors in Pten(+/-), which correlates with the relatively high level of Akt2 expression in the thyroid. Thus, unlike Akt1 deletion, Akt2 deletion is not sufficient to markedly inhibit tumorigenesis in Pten(+/-) mice in most tested tissues. The relatively small effect of Akt2 deletion on the inhibition of tumorigenesis in Pten(+/-) mice could be explained, in part, by an insufficient decrease in total Akt activity, due to the relatively lower Akt2 versus Akt1 expression, and relatively high blood insulin levels in Pten(+/-) Akt2(-/-) mice. The relatively high blood insulin levels in Pten(+/-) Akt2(-/-) mice may elevate the activity of Akt1, and possibly Akt3, thus, limiting the reduction of total Akt activity and preventing this activity from dropping to a threshold level required to inhibit tumorigenesis. Oncogene (2012) 31, 518-526; doi: 10.1038/onc.2011.243; published online 11 July 2011	[Xu, P-Z; Chen, M-L; Jeon, S-M; Peng, X-D; Hay, N.] Univ Illinois, Dept Biochem & Mol Genet, Coll Med, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Hay, N (corresponding author), Univ Illinois, Dept Biochem & Mol Genet MC 669, Coll Med, 900 S Ashland Ave, Chicago, IL 60607 USA.	nhay@uic.edu	Jeon, Sang-Min/I-7917-2018; Peng, Xiao-ding/B-2478-2012	Jeon, Sang-Min/0000-0002-0132-925X; Peng, Xiao-ding/0000-0002-9214-0136	NIH [CA090764, AG016927, AG025953]; NATIONAL CANCER INSTITUTE [R01CA090764] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG025953, R01AG016927] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000733] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Veterans Affairs(US Department of Veterans Affairs)	These studies were supported by NIH grants, CA090764, AG016927 and AG025953 to NH.	Bhaskar PT, 2007, DEV CELL, V12, P487, DOI 10.1016/j.devcel.2007.03.020; Cairns P, 1997, CANCER RES, V57, P4997; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chen ML, 2006, GENE DEV, V20, P1569, DOI 10.1101/gad.1395006; Chen WS, 2009, MOL CELL BIOL, V29, P3151, DOI 10.1128/MCB.01792-08; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Chin YR, 2010, MOL CELL, V38, P333, DOI 10.1016/j.molcel.2010.02.031; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Gallagher EJ, 2010, CURR DIABETES REP, V10, P93, DOI 10.1007/s11892-010-0101-y; Garofalo RS, 2003, J CLIN INVEST, V112, P197, DOI 10.1172/JCI200316885; Iliopoulos D, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000356; Irie HY, 2005, J CELL BIOL, V171, P1023, DOI 10.1083/jcb.200505087; Ju XM, 2007, P NATL ACAD SCI USA, V104, P7438, DOI 10.1073/pnas.0605874104; Li YW, 2009, BIOORG MED CHEM LETT, V19, P834, DOI 10.1016/j.bmcl.2008.12.017; Lindsley CW, 2010, CURR TOP MED CHEM, V10, P458, DOI 10.2174/156802610790980602; Maroulakou IG, 2007, CANCER RES, V67, P167, DOI 10.1158/0008-5472.CAN-06-3782; Muller M, 2000, Prostate Cancer Prostatic Dis, V3, pS32, DOI 10.1038/sj.pcan.4500457; Mutter GL, 2000, JNCI-J NATL CANCER I, V92, P924, DOI 10.1093/jnci/92.11.924; Novosyadlyy R, 2010, CANCER RES, V70, P741, DOI 10.1158/0008-5472.CAN-09-2141; Park JH, 2002, AM J PATHOL, V161, P727, DOI 10.1016/S0002-9440(10)64228-9; Parsons Ramon, 2003, Methods Mol Biol, V222, P147; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Ringel MD, 2001, CANCER RES, V61, P6105; Skeen JE, 2006, CANCER CELL, V10, P269, DOI 10.1016/j.ccr.2006.08.022; Stambolic V, 2000, CANCER RES, V60, P3605; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tashiro H, 1997, CANCER RES, V57, P3935; Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299	31	26	27	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2012	31	4					518	526		10.1038/onc.2011.243	http://dx.doi.org/10.1038/onc.2011.243			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891LU	21743498	hybrid, Green Published			2022-12-17	WOS:000300219300010
J	Heiska, L; Melikova, M; Zhao, F; Saotome, I; McClatchey, AI; Carpen, O				Heiska, L.; Melikova, M.; Zhao, F.; Saotome, I.; McClatchey, A. I.; Carpen, O.			Ezrin is key regulator of Src-induced malignant phenotype in three-dimensional environment	ONCOGENE			English	Article						Src; ezrin; ERM proteins; invasion; 3D matrix	HUMAN COLORECTAL-CANCER; HUMAN COLON-CANCER; ELEVATED C-SRC; CELL-MIGRATION; TYROSINE PHOSPHORYLATION; KINASE-ACTIVITY; PROTEIN EZRIN; ERM PROTEINS; EXPRESSION; ACTIVATION	The oncogenic tyrosine kinase Src has a role in cancer development, especially by promoting invasive and metastatic behavior. It is, however, unclear which of the Src-regulated signaling cascades induce malignant phenotype in three-dimensional environment. One of Src substrates is ezrin, a cytoskeletal organiser and regulator of signal transduction. Ezrin expression correlates with poor outcome of diverse cancers and is essential in experimental metastatic osteosarcoma. We reconstituted genetically ezrin-deficient cells with wild-type (WT) or phosphorylation-deficient Y477F ezrin together with constitutively active Src. In two-dimensional cultures, Src induced malignant features regardless of the presence or absence of ezrin. In contrast, only WT ezrin-expressing cells grew efficiently in soft agar or in suspension. In Matrigel, only WT ezrin significantly promoted growth and invasion, and was targeted to specific regions on the plasma membrane. WT and Y477F ezrin-expressing cells showed marked differences only when growing or scattering in three-dimensional matrix. Additional experiments showed that Y477-phosphorylated ezrin is also needed for the growth of Src-transformed epithelial cells in three-dimensional matrix. Cells lacking functional ezrin had reduced cyclin D levels and fewer cells in G2+S phase, possibly as a consequence of abnormal mTOR signaling, as ezrin Y477F cells showed lower expression of phosphorylated intermediates downstream of mTOR than WT cells. We conclude that the pathways activated by Src depend on the type of environment and that ezrin is a crucial element of Src-induced malignant features in cells growing inside three-dimensional environment. Oncogene (2011) 30, 4953-4962; doi:10.1038/onc.2011.207; published online 13 June 2011	[Carpen, O.] Univ Turku, Dept Pathol, FIN-20520 Turku, Finland; [Heiska, L.; Melikova, M.; Zhao, F.; Carpen, O.] Univ Helsinki, Dept Pathol, Helsinki, Finland; [Saotome, I.; McClatchey, A. I.] MGH Canc Ctr, Charlestown, MA USA; [Saotome, I.; McClatchey, A. I.] Harvard Univ, Sch Med, Dept Pathol, Charlestown, MA USA; [Melikova, M.] Turku Univ Hosp, FIN-20520 Turku, Finland	University of Turku; University of Helsinki; Harvard University; University of Turku	Carpen, O (corresponding author), Univ Turku, Dept Pathol, Kiinamyllynkatu 10, FIN-20520 Turku, Finland.	olli.carpen@utu.fi			Finnish Cancer Organizations, US Department of Defense [W81XWH-05-1-046]; Turku University Central Hospital District	Finnish Cancer Organizations, US Department of Defense; Turku University Central Hospital District	We thank JA Cooper for the pLXSH-SrcY527F plasmid; SL Fu for the RK3E cells, Sa Tsukita for the anti-moesin antibody; and H Ahola for technical assistance. The study was supported by Finnish Cancer Organizations, US Department of Defense grant W81XWH-05-1-046, and the Medical Research Fund of Turku University Central Hospital District to OC.	Alfthan K, 2004, J BIOL CHEM, V279, P18559, DOI 10.1074/jbc.M313916200; Allgayer H, 2002, CANCER, V94, P344, DOI 10.1002/cncr.10221; Autero M, 2003, FEBS LETT, V535, P82, DOI 10.1016/S0014-5793(02)03861-9; Blain SW, 2008, CELL CYCLE, V7, P892, DOI 10.4161/cc.7.7.5637; Boyd DD, 2004, CLIN CANCER RES, V10, P1545, DOI 10.1158/1078-0432.CCR-1565-02; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Bruce B, 2007, CLIN EXP METASTAS, V24, P69, DOI 10.1007/s10585-006-9050-x; CARTWRIGHT CA, 1994, J CLIN INVEST, V93, P509, DOI 10.1172/JCI117000; Cary LA, 2002, MOL CELL BIOL, V22, P2427, DOI 10.1128/MCB.22.8.2427-2440.2002; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Eleveld-Trancikova D, 2002, INT J ONCOL, V20, P501; Elliott BE, 2004, J CELL BIOCHEM, V92, P16, DOI 10.1002/jcb.20033; Elzagheid A, 2008, HUM PATHOL, V39, P1737, DOI 10.1016/j.humpath.2008.04.020; Even-Ram S, 2005, CURR OPIN CELL BIOL, V17, P524, DOI 10.1016/j.ceb.2005.08.015; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Fu SL, 2005, BIOCHEM BIOPH RES CO, V338, P830, DOI 10.1016/j.bbrc.2005.10.045; Gautreau A, 1999, P NATL ACAD SCI USA, V96, P7300, DOI 10.1073/pnas.96.13.7300; Geiger KD, 2000, AM J PATHOL, V157, P1785, DOI 10.1016/S0002-9440(10)64816-X; Heiska L, 2005, J BIOL CHEM, V280, P10244, DOI 10.1074/jbc.M411353200; Ilmonen S, 2005, MODERN PATHOL, V18, P503, DOI 10.1038/modpathol.3800300; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Jones RJ, 2002, BRIT J CANCER, V87, P1128, DOI 10.1038/sj.bjc.6600594; Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982; Kobel M, 2006, MODERN PATHOL, V19, P581, DOI 10.1038/modpathol.3800567; Kopetz S, 2007, CLIN CANCER RES, V13, P7232, DOI 10.1158/1078-0432.CCR-07-1902; KRIEG J, 1992, J BIOL CHEM, V267, P19258; Lamb RF, 2000, NAT CELL BIOL, V2, P281, DOI 10.1038/35010550; Makitie T, 2001, INVEST OPHTH VIS SCI, V42, P2442; Malek RL, 2002, ONCOGENE, V21, P7256, DOI 10.1038/sj.onc.1205900; Mao WG, 1997, ONCOGENE, V15, P3083, DOI 10.1038/sj.onc.1201496; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; MILLER AD, 1993, METHOD ENZYMOL, V217, P581; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Naba A, 2008, EMBO J, V27, P38, DOI 10.1038/sj.emboj.7601943; Ohtani K, 2002, CANCER LETT, V179, P79, DOI 10.1016/S0304-3835(01)00857-6; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Saotome I, 2004, DEV CELL, V6, P855, DOI 10.1016/j.devcel.2004.05.007; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; Srivastava J, 2005, MOL BIOL CELL, V16, P1481, DOI 10.1091/mbc.e04-08-0721; Summy JM, 2006, CLIN CANCER RES, V12, P1398, DOI 10.1158/1078-0432.CCR-05-2692; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; Wan XL, 2005, CANCER RES, V65, P2406, DOI 10.1158/0008-5472.CAN-04-3135; Weng WH, 2005, CLIN CANCER RES, V11, P6198, DOI 10.1158/1078-0432.CCR-05-0548; Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006; Yu YL, 2006, CANCER RES, V66, P1982, DOI 10.1158/0008-5472.CAN-05-2360	46	26	28	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2011	30	50					4953	4962		10.1038/onc.2011.207	http://dx.doi.org/10.1038/onc.2011.207			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865YJ	21666723				2022-12-17	WOS:000298346500004
J	Kahyo, T; Iwaizumi, M; Shinmura, K; Matsuura, S; Nakamura, T; Watanabe, Y; Yamada, H; Sugimura, H				Kahyo, T.; Iwaizumi, M.; Shinmura, K.; Matsuura, S.; Nakamura, T.; Watanabe, Y.; Yamada, H.; Sugimura, H.			A novel tumor-derived SGOL1 variant causes abnormal mitosis and unstable chromatid cohesion	ONCOGENE			English	Article						chromosomal instability; colon cancer; mitosis; shugoshin; splicing variant	PROTEIN PHOSPHATASE 2A; CHROMOSOMAL INSTABILITY; CENTROMERIC PROTECTION; DROSOPHILA MEI-S332; SPINDLE CHECKPOINT; SISTER CHROMATIDS; DOWN-REGULATION; CANCER-CELLS; MEIOSIS-I; SHUGOSHIN	Mitosis is the most conspicuous cell cycle phase, because it is the phase in which the dynamic physical distributions of cellular components into the two daughter cells occur. The separation of sister chromatids is especially important during mitosis, because of the extreme accuracy required for distribution to the next generation of cells. Shugoshin-like 1 (SGOL1) is a key protein in protecting sister chromatids from precocious separation. We have reported finding that chromosome instability is more likely in SGOL1-downregulated colorectal cancers, but it is still unknown whether there is an association between cancer and SGOL1 transcript variation. Here, we identified a novel SGOL1 variant, SGOL1-P1, in human colon cancer. The SGOL1-P1 transcript contains an exon-skip of exon 3 that results in a stop codon occurring within exon 4. Overexpression of SGOL1-P1 in HCT116 cells resulted in an increased number of cells with aberrant chromosome alignment, precociously separated chromatids and delayed mitotic progression, occasionally followed by inaccurate distribution of the chromosomes. These phenotypes, observed when SGOL1-P1 was present, were also observed very frequently in SGOL1-knockdown cells. Furthermore, the overexpression of SGOL1-P1 inhibited the localization of endogenous SGOL1 and cohesin subunit RAD21/SCC1 to the centromere. These results suggest that SGOL1-P1 may function as a negative factor to native SGOL1, and that abundant expression of SGOL1-P1 may be responsible for chromosomal instability. Oncogene (2011) 30, 4453-4463; doi: 10.1038/onc.2011.152; published online 2 May 2011	[Sugimura, H.] Hamamatsu Univ Sch Med, Dept Pathol 1, Higashi Ku, Hamamatsu, Shizuoka 4313192, Japan; [Iwaizumi, M.] Hamamatsu Univ Sch Med, Dept Med 1, Hamamatsu, Shizuoka 4313192, Japan; [Matsuura, S.] Hamamatsu Univ Sch Med, Dept Med 2, Hamamatsu, Shizuoka 4313192, Japan; [Nakamura, T.] Hamamatsu Univ Sch Med, Dept Surg 2, Hamamatsu, Shizuoka 4313192, Japan; [Watanabe, Y.] Univ Tokyo, Inst Mol & Cellular Biosci, Lab Chromosome Dynam, Tokyo, Japan	Hamamatsu University School of Medicine; Hamamatsu University School of Medicine; Hamamatsu University School of Medicine; Hamamatsu University School of Medicine; University of Tokyo	Sugimura, H (corresponding author), Hamamatsu Univ Sch Med, Dept Pathol 1, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan.	hsugimur@hama-med.ac.jp	Matsuura, Shun/AAW-5353-2021; Iwaizumi, Moriya/AAG-3173-2019; Shinmura, Kazuya/K-8940-2012; YAMADA, Hidetaka/AAK-5085-2021	Matsuura, Shun/0000-0001-8844-6100; Iwaizumi, Moriya/0000-0002-2629-0830; Shinmura, Kazuya/0000-0003-4963-746X; Watanabe, Yoshinori/0000-0002-5488-4812	Japanese Ministry of Education, Culture, Sports, Science and Technology [22590356, 20014007, 221S0001]; Japanese Ministry of Health [21-1]; Smoking Research Foundation; Grants-in-Aid for Scientific Research [22590356] Funding Source: KAKEN	Japanese Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japanese Ministry of Health; Smoking Research Foundation; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Dr Suzuki of The Jikei University School of Medicine for providing the anti-hSgo1 antibody. This work was supported by a Grant-in-Aid for Scientific Research (C) (22590356) and for priority areas (20014007 and 221S0001) from the Japanese Ministry of Education, Culture, Sports, Science and Technology, Grants-in-Aid for the 3rd Term Comprehensive 10-Year-Strategy for Cancer Control and Grants-in-Aid for Cancer Research from the Japanese Ministry of Health (21-1) and from the Smoking Research Foundation.	Bharadwaj R, 2004, ONCOGENE, V23, P2016, DOI 10.1038/sj.onc.1207374; Clift D, 2009, GENE DEV, V23, P766, DOI 10.1101/gad.507509; Dai J, 2009, J CELL SCI, V122, P4168, DOI 10.1242/jcs.054122; Eot-Houllier G, 2008, GENE DEV, V22, P2639, DOI 10.1101/gad.484108; Gisselsson D, 2001, AM J PATHOL, V158, P199, DOI 10.1016/S0002-9440(10)63958-2; GOLDSTEIN LSB, 1980, CHROMOSOMA, V78, P79, DOI 10.1007/BF00291909; Grady WM, 2004, CANCER METAST REV, V23, P11, DOI 10.1023/A:1025861527711; Hauf S, 2001, SCIENCE, V293, P1320, DOI 10.1126/science.1061376; Iwaizumi M, 2009, GUT, V58, P249, DOI 10.1136/gut.2008.149468; Kahyo T, 2008, FEBS LETT, V582, P2479, DOI 10.1016/j.febslet.2008.06.031; Kanda T, 1998, CURR BIOL, V8, P377, DOI 10.1016/S0960-9822(98)70156-3; Kapoor TM, 2006, SCIENCE, V311, P388, DOI 10.1126/science.1122142; Karamysheva Z, 2009, J BIOL CHEM, V284, P1772, DOI 10.1074/jbc.M807083200; Kawashima SA, 2010, SCIENCE, V327, P172, DOI 10.1126/science.1180189; KERREBROCK AW, 1995, CELL, V83, P247, DOI 10.1016/0092-8674(95)90166-3; Kienitz A, 2005, ONCOGENE, V24, P4301, DOI 10.1038/sj.onc.1208589; Kitajima TS, 2006, NATURE, V441, P46, DOI 10.1038/nature04663; Kitajima TS, 2005, CURR BIOL, V15, P353, DOI 10.1016/j.cub.2004.12.044; Kitajima TS, 2004, NATURE, V427, P510, DOI 10.1038/nature02312; Kothe M, 2007, BIOCHEMISTRY-US, V46, P5960, DOI 10.1021/bi602474j; Lee J, 2008, NAT CELL BIOL, V10, P42, DOI 10.1038/ncb1667; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Losada A, 2002, GENE DEV, V16, P3004, DOI 10.1101/gad.249202; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Marston AL, 2004, SCIENCE, V303, P1367, DOI 10.1126/science.1094220; Mayr C, 2009, CELL, V138, P673, DOI 10.1016/j.cell.2009.06.016; McGuinness BE, 2005, PLOS BIOL, V3, P433, DOI 10.1371/journal.pbio.0030086; Moore DP, 1998, J CELL BIOL, V140, P1003, DOI 10.1083/jcb.140.5.1003; Nasmyth K, 2000, SCIENCE, V288, P1379, DOI 10.1126/science.288.5470.1379; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Pihan GA, 1999, SEMIN CANCER BIOL, V9, P289, DOI 10.1006/scbi.1999.0131; Rabitsch KP, 2004, CURR BIOL, V14, P287, DOI 10.1016/j.cub.2004.01.051; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Riedel CG, 2006, NATURE, V441, P53, DOI 10.1038/nature04664; Sakuno T, 2009, NATURE, V458, P852, DOI 10.1038/nature07876; Salic A, 2004, CELL, V118, P567, DOI 10.1016/j.cell.2004.08.016; Shinmura K, 2008, J PATHOL, V216, P365, DOI 10.1002/path.2422; Sumara I, 2004, CURR BIOL, V14, P1712, DOI 10.1016/j.cub.2004.09.049; Sumara I, 2002, MOL CELL, V9, P515, DOI 10.1016/S1097-2765(02)00473-2; Suzuki H, 2006, CELL CYCLE, V5, P1094, DOI 10.4161/cc.5.10.2747; Tang TTL, 1998, GENE DEV, V12, P3843, DOI 10.1101/gad.12.24.3843; Tang ZY, 2006, DEV CELL, V10, P575, DOI 10.1016/j.devcel.2006.03.010; Tang ZY, 2004, P NATL ACAD SCI USA, V101, P18012, DOI 10.1073/pnas.0408600102; Wasch R, 2010, ONCOGENE, V29, P1, DOI 10.1038/onc.2009.325; Waizenegger IC, 2000, CELL, V103, P399, DOI 10.1016/S0092-8674(00)00132-X; Xu Z, 2009, MOL CELL, V35, P426, DOI 10.1016/j.molcel.2009.06.031; Yamagishi Y, 2008, NATURE, V455, P251, DOI 10.1038/nature07217	48	26	26	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2011	30	44					4453	4463		10.1038/onc.2011.152	http://dx.doi.org/10.1038/onc.2011.152			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	844FN	21532624				2022-12-17	WOS:000296733200001
J	Jiffar, T; Yilmaz, T; Lee, J; Hanna, E; El-Naggar, A; Yu, D; Myers, JN; Kupferman, ME				Jiffar, T.; Yilmaz, T.; Lee, J.; Hanna, E.; El-Naggar, A.; Yu, D.; Myers, J. N.; Kupferman, M. E.			KiSS1 mediates platinum sensitivity and metastasis suppression in head and neck squamous cell carcinoma	ONCOGENE			English	Article						head and neck squamous cell carcinoma; KiSS1; chemotherapy resistance; cisplatin; metastasis	NF-KAPPA-B; CISPLATIN-INDUCED APOPTOSIS; S-TRANSFERASE-PI; GENE-EXPRESSION; OVARIAN-CANCER; IMMUNOHISTOCHEMICAL EXPRESSION; POLY(ADP-RIBOSE) POLYMERASE; FUNCTIONAL-CHARACTERIZATION; LUNG-CANCER; P53 GENE	Although surgery and radiotherapy have been the standard treatment modalities for head and neck squamous cell carcinoma (HNSCC), the integration of cisplatin (CDDP)-based therapy has led to improvements in local and regional control of disease for patients. However, many trials show that only 10-20% of patients benefit from this treatment intensification, which can result in profound treatment-associated morbidity and mortality. Moreover, the marginal survival improvement suggests that CDDP resistance is an innate characteristic of HNSCC. To elucidate the biological mechanisms underpinning CDDP resistance in HNSCC, we utilized an experimental model of CDDP resistance in this disease. We first observed significant enhancements in local tumor growth and metastasis, as well as adverse survival, in CDDP-resistant (CR) tumors compared with sensitive tumors. To elucidate the molecular mechanisms of this phenotype, we undertook a systems biology-based approach utilizing high-throughput PCR arrays, and we identified a significant suppression of KiSS1 mRNA and protein expression in the CR cells, but no significant regions of genomic loss with array comparative genomic hybridization. Genetic suppression of KiSS1 in CDDP-sensitive cell lines rendered them CR, an observation that was mechanistically linked to alterations in glutathione S-transferase-pi expression and function. We next confirmed that, in human HNSCC tumors, loss of KiSS1 expression was associated with metastatic human HNSCC tumors compared with non-metastatic tumors. Genetic reconstitution of KiSS1 in CR cells abrogated cellular migration and induced CDDP sensitivity. To confirm these findings in a murine model, either CR or KiSS1-transfected CR cells were studied in an orthotopic model of HNSCC, or survival studies revealed significant improvement in survival of the mice bearing CR-KiSS1 tumors. Mechanistically, alterations in apoptotic pathways and CDDP metabolism contributed to KiSS1-associated chemotherapy sensitization. These studies provided further direct evidence for the role of KiSS1 loss in biologically aggressive HNSCC and suggest potential targets for therapy in CR cancers. Oncogene (2011) 30, 3163-3173; doi:10.1038/onc.2011.39; published online 7 March 2011	[Jiffar, T.; Yilmaz, T.; Lee, J.; Hanna, E.; Myers, J. N.; Kupferman, M. E.] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surgery Holcombe 1515, Houston, TX 77030 USA; [El-Naggar, A.] Dept Pathol 1515 Holcombe, Houston, TX USA; [Yu, D.] Dept Mol & Cellular Oncol 1515 Holcombe, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center	Kupferman, ME (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surgery Holcombe 1515, 1400 Pressler St,Unit 1445, Houston, TX 77030 USA.	mekupfer@mdanderson.org	Lee, Jack/P-7331-2019; Hanna, Ehab Y/B-1593-2017	Lee, Jack/0000-0002-4584-929X; Hanna, Ehab Y/0000-0003-3241-2440; Lee, J. Jack/0000-0001-5469-9214; Yu, Dihua/0000-0001-6231-9381	NIH [K08-DE019185]; Triological Society; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [K08DE019185] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Triological Society; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We thank Yongxiang Li BS for technical assistance and Terri Astin for administrative assistance. We also thank the members of the Small Animal Imaging Facility for their assistance with the mouse studies, Taylor Appleberry for assistance with the array CGH studies and Dr Douglas Boyd (MDACC) for providing the KiSS1 construct. This work is supported by the following funding sources: NIH Grant K08-DE019185 (MEK), Triological Society Career Development Award (MEK), MD Anderson	Antoun G, 2000, J CELL BIOCHEM, V77, P372, DOI 10.1002/(SICI)1097-4644(20000601)77:3<372::AID-JCB3>3.0.CO;2-P; Arai T, 2000, CANCER DETECT PREV, V24, P252; Bai F, 1996, CANCER, V78, P416; Chanvorachote P, 2006, CANCER RES, V66, P6353, DOI 10.1158/0008-5472.CAN-05-4533; Cho SG, 2009, CANCER RES, V69, P7062, DOI 10.1158/0008-5472.CAN-09-0476; Cooper JS, 2004, NEW ENGL J MED, V350, P1937, DOI 10.1056/NEJMoa032646; Cullen KJ, 2003, CANCER RES, V63, P8097; Di Pietro G, 2010, EXPERT OPIN DRUG MET, V6, P153, DOI 10.1517/17425250903427980; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Forastiere AA, 2003, NEW ENGL J MED, V349, P2091, DOI 10.1056/NEJMoa031317; Ganjavi H, 2005, CANCER GENE THER, V12, P397, DOI 10.1038/sj.cgt.7700798; Goldberg SF, 2003, CANCER RES, V63, P432; HAMAGUCHI K, 1993, CANCER RES, V53, P5225; Hu HB, 2005, CLIN CANCER RES, V11, P2379, DOI 10.1158/1078-0432.CCR-04-2084; Jiang Y, 2005, CLIN EXP METASTAS, V22, P369, DOI 10.1007/s10585-005-8186-4; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167; Khan K, 2010, HEAD NECK-J SCI SPEC, V32, P381, DOI 10.1002/hed.21195; Kigawa J, 2000, ADV EXP MED BIOL, V465, P207; Kim SJ, 2010, J MOL MED, V88, P1123, DOI 10.1007/s00109-010-0652-z; Kupferman ME, 2010, ONCOGENE, V29, P2047, DOI 10.1038/onc.2009.486; Kupferman Michael E, 2009, J Exp Ther Oncol, V8, P117; Lee JH, 1997, CANCER RES, V57, P2384; Li XX, 2002, EXP HEMATOL, V30, P285, DOI 10.1016/S0301-472X(02)00777-4; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Liu LZ, 2007, CANCER RES, V67, P6325, DOI 10.1158/0008-5472.CAN-06-4261; Lo HW, 2008, MOL CANCER RES, V6, P843, DOI 10.1158/1541-7786.MCR-07-2105; Marot D, 2007, ENDOCR-RELAT CANCER, V14, P691, DOI 10.1677/ERC-07-0012; Masanek U, 1997, ANTI-CANCER DRUG, V8, P189, DOI 10.1097/00001813-199702000-00010; Michaud WA, 2009, CLIN CANCER RES, V15, P1645, DOI 10.1158/1078-0432.CCR-08-2581; Mitchell DC, 2007, ONCOGENE, V26, P1739, DOI 10.1038/sj.onc.1209963; Moffat GJ, 1996, J BIOL CHEM, V271, P20740, DOI 10.1074/jbc.271.34.20740; Morceau F, 2004, BIOCHEM PHARMACOL, V67, P1227, DOI 10.1016/j.bcp.2003.10.036; Nash KT, 2007, JNCI-J NATL CANCER I, V99, P309, DOI 10.1093/jnci/djk053; Nash KT, 2006, FRONT BIOSCI-LANDMRK, V11, P647, DOI 10.2741/1824; Navenot JM, 2009, MOL PHARMACOL, V75, P1300, DOI 10.1124/mol.109.055095; Navenot JM, 2009, MOL PHARMACOL, V75, P1074, DOI 10.1124/mol.108.054270; Niedner H, 2001, MOL PHARMACOL, V60, P1153, DOI 10.1124/mol.60.6.1153; O'Donnell RK, 2005, ONCOGENE, V24, P1244, DOI 10.1038/sj.onc.1208285; Ohtaki T, 2001, NATURE, V411, P613, DOI 10.1038/35079135; Rouleau M, 2010, NAT REV CANCER, V10, P293, DOI 10.1038/nrc2812; Soussi T, 2007, ONCOGENE, V26, P2145, DOI 10.1038/sj.onc.1210280; Soussi T, 2007, CANCER CELL, V12, P303, DOI 10.1016/j.ccr.2007.10.001; Stewart DJ, 2007, CRIT REV ONCOL HEMAT, V63, P12, DOI 10.1016/j.critrevonc.2007.02.001; SUNGGOOK C, 2009, J CELL BIOCHEM, V107, P1139; WELCH DR, 1994, ONCOGENE, V9, P255; Yan CH, 2001, J BIOL CHEM, V276, P1164, DOI 10.1074/jbc.M008681200; Yazlovitskaya EM, 2001, BIOCHEM BIOPH RES CO, V283, P732, DOI 10.1006/bbrc.2001.4849; Yilmaz T, 2010, CANCER BIOL THER, V10, P644, DOI 10.4161/cbt.10.6.12782	49	26	28	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2011	30	28					3163	3173		10.1038/onc.2011.39	http://dx.doi.org/10.1038/onc.2011.39			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	792FQ	21383688	Green Accepted			2022-12-17	WOS:000292726300005
J	Lee, M; Daniels, MJ; Garnett, MJ; Venkitaraman, AR				Lee, M.; Daniels, M. J.; Garnett, M. J.; Venkitaraman, A. R.			A mitotic function for the high-mobility group protein HMG20b regulated by its interaction with the BRC repeats of the BRCA2 tumor suppressor	ONCOGENE			English	Article						HMG20b; mitosis; BRCA2; BRC repeats; cytokinesis	CANCER SUSCEPTIBILITY; DNA-BINDING; BREAST; CYTOKINESIS; GENETICS; COMPLEX; DEFICIENT; ANILLIN; MYOSIN	The inactivation of BRCA2, a suppressor of breast, ovarian and other epithelial cancers, triggers instability in chromosome structure and number, which are thought to arise from defects in DNA recombination and mitotic cell division, respectively. Human BRCA2 controls DNA recombination via eight BRC repeats, evolutionarily conserved motifs of similar to 35 residues, that interact directly with the recombinase RAD51. How BRCA2 controls mitotic cell division is debated. Several studies by different groups report that BRCA2 deficiency affects cytokinesis. Moreover, its interaction with HMG20b, a protein of uncertain function containing a promiscuous DNA-binding domain and kinesin-like coiled coils, has been implicated in the G2-M transition. We show here that HMG20b depletion by RNA interference disturbs the completion of cell division, suggesting a novel function for HMG20b. In vitro, HMG20b binds directly to the BRC repeats of BRCA2, and exhibits the highest affinity for BRC5, a motif that binds poorly to RAD51. Conversely, the BRC4 repeat binds strongly to RAD51, but not to HMG20b. In vivo, BRC5 overexpression inhibits the BRCA2-HMG20b interaction, recapitulating defects in the completion of cell division provoked by HMG20b depletion. In contrast, BRC4 inhibits the BRCA2-RAD51 interaction and the assembly of RAD51 at sites of DNA damage, but not the completion of cell division. Our findings suggest that a novel function for HMG20b in cytokinesis is regulated by its interaction with the BRC repeats of BRCA2, and separate this unexpected function for the BRC repeats from their known activity in DNA recombination. We propose that divergent tumor-suppressive pathways regulating chromosome segregation as well as chromosome structure may be governed by the conserved BRC motifs in BRCA2. Oncogene (2011) 30, 3360-3369; doi:10.1038/onc.2011.55; published online 14 March 2011	[Venkitaraman, A. R.] Univ Cambridge, Dept Oncol, MRC, Canc Cell Unit,Hutchison MRC Res Ctr, Cambridge CB2 0XZ, Cambs, England	University of Cambridge	Venkitaraman, AR (corresponding author), Univ Cambridge, Dept Oncol, MRC, Canc Cell Unit,Hutchison MRC Res Ctr, Hills Rd, Cambridge CB2 0XZ, Cambs, England.	arv22@cam.ac.uk	Lee, MiYoung/G-3748-2014	Daniels, Matthew/0000-0002-9250-6214	Canadian Institute for Health Research; Medical Research Council; Medical Research Council [G9900064, MC_U105359877, G0600332, G0700651] Funding Source: researchfish; MRC [MC_U105359877, G0600332, G9900064, G0700651] Funding Source: UKRI	Canadian Institute for Health Research(Canadian Institutes of Health Research (CIHR)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	ML performed the experiments reported here and conceived them with ARV. MJD and MJG generated preliminary data, suggested experiments and assisted with data interpretation. We thank Dr Mark Petronczki (Clare Hall Labs, London) for sharing protocols and the siRNA sequences Q#6 and I#7 (Lekomtsev et al., 2010), and the members of our lab for helpful discussions. MJG was supported in part by a fellowship from the Canadian Institute for Health Research, and ARV was supported by a grant from the Medical Research Council, which also funded ML and MJD.	Antoniou A, 2003, AM J HUM GENET, V72, P1117, DOI 10.1086/375033; Ayoub Nabieh, 2009, Curr Biol, V19, P1075, DOI 10.1016/j.cub.2009.05.057; Bork P, 1996, NAT GENET, V13, P22, DOI 10.1038/ng0596-22; Breast Canc Linkage Consortium, 1999, JNCI-J NATL CANCER I, V91, P1310; Carreira A, 2009, CELL, V136, P1032, DOI 10.1016/j.cell.2009.02.019; Chen CF, 1999, J BIOL CHEM, V274, P32931, DOI 10.1074/jbc.274.46.32931; Daniels MJ, 2004, SCIENCE, V306, P876, DOI 10.1126/science.1102574; Jonsdottir AB, 2009, CELL ONCOL, V31, P191, DOI 10.3233/CLO-2009-0465; King TA, 2007, ANN SURG ONCOL, V14, P2510, DOI 10.1245/s10434-007-9372-1; Lee M, 2004, ONCOGENE, V23, P865, DOI 10.1038/sj.onc.1207223; Lee YM, 2003, BIOCHEM J, V374, P497, DOI 10.1042/BJ20030452; Lekomtsev S, 2010, J CELL SCI, V123, P1395, DOI 10.1242/jcs.068015; Marmorstein LY, 2001, CELL, V104, P247, DOI 10.1016/S0092-8674(01)00209-4; Meng X, 2007, ONCOGENE, V26, P6253, DOI 10.1038/sj.onc.1210460; Nathanson KN, 2001, NAT MED, V7, P552, DOI 10.1038/87876; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Pellegrini L, 2002, NATURE, V420, P287, DOI 10.1038/nature01230; Rahman N, 1998, ANNU REV GENET, V32, P95, DOI 10.1146/annurev.genet.32.1.95; Rajendra E, 2010, NUCLEIC ACIDS RES, V38, P82, DOI 10.1093/nar/gkp873; Rowley M, 2011, GASTROENTEROLOGY, V140, P1303, DOI 10.1053/j.gastro.2010.12.039; Shivji MKK, 2006, NUCLEIC ACIDS RES, V34, P4000, DOI 10.1093/nar/gkl505; Shivji MKK, 2009, P NATL ACAD SCI USA, V106, P13254, DOI 10.1073/pnas.0906208106; Straight AF, 2005, MOL BIOL CELL, V16, P193, DOI 10.1091/mbc.E04-08-0758; Sumoy L, 2000, CYTOGENET CELL GENET, V88, P62, DOI 10.1159/000015486; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Vinciguerra P, 2010, J CLIN INVEST, V120, P3834, DOI 10.1172/JCI43391; Wang WD, 1998, P NATL ACAD SCI USA, V95, P492, DOI 10.1073/pnas.95.2.492; Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; Yu VPCC, 2000, GENE DEV, V14, P1400; Yuan SSF, 1999, CANCER RES, V59, P3547; Zhao WM, 2005, J BIOL CHEM, V280, P33516, DOI 10.1074/jbc.M504657200; Zhu CJ, 2005, P NATL ACAD SCI USA, V102, P343, DOI 10.1073/pnas.0408438102	34	26	26	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2011	30	30					3360	3369		10.1038/onc.2011.55	http://dx.doi.org/10.1038/onc.2011.55			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	798NO	21399666	Green Published, hybrid			2022-12-17	WOS:000293215700006
J	Abdel-Samad, R; Zalzali, H; Rammah, C; Giraud, J; Naudin, C; Dupasquier, S; Poulat, F; Boizet-Bonhoure, B; Lumbroso, S; Mouzat, K; Bonnans, C; Pignodel, C; Raynaud, P; Fort, P; Quittau-Prevostel, C; Blache, P				Abdel-Samad, R.; Zalzali, H.; Rammah, C.; Giraud, J.; Naudin, C.; Dupasquier, S.; Poulat, F.; Boizet-Bonhoure, B.; Lumbroso, S.; Mouzat, K.; Bonnans, C.; Pignodel, C.; Raynaud, P.; Fort, P.; Quittau-Prevostel, C.; Blache, P.			MiniSOX9, a dominant-negative variant in colon cancer cells	ONCOGENE			English	Article						PKC alpha; SOX9; Wnt/beta-catenin signaling pathway	MESSENGER-RNA POLYADENYLATION; BETA-CATENIN; TRANSCRIPTION FACTOR; CAMPOMELIC DYSPLASIA; GENE-EXPRESSION; FACTOR SOX9; MOUSE; IDENTIFICATION; INHIBITION; EPITHELIUM	Inherited and acquired changes in pre-mRNA processing have significant roles in human diseases, especially cancer. Characterization of aberrantly spliced mRNAs may thus contribute to understand malignant transformation. We recently reported an anti-oncogenic potential for the SOX9 transcription factor in the colon. For instance, the Sox9 gene knock out in the mouse intestine results in an excess of proliferation with appearance of hyperplasia. SOX9 is expressed in colon cancer cells but its endogenous activity is weak. We looked for SOX9 variants that may impair SOX9 activity in colon cancer cells and we discovered MiniSOX9, a truncated version of SOX9 devoid of transactivation domain as a result of retention of the second intron. A significant overexpression of MiniSOX9 mRNA in human tumor samples compared with their matched normal tissues was observed by real-time reverse transcriptase-PCR. Immunohistochemistry revealed that MiniSOX9 is expressed at high levels in human colon cancer samples whereas it is undetectable in the surrounding healthy tissues. Finally, we discovered that MiniSOX9 behaves as a SOX9 inhibitor, inhibits protein kinase C alpha promoter activity and stimulates the canonical Wnt pathway. This potential oncogenic activity of the SOX9 locus gives new insights on its role in colon cancer. Oncogene (2011) 30, 2493-2503; doi:10.1038/onc.2010.621; published online 7 February 2011	[Abdel-Samad, R.; Zalzali, H.; Rammah, C.; Giraud, J.; Naudin, C.; Dupasquier, S.; Bonnans, C.; Raynaud, P.; Quittau-Prevostel, C.; Blache, P.] Univ Montpellier 1, INSERM, CNRS, Inst Genom Fonct,UMR 5203,U661, F-34094 Montpellier 5, France; [Abdel-Samad, R.; Zalzali, H.; Rammah, C.; Giraud, J.; Naudin, C.; Dupasquier, S.; Bonnans, C.; Raynaud, P.; Quittau-Prevostel, C.; Blache, P.] Univ Montpellier 2, F-34094 Montpellier 5, France; [Poulat, F.; Boizet-Bonhoure, B.] UPR, CNRS, Inst Genet Humaine, Montpellier, France; [Lumbroso, S.; Mouzat, K.] CHU Nimes, Biochim Lab, Nimes, France; [Pignodel, C.] CHU Nimes, Serv Anat & Cytol Pathol, Nimes, France; [Fort, P.] CNRS, UMR 5237, Ctr Rech Biochim Macromol, Montpellier, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Universite de Montpellier; CHU de Nimes; Universite de Montpellier; CHU de Nimes; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Blache, P (corresponding author), Univ Montpellier 1, INSERM, CNRS, Inst Genom Fonct,UMR 5203,U661, 141 Rue Cardonille, F-34094 Montpellier 5, France.	philippe.blache@igf.cnrs.fr	POULAT, FRANCIS/AAV-2170-2020; Fort, Philippe/M-9498-2015; Prevostel, Corinne/AAO-1433-2020; Raynaud, Peggy/AAC-5749-2020; Lumbroso, Serge/AFS-0438-2022	POULAT, FRANCIS/0000-0003-2070-1296; Fort, Philippe/0000-0001-5997-8722; Raynaud, Peggy/0000-0003-1224-8495; Giraud, Julie/0000-0001-6173-4276; Abdel-Samad, Rana/0000-0002-7753-8779; PREVOSTEL, Corinne/0000-0002-7553-087X	Ligue Nationale contre le Cancer (Equipe Labellisee); Ligue Regionale contre le Cancer (Comite Languedoc-Roussillon); Association pour la Recherche sur le Cancer [4994]; Region Languedoc-Roussillon (Chercheur d'Avenir); CNRS du LIBAN; Ligue Nationale contre le Cancer; Association pour la Recherche sur le Cancer	Ligue Nationale contre le Cancer (Equipe Labellisee)(Ligue nationale contre le cancer); Ligue Regionale contre le Cancer (Comite Languedoc-Roussillon); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Region Languedoc-Roussillon (Chercheur d'Avenir)(Region Occitanie); CNRS du LIBAN; Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council)	This work was supported by the 'Ligue Nationale contre le Cancer (Equipe Labellisee)', the 'Ligue Regionale contre le Cancer (Comite Languedoc-Roussillon)', the 'Association pour la Recherche sur le Cancer (grant number 4994)' and the 'Region Languedoc-Roussillon (Chercheur d'Avenir)'. Rana Abdel-Samad and Hassan Zalzali fellowships were from 'CNRS du LIBAN'. Sebastien Dupasquier fellowships were from 'Ligue Nationale contre le Cancer' and 'Association pour la Recherche sur le Cancer'. Peggy Raynaud post-doctoral fellowship was from 'Association pour la Recherche sur le Cancer'. Cyrine Rammah doctoral fellowship was from the 'Ligue Nationale contre le Cancer'. We thank Dr Christine Perret for providing the APC Delta 14 mice, Dr Pascal Roger 'CHU Nimes tumorotheque' for human colon biopsy samples, Geraldine Leguelinel for preparation of RNA from biopsy samples and Dr Sabine Laurent-Chabalier for statistical analysis.	Afonja O, 2002, ONCOGENE, V21, P7850, DOI 10.1038/sj.onc.1205985; Agrawal R, 2009, FEBS J, V276, P4184, DOI 10.1111/j.1742-4658.2009.07127.x; Akiyama H, 2002, GENE DEV, V16, P2813, DOI 10.1101/gad.1017802; Aleman A, 2008, BRIT J CANCER, V98, P466, DOI 10.1038/sj.bjc.6604143; Antoniou A, 2009, GASTROENTEROLOGY, V136, P2325, DOI 10.1053/j.gastro.2009.02.051; Bastide P, 2007, J CELL BIOL, V178, P635, DOI 10.1083/jcb.200704152; Blache P, 2004, J CELL BIOL, V166, P37, DOI 10.1083/jcb.200311021; Brinkman BMN, 2004, CLIN BIOCHEM, V37, P584, DOI 10.1016/j.clinbiochem.2004.05.015; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Chaboissier MC, 2004, DEVELOPMENT, V131, P1891, DOI 10.1242/dev.01087; Chen M, 2009, NAT REV MOL CELL BIO, V10, P741, DOI 10.1038/nrm2777; Cheung M, 2005, DEV CELL, V8, P179, DOI 10.1016/j.devcel.2004.12.010; Colnot S, 2004, LAB INVEST, V84, P1619, DOI 10.1038/labinvest.3700180; Darido C, 2008, CANCER RES, V68, P4258, DOI 10.1158/0008-5472.CAN-07-5805; Dupasquier S, 2009, J CELL SCI, V122, P2191, DOI 10.1242/jcs.036483; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; GEISINGER KR, 1989, CANCER-AM CANCER SOC, V63, P280, DOI 10.1002/1097-0142(19890115)63:2<280::AID-CNCR2820630213>3.0.CO;2-N; Gilmartin GM, 2005, GENE DEV, V19, P2517, DOI 10.1101/gad.1378105; Giordano J, 2001, AM J MED GENET, V98, P176, DOI 10.1002/1096-8628(20010115)98:2<176::AID-AJMG1027>3.0.CO;2-Q; HOUSTON CS, 1983, AM J MED GENET, V15, P3, DOI 10.1002/ajmg.1320150103; Hu J, 2005, RNA, V11, P1485, DOI 10.1261/rna.2107305; Jay P, 2005, CANCER RES, V65, P2193, DOI 10.1158/0008-5472.CAN-04-1484; Jin L, 2008, EXP BIOL MED, V233, P849, DOI 10.3181/0712-RM-352; Kamachi Y, 2000, TRENDS GENET, V16, P182, DOI 10.1016/S0168-9525(99)01955-1; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lee JY, 2008, NUCLEIC ACIDS RES, V36, P5581, DOI 10.1093/nar/gkn540; Leung N, 2008, ONCOGENE, V27, P4943, DOI 10.1038/onc.2008.136; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Muller P, 2010, BREAST CANCER RES TR, V120, P317, DOI 10.1007/s10549-009-0381-6; Notarnicola C, 2006, GENE EXPR PATTERNS, V6, P695, DOI 10.1016/j.modgep.2006.01.001; Passeron T, 2009, J CLIN INVEST, V119, P954, DOI 10.1172/JCI34015; Pysz MA, 2009, EXP CELL RES, V315, P1415, DOI 10.1016/j.yexcr.2009.02.002; Retelska D, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-176; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Stolt CC, 2003, GENE DEV, V17, P1677, DOI 10.1101/gad.259003; Tago K, 2000, GENE DEV, V14, P1741; Topol LL, 2009, J BIOL CHEM, V284, P3323, DOI 10.1074/jbc.M808048200; Zalzali H, 2008, ONCOGENE, V27, P7131, DOI 10.1038/onc.2008.331; Zhang H, 2000, MOL HUM REPROD, V6, P146, DOI 10.1093/molehr/6.2.146	40	26	28	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2011	30	22					2493	2503		10.1038/onc.2010.621	http://dx.doi.org/10.1038/onc.2010.621			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	771ZE	21297661				2022-12-17	WOS:000291198400001
J	Kurahashi, S; Hayakawa, F; Miyata, Y; Yasuda, T; Minami, Y; Tsuzuki, S; Abe, A; Naoe, T				Kurahashi, S.; Hayakawa, F.; Miyata, Y.; Yasuda, T.; Minami, Y.; Tsuzuki, S.; Abe, A.; Naoe, T.			PAX5-PML acts as a dual dominant-negative form of both PAX5 and PML	ONCOGENE			English	Article						PAX5; PML; nuclear body; DNA binding; apoptosis; arsenic trioxide	ACUTE PROMYELOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; B-CELL DEVELOPMENT; ARSENIC-TRIOXIDE; RAR-ALPHA; MEDIATED APOPTOSIS; NUCLEAR-BODIES; FUSION GENES; DNA-DAMAGE; BSAP PAX-5	PAX5 is a transcription factor required for B-cell development and maintenance. PML is a tumor suppressor and a pro-apoptotic factor. A fusion gene, PAX5-PML, was found in acute lymphoblastic leukemia (ALL) with chromosomal translocation t(9;15)(p13;q24), but no functional analysis has been reported. Here, we demonstrate that PAX5-PML had a dominant-negative effect on both PAX5 and PML. PAX5-PML dominant negatively inhibited PAX5 transcriptional activity in the luciferase reporter assay and suppressed the expression of the PAX5 transcriptional targets in B-lymphoid cell line. Surprisingly, PAX5-PML hardly showed DNA-binding activity in vitro although it retained the DNA-binding domain of PAX5. Additional experiments, including chromatin immunoprecipitation (ChIP) assay, suggested that PAX5-PML bound to the promoter through the association with PAX5 on the promoter. On the other hand, coexpression of PAX5-PML inhibited PML sumoylation, disrupted PML nuclear bodies (NBs), and conferred apoptosis resistance on HeLa cells. Furthermore, treatment with arsenic trioxide (ATO) induced PML sumoylation and reconstitution of PML NBs, and overcame the anti-apoptotic effect of PAX5-PML in HeLa cells. These data suggest the possible involvement of this fusion protein in the leukemogenesis of B-ALL in a dual dominant-negative manner and the possibility that ALL with PAX5-PML can be treated with ATO. Oncogene (2011) 30, 1822-1830; doi:10.1038/onc.2010.554; published online 10 January 2011	[Hayakawa, F.] Nagoya Univ, Grad Sch Med, Dept Hematol & Oncol, Showa Ku, Nagoya, Aichi 4668550, Japan; [Tsuzuki, S.] Aichi Canc Ctr, Res Inst, Div Mol Med, Nagoya, Aichi 464, Japan	Nagoya University; Aichi Cancer Center	Hayakawa, F (corresponding author), Nagoya Univ, Grad Sch Med, Dept Hematol & Oncol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	bun-hy@med.nagoya-u.ac.jp	Yasuda, Takahiko/AGQ-5448-2022; Hayakawa, Fumihiko/I-7288-2014; Naoe, Tomoki/I-1888-2012	Yasuda, Takahiko/0000-0002-4686-0976; Tsuzuki, Shinobu/0000-0002-3209-3550	Kyowa Hakko Kirin Co., Ltd.; Wyeth; Chugai Pharmaceutical Co., Ltd.; National Institute of Biomedical Innovation; Ministry of Education, Culture, Sports, Science, and Technology of Japan	Kyowa Hakko Kirin Co., Ltd.(Kyowa Kirin Ltd); Wyeth(Wyeth); Chugai Pharmaceutical Co., Ltd.; National Institute of Biomedical Innovation(National Institute of Biomedical Innovation); Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	Dr Naoe received research funding from Kyowa Hakko Kirin Co., Ltd, Wyeth, and Chugai Pharmaceutical Co., Ltd. The remaining authors declare no conflict of interest.; We thank Dr Martin L Privalsky (University of California at Davis, CA, USA), Dr Masayuki Yamamoto (Tohoku University) and Dr Stefano Rivella (Memorial Sloan-Kettering Cancer Center) for kindly providing vectors. We are very grateful to Ryouhei Tanizaki, Yuka Nomura and Chika Wakamatsu for their technical assistance. This work was supported by Grants-in-Aid from the National Institute of Biomedical Innovation and the Ministry of Education, Culture, Sports, Science, and Technology of Japan.	Atsumi A, 2006, BIOCHEM BIOPH RES CO, V345, P1471, DOI 10.1016/j.bbrc.2006.05.047; Busslinger M, 2004, ANNU REV IMMUNOL, V22, P55, DOI 10.1146/annurev.immunol.22.012703.104807; Busslinger M, 1996, P NATL ACAD SCI USA, V93, P6129, DOI 10.1073/pnas.93.12.6129; Chen GQ, 1997, BLOOD, V89, P3345; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; Dellaire G, 2004, BIOESSAYS, V26, P963, DOI 10.1002/bies.20089; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Familiades J, 2009, LEUKEMIA, V23, P1989, DOI 10.1038/leu.2009.135; Fazio G, 2008, CANCER RES, V68, P181, DOI 10.1158/0008-5472.CAN-07-2778; Hayakawa F, 2004, CANCER CELL, V5, P389, DOI 10.1016/S1535-6108(04)00082-0; Hayakawa F, 2004, J LEUKOCYTE BIOL, V75, P529, DOI 10.1189/jlb.0603289; Hayakawa F, 2008, J BIOL CHEM, V283, P24420, DOI 10.1074/jbc.M802217200; Holmes ML, 2006, GENE DEV, V20, P933, DOI 10.1101/gad.1396206; Iida S, 1996, BLOOD, V88, P1787; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Jeanne M, 2010, CANCER CELL, V18, P88, DOI 10.1016/j.ccr.2010.06.003; Kawamata N, 2008, P NATL ACAD SCI USA, V105, P11921, DOI 10.1073/pnas.0711039105; Khan MM, 2001, MOL CELL, V7, P1233, DOI 10.1016/S1097-2765(01)00257-X; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; KOZMIK Z, 1992, MOL CELL BIOL, V12, P2662, DOI 10.1128/MCB.12.6.2662; Maier H, 2003, NUCLEIC ACIDS RES, V31, P5483, DOI 10.1093/nar/gkg785; Mikkola I, 2002, SCIENCE, V297, P110, DOI 10.1126/science.1067518; Miller WH, 2002, CANCER RES, V62, P3893; Morrison AM, 1998, SEMIN IMMUNOL, V10, P133, DOI 10.1006/smim.1998.0115; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Mullighan CG, 2007, NATURE, V446, P758, DOI 10.1038/nature05690; Nebral K, 2009, LEUKEMIA, V23, P134, DOI 10.1038/leu.2008.306; Nebral K, 2007, BRIT J HAEMATOL, V139, P269, DOI 10.1111/j.1365-2141.2007.06731.x; Niu C, 1999, BLOOD, V94, P3315, DOI 10.1182/blood.V94.10.3315.422k16_3315_3324; Nutt S L, 2001, Int Rev Immunol, V20, P65, DOI 10.3109/08830180109056723; Nutt SL, 1998, EMBO J, V17, P2319, DOI 10.1093/emboj/17.8.2319; Rivella S, 2003, BLOOD, V101, P2932, DOI 10.1182/blood-2002-10-3305; Schebesta M, 2002, IMMUNITY, V17, P473, DOI 10.1016/S1074-7613(02)00418-1; Souabni A, 2002, IMMUNITY, V17, P781, DOI 10.1016/S1074-7613(02)00472-7; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Wu WS, 2001, MOL CELL BIOL, V21, P2259, DOI 10.1128/MCB.21.7.2259-2268.2001; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869; Zhang XW, 2010, SCIENCE, V328, P240, DOI 10.1126/science.1183424; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978	43	26	26	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	15					1822	1830		10.1038/onc.2010.554	http://dx.doi.org/10.1038/onc.2010.554			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	749ZM	21217775				2022-12-17	WOS:000289512200009
J	Li, LY; Dai, HY; Yeh, FL; Kan, SF; Lang, J; Hsu, JL; Jeng, LB; Chen, YH; Sher, YP; Lin, WC; Hung, MC				Li, L-Y; Dai, H-Y; Yeh, F-L; Kan, S-F; Lang, J.; Hsu, J. L.; Jeng, L-B; Chen, Y-H; Sher, Y-P; Lin, W-C; Hung, M-C			Targeted hepatocellular carcinoma proapoptotic BikDD gene therapy	ONCOGENE			English	Article						liver cancer; alpha-fetoprotein; non-viral gene therapy; VISA	ALPHA-FETOPROTEIN PROMOTER; LIVER-CANCER; EXPRESSION; VECTOR; TUMOR; CONSTRUCTION; REPLICATION; SURVIVAL; CELL; DNA	Hepatocellular carcinoma (HCC), the third leading cause of cancer death in the world, is the most general type of primary liver cancer. Although current treatment modalities, such as liver transplantation, resection, percutaneous ablation, transarterial embolization, chemotherapy and radiotherapy are potentially curative, these methods are not universally applicable to all of HCC patients, especially for those with poor prognosis in which no effective remedy is available. Therefore, development of novel therapeutic approach for the treatment of HCC is urgently needed. In the current study, we developed a promising HCC-targeted gene therapy vector driven by liver cancer-specific alpha-fetoprotein promoter/enhancer coupled to an established platform technology. The activity of this expression vector is comparable with or even higher than that of strong cytomegalovirus (CMV) promoter and exhibits strong promoter activity in liver cancer cells/tumors, but has nearly no or very low activity in normal cells/organs in vitro and in orthotopic animal models in vivo. Its cancer specificity exceeds that of the CMV promoter, which expresses non-specifically in both normal and tumor cells. In addition, targeted expression of a therapeutic BikDD, a mutant of proapoptotic gene Bik effectively and preferentially killed liver cancer cells, but not normal cells and significantly repressed growth of HCC tumors, and prolonged survival in multiple xenograft and syngeneic orthotopic mouse models of HCC through intravenous systemic gene delivery. Importantly, systemic administration of BikDD by our expression vector exerted no systemically acute toxicity compared with CMV-BikDD in mice. Taken together, this study elucidates a relatively safe and highly effective and specific systemic gene therapy strategy for liver cancer, and is worthy of further development for future clinical trials. Oncogene (2011) 30, 1773-1783; doi:10.1038/onc.2010.558; published online 13 December 2010	[Li, L-Y; Dai, H-Y; Yeh, F-L; Kan, S-F; Chen, Y-H; Sher, Y-P; Hung, M-C] China Med Univ Hosp, Ctr Mol Med, Taichung, Taiwan; [Li, L-Y; Hung, M-C] China Med Univ, Grad Inst Canc Biol, Taichung, Taiwan; [Li, L-Y] Asia Univ, Dept Biotechnol, Taichung, Taiwan; [Lang, J.; Hsu, J. L.; Hung, M-C] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Jeng, L-B] China Med Univ, Dept Surg, Taichung, Taiwan; [Jeng, L-B] China Med Univ, Dept Med, Taichung, Taiwan; [Lin, W-C] China Med Univ, Dept Pharmacol, Taichung, Taiwan	China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; Asia University Taiwan; University of Texas System; UTMD Anderson Cancer Center; China Medical University Taiwan; China Medical University Taiwan; China Medical University Taiwan	Li, LY (corresponding author), China Med Univ & Hosp, Ctr Mol Med, Taichung 40447, Taiwan.	lyl@mail.cmu.edu.tw; mhung@mdanderson.org	Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Li, Long-Yuan/0000-0001-7472-8318	 [DOH97-TD-I-111-TM003];  [DOH98-TD-I-111-TM002];  [NHRI-EX98-9603BC];  [DOH98-TD-G-111-030];  [NSC96-3111-B-039];  [NSC97-3111-B-039];  [DOH99-TD-C-111-005]	; ; ; ; ; ; 	This work was supported by grants from DOH97-TD-I-111-TM003, DOH98-TD-I-111-TM002, NHRI-EX98-9603BC (to L-YL), DOH98-TD-G-111-030 (to M-CH), NSC96-3111-B-039, NSC97-3111-B-039 and DOH99-TD-C-111-005 (to M-CH and L-YL).	Abelev GI, 1999, SEMIN CANCER BIOL, V9, P95, DOI 10.1006/scbi.1998.0084; Avila MA, 2006, ONCOGENE, V25, P3866, DOI 10.1038/sj.onc.1209550; Bui LA, 1997, HUM GENE THER, V8, P2173, DOI 10.1089/hum.1997.8.18-2173; Chen JS, 2004, CANCER GENE THER, V11, P740, DOI 10.1038/sj.cgt.7700752; CHEN SH, 1992, CANCER RES, V52, P1329; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Guan M, 2006, CANCER RES, V66, P1620, DOI 10.1158/0008-5472.CAN-05-0877; Hoofnagle JH, 2004, GASTROENTEROLOGY, V127, pS319, DOI 10.1053/j.gastro.2004.09.047; Ido A, 2001, CANCER RES, V61, P3016; IZUMI R, 1992, J SURG ONCOL, V49, P151, DOI 10.1002/jso.2930490305; Kim JW, 2003, CARCINOGENESIS, V24, P363, DOI 10.1093/carcin/24.3.363; Lemken ML, 2005, WORLD J GASTROENTERO, V11, P5295, DOI 10.3748/wjg.v11.i34.5295; Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1; Lu SY, 2003, WORLD J GASTROENTERO, V9, P688, DOI 10.3748/wjg.v9.i4.688; Ma SH, 2010, GENE THER, V17, P905, DOI 10.1038/gt.2010.34; Mawatari F, 1998, CANCER GENE THER, V5, P301; NAKABAYASHI H, 1991, MOL CELL BIOL, V11, P5885, DOI 10.1128/MCB.11.12.5885; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Ren XW, 2006, CANCER GENE THER, V13, P159, DOI 10.1038/sj.cgt.7700868; Schafer DF, 1999, LANCET, V353, P1253, DOI 10.1016/S0140-6736(98)09148-X; Sher YP, 2009, ONCOGENE, V28, P3286, DOI 10.1038/onc.2009.187; Shi YJ, 2004, WORLD J GASTROENTERO, V10, P186; STILLWAGON GB, 1991, INT J RADIAT ONCOL, V20, P65, DOI 10.1016/0360-3016(91)90139-U; Suriawinata A, 2004, SEMIN LIVER DIS, V24, P77; Takahashi M, 2002, MOL THER, V5, P627, DOI 10.1006/mthe.2002.0589; Templeton NS, 1997, NAT BIOTECHNOL, V15, P647, DOI 10.1038/nbt0797-647; Xie XM, 2007, CANCER CELL, V12, P52, DOI 10.1016/j.ccr.2007.05.009; Xie XM, 2009, MOL CANCER THER, V8, P2375, DOI 10.1158/1535-7163.MCT-09-0056; Zufferey R, 1999, J VIROL, V73, P2886, DOI 10.1128/JVI.73.4.2886-2892.1999	29	26	27	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2011	30	15					1773	1783		10.1038/onc.2010.558	http://dx.doi.org/10.1038/onc.2010.558			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	749ZM	21151169	Bronze			2022-12-17	WOS:000289512200005
J	Marzec, M; Liu, X; Wong, W; Yang, Y; Pasha, T; Kantekure, K; Zhang, P; Woetmann, A; Cheng, M; Odum, N; Wasik, MA				Marzec, M.; Liu, X.; Wong, W.; Yang, Y.; Pasha, T.; Kantekure, K.; Zhang, P.; Woetmann, A.; Cheng, M.; Odum, N.; Wasik, M. A.			Oncogenic kinase NPM/ALK induces expression of HIF1 alpha mRNA	ONCOGENE			English	Article						oncogenic tyrosine kinase; anaplastic lymphoma kinase; STAT3; HIF1 alpha	ANAPLASTIC LYMPHOMA KINASE; NON-HODGKINS-LYMPHOMA; TYROSINE KINASE; NPM-ALK; STAT3 EXPRESSION; TUMOR-SUPPRESSOR; CANCER-THERAPY; CELL LYMPHOMA; PROTEIN; ACTIVATION	The mechanisms of malignant cell transformation mediated by the oncogenic anaplastic lymphoma kinase (ALK) tyrosine kinase remain only partially understood. In this study, we report that T-cell lymphoma (TCL) cells carrying the nucleophosmin (NPM)/ALK fusion protein (ALK + TCL) strongly express hypoxia-induced factor 1 alpha (HIF1 alpha) mRNA, even under normoxic conditions, and markedly upregulate HIF1 alpha protein expression under hypoxia. HIF1 alpha expression is strictly dependent on the expression and enzymatic activity of NPM/ALK, as shown in BaF3 cells transfected with wild-type NPM/ALK and kinase-inactive NPM/ALK K210R mutant and by the inhibition of the NPM/ALK function in ALK + TCL cells by a small-molecule ALK inhibitor. NPM/ALK induces HIF1 alpha expression by upregulating its gene transcription through its key signal transmitter signal transducer and activator of transcription 3 (STAT3), which binds to the HIF1 alpha gene promoter as shown by the chromatin immunoprecipitation assay and is required for HIF1 alpha gene expression as demonstrated by its small interfering RNA-mediated depletion. In turn, depletion of HIF1 alpha increases mammalian target of rapamycin complex 1 activation, cell growth and proliferation and decreases vascular endothelial growth factor synthesis. These results identify a novel cell-transforming property of NPM/ALK, namely its ability to induce the expression of HIF1 alpha, a protein with an important role in carcinogenesis. These results also provide another rationale to therapeutically target NPM/ALK and STAT3 in ALK + TCL. Oncogene (2011) 30, 1372-1378; doi:10.1038/onc.2010.505; published online 22 November 2010	[Wasik, M. A.] Univ Penn, Dept Pathol & Lab Med, Med Ctr, Stellar Chance Labs 413A, Philadelphia, PA 19104 USA; [Wong, W.] Univ Penn, Dept Canc Biol, Philadelphia, PA 19104 USA; [Wong, W.] Univ Penn, Abramson Canc Res Inst, Philadelphia, PA 19104 USA; [Woetmann, A.; Odum, N.] Univ Copenhagen, Inst Mol Biol, Copenhagen, Denmark; [Cheng, M.] Cephalon Inc, W Chester, PA USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Copenhagen; Teva Pharmaceutical Industries; Cephalon Inc.	Wasik, MA (corresponding author), Univ Penn, Dept Pathol & Lab Med, Med Ctr, Stellar Chance Labs 413A, 422 Curie Blvd, Philadelphia, PA 19104 USA.	wasik@mail.med.upenn.edu	Woetmann, Anders/AAJ-3171-2020; Marzec, Michal/O-6387-2016	Marzec, Michal/0000-0001-9698-6019; Woetmann, Anders/0000-0002-3008-735X	National Cancer Institute [R01-CA89194, R01-CA96856]; NATIONAL CANCER INSTITUTE [R01CA096856, R01CA089194] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported in part by grants from the National Cancer Institute- R01-CA89194 and R01-CA96856.	Bertout JA, 2008, NAT REV CANCER, V8, P967, DOI 10.1038/nrc2540; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Chiarle R, 2003, BLOOD, V101, P1919, DOI 10.1182/blood-2002-05-1343; Chiarle R, 2008, NAT REV CANCER, V8, P11, DOI 10.1038/nrc2291; Evens AM, 2008, BRIT J HAEMATOL, V141, P676, DOI 10.1111/j.1365-2141.2008.07093.x; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; Galkin AV, 2007, P NATL ACAD SCI USA, V104, P270, DOI 10.1073/pnas.0609412103; Giatromanolaki A, 2008, HEMATOL ONCOL, V26, P219, DOI 10.1002/hon.861; Kasprzycka M, 2006, P NATL ACAD SCI USA, V103, P9964, DOI 10.1073/pnas.0603507103; Kuefer MU, 1997, BLOOD, V90, P2901, DOI 10.1182/blood.V90.8.2901; Li RS, 2008, MED RES REV, V28, P372, DOI 10.1002/med.20109; Ling XY, 2005, CANCER RES, V65, P2532, DOI 10.1158/0008-5472.CAN-04-2425; Lu LH, 2009, BIOCHEMISTRY-US, V48, P3600, DOI 10.1021/bi8020923; Marzec M, 2007, ONCOGENE, V26, P5606, DOI 10.1038/sj.onc.1210346; Marzec M, 2005, LAB INVEST, V85, P1544, DOI 10.1038/labinvest.3700348; Marzec M, 2008, P NATL ACAD SCI USA, V105, P20852, DOI 10.1073/pnas.0810958105; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; Niu GL, 2008, MOL CANCER RES, V6, P1099, DOI 10.1158/1541-7786.MCR-07-2177; Passam FH, 2009, PATHOL RES PRACT, V205, P11, DOI 10.1016/j.prp.2008.07.007; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; SHIOTA M, 1994, ONCOGENE, V9, P1567; Wasik MA, 2009, SEMIN ONCOL, V36, pS27, DOI 10.1053/j.seminoncol.2009.02.007; Wright CW, 2009, SCIENCE, V323, P251, DOI 10.1126/science.1162818; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Yue P, 2009, EXPERT OPIN INV DRUG, V18, P45, DOI [10.1517/13543780802565791, 10.1517/13543780802565791 ]; Zhang Q, 2002, J IMMUNOL, V168, P466, DOI 10.4049/jimmunol.168.1.466; Zhang Q, 2007, NAT MED, V13, P1341, DOI 10.1038/nm1659	29	26	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	11					1372	1378		10.1038/onc.2010.505	http://dx.doi.org/10.1038/onc.2010.505			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	736JX	21102525				2022-12-17	WOS:000288492100011
J	Tommasi, S; Besaratinia, A; Wilczynski, SP; Pfeifer, GP				Tommasi, S.; Besaratinia, A.; Wilczynski, S. P.; Pfeifer, G. P.			Loss of Rassf1a enhances p53-mediated tumor predisposition and accelerates progression to aneuploidy	ONCOGENE			English	Article						aneuploidy; chromosomal abnormalities; cytokinesis; tetraploidy; tumor suppressor gene	DOMAIN FAMILY PROTEIN; SUPPRESSOR RASSF1A; EPIGENETIC INACTIVATION; MICROTUBULE STABILITY; GENOMIC INSTABILITY; P53; ASSOCIATION; CHECKPOINT; GENE; TETRAPLOIDY	Loss of RASSF1A leads to several mitotic abnormalities, including cytokinesis failure and tetraploidization. Uncontrolled proliferation of tetraploid cells is known to trigger genomic instability and tumor development and is normally prevented through activation of a p53-dependent tetraploidy checkpoint. RASSF1A is the most commonly silenced and p53 is the most frequently mutated tumor suppressor gene in human cancer. However, their mutual contribution to tumorigenesis has never been investigated in animal models. Here, we explore whether concomitant loss of RASSF1A and p53 will result in increased levels of aneuploidy, genomic instability and tumorigenesis. We have intercrossed Rassf1a-knockout mice with mice lacking the p53 gene and generated a combination of single-and compound-mutant animals. Rassf1a(-/-) p53(-/-) mice were viable and fertile and developed normally. However, these mice were remarkably tumor prone and succumbed to malignancies significantly faster than single-mutant littermates, with a median survival time of 136 days (versus 158 days in p53(-/-) mice, P = 0.0207, and > 600 days in Rassf1a(-/-) animals, P<0.0001). Rassf1a-null mice with one functional p53 allele displayed a more moderate, yet tumor-prone phenotype, characterized by increased tumor multiplicity as compared with single knockouts. On cell-cycle profiling and cytogenetic analysis, cells derived from Rassf1a(-/-) p53(-/-) mice exhibited several mitotic defects associated with high levels of tetraploidy/ aneuploidy. Conversely, cells with a proficient p53 allele could better cope with the mitotic failures imposed by Rassf1a loss. Altogether, we provide the first experimental evidence for a pivotal role of Rassf1a as an early 'gatekeeper' gene, whose loss of function deteriorates cellular fitness by enhancing tetraploidization. Concomitant loss of p53, which causes unrestrained propagation of tetraploids into aneuploid cells, further undermines genomic stability and accelerates tumorigenesis. Oncogene (2011) 30, 690-700; doi:10.1038/onc.2010.440; published online 4 October 2010	[Tommasi, S.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Canc Biol, Ctr Canc, Duarte, CA 91010 USA; [Wilczynski, S. P.] City Hope Natl Med Ctr, Ctr Canc, Dept Pathol Anat, Duarte, CA USA	City of Hope; Beckman Research Institute of City of Hope; City of Hope	Tommasi, S (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Canc Biol, Ctr Canc, Duarte, CA 91010 USA.	stommasi@coh.org	Tommasi, Stefania/J-6732-2012	Tommasi, Stefania/0000-0002-2157-2978; Besaratinia, Ahmad/0000-0001-7231-228X; Tommasi, Stella/0000-0001-6897-4985	University of California [17RT-0116]	University of California(University of California System)	We would like to thank Donna Isbell, Stefanie Wright-Golightly and Armando Amaya for mouse colony management; Lucy Brown and Claudio Spalla for FACS analysis; Dr Marilyn Slovak, Dr Joyce Collins and Victoria Bedell for cytogenetics on mouse cell lines and tumor PET sections. This work was supported by a grant from the University of California Tobacco related Disease Research Program (TRDRP grant 17RT-0116 to GPP).	Agathanggelou A, 2005, CANCER RES, V65, P3497, DOI 10.1158/0008-5472.CAN-04-4088; Attardi LD, 2004, ONCOGENE, V23, P973, DOI 10.1038/sj.onc.1207026; Baksh S, 2005, MOL CELL, V18, P637, DOI 10.1016/j.molcel.2005.05.010; Burds AA, 2005, P NATL ACAD SCI USA, V102, P11296, DOI 10.1073/pnas.0505053102; Caldwell CM, 2007, J CELL BIOL, V178, P1109, DOI 10.1083/jcb.200703186; Chi YH, 2009, INT J CANCER, V124, P1483, DOI 10.1002/ijc.24094; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Dallol A, 2004, CANCER RES, V64, P4112, DOI 10.1158/0008-5472.CAN-04-0267; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2003, HISTOL HISTOPATHOL, V18, P665, DOI 10.14670/HH-18.665; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Donninger H, 2007, J CELL SCI, V120, P3163, DOI 10.1242/jcs.010389; Duensing A, 2005, BIOCHEM BIOPH RES CO, V331, P694, DOI 10.1016/j.bbrc.2005.03.157; Foley CJ, 2008, MOL CELL BIOL, V28, P4520, DOI 10.1128/MCB.02011-07; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; Galipeau PC, 1996, P NATL ACAD SCI USA, V93, P7081, DOI 10.1073/pnas.93.14.7081; Ganem NJ, 2007, CURR OPIN GENET DEV, V17, P157, DOI 10.1016/j.gde.2007.02.011; GIARETTI W, 1994, LAB INVEST, V71, P904; Giono LE, 2006, J CELL PHYSIOL, V209, P13, DOI 10.1002/jcp.20689; Guo C, 2007, CURR BIOL, V17, P700, DOI 10.1016/j.cub.2007.02.055; Holland AJ, 2009, NAT REV MOL CELL BIO, V10, P478, DOI 10.1038/nrm2718; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Liu LM, 2003, ONCOGENE, V22, P8125, DOI 10.1038/sj.onc.1206984; Liu LY, 2005, CANCER RES, V65, P1830, DOI 10.1158/0008-5472.CAN-04-3896; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Lobrich M, 2007, NAT REV CANCER, V7, P861, DOI 10.1038/nrc2248; Matallanas D, 2007, MOL CELL, V27, P962, DOI 10.1016/j.molcel.2007.08.008; Praskova M, 2004, BIOCHEM J, V381, P453, DOI 10.1042/BJ20040025; PURDIE CA, 1994, ONCOGENE, V9, P603; Rabizadeh S, 2004, J BIOL CHEM, V279, P29247, DOI 10.1074/jbc.M401699200; Richter AM, 2009, BBA-REV CANCER, V1796, P114, DOI 10.1016/j.bbcan.2009.03.004; SEGERS P, 1994, CANCER GENET CYTOGEN, V75, P120, DOI 10.1016/0165-4608(94)90163-5; Senovilla L, 2009, CELL CYCLE, V8, P1380, DOI 10.4161/cc.8.9.8305; Shi QH, 2005, NATURE, V437, P1038, DOI 10.1038/nature03958; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Song MS, 2005, J BIOL CHEM, V280, P3920, DOI 10.1074/jbc.M409115200; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; Storchova Z, 2004, NAT REV MOL CELL BIO, V5, P45, DOI 10.1038/nrm1276; Storchova Z, 2008, J CELL SCI, V121, P3859, DOI 10.1242/jcs.039537; Tommasi S, 2005, CANCER RES, V65, P92; van der Weyden L, 2005, MOL CELL BIOL, V25, P8356, DOI 10.1128/MCB.25.18.8356-8367.2005; van der Weyden L, 2007, BBA-REV CANCER, V1776, P58, DOI 10.1016/j.bbcan.2007.06.003; VERDOODT B, 1994, CANCER GENET CYTOGEN, V78, P53, DOI 10.1016/0165-4608(94)90046-9; Vogel C, 2004, ONCOGENE, V23, P6845, DOI 10.1038/sj.onc.1207860; Vos MD, 2003, J BIOL CHEM, V278, P21938, DOI 10.1074/jbc.M211019200; Vos MD, 2004, CANCER RES, V64, P4244, DOI 10.1158/0008-5472.CAN-04-0339; Zender L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030; Zhou DW, 2009, CANCER CELL, V16, P425, DOI 10.1016/j.ccr.2009.09.026	50	26	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	6					690	700		10.1038/onc.2010.440	http://dx.doi.org/10.1038/onc.2010.440			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	719GY	20890300	Bronze			2022-12-17	WOS:000287192000006
J	Planel, S; Salomon, A; Jalinot, P; Feige, JJ; Cherradi, N				Planel, S.; Salomon, A.; Jalinot, P.; Feige, J-J; Cherradi, N.			A novel concept in antiangiogenic and antitumoral therapy: multitarget destabilization of short-lived mRNAs by the zinc finger protein ZFP36L1	ONCOGENE			English	Article						tumor angiogenesis; VEGF; ZFP36L1; tristetraprolin; mRNA stability; multitarget therapy	ENDOTHELIAL GROWTH-FACTOR; CELL-PENETRATING PEPTIDES; ARGININE-RICH PEPTIDES; HORMONAL-REGULATION; IN-VIVO; TRISTETRAPROLIN; DELIVERY; TRANSDUCTION; ANGIOGENESIS; EXPRESSION	Angiogenesis inhibitors have shown clinical benefits in patients with advanced cancer, but further therapeutic improvement is needed. We have previously shown that the zinc finger protein 36, C3H type-like 1 (ZFP36L1) enhances vascular endothelial growth factor (VEGF) mRNA decay through its interaction with AU-rich elements within VEGF 3'-untranslated region. In this study, we evaluated the possibility to develop an antiangiogenic and antitumoral strategy using the mRNA-destabilizing activity of ZFP36L1. We engineered a cell-penetrating ZFP36L1, by fusing it to the protein transduction domains (PTDs) TAT derived from HIV, or the polyarginine peptides R7 or R9. PTD-ZFP36L1 fusion proteins were expressed in bacterial cells and affinity-purified to homogeneity. TAT-, R7- and R9-ZFP36L1 were efficiently internalized into living cells and decreased both endogenous VEGF mRNA half-life and VEGF protein levels in vitro. Importantly, a single injection of R9-TIS11b fusion protein into a high-VEGF expressing tissue in vivo (in this study, the mouse adrenal gland) markedly decreased VEGF expression. We further evaluated the effect of R9-ZFP36L1 on tumor growth using Lewis Lung Carcinoma (LL/2) cells implanted subcutaneously into nude mice. Intratumoral injection of R9-ZFP36L1 significantly reduced tumor growth and markedly decreased the expression of multiple angiogenic and inflammatory cytokines, including VEGF, acidic fibroblast growth factor, tumor necrosis factor alpha, interleukin (IL)-1 alpha and IL-6, with a concomitant obliteration of tumor vascularization. These findings indicate that R9-ZFP36L1 fusion protein may represent a novel antiangiogenic and antitumoral agent, and supports the emerging idea that modulation of mRNA stability represents a promising therapeutic approach to treat cancer. Oncogene (2010) 29, 5989-6003; doi:10.1038/onc.2010.341; published online 30 August 2010	[Cherradi, N.] CEA Grenoble, INSERM, U878, LPAV,iRTSV, F-38054 Grenoble 09, Rhone Alpes, France; [Planel, S.; Salomon, A.; Feige, J-J; Cherradi, N.] Univ Grenoble 1, Grenoble, France; [Jalinot, P.] ENS Lyon, LBMC CNRS UMR5239, Lyon, France	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet	Cherradi, N (corresponding author), CEA Grenoble, INSERM, U878, LPAV,iRTSV, 17 Rue Martyrs, F-38054 Grenoble 09, Rhone Alpes, France.	nadia.cherradi@cea.fr	Feige, Jean-Jacques/M-8905-2017; Cherradi, Nadia/K-9695-2016; Jalinot, Pierre/M-7940-2014	Feige, Jean-Jacques/0000-0002-1354-7692; Cherradi, Nadia/0000-0002-4292-774X; 	Institut National de la Sante et de la Recherche Medicale (INSERM) [U878]; Commissariat a l'Energie Atomique (iRTSV/LAPV); Institut du Cancer (INCa); Canceropole Rhone-Alpes (CLARA); Groupement des Entreprises Francaises pour la Lutte contre le Cancer (GEFLUC)-Comite Dauphine -Savoie; Association pour la Recherche sur le Cancer; Fondation pour la Recherche Medicale	Institut National de la Sante et de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Commissariat a l'Energie Atomique (iRTSV/LAPV)(French Atomic Energy Commission); Institut du Cancer (INCa)(Institut National du Cancer (INCA) France); Canceropole Rhone-Alpes (CLARA); Groupement des Entreprises Francaises pour la Lutte contre le Cancer (GEFLUC)-Comite Dauphine -Savoie; Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale)	This work was supported by the Institut National de la Sante et de la Recherche Medicale (INSERM, U878), the Commissariat a l'Energie Atomique (iRTSV/LAPV), the Institut du Cancer (INCa, Program 'Emergence des Canceropoles 2004'), the Canceropole Rhone-Alpes (CLARA) and the Groupement des Entreprises Francaises pour la Lutte contre le Cancer (GEFLUC)-Comite Dauphine -Savoie. We also thank the Association pour la Recherche sur le Cancer and the Fondation pour la Recherche Medicale for their financial support to SP. We thank Dr Didier Grunwald (LTS, iRTSV, CEA-Grenoble) for helping us with the laser confocal microscopy platform of our institute. We also thank Dr Maryline Herbet and Dr Michael Thomas (INSERM U878, iRTSV, CEA-Grenoble) for their assistance in the 'in vivo' experiments and Dr Jean-Luc Coll (INSERM U883, UJF, Grenoble, France) for his generous gift of the LL/2-luciferase cell line.	Asoh S, 2008, ADV DRUG DELIVER REV, V60, P499, DOI 10.1016/j.addr.2007.09.011; Baou M, 2009, J BIOMED BIOTECHNOL, DOI 10.1155/2009/634520; Bell SE, 2006, DEV DYNAM, V235, P3144, DOI 10.1002/dvdy.20949; Benjamin D, 2007, EXPERT OPIN BIOL TH, V7, P1515, DOI 10.1517/14712598.7.10.1515; Benjamin D, 2006, MOL CELL BIOL, V26, P9497, DOI 10.1128/MCB.01099-06; Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442; Bigelow RLH, 2009, BREAST CANCER RES TR, V117, P31, DOI 10.1007/s10549-008-0170-7; Cai SR, 2006, EUR J PHARM SCI, V27, P311, DOI 10.1016/j.ejps.2005.10.011; Cao H, 2008, BIOTECHNOL PROGR, V24, P326, DOI 10.1021/bp070269n; Cao HP, 2009, BIOTECHNOL PROGR, V25, P461, DOI 10.1002/btpr.121; Cao HP, 2004, BIOCHEMISTRY-US, V43, P13724, DOI 10.1021/bi049014y; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chauhan A, 2007, J CONTROL RELEASE, V117, P148, DOI 10.1016/j.jconrel.2006.10.031; Cherradi N, 2006, MOL ENDOCRINOL, V20, P916, DOI 10.1210/me.2005-0121; Ciais D, 2004, ONCOGENE, V23, P8673, DOI 10.1038/sj.onc.1207939; Dirkx AEM, 2006, J LEUKOCYTE BIOL, V80, P1183, DOI 10.1189/jlb.0905495; Duchardt F, 2007, TRAFFIC, V8, P848, DOI 10.1111/j.1600-0854.2007.00572.x; Ellis LM, 2008, NAT REV CANCER, V8, P579, DOI 10.1038/nrc2403; Essafi-Benkhadir K, 2007, MOL BIOL CELL, V18, P4648, DOI 10.1091/mbc.E07-06-0570; Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Fittipaldi A, 2005, ADV DRUG DELIVER REV, V57, P597, DOI 10.1016/j.addr.2004.10.011; Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200; Gariano RF, 2006, GENE EXPR PATTERNS, V6, P187, DOI 10.1016/j.modgep.2005.06.008; Heath VL, 2009, NAT REV CLIN ONCOL, V6, P395, DOI 10.1038/nrclinonc.2009.52; Ho A, 2001, CANCER RES, V61, P474; Jalonen U, 2006, MEDIAT INFLAMM, V2006, DOI 10.1155/MI/2006/40691; Kuvaja P, 2005, ONCOLOGY-BASEL, V68, P196, DOI 10.1159/000086774; Lee SK, 2005, INT J CANCER, V117, P32, DOI 10.1002/ijc.21133; Levy AP, 1998, TRENDS CARDIOVAS MED, V8, P246, DOI 10.1016/S1050-1738(98)00020-6; Li B, 2009, CANCER RES, V69, P338, DOI 10.1158/0008-5472.CAN-08-1565; Lindsay MA, 2002, CURR OPIN PHARMACOL, V2, P587, DOI 10.1016/S1471-4892(02)00199-6; Lykke-Andersen J, 2005, GENE DEV, V19, P351, DOI 10.1101/gad.1282305; Nakase I, 2004, MOL THER, V10, P1011, DOI 10.1016/j.ymthe.2004.08.010; Offenberg H, 2008, MOL ONCOL, V2, P233, DOI 10.1016/j.molonc.2008.06.003; Ogilvie RL, 2009, J BIOL CHEM, V284, P11216, DOI 10.1074/jbc.M901229200; Onesto C, 2004, J BIOL CHEM, V279, P34217, DOI 10.1074/jbc.M400219200; Petrelli A, 2008, CURR MED CHEM, V15, P422; Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200; Saidi A, 2009, INT J CANCER, V125, P1054, DOI 10.1002/ijc.24380; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Snyder EL, 2004, PHARM RES-DORDR, V21, P389, DOI 10.1023/B:PHAM.0000019289.61978.f5; Stoecklin G, 2003, ONCOGENE, V22, P3554, DOI 10.1038/sj.onc.1206418; Stumpo DJ, 2009, BLOOD, V114, P2401, DOI 10.1182/blood-2009-04-214619; Stumpo DJ, 2004, MOL CELL BIOL, V24, P6445, DOI 10.1128/MCB.24.14.6445-6455.2004; Thomas M, 2004, ENDOCRINOLOGY, V145, P4320, DOI 10.1210/en.2004-0179; Tudor C, 2009, FEBS LETT, V583, P1933, DOI 10.1016/j.febslet.2009.04.039; Voronov E, 2003, P NATL ACAD SCI USA, V100, P2645, DOI 10.1073/pnas.0437939100; Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003	50	26	30	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	45					5989	6003		10.1038/onc.2010.341	http://dx.doi.org/10.1038/onc.2010.341			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	678VA	20802528				2022-12-17	WOS:000284108700002
J	Kim, DH; Kim, EH; Na, HK; Sun, Y; Surh, YJ				Kim, D-H; Kim, E-H; Na, H-K; Sun, Y.; Surh, Y-J			15-Deoxy-Delta(12,14)-prostaglandin J(2) stabilizes, but functionally inactivates p53 by binding to the cysteine 277 residue	ONCOGENE			English	Article						cyclopentenone prostaglandin; 15-deoxy-Delta(12,14)-prostaglandin J(2); p53; thiol modification	WILD-TYPE P53; NF-KAPPA-B; PROLIFERATOR-ACTIVATED RECEPTOR; BREAST-CANCER CELLS; TUMOR-SUPPRESSOR PROTEIN; DNA-BINDING; CYCLOPENTENONE PROSTAGLANDINS; MOUSE SKIN; COVALENT MODIFICATION; OXIDATIVE STRESS	15-Deoxy-Delta(12,14)-prostaglandin J(2) (15d-PGJ(2)), a representative cyclopentenone prostaglandin, has many interesting biological effects. In this study, treatment of human breast cancer cells (MCF-7) with 15d-PGJ(2) led to accumulation of p53 protein. However, the p53 DNA binding and its transcriptional activity were significantly reduced. 15d-PGJ(2) directly modified p53 as verified by reacting recombinant p53 with biotinylated 15d-PGJ(2). 9,10-Dihydro-15-deoxy-Delta(12,14)-prostaglandin J(2) lacking the electrophilic alpha,beta-unsaturated functionality failed to inhibit p53 DNA binding as well as to modify p53. Moreover, by conducting an in vitro [S-35]-labeled p53 translation assay, we identified cysteine 277 as a putative site of p53 modification by 15d-PGJ(2). The DNA-binding ability of a mutant p53 in which cysteine 277 was substituted by alanine was virtually unaffected by 15d-PGJ(2). Likewise, p53 binding activity of biotinylated 15d-PGJ(2) was abolished in mutant cells. In addition, cells expressing wild-type p53 exhibited p53 protein stability to a greater extent than mutant C277A cells. In conclusion, 15d-PGJ(2) can undergo nucleophilic addition to p53, presumably at the cysteine 277 residue, rendering this tumor suppressor less susceptible to proteasomal degradation. Oncogene (2010) 29, 2560-2576; doi:10.1038/onc.2010.8; published online 8 March 2010	[Kim, D-H; Kim, E-H; Surh, Y-J] Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea; [Na, H-K] Sungshin Womens Univ, Dept Food & Nutr, Seoul, South Korea; [Sun, Y.] Univ Michigan, Ctr Comprehens Canc, Dept Radiat Oncol, Ann Arbor, MI 48109 USA; [Surh, Y-J] Seoul Natl Univ, Dept Mol Med & Biopharmaceut Sci, Grad Sch Convergence Sci & Technol, Seoul 151742, South Korea; [Surh, Y-J] Seoul Natl Univ, Canc Res Inst, Seoul 151742, South Korea	Seoul National University (SNU); Sungshin Women's University; University of Michigan System; University of Michigan; Seoul National University (SNU); Seoul National University (SNU)	Surh, YJ (corresponding author), Seoul Natl Univ, Coll Pharm, 599 Kwanak Ro, Seoul 151742, South Korea.	surh@plaza.snu.ac.kr			IDRC [R11-2007-107-01002-0]; WCU, National Research Foundation, Republic of Korea [R31-008-000-10103-0]	IDRC; WCU, National Research Foundation, Republic of Korea	This work was supported by the Outstanding Scholar Support grant, IDRC Grant (R11-2007-107-01002-0), and the WCU project Grant (R31-008-000-10103-0) from the National Research Foundation, Republic of Korea.	Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Asher G, 2006, ISR MED ASSOC J, V8, P229; ATSMON J, 1990, CANCER RES, V50, P1879; Azuma Y, 2004, J PHARMACOL SCI, V94, P261, DOI 10.1254/jphs.94.261; Bar-Or RL, 2000, P NATL ACAD SCI USA, V97, P11250, DOI 10.1073/pnas.210171597; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Biramijamal F, 2001, CANCER RES, V61, P3119; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Brooks CL, 2007, J BIOL CHEM, V282, P22804, DOI 10.1074/jbc.M700961200; Bureau F, 2002, J IMMUNOL, V168, P5318, DOI 10.4049/jimmunol.168.10.5318; Buzek J, 2002, NUCLEIC ACIDS RES, V30, P2340, DOI 10.1093/nar/30.11.2340; CAGEN LM, 1975, BIOCHIM BIOPHYS ACTA, V398, P205, DOI 10.1016/0005-2760(75)90184-8; Calmels S, 1997, CANCER RES, V57, P3365; Cernuda-Morollon E, 2001, J BIOL CHEM, V276, P35530, DOI 10.1074/jbc.M104518200; Chene P, 1999, BIOCHEM BIOPH RES CO, V263, P1, DOI 10.1006/bbrc.1999.1294; Chinery R, 1999, CANCER RES, V59, P2739; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Clay CE, 2001, J BIOL CHEM, V276, P47131, DOI 10.1074/jbc.C100339200; de Moraes E, 2007, INT J CANCER, V121, P929, DOI 10.1002/ijc.22899; DELPHIN C, 1994, EUR J BIOCHEM, V223, P683, DOI 10.1111/j.1432-1033.1994.tb19041.x; Emi M, 2004, BIOCHEM PHARMACOL, V67, P1259, DOI 10.1016/j.bcp.2003.10.037; Fischer Susan M., 2002, Journal of Environmental Pathology Toxicology and Oncology, V21, P183; Furstenberger G, 2003, PROG EXP TUMOR RES, V37, P72; Gayarre J, 2005, FEBS LETT, V579, P5803, DOI 10.1016/j.febslet.2005.09.069; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; HAINAUT P, 1993, CANCER RES, V53, P4469; Han JA, 2002, EMBO J, V21, P5635, DOI 10.1093/emboj/cdf591; HOSODA S, 1974, J BIOL CHEM, V249, P6416; Kastan MB, 2003, CELL, V112, P1, DOI 10.1016/S0092-8674(02)01281-3; Kim EH, 2008, CARCINOGENESIS, V29, P688, DOI 10.1093/carcin/bgm299; Kim EH, 2006, ANN NY ACAD SCI, V1090, P375, DOI 10.1196/annals.1378.041; Kim EH, 2008, BIOCHEM PHARMACOL, V76, P1544, DOI 10.1016/j.bcp.2008.07.043; Kim HJ, 2007, CANCER RES, V67, P2595, DOI 10.1158/0008-5472.CAN-06-3043; Kim WJ, 2007, EMBO J, V26, P5020, DOI 10.1038/sj.emboj.7601920; Klatt P, 2002, METHOD ENZYMOL, V348, P157, DOI 10.1016/S0076-6879(02)48635-1; Kondo M, 2002, P NATL ACAD SCI USA, V99, P7367, DOI 10.1073/pnas.112212599; Kundu JK, 2006, CARCINOGENESIS, V27, P1465, DOI 10.1093/carcin/bgi349; Lambert JMR, 2009, CANCER CELL, V15, P376, DOI 10.1016/j.ccr.2009.03.003; Leung WK, 2001, BRIT J CANCER, V84, P335, DOI 10.1054/bjoc.2000.1607; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Levonen AL, 2004, BIOCHEM J, V378, P373, DOI 10.1042/BJ20031049; Levonen AL, 2001, ARTERIOSCL THROM VAS, V21, P1846, DOI 10.1161/hq1101.098488; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Liu B, 2008, FREE RADICAL BIO MED, V44, P1529, DOI 10.1016/j.freeradbiomed.2008.01.011; Merwin JR, 2002, CARCINOGENESIS, V23, P1609, DOI 10.1093/carcin/23.10.1609; Millan O, 2006, CARCINOGENESIS, V27, P328, DOI 10.1093/carcin/bgi213; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Moos PJ, 2000, P NATL ACAD SCI USA, V97, P9215, DOI 10.1073/pnas.160241897; Mullally JE, 2001, J BIOL CHEM, V276, P30366, DOI 10.1074/jbc.M102198200; Muller-Decker K, 2002, P NATL ACAD SCI USA, V99, P12483, DOI 10.1073/pnas.192323799; Na HK, 2003, BIOCHEM PHARMACOL, V66, P1381, DOI 10.1016/S0006-2952(03)00488-X; NOYORI R, 1993, SCIENCE, V259, P44, DOI 10.1126/science.8418493; Oh JY, 2008, BIOCHEM J, V411, P297, DOI [10.1042/BJ20071189, 10.1042/bj20071189]; Oliva JL, 2003, P NATL ACAD SCI USA, V100, P4772, DOI 10.1073/pnas.0735842100; Pande V, 2005, BIOORG MED CHEM LETT, V15, P4057, DOI 10.1016/j.bmcl.2005.06.025; PARKER J, 1992, BIOCHEM PHARMACOL, V43, P1053, DOI 10.1016/0006-2952(92)90612-M; Perez-Sala D, 2003, J BIOL CHEM, V278, P51251, DOI 10.1074/jbc.M309409200; Pignatelli M, 2005, CARCINOGENESIS, V26, P81, DOI 10.1093/carcin/bgh308; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; Rajakariar R, 2007, P NATL ACAD SCI USA, V104, P20979, DOI 10.1073/pnas.0707394104; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Scher JU, 2009, J INVEST MED, V57, P703, DOI 10.2310/JIM.0b013e31819aaa76; Seemann S, 2005, ONCOGENE, V24, P3853, DOI 10.1038/sj.onc.1208549; Shibata T, 2003, J BIOL CHEM, V278, P26046, DOI 10.1074/jbc.M303690200; Shigemasa K, 2003, INT J ONCOL, V22, P99; Shiraki T, 2005, J BIOL CHEM, V280, P14145, DOI 10.1074/jbc.M500901200; SMITH WL, 1992, AM J PHYSIOL, V263, P181; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Straus DS, 2001, MED RES REV, V21, P185, DOI 10.1002/med.1006; Tiano HF, 2002, CANCER RES, V62, P3395; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Velu CS, 2007, BIOCHEMISTRY-US, V46, P7765, DOI 10.1021/bi700425y; Verhaegh GW, 1997, MOL CELL BIOL, V17, P5699, DOI 10.1128/MCB.17.10.5699; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wu H.H., 1999, GEN THER MOL BIOL, V4, P119; Wu HH, 2000, BIOCHEM J, V351, P87, DOI 10.1042/0264-6021:3510087; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126	81	26	26	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	17					2560	2576		10.1038/onc.2010.8	http://dx.doi.org/10.1038/onc.2010.8			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	589RB	20208557				2022-12-17	WOS:000277169400011
J	Varela, E; Blasco, MA				Varela, E.; Blasco, M. A.			2009 Nobel Prize in Physiology or Medicine: telomeres and telomerase	ONCOGENE			English	Editorial Material							DYSFUNCTIONAL TELOMERES; EPIGENETIC REGULATION; TERMINAL TRANSFERASE; MAMMALIAN TELOMERES; YEAST TELOMERES; DEFICIENT MICE; HUMAN-DISEASE; HUMAN CANCER; LIFE-SPAN; CELLS		[Varela, E.; Blasco, M. A.] CNIO, Spanish Natl Canc Ctr, Telomeres & Telomerase Grp, Mol Oncol Program, Madrid, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO)	Varela, E (corresponding author), CNIO, Spanish Natl Canc Ctr, Telomeres & Telomerase Grp, Mol Oncol Program, Madrid, Spain.	mblasco@cnio.es	Blasco, Maria A./M-1694-2014	Blasco, Maria A./0000-0002-4211-233X				Artandi SE, 2002, P NATL ACAD SCI USA, V99, P8191, DOI 10.1073/pnas.112515399; Azzalin CM, 2008, CELL CYCLE, V7, P1161, DOI 10.4161/cc.7.9.5836; Azzalin CM, 2007, SCIENCE, V318, P798, DOI 10.1126/science.1147182; BATEMAN AJ, 1975, NATURE, V253, P379, DOI 10.1038/253379a0; Baur JA, 2001, SCIENCE, V292, P2075, DOI 10.1126/science.1062329; Bell DR, 2004, ONCOGENE, V23, P7290, DOI 10.1038/sj.onc.1207949; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; Blackburn EH, 2005, NATURE, V436, P922, DOI 10.1038/436922a; BLACKBURN EH, 1978, J MOL BIOL, V120, P33, DOI 10.1016/0022-2836(78)90294-2; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Blackburn EH, 2006, NAT MED, V12, P1133, DOI 10.1038/nm1006-1133; Blasco MA, 2005, NAT REV GENET, V6, P611, DOI 10.1038/nrg1656; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Blasco MA, 2007, NAT REV GENET, V8, P299, DOI 10.1038/nrg2047; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bryan TM, 1997, EUR J CANCER, V33, P767, DOI 10.1016/S0959-8049(97)00065-8; Canela A, 2004, MOL CELL BIOL, V24, P4275, DOI 10.1128/MCB.24.10.4275-4293.2004; CAVALIER.T, 1974, NATURE, V250, P467, DOI 10.1038/250467a0; Chan SRWL, 2004, PHILOS T R SOC B, V359, P109, DOI 10.1098/rstb.2003.1370; Choudhury AR, 2007, NAT GENET, V39, P99, DOI 10.1038/ng1937; Collins K, 2002, ONCOGENE, V21, P564, DOI 10.1038/sj.onc.1205083; Cooper JP, 1997, NATURE, V385, P744, DOI 10.1038/385744a0; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; DANCIS BM, 1979, J THEOR BIOL, V78, P211, DOI 10.1016/0022-5193(79)90265-0; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; DUNN B, 1984, CELL, V39, P191, DOI 10.1016/0092-8674(84)90205-8; Espejel S, 2004, J CELL BIOL, V167, P627, DOI 10.1083/jcb.200407178; Flores I, 2005, SCIENCE, V309, P1253, DOI 10.1126/science.1115025; Flores I, 2006, CURR OPIN CELL BIOL, V18, P254, DOI 10.1016/j.ceb.2006.03.003; Garcia-Cao M, 2004, NAT GENET, V36, P94, DOI 10.1038/ng1278; Gonzalez-Suarez E, 2000, NAT GENET, V26, P114, DOI 10.1038/79089; Gonzalez-Suarez E, 2005, ONCOGENE, V24, P2256, DOI 10.1038/sj.onc.1208413; Gonzalez-Suarez E, 2001, EMBO J, V20, P2619, DOI 10.1093/emboj/20.11.2619; Gonzalo S, 2006, NAT CELL BIOL, V8, P416, DOI 10.1038/ncb1386; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Greenberg RA, 1999, CELL, V97, P515, DOI 10.1016/S0092-8674(00)80761-8; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Hackett JA, 2002, ONCOGENE, V21, P619, DOI 10.1038/sj.onc.1205061; Hackett JA, 2001, CELL, V106, P275, DOI 10.1016/S0092-8674(01)00457-3; Hande MP, 1999, J CELL BIOL, V144, P589, DOI 10.1083/jcb.144.4.589; Hao LY, 2005, CELL, V123, P1121, DOI 10.1016/j.cell.2005.11.020; Harley CB, 2008, NAT REV CANCER, V8, P167, DOI 10.1038/nrc2275; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Hayflick Leonard, 1998, Keio Journal of Medicine, V47, P174; HERMANN MT, 2001, CELL, V107, P67; Herrera E, 2000, EMBO J, V19, P472, DOI 10.1093/emboj/19.3.472; Herrera E, 1999, EMBO J, V18, P2950, DOI 10.1093/emboj/18.11.2950; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kolquist KA, 1998, NAT GENET, V19, P182, DOI 10.1038/554; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Li S, 2005, J BIOL CHEM, V280, P23709, DOI 10.1074/jbc.M502782200; Luke B, 2009, EMBO J, V28, P2503, DOI 10.1038/emboj.2009.166; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; Mason PJ, 2005, CURR MOL MED, V5, P159, DOI 10.2174/1566524053586581; McClintock B, 1939, P NATL ACAD SCI USA, V25, P405, DOI 10.1073/pnas.25.8.405; McClintock B, 1941, GENETICS, V26, P234; McKay JD, 2008, NAT GENET, V40, P1404, DOI 10.1038/ng.254; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; Morrish TA, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000357; Muller H.J., 1938, COLLECTING NET, V13, P181; OLOVNIKO.AM, 1971, DOKL AKAD NAUK SSSR+, V201, P1496; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; Pardue ML, 2003, ANNU REV GENET, V37, P485, DOI 10.1146/annurev.genet.38.072902.093115; Rafnar T, 2009, NAT GENET, V41, P221, DOI 10.1038/ng.296; Samper E, 2001, J CELL BIOL, V154, P49, DOI 10.1083/jcb.200103049; Sarin KY, 2005, NATURE, V436, P1048, DOI 10.1038/nature03836; SCHOEFTNER S, 2009, SEMIN CELL DEV BIOL; Schoeftner S, 2008, NAT CELL BIOL, V10, P228, DOI 10.1038/ncb1685; Schoeftner S, 2009, EMBO J, V28, P2323, DOI 10.1038/emboj.2009.197; SHAMPAY J, 1984, NATURE, V310, P154, DOI 10.1038/310154a0; Shete S, 2009, NAT GENET, V41, P899, DOI 10.1038/ng.407; Siegl-Cachedenier I, 2007, GENE DEV, V21, P2234, DOI 10.1101/gad.430107; Stacey SN, 2009, NAT GENET, V41, P909, DOI 10.1038/ng.412; SZOSTAK JW, 1982, CELL, V29, P245, DOI 10.1016/0092-8674(82)90109-X; Tomas-Loba A, 2008, CELL, V135, P609, DOI 10.1016/j.cell.2008.09.034; Vera E, 2008, ONCOGENE, V27, P6817, DOI 10.1038/onc.2008.289; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; Wong KK, 2003, NATURE, V421, P643, DOI 10.1038/nature01385	83	26	27	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2010	29	11					1561	1565		10.1038/onc.2010.15	http://dx.doi.org/10.1038/onc.2010.15			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	570RC	20237481				2022-12-17	WOS:000275694700001
J	Checquolo, S; Palermo, R; Cialfi, S; Ferrara, G; Oliviero, C; Talora, C; Bellavia, D; Giovenco, A; Grazioli, P; Frati, L; Gulino, A; Screpanti, I				Checquolo, S.; Palermo, R.; Cialfi, S.; Ferrara, G.; Oliviero, C.; Talora, C.; Bellavia, D.; Giovenco, A.; Grazioli, P.; Frati, L.; Gulino, A.; Screpanti, I.			Differential subcellular localization regulates c-Cbl E3 ligase activity upon Notch3 protein in T-cell leukemia	ONCOGENE			English	Article						c-Cbl; E3 ligase; ubiquitinylation; Notch3; pre-TCR; T-cell leukemia	NF-KAPPA-B; PRE-TCR; TYROSINE PHOSPHORYLATION; CONSTITUTIVE ACTIVATION; SIGNALING PROMOTES; UBIQUITIN LIGASES; GAMMA-CHAIN; PKC-THETA; RECEPTOR; LEUKEMOGENESIS	Notch3 and pT alpha signaling events are essential for T-cell leukemogenesis and characterize murine and human T-cell acute lymphoblastic leukemia. Genetic ablation of pT alpha expression in Notch3 transgenic mice abrogates tumor development, indicating that pT alpha signaling is crucial to the Notch3-mediated leukemogenesis. Here we report a novel direct interaction between Notch3 and pT alpha. This interaction leads to the recruitment and persistence of the E3 ligase protein c-Cbl to the lipid rafts in Notch3-IC transgenic thymocytes. Conversely, deletion of pT alpha in Notch3 transgenic mice leads to cytoplasmic retention of c-Cbl that targets Notch3 protein to the proteasomal-degradative pathway. It appears that protein kinase C theta (PKC theta), by regulating tyrosine and serine phosphorylation of Cbl, is able to control its function. We report here that the increased Notch3-IC degradation correlates with higher levels of c-Cbl tyrosine phosphorylation in Notch3-IC/pT alpha(-/-) double-mutant thymocytes, which also display a decreased PKC theta activity. Our data indicate that pT alpha/pre-T-cell receptor is able to regulate the different subcellular localization of c-Cbl and, by regulating PKC theta activity, is also able to influence its ubiquitin ligase activity upon Notch3 protein. Oncogene (2010) 29, 1463-1474; doi:10.1038/onc.2009.446; published online 7 December 2009	[Frati, L.; Gulino, A.] Neuromed Inst, Pozzilli, Italy; [Checquolo, S.; Palermo, R.; Cialfi, S.; Ferrara, G.; Oliviero, C.; Talora, C.; Bellavia, D.; Giovenco, A.; Grazioli, P.; Frati, L.; Gulino, A.; Screpanti, I.] Univ Roma La Sapienza, Dept Expt Med, I-00185 Rome, Italy; [Screpanti, I.] Univ Roma La Sapienza, Inst Pasteur, Fdn Cenci Bolognetti, I-00185 Rome, Italy	IRCCS Neuromed; Sapienza University Rome; Fondazione Cenci Bolognetti; Sapienza University Rome	Screpanti, I (corresponding author), Univ Roma La Sapienza, Dept Expt Med, Viale Regina Elena 324, I-00161 Rome, Italy.	isabella.screpanti@uniroma1.it	Frati, Luigi/ABI-7437-2020; Palermo, Rocco/I-5140-2016; Talora, Claduio/AIC-4932-2022; Bellavia, Diana/AAO-6348-2021	Palermo, Rocco/0000-0003-0134-9370; Talora, Claduio/0000-0002-6973-2184; CHECQUOLO, Saula/0000-0001-5109-8392	Italian Association for Cancer Research (AIRC); Italian Ministry of University and Research (MIUR); PRIN; Italian Ministry of Health; European Union [LHSB-CT-2003-543410]	Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); Italian Ministry of University and Research (MIUR)(Ministry of Education, Universities and Research (MIUR)); PRIN(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); Italian Ministry of Health(Ministry of Health, Italy); European Union(European Commission)	We thank Dr A Joutel for Notch3 antibodies and Dr R Bei for purification of mouse monoclonal pT alpha antibody, Dr F Grassi for c-Cbl plasmid and Dr M Bouche for PKC theta plasmids. This work was supported by the Italian Association for Cancer Research (AIRC), the Italian Ministry of University and Research (MIUR), PRIN Program, the Italian Ministry of Health and the European Union (Euro-Thymaide FP6 Integrated Project; LHSB-CT-2003-543410).	Aifantis I, 2001, NAT IMMUNOL, V2, P403, DOI 10.1038/87704; Aifantis L, 1998, IMMUNITY, V9, P649, DOI 10.1016/S1074-7613(00)80662-7; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Bellavia D, 2000, EMBO J, V19, P3337, DOI 10.1093/emboj/19.13.3337; Bellavia D, 2002, P NATL ACAD SCI USA, V99, P3788, DOI 10.1073/pnas.062050599; Bellavia D, 2007, EMBO J, V26, P1670, DOI 10.1038/sj.emboj.7601626; Benson RA, 2005, EUR J IMMUNOL, V35, P859, DOI 10.1002/eji.200425562; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Brizzi MF, 1998, EXP HEMATOL, V26, P1229; Campese AF, 2003, SEMIN CELL DEV BIOL, V14, P151, DOI 10.1016/S1084-9521(02)00184-2; Deftos ML, 1998, IMMUNITY, V9, P777, DOI 10.1016/S1074-7613(00)80643-3; Deftos ML, 2000, IMMUNITY, V13, P73, DOI 10.1016/S1074-7613(00)00009-1; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FEHLING HJ, 1995, NATURE, V375, P795, DOI 10.1038/375795a0; Felli MP, 2005, ONCOGENE, V24, P992, DOI 10.1038/sj.onc.1208302; Gay DL, 2008, IMMUNOL RES, V42, P51, DOI 10.1007/s12026-008-8034-0; GROETTRUP M, 1992, EMBO J, V11, P2735, DOI 10.1002/j.1460-2075.1992.tb05339.x; Hehner SP, 2000, J IMMUNOL, V164, P3829, DOI 10.4049/jimmunol.164.7.3829; Hubbard EJA, 1997, GENE DEV, V11, P3182, DOI 10.1101/gad.11.23.3182; Irving BA, 1998, SCIENCE, V280, P905, DOI 10.1126/science.280.5365.905; Jehn BM, 2002, J BIOL CHEM, V277, P8033, DOI 10.1074/jbc.M108552200; Joutel A, 2004, AM J HUM GENET, V74, P338, DOI 10.1086/381506; Kassenbrock CK, 2004, J BIOL CHEM, V279, P28017, DOI 10.1074/jbc.M404114200; Liu YC, 2004, ANNU REV IMMUNOL, V22, P81, DOI 10.1146/annurev.immunol.22.012703.104813; Liu YH, 1999, J IMMUNOL, V162, P7095; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; Oberg C, 2001, J BIOL CHEM, V276, P35847, DOI 10.1074/jbc.M103992200; Ota S, 2000, J BIOL CHEM, V275, P414, DOI 10.1074/jbc.275.1.414; Panigada M, 2002, J EXP MED, V195, P1585, DOI 10.1084/jem.20020047; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; Peschard P, 2003, CANCER CELL, V3, P519, DOI 10.1016/S1535-6108(03)00136-3; Qiu L, 2000, J BIOL CHEM, V275, P35734, DOI 10.1074/jbc.M007300200; Rothenberg EV, 2001, NAT IMMUNOL, V2, P189, DOI 10.1038/85231; Saint-Ruf C, 2000, NATURE, V406, P524, DOI 10.1038/35020093; Schweisguth F, 1999, P NATL ACAD SCI USA, V96, P11382, DOI 10.1073/pnas.96.20.11382; SPOLSKI R, 1988, EUR J IMMUNOL, V18, P295; Talora C, 2006, BLOOD, V107, P3313, DOI 10.1182/blood-2005-07-2823; Villalba M, 2000, IMMUNITY, V12, P151, DOI 10.1016/S1074-7613(00)80168-5; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wu GY, 2001, MOL CELL BIOL, V21, P7403, DOI 10.1128/MCB.21.21.7403-7415.2001	41	26	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2010	29	10					1463	1474		10.1038/onc.2009.446	http://dx.doi.org/10.1038/onc.2009.446			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	566SD	19966856				2022-12-17	WOS:000275392400005
J	Kumar, C; Purandare, AV; Lee, FY; Lorenzi, MV				Kumar, C.; Purandare, A. V.; Lee, F. Y.; Lorenzi, M. V.			Kinase drug discovery approaches in chronic myeloproliferative disorders	ONCOGENE			English	Review						tyrosine kinase inhibitors; JAK2; BCR-ABL; hematopoeisis	CHRONIC MYELOMONOCYTIC LEUKEMIA; JAK2 EXON-12 MUTATIONS; POLYCYTHEMIA-VERA; TYROSINE KINASE; ESSENTIAL THROMBOCYTHEMIA; PHILADELPHIA-CHROMOSOME; CHRONIC-PHASE; MYELOID METAPLASIA; DASATINIB BMS-354825; IMATINIB RESISTANCE	Myeloproliferative disorders (MPDs) are clonal malignancies that arise from hematopoietic progenitors and characterized by overproduction of mature, functional blood cells. These disorders can be broadly characterized into Philadelphia chromosome-positive (Ph(+)) or negative (Ph(-)) genetic groupings. Chronic myeloid leukemia (CML) is a Ph(+) MPD that is defined on the basis of its molecular lesion, the BCR-ABL fusion gene. Inhibitors directed at the constitutive kinase activity of BCR-ABL have been shown to be disease modifying in CML and have dramatically altered the standard of care for this leukemia. The three main Ph(-) MPDs are polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF). The key features of these Ph(-) MPDs are an increased red blood cell mass in PV, a high platelet count in ET and bone marrow fibrosis in PMF, respectively. These disorders also share many clinical features such as long clinical course, increased risk for thrombosis, hemorrhage and elevated risk of leukemic transformation. Interest in these disorders has been ignited by the recent discovery of activating mutations in the tyrosine kinase gene, JAK2, in the predominance of Ph(-) MPD patients and has highlighted JAK2 as a therapeutic intervention point for drug discovery efforts with selective kinase inhibitors. This review will focus on the comparison of Ph(+) and Ph(-) MPDs, drug discovery and development efforts targeting these disorders, and will assess the new opportunities for targeted therapies for these diseases. Oncogene (2009) 28, 2305-2313; doi:10.1038/onc.2009.107; published online 4 May 2009	[Lorenzi, M. V.] Bristol Myers Squibb Co, Pharmaceut Res Inst, Oncol Drug Discovery, Res & Dev, Princeton, NJ 08540 USA; [Kumar, C.] SmartAnalyst, New York, NY USA	Bristol-Myers Squibb	Lorenzi, MV (corresponding author), Bristol Myers Squibb Co, Pharmaceut Res Inst, Oncol Drug Discovery, Res & Dev, POB 4000, Princeton, NJ 08540 USA.	matthew.lorenzi@bms.com						Abdel-Wahab OI, 2009, ANNU REV MED, V60, P233, DOI 10.1146/annurev.med.60.041707.160528; Baccarani M, 2008, HAEMATOL-HEMATOL J, V93, P161, DOI 10.3324/haematol.12588; BARTRAM CR, 1983, NATURE, V306, P277, DOI 10.1038/306277a0; Baxter EJ, 2005, LANCET, V365, P1054, DOI 10.1016/S0140-6736(05)71142-9; Bumm TGP, 2006, CANCER RES, V66, P11156, DOI 10.1158/0008-5472.CAN-06-2210; Campbell PJ, 2006, NEW ENGL J MED, V355, P2452, DOI 10.1056/NEJMra063728; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; Cervantes F, 2008, LEUKEMIA, V22, P905, DOI 10.1038/leu.2008.72; CERVANTES F, 1991, ACTA HAEMATOL-BASEL, V85, P124; Cervantes F, 2007, CANCER J, V13, P377, DOI 10.1097/PPO.0b013e31815a7c0a; Chen J, 2004, P NATL ACAD SCI USA, V101, P14479, DOI 10.1073/pnas.0404438101; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; DAMESHEK W, 1951, BLOOD, V6, P372, DOI 10.1182/blood.V6.4.372.372; Doesch C, 2008, J THROMB THROMBOLYS, V25, P193, DOI 10.1007/s11239-007-0082-0; DRUKER BJ, 2001, NEW ENGL J MED, V344, P1037; Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306; Finazzi G, 2007, BLOOD, V109, P5104, DOI 10.1182/blood-2006-12-038968; Finazzi Guido, 2008, V142, P51; Geron I, 2008, CANCER CELL, V13, P321, DOI 10.1016/j.ccr.2008.02.017; Giles FJ, 2007, BLOOD, V109, P500, DOI 10.1182/blood-2006-05-025049; Goerttler PS, 2005, BRIT J HAEMATOL, V129, P138, DOI 10.1111/j.1365-2141.2005.05416.x; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Guilhot F, 2004, ONCOLOGIST, V9, P271, DOI 10.1634/theoncologist.9-3-271; Harrison CN, 2005, NEW ENGL J MED, V353, P33, DOI 10.1056/NEJMoa043800; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Johansson P, 2004, J INTERN MED, V256, P161, DOI 10.1111/j.1365-2796.2004.01357.x; Kantarjian H, 2008, BLOOD, V111, P1774, DOI 10.1182/blood-2007-09-110189; Kantarjian HM, 2007, BLOOD, V110, P3540, DOI 10.1182/blood-2007-03-080689; Knapper S, 2006, BLOOD, V108, P3262, DOI 10.1182/blood-2006-04-015560; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Kutti J, 2001, PATHOL BIOL, V49, P164, DOI 10.1016/S0369-8114(00)00023-7; Lacout C, 2006, BLOOD, V108, P1652, DOI 10.1182/blood-2006-02-002030; LEE FY, 2005, BLOOD, V106, P1994; Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023; Levine RL, 2006, BLOOD, V107, P4139, DOI 10.1182/blood-2005-09-3900; Lombardo LJ, 2004, J MED CHEM, V47, P6658, DOI 10.1021/jm049486a; Lu XH, 2005, P NATL ACAD SCI USA, V102, P18962, DOI 10.1073/pnas.0509714102; Mesa RA, 2008, CURR OPIN HEMATOL, V15, P121, DOI 10.1097/MOH.0b013e3282f3debd; Mesa RA, 2007, CANCER-AM CANCER SOC, V109, P68, DOI 10.1002/cncr.22365; Mesa RA, 2006, BEST PRACT RES CL HA, V19, P495, DOI 10.1016/j.beha.2005.07.008; Morinaga K, 2008, INT J CANCER, V122, P2621, DOI 10.1002/ijc.23435; Murray PJ, 2007, J IMMUNOL, V178, P2623, DOI 10.4049/jimmunol.178.5.2623; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; Nam S, 2005, CANCER RES, V65, P9185, DOI 10.1158/0008-5472.CAN-05-1731; O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457; O'Hare T, 2005, CANCER RES, V65, P4500, DOI 10.1158/0008-5472.CAN-05-0259; O'Hare T, 2008, P NATL ACAD SCI USA, V105, P5507, DOI 10.1073/pnas.0800587105; O'Shea JJ, 2004, NAT REV DRUG DISCOV, V3, P555, DOI 10.1038/nrd1441; Pardanani A, 2007, LEUKEMIA, V21, P1960, DOI 10.1038/sj.leu.2404810; Pikman Y, 2006, PLOS MED, V3, P1140, DOI 10.1371/journal.pmed.0030270; Quintas-Cardama Alfonso, 2006, Future Oncol, V2, P655, DOI 10.2217/14796694.2.6.655; QUINTASCARDAMA A, 2008, LEUK RES IN PRESS; Saijo K, 1997, J EXP MED, V185, P351, DOI 10.1084/jem.185.2.351; Sawyers CL, 2005, COLD SH Q B, V70, P479, DOI 10.1101/sqb.2005.70.034; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Schittenhelm MM, 2006, CANCER RES, V66, P473, DOI 10.1158/0008-5472.CAN-05-2050; Scott LM, 2007, NEW ENGL J MED, V356, P459, DOI 10.1056/NEJMoa065202; Shah NP, 2007, J CLIN ONCOL, V25; Shah Neil P, 2007, Hematology Am Soc Hematol Educ Program, P371; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X; Sherbenou DW, 2007, J CLIN INVEST, V117, P2067, DOI 10.1172/JCI31988; Siendones E, 2007, HEMATOL ONCOL, V25, P30, DOI 10.1002/hon.805; Soverini S, 2007, HAEMATOLOGICA, V92, P401, DOI 10.3324/haematol.10822; Talpaz M, 2006, NEW ENGL J MED, V354, P2531, DOI 10.1056/NEJMoa055229; Tefferi A, 2008, LEUKEMIA, V22, P14, DOI 10.1038/sj.leu.2404955; Tefferi A, 2008, LEUKEMIA, V22, P1, DOI 10.1038/sj.leu.2404984; Tefferi A, 2005, BRIT J HAEMATOL, V131, P320, DOI 10.1111/j.1365-2141.2005.05776.x; Tefferi A, 2000, NEW ENGL J MED, V342, P1255, DOI 10.1056/NEJM200004273421706; Tefferi A, 2008, AM J HEMATOL, V83, P491, DOI 10.1002/ajh.21183; Tefferi A, 2007, BLOOD, V110, P1092, DOI 10.1182/blood-2007-04-083501; Theocharides A, 2007, BLOOD, V110, P375, DOI 10.1182/blood-2006-12-062125; Wang XD, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-11-r255; Wernig G, 2006, BLOOD, V107, P4274, DOI 10.1182/blood-2005-12-4824; Werning G, 2008, CANCER CELL, V13, P311, DOI 10.1016/j.ccr.2008.02.009; Wolanskyj AP, 2006, MAYO CLIN PROC, V81, P159, DOI 10.4065/81.2.159; Xiao S, 1998, NAT GENET, V18, P84, DOI 10.1038/ng0198-84; Zaleskas VM, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000018	77	26	72	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2009	28	24					2305	2313		10.1038/onc.2009.107	http://dx.doi.org/10.1038/onc.2009.107			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459GJ	19421140				2022-12-17	WOS:000267089100001
J	Hagelstrom, RT; Askin, KF; Williams, AJ; Ramaiah, L; Desaintes, C; Goodwin, EH; Ullrich, RL; Bailey, SM				Hagelstrom, R. T.; Askin, K. F.; Williams, A. J.; Ramaiah, L.; Desaintes, C.; Goodwin, E. H.; Ullrich, R. L.; Bailey, S. M.			DNA-PKcs and ATM influence generation of ionizing radiation-induced bystander signals	ONCOGENE			English	Article						DNA-PKcs; ATM; ionizing radiation; bystander effect	DEPENDENT PROTEIN-KINASE; SISTER-CHROMATID EXCHANGES; STRAND BREAK REPAIR; CATALYTIC SUBUNIT; INTERCELLULAR COMMUNICATION; V(D)J RECOMBINATION; ALPHA-PARTICLES; LOW FLUENCES; CELLS; DEFICIENCY	The phenomenon by which irradiated cells influence non-irradiated neighboring cells, referred to as the bystander effect (BSE), is not well understood in terms of the underlying pathways involved. We sought to enlighten connections between DNA damage repair and the BSE. Utilizing sister chromatid exchange (SCE) frequencies as a marker of the BSE, we performed cell transfer strategies that enabled us to distinguish between generation versus reception of a bystander signal. We find that DNA-dependent Protein Kinase catalytic subunit (DNA-PKcs) and Ataxia Telangectasia Mutated (ATM) are necessary for the generation of such a bystander signal in normal human cells following gamma (gamma)-ray exposure, but are not required for its reception. Importantly, we also show that directly irradiated human cells do not respond to receipt of a bystander signal, helping to explain why the BSE is a low-dose phenomenon. These studies provide the first evidence for a role of the DNA damage response proteins DNA-PKcs and ATM specifically in the generation of a bystander signal and intercellular signaling.	[Hagelstrom, R. T.; Askin, K. F.; Williams, A. J.; Ramaiah, L.; Ullrich, R. L.; Bailey, S. M.] Colorado State Univ, Dept Environm & Radiol Hlth Sci, Ft Collins, CO 80523 USA; [Desaintes, C.] CEN SCK, Radiobiol Lab, B-2400 Mol, Belgium; [Goodwin, E. H.] KromaTiD Inc, Ft Collins, CO USA	Colorado State University; Belgian Nuclear Research Centre (SCK-CEN)	Bailey, SM (corresponding author), Colorado State Univ, Dept Environm & Radiol Hlth Sci, Campus Delivery 1618, Ft Collins, CO 80523 USA.	sbailey@colostate.edu	Ramaiah, Lila/GPX-6746-2022		NIH/NCI [CA-09236-30, CA-043322-20]; US Department of Energy (DOE) [DE-FG02-01ER63239]; National Aeronautics and Space Administration (NASA) [NNJ04HD83G]; NATIONAL CANCER INSTITUTE [R01CA043322] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); US Department of Energy (DOE)(United States Department of Energy (DOE)); National Aeronautics and Space Administration (NASA)(National Aeronautics & Space Administration (NASA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dakim Gaines for technical assistance. Support for this research is gratefully acknowledged from the NIH/NCI, Grants CA-09236-30 (RLU) and CA-043322-20 (RLU and SMB), the US Department of Energy (DOE), Grant DE-FG02-01ER63239 (RLU and SMB), and from the National Aeronautics and Space Administration (NASA), Grant NNJ04HD83G (SMB).	ARDITO G, 1980, Bollettino Societa Italiana Biologia Sperimentale, V56, P719; Azzam EI, 1998, RADIAT RES, V150, P497, DOI 10.2307/3579865; Azzam EI, 2001, P NATL ACAD SCI USA, V98, P473, DOI 10.1073/pnas.011417098; Bailey SM, 1999, P NATL ACAD SCI USA, V96, P14899, DOI 10.1073/pnas.96.26.14899; Bailey SM, 2004, DNA REPAIR, V3, P225, DOI 10.1016/j.dnarep.2003.10.013; Bailey SM, 2001, SCIENCE, V293, P2462, DOI 10.1126/science.1062560; Banaz-Yasar F, 2008, J CELL BIOCHEM, V103, P149, DOI 10.1002/jcb.21395; Barzilai A, 2002, DNA REPAIR, V1, P3, DOI 10.1016/S1568-7864(01)00007-6; Blunt T, 1996, P NATL ACAD SCI USA, V93, P10285, DOI 10.1073/pnas.93.19.10285; Collis SJ, 2005, ONCOGENE, V24, P949, DOI 10.1038/sj.onc.1208332; Denchi EL, 2007, NATURE, V448, P1068, DOI 10.1038/nature06065; Deshpande A, 1996, RADIAT RES, V145, P260, DOI 10.2307/3578980; Dudley DD, 2005, ADV IMMUNOL, V86, P43, DOI 10.1016/S0065-2776(04)86002-4; Fritz G, 2006, MOL BIOL CELL, V17, P851, DOI 10.1091/mbc.E05-07-0606; Grifalconi M, 2007, MUTAT RES-FUND MOL M, V625, P102, DOI 10.1016/j.mrfmmm.2007.06.004; Hu BR, 2006, CARCINOGENESIS, V27, P245, DOI 10.1093/carcin/bgi224; Iyer R, 2002, RADIAT RES, V157, P3, DOI 10.1667/0033-7587(2002)157[0003:APIIIT]2.0.CO;2; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; Kanasugi Y, 2007, INT J RADIAT BIOL, V83, P73, DOI 10.1080/09553000601121116; Kashino G, 2007, J RADIAT RES, V48, P327, DOI 10.1269/jrr.07008; Lavin MF, 2007, CELL CYCLE, V6, P931, DOI 10.4161/cc.6.8.4180; Lehnert BE, 1997, CANCER RES, V57, P2164; Lieber MR, 1999, GENES CELLS, V4, P77, DOI 10.1046/j.1365-2443.1999.00245.x; Meek K, 2004, IMMUNOL REV, V200, P132, DOI 10.1111/j.0105-2896.2004.00162.x; Morgan WF, 2003, ONCOGENE, V22, P7094, DOI 10.1038/sj.onc.1206992; Mothersill C, 2004, RADIAT RES, V161, P256, DOI 10.1667/RR3136; Mothersill C, 1998, RADIAT RES, V149, P256, DOI 10.2307/3579958; Nagasawa H, 2005, RADIAT RES, V164, P141, DOI 10.1667/RR3420; Nagasawa H, 2003, INT J RADIAT BIOL, V79, P35, DOI 10.1080/0955300021000019230; Nagasawa H, 2002, MUTAT RES-FUND MOL M, V508, P121, DOI 10.1016/S0027-5107(02)00193-8; NAGASAWA H, 1992, CANCER RES, V52, P6394; O'Neill-Mehlenbacher A, 2007, INT J RADIAT BIOL, V83, P593, DOI 10.1080/09553000701481782; Okayasu R, 2000, CANCER RES, V60, P4342; Pandita TK, 2002, ONCOGENE, V21, P611, DOI 10.1038/sj.onc.1205060; Panta GR, 2004, MOL CELL BIOL, V24, P1823, DOI 10.1128/MCB.24.5.1823-1835.2004; Seymour CB, 2000, RADIAT RES, V153, P508, DOI 10.1667/0033-7587(2000)153[0508:RCOBAT]2.0.CO;2; Shao CL, 2006, RADIAT RES, V166, P479, DOI 10.1667/RR3600.1; Weil MM, 1997, GENETICS, V146, P1061; Weinstock DM, 2006, MOL CELL BIOL, V26, P131, DOI 10.1128/MCB.26.1.131-139.2006; WOLFF S, 1975, EXP CELL RES, V93, P23, DOI 10.1016/0014-4827(75)90418-8; Wu LJ, 1999, P NATL ACAD SCI USA, V96, P4959, DOI 10.1073/pnas.96.9.4959; Xu WM, 2000, NAT CELL BIOL, V2, P339, DOI 10.1038/35014028; Yang HY, 2007, RADIAT RES, V168, P292, DOI 10.1667/RR0864.1; Yu YJ, 2001, CANCER RES, V61, P1820; Zhang Y, 2007, CANCER LETT, V250, P63, DOI 10.1016/j.canlet.2006.09.021	45	26	29	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	2008	27	53					6761	6769		10.1038/onc.2008.276	http://dx.doi.org/10.1038/onc.2008.276			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	371XO	18679419				2022-12-17	WOS:000260866200006
J	Sobue, S; Murakami, M; Banno, Y; Ito, H; Kimura, A; Gao, S; Furuhata, A; Takagi, A; Kojima, T; Suzuki, M; Nozawa, Y; Murate, T				Sobue, S.; Murakami, M.; Banno, Y.; Ito, H.; Kimura, A.; Gao, S.; Furuhata, A.; Takagi, A.; Kojima, T.; Suzuki, M.; Nozawa, Y.; Murate, T.			v-Src oncogene product increases sphingosine kinase 1 expression through mRNA stabilization: alteration of AU-rich element-binding proteins	ONCOGENE			English	Article						v-Src; sphingosine kinase 1; gene expression; mRNA half-life; AUF1; HuR	N-TERMINAL KINASE; GENE-EXPRESSION; C ISOFORMS; CELL-LINE; ACTIVATION; HUR; PHOSPHORYLATION; LEUKEMIA; TURNOVER; CANCER	Sphingosine kinase 1 (SPHK1) is overexpressed in solid tumors and leukemia. However, the mechanism of SPHK1 overexpression by oncogenes has not been defined. We found that v-Src-transformed NIH3T3 cells showed a high SPHK1 mRNA, SPHK1 protein and SPHK enzyme activity. siRNA of SPHK1 inhibited the growth of v-Src-NIH3T3, suggesting the involvement of SPHK1 in v-Src-induced oncogenesis. v-Src-NIH3T3 showed activations of protein kinase C-alpha, signal transducers and activators of transcription 3 and c-Jun NH2-terminal kinase. Their inhibition suppressed SPHK1 expression in v-Src-NIH3T3, whereas their overexpression increased SPHK1 mRNA in NIH3T3. Unexpectedly, the nuclear run-on assay and the promoter analysis using 50-promoter region of mouse SPHK1 did not show any significant difference between mock-and v-Src-NIH3T3. Furthermore, the half-life of SPHK1 mRNA in mock-NIH3T3 was nearly 15 min, whereas that of v-SrcNIH3T3 was much longer. Examination of two AU-rich region-binding proteins, AUF1 and HuR, that regulate mRNA decay reciprocally, showed decreased total AUF1 protein associated with increased tyrosine-phosphorylated form and increased serine-phosphorylated HuR protein in v-Src-NIH3T3. Modulation of AUF1 and HuR by their overexpression or siRNA revealed that SPHK1 mRNA in v-Src- and mock-NIH3T3 was regulated reciprocally by these factors. Our results showed, for the first time, a novel mechanism of v-Src-induced SPHK1 overexpression.	[Sobue, S.; Murakami, M.; Ito, H.; Kimura, A.; Gao, S.; Furuhata, A.; Takagi, A.; Kojima, T.; Murate, T.] Nagoya Univ, Grad Sch Hlth Sci, Dept Med Technol, Nagoya, Aichi 4668673, Japan; [Banno, Y.] Gifu Univ, Grad Sch Med, Dept Biochem, Gifu, Japan; [Suzuki, M.] Nagoya Univ, Grad Sch Med, Div Mol Carcinogenesis, Nagoya, Aichi 4668673, Japan; [Nozawa, Y.] Gifu Int Inst Biotechnol, Kakamigahara, Japan	Nagoya University; Gifu University; Nagoya University	Murate, T (corresponding author), Nagoya Univ, Sch Hlth Sci, Dept Med Technol, Higashi Ku, Daiko Minami 1-1-20, Nagoya, Aichi 4668673, Japan.	murate@met.nagoya-u.ac.jp	Kojima, Tetsuhito/I-6271-2014; Suzuki, Motoshi/I-7246-2014	Kojima, Tetsuhito/0000-0002-1905-1065; Suzuki, Motoshi/0000-0003-0682-5006				Akao Y, 2006, BIOCHEM BIOPH RES CO, V342, P1284, DOI 10.1016/j.bbrc.2006.02.070; Alvarez SE, 2007, TRENDS ENDOCRIN MET, V18, P300, DOI 10.1016/j.tem.2007.07.005; Bektas M, 2005, ONCOGENE, V24, P178, DOI 10.1038/sj.onc.1208019; BLOBEL GA, 1991, P NATL ACAD SCI USA, V88, P1162, DOI 10.1073/pnas.88.4.1162; Bonhoure E, 2006, LEUKEMIA, V20, P95, DOI 10.1038/sj.leu.2404023; BORNER C, 1992, J BIOL CHEM, V267, P12900; Bromann PA, 2005, J BIOL CHEM, V280, P10253, DOI 10.1074/jbc.M413806200; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; Cussac D, 2004, BLOOD, V103, P1464; de Silanes IL, 2004, P NATL ACAD SCI USA, V101, P2987, DOI 10.1073/pnas.0306453101; Dehm S, 2001, FEBS LETT, V487, P367, DOI 10.1016/S0014-5793(00)02354-1; Dehm SM, 2004, BIOCHEM CELL BIOL, V82, P263, DOI 10.1139/o03-077; Doller A, 2007, MOL BIOL CELL, V18, P2137, DOI 10.1091/mbc.E06-09-0850; Fawal M, 2006, BLOOD, V108, P2780, DOI 10.1182/blood-2006-04-014902; Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111; French KJ, 2003, CANCER RES, V63, P5962; FRITZ G, 1995, J BIOL CHEM, V270, P25172, DOI 10.1074/jbc.270.42.25172; Gartsbein M, 2006, J CELL SCI, V119, P470, DOI 10.1242/jcs.02744; GOOD PJ, 1995, P NATL ACAD SCI USA, V92, P4557, DOI 10.1073/pnas.92.10.4557; Greulich H, 1996, ONCOGENE, V12, P1689; Hanford DS, 1996, MOL ENDOCRINOL, V10, P1719, DOI 10.1210/me.10.12.1719; Karni R, 2002, J BIOL CHEM, V277, P42919, DOI 10.1074/jbc.M206141200; Kawamori T, 2006, FASEB J, V20, P386, DOI 10.1096/fj.05-4331fje; Kloss S, 2004, MOL PHARMACOL, V65, P1440, DOI 10.1124/mol.65.6.1440; Kuo LY, 2006, J CELL PHYSIOL, V207, P729, DOI 10.1002/jcp.20616; Lal A, 2004, EMBO J, V23, P3092, DOI 10.1038/sj.emboj.7600305; Leclerc Guy J, 2002, Cancer Cell Int, V2, P1, DOI 10.1186/1475-2867-2-1; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Meyer S, 2004, CRIT REV BIOCHEM MOL, V39, P197, DOI 10.1080/10409230490513991; Murakami M, 2007, J NEUROCHEM, V102, P1585, DOI 10.1111/j.1471-4159.2007.04673.x; Nakade Y, 2003, BBA-MOL CELL BIOL L, V1635, P104, DOI 10.1016/j.bbalip.2003.11.001; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Pan YX, 2005, J BIOL CHEM, V280, P34609, DOI 10.1074/jbc.M507802200; Park YJ, 2002, MOL CELL ENDOCRINOL, V194, P77, DOI 10.1016/S0303-7207(02)00185-5; Patrone G, 2000, BIOTECHNIQUES, V29, P1012, DOI 10.2144/00295st02; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; Raineri I, 2004, NUCLEIC ACIDS RES, V32, P1279, DOI 10.1093/nar/gkh282; Shih SC, 1999, J BIOL CHEM, V274, P15407, DOI 10.1074/jbc.274.22.15407; Sobue S, 2006, LEUKEMIA, V20, P2042, DOI 10.1038/sj.leu.2404386; Sobue S, 2005, J NEUROCHEM, V95, P940, DOI 10.1111/j.1471-4159.2005.03399.x; STOECKLE MY, 1989, MOL CELL BIOL, V9, P4738, DOI 10.1128/MCB.9.11.4738; Stofega MR, 1997, CELL GROWTH DIFFER, V8, P113; Taha TA, 2006, J BIOCHEM MOL BIOL, V39, P113; Tezuka KI, 1996, J BIOL CHEM, V271, P22713, DOI 10.1074/jbc.271.37.22713; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Vlasova IA, 2005, GENOMICS, V86, P159, DOI 10.1016/j.ygeno.2005.04.013; Wilson GM, 2003, J BIOL CHEM, V278, P33029, DOI 10.1074/jbc.M305772200; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; Xia P, 2000, CURR BIOL, V10, P1527, DOI 10.1016/S0960-9822(00)00834-4; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622	51	26	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2008	27	46					6023	6033		10.1038/onc.2008.198	http://dx.doi.org/10.1038/onc.2008.198			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	358BO	18574469				2022-12-17	WOS:000259891600005
J	Hasselblatt, P; Gresh, L; Kudo, H; Guinea-Viniegra, J; Wagner, EF				Hasselblatt, P.; Gresh, L.; Kudo, H.; Guinea-Viniegra, J.; Wagner, E. F.			The role of the transcription factor AP-1 in colitis-associated and beta-catenin-dependent intestinal tumorigenesis in mice	ONCOGENE			English	Article						colitis-associated cancer; c-Jun; c-Fos; APC; azoxymethane; colorectal carcinoma	DEXTRAN SODIUM-SULFATE; C-JUN; CYCLIN D1; COLON CARCINOGENESIS; COLORECTAL-CANCER; MOUSE INTESTINE; APC LOSS; EXPRESSION; GENE; PROLIFERATION	Chronic inflammation is an important cancer risk factor but the molecular pathways linking inflammation and cancer are incompletely understood. The transcription factor c-Jun/AP-1 (activator protein 1) is involved in inflammatory responses and tumorigenesis and has been proposed as an essential mediator of oncogenic beta-catenin signaling in the intestine. Here, we examined the functions of c-Jun in two distinct mouse models of conditional and intestine-specific activation of beta-catenin. c-Jun is strongly expressed in the small intestine of mutant mice. However, beta-catenin-dependent cell proliferation is surprisingly not affected in mice lacking c-jun in intestinal epithelium, suggesting that c-Jun is not an essential immediate target of beta-catenin signaling in the small intestine. To examine the functions of Jun and Fos proteins during inflammation and cancer in the colon, colitis-associated tumors were induced chemically in the respective knockout mice. Tumors were characterized by activated beta-catenin and strongly expressed c-Jun and JunB. However, tumorigenesis was not affected by inactivation of c-Jun in either intestinal epithelium or myeloid cells. Moreover, tumorigenesis was not altered in mice lacking junB, junD, c-fos, fra-1 or fra-2, suggesting that inhibition of c-Jun or other single AP-1 proteins is not a determining factor in colitis-associated cancer in mice.	[Hasselblatt, P.; Gresh, L.; Kudo, H.; Guinea-Viniegra, J.; Wagner, E. F.] Res Inst Mol Pathol, A-1030 Vienna, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Wagner, EF (corresponding author), Spanish Natl Canc Ctr CNIO, Canc Cell Biol Program, Melchor Fernandez Almagro 3, E-28029 Madrid, Spain.	ewagner@cnio.es	Hasselblatt, Peter/AAF-3681-2021	Gresh, Lionel/0000-0002-2333-1748; Wagner, Erwin F/0000-0001-7872-0196; Kudo, Hiromi/0000-0003-4313-7165	Austrian Industrial Research Promotion Fund; WWTF; German Research Foundation; EMBO; Boehringer Ingelheim	Austrian Industrial Research Promotion Fund; WWTF; German Research Foundation(German Research Foundation (DFG)); EMBO(European Molecular Biology Organization (EMBO)); Boehringer Ingelheim(Boehringer Ingelheim)	We are very grateful to Drs L Bakiri, A Behrens, R Eferl and O Sansom for critical reading of the manuscript and helpful discussions, Drs S Robine, C Hartmann, M Taketo and O Sansom for providing mutant mice and V Komnenovic and M Grivej for technical assistance with immunohistochemistry. The IMP is funded by Boehringer Ingelheim and this work was also supported by the Austrian Industrial Research Promotion Fund and by a WWTF grant from the city of Vienna. PH and LG were funded by postdoctoral fellowships of the German Research Foundation and EMBO, respectively.	Andreu P, 2005, DEVELOPMENT, V132, P1443, DOI 10.1242/dev.01700; Bantel H, 2002, FASEB J, V16, P1832, DOI 10.1096/fj.02-0223fje; Becker C, 2004, IMMUNITY, V21, P491, DOI 10.1016/j.immuni.2004.07.020; Behrens A, 2002, EMBO J, V21, P1782, DOI 10.1093/emboj/21.7.1782; Clarke AR, 2006, ONCOGENE, V25, P7512, DOI 10.1038/sj.onc.1210065; Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Eferl R, 2004, EMBO J, V23, P2789, DOI 10.1038/sj.emboj.7600282; Eferl R, 2007, GENESIS, V45, P447, DOI 10.1002/dvg.20311; El Marjou F, 2004, GENESIS, V39, P186, DOI 10.1002/gene.20042; Fleischmann A, 2003, J NEUROSCI, V23, P9116; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Hasselblatt P, 2007, P NATL ACAD SCI USA, V104, P17105, DOI 10.1073/pnas.0706272104; Hulit J, 2004, MOL CELL BIOL, V24, P7598, DOI 10.1128/MCB.24.17.7598-7611.2004; Janne PA, 2000, NEW ENGL J MED, V342, P1960, DOI 10.1056/NEJM200006293422606; Kenner L, 2004, J CELL BIOL, V164, P613, DOI 10.1083/jcb.200308155; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Meixner A, 2004, EMBO J, V23, P1325, DOI 10.1038/sj.emboj.7600133; Nateri AS, 2005, NATURE, V437, P281, DOI 10.1038/nature03914; Radtke F, 2005, SCIENCE, V307, P1904, DOI 10.1126/science.1104815; Sabapathy K, 2001, J EXP MED, V193, P317, DOI 10.1084/jem.193.3.317; Sansom OJ, 2005, J BIOL CHEM, V280, P28463, DOI 10.1074/jbc.M500191200; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Sansom OJ, 2007, NATURE, V446, P676, DOI 10.1038/nature05674; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Suzuki R, 2004, CANCER SCI, V95, P721, DOI 10.1111/j.1349-7006.2004.tb03252.x; Takahashi M, 2004, CANCER SCI, V95, P475, DOI 10.1111/j.1349-7006.2004.tb03235.x; Taketo MM, 2006, ONCOGENE, V25, P7522, DOI 10.1038/sj.onc.1210058; Tanaka T, 2003, CANCER SCI, V94, P965, DOI 10.1111/j.1349-7006.2003.tb01386.x; Thepot D, 2000, DEVELOPMENT, V127, P143; Tong C, 2007, AM J PATHOL, V171, P297, DOI 10.2353/ajpath.2007.061036; Wagner EF, 2005, IMMUNOL REV, V208, P126, DOI 10.1111/j.0105-2896.2005.00332.x; Wang HL, 2000, CARCINOGENESIS, V21, P1313, DOI 10.1093/carcin/21.7.1313; Wang HLL, 2002, INT J CANCER, V101, P301, DOI 10.1002/ijc.10630	38	26	27	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2008	27	47					6102	6109		10.1038/onc.2008.211	http://dx.doi.org/10.1038/onc.2008.211			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	360UJ	18679426				2022-12-17	WOS:000260083100003
J	Gentile, A; D'Alessandro, L; Lazzari, L; Martinoglio, B; Bertotti, A; Mira, A; Lanzetti, L; Comoglio, PM; Medico, E				Gentile, A.; D'Alessandro, L.; Lazzari, L.; Martinoglio, B.; Bertotti, A.; Mira, A.; Lanzetti, L.; Comoglio, P. M.; Medico, E.			Met-driven invasive growth involves transcriptional regulation of Arhgap12	ONCOGENE			English	Article						HGF; Rac1; scatter; GTPase activating protein; Rho family; gene trapping	GTPASE-ACTIVATING PROTEINS; CELL-CELL ADHESION; HEPATOCYTE GROWTH; SCATTER-FACTOR; TYROSINE KINASE; RHO GTPASES; PHOSPHATIDYLINOSITOL 3-KINASE; EPITHELIAL-CELLS; FACTOR-RECEPTOR; IN-VITRO	Invasive growth is a complex biological program triggered by hepatocyte growth factor (HGF) through its tyrosine kinase receptor encoded by the Met proto-oncogene. The program involves-besides proliferation-cell dissociation, motility and invasiveness, controlled by intracellular signals impinging on PI3K and on the small G-proteins of the Rac/Rho family. The mechanism(s) unbalancing Rac/Rho activation are still not completely clarified. Here, we describe a functional link between HGF and Arhgap12, a gene encoding a previously uncharacterized protein of the RhoGAP family. We identified Arhgap12 as a transcriptional target of HGF, through a novel gene trapping strategy. We found that Arhgap12 mRNA and protein are robustly suppressed by HGF treatment, but not by serum. Arhgap12 displayed GTPase activating protein (GAP) activity towards Rac1 and, upon overexpression, impaired cell scattering, invasion and adhesion to fibronectin in response to HGF. Consistently, Arhgap12 silencing by RNA interference selectively increased the scatter and adhesion responses. These data show that HGF-driven invasive growth involves transcriptional regulation of a Rac1-specific GAP.	[Gentile, A.; D'Alessandro, L.; Lazzari, L.; Martinoglio, B.; Mira, A.; Medico, E.] Univ Turin, Sch Med, Lab Funct Genom, Oncogenom Ctr,Inst Canc Res & Treatment, I-10060 Turin, Italy; [Bertotti, A.; Comoglio, P. M.] Univ Turin, Sch Med, Div Mol Oncol, Inst Canc Res & Treatment, I-10060 Turin, Italy; [Lanzetti, L.] Univ Turin, Sch Med, Div Mol Angiogenesis, Inst Canc Res & Treatment, I-10060 Turin, Italy	University of Turin; University of Turin; University of Turin	Medico, E (corresponding author), Univ Turin, Sch Med, Lab Funct Genom, Oncogenom Ctr,Inst Canc Res & Treatment, Str Prov 142 Km 3,95, I-10060 Turin, Italy.	enzo.medico@ircc.it	Medico, Enzo/AAC-3185-2021; gentile, alessandra/L-4299-2013; Lazzari, Luca/AAH-6475-2020	Medico, Enzo/0000-0002-3917-2438; gentile, alessandra/0000-0002-3367-8833; MARTINOGLIO, BARBARA/0000-0002-2342-2500; Lazzari, Luca/0000-0001-6841-4240; Mira, Alessia/0000-0002-8456-8159; Comoglio, Paolo/0000-0002-7056-5328; Bertotti, Andrea/0000-0001-8196-7608; LANZETTI, Letizia/0000-0001-7541-5524	AIRC; EC; FIRB; MIUR; Ricerca Finalizzata; Regione Piemonte and San Paolo to EM and PMC	AIRC(Fondazione AIRC per la ricerca sul cancro); EC(European CommissionEuropean Commission Joint Research Centre); FIRB(Ministry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB)); MIUR(Ministry of Education, Universities and Research (MIUR)); Ricerca Finalizzata(Ministry of Health, ItalyMinistry of Health Italy - Ricerca Finalizzata (MOH-RF)); Regione Piemonte and San Paolo to EM and PMC	We thank Antonella Cignetto and Michela Bruno for secretarial assistance; Daniela Cantarella, Raffaella Albano, Laura Palmas and Solange Tienga for technical assistance and Giorgio Scita, Livio Trusolino and Lucia Biondi for helpful discussion and feedback. A particular thank to Luigi Naldini and Michele De Palma for early feedback on the design of viral traps. AG and AB are recipients of a fellowship from FIRC. This work was supported by grants from AIRC, EC (TRANSFOG EC Integrated project contract no. 503438), FIRB, MIUR, Ricerca Finalizzata, Regione Piemonte and San Paolo to EM and PMC.	Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bertotti A, 2003, TRENDS BIOCHEM SCI, V28, P527, DOI 10.1016/j.tibs.2003.09.001; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Bosse T, 2007, MOL CELL BIOL, V27, P6615, DOI 10.1128/MCB.00367-07; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; CICCHETTI P, 1995, EMBO J, V14, P3127, DOI 10.1002/j.1460-2075.1995.tb07315.x; Comoglio PM, 2002, J CLIN INVEST, V109, P857, DOI 10.1172/JCI200215392; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Finkielstein CV, 2006, J BIOL CHEM, V281, P27317, DOI 10.1074/jbc.M605560200; Follenzi A, 2000, NAT GENET, V25, P217, DOI 10.1038/76095; Furge KA, 2000, ONCOGENE, V19, P5582, DOI 10.1038/sj.onc.1203859; Furukawa Y, 2001, BIOCHEM BIOPH RES CO, V284, P643, DOI 10.1006/bbrc.2001.5022; Grisendi S, 2001, J BIOL CHEM, V276, P46632, DOI 10.1074/jbc.M104323200; Gual P, 2000, ONCOGENE, V19, P1509, DOI 10.1038/sj.onc.1203514; Guo FK, 2006, J BIOL CHEM, V281, P18652, DOI 10.1074/jbc.M603508200; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Itoh RE, 2002, MOL CELL BIOL, V22, P6582, DOI 10.1128/MCB.22.18.6582-6591.2002; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kurokawa K, 2004, MOL BIOL CELL, V15, P1003, DOI 10.1091/mbc.E03-08-0609; Ma PC, 2003, CANCER METAST REV, V22, P309, DOI 10.1023/A:1023768811842; Matsuda M, 2008, EXP CELL RES, V314, P939, DOI 10.1016/j.yexcr.2007.11.009; Medico E, 2001, CANCER RES, V61, P5861; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; Moon SY, 2003, TRENDS CELL BIOL, V13, P13, DOI 10.1016/S0962-8924(02)00004-1; NALDINI L, 1995, J BIOL CHEM, V270, P603, DOI 10.1074/jbc.270.2.603; Pankov R, 2005, J CELL BIOL, V170, P793, DOI 10.1083/jcb.200503152; PARKER PJ, 1995, CURR BIOL, V5, P577, DOI 10.1016/S0960-9822(95)00113-8; Peck J, 2002, FEBS LETT, V528, P27, DOI 10.1016/S0014-5793(02)03331-8; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; ROSEN EM, 1990, J CELL SCI, V96, P639; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Seoh ML, 2003, FEBS LETT, V539, P131, DOI 10.1016/S0014-5793(03)00213-8; Takenawa T, 2001, J CELL SCI, V114, P1801; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; Wheeler AP, 2006, J CELL SCI, V119, P2749, DOI 10.1242/jcs.03024; Zandy NL, 2007, P NATL ACAD SCI USA, V104, P17686, DOI 10.1073/pnas.0703077104; Zeng QH, 2002, J BIOL CHEM, V277, P25203, DOI 10.1074/jbc.M201598200; Zhang Z, 2002, INT J BIOCHEM CELL B, V34, P325, DOI 10.1016/S1357-2725(01)00134-0	49	26	26	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 18	2008	27	42					5590	5598		10.1038/onc.2008.173	http://dx.doi.org/10.1038/onc.2008.173			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349KX	18504429	Green Submitted			2022-12-17	WOS:000259280800005
J	Navab, R; Pedraza, C; Fallavollita, L; Wang, N; Chevet, E; Auguste, P; Jenna, S; You, Z; Bikfalvi, A; Hu, J; O'Connor, R; Erickson, A; Mort, JS; Brodt, P				Navab, R.; Pedraza, C.; Fallavollita, L.; Wang, N.; Chevet, E.; Auguste, P.; Jenna, S.; You, Z.; Bikfalvi, A.; Hu, J.; O'Connor, R.; Erickson, A.; Mort, J. S.; Brodt, P.			Loss of responsiveness to IGF-I in cells with reduced cathepsin L expression levels	ONCOGENE			English	Article						IGF; cathepsin L; apoptosis; invasion; metastasis	GROWTH-FACTOR RECEPTOR; CYSTEINE PROTEINASE; ENDOSOMAL PROTEOLYSIS; MELANOMA-CELLS; PROCATHEPSIN-L; ANTISENSE RNA; INSULIN; CANCER; CARCINOMA; METASTASIS	The lysosomal cysteine proteinase cathepsin L is involved in proteolytic processing of internalized proteins. In transformed cells, where it is frequently overexpressed, its intracellular localization and functions can be altered. Previously, we reported that treatment of highly metastatic, murine carcinoma H-59 cells with small molecule cysteine proteinase inhibitors altered the responsiveness of the type I insulin-like growth factor (IGF-I) receptor and consequently reduced cell invasion and metastasis. To assess more specifically the role of cathepsin L in IGF-I-induced signaling and tumorigenicity, we generated H-59 subclones with reduced cathepsin L expression levels. These clonal lines showed an altered responsiveness to IGF-I in vitro, as evidenced by (i) loss of IGF-I-induced receptor phosphorylation and Shc recruitment, (ii) reduced IGF-I (but not IGF-II)-induced cellular proliferation and migration, (iii) decreased anchorage-independent growth and (iv) reduced plasma membrane levels of IGF-IR. These changes resulted in increased apoptosis in vivo and an impaired ability of the cells to form liver metastases. The results demonstrate that cathepsin L expression levels regulate cell responsiveness to IGF-I and thereby identify a novel function for cathepsin L in the control of the tumorigenic/metastatic phenotype.	[Navab, R.; Pedraza, C.; Fallavollita, L.; Wang, N.; Chevet, E.; You, Z.; Mort, J. S.; Brodt, P.] McGill Univ, Dept Surg, Montreal, PQ H3A IA1, Canada; [Chevet, E.; Brodt, P.] McGill Univ, Dept Med, Montreal, PQ H3A IA1, Canada; [Chevet, E.; Auguste, P.; Jenna, S.; Brodt, P.] McGill Univ, Royal Victoria Hosp, Ctr Hlth, Organelle Signaling Lab, Montreal, PQ H3A IA1, Canada; [Chevet, E.; Auguste, P.] Univ Bordeaux 2, INSERM, Team Avenir, U889, F-33076 Bordeaux, France; [Bikfalvi, A.] Univ Bordeaux 1, INSERM, E0113, Bordeaux, France; [Auguste, P.] Univ Bordeaux 1, INSERM, U889, Bordeaux, France; [Hu, J.] Univ Toronto, Hosp Sick Children, Toronto, ON M5G 1X8, Canada; [O'Connor, R.] Univ Coll Cork, Dept Biochem, Cork, Ireland; [Erickson, A.] Univ N Carolina Chapel Hill, Dept Biochem & Biophys, N Carolina, NC USA; [Mort, J. S.] McGill Univ, Shriners Hosp, Montreal, PQ, Canada	McGill University; McGill University; McGill University; Royal Victoria Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University College Cork; University of North Carolina; University of North Carolina Chapel Hill; McGill University	Brodt, P (corresponding author), McGill Univ, Royal Victoria Hosp, Ctr Hlth, Organelle Signaling Lab, Room H6-25,687 Pine Ave W, Montreal, PQ H3A IA1, Canada.	pnina.brodt@muhc.mcgill.ca	chevet, eric/E-4992-2016; O'Connor, Rosemary/B-7902-2014; Navab, Roya/AGD-7380-2022	chevet, eric/0000-0001-5855-4522; O'Connor, Rosemary/0000-0002-0687-3422; Auguste, Patrick/0000-0003-1485-0295; Hu, Jim/0000-0001-9134-7103	Canadian Institute for Health Research [MT-10505]; National Cancer Institute of Canada; National Science Foundation [MCB-96141139]	Canadian Institute for Health Research(Canadian Institutes of Health Research (CIHR)); National Cancer Institute of Canada(Canadian Cancer Society (CCS)); National Science Foundation(National Science Foundation (NSF))	This work was supported initially by Grant MT-10505 from the Canadian Institute for Health Research and subsequently by a Terry Fox Frontiers Initiative Grant from the National Cancer Institute of Canada (to PB) and by Grant MCB-96141139 from the National Science Foundation (to AE). We thank Dr Edmund Ziomek (Biotechnology Research Institute, Montreal, QC, Canada) for gifts of CathC and CathS cDNA, and Drs Amir Samani and Donglei Zhang (formerly of the Division of Surgical Research, McGill University) for their help with the study.	Ahn K, 2002, TRAFFIC, V3, P147, DOI 10.1034/j.1600-0854.2002.030207.x; Authier F, 2005, FEBS LETT, V579, P4309, DOI 10.1016/j.febslet.2005.06.066; Authier F, 2002, J BIOL CHEM, V277, P9437, DOI 10.1074/jbc.M110188200; Authier F, 1999, J BIOL CHEM, V274, P33723, DOI 10.1074/jbc.274.47.33723; Baserga R, 2003, INT J CANCER, V107, P873, DOI 10.1002/ijc.11487; Benavides F, 2002, AM J PATHOL, V161, P693, DOI 10.1016/S0002-9440(10)64225-3; Boike G, 1992, Melanoma Res, V1, P333, DOI 10.1097/00008390-199201000-00004; BRODT P, 1992, BIOCHIM BIOPHYS ACTA, V1139, P77, DOI 10.1016/0925-4439(92)90085-2; BRODT P, 1986, CANCER RES, V46, P2442; Brodt P, 2001, J BIOL CHEM, V276, P33608, DOI 10.1074/jbc.M102754200; Buckley DA, 2002, J CLIN PATHOL-MOL PA, V55, P46, DOI 10.1136/mp.55.1.46; CHAMBERS AF, 1992, MOL CARCINOGEN, V5, P238, DOI 10.1002/mc.2940050311; Chow JC, 1998, J BIOL CHEM, V273, P4672, DOI 10.1074/jbc.273.8.4672; Clague MJ, 2001, J CELL SCI, V114, P3075; Collette J, 2004, INT REV CYTOL, V241, P1, DOI 10.1016/S0074-7696(04)41001-8; Denley A, 2003, HORM METAB RES, V35, P778; Desbuquois B, 2003, ENDOCRINOLOGY, V144, P5308, DOI 10.1210/en.2002-0154; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; Gocheva V, 2006, GENE DEV, V20, P543, DOI 10.1101/gad.1407406; Gocheva V, 2007, CELL CYCLE, V6, P60, DOI 10.4161/cc.6.1.3669; Gordon PV, 2005, AM J PHYSIOL-GASTR L, V289, pG79, DOI 10.1152/ajpgi.00384.2004; Goulet B, 2007, MOL CANCER RES, V5, P899, DOI 10.1158/1541-7786.MCR-07-0160; Guan J, 1996, ENDOCRINOLOGY, V137, P893, DOI 10.1210/en.137.3.893; Ishidoh K, 2002, BIOL CHEM, V383, P1827, DOI 10.1515/BC.2002.206; Ishidoh K, 1998, BIOL CHEM, V379, P131; Iwata Y, 1997, ARTHRITIS RHEUM, V40, P499, DOI 10.1002/art.1780400316; Kirschke H, 2000, EUR J CANCER, V36, P787, DOI 10.1016/S0959-8049(00)00014-9; Krueger S, 2001, CANCER GENE THER, V8, P522, DOI 10.1038/sj.cgt.7700341; Levicar N, 2003, CANCER GENE THER, V10, P141, DOI 10.1038/sj.cgt.7700546; Lin FT, 1998, J BIOL CHEM, V273, P31640, DOI 10.1074/jbc.273.48.31640; Long L, 1998, CANCER RES, V58, P3243; LONG L, 1995, CANCER RES, V55, P1006; Meyer GE, 2001, ONCOGENE, V20, P7542, DOI 10.1038/sj.onc.1204927; Mohamed MM, 2006, NAT REV CANCER, V6, P764, DOI 10.1038/nrc1949; Nam T, 2002, ENDOCRINOLOGY, V143, P30, DOI 10.1210/en.143.1.30; Nam TJ, 2000, ENDOCRINOLOGY, V141, P1100, DOI 10.1210/en.141.3.1100; Navab R, 2001, J BIOL CHEM, V276, P13644, DOI 10.1074/jbc.M100019200; Navab R, 1997, CLIN EXP METASTAS, V15, P121, DOI 10.1023/A:1018496625936; Nguyen DT, 2004, MOL BIOL CELL, V15, P4248, DOI 10.1091/mbc.E03-11-0851; NIP J, 1995, J CLIN INVEST, V95, P2096, DOI 10.1172/JCI117897; Nomura T, 2005, J MED INVESTIG, V52, P1, DOI 10.2152/jmi.52.1; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PORTNOY DA, 1986, J BIOL CHEM, V261, P4697; Reinheckel T, 2005, J CELL SCI, V118, P3387, DOI 10.1242/jcs.02469; Reinheckel T, 2001, BIOL CHEM, V382, P735, DOI 10.1515/BC.2001.089; Rousselet N, 2004, CANCER RES, V64, P146, DOI 10.1158/0008-5472.CAN-03-1717; ROWAN AD, 1992, BIOL CHEM H-S, V373, P427, DOI 10.1515/bchm3.1992.373.2.427; Samani A A, 2001, Surg Oncol Clin N Am, V10, P289; Samani AA, 2004, CANCER RES, V64, P3380, DOI 10.1158/0008-5472.CAN-03-3780; SAMANI AA, 2001, SURG ONCOL CLIN N AM, V10, pR8; Samani AA, 2007, ENDOCR REV, V28, P20, DOI 10.1210/er.2006-0001; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Turk B, 2000, BBA-PROTEIN STRUCT M, V1477, P98, DOI 10.1016/S0167-4838(99)00263-0; Wang N, 2006, CANCER RES, V66, P3062, DOI 10.1158/0008-5472.CAN-05-2638; WEXLER H, 1966, JNCI-J NATL CANCER I, V36, P641, DOI 10.1093/jnci/36.4.641; [杨啊晶 YANG Ajing], 2007, [中国新药杂志, Chinese Journal New Drugs], V16, P7; Yang M, 2007, NAT CELL BIOL, V9, P970, DOI 10.1038/ncb1623; Zhang DL, 2004, J BIOL CHEM, V279, P19683, DOI 10.1074/jbc.M313145200; Zhang DL, 2003, ONCOGENE, V22, P974, DOI 10.1038/sj.onc.1206197; Zwad O, 2002, FEBS LETT, V510, P211, DOI 10.1016/S0014-5793(01)03267-7	60	26	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2008	27	37					4973	4985		10.1038/onc.2008.144	http://dx.doi.org/10.1038/onc.2008.144			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GL	18469859				2022-12-17	WOS:000258914800001
J	Bonhomme, C; Calon, A; Martin, E; Robine, S; Neuville, A; Kedinger, M; Domon-Dell, C; Duluc, I; Freund, JN				Bonhomme, C.; Calon, A.; Martin, E.; Robine, S.; Neuville, A.; Kedinger, M.; Domon-Dell, C.; Duluc, I.; Freund, J-N			Cdx1, a dispensable homeobox gene for gut development with limited effect in intestinal cancer	ONCOGENE			English	Article						Cdx; intestine; cancer; development; mouse	DOWN-REGULATION; EXPRESSION; COLON; DIFFERENTIATION	The homeobox gene Cdx1 is involved in anteroposterior patterning in embryos and its expression selectively persists in the intestinal epithelium throughout life. In human colon cancers, Cdx1 is overexpressed in few cases and lost in the majority of adenocarcinomas. We used mouse models of gain and loss-of-function to investigate the role of Cdx1 in intestinal development and cancers. Transgenic mice overexpressing Cdx1 and knockout mice exhibited a morphologically normal intestine. Cell proliferation, specification into the four differentiated lineages and migration along the crypt-villus axis were unchanged compared to wild-type mice. Changing Cdx1 caused an inverse and dose-dependent modi. cation of the expression of the paralogous gene Cdx2, indicating that Cdx1. ne-tunes Cdx2 activity. Transgenenic and knockout mice failed to spontaneously develop tumours. Over-expressing Cdx1 was without incidence on the frequency of intestinal tumours induced chemically by azoxymethane treatment or genetically in Apc(Delta 14/+) mice. However, it augmented the severity of the tumours in Apc(Delta 14/+) mice. Inversely, the loss-of-function of Cdx1 in knockout mice was without incidence on the growth of tumours induced by azoxymethane. We conclude that Cdx1 is dispensable for intestinal development and that its overexpression could increase malignancy in early stages of tumourigenesis.	[Bonhomme, C.; Calon, A.; Martin, E.; Neuville, A.; Kedinger, M.; Domon-Dell, C.; Duluc, I.; Freund, J-N] INSERM U682, F-67200 Strasbourg, Bas Rhin, France; [Bonhomme, C.; Calon, A.; Martin, E.; Neuville, A.; Kedinger, M.; Domon-Dell, C.; Duluc, I.; Freund, J-N] Univ Louis Pasteur, Fac Med, Strasbourg, France; [Robine, S.] Inst Curie, CNRS, UMR144, F-75231 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Universite Paris Cite	Freund, JN (corresponding author), INSERM U682, 3 Ave Moliere, F-67200 Strasbourg, Bas Rhin, France.	jean-noel.freund@inserm.u-strasbg.fr	Calon, Alexandre/GPK-2061-2022; DULUC, Isabelle/AAA-7062-2022; Domon-Dell, Claire/P-2368-2017; Freund, Jean-Noel/R-4383-2016; Duluc, Isabelle/O-1972-2017	DULUC, Isabelle/0000-0001-8396-6385; Freund, Jean-Noel/0000-0002-0971-3774; Duluc, Isabelle/0000-0001-8396-6385; DOMON-DELL, Claire/0000-0002-8445-9593				Aoki K, 2003, NAT GENET, V35, P323, DOI 10.1038/ng1265; Bansal D, 2006, P NATL ACAD SCI USA, V103, P16924, DOI 10.1073/pnas.0604579103; Beck F, 1999, P NATL ACAD SCI USA, V96, P7318, DOI 10.1073/pnas.96.13.7318; Bonhomme C, 2003, GUT, V52, P1465, DOI 10.1136/gut.52.10.1465; Brabletz T, 2004, CANCER RES, V64, P6973, DOI 10.1158/0008-5472.CAN-04-1132; Domon-Dell C, 2003, ONCOGENE, V22, P7913, DOI 10.1038/sj.onc.1206756; Gross I, 2008, ONCOGENE, V27, P107, DOI 10.1038/sj.onc.1210601; Haigis K, 2006, J BIOL CHEM, V281, P638, DOI 10.1074/jbc.M509053200; Jonckheere N, 2007, J BIOL CHEM, V282, P22638, DOI 10.1074/jbc.M700905200; Lorentz O, 1997, J CELL BIOL, V139, P1553, DOI 10.1083/jcb.139.6.1553; Lynch J, 2000, J BIOL CHEM, V275, P4499, DOI 10.1074/jbc.275.6.4499; Mallo GV, 1997, INT J CANCER, V74, P35, DOI 10.1002/(SICI)1097-0215(19970220)74:1<35::AID-IJC7>3.0.CO;2-1; Mutoh H, 2004, GUT, V53, P1416, DOI 10.1136/gut.2003.032482; Pilozzi E, 2004, J PATHOL, V204, P289, DOI 10.1002/path.1641; Silberg DG, 2000, GASTROENTEROLOGY, V119, P961, DOI 10.1053/gast.2000.18142; Silberg DG, 1997, GASTROENTEROLOGY, V113, P478, DOI 10.1053/gast.1997.v113.pm9247467; Soubeyran P, 1999, GASTROENTEROLOGY, V117, P1326, DOI 10.1016/S0016-5085(99)70283-0; SUBRAMANIAN V, 1995, CELL, V83, P641, DOI 10.1016/0092-8674(95)90104-3; Vider BZ, 1997, BIOCHEM BIOPH RES CO, V232, P742, DOI 10.1006/bbrc.1997.6364	19	26	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2008	27	32					4497	4502		10.1038/onc.2008.78	http://dx.doi.org/10.1038/onc.2008.78			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329PU	18372917				2022-12-17	WOS:000257881700012
J	Jeon, YJ; Kim, IK; Hong, SH; Nan, H; Kim, HJ; Lee, HJ; Masuda, ES; Meyuhas, O; Oh, BH; Jung, YK				Jeon, Y-J; Kim, I. K.; Hong, S-H; Nan, H.; Kim, H-J; Lee, H-J; Masuda, E. S.; Meyuhas, O.; Oh, B-H; Jung, Y-K			Ribosomal protein S6 is a selective mediator of TRAIL-apoptotic signaling	ONCOGENE			English	Article						TRAIL; apoptosis; ribosomal protein S6; S6 kinase 1; DR4; tumor cell	MESSENGER-RNA TRANSLATION; CELLS; PHOSPHORYLATION; RECEPTOR; FAMILY; LIGAND; IDENTIFICATION; INHIBITION; INDUCTION; PATHWAY	TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) is a potent inducer of apoptosis in tumor cells and holds a promise as a therapeutic agent against cancer. To elucidate the death signaling evoked by TRAIL, we performed a functional genetic screening and rescued TRAIL-resistant Jurkat clones harboring ribosomal protein S6 (rpS6) cDNA in anti-sense frame. Reduction of rpS6 expression in Jurkat and HeLa cells attenuated apoptosis induced by TRAIL, but not those by other cell death signals, including tumor necrosis factor-a and cycloheximide, etoposide, doxorubicin, tunicamycin and staurosporine. Death receptor (DR) 4, but not DR5, was downregulated in rpS6 knockdown cells. Conversely, the sensitivity to TRAIL was increased by the ectopic expression of wild-type rpS6 and further by phospho-defective rpS6 mutant (S6-SS235,6AA), but not by phospho-mimic rpS6 mutant (S6-SS235,6DD). Also, unphosphorylatable rpS6 knock-in mouse embryo fibro-blasts (rpS6(P-/-) MEFs) were more sensitive to TRAIL than control MEFs. In addition, SKHep-1 tumor cells, which express less phospho-rpS6 and are more sensitive to TRAIL than other tumor cells, became effectively desensitized to TRAIL after rpS6 knockdown. These results suggest that rpS6, especially in its unphosphorylated form, is a selective mediator of TRAIL-induced apoptosis.	[Jeon, Y-J; Hong, S-H; Nan, H.; Kim, H-J; Lee, H-J; Jung, Y-K] Seoul Natl Univ, Sch Biol Sci, Biomax Inst, Seoul 151742, South Korea; [Kim, I. K.] Burnham Inst Med Res, La Jolla, CA USA; [Masuda, E. S.] Rigel Pharmaceut Inc, San Francisco, CA USA; [Meyuhas, O.] Hebrew Univ Jerusalem, Sch Med, Dept Biochem, IL-91010 Jerusalem, Israel; [Oh, B-H] Pohang Univ Sci & Technol, Dept Life Sci, Kyungbuk, South Korea	Seoul National University (SNU); Sanford Burnham Prebys Medical Discovery Institute; Hebrew University of Jerusalem; Pohang University of Science & Technology (POSTECH)	Jung, YK (corresponding author), Seoul Natl Univ, Sch Biol Sci, Biomax Inst, Seoul 151742, South Korea.	ykjung@snu.ac.kr	Lee, Ho-June/D-8855-2014	Lee, Ho-June/0000-0002-7019-2533; Jeon, Young-Jun/0000-0002-5998-9605; Masuda, Esteban/0000-0002-3175-2868; Jung, Yong-Keun/0000-0002-9686-3120				Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Beuvink I, 2005, CELL, V120, P747, DOI 10.1016/j.cell.2004.12.040; Fesik SW, 2005, NAT REV CANCER, V5, P876, DOI 10.1038/nrc1736; FRANCO R, 1990, J BIOL CHEM, V265, P4321; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Inoki K, 2005, NAT GENET, V37, P19, DOI 10.1038/ng1494; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Kim IK, 2000, BIOCHEM BIOPH RES CO, V277, P311, DOI 10.1006/bbrc.2000.3673; Kim KI, 2003, BRIT J CANCER, V88, P910, DOI 10.1038/sj.bjc.6600795; KRIEG J, 1988, J BIOL CHEM, V263, P11473; Nebbioso A, 2005, NAT MED, V11, P77, DOI 10.1038/nm1161; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Panner A, 2005, MOL CELL BIOL, V25, P8809, DOI 10.1128/MCB.25.20.8809-8823.2005; Pende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; RAYMOND AD, 2005, CELL RES, V15, P430; Ren YG, 2004, MOL BIOL CELL, V15, P5064, DOI 10.1091/mbc.e04-03-0184; Ruvinsky I, 2005, GENE DEV, V19, P2199, DOI 10.1101/gad.351605; SHASHIREKHA S, 2005, MOL CELL BIOL, V25, P5404; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Stromberg T, 2004, BLOOD, V103, P3138, DOI 10.1182/blood-2003-05-1543; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141	24	26	26	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2008	27	31					4344	4352		10.1038/onc.2008.73	http://dx.doi.org/10.1038/onc.2008.73			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	326WY	18362888				2022-12-17	WOS:000257691100009
J	Qiu, W; Wu, J; Walsh, EM; Zhang, Y; Chen, CY; Fujita, J; Xiao, ZXJ				Qiu, W.; Wu, J.; Walsh, E. M.; Zhang, Y.; Chen, C-Y; Fujita, J.; Xiao, Z-X J.			Retinoblastoma protein modulates gankyrin-MDM2 in regulation of p53 stability and chemosensitivity in cancer cells	ONCOGENE			English	Article						chemotherapy; gankyrin; MDM2; p53; retinoblastoma protein	TUMOR-SUPPRESSOR; ACIDIC DOMAIN; ONCOPROTEIN MDM2; RB FUNCTION; DEGRADATION; PHOSPHORYLATION; PRB; PATHWAYS; PROMOTES; BINDING	MDM2 is a key ubiquitin E3 ligase for p53 and its activity is critically regulated by a set of modulators, including ARF, p300, YY1 and recently by gankyrin, an oncoprotein frequently overexpressed in human heptocellular carcinomas. We have previously shown that MDM2 binds to and promotes retinoblastoma protein ( Rb) degradation. Here we show that Rb inhibits MDM2 E3 ligase activity resulting in stabilization of p53. In addition, we demonstrated that Rb inhibits MDM2-mediated p53 ubiquitination in a gankyrin-dependent manner and the Rb-gankyrin interaction is critical for Rb-induced p53 stabilization. Furthermore, acute ablation of Rb facilitates gankyrin-mediated p53 destabilization, and desensitizes cancer cells for chemotherapy-induced apoptosis. These results indicate that Rb antagonizes gankyrin to inhibit MDM2-mediate p53 ubiquitination in cancer cells and suggest that the status of both p53 and Rb is important for efficacy of cancer chemotherapy.	[Qiu, W.; Wu, J.; Walsh, E. M.; Xiao, Z-X J.] Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; [Qiu, W.; Xiao, Z-X J.] Boston Univ, Sch Med, Dept Med, Grad Program Mol Med, Boston, MA 02118 USA; [Zhang, Y.] Boston Univ, Sch Med, Dept Med, Ctr Pulm, Boston, MA 02118 USA; [Chen, C-Y] Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA; [Fujita, J.] Kyoto Univ, Grad Sch Med, Dept Clin Mol Biol, Sakyo Ku, Kyoto, Japan	Boston University; Boston University; Boston University; Boston University; Kyoto University	Xiao, ZXJ (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St, Boston, MA 02118 USA.	jxiao@bu.edu			NCI NIH HHS [CA79804] Funding Source: Medline; NIGMS NIH HHS [GM70017] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079804] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070017] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Argentini M, 2001, ONCOGENE, V20, P1267, DOI 10.1038/sj.onc.1204241; Beroud C, 1998, NUCLEIC ACIDS RES, V26, P200, DOI 10.1093/nar/26.1.200; Bond GL, 2005, CURR CANCER DRUG TAR, V5, P3, DOI 10.2174/1568009053332627; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; CordonCardo C, 1997, CANCER RES, V57, P1217; Dawson S, 2006, TRENDS CELL BIOL, V16, P229, DOI 10.1016/j.tcb.2006.03.001; de Bruin A, 2003, P NATL ACAD SCI USA, V100, P6546, DOI 10.1073/pnas.1031853100; Dick FA, 2003, MOL CELL, V12, P639, DOI 10.1016/S1097-2765(03)00344-7; Gotz C, 1999, EUR J BIOCHEM, V266, P493, DOI 10.1046/j.1432-1327.1999.00882.x; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Higashitsuji H, 2005, CANCER CELL, V8, P75, DOI 10.1016/j.ccr.2005.06.006; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; Hjerrild M, 2001, BIOCHEM J, V355, P347, DOI 10.1042/0264-6021:3550347; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Kawai H, 2003, MOL CELL BIOL, V23, P4939, DOI 10.1128/MCB.23.14.4939-4947.2003; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kulikov R, 2005, MOL CELL BIOL, V25, P7170, DOI 10.1128/MCB.25.16.7170-7180.2005; Kulikov R, 2006, J BIOL CHEM, V281, P28575, DOI 10.1074/jbc.M513311200; Lipinski MM, 2001, EMBO J, V20, P3402, DOI 10.1093/emboj/20.13.3402; Ma JH, 2006, BIOCHEMISTRY-US, V45, P9238, DOI 10.1021/bi060661u; Meulmeester E, 2003, MOL CELL BIOL, V23, P4929, DOI 10.1128/MCB.23.14.4929-4938.2003; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017; Sdek P, 2004, J BIOL CHEM, V279, P53317, DOI 10.1074/jbc.M406062200; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; Sui GC, 2004, CELL, V117, P859, DOI 10.1016/j.cell.2004.06.004; Uchida CH, 2005, EMBO J, V24, P160, DOI 10.1038/sj.emboj.7600486; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wang CG, 2005, EMBO J, V24, P3279, DOI 10.1038/sj.emboj.7600791; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Wu LZ, 2003, NATURE, V421, P942, DOI 10.1038/nature01417; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Xu HJ, 1996, CLIN CANCER RES, V2, P1169; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003	40	26	29	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 3	2008	27	29					4034	4043		10.1038/onc.2008.43	http://dx.doi.org/10.1038/onc.2008.43			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321RV	18332869				2022-12-17	WOS:000257325100003
J	Bonnomet, A; Polette, M; Strumane, K; Gilles, C; Dalstein, V; Kileztky, C; Berx, G; van Roy, F; Birembaut, P; Nawrocki-Raby, B				Bonnomet, A.; Polette, M.; Strumane, K.; Gilles, C.; Dalstein, V.; Kileztky, C.; Berx, G.; van Roy, F.; Birembaut, P.; Nawrocki-Raby, B.			The E-cadherin-repressed hNanos1 gene induces tumor cell invasion by upregulating MT1-MMP expression	ONCOGENE			English	Article						hNanos1; E-cadherin; MT1-MMP; cancer; cell invasion	MEMBRANE-TYPE-1 MATRIX-METALLOPROTEINASE; GERMLINE STEM-CELLS; MESSENGER-RNA; POSTERIOR DETERMINANT; DROSOPHILA GERMLINE; NANOS; PUMILIO; COMPLEX; CANCER; ADHESION	In this study, we examined the role of the E-cadherin-repressed gene human Nanos1 (hNanos1) in tumor invasion process. First, our in vivo study revealed that hNanos1 mRNAs were overexpressed in invasive lung carcinomas. Moreover, hNanos1 was co-localized with MT1-MMP (membrane type 1-matrix metalloproteinase) in E-cadherin-negative invasive lung tumor clusters. Using an inducible Tet-on system, we showed that induction of hNanos1 expression in DLD1 cells increased their migratory and invasive abilities in a three-dimensional migration and in a modified Boyden chamber assay. Accordingly, we demonstrated that hNanos1 upregulated MT1-MMP expression at the mRNA and protein levels. Inversely, using an RNA interference strategy to inhibit hNanos1 expression in invasive Hs578T, BT549 and BZR cancer cells, we observed a downregulation of MT1-MMP mRNA and protein and concomitantly a decrease of the invasive capacities of tumor cells in a modified Boyden chamber assay. Taken together, our results demonstrate that hNanos1, by regulating MT1-MMP expression, plays an important role in the acquisition of invasive properties by epithelial tumor cells.	[Bonnomet, A.; Polette, M.; Dalstein, V.; Kileztky, C.; Birembaut, P.; Nawrocki-Raby, B.] Univ Reims, Histol Lab, CHU Maison Blanche, IFR 53,INSERM UMRS 514, F-51100 Reims, France; [Bonnomet, A.; Gilles, C.] Univ Liege, CHU Sart Tilman, Lab Dev & Tumor Biol, Liege, Belgium; [Strumane, K.; Berx, G.; van Roy, F.] Univ Ghent VIB, Dept Mol Biomed Res, B-9052 Ghent, Belgium; [Strumane, K.] Leiden Univ, Med Ctr, Dept IHB, Leiden, Netherlands	CHU de Reims; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Reims Champagne-Ardenne; University of Liege; Flanders Institute for Biotechnology (VIB); Ghent University; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Nawrocki-Raby, B (corresponding author), Univ Reims, Histol Lab, CHU Maison Blanche, IFR 53,INSERM UMRS 514, 45 Rue Cognacq Jay, F-51100 Reims, France.	beatrice.raby@univ-reims.fr	POLETTE, Myriam/P-5147-2016; van Roy, Frans M/C-6123-2009; BIREMBAUT, Philippe/P-5210-2016; DALSTEIN, Véronique/P-5250-2016; Raby, Beatrice/P-5666-2016	van Roy, Frans M/0000-0003-4358-1039; Raby, Beatrice/0000-0002-3163-8619; BONNOMET, Arnaud/0000-0002-4933-3338; Berx, Geert/0000-0001-5770-2458; POLETTE, Myriam/0000-0001-8173-3246				Ara T, 2000, CANCER LETT, V157, P115, DOI 10.1016/S0304-3835(00)00494-8; Asaoka-Taguchi M, 1999, NAT CELL BIOL, V1, P431, DOI 10.1038/15666; Bartolome RA, 2006, CANCER RES, V66, P248, DOI 10.1158/0008-5472.CAN-05-2489; Behrens J, 2005, BIOCHEM SOC T, V33, P672, DOI 10.1042/BST0330672; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Bhat KM, 1999, GENETICS, V151, P1479; Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)82222-4; Deshpande G, 1999, CELL, V99, P271, DOI 10.1016/S0092-8674(00)81658-X; Edwards TA, 2001, CELL, V105, P281, DOI 10.1016/S0092-8674(01)00318-X; Forbes A, 1998, DEVELOPMENT, V125, P679; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; GILLES C, 2004, RISE FALL EPITHELIAL, P1; Hatzfeld M, 2005, EUR J CELL BIOL, V84, P205, DOI 10.1016/j.ejcb.2004.12.016; Hazgui S, 2005, AM J PHYSIOL-CELL PH, V289, pC1547, DOI 10.1152/ajpcell.00319.2005; Hlubek F, 2004, INT J CANCER, V108, P321, DOI 10.1002/ijc.11522; Jaruzelska J, 2003, DEV GENES EVOL, V213, P120, DOI 10.1007/s00427-003-0303-2; Kitadai Y, 1996, AM J PATHOL, V149, P1541; Kobayashi S, 1996, NATURE, V380, P708, DOI 10.1038/380708a0; Luo J, 1999, CANCER RES, V59, P3552; Mareel M, 1996, J CELL BIOCHEM, V61, P524; MOSQUERA L, 1993, DEVELOPMENT, V117, P377; MURATA Y, 1995, CELL, V80, P747, DOI 10.1016/0092-8674(95)90353-4; Nawrocki-Raby B, 2003, AM J PATHOL, V163, P653, DOI 10.1016/S0002-9440(10)63692-9; Polette M, 2005, CANCER RES, V65, P7691, DOI 10.1158/0008-5472.CAN-04-4230; Polette M, 1998, CLIN EXP METASTAS, V16, P105; Polette M, 2004, CRIT REV ONCOL HEMAT, V49, P179, DOI 10.1016/j.critrevonc.2003.10.008; Reynolds AB, 2004, ONCOGENE, V23, P7947, DOI 10.1038/sj.onc.1208161; Seiki M, 2003, CANCER LETT, V194, P1, DOI 10.1016/S0304-3835(02)00699-7; Sonoda J, 2001, GENE DEV, V15, P762, DOI 10.1101/gad.870801; Strumane K, 2006, CANCER RES, V66, P10007, DOI 10.1158/0008-5472.CAN-05-3096; Takahashi M, 2002, ONCOGENE, V21, P5861, DOI 10.1038/sj.onc.1205755; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WANG C, 1994, DEV DYNAM, V199, P103, DOI 10.1002/aja.1001990204	34	26	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2008	27	26					3692	3699		10.1038/sj.onc.1211035	http://dx.doi.org/10.1038/sj.onc.1211035			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312HH	18223680				2022-12-17	WOS:000256659300006
J	Chang, CL; Hong, E; Lao-Sirieix, P; Fitzgerald, RC				Chang, C-L; Hong, E.; Lao-Sirieix, P.; Fitzgerald, R. C.			A novel role for the retinoic acid-catabolizing enzyme CYP26A1 in Barrett's associated adenocarcinoma	ONCOGENE			English	Article						vitamin A; oesophageal adenocarcinoma; proliferation; invasion; bile acids	VITAMIN-A; RECEPTOR-GAMMA; HUMAN BREAST; IN-VITRO; EXPRESSION; CANCER; METABOLISM; GROWTH; DIFFERENTIATION; INHIBITION	Vitamin A deficiency is associated with carcinogenesis, and upregulation of CYP26A1, a major retinoic acid (RA)-catabolizing enzyme, has recently been shown in cancer. We have previously demonstrated alterations of RA biosynthesis in Barrett's oesophagus, the precursor lesion to oesophageal adenocarcinoma. The aims of this study were to determine CYP26A1 expression levels and functional effects in Barrett's associated carcinogenesis. Retinoic acid response element reporter cells were used to determine RA levels in non-dysplastic and dysplastic Barrett's cell lines and endoscopic biopsies. CYP26A1 expression levels, with or without induction by RA and lithocholic acid, were determined by quantitative reverse transcriptase-PCR (RT-PCR) and immunohistochemistry. CYP26A1 promoter activity was determined by a luciferase reporter construct. CYP26A1 was stably over-expressed in GihTERT cells, which were evaluated for gene-expression changes (pathway array and quantitative RT-PCR), cellular proliferation (cytometric DNA pro. le and colorimetric assay) and invasion (in vitro matrigel assay) with or without the CYP inhibitor ketaconazole. RA levels decreased progressively with the degree of dysplasia (P < 0.05) and were inversely correlated with CYP26A1 gene levels and activity (P < 0.01). CYP26A1 expression was increased synergistically by RA and lithocholic acid (P < 0.05). Overexpression of CYP26A1 led to induction of c-Myc, epidermal growth factor receptor and matrix metalloproteinase 3 as well as downregulation of tissue inhibitor metalloproteinase 1 and 3. Functional effects of CYP26A1 overexpression were increased proliferation (P < 0.01) and invasion in vitro (P < 0.01), which were inhibited by ketaconazole. Overexpression of CYP26A1 causes intracellular RA depletion and drives the cell into a highly proliferative and invasive state with induction of other known oncogenes.	[Chang, C-L; Hong, E.; Lao-Sirieix, P.; Fitzgerald, R. C.] MRC, Hutchison Res Ctr, Canc Cell Unit, Cambridge CB2 2XZ, England; [Chang, C-L] Mackay Mem Hosp, Dept Obstet & Gynecol, Taipei, Taiwan	Mackay Memorial Hospital	Fitzgerald, RC (corresponding author), MRC, Hutchison Res Ctr, Canc Cell Unit, Cambridge CB2 2XZ, England.	rcf@hutchison-mrc.cam.ac.uk	Chang, Chih-Long/AAJ-8784-2020	Chang, Chih-Long/0000-0003-3981-9366; Fitzgerald, Rebecca/0000-0002-3434-3568	Medical Research Council [MC_U105365007] Funding Source: Medline; MRC [MC_U105365007] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abu-Abed SS, 1998, J BIOL CHEM, V273, P2409, DOI 10.1074/jbc.273.4.2409; Avidan B, 2002, AM J GASTROENTEROL, V97, P1930, DOI 10.1111/j.1572-0241.2002.05902.x; Bancewicz J, 2002, LANCET, V359, P1727; Bax DA, 2005, J SURG ONCOL, V92, P89, DOI 10.1002/jso.20353; BERTRAM JS, 1993, ANN NY ACAD SCI, V686, P161, DOI 10.1111/j.1749-6632.1993.tb39170.x; Bigg HF, 2000, EUR J BIOCHEM, V267, P4150, DOI 10.1046/j.1432-1327.2000.01459.x; Brabender J, 2004, ONCOGENE, V23, P4780, DOI 10.1038/sj.onc.1207663; Chang CL, 2007, GUT, V56, P906, DOI 10.1136/gut.2006.097915; Downie D, 2005, CLIN CANCER RES, V11, P7369, DOI 10.1158/1078-0432.CCR-05-0466; Freemantle SJ, 2003, ONCOGENE, V22, P7305, DOI 10.1038/sj.onc.1206936; Hormi-Carver K, 2007, AM J PHYSIOL-GASTR L, V292, pG18, DOI 10.1152/ajpgi.00237.2006; Klamt F, 2003, MUTAT RES-GEN TOX EN, V539, P117, DOI 10.1016/S1383-5718(03)00155-4; Liu T, 2005, BRIT J CANCER, V93, P310, DOI 10.1038/sj.bjc.6602700; Lord RVN, 2001, SURGERY, V129, P267, DOI 10.1067/msy.2001.110856; Loudig O, 2005, BIOCHEM J, V392, P241, DOI 10.1042/BJ20050874; Niederreither K, 2002, NAT GENET, V31, P84, DOI 10.1038/ng876; Osanai M, 2005, MOL PHARMACOL, V67, P1808, DOI 10.1124/mol.104.005769; Palanca-Wessels MCA, 2003, CARCINOGENESIS, V24, P1183, DOI 10.1093/carcin/bgg076; Patel JB, 2004, J MED CHEM, V47, P6716, DOI 10.1021/jm0401457; Pohl H, 2005, J NATL CANCER I, V97, P142, DOI 10.1093/jnci/dji024; Radominska-Pandya A, 2002, BIOCHEMISTRY-US, V41, P4883, DOI 10.1021/bi0121151; Reifen R, 1998, INT J MOL MED, V1, P579; SAFFIOTTI U, 1967, CANCER-AM CANCER SOC, V20, P857, DOI 10.1002/1097-0142(1967)20:5&lt;857::AID-CNCR2820200545&gt;3.0.CO;2-3; Sah JF, 2002, J BIOL CHEM, V277, P9728, DOI 10.1074/jbc.M110897200; Schoenermark MP, 1999, ANN NY ACAD SCI, V878, P466, DOI 10.1111/j.1749-6632.1999.tb07703.x; Shelton DN, 2006, CANCER RES, V66, P7571, DOI 10.1158/0008-5472.CAN-06-1067; SMITH AH, 1991, AM J EPIDEMIOL, V133, P661, DOI 10.1093/oxfordjournals.aje.a115941; Van Heusden J, 2002, BRIT J CANCER, V86, P605, DOI 10.1038/sj.bjc.6600056; WALD N, 1980, LANCET, V2, P813; Webster RP, 1996, IN VIVO, V10, P113; Winters C, 1987, GASTROENTEROLOGY, V92, P118, DOI 10.1016/0016-5085(87)90847-X; Wolbach SB, 1925, J EXP MED, V42, P753, DOI 10.1084/jem.42.6.753; WOUTERS W, 1992, CANCER RES, V52, P2841; Yung BYM, 2004, FEBS LETT, V578, P211, DOI 10.1016/j.febslet.2004.08.089	34	26	27	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2008	27	21					2951	2960		10.1038/sj.onc.1210969	http://dx.doi.org/10.1038/sj.onc.1210969			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	298IP	18059332				2022-12-17	WOS:000255681700002
J	Gross, C; Dubois-Pot, H; Wasylyk, B				Gross, C.; Dubois-Pot, H.; Wasylyk, B.			The ternary complex factor Net/Elk-3 participates in the transcriptional response to hypoxia and regulates HIF-1 alpha	ONCOGENE			English	Article						siah-2; PHDs; egr-1; c-fos; VEGF	FACTOR NET; HIF-1; DOMAIN; RAS; INHIBITION; EXPRESSION; SYSTEM; CELLS; O-2	The ternary complex factor Net/Elk3 is downregulated in hypoxia and participates in the induction by hypoxia of several genes, including c-fos, vascular endothelial growth factor and egr-1. However, the global role of Net in hypoxia remains to be elucidated. We have identified, in a large-scale analysis of RNA expression using microarrays, more than 370 genes that are regulated by Net in hypoxia. In order to gain insights into the role of Net in hypoxia, we have analysed in parallel the genes regulated by HIF-1 alpha, the classical factor involved in the response to hypoxia. We identified about 190 genes that are regulated by HIF-1 alpha in hypoxia. Surprisingly, when we compare the genes induced by hypoxia that require either Net or HIF-1 alpha, the majority are the same (75%), suggesting that the functions of both factors are closely linked. Interestingly, in hypoxia, Net regulates the expression of several genes known to control HIF-1 alpha stability, including PHD2, PHD3 and Siah2, suggesting that Net regulates the stability of HIF-1 alpha. We found that inhibition of Net by RNAi leads to decreased HIF-1 alpha expression at the protein level in hypoxia. These results indicate that Net participates in the transcriptional response to hypoxia by regulation of HIF-1 alpha protein stability.	[Gross, C.; Dubois-Pot, H.; Wasylyk, B.] ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Wasylyk, B (corresponding author), ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries,BP 10142, F-67404 Illkirch Graffenstaden, France.	boh@igbmc.u-strasbg.fr	Wasylyk, Bohdan/ABG-6778-2020	Wasylyk, Bohdan/0000-0002-1718-1237				Aprelikova O, 2006, CANCER RES, V66, P5641, DOI 10.1158/0008-5472.CAN-05-3345; Ayadi A, 2001, EMBO J, V20, P5139, DOI 10.1093/emboj/20.18.5139; Brahimi-Horn C, 2001, TRENDS CELL BIOL, V11, pS32, DOI 10.1016/S0962-8924(01)02126-2; Buchwalter G, 2005, MOL CELL BIOL, V25, P10853, DOI 10.1128/MCB.25.24.10853-10862.2005; Buchwalter G, 2004, GENE, V324, P1, DOI 10.1016/j.gene.2003.09.028; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; Greijer AE, 2005, J PATHOL, V206, P291, DOI 10.1002/path.1778; Gross C, 2007, MOL CELL BIOL, V27, P4133, DOI 10.1128/MCB.01867-06; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Le Brigand K, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl485; Maira SM, 1996, EMBO J, V15, P5849, DOI 10.1002/j.1460-2075.1996.tb00972.x; Manalo DJ, 2005, BLOOD, V105, P659, DOI 10.1182/blood-2004-07-2958; Nakamura N, 2004, J PHYS CONF SER, V2, P1, DOI 10.1088/1742-6596/2/1/001; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Stiehl DP, 2006, J BIOL CHEM, V281, P23482, DOI 10.1074/jbc.M601719200; van Riggelen J, 2005, J BIOL CHEM, V280, P3286, DOI 10.1074/jbc.M409915200; Zheng H, 2003, GENE DEV, V17, P2283, DOI 10.1101/gad.272503	22	26	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2008	27	9					1333	1341		10.1038/sj.onc.1210736	http://dx.doi.org/10.1038/sj.onc.1210736			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	266BT	17704799				2022-12-17	WOS:000253407000018
J	Kieffer, I; Lorenzo, C; Dozier, C; Schmitt, E; Ducommun, B				Kieffer, I.; Lorenzo, C.; Dozier, C.; Schmitt, E.; Ducommun, B.			Differential mitotic degradation of the CDC25B phosphatase variants	ONCOGENE			English	Article						CDC25B phosphatase; degradation; mitosis; biosensors; FRET	CELL-CYCLE; BETA-TRCP; G(2)/M TRANSITION; AURORA-A; KEN-BOX; S-PHASE; PHOSPHORYLATION; PROTEIN; TRIGGERS; MITOSIS	CDC25 phosphatases control cell-cycle progression by dephosphorylating and activating cyclin-dependent kinases. CDC25B, one of the three members of this family in human cells, is thought to regulate initial mitotic events. CDC25B is an unstable protein whose proteasomal degradation is proposed to be controlled by beta-TrCP. Here, we have investigated the regulation of CDC25B during mitosis, using time-lapse video microscopy. We found that CDC25B expression is high during early mitosis, and that its degradation occurs after the metaphase-anaphase transition and cyclin B1 destruction. We also show that CDC25B degradation after metaphase is dependent on the integrity of the KEN-box and RRKSE motifs that are located within the alternatively spliced B domain, and that the CDC25B2 splice variant, that lacks this domain, is stable during mitosis. Furthermore, we show that the N-terminal region of CDC25B, encompassing the B domain, undergoes major conformational changes during mitosis that can be monitored by intramolecular fluorescence resonance energy transfer variation of specific CDC25B biosensors. This study demonstrates that CDC25B splice variants have differential mitotic stabilities, a feature that is likely to have major consequences on the local control of cyclin-dependent kinase-cyclin activities during mitotic progression.	[Kieffer, I.; Lorenzo, C.; Dozier, C.; Schmitt, E.; Ducommun, B.] Univ Toulouse 3, CNRS, LBCMCP UMR5088 IFR109, Inst Explorat Fonct Genomes, F-31062 Toulouse, France; [Ducommun, B.] CHU Purpan, F-40031 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse	Ducommun, B (corresponding author), Univ Toulouse 3, CNRS, LBCMCP UMR5088 IFR109, Inst Explorat Fonct Genomes, 118 Route Narbonne, F-31062 Toulouse, France.	ducommun@cict.fr	DOZIER, Christine/P-1539-2014; DUCOMMUN, Bernard/B-3208-2008	DUCOMMUN, Bernard/0000-0002-7126-8368				Baldin V, 1997, J BIOL CHEM, V272, P32731, DOI 10.1074/jbc.272.52.32731; Baldin V, 1997, ONCOGENE, V14, P2485, DOI 10.1038/sj.onc.1201063; Baldin V, 2003, BIOL CELL, V95, P547, DOI 10.1016/j.biolcel.2003.08.001; Baldin V, 2002, J BIOL CHEM, V277, P35176, DOI 10.1074/jbc.M204430200; Boutros R, 2006, CURR OPIN CELL BIOL, V18, P185, DOI 10.1016/j.ceb.2006.02.003; Bugler B, 2006, MOL CANCER THER, V5, P1446, DOI 10.1158/1535-7163.MCT-06-0099; Bulavin DV, 2002, CURR OPIN GENET DEV, V12, P92, DOI 10.1016/S0959-437X(01)00270-2; Busino L, 2003, NATURE, V426, P87, DOI 10.1038/nature02082; Cans C, 1999, MOL BIOL REP, V26, P53, DOI 10.1023/A:1006912105352; Cazales M, 2005, CELL CYCLE, V4, P1233, DOI 10.4161/cc.4.9.1964; Chen F, 2002, P NATL ACAD SCI USA, V99, P1990, DOI 10.1073/pnas.032428899; Clute P, 1999, NAT CELL BIOL, V1, P82, DOI 10.1038/10049; Davezac N, 2000, ONCOGENE, V19, P2179, DOI 10.1038/sj.onc.1203545; Donzelli M, 2002, EMBO J, V21, P4875, DOI 10.1093/emboj/cdf491; Donzelli M, 2004, CELL CYCLE, V3, P469; Dutertre S, 2004, J CELL SCI, V117, P2523, DOI 10.1242/jcs.01108; Escalas N, 2000, EXP CELL RES, V257, P206, DOI 10.1006/excr.2000.4878; Forrest ARR, 1999, BIOCHEM BIOPH RES CO, V260, P510, DOI 10.1006/bbrc.1999.0870; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Hernandez S, 2000, INT J CANCER, V89, P148, DOI 10.1002/(SICI)1097-0215(20000320)89:2<148::AID-IJC8>3.0.CO;2-R; Hernandez S, 2001, LAB INVEST, V81, P465, DOI 10.1038/labinvest.3780254; Jin JP, 2003, GENE DEV, V17, P3062, DOI 10.1101/gad.1157503; Kanemori Y, 2005, P NATL ACAD SCI USA, V102, P6279, DOI 10.1073/pnas.0501873102; Karlsson C, 1999, J CELL BIOL, V146, P573, DOI 10.1083/jcb.146.3.573; Korner K, 2001, J BIOL CHEM, V276, P9662, DOI 10.1074/jbc.M008696200; Kristjansdottir K, 2004, CHEM BIOL, V11, P1043, DOI 10.1016/j.chembiol.2004.07.007; Lemaire M, 2006, CELL CYCLE, V5, P1649, DOI 10.4161/cc.5.15.3006; Lindqvist A, 2004, J CELL SCI, V117, P4979, DOI 10.1242/jcs.01395; Lindqvist A, 2005, J CELL BIOL, V171, P35, DOI 10.1083/jcb.200503066; Manke IA, 2005, MOL CELL, V17, P37, DOI 10.1016/j.molcel.2004.11.021; Mirey G, 2005, CELL CYCLE, V4, P806, DOI 10.4161/cc.4.6.1716; MIYATA H, 2005, CANCER RES, V61, P3188; Miyawaki A, 2000, METHOD ENZYMOL, V327, P472, DOI 10.1016/S0076-6879(00)27297-2; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nishijima H, 1997, J CELL BIOL, V138, P1105, DOI 10.1083/jcb.138.5.1105; Pfleger CM, 2000, GENE DEV, V14, P655; Schmitt E, 2006, J CELL SCI, V119, P4269, DOI 10.1242/jcs.03200; Theis-Febvre N, 2003, ONCOGENE, V22, P220, DOI 10.1038/sj.onc.1206107; van Vugt MATM, 2005, ONCOGENE, V24, P2844, DOI 10.1038/sj.onc.1208617; van Vugt MATM, 2004, MOL CELL, V15, P799, DOI 10.1016/j.molcel.2004.07.015	40	26	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 13	2007	26	57					7847	7858		10.1038/sj.onc.1210596	http://dx.doi.org/10.1038/sj.onc.1210596			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248ON	17599046	Bronze			2022-12-17	WOS:000252163500003
J	Jin, W; Yun, C; Kwak, MK; Kim, TA; Kim, SJ				Jin, W.; Yun, C.; Kwak, M-K; Kim, T-A; Kim, S-J			TrkC binds to the type II TGF-beta receptor to suppress TGF-beta signaling	ONCOGENE			English	Article						neurotrophin receptors; TrkC; TGF-beta; cancer; signaling; ETV6-NTRK3	ETV6-NTRK3 GENE FUSION; GASTRIC-CANCER CELLS; HUMAN NEUROBLASTOMAS; EXPRESSION; TUMORS; NEUROTROPHINS; INHIBITOR; PROGNOSIS; PROSTATE; COMPLEX	Growing evidence suggests that overexpression of TrkC, a member of the Trk family of neurotrophin receptors, could drive tumorigenesis, invasion and metastatic capability in cancer cells. However, relatively little is known about the mechanism of TrkC-mediated oncogenesis. The TrkC gene is a partner of the Tel-TrkC (ETV6-NTRK3) chimeric tyrosine kinase, a potent oncoprotein expressed in tumors derived from multiple cell lineages. Recently, we have shown that ETV6-NTRK3 suppresses transforming growth factor-beta (TGF-beta) signaling by directly binding to the type II TGF-beta receptor (TbRII). Here, we report that expression of TrkC also suppresses TGF-beta-induced Smad2/3 phosphorylation and transcriptional activation. Silencing TrkC expression by small interfering RNA in the highly metastatic 4T1 mammary tumor cell line expressing endogenous TrkC significantly enhanced TGF-beta-induced Smad2/3 phosphorylation and restored TGF-b growth inhibitory activity. In contrast, expression of TrkC in 67NR cells, in which TrkC is not expressed, suppressed TGF-beta transcriptional activation. Moreover, we show that TrkC directly binds to the TbRII, thereby preventing it from interacting with the type I TGF-beta receptor (T beta RI). These results indicate that TrkC is an inhibitor of TGF-beta tumor suppressor activity.	[Jin, W.; Yun, C.; Kwak, M-K; Kim, T-A; Kim, S-J] NCI, Lab Canc Biol & Genet, NIH, Bethesda, MD 20892 USA; [Kim, S-J] Gachon Univ Med & Sci, Lee Gil Ya Canc & Diabet Inst, Lab Cell Regulat & Carcinogenesis, Inchon, South Korea	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Gachon University	Kim, SJ (corresponding author), NCI, Lab Canc Biol & Genet, NIH, Bldg 37,Room 5046D,9000 Rockville Pike, Bethesda, MD 20892 USA.	kims@mail.nih.gov			Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Bardelli A, 2003, SCIENCE, V300, P949, DOI 10.1126/science.1082596; Brodeur GM, 1997, J NEURO-ONCOL, V31, P49, DOI 10.1023/A:1005729329526; Chang J, 1997, CANCER RES, V57, P2856; Chao MV, 2002, NEURON, V33, P9, DOI 10.1016/S0896-6273(01)00573-6; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; Eguchi M, 1999, BLOOD, V93, P1355, DOI 10.1182/blood.V93.4.1355; Grotzer MA, 2000, J CLIN ONCOL, V18, P1027, DOI 10.1200/JCO.2000.18.5.1027; Guate JL, 1999, BJU INT, V84, P495; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Hisaoka M, 2002, J PATHOL, V197, P661, DOI 10.1002/path.1138; Horton CD, 2001, J NEUROCHEM, V76, P201, DOI 10.1046/j.1471-4159.2001.00017.x; Jin W, 2005, P NATL ACAD SCI USA, V102, P16239, DOI 10.1073/pnas.0503137102; Kim SJ, 2000, CYTOKINE GROWTH F R, V11, P159, DOI 10.1016/S1359-6101(99)00039-8; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; Lee BI, 2001, CANCER RES, V61, P931; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Nakagawara A, 2001, CANCER LETT, V169, P107, DOI 10.1016/S0304-3835(01)00530-4; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; Rickert CH, 2004, J NEUROPATH EXP NEUR, V63, P1211, DOI 10.1093/jnen/63.12.1211; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; Ruggeri BA, 1999, CURR MED CHEM, V6, P845; Ryden M, 1996, BRIT J CANCER, V74, P773, DOI 10.1038/bjc.1996.435; Satoh F, 2001, INT J UROL, V8, pS28, DOI 10.1046/j.1442-2042.2001.00331.x; SEGAL RA, 1994, P NATL ACAD SCI USA, V91, P12867, DOI 10.1073/pnas.91.26.12867; SUN LZ, 1994, J BIOL CHEM, V269, P26449; Tognon C, 2002, CANCER CELL, V2, P367, DOI 10.1016/S1535-6108(02)00180-0; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Yamashiro DJ, 1997, EUR J CANCER, V33, P2054, DOI 10.1016/S0959-8049(97)00309-2; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1	32	26	26	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 6	2007	26	55					7684	7691		10.1038/sj.onc.1210571	http://dx.doi.org/10.1038/sj.onc.1210571			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SK	17546043				2022-12-17	WOS:000251537800010
J	Lin, YC; Diccianni, MB; Kim, Y; Lin, HH; Lee, CH; Lin, RJ; Joo, SH; Li, J; Chuang, TJ; Yang, AS; Kuo, HH; Tsai, MD; Yu, AL				Lin, Y-C; Diccianni, M. B.; Kim, Y.; Lin, H-H; Lee, C-H; Lin, R-J; Joo, S. H.; Li, J.; Chuang, T-J; Yang, A-S; Kuo, H-H; Tsai, M-D; Yu, A. L.			Human p16 gamma, a novel transcriptional variant of p16(INK4A), coexpresses with p16(INK4A) in cancer cells and inhibits cell-cycle progression	ONCOGENE			English	Article						INK4A; alternative splicing; cell-cycle inhibitor	TUMOR-SUPPRESSOR P16(INK4A); P16INK4A RNA TRANSCRIPTS; DEPENDENT KINASES; P16; GENE; MUTATIONS; PROTEINS; DELETION; FREQUENT; PATHWAY	The INK4A locus encodes two tumor suppressor genes, p16(INK4A) and p14(ARF), transcribed using alternative exons 1 alpha or 1 beta spliced onto the same exons 2 and 3. Both p16(INK4A) and p14(ARF) are capable of inhibiting the cell-cycle progression, albeit in different manner; p16(INK4A) is phosphorylation of retinoblastoma (pRB) dependent while p14(ARF) is p53-dependent. In this study, we report the discovery of a novel variant of p16(INK4A), termed p16 gamma, in a primary T-cell acute lymphoblastic leukemia (T-ALL) patient sample and a neuroblastoma cell line, which was expressed at both the transcriptional and translational levels. Cloning and sequencing of the p16 gamma cDNA revealed that p16 gamma was identical to p16(INK4A), except that it contained an in-frame insertion of 197 bp between exons 2 and 3. p16 gamma expression was detected in the majority of p16(INK4A)-expressing primary T-ALL and B-ALL patient samples and other p16(INK4A)-expressing tumor samples, but was only barely detectable in some normal mononuclear cells and other non-tumor samples. Structural analysis by nuclear magnetic resonance and circular dichroism con. firmed that p16 gamma, like p16(INK4A), is also an ankyrin-repeat protein. Functional analysis of p16 gamma revealed that p16 gamma protein interacted with cyclin D-dependent kinase4 and inhibited its kinase activity. Using a luciferase reporter assay, the transfection of p16 gamma repressed the E2F response, the downstream target of pRB, with an efficacy equivalent to that of p16(INK4A). Moreover p16 gamma, like p16(INK4A), induced cell-cycle arrest at G(0)/G(1), and inhibited cell growth in colony formation assay.	Acad Sinica, Ctr Gene Res, Taipei 115, Taiwan; Univ Calif San Diego, Dept Pediat Hematol Oncol, San Diego, CA USA; Ohio State Univ, Dept Chem, Columbus, OH 43210 USA	Academia Sinica - Taiwan; University of California System; University of California San Diego; University System of Ohio; Ohio State University	Yu, AL (corresponding author), Acad Sinica, Ctr Gene Res, 128 Acad Rd,Sec 2 Nankang Dist, Taipei 115, Taiwan.	aliceyu@ucsd.edu	Lin, Hsin-Hung/J-5254-2013; , MitchDiccianni/AAF-8486-2019; Tsai, Ming-Daw/G-4689-2019	Lin, Hsin-Hung/0000-0001-8327-6835; , MitchDiccianni/0000-0002-5017-9585; Tsai, Ming-Daw/0000-0003-1374-0414; Yang, An-Suei/0000-0002-4699-873X; yu, alice/0000-0003-2444-0505; Lin, Ruey-Jen/0000-0001-5586-1770	NATIONAL CANCER INSTITUTE [P30CA023100, R01CA069472] Funding Source: NIH RePORTER; NCI NIH HHS [2 P30CA23100-18, CA69472] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; Aretz S, 2004, HUM MUTAT, V24, P370, DOI 10.1002/humu.20087; Batova A, 1997, CANCER RES, V57, P832; Byeon IJL, 1998, MOL CELL, V1, P421, DOI 10.1016/S1097-2765(00)80042-8; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; Chen YJ, 1997, INT J CANCER, V71, P350, DOI 10.1002/(SICI)1097-0215(19970502)71:3<350::AID-IJC7>3.0.CO;2-X; CHENG JQ, 1994, CANCER RES, V54, P5547; Cho JW, 2003, LIVER INT, V23, P194, DOI 10.1034/j.1600-0676.2003.00821.x; Diccianni MB, 1996, CANCER LETT, V104, P183, DOI 10.1016/0304-3835(96)04250-4; Diccianni MB, 1999, INT J CANCER, V80, P145, DOI 10.1002/(SICI)1097-0215(19990105)80:1<145::AID-IJC26>3.3.CO;2-7; Diccianni Mitchell B, 2004, J Exp Ther Oncol, V4, P223; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ElSharawy A, 2006, HUM MUTAT, V27, P1129, DOI 10.1002/humu.20377; Fu GH, 2005, FEBS LETT, V579, P2105, DOI 10.1016/j.febslet.2005.02.063; Harland M, 2001, HUM MOL GENET, V10, P2679, DOI 10.1093/hmg/10.23.2679; Hillman RT, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-2-r8; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JEN J, 1994, CANCER RES, V54, P6353; Kim WY, 2006, CELL, V127, P265, DOI 10.1016/j.cell.2006.10.003; Komata T, 2003, BRIT J CANCER, V88, P1277, DOI 10.1038/sj.bjc.6600862; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; Li JN, 2003, BIOCHEMISTRY-US, V42, P13476, DOI 10.1021/bi035390r; Li JN, 2002, BIOCHEMISTRY-US, V41, P3977, DOI 10.1021/bi011550s; Li JN, 1999, BIOCHEMISTRY-US, V38, P2930, DOI 10.1021/bi982286e; Li JN, 2006, BIOCHEMISTRY-US, V45, P15168, DOI 10.1021/bi062188q; Lin YC, 2000, ONCOGENE, V19, P2704, DOI 10.1038/sj.onc.1203582; MAO L, 1995, CANCER RES, V55, P2995; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; Omura-Minamisawa M, 2001, CLIN CANCER RES, V7, P3481; Omura-Minamisawa M, 2000, CLIN CANCER RES, V6, P1219; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; Pace C N, 1986, Methods Enzymol, V131, P266; QUELLE DE, 1995, CELL, V83, P993; Robertson KD, 1999, ONCOGENE, V18, P3810, DOI 10.1038/sj.onc.1202737; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; Schutte M, 1997, CANCER RES, V57, P3126; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; STONE S, 1995, CANCER RES, V55, P2988; Suh SI, 2000, CANCER LETT, V160, P81, DOI 10.1016/S0304-3835(00)00566-8; Suh SI, 2000, CANCER LETT, V153, P175, DOI 10.1016/S0304-3835(00)00369-4; Tevelev A, 1996, BIOCHEMISTRY-US, V35, P9475, DOI 10.1021/bi960211+; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; Yi Y, 2006, HUM MOL GENET, V15, P2192, DOI 10.1093/hmg/ddl144; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	46	26	29	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	49					7017	7027		10.1038/sj.onc.1210507	http://dx.doi.org/10.1038/sj.onc.1210507			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223YN	17486064				2022-12-17	WOS:000250412200007
J	Sekaric, P; Shamanin, VA; Luo, J; Androphy, EJ				Sekaric, P.; Shamanin, V. A.; Luo, J.; Androphy, E. J.			HAda3 regulates p14ARF-induced p53 acetylation and senescence	ONCOGENE			English	Article						p53; p14ARF; senescence; papillomavirus E6; hAda3	HUMAN-PAPILLOMAVIRUS TYPE-16; MAMMARY EPITHELIAL-CELLS; E6 ONCOPROTEIN; ONCOGENIC RAS; DNA-DAMAGE; HUMAN ADA3; MDM2; ACTIVATION; IMMORTALIZATION; P21(WAF1/CIP1)	Acetylation is thought to be a key event for p53 activation. We demonstrate that p14ARF-induced senescence of human mammary epithelial cells ( MEC) is associated with p53 acetylation and requires hAda3, a component of histone acetyltransferase complexes and a p53 transcriptional coactivator. Expression of the N-terminal domain of hAda3 that binds p53 but not p300 blocked p14ARF-induced p53 acetylation and protected MECs from senescence. Consistent with these findings, the human papillomavirus 16 E6 mutant Y54D, which selectively targets hAda3 but not p53 for degradation and protects MECs from p14ARF-induced senescence, inhibited p53 acetylation. In H1299 cells, hAda3 overexpression increased p300-mediated p53 acetylation, which conversely decreased following small interfering RNA ( siRNA) knockdown of hAda3. Moreover, depletion of hAda3 by siRNA inhibited endogenous p53 acetylation and accumulation of p21cip1 in response to ectopic p14ARF. These studies reveal that, in addition to its known ability to inhibit Mdm2-mediated p53 degradation, p14ARF signals through hAda3 to stimulate p53 acetylation and the induction of cell senescence.	Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA; Russian Acad Sci, Inst Cytol & Genet, Novosibirsk 630090, Russia; Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; Russian Academy of Sciences; Institute of Cytology & Genetics ICG SB RAS; University of Massachusetts System; University of Massachusetts Worcester	Androphy, EJ (corresponding author), Univ Massachusetts, Sch Med, Dept Med, LRB328,364 Plantat St, Worcester, MA 01605 USA.	elliot.androphy@umassmed.edu		Androphy, Elliot/0000-0002-8104-0703	NCI NIH HHS [R01 CA107394] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA107394] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Appella E, 2001, EUR J BIOCHEM, V268, P2763, DOI 10.1046/j.1432-1327.2001.02224.x; Balasubramanian R, 2002, J BIOL CHEM, V277, P7989, DOI 10.1074/jbc.M110849200; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Jin YT, 2003, EMBO J, V22, P6365, DOI 10.1093/emboj/cdg600; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Kumar A, 2002, MOL CELL BIOL, V22, P5801, DOI 10.1128/MCB.22.16.5801-5812.2002; Lee BY, 2006, AGING CELL, V5, P187, DOI 10.1111/j.1474-9726.2006.00199.x; Liu L, 1999, MOL CELL BIOL, V19, P1202; Liu Y, 1999, J VIROL, V73, P7297, DOI 10.1128/JVI.73.9.7297-7307.1999; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Nag A, 2007, J BIOL CHEM, V282, P8812, DOI 10.1074/jbc.M610443200; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Pedeux R, 2005, MOL CELL BIOL, V25, P6639, DOI 10.1128/MCB.25.15.6639-6648.2005; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shamanin VA, 2004, MOL CELL BIOL, V24, P2144, DOI 10.1128/MCB.24.5.2144-2152.2004; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; Thomas MC, 2005, MOL CELL, V17, P251, DOI 10.1016/j.molcel.2004.12.016; Vousden KH, 2002, CANCER CELL, V2, P351, DOI 10.1016/S1535-6108(02)00186-1; Wang T, 2001, EMBO J, V20, P6404, DOI 10.1093/emboj/20.22.6404; Wang XJ, 2004, FEBS LETT, V561, P195, DOI 10.1016/S0014-5793(04)00168-1; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; Zhang Z, 2004, J BIOL CHEM, V279, P16000, DOI 10.1074/jbc.M312264200; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999; 方岱宁, 1999, [力学与实践, Mechanics in Engineering], V21, P1	33	26	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2007	26	43					6261	6268		10.1038/sj.onc.1210462	http://dx.doi.org/10.1038/sj.onc.1210462			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	212GW	17452980				2022-12-17	WOS:000249583300002
J	Iwata, T; Mizusawa, N; Taketani, Y; Itakura, M; Yoshimoto, K				Iwata, T.; Mizusawa, N.; Taketani, Y.; Itakura, M.; Yoshimoto, K.			Parafibromin tumor suppressor enhances cell growth in the cells expressing SV40 large T antigen	ONCOGENE			English	Article						HRPT2; parafibromin; SV40 large T antigen; tumorigenesis; tumor suppressor	FAMILIAL ISOLATED HYPERPARATHYROIDISM; RNA-POLYMERASE-II; HEREDITARY HYPERPARATHYROIDISM; PARATHYROID CARCINOMA; GENE HRPT2; HUMAN PAF1; MUTATIONS; COMPLEX; TRANSFORMATION; TRANSCRIPTION	Parabromin (PF) is a 531-amino acid protein encoded by HRPT2, a putative tumor suppressor gene recently implicated in the autosomal-dominant hyperparathyroidism-jaw tumor familial cancer syndrome and sporadic parathyroid carcinoma. To investigate effects of PF's overexpression on cell proliferation, we performed assays in four different cell lines. The transient overexpression of PF inhibited cell growth in HEK293 and NIH3T3 cells, but enhanced cell growth in the SV40 large T antigen-expressing cell lines such as 293FT and COS7 cells. In 293FT cells, PF was found to interact with SV40 large T antigen and its overexpression promoted entry into the S phase, implying that the interaction enhanced progression through the cell cycle. The tumor suppressor protein PF acts as a positive regulator of cell growth similar to an oncoprotein in the presence of SV40 large T antigen.	Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Med & Pharmacol, Tokushima, Japan; Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Clin Nutr, Tokushima, Japan; Univ Tokushima, Grad Sch, Inst Hlth Biosci, Div Genet Informat, Tokushima, Japan	Tokushima University; Tokushima University; Tokushima University	Yoshimoto, K (corresponding author), Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Med & Pharmacol, 3-18-15 Kuramoto-cho, Tokushima, Japan.	yoshimot@dent.tokushima-u.ac.jp						Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; Arnold A, 2002, J BONE MINER RES, V17, pN30; Carpten JD, 2002, NAT GENET, V32, P676, DOI 10.1038/ng1048; CHEN S, 1990, J VIROL, V64, P3350, DOI 10.1128/JVI.64.7.3350-3357.1990; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; Grimelius L, 1997, SEMIN SURG ONCOL, V13, P142, DOI 10.1002/(SICI)1098-2388(199703/04)13:2<142::AID-SSU10>3.0.CO;2-0; Howell VM, 2003, J MED GENET, V40, P657, DOI 10.1136/jmg.40.9.657; JACKSON CE, 1990, SURGERY, V108, P1006; KASSEM M, 1994, CLIN ENDOCRINOL, V41, P415, DOI 10.1111/j.1365-2265.1994.tb02570.x; KIERSTEAD TD, 1993, J VIROL, V67, P1817, DOI 10.1128/JVI.67.4.1817-1829.1993; Marx S, 1998, ANN INTERN MED, V129, P484, DOI 10.7326/0003-4819-129-6-199809150-00011; Mizusawa N, 2006, CLIN ENDOCRINOL, V65, P9, DOI 10.1111/j.1365-2265.2006.02534.x; Moniaux N, 2006, ONCOGENE, V25, P3247, DOI 10.1038/sj.onc.1209353; Mosimann C, 2006, CELL, V125, P327, DOI 10.1016/j.cell.2006.01.053; Porter SE, 2002, EUKARYOT CELL, V1, P830, DOI 10.1128/EC.1.5.830-842.2002; ROWLAND BD, 2006, NAT REV CANCER, V6, P293; Rozenblatt-Rosen O, 2005, MOL CELL BIOL, V25, P612, DOI 10.1128/MCB.25.2.612-620.2005; Schuffenecker I, 1998, J CLIN ENDOCR METAB, V83, P487, DOI 10.1210/jc.83.2.487; Shattuck TM, 2003, NEW ENGL J MED, V349, P1722, DOI 10.1056/NEJMoa031237; Simmons DT, 2000, ADV VIRUS RES, V55, P75, DOI 10.1016/S0065-3527(00)55002-7; Simonds WF, 2004, J CLIN ENDOCR METAB, V89, P96, DOI 10.1210/jc.2003-030675; SZABO J, 1995, AM J HUM GENET, V56, P944; Tan MH, 2004, CLIN CANCER RES, V10, P6629, DOI 10.1158/1078-0432.CCR-04-0493; Villar JC, 2004, FILTR SEPARAT, V41, P32, DOI 10.1016/S0015-1882(04)00282-4; Wassif WS, 1999, CLIN ENDOCRINOL, V50, P191, DOI 10.1046/j.1365-2265.1999.00633.x; Woodard GE, 2005, ONCOGENE, V24, P1272, DOI 10.1038/sj.onc.1208274; Yart A, 2005, MOL CELL BIOL, V25, P5052, DOI 10.1128/MCB.25.12.5052-5060.2005; Yokoyama A, 2005, CELL, V123, P207, DOI 10.1016/j.cell.2005.09.025; Zhu B, 2005, GENE DEV, V19, P1668, DOI 10.1101/gad.1292105	29	26	28	4	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2007	26	42					6176	6183		10.1038/sj.onc.1210445	http://dx.doi.org/10.1038/sj.onc.1210445			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209PU	17404568				2022-12-17	WOS:000249401300008
J	Feng, Q; Sekula, D; Muller, R; Freemantle, SJ; Dmitrovsky, E				Feng, Q.; Sekula, D.; Muller, R.; Freemantle, S. J.; Dmitrovsky, E.			Uncovering residues that regulate cyclin D1 proteasomal degradation	ONCOGENE			English	Article						cyclin D1; all-trans-retinoic acid; ubiquitination	N-TERMINAL UBIQUITINATION; NUCLEAR-LOCALIZATION; RETINOIC ACID; PHOSPHORYLATION; PROTEOLYSIS; CANCER; SIGNAL; TARGET; UBE1L; PREVENTION	Cyclin D1 regulates G1 cell-cycle progression and is aberrantly expressed in carcinogenesis. Proteasomal degradation of cyclin D1 was highlighted as a cancer chemopreventive mechanism. To understand this mechanism better, residues responsible for degradation and ubiquitination of cyclin D1 were investigated. Eighteen lysines in cyclin D1 had single, double or multiple mutations engineered before transfection into BEAS-2B human bronchial epithelial (HBE) cells to evaluate stabilities after all-trans-retinoic acid (RA) or cycloheximide treatments. Specific mutations stabilized cyclin D1, including substitutions of lysines surrounding the cyclin box domain that inhibited RA-mediated degradation and extended the cyclin D1 half-life. Mutation of all cyclin D1 lysines blocked polyubiquitination. N-terminus (but not C-terminus) modification stabilized cyclin D1. Ubiquitination resistant mutants preferentially localized cyclin D1 to the nucleus, directly implicating subcellular localization in regulating cyclin D1 degradation. Taken together, these findings uncover specific residues conferring ubiquitination of cyclin D1. These provide a mechanistic basis for proteasomal degradation of cyclin D1.	Dartmouth Med Sch, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; Univ Marburg, IMT, Marburg, Germany; Dartmouth Med Sch, Dept Med, Hanover, NH USA; Dartmouth Med Sch, Norris Cotton Canc Ctr, Hanover, NH USA; Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA	Dartmouth College; Philipps University Marburg; Dartmouth College; Dartmouth College; Norris Cotton Cancer Center; Dartmouth College	Dmitrovsky, E (corresponding author), Dartmouth Med Sch, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA.	Ethan.Dmitrovsky@Dartmouth.EDU	Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248	NATIONAL CANCER INSTITUTE [R01CA087546, R01CA111422] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA111422, R01 CA087546] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; Aggarwal BB, 2004, ANTICANCER RES, V24, P2783; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Batonnet S, 2004, J BIOL CHEM, V279, P5413, DOI 10.1074/jbc.M310315200; Chernov MV, 2001, J BIOL CHEM, V276, P31819, DOI 10.1074/jbc.M103170200; Ciechanover A, 2004, TRENDS CELL BIOL, V14, P103, DOI 10.1016/j.tcb.2004.01.004; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Coulombe P, 2004, MOL CELL BIOL, V24, P6140, DOI 10.1128/MCB.24.14.6140-6150.2004; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 2002, CANCER BIOL THER, V1, P226, DOI 10.4161/cbt.72; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DMITROVSKY E, 2002, ENCY CANC, P449; Dragnev KH, 2005, J CLIN ONCOL, V23, P8757, DOI 10.1200/JCO.2005.01.9521; Dragnev KH, 2004, CLIN CANCER RES, V10, P2570, DOI 10.1158/1078-0432.CCR-03-0271; Dragnev KH, 2001, ANN NY ACAD SCI, V952, P13, DOI 10.1111/j.1749-6632.2001.tb02724.x; Fung TK, 2005, CELL CYCLE, V4, P1411, DOI 10.4161/cc.4.10.2046; Germain D, 2000, J BIOL CHEM, V275, P12074, DOI 10.1074/jbc.275.16.12074; Gladden AB, 2005, J CELL BIOCHEM, V96, P906, DOI 10.1002/jcb.20613; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; Kitareewan S, 2002, P NATL ACAD SCI USA, V99, P3806, DOI 10.1073/pnas.052011299; Klotzbucher A, 1996, EMBO J, V15, P3053, DOI 10.1002/j.1460-2075.1996.tb00668.x; KOBAYASHI H, 1992, MOL BIOL CELL, V3, P1279, DOI 10.1091/mbc.3.11.1279; Langenfeld J, 1997, P NATL ACAD SCI USA, V94, P12070, DOI 10.1073/pnas.94.22.12070; Lu FM, 2003, CANCER RES, V63, P7056; Ma Y, 2005, CANCER RES, V65, P6476, DOI 10.1158/0008-5472.CAN-05-0370; Patel MI, 2005, CLIN CANCER RES, V11, P1999, DOI 10.1158/1078-0432.CCR-04-1877; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Petty WJ, 2003, LUNG CANCER, V41, pS155, DOI 10.1016/S0169-5002(03)00159-4; Pitha-Rowe I, 2004, CANCER RES, V64, P8109, DOI 10.1158/0008-5472.CAN-03-3938; Pitha-Rowe I, 2004, J BIOL CHEM, V279, P18178, DOI 10.1074/jbc.M309259200; Radu A, 2003, MOL CELL BIOL, V23, P6139, DOI 10.1128/MCB.23.17.6139-6149.2003; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Solomon DA, 2003, J BIOL CHEM, V278, P30339, DOI 10.1074/jbc.M303969200; Spinella MJ, 1999, J BIOL CHEM, V274, P22013, DOI 10.1074/jbc.274.31.22013; Zwicker J, 1999, ONCOGENE, V18, P19, DOI 10.1038/sj.onc.1202286	38	26	28	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2007	26	35					5098	5106		10.1038/sj.onc.1210309	http://dx.doi.org/10.1038/sj.onc.1210309			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	196MT	17310991				2022-12-17	WOS:000248487400008
J	Bieler, G; Hasmim, M; Monnier, Y; Imaizumi, N; Ameyar, M; Bamat, J; Ponsonnet, L; Choualb, S; Grell, M; Goodman, SL; Lejeune, F; Ruegg, C				Bieler, G.; Hasmim, M.; Monnier, Y.; Imaizumi, N.; Ameyar, M.; Bamat, J.; Ponsonnet, L.; Choualb, S.; Grell, M.; Goodman, S. L.; Lejeune, F.; Rueegg, C.			Distinctive role of integrin-mediated adhesion in TNF-induced PKB/Akt and NF-kappa B activation and endothelial cell survival	ONCOGENE			English	Article						endothelium; cell death; cancer; signaling; angiogenesis	TUMOR-NECROSIS-FACTOR; ALPHA-INDUCED APOPTOSIS; PROTEIN-KINASE B/AKT; SHEAR-STRESS; CANCER CELLS; IFN-GAMMA; DEATH; INTERFERON; INHIBITION; PATHWAY	Tumor necrosis factor (TNF) is a pro-inflammatory cytokine exerting pleiotropic effects on endothelial cells. Depending on the vascular context it can induce endothelial cell activation and survival or death. The microenvironmental cues determining whether endothelial cells will survive or die, however, have remained elusive. Here we report that integrin ligation acts permissive for TNF-induced protein kinase B (PKB/Akt) but not nuclear factor (NF)-kappa B activation. Concomitant activation of PKB/Akt and NF-kappa B is essential for the survival of endothelial cells exposed to TNF. Active PKB/Akt strengthens integrin-dependent endothelial cell adhesion, whereas disruption of actin stress fibers abolishes the protective effect of PKB/Akt. Integrin-mediated adhesion also represses TNF-induced JNK activation, but JNK activity is not required for cell death. The alpha V beta 3/alpha V beta 5 integrin inhibitor EMD121974 sensitizes endothelial cells to TNF-dependent cytotoxicity and active PKB/ Akt attenuates this effect. Interferon gamma synergistically enhanced TNF-induced endothelial cell death in all conditions tested. Taken together, these observations reveal a novel permissive role for integrins in TNF-induced PKB/ Akt activation and prevention of TNF-induced death distinct of NF-kappa B, and implicate the actin cytoskeleton in PKB/Akt-mediated cell survival. The sensitizing effect of EMD121974 on TNF cytotoxicity may open new perspectives to the therapeutic use of TNF as anticancer agent.	Lausanne Canc Ctr, Div Expt Oncol, CH-1066 Epalinges, Switzerland; Swiss Inst Expt Canc Res, NCCR Mol Oncol, CH-1066 Epalinges, Switzerland; Inst Gustave Roussy, INSERM, UNIT U487, F-94805 Villejuif, France; Merck KGaA, Preclin Res Oncol, Darmstadt, Germany	Swiss Institute Experimental Cancer Research; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Merck KGaA	Ruegg, C (corresponding author), Lwoff Inst, CNRS, FRE 2944, 7 Rue Guy Moquet, F-94801 Villejuif, France.	curzio.ruegg@isrec.ch	Chouaib, Salem/F-7939-2016	Goodman, Simon L./0000-0002-3480-1346; Hasmim, Meriem/0000-0002-7920-2443				Agrawal S, 2002, MOL CELL BIOL, V22, P1981, DOI 10.1128/MCB.22.7.1981-1992.2002; Alghisi GC, 2006, ENDOTHELIUM-J ENDOTH, V13, P113, DOI 10.1080/10623320600698037; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; BALKWILL FR, 1987, CANCER RES, V47, P4755; Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Beyaert R, 2002, INT REV CYTOL, V214, P225; Bezzi M, 2003, J BIOL CHEM, V278, P43603, DOI 10.1074/jbc.M308114200; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Burow ME, 2000, BIOCHEM BIOPH RES CO, V271, P342, DOI 10.1006/bbrc.2000.2626; Byzova TV, 2000, MOL CELL, V6, P851, DOI 10.1016/S1097-2765(05)00076-6; Cai ZZ, 1997, J BIOL CHEM, V272, P96; Chen JX, 2004, AM J PHYSIOL-HEART C, V287, pH187, DOI 10.1152/ajpheart.01058.2003; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; Corada M, 1999, P NATL ACAD SCI USA, V96, P9815, DOI 10.1073/pnas.96.17.9815; Dechantsreiter MA, 1999, J MED CHEM, V42, P3033, DOI 10.1021/jm970832g; Fornaro M, 2003, J BIOL CHEM, V278, P50402, DOI 10.1074/jbc.M307627200; Gooch JL, 2000, CELL GROWTH DIFFER, V11, P335; Gourlay CW, 2005, NAT REV MOL CELL BIO, V6, P583, DOI 10.1038/nrm1682; Hermann C, 2000, ARTERIOSCL THROM VAS, V20, P402, DOI 10.1161/01.ATV.20.2.402; Imose M, 2003, LIVER INT, V23, P386, DOI 10.1034/j.1478-3231.2003.00867.x; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kim AH, 2002, NEURON, V35, P697, DOI 10.1016/S0896-6273(02)00821-8; Korff T, 1998, J CELL BIOL, V143, P1341, DOI 10.1083/jcb.143.5.1341; Laird SM, 1998, CELL SIGNAL, V10, P473, DOI 10.1016/S0898-6568(97)00173-3; Lejeune Ferdy J, 2006, Cancer Immun, V6, P6; MAREEL M, 1988, INT J CANCER, V42, P470, DOI 10.1002/ijc.2910420327; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; NOLOP KB, 1990, AM J PHYSIOL, V259, P123; Papadakis CM, 2000, EUR PHYS J E, V1, P275, DOI 10.1007/s101890050029; Pober JS, 1998, PATHOL BIOL, V46, P159; Ruegg C, 1998, NAT MED, V4, P408, DOI 10.1038/nm0498-408; SCANLON M, 1989, P NATL ACAD SCI USA, V86, P182, DOI 10.1073/pnas.86.1.182; Shyy JY, 2002, CIRC RES, V91, P769, DOI 10.1161/01.RES.0000038487.19924.18; Spagnuolo R, 2004, BLOOD, V103, P3005, DOI 10.1182/blood-2003-07-2459; Suk K, 2001, J IMMUNOL, V166, P4481, DOI 10.4049/jimmunol.166.7.4481; Surapisitchat J, 2001, P NATL ACAD SCI USA, V98, P6476, DOI 10.1073/pnas.101134098; Thorburn A, 2004, CELL SIGNAL, V16, P139, DOI 10.1016/j.cellsig.2003.08.007; Yilmaz A, 1998, INT J CANCER, V77, P592; Zhang R, 2005, ONCOGENE, V24, P3954, DOI 10.1038/sj.onc.1208548	40	26	27	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2007	26	39					5722	5732		10.1038/sj.onc.1210354	http://dx.doi.org/10.1038/sj.onc.1210354			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202EP	17369858				2022-12-17	WOS:000248885100004
J	Chassot, AA; Turchi, L; Virolle, T; Fitsialos, G; Batoz, M; Deckert, M; Dulic, V; Meneguzzi, G; Busca, R; Ponzio, G				Chassot, A-A; Turchi, L.; Virolle, T.; Fitsialos, G.; Batoz, M.; Deckert, M.; Dulic, V.; Meneguzzi, G.; Busca, R.; Ponzio, G.			Id3 is a novel regulator of p27(kip1) mRNA in early G1 phase and is required for cell-cycle progression	ONCOGENE			English	Article						Ids; cell-cycle; p27mRNA; wound healing	LOOP-HELIX PROTEINS; CDK INHIBITOR P27; P16(INK4A) EXPRESSION; TRANSCRIPTION; DIFFERENTIATION; PROLIFERATION; FIBROBLASTS; DEGRADATION; SENESCENCE; PATHWAYS	P27kip is a key inhibitory protein of the cell-cycle progression, which is rapidly downregulated in early G1 phase by a post-translational mechanism involving the proteosomal degradation. In this study, using a wounding model that induces cell-cycle entry of human dermal fibroblasts, we demonstrate that p27mRNA is downregulated when cells progress into the G1 phase, and then it returns to its basal level when cells approach the S phase. By using a quantitative polymerase chain reaction screening we identified inhibitors of differentiation (10), a bHLH transcriptional repressor, as a candidate mediator accounting for p27 mRNA decrease. Id3 silencing, using an small interfering RNA approach, reversed the injury mediated p27 downregulation demonstrating that 143 is involved in the transcriptional repression of p27. Reporter gene experiments and a chromatin immunoprecipitation assay showed that Id3 likely exerts its repressive action through ELK1 inhibition. By inhibiting early p27 downregulation, Id3 depletion blocked (i) the G1-phase progression as assessed by the inhibition of pRb phosphorylation and p130 degradation and (ii) the G1/S transition as observed by the inhibition of cyclin A induction, demonstrating that p27 mRNA decrease is required for cell proliferation. Apart from its effect on the early p27 diminution, 143 appears also involved in the control of the steady-state level of p27 at the G1/S boundary. In conclusion, this study identifies a novel mechanism of p27 regulation which besides p27 protein degradation also implicates a transcriptional mechanism mediated by 10.	Univ Nice, Fac Med, INSERM, U634, F-06107 Nice 02, France; Univ Nice, Hop Larchet, INSERM, U576, Nice, France; CNRS, CRBM, FRE 2593, F-34033 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Ponzio, G (corresponding author), Univ Nice, Fac Med, INSERM, U634, 28 Ave Valombrose, F-06107 Nice 02, France.	ponzio@unice.fr	Deckert, Marcel/T-3566-2019; Ponzio, Gilles/Q-1256-2016; Chassot, Anne-Amandine/O-2102-2016; Deckert, Marcel/M-4998-2016; Virolle, Thierry/E-5838-2016	Deckert, Marcel/0000-0003-2094-559X; Ponzio, Gilles/0000-0003-2741-0248; Chassot, Anne-Amandine/0000-0003-1242-9456; Turchi, Laurent/0000-0003-2020-5831; Meneguzzi, Guerrino/0000-0002-1609-6540; Dulic, Vjekoslav/0000-0003-1201-3901				Alani RM, 2001, P NATL ACAD SCI USA, V98, P7812, DOI 10.1073/pnas.141235398; Bagui TK, 2003, MOL CELL BIOL, V23, P7285, DOI 10.1128/MCB.23.20.7285-7290.2003; Benezra R, 2001, ONCOGENE, V20, P8288, DOI 10.1038/sj.onc.1205161; Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Busca R, 2005, J CELL BIOL, V170, P49, DOI 10.1083/jcb.200501067; Calderon M, 1996, J SURG RES, V61, P343, DOI 10.1006/jsre.1996.0127; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Chraibi H, 2004, J Wound Care, V13, P447; Deed RW, 1997, MOL CELL BIOL, V17, P6815, DOI 10.1128/MCB.17.12.6815; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Engel I, 2001, NAT REV IMMUNOL, V1, P193, DOI 10.1038/35105060; Everly DN, 2004, J VIROL, V78, P13470, DOI 10.1128/JVI.78.24.13470-13478.2004; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Kamura T, 2004, NAT CELL BIOL, V6, P1229, DOI 10.1038/ncb1194; Kee Y, 2005, GENE DEV, V19, P744, DOI 10.1101/gad.1257405; Kowanetz M, 2004, MOL CELL BIOL, V24, P4241, DOI 10.1128/MCB.24.10.4241-4254.2004; Kudo Y, 2005, ORAL ONCOL, V41, P105, DOI 10.1016/j.oraloncology.2004.05.003; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Loots MAM, 1999, ARCH DERMATOL RES, V291, P93, DOI 10.1007/s004030050389; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Minami S, 1997, FEBS LETT, V411, P1, DOI 10.1016/S0014-5793(97)00660-1; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Norton JD, 2000, J CELL SCI, V113, P3897; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Okabe M, 2001, MODERN PATHOL, V14, P1008, DOI 10.1038/modpathol.3880426; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; REZZONICO R, 1995, J BIOL CHEM, V270, P1261, DOI 10.1074/jbc.270.3.1261; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; Roberts EC, 2001, MOL CELL BIOL, V21, P524, DOI 10.1128/MCB.21.2.524-533.2001; Sakakibara K, 2005, J BIOL CHEM, V280, P25470, DOI 10.1074/jbc.M502320200; Servant MJ, 2000, J CELL BIOL, V148, P543, DOI 10.1083/jcb.148.3.543; Sharma A, 1997, MOL ENDOCRINOL, V11, P1608, DOI 10.1210/me.11.11.1608; Sherr CJ, 2002, CELL CYCLE, V1, P36, DOI 10.4161/cc.1.1.106; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Takahashi E, 2004, BIOCHEM BIOPH RES CO, V325, P1136, DOI 10.1016/j.bbrc.2004.10.148; Trausch-Azar JS, 2004, J BIOL CHEM, V279, P32614, DOI 10.1074/jbc.M403794200; Turchi L, 2002, J INVEST DERMATOL, V119, P56, DOI 10.1046/j.1523-1747.2002.01805.x; Yates PR, 1999, EMBO J, V18, P968, DOI 10.1093/emboj/18.4.968; Zheng WJ, 2004, J BIOL CHEM, V279, P31524, DOI 10.1074/jbc.M400365200	48	26	26	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2007	26	39					5772	5783		10.1038/sj.onc.1210386	http://dx.doi.org/10.1038/sj.onc.1210386			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202EP	17404577				2022-12-17	WOS:000248885100009
J	Karni-Schmidt, O; Friedler, A; Zupnick, A; McKinney, K; Mattia, M; Beckerman, R; Bouvet, P; Sheetz, M; Fersht, A; Prives, C				Karni-Schmidt, O.; Friedler, A.; Zupnick, A.; McKinney, K.; Mattia, M.; Beckerman, R.; Bouvet, P.; Sheetz, M.; Fersht, A.; Prives, C.			Energy-dependent nucleolar localization of p53 in vitro requires two discrete regions within the p53 carboxyl terminus	ONCOGENE			English	Article						p53; nucleolus; DNA damage; NoLS	TUMOR-SUPPRESSOR; DNA-DAMAGE; SUBCELLULAR LOCATION; BINDING PROTEIN; CELLULAR STRESS; NUCLEAR EXPORT; STABILIZES P53; CANCER-CELLS; HELA-CELLS; MDM2	The p53 tumor suppressor is a nucleocytoplasmic shuttling protein that is found predominantly in the nucleus of cells. In addition to mutation, abnormal p53 cellular localization is one of the mechanisms that inactivate p53 function. To further understand features of p53 that contribute to the regulation of its trafficking within the cell, we analysed the subnuclear localization of wild-type and mutant p53 in human cells that were either permeabilized with detergent or treated with the proteasome inhibitor MG132. We, here, show that either endogenously expressed or exogenously added p53 protein localizes to the nucleolus in detergent-permeabilized cells in a concentration- and ATP hydrolysis-dependent manner. Two discrete regions within the carboxyl terminus of p53 are essential for nucleolar localization in permeabilized cells. Similarly, localization of p53 to the nucleolus after proteasome inhibition in unpermeabilized cells requires sequences within the carboxyl terminus of p53. Interestingly, genotoxic stress markedly decreases the association of p53 with the nucleolus, and phosphorylation of p53 at S392, a site that is modified by such stress, partially impairs its nucleolar localization. The possible significance of these findings is discussed.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; MRC, Ctr Prot Engn, Dept MRC CPE, Cambridge CB2 2BB, England; Hebrew Univ Jerusalem, Dept Organ Chem, IL-91010 Jerusalem, Israel; Ecole Normale Super Lyon, UMR 5161, Lab Biol Mol Cellule, F-69364 Lyon, France	Columbia University; University of Cambridge; Hebrew University of Jerusalem; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet	Prives, C (corresponding author), Columbia Univ, Dept Biol Sci, 816 Fairchild, New York, NY 10027 USA.	clp3@columbia.edu	, Bouvet/AAC-8779-2020; Fersht, Alan R/B-2189-2008	Bouvet, Philippe/0000-0003-4524-2233	MRC [MC_U105474168] Funding Source: UKRI; Medical Research Council [MC_U105474168] Funding Source: Medline; NCI NIH HHS [CA58316, CA87497] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058316, R37CA058316, P01CA087497] Funding Source: NIH RePORTER	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Benninghoff J, 1999, CANCER LETT, V144, P55, DOI 10.1016/S0304-3835(99)00187-1; Budde A, 1999, ONCOGENE, V18, P1119, DOI 10.1038/sj.onc.1202402; Bykov VJN, 2002, CARCINOGENESIS, V23, P2011, DOI 10.1093/carcin/23.12.2011; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Carmo-Fonseca M, 2000, NAT CELL BIOL, V2, pE107, DOI 10.1038/35014078; Carmo-Fonseca M, 2002, TRENDS CELL BIOL, V12, P491, DOI 10.1016/S0962-8924(02)02387-5; Chan PK, 1996, CANCER LETT, V100, P191, DOI 10.1016/0304-3835(95)04100-1; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; Daniely Y, 2002, MOL CELL BIOL, V22, P6014, DOI 10.1128/MCB.22.16.6014-6022.2002; DUNDR M, 1995, J CELL SCI, V108, P2811; Fernandez-Fernandez MR, 2005, P NATL ACAD SCI USA, V102, P4735, DOI 10.1073/pnas.0501459102; GhisolfiNieto L, 1996, J MOL BIOL, V260, P34, DOI 10.1006/jmbi.1996.0380; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gobert C, 1996, BIOCHEMISTRY-US, V35, P5778, DOI 10.1021/bi952327w; Haaf T, 1996, EXP CELL RES, V224, P163, DOI 10.1006/excr.1996.0124; Horky M, 2001, J CELL SCI, V114, P663; Issaeva N, 2003, P NATL ACAD SCI USA, V100, P13303, DOI 10.1073/pnas.1835733100; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Jayaraman L, 1997, METHOD ENZYMOL, V283, P245; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Klibanov SA, 2001, J CELL SCI, V114, P1867; Lamond AI, 2003, CURR BIOL, V13, pR825, DOI 10.1016/j.cub.2003.10.012; Latonen L, 2003, CELL SIGNAL, V15, P95, DOI 10.1016/S0898-6568(02)00044-X; Leung AKL, 2003, CRIT REV EUKAR GENE, V13, P39, DOI 10.1615/CritRevEukaryotGeneExpr.v13.i1.40; Leung AKL, 2003, BIOCHEM J, V376, P553, DOI 10.1042/BJ20031169; Liang SH, 2001, EUR J BIOCHEM, V268, P2779, DOI 10.1046/j.1432-1327.2001.02227.x; Liu G, 2002, ONCOGENE, V21, P7195, DOI 10.1038/sj.onc.1205862; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Marciniak RA, 1998, P NATL ACAD SCI USA, V95, P6887, DOI 10.1073/pnas.95.12.6887; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; Mayer C, 2005, CELL CYCLE, V4, P1036, DOI 10.4161/cc.4.8.1925; Menendez D, 2006, MOL CELL BIOL, V26, P2297, DOI 10.1128/MCB.26.6.2297-2308.2006; MOGAKI M, 1993, CARCINOGENESIS, V14, P2589, DOI 10.1093/carcin/14.12.2589; Olson MOJ, 2005, HISTOCHEM CELL BIOL, V123, P203, DOI 10.1007/s00418-005-0754-9; Olson MOJ, 2000, TRENDS CELL BIOL, V10, P189, DOI 10.1016/S0962-8924(00)01738-4; Pokrovskaja K, 2001, J GEN VIROL, V82, P345, DOI 10.1099/0022-1317-82-2-345; Poyurovsky MV, 2003, MOL CELL, V12, P875, DOI 10.1016/S1097-2765(03)00400-3; Prives C, 1999, J PATHOL, V187, P112; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROKAEUS N, 2006, ONCOGENE; Rubbi CP, 2000, ONCOGENE, V19, P85, DOI 10.1038/sj.onc.1203378; Shirangi TR, 2002, FASEB J, V16, P420, DOI 10.1096/fj.01-0617fje; Stros M, 1998, EUR J BIOCHEM, V251, P427, DOI 10.1046/j.1432-1327.1998.2510427.x; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Thomas F, 2003, J CELL SCI, V116, P2409, DOI 10.1242/jcs.00464; Tsai RYL, 2002, GENE DEV, V16, P2991, DOI 10.1101/gad.55671; Visintin R, 2000, CURR OPIN CELL BIOL, V12, P752, DOI 10.1016/S0955-0674(00)00165-4; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Wesierska-Gadek J, 2002, INT J CANCER, V101, P128, DOI 10.1002/ijc.10580; Wong JMY, 2002, NAT CELL BIOL, V4, P731, DOI 10.1038/ncb846; Xirodimas DP, 2001, EXP CELL RES, V270, P66, DOI 10.1006/excr.2001.5314; Young PJ, 2002, J BIOL CHEM, V277, P2852, DOI 10.1074/jbc.M108769200; ZATSEPINA OV, 1989, EXP CELL RES, V181, P94, DOI 10.1016/0014-4827(89)90185-7; ZERRAHN J, 1992, ONCOGENE, V7, P1371; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zimber A, 2004, CELL SIGNAL, V16, P1085, DOI 10.1016/j.cellsig.2004.03.020; Zolotukhin AS, 1999, J VIROL, V73, P120, DOI 10.1128/JVI.73.1.120-127.1999	62	26	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 31	2007	26	26					3878	3891		10.1038/sj.onc.1210162	http://dx.doi.org/10.1038/sj.onc.1210162			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175PV	17237827				2022-12-17	WOS:000247026400011
J	Keler, T; He, L; Ramakrishna, V; Champion, B				Keler, T.; He, L.; Ramakrishna, V.; Champion, B.			Antibody-targeted vaccines	ONCOGENE			English	Review						monoclonal antibodies; targeted vaccines; antigen cross-presentation; dendritic cells	HUMAN DENDRITIC CELLS; C-TYPE LECTIN; PATTERN-RECOGNITION RECEPTOR; HUMAN CHORIONIC-GONADOTROPIN; MACROPHAGE MANNOSE RECEPTOR; CLASS-II MHC; ANTIGEN-PRESENTING CELLS; IN-VIVO; STEADY-STATE; DC-SIGN	The specificity and high affinity binding of antibodies provides these molecules with ideal properties for delivering a payload to target cells. This concept has been commercialized for cancer therapies using toxin- or radionucleotide-conjugated antibodies that are designed to selectively deliver cytotoxic molecules to cancer cells. Exploiting the same effective characteristics of antibodies, antibody-targeted vaccines (ATV) are designed to deliver disease-specific antigens to professional antigen-presenting cells (APCs), thus enabling the host's immune system to recognize and eliminate malignant or infected cells through adaptive immunity. The concept of ATVs has been in development for many years, and recently has entered clinical trials. Early studies with ATVs focused on the ability to induce humoral immunity in the absence of adjuvants. More recently, ATVs targeted to C-type lectin receptors have been exploited for induction of potent helper and cytolytic T-cell responses. To maximize their stimulatory capacity, the ATVs are being evaluated with a variety of adjuvants or other immunostimulatory agents. In the absence of co-administered immunostimulatory signals, APC-targeting can induce antigen-specific tolerance and, thus, may also be exploited in developing specific treatments for autoimmune and allergic diseases, or for preventing transplant rejection. The successful clinical application of this new class of antibody-based products will clearly depend on using appropriate combinations with other strategies that influence the immune system.	Celldex Therapeut Inc, Phillipsburg, NJ 08865 USA; Celldex Therapeut Ltd, Cambridge, England		Keler, T (corresponding author), Celldex Therapeut Inc, 222 Cameron Dr,Suite 400, Phillipsburg, NJ 08865 USA.	tkeler@celldextherapeutics.com						Allavena P, 2004, CRIT REV IMMUNOL, V24, P179, DOI 10.1615/CritRevImmunol.v24.i3.20; Apostolopoulos V, 2000, EUR J IMMUNOL, V30, P1714, DOI 10.1002/1521-4141(200006)30:6<1714::AID-IMMU1714>3.0.CO;2-C; Ariizumi K, 2000, J BIOL CHEM, V275, P20157, DOI 10.1074/jbc.M909512199; Bashirova AA, 2001, J EXP MED, V193, P671, DOI 10.1084/jem.193.6.671; Berry JD, 2003, HYBRIDOMA HYBRIDOM, V22, P23, DOI 10.1089/153685903321538053; BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; Bonifaz L, 2002, J EXP MED, V196, P1627, DOI 10.1084/jem.20021598; Bonifaz LC, 2004, J EXP MED, V199, P815, DOI 10.1084/jem.20032220; Boskovic J, 2006, J BIOL CHEM, V281, P8780, DOI 10.1074/jbc.M513277200; Brown GD, 2003, J EXP MED, V197, P1119, DOI 10.1084/jem.20021890; Brown GD, 2006, NAT REV IMMUNOL, V6, P33, DOI 10.1038/nri1745; Bruder D, 2005, DIABETES, V54, P3395, DOI 10.2337/diabetes.54.12.3395; Burgdorf S, 2006, J IMMUNOL, V176, P6770, DOI 10.4049/jimmunol.176.11.6770; Butler SA, 2003, CLIN CANCER RES, V9, P4666; CARAYANNIOTIS G, 1990, VACCINE, V8, P137, DOI 10.1016/0264-410X(90)90136-A; CARAYANNIOTIS G, 1987, NATURE, V327, P59, DOI 10.1038/327059a0; CARAYANNIOTIS G, 1991, MOL IMMUNOL, V28, P261, DOI 10.1016/0161-5890(91)90072-R; CARAYANNIOTIS G, 1988, MOL IMMUNOL, V25, P907, DOI 10.1016/0161-5890(88)90128-9; Carter RW, 2006, J IMMUNOL, V177, P2276, DOI 10.4049/jimmunol.177.4.2276; Carter RW, 2006, CELL IMMUNOL, V239, P87, DOI 10.1016/j.cellimm.2006.05.001; Charalambous A, 2006, J IMMUNOL, V177, P8410, DOI 10.4049/jimmunol.177.12.8410; Chen M, 2006, NAT CLIN PRACT NEURO, V2, P2, DOI 10.1038/ncpneuro0087; CHESNUT RW, 1981, J IMMUNOL, V126, P1075; Chieppa M, 2003, J IMMUNOL, V171, P4552, DOI 10.4049/jimmunol.171.9.4552; Dakappagari N, 2006, J IMMUNOL, V176, P426, DOI 10.4049/jimmunol.176.1.426; Deslee G, 2002, J ALLERGY CLIN IMMUN, V110, P763, DOI 10.1067/mai.2002.129121; EZEKOWITZ RAB, 1991, NATURE, V351, P155, DOI 10.1038/351155a0; Finkelman FD, 1996, J IMMUNOL, V157, P1406; Gantner BN, 2003, J EXP MED, V197, P1107, DOI 10.1084/jem.20021787; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; Gordon S, 2002, CELL, V111, P927, DOI 10.1016/S0092-8674(02)01201-1; Guo M, 2000, HUM IMMUNOL, V61, P729, DOI 10.1016/S0198-8859(00)00144-0; Hawiger D, 2001, J EXP MED, V194, P769, DOI 10.1084/jem.194.6.769; He Lizhen, 2006, Proceedings of the American Association for Cancer Research Annual Meeting, V47, P334; He LZ, 2004, CLIN CANCER RES, V10, P1920, DOI 10.1158/1078-0432.CCR-03-0264; Heath WR, 2001, ANNU REV IMMUNOL, V19, P47, DOI 10.1146/annurev.immunol.19.1.47; JIANG WP, 1995, NATURE, V375, P151, DOI 10.1038/375151a0; Kato M, 2006, INT IMMUNOL, V18, P857, DOI 10.1093/intimm/dxl022; Keler T, 2005, CURR OPIN MOL THER, V7, P157; Keler T, 2004, EXPERT OPIN BIOL TH, V4, P1953, DOI 10.1517/14712598.4.12.1953; Larche M, 2005, NAT MED, V11, pS69, DOI 10.1038/nm1226; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Le Cabec V, 2005, J LEUKOCYTE BIOL, V77, P934, DOI 10.1189/jlb.1204705; Mahnke K, 2005, CANCER RES, V65, P7007, DOI 10.1158/0008-5472.CAN-05-0938; Mahnke K, 2000, J CELL BIOL, V151, P673, DOI 10.1083/jcb.151.3.673; Maksimow M, 2006, BLOOD, V108, P1298, DOI 10.1182/blood-2005-11-008615; Mansour MK, 2006, J IMMUNOL, V176, P3053, DOI 10.4049/jimmunol.176.5.3053; McGreal EP, 2006, GLYCOBIOLOGY, V16, P422, DOI 10.1093/glycob/cwj077; McGreal EP, 2005, CURR OPIN IMMUNOL, V17, P18, DOI 10.1016/j.coi.2004.12.001; McKenzie EJ, 2002, TRENDS GLYCOSCI GLYC, V14, P273, DOI 10.4052/tigg.14.273; Melief CJM, 2003, EUR J IMMUNOL, V33, P2645, DOI 10.1002/eji.200324341; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; Mommaas AM, 1999, EUR J IMMUNOL, V29, P571, DOI 10.1002/(SICI)1521-4141(199902)29:02<571::AID-IMMU571>3.0.CO;2-E; Pohlmann S, 2001, TRENDS IMMUNOL, V22, P643, DOI 10.1016/S1471-4906(01)02081-6; Pyz E, 2006, ANN MED, V38, P242, DOI 10.1080/07853890600608985; Ramakrishna V, 2004, J IMMUNOL, V172, P2845, DOI 10.4049/jimmunol.172.5.2845; Rock KL, 1996, IMMUNOL TODAY, V17, P131, DOI 10.1016/0167-5699(96)80605-0; Rogers NC, 2005, IMMUNITY, V22, P507, DOI 10.1016/j.immuni.2005.03.004; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; Sato K, 2006, J BIOL CHEM, V281, P38854, DOI 10.1074/jbc.M606542200; Schjetne KW, 2005, EUR J IMMUNOL, V35, P3142, DOI 10.1002/eji.200425947; Schjetne KW, 2002, INT IMMUNOL, V14, P1423, DOI 10.1093/intimm/dxf110; SNIDER DP, 1987, J IMMUNOL, V139, P1609; SNIDER DP, 1990, J EXP MED, V171, P1957, DOI 10.1084/jem.171.6.1957; SNIDER DP, 1989, J IMMUNOL, V143, P59; STAHL PD, 1992, CURR OPIN IMMUNOL, V4, P49, DOI 10.1016/0952-7915(92)90123-V; Steinman RM, 2003, ANN NY ACAD SCI, V987, P15, DOI 10.1111/j.1749-6632.2003.tb06029.x; Tacken PJ, 2006, IMMUNOBIOLOGY, V211, P599, DOI 10.1016/j.imbio.2006.05.021; Tacken PJ, 2005, BLOOD, V106, P1278, DOI 10.1182/blood-2005-01-0318; Tan MCAA, 1998, INT IMMUNOL, V10, P1299, DOI 10.1093/intimm/10.9.1299; Tan MCAA, 1997, EUR J IMMUNOL, V27, P2426, DOI 10.1002/eji.1830270942; TONY HP, 1985, J EXP MED, V161, P223, DOI 10.1084/jem.161.1.223; Triozzi PL, 1999, ONCOL REP, V6, P7; Trumpfheller C, 2006, J EXP MED, V203, P607, DOI 10.1084/jem.20052005; Turville S, 2003, J LEUKOCYTE BIOL, V74, P710, DOI 10.1189/jlb.0503208; Uccini S, 1997, AM J PATHOL, V150, P929; van Kooyk Y, 2004, CURR OPIN IMMUNOL, V16, P488, DOI 10.1016/j.coi.2004.05.010; van Vliet SJ, 2006, NAT IMMUNOL, V7, P1200, DOI 10.1038/ni1390; van Vuuren AJ, 2006, J IMMUNOL, V176, P5833, DOI 10.4049/jimmunol.176.10.5833; Wang H, 2000, P NATL ACAD SCI USA, V97, P847, DOI 10.1073/pnas.97.2.847; Wenink MH, 2006, NETH J MED, V64, P103; Wollenberg A, 2002, J INVEST DERMATOL, V118, P327, DOI 10.1046/j.0022-202x.2001.01665.x; Zhang JM, 2005, J LEUKOCYTE BIOL, V78, P665, DOI 10.1189/jlb.1204699	83	26	32	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	25					3758	3767		10.1038/sj.onc.1210375	http://dx.doi.org/10.1038/sj.onc.1210375			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172PK	17530028	Bronze			2022-12-17	WOS:000246816100017
J	Kim, E; Deppert, W				Kim, E.; Deppert, W.			Interactions of mutant p53 with DNA: guilt by association	ONCOGENE			English	Review						mutant p53; DNA binding; chromatin interaction; non-B DNA; transcription	TUMOR-SUPPRESSOR P53; C-TERMINAL DOMAIN; ETS TRANSCRIPTION FACTORS; GENE-EXPRESSION; COMPLEX INTERACTIONS; BINDING-SITE; IN-VIVO; MUTATIONS; PROTEIN; ACTIVATION	Since the very early days of p53 research, the gain of oncogenic activities by some mutant p53 proteins had been suspected as an important factor contributing to cancer progression. Considerable progress towards understanding the biology of mutant p53 has been made during the last years, the quintessence being the realization that the impact of mutant p53 proteins on the transcriptome of a tumor cell is much more global than previously thought. The emerging role of mutant p53 proteins in coordinating oncogenic signaling and chromatin modifying activities reveals an until now unsuspected function of these proteins as important modifiers of the oncogenic transcriptional response. Notwithstanding the fact that the sequence specific DNA binding activity of mutant p53 proteins is impaired, they are still able to associate with specific loci on DNA by utilizing different mechanisms. The ability to associate with DNA appears to be crucial for the master role of mutant p53 proteins in coordinating oncogenic transcriptional responses.	Univ Gottingen, Dept Neurosurg, Translat Neurooncol Grp, D-37075 Gottingen, Germany; Heinrich Pette Inst, Hamburg, Germany	University of Gottingen; Heinrich Pette Institute	Kim, E (corresponding author), Univ Gottingen, Dept Neurosurg, Translat Neurooncol Grp, Robert Koch Str 40, D-37075 Gottingen, Germany.	ella.kim@med.uni-goettingen.de						Ahn J, 2001, NAT STRUCT BIOL, V8, P730, DOI 10.1038/nsb0901-730; Ang HC, 2006, J BIOL CHEM, V281, P21934, DOI 10.1074/jbc.M604209200; Bae BI, 2005, NEURON, V47, P29, DOI 10.1016/j.neuron.2005.06.005; Campomenosi P, 2001, ONCOGENE, V20, P3573, DOI 10.1038/sj.onc.1204468; Chicas A, 2000, BIOCHEM BIOPH RES CO, V279, P383, DOI 10.1006/bbrc.2000.3965; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Di Agostino S, 2006, CANCER CELL, V10, P191, DOI 10.1016/j.ccr.2006.08.013; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Feng Z, 2006, ONCOGENE, V25, P1, DOI 10.1038/sj.onc.1209021; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Gilliland DG, 2001, CLIN CANCER RES, V7, P451; Gohler T, 2002, J BIOL CHEM, V277, P41192, DOI 10.1074/jbc.M202344200; Gohler T, 2005, NUCLEIC ACIDS RES, V33, P1087, DOI 10.1093/nar/gki252; Gu LB, 2004, J BIOL CHEM, V279, P52141, DOI 10.1074/jbc.M407915200; Gu ZN, 1999, MOL CARCINOGEN, V24, P294, DOI 10.1002/(SICI)1098-2744(199904)24:4<294::AID-MC7>3.0.CO;2-Q; GUALBERTO A, 1995, MOL CELL BIOL, V15, P3450; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; Imbriano C, 2005, MOL CELL BIOL, V25, P3737, DOI 10.1128/MCB.25.9.3737-3751.2005; Inga A, 2001, ONCOGENE, V20, P501, DOI 10.1038/sj.onc.1204116; JOERGER AC, 2007, ONCOGNEE; Joerger AC, 2006, P NATL ACAD SCI USA, V103, P15056, DOI 10.1073/pnas.0607286103; Kim E, 2004, J CELL BIOCHEM, V93, P878, DOI 10.1002/jcb.20271; Kim E, 2003, ONCOGENE, V22, P7716, DOI 10.1038/sj.onc.1207155; Kim E, 2003, BIOCHEM CELL BIOL, V81, P141, DOI 10.1139/o03-046; Koga H, 2000, ONCOGENE, V19, P4178, DOI 10.1038/sj.onc.1203745; Koutsodontis G, 2005, BIOCHEM J, V389, P443, DOI 10.1042/BJ20041980; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Muller BF, 1996, ONCOGENE, V12, P1941; Nguyen TT, 2005, MOL CELL BIOL, V25, P2147, DOI 10.1128/MCB.25.6.2147-2157.2005; Oikawa T, 2004, CANCER SCI, V95, P626, DOI 10.1111/j.1349-7006.2004.tb03320.x; Okorokov AL, 2006, EMBO J, V25, P5191, DOI 10.1038/sj.emboj.7601382; Pang JH, 1996, EXP GERONTOL, V31, P97, DOI 10.1016/0531-5565(95)02019-5; Pastorcic M, 2000, J BIOL CHEM, V275, P34938, DOI 10.1074/jbc.M005411200; Sampath J, 2001, J BIOL CHEM, V276, P39359, DOI 10.1074/jbc.M103429200; Saveliev A, 2003, NATURE, V422, P909, DOI 10.1038/nature01596; Scian MJ, 2005, MOL CELL BIOL, V25, P10097, DOI 10.1128/MCB.25.22.10097-10110.2005; Scian MJ, 2004, CANCER RES, V64, P7447, DOI 10.1158/0008-5472.CAN-04-1568; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; Sigal A, 2000, CANCER RES, V60, P6788; Sinden RR, 2002, J BIOSCIENCES, V27, P53, DOI 10.1007/BF02703683; STENGER JE, 1994, EMBO J, V13, P6011, DOI 10.1002/j.1460-2075.1994.tb06947.x; TSUTSUMIISHII Y, 1995, CELL GROWTH DIFFER, V6, P1; Walter K, 2005, J BIOL CHEM, V280, P42497, DOI 10.1074/jbc.M507038200; WANG YH, 1995, GENOMICS, V25, P570, DOI 10.1016/0888-7543(95)80061-P; WEISSKER SN, 1992, ONCOGENE, V7, P1921; Yang XL, 1999, ONCOGENE, V18, P4546, DOI 10.1038/sj.onc.1202843; Zalcenstein A, 2003, ONCOGENE, V22, P5667, DOI 10.1038/sj.onc.1206724	47	26	27	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 2	2007	26	15					2185	2190		10.1038/sj.onc.1210312	http://dx.doi.org/10.1038/sj.onc.1210312			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	152XE	17401427				2022-12-17	WOS:000245394800007
J	Menendez, D; Inga, A; Jordan, JJ; Resnick, MA				Menendez, D.; Inga, A.; Jordan, J. J.; Resnick, M. A.			Changing the p53 master regulatory network: ELEMENTary, my dear Mr Watson	ONCOGENE			English	Review						p53; response element; mutants; transactivation; SNP; evolution	WILD-TYPE P53; TUMOR-SUPPRESSOR PROTEIN; DNA-BINDING SITE; RNA-POLYMERASE-II; TRANSCRIPTIONAL REPRESSION; IN-VIVO; FUNCTIONAL ASSAY; HUMAN GENOME; MUTANT P53; DIRECTED MUTAGENESIS	The p53 master regulatory network provides for the stress-responsive direct control of a vast number of genes in humans that can be grouped into several biological categories including cell-cycle control, apoptosis and DNA repair. Similar to other sequence-specific master regulators, there is a matrix of key components, which provide for variation within the p53 master regulatory network that include p53 itself, target response element sequences (REs) that provide for p53 regulation of target genes, chromatin, accessory proteins and transcription machinery. Changes in any of these can impact the expression of individual genes, groups of genes and the eventual biological responses. The many REs represent the core of the master regulatory network. Since defects or altered expression of p53 are associated with over 50% of all cancers and greater than 90% of p53 mutations are in the sequence-specific DNA-binding domain, it is important to understand the relationship between wildtype or mutant p53 proteins and the target response elements. In the words of the legendary detective Sherlock Holmes, it is 'Elementary, my dear Mr. Watson.'	Natl Inst Environm Hlth Sci, Chromosome Stabil Sect, Lab Mol Genet, NIH, Res Triangle Pk, NC 27709 USA; IST, Natl Inst Canc Res, Mol Mutageneis Unit, Dept Translat Oncol, Genoa, Italy	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Genoa; IRCCS AOU San Martino IST	Resnick, MA (corresponding author), Natl Inst Environm Hlth Sci, Chromosome Stabil Sect, Lab Mol Genet, NIH, 111 Alexander Dr,POB 12233, Res Triangle Pk, NC 27709 USA.	resnick@niehs.nih.gov	resnick, Michael/F-1668-2019; Inga, Alberto/AAC-3815-2022	resnick, Michael/0000-0002-8473-7506; Inga, Alberto/0000-0002-8767-1637	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES065079, Z01ES065079] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ahn J, 1999, ONCOGENE, V18, P5954, DOI 10.1038/sj.onc.1202986; Ahn J, 2001, NAT STRUCT BIOL, V8, P730, DOI 10.1038/nsb0901-730; An W, 2004, CELL, V117, P735, DOI 10.1016/j.cell.2004.05.009; Arva NC, 2005, J BIOL CHEM, V280, P26776, DOI 10.1074/jbc.M505203200; Ashur-Fabian C, 2004, P NATL ACAD SCI USA, V101, P12236, DOI 10.1073/pnas.0404998101; Avivi A, 2005, CELL CYCLE, V4, P368, DOI 10.4161/cc.4.3.1534; Bergamaschi D, 2003, CANCER CELL, V3, P387, DOI 10.1016/S1535-6108(03)00079-5; Bergamaschi D, 2006, NAT GENET, V38, P1133, DOI 10.1038/ng1879; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Bond GL, 2006, J MED GENET, V43, P950, DOI 10.1136/jmg.2006.043539; Bond GL, 2006, CANCER RES, V66, P5104, DOI 10.1158/0008-5472.CAN-06-0180; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Brachmann RK, 1996, P NATL ACAD SCI USA, V93, P4091, DOI 10.1073/pnas.93.9.4091; Campomenosi P, 2001, ONCOGENE, V20, P3573, DOI 10.1038/sj.onc.1204468; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Contente A, 2002, NAT GENET, V30, P315, DOI 10.1038/ng836; Deppert W, 2000, J CELL BIOCHEM, P115; Di Agostino S, 2006, CANCER CELL, V10, P191, DOI 10.1016/j.ccr.2006.08.013; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Espinosa JM, 2003, MOL CELL, V12, P1015, DOI 10.1016/S1097-2765(03)00359-9; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; FREEMAN J, 1994, EMBO J, V13, P5393, DOI 10.1002/j.1460-2075.1994.tb06874.x; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gomes NP, 2006, GENE DEV, V20, P601, DOI 10.1101/gad.1398206; Hamroun D, 2006, HUM MUTAT, V27, P14, DOI 10.1002/humu.20269; Ho J, 2003, CELL DEATH DIFFER, V10, P404, DOI 10.1038/sj.cdd.4401191; Ho JSL, 2005, MOL CELL BIOL, V25, P7423, DOI 10.1128/MCB.25.17.7423-7431.2005; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Hoh J, 2002, P NATL ACAD SCI USA, V99, P8467, DOI 10.1073/pnas.132268899; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; Inga A, 2005, HUM MOL GENET, V14, P1965, DOI 10.1093/hmg/ddi202; Inga A, 2002, ONCOGENE, V21, P5704, DOI 10.1038/sj.onc.1205779; Inga A, 2002, MOL CELL BIOL, V22, P8612, DOI 10.1128/MCB.22.24.8612-8625.2002; Inga A, 2001, ONCOGENE, V20, P3409, DOI 10.1038/sj.onc.1204457; Inga A, 2001, ONCOGENE, V20, P501, DOI 10.1038/sj.onc.1204116; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Johnson RA, 2001, J BIOL CHEM, V276, P27716, DOI 10.1074/jbc.C100121200; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Kannan K, 2001, ONCOGENE, V20, P3449, DOI 10.1038/sj.onc.1204446; Kato S, 2003, P NATL ACAD SCI USA, V100, P8424, DOI 10.1073/pnas.1431692100; Kitayner M, 2006, MOL CELL, V22, P741, DOI 10.1016/j.molcel.2006.05.015; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; Levine AJ, 2006, CELL DEATH DIFFER, V13, P1027, DOI 10.1038/sj.cdd.4401910; Li BQ, 2001, J BIOL CHEM, V276, P29729, DOI 10.1074/jbc.M101167200; LIM YP, 2006, ONCOGENE; Liu Suxing, 2004, Methods Mol Biol, V281, P33; LOHR D, 1995, FASEB J, V9, P777, DOI 10.1096/fasebj.9.9.7601342; MacIsaac KD, 2006, PLOS COMPUT BIOL, V2, P201, DOI 10.1371/journal.pcbi.0020036; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; McKinney K, 2004, MOL CELL, V16, P413, DOI 10.1016/j.molcel.2004.09.032; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; Menendez D, 2006, MOL CELL BIOL, V26, P2297, DOI 10.1128/MCB.26.6.2297-2308.2006; Menendez D, 2006, P NATL ACAD SCI USA, V103, P1406, DOI 10.1073/pnas.0508103103; MENENDEZ D, 2007, IN PRESS MOL CELL BI; Miled C, 2005, CANCER RES, V65, P5096, DOI 10.1158/0008-5472.CAN-04-4232; Minsky N, 2004, MOL CELL, V16, P631, DOI 10.1016/j.molcel.2004.10.016; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Nagaich AK, 1999, P NATL ACAD SCI USA, V96, P1875, DOI 10.1073/pnas.96.5.1875; Nagaich AK, 1997, J BIOL CHEM, V272, P14842, DOI 10.1074/jbc.272.23.14842; O'Farrell TJ, 2004, CANCER RES, V64, P8199, DOI 10.1158/0008-5472.CAN-03-3639; OLIVEIRA LS, 1994, DRY TECHNOL, V12, P1167, DOI 10.1080/07373939408960994; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Prives C, 1999, J PATHOL, V187, P112; Qian Hua, 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P1141; Reis AM, 2000, CANCER RES, V60, P1571; Resnick MA, 2003, P NATL ACAD SCI USA, V100, P9934, DOI 10.1073/pnas.1633803100; Resnick-Silverman L, 1998, GENE DEV, V12, P2102, DOI 10.1101/gad.12.14.2102; Rubbi CP, 2003, EMBO J, V22, P975, DOI 10.1093/emboj/cdg082; Shiraishi K, 2004, J BIOL CHEM, V279, P348, DOI 10.1074/jbc.M310815200; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; Storici F, 2003, P NATL ACAD SCI USA, V100, P14994, DOI 10.1073/pnas.2036296100; Storici F, 2001, NAT BIOTECHNOL, V19, P773, DOI 10.1038/90837; Storici F, 2006, METHOD ENZYMOL, V409, P329, DOI 10.1016/S0076-6879(05)09019-1; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; Tan T, 2002, MOL CELL BIOL, V22, P3247, DOI 10.1128/MCB.22.10.3247-3254.2002; Thomas M, 1999, MOL CELL BIOL, V19, P1092; Thornborrow EC, 2002, ONCOGENE, V21, P990, DOI 10.1038/sj.onc.1205069; THUKRAL SK, 1995, MOL CELL BIOL, V15, P5196; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; Tomso DJ, 2005, P NATL ACAD SCI USA, V102, P6431, DOI 10.1073/pnas.0501721102; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wallberg AE, 2003, MOL CELL, V12, P1137, DOI 10.1016/S1097-2765(03)00391-5; Wang LQ, 2001, J BIOL CHEM, V276, P43604, DOI 10.1074/jbc.M106570200; WANG Y, 1995, MOL CELL BIOL, V15, P2157; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043; Weinberg RL, 2005, J MOL BIOL, V348, P589, DOI 10.1016/j.jmb.2005.03.014; Xu H, 2003, ONCOL RES, V13, P429; Xu H, 2001, Biotechnol Annu Rev, V7, P131, DOI 10.1016/S1387-2656(01)07035-1; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhai WG, 2000, MOL CELL BIOL, V20, P5930, DOI 10.1128/MCB.20.16.5930-5938.2000; Zhang XT, 2005, MOL CELL, V19, P89, DOI 10.1016/j.molcel.2005.05.015; Zhao RB, 2000, GENE DEV, V14, P981	98	26	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 2	2007	26	15					2191	2201		10.1038/sj.onc.1210277	http://dx.doi.org/10.1038/sj.onc.1210277			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	152XE	17401428				2022-12-17	WOS:000245394800008
J	Masumi, A; Fukazawa, H; Shimazu, T; Yoshida, M; Ozato, K; Komuro, K; Yamaguchi, K				Masumi, A.; Fukazawa, H.; Shimazu, T.; Yoshida, M.; Ozato, K.; Komuro, K.; Yamaguchi, K.			Nucleolin is involved in interferon regulatory factor-2-dependent transcriptional activation	ONCOGENE			English	Article						IRF-2; nucleolin; acetylation	HISTONE ACETYLASE PCAF; H4 GENE-TRANSCRIPTION; HIV-1 TAT; BINDING PROTEIN; FACTOR FAMILY; IRF FAMILY; P300; ACETYLTRANSFERASE; FACTOR-2; COMPLEX	We have previously shown that interferon regulatory factor-2 (IRF-2) is acetylated in a cell growth-dependent manner, which enables it to contribute to the transcription of cell growth-regulated promoters. To clarify the function of acetylation of IRF-2, we investigated the proteins that associate with acetylated IRF-2. In 293T cells, the transfection of p300/CBP-associated factor (PCAF) enhanced the acetylation of IRF-2. In cells transfected with both IRF-2 and PCAF, IRF-2 associated with endogenous nucleolin, while in contrast, minimal association was observed when IRF-2 was transfected with a PCAF histone acetyl transferase (HAT) deletion mutant. In a pull-down experiment using stable transfectants, acetylation-defective mutant IRF-2 (IRF-2K75R) recruited nucleolin to a much lesser extent than wild-type IRF-2, suggesting that nucleolin preferentially associates with acetylated IRF-2. Nucleolin in the presence of PCAF enhanced IRF-2-dependent H4 promoter activity in NIH3T3 cells. Nucleolin knock-down using siRNA reduced the IRF-2/PCAF-mediated promoter activity. Chromatin immunoprecipitation analysis indicated that PCAF transfection increased nucleolin binding to IRF-2 bound to the H4 promoter. We conclude that nucleolin is recruited to acetylated IRF-2, thereby contributing to gene regulation crucial for the control of cell growth.	Natl Inst Infect Dis, Dept Safety Res Blood & Biol Prod, Tokyo 2080011, Japan; Natl Inst Infect Dis, Dept Bioact Mol, Tokyo, Japan; RIKEN, Chem Genet Lab, Wako, Saitama, Japan; NICHHD, Lab Mol Growth & Regulat, NIH, Bethesda, MD 20892 USA	National Institute of Infectious Diseases (NIID); National Institute of Infectious Diseases (NIID); RIKEN; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Masumi, A (corresponding author), Natl Inst Infect Dis, Dept Safety Res Blood & Biol Prod, 4-7-1,Gakuen, Tokyo 2080011, Japan.	amasumi@nih.go.jp	Yoshida, Minoru/C-8049-2014; SHIMAZU, Tadahiro/ABC-3950-2020	Yoshida, Minoru/0000-0002-4376-5674; 	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001310] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001310] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bannister AJ, 2000, CELL MOL LIFE SCI, V57, P1184, DOI 10.1007/PL00000758; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Benkirane M, 1998, J BIOL CHEM, V273, P24898, DOI 10.1074/jbc.273.38.24898; Caillaud A, 2002, J BIOL CHEM, V277, P49417, DOI 10.1074/jbc.M207484200; Chen LF, 2002, EMBO J, V21, P6539, DOI 10.1093/emboj/cdf660; Chow WA, 2000, J IMMUNOL, V164, P3512, DOI 10.4049/jimmunol.164.7.3512; Daniely Y, 2002, MOL CELL BIOL, V22, P6014, DOI 10.1128/MCB.22.16.6014-6022.2002; Deng LW, 2000, VIROLOGY, V277, P278, DOI 10.1006/viro.2000.0593; Ginisty H, 1999, J CELL SCI, V112, P761; Grinstein E, 2002, J EXP MED, V196, P1067, DOI 10.1084/jem.20011053; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Harrod R, 2000, J BIOL CHEM, V275, P11852, DOI 10.1074/jbc.275.16.11852; Hirano M, 2003, J BIOL CHEM, V278, P5109, DOI 10.1074/jbc.M207629200; Jiang H, 1999, MOL CELL BIOL, V19, P8136; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; Klibanov SA, 2001, J CELL SCI, V114, P1867; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lang SE, 2003, ONCOGENE, V22, P2836, DOI 10.1038/sj.onc.1206376; LAPEYRE B, 1987, P NATL ACAD SCI USA, V84, P1472, DOI 10.1073/pnas.84.6.1472; Lau OD, 2000, J BIOL CHEM, V275, P21953, DOI 10.1074/jbc.M003219200; Lau OD, 2000, MOL CELL, V5, P589, DOI 10.1016/S1097-2765(00)80452-9; Levy L, 2004, MOL CELL BIOL, V24, P3404, DOI 10.1128/MCB.24.8.3404-3414.2004; Li JW, 2000, MOL CELL BIOL, V20, P2031, DOI 10.1128/MCB.20.6.2031-2042.2000; Luo W, 1996, J BIOL CHEM, V271, P23445, DOI 10.1074/jbc.271.38.23445; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Masumi A, 2003, J BIOL CHEM, V278, P25401, DOI 10.1074/jbc.M213037200; Masumi A, 2001, J BIOL CHEM, V276, P20973, DOI 10.1074/jbc.M101707200; Masumi A, 1999, MOL CELL BIOL, V19, P1810; Ott M, 1999, CURR BIOL, V9, P1489, DOI 10.1016/S0960-9822(00)80120-7; Patel JH, 2004, MOL CELL BIOL, V24, P10826, DOI 10.1128/MCB.24.24.10826-10834.2004; Polesskaya A, 2001, MOL CELL BIOL, V21, P5312, DOI 10.1128/MCB.21.16.5312-5320.2001; Santos-Rosa H, 2003, NUCLEIC ACIDS RES, V31, P4285, DOI 10.1093/nar/gkg655; Schaefer BC, 1997, MOL CELL BIOL, V17, P873, DOI 10.1128/MCB.17.2.873; Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189; Spilianakis C, 2000, MOL CELL BIOL, V20, P8489, DOI 10.1128/MCB.20.22.8489-8498.2000; Srivastava M, 1999, FASEB J, V13, P1911, DOI 10.1096/fasebj.13.14.1911; Stellacci E, 2004, BIOCHEM J, V377, P367, DOI 10.1042/BJ20031166; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Suhara W, 2002, J BIOL CHEM, V277, P22304, DOI 10.1074/jbc.M200192200; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; Trievel RC, 2000, ANAL BIOCHEM, V287, P319, DOI 10.1006/abio.2000.4855; Vassilev A, 1998, MOL CELL, V2, P869, DOI 10.1016/S1097-2765(00)80301-9; Vaughan PS, 1998, J BIOL CHEM, V273, P194, DOI 10.1074/jbc.273.1.194; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Wang IM, 1996, MOL CELL BIOL, V16, P6313; Wolf D, 2002, J BIOL CHEM, V277, P25562, DOI 10.1074/jbc.M201196200; Xie RL, 2001, J BIOL CHEM, V276, P18624, DOI 10.1074/jbc.M010391200; YAMAMOTO H, 1994, ONCOGENE, V9, P1423; Yamauchi T, 2000, P NATL ACAD SCI USA, V97, P11303, DOI 10.1073/pnas.97.21.11303; Yanagida M, 2001, PROTEOMICS, V1, P1390, DOI 10.1002/1615-9861(200111)1:11<1390::AID-PROT1390>3.0.CO;2-Z; Ying GG, 2000, J BIOL CHEM, V275, P4152, DOI 10.1074/jbc.275.6.4152; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087	52	26	26	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 24	2006	25	37					5113	5124		10.1038/sj.onc.1209522	http://dx.doi.org/10.1038/sj.onc.1209522			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077WZ	16582966				2022-12-17	WOS:000240063700004
J	Walker, GE; Antoniono, RJ; Ross, HJ; Paisley, TE; Oh, Y				Walker, GE; Antoniono, RJ; Ross, HJ; Paisley, TE; Oh, Y			Neuroendocrine-like differentiation of non-small cell lung carcinoma cells: regulation by cAMP and the interaction of mac25/IGFBP-rP1 and 25.1	ONCOGENE			English	Article						cAMP; mac25/IGFBP-rP1; 25.1; NE differentiation; NSCLC; lung cancer	PROTEIN-RELATED PROTEIN-1; PROSTATE-CANCER CELLS; EPITHELIAL-CELLS; CHROMOGRANIN-A; GROWTH-FACTORS; STAGE-I; INSULIN; MARKERS; CHEMOTHERAPY; IDENTIFICATION	The need to develop more effective therapies for lung cancer has led to investigations in understanding the molecular mechanisms of the differentiation process, in particular neuroendocrine ( NE) differentiation. Recent studies have demonstrated that NE differentiation in nonsmall cell lung carcinoma (NSCLC) is not uncommon. Those NSCLCs with NE differentiation are considered a form of in transition NE carcinoma and show a more aggressive clinical course compared with NSCLC without NE differentiation. 25.1, a novel protein interacting with mac25/insulin-like growth factor-binding protein-related protein 1 (mac25/IGFBP-rP1), induced NE-like differentiation when collectively overexpressed in M12 prostate cancer cells. We have examined mac25/IGFBP-rP1 and 25.1 as potential molecular regulators in vitro of the NE-differentiation process in lung cancer. In a panel of SCLC and NSCLC cell lines, mac25/IGFBP-rP1 and 25.1 were expressed at higher levels in SCLC. An increase and sustained activation of adenosine 3',5'- cyclic monophosphate ( cAMP) levels induced NE-like differentiation in NSCLC cell lines, and a concomitant increase in the expression of mac25/IGFBP-rP1 and 25.1 was observed during the cAMP-regulated differentiation of NCI-H157 cells, suggesting the involvement of these proteins. Furthermore, the collective overexpression of mac25/IGFBP-rP1 and 25.1 in NSCLC cells induced NE-like differentiation as early as 6 h postinfection. The present data suggest that mac25/IGFBP-rP1 and 25.1 may play a functional role in the NE differentiation of NSCLC cell lines and may provide a novel therapeutic target for treating lung cancers, in particular NSCLC with NE differentiation.	Virginia Commonwealth Univ, Dept Pathol, Richmond, VA 23298 USA; Oregon Hlth Sci Univ, Dept Pediat, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Oregon Canc Ctr, Portland, OR 97201 USA; Earle A Chiles Res Inst, Portland, OR USA; Ist Auxol Italiano Piancavallo, Oggebbio, VA, Italy	Virginia Commonwealth University; Oregon Health & Science University; Oregon Health & Science University; IRCCS Istituto Auxologico Italiano	Oh, Y (corresponding author), Virginia Commonwealth Univ, Dept Pathol, Med Coll Virginia Campus,POB 980622,Sanger Hall, Richmond, VA 23298 USA.	yoh@vcu.edu						Ahmed S, 2003, BIOCHEM BIOPH RES CO, V310, P612, DOI 10.1016/j.bbrc.2003.09.058; AKAOGI K, 1994, BIOCHEM BIOPH RES CO, V198, P1046, DOI 10.1006/bbrc.1994.1149; Akaogi K, 1996, CELL GROWTH DIFFER, V7, P1671; BERENDSEN HH, 1989, J CLIN ONCOL, V7, P1614, DOI 10.1200/JCO.1989.7.11.1614; Burger AM, 1998, ONCOGENE, V16, P2459, DOI 10.1038/sj.onc.1201772; Carnaghi C, 2001, ANN ONCOL, V12, pS119, DOI 10.1093/annonc/12.suppl_2.S119; Cersosimo RJ, 2002, AM J HEALTH-SYST PH, V59, P611, DOI 10.1093/ajhp/59.7.611; Chen TS, 1999, CANCER RES, V59, P213; Cox ME, 2000, J BIOL CHEM, V275, P13812, DOI 10.1074/jbc.275.18.13812; Deeble PD, 2001, MOL CELL BIOL, V21, P8471, DOI 10.1128/MCB.21.24.8471-8482.2001; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Gajra A, 2002, LUNG CANCER-J IASLC, V36, P159, DOI 10.1016/S0169-5002(01)00463-9; GAZDAR AF, 1988, CANCER RES, V48, P4078; GOSNEY JR, 1995, THORAX, V50, P116, DOI 10.1136/thx.50.2.116; GRAZIANO SL, 1994, CANCER RES, V54, P2908; Graziano SL, 2001, LUNG CANCER, V33, P115, DOI 10.1016/S0169-5002(01)00183-0; Haugk KL, 2000, ENDOCRINOLOGY, V141, P100, DOI 10.1210/en.141.1.100; Heasley LE, 2001, ONCOGENE, V20, P1563, DOI 10.1038/sj.onc.1204183; Hwa V, 1999, ENDOCR REV, V20, P761, DOI 10.1210/er.20.6.761; Iyoda A, 2001, CANCER, V92, P1108, DOI 10.1002/1097-0142(20010901)92:5<1108::AID-CNCR1427>3.0.CO;2-7; Jiang SX, 1999, MODERN PATHOL, V12, P362; Jiang SX, 1996, AM J PATHOL, V148, P837; Jull BA, 2001, J CANCER RES CLIN, V127, P707; LINNOILA RI, 1994, CHEST S6, V106, P367; Lopez-Bermejo A, 2000, ENDOCRINOLOGY, V141, P4072, DOI 10.1210/en.141.11.4072; MURPHY M, 1993, CELL GROWTH DIFFER, V4, P715; Oh YM, 1996, J BIOL CHEM, V271, P30322, DOI 10.1074/jbc.271.48.30322; Pelosi G, 2003, CANCER-AM CANCER SOC, V97, P2487, DOI 10.1002/cncr.11376; Reynolds SD, 2000, AM J PHYSIOL-LUNG C, V278, pL1256, DOI 10.1152/ajplung.2000.278.6.L1256; Schleusener JT, 1996, CANCER-AM CANCER SOC, V77, P1284, DOI 10.1002/(SICI)1097-0142(19960401)77:7<1284::AID-CNCR9>3.0.CO;2-I; SHAW GL, 1993, CANCER RES, V53, P5181; SKOV BG, 1991, ANN ONCOL, V2, P355, DOI 10.1093/oxfordjournals.annonc.a057955; Sprenger CC, 1999, CANCER RES, V59, P2370; SWISSHELM K, 1995, P NATL ACAD SCI USA, V92, P4472, DOI 10.1073/pnas.92.10.4472; Tureckova J, 2001, J BIOL CHEM, V276, P39264, DOI 10.1074/jbc.M104991200; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wallace WAH, 2002, EUR J SURG ONCOL, V28, P63, DOI 10.1053/ejso.2001.1170; Wilson EM, 1997, J CLIN ENDOCR METAB, V82, P1301, DOI 10.1210/jc.82.4.1301; Wilson EM, 2001, J CLIN ENDOCR METAB, V86, P4504, DOI 10.1210/jc.86.9.4504; YAMAUCHI T, 1994, BIOCHEM J, V303, P591, DOI 10.1042/bj3030591; Yesner R, 2001, EXP MOL PATHOL, V70, P179, DOI 10.1006/exmp.2001.2373	41	26	32	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2006	25	13					1943	1954		10.1038/sj.onc.1209213	http://dx.doi.org/10.1038/sj.onc.1209213			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	024VQ	16302002				2022-12-17	WOS:000236224800011
J	Lausen, J; Liu, S; Fliegauf, M; Lubbert, M; Werner, MH				Lausen, J; Liu, S; Fliegauf, M; Lubbert, M; Werner, MH			ELA2 is regulated by hematopoietic transcription factors, but not repressed by AML1-ETO	ONCOGENE			English	Article						acute myeloid leukemia; neutrophil elastase; gene regulation; AML1-ETO	ACUTE MYELOID-LEUKEMIA; ENCODING NEUTROPHIL ELASTASE; T(8/21) FUSION PROTEIN; C/EBP-ALPHA; GRANULOCYTIC DIFFERENTIATION; TARGET GENE; C-MYB; N-COR; ETO; T(8-21)	A 117 bp fragment of the human ELA2 promoter has been characterized that can act as a minimal promoter for the expression of neutrophil elastase. Chromatin immunoprecipitation and siRNAs revealed that expression of ELA2 is regulated by the acute myeloid human leukemia 1 protein (AML1), C/EBP alpha, PU.1 and c-Myb transcription factors. ELA2 has also been investigated as a possible target of the leukemic fusion protein AML1-ETO resulting from the t(8;21) chromosomal translocation. AML1-ETO, like AML1, binds the ELA2 promoter in the myeloid cell lines Kasumi-1 and U937, but unexpectedly fails to significantly alter expression of ELA2. Although AML1-ETO downregulates the expression of C/EBP alpha, changes in C/EBP alpha expression do not correlate with changes in the expression of ELA2. Our observations indicate that AML1-ETO may not be a constitutive repressor of gene expression in every case in which it can associate with DNA, either on its own or in conjunction with C/EBP alpha. Since neither ETO nor AML1-ETO are typically expressed in hematopoietic progenitors, we hypothesize that it is the interactions between AML1-ETO and regulatory cofactors in disease-state cells that alter gene expression programs during hematopoiesis. These protein-protein interactions may not require simultaneous DNA binding by AML1-ETO for the deleterious effects of the fusion protein to be realized.	Rockefeller Univ, Lab Mol Biophys, New York, NY 10021 USA; Univ Freiburg, Ctr Med, Div Hematol & Oncol, Dept Med, Freiburg, Germany	Rockefeller University; University of Freiburg	Werner, MH (corresponding author), Rockefeller Univ, Lab Mol Biophys, 1230 York Ave,Box 42, New York, NY 10021 USA.	mwerner@portugal.rockefeller.edu						Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Ancliff PJ, 2001, BLOOD, V98, P2645, DOI 10.1182/blood.V98.9.2645; Banker DE, 1998, CLIN CANCER RES, V4, P3051; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Burel SA, 2001, MOL CELL BIOL, V21, P5577, DOI 10.1128/MCB.21.16.5577-5590.2001; Dale DC, 2000, BLOOD, V96, P2317, DOI 10.1182/blood.V96.7.2317.h8002317_2317_2322; ERICKSON P, 1992, BLOOD, V80, P1825; Fliegauf M, 2004, ONCOGENE, V23, P9070, DOI 10.1038/sj.onc.1208042; FOURET P, 1989, J EXP MED, V169, P833, DOI 10.1084/jem.169.3.833; Friedman AD, 2002, ONCOGENE, V21, P3377, DOI 10.1038/sj.onc.1205324; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Heidenreich O, 2003, BLOOD, V101, P3157, DOI 10.1182/blood-2002-05-1589; Hildebrand D, 2001, J BIOL CHEM, V276, P9889, DOI 10.1074/jbc.M010582200; HOHAUS S, 1995, MOL CELL BIOL, V15, P5830; Horwitz M, 1999, NAT GENET, V23, P433, DOI 10.1038/70544; Hug BA, 2004, ONCOGENE, V23, P4270, DOI 10.1038/sj.onc.1207674; Iwama A, 2002, J EXP MED, V195, P547, DOI 10.1084/jem.20011465; Lane AA, 2005, MOL CELL BIOL, V25, P23, DOI 10.1128/MCB.25.1.23-33.2005; Lane AA, 2003, CELL, V115, P305, DOI 10.1016/S0092-8674(03)00852-3; Lausen J, 2004, J BIOL CHEM, V279, P49281, DOI 10.1074/jbc.M407239200; Li FQ, 2004, J BIOL CHEM, V279, P2873, DOI 10.1074/jbc.M310759200; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; Liu SH, 2000, J BIOL CHEM, V275, P41364, DOI 10.1074/jbc.M004172200; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Lutterbach B, 2000, GENE, V245, P223, DOI 10.1016/S0378-1119(00)00014-7; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; Michaud J, 2003, CANCER INVEST, V21, P105, DOI 10.1081/CNV-120018821; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Nuchprayoon I, 1999, J BIOL CHEM, V274, P1085, DOI 10.1074/jbc.274.2.1085; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; Nuchprayoon I, 1997, BLOOD, V89, P4546, DOI 10.1182/blood.V89.12.4546; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Peterson LF, 2004, ONCOGENE, V23, P4255, DOI 10.1038/sj.onc.1207727; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; Shimada H, 2000, BLOOD, V96, P655; Vangala RK, 2003, BLOOD, V101, P270, DOI 10.1182/blood-2002-04-1288; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Wildonger J, 2005, DEVELOPMENT, V132, P2263, DOI 10.1242/dev.01824; YAN M, 2004, P NATL ACAD SCI USA, V49, P17186; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; Zhang JS, 2001, MOL CELL BIOL, V21, P156, DOI 10.1128/MCB.21.1.156-163.2001; Zhang JS, 2004, SCIENCE, V305, P1286, DOI 10.1126/science.1097937	48	26	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1349	1357		10.1038/sj.onc.1209181	http://dx.doi.org/10.1038/sj.onc.1209181			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16247445				2022-12-17	WOS:000235708200008
J	Rotzer, D; Krampert, M; Sulyok, S; Braun, S; Stark, HJ; Boukamp, P; Werner, S				Rotzer, D; Krampert, M; Sulyok, S; Braun, S; Stark, HJ; Boukamp, P; Werner, S			Id proteins: Novel targets of activin action, which regulate epidermal homeostasis	ONCOGENE			English	Article						epidermis; skin; TGF-beta; wound	BONE MORPHOGENETIC PROTEIN; GROWTH-FACTOR-BETA; TRANSGENIC MICE REVEALS; KERATINOCYTE CELL-LINE; LOOP-HELIX PROTEINS; WOUND REPAIR; FUNCTIONAL-CHARACTERIZATION; TRANSCRIPTION FACTOR; BINDING PROTEINS; EPITHELIAL-CELLS	Activin is a member of the transforming growth factor beta (TGF-beta) family, which plays a crucial role in skin morphogenesis and wound healing. To gain insight into the underlying mechanisms of action, we searched for activin-regulated genes in cultured keratinocytes. One of the identified target genes encodes Id1, a negative regulator of helix-loop-helix transcription factors. We show that Id1, Id2, and Id3 are strongly downregulated by activin in keratinocytes in vitro and in vivo. To determine the role of Id1 in keratinocyte biology, we generated stable HaCaT keratinocyte cell lines overexpressing this protein. Our results revealed that enhanced levels of Id1 do not affect proliferation of keratinocytes in monoculture under exponential culture conditions or in response to activin or TGF-beta 1. However, in three-dimensional organotypic cultures, Id1-overexpressing HaCaT cells formed a hyperthickened and disorganized epithelium that was characterized by enhanced keratinocyte proliferation, abnormal differentiation, and an increased rate of apoptosis. These results identify an important function of Id1 in the regulation of epidermal homeostasis.	ETH, Inst Cell Biol, Dept Biol, CH-8093 Zurich, Switzerland; German Canc Res Ctr, Dept Genet Skin Carcinogenesis, Heidelberg, Germany	Swiss Federal Institutes of Technology Domain; ETH Zurich; Helmholtz Association; German Cancer Research Center (DKFZ)	Werner, S (corresponding author), ETH, Inst Cell Biol, Dept Biol, HPM D42, CH-8093 Zurich, Switzerland.	sabine.werner@cell.biol.ethz.ch		Werner, Sabine/0000-0001-7397-8710				Bamberger C, 2005, AM J PATHOL, V167, P733, DOI 10.1016/S0002-9440(10)62047-0; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Bjorntorp E, 2003, ACTA DERM-VENEREOL, V83, P403, DOI 10.1080/00015550310015806; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Chambers RC, 2003, AM J PATHOL, V162, P533, DOI 10.1016/S0002-9440(10)63847-3; Chaturvedi V, 2003, EXP DERMATOL, V12, P255, DOI 10.1034/j.1600-0625.2003.00066.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Cruise BA, 2004, DEV BIOL, V271, P1, DOI 10.1016/j.ydbio.2004.04.003; DEED RW, 1994, GENE, V151, P309, DOI 10.1016/0378-1119(94)90676-9; Frank S, 1996, J BIOL CHEM, V271, P10188, DOI 10.1074/jbc.271.17.10188; HARA E, 1994, J BIOL CHEM, V269, P2139; Hubner G, 1996, DEV BIOL, V173, P490, DOI 10.1006/dbio.1996.0042; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; Kowanetz M, 2004, MOL CELL BIOL, V24, P4241, DOI 10.1128/MCB.24.10.4241-4254.2004; Kretschmer A, 2003, ONCOGENE, V22, P6748, DOI 10.1038/sj.onc.1206791; Kurisaki K, 2003, MOL CELL BIOL, V23, P4494, DOI 10.1128/MCB.23.13.4494-4510.2003; Langlands K, 2000, CANCER RES, V60, P5929; Lasorella A, 2001, ONCOGENE, V20, P8326, DOI 10.1038/sj.onc.1205093; Lin CQ, 1999, ENDOCR-RELAT CANCER, V6, P49, DOI 10.1677/erc.0.0060049; Ling MT, 2002, BBA-GEN SUBJECTS, V1570, P145, DOI 10.1016/S0304-4165(02)00189-7; Maas-Szabowski N, 2003, J CELL SCI, V116, P2937, DOI 10.1242/jcs.00474; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATHEWS LS, 1993, RECEPTOR, V3, P173; Munz B, 1999, EMBO J, V18, P5205, DOI 10.1093/emboj/18.19.5205; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; Ohga E, 1996, BIOCHEM BIOPH RES CO, V228, P391, DOI 10.1006/bbrc.1996.1672; Ruzinova MB, 2003, TRENDS CELL BIOL, V13, P410, DOI 10.1016/S0962-8924(03)00147-8; RYLE CM, 1989, DIFFERENTIATION, V40, P42, DOI 10.1111/j.1432-0436.1989.tb00812.x; Schaefer BM, 2001, EXP CELL RES, V266, P250, DOI 10.1006/excr.2001.5215; Schoop VM, 1999, J INVEST DERMATOL, V112, P343, DOI 10.1046/j.1523-1747.1999.00524.x; Seishima M, 1999, J INVEST DERMATOL, V112, P432, DOI 10.1046/j.1523-1747.1999.00558.x; Shimizu A, 1998, GENES CELLS, V3, P125, DOI 10.1046/j.1365-2443.1998.00174.x; SHIPLEY GD, 1986, CANCER RES, V46, P2068; Siegel PM, 2003, J BIOL CHEM, V278, P35444, DOI 10.1074/jbc.M301413200; Sikder HA, 2003, CANCER CELL, V3, P525, DOI 10.1016/S1535-6108(03)00141-7; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Smola H, 1998, EXP CELL RES, V239, P399, DOI 10.1006/excr.1997.3910; Stark HJ, 1999, J INVEST DERMATOL, V112, P681, DOI 10.1046/j.1523-1747.1999.00573.x; Tsuchida K, 2004, MOL CELL ENDOCRINOL, V220, P59, DOI 10.1016/j.mce.2004.03.009; Wankell M, 2001, J ENDOCRINOL, V171, P385, DOI 10.1677/joe.0.1710385; Wankell M, 2001, EMBO J, V20, P5361, DOI 10.1093/emboj/20.19.5361; Watt FM, 2002, EMBO J, V21, P3919, DOI 10.1093/emboj/cdf399; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; Werner S, 2001, ONCOGENE, V20, P7494, DOI 10.1038/sj.onc.1204937; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; Yamashita S, 2004, J AM SOC NEPHROL, V15, P91, DOI 10.1097/01.ASN.0000103225.68136.E6; Zhang L, 2005, MOL CELL BIOL, V25, P60, DOI 10.1128/MCB.25.1.60-65.2005	50	26	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	14					2070	2081		10.1038/sj.onc.1209230	http://dx.doi.org/10.1038/sj.onc.1209230			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16288215				2022-12-17	WOS:000236359700010
J	Wu, X; Jia, HL; Wang, YF; Ren, N; Ye, QH; Sun, HC; Wang, L; Liu, YK; Tang, ZY; Qin, LX				Wu, X; Jia, HL; Wang, YF; Ren, N; Ye, QH; Sun, HC; Wang, L; Liu, YK; Tang, ZY; Qin, LX			HTPAP gene on chromosome 8p is a candidate metastasis suppressor for human hepatocellular carcinoma	ONCOGENE			English	Article						hepatocellular carcinoma; metastasis; chromosome 8p; HTPAP gene	PUTATIVE-TUMOR-SUPPRESSOR; PROSTATE-CANCER METASTASIS; BLADDER-CANCER; LOCALIZATION; EXPRESSION; HETEROZYGOSITY; DELETION; IDENTIFICATION; IMBALANCE; INTERVAL	Our previous studies suggested that chromosome 8p deletion is associated with metastasis of hepatocellular carcinoma (HCC), in which some novel metastasis suppressor genes might be harbored. The present study aimed to identify the metastatic suppressor gene(s). A cDNA chip was constructed with the expressed sequence tags (ESTs) from chromosome 8p and used to compare the difference of expression pro. ling between the MHCC97-H and MHCC97-L cell lines with different metastatic potentials and similar genetic backgrounds. In all, 10 ESTs were significantly downregulated in MHCC97-H cell line with higher metastatic potential. One full-length gene, HTPAP (phosphatidic acid phosphatase type 2 domain containing 1B), was identified at chromosome 8p12. Sequencing and bioinformatic analyses revealed that HTPAP has 826 bp and encodes a putative protein of 175 amino acids with a transmembrane segment at the NH2 terminus, two protein kinase C phosphorylation site and one tyrosine kinase phosphorylation site. Its expression level in metastatic tumor tissues was much lower than that of primary HCC tissues. Both in vitro and in vivo assays suggested that HTPAP could suppress the invasion and metastasis of HCC. These suggested that HTPAP is a novel metastatic suppressor gene for HCC. The mechanism of the effect of HTPAP on HCC metastasis is not clear yet and deserves further investigation.	Fudan Univ, Liver Canc Inst, Shanghai 200032, Peoples R China; Fudan Univ, Zhongshan Hosp, Shanghai 200032, Peoples R China	Fudan University; Fudan University	Qin, LX (corresponding author), Fudan Univ, Liver Canc Inst, 180 Feng Lin Rd, Shanghai 200032, Peoples R China.	lxqin@zshospital.com	Wu, Xin/B-2244-2010	Ren, Ning/0000-0001-9776-2471; Sun, Hui-Chuan/0000-0003-3761-7058				Arai T, 1998, INT J CANCER, V79, P418, DOI 10.1002/(SICI)1097-0215(19980821)79:4<418::AID-IJC18>3.0.CO;2-0; Armes JE, 2004, ONCOGENE, V23, P5697, DOI 10.1038/sj.onc.1207740; Berger JC, 2004, ANTI-CANCER DRUG, V15, P559, DOI 10.1097/01.cad.0000132233.36512.fa; Bissig H, 1999, AM J PATHOL, V155, P267, DOI 10.1016/S0002-9440(10)65120-6; Bogenrieder T, 2003, ONCOGENE, V22, P6524, DOI 10.1038/sj.onc.1206757; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Giannelli G, 2002, AM J PATHOL, V161, P183, DOI 10.1016/S0002-9440(10)64170-3; Hussain SA, 2001, ANN ONCOL, V12, P161, DOI 10.1023/A:1008370324827; Ishii H, 1999, P NATL ACAD SCI USA, V96, P3928, DOI 10.1073/pnas.96.7.3928; Kauffman EC, 2003, J UROLOGY, V169, P1122, DOI 10.1097/01.ju.0000051580.89109.4b; Keller ET, 2004, CANCER LETT, V207, P131, DOI 10.1016/j.canlet.2004.02.006; Kujawski M, 1999, GENE CHROMOSOME CANC, V26, P253, DOI 10.1002/(SICI)1098-2264(199911)26:3<253::AID-GCC10>3.0.CO;2-A; Letunic I, 2004, NUCLEIC ACIDS RES, V32, pD142, DOI 10.1093/nar/gkh088; Li SP, 2001, J HEPATOL, V34, P840, DOI 10.1016/S0168-8278(01)00047-2; Li Y, 2004, J CANCER RES CLIN, V130, P460, DOI 10.1007/s00432-004-0564-9; Liao C, 2000, HEPATOLOGY, V32, P721, DOI 10.1053/jhep.2000.17967; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Muscheck M, 2000, LAB INVEST, V80, P1089, DOI 10.1038/labinvest.3780114; Nihei N, 2002, CANCER RES, V62, P367; Nonaka D, 2005, CANCER RES, V65, P1207, DOI 10.1158/0008-5472.CAN-04-3461; Ohgaki K, 1999, GENE CHROMOSOME CANC, V25, P1, DOI 10.1002/(SICI)1098-2264(199905)25:1<1::AID-GCC1>3.0.CO;2-3; Parada LA, 1999, CLIN EXP METASTAS, V17, P471, DOI 10.1023/A:1006646901556; Park WS, 2002, CANCER LETT, V178, P199, DOI 10.1016/S0304-3835(01)00841-2; Petersen S, 2000, BRIT J CANCER, V82, P65; Qin LX, 1999, CANCER RES, V59, P5662; Qin LX, 2001, J CANCER RES CLIN, V127, P482, DOI 10.1007/s004320100236; Takanishi DM, 1997, MOL DIAGN, V2, P3, DOI 10.1016/S1084-8592(97)80003-3; Takeo S, 2001, CANCER GENET CYTOGEN, V130, P127, DOI 10.1016/S0165-4608(01)00479-4; Tang ZY, 2001, WORLD J GASTROENTERO, V7, P445; Tang ZY, 2004, J CANCER RES CLIN, V130, P187, DOI 10.1007/s00432-003-0511-1; Tang ZY, 2000, J GASTROEN HEPATOL, V15, pG1, DOI 10.1046/j.1440-1746.2000.02257.x; Tantivejkul K, 2004, J CELL BIOCHEM, V91, P706, DOI 10.1002/jcb.10664; Thiagalingam S, 2002, CURR OPIN ONCOL, V14, P65, DOI 10.1097/00001622-200201000-00012; Wagner U, 1997, AM J PATHOL, V151, P753; Wang G, 2001, GENE CHROMOSOME CANC, V31, P221, DOI 10.1002/gcc.1138; Wang ZX, 2001, BRIT J CANCER, V85, P1162, DOI 10.1054/bjoc.2001.2059; Xu L, 2001, CANCER RES, V61, P3176; Yokota T, 1999, CANCER-AM CANCER SOC, V85, P447; Yuan BZ, 1998, CANCER RES, V58, P2196; Zhang LH, 2003, J CANCER RES CLIN, V129, P279, DOI 10.1007/s00432-002-0407-5	40	26	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	12					1832	1840		10.1038/sj.onc.1209191	http://dx.doi.org/10.1038/sj.onc.1209191			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	021VJ	16261160				2022-12-17	WOS:000236013700016
J	Hasina, R; Pontier, AL; Fekete, MJ; Martin, LE; Qi, XM; Brigaudeau, C; Pramanik, R; Cline, EI; Coignet, LJ; Lingen, MW				Hasina, R; Pontier, AL; Fekete, MJ; Martin, LE; Qi, XM; Brigaudeau, C; Pramanik, R; Cline, EI; Coignet, LJ; Lingen, MW			NOL7 is a nucleolar candidate tumor suppressor gene in cervical cancer that modulates the angiogenic phenotype	ONCOGENE			English	Article						cervical cancer; nucleolus; tumor suppressor gene; angiogenesis; VEGF; TSP-1	THROMBOSPONDIN-1 EXPRESSION; P53 GENE; IN-VIVO; CARCINOMA; RNA; IDENTIFICATION; PROGRESSION; REPRESSION; INDUCTION; LEUKEMIA	Cervical cancer is associated with human papilloma virus infection. However, this infection is insufficient to induce transformation and progression. Loss of heterozygosity analyses suggest the presence of a tumor suppressor gene (TSG) on chromosome 6p21.3-p25. Here we report the cloning NOL7, its mapping to chromosome band 6p23, and localization of the protein to the nucleolus. Fluorescence in situ hybridization analysis demonstrated an allelic loss of an NOL7 in cultured tumor cells and human tumor samples. Transfection of NOL7 into cervical carcinoma cells inhibited their growth in mouse xenografts, confirming its in vivo tumor suppressor activity. The induction of tumor dormancy correlated with an angiogenic switch caused by a decreased production of vascular endothelial growth factor and an increase in the production of the angiogenesis inhibitor thrombospondin-1. These data suggest that NOL7 may function as a TSG in part by modulating the expression of the angiogenic phenotype.	Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA; Vet Affairs Edward Hines Jr Hosp, Maywood, IL USA; Loyola Univ, Med Ctr, Maywood, IL 60153 USA; Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	University of Chicago; University of Chicago; University of Chicago; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; Loyola University Chicago; Roswell Park Cancer Institute	Lingen, MW (corresponding author), Univ Chicago, Dept Pathol, MC 6101,5841 S Maryland Ave, Chicago, IL 60637 USA.	mark.lingen@uchospitals.edu			NIDCR NIH HHS [DE12322, DE00470] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012322] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; Cannistra SA, 1996, NEW ENGL J MED, V334, P1030, DOI 10.1056/NEJM199604183341606; CHEN TM, 1993, CANCER RES, V53, P1167; Chen Z, 2000, CANCER GENET CYTOGEN, V121, P22, DOI 10.1016/S0165-4608(00)00222-3; Claudio PP, 2001, CANCER RES, V61, P462; Coignet LJA, 1999, GENE CHROMOSOME CANC, V25, P222, DOI 10.1002/(SICI)1098-2264(199907)25:3<222::AID-GCC4>3.0.CO;2-C; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Dejong V, 1999, ONCOGENE, V18, P3143, DOI 10.1038/sj.onc.1202654; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Huettner PC, 1998, HUM PATHOL, V29, P364, DOI 10.1016/S0046-8177(98)90117-4; Jinawath N, 2004, CANCER SCI, V95, P430, DOI 10.1111/j.1349-7006.2004.tb03227.x; Kersemaekers AMF, 1998, INT J CANCER, V79, P411, DOI 10.1002/(SICI)1097-0215(19980821)79:4<411::AID-IJC17>3.3.CO;2-Z; Kraemer M, 1999, CELL GROWTH DIFFER, V10, P193; Lazo PA, 1999, BRIT J CANCER, V80, P2008, DOI 10.1038/sj.bjc.6690635; Lingen MW, 1998, CANCER RES, V58, P5551; Lingen MW, 1997, CARCINOGENESIS, V18, P329, DOI 10.1093/carcin/18.2.329; LINGEN MW, 2002, WOUND HEALING METHOD, P337; Marconcini L, 1999, P NATL ACAD SCI USA, V96, P9671, DOI 10.1073/pnas.96.17.9671; MITRA AB, 1994, CANCER RES, V54, P4481; MONTGOMERY KD, 1995, GENE CHROMOSOME CANC, V14, P97, DOI 10.1002/gcc.2870140203; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; Muliokandov MR, 1996, CANCER RES, V56, P197; Nagai H, 1999, GENE CHROMOSOME CANC, V25, P277, DOI 10.1002/(SICI)1098-2264(199907)25:3<277::AID-GCC10>3.0.CO;2-L; Nakase K, 2000, LEUKEMIA RES, V24, P79, DOI 10.1016/S0145-2126(99)00139-3; Olson MOJ, 2000, TRENDS CELL BIOL, V10, P189, DOI 10.1016/S0962-8924(00)01738-4; Rader JS, 2000, GENE CHROMOSOME CANC, V27, P373, DOI 10.1002/(SICI)1098-2264(200004)27:4<373::AID-GCC6>3.0.CO;2-V; RAK J, 1995, CANCER RES, V55, P4575; Sheibani N, 1996, CANCER LETT, V107, P45, DOI 10.1016/0304-3835(96)04341-8; SLACK JL, 1994, CELL GROWTH DIFFER, V5, P1373; SRIVASTAVA S, 1992, CARCINOGENESIS, V13, P1273, DOI 10.1093/carcin/13.7.1273; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Takeshita A, 2004, CANCER GENET CYTOGEN, V152, P56, DOI 10.1016/j.cancergencyto.2003.10.002; Tikhonenko AT, 1996, J BIOL CHEM, V271, P30741, DOI 10.1074/jbc.271.48.30741; UEJIMA H, 1995, GENE CHROMOSOME CANC, V14, P120, DOI 10.1002/gcc.2870140206; Visintin R, 2000, CURR OPIN CELL BIOL, V12, P372, DOI 10.1016/S0955-0674(00)00102-2; Volpert OV, 1997, ONCOGENE, V14, P1495, DOI 10.1038/sj.onc.1200977; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Watnick RS, 2003, CANCER CELL, V3, P219, DOI 10.1016/S1535-6108(03)00030-8; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Wen SH, 2001, P NATL ACAD SCI USA, V98, P4622, DOI 10.1073/pnas.081063798; Wolf JK, 2001, CANCER INVEST, V19, P621, DOI 10.1081/CNV-100104290; YAGINUMA Y, 1991, CANCER RES, V51, P6506; ZABRENETZKY V, 1994, INT J CANCER, V59, P191, DOI 10.1002/ijc.2910590209; Zhang YW, 2003, P NATL ACAD SCI USA, V100, P12718, DOI 10.1073/pnas.2135113100	45	26	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	4					588	598		10.1038/sj.onc.1209070	http://dx.doi.org/10.1038/sj.onc.1209070			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	006KW	16205646	Bronze			2022-12-17	WOS:000234897400010
J	Vera, J; Jaumot, M; Estanyol, JM; Brun, S; Agell, N; Bachs, O				Vera, J; Jaumot, M; Estanyol, JM; Brun, S; Agell, N; Bachs, O			Heterogeneous nuclear ribonucleoprotein A2 is a SET-binding protein and a PP2A inhibitor	ONCOGENE			English	Article						SET protein; hnRNPA2; PP2A; cell cycle	LUNG-CANCER DETECTION; ACTIVATING FACTOR-I; PHOSPHATASE 2A; GRANZYME-A; MESSENGER-RNA; FISSION YEAST; RETINOBLASTOMA PROTEIN; TUMOR-SUPPRESSOR; CELL-CYCLE; HNRNP A2	The oncoprotein SET participates in a diversity of cellular functions including cell proliferation. Its role on cell cycle progression is likely mediated by inhibiting cyclin B-cdk1 and the protein phosphatase 2A (PP2A). On identifying new SET cellular partners, we found that SET interacts in vitro and in vivo with the heterogeneous nuclear ribonucleoprotein A2(hnRNPA2); a protein involved in various aspects of mRNA biogenesis. The SET-binding region of hnRNPA2 is the RNP1 sequence that belongs to the RNA-binding domain (RBD) of this protein. We also found that hnRNPA2 has much higher affinity for single-standed DNA than for SET. On analysing the effect of hnRNPA2 on PP2A inhibition by SET, we observed that hnRNPA2 cooperates with SET on PP2A inhibition. This is because we found that hnRNPA2 is also a PP2A inhibitor. HnRNPA2 interacts with PP2A by the RNP1 sequence; however, to inhibit PP2A activity, the complete RBD is needed. We also observed that overexpression of hnRNPA2 inhibits PP2A activity and stimulates cell proliferation. Interestingly, the overexpression of the complete RBD is sufficient to stimulate proliferation. As hnRNPA2 is overexpressed in a variety of human tumors, our results suggest that hnRNPA2 might participate in oncogenesis by stimulating cell proliferation.	Univ Barcelona, Fac Med, Dept Cell Biol & Pathol, Barcelona, Spain	University of Barcelona	Bachs, O (corresponding author), Univ Barcelona, Fac Med, Dept Biol Cellular & Anat Patol, Casanova 143, E-08036 Barcelona, Spain.	obachs@ub.edu	Estanyol, Josep M/I-1039-2015; Agell, Neus/E-9640-2016; Jaumot, Montserrat/F-2640-2016; Brun, Sonia/AAA-4585-2019	Estanyol, Josep M/0000-0001-8621-0057; Agell, Neus/0000-0002-1205-6074; Brun, Sonia/0000-0002-2056-3180; Jaumot, Montserrat/0000-0003-2864-357X				Adler HT, 1997, J BIOL CHEM, V272, P28407, DOI 10.1074/jbc.272.45.28407; Ainger K, 1997, J CELL BIOL, V138, P1077, DOI 10.1083/jcb.138.5.1077; Beresford PJ, 2001, J BIOL CHEM, V276, P43285, DOI 10.1074/jbc.M108137200; BOSSER R, 1995, MOL CELL BIOL, V15, P661; Canela N, 2003, J BIOL CHEM, V278, P1158, DOI 10.1074/jbc.M207497200; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; Chou DM, 2002, J BIOL CHEM, V277, P40520, DOI 10.1074/jbc.M207226200; CLARKE PR, 1993, MOL BIOL CELL, V4, P397, DOI 10.1091/mbc.4.4.397; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Elder RT, 2001, VIROLOGY, V287, P359, DOI 10.1006/viro.2001.1007; Estanyol JM, 1999, J BIOL CHEM, V274, P33161, DOI 10.1074/jbc.274.46.33161; Fan ZS, 2003, CELL, V112, P659, DOI 10.1016/S0092-8674(03)00150-8; Fan ZS, 2002, MOL CELL BIOL, V22, P2810, DOI 10.1128/MCB.22.8.2810-2820.2002; Fan ZS, 2003, NAT IMMUNOL, V4, P145, DOI 10.1038/ni885; Fielding P, 1999, CLIN CANCER RES, V5, P4048; Ford LP, 2002, ONCOGENE, V21, P580, DOI 10.1038/sj.onc.1205086; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; KELLOGG DR, 1995, J CELL BIOL, V130, P661, DOI 10.1083/jcb.130.3.661; KINOSHITA N, 1993, GENE DEV, V7, P1059, DOI 10.1101/gad.7.6.1059; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Kutney SN, 2004, J BIOL CHEM, V279, P30850, DOI 10.1074/jbc.M404969200; Kwon S, 1999, J CELL BIOL, V147, P247, DOI 10.1083/jcb.147.2.247; Li M, 1996, BIOCHEMISTRY-US, V35, P6998, DOI 10.1021/bi960581y; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; Lieberman J, 2003, CURR OPIN IMMUNOL, V15, P553, DOI 10.1016/S0952-7915(03)00108-0; MATSUMOTO K, 1993, J BIOL CHEM, V268, P10582; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Moran-Jones K, 2005, NUCLEIC ACIDS RES, V33, P486, DOI 10.1093/nar/gki203; Mulshine JL, 2000, CANCER-AM CANCER SOC, V89, P2465; Okuwaki M, 1998, J BIOL CHEM, V273, P34511, DOI 10.1074/jbc.273.51.34511; Pandey AV, 2003, J BIOL CHEM, V278, P2837, DOI 10.1074/jbc.M209527200; Patry C, 2003, CANCER RES, V63, P7679; Qu DB, 2002, J BIOL CHEM, V277, P7324, DOI 10.1074/jbc.M107270200; Sanchez-Piris M, 2002, J BIOL CHEM, V277, P17722, DOI 10.1074/jbc.M200104200; SCHONTHAL A, 1993, ONCOGENE, V8, P433; Schonthal AH, 2001, CANCER LETT, V170, P1, DOI 10.1016/S0304-3835(01)00561-4; Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092-8674(01)00196-9; Shikama N, 2000, MOL CELL BIOL, V20, P8933, DOI 10.1128/MCB.20.23.8933-8943.2000; Tockman MS, 1997, CLIN CANCER RES, V3, P2237; Van Hoof C, 2004, CANCER CELL, V5, P105, DOI 10.1016/S1535-6108(04)00027-3; VON LM, 1992, MOL CELL BIOL, V12, P3346; Yan Y, 1999, J BIOL CHEM, V274, P31917, DOI 10.1074/jbc.274.45.31917; Yan-Sanders Y, 2002, CANCER LETT, V183, P215, DOI 10.1016/S0304-3835(02)00168-4; Zhou J, 2001, BREAST CANCER RES TR, V66, P217, DOI 10.1023/A:1010631915831	44	26	26	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	2					260	270		10.1038/sj.onc.1209050	http://dx.doi.org/10.1038/sj.onc.1209050			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16170352				2022-12-17	WOS:000234583600010
J	Popov, N; Wahlstrom, T; Hurlin, PJ; Henriksson, M				Popov, N; Wahlstrom, T; Hurlin, PJ; Henriksson, M			Mnt transcriptional repressor is functionally regulated during cell cycle progression	ONCOGENE			English	Article						Myc; Mnt; mSin3; transcriptional repression; phosphorylation; HDAC activity	MAX-INTERACTING PROTEIN; HISTONE DEACETYLASE ACTIVITY; DNA-BINDING ACTIVITY; C-MYC; INDUCED-DIFFERENTIATION; MYC/MAX/MAD NETWORK; GENE-EXPRESSION; DROSOPHILA MYC; GROWTH; DOMAIN	The Myc/Max/Mad network of transcription factors regulates cell proliferation, differentiation, and transformation. Similar to other proteins of the network, Mnt forms heterodimers with Max and binds CACGTG E-Box elements. Transcriptional repression by Mnt is mediated through association with mSin3, and deletion of the mSin3-interacting domain (SID) converts Mnt to a transcriptional activator. Mnt is coexpressed with Myc in proliferating cells and has been suggested to be a modulator of Myc function. We report that Mnt is expressed both in growth-arrested and proliferating mouse fibroblasts and is phosphorylated when resting cells are induced to re-enter the cell cycle. Importantly, the interaction between Mnt and mSin3 is disrupted upon serum stimulation resulting in decreased Mnt-associated HDAC activity. Furthermore, we demonstrate that Mnt binds and recruits mSin3 to the Myc target gene cyclin D2 in quiescent mouse fibroblasts. Interference with Mnt expression by RNAi resulted in upregulation of cyclin D2 expression in growth-arrested fibroblasts, supporting the view that Mnt represses cyclin D2 transcription in quiescent cells. Our data suggest a model in which phosphorylation of Mnt at cell cycle entry results in disruption of Mnt-mSin3-HDAC1 interaction, which allows induction of Myc target genes by release of Mnt-mediated transcriptional repression.	Karolinska Inst, Microbiol & Tumor Biol Ctr, SE-17177 Stockholm, Sweden; Shriners Hosp Children, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA	Karolinska Institutet; Oregon Health & Science University	Henriksson, M (corresponding author), Karolinska Inst, Microbiol & Tumor Biol Ctr, Box 280, SE-17177 Stockholm, Sweden.	Marie.Henriksson@mtc.ki.se	Henriksson, Marie Arsenian/F-5010-2015	Arsenian Henriksson, Marie/0000-0001-6376-7792				AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, GENE DEV, V7, P2120; Barrera-Hernandez G, 2000, MOL CELL BIOL, V20, P4253, DOI 10.1128/MCB.20.12.4253-4264.2000; Bejarano MT, 2000, EXP CELL RES, V260, P61, DOI 10.1006/excr.2000.4996; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; BOUSSET K, 1993, ONCOGENE, V8, P3211; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; Cvekl A, 2004, EUR J CANCER, V40, P2525, DOI 10.1016/j.ejca.2004.08.005; Eberhardy SR, 2000, J BIOL CHEM, V275, P33798, DOI 10.1074/jbc.M005154200; Ellenrieder V, 2002, EMBO J, V21, P2451, DOI 10.1093/emboj/21.10.2451; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hurlin PJ, 1997, CURR TOP MICROBIOL, V224, P115; Hurlin PJ, 1999, EMBO J, V18, P7019, DOI 10.1093/emboj/18.24.7019; Hurlin PJ, 2004, CELL CYCLE, V3, P97; Hurlin PJ, 2003, EMBO J, V22, P4584, DOI 10.1093/emboj/cdg442; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Imai Y, 2004, MOL CELL BIOL, V24, P1033, DOI 10.1128/MCB.24.3.1033-1043.2004; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LARSSON LG, 1994, ONCOGENE, V9, P1247; Mao DYL, 2003, CURR BIOL, V13, P882, DOI 10.1016/S0960-9822(03)00297-5; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; Nigro Cristina Lo, 1998, Genomics, V49, P275, DOI 10.1006/geno.1998.5241; Nilsson JA, 2004, CELL CYCLE, V3, P588; Nilsson JA, 2004, MOL CELL BIOL, V24, P1560, DOI 10.1128/MCB.24.4.1560-1569.2004; O'Connell BC, 2003, J BIOL CHEM, V278, P12563, DOI 10.1074/jbc.M210462200; Orian A, 2003, GENE DEV, V17, P1101, DOI 10.1101/gad.1066903; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Park J, 2001, GENE DEV, V15, P1619, DOI 10.1101/gad.900101; Peyrefitte S, 2001, MECH DEVELOP, V104, P99, DOI 10.1016/S0925-4773(01)00360-4; Queva C, 1998, ONCOGENE, V16, P967, DOI 10.1038/sj.onc.1201611; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Smith AG, 2004, J CELL BIOCHEM, V92, P1282, DOI 10.1002/jcb.20121; Sommer A, 1999, INT J CANCER, V82, P810, DOI 10.1002/(SICI)1097-0215(19990909)82:6<810::AID-IJC7>3.0.CO;2-V; Sommer A, 1997, CURR BIOL, V7, P357, DOI 10.1016/S0960-9822(06)00183-7; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Takahashi T, 1998, JPN J CANCER RES, V89, P347, DOI 10.1111/j.1349-7006.1998.tb00569.x; Toyo-oka K, 2004, HUM MOL GENET, V13, P1057, DOI 10.1093/hmg/ddh116; Walker W, 2005, J CELL BIOL, V169, P405, DOI 10.1083/jcb.200411013; Wanzel M, 2003, TRENDS CELL BIOL, V13, P146, DOI 10.1016/S0962-8924(03)00003-5; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	53	26	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2005	24	56					8326	8337		10.1038/sj.onc.1208961	http://dx.doi.org/10.1038/sj.onc.1208961			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	993LV	16103876				2022-12-17	WOS:000233956500011
J	Jarvis, MC; Gray, TJB; Palmer, CNA				Jarvis, MC; Gray, TJB; Palmer, CNA			Both PPAR gamma and PPAR delta influence sulindac sulfide-mediated p21(WAF1/CIP1) upregulation in a human prostate epithelial cell line	ONCOGENE			English	Article						PPAR gamma; PPAR delta; p21; prostate cancer; NSAIDs	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ACTIVATED RECEPTOR-GAMMA; COLON-CANCER CELLS; COLORECTAL-CANCER; CARCINOGENESIS; PROLIFERATION; EXPRESSION; PROTEINS; TARGET; ALPHA	Nonsteroidal anti-inflammatory drugs (NSAIDs) including sulindac sulfide are known to exert cancer chemo-preventative activity in a range of cell lines. This activity has been shown to involve the upregulation of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1). It is also known that NSAIDs can act as peroxisome proliferator-activated receptor (PPAR) agonists and antagonists. In this study, we show that sulindac sulfide acts both as a PPARc agonist and a PPAR delta antagonist in an immortalized prostatic epithelial cell line (PNT1A). We utilized siRNA technology to show that PPAR gamma is required for both growth inhibition and p21(WAF1/CIP1) upregulation in response to sulindac sulfide treatment in PNT1A cells. In addition, the overexpression of PPARd partially rescued these cells from growth inhibition and also dramatically inhibited sulindac sulfide-mediated p21(WAF1/CIP1) upregulation. Together these data identify a novel link between PPAR gamma/PPAR delta/p21(WAF1/CIP1) and the cancer chemo-preventative properties of NSAIDs.	Univ Dundee, Ninewells Hosp & Med Sch, Ctr Biomed Res, Dundee DD1 9SY, Scotland; Sanofi Aventis, Dept Toxicol, Alnwick, England	University of Dundee; Sanofi-Aventis	Palmer, CNA (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Ctr Biomed Res, Dundee DD1 9SY, Scotland.	colin.palmer@cancer.org.uk	Palmer, Colin NA/C-7053-2008	Palmer, Colin NA/0000-0002-6415-6560				Adamson DJA, 2002, MOL PHARMACOL, V61, P7, DOI 10.1124/mol.61.1.7; CUSSENOT O, 1991, J UROLOGY, V146, P881, DOI 10.1016/S0022-5347(17)37953-3; Fredersdorf S, 1996, AM J PATHOL, V148, P825; Goldberg Y, 1996, ONCOGENE, V12, P893; Gupta RA, 2000, P NATL ACAD SCI USA, V97, P13275, DOI 10.1073/pnas.97.24.13275; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hong J, 2004, ENDOCRINOLOGY, V145, P5774, DOI 10.1210/en.2004-0686; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; LUPULESCU A, 1978, NATURE, V272, P634, DOI 10.1038/272634a0; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Morrison RF, 1999, J CELL BIOCHEM, P59; Mueller E, 2000, P NATL ACAD SCI USA, V97, P10990, DOI 10.1073/pnas.180329197; Nelson JE, 2000, ONCOL REP, V7, P169; Park BH, 2001, P NATL ACAD SCI USA, V98, P2598, DOI 10.1073/pnas.051630998; Piazza GA, 1997, CANCER RES, V57, P2909; Smalley W E, 1997, Adv Pharmacol, V39, P1, DOI 10.1016/S1054-3589(08)60067-8; Stephen RL, 2004, CANCER RES, V64, P3162, DOI 10.1158/0008-5472.CAN-03-2760; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Vosper H, 2001, J BIOL CHEM, V276, P44258, DOI 10.1074/jbc.M108482200; Wick M, 2002, MOL PHARMACOL, V62, P1207, DOI 10.1124/mol.62.5.1207; Yang WC, 2001, CANCER RES, V61, P6297; Young V, 2002, RHEUMATOLOGY, V41, P869, DOI 10.1093/rheumatology/41.8.869	23	26	31	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2005	24	55					8211	8215		10.1038/sj.onc.1208983	http://dx.doi.org/10.1038/sj.onc.1208983			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	991JL	16091736				2022-12-17	WOS:000233809400013
J	Jin, J; Woodgett, JR				Jin, J; Woodgett, JR			Chronic activation of protein kinase B beta/Akt2 leads to multinucleation and cell fusion in human epithelial kidney cells: events associated with tumorigenesis	ONCOGENE			English	Article						PKB; Akt; cell fusion; tumorigenesis; tamoxifen-induced; cytokinesis; endomitosis/endoreplication; phagocytosis; pinocytosis; autophagy	HUMAN BREAST; HUMAN CANCER; PHOSPHOINOSITIDE 3-KINASE; CENTROSOME AMPLIFICATION; TRANSCRIPTION FACTOR; PATHWAY; AKT; PHOSPHORYLATION; OVEREXPRESSION; DICTYOSTELIUM	Most cancers arise from the stepwise accumulation of genetic changes. There is also evidence for defects in the machinery and checkpoints for maintenance of normal diploid chromosome complements, resulting in genetic instability that helps fuel the accumulation of mutations that contribute to the development of cancer. The protooncogene protein kinase B (PKB/Akt), and its regulators including phosphatidylinositol 3' kinase and PTEN, has been shown to play critical roles in the regulation of multiple cellular functions such as transcription, cell survival, cell cycle progression, angiogenesis and cell motility - all of which are important to the malignant process. Here, we report the use of a membrane targeted PKB beta, the activation of which is under the control of a 4-hydroxy-Tamoxifen-responsive estrogen-receptor (ER) ligand binding domain. Induction of PKB beta-ER activity in human kidney epithelial cells (HEK293) resulted in changes in cellular growth, size, and in the appearance of aneuploid cells. Over time, in a PKB beta-dependent manner, cells also underwent extensive multinucleation caused due to a combination of both endomitosis and cell fusion. These findings suggest that chronic activation of PKB beta may contribute to genetic instability and autophagy, properties commonly found in tumor cells.	Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Ontario Canc Inst, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto	Woodgett, JR (corresponding author), Dept Med Biophys, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	jwoodget@uhnres.utoronto.ca	Woodgett, Jim/F-1087-2010	Woodgett, Jim/0000-0003-3731-5797				Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Arboleda MJ, 2003, CANCER RES, V63, P196; Bacus SS, 2002, ONCOGENE, V21, P3532, DOI 10.1038/sj.onc.1205438; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; Botelho RJ, 2004, CURR TOP MICROBIOL, V282, P1; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Chung CY, 2001, MOL CELL, V7, P937, DOI 10.1016/S1097-2765(01)00247-7; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Ellson CD, 2001, CURR BIOL, V11, P1631, DOI 10.1016/S0960-9822(01)00447-X; Funakoshi E, 2003, BMC CELL BIOL, V4, DOI 10.1186/1471-2121-4-12; Funamoto S, 2001, J CELL BIOL, V153, P795, DOI 10.1083/jcb.153.4.795; Goepfert TM, 2000, CURR TOP DEV BIOL, V49, P331; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hannak E, 2001, J CELL BIOL, V155, P1109, DOI 10.1083/jcb.200108051; Hutchinson JN, 2004, CANCER RES, V64, P3171, DOI 10.1158/0008-5472.CAN-03-3465; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Jin J, 2001, DEV CELL, V1, P817, DOI 10.1016/S1534-5807(01)00090-9; Katayama H, 1999, J NATL CANCER I, V91, P1160, DOI 10.1093/jnci/91.13.1160; Kenerson HL, 2002, CANCER RES, V62, P5645; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Mirza AM, 2000, CELL GROWTH DIFFER, V11, P279; Miyoshi Y, 2001, INT J CANCER, V92, P370, DOI 10.1002/ijc.1200; Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022; Otto SP, 2000, ANNU REV GENET, V34, P401, DOI 10.1146/annurev.genet.34.1.401; Razzini G, 2000, FASEB J, V14, P1179, DOI 10.1096/fasebj.14.9.1179; Rupper A, 2001, MOL BIOL CELL, V12, P2813, DOI 10.1091/mbc.12.9.2813; Rupper AC, 2001, J CELL SCI, V114, P1283; Russell DG, 2001, NAT REV MOL CELL BIO, V2, P569, DOI 10.1038/35085034; Sakakura C, 2001, BRIT J CANCER, V84, P824, DOI 10.1054/bjoc.2000.1684; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Scheid MP, 2002, MOL CELL BIOL, V22, P6247, DOI 10.1128/MCB.22.17.6247-6260.2002; Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065; Stephens L, 2002, CURR OPIN CELL BIOL, V14, P203, DOI 10.1016/S0955-0674(02)00311-3; Storchova Z, 2004, NAT REV MOL CELL BIO, V5, P45, DOI 10.1038/nrm1276; Sulis ML, 2003, TRENDS CELL BIOL, V13, P478, DOI 10.1016/S0962-8924(03)00175-2; Tee AR, 2003, J BIOL CHEM, V278, P37288, DOI 10.1074/jbc.M303257200; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Woods YL, 2001, BIOCHEM J, V355, P597, DOI 10.1042/bj3550597; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	50	26	26	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 18	2005	24	35					5459	5470		10.1038/sj.onc.1208704	http://dx.doi.org/10.1038/sj.onc.1208704			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	955JN	16007218				2022-12-17	WOS:000231222300006
J	Galm, O; Suzuki, H; Akiyama, Y; Esteller, M; Brock, MV; Osieka, R; Baylin, SB; Herman, JG				Galm, O; Suzuki, H; Akiyama, Y; Esteller, M; Brock, MV; Osieka, R; Baylin, SB; Herman, JG			Inactivation of the tissue inhibitor of metalloproteinases-2 gene by promoter hypermethylation in lymphoid malignancies	ONCOGENE			English	Article						promoter hypermethylation; non-Hodgkin's lymphoma; matrix metalloproteinases; angiogenesis	ENDOTHELIAL GROWTH-FACTOR; MATRIX METALLOPROTEINASES; CPG ISLAND; METHYLATION; EXPRESSION; TIMP-2; ANGIOGENESIS; PATTERNS; METHYLTRANSFERASE; SURVIVAL	The tissue inhibitor of metalloproteinases-2 (TIMP-2) is known to antagonize matrix metalloproteinase activity and to suppress tumor growth, angiogenesis, invasion and metastasis. We analysed the methylation status of the CpG island in the TIMP-2 promoter region by methylation-specific polymerase chain reaction (MSP) in hematopoietic cell lines. TIMP-2 promoter hypermethylation in the lymphoma cell line Raji and the leukemia cell line KG1a was associated with transcriptional repression. Treatment with the demethylating agent 5-aza-2'-deoxycytidine resulted in TIMP-2 upregulation in both cell lines. TIMP-2 was expressed in the cell lines HL60, U266 and XG1, which carry an unmethylated promoter region. MSP analysis of primary patient samples revealed aberrant methylation of TIMP-2 in 33/90 (36.7%) cases of non- Hodgkin's lymphoma (NHL), but not in normal peripheral blood lymphocytes as well as in nonmalignant bone marrow and lymph nodes. The frequency of TIMP-2 methylation was slightly higher in aggressive NHL subtypes compared to those with an indolent subtype (38.6 versus 33.3%). In contrast, TIMP-2 was not hypermethylated in any of the 40 cases of acute myelogenous leukemia examined. We conclude that promoter hypermethylation of TIMP-2 is a novel epigenetic event in the pathogenesis of lymphoid malignancies and may contribute to a more aggressive NHL phenotype.	Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD 21231 USA; Univ Klinikum Aachen, Med Klin 4, D-52074 Aachen, Germany; Spanish Natl Canc Ctr, Canc Epigenet Lab, Madrid 28029, Spain	Johns Hopkins University; Johns Hopkins Medicine; RWTH Aachen University; RWTH Aachen University Hospital; Centro Nacional de Investigaciones Oncologicas (CNIO)	Herman, JG (corresponding author), Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, 1650 Orleans St, Baltimore, MD 21231 USA.	hermanji@jhmi.edu	Esteller, Manel/L-5956-2014	Esteller, Manel/0000-0003-4490-6093	NATIONAL CANCER INSTITUTE [P50CA096888, U01CA084986] Funding Source: NIH RePORTER; NCI NIH HHS [CA84986, P50 CA96888] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBINI A, 1991, J NATL CANCER I, V83, P775, DOI 10.1093/jnci/83.11.775; Bachman KE, 1999, CANCER RES, V59, P798; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Cappabianca L, 2003, EXP CELL RES, V286, P209, DOI 10.1016/S0014-4827(03)00072-7; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Corn PG, 1999, CANCER RES, V59, P3352; Esteller M, 1999, CANCER RES, V59, P793; Esteller M, 2001, CANCER RES, V61, P3225; Esteller M, 2002, CANCER RES, V62, P5902; Esteller M, 2002, J NATL CANCER I, V94, P26; Fernandez CA, 2003, J BIOL CHEM, V278, P40989, DOI 10.1074/jbc.M306176200; Giannelli G, 2002, INT J CANCER, V97, P425, DOI 10.1002/ijc.1635; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; Hajitou A, 2001, CANCER RES, V61, P3450; Hammani K, 1996, J BIOL CHEM, V271, P25498, DOI 10.1074/jbc.271.41.25498; Herman JG, 1997, CANCER RES, V57, P837; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Ivanova T, 2004, INT J CANCER, V108, P882, DOI 10.1002/ijc.11652; Janowska-Wieczorek A, 1999, BRIT J HAEMATOL, V105, P402, DOI 10.1046/j.1365-2141.1999.01352.x; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Katzenellenbogen RA, 1999, BLOOD, V93, P4347, DOI 10.1182/blood.V93.12.4347.412k31_4347_4353; KOSSAKOWSKA AE, 1993, ONCOL RES, V5, P19; List AF, 2001, ONCOLOGIST, V6, P24, DOI 10.1634/theoncologist.6-suppl_5-24; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nakopoulou L, 2002, MODERN PATHOL, V15, P26, DOI 10.1038/modpathol.3880486; Rossi D, 2004, HAEMATOLOGICA, V89, P154; Seo DW, 2003, CELL, V114, P171, DOI 10.1016/S0092-8674(03)00551-8; Stamenkovic I, 2000, SEMIN CANCER BIOL, V10, P415, DOI 10.1006/scbi.2000.0379; StetlerStevenson M, 1997, BLOOD, V89, P1708, DOI 10.1182/blood.V89.5.1708.1708_1708_1715; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Takahashi T, 2004, CLIN CANCER RES, V10, P2928, DOI 10.1158/1078-0432.CCR-03-0716; Vacca A, 1999, BRIT J CANCER, V79, P965, DOI 10.1038/sj.bjc.6690154; Vergani V, 2001, INT J CANCER, V91, P241, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1035>3.3.CO;2-G; Yoshizaki T, 2001, INT J CANCER, V95, P44, DOI 10.1002/1097-0215(20010120)95:1<44::AID-IJC1008>3.3.CO;2-D	37	26	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2005	24	30					4799	4805		10.1038/sj.onc.1208599	http://dx.doi.org/10.1038/sj.onc.1208599			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	945CC	15870703				2022-12-17	WOS:000230477900006
J	Wang, BS; Ren, JW; Ooi, LLPJ; Chong, SS; Lee, CGL				Wang, BS; Ren, JW; Ooi, LLPJ; Chong, SS; Lee, CGL			Dinucleotide repeats negatively modulate the promoter activity of Cyr61 and is unstable in hepatocellular carcinoma patients	ONCOGENE			English	Article						Cyr61; hepatocellular carcinoma; d(CA) repeats; microsatellite instability; promoter analysis; cancer	IMMEDIATE-EARLY GENE; TISSUE GROWTH-FACTOR; HANDED Z-DNA; BREAST-CANCER; CCN FAMILY; MATRIX-METALLOPROTEINASE-9 GENE; INTEGRIN ALPHA(V)BETA(3); EXTRACELLULAR-MATRIX; ANGIOGENIC FACTOR; CHROMOSOME 1P	Cyr61 is a secreted, cysteine-rich, heparin-binding protein that mediates diverse functions including extracellular matrix formation, differentiation, cell proliferation, adhesion, migration, survival, as well as angiogenesis and tumorigenesis. In this study, we found that Cyr61 gene expression is significantly downregulated in the tumors of hepatocellular carcinoma (HCC) patients. To elucidate its mechanism of gene regulation, we examined the promoter of Cyr61. which contains two long stretches of repeats, each comprising d(CA) dinucleotide repeats downstream of HNF3 beta- and ATF-binding sites. We hypothesized that the d(CA) repeats may play an important role in regulating Cyr61 promoter activity and performed promoter reporter assays to examine this. We found that a greater number of d(CA) repeats resulted in significantly lower promoter activity of the Cyr61 gene in the KB3-1 and HepG2 cell lines, but not in the MCF-7 cell line. In addition, the d(CA) repeats, but not other random sequences, were found to be important for Cyr61 promoter activity. We further demonstrate that the ATF- and HNF3 beta-binding sites upstream the d(CA) repeats positively and negatively modulate Cyr61 promoter activity, respectively. An examination of the d(CA) dinucleotide patterns in the Cyr61 promoter in HCC patients revealed that similar to 32% of these patients exhibited either loss of heterozygosity or somatic mosaicism in either the tumors, adjacent normal liver tissues or both.	Natl Canc Ctr, Div Med Sci, Lab 5, Singapore 169610, Singapore; Natl Univ Singapore, Dept Biochem, Singapore 117548, Singapore; Natl Canc Ctr, Dept Surg Oncol, Singapore, Singapore; Singapore Gen Hosp, Dept Surg, Singapore 0316, Singapore; Natl Univ Singapore, Dept Pediat & Obstet & Gynecol, Singapore 117548, Singapore; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Gynecol & Obstet, Baltimore, MD 21205 USA	National Cancer Centre Singapore (NCCS); National University of Singapore; National Cancer Centre Singapore (NCCS); Singapore General Hospital; National University of Singapore; Johns Hopkins University; Johns Hopkins University	Lee, CGL (corresponding author), Natl Canc Ctr, Div Med Sci, Lab 5, Level 6,11 Hosp Dr, Singapore 169610, Singapore.	bchleec@nus.edu.sg	Ooi, London Lucien/AGK-1395-2022; Lee, Caroline G/M-8918-2019; Chong, Samuel S./D-8098-2015	Lee, Caroline G/0000-0002-4323-3635; Chong, Samuel S./0000-0002-1872-5937				Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; Borrmann L, 2003, ONCOGENE, V22, P756, DOI 10.1038/sj.onc.1206073; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Brigstock DR, 2003, J CLIN PATHOL-MOL PA, V56, P127, DOI 10.1136/mp.56.2.127; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; Chen NY, 2000, J BIOL CHEM, V275, P24953, DOI 10.1074/jbc.M003040200; Gebhardt F, 1999, J BIOL CHEM, V274, P13176, DOI 10.1074/jbc.274.19.13176; GEHRING M, 1995, CANCER RES, V55, P5366; Grzeszkiewicz TM, 2001, J BIOL CHEM, V276, P21943, DOI 10.1074/jbc.M100978200; HAINSWORTH PJ, 1992, BRIT J CANCER, V66, P131, DOI 10.1038/bjc.1992.229; HAMADA H, 1984, MOL CELL BIOL, V4, P2622, DOI 10.1128/MCB.4.12.2622; Hirasaki S, 2001, HEPATOL RES, V19, P294, DOI 10.1016/S1386-6346(00)00101-7; Huang TS, 2003, BIOCHEM BIOPH RES CO, V300, P901, DOI 10.1016/S0006-291X(02)02962-5; Jay P, 1997, ONCOGENE, V14, P1753, DOI 10.1038/sj.onc.1200986; Jedsadayanmata A, 1999, J BIOL CHEM, V274, P24321, DOI 10.1074/jbc.274.34.24321; Kireeva ML, 1998, J BIOL CHEM, V273, P3090, DOI 10.1074/jbc.273.5.3090; LATINKIC BV, 1991, NUCLEIC ACIDS RES, V19, P3261, DOI 10.1093/nar/19.12.3261; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Lee CGL, 2000, FASEB J, V14, P516, DOI 10.1096/fasebj.14.3.516; Lee CGL, 2003, ONCOGENE, V22, P2592, DOI 10.1038/sj.onc.1206337; Menendez JA, 2003, ENDOCR-RELAT CANCER, V10, P141, DOI 10.1677/erc.0.0100141; MIYASHITA A, 1995, NUCLEIC ACIDS RES, V23, P293, DOI 10.1093/nar/23.2.293; MORI Y, 1995, J BIOL CHEM, V270, P27788, DOI 10.1074/jbc.270.46.27788; NAYLOR LH, 1990, NUCLEIC ACIDS RES, V18, P1595, DOI 10.1093/nar/18.6.1595; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; Perbal B, 2001, J CLIN PATHOL-MOL PA, V54, P103, DOI 10.1136/mp.54.2.103; Peters DG, 1999, STROKE, V30, P2612, DOI 10.1161/01.STR.30.12.2612; Pilarsky CP, 1998, PROSTATE, V36, P85; RICH A, 1984, ANNU REV BIOCHEM, V53, P791, DOI 10.1146/annurev.bi.53.070184.004043; RICH A, 1993, GENE, V135, P99, DOI 10.1016/0378-1119(93)90054-7; Rothenburg S, 2001, P NATL ACAD SCI USA, V98, P8985, DOI 10.1073/pnas.121176998; ROTWEIN P, 1986, J BIOL CHEM, V261, P4828; Sampath D, 2001, ENDOCRINOLOGY, V142, P2540, DOI 10.1210/en.142.6.2540; Sampath D, 2001, J CLIN ENDOCR METAB, V86, P1707, DOI 10.1210/jc.86.4.1707; SCHROTH GP, 1992, J BIOL CHEM, V267, P11846; Schutze N, 2001, J CLIN PATHOL-MOL PA, V54, P170, DOI 10.1136/mp.54.3.170; Schwartz T, 2001, NAT STRUCT BIOL, V8, P761, DOI 10.1038/nsb0901-761; Schwartz T, 1999, SCIENCE, V284, P1841, DOI 10.1126/science.284.5421.1841; Shimajiri S, 1999, FEBS LETT, V455, P70, DOI 10.1016/S0014-5793(99)00863-7; SHIN E, 1993, JPN J CANCER RES, V84, P402, DOI 10.1111/j.1349-7006.1993.tb00150.x; SIMON D, 1991, ONCOGENE, V6, P765; TAE HJ, 1994, J BIOL CHEM, V269, P10475; Tong XJ, 2001, J BIOL CHEM, V276, P47709, DOI 10.1074/jbc.M107878200; Tsai MS, 2002, ONCOGENE, V21, P8178, DOI 10.1038/sj.onc.1205682; Tsai MS, 2000, CANCER RES, V60, P5603; WELLS RD, 1988, J BIOL CHEM, V263, P1095; Xie D, 2001, CANCER RES, V61, P8917; Xie D, 2001, J BIOL CHEM, V276, P14187, DOI 10.1074/jbc.M009755200; Xu L, 2001, CANCER RES, V61, P3176; YANG GP, 1991, CELL GROWTH DIFFER, V2, P351; Yu H, 2001, BREAST CANCER RES TR, V70, P117, DOI 10.1023/A:1012947027213	51	26	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2005	24	24					3999	4008		10.1038/sj.onc.1208550	http://dx.doi.org/10.1038/sj.onc.1208550			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	930RY	15782120				2022-12-17	WOS:000229435300016
J	Mukherjee, K; Syed, V; Ho, SM				Mukherjee, K; Syed, V; Ho, SM			Estrogen-induced loss of progesterone receptor expression in normal and malignant ovarian surface epithelial	ONCOGENE			English	Article						ICI 182,780; hormonal carcinogenesis; ovarian; surface epithelial cells; apoptosis; RU486; 17 beta hydroxysteroid dehydrogenase	STEROID-HORMONE RECEPTORS; BREAST-CANCER CELLS; NUCLEAR EXPORT SIGNAL; B-ISOFORM; TRANSCRIPTIONAL ACTIVITY; MONOCLONAL-ANTIBODY; ANDROGEN RECEPTOR; INDUCED APOPTOSIS; GENE-EXPRESSION; MESSENGER-RNA	While estrogens are suspected risk factors for epithelial ovarian cancer (OCa), progesterone (P4) has been shown to exert protective effects. The biological actions of P4 in target cells are mediated by progesterone receptors (PRs) that exist principally as A- and B-isoforms. We observed overexpression of PR-A and PR-B protein in two lines of OCa cells when compared to two lines of nontumorigenic, normal human ovarian surface epithelial (HOSE) cells. Treatment of HOSE or OCa cells with estrone or 17 beta-estradiol at 10(-8) M for a period of 72 h induced significant loss of PR-A and PR-B mRNA and protein expression, with the regulation primarily controlled at the transcriptional level. In contrast, breast cancer cells (line MCF-7) exposed to estrogens upregulated PR-A and PR-B expression. Of significance, both the inhibitory and stimulatory actions of estrogens were blocked by the specific ER-antagonist ICI 182,780 (ICI, 10(-5) M), con. firming estrogen speci. city. Cotreatment of estrogen-exposed HOSE, OCa, and MCF-7 cell lines with inhibitors of type 1- and type 2-17 beta hydroxysteroid dehydrogenase did not affect the previously observed changes in PR expression, suggesting that the action of each estrogen is direct and not mediated via conversion to its metabolic counterpart. Green fluorescence protein (GFP)-PR-A and GFP-PR-B were localized in the cytoplasmic compartment of untreated HOSE cells and translocated to the nucleus after P4 treatment, while both chimera PRs resided in the nuclei of OCa cells in a ligand-independent manner. In OCa cell cultures, P4 (10(-6) M), but not RU486 (10(-5) M), induced apoptosis that was blocked by cotreatment with the antiprogestin but enhanced by cotreatment with ICI. In sharp contrast, P4 induced proliferation, while ICI and RU486 caused cell death in MCF-7 cells. In conclusion, this study is first to demonstrate estrogens as negative regulators of PR expression in HOSE/OCa cells and to provide a mechanistic basis upon which to explain the antagonism of estrogens on the anti-OCa action of progestins. It also raises the possibility of using progestin and ICI as a combinational therapy for OCa treatment.	Univ Massachusetts, Sch Med, Dept Surg, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Ho, SM (corresponding author), Univ Massachusetts, Sch Med, Dept Surg, 364 Plantat St,Room 504,Lazare Res Bldg, Worcester, MA 01605 USA.	Shuk-mei.Ho@umassmed.edu			NCI NIH HHS [CA94221, CA091250] Funding Source: Medline; NIDDK NIH HHS [DK61084] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R03CA091250, R01CA094221] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061084] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akahira J, 2000, BRIT J CANCER, V83, P1488, DOI 10.1054/bjoc.2000.1463; BAST RC, 1981, J CLIN INVEST, V68, P1331, DOI 10.1172/JCI110380; BELL DA, 1991, HUM PATHOL, V22, P750, DOI 10.1016/0046-8177(91)90205-4; Bu SZ, 1997, CANCER, V79, P1944, DOI 10.1002/(SICI)1097-0142(19970515)79:10<1944::AID-CNCR15>3.0.CO;2-V; Clarke RB, 2004, TRENDS ENDOCRIN MET, V15, P316, DOI 10.1016/j.tem.2004.07.004; Clemm DL, 2000, MOL ENDOCRINOL, V14, P52, DOI 10.1210/me.14.1.52; DANDLIKER WB, 1978, CANCER RES, V38, P4212; Davis M, 1996, CANCER RES, V56, P741; Elbi C, 2004, P NATL ACAD SCI USA, V101, P2876, DOI 10.1073/pnas.0400116101; Flototto T, 2004, J STEROID BIOCHEM, V88, P131, DOI 10.1016/j.jsbmb.2003.11.004; Fujimura M, 2001, AM J SURG PATHOL, V25, P667, DOI 10.1097/00000478-200105000-00016; Gabra H, 1996, CANCER RES, V56, P950; GABRA H, 1995, BRIT J CANCER, V72, P367, DOI 10.1038/bjc.1995.340; Giangrande PH, 1997, J BIOL CHEM, V272, P32889, DOI 10.1074/jbc.272.52.32889; Graham JD, 2002, BREAST CANCER RES, V4, P187, DOI 10.1186/bcr450; GUIOCHONMANTEL A, 1994, P NATL ACAD SCI USA, V91, P7179, DOI 10.1073/pnas.91.15.7179; GuiochonMantel A, 1996, J STEROID BIOCHEM, V56, P3, DOI 10.1016/0960-0760(95)00268-5; GUIOCHONMANTEL A, 1991, EMBO J, V10, P3851, DOI 10.1002/j.1460-2075.1991.tb04954.x; HEINONEN PK, 1982, BRIT J OBSTET GYNAEC, V89, P84, DOI 10.1111/j.1471-0528.1982.tb04643.x; Hempling RE, 1998, AM J CLIN ONCOL-CANC, V21, P447, DOI 10.1097/00000421-199810000-00005; Hewitt SC, 2000, STEROIDS, V65, P551, DOI 10.1016/S0039-128X(00)00113-6; HO SM, 2003, REPROD BIOL ENDOCRIN, V73, P1; Hopp TA, 2004, CLIN CANCER RES, V10, P2751, DOI 10.1158/1078-0432.CCR-03-0141; Hornung R, 2004, CANCER LETT, V206, P97, DOI 10.1016/j.canlet.2003.10.034; Hu Z, 2000, Zhonghua Fu Chan Ke Za Zhi, V35, P423; Johnson J, 1996, J STEROID BIOCHEM, V56, P31, DOI 10.1016/0960-0760(95)00221-9; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KEY TJA, 1988, EUR J CANCER CLIN ON, V24, P29, DOI 10.1016/0277-5379(88)90173-3; KING WJ, 1984, NATURE, V307, P745, DOI 10.1038/307745a0; Knotts TA, 2001, J BIOL CHEM, V276, P8475, DOI 10.1074/jbc.M009805200; KONTULA K, 1975, ACTA ENDOCRINOL-COP, V78, P574, DOI 10.1530/acta.0.0780574; KRAUS WL, 1995, MOL CELL BIOL, V15, P1847; KREITMANN B, 1979, J STEROID BIOCHEM, V11, P1253, DOI 10.1016/0022-4731(79)90193-6; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Langdon SP, 1998, CLIN CANCER RES, V4, P2245; Lau KM, 1999, P NATL ACAD SCI USA, V96, P5722, DOI 10.1073/pnas.96.10.5722; Leslie KK, 2005, GYNECOL ONCOL, V96, P32, DOI 10.1016/j.ygyno.2004.09.057; Li AJ, 2003, AM J OBSTET GYNECOL, V189, P22, DOI 10.1067/mob.2003.328; Lim CS, 1999, MOL ENDOCRINOL, V13, P366, DOI 10.1210/me.13.3.366; Lindgren PR, 2004, MOL CELL ENDOCRINOL, V221, P97, DOI 10.1016/j.mce.2004.02.020; Luce Therese L, 2003, Nurse Pract, V28, P41, DOI 10.1097/00006205-200312000-00007; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MISRAHI M, 1988, NUCLEIC ACIDS RES, V16, P5459, DOI 10.1093/nar/16.12.5459; Modan B, 1998, AM J EPIDEMIOL, V147, P1038; Munstedt K, 2000, CANCER, V89, P1783, DOI 10.1002/1097-0142(20001015)89:8<1783::AID-CNCR19>3.0.CO;2-D; NARDULLI AM, 1988, ENDOCRINOLOGY, V122, P935, DOI 10.1210/endo-122-3-935; Passinen S, 2001, EUR J BIOCHEM, V268, P5337, DOI 10.1046/j.0014-2956.2001.02467.x; Petz LN, 2002, ENDOCRINOLOGY, V143, P4583, DOI 10.1210/en.2002-220369; Petz LN, 2000, MOL ENDOCRINOL, V14, P972, DOI 10.1210/me.14.7.972; Poirier D, 2001, MOL CELL ENDOCRINOL, V171, P119, DOI 10.1016/S0303-7207(00)00427-5; Qiu M, 2003, J STEROID BIOCHEM, V85, P147, DOI 10.1016/S0960-0760(03)00221-8; Qiu M, 2003, MOL ENDOCRINOL, V17, P628, DOI 10.1210/me.2002-0378; RAO BR, 1991, ENDOCR REV, V12, P14, DOI 10.1210/edrv-12-1-14; Richer JK, 2002, J BIOL CHEM, V277, P5209, DOI 10.1074/jbc.M110090200; Rickard DJ, 2002, J BONE MINER RES, V17, P580, DOI 10.1359/jbmr.2002.17.4.580; Riman T, 2002, JNCI-J NATL CANCER I, V94, P497, DOI 10.1093/jnci/94.7.497; Risch HA, 1998, JNCI-J NATL CANCER I, V90, P1774, DOI 10.1093/jnci/90.23.1774; Rodriguez GC, 1998, J SOC GYNECOL INVEST, V5, P271, DOI 10.1016/S1071-5576(98)00017-3; Rodriguez GC, 2002, JNCI-J NATL CANCER I, V94, P50; Ross G.T., 1981, TXB ENDOCRINOLOGY, P355; Saegusa M, 2000, JPN J CANCER RES, V91, P510, DOI 10.1111/j.1349-7006.2000.tb00975.x; Saporita AJ, 2003, J BIOL CHEM, V278, P41998, DOI 10.1074/jbc.M302460200; Sartorius CA, 2003, BREAST CANCER RES TR, V79, P287, DOI 10.1023/A:1024031731269; SARTORIUS CA, 1994, MOL ENDOCRINOL, V8, P1347, DOI 10.1210/me.8.10.1347; Schultz JR, 2003, MOL CELL ENDOCRINOL, V201, P165, DOI 10.1016/S0303-7207(02)00415-X; Scully RE, 1995, J CELL BIOCHEM, P208; SHAFIE S, 1979, J LAB CLIN MED, V94, P784; Shyamala G, 2000, P NATL ACAD SCI USA, V97, P3044, DOI 10.1073/pnas.97.7.3044; Shyamala G, 1998, P NATL ACAD SCI USA, V95, P696, DOI 10.1073/pnas.95.2.696; Simpson ET, 1981, TXB ENDOCRINOLOGY, P412; Smid-Koopman E, 2003, J SOC GYNECOL INVEST, V10, P49, DOI 10.1016/S1071-5576(02)00217-4; Smith CL, 2000, MOL ENDOCRINOL, V14, P956, DOI 10.1210/me.14.7.956; Syed V, 2001, CANCER RES, V61, P6768; Syed V, 2002, JNCI-J NATL CANCER I, V94, P617; Syed V, 2003, ONCOGENE, V22, P6883, DOI 10.1038/sj.onc.1206828; Takimoto GS, 1996, J BIOL CHEM, V271, P13308, DOI 10.1074/jbc.271.23.13308; Tang YT, 1996, MOL CELL BIOL, V16, P1989; Taube M, 2002, INT J ONCOL, V20, P589; Taube M, 2003, INT J ONCOL, V22, P1257; Tibbetts TA, 1998, BIOL REPROD, V59, P1143, DOI 10.1095/biolreprod59.5.1143; Tremblay MR, 1998, J STEROID BIOCHEM, V66, P179, DOI 10.1016/S0960-0760(98)00043-0; TSAO SW, 1995, EXP CELL RES, V218, P499, DOI 10.1006/excr.1995.1184; Tyagi RK, 1998, MOL ENDOCRINOL, V12, P1684, DOI 10.1210/me.12.11.1684; VAUGHN CB, 1976, J CLIN ENDOCR METAB, V43, P387, DOI 10.1210/jcem-43-2-387; VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244; Vienonen A, 2002, J STEROID BIOCHEM, V80, P307, DOI 10.1016/S0960-0760(02)00027-4; Wang Gang, 2004, Ai Zheng, V23, P406; WEI LL, 1988, MOL ENDOCRINOL, V2, P62, DOI 10.1210/mend-2-1-62; WELSHONS WV, 1984, NATURE, V307, P747, DOI 10.1038/307747a0; WEN DX, 1994, MOL CELL BIOL, V14, P8356, DOI 10.1128/MCB.14.12.8356; Yu S, 2001, J CELL BIOCHEM, V82, P445, DOI 10.1002/jcb.1171	92	26	26	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2005	24	27					4388	4400		10.1038/sj.onc.1208623	http://dx.doi.org/10.1038/sj.onc.1208623			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	938CG	15806153				2022-12-17	WOS:000229976900008
J	Patrussi, L; Savino, MT; Pellegrini, M; Paccani, SR; Migliaccio, E; Plyte, S; Lanfrancone, L; Pelicci, PG; Baldari, CT				Patrussi, L; Savino, MT; Pellegrini, M; Paccani, SR; Migliaccio, E; Plyte, S; Lanfrancone, L; Pelicci, PG; Baldari, CT			Cooperation and selectivity of the two Grb2 binding sites of p52Shc in T-cell antigen receptor signaling to Ras family GTPases and Myc-dependent survival	ONCOGENE			English	Article						TCR signaling; T-cell activation; T-cell survival; MAP kinases; stress activated kinases; Rac	PROTEIN-PROTEIN INTERACTIONS; ADAPTER PROTEIN; PHOSPHOTYROSINE-BINDING; SHC ADAPTER; TYROSINE KINASE; GENE ACTIVATION; MEMBRANE RAFTS; COLLAGEN SHC; ZETA-CHAIN; IN-VIVO	Shc proteins participate in a variety of processes regulating cell proliferation, survival and apoptosis. The two ubiquitously expressed isoforms, p52Shc/p46Shc, couple tyrosine kinase receptors to Ras by recruiting Grb2/Sos complexes to a membrane-proximal localization. Tyrosine residues 239/240 and 317 become phosphorylated following receptor engagement and, as such, form two Grb2 binding sites, which have been proposed to be differentially coupled to Myc-dependent survival and to fos-dependent proliferation, respectively. Here, we have addressed the individual function of YY239/240 and Y317 in T-cell antigen receptor (TCR) signaling. We show that p52Shc is phosphorylated on both YY239/240 and Y317 following TCR engagement. Mutation of either YY239/240 or Y317 results in impaired interaction with Grb2 and inhibition of Ras/MAP kinase activation and CD69 induction, supporting a role for both Grb2 binding sites in this function. Substitution of either YY239/240 or Y317 also results in a defective activation of Rac and the coupled stress kinases JNK and p38. Furthermore, mutation of Y317 or, to a larger extent, of YY239/240, results in increased activation-induced cell death, which in cells expressing the FF239/240 mutant is accompanied by impaired TCR-dependent c-myc transcription. The data underline a pleiotropic and nonredundant role of Shc, mediated by both YY239/240 and Y317, in T-cell activation and survival.	Univ Siena, Dept Evolutionary Biol, I-53100 Siena, Italy; European Inst Oncol, I-20141 Milan, Italy; Discovery Res Oncol, Nerviano, Italy	University of Siena; IRCCS European Institute of Oncology (IEO)	Baldari, CT (corresponding author), Univ Siena, Dept Evolutionary Biol, Via Aldo Moro 2, I-53100 Siena, Italy.	baldari@unisi.it	Patrussi, Laura/AAD-4332-2020; Lanfrancone, Luisa/AAC-8671-2019; Pelicci, Pier Giuseppe/AAL-6572-2020; Migliaccio, Enrica/AAQ-8880-2020	Lanfrancone, Luisa/0000-0002-4523-3815; Baldari, Cosima/0000-0002-4414-6744; Patrussi, Laura/0000-0003-1542-6955				Acuto O, 2000, ANNU REV IMMUNOL, V18, P165, DOI 10.1146/annurev.immunol.18.1.165; Alcover A, 2000, CRIT REV IMMUNOL, V20, P325; Atwal JK, 2000, NEURON, V27, P265, DOI 10.1016/S0896-6273(00)00035-0; Baron V, 1998, ENDOCRINOLOGY, V139, P3034, DOI 10.1210/en.139.6.3034; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Cantrell DA, 2003, IMMUNOL REV, V192, P122, DOI 10.1034/j.1600-065X.2003.00028.x; D'Oro U, 2002, J IMMUNOL, V169, P6269, DOI 10.4049/jimmunol.169.11.6269; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Fruman DA, 2002, SEMIN IMMUNOL, V14, P7, DOI 10.1006/smim.2001.0337; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Harmer SL, 1997, MOL CELL BIOL, V17, P4087, DOI 10.1128/MCB.17.7.4087; Hashimoto A, 1999, J BIOL CHEM, V274, P20139, DOI 10.1074/jbc.274.29.20139; Iwashima M, 2002, P NATL ACAD SCI USA, V99, P4544, DOI 10.1073/pnas.082647499; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; Koretzky GA, 1997, IMMUNOL TODAY, V18, P401, DOI 10.1016/S0167-5699(97)01088-8; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Lamkin TD, 1997, J BIOL CHEM, V272, P10396; Langlet C, 2000, CURR OPIN IMMUNOL, V12, P250, DOI 10.1016/S0952-7915(00)00084-4; Lotti LV, 1996, MOL CELL BIOL, V16, P1946; Macara IG, 1996, FASEB J, V10, P625, DOI 10.1096/fasebj.10.5.8621061; Magistrelli G, 1999, EUR J BIOCHEM, V266, P1166, DOI 10.1046/j.1432-1327.1999.00973.x; Matsui K, 2000, J IMMUNOL, V164, P3002, DOI 10.4049/jimmunol.164.6.3002; Matter ML, 2001, J BIOL CHEM, V276, P27757, DOI 10.1074/jbc.M102014200; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Milia E, 1996, ONCOGENE, V13, P767; Nelson BH, 2003, J IMMUNOL, V170, P5563, DOI 10.4049/jimmunol.170.11.5563; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Okabayashi Y, 1996, J BIOL CHEM, V271, P5265; Pacini S, 2004, MOL CELL BIOL, V24, P1747, DOI 10.1128/MCB.24.4.1747-1757.2004; Pacini S, 1998, J BIOL CHEM, V273, P20487, DOI 10.1074/jbc.273.32.20487; Pelicci G, 2002, MOL CELL BIOL, V22, P7351, DOI 10.1128/MCB.22.20.7351-7363.2002; Plyte S, 2001, J BIOL CHEM, V276, P14350, DOI 10.1074/jbc.M007854200; Plyte S, 2000, ONCOGENE, V19, P1529, DOI 10.1038/sj.onc.1203451; Pratt JC, 1999, J IMMUNOL, V163, P2586; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; Ravichandran KS, 2001, ONCOGENE, V20, P6322, DOI 10.1038/sj.onc.1204776; Ravichandran KS, 1997, MOL CELL BIOL, V17, P5540, DOI 10.1128/MCB.17.9.5540; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; Reynolds LF, 2002, J EXP MED, V195, P1103, DOI 10.1084/jem.20011663; Rodman JS, 2000, J CELL SCI, V113, P183; Roose JP, 2003, PLOS BIOL, V1, P271, DOI 10.1371/journal.pbio.0000053; Sakaguchi K, 2001, BIOCHEM BIOPH RES CO, V282, P1154, DOI 10.1006/bbrc.2001.4680; SALCINI AE, 1994, ONCOGENE, V9, P2827; THOMAS D, 1995, J BIOL CHEM, V270, P28924, DOI 10.1074/jbc.270.48.28924; Valitutti S, 1997, IMMUNOL TODAY, V18, P299, DOI 10.1016/S0167-5699(97)01075-X; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; Ventura A, 2002, J BIOL CHEM, V277, P22370, DOI 10.1074/jbc.M200280200; Walk SF, 1998, EUR J IMMUNOL, V28, P2265, DOI 10.1002/(SICI)1521-4141(199808)28:08<2265::AID-IMMU2265>3.0.CO;2-P; Zhang L, 2002, NAT IMMUNOL, V3, P749, DOI 10.1038/ni820; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	54	26	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2005	24	13					2218	2228		10.1038/sj.onc.1208384	http://dx.doi.org/10.1038/sj.onc.1208384			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909KD	15688026				2022-12-17	WOS:000227857900009
J	Hermsen, M; Snijders, A; Guervos, MA; Taenzer, S; Koerner, U; Baak, J; Pinkel, D; Albertson, D; van Diest, P; Meijer, G; Schrock, E				Hermsen, M; Snijders, A; Guervos, MA; Taenzer, S; Koerner, U; Baak, J; Pinkel, D; Albertson, D; van Diest, P; Meijer, G; Schrock, E			Centromeric chromosomal translocations show tissue-specific differences between squamous cell carcinomas and adenocarcinomas	ONCOGENE			English	Article						SKY; array CGH centromeres; whole arm translocation; squamous cell carcinoma; adenocarcinoma	IN-SITU HYBRIDIZATION; TOPOISOMERASE-II; CYTOGENETIC ABNORMALITIES; COLORECTAL ADENOMA; DNA; PROGRESSION; LEVEL; INSTABILITY; RESPECT; CANCER	Structural chromosomal aberrations are common in epithelial tumors. Here, we compared the location of centromeric breaks associated with whole arm translocations in seven adenocarcinoma cell lines and nine squamous cell carcinoma cell lines using SKY, micro-array-based comparative genomic hybridization (array CGH) and fluorescence in situ hybridization (FISH). Whole arm translocations were more frequent in squamous cell carcinomas (112 in nine cell lines and nine in one short-term culture) than in adenocarcinomas (13 in seven cases) and most often resulted in copy number alterations. Array CGH analysis demonstrated that in all squamous cell carcinomas and in most adenocarcinomas, the breakpoints of unbalanced whole arm translocations occurred between the two clones on the array flanking the centromeres. However, FISH with centromeric probes revealed that in squamous cell carcinomas, the marker chromosomes with whole arm translocations contained centromeres comprised of material from both participating chromosomes, while in adenocarcinomas centromeric material from only one of the chromosomes was present. These observations suggest that different mechanisms of centromeric instability underlie the formation of chromosomal aberrations in adenocarcinomas and squamous cell carcinomas.	Vrije Univ Amsterdam, Med Ctr, Dept Pathol, NL-1081 HV Amsterdam, Netherlands; Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA; Univ Jena, Inst Mol Biotechnol, D-6900 Jena, Germany; SiR Hosp, Dept Pathol, Stavanger, Norway; Humboldt Univ, Inst Med Genet, Berlin, Germany	Vrije Universiteit Amsterdam; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Friedrich Schiller University of Jena; Humboldt University of Berlin	Hermsen, M (corresponding author), Univ Principado Asturias, Dept Otolaryngol, Inst Oncol, Hosp Cent Asturias, Edificio Polivalente A,1 Planta,Calle Dr Emilio V, Oviedo 33006, Asturias, Spain.	mhermsen@hca.es	Guervós, Marta A./H-7446-2015		NCI NIH HHS [CA94407] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R33CA094407] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albertson DG, 2003, NAT GENET, V34, P369, DOI 10.1038/ng1215; Bakshi RP, 2001, CRIT REV BIOCHEM MOL, V36, P1, DOI 10.1080/20014091074165; CHEN TR, 1987, CANCER GENET CYTOGEN, V27, P125, DOI 10.1016/0165-4608(87)90267-6; Eshleman JR, 1998, ONCOGENE, V17, P719, DOI 10.1038/sj.onc.1201986; Floridia G, 2000, EMBO REP, V1, P489; HERMIEU JF, 2001, CORRESPONDANCES PELV, V1, P43; Hermsen M, 2002, GASTROENTEROLOGY, V123, P1109, DOI 10.1053/gast.2002.36051; Hermsen M, 2001, J PATHOL, V194, P177; Hermsen MAJA, 1998, J PATHOL, V186, P356; Hermsen MAJA, 1996, GENE CHROMOSOME CANC, V15, P1; Israeli O, 2003, GYNECOL ONCOL, V90, P629, DOI 10.1016/S0090-8258(03)00375-5; Jain AN, 2002, GENOME RES, V12, P325, DOI 10.1101/gr.210902; Jin C, 2000, GENE CHROMOSOME CANC, V28, P66, DOI 10.1002/(SICI)1098-2264(200005)28:1<66::AID-GCC8>3.3.CO;2-W; Jin YS, 2000, CHROMOSOMA, V109, P476, DOI 10.1007/s004120000107; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; Luk C, 2001, CANCER GENET CYTOGEN, V125, P87, DOI 10.1016/S0165-4608(00)00363-0; Martins C, 1999, EUR J CANCER, V35, P498, DOI 10.1016/S0959-8049(98)00368-2; Meijer GA, 1998, J CLIN PATHOL, V51, P901, DOI 10.1136/jcp.51.12.901; NAKAO K, 2004, CARCINOGENESIS  0304; Pei JM, 2001, GENE CHROMOSOME CANC, V31, P282, DOI 10.1002/gcc.1145; Petersen I, 1997, BRIT J CANCER, V75, P79, DOI 10.1038/bjc.1997.13; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Rattner JB, 1996, J CELL BIOL, V134, P1097, DOI 10.1083/jcb.134.5.1097; SCHLEGEL J, 1995, CANCER RES, V55, P6002; Schrock E, 1999, DIAGNOSTIC CYTOGENET, P416; SCHROCK E, 2001, CURRENT PROTOCOLS CY; Snijders AM, 2003, ONCOGENE, V22, P4370, DOI 10.1038/sj.onc.1206482; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; Soulie P, 1999, CANCER GENET CYTOGEN, V115, P118, DOI 10.1016/S0165-4608(99)00073-4; Sumner AT, 1998, J MED GENET, V35, P833, DOI 10.1136/jmg.35.10.833; TELENIUS H, 1992, GENE CHROMOSOME CANC, V4, P257, DOI 10.1002/gcc.2870040311; Tirkkonen M, 1997, CANCER RES, V57, P1222; van Grieken NCT, 2000, J PATHOL, V192, P301, DOI 10.1002/1096-9896(2000)9999:9999&lt;::AID-PATH697&gt;3.0.CO;2-F; van Triest B, 1999, CLIN CANCER RES, V5, P643; Varis A, 2001, CANCER GENET CYTOGEN, V127, P53, DOI 10.1016/S0165-4608(00)00423-4; Warburton PE, 1997, BIOESSAYS, V19, P97, DOI 10.1002/bies.950190203; Weiss MM, 2003, J PATHOL, V199, P157, DOI 10.1002/path.1260; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052; 2001, NCI NCBIS SKY M FISH	39	26	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2005	24	9					1571	1579		10.1038/sj.onc.1208294	http://dx.doi.org/10.1038/sj.onc.1208294			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME	15674345				2022-12-17	WOS:000227218200010
J	Baldus, SE; Schwarz, E; Lohrey, C; Zapatka, M; Landsberg, S; Hahn, SA; Schmidt, D; Dienes, HP; Schmiegel, WH; Schwarte-Waldhoff, I				Baldus, SE; Schwarz, E; Lohrey, C; Zapatka, M; Landsberg, S; Hahn, SA; Schmidt, D; Dienes, HP; Schmiegel, WH; Schwarte-Waldhoff, I			Smad4 deffiency in cervical carcinoma cells	ONCOGENE			English	Article						tumor suppressor gene; TGF-beta; multistep carcinogenesis; CIN lesion	GROWTH-FACTOR-BETA; TUMOR-SUPPRESSOR GENE; UTERINE CERVIX; PAPILLOMAVIRUS INFECTIONS; INTRAEPITHELIAL NEOPLASIA; GENOMIC INSTABILITY; COLORECTAL-CANCER; DPC4 INACTIVATION; TGF-BETA; EXPRESSION	Squamous cell carcinoma of the uterine cervix is one of the most frequent cancers affecting women worldwide. Carcinomas arise from cervical intraepithelial lesions, in which infection with high-risk human papillomavirus types has led to deregulated growth control through the actions of the viral E6 and E7 oncoproteins. The molecular mechanisms underlying progression to invasive tumor growth are poorly understood. One important feature, however, is the escape from growth inhibition by transforming growth factor beta (TGF-beta). Loss of chromosomal arm 18q is among the most frequent cytogenetic alterations in cervical cancers and has been associated with poor prognosis. Since the TGF-beta response is mediated by Smad proteins and the tumor suppressor gene Smad4 resides at 18q21, we have analysed the Smad4 gene for cervical cancer-associated alterations in cell lines and primary carcinomas. Here, we report Smad4 deficiency in four out of 13 cervical cancer cell lines which is due to an intronic rearrangement or deletions of 30 exons. All cell lines, however, showed either absent or moderate responsiveness to TGF-beta irrespective of their Smad4 status. In 41 primary squamous cervical carcinomas analysed, 10 samples showed loss of Smad4 protein expression and 26 samples a reduced expression. Altogether, our results strongly suggest that Smad4 gene alterations are involved in cervical carcinogenesis.	Ruhr Univ Bochum, Knappschaftskrankenhaus, Med Klin, IMBL,Dept Internal Med, D-44892 Bochum, Germany; Univ Cologne, Inst Pathol, D-50931 Cologne, Germany; German Canc Res Ctr, D-69120 Heidelberg, Germany; Inst Pathol, D-68159 Mannheim, Germany; Ruhr Univ Bochum, Dept Gastroenterol & Hepatol, D-44892 Bochum, Germany	Ruhr University Bochum; University of Cologne; Helmholtz Association; German Cancer Research Center (DKFZ); Ruhr University Bochum	Schwarte-Waldhoff, I (corresponding author), Ruhr Univ Bochum, Knappschaftskrankenhaus, Med Klin, IMBL,Dept Internal Med, Schornau 23-25, D-44892 Bochum, Germany.	irmgard.schwarte-waldhoff@ruhr-uni-bochum.de	Zapatka, Marc/G-9896-2013; Hahn, Stephan A./AAV-6062-2021; Hahn, Stephan/E-3880-2010	Zapatka, Marc/0000-0001-8287-5967; Hahn, Stephan A./0000-0003-0855-9741; Hahn, Stephan/0000-0003-0855-9741				AUERSPERG N, 1989, CANCER RES, V49, P3007; Baldus SE, 1998, INT J CANCER, V79, P133, DOI 10.1002/(SICI)1097-0215(19980417)79:2<133::AID-IJC6>3.0.CO;2-U; Blaker H, 2002, ONCOGENE, V21, P158, DOI 10.1038/sj.onc.1205041; Chu TY, 1999, INT J CANCER, V80, P506, DOI 10.1002/(SICI)1097-0215(19990209)80:4<506::AID-IJC4>3.3.CO;2-5; Dellas A, 1999, CANCER RES, V59, P3475; Duensing S, 2004, INT J CANCER, V109, P157, DOI 10.1002/ijc.11691; Duensing S, 2002, ONCOGENE, V21, P6241, DOI 10.1038/sj.onc.1205709; Einstein MH, 2002, CLIN CANCER RES, V8, P549; Fehrmann F, 2003, ONCOGENE, V22, P5201, DOI 10.1038/sj.onc.1206554; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hahn SA, 1998, CANCER RES, V58, P1124; Harima Y, 2001, INT J CANCER, V96, P286, DOI 10.1002/ijc.1027; Helt AM, 2003, CARCINOGENESIS, V24, P159, DOI 10.1093/carcin/24.2.159; Iacobuzio-Donahue CA, 2004, CLIN CANCER RES, V10, P1597, DOI 10.1158/1078-0432.CCR-1121-3; Kang SH, 1998, INT J CANCER, V77, P620, DOI 10.1002/(SICI)1097-0215(19980812)77:4<620::AID-IJC23>3.0.CO;2-8; Kersemaekers AMF, 1998, INT J CANCER, V79, P411, DOI 10.1002/(SICI)1097-0215(19980821)79:4<411::AID-IJC17>3.3.CO;2-Z; Kersemaekers AMF, 1998, BRIT J CANCER, V77, P192, DOI 10.1038/bjc.1998.33; Klaes R, 1999, CANCER RES, V59, P6132; Lee DK, 2002, J BIOL CHEM, V277, P38557, DOI 10.1074/jbc.M206786200; Lee SH, 2001, INT J CANCER, V94, P500, DOI 10.1002/ijc.1494; Luttges J, 2001, AM J PATHOL, V158, P1677, DOI 10.1016/S0002-9440(10)64123-5; Maitra A, 2000, AM J PATHOL, V157, P1105, DOI 10.1016/S0002-9440(10)64625-1; Maliekal TT, 2003, ONCOGENE, V22, P4889, DOI 10.1038/sj.onc.1206806; Maurice D, 2001, J BIOL CHEM, V276, P43175, DOI 10.1074/jbc.M105895200; Minami R, 1998, BBA-GENE STRUCT EXPR, V1443, P182, DOI 10.1016/S0167-4781(98)00217-6; MITRA AB, 1994, CANCER RES, V54, P4481; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Muliokandov MR, 1996, CANCER RES, V56, P197; Rader JS, 1996, ONCOGENE, V13, P2737; Reuter S, 1998, EMBO J, V17, P215, DOI 10.1093/emboj/17.1.215; Reyes G, 1996, CANCER RES, V56, P5713; Roth S, 2000, BRIT J CANCER, V83, P1015, DOI 10.1054/bjoc.2000.1387; Salovaara R, 2002, GUT, V51, P56, DOI 10.1136/gut.51.1.56; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Schutte M, 1996, CANCER RES, V56, P2527; Schwarte-Waldhoff I, 1999, ONCOGENE, V18, P3152, DOI 10.1038/sj.onc.1202641; Schwarte-Waldhoff I, 2000, P NATL ACAD SCI USA, V97, P9624, DOI 10.1073/pnas.97.17.9624; Slebos RJC, 1998, CANCER RES, V58, P5333; Villanueva A, 1998, ONCOGENE, V17, P1969, DOI 10.1038/sj.onc.1202118; Wilentz RE, 2000, AM J PATHOL, V156, P37, DOI 10.1016/S0002-9440(10)64703-7; Wilentz RE, 2000, CANCER RES, V60, P2002; Zhou Y, 1999, MOL CARCINOGEN, V25, P64, DOI 10.1002/(SICI)1098-2744(199905)25:1<64::AID-MC8>3.0.CO;2-Z; ZURHAUSEN H, 1995, INT J CANCER, V63, P315; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	44	26	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					810	819		10.1038/sj.onc.1208235	http://dx.doi.org/10.1038/sj.onc.1208235			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15531914				2022-12-17	WOS:000226577100007
J	Mourtada-Maarabouni, M; Kirkham, L; Farzaneh, F; Williams, GT				Mourtada-Maarabouni, M; Kirkham, L; Farzaneh, F; Williams, GT			Regulation of apoptosis by fau revealed by functional expression cloning and antisense expression	ONCOGENE			English	Article						fau; functional expression cloning; Finkel-Biskis-Reilly osteosarcoma virus; apoptosis	CHROMOSOMAL LOCALIZATION; DEPENDENT DEGRADATION; GENOMIC STRUCTURE; GENE-EXPRESSION; UBIQUITIN; PROTEIN; CDNA; SUPPRESSOR; CANCER; INVOLVEMENT	Functional expression cloning is a powerful strategy for identifying critical steps in biological pathways independently of prior assumptions. It is particularly suitable for the identification of molecules crucial to the control of apoptosis. Our screen for sequences suppressing T-cell apoptosis isolated a sequence antisense to fau (Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV)-associated ubiquitously expressed gene). The fox gene in FBR murine osteosarcoma virus is also antisense to fau and several reports have indicated that fau displays tumour suppressor and oncogenic properties in different contexts. Our observations indicate that the fau antisense sequence suppresses expression of endogenous fau mRNA and produces resistance to apoptosis induced both by the glucocorticoid analogue dexamethasone' by ultraviolet radiation, and by the anticancer drug cisplatin. In all cases, colony-forming ability is protected, indicating that fau affects the critical events prior to commitment to cell death. Overexpression of fau in the sense orientation induces cell death, which is inhibited both by Bcl-2 and by inhibition of caspases, in line with its proposed role in apoptosis.	Univ Keele, Sch Life Sci, Keele ST5 5BG, Staffs, England; GKT Sch Med, Rayne Inst, London SE21 7AN, England	Keele University; University of London; King's College London	Williams, GT (corresponding author), Univ Keele, Sch Life Sci, Keele ST5 5BG, Staffs, England.	bia19@biol.keele.ac.uk; g.t.williams@keele.ac.uk	Farzaneh, Farzin/B-4902-2009; Williams, Gwyn/GQY-7555-2022	Farzaneh, Farzin/0000-0002-9275-2415; /0000-0001-8324-1325; Williams, Gwyn/0000-0003-4556-9930				Anderson Claire L, 2003, ScientificWorldJournal, V3, P51; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; CASTEELS D, 1995, GENOMICS, V25, P291, DOI 10.1016/0888-7543(95)80140-H; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; DANIELSEN M, 1983, MOL CELL BIOL, V3, P1310, DOI 10.1128/MCB.3.7.1310; DELIC J, 1993, MOL CELL BIOL, V13, P4875, DOI 10.1128/MCB.13.8.4875; DENHARDT DT, 1992, NEW BIOL, V4, P473; Dimmeler S, 1999, J EXP MED, V189, P1815, DOI 10.1084/jem.189.11.1815; Fan WF, 1996, IMMUNOGENETICS, V44, P97, DOI 10.1007/s002510050095; Ferreira CG, 2002, CLIN CANCER RES, V8, P2024; Finkel M P, 1976, Recent Results Cancer Res, P92; Gabig TG, 1998, MAMM GENOME, V9, P660, DOI 10.1007/s003359900840; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Hiemstra PS, 1999, J LEUKOCYTE BIOL, V66, P423, DOI 10.1002/jlb.66.3.423; Hochstrasser M, 2000, SCIENCE, V289, P563, DOI 10.1126/science.289.5479.563; Huang X, 2002, P NATL ACAD SCI USA, V99, P11369, DOI 10.1073/pnas.172285799; Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2; KAS K, 1992, BIOCHEM BIOPH RES CO, V187, P927, DOI 10.1016/0006-291X(92)91286-Y; KAS K, 1993, HUM MOL GENET, V2, P349, DOI 10.1093/hmg/2.4.349; Katoh M, 2003, INT J ONCOL, V22, P1375; Knee R, 1997, NEUROCHEM INT, V31, P379, DOI 10.1016/S0197-0186(96)00108-8; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; Lee CGL, 2003, ONCOGENE, V22, P2592, DOI 10.1038/sj.onc.1206337; Li BY, 2000, P NATL ACAD SCI USA, V97, P3850, DOI 10.1073/pnas.070047997; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu YC, 1999, P NATL ACAD SCI USA, V96, P4313, DOI 10.1073/pnas.96.8.4313; Lock RB, 1996, INT J ONCOL, V8, P305; Longthorne VL, 1997, EMBO J, V16, P3805, DOI 10.1093/emboj/16.13.3805; Lund AH, 2002, NAT GENET, V32, P160, DOI 10.1038/ng956; Mayo LD, 2002, TRENDS BIOCHEM SCI, V27, P462, DOI 10.1016/S0968-0004(02)02166-7; MICHIELS L, 1993, ONCOGENE, V8, P2537; Mikkers H, 2002, NAT GENET, V32, P459, DOI 10.1038/ng1102-459b; MONIA BP, 1990, J BIOL CHEM, V265, P19356; Mourtada-Maarabouni M, 2003, CELL DEATH DIFFER, V10, P1016, DOI 10.1038/sj.cdd.4401274; NAKAMURA M, 1995, P NATL ACAD SCI USA, V92, P3463, DOI 10.1073/pnas.92.8.3463; Nakamura M, 2003, EUR J BIOCHEM, V270, P4052, DOI 10.1046/j.1432-1033.2003.03790.x; Ormandy CJ, 2003, BREAST CANCER RES TR, V78, P323, DOI 10.1023/A:1023033708204; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Raasi S, 2001, J BIOL CHEM, V276, P35334, DOI 10.1074/jbc.M105139200; RATHMELL JC, 2002, CELL S, V109, P97; RAYNER JR, 1994, MOL CELL BIOL, V14, P880, DOI 10.1128/MCB.14.2.880; Rossman TG, 2003, ONCOGENE, V22, P1817, DOI 10.1038/sj.onc.1206283; Rossman TG, 1999, CARCINOGENESIS, V20, P311, DOI 10.1093/carcin/20.2.311; ROY C, 1992, EXP CELL RES, V200, P416, DOI 10.1016/0014-4827(92)90190-J; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; SCHWARTZ LM, 1990, NEURON, V5, P411, DOI 10.1016/0896-6273(90)90080-Y; Seraj MJ, 2000, CANCER RES, V60, P2764; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Sutherland LC, 2000, ONCOGENE, V19, P3774, DOI 10.1038/sj.onc.1203720; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; VANBEVEREN C, 1984, VIROLOGY, V135, P229, DOI 10.1016/0042-6822(84)90133-8; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WLODARSKA I, 1993, GENE CHROMOSOME CANC, V8, P224, DOI 10.1002/gcc.2870080404; WOOLF TM, 1992, P NATL ACAD SCI USA, V89, P7305, DOI 10.1073/pnas.89.16.7305; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; Zannettino ACW, 1996, J IMMUNOL, V156, P611	58	26	26	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2004	23	58					9419	9426		10.1038/sj.onc.1208048	http://dx.doi.org/10.1038/sj.onc.1208048			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT	15543234				2022-12-17	WOS:000225764100013
J	Kopnin, PB; Kravchenko, IV; Furalyov, VA; Pylev, LN; Kopnin, BP				Kopnin, PB; Kravchenko, IV; Furalyov, VA; Pylev, LN; Kopnin, BP			Cell type-specific effects of asbestos on intracellular ROS levels, DNA oxidation and G1 cell cycle checkpoint	ONCOGENE			English	Article						asbestos; reactive oxygen species; mesothelial cells; p21(Cip1/Waf1); G1 checkpoint	PLEURAL MESOTHELIAL CELLS; INDUCED TRANSFORMATION; CROSS-LINKING; P53; EXPRESSION; MECHANISMS; DISEASE; ANTHRACYCLINES; ACTIVATION; APOPTOSIS	Exposure to asbestos fibers increases the risk of development of mesotheliomas and lung carcinomas, but not fibrosarcomas. We present data suggesting that resistance of fibroblasts to asbestos-induced carcinogenesis is likely to be connected with their lower ability to generate reactive oxygen species (ROS) in response to asbestos exposure and stricter control of proliferation of cells bearing asbestos/ROS-induced injuries. In fact, chrysotile (Mg6Si4O10(OH)(8)) asbestos exposure (5-10 mug/cm(2)) increased intracellular ROS and 8-oxo-guanine contents in rat pleural mesothelial cells, but not in lung fibroblasts. Simultaneously, moderate dosages of chrysotile and other agents increasing ROS levels ( hydrogen peroxide, H2O2 and ethyl-methanesulfonate, EMS) inhibited cell cycle progression, in particular G1-to-S transition, in fibroblasts, but not in mesothelial cells. The arrested fibroblasts underwent cell death, while the majority of chrysotile-treated mesothelial cells survived. The differences in cell cycle response to asbestos/ROS-induced injuries correlated with distinct activity of p53-p21(Cip1/Waf1) pathway in the two cell types. Chrysotile, H2O2 and EMS caused p53 upregulation in both cell types, but mesothelial cells, unlike fibroblasts, showed no accumulation of p21(Cip1/Waf1). Of note, treatment with doxorubicin caused similar p53-dependent p21(Cip1/Waf1) upregulation and cell cycle arrest in both cell types. This suggests differential response of fibroblasts and mesothelial cells specifically to asbestos/ROS exposure rather than to all DNA-damaging insults.	Blokhin Canc Res Ctr, Inst Carcinogenesis, Moscow 115478, Russia; VA Engelhardt Mol Biol Inst, Moscow 117984, Russia; Univ Oslo, Moscow Ctr Med Studies, Moscow, Russia	N.N. Blokhin Russian Cancer Research Center; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS	Kopnin, BP (corresponding author), Blokhin Canc Res Ctr, Inst Carcinogenesis, Kashirskoye Shosse 24, Moscow 115478, Russia.	bkopnin@yahoo.com	Kopnin, Pavel/R-8213-2019; Kravchenko, Irina V/K-5414-2015; Kopnin, Boris/R-8240-2019	Kopnin, Pavel/0000-0002-2078-4274; Kravchenko, Irina V/0000-0002-1715-1281; Kopnin, Boris/0000-0003-3100-2212				Agapova LS, 1999, ONCOGENE, V18, P3135, DOI 10.1038/sj.onc.1202386; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; BARRETT JC, 1994, ENVIRON HEALTH PERSP, V102, P19, DOI 10.2307/3432053; Bouvard V, 2000, ONCOGENE, V19, P649, DOI 10.1038/sj.onc.1203366; BRODY AR, 1993, ENVIRON HEALTH PERSP, V100, P21, DOI 10.2307/3431517; Burns TF, 2003, CANCER BIOL THER, V2, P431, DOI 10.4161/cbt.2.4.478; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Fei PW, 2002, CANCER RES, V62, P7316; Jaurand MC, 1997, ENVIRON HEALTH PERSP, V105, P1073, DOI 10.2307/3433512; JAURAND MC, 1981, IN VITRO CELL DEV B, V17, P98; KAMP DW, 1992, FREE RADICAL BIO MED, V12, P293, DOI 10.1016/0891-5849(92)90117-Y; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kravchenko IV, 1998, TERATOGEN CARCIN MUT, V18, P141, DOI 10.1002/(SICI)1520-6866(1998)18:3<141::AID-TCM5>3.3.CO;2-E; Kravchenko IV, 2001, TERATOGEN CARCIN MUT, V21, P315, DOI 10.1002/tcm.1019; Levresse V, 1997, AM J RESP CELL MOL, V17, P660, DOI 10.1165/ajrcmb.17.6.2854; Levresse V, 1998, ONCOGENE, V16, P1041, DOI 10.1038/sj.onc.1201627; Luce RA, 2001, METHOD ENZYMOL, V340, P396; Manning CB, 2002, INT IMMUNOPHARMACOL, V2, P191, DOI 10.1016/S1567-5769(01)00172-2; Marnett LJ, 2000, CARCINOGENESIS, V21, P361, DOI 10.1093/carcin/21.3.361; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Mossman BT, 1996, CANCER INVEST, V14, P466, DOI 10.3109/07357909609018904; Muhle H, 2000, INT ARCH OCC ENV HEA, V73, pS53, DOI 10.1007/PL00014627; Neuberger M, 2003, INT ARCH OCC ENV HEA, V76, P161, DOI 10.1007/s00420-002-0397-2; Pass HI, 1996, J CELL BIOCHEM, P142; Prives C, 1999, J PATHOL, V187, P112; PYLEV L, 2002, GIG SANIT, V3, P61; Richardson DS, 1997, BLOOD REV, V11, P201, DOI 10.1016/S0268-960X(97)90020-5; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; Sablina AA, 2003, J BIOL CHEM, V278, P27362, DOI 10.1074/jbc.M300547200; Sablina AA, 2001, ONCOGENE, V20, P899, DOI 10.1038/sj.onc.1204156; Shukla A, 2003, INT J BIOCHEM CELL B, V35, P1198, DOI 10.1016/S1357-2725(02)00315-1; SKLADANOWSKI A, 1994, BIOCHEM PHARMACOL, V47, P2269, DOI 10.1016/0006-2952(94)90265-8; Torday JS, 2001, PEDIATR RES, V49, P843, DOI 10.1203/00006450-200106000-00021; Vasilieva LA, 1998, CANCER LETT, V134, P209, DOI 10.1016/S0304-3835(98)00255-9	34	26	30	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2004	23	54					8834	8840		10.1038/sj.onc.1208108	http://dx.doi.org/10.1038/sj.onc.1208108			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	871VQ	15480427				2022-12-17	WOS:000225165100013
J	Umetani, N; Fujimoto, A; Takeuchi, H; Shinozaki, M; Bilchik, AJ; Hoon, DSB				Umetani, N; Fujimoto, A; Takeuchi, H; Shinozaki, M; Bilchik, AJ; Hoon, DSB			Allelic imbalance of APAF-1 locus at 12q23 is related to progression of colorectal carcinoma	ONCOGENE			English	Article						allelic imbalance; APAF-1; colorectal carcinoma; apoptosis; chromosome 12q23	DNA METHYLATION; MICROSATELLITE INSTABILITY; PROMOTER HYPERMETHYLATION; TRANSCRIPTIONAL TARGET; CUTANEOUS MELANOMA; CANCER; GENE; P53; DISEASE; TUMORS	APAF-1 gene, located at chromosome locus 12q23, is a key factor in the mitochondrial apoptotic pathway downstream of p53, and is a potential tumor suppressor gene. We hypothesized that APAF-1 gene dysfunction due to allelic imbalance ( AI) contributes to the development and progression of colorectal carcinoma (CRC). AI at APAF-1 locus and microsatellite instability (MIN) in CRCs and adenomas were assessed by multiple microsatellite markers. The frequency of AI significantly increased with tumor progression; 0 of 33 (0%) adenomas, 14 of 49 (29%) primary CRCs, and 18 of 34 (53%) liver metastases had AI. A total of 12 metastases were matched with corresponding primary CRCs; in 11 of 12 (92%) pairs, the metastasis had same AI status as the corresponding primary tumor. APAF-1 mRNA transcription level was significantly decreased with AI in liver metastases (P = 0.009). Promoter hypermethylation was found in three of 35 (9%) primary CRCs and one of 15 (7%) liver metastases by methylation-specific PCR but was not correlated with AI. MIN was observed in 11 of 49 (23%) primary CRCs and was a favorable prognostic factor. Our results suggest that APAF-1 gene haploinsufficiency caused by AI increases with tumor progression, and relates to hepatic metastasis.	St Johns Hlth Sci Ctr, John Wayne Canc Inst, Dept Mol Oncol, Santa Monica, CA 90404 USA; St Johns Hlth Sci Ctr, John Wayne Canc Inst, Div Gastrointestinal Oncol, Santa Monica, CA 90404 USA	John Wayne Cancer Institute; John Wayne Cancer Institute	Hoon, DSB (corresponding author), St Johns Hlth Sci Ctr, John Wayne Canc Inst, Dept Mol Oncol, 2200 Santa Monica Blvd, Santa Monica, CA 90404 USA.	hoon@jwci.org	Hoon, Dave SB/C-7146-2018	Hoon, Dave SB/0000-0003-1915-3683	NCI NIH HHS [P0 CA29605] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA029605] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Baylin SB, 1998, ADV CANCER RES, V72, P141; Boland CR, 1998, CANCER RES, V58, P5248; Deng GR, 1999, CANCER RES, V59, P2029; Esteller M, 2000, CANCER RES, V60, P4366; Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024; Fortin A, 2001, J CELL BIOL, V155, P207, DOI 10.1083/jcb.200105137; Fujimoto A, 2004, CANCER RES, V64, P2245, DOI 10.1158/0008-5472.CAN-03-2932; Gryfe R, 2000, NEW ENGL J MED, V342, P69, DOI 10.1056/NEJM200001133420201; Hao XP, 2002, GUT, V50, P834, DOI 10.1136/gut.50.6.834; Hatta Y, 1997, BRIT J CANCER, V75, P1256, DOI 10.1038/bjc.1997.214; Hemminki A, 2000, GASTROENTEROLOGY, V119, P921, DOI 10.1053/gast.2000.18161; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Herman JG, 2002, GASTROENTEROL CLIN N, V31, P945, DOI 10.1016/S0889-8553(02)00058-4; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Hermsen M, 2002, GASTROENTEROLOGY, V123, P1109, DOI 10.1053/gast.2002.36051; Hoon DSB, 2002, METHOD ENZYMOL, V356, P302; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; Jones PA, 1996, CANCER RES, V56, P2463; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Kim H, 1999, CYTOGENET CELL GENET, V87, P252, DOI 10.1159/000015436; Kimura M, 1998, CANCER RES, V58, P2456; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Murty VVVS, 1996, GENOMICS, V35, P562, DOI 10.1006/geno.1996.0398; Nakayama T, 2001, AM J PATHOL, V158, P1371, DOI 10.1016/S0002-9440(10)64088-6; RENBAUM P, 1990, NUCLEIC ACIDS RES, V18, P1145, DOI 10.1093/nar/18.5.1145; Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461; Robles AI, 2001, CANCER RES, V61, P6660; Schneider BG, 2003, J CLIN PATHOL-MOL PA, V56, P141, DOI 10.1136/mp.56.3.141; Shinozaki M, 2004, CLIN CANCER RES, V10, P1753, DOI 10.1158/1078-0432.CCR-1169-3; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Spugnardi M, 2003, CANCER RES, V63, P1639; Takeuchi H, 2004, J CLIN ONCOL, V22, P2671, DOI 10.1200/JCO.2004.12.009; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Watanabe T, 2001, NEW ENGL J MED, V344, P1196, DOI 10.1056/NEJM200104193441603; Xiong ZG, 2001, CANCER EPIDEM BIOMAR, V10, P799; Yatsuoka T, 2000, AM J GASTROENTEROL, V95, P2080	41	26	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2004	23	50					8292	8300		10.1038/sj.onc.1208022	http://dx.doi.org/10.1038/sj.onc.1208022			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	866CC	15378005				2022-12-17	WOS:000224749500011
J	Kim, CJ; Cho, YG; Park, CH; Kim, SY; Nam, SW; Lee, SH; Yoo, NJ; Lee, JY; Park, WS				Kim, CJ; Cho, YG; Park, CH; Kim, SY; Nam, SW; Lee, SH; Yoo, NJ; Lee, JY; Park, WS			Genetic alterations of the MYH gene in gastric cancer	ONCOGENE			English	Article						somatic mutation; stomach cancer; loss of heterozygosity; DNA repair	OXIDATIVE DNA-DAMAGE; SOMATIC G-C->T-A MUTATIONS; HELICOBACTER-PYLORI; ESCHERICHIA-COLI; MUTY GENE; ADENOMATOUS POLYPOSIS; GERMLINE MUTATIONS; TRANSVERSIONS; REPAIR; HOMOLOG	Increased oxygen free radicals produced in gastric mucosa by H. pylori induce DNA damage and lead to dyspalsia and gastric cancers. However, only a small percentage of individuals that carry H. pylori develop gastric cancer, indicating that other factors are involved. We have screened a set of 95 sporadic gastric cancers for mutations and allele loss of the DNA glycosylase MYH gene, which excises adenine misincorporated opposite unrepaired 8-oxoG. Two of 95 cancers had bi-allelic mutations of the MYH gene with somatic missense mutation of one allele and loss of the remaining allele. The mutations were missense mutations, P391S and Q400R, in exon 13 encoding NUDIX hydrolase domain of the gene. The patients were H. pylori-positive and the tumors were of advanced intestinal-type gastric cancer with lymph node metastasis. In addition, 4 (17.4%) of 23 informative cases showed allele loss at MYH locus. Therefore, our data suggest that somatic mutations of base excision repair gene MYH contribute to the development of a sub-set of sporadic gastric cancers.	Catholic Univ Korea, Coll Med, Dept Pathol, Seoul 137701, South Korea; Catholic Univ Korea, Coll Med, Dept Surg, Seoul 137701, South Korea	Catholic University of Korea; Catholic University of Korea	Park, WS (corresponding author), Catholic Univ Korea, Coll Med, Dept Pathol, 505 Banpo Dong, Seoul 137701, South Korea.	wonsang@catholic.ac.kr	Yoo, Nam Jin/GNM-9060-2022					Al-Tassan N, 2002, NAT GENET, V30, P227, DOI 10.1038/ng828; Baik SC, 1996, CANCER RES, V56, P1279; Cheadle JP, 2003, HUM MOL GENET, V12, pR159, DOI 10.1093/hmg/ddg259; Danese S, 2001, SCAND J GASTROENTERO, V36, P247, DOI 10.1080/003655201750074474; Farinati F, 1998, GUT, V42, P351, DOI 10.1136/gut.42.3.351; Halford SER, 2003, AM J PATHOL, V162, P1545, DOI 10.1016/S0002-9440(10)64288-5; JARUGA P, 1994, FEBS LETT, V341, P59, DOI 10.1016/0014-5793(94)80240-8; Jones S, 2002, HUM MOL GENET, V11, P2961, DOI 10.1093/hmg/11.23.2961; Lee JY, 1998, VIRCHOWS ARCH, V433, P305, DOI 10.1007/s004280050253; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Maaroos HI, 1999, SCAND J GASTROENTERO, V34, P864, DOI 10.1080/003655299750025318; MALINS DC, 1991, CANCER RES, V51, P5430; MCGOLDRICK JP, 1995, MOL CELL BIOL, V15, P989; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; MO JY, 1991, J MOL BIOL, V222, P925, DOI 10.1016/0022-2836(91)90586-U; MORIYA M, 1993, MOL GEN GENET, V239, P72, DOI 10.1007/BF00281603; NGHIEM Y, 1988, P NATL ACAD SCI USA, V85, P2709, DOI 10.1073/pnas.85.8.2709; Noguchi K, 2002, PATHOL INT, V52, P110, DOI 10.1046/j.1440-1827.2002.01331.x; OKAMOTO K, 1994, INT J CANCER, V58, P825, DOI 10.1002/ijc.2910580613; Sampson JR, 2003, LANCET, V362, P39, DOI 10.1016/S0140-6736(03)13805-6; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Sieber OM, 2003, NEW ENGL J MED, V348, P791, DOI 10.1056/NEJMoa025283; Slupska MM, 1996, J BACTERIOL, V178, P3885, DOI 10.1128/jb.178.13.3885-3892.1996; Smoot DT, 2000, CARCINOGENESIS, V21, P2091, DOI 10.1093/carcin/21.11.2091; Thomas D, 1997, MOL GEN GENET, V254, P171, DOI 10.1007/s004380050405	25	26	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2004	23	40					6820	6822		10.1038/sj.onc.1207574	http://dx.doi.org/10.1038/sj.onc.1207574			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	850ZT	15273732				2022-12-17	WOS:000223653600014
J	Treuner, K; Helton, R; Barlow, C				Treuner, K; Helton, R; Barlow, C			Loss of Rad52 partially rescues tumorigenesis and T-cell maturation in Atm-deficient mice	ONCOGENE			English	Article						Rad52; Ataxia Telangiectasia; Atm-/-mice; DNA repair; tumorigenesis	DOUBLE-STRAND BREAKS; HOMOLOGOUS RECOMBINATION; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; INCREASED FREQUENCY; PROTEIN; NEUROGENESIS; DISRUPTION; RESISTANCE; DOMAIN	Ataxia Telangiectasia (A-T) is an autosomal recessive disease caused by loss of function of the protein kinase ATM. Atm-deficient mice display several phenotypes consistent with the human disease, including predisposition to cancer, growth retardation, cell-proliferation defects and infertility. A-T patients have a several hundred fold increased risk of developing lymphomas and leukemias, which are typically highly invasive. By reducing homologous recombination through genetic deletion of the Rad52 protein, we were able to decrease substantially the development of T-cell lymphomas in Atm-/- mice, resulting in an increased life span of the double mutant mice. Additionally, we were able to partially rescue the T-cell development of Atm-/- mice. Other phenotypes, including growth defects, genomic instability, infertility and radiosensitivity, were not rescued. Our results suggest that excessive recombination is an important contributor to tumorigenesis in A-T.	Salk Inst Biol Studies, Genet Lab, La Jolla, CA 92037 USA	Salk Institute	Barlow, C (corresponding author), Salk Inst Biol Studies, Genet Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	carrolee_barlow@merck.com			NINDS NIH HHS [NS39601] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039601] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Baynton K, 2003, J BIOL CHEM, V278, P36476, DOI 10.1074/jbc.M303885200; Bishop AJR, 2003, CANCER RES, V63, P5335; Bishop AJR, 2000, CANCER RES, V60, P395; Chakraverty RK, 1999, BIOESSAYS, V21, P286; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; Germain RN, 2002, NAT REV IMMUNOL, V2, P309, DOI 10.1038/nri798; GERMAN J, 1995, DERMATOL CLIN, V13, P7, DOI 10.1016/S0733-8635(18)30101-3; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687; Kagawa W, 2002, MOL CELL, V10, P359, DOI 10.1016/S1097-2765(02)00587-7; Lee Y, 2000, GENE DEV, V14, P2576, DOI 10.1101/gad.837100; Lisby M, 2003, NAT CELL BIOL, V5, P572, DOI 10.1038/ncb997; Liyanage M, 2000, BLOOD, V96, P1940, DOI 10.1182/blood.V96.5.1940.h8001940_1940_1946; Luo LP, 1998, CANCER RES, V58, P2293; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; Mohaghegh P, 2001, HUM MOL GENET, V10, P741, DOI 10.1093/hmg/10.7.741; Petiniot LK, 2000, P NATL ACAD SCI USA, V97, P6664, DOI 10.1073/pnas.97.12.6664; Petiniot LK, 2002, MOL CELL BIOL, V22, P3174, DOI 10.1128/MCB.22.9.3174-3177.2002; Rijkers T, 1998, MOL CELL BIOL, V18, P6423, DOI 10.1128/MCB.18.11.6423; Sekiguchi J, 2001, P NATL ACAD SCI USA, V98, P3243, DOI 10.1073/pnas.051632098; Sigurdsson S, 2002, J BIOL CHEM, V277, P42790, DOI 10.1074/jbc.M208004200; Singleton MR, 2002, P NATL ACAD SCI USA, V99, P13492, DOI 10.1073/pnas.212449899; Solinger JA, 2002, MOL CELL, V10, P1175, DOI 10.1016/S1097-2765(02)00743-8; Symington LS, 2002, MICROBIOL MOL BIOL R, V66, P630, DOI 10.1128/MMBR.66.4.630-670.2002; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Wong KK, 2003, NATURE, V421, P643, DOI 10.1038/nature01385	29	26	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2004	23	27					4655	4661		10.1038/sj.onc.1207604	http://dx.doi.org/10.1038/sj.onc.1207604			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZX	15122331				2022-12-17	WOS:000221799200001
J	Perrotti, D; Calabretta, B				Perrotti, D; Calabretta, B			Translational regulation by the p210 BCR/ABL oncoprotein	ONCOGENE			English	Review						chronic myelogenous leukemia; BCR/ABL; translation	CHRONIC MYELOGENOUS LEUKEMIA; NUCLEAR RIBONUCLEOPROTEIN-K; BINDING PROTEIN ALPHA; C-MYC TRANSCRIPTION; MESSENGER-RNA SUBSETS; ABL TYROSINE KINASE; HUMAN LA ANTIGEN; HNRNP-K; BLAST CRISIS; ERYTHROID-DIFFERENTIATION	The ability of oncogenic proteins to regulate the rate of translation of specific mRNA subsets may be a rapid and efficient mechanism to modulate the levels and, in many cases, the activity of the corresponding proteins. In the past few years, we have identified several RNA binding proteins with translation regulatory activity whose expression is markedly activated in the blast crisis of chronic myelogenous leukemia, which represents the most malignant disease stage. Perturbation of the activity of some RNA binding proteins suppresses the leukemogenic potential of BCR/ABL-expressing cells. Most importantly, we have identified some of the targets of these RNA binding proteins. Two of these targets, c/ebpalpha and mdm2 mRNAs, are directly relevant for the altered differentiation and survival of leukemic cells. The identification of mRNA targets translationally regulated by RNA binding proteins overexpressed in tumor cells may lead to the development of therapeutic strategies aimed at modulating the translation rate of specific mRNAs.	Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Human Canc Genet Program, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Jefferson University	Perrotti, D (corresponding author), Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Human Canc Genet Program, Columbus, OH 43210 USA.	perrotti-1@medctr.osu.edu	Perrotti, Danilo/E-3852-2011		NCI NIH HHS [1R01 CA095512-01A2, P01 CA78890, P30 CA16058] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095512, P30CA016058, P01CA078890] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEDNAREK JM, 1988, J NATL CANCER I, V80, P251, DOI 10.1093/jnci/80.4.251; Blyn LB, 1997, J VIROL, V71, P6243, DOI 10.1128/JVI.71.8.6243-6246.1997; Bomsztyk K, 1997, FEBS LETT, V403, P113, DOI 10.1016/S0014-5793(97)00041-0; Brown V, 2001, CELL, V107, P477, DOI 10.1016/S0092-8674(01)00568-2; BUSTELO XR, 1995, MOL CELL BIOL, V15, P1324; Calkhoven CF, 2000, GENE DEV, V14, P1920; Cardinali B, 2003, J BIOL CHEM, V278, P35145, DOI 10.1074/jbc.M300722200; Carella A, 2001, CHRONIC MYELOID LEUK; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Cazzola M, 2000, BLOOD, V95, P3280, DOI 10.1182/blood.V95.11.3280.011k41_3280_3288; Clemens MJ, 1999, INT J BIOCHEM CELL B, V31, P1, DOI 10.1016/S1357-2725(98)00127-7; Collier B, 1998, J BIOL CHEM, V273, P22648, DOI 10.1074/jbc.273.35.22648; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; Cristofano A. D., 2001, J EXP MED, V194, P275; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; Derrigo M, 2000, INT J MOL MED, V5, P111; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Dua K, 2001, PROTEOMICS, V1, P1191, DOI 10.1002/1615-9861(200110)1:10<1191::AID-PROT1191>3.0.CO;2-8; Evans JR, 2003, ONCOGENE, V22, P8012, DOI 10.1038/sj.onc.1206645; Fan H, 1998, MOL CELL BIOL, V18, P3201, DOI 10.1128/MCB.18.6.3201; Fang GF, 2000, BLOOD, V96, P2246, DOI 10.1182/blood.V96.6.2246.h8002246_2246_2253; Feigenblum D, 1996, MOL CELL BIOL, V16, P5450; Fu LN, 1996, EMBO J, V15, P4392, DOI 10.1002/j.1460-2075.1996.tb00812.x; Fu LN, 1999, ONCOGENE, V18, P6419, DOI 10.1038/sj.onc.1203064; GAILLARD C, 1994, NUCLEIC ACIDS RES, V22, P4183, DOI 10.1093/nar/22.20.4183; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Gopalkrishnan RV, 1999, INT J BIOCHEM CELL B, V31, P151, DOI 10.1016/S1357-2725(98)00138-1; Graff J, 1998, J VIROL, V72, P9668, DOI 10.1128/JVI.72.12.9668-9675.1998; Gray NK, 1998, METH MOL B, V77, P379; GRIFFIN JD, 1983, BLOOD, V61, P85; Groysman M, 1998, ONCOGENE, V17, P1597, DOI 10.1038/sj.onc.1202074; Habelhah H, 2001, NAT CELL BIOL, V3, P325, DOI 10.1038/35060131; Han BG, 2003, ONCOGENE, V22, P5325, DOI 10.1038/sj.onc.1206783; Harford JB, 1997, MRNA METABOLISM POST; Holcik M, 2003, MOL CELL BIOL, V23, P280, DOI 10.1128/MCB.23.1.280-288.2003; Holcik M, 2000, MOL CELL BIOL, V20, P4648, DOI 10.1128/MCB.20.13.4648-4657.2000; Honda H, 2000, BLOOD, V95, P1144, DOI 10.1182/blood.V95.4.1144.004k04_1144_1150; Iervolino A, 2002, MOL CELL BIOL, V22, P2255, DOI 10.1128/MCB.22.7.2255-2266.2002; Intine RV, 2003, MOL CELL, V12, P1301, DOI 10.1016/S1097-2765(03)00429-5; Kahvejian A, 2001, COLD SPRING HARB SYM, V66, P293, DOI 10.1101/sqb.2001.66.293; Kantarjian HM, 2002, BLOOD, V99, P3547, DOI 10.1182/blood.V99.10.3547; KANTARJIAN HM, 1993, BLOOD, V82, P691; Keene JD, 2002, MOL CELL, V9, P1161, DOI 10.1016/S1097-2765(02)00559-2; Kim JH, 2003, MOL CELL BIOL, V23, P708, DOI 10.1128/MCB.23.2.708-720.2003; Kim YK, 2001, NUCLEIC ACIDS RES, V29, P5009, DOI 10.1093/nar/29.24.5009; KOZAK M, 2001, SCI STKE, V71, pPE1; Kuersten S, 2003, NAT REV GENET, V4, P626, DOI 10.1038/nrg1125; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Lee MH, 1996, J BIOL CHEM, V271, P3420; Lincoln AJ, 1998, J BIOL CHEM, V273, P9552, DOI 10.1074/jbc.273.16.9552; Makeyev AV, 2002, RNA, V8, P265, DOI 10.1017/S1355838202024627; Maraia RJ, 2001, MOL CELL BIOL, V21, P367, DOI 10.1128/MCB.21.2.367-379.2001; MATULONIS U, 1993, EXP HEMATOL, V21, P1460; Mazan-Mamczarz K, 2003, P NATL ACAD SCI USA, V100, P8354, DOI 10.1073/pnas.1432104100; Meijer HA, 2002, BIOCHEM J, V367, P1, DOI 10.1042/BJ20011706; Meric F, 2002, MOL CANCER THER, V1, P971; Miau LH, 1998, J BIOL CHEM, V273, P10784, DOI 10.1074/jbc.273.17.10784; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; Nowicki MO, 2003, ONCOGENE, V22, P3952, DOI 10.1038/sj.onc.1206620; Ostareck DH, 2001, CELL, V104, P281, DOI 10.1016/S0092-8674(01)00212-4; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; Ostareck-Lederer A, 2002, MOL CELL BIOL, V22, P4535, DOI 10.1128/MCB.22.13.4535-4543.2002; Ostareck-Lederer A, 1998, TRENDS BIOCHEM SCI, V23, P409, DOI 10.1016/S0968-0004(98)01301-2; Perrotti D, 2000, MOL CELL BIOL, V20, P6159, DOI 10.1128/MCB.20.16.6159-6169.2000; Perrotti D, 2002, ONCOGENE, V21, P8577, DOI 10.1038/sj.onc.1206085; Perrotti D, 2002, NAT GENET, V30, P48, DOI 10.1038/ng791; Perrotti D, 1998, EMBO J, V17, P4442, DOI 10.1093/emboj/17.15.4442; Pestova TV, 2001, P NATL ACAD SCI USA, V98, P7029, DOI 10.1073/pnas.111145798; Prats AC, 2002, PROG NUCLEIC ACID RE, V72, P367, DOI 10.1016/S0079-6603(02)72075-8; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; Raught B, 1996, CANCER RES, V56, P4382; Raught B, 2001, P NATL ACAD SCI USA, V98, P7037, DOI 10.1073/pnas.121145898; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; Rosenwald IB, 1996, BIOESSAYS, V18, P243, DOI 10.1002/bies.950180312; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Salesse S, 2002, ONCOGENE, V21, P8605, DOI 10.1038/sj.onc.1206088; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Sawyers CL, 2002, BLOOD, V99, P3530, DOI 10.1182/blood.V99.10.3530; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; Schullery DS, 1999, J BIOL CHEM, V274, P15101, DOI 10.1074/jbc.274.21.15101; Shyu AB, 2000, CELL, V102, P135, DOI 10.1016/S0092-8674(00)00018-0; Silvera D, 1999, J BIOL CHEM, V274, P38163, DOI 10.1074/jbc.274.53.38163; Skorski T, 1996, P NATL ACAD SCI USA, V93, P13137, DOI 10.1073/pnas.93.23.13137; Skorski T, 1998, BLOOD, V91, P406, DOI 10.1182/blood.V91.2.406.406_406_418; Skorski T, 2002, ONCOGENE, V21, P8591, DOI 10.1038/sj.onc.1206087; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Skorski T, 1996, BLOOD, V88, P1005, DOI 10.1182/blood.V88.3.1005.1005; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; Sonenberg N, 1993, CURR OPIN CELL BIOL, V5, P955, DOI 10.1016/0955-0674(93)90076-3; STEWART MJ, 1995, LEUKEMIA, V9, P1499; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; Tenenbaum SA, 2002, METHODS, V26, P191, DOI 10.1016/S1046-2023(02)00022-1; Tenenbaum SA, 2000, P NATL ACAD SCI USA, V97, P14085, DOI 10.1073/pnas.97.26.14085; Thisted T, 2001, J BIOL CHEM, V276, P17484, DOI 10.1074/jbc.M010594200; Timchenko NA, 1999, NUCLEIC ACIDS RES, V27, P4517, DOI 10.1093/nar/27.22.4517; Tomonaga T, 1996, P NATL ACAD SCI USA, V93, P5830, DOI 10.1073/pnas.93.12.5830; Trotta R, 2003, CANCER CELL, V3, P145, DOI 10.1016/S1535-6108(03)00020-5; van der Velden AW, 1999, INT J BIOCHEM CELL B, V31, P87, DOI 10.1016/S1357-2725(98)00134-4; Waggoner SA, 2003, MOL CELL BIOL, V23, P7055, DOI 10.1128/MCB.23.19.7055-7067.2003; Willis AE, 1999, INT J BIOCHEM CELL B, V31, P73, DOI 10.1016/S1357-2725(98)00133-2; Wolin SL, 2002, ANNU REV BIOCHEM, V71, P375, DOI 10.1146/annurev.biochem.71.090501.150003; WONG KK, 1995, MOL CELL BIOL, V15, P6535; Yin YL, 2002, NAT CELL BIOL, V4, P462, DOI 10.1038/ncb801; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zimmer SG, 2000, ANTICANCER RES, V20, P1343; Zou XM, 1999, J BIOL CHEM, V274, P18141, DOI 10.1074/jbc.274.26.18141; Zou XM, 1997, GENE DEV, V11, P654, DOI 10.1101/gad.11.5.654	109	26	28	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2004	23	18					3222	3229		10.1038/sj.onc.1207543	http://dx.doi.org/10.1038/sj.onc.1207543			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	813AJ	15094772				2022-12-17	WOS:000220879700011
J	Lin, SH; Nishino, M; Luo, WP; Aumais, JP; Galfione, M; Kuang, J; Yu-Lee, LY				Lin, SH; Nishino, M; Luo, WP; Aumais, JP; Galfione, M; Kuang, J; Yu-Lee, LY			Inhibition of prostate tumor growth by overexpression of NudC, a microtubule motor-associated protein	ONCOGENE			English	Article						NudC; dynein; microtubule; mitosis; prostate cancer	NUCLEAR MIGRATION GENE; CARCINOMA CELL-LINE; CYTOPLASMIC DYNEIN; MOVEMENT PROTEIN; ASPERGILLUS-NIDULANS; DYNACTIN REVEALS; HUMAN HOMOLOG; LIS1; LOCALIZATION; EXPRESSION	Microtubules play a central role in coordinating various cellular functions that are orchestrated by their interaction with molecular motors. Anticancer drugs that target microtubule dynamics have been shown to be effective in cancer treatment. However, the effect of microtubule motor-associated molecules on cancer cell proliferation is not clear. Here, we investigated the role of NudC, a nuclear movement protein associated with the microtubule motor dynein, on prostate tumorigenesis. Recombinant adenovirus expressing NudC (Ad-NudC) was used to examine the effects of NudC on the tumorigenicity of prostate cancer cells. Expression of NudC in LNCaP cells inhibited their anchorage-independent growth in a soft agar colony assay. Expression of NudC in DU145 or PC-3 cells inhibited tumor growth in a subcutaneous xenograft model. At the cellular level, expression of NudC in DU145 and PC-3 cells inhibited cell proliferation at 48 h after Ad-NudC infection. FACS analysis of cell cycle distribution showed that 50-60% of Ad-NudC-infected PC-3 cells have a G2/M-phase DNA content compared to about 16-19% in Ad-Luciferase (Ad-Luc)-infected control cells, suggesting that NudC overexpression resulted in aberrant cell cycle progression. Immunofluorescence microscopy revealed a significant increase in cells with a single enlarged nucleus and cells exhibiting multiple nuclei, along with a concomitant increase in cell size in Ad-NudC-infected cells. These results suggest that NudC overexpression led to a block in cell division of prostate cancer cells, and that Ad-NudC may provide a new anticancer drug approach targeting the function of a microtubule motor-associated protein.	Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Baylor Coll Med, Cell & Mol Biol Program, Houston, TX 77030 USA	Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	Yu-Lee, LY (corresponding author), Baylor Coll Med, Dept Med, Houston, TX 77030 USA.	yulee@bcm.tmc.edu		Nishino, Michiya/0000-0003-4692-4981	NCI NIH HHS [R01 CA86342] Funding Source: Medline; NIDDK NIH HHS [R01 DK53176] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA086342] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053176] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Angus SP, 2002, EXP CELL RES, V276, P201, DOI 10.1006/excr.2002.5510; Aumais JP, 2003, J CELL SCI, V116, P1991, DOI 10.1242/jcs.00412; Aumais JP, 2000, MOL BIOL CELL, V11, p353A; Aumais JP, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-24-j0002.2001; AXTELL SM, 1995, MOL ENDOCRINOL, V9, P312, DOI 10.1210/me.9.3.312; Baas PW, 1999, NEURON, V22, P23, DOI 10.1016/S0896-6273(00)80675-3; Banks JD, 2001, CURR BIOL, V11, pR128, DOI 10.1016/S0960-9822(01)00059-8; Beaudouin J, 2002, CELL, V108, P83, DOI 10.1016/S0092-8674(01)00627-4; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Chen JG, 2002, CANCER RES, V62, P1935; Chiu YH, 1997, MOL BIOL CELL, V8, P1735, DOI 10.1091/mbc.8.9.1735; Coquelle FM, 2002, MOL CELL BIOL, V22, P3089, DOI 10.1128/MCB.22.9.3089-3102.2002; Dujardin DL, 2002, CURR OPIN CELL BIOL, V14, P44, DOI 10.1016/S0955-0674(01)00292-7; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; Estrera VT, 2001, J BIOL CHEM, V276, P15547, DOI 10.1074/jbc.M008156200; Faulkner NE, 2000, NAT CELL BIOL, V2, P784, DOI 10.1038/35041020; Gartel AL, 2002, MOL CANCER THER, V1, P639; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; Gocke CD, 2000, HISTOCHEM CELL BIOL, V114, P293; Gocke CD, 2000, LEUKEMIA LYMPHOMA, V39, P447, DOI 10.3109/10428190009113375; Han GS, 2001, CURR BIOL, V11, P719, DOI 10.1016/S0960-9822(01)00200-7; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; KAIGHN ME, 1979, INVEST UROL, V17, P16; Karki S, 1998, J CELL BIOL, V142, P1023, DOI 10.1083/jcb.142.4.1023; Karki S, 1999, CURR OPIN CELL BIOL, V11, P45, DOI 10.1016/S0955-0674(99)80006-4; Ligon LA, 2003, MOL BIOL CELL, V14, P1405, DOI 10.1091/mbc.E02-03-0155; Lin SH, 1999, ANTICANCER RES, V19, P337; Miller BA, 1999, EXP HEMATOL, V27, P742, DOI 10.1016/S0301-472X(98)00074-5; Moreau N, 2001, INT J DEV BIOL, V45, P839; Morris NR, 2000, J CELL BIOL, V148, P1097, DOI 10.1083/jcb.148.6.1097; Morris SM, 1998, EXP CELL RES, V238, P23, DOI 10.1006/excr.1997.3822; Morris SM, 1997, MOL ENDOCRINOL, V11, P229, DOI 10.1210/me.11.2.229; Morris SM, 1998, CURR BIOL, V8, P603, DOI 10.1016/S0960-9822(98)70232-5; Niethammer M, 2000, NEURON, V28, P697, DOI 10.1016/S0896-6273(00)00147-1; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; OSMANI AH, 1990, J CELL BIOL, V111, P543, DOI 10.1083/jcb.111.2.543; Peterson JR, 2002, CHEM BIOL, V9, P1275, DOI 10.1016/S1074-5521(02)00284-3; Quintyne NJ, 1999, J CELL BIOL, V147, P321, DOI 10.1083/jcb.147.2.321; Quintyne NJ, 2002, J CELL BIOL, V159, P245, DOI 10.1083/jcb.200203089; ROCKWELL SC, 1972, J NATL CANCER I, V49, P735; ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004, DOI 10.1056/NEJM199504133321507; Salina D, 2002, CELL, V108, P97, DOI 10.1016/S0092-8674(01)00628-6; Smith DS, 2000, NAT CELL BIOL, V2, P767, DOI 10.1038/35041000; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; Straight AF, 2000, CURR BIOL, V10, pR760, DOI 10.1016/S0960-9822(00)00746-6; Tai CY, 2002, J CELL BIOL, V156, P959, DOI 10.1083/jcb.200109046; Talcott B, 2000, J BIOL CHEM, V275, P10099, DOI 10.1074/jbc.275.14.10099; Wood Kenneth W., 2001, Current Opinion in Pharmacology, V1, P370, DOI 10.1016/S1471-4892(01)00064-9; Yan XM, 2003, MOL CELL BIOL, V23, P1239, DOI 10.1128/MCB.23.4.1239-1250.2003; Zhang MY, 2002, EXP CELL RES, V273, P73, DOI 10.1006/excr.2001.5414; Zhou T, 2003, DEV CELL, V5, P127, DOI 10.1016/S1534-5807(03)00186-2	52	26	28	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2004	23	14					2499	2506		10.1038/sj.onc.1207343	http://dx.doi.org/10.1038/sj.onc.1207343			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808GQ	14676831				2022-12-17	WOS:000220558000007
J	Charrasse, S; Comunale, F; Gilbert, E; Delattre, O; Gauthier-Rouviere, C				Charrasse, S; Comunale, F; Gilbert, E; Delattre, O; Gauthier-Rouviere, C			Variation in cadherins and catenins expression is linked to both proliferation and transformation of Rhabdomyosarcoma	ONCOGENE			English	Article						rhabdomyosarcoma; cadherins; catenins; transformation	GROWTH-FACTOR-II; SERUM RESPONSE FACTOR; MOUSE C2C12 MYOBLASTS; RHO-FAMILY GTPASES; N-CADHERIN; CELL-ADHESION; MYOGENIC DIFFERENTIATION; TERMINAL DIFFERENTIATION; BREAST-CANCER; PEDIATRIC RHABDOMYOSARCOMA	Cadherins are a family of transmembrane glycoproteins that mediate Ca2+-dependent homophilic cell-cell adhesion and play a crucial role in cell differentiation. E-cadherin-mediated cell-cell adhesion is lost during the development of most epithelial cancers. This study examines cadherin-dependent adhesion in cell lines derived from rhabdomyosarcoma (RMS), a highly malignant soft-tissue tumor committed to the myogenic lineage, but arrested prior to terminal differentiation. We analysed the expression of cadherins and associated catenins at the mRNA and protein levels as well as their localization in nine RMS-derived cell lines relative to normal myoblasts. We show a decrease in the expression of cadherins and catenins in all RMS-derived cell lines compared to control cells. This decrease in the expression of N- and M-cadherin was confirmed in RMS biopsies. In contrast, R-cadherin is found expressed in RMS, whereas it is normally absent in normal myoblasts. We show that a decrease of R-cadherin expression using RNA interference inhibits cell proliferation of the RD cell line. In addition to their diminished expression, cadherins and catenins do not localize to intercellular contacts in embryonal RMS (ERMS), whereas specific persistent localization is seen in alveolar RMS (ARMS)-derived cell lines. Thus, RMS exhibit defects in the expression of molecules of the cadherin family. Defects in the localization of these adhesion molecules at the sites of cell-cell contact are specifically observed in the ERMS subtype. In addition, our data suggest that R-cadherin is a specific diagnostic marker for RMS and is also an important factor of RMS cell proliferation.	CNRS, UPR 1086, CRBM, F-34293 Montpellier, France; Inst Curie, INSERM,U509, Sect Rech, Lab Pathol Mol Canc, F-75248 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Gauthier-Rouviere, C (corresponding author), CNRS, UPR 1086, CRBM, 1919 Route Mende, F-34293 Montpellier, France.	gauthier@crbm.cnrs-mop.fr		Comunale, Franck/0000-0001-8838-2151; delattre, olivier/0000-0002-8730-2276; GAUTHIER-ROUVIERE, Cecile/0000-0002-8364-3882				Barr FG, 1999, CANCER RES, V59, p1711S; BesnardGuerin C, 1996, HUM GENET, V97, P163, DOI 10.1007/BF02265259; Bouche M, 2000, FASEB J, V14, P1147, DOI 10.1096/fasebj.14.9.1147; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Carnac G, 1998, MOL BIOL CELL, V9, P1891, DOI 10.1091/mbc.9.7.1891; Chalmers IJ, 2001, CANCER GENET CYTOGEN, V126, P39, DOI 10.1016/S0165-4608(00)00376-9; CHARDIN P, 1985, INT J CANCER, V35, P647, DOI 10.1002/ijc.2910350513; Charrasse S, 2002, J CELL BIOL, V158, P953, DOI 10.1083/jcb.200202034; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Daniel JM, 1999, MOL CELL BIOL, V19, P3614; DEGIOVANNI C, 1995, BRIT J CANCER, V72, P1224, DOI 10.1038/bjc.1995.490; DUBAND JL, 1987, J CELL BIOL, V104, P1361, DOI 10.1083/jcb.104.5.1361; ELBADRY OM, 1990, CELL GROWTH DIFFER, V1, P325; Eusebi V, 2000, AM J SURG PATHOL, V24, P223, DOI 10.1097/00000478-200002000-00008; Ferracini R, 1996, ONCOGENE, V12, P1697; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; Fukata M, 2001, NAT REV MOL CELL BIO, V2, P887, DOI 10.1038/35103068; GARSON JA, 1986, LANCET, V1, P1496; Gauthier-Rouviere C, 1998, MOL BIOL CELL, V9, P1379, DOI 10.1091/mbc.9.6.1379; GauthierRouviere C, 1996, MOL BIOL CELL, V7, P719, DOI 10.1091/mbc.7.5.719; GeorgeWeinstein M, 1997, DEV BIOL, V185, P14, DOI 10.1006/dbio.1997.8542; Goichberg P, 1998, MOL BIOL CELL, V9, P3119, DOI 10.1091/mbc.9.11.3119; Hajra KM, 2002, CANCER RES, V62, P1613; Hajra KM, 2002, GENE CHROMOSOME CANC, V34, P255, DOI 10.1002/gcc.10083; HATTA K, 1987, DEV BIOL, V120, P215, DOI 10.1016/0012-1606(87)90119-9; KALEBIC T, 1994, CANCER RES, V54, P5531; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; KIMURA Y, 1995, DEV BIOL, V169, P347, DOI 10.1006/dbio.1995.1149; Knudsen KA, 1990, CURR OPIN CELL BIOL, V2, P902, DOI 10.1016/0955-0674(90)90090-2; Ko K, 2000, AM J PHYSIOL-CELL PH, V279, pC147, DOI 10.1152/ajpcell.2000.279.1.C147; Kumar S, 2000, MODERN PATHOL, V13, P988, DOI 10.1038/modpathol.3880179; Linask KK, 1998, DEV BIOL, V202, P85, DOI 10.1006/dbio.1998.9025; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Marucci G., 2000, Pathologica (Genoa), V92, P198; Meriane M, 2002, ONCOGENE, V21, P2901, DOI 10.1038/sj.onc.1205396; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; MINNITI CP, 1994, AM J CLIN PATHOL, V101, P198, DOI 10.1093/ajcp/101.2.198; Nojima D, 2001, MOL CARCINOGEN, V32, P19, DOI 10.1002/mc.1060; Nollet F, 1999, Mol Cell Biol Res Commun, V2, P77, DOI 10.1006/mcbr.1999.0155; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; Ostrovsky O, 2002, J BIOL CHEM, V277, P40043, DOI 10.1074/jbc.M205494200; Pinkerton R, 1998, B CANCER, V85, P1015; Pohar-Marinsek Z, 2002, ANAL QUANT CYTOL, V24, P212; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; Proulx AA, 1997, CELL GROWTH DIFFER, V8, P533; Prowse DM, 1997, CELL BIOL INT, V21, P833, DOI 10.1006/cbir.1997.0202; Puri PL, 2000, GENE DEV, V14, P574; Ribeiro LA, 2002, MOL CARCINOGEN, V34, P187, DOI 10.1002/mc.10064; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; Rosenberg P, 1997, DEV BIOL, V187, P55, DOI 10.1006/dbio.1997.8602; SCRABLE H, 1989, P NATL ACAD SCI USA, V86, P7480, DOI 10.1073/pnas.86.19.7480; Sharp R, 2002, NAT MED, V8, P1276, DOI 10.1038/nm787; SOLER AP, 1993, EXP CELL RES, V208, P84, DOI 10.1006/excr.1993.1225; STRATTON MR, 1989, CANCER RES, V49, P6324; Suzuki H, 1996, GENE CHROMOSOME CANC, V17, P225, DOI 10.1002/(SICI)1098-2264(199612)17:4<225::AID-GCC4>3.0.CO;2-5; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; TAPSCOTT SJ, 1993, SCIENCE, V259, P1450, DOI 10.1126/science.8383879; VANDROMME M, 1992, J CELL BIOL, V118, P1489, DOI 10.1083/jcb.118.6.1489; Visser M, 1997, ONCOGENE, V15, P1309, DOI 10.1038/sj.onc.1201302; WANG NP, 1995, AM J PATHOL, V147, P1799; WEXLER LH, 1994, CA-CANCER J CLIN, V44, P211, DOI 10.3322/canjclin.44.4.211; ZESCHNIGK M, 1995, J CELL SCI, V108, P2973; ZHAN SL, 1994, J CLIN INVEST, V94, P445, DOI 10.1172/JCI117344; Zhang LJ, 1996, CANCER RES, V56, P1367	64	26	26	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2004	23	13					2420	2430		10.1038/sj.onc.1207382	http://dx.doi.org/10.1038/sj.onc.1207382			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	806IN	14691446				2022-12-17	WOS:000220427700016
J	Tomida, M; Saito, T				Tomida, M; Saito, T			The human hepatocyte growth factor (HGF) gene is transcriptionally activated by leukemia inhibitory factor through the Stat binding element	ONCOGENE			English	Article						human HGF promoter; LIF; Stat3	DNA-BINDING; CELL-LINES; DIFFERENTIATION; EXPRESSION; RECEPTOR; INDUCIBILITY; FIBROBLASTS; PROTEINS; CLONING; FAMILY	We found that human melanoma SEKI and neuroepithelioma NAGAI cells, which are known to secrete high concentrations of leukemia inhibitory factor (LIF), also secrete high levels of hepatocyte growth factor (HGF). We therefore examined the role of LIF in HGF expression and examined the human HGF promoter. The expression of both LIF and HGF mRNA is very low in HEK293 cells. Treatment of these cells with LIF stimulated the expression of HGF mRNA. The cis-acting regulatory element of the HGF promoter in SEKI and 293 cells was analysed by means of a transient expression assay. By deletion analysis, we showed that the region comprising the -181 to -73 bp was required for full activity of the HGF promoter in SEKI cells and for LIF responsiveness of 293 cells. This region contains putative consensus sequences for the Stat and NF-IL6 (C/EBP beta) transcription factors. The activity of the HGF promoter was abolished by mutation of the Stat site at -99/-91, while the activity only slightly decreased on mutation of the NF-IL6 site. Treatment with anti-LIF antibodies or interruption of Stat3 signaling by dominant-negative Stat3 also reduced the HGF promoter activity. Stat3 activation was constitutive in SEKI cells and induced on treatment of 293 cells with LIF. These results suggest that cytokines, growth factors and oncogenes (v-Src, etc.) that activate Stat3 are important regulators of HGF expression.	Saitama Canc Ctr, Div Res, Ina, Saitama 3620806, Japan; Saitama Small Enterprise Promot Corp, REDS Grp, Saitama Prefecture Collaborat Reg Entities Adv Te, Kawaguchi 3330844, Japan		Tomida, M (corresponding author), Saitama Canc Ctr, Div Res, 818 Komuro, Ina, Saitama 3620806, Japan.	tomida@cancer-c.pref.saitama.jp						AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; Auernhammer CJ, 2000, ENDOCR REV, V21, P313, DOI 10.1210/er.21.3.313; Barasch J, 1999, CELL, V99, P377, DOI 10.1016/S0092-8674(00)81524-X; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Ehret GB, 2001, J BIOL CHEM, V276, P6675, DOI 10.1074/jbc.M001748200; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Hung W, 2001, J BIOL CHEM, V276, P12395, DOI 10.1074/jbc.M010715200; ISEKI H, 1995, JPN J CANCER RES, V86, P562, DOI 10.1111/j.1349-7006.1995.tb02435.x; Jiang JG, 1997, MOL CELL BIOL, V17, P5758, DOI 10.1128/MCB.17.10.5758; KAMOHARA H, 1994, RES COMMUN MOL PATH, V85, P131; LI M, 1995, NATURE, V378, P724, DOI 10.1038/378724a0; LIU YH, 1994, J BIOL CHEM, V269, P4152; LOWE DG, 1989, DNA-J MOLEC CELL BIO, V8, P351, DOI 10.1089/dna.1.1989.8.351; Maina F, 1999, NAT NEUROSCI, V2, P213, DOI 10.1038/6310; Matsumoto K, 1996, J BIOCHEM-TOKYO, V119, P591; MIYAZAWA K, 1991, BIOCHEMISTRY-US, V30, P9170, DOI 10.1021/bi00102a007; Nakamura T, 1997, CANCER RES, V57, P3305; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; O'Farrell AM, 1998, EMBO J, V17, P1006, DOI 10.1093/emboj/17.4.1006; SANTOS OFP, 1994, DEV BIOL, V163, P525, DOI 10.1006/dbio.1994.1169; SCHMELZER CH, 1993, ARCH BIOCHEM BIOPHYS, V302, P484, DOI 10.1006/abbi.1993.1243; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; TAMURA M, 1993, J BIOL CHEM, V268, P8140; TOMIDA M, 1990, FEBS LETT, V268, P261, DOI 10.1016/0014-5793(90)81023-H; TOMIDA M, 1984, FEBS LETT, V178, P291, DOI 10.1016/0014-5793(84)80619-5; Tomida M, 1999, BLOOD, V93, P1934, DOI 10.1182/blood.V93.6.1934.406k05_1934_1941; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WARE CB, 1995, DEVELOPMENT, V121, P1283; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; WOOLF AS, 1995, J CELL BIOL, V128, P171, DOI 10.1083/jcb.128.1.171; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	37	26	29	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2004	23	3					679	686		10.1038/sj.onc.1207190	http://dx.doi.org/10.1038/sj.onc.1207190			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14647442				2022-12-17	WOS:000188304900006
J	Jhabvala-Romero, F; Evans, A; Guo, SH; Denton, M; Clinton, GM				Jhabvala-Romero, F; Evans, A; Guo, SH; Denton, M; Clinton, GM			Herstatin inhibits heregulin-mediated breast cancer cell growth and overcomes tamoxifen resistance in breast cancer cells that overexpress HER-2	ONCOGENE			English	Article						herstatin; heregulin; HER-2; HER-3; tamoxifen; breast cancer	NEU DIFFERENTIATION FACTOR; TYROSINE KINASE; ESTROGEN-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; HORMONAL-THERAPY; HER2/NEU ERBB-2; EXPRESSION; PROTEIN; PATHWAY	Ligands of the ErbB family of receptors and estrogens control the proliferation of breast cancer cells. Overexpression of human EGF receptor HER-2 (erbB2) leads to amplified heregulin (HRG) signaling, promoting more aggressive breast cancer that is nonresponsive to estrogen and the antiestrogenic drug tamoxifen. Herstatin (Hst), a secreted HER-2 gene product, binds to the HER-2 receptor ectodomain blocking receptor activation. The aim of this study was to investigate the impact of this HER-2 inhibitor on HRG-induced signaling, proliferation, and sensitivity to tamoxifen in breast cancer cells with and without HER-2 overexpression. The expression of Hst in MCF7 cells eliminated HRG signaling through both mitogen-activated protein kinase and Akt pathways and prevented HRG-mediated proliferation. The loss in signaling corresponded to downregulation of the HRG receptors, HER-3 and HER-4, whereas HER-2 overexpression strongly stimulated the levels of both HRG receptors. Although Hst blocked HRG signaling in both parental and HER-2 transfected cells, it enhanced sensitivity to tamoxifen only in the MCF7 cells that overexpressed HER-2. To evaluate further the efficacy of Hst as an anticancer agent, His-tagged Hst was expressed in transfected insect cells, purified, and added to the breast cancer cells. As in the transfected cells, purified Hst inhibited HER-3 levels and suppressed HRG-induced proliferation of MCF7 and BT474 breast cancer cells. In contrast, the HER-2 monoclonal antibody, herceptin, downregulated HER-2, but not HER-3. These results suggest the potential use of Hst against HRG-mediated growth of breast cancers with high and low levels of HER-2 and against tamoxifen resistance in HER-2 overexpressing breast cancer.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA	Oregon Health & Science University	Clinton, GM (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	clinton@ohsu.edu		Evans, Adam/0000-0002-4250-2127				Aguilar Z, 1999, ONCOGENE, V18, P6050, DOI 10.1038/sj.onc.1202993; ALIMANDI M, 1995, ONCOGENE, V10, P1813; Arteaga CL, 2001, SEMIN ONCOL, V28, P30, DOI 10.1053/sonc.2001.29722; Azios NG, 2001, ONCOGENE, V20, P5199, DOI 10.1038/sj.onc.1204555; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Christianson TA, 1998, CANCER RES, V58, P5123; Doherty JK, 1999, P NATL ACAD SCI USA, V96, P10869, DOI 10.1073/pnas.96.19.10869; Dowsett M, 2001, ENDOCR-RELAT CANCER, V8, P191, DOI 10.1677/erc.0.0080191; Dowsett M, 2001, CANCER RES, V61, P8452; Gilbertson RJ, 1998, CANCER RES, V58, P3932; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Heldin Carl-Henrik, 1996, Cytokine and Growth Factor Reviews, V7, P3, DOI 10.1016/1359-6101(96)00002-0; Hijazi MM, 2000, INT J ONCOL, V17, P629; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; JESCHKE M, 1995, INT J CANCER, V60, P730, DOI 10.1002/ijc.2910600527; Justman QA, 2002, J BIOL CHEM, V277, P20618, DOI 10.1074/jbc.M111359200; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Klapper LN, 2000, ADV CANCER RES, V77, P25; Kurokawa H, 2000, CANCER RES, V60, P5887; Lewis GD, 1996, CANCER RES, V56, P1457; Lopez GN, 2001, J BIOL CHEM, V276, P22177, DOI 10.1074/jbc.M010718200; Mazumdar A, 2001, CANCER RES, V61, P400; Nicholson BP, 2000, SEMIN ONCOL, V27, P33, DOI 10.1053/sonc.2000.19897; Pegram M, 2000, SEMIN ONCOL, V27, P13; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; Pinkas-Kramarski R, 1998, MOL CELL BIOL, V18, P6090, DOI 10.1128/MCB.18.10.6090; PinkasKramarski R, 1996, J BIOL CHEM, V271, P19029, DOI 10.1074/jbc.271.32.19029; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; Ram TG, 2000, J CELL PHYSIOL, V183, P301, DOI 10.1002/(SICI)1097-4652(200006)183:3<301::AID-JCP2>3.0.CO;2-W; READ LD, 1990, CANCER RES, V50, P3947; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Sartor CI, 2001, MOL CELL BIOL, V21, P4265, DOI 10.1128/MCB.21.13.4265-4275.2001; SCHLESSINGER J, 1988, COLD SPRING HARB SYM, V53, P515, DOI 10.1101/SQB.1988.053.01.059; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Sweeney C, 2001, J BIOL CHEM, V276, P22685, DOI 10.1074/jbc.M100602200; Tan M, 1999, CANCER RES, V59, P1620; Tang CK, 1996, CANCER RES, V56, P3350; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; Xiong SB, 2001, CANCER RES, V61, P1727	48	26	33	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	2003	22	50					8178	8186		10.1038/sj.onc.1206912	http://dx.doi.org/10.1038/sj.onc.1206912			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	740LG	14603258				2022-12-17	WOS:000186403400012
J	Levy-Nissenbaum, O; Sagi-Assif, O; Kapon, D; Hantisteanu, S; Burg, T; Raanani, P; Avigdor, A; Ben-Bassat, I; Witz, IP				Levy-Nissenbaum, O; Sagi-Assif, O; Kapon, D; Hantisteanu, S; Burg, T; Raanani, P; Avigdor, A; Ben-Bassat, I; Witz, IP			Dual-specificity phosphatase Pyst2-L is constitutively highly expressed in myeloid leukemia and other malignant cells	ONCOGENE			English	Article						Pyst2; leukemia; dual-specificity phosphatases; DNA microarray; cell activation; differentiation	MAP KINASE PHOSPHATASE; SIGNAL-TRANSDUCTION; IN-VIVO; CYCLE REGULATION; FX ENZYME; PROTEIN; DIFFERENTIATION; LINES; CDC25; GENE	Northern blotting confirmed previous results indicating that the mitogen-activated protein kinase ( MAPK) phosphatase Pyst2-L was highly expressed in leukocytes obtained from acute myeloid leukemia (AML) patients. High levels of Pyst2-L mRNA were expressed in bone marrow ( BM) and peripheral leukocytes from nine AML and acute lymphoblastic leukemia ( ALL) patients. BM from healthy individuals expressed very low levels of Pyst2-L. Whereas high levels of Pyst2-L mRNA and protein were detected in several leukemia cell lines, Pyst2-L mRNA was detected neither in 33/34 samples of normal peripheral blood mononuclear cells (PBMC) nor in leukocyte fractions enriched with CD34(+) cells. Certain solid tumor and lymphoblastoid cell lines expressed high levels of Pyst2-L mRNA. In view of the association of Pyst2-L to MAPK signaling cascades, we tested if cell activation, a process involving MAPK signaling, influences Pyst2-L expression. Indeed, activation of T cells and endothelial cells increased Pyst2-L in these cells. Furthermore, TPA, a known MAPK activator, induces the expression of both Pyst2-L mRNA as well as the Pyst2-L protein in leukemia cells. This induction was partially inhibited by PD098059, an Mek1/2-specific inhibitor. Based on the results of this and previous studies, we hypothesize that the high levels of Pyst2-L detected in the active state of AML and ALL diseases and in other types of cancer reflect an altered MAPK signaling pathway in such malignant processes. This alteration may be the result of a failed attempt to counter the constitutive activation of MAPK in transformed cells or alternatively, may represent the activated state of such cells.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Cell Res & Immunol, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Ela Kodesz Inst Res Canc Dev & Prevent, IL-69978 Tel Aviv, Israel; Chaim Sheba Med Ctr, Inst Hematol, IL-52621 Tel Hashomer, Israel; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel	Tel Aviv University; Tel Aviv University; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Witz, IP (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Cell Res & Immunol, IL-69978 Tel Aviv, Israel.	ipwitz@post.tau.ac.il						ADAMS PD, 1991, FEBS LETT, V290, P77, DOI 10.1016/0014-5793(91)81230-6; Andersen JN, 2001, BIOCHEM J, V354, P581, DOI 10.1042/0264-6021:3540581; Babcock GJ, 2000, IMMUNITY, V13, P497, DOI 10.1016/S1074-7613(00)00049-2; Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; Beghini A, 2000, HUM MOL GENET, V9, P2297, DOI 10.1093/oxfordjournals.hmg.a018921; Berndt N., 1999, FRONT BIOSCI, V4, pD22, DOI DOI 10.2741/BERNDT;PMID:9872729; Biethahn S, 1999, EXP HEMATOL, V27, P885, DOI 10.1016/S0301-472X(99)00017-X; CHORVATH B, 1983, NEOPLASMA, V30, P273; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; Dahia PLM, 2000, ENDOCR-RELAT CANCER, V7, P115, DOI 10.1677/erc.0.0070115; Dickinson RJ, 2002, BIOCHEM J, V364, P145, DOI 10.1042/bj3640145; Dowd S, 1998, J CELL SCI, V111, P3389; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Eckstein JW, 2000, INVEST NEW DRUG, V18, P149, DOI 10.1023/A:1006377913494; Eshel R, 2001, CELL IMMUNOL, V213, P141, DOI 10.1006/cimm.2001.1872; Eshel R, 2000, J BIOL CHEM, V275, P12833, DOI 10.1074/jbc.275.17.12833; Frearson JA, 1996, IMMUNOL TODAY, V17, P385, DOI 10.1016/0167-5699(96)10026-8; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Geller RB, 1997, LEUKEMIA RES, V21, P387, DOI 10.1016/S0145-2126(96)00107-5; Gopalakrishna R, 1999, CANCER LETT, V136, P143, DOI 10.1016/S0304-3835(98)00315-2; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; Hantisteanu S, 2002, PROCEEDINGS OF THE 2ND INTERNATIONAL CONFERENCE ON TUMOR MICROENVIRONMENT PROGRESSION, THERAPY & PREVENTION, P95; HASS R, 1989, EUR J CELL BIOL, V48, P282; He HC, 1999, CELL GROWTH DIFFER, V10, P307; Hernandez S, 1998, CANCER RES, V58, P1762; Horn S, 2001, LEUKEMIA, V15, P112, DOI 10.1038/sj.leu.2401990; Hwang PH, 2001, CANCER LETT, V172, P83, DOI 10.1016/S0304-3835(01)00632-2; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Johnson TR, 2000, J BIOL CHEM, V275, P31755, DOI 10.1074/jbc.M004182200; KEYSE SM, 1993, TRENDS BIOCHEM SCI, V18, P377, DOI 10.1016/0968-0004(93)90092-2; Klint P, 1999, ONCOGENE, V18, P3354, DOI 10.1038/sj.onc.1202680; KOEFFLER HP, 1981, CANCER RES, V41, P919; Lee JT, 2002, LEUKEMIA, V16, P486, DOI 10.1038/sj/leu/2402460; Levy-Nissenbaum O, 2002, PROCEEDINGS OF THE 2ND INTERNATIONAL CONFERENCE ON TUMOR MICROENVIRONMENT PROGRESSION, THERAPY & PREVENTION, P11; LEVYNISSENBAUM O, 2003, IN PRESS METHODS ENZ; LEVYNISSENBAUM O, 2003, IN PRESS CANC LETT; LEVYNISSENBAUM O, 2003, UNPUB GENES CHROMOSO; MARSHALL CJ, 1994, NATURE, V367, P686, DOI 10.1038/367686a0; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Mercurius KO, 2001, BMC CELL BIOL, V2, part. no., DOI 10.1186/1471-2121-2-18; Molla A, 2000, CELL GROWTH DIFFER, V11, P83; Moore S, 2000, LEUKEMIA LYMPHOMA, V38, P211, DOI 10.3109/10428190009087013; Muda M, 1997, J BIOL CHEM, V272, P5141, DOI 10.1074/jbc.272.8.5141; Nilsson I, 2000, Prog Cell Cycle Res, V4, P107; Ofek P, 2003, J BIOL CHEM, V278, P14299, DOI 10.1074/jbc.M211699200; Parsons Ramon, 1998, Current Opinion in Oncology, V10, P88, DOI 10.1097/00001622-199801000-00014; Pestell KE, 2000, ONCOGENE, V19, P6607, DOI 10.1038/sj.onc.1204084; Poetsch M, 2001, CANCER GENET CYTOGEN, V125, P21, DOI 10.1016/S0165-4608(00)00353-8; Rivedal E, 2001, CARCINOGENESIS, V22, P1543, DOI 10.1093/carcin/22.9.1543; ROMAGNANI S, 1995, J CLIN IMMUNOL, V15, P121, DOI 10.1007/BF01543103; Sambrook J., 1989, MOL CLONING; Sano K, 2000, BLOOD, V95, P1066, DOI 10.1182/blood.V95.3.1066.003k11_1066_1068; Saxena M, 2000, SEMIN IMMUNOL, V12, P387, DOI 10.1006/smim.2000.0219; Sebolt-Leopold JS, 2000, ONCOGENE, V19, P6594, DOI 10.1038/sj.onc.1204083; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shi G, 1996, CYTOGENET CELL GENET, V74, P295, DOI 10.1159/000134439; Shin DY, 1997, ONCOGENE, V14, P2633, DOI 10.1038/sj.onc.1201106; STEINITZ M, 1977, NATURE, V269, P420, DOI 10.1038/269420a0; Tanuma N, 2000, J BIOL CHEM, V275, P28216; Theodosiou A, 2002, GENOME BIOL, V3; Wagers AJ, 1998, J EXP MED, V188, P2225, DOI 10.1084/jem.188.12.2225; WEINSTEIN R, 1989, BLOOD, V73, P111; Wilkinson MG, 2000, FASEB J, V14, P2147, DOI 10.1096/fj.00-0102rev; Wu WG, 1998, CANCER RES, V58, P4082; Yamamoto M, 1999, LEUKEMIA, V13, P595, DOI 10.1038/sj.leu.2401372	65	26	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 23	2003	22	48					7649	7660		10.1038/sj.onc.1206971	http://dx.doi.org/10.1038/sj.onc.1206971			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KQ	14576828				2022-12-17	WOS:000186113000013
J	O'Nions, J; Allday, MJ				O'Nions, J; Allday, MJ			Epstein-Barr virus can inhibit genotoxin-induced G1 arrest downstream of p53 by preventing the inactivation of CDK2	ONCOGENE			English	Article						EBV; p21(WAF1/CIP1); CDK2; G1 arrest; genotoxins; B cells	HUMAN B-CELLS; GROWTH ARREST; DNA-DAMAGE; S-PHASE; APOPTOSIS; CYCLE; LYMPHOCYTES; P21; CHECKPOINTS; CANCER	Epstein-Barr virus (EBV) is involved in the pathogenesis of several B cell lymphoproliferations, but the precise contribution it makes to the aetiology of each remains unclear. In vitro, the virus has potent growth transforming activity and efficiently induces the continuous proliferation of normal human B cells. A comparison of EBV-infected primary B cells with an isogenic population induced to proliferate by CD40-ligand (CD40L) and IL4 has revealed that EBV can override - by a novel mechanism - the p53/pRb-mediated G1 checkpoint activated in normal B cells by a genotoxic stress. In cells responding to cisplatin, although p53 is stabilized and activated, EBV latent gene expression appears to inhibit the accumulation of newly synthesized p21(WAF1/CIP1) and the downregulation of cyclin D2 that occur in the normal cells. Consequently, in the EBV-infected cells, CDK2 remains active, hyperphosphorylation of pRb is maintained and the replication of damaged DNA can occur. Under conditions of severe genomic stress, this absence of p21(WAF1/CIP1) function can result in apoptosis; however, when damage is less sustained, genomic instability may arise and this in turn could contribute to the development of a variety of EBV-associated B cell malignancies.	Univ London Imperial Coll Sci Technol & Med, Dept Virol, London W2 1PG, England; Univ London Imperial Coll Sci Technol & Med, Fac Med, Wright Fleming Inst, Ludwig Inst Canc Res, London W2 1PG, England	Imperial College London; Imperial College London; Ludwig Institute for Cancer Research	Allday, MJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Virol, Norfolk Pl, London W2 1PG, England.							Agami R, 2002, CANCER LETT, V177, P111, DOI 10.1016/S0304-3835(01)00785-6; ALLDAY MJ, 1995, EMBO J, V14, P4994, DOI 10.1002/j.1460-2075.1995.tb00182.x; ALLDAY MJ, 1995, EMBO J, V14, P1382, DOI 10.1002/j.1460-2075.1995.tb07124.x; BANCHEREAU J, 1991, SCIENCE, V251, P70, DOI 10.1126/science.1702555; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; Bornkamm GW, 2001, PHILOS T R SOC B, V356, P437, DOI 10.1098/rstb.2000.0781; Cannell EJ, 1998, FEBS LETT, V439, P297, DOI 10.1016/S0014-5793(98)01391-X; Cannell EJ, 1996, ONCOGENE, V13, P1413; Chattopadhyay D, 2001, J VIROL, V75, P9844, DOI 10.1128/JVI.75.20.9844-9856.2001; DOTTO GP, 2000, BIOCHIM BIOPHYS ACTA, V1471, P43; GARRONE P, 1995, J EXP MED, V182, P1265, DOI 10.1084/jem.182.5.1265; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Kelly G, 2002, NAT MED, V8, P1098, DOI 10.1038/nm758; Kriwacki RW, 1996, P NATL ACAD SCI USA, V93, P11504, DOI 10.1073/pnas.93.21.11504; LINNDSTROM MS, 2002, CANC BIOL, V12, P381; LUI CW, 2003, SCIENCE, V299, P408; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; PALMERO I, 1993, ONCOGENE, V8, P1049; Parker GA, 2000, ONCOGENE, V19, P700, DOI 10.1038/sj.onc.1203327; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Rickinson A, 2001, PHILOS T ROY SOC B, V356, P595, DOI 10.1098/rstb.2000.0785; ROUSSET F, 1995, INT IMMUNOL, V7, P1243, DOI 10.1093/intimm/7.8.1243; Scott MT, 2002, EMBO J, V21, P6771, DOI 10.1093/emboj/cdf684; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shvarts A, 2002, GENE DEV, V16, P681, DOI 10.1101/gad.929302; SINCLAIR AJ, 1994, EMBO J, V13, P3321, DOI 10.1002/j.1460-2075.1994.tb06634.x; Speck SH, 2002, NAT MED, V8, P1086, DOI 10.1038/nm1002-1086; Spender LC, 1999, J VIROL, V73, P4678, DOI 10.1128/JVI.73.6.4678-4688.1999; Spender LC, 2001, J VIROL, V75, P3537, DOI 10.1128/JVI.75.8.3537-3546.2001; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Thorley-Lawson DA, 1999, LIFE SCI, V65, P1433, DOI 10.1016/S0024-3205(99)00214-3; Thorley-Lawson DA, 2001, NAT REV IMMUNOL, V1, P75, DOI 10.1038/35095584; Timms JM, 2003, LANCET, V361, P217, DOI 10.1016/S0140-6736(03)12271-4; Touitou R, 2001, EMBO J, V20, P2367, DOI 10.1093/emboj/20.10.2367; Wade M, 2000, MOL CELL BIOL, V20, P1344, DOI 10.1128/MCB.20.4.1344-1360.2000; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Zhang YK, 1999, ONCOGENE, V18, P1131, DOI 10.1038/sj.onc.1202426	42	26	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 16	2003	22	46					7181	7191		10.1038/sj.onc.1206838	http://dx.doi.org/10.1038/sj.onc.1206838			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732PP	14562046				2022-12-17	WOS:000185955000009
J	Loo, JCY; Liu, L; Hao, AH; Gao, LZ; Agatep, R; Shennan, M; Summers, A; Goldstein, AM; Tucker, MA; Deters, C; Fusaro, R; Blazer, K; Weitzel, J; Lassam, N; Lynch, H; Hogg, D				Loo, JCY; Liu, L; Hao, AH; Gao, LZ; Agatep, R; Shennan, M; Summers, A; Goldstein, AM; Tucker, MA; Deters, C; Fusaro, R; Blazer, K; Weitzel, J; Lassam, N; Lynch, H; Hogg, D			Germline splicing mutations of CDKN2A predispose to melanoma	ONCOGENE			English	Article						splice site mutations; melanoma; genetic predisposition	HAPLOTYPE ANALYSIS; PRONE FAMILIES; P16(INK4A); FOUNDER	Coding mutations of the CDKN2A gene on chromosome 9p21 cosegregate with 25-60% of familial melanoma cases, but there remains a number of 9p21-linked kindreds that lack germline coding mutations of CDKN2A. W e sequenced CDKN2A exons 1alpha, 2, 3, and the adjacent intronic regions in 167 melanoma-prone families ( at least two affected first-degree relatives), and detected four splice site variations, three of which cosegregate with the disease. RT-PCR experiments verified that these three variants, including an AGgt to ATgt mutation that demonstrates a founder effect, do affect splicing. While an exon 1alpha splice donor site mutation incompletely abolishes splicing, the correctly spliced mRNA yields a protein (Q50P) that cannot effectively interact with CDK4. We also performed RT-PCR on mRNA from 16 melanoma-prone kindreds to search for cryptic splice sites deep within introns, but identified no splice variants. Meanwhile, we screened 139 affected families using allele specific PCR for the recently discovered IVS2-105A >G mutation, but found only one family that possesses this alteration. We conclude that splice site mutations do predispose to disease in a subset of melanoma-prone kindreds. Characterization of additional splice site variants and other noncoding alterations of CDKN2A should allow us to detect a wider range of mutations in at-risk patients.	Univ Toronto, Dept Med Biophys, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; City Hope Comprehens Canc Ctr, Dept Clin Canc Genet, Duarte, CA 91010 USA; City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA 91010 USA; Creighton Univ, Hereditary Canc Inst, Omaha, NE 68178 USA; NCI, Genet Epidemiol Branch, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA; N York Gen Hosp, Dept Genet, Toronto, ON M2K 1E1, Canada	University of Toronto; University of Toronto; City of Hope; City of Hope; Beckman Research Institute of City of Hope; Creighton University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Toronto; University Toronto Affiliates; North York General Hospital	Hogg, D (corresponding author), Univ Toronto, Dept Med Biophys, Room 7368,Med Sci Bldg, Toronto, ON M5S 1A8, Canada.	david.hogg@utoronto.ca	Blazer, Kathleen/ABC-8530-2021; Tucker, Margaret A/B-4297-2015	Loo, Joanne Chung Yan/0000-0001-8429-6109				Byeon IJL, 1998, MOL CELL, V1, P421, DOI 10.1016/S1097-2765(00)80042-8; Ciotti P, 2000, AM J HUM GENET, V67, P311, DOI 10.1086/303001; Colitt R, 1999, LAT TRADE, V7, P22; Goldstein AM, 2001, BRIT J CANCER, V85, P527, DOI 10.1054/bjoc.2001.1944; GRUIS NA, 1995, MELANOMA RES, V5, P169, DOI 10.1097/00008390-199506000-00005; Harland M, 2001, HUM MOL GENET, V10, P2679, DOI 10.1093/hmg/10.23.2679; Hashemi J, 2001, GENE CHROMOSOME CANC, V31, P107, DOI 10.1002/gcc.1124; Hewitt C, 2002, HUM MOL GENET, V11, P1273, DOI 10.1093/hmg/11.11.1273; Hogg D, 1998, J Cutan Med Surg, V2, P172; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; Li JN, 1999, BIOCHEMISTRY-US, V38, P2930, DOI 10.1021/bi982286e; LIU L, 1995, ONCOGENE, V11, P405; Liu L, 1999, NAT GENET, V21, P128, DOI 10.1038/5082; Liu L, 1997, GENE CHROMOSOME CANC, V19, P52, DOI 10.1002/(SICI)1098-2264(199705)19:1<52::AID-GCC8>3.3.CO;2-S; Luh FY, 1997, NATURE, V389, P999, DOI 10.1038/40202; Lynch HT, 2002, CANCER-AM CANCER SOC, V94, P84, DOI 10.1002/cncr.10159; MacKie RM, 1998, J INVEST DERMATOL, V111, P269, DOI 10.1046/j.1523-1747.1998.00267.x; Monzon J, 1998, NEW ENGL J MED, V338, P879, DOI 10.1056/NEJM199803263381305; Moskaluk C A, 1998, Hum Mutat, V12, P70; Petronzelli F, 2001, GENE CHROMOSOME CANC, V31, P398, DOI 10.1002/gcc.1159; Pollock PM, 1998, HUM MUTAT, V11, P424, DOI 10.1002/(SICI)1098-1004(1998)11:6<424::AID-HUMU2>3.3.CO;2-U; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; Rizos H, 2001, ONCOGENE, V20, P5543, DOI 10.1038/sj.onc.1204728; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; RUTTER JL, IN PRESS ONCOGENE; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Shennan MG, 2000, ONCOGENE, V19, P1849, DOI 10.1038/sj.onc.1203507	27	26	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2003	22	41					6387	6394		10.1038/sj.onc.1206736	http://dx.doi.org/10.1038/sj.onc.1206736			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	725GK	14508519				2022-12-17	WOS:000185535300009
J	Yeh, CT; Lu, SC; Tseng, IC; Lai, HY; Tsao, ML; Huang, SF; Liaw, YF				Yeh, CT; Lu, SC; Tseng, IC; Lai, HY; Tsao, ML; Huang, SF; Liaw, YF			Antisense overexpression of BMAL2 enhances cell proliferation	ONCOGENE			English	Article						hepatocellular carcinoma; BMAL2; antisense; cell cycle; TNF-alpha; caspase-3	DIFFERENTIALLY EXPRESSED GENES; HEPATOCELLULAR-CARCINOMA; HEPATITIS-C; NUCLEAR-LOCALIZATION; IDENTIFICATION; PROTEIN; CLONING; CARCINOGENESIS; MICROARRAY; APOPTOSIS	To identify genes that are frequently downregulated in hepatocellular carcinoma (HCC), a panel of putative underexpressed genes was first established by an in-house cDNA macroarray method. Two different assays, semi-quantitative RT-PCR combined with Northern analysis and customized cDNA microarray analysis, were used to screen through these genes and the results were compared. Several genes, some with unknown function, were confirmed to be downregulated by both the methods. The effect of a downregulated gene, BMAL2, on cell proliferation was examined. Overexpression of antisense BMAL2 RNA in 293EBNA cells resulted in reduced cell cycle time, increased plating efficiency in soft agar, diminished TNF-alpha-induced increment of CPP32/caspase-3 activity, and a reduced proportion of cells in the G2 phase with a concomitantly increased proportion of cells in the S phase. In conclusion, by combining three different methods, we have obtained a panel of frequently down regulated genes in HCC, including BMAL2. Antisense overexpression of BMAL2 enhances cell proliferation.	Chang Gung Mem Hosp, Liver Res Unit, Taipei 10591, Taiwan; Chang Gung Univ, Coll Med, Dept Pathol, Taipei, Taiwan	Chang Gung Memorial Hospital; Chang Gung University	Yeh, CT (corresponding author), Chang Gung Mem Hosp, Liver Res Unit, 199 Tung Hwa N Rd, Taipei 10591, Taiwan.	chauting@adm.cgmh.org.tw	Liaw, Yun-Fan/B-4305-2009; Huang, Shiu-Feng Kathy/E-3977-2010; Tseng, I-Chu/C-1936-2013	Tseng, I-Chu/0000-0001-8522-6524				BEASLEY RP, 1984, SEMIN LIVER DIS, V4, P113, DOI 10.1055/s-2008-1040651; Boige V, 1997, CANCER RES, V57, P1986; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; CREWS ST, 1988, CELL, V52, P143, DOI 10.1016/0092-8674(88)90538-7; DiBisceglie AM, 1997, HEPATOLOGY, V26, pS34, DOI 10.1002/hep.510260706; Elferink CJ, 2001, MOL PHARMACOL, V59, P664, DOI 10.1124/mol.59.4.664; Gerber AN, 1996, MOL CELL BIOL, V16, P3901; HAMBOR JE, 1988, P NATL ACAD SCI USA, V85, P4010, DOI 10.1073/pnas.85.11.4010; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Hogenesch JB, 2000, J NEUROSCI, V20, part. no.; Hung SC, 2001, P NATL ACAD SCI USA, V98, P1865, DOI 10.1073/pnas.031584698; Iizuka N, 2002, CANCER RES, V62, P3939; Ikeda M, 2000, BIOCHEM BIOPH RES CO, V275, P493, DOI 10.1006/bbrc.2000.3248; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kolluri SK, 1999, GENE DEV, V13, P1742, DOI 10.1101/gad.13.13.1742; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Kusano N, 1999, HEPATOLOGY, V29, P1858, DOI 10.1002/hep.510290636; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; Marchio A, 1997, GENE CHROMOSOME CANC, V18, P59, DOI 10.1002/(SICI)1098-2264(199701)18:1<59::AID-GCC7>3.3.CO;2-N; Miyasaka Y, 2001, BRIT J CANCER, V85, P228, DOI 10.1054/bjoc.2001.1901; Moriya K, 1998, NAT MED, V4, P1065, DOI 10.1038/2053; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; Norton JD, 2000, J CELL SCI, V113, P3897; Okabe H, 2001, CANCER RES, V61, P2129; Okano T, 2001, GENES CELLS, V6, P825, DOI 10.1046/j.1365-2443.2001.00462.x; REDDY P, 1986, CELL, V46, P53, DOI 10.1016/0092-8674(86)90859-7; Scuric Z, 1998, HEPATOLOGY, V27, P943, DOI 10.1002/hep.510270408; Shirota Y, 2001, HEPATOLOGY, V33, P832, DOI 10.1053/jhep.2001.23003; Taylor BL, 1999, MICROBIOL MOL BIOL R, V63, P479, DOI 10.1128/MMBR.63.2.479-506.1999; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Wang ZX, 2001, BRIT J CANCER, V85, P1162, DOI 10.1054/bjoc.2001.2059; WU GS, 1995, LIFE SCI, V57, P1077, DOI 10.1016/0024-3205(95)02053-L; Xu XR, 2001, P NATL ACAD SCI USA, V98, P15089, DOI 10.1073/pnas.241522398; Yeh CT, 1998, J MED VIROL, V55, P42, DOI 10.1002/(SICI)1096-9071(199805)55:1<42::AID-JMV8>3.0.CO;2-O; Yeh CT, 2000, ONCOGENE, V19, P5213, DOI 10.1038/sj.onc.1203903; Yeh CT, 2001, J VIROL, V75, P11017, DOI 10.1128/JVI.75.22.11017-11024.2001; Yeh CT, 1997, J GEN VIROL, V78, P2761, DOI 10.1099/0022-1317-78-11-2761; YEH CT, 1993, P NATL ACAD SCI USA, V90, P6459, DOI 10.1073/pnas.90.14.6459	39	26	30	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2003	22	34					5306	5314		10.1038/sj.onc.1206674	http://dx.doi.org/10.1038/sj.onc.1206674			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917632				2022-12-17	WOS:000184734900010
J	Mathur, M; Das, S; Samuels, HH				Mathur, M; Das, S; Samuels, HH			PSF-TFE3 oncoprotein in papillary renal cell carcinoma inactivates TFE3 and p53 through cytoplasmic sequestration	ONCOGENE			English	Article						PSF-TFE3; TFE3; PSF-A; renal cell carcinoma; endosomes; cell transformation	SPLICING FACTOR PSF; HISTONE DEACETYLASE COMPLEX; NUCLEAR HORMONE-RECEPTORS; LOOP-HELIX PROTEINS; GENE-EXPRESSION; BINDING PROTEIN; TRANSCRIPTIONAL ACTIVATION; RNA INTERFERENCE; FUSION PARTNER; BREAST-CANCER	Papillary renal cell carcinomas are associated with chromosomal translocations involving the helix-loop-helix leucine-zipper region of the TFE3 gene on the X chromosome. These translocations lead to the expression of TFE3 chimeras of PRCC, RCC17, NonO and PSF (PTB-associated splicing factor). In this study, we explored the role of PSF-TFE3 fusion protein in mediating cell transformation. Unlike wild-type TFE3 or PSF, which are nuclear proteins, PSF-TFE3 is not a nuclear protein and is targeted to the endosomal compartment. Although PSF-TFE3 has no effect on the nuclear localization of wild-type PSF, it sequesters wildtype TFE3 as well as p53 in the extranuclear compartment leading to functionally null p53 and TFE3 cells. In UOK-145 papillary renal carcinoma cells, which endogenously express PSF-TFE3, siRNA complementary to the PSF-TFE3 fusion junction leads to a reduction in PSF-TFE3 and redistribution of endogenous TFE3 and p53 from the cytoplasmic compartment to the nucleus. Our results indicate that PSF-TFE3 acts through a novel mechanism, and exports TFE3, p53 and possibly other factors from the nucleus to the cytoplasm for degradation leading to the transformed phenotype. Thus, PSF-TFE3 is a promising target for the treatment for a subset of renal cell carcinomas.	NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; NYU, Sch Med, Dept Med, New York, NY 10016 USA	New York University; New York University	Samuels, HH (corresponding author), NYU, Sch Med, Dept Pharmacol, 550 1st Ave, New York, NY 10016 USA.				NATIONAL CANCER INSTITUTE [P30CA016087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K01AR002083] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK016636, R01DK016636, R37DK016636] Funding Source: NIH RePORTER; NCI NIH HHS [CA16087] Funding Source: Medline; NIAMS NIH HHS [AR02083] Funding Source: Medline; NIDDK NIH HHS [DK16636] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Afonja O, 2002, ONCOGENE, V21, P7850, DOI 10.1038/sj.onc.1205985; Akhmedov AT, 2000, NUCLEIC ACIDS RES, V28, P3022, DOI 10.1093/nar/28.16.3022; Angelo LS, 2002, CANCER RES, V62, P932; ARTANDI SE, 1995, NUCLEIC ACIDS RES, V23, P3865, DOI 10.1093/nar/23.19.3865; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; Carter RS, 1997, MOL CELL BIOL, V17, P18, DOI 10.1128/MCB.17.1.18; Chanas-Sacre G, 1999, J NEUROSCI RES, V57, P62, DOI 10.1002/(SICI)1097-4547(19990701)57:1<62::AID-JNR7>3.0.CO;2-Y; Clark J, 1997, ONCOGENE, V15, P2233, DOI 10.1038/sj.onc.1201394; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Dye BT, 2001, EXP CELL RES, V263, P131, DOI 10.1006/excr.2000.5097; FISHER DE, 1991, GENE DEV, V5, P2342, DOI 10.1101/gad.5.12a.2342; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Glukhova L, 1998, GENE CHROMOSOME CANC, V22, P171, DOI 10.1002/(SICI)1098-2264(199807)22:3<171::AID-GCC2>3.3.CO;2-K; GOZANI O, 1994, EMBO J, V13, P3356, DOI 10.1002/j.1460-2075.1994.tb06638.x; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Heimann P, 2001, CANCER RES, V61, P4130; Hsueh C, 2002, MODERN PATHOL, V15, P606, DOI 10.1038/modpathol.3880573; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Li DS, 1999, MOL CELL BIOL, V19, P7191; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Mahajan MA, 2002, MOL CELL BIOL, V22, P6883, DOI 10.1128/MCB.22.19.6883-6894.2002; Mansky KC, 2002, J LEUKOCYTE BIOL, V71, P304; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Mathur M, 2001, MOL CELL BIOL, V21, P2298, DOI 10.1128/MCB.21.7.2298-2311.2001; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; ODA H, 1995, CANCER RES, V55, P658; Paddison PJ, 2002, CANCER CELL, V2, P17, DOI 10.1016/S1535-6108(02)00092-2; PATTON JG, 1993, GENE DEV, V7, P393, DOI 10.1101/gad.7.3.393; Pipas JM, 2001, SEMIN CANCER BIOL, V11, P23, DOI 10.1006/scbi.2000.0343; Qi JS, 1999, MOL CELL BIOL, V19, P864; Qi JS, 1997, MOL CELL BIOL, V17, P7195, DOI 10.1128/MCB.17.12.7195; REITER RE, 1993, CANCER RES, V53, P3092; Rosenberger U, 2002, J CELL BIOCHEM, V86, P394, DOI 10.1002/jcb.10233; Sewer MB, 2002, ENDOCRINOLOGY, V143, P1280, DOI 10.1210/en.143.4.1280; Simon JP, 2000, METHODS, V20, P437, DOI 10.1006/meth.2000.0957; Skalsky YM, 2001, ONCOGENE, V20, P178, DOI 10.1038/sj.onc.1204056; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; Steingrimsson E, 2002, P NATL ACAD SCI USA, V99, P4477, DOI 10.1073/pnas.072071099; Tian G, 1999, MOL CELL BIOL, V19, P2946; Urban RJ, 2002, AM J PHYSIOL-ENDOC M, V283, pE794, DOI 10.1152/ajpendo.00174.2002; vandenBerg E, 1997, CANCER GENET CYTOGEN, V95, P103, DOI 10.1016/S0165-4608(96)00289-0; Weterman MAJ, 1996, P NATL ACAD SCI USA, V93, P15294, DOI 10.1073/pnas.93.26.15294; Weterman MAJ, 2000, ONCOGENE, V19, P69, DOI 10.1038/sj.onc.1203255; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZHAO GQ, 1993, MOL CELL BIOL, V13, P4505, DOI 10.1128/MCB.13.8.4505	46	26	27	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 7	2003	22	32					5031	5044		10.1038/sj.onc.1206643	http://dx.doi.org/10.1038/sj.onc.1206643			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	708QF	12902986				2022-12-17	WOS:000184578900011
J	Dunfield, LD; Nachtigal, MW				Dunfield, LD; Nachtigal, MW			Inhibition of the antiproliferative effect of TGF beta by EGF in primary human ovarian cancer cells	ONCOGENE			English	Article						ovarian cancer; TGF beta; EGF; p15(INK4B)	GROWTH-FACTOR-BETA; SIGNAL-TRANSDUCTION; SURFACE EPITHELIUM; GENE-MUTATIONS; RECEPTOR; SMAD7; IDENTIFICATION; EPIDEMIOLOGY; ANTAGONIST; CARCINOMA	The majority of ovarian cancers (OCs) arise from the ovarian surface epithelium (OSE). Proliferation of the OSE can be regulated by a number of autocrine and paracrine factors, including transforming growth factor beta (TGFbeta). Defects in the TGFbeta signaling pathway have been implicated in a number of cancers, including ovarian. We previously found that the TGFbeta signaling pathway is intact and functional in primary human OC cells, and that these cells stop growing in response to TGFbeta. Ovarian cancer cells in vivo are exposed to TGFbeta, yet continue to proliferate, therefore, mechanisms must exist to inhibit TGFbeta signaling contributing to uncontrolled cellular proliferation. Numerous signaling pathways converge with the TGFbeta pathway to modulate its effects, including signaling induced by epidermal growth factor (EGF). We hypothesized that EGF can modulate TGFbeta signaling and contribute to uncontrolled cellular proliferation of OC cells. Our results show that EGF abrogates the antiproliferative effect of TGFbeta. EGF does not modulate TGFbeta signaling by inhibiting receptor-activated Smad (R-Smad) phosphorylation or nuclear translocation. Rather, EGF decreases TGFbeta-induced mRNA expression of the cell cycle regulator, p15(INK4B), contributing to decreased sensitivity of OC cells to the antiproliferative effect of TGFbeta.	Dalhousie Univ, Dept Pharmacol, Halifax, NS B3H 1X5, Canada	Dalhousie University	Nachtigal, MW (corresponding author), Dalhousie Univ, Dept Pharmacol, 5850 Coll St, Halifax, NS B3H 1X5, Canada.	Mark.Nachtigal@Dal.ca		Nachtigal, Mark/0000-0003-3291-8628				Afrakhte M, 1998, BIOCHEM BIOPH RES CO, V249, P505, DOI 10.1006/bbrc.1998.9170; Auersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255; BERCHUCK A, 1992, AM J OBSTET GYNECOL, V166, P676, DOI 10.1016/0002-9378(92)91697-9; Chen T, 2001, CANCER RES, V61, P4679; Daly M, 1998, SEMIN ONCOL, V25, P255; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; Dunfield LD, 2002, ENDOCRINOLOGY, V143, P1174, DOI 10.1210/en.143.4.1174; Funaba M, 2002, J BIOL CHEM, V277, P41361, DOI 10.1074/jbc.M204597200; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; HURTEAU J, 1994, CANCER, V74, P93, DOI 10.1002/1097-0142(19940701)74:1<93::AID-CNCR2820740117>3.0.CO;2-P; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Lo RS, 2001, EMBO J, V20, P128, DOI 10.1093/emboj/20.1.128; Lynch MA, 1998, CANCER RES, V58, P4227; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Riggins GJ, 1997, CANCER RES, V57, P2578; Scully RE, 1995, J CELL BIOCHEM, P208; Sowter HM, 1999, INT J CANCER, V83, P476, DOI 10.1002/(SICI)1097-0215(19991112)83:4<476::AID-IJC7>3.0.CO;2-V; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; TORTOLEROLUNA G, 1994, OBSTET GYN CLIN N AM, V21, P1; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; VIGNE JL, 1994, BIOL REPROD, V51, P1213, DOI 10.1095/biolreprod51.6.1213; Wang D, 2000, CANCER RES, V60, P4507; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6	26	26	28	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2003	22	30					4745	4751		10.1038/sj.onc.1206617	http://dx.doi.org/10.1038/sj.onc.1206617			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879019				2022-12-17	WOS:000184157000015
J	Nishimura, N; Furukawa, Y; Sutheesophon, K; Nakamura, M; Kishi, K; Okuda, K; Sato, Y; Kano, Y				Nishimura, N; Furukawa, Y; Sutheesophon, K; Nakamura, M; Kishi, K; Okuda, K; Sato, Y; Kano, Y			Suppression of ARG kinase activity by STI571 induces cell cycle arrest through up-regulation of CDK inhibitor p18/INK4c	ONCOGENE			English	Article						STI571; ETV6/ARG; cell cycle arrest; p18/INK4c	ABL TYROSINE KINASE; CHRONIC MYELOID-LEUKEMIA; BCR-ABL; INK4 FAMILY; APOPTOSIS; DIFFERENTIATION; P18(INK4C); EXPRESSION; PROTEIN; FUSION	ARG is a tyrosine kinase closely related to ABL, which is oncogenic when fused to the transcriptional repressor ETV6 (ETS translocation variant 6). In this study, we investigated the growth-inhibitory effect of STI571 (signal transduction inhibitor number 571) on ETV6/ARG-expressing cells and its molecular mechanisms using HT93A, a cell line derived from a patient with AML-M3 carrying t(1;12). STI571 effectively suppressed overall tyrosyl phosphorylation of intracellular proteins including ETV6/ARG fusion protein, as well as the growth of HT93A cells with an IC50 of 200 nM. The growth inhibition was primarily because of cell cycle arrest at G1 phase when cells were treated with 100 nm STI571 for 48 h, and apoptosis was induced after longer exposure (72 h) or by a higher dose (1000 nM). STI571 increased the amount of p18/INK4c after 2 h of culture, when the cell cycle pattern was not yet affected, but not that of other CDK inhibitors (CKI). p18/INK4c was more abundant in G1-enriched fractions than in S- and G2/M-enriched fractions of STI571-treated HT93A cells, suggesting that the upregulation of p18/INK4c expression correlates with the cell cycle arrest. Treatment of HT93A cells with antisense oligonucleotides against the Ink4c gene abrogated the growth inhibition by STI571. These results suggest that leukemogenesis by an aberrant ARG kinase involves the suppression of p18/INK4c, which is ubiquitously expressed and considered the major CKI in hematopoietic stem cells. STI571 can be an effective drug for the treatment of leukemias with deregulated ARG kinase activity.	Jichi Med Sch, Ctr Mol Med, Div Stem Cell Regulat, Minamikachi, Tochigi 3290498, Japan; Tokai Univ, Sch Med, Dept Hematol & Rheumatol, Kanagawa 2591193, Japan; Kyoto Prefectural Univ Med, Dept Hyg, Kyoto 6020841, Japan; Int Med Ctr Japan, Div Mol Cytogenet, Tokyo 1620052, Japan; Tochigi Canc Ctr, Div Med Oncol, Utsunomiya, Tochigi 3200834, Japan	Jichi Medical University; Tokai University; Kyoto Prefectural University of Medicine; National Center for Global Health & Medicine - Japan; Tochigi Prefectural Cancer Center	Furukawa, Y (corresponding author), Jichi Med Sch, Ctr Mol Med, Div Stem Cell Regulat, 3311-1 Yakushiji, Minamikachi, Tochigi 3290498, Japan.	furuyu@jichi.ac.jp	Furukawa, Yusuke/Y-1342-2018	Furukawa, Yusuke/0000-0002-7249-6418				Andreasson P, 1997, GENE CHROMOSOME CANC, V20, P299; Cazzaniga G, 1999, BLOOD, V94, P4370, DOI 10.1182/blood.V94.12.4370.424k34_4370_4373; Drexler HG, 1998, LEUKEMIA, V12, P845, DOI 10.1038/sj.leu.2401043; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; Eguchi M, 1999, BLOOD, V93, P1355, DOI 10.1182/blood.V93.4.1355; Fang GF, 2000, BLOOD, V96, P2246, DOI 10.1182/blood.V96.6.2246.h8002246_2246_2253; Gesbert F, 2000, J BIOL CHEM, V275, P39223, DOI 10.1074/jbc.M007291200; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Iijima Y, 2000, BLOOD, V95, P2126; Iijima Y, 2002, ONCOGENE, V21, P4374, DOI 10.1038/sj.onc.1205544; Joensuu H, 2001, NEW ENGL J MED, V344, P1052, DOI 10.1056/NEJM200104053441404; Jonuleit T, 2000, BLOOD, V96, P1933, DOI 10.1182/blood.V96.5.1933.h8001933_1933_1939; Kano Y, 2001, BLOOD, V97, P1999, DOI 10.1182/blood.V97.7.1999; KRUSH GD, 1986, SCIENCE, V234, P1545; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Mauro MJ, 2001, ONCOLOGIST, V6, P233, DOI 10.1634/theoncologist.6-3-233; Morcos PA, 2001, GENESIS, V30, P94, DOI 10.1002/gene.1039; Morse L, 1997, IMMUNITY, V6, P47, DOI 10.1016/S1074-7613(00)80241-1; Oetzel C, 2000, CLIN CANCER RES, V6, P1958; Okuda K, 2001, BLOOD, V97, P2440, DOI 10.1182/blood.V97.8.2440; Parada Y, 2001, J BIOL CHEM, V276, P23572, DOI 10.1074/jbc.M101885200; PEREGO R, 1991, ONCOGENE, V6, P1899; Phelps DE, 1998, MOL CELL BIOL, V18, P2334, DOI 10.1128/MCB.18.4.2334; SAIJO M, 1994, FEBS LETT, V340, P181, DOI 10.1016/0014-5793(94)80133-9; Schiffer CA, 2001, SEMIN ONCOL, V28, P34, DOI 10.1016/S0093-7754(01)90101-0; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; TERUI Y, 1995, J CELL PHYSIOL, V164, P74, DOI 10.1002/jcp.1041640110; Thullberg M, 2000, FEBS LETT, V470, P161, DOI 10.1016/S0014-5793(00)01307-7; Toba K, 1998, EXP HEMATOL, V26, P135; Tschan MP, 1999, BRIT J HAEMATOL, V106, P644, DOI 10.1046/j.1365-2141.1999.01617.x; YAISH P, 1988, SCIENCE, V242, P933, DOI 10.1126/science.3263702	37	26	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	2003	22	26					4074	4082		10.1038/sj.onc.1206498	http://dx.doi.org/10.1038/sj.onc.1206498			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821941				2022-12-17	WOS:000183707600010
J	Alonso, MM; Asumendi, A; Villar, J; Gil, MJ; Martinez-Merino, V; Encio, IJ; Migliaccio, M				Alonso, MM; Asumendi, A; Villar, J; Gil, MJ; Martinez-Merino, V; Encio, IJ; Migliaccio, M			New benzo(b)thiophenesulphonamide 1,1-dioxide derivatives induce a reactive oxygen species-mediated process of apoptosis in tumour cells	ONCOGENE			English	Article						antineoplastic drugs; apoptosis; CCRF-CEM; reactive oxygen species; caspase-8	CERVICAL-CARCINOMA CELLS; JURKAT LEUKEMIA-CELLS; CYTOCHROME-C; N-(4-HYDROXYPHENYL)RETINAMIDE-INDUCED APOPTOSIS; DEATH; MITOCHONDRIA; CANCER; CHEMOTHERAPY; INVOLVEMENT; DIARYLSULFONYLUREAS	In this work, we describe the process of cell death induced by a series of new benzo(b)thiophenesulphonamide 1,1-dioxide derivatives (BTS) that have been selected as candidate antineoplastic drugs. Human leukaemic CCRF-CEM cells incubated with BTS undergo a typical apoptotic process that includes cell shrinkage, phosphatidylserine translocation to the cell surface, mitochondrial dysfunction, caspase activation, chromatin condensation and internucleosomal DNA degradation. Mitochondrial alterations included dissipation of the mitochondrial membrane potential, oxidation of the phospholipid cardiolipin, release of cytochrome c and uncoupling of the mitochondrial respiratory chain, leading to a decrease of the intracellular ATP pool. Activation of caspase-8, -9 and -3 takes place during BTS-induced apoptosis. Either the addition of the specific caspase-8 inhibitor Z-IETD-fmk, or the overexpression of the antiapoptotic protein Bcl-2 significantly prevented BTS-induced apoptosis, suggesting the involvement of both caspase-8-regulated and mitochondria-dependent signalling pathways in this process. BTS induce a significant increase in the production and accumulation of intracellular reactive oxygen species (ROS) that can be observed within minutes after drug addition. Moreover, cytochrome c release, caspase-3 activation and cell death can be completely abrogated by a previous incubation with the antioxidant N-acetyl-cysteine. These results suggest that ROS are essential mediators in BTS-induced apoptosis.	Univ Publ Navarra, Dept Hlth Sci, Pamplona 31008, Spain; Univ Basque Country, Dept Cell Biol, Leioa 31006, Spain; Univ Publ Navarra, Dept Appl Chem, Pamplona 31013, Spain	Universidad Publica de Navarra; University of Basque Country; Universidad Publica de Navarra	Migliaccio, M (corresponding author), Univ Publ Navarra, Dept Hlth Sci, Avd Baranain S-N, Pamplona 31008, Spain.	marco.migliaccio@una.varra.es	Alonso, Marta M/AAI-9457-2020; Martinez-Merino, Victor/K-5177-2014; Asumendi, Aintzane/ABF-7001-2021	Alonso, Marta M/0000-0002-7520-7351; Martinez-Merino, Victor/0000-0002-1873-0699; Encio, Ignacio/0000-0003-1732-1989; Asumendi, Aintzane/0000-0002-2156-2323				Alonso MM, 2001, BRIT J CANCER, V85, P1400, DOI 10.1054/bjoc.2001.2083; Boutonnat J, 2000, CYTOMETRY, V42, P50, DOI 10.1002/(SICI)1097-0320(20000215)42:1<50::AID-CYTO8>3.3.CO;2-3; BOZOLLA JJ, 1992, ELECT MICROSCOPY; BUTTKE TM, 1995, FREE RADICAL RES, V22, P389, DOI 10.3109/10715769509147548; Costantini P, 2000, J NATL CANCER I, V92, P1042, DOI 10.1093/jnci/92.13.1042; COTTER TG, 1992, ANTICANCER RES, V12, P773; Ferreira CG, 2000, CANCER RES, V60, P7133; Green D R, 1994, Important Adv Oncol, P37; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hartmann BL, 1999, ONCOGENE, V18, P713, DOI 10.1038/sj.onc.1202339; HOWBERT JJ, 1990, J MED CHEM, V33, P2393, DOI 10.1021/jm00171a013; Huschtscha LI, 1996, BRIT J CANCER, V73, P54, DOI 10.1038/bjc.1996.10; Keller JN, 1998, J NEUROSCI, V18, P687; Kim PKM, 2001, DRUG RESIST UPDATE, V4, P293, DOI 10.1054/drup.2001.0223; Koren R, 2000, J STEROID BIOCHEM, V73, P105, DOI 10.1016/S0960-0760(00)00068-6; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; MARTIN SJ, 1994, TRENDS BIOCHEM SCI, V19, P26, DOI 10.1016/0968-0004(94)90170-8; MARTINEZMERINO V, 2000, Patent No. 0063202; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nomura K, 2001, BIOL SIGNAL RECEPT, V10, P81; Oridate N, 1997, INT J CANCER, V70, P484, DOI 10.1002/(SICI)1097-0215(19970207)70:4<484::AID-IJC21>3.0.CO;2-E; Oridate N, 1997, J NATL CANCER I, V89, P1191, DOI 10.1093/jnci/89.16.1191; Oridate N, 1995, J CELL BIOCHEM, P80; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Reed JC, 2000, CELL DEATH DIFFER, V7, P1145, DOI 10.1038/sj.cdd.4400777; SCUDIERO DA, 1988, CANCER RES, V48, P4827; Seki K, 2000, CANCER CHEMOTH PHARM, V45, P199, DOI 10.1007/s002800050030; Shapiro HM, 2000, METHODS, V21, P271, DOI 10.1006/meth.2000.1007; Skulachev VP, 1998, FEBS LETT, V423, P275, DOI 10.1016/S0014-5793(98)00061-1; SOSINSKI J, 1993, BIOCHEM PHARMACOL, V45, P2135, DOI 10.1016/0006-2952(93)90027-T; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; Suzuki S, 1999, ONCOGENE, V18, P6380, DOI 10.1038/sj.onc.1203024; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Umansky V, 2000, J CELL BIOCHEM, V78, P578, DOI 10.1002/1097-4644(20000915)78:4<578::AID-JCB7>3.0.CO;2-A; Umansky V, 2001, EXP CELL RES, V265, P274, DOI 10.1006/excr.2001.5188; Zamai L, 2001, CYTOMETRY, V44, P57, DOI 10.1002/1097-0320(20010501)44:1<57::AID-CYTO1082>3.3.CO;2-F; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	40	26	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	2003	22	24					3759	3769		10.1038/sj.onc.1206435	http://dx.doi.org/10.1038/sj.onc.1206435			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802283				2022-12-17	WOS:000183551000010
J	La Sala, D; Macaluso, M; Trimarchi, C; Giordano, A; Cinti, C				La Sala, D; Macaluso, M; Trimarchi, C; Giordano, A; Cinti, C			Triggering of p73-dependent apoptosis in osteosarcoma is under the control of E2Fs-pRb/p130 complexes	ONCOGENE			English	Article						multidrug resistance; apoptosis; p53-independent pathways; pRb2/p130; p73; osteosarcoma	TUMOR-SUPPRESSOR; IN-VIVO; RETINOBLASTOMA PROTEIN; MULTIDRUG-RESISTANCE; GENE-EXPRESSION; P-GLYCOPROTEIN; DNA-BINDING; P53; P73; E2F	Mechanisms underlying multidrug resistance (MDR), one of the major causes of cancer treatment failure, are still poorly understood. We selected the osteosarcoma MDR HosDXR150 cell line by culturing Hos cells in the presence of increasing doxorubicin doses and showed that it is crossresistant to vinblastine. Similarly to the Hos parental cell line, HosDXR150 cells present mutated p53, functionally inactivated pRb/p105 and wild-type pRb2/p130. Owing to p53 mutation, MDR-1 gene, codifying for P-glycoprotein, is upregulated. Evasion of apoptosis in HosDXR150 cells is only partially explained by drug extrusion because of P-glycoprotein overexpression. Analysis of gene expression level profiles showed that parental cell line undergoes apoptosis through an E2F1/p73-dependent pathway while its resistant variant evades it. This result can be explained by the presence of distinct E2Fs-pRb2/p130 complexes on the p73 promoter. Namely, in Hos p73 transcription is activated by E2F1-Rb2/p130-p300 complexes, while in HosDXR150 it is kept repressed by E2F4-Rb2/p130-HDAC1 complexes.	IOR, CNR, ITOI, Unit Bologna, I-40136 Bologna, Italy; Univ Siena, Inst Pathol Anat & Histol, I-53100 Siena, Italy; Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19107 USA; CNR, Inst Neurosci, I-56100 Pisa, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Siena; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Consiglio Nazionale delle Ricerche (CNR); Istituto di Neuroscienze (IN-CNR)	Cinti, C (corresponding author), IOR, CNR, ITOI, Unit Bologna, Via Barbiano 1-10, I-40136 Bologna, Italy.	cinti@area.bo.cnr.it	Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X; Cinti, Caterina/0000-0001-8049-0369				An B, 1996, FEBS LETT, V399, P158, DOI 10.1016/S0014-5793(96)01311-7; Bellan C, 2002, INVEST OPHTH VIS SCI, V43, P3602; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; Cinti C, 2000, ONCOGENE, V19, P5098, DOI 10.1038/sj.onc.1203848; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; Dou Q. Ping, 1998, Frontiers in Bioscience, V3, pD419; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Gorlick R, 1999, J CLIN ONCOL, V17, P2781, DOI 10.1200/JCO.1999.17.9.2781; GOTTESMAN MM, 1988, TRENDS PHARMACOL SCI, V9, P54, DOI 10.1016/0165-6147(88)90117-4; HANSEN MF, 1991, CLIN ORTHOP RELAT R, P237; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Johnson David G., 1998, Frontiers in Bioscience, V3, pD447; JOHNSON DG, 1995, ONCOGENE, V11, P1685; KANE SE, 1990, J BIOENERG BIOMEMBR, V22, P593, DOI 10.1007/BF00762963; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; Lavia P, 1999, BIOESSAYS, V21, P221; LIN XH, 1994, CANCER RES, V54, P2751; Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578; Miller CW, 1996, J CANCER RES CLIN, V122, P559, DOI 10.1007/BF01213553; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; NGUYEN KT, 1994, ONCOL RES, V6, P71; Oda Y, 2000, ONCOL REP, V7, P859; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; PARK DJ, 1994, ONCOGENE, V9, P1899; Pucci B, 2002, ONCOGENE, V21, P5897, DOI 10.1038/sj.onc.1205750; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Seelan RS, 2002, NEOPLASIA, V4, P195, DOI 10.1038/sj.neo.7900237; SERRA M, 1993, ANTICANCER RES, V13, P323; Shnyder SD, 1998, BRIT J CANCER, V78, P757, DOI 10.1038/bjc.1998.573; Sigal A, 2000, CANCER RES, V60, P6788; Somasundaram K, 2000, FRONT BIOSCI, V5, pD424, DOI 10.2741/Somasund; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Strauss BE, 1995, BIOCHEM BIOPH RES CO, V217, P825, DOI 10.1006/bbrc.1995.2846; STRAUSS BE, 1995, BIOCHEM BIOPH RES CO, V217, P333, DOI 10.1006/bbrc.1995.2781; Takahashi Y, 2000, GENE DEV, V14, P804; Thottassery JV, 1997, P NATL ACAD SCI USA, V94, P11037, DOI 10.1073/pnas.94.20.11037; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WEINBERG RA, 1995, ANN NY ACAD SCI, V758, P331, DOI 10.1111/j.1749-6632.1995.tb24838.x; Zaika A, 2001, J BIOL CHEM, V276, P11310, DOI 10.1074/jbc.M005737200; Zini N, 2001, J CELL PHYSIOL, V189, P34, DOI 10.1002/jcp.1135	47	26	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2003	22	23					3518	3529		10.1038/sj.onc.1206487	http://dx.doi.org/10.1038/sj.onc.1206487			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	687WD	12789260				2022-12-17	WOS:000183399200002
J	Schraets, D; Lehmann, T; Dingermann, T; Marschalek, R				Schraets, D; Lehmann, T; Dingermann, T; Marschalek, R			MLL-mediated transcriptional gene regulation investigated by gene expression profiling	ONCOGENE			English	Article						MLL; expression profiling; development; differential gene expression	ACUTE LYMPHOBLASTIC-LEUKEMIA; PROTO-ONCOPROTEIN MLL; GROWTH-FACTOR-BETA; CELL-LINE; TRANSMEMBRANE-4 SUPERFAMILY; MOUSE EMBRYO; CDNA CLONING; ALL1 GENE; IN-VITRO; BINDING	The human mixed lineage leukemia (MLL) gene is involved in about 50 different chromosomal translocations, associated with the disease phenotype of acute leukemia. However, the normal function of MLL is less understood. Homozygous knockouts of murine Mll were embryonal lethal, while heterozygous disruption led to aberrant hox gene expression associated with skeletal malformations, growth retardation, and impaired hematopoiesis. To understand MLL functions on the molecular level, gene expression profiling experiments were performed with a pair of murine cell lines (MLL+/+ and MLL-/-). Microarray hybridization experiments revealed 197 potential target genes that are differentially expressed, providing new and important clues about MLL functions.	Univ Frankfurt, Bioctr N230, Inst Pharmaceut Biol, D-60439 Frankfurt, Germany	Goethe University Frankfurt	Marschalek, R (corresponding author), Univ Frankfurt, Bioctr N230, Inst Pharmaceut Biol, Marie Curie Str 9, D-60439 Frankfurt, Germany.		Marschalek, Rolf/D-3404-2011; Dingermann, Theodor/M-6970-2014	Marschalek, Rolf/0000-0003-4870-3445; Dingermann, Theodor/0000-0002-2788-1085				Alward WLM, 2000, AM J OPHTHALMOL, V130, P107, DOI 10.1016/S0002-9394(00)00525-0; Arakawa H, 1998, P NATL ACAD SCI USA, V95, P4573, DOI 10.1073/pnas.95.8.4573; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Attardi LD, 2000, GENE DEV, V14, P704; Ayton P, 2001, GENESIS, V30, P201, DOI 10.1002/gene.1066; Birke M, 2002, NUCLEIC ACIDS RES, V30, P958, DOI 10.1093/nar/30.4.958; Bluteau O, 2002, NAT GENET, V32, P312, DOI 10.1038/ng1001; Bollen M, 2000, CRIT REV BIOCHEM MOL, V35, P393, DOI 10.1080/10409230091169249; Bonilla IE, 2002, J NEUROSCI, V22, P1303, DOI 10.1523/JNEUROSCI.22-04-01303.2002; Burg MA, 1996, J BIOL CHEM, V271, P26110, DOI 10.1074/jbc.271.42.26110; Capdevila J, 1999, MOL CELL, V4, P839, DOI 10.1016/S1097-2765(00)80393-7; Caslini C, 2000, P NATL ACAD SCI USA, V97, P2797, DOI 10.1073/pnas.040574897; Cavodeassi F, 2001, DEVELOPMENT, V128, P2847; Chu PH, 2000, MECH DEVELOP, V95, P259, DOI 10.1016/S0925-4773(00)00341-5; Cimino G, 1998, HAEMATOLOGICA, V83, P350; Cogan JG, 2002, J BIOL CHEM, V277, P36433, DOI 10.1074/jbc.M203232200; delaPompa J, 1997, DEVELOPMENT, V124, P1139; DiMartino JF, 1999, BRIT J HAEMATOL, V106, P614, DOI 10.1046/j.1365-2141.1999.01439.x; Dou CL, 2000, MOL CELL BIOL, V20, P6201, DOI 10.1128/MCB.20.17.6201-6211.2000; Felix CA, 1998, BBA-GENE STRUCT EXPR, V1400, P233, DOI 10.1016/S0167-4781(98)00139-0; Francis NJ, 2001, NAT REV MOL CELL BIO, V2, P409, DOI 10.1038/35073039; Gong XQ, 2002, J BIOL CHEM, V277, P12310, DOI 10.1074/jbc.M110228200; Gopalakrishnan R, 2001, ENDOCRINOLOGY, V142, P4379, DOI 10.1210/en.142.10.4379; GREIL J, 1994, BRIT J HAEMATOL, V86, P275, DOI 10.1111/j.1365-2141.1994.tb04726.x; Hanashima C, 2002, J NEUROSCI, V22, P6526; Henkel GW, 2002, INT IMMUNOL, V14, P723, DOI 10.1093/intimm/dxf040; Hosokawa Y, 1999, NEUROSCI RES, V35, P281, DOI 10.1016/S0168-0102(99)00093-0; Hsieh JJD, 2003, MOL CELL BIOL, V23, P186, DOI 10.1128/MCB.23.1.186-194.2003; Iida K, 1997, DEVELOPMENT, V124, P4627; Irikura VM, 2002, J IMMUNOL, V169, P393, DOI 10.4049/jimmunol.169.1.393; IZPISUABELMONTE JC, 1990, DEVELOPMENT, V110, P733; Koutsourakis M, 1999, DEVELOPMENT, V126, P723; Lee KKH, 2001, DEV BIOL, V234, P188, DOI 10.1006/dbio.2001.0249; LELIAS JM, 1993, P NATL ACAD SCI USA, V90, P1479, DOI 10.1073/pnas.90.4.1479; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; Lochner K, 1996, CANCER RES, V56, P2171; MARSCHALEK R, 1995, BRIT J HAEMATOL, V90, P308, DOI 10.1111/j.1365-2141.1995.tb05151.x; Meins M, 2001, J NEUROSCI, V21, P8830, DOI 10.1523/JNEUROSCI.21-22-08830.2001; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; Meng YH, 2002, NEURON, V35, P121, DOI 10.1016/S0896-6273(02)00758-4; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; MONAGHAN AP, 1991, DEVELOPMENT, V112, P1053; Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165; Morrisey EE, 1998, GENE DEV, V12, P3579, DOI 10.1101/gad.12.22.3579; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Pasqualetti M, 2001, NAT GENET, V29, P34, DOI 10.1038/ng702; PERRIS R, 1993, DEV DYNAM, V198, P135, DOI 10.1002/aja.1001980207; Seeler JS, 2001, ONCOGENE, V20, P7243, DOI 10.1038/sj.onc.1204758; Seykora JT, 2002, J BIOL CHEM, V277, P2812, DOI 10.1074/jbc.M106813200; SKONIER J, 1992, DNA CELL BIOL, V11, P511, DOI 10.1089/dna.1992.11.511; So CW, 2002, MOL CELL BIOL, V22, P6542, DOI 10.1128/MCB.22.18.6542-6552.2002; Spandorfer SD, 2000, AM J REPROD IMMUNOL, V43, P6, DOI 10.1111/j.8755-8920.2000.430102.x; Suzuki T, 2002, GENE DEV, V16, P1356, DOI 10.1101/gad.962802; TAKAGI S, 1995, INT J CANCER, V61, P706, DOI 10.1002/ijc.2910610519; Taniguchi Y, 1998, MOL CELL BIOL, V18, P644, DOI 10.1128/MCB.18.1.644; Toft DJ, 2001, P NATL ACAD SCI USA, V98, P13055, DOI 10.1073/pnas.231364798; Wei LC, 2002, DEV BRAIN RES, V139, P9, DOI 10.1016/S0165-3806(02)00509-6; Wiemels JL, 1999, LANCET, V354, P1499, DOI 10.1016/S0140-6736(99)09403-9; Yagami K, 1999, J CELL BIOL, V147, P1097, DOI 10.1083/jcb.147.5.1097; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Yano T, 1997, P NATL ACAD SCI USA, V94, P7286, DOI 10.1073/pnas.94.14.7286; Yokoyama A, 2002, BLOOD, V100, P3710, DOI 10.1182/blood-2002-04-1015; YonedaKato N, 1996, ONCOGENE, V12, P265; Yu BD, 1998, P NATL ACAD SCI USA, V95, P10632, DOI 10.1073/pnas.95.18.10632; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735	67	26	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2003	22	23					3655	3668		10.1038/sj.onc.1206438	http://dx.doi.org/10.1038/sj.onc.1206438			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	687WD	12789274				2022-12-17	WOS:000183399200016
J	Geisen, C; Karsunky, H; Yucel, R; Moroy, T				Geisen, C; Karsunky, H; Yucel, R; Moroy, T			Loss of P27(Kip1) cooperates with cyclin E in T-cell lymphomagenesis	ONCOGENE			English	Article						cyclin E; p27(Kip11); oncogene cooperation; lymphomagenesis	MALIGNANT TRANSFORMATION; TRANSGENIC MICE; CDK INHIBITORS; PROGNOSTIC IMPLICATIONS; ONCOGENIC ACTIVITY; RESTRICTION POINT; TUMOR SUPPRESSION; DEPENDENT KINASES; HA-RAS; MYC	Cyclin E and p27(Kip1) are key regulators for cyclin-dependent kinases (Cdks) acting at the G1-/S-phase transition of the cell cycle. Whereas cyclin E is required for the activation of Cdk2, p27(Kip1) is a specific Cdk inhibitor and can block cell division. High levels of cyclin E and low levels of p27(Kip1) expression have been associated with malignant lymphomas in humans; the level of p27(Kip1) is even considered of prognostic significance. However, mice that lack p27(Kip1) do not develop any malignant lymphomas despite a pronounced lymphoid hyperplasia in thymus and spleen. We have previously described transgenic mice that carry a construct in which the cyclin E cDNA is under the control of the CD2 promoter/enhancer region and thus express high levels of cyclin E in the T-cell compartment (CD2-cyclin E). These animals are not predisposed for T-cell lymphomas in the absence of other cooperating events. Here we show that T-cells from CD2-cyclin E mice that at the same time are deficient for p27(Kip1) show a significantly higher Cdk2 activity than cells from wilde-type or single mutant animals. Accordingly, a higher percentage of T cells in S/G2/M phase is found in CD2-cyclin E/p27(Kip2-/-) mice. After a long latency period of over 200 days, these animals develop spontaneous monoclonal T cell lymphoma whereas none of the single CD2-cyclin E transgenics or the p27(Kip1)-deficient mice showed any sign of lymphoid malignancies. Our findings demonstrate that a deregulation of control mechanisms at the G1/S transition by the combination of high cyclin E levels in the absence of p27(Kip1) is sufficient to predispose mice to develop lymphoid malignancies and further support a role of p27(Kip1) as a tumor suppressor and of cyclin E as a dominant oncogene.	Univ Essen Gesamthsch Klinikum, IFZ, Inst Zellbiol Tumorforsch, D-45122 Essen, Germany	University of Duisburg Essen	Moroy, T (corresponding author), Univ Essen Gesamthsch Klinikum, IFZ, Inst Zellbiol Tumorforsch, Virchowstr 173, D-45122 Essen, Germany.		Moroy, Tarik/D-9923-2011					Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Donnellan R, 1999, FASEB J, V13, P773, DOI 10.1096/fasebj.13.8.773; Erlanson M, 1998, BLOOD, V92, P770; Erlanson M, 2001, LEUKEMIA LYMPHOMA, V40, P461, DOI 10.3109/10428190109097645; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Geisen C, 2002, J BIOL CHEM, V277, P39909, DOI 10.1074/jbc.M205919200; Haas K, 1997, ONCOGENE, V15, P179, DOI 10.1038/sj.onc.1201171; Haas K, 1997, ONCOGENE, V15, P2615, DOI 10.1038/sj.onc.1201434; HALL M, 1995, ONCOGENE, V11, P1581; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HOGAN B, 1994, MANIPULATING MOUSE E; Hwang HC, 2002, P NATL ACAD SCI USA, V99, P11293, DOI 10.1073/pnas.162356099; Karsunky H, 1999, ONCOGENE, V18, P7816, DOI 10.1038/sj.onc.1203205; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; LOVEC H, 1994, ONCOGENE, V9, P323; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; Luscher B, 2001, GENE, V277, P1, DOI 10.1016/S0378-1119(01)00697-7; Martins CP, 2002, EMBO J, V21, P3739, DOI 10.1093/emboj/cdf364; Minella AC, 2002, CURR BIOL, V12, P1817, DOI 10.1016/S0960-9822(02)01225-3; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOROY T, 1993, P NATL ACAD SCI USA, V90, P10734, DOI 10.1073/pnas.90.22.10734; MOROY T, 1990, EMBO J, V9, P3659, DOI 10.1002/j.1460-2075.1990.tb07577.x; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; PlanasSilva MD, 1997, CURR OPIN CELL BIOL, V9, P768, DOI 10.1016/S0955-0674(97)80076-2; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Sambrook J, 1989, MOL CLONING LAB MANU; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1	40	26	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 20	2003	22	11					1724	1729		10.1038/sj.onc.1206340	http://dx.doi.org/10.1038/sj.onc.1206340			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	655YH	12642875				2022-12-17	WOS:000181580500014
J	Isaksson, A; Berggren, M; Ricksten, A				Isaksson, A; Berggren, M; Ricksten, A			Epstein-Barr virus U leader exon contains an internal ribosome entry site	ONCOGENE			English	Article						Epstein-Barr virus; internal ribosome entry site; U leader exon; luciferase expression; chloramphenicol transferase expression	SARCOMA-ASSOCIATED HERPESVIRUS; LYMPHOMA CELL-LINES; C-MYC IRES; MESSENGER-RNA; EBNA-1 GENE; ENCEPHALOMYOCARDITIS VIRUS; 5'-UNTRANSLATED REGION; INITIATION SITE; F-PROMOTER; TRANSLATION	Eukaryotic translation can be initiated either by a cap-dependent mechanism or by internal ribosome entry, a process by which ribosomes are directly recruited to structured regions of mRNA upstream of the initiation codon. Here we report the finding of an internal ribosome entry site (IRES) in the untranslated region of the Epstein-Barr nuclear antigen 1 (EBNA1) gene. EBNA1 is the only nuclear protein expressed in all known states of Epstein-Barr virus (EBV) latency and in the virus lytic cycle, and is required for the maintenance of the EBV episome. Using cDNA reporter constructs and in vitro transfection assays, we found that sequences contained in the 5' untranslated region (UTR) of the Fp and Qp initiated EBNA1 mRNA increased the expression level 4-14- fold in different Burkitt lymphoma cell lines. The U leader exon, located within the 5' UTR, included in all known EBNA1 transcripts and also contained in the EBNA3, 4 and 6 mRNAs, was demonstrated by bicistronic expression analyses to contain an IRES. The EBNA IRES initiates translation more efficiently than the encephalomyocarditis virus IRES in EBV-positive lymphoma cells. We propose that the EBNA IRES constitute a novel mechanism, whereby EBV regulates latent gene expression.	Sahlgrens Univ Hosp, Inst Lab Med, Dept Clin Chem & Transfus Med, S-41345 Gothenburg, Sweden	Sahlgrenska University Hospital	Ricksten, A (corresponding author), Sahlgrens Univ Hosp, Inst Lab Med, Dept Clin Chem & Transfus Med, S-41345 Gothenburg, Sweden.	anne.ricksten@clinchem.gu.se						Akiri G, 1998, ONCOGENE, V17, P227, DOI 10.1038/sj.onc.1202019; BENBASSAT H, 1977, INT J CANCER, V19, P27, DOI 10.1002/ijc.2910190105; Bieleski L, 2001, J VIROL, V75, P1864, DOI 10.1128/JVI.75.4.1864-1869.2001; Creancier L, 2001, MOL CELL BIOL, V21, P1833, DOI 10.1128/MCB.21.5.1833-1840.2001; Davenport MG, 1999, J VIROL, V73, P3154, DOI 10.1128/JVI.73.4.3154-3161.1999; deQuinto SL, 1997, J VIROL, V71, P4171; Dufva M, 2002, NUCLEIC ACIDS RES, V30, P2131, DOI 10.1093/nar/30.10.2131; Grundhoff A, 2001, J VIROL, V75, P1857, DOI 10.1128/JVI.75.4.1857-1863.2001; Hinton TM, 2001, J GEN VIROL, V82, P2257, DOI 10.1099/0022-1317-82-9-2257; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; KERR BM, 1992, VIROLOGY, V187, P189, DOI 10.1016/0042-6822(92)90307-B; Kieff E, 2001, FIELDS VIROLOGY, V2, P2511; KLEIN G, 1972, INT J CANCER, V10, P44, DOI 10.1002/ijc.2910100108; KLEIN G, 1978, INT J CANCER, V21, P552, DOI 10.1002/ijc.2910210504; Le Quesne JPC, 2001, J MOL BIOL, V310, P111, DOI 10.1006/jmbi.2001.4745; Low W, 2001, J VIROL, V75, P2938, DOI 10.1128/JVI.75.6.2938-2945.2001; Marechal V, 1999, J VIROL, V73, P4385, DOI 10.1128/JVI.73.5.4385-4392.1999; MILLER G, 1973, P NATL ACAD SCI USA, V70, P190, DOI 10.1073/pnas.70.1.190; Nanbru C, 1997, J BIOL CHEM, V272, P32061, DOI 10.1074/jbc.272.51.32061; Nateri AS, 2000, J VIROL, V74, P6269, DOI 10.1128/JVI.74.14.6269-6277.2000; Nonkwelo C, 1996, J VIROL, V70, P623, DOI 10.1128/JVI.70.1.623-627.1996; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; REYNOLDS JE, 1995, EMBO J, V14, P6010, DOI 10.1002/j.1460-2075.1995.tb00289.x; RICKSTEN A, 1988, NUCLEIC ACIDS RES, V16, P8391, DOI 10.1093/nar/16.17.8391; Rowe David T., 1999, Frontiers in Bioscience, V4, pD346, DOI 10.2741/Rowe; Sambrook J., 2001, MOL CLONING; SAMPLE J, 1986, P NATL ACAD SCI USA, V83, P5096, DOI 10.1073/pnas.83.14.5096; SAWADA K, 1989, VIROLOGY, V168, P22, DOI 10.1016/0042-6822(89)90399-1; SCHAEFER BC, 1995, P NATL ACAD SCI USA, V92, P10565, DOI 10.1073/pnas.92.23.10565; SCHAEFER BC, 1995, J VIROL, V69, P5039, DOI 10.1128/JVI.69.8.5039-5047.1995; Sjoblom A, 1998, J VIROL, V72, P1365; Stoneley M, 2000, NUCLEIC ACIDS RES, V28, P687, DOI 10.1093/nar/28.3.687; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; TSAI CN, 1995, DNA CELL BIOL, V14, P767, DOI 10.1089/dna.1995.14.767; TSUKIYAMAKOHARA K, 1992, J VIROL, V66, P1476, DOI 10.1128/JVI.66.3.1476-1483.1992; Vagner S, 2001, EMBO REP, V2, P893, DOI 10.1093/embo-reports/kve208; van der Velden AW, 1999, INT J BIOCHEM CELL B, V31, P87, DOI 10.1016/S1357-2725(98)00134-4; WOISETSCHLAEGER M, 1990, P NATL ACAD SCI USA, V87, P1725, DOI 10.1073/pnas.87.5.1725; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; Zetterberg H, 1999, J GEN VIROL, V80, P457, DOI 10.1099/0022-1317-80-2-457; ZUKER M, 1989, METHOD ENZYMOL, P262	41	26	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	2003	22	4					572	581		10.1038/sj.onc.1206149	http://dx.doi.org/10.1038/sj.onc.1206149			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	637XC	12555070				2022-12-17	WOS:000180538200010
J	Rowley, M; Van Ness, B				Rowley, M; Van Ness, B			Activation of N-ras and K-ras induced by interleukin-6 in a myeloma cell line: implications for disease progression and therapeutic response	ONCOGENE			English	Article						Ras; myeloma; therapeutic response	MULTIPLE-MYELOMA; GROWTH-FACTOR; APOPTOSIS; DEXAMETHASONE; MUTATIONS; DIFFERENTIATION; ONCOGENES; PROTEINS; COMPLEX; ANBL6	Ras is a major signaling molecule activated by interleukin-6. There have been no published reports, however, that specifically examine the kinetics and percentage of Ras activation in response to IL-6. Model cell lines were used to study activation of N- and K-ras induced by IL-6. All of the myeloma cell lines we tested express both N-ras and K-ras, but not H-ras. GTP-bound Ras was measured and the percentage of the total Ras pool that was activated in response to IL-6 was calculated. IL-6 is able to transiently activate both Nand K-ras in the ANBL6 cell tine. In addition, increasing concentrations of IL-6 are able to activate increasing levels of both N- and K-ras. One ng/ml of IL-6 is able to activate approximately 10% of the N-ras pool and 18% of the K-ras pool. The amount of Ras-GTP in the cells correlates with the level of proliferation at low levels, but proliferation plateaus when higher levels of Ras-GTP are present. Protection from dexamethasone-induced apoptosis correlates with IL-6 concentration and Ras activation. However, IL-6 enhances apoptosis induced by doxorubicin. Interestingly, the ANBL6 cell line transfected with an N-ras12 or a K-ras12 gene is protected from doxorubicin-induced apoptosis.	Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA; Univ Minnesota, Grad Program Mol Cellular Dev Biol & Genet, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Van Ness, B (corresponding author), Canc Ctr Res Bldg,Mayo Mail Code 806, Minneapolis, MN 55455 USA.				NCI NIH HHS [P01CA62242] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA062242] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BATAILLE R, 1989, J CLIN INVEST, V84, P2008, DOI 10.1172/JCI114392; Billadeau D, 1997, CANCER RES, V57, P2268; BILLADEAU D, 1995, CANCER RES, V55, P3640; Brownell HL, 1997, DNA CELL BIOL, V16, P103, DOI 10.1089/dna.1997.16.103; Chauhan D, 1997, J BIOL CHEM, V272, P29995, DOI 10.1074/jbc.272.48.29995; Chauhan D, 1997, ONCOGENE, V15, P837, DOI 10.1038/sj.onc.1201253; CORRADINI P, 1993, EMBO J, V16, P6439; Hall A, 1998, SCIENCE, V280, P2074, DOI 10.1126/science.280.5372.2074; HARDIN J, 1994, BLOOD, V84, P3063; HATA Y, 1993, ONCOL RES, V5, P161; Hirano Toshio, 1997, Cytokine and Growth Factor Reviews, V8, P241, DOI 10.1016/S1359-6101(98)80005-1; Jones MK, 1998, J BIOL CHEM, V273, P1782, DOI 10.1074/jbc.273.3.1782; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KLEIN B, 1989, BLOOD, V73, P517; LICHTENSTEIN A, 1995, CELL IMMUNOL, V162, P248, DOI 10.1006/cimm.1995.1076; Liu PC, 1996, BLOOD, V88, P2699, DOI 10.1182/blood.V88.7.2699.bloodjournal8872699; MCCLOSKEY TW, 1994, CLIN IMMUNOL IMMUNOP, V71, P14, DOI 10.1006/clin.1994.1045; McCormick F, 1996, NAT STRUCT BIOL, V3, P653, DOI 10.1038/nsb0896-653; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; NERI A, 1989, J EXP MED, V170, P1715, DOI 10.1084/jem.170.5.1715; PAQUETTE RL, 1990, ONCOGENE, V5, P1659; PORTIER M, 1992, ONCOGENE, V7, P2539; Rowley M, 2000, BLOOD, V96, P3175, DOI 10.1182/blood.V96.9.3175.h8003175_3175_3180; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9	25	26	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 12	2002	21	57					8769	8775		10.1038/sj.onc.1205387	http://dx.doi.org/10.1038/sj.onc.1205387			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483530				2022-12-17	WOS:000179734400011
J	Buckwalter, TLF; Venkateswaran, A; Lavender, M; La Perle, KMD; Cho, JY; Robinson, ML; Jhiang, SM				Buckwalter, TLF; Venkateswaran, A; Lavender, M; La Perle, KMD; Cho, JY; Robinson, ML; Jhiang, SM			The roles of phosphotyrosines-294,-404, and-451 in RET/PTC1-induced thyroid tumor formation	ONCOGENE			English	Article						RET/PTC1; mutagenesis; thyroid tumor; transgene	TRANSGENIC MICE; SIGNAL-TRANSDUCTION; RET; EXPRESSION; ONCOGENE; CARCINOMAS	RET/PTC1 is a rearranged form of the RET protooneogene detected in human papillary thyroid carcinomas. We previously showed that thyroid-targeted expression of RET/PTC1 leads to thyroid tumor formation in Tg-PTC1 transgenic mice. Signal transduction pathways mediated by phosphotyrosine 294, 404, or 451 in RET/PTC1 have been shown to be critical for RET-induced transforming activity in vitro. To investigate the contribution of these signaling pathways in RET/PTC1-induced thyroid tumor formation in vivo, we generated and characterized transgenic mice expressing thyroid-targeted RET/PTC1 mutants carrying a site-directed mutation changing tyrosine (Y) to phenylalanine (F) at the residue 294, 404, or 451. In contrast to the 100% tumor formation rate in Tg-PTC1 transgenic mice, tumor formation rates were significantly decreased in Tg-PTC1-Y294F (6%), Tg-PTC1-Y404F (41%), and Tg-PTC1-Y451F (30%) transgenic mice. This indicates that signaling pathways mediated by pY294, pY404, and pY451 do play a role in RET/PTC1-induced tumor formation. However, as tumors are still able to form in some mice within these three mutant transgenic groups, it indicates that none of the signaling pathways mediated by pY294, pY404, or pY451, are solely essential for RET/PTC1-induced tumor formation.	Ohio State Univ, Dept Physiol & Cell Biol, Columbus, OH 43210 USA; Ohio State Univ, Dept Vet Biosci, Columbus, OH 43210 USA; Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA	Ohio State University; Ohio State University; Ohio State University	Jhiang, SM (corresponding author), Ohio State Univ, Dept Physiol & Cell Biol, 304 Hamilton Hall,1645 Neil Ave, Columbus, OH 43210 USA.		La Perle, Krista Marie DuBray/B-3099-2015		NCI NIH HHS [R01 CA60074] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060074] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; Cho JY, 1999, ONCOGENE, V18, P3659, DOI 10.1038/sj.onc.1202709; Jhiang SM, 1996, ENDOCRINOLOGY, V137, P375, DOI 10.1210/en.137.1.375; Jhiang SM, 2000, ONCOGENE, V19, P5590, DOI 10.1038/sj.onc.1203857; Kato M, 1999, ONCOGENE, V18, P837, DOI 10.1038/sj.onc.1202329; KATO M, 2002, ONCOGENE, V62, P2414; Powell DJ, 2001, ONCOGENE, V20, P3235, DOI 10.1038/sj.onc.1204425; Santoro M, 1996, ONCOGENE, V12, P1821; Sweetser DA, 1999, ONCOGENE, V18, P877, DOI 10.1038/sj.onc.1202376; Tallini G, 2001, ADV ANAT PATHOL, V8, P345, DOI 10.1097/00125480-200111000-00005; van Weering DHJ, 1998, RECENT RES CANCER, V154, P271; Xing S, 1998, J BIOL CHEM, V273, P4909, DOI 10.1074/jbc.273.9.4909	12	26	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 21	2002	21	53					8166	8172		10.1038/sj.onc.1205938	http://dx.doi.org/10.1038/sj.onc.1205938			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615DW	12444552				2022-12-17	WOS:000179231400010
J	Ishiguro, H; Shimokawa, T; Tsunoda, T; Tanaka, T; Fujii, Y; Nakamura, Y; Furukawa, Y				Ishiguro, H; Shimokawa, T; Tsunoda, T; Tanaka, T; Fujii, Y; Nakamura, Y; Furukawa, Y			Isolation of HELAD1, a novel human helicase gene up-regulated in colorectal carcinomas	ONCOGENE			English	Article						helicase; APC; HELAD1; colon cancer	DEAD BOX PROTEIN; BETA-CATENIN; DNA HELICASE; HEPATOCELLULAR CARCINOMAS; XERODERMA-PIGMENTOSUM; CYCLIN D1; CELL; MUTATIONS; TARGET; APC	To investigate the mechanisms of colorectal carcinogenesis, we searched for genes regulated by adenomatous polyposis coli gene product (APC) and identified a novel gene, termed HELAD1 (helicase, APC down-regulated 1). A recombinant polypeptide representing the ATPases associated with cellular activities (AAA) domain of the HELAD1 product showed 3' to 5' helicase activity and exonuclease activity in vitro. HELAD1 was abundantly expressed in 16 of 20 colon cancers examined but hardly detectable in corresponding non-cancerous mucosae. Treatment of colon-cancer cells with antisense oligonucleotides suppressed its expression and induced apoptosis. These data revealed an importance of HELAD1 in colorectal carcinogenesis and suggest that suppression of HELAD1 may be a promising therapeutic strategy.	Univ Tokyo, Mol Med Lab, Ctr Human Genome, Inst Med Sci,Minato Ku, Tokyo 1088639, Japan; Nagoya City Univ, Dept Surg 2, Sch Med, Mizuho Ku, Nagoya, Aichi 4678601, Japan; RIKEN, Inst Phys & Chem Res, SNP Res Ctr, Minato Ku, Tokyo 1088639, Japan	University of Tokyo; Nagoya City University; RIKEN	Nakamura, Y (corresponding author), Univ Tokyo, Mol Med Lab, Ctr Human Genome, Inst Med Sci,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	yusuke@ims.u-tokyo.ac.jp	Tanaka, Toshihiro/J-9310-2014; Tsunoda, Tatsuhiko/K-2061-2014; Shimokawa, Takashi/AAA-5870-2020	Tanaka, Toshihiro/0000-0001-6201-9784; Tsunoda, Tatsuhiko/0000-0002-5439-7918; Shimokawa, Takashi/0000-0001-6549-9277				Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; BROUGHTON BC, 1994, NAT GENET, V7, P189, DOI 10.1038/ng0694-189; CASTRESANA J, 1995, FEBS LETT, V374, P149, DOI 10.1016/0014-5793(95)01098-Y; CHAUVEAU J, 1956, EXP CELL RES, V11, P317, DOI 10.1016/0014-4827(56)90107-0; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Eisen A, 1998, BIOESSAYS, V20, P634, DOI 10.1002/(SICI)1521-1878(199808)20:8<634::AID-BIES6>3.0.CO;2-I; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Freeman A, 1999, CLIN CANCER RES, V5, P2121; Fujita M, 2001, CANCER RES, V61, P7722; Godbout R, 1998, J BIOL CHEM, V273, P21161, DOI 10.1074/jbc.273.33.21161; GUZDER SN, 1994, NATURE, V369, P578, DOI 10.1038/369578a0; GUZDER SN, 1994, NATURE, V367, P91, DOI 10.1038/367091a0; Hamada F, 1999, SCIENCE, V283, P1739, DOI 10.1126/science.283.5408.1739; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; HEDGECOCK EM, 1987, DEVELOPMENT, V100, P365; HEKIMI S, 1993, J NEUROSCI, V13, P4254; Ishiguro H, 2000, JPN J CANCER RES, V91, P597, DOI 10.1111/j.1349-7006.2000.tb00987.x; Kanemaki M, 1999, J BIOL CHEM, V274, P22437, DOI 10.1074/jbc.274.32.22437; Kawasoe T, 2000, CANCER RES, V60, P3354; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; Lin YM, 2001, CANCER RES, V61, P6345; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Miyoshi Y, 1998, CANCER RES, V58, P2524; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nakagawa Y, 1999, BRIT J CANCER, V80, P914, DOI 10.1038/sj.bjc.6690441; Nakamura T, 1998, GENES CELLS, V3, P395, DOI 10.1046/j.1365-2443.1998.00198.x; Neuwald AF, 1999, GENOME RES, V9, P27; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; Ono K, 2000, CANCER RES, V60, P5007; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Seto M, 1995, GENE, V166, P293, DOI 10.1016/0378-1119(95)00559-5; Shiratori M, 1999, J CELL BIOL, V144, P1, DOI 10.1083/jcb.144.1.1; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Stradal T, 1998, FEBS LETT, V431, P134, DOI 10.1016/S0014-5793(98)00751-0; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; Takisawa H, 2000, CURR OPIN CELL BIOL, V12, P690, DOI 10.1016/S0955-0674(00)00153-8; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tye BK, 2000, J BIOL CHEM, V275, P34833, DOI 10.1074/jbc.R000018200; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; Xu LF, 2000, GENE DEV, V14, P585; Yamada T, 2000, CANCER RES, V60, P4761; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	50	26	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 12	2002	21	41					6387	6394		10.1038/sj.onc.1205751	http://dx.doi.org/10.1038/sj.onc.1205751			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590NM	12214280				2022-12-17	WOS:000177829000016
J	DeChant, AK; Dee, K; Weyman, CM				DeChant, AK; Dee, K; Weyman, CM			Raf-induced effects on the differentiation and apoptosis of skeletal myoblasts are determined by the level of Raf signaling: abrogation of apoptosis by Raf is downstream of caspase 3 activation	ONCOGENE			English	Article						Raf; myoblast; differentiation; apoptosis	PROTEIN-KINASE; MUSCLE DIFFERENTIATION; CELL LINEAGES; CYTOCHROME-C; INHIBITION; DEATH; TRANSFORMATION; PROLIFERATION; RECRUITMENT; MYOGENESIS	We examined the effect of a constitutively active Raf protein (Raf-CAAX) on the differentiation and the coincident apoptosis of skeletal myoblasts. We found that a low level of Raf signaling leads to accelerated differentiation when compared to parental myoblasts, while a higher level of Raf signaling induces a transformed morphology and abrogates both differentiation and the coincident apoptosis. Raf signaling abrogates apoptosis without blocking the activation of caspase 3 and the subsequent cleavage of caspase 3 substrates. Eliminating the signal from Raf through MEK does not restore the ability to differentiate or to undergo apoptosis in the myoblasts with a high level of Raf signal, nor does it abrogate the accelerated differentiation observed in myoblasts with lower levels of Raf signal. Constitutive signaling through MEK is required, however, to maintain a transformed morphology. These results indicate that the effect of Raf on the differentiation and apoptosis of skeletal myoblasts is dictated by the level of Raf signaling, and that Raf signaling sufficient to abrogate the apoptosis coincident with differentiation does so downstream of caspase 3 signaling.	Cleveland State Univ, Dept Biol Geol & Environm Sci, Cleveland, OH 44115 USA	Cleveland State University	Weyman, CM (corresponding author), Cleveland State Univ, Dept Biol Geol & Environm Sci, Cleveland, OH 44115 USA.	c.weyman@csuohio.edu			NATIONAL CANCER INSTITUTE [R01CA084212] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA84212-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bertrand F, 1998, J BIOL CHEM, V273, P2931, DOI 10.1074/jbc.273.5.2931; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chen J, 2001, P NATL ACAD SCI USA, V98, P7783, DOI 10.1073/pnas.141224398; Chinni C, 1999, J BIOL CHEM, V274, P9169, DOI 10.1074/jbc.274.14.9169; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; De Maria R, 1999, NATURE, V401, P489, DOI 10.1038/46809; Dee K, 2002, CELL DEATH DIFFER, V9, P209, DOI 10.1038/sj/cdd/4400930; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Dorman CM, 1999, ONCOGENE, V18, P5167, DOI 10.1038/sj.onc.1202907; FIDZIANSKA A, 1991, ACTA NEUROPATHOL, V81, P572, DOI 10.1007/BF00310140; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; Gredinger E, 1998, J BIOL CHEM, V273, P10436, DOI 10.1074/jbc.273.17.10436; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Hatai T, 2000, J BIOL CHEM, V275, P26576, DOI 10.1074/jbc.M003412200; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Kazama H, 2000, J CELL BIOL, V148, P557, DOI 10.1083/jcb.148.3.557; KONIECZNY SF, 1989, ONCOGENE, V4, P473; KONIECZNY SF, 1985, MOL CELL BIOL, V5, P2423, DOI 10.1128/MCB.5.9.2423; KONIECZNY SF, 1984, CELL, V38, P791, DOI 10.1016/0092-8674(84)90274-5; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; Le Gall M, 2000, MOL BIOL CELL, V11, P1103, DOI 10.1091/mbc.11.3.1103; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Mampuru LJ, 1996, EXP CELL RES, V226, P372, DOI 10.1006/excr.1996.0238; MARSHALL M, 1995, MOL REPROD DEV, V42, P493, DOI 10.1002/mrd.1080420418; MILLER JB, 1986, J CELL BIOL, V103, P2197, DOI 10.1083/jcb.103.6.2197; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; Ramocki MB, 1997, MOL CELL BIOL, V17, P3547, DOI 10.1128/MCB.17.7.3547; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Samuel DS, 1999, HORM METAB RES, V31, P55, DOI 10.1055/s-2007-978699; Sandri M, 1996, BASIC APPL MYOL, V6, P257; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Stroh C, 1998, CELL DEATH DIFFER, V5, P997, DOI 10.1038/sj.cdd.4400451; Tamada M, 1997, ONCOGENE, V15, P2959, DOI 10.1038/sj.onc.1201582; Utz PJ, 2000, CELL DEATH DIFFER, V7, P589, DOI 10.1038/sj.cdd.4400696; von Gise A, 2001, MOL CELL BIOL, V21, P2324, DOI 10.1128/MCB.21.7.2324-2336.2001; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Weyman CM, 1998, ENDOCRINOLOGY, V139, P1794, DOI 10.1210/en.139.4.1794; Weyman CM, 1997, ONCOGENE, V14, P697, DOI 10.1038/sj.onc.1200874; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Yang JY, 2001, MOL CELL BIOL, V21, P5346, DOI 10.1128/MCB.21.16.5346-5358.2001; Zhong J, 2001, ONCOGENE, V20, P4807, DOI 10.1038/sj.onc.1204614; Zimmermann KC, 2001, PHARMACOL THERAPEUT, V92, P57, DOI 10.1016/S0163-7258(01)00159-0; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	45	26	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 8	2002	21	34					5268	5279		10.1038/sj.onc.1205648	http://dx.doi.org/10.1038/sj.onc.1205648			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579TL	12149648				2022-12-17	WOS:000177193900008
J	Orlovsky, K; Theodor, L; Malovani, H; Chowers, Y; Nir, U				Orlovsky, K; Theodor, L; Malovani, H; Chowers, Y; Nir, U			Gamma interferon down-regulates Fer and induces its association with inactive Stat3 in colon carcinoma cells	ONCOGENE			English	Article						Fer; gamma interferon; Stat3; colon carcinoma	TYROSINE KINASE FER; PROSTATE-CANCER CELLS; IFN-GAMMA; ACTIVATION; PROTEIN; GENE; PHOSPHORYLATION; TRANSCRIPTION; BINDING; ENCODES	Gamma interferon (IFN-gamma) is a regulator of cell growth, which suppresses the proliferation of HT-29 colon carcinoma cells. Here we show that in HT-29 cells IFN-gamma transiently increased the cellular level of the tyrosine kinase Fer, whose functioning was found to be essential for the proliferation of malignant cell-lines. The transient elevation in the level of Fer, was followed by its down-regulation, an effect which was most prominent after 6-8 h of IFN-gamma treatment. Up- and down-regulation of Fer was paralleled by the activation and subsequent deactivation of Stat3, which is a potent oncogene and a putative substrate of the tyrosine kinase Fer. Moreover, IFN-gamma induced the association of Fer and Stat3 and the newly formed complex was most stable at the down-regulated states of the two proteins. Formation of the Fer/Stat3 complex was accompanied by an attenuation in cell-cycle progression and accumulation of cells in the G1 phase. Thus, Fer and Stat3 are two proliferation-promoting factors whose down-regulation could contribute to the cytostatic activity of IFN-gamma in colon carcinoma cells.	Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel; Chaim Sheba Med Ctr, Dept Gastroenterol, IL-52621 Tel Hashomer, Israel	Bar Ilan University; Chaim Sheba Medical Center	Nir, U (corresponding author), Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel.			Chowers, Yehuda/0000-0001-5130-845X				Allard P, 2000, MOL CELL ENDOCRINOL, V159, P63, DOI 10.1016/S0303-7207(99)00205-1; Ben-Dor I, 1999, CELL GROWTH DIFFER, V10, P113; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2001, METHOD ENZYMOL, V333, P138; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Caldenhoven E, 1999, J LEUKOCYTE BIOL, V65, P391, DOI 10.1002/jlb.65.3.391; Chen ZY, 2000, FEBS LETT, V477, P67, DOI 10.1016/S0014-5793(00)01764-6; Craig AWB, 1999, J BIOL CHEM, V274, P19934, DOI 10.1074/jbc.274.28.19934; Craig AWB, 2001, MOL CELL BIOL, V21, P603, DOI 10.1128/MCB.21.2.603-613.2001; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; FISCHMAN K, 1990, MOL CELL BIOL, V10, P146, DOI 10.1128/MCB.10.1.146; HAO QL, 1989, MOL CELL BIOL, V9, P1587, DOI 10.1128/MCB.9.4.1587; Hobeika AC, 1998, INT J CANCER, V77, P138, DOI 10.1002/(SICI)1097-0215(19980703)77:1<138::AID-IJC21>3.0.CO;2-9; Iwanishi M, 2000, J BIOL CHEM, V275, P38995, DOI 10.1074/jbc.M006665200; KIM L, 1995, MOL CELL BIOL, V15, P4553; Kominsky SL, 2000, CANCER RES, V60, P3904; LETWIN K, 1988, ONCOGENE, V3, P621; NACY CA, 1991, CURR OPIN IMMUNOL, V3, P330, DOI 10.1016/0952-7915(91)90033-W; Orlovsky K, 2000, BIOCHEMISTRY-US, V39, P11084, DOI 10.1021/bi0005153; Paulson R, 1997, ONCOGENE, V14, P641, DOI 10.1038/sj.onc.1200875; PAWSON T, 1989, MOL CELL BIOL, V9, P5722, DOI 10.1128/MCB.9.12.5722; PENHALLOW RC, 1995, J BIOL CHEM, V270, P23362, DOI 10.1074/jbc.270.40.23362; Priel-Halachmi S, 2000, J BIOL CHEM, V275, P28902, DOI 10.1074/jbc.M003402200; Rane SG, 2000, ONCOGENE, V19, P5662, DOI 10.1038/sj.onc.1203925; Rosato R, 1998, MOL CELL BIOL, V18, P5762, DOI 10.1128/MCB.18.10.5762; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SEN GC, 1992, J BIOL CHEM, V267, P5017; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; TRINCHIERI G, 1984, LAB INVEST, V50, P489; VANMOORSELAAR RJA, 1991, PROSTATE, V18, P331, DOI 10.1002/pros.2990180407; Woldman I, 2001, J BIOL CHEM, V276, P45722, DOI 10.1074/jbc.M105320200	33	26	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 25	2002	21	32					4997	5001		10.1038/sj.onc.1205624	http://dx.doi.org/10.1038/sj.onc.1205624			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574EE	12118379				2022-12-17	WOS:000176874800015
J	Kontou, M; Adelfalk, C; Ramirez, MH; Ruppitsch, W; Hirsch-Kauffmann, M; Schweiger, M				Kontou, M; Adelfalk, C; Ramirez, MH; Ruppitsch, W; Hirsch-Kauffmann, M; Schweiger, M			Overexpressed thioredoxin compensates Fanconi anemia related chromosomal instability	ONCOGENE			English	Article						Fanconi anemia; thioredoxin; oxidoreduction potential	REDOX REGULATION; TRANSCRIPTION FACTOR; ACTIVATION; CELLS; ANTIOXIDANTS; SECRETION; PREVENTS; PROTEINS	The cause of the molecular defect of Fanconi anemia (FA) remains unknown. Cells from patients with FA exert an elevated spontaneous chromosomal instability which is further triggered by mitomycin C. The induced lability is reduced by overexpression of thioredoxin which is not the case for spontaneous instability. However, both are eliminated by overexpression of thioredoxin cDNA with an added nuclear localization signal. This implies that thioredoxin is lacking in the nuclei of FA cells. The total thioredoxin content in all FA cells tested is reduced. The resultant lack of nuclear thioredoxin can be the explanation for the major symptomatology in FA. Since thioredoxin is known to be the reactive cofactor of ribonucleotid reductase its shortcoming reduces the supply of deoxyribonucleotides thus hindering the DNA and replication repair with resultant chromosomal breaks. Furthermore, depression of tyrosine hydroxylase, the key enzyme of melanine synthesis, could be the basis for the pathognomotic 'cafe au lait' spots of FA. The observation of thioredoxin reduction in FA cells permits insight into the molecular phathophysiology of FA.	Free Univ Berlin, Inst Biochem, D-14195 Berlin, Germany; Univ Innsbruck, Inst Med Biol & Humangenet, A-6020 Innsbruck, Austria	Free University of Berlin; University of Innsbruck	Schweiger, M (corresponding author), Free Univ Berlin, Inst Biochem, Thielallee 63, D-14195 Berlin, Germany.	mschweig@chemie.fu-berlin.de	Ruppitsch, Werner/AAC-9295-2019	Ruppitsch, Werner/0000-0001-9940-3333				ALTER BP, 1993, BRIT J HAEMATOL, V85, P9, DOI 10.1111/j.1365-2141.1993.tb08638.x; Cumming RC, 2001, NAT MED, V7, P814, DOI 10.1038/89937; DALLAPICCOLA B, 1985, HUM GENET, V69, P62, DOI 10.1007/BF00295530; Fanconi G., 1927, JAHRB KINDERHEILK, V117, P257; FUJII S, 1991, VIRCHOWS ARCH A, V419, P317, DOI 10.1007/BF01606523; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; GILLE JJP, 1987, HUM GENET, V77, P28; Hirota K, 1999, J BIOL CHEM, V274, P27891, DOI 10.1074/jbc.274.39.27891; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.biochem.54.1.237; Izawa S, 1999, J BIOL CHEM, V274, P28459, DOI 10.1074/jbc.274.40.28459; JOENJE H, 1981, NATURE, V290, P142, DOI 10.1038/290142a0; KORKINA LG, 1992, J LEUKOCYTE BIOL, V52, P357, DOI 10.1002/jlb.52.3.357; Matsui M, 1996, DEV BIOL, V178, P179, DOI 10.1006/dbio.1996.0208; Oliveira L, 1999, J BIOL CHEM, V274, P516, DOI 10.1074/jbc.274.1.516; Ramirez MH, 1999, BIOCHEM BIOPH RES CO, V264, P518, DOI 10.1006/bbrc.1999.1482; RUBARTELLI A, 1995, CANCER RES, V55, P675; RUBARTELLI A, 1992, J BIOL CHEM, V267, P24161; Ruppitsch W, 1997, HUM GENET, V99, P710, DOI 10.1007/s004390050437; Ruppitsch W, 1998, FEBS LETT, V422, P99, DOI 10.1016/S0014-5793(97)01608-6; SAMBROOK J, 1989, MOL CLONING LAB MANU, P712; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SCHINDLER D, 1988, AM J HUM GENET, V43, P429; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Sittler A, 1996, HUM MOL GENET, V5, P95, DOI 10.1093/hmg/5.1.95; WOOD JM, 1991, BIOCHIM BIOPHYS ACTA, V1074, P378, DOI 10.1016/0304-4165(91)90088-X	26	26	27	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2406	2412		10.1038/sj.onc.1205299	http://dx.doi.org/10.1038/sj.onc.1205299			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY	11948424				2022-12-17	WOS:000174635600013
J	Suzukawa, K; Colburn, NH				Suzukawa, K; Colburn, NH			AP-1 transrepressing retinoic acid does not deplete coactivators or AP-1 monomers but may target specific Jun or Fos containing dimers	ONCOGENE			English	Article						AP-1; JB6 cells; retinoic acid; transrepression; GAL4 transactivation assay	ANCHORAGE-INDEPENDENT GROWTH; TRANSCRIPTIONAL ACTIVATION; INDUCED TRANSFORMATION; PROMOTION-RESISTANT; TUMOR PROMOTERS; EPIDERMAL-CELLS; KAPPA-B; TRANSACTIVATION; INHIBITION; EXPRESSION	Retinoic acid (RA) inhibits tumor promotion in many models in vivo and in vitro, among them mouse epidermal JB6 cells. RA treatment suppresses 12-O-tetradecanoyl-phorbol-13-acetate (TPA) induced AP-1 activity, an activity that is required for transformation of JB6 P+ cells. The molecular mechanism of AP-1 transrepression by retinoids is unclear, especially as related to inhibition of transformation. Overexpression of AP-1 components did not rescue TPA induced AP-1 activation nor did a GST pull down experiment implicate direct binding, thus rendering unlikely both a Jun/Fos-RA-RAR direct interaction and a Jun/Fos sequestration mechanism. Overexpression of p300, SRC-1 or pCAF did not abrogate AP-1 suppression by RA, thus arguing against coactivator competition. Overexpression of the corepressor silencing mediator for retinoic acid and thyroid hormone receptors (SMRT) suppressed AP-1 activity. However, SMRT but not RA inhibited cJun transactivation, suggesting SMRT does not mediate RA transrepression. RA treatment also did not block TPA induced ERK phosphorylation, Jun/Fos family protein expression except for cFos, or DNA binding of the AP-1 complex. The transcriptional activities of full-length JunB and full-length Fra-1, but not the transactivation domain fusions, were increased by TPA treatment and suppressed by RA. Since these full-length fusions have bzip domains, the results suggest that JunB and/or Fra-1-containing dimers may constitute one target of RA for transrepression of AP-1.	Natl Canc Inst Frederick, Basic Res Lab, Gene Regulat Sect, Ft Detrick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Colburn, NH (corresponding author), Natl Canc Inst Frederick, Basic Res Lab, Gene Regulat Sect, Bldg 560 Rm 21-89 POB B, Ft Detrick, MD 21702 USA.	Colburn@ncifcrf.gov		Suzukawa, Kazumi/0000-0001-9904-3905				Agarwal SK, 1999, CELL, V96, P143, DOI 10.1016/S0092-8674(00)80967-8; Angel P, 2001, ONCOGENE, V20, P2413, DOI 10.1038/sj.onc.1204380; Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; Bernstein LR, 1999, BBA-GENE STRUCT EXPR, V1489, P263, DOI 10.1016/S0167-4781(99)00191-8; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; BERNSTEIN LR, 1992, MOL CARCINOGEN, V6, P221, DOI 10.1002/mc.2940060308; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; BOLLAG W, 1992, ANN ONCOL, V3, P513, DOI 10.1093/oxfordjournals.annonc.a058252; Boutwell R K, 1989, Prog Clin Biol Res, V298, P3; Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chen JD, 1996, P NATL ACAD SCI USA, V93, P7567, DOI 10.1073/pnas.93.15.7567; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; COLBURN NH, 1982, J CELL BIOCHEM, V18, P261, DOI 10.1002/jcb.1982.240180302; COLBURN NH, 1981, ANN NY ACAD SCI, V359, P251, DOI 10.1111/j.1749-6632.1981.tb12751.x; COLBURN NH, 1979, NATURE, V281, P589, DOI 10.1038/281589a0; DiSepio D, 1999, Mol Cell Biol Res Commun, V1, P7, DOI 10.1006/mcbr.1999.0101; Dong ZG, 1996, J BIOL CHEM, V271, P9942, DOI 10.1074/jbc.271.17.9942; DONG ZG, 1995, CARCINOGENESIS, V16, P749, DOI 10.1093/carcin/16.4.749; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Felzien LK, 1998, P NATL ACAD SCI USA, V95, P5281, DOI 10.1073/pnas.95.9.5281; Fisher GJ, 1996, FASEB J, V10, P1002, DOI 10.1096/fasebj.10.9.8801161; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; Fukasawa H, 2000, BIOL PHARM BULL, V23, P1414; Goyette P, 2000, J BIOL CHEM, V275, P16497, DOI 10.1074/jbc.M909382199; Huang CS, 1999, J BIOL CHEM, V274, P29672, DOI 10.1074/jbc.274.42.29672; Huang CS, 1998, P NATL ACAD SCI USA, V95, P156, DOI 10.1073/pnas.95.1.156; KAKIZAWA T, 2000, J BIOL CHEM, V27, P27; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Klein G, 1981, NATURE, V294, P313, DOI 10.1038/294313a0; Lee HY, 1999, MOL CELL BIOL, V19, P1973; Lee SK, 2000, J BIOL CHEM, V275, P12470, DOI 10.1074/jbc.275.17.12470; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; Li JJ, 1996, CANCER RES, V56, P483; Li JJ, 1998, ONCOGENE, V16, P2711, DOI 10.1038/sj.onc.1201798; Li JJ, 1997, CANCER RES, V57, P3569; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; Resche-Rigon M, 1998, CURR OPIN CHEM BIOL, V2, P501, DOI 10.1016/S1367-5931(98)80126-9; Rosenberger SF, 1999, J BIOL CHEM, V274, P1124, DOI 10.1074/jbc.274.2.1124; RUDD CJ, 1993, CANCER LETT, V73, P41, DOI 10.1016/0304-3835(93)90186-D; SAATCIOGLU F, 1994, SEMIN CANCER BIOL, V5, P347; SCHULE R, 1991, TRENDS GENET, V7, P377, DOI 10.1016/0168-9525(91)90259-S; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SIMONSON MS, 1994, AM J PHYSIOL-RENAL, V267, pF805, DOI 10.1152/ajprenal.1994.267.5.F805; SMITH SE, 1992, CELL GROWTH DIFFER, V3, P523; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; SUTHERLAND JA, 1992, GENE DEV, V6, P1810, DOI 10.1101/gad.6.9.1810; VERMA AK, 1977, CANCER RES, V37, P2196; Watts RG, 1998, ONCOGENE, V17, P3493, DOI 10.1038/sj.onc.1202259; YANGYEN HF, 1991, NEW BIOL, V3, P1206; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; Young MR, 2002, MOL CELL BIOL, V22, P587, DOI 10.1128/MCB.22.2.587-598.2002; Zhou XF, 1999, MOL ENDOCRINOL, V13, P276, DOI 10.1210/me.13.2.276	58	26	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2002	21	14					2181	2190		10.1038/sj.onc.1205281	http://dx.doi.org/10.1038/sj.onc.1205281			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	533XJ	11948401				2022-12-17	WOS:000174555300007
J	Chaudhry, MA; Chodosh, LA; McKenna, WG; Muschel, RJ				Chaudhry, MA; Chodosh, LA; McKenna, WG; Muschel, RJ			Gene expression profiling of HeLa cells in G1 or G2 phases	ONCOGENE			English	Article						microarray; genechip; cell cycle	B1 MESSENGER-RNA; CYCLIN B1; CLUSTER-ANALYSIS; IDENTIFICATION; TARGETS	The cell division cycle is regulated through both transcriptional and post-transcriptional mechanisms. The altered expression of a number of genes at the mRNA level is known to be essential for progression through the cell cycle, however, a comprehensive gene expression profile of human cells remains to be completed. Here we sought to monitor the differential gene expression of genes after the transition of G2 cells into G1 prior to the restriction point. GeneChip containing microarrays of oligonucleotides corresponding to over 12 000 human genes were employed to profile differential gene expression in G1 and G2. After three independent experiments the resultant data was filtered and a set of genes was compiled based on at least threefold-altered expression, no background noise in determining expression and observation in all experiments. Our analysis identified 154 genes that were elevated in G2 phase of cells as compared to early G1 phase including 15 novel genes. This number included mRNAs whose upregulation is known to occur in G2 phase. Surprisingly only 19 genes were upregulated in G1 phase, among these six genes were novel. Some of these genes are candidates for transition through early G1. This gene inventory for G1 and G2 phases of cell cycle will provide the basis for understanding of cell cycle delay as a result of DNA damage.	Univ Penn, Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Canc Biol, Abramson Canc Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Muschel, RJ (corresponding author), Childrens Hosp, Dept Pathol & Lab Med, 269 John Morgan Bldg,3620 Hamilton Walk, Philadelphia, PA 19104 USA.	muschel@mail.med.upenn.edu			NCI NIH HHS [P01 CA75138] Funding Source: Medline; NIGMS NIH HHS [R01 GM47439] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA075138] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047439] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS B, 1994, MOL BIOL CELL, P369; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; Cho RJ, 2001, NAT GENET, V27, P48, DOI 10.1038/83751; Claverie JM, 2001, SCIENCE, V291, P1255, DOI 10.1126/science.1058969; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Ghosh S, 1998, EXP CELL RES, V242, P1, DOI 10.1006/excr.1998.4115; HEINTZ N, 1993, TRENDS BIOCHEM SCI, V18, P157, DOI 10.1016/0968-0004(93)90103-T; Hitomi M, 2001, FEBS LETT, V490, P123, DOI 10.1016/S0014-5793(01)02115-9; KATO J, 1999, FRONT BIOSCI, V1, P787; Kel AE, 2001, J MOL BIOL, V309, P99, DOI 10.1006/jmbi.2001.4650; Kong M, 2000, EMBO J, V19, P1378, DOI 10.1093/emboj/19.6.1378; Lee SE, 1997, MOL CELL BIOL, V17, P1425, DOI 10.1128/MCB.17.3.1425; MAITY A, 1994, RADIOTHER ONCOL, V31, P1, DOI 10.1016/0167-8140(94)90408-1; MAITY A, 1995, EMBO J, V14, P603, DOI 10.1002/j.1460-2075.1995.tb07036.x; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Murray AW, 2001, NATURE, V409, P844, DOI 10.1038/35057033; Nakanishi M, 2000, GENES CELLS, V5, P839, DOI 10.1046/j.1365-2443.2000.00367.x; PINES J, 1991, CELL GROWTH DIFFER, V2, P305; Sakai N, 1999, EXP CELL RES, V251, P224, DOI 10.1006/excr.1999.4552; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; Vidal A, 2000, GENE, V247, P1, DOI 10.1016/S0378-1119(00)00092-5; VINDELOV LL, 1990, CYTOMETRY, V11, P753, DOI 10.1002/cyto.990110702; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340; Werner T, 2001, PHARMACOGENOMICS, V2, P25, DOI 10.1517/14622416.2.1.25; Yang J, 1999, TRENDS CELL BIOL, V9, P207, DOI 10.1016/S0962-8924(99)01577-9	30	26	26	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2002	21	12					1934	1942		10.1038/sj.onc.1205264	http://dx.doi.org/10.1038/sj.onc.1205264			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	529DJ	11896627				2022-12-17	WOS:000174284500017
J	Bar-Shira, A; Rashi-Elkeles, S; Zlochover, L; Moyal, L; Smorodinsky, NI; Seger, R; Shiloh, Y				Bar-Shira, A; Rashi-Elkeles, S; Zlochover, L; Moyal, L; Smorodinsky, NI; Seger, R; Shiloh, Y			ATM-dependent activation of the gene encoding MAP kinase phosphatase 5 by radiomimetic DNA damage	ONCOGENE			English	Article						ataxia-telangiectasia; ATM; MAP kinases; MAP kinase phosphatase; JNK; p38	PROTEIN-KINASE PHOSPHATASE; ATAXIA-TELANGIECTASIA CELLS; C-JUN; SIGNAL-TRANSDUCTION; GAMMA-RADIATION; SACCHAROMYCES-CEREVISIAE; PERSISTENT ACTIVATION; NEGATIVE REGULATOR; GENOTOXIC STRESS; JNK	Cellular responses to DNA damage are mediated by an extensive network of signaling pathways. The ATM protein kinase is a master regulator of the response to double-strand breaks (DSBs), the most cytotoxic DNA lesion caused by ionizing radiation. ATM is the protein missing or inactive in patients with the pleiotropic genetic disorder ataxia-telangiectasia (A-T). A major response to DNA damage is altered expression of numerous genes. While studying gene expression in control and A-T cells following treatment with the radiomimetic chemical neocarzinostatin (NCS), we identified an expressed sequence tag that represented a gene that was induced by DSBs in an ATM-dependent manner. The corresponding cDNA encoded a dual specificity phosphatase of the MAP kinase phosphatase family, MKP-5. MKP-5 dephosphorylates and inactivates the stress-activated MAP kinases JNK and p38. The phosphorylation-dephosphorylation cycle of JNK and p38 by NCS was attenuated in A-T cells. Thus, ATM modulates this cycle in response to DSBs. These results further highlight ATM as a link between the DNA damage response and major signaling pathways involved in proliferative and apoptotic processes.	Tel Aviv Univ, Sackler Sch Med, Dept Human Genet & Mol Med, David & Inez Myers Lab Genet Res, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, George S Wise Fac Life Sci, Hybridoma Unit, IL-69978 Tel Aviv, Israel; Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Weizmann Institute of Science	Shiloh, Y (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Human Genet & Mol Med, David & Inez Myers Lab Genet Res, IL-69978 Tel Aviv, Israel.	yossih@post.tau.ac.il			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031763] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS31763] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amundson SA, 1999, ONCOGENE, V18, P3666, DOI 10.1038/sj.onc.1202676; Andegeko Y, 2001, J BIOL CHEM, V276, P38224; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Chen YR, 2000, INT J ONCOL, V16, P651; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; GOLDBERG IH, 1995, ENEDIYNE ANTIBIOTICS, P327; Haneda M, 1999, EUR J PHARMACOL, V365, P1, DOI 10.1016/S0014-2999(98)00857-7; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Jelinsky SA, 1999, P NATL ACAD SCI USA, V96, P1486, DOI 10.1073/pnas.96.4.1486; Karran P, 2000, CURR OPIN GENET DEV, V10, P144, DOI 10.1016/S0959-437X(00)00069-1; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; Kharbanda S, 2000, MOL CELL BIOL, V20, P4979, DOI 10.1128/MCB.20.14.4979-4989.2000; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Lee SA, 1998, J BIOL CHEM, V273, P32889, DOI 10.1074/jbc.273.49.32889; Li NX, 2001, J BIOL CHEM, V276, P8898, DOI 10.1074/jbc.M009809200; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; Lowndes NF, 2000, CURR OPIN GENET DEV, V10, P17, DOI 10.1016/S0959-437X(99)00050-7; Masuda K, 2000, CYTOGENET CELL GENET, V90, P71, DOI 10.1159/000015666; Masuda K, 2001, J BIOL CHEM, V276, P39002, DOI 10.1074/jbc.M104600200; Matsuguchi T, 2001, MOL CELL BIOL, V21, P6999, DOI 10.1128/MCB.21.20.6999-7009.2001; MELTZER B, 2001, J BIOL CHEM, V273, P33320; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; Obata T, 2000, CRIT CARE MED, V28, pN67, DOI 10.1097/00003246-200004001-00008; Piret B, 1999, ONCOGENE, V18, P2261, DOI 10.1038/sj.onc.1202541; Rincon M, 2000, FREE RADICAL BIO MED, V28, P1328, DOI 10.1016/S0891-5849(00)00219-7; Sanchez-Perez I, 1998, ONCOGENE, V16, P533, DOI 10.1038/sj.onc.1201578; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schaus SE, 2001, P NATL ACAD SCI USA, V98, P11075, DOI 10.1073/pnas.191340698; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Schmidt-Ullrich RK, 2000, RADIAT RES, V153, P245, DOI 10.1667/0033-7587(2000)153[0245:STACRR]2.0.CO;2; SHAFMAN TD, 1995, CANCER RES, V55, P3242; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; SHILOH Y, 1983, CARCINOGENESIS, V4, P1317, DOI 10.1093/carcin/4.10.1317; Shiloh Y, 2001, ADV CANCER RES, V83, P209, DOI 10.1016/S0065-230X(01)83007-4; Tanoue T, 1999, J BIOL CHEM, V274, P19949, DOI 10.1074/jbc.274.28.19949; Tanoue T, 2001, J BIOL CHEM, V276, P26629, DOI 10.1074/jbc.M101981200; Theodosiou A, 1999, ONCOGENE, V18, P6981, DOI 10.1038/sj.onc.1203185; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Verheij M, 1998, RADIOTHER ONCOL, V47, P225, DOI 10.1016/S0167-8140(98)00007-3; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143	46	26	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2002	21	5					849	855		10.1038/sj.onc.1205127	http://dx.doi.org/10.1038/sj.onc.1205127			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FB	11850813				2022-12-17	WOS:000173427000016
J	Itano, O; Ueda, M; Kikuchi, K; Hashimoto, O; Hayatsu, S; Kawaguchi, M; Seki, H; Aiura, K; Kitajima, M				Itano, O; Ueda, M; Kikuchi, K; Hashimoto, O; Hayatsu, S; Kawaguchi, M; Seki, H; Aiura, K; Kitajima, M			Correlation of postoperative recurrence in hepatocellular carcinoma with demethylation of repetitive sequences	ONCOGENE			English	Article						demethylation; repetitive sequence; hepatocellular carcinoma; postoperative recurrence; restriction landmark genomic scanning	GLOBAL DNA HYPOMETHYLATION; PROGNOSTIC FACTORS; METHYLATION; LIVER; EUKARYOTES; EXPRESSION; ONCOGENES	Restriction landmark genomic scanning (RLGS) was utilized to identify novel genomic alterations in hepatocellular carcinoma (HCC). Thirty-one HCC samples were examined by RLGS. Two high intensity spots were common to several RLGS profiles of different HCCs. Nucleotide sequencing and homology search analysis showed that these spots represented repetitive sequences, Human tandem repeat sequence (Genbank, L09552) and centromeric NotI cluster (Genbank, Y10752). These intensified signals were attributable to the occurrence of demethylated areas in the recognition sequence of the NotI site of the corresponding fragments. The intensity of these spots in the RLGS profile reflects their degree of demethylation, which was significantly correlated with postoperative recurrence, even in patients regarded as belonging to the good prognosis group by conventional prognostic factors. Multivariate analysis showed that the intensities of the two spots retained independent prognostic value. This is a new type of predictive factor for HCC based on epigenetic changes in hepatocarcinogenesis, and in the future it is expected to be of great value in making preoperative diagnosis and selecting postoperative therapy.	Keio Univ, Sch Med, Dept Surg, Shinjuku Ku, Tokyo 1608582, Japan; Tokyo Denryoku Hosp, Dept Surg, Shinjuku Ku, Tokyo 1600016, Japan	Keio University	Ueda, M (corresponding author), Keio Univ, Sch Med, Dept Surg, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.							Altschul Stephen F., J MOL BIOL, V215, P403, DOI [10.1016/S0022-2836(05)80360-2, DOI 10.1016/S0022-2836(05)80360-2]; ARII S, 1992, CANCER, V69, P913, DOI 10.1002/1097-0142(19920215)69:4<913::AID-CNCR2820690413>3.0.CO;2-T; Baylin SB, 1998, ADV CANCER RES, V72, P141; Bender J, 1998, TRENDS BIOCHEM SCI, V23, P252, DOI 10.1016/S0968-0004(98)01225-0; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; Cravo M, 1996, GUT, V39, P434, DOI 10.1136/gut.39.3.434; HATADA I, 1991, P NATL ACAD SCI USA, V88, P9523, DOI 10.1073/pnas.88.21.9523; HIMENO Y, 1988, LIVER, V8, P208; HSU HC, 1988, CANCER, V61, P2095, DOI 10.1002/1097-0142(19880515)61:10<2095::AID-CNCR2820611027>3.0.CO;2-H; Itano O, 2000, ONCOGENE, V19, P1676, DOI 10.1038/sj.onc.1203459; KIM YI, 1994, CANCER, V74, P893, DOI 10.1002/1097-0142(19940801)74:3<893::AID-CNCR2820740316>3.0.CO;2-B; Kubo S, 1998, JPN J CANCER RES, V89, P419, DOI 10.1111/j.1349-7006.1998.tb00580.x; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; Liew CT, 1999, ONCOGENE, V18, P789, DOI 10.1038/sj.onc.1202359; Lise M, 1998, CANCER, V82, P1028, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1028::AID-CNCR4>3.0.CO;2-A; *LIV CANC STUD GRO, 1997, CLASS PRIM LIV CANC, P1; MIWA W, 1995, ELECTROPHORESIS, V16, P227, DOI 10.1002/elps.1150160138; Nagai H, 1999, DNA Res, V6, P219, DOI 10.1093/dnares/6.4.219; Nagai H, 1999, GENE, V237, P15, DOI 10.1016/S0378-1119(99)00322-4; Narayan A, 1998, INT J CANCER, V77, P833, DOI 10.1002/(SICI)1097-0215(19980911)77:6<833::AID-IJC6>3.0.CO;2-V; OHSUMI T, 1995, ELECTROPHORESIS, V16, P203, DOI 10.1002/elps.1150160135; Qu GZ, 1999, MUTAT RES-FUND MOL M, V423, P91, DOI 10.1016/S0027-5107(98)00229-2; Shen LL, 1998, HEPATO-GASTROENTEROL, V45, P1753; Shiraishi M, 1999, BIOL CHEM, V380, P81, DOI 10.1515/BC.1999.010; SIRABE K, 1991, HEPATOLOGY, V14, P913; Soares J, 1999, CANCER, V85, P112, DOI 10.1002/(SICI)1097-0142(19990101)85:1<112::AID-CNCR16>3.0.CO;2-T; TEUBNER B, 1994, EXP CELL RES, V2102, P192; Thoraval D, 1996, GENE CHROMOSOME CANC, V17, P234, DOI 10.1002/(SICI)1098-2264(199612)17:4<234::AID-GCC5>3.0.CO;2-4; ZHANG XK, 1987, BIOCHEM BIOPH RES CO, V142, P932, DOI 10.1016/0006-291X(87)91503-8; ZRIHANLICHT S, 1995, INT J CANCER, P245	30	26	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2002	21	5					789	797		10.1038/sj.onc.1205124	http://dx.doi.org/10.1038/sj.onc.1205124			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FB	11850807				2022-12-17	WOS:000173427000010
J	Bakhanashvili, M				Bakhanashvili, M			p53 enhances the fidelity of DNA synthesis by human immunodeficiency virus type 1 reverse transcriptase	ONCOGENE			English	Article						p53; HIV-1 RT; 3 '-> 5 ' exonuclease; DNA replication fidelity	WILD-TYPE; IN-VITRO; EXONUCLEASE ACTIVITY; BASE-SUBSTITUTION; ESCHERICHIA-COLI; POLYMERASE-III; PROTEIN; EXPRESSION; EXTENSION; SPECIFICITY	The tumor suppressor protein p53 plays a critical role in the maintenance of genetic integrity. p53 possesses 3'-->5' exonuclease activity, however, the significance of this function in DNA replication process remains elusive. It was suggested that 3'-->5' exonuclease activity of p53 may provide a proofreading function for DNA polymerases. In order to better understand the significance of this activity, the purified wild-type recombinant p53 was further evaluated for substrate specificity and for contribution to the accuracy of DNA synthesis. p53-associated 3'-->5' exonuclease displays 3' terminal nucleotide excision from RNA/DNA template-primer using ribosomal RNA as a template. The data demonstrate that p53 is highly efficient in removing a terminal mispair. Analysis of mispair excision opposite the template adenine residue shows that p53 catalyzes 3' terminal mismatch excision with a specificity of A:G>A:A>A:C. Hence, the observed specificity of mismatch excision indicates that p53 exonucleolytic proofreading preferentially repairs transversion mutations. The influence of the p53 on the accuracy of DNA synthesis was determined with exonuclease-deficient human immunodeficiency virus-1 (HIV-1) reverse transcriptase (RT), a key enzyme in the life cycle of the virus, that contributes significantly to the low accuracy of proviral DNA synthesis. Using an in vitro biochemical assay with recombinant purified HIV-1 RT, p53 and defined RNA/DNA or DNA/DNA template-primers, two basic features related to fidelity of DNA synthesis were studied: the misinsertion and mispair extension. The misincorporation of non-complementary deoxynucleotides into nascent DNA and subsequent mispair extension by HIV-1 RT were substantially decreased in the presence of p53 with both RNA/DNA and DNA/DNA template-primers. In addition, the productive interaction between polymerization (by HIV-1 RT) and exonuclease (by p53) activities was observed; p53 preferentially hydrolyzes mispaired 3'-termini, permitting subsequent extension of the correctly paired 3'-terminus by HIV-1 RT. Taken together the data demonstrate that preferential excision of mismatched nucleotides by 3'-->5' exonuclease activity of wild-type p53 enhances the fidelity of DNA synthesis by HIV-1 RT in vitro, thus providing a biochemical mechanism to reduce mutations caused by incorporation of mismatched nucleotides. The fact that p53 is reactive with both RNA/DNA and DNA/DNA template-primers raises an interesting possibility of the existence of functional cooperation between p53 and HIV-1 RT in cytoplasm during the reverse transcription process, which may be important for maintaining HIV genomic integrity.	Chaim Sheba Med Ctr, Infect Dis Unit, IL-52621 Tel Hashomer, Israel	Chaim Sheba Medical Center	Bakhanashvili, M (corresponding author), Chaim Sheba Med Ctr, Infect Dis Unit, IL-52621 Tel Hashomer, Israel.	bakhanus@yahoo.com						Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; Bakhanashvili M, 1996, ARCH BIOCHEM BIOPHYS, V334, P89, DOI 10.1006/abbi.1996.0433; BAKHANASHVILI M, 1992, FEBS LETT, V306, P151, DOI 10.1016/0014-5793(92)80988-S; BAKHANASHVILI M, 1992, BIOCHEMISTRY-US, V31, P9393, DOI 10.1021/bi00154a010; Bakhanashvili M, 2001, EUR J BIOCHEM, V268, P2047, DOI 10.1046/j.1432-1327.2001.02075.x; BAKHANASHVILI M, 1993, BIOCHEMISTRY-US, V32, P7559, DOI 10.1021/bi00080a030; BRUTLAG D, 1972, J BIOL CHEM, V247, P241; CLARK PK, 1990, AIDS RES HUM RETROV, V6, P753, DOI 10.1089/aid.1990.6.753; COFFIN JM, 1986, CELL, V46, P1, DOI 10.1016/0092-8674(86)90851-2; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.bi.60.070191.002401; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FOORD O, 1993, MOL CELL BIOL, V13, P1378, DOI 10.1128/MCB.13.3.1378; Genini D, 2001, FASEB J, V15, P5; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; GRAND RJA, 1994, VIROLOGY, V203, P229, DOI 10.1006/viro.1994.1480; HIZI A, 1988, P NATL ACAD SCI USA, V85, P1218, DOI 10.1073/pnas.85.4.1218; Huang P, 1998, ONCOGENE, V17, P261, DOI 10.1038/sj.onc.1201946; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; KASTAN MB, 1991, CANCER RES, V51, P6304; KATZ RA, 1990, ANNU REV GENET, V24, P409, DOI 10.1146/annurev.ge.24.120190.002205; KERN SE, 1991, ONCOGENE, V6, P131; Komarova EA, 1997, CANCER RES, V57, P5217; KUNKEL TA, 1988, CELL, V53, P837, DOI 10.1016/S0092-8674(88)90189-4; KUNKEL TA, 1985, J BIOL CHEM, V260, P2866; KUNKEL TA, 1986, J BIOL CHEM, V261, P160; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; MAKI H, 1987, P NATL ACAD SCI USA, V84, P4389, DOI 10.1073/pnas.84.13.4389; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; Moll UM, 1996, MOL CELL BIOL, V16, P1126; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PERRINO FW, 1990, BIOCHEMISTRY-US, V29, P5226, DOI 10.1021/bi00474a002; PERRINO FW, 1989, P NATL ACAD SCI USA, V86, P8343, DOI 10.1073/pnas.86.21.8343; Prives C, 1999, J PATHOL, V187, P112; RAGIMOV N, 1993, ONCOGENE, V8, P1183; SINHA NK, 1987, P NATL ACAD SCI USA, V84, P915, DOI 10.1073/pnas.84.4.915; Skalski V, 2000, ONCOGENE, V19, P3321, DOI 10.1038/sj.onc.1203649; SLOANE DL, 1988, NUCLEIC ACIDS RES, V16, P6465, DOI 10.1093/nar/16.14.6465; SOUSSI T, 1995, MOL GENETICS CANC, P135; STEINMEYER K, 1988, ONCOGENE, V3, P501; SZEKELY L, 1995, ONCOGENE, V10, P1869; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	50	26	27	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 15	2001	20	52					7635	7644		10.1038/sj.onc.1204956	http://dx.doi.org/10.1038/sj.onc.1204956			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	491TC	11753641				2022-12-17	WOS:000172124100006
J	Chen, F; Zhang, Z; Leonard, SS; Shi, XL				Chen, F; Zhang, Z; Leonard, SS; Shi, XL			Contrasting roles of NF-kappa B and JNK in arsenite-induced p53-independent expression of GADD45 alpha	ONCOGENE			English	Article						arsenite; GADD45 alpha; NF-kappa B; JNK; cell cycle; p53	CELL-CYCLE CHECKPOINT; GENE-EXPRESSION; EPITHELIAL-CELLS; IKK-BETA; ACTIVATION; INDUCTION; KINASE; STRESS; TRANSCRIPTION; BRCA1	Growth arrest and DNA damage-inducible protein 45 alpha (GADD45 alpha) is an important cell cycle checkpoint protein that arrests cells at G2/M phase by inhibiting the activity of G2-specific kinase, cyclin B/p34cdc2. We report here that arsenite induces GADD45 alpha expression in a p53-independent fashion and that this GADD45a induction by arsenite is regulated by NF-KB and c-Jun-N-terminal kinase (JNK) oppositely. In human bronchial epithelial cells overexpressing a kinase-mutated form of I kappaB kinase beta (IKK beta -KM), the activation of NF-kappaB was inhibited. However, the G2/M cell cycle arrest and expression of GADB45 alpha was substantially enhanced in response to arsenite in these cells. Expression of a dominant-negative mutant of SEK1 that blocks JNK activation decreased arsenite-induced GADD45a expression. Analysis of GADD45 alpha expression in both wild-type and p53-/- fibroblasts indicated that the induction of GADD45a by arsenite was independent of the status of p53 protein.	NIOSH, Hlth Effects Lab Div, Morgantown, WV 26505 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)	Chen, F (corresponding author), NIOSH, Hlth Effects Lab Div, 1095 Willowdale Rd, Morgantown, WV 26505 USA.		Zhang, Zhuo/B-8601-2012; Shi, Xianglin/B-8588-2012					Barchowsky A, 1996, FREE RADICAL BIO MED, V21, P783, DOI 10.1016/0891-5849(96)00174-8; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; Chen F, 1999, CLIN CHEM, V45, P7; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; Du J, 2000, J BIOL CHEM, V275, P19661, DOI 10.1074/jbc.M907258199; Gebel T, 2000, TOXICOLOGY, V144, P155, DOI 10.1016/S0300-483X(99)00202-4; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; GERWIN BI, 1992, P NATL ACAD SCI USA, V89, P2759, DOI 10.1073/pnas.89.7.2759; Guttridge DC, 2000, SCIENCE, V289, P2363, DOI 10.1126/science.289.5488.2363; Hamilton JW, 1998, ENVIRON HEALTH PERSP, V106, P1005, DOI 10.2307/3434145; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; Huang SC, 1998, CARCINOGENESIS, V19, P889, DOI 10.1093/carcin/19.5.889; Jaspers I, 1999, J BIOL CHEM, V274, P31025, DOI 10.1074/jbc.274.43.31025; Jin SQ, 2000, ONCOGENE, V19, P4050, DOI 10.1038/sj.onc.1203759; Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200; Kapahi P, 2000, J BIOL CHEM, V275, P36062, DOI 10.1074/jbc.M007204200; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kayajanian GM, 2000, ECOTOX ENVIRON SAFE, V45, P195, DOI 10.1006/eesa.1999.1865; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Mazumder DNG, 1998, INT J EPIDEMIOL, V27, P871, DOI 10.1093/ije/27.5.871; O'Reilly MA, 2000, AM J PHYSIOL-LUNG C, V278, pL552, DOI 10.1152/ajplung.2000.278.3.L552; Roussel RR, 2000, ARCH BIOCHEM BIOPHYS, V377, P204, DOI 10.1006/abbi.2000.1770; Russell P, 1998, TRENDS BIOCHEM SCI, V23, P399, DOI 10.1016/S0968-0004(98)01291-2; Shaulian E, 1999, J BIOL CHEM, V274, P29595, DOI 10.1074/jbc.274.42.29595; Simeonova Petia P., 2000, Journal of Environmental Pathology Toxicology and Oncology, V19, P281; Simeonova PP, 2000, CANCER RES, V60, P3445; Styblo M, 1999, CHEM RES TOXICOL, V12, P560, DOI 10.1021/tx990050l; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Wang XT, 1999, J BIOL CHEM, V274, P29599, DOI 10.1074/jbc.274.42.29599; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Yang Q, 2000, J BIOL CHEM, V275, P36892, DOI 10.1074/jbc.M005319200; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zheng L, 2000, MOL CELL, V6, P757, DOI 10.1016/S1097-2765(00)00075-7	36	26	27	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2001	20	27					3585	3589		10.1038/sj.onc.1204442	http://dx.doi.org/10.1038/sj.onc.1204442			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429707				2022-12-17	WOS:000169478300016
J	Frost, V; Al-Mehairi, S; Sinclair, AJ				Frost, V; Al-Mehairi, S; Sinclair, AJ			Exploitation of a non-apoptotic caspase to regulate the abundance of the cdkI p27(KIP1) in transformed lymphoid cells	ONCOGENE			English	Article						cell cycle; apoptosis; lymphoma; protease	DEPENDENT KINASE INHIBITOR; EPSTEIN-BARR-VIRUS; BREAST-CANCER CELLS; CYCLE ARREST; GROWTH ARREST; T-CELLS; MDM2 ONCOPROTEIN; GENE P27(KIP1); B-LYMPHOCYTES; MICE LACKING	Expression of the cyclin dependent kinase inhibitor p27(KIP1) is intimately linked to the control of proliferation, and is itself regulated by transcription, translation, phosphorylation, protein stability or sequestration, p27(KIP1) is also regulated during apoptosis; cleavage occurs at (DPSDS)-S-139 and ESQD(108)V, by a sub-set of z-VAD-fmk-sensitive caspases, We have identified related but distinct mechanism that regulates p27(KIP1) in proliferating lymphoid cell lines. In a B-lymphoid cell line (BJAB), the abundance of p27(KIP1) oscillates inversely to proliferation; loss of full-length p27(KIP1) correlates with the appearance of a truncated version corresponding to cleavage at (DPSDS)-S-139, A direct correlation exists between the appearance of truncated p27(KIP1) and the presence of an activity able to cleave peptides representing (DPSDS)-S-139 and a caspase-8 substrate (Ac-IETD-AMC) in vitro. This activity is inhibited by Ac-IETD-CHO but not Z-VAD-fmk in vitro, Furthermore a requirement for caspase-8 has been excluded. The activity differs from the apoptosis related p27(KIP1)-cleaving activity; indeed few cells undergoing apoptosis are present in the population of proliferating cells, The activity is further distinguished by its inability to cleave a peptide based on ESQD(108)V in vitro, together with the lack of a corresponding cleavage product in vivo. Inhibition of the caspase activity in vivo promotes an accumulation of full length p27(KIP1), as well as a decrease in cell proliferation. Together these studies highlight the importance of non-apoptotic caspases in regulating p27(KIP1) in transformed lymphoid cells.	Univ Sussex, Sch Biol Sci, Brighton BN1 9QG, E Sussex, England	University of Sussex	Sinclair, AJ (corresponding author), Univ Sussex, Sch Biol Sci, Brighton BN1 9QG, E Sussex, England.			Sinclair, Alison/0000-0001-8510-8691				Agrawal D, 1996, MOL CELL BIOL, V16, P4327; Akita K, 1997, J BIOL CHEM, V272, P26595, DOI 10.1074/jbc.272.42.26595; Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; Barnouin K, 1999, ONCOGENE, V18, P6388, DOI 10.1038/sj.onc.1203162; Cannell EJ, 1998, FEBS LETT, V439, P297, DOI 10.1016/S0014-5793(98)01391-X; Cannell EJ, 1996, ONCOGENE, V13, P1413; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Chen LH, 1997, J BIOL CHEM, V272, P22966, DOI 10.1074/jbc.272.36.22966; CLEMENTS GB, 1975, INT J CANCER, V16, P125, DOI 10.1002/ijc.2910160114; Craig C, 1997, ONCOGENE, V14, P2283, DOI 10.1038/sj.onc.1201064; Ekert PG, 1999, CELL DEATH DIFFER, V6, P1081, DOI 10.1038/sj.cdd.4400594; Erhardt P, 1997, J BIOL CHEM, V272, P15049, DOI 10.1074/jbc.272.24.15049; Eymin B, 1999, ONCOGENE, V18, P4839, DOI 10.1038/sj.onc.1202860; Eymin B, 1999, ONCOGENE, V18, P1411, DOI 10.1038/sj.onc.1202437; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; Frost V, 2000, ONCOGENE, V19, P3115, DOI 10.1038/sj.onc.1203657; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Harvey KJ, 2000, J CELL BIOL, V148, P59, DOI 10.1083/jcb.148.1.59; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Hiromura K, 1999, J CLIN INVEST, V103, P597, DOI 10.1172/JCI5461; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kawamata S, 1998, BLOOD, V91, P561, DOI 10.1182/blood.V91.2.561.561_561_569; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Kwon TK, 1997, J IMMUNOL, V158, P5642; Kwon TK, 1996, GENE, V180, P113, DOI 10.1016/S0378-1119(96)00416-7; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Loubat A, 1999, ONCOGENE, V18, P3324, DOI 10.1038/sj.onc.1202668; Luo Y, 1996, MOL CELL BIOL, V16, P6744; Millard SS, 1997, J BIOL CHEM, V272, P7093, DOI 10.1074/jbc.272.11.7093; Miossec C, 1997, J BIOL CHEM, V272, P13459, DOI 10.1074/jbc.272.21.13459; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Morisaki H, 1997, BIOCHEM BIOPH RES CO, V240, P386, DOI 10.1006/bbrc.1997.7590; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nguyen H, 1999, MOL CELL BIOL, V19, P1190; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Park DS, 1998, J CELL BIOL, V143, P457, DOI 10.1083/jcb.143.2.457; Pochampally R, 1999, J BIOL CHEM, V274, P15271, DOI 10.1074/jbc.274.21.15271; Pochampally R, 1998, ONCOGENE, V17, P2629, DOI 10.1038/sj.onc.1202206; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Schreiber M, 1999, ONCOGENE, V18, P1663, DOI 10.1038/sj.onc.1202466; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SINCLAIR AJ, 1994, EMBO J, V13, P3321, DOI 10.1002/j.1460-2075.1994.tb06634.x; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; Spender LC, 1999, J VIROL, V73, P4678, DOI 10.1128/JVI.73.6.4678-4688.1999; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Wang XT, 1997, ONCOGENE, V15, P2991, DOI 10.1038/sj.onc.1201450; Wilhelm S, 1998, EUR J IMMUNOL, V28, P891, DOI 10.1002/(SICI)1521-4141(199803)28:03<891::AID-IMMU891>3.3.CO;2-O; Wu DMH, 1999, J IMMUNOL, V162, P1287; Zeuner A, 1999, CELL DEATH DIFFER, V6, P1075, DOI 10.1038/sj.cdd.4400596; Zhang YJ, 1998, J BIOL CHEM, V273, P1144, DOI 10.1074/jbc.273.2.1144	66	26	26	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 17	2001	20	22					2737	2748		10.1038/sj.onc.1204367	http://dx.doi.org/10.1038/sj.onc.1204367			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	432TP	11420686				2022-12-17	WOS:000168712000002
J	Yount, GL; Afshar, G; Ries, S; Korn, M; Shalev, N; Basila, D; McCormick, F; Haas-Kogan, DA				Yount, GL; Afshar, G; Ries, S; Korn, M; Shalev, N; Basila, D; McCormick, F; Haas-Kogan, DA			Transcriptional activation of TRADD mediates p53-independent radiation-induced apoptosis of glioma cells	ONCOGENE			English	Article						TRADD; glioma; radiation; apoptosis; cDNA array; gene therapy	DRUG-INDUCED APOPTOSIS; NF-KAPPA-B; APO-1/FAS RECEPTOR/LIGAND SYSTEM; MYC-INDUCED APOPTOSIS; IONIZING-RADIATION; BRAIN-TUMORS; C-MYC; CYCLIN-A; DEATH; EXPRESSION	Survival of patients with Glioblastoma Multiforme (GM), a highly malignant brain tumor, remains poor despite concerted efforts to improve therapy. The median survival of patients with GM has remained approximately 1 year regardless of the therapeutic approach, Since radiation therapy is the most effective adjuvant therapy for GM and nearly half of GM tumors harbor p53 mutations, we sought to identify genes that mediate p53-independent apoptosis of GM cells in response to ionizing radiation. Using broad-scale gene expression analysis we found that following radiation treatment, TRADD expression was induced in a uniquely radiosensitive GM cell line but not in radioresistant GM cell lines. TRADD over-expression killed GM cells and activated NF-kappaB, We found that blocking the TRADD-mediated pathway using a dominant-negative mutant of FADD (FADD-DN) enhanced radiation resistance of GM cells, as reflected in both susceptibility to apoptosis and clonogenic survival following irradiation, Conversely stable expression of exogenous TRADD enhanced radiation-induced apoptosis of GM cell lines, reflecting the biological significance of TRADD regulation in p53-independent apoptosis, These findings generate interest in utilizing TRADD in gene therapy for GM tumors, particularly in light of its dual function of directly inducing rapid apoptosis and sensitizing GM cells to standard anti-neoplastic therapy.	Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA 94143 USA; Calif Pacific Med Ctr, Complementary Med Res Inst, San Francisco, CA 94115 USA; Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94115 USA	University of California System; University of California San Francisco; California Pacific Medical Center; California Pacific Medical Center Research Institute; University of California System; University of California San Francisco	Haas-Kogan, DA (corresponding author), Univ Calif San Francisco, Dept Radiat Oncol, 505 Parnassus Ave, San Francisco, CA 94143 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001271] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR01271] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AKASHI M, 1995, J BIOL CHEM, V270, P19181, DOI 10.1074/jbc.270.32.19181; ALBRIGHT N, 1987, RADIAT RES, V112, P331, DOI 10.2307/3577260; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; BARR PJ, 1994, BIO-TECHNOL, V12, P487, DOI 10.1038/nbt0594-487; Baumler CB, 1996, BLOOD, V88, P1741; Brown JM, 1999, CANCER RES, V59, P1391; CHEN PC, 1995, CANCER GENET CYTOGEN, V82, P106, DOI 10.1016/0165-4608(94)00213-U; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; DATTA R, 1992, CELL GROWTH DIFFER, V3, P637; DeNardo GL, 1999, CLIN CANCER RES, V5, p3219S; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; FERRER I, 1992, BRAIN RES, V588, P351, DOI 10.1016/0006-8993(92)91599-A; FERRER I, 1995, INT J DEV NEUROSCI, V13, P21, DOI 10.1016/0736-5748(94)00064-A; FERTIL B, 1985, INT J RADIAT ONCOL, V11, P1699, DOI 10.1016/0360-3016(85)90223-8; French LE, 1999, NAT MED, V5, P146, DOI 10.1038/5505; Frenkel J, 1999, ONCOGENE, V18, P2901, DOI 10.1038/sj.onc.1202518; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fulda S, 1997, CANCER RES, V57, P3823; Gallagher WM, 1999, ANN ONCOL, V10, P139, DOI 10.1023/A:1008368500557; Goswami PC, 1996, MOL CELL BIOL, V16, P1500; Guo N, 2000, J BIOL CHEM, V275, P1715, DOI 10.1074/jbc.275.3.1715; Gura T, 1997, SCIENCE, V277, P768, DOI 10.1126/science.277.5327.768; Haas-Kogan D A, 1996, Cancer J Sci Am, V2, P114; HaasKogan DA, 1996, INT J RADIAT ONCOL, V36, P95, DOI 10.1016/S0360-3016(96)00244-1; Hagiyama H, 1999, ONCOGENE, V18, P4091, DOI 10.1038/sj.onc.1202772; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; ITOH N, 1993, J BIOL CHEM, V268, P10932; Joneson T, 1999, MOL CELL BIOL, V19, P5892; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Klefstrom J, 1997, EMBO J, V16, P7382, DOI 10.1093/emboj/16.24.7382; Knudsen KE, 1999, J BIOL CHEM, V274, P27632, DOI 10.1074/jbc.274.39.27632; Kolbus A, 2000, MOL CELL BIOL, V20, P575, DOI 10.1128/MCB.20.2.575-582.2000; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LUDGATE CM, 1988, INT J RADIAT ONCOL, V15, P1091, DOI 10.1016/0360-3016(88)90189-7; Merritt AJ, 1997, ONCOGENE, V14, P2759, DOI 10.1038/sj.onc.1201126; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Murphy S, 1990, METHODS NEUROSCIENCE, V2, P33; MUSCHEL RJ, 1991, CANCER RES, V51, P5113; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Prados MD, 1998, INT J RADIAT ONCOL, V40, P57, DOI 10.1016/S0360-3016(97)00566-X; SARKAR A, 1993, CANCER CHEMOTH PHARM, V32, P477, DOI 10.1007/BF00685893; SHELINE GE, 1977, CANCER, V39, P873, DOI 10.1002/1097-0142(197702)39:2+<873::AID-CNCR2820390725>3.0.CO;2-Y; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; TAGHIAN A, 1992, INT J RADIAT ONCOL, V23, P55, DOI 10.1016/0360-3016(92)90543-Q; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Trudel M, 1997, J EXP MED, V186, P1873, DOI 10.1084/jem.186.11.1873; Uberti D, 1999, EXP CELL RES, V252, P123, DOI 10.1006/excr.1999.4606; Villa R, 1996, INT J CANCER, V66, P104, DOI 10.1002/(SICI)1097-0215(19960328)66:1<104::AID-IJC18>3.0.CO;2-D; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Weinstein J, 1997, J BIOL CHEM, V272, P28501, DOI 10.1074/jbc.272.45.28501; Weinstein J, 1998, MOL GENET METAB, V64, P52, DOI 10.1006/mgme.1998.2698; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698	59	26	27	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 17	2001	20	22					2826	2835		10.1038/sj.onc.1204393	http://dx.doi.org/10.1038/sj.onc.1204393			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	432TP	11420694				2022-12-17	WOS:000168712000010
J	Patterson, T; Vuong, H; Liaw, YS; Wu, R; Kalvakolanu, DV; Reddy, SPM				Patterson, T; Vuong, H; Liaw, YS; Wu, R; Kalvakolanu, DV; Reddy, SPM			Mechanism of repression of squamous differentiation marker, SPRR1B, in malignant bronchial epithelial cells: role of critical TRE-sites and its transacting factors	ONCOGENE			English	Article						SPRR1; squamous cell differentiation; AP-1 proteins; bronchial epithelial cells	KERATINOCYTE TERMINAL DIFFERENTIATION; PROLINE-RICH PROTEIN; C-FOS; IN-VITRO; EXPRESSION; TRANSCRIPTION; BINDING; FRA-2; AP-1; SPR1	The overexpression of SPRR1B in bronchial epithelium is a marker for early metaplastic changes and the loss of its expression is associated with an irreversible malignant transformation. In the present study, we have used a model system consisting of normal and malignant bronchial epithelial (BE) cells to elucidate the differential transcriptional control of SPRR1B, SPRR1B expression is either detectable or PMA (phorbol 13-myristate 12-acetate) including squamous, adeno, small and large cell carcinomas. Loss of SPRR1B expression is correlated well with the lack of strong in vivo protein-DNA interactions at the -152 bp promoter, which contains two functional TRE sites. Even though the basal level AP-1 protein DNA binding pattern is different between normal and malignant cells, PMA significantly enhances Jun and Fos binding to the consensus TRE site in both cell types. Intriguingly, the composition of AP-1 protein binding to the -152 to -86 bp SPRR1B promoter is quite different. In untreated cells, SPRR1B promoter is predominantly occupied by JunD and Fra2, PMA significantly induced binding of JunB and Fra1 in normal cells, while JunB and Fra2 bound to TREs in the malignant cells. Overexpression of fr nl in malignant cells significantly enhanced SPRRIB promoter activity. In contrast, overexpression of fra2, but not fra1, strongly reduced both basal and PMA-inducible promoter activities in normal cells. Together, these results indicate that either temporal expression and/or differential activation of AP-1 proteins, especially Fra1 and Fra2, might contribute to the dysregulation of terminal differentiation marker, SPRR1B, expression in various BE cells.	Johns Hopkins Univ, Dept Environm Hlth Sci, Div Physiol, Sch Publ Hlth, Baltimore, MD 21205 USA; Univ Calif Davis, Sch Med, Davis, CA 95616 USA; Univ Maryland, Sch Med, Greenbaum Canc Ctr, Baltimore, MD 21201 USA	Johns Hopkins University; University of California System; University of California Davis; University System of Maryland; University of Maryland Baltimore	Reddy, SPM (corresponding author), Johns Hopkins Univ, Dept Environm Hlth Sci, Div Physiol, Sch Publ Hlth, Rm W7006,615 N Wolfe St, Baltimore, MD 21205 USA.				NCI NIH HHS [CA-71401, CA-78282] Funding Source: Medline; NHLBI NIH HHS [HL-58122] Funding Source: Medline; NIEHS NIH HHS [ES-06230, ES03819] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078282, R01CA071401] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058122, R29HL058122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES003819, R01ES006230] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABATE C, 1993, P NATL ACAD SCI USA, V90, P6766, DOI 10.1073/pnas.90.14.6766; Abraham JM, 1996, CELL GROWTH DIFFER, V7, P855; Anisowicz A, 1999, MOL MED, V5, P526, DOI 10.1007/BF03401980; BASBAUM C, 1990, AM J PHYSIOL, V259, pL38, DOI 10.1152/ajplung.1990.259.2.L38; CARRASCO D, 1995, ONCOGENE, V10, P1069; DeMuth JP, 1998, AM J RESP CELL MOL, V19, P25, DOI 10.1165/ajrcmb.19.1.3078; Deng J, 2000, J BIOL CHEM, V275, P5739, DOI 10.1074/jbc.275.8.5739; DiSepio D, 1999, DIFFERENTIATION, V64, P225, DOI 10.1046/j.1432-0436.1999.6440225.x; Eckert RL, 1996, MOL BIOL REP, V23, P59, DOI 10.1007/BF00357073; Fischer DF, 1999, GENOMICS, V55, P88, DOI 10.1006/geno.1998.5622; Fischer DF, 1996, MOL CELL BIOL, V16, P5365, DOI 10.1128/mcb.16.10.5365; Fong KM, 1999, J THORAC CARDIOV SUR, V118, P1136, DOI 10.1016/S0022-5223(99)70121-2; FUJIMOTO W, 1993, J INVEST DERMATOL, V101, P268, DOI 10.1111/1523-1747.ep12365200; GRUDA MC, 1994, ONCOGENE, V9, P2537; Hu R, 1998, LUNG CANCER, V20, P25, DOI 10.1016/S0169-5002(97)00097-4; Jetten A M, 1992, J Natl Cancer Inst Monogr, P93; JETTEN AM, 1989, ENVIRON HEALTH PERSP, V80, P149, DOI 10.2307/3430740; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Lau D, 2000, AM J RESP CELL MOL, V22, P92, DOI 10.1165/ajrcmb.22.1.3637; Lee HY, 1998, ONCOGENE, V16, P3039, DOI 10.1038/sj.onc.1201843; Lohman FP, 1997, EXP CELL RES, V231, P141, DOI 10.1006/excr.1996.3458; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; MCCLAREN M, 1994, J INVEST DERMATOL, V102, P375, DOI 10.1111/1523-1747.ep12371798; Momparler RL, 2000, J CELL PHYSIOL, V183, P145, DOI 10.1002/(SICI)1097-4652(200005)183:2<145::AID-JCP1>3.0.CO;2-V; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; Murakami M, 1997, ONCOGENE, V14, P2435, DOI 10.1038/sj.onc.1201077; PFEIFER AMA, 1989, ENVIRON HEALTH PERSP, V80, P209, DOI 10.2307/3430746; REDDY SPM, 1995, J BIOL CHEM, V270, P26451, DOI 10.1074/jbc.270.44.26451; Rutberg SE, 1997, ONCOGENE, V15, P1337, DOI 10.1038/sj.onc.1201293; Sark MWJ, 1998, J BIOL CHEM, V273, P24683, DOI 10.1074/jbc.273.38.24683; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Soto U, 2000, INT J CANCER, V86, P811, DOI 10.1002/(SICI)1097-0215(20000615)86:6<811::AID-IJC9>3.0.CO;2-J; Steinert PM, 1998, J STRUCT BIOL, V122, P76, DOI 10.1006/jsbi.1998.3957; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; Tesfaigzi Johannes, 1999, Cell Biochemistry and Biophysics, V30, P243, DOI 10.1007/BF02738069; Vuong H, 2000, J BIOL CHEM, V275, P32250, DOI 10.1074/jbc.M005227200; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; YAAR M, 1995, EXP CELL RES, V217, P217, DOI 10.1006/excr.1995.1081; Yuspa SH, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P147	39	26	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	2001	20	5					634	644		10.1038/sj.onc.1204134	http://dx.doi.org/10.1038/sj.onc.1204134			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	398KE	11313996				2022-12-17	WOS:000166755000011
J	Cui, XS; Donehower, LA				Cui, XS; Donehower, LA			Differential gene expression in mouse mammary adenocarcinomas in the presence and absence of wild type p53	ONCOGENE			English	Article						p53; mouse mammary tumor; Wnt-1; p21(WAF1/CIP1); c-kit; cyclin B1	TUMOR-CELL PROLIFERATION; MUSCLE ALPHA-ACTIN; CYCLIN-G; TRANSCRIPTIONAL TARGET; TRANSGENIC MICE; SUPPRESSOR P53; BREAST-CANCER; GROWTH; P21; ARREST	The tumor suppressor p53 transcriptionally regulates a large number of target genes that may affect cell growth and cell death pathways. To better understand the role of p53 loss in tumorigenesis, me have developed a mouse mammary cancer model, the Wnt-1 TG/p53 model. Wnt-1 transgenic females that are p53-/- develop mammary adenocarcinomas that arise sooner, grow faster, appear more anaplastic, and have higher levels of chromosomal instability than their Wnt-1 transgenic p53+/+ counterparts. In this study, we used several assays to determine whether the presence or absence of p53 affects gene expression patterns in the mammary adenocarcinomas. Most of the differentially expressed genes are increased in p53+/+ tumors and many of these represent known target genes of p53 (p21(WAF1/C1P1) cyclin G1, alpha smooth muscle actin, and cytokeratin 19), Some of these genes (cytokeratin 19, alpha smooth muscle actin, and kappa casein) represent mammary gland differentiation markers which may contribute to the inhibited tumor progression and are consistent with the more differentiated histopathology observed in the p53+/+ tumors. Several differentially expressed genes are growth regulatory in function (p21, c-kit, and cyclin B1) and their altered expression levels correlate well with the differing growth properties of the p53+/+ and p53-/- tumors. Thus, while tumors can arise and progress in the presence of functioning wild type p53, p53 may directly or indirectly regulate expression of an array of genes that facilitate differentiation and inhibit proliferation, contributing to a more differentiated, slow growing, and genomically stable phenotype.	Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Donehower, LA (corresponding author), Baylor Coll Med, Dept Mol Virol & Microbiol, 1 Baylor Plaza, Houston, TX 77030 USA.							Ashman LK, 1999, INT J BIOCHEM CELL B, V31, P1037, DOI 10.1016/S1357-2725(99)00076-X; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Comer KA, 1998, ONCOGENE, V16, P1299, DOI 10.1038/sj.onc.1201645; Donehower LA, 1996, BBA-REV CANCER, V1242, P171, DOI 10.1016/0304-419X(95)00013-6; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Ginger MR, 1999, COMP BIOCHEM PHYS B, V124, P133, DOI 10.1016/S0305-0491(99)00110-8; Gorospe M, 1999, GENE EXPRESSION, V7, P377; GUGLIOTTA P, 1988, J HISTOCHEM CYTOCHEM, V36, P659, DOI 10.1177/36.6.3367051; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HIBI K, 1991, ONCOGENE, V6, P2291; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Jones JM, 1997, CELL GROWTH DIFFER, V8, P829; Jones JM, 1999, CELL GROWTH DIFFER, V10, P213; Kirsch DG, 1998, J CLIN ONCOL, V16, P3158, DOI 10.1200/JCO.1998.16.9.3158; LEAVITT J, 1985, NATURE, V316, P840, DOI 10.1038/316840a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Lozano G, 2000, NATURE, V404, P24, DOI 10.1038/35003670; MAZARS R, 1992, CANCER RES, V52, P3918; MIYASHITA T, 1995, CELL, V80, P293; Moll UM, 1998, CRIT REV ORAL BIOL M, V9, P23, DOI 10.1177/10454411980090010101; MUSUNURU K, 1997, CELL CYCLE REGULATOR; NATALI PG, 1992, INT J CANCER, V52, P713, DOI 10.1002/ijc.2910520508; NATALI PG, 1992, INT J CANCER, V52, P197, DOI 10.1002/ijc.2910520207; NATALI PG, 1995, CANCER RES, V55, P1787; Nishida K, 1996, ANTICANCER RES, V16, P3397; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Okamoto K, 1999, ONCOGENE, V18, P4606, DOI 10.1038/sj.onc.1202821; OWENS GK, 1986, J CELL BIOL, V102, P343, DOI 10.1083/jcb.102.2.343; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; RUDLAND PS, 1993, J HISTOCHEM CYTOCHEM, V41, P543, DOI 10.1177/41.4.8450194; Shimizu A, 1998, BIOCHEM BIOPH RES CO, V242, P529, DOI 10.1006/bbrc.1997.8004; Smith ML, 1997, EXP CELL RES, V230, P61, DOI 10.1006/excr.1996.3402; Taylor WR, 1999, MOL BIOL CELL, V10, P3607, DOI 10.1091/mbc.10.11.3607; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Wallace-Brodeur RR, 1999, CELL MOL LIFE SCI, V55, P64, DOI 10.1007/s000180050270; WynfordThomas D, 1997, EUR J CANCER, V33, P716, DOI 10.1016/S0959-8049(97)00064-6; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhao RB, 2000, GENE DEV, V14, P981	47	26	26	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2000	19	52					5988	5996		10.1038/sj.onc.1203993	http://dx.doi.org/10.1038/sj.onc.1203993			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382MY	11146550				2022-12-17	WOS:000165827900005
J	Rahman, N; Teare, MD; Seal, S; Renard, H; Mangion, J; Cour, C; Thompson, D; Shugart, Y; Eccles, D; Devilee, P; Meijers, H; Nathanson, KL; Neuhausen, SL; Weber, B; Chang-Claude, J; Easton, DF; Goldgar, D; Stratton, MR				Rahman, N; Teare, MD; Seal, S; Renard, H; Mangion, J; Cour, C; Thompson, D; Shugart, Y; Eccles, D; Devilee, P; Meijers, H; Nathanson, KL; Neuhausen, SL; Weber, B; Chang-Claude, J; Easton, DF; Goldgar, D; Stratton, MR			Absence of evidence for a familial breast cancer susceptibility gene at chromosome 8p12-p22	ONCOGENE			English	Article						boast cancer; BRCA1; BRCA2; familial; chromosome 8p	LINKAGE ANALYSIS; SHORT ARM; OVARIAN-CANCER; BRCA1; MUTATIONS; HETEROZYGOSITY; REGION	Several recent studies indicate that the majority of families with five or fen er cases of breast cancer and no cases of ovarian cancer are not due to BRCA1 or BRCA2. It has been proposed that a further breast cancer susceptibility gene that may account for some of these families is located on chromosome 8p12-p22, We have identified 31 site-specific breast cancer families that have a greater than 80% posterior probability of being due to genes other than BRCA1 or BRCA2. These families have been examined for linkage to 8p12-p22 using markers flanking the putative location of the gene. The overall multi-point LOD score is strongly negative across the whole 44 cM. The individual multi-point LOD score is negative in 23 families and only exceeds 0.5 in a single family (with a multi-point LOD score of 1.22). The maximum heterogeneity LOD score was 0.03 at marker D8S136 with estimated proportion linked (alpha) of 3% (95% CI 0-30%), These data do not lend support to the hypothesis that chromosome 8p12-p22 harbours a familial breast cancer susceptibility gene.	Inst Canc Res, Sect Canc Genet, Sutton SM2 5NG, Surrey, England; Strangeways Res Lab, CRC, Genet Epidemiol Unit, Cambridge, England; IARC, Lyon, France; Princess Anne Hosp, Wessex Clin Genet Serv, Southampton, Hants, England; Leiden Univ, Dept Human Genet, NL-2300 RA Leiden, Netherlands; Erasmus Univ, Dept Clin Genet, NL-3000 DR Rotterdam, Netherlands; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Genet, Philadelphia, PA 19104 USA; Univ Utah, Sch Med, Div Genet Epidemiol, Salt Lake City, UT USA; Deutsch Krebsforschungszentrum, Div Genet Epidemiol, D-6900 Heidelberg, Germany	University of London; Institute of Cancer Research - UK; World Health Organization; International Agency for Research on Cancer (IARC); Leiden University; Leiden University - Excl LUMC; Erasmus University Rotterdam; University of Pennsylvania; University of Pennsylvania; Utah System of Higher Education; University of Utah; Helmholtz Association; German Cancer Research Center (DKFZ)	Rahman, N (corresponding author), Univ Wales Hosp, Heath Pk, Cardiff CF4 4XW, S Glam, Wales.		Rahman, Nazneen/B-8890-2012; DEVILEE, PETER/ABR-2140-2022; Eccles, Diana/K-6327-2019; Rahman, Nazneen/D-2802-2013	Eccles, Diana/0000-0002-9935-3169; Nathanson, Katherine/0000-0002-6740-0901; Teare, Marion Dawn/0000-0003-3994-0051; Rahman, Nazneen/0000-0003-4376-0440				CLAUS EB, 1991, AM J HUM GENET, V48, P232; EASTON DF, 1993, AM J HUM GENET, V52, P678; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; Hakansson S, 1997, AM J HUM GENET, V60, P1068; Imbert A, 1996, GENOMICS, V32, P29, DOI 10.1006/geno.1996.0073; KERANGUEVEN F, 1995, ONCOGENE, V10, P1023; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; Malone KE, 1998, JAMA-J AM MED ASSOC, V279, P922, DOI 10.1001/jama.279.12.922; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; OCONNELL JR, 1995, NAT GENET, V11, P402, DOI 10.1038/ng1295-402; Peto J, 1999, J NATL CANCER I, V91, P943, DOI 10.1093/jnci/91.11.943; PetrijBosch A, 1997, NAT GENET, V17, P341, DOI 10.1038/ng1197-341; Rahman N, 1998, ANNU REV GENET, V32, P95, DOI 10.1146/annurev.genet.32.1.95; Schubert EK, 1997, AM J HUM GENET, V60, P1031; Seitz S, 1997, BRIT J CANCER, V76, P983, DOI 10.1038/bjc.1997.497; Seitz S, 1997, ONCOGENE, V14, P741, DOI 10.1038/sj.onc.1200881; Serova OM, 1997, AM J HUM GENET, V60, P486; SPURR NK, 1995, CYTOGENET CELL GENET, V68, P148; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; YAREMKO ML, 1995, GENE CHROMOSOME CANC, V13, P186, DOI 10.1002/gcc.2870130308; Yaremko ML, 1996, GENE CHROMOSOME CANC, V16, P189, DOI 10.1002/(SICI)1098-2264(199607)16:3<189::AID-GCC6>3.0.CO;2-V	21	26	27	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 24	2000	19	36					4170	4173		10.1038/sj.onc.1203735	http://dx.doi.org/10.1038/sj.onc.1203735			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	347XU	10962578				2022-12-17	WOS:000088955100011
J	Odaka, R; Mally, A; Elliot, LT; Meyers, S				Odaka, R; Mally, A; Elliot, LT; Meyers, S			Nuclear import and subnuclear localization of the proto-oncoprotein ETO (MTG8)	ONCOGENE			English	Article						ETO; nuclear localization signal; nuclear import; subnuclear structure	ACUTE MYELOID-LEUKEMIA; CORE-BINDING-FACTOR; ACUTE MYELOGENOUS LEUKEMIA; GRANULOCYTIC DIFFERENTIATION; FUSION PROTEIN; NUCLEOCYTOPLASMIC TRANSPORT; SUBCELLULAR-LOCALIZATION; GENE; AML1; T(8-21)	ETO (MTG8) was first described due to its involvement in the (8;21) translocation frequently observed in acute myeloid leukemias. In the t(8;21) the AML1 gene on chromosome 21 is fused to ETO on chromosome 8. The resultant hybrid protein is comprised of the DNA, binding domain of AML-1 and the majority of ETO. This study examines the subnuclear distributions of ETO, AML-1B and AML-1/ETO proteins fused to green fluorescence protein in living cells using fluorescence microscopy. Further, we identified a 40 amino acid portion of ETO (amino acids 241-280) that was sufficient to cause nuclear import of green fluorescent protein. Mutational analysis demonstrated that lysine 265 and/or arginine 266 were required for nuclear impart of ETO, but that the surrounding basic residues were not critical, ETO interacted with the nuclear import proteins importin-alpha and beta in vitro, and mutations in ETO that abolish nuclear localization also abolished the in vitro interaction with importin-alpha and beta. These data suggest that ETO enters the nucleus via an importin-mediated pathway. additionally, ETO and AMIL-1/ETO co-localized to punctate nuclear bodies distinct from those containing promyelocytic leukemia protein. Nuclear body formation was dependent upon a region of ETO N-terminal to the nuclear localization signal. Thus, ETO and AML-1/ ETO reside in potentially novel subnuclear compartments.	Louisiana State Univ, Hlth Sci Ctr, Sch Med, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA; Louisiana State Univ, Hlth Sci Ctr, Sch Med, Feist Weiler Canc Ctr, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Meyers, S (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Sch Med, Dept Biochem & Mol Biol, F7-36,1501 Kings Highway, Shreveport, LA 71130 USA.		Odaka, Yoshinobu/AAY-6918-2021	Odaka, Yoshinobu/0000-0003-3966-5475	NATIONAL CANCER INSTITUTE [R29CA076186] Funding Source: NIH RePORTER; NCI NIH HHS [CA76186] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAM SA, 1995, TRENDS CELL BIOL, V5, P189, DOI 10.1016/S0962-8924(00)88991-6; Adya N, 1998, MOL CELL BIOL, V18, P7432, DOI 10.1128/MCB.18.12.7432; Ahn MY, 1998, P NATL ACAD SCI USA, V95, P1812, DOI 10.1073/pnas.95.4.1812; Calabi F, 1998, GENOMICS, V52, P332, DOI 10.1006/geno.1998.5429; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; Davis JN, 1999, ONCOGENE, V18, P1375, DOI 10.1038/sj.onc.1202412; DETHE H, 1991, CELL, V66; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; ERICKSON P, 1992, BLOOD, V80, P1825; Erickson PF, 1996, BLOOD, V88, P1813; FEINSTEIN PG, 1995, GENETICS, V140, P573; Frank R, 1995, ONCOGENE, V11, P2667; Gamou T, 1998, BLOOD, V91, P4028, DOI 10.1182/blood.V91.11.4028.411a45_4028_4037; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Hodges M, 1998, AM J HUM GENET, V63, P297, DOI 10.1086/301991; Kitabayashi I, 1998, MOL CELL BIOL, V18, P846, DOI 10.1128/MCB.18.2.846; KOHLER MS, 1997, FEBS LETT, V417, P107; Kohzaki H, 1999, ONCOGENE, V18, P4055, DOI 10.1038/sj.onc.1202735; KOZU T, 1993, BLOOD, V82, P1270; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; LENNY N, 1995, ONCOGENE, V11, P1761; Libermann TA, 1999, J BIOL CHEM, V274, P24671, DOI 10.1074/jbc.274.35.24671; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; McNeil S, 1999, P NATL ACAD SCI USA, V96, P14882, DOI 10.1073/pnas.96.26.14882; MELNIKOVA IN, 1993, J VIROL, V67, P2408, DOI 10.1128/JVI.67.4.2408-2411.1993; Meyers S, 1995, CRIT REV EUKAR GENE, V5, P365, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.70; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MEYERS S, 1995, MOL CELL BIOL, V15, P1947; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Moore JD, 1999, J CELL BIOL, V144, P213, DOI 10.1083/jcb.144.2.213; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; Nachury MV, 1998, P NATL ACAD SCI USA, V95, P582, DOI 10.1073/pnas.95.2.582; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; NIWAKAWAKITA M, 1995, GENOMICS, V29, P755, DOI 10.1006/geno.1995.9941; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; ONEILL RE, 1995, VIROLOGY, V206, P116, DOI 10.1016/S0042-6822(95)80026-3; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROWLEY JD, 1984, CANCER RES, V44, P3159; Sacchi N, 1996, ONCOGENE, V12, P437; Sacchi N, 1998, ONCOGENE, V16, P2609, DOI 10.1038/sj.onc.1201824; SHURTLEFF SA, 1995, BLOOD, V85, P3695, DOI 10.1182/blood.V85.12.3695.bloodjournal85123695; Speck NA, 1999, CANCER RES, V59, p1789S; Speck NA, 1995, CRIT REV EUKAR GENE, V5, P337, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.60; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; Takeda S, 1997, CYTOGENET CELL GENET, V76, P87, DOI 10.1159/000134521; Tanaka K, 1998, BLOOD, V91, P1688, DOI 10.1182/blood.V91.5.1688.1688_1688_1699; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Uchida N, 1997, BLOOD, V89, P2706, DOI 10.1182/blood.V89.8.2706; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; Welch K, 1999, MOL CELL BIOL, V19, P8400; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Zeng CM, 1997, P NATL ACAD SCI USA, V94, P6746, DOI 10.1073/pnas.94.13.6746; Zhang DE, 1996, MOL CELL BIOL, V16, P1231	63	26	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2000	19	32					3584	3597		10.1038/sj.onc.1203689	http://dx.doi.org/10.1038/sj.onc.1203689			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AF	10951564				2022-12-17	WOS:000088568300004
J	Schroeder, JA; Troyer, KL; Lee, DC				Schroeder, JA; Troyer, KL; Lee, DC			Cooperative induction of mammary tumorigenesis by TGF alpha and Wnts	ONCOGENE			English	Article						TGF alpha; MMTV; Wnt; mammary tumorigenesis; transgenics	GROWTH-FACTOR-ALPHA; MOUSE MAMMARY; TUMOR VIRUS; TRANSGENIC MICE; BETA-CATENIN; C-MYC; E-CADHERIN; EXPRESSION; GENE; TRANSFORMATION	We previously reported that multiparous WAP-TGF alpha transgenic mice develop mammary gland carcinomas with complete incidence, TGF alpha-induced tumors appear stochastically and with relatively long latency, indicating an additional requirement for other genetic alterations, To identify genes that cooperate with TGF alpha in mammary tumorigenesis, we used a retroviral insertion approach featuring a cloned and infectious hybrid MMTV (C3H/Mtv-1; (Shackleford and Varmus, 1988)), Tumor latency,vas decreased approximately 30% in MMTV-infected WAP-TGF alpha transgenic animals compared to noninfected transgenic controls, and >30% of the corresponding tumors displayed evidence of integrated C3H/Mtv-1 DNA, PCR-based analyses of DNAs from two virus-infected, transgenic tumors revealed integration of hybrid MMTV in 3' untranslated exons of the Wnt-1 or Wnt-3 oncogenes, Moreover, Northern blots confirmed dramatic induction of Wnt-1 or Wnt-3 transcripts in the respective turners, indicating that MMTV integration resulted in activated expression of these genes, Semi-quantitative RT-PCR analyses showed that overexpression of Wnt-1 or Wnt-3 was a common occurrence in MMTV-infected WAP-TGF alpha tumors, and some noninfected WAP-TGF alpha tumors also shelved evidence of elevated Wnt-3 transcripts, Collectively, these results reveal cooperative induction of mammary gland tumorigenesis by simultaneous deregulation of EGF-like (TGF alpha) and Wnt growth factors.	Univ N Carolina, Dept Microbiol & Immunol, Sch Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Sch Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Sch Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Lee, DC (corresponding author), Univ N Carolina, Dept Microbiol & Immunol, Sch Med, Chapel Hill, NC 27599 USA.			schroeder, joyce/0000-0003-1277-5172	NCI NIH HHS [CA71341, CA61896] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA071341, R01CA061896] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMUNDADOTTIR LT, 1995, CELL GROWTH DIFFER, V6, P737; BRANDTCARLSON C, 1993, VIROLOGY, V193, P171, DOI 10.1006/viro.1993.1113; BUI TD, 1996, ONCOGENE, P1249; Callahan R, 1996, BREAST CANCER RES TR, V39, P33, DOI 10.1007/BF01806076; CHOOI KF, 1994, CANCER RES, V54, P6434; Dierick H, 1999, CURR TOP DEV BIOL, V43, P153, DOI 10.1016/S0070-2153(08)60381-6; GOLOVKINA TV, 1994, J VIROL, V68, P5019, DOI 10.1128/JVI.68.8.5019-5026.1994; Hazan RB, 1998, J BIOL CHEM, V273, P9078, DOI 10.1074/jbc.273.15.9078; HELD W, 1994, IMMUNOL TODAY, V15, P184, DOI 10.1016/0167-5699(94)90317-4; HUGUET EL, 1994, CANCER RES, V54, P2615; Ilyas M, 1997, J PATHOL, V182, P128; Julius MA, 1999, ONCOGENE, V18, P149, DOI 10.1038/sj.onc.1202268; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; LEE DC, 1995, PHARMACOL REV, V47, P51; LEE FS, 1995, P NATL ACAD SCI USA, V92, P2268, DOI 10.1073/pnas.92.6.2268; MAJORS JE, 1983, J VIROL, V47, P495, DOI 10.1128/JVI.47.3.495-504.1983; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; PETERSON DO, 1985, J VIROL, V54, P525, DOI 10.1128/JVI.54.2.525-531.1985; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SANDGREN EP, 1995, CANCER RES, V55, P3915; Schroeder JA, 1998, CELL GROWTH DIFFER, V9, P451; Schroeder JA, 1997, J MAMMARY GLAND BIOL, V2, P119, DOI 10.1023/A:1026347629876; SHACKLEFORD GM, 1988, P NATL ACAD SCI USA, V85, P9655, DOI 10.1073/pnas.85.24.9655; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; Shibata T, 1996, ONCOGENE, V13, P883; VANOOYEN A, 1984, CELL, V39, P233, DOI 10.1016/0092-8674(84)90209-5; Wang YK, 1997, HUM MOL GENET, V6, P465, DOI 10.1093/hmg/6.3.465; Wang YS, 1996, J BIOL CHEM, V271, P4468; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278; Xu L, 1996, VIROLOGY, V215, P113, DOI 10.1006/viro.1996.0014	34	26	29	1	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 29	2000	19	28					3193	3199		10.1038/sj.onc.1203652	http://dx.doi.org/10.1038/sj.onc.1203652			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KX	10918574				2022-12-17	WOS:000088019200008
J	Nakaigawa, N; Weirich, G; Schmidt, L; Zbar, B				Nakaigawa, N; Weirich, G; Schmidt, L; Zbar, B			Tumorigenesis mediated by MET mutant M1268T is inhibited by dominant-negative Src	ONCOGENE			English	Article						MET; c-Src; papillary renal cancer	FACTOR SCATTER FACTOR; PAPILLARY RENAL CARCINOMAS; TYROSINE KINASE RECEPTOR; ROUS-SARCOMA VIRUS; C-SRC; PROTOONCOGENE PRODUCT; ACTIVATING MUTATIONS; CELL CARCINOMA; RON RECEPTOR; GROWTH	We recently described germline and somatic mutations in the MET gene associated with papillary renal carcinoma type 1, MET mutation M1268T was Located in a codon highly conserved among receptor tyrosine kinases, and homologous to the codon mutated in multiple endocrine neoplasia type 2B, and many cases of sporadic medullary carcinoma of the thyroid gland (Ret M918T), Ret M918T and MET M1268T have previously been shown to be highly active in mouse NIH3T3 transformation assays, and to change the substrate specificity of the kinase. We studied the mechanism of transformation mediated by MET M1268T by analysing a clone, F4, derived from NIH3T3 cells transformed by MET M1268T, In contrast to NIH3T3 cells, F4 cells grew in suspension in tissue culture, and rapidly formed tumors in nude mice. We found that c-Src was constitutively bound to MET proteins in F4 cells, and that Src kinase activity was elevated. Transfection of dominant negative Src constructs into F4 cells eliminated the ability of F4 cells to grow in suspension culture and retarded the growth of F4 cells in vivo. The ability of transfected dominant negative Src constructs to inhibit the growth of F4 cells correlated with the inhibition of phosphorylation of paxillin and focal adhesion kinase, Transfection of dominant negative Src constructs into F4 cells had no effect on Grb2 binding or PLC gamma phosphorylation, The results suggest that c-Src participates in the tumorigenic phenotype induced in NIH3T3 cells by MET M1268T by signaling through focal adhesion kinase and paxillin.	NCI, Frederick Canc Res & Dev Ctr, Immunobiol Lab, Frederick, MD 21702 USA; NCI, Frederick Canc Res & Dev Ctr, SAIC Frederick, Intramural Res Support Program, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Zbar, B (corresponding author), NCI, Frederick Canc Res & Dev Ctr, Immunobiol Lab, Frederick, MD 21702 USA.				OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-56000] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bardelli A, 1998, P NATL ACAD SCI USA, V95, P14379, DOI 10.1073/pnas.95.24.14379; Bentz M, 1996, CYTOGENET CELL GENET, V75, P17, DOI 10.1159/000134448; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GOULD KL, 1986, J CELL BIOL, V102, P660, DOI 10.1083/jcb.102.2.660; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; Jeffers M, 1999, ONCOGENE, V18, P5120, DOI 10.1038/sj.onc.1202902; Jeffers M, 1998, ONCOGENE, V17, P2691, DOI 10.1038/sj.onc.1202209; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; KOVACS G, 1993, ADV CANCER RES, V62, P89, DOI 10.1016/S0065-230X(08)60316-4; Lubensky IA, 1999, AM J PATHOL, V155, P517, DOI 10.1016/S0002-9440(10)65147-4; PASQUALE EB, 1986, P NATL ACAD SCI USA, V83, P5507, DOI 10.1073/pnas.83.15.5507; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; Santoro MM, 1998, ONCOGENE, V17, P741, DOI 10.1038/sj.onc.1201994; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schmidt L, 1999, ONCOGENE, V18, P2343, DOI 10.1038/sj.onc.1202547; SEFTON BM, 1981, CELL, V24, P165, DOI 10.1016/0092-8674(81)90512-2; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; WEEMINK PAO, 1995, J BIOL CHEM, V270, P2264; Williams TA, 1999, J CELL PHYSIOL, V181, P507, DOI 10.1002/(SICI)1097-4652(199912)181:3<507::AID-JCP15>3.0.CO;2-Q; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; ZBAR B, 1994, J UROLOGY, V151, P561, DOI 10.1016/S0022-5347(17)35015-2; Zbar B, 1998, ADV CANCER RES, V75, P163, DOI 10.1016/S0065-230X(08)60742-3; ZHU H, 1994, J BIOL CHEM, V269, P29943	31	26	26	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2000	19	26					2996	3002		10.1038/sj.onc.1203628	http://dx.doi.org/10.1038/sj.onc.1203628			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323TQ	10871851				2022-12-17	WOS:000087581400006
J	Bies, J; Feikova, S; Bottaro, DP; Wolff, L				Bies, J; Feikova, S; Bottaro, DP; Wolff, L			Hyperphosphorylation and increased proteolytic breakdown of c-Myb induced by the inhibition of Ser/Thr protein phosphatases	ONCOGENE			English	Article						c-Myb; proteolysis; phosphorylation; 26S proteasome; Ser/Thr phosphatases	NEGATIVE REGULATORY DOMAIN; INDUCED TRANSCRIPTION ACTIVATION; DNA-BINDING DOMAIN; KAPPA-B-ALPHA; V-MYB; PHOSPHORYLATION SITE; PROTEASOME PATHWAY; ONCOGENIC ACTIVATION; TRANS-ACTIVATION; TERMINAL REGION	The c-myb proto-oncogene encodes a nuclear phosphoprotein that plays a crucial role in normal hematopoiesis. It is a short-lived transcription factor rapidly degraded by the 26S proteasome, Although it has been shown that instability determinants reside in its carboxyl terminus, the molecular mechanism of c-Myb degradation is unknown, Here, we report the first evidence that phosphorylation plays a role in targeting the protein to the proteasome, Inhibition of cellular serine/threonine protein phosphatase activity by okadaic acid resulted in hyperphosphorylation of c-Myb and extremely rapid turnover, The hyperphosphorylation resulted in a protein with altered properties that was indicative of conformational changes. Its mobility on gel electrophoresis was altered as well as its recognition by specific monoclonal antibody, The altered hyperphosphorylated protein still bound to DNA with an affinity similar to that of the hypophosphorylated form, Phosphorylation of three previously identified sites, serines 11, 12, and 528, does not appear to be involved in the proposed changes in conformation or stability, However, phosphoamino acid analyses of the hyperphosphorylated form of c-Myb revealed increased c-Myb phosphorylation mainly on threonine residues that correlated with other okadaic acid-induced alterations of c-Myb, These findings indicate that Ser/Thr phosphatases prevent conformational changes that may play an important role in controlled degradation of c-Myb.	NCI, Cellular Oncol Lab, NIH, Bethesda, MD 20892 USA; Slovak Acad Sci, Canc Res Inst, Mol Virol Lab, Bratislava 83392, Slovakia; NCI, Cellular & Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Slovak Academy of Sciences; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wolff, L (corresponding author), NCI, Cellular Oncol Lab, NIH, Bethesda, MD 20892 USA.		Bottaro, Donald P/F-8550-2010; Bottaro, Donald P/AAF-3853-2020	Bottaro, Donald P/0000-0002-5057-5334; Bottaro, Donald P/0000-0002-5057-5334	NATIONAL CANCER INSTITUTE [Z01BC008952] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AZIZ N, 1993, ONCOGENE, V8, P2259; AZIZ N, 1995, P NATL ACAD SCI USA, V92, P6429, DOI 10.1073/pnas.92.14.6429; BADING H, 1989, ONCOGENE, V4, P33; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; Bies J, 1996, ONCOGENE, V12, P355; Bies J, 1999, J VIROL, V73, P2038, DOI 10.1128/JVI.73.3.2038-2044.1999; Bies J, 1997, ONCOGENE, V14, P203, DOI 10.1038/sj.onc.1200828; Biesova Z, 1997, ONCOGENE, V14, P233, DOI 10.1038/sj.onc.1200822; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Calkhoven CF, 1996, BIOCHEM J, V317, P329, DOI 10.1042/bj3170329; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; DAI P, 1996, GENE DEV, V10, P28; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Dubendorff JW, 1999, ONCOGENE, V18, P3452, DOI 10.1038/sj.onc.1202679; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; HOWE KM, 1991, NUCLEIC ACIDS RES, V19, P3913, DOI 10.1093/nar/19.14.3913; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; HU YL, 1991, ONCOGENE, V6, P1549; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; KRIEG J, 1995, ONCOGENE, V10, P2221; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; Miglarese MR, 1996, J BIOL CHEM, V271, P22697, DOI 10.1074/jbc.271.37.22697; Ness SA, 1996, BBA-REV CANCER, V1288, pF123, DOI 10.1016/S0304-419X(96)00027-3; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; OELGESCHLAGER M, 1995, MOL CELL BIOL, V15, P5966; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; Ogata K, 1996, NAT STRUCT BIOL, V3, P178, DOI 10.1038/nsb0296-178; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Tavner FJ, 1998, MOL CELL BIOL, V18, P989, DOI 10.1128/MCB.18.2.989; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; Wolff L, 1996, CRIT REV ONCOGENESIS, V7, P245, DOI 10.1615/CritRevOncog.v7.i3-4.60; WON KA, 1996, EMBO J, V15, P182	44	26	26	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 1	2000	19	24					2846	2854		10.1038/sj.onc.1203613	http://dx.doi.org/10.1038/sj.onc.1203613			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	320LX	10851088				2022-12-17	WOS:000087403600006
J	Rudolph, B; Hueber, AO; Evan, GI				Rudolph, B; Hueber, AO; Evan, GI			Reversible activation of c-Myc in thymocytes enhances positive selection and induces proliferation and apoptosis in vitro	ONCOGENE			English	Article						switchable c-myc; 4-OHT; T cell development; proliferation; apoptosis	T-CELL-RECEPTOR; TRANSGENIC MICE; CYCLE PROGRESSION; GENE-EXPRESSION; DNA-BINDING; MAX; DIFFERENTIATION; PROTEIN; DELETION; BCL-2	In order to study the effect of c-Myc activation in T lymphocytes in vivo, we generated transgenic mice that express a 4-hydroxytamoxifen (4-OHT)-dependent switchable c-myc oncoprotein under the control of the proximal lck promoter. Activation of c-MycER(TM) causes no obvious alteration in T cell ontogeny. However, using MHC class I restricted H-Y-TCR transgenic mice, we found that c-Myc activation in vivo enhances the efficiency of positive selection. Moreover, splenic T cells derived from lck-c-mycER(TM) transgenic mice in which c-Myc had been activated exhibited increased proliferation in vitro in response to activation with anti-CD3/CD28 antibody. Activation of c-MycER(TM) also promotes apoptosis in thymocytes in vitro.	Imperial Canc Res Fund, London WC2A 3PX, England	Cancer Research UK	Evan, GI (corresponding author), Imperial Canc Res Fund, 44 Lincolns Inn Fields,POB 123, London WC2A 3PX, England.		Anne-Odile, Hueber/P-9860-2019; Anne-Odile, Hueber/G-4352-2013	Anne-Odile, Hueber/0000-0003-3816-2446; Anne-Odile, Hueber/0000-0003-3816-2446				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Alarcon RM, 1996, CANCER RES, V56, P4315; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; ASKEW DS, 1991, ONCOGENE, V6, P1915; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLUTHMANN H, 1988, NATURE, V334, P156, DOI 10.1038/334156a0; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; BroussardDiehl C, 1996, J IMMUNOL, V156, P3141; CALNAN BJ, 1995, IMMUNITY, V3, P273; CARDING S, 1987, THYMUS, V10, P219; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Furr BJ, 1979, PHARMACOLOGICAL BIOC, V2, P355; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.iy.04.040186.001533; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LUCAS B, 1993, J IMMUNOL, V151, P4574; LYONS AB, 1994, J IMMUNOL METHODS, V171, P131, DOI 10.1016/0022-1759(94)90236-4; MARRACK P, 1993, IMMUNOL REV, V131, P79, DOI 10.1111/j.1600-065X.1993.tb01531.x; Miyazaki T, 1998, J EXP MED, V188, P715, DOI 10.1084/jem.188.4.715; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; ROBEY EA, 1992, INT IMMUNOL, V4, P969, DOI 10.1093/intimm/4.9.969; Shortman K, 1990, Semin Immunol, V2, P3; SPANOPOULOU E, 1989, NATURE, V342, P185, DOI 10.1038/342185a0; SPENCER CA, 1991, ADV CANCER RES, V56, P1; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; TEH HS, 1989, J EXP MED, V169, P795, DOI 10.1084/jem.169.3.795; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; Wells AD, 1997, J CLIN INVEST, V100, P3173, DOI 10.1172/JCI119873; WILDIN RS, 1991, J EXP MED, V173, P383, DOI 10.1084/jem.173.2.383	45	26	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	2000	19	15					1891	1900		10.1038/sj.onc.1203508	http://dx.doi.org/10.1038/sj.onc.1203508			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	303LX	10773879				2022-12-17	WOS:000086424300005
J	Liu, YG; Black, J; Kisiel, N; Kulesz-Martin, MF				Liu, YG; Black, J; Kisiel, N; Kulesz-Martin, MF			SPAF, a new AAA-protein specific to early spermatogenesis and malignant conversion	ONCOGENE			English	Article						SPAF; AAA-protein; spermatogenesis; carcinogenesis; mitochondria	MESSENGER-RNA; PEROXISOME BIOGENESIS; TRANSLATIONAL CONTROL; GENE-EXPRESSION; CELL-CYCLE; FAMILY; YEAST; SEQUENCE; MOUSE; P53	A novel spermatogenesis associated factor (SPAF) was found to be aberrantly expressed at the malignant conversion stage in a clonal epidermal model of chemical carcinogenesis. Sequence analysis revealed two ATPase modules, classifying this gene as a new member of the AAA-protein family (ATPase associated with diverse activities). Immunohistochemical staining of mouse testis sections with SPAE antibody localized expression to spermatogonia and early spermatocytes in the basal compartment of the seminiferous tubules, Northern and Western analysis of SPAE expression in testes of mice at different developmental stages confirmed its expression at early stages of spermatogenesis, In view of mitochondrial-localization-like signal, sequence similarities to membrane-associated proteins, ATP binding properties, and intracellular expression patterns in testis, we speculate that SPAE protein may be involved in morphological and functional mitochondrial transformations during spermatogenesis, Ectopic expression of the SPAE gene in malignant epidermal cells may signify adoption of an early germ cell-like phenotype advantageous in malignant conversion.	Roswell Pk Canc Inst, Program Biochem, Buffalo, NY 14263 USA; Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA	Roswell Park Cancer Institute; Roswell Park Cancer Institute	Kulesz-Martin, MF (corresponding author), Oregon Hlth Sci Univ, Sch Med, Dept Dermatol L468, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.				NATIONAL CANCER INSTITUTE [R01CA031101, P30CA016056] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA31101, CA16056] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; Babst M, 1997, EMBO J, V16, P1820, DOI 10.1093/emboj/16.8.1820; BALMAIN A, 1982, NUCLEIC ACIDS RES, V10, P4259, DOI 10.1093/nar/10.14.4259; BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; Beyer A, 1997, PROTEIN SCI, V6, P2043; BRAUN RE, 1989, GENE DEV, V3, P793, DOI 10.1101/gad.3.6.793; CLARKMAGUIRE S, 1994, GENETICS, V136, P533; CONFALONIERI F, 1994, J MOL BIOL, V235, P396, DOI 10.1016/S0022-2836(05)80047-6; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; DEMARTINO C, 1979, CELL TISSUE RES, V196, P1; EAKLE KA, 1988, MOL CELL BIOL, V8, P4098, DOI 10.1128/MCB.8.10.4098; EGERTON M, 1992, EMBO J, V11, P3533, DOI 10.1002/j.1460-2075.1992.tb05436.x; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; FEILER HS, 1995, EMBO J, V14, P5626, DOI 10.1002/j.1460-2075.1995.tb00250.x; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; FUKASAWA K, 1995, P NATL ACAD SCI USA, V92, P3430, DOI 10.1073/pnas.92.8.3430; HACKENBROCK CR, 1971, J CELL BIOL, V51, P123, DOI 10.1083/jcb.51.1.123; HAN KA, 1990, MOL CARCINOGEN, V3, P75, DOI 10.1002/mc.2940030205; HAN KA, 1992, CANCER RES, V52, P749; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HRUBAN Z, 1973, JNCI-J NATL CANCER I, V50, P1487, DOI 10.1093/jnci/50.6.1487; HRUBAN Z, 1966, LAB INVEST, V15, P576; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KULESZMARTIN MF, 1988, CARCINOGENESIS, V9, P171, DOI 10.1093/carcin/9.1.171; KUNAU WH, 1993, BIOCHIMIE, V75, P209, DOI 10.1016/0300-9084(93)90079-8; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; Liu YG, 1998, CARCINOGENESIS, V19, P683, DOI 10.1093/carcin/19.4.683; MIAN IS, 1993, TRENDS BIOCHEM SCI, V18, P125; NELBOCK P, 1990, SCIENCE, V248, P1650, DOI 10.1126/science.2194290; Nigg E A, 1991, Semin Cell Biol, V2, P261; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; Sambrook J, 1989, MOL CLONING LAB MANU; SCHNEIDER BL, 1993, J INVEST DERMATOL, V101, P595, DOI 10.1111/1523-1747.ep12366051; SCHWARTZ D, 1993, ONCOGENE, V8, P1487; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Sjoblom T, 1996, ONCOGENE, V12, P2499; TROUTT AB, 1992, P NATL ACAD SCI USA, V89, P9823, DOI 10.1073/pnas.89.20.9823; WAITES GMH, 1982, PHYSIOL REV, V62, P624, DOI 10.1152/physrev.1982.62.2.624; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WHITE MT, 1974, J NATL CANCER I, V53, P553, DOI 10.1093/jnci/53.2.553; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; WOLFES H, 1989, SCIENCE, V245, P740, DOI 10.1126/science.2475907; Zabludoff SD, 1996, ONCOGENE, V13, P649	44	26	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 16	2000	19	12					1579	1588		10.1038/sj.onc.1203442	http://dx.doi.org/10.1038/sj.onc.1203442			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297XN	10734318				2022-12-17	WOS:000086108100011
J	Manganini, M; Maier, JAM				Manganini, M; Maier, JAM			Transforming growth factor beta(2) inhibition of hepatocyte growth factor-induced endothelial proliferation and migration	ONCOGENE			English	Article						Hepatocyte Growth Factor; Met; signal transduction; endothelial cells	BLOOD-VESSEL FORMATION; KINASE IN-VITRO; TYROSINE KINASE; SCATTER FACTOR; MET RECEPTOR; C-MET; CELLS; PROTEIN; PHOSPHORYLATION; ACTIVATION	Angiogenesis is a highly controlled event,which depends on the proper equilibrium of activators and inhibitors present within the microenvironment, Hepatocyte Growth Factor (HGF) activates migration and proliferation of endothelial cells and is angiogenic, acting through the tyrosine kinase receptor encoded by the Met protooncogene. To get insights into the molecular mechanisms involved in HGF-induced angiogenesis, we searched for cDNAs differentially expressed in human endothelial cells exposed to HGF, a potent angiogenic factor. We found that HGF-treated endothelial cells upregulated the expression of Transforming Growth Factor (TGF) beta(2). To understand the significance of this finding, we cultured endothelial cells with HGF and TGF pi simultaneously. We found that TGF beta(2) impairs HGF-dependent proliferative and migratory responses, TGF Pt did not prevent the tyrosine phosphorylation of R-let, but it inhibited some signalling pathways activated by HGF. We show that endothelial proliferation induced by HGF required the activation of the MAPK cascade, while HGF-induced endothelial migration,vas dependent on the tyrosine phosphorylation of Src. Indeed, TGF beta(2), inhibited HGF effects because it prevented HGF-induced MAP kinase activation and tyrosine phosphorylation of Src. We suggest that the induction of TGF beta(2), by HGF in endothelial cells may represent a physiologic mechanism to counterbalance HGF angiogenic activity.	Univ Milan, Dept Biomed Sci & Technol, I-20133 Milan, Italy	University of Milan	Maier, JAM (corresponding author), Univ Milan, Dept Biomed Sci & Technol, Via Olgettina 60, I-20133 Milan, Italy.		Maier, Jeanette AM/H-4820-2012	Maier, Jeanette AM/0000-0002-6326-9221				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ATFI A, 1994, J BIOL CHEM, V269, P30688; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Cary LA, 1996, J CELL SCI, V109, P1787; Consalez GG, 1996, TRENDS GENET, V12, P455; Dragoni I, 1998, J BIOL CHEM, V273, P31119, DOI 10.1074/jbc.273.47.31119; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Fukuda K, 1998, ONCOGENE, V16, P3349, DOI 10.1038/sj.onc.1201896; Garfinkel S, 1996, J CELL BIOL, V134, P783, DOI 10.1083/jcb.134.3.783; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; Hirschi KK, 1999, CIRC RES, V84, P298, DOI 10.1161/01.RES.84.3.298; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; HUWILER A, 1994, FEBS LETT, V354, P255, DOI 10.1016/0014-5793(94)01132-X; Kapus A, 1999, J BIOL CHEM, V274, P8093, DOI 10.1074/jbc.274.12.8093; Maier JAM, 1996, ONCOGENE, V13, P1009; Maniatis T., 1982, MOL CLONING LAB MANU; MCCARTHY SA, 1991, TRENDS PHARMACOL SCI, V12, P462, DOI 10.1016/0165-6147(91)90637-8; MERWIN JR, 1991, AM J PATHOL, V138, P37; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PAZDRAK K, 1995, J IMMUNOL, V155, P4454; PELICCI G, 1995, ONCOGENE, V10, P1631; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; ROMER LH, 1994, MOL BIOL CELL, V5, P349, DOI 10.1091/mbc.5.3.349; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Wu ZH, 1998, AM J PATHOL, V152, P1599; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008	36	26	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 6	2000	19	1					124	133		10.1038/sj.onc.1203225	http://dx.doi.org/10.1038/sj.onc.1203225			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644987				2022-12-17	WOS:000084844300014
J	Doitsh, G; Shaul, Y				Doitsh, G; Shaul, Y			HBV transcription repression in response to genotoxic stress is p53-dependent and abrogated by pX	ONCOGENE			English	Article						HBV transcription; DNA-damage; cisplatin; HCC; pX and p53; HBV RNA half life	HEPATITIS-B-VIRUS; SUPPRESSOR GENE-PRODUCT; X-PROTEIN; HEPATOCELLULAR-CARCINOMA; C-ABL; ENCODED COACTIVATOR; ENHANCER ELEMENT; BINDING PROTEIN; TRANSGENIC MICE; P53	Transcription of hepatitis B Virus (HBV), an important risk factor of hepatocellular carcinoma (HCC), is controlled by cellular transcription activators including some of the cellular signaling targets, Consequently, HBV transcription rate changes in response to the cellular physiological conditions. In this report we investigated HBV gene expression and the role of physiological levels of the viral X protein (pX) under cisplatin induced genotoxic stress. We show that under these conditions the RNA level of an HBV mutant which does not express pX is sharply reduced. Studies revealed that transcription repression is responsible for the observed reduction in HBV RNA level. Repression of HBV transcription was obtained only in the p53 proficient cells. Furthermore, HBV transcription rate is recovered by the cotransfected p53 dominant negative plasmid, indicating that p53 is directly responsible for HBV transcription repression. Unexpectedly, p73, the recent p53 homologue, does not repress but rather activates HBV transcription. Interestingly, pX produced either by the HBV genome or by a cotransfected plasmid, relieves the p53 mediated repression. Collectively, these results attribute a physiological role to p53-inactivation by pX, and explain how pX may support HCC development.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Shaul, Y (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.							Agami R, 1998, ONCOGENE, V16, P1779, DOI 10.1038/sj.onc.1201708; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; Butz K, 1996, INT J CANCER, V68, P506, DOI 10.1002/(SICI)1097-0215(19961115)68:4<506::AID-IJC17>3.0.CO;2-2; CHEONG JH, 1995, EMBO J, V14, P142; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; DIKSTEIN R, 1992, CELL, V69, P751, DOI 10.1016/0092-8674(92)90287-M; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; FAKTOR O, 1990, J VIROL, V64, P1861, DOI 10.1128/JVI.64.4.1861-1863.1990; Farmer G, 1996, NUCLEIC ACIDS RES, V24, P4281, DOI 10.1093/nar/24.21.4281; Farmer G, 1996, MOL CELL BIOL, V16, P4295; FEITELSON MA, 1993, ONCOGENE, V8, P1109; FRITSCHE M, 1993, ONCOGENE, V8, P307; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GUIDOTTI LG, 1995, J VIROL, V69, P6158, DOI 10.1128/JVI.69.10.6158-6169.1995; Guidotti LG, 1996, IMMUNITY, V4, P25, DOI 10.1016/S1074-7613(00)80295-2; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; HAGEN TM, 1994, P NATL ACAD SCI USA, V91, P12808, DOI 10.1073/pnas.91.26.12808; Haviv I, 1998, MOL CELL BIOL, V18, P1562, DOI 10.1128/MCB.18.3.1562; HAVIV I, 1995, MOL CELL BIOL, V15, P1079; Haviv I, 1996, EMBO J, V15, P3413, DOI 10.1002/j.1460-2075.1996.tb00707.x; Haviv I, 1998, GENE DEV, V12, P1217, DOI 10.1101/gad.12.8.1217; HONIGWACHS J, 1989, J VIROL, V63, P919, DOI 10.1128/JVI.63.2.919-924.1989; HOSONO S, 1991, ONCOGENE, V6, P237; JAMEEL S, 1986, MOL CELL BIOL, V6, P710, DOI 10.1128/MCB.6.2.710; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lin Y, 1997, J BIOL CHEM, V272, P7132, DOI 10.1074/jbc.272.11.7132; Lin Y, 1997, CANCER RES, V57, P5137; LIU X, 1995, MOL CELL BIOL, V15, P6474; LUBER B, 1993, RES VIROLOGY, V144, P311, DOI 10.1016/S0923-2516(06)80047-6; NATOLI G, 1994, ONCOGENE, V9, P2837; Ohno H, 1997, J MED VIROL, V52, P413, DOI 10.1002/(SICI)1096-9071(199708)52:4<413::AID-JMV12>3.0.CO;2-H; Ori A, 1998, EMBO J, V17, P544, DOI 10.1093/emboj/17.2.544; Raney AK, 1997, J VIROL, V71, P1058, DOI 10.1128/JVI.71.2.1058-1071.1997; ROBERTS JJ, 1981, BIOCHIM BIOPHYS ACTA, V655, P146, DOI 10.1016/0005-2787(81)90004-6; Sambrook J, 1989, MOL CLONING LAB MANU; Schaefer S, 1998, J GEN VIROL, V79, P767, DOI 10.1099/0022-1317-79-4-767; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SELLS MA, 1987, P NATL ACAD SCI USA, V84, P1005, DOI 10.1073/pnas.84.4.1005; SHAUL Y, 1981, EUR J BIOCHEM, V116, P461, DOI 10.1111/j.1432-1033.1981.tb05358.x; SHAUL Y, 1985, EMBO J, V4, P427, DOI 10.1002/j.1460-2075.1985.tb03646.x; SHAULIAN E, 1995, ONCOGENE, V10, P671; SIEGRIST CA, 1993, MOL CELL BIOL, V13, P6375, DOI 10.1128/MCB.13.10.6375; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; SUREAU C, 1986, CELL, V47, P37, DOI 10.1016/0092-8674(86)90364-8; Takada S, 1997, ONCOGENE, V15, P1895, DOI 10.1038/sj.onc.1201369; Takada S, 1996, VIROLOGY, V216, P80, DOI 10.1006/viro.1996.0036; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; YEE JK, 1989, SCIENCE, V246, P658, DOI 10.1126/science.2554495; Yuan ZM, 1996, J BIOL CHEM, V271, P26457, DOI 10.1074/jbc.271.43.26457; Zhu JH, 1998, CANCER RES, V58, P5061	57	26	26	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	1999	18	52					7506	7513		10.1038/sj.onc.1203209	http://dx.doi.org/10.1038/sj.onc.1203209			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602509				2022-12-17	WOS:000084119600011
J	Okuda, H; Adachi, M; Miyazawa, M; Hinoda, Y; Imai, K				Okuda, H; Adachi, M; Miyazawa, M; Hinoda, Y; Imai, K			Protein kinase C alpha promotes apoptotic cell death in gastric cancer cells depending upon loss of anchorage	ONCOGENE			English	Article						anoikis; apoptosis; protein kinase C alpha; gastric adenocarcinoma	SIGNAL TRANSDUCTION; EPITHELIAL-CELLS; CACO-2 CELLS; EXPRESSION; ADHESION; DIFFERENTIATION; PROLIFERATION; SUPPRESSION; RECOMBINANT; SPECIFICITY	Disruption of interactions between epithelial cells and extracellular matrix proteins leads to apoptosis of the cells, a phenomenon termed anoikis, Anoikis seems to play important roles in control of cellular positioning and inhibition of inappropriate cell growth, Here are found that a protein kinase C (PKC) activator phorbol ester 12-O-tetradecanoyl phorbol-13-acetate (TPA) promoted cell death in human gastric cancer cell lines MKN45 and MKN74 only when they lost anchorage. Loss of anchorage slightly increased enzymatic activity of PKC alpha, and an addition of TPA promoted cell death with further increase of PKC alpha activity, but not PKC beta in MKN45 cells, implicating an involvement of PKC alpha in anoikis, Furthermore, vaccinia virus-mediated overexpression of PKC alpha strongly increased CPP32 activity in the detached MKN45 and MKN74 cells, and augmented anoikis, however it had little effect on viability and CPP32 activity in the attached cells. Taken together, PKC alpha promotes apoptotic cell death in gastric cancer cells depending upon loss of anchorage, thereby may be a modulator of anoikis.	Sapporo Med Univ, Sch Med, Dept Internal Med 1, Chuo Ku, Sapporo, Hokkaido 0608543, Japan; Kinki Univ, Sch Med, Dept Immunol, Osaka 589, Japan	Sapporo Medical University; Kindai University (Kinki University)	Adachi, M (corresponding author), Sapporo Med Univ, Sch Med, Dept Internal Med 1, Chuo Ku, S1 W16, Sapporo, Hokkaido 0608543, Japan.		Miyazawa, Masaaki/AAA-3916-2020	Miyazawa, Masaaki/0000-0002-7300-119X				Abraham C, 1998, GASTROENTEROLOGY, V114, P503, DOI 10.1016/S0016-5085(98)70533-5; ASAO T, 1994, CANCER LETT, V78, P57, DOI 10.1016/0304-3835(94)90031-0; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403, DOI 10.1128/MCB.5.12.3403; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CLEMENS MJ, 1992, J CELL SCI, V103, P881; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; EICHHOLTZ T, 1993, J BIOL CHEM, V268, P1982; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 1996, J CELL BIOL, V135, P1377, DOI 10.1083/jcb.135.5.1377; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; HOUSE C, 1987, J BIOL CHEM, V262, P772; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Juliano RL, 1993, CURR OPIN CELL BIOL, V5, P812, DOI 10.1016/0955-0674(93)90030-T; Khwaja A, 1997, J CELL BIOL, V139, P1017, DOI 10.1083/jcb.139.4.1017; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MEREDITH JE, 1993, MOL CELL BIOL, V123, P485; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Scaglione-Sewell B, 1998, CANCER RES, V58, P1074; SCHWARTZ MA, 1993, CANCER RES, V53, P1503; SMITH GL, 1983, P NATL ACAD SCI-BIOL, V80, P7155, DOI 10.1073/pnas.80.23.7155; Takaoka A, 1997, ONCOGENE, V14, P2971, DOI 10.1038/sj.onc.1201147; Verstovsek G, 1998, GASTROENTEROLOGY, V115, P75, DOI 10.1016/S0016-5085(98)70367-1; WAYS DK, 1992, J BIOL CHEM, V267, P4799; Yawata A, 1998, ONCOGENE, V16, P2681, DOI 10.1038/sj.onc.1201792; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161	32	26	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 30	1999	18	40					5604	5609		10.1038/sj.onc.1202946	http://dx.doi.org/10.1038/sj.onc.1202946			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	241QU	10523838	Bronze			2022-12-17	WOS:000082894700014
J	Perez-Juste, G; Aranda, A				Perez-Juste, G; Aranda, A			Differentiation of neuroblastoma cells by phorbol esters and insulin-like growth factor 1 is associated with induction of retinoic acid receptor beta gene expression	ONCOGENE			English	Article						neuroblastoma; retinoic acid; RAR beta; TPA; IGF-1; Ras	PROTEIN-KINASE-C; HUMAN NEURO-BLASTOMA; TRANSCRIPTIONAL ACTIVATION; RESPONSE ELEMENT; RAR-ALPHA; BINDING; PHOSPHORYLATION; RESPONSIVENESS; HETERODIMERS; TARGET	The retinoic acid (RA) receptor beta isoform (RAR beta) plays an important role in RA-induced differentiation of human neuroblastoma, In this study we show that insulin-like growth factor 1 (IGF-1) and tetradecanoyl phorbol acetate (TPA) induce RAR beta gene expression in neuroblastoma SH-SY5Y cells. IGF-1 and TPA caused a marked induction of RAR beta 2 promoter activity and had a synergistic effect with RA that also upregulates transcription. The effect of RA is mediated by two RA responsive elements (RAREs), whereas the IGF-1 and TPA actions are independent of the RAREs and map to sequences that overlap the TATA box. These results suggest that the signaling pathways stimulated by TPA and IGF-1 could modify the components assembled at the core RAR beta 2 promoter and activate transcription. Expression of Ras(Val12) mimics the effect of IGF-1 and TPA on the promoter, and a dominant negative Ras mutant abrogates activation. A dominant negative Raf also blocks activation showing that the Ras-Raf pathway mediates stimulation of the RAR beta 2 promoter. Our results show that neuronal differentiation induced by non-retinoid agents that activate Ras is accompanied by increased transcription of the RAR beta gene.	CSIC, Inst Invest Biomed, E-28029 Madrid, Spain; Univ Autonoma Madrid, Madrid 28029, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid	Aranda, A (corresponding author), CSIC, Inst Invest Biomed, Arturo Duperier 4, E-28029 Madrid, Spain.		Aranda, Ana/ABG-8820-2020	Aranda, Ana/0000-0002-8338-9589				BJELFMAN C, 1990, MOL CELL BIOL, V10, P361, DOI 10.1128/MCB.10.1.361; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; Carpentier A, 1997, ONCOGENE, V15, P1805, DOI 10.1038/sj.onc.1201335; Cheung B, 1996, BIOCHEM BIOPH RES CO, V229, P349, DOI 10.1006/bbrc.1996.1804; Desmarais D, 1996, J BIOL CHEM, V271, P24976, DOI 10.1074/jbc.271.40.24976; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DEY A, 1994, MOL CELL BIOL, V14, P8191, DOI 10.1128/MCB.14.12.8191; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Giannini G, 1997, J BIOL CHEM, V272, P26693, DOI 10.1074/jbc.272.42.26693; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Gudas Lorraine J., 1994, P443; Hampsey M, 1997, CURR BIOL, V7, pR44, DOI 10.1016/S0960-9822(06)00018-2; HAUSSLER M, 1983, P NATL ACAD SCI-BIOL, V80, P5525, DOI 10.1073/pnas.80.18.5525; Irving H, 1998, EUR J CANCER, V34, P111, DOI 10.1016/S0959-8049(97)10027-2; KAPLAN DR, 1993, NEURON, V11, P321, DOI 10.1016/0896-6273(93)90187-V; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KRUYT FAE, 1992, NUCLEIC ACIDS RES, V20, P6393, DOI 10.1093/nar/20.23.6393; LEITMAN DC, 1992, MOL CELL BIOL, V12, P1352, DOI 10.1128/MCB.12.3.1352; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; Lovat PE, 1997, EUR J CANCER, V33, P2075, DOI 10.1016/S0959-8049(97)00242-6; LOVAT PE, 1993, NEUROSCI LETT, V162, P109, DOI 10.1016/0304-3940(93)90572-3; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; PAHLMAN S, 1991, P NATL ACAD SCI USA, V88, P9994, DOI 10.1073/pnas.88.22.9994; PARROW V, 1992, J CELL PHYSIOL, V152, P536, DOI 10.1002/jcp.1041520313; Pawson T, 1992, CURR OPIN GENET DEV, V2, P4, DOI 10.1016/S0959-437X(05)80314-4; REDFERN CPF, 1994, BIOCHEM J, V304, P147, DOI 10.1042/bj3040147; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUBERTE E, 1991, DEVELOPMENT, V111, P45; RUIZ MDMV, 1991, EMBO J, V10, P3829, DOI 10.1002/j.1460-2075.1991.tb04952.x; Sanguedolce MV, 1997, EMBO J, V16, P2861, DOI 10.1093/emboj/16.10.2861; SCHONTHAL A, 1992, NEW BIOL, V4, P16; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; SUMANTRAN VN, 1993, ENDOCRINOLOGY, V132, P2017, DOI 10.1210/en.132.5.2017; Taneja R, 1997, EMBO J, V16, P6452, DOI 10.1093/emboj/16.21.6452; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; THIELE CJ, 1991, CANCER METAST REV, V10, P311, DOI 10.1007/BF00554793; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; VILLABLANCA JG, 1995, J CLIN ONCOL, V13, P894, DOI 10.1200/JCO.1995.13.4.894; WEFALD FC, 1990, NATURE, V344, P260, DOI 10.1038/344260a0; Weigel NL, 1996, BIOCHEM J, V319, P657, DOI 10.1042/bj3190657; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	48	26	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	1999	18	39					5393	5402		10.1038/sj.onc.1202906	http://dx.doi.org/10.1038/sj.onc.1202906			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238PL	10498893				2022-12-17	WOS:000082718600004
J	Bongarzone, I; Vigano, E; Alberti, L; Mondellini, P; Uggeri, M; Pasini, B; Borrello, MG; Pierotti, MA				Bongarzone, I; Vigano, E; Alberti, L; Mondellini, P; Uggeri, M; Pasini, B; Borrello, MG; Pierotti, MA			The Glu632-Leu633 deletion in cysteine rich domain of Bet induces constitutive dimerization and alters the processing of the receptor protein	ONCOGENE			English	Article						RET; oncogenic activation; dimerization	MEDULLARY-THYROID CARCINOMA; TYROSINE KINASE DOMAIN; NEOPLASIA TYPE 2B; RET PROTOONCOGENE; ENDOPLASMIC-RETICULUM; POINT MUTATIONS; ACTIVATION; FMTC; 2A; RESIDUES	Mutations of the RET gene, encoding a receptor tyrosine kinase, have been associated with the inherited cancer syndromes MEN 2A and MEN 2B, They have also further been associated with both familial and sporadic medullary thyroid carcinomas. Missense mutations affecting cysteine residues within the extracellular domain of the receptor causes constitutive tyrosine kinase activation through the formation of disulfide-bonded homodimers. We have recently reported that a somatic 6 bp in-frame deletion, originally coding for Glu632-Leu633, potently activates the RET gene. This activation is increased with respect to the frequent MEN 2A-associated missense mutation Cys634Arg. This finding specifically correlated to the clinic behavior of the corresponding tumor, which was characterized by an unusually aggressive progression with both multiple and recurrent metastases. By examining the possibility that this deletion acts in a manner similar to cysteine substitution, we have analysed the molecular mechanism by which this oncogenic activation occurs. Phosphorylated dimers of the deleted Ret receptor were detected in immunoprecipitates separated under non-reducing conditions. Like other Cys point mutations, this 6 bp deletion affecting two amino acid residues between two adjacent Cys, is capable of activating the transforming ability of Ret by promoting receptor dimerization, These results suggest that alteration to cysteine residue position or pairing is capable of inducing ligand independent dimerization, Furthermore, we present data demonstrating that the processing and sorting of the Bet membrane receptor to the cell surface is affected by mutation type.	Ist Nazl Tumori, Div Expt Oncol A, I-20133 Milan, Italy; Ist Nazl Tumori, Sci Direct, I-20133 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan	Bongarzone, I (corresponding author), Ist Nazl Tumori, Div Expt Oncol A, Via Venezian 1, I-20133 Milan, Italy.		Bongarzone, Italia/B-9544-2017; Pasini, Barbara/AHI-2004-2022; Borrello, Maria Grazia/C-3161-2017; Pierotti, Marco Alessandro/AAC-4728-2022	Bongarzone, Italia/0000-0003-2530-9170; Pasini, Barbara/0000-0002-4373-1212; Borrello, Maria Grazia/0000-0002-6854-2848; Pierotti, Marco Alessandro/0000-0002-7431-8332				ALEXANDER WS, 1995, EMBO J, V14, P5569, DOI 10.1002/j.1460-2075.1995.tb00244.x; ASAI N, 1995, MOL CELL BIOL, V15, P1613; BLAUGRUND JE, 1994, HUM MOL GENET, V3, P1895, DOI 10.1093/hmg/3.10.1895; BOLINO A, 1995, ONCOGENE, V10, P2415; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; Ceccherini I, 1997, ONCOGENE, V14, P2609, DOI 10.1038/sj.onc.1201079; Chappuis-Flament S, 1998, ONCOGENE, V17, P2851, DOI 10.1038/sj.onc.1202202; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; Eng C, 1996, CANCER RES, V56, P2167; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; ENG C, 1995, ONCOGENE, V10, P509; ENG C, 1995, GENE CHROMOSOME CANC, V12, P209, DOI 10.1002/gcc.2870120308; Hofstra RMW, 1996, J CLIN ENDOCR METAB, V81, P2881, DOI 10.1210/jc.81.8.2881; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Hoppner W, 1997, HUM MOL GENET, V6, P587, DOI 10.1093/hmg/6.4.587; Isidoro C, 1996, J BIOL CHEM, V271, P26138, DOI 10.1074/jbc.271.42.26138; KALININ V, 1998, IN PRESS J MOL MED; KOMMINOTH P, 1995, CANCER, V76, P479; Lotti LV, 1996, MOL CELL BIOL, V16, P1946; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, HUM MOL GENET, V3, P2163, DOI 10.1093/hmg/3.12.2163; MURAGAKI Y, 1995, J COMP NEUROL, V356, P387, DOI 10.1002/cne.903560306; Romei C, 1996, J CLIN ENDOCR METAB, V81, P1619, DOI 10.1210/jc.81.4.1619; Siegel PM, 1996, P NATL ACAD SCI USA, V93, P8878, DOI 10.1073/pnas.93.17.8878	26	26	26	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 26	1999	18	34					4833	4838		10.1038/sj.onc.1202848	http://dx.doi.org/10.1038/sj.onc.1202848			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229GH	10490816				2022-12-17	WOS:000082184800007
J	Yoneda-Kato, N; Fukuhara, S; Kato, J				Yoneda-Kato, N; Fukuhara, S; Kato, J			Apoptosis induced by the myelodysplastic syndrome-associated NPM-MLF1 chimeric protein	ONCOGENE			English	Article						apoptosis; myelodysplastic syndrome; anti-apoptotic oncoprotein; NPM-MLF1 chimeric protein; subcellular localization; dimerization	NON-HODGKINS-LYMPHOMA; S-PHASE ENTRY; CELL-DEATH; EXPRESSION; LEUKEMIA; NUCLEOPHOSMIN; FUSION; E2F-1; FAMILY; BCL-2	The NPM-MLF1 chimeric protein is produced by the t(3;5)(q25.1;q34) chromosomal translocation, which is associated with myelodysplastic syndrome (MDS) prior to progression into acute myeloid leukemia (AML). Here we report that K562 human leukemia cells ectopically expressing NPM-MLF1, but not those with wild-type;MLF1, mere gradually eliminated from the culture by undergoing apoptosis. NIH3T3 mouse fibroblasts engineered to overexpress NPM-MLF1 grew normally but serum deprivation triggered apoptotic cell death with slower kinetics than did other well-known apoptotic inducers such as c-Myc or E2F-1. Quantitative analysis of apoptotic induction confirmed that, neither NPM nor MLF1, but the NPM-RLF1 fusion protein was able to induce apoptosis. Analyses using a variety of deletion mutants of NPM-MLF1 revealed that induction of apoptosis required the N-terminal domain of MLF1 and the NPM domain containing nuclear localization signal and that removal of the NPM dimerization domain markedly impaired the ability to induce apoptosis. Go-expression of Bcl-2 rescued NIH3T3 fibroblasts from NPM-MLF1-mediated cell death without affecting the expression level or the subcellular localization of NPM-MLF1 and enabled cells to progress into S phase in low serum. These findings provide an NPM-MLF1-mediated novel mechanism of apoptotic induction and imply that NPM-MLF1 in collaboration with anti-apoptotic oncoproteins may play an important role in multi-step progression from MDS to AML.	Kansai Med Univ, Dept Internal Med 1, Osaka 5700074, Japan; Nara Inst Sci & Technol, Grad Sch Biol Sci, Nara 6300101, Japan	Kansai Medical University; Nara Institute of Science & Technology	Yoneda-Kato, N (corresponding author), Kansai Med Univ, Dept Internal Med 1, 10-15 Fumisono, Osaka 5700074, Japan.							Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; ASKEW DS, 1991, ONCOGENE, V6, P1915; BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb08475.x; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; CLARK DM, 1990, LEUKEMIA LYMPHOMA, V2, P415, DOI 10.3109/10428199009069295; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DELIA D, 1992, BLOOD, V79, P1291, DOI 10.1182/blood.V79.5.1291.bloodjournal7951291; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fenaux P, 1996, SEMIN HEMATOL, V33, P127; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; Gallagher A, 1997, HAEMATOLOGICA, V82, P191; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Koeffler HP, 1996, SEMIN HEMATOL, V33, P87; KOEFFLER HP, 1986, SEMIN HEMATOL, V23, P284; LIU QR, 1991, EUR J BIOCHEM, V200, P715, DOI 10.1111/j.1432-1033.1991.tb16236.x; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; McKenna SL, 1997, ADV CANCER RES, V71, P121, DOI 10.1016/S0065-230X(08)60098-6; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; OGAWA H, 1995, P NATL ACAD SCI USA, V92, P11899, DOI 10.1073/pnas.92.25.11899; PAQUETTE RL, 1993, BLOOD, V82, P590, DOI 10.1182/blood.V82.2.590.bloodjournal822590; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAIMONDI SC, 1989, LEUKEMIA, V3, P42; Rajapaksa R, 1996, BLOOD, V88, P4275; RAZA A, 1995, BLOOD, V86, P268, DOI 10.1182/blood.V86.1.268.bloodjournal861268; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; SCHMIDTZACHMANN MS, 1988, CHROMOSOMA, V96, P417, DOI 10.1007/BF00303035; SCHMIDTZACHMANN MS, 1987, EMBO J, V6, P1881, DOI 10.1002/j.1460-2075.1987.tb02447.x; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; WATTEL E, 1994, BLOOD, V84, P3148, DOI 10.1182/blood.V84.9.3148.3148; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; YonedaKato N, 1996, ONCOGENE, V12, P265; YOSHIDA Y, 1993, LEUKEMIA, V7, P144; YUNG BYM, 1987, BIOCHIM BIOPHYS ACTA, V925, P74, DOI 10.1016/0304-4165(87)90149-8	43	26	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 24	1999	18	25					3716	3724		10.1038/sj.onc.1202711	http://dx.doi.org/10.1038/sj.onc.1202711			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211BN	10391679				2022-12-17	WOS:000081140200005
J	De Graeve, F; Bahr, A; Sabapathy, KT; Hauss, C; Wagner, EF; Kedinger, C; Chatton, B				De Graeve, F; Bahr, A; Sabapathy, KT; Hauss, C; Wagner, EF; Kedinger, C; Chatton, B			Role of the ATFa/JNK2 complex in Jun activation	ONCOGENE			English	Article						ATF; Jun; JNK SAPK	DNA-BINDING ACTIVITY; C-JUN; PROTEIN-KINASE; TRANSCRIPTIONAL ACTIVATION; HETERODIMER FORMATION; SIGNAL-TRANSDUCTION; CELL-PROLIFERATION; RESPONSE ELEMENT; MAMMALIAN-CELLS; MAP KINASES	The ATFa proteins, which are members of the CREB/ATF family of transcription factors, display quite versatile properties, We have previously shown that they interact with the adenovirus E1a oncoprotein, mediating part of its transcriptional activity and heterodimerize with the Jun, Fos or related transcription factors, thereby modulating their DNA-binding specificity, In the present study, we report the sequence requirement of the N-terminal activation domain of ATFa and demonstrate the importance of specific threonine residues (Thr51 and Thr53) in addition to that of the metal-binding domain, in transcriptional activation processes. We also show that the N-terminal domain of ATFa which stably binds the Jun N-terminal kinase-2 (JNK2) (Bocco et al,, 1996), is not a substrate for this kinase in vivo but, instead, serves as a JNK2-docking site for ATFa-associated partners like JunD, allowing them to be phosphorylated by the bound kinase.	ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, CU Strasbourg, France; Inst Mol Pathol, A-1030 Vienna, Austria	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Kedinger, C (corresponding author), ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, BP163, F-67404 Illkirch Graffenstaden, CU Strasbourg, France.		CHATTON, Bruno/R-3813-2019	DE GRAEVE, Fabienne/0000-0002-3455-7507; CHATTON, Bruno/0000-0003-4515-7119; Wagner, Erwin F/0000-0001-7872-0196				ALLEGRETTO EA, 1990, J CELL BIOCHEM, V42, P193, DOI 10.1002/jcb.240420403; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BENBROOK DM, 1990, ONCOGENE, V5, P295; Bocco JL, 1996, ONCOGENE, V12, P1971; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRUSSELBACH S, 1995, ONCOGENE, V10, P79; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; CHATTON B, 1994, ONCOGENE, V9, P375; CHATTON B, 1995, BIOTECHNIQUES, V18, P142; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FLINT KJ, 1991, ONCOGENE, V6, P2019; Fuchs SY, 1997, J BIOL CHEM, V272, P32163, DOI 10.1074/jbc.272.51.32163; Fuchs SY, 1996, ONCOGENE, V13, P1531; GAIRE M, 1990, NUCLEIC ACIDS RES, V18, P3467, DOI 10.1093/nar/18.12.3467; Goetz J, 1996, J BIOL CHEM, V271, P29589, DOI 10.1074/jbc.271.47.29589; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kovalenko OV, 1996, P NATL ACAD SCI USA, V93, P2958, DOI 10.1073/pnas.93.7.2958; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LEE KAW, 1992, J CELL SCI, V103, P9; LEFF T, 1994, P NATL ACAD SCI USA, V81, P4381; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LIU F, 1993, NATURE, V366, P531; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MAEKAWA T, 1991, ONCOGENE, V6, P627; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; PAPAVASSILIOU AG, 1995, EMBO J, V14, P2014, DOI 10.1002/j.1460-2075.1995.tb07193.x; ROCHETTEEGLY C, 1994, BIOCHEM BIOPH RES CO, V204, P525, DOI 10.1006/bbrc.1994.2491; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Wang HL, 1996, ONCOGENE, V13, P2639; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063	48	26	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	1999	18	23					3491	3500		10.1038/sj.onc.1202723	http://dx.doi.org/10.1038/sj.onc.1202723			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205ZF	10376527				2022-12-17	WOS:000080850600007
J	Nakamura, N; Fujii, M; Tsukahara, T; Arai, M; Ohashi, T; Wakao, H; Kannagi, M; Yamamoto, N				Nakamura, N; Fujii, M; Tsukahara, T; Arai, M; Ohashi, T; Wakao, H; Kannagi, M; Yamamoto, N			Human T-cell leukemia virus type 1 Tax protein induces the expression of STAT1 and STAT5 genes in T-cells	ONCOGENE			English	Article						HTLV-1; tax; STAT; transformation	DNA-BINDING ACTIVITY; CONSTITUTIVE ACTIVATION; TRANSCRIPTION FACTOR; TRANSACTIVATOR GENE; MOLECULAR-CLONING; ABL ONCOGENE; HTLV-I; INTERLEUKIN-2; PATHWAY; LINES	Human T-cell leukemia virus type 1 (HTLV-1) Tax transforms normal T-cells in the presence of interleukin (IL)-2 in vitro. STAT is a family of transcription factors that play a pivotal role in cytokine-induced functions of a various type of cells. We investigated the involvement of STATs in the transformation of T-cells by HTLV-1, HTLV-1-transformed T-cell lines expressed higher amounts of STAT1, STAT3 and STAT5 RNA and proteins than virus-negative T cells. The expression of STAT1 and STAT5 in a human T-cell line was induced by Tax, IL-2 induced the DNA binding activity of STAT3 and STAT5 of a HTLV-1-transformed cell line and then stimulated its proliferation. In contrast, IL-2 did neither in a cell line lacking STAT3 and STAT5. The expression of STAT1, STAT3 and STAT5 mRNAs were also induced by a T-cell mitogen in normal human peripheral blood mononuclear cells, Our results suggest that the induction of STAT1 and STAT5 by Tax enhances cytokine-induced functions of virus-infected T-cells, hence the induction may play a role in IL-2-dependent transformation steps of T-cells by HTLV-1.	Tokyo Med & Dent Univ, Dept Immunotherapeut, Bunkyo Ku, Tokyo 113, Japan; Tokyo Med & Dent Univ, Dept Microbiol, Bunkyo Ku, Tokyo 113, Japan; Niigata Univ, Sch Med, Dept Virol, Niigata 9518510, Japan; Helix Res Inst, Chiba 292, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Niigata University	Fujii, M (corresponding author), Tokyo Med & Dent Univ, Dept Immunotherapeut, Bunkyo Ku, Yushima, Tokyo 113, Japan.		WAKAO, Hiroshi/A-4242-2012; Ohashi, Takashi/C-4671-2012	Ohashi, Takashi/0000-0002-3769-4224				AKAGI T, 1993, J VIROL, V67, P1211, DOI 10.1128/JVI.67.3.1211-1217.1993; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; CANN AJ, 1985, NATURE, V318, P571, DOI 10.1038/318571a0; Cao XM, 1996, MOL CELL BIOL, V16, P1595; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; Darnell JE, 1996, RECENT PROG HORM RES, V51, P391; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P1023; GOUILLEUX F, 1995, ENDOCRINOLOGY, V136, P5700, DOI 10.1210/en.136.12.5700; GouilleuxGruart V, 1996, BLOOD, V87, P1692; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; JOHNSTON JA, 1995, P NATL ACAD SCI USA, V92, P8705, DOI 10.1073/pnas.92.19.8705; KIM SJ, 1990, J EXP MED, V172, P121, DOI 10.1084/jem.172.1.121; KOBAYASHI N, 1984, EMBO J, V3, P1339, DOI 10.1002/j.1460-2075.1984.tb01974.x; LEE B, 1989, TOHOKU J EXP MED, V157, P1, DOI 10.1620/tjem.157.1; Lin JX, 1996, J BIOL CHEM, V271, P10738, DOI 10.1074/jbc.271.18.10738; Lindholm PF, 1996, J VIROL, V70, P2525, DOI 10.1128/JVI.70.4.2525-2532.1996; Low KG, 1997, J VIROL, V71, P1956, DOI 10.1128/JVI.71.3.1956-1962.1997; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; MIURA S, 1991, MOL CELL BIOL, V11, P1313, DOI 10.1128/MCB.11.3.1313; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; OHASHI T, 1995, BLOOD, V85, P1454, DOI 10.1182/blood.V85.6.1454.bloodjournal8561454; OHTANI K, 1989, NUCLEIC ACIDS RES, V17, P1589, DOI 10.1093/nar/17.4.1589; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; Schmitt I, 1998, J VIROL, V72, P633, DOI 10.1128/JVI.72.1.633-640.1998; SEIKI M, 1986, EMBO J, V5, P561, DOI 10.1002/j.1460-2075.1986.tb04247.x; Shuai K, 1996, ONCOGENE, V13, P247; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; SUGAMURA K, 1984, INT J CANCER, V34, P221, DOI 10.1002/ijc.2910340213; SUGAMURA K, 1986, Cancer Reviews, V1, P96; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; Takemoto S, 1997, P NATL ACAD SCI USA, V94, P13897, DOI 10.1073/pnas.94.25.13897; TSUCHIYA H, 1993, J VIROL, V67, P7001, DOI 10.1128/JVI.67.12.7001-7007.1993; UCHIJIMA M, 1994, J BIOL CHEM, V269, P14946; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; WAKAO H, 1995, EMBO J, V14, P854, DOI 10.1002/j.1460-2075.1995.tb07064.x; WeberNordt RM, 1996, BLOOD, V88, P809; YAMAMOTO N, 1982, SCIENCE, V217, P737, DOI 10.1126/science.6980467; YAMASHITA I, 1994, BLOOD, V84, P1573; YOSHIDA M, 1995, CURR TOP MICROBIOL, V193, P79; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	50	26	26	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 29	1999	18	17					2667	2675		10.1038/sj.onc.1202608	http://dx.doi.org/10.1038/sj.onc.1202608			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FH	10348340				2022-12-17	WOS:000080124900001
J	Sohm, F; Gaiddon, C; Antoine, M; Boutillier, AL; Loeffler, JP				Sohm, F; Gaiddon, C; Antoine, M; Boutillier, AL; Loeffler, JP			The retinoblastoma susceptibility gene product/Sp1 signalling pathway is modulated by Ca2+/calmodulin kinases II and IV activity	ONCOGENE			English	Article						Ca2+ signalling pathway; cell cycle; differentiation; retinoblastoma; SP1	DEPENDENT PROTEIN-KINASE; DNA-BINDING ACTIVITY; C-FOS TRANSCRIPTION; CELL-CYCLE; SP1-MEDIATED TRANSCRIPTION; RB PROTEIN; EXPRESSION; PHOSPHORYLATION; CALCIUM; PROMOTER	To investigate the possible link between Ca2+ signalling and cell cycle control we analysed Ca2+/calmodulin kinases (CamK) interaction with the retinoblastoma susceptibility gene product/SP1 pathway, CamK II and IV activate c-fos transcription through a short promoter region (-99 to -53) containing the retinoblastoma control element (RCE) and a cAMP response element (CRE) related sequences. Deletion analysis revealed that the RCE is a major CamK responsive element and is sufficient to confer CamK and Ca2+ regulation to a minimal promoter, Direct interactions between SP1 and RCE were confirmed by gel shift experiments. Using transient transfection experiments, we show that CamK-dependent transcription is regulated by the retinoblastoma (Rb) susceptibility gene product and the p107 Rb related protein. However, the stimulatory effects of CamKs and Rb on c-fos are blocked by overexpression of both proteins, These effects appear to be directly mediated by SP1 as shown by the use of a Gal4/SP1 fusion proteins. In conclusion, CamK II and IV, two major Ca2+-dependent intracellular effecters, may represent a molecular link between this second messenger transduction pathway and effecters that control cell cycle progression through Rb/SP1 signalling pathway.	IPCB, CNRS, UMR 7519, F-67084 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Loeffler, JP (corresponding author), IPCB, CNRS, UMR 7519, 21 Rene Descartes, F-67084 Strasbourg, France.		LOEFFLER, Jean-Philippe/AAS-4401-2020; Gaiddon, Christian/F-7321-2012	Gaiddon, Christian/0000-0003-4315-3851				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Antoine M, 1996, MOL CELL ENDOCRINOL, V120, P1, DOI 10.1016/0303-7207(96)03806-3; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; BARTON LL, 1995, ANAEROBE, V1, P1, DOI 10.1016/S1075-9964(95)80327-0; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GHOSH A, 1994, J NEUROBIOL, V25, P294, DOI 10.1002/neu.480250309; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; Hardingham GE, 1998, CELL CALCIUM, V23, P131, DOI 10.1016/S0143-4160(98)90111-7; Hollingsworth RE, 1993, CURR OPIN CELL BIOL, V5, P194, DOI 10.1016/0955-0674(93)90102-V; HOROWITZ JM, 1993, GENE CHROMOSOME CANC, V6, P124, DOI 10.1002/gcc.2870060211; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Johnson CM, 1997, J NEUROSCI, V17, P6189; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LOEFFLER JP, 1993, METHOD ENZYMOL, V217, P599; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MISRA RP, 1994, J BIOL CHEM, V269, P25483; NEVINS JR, 1992, SCIENCE, V258, P424; Nishinaka T, 1997, BBA-GENE STRUCT EXPR, V1351, P274, DOI 10.1016/S0167-4781(96)00210-2; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; Rubin Lee L., 1994, Current Opinion in Neurobiology, V4, P696, DOI 10.1016/0959-4388(94)90012-4; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SIF S, 1993, ONCOGENE, V8, P2501; SPITZER NC, 1994, TRENDS NEUROSCI, V17, P115, DOI 10.1016/0166-2236(94)90120-1; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; TAKUWA N, 1995, CELL SIGNAL, V7, P93, DOI 10.1016/0898-6568(94)00074-L; TAKUWA N, 1993, J BIOL CHEM, V268, P138; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; UDVADIA AJ, 1992, CELL GROWTH DIFFER, V3, P597; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; Wang Y, 1996, MOL CELL BIOL, V16, P5915; XU HJ, 1989, ONCOGENE, V4, P807; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	50	26	26	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 29	1999	18	17					2762	2769		10.1038/sj.onc.1202634	http://dx.doi.org/10.1038/sj.onc.1202634			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FH	10348351				2022-12-17	WOS:000080124900012
J	North, S; Espanel, X; Bantignies, F; Viollet, B; Vallet, V; Jalinot, P; Brun, G; Gillet, G				North, S; Espanel, X; Bantignies, F; Viollet, B; Vallet, V; Jalinot, P; Brun, G; Gillet, G			Regulation of cdc2 gene expression by the upstream stimulatory factors (USFs)	ONCOGENE			English	Article						cell cycle; differentiation; retina; cdc2; USF	TRANSCRIPTION FACTOR USF; HELIX-LOOP-HELIX; CELL-CYCLE REGULATION; MAMMALIAN-CELLS; IN-VIVO; PROMOTER; REGION; ACTIVATION; REPRESSION; IDENTIFICATION	cdc2 gene expression is under the control of multiple factors. Although E2F/DP proteins have been reported to play a central role, they cannot account for all aspects of the fine modulation of cdc2 gene expression during cell cycle and embryonic development. To characterize the transcription factors that control cdc2 gene expression during nerve cell differentiation in avians, we have previously cloned the quail cdc2 gene promoter region. We had identified an octamer (CAGGTGGC) containing an E-box, which has important activity in regulating cdc2 transcription. Using lit vivo genomic footprinting experiments, we show here that this motif, currently named TG, is the target of binding proteins at different stages of neuroretina development, confirming its importance as a regulatory response element for cdc2 gene expression. A subset of Helix-Loop-Helix family of transcription factors, known as Upstream Stimulatory Factors (USFs) specifically bind to this sequence as dimers, Moreover, our results indicate that USFs transactivate the promoter of cdc2 via the IG motif, These data may help to better understand the mechanisms that control cell division in differentiating nerve cells.	CNRS, Inst Biol & Chim Prot, UPR 412, F-69367 Lyon 07, France; CHU Cochin Port Royal, INSERM, U129, Unite Rech Genet & Pathol Mol, F-75014 Paris, France; Ecole Normale Super Lyon, UMR CNRS 49, Res Grp, Mol & Cellular Biol Lab, F-69364 Lyon 07, France; Ecole Normale Super Lyon, UMR CNRS 49, F-69364 Lyon 07, France	Centre National de la Recherche Scientifique (CNRS); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Ecole Normale Superieure de Lyon (ENS de LYON); Ecole Normale Superieure de Lyon (ENS de LYON)	Gillet, G (corresponding author), CNRS, Inst Biol & Chim Prot, UPR 412, 7 Passage Vercors, F-69367 Lyon 07, France.		Viollet, Benoit/O-6927-2017; Viollet, Benoit/N-2397-2019; gillet, germain/A-9095-2013	Viollet, Benoit/0000-0002-0121-0224; Viollet, Benoit/0000-0002-0121-0224; GILLET, Germain/0000-0002-1514-327X				BORN TL, 1994, MOL CELL BIOL, V14, P5710, DOI 10.1128/MCB.14.9.5710; Breen GAM, 1997, J BIOL CHEM, V272, P10538; Cobrinik D, 1996, CURR TOP MICROBIOL, V208, P31; COGSWELL JP, 1995, MOL CELL BIOL, V15, P2782; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DOREE M, 1994, FASEB J, V8, P1114, DOI 10.1096/fasebj.8.14.7958616; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; Espanel X, 1997, INT J DEV BIOL, V41, P469; ESPINAS ML, 1994, MOL CELL BIOL, V14, P4116, DOI 10.1128/MCB.14.6.4116; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; FOTEDAR R, 1995, MOL CELL BIOL, V15, P932; Ghosh AK, 1997, ONCOGENE, V14, P589, DOI 10.1038/sj.onc.1200866; GILLET G, 1993, ONCOGENE, V8, P565; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; Kastner A, 1998, CELL GROWTH DIFFER, V9, P857; Kenny JJ, 1997, VIROLOGY, V230, P381, DOI 10.1006/viro.1997.8501; KU DH, 1993, J BIOL CHEM, V268, P2255; Liu NS, 1996, NUCLEIC ACIDS RES, V24, P2905, DOI 10.1093/nar/24.15.2905; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; North S, 1996, CELL GROWTH DIFFER, V7, P339; NURSE P, 1993, PHILOS T ROY SOC B, V341, P449, DOI 10.1098/rstb.1993.0127; OUTRAM SV, 1994, J BIOL CHEM, V269, P26525; Rippe RA, 1997, J BIOL CHEM, V272, P1753, DOI 10.1074/jbc.272.3.1753; SARDET C, 1997, E2FS RETINOBLASTOMA; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SHIMIZU M, 1995, MOL CELL BIOL, V15, P2882; SHIMIZU T, 1995, CANCER RES, V55, P228; Sirito M, 1998, P NATL ACAD SCI USA, V95, P3758, DOI 10.1073/pnas.95.7.3758; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; SUGARMAN JL, 1995, MOL CELL BIOL, V15, P3282; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; Vallet VS, 1997, J BIOL CHEM, V272, P21944, DOI 10.1074/jbc.272.35.21944; Vallet VS, 1998, J BIOL CHEM, V273, P20175, DOI 10.1074/jbc.273.32.20175; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; WEN SC, 1995, EXP CELL RES, V217, P8, DOI 10.1006/excr.1995.1057; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	39	26	26	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 18	1999	18	11					1945	1955		10.1038/sj.onc.1202506	http://dx.doi.org/10.1038/sj.onc.1202506			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177DC	10208416				2022-12-17	WOS:000079191300004
J	Dan, S; Naito, M; Seimiya, H; Kizaki, A; Mashima, T; Tsuruo, T				Dan, S; Naito, M; Seimiya, H; Kizaki, A; Mashima, T; Tsuruo, T			Activation of c-Abl tyrosine kinase requires caspase activation and is not involved in JNK/SAPK activation during apoptosis of human monocytic leukemia U937 cells	ONCOGENE			English	Article						c-Abl; JNK1/SAPK; caspase; apoptosis	DEPENDENT PROTEIN-KINASE; DNA-DAMAGE; IONIZING-RADIATION; CELLULAR-RESPONSE; STRESS-RESPONSE; P53; 1-BETA-D-ARABINOFURANOSYLCYTOSINE; PHOSPHORYLATION; RESISTANCE; SUBSTRATE	Genotoxic stress triggers the activation of several sensor molecules, such as p53, JNK1/SAPK and c-Abl, and occasionally promotes the cells to apoptosis, We previously reported that JNK1/SAPK regulates genotoxic stress-induced apoptosis in p53-negative U937 cells by activating caspases, c-Abl is expected to act upstream of JNK1/SAPK activation upon treatment with genotoxic stressors, but its involvement in apoptosis development is still unclear. We herein investigated the kinase activities of c-Abl and JNK1/SAPK during apoptosis elicited by genotoxic anticancer drugs and tumor necrosis factor (TNF) in U937 cells and their apoptosis-resistant variant UK711 cells. We found that the activation of JNK1/SAPK and c-Abl correlated well with apoptosis development in these cell lines. Unexpectedly, however, the JNK1/SAPK activation preceded the c-Abl activation. Moreover, the caspase inhibitor Z-Asp suppressed c-Abl activation and the onset of apoptosis but not the JNK1/SAPK activation. Interestingly, c-Abl tyrosine kinase inhibition by CGP 57148 reduced apoptosis without interfering with JNK1/SAPK activation. These results indicate that c-Abl acts not upstream of JNK1/SAPK but downstream of caspases during the development of p53-independent apoptosis and is possibly involved in accelerating execution of the cell death pathway.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 1708455, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Tsuruo, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.			Seimiya, Hiroyuki/0000-0003-3314-9736				Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; Buchdunger E, 1996, CANCER RES, V56, P100; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; GUNJI H, 1991, CANCER RES, V51, P741; Han ZY, 1996, J BIOL CHEM, V271, P25035, DOI 10.1074/jbc.271.40.25035; Huang YY, 1997, ONCOGENE, V15, P1947, DOI 10.1038/sj.onc.1201376; KASTAN MB, 1991, CANCER RES, V51, P6304; KATAOKA S, 1994, EXP CELL RES, V215, P199, DOI 10.1006/excr.1994.1332; Kharbanda S, 1996, P NATL ACAD SCI USA, V93, P6898, DOI 10.1073/pnas.93.14.6898; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Mashima T, 1997, ONCOGENE, V14, P1007, DOI 10.1038/sj.onc.1200919; Mashima T, 1995, BIOCHEM BIOPH RES CO, V217, P1185, DOI 10.1006/bbrc.1995.2894; McConnell KR, 1997, J IMMUNOL, V158, P2083; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Teraoka H, 1996, FEBS LETT, V393, P1, DOI 10.1016/0014-5793(96)00842-3; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1996, J BIOL CHEM, V271, P26457, DOI 10.1074/jbc.271.43.26457; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0	32	26	27	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	1999	18	6					1277	1283		10.1038/sj.onc.1202423	http://dx.doi.org/10.1038/sj.onc.1202423			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FW	10022809				2022-12-17	WOS:000078510900003
J	Fournier, E; Blaikie, P; Rosnet, O; Margolis, B; Birnbaum, D; Borg, JP				Fournier, E; Blaikie, P; Rosnet, O; Margolis, B; Birnbaum, D; Borg, JP			Role of tyrosine residues and protein interaction domains of SHC adaptor in VEGF Receptor 3 signaling	ONCOGENE			English	Article						angiogenesis; FLT4; SHC; signal transduction; tyrosine kinase; VEGF receptor	PHOSPHOTYROSINE BINDING-DOMAIN; ENDOTHELIAL GROWTH-FACTOR; MIDDLE T-ANTIGEN; FLT4 RECEPTOR; PHOSPHORYLATION SITES; TRANSFORMING ACTIVITY; MULTIPLE CYTOKINES; KINASE ACTIVATION; V-SRC; LIGAND	The VEGFR3/FLT4 receptor, which is involved in vasculogenesis and angiogenesis, binds and phosphorylates SHC proteins on tyrosine residues. SHC contains two phosphotyrosine interaction domains: a PTB (Phosphotyrosine Binding) and a SH2 (Src Homology 2) domain. Previous studies have shown that SHC proteins are phosphorylated on Y239/Y240 and Y313 (Y317 in humans) by tyrosine kinases such as the EGF and IL3 receptors, We have investigated which of the SHC tyrosine residues are targeted by the VEGFR3/FLT4 kinase and the role of the SHC PTB and SH2 domains in this process. Our results show that Y239/Y240 and Y313 are simultaneously phosphorylated by the kinase, creating GRB2 binding sites. Mutation of SHC PTB, but not SH2, domain interferes with the SHC phosphorylation by VEGFR3/FLT4, Soft agar assay experiments revealed that the VEGFR3/FLT4 transforming capacity is increased by the mutation of Y239/Y240 to phenylalanines in SHC, suggesting that these two residues mediate an inhibitory signal for cell growth. Mutation of the two phosphorylation sites increases this effect, suggesting that they have a synergistic role.	INSERM, U119, Mol Oncol Lab, F-13258 Marseille, France; Dept Internal Med & Biol Chem, Ann Arbor, MI USA; Howard Hughes Med Inst, Ann Arbor, MI USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Howard Hughes Medical Institute	Birnbaum, D (corresponding author), INSERM, U119, Mol Oncol Lab, F-13258 Marseille, France.		Borg, Jean-Paul/AAX-8096-2020; Rosnet, Olivier/G-3536-2013	Borg, Jean-Paul/0000-0001-8418-3382; Rosnet, Olivier/0000-0002-3020-910X				Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Blaikie PA, 1997, J BIOL CHEM, V272, P20671, DOI 10.1074/jbc.272.33.20671; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/0968-0004(96)10033-5; BORG JP, 1995, ONCOGENE, V10, P973; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DeuterReinhard M, 1997, MOL CELL BIOL, V17, P2559, DOI 10.1128/MCB.17.5.2559; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; Fournier E, 1996, J BIOL CHEM, V271, P12956, DOI 10.1074/jbc.271.22.12956; FOURNIER E, 1995, ONCOGENE, V11, P921; GALLAND F, 1992, GENOMICS, V13, P475, DOI 10.1016/0888-7543(92)90277-Y; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; Gotoh N, 1997, MOL CELL BIOL, V17, P1824, DOI 10.1128/MCB.17.4.1824; Harmer SL, 1997, MOL CELL BIOL, V17, P4087, DOI 10.1128/MCB.17.7.4087; Isakoff SJ, 1996, J BIOL CHEM, V271, P3959; Joukov V, 1996, EMBO J, V15, P290; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KOEPELAINEN E, 1998, CURR OPIN CELL BIOL, V10, P159; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; Okada S, 1997, J BIOL CHEM, V272, P28042, DOI 10.1074/jbc.272.44.28042; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; PAJUSOLA K, 1992, CANCER RES, V52, P5738; PAJUSOLA K, 1994, ONCOGENE, V9, P3545; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; Ricketts WA, 1996, J BIOL CHEM, V271, P26165, DOI 10.1074/jbc.271.42.26165; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Thomas D, 1997, J BIOL CHEM, V272, P22293, DOI 10.1074/jbc.272.35.22293; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; VANDERKUUR J, 1995, J BIOL CHEM, V270, P7587, DOI 10.1074/jbc.270.13.7587; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; Wang JF, 1997, BLOOD, V90, P3507, DOI 10.1182/blood.V90.9.3507; Yajnik V, 1996, J BIOL CHEM, V271, P1813, DOI 10.1074/jbc.271.4.1813; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0; ZHOU S, 1995, J BIOL CHEM, V270, P14863	45	26	29	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					507	514		10.1038/sj.onc.1202315	http://dx.doi.org/10.1038/sj.onc.1202315			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927207				2022-12-17	WOS:000078166500023
J	Sanz, C; Leon, Y; Troppmair, J; Rapp, UR; Varela-Nieto, I				Sanz, C; Leon, Y; Troppmair, J; Rapp, UR; Varela-Nieto, I			Strict regulation of c-Raf kinase levels is required for early organogenesis of the vertebrate inner ear	ONCOGENE			English	Article						insulin-like growth factor-I; mitogen-activated protein kinase; NGF; organotypic otic vesicle cultures; RCAS vectors; retinoic acid	PROGRAMMED CELL-DEATH; GROWTH-FACTOR-I; ACTIVATED PROTEIN-KINASE; MAP KINASE; RETROVIRAL VECTORS; RETINOIC ACID; SIGNAL-TRANSDUCTION; FOS EXPRESSION; CHICK-EMBRYO; GENE	Regulation of organogenesis involves a dynamic balance of the mechanisms regulating cell division, differentiation and death. Here we have investigated the pattern of expression of c-Raf kinase in the inner ear during early developmental stages and the consequences of manipulating c-Raf levels by misexpression of c-raf viral vectors in organotypic cultures of otic vesicle explants. We found that otic vesicles expressed c-Raf and its level remained constant during embryonic days 2 and 3 (E2-E3). c-Raf activity was increased in response to insulin like growth factor-I (IGF-I) and the activation by IGF-I of the c-Raf kinase pathway was a requirement to turn on cell proliferation in the otic vesicle. Overexpression of c-raf in E2.5 explants increased the proliferative response to low serum and ICF-I and blocked differentiation induced by retinoic acid. The increase in c-Raf levels also prevented nerve growth factor (NGF)-dependent induction of programmed cell death. Consistent with these results, the expression of a dominant negative c-Raf mutant potentiated retinoic acid action and decreased the rate of cell proliferation. We conclude that a strict control of c-Raf levels is essential for the co-ordination of the biological processes that operate simultaneously during early inner ear development.	CSIC, Inst Invest Biomed, E-28029 Madrid, Spain; Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, MSZ, D-97078 Wurzburg, Germany	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); University of Wurzburg	Varela-Nieto, I (corresponding author), CSIC, Inst Invest Biomed, Arturo Duperier 4, E-28029 Madrid, Spain.		Varela-Nieto, Isabel/G-5289-2015; Leon, Yolanda/ABG-6797-2020; SANZ, CARMEN/L-7266-2014	Varela-Nieto, Isabel/0000-0003-3077-0500; SANZ, CARMEN/0000-0001-7025-6667; Leon Alvarez, Yolanda/0000-0002-4536-8373; Troppmair, Jakob/0000-0002-0611-3837				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; Bergeron L, 1998, CURR OPIN NEUROBIOL, V8, P55, DOI 10.1016/S0959-4388(98)80008-1; BISSONNETTE JP, 1996, J COMP NEUROL, V174, P1; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; Cacace AM, 1996, ONCOGENE, V13, P2517; CEPKO CL, 1992, CURRENT PROTOCOLS MO; CHAO TSO, 1994, J BIOL CHEM, V269, P7337; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; Federspiel MJ, 1997, METHOD CELL BIOL, V52, P179, DOI 10.1016/S0091-679X(08)60379-9; FEKETE DM, 1993, MOL CELL BIOL, V13, P2604, DOI 10.1128/MCB.13.4.2604; Fekete DM, 1997, DEVELOPMENT, V124, P2451; Fekete DM, 1996, CURR OPIN NEUROBIOL, V6, P533, DOI 10.1016/S0959-4388(96)80061-4; Frago LM, 1998, J CELL SCI, V111, P549; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HEMOND SG, 1991, ANAT EMBRYOL, V184, P1, DOI 10.1007/BF01744256; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; HUNTER E, 1979, METHOD ENZYMOL, P379; JANSEN HW, 1984, NATURE, V307, P281, DOI 10.1038/307281a0; Kiernan AE, 1997, AUDIOL NEURO-OTOL, V2, P12, DOI 10.1159/000259226; KOENEN M, 1988, ONCOGENE, V2, P179; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Lee KH, 1996, HEARING RES, V94, P1, DOI 10.1016/0378-5955(95)00220-0; Lein Y, 1998, J COMP NEUROL, V398, P323, DOI 10.1002/(SICI)1096-9861(19980831)398:3<323::AID-CNE2>3.0.CO;2-1; LEON Y, 1995, DEV BIOL, V167, P75, DOI 10.1006/dbio.1995.1008; LEON Y, 1995, ENDOCRINOLOGY, V136, P3494, DOI 10.1210/en.136.8.3494; MACNICOL AM, 1995, MOL CELL BIOL, V15, P6686; MAGNUSON NS, 1994, SEMIN CANCER BIOL, V5, P247; MARK GE, 1984, SCIENCE, V224, P285, DOI 10.1126/science.6324342; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MINER C, 1988, ROUX ARCH DEV BIOL, V197, P294, DOI 10.1007/BF00380023; MORRISON DK, 1995, MOL REPROD DEV, V42, P507, DOI 10.1002/mrd.1080420420; Naumann U, 1997, Recent Results Cancer Res, V143, P237; Oesterle EC, 1997, J COMP NEUROL, V380, P262, DOI 10.1002/(SICI)1096-9861(19970407)380:2<262::AID-CNE8>3.0.CO;2-1; PELECH SL, 1990, BIOCHEM CELL BIOL, V68, P1297, DOI 10.1139/o90-194; PERRIMON N, 1994, TRENDS BIOCHEM SCI, V19, P509, DOI 10.1016/0968-0004(94)90140-6; PETROPOULOS CJ, 1991, J VIROL, V65, P3728, DOI 10.1128/JVI.65.7.3728-3737.1991; PETROPOULOS CJ, 1989, MOL CELL BIOL, V9, P3785, DOI 10.1128/MCB.9.9.3785; Pritchard C, 1997, NAT GENET, V16, P214, DOI 10.1038/ng0797-214; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; REPRESA J, 1990, DEVELOPMENT, V110, P1081; Schulte TW, 1996, MOL CELL BIOL, V16, P5839; SPAGNOLI A, 1997, CURR OPIN ENDOCRINOL, V4, P1; STEWART L, 1990, J VIROL, V64, P5076, DOI 10.1128/JVI.64.10.5076-5092.1990; STORM SM, 1990, ONCOGENE, V5, P345; Torres M, 1998, MECH DEVELOP, V71, P5, DOI 10.1016/S0925-4773(97)00155-X; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; VONBARTHELD CS, 1991, DEVELOPMENT, V113, P455; Wassarman DA, 1996, GENE DEV, V10, P272, DOI 10.1101/gad.10.3.272; Weil M, 1997, CURR BIOL, V7, P281, DOI 10.1016/S0960-9822(06)00125-4; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293; Woods KA, 1996, NEW ENGL J MED, V335, P1363, DOI 10.1056/NEJM199610313351805; Xu RH, 1996, P NATL ACAD SCI USA, V93, P834, DOI 10.1073/pnas.93.2.834; Zheng JL, 1997, J NEUROSCI, V17, P216, DOI 10.1523/JNEUROSCI.17-01-00216.1997	59	26	28	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	1999	18	2					429	437		10.1038/sj.onc.1202312	http://dx.doi.org/10.1038/sj.onc.1202312			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927199				2022-12-17	WOS:000078166500015
J	Praml, C; Amler, LC; Dihlmann, S; Finke, LH; Schlag, P; Schwab, M				Praml, C; Amler, LC; Dihlmann, S; Finke, LH; Schlag, P; Schwab, M			Secretory Type II Phospholipase A(2) (PLA2G2A) expression status in colorectal carcinoma derived cell lines and in normal colonic mucosa	ONCOGENE			English	Article						secretory phospholipase A(2); PLA2G2A; Mom1; Min; FAP; 1p; colorectal cancer	FAMILIAL ADENOMATOUS POLYPOSIS; MULTIPLE INTESTINAL NEOPLASIA; MAJOR MODIFIER; MOM1 LOCUS; CANCER; GENE; IDENTIFICATION; MUTATION; MOUSE; COLI	There is good evidence now that the secretory, type II phospholipase A(2) (Pla2g2a) gene represents the Mom1 locus, a genetic modifier of tumor resistance in the multiple intestinal neoplasia (Min) mouse. Previously we have mapped the human homolog PLA2G2A to 1p35-36.1 within a region that is the target of frequent deletions in sporadic colorectal tumors. Here we show 64% loss of heterozygosity (LOH) at the PLA2G2A locus in primary tumors. We studied PLA2G2A expression in both colorectal tumor cell lines and normal mucosa. Most of the lines lacked detectable PLA2G2A transcripts by Northern analysis. Large differences in expression were seen among normal mucosa of different patients with sporadic tumors. We analysed the coding region of PLA2G2A in eight colorectal cancer cell lines with hemizygous deletion at 1p35-36/PLA2G2A, in none we did detect a mutation. Biallelic expression of PLA2G2A was observed in a cell line heterozygous for an exon 3 polymorphism, rendering unlikely that imprinting is a pathway participating in the loss of PLA2G2A function. It remains uncertain if PLA2G2A, in particular its apparent lack of expression in tumor cells, might be a factor in human colorectal tumorigenesis.	Deutsch Krebsforschungszentrum, Dept Cytogenet 0825, D-69120 Heidelberg, Germany; Humboldt Univ, Abt Chirurg & Chirurg Onkol, Robert Rossle Klin, Max Delbruck Ctr,Virchow Klinikum, D-13125 Berlin, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; Max Delbruck Center for Molecular Medicine; Humboldt University of Berlin	Schwab, M (corresponding author), Deutsch Krebsforschungszentrum, Dept Cytogenet 0825, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.			Dihlmann, Susanne/0000-0002-3737-7755				BRUDERLEIN S, 1990, GENE CHROMOSOME CANC, V2, P63, DOI 10.1002/gcc.2870020112; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; Dihlmann S, 1997, ONCOL RES, V9, P119; Dobbie Z, 1996, HUM GENET, V98, P386, DOI 10.1007/s004390050226; GLASER KB, 1993, TRENDS PHARMACOL SCI, V14, P92, DOI 10.1016/0165-6147(93)90071-Q; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V117, P217; LEPPERT M, 1990, NEW ENGL J MED, V322, P904, DOI 10.1056/NEJM199003293221306; LUONGO C, 1993, GENOMICS, V15, P3, DOI 10.1006/geno.1993.1002; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; MOSER AR, 1992, J CELL BIOL, V116, P1517, DOI 10.1083/jcb.116.6.1517; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; NEVALAINEN TJ, 1995, LAB INVEST, V72, P201; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; PRAML C, 1995, ONCOGENE, V11, P1357; PRAML C, 1995, CANCER RES, V55, P5504; PRUZANSKI W, 1991, IMMUNOL TODAY, V12, P143, DOI 10.1016/0167-5699(91)90077-7; RIGGINS GJ, 1995, CANCER RES, V55, P5184; Spirio LN, 1996, CANCER RES, V56, P955; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Tomlinson IPM, 1996, J MED GENET, V33, P268, DOI 10.1136/jmg.33.4.268; Tomlinson IPM, 1996, ANN HUM GENET, V60, P369, DOI 10.1111/j.1469-1809.1996.tb00434.x	27	26	26	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 15	1998	17	15					2009	2012		10.1038/sj.onc.1202121	http://dx.doi.org/10.1038/sj.onc.1202121			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	128TW	9788445				2022-12-17	WOS:000076423500015
J	Ichaso, N; Rodriguez, RE; Martin-Zanca, D; Gonzalez-Sarmiento, R				Ichaso, N; Rodriguez, RE; Martin-Zanca, D; Gonzalez-Sarmiento, R			Genomic characterization of the human trkC gene	ONCOGENE			English	Article						trkC gene; intron/exon structure; promoter sequence	NEUROTROPHIN RECEPTOR TRKC; MESSENGER-RNA; MOLECULAR-CLONING; RAT TRKC; EXPRESSION; NEUROBLASTOMAS; AFFERENTS; MUTATIONS; ONCOGENE; FAMILY	The trkC gene encodes the high-affinity receptor for neurotrophin 3 and plays an important role in the regulation of the survival and differentiation of the mammalian nervous system and in heart development. Chromosomal rearrangements of trkC have been recently reported in congenital fibrosarcoma and it has been proposed that abnormal activation of this gene might be involved in tumor development. To facilitate the search for new mutations and rearrangements in the human trkC locus we have partially characterized its genomic organization by restriction mapping and have obtained the complete intron-exon structure. Our results show that human trkC consists of 20 exons, including two that encode the inserts present in the extracellular and tyrosine kinase domains, and another two that encode the carboxyl-terminal tail of the truncated TRKC isoform. Analysis of the 5' flanking region revealed the absence of TATA box, a very high content in C/G compatible with a CpG island and the presence of putative binding sites for the AP1, AP2, GC, ATF, BRN2, AML1 and Nkx2.5 transcription factors.	Univ Salamanca, Dept Med, Unidad Med Mol, Salamanca 37007, Spain; Univ Salamanca, Dept Bioquim & Biol Mol, Salamanca 37007, Spain; Univ Salamanca, CSIC, Inst Microbiol Bioquim, E-37008 Salamanca, Spain	University of Salamanca; University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Funcional y Genomica (IBFG); University of Salamanca	Gonzalez-Sarmiento, R (corresponding author), Univ Salamanca, Dept Med, Unidad Med Mol, Avda Campo Charro S-N, Salamanca 37007, Spain.		Gonzalez-Sarmiento, Rogelio/V-5526-2019	Gonzalez-Sarmiento, Rogelio/0000-0002-2726-6795; Rodriguez Rodriguez, Raquel/0000-0003-1805-3066				AEBI M, 1987, CELL, V50, P237, DOI 10.1016/0092-8674(87)90219-4; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BARKER PA, 1993, J BIOL CHEM, V268, P15150; Chang BB, 1998, J BIOL CHEM, V273, P39, DOI 10.1074/jbc.273.1.39; Donovan MJ, 1996, NAT GENET, V14, P210, DOI 10.1038/ng1096-210; ERNFORS P, 1994, CELL, V77, P503, DOI 10.1016/0092-8674(94)90213-5; Greco A, 1996, ONCOGENE, V13, P2463; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Indo Y, 1996, NAT GENET, V13, P485, DOI 10.1038/ng0896-485; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3795; KLEIN R, 1994, NATURE, V368, P249, DOI 10.1038/368249a0; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; LAMBALLE F, 1993, EMBO J, V12, P3083, DOI 10.1002/j.1460-2075.1993.tb05977.x; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MCGREGOR LM, 1994, GENOMICS, V22, P267, DOI 10.1006/geno.1994.1383; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; Pierotti MA, 1996, GENE CHROMOSOME CANC, V16, P1; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Ryden M, 1996, BRIT J CANCER, V74, P773, DOI 10.1038/bjc.1996.435; SCHNEIDER R, 1991, ONCOGENE, V6, P1807; SEGAL RA, 1994, P NATL ACAD SCI USA, V91, P12867, DOI 10.1073/pnas.91.26.12867; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Sharp PA, 1997, CELL, V91, P875, DOI 10.1016/S0092-8674(00)80479-1; SHELTON DL, 1995, J NEUROSCI, V15, P477, DOI 10.1523/jneurosci.15-01-00477.1995; Tessarollo L, 1997, P NATL ACAD SCI USA, V94, P14776, DOI 10.1073/pnas.94.26.14776; TSOULFAS P, 1993, NEURON, V10, P975, DOI 10.1016/0896-6273(93)90212-A; VALENZUELA DM, 1993, NEURON, V10, P963, DOI 10.1016/0896-6273(93)90211-9; Yamashiro DJ, 1996, ONCOGENE, V12, P37	30	26	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	1998	17	14					1871	1875		10.1038/sj.onc.1202100	http://dx.doi.org/10.1038/sj.onc.1202100			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126PX	9778053				2022-12-17	WOS:000076303300013
J	Takeda, H; Matozaki, T; Fujioka, Y; Takada, T; Noguchi, T; Yamao, T; Tsuda, M; Ochi, F; Fukunaga, K; Narumiya, S; Yamamoto, T; Kasuga, M				Takeda, H; Matozaki, T; Fujioka, Y; Takada, T; Noguchi, T; Yamao, T; Tsuda, M; Ochi, F; Fukunaga, K; Narumiya, S; Yamamoto, T; Kasuga, M			Lysophosphatidic acid-induced association of SHP-2 with SHPS-1: roles of RHO, FAK, and a SRC family kinase	ONCOGENE			English	Article						SHPS-1; SHP-2; LPA; SRC; FAK; tyrosine phosphorylation	PROTEIN-TYROSINE-PHOSPHATASE; FOCAL ADHESION KINASE; SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; BOTULINUM C3 EXOENZYME; ACTIN STRESS FIBERS; SIGNAL-TRANSDUCTION; HOMOLOGY-2 DOMAINS; MAP KINASE; CELL-PROLIFERATION; COUPLED RECEPTORS	SHPS-1 is an similar to 120kDa glycosylated receptor like protein that contains three immunoglobulin-like domains in its extracellular region as well as four potential tyrosine phosphorylation and SRC homology 2 (SH2) domain binding sites in its cytoplasmic region. Lysophosphatidic acid (LPA) stimulated the rapid tyrosine phosphorylation of SHPS-1 and its subsequent association with SHP-2, a protein tyrosine phosphatase containing SH2 domains in Rat-1 fibroblasts. LAP-induced tyrosine phosphorylation of SHPS-1 was inhibited by Clostridium botulinum C3 exoenzyme (which inactivates RHO) but not by pertussis toxin, The protein kinase C activator phorbol ester, 12-O-tetradecanoylphorbol 13-acetate (TPA) also stimulated tyrosine phosphorylation of SHPS-1; however, down-regulation of protein kinase C by prolonged exposure of cells to TPA did not affect LAP-induced tyrosine phosphorylation of SHPS-1. LPA-induced tyrosine phosphorylation of SHPS-1 was markedly reduced in either focal adhesion kinase (FAK)-deficient mouse cells or CHO cells overexpressing the tyrosine kinase CSK. Overexpression of a catalytically inactivate SHP-2 markedly inhibited MAP kinase activation in response to low concentrations of LPA in CHO cells, whereas overexpression of a wild-type SHPS-1 did enhance this effect of LPA, Furthermore, MAP kinase activation in response to a low concentration of LPA was inhibited by botulinum C3 exoenzyme, These results indicate that LPA-induced tyrosine phosphorylation of SHPS-1 and its association with SHP-2 may be mediated by a RHO-dependent pathway that includes FAK and a SRC family kinase, Thus, in addition to its role in receptor tyrosine kinase-mediated MAP kinase activation, the formation of a complex between SHPS-1 and SHP-2 may, in part, play an important role in the activation of MAP kinase in response to low concentrations of LPA.	Kobe Univ, Sch Med, Dept Internal Med 2, Chuo Ku, Kobe, Hyogo 650, Japan; Kyoto Univ, Fac Med, Dept Pharmacol, Sakyo Ku, Kyoto 606, Japan; Univ Tokyo, Inst Med Sci, Dept Oncol, Minato Ku, Tokyo 108, Japan	Kobe University; Kyoto University; University of Tokyo	Matozaki, T (corresponding author), Kobe Univ, Sch Med, Dept Internal Med 2, Chuo Ku, Kusunoki Cho, Kobe, Hyogo 650, Japan.							Adachi M, 1996, CELL, V85, P15; Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; ILLC D, 1995, NATURE, V377, P539; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Kranenburg O, 1997, EMBO J, V16, P3097, DOI 10.1093/emboj/16.11.3097; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; KUMAGAI N, 1995, FEBS LETT, V366, P11, DOI 10.1016/0014-5793(95)00478-R; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MATOZAKI T, 1989, J BIOL CHEM, V264, P14729; Matozaki T, 1996, CELL SIGNAL, V8, P13, DOI 10.1016/0898-6568(95)02015-2; MATOZAKI T, 1994, BIOCHEM BIOPH RES CO, V204, P874, DOI 10.1006/bbrc.1994.2541; MATOZAKI T, 1995, ADV PROTEIN PHOSPHAT, V9, P319; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; Moolenaar Wouter H., 1994, Trends in Cell Biology, V4, P213, DOI 10.1016/0962-8924(94)90144-9; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NARUMIYA S, 1993, CELL SIGNAL, V5, P9, DOI 10.1016/0898-6568(93)90003-5; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Noguchi T, 1996, J BIOL CHEM, V271, P27652, DOI 10.1074/jbc.271.44.27652; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; Ohnishi H, 1996, J BIOL CHEM, V271, P25569, DOI 10.1074/jbc.271.41.25569; OKADA M, 1991, J BIOL CHEM, V266, P24249; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; Schaller Michael D., 1993, Trends in Cell Biology, V3, P258, DOI 10.1016/0962-8924(93)90053-4; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; SCHLAEPFER DD, 1994, NATURE, V372, P786; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; XIAO S, 1994, J BIOL CHEM, V269, P21244; Yamao T, 1997, BIOCHEM BIOPH RES CO, V231, P61, DOI 10.1006/bbrc.1996.6047; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; YANO H, 1993, J BIOL CHEM, V268, P25846; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	54	26	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 11	1998	16	23					3019	3027		10.1038/sj.onc.1201839	http://dx.doi.org/10.1038/sj.onc.1201839			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZT782	9662335				2022-12-17	WOS:000074125300009
J	Evans, MF; Koreth, J; Bakkenist, CJ; Herrington, CS; McGee, JOD				Evans, MF; Koreth, J; Bakkenist, CJ; Herrington, CS; McGee, JOD			Allelic deletion at 11q23.3-q25 is an early event in cervical neoplasia	ONCOGENE			English	Article						human chromosome 11; clonality; HPV; cervix	CHROMOSOME-11 SUPPRESSES TUMORIGENICITY; HUMAN PAPILLOMAVIRUS INFECTION; TERM FOLLOW-UP; SQUAMOUS CARCINOMA; PROGNOSTIC FACTORS; EPITHELIAL-CELLS; UTERINE CERVIX; HPV GENOTYPES; CANCER; HETEROZYGOSITY	Twenty per cent of cervical intraepithelial neoplasias-III (CIN-III) progress to invasive cancer. Human papillomavirus (HPV) infection alone does not determine progression. GIN-III lesions were collected from 161 women. Each tissue was microdissected into a maximum of 32 contiguous units and assayed at multiple microsatellite loci on chromosome 11q, a region frequently deleted in invasive cervical and other cancers. Eight of 108 informative cases (7%) had 11q23.3-q25 deletions; focally intra-lesional in six tone with focal loss of alternate alleles), and pan-lesional in two cases. Hence, 11q deletion can occur early in cervical neoplasia, and possibly predisposes to invasion.	John Radcliffe Hosp, Nuffield Dept Pathol & Bacteriol, Oxford OX3 9DU, England	University of Oxford	McGee, JOD (corresponding author), John Radcliffe Hosp, Nuffield Dept Pathol & Bacteriol, Oxford OX3 9DU, England.		Herrington, C Simon/I-4895-2014; Herrington, C Simon/O-4688-2017	Herrington, C Simon/0000-0001-9177-8165; Herrington, C Simon/0000-0001-9177-8165				ALNAFUSSI AI, 1994, J CLIN PATHOL, V47, P799, DOI 10.1136/jcp.47.9.799; BETHWAITE PB, 1995, BRIT J CANCER, V71, P814, DOI 10.1038/bjc.1995.157; BURGHARDT E, 1983, OBSTET GYNECOL, V62, P117; BURGHARDT E, 1992, LANCET, V340, P1543, DOI 10.1016/0140-6736(92)92793-F; DOWNEY GP, 1994, LANCET, V344, P432, DOI 10.1016/S0140-6736(94)91768-X; FUJINAGA Y, 1991, J GEN VIROL, V72, P1039, DOI 10.1099/0022-1317-72-5-1039; Gabra H, 1996, CANCER RES, V56, P950; GUDMUNDSSON J, 1995, BRIT J CANCER, V72, P696, DOI 10.1038/bjc.1995.396; HAMPTON GM, 1994, P NATL ACAD SCI USA, V91, P6953, DOI 10.1073/pnas.91.15.6953; HINCHLIFFE SA, 1995, BRIT J CANCER, V72, P943, DOI 10.1038/bjc.1995.438; HO GYF, 1995, JNCI-J NATL CANCER I, V87, P1365, DOI 10.1093/jnci/87.18.1365; Horikawa I, 1995, CANCER GENET CYTOGEN, V85, P97, DOI 10.1016/0165-4608(95)00147-6; HUETTNER PC, 1996, LAB INVESTIG S, V74, pA91; HUGHES JR, 1995, NONISOTOPIC METHODS, P145; KENTER GG, 1993, CANCER-AM CANCER SOC, V71, P397, DOI 10.1002/1097-0142(19930115)71:2&lt;397::AID-CNCR2820710221&gt;3.0.CO;2-G; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; KOI M, 1989, MOL CARCINOGEN, V2, P12, DOI 10.1002/mc.2940020103; Larson AA, 1997, CANCER RES, V57, P4171; MCINDOE WA, 1984, OBSTET GYNECOL, V64, P451; Muliokandov MR, 1996, CANCER RES, V56, P197; MUNGER K, 1992, CANCER SURV, V12, P197; NASIELL K, 1983, OBSTET GYNECOL, V61, P609; NASIELL K, 1986, OBSTET GYNECOL, V67, P665, DOI 10.1097/00006250-198605000-00012; OSHIMURA M, 1990, J CELL BIOCHEM, V42, P135, DOI 10.1002/jcb.240420304; Park TW, 1996, J NATL CANCER I, V88, P355, DOI 10.1093/jnci/88.6.355; PECORARO G, 1991, AM J PATHOL, V138, P1; REMMINK AJ, 1995, INT J CANCER, V61, P306, DOI 10.1002/ijc.2910610305; RochaZavaleta L, 1997, BRIT J CANCER, V75, P1144, DOI 10.1038/bjc.1997.197; Romanini C., 1995, Journal of Obstetrics and Gynaecology (Abingdon), V15, P324, DOI 10.3109/01443619509030933; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SCHIFFMAN MH, 1993, JNCI-J NATL CANCER I, V85, P958, DOI 10.1093/jnci/85.12.958; SPRIGGS AI, 1974, CHROMOSOMES CANCER, P423; SREEKANTAIAH C, 1991, CANCER GENET CYTOGEN, V53, P75, DOI 10.1016/0165-4608(91)90116-C; TOMLINSON IPM, 1995, J CLIN PATHOL, V48, P424, DOI 10.1136/jcp.48.5.424; TSUTSUMI K, 1992, AM J PATHOL, V140, P255; VANBOMMEL PFJ, 1993, GYNECOL ONCOL, V48, P333, DOI 10.1006/gyno.1993.1058; WAGGONER SE, 1990, GYNECOL ONCOL, V38, P407, DOI 10.1016/0090-8258(90)90082-V; Xiong Y, 1996, J VIROL, V70, P999, DOI 10.1128/JVI.70.2.999-1008.1996; YAJIMA A, 1979, TOHOKU J EXP MED, V129, P75, DOI 10.1620/tjem.129.75	39	26	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	1998	16	19					2557	2564		10.1038/sj.onc.1202039	http://dx.doi.org/10.1038/sj.onc.1202039			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN694	9627121				2022-12-17	WOS:000073672300013
J	Ravera, MW; Carcamo, J; Brissette, R; Alam-Moghe, A; Dedova, O; Cheng, W; Hsiao, KC; Klebanov, D; Shen, H; Tang, P; Blume, A; Mandecki, W				Ravera, MW; Carcamo, J; Brissette, R; Alam-Moghe, A; Dedova, O; Cheng, W; Hsiao, KC; Klebanov, D; Shen, H; Tang, P; Blume, A; Mandecki, W			Identification of an allosteric binding site on the transcription factor p53 using a phage-displayed peptide library	ONCOGENE			English	Article						antibody; PAb1620; epitope mapping; sequence; structure-function	MONOCLONAL-ANTIBODY; EPITOPE LIBRARY; MURINE P53; WILD-TYPE; ANTIGEN; PROTEIN; DNA; CONFORMATION; MUTATIONS; LIGANDS	Monoclonal antibody FAb1620 recognizes a conformational epitope on the transcription factor p53 and, upon binding, allosterically inhibits p53 binding to DNA, A highly diverse (1.5x10(10) members) phage-displayed library of peptides containing 40 random amino acids was used to identify the PAb1620 binding site on p53, Fanning this library against FAb1620 resulted in three unique peptides which have statistically significant sequence identities with p53 sufficient to identify the binding site as being composed of amino acids 106-113 and 146-156, Based on these results, we propose a mechanism by which PAb1620 can allosterically inhibit p53 binding to DNA through an indirect interaction between the antibody binding site and the L1 loop (amino acids 112-124) of p53, which is a component of the DNA binding region.	DGI BioTechnol, Edison, NJ 08818 USA		Mandecki, W (corresponding author), DGI BioTechnol, 40 Talmadge Rd,POB 424, Edison, NJ 08818 USA.							APPEL JR, 1990, J IMMUNOL, V144, P976; Chen YCJ, 1996, P NATL ACAD SCI USA, V93, P1997, DOI 10.1073/pnas.93.5.1997; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; ELLGAARD L, 1995, J IMMUNOL METHODS, V180, P53, DOI 10.1016/0022-1759(94)00298-B; Grihalde ND, 1995, GENE, V166, P187, DOI 10.1016/0378-1119(95)00658-3; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HALL AR, 1995, ONCOGENE, V10, P561; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; KAY BK, 1993, GENE, V128, P59, DOI 10.1016/0378-1119(93)90153-T; Lane DP, 1996, ONCOGENE, V12, P2461; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MANDECKI W, 1997, DISPLAY TECHNOLOGIES, P231; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1987, ONCOGENE, V1, P453; NIEWOLIK D, 1995, ONCOGENE, V10, P881; PINILLA C, 1993, GENE, V128, P71, DOI 10.1016/0378-1119(93)90155-V; RENSCHLER MF, 1994, P NATL ACAD SCI USA, V91, P3623, DOI 10.1073/pnas.91.9.3623; ROMANO JW, 1989, ONCOGENE, V4, P1483; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	26	26	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	1998	16	15					1993	1999		10.1038/sj.onc.1201717	http://dx.doi.org/10.1038/sj.onc.1201717			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZH166	9591783				2022-12-17	WOS:000073079400011
J	Dimitrijevic, N; Winkler, C; Wellbrock, C; Gomez, A; Duschl, J; Altschmied, J; Schartl, M				Dimitrijevic, N; Winkler, C; Wellbrock, C; Gomez, A; Duschl, J; Altschmied, J; Schartl, M			Activation of the Xmrk proto-oncogene of Xiphophorus by overexpression and mutational alterations	ONCOGENE			English	Article						transgenic medaka; melanoma; receptor tyrosine kinase; Xiphophorus; Xmrk; proto-oncogene	RECEPTOR TYROSINE KINASE; MESSENGER-RNA; MELANOMA; GENE; EXPRESSION; DNA; PROMOTER; EMBRYOS; LIGAND; FISH	Xmrk is a receptor tyrosine kinase closely related to the human EGF receptor, In the teleost fish Xiphophorus two versions of the Xmrk gene exist, an oncogene (ONC) and a proto-oncogene (INV), While ONC-Xmrk is the melanoma-inducing gene, INV-Xmrk appears not to be involved in transformation of pigment cells, To elucidate the mechanism that converts the proto-oncogene into a transforming oncogene a comparative analysis of the structure, expression and function of both versions of the gene was performed, In contrast to ONC-Xmrk which is expressed at high levels in melanoma cells, the protooncogene INV-Xmrk is ubiquitously expressed at very low levels indicating overexpression as one possible reason for tumorigenicity by ONC-Xmrk. As sequence comparison of the proto-oncogene and the oncogene revealed a number of amino acid changes, a possible effect of these mutations on the activation of the ONC-Xmrk receptor was determined, A constitutive activation of the oncogenic receptor was found and ectopic expression of INV-Xmrk after microinjection into medakafish embryos did not lead to the high tumour rate in transgenic fish as observed for the oncogene. Our data therefore suggest that overexpression of the receptor alone is not sufficient for melanoma induction, but that in addition activating mutations in ONC-Xmrk are responsible for its full tumorigenic potential.	Univ Wurzburg, Bioctr, Theodor Boveri Inst Biosci, D-97074 Wurzburg, Germany	University of Wurzburg	Schartl, M (corresponding author), Univ Wurzburg, Bioctr, Theodor Boveri Inst Biosci, D-97074 Wurzburg, Germany.		Winkler, Christoph/G-4822-2012; Gómez, Ana/K-6998-2014	Gómez, Ana/0000-0003-4714-8064; Winkler, Christoph/0000-0003-4688-6241; Wellbrock, Claudia/0000-0002-3825-6381; Schartl, Manfred/0000-0001-9882-5948				ADAM D, 1993, SCIENCE, V259, P816, DOI 10.1126/science.8430335; ADAM D, 1991, ONCOGENE, V6, P73; AHUJA MR, 1976, PROG EXP TUMOR RES, V20, P380; ANDERS F, 1991, PIGM CELL RES, V3, P7; AROIAN RV, 1994, EMBO J, V13, P360, DOI 10.1002/j.1460-2075.1994.tb06269.x; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; CALLAGHAN T, 1993, ONCOGENE, V8, P2939; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENDLY BM, 1990, CANCER RES, V50, P1550; Fornzler D, 1996, GENOME RES, V6, P102, DOI 10.1101/gr.6.2.102; FRIEND SH, 1993, SCIENCE, V259, P774, DOI 10.1126/science.8430329; HAUPTMANN G, 1994, TRENDS GENET, V10, P266, DOI 10.1016/0168-9525(90)90008-T; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; Kallman K.D., 1975, P81; Katz WS, 1996, MOL CELL BIOL, V16, P529; KUHN C, 1979, IN VITRO CELL DEV B, V15, P537, DOI 10.1007/BF02618156; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; LEMEUR M, 1981, CELL, V23, P561, DOI 10.1016/0092-8674(81)90152-5; MALITSCHEK B, 1994, J BIOL CHEM, V269, P10423; MAUELER W, 1988, ONCOGENE, V2, P421; MAUELER W, 1993, INT J CANCER, V55, P288, DOI 10.1002/ijc.2910550220; MICHIELS F, 1989, EMBO J, V8, P1559, DOI 10.1002/j.1460-2075.1989.tb03540.x; Nei M., 1987, MOL EVOLUTIONARY GEN; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHARTL M, 1995, EVOLUTION, V49, P827, DOI 10.1111/j.1558-5646.1995.tb02319.x; WAKAMATSU Y, 1981, CANCER RES, V41, P679; WELLBROCK C, 1995, ONCOGENE, V10, P2135; WINKLER C, 1994, ONCOGENE, V9, P1517; WINKLER C, 1991, MOL GEN GENET, V226, P129, DOI 10.1007/BF00273596; WINKLER C, 1997, TRANSGENIC ANIMALS, P387; WITTBRODT J, 1992, EMBO J, V11, P4239, DOI 10.1002/j.1460-2075.1992.tb05518.x; WITTBRODT J, 1989, NATURE, V341, P415, DOI 10.1038/341415a0; WITTBRODT J, 1994, GENE DEV, V8, P1448, DOI 10.1101/gad.8.12.1448; WOOLCOCK BW, 1994, CELL GROWTH DIFFER, V5, P575; YAMAMOTO TO, 1961, INT REV CYTOL, V12, P361	36	26	27	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 2	1998	16	13					1681	1690		10.1038/sj.onc.1201693	http://dx.doi.org/10.1038/sj.onc.1201693			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZE573	9582016				2022-12-17	WOS:000072807600006
J	Xiao, G; White, D; Bargonetti, J				Xiao, G; White, D; Bargonetti, J			p53 binds to a constitutively nucleosome free region of the mdm2 gene	ONCOGENE			English	Article						p53; mdm2; nucleosome; chromatin; transcription	WILD-TYPE P53; DNA-BINDING; MUTANT P53; TRANSCRIPTIONAL ACTIVATION; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; HISTONE DEACETYLASE; PROTEINS BIND; T-ANTIGEN; CHROMATIN	The mdm2 oncogene is a p53 responsive gene which contains both a p53 independent and a p53 dependent promoter (P1 and P2 respectively), We have utilized ligation mediated PCR genomic footprinting in order to investigate the intra-nuclear binding of p53 to the mdm2 P2 promoter. The DNase I protection pattern in nuclei from murine cells lacking p53 has been compared to the protection pattern in cells containing a temperature sensitive p53-Val135. At 32 degrees C p53-Val135 assumes a wild-type conformation while at 37 degrees C this p53 is conformationally mutant. We observed clear wild-type p53 dependent protection of the putative p53 response elements (REs) as well as protection of the adjacent TATA box. Interestingly the protection pattern observed with purified wild-type p53 on naked DNA showed less nucleotide sequence protection than the protection observed to be p53 dependent in nuclei. Constitutive DNase I hypersensitivity at both the mdm2 P1 and P2 promoters was detected by indirect Southern blot analysis. DNase I hypersensitivity reflects altered chromatin conformations resulting, most likely, from the absence of nucleosomes. Taken together our findings suggest that the mdm2 P2 promoter is maintained in a nucleosome free state which is pre-primed for transcriptional activation by p53.	CUNY, Inst Biomolec Struct & Funct, New York, NY 10021 USA; CUNY Hunter Coll, Dept Biol Sci, New York, NY 10021 USA; CUNY, Grad Sch, New York, NY 10021 USA	City University of New York (CUNY) System; City University of New York (CUNY) System; Hunter College (CUNY); City University of New York (CUNY) System	Bargonetti, J (corresponding author), CUNY, Inst Biomolec Struct & Funct, 695 Pk Ave, New York, NY 10021 USA.			Bargonetti, Jill/0000-0003-2692-0991	NCRR NIH HHS [RR-03037] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BROWN DR, 1993, MOL CELL BIOL, V13, P6849, DOI 10.1128/MCB.13.11.6849; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Chen JD, 1996, MOL CELL BIOL, V16, P2445; CHEN JY, 1993, ONCOGENE, V8, P2159; CHEN XB, 1995, CANCER RES, V55, P4257; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; Chin PL, 1997, ONCOGENE, V15, P87, DOI 10.1038/sj.onc.1201161; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HE J, 1994, GENE CHROMOSOME CANC, V11, P91, DOI 10.1002/gcc.2870110205; Hecker D, 1996, ONCOGENE, V12, P953; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LANDERS JE, 1994, ONCOGENE, V9, P2745; LEACH FS, 1993, CANCER RES, V53, P2231; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LUNA RMD, 1995, NATURE, V378, P203; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OREILLY DR, 1988, J VIROL, V62, P3109, DOI 10.1128/JVI.62.9.3109-3119.1988; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; REFENBERGER G, 1993, CANCER RES, V53, P2736; SHEIKH MS, 1993, CANCER RES, V53, P3226; STENGER JE, 1994, EMBO J, V13, P6011, DOI 10.1002/j.1460-2075.1994.tb06947.x; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG Y, 1995, MOL CELL BIOL, V15, P2157; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WEINTRAUB H, 1976, SCIENCE, V193, P848, DOI 10.1126/science.948749; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584	72	26	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 5	1998	16	9					1171	1181		10.1038/sj.onc.1201631	http://dx.doi.org/10.1038/sj.onc.1201631			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA170	9528859				2022-12-17	WOS:000072336000008
J	Levresse, V; Moritz, S; Renier, A; Kheuang, L; Galateau-Salle, F; Mege, JP; Piedbois, P; Salmons, B; Guenzburg, W; Jaurand, MC				Levresse, V; Moritz, S; Renier, A; Kheuang, L; Galateau-Salle, F; Mege, JP; Piedbois, P; Salmons, B; Guenzburg, W; Jaurand, MC			Effect of simian virus large T antigen expression on cell cycle control and apoptosis in rat pleural mesothelial cells exposed to DNA damaging agents	ONCOGENE			English	Article						apoptosis; cell cycle; TSV40; p53; asbestos; gamma radiations	MALIGNANT MESOTHELIOMA; ASBESTOS FIBERS; CROCIDOLITE ASBESTOS; IONIZING-RADIATION; INDUCE APOPTOSIS; G(2) ARREST; P53 PROTEIN; FIBROBLASTS; CHECKPOINT; MECHANISMS	Cell cycle progression and apoptosis are controlled by regulatory proteins, including p53, of which functional alterations are linked to carcinogenesis. Recently, malignant mesothelioma (MM), a primary tumour related to asbestos exposure, alternatively to post therapeutic radiations, has proven to be an important problem in oncogenesis. The p53 protein does not seem mutated or deleted in MM but a possible inactivation by binding to other proteins [mdm2; SV40 large T antigen (Tag)] has been suggested, The present work investigated cell cycle regulation in normal rat pleural mesothelial cells (RPMC) and in RPMC expressing Tag (RPMC-TSV40), under exposure to asbestos and radiations, In RPMC, these agents induced activation of cell cycle checkpoints located at G1/S and G2/M and/or mitosis but a lack of control at G1/S was found in RPMC-TSV40, A loss of G2/M control may account for the formation of micronuclei observed after exposure of RPMC-TSV40 to radiations, In RPMC-TSV40 the enhancement of abnormal mitoses and apoptosis after asbesto exposure, in comparison with RPMC, suggests a loss of mitotic control and a p53-independent mechanism of apoptosis, Thus Tag expression in mesothelial cells might have both adverse and beneficial effects by impairing the control of DNA integrity and enhancing apoptosis respectively.	Fac Med, INSERM, U139, F-94010 Creteil, France; CHRU, Dept Pathol, F-14033 Caen, France; Hop Henri Mondor, Unite Radiophys & Radioprotect, F-94010 Creteil, France; Bavarian Nord Res Inst, D-85758 Oberschleissheim, Germany; Univ Vet Sci, Inst Virol, A-1210 Vienna, Austria	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHU de Caen NORMANDIE; Universite de Caen Normandie; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Bavarian Nordic; University of Veterinary Medicine Vienna	Jaurand, MC (corresponding author), Fac Med, INSERM, U139, IM3,8 Rue Gen Sarrail, F-94010 Creteil, France.		Salle, Francoise BJ Galateau/J-1530-2015; Salmons, Brian/E-3001-2010; JAURAND, MARIE-CLAUDE/S-3538-2017	Salle, Francoise BJ Galateau/0000-0003-3642-0165; Salmons, Brian/0000-0002-9490-9447; JAURAND, MARIE-CLAUDE/0000-0002-0915-6728				Abend M, 1996, CELL PROLIFERAT, V29, P101; AKASHI M, 1995, J BIOL CHEM, V270, P19181, DOI 10.1074/jbc.270.32.19181; ALLDAY MJ, 1995, EMBO J, V14, P4994, DOI 10.1002/j.1460-2075.1995.tb00182.x; BAE IS, 1995, CANCER RES, V55, P2387; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BASES R, 1994, INT J RADIAT BIOL, V65, P591, DOI 10.1080/09553009414550681; BeruBe KA, 1996, AM J RESP CELL MOL, V15, P141, DOI 10.1165/ajrcmb.15.1.8679218; BOYLAN AM, 1992, J CLIN INVEST, V89, P1257, DOI 10.1172/JCI115710; Broaddus VC, 1996, J CLIN INVEST, V98, P2050, DOI 10.1172/JCI119010; BROWN DR, 1993, MOL CELL BIOL, V13, P6849, DOI 10.1128/MCB.13.11.6849; CARBONE M, 1994, ONCOGENE, V9, P1781; Carbone M, 1997, NAT MED, V3, P908, DOI 10.1038/nm0897-908; Cavazza A, 1996, CANCER, V77, P1379, DOI 10.1002/(SICI)1097-0142(19960401)77:7<1379::AID-CNCR24>3.3.CO;2-5; Chang THT, 1997, ONCOGENE, V14, P2383, DOI 10.1038/sj.onc.1201196; Churg A, 1996, AM J RESP CRIT CARE, V154, P1124, DOI 10.1164/ajrccm.154.4.8887617; Cristaudo A., 1995, Journal of Environmental Pathology Toxicology and Oncology, V14, P29; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DeLuca A, 1997, NAT MED, V3, P913, DOI 10.1038/nm0897-913; DEPPERT W, 1989, ONCOGENE, V4, P1103; DOLBEARE F, 1983, P NATL ACAD SCI-BIOL, V80, P5573, DOI 10.1073/pnas.80.18.5573; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Goi K, 1997, CANCER RES, V57, P1895; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HAWN MT, 1995, CANCER RES, V55, P3721; HESTERBERG TW, 1985, CARCINOGENESIS, V6, P473, DOI 10.1093/carcin/6.3.473; INOUE H, 1992, VIROLOGY, V187, P343, DOI 10.1016/0042-6822(92)90325-J; JAT PS, 1986, J VIROL, V59, P746, DOI 10.1128/JVI.59.3.746-750.1986; JAURAND MC, 1981, IN VITRO CELL DEV B, V17, P98; Jensen CG, 1996, CARCINOGENESIS, V17, P2013, DOI 10.1093/carcin/17.9.2013; JIANG D, 1993, ONCOGENE, V8, P2805; KAN ZY, 1995, MOL CELL BIOL, V15, P5849; KE Y, 1989, AM J PATHOL, V134, P979; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1985, PROC R SOC SER B-BIO, V226, P25, DOI 10.1098/rspb.1985.0077; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lenahan MK, 1996, ONCOGENE, V12, P1847; LEVRESSE V, IN PRESS AM J RESP C; LIU VF, 1995, STEM CELLS, V13, P117; MacFarlane M, 1996, MOL PHARMACOL, V50, P900; MAITY A, 1994, RADIOTHER ONCOL, V31, P1, DOI 10.1016/0167-8140(94)90408-1; Maizel JV, 1971, METHOD VIROL, V5, P179; METCALF RA, 1992, CANCER RES, V52, P2610; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MIYASHITA T, 1994, CANCER RES, V54, P3131; Mor O, 1997, AM J RESP CELL MOL, V16, P9, DOI 10.1165/ajrcmb.16.1.8998073; PATEROUR MJ, 1985, CARCINOGENESIS, V6, P523, DOI 10.1093/carcin/6.4.523; Pellegata NS, 1996, P NATL ACAD SCI USA, V93, P15209, DOI 10.1073/pnas.93.26.15209; Pepper C, 1996, THORAX, V51, P1074, DOI 10.1136/thx.51.11.1074; RAMAEL M, 1992, J PATHOL, V168, P371, DOI 10.1002/path.1711680406; Segers K, 1995, VIRCHOWS ARCH, V427, P431, DOI 10.1007/BF00199393; STEWART N, 1995, ONCOGENE, V10, P109; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Strickler HD, 1996, CANCER EPIDEM BIOMAR, V5, P473; TAUCHI H, 1994, INT J RADIAT BIOL, V65, P449, DOI 10.1080/09553009414550521; WAGNER JC, 1986, THORAX, V41, P161, DOI 10.1136/thx.41.3.161; WALKER C, 1992, AM J IND MED, V21, P253, DOI 10.1002/ajim.4700210214; WALKER DH, 1995, CELL GROWTH DIFFER, V6, P1053; WANG NS, 1987, AM J PATHOL, V126, P343; WOODS C, 1994, ONCOGENE, V9, P2943; ZHENG DQ, 1994, ONCOGENE, V9, P3345	60	26	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	1998	16	8					1041	1053		10.1038/sj.onc.1201627	http://dx.doi.org/10.1038/sj.onc.1201627			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA169	9519878				2022-12-17	WOS:000072335900010
J	Wang, XY; Smith, DI; Frederick, L; James, CD				Wang, XY; Smith, DI; Frederick, L; James, CD			Analysis of EGF receptor amplicons reveals amplification of multiple expressed sequences	ONCOGENE			English	Article						EST; amplicon; EGFR; glioblastoma	EPIDERMAL GROWTH-FACTOR; HUMAN-BREAST-CANCER; DEAD BOX GENE; INDEPENDENT AMPLIFICATION; AMPLIFIED REGIONS; MALIGNANT GLIOMAS; CARCINOMA-CELLS; PROTO-ONCOGENE; N-MYC; COAMPLIFICATION	In this study we have examined the epidermal growth factor receptor gene (EGFR) region for the amplification of novel expressed sequences in 28 glioblastoma tumors and two cell lines with EGFR gene amplification. Southern analysis with expressed sequence tag (EST) probes revealed instances of amplification for 11 of 13 loci investigated. Northern blot analysis with the same probes indicated that three ESTs identified transcripts that are over-expressed in cell lines having corresponding sequence amplification. The determination of increased dosage and transcript levels for multiple expressed sequences raises the possibility that there are genes in addition to EGFR whose elevated expression contribute to the biologic behavior of tumors with amplification of this region.	Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Expt Pathol, Rochester, MN 55905 USA	Mayo Clinic	James, CD (corresponding author), Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Expt Pathol, Rochester, MN 55905 USA.		James, Charles D/E-2721-2012	James, Charles D/0000-0002-1027-203X	NATIONAL CANCER INSTITUTE [R01CA055728, R01CA048031] Funding Source: NIH RePORTER; NCI NIH HHS [CA-55728, CA-48031] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berner JM, 1996, GENE CHROMOSOME CANC, V17, P254, DOI 10.1002/(SICI)1098-2264(199612)17:4<254::AID-GCC7>3.0.CO;2-2; Bieche I, 1996, CANCER RES, V56, P3886; Bringuier PP, 1996, ONCOGENE, V12, P1747; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; ELKAHLOUN AG, 1996, CANCER, V17, P205; FILMUS J, 1985, BIOCHEM BIOPH RES CO, V128, P898, DOI 10.1016/0006-291X(85)90131-7; George RE, 1996, ONCOGENE, V12, P1583; HALEY J, 1987, ONCOGENE RES, V1, P375; JAMES CD, 1988, CANCER RES, V48, P5546; KAWASAKI K, 1988, JPN J CANCER RES, V79, P1174, DOI 10.1111/j.1349-7006.1988.tb01542.x; MANOHAR CF, 1995, GENE CHROMOSOME CANC, V14, P196, DOI 10.1002/gcc.2870140307; MERLINO GT, 1984, SCIENCE, V224, P417, DOI 10.1126/science.6200934; RAMSAY G, 1986, MOL CELL BIOL, V6, P4450, DOI 10.1128/MCB.6.12.4450; Reifenberger G, 1996, CANCER RES, V56, P5141; Reiter JL, 1996, GENOMICS, V32, P97, DOI 10.1006/geno.1996.0081; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; TANIGAMI A, 1992, GENOMICS, V13, P21, DOI 10.1016/0888-7543(92)90196-Y; Tanner MM, 1996, CANCER RES, V56, P3441; TOMASETTO C, 1995, GENOMICS, V28, P367, DOI 10.1006/geno.1995.1163; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899	23	26	26	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	1998	16	2					191	195		10.1038/sj.onc.1201476	http://dx.doi.org/10.1038/sj.onc.1201476			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ827	9464536				2022-12-17	WOS:000071427100005
J	Bartunek, P; Karafiat, V; Dvorakova, M; Zahorova, V; Mandikova, S; Zenke, M; Dvorak, M				Bartunek, P; Karafiat, V; Dvorakova, M; Zahorova, V; Mandikova, S; Zenke, M; Dvorak, M			The Myb leucine zipper is essential for leukemogenicity of the v-Myb protein	ONCOGENE			English	Article						v-myb; leukemia; leucine zipper; protein-protein interaction	MYELOMONOCYTIC GROWTH-FACTOR; C-MYB; TRANSCRIPTIONAL ACTIVATION; MYELOID CELLS; CELLULAR PROGENITOR; MAMMALIAN-CELLS; DNA-BINDING; NF-M; TRANSFORMATION; ONCOGENE	The AMV v-Myb oncoprotein causes oncogenic transformation of myelomonocytic cells in vivo and in vitro, Its transforming capacity is strictly dependent upon the N-terminal DNA binding domain, the central transactivation region, and on the C-terminal domain containing a putative leucine zipper motif, Here we show that the v-Myb(L3.4A) mutant, in which Leu(325) and Leu(332) of the leucine zipper have been replaced by alanines, failed to induce leukemia in virus infected chicken, This demonstrates that the leucine zipper domain is indispensable for v-myb induced leukemogenesis in vivo, v-Myb(L3,3A) was, however, still able to transform myelomonocytic cells from chicken bone marrow in vitro. Yet, while v-myb(L3,4) transformed cells were impaired in growth at 37 degrees C, they failed to grow at 42 degrees C, the physiological body temperature of avian species, This might explain the loss of v-Myb(L3,4A) leukemogenic potential in vivo, We also demonstrate that the v-Myb leucine zipper domain interacts in vitro with two host cell proteins, p26 and p28, This interaction is compromised in v-Myb(L3,4A) indicating that binding of v-Myb to p26 and p28 might be important for the leukemogenic potential of v-Myb.	ACAD SCI CZECH REPUBL,INST MOL GENET,CR-16637 PRAGUE 6,CZECH REPUBLIC; MAX DELBRUCK CTR MOL MED,D-13125 BERLIN,GERMANY	Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; Helmholtz Association; Max Delbruck Center for Molecular Medicine			Dvorak, Michal/G-5861-2014; Bartunek, Petr/J-3897-2014; Dvořák, Michal/I-9939-2014; Škopová, Václava/F-4992-2017	Bartunek, Petr/0000-0002-6202-7650; Škopová, Václava/0000-0002-6560-4177				Bartunek P, 1996, CYTOKINE, V8, P14, DOI 10.1006/cyto.1996.0003; BEUG H, 1995, METHOD ENZYMOL, V254, P41; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN RH, 1993, MOL CELL BIOL, V13, P4423, DOI 10.1128/MCB.13.7.4423; CORBEL C, 1992, EXP CELL RES, V203, P91, DOI 10.1016/0014-4827(92)90043-8; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; EBNETH A, 1994, FEBS LETT, V337, P265, DOI 10.1016/0014-5793(94)80205-X; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; FAVIER D, 1994, ONCOGENE, V9, P305; FEY EG, 1986, J CELL BIOL, V102, P1654, DOI 10.1083/jcb.102.5.1654; FOOS G, 1993, ONCOGENE, V8, P1775; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; Fu SL, 1996, J VIROL, V70, P5600, DOI 10.1128/JVI.70.8.5600-5610.1996; Gonda TJ, 1996, CURR TOP MICROBIOL, V211, P99; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; HLOZANEK I, 1968, Veterinarni Medicina (Prague), V13, P489; HURST HC, 1995, PROTEIN PROFILE, V2, P105; IBANEZ CE, 1988, J VIROL, V62, P1981, DOI 10.1128/JVI.62.6.1981-1988.1988; INTRONA M, 1994, SEMIN CANCER BIOL, V5, P113; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KANEIISHII C, 1994, J BIOL CHEM, V269, P15768; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KASPERS B, 1993, VET IMMUNOL IMMUNOP, V36, P333, DOI 10.1016/0165-2427(93)90029-4; KAUFMAN J, 1990, J IMMUNOL, V144, P2258; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KORNFELD S, 1983, EXP CELL RES, V143, P383, DOI 10.1016/0014-4827(83)90065-4; LEUTZ A, 1989, EMBO J, V8, P175, DOI 10.1002/j.1460-2075.1989.tb03362.x; LEUTZ A, 1984, EMBO J, V3, P3191, DOI 10.1002/j.1460-2075.1984.tb02278.x; Lipsick JS, 1996, ONCOGENE, V13, P223; LIPSICK JS, 1986, J VIROL, V59, P267, DOI 10.1128/JVI.59.2.267-275.1986; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; Moscovici C, 1975, Curr Top Microbiol Immunol, V71, P79; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOMURA T, 1993, J BIOL CHEM, V268, P21914; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; OLSON WC, 1994, CELL IMMUNOL, V154, P328, DOI 10.1006/cimm.1994.1081; PECENKA V, 1988, FOLIA BIOL-PRAGUE, V34, P129; STERNECK E, 1992, MOL CELL BIOL, V12, P1728, DOI 10.1128/MCB.12.4.1728; STERNECK E, 1992, EMBO J, V11, P115, DOI 10.1002/j.1460-2075.1992.tb05034.x; Vainio O, 1996, J CELL BIOL, V135, P1655, DOI 10.1083/jcb.135.6.1655; VRANOVSKY K, 1992, GENE, V117, P233; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	45	26	26	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 11	1997	15	24					2939	2949		10.1038/sj.onc.1201457	http://dx.doi.org/10.1038/sj.onc.1201457			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK377	9416837				2022-12-17	WOS:A1997YK37700006
J	Welch, H; Maridonneau-Parini I				Welch, H; Maridonneau-Parini I			Lyn and Fgr are activated in distinct membrane fractions of human granulocytic cells	ONCOGENE			English	Article						Fgr; Lyn; Src; Hck; neutrophil; NB4 cells	PROTEIN-TYROSINE KINASE; ADHERENT HUMAN NEUTROPHILS; FC-GAMMA-RII; FUNCTIONAL ASSOCIATION; PLASMA-MEMBRANE; SRC; FAMILY; P58(C-FGR); RECEPTOR; HCK	We have previously shown that the src-family protein-tyrosine kinase Hck is localized on the azurophil granules of human granulocytes, translocates towards the phagosomes during phagocytosis of opsonized zymosan and is activated during this process. Hck is also activated upon cell stimulation with the calcium ionophore A23187, but not with PMA or the chemotactic peptide fMLP. Here, we investigated whether the src-family kinases Lyn and Fgr are activated under the same conditions. Upon stimulation of human neutrophils or retinoic acid-differentiated NB4 cells with fMLP, only Lyn is activated. Cell stimulation with opsonized zymosan or A23187 leads to simultaneous activation of Lyn and Fgr. In cell fractionation experiments with differentiated NB4 cells, kinases show a similar the subcellular localization: Both co-fractionate quantitatively with plasma-membrane marker in two fractions that sediment at 11000g and 200000g. Lyn is selectively activated in the 200 000 g fraction, whereas Fgr is activated in the 11 000 g fraction and distinct sets of tyrosine phosphorylated proteins are found in these fractions. The results suggest that these kinases exert their functional roles in distinct cellular compartments in human granulocytic cells.	CNRS, INST PHARMACOL & BIOL STRUCT,UPR 9062, F-31077 TOULOUSE, FRANCE	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)			Maridonneau-Parini, Isabelle/F-1985-2011	Welch, Heidi/0000-0001-7865-7000; Maridonneau-Parini, Isabelle/0000-0003-0189-0976				BERTON G, 1994, J CELL BIOL, V126, P1111, DOI 10.1083/jcb.126.4.1111; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; Brumelll JH, 1996, J BIOL CHEM, V271, P1455, DOI 10.1074/jbc.271.3.1455; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; ERICKSON HP, 1993, J CELL BIOL, V120, P1079, DOI 10.1083/jcb.120.5.1079; GAUDRY M, 1995, BLOOD, V86, P3567, DOI 10.1182/blood.V86.9.3567.bloodjournal8693567; GHAZIZADEH S, 1994, J BIOL CHEM, V269, P8878; GUTKIND JS, 1989, P NATL ACAD SCI USA, V86, P8783, DOI 10.1073/pnas.86.22.8783; HAMADA F, 1993, P NATL ACAD SCI USA, V90, P6305, DOI 10.1073/pnas.90.13.6305; Hardie G, 1995, PROTEIN KINASE FACTS, V2; Katagiri K, 1996, J BIOL CHEM, V271, P11557, DOI 10.1074/jbc.271.19.11557; KHANNAGUPTA A, 1994, BLOOD, V84, P294; KHARBANDA S, 1994, J BIOL CHEM, V269, P20739; KRYPTA RM, 1988, EMBO J, V7, P3837; LANOTTE M, 1991, BLOOD, V77, P1080; LOWELL CA, 1994, GENE DEV, V8, P387, DOI 10.1101/gad.8.4.387; Lowell CA, 1996, J CELL BIOL, V133, P895, DOI 10.1083/jcb.133.4.895; MARIDONNEAUPARINI I, 1992, J BIOL CHEM, V267, P6396; MOHN H, 1995, BIOCHEM J, V309, P657; MORIO T, 1994, EUR J IMMUNOL, V24, P651, DOI 10.1002/eji.1830240325; NOTARIO V, 1989, J CELL BIOL, V109, P3129, DOI 10.1083/jcb.109.6.3129; Parolini I, 1996, BLOOD, V87, P3783, DOI 10.1182/blood.V87.9.3783.bloodjournal8793783; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; STEFANOVA I, 1993, J BIOL CHEM, V268, P20725; TESTA U, 1994, CANCER RES, V54, P4508; VARMUS HE, 1994, BLOOD, V83, P5; WANG AVT, 1994, J EXP MED, V180, P1165, DOI 10.1084/jem.180.3.1165; Welch H, 1997, J BIOL CHEM, V272, P102; Welch Heidi, 1996, Methods (Orlando), V9, P607, DOI 10.1006/meth.1996.0067; YAN SR, 1995, J LEUKOCYTE BIOL, V58, P595, DOI 10.1002/jlb.58.5.595; Yan SR, 1995, J INFLAMM, V45, P297; Yan SR, 1996, J BIOL CHEM, V271, P23464, DOI 10.1074/jbc.271.38.23464; ZHOU MJ, 1995, J BIOL CHEM, V270, P13553, DOI 10.1074/jbc.270.22.13553	33	26	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 23	1997	15	17					2021	2029		10.1038/sj.onc.1201356	http://dx.doi.org/10.1038/sj.onc.1201356			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC284	9366519				2022-12-17	WOS:A1997YC28400003
J	Yasuhara, N; Sahara, S; Kamada, S; Eguchi, Y; Tsujimoto, Y				Yasuhara, N; Sahara, S; Kamada, S; Eguchi, Y; Tsujimoto, Y			Evidence against a functional site for Bcl-2 downstream of caspase cascade in preventing apoptosis	ONCOGENE			English	Article						apoptosis; bcl-2; bcl-x; caspase; ICE; CPP32; Fas; signal transduction	FAS-MEDIATED APOPTOSIS; PROGRAMMED CELL-DEATH; ENDOPLASMIC-RETICULUM; MITOCHONDRIAL-MEMBRANES; CYSTEINE PROTEASE; ACTIVATION; EXPRESSION; NUCLEAR; LOCALIZATION; ONCOPROTEIN	Apoptotic cell death is driven by ICE family proteases (caspases) and negatively regulated by Bcl-2 family proteins. Although it has been shown that Bcl-2 exerts anti-apoptotic activity by blocking a step(s) leading to the activation of caspases, a role for Bcl-2 and Bcl-x(L) downstream of the caspase cascade has remained unclear. Here, we show that purified active caspase-3 (CPP32/Yama/apopain) and caspase-1 (ICE) induces apoptosis when microinjected into the cytoplasm of cells, confirming our recent observations, and that the apoptosis is not at all prevented by Bcl-2 and Bcl-x(L), which are overexpressed more than sufficiently to prevent Fas-mediated and overexpressed procaspase-1-mediated apoptosis. Thus, Bcl-2 and Bcl-x(L) do not act downstream of the caspase cascade.	OSAKA UNIV,SCH MED,BIOMED RES CTR,DEPT MED GENET,SUITA,OSAKA 565,JAPAN	Osaka University								AKAO Y, 1994, CANCER RES, V54, P2468; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BAFFY G, 1993, J BIOL CHEM, V268, P6511; Boulakia CA, 1996, ONCOGENE, V12, P529; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; CLEM RJ, 1994, APOPTOSIS, V2, P89; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; Hasegawa J, 1996, CANCER RES, V56, P1713; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; Kamada S, 1997, CELL DEATH DIFFER, V4, P473, DOI 10.1038/sj.cdd.4400268; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; Marin MC, 1996, ONCOGENE, V12, P2259; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MATSUOKA Y, 1994, J CELL SCI, V107, P693; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PEZZELLA F, 1990, AM J PATHOL, V137, P225; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; Shimizu S, 1996, ONCOGENE, V13, P21; Shimizu S, 1996, ONCOGENE, V12, P2251; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; SUSIN SA, 1996, J EXP MED, V184, P1; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YAMAIZUMI M, 1978, CELL, V15, P245, DOI 10.1016/0092-8674(78)90099-5; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yasuhara N, 1997, GENES CELLS, V2, P55, DOI 10.1046/j.1365-2443.1997.1010302.x; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661	41	26	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 16	1997	15	16					1921	1928		10.1038/sj.onc.1201370	http://dx.doi.org/10.1038/sj.onc.1201370			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA872	9365238				2022-12-17	WOS:A1997YA87200006
J	Ueno, H; Honda, H; Nakamoto, T; Yamagata, T; Sasaki, K; Miyagawa, K; Mitani, K; Yazaki, Y; Hirai, H				Ueno, H; Honda, H; Nakamoto, T; Yamagata, T; Sasaki, K; Miyagawa, K; Mitani, K; Yazaki, Y; Hirai, H			The phosphatidylinositol 3' kinase pathway is required for the survival signal of leukocyte tyrosine kinase	ONCOGENE			English	Article						leukocyte tyrosine kinase; phosphatydylinositol 3' kinase; c-Cbl; signal transduction	INSULIN-RECEPTOR SUBSTRATE-1; GROWTH-FACTOR-I; PHOSPHOTYROSINE-DEPENDENT INTERACTION; HEMATOPOIETIC-CELLS; SH2 DOMAINS; NPEY MOTIF; HUMAN LTK; C-CBL; PROTEIN; 3'-KINASE	Leukocyte tyrosine kinase (LTK) is a receptor tyrosine kinase which belongs to the insulin receptor superfamily and is mainly expressed in pre-B lymphocytes and neuronal tissues, Recently, we demonstrated that LTK utilizes She and IRS-1 as two major substrates and while both equally activate the Ras pathway, only IRS-1 suppresses apoptosis of hematopoietic cells, suggesting the existence of another unidentified signaling pathway downstream of IRS-1, which is relevant to the anti-apoptotic activity, In the present study, we found that wortmannin, a specific inhibitor of phosphatidylinositol 3' (PI3)-kinase, abolished the survival effects of LTK. Although c-Cbl is found to be phosphorylated by LTK and therefore is a second candidate linking LTK with the P13-kinase pathway along with IRS-1, we found that the p85 subunit of PI3 kinase directly binds to tyrosine 753 of LTK, which is located within a YXXM motif, a consensus binding amino acid sequence for the SH2 domain of p85, but fails to bind to IRS-1 or c-Cbl. Ba/F3 cells which stably express the EGF receptor-LTK chimeric receptor carrying a mutation at tyrosine 753 fell into apoptotic death even in the presence of EGF, indicating that the PI3 kinase pathway is required for the survival effects of LTK.	UNIV TOKYO, DEPT INTERNAL MED 3, FAC MED, TOKYO 113, JAPAN	University of Tokyo								BACKER JM, 1993, J BIOL CHEM, V268, P8204; BEN-NERIAH Y, 1988, NATURE, V333, P672, DOI 10.1038/333672a0; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KOZUTSUMI H, 1994, ONCOGENE, V9, P2991; LANGDON WY, 1989, J VIROL, V63, P5420, DOI 10.1128/JVI.63.12.5420-5424.1989; MARU Y, 1990, ONCOGENE RES, V5, P199; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1994, J BIOL CHEM, V269, P28783; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TOYOSHIMA H, 1993, P NATL ACAD SCI USA, V90, P5404, DOI 10.1073/pnas.90.12.5404; UENO H, 1995, J BIOL CHEM, V270, P20135, DOI 10.1074/jbc.270.34.20135; Ueno H, 1996, J BIOL CHEM, V271, P27707, DOI 10.1074/jbc.271.44.27707; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074; Yao R, 1996, ONCOGENE, V13, P343; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	27	26	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	1997	14	25					3067	3072		10.1038/sj.onc.1201153	http://dx.doi.org/10.1038/sj.onc.1201153			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XG100	9223670				2022-12-17	WOS:A1997XG10000009
J	Kapoun, AM; Shackleford, GM				Kapoun, AM; Shackleford, GM			Preferential activation of Fgf8 by proviral insertion in mammary tumors of Wnt1 transgenic mice	ONCOGENE			English	Article						Fgf8; Wnt1; MMTV; oncogene cooperation; Fgf3; Fgf4; multistep tumorigenesis; growth factors	MESSENGER-RNA; GENE FAMILY; VIRUS; INT-2; EXPRESSION; ONCOGENE; CARCINOGENESIS; TUMORIGENESIS; INT-2/FGF-3; OUTGROWTH	Mouse mammary tumor virus (MMTV) is an insertional mutagen that has been demonstrated to transcriptionally activate flanking cellular proto-oncogenes. Previously we have used MMTV infection to accelerate mammary tumorigenesis in Wnt1 transgenic mice in order to identify genes that cooperate with the Wnt1 oncogene, Initial investigations into the resulting tumor collection, screened primarily by Southern analysis, showed that three fibroblast growth factor genes, Fgf8, Fgf3 and Fgf4, sustain activating insertion mutations in 10%, 42% and 6% of the tumors, respectively, Here, in an examination of the tumors from MMTV-infected Wnt1 transgenic mice that emphasizes Northern analysis, we report transcriptional activation of Fgf8 in 30 additional tumors (increasing the percentage of activations to 50%), while no significant changes in the activation frequency of Fgf3 or Fgf4 were found, To determine the frequency of insertional activation in normal mice, we examined tumors from MMTV-infected nontransgenic Littermates of the Wnt1 transgenics and from MMTV-infected BALB/c mice, Fgf8, Fgf3 and Fgf4 were found to be activated in 11%, 80% and 5%, respectively, of the tumors in the combined nontransgenic groups, Thus, there appears to be an increased predisposition for Fgf8 activations in Wnt1 transgenic mice versus normal mice, suggesting that cells expressing Wnt1 are especially sensitized to stimulation by FGF8 compared with FGF3 or FGF4, In contrast, the activation frequency of Fgf3 in tumors from MMTV-infected Wnt1 transgenic mice was approximately one-half that of normal mice, Our results show that this in vivo model of multistep tumorigenesis reveals significant differences in the activation rates of Fgf3 and Fgf8 depending upon the status of Wnt1 expression in the mammary gland, The differential activation of these Fgfs may relate to differences in their signaling pathways.	CHILDRENS HOSP LOS ANGELES,DIV HEMATOL ONCOL,LOS ANGELES,CA 90027; UNIV SO CALIF,SCH MED,DEPT PEDIAT,LOS ANGELES,CA 90027; UNIV SO CALIF,SCH MED,DEPT MOL MICROBIOL & IMMUNOL,LOS ANGELES,CA 90027	Children's Hospital Los Angeles; University of Southern California; University of Southern California					NCI NIH HHS [CA65104, CA58412] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058412, F32CA065104] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTHOLOMEW C, 1989, ONCOGENE, V4, P529; CHRISTIAN JL, 1992, EMBO J, V11, P33, DOI 10.1002/j.1460-2075.1992.tb05024.x; Crossley PH, 1996, NATURE, V380, P66, DOI 10.1038/380066a0; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; FOUREL G, 1994, EMBO J, V13, P2526, DOI 10.1002/j.1460-2075.1994.tb06542.x; FUNG YKT, 1985, MOL CELL BIOL, V5, P3337, DOI 10.1128/MCB.5.12.3337; KWAN H, 1992, MOL CELL BIOL, V12, P147, DOI 10.1128/MCB.12.1.147; LAZO PA, 1990, P NATL ACAD SCI USA, V87, P170, DOI 10.1073/pnas.87.1.170; LEE FS, 1995, P NATL ACAD SCI USA, V92, P2268, DOI 10.1073/pnas.92.6.2268; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; MACARTHUR CA, 1997, IN PRESS GENOMICS; MANSOUR SL, 1988, EMBO J, V7, P2035, DOI 10.1002/j.1460-2075.1988.tb03043.x; MARCHETTI A, 1991, J VIROL, V65, P4550, DOI 10.1128/JVI.65.8.4550-4554.1991; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; PETERS G, 1986, NATURE, V320, P628, DOI 10.1038/320628a0; PETERS G, 1989, P NATL ACAD SCI USA, V86, P5678, DOI 10.1073/pnas.86.15.5678; PETERS G, 1990, CELL GROWTH DIFFER, V1, P503; PETERS G, 1989, J VIROL, V63, P1448, DOI 10.1128/JVI.63.3.1448-1450.1989; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; SHACKLEFORD GM, 1988, P NATL ACAD SCI USA, V85, P9655, DOI 10.1073/pnas.85.24.9655; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; YANG YZ, 1995, CELL, V80, P939, DOI 10.1016/0092-8674(95)90297-X	28	26	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 19	1997	14	24					2985	2989		10.1038/sj.onc.1201146	http://dx.doi.org/10.1038/sj.onc.1201146			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XF555	9205106	Green Published			2022-12-17	WOS:A1997XF55500013
J	Wang, JK; Goldfarb, M				Wang, JK; Goldfarb, M			Amino acid residues which distinguish the mitogenic potentials of two FGF receptors	ONCOGENE			English	Article						FGFR; chimeric; BaF3; proliferation; autophosphorylation	GROWTH-FACTOR RECEPTOR; C-KIT RECEPTOR; DIFFERENT SIGNALING PATHWAYS; TYROSINE KINASE-ACTIVITY; INSULIN-RECEPTOR; POINT MUTATION; BINDING-SITE; MET PROTOONCOGENE; BETA-SUBUNIT; EGF RECEPTOR	Fibroblast growth factors mediate cellular responses by interacting with a family of related receptor tyrosine kinases (FGFRs), We have previously shown that FGFR-1, but not of FGFR-4, ectopically expressed in BaF3 lymphoid cells allows for proliferation in response to FGFs, and that the intracellular signaling halves of these two receptors distinguish their mitogenic potentials (Wang et al., 1994), In order to map the residues which functionally distinguish these receptors, a panel of chimeric receptors whose cytodomains bear different contributions from FGFR-1 and FGFR-4 were constructed and characterized, The behavior of these chimeras implicate amino acids from both the kinase insert and kinase domains in receptor-mediated proliferation, Specifically, two tyrosine residues present in the short kinase insert domain of FGFR-1 and absent from FGFR-4 are a necessary, but not sufficient, component bf a fully mitogenic receptor, suggesting that tyrosine phosphorylation in the kinase insert promotes a mitogenic signaling pathway, A strongly mitogenic receptor also requires one or two FGFR-1-specific residues from either of two regions within the kinase domain, One of these regions is within the kinase domain's activation loop, where FGFR-1, but not FGFR-4, bears a key aspartate residue, The mitogenic potentials of FGFR-1, FGFR-4, and the chimeric receptors strongly correlates with the magnitude of ligand-induced receptor autophosphorylation in BaF3 cells, We discuss mechanisms by which these few key amino acid differences may determine the levels of ligand-induced FGF receptor autophosphorylation and mitogenic potency.	CUNY MT SINAI SCH MED, BROOKDALE CTR MOL BIOL, NEW YORK, NY 10029 USA; COLUMBIA UNIV, COLL PHYS & SURG, DEPT BIOCHEM & MOL BIOPHYS, NEW YORK, NY 10032 USA; REGENERON PHARMACEUT INC, TARRYTOWN, NY 10591 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Columbia University; Regeneron					NATIONAL CANCER INSTITUTE [R01CA048054] Funding Source: NIH RePORTER; NCI NIH HHS [CA48054] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; DIFIORE PP, 1992, EMBO J, V11, P3927, DOI 10.1002/j.1460-2075.1992.tb05486.x; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KATO H, 1994, MOL ENDOCRINOL, V8, P40, DOI 10.1210/me.8.1.40; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LONGATI P, 1994, ONCOGENE, V9, P49; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MAISONPIERRE PC, 1993, ONCOGENE, V8, P1631; MANSUKHANI A, 1992, P NATL ACAD SCI USA, V89, P3305, DOI 10.1073/pnas.89.8.3305; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; Piao XH, 1996, BLOOD, V87, P3117, DOI 10.1182/blood.V87.8.3117.bloodjournal8783117; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; RODRIGUES GA, 1994, ONCOGENE, V9, P2019; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SATOH T, 1993, MOL CELL BIOL, V13, P3706, DOI 10.1128/MCB.13.6.3706; SERVE H, 1994, J BIOL CHEM, V269, P6026; SHAOUL E, 1995, ONCOGENE, V10, P1553; STARK KL, 1991, DEVELOPMENT, V113, P641; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; TORNQVIST HE, 1988, J BIOL CHEM, V263, P4593; TSUJIMURA T, 1995, INT ARCH ALLERGY IMM, V106, P377, DOI 10.1159/000236870; TSUJIMURA T, 1994, BLOOD, V83, P2619; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VAINIKKA S, 1994, J BIOL CHEM, V269, P18320; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; Wang JK, 1996, ONCOGENE, V13, P721; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; YU JC, 1991, MOL CELL BIOL, V11, P3780, DOI 10.1128/MCB.11.7.3780; ZHAN X, 1987, ONCOGENE, V1, P369; ZHANG B, 1991, J BIOL CHEM, V266, P990	57	26	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	1997	14	15					1767	1778		10.1038/sj.onc.1201021	http://dx.doi.org/10.1038/sj.onc.1201021			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW166	9150382				2022-12-17	WOS:A1997WW16600002
J	Alvaro, V; Prevostel, C; Joubert, D; Slosberg, E; Weinstein, BI				Alvaro, V; Prevostel, C; Joubert, D; Slosberg, E; Weinstein, BI			Ectopic expression of a mutant form of PKC alpha originally found in human tumors: Aberrant subcellular translocation and effects on growth control	ONCOGENE			English	Article						protein kinase c; somatic mutation; transformation; fibroblast	PROTEIN-KINASE-C; RAT FIBROBLASTS; EPSILON ISOFORM; DOWN-REGULATION; PHORBOL ESTERS; FOCAL CONTACTS; GENE-TRANSFER; CELL-LINES; RECEPTOR; OVEREXPRESSION	A point mutation in PKC alpha was originally discovered in a subpopulation of human pituitary tumors characterized by their invasive phenotype, and the same mutation was also seen in some thyroid neoplasms, To investigate the role of this mutation in tumorigenesis, normal and mutant human PKC alpha cDNAs were overexpressed in Rat6 embryo fibroblasts (R6), When extracts of R6 cells that expressed either the normal or mutant PKC alpha were assayed in the presence of calcium, phosphatidylserine and the phorbol ester TPA, for phosphorylation of either histone IIIS or the EGF-receptor peptide, both extracts gave similar results, However, the subcellular localization of the two proteins differed. Immunohistochemistry studies indicated that after treatment with TPA normal PKC alpha mainly translocated to the plasma membrane, but mutant PKC alpha translocated mainly to the perinuclear region and slightly to the nucleus, Furthermore, the cells that expressed the mutant PKC alpha displayed a decreased requirement for serum when compared to the cells expressing the normal human PKC alpha, and they formed small colonies in soft agar, By contrast, the cells expressing the normal human PKC alpha failed to form colonies in soft-agar, Thus, ectopic expression in rat fibroblasts of this mutant human PKC alpha sequence alters the growth properties of these cells and, when activated, the mutant PKC alpha displays aberrant intracellular translocation, Therefore, this mutation in PKC alpha could contribute to the process of tumor progression in certain human tumors.	CCIPE,INSERM U401,F-34094 MONTPELLIER 5,FRANCE; COLUMBIA UNIV COLL PHYS & SURG,COLUMBIA PRESBYTERIAN CANC CTR,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,CANC RES INST,NEW YORK,NY 10032	Institut National de la Sante et de la Recherche Medicale (Inserm); Columbia University; Columbia University			Prevostel, Corinne/AAO-1433-2020	PREVOSTEL, Corinne/0000-0002-7553-087X				AHMAD S, 1994, NEUROSURGERY, V35, P904, DOI 10.1227/00006123-199411000-00015; AHMAD S, 1993, MOL PHARMACOL, V43, P858; ALVARO V, 1992, INT J CANCER, V50, P724, DOI 10.1002/ijc.2910500510; ALVARO V, 1993, J CLIN ENDOCR METAB, V77, P1125, DOI 10.1210/jc.77.5.1125; BENZIL DL, 1992, CANCER RES, V52, P2951; BORNER C, 1992, J BIOL CHEM, V267, P12900; BORNER C, 1995, J BIOL CHEM, V270, P78, DOI 10.1074/jbc.270.1.78; BORNER C, 1992, J BIOL CHEM, V267, P12892; BORNER C, 1991, NATURE, V353, P78, DOI 10.1038/353078a0; BUCHNER K, 1995, EUR J BIOCHEM, V228, P211; CACACE AM, 1993, ONCOGENE, V8, P2095; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; Dieterich S, 1996, FEBS LETT, V381, P183, DOI 10.1016/0014-5793(96)00116-0; DONG LQ, 1993, CELL GROWTH DIFFER, V4, P793; ELDAR H, 1990, J BIOL CHEM, V265, P13290; FINKENZELLER G, 1990, NUCLEIC ACIDS RES, V18, P2183, DOI 10.1093/nar/18.8.2183; FINKENZELLER G, 1992, CELL SIGNAL, V4, P163, DOI 10.1016/0898-6568(92)90080-R; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; HYATT SL, 1994, BIOCHEMISTRY-US, V33, P1223, DOI 10.1021/bi00171a023; HYATT SL, 1990, MOL CARCINOGEN, V3, P45, DOI 10.1002/mc.2940030202; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; JAMES G, 1992, J CELL BIOL, V116, P863, DOI 10.1083/jcb.116.4.863; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; JONES CLA, 1994, PKC M TAOS NEW MEX; JUNCO M, 1994, EUR J BIOCHEM, V223, P259, DOI 10.1111/j.1432-1033.1994.tb18990.x; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; LEACH KL, 1989, J CELL BIOL, V109, P685, DOI 10.1083/jcb.109.2.685; LEACH KL, 1988, J BIOL CHEM, V263, P13223; LEHEL C, 1995, P NATL ACAD SCI USA, V92, P1406, DOI 10.1073/pnas.92.5.1406; LELI U, 1992, FEBS LETT, V297, P91, DOI 10.1016/0014-5793(92)80334-D; LIAO L, 1994, BIOCHEMISTRY-US, V33, P1229, DOI 10.1021/bi00171a024; LINNENBACH AJ, 1988, P NATL ACAD SCI USA, V85, P74, DOI 10.1073/pnas.85.1.74; LIU B, 1994, J NATL CANCER I, V86, P1145, DOI 10.1093/jnci/86.15.1145; MAPPELI E, 1994, INT J CANCER, V57, P281; MARKOWITZ D, 1990, ANN NY ACAD SCI, V612, P407; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OLSON EN, 1993, CELL GROWTH DIFFER, V4, P699; PARKER PJ, 1995, BIOCHEM SOC T, V23, P153, DOI 10.1042/bst0230153; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; PREVOSTEL C, 1995, ONCOGENE, V11, P669; STAUDINGER J, 1995, J CELL BIOL, V128, P263, DOI 10.1083/jcb.128.3.263; STUART RO, 1995, P NATL ACAD SCI USA, V92, P6072, DOI 10.1073/pnas.92.13.6072; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; YU G, 1991, CANCER COMMUN, V3, P181, DOI 10.3727/095535491820873263	47	26	28	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 13	1997	14	6					677	685		10.1038/sj.onc.1200880	http://dx.doi.org/10.1038/sj.onc.1200880			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WG430	9038375				2022-12-17	WOS:A1997WG43000006
J	Bell, B; Sadowski, I				Bell, B; Sadowski, I			Ras-responsiveness of the HIV-1 LTR requires RBF-1 and RBF-2 binding sites	ONCOGENE			English	Article						HIV-1 LTR; Ras; transcription; RBF-1; RBF-2	HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; NF-KAPPA-B; PROTEIN-KINASE-C; ETS DOMAIN PROTEIN; GENE-EXPRESSION; T-CELLS; TRANSCRIPTION FACTOR; ACTIVATES TRANSCRIPTION; FAMILY PROTEINS	Lentiviruses characteristically form latent integrated proviruses whose transcription can be induced by cell regulatory signals. The HIV-1 LTR responds to multiple signals, including the Ras pathway. We report here that Ras-responsive HIV-1 transcription requires two previously undescribed factors, RBF-1 and RBF-2 in Jurkat T cells. RBF-1 binds to Ets-like motifs located between nucleotides -151 and -142, and within the NF-kappa B binding sites, but is distinct from Ets-l or Elf-1. RBF-2 binds the HIV-1 LTR at nucleotides -131 and -121 and immediately 3' of the TATA box. Both RBF-1 and RBF-2 contain DNA binding subunits of relative molecular weight 100 kilodaltons. Mutation of the RBF-1 and RBF-2 binding elements (RBEs) prevents Ras stimulation of HIV-1 LTR-directed transcription. These data define a mechanism for Ras responsiveness of HIV-1 transcription that involves the previously uncharacterized factors RBF-1 and RBF-2.	UNIV BRITISH COLUMBIA, FAC MED, DEPT BIOCHEM & MOL BIOL, VANCOUVER, BC V6T 1Z3, CANADA	University of British Columbia								ARENZANASEISDEDOS F, 1989, ONCOGENE, V4, P1359; BALDARI CT, 1992, FEBS LETT, V304, P261, DOI 10.1016/0014-5793(92)80633-R; BRUDER JT, 1993, NUCLEIC ACIDS RES, V21, P5229, DOI 10.1093/nar/21.22.5229; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; CLARK NM, 1995, J VIROL, V69, P4854, DOI 10.1128/JVI.69.8.4854-4862.1995; CULLEN BR, 1993, CELL, V73, P417, DOI 10.1016/0092-8674(93)90126-B; DEHBI M, 1994, ONCOGENE, V9, P2399; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974; EICHER DM, 1994, J IMMUNOL, V152, P2710; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; Estable MC, 1996, J VIROL, V70, P4053, DOI 10.1128/JVI.70.6.4053-4062.1996; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FINCO TS, 1993, J BIOL CHEM, V268, P17676; Flory E, 1996, J VIROL, V70, P2260, DOI 10.1128/JVI.70.4.2260-2268.1996; GARCIA JA, 1994, AIDS, V8, pS3; GAYNOR R, 1992, AIDS, V6, P347, DOI 10.1097/00002030-199204000-00001; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GOLUB EI, 1990, J VIROL, V64, P3654, DOI 10.1128/JVI.64.8.3654-3660.1990; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hodge DR, 1996, ONCOGENE, V12, P11; HOHASHI N, 1995, INT IMMUNOL, V7, P1851, DOI 10.1093/intimm/7.11.1851; HOLZMEISTER J, 1993, BIOCHEM BIOPH RES CO, V197, P1229, DOI 10.1006/bbrc.1993.2608; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; JOHN S, 1995, MOL CELL BIOL, V15, P1786; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.biochem.63.1.717; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KATO H, 1991, SCIENCE, V251, P1476, DOI 10.1126/science.2006421; KELLER A, 1992, J VIROL, V66, P3946, DOI 10.1128/JVI.66.6.3946-3949.1992; KIM JYH, 1993, J VIROL, V67, P1658, DOI 10.1128/JVI.67.3.1658-1662.1993; KINTER AL, 1990, J VIROL, V64, P4306, DOI 10.1128/JVI.64.9.4306-4312.1990; KOKEN SEC, 1992, VIROLOGY, V191, P968, DOI 10.1016/0042-6822(92)90274-S; LEE AH, 1992, J VIROL, V66, P3236, DOI 10.1128/JVI.66.5.3236-3240.1992; LEYS RD, 1990, J VIROL, V64, P1207; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; LI YC, 1991, MOL CELL BIOL, V11, P1883, DOI 10.1128/MCB.11.4.1883; LU XB, 1993, J VIROL, V67, P1752, DOI 10.1128/JVI.67.4.1752-1760.1993; MALIM MH, 1988, NATURE, V335, P181, DOI 10.1038/335181a0; MARGOLIS DM, 1994, J VIROL, V68, P905, DOI 10.1128/JVI.68.2.905-910.1994; MICHAEL NL, 1994, J VIROL, V68, P3163, DOI 10.1128/JVI.68.5.3163-3174.1994; MOSES AV, 1994, J VIROL, V68, P298, DOI 10.1128/JVI.68.1.298-307.1994; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NABEL G, 1990, NATURE, V344, P178, DOI 10.1038/344178b0; Nabel Gary J., 1993, P49; NAKANISHI Y, 1991, J VIROL, V65, P6334, DOI 10.1128/JVI.65.11.6334-6338.1991; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; OU SHI, 1994, J VIROL, V68, P7188, DOI 10.1128/JVI.68.11.7188-7199.1994; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; ROULSTON A, 1995, MICROBIOL REV, V59, P481, DOI 10.1128/MMBR.59.3.481-505.1995; SETH A, 1993, AIDS RES HUM RETROV, V9, P1017, DOI 10.1089/aid.1993.9.1017; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; SHERIDAN PL, 1995, GENE DEV, V9, P2090, DOI 10.1101/gad.9.17.2090; SOUTHGATE CD, 1991, GENE DEV, V5, P2496, DOI 10.1101/gad.5.12b.2496; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; WASYLYK C, 1994, ONCOGENE, V9, P3665; WATERMAN M L, 1990, New Biologist, V2, P621; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656; WILLIAMS DH, 1995, EUR J IMMUNOL, V25, P42, DOI 10.1002/eji.1830250109; Yang BS, 1996, MOL CELL BIOL, V16, P538; YI Z, 1992, J VIROL, V66, P5631, DOI 10.1128/JVI.66.9.5631-5634.1992; ZEICHNER SL, 1991, J VIROL, V65, P2436, DOI 10.1128/JVI.65.5.2436-2444.1991	65	26	26	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 19	1996	13	12					2687	2697						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000143				2022-12-17	WOS:A1996VZ65400019
J	Wang, HL; Xie, ZR; Scott, RE				Wang, HL; Xie, ZR; Scott, RE			JunD phosphorylation, and expression of AP-1 DNA binding activity modulated by serum growth factors in quiescent murine 3T3T cells	ONCOGENE			English	Article						JunD; AP-1; cell proliferation; phosphorylation; transcription factors	C-JUN; PROTEINS; TRANSFORMATION; KINASE; GENE; FOS; ACTIVATION; FAMILY; RAS; DIFFERENTIATION	JunD has been implicated as a negative regulator of cell proliferation, If and how JunD is regulated by growth factors however has not been well investigated, We now report that in quiescent murine 3T3T cells, JunD is present in a hypophosphorylated form, but that when quiescent cells are stimulated to proliferate with serum, JunD undergoes a transient increase in its phosphorylation that occurs within 10 min and persists for up to 4 h, The increase in JunD phosphorylation correlates with the induction of cell proliferation since only those growth factors that promote cell proliferation can induce JunD phosphorylation, Treatment of quiescent 3T3T cells with serum also induces significant decreases in JunD/AP-1 DNA binding activity within 2 h and in JunD expression after 8-48 h, However, both hypophosphorylated and hyperphosphorylated forms of JunD can bind AP-1 DNA, These results suggest that serum growth factors can modulate JunD characteristics in a variety of apparently independent ways to overcome its negative regulatory effect in controlling cell proliferation, These include induction of a transient increase in JunD phosphorylation, repression of JunD AP-1 DNA binding activity and downregulation of JunD expression.	UNIV TENNESSEE,COLL MED,DEPT PATHOL,MEMPHIS,TN 38163	University of Tennessee System; University of Tennessee Health Science Center								ABEL T, 1989, NATURE, V341, P24, DOI 10.1038/341024a0; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; BANNISTER AJ, 1993, NUCLEIC ACIDS RES, V21, P1289, DOI 10.1093/nar/21.5.1289; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; DIAMOND L, 1977, NATURE, V269, P247, DOI 10.1038/269247a0; GABRIELSEN OS, 1989, NUCLEIC ACIDS RES, V17, P6253, DOI 10.1093/nar/17.15.6253; GROVERBARDWICK A, 1994, CARCINOGENESIS, V15, P1667, DOI 10.1093/carcin/15.8.1667; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HOERL BJ, 1989, J CELL PHYSIOL, V139, P68, DOI 10.1002/jcp.1041390111; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lagarrigue S, 1995, BIOCHEM BIOPH RES CO, V217, P501, DOI 10.1006/bbrc.1995.2804; LASKY SR, 1995, J BIOL CHEM, V270, P19676, DOI 10.1074/jbc.270.34.19676; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; Neyns B, 1996, ONCOGENE, V12, P1247; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; OTTER T, 1987, ANAL BIOCHEM, V162, P370, DOI 10.1016/0003-2697(87)90406-4; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; REZZONICO R, 1995, ONCOGENE, V11, P1069; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; RYSECK RP, 1991, ONCOGENE, V6, P533; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; WANG HL, 1994, P NATL ACAD SCI USA, V91, P4649, DOI 10.1073/pnas.91.11.4649; WANG HL, 1991, CELL GROWTH DIFFER, V2, P645; WANG HL, 1991, J CELL PHYSIOL, V147, P102, DOI 10.1002/jcp.1041470114; Wang HL, 1995, MOL CELL BIOCHEM, V153, P59, DOI 10.1007/BF01075919; YE ZS, 1987, J BIOL CHEM, V262, P6313	37	26	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2639	2647						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000138				2022-12-17	WOS:A1996VZ65400014
J	Portella, G; Salvatore, D; Botti, G; Cerrato, A; Zhang, L; Mineo, A; Chiappetta, G; Santelli, G; Pozzi, L; Vecchio, G; Fusco, A; Santoro, M				Portella, G; Salvatore, D; Botti, G; Cerrato, A; Zhang, L; Mineo, A; Chiappetta, G; Santelli, G; Pozzi, L; Vecchio, G; Fusco, A; Santoro, M			Development of mammary and cutaneous gland tumors in transgenic mice carrying the RET/PTC1 oncogene	ONCOGENE			English	Article						transgenic; oncogene; RET; mammary; thyroid	RET PROTO-ONCOGENE; TYROSINE KINASE; THYROID CARCINOMAS; METASTATIC DISEASE; NEU PROTOONCOGENE; RECEPTOR RET; HUMAN-BREAST; H4 D10S170; GENE; EXPRESSION	RET/PTC1 is a chimeric oncogene created by the fusion of the tyrosine kinase domain of RET to the 5'-terminal region of another gene named H4, So far, this oncogene has been found activated only in human papillary thyroid carcinomas, In order to investigate its transforming properties in vivo, we have produced transgenic mice carrying RET/PTC1 under the control of the H4 promoter, The transgene was expressed in several tissues, consistently with the ubiquitous expression of the wild type H4 gene, Mammary adenocarcinomas and, less frequently, hyperplasia of sebaceous glands and rare benign skin tumors, named pilomatrixomas, developed in these mice, The tumors were shown to express the transgene both at the RNA and protein level, These results demonstrate that the transforming ability of the RET/PTC1 oncogene is not restricted to the thyroid epithelium in vivo, Despite its ubiquitous expression, however, RET/PTC1 was able to induce only a limited number of tumor types; specifically mammary epithelium was affected by transgene expression, thus suggesting that RET/PTC1 is able to couple with transforming pathways specific for these glandular cells.	UNIV NAPLES,FAC MED & CHIRURG,DIPARTIMENTO BIOL & PATOL CELLULARE & MOL,CNR,I-80131 NAPLES,ITALY; FDN PASCALE,IST NAZL TUMORI NAPOLI,I-80131 NAPLES,ITALY; IST REGINA ELENA,I-00161 ROME,ITALY; UNIV REGGIO CALABRIA,FAC MED & CHIRURG CATANZARO,DIPARTIMENTO MED SPERIMENTALE & CLIN,I-88100 CATANZARO,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; IRCCS Fondazione Pascale; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria			Cerrato, Aniello/AAY-1484-2020; Salvatore, Domenico/D-4881-2013; Portella, Giuseppe/AFU-6826-2022	SALVATORE, DOMENICO/0000-0002-4556-7620; Fusco, Alfredo/0000-0003-3332-5197; PORTELLA, Giuseppe/0000-0001-8276-9769; Botti, Gerardo/0000-0002-6287-733X				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; CHALSTRE.LJ, 1966, BRIT J CANCER, V20, P670, DOI 10.1038/bjc.1966.78; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; FUGAZZOLA L, 1995, CANCER RES, V55, P5617; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; GRIECO M, 1994, ONCOGENE, V9, P2531; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; HEADINGTON JT, 1976, AM J PATHOL, V85, P480; HOGAN B, 1986, MANIPULATING MOUSE E, P79; ITO T, 1993, CANCER RES, V53, P2940; ITO T, 1994, LANCET, V344, P250; IWAMOTO T, 1991, EUR J IMMUNOL, V21, P1809, DOI 10.1002/eji.1830210805; IWAMOTO T, 1991, EMBO J, V10, P3167, DOI 10.1002/j.1460-2075.1991.tb04878.x; IWAMOTO T, 1990, ONCOGENE, V5, P533; Jhiang SM, 1996, ENDOCRINOLOGY, V137, P375, DOI 10.1210/en.137.1.375; Klugbauer S, 1995, ONCOGENE, V11, P2459; LANZI C, 1992, ONCOGENE, V7, P2189; Mak YF, 1996, CURR OPIN GENET DEV, V6, P82, DOI 10.1016/S0959-437X(96)90015-5; MALLORY SB, 1995, DERMATOL CLIN, V13, P27, DOI 10.1016/S0733-8635(18)30103-7; MICHAELS RD, 1993, J ENDOCRINOL INVEST, V11, P909; MOROY T, 1990, EMBO J, V9, P3659, DOI 10.1002/j.1460-2075.1990.tb07577.x; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; RASSOULZADEGAN M, 1990, ONCOGENE, V5, P1507; ROMANO A, 1995, ONCOGENE, V9, P2923; RON E, 1984, BRIT J CANCER, V49, P87, DOI 10.1038/bjc.1984.13; SANTORO M, 1993, BRIT J CANCER, V68, P460, DOI 10.1038/bjc.1993.370; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; Santoro M, 1996, ONCOGENE, V12, P1821; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SUDA Y, 1987, EMBO J, V6, P4055, DOI 10.1002/j.1460-2075.1987.tb02751.x; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TONG Q, 1995, ONCOGENE, V10, P1781	37	26	26	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 7	1996	13	9					2021	2026						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934550				2022-12-17	WOS:A1996VR79500023
J	Zariwala, M; Xiong, Y				Zariwala, M; Xiong, Y			Lack of mutation in the cyclin-dependent kinase inhibitor, p19(INK4d), in tumor-derived cell lines and primary tumors	ONCOGENE			English	Article						p15(INK4b); p16(INK4a); p18(INK4c); p19(INK4d); CDK inhibitors	SUPPRESSOR GENE; MOLECULAR ANALYSIS; HUMAN MALIGNANCIES; FAMILIAL MELANOMA; P15(INK4B) GENE; CDK6 INHIBITOR; P27(KIP1) GENE; HUMAN CANCERS; P18 GENES; EXPRESSION	Inhibitors of cyclin-dependent kinases provide a major mechanism of negative regulation on cell cycle progression, Defects in the function of the CDK inhibitors may lead to uncontrolled cell proliferation and potentially facilitate tumorigenesis. The p16(INK4) family of CDK inhibitors specifically prevent the phosphorylation of the retinoblastoma susceptibility gene product, pRb, by inhibiting the kinase activity of CDK4 and CDK6, thereby keeping pRb in its active form as a growth suppressor, The loss of p16(INK4) inhibitory activity would, therefore, have the same consequence as the loss of pRb growth suppressing activity, The p16(INK4) family currently includes four members, p15(INK4b), p16INK(4a)) p18INK(4c) and p19(INK4d). Two members, p15(INK4b) and p16(INK4a) have been found to be deleted and mutated in a variety of human tumor-derived cell lines and primary tumors, In the present study we have examined the genomic status of the newly isolated p19(INK4d) gene in 75 tumor-derived cell lines; 13 immortalized, transformed or normal cell lines; 19 ovarian tumors and 18 acute myelogenous leukemias, No deletions or point mutations were observed in the p19(INK4d) gene, A genetic polymorphism at codon 30 (CGC-->CGG) in exon 1 of the p19(INK4d) gene was observed in 10% of the samples under investigation, In the same set of samples, p16(INK4a) was found to be homozygously deleted in 32% of the tumor derived cell lines, These results together with our previous data that showed a 22% deletion frequency in p(15INK4b) and rare alterations in the p18(INK4c) gene, indicating that the p16(INK4a) and p15(INK4b), but not the p18(INK4c) and p19(INK4d) genes, are frequently mutated in human tumors, Hence, members of the p16(INK4) CDK inhibitor family, while evolutionary related and biochemically indistinguishable, carry out distinct biological functions.	UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill					NATIONAL CANCER INSTITUTE [R01CA065572] Funding Source: NIH RePORTER; NCI NIH HHS [CA 65572] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BHATIA K, 1995, CANCER RES, V55, P1431; BULLRICH F, 1995, CANCER RES, V55, P1199; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GAO X, 1995, ONCOGENE, V11, P1395; GLENDENING JM, 1995, CANCER RES, V55, P5531; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GRUIS NA, 1995, NAT GENET, V10, P351, DOI 10.1038/ng0795-351; Guan KL, 1996, MOL BIOL CELL, V7, P57, DOI 10.1091/mbc.7.1.57; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HAIDAR MA, 1995, BLOOD, V86, P311, DOI 10.1182/blood.V86.1.311.bloodjournal861311; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hara E, 1996, MOL CELL BIOL, V16, P859; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HATADA I, 1995, NAT GENET, V11, P204, DOI 10.1038/ng1095-204; HE J, 1994, CANCER RES, V54, P5804; Herman JG, 1996, CANCER RES, V56, P722; HERMAN JG, 1995, CANCER RES, V55, P4525; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HURET JL, 1993, LEUKEMIA, V7, P152; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAWAMATA N, 1995, CANCER RES, V55, P2266; KIECHLESCHWARZ M, 1994, GYNECOL ONCOL, V55, P198, DOI 10.1006/gyno.1994.1277; KODORU PRK, 1995, BLOOD, V86, P2900; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LI Y, 1994, CANCER RES, V54, P6078; LOIS AF, 1995, CANCER RES, V55, P4010; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Matsuoka S, 1996, P NATL ACAD SCI USA, V93, P3026, DOI 10.1073/pnas.93.7.3026; MOROSETTI R, 1995, BLOOD, V86, P1924, DOI 10.1182/blood.V86.5.1924.bloodjournal8651924; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OKAMOTO A, 1995, CANCER RES, V55, P1448; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; Orlow I, 1996, CANCER RES, V56, P1219; OTSUKI T, 1995, CANCER RES, V55, P1436; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PIETENPOL JA, 1995, CANCER RES, V55, P1206; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; QUELLE DE, 1995, CELL, V83, P993; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHERRANO M, 1996, CELL, V85, P27; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; Spirin KS, 1996, CANCER RES, V56, P2400; Stegmaier K, 1996, CANCER RES, V56, P1413; TAKEUCHI S, 1995, BLOOD, V86, P755, DOI 10.1182/blood.V86.2.755.bloodjournal862755; TAM SW, 1994, CANCER RES, V54, P5816; WALKER GJ, 1995, HUM MOL GENET, V4, P1845, DOI 10.1093/hmg/4.10.1845; WATANABE H, 1995, BBA-GENE STRUCT EXPR, V1263, P275, DOI 10.1016/0167-4781(95)00110-3; Wong H, 1996, EXP GERONTOL, V31, P311, DOI 10.1016/0531-5565(95)00025-9; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; XIONG Y, 1996, IN PRESS BIOCH BIOPH; XU L, 1994, CANCER RES, V54, P5262; Zariwala M, 1996, ONCOGENE, V12, P451; ZHANG SY, 1994, CANCER RES, V54, P5050	65	26	26	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 7	1996	13	9					2033	2038						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934552				2022-12-17	WOS:A1996VR79500025
J	Rachmilewitz, J; Elkin, M; Looijenga, LHJ; Verkerk, AJMH; Gonik, B; Lustig, G; Werner, D; deGroot, N; Hochberg, A				Rachmilewitz, J; Elkin, M; Looijenga, LHJ; Verkerk, AJMH; Gonik, B; Lustig, G; Werner, D; deGroot, N; Hochberg, A			Characterization of the imprinted IPW gene: Allelic expression in normal and tumorigenic human tissues	ONCOGENE			English	Article						IPW; imprinted genes; bi-allelic expression; testicular germ cell tumors; bladder carcinoma	GROWTH FACTOR-II; HUMAN H19 GENE; RELAXATION; INVITRO; REGION; LINE; IGF2	IPW (Imprinted gene in the Prader-Willi syndrome region) is a recently identified paternally expressed gene, Previous work has demonstrated IPW expression in the human fetus and adult, with monoallelic expression in adult lymphoblasts and fibroblasts, and in fetal tissues. To further examine the expression of IPW, a series of experiments were carried out using RT-PCR to measure IPW expression in placentae and various fetal and tumor tissues, Biallelic expression of IPW was found in testicular germ cell tumor and bladder cancer cells, suggesting loss of imprinting in the latter case. Both H19 and Insulin-like growth Factor 2 (IGF2), two additional imprinted genes, also showed biallelic expression in those same tumors that demonstrated IPW biallelic expression. Of note, the naturally occurring parthenogenetic-derived mature teratoma unexpectedly expressed large amounts of IPW, Lastly, the pluripotent embryonal cancer cell line Tera-2 expressed IPW at the same level before and after differentiation induced by retinoic acid, suggesting that this gene functions in a 'housekeeping' capacity throughout cell growth. This was in contradistinction to H19 and IGF2, both of which showed significant transcriptional upregulation after Tera-2 cell differentiation.	HEBREW UNIV JERUSALEM,SILBERMAN INST LIFE SCI,DEPT BIOL CHEM,IL-91904 JERUSALEM,ISRAEL; UNIV ROTTERDAM HOSP,DR DANIEL DEN HOED CANC CTR,LAB EXPT PATHOONCOL,NL-3075 EA ROTTERDAM,NETHERLANDS; WAYNE STATE UNIV,SCH MED,GRACE HOSP,DEPT OBSTET & GYNECOL,DETROIT,MI; GERMAN CANC RES CTR,D-69120 HEIDELBERG,GERMANY	Hebrew University of Jerusalem; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Wayne State University; Helmholtz Association; German Cancer Research Center (DKFZ)			Looijenga, Leendert/B-8145-2019	Looijenga, Leendert/0000-0002-8146-1911; Verkerk, Annemieke JMH/0000-0002-7523-3656				ANDREWS PW, 1984, LAB INVEST, V50, P147; ARIEL I, 1994, GYNECOL ONCOL, V53, P212, DOI 10.1006/gyno.1994.1118; Ausubel F. M., 1993, CURRENT PROTOCOLS MO, V1; DoucRasy S, 1996, ONCOGENE, V12, P423; GIANNOUKAKIS N, 1993, NAT GENET, V4, P98, DOI 10.1038/ng0593-98; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LINDER D, 1975, NEW ENGL J MED, V292, P63, DOI 10.1056/NEJM197501092920202; MCDONALD RJ, 1987, METHOD ENZYMOL, V152, P221; MOSSELMAN S, 1994, CANCER RES, V54, P220; MOSTOFI FK, 1987, SEMIN DIAGN PATHOL, V4, P320; MUTTER GL, 1993, AM J HUM GENET, V53, P1096; OOSTERHUIS JW, 1989, LAB INVEST, V60, P14; POIRIER F, 1991, DEVELOPMENT, V113, P1105; RACHMILEWITZ J, 1992, FEBS LETT, V309, P25, DOI 10.1016/0014-5793(92)80731-U; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; SOLTER D, 1988, ANNU REV GENET, V22, P127; SURANI MAH, 1987, BIOL REPROD, V36, P1, DOI 10.1095/biolreprod36.1.1; SZABO PE, 1995, GENE DEV, V9, P1857, DOI 10.1101/gad.9.15.1857; SZULMAN AE, 1987, GESTATIONAL TROPHOBL, P27; TADOKORO K, 1991, NUCLEIC ACIDS RES, V19, P6967, DOI 10.1093/nar/19.24.6967; TYCKO B, 1994, AM J PATHOL, V144, P431; VANGURP RJH, 1994, JNCI-J NATL CANCER I, V14, P1070; VILLAR AJ, 1995, DEV BIOL, V172, P264, DOI 10.1006/dbio.1995.0021; WALSH C, 1994, MECH DEVELOP, V46, P55, DOI 10.1016/0925-4773(94)90037-X; WEVRICK R, 1994, HUM MOL GENET, V3, P1877, DOI 10.1093/hmg/3.10.1877; Zhan SL, 1995, ONCOGENE, V11, P2503; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	27	26	27	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1687	1692						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895514				2022-12-17	WOS:A1996VM88700013
J	Chang, JY; Xia, WY; Shao, RP; Hung, MC				Chang, JY; Xia, WY; Shao, RP; Hung, MC			Inhibition of intratracheal lung cancer development by systemic delivery of E1A	ONCOGENE			English	Article						EIA; HER-2/neu; gene therapy; adenoviral vector; lung cancer	GROWTH-FACTOR RECEPTOR; NEU ONCOGENE; GENE-THERAPY; ADENOVIRUS TYPE-5; CYSTIC-FIBROSIS; OVARIAN-CANCER; SMALL-CELL; EXPRESSION; OVEREXPRESSION; METASTASIS	Amplification or overexpression of HER-2/neu in human lung cancer has been correlated with poor prognosis and chemoresistance, We have previously reported that the adenovirus type 5 early region 1A (E1A) gene product can suppress HER-2/neu-mediated transformation phenotypes through inhibition of HER-2/neu expression. To find an efficient way to treat HER-2/neu-overexpressing lung cancer with ELA, a replication-deficient adenovirus containing the E1A gene, Ad.E1A(+), was used to transduce E1A into HER-2/neu-overexpressing and low expressing human lung cancer cell lines, Tumour cell growth in vitro and colony formation in soft agarose were greatly inhibited by Ad.E1A(+) transduction in HER-2/neu-overexpressing lung cancer cell lines, In HER-2/neu low expressing cell lines, E1A could not inhibit cell growth in vitro but could reduce the colony formation ability in soft agarose, indicating different effects of E1A in these two types of cancer cells. To test the therapeutic efficacy of E1A to lung cancer by systemic delivery in vivo, tumor-bearing mice were established by intratracheal injection of lung cancer cells and treated by i.v. tail injections of Ad.E1A(+). As a result, Ad.E1A(+) suppressed HER-2/neu overexpression and inhibited intratracheal lung cancer growth. However, no significant tumor suppression effect of Ad.E1A(+) was observed in mice bearing HER-2/neu low expressing cell line when the same therapeutic procedure was followed, Thus, we conclude that systemic delivery of Ad.E1A(+) can efficiently achieve therapeutic effect in HER-2/neu-overexpressing lung cancer in vivo.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,BREAST CANC BASIC RES PROGRAM,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center			Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	NATIONAL CANCER INSTITUTE [R01CA060856, R01CA058880] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA60856, R01-CA58880] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BERCHUCK A, 1990, CANCER RES, V50, P4087; BYRD PJ, 1988, ONCOGENE, V2, P477; CHINNADURAI G, 1992, ONCOGENE, V7, P1255; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DAVENPORT EA, 1988, ANTICANCER RES, V8, P957; FRISCH SM, 1991, P NATL ACAD SCI USA, V88, P9077, DOI 10.1073/pnas.88.20.9077; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; FRISCH SM, 1995, CANCER RES, V55, P5551; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Graham FL, 1991, METHOD MOL BIOL, P109; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; HUNG MC, 1995, GENE, V159, P65, DOI 10.1016/0378-1119(94)00459-6; KAST WM, 1989, CELL, V59, P603, DOI 10.1016/0092-8674(89)90006-8; KERN JA, 1990, CANCER RES, V50, P5284; KNOWLES MR, 1995, NEW ENGL J MED, V333, P823, DOI 10.1056/NEJM199509283331302; LESOONWOOD LA, 1995, HUM GENE THER, V6, P395, DOI 10.1089/hum.1995.6.4-395; Minna JD, 1989, CANCER PRINCIPLES PR, P591; PERERA FP, 1991, ORIGINS OF HUMAN CANCER, P219; POZZATTI R, 1988, MOL CELL BIOL, V8, P2984, DOI 10.1128/MCB.8.7.2984; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHNEIDER PM, 1989, CANCER RES, V49, P4968; SHI DR, 1992, MOL CARCINOGEN, V5, P213, DOI 10.1002/mc.2940050308; SIMON RH, 1993, HUM GENE THER, V4, P771, DOI 10.1089/hum.1993.4.6-771; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; THIERRY AR, 1995, P NATL ACAD SCI USA, V92, P9742, DOI 10.1073/pnas.92.21.9742; TSAI CM, 1995, J NATL CANCER I, V87, P682, DOI 10.1093/jnci/87.9.682; TSAI CM, 1993, J NATL CANCER I, V85, P897, DOI 10.1093/jnci/85.11.897; WEINBERG RA, 1989, CANCER RES, V49, P3713; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YANG YP, 1994, NAT GENET, V7, P362, DOI 10.1038/ng0794-362; YU DH, 1992, ONCOGENE, V7, P2263; YU DH, 1991, MOL CELL BIOL, V11, P1745, DOI 10.1128/MCB.11.3.1745; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; YU DH, 1991, ONCOGENE, V6, P1991; YU DH, 1994, CANCER RES, V54, P3260; YU DH, 1995, ONCOGENE, V11, P1383; ZHANG YJ, 1995, ONCOGENE, V10, P2263	38	26	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 3	1996	13	7					1405	1412						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875978				2022-12-17	WOS:A1996VL38400005
J	DeBenedetti, VMG; Radice, P; Mondini, P; Spatti, G; Conti, A; Illeni, MT; Caligo, MA; Cipollini, G; Bevilaqua, G; Pilotti, S; Pierotti, MA				DeBenedetti, VMG; Radice, P; Mondini, P; Spatti, G; Conti, A; Illeni, MT; Caligo, MA; Cipollini, G; Bevilaqua, G; Pilotti, S; Pierotti, MA			Screening for mutations in exon 11 of the BRCA1 gene in 70 Italian breast and ovarian cancer patients by protein truncation test	ONCOGENE			English	Article						breast cancer; ovarian cancer; hereditary tumours; BRCA1; PTT	SUSCEPTIBILITY GENE; FAMILIAL BREAST; HISTOPROGNOSTIC GRADE; TUMORS; LINKAGE	The most common mutations in the familial breast and ovarian cancer susceptibility gene BRCA1 are frameshift and nonsense mutations, which lead to the synthesis of truncated proteins. On this ground, we have analysed BRCA1 exon 11, which includes about 61% of coding region, in germline DNA from 70 Italian breast and/or ovarian cancer patients, using the protein truncation test (PTT). BRCA1 mutations were identified in nine of 29 (similar to 31%) patients with a family history of cancer and in three of 41 (similar to 7%) women with early-onset breast carcinomas, and were subsequently characterized by sequence analysis. In addition, BRCA1 mutations were also detected in six affected relatives of two positive index cases, The observed frequencies of mutations were not significantly different from those expected on the basis of the phenotypic characteristics of patients and their families, indicating that PTT is a rapid and sensitive method that can be used for a first BRCA1 mutational screening, The histological findings in BRCA1 mutated cases showed that eight of nine (similar to 89%) breast carcinomas were of grade III and nine of 9 (100%) ovarian carcinomas were of the endometrioid type (eight of grade III and one of grade II). This suggests that specific histological characteristics may represent additional criteria for selection of cases eligible to BRCA1 mutational analysis.	IST NAZL TUMORI, DIV EXPT ONCOL A, I-20133 MILAN, ITALY; IST NAZL TUMORI, DIV SURG GYNECOL ONCOL, I-20133 MILAN, ITALY; IST NAZL TUMORI, DIV SURG ONCOL C, I-20133 MILAN, ITALY; IST NAZL TUMORI, DIV IMMUNOHEMATOL, I-20133 MILAN, ITALY; IST NAZL TUMORI, DIV ANAT PATHOL & CITOL, I-20133 MILAN, ITALY; UNIV PISA, INST PATHOL ANAT, I-56126 PISA, ITALY	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Pisa			Radice, Paolo/O-3119-2013; Pierotti, Marco Alessandro/AAC-4728-2022; Caligo, Adelaide Maria/K-4289-2018	Radice, Paolo/0000-0001-6298-4111; Pierotti, Marco Alessandro/0000-0002-7431-8332; Caligo, Adelaide Maria/0000-0003-0589-1829				BIGNON YJ, 1995, LANCET, V346, P258, DOI 10.1016/S0140-6736(95)91310-6; Collins FS, 1996, NEW ENGL J MED, V334, P186, DOI 10.1056/NEJM199601183340311; EASTON DF, 1993, AM J HUM GENET, V52, P678; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; FitzGerald MG, 1996, NEW ENGL J MED, V334, P143, DOI 10.1056/NEJM199601183340302; FORD D, 1995, AM J HUM GENET, V57, P1457; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HOGERVORST FBL, 1995, NAT GENET, V10, P208, DOI 10.1038/ng0695-208; HOSKING L, 1995, NAT GENET, V9, P343, DOI 10.1038/ng0495-343; HOULSTON RS, 1991, ANN HUM GENET, V55, P291, DOI 10.1111/j.1469-1809.1991.tb00856.x; JACQUEMIER J, 1995, LANCET, V345, P1503, DOI 10.1016/S0140-6736(95)91060-3; Langston AA, 1996, NEW ENGL J MED, V334, P137, DOI 10.1056/NEJM199601183340301; LINDBLOM A, 1995, BREAST CANCER RES TR, V34, P171, DOI 10.1007/BF00665789; MATSUSHIMA M, 1995, HUM MOL GENET, V4, P1953, DOI 10.1093/hmg/4.10.1953; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NAROD S, 1994, LANCET, V343, P236, DOI 10.1016/S0140-6736(94)91021-9; PIVER MS, 1993, CANCER-AM CANCER SOC, V71, P582; PLUMMER SJ, 1995, HUM MOL GENET, V4, P1989, DOI 10.1093/hmg/4.10.1989; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; ROEST PAM, 1993, HUM MOL GENET, V2, P1719, DOI 10.1093/hmg/2.10.1719; SANDER F, 1977, P NATL ACAD SCI USA, V74, P5463; Scully R. E, 1979, TUMORS OVARY MALDEVE; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; STRUEWING JP, 1995, AM J HUM GENET, V57, P1; SZABO CI, 1995, HUM MOL GENET, V4, P1811, DOI 10.1093/hmg/4.suppl_1.1811; TAKAHASHI H, 1995, CANCER RES, V55, P2998; TORNOS C, 1995, AM J SURG PATHOL, V19, P1343, DOI 10.1097/00000478-199512000-00001; VANRENSBURG EJ, 1995, J CLIN PATHOL, V48, P789, DOI 10.1136/jcp.48.9.789; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	32	26	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	1996	13	6					1353	1357						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808710				2022-12-17	WOS:A1996VJ20200027
J	Yuan, ZM; Huang, YY; Kraeft, SK; Chen, LB; Kharbanda, S; Kufe, D				Yuan, ZM; Huang, YY; Kraeft, SK; Chen, LB; Kharbanda, S; Kufe, D			Interaction of cyclin-dependent kinase 2 and the Lyn tyrosine kinase in cells treated with 1-beta-D-arabinofuranosylctosine	ONCOGENE			English	Article						cyclin dependent kinase; protein tyrosine kinase; 1-beta-D-arabinofuranosylcytosine; DNA damage; cell cycle arrest	MYELOID-LEUKEMIA CELLS; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; CATALYTIC SUBUNIT; ACTIVATING KINASE; HUMAN FIBROBLASTS; EPITHELIAL-CELLS; ANTIGEN RECEPTOR; MAMMALIAN-CELLS; SERINE KINASE	The cyclin dependent kinase 2 (Cdk2) is required for initiation and progression of DNA replication, Activation of Cdk2 involves binding to cyclin E or cyclin A and dephosphorylation of Tyr15, The present studies demonstrate that treatment of U-937 cells with 1-beta-D-arabinofuranosylcytosine (ara-C) is associated with tyrosine phosphorylation of Cdk2 and inhibition of Cdk2 activity, The results also demonstrate that Cdk2 directly associates with the Src-like tyrosine kinase Lyn as a consequence of ara-C-treatment, Confocal microscopy studies show that Lyn is detectable in the nucleus and that it colocalises with Cdk2, Subcellular fractionation and coimmunoprecipitation studies further demonstrate nuclear binding of Lyn and Cdk2, We also show that Lyn phosphorylates Tyr15 of Cdk2 and that incubation of Lyn with Cdk2 results in inhibition of Cdk2 activity, These findings suggest that the association of Lyn and Cdk2 in ara-C-treated cells may contribute to regulation of Cdk2-dependent cell cycle checkpoints.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CANC PHARMACOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CELLULAR & MOL BIOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School					NCI NIH HHS [CA29431] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA029431] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATHERTONFESSLER S, 1994, MOL BIOL CELL, V5, P989, DOI 10.1091/mbc.5.9.989; CICHOWSKI K, 1992, J BIOL CHEM, V267, P5025; DAVIDPFEUTY T, 1990, J CELL BIOL, V111, P3097, DOI 10.1083/jcb.111.6.3097; DRABEROVA L, 1993, P NATL ACAD SCI USA, V90, P3611, DOI 10.1073/pnas.90.8.3611; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; FRAM RJ, 1982, CANCER RES, V42, P4050; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GUNJI H, 1991, CANCER RES, V51, P741; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KHARBANDA S, 1994, ONCOGENE, V9, P3005; KHARBANDA S, 1994, J BIOL CHEM, V269, P20739; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KUFE DW, 1984, MOL PHARMACOL, V26, P128; KUFE DW, 1980, J BIOL CHEM, V255, P8997; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MAJOR PP, 1981, P NATL ACAD SCI-BIOL, V78, P3235, DOI 10.1073/pnas.78.5.3235; MAJOR PP, 1982, BIOCHEM PHARMACOL, V31, P2937, DOI 10.1016/0006-2952(82)90266-0; MINOGUCHI K, 1994, J BIOL CHEM, V269, P5249; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; OHNO Y, 1988, CANCER RES, V48, P1494; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; PLEIMAN CM, 1993, MOL CELL BIOL, V13, P5877, DOI 10.1128/MCB.13.9.5877; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SCHEUERMANN RH, 1994, P NATL ACAD SCI USA, V91, P4048, DOI 10.1073/pnas.91.9.4048; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; STANLEY E, 1991, MOL CELL BIOL, V11, P3399, DOI 10.1128/MCB.11.7.3399; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; TOWNSEND AJ, 1987, MOL PHARMACOL, V32, P330; TSAI LH, 1993, ONCOGENE, V8, P1593; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; YUAN ZM, 1995, BIOCHEMISTRY-US, V34, P1058, DOI 10.1021/bi00003a041; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	54	26	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					939	946						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806683				2022-12-17	WOS:A1996VG76600007
J	Taniguchi, T; Takaishi, K; Murayama, T; Ito, M; Iwata, N; Chihara, K; Sasaki, T; Takai, Y; Matsui, T				Taniguchi, T; Takaishi, K; Murayama, T; Ito, M; Iwata, N; Chihara, K; Sasaki, T; Takai, Y; Matsui, T			Cholecystokinin-B/gastrin receptors mediate rapid formation of actin stress fibers	ONCOGENE			English	Article						stress fiber; cholecystokinin; gastrin; rho p21; PDGF	PROTEIN RHO GDI; SWISS 3T3 CELLS; TYROSINE KINASE; HUMAN BRAIN; ADP-RIBOSYLTRANSFERASE; CLOSTRIDIUM-BOTULINUM; GASTRIN RECEPTOR; FOCAL ADHESIONS; GROWTH; CLONING	Specific receptors for brain-gut peptide hormones, cholecystokinin (CCK) and gastrin, are expressed in a variety of human tumor cells, CCK and gastrin promote the growth of NIH3T3 cells into which the CCK-B/gastrin receptor had been introduced via a eukaryotic expression vector. In this study, we have examined the effect of CCK-8 on the actin cytoskeleton by using two mouse fibroblast cell lines expressing human CCK-B/gastrin receptors. Treatment with very low concentrations of CCK-8 (10(-10) M) induced the formation of actin stress fibers within one minute. Stress fiber formation increased for 30 min, In contrast, a potent mitogen for fibroblasts, platelet-derived growth factor (PDGF), initially induced membrane ruffling and, later, a weak formation of stress fibers. Microinjection of rho GDP dissociation inhibitor or Clostridium botulinum ADP-ribosyltransferase C3 which is known to impair the function of a small GTP-binding protein, rho p21, inhibited the stress fiber formation by CCK-8 as well as by PDGF. These results indicate that CCK-B/gastrin receptor could regulate stress fiber formation in a rho p21-dependent manner. The signals from CCK-B/gastrin receptor might affect cell growth as well as cell motility or adhesion by regulating the actin cytoskeleton.	KOBE UNIV,SCH MED,DEPT MED,DIV 3,KOBE 650,JAPAN; OSAKA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,SUITA,OSAKA 565,JAPAN	Kobe University; Osaka University			Matsui, Toshimitsu/E-8065-2010	Matsui, Toshimitsu/0000-0002-2536-7584				CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; HOOSEIN NM, 1988, CANCER RES, V48, P7179; ISHIZUKA J, 1992, ANN SURG, V215, P528, DOI 10.1097/00000658-199205000-00016; ITO M, 1993, J BIOL CHEM, V268, P18300; ITO M, 1994, CELL GROWTH DIFFER, V5, P1127; JOHNSON LR, 1988, PHYSIOL REV, V68, P456, DOI 10.1152/physrev.1988.68.2.456; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LEE YM, 1993, J BIOL CHEM, V268, P8164; MATSUMORI Y, 1995, CANCER RES, V55, P276; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MIURA Y, 1993, J BIOL CHEM, V268, P510; NEMOTO Y, 1991, J BIOL CHEM, V266, P19312; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; PISEGNA JR, 1992, BIOCHEM BIOPH RES CO, V189, P296, DOI 10.1016/0006-291X(92)91557-7; RAUFMAN JP, 1984, AM J PHYSIOL, V247, pG95, DOI 10.1152/ajpgi.1984.247.1.G95; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; Sacerdote P, 1988, Peptides, V9 Suppl 1, P29, DOI 10.1016/0196-9781(88)90219-7; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SETHI T, 1991, CANCER RES, V51, P3621; SILEN ML, 1993, TRENDS ENDOCRIN MET, V4, P131, DOI 10.1016/1043-2760(93)90037-F; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TANIGUCHI T, 1994, ONCOGENE, V9, P861; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031; ZIMONJIC DB, 1994, CYTOGENET CELL GENET, V65, P184, DOI 10.1159/000133628	30	26	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 21	1996	12	6					1357	1360						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649838				2022-12-17	WOS:A1996UC06700021
J	AMFO, K; NEYNS, B; TEUGELS, E; LISSENS, W; BOURGAIN, C; DESUTTER, P; VANDAMME, B; VAMOS, E; DEGREVE, J				AMFO, K; NEYNS, B; TEUGELS, E; LISSENS, W; BOURGAIN, C; DESUTTER, P; VANDAMME, B; VAMOS, E; DEGREVE, J			FREQUENT DELETION OF CHROMOSOME-19 AND A RARE REARRANGEMENT OF 19P13.3 INVOLVING THE INSULIN-RECEPTOR GENE IN HUMAN OVARIAN-CANCER	ONCOGENE			English	Article						OVARIAN CANCER; LOSS OF HETEROZYGOSITY; REARRANGEMENT; INSULIN RECEPTOR; CHROMOSOME 19	RIBONUCLEIC-ACID; P53 GENE; C-JUN; DNA; HETEROZYGOSITY; CARCINOMAS; LOSSES; POLYMORPHISM; ABERRATIONS; ALLELOTYPE	Human ovarian cancer cells usually have multiple specific chromosomal deletions which can be detected by cytogenetic analysis or molecular techniques. Tumour suppressor genes might be located in these deleted chromosomal segments. The importance of these different loci is usually estimated from the frequency with which they are deleted. Here we report a 59% loss of heterozygosity for chromosome 19 in the DNA of human invasive epithelial ovarian cancer from a series of 37 patients. In all cases informative on both chromosomal arms a subchromosomal loss is observed, Analysis of the same tumours for chromosome 17p and 11p loss suggests that loss of chromosome 19p/q is less important than 17p loss, but more important than lip loss. The deletion of chromosome 19q seems to be associated with distant, hematogeneous metastasis (stage TV), In two patients with high grade tumours, the deletion involves a rearrangement of the insulin receptor locus (19p13.3), This suggests that some of the previously described frequent cytogenetic 19p(+) markers and 19p13.3 breaks observed in high grade ovarian cancers, might actually occur in the insulin receptor gene.	FREE UNIV BRUSSELS,AKAD ZIEKENHUIS,HOP BRUGMANN,MED ONCOL LAB,B-1090 JETTE,BELGIUM; FREE UNIV BRUSSELS,AKAD ZIEKENHUIS,HOP BRUGMANN,DEPT MED ONCOL & HEMATOL,B-1090 JETTE,BELGIUM; FREE UNIV BRUSSELS,AKAD ZIEKENHUIS,HOP BRUGMANN,EXPTL PATHOL LAB,B-1090 JETTE,BELGIUM; FREE UNIV BRUSSELS,AKAD ZIEKENHUIS,HOP BRUGMANN,DEPT GYNAECOL ONCOL,B-1090 JETTE,BELGIUM; FREE UNIV BRUSSELS,AKAD ZIEKENHUIS,HOP BRUGMANN,CYTOGENET LAB,B-1090 JETTE,BELGIUM; FREE UNIV BRUSSELS,AKAD ZIEKENHUIS,HOP BRUGMANN,MED GENET LAB,B-1090 JETTE,BELGIUM	Vrije Universiteit Brussel; Vrije Universiteit Brussel; Vrije Universiteit Brussel; Vrije Universiteit Brussel; Vrije Universiteit Brussel; Vrije Universiteit Brussel			Neyns, Bart/ABG-3145-2021; De Greve, Jacques/J-4939-2012; Lissens, Willy/B-2892-2013; Neyns, Bart/AAA-8267-2021	Neyns, Bart/0000-0003-0658-5903; De Greve, Jacques/0000-0002-2389-0742; Lissens, Willy/0000-0003-3875-9955; Teugels, Erik/0000-0002-7828-4555; De Sutter, Philippe/0000-0002-3064-3344				AMAN P, 1994, INT J ONCOL, V5, P177; Ausubel F.M., 1994, CURRENT PROTOCOLS MO, V1; BARKER D, 1987, CYTOGENET CELL GENET, V46, P576; Battey, 1986, BASIC METHODS MOL BI; BELLO MJ, 1990, INT J CANCER, V45, P50, DOI 10.1002/ijc.2910450111; BERCHUCK A, 1992, AM J OBSTET GYNECOL, V166, P674; BOYD P, 1986, HUM GENET, V73, P171, DOI 10.1007/BF00291609; BRYSCH W, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P401; CHEVENIXTRENCH G, 1992, ONCOGENE, V7, P1059; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLIBY W, 1993, CANCER RES, V53, P2393; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; ECCLES DM, 1990, ONCOGENE, V5, P1599; EHLEN T, 1990, ONCOGENE, V5, P219; ELLEIN SC, 1986, P NATL ACAD SCI USA, V83, P5223; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOULKES WD, 1993, INT J CANCER, V54, P220, DOI 10.1002/ijc.2910540210; FROSSARD PM, 1987, GENE, V51, P103, DOI 10.1016/0378-1119(87)90480-X; GOLDSTEIN BJ, 1987, MOL ENDOCRINOL, V1, P759, DOI 10.1210/mend-1-11-759; HOPPENER JWM, 1988, FEBS LETT, V233, P57, DOI 10.1016/0014-5793(88)81355-3; JENKINS RB, 1993, CANCER GENET CYTOGEN, V71, P76, DOI 10.1016/0165-4608(93)90205-Z; KORNELUK RG, 1991, NUCLEIC ACIDS RES, V19, P1157, DOI 10.1093/nar/19.5.1157; KUNKEL LM, 1977, P NATL ACAD SCI USA, V74, P1245, DOI 10.1073/pnas.74.3.1245; LEE JH, 1990, CANCER RES, V50, P2724; MAEDA N, 1983, P NATL ACAD SCI-BIOL, V80, P5012, DOI 10.1073/pnas.80.16.5012; MARKS JR, 1991, CANCER RES, V51, P2979; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MOK CH, 1992, CANCER RES, V52, P5119; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P5707, DOI 10.1093/nar/16.12.5707; OKAMOTO A, 1991, CANCER RES, V51, P5171; PEJOVIC T, 1992, GENE CHROMOSOME CANC, V4, P58, DOI 10.1002/gcc.2870040108; RUSSELL SEH, 1990, ONCOGENE, V5, P1581; SATO T, 1991, CANCER RES, V51, P5118; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SNDBERG AA, 1990, CHROMOSOMES HUMAN CA, P839; SOUTHERN EM, 1975, J MOL BIOL, V938, P503; TAVASSOLI M, 1993, GENE CHROMOSOME CANC, V8, P195, DOI 10.1002/gcc.2870080310; TSAO SW, 1991, ANTICANCER RES, V11, P1975; VANDAMME B, 1992, CANCER RES, V52, P6646; VONDEIMLING A, 1992, CANCER RES, V52, P4277; YANGFENG TL, 1993, INT J CANCER, V54, P546, DOI 10.1002/ijc.2910540405; Young R.C., 1993, CANC PRINCIPLES PRAC, P1226; ZHENG JP, 1991, CANCER RES, V51, P4045	45	26	26	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 20	1995	11	2					351	358						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7624149				2022-12-17	WOS:A1995RK95700015
J	WELLBROCK, C; LAMMERS, R; ULLRICH, A; SCHARTL, M				WELLBROCK, C; LAMMERS, R; ULLRICH, A; SCHARTL, M			ASSOCIATION BETWEEN THE MELANOMA-INDUCING RECEPTOR TYROSINE KINASE XMRK AND SRC FAMILY TYROSINE KINASES IN XIPHOPHORUS	ONCOGENE			English	Article						GROWTH FACTOR RECEPTOR; MELANOMA; PLC-GAMMA; SIGNAL TRANSDUCTION; SH2 DOMAIN; TYROSINE KINASES	GROWTH-FACTOR RECEPTOR; PHOSPHOLIPASE-C-GAMMA; FAINT-LITTLE-BALL; EGF RECEPTOR; ELEVATED EXPRESSION; SIGNAL-TRANSDUCTION; MALIGNANT-MELANOMA; SH2 DOMAINS; PROTEIN; GENE	Melanoma formation in the fish Xiphophorus is an in vivo model for the function of receptor tyrosine kinases (RTKs) in tumor development. The overexpression and high activity of the RTK Xmrk (Xiphophorus melanoma receptor kinase) is responsible for the formation of hereditary malignant melanoma in this fish, but the mechanism by which Xmrk signals cell proliferation has not been elucidated. Remarkably, in earlier experiments an elevated level of a pp60(c-src) related kinase activity was found in the melanomas. In order to evaluate the significance of src family SH2 domain interactions in the intracellular signalling of Xmrk, we determined its relative binding affinity to the ubiquitous general RTK substrate, PLC gamma, and to the Xiphophorus cytoplasmic kinases Xsrc, Xfyn and Xyes. Recombinant Xmrk purified from baculovirus infected Sf9 cells bound with high affinity to the SH2 domains of PLC gamma and Xfyn in vitro. The affinity of Xmrk to Xsrc and Xyes SH2 domains was 5- to 10-fold lower. Coprecipitation experiments revealed that the Xmrk/Xfyn interaction occurred also in melanoma cells. Moreover, stimulation of the Xmrk kinase activity was paralleled by an increase in Xfyn activity. These results suggest that in malignant melanoma of Xiphophorus the highly activated Xmrk may enhance the activity of Xfyn through direct interaction and that both kinases are linked in a signal transduction pathway.	UNIV WURZBURG, THEODOR BOVERI INST, BIOCTR, DEPT PHYSIOL CHEM 1, D-97074 WURZBURG, GERMANY; MAX PLANCK INST BIOCHEM, DEPT MOLEC BIOL, D-82152 MARTINSRIED, GERMANY	University of Wurzburg; Max Planck Society				Wellbrock, Claudia/0000-0002-3825-6381; Schartl, Manfred/0000-0001-9882-5948				ADAM D, 1993, SCIENCE, V259, P816, DOI 10.1126/science.8430335; ADAM D, 1991, ONCOGENE, V6, P73; ALTSCHMIED J, 1994, LEGACY CELL FUSION, P199; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BARNEKOW A, 1982, CANCER RES, V42, P2429; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; FENDLY BM, 1990, CANCER RES, V50, P1550; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HANNIG G, 1991, ONCOGENE, V6, P361; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LOGANZO F, 1993, ONCOGENE, V8, P2637; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MALITSCHEK B, 1994, J BIOL CHEM, V269, P10423; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MAUELER W, 1988, ONCOGENE, V3, P113; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; PAWSON T, 1994, CURR OPIN GENET DEV, V4, P1, DOI 10.1016/0959-437X(94)90084-1; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; RATH HM, 1990, J BIOL CHEM, V265, P3080; ROTIN D, 1992, J BIOL CHEM, V267, P9678; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SCHARTL M, 1985, INT J CANCER, V36, P199, DOI 10.1002/ijc.2910360212; SCHARTL M, 1982, CANCER RES, V42, P4222; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SIERKE SL, 1983, BIOL BIOPHYS RES COM, V191, P45; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, MOL CELL BIOL, V73, P321; WAKAMATSU Y, 1981, CANCER RES, V41, P679; WINKLER C, 1994, ONCOGENE, V9, P1517; WITTBRODT J, 1992, EMBO J, V11, P4239, DOI 10.1002/j.1460-2075.1992.tb05518.x; WITTBRODT J, 1989, NATURE, V341, P415, DOI 10.1038/341415a0; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHU GC, 1993, J BIOL CHEM, V268, P1775; ZHU GC, 1994, ONCOGENE, V9, P1379	41	26	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	1995	10	11					2135	2143						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7540277				2022-12-17	WOS:A1995RB70300008
J	ROLLING, C; TRETON, D; BECKMANN, P; GALANAUD, P; RICHARD, Y				ROLLING, C; TRETON, D; BECKMANN, P; GALANAUD, P; RICHARD, Y			JAK3 ASSOCIATES WITH THE HUMAN INTERLEUKIN-4 RECEPTOR AND IS TYROSINE-PHOSPHORYLATED FOLLOWING RECEPTOR TRIGGERING	ONCOGENE			English	Article						JAK3; PTK; PTP; IL4R; HUMAN B-CELLS	SIGNAL-TRANSDUCTION; GAMMA-CHAIN; INTERFERON-ALPHA/BETA; FUNCTIONAL COMPONENT; IGE SYNTHESIS; B-CELLS; PROTEIN; KINASE; IL-4; IGG4	In human B cells, interleukin 4 (IL4) acts in regulating proliferation, antigen expression, isotype switching and differentiation. These different effects are mediated through the LL4R complex including the IL2R gamma chain (gamma c) and a specific p130/140 binding unit referred below as human Interleukin 4 Receptor (IL4-R). Here, we studied the signal transduction events following LT4R activation and leading to CD23 expression on resting B cells. We demonstrate that LL4R triggering induced the tyrosine phosphorylation of JAK3 and of a p170 protein. Coimmunoprecipitation of JAK3 with the IL4R suggests a physical association which exists prior to IL4R complex stimulation. Orthovanadate treatment, while having no effect on IL4-induced p130 phosphorylation, leads to the hyperphosphorylation of the p170 and inhibits IL4-induced CD23 expression. These suggest that two mandatory steps exist in early IL4 signaling: one controlled by JAK3 activation and the other by the p170 phosphoprotein.	INST PARIS SUD CYTOKINES,INSERM,U131,CLAMART,FRANCE; IMMUNEX CORP,SEATTLE,WA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Immunex Corporation			RICHARD, Yolande/B-7926-2008	RICHARD, Yolande/0000-0001-8560-9250				ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; AVERSA G, 1993, J EXP MED, V178, P2213, DOI 10.1084/jem.178.6.2213; DELESPESSE G, 1992, IMMUNOL REV, V125, P77, DOI 10.1111/j.1600-065X.1992.tb00626.x; GASCAN H, 1991, J EXP MED, V173, P747, DOI 10.1084/jem.173.3.747; GOUJON L, 1994, P NATL ACAD SCI USA, V91, P957, DOI 10.1073/pnas.91.3.957; Isfort RJ, 1990, GROWTH FACTORS, V2, P213, DOI 10.3109/08977199009071507; IZUHARA K, 1993, J BIOL CHEM, V268, P13097; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KOETTNITZ K, 1993, EUR J IMMUNOL, V23, P988, DOI 10.1002/eji.1830230437; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; MIRESLUIS AR, 1991, J BIOL CHEM, V266, P18113; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; PARK LS, 1987, J EXP MED, V166, P476, DOI 10.1084/jem.166.2.476; PAUL WE, 1991, BLOOD, V77, P1859; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; RICHARD Y, 1986, EUR J IMMUNOL, V16, P1303, DOI 10.1002/eji.1830161019; ROLLING CH, 1994, IN PRESS LEUCOCYTE T, V5; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SEDIN DC, 1994, P NATL ACAD SCI USA, V91, P2140; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; TANAKA N, 1994, P NATL ACAD SCI USA, V91, P7271, DOI 10.1073/pnas.91.15.7271; VANDERKUUR JA, 1994, J BIOL CHEM, V34, P21709; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WALTING D, 1993, NATURE, V366, P166; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1992, P NATL ACAD SCI USA, V90, P4032; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x	36	26	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 4	1995	10	9					1757	1761						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7538655				2022-12-17	WOS:A1995QX46900009
J	TAYLOR, JP; POMERANTZ, RJ; OAKES, JW; KHALILI, K; AMINI, S				TAYLOR, JP; POMERANTZ, RJ; OAKES, JW; KHALILI, K; AMINI, S			A CNS-ENRICHED FACTOR THAT BINDS TO NF-KAPPA-B AND IS REQUIRED FOR INTERACTION WITH HIV-1 TAT	ONCOGENE			English	Note						TAT; HIV-1; NF-KAPPA-B; TRANSCRIPTION FACTOR; TAR	HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; TRANS-ACTIVATOR GENE; INDEPENDENT ACTIVATION; TRANSCRIPTION FACTOR; KAPOSIS-SARCOMA; NASCENT RNA; PROTEIN; TYPE-1; CELLS	The Human Immunodeficiency Virus type 1 (HIV-1) Tat protein is a potent activator of transcription directed by the long terminal repeat (LTR), an essential step in the life-cycle of HIV-1. While interaction of Tat with an RNA element encoded by downstream LTR sequences (termed TAR) is commonly considered essential to activation, numerous recent reports have implicated upstream transcription elements within the LTR as participants in mediating this activation. We have recently demonstrated that Tat activation occurs independent of the TAR element in certain cells derived from the central nervous system (CNS), and that this activation is mediated by the kappa B domain of the LTR. Further, CNS-derived cells were found to contain kappa B-binding activity capable of both interacting with Tat and activating LTR transcription in vitro, The present study demonstrates that the kappa B-binding transcription factor derived from CNS cells consists of a component indistinguishable from prototypical Nuclear Factor-kappa B (NEF-kappa B) (in size, mobility on native gel, kinetics of activation and cognate binding sequence) as well as a supershifting component that is dissociable under certain conditions. The supershifting activity is found to stabilize binding of the presumed NF-kappa B to DNA. Further, only the form of NF-kappa B which is associated with this supershifting activity is capable of binding Tat. We hypothesize a model in which Tat utilizes this interaction to activate HIV-1 through the NF-kappa B domain of the LTR in circumstances where TAR is absent. This model has implications with respect to the ability of Tat to alter cellular gene expression and perhaps contribute to the array of problems seen in HIV-1 infection such as altered immune status, CNS toxicity, and the formation of tumors.	THOMAS JEFFERSON UNIV,JEFFERSON INST MOLEC MED,DEPT BIOCHEM & MOLEC BIOL,MOLEC NEUROVIROL SECT,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT MED,DIV INFECT DIS,DORRANCE H HAMILTON LABS,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University			Taylor, J. Paul/N-2482-2018	Taylor, J. Paul/0000-0002-5794-0349	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028272, R01AI031836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS030916] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI28272, AI31836] Funding Source: Medline; NINDS NIH HHS [P01 NS30916] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAGASRA O, 1992, J VIROL, V66, P7522, DOI 10.1128/JVI.66.12.7522-7528.1992; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BERKHOUT B, 1990, CELL, V62, P757, DOI 10.1016/0092-8674(90)90120-4; BUONAGURO L, 1992, J VIROL, V66, P7159, DOI 10.1128/JVI.66.12.7159-7167.1992; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CULLEN BR, 1991, FASEB J, V5, P2361, DOI 10.1096/fasebj.5.10.1712325; CULLEN BR, 1990, CELL, V63, P655, DOI 10.1016/0092-8674(90)90129-3; CUPP C, 1993, ONCOGENE, V8, P2231; DAYTON AI, 1986, CELL, V44, P941, DOI 10.1016/0092-8674(86)90017-6; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; FEINBERG MB, 1991, P NATL ACAD SCI USA, V88, P4045, DOI 10.1073/pnas.88.9.4045; FISHER AG, 1986, NATURE, V320, P367, DOI 10.1038/320367a0; Frankel AD, 1992, CURR OPIN GENET DEV, V2, P293, DOI 10.1016/S0959-437X(05)80287-4; GARCIA JA, 1988, EMBO J, V7, P3143, DOI 10.1002/j.1460-2075.1988.tb03181.x; HARRICH D, 1990, EMBO J, V9, P4417, DOI 10.1002/j.1460-2075.1990.tb07892.x; HUANG LM, 1993, J VIROL, V67, P6937, DOI 10.1128/JVI.67.12.6937-6944.1993; JEANG KT, 1992, J BIOL CHEM, V267, P17891; JEANG KT, 1993, J VIROL, V67, P6224, DOI 10.1128/JVI.67.10.6224-6233.1993; KAMINE J, 1991, P NATL ACAD SCI USA, V88, P8510, DOI 10.1073/pnas.88.19.8510; KASHANCHI F, 1994, NATURE, V367, P295, DOI 10.1038/367295a0; KIM CM, 1992, ONCOGENE, V7, P1525; MARCINIAK RA, 1990, CELL, V63, P791, DOI 10.1016/0092-8674(90)90145-5; MARCINIAK RA, 1991, EMBO J, V10, P4189, DOI 10.1002/j.1460-2075.1991.tb04997.x; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; NABELL LM, 1994, CELL GROWTH DIFFER, V5, P87; NELBOCK P, 1990, SCIENCE, V248, P1650, DOI 10.1126/science.2194290; PONTEN J, 1968, ACTA PATHOL MIC SC, V74, P465; ROY S, 1990, J VIROL, V64, P1402, DOI 10.1128/JVI.64.3.1402-1406.1990; SASTRY KJ, 1990, J BIOL CHEM, V265, P20091; SCALA G, 1994, J EXP MED, V179, P961, DOI 10.1084/jem.179.3.961; SELBY MJ, 1990, CELL, V62, P769, DOI 10.1016/0092-8674(90)90121-T; SHARP PA, 1989, CELL, V59, P229, DOI 10.1016/0092-8674(89)90279-1; SOUTHGATE C, 1990, NATURE, V345, P640, DOI 10.1038/345640a0; TAYLOR JP, 1993, VIROLOGY, V195, P780, DOI 10.1006/viro.1993.1430; TAYLOR JP, 1994, J VIROL, V68, P3971, DOI 10.1128/JVI.68.6.3971-3981.1994; TAYLOR JP, 1992, EMBO J, V11, P3395, DOI 10.1002/j.1460-2075.1992.tb05418.x; TAYLOR JP, 1992, P NATL ACAD SCI USA, V89, P9617, DOI 10.1073/pnas.89.20.9617; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0	39	26	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 19	1995	10	2					395	400						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7838536				2022-12-17	WOS:A1995QC62400019
J	PLUMMER, SJ; SANTIBANEZKOREF, M; KUROSAKI, T; LIAO, S; NOBLE, B; FAIN, PR; ANTONCULVER, H; CASEY, G				PLUMMER, SJ; SANTIBANEZKOREF, M; KUROSAKI, T; LIAO, S; NOBLE, B; FAIN, PR; ANTONCULVER, H; CASEY, G			A GERMLINE 2.35-KB DELETION OF P53 GENOMIC DNA CREATING A SPECIFIC LOSS OF THE OLIGOMERIZATION DOMAIN INHERITED IN A LI-FRAUMENI-SYNDROME FAMILY	ONCOGENE			English	Article							CANCER-PRONE FAMILY; MUTANT P53; BREAST-CANCER; WILD-TYPE; SPLICING MUTATION; SUPPRESSOR GENE; PROTEINS; BINDING; PHOSPHORYLATION; TRANSACTIVATION	The primary genetic cancer predisposing event in many Li-Fraumeni syndrome families is a germline mutation in the p53 gene. We describe an extended Li-Fraumeni family with a germline mutation in the p53 gene involving a deletion of exon 10. The mutation is a 2.35 kilobase intragenic deletion encompassing exon 10, which results in the specific loss of the entire p53 oligomerization domain. This mutation segregates with the cancer phenotype. A lymphoblastoid cell line developed from a mutation carrier shows accumulation of mutant p53 protein by immunoblotting. However, tumor tissues from two affected carriers are negative by immunohistochemical staining. A major structural alteration specifically involving the oligomerization domain of a germline p53 gene has not been previously described and occurs in a region rarely mutated in sporadic tumors. The oligomerization domain is dispensable for many wild-type p53 functions, including transactivation, sequence-specific DNA binding, and suppression of oncogenic transformation. However, the domain appears to be required for trancriptional repression, and DNA strand reassociation. The identification of this mutation in an LFS family may yield insights into the importance of the oligomerization domain for suppressor function of the p53 tumor suppressor gene.	CLEVELAND CLIN FDN,DEPT CANC BIOL,CLEVELAND,OH 44195; UNIV CALIF IRVINE,DEPT MED,PROGRAM EPIDEMIOL,IRVINE,CA 92717; UNIV UTAH,DEPT MED INFORMAT,SALT LAKE CITY,UT 84108	Cleveland Clinic Foundation; University of California System; University of California Irvine; Utah System of Higher Education; University of Utah					NCI NIH HHS [CA56554] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R03CA056554] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADDISON C, 1990, ONCOGENE, V5, P423; ANDERSON MA, 1984, IN VITRO CELL DEV B, V20, P856; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BIRCH JM, 1994, CANCER RES, V54, P1298; BODNER SM, 1992, ONCOGENE, V7, P743; BORRESEN AL, 1992, CANCER RES, V52, P3234; BRAIN R, 1994, ONCOGENE, V9, P1775; BRUGIERES L, 1993, CANCER RES, V53, P452; CASEY G, 1993, HUM MOL GENET, V2, P1921, DOI 10.1093/hmg/2.11.1921; CASEY G, 1993, CANCER LETT, V69, P151, DOI 10.1016/0304-3835(93)90168-9; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FELIX CA, 1993, ONCOGENE, V8, P1203; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; FREBOURG T, 1992, J CLIN INVEST, V90, P1637, DOI 10.1172/JCI116034; GARBER JE, 1991, CANCER RES, V51, P6094; HAINAUT P, 1994, ONCOGENE, V9, P299; HARLOW E, 1988, ANTIBODIES LABORATOR; HORIO Y, 1994, ONCOGENE, V9, P1231; JOLLY KW, 1994, ONCOGENE, V9, P97; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEGROS Y, 1994, ONCOGENE, V9, P2071; LI FP, 1988, CANCER RES, V48, P5358; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1993, CANCER GENET CYTOGEN, V66, P83, DOI 10.1016/0165-4608(93)90233-C; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; MAZOYER S, 1994, ONCOGENE, V9, P1237; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIETENPOL JA, 1993, NATURE, V365, P17, DOI 10.1038/365017a0; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; Reed Michael, 1993, Gene Expression, V3, P95; SAMESHIMA Y, 1992, J NATL CANCER I, V48, P5358; SANTIBANEZKOREF MF, 1991, LANCET, V338, P1490, DOI 10.1016/0140-6736(91)92303-J; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; SRIVASTAVA S, 1993, CANCER RES, V53, P4452; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUBLER MA, 1994, ONCOGENE, V9, P1351; TARUNINA M, 1993, ONCOGENE, V8, P3165; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WARNEFORD SG, 1992, CELL GROWTH DIFFER, V3, P839	50	26	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3273	3280						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936651				2022-12-17	WOS:A1994PM65800020
J	BLACK, EJ; CATLING, AD; WOODGETT, JR; KILBEY, A; GILLESPIE, DAF				BLACK, EJ; CATLING, AD; WOODGETT, JR; KILBEY, A; GILLESPIE, DAF			TRANSCRIPTIONAL ACTIVATION BY THE V-JUN ONCOPROTEIN IS INDEPENDENT OF POSITIVE REGULATORY PHOSPHORYLATION	ONCOGENE			English	Note							DNA-BINDING ACTIVITY; C-JUN; PROTEIN-KINASE; MAMMALIAN-CELLS; DELTA DOMAIN; TRANSFORMATION; FIBROBLASTS; INVITRO; SERINE-63; ONCOGENE	Growth factors, phorbol esters, and oncogenes such as uas, svc, and sis are believed to stimulate c-Jun transcriptional activation by inducing increased phosphorylation at two serine residues (S63 and S73) within the N-terminal transactivation domain. Although S63 and S73 are conserved in the mutant v-Jun oncoprotein, they are not phosphorylated by two enzymes which target the corresponding residues in c-Jun in vitro; namely a partially purified c-Jun kinase from TPA-stimulated U937 cells and purified p54 mitogen activated protein (MAP) kinase. In addition, v-Jun activates transcription more strongly than c-Jun when fused to the Gal4 DNA-binding domain, and transcriptional activation by Gal4-v-Jun is unaffected when S63, S73, or both, are replaced with non-phosphorylatable alanine residues, amino acid substitutions which severely impair transcriptional activation by Gal4-c-Jun. The biochemical and transcriptional properties of result from deletion of a 27 amino acid segment, termed delta, which is important for transforming activity. On the basis of these results we propose that unlike c-jun, v-Jun transcriptional activation is independent of positive regulatory phosphorylation and that this may contribute to oncogenesis by v-Jun.	BEATSON INST CANC RES, BEATSON LABS, CANC RES CAMPAIGN, GLASGOW G62 1BD, LANARK, SCOTLAND; ONTARIO CANC INST, DIV CELLULAR & MOLEC BIOL, TORONTO M4X 1K9, ON, CANADA	Beatson Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto			Gillespie, David/R-4771-2019; Woodgett, Jim/F-1087-2010	Gillespie, David/0000-0002-6338-0544; Woodgett, Jim/0000-0003-3731-5797				Abate C, 1990, Semin Cancer Biol, V1, P19; ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ADLER V, 1992, J BIOL CHEM, V267, P17001; ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLACK EJ, 1991, ONCOGENE, V6, P1949; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CATLING AD, 1993, ONCOGENE, V8, P1875; FRAME MC, 1991, ONCOGENE, V6, P205; GILLESPIE DAF, 1991, SEMINARS VIROLOGY, V2, P329; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MORGAN IM, 1993, ONCOGENE, V8, P1135; NISHIMURA T, 1988, ONCOGENE, V3, P659; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; PULVERER BJ, 1993, ONCOGENE, V8, P407; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507	26	26	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1994	9	8					2363	2368						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036019				2022-12-17	WOS:A1994NX62900030
J	KNAPP, S; DELLEKARTH, G; FRIEDL, J; PURTSCHER, B; MITTERBAUER, G; DOMER, PH; JAEGER, U				KNAPP, S; DELLEKARTH, G; FRIEDL, J; PURTSCHER, B; MITTERBAUER, G; DOMER, PH; JAEGER, U			GUANINE-RICH (GGNNGG) ELEMENTS AT CHROMOSOMAL BREAKPOINTS INTERACT WITH A LOOP-FORMING, SINGLE-STRANDED DNA-BINDING PROTEIN	ONCOGENE			English	Note							POLYMERASE CHAIN-REACTION; ACUTE LEUKEMIAS; MINISATELLITE DNA; CLUSTER REGION; TRANSLOCATION; RECOMBINATION; GENE; SEQUENCES; ORGANIZATION; MECHANISM	Proto-oncogene-activation is frequently preceded by chromosomal translocations. Several models suggest that DNA single-strands and loops may serve as intermediates in the process of illegitimate recombination. Guanine-rich, repetitive elements are preferred sites of chromosomal exchange and can undergo conformational changes which result in the generation of single-stranded DNA. Here we describe a single-stranded DNA-binding protein which binds specifically to guanine-rich elements at the breakpoints of human reciprocal translocations, including the t(14;18), t(2;8), t(9;22), t(15;17) and t(4;11) in leukemia and lymphoma. The primitive binding consensus consists of two guanine-residues on either side separated by a spacer of at least two nucleotides (GGN-NGG). Binding activity is unaltered by a spacer length of up to 46 nucleotides. These data suggest that the protein has the unique ability to form or stabilize DNA-loops and may thus play a general role in recombination.	UNIV VIENNA,DEPT MED 1,DIV HEMATOL,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,DEPT CLIN CHEM & LAB MED,A-1090 VIENNA,AUSTRIA; NORTHWESTERN UNIV,NW MEM HOSP,MOLEC DIAGNOST LAB,CHICAGO,IL 60611	University of Vienna; University of Vienna; Northwestern Memorial Hospital; Northwestern University			Knapp, Sylvia/J-3973-2013	Knapp, Sylvia/0000-0001-9016-5244				ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; BAKHSHI A, 1987, P NATL ACAD SCI USA, V84, P2396, DOI 10.1073/pnas.84.8.2396; BALAGURUMOORTHY P, 1992, NUCLEIC ACIDS RES, V20, P4061, DOI 10.1093/nar/20.15.4061; BELL GI, 1980, NUCLEIC ACIDS RES, V8, P4091, DOI 10.1093/nar/8.18.4091; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P5673, DOI 10.1128/MCB.12.12.5673; CAMERINIOTERO RD, 1993, CELL, V73, P217, DOI 10.1016/0092-8674(93)90224-E; CHANG KS, 1992, BLOOD, V79, P554; CHEN SJ, 1989, ONCOGENE, V4, P195; COGGINS LW, 1992, GENE, V121, P279, DOI 10.1016/0378-1119(92)90132-9; COLLICK A, 1991, NUCLEIC ACIDS RES, V23, P6399; DOMER PH, 1993, P NATL ACAD SCI USA, V90, P7884, DOI 10.1073/pnas.90.16.7884; GERSTEIN RM, 1990, CELL, V63, P537, DOI 10.1016/0092-8674(90)90450-S; GODISKA R, 1990, CELL, V61, P1237, DOI 10.1016/0092-8674(90)90688-B; GU Y, 1992, P NATL ACAD SCI USA, V89, P10464, DOI 10.1073/pnas.89.21.10464; HANSEN SR, 1993, CELL, V73, P1403; HARTL P, 1987, MOL CELL BIOL, V7, P2037, DOI 10.1128/MCB.7.6.2037; ICHIHARA Y, 1988, EMBO J, V7, P4141, DOI 10.1002/j.1460-2075.1988.tb03309.x; JAEGER U, 1993, BLOOD, V81, P1833; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; KROWCZYNSKA AM, 1990, NUCLEIC ACIDS RES, V18, P1121, DOI 10.1093/nar/18.5.1121; LIEBER MR, 1992, CELL, V70, P873, DOI 10.1016/0092-8674(92)90237-7; MCKAY SJ, 1992, NUCLEIC ACIDS RES, V20, P6461, DOI 10.1093/nar/20.24.6461; MESELSON MS, 1975, P NATL ACAD SCI USA, V72, P358, DOI 10.1073/pnas.72.1.358; MIRKIN SM, 1987, NATURE, V330, P495, DOI 10.1038/330495a0; MITANI K, 1990, J BIOL CHEM, V265, P15203; NGAN BY, 1989, BLOOD, V73, P1759; OHSHIMA A, 1992, P NATL ACAD SCI USA, V89, P1016, DOI 10.1073/pnas.89.3.1016; RABBITTS PH, 1988, ONCOGENE, V3, P99; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; REABAN ME, 1990, NATURE, V348, P342, DOI 10.1038/348342a0; RIGGINS GJ, 1992, NAT GENET, V2, P186, DOI 10.1038/ng1192-186; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SMITH GR, 1983, CELL, V34, P709, DOI 10.1016/0092-8674(83)90525-1; STEINMETZ M, 1986, CELL, V44, P895, DOI 10.1016/0092-8674(86)90012-7; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; WAHLS WP, 1990, CELL, V60, P95, DOI 10.1016/0092-8674(90)90719-U; WYATT RT, 1992, J EXP MED, V175, P1575, DOI 10.1084/jem.175.6.1575	38	26	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1501	1505						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152814				2022-12-17	WOS:A1994NH40100025
J	YAMITHEZI, A; PLAKSIN, D; EISENBACH, L				YAMITHEZI, A; PLAKSIN, D; EISENBACH, L			C-FOS AND C-JUN OVEREXPRESSION IN MALIGNANT-CELLS REDUCES THEIR TUMORIGENIC AND METASTATIC POTENTIAL, AND AFFECTS THEIR MHC CLASS-I GENE-EXPRESSION	ONCOGENE			English	Article							NF-KAPPA-B; EMBRYONAL CARCINOMA-CELLS; MAJOR HISTOCOMPATIBILITY GENE; TRANS-ACTING FACTOR; PROTO-ONCOGENE FOS; NEGATIVE REGULATION; TUMOR-CELLS; TRANSCRIPTION FACTORS; BINDING AFFINITIES; CANCER METASTASIS	Reduced co-expression of the c-fos and c-jun protooncogenes has been correlated with the down regulation of H-2K class I major histocompatibility antigens in high-metastatic cell lines from the Lewis lung carcinoma, B16 melanoma and the K1735 melanoma. Transfection of c-jun and c-fos genes into the high metastatic clones D122 (3LL) and F10.9 (B16 melanoma) resulted in activation of H-2 class I gene expression. D122 transfectants expressing high levels of c-jun and c-fos and F10.9 transfectants expressing high levels of c-fos exhibited markedly reduced tumorigenicity and were of low metastatic potential. In contrast, transfection of junB into the low metastatic, high H-2K(b), D(b) expressor clone A9 (3LL), reduced MHC class I gene expression, and converted the parental low, into high-metastatic cells. The data demonstrate the involvement of genes from the fos and jun family in regulation of MHC class I expression and consequently in regulation of immunogenicity and metastatic competence of tumor cells.	WEIZMANN INST SCI, DEPT CELL BIOL, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science				Eisenbach, Lea R/0000-0002-4816-1968	NATIONAL CANCER INSTITUTE [R01CA028139] Funding Source: NIH RePORTER; NCI NIH HHS [CA 28139] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BALDWIN AS, 1987, MOL CELL BIOL, V7, P305, DOI 10.1128/MCB.7.1.305; BARZILAY J, 1987, LEUKEMIA, V1, P198; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; EISENBACH L, 1983, INT J CANCER, V32, P113, DOI 10.1002/ijc.2910320118; Eisenbach L, 1991, Semin Cancer Biol, V2, P179; EISENBACH L, 1984, INT J CANCER, V34, P567, DOI 10.1002/ijc.2910340421; Eisenbach L, 1983, Symp Fundam Cancer Res, V36, P101; Fidler I J, 1978, Adv Cancer Res, V28, P149, DOI 10.1016/S0065-230X(08)60648-X; FIDLER IJ, 1990, J NATL CANCER I, V82, P166, DOI 10.1093/jnci/82.3.166; FLANAGAN JR, 1991, P NATL ACAD SCI USA, V88, P3145, DOI 10.1073/pnas.88.8.3145; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HART IR, 1989, BIOCHIM BIOPHYS ACTA, V989, P65, DOI 10.1016/0304-419X(89)90035-8; HOWCROFT TK, 1993, EMBO J, V12, P3163, DOI 10.1002/j.1460-2075.1993.tb05985.x; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; ISRAEL A, 1987, P NATL ACAD SCI USA, V84, P2653, DOI 10.1073/pnas.84.9.2653; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; KIMURA A, 1986, CELL, V44, P261, DOI 10.1016/0092-8674(86)90760-9; KORBER B, 1988, SCIENCE, V239, P1302, DOI 10.1126/science.3125612; KRALOVA J, 1992, EMBO J, V11, P4591, DOI 10.1002/j.1460-2075.1992.tb05561.x; KRIPKE ML, 1979, JNCI-J NATL CANCER I, V63, P541, DOI 10.1093/jnci/63.3.541; KUSHTAI G, 1990, INT J CANCER, V45, P1131, DOI 10.1002/ijc.2910450624; KUSHTAI G, 1988, ONCOGENE, V2, P119; LENARDO MJ, 1988, P NATL ACAD SCI USA, V85, P8825, DOI 10.1073/pnas.85.23.8825; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MIYAZAKI J, 1986, P NATL ACAD SCI USA, V83, P9537, DOI 10.1073/pnas.83.24.9537; MULLER R, 1984, NATURE, V311, P438, DOI 10.1038/311438a0; MULLER R, 1985, NATURE, V314, P546, DOI 10.1038/314546a0; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; ONO SJ, 1991, P NATL ACAD SCI USA, V88, P4304, DOI 10.1073/pnas.88.10.4304; ONO SJ, 1991, P NATL ACAD SCI USA, V88, P4309, DOI 10.1073/pnas.88.10.4309; OZATO K, 1981, J IMMUNOL, V126, P317; PLAKSIN D, 1993, J EXP MED, V177, P1651, DOI 10.1084/jem.177.6.1651; PLAKSIN D, 1988, P NATL ACAD SCI USA, V85, P4463, DOI 10.1073/pnas.85.12.4463; PORGADOR A, 1989, J IMMUNOGENET, V16, P291; PORGADOR A, 1993, INT J CANCER, V53, P471, DOI 10.1002/ijc.2910530320; PORGADOR A, 1992, CANCER RES, V52, P3679; PORGADOR A, 1993, J IMMUNOL, V150, P1458; PORGADOR A, 1991, INT J CANCER, P54; POSTE G, 1980, NATURE, V283, P139, DOI 10.1038/283139a0; RICCIO A, 1985, NUCLEIC ACIDS RES, V13, P2759, DOI 10.1093/nar/13.8.2759; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; RUTHER U, 1988, CELL, V53, P847, DOI 10.1016/S0092-8674(88)90289-9; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1991, ONCOGENE, V6, P533; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SASSONECORSI P, 1988, COLD SPRING HARB SYM, V53, P749, DOI 10.1101/SQB.1988.053.01.085; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHIRAYOSHI Y, 1987, MOL CELL BIOL, V7, P4542, DOI 10.1128/MCB.7.12.4542; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; VERMA IM, 1990, CIBA F SYMP, V150, P128; VERMA IM, 1988, UCLA S MOL CELLULAR, V87; WALLICH R, 1985, NATURE, V315, P301, DOI 10.1038/315301a0; WANG ZQ, 1991, EMBO J, V10, P2437, DOI 10.1002/j.1460-2075.1991.tb07783.x; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; YANO O, 1987, EMBO J, V6, P3317, DOI 10.1002/j.1460-2075.1987.tb02652.x	80	26	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1994	9	4					1065	1079						15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134110				2022-12-17	WOS:A1994NC04800009
J	FEO, S; DILIEGRO, C; JONES, T; READ, M; FRIED, M				FEO, S; DILIEGRO, C; JONES, T; READ, M; FRIED, M			THE DNA REGION AROUND THE C-MYC GENE AND ITS AMPLIFICATION IN HUMAN TUMOR-CELL LINES	ONCOGENE			English	Note							HUMAN-BREAST CARCINOMA; BURKITT-LYMPHOMA; CHROMOSOMAL TRANSLOCATIONS; N-MYC; ONCOGENE; EXPRESSION; SEQUENCES; CANCER; LOCUS; REARRANGEMENT	In order to study amplicons containing the c-myc locus in human tumour cells we have analysed the region around the human c-myc gene. Using pulsed field gel electrophoresis we have constructed a 1.8 Mb map of the c-myc locus using six rare-cutting endonucleases. In addition we have cloned 130 kb of continuous DNA around the c-myc gene which includes 65 kb of 5' sequence and 65 kb of 3' sequence. The first exon of the pvt-1 gene was located 59 kb 3' of the c-myc gene. Using nine neighbouring probes, covering a region of about 395 kb around the c-myc gene, we were able to determine the extent and composition of c-myc amplicons in the HL60, NCI-N417, Colo320HSR, SkBr3 and the Sk-N-MC human tumour cell lines. Furthermore we analysed the chromosomal location of amplified c-myc DNA in NCI-N417 and SkBr3 cells. Similarities and differences between the amplified DNA in the different cell lines are discussed.	IMPERIAL CANC RES FUND,EUKARYOT GENE ORG & EXPRESS LAB,LONDON WC2A 3PX,ENGLAND; CNR,IST BIOL SVILUPPO,I-90123 PALERMO,ITALY; DIPARTIMENTO BIOL CELLULARE & SVILUPPO,I-90123 PALERMO,ITALY; IMPERIAL CANC RES FUND,HUMAN CYTOGENET LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK; Consiglio Nazionale delle Ricerche (CNR); Cancer Research UK			Corbett-Jones, Tania A/E-4891-2013; Feo, Salvatore/C-1333-2012; Jones, Tania/C-8912-2011	Corbett-Jones, Tania A/0000-0002-0067-3382; Feo, Salvatore/0000-0003-3877-2906; Jones, Tania/0000-0002-0067-3382; Di Liegro, Carlo Maria/0000-0001-7362-7814				ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BOEHM T, 1989, EUR J BIOCHEM, V185, P1, DOI 10.1111/j.1432-1033.1989.tb15074.x; BONILLA M, 1988, J NATL CANCER I, V80, P665, DOI 10.1093/jnci/80.9.665; BRISON O, 1993, BIOCHIM BIOPHYS ACTA, V1155, P25, DOI 10.1016/0304-419X(93)90020-D; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; COLLINS S, 1982, NATURE, V298, P679, DOI 10.1038/298679a0; DURST M, 1987, P NATL ACAD SCI USA, V84, P1070, DOI 10.1073/pnas.84.4.1070; ERIKSON J, 1983, P NATL ACAD SCI-BIOL, V80, P820, DOI 10.1073/pnas.80.3.820; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; FEO S, 1990, NUCLEIC ACIDS RES, V18, P4949, DOI 10.1093/nar/18.16.4949; FEO S, 1990, GENOMICS, V6, P192, DOI 10.1016/0888-7543(90)90467-9; FUKUMOTO M, 1993, SOMAT CELL MOLEC GEN, V19, P21, DOI 10.1007/BF01233951; HALUSKA FG, 1987, ANNU REV GENET, V21, P321, DOI 10.1146/annurev.ge.21.120187.001541; HEARD E, 1991, P NATL ACAD SCI USA, V88, P8242, DOI 10.1073/pnas.88.18.8242; JOOS S, 1992, CANCER RES, V52, P6547; KOZBOR D, 1984, CANCER RES, V44, P438; LAFAGE M, 1992, GENE CHROMOSOME CANC, V5, P40, DOI 10.1002/gcc.2870050107; LEHRACH H., 1990, GENOME ANAL, P39; LINDSAY S, 1987, NATURE, V327, P336, DOI 10.1038/327336a0; LITT M, 1985, P NATL ACAD SCI USA, V82, P6206, DOI 10.1073/pnas.82.18.6206; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; MENGLEGAW L, 1987, EMBO J, V6, P1959, DOI 10.1002/j.1460-2075.1987.tb02458.x; MOROY T, 1986, NATURE, V324, P276, DOI 10.1038/324276a0; MORSE B, 1988, NATURE, V333, P87, DOI 10.1038/333087a0; NOWELL P, 1983, NATURE, V306, P494, DOI 10.1038/306494a0; SCHWAB M, 1990, GENE CHROMOSOME CANC, V1, P181, DOI 10.1002/gcc.2870010302; SHTIVELMAN E, 1989, MOL CELL BIOL, V9, P1148, DOI 10.1128/MCB.9.3.1148; SHTIVELMAN E, 1989, P NATL ACAD SCI USA, V86, P3257, DOI 10.1073/pnas.86.9.3257; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SUN LK, 1986, NUCLEIC ACIDS RES, V14, P4037, DOI 10.1093/nar/14.10.4037; THEILLET C, 1989, ONCOGENE, V4, P915; THIELE CJ, 1987, J CLIN INVEST, V80, P804, DOI 10.1172/JCI113137; VANLOHUIZEN M, 1990, BIOCHIM BIOPHYS ACTA, V1032, P213, DOI 10.1016/0304-419X(90)90005-L; WHANGPENG J, 1982, GENE AMPLIFICATION, P107; WONG AJ, 1986, SCIENCE, V233, P461, DOI 10.1126/science.3014659	38	26	26	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					955	961						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108141				2022-12-17	WOS:A1994MW55100034
J	LI, PM; FUKAZAWA, H; YAMAMOTO, C; MIZUNO, S; TANAKA, K; HORI, M; YAGINUMA, S; SAITO, T; UEHARA, Y				LI, PM; FUKAZAWA, H; YAMAMOTO, C; MIZUNO, S; TANAKA, K; HORI, M; YAGINUMA, S; SAITO, T; UEHARA, Y			METHOD OF IDENTIFYING INHIBITORS OF ONCOGENIC TRANSFORMATION - SELECTIVE-INHIBITION OF CELL-GROWTH IN SERUM-FREE MEDIUM	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; PROTEIN-TYROSINE KINASES; RAT-KIDNEY CELLS; HERBIMYCIN-A; TYRPHOSTINS; ERBSTATIN; INVITRO	We developed a new method for evaluating inhibitors of onocogenic signal transduction pathways based on different growth abilities between normal and transformed cells in a defined serum-free medium. The growth rates of src, abl or ras oncogene-transformed cells, activated raf proto-oncogene transformed cells, and normal NIH3T3 cells were 60-90%, 20-30% and 10% in a serum-free medium, respectively, compared to the growth rates in a serum-containing medium. An addition of a growth factor (PDGF, FGF or TGF-beta) stimulated the growth of normal NIH3T3 cells by 40-80% in a serum-free medium. Herbimycin A, a specific cytoplasmic protein tyrosine kinase inhibitor, selectively inhibited the growth of src or abl transformed cells in the serum-free medium resulting in about 10-fold or fivefold lower IC50 than those in the serum-containing medium. The antibiotic did not show such an effect on ras transformed cells, and the treatment of src transformed cells with other protein kinase inhibitors or cytotoxic drugs showed tittle IC50 shifts between the two media. Thus, this method of comparing growth inhibition in the serum-free and the serum-containing media may be useful in evaluating specific inhibitors of signaling pathways mediated by growth factors and certain oncogene products.	NATL INST HLTH, DEPT BIOACT MOLEC, 1-23-1 TOYAMA, SHINJUKU KU, TOKYO 162, JAPAN; SHOWA COLL PHARMACEUT SCI, TOKYO 194, JAPAN; ASAHI CHEM IND CO LTD, SHIZUOKA 41023, JAPAN	Showa Pharmaceutical University								AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ARMAND JP, 1990, EUR J CANCER, V26, P417, DOI 10.1016/0277-5379(90)90005-E; BROWDER TM, 1989, CANCER CELL-MON REV, V1, P9; CUADRADO A, 1990, BIOCHEM BIOPH RES CO, V170, P526, DOI 10.1016/0006-291X(90)92123-H; FUKAZAWA H, 1990, BIOCHEM BIOPH RES CO, V173, P276, DOI 10.1016/S0006-291X(05)81053-8; FUKAZAWA H, 1991, BIOCHEM PHARMACOL, V42, P1661; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; HONMA Y, 1992, ANTICANCER RES, V12, P189; HONMA Y, 1989, CANCER RES, V49, P331; IMOTO M, 1990, BIOCHEM BIOPH RES CO, V173, P208, DOI 10.1016/S0006-291X(05)81042-3; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; LEVITZKI A, 1991, TRENDS PHARMACOL SCI, V12, P171, DOI 10.1016/0165-6147(91)90538-4; LYALL RM, 1989, J BIOL CHEM, V264, P14503; OKABE M, 1992, BLOOD, V80, P1330; PIRONIN M, 1992, INT J CANCER, V51, P980, DOI 10.1002/ijc.2910510624; SHINDOOKADA N, 1989, MOL CARCINOGEN, V2, P159, DOI 10.1002/mc.2940020309; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; TRITTON TR, 1990, CANCER CELL-MON REV, V2, P95; UEHARA Y, 1989, CANCER RES, V49, P780; UEHARA Y, 1988, VIROLOGY, V164, P294, DOI 10.1016/0042-6822(88)90649-6; UEHARA Y, 1986, MOL CELL BIOL, V6, P2198, DOI 10.1128/MCB.6.6.2198; UEHARA Y, 1985, JPN J CANCER RES, V76, P672; UEHARA Y, 1991, METHOD ENZYMOL, V201, P370; UMEZAWA H, 1986, J ANTIBIOT, V39, P170, DOI 10.7164/antibiotics.39.170; ZHAN X, 1986, MOL CELL BIOL, V6, P3541, DOI 10.1128/MCB.6.10.3541	26	26	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1993	8	7					1731	1735						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510919				2022-12-17	WOS:A1993LG68200003
J	SHACKLEFORD, GM; SHIVAKUMAR, S; SHIUE, L; MASON, J; KENYON, C; VARMUS, HE				SHACKLEFORD, GM; SHIVAKUMAR, S; SHIUE, L; MASON, J; KENYON, C; VARMUS, HE			2 WNT GENES IN CAENORHABDITIS-ELEGANS	ONCOGENE			English	Article							PROTO-ONCOGENE INT-1; SEGMENT-POLARITY GENE; XENOPUS EMBRYOS; C-ELEGANS; DROSOPHILA HOMOLOG; MESSENGER-RNA; SEQUENCE; EXPRESSION; PROTOONCOGENE; WINGLESS	wnt genes encode secretory glycoproteins that have been implicated in growth control and development in mice, frogs and insects. In this report we examine properties of two wnt genes recently identified in the nematode Caenorhabditis elegans. The first gene, Ce-wnt-1, was previously identified by a polymerase chain reaction-based screen of genomic DNA, and the second, Ce-wnt-2, was fortuitously encountered in a survey of clones in a cDNA library by the Caenorhabditis Genome Project. Full-length or nearly full-length cDNAs representing both mRNAs encode proteins that are similar in length, sequence and functional domains to other Wnt proteins. Primary products of 372 and 362 amino acids begin with a hydrophobic signal peptide, include two potential N-linked glycosylation sites and contain the 22 cysteine residues conserved throughout the wnt family. In contrast to mammalian and insect wnt genes with four or five exons and conserved intron-exon boundaries, Ce-wnt-1 has nine coding exons; only one of the eight identified introns interrupts the coding sequence at a position homologous to an intron position in other wnt genes. The major transcript derived from Ce-wnt-1 is 1.4 kb in length, and the 22 nucleotides at its 5' end are added by a trans-splicing mechanism. Ce-wnt-2 is also expressed via a single major transcript, 1.5 kb in length. Both RNAs are detectable in all larval forms and adults, but they are most abundant at the embryonic stage. Ce-wnt-1 is localized to the left arm of chromosome II and Ce-wnt-2 maps to a cluster of genes on chromosome IV.	UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT ANAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Mason, John O/A-1926-2010	Mason, John O/0000-0002-0489-2400				BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BLUMENTHAL T, 1988, TRENDS GENET, V4, P305, DOI 10.1016/0168-9525(88)90107-2; BRENNER S, 1974, GENETICS, V77, P71; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DIBB NJ, 1989, J MOL BIOL, V205, P603, DOI 10.1016/0022-2836(89)90229-5; EISENBERG LM, 1992, IN PRESS DEV BIOL; EMMONS SW, 1979, P NATL ACAD SCI USA, V76, P1333, DOI 10.1073/pnas.76.3.1333; FIELDS C, 1990, NUCLEIC ACIDS RES, V18, P1509, DOI 10.1093/nar/18.6.1509; FROHMAN M, 1992, IN PRESS METHODS ENZ; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; KAMB A, 1989, P NATL ACAD SCI USA, V86, P4372, DOI 10.1073/pnas.86.12.4372; KRAUSE M, 1990, CELL, V63, P907, DOI 10.1016/0092-8674(90)90494-Y; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; KRAUSE M, 1984, MOL BIOL CYTOSKELETO; Maniatis T., 1982, MOL CLONING; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; ROSENQUIST TA, 1988, GENE DEV, V2, P606, DOI 10.1101/gad.2.5.606; RUSSELL J, 1992, UNPUB DEVELOPMENT; SCHALLER D, 1990, NUCLEIC ACIDS RES, V18, P2033, DOI 10.1093/nar/18.8.2033; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; SMITH RF, 1990, P NATL ACAD SCI USA, V87, P118, DOI 10.1073/pnas.87.1.118; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; UZVOLGYI E, 1988, P NATL ACAD SCI USA, V85, P3034, DOI 10.1073/pnas.85.9.3034; VANOOYEN A, 1984, CELL, V39, P233, DOI 10.1016/0092-8674(84)90209-5; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WTERSTON R, 1992, NAT GENET, V1, P114	35	26	51	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1857	1864						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510930				2022-12-17	WOS:A1993LG68200018
J	NAKAZAWA, H; AGUELON, AM; YAMASAKI, H				NAKAZAWA, H; AGUELON, AM; YAMASAKI, H			IDENTIFICATION AND QUANTIFICATION OF A CARCINOGEN-INDUCED MOLECULAR INITIATION EVENT IN CELL-TRANSFORMATION	ONCOGENE			English	Article							BALB/C 3T3 CELLS; JUNCTIONAL INTERCELLULAR COMMUNICATION; HARVEY-RAS ONCOGENE; HA-RAS; MOUSE SKIN; CHEMICAL CARCINOGENESIS; TUMOR PROMOTERS; P53 GENE; ACTIVATION; MUTATION	All transformed foci of Balb/c 3T3 clone A31-1-1 cells induced by 7,12-dimethylbenz[a]anthracene (DMBA) (42 out of 42 examined) contained an A to T transversion at codon 61 (A182 to T) of the Ki-ras gene. The transformants induced by other carcinogens tested did not contain such a mutation, except one out of nine 12-O-tetradecanoyl phorbol 13-acetate (TPA)-induced transformed foci. Thus, we hypothesized that this mutation is a specific DMBA-induced initiating event in Balb/c 3T3 cell transformation and we have measured its frequency of induction before transformation occurs, employing our recently developed method. Such mutations can be detected in the cell population as early as 3 days after exposure to DMBA. The same mutation was also detected in the Ha-ras gene. No detectable level (<10(-6)) of these mutations was induced by other carcinogens tested. The mutation frequency of the Ha-ras gene reached a plateau after 1 week's exposure, but that of the Ki-ras gene continued to increase. These results suggest that the A182 to T mutation of the Ki-ras gene, but not that of the Ha-ras gene, contributes to morphological transformation of Balb/c 3T3 cells. We have demonstrated that the level of expression of ras genes determines the rate of recruitment of cells into transformation. Quantitative analysis of the frequencies of ras gene mutations (initiation) and of transformation suggests that about 25% of those cells with the Ki-ras mutation were recruited into the full transformation process and that, in the presence of the tumor promoter TPA, about 56% of them completed morphological cell transformation.			NAKAZAWA, H (corresponding author), INT AGCY RES CANC,MULTISTAGE CARCINOGENESIS UNIT,150 COURS ALBERT THOMAS,F-69372 LYON,FRANCE.				NCI NIH HHS [R01 CA40534] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040534] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTINI RJ, 1991, IN PRESS ANN REV GEN; BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARBU V, 1989, NUCLEIC ACIDS RES, V17, P7115, DOI 10.1093/nar/17.17.7115; Barrett J.C., 1985, MECHANISMS TOXICITY, P171; BIGNAMI M, 1988, MOL CARCINOGEN, V1, P67, DOI 10.1002/mc.2940010113; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BIZUB D, 1986, P NATL ACAD SCI USA, V83, P604; BORRELLO MG, 1987, CANCER RES, V47, P75; BRASH DE, 1991, P NATL ACAD SCI US, V88; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CHAKRABORTY AK, 1991, P NATL ACAD SCI USA, V88, P2217, DOI 10.1073/pnas.88.6.2217; CHANDLER LA, 1987, CELL, V50, P711, DOI 10.1016/0092-8674(87)90329-1; DANDEKAR S, 1986, MOL CELL BIOL, V6, P4104, DOI 10.1128/MCB.6.11.4104; ENOMOTO T, 1985, CANCER RES, V45, P2681; ENOMOTO T, 1984, CANCER RES, V44, P5200; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEINBERG AP, 1983, BIOCHEM BIOPH RES CO, V111, P47, DOI 10.1016/S0006-291X(83)80115-6; FITZGERALD DJ, 1989, MUTAGENESIS, V4, P286, DOI 10.1093/mutage/4.4.286; FUJIKI H, 1989, MOL CARCINOGEN, V2, P184, DOI 10.1002/mc.2940020403; GREENHALGH DA, 1989, MOL CARCINOGEN, V2, P199, DOI 10.1002/mc.2940020406; HARRIS CC, 1991, CANCER RES, V51, pS5023; Hayashi K, 1991, PCR Methods Appl, V1, P34; HILLOVA J, 1986, J NATL CANCER I, V77, P721, DOI 10.1093/jnci/77.3.721; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; KAKUNAGA T, 1973, INT J CANCER, V12, P463, DOI 10.1002/ijc.2910120217; KAKUNAGA T, 1980, SCIENCE, V209, P505, DOI 10.1126/science.7394516; KATOH F, 1991, CARCINOGENESIS, V12, P1923, DOI 10.1093/carcin/12.10.1923; KAWASAKI E, 1989, AMPLIFICATIONS PERKI, V4, P5; KOVARY K, 1989, ONCOGENE RES, V4, P55; KUMAR R, 1990, ONCOGENE, V5, P1271; KUROKI T, 1985, TRANSFORMATION ASSAY, P93; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; LERMAN LS, 1987, METHOD ENZYMOL, V155, P482; LERMAN LS, 1984, ANNU REV BIOPHYS BIO, V13, P339; LOKTIONOV A, 1990, MOL CARCINOGEN, V3, P134, DOI 10.1002/mc.2940030306; METTER J, 1989, NUCLEIC ACIDS RES, V17, P7089, DOI 10.1093/nar/17.17.7089; MURRAY AW, 1979, BIOCHEM BIOPH RES CO, V91, P395, DOI 10.1016/0006-291X(79)91535-3; NAKAZAWA H, 1990, MOL CARCINOGEN, V3, P202, DOI 10.1002/mc.2940030407; OHNO S, 1986, Cancer Reviews, V2, P65; PIERCEALL WE, 1991, ONCOGENE, V6, P2085; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; REDMOND SMS, 1988, ONCOGENE, V2, P259; REYNOLDS VL, 1987, ONCOGENE, V1, P323; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; ROSL F, 1988, EMBO J, V7, P1321, DOI 10.1002/j.1460-2075.1988.tb02947.x; Sambrook J., 1989, MOL CLONING; SUGIMURA T, 1986, SCIENCE, V233, P312, DOI 10.1126/science.3088728; THILLY WG, 1985, METHODS DETECTING DN, P511; TOFTGARD R, 1985, CARCINOGENESIS, V6, P655, DOI 10.1093/carcin/6.4.655; TOMATIS L, 1989, JPN J CANCER RES, V80, P795, DOI 10.1111/j.1349-7006.1989.tb01717.x; TOPAL MD, 1988, CARCINOGENESIS, V9, P691, DOI 10.1093/carcin/9.5.691; Trosko J E, 1982, Carcinog Compr Surv, V7, P565; VANDERLUBBE JLM, 1988, ONCOGENE RES, V3, P9; WEINSTEIN IB, 1991, SCIENCE, V251, P387, DOI 10.1126/science.1989073; YAMASAKI H, 1987, CANCER RES, V47, P5658; YAMASAKI H, 1988, CANCER RES, V48, P3490; YOTTI LP, 1979, SCIENCE, P2681; YUSPA SH, 1985, ROLE CHEM RAD ETIOLO, P201; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0; ZHANG R, 1991, CELL GROWTH DIFFER, V2, P1; 1985, CANCER RES, V45, P2395	63	26	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2295	2301						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437151				2022-12-17	WOS:A1992JW66500023
J	RICHARDSON, AL; HUMPHRIES, CG; TUCKER, PW				RICHARDSON, AL; HUMPHRIES, CG; TUCKER, PW			MOLECULAR-CLONING AND CHARACTERIZATION OF THE T(2 14) TRANSLOCATION ASSOCIATED WITH CHILDHOOD CHRONIC LYMPHOCYTIC-LEUKEMIA	ONCOGENE			English	Article							C-MYC ONCOGENE; GAMMA-GENES; B-CELL; PSEUDOAUTOSOMAL REGION; T(2-14) TRANSLOCATION; GENOMIC SEQUENCES; BURKITT-LYMPHOMA; RESTRICTION MAP; CHAIN; SWITCH	Two rare cases of chronic lymphocytic leukemia (CLL) in children, patients AS and LH, have been found to be associated with a unique chromosomal translocation, t(2;14)(p13;q32). Previous studies have shown the breakpoints of this translocation to be in the gamma-2 switch region of the Ig heavy-chain locus on chromosome 14 and in an uncharacterized region of chromosome 2. We have cloned and characterized the translocation breakpoints to examine the possibility that an oncogene contributed to the pathogenesis of these cases of CLL. Sequence analysis of AS and LH breakpoints established that the chromosome 2 breakage in the two patients occurred only 38 bp apart and within a strong non-methylated CpG island. Furthermore, human probes from the region cross-hybridized to other species, indicating strong evolutionary conservation. Northern analysis using the chromosome 2 probes detected a 2.85-kb transcript in the tumor cells and in a CD5+ B-cell line. These data suggest that a potential oncogene located near the 2p13 breakpoint may have been activated by the t(2;14) translocation in these two cases of chronic lymphocytic leukemia.			RICHARDSON, AL (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MICROBIOL,DALLAS,TX 75235, USA.				NIGMS NIH HHS [GM08014] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIRD AP, 1986, NATURE, V321, P9; BOUMSELL L, 1980, J EXP MED, V151, P1539; BRISSENDEN JE, 1985, CANCER RES, V45, P5593; BROWN WRA, 1988, EMBO J, V7, P2377, DOI 10.1002/j.1460-2075.1988.tb03082.x; BROWNELL E, 1988, ONCOGENE, V3, P93; BROWNELL E, 1988, ONCOGENE, V2, P527; CASALI P, 1987, SCIENCE, V236, P77, DOI 10.1126/science.3105056; DUNN IS, 1987, NUCLEIC ACIDS RES, V15, P2677; DUNNICK W, 1980, NATURE, V286, P669, DOI 10.1038/286669a0; FELL HP, 1986, SCIENCE, V232, P491, DOI 10.1126/science.3961491; FERAMISCO JR, 1982, J BIOL CHEM, V257, P1024; FLANAGAN JG, 1982, NATURE, V300, P709, DOI 10.1038/300709a0; FULTON TR, 1989, NUCLEIC ACIDS RES, V17, P271, DOI 10.1093/nar/17.1.271; GARDINER K, 1990, EMBO J, V9, P25, DOI 10.1002/j.1460-2075.1990.tb08076.x; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; KAMOUN M, 1981, J IMMUNOL, V127, P987; KINGSMORE SF, 1989, EMBO J, V8, P4073, DOI 10.1002/j.1460-2075.1989.tb08591.x; LEVINE EG, 1986, CANCER RES, V46, P6481; LINDSAY S, 1987, NATURE, V327, P336, DOI 10.1038/327336a0; Maniatis T., 1982, MOL CLONING; MARCU KB, 1982, NATURE, V298, P87, DOI 10.1038/298087a0; MITELMAN F, 1988, CANCER RES, V48, P7115; MONACO AP, 1986, NATURE, V323, P646, DOI 10.1038/323646a0; NIKAIDO T, 1982, J BIOL CHEM, V257, P7322; NISHIDA K, 1989, CANCER RES, V49, P1275; NOWELL PC, 1986, CANCER GENET CYTOGEN, V19, P219, DOI 10.1016/0165-4608(86)90050-6; PETIT C, 1988, EMBO J, V7, P2369, DOI 10.1002/j.1460-2075.1988.tb03081.x; PICCOLI SP, 1984, NATURE, V310, P327, DOI 10.1038/310327a0; RAPPOLD GA, 1988, NUCLEIC ACIDS RES, V16, P5361, DOI 10.1093/nar/16.12.5361; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANGER F, 1978, J MOL BIOL, V125, P225, DOI 10.1016/0022-2836(78)90346-7; SCHARF SJ, 1986, SCIENCE, V233, P1076, DOI 10.1126/science.3461561; SHOWE LC, 1985, MOL CELL BIOL, V5, P501, DOI 10.1128/MCB.5.3.501; SONNIER JA, 1983, NEW ENGL J MED, V309, P590, DOI 10.1056/NEJM198309083091005; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEINMETZ M, 1986, CELL, V44, P895, DOI 10.1016/0092-8674(86)90012-7; TAKAHASHI N, 1982, CELL, V29, P671, DOI 10.1016/0092-8674(82)90183-0; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; TRICOLI JV, 1985, CYTOGENET CELL GENET, V40, P762; VESHIMA Y, 1985, INT J CANCER, V36, P287; YOFFE G, 1990, J PEDIATR-US, V116, P114, DOI 10.1016/S0022-3476(05)81658-0	43	26	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1992	7	5					961	970						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1373880				2022-12-17	WOS:A1992HP64200016
J	MITRA, G				MITRA, G			MUTATIONAL ANALYSIS OF CONSERVED RESIDUES IN THE TYROSINE KINASE DOMAIN OF THE HUMAN TRK-ONCOGENE	ONCOGENE			English	Article							BIOCHEMICAL-CHARACTERIZATION; ACTIVATION; SEQUENCES; RECOMBINATION; PROTOONCOGENE; MUTAGENESIS	The human trk oncogene (originally identified in a colon carcinoma) was activated by a genetic rearrangement which resulted in replacement of the extracellular ligand-binding domain of the proto-trk transmembrane receptor by non-muscle tropomyosin sequences. The product of the trk oncogene, a protein of 70 kDa (p70trk), possesses tyrosine-specific protein kinase activity, is autophosphorylated in vitro on tyrosine and is phosphorylated on serine, threonine and tyrosine residues in trk-transformed cells. By site-directed mutagenesis of trk oncogene cDNA, the codon for lysine (367) at the putative ATP-binding site was changed to that for methionine and the codons for tyrosines (503 and 504) at the putative autophosphorylation sites were changed to those for phenylalanine. Replacement of Lys-367 by methionine results in a biologically inactive, kinase-negative mutant. Phe-ala mutants of trk showed drastically reduced ability to induce morphologic transformation, anchorage-independent growth and tumorigenicity in mouse NIH3T3 cells and showed reduced in vitro tyrosine kinase activity when assayed by autophosphorylation and phosphorylation of histone as exogenous substrate. The present study indicates the role of these specific conserved residues in regulating the biochemical and biological properties of p70trk oncoprotein.			MITRA, G (corresponding author), CLEVELAND CLIN FDN,RES INST,DEPT MOLEC BIOL,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.							BONGARZONE I, 1989, ONCOGENE, V4, P1457; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COULIER F, 1989, MOL CELL BIOL, V9, P15, DOI 10.1128/MCB.9.1.15; GEER PV, 1990, MOL CELL BIOL, V10, P2991; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KOZMA SC, 1988, EMBO J, V7, P147, DOI 10.1002/j.1460-2075.1988.tb02794.x; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MITRA G, 1989, P NATL ACAD SCI USA, V86, P8650, DOI 10.1073/pnas.86.22.8650; MITRA G, 1987, P NATL ACAD SCI USA, V84, P6707, DOI 10.1073/pnas.84.19.6707; OSKAM R, 1988, P NATL ACAD SCI USA, V85, P2964, DOI 10.1073/pnas.85.9.2964; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; ULRICH A, 1990, CELL, V61, P203; WEINMASTER G, 1984, CELL, V37, P559, DOI 10.1016/0092-8674(84)90386-6; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	25	26	26	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2237	2241						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1837350				2022-12-17	WOS:A1991GX73500009
J	DEPPERT, W; KURTH, M; GRAESSMANN, M; GRAESSMANN, A; KNIPPSCHILD, U				DEPPERT, W; KURTH, M; GRAESSMANN, M; GRAESSMANN, A; KNIPPSCHILD, U			ALTERED PHOSPHORYLATION AT SPECIFIC SITES CONFERS A MUTANT PHENOTYPE TO SV40 WILD-TYPE LARGE T-ANTIGEN IN A FLAT REVERTANT OF SV40-TRANSFORMED CELLS	ONCOGENE			English	Article							SIMIAN VIRUS-40; TUMOR-ANTIGEN; PROTEIN PHOSPHATASE-2A; TRANSFORMED-CELLS; DNA-REPLICATION; BINDING; P53; POLYOMAVIRUS; ASSOCIATION; SUPPRESSOR	The Rev2 cell line is a cellular revertant of the SV40 wild-type transformed rat cell line SV-52 [Bauer, M., Guhl, E., Graessmann, M. & Graessmann, A. (1987). J. Virol., 61, 1821-1827]. To characterize the level of cellular interference with the SV40 large T antigen (large T)-induced transformation pathway in Rev2 cells, we analysed the biological and biochemical properties of large T expressed in Rev2 cells. We found that Rev2 cells encoded an authentic wild-type large T, with regard to its sequence and its transforming functions. No differences were found in the metabolic stability of large T, or in complex formation with the cellular p53 protein, or in p53 metabolic stabilization. In contrast to SV-52 cells, Rev2 cells showed no association of large T with the chromatin fraction of isolated nuclei. This difference correlated with a reduced affinity of the Rev2 large T to SV40 DNA in vitro. The T proteins from both cell lines were phosphorylated at the same multiple sites. However, in Rev2 cells the phosphorylation of large T at specific serine -residues was significantly reduced. Thus the revertant phenotype of Rev2 cells may be due to an altered phosphorylation state of its large T protein, leading to altered nuclear localization and reduced transforming activity. The alterations of Rev2 large T properties and phosphorylation were very similar to the changes observed with mutant large T in FR(tsA58)A cells, an SV40 tsA58 N-type transformant, when the cells had reverted to the normal phenotype at the non-permissive growth temperature. Thus altered phosphorylation might provide a common structural basis for the biological inactivation of the large T proteins in these cells.	FREE UNIV BERLIN,INST MOLEK BIOL & BIOCHEM,W-1000 BERLIN 33,GERMANY	Free University of Berlin	DEPPERT, W (corresponding author), UNIV HAMBURG,HEINRICH PETTE INST EXPTL VIROL & IMMUNOL,MARTINISTR 52,W-2000 HAMBURG 20,GERMANY.							BAUER M, 1987, J VIROL, V61, P1821, DOI 10.1128/JVI.61.6.1821-1827.1987; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BOURRE F, 1983, NATURE, V305, P68, DOI 10.1038/305068a0; BUTEL JS, 1986, BIOCHIM BIOPHYS ACTA, V865, P171, DOI 10.1016/0304-419X(86)90027-2; DEPPERT W, 1989, CURR TOP MICROBIOL, V144, P77; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; DEPPERT W, 1989, ONCOGENE, V4, P1103; DEPPERT W, 1987, MOL CELL BIOL, V7, P4453, DOI 10.1128/MCB.7.12.4453; FANNING E, 1982, EMBO J, V1, P1023, DOI 10.1002/j.1460-2075.1982.tb01290.x; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GRAESSMANN M, 1983, METHOD ENZYMOL, V101, P482; GURNEY EG, 1986, J VIROL, V57, P1168, DOI 10.1128/JVI.57.3.1168-1172.1986; HINZPETER M, 1986, VIROLOGY, V148, P159, DOI 10.1016/0042-6822(86)90411-3; HINZPETER M, 1987, ONCOGENE, V1, P119; HOESS A, 1990, J VIROL, V64, P4799; KNIPPSCHILD U, 1991, J VIROL, V65, P4414, DOI 10.1128/JVI.65.8.4414-4423.1991; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LIVINGSTON DM, 1987, MOL BIOL MED, V4, P63; MANFREDI JJ, 1990, J VIROL, V64, P5250, DOI 10.1128/JVI.64.11.5250-5259.1990; Martin R G, 1981, Adv Cancer Res, V34, P1, DOI 10.1016/S0065-230X(08)60238-9; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PATSCHINSKY T, 1990, ONCOGENE, V5, P1071; PINTEL D, 1981, J VIROL, V38, P518, DOI 10.1128/JVI.38.2.518-528.1981; PRIVES C, 1990, CELL, V61, P735, DOI 10.1016/0092-8674(90)90179-I; RICHTER W, 1990, VIROLOGY, V174, P543, DOI 10.1016/0042-6822(90)90108-4; ROBB JA, 1973, EXP CELL RES, V81, P120, DOI 10.1016/0014-4827(73)90118-3; RYAN KW, 1985, MOL CELL BIOL, V5, P3577, DOI 10.1128/MCB.5.12.3577; SCHEIDTMANN KH, 1982, J VIROL, V44, P116, DOI 10.1128/JVI.44.1.116-133.1982; SCHEIDTMANN KH, 1984, J VIROL, V50, P1; SCHEIDTMANN KH, 1984, J VIROL, V50, P636, DOI 10.1128/JVI.50.2.636-640.1984; SCHEIDTMANN KH, 1991, J VIROL, V65, P1479, DOI 10.1128/JVI.65.3.1479-1490.1991; SCHIRMBECK R, 1988, VIROLOGY, V165, P527, DOI 10.1016/0042-6822(88)90597-1; SCHNEIDER J, 1988, J VIROL, V62, P1598, DOI 10.1128/JVI.62.5.1598-1605.1988; STAUFENBIEL M, 1983, EUR J CELL BIOL, V31, P341; STAUFENBIEL M, 1984, J CELL BIOL, V98, P1886, DOI 10.1083/jcb.98.5.1886; VANROY F, 1990, ONCOGENE, V5, P207; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; WULF E, 1979, P NATL ACAD SCI USA, V76, P4498, DOI 10.1073/pnas.76.9.4498; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988	41	26	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1931	1938						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923516				2022-12-17	WOS:A1991GX11800030
J	KAUFFMAN, MG; ROSE, PA; KELLY, TJ				KAUFFMAN, MG; ROSE, PA; KELLY, TJ			MUTATIONS IN THE THYMIDINE KINASE GENE THAT ALLOW EXPRESSION OF THE ENZYME IN QUIESCENT (G0) CELLS	ONCOGENE			English	Article							SERUM-STIMULATED CELLS; MESSENGER-RNA; MOLECULAR-CLONING; NUCLEAR ANTIGEN; S-PHASE; CYCLE; PROMOTER; PROGRESSION; SEQUENCE; LEVEL	Thymidine kinase (TK) is a nucleotide salvage pathway enzyme whose activity is highly dependent on the growth state and cell cycle phase of a cell. Cells in the resting or quiescent (G0) phase express very low levels of TK mRNA and protein. When quiescent cells are stimulated to enter the cell cycle by the addition of serum, TK mRNA, activity and polypeptide increase coordinately after about 10-15 h, at the beginning of S phase. When growth-independent heterologous promoters are substituted for the natural TK promoter, TK mRNA can be expressed in quiescent cells. Despite the presence of TK mRNA in such G0 cells, there is little expression of TK polypeptide; the normal increase in enzyme at S phase is observed following serum stimulation. Deletion of the introns and 3' untranslated sequences does not affect the expression of the TK gene in serum stimulation experiments. In contrast, deletion of the C-terminal 40 amino acids or fusion of a small segment of a beta-galactosidase to the C-terminus overcomes the block to expression of the TK polypeptide in G0 cells. These C-terminal alterations are the same as those which lead to constitutive expression of TK during the cell cycle of proliferating cells, suggesting that mechanisms which control the levels of TK in cycling cells may also operate in quiescent cells.	JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205	Johns Hopkins University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007309, R01GM042780] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42780-02, 5-T32-GM-07309-16] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELLO LJ, 1974, EXP CELL RES, V89, P263, DOI 10.1016/0014-4827(74)90790-3; BRADSHAW HD, 1984, MOL CELL BIOL, V4, P2316, DOI 10.1128/MCB.4.11.2316; BRADSHAW HD, 1983, P NATL ACAD SCI-BIOL, V80, P5588, DOI 10.1073/pnas.80.18.5588; CHEETHAM BF, 1982, J CELL PHYSIOL, V110, P114, DOI 10.1002/jcp.1041100203; CHEETHAM BF, 1982, MOL CELL BIOL, V2, P1295, DOI 10.1128/MCB.2.10.1295; COPPOCK DL, 1987, MOL CELL BIOL, V7, P2925, DOI 10.1128/MCB.7.8.2925; FEDER JN, 1989, J BIOL CHEM, V264, P20583; GROSS MK, 1987, DEV BIOL, V122, P439, DOI 10.1016/0012-1606(87)90308-3; GROSS MK, 1989, P NATL ACAD SCI USA, V86, P4987, DOI 10.1073/pnas.86.13.4987; GROUDINE M, 1984, NUCLEIC ACIDS RES, V12, P1427, DOI 10.1093/nar/12.3.1427; GUDAS JM, 1988, P NATL ACAD SCI USA, V85, P4705, DOI 10.1073/pnas.85.13.4705; HARGROVE JL, 1989, FASEB J, V3, P2360, DOI 10.1096/fasebj.3.12.2676679; HOFBAUER R, 1987, NUCLEIC ACIDS RES, V15, P741, DOI 10.1093/nar/15.2.741; ITO M, 1990, J BIOL CHEM, V265, P6954; JASKULSKI D, 1988, J BIOL CHEM, V263, P10175; JOHNSON LF, 1982, EXP CELL RES, V138, P79, DOI 10.1016/0014-4827(82)90093-3; KAUFFMAN MG, 1990, ANAL BIOCHEM, V191, P41, DOI 10.1016/0003-2697(90)90384-L; KAUFFMAN MG, 1991, IN PRESS MOL CELL BI, V11; KIT S, 1965, J BIOL CHEM, V240, P2565; KREIDBERG JA, 1986, MOL CELL BIOL, V6, P2903, DOI 10.1128/MCB.6.8.2903; KWOH TJ, 1984, NUCLEIC ACIDS RES, V23, P39595; LEWIS JA, 1986, MOL CELL BIOL, V6, P2262, DOI 10.1128/MCB.6.6.2262; LIEBERMAN HB, 1988, MOL CELL BIOL, V8, P5280, DOI 10.1128/MCB.8.12.5280; MERRILL GF, 1984, MOL CELL BIOL, V4, P1769, DOI 10.1128/MCB.4.9.1769; MORRIS GF, 1989, J BIOL CHEM, V264, P13856; PEDEN KWC, 1989, EXP CELL RES, V185, P60, DOI 10.1016/0014-4827(89)90037-2; ROEHL HH, 1990, MOL CELL BIOL, V10, P3834, DOI 10.1128/MCB.10.7.3834; SCHLOSSER CA, 1981, P NATL ACAD SCI USA, V74, P5463; SHERLEY JL, 1988, J BIOL CHEM, V263, P375; SHERLEY JL, 1988, J BIOL CHEM, V263, P8350; STEWART CJ, 1987, MOL CELL BIOL, V7, P1156, DOI 10.1128/MCB.7.3.1156; STUART P, 1985, MOL CELL BIOL, V5, P1490, DOI 10.1128/MCB.5.6.1490; TRAVALI S, 1988, MOL CELL BIOL, V8, P1551, DOI 10.1128/MCB.8.4.1551; WAHL AF, 1988, MOL CELL BIOL, V8, P5016, DOI 10.1128/MCB.8.11.5016	34	26	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1427	1435						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1909430				2022-12-17	WOS:A1991GX27200020
J	COROMINAS, M; LEON, J; KAMINO, H; CRUZALVAREZ, M; NOVICK, SC; PELLICER, A				COROMINAS, M; LEON, J; KAMINO, H; CRUZALVAREZ, M; NOVICK, SC; PELLICER, A			ONCOGENE INVOLVEMENT IN TUMOR-REGRESSION - H-RAS ACTIVATION IN THE RABBIT KERATOACANTHOMA MODEL	ONCOGENE			English	Article							BLADDER-CARCINOMA ONCOGENE; GROWTH-FACTOR RECEPTORS; MURINE SARCOMA-VIRUS; N-RAS; PROTO-ONCOGENE; NUCLEOTIDE-SEQUENCE; K-RAS; NEURONAL DIFFERENTIATION; GENETIC MECHANISMS; CELLS	Activated H-ras genes are present in a number of skin tumors induced in animals by carcinogen treatment. The involvement of the ras oncogenes in tumorigenesis was investigated in keratoacanthomas, benign and self-regressing tumors, as well as malignant squamous cell carcinomas. Both tumors were induced in rabbit ears by repeated applications of 7,12 dimethylbenz(a)anthracene (DMBA). The rabbit H-ras gene was cloned and sequenced. PCR analysis revealed that approximately 82% of the keratoacanthoma DNAs contained an A:T to T:A transversion in codon 61. The relative levels of H-ras transcript were increased in keratoacanthomas compared to normal skin and the activated allele was expressed in tumors, even during the regressing phase. Although a G:C to A:T mutation in codon 12 of the H-ras and an activated N-ras gene were found in two squamous cell carcinomas, the frequency of H-ras activation in codon 61 was much lower (40%) in the malignant tumours induced by the same carcinogen treatment. Therefore, DMBA induced at least two types of genetic lesions in this system: H-ras activation, present in most regressing keratoacanthomas, and activation of other unidentified oncogenes which may result in the development of malignant tumors. Our observations indicate that expression of an activated H-ras gene, in this system, is neither sufficient to induce a malignant phenotype nor even capable of maintaining the growth of a benign tumor and suggest that it could be involved in tumor regression.	NYU MED CTR,DEPT PATHOL,550 1ST AVE,NEW YORK,NY 10016; NYU MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016	New York University; New York University			Leon, Javier/K-4615-2014; Corominas, Montserrat/K-6528-2012	Corominas, Montserrat/0000-0002-0724-8346; Kamino, Hideko/0000-0001-9256-5284; Leon, Javier/0000-0001-5803-0112; Pellicer, Angel/0000-0002-5062-0692	NCI NIH HHS [CA 50434, CA 36327, CA 16239] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050434, R37CA036327, P01CA016239, R01CA036327] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALDAZ CM, 1988, CANCER RES, V48, P3253; BAILLEUL B, 1990, CELL, V62, P697, DOI 10.1016/0092-8674(90)90115-U; BALMAIN A, 1983, NATURE, V303, P72, DOI 10.1038/303072a0; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BIZUB D, 1986, P NATL ACAD SCI USA, V83, P6048, DOI 10.1073/pnas.83.16.6048; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BROWN K, 1990, P NATL ACAD SCI USA, V87, P538, DOI 10.1073/pnas.87.2.538; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CHANG EH, 1987, SCIENCE, V237, P1036, DOI 10.1126/science.3616624; CHENG JF, 1984, J MOL BIOL, V176, P1, DOI 10.1016/0022-2836(84)90379-6; COROMINAS M, 1989, P NATL ACAD SCI USA, V86, P6372, DOI 10.1073/pnas.86.16.6372; DIAMOND LE, 1988, MOL CELL BIOL, V8, P2233, DOI 10.1128/MCB.8.5.2233; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GHADIALLY FN, 1985, J PATHOLBACTERIOL, V75, P441; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUERRERO I, 1987, MUTAT RES, V185, P293, DOI 10.1016/0165-1110(87)90021-2; GUERRERO I, 1986, J CELL PHYSIOL, V129, P71, DOI 10.1002/jcp.1041290111; GUERRERO I, 1985, P NATL ACAD SCI USA, V82, P7810, DOI 10.1073/pnas.82.23.7810; GUERRERO I, 1988, BIOCHEM BIOPH RES CO, V150, P1185, DOI 10.1016/0006-291X(88)90754-1; HALL A, 1985, NUCLEIC ACIDS RES, V13, P5255, DOI 10.1093/nar/13.14.5255; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; ISHII S, 1986, SCIENCE, V232, P1410, DOI 10.1126/science.3012774; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; LEON J, 1988, MOL CELL BIOL, V8, P786, DOI 10.1128/MCB.8.2.786; LIU E, 1987, NATURE, V330, P186, DOI 10.1038/330186a0; Maniatis T., 1982, MOL CLONING; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PERANTONI AO, 1987, P NATL ACAD SCI USA, V84, P6317, DOI 10.1073/pnas.84.17.6317; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; PRUTKIN L, 1966, DERMATOLOGICA, V132, P16, DOI 10.1159/000254393; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; RAMSELAAR CG, 1976, ACTA DERM-VENEREOL, V56, P245; REDDY EP, 1983, SCIENCE, V220, P1061, DOI 10.1126/science.6844927; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; RUTA M, 1986, MOL CELL BIOL, V6, P1706, DOI 10.1128/MCB.6.5.1706; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHIH TY, 1979, VIROLOGY, V96, P64, DOI 10.1016/0042-6822(79)90173-9; SIGALIS, 1986, P NATL ACAD SCI USA, V83, P1986; SUKUMAR S, 1986, MOL CELL BIOL, V6, P2716, DOI 10.1128/MCB.6.7.2716; VILLASANTE A, 1986, MOL CELL BIOL, V6, P2409, DOI 10.1128/MCB.6.7.2409; WAKELAM MJO, 1986, NATURE, V323, P173, DOI 10.1038/323173a0; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; YUSPA SH, 1983, CANCER RES, V43, P6021; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	53	26	27	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1991	6	4					645	651						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	1840681				2022-12-17	WOS:A1991FR93900021
J	HIRAKAWA, T; MARUYAMA, K; KOHL, NE; KODAMA, T; RULEY, HE				HIRAKAWA, T; MARUYAMA, K; KOHL, NE; KODAMA, T; RULEY, HE			MASSIVE ACCUMULATION OF NEUTRAL LIPIDS IN CELLS CONDITIONALLY TRANSFORMED BY AN ACTIVATED H-RAS ONCOGENE	ONCOGENE			English	Article							LOW-DENSITY LIPOPROTEIN; DIFFERENTIATION-DEPENDENT GENE; DEVELOPMENTAL PROGRAM; ADIPOCYTE DIFFERENTIATION; GLUCOCORTICOID REGULATION; PROTEIN GAP; BINDING; FIBROBLASTS; GROWTH; MICROINJECTION	Phenotypic consequences of ras oncogene expression were studied in cells conditionally transformed by T24 H-ras and a temperature-sensitive SV40 large T antigen (tsA58). Previous studies have demonstrated that transformation of REF52 cells by ras and SV40 large T antigen requires continuous T antigen expression. Thus, tsA58/T24 H-ras transformants ceased growing when transferred to a restrictive temperature for T antigen expression. Inhibition of cell growth was accompanied by massive accumulations of cholesterol esters, triglycerides and a third lipid species, identified as glycerol ethers on the basis of mobility on TLC. Cholesterol esters were derived from serum lipoproteins, and appeared to accumulate because LDL receptor expression and activity did not decline in growth arrested cells. Triglycerides and glycerol ethers were products of cell metabolism. The process lacked features characteristic of adipocyte differentiation, but may suggest mechanisms important in diseases, such as atherosclerosis, that involve abnormal accumulations of neutral lipids. Accumulating lipid species may also include metabolites induced by ras that accumulate in growth-arrested cells.	MIT,CTR CANC,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; AJINOMOTO CO INC,CENT RES LABS,KAWASAKI,KANAGAWA 210,JAPAN; DYNAX RES INST,PALO ALTO,CA 94304; MERCK SHARP & DOHME LTD,W POINT,PA 19486	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Ajinomoto Co Inc; Merck & Company					NATIONAL CANCER INSTITUTE [R01CA040602] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA40602] Funding Source: Medline; PHS HHS [14051] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; ALONSO T, 1988, P NATL ACAD SCI USA, V85, P4271, DOI 10.1073/pnas.85.12.4271; BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CHAPMAN AB, 1984, J BIOL CHEM, V259, P5548; CHAPMAN AB, 1985, J CELL BIOL, V101, P1227, DOI 10.1083/jcb.101.4.1227; DOTTO GP, 1985, NATURE, V318, P472; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; GARRELS JI, 1989, J BIOL CHEM, V264, P5283; GOLDFARB M, 1982, NATURE, V296, P404, DOI 10.1038/296404a0; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GOLDSTEIN JL, 1975, J BIOL CHEM, V250, P8487; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; HUNT CR, 1986, P NATL ACAD SCI USA, V83, P3786, DOI 10.1073/pnas.83.11.3786; Kates M., 1972, LAB TECH BIOCH MOL B, V3, P268, DOI [10.1016/S0075-7535(08)70544-8, DOI 10.1016/S0075-7535(08)70544-8]; KIMES BW, 1976, EXP CELL RES, V98, P349, DOI 10.1016/0014-4827(76)90446-8; KOHL NE, 1987, ONCOGENE, V2, P41; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LOGAN J, 1981, VIROLOGY, V115, P419, DOI 10.1016/0042-6822(81)90126-4; MARUYAMA K, 1987, ONCOGENE, V1, P361; McClure DB, 1982, COLD SPRING HARBOR C, V9, P345; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; PREISS J, 1986, J BIOL CHEM, V261, P8587; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SAGER R, 1982, P NATL ACAD SCI-BIOL, V79, P480, DOI 10.1073/pnas.79.2.480; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SEGE RD, 1986, MOL CELL BIOL, V6, P3268, DOI 10.1128/MCB.6.9.3268; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; SUKUMAR S, 1988, SCIENCE, V240, P524, DOI 10.1126/science.3282307; WEBER KA, 1988, NATURE, V332, P553; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4	48	26	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1991	6	2					289	295						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ134	2000221				2022-12-17	WOS:A1991FZ13400015
J	NICKLIN, MJH; CASARI, G				NICKLIN, MJH; CASARI, G			A SINGLE SITE MUTATION IN A TRUNCATED FOS PROTEIN ALLOWS IT TO INTERACT WITH THE TRE INVITRO	ONCOGENE			English	Article							DNA-BINDING DOMAIN; LEUCINE ZIPPER; C-JUN; GCN4; TRANSCRIPTION; SPECIFICITY; HETERODIMER; COMMON; C/EBP; AP-1	The Fos and Jun proteins, which are components of the transcription factor AP1, associate through the interaction of their so-called leucine zipper domains and bind strongly and specifically to DNA at phorbol esterresponsive elements. Jun also homodimerizes and binds the same element whereas Fos seems to have no specific affinity for DNA. We show that a single amino-acid change in the leucine zipper of Fos is sufficient to allow a truncated Fos protein to homodimerize and thus form a complex with DNA, even in the absence of Jun. This Fos-derived homodimer recognizes the consensus phorbol-ester responsive element specifically, in vitro. We conclude that the structural requirements for specific DNA binding are present in the Fos protein itself, with the exception of its lack of self-affinity.			NICKLIN, MJH (corresponding author), FORSCHUNGSINST MOLEK PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA.			Nicklin, Martin/0000-0002-0127-1131				AGRE P, 1989, SCIENCE, V246, P922, DOI 10.1126/science.2530632; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BENBROOK DM, 1990, ONCOGENE, V5, P295; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; CURRAN T, 1984, CELL, V36, P259; DEGRADO WF, 1989, SCIENCE, V243, P622, DOI 10.1126/science.2464850; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; JANIN J, 1978, J MOL BIOL, V125, P357, DOI 10.1016/0022-2836(78)90408-4; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NAKABEPPU Y, 1989, EMBO J, V8, P3833, DOI 10.1002/j.1460-2075.1989.tb08561.x; NEUBERG M, 1989, NATURE, V341, P243, DOI 10.1038/341243a0; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; PARKS GD, 1986, J VIROL, V60, P376, DOI 10.1128/JVI.60.2.376-384.1986; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VANDERWERF S, 1986, P NATL ACAD SCI USA, V83, P2330; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088	31	26	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1991	6	1					173	179						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY039	1899479				2022-12-17	WOS:A1991EY03900026
J	GILGENKRANTZ, S; CHERY, M; TEBOUL, M; MUJICA, P; LEOTARD, B; GREGOIRE, MJ; BOMAN, F; DUPREZ, A; HANAUER, A				GILGENKRANTZ, S; CHERY, M; TEBOUL, M; MUJICA, P; LEOTARD, B; GREGOIRE, MJ; BOMAN, F; DUPREZ, A; HANAUER, A			SUBLOCALIZATION OF THE X BREAKPOINT IN THE TRANSLOCATION (X-18)(P11.2-Q11.2) PRIMARY CHANGE IN SYNOVIAL SARCOMAS	ONCOGENE			English	Note									UNIV NANCY, F-54500 VANDOEUVRE LES NANCY, FRANCE; UNIV STRASBOURG 1, GENET MOLEC EUCARYOT LAB, F-67085 STRASBOURG, FRANCE	Universite de Lorraine; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	GILGENKRANTZ, S (corresponding author), UNIV NANCY, CTR REG TRANSFUS SANGUINE, F-54511 VANDOEUVRE LES NANCY, FRANCE.							BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; CANIZZARO LA, 1989, CYTOGENET CELL GENET, V51, P974; CORSON JM, 1984, HUM PATHOL, V15, P615, DOI 10.1016/S0046-8177(84)80284-1; DURFY SJ, 1986, NUCLEIC ACIDS RES, V14, P9226, DOI 10.1093/nar/14.22.9226; Enzinger RM., 2011, SOFT TISSUE TUMORS, P1178; FISHER C, 1986, HUM PATHOL, V17, P996, DOI 10.1016/S0046-8177(86)80083-1; FRASER N, 1987, CYTOGENET CELL GENET, V46, P615; GASSON JC, 1985, NATURE, V315, P768, DOI 10.1038/315768a0; GREGOIRE MJ, 1989, CANCER GENET CYTOGEN, V38, P160, DOI 10.1016/0165-4608(89)90548-7; GRIFFIN CA, 1987, CANCER GENET CYTOGEN, V26, P181, DOI 10.1016/0165-4608(87)90148-8; GUSTERSON B, 1985, INT J CANCER, V36, P689; HANAUER A, 1984, EMBO J, V3, P2627, DOI 10.1002/j.1460-2075.1984.tb02185.x; HENRY I, 1989, HUM GENET, V81, P273, DOI 10.1007/BF00279003; HUEBNER K, 1986, P NATL ACAD SCI USA, V83, P3934, DOI 10.1073/pnas.83.11.3934; HUEBNER K, 1986, AM J HUM GENET, V38, P819; KARAKOUSIS CP, 1987, ARCH SURG-CHICAGO, V122, P1257; KNIGHT JC, 1989, CYTOGENET CELL GENET, V51, P1023; KRUSE TA, 1986, NUCLEIC ACIDS RES, V14, P1921, DOI 10.1093/nar/14.4.1921; LIMON J, 1989, CANCER GENET CYTOGEN, V38, P215, DOI 10.1016/0165-4608(89)90662-6; LIMON J, 1986, CANCER GENET CYTOGEN, V23, P87, DOI 10.1016/0165-4608(86)90152-4; Mahtani MM, 1988, GENOMICS, V2, P294, DOI 10.1016/0888-7543(88)90017-1; MANDAHL N, 1988, CANCER GENET CYTOGEN, V30, P323, DOI 10.1016/0165-4608(88)90202-6; MIETTINEN M, 1983, VIRCHOWS ARCH B, V44, P187, DOI 10.1007/BF02890169; MULLER U, 1987, CYTOGENET CELL GENET, V45, P16, DOI 10.1159/000132418; NOGUERA R, 1988, CANCER GENET CYTOGEN, V33, P311, DOI 10.1016/0165-4608(88)90040-4; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; PONTECORVO G, 1975, SOMAT CELL GENET, V1, P397, DOI 10.1007/BF01538671; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; REEVES BR, 1989, ONCOGENE, V4, P373; RUDDLE FH, 1989, CYTOGENET CELL GENET, V51, P1, DOI 10.1159/000132773; SCHARDIN M, 1985, HUM GENET, V71, P281, DOI 10.1007/BF00388452; SHENG WW, 1987, CANCER GENET CYTOGEN, V29, P179, DOI 10.1016/0165-4608(87)90048-3; SMITH S, 1987, CANCER GENET CYTOGEN, V26, P179, DOI 10.1016/0165-4608(87)90147-6; SPURR NK, 1987, ANN HUM GENET, V51, P189, DOI 10.1111/j.1469-1809.1987.tb00870.x; TOGUCHIDA J, 1989, NATURE, V338, P156, DOI 10.1038/338156a0; TUCKER JD, 1984, EMBO J, V3, P2627; TURCCAREL C, 1986, CANCER GENET CYTOGEN, V23, P93, DOI 10.1016/0165-4608(86)90153-6; TURCCAREL C, 1987, P NATL ACAD SCI USA, V84, P1981, DOI 10.1073/pnas.84.7.1981; UEDA T, 1988, CANCER GENET CYTOGEN, V30, P183, DOI 10.1016/0165-4608(88)90111-2; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WILLARD HF, 1989, HUM GENET, V81, P234	41	26	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1990	5	7					1063	1066						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP415	2165233				2022-12-17	WOS:A1990DP41500017
J	STACEY, M; GALLIMORE, PH; MCCONVILLE, C; TAYLOR, AMR				STACEY, M; GALLIMORE, PH; MCCONVILLE, C; TAYLOR, AMR			REARRANGEMENT OF THE SAME CHROMOSOME REGIONS IN DIFFERENT SV40-TRANSFORMED HUMAN SKIN KERATINOCYTE LINES IS ASSOCIATED WITH TUMORIGENICITY	ONCOGENE			English	Article											STACEY, M (corresponding author), UNIV BIRMINGHAM, SCH MED, CANC RES CAMPAIGN LABS, DEPT CANC STUDIES, BIRMINGHAM B15 2TJ, W MIDLANDS, ENGLAND.			Stacey, Michael/0000-0002-3807-6233				ATKIN NB, 1985, CANCER GENET CYTOGEN, V15, P253, DOI 10.1016/0165-4608(85)90169-4; BADEN HP, 1987, IN VITRO CELL DEV B, V23, P205; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BANKSSCHLEGEL SP, 1983, J CELL BIOL, V96, P330, DOI 10.1083/jcb.96.2.330; BENEDICT WF, 1987, CANCER RES, V47, P4189; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BROWN KW, 1987, BRIT J CANCER, V56, P545, DOI 10.1038/bjc.1987.240; CHANG SE, 1985, BIOCHIM BIOPHYS ACTA, V823, P161; DEBLOIS MC, 1986, CR ACAD SCI III-VIE, V302, P81; GLUZMAN Y, 1979, COLD SPRING HARB SYM, V44, P293; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HILL SM, 1987, CANCER GENET CYTOGEN, V24, P45, DOI 10.1016/0165-4608(87)90082-3; HOFFSCHIR F, 1988, CYTOGENET CELL GENET, V49, P264, DOI 10.1159/000132674; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; JIN YS, 1988, CANCER GENET CYTOGEN, V33, P11, DOI 10.1016/0165-4608(88)90043-X; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOVACS G, 1988, P NATL ACAD SCI USA, V85, P1571, DOI 10.1073/pnas.85.5.1571; MULERIS M, 1987, INT J CANCER, V39, P595, DOI 10.1002/ijc.2910390509; PARASKEVA C, 1989, CANCER RES, V49, P1282; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RHIM JS, 1986, SCIENCE, V232, P385, DOI 10.1126/science.2421406; RHIM JS, 1985, SCIENCE, V227, P1250, DOI 10.1126/science.2579430; SACKS PG, 1988, CANCER RES, V48, P2858; SASAKI M, 1989, CANCER RES, V49, P4402; SOUTHERN EM, 1974, ANAL BIOCHEM, V62, P317, DOI 10.1016/0003-2697(74)90395-9; STEINBERG ML, 1979, P NATL ACAD SCI USA, V76, P801, DOI 10.1073/pnas.76.2.801; TAYLORPAPADIMITRIOU J, 1982, CELL DIFFER DEV, V11, P169, DOI 10.1016/0045-6039(82)90008-2; TEYSSIER JR, 1987, CANCER GENET CYTOGEN, V25, P179, DOI 10.1016/0165-4608(87)90175-0; TEYSSIER JR, 1986, J NATL CANCER I, V77, P1187; TRENT J, 1985, CANCER GENET CYTOGEN, V16, P189, DOI 10.1016/0165-4608(85)90045-7; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; WURSTERHILL DH, 1984, CANCER GENET CYTOGEN, V13, P303, DOI 10.1016/0165-4608(84)90075-X; YOKOTA J, 1989, CANCER RES, V49, P3598	35	26	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1990	5	5					727	739						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG374	2161098				2022-12-17	WOS:A1990DG37400014
J	VANLEEUWEN, F; VANDEVIJVER, MJ; LOMANS, J; VANDEEMTER, L; JENSTER, G; AKIYAMA, T; YAMAMOTO, T; NUSSE, R				VANLEEUWEN, F; VANDEVIJVER, MJ; LOMANS, J; VANDEEMTER, L; JENSTER, G; AKIYAMA, T; YAMAMOTO, T; NUSSE, R			MUTATION OF THE HUMAN NEU PROTEIN FACILITATES DOWN-MODULATION BY MONOCLONAL-ANTIBODIES	ONCOGENE			English	Article									NETHERLANDS CANC INST,DIV MOLEC BIOL,PLESMANLAAN 121,1066 CX AMSTERDAM,NETHERLANDS; UNIV TOKYO,INST MED SCI,MINATO KU,TOKYO 108,JAPAN	Netherlands Cancer Institute; University of Tokyo			van Leeuwen, Frank/AAQ-6799-2020	van Leeuwen, Frank/0000-0003-1107-6513				AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; ALI IU, 1988, ONCOGENE RES, V3, P139; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BERGER MS, 1988, CANCER RES, V48, P1238; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; DREBIN JA, 1986, P NATL ACAD SCI USA, V83, P9129, DOI 10.1073/pnas.83.23.9129; DREBIN JA, 1988, ONCOGENE, V2, P273; DREBIN JA, 1984, NATURE, V312, P545, DOI 10.1038/312545a0; DREBIN JA, 1988, ONCOGENE, V2, P387; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KING CR, 1985, NUCLEIC ACIDS RES, V13, P8477, DOI 10.1093/nar/13.23.8477; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; RIJSEWIJK F, 1987, EMBO J, V6, P127, DOI 10.1002/j.1460-2075.1987.tb04729.x; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCHECHTER AL, 1985, SCIENCE, V229, P976, DOI 10.1126/science.2992090; SCHLESSINGER J, 1986, J CELL BIOL, V103, P2067, DOI 10.1083/jcb.103.6.2067; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SONNENBERG A, 1987, EMBO J, V6, P121, DOI 10.1002/j.1460-2075.1987.tb04728.x; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; STERNBERG MJE, 1989, NATURE, V339, P587, DOI 10.1038/339587a0; TAL M, 1988, CANCER RES, V48, P1517; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902; VANDEVIJVER MJ, 1988, ONCOGENE, V2, P175; VARLEY JM, 1987, ONCOGENE, V1, P423; VENTER DJ, 1987, LANCET, V2, P69, DOI 10.1016/S0140-6736(87)92736-X; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YOKOTA J, 1988, ONCOGENE, V2, P283; YOKOTA J, 1986, LANCET, V1, P765; ZHOU DJ, 1987, CANCER RES, V47, P6123	47	26	26	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1990	5	4					497	503						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB853	1970152				2022-12-17	WOS:A1990DB85300007
J	HUA, C; RAFFELD, M; KO, HS; FAST, P; BAKHSHI, A; COSSMAN, J				HUA, C; RAFFELD, M; KO, HS; FAST, P; BAKHSHI, A; COSSMAN, J			MECHANISM OF BCL-2 ACTIVATION IN HUMAN FOLLICULAR LYMPHOMA	ONCOGENE			English	Article									NCI,METAB BRANCH,BETHESDA,MD 20892; NCI,PATHOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; BLATT WF, 1986, ANAL BIOCHEM, V26, P151; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; HUA C, 1988, ONCOGENE RES, V2, P263; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; RAFFELD M, 1987, CANCER RES, V47, P2537; RAVETCH JV, 1981, CELL, V27, P583, DOI 10.1016/0092-8674(81)90400-1; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; STETLERSTEVENSON M, 1988, BLOOD, V72, P1822; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; YUNIS JJ, 1982, NEW ENGL J MED, V307, P1231, DOI 10.1056/NEJM198211113072002	16	26	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1990	5	2					233	235						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU029	2181381				2022-12-17	WOS:A1990CU02900010
J	MATIN, A; CHENG, KL; SUEN, TC; HUNG, MC				MATIN, A; CHENG, KL; SUEN, TC; HUNG, MC			EFFECT OF GLUCOCORTICOIDS ON ONCOGENE TRANSFORMED NIH3T3 CELLS	ONCOGENE			English	Article									UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,CTR CANC,DEPT TUMOR BIOL,1515 HOLCOMBE BLVD,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	NATIONAL CANCER INSTITUTE [R01CA045265] Funding Source: NIH RePORTER; NCI NIH HHS [CA-45265] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI IU, 1977, CELL, V11, P5; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CZERNILOFSKY AP, 1980, NATURE, V287, P198, DOI 10.1038/287198a0; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; DREBIN JA, 1984, NATURE, V312, P545, DOI 10.1038/312545a0; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; ENGVALL E, 1972, J IMMUNOL, V109, P129; FURCHT LT, 1979, NATURE, V277, P393, DOI 10.1038/277393a0; FURCHT LT, 1979, CANCER RES, V39, P2077; FURCHT LT, 1978, CELL, V13, P263, DOI 10.1016/0092-8674(78)90195-2; GOFF SP, 1982, J VIROL, V41, P271, DOI 10.1128/JVI.41.1.271-285.1982; HUNG MC, 1986, BIOCHEM BIOPH RES CO, V141, P1109, DOI 10.1016/S0006-291X(86)80158-9; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; MAUTNER V, 1977, J CELL BIOL, V75, P743, DOI 10.1083/jcb.75.3.743; OLIVER N, 1983, CELL, V33, P287, DOI 10.1016/0092-8674(83)90357-4; OZANNE B, 1980, J CELL PHYSIOL, V105, P163, DOI 10.1002/jcp.1041050118; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; SHIELDS A, 1979, J VIROL, V31, P557, DOI 10.1128/JVI.31.2.557-567.1979; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; TOOZE J, 1973, MOL BIOL TUMOR VIRUS; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YAMADA KM, 1978, NATURE, V275, P179, DOI 10.1038/275179a0; YAMADA KM, 1976, P NATL ACAD SCI USA, V73, P1217, DOI 10.1073/pnas.73.4.1217	27	26	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1990	5	1					111	116						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM620	2181373				2022-12-17	WOS:A1990CM62000015
J	SCHWARTZ, MA; RUPP, EE; FRANGIONI, JV; LECHENE, CP				SCHWARTZ, MA; RUPP, EE; FRANGIONI, JV; LECHENE, CP			CYTOPLASMIC PH AND ANCHORAGE-INDEPENDENT GROWTH INDUCED BY V-KI-RAS, V-SRC OR POLYOMA MIDDLE-T	ONCOGENE			English	Article									HARVARD UNIV, SCH MED, CELLULAR PHYSIOL LAB, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, MIT, DIV HLTH SCI & TECHNOL, CAMBRIDGE, MA 02139 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts Institute of Technology (MIT)	SCHWARTZ, MA (corresponding author), HARVARD UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, BOSTON, MA 02115 USA.			schwartz, martin/0000-0002-2071-1243	NCRR NIH HHS [5P441RR02064] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BIERMAN AJ, 1988, J BIOL CHEM, V263, P15253; BISHOP JM, 1985, CELL, V42, P23, DOI 10.1016/S0092-8674(85)80098-2; CASSEL D, 1987, J BIOL CHEM, V262, P4587; DOPPLER W, 1987, GENE, V54, P147, DOI 10.1016/0378-1119(87)90357-X; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; HAGAG N, 1987, MOL CELL BIOL, V7, P1984, DOI 10.1128/MCB.7.5.1984; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1982, J CELL BIOL, V95, P369, DOI 10.1083/jcb.95.2.369; INGER DE, 1989, UNPUB; MOOLENAAR WH, 1986, ANNU REV PHYSIOL, V48, P363; MORGAN WC, 1988, J VIROL, V62, P3407, DOI 10.1128/JVI.62.9.3407-3414.1988; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; OBER SS, 1987, P NATL ACAD SCI USA, V84, P345; PALLAS DC, 1988, J VIROL, V62, P3934, DOI 10.1128/JVI.62.11.3934-3940.1988; PERONA R, 1988, NATURE, V334, P438, DOI 10.1038/334438a0; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; SCHWARTZ MA, 1989, P NATL ACAD SCI USA, V86, P4525, DOI 10.1073/pnas.86.12.4525; SCHWARTZ MA, IN PRESS J BIOL CHEM; SMETS LA, 1980, BIOCHIM BIOPHYS ACTA, V605, P93, DOI 10.1016/0304-419X(80)90022-0	21	26	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1990	5	1					55	58						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM620	2181378				2022-12-17	WOS:A1990CM62000008
J	RHIM, JS; PARK, JB; JAY, G				RHIM, JS; PARK, JB; JAY, G			NEOPLASTIC TRANSFORMATION OF HUMAN KERATINOCYTES BY POLYBRENE-INDUCED DNA-MEDIATED TRANSFER OF AN ACTIVATED ONCOGENE	ONCOGENE			English	Article									AMER RED CROSS, JEROME H HOLLAND LAB, VIROL LAB, ROCKVILLE, MD 20855 USA	American Red Cross	RHIM, JS (corresponding author), NCI, CELLULAR & MOLEC BIOL, BETHESDA, MD 20892 USA.		Jay, Gregory/C-6346-2013					AUTRUP HN, 1983, HUMAN CARCINOGENESIS; BANKSSCHLEGEL SP, 1983, J CELL BIOL, V96, P330, DOI 10.1083/jcb.96.2.330; BOREK C, 1980, NATURE, V283, P776, DOI 10.1038/283776a0; BRASH DE, 1987, MOL CELL BIOL, V7, P2031, DOI 10.1128/MCB.7.5.2031; CROCE CM, 1975, P NATL ACAD SCI USA, V72, P1397, DOI 10.1073/pnas.72.4.1397; DIPAOLO JA, 1983, J NATL CANCER I, V70, P3; GANTT R, 1987, CANCER RES, V47, P1390; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; KAKUNAGA T, 1980, ADV MOD TOXICOL, V1, P355; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; MCCORMICK JJ, 1988, CARCINOGENESIS, V9, P2073, DOI 10.1093/carcin/9.11.2073; MILO GE, 1978, NATURE, V275, P130, DOI 10.1038/275130a0; MORGAN TL, 1986, IN VITRO CELL DEV B, V22, P317, DOI 10.1007/BF02623404; OBRIEN W, 1986, P NATL ACAD SCI USA, V83, P8659; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; REYNOLDS RK, 1988, P NATL ACAD SCI USA, V85, P3135, DOI 10.1073/pnas.85.9.3135; REYNOLDS RK, 1976, P NATL ACAD SCI USA, V2, P1337; RHIM JS, 1988, LEUKEMIA, V2, pS151; RHIM JS, 1985, SCIENCE, V227, P1250, DOI 10.1126/science.2579430; RHIM JS, 1976, PREVENTION DETECTION, V2, P1337; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SAGER R, 1983, P NATL ACAD SCI-BIOL, V80, P7601, DOI 10.1073/pnas.80.24.7601; SAGER R, 1984, CANCER CELL, V2, P487; SAWAI S, 1984, MOL CELL BIOL, V4, P1172; SCHLEGEL R, 1988, EMBO J, V7, P3181, DOI 10.1002/j.1460-2075.1988.tb03185.x; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STEINBERG ML, 1979, P NATL ACAD SCI USA, V76, P801, DOI 10.1073/pnas.76.2.801; SUTHERLAND BM, 1984, CANCER RES, V44, P2769	31	26	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1989	4	11					1403	1409						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AX659	2682464				2022-12-17	WOS:A1989AX65900019
J	PELLET, P; BERGER, R; BERNHEIM, A; BROUET, JC; TSAPIS, A				PELLET, P; BERGER, R; BERNHEIM, A; BROUET, JC; TSAPIS, A			MOLECULAR ANALYSIS OF A T(9-14)(P11-Q32) TRANSLOCATION OCCURRING IN A CASE OF HUMAN ALPHA-HEAVY CHAIN DISEASE	ONCOGENE			English	Article									HOP ST LOUIS,INSERM,U301,CYTOGENET LAB,F-75475 PARIS 10,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	PELLET, P (corresponding author), HOP ST LOUIS,INSERM,U108,IMMUNOCHEM & IMMUNOPATHOL LAB,1 AVE CLAUDE YELLEFAUX,F-75475 PARIS 10,FRANCE.							ALEXANDER A, 1988, J CLIN INVEST, V82, P1244, DOI 10.1172/JCI113722; BAKHSHI A, 1987, P NATL ACAD SCI USA, V84, P2396, DOI 10.1073/pnas.84.8.2396; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BERGER R, 1986, CANCER GENET CYTOGEN, V22, P219, DOI 10.1016/0165-4608(86)90158-5; BERNHEIM A, 1983, P NATL ACAD SCI USA, V79, P2971; BRITOBABAPULLE V, 1987, LEUKEMIA, V1, P789; CARE A, 1986, EMBO J, V5, P905, DOI 10.1002/j.1460-2075.1986.tb04302.x; CARROLL AJ, 1987, BLOOD, V70, P1962; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DIAZ MO, 1988, P NATL ACAD SCI USA, V85, P5259, DOI 10.1073/pnas.85.14.5259; ERIKSON J, 1983, P NATL ACAD SCI-BIOL, V80, P820, DOI 10.1073/pnas.80.3.820; ERIKSON J, 1982, P NATL ACAD SCI-BIOL, V79, P5611, DOI 10.1073/pnas.79.18.5611; FAN YS, 1988, CANCER GENET CYTOGEN, V31, P263, DOI 10.1016/0165-4608(88)90226-9; FLANAGAN JG, 1984, CELL, V36, P681, DOI 10.1016/0092-8674(84)90348-9; FLANAGAN JG, 1982, NATURE, V300, P709, DOI 10.1038/300709a0; GELMANN EP, 1983, NATURE, V306, P799, DOI 10.1038/306799a0; HALUSKA FG, 1987, P NATL ACAD SCI USA, V84, P6835, DOI 10.1073/pnas.84.19.6835; HALUSKA FG, 1986, NATURE, V324, P158, DOI 10.1038/324158a0; HARPER ME, 1981, CHROMOSOMA, V83, P431, DOI 10.1007/BF00327364; HAYDAY AC, 1984, NATURE, V307, P334, DOI 10.1038/307334a0; KLEIN G, 1985, IMMUNOL TODAY, V6, P208, DOI 10.1016/0167-5699(85)90036-2; Klein G, 1981, NATURE, V294, P313, DOI 10.1038/294313a0; LOENEN WAM, 1980, GENE, V10, P249, DOI 10.1016/0378-1119(80)90054-2; Maniatis T., 1982, MOL CLONING; NERI A, 1988, P NATL ACAD SCI USA, V85, P2748, DOI 10.1073/pnas.85.8.2748; RAVETCH JV, 1981, CELL, V27, P583, DOI 10.1016/0092-8674(81)90400-1; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROWLEY JD, 1982, SCIENCE, V216, P749, DOI 10.1126/science.7079737; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SELIGMANN M, 1968, SCIENCE, V162, P1396, DOI 10.1126/science.162.3860.1396; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WABL M, 1985, P NATL ACAD SCI USA, V82, P479, DOI 10.1073/pnas.82.2.479; WIMAN KG, 1984, P NATL ACAD SCI-BIOL, V81, P6798, DOI 10.1073/pnas.81.21.6798; YUNIS JJ, 1983, SCIENCE, V221, P227, DOI 10.1126/science.6336310	41	26	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1989	4	5					653	657						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U7688	2498807				2022-12-17	WOS:A1989U768800017
J	DOOLEY, TP; WILSON, RE; JONES, NC; HART, IR				DOOLEY, TP; WILSON, RE; JONES, NC; HART, IR			POLYOMA MIDDLE T-ABROGATES TPA REQUIREMENT OF MURINE MELANOCYTES AND INDUCES MALIGNANT-MELANOMA	ONCOGENE			English	Note									IMPERIAL CANC RES FUND,GENE REGULAT LAB,LONDON WC2A 3PX,ENGLAND; IMPERIAL CANC RES FUND,BIOL METASTASIS LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK; Cancer Research UK								BAUTCH VL, 1987, CELL, V51, P529, DOI 10.1016/0092-8674(87)90122-X; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; COLLINS M, 1982, BIOCHEM BIOPH RES CO, V104, P1159, DOI 10.1016/0006-291X(82)91372-9; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; FOURNIER A, 1987, NATURE, V330, P767, DOI 10.1038/330767a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; Maniatis T., 1982, MOL CLONING; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OOSTRA BA, 1983, NATURE, V304, P456, DOI 10.1038/304456a0; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SOLANKI V, 1981, P NATL ACAD SCI-BIOL, V78, P1722, DOI 10.1073/pnas.78.3.1722; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STABEL S, 1987, J CELL PHYSIOL, V130, P111, DOI 10.1002/jcp.1041300116; TOOZE J, 1980, MOL BIOL TUMOUR VIRU, V2; TREISMAN R, 1981, NATURE, V292, P595, DOI 10.1038/292595a0; WONG G, 1973, NATURE-NEW BIOL, V241, P213, DOI 10.1038/newbio241213a0; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887	26	26	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1988	3	5					531	535						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R5163	2856252				2022-12-17	WOS:A1988R516300007
J	Chen, XY; Chen, HT; Yao, HH; Zhao, K; Zhang, Y; He, D; Zhu, YX; Cheng, YX; Liu, R; Xu, RS; Cao, K				Chen, Xingyu; Chen, Haotian; Yao, Honghui; Zhao, Kai; Zhang, Yao; He, Dong; Zhu, Yuxing; Cheng, YaXin; Liu, Rui; Xu, Runshi; Cao, Ke			Turning up the heat on non-immunoreactive tumors: pyroptosis influences the tumor immune microenvironment in bladder cancer	ONCOGENE			English	Article							CELL-DEATH; BLOCKADE	The latest research confirms that cytotoxic lymphocytes rely on pyroptosis to kill tumor cells, suggesting that pyroptosis plays a vital role in immune response. However, the influence of pyroptosis on tumor microenvironment (TME) remodeling and immunotherapy is still unclear. We analyzed the variations in the expression of 28 pyroptosis-related molecules in pan-cancer tissues and normal tissues and the influence of genome changes. We investigated 2,214 bladder cancer samples and determined that there are three pyroptosis phenotypes in bladder cancer, and there are significant differences in cell infiltration characteristics in different pyroptosis phenotypes. Phenotypes with high expression of pyroptosis-related molecules are "hot tumors" with better immune function. We used a principal component analysis to measure the level of pyroptosis in patients with PyroScore, and confirmed that the PyroScore can predict the prognosis of bladder cancer patients, the sensitivity of the immune phenotype to chemotherapy, and the response to immunotherapy. Patients with a high PyroScore are more sensitive to chemotherapeutics such as cisplatin and gemcitabine, and have a better prognosis (HR = 0.7; 95%CI = 0.51-0.97, P = 0.041). Our study suggests a significant correlation between the expression imbalance of pyroptosis-related molecules and genome variation in various cancers and suggests pyroptosis plays an important role in modeling the TME. Evaluating pyroptosis modification patterns contributes to enhancing our understanding of TME infiltration and can guide more effective immunotherapy strategies.	[Chen, Xingyu; Chen, Haotian; Zhang, Yao; Zhu, Yuxing; Cheng, YaXin; Liu, Rui; Cao, Ke] Cent South Univ, Dept Oncol, Xiangya Hosp 3, 283 Tongzipo Rd, Changsha 410013, Peoples R China; [Yao, Honghui] Karolinska Inst, Dept Learning Informat Management & Eth, Solna, Sweden; [Zhao, Kai] Cent South Univ, Dept Hematol, Xiangya Hosp 3, Changsha 410013, Peoples R China; [Zhao, Kai] Cent South Univ, Key Lab Nonresolving Inflammat & Canc Hunan Prov, Xiangya Hosp 3, Changsha 410013, Peoples R China; [He, Dong] Hunan Univ Chinese Med, Dept Respirat, Peoples Hosp Hunan Prov 2, Changsha 410000, Peoples R China; [Xu, Runshi] Hunan Prov Hunan Univ Chinese Med, Changsha 410000, Peoples R China	Central South University; Karolinska Institutet; Central South University; Central South University; Hunan University of Chinese Medicine	Cao, K (corresponding author), Cent South Univ, Dept Oncol, Xiangya Hosp 3, 283 Tongzipo Rd, Changsha 410013, Peoples R China.	csucaoke@163.com	Xu, Runshi/AEI-9782-2022		National Natural Science Foundation of China [81874137]; science and technology innovation Program of Hunan Province [2020RC4011]; Outstanding Youth Foundation of Hunan Province [2018JJ1047]; Hunan Province Science and Technology Talent Promotion Project [2019TJ-Q10]; Young Scholars of "Furong Scholar Program" in Hunan Province; Wisdom Accumulation and Talent Cultivation Project of the Third xiangya hosipital of Central South University [BJ202001]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); science and technology innovation Program of Hunan Province; Outstanding Youth Foundation of Hunan Province; Hunan Province Science and Technology Talent Promotion Project; Young Scholars of "Furong Scholar Program" in Hunan Province; Wisdom Accumulation and Talent Cultivation Project of the Third xiangya hosipital of Central South University	This work was supported by the National Natural Science Foundation of China (81874137), the science and technology innovation Program of Hunan Province (2020RC4011), the Outstanding Youth Foundation of Hunan Province (2018JJ1047), the Hunan Province Science and Technology Talent Promotion Project (2019TJ-Q10), Young Scholars of "Furong Scholar Program" in Hunan Province, and the Wisdom Accumulation and Talent Cultivation Project of the Third xiangya hosipital of Central South University (BJ202001).	An H, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03454-9; Aran D, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1349-1; BECHT E, 2016, GENOME BIOL; Bergsbaken T, 2009, NAT REV MICROBIOL, V7, P99, DOI 10.1038/nrmicro2070; Bode C, 2021, EUR J IMMUNOL, V51, P1686, DOI 10.1002/eji.202048810; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Broz P, 2020, NAT REV IMMUNOL, V20, P143, DOI 10.1038/s41577-019-0228-2; Chen XY, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.672158; Cristescu R, 2019, SCIENCE, V363, DOI 10.1126/science.aax1384; Curran MA, 2010, P NATL ACAD SCI USA, V107, P4275, DOI 10.1073/pnas.0915174107; Decout A, 2021, NAT REV IMMUNOL, V21, P548, DOI 10.1038/s41577-021-00524-z; Finotello Francesca, 2019, Genome Med, V11, P34, DOI 10.1186/s13073-019-0638-6; Hou JW, 2020, NAT CELL BIOL, V22, P1264, DOI 10.1038/s41556-020-0575-z; Jiang MX, 2020, CELL DEATH DISCOV, V6, DOI 10.1038/s41420-020-00349-0; Kamoun A, 2020, EUR UROL, V77, P420, DOI 10.1016/j.eururo.2019.09.006; Li B, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1028-7; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501; Marin-Acevedo JA, 2019, MAYO CLIN PROC, V94, P1321, DOI 10.1016/j.mayocp.2019.03.012; Pitt JM, 2016, ANN ONCOL, V27, P1482, DOI 10.1093/annonc/mdw168; Qin XM, 2020, J PHYS CHEM A, V124, P10066, DOI 10.1021/acs.jpca.0c06019; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Rosenbaum SR, 2021, CANCER DISCOV, V11, P266, DOI 10.1158/2159-8290.CD-20-0805; Rosenberg JE, 2016, LANCET, V387, P1909, DOI 10.1016/S0140-6736(16)00561-4; Roupret M, 2021, EUR UROL, V79, P62, DOI 10.1016/j.eururo.2020.05.042; Sharma P, 2017, LANCET ONCOL, V18, P312, DOI 10.1016/S1470-2045(17)30065-7; SHEN X, 2021, CELL DEATH DIS, V12; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Van Opdenbosch N, 2019, IMMUNITY, V50, P1352, DOI 10.1016/j.immuni.2019.05.020; Wang QY, 2020, NATURE, V579, P421, DOI 10.1038/s41586-020-2079-1; Xi GM, 2019, INT IMMUNOPHARMACOL, V74, DOI 10.1016/j.intimp.2019.105713; Xiao Y, 2019, CLIN CANCER RES, V25, P5002, DOI 10.1158/1078-0432.CCR-18-3524; Zhang ZB, 2020, NATURE, V579, P415, DOI 10.1038/s41586-020-2071-9; Zheng M, 2020, CELL, V181, P674, DOI 10.1016/j.cell.2020.03.040; Zhou ZW, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.100872	35	25	25	11	32	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2021	40	45					6381	6393		10.1038/s41388-021-02024-9	http://dx.doi.org/10.1038/s41388-021-02024-9		SEP 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW1BA	34588621				2022-12-17	WOS:000701380400001
J	Chen, TL; Liu, HD; Liu, ZL; Li, KS; Qin, RX; Wang, Y; Liu, JL; Li, ZP; Gao, QL; Pan, C; Yang, F; Zhao, W; Zhang, ZL; Xu, YF				Chen, Tianli; Liu, Hongda; Liu, Zengli; Li, Kangshuai; Qin, Ruixi; Wang, Yue; Liu, Jialiang; Li, Zhipeng; Gao, Qinglun; Pan, Chang; Yang, Fan; Zhao, Wei; Zhang, Zongli; Xu, Yunfei			FGF19 and FGFR4 promotes the progression of gallbladder carcinoma in an autocrine pathway dependent on GPBAR1-cAMP-EGR1 axis	ONCOGENE			English	Article							FACTOR RECEPTOR 4; GROWTH-FACTOR 19; BILE-ACIDS; CANCER; IDENTIFICATION; MUTATIONS; METABOLISM; RESISTANCE; PROGNOSIS	Treatment options for gallbladder carcinoma (GBC) are limited and GBC prognosis remains poor. There is no well-accepted targeted therapy to date, so effective biomarkers of GBC are urgently needed. Here we investigated the expression and correlations of fibroblast growth factor receptors (FGFR1-4) and 18 fibroblast growth factors (FGFs) in two independent patient cohorts and evaluated their prognostic significance. Consequently, we demonstrated that both FGF19 and FGFR4 were unfavorable prognostic biomarkers, and their co-expression was a more sensitive predictor. By analyzing the correlations between all 18 FGFs and FGFR4, we showed that FGF19 expression was significantly associated with FGFR4 and promoted GBC progression via stimulating FGFR4. With experiments using GBC cells, GPBAR1(-/-) mice models, and human subjects, we demonstrated that elevated bile acids (BAs) could increase the transcription and expression of FGF19 and FGFR4 by activating GPBAR1-cAMP-EGR1 pathway. FGF19 secreted from GBC cells promoted GBC progression by stimulating FGFR4 and downstream ERK in an autocrine manner with bile as a potential carrier. Patients with GBC had significantly higher FGF19 in serum and bile, compared to patients with cholelithiasis. BLU9931 inhibited FGFR4 and attenuated its oncogenic effects in GBC cell line. In conclusion, upregulation of BAs elevated co-expression of FGF19 and FGFR4 by activating GPBAR1-cAMP-EGR1 pathway. Co-expression of FGF19 and FGFR4 was a sensitive and unfavorable prognostic marker. GBC cells secreted FGF19 and facilitated progression by activating FGFR4 with bile as a potential carrier in an autocrine pathway.	[Chen, Tianli; Liu, Zengli; Li, Kangshuai; Wang, Yue; Liu, Jialiang; Li, Zhipeng; Zhao, Wei; Zhang, Zongli; Xu, Yunfei] Shandong Univ, Qilu Hosp, Dept Gen Surg, Jinan, Peoples R China; [Liu, Hongda] Nanjing Med Univ, Affiliated Hosp 1, Dept Gen Surg, Nanjing, Peoples R China; [Qin, Ruixi] Shandong Univ, Qilu Hosp, Dept Pathol, Jinan, Peoples R China; [Li, Zhipeng] Shandong Univ, Shandong Prov ENT Hosp, Dept Gen Surg, Jinan, Peoples R China; [Gao, Qinglun] Shandong Prov Third Hosp, Dept Hepatobiliary Surg, Jinan, Peoples R China; [Pan, Chang] Shandong Univ, Qilu Hosp, Dept Emergency, Jinan, Peoples R China; [Yang, Fan] Shandong Univ, Sch Med, Minist Educ, Key Lab Expt Teratol, Jinan, Peoples R China; [Yang, Fan] Shandong Univ, Sch Med, Dept Biochem & Mol Biol, Jinan, Peoples R China	Shandong University; Nanjing Medical University; Shandong University; Shandong University; Shandong University; Shandong University; Shandong University	Zhang, ZL; Xu, YF (corresponding author), Shandong Univ, Qilu Hosp, Dept Gen Surg, Jinan, Peoples R China.	zzlzzl1900@163.com; xuyunfei1988@126.com		Chen, Tianli/0000-0003-3706-0712; Liu, Hongda/0000-0002-5977-9130	National Natural Science Foundation of China [82072676]; China Postdoctoral Science Foundation [2020M682190]; Shandong University Multidisciplinary Research and Innovation Team of Young Scholars [2020QNQT002]; Shandong Province Major Research and Design Program [2018GSF118169]; Natural Science Foundation of Shandong Province [ZR2019MH008]; Jinan City Science and Technology Development Program [201805017, 201805013]; Major Project of Shandong University Clinical Study [2020SDUCRCA018]; Project of Clinical New Techniques of Qilu Hospital affiliated to Shandong Universtiy, Clinical Research Innovation Fund Project [CXPJJH11800001-2018240]; Hengrui Hepatobiliary and Pancreatic Foundation [Y-2017-144]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Shandong University Multidisciplinary Research and Innovation Team of Young Scholars; Shandong Province Major Research and Design Program; Natural Science Foundation of Shandong Province(Natural Science Foundation of Shandong Province); Jinan City Science and Technology Development Program; Major Project of Shandong University Clinical Study; Project of Clinical New Techniques of Qilu Hospital affiliated to Shandong Universtiy, Clinical Research Innovation Fund Project; Hengrui Hepatobiliary and Pancreatic Foundation	Our study was supported by the National Natural Science Foundation of China (Grant No. 82072676), the China Postdoctoral Science Foundation (Grant No. 2020M682190), Shandong University Multidisciplinary Research and Innovation Team of Young Scholars (Grant No. 2020QNQT002), Shandong Province Major Research and Design Program (Grant No. 2018GSF118169), Natural Science Foundation of Shandong Province (ZR2019MH008), Jinan City Science and Technology Development Program (Grant No. 201805017, 201805013), the Major Project of Shandong University Clinical Study (Grant No. 2020SDUCRCA018), the Project of Clinical New Techniques of Qilu Hospital affiliated to Shandong Universtiy, Clinical Research Innovation Fund Project (CXPJJH11800001-2018240) and Hengrui Hepatobiliary and Pancreatic Foundation (Grant No.Y-2017-144).	Beenken A, 2009, NAT REV DRUG DISCOV, V8, P235, DOI 10.1038/nrd2792; Camilleri M, 2017, GASTROENTEROLOGY, V152, P1656, DOI 10.1053/j.gastro.2016.12.052; Choi M, 2006, NAT MED, V12, P1253, DOI 10.1038/nm1501; Dienstmann R, 2014, ANN ONCOL, V25, P552, DOI 10.1093/annonc/mdt419; Elzi David J, 2016, Genes Cancer, V7, P125, DOI 10.18632/genesandcancer.101; Gao LX, 2019, ONCOGENE, V38, P2394, DOI 10.1038/s41388-018-0591-7; Ge HF, 2014, J BIOL CHEM, V289, P30470, DOI 10.1074/jbc.M114.592022; Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666; Goyal L, 2017, CANCER DISCOV, V7, P252, DOI 10.1158/2159-8290.CD-16-1000; Hagel M, 2015, CANCER DISCOV, V5, P424, DOI 10.1158/2159-8290.CD-14-1029; Heinzle C, 2014, CURR PHARM DESIGN, V20, P2881, DOI 10.2174/13816128113199990594; Henley SJ, 2015, CANCER EPIDEM BIOMAR, V24, P1319, DOI 10.1158/1055-9965.EPI-15-0199; Inagaki T, 2005, CELL METAB, V2, P217, DOI 10.1016/j.cmet.2005.09.001; Javle M, 2016, CANCER-AM CANCER SOC, V122, P3838, DOI 10.1002/cncr.30254; Katoh M, 2014, MED RES REV, V34, P280, DOI 10.1002/med.21288; Keitel V, 2019, HANDB EXP PHARMACOL, V256, P19, DOI 10.1007/164_2019_230; Keitel V, 2013, CURR OPIN GASTROEN, V29, P299, DOI 10.1097/MOG.0b013e32835f3f14; Li F, 2020, ONCOGENE, V39, P3507, DOI 10.1038/s41388-020-1227-2; Li JN, 2019, BBA-MOL BASIS DIS, V1865, P895, DOI 10.1016/j.bbadis.2018.05.011; Li ML, 2014, NAT GENET, V46, P872, DOI 10.1038/ng.3030; Li Tiangang, 2015, Adv Pharmacol, V74, P263, DOI 10.1016/bs.apha.2015.04.003; Mhatre S, 2017, LANCET ONCOL, V18, P535, DOI 10.1016/S1470-2045(17)30167-5; Mitin T, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw324; Nakamura H, 2015, NAT GENET, V47, P1003, DOI 10.1038/ng.3375; PLEVRIS JN, 1995, GUT, V37, P127, DOI 10.1136/gut.37.1.127; Qiu B, 2019, EBIOMEDICINE, V50, P166, DOI 10.1016/j.ebiom.2019.11.021; Reue K, 2014, CURR OPIN LIPIDOL, V25, P140, DOI 10.1097/MOL.0000000000000060; Schaap FG, 2009, HEPATOLOGY, V49, P1228, DOI 10.1002/hep.22771; Song KH, 2009, HEPATOLOGY, V49, P297, DOI 10.1002/hep.22627; Sonne DP, 2016, J CLIN ENDOCR METAB, V101, P3002, DOI 10.1210/jc.2016-1607; Sugiyama N, 2010, CANCER RES, V70, P7851, DOI 10.1158/0008-5472.CAN-10-1223; Sun RQ, 2019, EBIOMEDICINE, V47, P142, DOI 10.1016/j.ebiom.2019.08.062; Taylor JG, 2009, J CLIN INVEST, V119, P3395, DOI 10.1172/JCI39703; Tiong KH, 2016, ONCOTARGET, V7, P57633, DOI 10.18632/oncotarget.9328; Tsilidis KK, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.g7607; Valle JW, 2021, LANCET, V397, P428, DOI 10.1016/S0140-6736(21)00153-7; Valle JW, 2017, CANCER DISCOV, V7, P943, DOI 10.1158/2159-8290.CD-17-0245; Wiedemann M, 2000, GENOMICS, V69, P275, DOI 10.1006/geno.2000.6332; Wu XL, 2011, EXPERT OPIN THER TAR, V15, P1307, DOI 10.1517/14728222.2011.624514; Wu YM, 2013, CANCER DISCOV, V3, P636, DOI 10.1158/2159-8290.CD-13-0050; Xu YF, 2019, ONCOGENE, V38, P868, DOI 10.1038/s41388-018-0485-8; Xu YF, 2014, BIOCHEM BIOPH RES CO, V446, P54, DOI 10.1016/j.bbrc.2014.02.050; Xu YF, 2017, ONCOTARGET, V8, P4888, DOI 10.18632/oncotarget.13982; Yang F, 2020, NATURE, V587, P499, DOI 10.1038/s41586-020-2569-1; Ye YW, 2011, CANCER-AM CANCER SOC, V117, P5304, DOI 10.1002/cncr.26207; Yu CD, 2000, J BIOL CHEM, V275, P15482, DOI 10.1074/jbc.275.20.15482; Zhou M, 2014, CANCER RES, V74, P3306, DOI 10.1158/0008-5472.CAN-14-0208; Zweers SJLB, 2012, HEPATOLOGY, V55, P575, DOI 10.1002/hep.24702	48	25	24	5	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2021	40	30					4941	4953		10.1038/s41388-021-01850-1	http://dx.doi.org/10.1038/s41388-021-01850-1		JUN 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TS1QO	34163030				2022-12-17	WOS:000664853000003
J	Patel, PS; Algouneh, A; Hakem, R				Patel, Parasvi S.; Algouneh, Arash; Hakem, Razq			Exploiting synthetic lethality to target BRCA1/2-deficient tumors: where we stand	ONCOGENE			English	Review								The principle of synthetic lethality, which refers to the loss of viability resulting from the disruption of two genes, which, individually, do not cause lethality, has become an attractive target approach due to the development and clinical success of Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi). In this review, we present the most recent findings on the use of PARPi in the clinic, which are currently approved for second-line therapy for advanced ovarian and breast cancer associated with mutations of BRCA1 or BRCA2 (BRCA1/2) genes. PARPi efficacy, however, appears to be limited by acquired and inherent resistance, highlighting the need for alternative and synergistic targets to eliminate these tumors. Here, we explore other identified synthetic lethal interactors of BRCA1/2, including DNA polymerase theta (POLQ), Fanconi anemia complementation group D2 (FANDC2), radiation sensitive 52 (RAD52), Flap structure-specific endonuclease 1 (FEN1), and apurinic/apyrimidinic endodeoxyribonuclease 2 (APE2), as well as other protein and nonprotein targets, for BRCA1/2-mutated cancers and their implications for future therapies. A wealth of information now exists for phenotypic and functional characterization of these novel synthetic lethal interactors of BRCA1/2, and leveraging these findings can pave the way for the development of new targeted therapies for patients suffering from these cancers.	[Patel, Parasvi S.; Algouneh, Arash; Hakem, Razq] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada; [Patel, Parasvi S.; Hakem, Razq] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [Algouneh, Arash; Hakem, Razq] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Toronto	Hakem, R (corresponding author), Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada.; Hakem, R (corresponding author), Univ Toronto, Dept Med Biophys, Toronto, ON, Canada.; Hakem, R (corresponding author), Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada.	rhakem@uhnres.utoronto.ca		Algouneh, Arash/0000-0002-2080-4941; Hakem, Razqallah/0000-0001-5948-7931	Canadian Institutes of Health Research [FDN 143214]; Canadian Cancer Society [705367, 706439]; STARS21; Terry Fox Foundation; Princess Margaret Cancer Foundation; Department of Medical Biophysics, University of Toronto; Ontario Graduate Scholarship, Government of Ontario; Canada Graduate Scholarships for Master's program; Ontario Graduate Scholarship; Department of Laboratory Medicine and Pathobiology, University of Toronto; Lee K. and Margaret Lau Chair in Breast Cancer Research	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Cancer Society(Canadian Cancer Society (CCS)); STARS21; Terry Fox Foundation; Princess Margaret Cancer Foundation(University of Toronto); Department of Medical Biophysics, University of Toronto; Ontario Graduate Scholarship, Government of Ontario; Canada Graduate Scholarships for Master's program; Ontario Graduate Scholarship(Ontario Graduate Scholarship); Department of Laboratory Medicine and Pathobiology, University of Toronto(University of Toronto); Lee K. and Margaret Lau Chair in Breast Cancer Research	We thank M.A. Pujana for critical reading of the paper. We would also like to thank all the members of the Hakem laboratory for helpful discussions. We apologize to investigators we were unable to reference due to length limitations. RH holds the Lee K. and Margaret Lau Chair in Breast Cancer Research, which is a joint project with the University of Toronto and The Princess Margaret hospital. RH is supported by the Canadian Institutes of Health Research (FDN 143214), and the Canadian Cancer Society (705367 and 706439). PSP is supported by STARS21, Terry Fox Foundation, Princess Margaret Cancer Foundation, Department of Medical Biophysics, University of Toronto, and the Ontario Graduate Scholarship, Government of Ontario. AA is supported by Canada Graduate Scholarships for Master's program, Ontario Graduate Scholarship, and the Department of Laboratory Medicine and Pathobiology, University of Toronto.	Abdel-Fatah TMA, 2014, MOL ONCOL, V8, P1326, DOI 10.1016/j.molonc.2014.04.009; Alvarez-Quilon A, 2020, MOL CELL, V78, P1152, DOI 10.1016/j.molcel.2020.05.021; Bane AL, 2007, AM J SURG PATHOL, V31, P121, DOI 10.1097/01.pas.0000213351.49767.0f; Bhargava R, 2016, TRENDS GENET, V32, P566, DOI 10.1016/j.tig.2016.06.007; Blessing C, 2020, MOL CELL, V80, P862, DOI 10.1016/j.molcel.2020.10.009; Boboila C, 2010, P NATL ACAD SCI USA, V107, P3034, DOI 10.1073/pnas.0915067107; Bryan TM, 2019, MOLECULES, V24, DOI 10.3390/molecules24193439; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Burkovics P, 2006, NUCLEIC ACIDS RES, V34, P2508, DOI 10.1093/nar/gkl259; Burkovics P, 2009, NUCLEIC ACIDS RES, V37, P4247, DOI 10.1093/nar/gkp357; Carbajosa S, 2019, CLIN CANCER RES, V25, P4049, DOI 10.1158/1078-0432.CCR-18-3516; Ceccaldi R, 2015, NATURE, V518, P258, DOI 10.1038/nature14184; Chen CC, 2018, ANNU REV CANC BIOL, V2, P313, DOI 10.1146/annurev-cancerbio-030617-050502; Chen HX, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00909; Chen SN, 2007, J CLIN ONCOL, V25, P1329, DOI 10.1200/JCO.2006.09.1066; Chopra N, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16142-7; Cramer-Morales K, 2013, BLOOD, V122, P1293, DOI 10.1182/blood-2013-05-501072; Davies H, 2017, NAT MED, V23, P517, DOI 10.1038/nm.4292; Dungrawala H, 2015, MOL CELL, V59, P998, DOI 10.1016/j.molcel.2015.07.030; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Feng WJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12234-1; Feng ZH, 2011, P NATL ACAD SCI USA, V108, P686, DOI 10.1073/pnas.1010959107; Fernandez-Vidal A, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5285; Gibb B, 2014, NAT STRUCT MOL BIOL, V21, P893, DOI 10.1038/nsmb.2886; Goff JP, 2009, RADIAT RES, V172, P165, DOI 10.1667/RR1598.1; Golan T, 2019, NEW ENGL J MED, V381, P317, DOI 10.1056/NEJMoa1903387; Gossage L, 2007, MOL DIAGN THER, V11, P361, DOI 10.1007/BF03256260; Grasby JA, 2012, TRENDS BIOCHEM SCI, V37, P74, DOI 10.1016/j.tibs.2011.10.003; Guikema JEJ, 2007, J EXP MED, V204, P3017, DOI 10.1084/jem.20071289; Guo E, 2020, P NATL ACAD SCI USA, V117, P19415, DOI 10.1073/pnas.2009237117; Hanamshet K, 2016, GENES-BASEL, V7, DOI 10.3390/genes7090063; He LF, 2017, MOL ONCOL, V11, P640, DOI 10.1002/1878-0261.12058; He LF, 2016, EBIOMEDICINE, V14, P32, DOI 10.1016/j.ebiom.2016.11.012; Hengel SR, 2016, ELIFE, V5, DOI 10.7554/eLife.14740; Hewitt G, 2021, MOL CELL, V81, P767, DOI 10.1016/j.molcel.2020.12.006; Horton JK, 2014, MOL CANCER RES, V12, P1128, DOI 10.1158/1541-7786.MCR-13-0502; Hromas R, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0912-8; Huang F, 2016, NUCLEIC ACIDS RES, V44, P4189, DOI 10.1093/nar/gkw087; Jensen KA, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60656-5; Jensen RB, 2010, NATURE, V467, P678, DOI 10.1038/nature09399; Joo W, 2011, SCIENCE, V333, P312, DOI 10.1126/science.1205805; Juhasz S, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb8626; Kais Z, 2008, CANCER BIOL THER, V7, P1540, DOI 10.4161/cbt.7.10.7053; Kais Z, 2016, CELL REP, V15, P2488, DOI 10.1016/j.celrep.2016.05.031; Kent T, 2016, ELIFE, V5, DOI 10.7554/eLife.13740; Kent T, 2015, NAT STRUCT MOL BIOL, V22, P230, DOI 10.1038/nsmb.2961; Knipscheer P, 2009, SCIENCE, V326, P1698, DOI 10.1126/science.1182372; Krais JJ, 2020, CANCER RES, V80, P2848, DOI 10.1158/0008-5472.CAN-19-3033; Krokan HE, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a012583; Kumar S, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408-018-0129-9; Larsen E, 2003, MOL CELL BIOL, V23, P5346, DOI 10.1128/MCB.23.15.5346-5353.2003; Li H, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01227-0; Lieberman R, 2016, MOL CARCINOGEN, V55, P953, DOI 10.1002/mc.22334; Lim KS, 2018, MOL CELL, V72, P925, DOI 10.1016/j.molcel.2018.10.045; Lok BH, 2013, ONCOGENE, V32, P3552, DOI 10.1038/onc.2012.391; Lord CJ, 2017, SCIENCE, V355, P1152, DOI 10.1126/science.aam7344; Lossaint G, 2013, MOL CELL, V51, P678, DOI 10.1016/j.molcel.2013.07.023; Ma CJ, 2017, J BIOL CHEM, V292, P11702, DOI 10.1074/jbc.M117.794545; Malacaria E, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09196-9; Mateo J, 2019, ANN ONCOL, V30, P1437, DOI 10.1093/annonc/mdz192; Mateo J, 2015, NEW ENGL J MED, V373, P1697, DOI 10.1056/NEJMoa1506859; Mateos-Gomez PA, 2017, NAT STRUCT MOL BIOL, V24, P1116, DOI 10.1038/nsmb.3494; Mateos-Gomez PA, 2015, NATURE, V518, P254, DOI 10.1038/nature14157; Mengwasser KE, 2019, MOL CELL, V73, P885, DOI 10.1016/j.molcel.2018.12.008; Mersch J, 2015, CANCER-AM CANCER SOC, V121, P269, DOI 10.1002/cncr.29041; Morales JC, 2014, CRIT REV EUKAR GENE, V24, P15, DOI 10.1615/CritRevEukaryotGeneExpr.2013006875; Motycka TA, 2004, J BIOL CHEM, V279, P13634, DOI 10.1074/jbc.M313779200; Mouw KW, 2017, CANCER DISCOV, V7, P675, DOI 10.1158/2159-8290.CD-17-0226; Murai J, 2014, MOL CANCER THER, V13, P433, DOI 10.1158/1535-7163.MCT-13-0803; Murai J, 2012, CANCER RES, V72, P5588, DOI 10.1158/0008-5472.CAN-12-2753; Nakanishi K, 2011, NAT STRUCT MOL BIOL, V18, P500, DOI 10.1038/nsmb.2029; Nalepa G, 2018, NAT REV CANCER, V18, P168, DOI 10.1038/nrc.2017.116; Neff RT, 2017, THER ADV MED ONCOL, V9, P519, DOI 10.1177/1758834017714993; Nepal M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081804; Nieminuszczy J, 2019, MOL CELL, V75, P605, DOI 10.1016/j.molcel.2019.05.026; Nikolova T, 2009, ANTICANCER RES, V29, P2453; Noordermeer SM, 2019, TRENDS CELL BIOL, V29, P820, DOI 10.1016/j.tcb.2019.07.008; Patel PS, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI140105; Pines A, 2012, J CELL BIOL, V199, P235, DOI 10.1083/jcb.201112132; Pommier Y, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf9246; Przetocka S, 2018, MOL CELL, V72, P568, DOI 10.1016/j.molcel.2018.09.014; Raab M, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1395; Renaud E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053693; Roy R, 2012, NAT REV CANCER, V12, P68, DOI 10.1038/nrc3181; Saharia A, 2010, J BIOL CHEM, V285, P27057, DOI 10.1074/jbc.M110.112276; Schlacher K, 2012, CANCER CELL, V22, P106, DOI 10.1016/j.ccr.2012.05.015; Schlacher K, 2011, CELL, V145, P529, DOI 10.1016/j.cell.2011.03.041; Schwab RA, 2015, MOL CELL, V60, P351, DOI 10.1016/j.molcel.2015.09.012; Sharp MF, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64868-7; Shi TY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050461; Shima N, 2004, MOL CELL BIOL, V24, P10381, DOI 10.1128/MCB.24.23.10381-10389.2004; Singh P, 2008, MOL CANCER RES, V6, P1710, DOI 10.1158/1541-7786.MCR-08-0269; Srinivasan G, 2019, P NATL ACAD SCI USA, V116, P17438, DOI 10.1073/pnas.1903150116; Sullivan-Reed K, 2018, CELL REP, V23, P3127, DOI 10.1016/j.celrep.2018.05.034; Sun CF, 2020, CELL MOL LIFE SCI, V77, P3583, DOI 10.1007/s00018-020-03493-z; Thompson LH, 2012, MUTAT RES-REV MUTAT, V751, P158, DOI 10.1016/j.mrrev.2012.06.002; van Pel DM, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003254; Verma P, 2021, NAT CELL BIOL, V23, P160, DOI 10.1038/s41556-020-00624-3; Vikas P, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00570; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; Wei LZ, 2015, P NATL ACAD SCI USA, V112, pE3495, DOI 10.1073/pnas.1507105112; Wei LZ, 2011, CANCER SCI, V102, P1840, DOI 10.1111/j.1349-7006.2011.02037.x; Willis J, 2013, P NATL ACAD SCI USA, V110, P10592, DOI 10.1073/pnas.1301445110; Wood RD, 2016, DNA REPAIR, V44, P22, DOI 10.1016/j.dnarep.2016.05.003; Xu H, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14432; Yang Q, 2019, BIOCHEM BIOPH RES CO, V514, P713, DOI 10.1016/j.bbrc.2019.04.201; Yi M, 2019, EXP HEMATOL ONCOL, V8, DOI 10.1186/s40164-019-0154-9; Yousefzadeh MJ, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004654; Zarrizi R, 2020, J CLIN INVEST, V130, P4069, DOI 10.1172/JCI127521; Zhang BY, 2020, ACTA PHARM SIN B, V10, P615, DOI 10.1016/j.apsb.2019.08.008; Zhang L, 2014, GENET MOL RES, V13, P228, DOI 10.4238/2014.January.14.2; Zhang YY, 2020, DIS MARKERS, V2020, DOI 10.1155/2020/2514090; Zimmer J, 2016, MOL CELL, V61, P449, DOI 10.1016/j.molcel.2015.12.004; Zong DL, 2019, MOL CELL, V73, P1267, DOI 10.1016/j.molcel.2018.12.010	114	25	25	3	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2021	40	17					3001	3014		10.1038/s41388-021-01744-2	http://dx.doi.org/10.1038/s41388-021-01744-2		MAR 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RV2NJ	33716297				2022-12-17	WOS:000628816100001
J	Huang, WJ; Tian, XP; Bi, SX; Zhang, SR; He, TS; Song, LY; Yun, JP; Zhou, ZG; Yu, RM; Li, M				Huang, Wei-Juan; Tian, Xiao-Peng; Bi, Si-Xue; Zhang, Si-Rui; He, Ting-Sha; Song, Li-Yan; Yun, Jing-Ping; Zhou, Zhong-Guo; Yu, Rong-Min; Li, Mei			The beta-catenin/TCF-4-LINC01278-miR-1258-Smad2/3 axis promotes hepatocellular carcinoma metastasis	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; WNT/BETA-CATENIN PATHWAY; LONG NONCODING RNAS; CELL-PROLIFERATION; ACTIVATION; CROSSTALK; NETWORKS; CERNA	Hepatocellular carcinoma (HCC) metastasis is largely responsible for HCC-associated recurrence and mortality. We aimed to identify metastasis-related long non-coding RNAs (lncRNAs) to understand the molecular mechanism of HCC metastasis. We first identified that miR-1258 was downregulated in HCC tissues both in The Cancer Genome Atlas (TCGA) and Sun Yat-sen University Cancer Center (SYSUCC) dataset. MiR-1258 expression negatively correlated with recurrence-free survival and overall survival of HCC patients. MiR-1258 overexpression inhibited migration and invasion of HCC cells both in vitro and in vivo, whereas miR-1258 downregulation promoted cell metastasis. Luciferase assays verified direct binding of miR-1258 to Smad2 and Smad3, thereby attenuating TGF-beta/Smad signaling. We further established that lncRNA LINC01278 was a negative regulator of miR-1258. In vivo and in vitro assays demonstrated that LINC01278-mediated HCC metastasis was dependent on miR-1258 expression. Furthermore, miR-1258 downregulation in turn increased LINC01278 expression. We also observed that TCF-4 could bind to the LINC01278 promoter site. In addition, LINC01278 downregulation decreased migration and invasion of HCC cells induced by beta-catenin and TGF-beta 1 both in vitro and in vivo. We uncovered a novel mechanism for beta-catenin/TCF-4-LINC01278-miR-1258-Smad2/3 feedback loop activation in HCC metastasis, and the study indicated that LINC01278 could serve as a therapeutic target for HCC metastasis.	[Huang, Wei-Juan; Bi, Si-Xue; Zhang, Si-Rui; He, Ting-Sha; Song, Li-Yan; Yu, Rong-Min] Jinan Univ, Coll Pharm, Dept Pharmacol, Guangzhou, Peoples R China; [Huang, Wei-Juan; Yu, Rong-Min] Jinan Univ, Integrated Chinese & Western Med Postdoctoral Res, Guangzhou, Peoples R China; [Huang, Wei-Juan; Yu, Rong-Min] Jinan Univ, Biotechnol Inst Chinese Mat Med, Guangzhou, Peoples R China; [Tian, Xiao-Peng; Yun, Jing-Ping; Li, Mei] Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Ctr Canc, Guangzhou, Peoples R China; [Yun, Jing-Ping; Li, Mei] Sun Yat Sen Univ, Ctr Canc, Dept Pathol, Guangzhou, Peoples R China; [Zhou, Zhong-Guo] Sun Yat Sen Univ, Ctr Canc, Dept Hepatol, Guangzhou, Peoples R China	Jinan University; Jinan University; Jinan University; State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Li, M (corresponding author), Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Ctr Canc, Guangzhou, Peoples R China.; Li, M (corresponding author), Sun Yat Sen Univ, Ctr Canc, Dept Pathol, Guangzhou, Peoples R China.	limei@sysucc.org.cn			National Natural Science Foundation of China [81973384]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants from National Natural Science Foundation of China (81973384).	Ally A, 2017, CELL, V169, P1327, DOI 10.1016/j.cell.2017.05.046; Anastasiadou E, 2018, NAT REV CANCER, V18, P5, DOI 10.1038/nrc.2017.99; Arun G, 2018, TRENDS MOL MED, V24, P257, DOI 10.1016/j.molmed.2018.01.001; Chen DL, 2017, THERANOSTICS, V7, P4836, DOI 10.7150/thno.20942; Clarke DC, 2008, TRENDS CELL BIOL, V18, P430, DOI 10.1016/j.tcb.2008.06.006; Ding N, 2013, CELL, V153, P601, DOI 10.1016/j.cell.2013.03.028; DiRenzo DM, 2016, CELL SIGNAL, V28, P498, DOI 10.1016/j.cellsig.2016.02.011; Farre D, 2003, NUCLEIC ACIDS RES, V31, P3651, DOI 10.1093/nar/gkg605; Forner A, 2018, LANCET, V391, P1301, DOI 10.1016/S0140-6736(18)30010-2; Gagliardi M, 2016, METHODS MOL BIOL, V1480, P73, DOI 10.1007/978-1-4939-6380-5_7; Joliat GR, 2018, EUR J GASTROEN HEPAT, V30, P792, DOI 10.1097/MEG.0000000000001115; Li GY, 2018, THERANOSTICS, V8, P2846, DOI 10.7150/thno.23463; Lin SJ, 2019, CANCER MANAG RES, V11, P8557, DOI 10.2147/CMAR.S217886; Liu W, 2019, BIOCHEM BIOPH RES CO, V510, P479, DOI 10.1016/j.bbrc.2019.01.139; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333; Paraskevopoulou MD, 2016, NUCLEIC ACIDS RES, V44, pD231, DOI 10.1093/nar/gkv1270; Ceballos MP, 2011, BIOCHEM PHARMACOL, V82, P1682, DOI 10.1016/j.bcp.2011.08.001; Qiu JL, 2017, J CLIN ONCOL, V35, P734, DOI [10.1200/JCO.2016.68.2153, 10.1200/jco.2016.68.2153]; Song YX, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00304-1; Su XQ, 2013, CHINESE J CANCER RES, V25, P235, DOI 10.3978/j.issn.1000-9604.2013.03.08; Taiyab A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092078; Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986; Tian XP, 2019, THERANOSTICS, V9, P1965, DOI 10.7150/thno.30958; Ueno M, 2015, J HEPATOL, V63, P1352, DOI 10.1016/j.jhep.2015.07.013; Vilchez V, 2016, WORLD J GASTROENTERO, V22, P823, DOI 10.3748/wjg.v22.i2.823; Wallace MC, 2015, EXPERT REV GASTROENT, V9, P765, DOI 10.1586/17474124.2015.1028363; Wang LQ, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0889-7; Xiao FF, 2009, NUCLEIC ACIDS RES, V37, pD105, DOI 10.1093/nar/gkn851; Xu L, 2017, J CELL MOL MED, V21, P1545, DOI 10.1111/jcmm.13085; Yang Y, 2018, CARCINOGENESIS, V39, P900, DOI 10.1093/carcin/bgy010; Yeh HW, 2018, NAT CELL BIOL, V20, P479, DOI 10.1038/s41556-018-0062-y; Zhang LX, 2011, CANCER RES, V71, P645, DOI 10.1158/0008-5472.CAN-10-1910; Zhang ZY, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12505	34	25	25	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2020	39	23					4538	4550		10.1038/s41388-020-1307-3	http://dx.doi.org/10.1038/s41388-020-1307-3		MAY 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LU5ZF	32372060	hybrid, Green Published			2022-12-17	WOS:000530617200001
J	Sierra, JC; Piazuelo, MB; Luis, PB; Barry, DP; Allaman, MM; Asim, M; Sebrell, TA; Finley, JL; Rose, KL; Hill, S; Holshouser, SL; Casero, RA; Cleveland, JL; Woster, PM; Schey, KL; Bimczok, D; Schneider, C; Gobert, AP; Wilson, KT				Sierra, Johanna C.; Piazuelo, M. Blanca; Luis, Paula B.; Barry, Daniel P.; Allaman, Margaret M.; Asim, Mohammad; Sebrell, Thomas A.; Finley, Jordan L.; Rose, Kristie L.; Hill, Salisha; Holshouser, Steven L.; Casero, Robert A.; Cleveland, John L.; Woster, Patrick M.; Schey, Kevin L.; Bimczok, Diane; Schneider, Claus; Gobert, Alain P.; Wilson, Keith T.			Spermine oxidase mediates Helicobacter pylori-induced gastric inflammation, DNA damage, and carcinogenic signaling	ONCOGENE			English	Article							BETA-CATENIN; ORNITHINE-DECARBOXYLASE; MACROPHAGE ACTIVATION; NITRIC-OXIDE; CANCER RISK; INFECTION; POLYAMINES; APOPTOSIS; PATHWAY; EGFR	Helicobacter pylori infection is the main risk factor for the development of gastric cancer, the third leading cause of cancer death worldwide. H. pylori colonizes the human gastric mucosa and persists for decades. The inflammatory response is ineffective in clearing the infection, leading to disease progression that may result in gastric adenocarcinoma. We have shown that polyamines are regulators of the host response to H. pylori, and that spermine oxidase (SMOX), which metabolizes the polyamine spermine into spermidine plus H2O2, is associated with increased human gastric cancer risk. We now used a molecular approach to directly address the role of SMOX, and demonstrate that Smox-deficient mice exhibit significant reductions of gastric spermidine levels and H. pylori-induced inflammation. Proteomic analysis revealed that cancer was the most significantly altered functional pathway in Smox(-/-) gastric organoids. Moreover, there was also less DNA damage and beta-catenin activation in H. pylori-infected Smox(-/-) mice or gastric organoids, compared to infected wild-type animals or gastroids. The link between SMOX and beta-catenin activation was confirmed in human gastric organoids that were treated with a novel SMOX inhibitor. These findings indicate that SMOX promotes H. pylori-induced carcinogenesis by causing inflammation, DNA damage, and activation of beta-catenin signaling.	[Sierra, Johanna C.; Piazuelo, M. Blanca; Barry, Daniel P.; Allaman, Margaret M.; Asim, Mohammad; Finley, Jordan L.; Gobert, Alain P.; Wilson, Keith T.] Vanderbilt Univ, Med Ctr, Dept Med, Div Gastroenterol Hepatol & Nutr, Nashville, TN 37232 USA; [Sierra, Johanna C.; Piazuelo, M. Blanca; Schneider, Claus; Gobert, Alain P.; Wilson, Keith T.] Vanderbilt Univ, Med Ctr, Ctr Mucosal Inflammat & Canc, Nashville, TN 37232 USA; [Luis, Paula B.; Schneider, Claus] Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; [Sebrell, Thomas A.; Bimczok, Diane] Montana State Univ, Dept Microbiol & Immunol, Bozeman, MT 59717 USA; [Rose, Kristie L.; Hill, Salisha; Schey, Kevin L.] Vanderbilt Univ, Med Ctr, Dept Biochem, Mass Spectrometry Res Ctr, Nashville, TN 37232 USA; [Holshouser, Steven L.; Woster, Patrick M.] Med Univ South Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA; [Casero, Robert A.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21287 USA; [Cleveland, John L.] H Lee Moffitt Canc Ctr & Res Inst, Dept Tumor Biol, Tampa, FL 33612 USA; [Wilson, Keith T.] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA; [Wilson, Keith T.] Vet Affairs Tennessee Valley Healthcare Syst, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Montana State University System; Montana State University Bozeman; Vanderbilt University; Medical University of South Carolina; Johns Hopkins University; Johns Hopkins Medicine; H Lee Moffitt Cancer Center & Research Institute; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Wilson, KT (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, Div Gastroenterol Hepatol & Nutr, Nashville, TN 37232 USA.; Wilson, KT (corresponding author), Vanderbilt Univ, Med Ctr, Ctr Mucosal Inflammat & Canc, Nashville, TN 37232 USA.; Wilson, KT (corresponding author), Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA.; Wilson, KT (corresponding author), Vet Affairs Tennessee Valley Healthcare Syst, Nashville, TN 37232 USA.	keith.wilson@vumc.org	Gobert, Alain P/AHB-1368-2022; Allaman, Margaret/GNO-9854-2022	Finley, Jordan/0000-0002-5600-4292; Allaman, Margaret M./0000-0002-2803-1365	NIH [R01CA190612, P01CA116087, P01CA028842, R21AI142042, R01AT006896, R03DK107960, R01GM131408, R01CA204345, R01CA235863, R01CA100603, P30DK058404]; Veterans Affairs Merit Review grant [I01BX001453]; Department of Defense [W81XWH-18-1-0301]; Thomas F. Frist Sr. Endowment; Vanderbilt Center for Mucosal Inflammation and Cancer; NCI Comprehensive Cancer Grant [P30CA76292]; Cortner-Couch Endowed Chair for Cancer Research from the University of South Florida; American Heart Association [16POST27250138]; Vanderbilt Ingram Cancer Center support grant [P30CA068485]; Vanderbilt Digestive Disease Research Center; Vanderbilt University Medical Center Digestive Disease Research Center - NIH [P30DK058404]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Veterans Affairs Merit Review grant(US Department of Veterans Affairs); Department of Defense(United States Department of Defense); Thomas F. Frist Sr. Endowment; Vanderbilt Center for Mucosal Inflammation and Cancer; NCI Comprehensive Cancer Grant; Cortner-Couch Endowed Chair for Cancer Research from the University of South Florida; American Heart Association(American Heart Association); Vanderbilt Ingram Cancer Center support grant; Vanderbilt Digestive Disease Research Center; Vanderbilt University Medical Center Digestive Disease Research Center - NIH	This work was funded by NIH grants R01CA190612 (K.T.W.), P01CA116087 (K.T.W.), P01CA028842 (K.T.W.), and R21AI142042 (K.T.W.); Veterans Affairs Merit Review grant I01BX001453 (K.T.W.); Department of Defense grant W81XWH-18-1-0301 (K.T.W.); the Thomas F. Frist Sr. Endowment (K.T.W.); and the Vanderbilt Center for Mucosal Inflammation and Cancer (K.T.W.). This work was also supported by NIH grants R01AT006896 (C.S.), R03DK107960 (D.B.), R01GM131408 (D.B.), R01CA204345 (R.A.C. and P.M.W.), R01CA235863 (R.A.C.), and R01CA100603 (J.L.C.). J.L.C. was also supported by the Cortner-Couch Endowed Chair for Cancer Research from the University of South Florida (J.L.C.) and NCI Comprehensive Cancer Grant P30CA76292 to the H. Lee Moffitt Cancer Center and Research Institute. P.B.L. was supported by a postdoctoral fellowship award from the American Heart Association (16POST27250138). Mass spectrometry analyses were supported in part by Core Scholarships from the Vanderbilt University Medical Center Digestive Disease Research Center funded by NIH grant P30DK058404, and the Vanderbilt Ingram Cancer Center support grant P30CA068485. Immunofluorescence confocal imaging was performed in the Vanderbilt Cell Imaging Shared Resource, supported by the Vanderbilt Digestive Disease Research Center and NIH grant P30DK058404.	Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chaturvedi R, 2015, ONCOGENE, V34, P3429, DOI 10.1038/onc.2014.273; Chaturvedi R, 2004, J BIOL CHEM, V279, P40161, DOI 10.1074/jbc.M401370200; Chaturvedi R, 2014, GASTROENTEROLOGY, V146, P1739, DOI 10.1053/j.gastro.2014.02.005; Chaturvedi R, 2011, GASTROENTEROLOGY, V141, P1696, DOI 10.1053/j.gastro.2011.07.045; Chaturvedi R, 2010, GASTROENTEROLOGY, V139, P1686, DOI 10.1053/j.gastro.2010.06.060; Clements WM, 2002, CANCER RES, V62, P3503; CORREA P, 1988, CANCER RES, V48, P3554; Ebert MPA, 2002, CARCINOGENESIS, V23, P87, DOI 10.1093/carcin/23.1.87; Franco AT, 2005, P NATL ACAD SCI USA, V102, P10646, DOI 10.1073/pnas.0504927102; Gobert AP, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01242; Goodwin AC, 2011, P NATL ACAD SCI USA, V108, P15354, DOI 10.1073/pnas.1010203108; Guo X, 2002, AM J PHYSIOL-CELL PH, V283, pC722, DOI 10.1152/ajpcell.00054.2002; Hardbower DM, 2017, P NATL ACAD SCI USA, V114, pE751, DOI 10.1073/pnas.1614958114; Hardbower DM, 2016, J CLIN INVEST, V126, P3296, DOI 10.1172/JCI83585; Hardbower DM, 2013, GUT MICROBES, V4, P475, DOI 10.4161/gmic.25583; Holshouser S, 2019, MEDCHEMCOMM, V10, P778, DOI 10.1039/c8md00610e; Hooi JKY, 2017, GASTROENTEROLOGY, V153, P420, DOI 10.1053/j.gastro.2017.04.022; Jaiswal M, 2001, AM J PHYSIOL-GASTR L, V281, pG626, DOI 10.1152/ajpgi.2001.281.3.G626; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Lewis ND, 2011, J IMMUNOL, V186, P3632, DOI 10.4049/jimmunol.1003431; Malfertheiner P, 2012, GUT, V61, P646, DOI 10.1136/gutjnl-2012-302084; Mera RM, 2018, GUT, V67, P1239, DOI 10.1136/gutjnl-2016-311685; Morgan DR, 2013, JAMA-J AM MED ASSOC, V309, P578, DOI 10.1001/jama.2013.311; Murata-Kamiya N, 2007, ONCOGENE, V26, P4617, DOI 10.1038/sj.onc.1210251; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; PATCHETT SE, 1995, GUT, V37, P13, DOI 10.1136/gut.37.1.13; Pegg AE, 2016, J BIOL CHEM, V291, P14904, DOI 10.1074/jbc.R116.731661; Radulescu S, 2013, ONCOGENE, V32, P2048, DOI 10.1038/onc.2012.224; Sebrell TA, 2018, CELL TISSUE RES, V371, P293, DOI 10.1007/s00441-017-2726-5; Sierra JC, 2019, P NATL ACAD SCI USA, V116, P5077, DOI 10.1073/pnas.1814497116; Sierra JC, 2018, GUT, V67, P1247, DOI 10.1136/gutjnl-2016-312888; Toller IM, 2011, P NATL ACAD SCI USA, V108, P14944, DOI 10.1073/pnas.1100959108; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; Vujcic S, 2002, BIOCHEM J, V367, P665, DOI 10.1042/BJ20020720; Wang YL, 2001, CANCER RES, V61, P5370; Xu HX, 2004, CANCER RES, V64, P8521, DOI 10.1158/0008-5472.CAN-04-3511; Xue JF, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7156; Yong X, 2016, CANCER LETT, V374, P292, DOI 10.1016/j.canlet.2016.02.032	40	25	25	3	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	22					4465	4474		10.1038/s41388-020-1304-6	http://dx.doi.org/10.1038/s41388-020-1304-6		APR 2020	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LR9IT	32350444	Green Accepted			2022-12-17	WOS:000529589900001
J	Huang, PB; Xu, QD; Yan, YC; Lu, YJ; Hu, ZG; Ou, B; Zhang, HY; Mao, K; Zhang, JL; Wang, J; Xiao, ZY				Huang, Pinbo; Xu, Qiaodong; Yan, Yongcong; Lu, Yingjuan; Hu, Zhigang; Ou, Bing; Zhang, Heyun; Mao, Kai; Zhang, Jianlong; Wang, Jie; Xiao, Zhiyu			HBx/ER alpha complex-mediated LINC01352 downregulation promotes HBV-related hepatocellular carcinoma via the miR-135b-APC axis	ONCOGENE			English	Article							LONG NONCODING RNA; HEPATITIS-B-VIRUS; GENETIC ALTERATIONS; ESTROGEN-RECEPTOR; LIVER-CANCER; METASTASIS; PROTEIN; PROLIFERATION; CONTRIBUTES; EXPRESSION	Hepatitis B virus (HBV) infection plays an important role in hepatocarcinogenesis, especially in hepatocellular carcinoma (HCC). Long non-coding RNAs (lncRNAs) have emerged as crucial biomarkers and regulators in many cancers. Novel lncRNAs involved in the initiation and progression of HBV-related hepatocellular carcinoma (HCC) need to be investigated. Here, we report that the long non-coding RNA LINC01352 is markedly downregulated by HBV/HBx (HBV X protein) in HCC cells and clinical samples. The LINC01352 expression level in HCC is an independent prognostic factor for survival. We found that HBx suppresses LINC01352 promoter activity by forming a complex with the estrogen receptor (ER alpha). Furthermore, using a combination of in vitro and in vivo studies, we confirmed that HBx promotes HCC cell growth and metastasis by inhibiting LINC01352 expression. Further investigation revealed that the downregulation of LINC01352, which acts as an endogenous sponge, increases the expression of miR-135b, leading to the reduced production of adenomatous polyposis coli (APC), consequently activating Wnt/beta-catenin signalling to facilitate tumour progression. These findings strongly suggest that the LINC01352-miR-135b-APC axis regulated by the HBx/ER alpha complex acts as an important pathogenic factor for tumour progression, which may help provide a theoretical basis for the identification of new therapeutic targets for HBV-related HCC.	[Huang, Pinbo; Yan, Yongcong; Hu, Zhigang; Zhang, Heyun; Mao, Kai; Zhang, Jianlong; Wang, Jie; Xiao, Zhiyu] Sun Yat Sen Univ, Dept Hepatobiliary Surg, Sun Yat Sen Mem Hosp, Guangzhou 510120, Peoples R China; [Huang, Pinbo; Yan, Yongcong; Hu, Zhigang; Xiao, Zhiyu] Sun Yat Sen Univ, Med Res Ctr, Sun Yat Sen Mem Hosp, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangzhou 510120, Peoples R China; [Xu, Qiaodong] Shantou Univ, Dept Biliary Pancreat Minimally Invas Surg, Affiliated Hosp 1, Coll Med, Shantou 515041, Peoples R China; [Lu, Yingjuan] Sun Yat Sen Univ, Dept Stomatol, Sun Yat Sen Mem Hosp, Guangzhou 510120, Peoples R China; [Ou, Bing] Sun Yat Sen Univ, Dept Ultrasonog, Sun Yat Sen Mem Hosp, Guangzhou 510120, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Shantou University; Sun Yat Sen University; Sun Yat Sen University	Wang, J; Xiao, ZY (corresponding author), Sun Yat Sen Univ, Dept Hepatobiliary Surg, Sun Yat Sen Mem Hosp, Guangzhou 510120, Peoples R China.; Xiao, ZY (corresponding author), Sun Yat Sen Univ, Med Res Ctr, Sun Yat Sen Mem Hosp, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangzhou 510120, Peoples R China.	jiewsysu@163.com; xzysurgeon@163.com			National Natural Science Foundation of China [81702404, 81572407, 81672405, 81372565]; Natural Science Foundation of Guangdong Province, China [2016A030311051, 2017A030313536]; Guangzhou Science Research Project [201607010225]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province, China(National Natural Science Foundation of Guangdong Province); Guangzhou Science Research Project	This work was supported by the National Natural Science Foundation of China (No. 81702404, 81572407, 81672405 and 81372565), the Natural Science Foundation of Guangdong Province, China (No. 2016A030311051 and 2017A030313536) and the Guangzhou Science Research Project (No. 201607010225).	Cesana M, 2011, CELL, V147, P358, DOI 10.1016/j.cell.2011.09.028; Chen LL, 2016, TRENDS BIOCHEM SCI, V41, P761, DOI 10.1016/j.tibs.2016.07.003; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Daud M, 2017, ARCH VIROL, V162, P2937, DOI 10.1007/s00705-017-3462-6; Ding J, 2014, CANCER LETT, V346, P17, DOI 10.1016/j.canlet.2013.12.024; Du YM, 2012, J BIOL CHEM, V287, P26302, DOI 10.1074/jbc.M112.342113; EISENFELD AJ, 1976, SCIENCE, V191, P862, DOI 10.1126/science.175442; El-Serag HB, 2012, GASTROENTEROLOGY, V142, P1264, DOI 10.1053/j.gastro.2011.12.061; Guichard C, 2012, NAT GENET, V44, P694, DOI 10.1038/ng.2256; Han JQ, 2006, NUCLEIC ACIDS RES, V34, P3095, DOI 10.1093/nar/gkl389; He Y, 2014, CANCER LETT, V344, P20, DOI 10.1016/j.canlet.2013.10.021; Hou ZH, 2017, AM J CANCER RES, V7, P845; Hu JJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep23521; Huang JF, 2013, HEPATOLOGY, V57, P1882, DOI 10.1002/hep.26195; Huang PB, 2015, CLIN CANCER RES, V21, P4420, DOI 10.1158/1078-0432.CCR-14-2067; Klingenberg M, 2018, HEPATOLOGY, V68, P1817, DOI 10.1002/hep.30102; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Lau SH, 2005, ACTA PHARMACOL SIN, V26, P659, DOI 10.1111/j.1745-7254.2005.00126.x; Laurent-Puig P, 2006, ONCOGENE, V25, P3778, DOI 10.1038/sj.onc.1209547; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Levrero M, 2016, J HEPATOL, V64, pS84, DOI 10.1016/j.jhep.2016.02.021; Li T, 2016, ONCOGENE, V35, P1575, DOI 10.1038/onc.2015.223; Liu F, 2016, ONCOGENE, V35, P5422, DOI 10.1038/onc.2016.80; Liu XH, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-92; Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521; Ng SA, 2011, J GASTROENTEROL, V46, P974, DOI 10.1007/s00535-011-0415-9; Park NH, 2006, POSTGRAD MED J, V82, P507, DOI 10.1136/pgmj.2006.047431; PATERLINI P, 1995, HEPATOLOGY, V21, P313, DOI 10.1002/hep.1840210208; PORTER LE, 1983, GASTROENTEROLOGY, V84, P704; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Schulze K, 2015, NAT GENET, V47, P505, DOI 10.1038/ng.3252; Serghiou S, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0535-1; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Villanueva A, 2014, NAT REV CLIN ONCOL, V11, P73, DOI [10.1038/nrclinonc.2013.243, 10.1038/nrclinonc.2013.227]; VITVITSKITREPO L, 1990, HEPATOLOGY, V12, P1278, DOI 10.1002/hep.1840120605; Wang JY, 2010, NUCLEIC ACIDS RES, V38, P5366, DOI 10.1093/nar/gkq285; Wang K, 2014, CIRC RES, V114, P1377, DOI 10.1161/CIRCRESAHA.114.302476; Wong CM, 2001, CANCER-AM CANCER SOC, V92, P136, DOI 10.1002/1097-0142(20010701)92:1<136::AID-CNCR1301>3.0.CO;2-R; Xie JJ, 2018, GASTROENTEROLOGY, V154, P2137, DOI 10.1053/j.gastro.2018.02.018; Xu LB, 2014, J HEPATOL, V60, P590, DOI 10.1016/j.jhep.2013.10.028; Yang F, 2013, MOL CELL, V49, P1083, DOI 10.1016/j.molcel.2013.01.010; Zhang H, 2015, CANCER RES, V75, P2363, DOI 10.1158/0008-5472.CAN-14-2928; Zhang L, 2013, CARCINOGENESIS, V34, P577, DOI 10.1093/carcin/bgs381	43	25	25	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	18					3774	3789		10.1038/s41388-020-1254-z	http://dx.doi.org/10.1038/s41388-020-1254-z		MAR 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LI5XR	32157216				2022-12-17	WOS:000518886000001
J	Meirson, T; Gil-Henn, H; Samson, AO				Meirson, Tomer; Gil-Henn, Hava; Samson, Abraham O.			Invasion and metastasis: the elusive hallmark of cancer	ONCOGENE			English	Letter							INVADOPODIA		[Meirson, Tomer; Gil-Henn, Hava] Bar Ilan Univ, Azrieli Fac Med, Cell Migrat & Invas Lab, Safed, Israel; [Meirson, Tomer; Samson, Abraham O.] Bar Ilan Univ, Azrieli Fac Med, Drug Discovery Lab, Safed, Israel	Bar Ilan University; Bar Ilan University	Meirson, T (corresponding author), Bar Ilan Univ, Azrieli Fac Med, Cell Migrat & Invas Lab, Safed, Israel.; Meirson, T (corresponding author), Bar Ilan Univ, Azrieli Fac Med, Drug Discovery Lab, Safed, Israel.	tomermrsn@gmail.com		Meirson, Tomer/0000-0002-5011-5477	Israel Cancer Association [20180089]; Estee Lauder Companies [20180089]; Israel Science Foundation [1462/17]; Israel Cancer Research Fund [17-902-AG]; Leir Foundation; Ginzburg Foundation; Foulkes Foundation	Israel Cancer Association; Estee Lauder Companies; Israel Science Foundation(Israel Science Foundation); Israel Cancer Research Fund; Leir Foundation; Ginzburg Foundation; Foulkes Foundation	This work was supported by the Israel Cancer Association and Estee Lauder Companies (grant number 20180089), the Israel Science Foundation (grant number 1462/17), and the Israel Cancer Research Fund (grant number 17-902-AG) (to HG-H), and by Leir Foundation and the Ginzburg Foundation (to AOS). TM is supported by the Foulkes Foundation fellowship for MD/PhD students.	Chegini N, 2010, SEMIN REPROD MED, V28, P179, DOI 10.1055/s-0030-1251476; Fouad YA, 2017, AM J CANCER RES, V7, P1016; Gandalovicova A, 2017, TRENDS CANCER, V3, P391, DOI 10.1016/j.trecan.2017.04.008; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2014, LANCET, V383, P558, DOI 10.1016/S0140-6736(13)62226-6; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hayes KE, 2013, ONCOGENE, V32, P4766, DOI 10.1038/onc.2012.513; Karagiannis GS, 2018, CLIN EXP METASTAS, V35, P269, DOI 10.1007/s10585-017-9870-x; Lazebnik Y, 2010, NAT REV CANCER, V10, P232, DOI 10.1038/nrc2827; Linde N, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02481-5; Marino-Enriquez A, 2014, NAT REV CANCER, V14, P701, DOI 10.1038/nrc3845; Meirson T, 2018, DRUG RESIST UPDATE, V39, P1, DOI 10.1016/j.drup.2018.05.002; Meirson Tomer, 2018, Oncotarget, V9, P22158, DOI 10.18632/oncotarget.25243; Monleon D, 2010, CANCER RES, V70, P8426, DOI 10.1158/0008-5472.CAN-10-1498; Nemlich Y, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04600-2; Paz H, 2014, ONCOGENE, V33, P4193, DOI 10.1038/onc.2013.393; Reiman JM, 2007, SEMIN CANCER BIOL, V17, P275, DOI 10.1016/j.semcancer.2007.06.009; Revach OY, 2019, CANCER RES, V79, P2634, DOI 10.1158/0008-5472.CAN-18-2316; Sleeman J, 2010, EUR J CANCER, V46, P1177, DOI 10.1016/j.ejca.2010.02.039; Yigit R, 2011, INT J GYNECOL CANCER, V21, P1241, DOI 10.1097/IGC.0b013e3182289ab1	20	25	25	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	9					2024	2026		10.1038/s41388-019-1110-1	http://dx.doi.org/10.1038/s41388-019-1110-1			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KP9VM	31745295				2022-12-17	WOS:000516579800015
J	Yang, R; Xu, JH; Hua, XH; Tian, ZX; Xie, QP; Li, JX; Jiang, GS; Cohen, M; Sun, H; Huang, CS				Yang, Rui; Xu, Jiheng; Hua, Xiaohui; Tian, Zhongxian; Xie, Qipeng; Li, Jingxia; Jiang, Guosong; Cohen, Mitchell; Sun, Hong; Huang, Chuanshu			Overexpressed miR-200a promotes bladder cancer invasion through direct regulating Dicer/miR-16/JNK2/MMP-2 axis	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; MATRIX-METALLOPROTEINASE (MMP)-2; CELL-MIGRATION; UP-REGULATION; ISORHAPONTIGENIN ISO; TRANSCRIPTION FACTOR; MICRORNA MACHINERY; DICER EXPRESSION; REPRESSORS ZEB1; DOWN-REGULATION	Invasive bladder cancer (BC) is one of the most lethal malignant urological tumors. Although miR-200a has been reported as an onco-miRNA that targets the PTEN gene in endometrioid carcinoma, its biological significance in BC invasion has been poorly explored. In the current study, we found that miR-200a was markedly overexpressed in both human BC tissues and BBN-induced muscle-invasive BC tissues. We further showed that miR-200a overexpression specifically promoted human BC cell invasion, but not migration, via transcriptional upregulation of matrix metalloproteinase (MMP)-2. Mechanistic studies indicated that the increased phosphorylation of c-Jun mediated the increasing levels of MMP-2 mRNA transcription. Further investigation revealed that Dicer was decreased in miR-200a overexpressed BC cells; this resulted in inhibition of miR-16 maturation and consequently led to increased JNK2 protein translation and c-Jun activation. Taken together, the studies here showed that miR-200a overexpression inhibited Dicer expression, in turn, resulted in inhibition of miR-16 maturation, leading to upregulation of JNK2 expression, c-Jun phosphorylation, MMP-2 transcription and, ultimately, BC invasion. Collectively, these results demonstrate that miR-200a is an onco-miRNA that is a positive regulator for BC invasion. This finding could be very useful in the ongoing development of new strategies to treat invasive BC patients.	[Yang, Rui; Xu, Jiheng; Hua, Xiaohui; Tian, Zhongxian; Xie, Qipeng; Li, Jingxia; Jiang, Guosong; Cohen, Mitchell; Sun, Hong; Huang, Chuanshu] NYU, Dept Environm Med, Sch Med, 341 East 25th St, New York, NY 10010 USA	New York University	Huang, CS (corresponding author), NYU, Dept Environm Med, Sch Med, 341 East 25th St, New York, NY 10010 USA.	Chuanshu.huang@nyulangone.org	Yang, Rui/CAF-8397-2022; xie, qipeng/ABG-5941-2021; Xu, Jiheng/AAV-5732-2020	Yang, Rui/0000-0002-1737-7168; Xu, Jiheng/0000-0002-3538-3174; Huang, Chuanshu/0000-0003-4133-5096	NIH/NCI [CA217923, CA177665, CA165980, CA229234]; NIH/NIEHS [ES000260]	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH/NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	The authors wish to thank Dr. Etty N. Benveniste (University of Alabama at Birmingham) for providing the Human MMP-2 promoter luciferase reporter. We also thank Ms. Emily Davison for her critical reading of the manuscript. This work was partially supported by Grants NIH/NCI CA217923, CA177665, CA165980, CA229234, and NIH/NIEHS ES000260.	Antoni S, 2017, EUR UROL, V71, P96, DOI 10.1016/j.eururo.2016.06.010; Becker LE, 2015, CARCINOGENESIS, V36, P2, DOI 10.1093/carcin/bgu202; Burger M, 2013, EUR UROL, V63, P234, DOI 10.1016/j.eururo.2012.07.033; Carmell MA, 2004, NAT STRUCT MOL BIOL, V11, P214, DOI 10.1038/nsmb729; Cheloufi S, 2010, NATURE, V465, P584, DOI 10.1038/nature09092; Chen JS, 2013, CARCINOGENESIS, V34, P10, DOI 10.1093/carcin/bgs274; Chen Y, 2017, EXP THER MED, V14, P10, DOI 10.3892/etm.2017.4488; Chen ZF, 2015, ONCOL LETT, V10, P329, DOI 10.3892/ol.2015.3179; Chiosea S, 2006, AM J PATHOL, V169, P1812, DOI 10.2353/ajpath.2006.060480; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Grelier G, 2009, BRIT J CANCER, V101, P673, DOI 10.1038/sj.bjc.6605193; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Hua XH, 2020, CELL DEATH DIFFER, V27, P632, DOI 10.1038/s41418-019-0377-7; Hua XH, 2018, CANCER LETT, V436, P38, DOI 10.1016/j.canlet.2018.08.013; Huang C, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-016-0376-9; Huang HS, 2017, MOL ONCOL, V11, P1579, DOI 10.1002/1878-0261.12132; Jakymiw A, 2010, GENE CHROMOSOME CANC, V49, P549, DOI 10.1002/gcc.20765; Jee D, 2018, MOL CELL, V69, P265, DOI 10.1016/j.molcel.2017.12.027; Jiang GS, 2016, CANCER PREV RES, V9, P567, DOI 10.1158/1940-6207.CAPR-15-0338; Jiang QQ, 2013, ASIAN PAC J CANCER P, V14, P4127, DOI 10.7314/APJCP.2013.14.7.4127; Jin HL, 2016, ONCOTARGET, V7, P56540, DOI 10.18632/oncotarget.10645; Jin HL, 2015, ONCOTARGET, V6, P522, DOI 10.18632/oncotarget.2680; Justus CR, 2014, JOVE-J VIS EXP, DOI 10.3791/51046; Karube Y, 2005, CANCER SCI, V96, P111, DOI 10.1111/j.1349-7006.2005.00015.x; Katoh Y, 2008, INT J MOL MED, V22, P271, DOI 10.3892/ijmm_00000019; Kaufman DS, 2009, LANCET, V374, P239, DOI 10.1016/S0140-6736(09)60491-8; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Li SP, 2016, ONCOTARGET, V7, P42431, DOI 10.18632/oncotarget.9883; Li XL, 2013, INT J ONCOL, V43, P793, DOI 10.3892/ijo.2013.1992; Liang YG, 2016, AUTOPHAGY, V12, P1229, DOI 10.1080/15548627.2016.1179403; Liu JY, 2010, J BIOL CHEM, V285, P26058, DOI 10.1074/jbc.M110.100271; Miao C, 2015, INT J CLIN EXP PATHO, V8, P10512; Nelson P, 2003, TRENDS BIOCHEM SCI, V28, P534, DOI 10.1016/j.tibs.2003.08.005; Pampalakis G, 2010, CLIN BIOCHEM, V43, P324, DOI 10.1016/j.clinbiochem.2009.09.014; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pectasides D, 2005, EUR UROL, V48, P60, DOI 10.1016/j.eururo.2005.03.025; Qin HW, 1999, J BIOL CHEM, V274, P29130, DOI 10.1074/jbc.274.41.29130; Ruvinsky I, 2006, TRENDS BIOCHEM SCI, V31, P342, DOI 10.1016/j.tibs.2006.04.003; Shen Y, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317705756; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Stenzl A, 2011, EUR UROL, V59, P1009, DOI 10.1016/j.eururo.2011.03.023; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Taki M, 2006, INT J ONCOL, V28, P487; Tao J, 2012, MOL MED REP, V5, P167, DOI 10.3892/mmr.2011.591; Troussard AA, 2000, ONCOGENE, V19, P5444, DOI 10.1038/sj.onc.1203928; Tseng JH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03972-7; van Rhijn BWG, 2009, EUR UROL, V56, P430, DOI 10.1016/j.eururo.2009.06.028; van Zijl F, 2011, MUTAT RES-REV MUTAT, V728, P23, DOI 10.1016/j.mrrev.2011.05.002; Wiesen JL, 2009, MOL IMMUNOL, V46, P1222, DOI 10.1016/j.molimm.2008.11.012; Wu DY, 2012, MOL MED REP, V5, P695, DOI 10.3892/mmr.2011.711; Xie QP, 2016, ONCOTARGET, V7, P16636, DOI 10.18632/oncotarget.7674; Yan LM, 2010, INT J MOL SCI, V11, P4441, DOI 10.3390/ijms11114441; Zhang Z, 2015, TUMOR BIOL, V36, P5071, DOI 10.1007/s13277-015-3158-z; Zhu JL, 2017, NEOPLASIA, V19, P672, DOI 10.1016/j.neo.2017.06.002; Zhu JL, 2014, CANCER PREV RES, V7, P1270, DOI 10.1158/1940-6207.CAPR-14-0233; Zhuang WZ, 2015, STEM CELLS, V33, P1985, DOI 10.1002/stem.1989; Zuo W, 2014, INT J MOL SCI, V15, P14298, DOI 10.3390/ijms150814298	58	25	25	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	9					1983	1996		10.1038/s41388-019-1120-z	http://dx.doi.org/10.1038/s41388-019-1120-z			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KP9VM	31772330	Green Published, Green Accepted, hybrid			2022-12-17	WOS:000516579800012
J	Gu, L; Zhu, YH; Lin, X; Tan, XY; Lu, BJ; Li, YJ				Gu, Li; Zhu, Yahui; Lin, Xi; Tan, Xingyu; Lu, Bingjun; Li, Youjun			Stabilization of FASN by ACAT1-mediated GNPAT acetylation promotes lipid metabolism and hepatocarcinogenesis	ONCOGENE			English	Article							FATTY-ACID SYNTHASE; HEPATOCELLULAR-CARCINOMA; EXPRESSION; CELLS; AKT; PHOSPHORYLATION; PLASMALOGENS; INACTIVATION; RECRUITMENT; STABILITY	Metabolic alteration for adaptation of the local environment has been recognized as a hallmark of cancer. GNPAT dysregulation has been implicated in hepatocellular carcinoma (HCC). However, the precise posttranslational regulation of GNPAT is still undiscovered. Here we show that ACAT1 is upregulated in response to extra palmitic acid (PA). ACAT1 acetylates GNPAT at K128, which represses TRIM21-mediated GNPAT ubiquitination and degradation. Conversely, GNPAT deacetylation by SIRT4 antagonizes ACAT1's function. GNPAT represses TRIM21-mediated FASN degradation and promotes lipid metabolism. Furthermore, shRNA-mediated ACAT1 ablation and acetylation deficiency of GNPAT repress lipid metabolism and tumor progression in xenograft and DEN/CCl4-induced HCC. Otherwise, ACAT1 inhibitor combination with sorafenib enormously retards tumor formation in mice. Collectively, we demonstrate that stabilization of FASN by ACAT1-mediated GNPAT acetylation plays a critical role in hepatocarcinogenesis.	[Gu, Li; Zhu, Yahui; Lin, Xi; Tan, Xingyu; Lu, Bingjun; Li, Youjun] Wuhan Univ, Coll Life Sci, Hubei Key Lab Cell Homeostasis, Wuhan 430072, Peoples R China; [Gu, Li; Zhu, Yahui; Lin, Xi; Tan, Xingyu; Lu, Bingjun; Li, Youjun] Wuhan Univ, Sch Med, Med Res Inst, Wuhan 430071, Peoples R China	Wuhan University; Wuhan University	Gu, L; Li, YJ (corresponding author), Wuhan Univ, Coll Life Sci, Hubei Key Lab Cell Homeostasis, Wuhan 430072, Peoples R China.; Gu, L; Li, YJ (corresponding author), Wuhan Univ, Sch Med, Med Res Inst, Wuhan 430071, Peoples R China.	gulicherry@whu.edu.cn; liy7@whu.edu.cn			National Nature Science Foundation of China [81772609, 81902843]; Medical Science Advancement Program (Basic Medical Sciences) of Wuhan University [TFJC2018005]; China Postdoctoral Science Foundation [2019T120681, 2019M652702]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Medical Science Advancement Program (Basic Medical Sciences) of Wuhan University; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	We thank Profs Qunying Lei (Fudan University, Shanghai) for the SIRT family vectors and FASN plasmid, Yan Wang (Wuhan University, Wuhan, China) for the AAV8 vector, Ping Wang (East China Normal University, Shanghai, China) for pcDNA3.1(+)-5'flag Luc vector and Jinxiang Zhang (Wuhan Union Hospital, Wuahn, China) for providing the HCC samples. This work was supported by grants from the National Nature Science Foundation of China (81772609, 81902843), Medical Science Advancement Program (Basic Medical Sciences) of Wuhan University (TFJC2018005), and China Postdoctoral Science Foundation (2019T120681, 2019M652702).	Alo PL, 2007, ANTICANCER RES, V27, P2523; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Budhu A, 2013, GASTROENTEROLOGY, V144, P1066, DOI 10.1053/j.gastro.2013.01.054; Dorninger F, 2017, J NEUROCHEM, V143, P569, DOI 10.1111/jnc.14082; Facciotti F, 2012, NAT IMMUNOL, V13, P474, DOI 10.1038/ni.2245; Fan J, 2016, MOL CELL, V64, P859, DOI 10.1016/j.molcel.2016.10.014; Fan J, 2014, MOL CELL, V53, P534, DOI 10.1016/j.molcel.2013.12.026; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Furuta E, 2008, CANCER RES, V68, P1003, DOI 10.1158/0008-5472.CAN-07-2489; Gingold JA, 2018, TRENDS MOL MED, V24, P395, DOI 10.1016/j.molmed.2018.02.006; Gong XL, 2016, WORLD J GASTROENTERO, V22, P6582, DOI 10.3748/wjg.v22.i29.6582; Gonzalez-Guerrico AM, 2016, ONCOTARGET, V7, P71151, DOI 10.18632/oncotarget.9463; Graner E, 2004, CANCER CELL, V5, P253, DOI 10.1016/S1535-6108(04)00055-8; Gu L, 2018, CANCER RES, V78, P5808, DOI 10.1158/0008-5472.CAN-18-0340; Haapalainen AM, 2006, TRENDS BIOCHEM SCI, V31, P64, DOI 10.1016/j.tibs.2005.11.011; Han H, 2013, HEPATOLOGY, V57, P2378, DOI 10.1002/hep.26302; Hossain MS, 2017, J NEUROSCI, V37, P4074, DOI 10.1523/JNEUROSCI.3941-15.2017; Jin JL, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13594; Kim DW, 2017, J GASTROINTEST ONCOL, V8, P256, DOI 10.21037/jgo.2016.09.07; Knobloch M, 2013, NATURE, V493, P226, DOI 10.1038/nature11689; Komljenovic D, 2009, CELL TISSUE RES, V337, P281, DOI 10.1007/s00441-009-0809-7; KUHAJDA FP, 1994, P NATL ACAD SCI USA, V91, P6379, DOI 10.1073/pnas.91.14.6379; Lee M, 2018, YONSEI MED J, V59, P1143, DOI 10.3349/ymj.2018.59.10.1143; Li L, 2016, J HEPATOL, V64, P333, DOI 10.1016/j.jhep.2015.10.004; Lin HP, 2016, CANCER RES, V76, P6924, DOI 10.1158/0008-5472.CAN-16-1597; Liu PD, 2013, NAT CELL BIOL, V15, P1340, DOI 10.1038/ncb2860; Lv L, 2011, MOL CELL, V42, P719, DOI 10.1016/j.molcel.2011.04.025; Ma C, 2016, NATURE, V531, P253, DOI 10.1038/nature16969; Malheiro AR, 2015, J INHERIT METAB DIS, V38, P111, DOI 10.1007/s10545-014-9795-3; Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222; O'Brien CA, 2012, CANCER CELL, V21, P777, DOI 10.1016/j.ccr.2012.04.036; Pan JA, 2016, MOL CELL, V61, P720, DOI 10.1016/j.molcel.2016.02.007; Rodemer C, 2003, HUM MOL GENET, V12, P1881, DOI 10.1093/hmg/ddg191; Souchek JJ, 2017, MOL CANCER THER, V16, P1819, DOI 10.1158/1535-7163.MCT-17-0013; Tesori V, 2015, SCI REP-UK, V5, DOI 10.1038/srep09149; Wang B, 2017, NATURE, V545, P365, DOI 10.1038/nature22344; Wei Z, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06812-y; Zaytseva YY, 2015, ONCOTARGET, V6, P18891, DOI 10.18632/oncotarget.3783; Zhang ZQ, 2013, NAT IMMUNOL, V14, P172, DOI 10.1038/ni.2492; Zhu YH, 2017, CELL DEATH DIFFER, V24, P2199, DOI 10.1038/cdd.2017.151	40	25	30	4	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	11					2437	2449		10.1038/s41388-020-1156-0	http://dx.doi.org/10.1038/s41388-020-1156-0		JAN 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KU0ZS	31974474				2022-12-17	WOS:000509037000002
J	Babicky, ML; Harper, MM; Chakedis, J; Cazes, A; Mose, ES; Jaquish, DV; French, RP; Childers, B; Alakus, H; Schmid, MC; Foubert, P; Miyamoto, J; Holman, PJ; Walterscheid, ZJ; Tang, CM; Varki, N; Sicklick, JK; Messer, K; Varner, JA; Waltz, SE; Lowy, AM				Babicky, Michele L.; Harper, Megan M.; Chakedis, Jeffery; Cazes, Alex; Mose, Evangeline S.; Jaquish, Dawn, V; French, Randall P.; Childers, Betzaira; Alakus, Hakan; Schmid, Michael C.; Foubert, Phillippe; Miyamoto, Jaclyn; Holman, Patrick J.; Walterscheid, Zakkary J.; Tang, Chih-Min; Varki, Nissi; Sicklick, Jason K.; Messer, Karen; Varner, Judith A.; Waltz, Susan E.; Lowy, Andrew M.			MST1R kinase accelerates pancreatic cancer progression via effects on both epithelial cells and macrophages	ONCOGENE			English	Article							DUCTAL ADENOCARCINOMA; TUMOR-GROWTH; EXPRESSION; PROMOTES; POLARIZATION; ACTIVATION; COOPERATE; SURVIVAL; KRAS	The MST1R (RON) kinase is overexpressed in >80% of human pancreatic cancers, but its role in pancreatic carcinogenesis is unknown. In this study, we examined the relevance of Mst1r kinase to Kras driven pancreatic carcinogenesis using genetically engineered mouse models. In the setting of mutant Kras, Mst1r overexpression increased acinar-ductal metaplasia (ADM), accelerated the progression of pancreatic intraepithelial neoplasia (PanIN), and resulted in the accumulation of (mannose receptor C type 1) MRC1+, (arginase 1) Arg+ macrophages in the tumor microenvironment. Conversely, absence of a functional Mst1r kinase slowed PanIN initiation, resulted in smaller tumors, prolonged survival and a reduced tumor-associated macrophage content. Mst1r expression was associated with increased production of its ligand Mst1, and in orthotopic models, suppression of Mst1 expression resulted in reduced tumor size, changes in macrophage polarization and enhanced T cell infiltration. This study demonstrates the functional significance of Mst1r during pancreatic cancer initiation and progression. Further, it provides proof of concept that targeting Mst1r can modulate pancreatic cancer growth and the microenvironment. This study provides further rationale for targeting Mst1r as a therapeutic strategy.	[Babicky, Michele L.; Harper, Megan M.; Chakedis, Jeffery; Cazes, Alex; Mose, Evangeline S.; Jaquish, Dawn, V; French, Randall P.; Childers, Betzaira; Alakus, Hakan; Miyamoto, Jaclyn; Holman, Patrick J.; Walterscheid, Zakkary J.; Tang, Chih-Min; Sicklick, Jason K.; Lowy, Andrew M.] Univ Calif San Diego, Div Surg Oncol, Dept Surg, La Jolla, CA 92093 USA; [Schmid, Michael C.; Foubert, Phillippe; Varner, Judith A.] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; [Varki, Nissi; Messer, Karen] Univ Calif San Diego, Dept Family Med & Epidemiol, La Jolla, CA 92093 USA; [Waltz, Susan E.] Univ Cincinnati, Dept Canc Biol, Coll Med, Cincinnati, OH 45267 USA; [Waltz, Susan E.] Cincinnati Vet Adm Med Ctr, Res Serv, Cincinnati, OH 45267 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University System of Ohio; University of Cincinnati; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center	Lowy, AM (corresponding author), Univ Calif San Diego, Div Surg Oncol, Dept Surg, La Jolla, CA 92093 USA.	alowy@ucsd.edu	Cazes, Alex/K-9899-2019	Schmid, Michael/0000-0002-3445-0013; Waltz, Susan/0000-0003-3572-4642; Childers, Betzaira/0000-0002-0173-4132; Harper, Megan/0000-0002-2935-6292	NIH [CA155620, T32CA121938]; Ride the Point; Cure Pancreatic Cancer Fund; NATIONAL CANCER INSTITUTE [T32CA121938, R01CA167426, R01CA155620] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ride the Point; Cure Pancreatic Cancer Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH CA155620 (AML), NIH T32CA121938 (MLB), Ride the Point (AML) and generous gifts to the Sally Ride Fund for Pancreatic Cancer Research (AML) and the Cure Pancreatic Cancer Fund (AML).	Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703; Baumgarth N, 2000, J IMMUNOL METHODS, V243, P77, DOI 10.1016/S0022-1759(00)00229-5; Bayne LJ, 2012, CANCER CELL, V21, P822, DOI 10.1016/j.ccr.2012.04.025; Benight NM, 2015, ONCOTARGET, V6, P17445, DOI 10.18632/oncotarget.3641; Bronte V, 2005, NAT REV IMMUNOL, V5, P641, DOI 10.1038/nri1668; Colegio OR, 2014, NATURE, V513, P559, DOI 10.1038/nature13490; Correll PH, 2004, J LEUKOCYTE BIOL, V75, P731, DOI 10.1189/jlb.0703347; Eyob H, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.25670; Gardner CR, 2012, TOXICOL APPL PHARM, V262, P139, DOI 10.1016/j.taap.2012.04.027; Gurusamy D, 2013, CANCER RES, V73, P1752, DOI 10.1158/0008-5472.CAN-12-2474; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Ko AH, 2015, J CLIN ONCOL, V33, P1779, DOI 10.1200/JCO.2014.59.7625; Liu QP, 1999, J IMMUNOL, V163, P6606; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Logan-Collins J, 2010, CANCER RES, V70, P1130, DOI 10.1158/0008-5472.CAN-09-0761; Martinez FO, 2006, J IMMUNOL, V177, P7303, DOI 10.4049/jimmunol.177.10.7303; Mazur PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013578; Monti P, 2003, CANCER RES, V63, P7451; Mosser DM, 2003, J LEUKOCYTE BIOL, V73, P209, DOI 10.1189/jlb.0602325; Pylayeva-Gupta Y, 2012, CANCER CELL, V21, P836, DOI 10.1016/j.ccr.2012.04.024; Sanford DE, 2013, CLIN CANCER RES, V19, P3404, DOI 10.1158/1078-0432.CCR-13-0525; Schmid MC, 2010, J ONCOL, V2010, DOI 10.1155/2010/201026; Sharda DR, 2011, J IMMUNOL, V187, P2181, DOI 10.4049/jimmunol.1003460; Singh A, 2009, CANCER CELL, V15, P489, DOI 10.1016/j.ccr.2009.03.022; Tactacan CM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-395; Thobe MN, 2010, ONCOGENE, V29, P214, DOI 10.1038/onc.2009.331; Thomas RM, 2007, CANCER RES, V67, P6075, DOI 10.1158/0008-5472.CAN-06-4128; Tseng WW, 2010, CLIN CANCER RES, V16, P3684, DOI 10.1158/1078-0432.CCR-09-2384; Vasiliauskas J, 2014, ONCOTARGET, V5, P5547, DOI 10.18632/oncotarget.2139; Waltz SE, 2001, J CLIN INVEST, V108, P567, DOI 10.1172/JCI200111881; Zhu Y, 2017, IMMUNITY, V47, P323, DOI 10.1016/j.immuni.2017.07.014; Zinser GM, 2006, CANCER RES, V66, P11967, DOI 10.1158/0008-5472.CAN-06-2473	33	25	28	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2019	38	28					5599	5611		10.1038/s41388-019-0811-9	http://dx.doi.org/10.1038/s41388-019-0811-9			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IH9RW	30967626	Green Accepted, Green Submitted			2022-12-17	WOS:000474845100004
J	Jiao, D; Huan, Y; Zheng, J; Wei, M; Zheng, GX; Han, DH; Wu, JH; Xi, WJ; Wei, FL; Yang, AG; Qin, WJ; Wang, H; Wen, WH				Jiao, Dian; Huan, Yi; Zheng, Jia; Wei, Ming; Zheng, Guoxu; Han, Donghui; Wu, Jieheng; Xi, Wenjin; Wei, Feilong; Yang, An-Gang; Qin, Weijun; Wang, He; Wen, Weihong			UHRF1 promotes renal cell carcinoma progression through epigenetic regulation of TXNIP	ONCOGENE			English	Article							THIOREDOXIN-BINDING PROTEIN-2; BREAST-CANCER; GROWTH; DNA; APOPTOSIS; PROLIFERATION; METHYLATION; EXPRESSION; INHIBITOR	UHRF1 is an important epigenetic regulator that belongs to the UHRF family. Overexpression of UHRF1 has been found in many kinds of tumors and its overexpression is associated with poor prognosis and short survival in certain cancer types. However, its function in renal cell carcinoma (RCC) is not clear. Here we report that RCC tumor tissues had obviously higher UHRF1 expression than normal renal tissues. Downregulation of UHRF1 by siRNA or shRNA in RCC cell lines resulted in decreased cell viability, inhibited cell migration and invasion, and increased apoptosis. UHRF1 knockdown RCC xenografts also resulted in obviously inhibited tumor growth in vivo. After downregulation of UHRF1 in RCC cells, the expression of TXNIP was upregulated. In addition, after UHRF1 and TXNIP were simultaneously downregulated, cell viability and cell invasion increased, whereas cell apoptosis decreased compared with UHRF1 single downregulated cells. We also showed that UHRF1 could recruit HDAC1 to the TXNIP promoter and mediate the deacetylation of histone H3K9, resulting in the inhibition of TXNIP expression. Our results confirm that UHRF1 has oncogenic function in RCC and UHRF1 may promote tumor progression through epigenetic regulation of TXNIP. UHRF1 might be used as a therapeutic target for RCC treatment.	[Jiao, Dian; Wang, He] Fourth Mil Med Univ, Dept Urol, Tangdu Hosp, Xian 710038, Shaanxi, Peoples R China; [Huan, Yi] Fourth Mil Med Univ, Dept Radiol, Xijing Hosp, Xian 710032, Shaanxi, Peoples R China; [Zheng, Jia] Zhengzhou Univ, Dept Oncol, Affiliated Hosp 1, Zhengzhou 450052, Henan, Peoples R China; [Wei, Ming] 150th Cent Hosp PLA, Dept Urol, Luoyang 471000, Peoples R China; [Zheng, Guoxu] Fourth Mil Med Univ, Dept Physiol & Pathophysiol, Xian 710032, Shaanxi, Peoples R China; [Han, Donghui; Qin, Weijun] Fourth Mil Med Univ, Dept Urol, Xijing Hosp, Xian 710032, Shaanxi, Peoples R China; [Wu, Jieheng; Xi, Wenjin; Yang, An-Gang; Wen, Weihong] Fourth Mil Med Univ, State Key Lab Canc Biol, Dept Immunol, Xian 710032, Shaanxi, Peoples R China; [Wei, Feilong] Fourth Mil Med Univ, Dept Orthoped, Tangdu Hosp, Xian 710038, Shaanxi, Peoples R China	Air Force Military Medical University; Air Force Military Medical University; Zhengzhou University; Air Force Military Medical University; Air Force Military Medical University; Air Force Military Medical University; Air Force Military Medical University	Wang, H (corresponding author), Fourth Mil Med Univ, Dept Urol, Tangdu Hosp, Xian 710038, Shaanxi, Peoples R China.; Qin, WJ (corresponding author), Fourth Mil Med Univ, Dept Urol, Xijing Hosp, Xian 710032, Shaanxi, Peoples R China.; Wen, WH (corresponding author), Fourth Mil Med Univ, State Key Lab Canc Biol, Dept Immunol, Xian 710032, Shaanxi, Peoples R China.	qinweij@fmmu.edu.cn; dusxjhw@fmmu.edu.cn; wenweih@fmmu.edu.cn	Jiao, Dian/HDN-6625-2022; Wu, Jieheng/ABF-2371-2021; 温, 家琦/GYV-3177-2022; Wei, Fei-Long/AAI-5371-2021; Wei, Fei-Long/GRS-0966-2022	Wu, Jieheng/0000-0003-4927-3897; Wei, Fei-Long/0000-0002-9260-5386; Wei, Fei-Long/0000-0002-9260-5386	National Natural Science Foundation of China [81772734, 81220108011, 81372225, 81372771]; open project program of the State Key Laboratory of Cancer Biology (Fourth Military Medical University) [CBSKL201705]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); open project program of the State Key Laboratory of Cancer Biology (Fourth Military Medical University)	This work was supported by grants from the National Natural Science Foundation of China (No. 81772734, 81220108011, 81372225, and 81372771) and the open project program of the State Key Laboratory of Cancer Biology (Fourth Military Medical University) (CBSKL201705).	Arita K, 2008, NATURE, V455, P818, DOI 10.1038/nature07249; Babbio F, 2012, ONCOGENE, V31, P4878, DOI 10.1038/onc.2011.641; Bhatt JR, 2014, NAT REV UROL, V11, P517, DOI 10.1038/nrurol.2014.194; Bostick M, 2007, SCIENCE, V317, P1760, DOI 10.1126/science.1147939; Butler LM, 2002, P NATL ACAD SCI USA, V99, P11700, DOI 10.1073/pnas.182372299; Cartron PF, 2013, MOL ONCOL, V7, P452, DOI 10.1016/j.molonc.2012.11.004; Creel PA, 2014, CLIN J ONCOL NURS, V18, P694, DOI 10.1188/14.CJON.694-700; Daskalos A, 2011, CANCER-AM CANCER SOC, V117, P1027, DOI 10.1002/cncr.25531; Dutta KK, 2005, LAB INVEST, V85, P798, DOI 10.1038/labinvest.3700280; Ge TT, 2016, J OVARIAN RES, V9, DOI 10.1186/s13048-016-0253-8; Geng Y, 2013, CANCER SCI, V104, P194, DOI 10.1111/cas.12052; Han SH, 2003, ONCOGENE, V22, P4035, DOI 10.1038/sj.onc.1206610; Hashimoto H, 2008, NATURE, V455, P826, DOI 10.1038/nature07280; Hervouet Eric, 2010, Genes Cancer, V1, P434, DOI 10.1177/1947601910373794; Hervouet E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011333; Ikarashi M, 2002, ANTICANCER RES, V22, P4045; Jenkins Y, 2005, MOL BIOL CELL, V16, P5621, DOI 10.1091/mbc.E05-03-0194; Kim JK, 2009, NUCLEIC ACIDS RES, V37, P493, DOI 10.1093/nar/gkn961; Li J, 2017, ONCOL REP, V37, P3369, DOI 10.3892/or.2017.5577; Liu XC, 2017, ONCOTARGET, V8, P10510, DOI 10.18632/oncotarget.14446; Lopez-Beltran A, 2009, INT J UROL, V16, P432, DOI 10.1111/j.1442-2042.2009.02302.x; Morrison JA, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-62; Mudbhary R, 2014, CANCER CELL, V25, P196, DOI 10.1016/j.ccr.2014.01.003; Nakamura K, 2016, ONCOTARGET, V7, P57821, DOI 10.18632/oncotarget.11067; Qin J, 2013, NATURE, V493, P236, DOI 10.1038/nature11674; Qin YY, 2014, ONCOL REP, V31, P2635, DOI 10.3892/or.2014.3145; Rini BI, 2009, LANCET, V373, P1119, DOI 10.1016/S0140-6736(09)60229-4; Sabatino L, 2012, ONCOGENE, V31, P5061, DOI 10.1038/onc.2012.3; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Sharif J, 2007, NATURE, V450, P908, DOI 10.1038/nature06397; Shen LL, 2015, P NATL ACAD SCI USA, V112, P5425, DOI 10.1073/pnas.1501555112; Sheng Y, 2016, GYNECOL ONCOL, V140, P145, DOI 10.1016/j.ygyno.2015.11.017; Sheth SS, 2006, ONCOGENE, V25, P3528, DOI 10.1038/sj.onc.1209394; Shi T, 2015, PLANT MOL BIOL, V89, P253, DOI 10.1007/s11103-015-0366-2; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Tauber M, 2015, NUCLEUS-PHILA, V6, P123, DOI 10.1080/19491034.2015.1026022; Unoki M, 2004, ONCOGENE, V23, P7601, DOI 10.1038/sj.onc.1208053; Wan XC, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0308-0; Wei M, 2017, ONCOTARGET, V8, P5323, DOI 10.18632/oncotarget.14142; Yan Feng, 2015, Asian Pac J Cancer Prev, V16, P1343; Zhang ZY, 2016, MED ONCOL, V33, DOI 10.1007/s12032-016-0799-8; Zhou JBA, 2011, INT J BIOCHEM CELL B, V43, P1668, DOI 10.1016/j.biocel.2011.09.005; Zhou JB, 2011, BLOOD, V118, P2830, DOI 10.1182/blood-2010-07-294827; Zhuo H, 2016, MOL CARCINOGEN, V55, P209, DOI 10.1002/mc.22270	44	25	27	0	18	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2019	38	28					5686	5699		10.1038/s41388-019-0822-6	http://dx.doi.org/10.1038/s41388-019-0822-6			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IH9RW	31043707				2022-12-17	WOS:000474845100010
J	Tiessen, I; Abildgaard, MH; Lubas, M; Gylling, HM; Steinhauer, C; Pietras, EJ; Diederichs, S; Frankel, LB; Lund, AH				Tiessen, Imke; Abildgaard, Marie H.; Lubas, Michal; Gylling, Helene M.; Steinhauer, Cornelia; Pietras, Elin J.; Diederichs, Sven; Frankel, Lisa B.; Lund, Anders H.			A high-throughput screen identifies the long non-coding RNA DRAIC as a regulator of autophagy	ONCOGENE			English	Article							SELECTIVE AUTOPHAGY; ACTIVATES AUTOPHAGY; CELL-PROLIFERATION; MECHANISMS; EXPRESSION; COMPLEX; LC3; TRANSCRIPTION; DISCOVERY; MIR-21	Autophagy is a conserved degradation process that occurs in all eukaryotic cells and its dysfunction has been associated with various diseases including cancer. While a number of large-scale attempts have recently identified new molecular players in autophagy regulation, including proteins and microRNAs, little is known regarding the function of long non-coding RNAs (lncRNAs) in the regulation of this process. To identify new long non-coding RNAs with functional implications in autophagy, we performed a high-throughput RNAi screen targeting more than 600 lncRNA transcripts and monitored their effects on autophagy in MCF-7 cells. We identified 63 lncRNAs that affected GFP-LC3B puncta numbers significantly. We validated the strongest hit, the lncRNA DRAIC previously shown to impact cell proliferation, and revealed a novel role for this lncRNA in the regulation of autophagic flux. Interestingly, we find DRAIC's pro-proliferative effects to be autophagy-independent. This study serves as a valuable resource for researchers from both the lncRNA and autophagy fields as it advances the current understanding of autophagy regulation by non-coding RNAs.	[Tiessen, Imke; Abildgaard, Marie H.; Lubas, Michal; Gylling, Helene M.; Steinhauer, Cornelia; Pietras, Elin J.; Frankel, Lisa B.; Lund, Anders H.] Univ Copenhagen, BRIC, DK-2200 Copenhagen, Denmark; [Abildgaard, Marie H.; Frankel, Lisa B.] Danish Canc Soc Res Ctr DCRC, DK-2100 Copenhagen, Denmark; [Diederichs, Sven] German Canc Res Ctr, Div RNA Biol & Canc, D-69120 Heidelberg, Germany; [Diederichs, Sven] Univ Freiburg, Fac Med, Med Ctr, Dept Thorac Surg,Div Canc Res, D-79106 Freiburg, Germany; [Diederichs, Sven] Univ Freiburg, German Canc Consortium DKTK, Partner Site Freiburg, D-79106 Freiburg, Germany	University of Copenhagen; Danish Cancer Society; Helmholtz Association; German Cancer Research Center (DKFZ); University of Freiburg; Helmholtz Association; German Cancer Research Center (DKFZ); University of Freiburg	Frankel, LB; Lund, AH (corresponding author), Univ Copenhagen, BRIC, DK-2200 Copenhagen, Denmark.; Frankel, LB (corresponding author), Danish Canc Soc Res Ctr DCRC, DK-2100 Copenhagen, Denmark.	frankel@cancer.dk; anders.lund@bric.ku.dk	Lund, Anders H./F-4786-2014; Diederichs, Sven/J-6237-2012	Lund, Anders H./0000-0002-7407-3398; Gylling, Helene Maria/0000-0002-6875-2845; Frankel, Lisa/0000-0001-7249-3607; Diederichs, Sven/0000-0001-7901-4752; Abildgaard, Marie Holm/0000-0002-6354-6102	European Union [607720]; Danish Council for Independent Research (Sapere Aude program); Novo Nordisk Foundation; Lundbeck Foundation; Danish Cancer Society; EU COST Action Transautophagy [CA15138]	European Union(European Commission); Danish Council for Independent Research (Sapere Aude program); Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Lundbeck Foundation(Lundbeckfonden); Danish Cancer Society(Danish Cancer Society); EU COST Action Transautophagy	We thank Sudeep Sahadevan for analysis of RNA-seq data, Bettina Mentz for technical assistance, Kevin Ryan for providing pLenti-CRISPR NTC, ATG5, and ATG7 constructs [44], W Lee Kraus for providing PInducer20-DRAIC and -EV constructs [34]. Imke Tiessen was supported by the People Program (Marie Sklodowska-Curie Actions) of the European Union's Seventh Framework Program FP7-PEOPLE-2013-ITN (Grant agreement no.: 607720). Work in the Lund laboratory was supported by the Danish Council for Independent Research (Sapere Aude program), the Novo Nordisk Foundation, the Lundbeck Foundation, the Danish Cancer Society and the EU COST Action Transautophagy (CA15138).	Abada A, 2014, EMBO REP, V15, P839, DOI 10.15252/embr.201439076; Alers S, 2012, MOL CELL BIOL, V32, P2, DOI 10.1128/MCB.06159-11; Bertoli C, 2013, NAT REV MOL CELL BIO, V14, P518, DOI 10.1038/nrm3629; Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002; Boutros M, 2008, NAT REV GENET, V9, P554, DOI 10.1038/nrg2364; Capparelli C, 2012, CELL CYCLE, V11, P3599, DOI 10.4161/cc.21884; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen CL, 2015, BIOMATERIALS, V44, P71, DOI 10.1016/j.biomaterials.2014.12.023; Chen YN, 2016, ONCOTARGET, V7, P52673, DOI 10.18632/oncotarget.10170; Dengjel J, 2005, P NATL ACAD SCI USA, V102, P7922, DOI 10.1073/pnas.0501190102; Deretic V, 2009, CELL HOST MICROBE, V5, P527, DOI 10.1016/j.chom.2009.05.016; Djebali S, 2012, NATURE, V489, P101, DOI 10.1038/nature11233; Doria A, 2013, NEW ENGL J MED, V368, P1845, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Farkas T, 2009, AUTOPHAGY, V5, P1018, DOI 10.4161/auto.5.7.9443; Figueiredo VC, 2017, CELL MOL LIFE SCI, V74, P2537, DOI 10.1007/s00018-017-2481-5; Frankel LB, 2008, J BIOL CHEM, V283, P1026, DOI 10.1074/jbc.M707224200; Frankel LB, 2017, AUTOPHAGY, V13, P3, DOI 10.1080/15548627.2016.1222992; Frankel LB, 2012, CARCINOGENESIS, V33, P2018, DOI 10.1093/carcin/bgs266; Frankel LB, 2011, EMBO J, V30, P4628, DOI 10.1038/emboj.2011.331; Fulda S, 2015, ONCOGENE, V34, P5105, DOI 10.1038/onc.2014.458; Ge D, 2014, AUTOPHAGY, V10, P957, DOI 10.4161/auto.28363; Geisler S, 2013, NAT REV MOL CELL BIO, V14, P699, DOI 10.1038/nrm3679; Gomez-Sanchez R, 2016, DATA BRIEF, V7, P641, DOI 10.1016/j.dib.2016.02.085; Green DR, 2014, CELL, V157, P65, DOI 10.1016/j.cell.2014.02.049; Guo SJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21106-5; Hosokawa N, 2006, FEBS LETT, V580, P2623, DOI 10.1016/j.febslet.2006.04.008; Hosokawa N, 2009, MOL BIOL CELL, V20, P1981, DOI 10.1091/mbc.E08-12-1248; Hoyer-Hansen M, 2007, MOL CELL, V25, P193, DOI 10.1016/j.molcel.2006.12.009; Hu YR, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0743-3; Huang FT, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0845-6; Huang SY, 2015, AUTOPHAGY, V11, P2172, DOI 10.1080/15548627.2015.1106663; Jiang H, 2010, CANCER RES, V70, P7882, DOI 10.1158/0008-5472.CAN-10-1604; Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017; Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152; Klingenberg M, 2018, HEPATOLOGY, V68, P1817, DOI 10.1002/hep.30102; Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356; Konig R, 2007, NAT METHODS, V4, P847, DOI 10.1038/NMETH1089; Lamark T, 2009, CELL CYCLE, V8, P1986, DOI 10.4161/cc.8.13.8892; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/nmeth.1923, 10.1038/NMETH.1923]; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Lipinski MM, 2010, DEV CELL, V18, P1041, DOI 10.1016/j.devcel.2010.05.005; Litovchick L, 2007, MOL CELL, V26, P539, DOI 10.1016/j.molcel.2007.04.015; Liu CH, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0619-z; Liu XW, 2016, NAT CELL BIOL, V18, P431, DOI 10.1038/ncb3328; Loayza-Puch F, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r32; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lubas M, 2018, EMBO REP, V19, DOI 10.15252/embr.201846072; McKnight NC, 2012, EMBO J, V31, P1931, DOI 10.1038/emboj.2012.36; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Mizushima N, 2010, NAT CELL BIOL, V12, P823, DOI 10.1038/ncb0910-823; Musiwaro P, 2013, AUTOPHAGY, V9, P1407, DOI 10.4161/auto.25455; Nakatogawa H, 2009, NAT REV MOL CELL BIO, V10, P458, DOI 10.1038/nrm2708; Notzold L, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02357-0; O'Prey J, 2017, METHOD ENZYMOL, V588, P79, DOI 10.1016/bs.mie.2016.09.076; Orvedahl A, 2011, NATURE, V480, P113, DOI 10.1038/nature10546; Pawar K, 2016, SCI REP-UK, V6, DOI 10.1038/srep19416; Polycarpou-Schwarz M, 2018, ONCOGENE, V37, P4750, DOI 10.1038/s41388-018-0281-5; Poulsen EG, 2016, METHODS MOL BIOL, V1449, P421, DOI 10.1007/978-1-4939-3756-1_28; Quinn JJ, 2016, NAT REV GENET, V17, P47, DOI 10.1038/nrg.2015.10; Sakurai K, 2015, MOL CANCER RES, V13, P828, DOI 10.1158/1541-7786.MCR-15-0016-T; Seiler J, 2017, NUCLEIC ACIDS RES, V45, P5458, DOI 10.1093/nar/gkx076; Song J, 2014, J ORTHOP RES, V32, P1628, DOI 10.1002/jor.22718; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun M, 2015, MOL CELL, V59, P698, DOI 10.1016/j.molcel.2015.06.023; Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009; Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986; van Beek N, 2018, BBA-MOL CELL RES, V1865, P803, DOI 10.1016/j.bbamcr.2018.03.002; Viereck J, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf1475; Wang Y, 2014, ONCOL LETT, V8, P1947, DOI 10.3892/ol.2014.2487; White E, 2015, CLIN CANCER RES, V21, P5037, DOI 10.1158/1078-0432.CCR-15-0490; Xu ZJ, 2017, ONCOL REP, V37, P1359, DOI 10.3892/or.2017.5416; Yang L, 2016, MOL BIOSYST, V12, P2605, DOI 10.1039/c6mb00114a; Yang LX, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.464; Ying L, 2013, MOL BIOSYST, V9, P407, DOI 10.1039/c2mb25386k; Zhang J, 2017, AUTOPHAGY, V13, P1004, DOI 10.1080/15548627.2017.1312041; Zhao Dan, 2018, Non-Coding RNA, V4, P39, DOI 10.3390/ncrna4040039; Zhao YG, 2018, CURR OPIN CELL BIOL, V53, P29, DOI 10.1016/j.ceb.2018.04.003; Zhao ZS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7212	81	25	28	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2019	38	26					5127	5141		10.1038/s41388-019-0783-9	http://dx.doi.org/10.1038/s41388-019-0783-9			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IF4AX	30872794				2022-12-17	WOS:000473025300002
J	Naik, R; Galande, S				Naik, Rutika; Galande, Sanjeev			SATB family chromatin organizers as master regulators of tumor progression	ONCOGENE			English	Review							SEQUENCE-BINDING PROTEIN-1; CANCER STEM-CELLS; INDEPENDENT PROGNOSTIC-FACTOR; GENE-EXPRESSION; T-CELLS; DENDRITIC CELLS; CHROMOSOME TERRITORIES; MESENCHYMAL TRANSITION; NUCLEAR ARCHITECTURE; SPATIAL-ORGANIZATION	SATB (Special AT-rich binding protein) family proteins have emerged as key regulators that integrate higher-order chromatin organization with the regulation of gene expression. Studies over the past decade have elucidated the specific roles of SATB1 and SATB2, two closely related members of this family, in cancer progression. SATB family chromatin organizers play diverse and important roles in regulating the dynamic equilibrium of apoptosis, cell invasion, metastasis, proliferation, angiogenesis, and immune modulation. This review highlights cellular and molecular events governed by SATB1 influencing the structural organization of chromatin and interacting with several co-activators and co-repressors of transcription towards tumor progression. SATB1 expression across tumor cell types generates cellular and molecular heterogeneity culminating in tumor relapse and metastasis. SATB1 exhibits dynamic expression within intratumoral cell types regulated by the tumor microenvironment, which culminates towards tumor progression. Recent studies suggested that cell-specific expression of SATB1 across tumor recruited dendritic cells (DC), cytotoxic T lymphocytes (CTL), T regulatory cells (Tregs) and tumor epithelial cells along with tumor microenvironment act as primary determinants of tumor progression and tumor inflammation. In contrast, SATB2 is differentially expressed in an array of cancer types and is involved in tumorigenesis. Survival analysis for patients across an array of cancer types correlated with expression of SATB family chromatin organizers suggested tissue-specific expression of SATB1 and SATB2 contributing to disease prognosis. In this context, it is pertinent to understand molecular players, cellular pathways, genetic and epigenetic mechanisms governed by cell types within tumors regulated by SATB proteins. We propose that patient survival analysis based on the expression profile of SATB chromatin organizers would facilitate their unequivocal establishment as prognostic markers and therapeutic targets for cancer therapy.	[Naik, Rutika; Galande, Sanjeev] Indian Inst Sci Educ & Res, Dept Biol, Ctr Excellence Epigenet, Pune 411008, Maharashtra, India	Indian Institute of Science Education & Research (IISER) Pune	Galande, S (corresponding author), Indian Inst Sci Educ & Res, Dept Biol, Ctr Excellence Epigenet, Pune 411008, Maharashtra, India.	sanjeev@iiserpune.ac.in			IISER Pune; Department of Biotechnology, Government of India; Department of Science and Technology, Science and Engineering Research Board, Government of India	IISER Pune; Department of Biotechnology, Government of India(Department of Biotechnology (DBT) India); Department of Science and Technology, Science and Engineering Research Board, Government of India	Work was supported by intramural funding from IISER Pune to SG. RN is supported by a postdoctoral fellowship from the Department of Biotechnology, Government of India, and the national postdoctoral fellowship of the Department of Science and Technology, Science and Engineering Research Board, Government of India. Authors wish to thank Drs. Prachi Patil for discussion and Chandan Kumar Sinha for insightful comments on the manuscript.	Agrelo R, 2013, ONCOGENE, V32, P5492, DOI 10.1038/onc.2013.158; Agrelo R, 2009, DEV CELL, V16, P507, DOI 10.1016/j.devcel.2009.03.006; Ahlfors H, 2010, BLOOD, V116, P1443, DOI 10.1182/blood-2009-11-252205; Akimova T, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.94075; Al-Sohaily S, 2014, HISTOPATHOLOGY, V65, P155, DOI 10.1111/his.12295; Alcamo EA, 2008, NEURON, V57, P364, DOI 10.1016/j.neuron.2007.12.012; Allis CD, 2007, CELL, V131, P633, DOI 10.1016/j.cell.2007.10.039; Alvarez JD, 2000, GENE DEV, V14, P521; Anaya J, 2016, PEERJ COMPUT SCI, DOI 10.7717/peerj-cs.67; Aprelikova O, 2010, CELL CYCLE, V9, P4387, DOI 10.4161/cc.9.21.13674; Arnaud O, 2018, CANCER LETT, V419, P266, DOI 10.1016/j.canlet.2018.01.046; Asanoma K, 2012, J BIOL CHEM, V287, P2257, DOI 10.1074/jbc.M111.287128; Balamotis MA, 2012, MOL CELL BIOL, V32, P333, DOI 10.1128/MCB.05917-11; Banyard J, 2015, CONNECT TISSUE RES, V56, P403, DOI 10.3109/03008207.2015.1060970; Beyer M, 2011, NAT IMMUNOL, V12, P898, DOI 10.1038/ni.2084; Bian TT, 2017, ONCOTARGET, V8, P63442, DOI 10.18632/oncotarget.18828; Borghesi L, 2014, J IMMUNOL, V193, P2053, DOI 10.4049/jimmunol.1400936; Britanova O, 2005, EUR J NEUROSCI, V21, P658, DOI 10.1111/j.1460-9568.2005.03897.x; Britanova O, 2008, NEURON, V57, P378, DOI 10.1016/j.neuron.2007.12.028; Britanova O, 2006, AM J HUM GENET, V79, P668, DOI 10.1086/508214; Brocato J, 2015, CARCINOGENESIS, V36, P186, DOI 10.1093/carcin/bgu322; Brown KE, 2003, CHROMOSOME RES, V11, P423, DOI 10.1023/A:1024966424909; Cai ST, 2006, NAT GENET, V38, P1278, DOI 10.1038/ng1913; Cai ST, 2003, NAT GENET, V34, P42, DOI 10.1038/ng1146; Chai JJ, 2005, CANCER RES, V65, P10192, DOI 10.1158/0008-5472.CAN-05-1896; Chatterjee A, 2018, SEMIN CANCER BIOL, V51, P149, DOI 10.1016/j.semcancer.2017.08.004; Chen B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064877; Cheng C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097406; Choi S, 2011, BIOCHEM BIOPH RES CO, V412, P207, DOI 10.1016/j.bbrc.2011.07.060; Choudhary D, 2018, UROL ONCOL-SEMIN ORI, V36, DOI 10.1016/j.urolonc.2017.10.004; Chu SH, 2014, MOL BIOL REP, V41, P977, DOI 10.1007/s11033-013-2942-3; Chu SH, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-149; Clapier CR, 2017, NAT REV MOL CELL BIO, V18, P407, DOI 10.1038/nrm.2017.26; Conejo-Garcia JR, 2016, PHARMACOL THERAPEUT, V164, P97, DOI 10.1016/j.pharmthera.2016.04.003; Cremer T, 2001, NAT REV GENET, V2, P292, DOI 10.1038/35066075; Cremer T, 2006, CURR OPIN CELL BIOL, V18, P307, DOI 10.1016/j.ceb.2006.04.007; Dalotto-Moreno T, 2013, CANCER RES, V73, P1107, DOI 10.1158/0008-5472.CAN-12-2418; de Belle I, 1998, J CELL BIOL, V141, P335, DOI 10.1083/jcb.141.2.335; de Laat W, 2003, CHROMOSOME RES, V11, P447, DOI 10.1023/A:1024922626726; Deng BW, 2013, SEMIN CANCER BIOL, V23, P65, DOI 10.1016/j.semcancer.2012.01.003; Deng YF, 2014, INT J CLIN EXP PATHO, V7, P2454; Ding M, 2018, CANCER INVEST, V36, P28, DOI 10.1080/07357907.2018.1423688; Dobreva G, 2003, GENE DEV, V17, P3048, DOI 10.1101/gad.1153003; Dobreva G, 2006, CELL, V125, P971, DOI 10.1016/j.cell.2006.05.012; Doi Y, 2018, CELL REP, V23, P3223, DOI 10.1016/j.celrep.2018.05.042; Dragomir A, 2014, AM J CLIN PATHOL, V141, P630, DOI 10.1309/AJCPWW2URZ9JKQJU; Eberhard J, 2012, BRIT J CANCER, V106, P931, DOI 10.1038/bjc.2012.34; Elebro J, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0289-8; ElShamy WM, 2013, CANCER LETT, V341, P2, DOI 10.1016/j.canlet.2013.06.020; Feng YL, 2018, EXP THER MED, V15, P4339, DOI 10.3892/etm.2018.5954; Fessing MY, 2011, J CELL BIOL, V194, P825, DOI 10.1083/jcb.201101148; FitzPatrick DR, 2003, HUM MOL GENET, V12, P2491, DOI 10.1093/hmg/ddg248; Fredholm S, 2018, J INVEST DERMATOL, V138, P1805, DOI 10.1016/j.jid.2018.03.1526; Freiman RN, 2003, CELL, V112, P11, DOI 10.1016/S0092-8674(02)01278-3; Fry CJ, 2001, CURR BIOL, V11, pR185, DOI 10.1016/S0960-9822(01)00090-2; Fu WX, 2012, NAT IMMUNOL, V13, P972, DOI 10.1038/ni.2420; Galande S, 2007, CURR OPIN GENET DEV, V17, P408, DOI 10.1016/j.gde.2007.08.003; Ganesan AP, 2013, J IMMUNOL, V191, P2009, DOI 10.4049/jimmunol.1301317; Gao XY, 2015, EXP THER MED, V9, P1665, DOI 10.3892/etm.2015.2329; Gibcus JH, 2018, SCIENCE, V359, P652, DOI 10.1126/science.aao6135; Gondor A, 2013, SEMIN CANCER BIOL, V23, P90, DOI 10.1016/j.semcancer.2013.01.002; Gong FR, 2011, NUCLEIC ACIDS RES, V39, P4640, DOI 10.1093/nar/gkr023; Gottimukkala KP, 2016, MOL IMMUNOL, V77, P34, DOI 10.1016/j.molimm.2016.07.005; Groth A, 2007, CELL, V128, P721, DOI 10.1016/j.cell.2007.01.030; Grzanka J, 2013, INT IMMUNOPHARMACOL, V16, P343, DOI 10.1016/j.intimp.2013.02.004; Gu JF, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12455; Guo CC, 2015, INT J CLIN EXP PATHO, V8, P3710; Han B, 2013, TUMOR BIOL, V34, P2943, DOI 10.1007/s13277-013-0857-1; Han HJ, 2008, NATURE, V452, P187, DOI 10.1038/nature06781; Hanker LC, 2011, BREAST, V20, P309, DOI 10.1016/j.breast.2010.10.002; Hao B, 2015, J EXP MED, V212, P809, DOI 10.1084/jem.20142207; Hedner C, 2014, VIRCHOWS ARCH, V465, P649, DOI 10.1007/s00428-014-1667-6; Helming KC, 2014, CANCER CELL, V26, P309, DOI 10.1016/j.ccr.2014.07.018; Hwang SS, 2017, BBA-GENE REGUL MECH, V1860, P383, DOI 10.1016/j.bbagrm.2017.01.008; Ilarregui JM, 2009, NAT IMMUNOL, V10, P981, DOI 10.1038/ni.1772; Iorns E, 2010, JNCI-J NATL CANCER I, V102, P1284, DOI 10.1093/jnci/djq243; Ishibashi T, 2018, BIOCHEM BIOPH RES CO, V495, P2338, DOI 10.1016/j.bbrc.2017.12.117; Jolly MK, 2017, MOL ONCOL, V11, P755, DOI 10.1002/1878-0261.12083; Kakugawa K, 2017, CELL REP, V19, P1176, DOI 10.1016/j.celrep.2017.04.038; Kitagawa Y, 2017, NAT IMMUNOL, V18, P173, DOI 10.1038/ni.3646; Kohwi-Shigematsu T, 2013, SEMIN CANCER BIOL, V23, P72, DOI 10.1016/j.semcancer.2012.06.009; Kohwi-Shigematsu T, 2012, METHODS, V58, P243, DOI 10.1016/j.ymeth.2012.06.019; Kolla V, 2015, BIOCHEM J, V468, P345, DOI 10.1042/BJ20150030; Kondo M, 2016, J IMMUNOL, V196, P563, DOI 10.4049/jimmunol.1501429; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Kowalczyk AE, 2016, CANCER GENOM PROTEOM, V13, P209; Krangel MS, 2007, NAT IMMUNOL, V8, P686, DOI 10.1038/ni1484; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Kucuksayan H, 2017, TUMOUR BIOL, V39; Kucuksayan H, 2016, LUNG CANCER, V98, P122, DOI 10.1016/j.lungcan.2016.05.032; Kumar P, 2007, NAT CELL BIOL, V9, P45, DOI 10.1038/ncb1516; Kurkewich JL, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006887; Lai AY, 2011, NAT REV CANCER, V11, P588, DOI 10.1038/nrc3091; Laurinavicius A, 2015, ONCOTARGET, V6, P41134, DOI 10.18632/oncotarget.5838; Lee JJ, 2016, BMB REP, V49, P578, DOI 10.5483/BMBRep.2016.49.10.156; Leone DP, 2015, CEREB CORTEX, V25, P3406, DOI 10.1093/cercor/bhu156; Li QQ, 2011, CELL DEATH DIFFER, V18, P16, DOI 10.1038/cdd.2010.103; Li Y, 2016, WORLD J GASTROENTERO, V22, P8528, DOI 10.3748/wjg.v22.i38.8528; Liu SH, 2017, MOL CELL BIOCHEM, V430, P47, DOI 10.1007/s11010-017-2953-9; Liu TS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031001; Lo PK, 2017, J BIOL CHEM, V292, P11466, DOI 10.1074/jbc.M117.775080; Ma J, 2017, TUMOUR BIOL, V39; Ma XC, 2016, DRUG DES DEV THER, V10, P1419, DOI 10.2147/DDDT.S102541; Ma Y, 2012, SEMIN CANCER BIOL, V22, P298, DOI 10.1016/j.semcancer.2012.02.010; Mansour MA, 2016, ONCOTARGET, V7, P4993, DOI 10.18632/oncotarget.6651; Mansouri L, 2018, SEMIN CANCER BIOL, V51, P1, DOI 10.1016/j.semcancer.2018.02.001; Mao LJ, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-111; Mardaryev AN, 2014, DEVELOPMENT, V141, P101, DOI 10.1242/dev.103200; Margueron R, 2005, CURR OPIN GENET DEV, V15, P163, DOI 10.1016/j.gde.2005.01.005; Meaburn KJ, 2008, J CELL BIOL, V180, P39, DOI 10.1083/jcb.200708204; Millard CJ, 2014, CANCER METAST REV, V33, P857, DOI 10.1007/s10555-014-9513-5; Mir R, 2016, ONCOGENE, V35, P1679, DOI 10.1038/onc.2015.232; Mir R, 2012, CURR DRUG TARGETS, V13, P1603, DOI 10.2174/138945012803530008; Misteli T, 2007, CELL, V128, P787, DOI 10.1016/j.cell.2007.01.028; Monteiro J, 2010, EUR J CANCER, V46, P1198, DOI 10.1016/j.ejca.2010.02.030; Nagpal N, 2013, CARCINOGENESIS, V34, P1889, DOI 10.1093/carcin/bgt107; Nixon BG, 2017, IMMUNITY, V46, P3, DOI 10.1016/j.immuni.2017.01.002; Nodin B, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-115; Notani D, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000296; Pavan KP, 2006, MOL CELL, V22, P231, DOI 10.1016/j.molcel.2006.03.010; Peng YR, 2017, NEURON, V95, P869, DOI 10.1016/j.neuron.2017.07.019; Qi HG, 2017, ONCOL LETT, V13, P2577, DOI 10.3892/ol.2017.5765; Raker VK, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00569; Rao HY, 2018, BIOL REPROD, V98, P810, DOI 10.1093/biolre/ioy033; Recillas-Targa F, 2001, CRIT REV EUKAR GENE, V11, P227; Reddy CNL, 2010, MOL MED REP, V3, P857, DOI 10.3892/mmr.2010.338; Reisman D, 2009, ONCOGENE, V28, P1653, DOI 10.1038/onc.2009.4; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Satoh Y, 2013, IMMUNITY, V38, P1105, DOI 10.1016/j.immuni.2013.05.014; Savarese F, 2009, GENE DEV, V23, P2625, DOI 10.1101/gad.1815709; Scheuermann RH, 1999, CRIT REV EUKAR GENE, V9, P295, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.140; Schubeler D, 2000, GENE DEV, V14, P940; Selinger CI, 2011, J THORAC ONCOL, V6, P1179, DOI 10.1097/JTO.0b013e31821b4ce0; Seong BKA, 2015, ONCOGENE, V34, P3582, DOI 10.1038/onc.2014.289; Shannon MF, 2003, NAT GENET, V34, P4, DOI 10.1038/ng0503-4; Shilatifard A, 2006, ANNU REV BIOCHEM, V75, P243, DOI 10.1146/annurev.biochem.75.103004.142422; Song GQ, 2017, ONCOTARGET, V8, P17771, DOI 10.18632/oncotarget.14849; Spector DL, 2003, ANNU REV BIOCHEM, V72, P573, DOI 10.1146/annurev.biochem.72.121801.161724; Stephen TL, 2017, IMMUNITY, V46, P51, DOI 10.1016/j.immuni.2016.12.015; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Sun JR, 2018, J INVEST DERMATOL, V138, P1795, DOI 10.1016/j.jid.2018.02.028; Sun ZK, 2015, MOL MED REP, V11, P3235, DOI 10.3892/mmr.2015.3192; Tan JAT, 2008, J BIOL CHEM, V283, P18124, DOI 10.1074/jbc.M800512200; Tan JAT, 2010, MOL CELL BIOL, V30, P2823, DOI 10.1128/MCB.01603-09; Tanaka Y, 2017, J IMMUNOL, V199, P4016, DOI 10.4049/jimmunol.1700550; Tesone AJ, 2016, CELL REP, V14, P1774, DOI 10.1016/j.celrep.2016.01.056; Torres-Aguilar H, 2010, J CLIN IMMUNOL, V30, P659, DOI 10.1007/s10875-010-9430-5; Toscano MA, 2007, NAT IMMUNOL, V8, P825, DOI 10.1038/ni1482; Tsuji T, 2009, CANCER RES, V69, P7135, DOI 10.1158/0008-5472.CAN-09-1618; Tu W, 2012, LIVER INT, V32, P1064, DOI 10.1111/j.1478-3231.2012.02815.x; Wan F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117518; Wang FF, 2015, P NATL ACAD SCI USA, V112, pE4995, DOI 10.1073/pnas.1513780112; Wang GB, 2015, TUMOR BIOL, V36, P4715, DOI 10.1007/s13277-015-3120-0; Wang JF, 2009, J IMMUNOL, V182, P4036, DOI 10.4049/jimmunol.0802981; Wang MJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056730; Wang Q, 2018, EXP THER MED, V15, P3028, DOI 10.3892/etm.2018.5792; Wang S, 2009, J PATHOL, V219, P114, DOI 10.1002/path.2575; Wang SX, 2015, JPN J CLIN ONCOL, V45, P812, DOI 10.1093/jjco/hyv093; Watanabe R, 2017, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0473; Wei JW, 2012, J CELL BIOL, V197, P509, DOI 10.1083/jcb.201201057; Wen J, 2005, BLOOD, V105, P3330, DOI 10.1182/blood-2004-08-2988; Will B, 2013, NAT IMMUNOL, V14, P437, DOI 10.1038/ni.2572; Wu DM, 2016, ONCOL LETT, V12, P4377, DOI 10.3892/ol.2016.5281; Xiang JD, 2012, ONCOL LETT, V3, P865, DOI 10.3892/ol.2012.571; Yamashita T, 2013, J CLIN INVEST, V123, P1911, DOI 10.1172/JCI66024; Yang MH, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-109; Yang MH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0085353; Yasui D, 2002, NATURE, V419, P641, DOI 10.1038/nature01084; Yu W, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05458-y; Yu W, 2017, STEM CELL RES, V19, P139, DOI 10.1016/j.scr.2017.01.011; Yuqian Yang, 2015, 2015 Asia-Pacific Microwave Conference (APMC). Proceedings, P1, DOI 10.1109/APMC.2015.7413222; Zhang HY, 2013, MOL CELL BIOCHEM, V378, P39, DOI 10.1007/s11010-013-1591-0; Zhang S, 2017, ONCOTARGET, V8, P48410, DOI 10.18632/oncotarget.16867; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301; Zheng J, 2008, WOMENS HEALTH, V4, P329, DOI 10.2217/17455057.4.4.329; Zhou LQ, 2012, J BIOL CHEM, V287, P30641, DOI 10.1074/jbc.M112.355271	176	25	25	3	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2019	38	12					1989	2004		10.1038/s41388-018-0541-4	http://dx.doi.org/10.1038/s41388-018-0541-4			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP6UR	30413763	Bronze			2022-12-17	WOS:000461822600001
J	Long, MD; Singh, PK; Russell, JR; Llimos, G; Rosario, S; Rizvi, A; van den Berg, PR; Kirk, J; Sucheston-Campbell, LE; Smiraglia, DJ; Campbell, MJ				Long, Mark D.; Singh, Prashant K.; Russell, James R.; Llimos, Gerard; Rosario, Spencer; Rizvi, Abbas; van den Berg, Patrick R.; Kirk, Jason; Sucheston-Campbell, Lara E.; Smiraglia, Dominic J.; Campbell, Moray J.			The miR-96 and RAR gamma signaling axis governs androgen signaling and prostate cancer progression	ONCOGENE			English	Article							13-CIS RETINOIC ACID; TUMOR-SUPPRESSOR; RECEPTOR; EXPRESSION; IDENTIFICATION; GENES; CELLS; DIFFERENTIATION; ACTIVATION; CHROMATIN	Expression levels of retinoic acid receptor gamma (NR1B3/RARG, encodes RAR gamma) are commonly reduced in prostate cancer (PCa). Therefore, we sought to establish the cellular and gene regulatory consequences of reduced RAR gamma expression, and determine RAR gamma regulatory mechanisms. RARG shRNA approaches in non-malignant (RWPE-1 and HPr1-AR) and malignant (LNCaP) prostate models revealed that reducing RAR gamma levels, rather than adding exogenous retinoid ligand, had the greatest impact on prostate cell viability and gene expression. ChIP-Seq defined the RAR gamma cistrome, which was significantly enriched at active enhancers associated with AR binding sites. Reflecting a significant genomic role for RAR gamma to regulate androgen signaling, RAR gamma knockdown in HPr1-AR cells significantly regulated the magnitude of the AR transcriptome. RAR gamma downregulation was explained by increased miR-96 in PCa cell and mouse models, and TCGA PCa cohorts. Biochemical approaches confirmed that miR-96 directly regulated RAR gamma expression and function. Capture of the miR-96 targetome by biotin-miR-96 identified that RAR gamma and a number of RAR gamma interacting co-factors including TACC1 were all targeted by miR-96, and expression of these genes were prominently altered, positively and negatively, in the TCGA-PRAD cohort. Differential gene expression analyses between tumors in the TCGA-PRAD cohort with lower quartile expression levels of RARG and TACC1 and upper quartile miR-96, compared to the reverse, identified a gene network including several RAR gamma target genes (e.g., SOX15) that significantly associated with worse disease-free survival (hazard ratio 2.23, 95% CI 1.58 to 2.88, p = 0.015). In summary, miR-96 targets a RAR gamma network to govern AR signaling, PCa progression and disease outcome.	[Long, Mark D.; Russell, James R.; Llimos, Gerard; Rosario, Spencer; van den Berg, Patrick R.; Smiraglia, Dominic J.] RPCCC, Dept Canc Genet & Genom, Buffalo, NY 14263 USA; [Singh, Prashant K.] Roswell Pk Comprehens Canc Ctr, Ctr Personalized Med, Buffalo, NY 14263 USA; [Llimos, Gerard] Ecole Polytech Fed Lausanne, Inst Bioengn, Lausanne, Switzerland; [Rizvi, Abbas; Sucheston-Campbell, Lara E.] Ohio State Univ, Coll Pharm, 500 W 12Th Ave, Columbus, OH 43210 USA; [van den Berg, Patrick R.] Leiden Univ, Leiden Inst Phys, NL-2300 RA Leiden, Netherlands; [Kirk, Jason] Roswell Pk Comprehens Canc Ctr, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA; [Sucheston-Campbell, Lara E.] Ohio State Univ, Coll Vet Med, Columbus, OH 43210 USA; [Campbell, Moray J.] Ohio State Univ, Coll Pharm, Div Pharmaceut & Pharmaceut Chem, 536 Pk Hall, Columbus, OH 43210 USA	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; University System of Ohio; Ohio State University; Leiden University; Leiden University - Excl LUMC; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Campbell, MJ (corresponding author), Ohio State Univ, Coll Pharm, Div Pharmaceut & Pharmaceut Chem, 536 Pk Hall, Columbus, OH 43210 USA.	campbell.1933@osu.edu	Rosario, Spencer/AAS-5728-2021; Campbell, Moray/ABF-1264-2021; Smiraglia, Dominic/R-2069-2019	Campbell, Moray/0000-0002-3355-0928; Smiraglia, Dominic/0000-0001-8852-1510; Llimos Aubach, Gerard/0000-0003-3311-6782; Long, Mark/0000-0003-1120-8176	Roswell Park Comprehensive Cancer Center-University of Pittsburgh Cancer Institute Ovarian Cancer Specialized Program of Research Excellence National Institutes of Health [P50CA159981-01A1]; Molecular Pharmacology and Experimental Therapeutics NRSA T32 program at Roswell Park Comprehensive Cancer Center [T32CA009072]; Prostate program of the Department of Defense Congressionally Directed Medical Research Programs [W81XWH-14-1-0608, W81XWH-11-2-0033]; National Cancer Institute (NCI) [P30CA016056, P30CA016058]; European Union-United States Atlantis Program [P116J090011]; NATIONAL CANCER INSTITUTE [P50CA159981, P30CA016058, P30CA016056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM095459] Funding Source: NIH RePORTER	Roswell Park Comprehensive Cancer Center-University of Pittsburgh Cancer Institute Ovarian Cancer Specialized Program of Research Excellence National Institutes of Health; Molecular Pharmacology and Experimental Therapeutics NRSA T32 program at Roswell Park Comprehensive Cancer Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Prostate program of the Department of Defense Congressionally Directed Medical Research Programs; National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); European Union-United States Atlantis Program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	LES-C acknowledges support, in part, of Roswell Park Comprehensive Cancer Center-University of Pittsburgh Cancer Institute Ovarian Cancer Specialized Program of Research Excellence National Institutes of Health [P50CA159981-01A1]. MDL acknowledges support of Molecular Pharmacology and Experimental Therapeutics NRSA T32 program (T32CA009072) held at Roswell Park Comprehensive Cancer Center. MJC and DJS acknowledge support in part from the Prostate program of the Department of Defense Congressionally Directed Medical Research Programs (W81XWH-14-1-0608, W81XWH-11-2-0033) and the National Cancer Institute (NCI) grant P30CA016056 involving the use of Roswell Park Comprehensive Cancer Center's Genomic Shared Resource. MJC, GL, AR, and PRvdB acknowledge support from the European Union-United States Atlantis Program (P116J090011). MJC and LES-C acknowledge support from the National Cancer Institute (NCI) grant P30CA016056 involving the use of OSUCCC The James, CCSG P30CA016058.	Abe M, 2011, BJU INT, V107, P126, DOI 10.1111/j.1464-410X.2010.09344.x; Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Alhasan AH, 2016, P NATL ACAD SCI USA, V113, P10655, DOI 10.1073/pnas.1611596113; Ambrosone CB, 2006, CANCER EPIDEM BIOMAR, V15, P1575, DOI 10.1158/1055-9965.EPI-06-0628; Andersson R, 2014, NATURE, V507, P455, DOI 10.1038/nature12787; Bao YH, 2017, EUR REV MED PHARMACO, V21, P4548; Beydoun HA, 2011, CANCER CAUSE CONTROL, V22, P1483, DOI 10.1007/s10552-011-9822-8; Bolton EC, 2007, GENE DEV, V21, P2005, DOI 10.1101/gad.1564207; Brohee L, 2015, ONCOTARGET, V6, P11264, DOI 10.18632/oncotarget.3595; Cai CM, 2011, CANCER RES, V71, P6503, DOI 10.1158/0008-5472.CAN-11-0532; Campbell MJ, 1998, ENDOCRINOLOGY, V139, P1972, DOI 10.1210/en.139.4.1972; Campbell MJ, 2008, PPAR RES, V2008, DOI 10.1155/2008/314974; Chen CF, 2004, ONCOGENE, V23, P5350, DOI 10.1038/sj.onc.1207682; Dhiman VK, 2015, ONCOTARGET, V6, P42575, DOI 10.18632/oncotarget.6471; Dingwall M, 2011, DIFFERENTIATION, V82, P57, DOI 10.1016/j.diff.2011.05.003; Dong DF, 2012, GENE EXPRESSION, V15, P153, DOI 10.3727/105221612X13372578119571; Dou MM, 2018, CELL PHYSIOL BIOCHEM, V45, P2497, DOI 10.1159/000488268; Dweep H, 2011, J BIOMED INFORM, V44, P839, DOI 10.1016/j.jbi.2011.05.002; Ellis L, 2016, PROSTATE, V76, P1192, DOI 10.1002/pros.23206; Ernst J, 2017, NAT PROTOC, V12, P2478, DOI 10.1038/nprot.2017.124; Ferrari AC, 2002, J CLIN ONCOL, V20, P538, DOI 10.1200/JCO.20.2.538; Foster BA, 1997, CANCER RES, V57, P3325; Fraser M, 2017, NATURE, V541, P359, DOI 10.1038/nature20788; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Guyot R, 2010, BMC MOL BIOL, V11, DOI 10.1186/1471-2199-11-3; Haflidadottir BS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072400; Hindley CJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep23208; Hua SJ, 2009, CELL, V137, P1259, DOI 10.1016/j.cell.2009.04.043; Huang H, 2014, CURR TOP MED CHEM, V14, P2175, DOI 10.2174/1568026614666141112101840; Itkonen HM, 2017, ONCOTARGET, V8, P38264, DOI 10.18632/oncotarget.16123; Jin FS, 2005, CANCER RES, V65, P6354, DOI 10.1158/0008-5472.CAN-04-4061; Jin M, 2014, CANCER RES, V74, P4183, DOI 10.1158/0008-5472.CAN-14-0404; Johannesson M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004794; Kashyap V, 2013, J CELL SCI, V126, P999, DOI 10.1242/jcs.119701; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; Kittler R, 2013, CELL REP, V3, P538, DOI 10.1016/j.celrep.2013.01.004; Kundaje A, 2015, NATURE, V518, P317, DOI 10.1038/nature14248; Kwabi-Addo B, 2001, P NATL ACAD SCI USA, V98, P11563, DOI 10.1073/pnas.201167798; Leushacke M, 2012, ONCOGENE, V31, P3009, DOI 10.1038/onc.2011.479; Liu NH, 2016, CANCER LETT, V378, P38, DOI 10.1016/j.canlet.2016.05.010; Liu PB, 2006, CANCER RES, V66, P4011, DOI 10.1158/0008-5472.CAN-05-3055; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; Long MD, 2015, NUCLEIC ACIDS RES, V43, P7330, DOI 10.1093/nar/gkv642; Long MD, 2015, NUCL RECEPT RES, V2; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lu XP, 1999, INT J CANCER, V80, P272, DOI 10.1002/(SICI)1097-0215(19990118)80:2<272::AID-IJC17>3.3.CO;2-O; Lun ATL, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkv1191; Luo ZJ, 2015, MOL CELL, V57, P685, DOI 10.1016/j.molcel.2015.01.007; Malinen M, 2017, NUCLEIC ACIDS RES, V45, P619, DOI 10.1093/nar/gkw855; MCBURNEY MW, 1993, CANCER INVEST, V11, P590, DOI 10.3109/07357909309011677; McCormick DL, 1999, CANCER RES, V59, P521; McDonald AC, 2018, PROSTATE, V78, P411, DOI 10.1002/pros.23485; McGrath MJ, 2013, CANCER RES, V73, P5066, DOI 10.1158/0008-5472.CAN-12-4520; Mihelich BL, 2011, J BIOL CHEM, V286, P44503, DOI 10.1074/jbc.M111.262915; Mo WJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056592; Murillo-Garzon V, 2017, NAT REV UROL, V14, P683, DOI 10.1038/nrurol.2017.144; Nash SH, 2015, CANCER EPIDEM BIOMAR, V24, P1507, DOI 10.1158/1055-9965.EPI-15-0394; Ngollo M, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-994; Olokpa E, 2017, PPAR RES, V2017, DOI 10.1155/2017/9456020; Ozpolat B, 2008, APOPTOSIS, V13, P915, DOI 10.1007/s10495-008-0222-9; Pi FM, 2018, NAT NANOTECHNOL, V13, P82, DOI 10.1038/s41565-017-0012-z; Pili R, 2012, BRIT J CANCER, V106, P77, DOI 10.1038/bjc.2011.527; Qiu JHJ, 2010, BLOOD, V115, P643, DOI 10.1182/blood-2009-07-232652; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Rivera-Gonzalez GC, 2012, NUCLEIC ACIDS RES, V40, P4825, DOI 10.1093/nar/gks143; Sanda MG, 2017, JAMA ONCOL, V3, P1085, DOI 10.1001/jamaoncol.2017.0177; Simandi Z, 2016, MOL CELL, V63, P647, DOI 10.1016/j.molcel.2016.06.039; Singal R, 2004, ONCOL REP, V12, P631; Singh PK, 2014, ONCOTARGET, V5, P824, DOI 10.18632/oncotarget.1776; Spahn M, 2010, INT J CANCER, V127, P394, DOI 10.1002/ijc.24715; Sun JK, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-168; Tan SM, 2016, METHODS MOL BIOL, V1358, P211, DOI 10.1007/978-1-4939-3067-8_13; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Thorne JL, 2011, NUCLEIC ACIDS RES, V39, P2045, DOI 10.1093/nar/gkq875; Thu KL, 2014, ONCOGENE, V33, P279, DOI 10.1038/onc.2012.595; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Torrano V, 2016, NAT CELL BIOL, V18, P645, DOI 10.1038/ncb3357; Trump DL, 1997, CANCER CHEMOTH PHARM, V39, P349, DOI 10.1007/s002800050582; TRUMP DL, 1994, LEUKEMIA, V8, pS50; Tsai YC, 2017, CANCER LETT, V384, P1, DOI 10.1016/j.canlet.2016.10.014; Ulz P, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12008; Urbanucci A, 2012, ONCOGENE, V31, P2153, DOI 10.1038/onc.2011.401; Viennois E, 2012, MOL CELL ENDOCRINOL, V351, P129, DOI 10.1016/j.mce.2011.08.036; Wang BD, 2015, CLIN CANCER RES, V21, P4970, DOI 10.1158/1078-0432.CCR-14-1566; Wang JH, 2011, CANCER RES, V71, P1325, DOI 10.1158/0008-5472.CAN-10-2210; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764; Wilde JJ, 2017, J NEUROSCI, V37, P2565, DOI 10.1523/JNEUROSCI.2121-16.2017; Zhang DX, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10798; Zhang J, 2010, ONCOGENE, V29, P723, DOI 10.1038/onc.2009.373; Zhang K, 2017, GENE, V619, P10, DOI 10.1016/j.gene.2017.03.038; Zhang SS, 2012, CELL BIOCHEM FUNCT, V30, P623, DOI 10.1002/cbf.2922; Zhu LJ, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-237	93	25	25	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2019	38	3					421	444		10.1038/s41388-018-0450-6	http://dx.doi.org/10.1038/s41388-018-0450-6			24	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HH6OP	30120411	Green Published, hybrid			2022-12-17	WOS:000455851200009
J	Merilahti, JAM; Elenius, K				Merilahti, Johannes A. M.; Elenius, Klaus			Gamma-secretase-dependent signaling of receptor tyrosine kinases	ONCOGENE			English	Review							REGULATED INTRAMEMBRANE PROTEOLYSIS; ALPHA-CONVERTING-ENZYME; GROWTH-FACTOR RECEPTOR; INTRACELLULAR DOMAIN; NUCLEAR-LOCALIZATION; CELL-PROLIFERATION; ESTROGEN-RECEPTOR; DOWN-REGULATION; ERBB4 ISOFORM; CLEAVAGE	Human genome harbors 55 receptor tyrosine kinases (RTK). At least half of the RTKs have been reported to be cleaved by gamma-secretase-mediated regulated intramembrane proteolysis. The two-step process involves releasing the RTK ectodomain to the extracellular space by proteolytic cleavage called shedding, followed by cleavage in the RTK transmembrane domain by the gamma-secretase complex resulting in release of a soluble RTK intracellular domain. This intracellular domain, including the tyrosine kinase domain, can in turn translocate to various cellular compartments, such as the nucleus or proteasome. The soluble intracellular domain may interact with transcriptional regulators and other proteins to induce specific effects on cell survival, proliferation, and differentiation, establishing an additional signaling mode for the cleavable RTKs. On the other hand, the same process can facilitate RTK turnover and proteasomal degradation. In this review we focus on the regulation of RTK shedding and gamma-secretase cleavage, as well as signaling promoted by the soluble RTK ICDs. In addition, therapeutic implications of increased knowledge on RTK cleavage on cancer drug development are discussed.	[Merilahti, Johannes A. M.; Elenius, Klaus] Univ Turku, Inst Biomed, Turku 20520, Finland; [Merilahti, Johannes A. M.; Elenius, Klaus] Univ Turku, Med Res Lab, Turku 20520, Finland; [Merilahti, Johannes A. M.] Univ Turku, Turku Doctoral Programme Mol Med, Turku 20520, Finland; [Elenius, Klaus] Turku Univ Hosp, Dept Oncol, Turku 20520, Finland	University of Turku; University of Turku; University of Turku; University of Turku	Elenius, K (corresponding author), Univ Turku, Inst Biomed, Turku 20520, Finland.; Elenius, K (corresponding author), Univ Turku, Med Res Lab, Turku 20520, Finland.; Elenius, K (corresponding author), Turku Univ Hosp, Dept Oncol, Turku 20520, Finland.	klaus.elenius@utu.fi	Elenius, Klaus/AAI-7594-2021	Elenius, Klaus/0000-0001-5700-0827; Merilahti, Johannes/0000-0002-9113-5175	Academy of Finland; Cancer Foundation Finland; Sigrid Juselius Foundation; Turku University Central Hospital; Orion Research Foundation; K. Albin Johansson foundation; Jenny and Antti Wihuri Foundation; Finnish Cultural Foundation	Academy of Finland(Academy of Finland); Cancer Foundation Finland; Sigrid Juselius Foundation(Sigrid Juselius Foundation); Turku University Central Hospital; Orion Research Foundation; K. Albin Johansson foundation; Jenny and Antti Wihuri Foundation; Finnish Cultural Foundation(Finnish Cultural FoundationFinnish IT center for science)	This work was supported by the Academy of Finland, Cancer Foundation Finland, Sigrid Juselius Foundation, Turku University Central Hospital, Orion Research Foundation, K. Albin Johansson foundation, Jenny and Antti Wihuri Foundation, and Finnish Cultural Foundation.	Ablonczy Z, 2009, J BIOL CHEM, V284, P30177, DOI 10.1074/jbc.M109.032391; Adrain C, 2012, SCIENCE, V335, P225, DOI 10.1126/science.1214400; Ancot F, 2009, ONCOGENE, V28, P2185, DOI 10.1038/onc.2009.88; Arasada RR, 2005, J BIOL CHEM, V280, P30783, DOI 10.1074/jbc.M506057200; Bache KG, 2004, EMBO J, V23, P2707, DOI 10.1038/sj.emboj.7600292; Bae SY, 2015, ONCOTARGET, V6, P10146, DOI 10.18632/oncotarget.3380; Bax DV, 2004, J BIOL CHEM, V279, P22377, DOI 10.1074/jbc.M400180200; Bernhofer M, 2016, PROTEINS, V84, P1706, DOI 10.1002/prot.25155; Bolduc DM, 2016, P NATL ACAD SCI USA, V113, pE509, DOI 10.1073/pnas.1512952113; Bonacchi A, 2008, HISTOL HISTOPATHOL, V23, P327, DOI 10.14670/HH-23.327; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Cai J, 2006, J BIOL CHEM, V281, P3604, DOI 10.1074/jbc.M507401200; Cai J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021164; Carpenter G, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008979; Chang W-H, 2017, P NATL ACAD SCI USA, V2017, P15772; Chavez-Gutierrez L, 2012, EMBO J, V31, P2261, DOI 10.1038/emboj.2012.79; Chen AC, 2015, J CELL BIOL, V211, P1157, DOI 10.1083/jcb.201502001; Chen MK, 2015, FEBS J, V282, P3693, DOI 10.1111/febs.13342; Christova Y, 2013, EMBO REP, V14, P884, DOI 10.1038/embor.2013.128; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; Degnin CR, 2011, MOL BIOL CELL, V22, P3861, DOI 10.1091/mbc.E11-01-0080; Diaz-Rodriguez E, 1999, EUR J NEUROSCI, V11, P1421, DOI 10.1046/j.1460-9568.1999.00552.x; Dombernowsky SL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8518; Du Z, 2018, MOL CANCER, V17, P1; Dusterhoft S, 2015, BIOCHEMISTRY-US, V54, P5791, DOI 10.1021/acs.biochem.5b00497; Elenius K, 1997, J BIOL CHEM, V272, P26761, DOI 10.1074/jbc.272.42.26761; Endres K, 2003, EUR J BIOCHEM, V270, P2386, DOI 10.1046/j.1432-1033.2003.03606.x; Fauvel B, 2014, MABS-AUSTIN, V6, P838, DOI 10.4161/mabs.29089; Foveau B, 2009, MOL BIOL CELL, V20, P2495, DOI 10.1091/mbc.E08-09-0969; Fukumori A, 2016, EMBO J, V35, P1628, DOI 10.15252/embj.201694151; Funamoto S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3529; Gilmore-Hebert M, 2010, MOL CANCER RES, V8, P1388, DOI 10.1158/1541-7786.MCR-10-0042; Glenn G, 2008, FEBS LETT, V582, P911, DOI 10.1016/j.febslet.2008.02.029; Glenn G, 2007, FEBS LETT, V581, P5377, DOI 10.1016/j.febslet.2007.10.031; Golde TE, 2013, BBA-BIOMEMBRANES, V1828, P2898, DOI 10.1016/j.bbamem.2013.06.005; Gooz P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033350; Goth CK, 2015, P NATL ACAD SCI USA, V112, P14623, DOI 10.1073/pnas.1511175112; Grieve AG, 2017, ELIFE, V6, DOI 10.7554/eLife.23968; Grotzinger J, 2017, BBA-MOL CELL RES, V1864, P2088, DOI 10.1016/j.bbamcr.2017.05.024; Guaiquil VH, 2010, J MOL MED, V88, P497, DOI 10.1007/s00109-010-0591-8; Haapasalo A, 2011, J ALZHEIMERS DIS, V25, P3, DOI 10.3233/JAD-2011-101065; Halford MM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075447; Hemming ML, 2008, PLOS BIOL, V6, P2314, DOI 10.1371/journal.pbio.0060257; Hoeing K, 2011, BBA-MOL CELL RES, V1813, P480, DOI 10.1016/j.bbamcr.2010.12.017; Hollmen M, 2009, ONCOGENE, V28, P1309, DOI 10.1038/onc.2008.481; Hollmen M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039413; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Inoue E, 2009, J CELL BIOL, V185, P551, DOI 10.1083/jcb.200809151; Iwamoto R, 2017, J CELL SCI, V130, P1321, DOI 10.1242/jcs.196618; Junttila TT, 2005, CANCER RES, V65, P1384, DOI 10.1158/0008-5472.CAN-04-3150; Kamp F, 2015, BIOPHYS J, V108, P1229, DOI 10.1016/j.bpj.2014.12.045; Kasuga K, 2007, BIOCHEM BIOPH RES CO, V360, P90, DOI 10.1016/j.bbrc.2007.06.022; Knittle AM, 2017, J BIOL CHEM, V292, P19890, DOI 10.1074/jbc.M117.794271; Kreitman M, 2018, FEBS LETT, V592, P2199, DOI 10.1002/1873-3468.13095; Lai C, 2004, BIOCHEM BIOPH RES CO, V314, P535, DOI 10.1016/j.bbrc.2003.12.131; Langosch D, 2015, TRENDS BIOCHEM SCI, V40, P318, DOI 10.1016/j.tibs.2015.04.001; Laurent SA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8333; Li X, 2015, P NATL ACAD SCI USA, V112, P6080, DOI 10.1073/pnas.1505649112; Linggi B, 2006, J BIOL CHEM, V281, P25373, DOI 10.1074/jbc.M603998200; Litterst C, 2007, J BIOL CHEM, V282, P16155, DOI 10.1074/jbc.M611449200; Liu PCC, 2006, CANCER BIOL THER, V5, P657, DOI 10.4161/cbt.5.6.2708; Lomize AL, 2017, NUCLEIC ACIDS RES, V45, pD250, DOI 10.1093/nar/gkw712; Lorenzen I, 2016, SCI REP-UK, V6, DOI 10.1038/srep35067; Lu YZ, 2017, FASEB J, V31, P1382, DOI 10.1096/fj.201600702R; Lyu J, 2008, DEV CELL, V15, P773, DOI 10.1016/j.devcel.2008.10.004; Maatta JA, 2006, MOL BIOL CELL, V17, P67, DOI 10.1091/mbc.E05-05-0402; Maretzky T, 2013, P NATL ACAD SCI USA, V110, P11433, DOI 10.1073/pnas.1302553110; Marron MB, 2007, J BIOL CHEM, V282, P30509, DOI 10.1074/jbc.M702535200; McElroy B, 2007, BIOCHEM BIOPH RES CO, V358, P1136, DOI 10.1016/j.bbrc.2007.05.062; McIlwain DR, 2012, SCIENCE, V335, P229, DOI 10.1126/science.1214448; Meckler X, 2016, J BIOL CHEM, V291, P12821, DOI 10.1074/jbc.M115.708297; Merilahti JAM, 2017, MOL BIOL CELL, V28, P3123, DOI 10.1091/mbc.E17-04-0261; Miller MA, 2017, CLIN CANCER RES, V23, P623, DOI 10.1158/1078-0432.CCR-16-0869; Miller MA, 2016, CANCER DISCOV, V6, P382, DOI 10.1158/2159-8290.CD-15-0933; Muraoka-Cook RS, 2006, MOL BIOL CELL, V17, P4118, DOI 10.1091/mbc.E06-02-0101; Murphy G, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-11-233; Murphy G, 2009, SEMIN CELL DEV BIOL, V20, P138, DOI 10.1016/j.semcdb.2008.09.004; Murphy G, 2008, NAT REV CANCER, V8, P929, DOI 10.1038/nrc2459; Na HW, 2012, J BIOL CHEM, V287, P25001, DOI 10.1074/jbc.M112.348904; Naresh A, 2006, CANCER RES, V66, P6412, DOI 10.1158/0008-5472.CAN-05-2368; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Orme JJ, 2016, CLIN IMMUNOL, V169, P58, DOI 10.1016/j.clim.2016.05.011; Osenkowski P, 2008, J BIOL CHEM, V283, P22529, DOI 10.1074/jbc.M801925200; Paatero I, 2014, J BIOL CHEM, V289, P22459, DOI 10.1074/jbc.M113.533497; Paatero I, 2012, J BIOL CHEM, V287, P9659, DOI 10.1074/jbc.M111.299537; Penington DJ, 2002, CELL GROWTH DIFFER, V13, P247; Rahimi N, 2009, CANCER RES, V69, P2607, DOI 10.1158/0008-5472.CAN-08-2905; Raikwar NS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112794; Reusch Petra, 2001, Angiogenesis, V4, P123, DOI 10.1023/A:1012226627813; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; Roberts DM, 2004, AM J PATHOL, V164, P1531, DOI 10.1016/S0002-9440(10)63711-X; Rovida E, 2001, J IMMUNOL, V166, P1583, DOI 10.4049/jimmunol.166.3.1583; Sannerud R, 2016, CELL, V166, P193, DOI 10.1016/j.cell.2016.05.020; Sardi SP, 2006, CELL, V127, P185, DOI 10.1016/j.cell.2006.07.037; Schauenburg L, 2018, SCI REP, V8, P1; Schelter F, 2010, J BIOL CHEM, V285, P26335, DOI 10.1074/jbc.M110.106435; Sommer A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11523; Srinivasan R, 2000, CANCER RES, V60, P1483; Sugiyama N, 2013, J CELL BIOL, V201, P467, DOI 10.1083/jcb.201205176; Sundvall M, 2012, J BIOL CHEM, V287, P23216, DOI 10.1074/jbc.M111.335927; Sundvall M, 2010, MOL BIOL CELL, V21, P4275, DOI 10.1091/mbc.E10-04-0332; Swendeman S, 2008, CIRC RES, V103, P916, DOI 10.1161/CIRCRESAHA.108.184416; Tejeda GS, 2016, J PATHOL, V238, P627, DOI 10.1002/path.4684; Thor AD, 2009, AM J PATHOL, V175, P1802, DOI 10.2353/ajpath.2009.090204; Thorp E, 2011, J BIOL CHEM, V286, P33335, DOI 10.1074/jbc.M111.263020; Urano Y, 2005, J LIPID RES, V46, P904, DOI 10.1194/jlr.M400333-JLR200; Urban S, 2014, CELL REP, V8, P1241, DOI 10.1016/j.celrep.2014.07.039; Van Schaeybroeck S, 2014, CELL REP, V7, P1940, DOI 10.1016/j.celrep.2014.05.032; Vetrivel KS, 2004, J BIOL CHEM, V279, P44945, DOI 10.1074/jbc.M407986200; Vidal GA, 2005, J BIOL CHEM, V280, P19777, DOI 10.1074/jbc.M412457200; Wakabayashi T, 2009, NAT CELL BIOL, V11, P1340, DOI 10.1038/ncb1978; Wali VB, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0501-z; Wheeler D. L., 2015, RECEPTOR TYROSINE KI; Wilhelmsen K, 2004, MOL CELL BIOL, V24, P454, DOI 10.1128/MCB.24.1.454-464.2004; Williams CC, 2004, J CELL BIOL, V167, P469, DOI 10.1083/jcb.200403155; Xu JD, 2009, J BIOL CHEM, V284, P27220, DOI 10.1074/jbc.M109.048728; Xu PL, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002689; Yumoto N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003322; Zhu Y, 2006, CANCER RES, V66, P7991, DOI 10.1158/0008-5472.CAN-05-4397; Zscheppang K, 2011, BBA-MOL CELL RES, V1813, P1717, DOI 10.1016/j.bbamcr.2011.06.020; Zscheppang K, 2011, AM J RESP CELL MOL, V45, P761, DOI 10.1165/rcmb.2010-0179OC; Zwick E, 2002, TRENDS MOL MED, V8, P17, DOI 10.1016/S1471-4914(01)02217-1	122	25	27	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2019	38	2					151	163		10.1038/s41388-018-0465-z	http://dx.doi.org/10.1038/s41388-018-0465-z			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG9XX	30166589	hybrid, Green Published			2022-12-17	WOS:000455366700001
J	Al Shareef, Z; Kardooni, H; Murillo-Garzon, V; Domenici, G; Stylianakis, E; Steel, JH; Rabano, M; Gorrono-Etxebarria, I; Zabalza, I; Vivanco, MD; Waxman, J; Kypta, RM				Al Shareef, Zainab; Kardooni, Hoda; Murillo-Garzon, Virginia; Domenici, Giacomo; Stylianakis, Emmanouil; Steel, Jennifer H.; Rabano, Miriam; Gorrono-Etxebarria, Irantzu; Zabalza, Ignacio; Vivanco, Maria dM; Waxman, Jonathan; Kypta, Robert M.			Protective effect of stromal Dickkopf-3 in prostate cancer: opposing roles for TGFBI and ECM-1	ONCOGENE			English	Article							EXTRACELLULAR-MATRIX PROTEIN-1; ACINAR MORPHOGENESIS; DKK-3 EXPRESSION; STEM-CELLS; STEM/PROGENITOR; METASTASIS; ACTIVATION; PROMOTER; INTEGRIN; BENIGN	Aberrant transforming growth factor-beta (TGF-beta) signaling is a hallmark of the stromal microenvironment in cancer. Dickkopf-3 (Dkk-3), shown to inhibit TGF-beta signaling, is downregulated in prostate cancer and upregulated in the stroma in benign prostatic hyperplasia, but the function of stromal Dkk-3 is unclear. Here we show that DKK3 silencing in WPMY-1 prostate stromal cells increases TGF-beta signaling activity and that stromal cell-conditioned media inhibit prostate cancer cell invasion in a Dkk-3-dependent manner. DKK3 silencing increased the level of the cell-adhesion regulator TGF-beta-induced protein (TGFBI) in stromal and epithelial cell-conditioned media, and recombinant TGFBI increased prostate cancer cell invasion. Reduced expression of Dkk-3 in patient tumors was associated with increased expression of TGFBI. DKK3 silencing reduced the level of extracellular matrix protein-1 (ECM-1) in prostate stromal cell-conditioned media but increased it in epithelial cell-conditioned media, and recombinant ECM-1 inhibited TGFBI-induced prostate cancer cell invasion. Increased ECM1 and DKK3 mRNA expression in prostate tumors was associated with increased relapse-free survival. These observations are consistent with a model in which the loss of Dkk-3 in prostate cancer leads to increased secretion of TGFBI and ECM-1, which have tumor-promoting and tumor-protective roles, respectively. Determining how the balance between the opposing roles of extracellular factors influences prostate carcinogenesis will be key to developing therapies that target the tumor microenvironment.	[Al Shareef, Zainab; Kardooni, Hoda; Stylianakis, Emmanouil; Steel, Jennifer H.; Waxman, Jonathan; Kypta, Robert M.] Imperial Coll London, Dept Surg & Canc, London, England; [Murillo-Garzon, Virginia; Domenici, Giacomo; Rabano, Miriam; Gorrono-Etxebarria, Irantzu; Vivanco, Maria dM; Kypta, Robert M.] CIC BioGUNE, Ctr Cooperat Res Biosci, Derio, Spain; [Zabalza, Ignacio] Galdakao Usansolo Hosp, Dept Pathol, Galdakao, Spain	Imperial College London; CIC bioGUNE; Galdakao Hospital	Kypta, RM (corresponding author), Imperial Coll London, Dept Surg & Canc, London, England.; Kypta, RM (corresponding author), CIC BioGUNE, Ctr Cooperat Res Biosci, Derio, Spain.	r.kypta@imperial.ac.uk	Domenici, Giacomo/AAG-6224-2019; Vivanco, Maria/G-2393-2011; Kypta, Robert/F-7699-2011	Vivanco, Maria/0000-0002-9540-247X; Kypta, Robert/0000-0002-2389-310X; Domenici, Giacomo/0000-0002-3947-5930; Stylianakis, Emmanouil/0000-0001-5750-0725; Mohamed Mohamed Abdoh AL Shareef, Zainab/0000-0003-4213-1052; Gorrono, Irantzu/0000-0003-4160-6781	UAE Ministry of Presidential Affairs; Harris Family Harvey Spack Memorial Fund; Garfield Weston Foundation; Rosetrees Trust; Basque Department of Education [BFI-2010-129]; Spanish Ministry of Science and Innovation [SAF2014-51966-R, SAF2017-84092-R, SAF2017-84934-R]	UAE Ministry of Presidential Affairs; Harris Family Harvey Spack Memorial Fund; Garfield Weston Foundation; Rosetrees Trust(Rosetrees Trust); Basque Department of Education; Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government)	We gratefully acknowledge the UAE Ministry of Presidential Affairs, The Harris Family Harvey Spack Memorial Fund, The Garfield Weston Foundation, Rosetrees Trust, Basque Department of Education (BFI-2010-129), and the Spanish Ministry of Science and Innovation (SAF2014-51966-R and SAF2017-84092-R (RMK) and SAF2017-84934-R (MdMV)) for funding, and the Cancer Research UK Imperial Centre, the Imperial Experimental Cancer Medicine Centre, the National Institute for Health Research Imperial Biomedical Research Centre, the Department of Industry, Tourism and Trade (Elkartek), the Department of Innovation Technology of the Government of the Autonomous Community of the Basque Country, and the Centre of Excellence Severo Ochoa (2017-2021) for infrastructure support.	Abarzua F, 2005, CANCER RES, V65, P9617, DOI 10.1158/0008-5472.CAN-05-0829; Augsten M, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00062; Ayala G, 2013, J PATHOL, V231, P77, DOI 10.1002/path.4217; Barron DA, 2012, ENDOCR-RELAT CANCER, V19, pR187, DOI 10.1530/ERC-12-0085; Bauderlique-Le Roy H, 2015, STEM CELLS DEV, V24, P1252, DOI 10.1089/scd.2014.0386; Bekhouche M, 2016, FASEB J, V30, P1741, DOI 10.1096/fj.15-279869; Bello-DeOcampo D, 2001, MUTAT RES-FUND MOL M, V480, P209, DOI 10.1016/S0027-5107(01)00201-9; Buscemi L, 2011, CURR BIOL, V21, P2046, DOI 10.1016/j.cub.2011.11.037; Busceti CL, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00111; Chen WY, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aam6826; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dutta A, 2015, BIOCHEM J, V466, P525, DOI 10.1042/BJ20140698; Fong D, 2009, CANCER SCI, V100, P1414, DOI 10.1111/j.1349-7006.2009.01208.x; Fu CY, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.395012; Fujimoto N, 2006, EXP DERMATOL, V15, P300, DOI 10.1111/j.0906-6705.2006.00409.x; Gao F, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0533-9; Gong YX, 2014, CANCERS, V6, P1298, DOI 10.3390/cancers6031298; Goswami CP, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-970; Goswami Chirayu Pankaj, 2013, J Clin Bioinforma, V3, P22, DOI 10.1186/2043-9113-3-22; Hangai M, 2002, AM J PATHOL, V161, P1429, DOI 10.1016/S0002-9440(10)64418-5; Kawano Y, 2006, ONCOGENE, V25, P6528, DOI 10.1038/sj.onc.1209661; Krupnik VE, 1999, GENE, V238, P301, DOI 10.1016/S0378-1119(99)00365-0; Kumon H, 2016, CANCER GENE THER, V23, P400, DOI 10.1038/cgt.2016.53; Kumon H, 2015, CLIN MED INSIGHTS-ON, V9, P31, DOI 10.4137/CMO.S23252; Leonard JL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181724; Li T, 2010, LAB INVEST, V90, P234, DOI 10.1038/labinvest.2009.127; Montecinos VP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029623; Niu YJ, 2008, P NATL ACAD SCI USA, V105, P12188, DOI 10.1073/pnas.0804701105; Piva M, 2014, EMBO MOL MED, V6, P66, DOI 10.1002/emmm.201303411; Prudova A, 2010, MOL CELL PROTEOMICS, V9, P894, DOI 10.1074/mcp.M000050-MCP201; Rohrschneider LR, 2005, DEV BIOL, V283, P503, DOI 10.1016/j.ydbio.2005.04.032; Romero D, 2016, CARCINOGENESIS, V37, P18, DOI 10.1093/carcin/bgv153; Romero Diana, 2013, Bioarchitecture, V3, P42, DOI 10.4161/bioa.25243; Romero D, 2013, J CELL SCI, V126, P1858, DOI 10.1242/jcs.119388; Ross-Adams H, 2015, EBIOMEDICINE, V2, P1133, DOI 10.1016/j.ebiom.2015.07.017; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Shah JN, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-284; Smits P, 1997, GENOMICS, V45, P487, DOI 10.1006/geno.1997.4918; St Croix B, 2000, SCIENCE, V289, P1197; Su P, 2016, J IMMUNOL, V197, P1054, DOI 10.4049/jimmunol.1502457; THALMANN GN, 1994, CANCER RES, V54, P2577; Tokar EJ, 2005, DIFFERENTIATION, V73, P463, DOI 10.1111/j.1432-0436.2005.00047.x; Tu Z, 2001, BLOOD, V98, P2028, DOI 10.1182/blood.V98.7.2028; Untergasser G, 2008, INT J CANCER, V122, P1539, DOI 10.1002/ijc.23255; Veeck J, 2012, BBA-REV CANCER, V1825, P18, DOI 10.1016/j.bbcan.2011.09.003; Wang XC, 2015, J BIOL CHEM, V290, P19844, DOI 10.1074/jbc.M115.641415; Webber JP, 2016, ONCOTARGET, V7, P20124, DOI 10.18632/oncotarget.7716; Webber MM, 1999, CARCINOGENESIS, V20, P1185, DOI 10.1093/carcin/20.7.1185; Ween MP, 2012, INT J MOL SCI, V13, P10461, DOI 10.3390/ijms130810461; Yu NW, 2010, UROLOGY, V76, DOI 10.1016/j.urology.2010.03.061; Zenzmaier C, 2008, PROSTATE, V68, P540, DOI 10.1002/pros.20711; Zenzmaier C, 2013, PROSTATE, V73, P1441, DOI 10.1002/pros.22691; Zhu MJ, 2014, FEBS J, V281, P3766, DOI 10.1111/febs.12902	54	25	26	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2018	37	39					5305	5324		10.1038/s41388-018-0294-0	http://dx.doi.org/10.1038/s41388-018-0294-0			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV0NW	29858602	Green Published, hybrid			2022-12-17	WOS:000445759700005
J	Guo, H; Zhao, LM; Shi, BH; Bao, JY; Zheng, DX; Zhou, BG; Shi, J				Guo, Hui; Zhao, Lianmei; Shi, Bianhua; Bao, Jiayu; Zheng, Dexian; Zhou, Baoguo; Shi, Juan			GALNT5 uaRNA promotes gastric cancer progression through its interaction with HSP90	ONCOGENE			English	Article							LONG NONCODING RNAS; 3' UNTRANSLATED REGIONS; HEAT-SHOCK PROTEINS; B-KINASE IKK; HISTONE METHYLTRANSFERASE; TRANSLATIONAL CONTROL; EXPRESSION; CELLS; HEAT-SHOCK-PROTEIN-90; PROLIFERATION	Recently, long noncoding RNAs (lncRNAs) have been reported to play a pivotal role in the occurrence and progression of cancer because of their unique characteristics and have therefore become an active area of cancer research. The object of this study was to screen lncRNAs that are dysregulated in gastric cancer and to investigate their potential functions. Global expression of lncRNAs in gastric cancer and adjacent normal tissues of patients was profiled using a microarray assay. We identified an lncRNA (GALNT5 uaRNA, UTR-associated RNA) that is derived from the 3'-UTR of GALNT5. This lncRNA was transcribed independently of the coding region of GALNT5 and was determined to be markedly upregulated in human gastric carcinoma relative to their corresponding normal gastric tissues by quantitative RT-PCR (qRT-PCR) analysis of tissues from 122 gastric carcinoma patients. The expression of GALNT5 uaRNA was significantly correlated with the TNM stage and with lymph node metastasis. Further results demonstrated that GALNT5 uaRNA facilitated the proliferation and migration of gastric cancer cells in vitro and promoted tumor growth in a mouse model of human gastric cancer. Our results also indicated that GALNT5 uaRNA might function in gastric cancer by binding with HSP90. Further studies indicated that the 5'-end stem-loop motifs of GALNT5 uaRNA promoted the binding of HSP90 and its client proteins, and thus inhibited ubiquitination of the clients. These results expanded our understanding of GALNT5 uaRNA as a new avenue for therapeutic intervention against gastric cancer progression.	[Guo, Hui; Zhao, Lianmei; Shi, Bianhua; Bao, Jiayu; Zheng, Dexian; Shi, Juan] Chinese Acad Med Sci, Inst Basic Med Sci, Natl Lab Med Mol Biol, Beijing 100005, Peoples R China; [Guo, Hui; Zhao, Lianmei; Shi, Bianhua; Bao, Jiayu; Zheng, Dexian; Shi, Juan] Peking Union Med Coll, Beijing 100005, Peoples R China; [Zhao, Lianmei] Hebei Med Univ, Hosp 4, Res Ctr, Shijiazhuang 050011, Hebei, Peoples R China; [Zhou, Baoguo] Harbin Med Univ, Affiliated Hosp 1, Dept Gen Surg, Harbin 150001, Heilongjiang, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Hebei Medical University; Harbin Medical University	Shi, J (corresponding author), Chinese Acad Med Sci, Inst Basic Med Sci, Natl Lab Med Mol Biol, Beijing 100005, Peoples R China.; Shi, J (corresponding author), Peking Union Med Coll, Beijing 100005, Peoples R China.; Zhou, BG (corresponding author), Harbin Med Univ, Affiliated Hosp 1, Dept Gen Surg, Harbin 150001, Heilongjiang, Peoples R China.	zhoubaoguo@msn.com; shijuantt@163.com		Zheng, Dexian/0000-0003-3966-1212; bao, jiayu/0000-0001-9476-3225; Guo, Hui/0000-0003-3901-6336	Natural Science Foundation of China [81572755, 81372200]; CAMS Initiative for Innovative Medicine (CAMS-I2M) [2016-I2M-1-001]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); CAMS Initiative for Innovative Medicine (CAMS-I2M)	This work was partially supported by the Natural Science Foundation of China (Grant No. 81572755, 81372200 to J. Shi), CAMS Initiative for Innovative Medicine (CAMS-I2M Grant No. 2016-I2M-1-001to J. Shi).	Abu-Farha M, 2008, MOL CELL PROTEOMICS, V7, P560, DOI 10.1074/mcp.M700271-MCP200; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; Batista PJ, 2013, CELL, V152, P1298, DOI 10.1016/j.cell.2013.02.012; Bennett EP, 2012, GLYCOBIOLOGY, V22, P736, DOI 10.1093/glycob/cwr182; Bishop SC, 2007, CURR CANCER DRUG TAR, V7, P369, DOI 10.2174/156800907780809778; Broemer M, 2004, ONCOGENE, V23, P5378, DOI 10.1038/sj.onc.1207705; Cao JN, 2014, BIOL PROCED ONLINE, V16, DOI 10.1186/1480-9222-16-11; Cao WJ, 2013, WORLD J GASTROENTERO, V19, P3658, DOI 10.3748/wjg.v19.i23.3658; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Frith MC, 2005, EUR J HUM GENET, V13, P894, DOI 10.1038/sj.ejhg.5201459; Furuno M, 2006, PLOS GENET, V2, P537, DOI 10.1371/journal.pgen.0020037; Hamamoto R, 2004, NAT CELL BIOL, V6, P731, DOI 10.1038/ncb1151; Hamm CA, 2015, PHARMACOL THERAPEUT, V151, P72, DOI 10.1016/j.pharmthera.2015.03.003; He H, 2014, BRIT J CANCER, V110, P2021, DOI 10.1038/bjc.2014.93; Khurana N, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00100; Klattenhoff CA, 2013, CELL, V152, P570, DOI 10.1016/j.cell.2013.01.003; Kretz M, 2013, NATURE, V493, P231, DOI 10.1038/nature11661; Kuersten S, 2003, NAT REV GENET, V4, P626, DOI 10.1038/nrg1125; Li H, 2014, ONCOTARGET, V5, P2318, DOI 10.18632/oncotarget.1913; Lianos GD, 2015, CANCER LETT, V360, P114, DOI 10.1016/j.canlet.2015.02.026; Liu XF, 2012, EMBO J, V31, P4415, DOI 10.1038/emboj.2012.292; Matoulkova E, 2012, RNA BIOL, V9, P563, DOI 10.4161/rna.20231; Mayer MP, 2015, MOL CELL, V58, P8, DOI 10.1016/j.molcel.2015.02.022; Mazumder B, 2003, TRENDS BIOCHEM SCI, V28, P91, DOI 10.1016/S0968-0004(03)00002-1; Mercer TR, 2011, NUCLEIC ACIDS RES, V39, P2393, DOI 10.1093/nar/gkq1158; Mercer TR, 2010, GENOME RES, V20, P1639, DOI 10.1101/gr.112128.110; Ota T, 2004, NAT GENET, V36, P40, DOI 10.1038/ng1285; Qing GL, 2006, CELL RES, V16, P895, DOI 10.1038/sj.cr.7310109; Rodrigues TC, 2014, FUTURE ONCOL, V10, P2449, DOI 10.2217/fon.14.149; Sandberg R, 2008, SCIENCE, V320, P1643, DOI 10.1126/science.1155390; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Stowell SR, 2015, ANNU REV PATHOL-MECH, V10, P473, DOI 10.1146/annurev-pathol-012414-040438; Sun M, 2016, CANCER RES, V76, P6299, DOI 10.1158/0008-5472.CAN-16-0356; Ten Hagen BG, 1998, J BIOL CHEM, V273, P27749; Tsutsumi S, 2007, CANCER SCI, V98, P1536, DOI 10.1111/j.1349-7006.2007.00561.x; Vahid S, 2017, RECENT PAT ANTI-CANC, V12, P35, DOI 10.2174/1574892811666161102125252; Zhao L, 2016, ONCOGENE, V35, P5770, DOI 10.1038/onc.2016.110; Zhou CC, 2016, HEPATOLOGY, V63, P850, DOI 10.1002/hep.28393	40	25	25	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 16	2018	37	33					4505	4517		10.1038/s41388-018-0266-4	http://dx.doi.org/10.1038/s41388-018-0266-4			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GQ5OV	29743591				2022-12-17	WOS:000441736700002
J	Cao, L; Wang, SY; Zhang, YQ; Wong, KC; Nakatsu, G; Wang, XH; Wong, S; Ji, JF; Yu, J				Cao, Lei; Wang, Shiyan; Zhang, Yanquan; Wong, Ka-Chun; Nakatsu, Geicho; Wang, Xiaohong; Wong, Sunny; Ji, Jiafu; Yu, Jun			Zinc-finger protein 471 suppresses gastric cancer through transcriptionally repressing downstream oncogenic PLS3 and TFAP2A	ONCOGENE			English	Article							FUNCTIONAL DIVERSITY; METHYLATION; EXPRESSION; PROGNOSIS; PROMOTER; SURVIVAL; HYPERMETHYLATION; PROGRESSION; PREDICTION; CARCINOMA	Zinc-finger protein 471 (ZNF471) was preferentially methylated in gastric cancer using promoter methylation array. The role of ZNF471 in human cancer is unclear. Here we elucidated the functional significance, molecular mechanisms and clinical impact of ZNF471 in gastric cancer. ZNF471 mRNA was silenced in 15 out of 16 gastric cancer cell lines due to promoter hypermethylation. Significantly higher ZNF471 promoter methylation was also observed in primary gastric cancers compared to their adjacent normal tissues (P < 0.001). ZNF471 promoter CpG-site hypermethylation correlated with poor survival of gastric cancer patients (n = 120, P = 0.001). Ectopic expression of ZNF471 in gastric cancer cell lines (AGS, BGC823, and MKN74) significantly suppressed cell proliferation, migration, and invasion, while it induced apoptosis in vitro and inhibited xenograft tumorigenesis in nude mice. Transcription factor AP-2 Alpha (TFAP2A) and plastin3 (PLS3) were two crucial downstream targets of ZNF471 demonstrated by bioinformatics modeling and ChIP-PCR assays. ZNF471 directly bound to the promoter of TFAP2A and PLS3 and transcriptionally inhibited their expression. TFAP2A and PLS3 showed oncogenic functions in gastric cancer cell lines. Moreover, ZNF471 recruited KAP1 to the promoter of the target genes, thereby inducing H3K9me3 enrichment for transcriptional repression and inhibition of oncogenic TFAP2A and PLS3. In conclusion, ZNF471 acts as a tumor suppressor in gastric cancer by transcriptionally inhibiting downstream targets TFAP2A and PLS3. KAP1 is a co-repressor of ZNF471 at the promoter of the target genes. The promoter CpG-site methylation is an independent prognostic factor for overall survival of gastric cancer patients.	[Cao, Lei; Wang, Shiyan; Zhang, Yanquan; Nakatsu, Geicho; Wong, Sunny; Yu, Jun] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Inst Digest Dis, Hong Kong, Hong Kong, Peoples R China; [Cao, Lei; Wang, Shiyan; Zhang, Yanquan; Nakatsu, Geicho; Wong, Sunny; Yu, Jun] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut, State Key Lab Digest Dis, Hong Kong, Hong Kong, Peoples R China; [Wong, Ka-Chun] City Univ Hong Kong Kowloon Tong, Dept Comp Sci, Kowloon Tong, Hong Kong, Peoples R China; [Wang, Xiaohong; Ji, Jiafu] Beijing Canc Hosp & Inst, Dept Gastrointestinal Surg, Minist Educ, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong	Yu, J (corresponding author), Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Inst Digest Dis, Hong Kong, Hong Kong, Peoples R China.; Yu, J (corresponding author), Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut, State Key Lab Digest Dis, Hong Kong, Hong Kong, Peoples R China.	junyu@cuhk.edu.hk	Nakatsu, Geicho/AAU-3089-2021; Yu, Jun/D-8569-2015; Wong, Ka-Chun/L-7160-2019; Wong, Sunny H/N-3754-2015; Zhang, Yanquan/D-5615-2017	Yu, Jun/0000-0001-5008-2153; Wong, Ka-Chun/0000-0001-6062-733X; Wong, Sunny H/0000-0002-3354-9310; Zhang, Yanquan/0000-0003-3527-9972	RGC-GRF Hong Kong [766613, 14106415, 14111216]; HMRF Hong Kong [1195728]; 135 program project China [2016YFC1303200]; Shenzhen Virtual University Park Support Scheme; CUHK direct grant	RGC-GRF Hong Kong(Hong Kong Research Grants Council); HMRF Hong Kong; 135 program project China; Shenzhen Virtual University Park Support Scheme; CUHK direct grant(Chinese University of Hong Kong)	This project was supported by RGC-GRF Hong Kong (766613, 14106415, 14111216), HMRF Hong Kong (1195728), 135 program project China (2016YFC1303200), Shenzhen Virtual University Park Support Scheme to CUHK Shenzhen Research Institute and CUHK direct grant (J. Yu).	Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Bennett KL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006931; Berlato C, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2838; Besson A, 2008, DEV CELL, V14, P159, DOI 10.1016/j.devcel.2008.01.013; Bhat S, 2017, VIRCHOWS ARCH, V470, P445, DOI 10.1007/s00428-017-2094-2; Choi IS, 2005, CELL RES, V15, P247, DOI 10.1038/sj.cr.7290293; Claus R, 2012, J CLIN ONCOL, V30, P2483, DOI 10.1200/JCO.2011.39.3090; Deng JY, 2014, ONCOTARGET, V5, P7420, DOI 10.18632/oncotarget.1973; Deng JY, 2014, AM J CANCER RES, V4, P518; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Grant CE, 2011, BIOINFORMATICS, V27, P1017, DOI 10.1093/bioinformatics/btr064; Groner AC, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000869; Huang L, 2015, AM J TRANSL RES, V7, P2141; Iyengar S, 2011, J BIOL CHEM, V286, P26267, DOI 10.1074/jbc.R111.252569; Jen JY, 2016, J BIOMED SCI, V23, DOI 10.1186/s12929-016-0269-9; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; Laity JH, 2001, CURR OPIN STRUC BIOL, V11, P39, DOI 10.1016/S0959-440X(00)00167-6; Lee TI, 2006, NAT PROTOC, V1, P729, DOI 10.1038/nprot.2006.98; Liu XS, 2016, CELL, V167, P233, DOI 10.1016/j.cell.2016.08.056; Liu ZJ, 2014, CLIN CANCER RES, V20, P4598, DOI 10.1158/1078-0432.CCR-13-3380; Lupo A, 2013, CURR GENOMICS, V14, P268, DOI 10.2174/13892029113149990002; Mitchell SM, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-54; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Najafabadi HS, 2015, NAT BIOTECHNOL, V33, P555, DOI 10.1038/nbt.3128; Peille AL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080741; Qu YP, 2013, CLIN CHIM ACTA, V424, P53, DOI 10.1016/j.cca.2013.05.002; Schmitges FW, 2016, GENOME RES, V26, P1742, DOI 10.1101/gr.209643.116; Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302; Shi DB, 2014, CANCER PREV RES, V7, P266, DOI 10.1158/1940-6207.CAPR-13-0271; Sigova AA, 2015, SCIENCE, V350, P978, DOI 10.1126/science.aad3346; Sripathy SP, 2006, MOL CELL BIOL, V26, P8623, DOI 10.1128/MCB.00487-06; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Ueda M, 2014, ANN SURG ONCOL, V21, P3680; Urrutia R, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-231; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wang N, 2016, ARCH MED RES, V47, P285, DOI 10.1016/j.arcmed.2016.07.011; Wang SY, 2013, GUT, V62, P833, DOI 10.1136/gutjnl-2011-301776; Wong CC, 2016, GASTROENTEROLOGY, V151, P945, DOI 10.1053/j.gastro.2016.07.011; Zouridis H, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004504	39	25	26	3	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	26					3601	3616		10.1038/s41388-018-0220-5	http://dx.doi.org/10.1038/s41388-018-0220-5			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GK7TM	29610526	hybrid, Green Published			2022-12-17	WOS:000436412500010
J	Jin, P; Shin, SH; Chun, YS; Shin, HW; Shin, YJ; Lee, Y; Kim, D; Nam, DH; Park, JW				Jin, Peng; Shin, Seung-Hyun; Chun, Yang-Sook; Shin, Hyun-Woo; Shin, Yong Jae; Lee, Yeri; Kim, Donggeon; Nam, Do-Hyun; Park, Jong-Wan			Astrocyte-derived CCL20 reinforces HIF-1-mediated hypoxic responses in glioblastoma by stimulating the CCR6-NF-kappa B signaling pathway	ONCOGENE			English	Article							NF-KAPPA-B; RECEPTOR CCR6; CHEMOKINE CCL20; CELLS; PROGRESSION; PROGNOSIS; GLIOMAS; CANCER; PROLIFERATION; ANGIOGENESIS	During tumor development, stromal cells are co-opted to the tumor milieu and provide favorable conditions for the tumor. Hypoxia stimulates cancer cells to acquire a more malignant phenotype via activation of hypoxia-inducible factor 1 (HIF-1). Given that cancer cells and astrocytes in glioblastomas coexist in a hypoxic microenvironment, we examined whether astrocytes affect the adaptation of glioblastoma cells to hypoxia. Immunoblotting, reporter assays, quantitative RT-PCR, and chromatin immunoprecipitation were performed to evaluate HIF-1 signaling in glioblastoma cells. Astrocyte-derived chemokine C-C motif ligand 20 (CCL20) was identified using cytokine arrays, and its role in glioblastoma development was evaluated in orthotopic xenografts. Astrocytes augmented HIF-1 alpha expression in glioblastoma cells under hypoxia. The expression of HIF-1 downstream genes, cancer colony formation, and Matrigel invasion of glioblastoma cells were stimulated by conditioned medium from astrocytes pre-exposed to hypoxia. CCL20 was secreted in a hypoxia-dependent manner from astrocytes and busted the hypoxic induction of HIF-1 alpha in glioblastoma cells. Mechanistically, the CCL20/CCR6 signaling pathway upregulates HIF-1 alpha by stimulating nuclear factor kappa B-driven transactivation of the HIF1A gene. Compared with the control tumors, CCR6-deficient glioblastoma xenografts grew more slowly, with poor vascularization, and expressed lower levels of HIF-1 alpha and its downstream proteins. Furthermore, CCR6 expression was correlated with HIF-1 alpha expression in GEO and TCGA datasets from human glioblastoma tissues. These results suggest that glioblastoma cells adapt well to hypoxic stress by virtue of CCL20 derived from neighboring astrocytes.	[Jin, Peng; Shin, Seung-Hyun; Chun, Yang-Sook; Shin, Hyun-Woo; Park, Jong-Wan] Seoul Natl Univ, Coll Med, Dept Biomed Sci, Plus Educ Program BK21, Seoul, South Korea; [Jin, Peng; Shin, Seung-Hyun; Shin, Hyun-Woo; Park, Jong-Wan] Seoul Natl Univ, Coll Med, Dept Pharmacol, Seoul, South Korea; [Jin, Peng; Shin, Seung-Hyun; Chun, Yang-Sook; Shin, Hyun-Woo; Park, Jong-Wan] Seoul Natl Univ, Coll Med, Ischem Hypox Dis Inst, Seoul, South Korea; [Jin, Peng; Shin, Seung-Hyun; Chun, Yang-Sook; Shin, Hyun-Woo; Park, Jong-Wan] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul, South Korea; [Shin, Yong Jae; Lee, Yeri; Kim, Donggeon; Nam, Do-Hyun] Samsung Med Ctr, Res Inst Future Med, Inst Refractory Canc Res, Seoul, South Korea; [Shin, Yong Jae; Nam, Do-Hyun] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Neurosurg, Seoul, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center	Park, JW (corresponding author), Seoul Natl Univ, Coll Med, Dept Biomed Sci, Plus Educ Program BK21, Seoul, South Korea.; Park, JW (corresponding author), Seoul Natl Univ, Coll Med, Dept Pharmacol, Seoul, South Korea.; Park, JW (corresponding author), Seoul Natl Univ, Coll Med, Ischem Hypox Dis Inst, Seoul, South Korea.; Park, JW (corresponding author), Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul, South Korea.	parkjw@snu.ac.kr			National Research Foundation of Korea [2017048432]; Korea Health Technology R&D Project through the Korea Health Industry Development Institute [HI14C3418]; Education and Research Encouragement Fund of Seoul National University Hospital	National Research Foundation of Korea(National Research Foundation of Korea); Korea Health Technology R&D Project through the Korea Health Industry Development Institute; Education and Research Encouragement Fund of Seoul National University Hospital	This work was supported by a grant of the National Research Foundation of Korea (2017048432) and a grant of Korea Health Technology R&D Project through the Korea Health Industry Development Institute (HI14C3418). Park JW was supported by the Education and Research Encouragement Fund of Seoul National University Hospital.	Ambrosini E, 2003, GLIA, V41, P290, DOI 10.1002/glia.10193; Ayrapetov MK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026064; Battaglia F, 2008, J LEUKOCYTE BIOL, V83, P648, DOI 10.1189/jlb.0607349; Charles NA, 2012, GLIA, V60, P502, DOI 10.1002/glia.21264; Ding XJ, 2012, J GASTROINTEST SURG, V16, P828, DOI 10.1007/s11605-011-1775-4; Fischer I, 2005, BRAIN PATHOL, V15, P297; Gagliano N, 2009, ONCOL REP, V22, P1349, DOI 10.3892/or_00000574; Ghadjar P, 2009, INT J CANCER, V125, P741, DOI 10.1002/ijc.24468; Giannopoulou E, 2006, IN VIVO, V20, P421; Gorlach Agnes, 2008, Biochem J, V412, pe17, DOI 10.1042/BJ20080920; Kaur B, 2005, NEURO-ONCOLOGY, V7, P134, DOI 10.1215/S1152851704001115; Ke QD, 2006, MOL PHARMACOL, V70, P1469, DOI 10.1124/mol.106.027029; Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183; Korkolopoulou P, 2004, NEUROPATH APPL NEURO, V30, P267, DOI 10.1111/j.1365-2990.2003.00535.x; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Lee YM, 2011, HEPATOLOGY, V53, P171, DOI 10.1002/hep.24010; Li R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094320; Lorger Mihaela, 2012, Cancers (Basel), V4, P218, DOI 10.3390/cancers4010218; Marsigliante S, 2013, J CELL PHYSIOL, V228, P1873, DOI 10.1002/jcp.24349; McColl SR, 2002, IMMUNOL CELL BIOL, V80, P489, DOI 10.1046/j.1440-1711.2002.01113.x; Mendez O, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-133; O'Brien ER, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00040; Okamoto T, 2007, CURR PHARM DESIGN, V13, P447, DOI 10.2174/138161207780162944; Olar A, 2014, J PATHOL, V232, P165, DOI 10.1002/path.4282; Placone AL, 2016, TUMOR BIOL, V37, P61, DOI 10.1007/s13277-015-4242-0; Rath BH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054752; Schutyser E, 2003, CYTOKINE GROWTH F R, V14, P409, DOI 10.1016/S1359-6101(03)00049-2; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; Toledo CM, 2015, CELL REP, V13, P2425, DOI 10.1016/j.celrep.2015.11.021; Vaupel P, 2004, ONCOLOGIST, V9, P10, DOI 10.1634/theoncologist.9-90005-10; Wang L, 2012, MED ONCOL, V29, P3491, DOI 10.1007/s12032-012-0314-9; Yang LQ, 2012, EXP CELL RES, V318, P2417, DOI 10.1016/j.yexcr.2012.07.017; Zeng W, 2014, EXP MOL PATHOL, V97, P184, DOI 10.1016/j.yexmp.2014.06.012	34	25	26	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	23					3070	3087		10.1038/s41388-018-0182-7	http://dx.doi.org/10.1038/s41388-018-0182-7			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GI6VO	29535421				2022-12-17	WOS:000434641400003
J	Shinno, N; Kimura, H; Sada, R; Takiguchi, S; Mori, M; Fumoto, K; Doki, Y; Kikuchi, A				Shinno, Naoki; Kimura, Hirokazu; Sada, Ryota; Takiguchi, Shuji; Mori, Masaki; Fumoto, Katsumi; Doki, Yuichiro; Kikuchi, Akira			Activation of the Dickkopf1-CKAP4 pathway is associated with poor prognosis of esophageal cancer and anti-CKAP4 antibody may be a new therapeutic drug	ONCOGENE			English	Article							SQUAMOUS-CELL CARCINOMA; GROWTH-FACTOR RECEPTOR; MULTIPLE-MYELOMA; ARL4C EXPRESSION; BETA-CATENIN/TCF; MEMBRANE-PROTEIN; WNT; DICKKOPF-1; TARGET; GENE	Aberrant expression of the secretory protein Dickkopf1 (DKK1) is associated with poor prognosis of esophageal squamous cell carcinoma (ESCC), but the underlying mechanism of how DKK1 is involved in aggressiveness of ESCC is not clear. In this study, we show that cytoskeleton-associated protein 4 (CKAP4) functions as a DKK1 receptor in ESCC cells. Immunohistochemical analyses of ESCC revealed that both DKK1 and CKAP4 are minimally expressed in associated normal esophageal squamous mucosa of non-tumor regions, but strongly expressed in tumor lesions. Forty-six of 119 cases (38.7%) were positive for both DKK1 and CKAP4. Those expressing both proteins showed poor prognosis and relapse-free survival. Multivariate analysis demonstrated that expression of both proteins was the poor prognostic factor. The Cancer Genome Atlas data set indicated that the mRNA levels of DKK1 and CKAP4 are significantly elevated in the tumor lesions compared to non-tumor regions. DKK1 bound to CKAP4 at endogenous levels. DKK1 induced the internalization of CKAP4 from and its recycling to the plasma membrane. AKT was activated in ESCC cells in which DKK1 was highly expressed and CKAP4 was localized to the plasma membrane. Knockdown of either DKK1 or CKAP4 inhibited AKT activity and cell proliferation in vitro and xenograft tumor formation. Wild-type CKAP4 or DKK1, but not a DKK1 mutant that was unable to bind to CKAP4, rescued phenotypes induced by CKAP4 or DKK1 knockdown, respectively. The anti-CKAP4 antibody also inhibited AKT activity and suppressed xenograft tumor formation. In contrast, in ESCC cells in which DKK1 was marginally expressed, knockdown of CKAP4 or anti-CKAP4 antibody affected neither AKT activity nor cell proliferation. These findings suggest that the DKK1-CKAP4 pathway promotes ESCC cell proliferation and that CKAP4 might represent a novel therapeutic target for ESCCs expressing both DKK1 and CKAP4.	[Shinno, Naoki; Takiguchi, Shuji; Mori, Masaki; Doki, Yuichiro] Osaka Univ, Grad Sch Med, Dept Surg Gastroenterol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan; [Kimura, Hirokazu; Sada, Ryota; Fumoto, Katsumi; Kikuchi, Akira] Osaka Univ, Grad Sch Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan	Osaka University; Osaka University	Kikuchi, A (corresponding author), Osaka Univ, Grad Sch Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	akikuchi@molbiobc.med.osaka-u.ac.jp			Ministry of Education, Culture, Sports, Science, and Technology of Japan [25250018, 16H06374, 23112004, 16H06944, T15K198870]; Project Promoting Support for Drug Discovery; Project for Cancer Research And Therapeutic Evolution (P-CREATE) from Japan Agency for Medical Research and development, AMED; Yasuda Memorial Foundation	Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Project Promoting Support for Drug Discovery; Project for Cancer Research And Therapeutic Evolution (P-CREATE) from Japan Agency for Medical Research and development, AMED(Japan Agency for Medical Research and Development (AMED)); Yasuda Memorial Foundation	We thank Drs. Yuri Terao and Yuka Umeki at the Center for Medical Research and Education and Department of Molecular Biology and Biochemistry, respectively, Graduate School of Medicine, Osaka University for the technical assistance for the preparation of MISSION TRC shRNAs and mRNA, and qPCR, and Western blotting. This work was supported by Grants-in-Aid for Scientific Research (2013-2015) (No. 25250018) and to AK (2016-2017) (No. 16H06374) to AK, Grants-in-Aid for Scientific Research on Innovative Areas (2011-2015) (No. 23112004) to AK, Grants-in-Aid for Young Scientists (Start-up) (2016-2017) (No. 16H06944) to HK, and Grant-in-Aid for Young Scientists (B) (2015-2017) (No. T15K198870) to NS from the Ministry of Education, Culture, Sports, Science, and Technology of Japan, and also supported by the Project Promoting Support for Drug Discovery to KF and the Project for Cancer Research And Therapeutic Evolution (P-CREATE) to AK from the Japan Agency for Medical Research and development, AMED, and by grants to AK from the Yasuda Memorial Foundation.	Adams GP, 2005, NAT BIOTECHNOL, V23, P1147, DOI 10.1038/nbt1137; Aguilera O, 2006, ONCOGENE, V25, P4116, DOI 10.1038/sj.onc.1209439; Bendell JC, 2016, J CLIN ONCOL S4S, V34, DOI [10.1200/jco.2016.34.4_suppl.111., DOI 10.1200/JCO.2016.34.4_SUPPL.111.]; Conrads TP, 2006, J BIOL CHEM, V281, P37836, DOI 10.1074/jbc.M604581200; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Fujii S, 2015, ONCOGENE, V34, P4834, DOI 10.1038/onc.2014.402; Fulciniti M, 2009, BLOOD, V114, P371, DOI 10.1182/blood-2008-11-191577; Gao YB, 2014, NAT GENET, V46, P1097, DOI 10.1038/ng.3076; Gao ZH, 2014, ONCOL LETT, V7, P1118, DOI 10.3892/ol.2014.1881; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; Goldstein SD, 2016, ONCOTARGET, V7, P21114, DOI 10.18632/oncotarget.8522; Gonzalex-Sancho JM, 2005, ONCOGENE, V24, P1098, DOI 10.1038/sj.onc.1208303; Gupta N, 2006, AM J PHYSIOL-LUNG C, V291, pL436, DOI 10.1152/ajplung.00415.2005; Haniu M, 2011, PROTEIN SCI, V20, P1802, DOI 10.1002/pro.705; Hino S, 2005, MOL CELL BIOL, V25, P9063, DOI 10.1128/MCB.25.20.9063-9072.2005; ITAKURA Y, 1994, CANCER, V74, P795, DOI 10.1002/1097-0142(19940801)74:3<795::AID-CNCR2820740303>3.0.CO;2-I; Kikuchi A, 2011, INT REV CEL MOL BIO, V291, P21, DOI 10.1016/B978-0-12-386035-4.00002-1; Kimura H, 2016, J CLIN INVEST, V126, P2689, DOI 10.1172/JCI84658; Li J, 2006, BONE, V39, P754, DOI 10.1016/j.bone.2006.03.017; Li MH, 2013, CANCER LETT, V337, P248, DOI 10.1016/j.canlet.2013.05.003; Li SX, 2014, CANCER-AM CANCER SOC, V120, P1520, DOI 10.1002/cncr.28593; Li SJ, 2011, J MOL HISTOL, V42, P491, DOI 10.1007/s10735-011-9347-1; Lin DC, 2014, NAT GENET, V46, P467, DOI 10.1038/ng.2935; Maehata T, 2008, WORLD J GASTROENTERO, V14, P2702, DOI 10.3748/wjg.14.2702; Makino T, 2009, ANN SURG ONCOL, V16, P2058, DOI 10.1245/s10434-009-0476-7; Matsumoto S, 2014, EMBO J, V33, P702, DOI 10.1002/embj.201386942; Mitsuishi Y, 2012, CANCER CELL, V22, P66, DOI 10.1016/j.ccr.2012.05.016; Niehrs C, 2006, ONCOGENE, V25, P7469, DOI 10.1038/sj.onc.1210054; Niida A, 2004, ONCOGENE, V23, P8520, DOI 10.1038/sj.onc.1207892; Ohashi S, 2015, GASTROENTEROLOGY, V149, P1700, DOI 10.1053/j.gastro.2015.08.054; Pennathur A, 2013, LANCET, V381, P400, DOI 10.1016/S0140-6736(12)60643-6; Pinto D, 2003, GENE DEV, V17, P1709, DOI 10.1101/gad.267103; Razzaq TM, 2003, J BIOL CHEM, V278, P42679, DOI 10.1074/jbc.M305695200; Rustgi AK, 2014, NEW ENGL J MED, V371, P2499, DOI 10.1056/NEJMra1314530; Sato A, 2015, SCI REP-UK, V5, DOI 10.1038/srep10536; Sato N, 2010, CANCER RES, V70, P5326, DOI 10.1158/0008-5472.CAN-09-3879; SCHWEIZER A, 1993, J CELL SCI, V104, P671; Scott AM, 2012, NAT REV CANCER, V12, P278, DOI 10.1038/nrc3236; Shojima K, 2015, SCI REP-UK, V5, DOI 10.1038/srep08042; Song YM, 2014, NATURE, V509, P91, DOI 10.1038/nature13176; Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847; Vedrenne C, 2006, TRAFFIC, V7, P639, DOI 10.1111/j.1600-0854.2006.00419.x; Visser E, 2017, ONCOTARGET, V8, P5566, DOI 10.18632/oncotarget.13328; Yamabuki T, 2007, CANCER RES, V67, P2517, DOI 10.1158/0008-5472.CAN-06-3369; Zhang WC, 2014, ANN THORAC SURG, V98, P513, DOI 10.1016/j.athoracsur.2014.03.015	45	25	27	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	26					3471	3484		10.1038/s41388-018-0179-2	http://dx.doi.org/10.1038/s41388-018-0179-2			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GK7TM	29563607				2022-12-17	WOS:000436412500001
J	Shen, PY; Jing, Y; Zhang, RY; Cai, MC; Ma, PF; Chen, HG; Zhuang, GL				Shen, Peiye; Jing, Ying; Zhang, Ruiyun; Cai, Mei-Chun; Ma, Pengfei; Chen, Haige; Zhuang, Guanglei			Comprehensive genomic profiling of neuroendocrine bladder cancer pinpoints molecular origin and potential therapeutics	ONCOGENE			English	Article							SMALL-CELL CARCINOMA; URINARY-BLADDER; ANTIANDROGEN RESISTANCE; LINEAGE PLASTICITY; PROSTATE-CANCER	Neuroendocrine bladder cancer is a relatively rare but often lethal malignancy, with cell of origin, oncogenomic architecture and standard treatment poorly defined. Here we performed comprehensive whole-genome and transcriptome sequencing on a unique cohort of genitourinary neuroendocrine neoplasms, mainly small cell carcinomas of the urinary bladder. The mutational landscape and signatures of neuroendocrine bladder cancer strikingly resembled those in conventional urothelial carcinoma, along with typically mixed histologies, supporting a common cellular origin. We identified pervasive age-related and APOBEC-mediated mutagenesis patterns, and one patient displayed a somatic fingerprint attributable to aristolochic acid exposure, an established etiology of urothelial cell carcinoma. Deep RNA sequencing revealed dysregulated tumorigenic pathways and novel fusion transcripts, including a targetable in-frame PVT1-ERBB2 variant associated with aberrant expression of ERBB2 gene (encoding HER2 receptor). Furthermore, we provided preliminary evidence that combined TP53 and RB1 depletion favored lineage switching from oncogene-addicted urothelial cancer cells to neuroendocrine-like tumor cells, and resulted in decreased response to targeted agents. Together, these data present the first high-resolution genomic portrait of neuroendocrine bladder cancer, which holds important implications for the biological understanding and rational treatment of this deadly disease.	[Shen, Peiye; Jing, Ying; Cai, Mei-Chun; Ma, Pengfei; Zhuang, Guanglei] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, State Key Lab Oncogenes & Related Genes,Shanghai, Shanghai, Peoples R China; [Shen, Peiye] Shanghai Jiao Tong Univ, Sch Biomed Engn, Shanghai, Peoples R China; [Shen, Peiye] Shanghai Jiao Tong Univ, Med X Res Inst, Shanghai, Peoples R China; [Chen, Haige] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Urol, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Zhuang, GL (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, State Key Lab Oncogenes & Related Genes,Shanghai, Shanghai, Peoples R China.; Chen, HG (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Urol, Shanghai, Peoples R China.	kirbyhaige@aliyun.com; zhuangguanglei@gmail.com		Zhuang, Guanglei/0000-0001-8141-5096; Jing, Ying/0000-0001-6364-6130	National Natural Science Foundation of China [81672514, 81472537, 81672714, 81502597]; Shanghai Natural Science Foundation [16ZR1420300]; Foundation of Shanghai Hospital Development Center [SHDC12015125]; State Key Laboratory of Oncogenes and Related Genes [91-15-12, SB17-06]; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support [20161313]; Shanghai Institutions of Higher Learning; Shanghai Rising-Star Program [16QA1403600]; Shanghai Municipal Commission of Health and Family Planning [20174Y0189, 20174Y0043]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Natural Science Foundation(Natural Science Foundation of Shanghai); Foundation of Shanghai Hospital Development Center; State Key Laboratory of Oncogenes and Related Genes; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support; Shanghai Institutions of Higher Learning; Shanghai Rising-Star Program; Shanghai Municipal Commission of Health and Family Planning	This work was supported by the National Natural Science Foundation of China (81672514 to HC; 81472537 and 81672714 to GZ; 81502597 to YJ), Shanghai Natural Science Foundation (16ZR1420300 to HC), Foundation of Shanghai Hospital Development Center (SHDC12015125 to HC), the Grants from the State Key Laboratory of Oncogenes and Related Genes (no. 91-15-12 to GZ; SB17-06 to M-CC), Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (20161313 to GZ), the Shanghai Institutions of Higher Learning (Eastern Scholar to GZ), Shanghai Rising-Star Program (16QA1403600 to GZ), Shanghai Municipal Commission of Health and Family Planning (20174Y0189 to YJ and 20174Y0043 to M-CC).	Chang MT, 2017, CLIN CANC RES; Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349; Cheng L, 2005, AM J PATHOL, V166, P1533, DOI 10.1016/S0002-9440(10)62369-3; Gui YT, 2011, NAT GENET, V43, P875, DOI 10.1038/ng.907; Hoang ML, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006200; Kouba E, 2016, ENDOCR PATHOL, V27, P188, DOI 10.1007/s12022-016-9444-5; Kouba EJ, 2017, JAMA ONCOL, V3, P1570, DOI 10.1001/jamaoncol.2016.7013; Ku SY, 2017, SCIENCE, V355, P78, DOI 10.1126/science.aah4199; Mu P, 2017, SCIENCE, V355, P84, DOI 10.1126/science.aah4307; Niederst MJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7377; Poon SL, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006086; Priemer D.S., 2017, EUR UROL FOCUS; Rickman DS, 2017, NAT MED, V23, P664, DOI 10.1038/nm.4341; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965	15	25	28	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	22					3039	3044		10.1038/s41388-018-0192-5	http://dx.doi.org/10.1038/s41388-018-0192-5			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GH8RM	29535424				2022-12-17	WOS:000433936300010
J	Hanna, JA; Garcia, MR; Lardennois, A; Leavey, PJ; Maglic, D; Fagnan, A; Go, JC; Roach, J; Wang, YD; Finkelstein, D; Hatley, ME				Hanna, Jason A.; Garcia, Matthew R.; Lardennois, Alicia; Leavey, Patrick J.; Maglic, Dino; Fagnan, Alexandre; Go, Jonathan C.; Roach, Jordan; Wang, Yong-Dong; Finkelstein, David; Hatley, Mark E.			PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma	ONCOGENE			English	Article							DOWN-REGULATION; PEDIATRIC RHABDOMYOSARCOMA; MICRORNA THERAPEUTICS; NORMAL ERYTHROPOIESIS; TUMOR PROGRESSION; IN-VIVO; GENE; EXPRESSION; FUSION; CANCER	Rhabdomyosarcoma is the most common soft-tissue sarcoma in childhood and histologically resembles developing skeletal muscle. Alveolar rhabdomyosarcoma (ARMS) is an aggressive subtype with a higher rate of metastasis and poorer prognosis. The majority of ARMS tumors (80%) harbor a PAX3-FOXO1 or less commonly a PAX7-FOXO1 fusion gene. The presence of either the PAX3-FOXO1 or PAX7-FOXO1 fusion gene foretells a poorer prognosis resulting in clinical reclassification as either fusion-positive (FP-RMS) or fusion-negative RMS (FN-RMS). The PAX3/7-FOXO1 fusion genes result in the production of a rogue transcription factors that drive FP-RMS pathogenesis and block myogenic differentiation. Despite knowing the molecular driver of FP-RMS, targeted therapies have yet to make an impact for patients, highlighting the need for a greater understanding of the molecular consequences of PAX3-FOXO1 and its target genes including microRNAs. Here we show FP-RMS patient-derived xenografts and cell lines display a distinct microRNA expression pattern. We utilized both loss-and gain-of function approaches in human cell lines with knockdown of PAX3-FOXO1 in FP-RMS cell lines and expression of PAX3-FOXO1 in human myoblasts and identified microRNAs both positively and negatively regulated by the PAX3-FOXO1 fusion protein. We demonstrate PAX3-FOXO1 represses miR-221/222 that functions as a tumor suppressing microRNA through the negative regulation of CCND2, CDK6, and ERBB3. In contrast, miR-486-5p is transcriptionally activated by PAX3-FOXO1 and promotes FP-RMS proliferation, invasion, and clonogenic growth. Inhibition of miR-486-5p in FP-RMS xenografts decreased tumor growth, illustrating a proof of principle for future therapeutic intervention. Therefore, PAX3-FOXO1 regulates key microRNAs that may represent novel therapeutic vulnerabilities in FP-RMS.	[Hanna, Jason A.; Garcia, Matthew R.; Lardennois, Alicia; Leavey, Patrick J.; Maglic, Dino; Fagnan, Alexandre; Go, Jonathan C.; Roach, Jordan; Hatley, Mark E.] St Jude Childrens Res Hosp, Dept Oncol, 332 N Lauderdale St, Memphis, TN 38105 USA; [Wang, Yong-Dong; Finkelstein, David] St Jude Childrens Res Hosp, Dept Computat Biol, 332 N Lauderdale St, Memphis, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital	Hatley, ME (corresponding author), St Jude Childrens Res Hosp, Dept Oncol, 332 N Lauderdale St, Memphis, TN 38105 USA.	mark.hatley@stjude.org	Hanna, Jason A./N-6157-2018; Hatley, Mark Edward/G-8764-2018; Hanna, Jason/ABH-2969-2021	Hanna, Jason A./0000-0001-7253-7964; Hatley, Mark Edward/0000-0001-7147-3946; Hanna, Jason/0000-0001-7253-7964; Lardennois, Alicia/0000-0002-5054-7448	National Cancer Institute of the National Institutes of Health [R01CA216344, K08CA151649, 5R25CA23944]; V foundation for Cancer Research; Hyundai Hope on Wheels; Alex's Lemonade Stand Foundation; American Lebanese Syrian Associated Charities; NATIONAL CANCER INSTITUTE [R25CA023944, R01CA216344, K08CA151649, P30CA021765] Funding Source: NIH RePORTER	National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); V foundation for Cancer Research; Hyundai Hope on Wheels; Alex's Lemonade Stand Foundation; American Lebanese Syrian Associated Charities(American Lebanese Syrian Associated Charities (ALSAC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Cancer Institute of the National Institutes of Health under award numbers R01CA216344 and K08CA151649 to M.E.H. and 5R25CA23944 to D.M. and J.R. The Hatley lab is also supported by the V foundation for Cancer Research, Hyundai Hope on Wheels, and Alex's Lemonade Stand Foundation and by the American Lebanese Syrian Associated Charities.	Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005; Alexander MS, 2014, J CLIN INVEST, V124, P2651, DOI 10.1172/JCI73579; Alexander MS, 2011, SKELET MUSCLE, V1, DOI 10.1186/2044-5040-1-27; Ayyanathan K, 2000, CANCER RES, V60, P5803; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bernasconi M, 1996, P NATL ACAD SCI USA, V93, P13164, DOI 10.1073/pnas.93.23.13164; Bersani F, 2016, CANCER RES, V76, P6095, DOI 10.1158/0008-5472.CAN-16-0709; Brioschi M, 2010, NEOPLASIA, V12, P866, DOI 10.1593/neo.10482; Cardinali B, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.10; Cardinali B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007607; Chen L, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005075; Chen X, 2013, CANCER CELL, V24, P710, DOI 10.1016/j.ccr.2013.11.002; Ciarapica R, 2009, CELL CYCLE, V8, P172, DOI 10.4161/cc.8.1.7292; DAVIS RJ, 1994, CANCER RES, V54, P2869; Dey BK, 2011, MOL CELL BIOL, V31, P203, DOI 10.1128/MCB.01009-10; Di Leva G, 2014, ANNU REV PATHOL-MECH, V9, P287, DOI 10.1146/annurev-pathol-012513-104715; DOUGLASS EC, 1987, CYTOGENET CELL GENET, V45, P148, DOI 10.1159/000132446; Duan FH, 2012, GENE CHROMOSOME CANC, V51, P662, DOI 10.1002/gcc.21953; Ebauer M, 2007, ONCOGENE, V26, P7267, DOI 10.1038/sj.onc.1210525; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Felli N, 2005, P NATL ACAD SCI USA, V102, P18081, DOI 10.1073/pnas.0506216102; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Garofalo M, 2012, CURR MOL MED, V12, P27, DOI 10.2174/156652412798376170; Hanna JA, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.159; Hatley ME, 2012, CANCER CELL, V22, P536, DOI 10.1016/j.ccr.2012.09.004; Hatley ME, 2010, CANCER CELL, V18, P282, DOI 10.1016/j.ccr.2010.08.013; Hausser J, 2014, NAT REV GENET, V15, P599, DOI 10.1038/nrg3765; Hitachi K, 2014, INT J BIOCHEM CELL B, V47, P93, DOI 10.1016/j.biocel.2013.12.003; Karakatsanis A, 2013, MOL CARCINOGEN, V52, P297, DOI 10.1002/mc.21864; Kashi VP, 2015, NAT REV CANCER, V15, P426, DOI 10.1038/nrc3961; Kneitz B, 2014, CANCER RES, V74, P2591, DOI 10.1158/0008-5472.CAN-13-1606; Koelz M, 2011, INT J ONCOL, V38, P503, DOI 10.3892/ijo.2010.857; Li L, 2012, LAB INVEST, V92, P571, DOI 10.1038/labinvest.2012.10; Machado E, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500603; Mahajan P, 2015, ONCOGENE, V34, P2681, DOI 10.1038/onc.2014.209; Marshall AD, 2012, SKELET MUSCLE, V2, DOI 10.1186/2044-5040-2-25; Matsuzaki J, 2015, J CLIN MED, V4, P1566, DOI 10.3390/jcm4081566; Missiaglia E, 2017, CANCER LETT, V385, P251, DOI 10.1016/j.canlet.2016.10.011; Missiaglia E, 2012, J CLIN ONCOL, V30, P1670, DOI 10.1200/JCO.2011.38.5591; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Mosakhani N, 2012, GENE CHROMOSOME CANC, V51, P1, DOI 10.1002/gcc.20925; Narducci MG, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.32; Nordberg J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050819; Oh HK, 2011, CLIN CANCER RES, V17, P2657, DOI 10.1158/1078-0432.CCR-10-3152; Omura N, 2016, ONCOTARGET, V7, P34977, DOI 10.18632/oncotarget.9009; Parham DM, 2013, WHO CLASSIFICATION T, P130; Peng Y, 2013, P NATL ACAD SCI USA, V110, P15043, DOI 10.1073/pnas.1307107110; Petak I, 2000, CLIN CANCER RES, V6, P4119; Poliseno L, 2006, BLOOD, V108, P3068, DOI 10.1182/blood-2006-01-012369; Porkka KP, 2007, CANCER RES, V67, P6130, DOI 10.1158/0008-5472.CAN-07-0533; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Ricci C, 2000, INT J CANCER, V87, P29, DOI 10.1002/1097-0215(20000701)87:1<29::AID-IJC5>3.3.CO;2-A; Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246; Saab R, 2006, MOL CANCER THER, V5, P1299, DOI 10.1158/1535-7163.MCT-05-0383; Seyyedi SS, 2016, TUMOR BIOL, V37, P4841, DOI 10.1007/s13277-015-4289-y; Shaham L, 2015, BLOOD, V125, P1292, DOI 10.1182/blood-2014-06-581892; SHAPIRO DN, 1993, CANCER RES, V53, P5108; Shern JF, 2014, CANCER DISCOV, V4, P216, DOI 10.1158/2159-8290.CD-13-0639; Skapek SX, 2013, PEDIATR BLOOD CANCER, V60, P1411, DOI 10.1002/pbc.24532; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Small EM, 2010, P NATL ACAD SCI USA, V107, P4218, DOI 10.1073/pnas.1000300107; Song LB, 2013, CELL RES, V23, P274, DOI 10.1038/cr.2012.174; Sorensen PHB, 2002, J CLIN ONCOL, V20, P2672, DOI 10.1200/JCO.2002.03.137; Stewart E, 2016, DEV BIOL, V411, P287, DOI 10.1016/j.ydbio.2015.03.001; Subramanian S, 2008, ONCOGENE, V27, P2015, DOI 10.1038/sj.onc.1210836; Sultan I, 2009, J CLIN ONCOL, V27, P3391, DOI 10.1200/JCO.2008.19.7483; Svoronos AA, 2016, CANCER RES, V76, P3666, DOI 10.1158/0008-5472.CAN-16-0359; van Rooij E, 2012, NAT REV DRUG DISCOV, V11, P860, DOI 10.1038/nrd3864; Wang LS, 2015, BLOOD, V125, P1302, DOI 10.1182/blood-2014-06-581926; Wiederschain D, 2009, CELL CYCLE, V8, P498, DOI 10.4161/cc.8.3.7701; Williamson D, 2010, J CLIN ONCOL, V28, P2151, DOI 10.1200/JCO.2009.26.3814; Xu J, 2012, KIDNEY INT, V82, P401, DOI 10.1038/ki.2012.84; Yang QE, 2013, DEVELOPMENT, V140, P280, DOI 10.1242/dev.087403; Youness RA, 2016, ONCOL LETT, V12, P2567, DOI 10.3892/ol.2016.4914; Zhang JS, 2004, CANCER RES, V64, P6026, DOI 10.1158/0008-5472.CAN-03-2594; Zhou DX, 1997, J CELL BIOL, V136, P621, DOI 10.1083/jcb.136.3.621; Zhu CH, 2007, AGING CELL, V6, P515, DOI 10.1111/j.1474-9726.2007.00306.x	78	25	27	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	15					1991	2007		10.1038/s41388-017-0081-3	http://dx.doi.org/10.1038/s41388-017-0081-3			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GC6KH	29367756	hybrid, Green Published, Green Accepted			2022-12-17	WOS:000429899400004
J	Goreczny, GJ; Forsythe, IJ; Turner, CE				Goreczny, Gregory J.; Forsythe, Ian J.; Turner, Christopher E.			Hic-5 regulates fibrillar adhesion formation to control tumor extracellular matrix remodeling through interaction with tensin1	ONCOGENE			English	Article							FOCAL-ADHESION; BREAST-CANCER; IN-VIVO; PAXILLIN; INTEGRINS; PROTEIN; FIBRONECTIN; BINDING; KINASE; ACTIN	The linearization of the stromal extracellular matrix (ECM) by cancer-associated fibroblasts (CAFs) facilitates tumor cell growth and metastasis. However, the mechanism by which the ECM is remodeled is not fully understood. Hic-5 (TGF beta 1i1), a focal adhesion scaffold protein, has previously been reported to be crucial for stromal ECM deposition and remodeling in vivo. Herein we show that CAFs lacking Hic-5 exhibit a significant reduction in the ability to form fibrillar adhesions, a specialized form of focal adhesion that promote fibronectin fibrillogenesis. Hic-5 was found to promote fibrillar adhesion formation through a newly characterized interaction with tensin1. Furthermore, Src-dependent phosphorylation of Hic-5 facilitated the interaction with tensin1 to prevent beta 1 integrin internalization and trafficking to the lysosome. The interaction between Hic-5 and tensin1 was mechanosensitive, promoting fibrillar adhesion formation and fibronectin fibrillogenesis in a rigidity-dependent fashion. Importantly, this Src-dependent mechanism was conserved in three-dimensional (3D) ECM environments. Immunohistochemistry of tensin1 showed enrichment in CAFs in vivo, which was abrogated upon deletion of Hic-5. Interestingly, elevated Hic-5 expression correlates with reduced distant metastasis-free survival in patients with basal-like, HER2+ and grade 3 tumors. Thus, we have identified Hic-5 as a crucial regulator of ECM remodeling in CAFs by promoting fibrillar adhesion formation through a novel interaction with tensin1.	[Goreczny, Gregory J.; Forsythe, Ian J.; Turner, Christopher E.] SUNY Upstate Med Univ, Dept Cell & Dev Biol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Turner, CE (corresponding author), SUNY Upstate Med Univ, Dept Cell & Dev Biol, Syracuse, NY 13210 USA.	turnerce@upstate.edu			National Institutes of Health [R01 CA163296, R01 GM047607]; Carol M Baldwin Breast Cancer Research Fund of CNY; NATIONAL CANCER INSTITUTE [R01CA163296] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047607] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Carol M Baldwin Breast Cancer Research Fund of CNY; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We would like to thank members of the Turner lab for helpful discussions and critical reading of this manuscript and thank Theresa Stowell for performing the qPCR analyses. Financial Support: National Institutes of Health Grant R01 CA163296 and R01 GM047607 to CET and the Carol M Baldwin Breast Cancer Research Fund of CNY awards to CET.	Acerbi I, 2015, INTEGR BIOL-UK, V7, P1120, DOI 10.1039/c5ib00040h; Bottcher RT, 2012, NAT CELL BIOL, V14, P584, DOI 10.1038/ncb2501; Boyd NF, 2005, LANCET ONCOL, V6, P798, DOI 10.1016/S1470-2045(05)70390-9; Brown MC, 2004, PHYSIOL REV, V84, P1315, DOI 10.1152/physrev.00002.2004; Carraher CL, 2013, J BIOL CHEM, V288, P14805, DOI 10.1074/jbc.M112.435271; Caswell PT, 2009, NAT REV MOL CELL BIO, V10, P843, DOI 10.1038/nrm2799; Chao WT, 2009, FEBS LETT, V583, P1337, DOI 10.1016/j.febslet.2009.03.037; Conklin MW, 2011, AM J PATHOL, V178, P1221, DOI 10.1016/j.ajpath.2010.11.076; Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829; DAVIS S, 1991, SCIENCE, V252, P712, DOI 10.1126/science.1708917; Deakin NO, 2014, J CELL BIOL, V206, P395, DOI 10.1083/jcb.201403039; Deakin NO, 2011, MOL BIOL CELL, V22, P327, DOI 10.1091/mbc.E10-09-0790; Deakin Nicholas O, 2012, Genes Cancer, V3, P362, DOI 10.1177/1947601912458582; Deakin NO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037990; Doyle AD, 2016, EXP CELL RES, V343, P60, DOI 10.1016/j.yexcr.2015.10.033; Ezratty EJ, 2009, J CELL BIOL, V187, P733, DOI 10.1083/jcb.200904054; Friedland JC, 2009, SCIENCE, V323, P642, DOI 10.1126/science.1168441; Fujita H, 1998, J BIOL CHEM, V273, P26516, DOI 10.1074/jbc.273.41.26516; Georgiadou M, 2017, J CELL BIOL, V216, P1107, DOI 10.1083/jcb.201609066; Goreczny GJ, 2017, ONCOGENE, V36, P2693, DOI 10.1038/onc.2016.422; Hall EH, 2010, MOL CELL PROTEOMICS, V9, P2853, DOI 10.1074/mcp.M110.003665; Kadler KE, 2008, CURR OPIN CELL BIOL, V20, P495, DOI 10.1016/j.ceb.2008.06.008; Kim-Kaneyama J, 2005, J CELL SCI, V118, P937, DOI 10.1242/jcs.01683; Kolacna L, 2007, PHYSIOL RES, V56, pS51, DOI 10.33549/physiolres.931302; Legate KR, 2009, J CELL SCI, V122, P187, DOI 10.1242/jcs.041624; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; LO SH, 1994, J CELL BIOL, V125, P1067, DOI 10.1083/jcb.125.5.1067; Lu PF, 2012, J CELL BIOL, V196, P395, DOI 10.1083/jcb.201102147; Molkentin JD, 2017, CIRCULATION, V136, P549, DOI 10.1161/CIRCULATIONAHA.116.026238; Nikolopoulos SN, 2000, J CELL BIOL, V151, P1435, DOI 10.1083/jcb.151.7.1435; Nikolopoulos SN, 2001, J BIOL CHEM, V276, P23499, DOI 10.1074/jbc.M102163200; Pankov R, 2000, J CELL BIOL, V148, P1075, DOI 10.1083/jcb.148.5.1075; Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010; Pickup MW, 2014, EMBO REP, V15, P1243, DOI 10.15252/embr.201439246; Pignatelli J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046228; Pignatelli J, 2012, J CELL BIOL, V197, P421, DOI 10.1083/jcb.201108143; Provenzano PP, 2011, J CELL SCI, V124, P1195, DOI 10.1242/jcs.067009; Rainero E, 2015, CELL REP, V10, P398, DOI 10.1016/j.celrep.2014.12.037; Ringner M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017911; Schiller HB, 2013, NAT CELL BIOL, V15, P625, DOI 10.1038/ncb2747; Schwartz MA, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a005066; Singh P, 2010, ANNU REV CELL DEV BI, V26, P397, DOI 10.1146/annurev-cellbio-100109-104020; Stanchi F, 2009, J CELL SCI, V122, P1800, DOI 10.1242/jcs.044602; Stutchbury B, 2017, J CELL SCI, V130, P1612, DOI 10.1242/jcs.195362; Tchou J, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-39; Thomas SM, 1999, J CELL SCI, V112, P181; Torgler CN, 2004, DEV CELL, V6, P357, DOI 10.1016/S1534-5807(04)00055-3; Tumbarello DA, 2007, J CELL PHYSIOL, V211, P736, DOI 10.1002/jcp.20991; Volberg T, 2001, J CELL SCI, V114, P2279; Wormer DB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091815; Zaidel-Bar R, 2007, J CELL SCI, V120, P137, DOI 10.1242/jcs.03314; Zamir E, 2000, NAT CELL BIOL, V2, P191, DOI 10.1038/35008607; Zhao ZH, 2016, BIOL OPEN, V5, P499, DOI 10.1242/bio.016428	53	25	25	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	13					1699	1713		10.1038/s41388-017-0074-2	http://dx.doi.org/10.1038/s41388-017-0074-2			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GA9AE	29348458	Green Accepted			2022-12-17	WOS:000428632600002
J	Rasheed, SAK; Leong, HS; Lakshmanan, M; Raju, A; Dadlani, D; Chong, FT; Shannon, NB; Rajarethinam, R; Skanthakumar, T; Tan, EY; Hwang, JSG; Lim, KH; Tan, DSW; Ceppi, P; Wang, M; Tergaonkar, V; Casey, PJ; Iyer, NG				Rasheed, Suhail Ahmed Kabeer; Leong, Hui Sun; Lakshmanan, Manikandan; Raju, Anandhkumar; Dadlani, Dhivya; Chong, Fui-Teen; Shannon, Nicholas B.; Rajarethinam, Ravisankar; Skanthakumar, Thakshayeni; Tan, Ern Yu; Hwang, Jacqueline Siok Gek; Lim, Kok Hing; Tan, Daniel Shao-Weng; Ceppi, Paolo; Wang, Mei; Tergaonkar, Vinay; Casey, Patrick J.; Iyer, N. Gopalakrishna			GNA13 expression promotes drug resistance and tumor-initiating phenotypes in squamous cell cancers	ONCOGENE			English	Article							HETEROTRIMERIC G-PROTEINS; EPIDERMAL-GROWTH-FACTOR; BREAST-CANCER; STEM-CELLS; MESENCHYMAL TRANSITION; MICROARRAY DATA; BETA-CATENIN; LUNG-CANCER; G12 FAMILY; METASTASIS	Treatment failure in solid tumors occurs due to the survival of specific subpopulations of cells that possess tumor-initiating (TIC) phenotypes. Studies have implicated G protein-coupled-receptors (GPCRs) in cancer progression and the acquisition of TIC phenotypes. Many of the implicated GPCRs signal through the G protein GNA13. In this study, we demonstrate that GNA13 is upregulated in many solid tumors and impacts survival and metastases in patients. GNA13 levels modulate drug resistance and TIC-like phenotypes in patient-derived head and neck squamous cell carcinoma (HNSCC) cells in vitro and in vivo. Blockade of GNA13 expression, or of select downstream pathways, using small-molecule inhibitors abrogates GNA13-induced TIC phenotypes, rendering cells vulnerable to standard-of-care cytotoxic therapies. Taken together, these data indicate that GNA13 expression is a potential prognostic biomarker for tumor progression, and that interfering with GNA13-induced signaling provides a novel strategy to block TICs and drug resistance in HNSCCs.	[Rasheed, Suhail Ahmed Kabeer; Dadlani, Dhivya; Wang, Mei; Casey, Patrick J.; Iyer, N. Gopalakrishna] Duke NUS Med Sch, Programme Canc & Stem Cell Biol, Singapore, Singapore; [Leong, Hui Sun; Chong, Fui-Teen; Tan, Daniel Shao-Weng; Iyer, N. Gopalakrishna] Natl Canc Ctr, Canc Therapeut Res Lab, Singapore, Singapore; [Lakshmanan, Manikandan; Raju, Anandhkumar; Tergaonkar, Vinay] Inst Mol & Cell Biol, Mouse Models Human Canc Unit, Singapore, Singapore; [Shannon, Nicholas B.; Skanthakumar, Thakshayeni; Iyer, N. Gopalakrishna] Natl Canc Ctr, Dept Surg Oncol, Singapore, Singapore; [Rajarethinam, Ravisankar] Adv Mol Pathol Lab, Singapore, Singapore; [Tan, Ern Yu] Tan Tock Seng Hosp, Dept Gen Surg, Singapore, Singapore; [Hwang, Jacqueline Siok Gek; Lim, Kok Hing] Singapore Gen Hosp, Dept Pathol, Singapore, Singapore; [Ceppi, Paolo] Friedrich Alexander Univ Erlangen Nuernberg, IZKF Jr Res Grp, Erlangen, Germany; [Casey, Patrick J.] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC USA	National University of Singapore; National Cancer Centre Singapore (NCCS); Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National Cancer Centre Singapore (NCCS); Tan Tock Seng Hospital; Singapore General Hospital; University of Erlangen Nuremberg; Duke University	Casey, PJ; Iyer, NG (corresponding author), Duke NUS Med Sch, Programme Canc & Stem Cell Biol, Singapore, Singapore.; Iyer, NG (corresponding author), Natl Canc Ctr, Canc Therapeut Res Lab, Singapore, Singapore.; Iyer, NG (corresponding author), Natl Canc Ctr, Dept Surg Oncol, Singapore, Singapore.	patrick.casey@duke-nus.edu.sg; gopaliyer@nccs.com.sg	Rasheed, Suhail Ahmed Kabeer/P-1257-2019; Ceppi, Paolo/GPS-8668-2022	Rasheed, Suhail Ahmed Kabeer/0000-0002-7674-7560; Ceppi, Paolo/0000-0002-3632-8476; Shannon, Nicholas Brian/0000-0001-8742-8285; Wang, Mei/0000-0001-6887-6840; Casey, Patrick/0000-0002-7366-9309	National Medical Research Council, Singapore [NMRC/BNIG/2041/2015, NMRC/CBRG/0044/2013, NMRC/CSA-INV/011/2016, NMRC/CIRG/1434/2015]; Inter- disciplinary Center for Clinical Research (IZKF) at the University Hospital of the University of Erlangen-Nuremberg	National Medical Research Council, Singapore(National Medical Research Council, Singapore); Inter- disciplinary Center for Clinical Research (IZKF) at the University Hospital of the University of Erlangen-Nuremberg	This work was supported by grants from National Medical Research Council, Singapore (NMRC/BNIG/2041/2015 to SAKR, NMRC/CBRG/0044/2013 to PJC, NMRC/CSA-INV/011/2016 and NMRC/CIRG/1434/2015 to NGI). PC was supported by the Inter- disciplinary Center for Clinical Research (IZKF) at the University Hospital of the University of Erlangen-Nuremberg.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chia S, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00451-5; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Ghosh P, 2015, AGING-US, V7, P469, DOI 10.18632/aging.100781; Goldsmith ZG, 2007, ONCOGENE, V26, P3122, DOI 10.1038/sj.onc.1210407; Gyorffy B, 2012, ENDOCR-RELAT CANCER, V19, P197, DOI 10.1530/ERC-11-0329; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Hong X, 2014, EMBO J, V33, P2447, DOI 10.15252/embj.201489385; Ibrahim EE, 2012, STEM CELLS, V30, P2076, DOI 10.1002/stem.1182; Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808; Juneja J, 2009, BRIT J PHARMACOL, V158, P32, DOI 10.1111/j.1476-5381.2009.00180.x; Kaplan DD, 2001, J BIOL CHEM, V276, P44037, DOI 10.1074/jbc.M106121200; Kelley GG, 2004, BIOCHEM J, V378, P129, DOI 10.1042/BJ20031370; Kelly P, 2007, BIOCHEMISTRY-US, V46, P6677, DOI 10.1021/bi700235f; Kelly P, 2006, J BIOL CHEM, V281, P26483, DOI 10.1074/jbc.M604376200; Kelly P, 2006, P NATL ACAD SCI USA, V103, P8173, DOI 10.1073/pnas.0510254103; Kuo SZ, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-556; Lappano R, 2012, ACTA PHARMACOL SIN, V33, P351, DOI 10.1038/aps.2011.183; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; Leong HS, 2014, STEM CELL TRANSL MED, V3, P1055, DOI 10.5966/sctm.2013-0214; Liu SC, 2009, CANCER RES, V69, P6122, DOI 10.1158/0008-5472.CAN-08-3435; Ma I, 2011, STEM CELL REV REP, V7, P292, DOI 10.1007/s12015-010-9208-4; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mo JS, 2014, EMBO REP, V15, P642, DOI 10.15252/embr.201438638; Montgomery ER, 2014, MOL PHARMACOL, V85, P586, DOI 10.1124/mol.113.088443; O'Hayre M, 2014, CURR OPIN CELL BIOL, V27, P126, DOI 10.1016/j.ceb.2014.01.005; Pattabiraman DR, 2014, NAT REV DRUG DISCOV, V13, P497, DOI 10.1038/nrd4253; Prud'homme GJ, 2012, CURR PHARM DESIGN, V18, P2838; Rasheed SAK, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0337-x; Rasheed SAK, 2013, J BIOL CHEM, V288, P7986, DOI 10.1074/jbc.M112.437749; Rasheed SAK, 2010, INT J CANCER, V127, P1475, DOI 10.1002/ijc.25315; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Saha S, 2016, CANCER RES, V76, P2000, DOI 10.1158/0008-5472.CAN-15-1360; Singh JK, 2013, CLIN CANCER RES, V19, P643, DOI 10.1158/1078-0432.CCR-12-1063; Szasz AM, 2016, ONCOTARGET, V7, P49322, DOI 10.18632/oncotarget.10337; Tan DSW, 2017, NAT MED, V23, P1167, DOI 10.1038/nm.4401; Teo CR, 2016, CELL SIGNAL, V28, P1479, DOI 10.1016/j.cellsig.2016.07.001; Turm H, 2010, J BIOL CHEM, V285, P15137, DOI 10.1074/jbc.M109.072843; Vermeulen L, 2008, P NATL ACAD SCI USA, V105, P13427, DOI 10.1073/pnas.0805706105; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; von Rahden BHA, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-23; Yagi H, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002221; Yi TF, 2014, P NATL ACAD SCI USA, V111, pE2182, DOI 10.1073/pnas.1404943111; Yip NC, 2011, BRIT J CANCER, V104, P1564, DOI 10.1038/bjc.2011.126; Yu FX, 2012, CELL, V150, P780, DOI 10.1016/j.cell.2012.06.037; Zhang HH, 2013, INT J CLIN EXP PATHO, V6, P1734; Zhang JX, 2014, ANN ONCOL, V25, P2196, DOI 10.1093/annonc/mdu439; Zhang JX, 2016, ONCOTARGET, V7, P4414, DOI 10.18632/oncotarget.6780; Zhao Y, 2008, ONCOGENE, V27, P1, DOI 10.1038/sj.onc.1210625	52	25	26	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	10					1340	1353		10.1038/s41388-017-0038-6	http://dx.doi.org/10.1038/s41388-017-0038-6			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ0RI	29255247	Green Published, hybrid			2022-12-17	WOS:000427279300006
J	Yang, JB; Zhao, ZB; Liu, QZ; Hu, TD; Long, J; Yan, K; Lian, ZX				Yang, Jing-Bo; Zhao, Zhi-Bin; Liu, Qing-Zhi; Hu, Tai-Dou; Long, Jie; Yan, Kai; Lian, Zhe-Xiong			FoxO1 is a regulator of MHC-II expression and anti-tumor effect of tumor-associated macrophages	ONCOGENE			English	Article							DENDRITIC CELLS; MYELOID CELLS; IN-VIVO; PROGRESSION; CANCER; POLARIZATION; METASTASIS; HYPOXIA; MICE; INVASION	Macrophages are a critical component in host immune responses against tumor. In this work we investigated the role of forkhead box O1 (FoxO1) in the transcriptional regulation in macrophages, which affects the anti-tumor functions of tumor-associated macrophages (TAMs). First, we showed that TAMs expressed reduced levels of FoxO1, which was associated with their protumoral M2 polarization state. The suppression of FoxO1 expression in TAM was induced by the hypoxic condition in the tumor microenviroment. Next, we confirmed that FoxO1 positively regulates MHC-II genes by binding to the promoter region of Ciita gene, the master activator of multiple MHC-II genes. Loss of FoxO1 in TAMs resulted in reduced MHC-II expression. Furthermore, we used FoxO1 conditional knockout mice to show that FoxO1 deficiency in myeloid cells exacerbates tumor growth. These results demonstrate that the protumoral property of TAMs is induced by the hypoxia-triggered FoxO1 deficiency, which could be a potential target of novel anti-tumor therapies.	[Yang, Jing-Bo; Zhao, Zhi-Bin; Liu, Qing-Zhi; Hu, Tai-Dou; Long, Jie; Yan, Kai; Lian, Zhe-Xiong] Univ Sci & Technol China, Sch Life Sci, CAS Key Lab Innate Immun & Chron Dis, Liver Immunol Lab, Hefei, Anhui, Peoples R China; [Yang, Jing-Bo; Zhao, Zhi-Bin; Liu, Qing-Zhi; Hu, Tai-Dou; Long, Jie; Yan, Kai; Lian, Zhe-Xiong] Univ Sci & Technol China, Med Ctr, Hefei, Anhui, Peoples R China; [Zhao, Zhi-Bin; Liu, Qing-Zhi; Hu, Tai-Dou; Long, Jie; Yan, Kai; Lian, Zhe-Xiong] South China Univ Technol, Inst Life Sci, Chron Dis Lab, Guangzhou, Guangdong, Peoples R China; [Zhao, Zhi-Bin; Liu, Qing-Zhi; Hu, Tai-Dou; Long, Jie; Yan, Kai; Lian, Zhe-Xiong] South China Univ Technol, Sch Med, Guangzhou, Guangdong, Peoples R China; [Lian, Zhe-Xiong] Hefei Natl Lab Phys Sci Microscale, Innovat Ctr Cell Signaling Network, Hefei, Anhui, Peoples R China	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; South China University of Technology; South China University of Technology	Lian, ZX (corresponding author), Univ Sci & Technol China, Sch Life Sci, CAS Key Lab Innate Immun & Chron Dis, Liver Immunol Lab, Hefei, Anhui, Peoples R China.; Lian, ZX (corresponding author), Univ Sci & Technol China, Med Ctr, Hefei, Anhui, Peoples R China.; Lian, ZX (corresponding author), South China Univ Technol, Inst Life Sci, Chron Dis Lab, Guangzhou, Guangdong, Peoples R China.; Lian, ZX (corresponding author), South China Univ Technol, Sch Med, Guangzhou, Guangdong, Peoples R China.; Lian, ZX (corresponding author), Hefei Natl Lab Phys Sci Microscale, Innovat Ctr Cell Signaling Network, Hefei, Anhui, Peoples R China.	zxlian1@ustc.edu.cn	Liu, Qing-zhi/B-3140-2019; 刘, 清枝/GLR-7060-2022; Zhao, Zhi-Bin/V-3278-2017	Zhao, Zhi-Bin/0000-0003-0691-2556	National Natural Science Foundation of China [81430034, 91542123]; National Basic Research Program of China under Grant 973 Program [2013CB944900]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Basic Research Program of China under Grant 973 Program(National Basic Research Program of China)	This work was supported by the National Natural Science Foundation of China under Grant 81430034 and 91542123; National Basic Research Program of China under Grant 973 Program-2013CB944900.	Allavena P, 2008, CRIT REV ONCOL HEMAT, V66, P1, DOI 10.1016/j.critrevonc.2007.07.004; Anaya J, 2016, PEERJ COMPUT SCI, DOI 10.7717/peerj-cs.67; Beatty GL, 2011, SCIENCE, V331, P1612, DOI 10.1126/science.1198443; Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937; Chen J, 2014, TUMOR BIOL, V35, P7195, DOI 10.1007/s13277-014-1913-1; Chung S, 2016, ONCOTARGET, V7, P17532, DOI 10.18632/oncotarget.8162; Chung S, 2015, J LEUKOCYTE BIOL, V97, P327, DOI 10.1189/jlb.3A0514-251R; Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960; Coates PJ, 2008, CANCER RES, V68, P450, DOI 10.1158/0008-5472.CAN-07-3050; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Cramer T, 2003, CELL, V112, P645, DOI 10.1016/S0092-8674(03)00154-5; Doedens AL, 2010, CANCER RES, V70, P7465, DOI 10.1158/0008-5472.CAN-10-1439; Fan WQ, 2010, EMBO J, V29, P4223, DOI 10.1038/emboj.2010.268; Fukuda Koji, 2012, Front Biosci (Schol Ed), V4, P787; Gosselin D, 2014, CELL, V159, P1327, DOI 10.1016/j.cell.2014.11.023; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Huang HJ, 2011, BBA-MOL CELL RES, V1813, P1961, DOI 10.1016/j.bbamcr.2011.01.007; Jiang GS, 2016, CANCER PREV RES, V9, P567, DOI 10.1158/1940-6207.CAPR-15-0338; Kode A, 2016, LEUKEMIA, V30, P1, DOI 10.1038/leu.2015.161; Kusmartsev S, 2002, CANCER IMMUNOL IMMUN, V51, P293, DOI 10.1007/s00262-002-0280-8; Li QS, 2004, CANCER RES, V64, P1130, DOI 10.1158/0008-5472.CAN-03-1715; Lu HR, 2011, NEOPLASIA, V13, P854, DOI 10.1593/neo.11594; Maiese K, 2009, OXID MED CELL LONGEV, V2, P119, DOI 10.4161/oxim.2.3.8916; Mathelier A, 2016, NUCLEIC ACIDS RES, V44, pD110, DOI 10.1093/nar/gkv1176; Matsuzaki H, 2003, P NATL ACAD SCI USA, V100, P11285, DOI 10.1073/pnas.1934283100; Moritoki Y, 2009, GASTROENTEROLOGY, V136, P1037, DOI 10.1053/j.gastro.2008.11.035; Movahedi K, 2010, CANCER RES, V70, P5728, DOI 10.1158/0008-5472.CAN-09-4672; Murdoch C, 2008, NAT REV CANCER, V8, P618, DOI 10.1038/nrc2444; Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010; Orsini G, 2013, INT J MOL SCI, V14, P22022, DOI 10.3390/ijms141122022; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Pardee AD, 2014, J IMMUNOL, V193, P5723, DOI 10.4049/jimmunol.1400725; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Rolny C, 2011, CANCER CELL, V19, P31, DOI 10.1016/j.ccr.2010.11.009; Schartner JM, 2005, GLIA, V51, P279, DOI 10.1002/glia.20201; Sica A, 2008, SEMIN CANCER BIOL, V18, P349, DOI 10.1016/j.semcancer.2008.03.004; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Sykes SM, 2011, CELL, V146, P697, DOI 10.1016/j.cell.2011.07.032; Tikhanovich I, 2013, J GASTROEN HEPATOL, V28, P125, DOI 10.1111/jgh.12021; Varia MA, 1998, GYNECOL ONCOL, V71, P270, DOI 10.1006/gyno.1998.5163; Wang BF, 2011, BMC IMMUNOL, V12, DOI 10.1186/1471-2172-12-43; Wang YC, 2016, CLIN REV ALLERG IMMU, V51, P353, DOI 10.1007/s12016-016-8531-1; White JR, 2004, GENOMICS, V83, P1, DOI 10.1016/S0888-7543(03)00215-5; Wynn TA, 2013, NATURE, V496, P445, DOI 10.1038/nature12034; Yang YQ, 2016, ONCOTARGET, V7, P26992, DOI 10.18632/oncotarget.8853; Yao Y, 2014, J AUTOIMMUN, V51, P99, DOI 10.1016/j.jaut.2014.02.009; Ying W, 2013, JOVE-J VIS EXP, DOI 10.3791/50323; Zhao Y, 2010, NAT CELL BIOL, V12, P665, DOI 10.1038/ncb2069	49	25	27	0	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	9					1192	1204		10.1038/s41388-017-0048-4	http://dx.doi.org/10.1038/s41388-017-0048-4			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FY0MK	29238041				2022-12-17	WOS:000426505400005
J	Fujishita, T; Kojima, Y; Kajino-Sakamoto, R; Taketo, MM; Aoki, M				Fujishita, T.; Kojima, Y.; Kajino-Sakamoto, R.; Taketo, M. M.; Aoki, M.			Tumor microenvironment confers mTOR inhibitor resistance in invasive intestinal adenocarcinoma	ONCOGENE			English	Article							RENAL-CELL CARCINOMA; APC(DELTA-716) MICE; ANTITUMOR-ACTIVITY; COLORECTAL-CANCER; KINASE INHIBITOR; POLYP FORMATION; BREAST-CANCER; AZD8055; THERAPY; GRB10	Mechanistic target of rapamycin (mTOR) complex 1 (mTORC1) is frequently activated in cancers and can be counteracted with the clinical mTORC1 inhibitors everolimus and temsirolimus. Although mTORC1 and dual mTORC1/2 inhibitors are currently under development to treat various malignancies, the emergence of drug resistance has proven to be a major complication. Using the cis-Apc/Smad4 mouse model of locally invasive intestinal adenocarcinoma, we show that administration of everolimus or the dual mTORC1/2 inhibitor AZD8055 significantly reduces the growth of intestinal tumors. In contrast, although everolimus treatment at earlier phase of tumor progression delayed invasion of the tumors, both inhibitors exhibited little effect on blocking invasion of the tumors when administered later in their progression. Biochemical and immunohistochemical analyses revealed that treatment of cis-Apc/Smad4 mice with everolimus or AZD8055 induced marked increases in epidermal growth factor receptor (EGFR) and MEK/ERK signaling in tumor epithelial and stromal cells, respectively. Notably, co-administration of AZD8055 and the EGFR inhibitor erlotinib or the MEK inhibitor trametinib was sufficient to suppress tumor invasion in cis-Apc/Smad4 mice. These data indicate that mTOR inhibitor resistance in invasive intestinal tumors involves feedback signaling from both cancer epithelial and stromal cells, highlighting the role of tumor microenvironment in drug resistance, and support that simultaneous inhibition of mTOR and EGFR or MEK may be more effective in treating colon cancer.	[Fujishita, T.; Kojima, Y.; Kajino-Sakamoto, R.; Aoki, M.] Aichi Canc Ctr, Div Mol Pathol, Res Inst, Nagoya, Aichi, Japan; [Fujishita, T.; Taketo, M. M.] Kyoto Univ, Grad Sch Med, Dept Pharmacol, Sakyo Ku, Yoshida Konoe Cho, Kyoto, Japan; [Aoki, M.] Nagoya Univ, Grad Sch Med, Program Funct Construct Med, Dept Canc Genet, Nagoya, Aichi, Japan	Aichi Cancer Center; Kyoto University; Nagoya University	Aoki, M (corresponding author), Aichi Canc Ctr, Div Mol Pathol, Res Inst, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	msaoki@aichi-cc.jp	Aoki, Masahiro/A-5149-2016; Fujishita, Teruaki/O-1367-2019	Aoki, Masahiro/0000-0003-4316-9490; Fujishita, Teruaki/0000-0002-4397-2438	JSPS KAKENHI [24790382]; Third Term Comprehensive Control Research for Cancer from the Ministry of Health, Labour and Welfare; Yasuda Medical Foundation; Suzuken Memorial Foundation; Nagono Medical Foundation; Shimabara Science Promotion Foundation; Takeda Science Foundation; Princess Takamatsu Cancer Research Fund; Grants-in-Aid for Scientific Research [26111005] Funding Source: KAKEN	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Third Term Comprehensive Control Research for Cancer from the Ministry of Health, Labour and Welfare; Yasuda Medical Foundation; Suzuken Memorial Foundation; Nagono Medical Foundation; Shimabara Science Promotion Foundation; Takeda Science Foundation(Takeda Science Foundation (TSF)); Princess Takamatsu Cancer Research Fund; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	The authors thank PM McSheehy for everolimus; M Oshima, T Kitamura, M Sonoshita, S Arimura, F Kakizaki, A Deguchi, K Sakuma and K Aoki for discussions; and R Mitsuya, M Tsuda, A Kojima, K Kobori and Y Goto for technical assistance. This work was supported by JSPS KAKENHI Grant Number 24790382 (to TF), Third Term Comprehensive Control Research for Cancer from the Ministry of Health, Labour and Welfare (to MA), The Yasuda Medical Foundation, Suzuken Memorial Foundation, Nagono Medical Foundation, The Shimabara Science Promotion Foundation (to TF), Takeda Science Foundation (to TF and MA), and Princess Takamatsu Cancer Research Fund (to MA).	Chen SM, 2014, INT J CANCER, V135, P2462, DOI 10.1002/ijc.28880; Choo AY, 2008, P NATL ACAD SCI USA, V105, P17414, DOI 10.1073/pnas.0809136105; Chresta CM, 2010, CANCER RES, V70, P288, DOI 10.1158/0008-5472.CAN-09-1751; Easton JB, 2006, ONCOGENE, V25, P6436, DOI 10.1038/sj.onc.1209886; Fujishita T, 2008, P NATL ACAD SCI USA, V105, P13544, DOI 10.1073/pnas.0800041105; Fujishita T, 2015, CANCER SCI, V106, P692, DOI 10.1111/cas.12670; Fujishita T, 2011, GASTROENTEROLOGY, V140, P1556, DOI 10.1053/j.gastro.2011.02.007; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; He WM, 1998, J BIOL CHEM, V273, P6860, DOI 10.1074/jbc.273.12.6860; Herszenyi L, 2012, INT J MOL SCI, V13, P13240, DOI 10.3390/ijms131013240; Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599; Holt SV, 2012, CANCER RES, V72, P1804, DOI 10.1158/0008-5472.CAN-11-1780; Hsu PP, 2011, SCIENCE, V332, P1317, DOI 10.1126/science.1199498; Hudes G, 2007, NEW ENGL J MED, V356, P2271, DOI 10.1056/NEJMoa066838; Jiang Q, 2011, CANCER RES, V71, P4074, DOI 10.1158/0008-5472.CAN-10-3968; Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244; Kitamura T, 2007, NAT GENET, V39, P467, DOI 10.1038/ng1997; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Metcalfe C, 2010, CANCER RES, V70, P6629, DOI 10.1158/0008-5472.CAN-10-1616; Mohamed A, 2013, AM J PATHOL, V183, P1096, DOI 10.1016/j.ajpath.2013.07.005; Motzer RJ, 2008, LANCET, V372, P449, DOI 10.1016/S0140-6736(08)61039-9; Oshima H, 2012, J GASTROENTEROL, V47, P97, DOI 10.1007/s00535-011-0523-6; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Rodrik-Outmezguine VS, 2011, CANCER DISCOV, V1, P248, DOI 10.1158/2159-8290.CD-11-0085; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Wander SA, 2011, J CLIN INVEST, V121, P1231, DOI 10.1172/JCI44145; Wang Q, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0066417, 10.1371/journal.pone.0068894]; Yu YH, 2011, SCIENCE, V332, P1322, DOI 10.1126/science.1199484	28	25	25	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	2017	36	46					6480	6489		10.1038/onc.2017.242	http://dx.doi.org/10.1038/onc.2017.242			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM9WN	28759045				2022-12-17	WOS:000415622900011
J	Chen, WY; Tsai, YC; Siu, MK; Yeh, HL; Chen, CL; Yin, JJ; Huang, J; Liu, YN				Chen, W-Y; Tsai, Y-C; Siu, M. K.; Yeh, H-L; Chen, C-L; Yin, J. J.; Huang, J.; Liu, Y-N			Inhibition of the androgen receptor induces a novel tumor promoter, ZBTB46, for prostate cancer metastasis	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; CLASSICAL DENDRITIC CELLS; TRANSCRIPTION FACTOR ZDC; DEPRIVATION THERAPY; BONE METASTASIS; EXPRESSION; PROGRESSION; RESISTANCE; ACTIVATION; SUPPRESSOR	Current therapeutic regimens for prostate cancer focus on targeting androgen receptor (AR) signaling. However, the AR is a key factor in luminal epithelium differentiation and was shown to have a role as a tumor suppressor. Thus, its inhibition may activate oncogenic pathways that contribute to metastatic castration-resistant prostate cancer (CRPC). Herein, we report a novel tumor promoter, ZBTB46, which is negatively regulated by AR signaling via microRNA (miR)-1-mediated downregulation. ZBTB46 is associated with malignant prostate cancer and is essential for metastasis. Its overexpression can overcome the antitumor effects of miR-1 and promote androgen-independent proliferation. We demonstrated that ZBTB46 can transcriptionally regulate SNAI1, a key epithelial-to-mesenchymal transition (EMT) driver, which could contribute to induction of the EMT after androgen-deprivation therapy and metastasis. Our findings are supportive of the model that disruption of AR's function may predispose prostate cancer to progress to metastatic CRPC.	[Chen, W-Y; Chen, C-L] Taipei Med Univ, Coll Med, Sch Med, Dept Pathol, Taipei, Taiwan; [Chen, W-Y] Taipei Med Univ, Wan Fang Hosp, Dept Pathol, Taipei, Taiwan; [Tsai, Y-C; Siu, M. K.; Liu, Y-N] Taipei Med Univ, Coll Med Sci & Technol, Grad Inst Canc Biol & Drug Discovery, 250 Wu Hsing St, Taipei 11031, Taiwan; [Siu, M. K.] Taipei Med Univ, Wan Fang Hosp, Dept Anesthesiol, Taipei, Taiwan; [Yeh, H-L] Natl Tsing Hua Univ, Inst Informat Syst & Applicat, Hsinchu, Taiwan; [Chen, C-L] Taipei Med Univ, Grad Inst Clin Med, Coll Med, Taipei, Taiwan; [Chen, C-L] Taipei Med Univ, Taipei Med Univ Hosp, Dept Pathol, Taipei, Taiwan; [Yin, J. J.] NCI, Lab Genitourinary Canc Pathogenesis, NIH, Bethesda, MD 20892 USA; [Huang, J.] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA	Taipei Medical University; Taipei Medical University; Taipei Municipal WanFang Hospital; Taipei Medical University; Taipei Medical University; Taipei Municipal WanFang Hospital; National Tsing Hua University; Taipei Medical University; Taipei Medical University; Taipei Medical University Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Duke University	Liu, YN (corresponding author), Taipei Med Univ, Coll Med Sci & Technol, Grad Inst Canc Biol & Drug Discovery, 250 Wu Hsing St, Taipei 11031, Taiwan.; Huang, J (corresponding author), Duke Univ, Sch Med, Dept Pathol, Room 301M,Duke South,DUMC 3712,40 Duke Med Circle, Durham, NC 27710 USA.	jiaoti.huang@duke.edu; liuy@tmu.edu.tw	Liu, Yen-Nien/AAW-4698-2021		Ministry of Science and Technology of Taiwan [MOST104-2314-B-038-045-MY3, MOST105-2320-B- 038-044, MOST104-2320-B-038-055-MY3]; National Health Research Institutes of Taiwan [NHRI-EX106-10308BC]; Taipei Medical University [TMU104-AE1-B22]; Health and Welfare Surcharge of Tobacco Products [MOHW106-TDU-B-212-144001]	Ministry of Science and Technology of Taiwan(Ministry of Science and Technology, Taiwan); National Health Research Institutes of Taiwan(National Health Research Institutes - Taiwan); Taipei Medical University; Health and Welfare Surcharge of Tobacco Products	This work was jointly supported by grants from the Ministry of Science and Technology of Taiwan (MOST104-2314-B-038-045-MY3) to YNL, (MOST105-2320-B- 038-044) to WYC, (MOST104-2320-B-038-055-MY3) to YCT, by the National Health Research Institutes of Taiwan (NHRI-EX106-10308BC) to YNL, by Taipei Medical University (TMU104-AE1-B22) to WYC, and by the Health and Welfare Surcharge of Tobacco Products (MOHW106-TDU-B-212-144001) to YNL.	Ambs S, 2008, CANCER RES, V68, P6162, DOI 10.1158/0008-5472.CAN-08-0144; Beltran H, 2016, NAT MED, V22, P298, DOI 10.1038/nm.4045; Boyd LK, 2012, NAT REV UROL, V9, P652, DOI 10.1038/nrurol.2012.185; Cao JP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077922; Crea F, 2015, TRENDS MOL MED, V21, P206, DOI 10.1016/j.molmed.2015.02.005; De Craene B, 2014, CELL DEATH DIFFER, V21, P310, DOI 10.1038/cdd.2013.148; Doane AS, 2006, ONCOGENE, V25, P3994, DOI 10.1038/sj.onc.1209415; Eisenberger MA, 1998, NEW ENGL J MED, V339, P1036, DOI 10.1056/NEJM199810083391504; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Ferraldeschi R, 2015, ONCOGENE, V34, P1745, DOI 10.1038/onc.2014.115; Gao J, 2001, CANCER RES, V61, P5038; Gmyrek GA, 2001, AM J PATHOL, V159, P579, DOI 10.1016/S0002-9440(10)61729-4; Han C, 2015, TUMOR BIOL, V36, P6715, DOI 10.1007/s13277-015-3358-6; Hsieh CL, 2015, CANCER RES, V75, P1944, DOI 10.1158/0008-5472.CAN-14-3602; Hudson RS, 2012, NUCLEIC ACIDS RES, V40, P3689, DOI 10.1093/nar/gkr1222; Humphrey PA, 2012, HISTOPATHOLOGY, V60, P59, DOI 10.1111/j.1365-2559.2011.04039.x; Izumi K, 2013, EMBO MOL MED, V5, P1383, DOI 10.1002/emmm.201202367; Jennbacken K, 2010, ENDOCR-RELAT CANCER, V17, P469, DOI 10.1677/ERC-10-0015; Karantanos T, 2013, ONCOGENE, V32, P5501, DOI 10.1038/onc.2013.206; Karatas OF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098675; Kudo-Saito C, 2009, CANCER CELL, V15, P195, DOI 10.1016/j.ccr.2009.01.023; Lee SU, 2012, IMMUNOL REV, V247, P107, DOI 10.1111/j.1600-065X.2012.01116.x; Linja MJ, 2001, CANCER RES, V61, P3550; Litvinov IV, 2003, J CLIN ENDOCR METAB, V88, P2972, DOI 10.1210/jc.2002-022038; Liu YN, 2013, ONCOGENE, V32, P296, DOI 10.1038/onc.2012.58; Liu YN, 2015, MOL CELL BIOL, V35, P1940, DOI 10.1128/MCB.00008-15; Liu YN, 2012, MOL CELL BIOL, V32, P941, DOI 10.1128/MCB.06306-11; MagiGalluzzi C, 1997, MODERN PATHOL, V10, P839; Martens-Uzunova ES, 2012, ONCOGENE, V31, P978, DOI 10.1038/onc.2011.304; Mendiratta P, 2009, J CLIN ONCOL, V27, P2022, DOI 10.1200/JCO.2008.17.2882; Meredith MM, 2012, J EXP MED, V209, P1583, DOI 10.1084/jem.20121003; Meredith MM, 2012, J EXP MED, V209, P1153, DOI 10.1084/jem.20112675; Nicoloso MS, 2009, NAT REV CANCER, V9, P293, DOI 10.1038/nrc2619; Niu YJ, 2008, P NATL ACAD SCI USA, V105, P12182, DOI 10.1073/pnas.0804700105; Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Satpathy AT, 2012, J EXP MED, V209, P1135, DOI 10.1084/jem.20120030; Schrader AJ, 2014, EUR UROL, V65, P30, DOI 10.1016/j.eururo.2013.06.042; Shah RB, 2004, CANCER RES, V64, P9209, DOI 10.1158/0008-5472.CAN-04-2442; Siu MK, 2017, PROSTATE CANCER P D, V20, P172, DOI 10.1038/pcan.2017.2; Siu MK, 2014, ONCOTARGET, V5, P3770, DOI 10.18632/oncotarget.1994; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun YT, 2012, CANCER RES, V72, P527, DOI 10.1158/0008-5472.CAN-11-3004; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tomlins SA, 2007, NAT GENET, V39, P41, DOI 10.1038/ng1935; Varkaris A, 2011, EXPERT OPIN INV DRUG, V20, P1677, DOI 10.1517/13543784.2011.631523; Yan D, 2009, J BIOL CHEM, V284, P29596, DOI 10.1074/jbc.M109.020511; Yin JJ, 2010, CANCER RES, V70, P8662, DOI 10.1158/0008-5472.CAN-10-1435; Yin JJ, 2007, MOL CELL BIOL, V27, P7538, DOI 10.1128/MCB.00955-07; Yin JJ, 2014, CANCER RES, V74, P4306, DOI 10.1158/0008-5472.CAN-13-3233	50	25	25	4	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2017	36	45					6213	6224		10.1038/onc.2017.226	http://dx.doi.org/10.1038/onc.2017.226			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM1WY	28692046				2022-12-17	WOS:000414774800001
J	Roarty, K; Pfefferle, AD; Creighton, CJ; Perou, CM; Rosen, JM				Roarty, K.; Pfefferle, A. D.; Creighton, C. J.; Perou, C. M.; Rosen, J. M.			Ror2-mediated alternative Wnt signaling regulates cell fate and adhesion during mammary tumor progression	ONCOGENE			English	Article							BREAST-CANCER; GENE-EXPRESSION; TYROSINE KINASE; ERM PROTEINS; PATHWAY; HETEROGENEITY; ROR2; MODEL; ACTIVATION; PREDICTS	Cellular heterogeneity is a common feature in breast cancer, yet an understanding of the coexistence and regulation of various tumor cell subpopulations remains a significant challenge in cancer biology. In the current study, we approached tumor cell heterogeneity from the perspective of Wnt pathway biology to address how different modes of Wnt signaling shape the behaviors of diverse cell populations within a heterogeneous tumor landscape. Using a syngeneic TP53-null mouse model of breast cancer, we identified distinctions in the topology of canonical Wnt beta-catenin-dependent signaling activity and non-canonical beta-catenin-independent Ror2-mediated Wnt signaling across subtypes and within tumor cell subpopulations in vivo. We further discovered an antagonistic role for Ror2 in regulating canonical Wnt/beta-catenin activity in vivo, where lentiviral shRNA depletion of Ror2 expression augmented canonical Wnt/beta-catenin signaling activity across multiple basal-like models. Depletion of Ror2 expression yielded distinct phenotypic outcomes and divergent alterations in gene expression programs among different tumors, despite all sharing basal-like features. Notably, we uncovered cell state plasticity and adhesion dynamics regulated by Ror2, which influenced Ras Homology Family Member A (RhoA) and Rho-Associated Coiled-Coil Kinase 1 (ROCK1) activity downstream of Dishevelled-2 (Dvl2). Collectively, these studies illustrate the integration and collaboration of Wnt pathways in basal-like breast cancer, where Ror2 provides a spatiotemporal function to regulate the balance of Wnt signaling and cellular heterogeneity during tumor progression.	[Roarty, K.; Rosen, J. M.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Pfefferle, A. D.; Perou, C. M.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Creighton, C. J.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Creighton, C. J.] Baylor Coll Med, Dan L Duncan Comprehens Canc Ctr, Houston, TX 77030 USA	Baylor College of Medicine; University of North Carolina; University of North Carolina Chapel Hill; Baylor College of Medicine; Baylor College of Medicine	Rosen, JM (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Texas Med Ctr, One Baylor Plaza,M638A, Houston, TX 77030 USA.	jrosen@bcm.edu	Perou, Charles M/H-9934-2014	Perou, Charles M/0000-0001-9827-2247	Dan L. Duncan Cancer Center; John S. Dunn Gulf Coast Consortium for Chemical Genomics; Lester and Sue Smith Breast Center Pathology Core; National Cancer Institute [NCI R01 CA016303-40, NIH R01 CA195754]; Department of Defense [W81XWH-10-0356, NIH CA125123]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD007495] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD007495, T32HD007495] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA195754, R01CA016303, P30CA125123, K22CA207463] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR024574] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036211] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056338] Funding Source: NIH RePORTER	Dan L. Duncan Cancer Center; John S. Dunn Gulf Coast Consortium for Chemical Genomics; Lester and Sue Smith Breast Center Pathology Core; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Defense(United States Department of Defense); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was conducted with the help of the Baylor College of Medicine Cytometry and Cell Sorting Core (National Institutes of Health [NIH] P30 AI036211 and S10 RR024574), the Genomics and RNA Profiling Core, the Integrated Microscopy Core (NIH HD007495, DK56338 and CA125123), with funding from the Dan L. Duncan Cancer Center, the John S. Dunn Gulf Coast Consortium for Chemical Genomics and the Lester and Sue Smith Breast Center Pathology Core. We would also like to thank Yiqun Zhang for help and expertise with the microarray analysis. This work was funded by a National Cancer Institute Award NCI R01 CA016303-40 to JMR, NIH R01 CA195754 to CMP and JMR, a Department of Defense Award W81XWH-10-0356 to KPR and NIH CA125123 to CJC.	Angers S, 2009, NAT REV MOL CELL BIO, V10, P468, DOI 10.1038/nrm2717; Arpin M, 2011, CELL ADHES MIGR, V5, P199, DOI 10.4161/cam.5.2.15081; Aulehla A, 2008, NAT CELL BIOL, V10, P186, DOI 10.1038/ncb1679; Beermann A, 2011, DEVELOPMENT, V138, P2793, DOI 10.1242/dev.063644; Borcherding N, 2015, CANCER RES, V75, P1972, DOI 10.1158/0008-5472.CAN-14-2761; Brechbuhl HM, 2011, AM J PATHOL, V179, P367, DOI 10.1016/j.ajpath.2011.03.016; Chalcrabarti R, 2014, NAT CELL BIOL, V16, P1004, DOI 10.1038/ncb3040; Cleary AS, 2014, NATURE, V508, P113, DOI 10.1038/nature13187; Clevers H, 2014, SCIENCE, V346, P54, DOI 10.1126/science.1248012; Clucas J, 2014, J CELL SCI, V127, P267, DOI 10.1242/jcs.133108; Creighton CJ, 2008, RNA, V14, P2290, DOI 10.1261/rna.1188208; Creighton CJ, 2008, J CLIN ONCOL, V26, P4078, DOI 10.1200/JCO.2007.13.4429; Creighton CJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034546; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Dass RA, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006217; DeChiara TM, 2000, NAT GENET, V24, P271, DOI 10.1038/73488; Dembowy J, 2015, ONCOGENE, V34, P3514, DOI 10.1038/onc.2014.279; Fehon RG, 2010, NAT REV MOL CELL BIO, V11, P276, DOI 10.1038/nrm2866; Fuerer C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009370; Gao B, 2011, DEV CELL, V20, P163, DOI 10.1016/j.devcel.2011.01.001; Geyer FC, 2011, MODERN PATHOL, V24, P209, DOI 10.1038/modpathol.2010.205; Gluck S, 2012, BREAST CANCER RES TR, V132, P781, DOI 10.1007/s10549-011-1412-7; Green JL, 2013, P NATL ACAD SCI USA, V110, P6991, DOI 10.1073/pnas.1303671110; Grumolato L, 2010, GENE DEV, V24, P2517, DOI 10.1101/gad.1957710; Gujral TS, 2014, CELL, V159, P844, DOI 10.1016/j.cell.2014.10.032; Henry C, 2015, J CANCER RES CLIN, V141, P243, DOI 10.1007/s00432-014-1824-y; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Herschkowitz JI, 2012, P NATL ACAD SCI USA, V109, P2778, DOI 10.1073/pnas.1018862108; Ho HYH, 2012, P NATL ACAD SCI USA, V109, P4044, DOI 10.1073/pnas.1200421109; Huang SX, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-10-r84; Jerry DJ, 2000, ONCOGENE, V19, P1052, DOI 10.1038/sj.onc.1203270; Jiang W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058329; Jonsson M, 2002, CANCER RES, V62, P409; Khramtsov AI, 2010, AM J PATHOL, V176, P2911, DOI 10.2353/ajpath.2010.091125; Lawson CD, 2016, CANCER RES, V76, P3826, DOI 10.1158/0008-5472.CAN-15-2923; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; LEJEUNE S, 1995, CLIN CANCER RES, V1, P215; Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Luis TC, 2011, CELL STEM CELL, V9, P345, DOI 10.1016/j.stem.2011.07.017; Martelotto LG, 2013, BREAST CANCER RES, V16, P210; Medina D, 2002, FASEB J, V16, P881, DOI 10.1096/fj.01-0885fje; Mikels AJ, 2006, PLOS BIOL, V4, P570, DOI 10.1371/journal.pbio.0040115; Miyoshi K, 2002, ONCOGENE, V21, P5548, DOI 10.1038/sj.onc.1205686; Neisch AL, 2011, CURR OPIN CELL BIOL, V23, P377, DOI 10.1016/j.ceb.2011.04.011; Ng CKY, 2012, EXPERT REV ANTICANC, V12, P1021, DOI [10.1586/ERA.12.85, 10.1586/era.12.85]; Oishi I, 1999, GENES CELLS, V4, P41, DOI 10.1046/j.1365-2443.1999.00234.x; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pfefferle AD, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-11-r125; Polakis P, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008052; Prat A, 2013, BREAST CANCER RES TR, V142, P237, DOI 10.1007/s10549-013-2743-3; Prat A, 2011, MOL ONCOL, V5, P5, DOI 10.1016/j.molonc.2010.11.003; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Prat A, 2009, NAT MED, V15, P842, DOI 10.1038/nm0809-842; Puvirajesinghe TM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10318; Ren L, 2009, ONCOGENE, V28, P792, DOI 10.1038/onc.2008.437; Roarty K, 2015, J CELL BIOL, V208, P351, DOI 10.1083/jcb.201408058; Roarty K, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2244; Rosner A, 2002, AM J PATHOL, V161, P1087, DOI 10.1016/S0002-9440(10)64269-1; Russnes HG, 2011, J CLIN INVEST, V121, P3810, DOI 10.1172/JCI57088; Schlessinger K, 2009, GENE DEV, V23, P265, DOI 10.1101/gad.1760809; Shi J, 2014, CANCER CELL, V25, P210, DOI 10.1016/j.ccr.2014.01.028; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Takeuchi S, 2000, GENES CELLS, V5, P71, DOI 10.1046/j.1365-2443.2000.00300.x; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; van Amerongen R, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007914; van Amerongen R, 2009, DEVELOPMENT, V136, P3205, DOI 10.1242/dev.033910; Waclaw B, 2015, NATURE, V525, P261, DOI 10.1038/nature14971; Wang JB, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007963; Weber K, 2008, MOL THER, V16, P698, DOI 10.1038/mt.2008.6; Yamaguchi TP, 1999, DEVELOPMENT, V126, P1211; Zhang M, 2015, CANCER DISCOV, V5, P520, DOI 10.1158/2159-8290.CD-14-1101; Zhang M, 2010, P NATL ACAD SCI USA, V107, P3522, DOI 10.1073/pnas.0910179107; Zhang SP, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0031127, 10.1371/journal.pone.0046853]	75	25	26	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 26	2017	36	43					5958	5968		10.1038/onc.2017.206	http://dx.doi.org/10.1038/onc.2017.206			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK9OT	28650466	Green Published, Green Accepted, hybrid			2022-12-17	WOS:000413841400005
J	Kiyohara, MH; Dillard, C; Tsui, J; Kim, SR; Lu, J; Sachdev, D; Goodglick, L; Tong, M; Torous, VF; Aryasomayajula, C; Wang, W; Najafzadeh, P; Gordon, LK; Braun, J; McDermott, S; Wicha, MS; Wadehra, M				Kiyohara, M. H.; Dillard, C.; Tsui, J.; Kim, S. R.; Lu, J.; Sachdev, D.; Goodglick, L.; Tong, M.; Torous, V. F.; Aryasomayajula, C.; Wang, W.; Najafzadeh, P.; Gordon, L. K.; Braun, J.; McDermott, S.; Wicha, M. S.; Wadehra, M.			EMP2 is a novel therapeutic target for endometrial cancer stem cells	ONCOGENE			English	Article							EPITHELIAL MEMBRANE PROTEIN-2; EXPRESSION; RESISTANCE; CHEMOTHERAPY; ASSOCIATION; NICHE; TUMORIGENESIS; METASTASIS; INHIBITION; PREDICTOR	Previous studies have suggested that overexpression of the oncogenic protein epithelial membrane protein-2 (EMP2) correlates with endometrial carcinoma progression and ultimately poor survival from disease. To understand the role of EMP2 in the etiology of disease, gene analysis was performed to show transcripts that are reciprocally regulated by EMP2 levels. In particular, EMP2 expression correlates with and helps regulate the expression of several cancer stem cell associated markers including aldehyde dehydrogenase 1 (ALDH1). ALDH expression significantly promotes tumor initiation and correlates with the levels of EMP2 expression in both patient samples and tumor cell lines. As therapy against cancer stem cells in endometrial cancer is lacking, the ability of anti-EMP2 IgG1 therapy to reduce primary and secondary tumor formation using xenograft HEC1A models was determined. Anti-EMP2 IgG1 reduced the expression and activity of ALDH and correspondingly reduced both primary and secondary tumor load. Our results collectively suggest that anti-EMP2 therapy may be a novel method of reducing endometrial cancer stem cells.	[Kiyohara, M. H.; Dillard, C.; Tsui, J.; Goodglick, L.; Tong, M.; Aryasomayajula, C.; Najafzadeh, P.; Braun, J.; Wadehra, M.] UCLA, David Geffen Sch Med, Dept Pathol & Lab Med, 675 Charles Young Dr South,Box 951732, Los Angeles, CA 90095 USA; [Lu, J.; Wadehra, M.] Charles Drew Univ, Ctr Eliminate Canc Hlth Dispar, Los Angeles, CA USA; [Sachdev, D.; Goodglick, L.; Braun, J.; Wadehra, M.] UCLA, David Geffen Sch Med, Dept Internal Med, Los Angeles, CA USA; [Torous, V. F.] Beth Israel Deaconess Med Ctr, Dept Pathol & Lab Med, Boston, MA USA; [Wang, W.; Gordon, L. K.] UCLA, Dept Ophthalmol, David Geffen Sch Med, Los Angeles, CA USA; [McDermott, S.; Wicha, M. S.] Univ Michigan, Med Oncol, Ann Arbor, MI USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Charles R. Drew University of Medicine & Science; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Harvard University; Beth Israel Deaconess Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Michigan System; University of Michigan	Wadehra, M (corresponding author), UCLA, David Geffen Sch Med, Dept Pathol & Lab Med, 675 Charles Young Dr South,Box 951732, Los Angeles, CA 90095 USA.	mwadehra@mednet.ucla.edu	Wicha, Max/AAE-7268-2019	Braun, Jonathan/0000-0003-1646-2974	Early Detection Research Network [NCI CA-86366, CA016042]; Charles Drew University/UCLA NIH [U54-CA-143931]; NIH/National Center for Advancing Translational Sciences (NCATS) [UL1TR000124]; NCI [R01 CA163971]; NATIONAL CANCER INSTITUTE [U54CA143931, R01CA163971, P30CA016042, U24CA086366] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000124] Funding Source: NIH RePORTER	Early Detection Research Network; Charles Drew University/UCLA NIH; NIH/National Center for Advancing Translational Sciences (NCATS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	This work was generously supported by the Early Detection Research Network NCI CA-86366 (L Goodglick), CA016042 (University of California at Los Angeles Jonsson Comprehensive Cancer Center Flow Cytometry Core), Charles Drew University/UCLA NIH U54-CA-143931 (JL and MW), the NIH/National Center for Advancing Translational Sciences (NCATS) UL1TR000124, and NCI R01 CA163971 (MW).	Alam M, 2013, J BIOL CHEM, V288, P30892, DOI 10.1074/jbc.M113.477158; Alonso-Alconada L, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-223; Ayhan A, 2001, GYNECOL ONCOL, V80, P355, DOI 10.1006/gyno.2000.6014; Barnett SF, 2005, BIOCHEM J, V385, P399, DOI 10.1042/BJ20041140; Boman BM, 2008, J CLIN ONCOL, V26, P2795, DOI 10.1200/JCO.2008.17.7436; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Charafe-Jauffret E, 2010, CLIN CANCER RES, V16, P45, DOI 10.1158/1078-0432.CCR-09-1630; Charafe-Jauffret E, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-202; Conley SJ, 2012, P NATL ACAD SCI USA, V109, P2784, DOI 10.1073/pnas.1018866109; Croker AK, 2012, BREAST CANCER RES TR, V133, P75, DOI 10.1007/s10549-011-1692-y; Daoud SA, 2013, J AM SCI, V9, P900; Dedes KJ, 2011, NAT REV CLIN ONCOL, V8, P261, DOI 10.1038/nrclinonc.2010.216; Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733; Dossus L, 2011, INT J CANCER, V129, P2032, DOI 10.1002/ijc.25840; Eyler CE, 2008, J CLIN ONCOL, V26, P2839, DOI 10.1200/JCO.2007.15.1829; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Franovic A, 2009, P NATL ACAD SCI USA, V106, P21306, DOI 10.1073/pnas.0906432106; Fu M, 2014, MOL CANCER THER, V13, P902, DOI 10.1158/1535-7163.MCT-13-0199; Fu MY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019945; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Ginestier C, 2009, CELL CYCLE, V8, P3297, DOI 10.4161/cc.8.20.9761; Glinsky GV, 2007, STEM CELL REV, V3, P79, DOI 10.1007/s12015-007-0011-9; Gordon LK, 2013, ONCOGENE, V32, P5369, DOI 10.1038/onc.2012.622; Gyorffy B, 2006, INT J CANCER, V118, P1699, DOI 10.1002/ijc.21570; Habeeb O, 2010, CANCER-AM CANCER SOC, V116, P4718, DOI 10.1002/cncr.25259; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Hubbard SA, 2009, CANCER RES, V69, P8241, DOI 10.1158/0008-5472.CAN-08-4808; Kao J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006146; Kim RJ, 2013, CANCER LETT, V333, P18, DOI 10.1016/j.canlet.2012.11.026; Korkaya H, 2008, ONCOGENE, V27, P6120, DOI 10.1038/onc.2008.207; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Krivtsov AV, 2006, NATURE, V442, P818, DOI 10.1038/nature04980; Kurebayashi J, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-568; Kyo S, 2013, CURR OBSTET GYNECOL, V2, P1, DOI 10.1007/s13669-012-0030-7; Leblanc M, 2001, VIRCHOWS ARCH, V438, P78, DOI 10.1007/s004280000269; Levina V, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003077; Liang DM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-201; Lu HH, 2014, NAT CELL BIOL, V16, P1105, DOI 10.1038/ncb3041; Luo M, 2009, CANCER RES, V69, P466, DOI 10.1158/0008-5472.CAN-08-3078; Mamat Suhana, 2011, Genes Cancer, V2, P979, DOI 10.1177/1947601911436009; Marcato P, 2011, STEM CELLS, V29, P32, DOI 10.1002/stem.563; Mendez O, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-133; Mirantes C, 2013, HUM PATHOL, V44, P1973, DOI 10.1016/j.humpath.2013.04.009; Morales SA, 2007, EXP EYE RES, V85, P790, DOI 10.1016/j.exer.2007.08.014; Nandy SB, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-644; O'Brien CA, 2010, CLIN CANCER RES, V16, P3113, DOI 10.1158/1078-0432.CCR-09-2824; Plaks V, 2015, CELL STEM CELL, V16, P225, DOI 10.1016/j.stem.2015.02.015; Rahadiani N, 2011, CANCER SCI, V102, P903, DOI 10.1111/j.1349-7006.2011.01864.x; Rutella S, 2009, CLIN CANCER RES, V15, P4299, DOI 10.1158/1078-0432.CCR-08-1883; Salvesen HB, 2012, LANCET ONCOL, V13, pE353, DOI 10.1016/S1470-2045(12)70213-9; Samanta D, 2014, P NATL ACAD SCI USA, V111, pE5429, DOI 10.1073/pnas.1421438111; Shapiro IM, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008639; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Soltysova A, 2005, NEOPLASMA, V52, P435; Tanei T, 2009, CLIN CANCER RES, V15, P4234, DOI 10.1158/1078-0432.CCR-08-1479; Tirino Virginia, 2012, Methods Mol Biol, V879, P513, DOI 10.1007/978-1-61779-815-3_32; Wadehra M, 2006, DEV BIOL, V292, P430, DOI 10.1016/j.ydbio.2006.01.015; Wadehra M, 2005, DEV BIOL, V287, P336, DOI 10.1016/j.ydbio.2005.09.003; Wadehra M, 2006, CANCER-AM CANCER SOC, V107, P90, DOI 10.1002/cncr.21957; Wang MY, 2006, CANCER RES, V66, P7864, DOI 10.1158/0008-5472.CAN-04-4392; Whitcomb BP, 2008, SURG CLIN N AM, V88, P301, DOI 10.1016/j.suc.2008.01.004; Wicha MS, 2006, CANCER RES, V66, P1883, DOI 10.1158/0008-5472.CAN-05-3153; Wu YJ, 2009, STEM CELLS DEV, V18, P1127, DOI 10.1089/scd.2008.0338; Xing F, 2011, ONCOGENE, V30, P4075, DOI 10.1038/onc.2011.122; Ye J, 2014, TUMOR BIOL, V35, P3945, DOI 10.1007/s13277-013-1561-x	66	25	25	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2017	36	42					5793	5807		10.1038/onc.2017.142	http://dx.doi.org/10.1038/onc.2017.142			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK2DN	28604744	Green Accepted			2022-12-17	WOS:000413292900002
J	Mu, P; Akashi, T; Lu, F; Kishida, S; Kadomatsu, K				Mu, P.; Akashi, T.; Lu, F.; Kishida, S.; Kadomatsu, K.			A novel nuclear complex of DRR1, F-actin and COMMD1 involved in NF-kappa B degradation and cell growth suppression in neuroblastoma	ONCOGENE			English	Article							II-DEPENDENT TRANSCRIPTION; PANCREATIC-CANCER CELLS; WASH COMPLEX; PROMOTES NEUROBLASTOMA; DOWN-REGULATION; LAEVIS OOCYTES; GENE; EXPRESSION; UBIQUITINATION; IDENTIFICATION	Downregulated in renal cell carcinoma 1 (DRR1) has important roles in tumor cell growth, neuron survival and spine formation, and was recently shown to bind actin. However, the roles of nuclear DRR1 remain largely unexplored. Here, we identified an interaction between filamentous actin (F-actin) and DRR1 in the nucleus, and demonstrated that copper metabolism MURR1 domain-containing 1 (COMMD1) is another binding partner of DRR1. Accordingly, DRR1, F-actin and COMMD1 were shown to form a complex in the nucleus, and the stability of COMMD1 was enhanced in this complex. Increased nuclear COMMD1 in turn promoted the degradation of NF-kappa B. In addition, DRR1 and COMMD1 suppressed the cyclin D1 expression, G1/S transition and cell proliferation of neuroblastoma cells. The binding between DRR1 and F-actin in the nucleus was required for these events. Consistent with these facts, low expressions of DRR1 were associated with tumorigenesis of human neuroblastoma and its mouse model. This study has thus revealed a novel nuclear complex of F-actin, DRR1 and COMMD1 that is involved in NF-kappa B degradation and cell cycle suppression in neuroblastoma cells.	[Mu, P.; Lu, F.; Kishida, S.; Kadomatsu, K.] Nagoya Univ, Grad Sch Med, Dept Biochem, Nagoya, Aichi, Japan; [Akashi, T.] Nagoya Univ, Grad Sch Med, Ctr Neurol Dis & Canc, Div Omics Anal, Nagoya, Aichi, Japan; [Lu, F.] Tianjin Univ Tradit Chinese Med, Sch Chinese Mat Med, Tianjin, Peoples R China; [Lu, F.] Tianjin Univ Tradit Chinese Med, Tianjin State Key Lab Modern Chinese Med, Tianjin, Peoples R China	Nagoya University; Nagoya University; Tianjin University of Traditional Chinese Medicine; Tianjin University of Traditional Chinese Medicine	Kadomatsu, K (corresponding author), Nagoya Univ, Grad Sch Med, Dept Biochem, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	kkadoma@med.nagoya-u.ac.jp	Kadomatsu, Kenji/G-8083-2012		Japan Science and Technology Agency, Core Research for Evolutionary Science and Technology (JST CREST) [16010731701]; Japan Agency for Medical Research and Development (AMED) [16ck0106011h0503]; Ministry of Education, Culture, Sports, Science and Technology (MEXT) [22890080]	Japan Science and Technology Agency, Core Research for Evolutionary Science and Technology (JST CREST); Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Ministry of Education, Culture, Sports, Science and Technology (MEXT)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank Dr Bernd Knoll for the Flag-NLS-WT-actin, Flag-NLS-S14C-actin and Flag-NLS-R62D-actin constructs. This work was supported in part by a Grants-in-Aid (16010731701) from Japan Science and Technology Agency, Core Research for Evolutionary Science and Technology (JST CREST) to K. Kadomatsu, a Grants-in-Aid (16ck0106011h0503) from Japan Agency for Medical Research and Development (AMED) (Tailor-made Medical Treatment Program) to K. Kadomatsu, and a Grant-in-Aid (22890080) from Ministry of Education, Culture, Sports, Science and Technology (MEXT) to P. Mu.	Almuzzaini B, 2015, BMC BIOL, V13, DOI 10.1186/s12915-015-0147-z; Asano Y, 2010, BIOCHEM BIOPH RES CO, V394, P829, DOI 10.1016/j.bbrc.2010.03.085; Baarlink C, 2013, SCIENCE, V340, P864, DOI 10.1126/science.1235038; Belin BJ, 2013, MOL BIOL CELL, V24, P982, DOI 10.1091/mbc.E12-09-0685; CLARK TG, 1977, CELL, V12, P883, DOI 10.1016/0092-8674(77)90152-0; CLARK TG, 1979, CELL, V18, P1101, DOI 10.1016/0092-8674(79)90223-X; Deng ZH, 2015, J CELL SCI, V128, P373, DOI 10.1242/jcs.161513; Dudley A, 2014, ONCOGENE, V33, P4952, DOI 10.1038/onc.2013.436; Fedoseienko A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165385; Galarneau L, 2000, MOL CELL, V5, P927, DOI 10.1016/S1097-2765(00)80258-0; Geng H, 2009, EMBO REP, V10, P381, DOI 10.1038/embor.2009.10; Gomez TS, 2009, DEV CELL, V17, P699, DOI 10.1016/j.devcel.2009.09.009; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hansford LM, 2004, P NATL ACAD SCI USA, V101, P12664, DOI 10.1073/pnas.0401083101; Harbour ME, 2012, BIOCHEM J, V442, P209, DOI 10.1042/BJ20111761; Huang J, 2012, HISTOCHEM CELL BIOL, V138, P41, DOI 10.1007/s00418-012-0932-5; Huang P, 2011, CANCER RES, V71, P2938, DOI 10.1158/0008-5472.CAN-10-3524; Huang Y, 2008, J BIOL CHEM, V283, P11453, DOI 10.1074/jbc.M708544200; Kishida S, 2013, CANCER RES, V73, P1318, DOI 10.1158/0008-5472.CAN-12-3070; Kokai E, 2014, HISTOCHEM CELL BIOL, V141, P123, DOI 10.1007/s00418-013-1151-4; Le PU, 2010, ONCOGENE, V29, P4636, DOI 10.1038/onc.2010.216; LE PU, 2010, ELIFE, V29, P4636, DOI DOI 10.1038/ONC.2010.216; Li HY, 2014, GASTROENTEROLOGY, V147, P184, DOI 10.1053/j.gastro.2014.04.007; Lim KL, 2005, J NEUROSCI, V25, P2002, DOI 10.1523/JNEUROSCI.4474-04.2005; Liu Q, 2009, ONCOL REP, V22, P1069, DOI 10.3892/or_00000538; Lu FJ, 2016, ONCOL RES, V24, P171, DOI 10.3727/096504016X14634208142987; Lu FJ, 2015, CANCER SCI, V106, P390, DOI 10.1111/cas.12628; Maine GN, 2007, EMBO J, V26, P436, DOI 10.1038/sj.emboj.7601489; Masana M, 2014, PSYCHONEUROENDOCRINO, V48, P98, DOI 10.1016/j.psyneuen.2014.06.009; Miyamoto K, 2013, SCIENCE, V341, P1002, DOI 10.1126/science.1240376; Miyamoto K, 2011, GENE DEV, V25, P946, DOI 10.1101/gad.615211; Molenaar JJ, 2012, NATURE, V483, P589, DOI 10.1038/nature10910; Mu P, 2009, INT J CANCER, V125, P2978, DOI 10.1002/ijc.24382; Muller PAJ, 2009, TRAFFIC, V10, P514, DOI 10.1111/j.1600-0854.2009.00892.x; O'Hara A, 2014, J CELL SCI, V127, P3659, DOI 10.1242/jcs.149328; Obrdlik A, 2011, NUCLEUS-PHILA, V2, P72, DOI 10.4161/nucl.2.1.14508; Pastuszak-Lewandoska D, 2015, ADV EXP MED BIOL, V852, P39, DOI 10.1007/5584_2014_109; Phillips-Krawczak CA, 2015, MOL BIOL CELL, V26, P91, DOI 10.1091/mbc.E14-06-1073; Plessner M, 2015, J BIOL CHEM, V290, P11209, DOI 10.1074/jbc.M114.627166; Pollen AA, 2015, CELL, V163, P55, DOI 10.1016/j.cell.2015.09.004; Rual JF, 2005, NATURE, V437, P1173, DOI 10.1038/nature04209; Sato M, 2013, ONCOL RES, V21, P333, DOI 10.3727/096504014X14024160459249; Schmidt MV, 2011, P NATL ACAD SCI USA, V108, P17213, DOI 10.1073/pnas.1103318108; Takahashi Y, 2013, SCIENCE, V341, P860, DOI 10.1126/science.1230717; Udali S, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0077-1; van de Sluis B, 2002, HUM MOL GENET, V11, P165, DOI 10.1093/hmg/11.2.165; van de Sluis B, 2007, MOL CELL BIOL, V27, P4142, DOI 10.1128/MCB.01932-06; van de Sluis B, 2010, J CLIN INVEST, V120, P2119, DOI 10.1172/JCI40583; van den Boom J, 2006, INT J CANCER, V119, P2330, DOI 10.1002/ijc.22108; Vonk WIM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029183; Wang L, 2000, GENE CHROMOSOME CANC, V27, P1, DOI 10.1002/(SICI)1098-2264(200001)27:1<1::AID-GCC1>3.0.CO;2-6; Wu XY, 2006, NAT CELL BIOL, V8, P756, DOI 10.1038/ncb1433; Xia PY, 2014, J EXP MED, V211, P2119, DOI 10.1084/jem.20140169; Yamazaki S, 2016, HISTOCHEM CELL BIOL, V145, P389, DOI 10.1007/s00418-016-1416-9; Yeh DW, 2016, CELL DEATH DIFFER, V23, P841, DOI 10.1038/cdd.2015.147; Yoo YD, 2007, J BIOL CHEM, V282, P7616, DOI 10.1074/jbc.M607596200; Zhao XY, 2007, BIOCHEM BIOPH RES CO, V361, P74, DOI 10.1016/j.bbrc.2007.06.158	57	25	28	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 12	2017	36	41					5745	5756		10.1038/onc.2017.181	http://dx.doi.org/10.1038/onc.2017.181			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FJ6DJ	28604741				2022-12-17	WOS:000412843900008
J	Li, X; Kang, Y; Roife, D; Lee, Y; Pratt, M; Perez, MR; Dai, B; Koay, EJ; Fleming, JB				Li, X.; Kang, Y.; Roife, D.; Lee, Y.; Pratt, M.; Perez, M. R.; Dai, B.; Koay, E. J.; Fleming, J. B.			Prolonged exposure to extracellular lumican restrains pancreatic adenocarcinoma growth	ONCOGENE			English	Article							CANCER; CELLS; EXPRESSION; DORMANCY	We previously demonstrated that pancreatic stellate cells within pancreatic ductal adenocarcinoma (PDAC) stroma secrete lumican and its presence is associated with prolonged survival of patients with localized PDAC. Here, we observed that extracellular lumican decreases PDAC tumour cell growth in xenograft and syngeneic orthotopic animal models, and induces growth inhibition of low-passage human PDAC cells in a species-specific manner. PDAC cells grown in variant culture conditions and exposed to extracellular lumican display typical characterizations of cancer cell in a quiescent state, such as growth inhibition, apoptosis, G0/G1 arrest and chemoresistance. Importantly, extracellular lumican is associated with diminished ERK1/2 phosphorylation and increased p38 phosphorylation within PDAC cells. We further demonstrated that extracellular lumican physically binds with EGFR to trigger EGFR internalization and downregulation of EGFR and its downstream signal molecule ERK. Lumican enhances casitas B-lineage lymphoma expression, which stabilized the TGF beta Type II receptor sensitizing PDAC cells to TGF beta-mediated activation of p38 and SMAD signals. These provide a mechanism for the shift in signalling and phenotypic changes we observed after prolonged exposure to lumican. Together, our findings demonstrate that stromal lumican restrains PDAC cell growth through mediating cell entry into a quiescent state.	[Li, X.; Kang, Y.; Pratt, M.; Perez, M. R.; Dai, B.; Fleming, J. B.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, 1515 Holcombe Blvd,Unit 1484, Houston, TX 77030 USA; [Roife, D.] Univ Texas MD Anderson Canc Ctr, Dept Gen Surg, 1515 Holcombe Blvd,Unit 1484, Houston, TX 77030 USA; [Lee, Y.; Koay, E. J.] Univ Texas MD Anderson Canc Ctr, Div Radiat Oncol, 1515 Holcombe Blvd,Unit 1484, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Fleming, JB (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, 1515 Holcombe Blvd,Unit 1484, Houston, TX 77030 USA.	jbflemin@mdanderson.org		Roife, David/0000-0001-9052-2248	Skip Viragh Family Foundation; W. Smith Foundation; National Institutes of Health (NIH) [T32CA009599]; CABI GE in-kind grant;  [U54 CA210181-01]; NATIONAL CANCER INSTITUTE [U54CA210181, T32CA009599] Funding Source: NIH RePORTER	Skip Viragh Family Foundation; W. Smith Foundation; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CABI GE in-kind grant; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from the Skip Viragh Family Foundation (to JF), the W. Smith Foundation (to JF), National Institutes of Health (NIH) grant T32CA009599 (to DR and MRP), U54 CA210181-01 'Center for Immunotherapeutic Transport Oncophysics (CITO)' grant (to EK), and CABI GE in-kind grant (to EK). This research was conducted at the MD Anderson Cancer Center for Advanced Biomedical Imaging in-part with equipment support from General Electric Healthcare.	Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684; Bui AT, 2015, CELL CYCLE, V14, P1218, DOI 10.1080/15384101.2015.1014145; Baba H, 2001, JPN CIRC J, V65, P445, DOI 10.1253/jcj.65.445; Bragado P, 2013, NAT CELL BIOL, V15, P1351, DOI 10.1038/ncb2861; Gruber T, 2013, J MOL CELL BIOL, V5, P358, DOI 10.1093/jmcb/mjt017; Ishiwata T, 2007, ONCOL REP, V18, P537; Kang JM, 2012, ONCOGENE, V31, P5123, DOI 10.1038/onc.2012.18; Kang Y, 2016, CLIN CANCER RES, V22, P4934, DOI 10.1158/1078-0432.CCR-15-2780; Kim MP, 2012, ANN SURG ONCOL, V19, pS395, DOI 10.1245/s10434-011-1839-4; Kim MP, 2009, NAT PROTOC, V4, P1670, DOI 10.1038/nprot.2009.171; Li X, 2016, ONCOGENE, V35, P4881, DOI 10.1038/onc.2016.20; Li XQ, 2014, CLIN CANCER RES, V20, P6529, DOI 10.1158/1078-0432.CCR-14-0970; Lu YP, 2002, PATHOL INT, V52, P519, DOI 10.1046/j.1440-1827.2002.01384.x; Maykel J, 2014, DIGEST DIS SCI, V59, P1169, DOI 10.1007/s10620-014-3168-5; Ozdemir BC, 2014, CANCER CELL, V25, P719, DOI 10.1016/j.ccr.2014.04.005; Proia DA, 2005, CELL CYCLE, V4, P1022, DOI 10.4161/cc.4.8.1903; Ranganathan AC, 2006, CELL CYCLE, V5, P1799, DOI 10.4161/cc.5.16.3109; Rhim AD, 2014, CANCER CELL, V25, P735, DOI 10.1016/j.ccr.2014.04.021; Salm SN, 2005, J CELL BIOL, V170, P81, DOI 10.1083/jcb.200412015; Suetsugu A, 2012, J CELL BIOCHEM, V113, P2290, DOI 10.1002/jcb.24099; Williams KE, 2011, CANCER MICROENVIRON, V4, P115, DOI 10.1007/s12307-010-0056-1; Yamamoto T, 2012, CANCER LETT, V320, P31, DOI 10.1016/j.canlet.2012.01.023; Yamanaka O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082730; Zuo W, 2013, MOL CELL, V49, P499, DOI 10.1016/j.molcel.2012.12.002	24	25	26	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2017	36	38					5432	5438		10.1038/onc.2017.125	http://dx.doi.org/10.1038/onc.2017.125			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FH7PJ	28534517	Green Accepted			2022-12-17	WOS:000411382100009
J	Han, AL; Veeneman, BA; El-Sawy, L; Day, KC; Day, ML; Tomlins, SA; Keller, ET				Han, A. L.; Veeneman, B. A.; El-Sawy, L.; Day, K. C.; Day, M. L.; Tomlins, S. A.; Keller, E. T.			Fibulin-3 promotes muscle-invasive bladder cancer	ONCOGENE			English	Article							INHIBITS CELL-MIGRATION; BREAST-CANCER; IN-VIVO; POOR-PROGNOSIS; GROWTH; GENE; METHYLATION; EXPRESSION; EFEMP1; IGFBP-5	Urothelial carcinoma is the most common type of bladder cancer and can be categorized as either non-muscle-invasive (Ta-T1) or muscle-invasive (>= T2). The majority of bladder cancers are non-muscle-invasive at presentation; however, the recurrence rate for these tumors is high and a subset can progress to T2. In this study, we aimed to identify genes differentially expressed between T1 vs T2 bladder cancer to identify key regulators of bladder cancer progression and/or invasion. We performed RNA-Seq on T1 and T2 bladder cancer tissues and used publicly available bladder cancer profiling studies to prioritize differentially expressed genes for validation and functional assessment. This integrative approach nominated an extracellular matrix glycoprotein, fibulin-3 (FBLN3, also known as EFEMP1), as being highly expressed in T2 vs T1 bladder cancer and aggressive vs indolent disease. We confirmed the overexpression of fibulin-3 in >= T2 vs non-muscle-invasive bladder cancer (NMIBC) by quantitative reverse transcriptase-PCR. Consistent with these findings, fibulin-3 expression level correlated with the invasive ability of several bladder cancer cell lines and modulation of fibulin-3 expression directly affected invasion. Fibulin-3 knockdown in bladder cancer cells decreased the incidence of MIBCs in a murine orthotopic bladder cancer model and decreased the expression of insulin-like growth factor-binding protein-5 (IGFBP5). Restoring IGFBP5 in these cells rescued their invasive and migratory potential. These results indicate that fibulin-3 serves as a pro-invasive factor in bladder cancer, which may be mediated through modulation of IGFBP5 expression. This also suggests fibulin-3 and IGFBP5 may have potential as biomarkers of aggressive bladder cancer or therapeutic targets.	[Han, A. L.; Tomlins, S. A.; Keller, E. T.] Univ Michigan, Sch Med, Dept Pathol, NCRC B14 RM116,2800 Plymouth Rd, Ann Arbor, MI 48109 USA; [Veeneman, B. A.] Univ Michigan, Sch Med, Dept Computat Med & Bioinformat, NCRC B14 RM116,2800 Plymouth Rd, Ann Arbor, MI 48109 USA; [El-Sawy, L.; Day, K. C.; Day, M. L.; Tomlins, S. A.; Keller, E. T.] Univ Michigan, Sch Med, Dept Urol, NCRC B14 RM116,2800 Plymouth Rd, Ann Arbor, MI 48109 USA; [Tomlins, S. A.] Univ Michigan, Sch Med, Michigan Ctr Translat Pathol, NCRC B14 RM116,2800 Plymouth Rd, Ann Arbor, MI 48109 USA; [Keller, E. T.] Univ Michigan, Biointerfaces Inst, NCRC B14 RM116,2800 Plymouth Rd, Ann Arbor, MI 48109 USA; [El-Sawy, L.] European Egyptian Pharmaceut Ind, Alexandria, Egypt	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Keller, ET (corresponding author), Univ Michigan, Sch Med, Dept Urol, NCRC B14 RM116,2800 Plymouth Rd, Ann Arbor, MI 48109 USA.	etkeller@med.umich.edu	Keller, Evan T/M-1446-2016	Keller, Evan T/0000-0002-7592-7535	University of Michigan Comprehensive Cancer Center Research Grant; Robert M and Elizabeth C Teeter Bladder Cancer Research Fund; A Alfred Taubman Medical Institute; NATIONAL CANCER INSTITUTE [P30CA046592] Funding Source: NIH RePORTER	University of Michigan Comprehensive Cancer Center Research Grant; Robert M and Elizabeth C Teeter Bladder Cancer Research Fund; A Alfred Taubman Medical Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the University of Michigan DNA Sequencing Core for the RNA-Seq. University of Michigan Comprehensive Cancer Center Research Grant (to ETK), the Robert M and Elizabeth C Teeter Bladder Cancer Research Fund (to SAT) and the MacLeod Family (to SAT). SAT is supported by the A Alfred Taubman Emerging Scholar Award from the A Alfred Taubman Medical Institute.	Almeida M, 2014, J CELL MOL MED, V18, P2287, DOI 10.1111/jcmm.12394; Arechederra M, 2015, J BIOL CHEM, V290, P4383, DOI 10.1074/jbc.M114.582239; Beattie J, 2006, BIOCHEM J, V395, P1, DOI 10.1042/BJ20060086; Botteman MF, 2003, PHARMACOECONOMICS, V21, P1315, DOI 10.1007/BF03262330; Camaj P, 2009, BIOL CHEM, V390, P1293, DOI 10.1515/BC.2009.140; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chang SS, 2016, J UROLOGY, V196, P1021, DOI 10.1016/j.juro.2016.06.049; Chen JJ, 2013, MATH PROBL ENG, V2013, DOI 10.1155/2013/768756; Chen XJ, 2014, CARCINOGENESIS, V35, P1707, DOI 10.1093/carcin/bgu023; Choi W, 2014, CANCER CELL, V25, P152, DOI 10.1016/j.ccr.2014.01.009; COOPER MJ, 1994, ONCOL RES, V6, P569; Damrauer JS, 2014, P NATL ACAD SCI USA, V111, P3110, DOI 10.1073/pnas.1318376111; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Gui YT, 2011, NAT GENET, V43, P875, DOI 10.1038/ng.907; Guo GW, 2013, NAT GENET, V45, P1459, DOI 10.1038/ng.2798; Hu B, 2012, CANCER RES, V72, P3873, DOI 10.1158/0008-5472.CAN-12-1060; Hu B, 2009, MOL CANCER RES, V7, P1756, DOI 10.1158/1541-7786.MCR-09-0207; Hwang CF, 2010, J PATHOL, V222, P367, DOI 10.1002/path.2776; Kim EJ, 2012, INT J ONCOL, V40, P402, DOI 10.3892/ijo.2011.1191; Kim IG, 2014, ONCOGENE, V33, P3908, DOI 10.1038/onc.2013.373; Klenotic PA, 2004, J BIOL CHEM, V279, P30469, DOI 10.1074/jbc.M403026200; Kricker JA, 2003, ENDOCRINOLOGY, V144, P2807, DOI 10.1210/en.2002-221086; Liang PI, 2013, J CLIN PATHOL, V66, P573, DOI 10.1136/jclinpath-2012-201278; McCaig C, 2002, J CELL SCI, V115, P4293, DOI 10.1242/jcs.00097; Nandhu MS, 2014, CANCER RES, V74, P5435, DOI 10.1158/0008-5472.CAN-14-0685; OH Y, 1993, ENDOCRINOLOGY, V132, P1337, DOI 10.1210/en.132.3.1337; Raitanen MP, 2001, ANN CHIR GYNAECOL, V90, P261; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Sabichi A, 2006, J UROLOGY, V175, P1133, DOI 10.1016/S0022-5347(05)00323-X; Sadr-Nabavi A, 2009, INT J CANCER, V124, P1727, DOI 10.1002/ijc.24108; Seeliger H, 2009, MOL CANCER RES, V7, P189, DOI 10.1158/1541-7786.MCR-08-0132; Sercu S, 2009, MATRIX BIOL, V28, P160, DOI 10.1016/j.matbio.2009.02.003; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sjodahl G, 2012, CLIN CANCER RES, V18, P3377, DOI 10.1158/1078-0432.CCR-12-0077-T; SOLOWAY MS, 1985, UROLOGY, V26, P18; Song EL, 2011, GYNECOL ONCOL, V121, P174, DOI 10.1016/j.ygyno.2010.11.004; Song EL, 2010, GYNECOL ONCOL, V117, P417, DOI 10.1016/j.ygyno.2009.12.016; Sureshbabu A, 2012, J CELL SCI, V125, P1693, DOI 10.1242/jcs.092882; Sylvester RJ, 2006, EUR UROL, V49, P466, DOI 10.1016/j.eururo.2005.12.031; Tian H, 2015, ONCOGENE, V34, P5635, DOI 10.1038/onc.2015.13; Tong JD, 2011, NEOPLASMA, V58, P441, DOI 10.4149/neo_2011_05_441; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wang Z, 2012, PATHOL ONCOL RES, V18, P263, DOI 10.1007/s12253-011-9437-0; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; Wu XR, 2005, NAT REV CANCER, V5, P713, DOI 10.1038/nrc1697; Xu S, 2014, ONCOL REP, V31, P79, DOI 10.3892/or.2013.2799; Zhang YW, 2010, EXP EYE RES, V90, P374, DOI 10.1016/j.exer.2009.09.018	49	25	25	1	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 14	2017	36	37					5243	5251		10.1038/onc.2017.149	http://dx.doi.org/10.1038/onc.2017.149			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FG8HT	28504717				2022-12-17	WOS:000410671700003
J	Kitajima, S; Yoshida, A; Kohno, S; Li, F; Suzuki, S; Nagatani, N; Nishimoto, Y; Sasaki, N; Muranaka, H; Wan, Y; Thai, TC; Okahashi, N; Matsuda, F; Shimizu, H; Nishiuchi, T; Suzuki, Y; Tominaga, K; Gotoh, N; Suzuki, M; Ewen, ME; Barbie, DA; Hirose, O; Tanaka, T; Takahashi, C				Kitajima, S.; Yoshida, A.; Kohno, S.; Li, F.; Suzuki, S.; Nagatani, N.; Nishimoto, Y.; Sasaki, N.; Muranaka, H.; Wan, Y.; Thai, T. C.; Okahashi, N.; Matsuda, F.; Shimizu, H.; Nishiuchi, T.; Suzuki, Y.; Tominaga, K.; Gotoh, N.; Suzuki, M.; Ewen, M. E.; Barbie, D. A.; Hirose, O.; Tanaka, T.; Takahashi, C.			The RB-IL-6 axis controls self-renewal and endocrine therapy resistance by fine-tuning mitochondrial activity	ONCOGENE			English	Article							RETINOBLASTOMA TUMOR-SUPPRESSOR; COMPREHENSIVE MOLECULAR PORTRAITS; FATTY-ACID OXIDATION; CANCER STEM-CELLS; RB; METABOLISM; INHIBITION; DEFICIENT; GLUTAMINE; NETWORKS	Retinoblastoma (RB) protein inactivation during tumor progression is often associated with acquisition of immature phenotypes and resistance to therapy. Determination of an RB inactivation signature in a context of gaining undifferentiated phenotype in a p53-null sarcoma system revealed a critical role for interleukin (IL)-6. Using a Gene Set Enrichment Analysis (GSEA), we discovered that poorly differentiated breast cancers are enriched for this RB inactivation signature. Accelerated IL-6 secretion following RB inactivation in an RB-intact luminal-type breast cancer cell line MCF-7 promoted a positive feed forward loop between IL-6 and STAT3 driving tumor growth and endocrine therapy resistance. In addition, some of RB-intact basal-like type breast cancer cell lines exhibited a similar phenotype following RB depletion. The mechanism whereby RB inactivation increases IL-6 production in MCF-7 cells appeared to involve fatty acid oxidation (FAO)-dependent mitochondrial metabolism and c-Jun NH(2)-terminal kinase (JNK). In addition, IL-6, via STAT3-mediated feedback to mitochondria, autonomously adjusts mitochondrial superoxide to levels suitable to maintain stem cell-like activity. The gene expression profile of luminal-type breast cancer patients with low RB expression revealed high enrichment of genes involved in mitochondrial respiration and downstream targets of IL-6. These findings unveiled an unexpected strategy whereby RB suppresses malignant features of cancer cells through metabolic reprogramming and cell-autonomous inflammation.	[Kitajima, S.; Yoshida, A.; Kohno, S.; Li, F.; Nagatani, N.; Nishimoto, Y.; Sasaki, N.; Muranaka, H.; Wan, Y.; Suzuki, M.; Takahashi, C.] Kanazawa Univ, Canc Res Inst, Div Oncol & Mol Biol, Kanazawa, Ishikawa 9201192, Japan; [Kitajima, S.; Thai, T. C.; Barbie, D. A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Yoshida, A.] Kanazawa Univ, Grad Sch Med Sci, Dept Cellular Transplantat Biol, Kanazawa, Ishikawa, Japan; [Suzuki, S.; Tanaka, T.] Chiba Univ, Grad Sch Med, Dept Clin Cell Biol & Med, Chiba, Japan; [Okahashi, N.; Matsuda, F.; Shimizu, H.] Osaka Univ, Grad Sch Informat Sci & Technol, Dept Bioinformat Engn, Suita, Osaka, Japan; [Nishiuchi, T.] Kanazawa Univ, Adv Sci Res Ctr, Div Funct Genom, Kanazawa, Ishikawa, Japan; [Suzuki, Y.] Univ Tokyo, Sch Engn, Dept Chem & Biotechnol, Chiba, Japan; [Tominaga, K.] Univ Tokyo, Inst Med Sci, Div Mol Therapy, Minato Ku, Tokyo, Japan; [Gotoh, N.] Kanazawa Univ, Canc Res Inst, Div Canc Cell Biol, Kanazawa, Ishikawa, Japan; [Ewen, M. E.] Tufts Med Ctr, Mol Oncol Res Inst, Boston, MA USA; [Barbie, D. A.] Broad Inst Harvard & MIT, Cambridge, MA USA; [Hirose, O.] Kanazawa Univ, Grad Sch Nat Sci & Technol, Div Elect Engn & Comp Sci, Kanazawa, Ishikawa, Japan	Kanazawa University; Harvard University; Dana-Farber Cancer Institute; Kanazawa University; Chiba University; Osaka University; Kanazawa University; University of Tokyo; University of Tokyo; Kanazawa University; Tufts Medical Center; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Kanazawa University	Takahashi, C (corresponding author), Kanazawa Univ, Canc Res Inst, Div Oncol & Mol Biol, Kanazawa, Ishikawa 9201192, Japan.	chtakaha@staff.kanazawa-u.ac.jp	Sasaki, Nobunari/ABF-6656-2020; Okahashi, Nobuyuki/AAL-6437-2021; Hirose, Osamu/K-7890-2015; Okahashi, Nobuyuki/AAM-5359-2021; Shimizu, Hiroshi/C-3688-2017; GOTOH, Noriko/D-8430-2015	Okahashi, Nobuyuki/0000-0001-9582-355X; Hirose, Osamu/0000-0002-8077-8589; Okahashi, Nobuyuki/0000-0001-9582-355X; Shimizu, Hiroshi/0000-0002-8986-0861; Nishiuchi, Takumi/0000-0001-9429-5396; Gotoh, Noriko/0000-0003-3733-260X; Tominaga, Kana/0000-0001-5136-5091	Funding Program for Next Generation World-Leading Researchers; Hokuriku Bank Research Grant for Young Scientists	Funding Program for Next Generation World-Leading Researchers(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Hokuriku Bank Research Grant for Young Scientists	We thank Drs T Kitamura, N Mukaida, K Yoshioka and Chugai Pharmaceuticals Co. Ltd. for providing materials, Drs T Baba, K Hinohara, A Hirao, T Hoshii, A Ishimura, K Matsumoto, K Sakai, S Sasaki, T Sato, T Shimamura, T Suzuki and Y Tadokoro for technical instruction, Dr A Ooi for pathological diagnosis, Drs I Ajioka and R Jenkins for critical reading of this manuscript, and Dr C Prives for advice. This work was supported by Funding Program for Next Generation World-Leading Researchers to CT, Grant-in-Aid for Scientific Research to CT, S Kitajima and NS, and Hokuriku Bank Research Grant for Young Scientists to S Kitajima.	Barbie TU, 2014, J CLIN INVEST, V124, P5411, DOI 10.1172/JCI75661; Blanchet E, 2011, NAT CELL BIOL, V13, P1146, DOI 10.1038/ncb2309; Bosco EE, 2007, J CLIN INVEST, V117, P218, DOI 10.1172/JCI28803; Bulua AC, 2011, J EXP MED, V208, P519, DOI 10.1084/jem.20102049; Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399; Calo E, 2010, NATURE, V466, P1110, DOI 10.1038/nature09264; Cam H, 2004, MOL CELL, V16, P399, DOI 10.1016/j.molcel.2004.09.037; Carracedo A, 2013, NAT REV CANCER, V13, P227, DOI 10.1038/nrc3483; Chavey C, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1648; Choi J, 2010, AM J PATHOL, V177, P2645, DOI 10.2353/ajpath.2010.100306; Ciavarra G, 2010, J CELL BIOL, V191, P291, DOI 10.1083/jcb.201005067; Ciriello G, 2015, CELL, V163, P506, DOI 10.1016/j.cell.2015.09.033; Croonquist PA, 2003, BLOOD, V102, P2581, DOI 10.1182/blood-2003-04-1227; Cuperus R, 2010, CELL MOL LIFE SCI, V67, P807, DOI 10.1007/s00018-009-0212-2; Das M, 2011, GENE DEV, V25, P634, DOI 10.1101/gad.1989311; Denechaud PD, 2016, J CLIN INVEST, V126, P137, DOI 10.1172/JCI81542; Gauthier ML, 2007, CANCER CELL, V12, P479, DOI 10.1016/j.ccr.2007.10.017; Gough DJ, 2009, SCIENCE, V324, P1713, DOI 10.1126/science.1171721; Guo DJ, 2012, ONCOL LETT, V4, P311, DOI 10.3892/ol.2012.733; HARVEY M, 1995, CANCER RES, V55, P1146; Herschkowitz JI, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2142; Hinohara K, 2012, P NATL ACAD SCI USA, V109, P6584, DOI 10.1073/pnas.1113271109; Hsieh MCF, 2008, J BIOL CHEM, V283, P27410, DOI 10.1074/jbc.M802418200; Iliopoulos D, 2011, P NATL ACAD SCI USA, V108, P1397, DOI 10.1073/pnas.1018898108; Ishimoto T, 2011, CANCER CELL, V19, P387, DOI 10.1016/j.ccr.2011.01.038; Ito K, 2012, NAT MED, V18, P1350, DOI 10.1038/nm.2882; Jiang Z, 2011, CELL CYCLE, V10, P1563, DOI 10.4161/cc.10.10.15703; Jiang Z, 2010, J CLIN INVEST, V120, P3296, DOI 10.1172/JCI41490; Jones RA, 2016, J CLIN INVEST, V126, P3739, DOI 10.1172/JCI81568; Kadota K, 2008, ALGORITHM MOL BIOL, V3, DOI 10.1186/1748-7188-3-8; Kareta MS, 2015, CELL STEM CELL, V16, P39, DOI 10.1016/j.stem.2014.10.019; Kitajima S, 2015, STEM CELLS, V33, P1657, DOI 10.1002/stem.1971; Knudsen ES, 2008, NAT REV CANCER, V8, P714, DOI 10.1038/nrc2401; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kohno S, 2016, WORLD J STEM CELLS, V8, P170, DOI 10.4252/wjsc.v8.i4.170; Korkaya H, 2012, MOL CELL, V47, P570, DOI 10.1016/j.molcel.2012.06.014; Korkaya H, 2011, J CLIN INVEST, V121, P3804, DOI 10.1172/JCI57099; Li F, 2010, CELL STEM CELL, V7, P508, DOI 10.1016/j.stem.2010.09.003; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Liu YQ, 2009, CELL STEM CELL, V4, P336, DOI 10.1016/j.stem.2009.02.015; Marotta LLC, 2011, J CLIN INVEST, V121, P2723, DOI 10.1172/JCI44745; Mitsuishi Y, 2012, CANCER CELL, V22, P66, DOI 10.1016/j.ccr.2012.05.016; Nicolay BN, 2015, GENE DEV, V29, P1875, DOI 10.1101/gad.264127.115; Nicolay BN, 2013, GENE DEV, V27, P182, DOI 10.1101/gad.206227.112; Ohsawa S, 2012, NATURE, V490, P547, DOI 10.1038/nature11452; Pajcini KV, 2010, CELL STEM CELL, V7, P198, DOI 10.1016/j.stem.2010.05.022; Petrov PD, 2016, J CELL PHYSIOL, V231, P708, DOI 10.1002/jcp.25121; Petrov PD, 2015, AM J PHYSIOL-ENDOC M, V308, pE172, DOI 10.1152/ajpendo.00308.2014; Reynolds MR, 2014, ONCOGENE, V33, P556, DOI 10.1038/onc.2012.635; Sage J, 2012, GENE DEV, V26, P1409, DOI 10.1101/gad.193730.112; Sankaran VG, 2008, GENE DEV, V22, P463, DOI 10.1101/gad.1627208; Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533; Sansone P, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10442; Shamma A, 2013, MOL CELL BIOL, V33, P3113, DOI 10.1128/MCB.01597-12; Shamma A, 2009, CANCER CELL, V15, P255, DOI 10.1016/j.ccr.2009.03.001; Takahashi C, 2012, CANCER SCI, V103, P1182, DOI 10.1111/j.1349-7006.2012.02284.x; Takebayashi S, 2015, AGING CELL, V14, P689, DOI 10.1111/acel.12351; TSUKADA T, 1993, ONCOGENE, V8, P3313; Varaljai R, 2015, GENE DEV, V29, P1817, DOI 10.1101/gad.264036.115; Viale A, 2014, NATURE, V514, P628, DOI 10.1038/nature13611; Viatour P, 2011, DIS MODEL MECH, V4, P581, DOI 10.1242/dmm.008060; Visvader JE, 2014, GENE DEV, V28, P1143, DOI 10.1101/gad.242511.114; Wang LY, 2016, CELL REP, V16, P3016, DOI 10.1016/j.celrep.2016.08.018; Wegrzyn J, 2009, SCIENCE, V323, P793, DOI 10.1126/science.1164551; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; Wruck CJ, 2011, J BIOL CHEM, V286, P4493, DOI 10.1074/jbc.M110.162008; Zhu ZH, 2014, CANCER DISCOV, V4, P452, DOI 10.1158/2159-8290.CD-13-0646	68	25	26	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	2017	36	36					5145	5157		10.1038/onc.2017.124	http://dx.doi.org/10.1038/onc.2017.124			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF9XD	28481867				2022-12-17	WOS:000409371100006
J	Hu, PS; Xia, QS; Wu, F; Li, DK; Qi, YJ; Hu, Y; Wei, ZZ; Li, SS; Tian, NY; Wei, QF; Shen, LJ; Yin, B; Jiang, T; Yuan, JG; Qiang, BQ; Han, W; Peng, XZ				Hu, P-S; Xia, Q-S; Wu, F.; Li, D-K; Qi, Y-J; Hu, Y.; Wei, Z-Z; Li, S-S; Tian, N-Y; Wei, Q-F; Shen, L-J; Yin, B.; Jiang, T.; Yuan, J-G; Qiang, B-Q; Han, W.; Peng, X-Z			NSPc1 promotes cancer stem cell self-renewal by repressing the synthesis of all-trans retinoic acid via targeting RDH16 in malignant glioma	ONCOGENE			English	Article							SIDE POPULATION; POLYCOMB GENE; COMPLEX 1; BMI1; GROWTH; IDENTIFICATION; MAINTENANCE; ASTROCYTES; EXPRESSION; REGULATOR	Polycomb group (PcG) proteins play an important role in development and stem cell maintenance, and their dysregulation have been closely linked to oncogenesis and cancer stem cell phenotypes. Here, we found that nervous system polycomb 1 (NSPc1) was highly expressed in stem cell-like glioma cells (SLCs). Knockdown of NSPc1 in SLCs resulted in impaired neurosphere formation and self-renewal abilities, down-regulated expression of stemness markers such as NESTIN, CD133 and SOX2, and decreased capacity to propagate subcutaneous xenografts. In contrast, glioma cells overexpressing NSPc1 exhibited a stem cell-like phenotype, upregulated expression of stemness markers NESTIN, CD133 and SOX2, and an enhanced capacity to propagate subcutaneous xenografts. Furthermore, we identified that NSPc1 epigenetically repressed the expression of retinol dehydrogenase 16 (RDH16) by directly binding to a region upstream (-1073 to -823) of the RDH16 promoter. Next, we confirmed that RDH16 is a stemness suppressor that partially rescues SLCs from the NSPc1-induced increase in neurosphere formation. Finally, we showed that ATRA partly reversed the NSPc1-induced stemness enhancement in SLCs, through mechanisms correlated with an ATRA-dependent decrease in the expression of NSPc1. Thus, our results demonstrate that NSPc1 promotes cancer stem cell self-renewal by repressing the synthesis of ATRA via targeting RDH16 and may provide novel targets for glioma treatment in the future.	[Hu, P-S; Xia, Q-S; Wu, F.; Li, D-K; Qi, Y-J; Hu, Y.; Wei, Z-Z; Li, S-S; Tian, N-Y; Wei, Q-F; Shen, L-J; Yin, B.; Yuan, J-G; Qiang, B-Q; Han, W.; Peng, X-Z] Chinese Acad Med Sci, State Key Lab Med Mol Biol, Dept Mol Biol & Biochem,Sch Basic Med,Peking Unio, Inst Basic Med Sci,Med Primate Res Ctr,Neurosci C, Beijing, Peoples R China; [Jiang, T.] Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Capital Medical University	Han, W; Peng, XZ (corresponding author), Chinese Acad Med Sci, State Key Lab Med Mol Biol, Dept Mol Biol & Biochem, Inst Basic Med Sci,Med Primate Res Ctr,Neurosci C, Beijing 100005, Peoples R China.; Han, W; Peng, XZ (corresponding author), Peking Union Med Coll, Beijing 100005, Peoples R China.	hanweijx2002@163.com; pengxiaozhong@pumc.edu.cn		wei, zhizhong/0000-0002-9840-1878	National Key Research and Development Plan [2016YFC0902502, 2016YFA0100702]; 973 project [2013CB531304]; National Sciences Foundation of China [31671316, 31301152, 31370789, 31670789]; CAMS Innovation Fund for Medical Sciences (CIFMS) [2016-I2M-1-001, 2016-I2M-2-001, 2016-I2M-1-004]	National Key Research and Development Plan; 973 project(National Basic Research Program of China); National Sciences Foundation of China(National Natural Science Foundation of China (NSFC)); CAMS Innovation Fund for Medical Sciences (CIFMS)	This work was supported by grants from The National Key Research and Development Plan (2016YFC0902502, 2016YFA0100702), 973 project No. 2013CB531304, National Sciences Foundation of China (31671316, 31301152, 31370789, 31670789), CAMS Innovation Fund for Medical Sciences (2016-I2M-1-001, CIFMS, 2016-I2M-2-001, 2016-I2M-1-004). We thank Dr Zeper Abliz and Ruiping Zhang from the State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, for assistance with retinoid quantification.	Abdouh M, 2009, J NEUROSCI, V29, P8884, DOI 10.1523/JNEUROSCI.0968-09.2009; Aguilar-Gallardo C, 2013, SEMIN REPROD MED, V31, P5, DOI 10.1055/s-0032-1331792; Ahmed AU, 2013, EXPERT REV NEUROTHER, V13, P545, DOI [10.1586/ern.13.42, 10.1586/ERN.13.42]; Chen H, 2011, HEAD NECK-J SCI SPEC, V33, P1115, DOI 10.1002/hed.21576; Chockalingam S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083877; Choschzick I, 2014, NEUROSCIENCE, V279, P44, DOI 10.1016/j.neuroscience.2014.07.078; Duester G, 2008, CELL, V134, P921, DOI 10.1016/j.cell.2008.09.002; Gong YH, 2006, NUCLEIC ACIDS RES, V34, P6158, DOI 10.1093/nar/gkl834; Gong YH, 2005, FEBS LETT, V579, P115, DOI 10.1016/j.febslet.2004.11.056; Gudas LJ, 2011, J CELL PHYSIOL, V226, P322, DOI 10.1002/jcp.22417; Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100; ISHIDA A, 1993, GENE, V129, P249, DOI 10.1016/0378-1119(93)90275-8; Iwama A, 2004, IMMUNITY, V21, P843, DOI 10.1016/j.immuni.2004.11.004; Jiang T, 2016, CANCER LETT, V375, P263, DOI 10.1016/j.canlet.2016.01.024; Jordan CT, 2004, CURR OPIN CELL BIOL, V16, P708, DOI 10.1016/j.ceb.2004.09.002; Jurcic Joseph G, 2007, Curr Oncol Rep, V9, P337, DOI 10.1007/s11912-007-0045-9; Kimura M, 2011, CANCER SCI, V102, P983, DOI 10.1111/j.1349-7006.2011.01891.x; Kondo T, 2004, P NATL ACAD SCI USA, V101, P781, DOI 10.1073/pnas.0307618100; Levine SS, 2002, MOL CELL BIOL, V22, P6070, DOI 10.1128/MCB.22.17.6070-6078.2002; Li H, 2013, BIOCHEM BIOPH RES CO, V440, P527, DOI 10.1016/j.bbrc.2013.09.095; Liang Y, 2015, FRONT MED-PRC, V9, P57, DOI 10.1007/s11684-015-0389-8; Lorie EP, 2009, ARCH DERMATOL RES, V301, P475, DOI 10.1007/s00403-009-0937-7; Molofsky AV, 2005, GENE DEV, V19, P1432, DOI 10.1101/gad.1299505; Moon JH, 2008, BIOCHEM BIOPH RES CO, V371, P267, DOI 10.1016/j.bbrc.2008.04.068; Napoli JL, 1999, BBA-MOL CELL BIOL L, V1440, P139, DOI 10.1016/S1388-1981(99)00117-1; Nunes M, 2001, MECH DEVELOP, V102, P219, DOI 10.1016/S0925-4773(01)00288-X; Oliviero G, 2015, SCI REP-UK, V5, DOI 10.1038/srep18388; Ostrom QT, 2015, CANCER TREAT RES, V163, P1, DOI 10.1007/978-3-319-12048-5_1; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Richly H, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.84; Ross K, 2012, BLOOD, V119, P4152, DOI 10.1182/blood-2011-09-382390; Sakoe Y, 2010, BLOOD, V115, P3787, DOI 10.1182/blood-2009-05-222976; Schwartz YB, 2008, CURR OPIN CELL BIOL, V20, P266, DOI 10.1016/j.ceb.2008.03.002; Sher F, 2011, CELL REPROGRAM, V13, P1, DOI 10.1089/cell.2010.0052; Siddikuzzaman, 2011, IMMUNOPHARM IMMUNOT, V33, P241, DOI 10.3109/08923973.2010.521507; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Smith LL, 2011, CELL STEM CELL, V8, P649, DOI 10.1016/j.stem.2011.05.004; Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991; Stiles CD, 2008, NEURON, V58, P832, DOI 10.1016/j.neuron.2008.05.031; Udali S, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0077-1; Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007; Wan F, 2010, BRAIN PATHOL, V20, P877, DOI 10.1111/j.1750-3639.2010.00379.x; Wang HX, 2015, NEOPLASIA, V17, P239, DOI 10.1016/j.neo.2015.02.002; Wang J, 2008, INT J CANCER, V122, P761, DOI 10.1002/ijc.23130; Wang L, 2004, MOL CELL, V14, P637, DOI 10.1016/j.molcel.2004.05.009; Wang X, 2012, ONCOGENE, V31, P187, DOI 10.1038/onc.2011.232; Wu XD, 2008, NUCLEIC ACIDS RES, V36, P3590, DOI 10.1093/nar/gkn243; Wu XD, 2013, MOL CELL, V49, P1134, DOI 10.1016/j.molcel.2013.01.016; Yadirgi G, 2011, STEM CELLS, V29, P700, DOI 10.1002/stem.614; Yin CL, 2014, FRONT BIOSCI-LANDMRK, V19, P818, DOI 10.2741/4249; Ying M, 2011, ONCOGENE, V30, P3454, DOI 10.1038/onc.2011.58; Yu SC, 2008, CANCER LETT, V265, P124, DOI 10.1016/j.canlet.2008.02.010; Zhang P, 2009, CANCER LETT, V277, P227, DOI 10.1016/j.canlet.2008.12.015	54	25	26	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2017	36	33					4706	4718		10.1038/onc.2017.34	http://dx.doi.org/10.1038/onc.2017.34			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD7JM	28394339				2022-12-17	WOS:000407702400004
J	Motzik, A; Amir, E; Erlich, T; Wang, J; Kim, BG; Han, JM; Kim, JH; Nechushtan, H; Guo, M; Razin, E; Tshori, S				Motzik, A.; Amir, E.; Erlich, T.; Wang, J.; Kim, B-G; Han, J. M.; Kim, J. H.; Nechushtan, H.; Guo, M.; Razin, E.; Tshori, S.			Post-translational modification of HINT1 mediates activation of MITF transcriptional activity in human melanoma cells	ONCOGENE			English	Article							TRANSFER-RNA SYNTHETASE; MAST-CELLS; TUMOR-SUPPRESSOR; AXONAL NEUROPATHY; GENE-EXPRESSION; GASTRIC-CANCER; PROTEIN; MICROPHTHALMIA; MECHANISM; NEUROMYOTONIA	Microphthalmia transcription factor (MITF) is a basic helix-loop-helix leucine zipper (bHLH-Zip) DNA-binding protein. This transcription factor plays a crucial role in the physiological and pathological functions of distinct cell types. MITF transcriptional activity is inhibited by the histidine triad nucleotide-binding protein 1 (HINT1) through direct binding. We previously reported that this association is disrupted by the binding of the second messenger Ap4A to HINT1. Ap4A is mainly produced in the mammalian cells by S207-phosphorylated Lysyl-tRNA synthetase. In this study, we found first that HINT1 was subjected to K21 acetylation and Y109 phosphorylation in activated mast cells, together with the Ap4A-triggered HINT1 dissociation from MITF. Mutational analysis confirmed that these modifications promote MITF transcriptional and oncogenic activity in melanoma cell lines, derived from human melanoma patients. Thus, we provided here an example that manipulation of the LysRS-Ap4A-HINT1-MITF signalling pathway in melanoma through post-translational modifications of HINT1 can affect the activity of the melanoma oncogene MITF.	[Motzik, A.; Amir, E.; Erlich, T.; Razin, E.] Hebrew Univ Jerusalem, Hadassah Med Sch, Inst Med Res Israel Canada, Dept Biochem & Mol Biol, POB 12272, IL-91120 Jerusalem, Israel; [Wang, J.] Chinese Acad Sci, Shanghai Inst Organ Chem, State Key Lab Bioorgan & Nat Prod Chem, Shanghai, Peoples R China; [Kim, B-G] Seoul Natl Univ, Coll Pharm, Med Bioconvergence Res Ctr, Seoul, South Korea; [Han, J. M.] Yonsei Univ, Dept Integrated OMICS Biomed Sci, Seoul, South Korea; [Han, J. M.] Seoul Natl Univ, Dept Mol Med & Biopharmaceut Sci, Seoul, South Korea; [Kim, J. H.] Yonsei Univ, Coll Pharm, Seoul, South Korea; [Nechushtan, H.] Hadassah Hebrew Univ Med Ctr, Oncol Dept, Jerusalem, Israel; [Guo, M.] Scripps Res Inst, Dept Canc Biol, Jupiter, FL USA; [Tshori, S.] Kaplan Med Ctr, Dept Nucl Med, Rehovot, Israel	Hebrew University of Jerusalem; Chinese Academy of Sciences; Shanghai Institute of Organic Chemistry, CAS; Seoul National University (SNU); Yonsei University; Seoul National University (SNU); Yonsei University; Hebrew University of Jerusalem; Scripps Research Institute; Hebrew University of Jerusalem; Kaplan Medical Center	Razin, E (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Inst Med Res Israel Canada, Dept Biochem & Mol Biol, POB 12272, IL-91120 Jerusalem, Israel.	ehudr@ekmd.huji.ac.il	nechushtan, hovav/Z-3564-2019; Amir, Eitan/L-6052-2019	Han, Jung Min/0000-0003-3372-7575; Erlich, Tal/0000-0003-0601-2574; Wang, Jing/0000-0002-7566-1212	National Institute of Health [GM100136]; American Asthma Foundation [AAF15-0080]; National Research Foundation of Singapore (Hebrew University of Jerusalem-Campus for Research Excellence and Technological Enterprise); Israel Science Foundation; Israel Cancer Association, Boca Grove Fellowship Fund	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Asthma Foundation; National Research Foundation of Singapore (Hebrew University of Jerusalem-Campus for Research Excellence and Technological Enterprise); Israel Science Foundation(Israel Science Foundation); Israel Cancer Association, Boca Grove Fellowship Fund	We thank Prof Norman Grover from the Hebrew University for conducting the statistical analysis. Patient-derived cutaneous metastatic melanoma cells (line TC-2514) were kindly provided by Dr John Wunderlich (Surgery Branch National Cancer Institute). This work was supported in part by grants from the National Institute of Health GM100136 and American Asthma Foundation AAF15-0080 to MG, and National Research Foundation of Singapore (Hebrew University of Jerusalem-Campus for Research Excellence and Technological Enterprise) and Israel Science Foundation to ER and the Israel Cancer Association, Boca Grove Fellowship Fund to ER.	Aminkeng F, 2013, CLIN GENET, V83, P31, DOI 10.1111/cge.12030; Bertolotto C, 2011, NATURE, V480, P94, DOI 10.1038/nature10539; Carmi-Levy I, 2008, MOL CELL BIOL, V28, P5777, DOI 10.1128/MCB.00106-08; Carmi-Levy I, 2011, MOL CELL BIOL, V31, P2111, DOI 10.1128/MCB.01159-10; Chen Q, 2008, SCHIZOPHR RES, V106, P200, DOI 10.1016/j.schres.2008.08.006; Dolot R, 2016, INT J BIOL MACROMOL, V87, P62, DOI 10.1016/j.ijbiomac.2016.02.047; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Garraway LA, 2006, NAT REV CANCER, V6, P593, DOI 10.1038/nrc1947; Genovese G, 2012, CELL CYCLE, V11, P2206, DOI 10.4161/cc.20765; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; Hori T, 2000, MOL BIOL CELL, V11, P3645, DOI 10.1091/mbc.11.10.3645; Huang HY, 2011, INT J ONCOL, V38, P1557, DOI 10.3892/ijo.2011.994; Jackson KJ, 2011, PHARMACOGENOMICS J, V11, P251, DOI 10.1038/tpj.2010.41; Johannessen CM, 2013, NATURE, V504, P138, DOI 10.1038/nature12688; Lee YN, 2005, MOL CELL BIOL, V25, P8904, DOI 10.1128/MCB.25.20.8904-8912.2005; Lee YN, 2004, IMMUNITY, V20, P145, DOI 10.1016/S1074-7613(04)00020-2; Levy C, 2006, TRENDS MOL MED, V12, P406, DOI 10.1016/j.molmed.2006.07.008; Li H, 2006, ONCOGENE, V25, P713, DOI 10.1038/sj.onc.1209111; Li HY, 2008, J CELL BIOL, V183, P253, DOI 10.1083/jcb.200711150; Miller AJ, 2006, NEW ENGL J MED, V355, P51, DOI 10.1056/NEJMra052166; Nechushtan H, 2002, MOL IMMUNOL, V38, P1177, DOI 10.1016/S0161-5890(02)00059-7; Ofir-Birin Y, 2013, MOL CELL, V49, P30, DOI 10.1016/j.molcel.2012.10.010; RANDERATH K, 1966, BIOCHEM BIOPH RES CO, V24, P98, DOI 10.1016/0006-291X(66)90416-5; Razin E, 1999, J BIOL CHEM, V274, P34272, DOI 10.1074/jbc.274.48.34272; Sonnenblick A, 2005, J IMMUNOL, V175, P1450, DOI 10.4049/jimmunol.175.3.1450; Su T, 2003, P NATL ACAD SCI USA, V100, P7824, DOI 10.1073/pnas.1332160100; Swarbrick JD, 2005, J BIOL CHEM, V280, P8471, DOI 10.1074/jbc.M412318200; Tang TY, 2016, ANTICANCER RES, V36, P3229; Weiske J, 2006, J BIOL CHEM, V281, P27356, DOI 10.1074/jbc.M513452200; Wellbrock C, 2015, PIGM CELL MELANOMA R, V28, P390, DOI 10.1111/pcmr.12370; YANG DCH, 1985, CURR TOP CELL REGUL, V26, P325; Yannay-Cohen N, 2009, MOL CELL, V34, P603, DOI 10.1016/j.molcel.2009.05.019; Yokoyama S, 2011, NATURE, V480, P99, DOI 10.1038/nature10630; Yuan BZ, 2004, NEOPLASIA, V6, P412, DOI 10.1593/neo.03490; Zimon M, 2012, NAT GENET, V44, P1080, DOI 10.1038/ng.2406; Zuk K, 2012, ONCOL LETT, V3, P219, DOI 10.3892/ol.2011.456	37	25	25	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2017	36	33					4732	4738		10.1038/onc.2017.81	http://dx.doi.org/10.1038/onc.2017.81			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD7JM	28394346				2022-12-17	WOS:000407702400006
J	Zoni, E; Chen, L; Karkampouna, S; Granchi, Z; Verhoef, EI; La Manna, F; Kelber, J; Pelger, RCM; Henry, MD; Snaar-Jagalska, E; van Leenders, GJLH; Beimers, L; Kloen, P; Gray, PC; van der Pluijm, G; Julio, MKD				Zoni, E.; Chen, L.; Karkampouna, S.; Granchi, Z.; Verhoef, E. I.; La Manna, F.; Kelber, J.; Pelger, R. C. M.; Henry, M. D.; Snaar-Jagalska, E.; van Leenders, G. J. L. H.; Beimers, L.; Kloen, P.; Gray, P. C.; van der Pluijm, G.; Julio, M. Kruithof-de			CRIPTO and its signaling partner GRP78 drive the metastatic phenotype in human osteotropic prostate cancer	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; STEM-CELLS; TGF-BETA; BONE METASTASIS; EMBRYONIC GENE; GROWTH; EXPRESSION; ZEBRAFISH; PROMOTES; DIFFERENTIATION	CRIPTO (CR-1, TDGF1) is a cell surface/secreted oncoprotein actively involved in development and cancer. Here, we report that high expression of CRIPTO correlates with poor survival in stratified risk groups of prostate cancer (PCa) patients. CRIPTO and its signaling partner glucose-regulated protein 78 (GRP78) are highly expressed in PCa metastases and display higher levels in the metastatic ALDH(high) sub-population of PC-3M-Pro4Luc2 PCa cells compared with non-metastatic ALDH(low). Coculture of the osteotropic PC-3M-Pro4Luc2 PCa cells with differentiated primary human osteoblasts induced CRIPTO and GRP78 expression in cancer cells and increases the size of the ALDH(high) sub-population. Additionally, CRIPTO or GRP78 knockdown decreases proliferation, migration, clonogenicity and the size of the metastasis-initiating ALDH(high) sub-population. CRIPTO knockdown reduces the invasion of PC-3M-Pro4Luc2 cells in zebrafish and inhibits bone metastasis in a preclinical mouse model. These results highlight a functional role for CRIPTO and GRP78 in PCa metastasis and suggest that targeting CRIPTO/GRP78 signaling may have significant therapeutic potential.	[Zoni, E.; Karkampouna, S.; La Manna, F.; Pelger, R. C. M.; van der Pluijm, G.; Julio, M. Kruithof-de] Leiden Univ, Dept Urol, Med Ctr, Leiden, Netherlands; [Zoni, E.; Karkampouna, S.; La Manna, F.; Snaar-Jagalska, E.; Julio, M. Kruithof-de] Univ Bern, Urol Res Lab, Dept Urol, Murtenstr 35, CH-3008 Bern, Switzerland; [Zoni, E.; Karkampouna, S.; La Manna, F.; Snaar-Jagalska, E.; Julio, M. Kruithof-de] Univ Bern, Dept Clin Res, Murtenstr 35, CH-3008 Bern, Switzerland; [Chen, L.] Leiden Univ, Inst Biol, Dept Mol Cell Biol, Leiden, Netherlands; [Granchi, Z.] Genome Scan, Leiden, Netherlands; [Verhoef, E. I.; van Leenders, G. J. L. H.] Erasmus MC, Dept Pathol, Rotterdam, Netherlands; [Kelber, J.] Calif State Univ Northbridge, Dept Biol, Northbridge, CA USA; [Henry, M. D.] Univ Iowa, Dept Mol Physiol & Biophys, Iowa City, IA USA; [Beimers, L.] Slotervaart Med Ctr, Dept Orthoped Surg, Amsterdam, Netherlands; [Kloen, P.] Acad Med Ctr, Dept Orthoped Trauma Surg, Amsterdam, Netherlands; [Gray, P. C.] Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Bern; University of Bern; Leiden University; Leiden University - Excl LUMC; Erasmus University Rotterdam; Erasmus MC; University of Iowa; Slotervaart Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Salk Institute	Julio, MKD (corresponding author), Univ Bern, Urol Res Lab, Dept Urol, Murtenstr 35, CH-3008 Bern, Switzerland.; Julio, MKD (corresponding author), Univ Bern, Dept Clin Res, Murtenstr 35, CH-3008 Bern, Switzerland.	marianna.kruithofdejulio@dkf.unibe.ch	Pelger, Rob/ABF-9029-2021; Zoni, Eugenio/AAH-7016-2019	Pelger, Rob/0000-0001-6328-6462; Zoni, Eugenio/0000-0002-3070-7694; van der Pluijm, Gabri/0000-0002-1351-1884; La Manna, Federico/0000-0003-3644-8395; Kelber, Jonathan/0000-0002-4606-1445; Verhoef, Esther/0000-0002-2734-0254; Granchi, Zoraide/0000-0002-0227-9266; Henry, Michael/0000-0002-7871-245X; Kruithof-de Julio, Marianna/0000-0002-6085-7706	FP7 Marie Curie ITN [264817-BONE-NET]; Dutch Cancer Society [UL2015-7599 KWF]; Leiden University Fond; Clayton Foundation for Biomedical Research; NATIONAL CANCER INSTITUTE [P30CA086862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [SC1GM121182] Funding Source: NIH RePORTER	FP7 Marie Curie ITN; Dutch Cancer Society(KWF Kankerbestrijding); Leiden University Fond; Clayton Foundation for Biomedical Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Tim Rodenburg and Janine Melsen (Department of Urology, LUMC) for technical support and Dr Boudewijn PT Kruithof (Department of Molecular Cell Biology, LUMC) for technical support and critical reading of the manuscript, Guido de Roo from the Flow cytometry facility (Department of Hematology, LUMC) and Jan Kroon (Department of Urology, LUMC) for providing experimental metastases. This research received funding from: FP7 Marie Curie ITN, Grant No. 264817-BONE-NET (to GvdP, EZ, ZG); Dutch Cancer Society, Grant No. UL2015-7599 KWF (to MK-dJ, GvdP, PK); Leiden University Fond (to MK-dJ) and Clayton Foundation for Biomedical Research (to PCG).	Bianco C, 2005, CURR TOP DEV BIOL, V67, P85, DOI 10.1016/S0070-2153(05)67003-2; Castro NP, 2015, ONCOTARGET, V6, P11910, DOI 10.18632/oncotarget.4182; Chandran UR, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-64; Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078-0432.CCR-06-0931; de Castro NP, 2010, FUTURE ONCOL, V6, P1127, DOI 10.2217/FON.10.68; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Ghotra VPS, 2015, CANCER RES, V75, P230, DOI 10.1158/0008-5472.CAN-14-0629; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Gray PC, 2006, MOL CELL BIOL, V26, P9268, DOI 10.1128/MCB.01168-06; Gray PC, 2012, FEBS LETT, V586, P1836, DOI 10.1016/j.febslet.2012.01.051; Guzman C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092444; Haldi Maryann, 2006, Angiogenesis, V9, P139, DOI 10.1007/s10456-006-9040-2; He SN, 2012, J PATHOL, V227, P431, DOI 10.1002/path.4013; Isogai S, 2003, DEVELOPMENT, V130, P5281, DOI 10.1242/dev.00733; Jemal A, 2010, CANCER EPIDEM BIOMAR, V19, P1893, DOI 10.1158/1055-9965.EPI-10-0437; Karkampouna S, 2014, MOL THER-NUCL ACIDS, V3, DOI 10.1038/mtna.2013.69; Kelber JA, 2009, ONCOGENE, V28, P2324, DOI 10.1038/onc.2009.97; Klauzinska M, 2014, SEMIN CANCER BIOL, V29, P51, DOI 10.1016/j.semcancer.2014.08.003; Kroon J, 2014, ONCOTARGET, V5, P8986, DOI 10.18632/oncotarget.1510; Lawrence MG, 2011, PROSTATE, V71, P1198, DOI 10.1002/pros.21335; Lawson ND, 2002, DEV BIOL, V248, P307, DOI 10.1006/dbio.2002.0711; Lee AS, 2007, CANCER RES, V67, P3496, DOI 10.1158/0008-5472.CAN-07-0325; Malanchi I, 2012, NATURE, V481, P85, DOI 10.1038/nature10694; Morhayim J, 2015, FASEB J, V29, P274, DOI 10.1096/fj.14-261404; Nagaoka T, 2012, GROWTH FACTORS, V30, P13, DOI 10.3109/08977194.2011.641962; Nakagawa T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002318; Ozdemir B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107407; Pettaway CA, 1996, CLIN CANCER RES, V2, P1627; Pilli VS, 2015, FEBS LETT, V589, P1249, DOI 10.1016/j.febslet.2015.04.005; Pootrakul L, 2006, CLIN CANCER RES, V12, P5987, DOI 10.1158/1078-0432.CCR-06-0133; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Salomon DS, 2000, ENDOCR-RELAT CANCER, V7, P199, DOI 10.1677/erc.0.0070199; Shani G, 2008, MOL CELL BIOL, V28, P666, DOI 10.1128/MCB.01716-07; Shiozawa Y, 2011, J CLIN INVEST, V121, P1298, DOI 10.1172/JCI43414; Spike BT, 2014, STEM CELL REP, V2, P427, DOI 10.1016/j.stemcr.2014.02.010; Stoletov K, 2007, P NATL ACAD SCI USA, V104, P17406, DOI 10.1073/pnas.0703446104; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Terry S, 2015, ONCOTARGET, V6, P11994, DOI 10.18632/oncotarget.2740; THALMANN GN, 1994, CANCER RES, V54, P2577; van den Hoogen C, 2011, AM J PATHOL, V179, P2559, DOI 10.1016/j.ajpath.2011.07.011; van den Hoogen C, 2010, CANCER RES, V70, P5163, DOI 10.1158/0008-5472.CAN-09-3806; van der Horst G, 2003, BONE, V33, P899, DOI 10.1016/j.bone.2003.07.004; van der Pluijm G, 2011, BONE, V48, P37, DOI 10.1016/j.bone.2010.07.023; Zoni E, 2015, CANCER RES, V75, P2326, DOI 10.1158/0008-5472.CAN-14-2155	44	25	27	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2017	36	33					4739	4749		10.1038/onc.2017.87	http://dx.doi.org/10.1038/onc.2017.87			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD7JM	28394345	Green Published, hybrid			2022-12-17	WOS:000407702400007
J	Madapura, HS; Nagy, N; Ujvari, D; Kallas, T; Krohnke, MCL; Amu, S; Bjorkholm, M; Stenke, L; Mandal, PK; McMurray, JS; Keszei, M; Westerberg, LS; Cheng, H; Xue, F; Klein, G; Klein, E; Salamon, D				Madapura, H. S.; Nagy, N.; Ujvari, D.; Kallas, T.; Krohnke, M. C. L.; Amu, S.; Bjorkholm, M.; Stenke, L.; Mandal, P. K.; McMurray, J. S.; Keszei, M.; Westerberg, L. S.; Cheng, H.; Xue, F.; Klein, G.; Klein, E.; Salamon, D.			Interferon gamma is a STAT1-dependent direct inducer of BCL6 expression in imatinib-treated chronic myeloid leukemia cells	ONCOGENE			English	Article							IFN-GAMMA; STEM-CELLS; T-CELLS; TARGETED THERAPY; INHIBITORS; REPRESSION; RESPONSES; SURVIVAL; CANCER; MCL-1	B-cell CLL/lymphoma 6 (BCL6) exerts oncogenic effects in several human hematopoietic malignancies including chronic myeloid leukemia (CML), where BCL6 expression was shown to be essential for CML stem cell survival and self-renewal during imatinib mesylate (IM) treatment. As several lines of evidence suggest that interferon gamma(IFN gamma) production in CML patients might have a central role in the response to tyrosine kinase inhibitor (TKI) therapy, we analyzed if IFN gamma modulates BCL6 expression in CML cells. Although separate IFN gamma or IM treatment only slightly upregulated BCL6 expression, combined treatment induced remarkable BCL6 upregulation in CML lines and primary human CD34+ CML stem cells. We proved that during combined treatment, inhibition of constitutive signal transducer and activator of transcription (STAT) 5 activation by IM allowed the specific enhancement of the STAT1 dependent, direct upregulation of BCL6 by IFN gamma in CML cells. By using colony-forming assay, we found that IFN gamma enhanced the ex vivo colony or cluster-forming capacity of human CML stem cells in the absence or presence of IM, respectively. Furthermore, inhibition of the transcriptional repressor function of BCL6 in the presence of IM and IFN gamma almost completely blocked the cluster formation of human CML stem cells. On the other hand, by using small interfering RNA knockdown of BCL6, we demonstrated that in an IM-treated CML line the antiapoptotic effect of IFN gamma was independent of BCL6 upregulation. We found that IFN gamma also upregulated several antiapoptotic members of the BCL2 and BIRC gene families in CML cells, including the long isoform of MCL1, which proved to be essential for the antiapoptotic effect of IFN gamma in an IM-treated CML line. Our results suggest that combination of TKIs with BCL6 and MCL1 inhibitors may potentially lead to the complete eradication of CML stem cells.	[Madapura, H. S.; Nagy, N.; Kallas, T.; Krohnke, M. C. L.; Amu, S.; Keszei, M.; Westerberg, L. S.; Klein, G.; Klein, E.; Salamon, D.] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden; [Ujvari, D.; Salamon, D.] Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden; [Bjorkholm, M.; Stenke, L.] Karolinska Univ, Hosp Solna, Dept Med, Div Hematol, Stockholm, Sweden; [Bjorkholm, M.; Stenke, L.] Karolinska Inst, Stockholm, Sweden; [Mandal, P. K.; McMurray, J. S.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Cheng, H.; Xue, F.] Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; University of Texas System; UTMD Anderson Cancer Center; University System of Maryland; University of Maryland Baltimore	Salamon, D (corresponding author), Karolinska Inst, Dept Microbiol Tumor & Cell Biol MTC, Nobels Vag 16, SE-17177 Stockholm, Sweden.	Daniel.Salamon@ki.se	Salamon, Daniel/AAZ-4807-2021; Nagy, Noemi/J-2936-2012; Ujvari, Dorina/AAS-8724-2021; Westerberg, Lisa/AAB-3808-2019; Keszei, Marton/F-3295-2014	Keszei, Marton/0000-0002-1158-2179; Amu, Sylvie/0000-0001-9593-7952; Westerberg, Lisa/0000-0003-2943-2192; Salamon, Daniel/0000-0001-6630-3993; Kallas, Tomasz/0000-0001-8838-697X; Nagy, Noemi/0000-0002-7800-3493	Swedish Cancer Society (Cancerfonden); Adolf H Lundin Charitable Foundation; Karolinska Institutet; Cancer Research Fellowship of the Cancer Research Institute (New York)/Concern Foundation (Los Angeles)	Swedish Cancer Society (Cancerfonden)(Swedish Cancer Society); Adolf H Lundin Charitable Foundation; Karolinska Institutet(Karolinska Institutet); Cancer Research Fellowship of the Cancer Research Institute (New York)/Concern Foundation (Los Angeles)	This work was supported by grants from the the Swedish Cancer Society (Cancerfonden), Adolf H Lundin Charitable Foundation and Karolinska Institutet. HM, NN, TK and DS are or were recipients of Cancer Research Fellowship of the Cancer Research Institute (New York)/Concern Foundation (Los Angeles).	Aichberger KJ, 2005, BLOOD, V105, P3303, DOI 10.1182/blood-2004-02-0749; Aswald JM, 2002, CYTOKINES CELL MOL T, V7, P143, DOI 10.1080/13684730210002319; Basso K, 2012, IMMUNOL REV, V247, P172, DOI 10.1111/j.1600-065X.2012.01112.x; Basso K, 2010, ADV IMMUNOL, V105, P193, DOI 10.1016/S0065-2776(10)05007-8; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Bonmort M, 2007, BIOCHIMIE, V89, P872, DOI 10.1016/j.biochi.2007.04.014; Bunting KL, 2013, CURR OPIN IMMUNOL, V25, P339, DOI 10.1016/j.coi.2013.05.003; Cardenas MG, 2016, J CLIN INVEST, V126, P3351, DOI 10.1172/JCI85795; Chomel JC, 2011, ONCOTARGET, V2, P713; Christiansson L, 2015, MOL CANCER THER, V14, P1181, DOI 10.1158/1535-7163.MCT-14-0849; Cunard R, 2004, J IMMUNOL, V172, P7530, DOI 10.4049/jimmunol.172.12.7530; de Mattos SF, 2004, MOL CELL BIOL, V24, P10058, DOI 10.1128/MCB.24.22.10058-10071.2004; DiNoto R, 1997, LEUKEMIA, V11, P1554; Dunn GP, 2006, NAT REV IMMUNOL, V6, P836, DOI 10.1038/nri1961; Duy C, 2011, NATURE, V473, P384, DOI 10.1038/nature09883; Gough DJ, 2008, CYTOKINE GROWTH F R, V19, P383, DOI 10.1016/j.cytogfr.2008.08.004; Green MR, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4904; Held SAE, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1065368; Hideshima T, 2010, BLOOD, V115, P3772, DOI 10.1182/blood-2010-02-270082; Huang BB, 2001, J INVEST DERMATOL, V116, P305, DOI 10.1046/j.1523-1747.2001.01242.x; Hurtz C, 2011, J EXP MED, V208, P2163, DOI 10.1084/jem.20110304; Jaras M, 2010, P NATL ACAD SCI USA, V107, P16280, DOI 10.1073/pnas.1004408107; Kim DH, 2010, CLIN CANCER RES, V16, P5339, DOI 10.1158/1078-0432.CCR-10-1638; KLEIN E, 1968, CANCER RES, V28, P1300; Krusch M, 2011, CURR MED CHEM, V18, P5174, DOI 10.2174/092986711798184271; KUBONISHI I, 1983, International Journal of Cell Cloning, V1, P105; Kuroda J, 2006, P NATL ACAD SCI USA, V103, P14907, DOI 10.1073/pnas.0606176103; Kurosu T, 2003, ONCOGENE, V22, P4459, DOI 10.1038/sj.onc.1206755; Lee SK, 2012, IMMUNITY, V37, P880, DOI 10.1016/j.immuni.2012.10.010; Leverson JD, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.561; Mandal PK, 2015, J MED CHEM, V58, P8970, DOI 10.1021/acs.jmedchem.5b01321; Nakayamada S, 2014, J IMMUNOL, V192, P2156, DOI 10.4049/jimmunol.1300675; Nelson EA, 2011, BLOOD, V117, P3421, DOI 10.1182/blood-2009-11-255232; O'Hare T, 2012, NAT REV CANCER, V12, P513, DOI 10.1038/nrc3317; OHASHI K, 1995, BIOCHEM BIOPH RES CO, V214, P461, DOI 10.1006/bbrc.1995.2309; Opferman JT, 2005, SCIENCE, V307, P1101, DOI 10.1126/science.1106114; Petzer AL, 1996, J EXP MED, V183, P2551, DOI 10.1084/jem.183.6.2551; Prost S, 2015, NATURE, V525, P380, DOI 10.1038/nature15248; Ritz O, 2013, ONCOTARGET, V4, P1093, DOI 10.18632/oncotarget.1149; Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252; Schurch C, 2013, J EXP MED, V210, P605, DOI 10.1084/jem.20121229; Srinivasula SM, 2008, MOL CELL, V30, P123, DOI 10.1016/j.molcel.2008.03.008; Tsuyama N, 2005, BIOCHEM BIOPH RES CO, V337, P201, DOI 10.1016/j.bbrc.2005.09.036; Walker SR, 2007, ONCOGENE, V26, P224, DOI 10.1038/sj.onc.1209775; Walker SR, 2013, MOL CELL BIOL, V33, P2879, DOI 10.1128/MCB.01620-12; Warsch W, 2013, BLOOD, V122, P2167, DOI 10.1182/blood-2013-02-485573; Warsch W, 2011, BLOOD, V117, P3409, DOI 10.1182/blood-2009-10-248211; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Zhang X, 2004, BLOOD, V104, P3276, DOI 10.1182/blood-2004-02-0664; Zhou G, 2005, EXP MOL PATHOL, V78, P25, DOI 10.1016/j.yexmp.2004.08.008; Zoubir Moustapha, 2010, Endocrine Metabolic & Immune Disorders-Drug Targets, V10, P1	51	25	26	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2017	36	32					4619	4628		10.1038/onc.2017.85	http://dx.doi.org/10.1038/onc.2017.85			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD0RK	28368400				2022-12-17	WOS:000407246200009
J	Zhang, Y; Ren, YJ; Guo, LC; Ji, C; Hu, J; Zhang, HH; Xu, QH; Zhu, WD; Ming, ZJ; Yuan, YS; Ren, X; Song, J; Yang, JM				Zhang, Y.; Ren, Y-J; Guo, L-C; Ji, C.; Hu, J.; Zhang, H-H; Xu, Q-H; Zhu, W-D; Ming, Z-J; Yuan, Y-S; Ren, X.; Song, J.; Yang, J-M			Nucleus accumbens-associated protein-1 promotes glycolysis and survival of hypoxic tumor cells via the HDAC4-HIF-1 alpha axis	ONCOGENE			English	Article							HISTONE DEACETYLASE-4; INDUCIBLE FACTORS; OVARIAN-CANCER; NACL; PLURIPOTENCY; ACETYLATION; BEVACIZUMAB; NETWORK; KINASE; GROWTH	Nucleus accumbens-associated protein-1 (NAC1), a nuclear factor of the BTB/POZ gene family, has emerging roles in cancer. In this study, we identified the NAC1-HDAC4-HIF-1 alpha axis as an important pathway in regulating glycolysis and hypoxic adaptation in tumor cells. We show that nuclear NAC1 binds to histone deacetylase type 4 (HDAC4), hindering phosphorylation of HDAC4 at Ser(246) and preventing its nuclear export that leads to cytoplasmic degradation of the deacetylase. Accumulation of HDAC4 in the nuclei results in an attenuation of HIF-1 alpha acetylation, enhancing the stabilization and transcriptional activity of HIF-1 alpha and strengthening adaptive response of cells to hypoxia. We also show the role of NAC1 in promoting glycolysis in a mouse xenograft model, and demonstrate that knockdown of NAC1 expression can reinforce the antitumor efficacy of bevacizumab, an inhibitor of angiogenesis. Clinical implication of the NAC1-HDAC4-HIF-1 alpha pathway is suggested by the results showing that expression levels of these proteins are significantly correlative in human tumor specimens and associated with the disease progression. This study not only reveals an important function of NAC1 in regulating glycolysis, but also identifies the NAC1-HDAC4-HIF-1 alpha axis as a novel molecular pathway that promotes survival of hypoxic tumor cells.	[Zhang, Y.; Ren, Y-J; Guo, L-C; Ji, C.; Hu, J.; Zhang, H-H; Xu, Q-H; Zhu, W-D; Ming, Z-J] Soochow Univ, Dept Pharmacol, Coll Pharmaceut Sci, Affiliated Hosp 1, 199 Renai Rd, Suzhou 215123, Jiangsu, Peoples R China; [Yuan, Y-S] Shanghai Jiao Tong Univ, Sch Pharm, Engn Res Ctr Cell & Therapeut Antibody, Shanghai, Peoples R China; [Ren, X.; Song, J.; Yang, J-M] Penn State Univ, Coll Med, Penn State Hershey Canc Inst, Dept Pharmacol & Microbiol & Immunol, 500 Univ Dr,POB 850, Hershey, PA 17033 USA	Soochow University - China; Shanghai Jiao Tong University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Zhang, Y (corresponding author), Soochow Univ, Dept Pharmacol, Coll Pharmaceut Sci, Affiliated Hosp 1, 199 Renai Rd, Suzhou 215123, Jiangsu, Peoples R China.; Yang, JM (corresponding author), Penn State Univ, Coll Med, Penn State Hershey Canc Inst, Dept Pharmacol & Microbiol & Immunol, 500 Univ Dr,POB 850, Hershey, PA 17033 USA.	zhangyi@suda.edu.cn; juy16@psu.edu			National Natural Sciences Foundation of China [81473240, BK20151209]; China Postdoctoral Science Foundation [2015T80585, 2014M550308]; Natural Science Foundation of Jiangsu Province of China [BK20151209, BK20141197]; Science and Technology Foundation of Suzhou City [SYS201319]	National Natural Sciences Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Natural Science Foundation of Jiangsu Province of China(Natural Science Foundation of Jiangsu Province); Science and Technology Foundation of Suzhou City	This work was supported by grants from National Natural Sciences Foundation of China (81473240), Special Financial Grant by China Postdoctoral Science Foundation (2015T80585), China Postdoctoral Science Foundation (2014M550308), Natural Science Foundation of Jiangsu Province of China (BK20141197), Science and Technology Foundation of Suzhou City (SYS201319) to Yi Zhang; and Natural Science Foundation of Jiangsu Province of China (BK20151209) to Cheng Ji.	Backs J, 2006, J CLIN INVEST, V116, P1853, DOI 10.1172/JCI27438; Brahimi-Horn MC, 2007, J MOL MED-JMM, V85, P1301, DOI 10.1007/s00109-007-0281-3; Cardenas-Navia LI, 2007, FRONT BIOSCI-LANDMRK, V12, P4061, DOI 10.2741/2372; Cernotta N, 2011, MOL BIOL CELL, V22, P278, DOI 10.1091/mbc.E10-07-0616; Cheng Y, 2016, ONCOGENE, V35, P6293, DOI 10.1038/onc.2016.166; Fack F, 2015, ACTA NEUROPATHOL, V129, P115, DOI 10.1007/s00401-014-1352-5; Folkman J, 2007, J PEDIATR SURG, V42, P1, DOI 10.1016/j.jpedsurg.2006.09.048; Generali D, 2009, J CLIN ONCOL, V27, P227, DOI 10.1200/JCO.2007.13.7083; Geng H, 2012, J BIOL CHEM, V287, P35496, DOI 10.1074/jbc.M112.400697; Geng H, 2011, J BIOL CHEM, V286, P38095, DOI 10.1074/jbc.M111.257055; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; Jinawath N, 2009, ONCOGENE, V28, P1941, DOI 10.1038/onc.2009.37; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Kim JW, 2008, CELL, V132, P1049, DOI 10.1016/j.cell.2008.02.039; Korutla L, 2005, J NEUROCHEM, V94, P786, DOI 10.1111/j.1471-4159.2005.03206.x; Korutla L, 2014, NEUROSCIENCE, V257, P86, DOI 10.1016/j.neuroscience.2013.11.001; Lim JH, 2010, MOL CELL, V38, P864, DOI 10.1016/j.molcel.2010.05.023; Malleshaiah M, 2016, CELL REP, V14, P1181, DOI 10.1016/j.celrep.2015.12.101; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mesange P, 2014, ONCOTARGET, V5, P4709, DOI 10.18632/oncotarget.1671; Moeller BJ, 2004, SEMIN RADIAT ONCOL, V14, P215, DOI 10.1016/j.semradonc.2004.04.005; Moussaieff A, 2015, CELL METAB, V21, P392, DOI 10.1016/j.cmet.2015.02.002; Nakayama K, 2007, CANCER RES, V67, P8058, DOI 10.1158/0008-5472.CAN-07-1357; Nakayama K, 2006, P NATL ACAD SCI USA, V103, P18739, DOI 10.1073/pnas.0604083103; Nakayama K, 2010, GYNECOL ONCOL, V119, P469, DOI 10.1016/j.ygyno.2010.08.031; Shyh-Chang N, 2013, SCIENCE, V339, P222, DOI 10.1126/science.1226603; Perez-Torrado R, 2006, BIOESSAYS, V28, P1194, DOI 10.1002/bies.20500; Qian DZ, 2006, CANCER RES, V66, P8814, DOI 10.1158/0008-5472.CAN-05-4598; Rahman MT, 2012, BRIT J CANCER, V107, P300, DOI 10.1038/bjc.2012.246; Rapisarda A, 2009, MOL CANCER THER, V8, P1867, DOI 10.1158/1535-7163.MCT-09-0274; Rivera LB, 2014, SCIENCE, V344, P1449, DOI 10.1126/science.1257071; Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021; Shao MH, 2012, MOL CANCER THER, V11, P1576, DOI 10.1158/1535-7163.MCT-11-0961; Shih IM, 2011, MODERN PATHOL, V24, P638, DOI 10.1038/modpathol.2010.230; Shimizu E, 2014, J BIOL CHEM, V289, P21340, DOI 10.1074/jbc.M114.550699; Stead MA, 2014, BIOSCIENCE REP, V34, P227, DOI 10.1042/BSR20140049; Ueda SM, 2010, J ONCOL, V2010, DOI 10.1155/2010/285191; Wang AH, 2001, MOL CELL BIOL, V21, P5992, DOI 10.1128/MCB.21.17.5992-6005.2001; Wang AH, 2000, MOL CELL BIOL, V20, P6904, DOI 10.1128/MCB.20.18.6904-6912.2000; Wang JL, 2006, NATURE, V444, P364, DOI 10.1038/nature05284; Yap KL, 2012, CANCER RES, V72, P4085, DOI 10.1158/0008-5472.CAN-12-0302; Yeasmin S, 2012, HUM PATHOL, V43, P506, DOI 10.1016/j.humpath.2011.05.021; Zhang Y, 2012, ONCOGENE, V31, P1055, DOI 10.1038/onc.2011.290; Zhang Y, 2012, CANCER RES, V72, P4262, DOI 10.1158/0008-5472.CAN-12-0139; Zhao X, 2001, J BIOL CHEM, V276, P35042, DOI 10.1074/jbc.M105086200	47	25	26	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2017	36	29					4171	4181		10.1038/onc.2017.51	http://dx.doi.org/10.1038/onc.2017.51			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB0LE	28319066	Green Published, hybrid			2022-12-17	WOS:000405835800008
J	Thaper, D; Vahid, S; Nip, KM; Moskalev, I; Shan, X; Frees, S; Roberts, ME; Ketola, K; Harder, KW; Gregory-Evans, C; Bishop, JL; Zoubeidi, A				Thaper, D.; Vahid, S.; Nip, K. M.; Moskalev, I.; Shan, X.; Frees, S.; Roberts, M. E.; Ketola, K.; Harder, K. W.; Gregory-Evans, C.; Bishop, J. L.; Zoubeidi, A.			Targeting Lyn regulates Snail family shuttling and inhibits metastasis	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; RESISTANT PROSTATE-CANCER; BREAST-CANCER; GENE-EXPRESSION; TYROSINE KINASE; GSK-3-BETA-MEDIATED PHOSPHORYLATION; SIGNAL-TRANSDUCTION; TUMOR-SUPPRESSOR; LEUKEMIA-CELLS; IN-VIVO	The acquisition of an invasive phenotype by epithelial cells occurs through a loss of cellular adhesion and polarity, heralding a multistep process that leads to metastatic dissemination. Since its characterization in 1995, epithelial-mesenchymal transition (EMT) has been closely linked to the metastatic process. As a defining aspect of EMT, loss of cell adhesion through downregulation of E-cadherin is carried out by several transcriptional repressors; key among them the SNAI family of transcription factors. Here we identify for the first time that Lyn kinase functions as a key modulator of SNAI family protein localization and stability through control of the Vav-Rac1-PAK1 (Vav-Rac1-p21-activated kinase) pathway. Accordingly, targeting Lyn in vitro reduces EMT and in vivo reduces metastasis of primary tumors. We also demonstrate the clinical relevance of targeting Lyn as a key player controlling EMT; patient samples across many cancers revealed a strong negative correlation between Lyn and E-cadherin, and high Lyn expression in metastatic tumors as well as metastasis-prone primary tumors. This work reveals a novel pancancer mechanism of Lyndependent control of EMT and further underscores the role of this kinase in tumor progression.	[Thaper, D.; Vahid, S.; Nip, K. M.; Moskalev, I.; Frees, S.; Ketola, K.; Bishop, J. L.; Zoubeidi, A.] Univ British Columbia, Vancouver Prostate Ctr, Dept Urol, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada; [Thaper, D.; Vahid, S.; Nip, K. M.; Zoubeidi, A.] Univ British Columbia, Dept Urol Sci, Fac Med, Vancouver, BC, Canada; [Shan, X.; Gregory-Evans, C.] Univ British Columbia, Dept Ophthalmol & Visual Sci, Fac Med, Vancouver, BC, Canada; [Roberts, M. E.; Harder, K. W.] Univ British Columbia, Dept Microbiol & Immunol, Fac Sci, Vancouver, BC, Canada	University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia	Zoubeidi, A (corresponding author), Univ British Columbia, Vancouver Prostate Ctr, Dept Urol, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.	azoubeidi@prostatecentre.com	Ketola, Kirsi/O-1071-2016; Gregory-Evans, Cheryl Y/G-9550-2011	Ketola, Kirsi/0000-0001-6484-9861; Roberts, Morgan/0000-0002-5850-7985	Terry Fox Research Institute; Prostate Cancer Canada; Canadian Institutes of Health Research; Michael Smith Foundation	Terry Fox Research Institute; Prostate Cancer Canada; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Michael Smith Foundation(Michael Smith Foundation for Health Research)	This work was supported by the Terry Fox Research Institute, Michael Smith Foundation, Prostate Cancer Canada and Canadian Institutes of Health Research. We would like to thank Dr Peter Black for the UC13 and UC13-luciferase cells, and Dr Yuzhou Wang for Oncomine access. We also appreciate the assistance of Eliana Beraldi and Shannon Awery for experimental support.	Bates RC, 2001, CANCER RES, V61, P5275; Bid HK, 2013, MOL CANCER THER, V12, P1925, DOI 10.1158/1535-7163.MCT-13-0164; Blaveri E, 2005, CLIN CANCER RES, V11, P4044, DOI 10.1158/1078-0432.CCR-04-2409; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Bougeret C, 2001, J BIOL CHEM, V276, P33711, DOI 10.1074/jbc.M104209200; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; Choi YL, 2010, CANCER RES, V70, P2296, DOI 10.1158/0008-5472.CAN-09-3141; Cordonnier T, 2015, INT J CANCER, V136, pE496, DOI 10.1002/ijc.29122; De Mesquita DD, 2001, FEBS LETT, V502, P84, DOI 10.1016/S0014-5793(01)02669-2; Delaney MK, 2012, ARTERIOSCL THROM VAS, V32, P2761, DOI 10.1161/ATVBAHA.112.254920; Dyrskjot L, 2004, CANCER RES, V64, P4040, DOI 10.1158/0008-5472.CAN-03-3620; Eswaran J, 2012, CLIN CANCER RES, V18, P3743, DOI 10.1158/1078-0432.CCR-11-1952; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gelman IH, 2014, MOL CANCER RES, V12, P1470, DOI 10.1158/1541-7786.MCR-13-0490-T; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Guan H, 2008, MOL CANCER THER, V7, P1807, DOI 10.1158/1535-7163.MCT-08-0058; Guarino M, 2010, J CELL PHYSIOL, V223, P14, DOI 10.1002/jcp.22011; Hatzis C, 2011, JAMA-J AM MED ASSOC, V305, P1873, DOI 10.1001/jama.2011.593; HIBBS ML, 1995, GENE, V156, P175, DOI 10.1016/0378-1119(95)00022-X; Hochgrafe F, 2010, CANCER RES, V70, P9391, DOI 10.1158/0008-5472.CAN-10-0911; Holzbeierlein J, 2004, AM J PATHOL, V164, P217, DOI 10.1016/S0002-9440(10)63112-4; Ingley E, 2012, CELL COMMUN SIGNAL, V10, DOI 10.1186/1478-811X-10-21; Jager W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059536; Kantarjian H, 2010, CANCER-AM CANCER SOC, V116, P2665, DOI 10.1002/cncr.25079; Kao KJ, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-143; Kasahara K, 2004, J CELL BIOL, V165, P641, DOI 10.1083/jcb.200403011; Kilpinen S, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r139; Kim JY, 2012, FEBS J, V279, P2929, DOI 10.1111/j.1742-4658.2012.08674.x; Kim J, 2014, EMBO REP, V15, P1062, DOI 10.15252/embr.201438587; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kumar R, 2006, NAT REV CANCER, V6, P459, DOI 10.1038/nrc1892; Lowell CA, 2004, MOL IMMUNOL, V41, P631, DOI 10.1016/j.molimm.2004.04.010; Maness PF, 1996, PERSPECT DEV NEUROBI, V4, P169; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Modlich O, 2004, CLIN CANCER RES, V10, P3410, DOI 10.1158/1078-0432.CCR-03-0134; OPPERMANN H, 1979, P NATL ACAD SCI USA, V76, P1804, DOI 10.1073/pnas.76.4.1804; Parsons SJ, 2004, ONCOGENE, V23, P7906, DOI 10.1038/sj.onc.1208160; Pecina-Slaus N, 2003, CANCER CELL INT, V3, DOI 10.1186/1475-2867-3-17; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Rahaman SO, 2011, J BIOL CHEM, V286, P7010, DOI 10.1074/jbc.M110.192450; Ren XP, 2002, CANCER BIOL THER, V1, P703, DOI 10.4161/cbt.323; Sanchez-Carbayo M, 2006, J CLIN ONCOL, V24, P778, DOI 10.1200/JCO.2005.03.2375; Shih JY, 2011, CARCINOGENESIS, V32, P1299, DOI 10.1093/carcin/bgr110; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; Stebbins CC, 2003, MOL CELL BIOL, V23, P6291, DOI 10.1128/MCB.23.17.6291-6299.2003; Stettner AR, 2005, CANCER RES, V65, P5535, DOI 10.1158/0008-5472.CAN-04-3688; Stransky N, 2006, NAT GENET, V38, P1386, DOI 10.1038/ng1923; Tabaries S, 2015, ONCOTARGET, V6, P9476, DOI 10.18632/oncotarget.3269; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Teng Y, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-453; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tomlins SA, 2007, NAT GENET, V39, P41, DOI 10.1038/ng1935; Vinas-Castells R, 2010, J BIOL CHEM, V285, P3794, DOI 10.1074/jbc.M109.065995; Wang SP, 2009, NAT CELL BIOL, V11, P694, DOI 10.1038/ncb1875; Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670; Wu J, 2008, BLOOD, V111, P3821, DOI 10.1182/blood-2007-08-109330; Wu ZQ, 2012, P NATL ACAD SCI USA, V109, P16654, DOI 10.1073/pnas.1205822109; Yang ZB, 2005, CANCER RES, V65, P3179, DOI 10.1158/0008-5472.CAN-04-3480; Yazawa N, 2003, BLOOD, V102, P1374, DOI 10.1182/blood-2002-11-3573; Yokota A, 2007, BLOOD, V109, P306, DOI 10.1182/blood-2006-03-013250; Yoo SK, 2011, NATURE, V480, P109, DOI 10.1038/nature10632; Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158; Zardan A, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2014.30; Zhang SY, 2012, TRENDS PHARMACOL SCI, V33, P122, DOI 10.1016/j.tips.2011.11.002; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	66	25	26	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2017	36	28					3964	3975		10.1038/onc.2017.5	http://dx.doi.org/10.1038/onc.2017.5			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FA3YD	28288135				2022-12-17	WOS:000405379900003
J	Yi, H; Geng, L; Black, A; Talmon, G; Berim, L; Wang, J				Yi, H.; Geng, L.; Black, A.; Talmon, G.; Berim, L.; Wang, J.			The miR-487b-3p/GRM3/TGF beta signaling axis is an important regulator of colon cancer tumorigenesis	ONCOGENE			English	Article							GROWTH-FACTOR-BETA; METABOTROPIC GLUTAMATE RECEPTORS; CONFERS DRUG-RESISTANCE; COLORECTAL-CANCER; PHARMACOLOGICAL BLOCKADE; CARCINOMA; EXPRESSION; CELLS; METASTASIS; PROLIFERATION	Molecular targeting is an import strategy to treat advanced colon cancer. The current study demonstrates that expression of GRM3, a metabotropic glutamate receptor mainly expressed in mammalian central nervous system, is significantly upregulated in majority of human colonic adenocarcinomas tested and colon cancer cell lines. Knockdown of GRM3 expression or inhibition of GRM3 activation in colon cancer cells reduces cell survival and anchorage-independent growth in vitro and inhibits tumor growth in vivo. Mechanistically, GRM3 antagonizes TGF beta-mediated activation of protein kinase A and inhibition of Protein kinase B (AKT). In addition, TGF beta signaling increases GRM3 protein stability and knockdown of GRM3 enhances TGF beta-mediated tumor suppressor function. Further studies indicate that miR-487b-3p directly targets GRM3. Overexpression of miR-487b-3p mimics the effects of GRM3 knockdown and suppresses the tumorigenicity of colon cancer cells in vivo. Expression of miR-487b-3p is decreased in colon adenocarcinomas and inversely correlates with GRM3 expression. Taken together, these studies indicate that upregulation of GRM3 expression is a functionally important molecular event in colon cancer, and that GRM3 is a promising molecular target for colon cancer treatment. This is particularly interesting and important from a therapeutic standpoint because numerous metabotropic glutamate receptor antagonists are available, many of which have been found unsuitable for treatment of neuropsychiatric disorders for reasons such as inability to readily penetrate blood brain barriers. As GRM3 is upregulated in colon cancer, but rarely expressed in normal peripheral tissues, targeting GRM3 with such agents would not likely cause adverse neurological or peripheral side effects, making GRM3 an attractive and specific molecular target for colon cancer treatment.	[Yi, H.; Wang, J.] Univ Nebraska Med Ctr, Dept Genet Cell Biol & Anat, Omaha, NE USA; [Geng, L.; Black, A.; Wang, J.] Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE USA; [Talmon, G.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA; [Berim, L.] Univ Nebraska Med Ctr, Dept Internal Med Oncol Hematol, Omaha, NE USA; [Wang, J.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Wang, J (corresponding author), Univ Nebraska Med Ctr, 985950 Nebraska Med Ctr, Omaha, NE 68198 USA.	jjwang@unmc.edu			Chinese Scholar Council;  [NIH/NCI R01CA140988-01]	Chinese Scholar Council; 	This work was supported by NIH/NCI R01CA140988-01 to JW. HY was partially supported by Chinese Scholar Council.	ARAMORI I, 1992, NEURON, V8, P757, DOI 10.1016/0896-6273(92)90096-V; Arcella A, 2005, NEURO-ONCOLOGY, V7, P236, DOI 10.1215/S1152851704000961; Bacman D, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-156; Banerjee A, 2011, BIOMED PHARMACOTHER, V65, P293, DOI 10.1016/j.biopha.2011.03.009; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Betel D, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-8-r90; BOYD DD, 1988, CANCER RES, V48, P2469; Bu PC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7879; Calon A, 2012, CANCER CELL, V22, P571, DOI 10.1016/j.ccr.2012.08.013; Cha JHJ, 1998, P NATL ACAD SCI USA, V95, P6480, DOI 10.1073/pnas.95.11.6480; Chang HJ, 2005, CLIN CANCER RES, V11, P3288, DOI 10.1158/1078-0432.CCR-04-1912; Chowdhury S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019335; Chowdhury SP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068818; Ciceroni C, 2008, NEUROPHARMACOLOGY, V55, P568, DOI 10.1016/j.neuropharm.2008.06.064; CURTIS DR, 1959, NATURE, V183, P611, DOI 10.1038/183611a0; D'Onofrio M, 2003, J NEUROCHEM, V84, P1288, DOI 10.1046/j.1471-4159.2003.01633.x; da Costa LT, 1999, ONCOGENE, V18, P5010, DOI 10.1038/sj.onc.1202872; Du TT, 2005, DEVELOPMENT, V132, P4645, DOI 10.1242/dev.02070; Forrester E, 2005, CANCER RES, V65, P2296, DOI 10.1158/0008-5472.CAN-04-3272; Geng L, 2014, ONCOGENE, V33, P5332, DOI 10.1038/onc.2013.478; Geng LY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059918; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; Gulubova M, 2010, INT J COLORECTAL DIS, V25, P591, DOI 10.1007/s00384-010-0906-9; Hamamoto T, 2002, CANCER RES, V62, P5955; HAYASHI TAKASHI, 1952, JAPANESE JOUR PHYSIOL, V3, P46; Hoogduijn MJ, 2006, PIGM CELL RES, V19, P58, DOI 10.1111/j.1600-0749.2005.00284.x; Kim MS, 2008, ONCOGENE, V27, P2045, DOI 10.1038/sj.onc.1210842; Kingston AE, 1998, NEUROPHARMACOLOGY, V37, P1, DOI 10.1016/S0028-3908(97)00191-3; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Martino JJ, 2013, ONCOGENE, V32, P4366, DOI 10.1038/onc.2012.471; Minoshima T, 1999, J BIOCHEM-TOKYO, V126, P889, DOI 10.1093/oxfordjournals.jbchem.a022531; Munoz NM, 2006, CANCER RES, V66, P9837, DOI 10.1158/0008-5472.CAN-06-0890; Neto FL, 2000, MOL BRAIN RES, V81, P140; Neto FL, 2001, J NEUROSCI RES, V63, P356, DOI 10.1002/1097-4547(20010215)63:4<356::AID-JNR1030>3.0.CO;2-3; Prickett TD, 2011, NAT GENET, V43, P1119, DOI 10.1038/ng.950; Roig AI, 2010, GASTROENTEROLOGY, V138, P1012, DOI 10.1053/j.gastro.2009.11.052; Schoepp DD, 1999, NEUROPHARMACOLOGY, V38, P1431, DOI 10.1016/S0028-3908(99)00092-1; Simms NAK, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-221; Skerry TM, 2001, TRENDS PHARMACOL SCI, V22, P174, DOI 10.1016/S0165-6147(00)01642-4; Sodir NM, 2006, CANCER RES, V66, P8430, DOI 10.1158/0008-5472.CAN-06-1437; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; Tong QC, 2002, AM J PHYSIOL-ENDOC M, V282, pE1324, DOI 10.1152/ajpendo.00460.2001; Veenendaal LM, 2008, CELL ONCOL, V30, P1; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wang J, 1996, J BIOL CHEM, V271, P17366, DOI 10.1074/jbc.271.29.17366; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; Wang J, 2008, CANCER RES, V68, P3152, DOI 10.1158/0008-5472.CAN-07-5348; Woodford-Richens KL, 2001, P NATL ACAD SCI USA, V98, P9719, DOI 10.1073/pnas.171321498; Yang L, 2008, CANCER CELL, V13, P23, DOI 10.1016/j.ccr.2007.12.004; Ye SC, 1999, CANCER RES, V59, P4725; Zeng QH, 2009, CANCER RES, V69, P678, DOI 10.1158/0008-5472.CAN-08-3980; Zhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028; Zhang Y, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.200; Zhang Y, 2015, J BIOL CHEM, V290, P6215, DOI 10.1074/jbc.M114.620252; Zhou K, 2014, CELL BIOL INT, V38, P426, DOI 10.1002/cbin.10207	57	25	27	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2017	36	24					3477	3489		10.1038/onc.2016.499	http://dx.doi.org/10.1038/onc.2016.499			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EX6GL	28114282	Green Accepted			2022-12-17	WOS:000403340700011
J	Chroma, K; Mistrik, M; Moudry, P; Gursky, J; Liptay, M; Strauss, R; Skrott, Z; Vrtel, R; Bartkova, J; Kramara, J; Bartek, J				Chroma, K.; Mistrik, M.; Moudry, P.; Gursky, J.; Liptay, M.; Strauss, R.; Skrott, Z.; Vrtel, R.; Bartkova, J.; Kramara, J.; Bartek, J.			Tumors overexpressing RNF168 show altered DNA repair and responses to genotoxic treatments, genomic instability and resistance to proteotoxic stress	ONCOGENE			English	Article							ONCOGENE-INDUCED SENESCENCE; DAMAGE-RESPONSE; HOMOLOGOUS RECOMBINATION; 53BP1 RECRUITMENT; CHROMATIN RESPONSE; PARP INHIBITORS; PROTEIN; BRCA1; CELLS; ACCUMULATION	Chromatin DNA damage response (DDR) is orchestrated by the E3 ubiquitin ligase ring finger protein 168 (RNF168), resulting in ubiquitin-dependent recruitment of DDR factors and tumor suppressors breast cancer 1 (BRCA1) and p53 binding protein 1 (53BP1). This ubiquitin signaling regulates pathway choice for repair of DNA double-strand breaks (DSB), toxic lesions whose frequency increases during tumorigenesis. Recruitment of 53BP1 curbs DNA end resection, thereby limiting homologous recombination (HR) and directing DSB repair toward error-prone non-homologous end joining (NHEJ). Under cancer-associated ubiquitin starvation conditions reflecting endogenous or treatment-evoked proteotoxic stress, the ubiquitin-dependent accrual of 53BP1 and BRCA1 at the DNA damage sites is attenuated or lost. Challenging this current paradigm, here we identified diverse human cancer cell lines that display 53BP1 recruitment to DSB sites even under proteasome inhibitor-induced proteotoxic stress, that is, under substantial depletion of free ubiquitin. We show that central to this unexpected phenotype is overabundance of RNF168 that enables more efficient exploitation of the residual-free ubiquitin. Cells with elevated RNF168 are more resistant to combined treatment by ionizing radiation and proteasome inhibition, suggesting that such aberrant RNF168-mediated signaling might reflect adaptation to chronic proteotoxic and genotoxic stresses experienced by tumor cells. Moreover, the overabundant RNF168 and the ensuing unorthodox recruitment patterns of 53BP1, RIF1 and REV7 (monitored on laser micro-irradiation-induced DNA damage) shift the DSB repair balance from HR toward NHEJ, a scenario accompanied by enhanced chromosomal instability/micronuclei formation and sensitivity under replication stress-inducing treatments with camptothecin or poly(ADP-ribose) polymerase (PARP) inhibitor. Overall, our data suggest that the deregulated RNF168/53BP1 pathway could promote tumorigenesis by selecting for a more robust, better stress-adapted cancer cell phenotype, through altered DNA repair, fueling genomic instability and tumor heterogeneity. Apart from providing insights into cancer (patho) biology, the elevated RNF168, documented here also by immunohistochemistry on human clinical tumor specimens, may impact responses to standard-of-care and some emerging targeted cancer therapies.	[Chroma, K.; Mistrik, M.; Moudry, P.; Gursky, J.; Liptay, M.; Skrott, Z.; Kramara, J.; Bartek, J.] Palacky Univ, Fac Med & Dent, Inst Mol & Translat Med, Hnevotinska 5, Olomouc 77515, Czech Republic; [Moudry, P.; Strauss, R.; Bartkova, J.; Bartek, J.] Danish Canc Soc Res Ctr, Genome Integr Unit, Strandboulevarden 49, DK-2100 Copenhagen, Denmark; [Vrtel, R.] Univ Hosp Olomouc, Dept Clin Genet, Olomouc, Czech Republic; [Bartkova, J.; Bartek, J.] Karolinska Inst, Div Translat Med & Chem Biol, Dept Med Biochem & Biophys, Sci Life Lab, Solna, Sweden	Palacky University Olomouc; Danish Cancer Society; University Hospital Olomouc; Karolinska Institutet	Kramara, J (corresponding author), Palacky Univ, Fac Med & Dent, Inst Mol & Translat Med, Hnevotinska 5, Olomouc 77515, Czech Republic.; Bartek, J (corresponding author), Danish Canc Soc Res Ctr, Genome Integr Unit, Strandboulevarden 49, DK-2100 Copenhagen, Denmark.	juraj.kramara@upol.cz; jb@cancer.dk		Chroma, Katarina/0000-0003-0141-0469; Skrott, Zdenek/0000-0001-6004-3609; Mistrik, Martin/0000-0002-2321-0348	Grant Agency of the Czech Republic [13-17555S]; Czech National Program of Sustainability [LO1304]; Kellner Family Foundation; Norwegian Financial Mechanism CZ09 [PHOSCAN 7F14061]; MEYS CR [LM2015062]; EU operation program [CZ.1.07/2.3.00/30.0004]; Danish National Research Foundation [DNRF125]; Danish Cancer Society; Swedish Research Council; Lundbeck Foundation; Cancer Fonden; Danish Council for Independent Research;  [IGA-LF-2016-030]; Novo Nordisk Fonden [NNF15OC0016584, NNF12OC0002290] Funding Source: researchfish; The Danish Cancer Society [R124-A7785] Funding Source: researchfish	Grant Agency of the Czech Republic(Grant Agency of the Czech Republic); Czech National Program of Sustainability; Kellner Family Foundation; Norwegian Financial Mechanism CZ09; MEYS CR; EU operation program; Danish National Research Foundation(Danmarks Grundforskningsfond); Danish Cancer Society(Danish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Lundbeck Foundation(Lundbeckfonden); Cancer Fonden(Swedish Cancer Society); Danish Council for Independent Research(Det Frie Forskningsrad (DFF)); ; Novo Nordisk Fonden(Novo Nordisk Foundation); The Danish Cancer Society(Danish Cancer Society)	We thank Jan Bouchal, Katerina Bouchalova and our colleagues from the Laboratory of Genome Integrity for technical assistance, suggestions and comments on the manuscript. This work was supported by grants from the following foundations: Grant Agency of the Czech Republic 13-17555S, Czech National Program of Sustainability LO1304, the Kellner Family Foundation, the Norwegian Financial Mechanism CZ09 (Project PHOSCAN 7F14061), MEYS CR (LM2015062 Czech-BioImaging), the internal grant IGA-LF-2016-030, the EU operation program CZ.1.07/2.3.00/30.0004, the Danish National Research Foundation (DNRF125, project CARD), Danish Cancer Society, the Swedish Research Council, the Lundbeck Foundation, Cancer Fonden, and the Danish Council for Independent Research.	Acs K, 2011, NAT STRUCT MOL BIOL, V18, P1345, DOI 10.1038/nsmb.2188; Bartek J, 2007, ONCOGENE, V26, P7773, DOI 10.1038/sj.onc.1210881; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bekker-Jensen S, 2010, NAT CELL BIOL, V12, P80, DOI 10.1038/ncb2008; Botuyan MV, 2006, CELL, V127, P1361, DOI 10.1016/j.cell.2006.10.043; Bouwman P, 2010, NAT STRUCT MOL BIOL, V17, P688, DOI 10.1038/nsmb.1831; Bunting SF, 2010, CELL, V141, P243, DOI 10.1016/j.cell.2010.03.012; Burrell RA, 2013, NATURE, V494, P492, DOI 10.1038/nature11935; Callen E, 2013, CELL, V153, P1266, DOI 10.1016/j.cell.2013.05.023; Certo MT, 2011, NAT METHODS, V8, P671, DOI [10.1038/NMETH.1648, 10.1038/nmeth.1648]; Chapman JR, 2013, MOL CELL, V49, P858, DOI 10.1016/j.molcel.2013.01.002; Chauhan D, 2005, ANNU REV PHARMACOL, V45, P465, DOI 10.1146/annurev.pharmtox.45.120403.100037; Chen L, 2005, CANCER RES, V65, P5599, DOI 10.1158/0008-5472.CAN-05-0201; Daley JM, 2014, MOL CELL BIOL, V34, P1380, DOI 10.1128/MCB.01639-13; Dantuma NP, 2006, J CELL BIOL, V173, P19, DOI 10.1083/jcb.200510071; Densham RM, 2016, NAT STRUCT MOL BIOL, V23, P647, DOI 10.1038/nsmb.3236; Deshaies RJ, 2014, BMC BIOL, V12, DOI 10.1186/s12915-014-0094-0; Devgan SS, 2011, CELL DEATH DIFFER, V18, P1500, DOI 10.1038/cdd.2011.18; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Doil C, 2009, CELL, V136, P435, DOI 10.1016/j.cell.2008.12.041; Evangelou K, 2013, CELL DEATH DIFFER, V20, P1485, DOI 10.1038/cdd.2013.76; Fradet-Turcotte A, 2013, NATURE, V499, P50, DOI 10.1038/nature12318; Gething MJ, 1999, SEMIN CELL DEV BIOL, V10, P465, DOI 10.1006/scdb.1999.0318; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Gudjonsson T, 2012, CELL, V150, P697, DOI 10.1016/j.cell.2012.06.039; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Hjerpe R, 2012, BIOCHEM J, V441, P927, DOI 10.1042/BJ20111671; Inbar-Rozensal D, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2445; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Jacquemont C, 2007, CANCER RES, V67, P7395, DOI 10.1158/0008-5472.CAN-07-1015; Kocylowski MK, 2015, CELL CYCLE, V14, P1748, DOI 10.1080/15384101.2015.1010918; Livraghi L, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0425-1; Lukas J, 2011, NAT CELL BIOL, V13, P1161, DOI 10.1038/ncb2344; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Ma T, 2013, MOL CELL, V49, P897, DOI 10.1016/j.molcel.2013.01.006; Mallette FA, 2012, EMBO J, V31, P1865, DOI 10.1038/emboj.2012.47; Mattiroli F, 2012, CELL, V150, P1182, DOI 10.1016/j.cell.2012.08.005; Mistrik M, 2016, SCI REP-UK, V6, DOI 10.1038/srep19567; Munoz MC, 2014, NUCLEIC ACIDS RES, V42, P7720, DOI 10.1093/nar/gku421; Munoz MC, 2012, J BIOL CHEM, V287, P40618, DOI 10.1074/jbc.M112.410951; Panier S, 2014, NAT REV MOL CELL BIO, V15, P7, DOI 10.1038/nrm3719; Reinhardt HC, 2013, NAT REV MOL CELL BIO, V14, P563, DOI 10.1038/nrm3640; Ricks TK, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00222; Rodgers K, 2016, J CELL PHYSIOL, V231, P15, DOI 10.1002/jcp.25053; Stewart GS, 2009, CELL, V136, P420, DOI 10.1016/j.cell.2008.12.042; Tang JB, 2013, NAT STRUCT MOL BIOL, V20, P317, DOI 10.1038/nsmb.2499; Thorslund T, 2015, NATURE, V527, P389, DOI 10.1038/nature15401; Tiscornia G, 2006, NAT PROTOC, V1, P241, DOI 10.1038/nprot.2006.37; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Velimezi G, 2013, NAT CELL BIOL, V15, P967, DOI 10.1038/ncb2795; Watanabe S, 2013, NAT STRUCT MOL BIOL, V20, P1425, DOI 10.1038/nsmb.2702; Wee S, 2008, P NATL ACAD SCI USA, V105, P13057, DOI 10.1073/pnas.0802655105; Wiederschain D, 2009, CELL CYCLE, V8, P498, DOI 10.4161/cc.8.3.7701; Xu GT, 2015, NATURE, V521, P541, DOI 10.1038/nature14328; Zhao Y, 2014, TRENDS CELL BIOL, V24, P426, DOI 10.1016/j.tcb.2014.01.005; Zimmermann M, 2013, SCIENCE, V339, P700, DOI 10.1126/science.1231573; Zong DL, 2015, NUCLEIC ACIDS RES, V43, P4950, DOI 10.1093/nar/gkv336	59	25	25	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 27	2017	36	17					2405	2422		10.1038/onc.2016.392	http://dx.doi.org/10.1038/onc.2016.392			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET4QE	27841863				2022-12-17	WOS:000400268900007
J	Chen, R; Duan, J; Li, L; Ma, Q; Sun, Q; Ma, J; Li, C; Zhou, X; Chen, H; Jing, Y; Zhao, S; Wu, X; Zhang, H				Chen, R.; Duan, J.; Li, L.; Ma, Q.; Sun, Q.; Ma, J.; Li, C.; Zhou, X.; Chen, H.; Jing, Y.; Zhao, S.; Wu, X.; Zhang, H.			mTOR promotes pituitary tumor development through activation of PTTG1	ONCOGENE			English	Article							TUBEROUS SCLEROSIS COMPLEX; TRANSFORMING GENE PTTG; PROLACTIN-SECRETING CELLS; RECEPTOR-DEFICIENT MICE; LACTOTROPH HYPERPLASIA; MAMMALIAN TARGET; SUPPRESSOR GENE; TRANSGENIC MICE; MOUSE MODEL; ADENOMAS	As one of the most common intracranial tumors, pituitary tumor is associated with high morbidity. Effective therapy is currently not available for some pituitary tumors due to the largely undefined pathological processes of pituitary tumorigenesis. In this study, hyperactivation of mammalian/mechanistic target of rapamycin (mTOR) signaling was observed in estrogen-induced rat pituitary tumor and mTOR inhibitor rapamycin blocked the tumor development. Pituitary knockout of either mTOR signaling pathway negative regulator Tsc1 or Pten caused mouse pituitary prolactinoma, which was abolished by rapamycin treatment. Mechanistically, the expression of pituitary tumor transforming gene 1 (PTTG1) was upregulated in an mTOR complex 1-dependent manner. Overexpressed PTTG1 was crucial in hyperactive mTOR-mediated tumorigenesis. mTOR-PTTG1 signaling axis may be targeted for the treatment of tumors with mTOR hyperactivation.	[Chen, R.; Duan, J.; Li, L.; Ma, Q.; Sun, Q.; Ma, J.; Li, C.; Zhou, X.; Chen, H.; Jing, Y.; Zhao, S.; Zhang, H.] Chinese Acad Med Sci, Peking Union Med Coll, Grad Sch,State Key Lab Med Mol Biol, Sch Basic Med,Inst Basic Med Sci,Dept Physiol, Beijing, Peoples R China; [Wu, X.] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Internal Med, Div Endocrinol, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital	Zhang, H (corresponding author), Chinese Acad Med Sci, Inst Basic Med Sci, Dept Physiol & Pathophysiol, Room 445,Old Res Bldg,5 Dong Dan San Tiao, Beijing 100005, Peoples R China.	hbzhang@ibms.pumc.edu.cn			National Basic Research Program of China (973 Program) [2015CB553802]; National Natural Science Foundation of China [81372861, 30788004]; Ministry of Education of China (111 project) [B08007]	National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Education of China (111 project)	We thank the staff of Animal Center, and Department of Pathology, Peking Union Medical College (Beijing, China) for help with in vivo studies and instructions on pathological analysis. This work was supported by the National Basic Research Program of China (973 Program) (2015CB553802), the National Natural Science Foundation of China (81372861, 30788004), and the Ministry of Education of China (111 project: B08007).	Abbud RA, 2005, MOL ENDOCRINOL, V19, P1383, DOI 10.1210/me.2004-0403; Asa SL, 1999, ENDOCRINOLOGY, V140, P5348, DOI 10.1210/en.140.11.5348; Asa SL, 2009, ANNU REV PATHOL-MECH, V4, P97, DOI 10.1146/annurev.pathol.4.110807.092259; Bissler JJ, 2008, NEW ENGL J MED, V358, P140, DOI 10.1056/NEJMoa063564; Cano DA, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00203; Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933; Carson RP, 2012, NEUROBIOL DIS, V45, P369, DOI 10.1016/j.nbd.2011.08.024; Chesnokova V, 2005, MOL ENDOCRINOL, V19, P2371, DOI 10.1210/me.2005-0137; Cruz-Soto ME, 2002, ENDOCRINOLOGY, V143, P4429, DOI 10.1210/en.2002-220173; Donangelo I, 2006, ENDOCRINOLOGY, V147, P4781, DOI 10.1210/en.2006-0544; Dworakowska D, 2009, ENDOCR-RELAT CANCER, V16, P1329, DOI 10.1677/ERC-09-0101; Fedele M, 2002, ONCOGENE, V21, P3190, DOI 10.1038/sj.onc.1205428; Fedele M, 2006, CANCER CELL, V9, P459, DOI 10.1016/j.ccr.2006.04.024; Fedele M, 2010, MOL CELL ENDOCRINOL, V326, P19, DOI 10.1016/j.mce.2010.03.019; Feng ZZ, 2012, MED ONCOL, V29, P304, DOI 10.1007/s12032-010-9775-x; Fukuoka H, 2011, J CLIN INVEST, V121, P4712, DOI 10.1172/JCI60417; Heaney AP, 1999, NAT MED, V5, P1317, DOI 10.1038/15275; Heaney AP, 2000, LANCET, V355, P716, DOI 10.1016/S0140-6736(99)10238-1; Hikake T, 2009, J ENDOCRINOL, V203, P231, DOI 10.1677/JOE-09-0232; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Kelly MA, 1997, NEURON, V19, P103, DOI 10.1016/S0896-6273(00)80351-7; Kenerson H, 2005, PEDIATR RES, V57, P67, DOI 10.1203/01.PDR.0000147727.78571.07; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Lee L, 2005, GENE CHROMOSOME CANC, V42, P213, DOI 10.1002/gcc.20118; Lee M, 2015, CLIN CANCER RES, V21, P3204, DOI 10.1158/1078-0432.CCR-15-0288; Lesche R, 2002, GENESIS, V32, P148, DOI 10.1002/gene.10036; Liang M, 2015, TUMOR BIOL, V36, P7085, DOI 10.1007/s13277-015-3420-4; Lin SJ, 2015, ONCOTARGET, V6, P39329, DOI 10.18632/oncotarget.5744; Lin YH, 2015, TUMOUR BIOL; Lin Y, 2009, ENDOCR-RELAT CANCER, V16, P301, DOI 10.1677/ERC-08-0167; Lines KE, 2016, MOL CELL ENDOCRINOL, V421, P68, DOI 10.1016/j.mce.2015.08.024; Lu CX, 2008, ENDOCRINOLOGY, V149, P3339, DOI 10.1210/en.2007-1696; Ma JH, 2010, J CLIN INVEST, V120, P103, DOI 10.1172/JCI37964; Malhowski AJ, 2011, HUM MOL GENET, V20, P1290, DOI 10.1093/hmg/ddq570; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Marko NF, 2012, NAT REV ENDOCRINOL, V8, P572, DOI 10.1038/nrendo.2012.143; McCormack FX, 2011, NEW ENGL J MED, V364, P1595, DOI 10.1056/NEJMoa1100391; Melmed S, 2011, NAT REV ENDOCRINOL, V7, P257, DOI 10.1038/nrendo.2011.40; Monsalves E, 2014, ENDOCR-RELAT CANCER, V21, pR331, DOI 10.1530/ERC-14-0188; Musat M, 2005, ENDOCR-RELAT CANCER, V12, P423, DOI 10.1677/erc.1.00949; Palumbo T, 2013, ONCOGENE, V32, P1651, DOI 10.1038/onc.2012.190; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; Pelletier G, 2003, NEUROENDOCRINOLOGY, V77, P324, DOI 10.1159/000070898; Peng H, 2013, ONCOGENE, V32, P4702, DOI 10.1038/onc.2012.481; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Rubinfeld H, 2012, ENDOCRINE, V42, P285, DOI 10.1007/s12020-012-9682-3; Schuff KG, 2002, J CLIN INVEST, V110, P973, DOI 10.1172/JCI200215912; Squarize CH, 2008, CANCER RES, V68, P7066, DOI 10.1158/0008-5472.CAN-08-0922; Stefaneanu L, 1999, ENDOCRINOLOGY, V140, P3881, DOI 10.1210/en.140.9.3881; Thompson AD, 2005, FEBS LETT, V579, P3195, DOI 10.1016/j.febslet.2005.05.008; Vlotides G, 2006, MOL ENDOCRINOL, V20, P3321, DOI 10.1210/me.2006-0280; Vlotides G, 2007, ENDOCR REV, V28, P165, DOI 10.1210/er.2006-0042; Xie R, 2015, J NEURO-ONCOL, V125, P79, DOI 10.1007/s11060-015-1895-x; Yin Z, 2008, GENESIS, V46, P37, DOI 10.1002/dvg.20362; Yoon CH, 2012, J BIOL CHEM, V287, P19516, DOI 10.1074/jbc.M111.337428; Yu J, 2006, CANCER RES, V66, P9461, DOI 10.1158/0008-5472.CAN-06-1895; Yu R, 2010, PROG BRAIN RES, V182, P207, DOI 10.1016/S0079-6123(10)82009-6; Zha XJ, 2011, CANCER RES, V71, P13, DOI 10.1158/0008-5472.CAN-10-1668; Zhang HB, 2007, J CLIN INVEST, V117, P730, DOI 10.1172/JCI28984; Zhang X, 1999, J CLIN ENDOCR METAB, V84, P761, DOI 10.1210/jc.84.2.761; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	62	25	26	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 16	2017	36	7					979	988		10.1038/onc.2016.264	http://dx.doi.org/10.1038/onc.2016.264			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8JG	27524416				2022-12-17	WOS:000394169100010
J	Doudican, NA; Orlow, SJ				Doudican, N. A.; Orlow, S. J.			Inhibition of the CRAF/prohibitin interaction reverses CRAF-dependent resistance to vemurafenib	ONCOGENE			English	Article							BRAF V600E MUTATION; RAF INHIBITION; B-RAF; MELANOMA; PROHIBITIN; CELLS; SURVIVAL; PATHWAY; MEK; ACTIVATION	Activating BRAF mutations promote constitutive activation of the mitogen-activated protein kinase (MAPK) signaling pathway and are common in a variety of human malignancies, including melanoma and colon cancer. Several small molecule BRAF inhibitors such as vemurafenib have been developed and demonstrate remarkable clinical efficacy. However, resistance typically emerges in most melanoma patients. Studies have demonstrated that reactivation of MAPK signaling via CRAF overexpression and dysregulation is a mechanism for vemurafenib resistance in melanoma. Prohibitins (PHBs) are highly conserved proteins that are thought to control the cell cycle, senescence and tumor suppression. PHB1 is essential for CRAF-mediated ERK1/2 activation through direct binding to CRAF. We developed a CRAF-mediated model of vemurafenib resistance in melanoma cells to assess the importance of the interaction between CRAF and PHB1 in resistance to BRAF-targeting agents. We demonstrate that CRAF overexpression renders melanoma cells resistant to BRAF-targeting agents. Moreover, treatment with the natural compound rocaglamide A disrupts the interaction between PHB and CRAF in melanoma cells, thus reducing MEK1/2 and ERK1/2 signaling, inhibiting melanoma cell growth and inducing apoptosis. The efficacy of these compounds was also demonstrated in a human melanoma xenograft model. Taken together, these data suggest that PHB1 may serve as a novel, druggable target in CRAF-mediated vemurafenib resistance.	[Doudican, N. A.; Orlow, S. J.] NYU, Sch Med, Ronald O Perelman Dept Dermatol, 522 First Ave,Smilow 401, New York, NY 10016 USA; [Orlow, S. J.] NYU, Sch Med, Dept Cell Biol, New York, NY USA	New York University; New York University	Orlow, SJ (corresponding author), NYU, Sch Med, Ronald O Perelman Dept Dermatol, 522 First Ave,Smilow 401, New York, NY 10016 USA.	seth.orlow@nyumc.org		Orlow, Seth/0000-0003-2548-7380	Orbuch & Brand Pilot Grant Program for Cancers of the Skin; Cancer Center Support Grant at the Laura and Isaac Perlmutter Cancer Center [P30CA016087]; NATIONAL CANCER INSTITUTE [P30CA016087] Funding Source: NIH RePORTER	Orbuch & Brand Pilot Grant Program for Cancers of the Skin; Cancer Center Support Grant at the Laura and Isaac Perlmutter Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the NYUMC Immunohistochemistry Core for their help with the immunohistochemistry experiments. This study was supported by the Orbuch & Brand Pilot Grant Program for Cancers of the Skin. The NYUMC Immunohistochemistry Core performed the immunohistochemistry experiments outlined in this manuscript. This shared resource is partially supported by the Cancer Center Support Grant, P30CA016087, at the Laura and Isaac Perlmutter Cancer Center.	Al-Obeidi FA, 2000, ONCOGENE, V19, P5690, DOI 10.1038/sj.onc.1203926; ASAMOTO M, 1994, CANCER LETT, V83, P201, DOI 10.1016/0304-3835(94)90320-4; Barras David, 2015, Biomark Cancer, V7, P9, DOI 10.4137/BIC.S25248; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Choi J, 2014, PIGM CELL MELANOMA R, V27, DOI 10.1111/pcmr.12197; Chowdhury Indrajit, 2012, Front Biosci (Elite Ed), V4, P690; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Doudican N, 2008, MOL CANCER RES, V6, P1308, DOI 10.1158/1541-7786.MCR-07-2159; Emery CM, 2009, P NATL ACAD SCI USA, V106, P20411, DOI 10.1073/pnas.0905833106; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Hossen MN, 2010, J CONTROL RELEASE, V147, P261, DOI 10.1016/j.jconrel.2010.07.100; Jakob JA, 2012, CANCER-AM CANCER SOC, V118, P4014, DOI 10.1002/cncr.26724; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Johansson CH, 2014, PHARMACOL THERAPEUT, V142, P176, DOI 10.1016/j.pharmthera.2013.11.011; Katona TM, 2007, AM J SURG PATHOL, V31, P1029, DOI 10.1097/PAS.0b013e31802b3488; Li DD, 2015, FRONT BIOSCI-LANDMRK, V20, P1068, DOI 10.2741/4359; Luan Z, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-38; Mao ML, 2013, CLIN CANCER RES, V19, P657, DOI 10.1158/1078-0432.CCR-11-1446; Martin-Liberal J, 2015, FUTURE ONCOL, V11, P579, DOI 10.2217/fon.14.252; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Osman C, 2009, J CELL BIOL, V184, P583, DOI 10.1083/jcb.200810189; Paraiso KHT, 2011, CANCER RES, V71, P2750, DOI 10.1158/0008-5472.CAN-10-2954; Peng YT, 2015, APOPTOSIS, V20, P1135, DOI 10.1007/s10495-015-1143-z; Polier G, 2012, CHEM BIOL, V19, P1093, DOI 10.1016/j.chembiol.2012.07.012; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Rajalingam K, 2005, NAT CELL BIOL, V7, P837, DOI 10.1038/ncb1283; Rajalingam K, 2007, BBA-MOL CELL RES, V1773, P1177, DOI 10.1016/j.bbamcr.2007.01.012; Robert C, 2011, CURR OPIN ONCOL, V23, P177, DOI 10.1097/CCO.0b013e3283436e8c; Ross JA, 2008, J BIOL CHEM, V283, P4699, DOI 10.1074/jbc.M708232200; Smalley KSM, 2008, MOL CANCER THER, V7, P2876, DOI 10.1158/1535-7163.MCT-08-0431; Sosman JA, 2012, NEW ENGL J MED, V366, P707, DOI 10.1056/NEJMoa1112302; Spagnolo F, 2015, ONCOTARGETS THER, V8, P157, DOI 10.2147/OTT.S39096; Sripathi SR, 2011, BIOCHEMISTRY-US, V50, P8342, DOI 10.1021/bi2008933; Su F, 2012, CANCER RES, V72, P969, DOI 10.1158/0008-5472.CAN-11-1875; Sullivan RJ, 2013, ONCOGENE, V32, P2373, DOI 10.1038/onc.2012.345; Tan YH, 2008, PATHOLOGY, V40, P295, DOI 10.1080/00313020801911512; Tu NN, 2015, J THORAC ONCOL, V10, P1396, DOI 10.1097/JTO.0000000000000644; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Wagle N, 2011, J CLIN ONCOL, V29, P3085, DOI 10.1200/JCO.2010.33.2312; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Yancovitz M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029336; Zhou TB, 2013, J RECEPT SIG TRANSD, V33, P28, DOI 10.3109/10799893.2012.752006; Zhu JY, 2007, INT J CANCER, V121, P1839, DOI 10.1002/ijc.22883	45	25	26	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 19	2017	36	3					423	428		10.1038/onc.2016.214	http://dx.doi.org/10.1038/onc.2016.214			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IB	27321184				2022-12-17	WOS:000394166000011
J	Su, R; Dong, L; Zou, D; Zhao, H; Ren, Y; Li, F; Yi, P; Li, L; Zhu, Y; Ma, Y; Wang, J; Wang, F; Yu, J				Su, R.; Dong, L.; Zou, D.; Zhao, H.; Ren, Y.; Li, F.; Yi, P.; Li, L.; Zhu, Y.; Ma, Y.; Wang, J.; Wang, F.; Yu, J.			microRNA-23a,-27a and-24 synergistically regulate JAK1/Stat3 cascade and serve as novel therapeutic targets in human acute erythroid leukemia	ONCOGENE			English	Article							ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; DIFFERENTIATION; ERYTHROLEUKEMIA; PATHWAY; GATA-1; CELLS; ERYTHROPOIESIS; PROLIFERATION; RUXOLITINIB	Acute erythroid leukemia (AEL) is characterized by lower incidence, poorer prognosis and worse survival than other types of leukemia and results from collaboration of malignant proliferation and erythroid differentiation blockage. The expression, function and therapeutic significance of noncoding RNAs in AEL have not been well studied. Here, we show that one miRNA cluster, including miR-23a,-27a and -24, is dramatically downregulated in AEL patients. Restoration of miR-23a,-27a and -24 expression induces apoptosis and erythropoiesis, inhibits adverse growth and partly relieves the leukemic symptoms of AEL patients. At the whole-genome scale, we identify that miR-23a,-27a and -24 synergistically target multiple members of the oncogenic gp130-JAK1-Stat3 pathway, and thus reinforce their inhibition on the cascade to regulate cell proliferation and apoptosis. Importantly, Ruxolitinib, a JAK1 inhibitor, could rescue the phenotypic changes induced by miR-23a,-27a and -24 inhibitors. Furthermore, miR-23a cluster-mediated-inactivation of the JAK1-Stat3 pathway promotes the expression and activity of GATA1 via inhibiting PU. 1, thereby improving erythroid differentiation. Collectively, we reveal an important regulatory circuit comprising GATA1, the miR-23a cluster and gp130-JAK1-Stat3 pathway, that synergistically facilitates apoptosis and erythropoiesis and restrains adverse proliferation, indicating the therapeutic significance of miR-23a,-27a and -24 for AEL treatment.	[Su, R.; Dong, L.; Zou, D.; Zhao, H.; Ren, Y.; Li, F.; Zhu, Y.; Ma, Y.; Wang, F.; Yu, J.] Chinese Acad Med Sci, Inst Basic Med Sci, State Key Lab Med Mol Biol, Dept Biochem, Beijing, Peoples R China; [Su, R.; Dong, L.; Zou, D.; Zhao, H.; Ren, Y.; Li, F.; Zhu, Y.; Ma, Y.; Wang, J.; Wang, F.; Yu, J.] Peking Union Med Coll, Beijing, Peoples R China; [Su, R.] Univ Cincinnati, Coll Med, Dept Canc Biol, Cincinnati, OH 45219 USA; [Zou, D.] Chongqing Canc Inst, Dept Gynecol Oncol, Chongqing, Peoples R China; [Yi, P.; Li, L.] Third Millitary Med Univ, Dept Obstet & Gynecol, Daping Hosp, Inst Surg Res, Chongqing, Peoples R China; [Wang, J.] Chinese Acad Med Sci, Inst Basic Med Sci, Dept Pathophysiol, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; University System of Ohio; University of Cincinnati; Army Medical University; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS	Su, R (corresponding author), Univ Cincinnati, Coll Med, Dept Canc Biol, Cincinnati, OH 45219 USA.; Wang, F; Yu, J (corresponding author), Peking Union Med Coll, Inst Basic Med Sci, New Res Bldg,Room 608,5 Dong Dan San Tiao, Beijing 100005, Peoples R China.	suri@ucmail.uc.edu; wo_wfang@hotmail.com; j-yu@ibms.pumc.edu.cn	Su, Rui/Y-8157-2018; Dong, Lei/AAA-9495-2020	Dong, Lei/0000-0001-9574-0148; Yu, Jia/0000-0003-3499-5133; Su, Rui/0000-0002-4807-6229	National Key Basic Research Program of China [2011CBA01100]; National Natural Science Foundation of China [81530007, 31040021, 31171311, 31471227, 30970616]	National Key Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank for Dr Jianjun Chen for his assistance and constructive suggestions. This work was supported by the National Key Basic Research Program of China (2011CBA01100 to JY); National Natural Science Foundation of China (81530007 to JY, 31040021 to JY, 31171311 to FW, 31471227 to FW and 30970616 to FW).	BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; Blum S, 2012, BLOOD, V120, P1974, DOI 10.1182/blood-2011-11-390047; Cui JW, 2007, BLOOD, V110, P2631, DOI 10.1182/blood-2006-10-053850; de Thonel A, 2010, BLOOD, V116, P85, DOI 10.1182/blood-2009-09-241778; Eaves CJ, 2010, NEW ENGL J MED, V362, P2326, DOI 10.1056/NEJMcibr1003522; Fan CQ, 2011, LEUKEMIA LYMPHOMA, V52, P502, DOI 10.3109/10428194.2010.543712; Fazi F, 2005, CELL, V123, P819, DOI 10.1016/j.cell.2005.09.023; Felli N, 2005, P NATL ACAD SCI USA, V102, P18081, DOI 10.1073/pnas.0506216102; Gallipoli P, 2014, BLOOD, V124, P1492, DOI 10.1182/blood-2013-12-545640; Gao XN, 2011, LEUKEMIA RES, V35, P1226, DOI 10.1016/j.leukres.2011.06.010; Goldberg SL, 1998, AM J CLIN ONCOL-CANC, V21, P42, DOI 10.1097/00000421-199802000-00010; Grossmann V, 2013, LEUKEMIA, V27, P1940, DOI 10.1038/leu.2013.144; Hasserjian RP, 2010, BLOOD, V115, P1985, DOI 10.1182/blood-2009-09-243964; Hegde S, 2009, ONCOGENE, V28, P3349, DOI 10.1038/onc.2009.202; Jiang X, 2012, CANCER CELL, V22, P524, DOI 10.1016/j.ccr.2012.08.028; Kadri Z, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000123; Kayali S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046799; Lo MC, 2013, LEUKEMIA, V27, P2272, DOI 10.1038/leu.2013.197; Lunghi P, 2005, LEUKEMIA, V19, P234, DOI 10.1038/sj.leu.2403585; Ma YN, 2015, EMBO J, V34, P361, DOI 10.15252/embj.201489957; Ma YN, 2013, MOL CELL BIOL, V33, P3994, DOI 10.1128/MCB.00623-13; Mancini E, 2012, EMBO J, V31, P351, DOI 10.1038/emboj.2011.390; Mascarenhas J, 2012, CLIN CANCER RES, V18, P3008, DOI 10.1158/1078-0432.CCR-11-3145; Maude SL, 2015, BLOOD, V125, P1759, DOI 10.1182/blood-2014-06-580480; McCubrey JA, 2014, LEUKEMIA, V28, P15, DOI 10.1038/leu.2013.184; Monaghan KA, 2011, LEUKEMIA, V25, P1891, DOI 10.1038/leu.2011.175; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Neri LM, 2014, LEUKEMIA, V28, P739, DOI 10.1038/leu.2013.226; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; Ren JG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012520; Rhodes J, 2005, DEV CELL, V8, P97, DOI 10.1016/j.devcel.2004.11.014; Santos FPS, 2009, LEUKEMIA, V23, P2275, DOI 10.1038/leu.2009.181; Steelman LS, 2008, LEUKEMIA, V22, P686, DOI 10.1038/leu.2008.26; Steelman LS, 2011, LEUKEMIA, V25, P1080, DOI 10.1038/leu.2011.66; Su R, 2015, ONCOGENE, V34, P3226, DOI 10.1038/onc.2014.274; Suzuki M, 2013, GENES CELLS, V18, P921, DOI 10.1111/gtc.12086; Teramo A, 2013, BLOOD, V121, P3843, DOI 10.1182/blood-2012-07-441378; Vainchenker W, 2013, ONCOGENE, V32, P2601, DOI 10.1038/onc.2012.347; Vannucchi AM, 2013, LEUKEMIA, V27, P1861, DOI 10.1038/leu.2013.119; Wang F, 2014, NUCLEIC ACIDS RES, V42, P442, DOI 10.1093/nar/gkt848; Wells AW, 2001, J CLIN PATHOL, V54, P608, DOI 10.1136/jcp.54.8.608; Zhang P, 2000, BLOOD, V96, P2641; Zhou T, 2014, LEUKEMIA, V28, P471, DOI 10.1038/leu.2013.299; Zhu Y, 2013, NUCLEIC ACIDS RES, V41, P4129, DOI 10.1093/nar/gkt093	44	25	25	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2016	35	46					6001	6014		10.1038/onc.2016.127	http://dx.doi.org/10.1038/onc.2016.127			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED0CA	27086927				2022-12-17	WOS:000388509400007
J	Darido, C; Georgy, SR; Jane, SM				Darido, C.; Georgy, S. R.; Jane, S. M.			The role of barrier genes in epidermal malignancy	ONCOGENE			English	Review							GROWTH-FACTOR RECEPTOR; REGULATES KERATINOCYTE PROLIFERATION; EPITHELIAL STEM-CELLS; NF-KAPPA-B; PERMEABILITY BARRIER; STRATUM-CORNEUM; ALPHA-CATENIN; MICE LACKING; TERMINAL DIFFERENTIATION; ABCA12 MUTATIONS	The outermost layer of the mammalian skin, the epidermis, forms a protective barrier against pathogenic microbes and tissue dehydration. This barrier is formed and maintained by complex genetic networks that connect cellular differentiation processes, enzymatic activities and cellular junctions. Disruption in these networks affects the balance between keratinocyte proliferation and differentiation resulting in barrier function impairment, epidermal hyperproliferation and in some cases, squamous cell carcinoma (SCC). Recent studies in wound-induced inflammation-mediated cancers in mice have identified dysregulation of core barrier components as tumor drivers. We therefore propose a hypothesis in which loss of key barrier genes, induce barrier dysfunction, and promote inflammation-driven epidermal hyperplasia and carcinogenesis over time. This emerging vision suggests that under specific genetic circumstances, localized barrier impairment could be considered as a hallmark of initiating lesions in epidermal SCC.	[Darido, C.; Georgy, S. R.; Jane, S. M.] Alfred Hosp, Dept Med, Epidermal Dev Lab, Prahran, Vic, Australia; [Darido, C.; Georgy, S. R.; Jane, S. M.] Monash Univ, Cent Clin Sch, Prahran, Vic, Australia; [Darido, C.] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia; [Jane, S. M.] Alfred Hosp, Dept Hematol, Prahran, Vic, Australia	Florey Institute of Neuroscience & Mental Health; Monash University; Peter Maccallum Cancer Center; University of Melbourne; Florey Institute of Neuroscience & Mental Health	Darido, C (corresponding author), Monash Univ, Cent Clin Sch, Dept Med, Level 1,Walkway Via Alfred Ctr 99 Commercial Rd, Melbourne, Vic 3004, Australia.	charbel.darido@petermac.org	Darido, Charbel/H-2800-2016	Darido, Charbel/0000-0002-6541-324X; Jane, Stephen Marsden/0000-0002-1045-0481; Georgy, Smitha Rose/0000-0003-4716-8559	Australian National Health and Medical Research Council; Association for International Cancer Research; Victorian Cancer Agency Clare Oliver Memorial Fellowship	Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Association for International Cancer Research; Victorian Cancer Agency Clare Oliver Memorial Fellowship	We thank Dr Stephen Goldie and Dr Sebastian Dworkin for their critical reading of the review. The authors are supported by grants from the Australian National Health and Medical Research Council, the Association for International Cancer Research (to SMJ and CD) and the Victorian Cancer Agency Clare Oliver Memorial Fellowship (to CD).	Abel EL, 2009, NAT PROTOC, V4, P1350, DOI 10.1038/nprot.2009.120; Akiyama M, 2010, HUM MUTAT, V31, P1090, DOI 10.1002/humu.21326; Ambler CA, 2010, DEVELOPMENT, V137, P3569, DOI 10.1242/dev.050310; Arabzadeh A, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-196; Arwert EN, 2012, NAT REV CANCER, V12, P170, DOI 10.1038/nrc3217; Arwert EN, 2010, P NATL ACAD SCI USA, V107, P19903, DOI 10.1073/pnas.1007404107; Bhandari A, 2013, ONCOGENE, V32, P1497, DOI 10.1038/onc.2012.168; Biniek K, 2012, P NATL ACAD SCI USA, V109, P17111, DOI 10.1073/pnas.1206851109; Blanpain C, 2006, ANNU REV CELL DEV BI, V22, P339, DOI 10.1146/annurev.cellbio.22.010305.104357; Boglev Y, 2011, DEV BIOL, V349, P512, DOI 10.1016/j.ydbio.2010.11.011; Caddy J, 2010, DEV CELL, V19, P138, DOI 10.1016/j.devcel.2010.06.008; Cangkrama M, 2016, J INVEST DERMATOL, V136, P1438, DOI 10.1016/j.jid.2016.02.806; Cangkrama M, 2013, INT J MOL SCI, V14, P13670, DOI 10.3390/ijms140713670; Cavallaro U, 2011, NAT REV MOL CELL BIO, V12, P189, DOI 10.1038/nrm3068; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; Darido C, 2008, CANCER RES, V68, P4258, DOI 10.1158/0008-5472.CAN-07-5805; Darido C, 2013, ADV WOUND CARE, V2, P87, DOI 10.1089/wound.2011.0352; Darido C, 2011, CANCER CELL, V20, P635, DOI 10.1016/j.ccr.2011.10.014; Darido Charbel, 2010, Small GTPases, V1, P104, DOI 10.4161/sgtp.1.2.13620; de la Garza G, 2013, J INVEST DERMATOL, V133, P68, DOI 10.1038/jid.2012.269; Demehri S, 2008, PLOS BIOL, V6, P992, DOI 10.1371/journal.pbio.0060123; Demehri S, 2012, CANCER CELL, V22, P494, DOI 10.1016/j.ccr.2012.08.017; Demehri S, 2009, CANCER CELL, V16, P55, DOI 10.1016/j.ccr.2009.05.016; Derksen PWB, 2006, CANCER CELL, V10, P437, DOI 10.1016/j.ccr.2006.09.013; Descargues P, 2008, EMBO J, V27, P2639, DOI 10.1038/emboj.2008.196; Di Piazza M, 2012, CANCER CELL, V22, P479, DOI 10.1016/j.ccr.2012.08.016; Dumortier A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009258; Dworkin S, 2011, ORGANOGENESIS, V7, P202, DOI 10.4161/org.7.3.18431; Fadloun A, 2007, DEVELOPMENT, V134, P2947, DOI 10.1242/dev.005041; Fehrenschild D, 2012, J INVEST DERMATOL, V132, P337, DOI 10.1038/jid.2011.301; Furuse M, 2002, J CELL BIOL, V156, P1099, DOI 10.1083/jcb.200110122; Gareus R, 2007, NAT CELL BIOL, V9, P461, DOI 10.1038/ncb1560; Georgy SR, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv152; Girardi M, 2002, J EXP MED, V195, P855, DOI 10.1084/jem.20012000; Girardi M, 2001, SCIENCE, V294, P605, DOI 10.1126/science.1063916; Girardi M, 2006, J INVEST DERMATOL, V126, P808, DOI 10.1038/sj.jid.5700120; Gordon WM, 2014, J CLIN INVEST, V124, P5205, DOI 10.1172/JCI77138; Grigoryan T, 2008, GENE DEV, V22, P2308, DOI 10.1101/gad.1686208; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Grose R, 2007, EMBO J, V26, P1268, DOI 10.1038/sj.emboj.7601583; Harris TJC, 2010, NAT REV MOL CELL BIO, V11, P502, DOI 10.1038/nrm2927; Herron BJ, 2005, NAT GENET, V37, P1210, DOI 10.1038/ng1652; Hitomi K, 2005, EUR J DERMATOL, V15, P313; Hobbs RM, 2003, J BIOL CHEM, V278, P19798, DOI 10.1074/jbc.M300513200; Hoste E, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6932; Huebner AJ, 2012, DEV CELL, V23, P1238, DOI 10.1016/j.devcel.2012.11.002; Ingraham CR, 2006, NAT GENET, V38, P1335, DOI 10.1038/ng1903; Jensen JM, 2000, J INVEST DERMATOL, V115, P708, DOI 10.1046/j.1523-1747.2000.00103.x; Jiang YJ, 2010, J INVEST DERMATOL, V130, P511, DOI 10.1038/jid.2009.245; Jonca N, 2011, EUR J DERMATOL, V21, P35, DOI 10.1684/ejd.2011.1264; Kim DJ, 2004, J BIOL CHEM, V279, P23719, DOI 10.1074/jbc.M312063200; Kobielak A, 2006, P NATL ACAD SCI USA, V103, P2322, DOI 10.1073/pnas.0510422103; Koehler K, 2011, EUR J CELL BIOL, V90, P565, DOI 10.1016/j.ejcb.2010.10.017; Koster MI, 2007, P NATL ACAD SCI USA, V104, P3255, DOI 10.1073/pnas.0611376104; Koster MI, 2006, DEV BIOL, V289, P253, DOI 10.1016/j.ydbio.2005.10.041; Kuramoto N, 2002, J CLIN INVEST, V109, P243, DOI 10.1172/JCI13563; Leclerc EA, 2009, J CELL SCI, V122, P2699, DOI 10.1242/jcs.050302; Leonard MK, 2011, CELL DEATH DIFFER, V18, P1924, DOI 10.1038/cdd.2011.73; Li J, 2012, CARCINOGENESIS, V33, P1239, DOI 10.1093/carcin/bgs143; Li QT, 2011, CARCINOGENESIS, V32, P1782, DOI 10.1093/carcin/bgr207; Liu BG, 2008, CANCER CELL, V14, P212, DOI 10.1016/j.ccr.2008.07.017; Lopez-Pajares V, 2013, TRENDS GENET, V29, P31, DOI 10.1016/j.tig.2012.10.005; Man MQ, 2008, J INVEST DERMATOL, V128, P370, DOI 10.1038/sj.jid.5701026; Matsuki M, 1998, P NATL ACAD SCI USA, V95, P1044, DOI 10.1073/pnas.95.3.1044; Meyer M, 2011, J INVEST DERM SYMP P, V15, P48, DOI 10.1038/jidsymp.2011.1; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Mlacki M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089247; Montagner A, 2014, EMBO MOL MED, V6, P80, DOI 10.1002/emmm.201302666; Natsuga K, 2007, J INVEST DERMATOL, V127, P2669, DOI 10.1038/sj.jid.5700885; Nishi K, 2009, J CELL BIOCHEM, V106, P63, DOI 10.1002/jcb.21978; Parsa R, 1999, J INVEST DERMATOL, V113, P1099, DOI 10.1046/j.1523-1747.1999.00780.x; Perez-Moreno M, 2006, CELL, V124, P631, DOI 10.1016/j.cell.2005.11.043; Perez-Moreno M, 2008, P NATL ACAD SCI USA, V105, P15399, DOI 10.1073/pnas.0807301105; Peters JM, 2012, NAT REV CANCER, V12, P181, DOI 10.1038/nrc3214; Plikus MV, 2012, SEMIN CELL DEV BIOL, V23, P946, DOI 10.1016/j.semcdb.2012.10.001; Restivo G, 2011, EMBO J, V30, P4571, DOI 10.1038/emboj.2011.325; Richardson RJ, 2006, NAT GENET, V38, P1329, DOI 10.1038/ng1894; Santos M, 2002, J BIOL CHEM, V277, P19122, DOI 10.1074/jbc.M201001200; Schafer M, 2008, NAT REV MOL CELL BIO, V9, P628, DOI 10.1038/nrm2455; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; Sen GL, 2012, DEV CELL, V22, P669, DOI 10.1016/j.devcel.2011.12.001; She QB, 2002, CANCER RES, V62, P1343; Tan NS, 2001, GENE DEV, V15, P3263, DOI 10.1101/gad.207501; Tian XR, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/567305; Ting SB, 2005, SCIENCE, V308, P411, DOI 10.1126/science.1107511; Ting SB, 2003, NAT MED, V9, P1513, DOI 10.1038/nm961; Tinkle CL, 2008, P NATL ACAD SCI USA, V105, P15405, DOI 10.1073/pnas.0807374105; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; Tunggal JA, 2005, EMBO J, V24, P1146, DOI 10.1038/sj.emboj.7600605; Turksen K, 2011, BBA-REV CANCER, V1816, P73, DOI 10.1016/j.bbcan.2011.04.001; Vasioukhin V, 2001, CELL, V104, P605, DOI 10.1016/S0092-8674(01)00246-X; Wang X, 2006, J CELL BIOL, V172, P409, DOI 10.1083/jcb.200510002; Wang X, 2008, J CELL BIOL, V183, P37, DOI 10.1083/jcb.200804030; Wikramanayake TC, 2014, ADV WOUND CARE, V3, P272, DOI 10.1089/wound.2013.0503; Xiao MJ, 2009, CANCER RES, V69, P2010, DOI 10.1158/0008-5472.CAN-08-3479; Yang JX, 2010, J CELL BIOL, V188, P935, DOI 10.1083/jcb.200910126; Yu ZQ, 2006, DEV BIOL, V299, P122, DOI 10.1016/j.ydbio.2006.07.015; Zhong R, 2015, CANCER RES, V75, P3958, DOI 10.1158/0008-5472.CAN-15-0199; Zhu F, 2009, HISTOL HISTOPATHOL, V24, P265, DOI 10.14670/HH-24.265; Zuo Y, 2008, J BIOL CHEM, V283, P36624, DOI 10.1074/jbc.M807377200	101	25	25	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2016	35	44					5705	5712		10.1038/onc.2016.84	http://dx.doi.org/10.1038/onc.2016.84			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XQ	27041586				2022-12-17	WOS:000386998400002
J	Lee, I; Maniar, K; Lydon, JP; Kim, JJ				Lee, Il; Maniar, K.; Lydon, J. P.; Kim, J. J.			Akt regulates progesterone receptor B-dependent transcription and angiogenesis in endometrial cancer cells	ONCOGENE			English	Article							ENDOTHELIAL GROWTH-FACTOR; MEDROXYPROGESTERONE ACETATE; GLUCOCORTICOID-RECEPTOR; GENE-EXPRESSION; DOWN-REGULATION; STROMAL CELLS; YOUNG-WOMEN; CARCINOMA; 14-3-3-SIGMA; 14-3-3-PROTEINS	Progestins have long been used clinically for the treatment of endometrial cancers; however, the response rates to progestin therapy vary and the molecular mechanisms behind progestin insensitivity are poorly understood. We hypothesized that in PTEN-mutated endometrial cancers, hyperactive Akt signaling downregulates progesterone receptor B (PRB) transcriptional activity, leading to overall impaired progestin responses. We report that inhibition of Akt with the Akt inhibitor, MK-2206 (MK), in conjunction with progestin (R5020) treatment, is sufficient to upregulate a subset of PRB target genes in Ishikawa cells stably expressing PRB (PRB-Ishikawa). Through gene ontology analysis of Akt-regulated PRB target genes, angiogenesis was found to be the principle process regulated by Akt-PRB. To further interrogate the mechanism by which Akt modulates PRB transcriptional activity, ChIP-Mass spectrometry was performed to identify potential cofactors that differentially interact with PRB in the presence of R5020 and MK+R5020. 14-3-3 sigma was identified as a protein enriched in the MK+R5020 data set, and it was demonstrated that 14-3-3 sigma is required for the upregulation in PRB target gene expression following inhibition of Akt. To determine the ramifications of MK+R5020 treatment on angiogenesis, in vitro assays were performed and combinatorial MK+R5020 treatment significantly decreased endothelial cell invasion and tube formation more than MK or R5020 treatment alone. Furthermore, we found that combinatorial MK-2206+progesterone treatments decreased angiogenesis and proliferation in the Pten(d/d) conditional mouse model of endometrial cancer. Taken together, these findings suggest that a combinatorial therapeutic approach utilizing Akt inhibitors with progestins may improve the efficacy of progestin therapy for the treatment of endometrial cancer.	[Lee, Il; Kim, J. J.] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Div Reprod Sci Med,Dept Obstet & Gynecol, Chicago, IL 60611 USA; [Maniar, K.] Northwestern Univ, Dept Pathol, Feinberg Sch Med, Chicago, IL 60611 USA; [Lydon, J. P.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Feinberg School of Medicine; Baylor College of Medicine	Kim, JJ (corresponding author), Northwestern Univ, OB GYN, 303 E Super St Lurie 4-117, Chicago, IL 60611 USA.	j-kim4@northwestern.edu		Kim, J Julie/0000-0001-9834-8213; Lee, Irene/0000-0002-5749-9389	Robert H. Lurie Comprehensive Cancer Center of Northwestern University; NIH/NICHD [R01HD042311]; NIH/NCI [T32CA09560, R01CA155513]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD042311] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA060553, R01CA155513, T32CA009560] Funding Source: NIH RePORTER	Robert H. Lurie Comprehensive Cancer Center of Northwestern University; NIH/NICHD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to acknowledge the Northwestern Genomics Core Facility, the Northwestern Proteomics Core Facility, and the Northwestern Next Generation Sequencing Core Facility. We would also like to thank members of the Kim laboratory for technical assistance and insightful discussion and review of the manuscript. This work is supported by NIH/NCI training grant T32CA09560 (IIL), Malkin Scholars Program from the Robert H. Lurie Comprehensive Cancer Center of Northwestern University (IIL), NIH/NICHD grant R01HD042311 (JPL) and NIH/NCI grant R01CA155513 (JJK).	Aitken A, 2006, SEMIN CANCER BIOL, V16, P162, DOI 10.1016/j.semcancer.2006.03.005; Bansal N, 2009, CANCER CONTROL, V16, P8, DOI 10.1177/107327480901600102; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Clarke CL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035859; Dai D, 2002, CANCER RES, V62, P881; Dai DH, 2001, AM J OBSTET GYNECOL, V184, P790, DOI 10.1067/mob.2001.113844; Daikoku T, 2008, CANCER RES, V68, P5619, DOI 10.1158/0008-5472.CAN-08-1274; Erkanli S, 2010, INT J GYNECOL CANCER, V20, P1170, DOI 10.1111/IGC.0b013e3181e94f5a; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Gibson DA, 2015, HUM REPROD, V30, P1290, DOI 10.1093/humrep/dev067; Goddard LM, 2014, CELL, V156, P549, DOI 10.1016/j.cell.2013.12.025; Goto T, 2008, ONCOGENE, V27, P9, DOI 10.1038/sj.onc.1210626; Gu CO, 2011, CANCER SCI, V102, P557, DOI 10.1111/j.1349-7006.2010.01829.x; Hsu SP, 2008, CELL MOL LIFE SCI, V65, P3839, DOI 10.1007/s00018-008-8441-3; Lebovic DI, 2000, HUM REPROD, V15, P67, DOI 10.1093/humrep/15.suppl_3.67; De Vries-van Leeuwen IJ, 2013, P NATL ACAD SCI USA, V110, P8894, DOI 10.1073/pnas.1220809110; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lodygin D, 2004, ONCOGENE, V23, P9034, DOI 10.1038/sj.onc.1208004; Mhawech P, 2005, MODERN PATHOL, V18, P340, DOI 10.1038/modpathol.3800240; Mohammed H, 2013, CELL REP, V3, P342, DOI 10.1016/j.celrep.2013.01.010; Nakayama H, 2005, PATHOL INT, V55, P707, DOI 10.1111/j.1440-1827.2005.01900.x; National Cancer Institute, 2015, SEER STAT FACT SHEET, V2015; Okada H, 2011, FERTIL STERIL, V96, P786, DOI 10.1016/j.fertnstert.2011.06.048; Pant A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041593; Park JY, 2015, ONCOLOGIST, V20, P270, DOI 10.1634/theoncologist.2013-0445; Quayle SN, 2007, CANCER LETT, V254, P137, DOI 10.1016/j.canlet.2007.03.003; Ramirez PT, 2004, GYNECOL ONCOL, V95, P133, DOI 10.1016/j.ygyno.2004.06.045; Razandi M, 2000, J BIOL CHEM, V275, P38540, DOI 10.1074/jbc.M007555200; Rubel CA, 2012, MOL ENDOCRINOL, V26, P1428, DOI 10.1210/me.2011-1355; Sefton EC, 2013, ENDOCRINOLOGY, V154, P4046, DOI 10.1210/en.2013-1389; Shifren JL, 1996, J CLIN ENDOCR METAB, V81, P3112, DOI 10.1210/jc.81.8.3112; Smid-Koopman E, 2003, J SOC GYNECOL INVEST, V10, P49, DOI 10.1016/S1071-5576(02)00217-4; Takano M, 2007, MOL ENDOCRINOL, V21, P2334, DOI 10.1210/me.2007-0058; Thigpen JT, 1999, J CLIN ONCOL, V17, P1736, DOI 10.1200/JCO.1999.17.6.1736; Titus MA, 2009, CLIN CANCER RES, V15, P7571, DOI 10.1158/1078-0432.CCR-08-1976; Ushijima K, 2007, J CLIN ONCOL, V25, P2798, DOI 10.1200/JCO.2006.08.8344; Vasquez YM, 2015, MOL ENDOCRINOL, V29, P421, DOI 10.1210/me.2014-1292; Wakui H, 1997, J BIOL CHEM, V272, P8153, DOI 10.1074/jbc.272.13.8153; Winter S, 2008, EMBO J, V27, P88, DOI 10.1038/sj.emboj.7601954; Yang S, 2011, TRENDS ENDOCRIN MET, V22, P145, DOI 10.1016/j.tem.2011.01.005; Zilliacus J, 2001, MOL ENDOCRINOL, V15, P501, DOI 10.1210/me.15.4.501	41	25	26	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2016	35	39					5191	5201		10.1038/onc.2016.56	http://dx.doi.org/10.1038/onc.2016.56			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX5PI	26996671	Green Accepted			2022-12-17	WOS:000384433000010
J	Chan, JY; LaPara, K; Yee, D				Chan, J. Y.; LaPara, K.; Yee, D.			Disruption of insulin receptor function inhibits proliferation in endocrine-resistant breast cancer cells	ONCOGENE			English	Article							GROWTH-FACTOR-I; ADVANCED SOLID TUMORS; DOWN-REGULATION; MONOCLONAL-ANTIBODIES; CLINICAL-IMPLICATIONS; PHASE-I; EXPRESSION; TAMOXIFEN; ESTROGEN; THERAPY	The insulin-like growth factor (IGF) system is a well-studied growth regulatory pathway implicated in breast cancer biology. Clinical trials testing monoclonal antibodies directed against the type I IGF receptor (IGF1R) in combination with estrogen receptor-a (ER) targeting have been completed, but failed to show benefits in patients with endocrine-resistant tumors compared to ER targeting alone. We have previously shown that the closely related insulin receptor (InsR) is expressed in tamoxifen-resistant (TamR) breast cancer cells. Here we examined if inhibition of InsR affected TamR breast cancer cells. InsR function was inhibited by three different mechanisms: InsR short hairpin RNA, a small InsR-blocking peptide, S961 and an InsR monoclonal antibody (mAb). Suppression of InsR function by these methods in TamR cells successfully blocked insulin-mediated signaling, monolayer proliferation, cell cycle progression and anchorage-independent growth. This strategy was not effective in parental cells likely because of the presence of IGFR/InsR hybrid receptors. Downregulation of IGF1R in conjunction with InsR inhibition was more effective in blocking IGF- and insulin-mediated signaling and growth in parental cells compared with single-receptor targeting alone. Our findings show TamR cells were stimulated by InsR and were not sensitive to IGF1R inhibition, whereas in tamoxifen-sensitive parental cancer cells, the presence of both receptors, especially hybrid receptors, allowed cross-reactivity of ligand-mediated activation and growth. To suppress the IGF system, targeting of both IGF1R and InsR is optimal in endocrine-sensitive and -resistant breast cancer.	[Chan, J. Y.; Yee, D.] Univ Minnesota, Dept Pharmacol, 3-249 Millard Hall, Minneapolis, MN 55455 USA; [LaPara, K.; Yee, D.] Univ Minnesota, Mason Canc Ctr, MMC 806,420 Delaware St SE, Minneapolis, MN 55414 USA; [Yee, D.] Univ Minnesota, Dept Med, Box 736 UMHC, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Yee, D (corresponding author), Univ Minnesota, Mason Canc Ctr, MMC 806,420 Delaware St SE, Minneapolis, MN 55414 USA.	yeexx006@umn.edu		Yee, Douglas/0000-0002-3387-4009	NIH/NCI [2P30-CA077598, P50CA116201]; Komen for the Cure [SAC110039]; NATIONAL CANCER INSTITUTE [P50CA116201, P30CA077598] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Komen for the Cure(Susan G. Komen Breast Cancer Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge the assistance of the University Flow Cytometry Resource at the University of Minnesota; Novo Nordisk for supplying S961 peptides. Funding was provided by NIH/NCI 2P30-CA077598 (JYC, KL and DY), NIH/NCI P50CA116201 (DY), and Komen for the Cure SAC110039 (DY).	Arnedos M, 2014, ANN ONCOL, V25, P605, DOI 10.1093/annonc/mdt575; Arpino G, 2009, ONCOLOGY-BASEL, V77, P23, DOI 10.1159/000258493; Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653; Becker MA, 2011, MOL ENDOCRINOL, V25, P516, DOI 10.1210/me.2010-0373; Belfiore A, 2011, ENDOCR-RELAT CANCER, V18, pR125, DOI 10.1530/ERC-11-0074; Belfiore A, 2009, ENDOCR REV, V30, P586, DOI 10.1210/er.2008-0047; Chen HX, 2013, CHIN J CANCER, V32, P242, DOI 10.5732/cjc.012.10263; Dowling RJO, 2012, J MOL ENDOCRINOL, V48, pR31, DOI 10.1530/JME-12-0007; Drury SC, 2011, ENDOCR-RELAT CANCER, V18, P565, DOI 10.1530/ERC-10-0046; Fagan DH, 2012, CANCER RES, V72, P3372, DOI 10.1158/0008-5472.CAN-12-0684; Fagan D, 2008, J MAMMARY GLAND BIOL, V13, P423, DOI 10.1007/s10911-008-9098-0; Frasca F, 1999, MOL CELL BIOL, V19, P3278, DOI 10.1128/mcb.19.5.3278; Fulzele K, 2007, J BIOL CHEM, V282, P25649, DOI 10.1074/jbc.M700651200; Garber K, 2014, SCIENCE, V345, P865, DOI 10.1126/science.345.6199.865; Giovannucci E, 2010, CA-CANCER J CLIN, V60, P207, DOI 10.3322/caac.20078; Giuliano M, 2011, BREAST, V20, pS42, DOI 10.1016/S0960-9776(11)70293-4; Harrington SC, 2012, GROWTH HORM IGF RES, V22, P108, DOI 10.1016/j.ghir.2012.04.001; JAQUES G, 1989, EXP CELL RES, V184, P396, DOI 10.1016/0014-4827(89)90339-X; Jiang LY, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-131; Jones HE, 2006, BRIT J CANCER, V95, P172, DOI 10.1038/sj.bjc.6603237; Jones RL, 2015, CLIN CANCER RES, V21, P693, DOI 10.1158/1078-0432.CCR-14-0265; Josefson D, 2000, BRIT MED J, V320, P1496; Kalli KR, 2002, ENDOCRINOLOGY, V143, P3259, DOI 10.1210/en.2001-211408; Knudsen L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051972; Lee AV, 1997, J ENDOCRINOL, V152, P39, DOI 10.1677/joe.0.1520039; Macaskill EJ, 2006, ONCOLOGIST, V11, P1081, DOI 10.1634/theoncologist.11-10-1081; MILAZZO G, 1992, CANCER RES, V52, P3924; MOLLER DE, 1989, MOL ENDOCRINOL, V3, P1263, DOI 10.1210/mend-3-8-1263; Nadji M, 2005, AM J CLIN PATHOL, V123, P21, DOI 10.1309/4WV79N2GHJ3X1841; OBRIEN RM, 1987, EMBO J, V6, P4003, DOI 10.1002/j.1460-2075.1987.tb02743.x; PAPA V, 1990, J CLIN INVEST, V86, P1503, DOI 10.1172/JCI114868; Paridaens RJ, 2008, J CLIN ONCOL, V26, P4883, DOI 10.1200/JCO.2007.14.4659; Puzanov I, 2015, CLIN CANCER RES, V21, P701, DOI 10.1158/1078-0432.CCR-14-0303; Ramos RR, 2007, P NATL ACAD SCI USA, V104, P10470, DOI 10.1073/pnas.0701114104; Ring A, 2004, ENDOCR-RELAT CANCER, V11, P643, DOI 10.1677/erc.1.00776; Rose DP, 2007, ENDOCR REV, V28, P763, DOI 10.1210/er.2006-0019; Rostoker R, 2015, ENDOCR-RELAT CANCER, V22, P145, DOI 10.1530/ERC-14-0490; Shah SP, 2009, NATURE, V461, P809, DOI 10.1038/nature08489; SOOS MA, 1986, BIOCHEM J, V235, P199, DOI 10.1042/bj2350199; Thompson MD, 2015, CANCER PREV RES, V8, P231, DOI 10.1158/1940-6207.CAPR-14-0181-T; Ulanet DB, 2010, P NATL ACAD SCI USA, V107, P10791, DOI 10.1073/pnas.0914076107; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; Weinstein D, 2014, ENDOCR CONNECT, V3, P24, DOI 10.1530/EC-13-0086; Yee D, 2012, JNCI-J NATL CANCER I, V104, P975, DOI 10.1093/jnci/djs258; Zhang H, 2010, ONCOGENE, V29, P2517, DOI 10.1038/onc.2010.17; Zhang H, 2007, CANCER RES, V67, P391, DOI 10.1158/0008-5472.CAN-06-1712; Zhang H, 2009, BREAST CANCER RES TR, V114, P277, DOI 10.1007/s10549-008-0014-5	47	25	26	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	32					4235	4243		10.1038/onc.2015.488	http://dx.doi.org/10.1038/onc.2015.488			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3YY	26876199	Green Accepted			2022-12-17	WOS:000382149800008
J	Zhu, B; Zhang, M; Williams, EM; Keller, C; Mansoor, A; Davie, JK				Zhu, B.; Zhang, M.; Williams, E. M.; Keller, C.; Mansoor, A.; Davie, J. K.			TBX2 represses PTEN in rhabdomyosarcoma and skeletal muscle	ONCOGENE			English	Article							CELL-CYCLE ARREST; EGR-1 TRANSCRIPTION FACTOR; BREAST-CANCER; MYOGENIC DIFFERENTIATION; SIGNALING PATHWAY; TUMOR SUPPRESSION; MUTANT MICE; KINASE-B; IN-VIVO; EXPRESSION	Rhabdomyosarcoma (RMS) is the most frequent soft tissue sarcoma in children that shares many features of developing skeletal muscle. TBX2, a T-box family member, is highly upregulated in tumor cells of both major RMS subtypes where it functions as an oncogene. TBX2 is a repressor that is often overexpressed in cancer cells and functions in bypassing cell growth control, including the repression of the cell cycle regulators p14 and p21. We have found that TBX2 directly represses the tumor-suppressor phosphatase and tensin homolog (PTEN) in both RMS and normal muscle. Exogenous expression of TBX2 in normal muscle cells downregulates PTEN, and depletion or interference with TBX2 in RMS cells upregulates PTEN. Human RMS tumors show high levels of TBX2 and correspondingly low levels of PTEN. The expression of PTEN in clinical RMS samples is relatively uncharacterized, and we establish that suppression of PTEN is a frequent event in both subtypes of RMS. TBX2 represses PTEN by directly binding to the promoter and recruiting the histone deacetylase, HDAC1. RMS cells have high levels of activated AKT owing to the deregulation of phosphoinositide-3 kinase (PI3K) signaling, and depletion or interference with TBX2, which upregulates PTEN, results in a reduction of phospho-AKT. We have also found that the highly related T-box family member TBX3 does not repress PTEN in the muscle lineage. This work suggests that TBX2 is a central component of the PTEN/PI3K/AKT signaling pathway deregulation in RMS cells and that targeting TBX2 in RMS tumors may offer a novel therapeutic approach for RMS.	[Zhu, B.; Zhang, M.; Davie, J. K.] Southern Illinois Univ, Sch Med, Dept Biochem & Mol Biol, 229 Neckers Bldg,1245 Lincoln Dr, Carbondale, IL 62901 USA; [Zhu, B.; Zhang, M.; Davie, J. K.] Southern Illinois Univ, Sch Med, Simmons Canc Inst, 229 Neckers Bldg,1245 Lincoln Dr, Carbondale, IL 62901 USA; [Williams, E. M.; Mansoor, A.] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97201 USA; [Keller, C.] Childrens Canc Therapy Dev Inst, Ft Collins, CO USA; [Zhu, B.] Yale Univ, Dept Pharmacol, New Haven, CT 06520 USA; [Zhang, M.] Yale Univ, Dept Pathol, New Haven, CT 06520 USA	Southern Illinois University System; Southern Illinois University; Southern Illinois University System; Southern Illinois University; Oregon Health & Science University; Yale University; Yale University	Davie, JK (corresponding author), Southern Illinois Univ, Sch Med, Dept Biochem & Mol Biol, 229 Neckers Bldg,1245 Lincoln Dr, Carbondale, IL 62901 USA.; Davie, JK (corresponding author), Southern Illinois Univ, Sch Med, Simmons Canc Inst, 229 Neckers Bldg,1245 Lincoln Dr, Carbondale, IL 62901 USA.	jdavie@siumed.edu		Keller, Charles/0000-0003-2505-7487	American Cancer Society, Illinois Division [159609]; National Institute of Health, NIAMS division [RAR 060017A]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R15AR060017, R15AR068622] Funding Source: NIH RePORTER	American Cancer Society, Illinois Division(American Cancer Society); National Institute of Health, NIAMS division; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We thank Terry Morgan, MD, PhD, Oregon Health and Sciences University for help with the statistical analysis of the archival RMS tumor samples. We thank Steven Verhulst, PhD, Southern Illinois University School of Medicine for help with the statistical analysis of the primary RMS tumor samples. This work was supported by grant 159609 from the American Cancer Society, Illinois Division to JD and by grant RAR 060017A from the National Institute of Health, NIAMS division.	Burgucu D, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-481; Carlson H, 2002, ONCOGENE, V21, P3827, DOI 10.1038/sj.onc.1205476; Castellino RC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010849; Chalhoub N, 2009, ANNU REV PATHOL-MECH, V4, P127, DOI 10.1146/annurev.pathol.4.110807.092311; Chung JH, 2005, CANCER RES, V65, P8096, DOI 10.1158/0008-5472.CAN-05-1888; Ciccarelli C, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-41; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Douglas NC, 2013, J MAMMARY GLAND BIOL, V18, P143, DOI 10.1007/s10911-013-9282-8; Fan WW, 2004, CANCER RES, V64, P5132, DOI 10.1158/0008-5472.CAN-04-0615; Hollenbach AD, 1999, EMBO J, V18, P3702, DOI 10.1093/emboj/18.13.3702; Huang W, 2007, ONCOGENE, V26, P2471, DOI 10.1038/sj.onc.1210033; Jacobs JJL, 2000, NAT GENET, V26, P291, DOI 10.1038/81583; Jonsson G, 2007, ONCOGENE, V26, P4738, DOI 10.1038/sj.onc.1210252; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li HG, 2007, CANCER LETT, V253, P215, DOI 10.1016/j.canlet.2007.01.020; Li J, 2014, J BIOL CHEM, V289, P35633, DOI 10.1074/jbc.M114.596411; Liu F, 2013, PIGM CELL MELANOMA R, V26, P67, DOI 10.1111/pcmr.12029; Lomnytska M, 2006, INT J CANCER, V118, P412, DOI 10.1002/ijc.21332; Londhe P, 2011, SKELET MUSCLE, V1, DOI 10.1186/2044-5040-1-14; Londhe P, 2011, MOL CELL BIOL, V31, P2854, DOI 10.1128/MCB.05397-11; Lyng H, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-268; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Mahlamaki EH, 2002, GENE CHROMOSOME CANC, V35, P353, DOI 10.1002/gcc.10122; Mandl A, 2007, MOL CELL BIOL, V27, P8098, DOI 10.1128/MCB.00756-07; Okamura H, 2005, J CELL BIOCHEM, V94, P117, DOI 10.1002/jcb.20283; Peres J, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-117; Peres Jade, 2010, Genes Cancer, V1, P272, DOI 10.1177/1947601910365160; Prince S, 2004, CANCER RES, V64, P1669, DOI 10.1158/0008-5472.CAN-03-3286; Radu A, 2003, MOL CELL BIOL, V23, P6139, DOI 10.1128/MCB.23.17.6139-6149.2003; Redmond KL, 2010, ONCOGENE, V29, P3252, DOI 10.1038/onc.2010.84; Relaix F, 2003, GENE DEV, V17, P2950, DOI 10.1101/gad.281203; Renshaw J, 2013, CLIN CANCER RES, V19, P5940, DOI 10.1158/1078-0432.CCR-13-0850; Rodriguez M, 2008, CANCER RES, V68, P7872, DOI 10.1158/0008-5472.CAN-08-0301; Ross AH, 2009, P NATL ACAD SCI USA, V106, P1297, DOI 10.1073/pnas.0812473106; Rowley M, 2004, J MAMMARY GLAND BIOL, V9, P109, DOI 10.1023/B:JOMG.0000037156.64331.3f; Sarver AL, 2010, CANCER RES, V70, P9570, DOI 10.1158/0008-5472.CAN-10-2074; Shao J, 2007, CARCINOGENESIS, V28, P2476, DOI 10.1093/carcin/bgm186; Shen WH, 2007, CELL, V128, P157, DOI 10.1016/j.cell.2006.11.042; Shern JF, 2014, CANCER DISCOV, V4, P216, DOI 10.1158/2159-8290.CD-13-0639; Sinclair CS, 2002, CANCER RES, V62, P3587; Singh S, 2010, AM J PATHOL, V177, P2055, DOI 10.2353/ajpath.2010.091195; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Vance KW, 2005, CANCER RES, V65, P2260, DOI 10.1158/0008-5472.CAN-04-3045; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Wan XL, 2003, ONCOGENE, V22, P8205, DOI 10.1038/sj.onc.1206878; Weng LP, 2002, HUM MOL GENET, V11, P1687, DOI 10.1093/hmg/11.15.1687; Weng LP, 2001, HUM MOL GENET, V10, P599, DOI 10.1093/hmg/10.6.599; Wijesekara N, 2005, MOL CELL BIOL, V25, P1135, DOI 10.1128/MCB.25.3.1135-1145.2005; Zhu B, 2014, INT J CANCER, V135, P785, DOI 10.1002/ijc.28721; Zhu XY, 2001, CANCER RES, V61, P4569; 2005, SCIENCE, V307, P1098, DOI DOI 10.1126/SCIENCE.1106148	55	25	26	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	32					4212	4224		10.1038/onc.2015.486	http://dx.doi.org/10.1038/onc.2015.486			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3YY	26686089	Green Accepted, Green Submitted			2022-12-17	WOS:000382149800006
J	Hunter, JE; Butterworth, JA; Zhao, B; Sellier, H; Campbell, KJ; Thomas, HD; Bacon, CM; Cockell, SJ; Gewurz, BE; Perkins, ND				Hunter, J. E.; Butterworth, J. A.; Zhao, B.; Sellier, H.; Campbell, K. J.; Thomas, H. D.; Bacon, C. M.; Cockell, S. J.; Gewurz, B. E.; Perkins, N. D.			The NF-kappa B subunit c-Rel regulates Bach2 tumour suppressor expression in B-cell lymphoma	ONCOGENE			English	Article							CLASSICAL HODGKIN LYMPHOMA; MYC-INDUCED LYMPHOMAGENESIS; REPRESSOR BACH2; SURVIVAL; GENE; ACTIVATION; MUTATIONS; ROLES; ONCOPROTEIN; ASSOCIATION	The REL gene, encoding the NF-kappa B subunit c-Rel, is frequently amplified in B-cell lymphoma and functions as a tumour-promoting transcription factor. Here we report the surprising result that c-rel-/- mice display significantly earlier lymphomagenesis in the c-Myc driven, E mu-Myc model of B-cell lymphoma. c-Rel loss also led to earlier onset of disease in a separate TCL1-Tg-driven lymphoma model. Tumour reimplantation experiments indicated that this is an effect intrinsic to the E mu-Myc lymphoma cells but, counterintuitively, c-rel-/- E mu-Myc lymphoma cells were more sensitive to apoptotic stimuli. To learn more about why loss of c-Rel led to earlier onset of disease, microarray gene expression analysis was performed on B cells from 4-week-old, wild-type and c-rel-/E mu- Myc mice. Extensive changes in gene expression were not seen at this age, but among those transcripts significantly downregulated by the loss of c-Rel was the B-cell tumour suppressor BTB and CNC homology 2 ( Bach2). Quantitative PCR and western blot analysis confirmed loss of Bach2 in c-Rel mutant E mu-Myc tumours at both 4 weeks and the terminal stages of disease. Moreover, Bach2 expression was also downregulated in c-rel-/- TCL1-Tg mice and RelA Thr505Ala mutant E mu-Myc mice. Analysis of wild-type E mu-Myc mice demonstrated that the population expressing low levels of Bach2 exhibited the earlier onset of lymphoma seen in c-rel-/- mice. Confirming the relevance of these findings to human disease, analysis of chromatin immunoprecipitation sequencing data revealed that Bach2 is a c-Rel and NF-kappa B target gene in transformed human B cells, whereas treatment of Burkitt's lymphoma cells with inhibitors of the NF-kappa B/I kappa B kinase pathway or deletion of c-Rel or RelA resulted in loss of Bach2 expression. These data reveal a surprising tumour suppressor role for c-Rel in lymphoma development explained by regulation of Bach2 expression, underlining the context-dependent complexity of NF-kappa B signalling in cancer.	[Hunter, J. E.; Butterworth, J. A.; Sellier, H.; Perkins, N. D.] Newcastle Univ, Sch Med, Inst Cell & Mol Biosci ICaMB, Catherine Cookson Bldg,Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; [Zhao, B.; Gewurz, B. E.] Brigham & Womens Hosp, Boston, MA 02115 USA; [Campbell, K. J.] Beatson Inst Canc Res, Glasgow, Lanark, Scotland; [Thomas, H. D.; Bacon, C. M.] Northern Inst Canc Res, Newcastle Upon Tyne, Tyne & Wear, England; [Cockell, S. J.] Newcastle Univ, Fac Med Sci, Bioinformat Support Unit, Newcastle Upon Tyne, Tyne & Wear, England	Newcastle University - UK; Harvard University; Brigham & Women's Hospital; Beatson Institute; Newcastle University - UK; Newcastle University - UK	Perkins, ND (corresponding author), Newcastle Univ, Sch Med, Inst Cell & Mol Biosci ICaMB, Catherine Cookson Bldg,Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	neil.perkins@ncl.ac.uk		Cockell, Simon/0000-0002-6831-9806; Bacon, Chris/0000-0002-8268-2812	Leukemia Lymphoma Research [11022]; Wellcome Trust [094409]; NDP lab from Cancer Research UK [C1443/A12750]; Welcome Trust Equipment grant [087961]; US National Institutes of Health [K08 CA140780, RO1 CA12850]; Burroughs Wellcome Medical Scientist career award; NATIONAL CANCER INSTITUTE [K08CA140780, R01CA085180] Funding Source: NIH RePORTER; Cancer Research UK [22095, 22311, 12750] Funding Source: researchfish	Leukemia Lymphoma Research; Wellcome Trust(Wellcome TrustEuropean Commission); NDP lab from Cancer Research UK; Welcome Trust Equipment grant; US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Burroughs Wellcome Medical Scientist career award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Research UK(Cancer Research UK)	We thank Fiona Oakley, Sonia Rocha, Derek Mann, Claire Richardson, Saimir Luli, Elaine Willmore and all members of the NDP laboratory for their helpful advice and assistance. We are very grateful to Michael J. Walsh for assistance with generation of CRISPR/Cas9 knock-out cell lines. JEH is funded by Leukemia Lymphoma Research grant 11022, JAB and HS are funded by the Wellcome Trust grant 094409, further funding from the NDP lab was obtained from Cancer Research UK grant C1443/A12750. The IVIS Spectrum was funded by Welcome Trust Equipment grant 087961. BZ and BEG are funded by US National Institutes of Health (grants K08 CA140780 and RO1 CA12850) and by a Burroughs Wellcome Medical Scientist career award.	Barth TFE, 2003, BLOOD, V101, P3681, DOI 10.1182/blood-2002-08-2577; Cariappa A, 2000, J EXP MED, V192, P1175, DOI 10.1084/jem.192.8.1175; Carlsen H, 2002, J IMMUNOL, V168, P1441, DOI 10.4049/jimmunol.168.3.1441; Casolari DA, 2013, LEUKEMIA, V27, P409, DOI 10.1038/leu.2012.220; Chien YC, 2011, GENE DEV, V25, P2125, DOI 10.1101/gad.17276711; Chin M, 2009, ONCOGENE, V28, P2100, DOI 10.1038/onc.2009.74; Courtois G, 2006, ONCOGENE, V25, P6831, DOI 10.1038/sj.onc.1209939; Curry Choladda V, 2009, J Hematop, V2, P20, DOI 10.1007/s12308-009-0021-4; Davis RE, 2001, J EXP MED, V194, P1861, DOI 10.1084/jem.194.12.1861; Doench JG, 2014, NAT BIOTECHNOL, V32, P1262, DOI 10.1038/nbt.3026; Du P, 2008, BIOINFORMATICS, V24, P1547, DOI 10.1093/bioinformatics/btn224; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Enciso-Mora V, 2010, NAT GENET, V42, P1126, DOI 10.1038/ng.696; Fan YJ, 2004, ONCOGENE, V23, P1030, DOI 10.1038/sj.onc.1207221; Fan YJ, 2008, ADV EXP MED BIOL, V615, P223, DOI 10.1007/978-1-4020-6554-5_11; Feuerhake F, 2005, BLOOD, V106, P1392, DOI 10.1182/blood-2004-12-4901; Fullard N, 2012, INT J BIOCHEM CELL B, V44, P851, DOI 10.1016/j.biocel.2012.02.017; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; Greenfeld H, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004890; Grossmann M, 1999, P NATL ACAD SCI USA, V96, P11848, DOI 10.1073/pnas.96.21.11848; GRUMONT RJ, 1994, CELL GROWTH DIFFER, V5, P1321; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; Hoshino H, 2000, J BIOL CHEM, V275, P15370, DOI 10.1074/jbc.275.20.15370; Hoyer KK, 2002, P NATL ACAD SCI USA, V99, P14392, DOI 10.1073/pnas.212410199; Ichikawa S, 2014, CANCER SCI, V105, P437, DOI 10.1111/cas.12361; Jing H, 2011, GENE DEV, V25, P2137, DOI 10.1101/gad.17620611; Joos S, 2002, BLOOD, V99, P1381, DOI 10.1182/blood.V99.4.1381; Keller U, 2005, ONCOGENE, V24, P6231, DOI 10.1038/sj.onc.1208779; Keller U, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-348; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; Kuppers R, 2009, NAT REV CANCER, V9, P15, DOI 10.1038/nrc2542; Lenz G, 2008, SCIENCE, V319, P1676, DOI 10.1126/science.1153629; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; Martin-Subero JI, 2002, BLOOD, V99, P1474, DOI 10.1182/blood.V99.4.1474; Msaki A, 2011, MOL BIOL CELL, V22, P3032, DOI 10.1091/mbc.E11-04-0280; Muto A, 2002, J BIOL CHEM, V277, P20724, DOI 10.1074/jbc.M112003200; Naito Y, 2015, BIOINFORMATICS, V31, P1120, DOI 10.1093/bioinformatics/btu743; Perkins ND, 2012, NAT REV CANCER, V12, P121, DOI 10.1038/nrc3204; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pham LV, 2005, BLOOD, V106, P3940, DOI 10.1182/blood-2005-03-1167; Rosenwald A, 2003, J EXP MED, V198, P851, DOI 10.1084/jem.20031074; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Sasaki S, 2000, ONCOGENE, V19, P3739, DOI 10.1038/sj.onc.1203716; Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23; Starczynowski DT, 2003, ONCOGENE, V22, P6928, DOI 10.1038/sj.onc.1206801; Staudt LM, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000109; Swaminathan S, 2013, NAT MED, V19, P1014, DOI 10.1038/nm.3247; Tumang JR, 1998, EUR J IMMUNOL, V28, P4299, DOI 10.1002/(SICI)1521-4141(199812)28:12<4299::AID-IMMU4299>3.0.CO;2-Y; Tumang JR, 2002, CELL IMMUNOL, V217, P47, DOI 10.1016/S0008-8749(02)00513-0; WEIH F, 1994, ONCOGENE, V9, P3289; Zhao B, 2014, CELL REP, V8, P1595, DOI 10.1016/j.celrep.2014.07.037	52	25	25	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2016	35	26					3476	3484		10.1038/onc.2015.399	http://dx.doi.org/10.1038/onc.2015.399			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DQ5UI	26522720	Green Published, Green Accepted, hybrid			2022-12-17	WOS:000379270100012
J	Kim, SB; Bozeman, RG; Kaisani, A; Kim, W; Zhang, L; Richardson, JA; Wright, WE; Shay, JW				Kim, S. B.; Bozeman, R. G.; Kaisani, A.; Kim, W.; Zhang, L.; Richardson, J. A.; Wright, W. E.; Shay, J. W.			Radiation promotes colorectal cancer initiation and progression by inducing senescence-associated inflammatory responses	ONCOGENE			English	Article							SOLAR PARTICLE EVENT; PROTON-BEAM THERAPY; CDDO-METHYL ESTER; EPITHELIAL-CELLS; MOUSE MODEL; DNA-DAMAGE; SPACE RADIATION; LUNG-CANCER; AUGUST 1972; TRITERPENOIDS	Proton radiotherapy is becoming more common as protons induce more precise DNA damage at the tumor site with reduced side effects to adjacent normal tissues. However, the long-term biological effects of proton irradiation in cancer initiation compared with conventional photon irradiation are poorly characterized. In this study, using a human familial adenomatous polyposis syndrome susceptible mouse model, we show that whole-body irradiation with protons are more effective in inducing senescence-associated inflammatory responses (SIRs), which are involved in colon cancer initiation and progression. After proton irradiation, a subset of SIR genes (Troy, Sox17, Opg, Faim2, Lpo, Tlr2 and Ptges) and a gene known to be involved in invasiveness (Plat), along with the senescence-associated gene (P19Arf), are markedly increased. Following these changes, loss of Casein kinase I alpha and induction of chronic DNA damage and TP53 mutations are increased compared with X-ray irradiation. Proton irradiation also increases the number of colonic polyps, carcinomas and invasive adenocarcinomas. Pretreatment with the non-steroidal anti-inflammatory drug, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid-ethyl amide (CDDO-EA), reduces proton irradiation-associated SIR and tumorigenesis. Thus exposure to proton irradiation elicits significant changes in colorectal cancer initiation and progression that can be mitigated using CDDO-EA.	[Kim, S. B.; Bozeman, R. G.; Kaisani, A.; Kim, W.; Zhang, L.; Wright, W. E.; Shay, J. W.] Univ Texas Southwestern Med Ctr, Dept Cell Biol, 5323 Harry Hines Blvd,MC9039, Dallas, TX 75390 USA; [Richardson, J. A.] Univ Texas Southwestern Med Ctr, Dept Pathol, Dallas, TX USA; [Richardson, J. A.] Univ Texas Southwestern Med Ctr, Dept Mol Biol, Dallas, TX USA; [Richardson, J. A.] Univ Texas Southwestern Med Ctr, Dept Plast Surg, Dallas, TX USA; [Shay, J. W.] King Abdulaziz Univ, Ctr Excellence Genom Med Res, Jeddah, Saudi Arabia	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; King Abdulaziz University	Shay, JW (corresponding author), Univ Texas Southwestern Med Ctr, Dept Cell Biol, 5323 Harry Hines Blvd,MC9039, Dallas, TX 75390 USA.	jerry.shay@utsouthwestern.edu		Kim, Sang Bum/0000-0001-5965-3354	NIH grant [C06 RR30414]; NASA Grant [NNX15AI21G, NNX11AC15G, NNJ05HD36G, NNX09AU95G]; NATIONAL CANCER INSTITUTE [P50CA070907, T32CA124334] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR030414] Funding Source: NIH RePORTER	NIH grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NASA Grant(National Aeronautics & Space Administration (NASA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	We thank the support team at Brookhaven National Laboratory (BNL) and NASA Space Radiation Laboratory (NSRL) (Upton, NY, USA) for helping with the Proton and HZE particles delivery to animals. We thank Dr Michael Sporn (Hanover, NH, USA) and Reata Pharmaceuticals (Irving, TX, USA) for providing CDDO-EA reagent, Summer Barron (UT Southwestern, Dallas, TX, USA) for mouse colony maintenance and Gail Fasciani (UT Southwestern, Dallas, TX, USA) for histological processing. This work was performed in laboratories constructed with support from NIH grant C06 RR30414. This work was supported by NASA Grant nos. NNX15AI21G, NNX11AC15G, NNJ05HD36G and NNX09AU95G to JWS.	Ahn PH, 2014, CANCER J, V20, P421, DOI 10.1097/PPO.0000000000000077; Arnold CN, 2005, CANCER-AM CANCER SOC, V104, P2035, DOI 10.1002/cncr.21462; Bahnassy AA, 2004, BMC GASTROENTEROL, V4, DOI 10.1186/1471-230X-4-22; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Boivin GP, 2003, GASTROENTEROLOGY, V124, P762, DOI 10.1053/gast.2003.50094; Breuer H, 2013, PROTON THERAPY RADIO; Collis SJ, 2004, J BIOL CHEM, V279, P49624, DOI 10.1074/jbc.M409600200; Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; DANGIO GJ, 1963, NUCLEONICS, V21, P56; Delgado O, 2014, CLIN CANCER RES, V20, P1610, DOI 10.1158/1078-0432.CCR-13-2589; Dicello JF, 2002, J RADIAT RES, V43, pS1; Eaton BR, 2014, CANCER J, V20, P403, DOI 10.1097/PPO.0000000000000079; Elyada E, 2011, NATURE, V470, P409, DOI 10.1038/nature09673; Eskiocak U, 2010, RADIAT RES, V174, P27, DOI 10.1667/RR2155.1; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; George K, 2003, RADIAT RES, V160, P425, DOI 10.1667/RR3064; Hall EJ., 2006, RADIOBIOLOGY RADIOLO; Hellweg CE, 2007, NATURWISSENSCHAFTEN, V94, P517, DOI 10.1007/s00114-006-0204-0; Hinoi T, 2007, CANCER RES, V67, P9721, DOI 10.1158/0008-5472.CAN-07-2735; Keole S, 2014, CANCER J, V20, P409, DOI 10.1097/PPO.0000000000000084; Kim SB, 2014, LIFE SCI SPACE RES, V1, P67, DOI 10.1016/j.lssr.2014.02.001; Kim SB, 2013, RADIAT RES, V180, P259, DOI 10.1667/RR3371.1; Kim SB, 2012, P NATL ACAD SCI USA, V109, pE2949, DOI 10.1073/pnas.1207718109; Kim SB, 2014, GRAVIT SPACE RES, V2, P32; KUDO S, 1993, ENDOSCOPY, V25, P455, DOI 10.1055/s-2007-1010367; Lawrence J H, 1964, Trans Am Clin Climatol Assoc, V75, P111; Liby K, 2007, CANCER RES, V67, P2414, DOI 10.1158/0008-5472.CAN-06-4534; Ludlow AT, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku439; Miyaoka Y, 2014, NAT METHODS, V11, P291, DOI 10.1038/nmeth.2840; Moravek Z, 2009, Z MED PHYS, V19, P174, DOI 10.1016/j.zemedi.2009.04.006; Neymotin A, 2011, FREE RADICAL BIO MED, V51, P88, DOI 10.1016/j.freeradbiomed.2011.03.027; Parsons JL, 2000, RADIAT RES, V153, P729, DOI 10.1667/0033-7587(2000)153[0729:ICDRFT]2.0.CO;2; Petronelli A, 2009, ANTI-CANCER DRUG, V20, P880, DOI 10.1097/CAD.0b013e328330fd90; Pribluda A, 2013, CANCER CELL, V24, P242, DOI 10.1016/j.ccr.2013.06.005; Pugh TJ, 2014, CANCER J, V20, P415, DOI 10.1097/PPO.0000000000000083; Reisman SA, 2014, RADIAT RES, V181, P512, DOI 10.1667/RR13578.1; Rithidech KN, 2013, MUTAT RES-GEN TOX EN, V756, P127, DOI 10.1016/j.mrgentox.2013.06.001; Rutter MD, 2010, FRONTLINE GASTROENTE, V1, P126, DOI 10.1136/fg.2010.001438; Simone CB, 2014, CANCER J, V20, P427, DOI 10.1097/PPO.0000000000000080; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; SUIT HD, 1975, CANCER-AM CANCER SOC, V35, P1646, DOI 10.1002/1097-0142(197506)35:6<1646::AID-CNCR2820350626>3.0.CO;2-1; Thimmulappa RK, 2007, ANTIOXID REDOX SIGN, V9, P1963, DOI 10.1089/ars.2007.1745; TOWNSEND LW, 1991, RADIAT RES, V126, P108, DOI 10.2307/3578178; Van Dyke T, 2002, CELL, V108, P135, DOI 10.1016/S0092-8674(02)00621-9; Vannini N, 2007, MOL CANCER THER, V6, P3139, DOI 10.1158/1535-7163.MCT-07-0451; VERHEY LJ, 1982, ANNU REV BIOPHYS BIO, V11, P331, DOI 10.1146/annurev.bb.11.060182.001555; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Williams JR, 1999, MUTAT RES-FUND MOL M, V430, P255, DOI 10.1016/S0027-5107(99)00137-2; Wilson JW, 1999, RADIAT MEAS, V30, P361, DOI 10.1016/S1350-4487(99)00063-3	50	25	25	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2016	35	26					3365	3375		10.1038/onc.2015.395	http://dx.doi.org/10.1038/onc.2015.395			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DQ5UI	26477319	Green Accepted			2022-12-17	WOS:000379270100002
J	Godin-Heymann, N; Brabetz, S; Murillo, MM; Saponaro, M; Santos, CR; Lobley, A; East, P; Chakravarty, P; Matthews, N; Kelly, G; Jordan, S; Castellano, E; Downward, J				Godin-Heymann, N.; Brabetz, S.; Murillo, M. M.; Saponaro, M.; Santos, C. R.; Lobley, A.; East, P.; Chakravarty, P.; Matthews, N.; Kelly, G.; Jordan, S.; Castellano, E.; Downward, J.			Tumour-suppression function of KLF12 through regulation of anoikis	ONCOGENE			English	Article							INTESTINAL EPITHELIAL-CELLS; KRUPPEL-LIKE-FACTORS; MESENCHYMAL TRANSITION; CANCER-CELLS; EXTRACELLULAR-MATRIX; DOWN-REGULATION; BREAST-CANCER; UP-REGULATION; CYCLE ARREST; RAS	Suppression of detachment-induced cell death, known as anoikis, is an essential step for cancer metastasis to occur. We report here that expression of KLF12, a member of the Kruppel-like family of transcription factors, is downregulated in lung cancer cell lines that have been selected to grow in the absence of cell adhesion. Knockdown of KLF12 in parental cells results in decreased apoptosis following cell detachment from matrix. KLF12 regulates anoikis by promoting the cell cycle transition through S phase and therefore cell proliferation. Reduced expression levels of KLF12 results in increased ability of lung cancer cells to form tumours in vivo and is associated with poorer survival in lung cancer patients. We therefore identify KLF12 as a novel metastasis-suppressor gene whose loss of function is associated with anoikis resistance through control of the cell cycle.	[Godin-Heymann, N.; Brabetz, S.; Murillo, M. M.; Jordan, S.; Castellano, E.; Downward, J.] Canc Res UK London Res Inst, Signal Transduct, London WC2A 3PX, England; [Murillo, M. M.; Downward, J.] Inst Canc Res, London SW3 6JB, England; [Saponaro, M.] Canc Res UK London Res Inst, Clare Hall Labs, Mechanisms Gene Transcript Lab, London WC2A 3PX, England; [Santos, C. R.] Canc Res UK London Res Inst, Translat Canc Therapeut, London WC2A 3PX, England; [Lobley, A.; East, P.; Chakravarty, P.; Kelly, G.] Canc Res UK London Res Inst, Bioinformat & Biostat Labs, London WC2A 3PX, England; [Matthews, N.] Canc Res UK London Res Inst, Adv Sequencing Facil, London WC2A 3PX, England; [Castellano, E.] Univ London, Ctr Canc & Inflammat, Barts Canc Inst, Charterhouse Sq, London EC1M 6BP, England	Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Cancer Research UK; Cancer Research UK; Cancer Research UK; Cancer Research UK; University of London; Queen Mary University London	Downward, J (corresponding author), Signal Transduct Lab Canc Res UK, 44 Lincolns Inn Fields, London WC2A 3LY, England.	downward@cancer.org.uk	Sánchez, Esther Castellano/AAA-8087-2020; Kelly, Gavin/ABG-2715-2021; Saponaro, Marco/M-1854-2015	Sánchez, Esther Castellano/0000-0002-8449-4081; Kelly, Gavin/0000-0001-7219-560X; Saponaro, Marco/0000-0002-9302-2553; Downward, Julian/0000-0002-2331-4729; chakravarty, probir/0000-0003-1146-8824	Cancer Research UK, from the European Commission [259770]; European Research Council Advanced Grant RASTARGET; Cancer Research UK [15680] Funding Source: researchfish; The Francis Crick Institute [10074, 10070, 10002, 10071] Funding Source: researchfish	Cancer Research UK, from the European Commission; European Research Council Advanced Grant RASTARGET; Cancer Research UK(Cancer Research UK); The Francis Crick Institute	We thank Elza de Bruin and Clare Sheridan for advice. We also thank Mike Howell and LRI Core Technology Facilities, including Equipment Park, FACS lab and Cell Services. This work was funded by Cancer Research UK, funding from the European Commission's Seventh Framework Programme (FP7/2007-2013) under the grant agreement LUNGTARGET (project 259770) and from the European Research Council Advanced Grant RASTARGET.	Bateman NW, 2004, J BIOL CHEM, V279, P12093, DOI 10.1074/jbc.M311532200; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Boudreau N, 1996, P NATL ACAD SCI USA, V93, P3509, DOI 10.1073/pnas.93.8.3509; Bretland AJ, 2001, CELL PROLIFERAT, V34, P199, DOI 10.1046/j.1365-2184.2001.00198.x; Buchheit CL, 2012, SEMIN CELL DEV BIOL, V23, P402, DOI 10.1016/j.semcdb.2012.04.007; Bureau C, 2009, CURR GENOMICS, V10, P353, DOI 10.2174/138920209788921010; Castedo M, 2002, CELL DEATH DIFFER, V9, P1287, DOI 10.1038/sj.cdd.4401130; Chen CS, 2001, GENE CHROMOSOME CANC, V31, P333, DOI 10.1002/gcc.1152; Collins NL, 2005, MOL CELL BIOL, V25, P5282, DOI 10.1128/MCB.25.12.5282-5291.2005; Davies M, 2005, J CELL BIOCHEM, V95, P918, DOI 10.1002/jcb.20458; Derouet M, 2007, NEOPLASIA, V9, P536, DOI 10.1593/neo.07217; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 2013, J CELL SCI, V126, P21, DOI 10.1242/jcs.120907; Fritsch R, 2013, CELL, V153, P1050, DOI 10.1016/j.cell.2013.04.031; Giefing M, 2008, NEOPLASMA, V55, P55; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Guadamillas MC, 2011, J CELL SCI, V124, P3189, DOI 10.1242/jcs.072165; Gumireddy K, 2009, NAT CELL BIOL, V11, P1297, DOI 10.1038/ncb1974; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Imhof A, 1999, MOL CELL BIOL, V19, P194; Kainu T, 2000, P NATL ACAD SCI USA, V97, P9603, DOI 10.1073/pnas.97.17.9603; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Kim HRC, 1999, CANCER RES, V59, P4148; Kumar MS, 2012, CELL, V149, P642, DOI 10.1016/j.cell.2012.02.059; Lahiri SK, 2012, AM J TRANSL RES, V4, P357; Ley R, 2005, CELL DEATH DIFFER, V12, P1008, DOI 10.1038/sj.cdd.4401688; Liu ZP, 2006, J BIOL CHEM, V281, P14738, DOI 10.1074/jbc.M508664200; Liu ZP, 2005, J BIOL CHEM, V280, P37383, DOI 10.1074/jbc.M503724200; McFall A, 2001, MOL CELL BIOL, V21, P5488, DOI 10.1128/MCB.21.16.5488-5499.2001; Nakamura Y, 2009, INT J CANCER, V125, P1859, DOI 10.1002/ijc.24538; Paoli P, 2013, BBA-MOL CELL RES, V1833, P3481, DOI 10.1016/j.bbamcr.2013.06.026; Petersen GM, 2010, NAT GENET, V42, P224, DOI 10.1038/ng.522; Pucci B, 2000, NEOPLASIA, V2, P291, DOI 10.1038/sj.neo.7900101; Rabien A, 2012, CANCER SCI, V103, P169, DOI 10.1111/j.1349-7006.2011.02140.x; Rosen K, 2000, J CELL BIOL, V149, P447, DOI 10.1083/jcb.149.2.447; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; Steckel M, 2012, CELL RES, V22, P1227, DOI 10.1038/cr.2012.82; Tetreault MP, 2013, NAT REV CANCER, V13, P701, DOI 10.1038/nrc3582; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Wei HJ, 2006, J BIOL CHEM, V281, P16664, DOI 10.1074/jbc.M513135200; Wei L, 2004, ONCOGENE, V23, P9052, DOI 10.1038/sj.onc.1208091; Yang YZ, 2012, CELL CYCLE, V11, P4033, DOI 10.4161/cc.22265; Yoo BH, 2011, J BIOL CHEM, V286, P38894, DOI 10.1074/jbc.M111.290692; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Zhao JH, 2003, MOL CELL, V11, P1503, DOI 10.1016/S1097-2765(03)00179-5; Zhong XL, 2012, CELL SIGNAL, V24, P393, DOI 10.1016/j.cellsig.2011.10.005	48	25	26	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 23	2016	35	25					3324	3334		10.1038/onc.2015.394	http://dx.doi.org/10.1038/onc.2015.394			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP2GN	26455320	Green Published, hybrid			2022-12-17	WOS:000378306400011
J	Zhang, S; Chung, WC; Xu, K				Zhang, S.; Chung, W-C; Xu, K.			Lunatic Fringe is a potent tumor suppressor in Kras-initiated pancreatic cancer	ONCOGENE			English	Article							GROWTH-FACTOR-BETA; TGF-BETA; DUCTAL ADENOCARCINOMA; PROGENITOR CELLS; NOTCH; EXPRESSION; PROGRESSION; PATHWAY; NEOPLASIA; PROSTATE	Notch controls pancreatic differentiation during development and is reactivated in pancreatic cancer. In recent years, the importance of Notch signaling in pancreatic tumorigenesis has become increasingly evident; however, it remains unclear how Notch activities are regulated in this context. Here we report differential regulation of Notch receptors by Lunatic Fringe (Lfng), which encodes an O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase known to modify epidermal growth factor repeats in the Notch extracellular domain, during pathogenesis of Kras-induced pancreatic ductal adenocarcinoma (PDAC). We show that Lfng is uniquely expressed in a subset of acinar cells in the adult pancreas. Deletion of Lfng in the Kras(LSL-G12D/+); Pdx1-Cre mouse model caused increased activation of Notch3 throughout PDAC initiation and progression, and Notch1 after the onset of disease, associated with marked upregulation of Notch target gene Hes1. Deletion of Lfng also resulted in accumulation of Aldh1-positive cell population. We found that loss of Lfng significantly accelerated Kras-initiated PDAC development and shortened survival of the PDAC mice. Interestingly, Lfng-deficient tumors showed a propensity for a poorly differentiated state with features of epithelial-tomesenchymal transition. Likewise, knockdown of LFNG in human PDAC cell lines caused elevated Notch activation, associated with either accelerated cell proliferation or expanded Aldh1-positive cell population. Deletion of Lfng resulted in downregulation of Tgfb1, Tgfb2 and Tgfbr2 expression in the wild-type pancreas at all ages examined, and in the Kras(LSL-G12D/+); Pdx1-Cre pancreas after PDAC onset, as well as reduced phospho-Smad2 levels in pancreatic tumors. We provide evidence that Lfng regulates transforming growth factor (TGF)-beta-signaling through Notch-mediated transcriptional repression of TGF-beta pathway genes. Taken together, our results reveal a potent tumor-suppressive function for Lfng and crosstalk between Notch and TGF-beta pathways in the pancreas, which provides new insight into initiation of PDAC and signals involved in disease progression.	[Zhang, S.; Chung, W-C; Xu, K.] Univ Mississippi, Med Ctr, Inst Canc, 2500 North State St, Jackson, MS 39216 USA; [Zhang, S.] Cent S Univ, State Key Lab Med Genet, Changsha, Hunan, Peoples R China; [Zhang, S.] Cent S Univ, Sch Life Sci, Changsha, Hunan, Peoples R China; [Xu, K.] Univ Mississippi, Med Ctr, Dept Neurobiol & Anat Sci, Jackson, MS 39216 USA	University of Mississippi; University of Mississippi Medical Center; Central South University; Central South University; University of Mississippi; University of Mississippi Medical Center	Xu, K (corresponding author), Univ Mississippi, Med Ctr, Inst Canc, 2500 North State St, Jackson, MS 39216 USA.	kxu@umc.edu			NIH [R21CA175136]; UMMC Cancer Institute; NATIONAL CANCER INSTITUTE [R21CA175136] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UMMC Cancer Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors are thankful to Sean Egan and Tom Gridley for providing mouse strains. We also thank Sean Egan for critical reading of the manuscript. This work was supported in part by NIH grant R21CA175136 and by start-up funds from UMMC Cancer Institute to KX.	Apelqvist A, 1999, NATURE, V400, P877, DOI 10.1038/23716; Avila JL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052133; Bardeesy N, 2006, GENE DEV, V20, P3130, DOI 10.1101/gad.1478706; Baumgart A, 2014, ONCOGENE, V34, P578; Court H, 2013, J CLIN INVEST, V123, P4681, DOI 10.1172/JCI65764; De Waele E, 2014, PANCREAS, V43, P1083, DOI 10.1097/MPA.0000000000000154; Doucas H, 2008, J SURG ONCOL, V97, P63, DOI 10.1002/jso.20894; Ellenrieder V, 2001, INT J CANCER, V93, P204, DOI 10.1002/ijc.1330; Haines N, 2003, NAT REV MOL CELL BIO, V4, P786, DOI 10.1038/nrm1228; Han LF, 2014, CANCER RES, V74, P6509, DOI 10.1158/0008-5472.CAN-14-0816; Hanlon L, 2010, CANCER RES, V70, P4280, DOI 10.1158/0008-5472.CAN-09-4645; Hezel AF, 2012, CANCER RES, V72, P4840, DOI 10.1158/0008-5472.CAN-12-0634; Hicks C, 2000, NAT CELL BIOL, V2, P515, DOI 10.1038/35019553; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Ijichi H, 2006, GENE DEV, V20, P3147, DOI 10.1101/gad.1475506; Ischenko I, 2014, P NATL ACAD SCI USA, V111, P3466, DOI 10.1073/pnas.1319911111; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Jean-Paul D, 2008, P NATL ACAD SCI USA, V105, P18907, DOI 10.1073/pnas.0810111105; Kopinke D, 2012, DEV BIOL, V362, P57, DOI 10.1016/j.ydbio.2011.11.010; Kopp JL, 2012, CANCER CELL, V22, P737, DOI 10.1016/j.ccr.2012.10.025; Leung L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084366; Liu H, 2009, CIRC RES, V104, P466, DOI 10.1161/CIRCRESAHA.108.184846; Maniati E, 2011, J CLIN INVEST, V121, P4685, DOI 10.1172/JCI45797; Mann CD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051119; Mazur PK, 2010, P NATL ACAD SCI USA, V107, P13438, DOI 10.1073/pnas.1002423107; Misra K, 2014, DEVELOPMENT, V141, P187, DOI 10.1242/dev.092536; Miyamoto Y, 2003, CANCER CELL, V3, P565, DOI 10.1016/S1535-6108(03)00140-5; Murtaugh LC, 2003, P NATL ACAD SCI USA, V100, P14920, DOI 10.1073/pnas.2436557100; Ohnuki H, 2014, CANCER RES, V74, P2038, DOI 10.1158/0008-5472.CAN-13-3118; Principe DR, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt369; Rovira M, 2010, P NATL ACAD SCI USA, V107, P75, DOI 10.1073/pnas.0912589107; Ryan DP, 2014, NEW ENGL J MED, V371, P1039, DOI 10.1056/NEJMra1404198; Schiavone M, 2014, DIS MODEL MECH, V7, P883, DOI 10.1242/dmm.014969; Shih HP, 2012, DEVELOPMENT, V139, P2488, DOI 10.1242/dev.078634; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; Svensson P, 2009, MOL CELL BIOL, V29, P2129, DOI 10.1128/MCB.01644-08; Ungefroren H, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-67; Valdez JM, 2012, CELL STEM CELL, V11, P676, DOI 10.1016/j.stem.2012.07.003; Vo K, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-138; Xie MJ, 2002, PANCREAS, V25, P234, DOI 10.1097/00006676-200210000-00004; Xu KL, 2012, CANCER CELL, V21, P626, DOI 10.1016/j.ccr.2012.03.041; Xu KL, 2010, AM J PHYSIOL-LUNG C, V298, pL45, DOI 10.1152/ajplung.90550.2008; Yen WC, 2015, CLIN CANCER RES, V21, P2084, DOI 10.1158/1078-0432.CCR-14-2808; Yu XB, 2006, STEM CELLS, V24, P876, DOI 10.1634/stemcells.2005-0598; Zhang NA, 1998, NATURE, V394, P374, DOI 10.1038/28625; Zhang SB, 2014, NEOPLASIA, V16, P158, DOI 10.1593/neo.131870	46	25	25	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2016	35	19					2485	2495		10.1038/onc.2015.306	http://dx.doi.org/10.1038/onc.2015.306			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GQ	26279302				2022-12-17	WOS:000376165500007
J	Meads, MB; Fang, B; Mathews, L; Gemmer, J; Nong, L; Rosado-Lopez, I; Nguyen, T; Ring, JE; Matsui, W; MacLeod, AR; Pachter, JA; Hazlehurst, LA; Koomen, JM; Shain, KH				Meads, M. B.; Fang, B.; Mathews, L.; Gemmer, J.; Nong, L.; Rosado-Lopez, I.; Nguyen, T.; Ring, J. E.; Matsui, W.; MacLeod, A. R.; Pachter, J. A.; Hazlehurst, L. A.; Koomen, J. M.; Shain, K. H.			Targeting PYK2 mediates microenvironment-specific cell death in multiple myeloma	ONCOGENE			English	Article							BONE-MARROW MICROENVIRONMENT; NOVO DRUG-RESISTANCE; TYROSINE KINASE PYK2; KAPPA-B; GROWTH-FACTOR; CANCER-CELLS; LUNG-CANCER; ACTIVATION; THERAPY; INHIBITION	Multiple myeloma (MM) remains an incurable malignancy due, in part, to the influence of the bone marrow microenvironment on survival and drug response. Identification of microenvironment-specific survival signaling determinants is critical for the rational design of therapy and elimination of MM. Previously, we have shown that collaborative signaling between beta(1) integrin-mediated adhesion to fibronectin and interleukin-6 confers a more malignant phenotype via amplification of signal transducer and activator of transcription 3 (STAT3) activation. Further characterization of the events modulated under these conditions with quantitative phosphotyrosine profiling identified 193 differentially phosphorylated peptides. Seventy-seven phosphorylations were upregulated upon adhesion, including PYK2/FAK2, Paxillin, CASL and p130CAS consistent with focal adhesion (FA) formation. We hypothesized that the collaborative signaling between beta(1) integrin and gp130 (IL-6 beta receptor, IL-6 signal transducer) was mediated by FA formation and proline-rich tyrosine kinase 2 (PYK2) activity. Both pharmacological and molecular targeting of PYK2 attenuated the amplification of STAT3 phosphorylation under co-stimulatory conditions. Co-culture of MM cells with patient bone marrow stromal cells (BMSC) showed similar beta(1) integrin-specific enhancement of PYK2 and STAT3 signaling. Molecular and pharmacological targeting of PYK2 specifically induced cell death and reduced clonogenic growth in BMSC-adherent myeloma cell lines, aldehyde dehydrogenase-positive MM cancer stem cells and patient specimens. Finally, PYK2 inhibition similarly attenuated MM progression in vivo. These data identify a novel PYK2-mediated survival pathway in MM cells and MM cancer stem cells within the context of microenvironmental cues, providing preclinical support for the use of the clinical stage FAK/PYK2 inhibitors for treatment of MM, especially in a minimal residual disease setting.	[Meads, M. B.; Mathews, L.; Gemmer, J.; Nong, L.; Rosado-Lopez, I.; Nguyen, T.; Shain, K. H.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Chem Biol & Mol Med Program, Tampa, FL 33612 USA; [Meads, M. B.; Mathews, L.; Gemmer, J.; Nong, L.; Rosado-Lopez, I.; Nguyen, T.; Shain, K. H.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, 12902 Magnolia Dr SRB2, Tampa, FL 33612 USA; [Fang, B.; Koomen, J. M.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Prote Core Facil, Tampa, FL 33612 USA; [Ring, J. E.; Pachter, J. A.] Verastem Inc, Needham, MA USA; [Matsui, W.] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA; [MacLeod, A. R.] ISIS Pharmaceut, Carlsbad, CA USA; [Hazlehurst, L. A.; Koomen, J. M.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Johns Hopkins University; Johns Hopkins Medicine; Isis Pharmaceuticals Inc; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Shain, KH (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, 12902 Magnolia Dr SRB2, Tampa, FL 33612 USA.	ken.shain@moffitt.org			Florida Department of Health Bankhead-Coley Team Science Program grant [2BT03]; US Army Medical Research and Materiel Command for a National Functional Genomics Center [W81XWH-08-2-0101]; National Cancer Institute as a Cancer Center Support Grant [P30-CA076292]; Moffitt Foundation; NATIONAL CANCER INSTITUTE [P30CA076292, K24CA198315, R01CA174951, P30CA006973, R01CA193887] Funding Source: NIH RePORTER	Florida Department of Health Bankhead-Coley Team Science Program grant; US Army Medical Research and Materiel Command for a National Functional Genomics Center; National Cancer Institute as a Cancer Center Support Grant; Moffitt Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Jianguo Tao and William S Dalton for helpful discussions and critical reading of the manuscript. This work was supported by Florida Department of Health Bankhead-Coley Team Science Program grant 2BT03 (to KSH and LHA). The Moffitt Proteomics Facility is supported by the US Army Medical Research and Materiel Command under Award W81XWH-08-2-0101 for a National Functional Genomics Center, the National Cancer Institute under Award P30-CA076292 as a Cancer Center Support Grant and the Moffitt Foundation. Patient specimens were obtained from the Total Cancer Care program at Moffitt Cancer Center. Patient specimen collection, phosphoproteome mapping and flow cytometry were performed by the Translational Research, Proteomics and Flow Cytometry Core facilities at Moffitt Cancer Center. Antisense oligonucleotides were provided by Isis Pharmaceuticals (Carlsbad, CA, USA). The focal adhesion kinase inhibitors VS-6062, VS-6063 (defactinib), and VS-4718 were provided by Verastem, Inc. (Needham, MA, USA).	[Anonymous], 2012, AUTHENTICATION HUMAN; Ara T, 2013, CANCER RES, V73, P3852, DOI 10.1158/0008-5472.CAN-12-2353; Azab AK, 2009, BLOOD, V113, P4341, DOI 10.1182/blood-2008-10-186668; Benbernou N, 2000, J BIOL CHEM, V275, P7060, DOI 10.1074/jbc.275.10.7060; Boucher K, 2012, CLIN CANCER RES, V18, P6155, DOI 10.1158/1078-0432.CCR-12-0531; Buckbinder L, 2007, P NATL ACAD SCI USA, V104, P10619, DOI 10.1073/pnas.0701421104; Burel SA, 2013, NUCLEIC ACID THER, V23, P213, DOI 10.1089/nat.2013.0422; Butler B, 2005, J BIOL CHEM, V280, P14556, DOI 10.1074/jbc.M411765200; Chauhan D, 1999, ONCOGENE, V18, P6733, DOI 10.1038/sj.onc.1203082; Chauhan D, 2000, J BIOL CHEM, V275, P27845; Codony-Servat J, 2013, PROSTATE, V73, P512, DOI 10.1002/pros.22591; Fuhler GM, 2012, MOL MED, V18, P65, DOI 10.2119/molmed.2011.00178; Golubovskaya V, 2010, ANTI-CANCER AGENT ME, V10, P713, DOI 10.2174/187152010794728693; Guessous F, 2012, MOL CANCER THER, V11, P288, DOI 10.1158/1535-7163.MCT-11-0490; Hazlehurst LA, 2009, CANCER CONTROL, V16, P100, DOI 10.1177/107327480901600202; Kerr WG, 2011, ANN NY ACAD SCI, V1217, P1, DOI 10.1111/j.1749-6632.2010.05869.x; Kesanakurti D, 2013, ONCOGENE, V32, P327, DOI 10.1038/onc.2012.52; Kim SM, 2012, MOL CANCER THER, V11, P2254, DOI 10.1158/1535-7163.MCT-12-0311; Kingsley LA, 2007, P NATL ACAD SCI USA, V104, P10753, DOI 10.1073/pnas.0704357104; Kirshner J, 2008, BLOOD, V112, P2935, DOI 10.1182/blood-2008-02-142430; Landowski TH, 2003, ONCOGENE, V22, P2417, DOI 10.1038/sj.onc.1206315; Li JN, 2010, NAT CHEM BIOL, V6, P291, DOI [10.1038/NCHEMBIO.332, 10.1038/nchembio.332]; Lin HY, 2012, J AGR FOOD CHEM, V60, P2480, DOI 10.1021/jf204362n; Matsui W, 2004, BLOOD, V103, P2332, DOI 10.1182/blood-2003-09-3064; Matsui W, 2008, CANCER RES, V68, P190, DOI 10.1158/0008-5472.CAN-07-3096; McMillin DW, 2010, NAT MED, V16, P483, DOI 10.1038/nm.2112; Meads MB, 2008, CLIN CANCER RES, V14, P2519, DOI 10.1158/1078-0432.CCR-07-2223; Meads MB, 2010, J IMMUNOL, V185, P1606, DOI 10.4049/jimmunol.0902026; Meads MB, 2009, NAT REV CANCER, V9, P665, DOI 10.1038/nrc2714; Meyer AN, 2004, J BIOL CHEM, V279, P28450, DOI 10.1074/jbc.M403335200; Miyazaki T, 1998, GENE DEV, V12, P770, DOI 10.1101/gad.12.6.770; Nefedova Y, 2004, BLOOD, V103, P3503, DOI 10.1182/blood-2003-07-2340; Nefedova Y, 2003, LEUKEMIA, V17, P1175, DOI 10.1038/sj.leu.2402924; Palumbo A, 2011, NEW ENGL J MED, V364, P1046, DOI 10.1056/NEJMra1011442; Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046; Podar K, 2009, LEUKEMIA, V23, P10, DOI 10.1038/leu.2008.259; Rajkumar SV, 2013, AM J HEMATOL, V88, P225, DOI 10.1002/ajh.23390; Rajkumar SV, 2011, AM J HEMATOL, V86, P57, DOI 10.1002/ajh.21913; Rush J, 2005, NAT BIOTECHNOL, V23, P94, DOI 10.1038/nbt1046; Shain KH, 2009, EXPERT REV HEMATOL, V2, P649, DOI [10.1586/ehm.09.55, 10.1586/EHM.09.55]; Shain KH, 2009, CANCER RES, V69, P1009, DOI 10.1158/0008-5472.CAN-08-2419; Shi CS, 2004, J BIOL CHEM, V279, P17224, DOI 10.1074/jbc.M311875200; Shi Z, 2012, BREAST CANCER RES TR, V135, P737, DOI 10.1007/s10549-012-2196-0; St-Germain JR, 2009, P NATL ACAD SCI USA, V106, P20127, DOI 10.1073/pnas.0910957106; Takaoka A, 1999, EMBO J, V18, P2480, DOI 10.1093/emboj/18.9.2480; Voorhees PM, 2009, BRIT J HAEMATOL, V145, P481, DOI 10.1111/j.1365-2141.2009.07647.x; Wang L, 2008, NAT IMMUNOL, V9, P186, DOI 10.1038/ni1548; Yang Y, 2015, CANCER RES, V75, P594, DOI 10.1158/0008-5472.CAN-14-2362; Yarde DN, 2009, CANCER RES, V69, P9367, DOI 10.1158/0008-5472.CAN-09-2616; Zhang GL, 2011, J PROTEOME RES, V10, P305, DOI 10.1021/pr1006203; Zhang Y, 2014, BLOOD, V124, P2675, DOI 10.1182/blood-2014-03-563981	51	25	26	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2016	35	21					2723	2734		10.1038/onc.2015.334	http://dx.doi.org/10.1038/onc.2015.334			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MJ	26387544	Green Accepted			2022-12-17	WOS:000377472700006
J	Howley, BV; Hussey, GS; Link, LA; Howe, PH				Howley, B. V.; Hussey, G. S.; Link, L. A.; Howe, P. H.			Translational regulation of inhibin beta A by TGF beta via the RNA-binding protein hnRNP E1 enhances the invasiveness of epithelial-to-mesenchymal transitioned cells	ONCOGENE			English	Article							ACTIVIN-A; STEM-CELLS; BREAST; CANCER; EXPRESSION; ACTIVATION; PATHWAY; STATES; INHBA	The epithelial-to-mesenchymal transition (EMT) is a cellular process that functions during embryonic development and tissue regeneration, thought to be aberrantly activated in epithelial-derived cancer and has an important role in the process of metastasis. The transforming growth factor (TGF)-beta signaling pathway is a key inducer of EMT and we have elucidated a posttranscriptional mechanism by which TGF beta modulates expression of select transcripts via the RNA-binding protein hnRNP E1 during EMT. One such transcript inhibin beta A is a member of the TGF beta superfamily. Here, we show by polysome profiling that inhibin beta A is translationally regulated by TGF beta via hnRNP E1. TGF beta treatment or knockdown of hnRNP E1 relieves silencing of the inhibin beta A transcript, resulting in increased protein expression and secreted levels of the inhibin beta A homodimer, activin A. Our data indicate that the translational upregulation of inhibin beta A enhances the migration and invasion of cells that have undergone an EMT and promotes cancer progression in vivo.	[Howley, B. V.; Hussey, G. S.; Link, L. A.; Howe, P. H.] Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave,MSC 509,Room 501, Charleston, SC 29425 USA; [Howley, B. V.; Hussey, G. S.; Link, L. A.; Howe, P. H.] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA; [Link, L. A.] Kent State Univ, Dept Biomed Sci, Kent, OH 44242 USA	Medical University of South Carolina; Medical University of South Carolina; University System of Ohio; Kent State University; Kent State University Kent; Kent State University Salem	Howe, PH (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave,MSC 509,Room 501, Charleston, SC 29425 USA.	howep@musc.edu			National Cancer Institute [CA055536, CA154663]; Abney Foundation; American Heart Association Pre-doctoral Fellowship [10PRE3870024]; National Institute of General Medicine [P30GM103331, P30GM103342, P30CA138313]; Biorepository & Tissue Analysis Shared Resource, Hollings Cancer Center, MUSC; Gene Targeting and Knockout Shared Resource at MUSC; NATIONAL CANCER INSTITUTE [R01CA154663, R01CA055536] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Abney Foundation; American Heart Association Pre-doctoral Fellowship(American Heart Association); National Institute of General Medicine(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Biorepository & Tissue Analysis Shared Resource, Hollings Cancer Center, MUSC; Gene Targeting and Knockout Shared Resource at MUSC; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by Grants CA055536 and CA154663 from the National Cancer Institute. BVH was supported by funding from the Abney Foundation. GSH was supported by an American Heart Association Pre-doctoral Fellowship 10PRE3870024. This study used the services of the MUSC Center for Oral Health Research (COHR), which is partially supported by the National Institute of General Medicine grant P30GM103331, the MUSC Flow Cytometry Facility which is supported by P30GM103342, the Cell & Molecular Imaging Shared Resource of MUSC supported by P30CA138313, the Biorepository & Tissue Analysis Shared Resource, Hollings Cancer Center, MUSC and the Gene Targeting and Knockout Shared Resource at MUSC. We would like to thank Maya El Sabban for assisting us with xenograft experiments.	Antenos M, 2007, MOL ENDOCRINOL, V21, P1670, DOI 10.1210/me.2007-0050; Arai KY, 2011, ENDOCRINOLOGY, V152, P3779, DOI 10.1210/en.2011-0255; Burdette JE, 2005, CANCER RES, V65, P7968, DOI 10.1158/0008-5472.CAN-04-3553; Chaudhury A, 2010, NAT CELL BIOL, V12, P286, DOI 10.1038/ncb2029; Gunasinghe NPAD, 2012, CANCER METAST REV, V31, P469, DOI 10.1007/s10555-012-9377-5; Hussey GS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052624; Hussey GS, 2011, MOL CELL, V41, P419, DOI 10.1016/j.molcel.2011.02.003; Kang HY, 2009, J BONE MINER RES, V24, P1180, DOI [10.1359/JBMR.090219, 10.1359/jbmr.090219]; Kim ES, 2005, CYTOKINE, V29, P84, DOI 10.1016/j.cyto.2004.10.001; Kim H, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-51; Le Bras GF, 2014, LAB INVEST, V94, P1134, DOI 10.1038/labinvest.2014.97; Lee KL, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002130; Leto G, 2006, CLIN EXP METASTAS, V23, P117, DOI 10.1007/s10585-006-9010-5; LI RH, 1995, ENDOCRINOLOGY, V136, P849, DOI 10.1210/en.136.3.849; Lonardo E, 2011, CELL STEM CELL, V9, P433, DOI 10.1016/j.stem.2011.10.001; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; MATZUK MM, 1995, NATURE, V374, P354, DOI 10.1038/374354a0; OGAWA Y, 1992, J BIOL CHEM, V267, P14233; Pearson S, 2008, DEVELOPMENT, V135, P1525, DOI 10.1242/dev.011767; Piek E, 1999, J CELL SCI, V112, P4557; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Radisky DC, 2005, J CELL SCI, V118, P4325, DOI 10.1242/jcs.02552; Reis FM, 2002, J CLIN ENDOCR METAB, V87, P2277, DOI 10.1210/jc.87.5.2277; Scheel C, 2011, CELL, V145, P926, DOI 10.1016/j.cell.2011.04.029; Schmierer B, 2007, NAT REV MOL CELL BIO, V8, P970, DOI 10.1038/nrm2297; Seder CW, 2009, NEOPLASIA, V11, P388, DOI 10.1593/neo.81582; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Valcourt U, 2005, MOL BIOL CELL, V16, P1987, DOI 10.1091/mbc.e04-08-0658; Walia V, 2010, STEM CELLS DEV, V19, P1175, DOI 10.1089/scd.2009.0430; Wamsley JJ, 2015, CANCER RES, V75, P426, DOI 10.1158/0008-5472.CAN-13-2702; Wang Q, 2012, MED ONCOL, V29, P77, DOI 10.1007/s12032-010-9766-y; Wildi S, 2001, GUT, V49, P409, DOI 10.1136/gut.49.3.409	32	25	26	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2016	35	13					1725	1735		10.1038/onc.2015.238	http://dx.doi.org/10.1038/onc.2015.238			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DH8RP	26096938	Green Accepted			2022-12-17	WOS:000373064200011
J	Hein, SM; Haricharan, S; Johnston, AN; Toneff, MJ; Reddy, JP; Dong, J; Bu, W; Li, Y				Hein, S. M.; Haricharan, S.; Johnston, A. N.; Toneff, M. J.; Reddy, J. P.; Dong, J.; Bu, W.; Li, Y.			Luminal epithelial cells within the mammary gland can produce basal cells upon oncogenic stress	ONCOGENE			English	Article							HUMAN-BREAST-CANCER; MIDDLE T-ANTIGEN; STEM-CELLS; MOUSE MODEL; IDENTIFICATION; PROGENITORS; EXPRESSION; LINEAGE; TRANSFORMATION; TUMORIGENESIS	In the normal mammary gland, the basal epithelium is known to be bipotent and can generate either basal or luminal cells, whereas the luminal epithelium has not been demonstrated to contribute to the basal compartment in an intact and normally developed mammary gland. It is not clear whether cellular heterogeneity within a breast tumor results from transformation of bipotent basal cells or from transformation and subsequent basal conversion of the more differentiated luminal cells. Here we used a retroviral vector to express an oncogene specifically in a small number of the mammary luminal epithelial cells and tested their potential to produce basal cells during tumorigenesis. This in-vivo lineage-tracing work demonstrates that luminal cells are capable of producing basal cells on activation of either polyoma middle T antigen or ErbB2 signaling. These findings reveal the plasticity of the luminal compartment during tumorigenesis and provide an explanation for cellular heterogeneity within a cancer.	[Hein, S. M.; Toneff, M. J.; Reddy, J. P.; Dong, J.; Bu, W.; Li, Y.] Baylor Coll Med, Dept Mol & Cellular Biol, One Baylor Plaza MS600, Houston, TX 77030 USA; [Hein, S. M.; Haricharan, S.; Johnston, A. N.; Dong, J.; Bu, W.; Li, Y.] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA; [Reddy, J. P.] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center	Li, Y (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, One Baylor Plaza MS600, Houston, TX 77030 USA.	liyi@bcm.edu	; Li, Yi/A-7635-2009	Reddy, Jay Paul/0000-0001-9378-4585; Li, Yi/0000-0002-9976-518X	NIH [CA124820, U54CA149196, T32AG000183, T32GM088129, P30 AI036211, P30 CA125123, S10 RR024574]; DOD [BC085050, BC112704, BC073703]; Nancy Owens Memorial Foundation; CPRIT Training Program [RP101499]; Cytometry and Cell Sorting Core at Baylor College of Medicine; Dan L. Duncan Cancer Center [P30CA125123]; Lester & Sue Smith Breast Center [P50CA058183, P50-CA186784]; NATIONAL CANCER INSTITUTE [U54CA149196] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM088129] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD(United States Department of Defense); Nancy Owens Memorial Foundation; CPRIT Training Program; Cytometry and Cell Sorting Core at Baylor College of Medicine; Dan L. Duncan Cancer Center; Lester & Sue Smith Breast Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Jeffrey Rosen for critical reading of this manuscript. This work was supported in part by funds from NIH CA124820 (to YL) and U54CA149196 (to YL; PI: Stephan Wong); from DOD CDMRP BC085050 (to YL), BC112704 (to YL) and BC073703 (YL); and from the Nancy Owens Memorial Foundation (to YL); as well as by the resources from the Dan L. Duncan Cancer Center (P30CA125123) and the Lester & Sue Smith Breast Center (P50CA058183 & P50-CA186784). SMH was supported by the CPRIT Training Program (RP101499) and by NIH training award T32AG000183. ANJ was supported by NIH training award T32GM088129. This project was supported by the Cytometry and Cell Sorting Core at Baylor College of Medicine with funding from the NIH (P30 AI036211, P30 CA125123 and S10 RR024574) and the expert assistance of Joel M. Sederstrom.	Chang THT, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3593; Desai TJ, 2014, NATURE, V507, P190, DOI 10.1038/nature12930; Driessens G, 2012, NATURE, V488, P527, DOI 10.1038/nature11344; Du ZJ, 2006, P NATL ACAD SCI USA, V103, P17396, DOI 10.1073/pnas.0608607103; Fluck MM, 2009, MICROBIOL MOL BIOL R, V73, P542, DOI 10.1128/MMBR.00009-09; Gastaldi S, 2013, ONCOGENE, V32, P1428, DOI 10.1038/onc.2012.154; Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Haricharan S, 2014, ONCOGENE, V33, P5729, DOI 10.1038/onc.2013.521; Haricharan S, 2013, ELIFE, V2, DOI 10.7554/eLife.00996; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Holland EC, 2000, AM J PATHOL, V157, P1031, DOI 10.1016/S0002-9440(10)64615-9; Ichaso N, 2001, ONCOGENE, V20, P7908, DOI 10.1038/sj.onc.1204859; Ince TA, 2007, CANCER CELL, V12, P160, DOI 10.1016/j.ccr.2007.06.013; Keller PJ, 2012, P NATL ACAD SCI USA, V109, P2772, DOI 10.1073/pnas.1017626108; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Ling H, 2013, ONCOGENE, V32, P3410, DOI 10.1038/onc.2012.341; Malzahn K, 1998, VIRCHOWS ARCH, V433, P119, DOI 10.1007/s004280050226; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; Navin N, 2011, NATURE, V472, P90, DOI 10.1038/nature09807; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pfefferle AD, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-11-r125; Proia TA, 2011, CELL STEM CELL, V8, P149, DOI 10.1016/j.stem.2010.12.007; Rakha EA, 2008, J CLIN ONCOL, V26, P2568, DOI 10.1200/JCO.2007.13.1748; Reddy JP, 2010, P NATL ACAD SCI USA, V107, P3728, DOI 10.1073/pnas.0910665107; Reddy JP, 2009, J MAMMARY GLAND BIOL, V14, P405, DOI 10.1007/s10911-009-9157-1; Reis JS, 2006, HISTOPATHOLOGY, V49, P10, DOI 10.1111/j.1365-2559.2006.02467.x; Revillion F, 1998, EUR J CANCER, V34, P791, DOI 10.1016/S0959-8049(97)10157-5; Rios AC, 2014, NATURE, V506, P322, DOI 10.1038/nature12948; ROBINSON GW, 1995, DEVELOPMENT, V121, P2079; Rosner A, 2002, AM J PATHOL, V161, P1087, DOI 10.1016/S0002-9440(10)64269-1; Schepers AG, 2012, SCIENCE, V337, P730, DOI 10.1126/science.1224676; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Toneff MJ, 2010, NEOPLASIA, V12, P718, DOI 10.1593/neo.10516; van Amerongen R, 2012, CELL STEM CELL, V11, P387, DOI 10.1016/j.stem.2012.05.023; Van Keymeulen A, 2011, NATURE, V479, P189, DOI 10.1038/nature10573; Youssef KK, 2010, NAT CELL BIOL, V12, P299, DOI 10.1038/ncb2031; Zhang M, 2008, CANCER RES, V68, P4674, DOI 10.1158/0008-5472.CAN-07-6353	44	25	25	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2016	35	11					1461	1467		10.1038/onc.2015.206	http://dx.doi.org/10.1038/onc.2015.206			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG6LQ	26096929	Green Accepted			2022-12-17	WOS:000372196400012
J	Williamson, M; de Winter, P; Masters, JR				Williamson, M.; de Winter, P.; Masters, J. R.			Plexin-B1 signalling promotes androgen receptor translocation to the nucleus	ONCOGENE			English	Article							SERINE 81 PHOSPHORYLATION; PROSTATE-CANCER CELLS; THERAPEUTIC TARGETS; R-RAS; BINDING; GROWTH; SEMAPHORINS; ACTIVATION; EXPRESSION; MECHANISMS	Semaphorins and their receptors plexins have diverse roles in many cancers affecting tumour growth, metastasis and angiogenesis. Plexin-B1, the receptor for semaphorin4D (Sema4D), has been implicated in prostate cancer where mutation of the gene and overexpression of the protein occur. It is not clear, however, as to which of the several Sema4D-activated signalling pathways downstream of plexin-B1 function in prostate cancer progression. We show here that Sema4D/plexin-B1 increases the expression of androgen-responsive genes and activates the transcriptional activity of the androgen receptor (AR). Activation of plexin-B1 results in phosphorylation of AR at Serine 81, a site that is phosphorylated by nuclear kinases. Cell fractionation and immunocytochemistry studies demonstrated that the proportion of cells with AR in the nucleus increases significantly upon Sema4D treatment. The N-terminal (AF-1) domain of AR, which contains binding sites for transcription regulators, is not required for this response. Depletion of AR suppressed Sema4D-induced anchorage-independent growth of LNCaP and LNCaP-LN3 cells, demonstrating the functional significance of these findings. These results show that Sema4D/plexin-B1 signalling promotes the translocation of AR to the nucleus and thereby enhances AR transcriptional activity. Plexin-B1 is therefore a promising target for cancer therapy, especially in low androgen situations such as those imposed by androgen deprivation therapy.	[Williamson, M.] Kings Coll London, Fac Life Sci & Med, Randall Div Cell & Mol Biophys, London SE1 1UL, England; [de Winter, P.] UCL, Div Surg & Intervent Sci, Translat Urooncol Grp, London, England; [Masters, J. R.] UCL, Prostate Canc Res Ctr, London, England	University of London; King's College London; University of London; University College London; University of London; University College London	Williamson, M (corresponding author), Kings Coll London, Fac Life Sci & Med, Randall Div Cell & Mol Biophys, London SE1 1UL, England.	magali.williamson@ucl.ac.uk		Williamson, Magali/0000-0002-7183-7495	Prostate Cancer Research Centre; Smith's Charity; Rosetrees Trust; Barcapel Foundation; McAlpine Foundation; Orchid Appeal	Prostate Cancer Research Centre; Smith's Charity; Rosetrees Trust(Rosetrees Trust); Barcapel Foundation; McAlpine Foundation; Orchid Appeal	We thank the Prostate Cancer Research Centre, Smith's Charity, the Rosetrees Trust, the Barcapel Foundation, the McAlpine Foundation and the Orchid Appeal for funding.	Capparuccia L, 2009, J CELL SCI, V122, P1723, DOI 10.1242/jcs.030197; Chen SY, 2012, J BIOL CHEM, V287, P8571, DOI 10.1074/jbc.M111.325290; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; Damola A, 2013, PROSTATE, V73, P1326, DOI 10.1002/pros.22678; Giordano S, 2002, NAT CELL BIOL, V4, P720, DOI 10.1038/ncb843; Gordon V, 2010, MOL ENDOCRINOL, V24, P2267, DOI 10.1210/me.2010-0238; Gravina GL, 2004, INT J ONCOL, V25, P97; Gregory CW, 1999, ENDOCRINOLOGY, V140, P2372, DOI 10.1210/en.140.5.2372; Gross M, 2007, CLIN CANCER RES, V13, P1979, DOI 10.1158/1078-0432.CCR-06-1156; Hota PK, 2012, CELL MOL LIFE SCI, V69, P3765, DOI 10.1007/s00018-012-1019-0; Ito Y, 2006, EMBO REP, V7, P704, DOI 10.1038/sj.embor.7400737; Kesler CT, 2007, MOL ENDOCRINOL, V21, P2071, DOI 10.1210/me.2007-0240; Laht P, 2014, EXP CELL RES, V326, P174, DOI 10.1016/j.yexcr.2014.06.005; Mann F, 2007, J NEUROCHEM, V102, P316, DOI 10.1111/j.1471-4159.2007.04578.x; Massie CE, 2011, EMBO J, V30, P2719, DOI 10.1038/emboj.2011.158; Mellinghoff IK, 2004, CANCER CELL, V6, P517, DOI 10.1016/j.ccr.2004.09.031; Minner S, 2010, CLIN CANCER RES, V16, P1553, DOI 10.1158/1078-0432.CCR-09-2546; Neufeld G, 2008, NAT REV CANCER, V8, P632, DOI 10.1038/nrc2404; Oinuma I, 2004, SCIENCE, V305, P862, DOI 10.1126/science.1097545; Oinuma I, 2003, J BIOL CHEM, V278, P25671, DOI 10.1074/jbc.M303047200; Okada T, 2015, NAT CELL BIOL, V17, P81, DOI 10.1038/ncb3082; Rody A, 2009, EUR J CANCER, V45, P405, DOI 10.1016/j.ejca.2008.10.016; Schmidt EF, 2007, ADV EXP MED BIOL, V600, P1; Segawa T, 2002, ONCOGENE, V21, P8749, DOI 10.1038/sj.onc.1205992; Soong J, 2013, J CELL SCI, V126, P688, DOI 10.1242/jcs.119487; Stevens L, 2010, J INVEST DERMATOL, V130, P1636, DOI 10.1038/jid.2010.13; Swiercz JM, 2004, J CELL BIOL, V165, P869, DOI 10.1083/jcb.200312094; Swiercz JM, 2002, NEURON, V35, P51, DOI 10.1016/S0896-6273(02)00750-X; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; Tamagnone L, 2012, CANCER CELL, V22, P145, DOI 10.1016/j.ccr.2012.06.031; Thadani-Mulero M, 2012, CANCER RES, V72, P4611, DOI 10.1158/0008-5472.CAN-12-0783; Togashi H, 2006, J NEUROSCI, V26, P4961, DOI 10.1523/JNEUROSCI.0704-06.2006; Tong Y, 2007, J BIOL CHEM, V282, P37215, DOI 10.1074/jbc.M703800200; Vikis HG, 2000, P NATL ACAD SCI USA, V97, P12457, DOI 10.1073/pnas.220421797; Wang LG, 2001, CANCER RES, V61, P7544; Wang YX, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002636; Worzfeld T, 2014, NAT REV DRUG DISCOV, V13, P603, DOI 10.1038/nrd4337; Worzfeld T, 2012, J CLIN INVEST, V122, P1296, DOI 10.1172/JCI60568; Ye SM, 2010, BMC CANCER, V105, DOI 10.1186/1471-2407-10-611; Yoshizawa A, 2006, ENDOCR J, V53, P811, DOI 10.1507/endocrj.K06-017; Zhou C, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-11	41	25	27	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2016	35	8					1066	1072		10.1038/onc.2015.160	http://dx.doi.org/10.1038/onc.2015.160			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE7NF	25982277	Green Submitted			2022-12-17	WOS:000370823300012
J	Garant, KA; Shmulevitz, M; Pan, L; Daigle, RM; Ahn, DG; Gujar, SA; Lee, PWK				Garant, K. A.; Shmulevitz, M.; Pan, L.; Daigle, R. M.; Ahn, D-G; Gujar, S. A.; Lee, P. W. K.			Oncolytic reovirus induces intracellular redistribution of Ras to promote apoptosis and progeny virus release	ONCOGENE			English	Article							GOLGI-COMPLEX; H-RAS; FRAGMENTATION; LOCALIZATION; INHIBITION; CANCER; TRAFFICKING; APPARATUS; PROTEINS; REQUIRES	Reovirus is a naturally oncolytic virus that preferentially replicates in Ras-transformed cells and is currently undergoing clinical trials as a cancer therapeutic. Ras transformation promotes reovirus oncolysis by enhancing virion disassembly during entry, viral progeny production, and virus release through apoptosis; however, the mechanism behind the latter is not well understood. Here, we show that reovirus alters the intracellular location of oncogenic Ras to induce apoptosis of H-RasV12-transformed fibroblasts. Reovirus infection decreases Ras palmitoylation levels and causes accumulation of Ras in the Golgi through Golgi fragmentation. With the Golgi being the site of Ras palmitoylation, treatment of target cells with the palmitoylation inhibitor, 2-bromopalmitate (2BP), prompts a greater accumulation of H-RasV12 in the Golgi, and a dose-dependent increase in progeny virus release and subsequent spread. Conversely, tethering H-RasV12 to the plasma membrane (thereby preventing its movement to the Golgi) allows for efficient virus production, but results in basal levels of reovirus-induced cell death. Analysis of Ras downstream signaling reveals that cells expressing cycling H-RasV12 have elevated levels of phosphorylated JNK (c-Jun N-terminal kinase), and that Ras retained at the Golgi body by 28P increases activation of the MEKK1/MKK4/JNK signaling pathway to promote cell death. Collectively, our data suggest that reovirus induces Golgi fragmentation of target cells, and the subsequent accumulation of oncogenic Ras in the Golgi body initiates apoptotic signaling events required for virus release and spread.	[Garant, K. A.; Ahn, D-G; Gujar, S. A.; Lee, P. W. K.] Dalhousie Univ, Dept Microbiol & Immunol, 5850 Coll St,7P Sir Charles Tupper Med Bldg, Halifax, NS B3H 1X5, Canada; [Shmulevitz, M.] Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB, Canada; [Pan, L.] Toronto Western Res Inst, Div Fundamental Neurobiol, Toronto, ON, Canada; [Daigle, R. M.] Dalhousie Univ, Dept Oceanog, Halifax, NS B3H 1X5, Canada; [Gujar, S. A.] IWK Hlth Ctr, Strategy & Org Performance, Halifax, NS, Canada; [Lee, P. W. K.] Dalhousie Univ, Dept Pathol, Halifax, NS B3H 1X5, Canada	Dalhousie University; University of Alberta; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Dalhousie University; Dalhousie University; Dalhousie University	Gujar, SA; Lee, PWK (corresponding author), Dalhousie Univ, Dept Microbiol & Immunol, 5850 Coll St,7P Sir Charles Tupper Med Bldg, Halifax, NS B3H 1X5, Canada.	shashi.gujar@dal.ca; patrick.lee@dal.ca	Daigle, Remi M/H-3160-2019; Ahn, Dae-Gyun/L-7106-2015	Daigle, Remi M/0000-0001-8832-4189; Shmulevitz, Maya/0000-0002-8627-068X; Ahn, Dae-Gyun/0000-0001-8251-8820; Gujar, Shashi/0000-0002-5427-0829	Canadian Institutes for Health Research [130574]; Terry Fox Research Institute (TFRI) New Frontiers Program in Cancer Research; National Sciences and Engineering Research Council of Canada; Killam Trusts; Nova Scotia Health Research Foundation; Canadian Institute of Health Research (CIHR)-Cancer Research Training Program; Beatrice Hunter Cancer Research Institute (BHCRI); CIHR postdoctoral fellowship	Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); Terry Fox Research Institute (TFRI) New Frontiers Program in Cancer Research; National Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)); Killam Trusts; Nova Scotia Health Research Foundation; Canadian Institute of Health Research (CIHR)-Cancer Research Training Program(Canadian Institutes of Health Research (CIHR)); Beatrice Hunter Cancer Research Institute (BHCRI); CIHR postdoctoral fellowship(Canadian Institutes of Health Research (CIHR))	This work was supported by the research grants from the Canadian Institutes for Health Research (Grant FRN # 130574) and the Terry Fox Research Institute (TFRI) New Frontiers Program in Cancer Research (through Canadian Oncolytic Virus Consortium (COVCo)) to PWKL and SAG. Funding for KA Garant was awarded through the National Sciences and Engineering Research Council of Canada, the Killam Trusts and the Nova Scotia Health Research Foundation. Plasma membrane-tethered CD8-H-RasV12xx in pCEFL was a gift from Dr Piero Crespo (University of Cantabria, Cantabria, Spain). D-G Ahn was supported by the Canadian Institute of Health Research (CIHR)-Cancer Research Training Program and the Beatrice Hunter Cancer Research Institute (BHCRI). SG was supported by CIHR postdoctoral fellowship.	Ahearn IM, 2012, NAT REV MOL CELL BIO, V13, P39, DOI 10.1038/nrm3255; Ahearn IM, 2011, MOL CELL, V41, P173, DOI 10.1016/j.molcel.2011.01.001; AVITABILE E, 1995, J VIROL, V69, P7472, DOI 10.1128/JVI.69.12.7472-7482.1995; Baines AT, 2011, FUTURE MED CHEM, V3, P1787, DOI [10.4155/FMC.11.121, 10.4155/fmc.11.121]; BOS JL, 1989, CANCER RES, V49, P4682; Boyartchuk VL, 1997, SCIENCE, V275, P1796, DOI 10.1126/science.275.5307.1796; Calvo F, 2010, BIOESSAYS, V32, P412, DOI 10.1002/bies.200900155; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Clarke P, 2004, J VIROL, V78, P13132, DOI 10.1128/JVI.78.23.13132-13138.2004; Coffey MC, 1998, SCIENCE, V282, P1332, DOI 10.1126/science.282.5392.1332; Colanzi A, 2003, CURR OPIN CELL BIOL, V15, P462, DOI 10.1016/S0955-0674(03)00067-X; Dai Q, 1998, J BIOL CHEM, V273, P15030, DOI 10.1074/jbc.273.24.15030; Dekker FJ, 2010, NAT CHEM BIOL, V6, P449, DOI 10.1038/nchembio.362; DER CJ, 1982, P NATL ACAD SCI-BIOL, V79, P3637, DOI 10.1073/pnas.79.11.3637; Drisdel RC, 2006, METHODS, V40, P127, DOI 10.1016/j.ymeth.2006.04.015; Duncan JA, 1998, J BIOL CHEM, V273, P15830, DOI 10.1074/jbc.273.25.15830; Goodwin JS, 2005, J CELL BIOL, V170, P261, DOI 10.1083/jcb.200502063; Grabocka E, 2014, CANCER CELL, V25, P243, DOI 10.1016/j.ccr.2014.01.005; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Heinemann L, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-221; Hirasawa K, 2002, CANCER RES, V62, P1696; Ilkow CS, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003836; Kominsky DJ, 2002, CELL DEATH DIFFER, V9, P926, DOI 10.1038/sj.cdd.4401045; Kominsky DJ, 2002, J VIROL, V76, P11414, DOI 10.1128/JVI.76.22.11414-11424.2002; Marcato P, 2007, MOL THER, V15, P1522, DOI 10.1038/sj.mt.6300179; Matallanas D, 2006, MOL CELL BIOL, V26, P100, DOI 10.1128/MCB.26.1.100-116.2006; Mendez II, 2000, J VIROL METHODS, V90, P59, DOI 10.1016/S0166-0934(00)00217-2; Mukherjee S, 2007, TRAFFIC, V8, P369, DOI 10.1111/j.1600-0854.2007.00542.x; Norman KL, 2002, HUM GENE THER, V13, P641, DOI 10.1089/10430340252837233; Nozawa K, 2002, ARTHRITIS RES, V4, DOI 10.1186/ar422; Parker JSL, 2002, J VIROL, V76, P4483, DOI 10.1128/JVI.76.9.4483-4496.2002; Resh MD, 2006, METHODS, V40, P191, DOI 10.1016/j.ymeth.2006.04.013; Rocks O, 2005, SCIENCE, V307, P1746, DOI 10.1126/science.1105654; Roy S, 2005, MOL CELL BIOL, V25, P6722, DOI 10.1128/MCB.25.15.6722-6733.2005; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SHAHINIAN S, 1995, BIOCHEMISTRY-US, V34, P3813, DOI 10.1021/bi00011a039; SHARPE AH, 1982, VIROLOGY, V120, P399, DOI 10.1016/0042-6822(82)90040-X; SHIMIZU K, 1983, P NATL ACAD SCI-BIOL, V80, P383, DOI 10.1073/pnas.80.2.383; Shmulevitz M, 2010, CANCER RES, V70, P4912, DOI 10.1158/0008-5472.CAN-09-4676; Stickney JT, 2001, METHOD ENZYMOL, V332, P64; Strong JE, 1998, EMBO J, V17, P3351, DOI 10.1093/emboj/17.12.3351; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; Swarthout JT, 2005, J BIOL CHEM, V280, P31141, DOI 10.1074/jbc.M504113200; Vigil D, 2010, NAT REV CANCER, V10, P842, DOI 10.1038/nrc2960; Webb Y, 2000, J BIOL CHEM, V275, P261, DOI 10.1074/jbc.275.1.261	48	25	25	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2016	35	6					771	782		10.1038/onc.2015.136	http://dx.doi.org/10.1038/onc.2015.136			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RF	25961930				2022-12-17	WOS:000370331300010
J	Png, CW; Weerasooriya, M; Guo, J; James, SJ; Poh, HM; Osato, M; Flavell, RA; Dong, C; Yang, H; Zhang, Y				Png, C. W.; Weerasooriya, M.; Guo, J.; James, S. J.; Poh, H. M.; Osato, M.; Flavell, R. A.; Dong, C.; Yang, H.; Zhang, Y.			DUSP10 regulates intestinal epithelial cell growth and colorectal tumorigenesis	ONCOGENE			English	Article							KRUPPEL-LIKE FACTOR-5; IMMUNE-RESPONSES; GENE-EXPRESSION; UP-REGULATION; CANCER; PHOSPHATASE; COLON; MUTATIONS; INNATE; KRAS	Dual specificity phosphatase 10 (DUSP10), also known as MAP kinase phosphatase 5 (MKP5), negatively regulates the activation of MAP kinases. Genetic polymorphisms and aberrant expression of this gene are associated with colorectal cancer (CRC) in humans. However, the role of DUSP10 in intestinal epithelial tumorigenesis is not clear. Here, we showed that DUSP10 knockout (KO) mice had increased intestinal epithelial cell (IEC) proliferation and migration and developed less severe colitis than wild-type (WT) mice in response to dextran sodium sulphate (DSS) treatment, which is associated with increased ERK1/2 activation and Kruppel-like factor 5 (KLF5) expression in IEC. In line with increased IEC proliferation, DUSP10 KO mice developed more colon tumours with increased severity compared with WT mice in response to administration of DSS and azoxymethane (AOM). Furthermore, survival analysis of CRC patients demonstrated that high DUSP10 expression in tumours was associated with significant improvement in survival probability. Overexpression of DUSP10 in Caco-2 and RCM-1 cells inhibited cell proliferation. Our study showed that DUSP10 negatively regulates IEC growth and acts as a suppressor for CRC. Therefore, it could be targeted for the development of therapies for colitis and CRC.	[Png, C. W.; Weerasooriya, M.; James, S. J.; Poh, H. M.; Zhang, Y.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Microbiol, Singapore 117597, Singapore; [Png, C. W.; Weerasooriya, M.; James, S. J.; Poh, H. M.; Zhang, Y.] Natl Univ Singapore, Inst Life Sci, Immunol Programme, Singapore 117597, Singapore; [Guo, J.; Osato, M.; Yang, H.] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore 117548, Singapore; [Flavell, R. A.] Yale Univ, Howard Hughes Med Inst, Dept Immunol, New Haven, CT 06511 USA; [Dong, C.] Tsinghua Univ, Sch Med, Dept Basic Med Sci, Beijing 100084, Peoples R China	National University of Singapore; National University of Singapore; National University of Singapore; Howard Hughes Medical Institute; Yale University; Tsinghua University	Zhang, Y (corresponding author), Natl Univ Singapore, Dept Microbiol, Ctr Life Sci Inst, Immunol Programme, 28 Med Dr, Singapore 117597, Singapore.	miczy@nus.edu.sg	Osato, Motomi/N-5056-2014; dong, chen/B-3181-2009	Osato, Motomi/0000-0003-3982-9054; dong, chen/0000-0002-0084-9130	Office of Deputy President, National University of Singapore; Ministry of Education [MOE2010-T2-1-079]; National Medical Research Council of Singapore [IRG10nov091, CBRG11nov101]	Office of Deputy President, National University of Singapore(National University of Singapore); Ministry of Education; National Medical Research Council of Singapore(National Medical Research Council, Singapore)	We would like to thank Nicholas Gascoigne for advice and helpful discussion. This study was supported by grants from the Office of Deputy President, National University of Singapore, the Ministry of Education (MOE2010-T2-1-079) and the National Medical Research Council (IRG10nov091 and CBRG11nov101) of Singapore.	Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Cao WS, 2008, J EXP MED, V205, P1491, DOI 10.1084/jem.20071728; Chua SW, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl024; Conkright MD, 1999, NUCLEIC ACIDS RES, V27, P1263, DOI 10.1093/nar/27.5.1263; Cornell TT, 2012, AM J PHYSIOL-LUNG C, V303, pL251, DOI 10.1152/ajplung.00063.2012; De Robertis Mariangela, 2011, J Carcinog, V10, P9, DOI 10.4103/1477-3163.78279; Delaunoit T, 2006, CLIN GASTROENTEROL H, V4, P335, DOI 10.1016/j.cgh.2005.12.035; Egan LJ, 2003, AM J PHYSIOL-CELL PH, V285, pC1028, DOI 10.1152/ajpcell.00167.2003; Farooq A, 2004, CELL SIGNAL, V16, P769, DOI 10.1016/j.cellsig.2003.12.008; Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235; Foty R, 2011, JOVE-J VIS EXP, DOI 10.3791/2720; Groschl B, 2013, INT J CANCER, V132, P1537, DOI 10.1002/ijc.27834; Heazlewood CK, 2008, PLOS MED, V5, P440, DOI 10.1371/journal.pmed.0050054; Houlston RS, 2010, NAT GENET, V42, P973, DOI 10.1038/ng.670; Hrabe JE, 2014, J SURG ONCOL, V109, P117, DOI 10.1002/jso.23465; Kinnebrew MA, 2012, IMMUNOL REV, V245, P113, DOI 10.1111/j.1600-065X.2011.01081.x; Koch S, 2011, GASTROENTEROLOGY, V141, P259, DOI 10.1053/j.gastro.2011.03.043; Lee SH, 2010, NAT MED, V16, P665, DOI 10.1038/nm.2143; Liu YS, 2007, NAT REV IMMUNOL, V7, P202, DOI 10.1038/nri2035; Marisa L, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001453; Matsubayashi Y, 2004, CURR BIOL, V14, P731, DOI 10.1016/j.cub.2004.03.060; Matta R, 2012, AM J PHYSIOL-GASTR L, V302, pG1322, DOI 10.1152/ajpgi.00018.2012; McConnell BB, 2011, GASTROENTEROLOGY, V141, P1302, DOI 10.1053/j.gastro.2011.06.086; McConnell BB, 2011, GASTROENTEROLOGY, V140, P540, DOI 10.1053/j.gastro.2010.10.061; McConnell BB, 2009, CANCER RES, V69, P4125, DOI 10.1158/0008-5472.CAN-08-4402; Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156; Mori A, 2009, MOL CANCER RES, V7, P1390, DOI 10.1158/1541-7786.MCR-08-0525; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nandan MO, 2008, GASTROENTEROLOGY, V134, P120, DOI 10.1053/j.gastro.2007.10.023; Nandan MO, 2005, FEBS LETT, V579, P4757, DOI 10.1016/j.febslet.2005.07.053; Nomura M, 2012, ONCOL REP, V28, P931, DOI 10.3892/or.2012.1862; Oliveira C, 2007, ONCOGENE, V26, P158, DOI 10.1038/sj.onc.1209758; Pai R, 1998, GASTROENTEROLOGY, V114, P706, DOI 10.1016/S0016-5085(98)70584-0; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Podolsky DK, 2002, NEW ENGL J MED, V347, P417, DOI 10.1056/NEJMra0804647; Popovici V, 2012, J CLIN ONCOL, V30, P1288, DOI 10.1200/JCO.2011.39.5814; Qian F, 2012, AM J PHYSIOL-LUNG C, V302, pL866, DOI 10.1152/ajplung.00277.2011; Radtke F, 2005, SCIENCE, V307, P1904, DOI 10.1126/science.1104815; Rimoldi M, 2005, NAT IMMUNOL, V6, P507, DOI 10.1038/ni1192; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Shi H, 2013, J CLIN INVEST, V123, P2064, DOI 10.1172/JCI64375; Spain SL, 2012, HUM MOL GENET, V21, P934, DOI 10.1093/hmg/ddr523; Sturm A, 2008, WORLD J GASTROENTERO, V14, P348, DOI 10.3748/wjg.14.348; Sun RG, 2001, J BIOL CHEM, V276, P6897, DOI 10.1074/jbc.C000870200; Takahashi M, 2000, CARCINOGENESIS, V21, P1117, DOI 10.1093/carcin/21.6.1117; Takahashi M, 2004, CANCER SCI, V95, P475, DOI 10.1111/j.1349-7006.2004.tb03235.x; Tanoue T, 1999, J BIOL CHEM, V274, P19949, DOI 10.1074/jbc.274.28.19949; Theodosiou A, 1999, ONCOGENE, V18, P6981, DOI 10.1038/sj.onc.1203185; Turusov VS, 1990, PATHOLOGY TUMOURS LA; Usui S, 2004, J BIOL CHEM, V279, P12300, DOI 10.1074/jbc.M305025200; Wang DZ, 2006, J EXP MED, V203, P941, DOI 10.1084/jem.20052124; Whiffin N, 2013, HUM MOL GENET, V22, P5075, DOI 10.1093/hmg/ddt357; Yang YZ, 2007, FASEB J, V21, P543, DOI 10.1096/fj.06-6694com; Zhang JH, 2006, GASTROENTEROLOGY, V131, P1179, DOI 10.1053/j.gastro.2006.08.007; Zhang T, 2014, EUR J CANCER PREV, V23, P173, DOI 10.1097/CEJ.0b013e3283647408; Zhang XL, 2005, BIOTECHNOL PROGR, V21, P1289, DOI 10.1021/bp050003l; Zhang YL, 2004, NATURE, V430, P793, DOI 10.1038/nature02764; Zhao Q, 2006, J EXP MED, V203, P131, DOI 10.1084/jem.20051794	58	25	26	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2016	35	2					206	217		10.1038/onc.2015.74	http://dx.doi.org/10.1038/onc.2015.74			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB0JH	25772234				2022-12-17	WOS:000368193900007
J	Kang, JY; Song, SH; Yun, J; Jeon, MS; Kim, HP; Han, SW; Kim, TY				Kang, J. Y.; Song, S. H.; Yun, J.; Jeon, M. S.; Kim, H. P.; Han, S. W.; Kim, T. Y.			Disruption of CTCF/cohesin-mediated high-order chromatin structures by DNA methylation downregulates PTGS2 expression	ONCOGENE			English	Article							GENE-EXPRESSION; CTCF; COHESIN; CYCLOOXYGENASE-2; BINDING; CANCER; TRANSCRIPTION; ORGANIZATION; GENOME; PARENT	The CCCTC-binding factor (CTCF)/cohesin complex regulates gene transcription via high-order chromatin organization of the genome. De novo methylation of CpG islands in the promoter region is an epigenetic hallmark of gene silencing in cancer. Although the CTCF/cohesin complex preferentially targets hypomethylated DNA, it remains unclear whether the CTCF/cohesin-mediated high-order chromatin structure is affected by DNA methylation during tumorigenesis. We found that DNA methylation downregulates the expression of prostaglandin-endoperoxide synthase 2 (PTGS2), which is an inducible, rate-limiting enzyme for prostaglandin synthesis, by disrupting CTCF/cohesin-mediated chromatin looping. We show that the CTCF/cohesin complex is enriched near a CpG island associated with PTGS2 and that the PTGS2 locus forms chromatin loops through methylation-sensitive binding of the CTCF/cohesin complex. DNA methylation abolishes the association of the CTCF/cohesin complex with the PTGS2 CpG island. Disruption of chromatin looping by DNA methylation abrogates the enrichment of transcriptional components, such as positive elongation factor b, at the transcriptional start site of the PTGS2 locus. These alterations result in the downregulation of PTGS2. Our results provide evidence that CTCF/cohesin-mediated chromatin looping of the PTGS2 locus is dynamically influenced by the DNA methylation status.	[Kang, J. Y.; Song, S. H.; Yun, J.; Jeon, M. S.; Kim, H. P.; Han, S. W.; Kim, T. Y.] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul, South Korea; [Kang, J. Y.; Yun, J.; Jeon, M. S.; Kim, T. Y.] Seoul Natl Univ, Coll Med, Dept Mol Med & Biopharmaceut Sci, Grad Sch Convergence Sci & Technol, Seoul, South Korea; [Han, S. W.; Kim, T. Y.] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University Hospital	Kim, TY (corresponding author), Seoul Natl Univ Hosp, Dept Internal Med, 28 Yongon Dong, Seoul 110744, South Korea.	kimty@snu.ac.kr	/Y-5959-2019		National R&D Program for Cancer Control (MOHW) [0720540]; Basic Science Research Program (MOE) [NRF-2011-0021123]; Mid-career Researcher Program (MSIP) [NRF-2013R1A2A2A01009297]; Korea Health Technology R&D Project (MOHW), Republic of Korea [HI14C1277]	National R&D Program for Cancer Control (MOHW); Basic Science Research Program (MOE); Mid-career Researcher Program (MSIP); Korea Health Technology R&D Project (MOHW), Republic of Korea	The authors are grateful to all members of our group for their helpful advice. This research was supported by a grant from the National R&D Program for Cancer Control (MOHW, 0720540), the Basic Science Research Program (MOE, NRF-2011-0021123), the Mid-career Researcher Program (MSIP, NRF-2013R1A2A2A01009297) and the Korea Health Technology R&D Project (MOHW, HI14C1277), Republic of Korea.	Batlle-Lopez A, 2015, ONCOGENE, V34, P246, DOI 10.1038/onc.2013.535; Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; Chang JF, 2010, P NATL ACAD SCI USA, V107, P21836, DOI 10.1073/pnas.1002130107; Coward WR, 2014, FASEB J, V28, P3183, DOI 10.1096/fj.13-241760; de Maat MFG, 2007, J CLIN ONCOL, V25, P4887, DOI 10.1200/JCO.2006.09.8921; de Wit E, 2013, NATURE, V501, P227, DOI 10.1038/nature12420; Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799; DeMare LE, 2013, GENOME RES, V23, P1224, DOI 10.1101/gr.156570.113; Dorsett D, 2012, CURR BIOL, V22, pR240, DOI 10.1016/j.cub.2012.02.046; Easwaran H, 2012, GENOME RES, V22, P837, DOI 10.1101/gr.131169.111; Egloff S, 2012, TRENDS GENET, V28, P333, DOI 10.1016/j.tig.2012.03.007; Gilroy DW, 2001, FASEB J, V15, P288; Gomes NP, 2010, GENE DEV, V24, P1022, DOI 10.1101/gad.1881010; Hadjur S, 2009, NATURE, V460, P410, DOI 10.1038/nature08079; Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966; Hou CH, 2010, P NATL ACAD SCI USA, V107, P3651, DOI 10.1073/pnas.0912087107; Jin BL, 2013, ADV EXP MED BIOL, V754, P3, DOI 10.1007/978-1-4419-9967-2_1; Kanduri C, 2000, CURR BIOL, V10, P853, DOI 10.1016/S0960-9822(00)00597-2; Krivega I, 2012, CURR OPIN GENET DEV, V22, P79, DOI 10.1016/j.gde.2011.11.001; Lai AY, 2010, J EXP MED, V207, P1939, DOI 10.1084/jem.20100204; McGarvey KM, 2008, CANCER RES, V68, P5753, DOI 10.1158/0008-5472.CAN-08-0700; Murrell A, 2004, NAT GENET, V36, P889, DOI 10.1038/ng1402; Nagano T, 2013, NATURE, V502, P59, DOI 10.1038/nature12593; Nitzsche A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019470; Ong CT, 2014, NAT REV GENET, V15, P234, DOI 10.1038/nrg3663; Parelho V, 2008, CELL, V132, P422, DOI 10.1016/j.cell.2008.01.011; Phillips-Cremins JE, 2013, CELL, V153, P1281, DOI 10.1016/j.cell.2013.04.053; Rhodes JM, 2011, MOL CANCER RES, V9, P1587, DOI 10.1158/1541-7786.MCR-11-0382; Rizzo MT, 2011, CLIN CHIM ACTA, V412, P671, DOI 10.1016/j.cca.2010.12.026; Rodriguez C, 2010, BIOCHEM BIOPH RES CO, V392, P129, DOI 10.1016/j.bbrc.2009.12.159; Rodriguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305; Rubio ED, 2008, P NATL ACAD SCI USA, V105, P8309, DOI 10.1073/pnas.0801273105; Schaaf CA, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003382; Schoenfelder S, 2010, NAT GENET, V42, P53, DOI 10.1038/ng.496; Seitan VC, 2013, GENOME RES, V23, P2066, DOI 10.1101/gr.161620.113; Song SH, 2007, MOL CELL, V28, P810, DOI 10.1016/j.molcel.2007.09.025; Song SH, 2001, CANCER RES, V61, P4628; Stadler MB, 2011, NATURE, V480, P490, DOI 10.1038/nature10716; Tolhuis B, 2002, MOL CELL, V10, P1453, DOI 10.1016/S1097-2765(02)00781-5; Toyota M, 2000, CANCER RES, V60, P4044; Wang DZ, 2010, NAT REV CANCER, V10, P181, DOI 10.1038/nrc2809; Wendt KS, 2008, NATURE, V451, P796, DOI 10.1038/nature06634; Yan J, 2013, CELL, V154, P801, DOI 10.1016/j.cell.2013.07.034; Yun J, 2012, LAB INVEST, V92, P1033, DOI 10.1038/labinvest.2012.61	45	25	28	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 5	2015	34	45					5677	5684		10.1038/onc.2015.17	http://dx.doi.org/10.1038/onc.2015.17			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CV9GA	25703332	Bronze			2022-12-17	WOS:000364594300008
J	Leroy, C; Shen, Q; Strande, V; Meyer, R; McLaughlin, ME; Lezan, E; Bentires-Alj, M; Voshol, H; Bonenfant, D; Gaither, LA				Leroy, C.; Shen, Q.; Strande, V.; Meyer, R.; McLaughlin, M. E.; Lezan, E.; Bentires-Alj, M.; Voshol, H.; Bonenfant, D.; Gaither, L. Alex			CUB-domain-containing protein 1 overexpression in solid cancers promotes cancer cell growth by activating Src family kinases	ONCOGENE			English	Article							TYROSINE PHOSPHORYLATION; PKC-DELTA; METASTASIS; CDCP1; EPITHELIA; MIGRATION; INVASION; REVEALS; FYN	The transmembrane glycoprotein, CUB (complement C1r/C1s, Uegf, Bmp1) domain-containing protein 1 (CDCP1) is overexpressed in several cancer types and is a predictor of poor prognosis for patients on standard of care therapies. Phosphorylation of CDCP1 tyrosine sites is induced upon loss of cell adhesion and is thought to be linked to metastatic potential of tumor cells. Using a tyrosine-phosphoproteomics screening approach, we characterized the phosphorylation state of CDCP1 across a panel of breast cancer cell lines. We focused on two phospho-tyrosine pTyr peptides of CDCP1, containing Tyr707 and Tyr806, which were identified in all six lines, with the human epidermal growth factor 2-positive HCC1954 cells showing a particularly high phosphorylation level. Pharmacological modulation of tyrosine phosphorylation indicated that, the Src family kinases (SFKs) were found to phosphorylate CDCP1 at Tyr707 and Tyr806 and play a critical role in CDCP1 activity. We demonstrated that CDCP1 overexpression in HEK293 cells increases global phosphotyrosine content, promotes anchorage-independent cell growth and activates several SFK members. Conversely, CDCP1 downregulation in multiple solid cancer cell lines decreased both cell growth and SFK activation. Analysis of primary human tumor samples demonstrated a correlation between CDCP1 expression, SFK and protein kinase C (PKC) activity. Taken together, our results suggest that CDCP1 overexpression could be an interesting therapeutic target in multiple solid cancers and a good biomarker to stratify patients who could benefit from an anti-SFK-targeted therapy. Our data also show that multiple tyrosine phosphorylation sites of CDCP1 are important for the functional regulation of SFKs in several tumor types.	[Leroy, C.; Strande, V.; Lezan, E.; Voshol, H.; Bonenfant, D.] Novartis Inst BioMed Res, Basel, Switzerland; [Shen, Q.; Meyer, R.; McLaughlin, M. E.; Gaither, L. Alex] Novartis Inst BioMed Res Inc, Cambridge, MA 02139 USA; [Bentires-Alj, M.] Friedrich Miescher Inst, CH-4002 Basel, Switzerland	Novartis; Novartis; Friedrich Miescher Institute for Biomedical Research	Gaither, LA (corresponding author), Novartis Inst BioMed Res Inc, 500 Technol Sq, Cambridge, MA 02139 USA.	alex.gaither@novartis.com	Bentires-Alj, Mohamed/F-4484-2015	Bentires-Alj, Mohamed/0000-0001-6344-1127				Alajati A, 2013, CANCER RES, V73, P5320, DOI 10.1158/0008-5472.CAN-12-3186; Benes CH, 2005, CELL, V121, P271, DOI 10.1016/j.cell.2005.02.019; Brown TA, 2004, J BIOL CHEM, V279, P14772, DOI 10.1074/jbc.M309678200; Casar B, 2014, ONCOGENE, V33, P255, DOI 10.1038/onc.2012.547; Hochgrafe F, 2010, CANCER RES, V70, P9391, DOI 10.1158/0008-5472.CAN-10-0911; Ikeda JI, 2009, CANCER SCI, V100, P429, DOI 10.1111/j.1349-7006.2008.01066.x; Kim LC, 2009, NAT REV CLIN ONCOL, V6, P587, DOI 10.1038/nrclinonc.2009.129; Leroy C, 2009, CANCER RES, V69, P2279, DOI 10.1158/0008-5472.CAN-08-2354; Liu H, 2011, P NATL ACAD SCI USA, V108, P1379, DOI 10.1073/pnas.1017228108; Manes G, 2000, MOL CELL BIOL, V20, P3396, DOI 10.1128/MCB.20.10.3396-3406.2000; Miyazawa Y, 2010, CANCER RES, V70, P5136, DOI 10.1158/0008-5472.CAN-10-0220; Oneyama C, 2008, MOL CELL, V30, P426, DOI 10.1016/j.molcel.2008.03.026; Razorenova OV, 2011, P NATL ACAD SCI USA, V108, P1931, DOI 10.1073/pnas.1011777108; Salmond RJ, 2009, IMMUNOL REV, V228, P9, DOI 10.1111/j.1600-065X.2008.00745.x; Sirvent A, 2010, ONCOGENE, V29, P1303, DOI 10.1038/onc.2009.450; Siva AC, 2008, CANCER RES, V68, P3759, DOI 10.1158/0008-5472.CAN-07-1657; Uekita T, 2011, CANCER SCI, V102, P1943, DOI 10.1111/j.1349-7006.2011.02052.x; Verma R, 2003, J BIOL CHEM, V278, P20716, DOI 10.1074/jbc.M301689200; Wong CH, 2009, CLIN CANCER RES, V15, P2311, DOI 10.1158/1078-0432.CCR-08-2533; Wortmann A, 2009, IUBMB LIFE, V61, P723, DOI 10.1002/iub.198	20	25	25	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2015	34	44					5593	5598		10.1038/onc.2015.19	http://dx.doi.org/10.1038/onc.2015.19			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CV9FX	25728678	Green Published, hybrid			2022-12-17	WOS:000364594000008
J	Lin, YG; Shen, J; Yoo, E; Liu, R; Yen, HY; Mehta, A; Rajaei, A; Yang, W; Mhawech-Fauceglia, P; DeMayo, FJ; Lydon, J; Gill, P; Lee, AS				Lin, Y. G.; Shen, J.; Yoo, E.; Liu, R.; Yen, H-Y; Mehta, A.; Rajaei, A.; Yang, W.; Mhawech-Fauceglia, P.; DeMayo, F. J.; Lydon, J.; Gill, P.; Lee, A. S.			Targeting the glucose-regulated protein-78 abrogates Pten-null driven AKT activation and endometrioid tumorigenesis	ONCOGENE			English	Article							ENDOPLASMIC-RETICULUM STRESS; TUMOR-GROWTH; GRP78; CANCER; EXPRESSION; CHAPERONE; CELLS; KNOCKOUT; PROGRESSION; PREDICTOR	Rates of the most common gynecologic cancer, endometrioid adenocarcinoma (EAC), continue to rise, mirroring the global epidemic of obesity, a well-known EAC risk factor. Thus, identifying novel molecular targets to prevent and/or mitigate EAC is imperative. The prevalent Type 1 EAC commonly harbors loss of the tumor suppressor, Pten, leading to AKT activation. The major endoplasmic reticulum (ER) chaperone, GRP78, is a potent pro-survival protein to maintain ER homeostasis, and as a cell surface protein, is known to regulate the phosphatidylinositol 3-kinase (PI3K)/AKT pathway. To determine whether targeting GRP78 could suppress EAC development, we created a conditional knockout mouse model using progesterone receptor-Cre-recombinase to achieve Pten and Grp78 (cPten(f/f)Grp78(f/f)) deletion in the endometrial epithelium. Mice with a single Pten (cPten(f/f)) deletion developed well-differentiated EAC by 4 weeks. In contrast, no cPten(f/f)Grp78(f/f) mice developed EAC, even after more than 8 months of observation. Histologic examination of uteri from cPten(f/f)Grp78(f/f) mice also revealed no complex atypical hyperplasia, a well-established EAC precursor. These histologic observations among the cPten(f/f)Grp78(f/f) murine uteri also corresponded to abrogation of AKT activation within the endometrium. We further observed that GRP78 co-localized with activated AKT on the surface of EAC, thus providing an opportunity for therapeutic targeting. Consistent with previous findings that cell surface GRP78 is an upstream regulator of PI3K/AKT signaling, we show here that in vivo short-term systemic treatment with a highly specific monoclonal antibody against GRP78 suppressed AKT activation and increased apoptosis in the cPtenf/f tumors. Collectively, these findings present GRP78-targeting therapy as an efficacious therapeutic option for EAC.	[Lin, Y. G.; Yoo, E.] Univ So Calif, Keck Sch Med, Dept Obstet & Gynecol, Div Gynecol Oncol,USC Norris Comprehens Canc Ctr, Los Angeles, CA 90089 USA; [Shen, J.; Lee, A. S.] Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, USC Norris Comprehens Canc Ctr, Los Angeles, CA 90089 USA; [Liu, R.; Yen, H-Y; Mehta, A.; Rajaei, A.; Yang, W.; Gill, P.] Univ So Calif, Keck Sch Med, Dept Hematol Oncol, USC Norris Comprehens Canc Ctr, Los Angeles, CA 90089 USA; [Mhawech-Fauceglia, P.] Univ So Calif, Keck Sch Med, Dept Pathol, USC Norris Comprehens Canc Ctr, Los Angeles, CA 90089 USA; [DeMayo, F. J.; Lydon, J.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	University of Southern California; University of Southern California; University of Southern California; University of Southern California; Baylor College of Medicine	Lee, AS (corresponding author), Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, USC Norris Comprehens Canc Ctr, 1441 Eastlake Ave,NOR 5308, Los Angeles, CA 90089 USA.	yvonne.g.lin@gmail.com; amylee@usc.edu	MEHTA, ARJUN/AAH-2251-2021; DeMayo, Francesco/C-6255-2019; Mehta, Arjun/AFO-2449-2022	DeMayo, Francesco/0000-0002-9480-7336; Lee, Amy/0000-0002-0378-5443; mehta, arjun/0000-0002-8778-7832; Shen, Jieli/0000-0003-1905-9101	USC Department of Obstetrics & Gynecology Seed Grant; Stop Cancer Career Development Award; NIH [R01 CA027607, K08 CA175161, P30 DK048522]; NCI Cancer Center Support Grant [P30 CA014089]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD042311] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA014089, R01CA027607, K08CA175161] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK048522] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES103311] Funding Source: NIH RePORTER	USC Department of Obstetrics & Gynecology Seed Grant; Stop Cancer Career Development Award; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank the USC Norris Comprehensive Cancer Center Translational Pathology Core for tissue processing and the USC Research Center for Liver Diseases Cell and Tissue Imaging Core. We also thank the members of the Lee lab, particularly Wan-Ting Chen, Genyuan Zhu and Michelle Pong for their input and assistance throughout this project. This work was supported by the USC Department of Obstetrics & Gynecology Seed Grant (YGL), Stop Cancer Career Development Award (YGL), NIH Grant R01 CA027607 (ASL), NIH Grant K08 CA175161 (YGL) and NCI Cancer Center Support Grant (P30 CA014089, ASL/YGL). Microscopy at the Cell and Tissue Imaging Core of the USC Research Center for Liver Diseases was supported by NIH Grant P30 DK048522.	Arap MA, 2004, CANCER CELL, V6, P275, DOI 10.1016/j.ccr.2004.08.018; Bifulco G, 2012, GYNECOL ONCOL, V125, P220, DOI 10.1016/j.ygyno.2011.11.045; BOKHMAN JV, 1985, GYNECOL ONCOL, V20, P139, DOI 10.1016/0090-8258(85)90135-0; Cali G, 2014, J CELL PHYSIOL, V229, P1417, DOI 10.1002/jcp.24578; Chen WT, 2014, HEPATOLOGY, V59, P947, DOI 10.1002/hep.26711; Conley-LaComb MK, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-85; Cordero-Espinoza L, 2013, J BIOL CHEM, V288, P36020, DOI 10.1074/jbc.M113.510289; Daikoku T, 2008, CANCER RES, V68, P5619, DOI 10.1158/0008-5472.CAN-08-1274; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Fu Y, 2008, P NATL ACAD SCI USA, V105, P19444, DOI 10.1073/pnas.0807691105; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Gonzalez-Gronow M, 2009, ANTIOXID REDOX SIGN, V11, P2299, DOI [10.1089/ars.2009.2568, 10.1089/ARS.2009.2568]; Gray MJ, 2013, INT J CANCER, V133, P21, DOI 10.1002/ijc.27994; He LN, 2010, AM J PATHOL, V176, P2302, DOI 10.2353/ajpath.2010.090931; Hill R, 2012, MOL CANCER THER, V11, P2127, DOI 10.1158/1535-7163.MCT-12-0342; Hotamisligil GS, 2010, CELL, V140, P900, DOI 10.1016/j.cell.2010.02.034; Iglesias David A, 2012, Clin Adv Hematol Oncol, V10, P797; Lee AS, 2014, NAT REV CANCER, V14, P263, DOI 10.1038/nrc3701; Lee E, 2006, CANCER RES, V66, P7849, DOI 10.1158/0008-5472.CAN-06-1660; Lee E, 2011, INT J CANCER, V128, P726, DOI 10.1002/ijc.25370; Leslie KK, 2012, OBSTET GYN CLIN N AM, V39, P255, DOI 10.1016/j.ogc.2012.04.001; Li JZ, 2006, CURR MOL MED, V6, P45, DOI 10.2174/156652406775574523; Liu R, 2013, CLIN CANCER RES, V19, P6802, DOI 10.1158/1078-0432.CCR-13-1106; Liu R, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-269; Luo B, 2013, ONCOGENE, V32, P805, DOI 10.1038/onc.2012.130; Ma YJ, 2004, NAT REV CANCER, V4, P966, DOI 10.1038/nrc1505; Mahadevan NR, 2011, P NATL ACAD SCI USA, V108, P6561, DOI 10.1073/pnas.1008942108; Matsuo K, 2013, GYNECOL ONCOL, V128, P552, DOI 10.1016/j.ygyno.2012.11.024; Misra UK, 2006, J BIOL CHEM, V281, P13694, DOI 10.1074/jbc.M511694200; Ni M, 2007, FEBS LETT, V581, P3641, DOI 10.1016/j.febslet.2007.04.045; Ni M, 2011, BIOCHEM J, V434, P181, DOI 10.1042/BJ20101569; Pootrakul L, 2006, CLIN CANCER RES, V12, P5987, DOI 10.1158/1078-0432.CCR-06-0133; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Sato M, 2010, ADV GENET, V69, P97, DOI 10.1016/S0065-2660(10)69006-2; Schmandt RE, 2011, AM J OBSTET GYNECOL, V205, P518, DOI 10.1016/j.ajog.2011.05.042; Shin BK, 2003, J BIOL CHEM, V278, P7607, DOI 10.1074/jbc.M210455200; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Wey S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039047; Wey S, 2012, BLOOD, V119, P817, DOI 10.1182/blood-2011-06-357384; Wu J, 2006, CELL DEATH DIFFER, V13, P374, DOI 10.1038/sj.cdd.4401840; Zhang LH, 2011, BRAIN RES, V1371, P23, DOI 10.1016/j.brainres.2010.11.063; Zhang Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080071; Zhang Y, 2010, J BIOL CHEM, V285, P15065, DOI 10.1074/jbc.M109.087445; Zhuang LQ, 2009, HISTOPATHOLOGY, V54, P462, DOI 10.1111/j.1365-2559.2009.03242.x	44	25	25	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2015	34	43					5418	5426		10.1038/onc.2015.4	http://dx.doi.org/10.1038/onc.2015.4			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU4EM	25684138	Green Accepted			2022-12-17	WOS:000363479700002
J	Xu, Y; Miriyala, S; Fang, F; Bakthavatchalu, V; Noel, T; Schell, DM; Wang, C; St Clair, WH; St Clair, DK				Xu, Y.; Miriyala, S.; Fang, F.; Bakthavatchalu, V.; Noel, T.; Schell, D. M.; Wang, C.; St Clair, W. H.; St Clair, D. K.			Manganese superoxide dismutase deficiency triggers mitochondrial uncoupling and the Warburg effect	ONCOGENE			English	Article							SKIN CARCINOGENESIS MODEL; LIPID-PEROXIDATION; CANCER METABOLISM; OXIDATIVE STRESS; EPITHELIAL-CELLS; PROTEIN-2; OVEREXPRESSION; EXPRESSION; GLUCOSE; ALPHA	Manganese superoxide dismutase (MnSOD) is a mitochondrially localized primary antioxidant enzyme, known to be essential for the survival of aerobic life and to have important roles in tumorigenesis. Here, we show that MnSOD deficiency in skin tissues of MnSOD-heterozygous knockout (Sod2(+/) (-)) mice leads to increased expresson of uncoupling proteins (UCPs). When MnSOD is deficient, superoxide radical and its resulting reactive oxygen species (ROS) activate ligand binding to peroxisome proliferator-activated receptor alpha (PPAR alpha), suggesting that the activation of PPAR alpha signaling is a major mechanism underlying MnSOD-dependent UCPs expression that consequently triggers the PI3K/Akt/mTOR pathway, leading to increased aerobic glycolysis. Knockdown of UCPs and mTOR suppresses lactate production and increases ATP levels, suggesting that UCPs contribute to increased glycolysis. These results highlight the existence of a free radical-mediated mechanism that activates mitochondria uncoupling to reduce ROS production, which precedes the glycolytic adaptation described as the Warburg Effect.	[Xu, Y.] Nanjing Med Univ, Nanjing Hosp 1, Dept Oncol, Nanjing, Jiangsu, Peoples R China; [Miriyala, S.; Bakthavatchalu, V.; Noel, T.; Schell, D. M.; St Clair, D. K.] Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA; [Fang, F.; St Clair, W. H.] Univ Kentucky, Dept Radiat Med, Lexington, KY USA; [Wang, C.; St Clair, D. K.] Univ Kentucky, Markey Canc Ctr, Lexington, KY USA	Nanjing Medical University; University of Kentucky; University of Kentucky; University of Kentucky	St Clair, DK (corresponding author), Univ Kentucky, Coll Med, Grad Ctr Toxicol, 1095 VA Dr, Lexington, KY 40536 USA.	yxu03558@yahoo.com; dstcl00@uky.edu		Miriyala, Sumitra/0000-0001-7158-9295	National Institutes of Health [CA 049797, CA 143428]; Edward P. Evans Foundation grant; National Nature Science Foundation of China [81372199];  [CA 073599]; NATIONAL CANCER INSTITUTE [R01CA049797, R01CA143428, R29CA049797, R01CA073599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007778] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Edward P. Evans Foundation grant; National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by National Institutes of Health grants CA 049797 and CA 143428, and an Edward P. Evans Foundation grant to Daret K. St Clair; CA 073599 and CA 143428 to William H. St Clair; and National Nature Science Foundation of China grant 81372199 to Yong Xu. We would like to thank Dr Ronald M. Evans, Howard Hughes Medical Institute, San Diego, California 92186, USA, for providing the PPREx3-TK-luciferase construct for this study.	Aubert J, 1997, BIOCHEM BIOPH RES CO, V238, P606, DOI 10.1006/bbrc.1997.7348; Baffy G, 2010, MITOCHONDRION, V10, P243, DOI 10.1016/j.mito.2009.12.143; Boss O, 2000, DIABETES, V49, P143, DOI 10.2337/diabetes.49.2.143; Bouillaud F, 2009, BBA-BIOENERGETICS, V1787, P377, DOI 10.1016/j.bbabio.2009.01.003; Criscuolo F, 2006, BBA-BIOENERGETICS, V1757, P1284, DOI 10.1016/j.bbabio.2006.06.002; Dhar SK, 2011, CANCER RES, V71, P6684, DOI 10.1158/0008-5472.CAN-11-1233; Diano S, 2012, TRENDS MOL MED, V18, P52, DOI 10.1016/j.molmed.2011.08.003; Echtay KS, 2007, FREE RADICAL BIO MED, V43, P1351, DOI 10.1016/j.freeradbiomed.2007.08.011; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Ferreira LMR, 2010, EXP MOL PATHOL, V89, P372, DOI 10.1016/j.yexmp.2010.08.006; Finkel T, 2011, J CELL BIOL, V194, P7, DOI 10.1083/jcb.201102095; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Holley AK, 2014, ANTIOXID REDOX SIGN, V20, P2347, DOI 10.1089/ars.2013.5204; Holley AK, 2013, MITOCHONDRION, V13, P170, DOI 10.1016/j.mito.2012.07.104; Hong Y, 2001, ENDOCRINOLOGY, V142, P249, DOI 10.1210/en.142.1.249; Horimoto M, 2004, CLIN CANCER RES, V10, P6203, DOI 10.1158/1078-0432.CCR-04-0419; Ilizarov AM, 2001, AM J RESP CELL MOL, V24, P436, DOI 10.1165/ajrcmb.24.4.4240; Jansen S, 2009, REPRODUCTION, V138, P493, DOI 10.1530/REP-09-0038; Jarmuszkiewicz W, 2010, BBA-BIOENERGETICS, V1797, P792, DOI 10.1016/j.bbabio.2009.12.005; Joseph JW, 2004, J BIOL CHEM, V279, P51049, DOI 10.1074/jbc.M409189200; Keller JN, 1998, J NEUROSCI, V18, P687; Kiningham KK, 1999, FASEB J, V13, P1601, DOI 10.1096/fasebj.13.12.1601; KLINGENBERG M, 1990, TRENDS BIOCHEM SCI, V15, P108, DOI 10.1016/0968-0004(90)90194-G; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Lin J, 2010, CANCER PREV RES, V3, P505, DOI 10.1158/1940-6207.CAPR-09-0263; Mathupala SP, 2010, BBA-BIOENERGETICS, V1797, P1225, DOI 10.1016/j.bbabio.2010.03.025; Miller DM, 2012, CLIN CANCER RES, V18, P5546, DOI 10.1158/1078-0432.CCR-12-0977; Miriyala S, 2011, ANTI-CANCER AGENT ME, V11, P181, DOI 10.2174/187152011795255920; Nagano Y, 2012, J PHYSIOL PHARMACOL, V63, P137; OBERLEY LW, 1988, MOL CELL BIOCHEM, V84, P147, DOI 10.1007/BF00421049; OBERLEY LW, 1979, CANCER RES, V39, P1141; Oberley TD, 2004, ANTIOXID REDOX SIGN, V6, P537, DOI 10.1089/152308604773934297; Okiyama W, 2009, J HEPATOL, V50, P1236, DOI 10.1016/j.jhep.2009.01.025; Patterson AD, 2012, HEPATOLOGY, V56, P281, DOI 10.1002/hep.25645; Pecqueur C, 2008, FASEB J, V22, P9, DOI 10.1096/fj.07-8945com; Porter RK, 2001, BBA-BIOENERGETICS, V1504, P120, DOI 10.1016/S0005-2728(00)00246-2; Ray PD, 2012, CELL SIGNAL, V24, P981, DOI 10.1016/j.cellsig.2012.01.008; Samudio I, 2008, CANCER RES, V68, P5198, DOI 10.1158/0008-5472.CAN-08-0555; Sears IB, 1996, MOL CELL BIOL, V16, P3410; Silva JP, 2005, EMBO J, V24, P4061, DOI 10.1038/sj.emboj.7600866; Sluse FE, 2006, BBA-BIOENERGETICS, V1757, P480, DOI 10.1016/j.bbabio.2006.02.004; Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330; Teruel T, 2003, J BIOL CHEM, V278, P263, DOI 10.1074/jbc.M207200200; Valle Adamo, 2010, Cancers (Basel), V2, P567, DOI 10.3390/cancers2020567; Van Remmen H, 2001, AM J PHYSIOL-HEART C, V281, pH1422, DOI 10.1152/ajpheart.2001.281.3.H1422; Van Remmen H, 1999, ARCH BIOCHEM BIOPHYS, V363, P91, DOI 10.1006/abbi.1998.1060; Vozza A, 2014, P NATL ACAD SCI USA, V111, P960, DOI 10.1073/pnas.1317400111; Xu Y, 2013, CANCER RES, V73, P4406, DOI 10.1158/0008-5472.CAN-12-4297; Zhao YF, 2001, CANCER RES, V61, P6082; Zhao YF, 2005, CANCER RES, V65, P3745, DOI 10.1158/0008-5472.CAN-04-3835	50	25	25	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	2015	34	32					4229	4237		10.1038/onc.2014.355	http://dx.doi.org/10.1038/onc.2014.355			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO5LE	25362851	Green Accepted			2022-12-17	WOS:000359199800009
J	Kobayashi, T; Masoumi, KC; Massoumi, R				Kobayashi, T.; Masoumi, K. C.; Massoumi, R.			Deubiquitinating activity of CYLD is impaired by SUMOylation in neuroblastoma cells	ONCOGENE			English	Article							NF-KAPPA-B; HIGH-RISK NEUROBLASTOMA; ACID-INDUCED DIFFERENTIATION; HUMAN NEURO-BLASTOMA; TRANS-RETINOIC ACID; 13-CIS-RETINOIC ACID; GENE-EXPRESSION; ENZYME; POLYUBIQUITIN; APOPTOSIS	CYLD is a deubiquitinating (DUB) enzyme that has a pivotal role in modulating nuclear factor kappa B (NF-kappa B) signaling pathways by removing the lysine 63- and linear-linked ubiquitin chain from substrates such as tumor necrosis factor receptor-associated factor 2 (TRAF2) and TRAF6. Loss of CYLD activity is associated with tumorigenicity, and levels of CYLD are lost or downregulated in different types of human tumors. In the present study, we found that high CYLD expression was associated with better overall survival and relapse-free neuroblastoma patient outcome, as well as inversely correlated with the stage of neuroblastoma. Retinoic acid-mediated differentiation of neuroblastoma restored CYLD expression and promoted SUMOylation of CYLD. This posttranslational modification inhibited deubiquitinase activity of CYLD against TRAF2 and TRAF6 and facilitated NF-kappa B signaling. Overexpression of non-SUMOylatable mutant CYLD in neuroblastoma cells reduced retinoic acid-induced NF-kappa B activation and differentiation of cells, but instead promoted cell death.	[Kobayashi, T.; Masoumi, K. C.; Massoumi, R.] Lund Univ, Translat Canc Res, Div Mol Tumor Pathol, Dept Lab Med, S-22363 Lund, Sweden	Lund University	Massoumi, R (corresponding author), Lund Univ, Translat Canc Res, Div Mol Tumor Pathol, Dept Lab Med, Bldg 404,A3,Scheelevagen 8, S-22363 Lund, Sweden.	Ramin.Massoumi@med.lu.se	Massoumi, Ramin/AAG-4786-2019	Masoumi, Katarzyna/0000-0002-9277-6505	Swedish Cancer Foundation; Swedish Medical Research Council; Royal Physiographic Society in Lund; Gunnar Nilsson Foundations; Gyllenstiernska Krapperupps Foundations; BioCARE; European Research Council (ERC), under the European Union [260460]	Swedish Cancer Foundation; Swedish Medical Research Council(Swedish Medical Research Council (SMRC)); Royal Physiographic Society in Lund; Gunnar Nilsson Foundations; Gyllenstiernska Krapperupps Foundations; BioCARE; European Research Council (ERC), under the European Union(European Research Council (ERC))	The plasmid for mammalian expression of His-SUMO1, His-SUMO2 and MYC-SUMO1 plasmids were a kind gift from Dr Frauke Melchior (ZMBH, Heidelberg, Germany). Flag-TRAF2 and Flag-TRAF6 plasmids were a kind gift from Dr Rene Bernards (The Netherlands Cancer Institute, Amsterdam, The Netherlands). We thank Dr Ingrid Ora for her critical reading of this manuscript. This work was supported by the Swedish Cancer Foundation, the Swedish Medical Research Council, the Royal Physiographic Society in Lund, the Gunnar Nilsson Foundations, the Gyllenstiernska Krapperupps Foundations, the BioCARE and by funding from the European Research Council (ERC), under the European Union's Seventh Framework Programme for Research and Technology Development (grant agreement no. 260460, awarded to RM).	ANDERSON DJ, 1986, CELL, V47, P1079, DOI 10.1016/0092-8674(86)90823-8; ANDERSON DJ, 1991, J NEUROSCI, V11, P3507; Bauters TGM, 2011, INT J CLIN PHARM-NET, V33, P597, DOI 10.1007/s11096-011-9519-9; Bignell GR, 2000, NAT GENET, V25, P160, DOI 10.1038/76006; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Bryan B, 2004, J BIOL CHEM, V279, P45824, DOI 10.1074/jbc.M406216200; Celay J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062771; Chen JQ, 2013, CURR OPIN IMMUNOL, V25, P4, DOI 10.1016/j.coi.2012.12.005; Cheung NKV, 2013, NAT REV CANCER, V13, P397, DOI 10.1038/nrc3526; Clagett-Dame M, 2006, J NEUROBIOL, V66, P739, DOI 10.1002/neu.20241; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Deyrieux AF, 2007, J CELL SCI, V120, P125, DOI 10.1242/jcs.03317; Feng ZW, 1999, J BIOL CHEM, V274, P30341, DOI 10.1074/jbc.274.43.30341; Fredlund E, 2008, P NATL ACAD SCI USA, V105, P14094, DOI 10.1073/pnas.0804455105; KAPLAN DR, 1993, NEURON, V11, P321, DOI 10.1016/0896-6273(93)90187-V; Kiningham KK, 2008, FREE RADICAL BIO MED, V44, P1610, DOI 10.1016/j.freeradbiomed.2008.01.015; KOGNER P, 1993, CANCER RES, V53, P2044; KOHL NE, 1984, SCIENCE, V226, P1335, DOI 10.1126/science.6505694; Komander D, 2008, MOL CELL, V29, P451, DOI 10.1016/j.molcel.2007.12.018; Komander D, 2009, EMBO REP, V10, P466, DOI 10.1038/embor.2009.55; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Lee Moon H, 2011, MOL CELL, V43, P180; Liu TX, 2000, BLOOD, V96, P1496, DOI 10.1182/blood.V96.4.1496.h8001496_1496_1504; Lovat PE, 1997, JNCI-J NATL CANCER I, V89, P446, DOI 10.1093/jnci/89.6.446; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Maris JM, 2010, NEW ENGL J MED, V362, P2202, DOI 10.1056/NEJMra0804577; Massoumi R, 2006, CELL, V125, P665, DOI 10.1016/j.cell.2006.03.041; Massoumi R, 2011, FUTURE ONCOL, V7, P285, DOI 10.2217/FON.10.187; Matthay KK, 2009, J CLIN ONCOL, V27, P1007, DOI 10.1200/JCO.2007.13.8925; Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601; Molenaar JJ, 2012, NATURE, V483, P589, DOI 10.1038/nature10910; O'Donnell MA, 2011, NAT CELL BIOL, V13, P1437, DOI 10.1038/ncb2362; ORTOFT E, 1993, MOL CELL NEUROSCI, V4, P549, DOI 10.1006/mcne.1993.1068; PAHLMAN S, 1984, CELL DIFFER DEV, V14, P135, DOI 10.1016/0045-6039(84)90038-1; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SIDELL N, 1983, EXP CELL RES, V148, P21, DOI 10.1016/0014-4827(83)90184-2; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Wagner LM, 2009, J CELL BIOCHEM, V107, P46, DOI 10.1002/jcb.22094; Westermark UK, 2011, SEMIN CANCER BIOL, V21, P256, DOI 10.1016/j.semcancer.2011.08.001; Wilkinson KA, 2010, BRAIN RES REV, V64, P195, DOI 10.1016/j.brainresrev.2010.04.002; Wright A, 2007, DEV CELL, V13, P705, DOI 10.1016/j.devcel.2007.09.007	43	25	26	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 23	2015	34	17					2251	2260		10.1038/onc.2014.159	http://dx.doi.org/10.1038/onc.2014.159			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG7HG	24909169	Green Submitted			2022-12-17	WOS:000353473000010
J	Sato, T; Takahashi, H; Hatakeyama, S; Iguchi, A; Ariga, T				Sato, T.; Takahashi, H.; Hatakeyama, S.; Iguchi, A.; Ariga, T.			The TRIM-FLMN protein TRIM45 directly interacts with RACK1 and negatively regulates PKC-mediated signaling pathway	ONCOGENE			English	Article							KINASE-C; CANCER-CELLS; MAP KINASES; TRANSCRIPTION; ACTIVATION; RECEPTOR; SITE; MECHANISMS; STRESS; FAMILY	The receptor for activated C-kinase (RACK1), a scaffolding protein that participates in the protein kinase C (PKC) signaling pathway, has an important role in shuttling active PKCs to its substrate. Indeed, recent studies have revealed that RACK1 has an important role in tumorigenesis and that enhancement of the feed-forward mechanism of the c-Jun N-terminal kinase (JNK)-Jun pathway via RACK1 is associated with constitutive activation of MEK (MAPK-ERK kinase)-ERK (extracellular signal-regulated kinase) signaling in human melanoma cells. Taken together, RACK1 additionally has a very important role in the mitogen-activated protein kinase (MAPK) signaling pathway. Here, we show that one of the tripartite motif-containing (TRIM) family ubiquitin ligases, TRIM45, is a novel RACK1-interacting protein and downregulates MAPK signal transduction. Importantly, the expression of TRIM45 is induced when growth-promoting extracellular stimuli activate the MAPK signaling pathway, resulting in attenuation of activation of the MAPK pathway. These findings suggest that TRIM45 functions as a member of the negative feedback loop of the MAPK pathway.	[Sato, T.; Iguchi, A.; Ariga, T.] Hokkaido Univ, Grad Sch Med, Dept Pediat, Sapporo, Hokkaido 0608638, Japan; [Sato, T.; Takahashi, H.; Hatakeyama, S.] Hokkaido Univ, Grad Sch Med, Dept Biochem, Sapporo, Hokkaido 0608638, Japan	Hokkaido University; Hokkaido University	Sato, T (corresponding author), Hokkaido Univ, Grad Sch Med, Dept Pediat, Kita Ku, Kita 15,Nishi 7, Sapporo, Hokkaido 0608638, Japan.	tomsato@med.hokudai.ac.jp	Hatakeyama, Shigetsugu/C-8333-2012	Hatakeyama, Shigetsugu/0000-0002-2150-9979	Ministry of Education, Culture, Sports, Science and Technology in Japan; Japan Foundation for Applied Enzymology; Children's Cancer Association of Japan; Grants-in-Aid for Scientific Research [24112006, 24390065] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology in Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Foundation for Applied Enzymology; Children's Cancer Association of Japan; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Dr Toshio Kitamura (Tokyo University) for the plasmid and cell lines. This work was supported in part by a research grant from Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology in Japan, Japan Foundation for Applied Enzymology, and Children's Cancer Association of Japan.	Adams DR, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-22; Al-Reefy S, 2010, ONCOGENE, V29, P5651, DOI 10.1038/onc.2010.291; Arimoto K, 2008, NAT CELL BIOL, V10, P1324, DOI 10.1038/ncb1791; Avruch J, 2007, BBA-MOL CELL RES, V1773, P1150, DOI 10.1016/j.bbamcr.2006.11.006; Bauman AL, 2002, NAT CELL BIOL, V4, pE203, DOI 10.1038/ncb0802-e203; Bourd-Boittin K, 2008, J BIOL CHEM, V283, P26000, DOI 10.1074/jbc.M709829200; Calvo F, 2010, BIOESSAYS, V32, P412, DOI 10.1002/bies.200900155; Cargnello M, 2011, MICROBIOL MOL BIOL R, V75, P50, DOI 10.1128/MMBR.00031-10; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; Chou YC, 1999, BBA-GENE STRUCT EXPR, V1489, P315, DOI 10.1016/S0167-4781(99)00213-4; Dorn GW, 2002, ANNU REV PHYSIOL, V64, P407, DOI 10.1146/annurev.physiol.64.081501.155903; Hatakeyama S, 2011, NAT REV CANCER, V11, P792, DOI 10.1038/nrc3139; He DY, 2010, J BIOL CHEM, V285, P19043, DOI 10.1074/jbc.M110.100693; Imajo M, 2006, IUBMB LIFE, V58, P312, DOI 10.1080/15216540600746393; Kano S, 2008, CANCER RES, V68, P5572, DOI 10.1158/0008-5472.CAN-07-6231; Kondoh K, 2007, BBA-MOL CELL RES, V1773, P1227, DOI 10.1016/j.bbamcr.2006.12.002; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lopez-Bergami P, 2005, MOL CELL, V19, P309, DOI 10.1016/j.molcel.2005.06.025; Lopez-Bergami P, 2008, INT J BIOCHEM CELL B, V40, P1055, DOI 10.1016/j.biocel.2007.11.011; Lopez-Bergami P, 2007, CANCER CELL, V11, P447, DOI 10.1016/j.ccr.2007.03.009; Lopez-Bergami P, 2010, NAT REV CANCER, V10, P65, DOI 10.1038/nrc2681; Maurer G, 2011, ONCOGENE, V30, P3477, DOI 10.1038/onc.2011.160; McCahill A, 2002, MOL PHARMACOL, V62, P1261, DOI 10.1124/mol.62.6.1261; Meroni G, 2005, BIOESSAYS, V27, P1147, DOI 10.1002/bies.20304; Miyajima N, 2008, CANCER RES, V68, P3486, DOI 10.1158/0008-5472.CAN-07-6059; Nisole S, 2005, NAT REV MICROBIOL, V3, P799, DOI 10.1038/nrmicro1248; Noguchi K, 2011, CARCINOGENESIS, V32, P995, DOI 10.1093/carcin/bgr068; Prusty BK, 2005, INT J CANCER, V113, P951, DOI 10.1002/ijc.20668; Quaderi NA, 1997, NAT GENET, V17, P285, DOI 10.1038/ng1197-285; Raman M, 2007, ONCOGENE, V26, P3100, DOI 10.1038/sj.onc.1210392; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; RON D, 1995, P NATL ACAD SCI USA, V92, P492, DOI 10.1073/pnas.92.2.492; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Rotenberg SA, 1998, J BIOL CHEM, V273, P2390, DOI 10.1074/jbc.273.4.2390; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Sato T, 2012, J CELL SCI, V125, P1544, DOI 10.1242/jcs.095273; Sato T, 2011, J CELL SCI, V124, P3492, DOI 10.1242/jcs.088799; Shi S, 2012, J BIOL CHEM, V287, P7845, DOI 10.1074/jbc.M111.315416; Shibata M, 2012, BIOCHEM BIOPH RES CO, V423, P104, DOI 10.1016/j.bbrc.2012.05.090; Soh JW, 2003, J BIOL CHEM, V278, P34709, DOI 10.1074/jbc.M302016200; Takahashi H, 2005, J BIOL CHEM, V280, P5611, DOI 10.1074/jbc.M408130200; Takahashi H, 2011, CELL, V146, P92, DOI 10.1016/j.cell.2011.06.005; Wang YQ, 2004, BIOCHEM BIOPH RES CO, V323, P9, DOI 10.1016/j.bbrc.2004.08.048; Wei WY, 2005, CANCER CELL, V8, P25, DOI 10.1016/j.ccr.2005.06.005; Wiggin GR, 2002, MOL CELL BIOL, V22, P2871, DOI 10.1128/MCB.22.8.2871-2881.2002; Zhang WZ, 2008, J BIOL CHEM, V283, P16416, DOI 10.1074/jbc.M802360200	47	25	26	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	2015	34	10					1280	1291		10.1038/onc.2014.68	http://dx.doi.org/10.1038/onc.2014.68			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC9JX	24681954				2022-12-17	WOS:000350687100008
J	Gillam, MP; Nimbalkar, D; Sun, L; Christov, K; Ray, D; Kaldis, P; Liu, X; Kiyokawa, H				Gillam, M. P.; Nimbalkar, D.; Sun, L.; Christov, K.; Ray, D.; Kaldis, P.; Liu, X.; Kiyokawa, H.			MEN1 tumorigenesis in the pituitary and pancreatic islet requires Cdk4 but not Cdk2	ONCOGENE			English	Article						cell cycle; menin; insulinoma; pituitary; knockout mice	MULTIPLE-ENDOCRINE-NEOPLASIA; DEPENDENT KINASE INHIBITORS; BETA-CELL PROLIFERATION; MAMMARY TUMORIGENESIS; GERMLINE MUTATIONS; KNOCKOUT MICE; MUTANT MICE; TUMORS; P27(KIP1); TYPE-1	Recent studies suggest that physiological and tumorigenic proliferation of mammalian cells is controlled by multiple cyclin-dependent kinases (CDKs) largely in tissue-specific manners. We and others previously demonstrated that adult mice deficient for the Cyclin D partner CDK4 (Cdk4(-/-) mice) exhibit hypoplasia in the pituitary and pancreatic islet due to primary postnatal defects in proliferation. Intriguingly, those neuroendocrine tissues affected in Cdk4(-/-) mice are the primary targets of tumorigenesis in the syndrome of multiple endocrine neoplasia type-1 (MEN1). Mice with heterozygous disruption of the tumor suppressor Men1 gene (Men1(+/-)) develop tumors in the pituitary, pancreatic islets and other neuroendocrine tissues, which is analogous to humans with MEN1 mutations. To explore the genetic interactions between loss of Men1 and activation of CDKs, we examined the impact of Cdk4 or Cdk2 disruption on tumorigenesis in Men1(+/-) mice. A majority of Men1(+/-) mice with wild-type CDKs developed pituitary and islet tumors by 15 months of age. Strikingly, Men1(+/-); Cdk4(-/-) mice did not develop any tumors, and their islets and pituitaries remained hypoplastic with decreased proliferation. In contrast, Men1(+/-); Cdk2(-/-) mice showed pituitary and islet tumorigenesis comparable to those in Men1(+/-) mice. Pituitaries of Men1(+/-); Cdk4(-/-) mice showed no signs of loss of heterozygosity (LOH) in the Men1 locus, whereas tumors in Men1(+/-) mice and Men1(+/-); Cdk2(-/-) mice exhibited LOH. Consistently, CDK4 knockdown in INS-1 insulinoma cells inhibited glucose-stimulated cell cycle progression with a significant decrease in phosphorylation of retinoblastoma protein (RB) at specific sites including Ser780. CDK2 knockdown had minimum effects on RB phosphorylation and cell cycle progression. These data suggest that CDK4 is a critical downstream target of MEN1-dependent tumor suppression and is required for tumorigenic proliferation in the pituitary and pancreatic islet, whereas CDK2 is dispensable for tumorigenesis in these neuroendocrine cell types.	[Gillam, M. P.; Nimbalkar, D.; Sun, L.; Liu, X.; Kiyokawa, H.] Northwestern Univ, Feinberg Sch Med, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60611 USA; [Christov, K.] Univ Illinois, Dept Surg Oncol, Chicago, IL USA; [Ray, D.] Univ Michigan, Sch Med, Dept Radiat Oncol, Ann Arbor, MI USA; [Kaldis, P.] ASTAR, IMCB, Singapore, Singapore; [Kaldis, P.] Natl Univ Singapore, Dept Biochem, Singapore 117548, Singapore; [Kiyokawa, H.] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Michigan System; University of Michigan; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center	Gillam, MP (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Mol Pharmacol & Biol Chem, 303 E Super St,Lurie 3-113, Chicago, IL 60611 USA.	Mary.p.gillam@gmail.com; kiyokawa@northwestern.edu	Kaldis, Philipp/G-2714-2010	Kaldis, Philipp/0000-0002-7247-7591; Kiyokawa, Hiroaki/0000-0002-7942-6455	National Institutes of Health [R01-HD38085, CA100204, CA112282, DK066044]; Lynn Sage Cancer Research Foundation; Phi Beta Psi Sorority; Searle Leadership Fund; Zell Fund; H. Foundation; Director Fund of Robert H. Lurie Comprehensive Cancer Center; Department of Molecular Pharmacology and Biological Chemistry; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD038085] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA112282, R01CA100204] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK066044] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Lynn Sage Cancer Research Foundation; Phi Beta Psi Sorority; Searle Leadership Fund; Zell Fund; H. Foundation; Director Fund of Robert H. Lurie Comprehensive Cancer Center; Department of Molecular Pharmacology and Biological Chemistry; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This paper is dedicated in fond memory to Patricia Lorenzo, a former member of the Molecular Oncogenesis NCI study section and the University of Hawaii Cancer Center, who brightened deliberations with her compassion, affability and dedication. Her remarkable courage in the face of terminal cancer has been inspirational. We thank William Lowe Jr, Alfred Rademaker, Evan Osmundson, Finola Moore and Yiran Zhou for their scientific advice, and Thomas O'Grady, Brian Zwecker, Alba Santana and Suchitra Prasad for their excellent technical assistance. This work was supported by funds from the National Institutes of Health (R01-HD38085, CA100204, and CA112282 to HK and DK066044 to MPG), Lynn Sage Cancer Research Foundation, Phi Beta Psi Sorority, Searle Leadership Fund, Zell Fund, H. Foundation, the Director Fund of Robert H. Lurie Comprehensive Cancer Center and the Department of Molecular Pharmacology and Biological Chemistry.	Agudo J, 2008, DIABETOLOGIA, V51, P1862, DOI 10.1007/s00125-008-1087-8; Akerblom B, 2007, MOL CELL ENDOCRINOL, V270, P73, DOI 10.1016/j.mce.2007.02.009; Aleem E, 2005, NAT CELL BIOL, V7, P831, DOI 10.1038/ncb1284; Bazzi W, 2008, GASTROENTEROLOGY, V135, P1698, DOI 10.1053/j.gastro.2008.07.031; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Berthet C, 2006, DEV CELL, V10, P563, DOI 10.1016/j.devcel.2006.03.004; Bertolino P, 2003, MOL ENDOCRINOL, V17, P1880, DOI 10.1210/me.2003-0154; Crabtree JS, 2001, P NATL ACAD SCI USA, V98, P1118, DOI 10.1073/pnas.98.3.1118; Dor Y, 2004, NATURE, V429, P41, DOI 10.1038/nature02520; Fatrai S, 2006, DIABETES, V55, P318, DOI 10.2337/diabetes.55.02.06.db05-0757; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fiaschi-Taesch N, 2009, DIABETES, V58, P882, DOI 10.2337/db08-0631; Franklin DS, 2000, MOL CELL BIOL, V20, P6147, DOI 10.1128/MCB.20.16.6147-6158.2000; Franklin DS, 1998, GENE DEV, V12, P2899, DOI 10.1101/gad.12.18.2899; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Harding B, 2009, ENDOCR-RELAT CANCER, V16, P1313, DOI 10.1677/ERC-09-0082; Jirawatnotai S, 2004, J BIOL CHEM, V279, P51100, DOI 10.1074/jbc.M409080200; Jirawatnotai S, 2003, J BIOL CHEM, V278, P17021, DOI 10.1074/jbc.M301206200; Karnik SK, 2007, SCIENCE, V318, P806, DOI 10.1126/science.1146812; Karnik SK, 2005, P NATL ACAD SCI USA, V102, P14659, DOI 10.1073/pnas.0503484102; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Malumbres M, 2004, CELL, V118, P493, DOI 10.1016/j.cell.2004.08.002; Malumbres M, 2007, CURR OPIN GENET DEV, V17, P60, DOI 10.1016/j.gde.2006.12.008; Martin J, 2003, ONCOGENE, V22, P5261, DOI 10.1038/sj.onc.1206506; Marx SJ, 2005, NAT REV CANCER, V5, P367, DOI 10.1038/nrc1610; Mettus RV, 2003, ONCOGENE, V22, P8413, DOI 10.1038/sj.onc.1206888; Milne TA, 2005, P NATL ACAD SCI USA, V102, P749, DOI 10.1073/pnas.0408836102; Molven A, 2005, GENE CHROMOSOME CANC, V44, P10, DOI 10.1002/gcc.20202; Mould AW, 2007, INT J CANCER, V121, P776, DOI 10.1002/ijc.22734; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Pannett AAJ, 2001, J CLIN ENDOCR METAB, V86, P4371, DOI 10.1210/jc.86.9.4371; Pei XH, 2004, MOL CELL BIOL, V24, P6653, DOI 10.1128/mcb.24.15.6653-6664.2004; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; Ray D, 2007, CANCER RES, V67, P984, DOI 10.1158/0008-5472.CAN-06-3927; Ray D, 2011, NEOPLASIA, V13, P439, DOI 10.1593/neo.101704; Sayo Y, 2002, ENDOCRINOLOGY, V143, P2437, DOI 10.1210/en.143.6.2437; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Sherr CJ, 2000, CANCER RES, V60, P3689; Soufir N, 1998, HUM MOL GENET, V7, P209, DOI 10.1093/hmg/7.2.209; Tang LH, 2012, CLIN CANCER RES, V18, P4612, DOI 10.1158/1078-0432.CCR-11-3264; Tsutsui T, 1999, MOL CELL BIOL, V19, P7011; Wu Xinjiang, 2008, Curr Mol Med, V8, P805, DOI 10.2174/156652408786733702; Yu QY, 2006, CANCER CELL, V9, P23, DOI 10.1016/j.ccr.2005.12.012; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	45	25	30	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2015	34	7					932	938		10.1038/onc.2014.3	http://dx.doi.org/10.1038/onc.2014.3			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB2QF	24531709	Green Accepted			2022-12-17	WOS:000349472000013
J	Tada, Y; Yamaguchi, Y; Kinjo, T; Song, X; Akagi, T; Takamura, H; Ohta, T; Yokota, T; Koide, H				Tada, Y.; Yamaguchi, Y.; Kinjo, T.; Song, X.; Akagi, T.; Takamura, H.; Ohta, T.; Yokota, T.; Koide, H.			The stem cell transcription factor ZFP57 induces IGF2 expression to promote anchorage-independent growth in cancer cells	ONCOGENE			English	Article						ZFP57; IGF2; anchorage-independent growth; HT1080; transformation	SELF-RENEWAL; DNA METHYLATION; PLURIPOTENCY; NANOG; GENE; ACTIVATION; OCT-3/4; DIFFERENTIATION; IDENTIFICATION; MAINTENANCE	Several common biological properties between cancer cells and embryonic stem (ES) cells suggest the possibility that some genes expressed in ES cells might have important roles in cancer cell growth. The transcription factor ZFP57 is expressed in self-renewing ES cells and its expression level decreases during ES cell differentiation. This study showed that ZFP57 is involved in the anchorage-independent growth of human fibrosarcoma HT1080 cells in soft agar. ZFP57 overexpression enhanced, whereas knockdown suppressed, HT1080 tumor formation in nude mice. Furthermore, ZFP57 regulates the expression of insulin-like growth factor 2 (IGF2), which has a critical role in ZFP57-induced anchorage-independent growth. ZFP57 also promotes anchorage-independent growth in ES cells and immortal fibroblasts. Finally, immunohistochemical analysis revealed that ZFP57 is overexpressed in human cancer clinical specimens. Taken together, these results suggest that the ES-specific transcription factor ZFP57 is a novel oncogene.	[Tada, Y.; Kinjo, T.; Song, X.; Akagi, T.; Yokota, T.; Koide, H.] Kanazawa Univ, Grad Sch Med Sci, Dept Stem Cell Biol, Kanazawa, Ishikawa 9208640, Japan; [Yamaguchi, Y.; Takamura, H.; Ohta, T.] Kanazawa Univ, Grad Sch Med Sci, Dept Surg Gastroenterol, Kanazawa, Ishikawa 9208640, Japan	Kanazawa University; Kanazawa University	Koide, H (corresponding author), Kanazawa Univ, Grad Sch Med Sci, Dept Stem Cell Biol, 13-1 Takara Machi, Kanazawa, Ishikawa 9208640, Japan.	hkoide@med.kanazawa-u.ac.jp	Yokota, Takashi/J-8483-2015; Akagi, Tadayuki/E-1078-2011	Akagi, Tadayuki/0000-0002-1733-9452; Koide, Hiroshi/0000-0001-5916-3179; Kinjo, Tomoaki/0000-0003-0939-7756	Ministry of Education, Culture, Sports, Science and Technology of Japan; Hokkoku Foundation for Cancer Research; Cancer Research Institute, Kanazawa University	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Hokkoku Foundation for Cancer Research; Cancer Research Institute, Kanazawa University	We are grateful to Drs Chuanhai Sun and Hitoshi Niwa for providing pCAGPMN(PvuII-MfeI)- CreER and pBRPyCAG-fKlf4-DsRed-IP, respectively. We also thank the Center for Biomedical Research and Education at Kanazawa University for the use of their DNA sequencer. This work was partly supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan, a grant from the Hokkoku Foundation for Cancer Research and an Extramural Collaborative Research Grant from the Cancer Research Institute, Kanazawa University.	Akagi T, 2005, BIOCHEM BIOPH RES CO, V331, P23, DOI 10.1016/j.bbrc.2005.03.118; Alonso MBD, 2004, J BIOL CHEM, V279, P25653, DOI 10.1074/jbc.M400415200; Baglivo I, 2013, FEBS LETT, V587, P1474, DOI 10.1016/j.febslet.2013.02.045; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Chambers I, 2007, NATURE, V450, P1230, DOI 10.1038/nature06403; Chao W, 2008, CYTOKINE GROWTH F R, V19, P111, DOI 10.1016/j.cytogfr.2008.01.005; CIFONE MA, 1980, P NATL ACAD SCI-BIOL, V77, P1039, DOI 10.1073/pnas.77.2.1039; Evangelista M, 2006, CLIN CANCER RES, V12, P5924, DOI 10.1158/1078-0432.CCR-06-1736; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Falix FA, 2012, BBA-MOL BASIS DIS, V1822, P988, DOI 10.1016/j.bbadis.2012.02.003; Farazi TA, 2011, J PATHOL, V223, P102, DOI 10.1002/path.2806; Gilmore AP, 2005, CELL DEATH DIFFER, V12, P1473, DOI 10.1038/sj.cdd.4401723; Holm TM, 2005, CANCER CELL, V8, P275, DOI 10.1016/j.ccr.2005.09.007; Huarte M, 2010, HUM MOL GENET, V19, pR152, DOI 10.1093/hmg/ddq353; Jelinic P, 2007, J PATHOL, V211, P261, DOI 10.1002/path.2116; Jeter CR, 2009, STEM CELLS, V27, P993, DOI 10.1002/stem.29; Li XJ, 2008, DEV CELL, V15, P547, DOI 10.1016/j.devcel.2008.08.014; Loh YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760; Lui JC, 2013, P NATL ACAD SCI USA, V110, P6181, DOI 10.1073/pnas.1219079110; Mackay DJG, 2008, NAT GENET, V40, P949, DOI 10.1038/ng.187; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; Masui S, 2007, NAT CELL BIOL, V9, P625, DOI 10.1038/ncb1589; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Mori S, 2009, ONCOGENE, V28, P2796, DOI 10.1038/onc.2009.139; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Niwa H, 2007, DEVELOPMENT, V134, P635, DOI 10.1242/dev.02787; Ogawa K, 2006, BIOCHEM BIOPH RES CO, V343, P159, DOI 10.1016/j.bbrc.2006.02.127; OKAZAKI S, 1994, J BIOL CHEM, V269, P6900; Polakis P, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008052; Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536; Quenneville S, 2011, MOL CELL, V44, P361, DOI 10.1016/j.molcel.2011.08.032; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Royo H, 2008, BIOL CELL, V100, P149, DOI 10.1042/BC20070126; Samani AA, 2007, ENDOCR REV, V28, P20, DOI 10.1210/er.2006-0001; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Schoonjans K, 2005, P NATL ACAD SCI USA, V102, P2058, DOI 10.1073/pnas.0409756102; Smith AG, 2001, ANNU REV CELL DEV BI, V17, P435, DOI 10.1146/annurev.cellbio.17.1.435; Taddei ML, 2012, J PATHOL, V226, P380, DOI 10.1002/path.3000; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Takao Y, 2007, BIOCHEM BIOPH RES CO, V353, P699, DOI 10.1016/j.bbrc.2006.12.072; Ueda A., 2012, J JUZEN MED SOC, V121, P38; Yoshida-Koide U, 2004, BIOCHEM BIOPH RES CO, V313, P475, DOI 10.1016/j.bbrc.2003.11.138; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Zuo XP, 2012, J BIOL CHEM, V287, P2107, DOI 10.1074/jbc.M111.322644	49	25	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2015	34	6					752	760		10.1038/onc.2013.599	http://dx.doi.org/10.1038/onc.2013.599			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DG	24469060	Green Submitted			2022-12-17	WOS:000348853800008
J	Lei, Y; Henderson, BR; Emmanuel, C; Harnett, PR; Defazio, A				Lei, Y.; Henderson, B. R.; Emmanuel, C.; Harnett, P. R.; deFazio, A.			Inhibition of ANKRD1 sensitizes human ovarian cancer cells to endoplasmic reticulum stress-induced apoptosis	ONCOGENE			English	Article						ANKRD1; apoptosis; ER stress and ER stress-induced apoptosis; ovarian cancer; platinum-based therapy	ANKYRIN REPEAT PROTEIN; X-LINKED INHIBITOR; CISPLATIN-INDUCED APOPTOSIS; CARCINOMA-CELLS; MELANOMA-CELLS; AKT PHOSPHORYLATION; SKELETAL-MUSCLE; CHOP GADD153; IN-VITRO; DEATH	High expression of Ankyrin Repeat Domain 1 (ANKRD1) in ovarian carcinoma is associated with poor survival, and in ovarian cancer cell lines is associated with platinum resistance. Importantly, decreasing ANKRD1 expression using siRNA increases cisplatin sensitivity. In this study, we investigated possible mechanisms underlying the association of ANKRD1 with cisplatin response. We first demonstrated that cisplatin-induced apoptosis in ovarian cancer cell lines was associated with endoplasmic reticulum (ER) stress, evidenced by induction of Glucose-Regulated Protein 78 (GRP78), growth arrest-and DNA damage-inducible gene 153 (GADD153) and increased intracellular Ca2+ release. The level of sensitivity to cisplatin-induced apoptosis was associated with ANKRD1 protein levels and poly (ADP-ribose) polymerase (PARP) cleavage. COLO 316 ovarian cancer cells, which express high ANKRD1 levels, were relatively resistant to cisplatin, and ER stress-induced apoptosis, whereas OAW42 and PEO14 cells, which express lower ANKRD1 levels, are more sensitive to ER stress-induced apoptosis. Furthermore, we show that overexpression of ANKRD1 attenuated cisplatin-induced cytotoxicity, and conversely siRNA knockdown of ANKRD1 sensitized ovarian cancer cells to cisplatin and ER stress-induced apoptosis associated with induction of GADD153, and downregulation of BCL2 and BCL-X-L. Taken together, these results suggest that ANKRD1 has a significant role in the regulation of apoptosis in human ovarian cancer cells, and is a potential molecular target to enhance sensitivity of ovarian cancer to chemotherapy.	[Lei, Y.; Emmanuel, C.; deFazio, A.] Westmead Hosp, Dept Gynaecol Oncol, Westmead, NSW 2145, Australia; [Lei, Y.; Henderson, B. R.; Emmanuel, C.; Harnett, P. R.; deFazio, A.] Univ Sydney, Westmead Inst Canc Res, Westmead Millennium Inst, Westmead, NSW 2154, Australia; [Harnett, P. R.; deFazio, A.] Westmead Hosp, Crown Princess Mary Canc Ctr, Westmead, NSW 2145, Australia	University of Sydney; University of Sydney; Westmead Institute for Medical Research; University of Sydney	Defazio, A (corresponding author), Univ Sydney, Westmead Hosp, Dept Gynaecol Oncol, Westmead Millennium Inst, Westmead, NSW 2154, Australia.	anna.defazio@sydney.edu.au	DeFazio, Anna/O-2385-2019; Harnett, Paul R/D-4090-2014	DeFazio, Anna/0000-0003-0057-4744; Harnett, Paul R/0000-0001-7021-0642	Cancer Council New South Wales, Australia; Cancer Australia [632595]	Cancer Council New South Wales, Australia(Cancer Council New South Wales); Cancer Australia	This work was supported by grants from Cancer Council New South Wales, Australia and Cancer Australia (Project 632595). Special thanks to Dr Maggie Wang, Westmead Millennium Institute Flow Cytometry Facility, for her help with analysis.	Abedini MR, 2010, ONCOGENE, V29, P11, DOI 10.1038/onc.2009.300; Abedini MR, 2004, ONCOGENE, V23, P6997, DOI 10.1038/sj.onc.1207925; Adachi T, 2008, BIOCHEM BIOPH RES CO, V367, P377, DOI 10.1016/j.bbrc.2007.12.142; Ahmed AA, 2010, J PATHOL, V221, P49, DOI 10.1002/path.2696; Bakhshi J, 2008, APOPTOSIS, V13, P904, DOI 10.1007/s10495-008-0221-x; Boyce M, 2006, CELL DEATH DIFFER, V13, P363, DOI 10.1038/sj.cdd.4401817; Breckenridge DG, 2003, ONCOGENE, V22, P8608, DOI 10.1038/sj.onc.1207108; Bromati CR, 2011, AM J PHYSIOL-REG I, V300, pR92, DOI 10.1152/ajpregu.00169.2010; Chen R, 2011, FOLIA BIOL-PRAGUE, V57, P87; CHU W, 1995, J BIOL CHEM, V270, P10236, DOI 10.1074/jbc.270.17.10236; Corazzari M, 2007, BRIT J CANCER, V96, P1062, DOI 10.1038/sj.bjc.6603672; Dan HC, 2004, J BIOL CHEM, V279, P5405, DOI 10.1074/jbc.M312044200; Del Bello B, 2007, ONCOGENE, V26, P2717, DOI 10.1038/sj.onc.1210079; ENDRESEN PC, 1995, CYTOMETRY, V20, P162, DOI 10.1002/cyto.990200209; Ermak G, 2002, MOL IMMUNOL, V38, P713, DOI 10.1016/S0161-5890(01)00108-0; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Fraser M, 2003, CANCER RES, V63, P7081; Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384; Gorlach A, 2006, ANTIOXID REDOX SIGN, V8, P1391, DOI 10.1089/ars.2006.8.1391; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Guminski AD, 2002, LANCET ONCOL, V3, P312, DOI 10.1016/S1470-2045(02)00733-7; Han XJ, 2005, J BIOL CHEM, V280, P23122, DOI 10.1074/jbc.M501095200; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Hitomi J, 2004, J CELL BIOL, V165, P347, DOI 10.1083/jcb.200310015; Hu LM, 2002, CANCER RES, V62, P1087; Ishiguro N, 2002, AM J PATHOL, V160, P1767, DOI 10.1016/S0002-9440(10)61123-6; Ishiguro N, 2008, HUM PATHOL, V39, P1673, DOI 10.1016/j.humpath.2008.04.009; Jeyaseelan R, 1997, J BIOL CHEM, V272, P22800, DOI 10.1074/jbc.272.36.22800; Jiang CC, 2009, CARCINOGENESIS, V30, P197, DOI 10.1093/carcin/bgn220; Kidd VJ, 2000, SEMIN CELL DEV BIOL, V11, P191, DOI 10.1006/scdb.2000.0165; Kojic S, 2010, ARCH BIOCHEM BIOPHYS, V502, P60, DOI 10.1016/j.abb.2010.06.029; Labbe E, 2007, CANCER RES, V67, P75, DOI 10.1158/0008-5472.CAN-06-2559; Laure L, 2009, FEBS J, V276, P669, DOI 10.1111/j.1742-4658.2008.06814.x; Lee AH, 2003, P NATL ACAD SCI USA, V100, P9946, DOI 10.1073/pnas.1334037100; Lee MJ, 2009, EXP MOL MED, V41, P243, DOI 10.3858/emm.2009.41.4.027; Lei Y, 2005, PARASITOLOGY, V131, P467, DOI 10.1017/S003118200500805X; Li G, 2009, J CELL BIOL, V186, P783, DOI 10.1083/jcb.200904060; Li JL, 2001, ENDOCRINOLOGY, V142, P370, DOI 10.1210/en.142.1.370; Ma YJ, 2004, NAT REV CANCER, V4, P966, DOI 10.1038/nrc1505; Mandic A, 2003, J BIOL CHEM, V278, P9100, DOI 10.1074/jbc.M210284200; Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704; Masuda Y, 2007, BIOL PHARM BULL, V30, P880, DOI 10.1248/bpb.30.880; Matsumoto M, 1996, FEBS LETT, V395, P143, DOI 10.1016/0014-5793(96)01016-2; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Miller MK, 2003, J MOL BIOL, V333, P951, DOI 10.1016/j.jmb.2003.09.012; Nawrocki ST, 2005, CANCER RES, V65, P11658, DOI 10.1158/0008-5472.CAN-05-2370; PEREZSALA D, 1995, J CELL PHYSIOL, V163, P523, DOI 10.1002/jcp.1041630312; Peyrou M, 2007, TOXICOL SCI, V99, P346, DOI 10.1093/toxsci/kfm152; Pizzo P, 2007, TRENDS CELL BIOL, V17, P511, DOI 10.1016/j.tcb.2007.07.011; Puthalakath H, 2007, CELL, V129, P1337, DOI 10.1016/j.cell.2007.04.027; Rabik CA, 2008, J PHARMACOL EXP THER, V327, P442, DOI 10.1124/jpet.108.141291; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Rudner J, 2002, APOPTOSIS, V7, P441, DOI 10.1023/A:1020087108926; Sasaki H, 2000, CANCER RES, V60, P5659; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Scurr LL, 2008, CLIN CANCER RES, V14, P6924, DOI 10.1158/1078-0432.CCR-07-5189; Srivastava RK, 1999, MOL CELL BIOL, V19, P5659; Tombal B, 1999, CELL CALCIUM, V25, P19, DOI 10.1054/ceca.1998.0005; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Yacoub A, 2010, MOL PHARMACOL, V77, P298, DOI 10.1124/mol.109.061820; Yamaguchi H, 2004, J BIOL CHEM, V279, P45495, DOI 10.1074/jbc.M406933200; Yu H, 2011, EUR J CANCER, V47, P1585, DOI 10.1016/j.ejca.2011.01.019; Yuan ZQ, 2003, J BIOL CHEM, V278, P23432, DOI 10.1074/jbc.M302674200; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x; Zou YM, 1997, DEVELOPMENT, V124, P793	67	25	26	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2015	34	4					485	495		10.1038/onc.2013.566	http://dx.doi.org/10.1038/onc.2013.566			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ8FU	24531715				2022-12-17	WOS:000348451300009
J	Wu, L; de Bruin, A; Wang, H; Simmons, T; Cleghorn, W; Goldenberg, LE; Sites, E; Sandy, A; Trimboli, A; Fernandez, SA; Eng, C; Shapiro, C; Leone, G				Wu, L.; de Bruin, A.; Wang, H.; Simmons, T.; Cleghorn, W.; Goldenberg, L. E.; Sites, E.; Sandy, A.; Trimboli, A.; Fernandez, S. A.; Eng, C.; Shapiro, C.; Leone, G.			Selective roles of E2Fs for ErbB2-and Myc-mediated mammary tumorigenesis	ONCOGENE			English	Article						Myc; ErbB2; E2F; mammary tumorigenesis; oncogene	TRANSCRIPTION FACTOR; RB DEFICIENCY; MOUSE MODEL; OVEREXPRESSION; PROLIFERATION; EXPRESSION; CANCER; INACTIVATION; FAMILY; TARGET	Previous studies have demonstrated that cyclin D1, an upstream regulator of the Rb/E2F pathway, is an essential component of the ErbB2/Ras (but not the Wnt/Myc) oncogenic pathway in the mammary epithelium. However, the role of specific E2fs for ErbB2/Ras-mediated mammary tunnorigenesis remains unknown. Here, we show that in the majority of mouse and human primary mammary carcinomas with ErbB2/HER2 overexpression, E2f3a is up-regulated, raising the possibility that E2F3a is a critical effector of the ErbB2 oncogenic signaling pathway in the mammary gland. We examined the consequence of ablating individual E2fs in mice on ErbB2-triggered mammary tumorigenesis in comparison to a comparable Myc-driven mammary tumor model. We found that loss of E2f1 or E2f3 led to a significant delay in tumor onset in both oncogenic models, whereas loss of E2f2 accelerated mammary tumorigenesis driven by Myc-overexpression. Furthermore, southern blot analysis of final tumors derived from conditionally deleted E2f3(-/loxP) mammary glands revealed that there is a selection against E2f3(-/-) cells from developing mammary carcinomas, and that such selection pressure is higher in the presence of ErbB2 activation than in the presence of Myc activation. Taken together, our data suggest oncogenic activities of E2F1 and E2F3 in ErbB2- or Myc-triggered mammary tumorigenesis, and a tumor suppressor role of E2F2 in Myc-mediated mammary tumorigenesis.	[Wu, L.; de Bruin, A.; Wang, H.; Simmons, T.; Cleghorn, W.; Goldenberg, L. E.; Sites, E.; Sandy, A.; Trimboli, A.; Leone, G.] Ohio State Univ, Dept Mol Genet, Coll Biol Sci, Columbus, OH 43210 USA; [Wu, L.; de Bruin, A.; Wang, H.; Simmons, T.; Cleghorn, W.; Goldenberg, L. E.; Sites, E.; Sandy, A.; Trimboli, A.; Leone, G.] Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, Columbus, OH 43210 USA; [Wu, L.; de Bruin, A.; Wang, H.; Simmons, T.; Cleghorn, W.; Goldenberg, L. E.; Sites, E.; Sandy, A.; Trimboli, A.; Leone, G.] Ohio State Univ, Coll Med, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; [Fernandez, S. A.] Ohio State Univ, Ctr Biostat, Columbus, OH 43210 USA; [Eng, C.] Cleveland Clin, Genom Med Inst, Cleveland, OH 44106 USA; [Shapiro, C.] Ohio State Univ, Coll Med, Div Hematol & Oncol, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Cleveland Clinic Foundation; University System of Ohio; Ohio State University	Wu, L (corresponding author), Rutgers New Jersey Med Sch, Ctr Canc, 205 South Orange Ave, Newark, NJ 07103 USA.	wuli@njms.rutgers.edu	de Bruin, Alain/AAL-9195-2020	de Bruin, Alain/0000-0001-8579-2649	NIH [R01CA85619, R01CA82259, R01HD047470, R01 CA121275, P01CA097189]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD047470] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA016058, R01CA082259, R01CA121275, R01CA085619, P01CA097189] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank L Rawahneh, J Moffitt and N Lovett for technical assistance with histology. We also thank OSUCCC Shared Resources for microarray and nucleic acid. This work was funded by NIH grants to GL (R01CA85619, R01CA82259, R01HD047470, R01 CA121275; P01CA097189). GL is a Pew Charitable Trust Scholar and a Leukemia and Lymphoma Society Scholar.	Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; Agger K, 2005, ONCOGENE, V24, P780, DOI 10.1038/sj.onc.1208248; Baudino TA, 2003, MOL CELL, V11, P905, DOI 10.1016/S1097-2765(03)00102-3; Bracken AP, 2004, TRENDS BIOCHEM SCI, V29, P409, DOI 10.1016/j.tibs.2004.06.006; Conner EA, 2000, ONCOGENE, V19, P5054, DOI 10.1038/sj.onc.1203885; Cooper CS, 2006, LUNG CANCER, V54, P155, DOI 10.1016/j.lungcan.2006.07.005; DeGregori J, 2004, J CELL SCI, V117, P3411, DOI 10.1242/jcs.01189; DeGregori J, 2006, CURR MOL MED, V6, P739; Denchi EL, 2005, MOL CELL BIOL, V25, P2660, DOI 10.1128/MCB.25.7.2660-2672.2005; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Feber A, 2004, ONCOGENE, V23, P1627, DOI 10.1038/sj.onc.1207274; Foster CS, 2004, ONCOGENE, V23, P5871, DOI 10.1038/sj.onc.1207800; Fujiwara K, 2011, CANCER RES, V71, P1924, DOI 10.1158/0008-5472.CAN-10-2386; Gaubatz S, 2000, MOL CELL, V6, P729, DOI 10.1016/S1097-2765(00)00071-X; Grasemann C, 2005, ONCOGENE, V24, P6441, DOI 10.1038/sj.onc.1208792; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He YW, 2002, J BIOL CHEM, V277, P23493, DOI 10.1074/jbc.M202629200; Humbert PO, 2000, GENE DEV, V14, P690; Hurst CD, 2008, ONCOGENE, V27, P2716, DOI 10.1038/sj.onc.1210934; Iwamoto M, 2004, CANCER BIOL THER, V3, P395, DOI 10.4161/cbt.3.4.733; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Leone G, 2001, MOL CELL, V8, P105, DOI 10.1016/S1097-2765(01)00275-1; Leone G, 2000, MOL CELL BIOL, V20, P3626, DOI 10.1128/MCB.20.10.3626-3632.2000; Maddison LA, 2004, CANCER RES, V64, P6018, DOI 10.1158/0008-5472.CAN-03-2509; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Oeggerli M, 2004, ONCOGENE, V23, P5616, DOI 10.1038/sj.onc.1207749; Opavsky R, 2007, P NATL ACAD SCI USA, V104, P15400, DOI 10.1073/pnas.0706307104; Orlic M, 2006, GENE CHROMOSOME CANC, V45, P72, DOI 10.1002/gcc.20263; Paulson QX, 2006, CELL CYCLE, V5, P184, DOI 10.4161/cc.5.2.2307; Pusapati RV, 2010, MOL CARCINOGEN, V49, P152, DOI 10.1002/mc.20584; Rempel RE, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000640; Rounbehler RJ, 2002, CANCER RES, V62, P3276; SANDGREN EP, 1995, CANCER RES, V55, P3915; Scheijen B, 2004, J BIOL CHEM, V279, P10476, DOI 10.1074/jbc.M313682200; Sharma N, 2006, J BIOL CHEM, V281, P36124, DOI 10.1074/jbc.M604152200; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Simin K, 2004, PLOS BIOL, V2, P194, DOI 10.1371/journal.pbio.0020022; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Suzuki T, 1999, INT J CANCER, V81, P535, DOI 10.1002/(SICI)1097-0215(19990517)81:4<535::AID-IJC5>3.0.CO;2-4; Timmers C, 2007, MOL CELL BIOL, V27, P65, DOI 10.1128/MCB.02147-06; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zhou ZX, 2007, CANCER RES, V67, P5683, DOI 10.1158/0008-5472.CAN-07-0768; Zhou ZX, 2006, CANCER RES, V66, P7889, DOI 10.1158/0008-5472.CAN-06-0486; Ziebold U, 2003, MOL CELL BIOL, V23, P6542, DOI 10.1128/MCB.23.18.6542-6552.2003	50	25	26	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 2	2015	34	1					119	128		10.1038/onc.2013.511	http://dx.doi.org/10.1038/onc.2013.511			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB6MC	24276244	Green Accepted			2022-12-17	WOS:000349740100011
J	Zhong, J; Cao, RX; Liu, JH; Liu, YB; Wang, J; Liu, LP; Chen, YJ; Yang, J; Zhang, QH; Wu, Y; Ding, WJ; Hong, T; Xiao, XH; Zu, XY; Wen, GB				Zhong, J.; Cao, R-X; Liu, J-H; Liu, Y-B; Wang, J.; Liu, L-P; Chen, Y-J; Yang, J.; Zhang, Q-H; Wu, Y.; Ding, W-J; Hong, T.; Xiao, X-H; Zu, X-Y; Wen, G-B			Nuclear loss of protein arginine N-methyltransferase 2 in breast carcinoma is associated with tumor grade and overexpression of cyclin D1 protein	ONCOGENE			English	Article						nuclear loss; PRMT2; cyclin D1; breast cancer	ESTROGEN-RECEPTOR-ALPHA; GENE-EXPRESSION; KAPPA-B; IN-VIVO; CANCER; IDENTIFICATION; METHYLATION; PROMOTER; PRMT2; CELL	Human protein arginine N-methyltransferase 2 (PRMT2, HRMT1L1) is a protein that belongs to the arginine methyltransferase family, and it has diverse roles in transcriptional regulation through different mechanisms depending on its binding partners. In this study, we provide evidences for the negative effect of PRMT2 on breast cancer cell proliferation in vitro and in vivo. Morever, cyclin D1, one of the key modulators of cell cycle, was found to be downregulated by PRMT2, and PRMT2 was further shown to suppress the estrogen receptor alpha-binding affinity to the activator protein-1 (AP-1) site in cyclin D1 promoter through indirect binding with AP-1 site, resulting in the inhibition of cyclin D1 promoter activity in MCF-7 cells. Furthermore, a positive correlation between the expression of PRMT2 and cyclin D1 was confirmed in the breast cancer tissues by using tissue microarray assay. In addition, PRMT2 was found to show a high absent percentage in breast caner cell nuclei and the nuclear loss ratio of PRMT2 was demonstrated to positively correlate with cyclin D1 expression and the increasing tumor grade of invasive ductal carcinoma. Those results offer an essential insight into the effect of PRMT2 on breast carcinogenesis, and PRMT2 nuclear loss might be an important biological marker for the diagnosis of breast cancer.	[Zhong, J.; Cao, R-X; Liu, J-H; Liu, Y-B; Wang, J.; Liu, L-P; Chen, Y-J; Yang, J.; Zhang, Q-H; Wu, Y.; Ding, W-J; Hong, T.; Xiao, X-H; Zu, X-Y; Wen, G-B] Univ South China, Affiliated Hosp 1, Inst Clin Med, 69 Chuanshan Rd, Hengyang 421001, Peoples R China; [Cao, R-X; Liu, J-H; Yang, J.; Hong, T.; Xiao, X-H] Univ South China, Affiliated Hosp 1, Dept Metab & Endocrinol, Hengyang 421001, Peoples R China	University of South China; University of South China	Zu, XY (corresponding author), Univ South China, Affiliated Hosp 1, Inst Clin Med, 69 Chuanshan Rd, Hengyang 421001, Peoples R China.	zuxuyu0108@hotmail.com; wen_gb@hotmail.com	Zhong, Jing/M-1057-2018	Zhong, Jing/0000-0003-4593-4897	National Natural Science Foundation of P.R.China [31200573, 81272906, 81272355, 81172542]; Hunan Provincial Natural Science Foundation of China [12JJ3116]; Education Department of Hunan Province Youth Fund [12B108]	National Natural Science Foundation of P.R.China(National Natural Science Foundation of China (NSFC)); Hunan Provincial Natural Science Foundation of China(Natural Science Foundation of Hunan Province); Education Department of Hunan Province Youth Fund	This work is supported by projects from the National Natural Science Foundation of P.R.China (Grant No. 31200573, 81272906, 81272355 and 81172542), Hunan Provincial Natural Science Foundation of China (12JJ3116) and The Education Department of Hunan Province Youth Fund (12B108).	ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Arnold A, 2005, J CLIN ONCOL, V23, P4215, DOI 10.1200/JCO.2005.05.064; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Bartusel T, 2005, GENE, V351, P171, DOI 10.1016/j.gene.2005.03.035; Besson V, 2007, HUM MOL GENET, V16, P2040, DOI 10.1093/hmg/ddm152; Blythe SA, 2010, DEV CELL, V19, P220, DOI 10.1016/j.devcel.2010.07.007; Bocchinfuso WP, 1997, J MAMMARY GLAND BIOL, V2, P323, DOI 10.1023/A:1026339111278; Castro-Rivera E, 2001, J BIOL CHEM, V276, P30853, DOI 10.1074/jbc.M103339200; Chen SL, 2002, J BIOL CHEM, V277, P4324, DOI 10.1074/jbc.M109835200; Cheng ASL, 2006, MOL CELL, V21, P393, DOI 10.1016/j.molcel.2005.12.016; Chung KH, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl143; DeNardo DG, 2005, MOL ENDOCRINOL, V19, P362, DOI 10.1210/me.2004-0267; Eeckhoute J, 2006, GENE DEV, V20, P2513, DOI 10.1101/gad.1446006; El Messaoudi S, 2006, P NATL ACAD SCI USA, V103, P13351, DOI 10.1073/pnas.0605692103; Feng Y, 2007, P NATL ACAD SCI USA, V104, P14718, DOI 10.1073/pnas.0706933104; Ferguson AT, 1997, CRIT REV ONCOGENESIS, V8, P29, DOI 10.1615/CritRevOncog.v8.i1.20; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Ganesh L, 2006, MOL CELL BIOL, V26, P3864, DOI 10.1128/MCB.26.10.3864-3874.2006; Goulet I, 2007, J BIOL CHEM, V282, P33009, DOI 10.1074/jbc.M704349200; Herrmann F, 2009, J CELL SCI, V122, P667, DOI 10.1242/jcs.039933; Iwasaki H, 2010, CIRC RES, V107, P992, DOI 10.1161/CIRCRESAHA.110.225326; Katsanis N, 1997, MAMM GENOME, V8, P526, DOI 10.1007/s003359900491; Katzenellenbogen BS, 2000, RECENT PROG HORM RES, V55, P163; Katzenellenbogen BS, 2000, RECENT PROG HORM RES, V55, P194; Kawakubo H, 2006, CANCER RES, V66, P7075, DOI 10.1158/0008-5472.CAN-06-0379; Kim JK, 2009, J CELL PHYSIOL, V220, P292, DOI 10.1002/jcp.21791; Klein EA, 2008, J CELL SCI, V121, P3853, DOI 10.1242/jcs.039131; Lakowski TM, 2009, BIOCHEM J, V421, P253, DOI 10.1042/BJ20090268; Le Romancer M, 2011, ENDOCR REV, V32, P597, DOI 10.1210/er.2010-0016; Li HW, 2002, J BIOL CHEM, V277, P44623, DOI 10.1074/jbc.M206187200; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; Lukong KE, 2004, NAT STRUCT MOL BIOL, V11, P914, DOI 10.1038/nsmb1004-914; Marampon F, 2008, MOL BIOL CELL, V19, P2566, DOI 10.1091/mbc.E06-12-1110; McBride AE, 2001, CELL, V106, P5, DOI 10.1016/S0092-8674(01)00423-8; Meister G, 2002, EMBO J, V21, P5853, DOI 10.1093/emboj/cdf585; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Meyer R, 2007, J STEROID BIOCHEM, V107, P1, DOI 10.1016/j.jsbmb.2007.05.006; Ong CS, 2010, CANCER LETT, V298, P167, DOI 10.1016/j.canlet.2010.07.001; Qi C, 2002, J BIOL CHEM, V277, P28624, DOI 10.1074/jbc.M201053200; Sabbah M, 1999, P NATL ACAD SCI USA, V96, P11217, DOI 10.1073/pnas.96.20.11217; Saville B, 2000, J BIOL CHEM, V275, P5379, DOI 10.1074/jbc.275.8.5379; Sayeed A, 2007, CANCER RES, V67, P7746, DOI 10.1158/0008-5472.CAN-06-3724; Scott HS, 1998, GENOMICS, V48, P330, DOI 10.1006/geno.1997.5190; Shen Q, 2008, ONCOGENE, V27, P366, DOI 10.1038/sj.onc.1210643; Steeg PS, 1998, BREAST CANCER RES TR, V52, P17, DOI 10.1023/A:1006102916060; STEIN B, 1995, MOL CELL BIOL, V15, P4971; Takahashi-Yanaga F, 2008, CELL SIGNAL, V20, P581, DOI 10.1016/j.cellsig.2007.10.018; Tashiro E, 2007, CANCER SCI, V98, P629, DOI 10.1111/j.1349-7006.2007.00449.x; Thomassen M, 2009, BREAST CANCER RES TR, V113, P239, DOI 10.1007/s10549-008-9927-2; Torres-Padilla ME, 2007, NATURE, V445, P214, DOI 10.1038/nature05458; Ye XM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055615; Ye Y, 2010, ONCOGENE, V29, P1451, DOI 10.1038/onc.2009.433; Yildirim AO, 2006, AM J RESP CELL MOL, V35, P436, DOI 10.1165/rcmb.2006-0097OC; Yoshimoto T, 2006, EXP CELL RES, V312, P2040, DOI 10.1016/j.yexcr.2006.03.001; Zhong J, 2012, FEBS J, V279, P316, DOI 10.1111/j.1742-4658.2011.08426.x; Zhong J, 2011, GENE, V487, P1, DOI 10.1016/j.gene.2011.06.022; Zu XY, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2843	57	25	28	3	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 27	2014	33	48					5546	5558		10.1038/onc.2013.500	http://dx.doi.org/10.1038/onc.2013.500			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW1ZO	24292672				2022-12-17	WOS:000346087900007
J	Zheng, XQ; Guo, JP; Yang, H; Kanai, M; He, LL; Li, YY; Koomen, JM; Minton, S; Gao, M; Ren, XB; Coppola, D; Cheng, JQ				Zheng, X. Q.; Guo, J. P.; Yang, H.; Kanai, M.; He, L. L.; Li, Y. Y.; Koomen, J. M.; Minton, S.; Gao, M.; Ren, X. B.; Coppola, D.; Cheng, J. Q.			Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ER alpha in breast cancer	ONCOGENE			English	Article						Aurora-A; tamoxifen resistance; ER alpha; phosphorylation; transcriptional activation	ESTROGEN-RECEPTOR-ALPHA; ANTIESTROGEN RESISTANCE; ENDOCRINE RESISTANCE; MAMMARY EPITHELIUM; SERINE 305; KINASE; AMPLIFICATION; EXPRESSION; CELLS; OVEREXPRESSION	Despite the clinical success of tamoxifen, its resistance remains a major challenge in breast cancer. Here we show that Aurora-A determines tamoxifen sensitivity by regulation of oestrogen receptor (ER)alpha. Ectopic expression of Aurora-A decreases and depletion of Aurora-A enhances tamoxifen sensitivity in ER alpha-positive breast cancer. Elevated Aurora-A was significantly associated with the recurrence of ER alpha-positive tumours. Notably, Aurora-A inhibitor MLN8237, which is currently in clinical trial, synergizes with tamoxifen and overcomes tamoxifen resistance. Furthermore, Aurora-A interacts with and phosphorylates ER alpha on serine-167 and -305, leading to increase in ER alpha DNA-binding and transcriptional activity. Elevated levels of Aurora-A are significantly associated with disease-free survival in ER alpha-positive but not ER alpha-negative breast cancers. These data suggest that Aurora-A has a pivotal role in tamoxifen resistance and ER alpha is a bona fide substrate of Aurora-A. Thus, Aurora-A represents a prognostic marker in ER alpha-positive tumour and a critical therapeutic target in tamoxifen-resistant breast cancer, and Aurora-A inhibitor could be used as either an independent or concurrent agent in tamoxifen-resistant tumour.	[Zheng, X. Q.; Guo, J. P.; Yang, H.; Kanai, M.; He, L. L.; Li, Y. Y.; Koomen, J. M.; Cheng, J. Q.] H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, Tampa, FL 33612 USA; [Zheng, X. Q.; Gao, M.] Tianjin Med Univ, Canc Inst & Hosp, Natl Clin Res Ctr Canc, Dept Thyroid,Oncol Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China; [Zheng, X. Q.; Gao, M.] Tianjin Med Univ, Canc Inst & Hosp, Natl Clin Res Ctr Canc, Dept Neck Tumour,Oncol Key Lab Canc Prevent & The, Tianjin, Peoples R China; [Zheng, X. Q.; Ren, X. B.] Tianjin Med Univ, Canc Inst & Hosp, Natl Clin Res Ctr Canc, Dept Immunol,Oncol Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China; [Minton, S.] H Lee Moffitt Canc Ctr & Res Inst, Dept Womens Oncol, Tampa, FL 33612 USA; [Minton, S.; Coppola, D.] Res Inst, Tampa, FL USA; [Coppola, D.] H Lee Moffitt Canc Ctr & Res Inst, Dept Womens Pathol, Tampa, FL USA	H Lee Moffitt Cancer Center & Research Institute; Tianjin Medical University; Tianjin Medical University; Tianjin Medical University; H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute	Zheng, XQ (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, 12902 Magnolia Dr,SRB3, Tampa, FL 33612 USA.	jin.cheng@moffitt.org	Kanai, Motomu/J-6807-2016	Kanai, Motomu/0000-0003-1977-7648	NIH [CA160455]; Florida James and Esther King Biomedical Research Program [1KG02]; NATIONAL CANCER INSTITUTE [R01CA137041, R01CA160455, P30CA076292] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Florida James and Esther King Biomedical Research Program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We appreciate Dr Kenji Fukasawa for his scientific input. We are grateful for Tissue Procurement, DNA Sequence, Proteomics and Image Core Facilities at H. Lee Moffitt Cancer Center for providing cancer specimens, sequencing and cell apoptosis analysis. This work was partially supported by grants from NIH grant CA160455 (JQC) and Florida James and Esther King Biomedical Research Program 1KG02 (JQC).	Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Barkhem Tomas, 2004, Am J Pharmacogenomics, V4, P19, DOI 10.2165/00129785-200404010-00003; Bodvarsdottir SK, 2007, CANCER LETT, V248, P96, DOI 10.1016/j.canlet.2006.06.003; Bostner J, 2007, ONCOGENE, V26, P6997, DOI 10.1038/sj.onc.1210506; Bostner J, 2010, CLIN CANCER RES, V16, P1624, DOI 10.1158/1078-0432.CCR-09-1733; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Clarke R, 2003, ONCOGENE, V22, P7316, DOI 10.1038/sj.onc.1206937; Cutrupi S, 2012, ONCOGENE, V31, P4353, DOI 10.1038/onc.2011.627; D'Assoro AB, 2014, ONCOGENE, V33, P599, DOI 10.1038/onc.2012.628; Ferrari S, 2005, BIOCHEM J, V390, P293, DOI 10.1042/BJ20050343; Guo JP, 2010, J BIOL CHEM, V285, P3676, DOI 10.1074/jbc.M109.078212; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Harvey JM, 1999, J CLIN ONCOL, V17, P1474, DOI 10.1200/JCO.1999.17.5.1474; Holm C, 2009, J PATHOL, V217, P372, DOI 10.1002/path.2455; Holz MK, 2012, CELL CYCLE, V11, P3159, DOI 10.4161/cc.21194; Joel PB, 1998, MOL CELL BIOL, V18, P1978, DOI 10.1128/MCB.18.4.1978; JOHNSTON SRD, 1995, CANCER RES, V55, P3331; Jordan VC, 2007, J CLIN ONCOL, V25, P5815, DOI 10.1200/JCO.2007.11.3886; Klinge CM, 2001, NUCLEIC ACIDS RES, V29, P2905, DOI 10.1093/nar/29.14.2905; Kok M, 2011, BREAST CANCER RES TR, V125, P1, DOI 10.1007/s10549-010-0798-y; Le Romancer M, 2011, ENDOCR REV, V32, P597, DOI 10.1210/er.2010-0016; Li JJ, 2004, P NATL ACAD SCI USA, V101, P18123, DOI 10.1073/pnas.0408273101; Li QY, 2004, J BIOL CHEM, V279, P52175, DOI 10.1074/jbc.M406802200; Lim KH, 2010, MOL CELL BIOL, V30, P508, DOI 10.1128/MCB.00916-08; Lundgren K, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3161; Lupien M, 2010, GENE DEV, V24, P2219, DOI 10.1101/gad.1944810; LYKKESFELDT AE, 1994, CANCER RES, V54, P1587; Manfredi MG, 2011, CLIN CANCER RES, V17, P7614, DOI 10.1158/1078-0432.CCR-11-1536; Michalides R, 2004, CANCER CELL, V5, P597, DOI 10.1016/j.ccr.2004.05.016; Murphy LC, 2011, ENDOCR-RELAT CANCER, V18, pR1, DOI 10.1677/ERC-10-0070; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Nagashima T, 2007, J BIOL CHEM, V282, P4045, DOI 10.1074/jbc.M608653200; Ohishi T, 2010, CANCER RES, V70, P2041, DOI 10.1158/0008-5472.CAN-09-2008; Pugacheva EN, 2007, CELL, V129, P1351, DOI 10.1016/j.cell.2007.04.035; Qi WQ, 2011, BIOCHEM PHARMACOL, V81, P881, DOI 10.1016/j.bcp.2011.01.017; Ring A, 2004, ENDOCR-RELAT CANCER, V11, P643, DOI 10.1677/erc.1.00776; Sehdev V, 2012, MOL CANCER THER, V11, P763, DOI 10.1158/1535-7163.MCT-11-0623; TONETTI DA, 1995, ANTI-CANCER DRUG, V6, P498, DOI 10.1097/00001813-199508000-00002; Wang LH, 2010, CANCER RES, V70, P9118, DOI 10.1158/0008-5472.CAN-10-1246; Wang RA, 2002, EMBO J, V21, P5437, DOI 10.1093/emboj/cdf543; Wang X, 2006, ONCOGENE, V25, P7148, DOI 10.1038/sj.onc.1209707; Warner SL, 2003, MOL CANCER THER, V2, P589; Yang H, 2004, CANCER RES, V64, P463, DOI 10.1158/0008-5472.CAN-03-2907	44	25	27	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2014	33	42					4985	4996		10.1038/onc.2013.444	http://dx.doi.org/10.1038/onc.2013.444			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OB	24166501	Green Accepted			2022-12-17	WOS:000343768000003
J	Sparks, A; Dayal, S; Das, J; Robertson, P; Menendez, S; Saville, MK				Sparks, A.; Dayal, S.; Das, J.; Robertson, P.; Menendez, S.; Saville, M. K.			The degradation of p53 and its major E3 ligase Mdm2 is differentially dependent on the proteasomal ubiquitin receptor S5a	ONCOGENE			English	Article						p53; Mdm2; S5a; Rpn10; proteasome; proteasomal recognition	CONJUGATING ENZYMES; PROTEIN-DEGRADATION; 26S PROTEASOME; TUMOR-CELLS; SUBUNIT; ACTIVATION; BINDING; ONCOPROTEIN; RECOGNITION; SUBSTRATE	p53 and its major E3 ligase Mdm2 are both ubiquitinated and targeted to the proteasome for degradation. Despite the importance of this in regulating the p53 pathway, little is known about the mechanisms of proteasomal recognition of ubiquitinated p53 and Mdm2. In this study, we show that knockdown of the proteasomal ubiquitin receptor S5a/PSMD4/Rpn10 inhibits p53 protein degradation and results in the accumulation of ubiquitinated p53. Overexpression of a dominant-negative deletion of S5a lacking its ubiquitin-interacting motifs (UIM)s, but which can be incorporated into the proteasome, also causes the stabilization of p53. Furthermore, small-interferring RNA (siRNA) rescue experiments confirm that the UIMs of S5a are required for the maintenance of low p53 levels. These observations indicate that S5a participates in the recognition of ubiquitinated p53 by the proteasome. In contrast, targeting S5a has no effect on the rate of degradation of Mdm2, indicating that proteasomal recognition of Mdm2 can be mediated by an S5a-independent pathway. S5a knockdown results in an increase in the transcriptional activity of p53. The selective stabilization of p53 and not Mdm2 provides a mechanism for p53 activation. Depletion of S5a causes a p53-dependent decrease in cell proliferation, demonstrating that p53 can have a dominant role in the response to targeting S5a. This study provides evidence for alternative pathways of proteasomal recognition of p53 and Mdm2. Differences in recognition by the proteasome could provide a means to modulate the relative stability of p53 and Mdm2 in response to cellular signals. In addition, they could be exploited for p53-activating therapies. This work shows that the degradation of proteins by the proteasome can be selectively dependent on S5a in human cells, and that this selectivity can extend to an E3 ubiquitin ligase and its substrate.	[Sparks, A.; Dayal, S.; Das, J.; Saville, M. K.] Univ Dundee, Ninewells Hosp & Med Sch, Jacqui Wood Canc Ctr, Div Canc Res,Med Res Inst, Dundee DD1 9SY, Scotland; [Robertson, P.] Univ Dundee, Coll Life Sci, Div Mol Med, Dundee DD1 9SY, Scotland; [Menendez, S.] Univ Edinburgh, MRC, Ctr Regenerat Med, Edinburgh, Midlothian, Scotland	University of Dundee; University of Dundee; University of Edinburgh	Saville, MK (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Jacqui Wood Canc Ctr, Div Canc Res,Med Res Inst, James Arrott Dr, Dundee DD1 9SY, Scotland.	m.k.saville@dundee.ac.uk		Das, Joyutpal/0000-0002-9166-4624; Menendez, Sergio/0000-0002-7929-8641	Wellcome Trust [094208/Z/10/Z]; European Research Council; Cancer Research UK	Wellcome Trust(Wellcome TrustEuropean Commission); European Research Council(European Research Council (ERC)European Commission); Cancer Research UK(Cancer Research UK)	This work was funded by the Wellcome Trust (grant no. 094208/Z/10/Z), the European Research Council and Cancer Research UK.	Allende-Vega N, 2013, ONCOGENE, V32, P1, DOI 10.1038/onc.2012.38; Allende-Vega N, 2010, ONCOGENE, V29, P432, DOI 10.1038/onc.2009.330; Allende-Vega N, 2010, SEMIN CANCER BIOL, V20, P29, DOI 10.1016/j.semcancer.2009.10.004; Arlt A, 2009, ONCOGENE, V28, P3983, DOI 10.1038/onc.2009.264; Bedford L, 2010, TRENDS CELL BIOL, V20, P391, DOI 10.1016/j.tcb.2010.03.007; Boehringer J, 2012, BIOCHEM J, V448, P55, DOI 10.1042/BJ20120542; Bond GL, 2007, ONCOGENE, V26, P1317, DOI 10.1038/sj.onc.1210199; Bousquet-Dubouch MP, 2011, EXPERT REV PROTEOMIC, V8, P459, DOI 10.1586/EPR.11.41; Brignone C, 2004, ONCOGENE, V23, P4121, DOI 10.1038/sj.onc.1207540; Carter S, 2007, NAT CELL BIOL, V9, P428, DOI 10.1038/ncb1562; Cheok CF, 2007, MOL CANCER RES, V5, P1133, DOI 10.1158/1541-7786.MCR-07-0161; Crawford LJ, 2011, J CELL COMMUN SIGNAL, V5, P101, DOI 10.1007/s12079-011-0121-7; Cross B, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M111.228981; Dantuma NP, 2009, DNA REPAIR, V8, P449, DOI 10.1016/j.dnarep.2009.01.005; Dantuma NP, 2006, J CELL BIOL, V173, P19, DOI 10.1083/jcb.200510071; Dayal S, 2009, J BIOL CHEM, V284, P5030, DOI 10.1074/jbc.M805871200; Dick LR, 2010, DRUG DISCOV TODAY, V15, P243, DOI 10.1016/j.drudis.2010.01.008; Dikic I, 2009, NAT REV MOL CELL BIO, V10, P659, DOI 10.1038/nrm2767; Elangovan M, 2010, BIOCHEM BIOPH RES CO, V396, P425, DOI 10.1016/j.bbrc.2010.04.108; Elangovan M, 2009, BIOCHEM BIOPH RES CO, V388, P723, DOI 10.1016/j.bbrc.2009.08.078; Elsasser S, 2005, NAT CELL BIOL, V7, P742, DOI 10.1038/ncb0805-742; Fatimababy AS, 2010, FEBS J, V277, P796, DOI 10.1111/j.1742-4658.2009.07531.x; Finley D, 2009, ANNU REV BIOCHEM, V78, P477, DOI 10.1146/annurev.biochem.78.081507.101607; Fu HY, 2010, TRENDS PLANT SCI, V15, P375, DOI 10.1016/j.tplants.2010.03.004; Fu HY, 1998, J BIOL CHEM, V273, P1970, DOI 10.1074/jbc.273.4.1970; Gallastegui N, 2010, TRENDS BIOCHEM SCI, V35, P634, DOI 10.1016/j.tibs.2010.05.005; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Glockzin S, 2003, MOL CELL BIOL, V23, P8960, DOI 10.1128/MCB.23.24.8960-8969.2003; Gomez TA, 2011, BMC BIOL, V9, DOI 10.1186/1741-7007-9-33; Hamazaki J, 2007, MOL CELL BIOL, V27, P6629, DOI 10.1128/MCB.00509-07; Haririnia A, 2008, J MOL BIOL, V375, P979, DOI 10.1016/j.jmb.2007.11.016; Higashitsuji H, 2005, CANCER CELL, V8, P75, DOI 10.1016/j.ccr.2005.06.006; Hishiya A, 2006, EMBO J, V25, P554, DOI 10.1038/sj.emboj.7600945; Hiyama H, 1999, J BIOL CHEM, V274, P28019, DOI 10.1074/jbc.274.39.28019; Hock AK, 2013, BIOCHIM BIOPHYS ACTA; Husnjak K, 2008, NATURE, V453, P481, DOI 10.1038/nature06926; Inuzuka H, 2010, ONCOTARGET, V1, P685; Inuzuka H, 2010, CANCER CELL, V18, P147, DOI 10.1016/j.ccr.2010.06.015; Isasa M, 2010, MOL CELL, V38, P733, DOI 10.1016/j.molcel.2010.05.001; Itahana K, 2007, CANCER CELL, V12, P355, DOI 10.1016/j.ccr.2007.09.007; Jin Y, 2008, MOL CELL BIOL, V28, P1218, DOI 10.1128/MCB.01198-07; Kaeser MD, 2004, J BIOL CHEM, V279, P7598, DOI 10.1074/jbc.M311732200; Kaneko T, 2009, CELL, V137, P914, DOI 10.1016/j.cell.2009.05.008; Kaur M, 2007, ONCOGENE, V26, P1231, DOI 10.1038/sj.onc.1209865; Kawahara H, 2000, EMBO J, V19, P4144, DOI 10.1093/emboj/19.15.4144; Kim HT, 2009, EMBO J, V28, P1867, DOI 10.1038/emboj.2009.115; Kleijnen MF, 2003, MOL BIOL CELL, V14, P3868, DOI 10.1091/mbc.E02-11-0766; Kravtsova-Ivantsiv Y, 2012, J CELL SCI, V125, P539, DOI 10.1242/jcs.093567; Kulikov R, 2010, P NATL ACAD SCI USA, V107, P10038, DOI 10.1073/pnas.0911716107; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Lee MJ, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.R110.003871; Linares LK, 2007, NAT CELL BIOL, V9, P331, DOI 10.1038/ncb1545; Lipinszki Z, 2012, BIOCHEMISTRY-US, V51, P2461, DOI 10.1021/bi3001006; Lipinszki Z, 2009, J CELL SCI, V122, P3083, DOI 10.1242/jcs.049049; Lozano G, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001115; Mayor T, 2007, MOL CELL PROTEOMICS, V6, P1885, DOI 10.1074/mcp.M700264-MCP200; Midorikawa Y, 2002, JPN J CANCER RES, V93, P636, DOI 10.1111/j.1349-7006.2002.tb01301.x; Mimnaugh EG, 1997, BIOCHEMISTRY-US, V36, P14418, DOI 10.1021/bi970998j; Nair VD, 2006, J BIOL CHEM, V281, P39550, DOI 10.1074/jbc.M603950200; Nickell S, 2009, P NATL ACAD SCI USA, V106, P11943, DOI 10.1073/pnas.0905081106; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Pei DS, 2012, ONCOTARGET, V3, P228; Peth A, 2010, MOL CELL, V40, P671, DOI 10.1016/j.molcel.2010.11.002; Raasi S, 2005, NAT STRUCT MOL BIOL, V12, P708, DOI 10.1038/nsmb962; Ruschak AM, 2011, J NATL CANCER I, V103, P1007, DOI 10.1093/jnci/djr160; Saeki Y, 2002, BIOCHEM BIOPH RES CO, V293, P986, DOI 10.1016/S0006-291X(02)00340-6; Santamaria PG, 2003, J BIOL CHEM, V278, P6687, DOI 10.1074/jbc.M209420200; Saville MK, 2004, J BIOL CHEM, V279, P42169, DOI 10.1074/jbc.M403362200; Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017; Shaughnessy JD, 2011, BLOOD, V118, P3512, DOI 10.1182/blood-2010-12-328252; Shen YH, 2011, TOXICOL LETT, V205, P341, DOI 10.1016/j.toxlet.2011.06.028; Stevenson LF, 2007, EMBO J, V26, P976, DOI 10.1038/sj.emboj.7601567; Stommel JM, 2004, EMBO J, V23, P1547, DOI 10.1038/sj.emboj.7600145; Su V, 2009, CELL MOL LIFE SCI, V66, P2819, DOI 10.1007/s00018-009-0048-9; Sun XM, 2004, MOL CELL, V14, P81, DOI 10.1016/S1097-2765(04)00156-X; Szlanka T, 2003, J CELL SCI, V116, P1023, DOI 10.1242/jcs.00332; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Verma R, 2004, CELL, V118, P99, DOI 10.1016/j.cell.2004.06.014; Wade M, 2006, J BIOL CHEM, V281, P33036, DOI 10.1074/jbc.M605405200; Wade M, 2010, TRENDS CELL BIOL, V20, P299, DOI 10.1016/j.tcb.2010.01.009; Wan Y, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-208; Wang YV, 2007, P NATL ACAD SCI USA, V104, P12365, DOI 10.1073/pnas.0701497104; Wei SJ, 2008, J MOL BIOL, V383, P693, DOI 10.1016/j.jmb.2008.08.044; Winget JM, 2010, MOL CELL, V38, P627, DOI 10.1016/j.molcel.2010.05.003; Wojcik C, 2002, J BIOL CHEM, V277, P6188, DOI 10.1074/jbc.M109996200; Xu Q, 2004, MOL CANCER THER, V3, P1263; Young P, 1998, J BIOL CHEM, V273, P5461, DOI 10.1074/jbc.273.10.5461; Zhu Q, 2007, ONCOGENE, V26, P4199, DOI 10.1038/sj.onc.1210191	88	25	25	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	2014	33	38					4685	4696		10.1038/onc.2013.413	http://dx.doi.org/10.1038/onc.2013.413			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AP3VX	24121268	Green Published, Green Accepted, hybrid			2022-12-17	WOS:000342007200007
J	Yao, R; Kondoh, Y; Natsume, Y; Yamanaka, H; Inoue, M; Toki, H; Takagi, R; Shimizu, T; Yamori, T; Osada, H; Noda, T				Yao, R.; Kondoh, Y.; Natsume, Y.; Yamanaka, H.; Inoue, M.; Toki, H.; Takagi, R.; Shimizu, T.; Yamori, T.; Osada, H.; Noda, T.			A small compound targeting TACC3 revealed its different spatiotemporal contributions for spindle assembly in cancer cells	ONCOGENE			English	Article						TACC3; TOGp; spindle assembly	KINETOCHORE FIBERS CONTRIBUTES; POLE ORGANIZATION; GENE-EXPRESSION; PROTEIN; MICROTUBULES; CH-TOG/XMAP215; CAPTURE; MITOSIS; MCAK	The mitotic spindle is assembled by the coordinated action of centrosomes and kinetochore microtubules. An evolutionally conserved protein family, transforming acidic coiled-coil (TACC), has been shown to be involved in this process. In humans, TACC3 is aberrantly expressed in a variety of human cancers, but its biological significance remains to be elucidated. Here, using a novel compound targeting TACC3, spindlactone (SPL), we show that the perturbation of TACC3 selectively inhibited the nucleation of centrosome microtubules in ovarian cancer cells. In contrast to centrosome microtubules, the kinetochore microtubules were robustly assembled, forming ectopic spindle poles that resulted in multipolar spindles. Interestingly, the extensive inhibition of TACC3 partially suppressed the nucleation of kinetochore microtubules. These dose-dependent effects of SPL were consistent with the results observed by the depletion of TACC3 and its binding partner, colonic and hepatic tumor overexpressed gene protein (TOGp). Although these proteins both have roles in the assembly of centrosome and kinetochore microtubules, their contributions were spatiotemporally different. Notably, SPL did not affect spindle assembly in normal cells. Furthermore, the oral administration of SPL significantly suppressed tumor growth in vivo. The unique mechanism of action of SPL not only enables it to be used as a tool to dissect the molecular basis of spindle assembly but also to provide a rationale for the use of TACC3 as a molecular target for cancer treatment. This rationale offers an opportunity to develop new strategies for cancer chemotherapy that overcome the limitations of microtubule toxins and expand their scope and clinical efficacy.	[Yao, R.; Natsume, Y.; Yamanaka, H.; Inoue, M.; Noda, T.] Japanese Fdn Canc Res, Dept Cell Biol, Inst Canc, Tokyo 1358550, Japan; [Kondoh, Y.; Takagi, R.; Shimizu, T.; Osada, H.] RIKEN, Chem Biol Core Facil, Adv Sci Inst, Saitama, Japan; [Inoue, M.; Toki, H.; Noda, T.] RIKEN, Bioresource Ctr, Team Adv Dev & Evaluat Human Dis Models, Tsukuba, Ibaraki, Japan; [Yamori, T.] Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Div Mol Pharmacol, Tokyo 1358550, Japan	Japanese Foundation for Cancer Research; RIKEN; RIKEN; Japanese Foundation for Cancer Research	Yao, R (corresponding author), Japanese Fdn Canc Res, Dept Cell Biol, Inst Canc, Koto Ku, 3-8-31 Ariake, Tokyo 1358550, Japan.	ryao@jfcr.or.jp	KONDOH, Yasumitsu/C-7461-2017; Osada, Hiroyuki/AAY-6254-2020; Osada, Hiroyuki/N-4305-2014; Noda, Tetsuo/B-1667-2016	KONDOH, Yasumitsu/0000-0002-3481-5481; 	Ministry of Education, Culture, Sports, Science and Technology of Japan; Grants-in-Aid for Scientific Research [26350976, 221S0001] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank T Hirota for providing the mCherry-CENP-A construct, K Yamazaki for preparing the cells for the JFCR cancer panels, K Honda for excellent technical support with the chemical screening and T Saito for supplying compounds from NPDepo. This study was performed as a research program of the Project for Development of Innovative Research on Cancer Therapeutics (P-Direct), Ministry of Education, Culture, Sports, Science and Technology of Japan, and was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Barr AR, 2008, MOL CELL BIOL, V28, P7199, DOI 10.1128/MCB.01040-08; Brouhard GJ, 2008, CELL, V132, P79, DOI 10.1016/j.cell.2007.11.043; Bruning-Richardson A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038945; Cappell KM, 2012, MOL CELL BIOL, V32, P4131, DOI 10.1128/MCB.00686-12; Cassimeris L, 2004, MOL BIOL CELL, V15, P1580, DOI 10.1091/mbc.E03-07-0544; CHARRASSE S, 1995, EUR J BIOCHEM, V234, P406, DOI 10.1111/j.1432-1033.1995.406_b.x; Cullen CF, 2001, NAT CELL BIOL, V3, P637, DOI 10.1038/35083025; DEBRABANDER M, 1981, CELL MOTIL CYTOSKEL, V1, P469, DOI 10.1002/cm.970010407; Fielding AB, 2011, ONCOGENE, V30, P521, DOI 10.1038/onc.2010.431; Gergely F, 2003, GENE DEV, V17, P336, DOI 10.1101/gad.245603; Harrison Michael R, 2009, Clin Adv Hematol Oncol, V7, P54; Hayama S, 2006, CANCER RES, V66, P10339, DOI 10.1158/0008-5472.CAN-06-2137; Hayashi K, 1999, J CELL SCI, V112, P1149; Holmfeldt P, 2004, EMBO J, V23, P627, DOI 10.1038/sj.emboj.7600076; Jackson JR, 2007, NAT REV CANCER, V7, P107, DOI 10.1038/nrc2049; Kavallaris M, 2010, NAT REV CANCER, V10, P194, DOI 10.1038/nrc2803; Kawatani M, 2008, P NATL ACAD SCI USA, V105, P11691, DOI 10.1073/pnas.0712239105; Keen N, 2004, NAT REV CANCER, V4, P927, DOI 10.1038/nrc1502; Khodjakov A, 2000, CURR BIOL, V10, P59, DOI 10.1016/S0960-9822(99)00276-6; Khodjakov A, 2003, J CELL BIOL, V160, P671, DOI 10.1083/jcb.200208143; Kiemeney LA, 2010, NAT GENET, V42, P415, DOI 10.1038/ng.558; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; Lauffart Brenda, 2005, BMC Womens Health, V5, P8, DOI 10.1186/1472-6874-5-8; Lee MJ, 2001, NAT CELL BIOL, V3, P643, DOI 10.1038/35083033; Lens SMA, 2010, NAT REV CANCER, V10, P825, DOI 10.1038/nrc2964; Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100; Maiato H, 2004, J CELL BIOL, V167, P831, DOI 10.1083/jcb.200407090; Mashima T, 2005, JNCI-J NATL CANCER I, V97, P765, DOI 10.1093/jnci/dji133; Miyazaki I, 2010, METHODS MOL BIOL, V669, P95, DOI 10.1007/978-1-60761-845-4_8; Peset I, 2008, TRENDS CELL BIOL, V18, P379, DOI 10.1016/j.tcb.2008.06.005; Peters DG, 2005, CANCER EPIDEM BIOMAR, V14, P1717, DOI 10.1158/1055-9965.EPI-04-0704; Radulescu AE, 2010, TRENDS CELL BIOL, V20, P214, DOI 10.1016/j.tcb.2010.01.003; Schneider L, 2007, J BIOL CHEM, V282, P29273, DOI 10.1074/jbc.M704151200; Shamma A, 2009, CANCER CELL, V15, P255, DOI 10.1016/j.ccr.2009.03.001; Still IH, 1999, GENOMICS, V58, P165, DOI 10.1006/geno.1999.5829; Strebhardt K, 2006, NAT REV CANCER, V6, P321, DOI 10.1038/nrc1841; Sudakin V, 2007, BIODRUGS, V21, P225, DOI 10.2165/00063030-200721040-00003; Tulu US, 2006, CURR BIOL, V16, P536, DOI 10.1016/j.cub.2006.01.060; Ulisse S, 2007, ENDOCR-RELAT CANCER, V14, P827, DOI 10.1677/ERC-07-0053; Urbanucci A, 2012, ONCOGENE, V31, P2153, DOI 10.1038/onc.2011.401; Wacker SA, 2012, NAT CHEM BIOL, V8, P235, DOI [10.1038/NCHEMBIO.779, 10.1038/nchembio.779]; Wollman R, 2005, CURR BIOL, V15, P828, DOI 10.1016/j.cub.2005.03.019; Yao R, 2012, ONCOGENE, V31, P135, DOI 10.1038/onc.2011.235; Yao R, 2007, CANCER SCI, V98, P555, DOI 10.1111/j.1349-7006.2007.00433.x	44	25	25	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2014	33	33					4242	4252		10.1038/onc.2013.382	http://dx.doi.org/10.1038/onc.2013.382			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MB	24077290				2022-12-17	WOS:000341155800006
J	DeCaprio, JA				DeCaprio, J. A.			Human papillomavirus type 16 E7 perturbs DREAM to promote cellular proliferation and mitotic gene expression	ONCOGENE			English	Editorial Material							CERVICAL-CANCER; TRANSCRIPTION FACTOR; TUMOR-SUPPRESSOR; PROTEIN; COMPLEX; DEGRADATION; PROGRESSION; BINDS	The study of the small DNA tumor viruses continues to provide valuable new insights into oncogenesis and fundamental biological processes. Although much has already been revealed about how the human papillomaviruses (HPVs) can transform cells and contribute to cervical and oropharyngeal cancer, there clearly is much more to learn. In this issue of Oncogene, Pang et al., doi: 10.1038/onc.2013.426, demonstrate that the high-risk HPV16 E7 oncogene can promote cellular proliferation by interacting with the DREAM (DP, RB-like, E2F and MuvB) complex at two distinct phases of the cell cycle. Consistent with earlier work, HPV16 E7 can bind to the retinoblastoma tumor suppressor (RB) family member p130 (RBL2) protein and promote its proteasome-mediated destruction thereby disrupting the DREAM complex and can prevent exit from the cell cycle into quiescence. In addition, they demonstrate that HPV16 E7 can bind to MuvB core complex in association with BMYB and FOXM1 and activate gene expression during the G2 and M phase of the cell cycle. Thus, HPV16 E7 acts to prevent exit from the cell cycle entry and promotes mitotic proliferation and may account for the high levels of FOXM1 often observed in poor-risk cervical cancers.	[DeCaprio, J. A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA; [DeCaprio, J. A.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; [DeCaprio, J. A.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	DeCaprio, JA (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave,Mayer 440, Boston, MA 02215 USA.	james_decaprio@dfci.harvard.edu			NCI NIH HHS [R01 CA063113, P01 CA050661, R01 CA173023] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063113, R01CA173023, P01CA050661] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chan DW, 2008, J PATHOL, V215, P245, DOI 10.1002/path.2355; Fu Z, 2008, NAT CELL BIOL, V10, P1076, DOI 10.1038/ncb1767; He SY, 2012, GYNECOL ONCOL, V127, P601, DOI 10.1016/j.ygyno.2012.08.036; Huh K, 2007, J VIROL, V81, P9737, DOI 10.1128/JVI.00881-07; Jones DL, 1997, VIROLOGY, V239, P97, DOI 10.1006/viro.1997.8851; Litovchick L, 2011, GENE DEV, V25, P801, DOI 10.1101/gad.2034211; Luscher-Firzlaff JM, 1999, ONCOGENE, V18, P5620, DOI 10.1038/sj.onc.1202967; Muller GA, 2012, NUCLEIC ACIDS RES, V40, P1561, DOI 10.1093/nar/gkr793; Osterloh L, 2007, EMBO J, V26, P144, DOI 10.1038/sj.emboj.7601478; Pang CL, 2014, ONCOGENE, V33, P4039, DOI 10.1038/onc.2013.426; Roman A, 2013, VIROLOGY, V445, P138, DOI 10.1016/j.virol.2013.04.013; Sadasivam S, 2013, NAT REV CANCER, V13, P585, DOI 10.1038/nrc3556; Schmit F, 2009, FEBS J, V276, P5703, DOI 10.1111/j.1742-4658.2009.07261.x; Shin MK, 2012, CANCER RES, V72, P5418, DOI 10.1158/0008-5472.CAN-12-2083; Zhang BY, 2006, P NATL ACAD SCI USA, V103, P437, DOI 10.1073/pnas.0510012103	15	25	25	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2014	33	31					4036	4038		10.1038/onc.2013.449	http://dx.doi.org/10.1038/onc.2013.449			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AN4YG	24166507	Green Accepted			2022-12-17	WOS:000340595300002
J	Cipriano, R; Bryson, BL; Miskimen, KLS; Bartel, CA; Hernandez-Sanchez, W; Bruntz, RC; Scott, SA; Lindsley, CW; Brown, HA; Jackson, MW				Cipriano, R.; Bryson, B. L.; Miskimen, K. L. S.; Bartel, C. A.; Hernandez-Sanchez, W.; Bruntz, R. C.; Scott, S. A.; Lindsley, C. W.; Brown, H. A.; Jackson, M. W.			Hyperactivation of EGFR and downstream effector phospholipase D1 by oncogenic FAM83B	ONCOGENE			English	Article						FAM83B; EGFR; PLD1; MAPK; mTOR; HMEC transformation	HUMAN BREAST-CANCER; PHOSPHATIDIC-ACID; CELLS; TRANSFORMATION; ACTIVATION; KINASE; SURVIVAL; RAS; RESISTANCE; NUTLIN-3	Despite the progress made in targeted anticancer therapies in recent years, challenges remain. The identification of new potential targets will ensure that the arsenal of cancer therapies continues to expand. FAM83B was recently discovered in a forward genetic screen for novel oncogenes that drive human mammary epithelial cell (HMEC) transformation. We report here that elevated FAM83B expression increases Phospholipase D (PLD) activity, and that suppression of PLD1 activity prevents FAM83B-mediated transformation. The increased PLD activity is engaged by hyperactivation of epidermal growth factor receptor (EGFR), which is regulated by an interaction involving FAM83B and EGFR. Preventing the FAM83B/EGFR interaction by site-directed mutation of lysine 230 of FAM83B suppressed PLD activity and MAPK signaling. Furthermore, ablation of FAM83B expression from breast cancer cells inhibited EGFR phosphorylation and suppressed cell proliferation. We propose that understanding the mechanism of FAM83B-mediated transformation will provide a foundation for future therapies aimed at targeting its function as an intermediary in EGFR, MAPK and mTOR activation.	[Cipriano, R.; Bryson, B. L.; Miskimen, K. L. S.; Bartel, C. A.; Hernandez-Sanchez, W.; Jackson, M. W.] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA; [Bruntz, R. C.; Scott, S. A.; Brown, H. A.] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Vanderbilt Inst Chem Biol,Vanderbilt Ingram Canc, Nashville, TN 37232 USA; [Lindsley, C. W.] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Vanderbilt Ctr Neurosci Drug Discovery, Nashville, TN 37232 USA; [Lindsley, C. W.] Vanderbilt Univ, Med Ctr, Dept Chem, Vanderbilt Ctr Neurosci Drug Discovery, Nashville, TN USA; [Brown, H. A.] Vanderbilt Univ, Med Ctr, Vanderbilt Inst Chem Biol, Vanderbilt Ingram Canc Ctr,Dept Chem, Nashville, TN USA; [Brown, H. A.] Vanderbilt Univ, Med Ctr, Vanderbilt Inst Chem Biol, Vanderbilt Ingram Canc Ctr,Dept Biochem, Nashville, TN USA; [Jackson, M. W.] Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA	Case Western Reserve University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Case Western Reserve University	Jackson, MW (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pathol, Case Comprehens Canc Ctr, 2103 Cornell Rd,WRB 3-134, Cleveland, OH 44106 USA.	mark.w.jackson@case.edu	Bryson, Benjamin L/D-1070-2014	Bryson, Benjamin L/0000-0003-4131-0200; Hernandez-Sanchez, Wilnelly/0000-0003-0723-9738	US National Institutes of Health [R01CA138421, T32CA059366]; Department of Defense Breast Cancer Research Program [BC095847, BC074072]; American Cancer Society [RSG-10-072-01-TBG]; McDonnell Foundation; NIH MLPCN Vanderbilt Specialized Chemistry Center [U54 MH084659]; NATIONAL CANCER INSTITUTE [T32CA059366, P30CA043703, R01CA138421, T32CA009592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007250, T32GM007628] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [U54MH084659] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense Breast Cancer Research Program(United States Department of Defense); American Cancer Society(American Cancer Society); McDonnell Foundation; NIH MLPCN Vanderbilt Specialized Chemistry Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	We are grateful to Chase Foy for technical help and Damian Junk for helpful discussions. The core facilities provided by the Case Comprehensive Cancer Center (P30 CA43703; Athymic Animal and Xenograft Core Facility; Gene Expression and Genotyping Core Facility; Cytometry and Imaging Microscopy Core Facility; Radiation Resources Core Facility). This work was supported by the US National Institutes of Health (R01CA138421 to MWJ; T32CA059366 to RC and CB), the Department of Defense Breast Cancer Research Program (BC095847 and BC074072 to MWJ), the American Cancer Society (RSG-10-072-01-TBG to MWJ) and the McDonnell Foundation for brain cancer research (HAB) and the NIH MLPCN U54 MH084659 (CWL) Vanderbilt Specialized Chemistry Center for Accelerated Probe Development.	Brown HA, 2007, METHOD ENZYMOL, V434, P49, DOI 10.1016/S0076-6879(07)34004-4; Buchanan FG, 2005, P NATL ACAD SCI USA, V102, P1638, DOI 10.1073/pnas.0406698102; Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/jCI34739, 10.1172/JCI34739]; Carraway H, 2004, BREAST CANCER RES, V6, P219, DOI 10.1186/bcr927; Chen YH, 2003, ONCOGENE, V22, P3937, DOI 10.1038/sj.onc.1206565; Chien YC, 2006, CELL, V127, P157, DOI 10.1016/j.cell.2006.08.034; Cipriano R, 2013, ONCOTARGET, V4, P729, DOI 10.18632/oncotarget.1027; Cipriano R, 2012, J CLIN INVEST, V122, P3197, DOI 10.1172/JCI60517; Cipriano R, 2010, CELL CYCLE, V9, P1373, DOI 10.4161/cc.9.7.11193; Foster D., 2006, CURRENT SIGNAL TRANS; Foster DA, 2003, MOL CANCER RES, V1, P789; Foster DA, 2007, CANCER RES, V67, P1, DOI 10.1158/0008-5472.CAN-06-3016; Foster DA, 2009, BBA-MOL CELL BIOL L, V1791, P949, DOI 10.1016/j.bbalip.2009.02.009; Ghosh S, 1997, BIOCHEM SOC T, V25, P561, DOI 10.1042/bst0250561; Grant S, 2008, J CLIN INVEST, V118, P3003, DOI 10.1172/JCI36898; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Jackson MW, 2004, ONCOGENE, V23, P4477, DOI 10.1038/sj.onc.1207575; Joseph T, 2001, BIOCHEM BIOPH RES CO, V289, P1019, DOI 10.1006/bbrc.2001.6118; Kan CE, 2007, CANCER RES, V67, P9862, DOI 10.1158/0008-5472.CAN-07-0259; Kassam F, 2009, CLIN BREAST CANCER, V9, P29, DOI 10.3816/CBC.2009.n.005; Kinkade CW, 2008, J CLIN INVEST, V118, P3051, DOI 10.1172/JCI34764; Kraft CA, 2008, J BIOL CHEM, V283, P36636, DOI 10.1074/jbc.M804633200; Ladeda V, 2001, BIOCHEM BIOPH RES CO, V283, P854, DOI 10.1006/bbrc.2001.4845; Lee SY, 2012, J CLIN INVEST, V122, P3211, DOI 10.1172/JCI60498; Noh DY, 2000, CANCER LETT, V161, P207, DOI 10.1016/S0304-3835(00)00612-1; Patton JT, 2006, CANCER RES, V66, P3169, DOI 10.1158/0008-5472.CAN-05-3832; Rangarajan A, 2004, CANCER CELL, V6, P171, DOI 10.1016/j.ccr.2004.07.009; REICH R, 1995, CLIN EXP METASTAS, V13, P134, DOI 10.1007/BF00133618; Rizzo MA, 2000, J BIOL CHEM, V275, P23911, DOI 10.1074/jbc.M001553200; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422; Scott SA, 2009, NAT CHEM BIOL, V5, P108, DOI 10.1038/nchembio.140; Selvy PE, 2011, CHEM REV, V111, P6064, DOI 10.1021/cr200296t; Shi M, 2007, CANCER LETT, V258, P268, DOI 10.1016/j.canlet.2007.09.003; Toschi A, 2009, MOL CELL BIOL, V29, P1411, DOI 10.1128/MCB.00782-08; Uchida H, 1999, ANTICANCER RES, V19, P671; Uchida N, 1997, J CANCER RES CLIN, V123, P280, DOI 10.1007/s004320050060; Williger BT, 1999, J BIOL CHEM, V274, P735, DOI 10.1074/jbc.274.2.735; Xie Z, 1998, J BIOL CHEM, V273, P34679, DOI 10.1074/jbc.273.52.34679	39	25	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2014	33	25					3298	3306		10.1038/onc.2013.293	http://dx.doi.org/10.1038/onc.2013.293			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK5DA	23912460	Green Accepted			2022-12-17	WOS:000338443400009
J	Calderon-Montano, JM; Burgos-Moron, E; Lopez-Lazaro, M				Calderon-Montano, J. M.; Burgos-Moron, E.; Lopez-Lazaro, M.			The in vivo antitumor activity of cardiac glycosides in mice xenografted with human cancer cells is probably an experimental artifact	ONCOGENE			English	Letter							OUABAIN/NA,K-ATPASE; NEUROBLASTOMA; QUIESCENCE; GAMMA-H2AX; APOPTOSIS; GROWTH		[Calderon-Montano, J. M.; Burgos-Moron, E.; Lopez-Lazaro, M.] Univ Seville, Fac Pharm, Dept Pharmacol, Seville, Spain	University of Sevilla	Calderon-Montano, JM (corresponding author), Univ Seville, Fac Pharm, Dept Pharmacol, Seville, Spain.	mlopezlazaro@us.es	Morón, Estefanía Burgos/P-4051-2016; Calderón-Montaño, José Manuel/C-3295-2017; Montaño, José Manuel Calderón/AAA-1742-2019	Morón, Estefanía Burgos/0000-0002-6231-190X; Calderón-Montaño, José Manuel/0000-0001-6845-797X; Montaño, José Manuel Calderón/0000-0001-6845-797X				Badr CE, 2011, NEURO-ONCOLOGY, V13, P1213, DOI 10.1093/neuonc/nor067; Calderon-Montano JM, 2013, BRIT J CANCER, V108, P2189, DOI 10.1038/bjc.2013.234; Cheng C.F, 2013, EVID-BASED COMPL ALT, V2013, DOI DOI 10.1155/2013/958025; GUPTA RS, 1986, J CELL PHYSIOL, V127, P197, DOI 10.1002/jcp.1041270202; Hiyoshi H, 2012, BRIT J CANCER, V106, P1807, DOI 10.1038/bjc.2012.159; Lopez-Lazaro M, 2007, EXPERT OPIN THER TAR, V11, P1043, DOI 10.1517/14728222.11.8.1043; Lopez-Lazaro M, 2009, P NATL ACAD SCI USA, V106, pE26, DOI 10.1073/pnas.0813047106; Tailler M, 2012, ONCOGENE, V31, P3536, DOI 10.1038/onc.2011.521; Xie XB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047375; Zhang DM, 2013, CARCINOGENESIS, V34, P1331, DOI 10.1093/carcin/bgt060; Zhang DM, 2012, EUR J PHARMACOL, V692, P19, DOI 10.1016/j.ejphar.2012.06.045; Zhang HF, 2008, P NATL ACAD SCI USA, V105, P19579, DOI 10.1073/pnas.0809763105	12	25	25	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2014	33	22					2947	2948		10.1038/onc.2013.229	http://dx.doi.org/10.1038/onc.2013.229			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EI	23752179				2022-12-17	WOS:000337231800014
J	Rudrapatna, VA; Bangi, E; Cagan, RL				Rudrapatna, V. A.; Bangi, E.; Cagan, R. L.			A Jnk-Rho-Actin remodeling positive feedback network directs Src-driven invasion	ONCOGENE			English	Article						Drosophila; Cofilin; Actin; Jnk; invasion; enabled	NUCLEAR ACTIN; CELL BIOLOGY; DROSOPHILA; CANCER; MICROENVIRONMENT; TRANSCRIPTION; LOCALIZATION; EXPRESSION; APOPTOSIS; MIGRATION	Current models of tumor cell invasion propose that oncogenic signaling converges upon key orchestrators of cytoskeletal dynamics, including c-Jun N-terminal kinase (Jnk) and RhoGTPase family members; these signals dynamically direct Actin remodeling proteins (ARPs) to catalyze the cytoskeletal changes required for migration. Src is a key driver of tumor aggression, metastasis and patient mortality. To clarify how Src regulates Actin dynamics to promote invasive migration, we performed a genetic modifier screen in a Drosophila model of invasion. Nine genes linked to Actin dynamics were identified that mediate invasion in situ. We found that ARPs were required for many oncogenic effects of Src including Mmp1 expression and initiation of apoptosis. Surprisingly, they were also regulators of Jnk pathway activity: both Src and the small GTPase Rho1 activated Jnk in a manner dependent on ARPs during invasion. Our results suggest that ARPs are not simply downstream executors of signal transduction pathways. Rather, they participate in a positive feedback network involving canonical oncogenic signaling pathways that promote tumor invasion.	[Rudrapatna, V. A.; Bangi, E.; Cagan, R. L.] Mt Sinai Sch Med, Dept Dev & Regenerat Biol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Cagan, RL (corresponding author), Mt Sinai Sch Med, Dept Dev & Regenerat Biol, One Gustave L Levy Pl,Annenberg 25-40, New York, NY 10029 USA.	ross.cagan@mssm.edu	Tsai, Yu-Chen/B-5852-2008; Cagan, Ross Leigh/AAV-9528-2021	Cagan, Ross/0000-0001-5297-450X; Rudrapatna, Vivek/0000-0003-1789-3004	National Institutes of Health [NCI R01 CA109730, 5R01EY011495];  [5T32CA078207];  [5T32GM007280]; NATIONAL CANCER INSTITUTE [T32CA078207, R01CA109730] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY011495] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007280] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank members of the Cagan laboratory for important discussions and especially Jay Pendse for statistical assistance and Ruth Johnson for discussions and support regarding actin remodeling. Stocks were obtained from the Bloomington Drosophila Stock Center, Vienna Drosophila RNAi Center and the National Institute of Genetics Fly Stock Center. VAR was supported by 5T32CA078207 and 5T32GM007280. This work was also supported by the National Institutes of Health grants NCI R01 CA109730 and 5R01EY011495.	Bernstein BW, 2010, TRENDS CELL BIOL, V20, P187, DOI 10.1016/j.tcb.2010.01.001; Cagan RL, 2012, DEV CELL, V22, P472, DOI 10.1016/j.devcel.2012.02.014; Fan Y, 2010, CELL DEATH DIFFER, V17, P534, DOI 10.1038/cdd.2009.185; Fox DT, 2005, DEVELOPMENT, V132, P4819, DOI 10.1242/dev.02056; Godt D, 1998, NATURE, V395, P387, DOI 10.1038/26493; Goetz JG, 2011, CELL, V146, P148, DOI 10.1016/j.cell.2011.05.040; Guarino M, 2010, J CELL PHYSIOL, V223, P14, DOI 10.1002/jcp.22011; Kustermans G, 2008, BIOCHEM PHARMACOL, V76, P1310, DOI 10.1016/j.bcp.2008.05.028; Le Clainche C, 2008, PHYSIOL REV, V88, P489, DOI 10.1152/physrev.00021.2007; Leung CT, 2012, NATURE, V482, P410, DOI 10.1038/nature10826; Martin-Blanco E, 1998, GENE DEV, V12, P557, DOI 10.1101/gad.12.4.557; Olson EN, 2010, NAT REV MOL CELL BIO, V11, P353, DOI 10.1038/nrm2890; Olson MF, 2009, CLIN EXP METASTAS, V26, P273, DOI 10.1007/s10585-008-9174-2; Rottner K, 2011, CURR OPIN CELL BIOL, V23, P569, DOI 10.1016/j.ceb.2011.07.003; Rudrapatna VA, 2013, EMBO REP, V14, P172, DOI 10.1038/embor.2012.217; Schwartz MA, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a005066; Speck O, 2003, NATURE, V421, P83, DOI 10.1038/nature01295; Szerlong H, 2008, NAT STRUCT MOL BIOL, V15, P469, DOI 10.1038/nsmb.1403; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; Uhlirova M, 2006, EMBO J, V25, P5294, DOI 10.1038/sj.emboj.7601401; Vartiainen MK, 2007, SCIENCE, V316, P1749, DOI 10.1126/science.1141084; Vega FM, 2008, FEBS LETT, V582, P2093, DOI 10.1016/j.febslet.2008.04.039; Vidal M, 2006, DEV CELL, V10, P33, DOI 10.1016/j.devcel.2005.11.007; Vidal M, 2010, AM J PATHOL, V176, P3007, DOI 10.2353/ajpath.2010.090253; Zheng B, 2009, FEBS J, V276, P2669, DOI 10.1111/j.1742-4658.2009.06986.x	25	25	25	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2014	33	21					2801	2806		10.1038/onc.2013.232	http://dx.doi.org/10.1038/onc.2013.232			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EH	23831567				2022-12-17	WOS:000337231700013
J	Koyama-Nasu, R; Haruta, R; Nasu-Nishimura, Y; Taniue, K; Katou, Y; Shirahige, K; Todo, T; Ino, Y; Mukasa, A; Saito, N; Matsui, M; Takahashi, R; Hoshino-Okubo, A; Sugano, H; Manabe, E; Funato, K; Akiyama, T				Koyama-Nasu, R.; Haruta, R.; Nasu-Nishimura, Y.; Taniue, K.; Katou, Y.; Shirahige, K.; Todo, T.; Ino, Y.; Mukasa, A.; Saito, N.; Matsui, M.; Takahashi, R.; Hoshino-Okubo, A.; Sugano, H.; Manabe, E.; Funato, K.; Akiyama, T.			The pleiotrophin-ALK axis is required for tumorigenicity of glioblastoma stem cells	ONCOGENE			English	Article						ALK; cancer stem cell; glioblastoma; kinase; pleiotrophin; SOX2	ANAPLASTIC LYMPHOMA KINASE; EMBRYONIC STEM; MOUSE MODELS; LUNG-CANCER; HB-GAM; SOX2; EXPRESSION; GENE; IDENTIFICATION; MOLECULE	Increasing evidence suggests that brain tumors arise from the transformation of neural stem/precursor/progenitor cells. Much current research on human brain tumors is focused on the stem-like properties of glioblastoma. Here we show that anaplastic lymphoma kinase (ALK) and its ligand pleiotrophin are required for the self-renewal and tumorigenicity of glioblastoma stem cells (GSCs). Furthermore, we demonstrate that pleiotrophin is transactivated directly by SOX2, a transcription factor essential for the maintenance of both neural stem cells and GSCs. We speculate that the pleiotrophin-ALK axis may be a promising target for the therapy of glioblastoma.	[Koyama-Nasu, R.; Haruta, R.; Nasu-Nishimura, Y.; Taniue, K.; Takahashi, R.; Hoshino-Okubo, A.; Sugano, H.; Manabe, E.; Funato, K.; Akiyama, T.] Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, Tokyo 1130032, Japan; [Katou, Y.; Shirahige, K.] Univ Tokyo, Inst Mol & Cellular Biosci, Ctr Epigenet Dis, Lab Genome Struct & Funct,Bunkyo Ku, Tokyo 1130032, Japan; [Todo, T.; Ino, Y.; Mukasa, A.; Saito, N.] Tokyo Univ Hosp, Dept Neurosurg, Bunkyo Ku, Tokyo 113, Japan	University of Tokyo; University of Tokyo; University of Tokyo	Akiyama, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, Yayoi 1-1-1, Tokyo 1130032, Japan.	akiyama@iam.u-tokyo.ac.jp	Mukasa, Akitake/H-7615-2019	Mukasa, Akitake/0000-0001-7776-9086; Todo, Tomoki/0000-0003-0523-8010; Funato, Kosuke/0000-0003-2437-1116	Research Program of Innovative Cell Biology by Innovative Technology (Integrated Systems Analysis of Cellular Oncogenic Signaling Networks); Global COE Program (Integrative Life Science Based on the Study of Biosignaling Mechanisms), MEXT, Japan; Grants-in-Aid for Scientific Research [25670138] Funding Source: KAKEN	Research Program of Innovative Cell Biology by Innovative Technology (Integrated Systems Analysis of Cellular Oncogenic Signaling Networks); Global COE Program (Integrative Life Science Based on the Study of Biosignaling Mechanisms), MEXT, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by the Research Program of Innovative Cell Biology by Innovative Technology (Integrated Systems Analysis of Cellular Oncogenic Signaling Networks), Grants-in-Aid for Scientific Research on Innovative Areas (Integrative Research on Cancer Microenvironment Network), Takeda Science Foundation and, in part, by Global COE Program (Integrative Life Science Based on the Study of Biosignaling Mechanisms), MEXT, Japan.	Amet LEA, 2001, MOL CELL NEUROSCI, V17, P1014, DOI 10.1006/mcne.2001.0998; Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bernhardt M, 2012, BIOTECHNOL J, V7, P810, DOI 10.1002/biot.201100347; Camidge DR, 2012, NAT REV CLIN ONCOL, V9, P268, DOI 10.1038/nrclinonc.2012.43; Carpenter EL, 2012, NAT REV CLIN ONCOL, V9, P391, DOI 10.1038/nrclinonc.2012.72; Cavallaro M, 2008, DEVELOPMENT, V135, P541, DOI 10.1242/dev.010801; Chen J, 2012, CELL, V149, P36, DOI 10.1016/j.cell.2012.03.009; Chen SS, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0036784, 10.1371/journal.pone.0045763, 10.1371/journal.pone.0049275, 10.1371/journal.pone.0050456]; Chew JL, 2005, MOL CELL BIOL, V25, P6031, DOI 10.1128/MCB.25.14.6031-6046.2005; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Dirks WG, 2002, INT J CANCER, V100, P49, DOI 10.1002/ijc.10435; Episkopou V, 2005, TRENDS NEUROSCI, V28, P219, DOI 10.1016/j.tins.2005.03.003; Ferri ALM, 2004, DEVELOPMENT, V131, P3805, DOI 10.1242/dev.01204; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Gandhi L, 2012, CLIN CANCER RES, V18, P3737, DOI 10.1158/1078-0432.CCR-11-2393; Gangemi RMR, 2009, STEM CELLS, V27, P40, DOI 10.1634/stemcells.2008-0493; Hienola A, 2004, MOL CELL NEUROSCI, V26, P75, DOI 10.1016/j.mcn.2004.01.018; Kadomatsu KJ, 2004, CANCER LETT, V204, P127, DOI 10.1016/S0304-3835(03)00450-6; Kim J, 2010, CELL, V143, P313, DOI 10.1016/j.cell.2010.09.010; Kondo T, 2004, GENE DEV, V18, P2963, DOI 10.1101/gad.309404; Koyama-Nasu R, 2013, ONCOGENE, V32, P3840, DOI 10.1038/onc.2012.399; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Leis O, 2012, ONCOGENE, V31, P1354, DOI 10.1038/onc.2011.338; Lottaz C, 2010, CANCER RES, V70, P2030, DOI 10.1158/0008-5472.CAN-09-1707; McDermott U, 2008, CANCER RES, V68, P3389, DOI 10.1158/0008-5472.CAN-07-6186; Melosky B, 2012, CURR ONCOL, V19, pS59, DOI 10.3747/co.19.1054; Meng K, 2000, P NATL ACAD SCI USA, V97, P2603, DOI 10.1073/pnas.020487997; Mizrak D, 2008, J PATHOL, V214, P3, DOI 10.1002/path.2283; Palmer RH, 2009, BIOCHEM J, V420, P345, DOI 10.1042/BJ20090387; Parikh JR, 2010, NUCLEIC ACIDS RES, V38, pW109, DOI 10.1093/nar/gkq424; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Perez-Pinera P, 2007, CELL CYCLE, V6, P2877, DOI 10.4161/cc.6.23.5090; Powers C, 2002, J BIOL CHEM, V277, P14153, DOI 10.1074/jbc.M112354200; Raetz EA, 2002, AM J PATHOL, V161, P875, DOI 10.1016/S0002-9440(10)64248-4; RAULO E, 1994, J BIOL CHEM, V269, P12999; Sarkar A, 2013, CELL STEM CELL, V12, P15, DOI 10.1016/j.stem.2012.12.007; Schmitz M, 2007, BRIT J CANCER, V96, P1293, DOI 10.1038/sj.bjc.6603696; Sell S, 2006, TUMOR BIOL, V27, P59, DOI 10.1159/000092323; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Stylianou DC, 2009, ONCOGENE, V28, P3296, DOI 10.1038/onc.2009.184; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tavazoie S, 1999, NAT GENET, V22, P281, DOI 10.1038/10343; Turner SD, 2005, LEUKEMIA, V19, P1128, DOI 10.1038/sj.leu.2403797; Wurdak H, 2010, CELL STEM CELL, V6, P37, DOI 10.1016/j.stem.2009.11.002; Ying M, 2011, ONCOGENE, V30, P3454, DOI 10.1038/onc.2011.58; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635; Zhang JM, 2009, NAT REV CANCER, V9, P28, DOI 10.1038/nrc2559	50	25	26	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2014	33	17					2236	2244		10.1038/onc.2013.168	http://dx.doi.org/10.1038/onc.2013.168			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AF8WJ	23686309				2022-12-17	WOS:000334996000009
J	Francescone, R; Ngernyuang, N; Yan, W; Bentley, B; Shao, R				Francescone, R.; Ngernyuang, N.; Yan, W.; Bentley, B.; Shao, R.			Tumor-derived mural-like cells coordinate with endothelial cells: role of YKL-40 in mural cell-mediated angiogenesis	ONCOGENE			English	Article						YKL-40; cadherins; vessel permeability; mural cells; tumor angiogenesis; VEGF	CHITINASE PROTEIN FAMILY; VE-CADHERIN; GROWTH-FACTOR; VESSEL MATURATION; BREAST-CANCER; N-CADHERIN; VASCULAR MORPHOGENESIS; COLORECTAL-CANCER; ADHERENS JUNCTION; ANDES VIRUS	Tumor neo-vasculature is characterized by spatial coordination of endothelial cells with mural cells, which delivers oxygen and nutrients. Here, we explored a key role of the secreted glycoprotein YKL-40, a mesenchymal marker, in the interaction between endothelial cells and mesenchymal mural-like cells for tumor angiogenesis. Xenotransplantation of tumor-derived mural-like cells (GSDCs) expressing YKL-40 in mice developed extensive and stable blood vessels covered with more GSDCs than those in YKL-40 gene knockdown tumors. YKL-40 expressed by GSDCs was associated with increased interaction of neural cadherin/beta-catenin/smooth muscle alpha actin; thus, mediating cell-cell adhesion and permeability. YKL-40 also induced the interaction of vascular endothelial cadherin/beta-catenin/actin in endothelial cells (HMVECs). In cell co-culture systems, YKL-40 enhanced both GSDC and HMVEC contacts, restricted vascular leakage, and stabilized vascular networks. Collectively, the data inform new mechanistic insights into the cooperation of mural cells with endothelial cells induced by YKL-40 during tumor angiogenesis, and also enhance our understanding of YKL-40 in both mural and endothelial cell biology.	[Francescone, R.; Shao, R.] Univ Massachusetts, Morrill Sci Ctr, Mol & Cellular Biol Program, Amherst, MA 01003 USA; [Ngernyuang, N.] Khon Khaen Univ, Grad Sch, Khon Khaen, Thailand; [Yan, W.; Bentley, B.; Shao, R.] Pioneer Valley Life Sci Inst, Springfield, MA USA; [Shao, R.] Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst; Khon Kaen University; University of Massachusetts System; University of Massachusetts Amherst	Shao, R (corresponding author), Univ Massachusetts Amherst, Pioneer Valley Life Sci Inst, Springfield, MA 01107 USA.	rong.shao@bhs.org		Francescone, Ralph/0000-0002-3149-6825; Ngernyuang, Nipaporn/0000-0002-8586-6115	NCI [R01 CA120659]; CEAR grant, John Adams Innovation Institute, Massachusetts; NATIONAL CANCER INSTITUTE [R01CA120659] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); CEAR grant, John Adams Innovation Institute, Massachusetts; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NCI R01 CA120659 and CEAR grant, John Adams Innovation Institute, Massachusetts (RS).	Abramsson A, 2003, J CLIN INVEST, V112, P1142, DOI 10.1172/JCI200318549; Armulik A, 2011, DEV CELL, V21, P193, DOI 10.1016/j.devcel.2011.07.001; Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929; Bergmann OJ, 2005, CLIN CANCER RES, V11, P8644, DOI 10.1158/1078-0432.CCR-05-1317; Bloch W, 2000, FASEB J, V14, P2373; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Carmeliet P, 2011, NAT REV DRUG DISCOV, V10, P417, DOI 10.1038/nrd3455; Chambers RC, 2003, AM J PATHOL, V162, P533, DOI 10.1016/S0002-9440(10)63847-3; Chen XL, 2012, DEV CELL, V22, P146, DOI 10.1016/j.devcel.2011.11.002; Cintin C, 1999, BRIT J CANCER, V79, P1494, DOI 10.1038/sj.bjc.6690238; Dejana E, 2008, J CELL SCI, V121, P2115, DOI 10.1242/jcs.017897; Dejana E, 2009, DEV CELL, V16, P209, DOI 10.1016/j.devcel.2009.01.004; Elenbaas B, 2001, EXP CELL RES, V264, P169, DOI 10.1006/excr.2000.5133; Erber R, 2003, FASEB J, V17, P338, DOI 10.1096/fj.03-0271fje; Faibish M, 2011, MOL CANCER THER, V10, P742, DOI 10.1158/1535-7163.MCT-10-0868; Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483; Francescone R, 2012, J BIOL CHEM, V287, P24821, DOI 10.1074/jbc.M111.334540; Francescone RA, 2011, J BIOL CHEM, V286, P15332, DOI 10.1074/jbc.M110.212514; Fusetti F, 2003, J BIOL CHEM, V278, P37753, DOI 10.1074/jbc.M303137200; Gavard J, 2006, NAT CELL BIOL, V8, P1223, DOI 10.1038/ncb1486; Gerhardt H, 2000, DEV DYNAM, V218, P472, DOI 10.1002/1097-0177(200007)218:3<472::AID-DVDY1008>3.0.CO;2-#; Gerhardt H, 2008, J MOL MED, V86, P135, DOI 10.1007/s00109-007-0258-2; Gorbunova E, 2010, J VIROL, V84, P7405, DOI 10.1128/JVI.00576-10; Greenberg JI, 2008, NATURE, V456, P809, DOI 10.1038/nature07424; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; Helfrich I, 2010, J EXP MED, V207, P491, DOI 10.1084/jem.20091846; Hellberg C, 2010, RECENT RESULTS CANC, V180, P103, DOI 10.1007/978-3-540-78281-0_7; Hellstrom M, 2001, J CELL BIOL, V153, P543, DOI 10.1083/jcb.153.3.543; Hogdall EVS, 2003, ONCOL REP, V10, P1535; Hottinger AF, 2011, ANN NEUROL, V70, P163, DOI 10.1002/ana.22360; Hu B, 1996, J BIOL CHEM, V271, P19415, DOI 10.1074/jbc.271.32.19415; Huang FJ, 2010, DEV BIOL, V344, P1035, DOI 10.1016/j.ydbio.2010.06.023; Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685; Jayson GC, 2005, J CLIN ONCOL, V23, P973, DOI 10.1200/JCO.2005.01.032; Jensen BV, 2003, CLIN CANCER RES, V9, P4423; JOHANSEN JS, 1992, J BONE MINER RES, V7, P501; Kzhyshkowska J, 2007, BIOMARK INSIGHTS, V2, P128; Lambeng N, 2005, CIRC RES, V96, P384, DOI 10.1161/01.RES.0000156652.99586.9f; Lin MI, 2007, CANCER RES, V67, P2849, DOI 10.1158/0008-5472.CAN-06-4082; Liu JQ, 2011, CLIN CANCER RES, V17, P3638, DOI 10.1158/1078-0432.CCR-10-2456; Luo Y, 2006, DEV BIOL, V299, P517, DOI 10.1016/j.ydbio.2006.09.003; Nakamura Y, 2008, CIRC RES, V102, P1182, DOI 10.1161/CIRCRESAHA.107.167080; NYIRKOS P, 1990, BIOCHEM J, V269, P265, DOI 10.1042/bj2690265; Orlova VV, 2006, J EXP MED, V203, P2703, DOI 10.1084/jem.20051730; Paik JH, 2004, GENE DEV, V18, P2392, DOI 10.1101/gad.1227804; Pelloski CE, 2005, CLIN CANCER RES, V11, P3326, DOI 10.1158/1078-0432.CCR-04-1765; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Rehli M, 1997, GENOMICS, V43, P221, DOI 10.1006/geno.1997.4778; Renkema GH, 1998, EUR J BIOCHEM, V251, P504, DOI 10.1046/j.1432-1327.1998.2510504.x; SHACKELTON LM, 1995, J BIOL CHEM, V270, P13076, DOI 10.1074/jbc.270.22.13076; Shao R, 2009, ONCOGENE, V28, P4456, DOI 10.1038/onc.2009.292; Shay-Salit A, 2002, P NATL ACAD SCI USA, V99, P9462, DOI 10.1073/pnas.142224299; Shrivastava-Ranjan P, 2010, J VIROL, V84, P11227, DOI 10.1128/JVI.01405-10; Stockmann C, 2008, NATURE, V456, P814, DOI 10.1038/nature07445; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; Vestweber D, 2008, ARTERIOSCL THROM VAS, V28, P223, DOI 10.1161/ATVBAHA.107.158014; Weis S, 2004, J CELL BIOL, V167, P223, DOI 10.1083/jcb.200408130; Yan W, 2008, MOL BIOL CELL, V19, P2278, DOI 10.1091/mbc.E07-10-1068; Yan W, 2010, J BIOL CHEM, V285, P14042, DOI 10.1074/jbc.M110.105262; Yonenaga Y, 2005, ONCOLOGY-BASEL, V69, P159, DOI 10.1159/000087840	61	25	26	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	2014	33	16					2110	2122		10.1038/onc.2013.160	http://dx.doi.org/10.1038/onc.2013.160			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AF3GH	23665676	Green Accepted			2022-12-17	WOS:000334599100010
J	Sokolowski, E; Turina, CB; Kikuchi, K; Langenau, DM; Keller, C				Sokolowski, E.; Turina, C. B.; Kikuchi, K.; Langenau, D. M.; Keller, C.			Proof-of-concept rare cancers in drug development: the case for rhabdomyosarcoma	ONCOGENE			English	Review						rhabdomyosarcoma; biomarker; proof-of-concept disease; kinase; rare cancers; drug development	TESTING STAGE 1; FACTOR-I RECEPTOR; SMALL-MOLECULE INHIBITOR; ENDOTHELIAL GROWTH-FACTOR; PEDIATRIC SOLID TUMORS; SOFT-TISSUE SARCOMAS; EMBRYONAL RHABDOMYOSARCOMA; GENE-EXPRESSION; MYOGENIC DIFFERENTIATION; CELL-LINES	Rare diseases typically affect fewer than 200 000 patients annually, yet because thousands of rare diseases exist, the cumulative impact is millions of patients worldwide. Every form of childhood cancer qualifies as a rare disease-including the childhood muscle cancer, rhabdomyosarcoma (RMS). The next few years promise to be an exceptionally good era of opportunity for public-private collaboration for rare and childhood cancers. Not only do certain governmental regulation advantages exist, but these advantages are being made permanent with special incentives for pediatric orphan drug-product development. Coupled with a growing understanding of sarcoma tumor biology, synergy with pharmaceutical muscle disease drug-development programs, and emerging publically available preclinical and clinical tools, the outlook for academic-community-industry partnerships in RMS drug development looks promising.	[Sokolowski, E.; Turina, C. B.] Oregon State Univ, Dept Student Affairs, Corvallis, OR 97331 USA; [Turina, C. B.; Kikuchi, K.; Keller, C.] Oregon Hlth & Sci Univ, Pape Family Pediat Res Inst, Dept Pediat, Pediat Canc Biol Program, Portland, OR 97239 USA; [Langenau, D. M.] Massachusetts Gen Hosp, Div Mol Pathol, Boston, MA 02114 USA; [Langenau, D. M.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA; [Langenau, D. M.] Harvard Univ, Sch Med, Boston, MA USA; [Langenau, D. M.] Harvard Stem Cell Inst, Boston, MA USA	Oregon State University; Oregon Health & Science University; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University	Keller, C (corresponding author), Oregon Hlth & Sci Univ, Pape Family Pediat Res Inst, Dept Pediat, Pediat Canc Biol Program, 3181 SW Sam Jackson Pk Rd,MC L321, Portland, OR 97239 USA.	keller@ohsu.edu	Langenau, David/GXI-0197-2022; Kikuchi, Ken/ABG-8290-2020	Langenau, David/0000-0001-6664-8318; Kikuchi, Ken/0000-0003-3097-7480; Keller, Charles/0000-0003-2505-7487	Harvard Stem Cell Institute; Ethan Jostad Foundation for Childhood Cancer;  [R01CA133229];  [R01CA15923];  [R21CA156056]; NATIONAL CANCER INSTITUTE [R01CA133229, R21CA156056] Funding Source: NIH RePORTER	Harvard Stem Cell Institute; Ethan Jostad Foundation for Childhood Cancer; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was funded by R01CA133229 (CK), R01CA15923 (DML), R21CA156056 (DML), the Harvard Stem Cell Institute and a gift from the Ethan Jostad Foundation for Childhood Cancer. We thank M Imran Aslam, Lara Davis, Ailin Jiang, Leanna Mah, Marissa Peterson, Victoria Reinke, Teagen Settlemeyer, Suman Malempati and R Lor Randall for their contributions to and discussions regarding this topic. Important input on cell lines was made by Karoly Szuhai, Beat Schafer, Frederic Barr, Javed Khan, Corinne Linardic and Peter Houghton. We are grateful for the critical comments of Douglas Hawkins, Malcolm Smith, Idriss Bennani-Baiti, M Simone Nsouli, Parkash Gill, Kathryn Gould, Sandra Smith, Steven Townson, Max Wallace, John Mackintosh, Tommy Pham, Jay Scott, Nadim Nsouli, Christopher Winter and Owen Lockerbie.	Abraham J, 2012, BIOCHEM BIOPH RES CO, V426, P363, DOI 10.1016/j.bbrc.2012.08.092; Abraham J, 2011, MOL CANCER THER, V10, P697, DOI 10.1158/1535-7163.MCT-10-0695; Adamson PC, 2013, PEDIATR BLOOD CANCER, V60, P955, DOI 10.1002/pbc.24399; Agarwal A, 2011, 53 ASH ANN M EXP AM; Alabran JL, 2013, PEDIATR BLOOD CANCER, V60, P204, DOI 10.1002/pbc.24320; Andrade Cléverton Roberto de, 2010, Braz. Dent. J., V21, P68, DOI 10.1590/S0103-64402010000100011; [Anonymous], 2012, PROOF OF CONC REC PR; Armistead PM, 2007, CANCER, V110, P2293, DOI 10.1002/cncr.23038; Arndt CAS, 2006, J PEDIAT HEMATOL ONC, V28, P563, DOI 10.1097/01.mph.0000212978.21372.97; Arndt CAS, 1999, NEW ENGL J MED, V341, P342, DOI 10.1056/NEJM199907293410507; Barber TD, 2002, GENOMICS, V79, P278, DOI 10.1006/geno.2002.6703; Barber-Rotenberg JS, 2012, ONCOTARGET, V3, P172; Belyea BC, 2011, CLIN CANCER RES, V17, P7324, DOI 10.1158/1078-0432.CCR-11-1004; Bennani-Baiti IM, 2011, EPIGENOMICS-UK, V3, P715, DOI [10.2217/EPI.11.93, 10.2217/epi.11.93]; Bennani-Baiti IM, 2010, CLIN CANCER RES, V16, P3769, DOI 10.1158/1078-0432.CCR-10-0558; Berardi AC, 2008, ANTICANCER RES, V28, P763; Blandford MC, 2006, PEDIATR BLOOD CANCER, V46, P329, DOI 10.1002/pbc.20466; Bouron-Dal Soglio D, 2009, PEDIATR DEVEL PATHOL, V12, P371, DOI 10.2350/08-11-0553.1; Braun MM, 2010, NAT REV DRUG DISCOV, V9, P519, DOI 10.1038/nrd3160; Breneman JC, 2003, J CLIN ONCOL, V21, P78, DOI 10.1200/JCO.2003.06.129; Cam H, 2006, CANCER CELL, V10, P281, DOI 10.1016/j.ccr.2006.08.024; Camboni M, 2012, J PATHOL, V226, P40, DOI 10.1002/path.2996; Canner JA, 2009, BRIT J CANCER, V101, P774, DOI 10.1038/sj.bjc.6605199; Cao L, 2008, CANCER RES, V68, P8039, DOI 10.1158/0008-5472.CAN-08-1712; Cao LA, 2010, CANCER RES, V70, P6497, DOI 10.1158/0008-5472.CAN-10-0582; Carboni JM, 2009, MOL CANCER THER, V8, P3341, DOI 10.1158/1535-7163.MCT-09-0499; Carol H, 2013, PEDIATR BLOOD CANCER, V60, P633, DOI 10.1002/pbc.24235; Carol H, 2011, CANCER CHEMOTH PHARM, V68, P1291, DOI 10.1007/s00280-011-1618-8; Carol H, 2010, PEDIATR BLOOD CANCER, V55, P1329, DOI 10.1002/pbc.22710; Cen L, 2007, BRIT J CANCER, V97, P785, DOI 10.1038/sj.bjc.6603952; Cen L, 2007, MODERN PATHOL, V20, P936, DOI 10.1038/modpathol.3800834; Chadalapaka G, 2013, INT J CANCER, V132, P795, DOI 10.1002/ijc.27730; Chamberlain JS, 2007, FASEB J, V21, P2195, DOI 10.1096/fj.06-7353com; Charytonowicz E, 2012, CLIN TRANSL ONCOL, V14, P197, DOI 10.1007/s12094-012-0784-4; Chen CL, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-111; Chen L, 2013, MANAGE COMMUN Q, V27, P3, DOI 10.1177/0893318913475485; Chen YY, 2007, GENE CHROMOSOME CANC, V46, P348, DOI 10.1002/gcc.20416; Cheney MD, 2008, CANCER BIOL THER, V7, P38, DOI 10.4161/cbt.7.1.5125; Chisholm J., 2012, COMMUNICATIONS; Conboy MJ, 2010, METHODS MOL BIOL, V621, P165, DOI 10.1007/978-1-60761-063-2_11; Corao DA, 2009, PEDIATR DEVEL PATHOL, V12, P275, DOI 10.2350/08-03-0434.1; Davicioni E, 2009, AM J PATHOL, V174, P550, DOI 10.2353/ajpath.2009.080631; Davis L, 2012, AACR ED BOOK, P205; DeFrancesco L, 2011, NAT BIOTECHNOL, V29, P850, DOI 10.1038/nbt1011-851; DeGiovanni C, 1996, CANCER RES, V56, P3898; DEGIOVANNI C, 1995, BRIT J CANCER, V72, P1224, DOI 10.1038/bjc.1995.490; Dhimolea E, 2010, MABS-AUSTIN, V2, P3, DOI 10.4161/mabs.2.1.10328; DIAS P, 1990, INT J CANCER, V45, P593, DOI 10.1002/ijc.2910450403; Diomedi-Camassei F, 2008, CLIN CANCER RES, V14, P4119, DOI 10.1158/1078-0432.CCR-07-4446; Druker BJ, 2004, CELL CYCLE, V3, P833; Dupont, 2012, TEST METH US ONCOMOU; Durbin AD, 2009, J CLIN INVEST, V119, P1558, DOI 10.1172/JCI37958; Eichenmuller M, 2010, BRIT J CANCER, V103, P43, DOI 10.1038/sj.bjc.6605715; ELBADRY OM, 1990, CELL GROWTH DIFFER, V1, P325; Fernandez K, 2010, AM J PATHOL, V176, P416, DOI 10.2353/ajpath.2010.090405; Fiddler TA, 1996, MOL CELL BIOL, V16, P5048; Fine SW, 2005, APPL IMMUNOHISTO M M, V13, P231, DOI 10.1097/00129039-200509000-00003; Fleischmann A, 2003, CANCER CELL, V4, P477, DOI 10.1016/S1535-6108(03)00280-0; Food and Drug Administration US, 2012, FREQ ASK QUEST PAT E; Frascella E, 2000, CANCER GENET CYTOGEN, V121, P139, DOI 10.1016/S0165-4608(00)00258-2; Gaddipati H, 2012, CLIN CANCER RES, V18, P5172, DOI 10.1158/1078-0432.CCR-12-1135; Ganti R, 2006, MODERN PATHOL, V19, P1213, DOI 10.1038/modpathol.3800636; Gee MFW, 2005, ONCOGENE, V24, P8025, DOI 10.1038/sj.onc.1208939; Ghule P, 2006, MED SCI MONITOR, V12, pBR385; Goldstein M, 2007, GENE CHROMOSOME CANC, V46, P1028, DOI 10.1002/gcc.20489; Goldstein M, 2006, NEOPLASIA, V8, P332, DOI 10.1593/neo.05829; Goozner M, 2012, J NATL CANCER I, V104, P84, DOI 10.1093/jnci/djr552; Gore L, 2013, LANCET ONCOL, V14, pE70, DOI 10.1016/S1470-2045(12)70530-2; Gorlick R, 2012, PEDIATR BLOOD CANCER, V59, P1266, DOI 10.1002/pbc.24073; Gorlick R, 2009, PEDIATR BLOOD CANCER, V53, P594, DOI 10.1002/pbc.21989; Grass B, 2009, HISTOPATHOLOGY, V54, P873, DOI 10.1111/j.1365-2559.2009.03303.x; Grymula K, 2010, INT J CANCER, V127, P2554, DOI 10.1002/ijc.25245; Gurney JG, 1999, SOFT TISSUE SARCOMAS; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; Hawkins DS, 2013, PEDIATR BLOOD CANCER, V60, P1001, DOI 10.1002/pbc.24435; HAYASHI Y, 1990, INT J CANCER, V45, P705, DOI 10.1002/ijc.2910450423; Herper Matthew, 2012, FORBES MAGAZINE; Hettmer S, 2011, P NATL ACAD SCI USA, V108, P20002, DOI 10.1073/pnas.1111733108; Hilari JM, 2009, ANN SURG ONCOL, V16, P177, DOI 10.1245/s10434-008-0183-9; Hirotsu M, 2009, BRIT J CANCER, V101, P2030, DOI 10.1038/sj.bjc.6605407; Horton TM, 2011, EUR J PEDIATR, V170, P555, DOI 10.1007/s00431-010-1374-5; Hoshida Y, 2009, CANCER RES, V69, P7385, DOI 10.1158/0008-5472.CAN-09-1089; Hosoi H, 1999, CANCER RES, V59, P886; Hosoyama T, 2011, CLIN CANCER RES, V17, P2757, DOI 10.1158/1078-0432.CCR-10-3445; Hosur V, 2012, CANCER GENET-NY, V205, P232, DOI 10.1016/j.cancergen.2012.03.005; Hou JX, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-64; Houghton PJ, 2008, PEDIATR BLOOD CANCER, V50, P799, DOI 10.1002/pbc.21296; Houghton PJ, 2007, PEDIATR BLOOD CANCER, V49, P928, DOI 10.1002/pbc.21078; Houghton PJ, 2012, PEDIATR BLOOD CANCER, V58, P636, DOI 10.1002/pbc.23167; Houghton PJ, 2012, PEDIATR BLOOD CANCER, V58, P191, DOI 10.1002/pbc.22935; Houghton PJ, 2010, PEDIATR BLOOD CANCER, V54, P921, DOI 10.1002/pbc.22367; Houghton PJ, 2011, AACR NCI EORTC INT C; Huang E, 2011, PEDIATR BLOOD CANCER, V57, P899, DOI 10.1002/pbc.23136; Huang F, 2009, CANCER RES, V69, P161, DOI 10.1158/0008-5472.CAN-08-0835; Ignatius MS, 2012, CANCER CELL, V21, P680, DOI 10.1016/j.ccr.2012.03.043; Institute of Medicine CoARDRaOPD, RAR DIS ORPH PROD AC; Iolascon A, 1996, GENE CHROMOSOME CANC, V15, P217, DOI 10.1002/(SICI)1098-2264(199604)15:4<217::AID-GCC3>3.3.CO;2-X; Jankowski K, 2003, CANCER RES, V63, P7926; Jenkins C, 2012, ANEMIA, V2012, DOI 10.1155/2012/481583; KALEBIC T, 1994, CANCER RES, V54, P5531; Kantarjian HM, 2007, LEUKEMIA LYMPHOMA, V48, P1922, DOI 10.1080/10428190701545644; Keleti J, 1996, AM J PATHOL, V149, P143; Keller C, 2004, GENE DEV, V18, P2614, DOI 10.1101/gad.1244004; Kesselheim AS, 2011, JAMA-J AM MED ASSOC, V305, P2320, DOI 10.1001/jama.2011.769; KHATIB ZA, 1993, CANCER RES, V53, P5535; Kids-v-Cancer, 2012, KIDS V CANC PROGR PR; Kikuchi K, 2013, ONCOGENE, V32, P286, DOI 10.1038/onc.2012.46; Kikuchi K, 2011, CURR TOP DEV BIOL, V96, P33, DOI 10.1016/B978-0-12-385940-2.00002-4; Kolb EA, 2008, PEDIATR BLOOD CANCER, V50, P1190, DOI 10.1002/pbc.21450; Kolb EA, 2010, PEDIATR BLOOD CANCER, V55, P668, DOI 10.1002/pbc.22576; Kramer DB, 2012, NEW ENGL J MED, V367, P1277, DOI 10.1056/NEJMp1207800; Kusafuka T, 1997, J PEDIATR SURG, V32, P1175, DOI 10.1016/S0022-3468(97)90677-1; Lae M, 2007, J PATHOL, V212, P143, DOI 10.1002/path.2170; Landuzzi L, 1998, INT J CANCER, V78, P441, DOI 10.1002/(SICI)1097-0215(19981109)78:4<441::AID-IJC9>3.3.CO;2-H; Langenau DM, 2008, ONCOGENE, V27, P4242, DOI 10.1038/onc.2008.56; Langenau DM, 2007, GENE DEV, V21, P1382, DOI 10.1101/gad.1545007; Lee MH, 2011, CANCER RES, V71, P3921, DOI 10.1158/0008-5472.CAN-10-3358; Lee Y, 2007, ONCOGENE, V26, P6442, DOI 10.1038/sj.onc.1210467; Lee Y, 2006, CANCER RES, V66, P6964, DOI 10.1158/0008-5472.CAN-06-0505; LI FP, 1969, J NATL CANCER I, V43, P1365; Li HG, 2007, CANCER LETT, V253, P215, DOI 10.1016/j.canlet.2007.01.020; Libura J, 2002, BLOOD, V100, P2597, DOI 10.1182/blood-2002-01-0031; Liu AG, 2011, CANCER SCI, V102, P1381, DOI 10.1111/j.1349-7006.2011.01932.x; Liu L, 2008, ONCOGENE, V27, P4998, DOI 10.1038/onc.2008.137; Lock RB, 2012, PEDIATR BLOOD CANCER, V58, P916, DOI 10.1002/pbc.23176; Loh ML, 2013, BLOOD, V121, P485, DOI 10.1182/blood-2012-04-422691; Lukasiewicz E, 2009, FOLIA HISTOCHEM CYTO, V47, P485, DOI 10.2478/v10042-009-0108-x; Ma HW, 2003, MOL CANCER RES, V1, P739; Malempati S, 2012, PEDIATR BLOOD CANCER, V59, P5, DOI 10.1002/pbc.24118; Malik SM, 2010, CLIN CANCER RES, V16, P4921, DOI 10.1158/1078-0432.CCR-10-1214; Mann BS, 2007, ONCOLOGIST, V12, P1247, DOI 10.1634/theoncologist.12-10-1247; Mao J, 2006, CANCER RES, V66, P10171, DOI 10.1158/0008-5472.CAN-06-0657; Marampon F, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-31; Marampon F, 2009, MOL CANCER THER, V8, P543, DOI 10.1158/1535-7163.MCT-08-0570; Maris JM, 2010, PEDIATR BLOOD CANCER, V55, P26, DOI 10.1002/pbc.22430; Marshall AD, 2012, MOL CARCINOGEN, V51, P807, DOI 10.1002/mc.20848; Martinelli S, 2009, GENE CHROMOSOME CANC, V48, P975, DOI 10.1002/gcc.20702; Mascarenhas L, 2010, J CLIN ONCOL, V28, P4658, DOI 10.1200/JCO.2010.29.7390; Mayeenuddin LH, 2010, ONCOGENE, V29, P6367, DOI 10.1038/onc.2010.364; McDermott U, 2009, CANCER RES, V69, P3937, DOI 10.1158/0008-5472.CAN-08-4327; McKenzie PP, 2002, MOL CANCER THER, V1, P1097; Medic S, 2011, BIOCHEM BIOPH RES CO, V411, P832, DOI 10.1016/j.bbrc.2011.07.053; Michaelis M, 2009, CANCER RES, V69, P416, DOI 10.1158/0008-5472.CAN-08-1856; Miekus K, 2010, FOLIA HISTOCHEM CYTO, V48, P104, DOI 10.2478/v10042-008-0091-7; MINNITI CP, 1992, CANCER RES, V52, P1830; Missiaglia E, 2012, J CLIN ONCOL, V30, P1670, DOI 10.1200/JCO.2011.38.5591; Missiaglia E, 2009, GENE CHROMOSOME CANC, V48, P455, DOI 10.1002/gcc.20655; Miyachi M, 2009, CLIN CANCER RES, V15, P4077, DOI 10.1158/1078-0432.CCR-08-2955; Moreau P, 2012, BLOOD, V120, P947, DOI 10.1182/blood-2012-04-403733; Nanni P, 2003, CANCER RES, V63, P2728; Nanni P, 2009, MOL CANCER THER, V8, P754, DOI 10.1158/1535-7163.MCT-08-0678; Nationwide Children's Hospital Biopathology Center, 2012, TISS MICROARRAYS; Neale G, 2008, CLIN CANCER RES, V14, P4572, DOI 10.1158/1078-0432.CCR-07-5090; Nishijo K, 2009, CANCER RES, V69, P2902, DOI 10.1158/0008-5472.CAN-08-3723; Nitzki F, 2011, ONCOGENE, V30, P4428, DOI 10.1038/onc.2011.157; Nordberg J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050819; Norris RE, 2012, NAT REV CANCER, V12, P776, DOI 10.1038/nrc3370; Northwest Sarcoma Foundation, 2012, LEAV LEG PROGR; Ognjanovic Simona, 2012, Sarcoma, V2012, P492086, DOI 10.1155/2012/492086; Ognjanovic S, 2009, CANCER-AM CANCER SOC, V115, P4218, DOI 10.1002/cncr.24465; Ohali A, 2008, GENE CHROMOSOME CANC, V47, P965, DOI 10.1002/gcc.20600; Onisto M, 2005, INT J ONCOL, V27, P791; Paulson V, 2011, GENE CHROMOSOME CANC, V50, P397, DOI 10.1002/gcc.20864; Perez EA, 2011, J SURG RES, V170, pE243, DOI 10.1016/j.jss.2011.03.001; Phillips DC, 2007, CELL DEATH DIFFER, V14, P1780, DOI 10.1038/sj.cdd.4402198; Pillay K, 2002, HISTOPATHOLOGY, V41, P461, DOI 10.1046/j.1365-2559.2002.01534.x; Pressey JG, 2011, PEDIATR BLOOD CANCER, V57, P930, DOI 10.1002/pbc.23174; Raimondi L, 2012, CELL DEATH DIFFER, V19, P871, DOI 10.1038/cdd.2011.171; Reynolds CP, 2013, PEDIATR BLOOD CANCER, V60, P791, DOI 10.1002/pbc.24301; Ricci C, 2000, INT J CANCER, V87, P29, DOI 10.1002/1097-0215(20000701)87:1<29::AID-IJC5>3.3.CO;2-A; Riuzzi F, 2007, AM J PATHOL, V171, P947, DOI 10.2353/ajpath.2007.070049; Robert NJ, 2011, J CLIN ONCOL, V29, P1252, DOI 10.1200/JCO.2010.28.0982; Rodriguez-Perales S, 2004, CANCER GENET CYTOGEN, V148, P35, DOI 10.1016/S0165-4608(03)00216-4; Roma J, 2011, CLIN CANCER RES, V17, P505, DOI 10.1158/1078-0432.CCR-10-0166; Romualdi C, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-287; Rossi S, 2011, J CELL MOL MED, V15, P2553, DOI 10.1111/j.1582-4934.2011.01364.x; Rossi S, 2011, EUR J CANCER, V47, P761, DOI 10.1016/j.ejca.2010.10.018; Rubin BP, 2011, CANCER CELL, V19, P177, DOI 10.1016/j.ccr.2010.12.023; Santoriello C, 2009, DIS MODEL MECH, V2, P56, DOI 10.1242/dmm.001016; Sarcoma Foundation of America, 2012, PAT REG PROGR; Sartori F, 2006, CANCER, V106, P1766, DOI 10.1002/cncr.21772; Sarver AL, 2010, CANCER RES, V70, P9570, DOI 10.1158/0008-5472.CAN-10-2074; Sateren WB, 2002, J CLIN ONCOL, V20, P2109, DOI 10.1200/JCO.2002.08.056; Schaaf G, 2010, CANCER RES, V70, P762, DOI 10.1158/0008-5472.CAN-09-2532; Schaffer BS, 2010, MOL CANCER THER, V9, P2354, DOI 10.1158/1535-7163.MCT-10-0207; Scotlandi K, 2005, CANCER RES, V65, P3868, DOI 10.1158/0008-5472.CAN-04-3192; Shalaby T, 2010, MOL CANCER THER, V9, P167, DOI 10.1158/1535-7163.MCT-09-0586; SHAPIRO DN, 1990, CANCER RES, V50, P6002; SHAPIRO DN, 1994, J CLIN INVEST, V94, P1235, DOI 10.1172/JCI117441; Sharp R, 2002, NAT MED, V8, P1276, DOI 10.1038/nm787; Sharpless NE, 2001, MOL CELL, V8, P1187, DOI 10.1016/S1097-2765(01)00425-7; Shor AC, 2007, CANCER RES, V67, P2800, DOI 10.1158/0008-5472.CAN-06-3469; Shukla N, 2012, CLIN CANCER RES, V18, P748, DOI 10.1158/1078-0432.CCR-11-2056; Simon-Keller K, 2013, EXPERT OPIN THER TAR, V17, P127, DOI 10.1517/14728222.2013.734500; Smith MA, 2012, AACR ANN M AM ASS CA; Smith MA, 2012, 54 ASH ANN M EXP AM; Smith MA, 2008, PEDIATR BLOOD CANCER, V51, P34, DOI 10.1002/pbc.21508; Smithey BE, 2002, AM J SURG PATHOL, V26, P486, DOI 10.1097/00000478-200204000-00011; Soundararajan A, 2012, PEDIATR BLOOD CANCER, V59, P485, DOI 10.1002/pbc.24075; Spunt SL, 2012, CANCER-AM CANCER SOC, V118, P3002, DOI 10.1002/cncr.26620; Steinbrook R, 2012, JAMA-J AM MED ASSOC, V308, P1437, DOI 10.1001/jama.2012.12829; Stephens PJ, 2011, CELL, V144, P27, DOI 10.1016/j.cell.2010.11.055; Takahashi Y, 2004, MODERN PATHOL, V17, P660, DOI 10.1038/modpathol.3800101; Takaoka E, 2012, AM J CANCER RES, V2, P141; Taniguchi E, 2008, ONCOGENE, V27, P6550, DOI 10.1038/onc.2008.255; Taylor AC, 2000, MED PEDIATR ONCOL, V35, P96, DOI 10.1002/1096-911X(200008)35:2<96::AID-MPO2>3.0.CO;2-Z; Taylor JG, 2009, J CLIN INVEST, V119, P3395, DOI 10.1172/JCI39703; Thompson CA, 2009, AM J HEALTH-SYST PH, V66, P1890, DOI 10.2146/news090080; Tostar U, 2006, J PATHOL, V208, P17, DOI 10.1002/path.1882; Tostar U, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037761; Tostar Ulrica, 2010, Genes Cancer, V1, P941, DOI 10.1177/1947601910385449; VERNETDERGARABEDIAN B, 1994, J CLIN INVEST, V94, P555, DOI 10.1172/JCI117369; Wachtel M, 2006, J CLIN ONCOL, V24, P816, DOI 10.1200/JCO.2005.03.4934; Wachtel M, 2004, CANCER RES, V64, P5539, DOI 10.1158/0008-5472.CAN-04-0844; Wan XL, 2012, CANCER RES, V72, P5889, DOI 10.1158/0008-5472.CAN-12-1991; Wang H, 2003, INT J EXP PATHOL, V84, P153, DOI 10.1046/j.1365-2613.2003.00347.x; Wang SL, 2010, CANCER SCI, V101, P1108, DOI 10.1111/j.1349-7006.2010.01512.x; Wei CC, 2011, INT J ONCOL, V38, P279, DOI 10.3892/ijo_00000848; Weigel B, 2010, J CLIN ONCOL, V28; Weihkopf T, 2008, EUR J CANCER, V44, P432, DOI 10.1016/j.ejca.2007.11.013; Whiteford CC, 2007, CANCER RES, V67, P32, DOI 10.1158/0008-5472.CAN-06-0610; Williams BA, 2004, J PEDIAT HEMATOL ONC, V26, P243, DOI 10.1097/00043426-200404000-00006; Wysoczynski M, 2007, CANCER RES, V67, P2131, DOI 10.1158/0008-5472.CAN-06-1021; Xu JM, 2010, CANCER RES, V70, P6566, DOI 10.1158/0008-5472.CAN-10-0942; Yamanaka H, 2010, MOL MED REP, V3, P133, DOI 10.3892/mmr_00000230; Yan D, 2009, J BIOL CHEM, V284, P29596, DOI 10.1074/jbc.M109.020511; Yang XHR, 2009, NAT GENET, V41, P1176, DOI 10.1038/ng.454; Ye L, 2005, CHINESE MED J-PEKING, V118, P678; Ye L, 2006, INT J ONCOL, V29, P1149; Yoo JY, 1997, ARCH PATHOL LAB MED, V121, P395; Yoon JW, 2002, J BIOL CHEM, V277, P5548, DOI 10.1074/jbc.M105708200; Yoshida A, 2013, MODERN PATHOL, V26, P772, DOI 10.1038/modpathol.2012.222; Yu SJ, 2004, CLIN CANCER RES, V10, P6750, DOI 10.1158/1078-0432.CCR-04-0223; Zhang JS, 2004, CANCER RES, V64, P6026, DOI 10.1158/0008-5472.CAN-03-2594; Zhang L, 2003, J BIOL CHEM, V278, P27, DOI 10.1074/jbc.M205424200	237	25	25	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2014	33	15					1877	1889		10.1038/onc.2013.129	http://dx.doi.org/10.1038/onc.2013.129			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RK	23665679				2022-12-17	WOS:000334346300001
J	Lin, H; Lin, Q; Liu, M; Lin, Y; Wang, X; Chen, H; Xia, Z; Lu, B; Ding, F; Wu, Q; Wang, HR				Lin, H.; Lin, Q.; Liu, M.; Lin, Y.; Wang, X.; Chen, H.; Xia, Z.; Lu, B.; Ding, F.; Wu, Q.; Wang, H-R			PKA/Smurf1 signaling-mediated stabilization of Nur77 is required for anticancer drug cisplatin-induced apoptosis	ONCOGENE			English	Article						Smurf1; Nur77; apoptosis; PKA; JNK; cisplatin	UBIQUITIN LIGASE SMURF2; NUCLEAR RECEPTOR NUR77; N-TERMINAL KINASE; PROTEIN-KINASE; CELL APOPTOSIS; CANCER-CELLS; DEGRADATION; PHOSPHORYLATION; MECHANISMS; POLARITY	The orphan nuclear receptor Nur77 regulates diverse cellular activities, including cell proliferation, differentiation and apoptosis. The c-Jun N-terminal kinase (JNK) have a dual role in controlling the function of Nur77. While JNK-mediated phosphorylation of Nur77 positively regulates its translocation to the mitochondria to induce apoptosis, it negatively regulates the stability of Nur77. The underlying mechanism for the dual role of JNK in regulating Nur77, however, is unclear. Here, we report that E3 ubiquitin ligase Smad ubiquitination regulatory factor 1 (Smurf1) prevents Nur77 degradation through mediating its unconventional ubiquitination, thereby mitigating the JNK-mediated downregulating effect, which leads to Nur77 accumulation and subsequent translocation to mitochondria to trigger apoptosis. In this process, protein kinase A (PKA)-mediated phosphorylation of Smurf1 at Thr306 is a prerequisite step. Accordingly, cyclic AMP/PKA signaling switches the fate of Nur77 from degradation to triggering apoptosis in chemotherapy drug cisplatin-treated cells. Hence, our study revealed a novel mechanism, by which PKA/Smurf1 antagonizes the downregulating effect of JNK on Nur77, leading to the accumulation of Nur77 for apoptosis induction triggered by cisplatin.	[Lin, H.; Lin, Q.; Liu, M.; Lin, Y.; Wang, X.; Chen, H.; Ding, F.; Wu, Q.; Wang, H-R] Xiamen Univ, Sch Life Sci, State Key Lab Cellular Stress Biol, Xiamen 361102, Fujian, Peoples R China; [Xia, Z.] Zhejiang Univ, Inst Life Sci, Hangzhou 310003, Zhejiang, Peoples R China; [Xia, Z.] Zhejiang Univ, Coll Med, Hangzhou 310003, Zhejiang, Peoples R China; [Lu, B.] Univ Pittsburgh, Sch Med, Dept Immunol, Pittsburgh, PA USA	Xiamen University; Zhejiang University; Zhejiang University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Wang, HR (corresponding author), Xiamen Univ, Sch Life Sci, State Key Lab Cellular Stress Biol, D301,Huang Chao Yang Bldg, Xiamen 361102, Fujian, Peoples R China.	wanghr@xmu.edu.cn	Ding, Feng/AAH-7335-2019; Lin, Huayue/G-8760-2017	Lin, Huayue/0000-0003-0151-3206; Wang, Hong-Rui/0000-0002-2916-8849	Ministry of Science and Technology of China [2011CB910800]; National Natural Science Foundation of China [31070771, 30970614, 81272248]; Fundamental Research Funds for the Central Universities [2010121087]; Specialized Research Fund for the Doctoral Program of Higher Education of China [20090121120017]; State Bureau of Foreign Experts and Ministry of Education [B12001]	Ministry of Science and Technology of China(Ministry of Science and Technology, China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Specialized Research Fund for the Doctoral Program of Higher Education of China(Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP)); State Bureau of Foreign Experts and Ministry of Education	This work was supported by the Ministry of Science and Technology of China (2011CB910800), the National Natural Science Foundation of China (31070771, 30970614, 81272248), the Fundamental Research Funds for the Central Universities (2010121087), the Specialized Research Fund for the Doctoral Program of Higher Education of China (20090121120017) and Project 111 sponsored by the State Bureau of Foreign Experts and Ministry of Education (B12001). We thank SC Lin for commenting on the manuscript.	Cepeda V, 2007, ANTI-CANCER AGENT ME, V7, P3, DOI 10.2174/187152007779314044; Chen HZ, 2012, GUT, V61, P714, DOI 10.1136/gutjnl-2011-300783; Cheng PL, 2011, NEURON, V69, P231, DOI 10.1016/j.neuron.2010.12.021; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384; Han YH, 2006, ONCOGENE, V25, P2974, DOI 10.1038/sj.onc.1209358; HAZEL TG, 1991, MOL CELL BIOL, V11, P3239, DOI 10.1128/MCB.11.6.3239; HIRATA Y, 1993, J BIOL CHEM, V268, P24808; Hoeller D, 2006, NAT REV CANCER, V6, P776, DOI 10.1038/nrc1994; Holmes WF, 2003, ONCOGENE, V22, P6377, DOI 10.1038/sj.onc.1206694; Hsu SC, 2003, BLOOD, V101, P970, DOI 10.1182/blood-2002-03-0744; Insel PA, 2012, ACTA PHYSIOL, V204, P277, DOI 10.1111/j.1748-1716.2011.02273.x; Izzi L, 2004, ONCOGENE, V23, P2071, DOI 10.1038/sj.onc.1207412; Jacobs CM, 2004, J BIOL CHEM, V279, P50097, DOI 10.1074/jbc.M409145200; Jin YH, 2004, J BIOL CHEM, V279, P29409, DOI 10.1074/jbc.M313120200; Kartalou M, 2001, MUTAT RES-FUND MOL M, V478, P23, DOI 10.1016/S0027-5107(01)00141-5; Kulathu Y, 2012, NAT REV MOL CELL BIO, V13, P508, DOI 10.1038/nrm3394; Lebwohl D, 1998, EUR J CANCER, V34, P1522, DOI 10.1016/S0959-8049(98)00224-X; Lee SO, 2011, EXPERT OPIN THER TAR, V15, P195, DOI 10.1517/14728222.2011.547481; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; Liu B, 2007, ENDOCRINOLOGY, V148, P34, DOI 10.1210/en.2006-0800; Liu JJ, 2010, CANCER RES, V70, P3628, DOI 10.1158/0008-5472.CAN-09-3160; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; Masuyama N, 2001, J BIOL CHEM, V276, P32799, DOI 10.1074/jbc.M105431200; Moll UM, 2006, ONCOGENE, V25, P4725, DOI 10.1038/sj.onc.1209601; Narimatsu M, 2009, CELL, V137, P295, DOI 10.1016/j.cell.2009.02.025; Nie J, 2010, J BIOL CHEM, V285, P22816, DOI 10.1074/jbc.M110.126920; Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718; Pearen MA, 2010, MOL ENDOCRINOL, V24, P1891, DOI 10.1210/me.2010-0015; Pekarsky Y, 2001, P NATL ACAD SCI USA, V98, P3690, DOI 10.1073/pnas.051003198; Popov N, 2010, NAT CELL BIOL, V12, P973, DOI 10.1038/ncb2104; Sanna MG, 2002, MOL CELL BIOL, V22, P1754, DOI 10.1128/MCB.22.6.1754-1766.2002; Schwamborn JC, 2007, EMBO J, V26, P1410, DOI 10.1038/sj.emboj.7601580; Wang AB, 2009, J IMMUNOL, V183, P3268, DOI 10.4049/jimmunol.0900894; Wang HR, 2006, METHOD ENZYMOL, V406, P437, DOI 10.1016/S0076-6879(06)06032-0; Wang HR, 2003, SCIENCE, V302, P1775, DOI 10.1126/science.1090772; Wiesner S, 2007, CELL, V130, P651, DOI 10.1016/j.cell.2007.06.050; Wingate AD, 2006, BIOCHEM J, V393, P715, DOI 10.1042/BJ20050967; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; Yamashita M, 2005, CELL, V121, P101, DOI 10.1016/j.cell.2005.01.035; Yang H, 2011, HEPATOLOGY, V53, P865, DOI 10.1002/hep.24101; Yao LM, 2012, CARCINOGENESIS, V33, P301, DOI 10.1093/carcin/bgr287; Yoon K, 2011, CARCINOGENESIS, V32, P836, DOI 10.1093/carcin/bgr040; Yu H, 2007, CANCER BIOL THER, V6, P405, DOI 10.4161/cbt.6.3.3755; Zambon AC, 2005, P NATL ACAD SCI USA, V102, P8561, DOI 10.1073/pnas.0503363102; Zhang LZ, 2008, J BIOL CHEM, V283, P4304, DOI 10.1074/jbc.M708673200; Zhao M, 2003, J BIOL CHEM, V278, P27939, DOI 10.1074/jbc.M304132200	47	25	29	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2014	33	13					1629	1639		10.1038/onc.2013.116	http://dx.doi.org/10.1038/onc.2013.116			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9QY	23584473				2022-12-17	WOS:000334344700003
J	Reyes, D; Ballare, C; Castellano, G; Soronellas, D; Bago, JR; Blanco, J; Beato, M				Reyes, D.; Ballare, C.; Castellano, G.; Soronellas, D.; Bago, J. R.; Blanco, J.; Beato, M.			Activation of mitogen- and stress-activated kinase 1 is required for proliferation of breast cancer cells in response to estrogens or progestins	ONCOGENE			English	Article						breast cancer; xenografts; estrogen receptor; progesterone receptor; T47D; hormone signaling	NF-KAPPA-B; PROGESTERONE-RECEPTOR; HISTONE H3; GENE-REGULATION; PHOSPHORYLATION; PROTEIN; PATHWAY; MSK1; INDUCTION; ESTRADIOL	Growth of breast cancers is often dependent on ovarian steroid hormones making the tumors responsive to antagonists of hormone receptors. However, eventually the tumors become hormone independent, raising the need to identify downstream targets for the inhibition of tumor growth. One possibility is to focus on the signaling mechanisms used by ovarian steroid hormones to induce breast cancer cell proliferation. Here we report that the mitogen- and stress-activated kinase 1 (MSK1) could be a potential druggable target. Using the breast cancer cell line T47D, we show that estrogens (E2) and progestins activate MSK1, which forms a complex with the corresponding hormone receptor. Inhibition of MSK1 activity with H89 or its depletion by MSK1 short hairpin RNAs (shRNAs) specifically abrogates cell proliferation in response to E2 or progestins without affecting serum-induced cell proliferation. MSK1 activity is required for the transition from the G1- to the S-phase of the cell cycle and inhibition of MSK1 compromises both estradiol- and progestin-dependent induction of cell cycle genes. ChIP-seq experiments identified binding of MSK1 to progesterone receptor-binding sites associated with hormone-responsive genes. MSK1 recruitment to epigenetically defined enhancer regions supports the need of MSK1 as a chromatin remodeler in hormone-dependent regulation of gene transcription. In agreement with this interpretation, expression of a histone H3 mutated at S10 eliminates the hormonal effect on cell proliferation and on induction of relevant target genes. Finally, we show that E2- or progestin-dependent growth of T47D cells xenografted in immunodefficient mice is inhibited by depletion of MSK1, indicating that our findings are not restricted to cultured cells, and that MSK1 plays an important role for hormone-dependent breast cancer growth in a more physiological context.	[Reyes, D.; Ballare, C.; Castellano, G.; Soronellas, D.; Beato, M.] CRG, Barcelona 08003, Spain; [Reyes, D.; Ballare, C.; Castellano, G.; Soronellas, D.; Beato, M.] UPF, Barcelona, Spain; [Bago, J. R.; Blanco, J.] CIBER BBN, CSIC ICCC, Cardiovasc Res Ctr, Barcelona, Spain	Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); Pompeu Fabra University; CIBER - Centro de Investigacion Biomedica en Red; CIBERBBN; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Institut Catala de Ciencies Cardiovasculars (ICCC)	Beato, M (corresponding author), CRG, Doctor Aiguader 88, Barcelona 08003, Spain.	miguel.beato@crg.eu	BAGO, JULI R/M-3526-2018; Beato, Miguel/B-5564-2015; Reyes, Diana/GSI-6210-2022; Reyes Garau, Diana/ABF-9958-2021; Reyes, Diana/A-9441-2017; Blanco, Jeronimo/H-2764-2015; Ballare, Cecilia/F-2593-2016	BAGO, JULI R/0000-0002-2862-4048; Beato, Miguel/0000-0002-2878-2222; Reyes Garau, Diana/0000-0002-9746-6485; Blanco, Jeronimo/0000-0003-3765-0640; Ballare, Cecilia/0000-0002-9442-807X; Castellano, Giancarlo/0000-0002-5715-7733	Spanish government [BMC 2003-02902, 2010-15313, CSD2006-00049]; European Union (IP HEROIC); Catalan government (AGAUR); fellowship from the Spanish Ministry of Science	Spanish government(Spanish GovernmentEuropean Commission); European Union (IP HEROIC); Catalan government (AGAUR)(Agencia de Gestio D'Ajuts Universitaris de Recerca Agaur (AGAUR)); fellowship from the Spanish Ministry of Science	We thank Luciano Di Croce, CRG, for providing the expression vector for histone H3, the CRG ultrasequencing facility and Dr Juan Valcarcel for help with the manuscript. The experimental work has been supported by grants from the Spanish government (BMC 2003-02902 and 2010-15313; CSD2006-00049), the European Union (IP HEROIC) and the Catalan government (AGAUR). DR was the recipient of a fellowship from the Spanish Ministry of Science.	Allred DC, 2001, ENDOCR-RELAT CANCER, V8, P47, DOI 10.1677/erc.0.0080047; Arthur JSC, 2004, J NEUROSCI, V24, P4324, DOI 10.1523/JNEUROSCI.5227-03.2004; Ballare C, 2003, MOL CELL BIOL, V23, P1994, DOI 10.1128/MCB.23.6.1994-2008.2003; Ballare C, 2013, MOL CELL, V49, P67, DOI 10.1016/j.molcel.2012.10.019; Banks E, 2003, LANCET, V362, P419, DOI 10.1016/S0140-6736(03)14065-2; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BLOBEL GA, 1995, MOL CELL BIOL, V15, P3147; Boonyaratanakornkit V, 2001, MOL CELL, V8, P269, DOI 10.1016/S1097-2765(01)00304-5; Cerillo G, 1998, J STEROID BIOCHEM, V67, P79, DOI 10.1016/S0960-0760(98)00078-8; Chang S, CANC INVEST, V29, P240; CLARKE CL, 1990, J BIOL CHEM, V265, P12694; Clarke R, 2003, ONCOGENE, V22, P7316, DOI 10.1038/sj.onc.1206937; Cui KR, 2009, CELL STEM CELL, V4, P80, DOI 10.1016/j.stem.2008.11.011; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Drobic B, NUCL ACIDS RES, V38, P3196; Drobic B, 2010, NUCLEIC ACIDS RES, V38, P3196, DOI 10.1093/nar/gkq030; Foidart JM, 1998, FERTIL STERIL, V69, P963, DOI 10.1016/S0015-0282(98)00042-9; Harrell JC, 2007, CANCER RES, V67, P10582, DOI 10.1158/0008-5472.CAN-07-1655; Hewitt SC, 2005, ANNU REV PHYSIOL, V67, P285, DOI 10.1146/annurev.physiol.67.040403.115914; Hirota T, 2005, NATURE, V438, P1176, DOI 10.1038/nature04254; Khan SA, 1998, J NATL CANCER I, V90, P37, DOI 10.1093/jnci/90.1.37; Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4; Kuukasjarvi T, 1996, J CLIN ONCOL, V14, P2584, DOI 10.1200/JCO.1996.14.9.2584; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Lauper N, 1998, ONCOGENE, V17, P2637, DOI 10.1038/sj.onc.1202477; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lochner A, 2006, CARDIOVASC DRUG REV, V24, P261, DOI 10.1111/j.1527-3466.2006.00261.x; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; NANDI S, 1958, J NATL CANCER I, V21, P1039; Vicent GP, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000567; Prigent C, 2003, J CELL SCI, V116, P3677, DOI 10.1242/jcs.00735; Ritchie ME, 2007, BIOINFORMATICS, V23, P2700, DOI 10.1093/bioinformatics/btm412; Sancho M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000227; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; Strutt H, 1999, METH MOL B, V119, P455; Subtil-Rodriguez A, 2008, MOL CELL BIOL, V28, P3830, DOI 10.1128/MCB.01217-07; Thomson S, 1999, SEMIN CELL DEV BIOL, V10, P205, DOI 10.1006/scdb.1999.0302; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Vicent GP, GENES DEV, V25, P845; Vicent GP, 2006, MOL CELL, V24, P367, DOI 10.1016/j.molcel.2006.10.011; Vicent Guillermo P, 2009, Nucl Recept Signal, V7, pe008, DOI 10.1621/nrs.07008; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Weinstein-Oppenheimer CR, 2002, CANCER BIOL THER, V1, P256, DOI 10.4161/cbt.77; Wiggin GR, 2002, MOL CELL BIOL, V22, P2871, DOI 10.1128/MCB.22.8.2871-2881.2002; WILSON JE, 1972, BIOCHIM BIOPHYS ACTA, V276, P568, DOI 10.1016/0005-2744(72)91022-4; Wright RHG, 2012, GENE DEV, V26, P1972, DOI 10.1101/gad.193193.112	50	25	25	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	2014	33	12					1570	1580		10.1038/onc.2013.95	http://dx.doi.org/10.1038/onc.2013.95			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD4TS	23604116				2022-12-17	WOS:000333244200010
J	Oh, ET; Park, MT; Song, MJ; Lee, H; Cho, YU; Kim, SJ; Chu, YC; Choi, EK; Park, HJ				Oh, E-T; Park, M-T; Song, M-J; Lee, H.; Cho, Y. U.; Kim, S. J.; Chu, Y-C; Choi, E. K.; Park, H. J.			Radiation-induced angiogenic signaling pathway in endothelial cells obtained from normal and cancer tissue of human breast	ONCOGENE			English	Article						angiogenesis; cancer endothelial cells; ionizing radiation	MATRIX METALLOPROTEINASE-2 EXPRESSION; IONIZING-RADIATION; TUMOR-GROWTH; IN-VITRO; INTERLEUKIN-6 EXPRESSION; GENE-EXPRESSION; C-JUN; ANGIOSTATIN; RADIOSENSITIVITY; INHIBITOR	Despite strong possibility that endothelial cells (ECs) of tumors and normal tissues may differ in various aspects, most previous studies on ECs have used normal cells. Here, we purified ECs from tumorous and normal human breast tissues, and studied the effect of radiation on angiogenesis and relevant molecular mechanisms in these cells. We found that in normal tissue-derived ECs (NECs), 4 Gy irradiation increased tube formation, matrix metalloproteinase 2 (MMP-2) expression and extracellular signal-regulated kinase (ERK) pathway activation. In cancer-derived ECs (CECs), however, 4Gy irradiation significantly reduced tube formation, increased the production of angiostatin and interleukin-6 (IL-6), and upregulated AKT and c-Jun N-terminal kinase (JNK) pathway activation. Knockdown experiments showed that siMMP-2 efficiently inhibited tube formation by irradiated NECs, whereas siPlasminogen effectively attenuated the radiation-induced suppression of tube formation and the upregulation of angiostatin in CECs. Moreover, silL-6 clearly inhibited the radiation-induced generation of angiostatin in CECs. Inhibition of ERK with a pharmacological inhibitor or small interfering RNAs (siRNAs) markedly suppressed the radiation-induced tube formation and MMP-2 upregulation in NECs, whereas the inhibition of either AKT or JNK with pharmacological inhibitor or siRNA treatment of CECs markedly attenuated the inhibition of tube formation and the upregulation of angiostatin and IL-6 caused by 4 Gy irradiation. These observations collectively demonstrate that there are distinct differences in the radiation responses of NECs and CECs, and might provide important clues for improving the efficacy of radiation therapy.	[Oh, E-T; Park, M-T; Song, M-J; Lee, H.; Park, H. J.] Inha Univ, Coll Med, Dept Microbiol, Ctr Adv Med Educ,Project BK21, Inchon 400712, South Korea; [Cho, Y. U.; Kim, S. J.] Inha Univ, Coll Med, Dept Surg, Inchon 400712, South Korea; [Chu, Y-C] Inha Univ, Coll Med, Dept Pathol, Inchon 400712, South Korea; [Choi, E. K.] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Radiat Oncol, Seoul, South Korea	Inha University; Inha University; Inha University; University of Ulsan; Asan Medical Center	Park, HJ (corresponding author), Inha Univ, Coll Med, Dept Microbiol, Jungsuck B-D B Dong 3F,7-241,3rd St, Inchon 400712, South Korea.	park001@inha.ac.kr			National Nuclear R&D Program through the National Research Foundation of Korea (NRF); Ministry of Education, Science and Technology [2011-0015230, 2009-0093747]; Korean Health Technology R&D Project, Ministry of Health and Welfare [A062254]	National Nuclear R&D Program through the National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea); Korean Health Technology R&D Project, Ministry of Health and Welfare	This research was supported by the National Nuclear R&D Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2011-0015230 and 2009-0093747), and by a grant of the Korean Health Technology R&D Project, Ministry of Health and Welfare (A062254).	Adya R, 2008, CARDIOVASC RES, V78, P356, DOI 10.1093/cvr/cvm111; Ahmad M, 2007, MICROVASC RES, V73, P14, DOI 10.1016/j.mvr.2006.08.005; Badiga AV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020614; Bannach FG, 2004, J THROMB HAEMOST, V2, P2205, DOI 10.1111/j.1538-7836.2004.01022.x; Barcellos-Hoff MH, 2005, NAT REV CANCER, V5, P867, DOI 10.1038/nrc1735; Brown M, 2003, SCIENCE, V302; Burwick NR, 2005, J BIOL CHEM, V280, P1740, DOI 10.1074/jbc.M405947200; Bussink J, 2008, LANCET ONCOL, V9, P288, DOI 10.1016/S1470-2045(08)70073-1; Chan DA, 2007, CANCER METAST REV, V26, P333, DOI 10.1007/s10555-007-9063-1; Chen FH, 2011, INT J RADIAT ONCOL, V80, P1512, DOI 10.1016/j.ijrobp.2011.02.055; Chou CH, 2009, INT J RADIAT ONCOL, V75, P1553, DOI 10.1016/j.ijrobp.2009.08.034; Creemers EEJM, 2001, CIRC RES, V89, P201, DOI 10.1161/hh1501.094396; Djonov V, 2002, INT J ONCOL, V21, P25; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fee D, 2000, CYTOKINE, V12, P655, DOI 10.1006/cyto.1999.0599; Fokas E, 2012, CANCER METAST REV, V31, P823, DOI 10.1007/s10555-012-9394-4; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Garcia-Barros M, 2003, SCIENCE, V300, P1155, DOI 10.1126/science.1082504; Gerweck LE, 2006, CANCER RES, V66, P8352, DOI 10.1158/0008-5472.CAN-06-0533; Gorski DH, 1998, CANCER RES, V58, P5686; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Haimovitz-Fredman A., 1995, RADIAT ONCOL INVEST, V3, P1; Hatzi E, 2002, ONCOGENE, V21, P3552, DOI 10.1038/sj.onc.1205440; Hida K, 2004, CANCER RES, V64, P8249, DOI 10.1158/0008-5472.CAN-04-1567; Hida K, 2008, CANCER SCI, V99, P459, DOI 10.1111/j.1349-7006.2007.00704.x; Ji WDR, 1998, FASEB J, V12, P1731, DOI 10.1096/fasebj.12.15.1731; Karar J, 2009, CANCER BIOL THER, V8, P1994, DOI 10.4161/cbt.8.21.9988; Kim KH, 2011, IMMUNE NETW, V11, P123, DOI DOI 10.4110/IN.2011.11.2.123; Konerding MA, 2001, BRIT J CANCER, V84, P1354, DOI 10.1054/bjoc.2001.1809; Lin HY, 2011, J CELL PHYSIOL, V226, P1573, DOI 10.1002/jcp.22489; Lunt SJ, 2009, CLIN EXP METASTAS, V26, P19, DOI 10.1007/s10585-008-9182-2; Milliat F, 2006, AM J PATHOL, V169, P1484, DOI 10.2353/ajpath.2006.060116; Moeller BJ, 2004, CANCER CELL, V5, P429, DOI 10.1016/S1535-6108(04)00115-1; Nguyen V, 2000, RADIAT RES, V154, P531, DOI 10.1667/0033-7587(2000)154[0531:LEOIRO]2.0.CO;2; Nilsson MB, 2005, CANCER RES, V65, P10794, DOI 10.1158/0008-5472.CAN-05-0623; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Pang XF, 2009, CANCER RES, V69, P5893, DOI 10.1158/0008-5472.CAN-09-0755; Park HJ, 2012, RADIAT RES, V177, P311, DOI 10.1667/RR2773.1; Park HJ, 2003, RADIAT RES, V159, P86, DOI 10.1667/0033-7587(2003)159[0086:IOEPOG]2.0.CO;2; Park MT, 2012, J RADIAT RES, V53, P570, DOI 10.1093/jrr/rrs011; Park MT, 2012, MICROVASC RES, V84, P140, DOI 10.1016/j.mvr.2012.06.002; Ribatti D, 2009, LEUKEMIA RES, V33, P638, DOI 10.1016/j.leukres.2008.11.019; Shao ZL, 2006, CIRC RES, V98, P111, DOI 10.1161/01.RES.0000197781.20524.b9; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; Skuli N, 2009, CANCER RES, V69, P3308, DOI 10.1158/0008-5472.CAN-08-2158; Soff GA, 2000, CANCER METAST REV, V19, P97, DOI 10.1023/A:1026525121027; Song CW, 1971, CANCER RES, V4, P31; St Croix B, 2000, SCIENCE, V289, P1197; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Sweeney NV, 2004, CARDIOVASC RES, V63, P625, DOI 10.1016/j.cardiores.2004.05.008; Truman JP, 2010, PLOS ONE, V5, DOI [10.1371/annotation/6e222ad5-b175-4a00-9d04-4d120568a897, 10.1371/journal.pone.0012310]; Vala IS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011222; VanderMeeren A, 1997, MEDIAT INFLAMM, V6, P185, DOI 10.1080/09629359791677; Verhoeff JJC, 2009, EUR J CANCER, V45, P3074, DOI 10.1016/j.ejca.2009.08.004; Vincenti S, 2007, MICROVASC RES, V73, P14; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; Vorotnikova E, 2004, RADIAT RES, V161, P174, DOI 10.1667/RR3107; Wei JW, 2007, ANTICANCER RES, V27, P1415; Wu WT, 2005, ENDOCRINOLOGY, V146, P3387, DOI 10.1210/en.2004-1654; Zhao WL, 2004, RADIAT RES, V161, P418, DOI 10.1667/3155	61	25	26	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2014	33	10					1229	1238		10.1038/onc.2013.70	http://dx.doi.org/10.1038/onc.2013.70			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AC6KI	23503466				2022-12-17	WOS:000332631100003
J	Marques, N; Sese, M; Canovas, V; Valente, F; Bermudo, R; de Torres, I; Fernandez, Y; Abasolo, I; Fernandez, PL; Contreras, H; Castellon, E; Celia-Terrassa, T; Mendez, R; Cajal, SRY; Thomson, TM; Paciucci, R				Marques, N.; Sese, M.; Canovas, V.; Valente, F.; Bermudo, R.; de Torres, I.; Fernandez, Y.; Abasolo, I.; Fernandez, P. L.; Contreras, H.; Castellon, E.; Celia-Terrassa, T.; Mendez, R.; Ramon y Cajal, S.; Thomson, T. M.; Paciucci, R.			Regulation of protein translation and c-Jun expression by prostate tumor overexpressed 1	ONCOGENE			English	Article						PTOV1; c-Jun; translation; prostate cancer; invasion	RECEPTOR-INTERACTING PROTEIN; TRANSCRIPTION FACTOR SNAIL; GENE-EXPRESSION; KINASE-C; RACK1; ACTIVATION; CANCER; INVASION; GROWTH; VP16	Prostate tumor overexpressed-1 (PTOV1), a modulator of the Mediator transcriptional regulatory complex, is expressed at high levels in prostate cancer and other neoplasias in association with a more aggressive disease. Here we show that PTOV1 interacts directly with receptor of activated protein C kinase 1 (RACK1), a regulator of protein kinase C and Jun signaling and also a component of the 40S ribosome. Consistent with this interaction, PTOV1 was associated with ribosomes and its overexpression promoted global protein synthesis in prostate cancer cells and COS-7 fibroblasts in a mTORC1-dependent manner. Transfection of ectopic PTOV1 enhanced the expression of c-Jun protein without affecting the levels of c-Jun or RACK1 mRNA. Conversely, knockdown of PTOV1 caused significant declines in global protein synthesis and c-Jun protein levels. High levels of PTOV1 stimulated the motility and invasiveness of prostate cancer cells, which required c-Jun, whereas knockdown of PTOV1 strongly inhibited the tumorigenic and metastatic potentials of PC-3 prostate cancer cells. In human prostate cancer samples, the expression of high levels of PTOV1 in primary and metastatic tumors was significantly associated with increased nuclear localization of active c-Jun. These results unveil new functions of PTOV1 in the regulation of protein translation and in the progression of prostate cancer to an invasive and metastatic disease.	[Marques, N.; Sese, M.; Canovas, V.; Valente, F.; Paciucci, R.] Univ Autonoma Barcelona, Vall dHebron Inst Res, Res Unit Biomed Translat & Pediat Onco, E-08193 Barcelona, Spain; [Bermudo, R.; Celia-Terrassa, T.; Thomson, T. M.] CSIC, Inst Mol Biol, Dept Cell Biol, Barcelona, Spain; [Bermudo, R.; Fernandez, P. L.] Univ Barcelona, Inst Invest Biomed August Pi i Sunyer, Dept Pathol & Tumour Bank, Hosp Clin, Barcelona, Spain; [de Torres, I.; Ramon y Cajal, S.] Univ Autonoma Barcelona, Vall dHebron Hosp, Dept Pathol, E-08193 Barcelona, Spain; [Fernandez, Y.; Abasolo, I.] Vall dHebron Inst Recerca, Mol Imaging Platform CIBBIM Nanomed, Barcelona, Spain; [Contreras, H.; Castellon, E.] Univ Chile, Dept Physiol & Biophys, Lab Mol & Cellular Androl, Fac Med, Santiago, Chile; [Mendez, R.] Univ Barcelona, Inst Res Biomed, Barcelona, Spain	Autonomous University of Barcelona; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB); University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Universidad de Chile; Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; University of Barcelona	Paciucci, R (corresponding author), Translat & Pediat Oncol Vall dHebron Inst Res, Res Unit Biomed, Collserola Bldg,Pg Vall dHebron 119-129, Barcelona 08035, Spain.		Paciucci, Rosanna/AGP-3844-2022; Thomson, Timothy/Z-6271-2019; Ramon y Cajal, Santiago/H-4955-2016; Abasolo, Ibane/H-7741-2012; Contreras, Hector/CAE-9087-2022; Fernandez, Pedro L/H-2594-2017; Sese, Marta/AAH-9749-2021; Castellon, Enrique A/D-3436-2014; Celia-Terrassa, Toni/M-4808-2014	Paciucci, Rosanna/0000-0001-5651-5933; Thomson, Timothy/0000-0002-4670-9440; Ramon y Cajal, Santiago/0000-0002-3867-1390; Abasolo, Ibane/0000-0001-5970-6276; Sese, Marta/0000-0003-1473-4833; Castellon, Enrique/0000-0002-3770-8550; Mendez, Raul/0000-0002-1952-6905; Celia-Terrassa, Toni/0000-0002-0615-8744; Valente, Filippo/0000-0001-5760-5949; Canovas, Veronica/0000-0002-1994-5763; Contreras, Hector/0000-0003-4012-2662	Ministry of Science and Innovation; MINECO [SAF2008-03936, SAF2011-30496]; TV3 Telemarathon; Instituto Carlos III [RD06/0020/0058 RETICS]; AGAUR [2009SGR1482]; Red Nacional de Biobancos, Instituto Carlos III; Fondo de Investigaciones de la Seguridad Social [PI20231];  [SAF2008-04136-C02-01];  [SAF2011-24686]	Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); MINECO(Spanish Government); TV3 Telemarathon; Instituto Carlos III(Instituto de Salud Carlos III); AGAUR(Agencia de Gestio D'Ajuts Universitaris de Recerca Agaur (AGAUR)); Red Nacional de Biobancos, Instituto Carlos III; Fondo de Investigaciones de la Seguridad Social; ; 	We thank A. Esquerra, T. Moline and P. Guijarro for excellent technical help, J.J. Lozano for help with statistical analysis and J. Reventos for advice and support. This study was supported by Ministry of Science and Innovation and MINECO SAF2008-03936, SAF2011-30496, TV3 Telemarathon, and Instituto Carlos III RD06/0020/0058 RETICS (to RP); SAF2008-04136-C02-01 and SAF2011-24686 (to TMT); AGAUR 2009SGR1482 (to RP and TMT); Red Nacional de Biobancos, Instituto Carlos III (to RB); and Fondo de Investigaciones de la Seguridad Social PI20231 (to PLF).	Adams DR, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-22; Antonyak MA, 2002, ONCOGENE, V21, P5038, DOI 10.1038/sj.onc.1205593; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Benedit P, 2001, ONCOGENE, V20, P1455, DOI 10.1038/sj.onc.1204233; Benzinger A, 2005, CELL RES, V15, P219, DOI 10.1038/sj.cr.7290290; Bilanges B, 2007, MOL CELL BIOL, V27, P5746, DOI 10.1128/MCB.02136-06; Bontems F, 2011, J STRUCT BIOL, V174, P245, DOI 10.1016/j.jsb.2010.10.011; Buensuceso CS, 2001, J CELL SCI, V114, P1691; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chantrel Y, 1998, GENETICS, V148, P559; Coleman LJ, 2009, BRIT J CANCER, V100, P1393, DOI 10.1038/sj.bjc.6605044; Coyle SM, 2009, MOL CELL BIOL, V29, P1626, DOI 10.1128/MCB.01718-08; Diaz VM, 2002, GASTROENTEROLOGY, V122, P806, DOI 10.1053/gast.2002.31885; Dresios J, 2006, MOL MICROBIOL, V59, P1651, DOI 10.1111/j.1365-2958.2006.05054.x; Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038; Fernandez S, 2011, VIRCHOWS ARCH, V458, P323, DOI 10.1007/s00428-010-1018-1; Graff JR, 2009, CANCER RES, V69, P3866, DOI 10.1158/0008-5472.CAN-08-3472; Grosso S, 2008, BIOCHEM J, V415, P77, DOI 10.1042/BJ20080463; Hermanto U, 2002, MOL CELL BIOL, V22, P2345, DOI 10.1128/MCB.22.7.2345-2365.2002; Hong IK, 2006, J BIOL CHEM, V281, P24279, DOI 10.1074/jbc.M601209200; Hovland R, 1996, INT J BIOCHEM CELL B, V28, P1089, DOI 10.1016/1357-2725(96)00059-3; Ikenoue T, 2008, EMBO J, V27, P1919, DOI 10.1038/emboj.2008.119; Janulis M, 1999, J BIOL CHEM, V274, P801, DOI 10.1074/jbc.274.2.801; Jiao XM, 2010, J BIOL CHEM, V285, P8218, DOI 10.1074/jbc.M110.100792; Kiely PA, 2002, J BIOL CHEM, V277, P22581, DOI 10.1074/jbc.M201758200; Knirsh R, 2009, MOL BIOL CELL, V20, P2121, DOI 10.1091/mbc.E08-12-1196; Kozak M, 2005, GENE, V361, P13, DOI 10.1016/j.gene.2005.06.037; Lee HK, 2007, EMBO J, V26, P3545, DOI 10.1038/sj.emboj.7601797; Li Y, 2010, J DERMATOL SCI, V60, P105, DOI 10.1016/j.jdermsci.2010.08.003; Lopez T, 2002, CANCER CELL, V1, P339, DOI 10.1016/S1535-6108(02)00055-7; Lopez-Bergami P, 2005, MOL CELL, V19, P309, DOI 10.1016/j.molcel.2005.06.025; Lynch M, 2004, J BIOL CHEM, V279, P3327, DOI 10.1074/jbc.M310872200; Malliri A, 1998, J CELL BIOL, V143, P1087, DOI 10.1083/jcb.143.4.1087; Merrick WC, 2004, GENE, V332, P1, DOI 10.1016/j.gene.2004.02.051; Milbradt AG, 2011, NAT STRUCT MOL BIOL, V18, P410, DOI 10.1038/nsmb.1999; Mittler G, 2003, EMBO J, V22, P6494, DOI 10.1093/emboj/cdg619; Nateri AS, 2005, NATURE, V437, P281, DOI 10.1038/nature03914; Nilsson J, 2004, EMBO REP, V5, P1137, DOI 10.1038/sj.embor.7400291; Ozanne BW, 2007, ONCOGENE, V26, P1, DOI 10.1038/sj.onc.1209759; PETRAK D, 1994, J IMMUNOL, V153, P2046; Regmi S, 2008, MOL MICROBIOL, V70, P724, DOI 10.1111/j.1365-2958.2008.06443.x; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Ruan YY, 2012, J CLIN INVEST, V122, P2554, DOI 10.1172/JCI58488; Santamaria A, 2005, MOL CELL BIOL, V25, P1900, DOI 10.1128/MCB.25.5.1900-1911.2005; Santamaria A, 2003, AM J PATHOL, V162, P897, DOI 10.1016/S0002-9440(10)63885-0; Sengupta J, 2004, NAT STRUCT MOL BIOL, V11, P957, DOI 10.1038/nsmb822; Stemmer V, 2008, ONCOGENE, V27, P5075, DOI 10.1038/onc.2008.140; Vesely PW, 2009, MUTAT RES-REV MUTAT, V682, P7, DOI 10.1016/j.mrrev.2009.01.001; Vojnic E, 2011, NAT STRUCT MOL BIOL, V18, P404, DOI 10.1038/nsmb.1997; Wang JH, 2010, MOL CANCER RES, V8, P266, DOI 10.1158/1541-7786.MCR-09-0221; Yan LQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016515; Yang FJ, 2004, P NATL ACAD SCI USA, V101, P2339, DOI 10.1073/pnas.0308676100; Yang YM, 2003, CLIN CANCER RES, V9, P391; Zhang J, 2012, ONCOGENE, V31, P1835, DOI 10.1038/onc.2011.369; Zhang WZ, 2006, MOL CELL BIOL, V26, P413, DOI 10.1128/MCB.26.2.413-424.2006; Zolotukhin AS, 2009, NUCLEIC ACIDS RES, V37, P7151, DOI 10.1093/nar/gkp782	56	25	25	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	2014	33	9					1124	1134		10.1038/onc.2013.51	http://dx.doi.org/10.1038/onc.2013.51			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XT	23455324				2022-12-17	WOS:000331933800006
J	Binsky-Ehrenreich, I; Marom, A; Sobotta, MC; Shvidel, L; Berrebi, A; Hazan-Halevy, I; Kay, S; Aloshin, A; Sagi, I; Goldenberg, DM; Leng, L; Bucala, R; Herishanu, Y; Haran, M; Shachar, I				Binsky-Ehrenreich, I.; Marom, A.; Sobotta, M. C.; Shvidel, L.; Berrebi, A.; Hazan-Halevy, I.; Kay, S.; Aloshin, A.; Sagi, I.; Goldenberg, D. M.; Leng, L.; Bucala, R.; Herishanu, Y.; Haran, M.; Shachar, I.			CD84 is a survival receptor for CLL cells	ONCOGENE			English	Article						CD84; CD74; MIF; survival; apoptosis	CHRONIC LYMPHOCYTIC-LEUKEMIA; MIGRATION-INHIBITORY FACTOR; INVARIANT CHAIN; SLAM FAMILY; FACTOR MIF; TUMOR-GROWTH; B-CELLS; EXPRESSION; CANCER; SAP	Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of CD5+ B lymphocytes in peripheral blood, lymphoid organs and bone marrow. The main feature of the disease is accumulation of the malignant cells due to decreased apoptosis. CD84 belongs to the signaling lymphocyte activating molecule family of immunoreceptors, and has an unknown function in CLL cells. Here, we show that the expression of CD84 is significantly elevated from the early stages of the disease, and is regulated by macrophage migration inhibitory factor and its receptor, CD74. Activation of cell surface CD84 initiates a signaling cascade that enhances CLL cell survival. Both downmodulation of CD84 expression and its immune-mediated blockade induce cell death in vitro and in vivo. In addition, analysis of samples derived from an on-going clinical trial, in which human subjects were treated with humanized anti-CD74 (milatuzumab), shows a decrease in CD84 messenger RNA and protein levels in milatuzumab-treated cells. This downregulation was correlated with reduction of Bcl-2 and Mcl-1 expression. Thus, our data show that overexpression of CD84 in CLL is an important survival mechanism that appears to be an early event in the pathogenesis of the disease. These findings suggest novel therapeutic strategies based on the blockade of this CD84-dependent survival pathway.	[Binsky-Ehrenreich, I.; Marom, A.; Sobotta, M. C.; Shachar, I.] Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel; [Shvidel, L.; Berrebi, A.; Haran, M.] Kaplan Med Ctr, Hematol Inst, Rehovot, Israel; [Hazan-Halevy, I.; Kay, S.; Herishanu, Y.] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Dept Hematol, IL-69978 Tel Aviv, Israel; [Aloshin, A.; Sagi, I.] Weizmann Inst Sci, IL-76100 Rehovot, Israel; [Goldenberg, D. M.] Ctr Mol Med & Immunol, Garden State Canc Ctr, Morris Plains, NJ USA; [Leng, L.; Bucala, R.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA	Weizmann Institute of Science; Hebrew University of Jerusalem; Kaplan Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Weizmann Institute of Science; Yale University	Shachar, I (corresponding author), Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel.	idit.shachar@weizmann.ac.il		Leng, Lin/0000-0002-0605-358X	Israel Science Foundation; Israel Cancer Association; Gurwin Foundation; Israel Cancer Research Foundation (ICRF); NIH; Alliance for Lupus Research; USPHS from the National Cancer Institute, NIH [PO1-CA103985]; United Israel Appeal of Canada; NATIONAL CANCER INSTITUTE [P01CA103985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR050498] Funding Source: NIH RePORTER	Israel Science Foundation(Israel Science Foundation); Israel Cancer Association; Gurwin Foundation; Israel Cancer Research Foundation (ICRF); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Alliance for Lupus Research; USPHS from the National Cancer Institute, NIH; United Israel Appeal of Canada; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	The authors gratefully acknowledge members of the Shachar laboratory team for helpful discussions. This research was supported by the Israel Science Foundation, the Israel Cancer Association, The Gurwin Foundation, Israel Cancer Research Foundation (ICRF), the NIH and the Alliance for Lupus Research (RB, LL), and in part by USPHS grant PO1-CA103985 from the National Cancer Institute, NIH (DMG), and by the United Israel Appeal of Canada. I Shachar is the incumbent of the Dr Morton and Ann Kleiman Professorial Chair.	Bando H, 2002, JPN J CANCER RES, V93, P389, DOI 10.1111/j.1349-7006.2002.tb01269.x; BERNHAGEN J, 1994, BIOCHEMISTRY-US, V33, P14144, DOI 10.1021/bi00251a025; Bifulco C, 2008, CURR PHARM DESIGN, V14, P3790, DOI 10.2174/138161208786898608; Binsky I, 2007, P NATL ACAD SCI USA, V104, P13408, DOI 10.1073/pnas.0701553104; Binsky I, 2010, J IMMUNOL, V184, P4761, DOI 10.4049/jimmunol.0904149; Caligaris-Cappio F, 1999, J CLIN ONCOL, V17, P399, DOI 10.1200/JCO.1999.17.1.399; Calpe S, 2006, IMMUNOGENETICS, V58, P15, DOI 10.1007/s00251-005-0056-3; Cannons JL, 2010, IMMUNITY, V32, P253, DOI 10.1016/j.immuni.2010.01.010; Chesney J, 1999, MOL MED, V5, P181, DOI 10.1007/BF03402061; Cheson BD, 1996, BLOOD, V87, P4990, DOI 10.1182/blood.V87.12.4990.bloodjournal87124990; COCKS BG, 1995, NATURE, V376, P260, DOI 10.1038/376260a0; Cohen S, 2012, J IMMUNOL, V188, P259, DOI 10.4049/jimmunol.1101468; Datta MW, 2000, APPL IMMUNOHISTO M M, V8, P210, DOI 10.1097/00022744-200009000-00007; delaFuente MA, 1997, BLOOD, V90, P2398; Dios A, 2002, J MED CHEM, V45, P2410, DOI 10.1021/jm010534q; Durig J, 2007, CANCER RES, V67, P8653, DOI 10.1158/0008-5472.CAN-07-1198; Engel P, 2003, NAT REV IMMUNOL, V3, P813, DOI 10.1038/nri1202; Flaishon L, 2004, BLOOD, V104, P933, DOI 10.1182/blood-2003-11-4013; Goldman JP, 1998, BRIT J HAEMATOL, V103, P335, DOI 10.1046/j.1365-2141.1998.00980.x; Gordin M, 2010, J IMMUNOL, V185, P2020, DOI 10.4049/jimmunol.0902566; Gore Y, 2008, J BIOL CHEM, V283, P2784, DOI 10.1074/jbc.M703265200; Hallek M, 2008, BLOOD, V111, P5446, DOI 10.1182/blood-2007-06-093906; Haran M, 2004, LEUKEMIA, V18, P1948, DOI 10.1038/sj.leu.2403512; Hartmann TN, 2009, CANCER RES, V69, P3121, DOI 10.1158/0008-5472.CAN-08-4136; HO MK, 1984, METHOD ENZYMOL, V108, P313; Howie D, 2002, BLOOD, V99, P957, DOI 10.1182/blood.V99.3.957; Inabe K, 2002, BLOOD, V99, P584, DOI 10.1182/blood.V99.2.584; Ioachim HL, 1996, AM J SURG PATHOL, V20, P64, DOI 10.1097/00000478-199601000-00007; Ishigami S, 2001, CANCER LETT, V168, P87, DOI 10.1016/S0304-3835(01)00503-1; Kay S, 2006, CYTOM PART B-CLIN CY, V70B, P218, DOI 10.1002/cyto.b.20078; Latour S, 2004, SEMIN IMMUNOL, V16, P409, DOI 10.1016/j.smim.2004.08.020; Lazova R, 1997, CANCER-AM CANCER SOC, V79, P2115, DOI 10.1002/(SICI)1097-0142(19970601)79:11<2115::AID-CNCR8>3.0.CO;2-N; Leng L, 2003, J EXP MED, V197, P1467, DOI 10.1084/jem.20030286; Luger D, 2004, J CLIN IMMUNOL, V24, P579, DOI 10.1007/s10875-004-6245-2; Martin M, 2001, J IMMUNOL, V167, P3668, DOI 10.4049/jimmunol.167.7.3668; Matza D, 2003, TRENDS IMMUNOL, V24, P264, DOI 10.1016/S1471-4906(03)00073-5; Matza D, 2002, IMMUNITY, V17, P549, DOI 10.1016/S1074-7613(02)00455-7; Matza D, 2002, P NATL ACAD SCI USA, V99, P3018, DOI 10.1073/pnas.052703299; Matza D, 2001, J BIOL CHEM, V276, P27203, DOI 10.1074/jbc.M104684200; Meyer-Siegler KL, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-34; MeyerSiegler K, 1996, UROLOGY, V48, P448, DOI 10.1016/S0090-4295(96)00207-5; Mizue Y, 2000, INT J MOL MED, V5, P397; Morra M, 2001, EMBO J, V20, P5840, DOI 10.1093/emboj/20.21.5840; Nagy N, 2000, INT J CANCER, V88, P439, DOI 10.1002/1097-0215(20001101)88:3<439::AID-IJC17>3.0.CO;2-#; Nanda N, 2005, BLOOD, V106, P3028, DOI 10.1182/blood-2005-01-0333; NARNI F, 1986, BLOOD, V68, P372; Nichols KE, 2005, IMMUNOL REV, V203, P180, DOI 10.1111/j.0105-2896.2005.00230.x; Nishihira J, 2003, ANN NY ACAD SCI, V995, P171, DOI 10.1111/j.1749-6632.2003.tb03220.x; Oliver-Vila I, 2008, MOL IMMUNOL, V45, P2138, DOI 10.1016/j.molimm.2007.12.006; Palou E, 2000, TISSUE ANTIGENS, V55, P118, DOI 10.1034/j.1399-0039.2000.550203.x; Romero X, 2005, J IMMUNOL, V174, P7033, DOI 10.4049/jimmunol.174.11.7033; Shachar I, 1996, SCIENCE, V274, P106, DOI 10.1126/science.274.5284.106; Starlets D, 2006, BLOOD, V107, P4807, DOI 10.1182/blood-2005-11-4334; Stein R, 2004, BLOOD, V104, P3705, DOI 10.1182/blood-2004-03-0890; Stein R, 2007, CLIN CANCER RES, V13, p5556S, DOI 10.1158/1078-0432.CCR-07-1167; Stumptner-Cuvelette P, 2002, BBA-MOL CELL RES, V1542, P1, DOI 10.1016/S0167-4889(01)00166-5; Tangye SG, 2002, EUR J IMMUNOL, V32, P1640, DOI 10.1002/1521-4141(200206)32:6<1640::AID-IMMU1640>3.0.CO;2-S; Veenstra H, 1996, CELL IMMUNOL, V171, P68, DOI 10.1006/cimm.1996.0174; Veillette A, 2006, NAT REV IMMUNOL, V6, P56, DOI 10.1038/nri1761; Veillette A, 2003, CURR OPIN IMMUNOL, V15, P277, DOI 10.1016/S0952-7915(03)00041-4; Yan QR, 2007, P NATL ACAD SCI USA, V104, P10583, DOI 10.1073/pnas.0703893104; Young AN, 2001, AM J PATHOL, V158, P1639, DOI 10.1016/S0002-9440(10)64120-X	62	25	26	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	2014	33	8					1006	1016		10.1038/onc.2013.31	http://dx.doi.org/10.1038/onc.2013.31			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XO	23435417	Green Accepted			2022-12-17	WOS:000331933200008
J	Leikam, C; Hufnagel, A; Walz, S; Kneitz, S; Fekete, A; Muller, MJ; Eilers, M; Schartl, M; Meierjohann, S				Leikam, C.; Hufnagel, A.; Walz, S.; Kneitz, S.; Fekete, A.; Mueller, M. J.; Eilers, M.; Schartl, M.; Meierjohann, S.			Cystathionase mediates senescence evasion in melanocytes and melanoma cells	ONCOGENE			English	Article						ROS; melanoma; melanocyte; transsulfuration	MYC DOWN-REGULATION; EPIDERMAL-GROWTH-FACTOR; C-MYC; REACTIVE OXYGEN; GAMMA-LYASE; TRANSSULFURATION PATHWAY; UVEAL MELANOMA; BETA-SYNTHASE; EXPRESSION; PHOSPHORYLATION	The development of malignant melanoma is a highly complex process, which is still poorly understood. A majority of human melanomas are found to express a few oncogenic proteins, such as mutant RAS and BRAF variants. However, these oncogenes are also found in nevi, and it is now a well-accepted fact that their expression alone leads to senescence. This renders the understanding of senescence escape mechanisms an important point to understand tumor development. Here, we approached the question of senescence evasion by expressing the transcription factor v-myc myelocytomatosis viral oncogene homolog (c-MYC), which is known to act synergistically with many oncogenes, in melanocytes. We observed that MYC drives the evasion of reactive-oxygen stress-induced melanocyte senescence, caused by activated receptor tyrosine kinase signaling. Conversely, MIZ1, the growth suppressing interaction partner of MYC, is involved in mediating melanocyte senescence. Both, MYC overexpression and Miz1 knockdown led to a strong reduction of endogenous reactive-oxygen species (ROS), DNA damage and senescence. We identified the cystathionase (CTH) gene product as mediator of the ROS-related MYC and MIZ1 effects. Blocking CTH enzymatic activity in MYC-overexpressing and Miz1 knockdown cells increased intracellular stress and senescence. Importantly, pharmacological inhibition of CTH in human melanoma cells also reconstituted senescence in the majority of cell lines, and CTH knockdown reduced tumorigenic effects such as proliferation, H2O2 resistance and soft agar growth. Thus, we identified CTH as new MYC target gene with an important function in senescence evasion.	[Leikam, C.; Hufnagel, A.; Kneitz, S.; Schartl, M.; Meierjohann, S.] Univ Wurzburg, Dept Physiol Chem 1, Bioctr, D-97074 Wurzburg, Germany; [Walz, S.; Eilers, M.] Univ Wurzburg, Dept Biochem & Mol Biol, Bioctr, D-97074 Wurzburg, Germany; [Fekete, A.; Mueller, M. J.] Univ Wurzburg, Dept Pharmaceut Biol, Julius von Sachs Inst Biol Sci, D-97074 Wurzburg, Germany	University of Wurzburg; University of Wurzburg; University of Wurzburg	Meierjohann, S (corresponding author), Univ Wurzburg, Dept Physiol Chem 1, Bioctr, D-97074 Wurzburg, Germany.	svenja.meierjohann@biozentrum.uni-wuerzburg.de	Fekete, Agnes/C-8048-2019; mueller, martin j/C-7616-2019	Fekete, Agnes/0000-0003-3058-7570; Eilers, Martin/0000-0002-0376-6533; Schartl, Manfred/0000-0001-9882-5948	Deutsche Forschungsgesellschaft, Transregio 17 ('RAS-dependent pathways in human cancer'); German Excellence Initiative	Deutsche Forschungsgesellschaft, Transregio 17 ('RAS-dependent pathways in human cancer'); German Excellence Initiative	We thank Dorothy Bennett, St George's, University of London (Wellcome Trust Functional Genomics Cell Bank) for providing the cell lines Hermes 3a and melan-a sut. This work was supported by the Deutsche Forschungsgesellschaft, Transregio 17 ('RAS-dependent pathways in human cancer'). CL was supported by a grant of the German Excellence Initiative to the Graduate School of Life Sciences, University of Wurzburg.	Aziz N, 1999, MOL CELL BIOL, V19, P1101; Benassi B, 2006, MOL CELL, V21, P509, DOI 10.1016/j.molcel.2006.01.009; Benassi B, 2007, MOL PHARMACOL, V72, P1015, DOI 10.1124/mol.107.038687; Biroccio A, 2001, MOL PHARMACOL, V60, P174, DOI 10.1124/mol.60.1.174; Biroccio A, 2003, J BIOL CHEM, V278, P35693, DOI 10.1074/jbc.M304597200; Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; Blanco-Bose WE, 2008, HEPATOLOGY, V48, P1302, DOI 10.1002/hep.22475; Bucci B, 2005, CLIN CANCER RES, V11, P2756, DOI 10.1158/1078-0432.CCR-04-1582; Campaner S, 2010, NAT CELL BIOL, V12, P54, DOI 10.1038/ncb2004; Cao QH, 2010, ANTIOXID REDOX SIGN, V12, P1101, DOI 10.1089/ars.2009.2915; Chintala S, 2005, P NATL ACAD SCI USA, V102, P10964, DOI 10.1073/pnas.0502856102; Conrad M, 2012, AMINO ACIDS, V42, P231, DOI 10.1007/s00726-011-0867-5; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; Denoyelle C, 2006, NAT CELL BIOL, V8, P1053, DOI 10.1038/ncb1471; Dickhout JG, 2012, J BIOL CHEM, V287, P7603, DOI 10.1074/jbc.M111.304576; Fried L, 2008, PIGM CELL MELANOMA R, V21, P117, DOI 10.1111/j.1755-148X.2008.00451.x; Grandori C, 2003, GENE DEV, V17, P1569, DOI 10.1101/gad.1100303; Gray-Schopfer VC, 2006, BRIT J CANCER, V95, P496, DOI 10.1038/sj.bjc.6603283; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; Herold S, 2008, EMBO J, V27, P2851, DOI 10.1038/emboj.2008.200; Huang SF, 2010, J MOL BIOL, V396, P708, DOI 10.1016/j.jmb.2009.11.058; Hydbring P, 2010, P NATL ACAD SCI USA, V107, P58, DOI 10.1073/pnas.0900121106; Jamerson MH, 2000, ONCOGENE, V19, P1065, DOI 10.1038/sj.onc.1203268; Jhee KH, 2005, ANTIOXID REDOX SIGN, V7, P813, DOI 10.1089/ars.2005.7.813; Kandil S, 2010, NEUROCHEM INT, V56, P611, DOI 10.1016/j.neuint.2010.01.004; KOST DP, 1990, J CELL PHYSIOL, V144, P122, DOI 10.1002/jcp.1041440116; Kress TR, 2011, MOL CELL, V41, P445, DOI 10.1016/j.molcel.2011.01.023; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Leikam C, 2008, ONCOGENE, V27, P7070, DOI 10.1038/onc.2008.323; Li SKM, 2008, J BIOL CHEM, V283, P16545, DOI 10.1074/jbc.M709604200; Mallette FA, 2007, J BIOL CHEM, V282, P34938, DOI 10.1074/jbc.M707074200; Meierjohann S, 2006, CANCER RES, V66, P3145, DOI 10.1158/0008-5472.CAN-05-2667; Meierjohann S, 2006, TRENDS GENET, V22, P654, DOI 10.1016/j.tig.2006.09.013; Nogueira V, 2008, CANCER CELL, V14, P458, DOI 10.1016/j.ccr.2008.11.003; Onken MD, 2008, INVEST OPHTH VIS SCI, V49, P5230, DOI 10.1167/iovs.08-2145; Park J, 2007, BIOCHEM BIOPH RES CO, V360, P447, DOI 10.1016/j.bbrc.2007.06.077; Parrella P, 2001, INVEST OPHTH VIS SCI, V42, P1679; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; Popov N, 2007, CELL CYCLE, V6, P2327, DOI 10.4161/cc.6.19.4804; Popov N, 2010, NAT CELL BIOL, V12, P973, DOI 10.1038/ncb2104; Rai P, 2011, ONCOGENE, V30, P1489, DOI 10.1038/onc.2010.520; RAO AM, 1990, J NUTR, V120, P837, DOI 10.1093/jn/120.8.837; Robinson K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005951; Rosado JO, 2007, MOL CELL BIOCHEM, V301, P1, DOI 10.1007/s11010-006-9389-y; Rzymski T, 2009, CELL CYCLE, V8, P3838, DOI 10.4161/cc.8.23.10086; Sankar N, 2009, J BIOL CHEM, V284, P15193, DOI 10.1074/jbc.M900776200; Schlagbauer-Wadl H, 1999, J INVEST DERMATOL, V112, P332, DOI 10.1046/j.1523-1747.1999.00506.x; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Sun QX, 2009, J BIOL CHEM, V284, P3076, DOI 10.1074/jbc.M805459200; Szabo C, 2007, NAT REV DRUG DISCOV, V6, P917, DOI 10.1038/nrd2425; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Tulley PN, 2004, BRIT J OPHTHALMOL, V88, P1563, DOI 10.1136/bjo.2003.033498; Van Raamsdonk CD, 2009, NATURE, V457, P599, DOI 10.1038/nature07586; van Riggelen J, 2010, GENE DEV, V24, P1281, DOI 10.1101/gad.585710; Vene R, 2011, ANTIOXID REDOX SIGN, V15, P2439, DOI 10.1089/ars.2010.3830; Wanzel M, 2003, TRENDS CELL BIOL, V13, P146, DOI 10.1016/S0962-8924(03)00003-5; Wanzel M, 2005, NAT CELL BIOL, V7, P30, DOI 10.1038/ncb1202; Whitwam T, 2007, ONCOGENE, V26, P4563, DOI 10.1038/sj.onc.1210239; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; YAMAMOTO N, 1995, J NUTR SCI VITAMINOL, V41, P197, DOI 10.3177/jnsv.41.197; Yang GD, 2004, J BIOL CHEM, V279, P49199, DOI 10.1074/jbc.M408997200; Yang GD, 2008, SCIENCE, V322, P587, DOI 10.1126/science.1162667; Zhuang D, 2008, ONCOGENE, V27, P6623, DOI 10.1038/onc.2008.258	64	25	25	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2014	33	6					771	782		10.1038/onc.2012.641	http://dx.doi.org/10.1038/onc.2012.641			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5IL	23353821				2022-12-17	WOS:000331129200011
J	Yu, L; Yuan, X; Wang, D; Barakat, B; Williams, ED; Hannigan, GE				Yu, L.; Yuan, X.; Wang, D.; Barakat, B.; Williams, E. D.; Hannigan, G. E.			Selective regulation of p38 beta protein and signaling by integrin-linked kinase mediates bladder cancer cell migration	ONCOGENE			English	Article						integrin-linked kinase; p38(MAPK) protein kinases; p38 beta isoform; bladder cancer; cell migration; heat shock protein 27	P38-ALPHA MAP KINASE; IN-SITU; PROXIMITY LIGATION; ENDOTHELIAL-CELLS; P38; GROWTH; CARCINOMA; EXPRESSION; ADHESION; ILK	Integrin-linked kinase (ILK) and p38(MAPK) are protein kinases that transduce extracellular signals regulating cell migration and actin cytoskeletal organization. ILK-dependent regulation of p38(MAPK) is critical for mammalian kidney development and in smooth muscle cell migration, however, specific p38 isoforms has not been previously examined in ILK-regulated responses. Signaling by ILK and p38(MAPK) is often dysregulated in bladder cancer, and here we report a strong positive correlation between protein levels of ILK and p38 beta, which is the predominant isoform found in bladder cancer cells, as well as in patient-matched normal bladder and tumor samples. Knockdown by RNA interference of either p38 beta or ILK disrupts serum-induced, Rac1-dependent migration and actin cytoskeletal organization in bladder cancer cells. Surprisingly, ILK knockdown causes the selective reduction in p38 beta cellular protein level, without inhibiting p38 beta messenger RNA (mRNA) expression. The loss of p38 beta protein in ILK-depleted cells is partially rescued by the 26S proteasomal inhibitor MG132. Using co-precipitation and bimolecular fluorescent complementation assays, we find that ILK selectively forms cytoplasmic complexes with p38 beta. In situ proximity ligation assays further demonstrate that serum-stimulated assembly of endogenous ILK-p38 beta complexes is sensitive to QLT-0267, a small molecule ILK kinase inhibitor. Finally, inhibition of ILK reduces the amplitude and period of serum-induced activation of heat shock protein 27 (Hsp27), a target of p38 beta implicated in actin cytoskeletal reorganization. Our work identifies Hsp27 as a novel target of ILK-p38 beta signaling complexes, playing a key role in bladder cancer cell migration.	[Yu, L.; Yuan, X.; Wang, D.; Barakat, B.; Williams, E. D.; Hannigan, G. E.] Monash Univ, Monash Inst Med Res, Ctr Canc Res, Clayton, Vic, Australia; [Yuan, X.] Univ Sch Med, Xinhua Hosp, Dept Clin Lab, Shanghai, Peoples R China	Monash University	Williams, ED (corresponding author), Monash Univ, Monash Inst Med Res, Ctr Canc Res, Clayton, Vic, Australia.	elizabeth.williams@monash.edu; greg.hannigan@monash.edu	Yu, Liang/D-6771-2014; Wang, Die/H-8860-2017; Williams, Elizabeth D/B-1538-2008	Wang, Die/0000-0001-7628-7309; Williams, Elizabeth D/0000-0002-3364-6655	National Health and Medical Research Council of Australia; Victorian Government's Operational Infrastructure Support Program	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Victorian Government's Operational Infrastructure Support Program	We thank Drs Aaron Irving, Dakang Xu and Howard Yim (Centre for Cancer Research, MIMR) for consultation and helpful discussions. Dr S Dedhar (University of British Columbia) kindly provided QLT-0267. This work was supported by grants to GH and EDW from the National Health and Medical Research Council of Australia, with additional support through the Victorian Government's Operational Infrastructure Support Program.	Cabodi S, 2010, NAT REV CANCER, V10, P858, DOI 10.1038/nrc2967; Chaffer CL, 2005, CLIN EXP METASTAS, V22, P115, DOI 10.1007/s10585-005-5141-3; Cornford PA, 2000, CANCER RES, V60, P7099; Coso S, 2011, EXP CELL RES, V317, P2397, DOI 10.1016/j.yexcr.2011.07.023; Coulthard LR, 2009, TRENDS MOL MED, V15, P369, DOI 10.1016/j.molmed.2009.06.005; Cuenda A, 2007, BBA-MOL CELL RES, V1773, P1358, DOI 10.1016/j.bbamcr.2007.03.010; Barrantes IDB, 2011, P NATL ACAD SCI USA, V108, P12764, DOI 10.1073/pnas.1015013108; DJAKIEW D, 1993, CANCER RES, V53, P1416; Dolado I, 2007, CANCER CELL, V11, P191, DOI 10.1016/j.ccr.2006.12.013; Esfandiarei Mitra, 2010, BMC Cell Biol, V11, P16, DOI 10.1186/1471-2121-11-16; Estrada Y, 2009, PIGM CELL MELANOMA R, V22, P66, DOI 10.1111/j.1755-148X.2008.00520.x; Filipenko NR, 2005, ONCOGENE, V24, P5837, DOI 10.1038/sj.onc.1208737; Fukuda T, 2003, J BIOL CHEM, V278, P51324, DOI 10.1074/jbc.M309122200; Gao J, 2011, INT J BIOCHEM CELL B, V43, P1294, DOI 10.1016/j.biocel.2011.05.003; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Herbsleb M, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-37; Hui LJ, 2007, NAT GENET, V39, P741, DOI 10.1038/ng2033; Irving AT, 2012, IMMUNITY, V36, P795, DOI 10.1016/j.immuni.2012.02.020; Cerezo-Guisado MI, 2011, CARCINOGENESIS, V32, P1093, DOI 10.1093/carcin/bgr079; Jarvius M, 2007, MOL CELL PROTEOMICS, V6, P1500, DOI 10.1074/mcp.M700166-MCP200; Jones TJ, 2012, J CELL PHYSIOL, V227, P70, DOI 10.1002/jcp.22704; Junttila MR, 2007, ONCOGENE, V26, P5267, DOI 10.1038/sj.onc.1210332; Kumar B, 2010, CANCER RES, V70, P832, DOI 10.1158/0008-5472.CAN-09-2918; Leung-Hagesteijn C, 2005, MOL CELL BIOL, V25, P3648, DOI 10.1128/MCB.25.9.3648-3657.2005; Li QX, 2008, J BIOL CHEM, V283, P11014, DOI 10.1074/jbc.M709682200; Lu HZ, 2006, CIRCULATION, V114, P2271, DOI 10.1161/CIRCULATIONAHA.106.642330; Mackinnon AC, 2002, CURR BIOL, V12, P787, DOI 10.1016/S0960-9822(02)00810-2; Matsui Y, 2012, INT J CANCER, V130, P521, DOI 10.1002/ijc.26008; Maydan M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012356; Mongroo PS, 2004, ONCOGENE, V23, P8959, DOI 10.1038/sj.onc.1208112; Montanez E, 2009, EMBO J, V28, P3132, DOI 10.1038/emboj.2009.295; Nakrieko KA, 2008, MOL BIOL CELL, V19, P1462, DOI 10.1091/mbc.E07-06-0526; New L, 2003, MOL BIOL CELL, V14, P2603, DOI 10.1091/mbc.E02-08-0538; New L, 1998, EMBO J, V17, P3372, DOI 10.1093/emboj/17.12.3372; Otto KB, 2011, UROL ONCOL, V30, P415; Qian Y, 2005, ONCOGENE, V24, P3154, DOI 10.1038/sj.onc.1208525; Remy G, 2010, CELL SIGNAL, V22, P660, DOI 10.1016/j.cellsig.2009.11.020; Roussos ET, 2011, NAT REV CANCER, V11, P573, DOI 10.1038/nrc3078; Sakai T, 2003, GENE DEV, V17, P926, DOI 10.1101/gad.255603; Schindler EM, 2009, CANCER RES, V69, P4648, DOI 10.1158/0008-5472.CAN-08-4455; Shyu YJ, 2008, NAT PROTOC, V3, P588, DOI 10.1038/nprot.2008.16; Silva G, 2006, J IMMUNOL, V177, P1894, DOI 10.4049/jimmunol.177.3.1894; Smeeton J, 2010, DEVELOPMENT, V137, P3233, DOI 10.1242/dev.052845; Soderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947; Song HY, 2006, J CANCER RES CLIN, V132, P92, DOI 10.1007/s00432-005-0044-x; Tan C, 2002, J BIOL CHEM, V277, P3109, DOI 10.1074/jbc.M108673200; Ventura JJ, 2007, NAT GENET, V39, P750, DOI 10.1038/ng2037; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Wang AX, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-167; Yong HY, 2009, EXPERT OPIN INV DRUG, V18, P1893, DOI 10.1517/13543780903321490; Zervas CG, 2001, J CELL BIOL, V152, P1007, DOI 10.1083/jcb.152.5.1007; Zhu ZK, 2010, MOL PHARMACEUT, V7, P1283, DOI 10.1021/mp100073s	54	25	26	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2014	33	6					690	701		10.1038/onc.2013.20	http://dx.doi.org/10.1038/onc.2013.20			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5IL	23435415				2022-12-17	WOS:000331129200004
J	Lu, C; Li, JY; Ge, Z; Zhang, L; Zhou, GP				Lu, C.; Li, J-Y; Ge, Z.; Zhang, L.; Zhou, G-P			Par-4/THAP1 complex and Notch3 competitively regulated pre-mRNA splicing of CCAR1 and affected inversely the survival of T-cell acute lymphoblastic leukemia cells	ONCOGENE			English	Article						Par-4; THAP1; CCAR1; Notch3; apoptosis; leukemia	TARGET GENE; EXPRESSION; APOPTOSIS; IDENTIFICATION; TRANSCRIPTION; GROWTH; PAR-4; THAP1; CYCLE	Although the intensification of therapy for children with T-cell acute lymphoblastic leukemia (T-ALL) has substantially improved clinical outcomes, T-ALL remains an important challenge in pediatric oncology. Here, we report that the cooperative synergy between prostate apoptosis response factor-4 (Par-4) and THAP1 induces cell cycle and apoptosis regulator 1 (CCAR1) gene expression and cellular apoptosis in human T-ALL cell line Jurkat cells, CEM cells and primary cultured neoplastic T lymphocytes from children with T-ALL. Par-4 and THAP1 collaborated to activate the promoter of CCAR1 gene. Mechanistic investigations revealed that Par-4 and THAP1 formed a protein complex by the interaction of their carboxyl termini, and THAP1 bound to CCAR1 promoter though its zinc-dependent DNA-binding domain at amino terminus. Par-4/THAP1 complex and Notch3 competitively bound to CCAR1 promoter and competitively modulated alternative pre-mRNA splicing of CCAR1, which resulted in two different transcripts and played an opposite role in T-ALL cell survival. Despite Notch3 induced a shift splicing from the full-length isoform toward a shorter form of CCAR1 mRNA by splicing factor SRp40 and SRp55, Par-4/THAP1 complex strongly antagonized this inductive effect. Our finding revealed a mechanistic rationale for Par-4/THAP1-induced apoptosis in T-ALL cells that would be of benefit to develop a new therapy strategy for T-ALL.	[Lu, C.; Zhang, L.; Zhou, G-P] Nanjing Med Univ, Affiliated Hosp 1, Dept Pediat, Nanjing 210029, Jiangsu, Peoples R China; [Li, J-Y; Ge, Z.] Nanjing Med Univ, Affiliated Hosp 1, Dept Hematol, Nanjing 210029, Jiangsu, Peoples R China	Nanjing Medical University; Nanjing Medical University	Lu, C (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Pediat, Guangzhou Rd 300, Nanjing 210029, Jiangsu, Peoples R China.	luchaodoctor@163.com; gpzhou2013@163.com			National Natural Science Foundation of China [81170487]; National Major Scientific and Technological Special Project for 'Significant New Drugs Development' [2011ZX09302-003-02]; Jiangsu Province Major Scientific and Technological Special Project [BM2011017]; Priority Academic Program Development of Jiangsu Higher Education Institutions	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Major Scientific and Technological Special Project for 'Significant New Drugs Development'; Jiangsu Province Major Scientific and Technological Special Project; Priority Academic Program Development of Jiangsu Higher Education Institutions	This work was supported by the National Natural Science Foundation of China (81170487), the National Major Scientific and Technological Special Project for 'Significant New Drugs Development' (2011ZX09302-003-02), the Jiangsu Province Major Scientific and Technological Special Project (BM2011017) and the Priority Academic Program Development of Jiangsu Higher Education Institutions.	Aravind L, 2000, TRENDS BIOCHEM SCI, V25, P112, DOI 10.1016/S0968-0004(99)01537-6; Bellavia D, 2007, EMBO J, V26, P1670, DOI 10.1038/sj.emboj.7601626; Boehrer S, 2006, LEUKEMIA RES, V30, P597, DOI 10.1016/j.leukres.2005.09.003; Campagne S, 2010, NUCLEIC ACIDS RES, V38, P3466, DOI 10.1093/nar/gkq053; Cheema SK, 2003, J BIOL CHEM, V278, P19995, DOI 10.1074/jbc.M205865200; Chow KU, 2005, LEUKEMIA, V19, P1103, DOI 10.1038/sj.leu.2403739; Clouaire T, 2005, P NATL ACAD SCI USA, V102, P6907, DOI 10.1073/pnas.0406882102; Glienke W, 2006, LEUKEMIA LYMPHOMA, V47, P1629, DOI 10.1080/10428190600625398; Hebbar N, 2012, J CELL PHYSIOL, V227, P3715, DOI 10.1002/jcp.24098; Kent S, 2011, CELL CYCLE, V10; Kim JH, 2008, MOL CELL, V31, P510, DOI 10.1016/j.molcel.2008.08.001; Ling X, 2005, LUNG CANCER, V49, P353, DOI 10.1016/j.lungcan.2005.03.037; Lu CT, 2008, INT J ARTIF INTELL T, V17, P1; McFie PJ, 2006, J BIOL CHEM, V281, P18069, DOI 10.1074/jbc.M512734200; Ou CY, 2009, J BIOL CHEM, V284, P20629, DOI 10.1074/jbc.M109.014332; Park JT, 2008, CANCER RES, V68, P8852, DOI 10.1158/0008-5472.CAN-08-0517; Roussigne M, 2003, ONCOGENE, V22, P2432, DOI 10.1038/sj.onc.1206271; Schrappe M, 2012, NEW ENGL J MED, V366, P1371, DOI 10.1056/NEJMoa1110169; Tzoneva G, 2012, CURR TOP MICROBIOL, V360, P163, DOI 10.1007/82_2012_232; Van Vlierberghe P, 2012, J CLIN INVEST, V122, P3398, DOI 10.1172/JCI61269; Wei BB, 2010, J BIOMED RES, V24, P58, DOI 10.1016/S1674-8301(10)60009-7; Zhang DX, 2011, J BIOL CHEM, V286, P17746, DOI 10.1074/jbc.M110.206029; Zhang LY, 2007, MOL CANCER THER, V6, P1661, DOI 10.1158/1535-7163.MCT-06-0653	23	25	26	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 12	2013	32	50					5602	5613		10.1038/onc.2013.349	http://dx.doi.org/10.1038/onc.2013.349			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272LF	23975424	Green Published, hybrid			2022-12-17	WOS:000328461400005
J	Kostaras, E; Sflomos, G; Pedersen, NM; Stenmark, H; Fotsis, T; Murphy, C				Kostaras, E.; Sflomos, G.; Pedersen, N. M.; Stenmark, H.; Fotsis, T.; Murphy, C.			SARA and RNF11 interact with each other and ESCRT-0 core proteins and regulate degradative EGFR trafficking	ONCOGENE			English	Article							EPIDERMAL-GROWTH-FACTOR; FYVE DOMAIN PROTEIN; FACTOR RECEPTOR; ENDOCYTIC TRAFFICKING; ENDOTHELIAL-CELLS; EARLY ENDOSOMES; A431 CELLS; E3 LIGASE; HRS; BINDING	Smad anchor for receptor activation (SARA) is highly enriched on endocytic membranes via binding to phosphatidylinositol 3-phosphates through its FYVE (Fab1p-YOTB-Vps27p-EEA1) domain. SARA was originally identified as a protein that recruits non-phosphorylated SMAD2/3 to the activated TGF beta receptors for phosphorylation, but later reports suggested a regulatory role in endocytic trafficking. Here we demonstrate that the ubiquitin ligase RNF11 is a SARA-interacting protein residing on early and late endosomes, as well as the fast recycling compartment. RNF11 and SARA interact with the ESCRT-0 subunits STAM2 and Eps15b, but only RNF11 associates with the core subunit Hrs. Both gain- and loss-of-function perturbation of RNF11 and SARA levels result in delayed degradation of epidermal growth factor (EGF)-activated EGF receptor (EGFR), while loss-of-function sustained/enhanced EGF-induced ERK1/2 phosphorylation. These findings suggest that RNF11 and SARA are functional components of the ESCRT-0 complexes. Moreover, SARA interacts with clathrin, the ESCRT-I subunit Tsg101 and ubiquitinated cargo exhibiting all the properties of Hrs concerning ESCRT-0 function, indicating that it could substitute Hrs in some ESCRT-0 complexes. These results suggest that RNF11 and SARA participate structurally and functionally in the ESCRT-dependent lysosomal degradation of receptors. As a consequence, the negative influence that perturbation of RNF11 and SARA levels exerts on the lysosomal degradation of EGFRs could underscore the reported overexpression of RNF11 in several cancers. In these cancers, deficient termination of the oncogenic signaling of mutated receptors, such as the EGFRs, through suboptimal lysosomal degradation could contribute to the process of malignant transformation.	[Kostaras, E.; Sflomos, G.; Fotsis, T.] Univ Ioannina, Sch Med, Lab Biol Chem, GR-45110 Ioannina, Greece; [Kostaras, E.; Sflomos, G.; Fotsis, T.; Murphy, C.] Fdn Res & Technol Hellas, Dept Biomed Res, Inst Mol Biol & Biotechnol, Ioannina 45110, Greece; [Pedersen, N. M.; Stenmark, H.] Univ Oslo, Ctr Canc Biomed, Fac Med, Oslo, Norway	University of Ioannina; Foundation for Research & Technology - Hellas (FORTH); University of Oslo	Murphy, C (corresponding author), Fdn Res & Technol Hellas, Dept Biomed Res, Inst Mol Biol & Biotechnol, Univ Campus Ioannina, Ioannina 45110, Greece.	cmurphy@cc.uoi.gr	Stenmark, Harald/B-8868-2008; Sflomos, George/Q-2826-2019; Sflomos, George/D-9275-2016; Murphy, Carol/ABE-4282-2021	Sflomos, George/0000-0003-2972-0549; Murphy, Carol/0000-0003-1353-8558	European Union [LSH-2004-1.1.5-2]	European Union(European Commission)	We thank the confocal laser microscope facility of the University of Ioannina for the use of the Leica TCS-SP scanning confocal microscope. This work was supported by the European Union integrated project ENDOTRACK (EU FP6, LSH-2004-1.1.5-2).	Amano Y, 2011, J BIOL CHEM, V286, P15458, DOI 10.1074/jbc.M110.191924; Anderson LR, 2007, J NEUROPATH EXP NEUR, V66, P955, DOI 10.1097/nen.0b013e3181567f17; Azmi P, 2005, EUR J CANCER, V41, P2549, DOI 10.1016/j.ejca.2005.08.020; Bache KG, 2003, J CELL BIOL, V162, P435, DOI 10.1083/jcb.200302131; Bache KG, 2003, J BIOL CHEM, V278, P12513, DOI 10.1074/jbc.M210843200; Bache KG, 2006, MOL BIOL CELL, V17, P2513, DOI 10.1091/mbc.E05-10-0915; Bagli E, 2004, CANCER RES, V64, P7936, DOI 10.1158/0008-5472.CAN-03-3104; Bellou S, 2009, AM J PHYSIOL-CELL PH, V297, pC1477, DOI 10.1152/ajpcell.00058.2009; Bennett D, 2002, NAT GENET, V31, P419, DOI 10.1038/ng938; Bilodeau PS, 2003, J CELL BIOL, V163, P237, DOI 10.1083/jcb.200305007; Burack WR, 2000, CURR OPIN CELL BIOL, V12, P211, DOI 10.1016/S0955-0674(99)00078-2; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; Chen C, 2008, ONCOGENE, V27, P6845, DOI 10.1038/onc.2008.288; Chuang JZ, 2007, CELL, V130, P535, DOI 10.1016/j.cell.2007.06.030; Colland F, 2004, GENOME RES, V14, P1324, DOI 10.1101/gr.2334104; Collinet C, 2010, NATURE, V464, P243, DOI 10.1038/nature08779; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Grandal MV, 2008, J CELL MOL MED, V12, P1527, DOI 10.1111/j.1582-4934.2008.00298.x; Gullapalli A, 2006, MOL BIOL CELL, V17, P1228, DOI 10.1091/mbc.E05-09-0899; Hislop JN, 2004, J BIOL CHEM, V279, P22522, DOI 10.1074/jbc.M311062200; Hu Y, 2002, J CELL SCI, V115, P4755, DOI 10.1242/jcs.00177; Johannessen LE, 2006, MOL CELL BIOL, V26, P389, DOI 10.1128/MCB.26.2.389-401.2006; Katzmann DJ, 2003, J CELL BIOL, V162, P413, DOI 10.1083/jcb.200302136; Kitching R, 2003, BBA-MOL BASIS DIS, V1639, P104, DOI 10.1016/j.bbadis.2003.07.001; Li HX, 2004, ONCOGENE, V23, P1801, DOI 10.1038/sj.onc.1207319; Locasale JW, 2007, P NATL ACAD SCI USA, V104, P13307, DOI 10.1073/pnas.0706311104; Malerod L, 2007, TRAFFIC, V8, P1617, DOI 10.1111/j.1600-0854.2007.00630.x; Mimeault M, 2011, BRAIN PATHOL, V21, P479, DOI 10.1111/j.1750-3639.2011.00505.x; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Nielsen E, 2000, J CELL BIOL, V151, P601, DOI 10.1083/jcb.151.3.601; Panopoulou E, 2002, J BIOL CHEM, V277, P18046, DOI 10.1074/jbc.M107983200; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; Petiot A, 2003, J CELL BIOL, V162, P971, DOI 10.1083/jcb.200303018; Raiborg C, 2001, EMBO J, V20, P5008, DOI 10.1093/emboj/20.17.5008; Raiborg C, 2001, BIOCHEM SOC T, V29, P472, DOI 10.1042/BST0290472; Raiborg C, 2008, EXP CELL RES, V314, P801, DOI 10.1016/j.yexcr.2007.10.014; Raiborg C, 2009, NATURE, V458, P445, DOI 10.1038/nature07961; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Roxrud I, 2008, J CELL BIOL, V180, P1205, DOI 10.1083/jcb.200708115; Santonico E, 2010, ONCOGENE, V29, P5604, DOI 10.1038/onc.2010.294; Sflomos G, 2011, J CELL SCI, V124, P3209, DOI 10.1242/jcs.062307; Shembade N, 2009, EMBO J, V28, P513, DOI 10.1038/emboj.2008.285; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Skarpen E, 1998, EXP CELL RES, V243, P161, DOI 10.1006/excr.1998.4127; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; SORKIN AD, 1988, EXP CELL RES, V175, P192, DOI 10.1016/0014-4827(88)90266-2; STENMARK H, 1995, METHOD ENZYMOL, V257, P155; Stuffers S, 2009, TRAFFIC, V10, P925, DOI 10.1111/j.1600-0854.2009.00920.x; Subramaniam V, 2003, BRIT J CANCER, V89, P1538, DOI 10.1038/sj.bjc.6601301; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Wollert T, 2010, NATURE, V464, P864, DOI 10.1038/nature08849; Yamashita Y, 2008, J CELL SCI, V121, P1727, DOI 10.1242/jcs.024455	53	25	26	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 31	2013	32	44					5220	5232		10.1038/onc.2012.554	http://dx.doi.org/10.1038/onc.2012.554			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245XH	23222715	Bronze			2022-12-17	WOS:000326497100005
J	Bakker, ERM; Hoekstra, E; Franken, PF; Helvensteijn, W; van Deurzen, CHM; van Veelen, W; Kuipers, EJ; Smits, R				Bakker, E. R. M.; Hoekstra, E.; Franken, P. F.; Helvensteijn, W.; van Deurzen, C. H. M.; van Veelen, W.; Kuipers, E. J.; Smits, R.			beta-Catenin signaling dosage dictates tissue-specific tumor predisposition in Apc-driven cancer	ONCOGENE			English	Article						beta-catenin; APC; intestinal cancer; mammary tumor	FAMILIAL ADENOMATOUS POLYPOSIS; MOUSE MODEL; INTESTINAL TUMORS; SOMATIC MUTATION; ONCOGENIC KRAS; PROGRESSION; GENE; HETEROZYGOSITY; INSTABILITY; ACTIVATION	Apc-driven tumor formation in patients and Apc-mutant mouse models is generally attributed to increased levels of beta-catenin signaling. We and others have proposed that a specific level of b-catenin signaling is required to successfully initiate tumor formation, and that each tissue prefers different dosages of signaling. This is illustrated by APC genotype - tumor phenotype correlations in cancer patients, and by the different tumor phenotypes displayed by different Apc-mutant mouse models. Apc1638N mice, associated with intermediate b-catenin signaling, characteristically develop intestinal tumors (< 10) and extra-intestinal tumors, including cysts and desmoids. Apc1572T mice associated with lower levels of b-catenin signaling are free of intestinal tumors, but instead develop mammary tumors. Although the concept of b-catenin signaling dosage and its impact on tumor growth among tissues is gaining acceptance, it has not been formally proven. Additionally, alternative explanations for Apc-driven tumor formation have been proposed. To obtain direct evidence for the dominant role of b-catenin dosage in tumor formation and tissue-specific tumor predisposition, we crossed Apc1638N mice with heterozygous b-catenin knockout mice, thereby reducing b-catenin levels. Whereas all the Apc1638N; Ctnnb1(+/+) mice developed gastrointestinal tumors, none were present in the Apc1638N; Ctnnb1(-/-) mice. Incidence of other Apc1638N-associated lesions, including desmoids and cysts, was strongly reduced as well. Interestingly, Apc1638N; Ctnnb1(-/-) females showed an increased incidence of mammary tumors, which are normally rarely observed in Apc1638N mice, and the histological composition of the tumors resembled that of Apc1572T-related tumors. Hereby, we provide in vivo genetic evidence confirming the dominant role of b-catenin dosage in tumor formation and in dictating tumor predisposition among tissues in Apc-driven cancer.	[Bakker, E. R. M.; Hoekstra, E.; Helvensteijn, W.; van Veelen, W.; Kuipers, E. J.; Smits, R.] Erasmus MC Univ Med Ctr, Dept Gastroenterol & Hepatol, NL-3015 CE Rotterdam, Netherlands; [Franken, P. F.; van Deurzen, C. H. M.] Erasmus MC Univ Med Ctr, Dept Pathol, NL-3015 CE Rotterdam, Netherlands; [Kuipers, E. J.] Erasmus MC Univ Med Ctr, Dept Internal Med, NL-3015 CE Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	Smits, R (corresponding author), Erasmus MC Univ Med Ctr, Dept Gastroenterol & Hepatol, S Gravendijkwal 230, NL-3015 CE Rotterdam, Netherlands.	m.j.m.smits@erasmusmc.nl	Hoekstra, Elmer/P-5440-2014; Kuipers, Ernst J/H-3293-2019	Hoekstra, Elmer/0000-0001-8840-8294; Kuipers, Ernst J/0000-0002-0633-3098				Albuquerque C, 2002, HUM MOL GENET, V11, P1549, DOI 10.1093/hmg/11.13.1549; Albuquerque C, 2011, BBA-REV CANCER, V1816, P219, DOI 10.1016/j.bbcan.2011.07.005; Albuquerque C, 2010, GENE CHROMOSOME CANC, V49, P746, DOI 10.1002/gcc.20786; Athineos D, 2010, ONCOGENE, V29, P2585, DOI 10.1038/onc.2010.5; Buchert M, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000816; Crabtree M, 2003, ONCOGENE, V22, P4257, DOI 10.1038/sj.onc.1206471; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; Fodde R, 2010, J PATHOL, V221, P239, DOI 10.1002/path.2718; Gaspar C, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000547; Haigis KM, 2003, NAT GENET, V33, P33, DOI 10.1038/ng1055; Hamada F, 2004, DEV CELL, V7, P677, DOI 10.1016/j.devcel.2004.08.022; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Hinoi T, 2007, CANCER RES, V67, P9721, DOI 10.1158/0008-5472.CAN-07-2735; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; Incassati A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2723; Janssen KP, 2006, GASTROENTEROLOGY, V131, P1096, DOI 10.1053/j.gastro.2006.08.011; Lamlum H, 1999, NAT MED, V5, P1071, DOI 10.1038/12511; Leedham SJ, 2012, GUT, DOI [10.1136/gutjnl-2011-301601, DOI 10.1136/GUTJNL-2011-301601)]; Lewis A, 2012, J PATHOL, V226, P73, DOI 10.1002/path.2972; Mahmoud NN, 1999, CANCER RES, V59, P353; Murphy DJ, 2008, CANCER CELL, V14, P447, DOI 10.1016/j.ccr.2008.10.018; Nathke I, 2006, NAT REV CANCER, V6, P967, DOI 10.1038/nrc2010; Obrador-Hevia A, 2010, J PATHOL, V221, P57, DOI 10.1002/path.2685; Phelps RA, 2009, CELL, V137, P623, DOI 10.1016/j.cell.2009.02.037; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Schneikert J, 2011, HUM MOL GENET, V20, P3554, DOI 10.1093/hmg/ddr273; Shoemaker AR, 1997, CANCER RES, V57, P1999; Smits R, 2000, GENE CHROMOSOME CANC, V29, P229, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1033>3.0.CO;2-R; Smits R, 1998, GASTROENTEROLOGY, V114, P275, DOI 10.1016/S0016-5085(98)70478-0; Smits R, 1997, CARCINOGENESIS, V18, P321, DOI 10.1093/carcin/18.2.321; Smits R, 1999, GENE DEV, V13, P1309, DOI 10.1101/gad.13.10.1309; van Veelen W, 2011, GUT, V60, P1204, DOI 10.1136/gut.2010.233460	33	25	25	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 19	2013	32	38					4579	4585		10.1038/onc.2012.449	http://dx.doi.org/10.1038/onc.2012.449			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223SW	23045279	Green Submitted			2022-12-17	WOS:000324831300014
J	Barroilhet, L; Yang, J; Hasselblatt, K; Paranal, RM; Ng, SK; Rauh-Hain, JA; Welch, WR; Bradner, JE; Berkowitz, RS; Ng, SW				Barroilhet, L.; Yang, J.; Hasselblatt, K.; Paranal, R. M.; Ng, S-K; Rauh-Hain, J. A.; Welch, W. R.; Bradner, J. E.; Berkowitz, R. S.; Ng, S-W			C-terminal binding protein-2 regulates response of epithelial ovarian cancer cells to histone deacetylase inhibitors	ONCOGENE			English	Article						ovarian cancer; tumor antigens; HDAC inhibitors	TRANSCRIPTIONAL COREPRESSOR; BETA-CATENIN; CTBP; REPRESSOR; BINDING-PROTEIN-1; ASSOCIATION	Ovarian cancer survival rates have stagnated in the last 20 years despite the development of novel chemotherapeutic agents. Modulators of gene expression, such as histone deacetylase (HDAC) inhibitors, are among the new agents being used in clinical trials. Predictors of sensitivity to chemotherapy have remained elusive. In this study, we show that the expression of the transcriptional corepressor C-terminal binding protein-2 (CtBP2) is elevated in human ovarian tumors. Downregulation of CtBP2 expression in ovarian cancer cell lines using short-hairpin RNA strategy suppressed the growth rate and migration of the resultant cancer cells. The knockdown cell lines also showed upregulation of HDAC activity and increased sensitivity to selected HDAC inhibitors. Conversely, forced expression of wild-type CtBP2 in the knockdown cell lines reversed HDAC activity and partially rescued cellular sensitivity to the HDAC inhibitors. We propose that CtBP2 is an ovarian cancer oncogene that regulates gene expression program by modulating HDAC activity. CtBP2 expression may be a surrogate indicator of cellular sensitivity to HDAC inhibitors.	[Barroilhet, L.; Yang, J.; Hasselblatt, K.; Rauh-Hain, J. A.; Berkowitz, R. S.; Ng, S-W] Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA; [Paranal, R. M.; Bradner, J. E.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Ng, S-K] Griffith Univ, Griffith Hlth Inst, Sch Med, Meadowbrook, Qld 4131, Australia; [Welch, W. R.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Griffith University; Menzies Health Institute Queensland; Harvard University; Brigham & Women's Hospital	Ng, SW (corresponding author), Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, 221 Longwood Ave BLI-449A, Boston, MA 02115 USA.	sng@partners.org		Ng, Shu Kay/0000-0002-6865-9384	Ruth N White Gynecologic Oncology Research Fellowship; Robert and Deborah First Fund; Sperling Family Fund Foundation; Women's Cancer Program; Gillette Center for Women's Cancer from Dana-Farber Cancer Institute; Ovarian Cancer Research Foundation; Adler Foundation, Inc.; Friends of Dana-Farber Cancer Institute	Ruth N White Gynecologic Oncology Research Fellowship; Robert and Deborah First Fund; Sperling Family Fund Foundation; Women's Cancer Program; Gillette Center for Women's Cancer from Dana-Farber Cancer Institute; Ovarian Cancer Research Foundation; Adler Foundation, Inc.; Friends of Dana-Farber Cancer Institute	We thank critical reading of the manuscript by Professor YF Wong. We acknowledge the provision of belinostat, vorinostat, MGCD0103 from Selleck Inc. LB was supported by Ruth N White Gynecologic Oncology Research Fellowship. The Laboratory of Gynecologic Oncology was partly supported by Robert and Deborah First Fund, the Sperling Family Fund Foundation, Women's Cancer Program and Gillette Center for Women's Cancer from Dana-Farber Cancer Institute, Ovarian Cancer Research Foundation, Adler Foundation, Inc., and Friends of Dana-Farber Cancer Institute.	Altekruse SF, 2010, SEER CANC STAT REV 1; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Bradner JE, 2010, NAT CHEM BIOL, V6, P238, DOI 10.1038/NCHEMBIO.313; Chinnadurai G, 2007, INT J BIOCHEM CELL B, V39, P1593, DOI 10.1016/j.biocel.2007.01.025; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Chinnadurai G, 2009, CANCER RES, V69, P731, DOI 10.1158/0008-5472.CAN-08-3349; Cuilliere-Dartigues P, 2006, ONCOGENE, V25, P4441, DOI 10.1038/sj.onc.1209471; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Engers R, 2000, J CANCER RES CLIN, V126, P682, DOI 10.1007/s004320000148; Fang M, 2006, EMBO J, V25, P2735, DOI 10.1038/sj.emboj.7601153; Fournel M, 2008, MOL CANCER THER, V7, P759, DOI 10.1158/1535-7163.MCT-07-2026; Glaser KB, 2007, BIOCHEM PHARMACOL, V74, P659, DOI 10.1016/j.bcp.2007.04.007; Grooteclaes M, 2003, P NATL ACAD SCI USA, V100, P4568, DOI 10.1073/pnas.0830998100; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Hamada F, 2004, DEV CELL, V7, P677, DOI 10.1016/j.devcel.2004.08.022; Hildebrand JD, 2002, MOL CELL BIOL, V22, P5296, DOI 10.1128/MCB.22.15.5296-5307.2002; Huang KC, 2006, INT J CANCER, V118, P2433, DOI 10.1002/ijc.21671; Katsanis N, 1998, GENOMICS, V47, P294, DOI 10.1006/geno.1997.5115; Khan N, 2008, BIOCHEM J, V409, P581, DOI 10.1042/BJ20070779; Lin X, 2003, MOL CELL, V11, P1389, DOI 10.1016/S1097-2765(03)00175-8; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Sierra J, 2006, GENE DEV, V20, P586, DOI 10.1101/gad.1385806; Tang LD, 2010, EUR J CANCER, V46, P170, DOI 10.1016/j.ejca.2009.10.003; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930; Zhang CL, 2001, J BIOL CHEM, V276, P35, DOI 10.1074/jbc.M007364200; Zhao LJ, 2006, J BIOL CHEM, V281, P4183, DOI 10.1074/jbc.M509051200	29	25	26	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2013	32	33					3896	3903		10.1038/onc.2012.380	http://dx.doi.org/10.1038/onc.2012.380			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202JH	22945647				2022-12-17	WOS:000323210200012
J	Ketchart, W; Smith, KM; Krupka, T; Wittmann, BM; Hu, Y; Rayman, PA; Doughman, YQ; Albert, JM; Bai, X; Finke, JH; Xu, Y; Exner, AA; Montano, MM				Ketchart, W.; Smith, K. M.; Krupka, T.; Wittmann, B. M.; Hu, Y.; Rayman, P. A.; Doughman, Y. Q.; Albert, J. M.; Bai, X.; Finke, J. H.; Xu, Y.; Exner, A. A.; Montano, M. M.			Inhibition of metastasis by HEXIM1 through effects on cell invasion and angiogenesis	ONCOGENE			English	Article						HEXIM1; breast cancer; metastasis; angiogenesis	67-KDA LAMININ RECEPTOR; ENDOTHELIAL PROGENITOR CELLS; BREAST-CANCER; GROWTH-FACTOR; HEXAMETHYLENE BISACETAMIDE; TUMOR VASCULATURE; TGF-BETA; EXPRESSION; IDENTIFICATION; CHEMOTHERAPY	We report on the role of hexamethylene-bis-acetamide-inducible protein 1 (HEXIM1) as an inhibitor of metastasis. HEXIM1 expression is decreased in human metastatic breast cancers when compared with matched primary breast tumors. Similarly we observed decreased expression of HEXIM1 in lung metastasis when compared with primary mammary tumors in a mouse model of metastatic breast cancer, the polyoma middle T antigen (PyMT) transgenic mouse. Re-expression of HEXIM1 (through transgene expression or localized delivery of a small molecule inducer of HEXIM1 expression, hexamethylene-bis-acetamide) in PyMT mice resulted in inhibition of metastasis to the lung. Our present studies indicate that HEXIM1 downregulation of HIF-1 alpha protein allows not only for inhibition of vascular endothelial growth factor-regulated angiogenesis, but also for inhibition of compensatory proangiogenic pathways and recruitment of bone marrow-derived cells (BMDCs). Another novel finding is that HEXIM1 inhibits cell migration and invasion that can be partly attributed to decreased membrane localization of the 67 kDa laminin receptor, 67LR, and inhibition of the functional interaction of 67LR with laminin. Thus, HEXIM1 re-expression in breast cancer has therapeutic advantages by simultaneously targeting more than one pathway involved in angiogenesis and metastasis. Our results also support the potential for HEXIM1 to indirectly act on multiple cell types to suppress metastatic cancer.	[Ketchart, W.; Wittmann, B. M.; Hu, Y.; Doughman, Y. Q.; Montano, M. M.] Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA; [Smith, K. M.; Xu, Y.] Cleveland State Univ, Dept Chem, Cleveland, OH 44115 USA; [Krupka, T.; Exner, A. A.] Case Western Reserve Univ, Dept Radiol, Cleveland, OH 44106 USA; [Rayman, P. A.; Finke, J. H.] Cleveland Clin, Lerner Res Inst, Dept Immunol, Cleveland, OH 44106 USA; [Albert, J. M.] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA; [Bai, X.] Case Western Reserve Univ, Ctr RNA Mol Biol, Cleveland, OH USA	Case Western Reserve University; University System of Ohio; Cleveland State University; Case Western Reserve University; Cleveland Clinic Foundation; Case Western Reserve University; Case Western Reserve University	Montano, MM (corresponding author), Case Western Reserve Univ, Dept Pharmacol, Sch Med, HG Wood Bldg W305,2109 Adelbert Rd, Cleveland, OH 44106 USA.	mxm126@case.edu	Xu, Yan/AAW-4085-2021; Smith, Kerri/P-4609-2019; Smith, Kerri M/D-9878-2011; Albert, Jeffrey/P-7273-2019	Albert, Jeffrey/0000-0003-2245-1745; Exner, Agata/0000-0003-3913-7066; Smith, Kerri/0000-0001-5161-3278	National Institute of Health [CA92440, R01CA118399]; Chulalongkorn University in Thailand; National Science Foundation MRI [CHE-0923308]; US Department of Education GAANN [P200A070595-08]; NATIONAL CANCER INSTITUTE [R01CA092440, R01CA118399] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Chulalongkorn University in Thailand; National Science Foundation MRI(National Science Foundation (NSF)); US Department of Education GAANN(US Department of Education); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by National Institute of Health grants CA92440 grant to MMM and R01CA118399 to AAE. WK was supported by a Scholarship for the Development of New Faculty Staff from the Chulalongkorn University in Thailand. The HPLC-MS-MS instrument used for HMBA analysis was funded by National Science Foundation MRI grant (CHE-0923308) to YX. KS is supported by a US Department of Education GAANN grant (P200A070595-08) to YX.	Ahn GO, 2009, ANGIOGENESIS, V12, P159, DOI 10.1007/s10456-009-9135-7; Ardini E, 2002, CANCER RES, V62, P1321; Barker HE, 2011, CANCER RES, V71, P1561, DOI 10.1158/0008-5472.CAN-10-2868; Buto S, 1998, J CELL BIOCHEM, V69, P244, DOI 10.1002/(SICI)1097-4644(19980601)69:3<244::AID-JCB2>3.0.CO;2-R; Casanovas O, 2005, CANCER CELL, V8, P299, DOI 10.1016/j.ccr.2005.09.005; CASTRONOVO V, 1993, INVAS METAST, V13, P1; Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075; Chan DA, 2009, CANCER CELL, V15, P527, DOI 10.1016/j.ccr.2009.04.010; de Graauw M, 2010, P NATL ACAD SCI USA, V107, P6340, DOI 10.1073/pnas.0913360107; Desai KV, 2002, P NATL ACAD SCI USA, V99, P6967, DOI 10.1073/pnas.102172399; Desmedt C, 2007, CLIN CANCER RES, V13, P3207, DOI 10.1158/1078-0432.CCR-06-2765; Dome B, 2009, CRIT REV ONCOL HEMAT, V69, P108, DOI 10.1016/j.critrevonc.2008.06.009; Du R, 2008, CANCER CELL, V13, P206, DOI 10.1016/j.ccr.2008.01.034; Gad HA, 2008, AAPS PHARMSCITECH, V9, P878, DOI 10.1208/s12249-008-9126-9; Gao D, 2009, TRENDS MOL MED, V15, P333, DOI 10.1016/j.molmed.2009.06.006; Givant-Horwitz V, 2004, CANCER RES, V64, P3572, DOI 10.1158/0008-5472.CAN-03-3424; Grepin R, 2010, J ONCOL, V2010, DOI 10.1155/2010/835680; Gu YC, 2003, BLOOD, V101, P877, DOI 10.1182/blood-2002-03-0796; GUILBAUD NF, 1990, J CELL PHYSIOL, V145, P162, DOI 10.1002/jcp.1041450122; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; HINEK A, 1994, CELL ADHES COMMUN, V2, P185, DOI 10.3109/15419069409004436; Hiratsuka S, 2006, NAT CELL BIOL, V8, P1369, DOI 10.1038/ncb1507; Hoenig MR, 2008, CURR DRUG TARGETS, V9, P422, DOI 10.2174/138945008784221215; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Jiang M, 2008, INT J BIOCHEM CELL B, V40, P2284, DOI 10.1016/j.biocel.2008.03.012; Kerbel RS, 2008, NEW ENGL J MED, V358, P2039, DOI 10.1056/NEJMra0706596; Ketchart W, 2011, ONCOGENE, V30, P3563, DOI 10.1038/onc.2011.76; Lee K, 2009, P NATL ACAD SCI USA, V106, P2353, DOI 10.1073/pnas.0812801106; Liao D, 2007, CANCER RES, V67, P563, DOI 10.1158/0008-5472.CAN-06-2701; Lin EY, 2006, CANCER RES, V66, P11238, DOI 10.1158/0008-5472.CAN-06-1278; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Magnifico A, 1996, J BIOL CHEM, V271, P31179, DOI 10.1074/jbc.271.49.31179; Marks P A, 1978, Antibiot Chemother (1971), V23, P33; Montano MM, 1999, P NATL ACAD SCI USA, V96, P6947, DOI 10.1073/pnas.96.12.6947; Montuori N, 1996, CURR TOP MICROBIOL, V213, P205; Nannuru KC, 2010, CANCER RES, V70, P3494, DOI 10.1158/0008-5472.CAN-09-3251; Ogba N, 2010, ONCOGENE, V29, P3639, DOI 10.1038/onc.2010.110; Ogba N, 2008, CANCER RES, V68, P7015, DOI 10.1158/0008-5472.CAN-08-0814; Peinado H, 2011, SEMIN CANCER BIOL, V21, P139, DOI 10.1016/j.semcancer.2011.01.002; Ravivarapu H B, 2000, AAPS PharmSciTech, V1, pE1, DOI 10.1208/pt010101; Relf M, 1997, CANCER RES, V57, P963; REUBEN RC, 1976, P NATL ACAD SCI USA, V73, P862, DOI 10.1073/pnas.73.3.862; Saltz LB, 2008, J CLIN ONCOL, V26, P2013, DOI 10.1200/JCO.2007.14.9930; Schietke R, 2010, J BIOL CHEM, V285, P6658, DOI 10.1074/jbc.M109.042424; Seagroves TN, 2009, PHARMACEUTICAL PERSPECTIVES OF CANCER THERAPEUTICS, P521, DOI 10.1007/978-1-4419-0131-6_16; Selleri C, 2006, BLOOD, V108, P2476, DOI 10.1182/blood-2005-11-012625; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shojaei F, 2007, NAT BIOTECHNOL, V25, P911, DOI 10.1038/nbt1323; Siler U, 2000, BLOOD, V96, P4194; Smith KM, 2011, J CHROMATOGR B, V879, P2206, DOI 10.1016/j.jchromb.2011.06.002; Southard G L, 1998, Expert Opin Investig Drugs, V7, P1483, DOI 10.1517/13543784.7.9.1483; Taylor MA, 2011, GENE EXPRESSION, V15, P117, DOI 10.3727/105221611X13176664479322; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Udagawa T, 2006, FASEB J, V20, P95, DOI 10.1096/fj.04-3669com; Viacava P, 1997, J PATHOL, V182, P36, DOI 10.1002/(SICI)1096-9896(199705)182:1<36::AID-PATH802>3.0.CO;2-W; Wang JH, 2006, CANCER METAST REV, V25, P573, DOI 10.1007/s10555-006-9019-x; Westwell AD, 2004, DRUG DISCOV TODAY, V9, P625, DOI 10.1016/S1359-6446(04)03162-9; Wittmann BM, 2005, ONCOGENE, V24, P5576, DOI 10.1038/sj.onc.1208728; Wittmann BM, 2003, CANCER RES, V63, P5151; Yang L, 2004, CANCER CELL, V6, P409, DOI 10.1016/j.ccr.2004.08.031; YOUNG CW, 1988, CANCER RES, V48, P7304	62	25	25	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2013	32	33					3829	3839		10.1038/onc.2012.405	http://dx.doi.org/10.1038/onc.2012.405			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202JH	22964639	Green Accepted			2022-12-17	WOS:000323210200005
J	Gillis, LD; Lewis, SM				Gillis, L. D.; Lewis, S. M.			Decreased eIF3e/Int6 expression causes epithelial-to-mesenchymal transition in breast epithelial cells	ONCOGENE			English	Article						migration; metastasis; breast cancer; Snail1; Zeb2; translation initiation	MAMMARY-TUMOR VIRUS; TRANSLATION INITIATION; GENE-EXPRESSION; MIR-200 FAMILY; SNAIL; INT6; TRANSCRIPTION; PHOSPHORYLATION; PROGRESSION; INT6/EIF3E	eIF3e/Int6 is a component of the multi-subunit eIF3 complex, which binds directly to the 40S ribosome to facilitate ribosome recruitment to mRNA and hence protein synthesis. Reduced expression of eIF3e/Int6 has been found in up to 37% of human breast cancers, and expression of a truncated mutant version of the mouse eIF3e/Int6 protein leads to malignant transformation of normal mammary cells. These findings suggest that eIF3e/Int6 is a tumor suppressor; however, a recent study has reported that a reduction of eIF3e/Int6 expression in breast cancer cells leads to reduced translation of oncogenes, suggesting that eIF3e/Int6 may in fact have an oncogenic role in breast cancer. To gain a better understanding of the role of eIF3e/Int6 in breast cancer, we have examined the effects of decreased eIF3e/Int6 expression in an immortalized breast epithelial cell line, MCF-10A. Surprisingly, we find that decreased expression of eIF3e/Int6 causes breast epithelial cells to undergo epithelial-to-mesenchymal transition (EMT). We show that EMT induced by a decrease in eIF3e/Int6 expression imparts invasive and migratory properties to breast epithelial cells, suggesting that regulation of EMT by eIF3e/Int6 may have an important role in breast cancer metastasis. Furthermore, we show that reduced eIF3e/Int6 expression in breast epithelial cells causes a specific increase in the expression of the key EMT regulators Snail1 and Zeb2, which occurs at both the transcriptional and post-transcriptional levels. Together, our data indicate a novel role of eIF3e/Int6 in the regulation of EMT in breast epithelial cells and support a tumor suppressor role of eIF3e/Int6.	[Gillis, L. D.; Lewis, S. M.] Hotel Dieu Pavil, Atlantic Canc Res Inst, Moncton, NB E1C 8X3, Canada; [Lewis, S. M.] Dalhousie Univ, Dept Microbiol & Immunol, Halifax, NS, Canada; [Lewis, S. M.] Univ New Brunswick, Dept Biol, St John, NB E2L 4L5, Canada	Dalhousie University; University of New Brunswick	Lewis, SM (corresponding author), Hotel Dieu Pavil, Atlantic Canc Res Inst, 35 Providence St, Moncton, NB E1C 8X3, Canada.	stephenl@canceratl.ca	Lewis, Stephen/E-5533-2010	Lewis, Stephen/0000-0001-9537-5822	Canadian Breast Cancer Foundation-Atlantic Chapter; Canadian Institutes of Health Research-Regional [RSH-108667]	Canadian Breast Cancer Foundation-Atlantic Chapter; Canadian Institutes of Health Research-Regional	We thank Dr Craig McCormick for the generous gift of the retroviral transduction system used in this study, Dr Anirban Ghosh for advice on confocal immunofluorescence microscopy and Dr Martin Holcik for critical comments on the manuscript. This research was supported by a grant to SML from the Canadian Breast Cancer Foundation-Atlantic Chapter. SML is a Senior Scientist of the Beatrice Hunter Cancer Research Institute and a Canadian Institutes of Health Research-Regional Partnerships Program New Investigator (RSH-108667).	Ansieau S, 2008, CANCER CELL, V14, P79, DOI 10.1016/j.ccr.2008.06.005; Bandyopadhyay A, 2000, MOL BIOL CELL, V11, P4005, DOI 10.1091/mbc.11.11.4005; Barbera MJ, 2004, ONCOGENE, V23, P7345, DOI 10.1038/sj.onc.1207990; Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Beltran M, 2008, GENE DEV, V22, P756, DOI 10.1101/gad.455708; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; Chaudhury A, 2010, NAT CELL BIOL, V12, P286, DOI 10.1038/ncb2029; Chiluiza D, 2011, J BIOL CHEM, V286, P31288, DOI 10.1074/jbc.M111.267294; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Evdokimova V, 2009, CELL CYCLE, V8, P2901, DOI 10.4161/cc.8.18.9537; Evdokimova V, 2009, CANCER CELL, V15, P402, DOI 10.1016/j.ccr.2009.03.017; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Grzmil M, 2010, ONCOGENE, V29, P4080, DOI 10.1038/onc.2010.152; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Jechlinger M, 2003, ONCOGENE, V22, P7155, DOI 10.1038/sj.onc.1206887; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; Kurrey NK, 2009, STEM CELLS, V27, P2059, DOI 10.1002/stem.154; LeFebvre AK, 2006, J BIOL CHEM, V281, P22917, DOI 10.1074/jbc.M605418200; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luo DC, 2011, MOL CANCER RES, V9, P234, DOI 10.1158/1541-7786.MCR-10-0214; Mack DL, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1742; MARCHETTI A, 1995, J VIROL, V69, P1932, DOI 10.1128/JVI.69.3.1932-1938.1995; Marchetti A, 2001, INT J ONCOL, V18, P175; Morris C, 2005, ONCOGENE, V24, P1203, DOI 10.1038/sj.onc.1208268; Morris C, 2007, EMBO REP, V8, P596, DOI 10.1038/sj.embor.7400955; PAINE TM, 1992, INT J CANCER, V50, P463, DOI 10.1002/ijc.2910500323; Petz M, 2007, NUCLEIC ACIDS RES, V35, P2473, DOI 10.1093/nar/gkm096; Rasmussen SB, 2001, ONCOGENE, V20, P5291, DOI 10.1038/sj.onc.1204624; Raun R, MRNA FORMATION FUNCT, P305; SOULE HD, 1990, CANCER RES, V50, P6075; Suo J, 2011, ONCOGENE, V30, P724, DOI 10.1038/onc.2010.445; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Yen HCS, 2003, CELL, V112, P207, DOI 10.1016/S0092-8674(03)00043-6; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183; Zhao TT, 2009, CELL DEATH DIFFER, V16, P244, DOI 10.1038/cdd.2008.146; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173; Zhou CS, 2005, BMC BIOL, V3, DOI 10.1186/1741-7007-3-14; Zhou M, 2008, P NATL ACAD SCI USA, V105, P18139, DOI 10.1073/pnas.0801313105	40	25	25	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	2013	32	31					3598	3605		10.1038/onc.2012.371	http://dx.doi.org/10.1038/onc.2012.371			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194MW	22907435				2022-12-17	WOS:000322638400004
J	Maier, HJ; Wagner, M; Schips, TG; Salem, HH; Baumann, B; Wirth, T				Maier, H. J.; Wagner, M.; Schips, T. G.; Salem, H. H.; Baumann, B.; Wirth, T.			Requirement of NEMO/IKK gamma for effective expansion of KRAS-induced precancerous lesions in the pancreas	ONCOGENE			English	Article						pancreatic intraepithelial neoplasia; pancreatic carcinoma; animal model; KRAS; NEMO/IKK gamma	NF-KAPPA-B; CONSTITUTIVE IKK2 ACTIVATION; INTRAEPITHELIAL NEOPLASIA; DUCTAL ADENOCARCINOMA; MOUSE MODEL; CANCER; PROGRESSION; CELLS; MICE; INFLAMMATION	Pancreatic carcinoma, a leading cause of cancer death, is thought to develop out of pancreatic intraepithelial neoplasia (PanIN). PanIN lesions have not yet attained the fully malignant phenotype, but show increased proliferation and dysplasia, and frequently bear an oncogenic KRAS mutation. Pancreatic cancer development is associated with increased activity of the transcription factor NF-kappa B. NEMO (IKK gamma) is a subunit of the IKK complex essential for the activation of canonical NF-kappa B signaling and has been ascribed both oncogenic and tumor-suppressive roles in gastrointestinal tumors. Here, we wanted to address the function of NEMO in pancreatic tumorigenesis. We therefore conditionally ablated NEMO in a mouse model for pancreatic carcinoma based on the expression of oncogenic KRAS in pancreatic precursor cells. Mice were analyzed for PanIN lesions and for the activation of associated signaling pathways. NEMO ablation in the pancreas, while in itself not causing any overt pathology, led to a drastic (>93%) decrease in the prevalence of both low-grade and high-grade PanIN in 10-month-old mice expressing oncogenic KRAS. Also, the inflammatory and fibrotic response associated with KRAS action in the pancreas was virtually abolished, including expression of inflammatory cytokines and activation of the interleukin-6/STAT3 axis. Moreover, the activation of MAPK signaling, Notch and KLF4 signaling normally observed in KRAS-induced PanIN was strongly reduced or absent when NEMO was ablated. Our study suggests that NEMO, an IKK subunit necessary for canonical NF-kappa B activation, is dispensable for normal pancreatic development and function, but essential for the propagation of KRAS-induced PanIN lesions.	[Maier, H. J.; Schips, T. G.; Salem, H. H.; Baumann, B.; Wirth, T.] Univ Ulm, Inst Physiol Chem, D-89081 Ulm, Germany; [Wagner, M.] Univ Ulm, Dept Internal Med 1, Ctr Internal Med, D-89081 Ulm, Germany; [Salem, H. H.] Cairo Univ, Dept Biochem, Fac Pharm, Cairo, Egypt	Ulm University; Ulm University; Egyptian Knowledge Bank (EKB); Cairo University	Wirth, T (corresponding author), Univ Ulm, Inst Physiol Chem, Albert Einstein Allee 11, D-89081 Ulm, Germany.	thomas.wirth@uni-ulm.de	Wirth, Thomas/X-7172-2019	Salem, Heba/0000-0002-3289-5588				Aleksic T, 2007, GUT, V56, P227, DOI 10.1136/gut.2005.084665; Baumann B, 2007, J CLIN INVEST, V117, P1502, DOI 10.1172/JCI30876; Baumgart S, GUT, DOI [10.1136/gutjnl-2011-301008, DOI 10.1136/GUTJNL-2011-301008)]; Ben-Neriah Y, 2011, NAT IMMUNOL, V12, P715, DOI 10.1038/ni.2060; Corcoran RB, 2011, CANCER RES, V71, P5020, DOI 10.1158/0008-5472.CAN-11-0908; Daniluk J, 2012, J CLIN INVEST, V122, P1519, DOI 10.1172/JCI59743; Fendrich V, 2010, GUT, V59, P630, DOI 10.1136/gut.2009.188961; Fukuda A, 2011, CANCER CELL, V19, P441, DOI 10.1016/j.ccr.2011.03.002; Funahashi H, 2007, CANCER RES, V67, P7068, DOI 10.1158/0008-5472.CAN-07-0970; Greer JB, 2009, CURR OPIN PHARMACOL, V9, P411, DOI 10.1016/j.coph.2009.06.011; Guerra C, 2007, CANCER CELL, V11, P291, DOI 10.1016/j.ccr.2007.01.012; Guerra C, 2011, CANCER CELL, V19, P728, DOI 10.1016/j.ccr.2011.05.011; Herrera PL, 2000, DEVELOPMENT, V127, P2317; Hezel AF, 2006, GENE DEV, V20, P1218, DOI 10.1101/gad.1415606; Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hruban Ralph H, 2008, Gastrointest Cancer Res, V2, pS10; Hruban RH, 2008, INT J CLIN EXP PATHO, V1, P306; Hruban RH, 2001, AM J SURG PATHOL, V25, P579, DOI 10.1097/00000478-200105000-00003; Ji H, 2006, ONCOGENE, V25, P2105, DOI 10.1038/sj.onc.1209237; Lesina M, 2011, CANCER CELL, V19, P456, DOI 10.1016/j.ccr.2011.03.009; Ling JH, 2012, CANCER CELL, V21, P105, DOI 10.1016/j.ccr.2011.12.006; Liptay S, 2003, INT J CANCER, V105, P735, DOI 10.1002/ijc.11081; Lohr M, 2005, NEOPLASIA, V7, P17, DOI 10.1593/neo.04445; Luedde T, 2007, CANCER CELL, V11, P119, DOI 10.1016/j.ccr.2006.12.016; Maier HJ, 2010, CANCER LETT, V295, P214, DOI 10.1016/j.canlet.2010.03.003; Maniati E, 2011, J CLIN INVEST, V121, P4685, DOI 10.1172/JCI45797; Nenci A, 2007, NATURE, V446, P557, DOI 10.1038/nature05698; Oeckinghaus A, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000034; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; Schneider G, 2005, GASTROENTEROLOGY, V128, P1606, DOI 10.1053/j.gastro.2005.04.001; Vlantis K, 2011, J CLIN INVEST, V121, P2781, DOI 10.1172/JCI45349; Wang WX, 1999, CLIN CANCER RES, V5, P119; Ying HQ, 2011, CANCER DISCOV, V1, P158, DOI 10.1158/2159-8290.CD-11-0031	34	25	25	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2013	32	21					2690	2695		10.1038/onc.2012.272	http://dx.doi.org/10.1038/onc.2012.272			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	156FH	22751123				2022-12-17	WOS:000319806700010
J	Ortiz-Padilla, C; Gallego-Ortega, D; Browne, BC; Hochgrafe, F; Caldon, CE; Lyons, RJ; Croucher, DR; Rickwood, D; Ormandy, CJ; Brummer, T; Daly, RJ				Ortiz-Padilla, C.; Gallego-Ortega, D.; Browne, B. C.; Hochgraefe, F.; Caldon, C. E.; Lyons, R. J.; Croucher, D. R.; Rickwood, D.; Ormandy, C. J.; Brummer, T.; Daly, R. J.			Functional characterization of cancer-associated Gab1 mutations	ONCOGENE			English	Article						signal transduction; protein phosphorylation; mammary; breast cancer	EPITHELIAL MORPHOGENESIS DOWNSTREAM; RECEPTOR TYROSINE KINASE; HUMAN BREAST-CANCER; DOCKING PROTEIN; MET RECEPTOR; SCAFFOLDING ADAPTER; PHOSPHATIDYLINOSITOL 3-KINASE; CELL-PROLIFERATION; PHOSPHATASE SHP-2; GENE-EXPRESSION	Grb2-associated binder 1 (Gab1) is a docking protein that transduces signals from a variety of tyrosine kinases, including Met and the epidermal growth factor receptor (EGFR). Although the related protein Gab2 is strongly implicated in human cancer, a role for Gab1 has been less clear. However, a screen for gene mutations in breast cancer identified two somatic mutations in Gab1, Y83C and T387N. In this paper we describe the functional characterization of these Gab1 mutants. MCF-10A immortalized mammary epithelial cells overexpressing Gab1 Y83C and T387N exhibited a more elongated, fibroblastic phenotype compared with wild-type Gab1 controls. Expression of Gab1 or the mutants promoted epidermal growth factor (EGF)-independent proliferation in monolayer culture to a similar degree. However, in Matrigel culture, both mutants enhanced the formation of acini exhibiting an aberrant, branched morphology. In addition, expression of the mutants modestly increased Erk activation. The two mutants also enhanced branching morphogenesis in a different mammary epithelial cell line, HC11. To gain further insights into the mechanism of action of these mutations, we mapped Gab1 phosphorylation sites by mass spectrometry. This detected phosphorylation of T387 but; not Y83. Cellular stimulation with EGF or hepatocyte growth factor (HGF) led to a transient, or sustained, induction of T387 phosphorylation, respectively. As T387 corresponds in position to Gab2 T391, which suppresses Gab2 signaling in a phosphorylation-dependent manner, these data support a model in which the T387N mutation abrogates negative-feedback regulation of Gab1. Interrogation of publically-available databases revealed additional cancer-associated mutations at, or in close proximity to, identified serine/threonine phosphorylation sites in other docking proteins. These data indicate that aberrant Gab1 signaling can directly contribute to breast cancer progression, and that negative feedback sites in docking proteins can be targeted by oncogenic mutations.	[Ortiz-Padilla, C.; Gallego-Ortega, D.; Browne, B. C.; Hochgraefe, F.; Caldon, C. E.; Lyons, R. J.; Croucher, D. R.; Rickwood, D.; Ormandy, C. J.; Daly, R. J.] Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia; [Brummer, T.] Univ Freiburg, Ctr Biol Syst Anal ZBSA, D-79106 Freiburg, Germany; [Brummer, T.] Univ Freiburg, Inst Biol 3, D-79106 Freiburg, Germany; [Brummer, T.] Univ Freiburg, Ctr Biol Signalling Studies BIOSS, D-79106 Freiburg, Germany; [Ormandy, C. J.; Daly, R. J.] Univ New S Wales, St Vincents Hosp, Sch Clin, Sydney, NSW, Australia	Garvan Institute of Medical Research; University of Freiburg; University of Freiburg; University of Freiburg; St Vincents Hospital Sydney; University of New South Wales Sydney	Daly, RJ (corresponding author), Garvan Inst Med Res, Canc Res Program, 384 Victoria St, Sydney, NSW 2010, Australia.	r.daly@garvan.org.au	Brummer, Tilman/AAA-9428-2020; Caldon, Liz/C-1559-2009; Gallego-Ortega, David/AAK-9067-2020; Ormandy, Chris/G-4165-2014; Brummer, Tilman/B-6218-2016	Brummer, Tilman/0000-0003-4387-7905; Caldon, Liz/0000-0003-1392-3472; Gallego-Ortega, David/0000-0002-2347-7835; Brummer, Tilman/0000-0003-4387-7905; Croucher, David/0000-0003-4965-8674; Daly, Roger/0000-0002-5739-8027; Ormandy, Christopher/0000-0002-2504-7919	National Health and Medical Research Council of Australia; Cancer Institute New South Wales Early Career Fellowships; New South Wales Cancer Council; Banque Nationale de Paris-Paribas Australia; German Research Foundation (DFG) through the Emmy-Noether-Program [CRC850, EXC294]; National Breast Cancer Foundation [NC-12-24, PF-12-06] Funding Source: researchfish	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Cancer Institute New South Wales Early Career Fellowships; New South Wales Cancer Council(Cancer Council New South Wales); Banque Nationale de Paris-Paribas Australia; German Research Foundation (DFG) through the Emmy-Noether-Program(German Research Foundation (DFG)); National Breast Cancer Foundation	This work was supported by the National Health and Medical Research Council of Australia. CEC and DRC are recipients of Cancer Institute New South Wales Early Career Fellowships. DG-O is a National Breast Cancer Foundation and Cure Cancer Australia Fellow. CJO is supported by New South Wales Cancer Council and Banque Nationale de Paris-Paribas Australia. TB is supported by the German Research Foundation (DFG) through the Emmy-Noether-Program, CRC850 and EXC294 BIOSS.	Abella JV, 2010, J CELL SCI, V123, P1306, DOI 10.1242/jcs.062570; Aitken A, 2006, SEMIN CANCER BIOL, V16, P162, DOI 10.1016/j.semcancer.2006.03.005; Arnaud M, 2004, J IMMUNOL, V173, P3962, DOI 10.4049/jimmunol.173.6.3962; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; Bentires-Alj M, 2006, NAT MED, V12, P114, DOI 10.1038/nm1341; Bocanegra M, 2010, ONCOGENE, V29, P774, DOI 10.1038/onc.2009.364; Brown LA, 2008, GENE CHROMOSOME CANC, V47, P481, DOI 10.1002/gcc.20549; Brummer T, 2006, J BIOL CHEM, V281, P626, DOI 10.1074/jbc.M509567200; Brummer T, 2008, EMBO J, V27, P2305, DOI 10.1038/emboj.2008.159; Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933; Chernoff KA, 2009, CLIN CANCER RES, V15, P4288, DOI 10.1158/1078-0432.CCR-09-0280; Daly RJ, 2002, ONCOGENE, V21, P5175, DOI 10.1038/sj.onc.1205522; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Drasin DJ, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3037; Ellison DW, 2011, ACTA NEUROPATHOL, V121, P381, DOI 10.1007/s00401-011-0800-8; Eulenfeld R, 2009, J CELL SCI, V122, P55, DOI 10.1242/jcs.037226; Ferguson KM, 2000, MOL CELL, V6, P373, DOI 10.1016/S1097-2765(00)00037-X; Fleuren EDG, 2010, INT J CANCER, V127, P1486, DOI 10.1002/ijc.25172; Gual P, 2001, ONCOGENE, V20, P156, DOI 10.1038/sj.onc.1204047; Horst B, 2009, AM J PATHOL, V174, P1524, DOI 10.2353/ajpath.2009.080543; JANES PW, 1994, ONCOGENE, V9, P3601; Juric D, 2007, J CLIN ONCOL, V25, P1341, DOI 10.1200/JCO.2006.09.3534; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; Landgraf KE, 2008, BIOCHEMISTRY-US, V47, P12260, DOI 10.1021/bi801683k; Laramee M, 2007, J BIOL CHEM, V282, P7758, DOI 10.1074/jbc.M611327200; Lee SH, 2007, PATHOLOGY, V39, P326, DOI 10.1080/00313020701329773; Lock LS, 2003, J BIOL CHEM, V278, P30083, DOI 10.1074/jbc.M302675200; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; Lynch DK, 2002, EMBO J, V21, P72, DOI 10.1093/emboj/21.1.72; Maroun CR, 2000, MOL CELL BIOL, V20, P8513, DOI 10.1128/MCB.20.22.8513-8525.2000; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; Mood K, 2006, MOL BIOL CELL, V17, P3717, DOI 10.1091/mbc.e06-03-0244; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Reginato MJ, 2005, MOL CELL BIOL, V25, P4591, DOI 10.1128/MCB.25.11.4591-4601.2005; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; SOULE HD, 1990, CANCER RES, V50, P6075; Wohrle FU, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-22; Wrobel CN, 2004, J CELL BIOL, V165, P263, DOI 10.1083/jcb.200309102; Xian W, 2005, J CELL BIOL, V171, P663, DOI 10.1083/jcb.200505098; Yu CF, 2001, J BIOL CHEM, V276, P32552, DOI 10.1074/jbc.M104493200; Zatkova A, 2006, GENE CHROMOSOME CANC, V45, P798, DOI 10.1002/gcc.20344	42	25	27	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 23	2013	32	21					2696	2702		10.1038/onc.2012.271	http://dx.doi.org/10.1038/onc.2012.271			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	156FH	22751113				2022-12-17	WOS:000319806700011
J	Kikuchi, K; Soundararajan, A; Zarzabal, LA; Weems, CR; Nelon, LD; Hampton, ST; Michalek, JE; Rubin, BP; Fields, AP; Keller, C				Kikuchi, K.; Soundararajan, A.; Zarzabal, L. A.; Weems, C. R.; Nelon, L. D.; Hampton, S. T.; Michalek, J. E.; Rubin, B. P.; Fields, A. P.; Keller, C.			Protein kinase C iota as a therapeutic target in alveolar rhabdomyosarcoma	ONCOGENE			English	Article						alveolar rhabdomyosarcoma; protein kinase C iota; Rac1; mitosis; aurothiomalate; vincristine	TRANSFORMED GROWTH; CELL; EXPRESSION; VINCRISTINE; ACTIVATION; PAX3-FKHR; ONCOGENE; PHARMACOKINETICS; DIFFERENTIATION; RESISTANCE	Alveolar rhabdomyosarcoma is an aggressive pediatric cancer exhibiting skeletal-muscle differentiation. New therapeutic targets are required to improve the dismal prognosis for invasive or metastatic alveolar rhabdomyosarcoma. Protein kinase C iota (PKC iota) has been shown to have an important role in tumorigenesis of many cancers, but little is known about its role in rhabdomyosarcoma. Our gene-expression studies in human tumor samples revealed overexpression of PRKCl. We confirmed overexpression of PKC iota at the mRNA and protein levels using our conditional mouse model that authentically recapitulates the progression of rhabdomyosarcoma in humans. Inhibition of Prkci by RNA interference resulted in a dramatic decrease in anchorage-independent colony formation. Interestingly, treatment of primary cell cultures using aurothiomalate (ATM), which is a gold-containing classical anti-rheumatic agent and a PKC iota-specific inhibitor, resulted in decreased interaction between PKC iota and Par6, decreased Rac1 activity and reduced cell viability at clinically relevant concentrations. Moreover, co-treatment with ATM and vincristine (VCR), a nnicrotubule inhibitor currently used in rhabdomyosarcoma treatment regimens, resulted in a combination index of 0.470-0.793 through cooperative accumulation of non-proliferative multinuclear cells in the G2/M phase, indicating that these two drugs synergize. For in vivo tumor growth inhibition studies, ATM demonstrated a trend toward enhanced VCR sensitivity. Overall, these results suggest that PKC iota is functionally important in alveolar rhabdomyosarcoma anchorage-independent growth and tumor-cell proliferation and that combination therapy with ATM and microtubule inhibitors holds promise for the treatment of alveolar rhabdomyosarcoma. Oncogene (2013) 32, 286-295; doi:10.1038/onc.2012.46; published online 20 February 2012	[Kikuchi, K.; Keller, C.] Oregon Hlth & Sci Univ, Dept Pediat, Pape Family Pediat Res Inst, Pediat Canc Biol Program, Portland, OR 97239 USA; [Soundararajan, A.; Nelon, L. D.; Hampton, S. T.] Univ Texas Hlth Sci Ctr San Antonio, Greehey Childrens Canc Res Inst, San Antonio, TX 78229 USA; [Zarzabal, L. A.; Michalek, J. E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol, San Antonio, TX 78229 USA; [Zarzabal, L. A.; Michalek, J. E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biostat, San Antonio, TX 78229 USA; [Weems, C. R.; Fields, A. P.] Mayo Clin, Ctr Comprehens Canc, Dept Canc Biol, Jacksonville, FL 32224 USA; [Rubin, B. P.] Cleveland Clin, Taussig Canc Ctr, Dept Anat Pathol, Cleveland, OH 44106 USA; [Rubin, B. P.] Cleveland Clin, Taussig Canc Ctr, Dept Mol Genet, Cleveland, OH 44106 USA; [Rubin, B. P.] Lerner Res Inst, Cleveland, OH USA	Oregon Health & Science University; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Mayo Clinic; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Keller, C (corresponding author), Oregon Hlth & Sci Univ, Dept Pediat, Pape Family Pediat Res Inst, Pediat Canc Biol Program, 3181 SW Sam Jackson Pk Rd,Mail Code L321, Portland, OR 97239 USA.	keller@ohsu.edu	Kikuchi, Ken/ABG-8290-2020	Kikuchi, Ken/0000-0003-3097-7480; Keller, Charles/0000-0003-2505-7487	NIH/NCI Grant [1R01CA133229-04, 1R01CA133229-05, 4R01CA081436-13]; V Foundation for Cancer Research; National Cancer Institute; NICHD; NATIONAL CANCER INSTITUTE [R01CA081436, R01CA133229] Funding Source: NIH RePORTER	NIH/NCI Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); V Foundation for Cancer Research; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH/NCI Grant 1R01CA133229-04 and -05 awarded to CK, NIH/NCI Grant 4R01CA081436-13 and the V Foundation for Cancer Research awarded to APF. Human tissue samples were provided by the Pediatric Cooperative Human Tissue network, which is funded by the National Cancer Institute. The Developmental Studies Hybridoma Bank is developed under the auspices of the NICHD and maintained by the University of Iowa, Iowa City, IA, USA.	Ali AS, 2009, CANCER TREAT REV, V35, P1, DOI 10.1016/j.ctrv.2008.07.006; Amstutz R, 2008, CANCER RES, V68, P3767, DOI 10.1158/0008-5472.CAN-07-2447; Anderson J, 1999, GENE CHROMOSOME CANC, V26, P275, DOI 10.1002/(SICI)1098-2264(199912)26:4<275::AID-GCC1>3.0.CO;2-3; Arndt CAS, 1999, NEW ENGL J MED, V341, P342, DOI 10.1056/NEJM199907293410507; BLOCKA KLN, 1986, CLIN PHARMACOKINET, V11, P133, DOI 10.2165/00003088-198611020-00003; BOUCHE M, 1995, CELL GROWTH DIFFER, V6, P845; Breneman JC, 2003, J CLIN ONCOL, V21, P78, DOI 10.1200/JCO.2003.06.129; Cen L, 2007, MODERN PATHOL, V20, P936, DOI 10.1038/modpathol.3800834; Chen LG, 1999, GYNECOL ONCOL, V72, P171, DOI 10.1006/gyno.1998.5242; Erdogan E, 2006, J BIOL CHEM, V281, P28450, DOI 10.1074/jbc.M606054200; Etienne-Manneville S, 2003, CURR OPIN CELL BIOL, V15, P67, DOI 10.1016/S0955-0674(02)00005-4; Fields AP, 2007, BIOCHEM SOC T, V35, P996, DOI 10.1042/BST0350996; Fields AP, 2007, PHARMACOL RES, V55, P487, DOI 10.1016/j.phrs.2007.04.015; Fields AP, 2008, ADV ENZYME REGUL, V48, P166, DOI 10.1016/j.advenzreg.2007.11.014; GERMANI A, 1994, BIOCHEM BIOPH RES CO, V202, P17, DOI 10.1006/bbrc.1994.1887; Griner EM, 2007, NAT REV CANCER, V7, P281, DOI 10.1038/nrc2110; Hayes-Jordan A, 2009, CURR OPIN PEDIATR, V21, P373, DOI 10.1097/MOP.0b013e32832b4171; HOUGHTON JA, 1982, CANCER RES, V42, P535; Ishiguro H, 2009, P NATL ACAD SCI USA, V106, P16369, DOI 10.1073/pnas.0907044106; JORDAN MA, 1991, CANCER RES, V51, P2212; Keller C, 2004, GENE DEV, V18, P2614, DOI 10.1101/gad.1244004; Keller C, 2004, GENE DEV, V18, P2608, DOI 10.1101/gad.1243904; Limatola C, 1997, BIOCHEM J, V321, P497, DOI 10.1042/bj3210497; Liu LN, 1998, CELL GROWTH DIFFER, V9, P699; Mackay HJ, 2007, NAT REV CANCER, V7, P554, DOI 10.1038/nrc2168; Maroto B, 2008, ONCOGENE, V27, P4900, DOI 10.1038/onc.2008.131; Murray NR, 2011, J CELL PHYSIOL, V226, P879, DOI 10.1002/jcp.22463; Murray NR, 1997, J BIOL CHEM, V272, P27521, DOI 10.1074/jbc.272.44.27521; Murray NR, 2004, J CELL BIOL, V164, P797, DOI 10.1083/jcb.200311011; NELSON RL, 1982, MED PEDIATR ONCOL, V10, P115, DOI 10.1002/mpo.2950100202; Nishijo K, 2009, CANCER RES, V69, P2902, DOI 10.1158/0008-5472.CAN-08-3723; Regala RP, 2008, CANCER RES, V68, P5888, DOI 10.1158/0008-5472.CAN-08-0438; Regala RP, 2009, CANCER RES, V69, P7603, DOI 10.1158/0008-5472.CAN-09-2066; Regala RP, 2005, CANCER RES, V65, P8905, DOI 10.1158/0008-5472.CAN-05-2372; Regala RP, 2005, J BIOL CHEM, V280, P31109, DOI 10.1074/jbc.M505402200; Rubin BP, 2011, CANCER CELL, V19, P177, DOI 10.1016/j.ccr.2010.12.023; Scotti ML, 2010, CANCER RES, V70, P2064, DOI 10.1158/0008-5472.CAN-09-2684; Sorensen PHB, 2002, J CLIN ONCOL, V20, P2672, DOI 10.1200/JCO.2002.03.137; Stallings-Mann M, 2006, CANCER RES, V66, P1767, DOI 10.1158/0008-5472.CAN-05-3405; Sundberg C, 2004, J BIOL CHEM, V279, P51601, DOI 10.1074/jbc.M403753200; Svensson K, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-10; TENNYSON GS, 1983, CANCER TREAT REP, V67, P1113; Thimmaiah KN, 2010, CANCER RES, V70, P2000, DOI 10.1158/0008-5472.CAN-09-3693; Thompson J, 1999, CLIN CANCER RES, V5, P3617; Wachtel M, 2010, CANCER TREAT REV, V36, P318, DOI 10.1016/j.ctrv.2010.02.007; Win HY, 2009, CELL PROLIFERAT, V42, P182, DOI 10.1111/j.1365-2184.2009.00582.x; Win HY, 2008, CANCER LETT, V270, P302, DOI 10.1016/j.canlet.2008.05.023; Wittmann T, 2004, J BIOL CHEM, V279, P6196, DOI 10.1074/jbc.M307261200; Woodcock SA, 2010, CURR BIOL, V20, P669, DOI 10.1016/j.cub.2010.02.033; Zhang L, 2006, CANCER RES, V66, P4627, DOI 10.1158/0008-5472.CAN-05-4527	50	25	25	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2013	32	3					286	295		10.1038/onc.2012.46	http://dx.doi.org/10.1038/onc.2012.46			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087BP	22349825	Green Accepted			2022-12-17	WOS:000314736600003
J	Paget, JA; Restall, IJ; Daneshmand, M; Mersereau, JA; Simard, MA; Parolin, DAE; Lavictoire, SJ; Amin, MS; Islam, S; Lorimer, IAJ				Paget, J. A.; Restall, I. J.; Daneshmand, M.; Mersereau, J. A.; Simard, M. A.; Parolin, D. A. E.; Lavictoire, S. J.; Amin, M. S.; Islam, S.; Lorimer, I. A. J.			Repression of cancer cell senescence by PKC iota	ONCOGENE			English	Article						atypical protein kinase-C; PIK3CA; breast cancer; glioblastoma; senescence; aurora kinase	KINASE-C-IOTA; SUPPRESSES TUMOR-GROWTH; BREAST-CANCER; IN-VIVO; PIK3CA MUTATIONS; CYCLE ARREST; AURORA-A; PROTEIN; ONCOGENE; PHOSPHORYLATION	Senescence is an irreversible growth arrest phenotype adopted by cells that has a key role in protecting organisms from cancer. There is now considerable interest in therapeutic strategies that reactivate this process to control the growth of cancer cells. Protein kinase-C iota (PKC iota) is a member of the atypical PKC family and an important downstream mediator in the phosphoinositide-3-kinase (PI-3-kinase) pathway. PKC iota expression was found to be upregulated in a subset of breast cancers and breast cancer cell lines. Activation of the PI-3-kinase pathway by introduction of mutant, oncogenic PIK3CA into breast mammary epithelial cells increased both the expression and activation of PKC iota. In breast cancer cells lines overexpressing PKC iota, depletion of PKC iota increased the number of senescent cells, as assessed by senescence-associated beta-galactosidase, morphology and bromodeoxyuridine incorporation. This phenomenon was not restricted to breast cancer cells, as it was also seen in glioblastoma cells in which PKC iota is activated by loss of PTEN. Senescence occurred in the absence of a detectable DNA-damage response, was dependent on p21 and was enhanced by the aurora kinase inhibitor VX-680, suggesting that senescence is triggered by defects in mitosis. Depletion of PKCi had no effect on senescence in normal mammary epithelial cell lines. We conclude that PKC iota is overexpressed in a subset of cancers where it functions to suppress premature senescence. This function appears to be restricted to cancer cells and inhibition of PKC iota may therefore be an effective way to selectively activate premature senescence in cancer cells. Oncogene (2012) 31, 3584-3596; doi:10.1038/onc.2011.524; published online 28 November 2011	[Lorimer, I. A. J.] Ottawa Hosp, Reg Canc Ctr, Ctr Canc Therapeut, Res Inst, Ottawa, ON K1H 8L6, Canada; [Paget, J. A.; Restall, I. J.; Lorimer, I. A. J.] Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada; [Amin, M. S.; Islam, S.] Ottawa Hosp, Dept Pathol, Ottawa, ON K1H 8L6, Canada; [Lorimer, I. A. J.] Univ Ottawa, Dept Med, Ottawa, ON, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa	Lorimer, IAJ (corresponding author), Ottawa Hosp, Reg Canc Ctr, Ctr Canc Therapeut, Res Inst, 3rd Floor,501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.	ilorimer@ohri.ca		Simard, Manon/0000-0001-5363-1699	Canadian Institutes of Health Research; Ottawa Regional Cancer Foundation; Canadian Institutes of Health Research Banting; Best MSc Scholarship; Ontario Graduate Scholarship in Science and Technology	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Ottawa Regional Cancer Foundation; Canadian Institutes of Health Research Banting(Canadian Institutes of Health Research (CIHR)); Best MSc Scholarship; Ontario Graduate Scholarship in Science and Technology	This work was supported by grants from the Canadian Institutes of Health Research and the Ottawa Regional Cancer Foundation (to IAJL). JP was supported by a Canadian Institutes of Health Research Banting and Best MSc Scholarship. IR is supported by an Ontario Graduate Scholarship in Science and Technology. We thank Sharon Rowan and Mara Coiciu for their work on the initial characterization of PKC iota activation in breast cancer cells.	Baker DJ, 2004, NAT GENET, V36, P744, DOI 10.1038/ng1382; Baldwin RM, 2008, ONCOGENE, V27, P3587, DOI 10.1038/sj.onc.1211027; Baldwin RM, 2006, ONCOGENE, V25, P2909, DOI 10.1038/sj.onc.1209312; Baldwin RM, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-233; Balendran A, 2000, J BIOL CHEM, V275, P20806, DOI 10.1074/jbc.M000421200; Barr AR, 2007, J CELL SCI, V120, P2987, DOI 10.1242/jcs.013136; Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; Carracedo A, 2011, CANCER RES, V71, P629, DOI 10.1158/0008-5472.CAN-10-2488; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; Crowder RJ, 2009, CANCER RES, V69, P3955, DOI 10.1158/0008-5472.CAN-08-4450; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Debacq-Chainiaux F, 2009, NAT PROTOC, V4, P1798, DOI 10.1038/nprot.2009.191; Denoyelle C, 2006, NAT CELL BIOL, V8, P1053, DOI 10.1038/ncb1471; di Fagagna FD, 2003, NATURE, V426, P194, DOI 10.1038/nature02118; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Eder AM, 2005, P NATL ACAD SCI USA, V102, P12519, DOI 10.1073/pnas.0505641102; Fields AP, 2007, PHARMACOL RES, V55, P487, DOI 10.1016/j.phrs.2007.04.015; Freeley M, 2011, CELL SIGNAL, V23, P753, DOI 10.1016/j.cellsig.2010.10.013; Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008; Gewirtz DA, 2008, BIOCHEM PHARMACOL, V76, P947, DOI 10.1016/j.bcp.2008.06.024; Gorgun G, 2010, BLOOD, V115, P5202, DOI 10.1182/blood-2009-12-259523; Harrington EA, 2004, NAT MED, V10, P262, DOI 10.1038/nm1003; HERMAN JG, 1995, CANCER RES, V55, P4525; Huck JJ, 2010, MOL CANCER RES, V8, P373, DOI 10.1158/1541-7786.MCR-09-0300; Isakoff SJ, 2005, CANCER RES, V65, P10992, DOI 10.1158/0008-5472.CAN-05-2612; Ishii N, 1999, BRAIN PATHOL, V9, P469, DOI 10.1111/j.1750-3639.1999.tb00536.x; Kanzaki M, 2004, J CELL BIOL, V164, P279, DOI 10.1083/jcb.200306152; Karakas B, 2006, BRIT J CANCER, V94, P455, DOI 10.1038/sj.bjc.6602970; Kojima Y, 2008, HUM PATHOL, V39, P824, DOI 10.1016/j.humpath.2007.11.001; Lawless C, 2010, EXP GERONTOL, V45, P772, DOI 10.1016/j.exger.2010.01.018; Lin HK, 2010, NATURE, V464, P374, DOI 10.1038/nature08815; Lorimer IAJ, 2000, J IMMUNOL METHODS, V237, P147, DOI 10.1016/S0022-1759(99)00219-7; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Nolan ME, 2008, CANCER RES, V68, P8201, DOI 10.1158/0008-5472.CAN-07-6567; OConnor PM, 1997, CANCER RES, V57, P4285; Passos JF, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.5; Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822; Peifer C, 2008, CHEMMEDCHEM, V3, P1810, DOI 10.1002/cmdc.200800195; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Regala RP, 2005, CANCER RES, V65, P8905, DOI 10.1158/0008-5472.CAN-05-2372; Schmitt CA, 2007, BBA-REV CANCER, V1775, P5, DOI 10.1016/j.bbcan.2006.08.005; Scott MT, 2002, EMBO J, V21, P6771, DOI 10.1093/emboj/cdf684; Scotti ML, 2010, CANCER RES, V70, P2064, DOI 10.1158/0008-5472.CAN-09-2684; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Vasudevan KM, 2009, CANCER CELL, V16, P21, DOI 10.1016/j.ccr.2009.04.012; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Wu CH, 2007, P NATL ACAD SCI USA, V104, P13028, DOI 10.1073/pnas.0701953104; Xu LJ, 2006, J BIOL CHEM, V281, P4457, DOI 10.1074/jbc.M510721200; Yuan TL, 2011, CURR BIOL, V21, P173, DOI 10.1016/j.cub.2010.12.047; Zhang L, 2006, CANCER RES, V66, P4627, DOI 10.1158/0008-5472.CAN-05-4527	51	25	26	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2012	31	31					3584	3596		10.1038/onc.2011.524	http://dx.doi.org/10.1038/onc.2011.524			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985EG	22120720				2022-12-17	WOS:000307245600002
J	Lindzen, M; Carvalho, S; Starr, A; Ben-Chetrit, N; Pradeep, CR; Koestler, WJ; Rabinkov, A; Lavi, S; Bacus, SS; Yarden, Y				Lindzen, M.; Carvalho, S.; Starr, A.; Ben-Chetrit, N.; Pradeep, C-R; Koestler, W. J.; Rabinkov, A.; Lavi, S.; Bacus, S. S.; Yarden, Y.			A recombinant decoy comprising EGFR and ErbB-4 inhibits tumor growth and metastasis	ONCOGENE			English	Article						cancer therapy; EGF; growth factor; tyrosine kinase; signal transduction	CORRESPONDING PRIMARY TUMORS; FACTOR RECEPTOR; IN-VIVO; BREAST-CANCER; LUNG-CANCER; SIGNALING NETWORK; FAMILY-MEMBERS; FACTOR-ALPHA; CELL-LINES; CARCINOMA	Epidermal growth factor (EGF)-like growth factors control tumor progression as well as evasion from the toxic effects of chemotherapy. Accordingly, antibodies targeting the cognate receptors, such as EGFR/ErbB-1 and the co-receptor HER2/ErbB-2, are widely used to treat cancer patients, but agents that target the EGF-like growth factors are not available. To circumvent the existence of 11 distinct ErbB ligands, we constructed a soluble fusion protein (hereinafter: TRAP-Fc) comprising truncated extracellular domains of EGFR/ErbB-1 and ErbB-4. The recombinant TRAP-Fc retained high-affinity ligand binding to EGF-like growth factors and partially inhibited growth of a variety of cultured tumor cells. Consistently, TRAP-Fc displayed an inhibitory effect in xenograft models of human cancer, as well as synergy with chemotherapy. Additionally, TRAP-Fc inhibited invasive growth of mammary tumor cells and reduced their metastatic seeding in the lungs of animals. Taken together, the activities displayed by TRAP-Fc reinforce critical roles of EGF-like growth factors in tumor progression, and they warrant further tests of TRAP-Fc in preclinical models. Oncogene (2012) 31, 3505-3515; doi:10.1038/onc.2011.518; published online 21 November 2011	[Lindzen, M.; Carvalho, S.; Ben-Chetrit, N.; Pradeep, C-R; Koestler, W. J.; Lavi, S.; Yarden, Y.] Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; [Starr, A.] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Dept Pulm Dis, IL-69978 Tel Aviv, Israel; [Rabinkov, A.] Weizmann Inst Sci, Dept Biol Serv, IL-76100 Rehovot, Israel; [Bacus, S. S.] Quintiles, Westmont, IL USA	Weizmann Institute of Science; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Weizmann Institute of Science; IQVIA	Yarden, Y (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.	yosef.yarden@weizmann.ac.il	YARDEN, YOSEF/K-1467-2012	Starr, Alexander/0000-0002-9329-3740	National Cancer Institute [CA072981]; Israel Cancer Research Fund; Dr Miriam and Sheldon G Adelson Medical Research Foundation; Linda and Michael Jacobs Charitable Trust; NATIONAL CANCER INSTITUTE [R01CA072981, R37CA072981] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Israel Cancer Research Fund; Dr Miriam and Sheldon G Adelson Medical Research Foundation; Linda and Michael Jacobs Charitable Trust; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge the help of the Israel Structural Proteomics Center. Our lab is supported by the National Cancer Institute (CA072981), the Israel Cancer Research Fund and Dr Miriam and Sheldon G Adelson Medical Research Foundation. WJK received a fellowship for PhD track for specialist medical doctors from the Linda and Michael Jacobs Charitable Trust. YY is the incumbent of the Harold and Zelda Goldenberg Professorial Chair.	ABOUDPIRAK E, 1988, J NATL CANCER I, V80, P1605, DOI 10.1093/jnci/80.20.1605; Adams TE, 2009, GROWTH FACTORS, V27, P141, DOI 10.1080/08977190902843565; Atlas E, 2003, MOL CANCER RES, V1, P165; Barozzi C, 2002, CANCER-AM CANCER SOC, V94, P647, DOI 10.1002/cncr.10278; Baselga J, 2006, SCIENCE, V312, P1175, DOI 10.1126/science.1125951; Bianchi S, 2006, J CELL PHYSIOL, V206, P702, DOI 10.1002/jcp.20535; Bijman MNA, 2009, ANTI-CANCER DRUG, V20, P450, DOI 10.1097/CAD.0b013e32832afc24; Britten CD, 2004, MOL CANCER THER, V3, P1335; Chen XM, 1996, J BIOL CHEM, V271, P7620, DOI 10.1074/jbc.271.13.7620; De Jong KP, 1998, HEPATOLOGY, V28, P971, DOI 10.1002/hep.510280411; De Luca A, 2008, J CELL PHYSIOL, V214, P559, DOI 10.1002/jcp.21260; Domagala T, 2000, GROWTH FACTORS, V18, P11, DOI 10.3109/08977190009003231; Elleman TC, 2001, BIOCHEMISTRY-US, V40, P8930, DOI 10.1021/bi010037b; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Fitzpatrick VD, 1998, FEBS LETT, V431, P102, DOI 10.1016/S0014-5793(98)00737-6; Freeman DJ, 2009, MOL CANCER THER, V8, P1536, DOI 10.1158/1535-7163.MCT-08-0978; Grandis JR, 1998, J CELL BIOCHEM, V69, P55, DOI 10.1002/(SICI)1097-4644(19980401)69:1<55::AID-JCB6>3.0.CO;2-U; Hsieh SY, 2011, HEPATOLOGY, V53, P504, DOI 10.1002/hep.24083; Ishikawa N, 2005, CANCER RES, V65, P9176, DOI 10.1158/0008-5472.CAN-05-1556; Jones JT, 1999, FEBS LETT, V447, P227, DOI 10.1016/S0014-5793(99)00283-5; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Karamouzis MV, 2007, INT J BIOCHEM CELL B, V39, P851, DOI 10.1016/j.biocel.2006.11.017; Krane IM, 1996, ONCOGENE, V12, P1781; Lindzen M, 2010, P NATL ACAD SCI USA, V107, P12559, DOI 10.1073/pnas.1006218107; Mackenzie RP, 2009, EXPERT REV ANTICANC, V9, P1473, DOI [10.1586/era.09.109, 10.1586/ERA.09.109]; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Ritter CA, 2007, CLIN CANCER RES, V13, P4909, DOI 10.1158/1078-0432.CCR-07-0701; Sanui A, 2010, ANTICANCER RES, V30, P3143; Sarup J, 2008, MOL CANCER THER, V7, P3223, DOI 10.1158/1535-7163.MCT-07-2151; Sheng Q, 2010, CANCER CELL, V17, P298, DOI 10.1016/j.ccr.2009.12.047; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; Sun MH, 2009, CLIN CANCER RES, V15, P4829, DOI 10.1158/1078-0432.CCR-08-2921; Thogersen VB, 2001, CANCER RES, V61, P6227; Tsujioka H, 2011, CURR OPIN OBSTET GYN, V23, P24, DOI 10.1097/GCO.0b013e3283409c91; Valabrega G, 2005, ONCOGENE, V24, P3002, DOI 10.1038/sj.onc.1208478; Weiner Louis M., 2006, Human Antibodies, V15, P103; Wheeler DL, 2008, ONCOGENE, V27, P3944, DOI 10.1038/onc.2008.19; Witsch E, 2010, PHYSIOLOGY, V25, P85, DOI 10.1152/physiol.00045.2009; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhou BBS, 2006, CANCER CELL, V10, P39, DOI 10.1016/j.ccr.2006.05.024	40	25	27	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2012	31	30					3505	3515		10.1038/onc.2011.518	http://dx.doi.org/10.1038/onc.2011.518			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	979UA	22105361	Green Accepted			2022-12-17	WOS:000306844100003
J	Heinke, J; Kerber, M; Rahner, S; Mnich, L; Lassmann, S; Helbing, T; Werner, M; Patterson, C; Bode, C; Moser, M				Heinke, J.; Kerber, M.; Rahner, S.; Mnich, L.; Lassmann, S.; Helbing, T.; Werner, M.; Patterson, C.; Bode, C.; Moser, M.			Bone morphogenetic protein modulator BMPER is highly expressed in malignant tumors and controls invasive cell behavior	ONCOGENE			English	Article						BMPER; BMPs; MMPs; tumor progression; tumor angiogenesis	BREAST-CANCER CELLS; MATRIX METALLOPROTEINASES; EXTRACELLULAR REGULATION; ID1 EXPRESSION; DIRECT BINDING; METASTASIS; GROWTH; ANGIOGENESIS; ANTAGONIST; PROSTATE	Bone morphogenetic proteins (BMPs) are growth factors that exert important functions in cell proliferation, migration and differentiation. Till date, multiple human tumors have been reported to display a dysregulation of several members of the BMP pathway that is associated with enhanced malignant tumor growth and metastasis. BMPER (BMP endothelial cell precursor-derived regulator) is a direct BMP modulator that is necessary for BMPs to exert their full-range signaling activity. Moreover, BMPER is expressed by endothelial cells and their progenitors, and has pro-angiogenic features in these cells. Here, we describe the expression of BMPER in human specimens of lung, colon and cervix carcinomas and cell lines derived from such carcinomas. In contrast to healthy tissues, BMPER is highly expressed upon malignant deterioration. Functionally, loss of BMPER in the lung tumor cell line A549 impairs proliferation, migration, invasion as well as tumor cell-induced endothelial cell sprout formation. In contrast, stimulation of A549 cells with exogenous BMPER had no further effect. We found that the BMPER effect may be transduced by regulation of the BMP target transcription factor inhibitor of DNA binding 1 (Id1) and matrix metalloproteinases (MMPs) 9 and 2. These facilitators of cell migration are down-regulated when BMPER is absent. To prove the relevance of our in vitro results in vivo, we generated Lewis lung carcinoma cells with impaired BMPER expression and implanted them into the lungs of C57BL/6 mice. In this model, the absence of BMPER resulted in severely reduced tumor growth and tumor angiogenesis. Taken together, these data unequivocally demonstrate that the BMP modulator BMPER is highly expressed in malignant tumors and tumor growth is dependent on the presence of BMPER.	[Heinke, J.; Kerber, M.; Rahner, S.; Mnich, L.; Helbing, T.; Bode, C.; Moser, M.] Univ Freiburg, Dept Med 3, D-79106 Freiburg, Germany; [Lassmann, S.; Werner, M.] Univ Freiburg, Univ Med Ctr, Inst Pathol, D-79106 Freiburg, Germany; [Patterson, C.] Univ N Carolina, Carolina Cardiovasc Biol Ctr, Chapel Hill, NC USA	University of Freiburg; University of Freiburg; University of North Carolina; University of North Carolina Chapel Hill	Moser, M (corresponding author), Univ Freiburg, Dept Med 3, Hugstetter Str 55, D-79106 Freiburg, Germany.	Martin.Moser@uniklinik-freiburg.de		Esser, Jennifer/0000-0002-8494-2016	German Research Foundation (DFG) [SFB-TR23 (A1), Mo973/5-1, Mo973/6-1, SFB850, SFB850 TP C5, TP Z1]; LandesStiftung Baden-Wurttemberg; Mushett Family Foundation (Chester, NJ, USA); Robert-Bosch-Stiftung; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061656] Funding Source: NIH RePORTER	German Research Foundation (DFG)(German Research Foundation (DFG)); LandesStiftung Baden-Wurttemberg; Mushett Family Foundation (Chester, NJ, USA); Robert-Bosch-Stiftung; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Bianca Engert, Anja Schopflin and Ute Wering for excellent technical assistance. Work in MM's laboratory is supported by German Research Foundation (DFG) SFB-TR23 (A1), DFG Mo973/5-1 and DFG Mo973/6-1. Work in the laboratory of SL and MW is supported by the German Research Foundation/DFG (SFB850 TP C5, TP Z1), the LandesStiftung Baden-Wurttemberg and the Mushett Family Foundation (Chester, NJ, USA) and the Robert-Bosch-Stiftung.	Alarmo EL, 2010, ENDOCR-RELAT CANCER, V17, pR123, DOI 10.1677/ERC-09-0273; Arihiro K, 2001, PATHOL INT, V51, P100, DOI 10.1046/j.1440-1827.2001.01164.x; Bailey JM, 2007, J CELL BIOCHEM, V102, P829, DOI 10.1002/jcb.21509; Balemans W, 2002, DEV BIOL, V250, P231, DOI 10.1006/dbio.2002.0779; Balmanno K, 2009, CELL DEATH DIFFER, V16, P368, DOI 10.1038/cdd.2008.148; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Blish KR, 2008, MOL BIOL CELL, V19, P457, DOI 10.1091/mbc.E07-05-0433; Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811; Buijs JT, 2007, CANCER RES, V67, P8742, DOI 10.1158/0008-5472.CAN-06-2490; Buijs JT, 2007, AM J PATHOL, V171, P1047, DOI 10.2353/ajpath.2007.070168; Conley CA, 2000, DEVELOPMENT, V127, P3947; Deckers MML, 2002, ENDOCRINOLOGY, V143, P1545, DOI 10.1210/en.143.4.1545; Deng HY, 2007, EXP CELL RES, V313, P1033, DOI 10.1016/j.yexcr.2006.12.020; Doki Y, 1999, BRIT J CANCER, V79, P1121, DOI 10.1038/sj.bjc.6690178; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Feeley BT, 2005, J BONE MINER RES, V20, P2189, DOI 10.1359/JBMR.050802; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Gautschi O, 2008, CANCER RES, V68, P2250, DOI 10.1158/0008-5472.CAN-07-6403; Gordon KJ, 2009, CARCINOGENESIS, V30, P238, DOI 10.1093/carcin/bgn274; Goumans MJ, 2009, CELL RES, V19, P116, DOI 10.1038/cr.2008.326; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heinke J, 2008, CIRC RES, V103, P804, DOI 10.1161/CIRCRESAHA.108.178434; Heinke J, 2007, CARDIOVASC RES, V76, P390, DOI 10.1016/j.cardiores.2007.08.003; Iemura S, 1998, P NATL ACAD SCI USA, V95, P9337, DOI 10.1073/pnas.95.16.9337; Ikeya M, 2006, DEVELOPMENT, V133, P4463, DOI 10.1242/dev.02647; Katsuno Y, 2008, ONCOGENE, V27, P6322, DOI 10.1038/onc.2008.232; Kelley R, 2009, J CELL BIOL, V184, P597, DOI 10.1083/jcb.200808064; Klose A, 2011, NEOPLASIA, V13, P276, DOI 10.1593/neo.101540; Krause C, 2010, J BIOL CHEM, V285, P41614, DOI 10.1074/jbc.M110.153890; Langenfeld EM, 2006, ONCOGENE, V25, P685, DOI 10.1038/sj.onc.1209110; Langenfeld EM, 2004, MOL CANCER RES, V2, P141; Langenfeld EM, 2003, CARCINOGENESIS, V24, P1445, DOI 10.1093/carcin/bgg100; Laurikkala J, 2003, DEV BIOL, V264, P91, DOI 10.1016/j.ydbio.2003.08.011; Lin KY, 2007, CANCER RES, V67, P1832, DOI 10.1158/0008-5472.CAN-06-3014; Ling MT, 2005, CARCINOGENESIS, V26, P1668, DOI 10.1093/carcin/bgi128; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Maegdefrau U, 2009, J PATHOL, V218, P520, DOI 10.1002/path.2563; Miyazono Kohei, 2002, Sci STKE, V2002, ppe40, DOI 10.1126/stke.2002.151.pe40; Moll F, 2006, FASEB J, V20, P240, DOI 10.1096/fj.05-4126com; Moser M, 2005, THROMB HAEMOSTASIS, V94, P713, DOI 10.1160/TH05-05-0312; Moser M, 2003, MOL CELL BIOL, V23, P5664, DOI 10.1128/MCB.23.16.5664-5679.2003; Oelgeschlager M, 2000, NATURE, V405, P757, DOI 10.1038/35015500; Orlichenko LS, 2008, CLIN EXP METASTAS, V25, P593, DOI 10.1007/s10585-008-9143-9; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; Piccolo S, 1999, NATURE, V397, P707, DOI 10.1038/17820; Pouliot F, 2002, J ENDOCRINOL, V172, P187, DOI 10.1677/joe.0.1720187; Raida M, 2005, INT J ONCOL, V26, P1465; Rentzsch F, 2006, DEVELOPMENT, V133, P801, DOI 10.1242/dev.02250; Rothhammer T, 2007, ONCOGENE, V26, P4158, DOI 10.1038/sj.onc.1210182; Rothhammer T, 2005, CANCER RES, V65, P448; Rothhammer T, 2008, EUR J CANCER, V44, P2526, DOI 10.1016/j.ejca.2008.07.029; Schmierer B, 2007, NAT REV MOL CELL BIO, V8, P970, DOI 10.1038/nrm2297; Serpe M, 2008, DEV CELL, V14, P940, DOI 10.1016/j.devcel.2008.03.023; Sheu BC, 2009, FRONT BIOSCI-LANDMRK, V14, P1571, DOI 10.2741/3325; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; Soda H, 1998, ANTI-CANCER DRUG, V9, P327, DOI 10.1097/00001813-199804000-00006; Stabile H, 2007, BLOOD, V109, P1834, DOI 10.1182/blood-2006-06-032276; ten Dijke P, 2003, MOL CELL ENDOCRINOL, V211, P105, DOI 10.1016/j.mce.2003.09.016; Thawani JP, 2010, NEUROSURGERY, V66, P233, DOI 10.1227/01.NEU.0000363722.42097.C2; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Umulis D, 2009, DEVELOPMENT, V136, P3715, DOI 10.1242/dev.031534; Valdimarsdottir G, 2002, CIRCULATION, V106, P2263, DOI 10.1161/01.CIR.0000033830.36431.46; Weiss KR, 2006, CLIN ORTHOP RELAT R, P111, DOI 10.1097/01.blo.0000229333.98781.56; Wong ML, 2005, BIOTECHNIQUES, V39, P75, DOI 10.2144/05391RV01; Wu JB, 2011, CANCER GENE THER, V18, P20, DOI 10.1038/cgt.2010.55; YAMASHITA H, 1995, J CELL BIOL, V130, P217, DOI 10.1083/jcb.130.1.217; Yanagita M, 2004, BIOCHEM BIOPH RES CO, V316, P490, DOI 10.1016/j.bbrc.2004.02.075; Yang SX, 2005, CANCER RES, V65, P5769, DOI 10.1158/0008-5472.CAN-05-0289; Yu XY, 2008, DEV DYNAM, V237, P3613, DOI 10.1002/dvdy.21769; Zhao H, 2008, GENE DEV, V22, P722, DOI 10.1101/gad.1636408	70	25	25	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2012	31	24					2919	2930		10.1038/onc.2011.473	http://dx.doi.org/10.1038/onc.2011.473			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960LD	22020334	Green Published, Green Accepted			2022-12-17	WOS:000305388400002
J	Spivey, KA; Chung, I; Banyard, J; Adini, I; Feldman, HA; Zetter, BR				Spivey, K. A.; Chung, I.; Banyard, J.; Adini, I.; Feldman, H. A.; Zetter, B. R.			A role for collagen XXIII in cancer cell adhesion, anchorage-independence and metastasis	ONCOGENE			English	Article						collagen; metastasis; adhesion; anchorage-independence	XIII COLLAGEN; TRANSMEMBRANE PROTEINS; CLAC BINDS; EXPRESSION; CADHERIN; ASSOCIATION; PROMOTES; GROWTH; ATTACHMENT; XVII/BP180	Collagen XXIII is a transmembrane collagen previously shown to be upregulated in metastatic prostate cancer that has been used as a tissue and fluid biomarker for non-small cell lung cancer and prostate cancer. To determine whether collagen XXIII facilitates cancer cell metastasis in vivo and to establish a function for collagen XXIII in cancer progression, collagen XXIII knockdown cells were examined for alterations in in vivo metastasis as well as in vitro cell adhesion. In experimental and spontaneous xenograft models of metastasis, H460 cells expressing collagen XXIII shRNA formed fewer lung metastases than control cells. Loss of collagen XXIII in H460 cells also impaired cell adhesion, anchorage-independent growth and cell seeding to the lung, but did not affect cell proliferation. Corroborating a role for collagen XXIII in cell adhesion, overexpression of collagen XXIII in H1299 cells, which do not express endogenous collagen XXIII, enhanced cell adhesion. Consequent reduction in OB-cadherin, alpha-catenin, gamma-catenin, beta-catenin, vimentin and galectin-3 protein expression was also observed in response to loss of collagen XXIII. This study suggests a potential role for collagen XXIII in mediating metastasis by facilitating cell-cell and cell-matrix adhesion as well as anchorage-independent cell growth. Oncogene (2012) 31, 2362-2372; doi:10.1038/onc.2011.406; published online 3 October 2011	[Spivey, K. A.; Chung, I.; Banyard, J.; Adini, I.; Zetter, B. R.] Childrens Hosp, Karp Family Res Labs, Dept Surg, Vasc Biol Program, Boston, MA 02115 USA; [Feldman, H. A.] Childrens Hosp, Clin Res Program, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital	Zetter, BR (corresponding author), Childrens Hosp, Karp Family Res Labs, Dept Surg, Vasc Biol Program, Room 11-125,1 Blackfan Circle, Boston, MA 02115 USA.	Bruce.Zetter@childrens.harvard.edu	Chung, Ivy/C-3804-2012; Feldman, Henry/M-2302-2013		NCI NIH HHS [R01 CA037393, R37 CA037393] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037393, R37CA037393] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Banyard J, 2003, J BIOL CHEM, V278, P20989, DOI 10.1074/jbc.M210616200; Banyard J, 2007, CLIN CANCER RES, V13, P2634, DOI 10.1158/1078-0432.CCR-06-2163; Barczyk M, 2010, CELL TISSUE RES, V339, P269, DOI 10.1007/s00441-009-0834-6; Bussemakers MJG, 2000, INT J CANCER, V85, P446, DOI 10.1002/(SICI)1097-0215(20000201)85:3<446::AID-IJC23>3.3.CO;2-2; Chu K, 2008, MOL CANCER RES, V6, P1259, DOI 10.1158/1541-7786.MCR-08-0077; CIFONE MA, 1980, P NATL ACAD SCI-BIOL, V77, P1039, DOI 10.1073/pnas.77.2.1039; Di Benedetto A, 2010, J CELL SCI, V123, P2640, DOI 10.1242/jcs.067777; DIAZ LA, 1990, J CLIN INVEST, V86, P1088, DOI 10.1172/JCI114812; Forsell C, 2010, NEUROBIOL AGING, V31, P409, DOI 10.1016/j.neurobiolaging.2008.04.009; Franzke CW, 2009, J BIOL CHEM, V284, P23386, DOI 10.1074/jbc.M109.034090; Franzke CW, 2002, EMBO J, V21, P5026, DOI 10.1093/emboj/cdf532; Franzke CW, 2004, J BIOL CHEM, V279, P24521, DOI 10.1074/jbc.M308835200; Franzke CW, 2003, MATRIX BIOL, V22, P299, DOI 10.1016/S0945-053X(03)00051-9; Franzke CW, 2005, J BIOL CHEM, V280, P4005, DOI 10.1074/jbc.R400034200; Gilles C, 1996, J PATHOL, V180, P175, DOI 10.1002/(SICI)1096-9896(199610)180:2<175::AID-PATH630>3.0.CO;2-G; Glinsky VV, 2003, CANCER RES, V63, P3805; Gordon MK, 2005, INVEST OPHTH VIS SCI, V46; Hagg P, 2001, MATRIX BIOL, V19, P727, DOI 10.1016/S0945-053X(00)00119-0; Hashimoto T, 2002, EMBO J, V21, P1524, DOI 10.1093/emboj/21.7.1524; Hu L, 2004, ONCOGENE, V23, P298, DOI 10.1038/sj.onc.1206483; ISAACS JT, 1986, PROSTATE, V9, P261, DOI 10.1002/pros.2990090306; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kakuyama H, 2005, BIOCHEMISTRY-US, V44, P15602, DOI 10.1021/bi051263e; Khaldoyanidi SK, 2003, J BIOL CHEM, V278, P4127, DOI 10.1074/jbc.M209590200; Kvist AP, 2001, AM J PATHOL, V159, P1581, DOI 10.1016/S0002-9440(10)62542-4; Miles FL, 2008, CLIN EXP METASTAS, V25, P305, DOI 10.1007/s10585-007-9098-2; Mukhopadhyay R, 1999, CLIN EXP METASTAS, V17, P325; NOMURA Y, 1989, CANCER RES, V49, P5288; OKAZAKI M, 1994, J BIOL CHEM, V269, P12092; Orr F W, 2001, Surg Oncol Clin N Am, V10, P357; Osada Y, 2005, J BIOL CHEM, V280, P8596, DOI 10.1074/jbc.M413340200; PIHLAJANIEMI T, 1990, J BIOL CHEM, V265, P16922; Pishvaian MJ, 1999, CANCER RES, V59, P947; Roman J, 2010, AM J RESP CELL MOL, V43, P684, DOI 10.1165/rcmb.2009-0375OC; Schmidmaier R, 2008, CURR MED CHEM, V15, P978, DOI 10.2174/092986708784049667; SIMONNEAU L, 1995, CELL ADHES COMMUN, V3, P115, DOI 10.3109/15419069509081281; Soderberg L, 2005, FEBS J, V272, P2231, DOI 10.1111/j.1742-4658.2005.04647.x; Spivey KA, 2010, CANCER EPIDEM BIOMAR, V19, P1362, DOI 10.1158/1055-9965.EPI-09-1095; Takenaka K, 2000, INT J ONCOL, V17, P1187; Tomita K, 2000, CANCER RES, V60, P3650; Tong Y, 2010, NEUROGENETICS, V11, P41, DOI 10.1007/s10048-009-0201-5; Torimura T, 1999, J HEPATOL, V31, P734, DOI 10.1016/S0168-8278(99)80355-9; Tu HM, 2002, J BIOL CHEM, V277, P23092, DOI 10.1074/jbc.M107583200; Vaisanen MR, 2004, BIOCHEM J, V380, P685, DOI 10.1042/BJ20031974; Vaisanen T, 2005, J PATHOL, V207, P324, DOI 10.1002/path.1836; Veit G, 2007, J BIOL CHEM, V282, P27424, DOI 10.1074/jbc.M703425200; Veit G, 2011, J BIOL CHEM, V286, P27804, DOI 10.1074/jbc.M111.220046; Wewer UM, 1997, AM J PATHOL, V151, P1191; Whiteside TL, 2008, ONCOGENE, V27, P5904, DOI 10.1038/onc.2008.271; WS Rasband, 2010, IMAGEJ, P1997	50	25	27	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	18					2362	2372		10.1038/onc.2011.406	http://dx.doi.org/10.1038/onc.2011.406			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	936SR	21963851	Green Accepted			2022-12-17	WOS:000303610800010
J	Paranjape, AN; Mandal, T; Mukherjee, G; Kumar, MV; Sengupta, K; Rangarajan, A				Paranjape, A. N.; Mandal, T.; Mukherjee, G.; Kumar, M. V.; Sengupta, K.; Rangarajan, A.			Introduction of SV40ER and hTERT into mammospheres generates breast cancer cells with stem cell properties	ONCOGENE			English	Article						adenocarcinoma; breast cancer stem cells; EMT; mammospheres; SV40ER; telomerase	MAMMARY STEM/PROGENITOR CELLS; LARGE T-ANTIGEN; EPITHELIAL-CELLS; SELF-RENEWAL; TRANSFORMATION; EXPRESSION; CULTURE; NOTCH; P53; IMMORTALIZATION	Emerging evidence suggests that cancers arise in stem/progenitor cells. Yet, the requirements for transformation of these primitive cells remains poorly understood. In this study, we have exploited the 'mammosphere' system that selects for primitive mammary stem/progenitor cells to explore their potential and requirements for transformation. Introduction of Simian Virus 40 Early Region and hTERT into mammosphere-derived cells led to the generation of NBLE, an immortalized mammary epithelial cell line. The NBLEs largely comprised of bi-potent progenitors with long-term self-renewal and multi-lineage differentiation potential. Clonal and karyotype analyses revealed the existence of heterogeneous population within NBLEs with varied proliferation, differentiation and sphere-forming potential. Significantly, injection of NBLEs into immunocompromised mice resulted in the generation of invasive ductal adenocarcinomas. Further, these cells harbored a sub-population of CD44(+)/CD24(-) fraction that alone had sphere- and tumor-initiating potential and resembled the breast cancer stem cell gene signature. Interestingly, prolonged in vitro culturing led to their further enrichment. The NBLE cells also showed increased expression of stemness and epithelial to mesenchymal transition markers, deregulated self-renewal pathways, activated DNA-damage response and cancer-associated chromosomal aberrations-all of which are likely to have contributed to their tumorigenic transformation. Thus, unlike previous in vitro transformation studies that used adherent, more differentiated human mammary epithelial cells our study demonstrates that the mammosphere-derived, less-differentiated cells undergo tumorigenic conversion with only two genetic elements, without requiring oncogenic Ras. Moreover, the striking phenotypic and molecular resemblance of the NBLE-generated tumors with naturally arising breast adenocarcinomas supports the notion of a primitive breast cell as the origin for this subtype of breast cancer. Finally, the NBLEs represent a heterogeneous population of cells with striking plasticity, capable of differentiation, self-renewal and tumorigenicity, thus offering a unique model system to study the molecular mechanisms involved with these processes. Oncogene (2012) 31, 1896-1909; doi:10.1038/onc.2011.378; published online 29 August 2011	[Paranjape, A. N.; Mandal, T.; Rangarajan, A.] Indian Inst Sci, Dept Mol Reprod Dev & Genet, Bangalore 560012, Karnataka, India; [Paranjape, A. N.; Mukherjee, G.; Kumar, M. V.] Kidwai Mem Inst Oncol, Dept Pathol, Bangalore, Karnataka, India; [Sengupta, K.] Indian Inst Sci Educ & Res, Dept Biol, Pune, Maharashtra, India	Indian Institute of Science (IISC) - Bangalore; Kidwai Memorial Institute of Oncology; Indian Institute of Science Education & Research (IISER) Pune	Rangarajan, A (corresponding author), Indian Inst Sci, Dept Mol Reprod Dev & Genet, CV Raman Ave, Bangalore 560012, Karnataka, India.	anu@mrdg.iisc.ernet.in	Mandal, Tamoghna/AAX-3710-2021; Paranjape, Anurag N./P-1255-2018	Mandal, Tamoghna/0000-0003-4372-6760; Paranjape, Anurag N./0000-0001-6119-0766; Mukherjee, Geetashree/0000-0003-4954-0035; M, Vijayakumar/0000-0002-0711-1737	DBT; UGC	DBT(Department of Biotechnology (DBT) India); UGC(University Grants Commission, India)	We thank Dr Robert A Weinberg (Whitehead Institute) for hTERT cDNA, HMLE and HMLER cells and Dr Inder M Verma (Salk Institute) for pCSCG lentiviral vector. We acknowledge Swati Maiti for insightful discussions, and thank D Alaguraj, Drs Omana Joy, William Surin (IISc) and H Krishnamurthy (NCBS) for help with flow cytometry. We also thank Dr Paturu Kondaiah and Imran Khan (IISc), and Mohammed Aiyaz (Genotypic India Pvt. Ltd) for help with microarray experiments and data analysis. This work was largely supported by research grants from DBT to AR for equipment and consumables. We acknowledge the confocal, IRIS, FACS and animal facilities at IISc, and grants from UGC to the Department of MRDG, IISc.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; Ali-Seyed M, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-54; Ayyanan A, 2006, P NATL ACAD SCI USA, V103, P3799, DOI 10.1073/pnas.0600065103; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bhat-Nakshatri P, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-411; Bissell MJ, 1999, CANCER RES, V59, p1757S; Charafe-Jauffret E, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-202; Chu PG, 2002, HISTOPATHOLOGY, V40, P403, DOI 10.1046/j.1365-2559.2002.01387.x; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Dey D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005329; Dimri G, 2005, BREAST CANCER RES, V7, P171, DOI 10.1186/bcr1275; Dontu G, 2005, J MAMMARY GLAND BIOL, V10, P75, DOI 10.1007/s10911-005-2542-5; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Gudjonsson T, 2002, GENE DEV, V16, P693, DOI 10.1101/gad.952602; Gutierrez GM, 2008, P NATL ACAD SCI USA, V105, P18402, DOI 10.1073/pnas.0805925105; Ince TA, 2007, CANCER CELL, V12, P160, DOI 10.1016/j.ccr.2007.06.013; Jerry DJ, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2133; Liao MJ, 2007, CANCER RES, V67, P8131, DOI 10.1158/0008-5472.CAN-06-4493; Liu SL, 2005, BREAST CANCER RES, V7, P86, DOI 10.1186/bcr1021; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Muschler J, 1999, MOL BIOL CELL, V10, P2817, DOI 10.1091/mbc.10.9.2817; O'Brien CA, 2010, CLIN CANCER RES, V16, P3113, DOI 10.1158/1078-0432.CCR-09-2824; Pardal R, 2005, COLD SH Q B, V70, P177, DOI 10.1101/sqb.2005.70.057; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; Phesse TJ, 2009, BRIT J CANCER, V100, P221, DOI 10.1038/sj.bjc.6604850; Ponti D, 2006, EUR J CANCER, V42, P1219, DOI 10.1016/j.ejca.2006.01.031; ROCHLITZ CF, 1989, CANCER RES, V49, P357; Salas NR, 2010, CLIN TRANSL ONCOL, V12, P395, DOI 10.1007/s12094-010-0526-4; Sarin KY, 2005, NATURE, V436, P1048, DOI 10.1038/nature03836; Shackleton M, 2010, SEMIN CANCER BIOL, V20, P85, DOI 10.1016/j.semcancer.2010.04.002; Tan BT, 2006, LAB INVEST, V86, P1203, DOI 10.1038/labinvest.3700488; Tao LW, 2011, STEM CELLS, V29, P119, DOI 10.1002/stem.552; Uchino M, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-414; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687; WOODS C, 1994, ONCOGENE, V9, P2943; Woodward WA, 2005, J CELL SCI, V118, P3585, DOI 10.1242/jcs.02532; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988; Zhao XS, 2010, P NATL ACAD SCI USA, V107, P14146, DOI 10.1073/pnas.1009030107	41	25	25	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	15					1896	1909		10.1038/onc.2011.378	http://dx.doi.org/10.1038/onc.2011.378			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	926CW	21874052				2022-12-17	WOS:000302809900003
J	Benes, CH; Poulogiannis, G; Cantley, LC; Soltoff, SP				Benes, C. H.; Poulogiannis, G.; Cantley, L. C.; Soltoff, S. P.			The SRC-associated protein CUB Domain-Containing Protein-1 regulates adhesion and motility	ONCOGENE			English	Article						signaling; mass spectrometry; SRC; adhesion; motility; metastasis	TYROSINE-PHOSPHATASE SHP-2; HUMAN COLORECTAL-CANCER; HUMAN-COLON CARCINOMA; FOCAL-ADHESION; KINASE-ACTIVITY; CELL-MIGRATION; SIGNAL-TRANSDUCTION; FAMILY KINASES; GROWTH-FACTOR; TUMOR-CELLS	Multiple SRC-family kinases (SFKs) are commonly activated in carcinoma and appear to have a role in metastasis through incompletely understood mechanisms. Recent studies have shown that CDCP1 (CUB (complement C1r/C1s, Uegf, Bmp1) Domain-Containing Protein-1) is a transmembrane protein and an SRC substrate potentially involved in metastasis. Here we show that increased SFK and CDCP1 tyrosine phosphorylation is, surprisingly, associated with a decrease in FAK phosphorylation. This appears to be true in human tumors as shown by our correlation analysis of a mass spectrometric data set of affinity-purified phosphotyrosine peptides obtained from normal and cancer lung tissue samples. Induction of tyrosine phosphorylation of CDCP1 in cell culture, including by a mAb that binds to its extracellular domain, promoted changes in SFK and FAK tyrosine phosphorylation, as well as in PKC (TM), a protein known to associate with CDCP1, and these changes are accompanied by increases in adhesion and motility. Thus, signaling events that accompany the CDCP1 tyrosine phosphorylation observed in cell lines and human lung tumors may explain how the CDCP1/SFK complex regulates motility and adhesion. Oncogene (2012) 31, 653-663; doi:10.1038/onc.2011.262; published online 4 July 2011	[Benes, C. H.; Poulogiannis, G.; Cantley, L. C.; Soltoff, S. P.] Beth Israel Deaconess Med Ctr, Div Signal Transduct, Dept Med, Boston, MA 02215 USA; [Poulogiannis, G.; Cantley, L. C.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Soltoff, SP (corresponding author), Beth Israel Deaconess Med Ctr, Div Signal Transduct, Dept Med, 330 Brookline Ave,CLS-406, Boston, MA 02215 USA.	ssoltoff@bidmc.harvard.edu	Poulogiannis, George/AAE-1966-2019; Cantley, Lewis C/D-1800-2014; Poulogiannis, George/AAY-2210-2021	Poulogiannis, George/0000-0002-0529-8614; Cantley, Lewis C/0000-0002-1298-7653; 	NIGMS NIH HHS [R01 GM056203] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056203] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allgayer H, 2002, CANCER, V94, P344, DOI 10.1002/cncr.10221; Alvares SM, 2008, BBA-GEN SUBJECTS, V1780, P486, DOI 10.1016/j.bbagen.2008.01.010; Awakura Y, 2008, J CANCER RES CLIN, V134, P1363, DOI 10.1007/s00432-008-0412-4; Benes CH, 2005, CELL, V121, P271, DOI 10.1016/j.cell.2005.02.019; Bhatt AS, 2005, ONCOGENE, V24, P5333, DOI 10.1038/sj.onc.1208582; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; Bromann PA, 2004, ONCOGENE, V23, P7957, DOI 10.1038/sj.onc.1208079; Brunton VG, 2008, CURR OPIN PHARMACOL, V8, P427, DOI 10.1016/j.coph.2008.06.012; Brunton VG, 2005, CANCER RES, V65, P1335, DOI 10.1158/0008-5472.CAN-04-1949; Buhring HJ, 2004, STEM CELLS, V22, P334, DOI 10.1634/stemcells.22-3-334; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; Chan KT, 2009, J CELL BIOL, V185, P357, DOI 10.1083/jcb.200809110; Cooper JA, 2008, BIOCHEMISTRY-US, V47, P5681, DOI 10.1021/bi8003044; Courtneidge SA, 2002, BIOCHEM SOC T, V30, P11, DOI 10.1042/bst0300011; Deryugina EI, 2009, MOL CANCER RES, V7, P1197, DOI 10.1158/1541-7786.MCR-09-0100; Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; He Y, 2010, J BIOL CHEM, V285, P26162, DOI 10.1074/jbc.M109.096453; Hooper JD, 2003, ONCOGENE, V22, P1783, DOI 10.1038/sj.onc.1206220; Huveneers S, 2009, J CELL SCI, V122, P1059, DOI 10.1242/jcs.039446; Ikeda JI, 2009, CANCER SCI, V100, P429, DOI 10.1111/j.1349-7006.2008.01066.x; ILLC D, 1995, NATURE, V377, P539; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Leroy C, 2009, CANCER RES, V69, P2279, DOI 10.1158/0008-5472.CAN-08-2354; Liu H, 2011, P NATL ACAD SCI USA, V108, P1379, DOI 10.1073/pnas.1017228108; Lu ZM, 2001, MOL CELL BIOL, V21, P4016, DOI 10.1128/MCB.21.12.4016-4031.2001; Manes S, 1999, MOL CELL BIOL, V19, P3125; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Miyazawa Y, 2010, CANCER RES, V70, P5136, DOI 10.1158/0008-5472.CAN-10-0220; Perry SE, 2007, FEBS LETT, V581, P1137, DOI 10.1016/j.febslet.2007.02.025; Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025; Scherl-Mostageer M, 2001, ONCOGENE, V20, P4402, DOI 10.1038/sj.onc.1204566; Serrels A, 2006, MOL CANCER THER, V5, P3014, DOI 10.1158/1535-7163.MCT-06-0382; Serrels B, 2007, NAT CELL BIOL, V9, P1046, DOI 10.1038/ncb1626; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; Spassov DS, 2011, MOL CELL BIOL, V31, P766, DOI 10.1128/MCB.00841-10; Spassov DS, 2009, AM J PATHOL, V174, P1756, DOI 10.2353/ajpath.2009.080890; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; Tilghman RW, 2005, J CELL SCI, V118, P2613, DOI 10.1242/jcs.02380; Uekita T, 2008, AM J PATHOL, V172, P1729, DOI 10.2353/ajpath.2008.070981; Uekita T, 2007, MOL CELL BIOL, V27, P7649, DOI 10.1128/MCB.01246-07; Vitale S, 2008, EUR J CELL BIOL, V87, P569, DOI 10.1016/j.ejcb.2008.04.002; Vultur A, 2008, MOL CANCER THER, V7, P1185, DOI 10.1158/1535-7163.MCT-08-0126; Wortmann A, 2009, IUBMB LIFE, V61, P723, DOI 10.1002/iub.198; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4; Zheng YH, 2009, MOL CELL, V35, P11, DOI 10.1016/j.molcel.2009.06.013	52	25	26	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	5					653	663		10.1038/onc.2011.262	http://dx.doi.org/10.1038/onc.2011.262			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891MS	21725358	Green Accepted			2022-12-17	WOS:000300221800011
J	Wang, D; Ning, W; Xie, D; Guo, L; DuBois, RN				Wang, D.; Ning, W.; Xie, D.; Guo, L.; DuBois, R. N.			Peroxisome proliferator-activated receptor delta confers resistance to peroxisome proliferator-activated receptor gamma-induced apoptosis in colorectal cancer cells	ONCOGENE			English	Article						peroxisome proliferator-activated receptors; colorectal cancer; survivin; apoptosis	INTESTINAL ADENOMA GROWTH; PPAR-GAMMA; COLON CARCINOGENESIS; SURVIVIN EXPRESSION; C57BL/6J-APC(MIN)/+ MICE; THERAPEUTIC TARGET; GENETIC DISRUPTION; PANCREATIC-CANCER; SIGNALING PATHWAY; PTEN EXPRESSION	Peroxisome proliferator-activated receptor gamma (PPAR gamma) may serve as a useful target for drug development in nondiabetic diseases. However, some colorectal cancer cells are resistant to PPAR gamma agonists by mechanisms that are poorly understood. Here, we provide the first evidence that elevated PPAR delta expression and/or activation of PPAR delta antagonize the ability of PPAR gamma to induce colorectal carcinoma cell death. More importantly, the opposing effects of PPAR delta and PPAR gamma in regulating programmed cell death are mediated by survivin and caspase-3. We found that activation of PPAR gamma results in decreased survivin expression and increased caspase-3 activity, whereas activation of PPAR delta counteracts these effects. Our findings suggest that PPAR delta and PPAR gamma coordinately regulate cancer cell fate by controlling the balance between the cell death and survival and demonstrate that inhibition of PPAR delta can reprogram PPAR gamma ligand-resistant cells to respond to PPAR gamma agonists. Oncogene (2012) 31, 1013-1023; doi:10.1038/onc.2011.299; published online 18 July 2011	[DuBois, R. N.] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Unit 1492, Houston, TX 77030 USA; [Wang, D.; Xie, D.; Guo, L.; DuBois, R. N.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; [Ning, W.] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Vanderbilt University	DuBois, RN (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Unit 1492, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rdubois@mdanderson.org	DuBois, Raymond N./AAX-8869-2020		National Colorectal Cancer Research Alliance (NCCRA); NIH MERIT [R37 DK47297, RO1 DK 62112, NCI P01 CA77839, CPRIT RP100960]; NATIONAL CANCER INSTITUTE [R01CA184820, P01CA077839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062112, R37DK047297] Funding Source: NIH RePORTER	National Colorectal Cancer Research Alliance (NCCRA); NIH MERIT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank the National Colorectal Cancer Research Alliance (NCCRA) for its generous support (RND). This work is supported, in part, by the NIH MERIT award R37 DK47297, RO1 DK 62112, NCI P01 CA77839 and CPRIT RP100960.	Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Asanuma K, 2000, JPN J CANCER RES, V91, P1204, DOI 10.1111/j.1349-7006.2000.tb00906.x; Burstein HJ, 2003, BREAST CANCER RES TR, V79, P391, DOI 10.1023/A:1024038127156; Cellai I, 2006, BRIT J CANCER, V95, P879, DOI 10.1038/sj.bjc.6603344; Di-Poi N, 2003, J STEROID BIOCHEM, V85, P257, DOI 10.1016/S0960-0760(03)00215-2; Di-Poi N, 2002, MOL CELL, V10, P721, DOI 10.1016/S1097-2765(02)00646-9; Farrow B, 2003, BIOCHEM BIOPH RES CO, V301, P50, DOI 10.1016/S0006-291X(02)02983-2; Fukuda S, 2002, BLOOD, V100, P2463, DOI 10.1182/blood.V100.7.2463; Girnun GD, 2002, P NATL ACAD SCI USA, V99, P13771, DOI 10.1073/pnas.162480299; Gupta RA, 2001, J BIOL CHEM, V276, P29681, DOI 10.1074/jbc.M103779200; Gupta RA, 2004, NAT MED, V10, P245, DOI 10.1038/nm993; Han SW, 2006, MOL CANCER THER, V5, P430, DOI 10.1158/1535-7163.MCT-05-0347; Hao CM, 2002, J BIOL CHEM, V277, P21341, DOI 10.1074/jbc.M200695200; Harman FS, 2004, NAT MED, V10, P481, DOI 10.1038/nm1026; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Kato Y, 2006, ONCOGENE, V25, P2736, DOI 10.1038/sj.onc.1209299; Kawasaki H, 1998, CANCER RES, V58, P5071; Kim EJ, 2003, J PHARMACOL EXP THER, V307, P505, DOI 10.1124/jpet.103.053876; Kulke MH, 2002, CANCER J, V8, P395, DOI 10.1097/00130404-200209000-00010; Kuo PC, 2004, J BIOL CHEM, V279, P55875, DOI 10.1074/jbc.M407985200; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; Li MY, 2005, J CELL BIOCHEM, V96, P760, DOI 10.1002/jcb.20474; Nadra K, 2006, MOL CELL BIOL, V26, P3266, DOI 10.1128/MCB.26.8.3266-3281.2006; O'Connor DS, 2002, CANCER CELL, V2, P43, DOI 10.1016/S1535-6108(02)00084-3; Olie RA, 2000, CANCER RES, V60, P2805; Osawa E, 2003, GASTROENTEROLOGY, V124, P361, DOI 10.1053/gast.2003.50067; Panigrahy D, 2005, CANCER BIOL THER, V4, P687, DOI 10.4161/cbt.4.7.2014; Park BH, 2001, P NATL ACAD SCI USA, V98, P2598, DOI 10.1073/pnas.051630998; Peters JM, 2000, MOL CELL BIOL, V20, P5119, DOI 10.1128/MCB.20.14.5119-5128.2000; Pino MV, 2004, TOXICOL PATHOL, V32, P58, DOI 10.1080/01926230490261320; Saez E, 1998, NAT MED, V4, P1058, DOI 10.1038/2042; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Sarela AI, 2001, ANN SURG ONCOL, V8, P305; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Takayama O, 2006, BRIT J CANCER, V95, P889, DOI 10.1038/sj.bjc.6603343; Teresi RE, 2006, INT J CANCER, V118, P2390, DOI 10.1002/ijc.21799; Ueda Y, 2004, J BIOL CHEM, V279, P24505, DOI 10.1074/jbc.M400081200; Wang DZ, 2006, P NATL ACAD SCI USA, V103, P19069, DOI 10.1073/pnas.0607948103; Wang DZ, 2006, J EXP MED, V203, P941, DOI 10.1084/jem.20052124; Wang DZ, 2005, CANCER RES, V65, P1822, DOI 10.1158/0008-5472.CAN-04-3671; Wang DZ, 2004, CANCER CELL, V6, P285, DOI 10.1016/j.ccr.2004.08.011; Williams CS, 1996, GASTROENTEROLOGY, V111, P1134, DOI 10.1016/S0016-5085(96)70083-5; Yin YZ, 2005, CANCER RES, V65, P3950, DOI 10.1158/0008-5472.CAN-04-3990; Zaffaroni N, 2002, DRUG RESIST UPDATE, V5, P65, DOI 10.1016/S1368-7646(02)00049-3; Zhang T, 2001, CANCER RES, V61, P8664; Zhao J, 2000, J CELL SCI, V113, P4363; Zuo XS, 2009, JNCI-J NATL CANCER I, V101, P762, DOI 10.1093/jnci/djp078	48	25	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2012	31	8					1013	1023		10.1038/onc.2011.299	http://dx.doi.org/10.1038/onc.2011.299			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898BG	21765467	Green Accepted			2022-12-17	WOS:000300709700007
J	Rego, MA; Harney, JA; Mauro, M; Shen, M; Howlett, NG				Rego, M. A.; Harney, J. A.; Mauro, M.; Shen, M.; Howlett, N. G.			Regulation of the activation of the Fanconi anemia pathway by the p21 cyclin-dependent kinase inhibitor	ONCOGENE			English	Article						Fanconi anemia; ubiquitination; deubiquitination; genome stability; DNA repair	P53-MEDIATED G(1) ARREST; FRAGILE-SITE STABILITY; CELL NUCLEAR ANTIGEN; DNA-DAMAGE RESPONSE; CROSS-LINK REPAIR; MONOUBIQUITINATED FANCD2; UBIQUITIN LIGASE; COMPLEX; PROTEIN; GENE	Fanconi anemia (FA) is a rare disease characterized by congenital defects, progressive bone marrow failure and heightened cancer susceptibility. The FA proteins, BRCA1 and FANCD1/BRCA2 function cooperatively in the FA-BRCA pathway to repair damaged DNA. Activation of the FA-BRCA pathway occurs via the monoubiquitination of the FANCD2 and FANCI proteins, targeting these proteins to discrete nuclear foci where they function in DNA repair. The cellular regulation of FANCD2/I monoubiquitination, however, remains poorly understood. In this study, we have examined the roles of the p53 tumor suppressor protein, as well as its downstream target, the p21(Cip1/Waf1) cyclin-dependent kinase inhibitor, in the regulation of the activation of the FA-BRCA pathway. We demonstrate that, in contrast to p53, p21 has a major role in the regulation of the activation of the FA-BRCA pathway: p21 promotes S-phase and DNA damage-inducible FANCD2/I monoubiquitination and nuclear foci formation. Several lines of evidence establish that this effect is not a consequence of a defective G1-S checkpoint or altered cell-cycle progression in the absence of p21. Instead, we demonstrate that p21 is required for the transcriptional repression of the USP1 deubiquitinating enzyme upon exposure to DNA-damaging agents. In the absence of p21, persistent USP1 expression precludes the DNA damage-inducible accumulation of monoubiquitinated FANCD2 and FANCI. Consequently, p21(-/-) cells exhibit increased levels of mitomycin C-inducible complex chromosomal aberrations and elevated gamma H2AX nuclear foci formation. Our results demonstrate that p21 has a critical role in the regulation of the activation of the FA-BRCA pathway and suggest a broader role for p21 in the orchestration of DNA repair processes following exposure to DNA crosslinking agents. Oncogene (2012) 31, 366-375; doi:10.1038/onc.2011.237; published online 20 June 2011	[Howlett, N. G.] Univ Rhode Isl, Ctr Biotechnol & Life Sci 379, Dept Cell & Mol Biol, Kingston, RI 02881 USA	University of Rhode Island	Howlett, NG (corresponding author), Univ Rhode Isl, Ctr Biotechnol & Life Sci 379, Dept Cell & Mol Biol, 120 Flagg Rd, Kingston, RI 02881 USA.	nhowlett@mail.uri.edu		Mauro, Maurizio/0000-0002-5452-0795	Leukemia Research Foundation; RI-INBRE from the National Center for Research Resources [P20RR016457-09]; National Institutes of Health/National Heart, Lung and Blood Institute [R21HL095991-01]; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016457] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL101977, R21HL095991] Funding Source: NIH RePORTER	Leukemia Research Foundation; RI-INBRE from the National Center for Research Resources; National Institutes of Health/National Heart, Lung and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank the members of the Howlett laboratory, Paul R Andreassen, Matthew Stoner and Patrick Sung for helpful discussions. We thank Tony T Huang and Patrick Sung for the anti-USP1 and anti-FANCI antibodies, respectively. We thank Bert Vogelstein for cells. This work was supported by a Leukemia Research Foundation New Investigator grant (NGH), RI-INBRE Grant P20RR016457-09 from the National Center for Research Resources (NGH) and National Institutes of Health/National Heart, Lung and Blood Institute Grant R21HL095991-01 (NGH).	Abbas T, 2008, GENE DEV, V22, P2496, DOI 10.1101/gad.1676108; Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Abukhdeir Abde M., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000744; Adamo A, 2010, MOL CELL, V39, P25, DOI 10.1016/j.molcel.2010.06.026; Alpi A, 2007, MOL CELL BIOL, V27, P8421, DOI 10.1128/MCB.00504-07; Andreassen PR, 2004, GENE DEV, V18, P1958, DOI 10.1101/gad.1196104; Arlt MF, 2004, MOL CELL BIOL, V24, P6701, DOI 10.1128/mcb.24.15.6701-6709.2004; AUERBACH AD, 1993, EXP HEMATOL, V21, P731; Avkin S, 2006, MOL CELL, V22, P407, DOI 10.1016/j.molcel.2006.03.022; Bendjennat M, 2003, CELL, V114, P599, DOI 10.1016/j.cell.2003.08.001; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chan KL, 2009, NAT CELL BIOL, V11, P753, DOI 10.1038/ncb1882; Chen JJ, 1996, P NATL ACAD SCI USA, V93, P11597, DOI 10.1073/pnas.93.21.11597; Cohn MA, 2007, MOL CELL, V28, P786, DOI 10.1016/j.molcel.2007.09.031; Collis SJ, 2007, NAT CELL BIOL, V9, P391, DOI 10.1038/ncb1555; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Harney JA, 2008, PEDIAT HLTH, V2, P175; Hoskins EE, 2008, ONCOGENE, V27, P4798, DOI 10.1038/onc.2008.121; Howlett NG, 2005, HUM MOL GENET, V14, P693, DOI 10.1093/hmg/ddi065; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Howlett NG, 2009, J BIOL CHEM, V284, P28935, DOI 10.1074/jbc.M109.016352; Huang TT, 2006, NAT CELL BIOL, V8, P339, DOI 10.1038/ncb1378; Kee Y, 2010, GENE DEV, V24, P1680, DOI 10.1101/gad.1955310; Kim Y, 2011, NAT GENET, V43, P142, DOI 10.1038/ng.750; Kim Y, 2008, GENE DEV, V22, P2507, DOI 10.1101/gad.1703708; Kratz K, 2010, CELL, V142, P77, DOI 10.1016/j.cell.2010.06.022; Liu T, 2010, SCIENCE, V329, P693, DOI 10.1126/science.1192656; Machida YJ, 2006, MOL CELL, V23, P589, DOI 10.1016/j.molcel.2006.06.024; MacKay C, 2010, CELL, V142, P65, DOI 10.1016/j.cell.2010.06.021; Mathew CG, 2006, ONCOGENE, V25, P5875, DOI 10.1038/sj.onc.1209878; Meetei AR, 2003, NAT GENET, V35, P165, DOI 10.1038/ng1241; Moldovan GL, 2009, ANNU REV GENET, V43, P223, DOI 10.1146/annurev-genet-102108-134222; Naim V, 2009, NAT CELL BIOL, V11, P761, DOI 10.1038/ncb1883; Nakanishi K, 2005, P NATL ACAD SCI USA, V102, P1110, DOI 10.1073/pnas.0407796102; Nijman SMB, 2005, MOL CELL, V17, P331, DOI 10.1016/j.molcel.2005.01.008; Pace P, 2010, SCIENCE, V329, P219, DOI 10.1126/science.1192277; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P8869, DOI 10.1021/bi00027a039; Prives C, 2008, CELL CYCLE, V7, P3840, DOI 10.4161/cc.7.24.7243; Rego MA, 2009, MUTAT RES-FUND MOL M, V668, P27, DOI 10.1016/j.mrfmmm.2008.11.018; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Sims AE, 2007, NAT STRUCT MOL BIOL, V14, P564, DOI 10.1038/nsmb1252; Smogorzewska A, 2007, CELL, V129, P289, DOI 10.1016/j.cell.2007.03.009; Smogorzewska A, 2010, MOL CELL, V39, P36, DOI 10.1016/j.molcel.2010.06.023; Stoepker C, 2011, NAT GENET, V43, P138, DOI 10.1038/ng.751; Taniguchi T, 2002, BLOOD, V100, P2414, DOI 10.1182/blood-2002-01-0278; Vaz F, 2010, NAT GENET, V42, P406, DOI 10.1038/ng.570; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang XZ, 2007, MOL CELL BIOL, V27, P3098, DOI 10.1128/MCB.02357-06; Wang XZ, 2004, MOL CELL BIOL, V24, P5850, DOI 10.1128/MCB.24.13.5850-5862.2004; Yamamoto K, 2005, MOL CELL BIOL, V25, P34, DOI 10.1128/MCB.25.1.34-43.2005; Yamazoe M, 2004, DNA REPAIR, V3, P1175, DOI 10.1016/j.dnarep.2004.03.039	54	25	26	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2012	31	3					366	375		10.1038/onc.2011.237	http://dx.doi.org/10.1038/onc.2011.237			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	882DQ	21685936	Green Accepted			2022-12-17	WOS:000299542100009
J	Saha, B; Adhikary, A; Ray, P; Saha, S; Chakraborty, S; Mohanty, S; Das, K; Mukherjee, S; Mazumdar, M; Lahiri, L; Hossain, DMS; Sa, G; Das, T				Saha, B.; Adhikary, A.; Ray, P.; Saha, S.; Chakraborty, S.; Mohanty, S.; Das, K.; Mukherjee, S.; Mazumdar, M.; Lahiri, L.; Hossain, D. M. S.; Sa, G.; Das, T.			Restoration of tumor suppressor p53 by differentially regulating pro- and anti-p53 networks in HPV-18-infected cervical cancer cells	ONCOGENE			English	Article						apoptosis; celecoxib; Cox-2; HPV-18; E6; p53	HUMAN-PAPILLOMAVIRUS TYPE-16; WILD-TYPE P53; CARCINOMA-CELLS; CYCLOOXYGENASE-2 EXPRESSION; CYTOPLASMIC SEQUESTRATION; SIGNALING PATHWAY; DOWN-REGULATION; POSTTRANSLATIONAL MODIFICATIONS; NITRIC-OXIDE; COLON-CANCER	Abrogation of functional p53 is responsible for malignant cell transformation and maintenance of human papilloma virus (HPV)-infected cancer cells. Restoration of p53 has, therefore, been regarded as an important strategy for molecular intervention of HPV-associated malignancies. Here we report that differential regulation of pro-and anti-p53 setups not only upregulates p53 transcription but also stabilizes and activates p53 protein to ensure p53-induced apoptosis in HPV-18-infected cervical cancer. Functional restoration of p53 can be achieved by nonsteroidal anti-inflammatory drug celecoxib via multiple molecular mechanisms: (i) inhibition of p53 degradation by suppressing viral oncoprotein E6 expression, (ii) promoting p53 transcription by downmodulating cycloxygenase-2 (Cox-2) and simultaneously retrieving p53 from Cox-2 association and (iii) activation of p53 via ataxia telangiectasia mutated-/p38 mitogen-activated protein kinase-mediated phosphorylations at serine-15/-46 residues. That restored p53 is functional has been confirmed by its ability of transactivating Bax and p53-upregulated modulator of apoptosis, which in turn switch on the apoptotic machinery in these cells. Studies undertaken in biopsy samples of cervical carcinoma further validated celecoxib effect. Our approaches involving gene manipulation and pharmacological interference finally highlight that celecoxib alters pro-and anti-p53 networks, not in isolation but in concert, to rejuvenate p53-dependent apoptotic program in HPV-infected cervical cancer cells. Oncogene (2012) 31, 173-186; doi:10.1038/onc.2011.234; published online 18 July 2011	[Saha, B.; Adhikary, A.; Ray, P.; Saha, S.; Chakraborty, S.; Mohanty, S.; Das, K.; Mukherjee, S.; Mazumdar, M.; Lahiri, L.; Hossain, D. M. S.; Sa, G.; Das, T.] Bose Inst, Div Mol Med, Kolkata 700054, W Bengal, India	Department of Science & Technology (India); Bose Institute	Das, T (corresponding author), Bose Inst, Div Mol Med, P-1-12 Calcutta Improvement Trust Scheme VIIM, Kolkata 700054, W Bengal, India.	tanya@boseinst.ernet.in	Chakraborty, Samik/Q-1779-2018	Chakraborty, Samik/0000-0002-5232-0474	DST; CSIR; UGC, Govt of India	DST(Department of Science & Technology (India)); CSIR(Council of Scientific & Industrial Research (CSIR) - India); UGC, Govt of India(University Grants Commission, India)	We gratefully acknowledge Dr S Biswas, Department of Surgery, SSKM Hospital, Kolkata, for providing primary lesions of cervical cancer and normal cervical tissues. We are thankful to R Sarkar for editing the manuscript. Thanks are also due to U Ghosh and R Dutta for technical help. This work was supported by the grants from DST, CSIR and UGC, Govt of India.	Adhikary A, 2010, FEBS LETT, V584, P7, DOI 10.1016/j.febslet.2009.10.081; Amano T, 2009, J NEURO-ONCOL, V92, P357, DOI 10.1007/s11060-009-9844-1; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Becker K, 2007, CELL DEATH DIFFER, V14, P1350, DOI 10.1038/sj.cdd.4402126; Bhattacharyya S, 2007, J BIOL CHEM, V282, P15954, DOI 10.1074/jbc.M608189200; Blagosklonny MV, 2000, FASEB J, V14, P1901, DOI 10.1096/fj.99-1078rev; Butz K, 2000, P NATL ACAD SCI USA, V97, P6693, DOI 10.1073/pnas.110538897; Butz K, 2003, ONCOGENE, V22, P5938, DOI 10.1038/sj.onc.1206894; Chakrabarti O, 2003, J BIOSCIENCES, V28, P337, DOI 10.1007/BF02970152; Chakraborty J, 2010, J BIOL CHEM, V285, P33104, DOI 10.1074/jbc.M110.122705; Choudhuri T, 2005, J BIOL CHEM, V280, P20059, DOI 10.1074/jbc.M410670200; Corcoran CA, 2005, ONCOGENE, V24, P1634, DOI 10.1038/sj.onc.1208353; Das T, 2008, J IMMUNOL, V180, P4687, DOI 10.4049/jimmunol.180.7.4687; Das T, 2008, CANCER RES, V68, P2014, DOI 10.1158/0008-5472.CAN-07-6037; de Moraes E, 2007, INT J CANCER, V121, P929, DOI 10.1002/ijc.22899; El-Deiry WS, 2003, ONCOGENE, V22, P7486, DOI 10.1038/sj.onc.1206949; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Frank S, 2006, EXP DERMATOL, V15, P130, DOI 10.1111/j.1600-0625.2005.00397.x; Fuster JJ, 2007, TRENDS MOL MED, V13, P192, DOI 10.1016/j.molmed.2007.03.002; Grosch S, 2005, BIOCHEM PHARMACOL, V69, P831, DOI 10.1016/j.bcp.2004.11.026; Han JA, 2002, EMBO J, V21, P5635, DOI 10.1093/emboj/cdf591; Hengstermann A, 2005, J VIROL, V79, P9296, DOI 10.1128/JVI.79.14.9296-9300.2005; Horner SM, 2004, J VIROL, V78, P4063, DOI 10.1128/JVI.78.8.4063-4073.2004; Ichwan SJA, 2006, ONCOGENE, V25, P1216, DOI 10.1038/sj.onc.1209158; Ishida K, 2003, BIOCHEM BIOPH RES CO, V300, P201, DOI 10.1016/S0006-291X(02)02790-0; Jeong SJ, 2005, J BIOL CHEM, V280, P10326, DOI 10.1074/jbc.M412643200; Kang KB, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-66; Kastan MB, 2007, CELL, V128, P837, DOI 10.1016/j.cell.2007.02.022; Kawamata Y, 2002, INT J ONCOL, V21, P561; Kuperwasser C, 2000, CANCER RES, V60, P2723; Lahiry L, 2008, APOPTOSIS, V13, P771, DOI 10.1007/s10495-008-0213-x; Lahiry L, 2010, CARCINOGENESIS, V31, P259, DOI 10.1093/carcin/bgp240; Lee HC, 2008, MOL CANCER RES, V6, P996, DOI 10.1158/1541-7786.MCR-08-0113; Malanchi I, 2002, ONCOGENE, V21, P5665, DOI 10.1038/sj.onc.1205617; Mestre JR, 1997, CANCER RES, V57, P2890; Meulmeester E, 2008, CURR CANCER DRUG TAR, V8, P87, DOI 10.2174/156800908783769337; Molina MA, 1999, CANCER RES, V59, P4356; Moody CA, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000605; Munkarah A, 2005, CURR OPIN OBSTET GYN, V17, P49; Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641; Narayanan BA, 2006, MOL CANCER THER, V5, P1117, DOI 10.1158/1535-7163.MCT-05-0520; Park SW, 2005, ONCOGENE, V24, P6689, DOI 10.1038/sj.onc.1208816; Perfettini JL, 2005, J EXP MED, V201, P279, DOI 10.1084/jem.20041502; Prince ME, 2007, HEAD NECK-J SCI SPEC, V29, P465, DOI 10.1002/hed.20547; Reddy BS, 2000, CANCER RES, V60, P293; ROMANCZUK H, 1991, J VIROL, V65, P2739, DOI 10.1128/JVI.65.5.2739-2744.1991; Royds JA, 2006, CELL DEATH DIFFER, V13, P1017, DOI 10.1038/sj.cdd.4401913; Ryu HS, 2000, GYNECOL ONCOL, V76, P320, DOI 10.1006/gyno.1999.5690; Saito S, 2003, J BIOL CHEM, V278, P37536, DOI 10.1074/jbc.M305135200; Sato T, 1997, PROSTAGLANDINS, V53, P355, DOI 10.1016/0090-6980(97)00036-1; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Sigal A, 2000, CANCER RES, V60, P6788; Subbaramaiah K, 2007, CANCER RES, V67, P3976, DOI 10.1158/0008-5472.CAN-06-4273; Swamy MV, 2003, CANCER RES, V63, P5239; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Walker C, 2006, AM J PATHOL, V168, P1526, DOI 10.2353/ajpath.2006.050603; Wang WG, 2003, MOL CELL BIOL, V23, P2171, DOI 10.1128/MCB.23.6.2171-2181.2003; YASUMOTO S, 1991, J VIROL, V65, P2000, DOI 10.1128/JVI.65.4.2000-2009.1991; Zhao CY, 2010, CANCER RES, V70, P3372, DOI 10.1158/0008-5472.CAN-09-2787; Zhao LY, 2003, J VIROL, V77, P13171, DOI 10.1128/JVI.77.24.13171-13181.2003	60	25	25	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	2					173	186		10.1038/onc.2011.234	http://dx.doi.org/10.1038/onc.2011.234			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	879CN	21765464				2022-12-17	WOS:000299307400004
J	Stein, SJ; Baldwin, AS				Stein, S. J.; Baldwin, A. S.			NF-kappa B suppresses ROS levels in BCR-ABL(+) cells to prevent activation of JNK and cell death	ONCOGENE			English	Article						IKK beta inhibitor; BCR-ABL; ROS; NF-kappa B; JNK	ALPHA-INDUCED APOPTOSIS; REACTIVE OXYGEN; OXIDATIVE STRESS; C-JUN; TRANSFORMED FIBROBLASTS; IMATINIB RESISTANCE; MEDIATED MECHANISM; SIGNALING PATHWAY; CANCER-CELLS; CML CELLS	Elevated levels of reactive oxygen species (ROS) are found in most oncogenically transformed cells and are proposed to promote cellular transformation through mechanisms such as inhibition of phosphatases. BCR-ABL, the oncoprotein associated with the majority of chronic myeloid leukemias (CMLs), induces accumulation of intracellular ROS, causing enhanced signaling down-stream of PI3K. Previously we have shown that the transcription factor nuclear factor-kappa B (NF-kappa B) is activated by BCR-ABL expression and is required for BCR-ABL-mediated cellular transformation. Inhibition of I kappa B kinase (IKK beta) and NF-kappa B leads to cell death through an unknown mechanism. Here, we analyze the potential involvement of NF-kappa B in moderating BCR-ABL-induced ROS levels to protect from death. The data confirm that BCR-ABL promotes ROS and demonstrate that NF-kappa B prevents excessive levels. Inhibition of NF-kappa B leads to an increase in ROS levels and to cell death, which is at least partially controlled through ROS-induced c-Jun N-terminal kinase activity. The data demonstrate that one function for NF-kappa B in oncogenesis is the suppression of oncoprotein-induced ROS levels and that inhibition of NF-jB in some cancers, including CML, will increase ROS levels and promote cell death. Oncogene (2011) 30, 4557-4566; doi: 10.1038/onc.2011.156; published online 30 May 2011	[Baldwin, A. S.] Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Baldwin, A. S.] Univ N Carolina, Sch Med, Dept Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Baldwin, AS (corresponding author), Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, 22-000 LCCC,CB 7295, Chapel Hill, NC 27599 USA.	abaldwin@med.unc.edu			Leukemia and Lymphoma Society; NIH [CA73756, CA75080]; Samuel Waxman Cancer Research Foundation; NATIONAL CANCER INSTITUTE [R01CA075080, R01CA073756] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI035098] Funding Source: NIH RePORTER	Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Samuel Waxman Cancer Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank Justina Chen for technical support and members of the Baldwin lab for advice and discussion. We acknowledge grant support from the Leukemia and Lymphoma Society, from the NIH (CA73756 and CA75080), and from the Samuel Waxman Cancer Research Foundation.	Basseres DS, 2006, ONCOGENE, V25, P6817, DOI 10.1038/sj.onc.1209942; Benhar M, 2002, EMBO REP, V3, P420, DOI 10.1093/embo-reports/kvf094; Braun T, 2006, CELL DEATH DIFFER, V13, P748, DOI 10.1038/sj.cdd.4401874; Chandra J, 2006, BLOOD, V107, P2501, DOI 10.1182/blood-2005-07-2966; Cilloni D, 2006, LEUKEMIA, V20, P61, DOI 10.1038/sj.leu.2403998; Courtois G, 2006, ONCOGENE, V25, P6831, DOI 10.1038/sj.onc.1209939; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Dhanasekaran DN, 2008, ONCOGENE, V27, P6245, DOI 10.1038/onc.2008.301; Diaz-Blanco E, 2007, LEUKEMIA, V21, P494, DOI 10.1038/sj.leu.2404549; Duncan EA, 2008, MOL CANCER THER, V7, P391, DOI 10.1158/1535-7163.MCT-07-0305; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Hamdane M, 1997, ONCOGENE, V15, P2267, DOI 10.1038/sj.onc.1201411; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hess P, 2002, NAT GENET, V32, P201, DOI 10.1038/ng946; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Iida T, 2001, NEURO-ONCOLOGY, V3, P73, DOI 10.1093/neuonc/3.2.73; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kim JH, 2005, BLOOD, V105, P1717, DOI 10.1182/blood-2004-03-0849; Lee DF, 2007, CELL, V130, P440, DOI 10.1016/j.cell.2007.05.058; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Mao X, 2008, CELL RES, V18, P879, DOI 10.1038/cr.2008.86; Mitsushita J, 2004, CANCER RES, V64, P3580, DOI 10.1158/0008-5472.CAN-03-3909; Naughton R, 2009, LEUKEMIA, V23, P1432, DOI 10.1038/leu.2009.49; Pelicano H, 2004, DRUG RESIST UPDATE, V7, P97, DOI 10.1016/j.drup.2004.01.004; Pham CG, 2004, CELL, V119, P529, DOI 10.1016/j.cell.2004.10.017; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Sakon S, 2003, EMBO J, V22, P3898, DOI 10.1093/emboj/cdg379; Sattler M, 2000, J BIOL CHEM, V275, P24273, DOI 10.1074/jbc.M002094200; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Schimmel M, 2002, ONCOGENE, V21, P5886, DOI 10.1038/sj.onc.1205740; Senthil K, 2004, CLIN CHIM ACTA, V339, P27, DOI 10.1016/j.cccn.2003.08.017; Shen HM, 2006, FREE RADICAL BIO MED, V40, P928, DOI 10.1016/j.freeradbiomed.2005.10.056; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Tang FM, 2002, MOL CELL BIOL, V22, P8571, DOI 10.1128/MCB.22.24.8571-8579.2002; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; TOYOKUNI S, 1995, FEBS LETT, V358, P1, DOI 10.1016/0014-5793(94)01368-B; Trachootham D, 2006, CANCER CELL, V10, P241, DOI 10.1016/j.ccr.2006.08.009; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Ventura JJ, 2004, GENE DEV, V18, P2905, DOI 10.1101/gad.1223004; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107; Yu CF, 2004, MOL CELL, V13, P329, DOI 10.1016/S1097-2765(04)00028-0; Zhang H, 2008, LEUKEMIA, V22, P1191, DOI 10.1038/leu.2008.74; Zhou Y, 2003, BLOOD, V101, P4098, DOI 10.1182/blood-2002-08-2512; Ziegelbauer K, 2005, BRIT J PHARMACOL, V145, P178, DOI 10.1038/sj.bjp.0706176	50	25	26	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 10	2011	30	45					4557	4566		10.1038/onc.2011.156	http://dx.doi.org/10.1038/onc.2011.156			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	846IO	21625221	Green Accepted, Green Submitted			2022-12-17	WOS:000296890700003
J	Nam, SY; Sabapathy, K				Nam, S. Y.; Sabapathy, K.			p53 promotes cellular survival in a context-dependent manner by directly inducing the expression of haeme-oxygenase-1	ONCOGENE			English	Article						haeme-oxygenease-1; hydrogen peroxide; p53; survival	MALIGNANT GLIOMA-CELLS; HEME OXYGENASE-1 INDUCTION; NITRIC-OXIDE; ANTICANCER TREATMENT; INDUCED APOPTOSIS; TUMOR-SUPPRESSOR; SENSITIVITY; PROTEIN; MICE; O-6-METHYLGUANINE	A variety of cellular insults activate the tumour suppressor p53, leading generally to cell-cycle arrest or apoptosis. However, it is not inconceivable that cellular protective mechanisms may be required to keep cells alive while cell-fate decisions are made. In this respect, p53 has been suggested to perform functions that allow cells to survive, by halting of the cell-cycle, and thus preventing immediate cell death. Nonetheless, the existence of direct prosurvival p53 target genes regulating cellular survival is lacking. We show here evidence for p53-dependent cellular survival in a context-dependent manner. Both mouse and human cells lacking p53 are hypersensitive to hydrogen peroxide (H2O2)-induced cell death compared with their isogenic wild-type counterparts. By contrast, p53(-/-) cells are expectedly resistant to cell death upon exposure to DNA-damaging agents such as cisplatin (CDDP) and etoposide. Although p53 and its classical targets such as p21 and Mdm2 are activated by both H2O2 and CDDP, we found that the expression of haeme-oxygenase-1 (HO-1)-an antioxidant and antiapoptotic protein-was directly induced only upon H2O2 treatment in a p53-dependent manner. Consistently, p53, but not its homologue p73, activated HO-1 expression and was bound to the HO-1 promoter specifically only upon H2O2 treatment. Moreover, silencing HO-1 expression enhanced cell death upon H2O2 treatment only in p53-proficient cells. Finally, H2O2-mediated cell death was rescued significantly in p53-deficient cells by antioxidant treatment, as well as by bilirubin, a by-product of HO-1 metabolism. Taken together, these data demonstrate a direct role for p53 in promoting cellular survival in a context-specific manner through the activation of a direct transcriptional target, HO-1. Oncogene (2011) 30, 4476-4486; doi: 10.1038/onc.2011.150; published online 9 May 2011	[Nam, S. Y.; Sabapathy, K.] Natl Canc Ctr, Humphrey Oei Inst Canc Res, Div Cellular & Mol Res, Singapore 169610, Singapore; [Sabapathy, K.] Duke NUS Grad Med Sch, Canc & Stem Cell Biol Program, Singapore, Singapore; [Sabapathy, K.] Natl Univ Singapore, Dept Biochem, Singapore 117548, Singapore	National Cancer Centre Singapore (NCCS); National University of Singapore; National University of Singapore	Sabapathy, K (corresponding author), Natl Canc Ctr, Humphrey Oei Inst Canc Res, Div Cellular & Mol Res, 11 Hosp Dr, Singapore 169610, Singapore.	cmrksb@nccs.com.sg			National Medical Research Council of Singapore	National Medical Research Council of Singapore(National Medical Research Council, Singapore)	We thank Dr Vogelstein for the gift of the RKO cells; Ms Amy Chua HW for technical assistance during the revision phase; Dr Lee MK for critical reading of the paper and the National Medical Research Council of Singapore for the funding to KS.	Batista LFZ, 2007, CANCER RES, V67, P11886, DOI 10.1158/0008-5472.CAN-07-2964; Brooks CL, 2010, CELL RES, V20, P614, DOI 10.1038/cr.2010.53; Brown CJ, 2009, NAT REV CANCER, V9, P862, DOI 10.1038/nrc2763; Burdelya LG, 2006, CANCER RES, V66, P9356, DOI 10.1158/0008-5472.CAN-06-1223; Buzek J, 2002, NUCLEIC ACIDS RES, V30, P2340, DOI 10.1093/nar/30.11.2340; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; Fang J, 2004, APOPTOSIS, V9, P27, DOI 10.1023/B:APPT.0000012119.83734.4e; Ferris CD, 1999, NAT CELL BIOL, V1, P152, DOI 10.1038/11072; Foresti R, 1997, J BIOL CHEM, V272, P18411, DOI 10.1074/jbc.272.29.18411; Gozzelino R, 2010, ANNU REV PHARMACOL, V50, P323, DOI 10.1146/annurev.pharmtox.010909.105600; Gudkov AV, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001180; Helton ES, 2007, J CELL BIOCHEM, V100, P883, DOI 10.1002/jcb.21091; Hermisson M, 2006, J NEUROCHEM, V96, P766, DOI 10.1111/j.1471-4159.2005.03583.x; Hu WW, 2007, NATURE, V450, P721, DOI 10.1038/nature05993; Janicke RU, 2008, CELL DEATH DIFFER, V15, P959, DOI 10.1038/cdd.2008.33; Jing CR, 2005, J NEUROSCI RES, V82, P802, DOI 10.1002/jnr.20681; Jozkowicz A, 2007, ANTIOXID REDOX SIGN, V9, P2099, DOI 10.1089/ars.2007.1659; Komarova EA, 2004, ONCOGENE, V23, P3265, DOI 10.1038/sj.onc.1207494; Lackinger D, 2000, MUTAT RES-FUND MOL M, V457, P113, DOI 10.1016/S0027-5107(00)00133-0; Laptenko O, 2006, CELL DEATH DIFFER, V13, P951, DOI 10.1038/sj.cdd.4401916; Lassus P, 1996, EMBO J, V15, P4566, DOI 10.1002/j.1460-2075.1996.tb00834.x; Lee MK, 2005, J CELL SCI, V118, P819, DOI 10.1242/jcs.01673; Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723; Meiller A, 2007, NUCLEIC ACIDS RES, V35, P6924, DOI 10.1093/nar/gkm824; Motterlini R, 2002, ANTIOXID REDOX SIGN, V4, P615, DOI 10.1089/15230860260220111; Motterlini R, 2000, J BIOL CHEM, V275, P13613, DOI 10.1074/jbc.275.18.13613; Persons DL, 2000, J BIOL CHEM, V275, P35778, DOI 10.1074/jbc.M004267200; Petrache I, 2000, AM J PHYSIOL-LUNG C, V278, pL312, DOI 10.1152/ajplung.2000.278.2.L312; Roepke M, 2007, CANCER BIOL THER, V6, P160, DOI 10.4161/cbt.6.2.3575; Roos WP, 2007, ONCOGENE, V26, P186, DOI 10.1038/sj.onc.1209785; Sabapathy K, 2004, MOL CELL, V15, P713, DOI 10.1016/j.molcel.2004.08.028; Sur S, 2009, P NATL ACAD SCI USA, V106, P3964, DOI 10.1073/pnas.0813333106; Vikhanskaya F, 1998, EXP CELL RES, V241, P96, DOI 10.1006/excr.1998.4018; Vikhanskaya F, 2007, NAT CELL BIOL, V9, P698, DOI 10.1038/ncb1598; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhang Y, 2009, INT J BIOCHEM CELL B, V41, P907, DOI 10.1016/j.biocel.2008.08.040; Zuckerman V, 2009, J PATHOL, V219, P3, DOI 10.1002/path.2584	37	25	25	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2011	30	44					4476	4486		10.1038/onc.2011.150	http://dx.doi.org/10.1038/onc.2011.150			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	844FN	21552291				2022-12-17	WOS:000296733200003
J	Cheng, JC; Auersperg, N; Leung, PCK				Cheng, J-C; Auersperg, N.; Leung, P. C. K.			Inhibition of p53 represses E-cadherin expression by increasing DNA methyltransferase-1 and promoter methylation in serous borderline ovarian tumor cells	ONCOGENE			English	Article						serous borderline ovarian tumors; p53; ovarian cancer; DNMT1; E-cadherin; methylation	EPITHELIAL-MESENCHYMAL TRANSITION; DE-NOVO METHYLATION; MOLECULE E-CADHERIN; EPIGENETIC REGULATION; SUPPRESSOR GENE; LOW-GRADE; CANCER; CPG; TUMORIGENESIS; PROTEIN	The mechanisms underlying the progression of noninvasive serous borderline ovarian tumors (SBOT) to low-grade invasive carcinomas are poorly understood. We recently showed that inhibition of p53 induces SBOT invasion by activating the PI3K/Akt pathway and transcriptionally repressing E-cadherin. In human cancers, aberrant DNA methylation is a common phenomenon, and it is thought to be involved in the progression from noninvasive to invasive ovarian carcinomas. In this study, we tested the hypothesis that inhibition of p53 downregulates E-cadherin by regulating the methylation of its promoter in SBOT cells. Here, we show that DNA methyltransferase-1 (DNMT1), but not DNMT3a or DNMT3b, was increased in SV40 LT-infected SBOT4 cells, SBOT4-LT and the low-grade invasive serous ovarian carcinoma-derived cell line MPSC1. Treatment with 5-Aza-dC, a DNMT1 inhibitor, restored E-cadherin promoter methylation and expression, and inhibited cell invasion in both invasive SBOT4-LT and MPSC1 cells. Moreover, knockdown of endogenous p53 using siRNA in SBOT3.1 cells induced DNMT1 expression and led to an increase in E-cadherin promoter methylation. Additionally, activation of the PI3K/Akt pathway is required for p53 inhibition-induced DNMT1 expression. The increase in DNMT1 was associated with the inhibition of p53-induced downregulation of E-cadherin and cell invasion. Our findings show an important role for p53 in the progression of SBOT to an invasive carcinoma, and suggest that downregulation of E-cadherin by DNMT1-mediated promoter methylation contributes to this process. Oncogene (2011) 30, 3930-3942; doi:10.1038/onc.2011.117; published online 11 April 2011	[Cheng, J-C; Auersperg, N.; Leung, P. C. K.] Univ British Columbia, Dept Obstet & Gynecol, Child & Family Res Inst, Vancouver, BC V6H 3V5, Canada	Child & Family Research Institute; University of British Columbia	Leung, PCK (corresponding author), Univ British Columbia, Dept Obstet & Gynecol, Child & Family Res Inst, Vancouver, BC V6H 3V5, Canada.	peleung@interchange.ubc.ca	Cheng, Jung-Chien/T-4258-2019	Cheng, Jung-Chien/0000-0002-5399-9327; Leung, Peter/0000-0003-3152-3800	Canadian Institutes of Health Research; National Cancer Institute of Canada; Canadian Cancer Society; Child & Family Research Institute; University of British Columbia	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); National Cancer Institute of Canada(Canadian Cancer Society (CCS)); Canadian Cancer Society(Canadian Cancer Society (CCS)); Child & Family Research Institute; University of British Columbia	This work was supported by grants from the Canadian Institutes of Health Research to PCKL and National Cancer Institute of Canada with funds from the Canadian Cancer Society to NA. PCKL is the recipient of a Child & Family Research Institute Distinguished Investigator Award. JCC is the recipient of four year fellowships for PhD students from University of British Columbia.	Ahluwalia A, 2001, GYNECOL ONCOL, V82, P299, DOI 10.1006/gyno.2001.6284; Asadollahi R, 2010, GYNECOL ONCOL, V118, P81, DOI 10.1016/j.ygyno.2010.03.015; Astanehe A, 2008, J CELL SCI, V121, P664, DOI 10.1242/jcs.013029; Balch C, 2009, ENDOCRINOLOGY, V150, P4003, DOI 10.1210/en.2009-0404; Benton G, 2009, FASEB J, V23, P3884, DOI 10.1096/fj.08-128702; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; BIRD AP, 1980, NUCLEIC ACIDS RES, V8, P1499, DOI 10.1093/nar/8.7.1499; Bonome T, 2005, CANCER RES, V65, P10602, DOI 10.1158/0008-5472.CAN-05-2240; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Cheng JC, 2011, ONCOGENE, V30, P1020, DOI 10.1038/onc.2010.486; Cheng P, 1997, BRIT J CANCER, V75, P396, DOI 10.1038/bjc.1997.64; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Darai E, 1997, HUM PATHOL, V28, P922, DOI 10.1016/S0046-8177(97)90007-1; Fan H, 2007, EUR J GASTROEN HEPAT, V19, P952, DOI 10.1097/MEG.0b013e3282c3a89e; Gershenson DM, 1998, CANCER, V83, P2157, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2157::AID-CNCR14>3.0.CO;2-D; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; GRAFF JR, 1995, CANCER RES, V55, P5195; Grille SJ, 2003, CANCER RES, V63, P2172; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hudson LG, 2008, CLIN EXP METASTAS, V25, P643, DOI 10.1007/s10585-008-9171-5; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Lee JO, 2005, ONCOGENE, V24, P6617, DOI 10.1038/sj.onc.1208827; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; MACLEOD AR, 1995, J BIOL CHEM, V270, P8037, DOI 10.1074/jbc.270.14.8037; Makarla PB, 2005, CLIN CANCER RES, V11, P5365, DOI 10.1158/1078-0432.CCR-04-2455; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Pecina-Slaus N, 2003, CANCER CELL INT, V3, DOI 10.1186/1475-2867-3-17; Peterson EJ, 2003, CANCER RES, V63, P6579; Pohl G, 2005, CANCER RES, V65, P1994, DOI 10.1158/0008-5472.CAN-04-3625; Rahnama F, 2006, ENDOCRINOLOGY, V147, P5275, DOI 10.1210/en.2006-0288; Rahnama F, 2009, ENDOCRINOLOGY, V150, P1466, DOI 10.1210/en.2008-1142; Ramchandani S, 1997, P NATL ACAD SCI USA, V94, P684, DOI 10.1073/pnas.94.2.684; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Schuijer M, 2003, HUM MUTAT, V21, P285, DOI 10.1002/humu.10181; Sheng SJ, 2009, J CELL PHYSIOL, V218, P451, DOI 10.1002/jcp.21616; Shi HD, 2003, CANCER RES, V63, P2164; Shieh YS, 2005, CANCER-AM CANCER SOC, V104, P1013, DOI 10.1002/cncr.21278; Shih IM, 2004, AM J PATHOL, V164, P1511, DOI 10.1016/S0002-9440(10)63708-X; Singer G, 2005, AM J SURG PATHOL, V29, P218, DOI 10.1097/01.pas.0000146025.91953.8d; Sun LD, 2007, CELL SIGNAL, V19, P2255, DOI 10.1016/j.cellsig.2007.06.014; Tam KF, 2007, J CANCER RES CLIN, V133, P331, DOI 10.1007/s00432-006-0178-5; Van Aken E, 2001, VIRCHOWS ARCH, V439, P725, DOI 10.1007/S004280100516; Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007; VEATCH AL, 1994, INT J CANCER, V58, P393, DOI 10.1002/ijc.2910580315; Vergara D, 2010, CURR CANCER DRUG TAR, V10, P107, DOI 10.2174/156800910790980269; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Woo MMM, 2007, IN VITRO CELL DEV-AN, V43, P7, DOI 10.1007/s11626-006-9002-4; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416	53	25	25	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2011	30	37					3930	3942		10.1038/onc.2011.117	http://dx.doi.org/10.1038/onc.2011.117			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820FG	21478913				2022-12-17	WOS:000294890400003
J	Mainwaring, LA; Kenney, AM				Mainwaring, L. A.; Kenney, A. M.			Divergent functions for eIF4E and S6 kinase by sonic hedgehog mitogenic signaling in the developing cerebellum	ONCOGENE			English	Article						sonic hedgehog; eIF4E; S6 kinase; proliferation	CELL-CYCLE PROGRESSION; TRANSLATION INITIATION; GROWTH-FACTOR; N-MYC; PROTEIN PHOSPHATASES; NEURONAL SURVIVAL; NERVOUS-SYSTEM; PHOSPHORYLATION; PROLIFERATION; PATHWAY	Cerebellar development entails rapid peri-natal proliferation of cerebellar granule neuron precursors (CGNPs), proposed cells-of-origin for certain medulloblastomas. CGNPs require insulin-like growth factor (IGF) for survival and sonic hedgehog (Shh)-implicated in medulloblastoma-for proliferation. The IGF-responsive kinase mammalian target of rapamycin (mTOR) drives proliferation-associated protein synthesis. We asked whether Shh signaling regulates mTOR targets to promote CGNP proliferation despite constitutive IGF signaling under proliferative and differentiation-promoting conditions. Surprisingly, Shh promoted eukaryotic initiation factor 4E (eIF4E) expression, but inhibited S6 kinase (S6K). In vivo, S6K activity specifically marked the CGNP population transitioning from proliferation-competent to post-mitotic. Indeed, eIF4E was required for CGNP proliferation, while S6K activation drove cell cycle exit. Protein phosphatase 2A (PP2A) inhibition rescued S6K activity. Moreover, Shh upregulated the PP2A B56 gamma subunit, which targets S6K for inactivation and was required for CGNP proliferation. These findings reveal unique developmental functions for eIF4E and S6 kinase wherein their activity is specifically uncoupled by mitogenic Shh signaling. Oncogene (2011) 30, 1784-1797; doi:10.1038/onc.2010.564; published online 21 February 2011	[Mainwaring, L. A.; Kenney, A. M.] Cornell Univ, Weill Med Coll, Biochem Cell & Mol Biol Program, New York, NY 10021 USA; [Mainwaring, L. A.; Kenney, A. M.] Mem Sloan Kettering Canc Ctr, Dept Canc Biol & Genet, New York, NY 10021 USA	Cornell University; Memorial Sloan Kettering Cancer Center	Kenney, AM (corresponding author), Vanderbilt Univ, Dept Neurosurg, Nashville, TN 37232 USA.	Anna.Kenney@vanderbilt.edu			NINDS [R01NS061070]; Handler Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS061070] Funding Source: NIH RePORTER	NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Handler Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank John Blenis (Harvard Medical School) for providing the HA-tagged S6 kinase plasmid. These studies were supported by grants to AMK from the NINDS (R01NS061070) and the Handler Foundation.	Altman J., 1996, DEV CEREBELLAR SYSTE; Bateman JM, 2004, CELL, V119, P87, DOI 10.1016/j.cell.2004.08.028; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; Bielinski VA, 2007, EXP CELL RES, V313, P3117, DOI 10.1016/j.yexcr.2007.05.008; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; Ciemerych MA, 2002, GENE DEV, V16, P3277, DOI 10.1101/gad.1023602; Corradetti MN, 2006, ONCOGENE, V25, P6347, DOI 10.1038/sj.onc.1209885; D'Mello SR, 1997, J NEUROSCI, V17, P1548; Dahmane N, 1999, DEVELOPMENT, V126, P3089; Dahmane N, 2001, DEVELOPMENT, V128, P5201; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Dutton R, 1999, CLIN EXP PHARMACOL P, V26, P746, DOI 10.1046/j.1440-1681.1999.03108.x; Dutton R, 1999, J NEUROSCI, V19, P2601; Fernandez A, 2009, GENE DEV, V23, P2729, DOI 10.1101/gad.1824509; Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004; Fogarty MP, 2007, P NATL ACAD SCI USA, V104, P2973, DOI 10.1073/pnas.0605770104; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Goslin, 1998, CULTURING NERVE CELL, P419; Hahn H, 2000, J BIOL CHEM, V275, P28341, DOI 10.1074/jbc.C000352200; Hahn K, 2010, CELL METAB, V11, P438, DOI 10.1016/j.cmet.2010.03.015; Hartley D, 2002, J CELL BIOCHEM, V85, P304, DOI 10.1002/jcb.10135; Hartmann W, 2005, AM J PATHOL, V166, P1153, DOI 10.1016/S0002-9440(10)62335-8; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Hepker J, 1997, DEVELOPMENT, V124, P549; Ho KS, 2002, CURR OPIN NEUROBIOL, V12, P57, DOI 10.1016/S0959-4388(02)00290-8; Katoh Y, 2009, CURR MOL MED, V9, P873, DOI 10.2174/156652409789105570; Kenney AM, 2004, DEVELOPMENT, V131, P217, DOI 10.1242/dev.00891; Kenney AM, 2003, DEVELOPMENT, V130, P15, DOI 10.1242/dev.00182; Kenney AM, 2000, MOL CELL BIOL, V20, P9055, DOI 10.1128/MCB.20.23.9055-9067.2000; Khaleghpour K, 1999, MOL CELL BIOL, V19, P4302; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; MARES V, 1970, BRAIN RES, V23, P323, DOI 10.1016/0006-8993(70)90060-0; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; Northcott PA, 2009, CANCER RES, V69, P3249, DOI 10.1158/0008-5472.CAN-08-4710; Oliver TG, 2003, P NATL ACAD SCI USA, V100, P7331, DOI 10.1073/pnas.0832317100; Parathath SR, 2008, DEVELOPMENT, V135, P3291, DOI 10.1242/dev.022871; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Rios I, 2004, DEVELOPMENT, V131, P3159, DOI 10.1242/dev.01188; Rorick AM, 2007, DEV BIOL, V302, P477, DOI 10.1016/j.ydbio.2006.10.011; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Roux PP, 2007, J BIOL CHEM, V282, P14056, DOI 10.1074/jbc.M700906200; Ruggero D, 2004, NAT MED, V10, P484, DOI 10.1038/nm1042; Ruvinsky I, 2005, GENE DEV, V19, P2199, DOI 10.1101/gad.351605; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Sjostrom SK, 2005, DEV CELL, V9, P327, DOI 10.1016/j.devcel.2005.07.014; Uziel T, 2009, P NATL ACAD SCI USA, V106, P2812, DOI 10.1073/pnas.0809579106; Virshup DM, 2009, MOL CELL, V33, P537, DOI 10.1016/j.molcel.2009.02.015; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; vonManteuffel SR, 1997, MOL CELL BIOL, V17, P5426, DOI 10.1128/MCB.17.9.5426; Wallace VA, 1999, CURR BIOL, V9, P445, DOI 10.1016/S0960-9822(99)80195-X; Wechsler-Reya R, 2001, ANNU REV NEUROSCI, V24, P385, DOI 10.1146/annurev.neuro.24.1.385; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; Ye P, 1996, DEV BRAIN RES, V95, P44	57	25	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	15					1784	1797		10.1038/onc.2010.564	http://dx.doi.org/10.1038/onc.2010.564			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	749ZM	21339731	Green Accepted			2022-12-17	WOS:000289512200006
J	Meng, L; Hsu, JK; Tsai, RYL				Meng, L.; Hsu, J. K.; Tsai, R. Y. L.			GNL3L depletion destabilizes MDM2 and induces p53-dependent G2/M arrest	ONCOGENE			English	Article						colorectal carcinoma; G2/M arrest; GNL3L; MDM2; nucleostemin; p53	CELL-CYCLE ARREST; RIBOSOMAL-PROTEIN L23; STEM-CELLS; ACTIVATES P53; NUCLEOSTEMIN; DEGRADATION; INHIBITION; STABILIZES; PROLIFERATION; PROGRESSION	Guanine nucleotide binding protein-like 3-like (GNL3L) is a nucleolar protein and the vertebrate paralogue of nucleostemin (NS). We previously reported that nucleoplasmic mobilization of NS stabilizes MDM2 (mouse double minute 2). Here, we investigated the role of GNL3L as a novel MDM2 regulator. We found that GNL3L binds MDM2 in vivo and displays the same function as NS in stabilizing MDM2 protein and preventing its ubiquitylation. The interaction between GNL3L and MDM2 also takes place in the nucleoplasm. However, the MDM2 regulatory activity of GNL3L occurs constitutively and does not so much depend on the nucleolar release mechanism as NS does. GNL3L depletion triggers G2/M arrest in the p53-wild-type HCT116 cells more than in the p53-null cells, and upregulates specific p53 targets (that is, Bax, 14-3-3 sigma and p21) without affecting the ubiquitylation or stability of p53 proteins. The inhibitory activity of GNL3L on p53-mediated transcription correlates with the increased expression of GNL3L and reduced expression of 14-3-3 sigma and p21 in human gastrointestinal tumors. This work shows that in contrast to most nucleolar proteins that negatively control MDM2, GNL3L and NS are the only two that are designed to stabilize MDM2 protein under basal or induced condition, respectively, and may act as tumor-promoting genes. Oncogene (2011) 30, 1716-1726; doi:10.1038/onc.2010.550; published online 6 December 2010	[Meng, L.; Hsu, J. K.; Tsai, R. Y. L.] Texas A&M Hlth Sci Ctr, Alkek Inst Biosci & Technol, Ctr Canc & Stem Cell Biol, Houston, TX 77030 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Tsai, RYL (corresponding author), Texas A&M Hlth Sci Ctr, Alkek Inst Biosci & Technol, Ctr Canc & Stem Cell Biol, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	rtsai@ibt.tamhsc.edu	Hsu, Joseph Kuang-Wu/N-2847-2013	Tsai, Robert/0000-0002-8357-0812	NCI-PHS [R01 CA113750]; NATIONAL CANCER INSTITUTE [R01CA113750] Funding Source: NIH RePORTER	NCI-PHS; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We gratefully acknowledge Bert Vogelstein of the Johns Hopkins Oncology Center for providing the HCT116 cells. This work is supported by NCI-PHS grant R01 CA113750 to RY Tsai.	Baddoo M, 2003, J CELL BIOCHEM, V89, P1235, DOI 10.1002/jcb.10594; Beekman C, 2006, MOL CELL BIOL, V26, P9291, DOI 10.1128/MCB.01183-06; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Dai MS, 2008, MOL CELL BIOL, V28, P4365, DOI 10.1128/MCB.01662-07; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Fu D, 2007, MOL CELL, V28, P773, DOI 10.1016/j.molcel.2007.09.023; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Huang M, 2009, CANCER RES, V69, P3004, DOI 10.1158/0008-5472.CAN-08-3413; Jin A, 2004, MOL CELL BIOL, V24, P7669, DOI 10.1128/MCB.24.17.7669-7680.2004; Kubbutat MHG, 1999, CELL GROWTH DIFFER, V10, P87; Kurki S, 2004, CANCER CELL, V5, P465, DOI 10.1016/S1535-6108(04)00110-2; Ma HH, 2007, MOL BIOL CELL, V18, P2630, DOI 10.1091/mbc.E07-03-0244; Maki N, 2007, DEV DYNAM, V236, P941, DOI 10.1002/dvdy.21027; Meng LJ, 2007, MOL CELL BIOL, V27, P8670, DOI 10.1128/MCB.00635-07; Meng LJ, 2006, J CELL SCI, V119, P5124, DOI 10.1242/jcs.03292; Meng LJ, 2008, J CELL SCI, V121, P4037, DOI 10.1242/jcs.037952; Nikpour P, 2009, CELL PROLIFERAT, V42, P762, DOI 10.1111/j.1365-2184.2009.00635.x; Ohmura M, 2008, STEM CELLS, V26, P3237, DOI 10.1634/stemcells.2008-0506; Pederson T, 2009, J CELL BIOL, V184, P771, DOI 10.1083/jcb.200812014; Siddiqi S, 2008, CIRC RES, V103, P89, DOI 10.1161/CIRCRESAHA.107.169334; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Tsai RYL, 2009, INT J BIOCHEM CELL B, V41, P2122, DOI 10.1016/j.biocel.2009.05.020; Tsai RYL, 2002, GENE DEV, V16, P2991, DOI 10.1101/gad.55671; Wallace M, 2006, MOL CELL, V23, P251, DOI 10.1016/j.molcel.2006.05.029; Yasumoto H, 2007, J CELL SCI, V120, P2532, DOI 10.1242/jcs.009878; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003; Zhu QB, 2006, MOL CELL BIOL, V26, P9279, DOI 10.1128/MCB.00724-06; Zhu QB, 2009, J CELL BIOL, V185, P827, DOI 10.1083/jcb.200812121	30	25	31	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2011	30	14					1716	1726		10.1038/onc.2010.550	http://dx.doi.org/10.1038/onc.2010.550			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	746IS	21132010	Green Accepted			2022-12-17	WOS:000289239400009
J	He, X; Wang, J; Messing, EM; Wu, G				He, X.; Wang, J.; Messing, E. M.; Wu, G.			Regulation of receptor for activated C kinase 1 protein by the von Hippel-Lindau tumor suppressor in IGF-I-induced renal carcinoma cell invasiveness	ONCOGENE			English	Article						VHL; RACK1; IGF-I; renal cell carcinoma	GROWTH-FACTOR RECEPTOR; ALVEOLAR EPITHELIAL-CELLS; BETA-SUBUNIT; PHOSPHOINOSITIDE 3-KINASE; GENE-PRODUCT; INSULIN; RACK1; EXPRESSION; CANCER; IDENTIFICATION	von Hippel-Lindau (VHL) tumor suppressor loss is associated with renal cell carcinoma (RCC) pathogenesis. Meanwhile, aberrant activation of the insulin-like growth factor-I (IGF-I) signaling has been implicated in the development of highly invasive metastatic RCC. However, the link between VHL inactivation and RCC invasiveness is still unexplored. Here, we show that the receptor for activated C kinase 1 (RACK1) is a novel pVHLinteracting protein. pVHL competes with IGF-I receptor (IGF-IR) for binding to RACK1 thus potentially modulating the downstream IGF-I signal pathway. Upon IGFI stimulation, pVHL-deficient RCC cells exhibit increased RACK1/IGF-IR binding and increased IGF-IR tyrosine kinase activity. pVHL-deficient RCC cells also demonstrate elevated PI3K/Akt signaling and matrix metallo-proteinase-2 activity that culminates in enhanced cellular invasiveness, which can be partially suppressed by RACK1 small interfering RNA. Domain mapping analysis showed that the pVHL alpha-domain and the RACK1 WD 6-7 domains are critical for the interaction. Additionally, the RACK1 expression level is not regulated by pVHL expression status, suggesting that pVHL modifies RACK1 functions independent of the VHL/elongin E3 ubiquitin ligase complex. Our data indicate that RACK1 serves as a direct mediator between loss of pVHL function and enhanced IGF-IR signaling pathway in RCC. Oncogene (2011) 30, 535-547; doi: 10.1038/onc.2010.427; published online 27 September 2010	[He, X.; Messing, E. M.; Wu, G.] Univ Rochester, Med Ctr, Dept Urol, Rochester, NY 14642 USA; [Wang, J.] Univ Rochester, Med Ctr, Dept Pediat, Rochester, NY 14642 USA; [He, X.; Messing, E. M.; Wu, G.] Univ Rochester, Med Ctr, James P Wilmot Canc Ctr, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester	Wu, G (corresponding author), Univ Rochester, Med Ctr, Dept Urol, 601 Elmwood Ave, Rochester, NY 14642 USA.	guan_wu@urmc.rochester.edu			James P Wilmot Cancer Center	James P Wilmot Cancer Center	Funding: This work was supported in part by the James P Wilmot Cancer Center grant to X He.	Alberghini A, 2005, J BIOL CHEM, V280, P30120, DOI 10.1074/jbc.M500971200; Berns H, 2000, FASEB J, V14, P2549, DOI 10.1096/fj.99-1038com; Brader S, 2004, TUMORI J, V90, P2, DOI 10.1177/030089160409000102; Brodt P, 2001, J BIOL CHEM, V276, P33608, DOI 10.1074/jbc.M102754200; Brodt P, 2000, BIOCHEM PHARMACOL, V60, P1101, DOI 10.1016/S0006-2952(00)00422-6; Chang BY, 2002, ONCOGENE, V21, P7619, DOI 10.1038/sj.onc.1206002; Cohen HT, 2005, NEW ENGL J MED, V353, P2477, DOI 10.1056/NEJMra043172; Datta K, 2000, J BIOL CHEM, V275, P20700, DOI 10.1074/jbc.M909970199; Dunn SE, 1998, CANCER RES, V58, P3353; Dupont J, 2003, HORM METAB RES, V35, P740; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; Hansen WJ, 2002, MOL CELL BIOL, V22, P1947, DOI 10.1128/MCB.22.6.1947-1960.2002; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Kiely PA, 2005, J BIOL CHEM, V280, P7624, DOI 10.1074/jbc.M412889200; Koochekpour S, 1999, MOL CELL BIOL, V19, P5902; Kugler A, 1998, J UROLOGY, V160, P1914, DOI 10.1016/S0022-5347(01)62443-1; Kugler A, 1999, ANTICANCER RES, V19, P1589; Li ZB, 2002, BIOCHEM BIOPH RES CO, V294, P700, DOI 10.1016/S0006-291X(02)00534-X; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; Liu YV, 2007, MOL CELL, V25, P207, DOI 10.1016/j.molcel.2007.01.001; Long L, 1998, CANCER RES, V58, P3243; Loughran G, 2005, ONCOGENE, V24, P6185, DOI 10.1038/sj.onc.1208772; MACAULAY VM, 1992, BRIT J CANCER, V65, P311, DOI 10.1038/bjc.1992.65; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; McCahill A, 2002, MOL PHARMACOL, V62, P1261, DOI 10.1124/mol.62.6.1261; Min Y, 2005, GUT, V54, P591, DOI 10.1136/gut.2004.048926; MOCHLYROSEN D, 1995, BIOCHEM SOC T, V23, P596, DOI 10.1042/bst0230596; Motzer RJ, 2000, J UROLOGY, V163, P408, DOI 10.1016/S0022-5347(05)67889-5; Na X, 2003, EMBO J, V22, P4249, DOI 10.1093/emboj/cdg410; O'Connor R, 2003, HORM METAB RES, V35, P771; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; Rajala RVS, 2004, BIOCHEMISTRY-US, V43, P5637, DOI 10.1021/bi035913v; Rodriguez MM, 1999, BIOCHEMISTRY-US, V38, P13787, DOI 10.1021/bi991055k; Rosendahl A, 2004, INT J ONCOL, V25, P1327; Schips L, 2004, AM J CLIN PATHOL, V122, P931, DOI 10.1309/G7PY0RE7T86HQYV; Sekharam M, 2003, ANTICANCER RES, V23, P1517; Shaw LM, 2001, MOL CELL BIOL, V21, P5082, DOI 10.1128/MCB.21.15.5082-5093.2001; Stawowy P, 2004, BIOCHEM BIOPH RES CO, V321, P531, DOI 10.1016/j.bbrc.2004.07.001; Steele MR, 2001, CELL SIGNAL, V13, P507, DOI 10.1016/S0898-6568(01)00167-X; Tanno S, 2001, CANCER RES, V61, P589; Wang J, 2005, INFECT IMMUN, V73, P2766, DOI 10.1128/IAI.73.5.2766-2777.2005; Wang J, 2007, AM J PHYSIOL-LUNG C, V292, pL1495, DOI 10.1152/ajplung.00452.2006; Wang Y, 2005, MOL CANCER THER, V4, P1214, DOI 10.1158/1535-7163.MCT-05-0048; Yoon A, 2001, MOL CELL BIOCHEM, V223, P1, DOI 10.1023/A:1017549222677; Zagzag D, 2005, CANCER RES, V65, P6178, DOI 10.1158/0008-5472.CAN-04-4406; Zhang WZ, 2006, MOL CELL BIOL, V26, P413, DOI 10.1128/MCB.26.2.413-424.2006; Zhou MI, 2004, CANCER RES, V64, P1278, DOI 10.1158/0008-5472.CAN-03-0884	52	25	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	5					535	547		10.1038/onc.2010.427	http://dx.doi.org/10.1038/onc.2010.427			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	715WG	20871634				2022-12-17	WOS:000286922300003
J	Rugo, RE; Mutamba, JT; Mohan, KN; Yee, T; Chaillet, JR; Greenberger, JS; Engelward, BP				Rugo, R. E.; Mutamba, J. T.; Mohan, K. N.; Yee, T.; Chaillet, J. R.; Greenberger, J. S.; Engelward, B. P.			Methyltransferases mediate cell memory of a genotoxic insult	ONCOGENE			English	Article						epigenetics; memory; genomic instability; methyltransferase; bystander effect; persistent effects	DELAYED GENOMIC INSTABILITY; IONIZING-RADIATION; IN-VIVO; CHROMOSOMAL INSTABILITY; UNIRRADIATED CELLS; ALPHA-PARTICLES; DNA METHYLATION; BYSTANDER CELLS; EXPOSURE; DNMT1	Characterization of the direct effects of DNA-damaging agents shows how DNA lesions lead to specific mutations. Yet, serum from Hiroshima survivors, Chernobyl liquidators and radiotherapy patients can induce a clastogenic effect on naive cells, showing indirect induction of genomic instability that persists years after exposure. Such indirect effects are not restricted to ionizing radiation, as chemical genotoxins also induce heritable and transmissible genomic instability phenotypes. Although such indirect induction of genomic instability is well described, the underlying mechanism has remained enigmatic. Here, we show that mouse embryonic stem cells exposed to gamma-radiation bear the effects of the insult for weeks. Specifically, conditioned media from the progeny of exposed cells can induce DNA damage and homologous recombination in naive cells. Notably, cells exposed to conditioned media also elicit a genome-destabilizing effect on their neighbouring cells, thus demonstrating transmission of genomic instability. Moreover, we show that the underlying basis for the memory of an insult is completely dependent on two of the major DNA cytosine methyltransferases, Dnmt1 and Dnmt3a. Targeted disruption of these genes in exposed cells completely eliminates transmission of genomic instability. Furthermore, transient inactivation of Dnmt1, using a tet-suppressible allele, clears the memory of the insult, thus protecting neighbouring cells from indirect induction of genomic instability. We have thus demonstrated that a single exposure can lead to long-term, genome-destabilizing effects that spread from cell to cell, and we provide a specific molecular mechanism for these persistent bystander effects. Collectively, our results impact the current understanding of risks from toxin exposures and suggest modes of intervention for suppressing genomic instability in people exposed to carcinogenic genotoxins. Oncogene (2011) 30, 751-756; doi:10.1038/onc.2010.480; published online 8 November 2010	[Rugo, R. E.; Mutamba, J. T.; Yee, T.; Engelward, B. P.] MIT, Dept Biol Engn, Cambridge, MA 02139 USA; [Mohan, K. N.; Chaillet, J. R.] Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Pittsburgh, PA USA; [Greenberger, J. S.] Univ Pittsburgh, Inst Canc, Dept Radiat Oncol, Pittsburgh, PA USA	Massachusetts Institute of Technology (MIT); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Engelward, BP (corresponding author), MIT, Dept Biol Engn, 77 Massachusetts Ave,16-743, Cambridge, MA 02139 USA.	bevin@mit.edu			NIH [RO1-CA83876-8]; NIH/NIAID CMCR [U19 AI068021]; Department of Energy [DE-FG02-05ER64053]; NIEHS Center for Environmental Health Sciences [P30-ES002109]; TY; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD044133] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA083876] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI068021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES002109] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/NIAID CMCR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Energy(United States Department of Energy (DOE)); NIEHS Center for Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); TY; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank M Okano and E Li for MTase-deficient ES cells. This work was supported primarily by NIH Grant RO1-CA83876-8, NIH/NIAID CMCR U19 AI068021, with partial support from the Department of Energy DE-FG02-05ER64053. We thank the NIEHS Center for Environmental Health Sciences (P30-ES002109), the Cancer Research Center Flow Cytometry Facility and Debby Pheasant for technical support. We thank Benjamin Greenberger, Paavni Komanduri and Werner Olipitz for their contributions.; RER designed and performed all experiments with support from TY; KNM and JRC engineered the dox controllable Dnmt1 system and performed western analysis; BPE prepared the paper with support from JTM; BPE and JSG oversaw the study design. All authors discussed the results and commented on the paper.	Azzam EI, 2002, CANCER RES, V62, P5436; BENDER MA, 1962, RADIAT RES, V16, P44, DOI 10.2307/3571128; Borowczyk E, 2009, P NATL ACAD SCI USA, V106, P20806, DOI 10.1073/pnas.0905668106; Burr KL, 2010, RADIAT RES, V173, P760, DOI 10.1667/RR1937.1; CHANG WP, 1992, CARCINOGENESIS, V13, P923, DOI 10.1093/carcin/13.6.923; CHEN L, 1991, BIOCHEMISTRY-US, V30, P11018, DOI 10.1021/bi00110a002; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; Dickey JS, 2009, CARCINOGENESIS, V30, P1686, DOI 10.1093/carcin/bgp192; Dolinoy DC, 2006, ENVIRON HEALTH PERSP, V114, P567, DOI 10.1289/ehp.8700; Engelward BP, 1996, EMBO J, V15, P945, DOI 10.1002/j.1460-2075.1996.tb00429.x; Feng J, 2010, NAT NEUROSCI, V13, P423, DOI 10.1038/nn.2514; Friedberg E.C., 2006, DNA REPAIR MUTAGENES; Goldberg AD, 2007, CELL, V128, P635, DOI 10.1016/j.cell.2007.02.006; Goldberg Z, 2002, INT J ONCOL, V21, P337; Hermann A, 2004, CELL MOL LIFE SCI, V61, P2571, DOI 10.1007/s00018-004-4201-1; Hoeijmakers JHJ, 2009, NEW ENGL J MED, V361, P1475, DOI 10.1056/NEJMra0804615; Huang L, 2007, CANCER RES, V67, P1099, DOI 10.1158/0008-5472.CAN-06-3697; Huo LH, 2001, RADIAT RES, V156, P521, DOI 10.1667/0033-7587(2001)156[0521:HMIIBC]2.0.CO;2; KADHIM MA, 1992, NATURE, V355, P738, DOI 10.1038/355738a0; Kim M, 2004, NUCLEIC ACIDS RES, V32, P5742, DOI 10.1093/nar/gkh912; Koturbash I, 2006, ONCOGENE, V25, P4267, DOI 10.1038/sj.onc.1209467; Kovalchuk O, 2008, ENVIRON MOL MUTAGEN, V49, P16, DOI 10.1002/em.20361; Lei H, 1996, DEVELOPMENT, V122, P3195; Lewis DA, 2001, RADIAT RES, V156, P251, DOI 10.1667/0033-7587(2001)156[0251:PODDAN]2.0.CO;2; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Limoli CL, 1998, PHOTOCHEM PHOTOBIOL, V67, P233, DOI 10.1562/0031-8655(1998)067<0233:IOCAAD>2.3.CO;2; Little JB, 2003, ONCOGENE, V22, P6978, DOI 10.1038/sj.onc.1206988; LITTLE JB, 1990, INT J RADIAT ONCOL, V19, P1425, DOI 10.1016/0360-3016(90)90354-M; Lorimore SA, 2005, CANCER RES, V65, P5668, DOI 10.1158/0008-5472.CAN-05-0834; Lorimore SA, 2003, ONCOGENE, V22, P7058, DOI 10.1038/sj.onc.1207044; Maltseva DV, 2010, BIOCHEMISTRY-MOSCOW+, V75, P173, DOI 10.1134/S0006297910020070; Maxwell CA, 2008, CANCER RES, V68, P8304, DOI 10.1158/0008-5472.CAN-08-1212; Morgan WF, 2005, P NATL ACAD SCI USA, V102, P14127, DOI 10.1073/pnas.0507119102; Morgan WF, 2003, RADIAT RES, V159, P581, DOI 10.1667/0033-7587(2003)159[0581:NADEOE]2.0.CO;2; Mortusewicz O, 2005, P NATL ACAD SCI USA, V102, P8905, DOI 10.1073/pnas.0501034102; Mothersill C, 1998, INT J RADIAT BIOL, V74, P673, DOI 10.1080/095530098140934; Mothersill C, 2004, NAT REV CANCER, V4, P158, DOI 10.1038/nrc1277; Mothersill C, 2002, RADIAT PROT DOSIM, V99, P163, DOI 10.1093/oxfordjournals.rpd.a006752; Mothersill C, 2001, RADIAT RES, V155, P759, DOI 10.1667/0033-7587(2001)155[0759:RIBEPH]2.0.CO;2; Mothersill Carmel, 2006, Dose-Response, V4, P283, DOI 10.2203/dose-response.06-111.Mothersill; Mothersill C, 2007, ENVIRON SCI TECHNOL, V41, P3382, DOI 10.1021/es062978n; Mothersill Carmel, 2005, Med Confl Surviv, V21, P101, DOI 10.1080/13623690500073398; Nagar S, 2003, CANCER RES, V63, P324; NAGASAWA H, 1992, CANCER RES, V52, P6394; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Olive PL, 2006, NAT PROTOC, V1, P23, DOI 10.1038/nprot.2006.5; PAMPFER S, 1989, INT J RADIAT BIOL, V55, P85, DOI 10.1080/09553008914550091; PANT GS, 1977, HIROSHIMA J MED SCI, V26, P149; Rodier F, 2009, NAT CELL BIOL, V11, P1272, DOI 10.1038/ncb1009-1272a; Rugo RE, 2005, ONCOGENE, V24, P5016, DOI 10.1038/sj.onc.1208690; STEIN R, 1982, P NATL ACAD SCI-BIOL, V79, P61, DOI 10.1073/pnas.79.1.61; Tsumura A, 2006, GENES CELLS, V11, P805, DOI 10.1111/j.1365-2443.2006.00984.x; Watson GE, 2000, CANCER RES, V60, P5608; Yang G, 2008, RADIAT RES, V170, P372, DOI 10.1667/RR1324.1; Zhou HN, 2000, P NATL ACAD SCI USA, V97, P2099, DOI 10.1073/pnas.030420797	55	25	28	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	6					751	756		10.1038/onc.2010.480	http://dx.doi.org/10.1038/onc.2010.480			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	719GY	21057543	Green Accepted, Green Submitted			2022-12-17	WOS:000287192000011
J	DeCicco-Skinner, KL; Trovato, EL; Simmons, JK; Lepage, PK; Wiest, JS				DeCicco-Skinner, K. L.; Trovato, E. L.; Simmons, J. K.; Lepage, P. K.; Wiest, J. S.			Loss of tumor progression locus 2 (tpl2) enhances tumorigenesis and inflammation in two-stage skin carcinogenesis	ONCOGENE			English	Article						Tpl2; skin cancer; inflammation; MAP3K8; NF-kappa B	NF-KAPPA-B; PROTEIN-KINASE-C; NF-KAPPA-B1 P105; MOUSE SKIN; SIGNALING PATHWAYS; CANCER DEVELOPMENT; TRANSGENIC MICE; T-CELLS; IN-VIVO; ACTIVATION	Tumor progression locus 2 (Tpl2) is a serine/threonine kinase in the mitogen-activated protein kinase signal transduction cascade known to regulate inflammatory pathways. Previously identified as an oncogene, its mutation or overexpression is reported in a variety of human cancers. To address its role in skin carcinogenesis, Tpl2(-/-) or wild-type (WT) C57BL/6 mice were subjected to a two-stage dimethylbenzanthracene/12-O-tetradecanoylphorbol- 13-acetate (TPA) mouse skin carcinogenesis model. Tpl2(-/-) mice developed a significantly higher incidence of tumors (80%) than WT mice (17%), as well as a reduced tumor latency and a significantly higher number of total tumors (113 vs 6). Moreover, Tpl2(-/-) mice treated with TPA experienced significantly higher nuclear factor kappaB (NF-kappa B) activation, edema, infiltrating neutrophils and production of proinflammatory cytokines than did WT mice. We investigated the role of the p38, JNK, MEK and NF-kappa B signaling pathways both in vitro and in vivo in WT and Tpl2(-/-) mice by using inhibitors for each of these pathways. We confirmed that the proinflammatory effect in Tpl2(-/-) mice was due to heightened activity of the NF-kappa B pathway. These studies indicate that Tpl2 may serve more as a tumor suppressor than as an oncogene in chemically induced skin carcinogenesis, with its absence contributing to both tumorigenesis and inflammation. Oncogene (2011) 30, 389-397; doi: 10.1038/onc.2010.447; published online 11 October 2010	[DeCicco-Skinner, K. L.; Trovato, E. L.] NCI, Lab Canc Biol & Genet, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Trovato, E. L.; Simmons, J. K.; Lepage, P. K.; Wiest, J. S.] American Univ, Dept Biol, Washington, DC 20016 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); American University	Wiest, JS (corresponding author), NCI, Lab Canc Biol & Genet, Ctr Canc Res, NIH, 37 Convent Dr, Bethesda, MD 20892 USA.	wiestj@mail.nih.gov		DeCicco-Skinner, Kathleen/0000-0002-0256-5609	NCI/NIH; NATIONAL CANCER INSTITUTE [ZIABC011108] Funding Source: NIH RePORTER	NCI/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Jyotsna Pandey for her assistance with confocal microscopy. This work was supported by the NCI/NIH Intramural Research Program.	AOKI M, 1991, ONCOGENE, V6, P1515; Beinke S, 2004, MOL CELL BIOL, V24, P9658, DOI 10.1128/MCB.24.21.9658-9667.2004; Beinke S, 2003, MOL CELL BIOL, V23, P4739, DOI 10.1128/MCB.23.14.4739-4752.2003; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; BRUNDA MJ, 1993, J EXP MED, V178, P1223, DOI 10.1084/jem.178.4.1223; Cataisson C, 2005, J IMMUNOL, V174, P1686, DOI 10.4049/jimmunol.174.3.1686; Ceci JD, 1997, GENE DEV, V11, P688, DOI 10.1101/gad.11.6.688; Chiariello M, 2000, MOL CELL BIOL, V20, P1747, DOI 10.1128/MCB.20.5.1747-1758.2000; Clark AM, 2004, GENE CHROMOSOME CANC, V41, P99, DOI 10.1002/gcc.20069; Colombo MP, 1996, CANCER RES, V56, P2531; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; de Visser KE, 2006, NAT REV CANCER, V6, P24, DOI 10.1038/nrc1782; DIGIOVANNI J, 1984, CARCINOGENESIS, V5, P1493, DOI 10.1093/carcin/5.11.1493; Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5; Glick A, 2007, MOL CARCINOGEN, V46, P605, DOI 10.1002/mc.20345; Griner EM, 2007, NAT REV CANCER, V7, P281, DOI 10.1038/nrc2110; Hu YH, 2006, BIOORG MED CHEM LETT, V16, P6067, DOI 10.1016/j.bmcl.2006.08.102; Jansen AP, 2001, CANCER RES, V61, P808; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Kane LP, 2002, MOL CELL BIOL, V22, P5962, DOI 10.1128/MCB.22.16.5962-5974.2002; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kimura YN, 2007, CANCER SCI, V98, P2009, DOI 10.1111/j.1349-7006.2007.00633.x; Lichti U, 2008, NAT PROTOC, V3, P799, DOI 10.1038/nprot.2008.50; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; Mueller MM, 2006, EUR J CANCER, V42, P735, DOI 10.1016/j.ejca.2006.01.014; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; PATRIOTIS C, 1993, P NATL ACAD SCI USA, V90, P2251, DOI 10.1073/pnas.90.6.2251; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; Reddig PJ, 1999, CANCER RES, V59, P5710; RIJZEWIJK JJ, 1989, ACTA DERM-VENEREOL, V69, P512; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; Sharma SD, 2009, CARCINOGENESIS, V30, P1970, DOI 10.1093/carcin/bgp228; Sourvinos G, 1999, ONCOGENE, V18, P4968, DOI 10.1038/sj.onc.1202891; Sugimoto K, 2004, J CLIN INVEST, V114, P857, DOI 10.1172/JCI200420014; Sur I, 2008, INT REV IMMUNOL, V27, P205, DOI 10.1080/08830180802130319; TAHARA H, 1994, CANCER RES, V54, P182; Tomczak MF, 2006, J IMMUNOL, V176, P1244, DOI 10.4049/jimmunol.176.2.1244; Tsatsanis C, 2000, INT J MOL MED, V5, P583; Tsatsanis C, 1998, ONCOGENE, V17, P2609, DOI 10.1038/sj.onc.1202460; Tsatsanis C, 2008, P NATL ACAD SCI USA, V105, P2987, DOI 10.1073/pnas.0708381104; Van Acker GJD, 2007, J BIOL CHEM, V282, P22140, DOI 10.1074/jbc.M702225200; Velasco-Sampayo A, 2001, J IMMUNOL, V166, P6084, DOI 10.4049/jimmunol.166.10.6084; Watford WT, 2008, J EXP MED, V205, P2803, DOI 10.1084/jem.20081461; Yuspa SH, 1998, J DERMATOL SCI, V17, P1, DOI 10.1016/S0923-1811(97)00071-6	44	25	25	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	4					389	397		10.1038/onc.2010.447	http://dx.doi.org/10.1038/onc.2010.447			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711WH	20935675	Green Accepted			2022-12-17	WOS:000286621600002
J	He, H; Hua, X; Yan, J				He, H.; Hua, X.; Yan, J.			Epigenetic regulations in hematopoietic Hox code	ONCOGENE			English	Review						Hox code; epigenetic; hematopoiesis; leukemia; polycomb and trithorax groups	HISTONE METHYLTRANSFERASE ACTIVITY; HOMEOBOX GENE-EXPRESSION; DNA METHYLATION; DIFFERENTIAL EXPRESSION; RESPONSE ELEMENT; CELLULAR MEMORY; STEM-CELLS; MLL; POLYCOMB; PROTEIN	Hox genes encode DNA-binding proteins that are deployed in overlapping domains along various body axes during embryonic development. This sequential activation of Hox genes in temporal and spatial mode, the Hox code, is critical for the proper positioning of segmented structures along those axes, which include the vertebrate, limbs and, also digestive and reproductive tracts. It remains unknown how Hox genes are regulated to determine the identity of hematopoietic stem cells and their derivatives, which migrate and express most Hox genes. The key questions are whether the hematopoietic system has an axis, how epigenetic mechanisms restrict expression of Hox genes to specific cell types and what role Hox genes play in leukemic transformation? Taking in account these questions, we propose a combinatorial axial model of hematopoietic Hox code to predict the positional identity of the hematopoietic cells. This model will provide new insight into epigenetic therapy in leukemia. Oncogene (2011) 30, 379-388; doi:10.1038/onc.2010.484; published online 25 October 2010	[He, H.; Yan, J.] Shanghai Ocean Univ, Inst Marine Biosyst & Neurosci, Coll Fisheries & Life Sci, Dept Hydrobiol, Shanghai 201306, Peoples R China; [Hua, X.] Univ Penn, Abramson Family Canc Res Inst, Dept Canc Biol, Philadelphia, PA 19104 USA	Shanghai Ocean University; University of Pennsylvania; Pennsylvania Medicine	Yan, J (corresponding author), Shanghai Ocean Univ, Inst Marine Biosyst & Neurosci, Coll Fisheries & Life Sci, Dept Hydrobiol, 999 Hucheng Huan Rd, Shanghai 201306, Peoples R China.	jyan2@shou.edu.cn		Yan, Jizhou/0000-0001-7482-7842	Shanghai Ocean University [A2302100002]; Shanghai Leading Academic Discipline Project [S30701]	Shanghai Ocean University; Shanghai Leading Academic Discipline Project(Shanghai Leading Academic Discipline Project)	We apologize to authors whose work has not been cited here owing to the stringent limit of space and our knowledge. We thank Shivani Sethi's assistance in editing the manuscript. This work was supported by the International Cooperation Initiative Program of Shanghai Ocean University (A2302100002) and the Shanghai Leading Academic Discipline Project (S30701).	Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907; Akbas GE, 2004, J MOL BIOL, V340, P1013, DOI 10.1016/j.jmb.2004.05.052; Akin ZN, 2005, CELL MOL NEUROBIOL, V25, P697, DOI 10.1007/s10571-005-3971-9; Amores A, 1998, SCIENCE, V282, P1711, DOI 10.1126/science.282.5394.1711; Arderiu G, 2007, CELL ADHES MIGR, V1, P185, DOI 10.4161/cam.1.4.5448; Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9; Bel-Vialar S, 2002, DEVELOPMENT, V129, P5103; Bullinger L, 2010, CANCER CELL, V17, P1, DOI 10.1016/j.ccr.2009.12.033; Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001; Cao R, 2004, MOL CELL, V15, P57, DOI 10.1016/j.molcel.2004.06.020; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; CELETTI A, 1993, INT J CANCER, V53, P237, DOI 10.1002/ijc.2910530211; Chambeyron S, 2004, GENE DEV, V18, P1119, DOI 10.1101/gad.292104; Chen YX, 2006, P NATL ACAD SCI USA, V103, P1018, DOI 10.1073/pnas.0510347103; Davidson AJ, 2003, NATURE, V425, P300, DOI 10.1038/nature01973; Dejardin J, 2004, EMBO J, V23, P857, DOI 10.1038/sj.emboj.7600108; Dellino GI, 2004, MOL CELL, V13, P887, DOI 10.1016/S1097-2765(04)00128-5; Deschamps J, 2005, DEVELOPMENT, V132, P2931, DOI 10.1242/dev.01897; Dillon SC, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-8-227; Dobson CL, 1999, EMBO J, V18, P3564, DOI 10.1093/emboj/18.13.3564; Duboule D, 2004, DEV CELL, V6, P738, DOI 10.1016/j.devcel.2004.05.016; DUBOULE D, 1994, TRENDS GENET, V10, P358, DOI 10.1016/0168-9525(94)90132-5; Erfurth FE, 2008, P NATL ACAD SCI USA, V105, P7517, DOI 10.1073/pnas.0800090105; Ernst P, 2004, CURR BIOL, V14, P2063, DOI 10.1016/j.cub.2004.11.012; Esteller M, 2006, CARCINOGENESIS, V27, P1121, DOI 10.1093/carcin/bgl033; Faber J, 2009, BLOOD, V113, P2375, DOI 10.1182/blood-2007-09-113597; FAIELLA A, 1994, P NATL ACAD SCI USA, V91, P5335, DOI 10.1073/pnas.91.12.5335; Felsenfeld G, 2004, COLD SPRING HARB SYM, V69, P245, DOI 10.1101/sqb.2004.69.245; Francis NJ, 2004, SCIENCE, V306, P1574, DOI 10.1126/science.1100576; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; Garcia-Fernandez J, 2005, HEREDITY, V94, P145, DOI 10.1038/sj.hdy.6800621; Gaufo GO, 2003, DEVELOPMENT, V130, P5191, DOI 10.1242/dev.00730; Gaunt SJ, 2004, INT J DEV BIOL, V48, P613, DOI 10.1387/ijdb.041829sg; Gaunt SJ, 2008, DEVELOPMENT, V135, P2511, DOI 10.1242/dev.015909; Geisen MJ, 2008, PLOS BIOL, V6, P1178, DOI 10.1371/journal.pbio.0060142; Grier DG, 2005, J PATHOL, V205, P154, DOI 10.1002/path.1710; Gruss P, 1991, CURR OPIN GENET DEV, V1, P204, DOI 10.1016/S0959-437X(05)80071-1; Guo YL, 2003, STEM CELLS, V21, P15, DOI 10.1634/stemcells.21-1-15; GUTMAN A, 1994, MOL CELL BIOL, V14, P8143, DOI 10.1128/MCB.14.12.8143; Hazzalin CA, 2005, PLOS BIOL, V3, P2111, DOI 10.1371/journal.pbio.0030393; Hess JL, 2004, TRENDS MOL MED, V10, P500, DOI 10.1016/j.molmed.2004.08.005; Hughes CM, 2004, MOL CELL, V13, P587, DOI 10.1016/S1097-2765(04)00081-4; Huynh HD, 2008, STEM CELLS, V26, P1628, DOI 10.1634/stemcells.2008-0064; Jackson JP, 2002, NATURE, V416, P556, DOI 10.1038/nature731; Jackson JP, 2004, CHROMOSOMA, V112, P308, DOI 10.1007/s00412-004-0275-7; Johnson JJ, 2003, BLOOD, V101, P3229, DOI 10.1182/blood-2002-05-1515; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; Kmita M, 2000, NAT GENET, V26, P451, DOI 10.1038/82593; Kmita M, 2003, SCIENCE, V301, P331, DOI 10.1126/science.1085753; KNITTEL T, 1995, DEVELOPMENT, V121, P1077; Kobrossy L, 2006, J BIOL CHEM, V281, P25926, DOI 10.1074/jbc.M602555200; Kondo T, 1998, MOL CELL, V1, P289, DOI 10.1016/S1097-2765(00)80029-5; Kouskouti A, 2005, EMBO J, V24, P347, DOI 10.1038/sj.emboj.7600516; Kumar AR, 2004, BLOOD, V103, P1823, DOI 10.1182/blood-2003-07-2582; Kwan CT, 2001, DEV BIOL, V232, P176, DOI 10.1006/dbio.2001.0157; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Lawrence HJ, 1996, STEM CELLS, V14, P281, DOI 10.1002/stem.140281; Lee JH, 2005, J BIOL CHEM, V280, P41725, DOI 10.1074/jbc.M508312200; Lehoczky JA, 2004, EVOL DEV, V6, P423, DOI 10.1111/j.1525-142X.2004.04050.x; Leroy P, 2004, J LEUKOCYTE BIOL, V75, P680, DOI 10.1189/jlb.0503246; Linggi BE, 2005, J CELL BIOCHEM, V96, P938, DOI 10.1002/jcb.20604; Lohnes D, 2003, BIOESSAYS, V25, P971, DOI 10.1002/bies.10340; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Mace KA, 2005, J CELL SCI, V118, P2567, DOI 10.1242/jcs.02399; Magli MC, 1997, J CELL PHYSIOL, V173, P168, DOI 10.1002/(SICI)1097-4652(199711)173:2<168::AID-JCP16>3.0.CO;2-C; Manley NR, 1998, DEV BIOL, V195, P1, DOI 10.1006/dbio.1997.8827; Manley NR, 1997, DEV BIOL, V192, P274, DOI 10.1006/dbio.1997.8765; Manzanares M, 2001, DEVELOPMENT, V128, P3595; Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761; Mathieu O, 2005, EMBO J, V24, P2783, DOI 10.1038/sj.emboj.7600743; Maves L, 2005, DEV BIOL, V285, P593, DOI 10.1016/j.ydbio.2005.07.015; Milne TA, 2005, P NATL ACAD SCI USA, V102, P749, DOI 10.1073/pnas.0408836102; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; Monge I, 2003, DEV BIOL, V256, P212, DOI 10.1016/S0012-1606(02)00136-7; Morgan R, 2008, INT J HEMATOL, V87, P246, DOI 10.1007/s12185-008-0057-8; Muller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; Nowling T, 1999, DEV BIOL, V208, P134, DOI 10.1006/dbio.1998.9189; Oosterveen T, 2003, J BIOL CHEM, V278, P24103, DOI 10.1074/jbc.M300774200; Oosterveen T, 2003, EMBO J, V22, P262, DOI 10.1093/emboj/cdg029; Owens BM, 2002, STEM CELLS, V20, P364, DOI 10.1634/stemcells.20-5-364; Pineault N, 2002, EXP HEMATOL, V30, P49, DOI 10.1016/S0301-472X(01)00757-3; Popovic R, 2005, J CELL BIOCHEM, V95, P234, DOI 10.1002/jcb.20430; POPPERL H, 1992, EMBO J, V11, P3673, DOI 10.1002/j.1460-2075.1992.tb05452.x; PUSCHEL AW, 1991, DEVELOPMENT, V112, P279; Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907; Rinn JL, 2006, PLOS GENET, V2, P1084, DOI 10.1371/journal.pgen.0020119; Roelen BAJ, 2002, MECH DEVELOP, V119, P81, DOI 10.1016/S0925-4773(02)00329-5; Saurin AJ, 2001, NATURE, V412, P655, DOI 10.1038/35088096; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; Shao ZH, 1999, CELL, V98, P37, DOI 10.1016/S0092-8674(00)80604-2; Sharpe J, 1998, EMBO J, V17, P1788, DOI 10.1093/emboj/17.6.1788; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; SORENSEN PHB, 1994, J CLIN INVEST, V93, P429, DOI 10.1172/JCI116978; Spirov AV, 2002, NUCLEIC ACIDS RES, V30, P351, DOI 10.1093/nar/30.1.351; Spitz F, 2003, CELL, V113, P405, DOI 10.1016/S0092-8674(03)00310-6; Suemori H, 2000, DEV BIOL, V220, P333, DOI 10.1006/dbio.2000.9651; Tabaries S, 2005, MOL CELL BIOL, V25, P1389, DOI 10.1128/MCB.25.4.1389-1401.2005; Taghon T, 2003, LEUKEMIA, V17, P1157, DOI 10.1038/sj.leu.2402947; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; Terranova R, 2006, P NATL ACAD SCI USA, V103, P6629, DOI 10.1073/pnas.0507425103; Thiel AT, 2010, CANCER CELL, V17, P148, DOI 10.1016/j.ccr.2009.12.034; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Vasanthi D, 2008, J GENET GENOMICS, V35, P413, DOI 10.1016/S1673-8527(08)60059-4; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Wang KC, 2009, TRENDS CELL BIOL, V19, P268, DOI 10.1016/j.tcb.2009.03.007; Wang L, 2004, MOL CELL, V14, P637, DOI 10.1016/j.molcel.2004.05.009; Wei J, 2008, CANCER CELL, V13, P483, DOI 10.1016/j.ccr.2008.04.020; West AG, 2002, GENE DEV, V16, P271, DOI 10.1101/gad.954702; Yan JZ, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000047; Yan JZ, 2006, MOL CELL BIOL, V26, P155, DOI 10.1128/MCB.26.1.155-168.2006; Yokoyama A, 2004, MOL CELL BIOL, V24, P5639, DOI 10.1128/MCB.24.13.5639-5649.2004; Yokoyama A, 2005, CELL, V123, P207, DOI 10.1016/j.cell.2005.09.025; Yokoyama A, 2010, CANCER CELL, V17, P198, DOI 10.1016/j.ccr.2009.12.040; Yu BD, 1998, P NATL ACAD SCI USA, V95, P10632, DOI 10.1073/pnas.95.18.10632; Zaret KS, 2008, COLD SH Q B, V73, P119, DOI 10.1101/sqb.2008.73.040; Zhou JM, 2004, MOL CELL, V16, P500, DOI 10.1016/S1097-2765(04)00680-X	122	25	28	0	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	4					379	388		10.1038/onc.2010.484	http://dx.doi.org/10.1038/onc.2010.484			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711WH	20972460				2022-12-17	WOS:000286621600001
J	Nitta, RT; Del Vecchio, CA; Chu, AH; Mitra, SS; Godwin, AK; Wong, AJ				Nitta, R. T.; Del Vecchio, C. A.; Chu, A. H.; Mitra, S. S.; Godwin, A. K.; Wong, A. J.			The role of the c-Jun N-terminal kinase 2-alpha-isoform in non-small cell lung carcinoma tumorigenesis	ONCOGENE			English	Article						NSCLC; JNK; STAT3; MAPK	SERINE PHOSPHORYLATION; NH2-TERMINAL KINASE; SIGNAL TRANSDUCER; TUMOR-GROWTH; CANCER CELLS; STAT3; ACTIVATION; PATHWAY; ONCOGENE; JNK	The c-Jun N-terminal kinases (JNKs) are members of the mitogen-activated protein kinase family and have been implicated in tumorigenesis. One isoform in particular, JNK2 alpha, has been shown to be frequently activated in primary brain tumors, to enhance several tumorigenic phenotypes and to increase tumor formation in mice. As JNK is frequently activated in non-small cell lung carcinoma (NSCLC), we investigated the role of the JNK2 alpha isoform in NSCLC formation by examining its expression in primary tumors and by modulating its expression in cultured cell lines. We discovered that 60% of the tested primary NSCLC tumors had three-fold higher JNK2 protein and two-to three-fold higher JNK2 alpha mRNA expression than normal lung control tissue. To determine the importance of JNK2 alpha in NSCLC progression, we reduced JNK2 alpha expression in multiple NSCLC cell lines using short hairpin RNA. Cell lines deficient in JNK2 alpha had decreased cellular growth and anchorage-independent growth, and the tumors were four-fold smaller in mass. To elucidate the mechanism by which JNK2 alpha induces NSCLC growth, we analyzed the JNK substrate, signal transducer and activator of transcription 3 (STAT3). Our data demonstrates for the first time that JNK2 alpha can regulate the transcriptional activity of STAT3 by phosphorylating the Ser727 residue, thereby regulating the expression of oncogenic genes, such as c-Myc. Furthermore, reintroduction of JNK2 alpha 2 or STAT3 restored the tumorigenicity of the NSCLC cells, demonstrating that JNK2 alpha is important for NSCLC progression. Our studies reveal a novel mechanism in which phosphorylation of STAT3 is mediated by a constitutively active JNK2 isoform, JNK2 alpha. Oncogene (2011) 30, 234-244; doi: 10.1038/onc.2010.414; published online 27 September 2010	[Wong, A. J.] Stanford Univ, Med Ctr, Dept Neurosurg, Canc Biol Program,Sch Med, Stanford, CA 94305 USA; [Del Vecchio, C. A.; Wong, A. J.] Stanford Univ, Sch Med, Canc Biol Grad Program, Stanford, CA 94305 USA; [Godwin, A. K.] Fox Chase Canc Ctr, Dept Med Oncol, Womens Canc Program, Philadelphia, PA 19111 USA	Stanford University; Stanford University; Fox Chase Cancer Center	Wong, AJ (corresponding author), Stanford Univ, Med Ctr, Dept Neurosurg, Canc Biol Program,Sch Med, 300 Pasteur Dr,Edwards R221, Stanford, CA 94305 USA.	ajwong@stanford.edu			Mark Linder/American Brain Tumor Association; NIH [CA69495, CA124832]; National Brain Tumor Foundation; NATIONAL CANCER INSTITUTE [R01CA096539, R01CA124832, R01CA069495, P30CA124435] Funding Source: NIH RePORTER	Mark Linder/American Brain Tumor Association; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Brain Tumor Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Emily Piccione, Shawn Badal, Tiffany Lieu and Marina Holgado-Madruga for their useful discussions and critical review of the paper. This work was supported by the Mark Linder/American Brain Tumor Association Fellowship, NIH grants CA69495 and CA124832 and a research grant from the National Brain Tumor Foundation.	Achcar RDD, 2007, ARCH PATHOL LAB MED, V131, P1350; Alvarez JV, 2006, CANCER RES, V66, P3162, DOI 10.1158/0008-5472.CAN-05-3757; Arbour N, 2002, J EXP MED, V195, P801, DOI 10.1084/jem.20011481; Berner JM, 1999, GENE CHROMOSOME CANC, V26, P151, DOI 10.1002/(SICI)1098-2264(199910)26:2<151::AID-GCC7>3.3.CO;2-1; Bhattacharya S, 2005, BIOCHEM J, V392, P335, DOI 10.1042/BJ20050465; Bode AM, 2007, MOL CARCINOGEN, V46, P591, DOI 10.1002/mc.20348; Bogoyevitch MA, 2008, BBA-PROTEINS PROTEOM, V1784, P76, DOI 10.1016/j.bbapap.2007.09.013; Bogoyevitch MA, 2006, BIOESSAYS, V28, P923, DOI 10.1002/bies.20458; BROERS JLV, 1993, AM J RESP CELL MOL, V9, P33, DOI 10.1165/ajrcmb/9.1.33; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Butterfield L, 1997, J BIOL CHEM, V272, P10110; Chen NY, 2001, CANCER RES, V61, P3908; Cheng A, 2002, DEV CELL, V2, P497, DOI 10.1016/S1534-5807(02)00149-1; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Cui J, 2005, J BIOL CHEM, V280, P9913, DOI 10.1074/jbc.M412165200; Ford J, 2008, CELL CYCLE, V7, P3091, DOI 10.4161/cc.7.19.6799; GAO SP, 2006, SCI STKE, pPE30; GAZZERI S, 1994, INT J CANCER, V58, P24, DOI 10.1002/ijc.2910580106; Gough DJ, 2009, SCIENCE, V324, P1713, DOI 10.1126/science.1171721; Haura EB, 2005, CLIN CANCER RES, V11, P8288, DOI 10.1158/1078-0432.CCR-05-0827; Khatlani TS, 2007, ONCOGENE, V26, P2658, DOI 10.1038/sj.onc.1210050; Kortylewski M, 2005, CANCER METAST REV, V24, P315, DOI 10.1007/s10555-005-1580-1; Lee C, 2008, CANCER RES, V68, P8661, DOI 10.1158/0008-5472.CAN-08-1082; Lee SO, 2004, PROSTATE, V60, P178, DOI 10.1002/pros.20045; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; Lufei C, 2007, ONCOGENE, V26, P7656, DOI 10.1038/sj.onc.1210567; Maeda S, 2003, CANCER CELL, V3, P102, DOI 10.1016/S1535-6108(03)00025-4; Nitta RT, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000963; Nitta RT, 2006, MOL CELL BIOL, V26, P5360, DOI 10.1128/MCB.02464-05; Nitta R, 2008, NAT STRUCT MOL BIOL, V15, P1067, DOI 10.1038/nsmb.1487; Oleinik NV, 2007, ONCOGENE, V26, P7222, DOI 10.1038/sj.onc.1210526; Onishi A, 2008, EXP CELL RES, V314, P377, DOI 10.1016/j.yexcr.2007.09.018; Potapova O, 2000, J BIOL CHEM, V275, P24767, DOI 10.1074/jbc.M904591199; Qin HR, 2008, CANCER RES, V68, P7736, DOI 10.1158/0008-5472.CAN-08-1125; Rapp UR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006029; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; Shair KHY, 2007, PLOS PATHOG, V3, P1669, DOI 10.1371/journal.ppat.0030166; Tang Gu-Sheng, 2006, Ai Zheng, V25, P269; Tsuiki H, 2003, CANCER RES, V63, P250; Weerasinghe P, 2007, INT J ONCOL, V31, P129; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wu XM, 2008, CELL, V133, P340, DOI 10.1016/j.cell.2008.01.052; Xie W, 1997, ANTICANCER RES, V17, P2627; Xu X, 1996, ONCOGENE, V13, P135; Yakut T, 2003, LUNG, V181, P245, DOI 10.1007/s00408-003-1026-x; Yang YM, 2003, CLIN CANCER RES, V9, P391; YEAGER T, 1995, CANCER RES, V55, P493; Yeh HH, 2009, DNA CELL BIOL, V28, P131, DOI 10.1089/dna.2008.0762; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; Zhang XL, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-149	50	25	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	2					234	244		10.1038/onc.2010.414	http://dx.doi.org/10.1038/onc.2010.414			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709LG	20871632	Green Accepted			2022-12-17	WOS:000286438900011
J	Haller, BK; Brave, A; Wallgard, E; Roswall, P; Sunkari, VG; Mattson, U; Hallengard, D; Catrina, SB; Hellstrom, M; Pietras, K				Haller, B. K.; Brave, A.; Wallgard, E.; Roswall, P.; Sunkari, V. G.; Mattson, U.; Hallengard, D.; Catrina, S-B; Hellstrom, M.; Pietras, K.			Therapeutic efficacy of a DNA vaccine targeting the endothelial tip cell antigen delta-like ligand 4 in mammary carcinoma	ONCOGENE			English	Article						angiogenesis; DNA vaccination; breast cancer; Delta-like ligand 4; endothelial tip cell	INHIBITS TUMOR-GROWTH; CANCER VACCINES; DLL4; ANGIOGENESIS; BLOCKADE; EXPRESSION; CHALLENGE; PROTECTS; TRIAL; COLON	The Notch ligand delta-like ligand 4 (DLL4) is an essential component expressed by endothelial tip cells during angiogenic sprouting. We have described a conceptually novel therapeutic strategy for targeting tumor angiogenesis and endothelial tip cells based on DNA vaccination against DLL4. Immunization with DLL4-encoding plasmid DNA by in vivo electroporation severely retarded the growth of orthotopically implanted mammary carcinomas in mice by induction of a nonproductive angiogenic response. Mechanistically, vaccination brought about a break in tolerance against the self-antigen, DLL4, as evidenced by the production of inhibitory and inherently therapeutic antibodies against mouse DLL4. Importantly, no evidence for a delayed wound healing response, or for toxicity associated with pharmacological blockade of DLL4 signaling, was noted in mice immunized with the DLL4 vaccine. We have thus developed a well-tolerated DNA vaccination strategy targeting the endothelial tip cells and the antigen DLL4 with proven therapeutic efficacy in mouse models of mammary carcinoma; a disease that has been reported to dramatically induce the expression of DLL4. Conceivably, induction of immunity toward principal mediators of pathological angiogenesis could provide protection against recurrent malignant disease in the adjuvant setting. Oncogene (2010) 29, 4276-4286; doi: 10.1038/onc.2010.176; published online 24 May 2010	[Wallgard, E.; Roswall, P.; Pietras, K.] Karolinska Inst, Div Vasc Biol, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden; [Haller, B. K.; Brave, A.; Hallengard, D.] Swedish Inst Infect Dis Control, Dept Virol, Stockholm, Sweden; [Haller, B. K.; Brave, A.; Hallengard, D.] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, SE-17177 Stockholm, Sweden; [Sunkari, V. G.; Catrina, S-B] Karolinska Inst, Dept Mol Med & Surg, SE-17177 Stockholm, Sweden; [Mattson, U.; Hellstrom, M.] Bioinvent Int, Lund, Sweden	Karolinska Institutet; Swedish Institute for Infectious Disease Control; Karolinska Institutet; Karolinska Institutet	Pietras, K (corresponding author), Karolinska Inst, Div Vasc Biol, Dept Med Biochem & Biophys, House A4,Level 4,Scheeles Vag 2, SE-17177 Stockholm, Sweden.	kristian.pietras@ki.se	Pietras, Kristian/ABG-2097-2021; Pietras, Kristian/ABE-8727-2020	Pietras, Kristian/0000-0001-6738-4705; Haller, Kristian/0000-0002-9060-0928; Catrina, Sergiu/0000-0002-6914-3902; Sunkari, Vivekananda/0000-0003-4599-5120; Hellstrom, Mats/0000-0002-7088-9533	Swedish Cancer Society; Swedish Research Council; Karolinska Institutet Cancer network; Ake Wiberg's foundation; Jeansson's foundation; Swedish National Board of Health and Welfare; Alex and Eva Wallstrom foundation; Magn. Bergvall foundation; Karolinska Institute Research foundations	Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Karolinska Institutet Cancer network; Ake Wiberg's foundation; Jeansson's foundation; Swedish National Board of Health and Welfare; Alex and Eva Wallstrom foundation; Magn. Bergvall foundation; Karolinska Institute Research foundations(Karolinska Institutet)	We are grateful to Cyto Pulse Sciences, Inc., Glen Burnie, MD, USA for providing the technology for in vivo electroporation. This study was supported by grants to KP from the Swedish Cancer Society (Young Investigator Award and project grant), the Swedish Research Council (including a Linnaeus grant for the STARGET consortium), by a strategic grant from the Karolinska Institutet Cancer network, Ake Wiberg's foundation and Jeansson's foundation. BKH recieved support from the The Swedish National Board of Health and Welfare, The Alex and Eva Wallstrom foundation, The Magn. Bergvall foundation and Karolinska Institute Research foundations.	Ayyanan A, 2006, P NATL ACAD SCI USA, V103, P3799, DOI 10.1073/pnas.0600065103; Bergman PJ, 2003, CLIN CANCER RES, V9, P1284; Botusan IR, 2008, P NATL ACAD SCI USA, V105, P19426, DOI 10.1073/pnas.0805230105; Davis BS, 2001, J VIROL, V75, P4040, DOI 10.1128/JVI.75.9.4040-4047.2001; Hellstrom M, 2007, NATURE, V445, P776, DOI 10.1038/nature05571; Hoey T, 2009, CELL STEM CELL, V5, P168, DOI 10.1016/j.stem.2009.05.019; Holmgren L, 2006, P NATL ACAD SCI USA, V103, P9208, DOI 10.1073/pnas.0603110103; Jones S, 2009, VACCINE, V27, P2506, DOI 10.1016/j.vaccine.2009.02.061; Jubb AM, 2009, BRIT J CANCER, V101, P1749, DOI 10.1038/sj.bjc.6605368; Jubb AM, 2010, AM J PATHOL, V176, P2019, DOI 10.2353/ajpath.2010.090908; Kaplan CD, 2006, VACCINE, V24, P6994, DOI 10.1016/j.vaccine.2006.04.071; Li JL, 2007, CANCER RES, V67, P11244, DOI 10.1158/0008-5472.CAN-07-0969; Liu MA, 2006, HUM GENE THER, V17, P1051, DOI 10.1089/hum.2006.17.1051; Niethammer AG, 2002, NAT MED, V8, P1369, DOI 10.1038/nm794; Noguera-Troise I, 2006, NATURE, V444, P1032, DOI 10.1038/nature05355; Patel NS, 2005, CANCER RES, V65, P8690, DOI 10.1158/0008-5472.CAN-05-1208; Pejawar-Gaddy S, 2008, CRIT REV ONCOL HEMAT, V67, P93, DOI 10.1016/j.critrevonc.2008.02.010; Plum SM, 2004, IMMUNOPHARM IMMUNOT, V26, P29, DOI 10.1081/IPH-120029942; Pourgholami Mohammad H., 2008, Cardiovascular & Hematological Agents in Medicinal Chemistry, V6, P343, DOI 10.2174/187152508785909528; Ridgway J, 2006, NATURE, V444, P1083, DOI 10.1038/nature05313; Scehnet JS, 2007, BLOOD, V109, P4753, DOI 10.1182/blood-2006-12-063933; Schlom J, 2007, CLIN CANCER RES, V13, P3776, DOI 10.1158/1078-0432.CCR-07-0588; Segarra M, 2008, BLOOD, V112, P1904, DOI 10.1182/blood-2007-11-126045; Suchting S, 2007, P NATL ACAD SCI USA, V104, P3225, DOI 10.1073/pnas.0611177104; Ullenhag GJ, 2004, CLIN CANCER RES, V10, P3273, DOI 10.1158/1078-0432.CCR-03-0706; Wei WZ, 1999, INT J CANCER, V81, P748, DOI 10.1002/(SICI)1097-0215(19990531)81:5<748::AID-IJC14>3.0.CO;2-6; Yan MH, 2010, NATURE, V463, pE6, DOI 10.1038/nature08751	27	25	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2010	29	30					4276	4286		10.1038/onc.2010.176	http://dx.doi.org/10.1038/onc.2010.176			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	633ZV	20498640				2022-12-17	WOS:000280547900004
J	Liddiard, K; Hills, R; Burnett, AK; Darley, RL; Tonks, A				Liddiard, K.; Hills, R.; Burnett, A. K.; Darley, R. L.; Tonks, A.			OGG1 is a novel prognostic indicator in acute myeloid leukaemia	ONCOGENE			English	Article						OGG1; acute myeloid leukaemia; prognosis; DNA repair	ACUTE MYELOGENOUS LEUKEMIA; DNA GLYCOSYLASE; EMBRYONIC LETHALITY; PROGENITOR CELLS; EXPRESSION; GENE; DAMAGE; REPAIR; FUSION; AML1-ETO	OGG1 (8-oxoguanine DNA glycosylase) constitutes a key component of the DNA base excision repair pathway, catalysing the removal of 8-oxoguanine nucleotides from DNA, thereby suppressing mutagenesis and cell death. We found that OGG1 expression was significantly downregulated by the RUNX1-ETO fusion protein product of the t(8;21) chromosome translocation in normal haematopoietic progenitor cells and in patients with acute myeloid leukaemia (AML). Further examination of OGG1 expression in 174 AML trial patients using Affymetrix microarrays showed that the prevalence rate of OGG1 expression was 33% and correlated strongly with adverse cytogenetics. OGG1-expressing patients had a worse relapse-free survival and overall survival and an increased risk of relapse at 5-years of follow-up. There remained a trend towards increased relapse rate among OGG1-expressing patients, even after adjusting for other known risk factors in comprehensive stratified analyses. We also determined a trend for OGG1 expression to have a more adverse impact on disease outcome in the context of the FLT3-ITD mutation. This study highlights OGG1 as a valuable prognostic marker that could be used to sub-stratify AML patients to predict those likely to fail conventional chemotherapies but those likely to benefit from novel therapeutic approaches that modulate DNA repair activity. Oncogene (2010) 29, 2005-2012; doi:10.1038/onc.2009.462; published online 21 December 2009	[Liddiard, K.; Hills, R.; Burnett, A. K.; Darley, R. L.; Tonks, A.] Cardiff Univ, Sch Med, Dept Haematol, Cardiff CF14 4XN, S Glam, Wales	Cardiff University	Tonks, A (corresponding author), Cardiff Univ, Sch Med, Dept Haematol, Cardiff CF14 4XN, S Glam, Wales.	tonksa@cf.ac.uk	DARLEY, RICHARD/J-8563-2013; Tonks, Alex/C-1174-2012; Tonks, Alex/Y-8301-2019	Tonks, Alex/0000-0002-6073-4976; Tonks, Alex/0000-0002-6073-4976; Hills, Robert/0000-0003-0166-0062	Wales Office of Research and Development (Welsh Assembly Government); Medical Research Council UK; Leukaemia Research UK	Wales Office of Research and Development (Welsh Assembly Government); Medical Research Council UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Leukaemia Research UK	This study was supported by the Wales Office of Research and Development (Welsh Assembly Government) and the Medical Research Council UK. Dr A Tonks is also supported by Leukaemia Research UK. We thank Amanda Gilkes and Megan Musson (Cardiff University) for their technical assistance in processing microarray samples. We also thank Professor Ken Mills (Queen's University, Belfast) for help in microarray analyses. We acknowledge the MRC for access to patient sample material enrolled in the NCRI clinical trials.	Alcalay M, 2003, J CLIN INVEST, V112, P1751, DOI 10.1172/JCI17595; Beillard E, 2003, LEUKEMIA, V17, P2474, DOI 10.1038/sj.leu.2403136; BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; Bullinger L, 2007, BLOOD, V110, P1291, DOI 10.1182/blood-2006-10-049783; Chatterjee A, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-235; de Souza-Pinto NC, 2001, CANCER RES, V61, P5378; ERICKSON P, 1992, BLOOD, V80, P1825; Fishel ML, 2003, CANCER RES, V63, P608; FLOYD RA, 1990, CARCINOGENESIS, V11, P1447, DOI 10.1093/carcin/11.9.1447; Frosina G, 2000, EUR J BIOCHEM, V267, P2135, DOI 10.1046/j.1432-1327.2000.01266.x; Grignani F, 1998, CANCER RES, V58, P14; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; Gustafson SA, 2009, AM J CLIN PATHOL, V131, P647, DOI 10.1309/AJCP5ETHDXO6NCGZ; Higuchi M, 2002, CANCER CELL, V1, P63, DOI 10.1016/S1535-6108(02)00016-8; Hill JW, 2007, CANCER DETECT PREV, V31, P237, DOI 10.1016/j.cdp.2007.05.001; Husain A, 1998, CANCER RES, V58, P1120; Hyun JW, 2000, ONCOGENE, V19, P4476, DOI 10.1038/sj.onc.1203787; Hyun JW, 2006, INT J CANCER, V118, P302, DOI 10.1002/ijc.21329; Ishchenko A, 2003, MED SCI MONITOR, V9, pBR16; Jankowska AM, 2008, LEUKEMIA, V22, P551, DOI 10.1038/sj.leu.2405055; KEATING MJ, 1988, LEUKEMIA, V2, P403; Kinsella TJ, 2009, CLIN CANCER RES, V15, P1853, DOI 10.1158/1078-0432.CCR-08-1307; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; Krejci O, 2008, BLOOD, V111, P2190, DOI 10.1182/blood-2007-06-093682; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Nishioka K, 1999, MOL BIOL CELL, V10, P1637, DOI 10.1091/mbc.10.5.1637; OSHIMURA M, 1982, GANN, V73, P212; Osterod M, 2001, CARCINOGENESIS, V22, P1459, DOI 10.1093/carcin/22.9.1459; Peterson LF, 2004, ONCOGENE, V23, P4255, DOI 10.1038/sj.onc.1207727; Peterson LF, 2007, BLOOD, V109, P4392, DOI 10.1182/blood-2006-03-012575; QUESNEL B, 1993, J CLIN ONCOL, V11, P2370, DOI 10.1200/JCO.1993.11.12.2370; Radyuk SN, 2006, FREE RADICAL BIO MED, V41, P757, DOI 10.1016/j.freeradbiomed.2006.05.021; Rombouts WJC, 2000, LEUKEMIA, V14, P675, DOI 10.1038/sj.leu.2401731; Ross ME, 2004, BLOOD, V104, P3679, DOI 10.1182/blood-2004-03-1154; Saebo M, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-208; Sallmyr A, 2008, BLOOD, V111, P3173, DOI 10.1182/blood-2007-05-092510; Shirota Y, 2001, J CLIN ONCOL, V19, P4298, DOI 10.1200/JCO.2001.19.23.4298; Sunaga N, 2001, CARCINOGENESIS, V22, P1355, DOI 10.1093/carcin/22.9.1355; Tonks A, 2007, LEUKEMIA, V21, P2495, DOI 10.1038/sj.leu.2404961; Tonks A, 2004, LEUKEMIA, V18, P1238, DOI 10.1038/sj.leu.2403396; vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197; Viale A, 2009, NATURE, V457, P51, DOI 10.1038/nature07618; Weiss JM, 2005, MOL CARCINOGEN, V42, P127, DOI 10.1002/mc.20067; Xie YL, 2004, CANCER RES, V64, P3096, DOI 10.1158/0008-5472.CAN-03-3834; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303	48	25	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2010	29	13					2005	2012		10.1038/onc.2009.462	http://dx.doi.org/10.1038/onc.2009.462			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	577CV	20023702				2022-12-17	WOS:000276199600013
J	Serrano, J; Fernandez, AP; Martinez-Murillo, R; Martinez, A				Serrano, J.; Fernandez, A. P.; Martinez-Murillo, R.; Martinez, A.			High sensitivity to carcinogens in the brain of a mouse model of Alzheimer's disease	ONCOGENE			English	Article						brain tumors; Alzheimer's disease; tumor microenvironment; inflammatory mediators; carcinogenesis	ELDERLY-PATIENTS; TUMOR MICROENVIRONMENT; INFLAMMATORY RESPONSE; CEREBRAL-CORTEX; STEM-CELLS; EXPRESSION; GLIOBLASTOMA; DEMENTIA; COMORBIDITY; CANCER	Cancer and Alzheimer's disease (AD) are commonly found among elderly patients. Chronic inflammation is the characteristic of both diseases. Amyloid-beta peptide is the main inducer of inflammation in AD. Moreover, chronic inflammation promotes cancer, suggesting that AD patients may be more prone to develop cancer than non-demented people. To test this hypothesis, we injected the carcinogen 20-methylcholanthrene in the brain of transgenic mice overexpressing the mutant forms of amyloid precursor protein (APP) and presenilin 1 (PS1), as a model of AD, and their wild-type (WT) littermates. Mutant mice developed tumors faster and with higher incidence than their WT counterparts. Expression of the inflammatory markers interleukin (IL)-1 alpha, IL-1 beta, IL-6, IP-10 and tumor necrosis factor-alpha (TNF-alpha) was measured in AD and WT mice of 3 and 12 months of age that had not been exposed to the carcinogen. These cytokines were elevated in older AD mice, indicating the existence of a highly inflammatory milieu in these animals. We also found elevated expression of a mutated form of p53 in older AD mice, suggesting an alternative mechanism for the predisposition of AD brains to develop brain tumors. Clinical studies reporting comorbidity of AD and brain cancer are needed to understand whether our observations hold true for humans. Oncogene (2010) 29, 2165-2171; doi: 10.1038/onc.2009.503; published online 25 January 2010	[Serrano, J.; Fernandez, A. P.; Martinez-Murillo, R.] CSIC, Inst Cajal, Dept Mol Cellular & Dev Neurobiol, E-28002 Madrid, Spain; [Martinez, A.] Ctr Biomed Res La Rioja CIBIR, Logrono, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto Cajal (IC)	Martinez-Murillo, R (corresponding author), CSIC, Inst Cajal, Dept Cellular Mol & Dev Neurobiol, Avda Doctor Arce 37, E-28002 Madrid, Spain.	r.martinez@cajal.csic.es	Fernández, Ana Patricia/K-7901-2014; Martinez, Alfredo/GQH-5998-2022; Martinez-Murillo, Ricardo/K-7596-2014	Fernández, Ana Patricia/0000-0002-3843-4715; Martinez, Alfredo/0000-0003-4882-4044; Martinez-Murillo, Ricardo/0000-0003-3657-3890	Spanish Ministry of Science and Innovation [SAF2007-60010]; Instituto de Salud Carlos III [RD06/0026/1001]	Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission)	We gratefully acknowledge Professor Ignacio Torres (Instituto Cajal, Madrid, Spain) for the breeding pairs to initiate the mouse colony. We are also grateful to Dr Josune Garcia-Sanmartin (CIBIR, Logrono, Spain) for her valuable help in statistical analysis. This work was supported by Spanish Ministry of Science and Innovation Grant SAF2007-60010, and Instituto de Salud Carlos III Grant RD06/0026/1001.	Anisimov Vladimir N, 2007, Cancer Control, V14, P23; Apte RN, 2006, CANCER METAST REV, V25, P387, DOI 10.1007/s10555-006-9004-4; Beard CM, 1996, ANN EPIDEMIOL, V6, P195, DOI 10.1016/1047-2797(95)00068-2; Borchelt DR, 1997, NEURON, V19, P939, DOI 10.1016/S0896-6273(00)80974-5; Chang CY, 2005, J CLIN NEUROSCI, V12, P930, DOI 10.1016/j.jocn.2004.11.017; Chicoine MR, 1997, J NEURO-ONCOL, V35, P249, DOI 10.1023/A:1005808315821; Chu GC, 2007, J CELL BIOCHEM, V101, P887, DOI 10.1002/jcb.21209; Correa P, 2007, GASTROENTEROLOGY, V133, P659, DOI 10.1053/j.gastro.2007.06.026; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Di Domenico F, 2009, NEUROCHEM RES, V34, P727, DOI 10.1007/s11064-009-9924-9; Driver JA, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a2467; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Formiga F, 2008, REV NEUROLOGIA, V46, P72, DOI 10.33588/rn.4602.2007490; Formiga F, 2007, REV CLIN ESP, V207, P495, DOI 10.1157/13111547; Gambassi G, 1999, NEUROLOGY, V53, P508, DOI 10.1212/WNL.53.3.508; Gasper Mason C, 2005, Am J Geriatr Pharmacother, V3, P1, DOI 10.1016/j.amjopharm.2005.02.001; Giunta B, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-51; Griffin RJ, 2005, J NEUROCHEM, V93, P105, DOI 10.1111/j.1471-4159.2004.02949.x; Harikumar KB, 2008, CELL CYCLE, V7, P1020, DOI 10.4161/cc.7.8.5740; Hong SH, 2000, FASEB J, V14, P1499, DOI 10.1096/fj.99-0802com; Hoozemans JJM, 2008, CURR PHARM DESIGN, V14, P1419, DOI 10.2174/138161208784480171; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Hu M, 2008, EUR J CANCER, V44, P2760, DOI 10.1016/j.ejca.2008.09.038; Hussain SP, 2003, NAT REV CANCER, V3, P276, DOI 10.1038/nrc1046; Kamer AR, 2008, J ALZHEIMERS DIS, V13, P437; Kim S, 2009, NATURE, V457, P102, DOI 10.1038/nature07623; Lanni C, 2008, CURR PHARM DESIGN, V14, P2665, DOI 10.2174/138161208786264133; Leonard BE, 2007, NEUROCHEM RES, V32, P1749, DOI 10.1007/s11064-007-9385-y; Mbeunkui F, 2009, CANCER CHEMOTH PHARM, V63, P571, DOI 10.1007/s00280-008-0881-9; Murat A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005947; Nelson JS, 2002, ARCH PATHOL LAB MED, V126, P1515; Paugh BS, 2009, J BIOL CHEM, V284, P3408, DOI 10.1074/jbc.M807170200; Peebles KA, 2007, EXPERT REV ANTICANC, V7, P1405, DOI 10.1586/14737140.7.10.1405; Psaila B, 2009, NAT REV CANCER, V9, P285, DOI 10.1038/nrc2621; Quante M, 2008, PHYSIOLOGY, V23, P350, DOI 10.1152/physiol.00031.2008; Ribatti D, 2006, CLIN EXP MED, V6, P145, DOI 10.1007/s10238-006-0117-4; Rodrigo J, 2004, NEUROSCIENCE, V128, P73, DOI 10.1016/j.neuroscience.2004.06.030; Roe CM, 2005, NEUROLOGY, V64, P895, DOI 10.1212/01.WNL.0000152889.94785.51; Rogers J, 2008, J PERIODONTOL, V79, P1535, DOI 10.1902/jop.2008.080171; Saetre P, 2007, BMC PSYCHIATRY, V7, DOI 10.1186/1471-244X-7-46; Salminen A, 2009, PROG NEUROBIOL, V87, P181, DOI 10.1016/j.pneurobio.2009.01.001; Sanders P, 2007, BRAIN RES REV, V54, P274, DOI 10.1016/j.brainresrev.2007.03.001; Sastre M, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-25; Serrano J, 2008, BRAIN PATHOL, V18, P434, DOI 10.1111/j.1750-3639.2008.00142.x; Steinman L, 2008, J CLIN INVEST, V118, P3557, DOI 10.1172/JCI36532; Stock D, 2008, UROL CLIN N AM, V35, P117, DOI 10.1016/j.ucl.2007.09.006; Stolt CC, 2003, GENE DEV, V17, P1677, DOI 10.1101/gad.259003; Tansey MG, 2008, FRONT BIOSCI-LANDMRK, V13, P709, DOI 10.2741/2713; Uberti D, 2008, NEURODEGENER DIS, V5, P209, DOI 10.1159/000113704; Vesce S, 2007, INT REV NEUROBIOL, V82, P57, DOI 10.1016/S0074-7742(07)82003-4; Wang Y, 2009, CANCER CELL, V15, P514, DOI 10.1016/j.ccr.2009.04.001; Yamada M, 1999, J AM GERIATR SOC, V47, P189, DOI 10.1111/j.1532-5415.1999.tb04577.x; Yeruva S, 2008, INT J COLORECTAL DIS, V23, P305, DOI 10.1007/s00384-007-0396-6; Zimmerman HM, 1941, CANCER RES, V1, P919	54	25	27	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2010	29	15					2165	2171		10.1038/onc.2009.503	http://dx.doi.org/10.1038/onc.2009.503			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583NT	20101216				2022-12-17	WOS:000276685200002
J	Torosyan, Y; Dobi, A; Glasman, M; Mezhevaya, K; Naga, S; Huang, W; Paweletz, C; Leighton, X; Pollard, HB; Srivastava, M				Torosyan, Y.; Dobi, A.; Glasman, M.; Mezhevaya, K.; Naga, S.; Huang, W.; Paweletz, C.; Leighton, X.; Pollard, H. B.; Srivastava, M.			Role of multi-hnRNP nuclear complex in regulation of tumor suppressor ANXA7 in prostate cancer cells	ONCOGENE			English	Article						Annexin A7, ANXA7 (or synexin); heterogeneous nuclear ribonucleoprotein; hnRNP; prostate cancer; DNA affinity enrichment/identification of nuclear proteins; mass spectrometry	ELEMENT-BINDING-PROTEIN; ANNEXIN-VII GENE; IN-VIVO; RIBONUCLEOPROTEIN-K; ANDROGEN RECEPTOR; MESSENGER-RNA; TRANSCRIPTIONAL ACTIVITY; GLUCOCORTICOID-RECEPTOR; CORE PROMOTER; EXPRESSION	Annexin-A7 (ANXA7) tumor suppressor role has been shown in various tumors, and ANXA7 expression has been particularly lost in androgen-resistant prostate cancers. In this study, we studied ANXA7 regulation in normal prostate versus androgen-sensitive and -resistant prostate cancer cells. Deletion mapping analysis showed lowest ANXA7-promoter activities in androgen-sensitive LNCaP prostate cancer cells. Genomatix analysis of ANXA7 promoter identified a cluster of steroid nuclear hormone receptor elements, including V$GREF (V$GRE.02/ARE.02). Gelshift analysis clearly indicated distinct nuclear protein occupancy at this ANXA7-promoter site (-1086/-890) in prostate cancer (LNCaP, DU145, and PC3) versus normal prostate (PrEC) cells. In matrix-assisted laser desorption time-of-light mass spectrometry-based search for ANXA7 nuclear regulators, we identified several heterogeneous nuclear ribonucleoproteins (hnRNPs) (A1, A2/B1 and K) attached to the steroid-associated ANXA7-promoter site in the androgen-resistant PC3 prostate cancer cells with high ANXA7 gene copy number, but not in PrEC. The hnPNP role in ANXA7 regulation (that was validated by hnRNPA2/B1 antibody interference) resulted in multiple ANXA7 cDNA and protein products in PC3, but not in PrEC. Ingenuity pathways analysis showed plausible molecular paths between ANXA7 and the hnRNP-associated network in prostate cancer progression. Thus, a multi-hnRNP complex can be responsible for aberrant ANXA7 transcription and splicing, thereby affecting ANXA7 expression pattern and tumor suppressor function in prostate cancer. Oncogene (2010) 29, 2457-2466; doi:10.1038/onc.2010.2; published online 1 March 2010	[Torosyan, Y.; Glasman, M.; Mezhevaya, K.; Naga, S.; Huang, W.; Paweletz, C.; Leighton, X.; Pollard, H. B.; Srivastava, M.] Uniformed Serv Univ Sch Med USUHS, Dept Anat Physiol & Genet, Inst Mol Med, Bethesda, MD USA; [Dobi, A.] CPDR, Sect Gene Regulat & Bioinformat, Rockville, MD USA		Srivastava, M (corresponding author), USU Sch Med, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd,B2-034, Bethesda, MD 20814 USA.	msrivastava@usuhs.mil			US Department of Defense (DoD)	US Department of Defense (DoD)(United States Department of Defense)	We thank Dr Gideon Dreyfuss (University of Pennsylvania School of Medicine) for providing hnRNPA2/B1 antibody. This work was supported by grants funded by the US Department of Defense (DoD).	Adachi K, 1999, ENDOCRINOLOGY, V140, P618, DOI 10.1210/en.140.2.618; Auboeuf D, 2002, SCIENCE, V298, P416, DOI 10.1126/science.1073734; Barboro P, 2009, BRIT J CANCER, V100, P1608, DOI 10.1038/sj.bjc.6605057; BURD CG, 1989, P NATL ACAD SCI USA, V86, P9788, DOI 10.1073/pnas.86.24.9788; Caron D, 2008, J PROTEOME RES, V7, P4492, DOI 10.1021/pr8002497; Carpenter B, 2006, BBA-REV CANCER, V1765, P85, DOI 10.1016/j.bbcan.2005.10.002; Chen H, 2005, ENDOCRINOLOGY, V146, P4266, DOI 10.1210/en.2005-0160; Chen SY, 1997, J BIOL CHEM, V272, P14087, DOI 10.1074/jbc.272.22.14087; Chen TC, 2000, CLIN CANCER RES, V6, P901; Cooper TA, 2009, CELL, V136, P777, DOI 10.1016/j.cell.2009.02.011; Courchet J, 2008, J BIOL CHEM, V283, P32131, DOI 10.1074/jbc.M802927200; Dobi A, 2002, BIOTECHNIQUES, V33, P868, DOI 10.2144/02334rr03; Duncan R, 2008, BRIT J CANCER, V98, P426, DOI 10.1038/sj.bjc.6604128; Eggert H, 2001, J STEROID BIOCHEM, V78, P59, DOI 10.1016/S0960-0760(01)00074-7; Enge M, 2009, CANCER CELL, V15, P171, DOI 10.1016/j.ccr.2009.01.019; Graveley BR, 2009, NAT STRUCT MOL BIOL, V16, P13, DOI 10.1038/nsmb0109-13; He YW, 2005, J CELL SCI, V118, P3173, DOI 10.1242/jcs.02448; Heemers HV, 2006, MOL ENDOCRINOL, V20, P2265, DOI 10.1210/me.2005-0479; Hellwinkel OJC, 2008, BJU INT, V101, P1454, DOI 10.1111/j.1464-410X.2008.07540.x; Hilbe W, 2004, EUR J CANCER PREV, V13, P425, DOI 10.1097/00008469-200410000-00011; Juven-Gershon T, 2008, CURR OPIN CELL BIOL, V20, P253, DOI 10.1016/j.ceb.2008.03.003; Kang HS, 2007, PHYSIOL GENOMICS, V31, P281, DOI 10.1152/physiolgenomics.00098.2007; KARAGIANNI N, 1994, ONCOGENE, V9, P2327; Kim TH, 2005, NATURE, V436, P876, DOI 10.1038/nature03877; Kimura E, 2003, BIOSCI BIOTECH BIOCH, V67, P1786, DOI 10.1271/bbb.67.1786; Lee BJ, 2006, CELL, V126, P543, DOI 10.1016/j.cell.2006.05.049; Li TW, 2004, P NATL ACAD SCI USA, V101, P8551, DOI 10.1073/pnas.0402889101; MAGENDZO K, 1991, J BIOL CHEM, V266, P3228; Mikula M, 2006, PROTEOMICS, V6, P2395, DOI 10.1002/pmic.200500632; Mukhopadhyay NK, 2009, CANCER RES, V69, P2210, DOI 10.1158/0008-5472.CAN-08-2308; Myslinski E, 2006, J BIOL CHEM, V281, P39953, DOI 10.1074/jbc.M608507200; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Patry C, 2003, CANCER RES, V63, P7679; Pollard H B, 1998, Adv Pharmacol, V42, P81; Reed R, 2002, CELL, V108, P523, DOI 10.1016/S0092-8674(02)00627-X; Rizzo G, 2006, CURR OPIN PHARMACOL, V6, P421, DOI 10.1016/j.coph.2006.03.012; Rozanov DV, 2008, CANCER RES, V68, P4086, DOI 10.1158/0008-5472.CAN-07-6458; Sakaguchi M, 2007, J BIOL CHEM, V282, P35679, DOI 10.1074/jbc.M707538200; Shi LH, 2008, J BIOL CHEM, V283, P36474, DOI 10.1074/jbc.M805980200; Shi Y, 2007, MOL CELL, V28, P79, DOI 10.1016/j.molcel.2007.08.028; SHIRVAN A, 1994, BIOCHEMISTRY-US, V33, P6888, DOI 10.1021/bi00188a019; Srivastava M, 2003, P NATL ACAD SCI USA, V100, P14287, DOI 10.1073/pnas.2235927100; Srivastava M, 2000, CELL BIOL INT, V24, P475, DOI 10.1006/cbir.2000.0511; Srivastava M, 1999, P NATL ACAD SCI USA, V96, P13783, DOI 10.1073/pnas.96.24.13783; Srivastava M, 2007, INT J CANCER, V121, P2628, DOI 10.1002/ijc.23008; Tokusumi Y, 2007, MOL CELL BIOL, V27, P1844, DOI 10.1128/MCB.01363-06; Torosyan Y, 2006, CANCER RES, V66, P9609, DOI 10.1158/0008-5472.CAN-06-1574; Torosyan Y, 2009, INT J CANCER, V125, P2528, DOI 10.1002/ijc.24592; Yemelyanov A, 2007, ONCOGENE, V26, P1885, DOI 10.1038/sj.onc.1209991; Zheng Z, 2006, J BIOL CHEM, V281, P4002, DOI 10.1074/jbc.M509260200	51	25	28	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	17					2457	2466		10.1038/onc.2010.2	http://dx.doi.org/10.1038/onc.2010.2			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	589RB	20190808				2022-12-17	WOS:000277169400001
J	Guha, M; Xia, F; Raskett, CM; Altieri, DC				Guha, M.; Xia, F.; Raskett, C. M.; Altieri, D. C.			Caspase 2-mediated tumor suppression involves survivin gene silencing	ONCOGENE			English	Article						caspase-2; survivin; NF kappa B; RIP1; tumor growth; gene expression	NF-KAPPA-B; WILD-TYPE P53; INDUCED APOPTOSIS; DRUG DISCOVERY; MELANOMA-CELLS; ACTIVATION; CANCER; PATHWAY; PHOSPHORYLATION; EXPRESSION	One of the pivotal functions of endogenous tumor suppression is to oppose aberrant cell survival, but the molecular requirements of this process are not completely understood. Here, we show that caspase 2, a death effector with largely unknown functions, represses transcription of the survivin gene, a general regulator of cell division and cytoprotection in tumors. This pathway involves caspase 2 proteolytic cleavage of the nuclear factor kappa B (NF kappa B) activator, RIP1. In turn, loss of RIP1 abolishes transcription of NF kappa B target genes, including survivin, resulting in deregulated mitotic transitions, enhanced apoptosis and suppression of tumorigenicity in vivo. Therefore, caspase 2 functions as an endogenous inhibitor of NF kappa B-dependent cell survival and this mechanism may contribute to tumor suppression in humans. Oncogene (2010) 29, 1280-1292; doi: 10.1038/onc.2009.428; published online 23 November 2009	[Guha, M.; Xia, F.; Raskett, C. M.; Altieri, D. C.] Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01609 USA	University of Massachusetts System; University of Massachusetts Worcester	Altieri, DC (corresponding author), Univ Massachusetts, Sch Med, Dept Canc Biol, LRB428,364 Plantat St, Worcester, MA 01609 USA.	dario.altieri@umassmed.edu			National Institutes of Health [CA78810, CA90917, CA118005]; NATIONAL CANCER INSTITUTE [R01CA090917, R01CA078810, R01CA118005] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs Bert Vogelstein, Michelle Kelliher and Neal Silverman for reagents. This work was supported by the National Institutes of Health grants CA78810, CA90917 and CA118005.	Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Altieri DC, 2008, NAT REV CANCER, V8, P61, DOI 10.1038/nrc2293; Anand P, 2008, CANCER RES, V68, P8861, DOI 10.1158/0008-5472.CAN-08-1902; Baptiste-Okoh N, 2008, P NATL ACAD SCI USA, V105, P1937, DOI 10.1073/pnas.0711800105; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Bouchier-Hayes L, 2009, MOL CELL, V35, P830, DOI 10.1016/j.molcel.2009.07.023; Castedo M, 2004, ONCOGENE, V23, P4362, DOI 10.1038/sj.onc.1207572; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Fesik SW, 2005, NAT REV CANCER, V5, P876, DOI 10.1038/nrc1736; Festjens N, 2007, CELL DEATH DIFFER, V14, P400, DOI 10.1038/sj.cdd.4402085; Ghosh JC, 2008, J BIOL CHEM, V283, P5188, DOI 10.1074/jbc.M705904200; Guha M, 2009, CANCER RES, V69, P4954, DOI 10.1158/0008-5472.CAN-09-0584; Ho LH, 2008, ONCOGENE, V27, P3393, DOI 10.1038/sj.onc.1211005; Ho LH, 2009, P NATL ACAD SCI USA, V106, P5336, DOI 10.1073/pnas.0811928106; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Janssens S, 2005, CELL, V123, P1079, DOI 10.1016/j.cell.2005.09.036; Jiang YY, 2004, J BIOL CHEM, V279, P40511, DOI 10.1074/jbc.M404496200; Kang BH, 2006, J BIOL CHEM, V281, P24721, DOI 10.1074/jbc.M603175200; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kawakami H, 2005, INT J CANCER, V115, P967, DOI 10.1002/ijc.20954; Krumschnabel G, 2009, CELL DEATH DIFFER, V16, P195, DOI 10.1038/cdd.2008.170; Lamkanfi M, 2005, J BIOL CHEM, V280, P6923, DOI 10.1074/jbc.M411180200; Lee CW, 2008, CANCER RES, V68, P5273, DOI 10.1158/0008-5472.CAN-07-6673; Li FZ, 1999, BIOCHEM J, V344, P305, DOI 10.1042/0264-6021:3440305; Li HL, 1997, J BIOL CHEM, V272, P21010, DOI 10.1074/jbc.272.34.21010; Li J, 2008, ONCOGENE, V27, P6194, DOI 10.1038/onc.2008.297; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Makishi S, 2008, BRIT J HAEMATOL, V142, P583, DOI 10.1111/j.1365-2141.2008.07229.x; Mhaidat NM, 2007, MOL CANCER THER, V6, P752, DOI 10.1158/1535-7163.MCT-06-0564; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; Mita AC, 2008, CLIN CANCER RES, V14, P5000, DOI 10.1158/1078-0432.CCR-08-0746; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; Rebe C, 2007, BLOOD, V109, P1442, DOI 10.1182/blood-2006-03-011585; Shi MG, 2009, CELL, V136, P508, DOI 10.1016/j.cell.2008.12.021; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Shin MS, 2002, BLOOD, V99, P4094, DOI 10.1182/blood.V99.11.4094; Soung YH, 2004, HUM GENET, V115, P112, DOI 10.1007/s00439-004-1129-3; Srinivasula SM, 2008, MOL CELL, V30, P123, DOI 10.1016/j.molcel.2008.03.008; Stupack DG, 2006, NATURE, V439, P95, DOI 10.1038/nature04323; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Tinel A, 2007, EMBO J, V26, P197, DOI 10.1038/sj.emboj.7601473; Troy CM, 2003, CELL DEATH DIFFER, V10, P101, DOI 10.1038/sj.cdd.4401175; Upton JP, 2008, MOL CELL BIOL, V28, P3943, DOI 10.1128/MCB.00013-08; Vaira V, 2007, ONCOGENE, V26, P2678, DOI 10.1038/sj.onc.1210094; Van de Craen M, 1999, CELL DEATH DIFFER, V6, P1117, DOI 10.1038/sj.cdd.4400589; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Wang RH, 2008, MOL CELL, V32, P11, DOI 10.1016/j.molcel.2008.09.011; Wheatley SP, 2007, CELL CYCLE, V6, P1220, DOI 10.4161/cc.6.10.4179; Xia F, 2006, CANCER RES, V66, P3392, DOI 10.1158/0008-5472.CAN-05-4537; Yeung BHY, 2006, J BIOL CHEM, V281, P11923, DOI 10.1074/jbc.M508533200; You L, 2004, CANCER RES, V64, P5385, DOI 10.1158/0008-5472.CAN-04-1227; Zhou JB, 2009, BLOOD, V113, P4052, DOI 10.1182/blood-2008-05-156422	57	25	28	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2010	29	9					1280	1292		10.1038/onc.2009.428	http://dx.doi.org/10.1038/onc.2009.428			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	563XJ	19935698	Green Accepted			2022-12-17	WOS:000275170600004
J	Fischer, M; Bauer, T; Oberthur, A; Hero, B; Theissen, J; Ehrich, M; Spitz, R; Eils, R; Westermann, F; Brors, B; Konig, R; Berthold, F				Fischer, M.; Bauer, T.; Oberthuer, A.; Hero, B.; Theissen, J.; Ehrich, M.; Spitz, R.; Eils, R.; Westermann, F.; Brors, B.; Koenig, R.; Berthold, F.			Integrated genomic profiling identifies two distinct molecular subtypes with divergent outcome in neuroblastoma with loss of chromosome 11q	ONCOGENE			English	Article						neuroblastoma; integrative genomics; loss of 11q; gene expression; outcome; cancer	DNA COPY NUMBER; HIGH-RESOLUTION ANALYSIS; GENE-EXPRESSION; MICROARRAY ANALYSIS; 4S NEUROBLASTOMA; CANDIDATE GENES; RISK; PROGRESSION; DELETIONS; TUMORS	Imbalances in chromosome 11q occur in approximately 30% of primary neuroblastoma and are associated with poor outcome. It has been suggested that 11q loss constitutes a distinct clinico-genetic neuroblastoma subgroup by affecting expression levels of corresponding genes. This study analysed the relationship of 11q loss, clinical phenotype and global transcriptomic profiles in four clinico-genetic subgroups (11q alteration/favourable outcome, n = 7; 11q alteration/unfavourable outcome, n 14; no 11q alteration/favourable outcome, n 81; no 11q alteration/unfavourable outcome, n 8; tumours with MYCN amplification and/or 1p loss were excluded). Unsupervised and supervised comparisons of gene expression profiles consistently showed significantly different mRNA patterns between favourable and unfavourable neuroblastomas, both in the subgroups with and without 11q loss. In contrast, favourable tumours with and without 11q loss showed highly similar transcriptomic profiles. Disproportionate downregulation of 11q genes was observed only in unfavourable tumours with 11q loss. The diverging molecular profiles were neither caused by considerable differences in the size of the deleted regions nor by differential methylation patterns of 11q genes. Together, this study shows that neuroblastoma with 11q loss comprises two biological subgroups that differ both in their clinical phenotype and gene expression patterns, indicating that 11q loss is not a primary determinant of neuroblastoma tumour behaviour. Oncogene (2010) 29, 865-875; doi:10.1038/onc.2009.390; published online 9 November 2009	[Fischer, M.; Oberthuer, A.; Hero, B.; Theissen, J.; Spitz, R.; Berthold, F.] Univ Childrens Hosp, Dept Paediat Oncol, D-50924 Cologne, NRW, Germany; [Fischer, M.; Oberthuer, A.; Hero, B.; Theissen, J.; Spitz, R.; Berthold, F.] CMMC, Cologne, Germany; [Bauer, T.; Eils, R.; Koenig, R.] Inst Pharm & Mol Biotechnol, Dept Bioinformat & Funct Genom, Heidelberg, Germany; [Bauer, T.; Eils, R.; Brors, B.; Koenig, R.] German Canc Res Ctr, Dept Theoret Bioinformat, Heidelberg, Germany; [Ehrich, M.] SEQUENOM Inc, San Diego, CA USA; [Westermann, F.] German Canc Res Ctr, Dept Tumourbiol, Heidelberg, Germany	University of Cologne; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Cologne; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Sequenom; Helmholtz Association; German Cancer Research Center (DKFZ)	Fischer, M (corresponding author), Univ Childrens Hosp, Dept Paediat Oncol, Kerpener St 62, D-50924 Cologne, NRW, Germany.	matthias.fischer@uk-koeln.de	Westermann, Frank/F-7509-2013; Brors, Benedikt/E-5620-2013; Eils, Roland/B-6121-2009	Brors, Benedikt/0000-0001-5940-3101; Eils, Roland/0000-0002-0034-4036; Bauer, Tobias/0000-0002-4961-3639	Deutsche Krebshilfe [50-2719]; Bundesministerium fur Bildung und Forschung (BMBF) through the National Genome Research Network 2 (NGFN2) [01GS0456, 01GR0450]; Competence Network Paediatric Oncology and Hematology (KPOH); Fordergesellschaft Kinderkrebs-Neuroblastom-Forschung e.V.	Deutsche Krebshilfe(Deutsche Krebshilfe); Bundesministerium fur Bildung und Forschung (BMBF) through the National Genome Research Network 2 (NGFN2)(Federal Ministry of Education & Research (BMBF)); Competence Network Paediatric Oncology and Hematology (KPOH); Fordergesellschaft Kinderkrebs-Neuroblastom-Forschung e.V.	We are grateful to Yvonne Kahlert for excellent technical assistance and to Dr Roman Thomas for critical reading of the paper. This work was supported by grants from the Deutsche Krebshilfe (Grant 50-2719), the Bundesministerium fur Bildung und Forschung (BMBF) through the National Genome Research Network 2 (NGFN2, Grants 01GS0456 and 01GR0450) and the Competence Network Paediatric Oncology and Hematology (KPOH) as well as the Fordergesellschaft Kinderkrebs-Neuroblastom-Forschung e.V.	Alaminos M, 2003, CANCER RES, V63, P4538; Ambros PF, 2001, MED PEDIATR ONCOL, V37, P492, DOI 10.1002/mpo.1242; Asgharzadeh S, 2006, JNCI-J NATL CANCER I, V98, P1193, DOI 10.1093/jnci/djj330; Attiyeh EF, 2005, NEW ENGL J MED, V353, P2243, DOI 10.1056/NEJMoa052399; Berwanger B, 2002, CANCER CELL, V2, P377, DOI 10.1016/S1535-6108(02)00179-4; Bilke S, 2005, J CLIN ONCOL, V23, P7322, DOI 10.1200/JCO.2005.03.2821; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Chen W, 2007, GENE CHROMOSOME CANC, V46, P288, DOI 10.1002/gcc.20411; Classen S, 2007, J IMMUNOL, V178, P6931, DOI 10.4049/jimmunol.178.11.6931; Cohn SL, 2009, J CLIN ONCOL, V27, P289, DOI 10.1200/JCO.2008.16.6785; Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102; Fischer M, 2008, KLIN PADIATR, V220, P137, DOI 10.1055/s-2008-1065345; Fischer M, 2006, CLIN CANCER RES, V12, P5118, DOI 10.1158/1078-0432.CCR-06-0985; Henrich KO, 2006, CLIN CANCER RES, V12, P131, DOI 10.1158/1078-0432.CCR-05-1431; Huang J, 2006, FEBS LETT, V580, P3571, DOI 10.1016/j.febslet.2006.05.032; Janoueix-Lerosey I, 2009, J CLIN ONCOL, V27, P1026, DOI 10.1200/JCO.2008.16.0630; Lastowska M, 2007, ONCOGENE, V26, P7432, DOI 10.1038/sj.onc.1210552; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; McArdle L, 2004, CARCINOGENESIS, V25, P1599, DOI 10.1093/carcin/bgh173; Mosse YP, 2008, NATURE, V455, P930, DOI 10.1038/nature07261; Mosse YP, 2007, GENE CHROMOSOME CANC, V46, P936, DOI 10.1002/gcc.20477; Nigro JM, 2005, CANCER RES, V65, P1678, DOI 10.1158/0008-5472.CAN-04-2921; Oberthuer A, 2008, CLIN CANCER RES, V14, P6590, DOI 10.1158/1078-0432.CCR-07-4377; Oberthuer A, 2006, J CLIN ONCOL, V24, P5070, DOI 10.1200/JCO.2006.06.1879; Ohira M, 2005, CANCER CELL, V7, P337, DOI 10.1016/j.ccr.2005.03.019; Platzer P, 2002, CANCER RES, V62, P1134; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Potter N, 2008, NEOPLASIA, V10, P757, DOI 10.1593/neo.07914; Ruiz MIG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001722; Savelyeva L, 2001, CANCER LETT, V167, P115, DOI 10.1016/S0304-3835(01)00472-4; Spitz R, 2006, CLIN CANCER RES, V12, P3368, DOI 10.1158/1078-0432.CCR-05-2495; Spitz R, 2003, CLIN CANCER RES, V9, P52; Spitz R, 2006, GENE CHROMOSOME CANC, V45, P1130, DOI 10.1002/gcc.20376; Stallings RL, 2007, CYTOGENET GENOME RES, V118, P110, DOI 10.1159/000108291; Stallings RL, 2006, CANCER RES, V66, P3673, DOI 10.1158/0008-5472.CAN-05-4154; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wang Q, 2006, CANCER RES, V66, P6050, DOI 10.1158/0008-5472.CAN-05-4618; Westermann F, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-10-r150; Yoshimoto T, 2007, J PATHOL, V213, P392, DOI 10.1002/path.2239	40	25	26	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	2010	29	6					865	875		10.1038/onc.2009.390	http://dx.doi.org/10.1038/onc.2009.390			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553WP	19901960				2022-12-17	WOS:000274397800009
J	Chung, S; Furihata, M; Tamura, K; Uemura, M; Daigo, Y; Nasu, Y; Miki, T; Shuin, T; Fujioka, T; Nakamura, Y; Nakagawa, H				Chung, S.; Furihata, M.; Tamura, K.; Uemura, M.; Daigo, Y.; Nasu, Y.; Miki, T.; Shuin, T.; Fujioka, T.; Nakamura, Y.; Nakagawa, H.			Overexpressing PKIB in prostate cancer promotes its aggressiveness by linking between PKA and Akt pathways	ONCOGENE			English	Article						CRPC; PKIB; protein kinase A; Akt phosphorylation	DEPENDENT PROTEIN-KINASE; REGULATORY SUBUNITS; SIGNAL-TRANSDUCTION; ANDROGEN RECEPTOR; CATALYTIC SUBUNIT; GENE-EXPRESSION; PHOSPHORYLATION; CAMP; MITOXANTRONE; PREDNISONE	Prostate cancer (PC) is the most common malignancy in males. Despite high response rates and clinical benefits, androgen-ablation therapy is ineffective for advanced or relapsed PC because of the emergence of aggressive castration-resistant prostate cancer (CRPC). Through our genome-wide gene expression analysis of PC cells purified from clinical CRPC tissues, we here identified a novel molecular target, PKIB (cAMP-dependent protein kinase inhibitor-beta), which was overexpressed specifically in CRPCs and aggressive PCs. Immunohistochemical analysis confirmed its overexpression in CRPCs and its strong correlation with high Gleason scores of PCs. Knockdown of PKIB by siRNA resulted in drastic growth suppression of PC cells, and, concordantly, exogenous introduction of PKIB into PC cells enhanced their growth and mobility. We found the direct interaction between PKIB and cAMP-dependent protein kinase A catalytic subunit (PKA-C), and showed that knockdown of PKIB in PC cells diminished the nuclear translocation of PKA-C. Knockdown of PKIB also decreased the phosphorylation level of Akt at Ser473 in PC cells, and exogenous PKIB introduction enhanced Akt phosphorylation in PC cells by incorporating with endogenous PKA-C kinase. In vitro kinase assay validated the recombinant PKIB enhanced phosphorylation of Akt at Ser473 by PKA-C kinase. These findings show that PKIB and PKA-C kinase can have critical functions of aggressive phenotype of PCs through Akt phosphorylation and that they should be a promising molecular target for PC treatment. Oncogene (2009) 28, 2849-2859; doi:10.1038/onc.2009.144; published online 1 June 2009	[Nakagawa, H.] RIKEN, Ctr Genom Med, Lab Biomarker Dev, Minato Ku, Tokyo 1088639, Japan; [Chung, S.; Tamura, K.; Uemura, M.; Daigo, Y.; Nakamura, Y.; Nakagawa, H.] Univ Tokyo, Inst Med Sci, Mol Med Lab, Ctr Human Genome, Tokyo, Japan; [Furihata, M.] Kochi Med Sch, Dept Pathol, Nankoku, Kochi, Japan; [Tamura, K.; Shuin, T.] Kochi Med Sch, Dept Urol, Nankoku, Kochi, Japan; [Nasu, Y.] Okayama Univ, Sch Med, Dept Urol, Okayama 700, Japan; [Miki, T.] Kyoto Prefectural Univ Med, Dept Urol, Kyoto, Japan; [Fujioka, T.] Iwate Med Univ, Dept Urol, Morioka, Iwate 020, Japan	RIKEN; University of Tokyo; Kochi University; Kochi University; Okayama University; Kyoto Prefectural University of Medicine; Iwate Medical University	Nakagawa, H (corresponding author), RIKEN, Ctr Genom Med, Lab Biomarker Dev, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	hidewaki@ims.u-tokyo.ac.jp	uemura, motohide/G-6101-2011	Daigo, Yataro/0000-0002-0915-3025	Japan Society for the Promotion of Science [18590323, 00L01402]	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	We would like to thank Ms Mami U and Ms Hitomi Uchida for their technical assistance, and Dr Ryo Takada at Iwate Medical University for his preparation of prostate cancer tissues. This work was supported by Grant-in-Aid for Scientific Research #18590323 (H Nakagawa) and Research for the Future Program Grants #00L01402 (Y Nakamura) from the Japan Society for the Promotion of Science.	Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; Chio CC, 2004, CELL SIGNAL, V16, P565, DOI 10.1016/j.cellsig.2003.10.003; Cox ME, 2000, J BIOL CHEM, V275, P13812, DOI 10.1074/jbc.275.18.13812; Dalton GD, 2006, NEUROPEPTIDES, V40, P23, DOI 10.1016/j.npep.2005.10.002; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Deeble PD, 2007, CANCER RES, V67, P3663, DOI 10.1158/0008-5472.CAN-06-2616; Feilotter HE, 1998, ONCOGENE, V16, P1743, DOI 10.1038/sj.onc.1200205; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Filippa N, 1999, MOL CELL BIOL, V19, P4989; GAMM DM, 1995, J BIOL CHEM, V270, P7227, DOI 10.1074/jbc.270.13.7227; Gronberg H, 2003, LANCET, V361, P859, DOI 10.1016/S0140-6736(03)12713-4; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; Hay N, 2005, CANCER CELL, V8, P179, DOI 10.1016/j.ccr.2005.08.008; Hsing AW, 2001, EPIDEMIOL REV, V23, P3, DOI 10.1093/oxfordjournals.epirev.a000792; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Kreisberg JI, 2004, CANCER RES, V64, P5232, DOI 10.1158/0008-5472.CAN-04-0272; LALLI E, 1994, J BIOL CHEM, V269, P17359; Majumder PK, 2005, ONCOGENE, V24, P7465, DOI 10.1038/sj.onc.1209096; Malik SN, 2002, CLIN CANCER RES, V8, P1168; McDonald PC, 2008, CANCER RES, V68, P1618, DOI 10.1158/0008-5472.CAN-07-5869; Miller WR, 2002, ANN NY ACAD SCI, V968, P37, DOI 10.1111/j.1749-6632.2002.tb04325.x; Mitsiades CS, 2004, CURR CANCER DRUG TAR, V4, P235, DOI 10.2174/1568009043333032; Orloff MS, 2008, ONCOGENE, V27, P5387, DOI 10.1038/onc.2008.237; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318; Sadar MD, 1999, J BIOL CHEM, V274, P7777, DOI 10.1074/jbc.274.12.7777; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Scher HI, 2005, J CLIN ONCOL, V23, P8253, DOI 10.1200/JCO.2005.03.4777; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Tamura K, 2007, CANCER RES, V67, P5117, DOI 10.1158/0008-5472.CAN-06-4040; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Tasken K, 2004, PHYSIOL REV, V84, P137, DOI 10.1152/physrev.00021.2003; Taylor SS, 2005, BBA-PROTEINS PROTEOM, V1754, P25, DOI 10.1016/j.bbapap.2005.08.024; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; WEN W, 1994, J BIOL CHEM, V269, P32214; Wiley JC, 1999, J BIOL CHEM, V274, P6381, DOI 10.1074/jbc.274.10.6381	38	25	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2009	28	32					2849	2859		10.1038/onc.2009.144	http://dx.doi.org/10.1038/onc.2009.144			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482VJ	19483721				2022-12-17	WOS:000268917100001
J	Freedman, JA; Chang, JT; Jakoi, L; Nevins, JR				Freedman, J. A.; Chang, J. T.; Jakoi, L.; Nevins, J. R.			A combinatorial mechanism for determining the specificity of E2F activation and repression	ONCOGENE			English	Article						E2F; transcription; gene regulation	TRANSCRIPTION FACTOR; CELL-CYCLE; DNA-REPLICATION; FAMILY-MEMBERS; IN-VIVO; APOPTOSIS; PROLIFERATION; PROMOTER; DISTINCT; BINDING	Various studies have detailed the role of E2F proteins in both transcription activation and repression. Further study has shown that distinct promoter elements, but comprising the same E2F-recognition motif, confer positive or negative E2F control and that this reflects binding of either activator or repressor E2F proteins, respectively. We now show that the specificity of binding of an activator or repressor E2F protein is determined by adjacent sequences that bind a cooperating transcription factor. We propose that the functional E2F element is a module comprising not only the E2F-binding site but also the adjacent site for the cooperating transcription factor. Oncogene (2009) 28, 2873-2881; doi:10.1038/onc.2009.153; published online 22 June 2009	[Freedman, J. A.; Chang, J. T.; Jakoi, L.; Nevins, J. R.] Duke Univ, Med Ctr, Duke Inst Genome Sci & Policy, Durham, NC 27710 USA	Duke University	Nevins, JR (corresponding author), Duke Univ, Med Ctr, Duke Inst Genome Sci & Policy, 2123 CIEMAS, Durham, NC 27710 USA.	j.nevins@duke.edu			National Cancer Institute [R01CA104663]; NATIONAL CANCER INSTITUTE [R01CA104663] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [R00LM009837] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	We thank the members of the Nevins laboratory for valuable input throughout the course of this study and for comments on the paper. The project described was supported by award number R01CA104663 from the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or of the National Institutes of Health.	Aparicio Oscar, 2005, Curr Protoc Mol Biol, VChapter 21, DOI 10.1002/0471142727.mb2103s69; Araki K, 2003, ONCOGENE, V22, P7632, DOI 10.1038/sj.onc.1206840; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bryne JC, 2008, NUCLEIC ACIDS RES, V36, pD102, DOI 10.1093/nar/gkm955; Christensen J, 2005, NUCLEIC ACIDS RES, V33, P5458, DOI 10.1093/nar/gki855; Croxton R, 2002, ONCOGENE, V21, P1359, DOI 10.1038/sj.onc.1205157; de Bruin A, 2003, J BIOL CHEM, V278, P42041, DOI 10.1074/jbc.M308105200; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DeGregori J, 2006, CURR MOL MED, V6, P739; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Giangrande PH, 2003, MOL CELL BIOL, V23, P3707, DOI 10.1128/MCB.23.11.3707-3720.2003; Giangrande PH, 2004, GENE DEV, V18, P2941, DOI 10.1101/gad.1239304; Hallstrom TC, 2006, GENE DEV, V20, P613, DOI 10.1101/gad.1345006; Hallstrom TC, 2003, P NATL ACAD SCI USA, V100, P10848, DOI 10.1073/pnas.1831408100; Hallstrom TC, 2008, CANCER CELL, V13, P11, DOI 10.1016/j.ccr.2007.11.031; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Kong LJ, 2007, ONCOGENE, V26, P321, DOI 10.1038/sj.onc.1209817; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; Kuhn RM, 2009, NUCLEIC ACIDS RES, V37, pD755, DOI 10.1093/nar/gkn875; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Logan N, 2005, ONCOGENE, V24, P5000, DOI 10.1038/sj.onc.1208703; Matys V, 2006, NUCLEIC ACIDS RES, V34, pD108, DOI 10.1093/nar/gkj143; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Muller M J, 2001, Obes Rev, V2, P15; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Pilpel Y, 2001, NAT GENET, V29, P153, DOI 10.1038/ng724; Polager S, 2002, ONCOGENE, V21, P437, DOI 10.1038/sj.onc.1205102; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Rogoff HA, 2004, MOL CELL BIOL, V24, P2968, DOI 10.1128/MCB.24.7.2968-2977.2004; Schlisio S, 2002, EMBO J, V21, P5775, DOI 10.1093/emboj/cdf577; Sears RC, 2002, J BIOL CHEM, V277, P11617, DOI 10.1074/jbc.R100063200; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Smale ST, 2001, GENE DEV, V15, P2503, DOI 10.1101/gad.937701; STANOJEVIC D, 1991, SCIENCE, V254, P1385, DOI 10.1126/science.1683715; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Takahashi Y, 2000, GENE DEV, V14, P804; Tao YX, 1997, MOL CELL BIOL, V17, P6994, DOI 10.1128/MCB.17.12.6994; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Trimarchi JM, 2001, P NATL ACAD SCI USA, V98, P1519, DOI 10.1073/pnas.041597698; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Wysocka J, 2003, TRENDS BIOCHEM SCI, V28, P294, DOI 10.1016/S0968-0004(03)00088-4; Yamamoto KR, 1998, COLD SPRING HARB SYM, V63, P587, DOI 10.1101/sqb.1998.63.587; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603; Zheng N, 1999, GENE DEV, V13, P666, DOI 10.1101/gad.13.6.666; Zhu WC, 2004, EMBO J, V23, P4615, DOI 10.1038/sj.emboj.7600459; Ziebold U, 2001, GENE DEV, V15, P386, DOI 10.1101/gad.858801	54	25	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2009	28	32					2873	2881		10.1038/onc.2009.153	http://dx.doi.org/10.1038/onc.2009.153			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482VJ	19543322	Green Accepted			2022-12-17	WOS:000268917100003
J	Spinello, I; Quaranta, MT; Pasquini, L; Pelosi, E; Petrucci, E; Pagliuca, A; Castelli, G; Mariani, G; Diverio, D; Foa, R; Testa, U; Labbaye, C				Spinello, I.; Quaranta, M. T.; Pasquini, L.; Pelosi, E.; Petrucci, E.; Pagliuca, A.; Castelli, G.; Mariani, G.; Diverio, D.; Foa, R.; Testa, U.; Labbaye, C.			PLZF-mediated control on c-kit expression in CD34(+) cells and early erythropoiesis	ONCOGENE			English	Article						PLZF; c-kit; hematopoietic progenitor cells; erythropoiesis	RECEPTOR TYROSINE KINASE; ACUTE MYELOID-LEUKEMIA; PROMYELOCYTIC LEUKEMIA; TRANSCRIPTION FACTORS; GERM-CELLS; STEM-CELLS; PROTEIN; CD117; DIFFERENTIATION; IDENTIFICATION	The promyelocytic leukemia zinc-finger protein (PLZF) is a transcription factor and c-kit is a receptor tyrosine kinase associated with human disease, particularly in hematopoietic cells. MicroRNAs (miRs) are post-transcriptional regulators of gene expression, and c-kit has been described as a target of miRs-221 and -222 in erythropoiesis. In the present study, we identified c-kit as a target of PLZF in normal and leukemic cells. Particularly, in erythropoietic (E) culture of CD34(+) progenitors, PLZF is downregulated, whereas c-kit expression at both the mRNA and protein levels inversely increases during the first days of E differentiation. In functional experiments, PLZF transfection induces c-kit downregulation, inhibits E proliferation and delays differentiation, whereas PLZF knockdown induces opposite effects, independently of miRs-221 and -222 expression. The inverse correlation between PLZF and c-kit expression was found in normal CD34(+)38(+/-) hematopoietic progenitor/stem cells and in acute myeloid leukemias of M0/M1 French-American-British subtypes, suggesting that the control of PLZF on c-kit expression may be crucial at the level of the stem cell/progenitor compartment. Altogether, our data indicate a new mechanism of regulation of c-kit expression that involves a transcriptional control by PLZF in CD34(+) cells and early erythropoiesis. Oncogene (2009) 28, 2276-2288; doi: 10.1038/onc.2009.87; published online 4 May 2009	[Spinello, I.; Quaranta, M. T.; Pasquini, L.; Pelosi, E.; Petrucci, E.; Pagliuca, A.; Castelli, G.; Mariani, G.; Testa, U.; Labbaye, C.] Ist Super Sanita, Dept Hematol Oncol & Mol Med, I-00161 Rome, Italy; [Diverio, D.; Foa, R.] Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, Div Hematol, Rome, Italy	Istituto Superiore di Sanita (ISS); Sapienza University Rome	Labbaye, C (corresponding author), Ist Super Sanita, Dept Hematol Oncol & Mol Med, Viale Regina Elena 299, I-00161 Rome, Italy.	catherine.labbaye@iss.it	SPINELLO, ISABELLA/J-8779-2016; pagliuca, alfredo/J-3107-2012; pelosi, elvira/J-7298-2016; Quaranta, Maria Teresa/AAC-2134-2019; Pagliuca, Alfredo/AAI-3689-2020; PETRUCCI, ELEONORA/J-8778-2016; pasquini, luca/J-8319-2016; Testa, Ugo/J-6472-2016; Labbaye, Catherine/J-9930-2016; castelli, germana/J-7244-2016	pagliuca, alfredo/0000-0002-8703-2077; pelosi, elvira/0000-0002-3043-6249; Quaranta, Maria Teresa/0000-0002-5886-507X; PETRUCCI, ELEONORA/0000-0001-6459-490X; pasquini, luca/0000-0002-3484-6288; Testa, Ugo/0000-0001-7900-8942; castelli, germana/0000-0002-3593-1230; Labbaye, Catherine/0000-0003-1255-4396	Italian Ministry of Health; Associazione Italiana per la Ricerca sul Cancro (AIRC); 'Fondazione Roma', Rome, Italy	Italian Ministry of Health(Ministry of Health, Italy); Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); 'Fondazione Roma', Rome, Italy(Fondazione Roma)	We thank Dr F Spadaro, from the Department of Cell Biology and Neuroscience, for her help with confocal microscopy and G Loreto for graphics. This work was supported by institutional grants from the Italian Ministry of Health to UT and CL, from Associazione Italiana per la Ricerca sul Cancro ( AIRC) to RF, and from 'Fondazione Roma', Rome, Italy to UT.	Ball HJ, 1999, NUCLEIC ACIDS RES, V27, P4106, DOI 10.1093/nar/27.20.4106; Bene MC, 1998, BLOOD, V92, P596, DOI 10.1182/blood.V92.2.596.414k05_596_599; Broudy VC, 1997, BLOOD, V90, P1345, DOI 10.1182/blood.V90.4.1345.1345_1345_1364; Buaas FW, 2004, NAT GENET, V36, P647, DOI 10.1038/ng1366; Cascavilla N, 1998, HAEMATOLOGICA, V83, P392; Costoya JA, 2004, NAT GENET, V36, P653, DOI 10.1038/ng1367; Dang DT, 2000, INT J BIOCHEM CELL B, V32, P1103, DOI 10.1016/S1357-2725(00)00059-5; Edling CE, 2007, INT J BIOCHEM CELL B, V39, P1995, DOI 10.1016/j.biocel.2006.12.005; Felicetti F, 2004, ONCOGENE, V23, P4567, DOI 10.1038/sj.onc.1207597; Felli N, 2005, P NATL ACAD SCI USA, V102, P18081, DOI 10.1073/pnas.0506216102; Filipponi D, 2007, MOL CELL BIOL, V27, P6770, DOI 10.1128/MCB.00479-07; Gabbianelli M, 2000, BLOOD, V95, P3555, DOI 10.1182/blood.V95.11.3555.011k16_3555_3561; Gazitt Y, 2004, LEUKEMIA, V18, P1, DOI 10.1038/sj.leu.2403173; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Isken F, 2008, BRIT J HAEMATOL, V140, P153, DOI 10.1111/j.1365-2141.2007.06915.x; Ivins S, 2003, ONCOGENE, V22, P3685, DOI 10.1038/sj.onc.1206328; Jing HI, 2008, MOL CELL, V29, P232, DOI 10.1016/j.molcel.2007.11.020; Kelly KF, 2006, TRENDS CELL BIOL, V16, P578, DOI 10.1016/j.tcb.2006.09.003; Labbaye C, 2002, ONCOGENE, V21, P6669, DOI 10.1038/sj.onc.1205884; Labbaye C, 2008, NAT CELL BIOL, V10, P788, DOI 10.1038/ncb1741; Lennartsson J, 2005, STEM CELLS, V23, P16, DOI 10.1634/stemcells.2004-0117; Majeti R, 2007, CELL STEM CELL, V1, P635, DOI 10.1016/j.stem.2007.10.001; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Munugalavadla V, 2005, CRIT REV ONCOL HEMAT, V54, P63, DOI 10.1016/j.critrevonc.2004.11.005; MUTA K, 1995, BLOOD, V86, P572, DOI 10.1182/blood.V86.2.572.bloodjournal862572; Parrado A, 2000, Hematol J, V1, P15, DOI 10.1038/sj.thj.6200012; Patnaik MM, 2007, CURR CANCER DRUG TAR, V7, P492; Quaranta MT, 2006, ONCOGENE, V25, P399, DOI 10.1038/sj.onc.1209060; Scolnik MP, 2002, LEUKEMIA RES, V26, P615, DOI 10.1016/S0145-2126(01)00182-5; Sperling C, 1997, HAEMATOLOGICA, V82, P617; Tsuzuki S, 2002, BLOOD, V99, P3404, DOI 10.1182/blood.V99.9.3404; Wessely O, 1997, CELL GROWTH DIFFER, V8, P481; YAMAMOTO K, 1993, JPN J CANCER RES, V84, P1136, DOI 10.1111/j.1349-7006.1993.tb02813.x	33	25	27	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 11	2009	28	23					2276	2288		10.1038/onc.2009.87	http://dx.doi.org/10.1038/onc.2009.87			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456XM	19421145				2022-12-17	WOS:000266886300004
J	Guo, Y; Schoell, MC; Freeman, RS				Guo, Y.; Schoell, M. C.; Freeman, R. S.			The von Hippel-Lindau protein sensitizes renal carcinoma cells to apoptotic stimuli through stabilization of BIMEL	ONCOGENE			English	Article						VHL; BIMEL; renal cell carcinoma; apoptosis; protein stability	TUMOR-SUPPRESSOR PROTEIN; PROLYL HYDROXYLASE; MOLECULAR-BASIS; GENE-PRODUCT; HIF-ALPHA; CANCER; PHOSPHORYLATION; EXPRESSION; COMPLEX; FAMILY	von Hippel-Lindau (VHL) disease is caused by germ-line mutations in the VHL tumor suppressor gene and is the most common cause of inherited renal cell carcinoma (RCC). Mutations in the VHL gene also occur in a large majority of sporadic cases of clear-cell RCC, which have high intrinsic resistance to chemotherapy and radiotherapy. Here we show that VHL-deficient RCC cells express lower levels of the proapoptotic Bcl-2 family protein BIMEL and are more resistant to etoposide and UV radiation-induced death compared to the same cells stably expressing the wild-type VHL protein (pVHL). Reintroducing pVHL into VHL-null cells increased the half-life of BIMEL protein without affecting its mRNA expression, and overexpressing pVHL inhibited BIMEL polyubiquitination. Suppressing pVHL expression with RNA interference resulted in a decrease in BIMEL protein and a corresponding decrease in the sensitivity of RCC cells to apoptotic stimuli. Directly inhibiting BIMEL expression in pVHL-expressing RCC cells caused a similar decrease in cell death. These results demonstrate that pVHL acts to promote BIMEL protein stability in RCC cells, and that destabilization of BIMEL in the absence of pVHL contributes to the increased resistance of VHL-null RCC cells to certain apoptotic stimuli.	[Schoell, M. C.; Freeman, R. S.] Univ Rochester, Sch Med, Dept Physiol & Pharmacol, Rochester, NY 14642 USA; [Guo, Y.] Univ Rochester, Sch Med, Interdept Grad Program Neurosci, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Freeman, RS (corresponding author), Univ Rochester, Sch Med, Dept Physiol & Pharmacol, 601 Elmwood Ave,Room 4-6718, Rochester, NY 14642 USA.	robert_freeman@urmc.rochester.edu			National Institutes of Health [NS034400, NS058868]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS058868, R56NS034400, R01NS034400] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Dr William Kaelin for providing cell lines and Dr Thomas Benzing and Dr Patricia Hinkle for providing plasmids used in this study. This work was supported by grants NS034400 and NS058868 from the National Institutes of Health.	Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Cohen HT, 1999, CURR OPIN NEPHROL HY, V8, P325, DOI 10.1097/00041552-199905000-00008; Devarajan P, 2001, J BIOL CHEM, V276, P40599, DOI 10.1074/jbc.M103424200; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Ewings KE, 2007, CELL CYCLE, V6, P2236, DOI 10.4161/cc.6.18.4728; Frew IJ, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.124pe30; Fu J, 2007, J BIOL CHEM, V282, P12410, DOI 10.1074/jbc.M608748200; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Gorospe M, 1999, MOL CELL BIOL, V19, P1289; Hergovich A, 2003, NAT CELL BIOL, V5, P64, DOI 10.1038/ncb899; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Kim M, 2004, BIOCHEM BIOPH RES CO, V320, P945, DOI 10.1016/j.bbrc.2004.06.042; Kurban G, 2008, ONCOGENE, V27, P1004, DOI 10.1038/sj.onc.1210709; Lee S, 2005, CANCER CELL, V8, P155, DOI 10.1016/j.ccr.2005.06.015; Ley R, 2005, CELL DEATH DIFFER, V12, P1008, DOI 10.1038/sj.cdd.4401688; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Lipscomb EA, 1999, J NEUROCHEM, V73, P429, DOI 10.1046/j.1471-4159.1999.0730429.x; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Nyhan MJ, 2008, BIOCHEM SOC T, V36, P472, DOI 10.1042/BST0360472; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Okuda H, 2001, J BIOL CHEM, V276, P43611, DOI 10.1074/jbc.M107880200; Qi H, 2003, CANCER RES, V63, P7076; Qi XJ, 2006, J BIOL CHEM, V281, P813, DOI 10.1074/jbc.M505546200; Roe JS, 2006, MOL CELL, V22, P395, DOI 10.1016/j.molcel.2006.04.006; Schermer B, 2006, J CELL BIOL, V175, P547, DOI 10.1083/jcb.200605092; Schoenfeld AR, 2000, ONCOGENE, V19, P5851, DOI 10.1038/sj.onc.1203985; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; van Houwelingen KP, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-57; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Xie L, 2005, J CELL BIOL, V168, P911, DOI 10.1083/jcb.200407079; YAGODA A, 1995, SEMIN ONCOL, V22, P42; Yang H, 2007, MOL CELL, V28, P15, DOI 10.1016/j.molcel.2007.09.010; Zantl N, 2007, ONCOGENE, V26, P7038, DOI 10.1038/sj.onc.1210510; Zhang WZ, 2008, J BIOL CHEM, V283, P16416, DOI 10.1074/jbc.M802360200; Zhou MI, 2002, J BIOL CHEM, V277, P39887, DOI 10.1074/jbc.M205040200	42	25	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 23	2009	28	16					1864	1874		10.1038/onc.2009.35	http://dx.doi.org/10.1038/onc.2009.35			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	439PW	19305426	Green Accepted			2022-12-17	WOS:000265640500005
J	Thayaparasingham, B; Kunz, A; Peters, N; Kulms, D				Thayaparasingham, B.; Kunz, A.; Peters, N.; Kulms, D.			Sensitization of melanoma cells to TRAIL by UVB-induced and NF-kappa B-mediated downregulation of xIAP	ONCOGENE			English	Article						apoptosis; TRAIL; UVB; xIAP; NF-kappa B	X-LINKED INHIBITOR; INDUCED APOPTOSIS; MALIGNANT-MELANOMA; FLIP EXPRESSION; LIGAND; ACTIVATION; RESISTANCE; CASPASE-8; PROTEINS; MEMBER	Effective treatment of malignant melanoma with the tumor-selective death ligand tumor necrosis-related apoptosis-inducing ligand (TRAIL) is curtailed by the fact that many melanoma cell lines are a priori resistant against TRAIL-induced apoptosis. By investigating 18 melanoma cell lines, we show that TRAIL susceptibility is completely independent of the tumor progression stage but can be positively stimulated by co-exposure to a sublethal ultraviolet B light (UVB) dose, providing an excellent tool to study the mechanism underlying TRAIL resistance. TRAIL resistance could be linked to the ratio of x-linked inhibitor of apoptosis proteins (xIAP) and caspase-3 levels within the cell. UVB-induced sensitization coincides with enhanced xIAP degradation, allowing full caspase-3 processing and activation. It is also accompanied by concomitant I kappa B alpha degradation, resulting in nuclear factor-kappa B (NF-kappa B)-dependent transcriptional repression of xIAP. Loss of xIAP in turn was reduced upon overexpression of an I kappa B alpha super-repressor, thus NF-kappa B activation seems to be responsible for differential regulation of xIAP and consequently determines TRAIL susceptibility. As xIAP-mediated blockade of apoptosis seems to be the dominant cause of TRAIL resistance of all melanoma cell lines investigated here, our data suggest that direct chemical xIAP inhibition or combination treatment with DNA-damaging agents may offer new therapeutic strategies to generally sensitize melanoma toward TRAIL-induced apoptosis.	[Thayaparasingham, B.; Kunz, A.; Peters, N.; Kulms, D.] Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Germany	University of Stuttgart	Kulms, D (corresponding author), Univ Stuttgart, Inst Cell Biol & Immunol, Allmandring 31, D-70569 Stuttgart, Germany.	Dagmar.Kulms@izi.uni-stuttgart.de	Kulms, Dagmar/H-1653-2014		Deutsche Krebshilfe [106699]	Deutsche Krebshilfe(Deutsche Krebshilfe)	We thank Amgen/Genentech (Seattle, USA) for providing TRAIL antibodies. We are grateful to F Meier (Department of Dermato-Oncology, University of Tubingen) for providing melanoma cell lines and melanocytes, H Walczak (Tumour Immunology Unit, Imperial College London) for supplying iz-TRAIL and to H Kashkar (Institute for Medical Microbiology, University of Cologne) for the xIAP-pEGFPC3 construct. This study was funded by Deutsche Krebshilfe 106699.	Amiri KI, 2005, CANCER METAST REV, V24, P301, DOI 10.1007/s10555-005-1579-7; Bouralexis S, 2003, BRIT J CANCER, V89, P206, DOI 10.1038/sj.bjc.6601021; Bullani RR, 2001, J INVEST DERMATOL, V117, P360, DOI 10.1046/j.0022-202x.2001.01418.x; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; Chawla-Sarkar M, 2004, CELL DEATH DIFFER, V11, P915, DOI 10.1038/sj.cdd.4401416; Cheung HH, 2008, MOL BIOL CELL, V19, P2729, DOI 10.1091/mbc.E08-01-0107; CLARK WH, 1991, CANCER METAST REV, V10, P83, DOI 10.1007/BF00049406; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Dohi T, 2004, J BIOL CHEM, V279, P34087, DOI 10.1074/jbc.C400236200; Eckelman BP, 2006, EMBO REP, V7, P988, DOI 10.1038/sj.embor.7400795; Ehrhardt H, 2003, ONCOGENE, V22, P3842, DOI 10.1038/sj.onc.1206520; ELDER DE, 1993, SEMIN DIAGN PATHOL, V10, P18; Falschlehner C, 2007, INT J BIOCHEM CELL B, V39, P1462, DOI 10.1016/j.biocel.2007.02.007; Flaherty KT, 2006, CLIN CANCER RES, V12, p2366S, DOI 10.1158/1078-0432.CCR-05-2505; Franco AV, 2001, J IMMUNOL, V166, P5337, DOI 10.4049/jimmunol.166.9.5337; Ganten TM, 2006, CLIN CANCER RES, V12, P2640, DOI 10.1158/1078-0432.CCR-05-2635; Geserick P, 2008, ONCOGENE, V27, P3211, DOI 10.1038/sj.onc.1210985; Griffith TS, 1998, J IMMUNOL, V161, P2833; Jeremias I, 1998, EUR CYTOKINE NETW, V9, P687; Kashkar H, 2003, J EXP MED, V198, P341, DOI 10.1084/jem.20021279; Kashkar H, 2007, BLOOD, V109, P3982, DOI 10.1182/blood-2006-10-053959; Koschny R, 2007, J MOL MED, V85, P923, DOI 10.1007/s00109-007-0194-1; Kothny-Wilkes G, 1998, J BIOL CHEM, V273, P29247, DOI 10.1074/jbc.273.44.29247; Kurbanov BM, 2005, J INVEST DERMATOL, V125, P1010, DOI 10.1111/j.0022-202X.2005.23900.x; Larribere L, 2004, CELL DEATH DIFFER, V11, P1084, DOI 10.1038/sj.cdd.4401475; Lasithiotakis KG, 2006, CANCER-AM CANCER SOC, V107, P1331, DOI 10.1002/cncr.22126; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Meier F, 2005, FRONT BIOSCI-LANDMRK, V10, P2986, DOI 10.2741/1755; Meier F., 1998, FRONT BIOSCI J VIS L, V3, P1005, DOI [10.2741/a341, DOI 10.2741/A341]; Merino D, 2007, EXPERT OPIN THER TAR, V11, P1299, DOI 10.1517/14728222.11.10.1299; Merino D, 2006, MOL CELL BIOL, V26, P7046, DOI 10.1128/MCB.00520-06; Micheau O, 2002, J BIOL CHEM, V277, P45162, DOI 10.1074/jbc.M206882200; Micheau O, 2004, LEUKEMIA, V18, P1578, DOI 10.1038/sj.leu.2403497; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Panner A, 2005, MOL CELL BIOL, V25, P8809, DOI 10.1128/MCB.25.20.8809-8823.2005; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Poppelmann B, 2005, J BIOL CHEM, V280, P15635, DOI 10.1074/jbc.M413006200; Ricci MS, 2004, MOL CELL BIOL, V24, P8541, DOI 10.1128/MCB.24.19.8541-8555.2004; Riccioni R, 2005, HAEMATOLOGICA, V90, P612; Shi RX, 2005, CANCER RES, V65, P7815, DOI 10.1158/0008-5472.CAN-04-3875; Sohn D, 2006, MOL CELL BIOL, V26, P1967, DOI 10.1128/MCB.26.5.1967-1978.2006; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Strozyk E, 2006, ONCOGENE, V25, P6239, DOI 10.1038/sj.onc.1209655; Ueda Y, 2006, PIGM CELL RES, V19, P112, DOI 10.1111/j.1600-0749.2006.00304.x; Wajant H, 2001, ONCOGENE, V20, P4101, DOI 10.1038/sj.onc.1204558; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang YF, 2002, ENDOCRINOLOGY, V143, P2732, DOI 10.1210/en.143.7.2732; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Xiao C, 2005, EXP CELL RES, V304, P244, DOI 10.1016/j.yexcr.2004.11.002; Zeise E, 2004, J INVEST DERMATOL, V123, P746, DOI 10.1111/j.0022-202X.2004.23420.x; Zhang XD, 2006, CLIN CANCER RES, V12, P1355, DOI 10.1158/1078-0432.CCR-05-2084	54	25	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2009	28	3					345	362		10.1038/onc.2008.397	http://dx.doi.org/10.1038/onc.2008.397			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395UZ	18978816				2022-12-17	WOS:000262550300004
J	Guo, X; Waddell, DS; Wang, W; Wang, Z; Liberati, NT; Yong, S; Liu, X; Wang, XF				Guo, X.; Waddell, D. S.; Wang, W.; Wang, Z.; Liberati, N. T.; Yong, S.; Liu, X.; Wang, X-F			Ligand-dependent ubiquitination of Smad3 is regulated by casein kinase 1 gamma 2, an inhibitor of TGF-beta signaling	ONCOGENE			English	Article						Smad3; TGF-beta; CKI gamma 2; ubiquitination; phosphorylation	GROWTH-FACTOR-BETA; TRANSCRIPTION FACTORS; CELL-MEMBRANE; MH1 DOMAIN; I FAMILY; DEGRADATION; ACTIVATION; WNT; MECHANISM; PROTEINS	Transforming growth factor-beta (TGF-beta) elicits a variety of cellular activities primarily through a signaling cascade mediated by two key transcription factors, Smad2 and Smad3. Numerous regulatory mechanisms exist to control the activity of Smad3, thereby modulating the strength and specificity of TGF-beta responses. In search for potential regulators of Smad3 through a yeast two-hybrid screen, we identified casein kinase 1 gamma 2 (CKI gamma 2) as a novel Smad3-interacting protein. In mammalian cells, CKI gamma 2 selectively and constitutively binds Smad3 but not Smad1, -2 or -4. Functionally, CKI gamma 2 inhibits Smad3-mediated TGF-beta responses including induction of target genes and cell growth arrest, and this inhibition is dependent on CKI gamma 2 kinase activity. Mechanistically, CKI gamma 2 does not affect the basal levels of Smad proteins or activity of the receptors. Rather, CKI gamma 2 preferentially promotes the ubiquitination and degradation of activated Smad3 through direct phosphorylation of its MH2 domain at Ser418. Importantly, mutation of Ser418 to alanine or aspartic acid causes an increase or decrease of Smad3 activity, respectively, in the presence of TGF-beta. CKI gamma 2 is the first kinase known to mark activated Smad3 for destruction. Given its negative function in TGF-beta signaling and its reported overexpression in human cancers, CKI gamma 2 may act as an oncoprotein during tumorigenesis.	[Guo, X.; Waddell, D. S.; Liberati, N. T.; Yong, S.; Wang, X-F] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; [Wang, W.; Liu, X.] Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA; [Wang, Z.] Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA	Duke University; University of Colorado System; University of Colorado Boulder; Duke University	Wang, XF (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, C218 LSRC Bldg,La Salle St Extens, Durham, NC 27710 USA.	wang0011@mc.duke.edu	Waddell, David/J-7435-2015; Waddell, David/AAG-3774-2020	Waddell, David/0000-0001-6749-4461; Waddell, David/0000-0001-6749-4461; LIU, XUEDONG/0000-0001-7209-4964	NIH [DK064113, GM083000, GM083172]; Department of Defense Breast Cancer [DAMD17-00-1-0299]; National Science Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064113] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM083172, R01GM083000] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense Breast Cancer(United States Department of Defense); National Science Foundation(National Science Foundation (NSF)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Drs Jun Kusuda, Joan Massague, Xin-Hua Feng, Rik Derynck, Jun-Lin Guan, James Woodgett and Anita Roberts for valuable reagents. We appreciate the Wang laboratory members for insightful scienti. c discussions and excellent technical support. We thank Natalie Ahn, Kathryn Resing and Will Old for MS facility and support. This work was supported by NIH grants DK064113 and GM083000 to X-F W, and an NIH Grant GM083172 to XL. DSW was supported by Department of Defense Breast Cancer Predoctoral Fellowship DAMD17-00-1-0299. NTL was supported by a National Science Foundation Predoctoral Fellowship.	Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Davidson G, 2005, NATURE, V438, P867, DOI 10.1038/nature04170; Dennler S, 1999, ONCOGENE, V18, P1643, DOI 10.1038/sj.onc.1202729; Dunn NR, 2005, GENE DEV, V19, P152, DOI 10.1101/gad.1243205; Fukuchi M, 2001, MOL BIOL CELL, V12, P1431, DOI 10.1091/mbc.12.5.1431; Gross SD, 1998, CELL SIGNAL, V10, P699, DOI 10.1016/S0898-6568(98)00042-4; Guo X, 2008, GENE DEV, V22, P106, DOI 10.1101/gad.1590908; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Heldin CH, 1999, NAT CELL BIOL, V1, pE195, DOI 10.1038/70223; Imoto S, 2005, FEBS LETT, V579, P2853, DOI 10.1016/j.febslet.2005.04.023; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Izzi L, 2006, NEOPLASIA, V8, P677, DOI 10.1593/neo.06472; Jayaraman L, 2000, J BIOL CHEM, V275, P40710, DOI 10.1074/jbc.M005799200; Kitabayashi AN, 1997, GENOMICS, V46, P133, DOI 10.1006/geno.1997.4991; Knippschild U, 2005, CELL SIGNAL, V17, P675, DOI 10.1016/j.cellsig.2004.12.011; Komuro A, 2004, ONCOGENE, V23, P6914, DOI 10.1038/sj.onc.1207885; Kretschmer A, 2003, ONCOGENE, V22, P6748, DOI 10.1038/sj.onc.1206791; Liberati NT, 2001, J BIOL CHEM, V276, P22595, DOI 10.1074/jbc.M010778200; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Lin X, 2006, CELL, V125, P915, DOI 10.1016/j.cell.2006.03.044; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258; Long JY, 2004, P NATL ACAD SCI USA, V101, P99, DOI 10.1073/pnas.0307598100; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; Poncelet AC, 2007, J BIOL CHEM, V282, P15534, DOI 10.1074/jbc.M701991200; Price MA, 2002, CELL, V108, P823, DOI 10.1016/S0092-8674(02)00664-5; Price MA, 2006, GENE DEV, V20, P399, DOI 10.1101/gad.1394306; Reguly T, 2003, TRENDS CELL BIOL, V13, P216, DOI 10.1016/S0962-8924(03)00075-8; Roberts AB, 2006, CYTOKINE GROWTH F R, V17, P19, DOI 10.1016/j.cytogfr.2005.09.008; Schilling SH, 2006, CELL, V125, P838, DOI 10.1016/j.cell.2006.05.015; Schmierer B, 2005, MOL CELL BIOL, V25, P9845, DOI 10.1128/MCB.25.22.9845-9858.2005; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Vielhaber E, 2001, IUBMB LIFE, V51, P73, DOI 10.1080/15216540152122049; Waddell DS, 2004, J BIOL CHEM, V279, P29236, DOI 10.1074/jbc.M400880200; Wang WS, 2005, NEPHROLOGY, V10, P48, DOI 10.1111/j.1440-1797.2005.00334.x; Weinstein M, 2000, CYTOKINE GROWTH F R, V11, P49, DOI 10.1016/S1359-6101(99)00028-3; Xu L, 2002, MOL CELL, V10, P271, DOI 10.1016/S1097-2765(02)00586-5; Yagi K, 1999, J BIOL CHEM, V274, P703, DOI 10.1074/jbc.274.2.703; Zeng X, 2005, NATURE, V438, P873, DOI 10.1038/nature04185; ZHAI LM, 1995, J BIOL CHEM, V270, P12717, DOI 10.1074/jbc.270.21.12717	46	25	28	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27	58					7235	7247		10.1038/onc.2008.337	http://dx.doi.org/10.1038/onc.2008.337			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382FI	18794808	Green Accepted			2022-12-17	WOS:000261590300002
J	McKenzie, S; Sakamoto, S; Kyprianou, N				McKenzie, S.; Sakamoto, S.; Kyprianou, N.			Maspin modulates prostate cancer cell apoptotic and angiogenic response to hypoxia via targeting AKT	ONCOGENE			English	Article						hypoxia; maspin; prostate cancer; apoptosis; tumor suppression; angiogenesis	INDUCIBLE FACTOR-I; TUMOR-SUPPRESSOR; UP-REGULATION; HUMAN BREAST; EXPRESSION; ADHESION; VEGF; CONTRIBUTES; PROGRESSION; METASTASIS	Hypoxia has been previously linked to the development of both benign prostatic hyperplasia and prostate cancer. This study investigated the effect of maspin, an extracellular matrix (ECM) tumor suppressor, on the apoptotic response of prostate cancer cells to hypoxia. Gene expression pro. ling of human benign and malignant prostate epithelial cells after exposure to hypoxia or normoxia revealed dramatic changes in ECM regulators. Maspin was found to be overexpressed in response to hypoxia in prostate cancer cells, but not in benign prostate cells. To dissect the contribution of maspin to tumor cell responses within a hypoxic microenvironment, we used maspin-overexpressing DU-145 human prostate cancer cells. Exposure to hypoxic conditions (1% O-2) led to a significant increase in apoptosis in the DU-145 maspin cells, compared to DU-145 neo-transfectants without a significant effect on cell migration. This enhanced sensitivity to hypoxia-induced apoptosis leads to a significant suppression of tumor growth and tumor vascularity in vivo by targeting Akt and focal adhesion kinase activation. Our findings implicate maspin in prostate cancer cell response to hypoxia via recruitment of intracellular signaling partners. This study may have significance in the identification of maspin-driven therapeutic targeting in advanced metastatic prostate cancer.	[McKenzie, S.; Sakamoto, S.; Kyprianou, N.] Univ Kentucky, Div Urol, Dept Surg, Lucille P Markey Canc Ctr,Coll Med, Lexington, KY 40536 USA; [McKenzie, S.; Sakamoto, S.; Kyprianou, N.] Univ Kentucky, Dept Mol & Cellular Biochem, Coll Med, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA; [McKenzie, S.; Sakamoto, S.; Kyprianou, N.] Univ Kentucky, Dept Pathol, Coll Med, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky; University of Kentucky	Kyprianou, N (corresponding author), Univ Kentucky, Div Urol, Dept Surg, Lucille P Markey Canc Ctr,Coll Med, MS 283,800 Rose St, Lexington, KY 40536 USA.	nkypr2@uky.edu			National Institutes of Health, NIH [CA107575-01]; NATIONAL CANCER INSTITUTE [R01CA107575] Funding Source: NIH RePORTER	National Institutes of Health, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by a grant from the National Institutes of Health, NIH CA107575-01 (NK). We thank Menglei Zhu for expert assistance with the preparation of the figures and Lorie Howard for help with the paper submission.	Abraham S, 2003, J UROLOGY, V169, P1157, DOI 10.1097/01.ju.0000040245.70349.37; Amir S, 2005, CANCER BIOL THER, V4, P400; Blacque OE, 2002, J BIOL CHEM, V277, P10783, DOI 10.1074/jbc.M110992200; Cher ML, 2003, P NATL ACAD SCI USA, V100, P7847, DOI 10.1073/pnas.1331360100; Corley KM, 2005, J CELL BIOCHEM, V96, P971, DOI 10.1002/jcb.20559; Debes JD, 2004, NEW ENGL J MED, V351, P1488, DOI 10.1056/NEJMp048178; Denk AE, 2007, PIGM CELL RES, V20, P112, DOI 10.1111/j.1600-0749.2007.00363.x; Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Fu XYS, 2005, PROSTATE, V63, P215, DOI 10.1002/pros.20190; Gao N, 2004, MOL CELL BIOCHEM, V255, P33, DOI 10.1023/B:MCBI.0000007259.65742.16; Garrison JB, 2007, CANCER RES, V67, P11344, DOI 10.1158/0008-5472.CAN-07-1662; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Jiang N, 2002, ONCOGENE, V21, P4089, DOI 10.1038/sj.onc.1205507; Kimbro KS, 2006, ENDOCR-RELAT CANCER, V13, P739, DOI 10.1677/erc.1.00728; Kyprianou N, 2000, HISTOL HISTOPATHOL, V15, P1211, DOI 10.14670/HH-15.1211; Lee BL, 2008, CARCINOGENESIS, V29, P44, DOI 10.1093/carcin/bgm232; Lee SM, 2006, CANCER LETT, V242, P231, DOI 10.1016/j.canlet.2005.11.001; Liu JY, 2004, CANCER RES, V64, P1703, DOI 10.1158/0008-5472.CAN-03-2568; McKenzie S, 2006, J CELL BIOCHEM, V97, P18, DOI 10.1002/jcb.20634; Ngamkitidechakul C, 2003, J BIOL CHEM, V278, P31796, DOI 10.1074/jbc.M302408200; Rennebeck G, 2005, CANCER RES, V65, P11230, DOI 10.1158/0008-5472.CAN-05-2763; Rofstad EK, 2005, CANCER RES, V65, P2387, DOI 10.1158/0008-5472.CAN-04-3039; Schaefer JS, 2003, CURR MOL MED, V3, P653, DOI 10.2174/1566524033479519; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; Shi YH, 2005, J PATHOL, V205, P530, DOI 10.1002/path.1734; Tahmatzopoulos A, 2005, ONCOGENE, V24, P5375, DOI 10.1038/sj.onc.1208684; Welsh SJ, 2003, CURR CANCER DRUG TAR, V3, P391, DOI 10.2174/1568009033481732; Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	32	25	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27	57					7171	7179		10.1038/onc.2008.321	http://dx.doi.org/10.1038/onc.2008.321			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	379GG	18931702	Green Accepted			2022-12-17	WOS:000261384100004
J	Nakamura, M; Shimada, K; Konishi, N				Nakamura, M.; Shimada, K.; Konishi, N.			The role of HRK gene in human cancer	ONCOGENE			English	Review						HRK; prostate cancer; glioblastoma; primary central nervous system lymphoma	HUMAN PROSTATE-CANCER; PROMOTER METHYLATION; CELL-DEATH; SECONDARY GLIOBLASTOMAS; PROTEIN EXPRESSION; COLORECTAL-CANCER; DNA METHYLATION; APOPTOTIC INDEX; NERVOUS-SYSTEM; INACTIVATION	Apoptosis regulators play one of the most critical roles in tumorigenesis, and an imbalance between cell proliferation and apoptosis may contribute to tumor progression. HRK was itself originally identified as a proapoptotic gene induced by diminished levels of cytokine in hematopoietic cells and cultured neurons and repressed by the expression of death-repressor proteins. A few analyses of HRK protein expression in primary central nervous system lymphomas have been performed, and little is known about the epigenetic or post-transcriptional mechanisms that may participate in HRK inactivation. Here we show the data on the 5'-CpG methylation status, loss of heterozygosity on 12q13.1 and its association with HRK expression in human malignancies, including prostate cancers, astrocytic tumors and primary central nervous system lymphomas. Aberrant methylation of CpG islands within the promoter is an epigenetic event largely responsible for the silencing of the HRK gene and subsequent low apoptotic counts in our series of malignancies. Inactivation of HRK apparently occurs in a substantial proportion of all tumor phenotypes and, as a potential proapoptotic gene, HRK may contribute to the development and progression of many human cancers. Oncogene (2009) 27, S105-S113; doi: 10.1038/onc.2009.48	[Nakamura, M.; Shimada, K.; Konishi, N.] Nara Med Univ, Dept Pathol, Sch Med, Kashihara, Nara 6348521, Japan	Nara Medical University	Konishi, N (corresponding author), Nara Med Univ, Dept Pathol, Sch Med, 840 Shijo Cho, Kashihara, Nara 6348521, Japan.	nkonishi@naramed-u.ac.jp						Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Debatin KM, 2003, SEMIN CANCER BIOL, V13, P149, DOI 10.1016/S1044-579X(02)00132-3; Downward J, 1999, NAT CELL BIOL, V1, pE33, DOI 10.1038/10026; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Esteller M, 2001, CANCER RES, V61, P3225; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Giovanni A, 2000, J BIOL CHEM, V275, P11553, DOI 10.1074/jbc.275.16.11553; Harris CA, 2001, J BIOL CHEM, V276, P37754; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Higuchi T, 2008, PROSTATE, V68, P105, DOI 10.1002/pros.20600; Imaizumi K, 1999, J BIOL CHEM, V274, P7975, DOI 10.1074/jbc.274.12.7975; Imaizumi K, 1997, J BIOL CHEM, V272, P18842, DOI 10.1074/jbc.272.30.18842; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; Kim HS, 2001, CANCER DETECT PREV, V25, P237; Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215, DOI 10.1093/jnen/61.3.215; Konishi N, 2005, CLIN CANCER RES, V11, P5090, DOI 10.1158/1078-0432.CCR-05-0195; Konishi N, 2005, PATHOL INT, V55, P531, DOI 10.1111/j.1440-1827.2005.01865.x; Konishi N, 2008, CLIN CANCER RES, V14, P4408, DOI 10.1158/1078-0432.CCR-07-4120; Nakamura M, 2001, CARCINOGENESIS, V22, P1715, DOI 10.1093/carcin/22.10.1715; Nakamura M, 2005, ACTA NEUROPATHOL, V110, P402, DOI 10.1007/s00401-005-1065-x; Nakamura M, 2005, LAB INVEST, V85, P165, DOI 10.1038/labinvest.3700223; Nakamura M, 1997, CANCER, V80, P242, DOI 10.1002/(SICI)1097-0142(19970715)80:2<242::AID-CNCR12>3.0.CO;2-U; Nakamura M, 2001, BRAIN PATHOL, V11, P159; Nakamura M, 2006, ONCOLOGY-BASEL, V70, P212, DOI 10.1159/000094322; Nelson WG, 2003, NEW ENGL J MED, V349, P366, DOI 10.1056/NEJMra021562; Obata T, 2003, CLIN CANCER RES, V9, P6410; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj/cdd/4400998; REED JC, 1995, HEMATOL ONCOL CLIN N, V9, P451, DOI 10.1016/S0889-8588(18)30104-7; Sanz C, 2000, BLOOD, V95, P2742, DOI 10.1182/blood.V95.9.2742.009k24_2742_2747; Sanz C, 2002, HAEMATOLOGICA, V87, P903; Sasaki Y, 2001, GENE THER, V8, P1401, DOI 10.1038/sj.gt.3301538; Shimada K, 2006, HISTOL HISTOPATHOL, V21, P415, DOI 10.14670/HH-21.415; Shimada K, 2005, J PATHOL, V206, P423, DOI 10.1002/path.1791; Shimada K, 2008, CANCER SCI, V99, P39, DOI 10.1111/j.1349-7006.2007.00655.x; Steinbach JP, 2002, BRAIN PATHOL, V12, P12; Sunayama J, 2004, CELL DEATH DIFFER, V11, P771, DOI 10.1038/sj.cdd.4401418; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Vakkala M, 1999, CLIN CANCER RES, V5, P319; Wistuba II, 2001, CANCER RES, V61, P3795; Zhang GJ, 1998, ANTICANCER RES, V18, P1989; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	42	25	25	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27			1			S105	S113		10.1038/onc.2009.48	http://dx.doi.org/10.1038/onc.2009.48			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	478DA	19641496				2022-12-17	WOS:000268566800009
J	Braden, WA; McClendon, AK; Knudsen, ES				Braden, W. A.; McClendon, A. K.; Knudsen, E. S.			Cyclin-dependent kinase 4/6 activity is a critical determinant of pre-replication complex assembly	ONCOGENE			English	Article						CDK; cyclin; pre-RC; tumor suppressor; cancer	DNA-REPLICATION; S-PHASE; CELL-CYCLE; PREREPLICATION COMPLEX; CHROMOSOME-REPLICATION; CHROMATIN ASSOCIATION; ORIGIN RECOGNITION; EUKARYOTIC CELLS; RE-REPLICATION; HUMAN CANCER	Cyclin-dependent kinases (CDKs) are important in regulating cell cycle transitions, particularly in coordinating DNA replication. Although the role of CDK2 activity on the replication apparatus has been extensively studied, the role of CDK4/6 in DNA replication control is less understood. Through targeted inhibition of CDK4/6 activity, we demonstrate that CDK4/6 kinase activity promotes cdc6 and cdt1 expression, and pre-replication complex (pre-RC) assembly in cycling cells. Conversely, CDK2 inhibition had no effect on the pre-RC assembly. The inhibition of pre-RC assembly is dependent on a functional retinoblastoma (RB) protein, which mediates downstream effects. As such, CDK4/6 inhibition has minimal effect on the replication apparatus in the absence of RB. The requirement of CDK4/6 was further interrogated using cells lacking D-type cyclins, in which replication complexes form normally, and correspondingly CDK4/6 inhibition had no effect on cell cycle or replication control. However, in the absence of D-type cyclins, CDK2 inhibition resulted in the attenuation of cdc6 and cdt1 levels, suggesting overlapping roles for CDK4/6 and CDK2 in regulating replication protein activity. Finally, CDK4/6 inhibition prevented the accumulation of cdc6 and cdt1 as cells progressed from mitosis through the subsequent G(1). Combined, these studies indicate that CDK4/6 activity is important in regulating the expression of these critical mediators of DNA replication.	[Knudsen, E. S.] Thomas Jefferson Univ, Dept Canc Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Knudsen, ES (corresponding author), Thomas Jefferson Univ, Dept Canc Biol, 233 S 10th St, Philadelphia, PA 19107 USA.	eknudsen@kimmalcancercenter.org			NIEHS [T32 ES07250-16];  [NCI CA106471]; NATIONAL CANCER INSTITUTE [R01CA106471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007250] Funding Source: NIH RePORTER	NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Dr Karen Knudsen and members of both Knudsen laboratories for critical review of the paper. Critical reagents were provided by Dr Piotr Sicinski and Pfizer Corp. This study was funded by a grant to ESK from the NCI CA106471. WAB and AKM are supported by NIEHS training grant T32 ES07250-16.	Aggarwal P, 2007, GENE DEV, V21, P2908, DOI 10.1101/gad.1586007; Angus SP, 2004, MOL CELL BIOL, V24, P5404, DOI 10.1128/MCB.24.12.5404-5420.2004; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; Bartkova J, 1997, Prog Cell Cycle Res, V3, P211; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Blow JJ, 2002, TRENDS CELL BIOL, V12, P72, DOI 10.1016/S0962-8924(01)02203-6; Braden WA, 2006, MOL CELL BIOL, V26, P7667, DOI 10.1128/MCB.00045-06; Broceno C, 2002, P NATL ACAD SCI USA, V99, P14200, DOI 10.1073/pnas.212519499; Coverley D, 2002, NAT CELL BIOL, V4, P523, DOI 10.1038/ncb813; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; Diehl JA, 2002, CANCER BIOL THER, V1, P226, DOI 10.4161/cbt.72; Diffley JFX, 2004, CURR BIOL, V14, pR778, DOI 10.1016/j.cub.2004.09.019; Diffley JFX, 2002, J CELL SCI, V115, P869; DIFFLEY JFX, 1994, CURR OPIN CELL BIOL, V6, P368, DOI 10.1016/0955-0674(94)90028-0; Dimitrova DS, 2002, J CELL SCI, V115, P51; Dimitrova DS, 1999, J CELL BIOL, V146, P709, DOI 10.1083/jcb.146.4.709; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ekholm-Reed S, 2004, J CELL BIOL, V165, P789, DOI 10.1083/jcb.200404092; Fry DW, 2004, MOL CANCER THER, V3, P1427; Fujita M, 1996, J BIOL CHEM, V271, P4349; Geng Y, 2007, MOL CELL, V25, P127, DOI 10.1016/j.molcel.2006.11.029; Guo Y, 2002, ONCOGENE, V21, P7545, DOI 10.1038/sj.onc.1205907; Hateboer G, 1998, MOL CELL BIOL, V18, P6679, DOI 10.1128/MCB.18.11.6679; Hua XH, 1997, J CELL BIOL, V137, P183, DOI 10.1083/jcb.137.1.183; Hwang HC, 2005, ONCOGENE, V24, P2776, DOI 10.1038/sj.onc.1208613; Knudsen KE, 2006, ONCOGENE, V25, P1620, DOI 10.1038/sj.onc.1209371; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Kozar K, 2004, CELL, V118, P477, DOI 10.1016/j.cell.2004.07.025; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Labib K, 2001, MOL BIOL CELL, V12, P3658, DOI 10.1091/mbc.12.11.3658; Lei M, 1997, GENE DEV, V11, P3365, DOI 10.1101/gad.11.24.3365; Liu EB, 2004, J BIOL CHEM, V279, P17283, DOI 10.1074/jbc.C300549200; Mailand N, 2005, CELL, V122, P915, DOI 10.1016/j.cell.2005.08.013; Malumbres M, 2004, CELL, V118, P493, DOI 10.1016/j.cell.2004.08.002; Markey MP, 2002, CANCER RES, V62, P6587; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Mimura S, 2004, NATURE, V431, P1118, DOI 10.1038/nature03024; Nguyen VQ, 2001, NATURE, V411, P1068, DOI 10.1038/35082600; Noton E, 2000, MOL CELL, V5, P85, DOI 10.1016/S1097-2765(00)80405-0; Okuno Y, 2001, EMBO J, V20, P4263, DOI 10.1093/emboj/20.15.4263; Palmero I, 1996, CANCER SURV, V27, P351; Savio M, 2006, CELL CYCLE, V5, P2153, DOI 10.4161/cc.5.18.3235; Senga T, 2006, J BIOL CHEM, V281, P6246, DOI 10.1074/jbc.M512705200; Sever-Chroneos Z, 2001, MOL CELL BIOL, V21, P4032, DOI 10.1128/MCB.21.12.4032-4045.2001; Sherr C J, 2000, Harvey Lect, V96, P73; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Stillman B, 2005, FEBS LETT, V579, P877, DOI 10.1016/j.febslet.2004.12.011; Sullivan M, 2007, NAT REV MOL CELL BIO, V8, P894, DOI 10.1038/nrm2276; Tanaka S, 2002, GENE DEV, V16, P2639, DOI 10.1101/gad.1011002; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; Woo RA, 2003, CELL CYCLE, V2, P316, DOI 10.4161/cc.2.4.468; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603; Yang K, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-32	58	25	29	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2008	27	56					7083	7093		10.1038/onc.2008.319	http://dx.doi.org/10.1038/onc.2008.319			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376PQ	18776921				2022-12-17	WOS:000261195900003
J	Ogiwara, H; Kohno, T; Nakanishi, H; Nagayama, K; Sato, M; Yokota, J				Ogiwara, H.; Kohno, T.; Nakanishi, H.; Nagayama, K.; Sato, M.; Yokota, J.			Unbalanced translocation, a major chromosome alteration causing loss of heterozygosity in human lung cancer	ONCOGENE			English	Article						unbalanced translocation; loss of heterozygosity; lung adenocarcinoma; tumor suppressor gene; mitotic recombination	COLORECTAL CANCERS; DNA-DAMAGE; MOLECULAR PROCESSES; 9P21 DELETIONS; ALLELIC LOSS; MECHANISMS; INSTABILITY; GENE; P53; RETINOBLASTOMA	Loss of heterozygosity (LOH) is a major genetic event causing inactivation of tumor suppressor genes in human carcinogenesis. To elucidate chromosomal mechanisms causing LOH, 201 LOHs in 10 cases of human lung cancer, which were detected bya genome-wide single nucleotide polymorphism array analysis, were investigated for responsible chromosome alterations by integrating information on breakpoints for DNA copy number changes obtained by array-comparative genome hybridization and on numerical and structural chromosomal alterations obtained by spectral karyotyping. The majority(80%) of LOHs were partial chromosome LOHs caused by structural chromosomal alterations, while the remaining (20%) were whole chromosome LOHs caused by whole chromosome deletions. Unbalanced translocation was defined as the most frequent alteration, and it accounted for 30% of all LOHs. Three other structural alterations-interstitial deletion (19%), mitotic recombination (9%) and gene conversion (6%)-also contributed to the occurrence of LOH, while terminal deletion contributed to only a small subset (1%). Since unbalanced translocation is a common chromosomal alteration in lung cancer cells, the results in the present study strongly indicate that a considerable fraction of LOHs detected in lung cancer cells are caused by unbalanced translocation.	[Ogiwara, H.; Kohno, T.; Nakanishi, H.; Nagayama, K.; Sato, M.; Yokota, J.] Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, Tokyo 1040045, Japan	National Cancer Center - Japan	Yokota, J (corresponding author), Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, 1-1,Tsukiji 5 Chome, Tokyo 1040045, Japan.	jyokota@ncc.go.jp		Ogiwara, Hideaki/0000-0003-0860-1807				Abdel-Rahman WM, 2001, P NATL ACAD SCI USA, V98, P2538, DOI 10.1073/pnas.041603298; Adams J, 2005, CANCER RES, V65, P66; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bosco G, 1998, GENETICS, V150, P1037; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; COLVY T, 2004, WHO CLASSIFICATION T, P31; Florl AR, 2003, GENE CHROMOSOME CANC, V37, P141, DOI 10.1002/gcc.10192; Gaasenbeek M, 2006, CANCER RES, V66, P3471, DOI 10.1158/0008-5472.CAN-05-3285; Girard L, 2000, CANCER RES, V60, P4894; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Grigorova M, 2005, CANCER GENET CYTOGEN, V162, P1, DOI 10.1016/j.cancergencyto.2005.03.007; JAMES CD, 1989, P NATL ACAD SCI USA, V86, P2858, DOI 10.1073/pnas.86.8.2858; Katsura Y, 2007, DNA REPAIR, V6, P639, DOI 10.1016/j.dnarep.2006.12.002; Kohno T, 2006, DNA REPAIR, V5, P1273, DOI 10.1016/j.dnarep.2006.05.021; LASKO D, 1991, ANNU REV GENET, V25, P281, DOI 10.1146/annurev.ge.25.120191.001433; Lieber MR, 2003, NAT REV MOL CELL BIO, V4, P712, DOI 10.1038/nrm1202; Masuda A, 2002, ONCOGENE, V21, P6884, DOI 10.1038/sj.onc.1205566; Mitelman F, 2000, MUTAT RES-REV MUTAT, V462, P247, DOI 10.1016/S1383-5742(00)00006-5; MORI N, 1989, CANCER RES, V49, P5130; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; Pennaneach V, 2006, MOL MICROBIOL, V59, P1357, DOI 10.1111/j.1365-2958.2006.05026.x; Phelps RM, 1996, J CELL BIOCHEM, P32; Robles AI, 2002, ONCOGENE, V21, P6898, DOI 10.1038/sj.onc.1205563; Roschke AV, 2003, CANCER RES, V63, P8634; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; Sasaki S, 2003, ONCOGENE, V22, P3792, DOI 10.1038/sj.onc.1206589; Sato M, 2005, GENE CHROMOSOME CANC, V44, P405, DOI 10.1002/gcc.20253; Sato M, 2007, J THORAC ONCOL, V2, P327, DOI 10.1097/01.JTO.0000263718.69320.4c; Schmidt L, 1995, Cancer J Sci Am, V1, P191; Schrock E, 1996, SCIENCE, V273, P494, DOI 10.1126/science.273.5274.494; Sekido Y, 2003, ANNU REV MED, V54, P73, DOI 10.1146/annurev.med.54.101601.152202; Sengupta S, 2005, NAT REV MOL CELL BIO, V6, P44, DOI 10.1038/nrm1546; Shiseki M, 1996, GENE CHROMOSOME CANC, V17, P71, DOI 10.1002/(SICI)1098-2264(199610)17:2<71::AID-GCC1>3.0.CO;2-Y; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; Thiagalingam S, 2001, P NATL ACAD SCI USA, V98, P2698, DOI 10.1073/pnas.051625398; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Virmani AK, 1998, GENE CHROMOSOME CANC, V21, P308, DOI 10.1002/(SICI)1098-2264(199804)21:4<308::AID-GCC4>3.0.CO;2-2; Weinberg RA, 2007, BIOL CANC, P209; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; Yokota J, 2004, CANCER SCI, V95, P197, DOI 10.1111/j.1349-7006.2004.tb02203.x; Zhao XJ, 2004, CANCER RES, V64, P3060, DOI 10.1158/0008-5472.CAN-03-3308; Zhu CM, 2002, CELL, V109, P811, DOI 10.1016/S0092-8674(02)00770-5; ZHU X, 1992, CYTOGENET CELL GENET, V59, P248, DOI 10.1159/000133261	43	25	26	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2008	27	35					4788	4797		10.1038/onc.2008.113	http://dx.doi.org/10.1038/onc.2008.113			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337OJ	18408757				2022-12-17	WOS:000258445100004
J	Ropero, S; Ballestar, E; Alaminos, M; Arango, D; Schwartz, S; Esteller, M				Ropero, S.; Ballestar, E.; Alaminos, M.; Arango, D.; Schwartz, S., Jr.; Esteller, M.			Transforming pathways unleashed by a HDAC2 mutation in human cancer	ONCOGENE			English	Article						histone; HDAC2; deacetylase; epigenetics; chromatin	HISTONE MODIFICATIONS; ACETYLATION; EXPRESSION; EPIGENOMICS; BINDING	Although disruption of histone modi. cation patterns is a common hallmark of human cancer, our knowledge of the mechanistic role of histone-modifying enzymes in its generation is very limited. We have recently identified an inactivating mutation in the histone deacetylase-2 (HDAC2) in sporadic carcinomas with microsatellite instability and in tumors arising in individuals with hereditary nonpolyposis colorectal cancer syndrome. Since HDAC2 seems to be a central player in epigenetic gene repression, we wondered whether HDAC2-truncating mutations conferred a particular expression signature on these cancer cells. Using unsupervised clustering analysis in microsatellite-unstable colorectal cancer cell lines, we have found that HDAC2 mutant cells (RKO and Co115) show a characteristically different expression microarray signature from HDAC2 wild-type cells (HCT-116, SW48, HCT-15 and LoVo). HDAC2 mutant cells exhibit upregulation of tumor-promoting genes, such as those of tyrosine kinases, mediators of cell cycle progression and angiogenic factors. The overexpression of these genes is associated with a loss of HDAC2 recruitment and a gain of histone H4 hyperacetylation in their particular 5'-end promoters, as observed by chromatin immunoprecipitation. Transfection of wild-type HDAC2 in mutant cells reverted this epigenetic pattern by repressing the transforming genes in association with HDAC2 promoter occupancy. These results suggest a role for HDAC2 mutations in human tumorigenesis through the derepression of key genes from multiple cellular transformation pathways.	[Ropero, S.; Ballestar, E.; Esteller, M.] Spanish Natl Canc Ctr CNIO, Canc Epigenet Lab, Madrid 28029, Spain; [Alaminos, M.] Univ Granada, Dept Histol, Granada, Spain; [Alaminos, M.] Hosp Clin Fdn, Granada, Spain; [Alaminos, M.; Arango, D.] Hosp Univ Vall Hebron, Ctr Invest Bioquim & Biol Mol, Barcelona, Catalonia, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); University of Granada; Hospital Universitari Vall d'Hebron	Esteller, M (corresponding author), Spanish Natl Canc Ctr CNIO, Canc Epigenet Lab, Melchor Fernandez Almagro 3, Madrid 28029, Spain.	mesteller@cnio.es	Schwartz, Simo/H-7776-2012; Arango, Diego/AFW-0125-2022; Arango, Diego/M-5667-2016; Esteller, Manel/L-5956-2014; Ballestar, Esteban/ABG-8561-2020; ALAMINOS, MIGUEL/N-9960-2016	Arango, Diego/0000-0003-2953-3284; Arango, Diego/0000-0003-2953-3284; Esteller, Manel/0000-0003-4490-6093; ALAMINOS, MIGUEL/0000-0003-4876-2672; Ballestar, Esteban/0000-0002-1400-2440; Schwartz, Simo/0000-0001-8297-7971	Direct For Biological Sciences [0757780] Funding Source: National Science Foundation	Direct For Biological Sciences(National Science Foundation (NSF)NSF - Directorate for Biological Sciences (BIO))		Ballestar E, 2003, EMBO J, V22, P6335, DOI 10.1093/emboj/cdg604; Dopazo J, 1997, J MOL EVOL, V44, P226, DOI 10.1007/PL00006139; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Fahrner JA, 2002, CANCER RES, V62, P7213; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; Glozak MA, 2007, ONCOGENE, V26, P5420, DOI 10.1038/sj.onc.1210610; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Montgomery RL, 2007, GENE DEV, V21, P1790, DOI 10.1101/gad.1563807; Nguyen CT, 2001, NUCLEIC ACIDS RES, V29, P4598, DOI 10.1093/nar/29.22.4598; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Ropero S, 2006, NAT GENET, V38, P566, DOI 10.1038/ng1773; Ropero S, 2007, MOL ONCOL, V1, P19, DOI 10.1016/j.molonc.2007.01.001; Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Trivedi CM, 2007, NAT MED, V13, P324, DOI 10.1038/nm1552; Zhu P, 2004, CANCER CELL, V5, P455, DOI 10.1016/S1535-6108(04)00114-X	18	25	27	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2008	27	28					4008	4012		10.1038/onc.2008.31	http://dx.doi.org/10.1038/onc.2008.31			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	318JZ	18264134				2022-12-17	WOS:000257089000012
J	Bourdeaut, F; Ribeiro, A; Paris, R; Pierron, G; Couturier, J; Peuchmaur, M; Delattre, O				Bourdeaut, F.; Ribeiro, A.; Paris, R.; Pierron, G.; Couturier, J.; Peuchmaur, M.; Delattre, O.			In neuroblastic tumours, Schwann cells do not harbour the genetic alterations of neuroblasts but may nevertheless share the same clonal origin	ONCOGENE			English	Article						Schwann cell; neuroblastoma; clonality; differentiation; X inactivation	PATCH SIZE; DIFFERENTIATION; GANGLIONEUROBLASTOMA; MATURATION	Neuroblastic tumours are composed of variable proportions of neuroblasts and Schwann cells. Whether both components share a common neoplastic origin is highly debated and discrepant results have been reported about the presence of tumour-related genetic alterations in Schwann cells. We have used X-methylation analysis and array-CGH to investigate contiguous Schwannian and neuroblastic areas in tumours with a nodular pattern. A skewed X inactivation was observed in four out of five stromal components. Interestingly, in these four cases, the X-inactivation profiles of the neuroblastic components were identical to the matched stromal areas. However, whereas all neuroblastic areas displayed chromosomal imbalances, no alteration was found in any Schwann cell components. Similarly, no alteration was observed in a series of 19 tumours with a single stroma-rich component, which occasionally exhibited a skewed X-inactivation pattern (3/17 informative tumours). Altogether, this indicates that most stroma-rich tumours display a polyclonal proliferation and that Schwann cells do not derive from neuroblasts. However, in tumours with both stroma-rich and -poor components, our results suggest that cells from both areas share a common progenitor.	[Bourdeaut, F.; Delattre, O.] Inst Curie, INSERM, Unite Genet & Biol Canc, Sect Rech,U830, F-75248 Paris 05, France; [Ribeiro, A.; Pierron, G.; Delattre, O.] Inst Curie, Unite Genet Somat, Paris, France; [Paris, R.; Peuchmaur, M.] Univ Paris 07, AP HP Hop R Debre, EA3102, Serv Patol, Paris, France; [Couturier, J.] Inst Curie, Cytogenet Unit, Paris, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Delattre, O (corresponding author), Inst Curie, INSERM, Unite Genet & Biol Canc, Sect Rech,U830, 26 Rue Ulm, F-75248 Paris 05, France.	olivier.delattre@curie.fr	, Bourdeaut/AAG-8494-2019	delattre, olivier/0000-0002-8730-2276				Ambros IM, 1996, NEW ENGL J MED, V334, P1505, DOI 10.1056/NEJM199606063342304; Ambros IM, 2001, MED PEDIATR ONCOL, V36, P163; Bhattacharyya I, 1999, ORAL SURG ORAL MED O, V88, P586, DOI 10.1016/S1079-2104(99)70090-9; Chen GL, 2007, BLOOD, V110, P1410, DOI 10.1182/blood-2006-09-018655; Coco S, 2005, J PATHOL, V207, P346, DOI 10.1002/path.1843; DUPIN E, 1990, P NATL ACAD SCI USA, V87, P1119, DOI 10.1073/pnas.87.3.1119; HAAS D, 1988, CANCER, V62, P815; Idbaih A, 2005, ANN NEUROL, V58, P483, DOI 10.1002/ana.20607; Jovanovic L, 2003, J CLIN ENDOCR METAB, V88, P3284, DOI 10.1210/jc.2002-021552; Kubota T, 1999, HUM GENET, V104, P49, DOI 10.1007/s004390050909; La Rosa P, 2006, BIOINFORMATICS, V22, P2066, DOI 10.1093/bioinformatics/btl359; Liu SQ, 2005, AM J PATHOL, V166, P891, DOI 10.1016/S0002-9440(10)62309-7; MERLO GR, 1991, BIOTECHNIQUES, V11, P166; Mora J, 2001, CANCER RES, V61, P6892; Nishihira H, 2000, J CLIN ONCOL, V18, P3012, DOI 10.1200/JCO.2000.18.16.3012; Novelli M, 2003, P NATL ACAD SCI USA, V100, P3311, DOI 10.1073/pnas.0437825100; Peuchmaur M, 2003, CANCER, V98, P2274, DOI 10.1002/cncr.11773; RANGECROFT L, 1978, ARCH DIS CHILD, V53, P815, DOI 10.1136/adc.53.10.815; Raskind WH, 1998, LEUKEMIA, V12, P108, DOI 10.1038/sj.leu.2400934; SUGIMOTO T, 1988, CANCER RES, V48, P2531; Tsai YC, 1996, CANCER RES, V56, P402	21	25	30	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2008	27	21					3066	3071		10.1038/sj.onc.1210965	http://dx.doi.org/10.1038/sj.onc.1210965			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	298IP	18071318				2022-12-17	WOS:000255681700014
J	Cai, CQ; Peng, Y; Buckley, MT; Wei, J; Chen, F; Liebes, L; Gerald, WI; Pincus, MR; Osman, I; Lee, P				Cai, C. Q.; Peng, Y.; Buckley, M. T.; Wei, J.; Chen, F.; Liebes, L.; Gerald, W. I.; Pincus, M. R.; Osman, I.; Lee, P.			Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations	ONCOGENE			English	Article						EGFR; mutation; prostate cancer	CELL LUNG-CANCER; ONCOGENIC TRANSFORMATION; SOMATIC MUTATIONS; SIGNAL TRANSDUCER; EGFR MUTATIONS; KINASE DOMAIN; GEFITINIB; STAT3; INHIBITION; GENE	While epidermal growth factor receptor (EGFR) dysregulation is known to play a critical role in prostate carcinogenesis, there has been no direct evidence indicating EGFR mutations induce tumorigenesis in prostate cancer. We previously identified four novel EGFR somatic mutations in the EGFR tyrosine kinase domain of prostate cancer patients: G735S, G796S, E804G and R841K. In this study, we investigated the oncogenic potential of these somatic mutations by establishing stable clonal NIH3T3 cells expressing these four mutations and WT EGFR to determine their ability to increase cell proliferation and invasion. In the absence of the EGF ligand, cell proliferation was readily increased in G735S, G796S and E804G mutants compared to WT EGFR. The addition of EGF ligand greatly increased cell growth and transforming ability of these same EGFR mutants. Matrigel invasion assays showed enhanced invasion with G735S, G796S and E804G mutants. Western blot analysis showed that these EGFR mutations enhanced cell growth and invasion via constitutive and hyperactive tyrosine phosphorylation and led to the activation of mitogen-activated protein kinase (MAPK), signal transducer and activator of transcription 3 (STAT3) and Akt pathways. Our findings demonstrate the oncogenic activation of three novel EGFR somatic missense mutations in prostate cancer. Molecules that regulate the mechanisms of their oncogenic activation represent novel targets for limiting tumor cell progression, and further elucidation of these mutations will have utility in prostate cancer treatment.	[Cai, C. Q.; Peng, Y.; Wei, J.; Chen, F.; Lee, P.] NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; [Buckley, M. T.; Liebes, L.; Osman, I.] NYU, Sch Med, Dept Med, New York, NY 10016 USA; [Gerald, W. I.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; [Pincus, M. R.; Lee, P.] New York Harbor Healthcare Syst, New York, NY USA; [Pincus, M. R.] SUNY, Dept Pathol, New York, NY USA; [Osman, I.] NYU, Sch Med, Dept Urol, New York, NY 10003 USA	New York University; New York University; Memorial Sloan Kettering Cancer Center; State University of New York (SUNY) System; SUNY Community College; SUNY Maritime College; SUNY Optometry; New York University	Osman, I (corresponding author), NYU, Sch Med, Dept Urol & Med, 522 1st Ave,SML 405, New York, NY 10016 USA.	iman.osman@med.nyu.edu						Arteaga CL, 2006, CANCER CELL, V9, P421, DOI 10.1016/j.ccr.2006.05.014; Barton BE, 2004, MOL CANCER THER, V3, P11; Bell DW, 2005, J CLIN ONCOL, V23, P8081, DOI 10.1200/JCO.2005.02.7078; Bellezza I, 2006, AM J PATHOL, V169, P2199, DOI 10.2353/ajpath.2006.060171; Choi SH, 2007, ONCOGENE, V26, P1567, DOI 10.1038/sj.onc.1209957; CHU YW, 1993, P NATL ACAD SCI USA, V90, P4261, DOI 10.1073/pnas.90.9.4261; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Danielsen AJ, 2002, EXP CELL RES, V275, P9, DOI 10.1006/excr.2002.5494; DeMiguel F, 2002, PROSTATE, V52, P123, DOI 10.1002/pros.10110; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; Douglas DA, 2006, FRONT BIOSCI-LANDMRK, V11, P2518, DOI 10.2741/1986; Giri D, 2001, AM J PATHOL, V159, P2159, DOI 10.1016/S0002-9440(10)63067-2; Greulich H, 2005, PLOS MED, V2, P1167, DOI 10.1371/journal.pmed.0020313; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Huang HF, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-2; Hubbard SR, 2005, CANCER CELL, V7, P287, DOI 10.1016/j.ccr.2005.04.004; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Lee JC, 2006, PLOS MED, V3, P2264, DOI 10.1371/journal.pmed.0030485; Lee JW, 2005, CLIN CANCER RES, V11, P2879, DOI 10.1158/1078-0432.CCR-04-2029; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Nagahara H, 2005, CLIN CANCER RES, V11, P1368, DOI 10.1158/1078-0432.CCR-04-1894; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Ratan HL, 2003, BJU INT, V92, P890, DOI 10.1111/j.1464-410X.2003.04503.x; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SCHREIBER AB, 1983, J BIOL CHEM, V258, P846; Shao H, 2003, CANCER RES, V63, P3923; Sherwood ER, 1998, BRIT J CANCER, V77, P855, DOI 10.1038/bjc.1998.142; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Spiotto MT, 2000, PROSTATE, V42, P88, DOI 10.1002/(SICI)1097-0045(20000201)42:2<88::AID-PROS2>3.0.CO;2-P; Torring N, 2003, PROSTATE, V56, P142, DOI 10.1002/pros.10245; USHIRO H, 1980, J BIOL CHEM, V255, P8363; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013	34	25	26	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	22					3201	3210		10.1038/sj.onc.1210983	http://dx.doi.org/10.1038/sj.onc.1210983			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301LL	18193092				2022-12-17	WOS:000255897600013
J	Caldon, C; Lee, C; Sutherland, R; Musgrove, E				Caldon, Ce; Lee, Csl; Sutherland, Rl; Musgrove, Ea			Wilms' tumor protein 1: an early target of progestin regulation in T-47D breast cancer cells that modulates proliferation and differentiation	ONCOGENE			English	Article						Wt1; progesterone; cyclin D1; proliferation; lipogenesis	SUPPRESSOR GENE WT1; DEPENDENT KINASE INHIBITORS; CYCLIN D1; TRANSCRIPTIONAL ACTIVATION; GROWTH-FACTOR; EXPRESSION; PROGRESSION; ESTROGEN; RECEPTOR; INDUCTION	Progesterone regulates the proliferation and differentiation of normal mammary epithelium. In breast cancer cells, progesterone and its synthetic analogs, progestins, induce long-term growth inhibition and differentiation. However, the mechanisms responsible are not fully understood. When T-47D breast cancer cells were treated with the synthetic progestin ORG 2058 (16 alpha-ethoxy-21-hydroxy-19-norpregn-4-en-3,20-dione), all isoforms of Wilms' tumor protein 1 (Wt1) mRNA and protein were rapidly downregulated. We reasoned that the decrease in Wt1 levels may contribute to the long-term antiproliferative and differentiative effects of progestins as proliferation and differentiation are known end points of Wt1 action. Consistent with this idea, Wt1 small interfering RNA led to a decrease in S phase and cyclin D1 levels, and increased Oil-Red-O staining, indicating increased lipogenesis. Conversely, overexpression of Wt1 attenuated the decrease in S phase induced by ORG 2058 at 48-96 h. This was accompanied by the sustained expression of cyclin D1 despite progestin treatment, and increased levels of retinoblastoma (Rb) phosphorylation at sites targeted by cyclin D1-Cdk4 (Ser249/ Thr252). Wt1 overexpression also attenuated the ORG 2058-mediated increase in fatty acid synthase levels and reduced lipogenesis. Thus, Wt1 downregulation was sufficient to mimic the effects of progestin and was necessary for complete progestin-mediated proliferative arrest and subsequent differentiation. Furthermore, Wt1 overexpression modulated the effects of progestins but not anti-estrogens or androgens. These results indicate that Wt1 is an important early target of progestins that regulates both proliferation and differentiation in breast cancer cells.	[Caldon, Ce; Lee, Csl; Sutherland, Rl; Musgrove, Ea] St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Darlinghurst, NSW 2010, Australia; [Caldon, Ce; Sutherland, Rl; Musgrove, Ea] Univ New S Wales, Fac Med, St Vincents Clin Sch, Kensington, NSW 2033, Australia	Garvan Institute of Medical Research; St Vincents Hospital Sydney; University of New South Wales Sydney	Caldon, C (corresponding author), St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, 384 Victoria St, Darlinghurst, NSW 2010, Australia.	e.musgrove@garvan.org.au	Caldon, Liz/C-1559-2009; Sutherland, Robert L/A-8378-2008	Caldon, Liz/0000-0003-1392-3472; 				Anthony FW, 2003, J SOC GYNECOL INVEST, V10, P509, DOI 10.1016/S1071-5576(03)00147-3; Baudry D, 2000, CLIN CANCER RES, V6, P3957; Bray JD, 2005, J STEROID BIOCHEM, V97, P328, DOI 10.1016/j.jsbmb.2005.06.032; Burwell EA, 2007, ONCOGENE, V26, P3423, DOI 10.1038/sj.onc.1210127; Castro-Rivera E, 2001, J BIOL CHEM, V276, P30853, DOI 10.1074/jbc.M103339200; CHAMBON M, 1989, J STEROID BIOCHEM, V33, P915, DOI 10.1016/0022-4731(89)90240-9; Englert C, 1997, CANCER RES, V57, P1429; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Graham JD, 2005, MOL ENDOCRINOL, V19, P2713, DOI 10.1210/me.2005-0126; Groshong SD, 1997, MOL ENDOCRINOL, V11, P1593, DOI 10.1210/me.11.11.1593; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; Han YQ, 2004, ONCOGENE, V23, P6933, DOI 10.1038/sj.onc.1207609; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Hui R, 2002, CANCER RES, V62, P6916; Jomgeow T, 2006, CANCER SCI, V97, P259, DOI 10.1111/j.1349-7006.2006.00169.x; Kester HA, 1997, J BIOL CHEM, V272, P16637, DOI 10.1074/jbc.272.26.16637; KUDOH T, 1995, P NATL ACAD SCI USA, V92, P4517, DOI 10.1073/pnas.92.10.4517; Lee SB, 2001, EXP CELL RES, V264, P74, DOI 10.1006/excr.2000.5131; Lee TH, 1999, NUCLEIC ACIDS RES, V27, P2889, DOI 10.1093/nar/27.14.2889; Loeb DM, 2001, CANCER RES, V61, P921; Loeb DM, 2002, INT J HEMATOL, V76, P117, DOI 10.1007/BF02982573; Loeb DM, 2002, J BIOL CHEM, V277, P19627, DOI 10.1074/jbc.M201336200; Martel PM, 2006, EXP CELL RES, V312, P278, DOI 10.1016/j.yexcr.2005.10.022; Miyoshi Y, 2002, CLIN CANCER RES, V8, P1167; Musgrove EA, 2001, J BIOL CHEM, V276, P47675, DOI 10.1074/jbc.M106371200; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; Musgrove EA, 1998, MOL CELL BIOL, V18, P1812, DOI 10.1128/MCB.18.4.1812; MUSGROVE EA, 1991, MOL CELL BIOL, V11, P5032, DOI 10.1128/MCB.11.10.5032; MUSGROVE EA, 1995, INT J CANCER, V63, P584, DOI 10.1002/ijc.2910630420; Nakatsuka S, 2006, MODERN PATHOL, V19, P804, DOI 10.1038/modpathol.3800588; Oji Y, 1999, JPN J CANCER RES, V90, P194, DOI 10.1111/j.1349-7006.1999.tb00733.x; ORMANDY CJ, 1992, INT J CANCER, V50, P777, DOI 10.1002/ijc.2910500519; Rae FK, 2004, ONCOGENE, V23, P3067, DOI 10.1038/sj.onc.1207360; RAMIREZZACARIAS JL, 1992, HISTOCHEMISTRY, V97, P493, DOI 10.1007/BF00316069; Reizner N, 2005, J MOL ENDOCRINOL, V35, P135, DOI 10.1677/jme.1.01761; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Sakamaki T, 2006, MOL CELL BIOL, V26, P5449, DOI 10.1128/MCB.02074-05; Scharnhorst V, 2001, GENE, V273, P141, DOI 10.1016/S0378-1119(01)00593-5; Siehl JM, 2004, ANN HEMATOL, V83, P745, DOI 10.1007/s00277-004-0941-0; Silberstein GB, 2002, ONCOGENE, V21, P1009, DOI 10.1038/sj.onc.1205172; Silberstein GB, 1997, P NATL ACAD SCI USA, V94, P8132, DOI 10.1073/pnas.94.15.8132; Sutherland RL, 1998, J MAMMARY GLAND BIOL, V3, P63, DOI 10.1023/A:1018774302092; Swarbrick A, 2000, MOL CELL BIOL, V20, P2581, DOI 10.1128/MCB.20.7.2581-2591.2000; Sweeney KJ, 1998, ONCOGENE, V16, P2865, DOI 10.1038/sj.onc.1201814; Tuna M, 2005, ONCOGENE, V24, P1648, DOI 10.1038/sj.onc.1208345; Wagner KD, 2002, EMBO J, V21, P1398, DOI 10.1093/emboj/21.6.1398; Wagner N, 2005, DEVELOPMENT, V132, P1327, DOI 10.1242/dev.01682; Wagner N, 2002, CELL GROWTH DIFFER, V13, P297; WATTS CKW, 1995, MOL ENDOCRINOL, V9, P1804, DOI 10.1210/me.9.12.1804; Zaia A, 2001, ANTICANCER RES, V21, P1; Zapata-Benavides P, 2002, BIOCHEM BIOPH RES CO, V295, P784, DOI 10.1016/S0006-291X(02)00751-9	52	25	27	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 3	2008	27	1					126	138		10.1038/sj.onc.1210622	http://dx.doi.org/10.1038/sj.onc.1210622			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	247YO	17599043				2022-12-17	WOS:000252118700013
J	Rigas, AC; Robson, CN; Curtin, NJ				Rigas, A. C.; Robson, C. N.; Curtin, N. J.			Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer	ONCOGENE			English	Article						androgen-independent prostate cancer; bicalutamide; cyclin-dependent kinase inhibitor; LNCaP	GROWTH-INHIBITION; CYCLIN; RECEPTOR; CELLS; BICALUTAMIDE; EXPRESSION; P27(KIP1); PHOSPHORYLATION; PROGRESSION; ANTAGONIST	Antiandrogens are initially effective in controlling prostate cancer (CaP), the second most common cancer in men, but resistance, associated with the loss of androgen-regulated cell cycle control, is a major problem. At present there is no effective treatment for androgen-independent prostate cancer ( AIPC). Cellular proliferation is driven by cyclin-dependent kinases (CDKs) with kinase inhibitors (for example, p27) applying the breaks. We present the first investigation of the therapeutic potential of CDK inhibitors, using the guanine-based CDK inhibitor NU2058 (CDK2 IC50=17 mu M, CDK1 IC50 26 mu M), in comparison with the antiandrogen bicalutamide ( Casodex) in AIPC cells. A panel of AIPC cells was found to be resistant to Casodex-induced growth inhibition, but with the exception of PC3 (GI(50)=38 mu M) and CWR22Rv1 (GI(50)=46 mu M) showed similar sensitivity to NU2058 (GI(50)=10-17 mu M) compared to androgen-sensitive LNCaP cells (GI(50)=15 mu M). In LNCaP cells and their Casodex-resistant derivative, LNCaP-cdxR, growth inhibition by NU2058 was accompanied by a concentration-dependent increase in p27 levels, reduced CDK2 activity and pRb phosphorylation, a decrease in early gene expression and G1 cell cycle phase arrest in both cell lines. In response to Casodex, there were similar observations in LNCaP cells ( GI(50)=6 +/- 3 mu M Casodex) but not in LNCaP-cdxR cells (GI(50)=24 +/- 5 lM Casodex).	[Rigas, A. C.; Robson, C. N.; Curtin, N. J.] Newcastle Univ, No Inst Canc Res, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Curtin, NJ (corresponding author), Newcastle Univ, No Inst Canc Res, Paul OGorman Bldg,Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	n.j.curtin@ncl.ac.uk		Curtin, Nicola/0000-0003-1369-1843	MRC [G0500966] Funding Source: UKRI; Medical Research Council [G0500966] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Aleem E, 2005, NAT CELL BIOL, V7, P831, DOI 10.1038/ncb1284; Angus SP, 2002, J BIOL CHEM, V277, P44376, DOI 10.1074/jbc.M205911200; Arris CE, 2000, J MED CHEM, V43, P2797, DOI 10.1021/jm990628o; Cai DP, 2006, CANCER RES, V66, P9270, DOI 10.1158/0008-5472.CAN-06-1758; Drees M, 1997, CLIN CANCER RES, V3, P273; Edwards BK, 2005, JNCI-J NATL CANCER I, V97, P1407, DOI 10.1093/jnci/dji289; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Ferrando AA, 1996, HUM GENET, V97, P91; Gregory CW, 2001, J ANDROL, V22, P537; Guo YP, 1997, CLIN CANCER RES, V3, P2269; Halkidou K, 2003, ONCOGENE, V22, P2466, DOI 10.1038/sj.onc.1206342; Hara T, 2003, CANCER RES, V63, P149; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Hardcastle IR, 2004, J MED CHEM, V47, P3710, DOI 10.1021/jm0311442; Hu B, 2001, MOL CELL BIOL, V21, P2755, DOI 10.1128/MCB.21.8.2755-2766.2001; Karan D, 2002, CARCINOGENESIS, V23, P967, DOI 10.1093/carcin/23.6.967; KAWAMATA N, 1995, CANCER RES, V55, P2266; Knillova J, 2004, NEOPLASMA, V51, P358; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Kokontis JM, 2005, PROSTATE, V65, P287, DOI 10.1002/pros.20285; Li YW, 2000, INT J ONCOL, V17, P755; Macri E, 1998, CANCER METAST REV, V17, P337, DOI 10.1023/A:1006133620914; Masiello D, 2002, J BIOL CHEM, V277, P26321, DOI 10.1074/jbc.M203310200; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Taneja SS, 2002, J CELL BIOCHEM, V84, P188, DOI 10.1002/jcb.1278; Tepper CG, 2002, CANCER RES, V62, P6606; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9	29	25	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 6	2007	26	55					7611	7619		10.1038/sj.onc.1210586	http://dx.doi.org/10.1038/sj.onc.1210586			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SK	17599054				2022-12-17	WOS:000251537800002
J	Taneja, P; Mallakin, A; Matise, LA; Frazier, DP; Choudhary, M; Inoue, K				Taneja, P.; Mallakin, A.; Matise, L. A.; Frazier, D. P.; Choudhary, M.; Inoue, K.			Repression of Dmp1 and Arf transcription by anthracyclins: critical roles of the NF-kappa B subunit p65	ONCOGENE			English	Article						Dmp1; Arf; p53; NF-kappa B; anthracyclin; UV-C	CELL-CYCLE ARREST; TUMOR SUPPRESSION; GENE-EXPRESSION; P53; RAS; TRANSFORMATION; RESPONSES; CANCER	Both genotoxic and oncogenic stress activates the nuclear factor-kappa B (NF-kappa B) and p53 proteins however the p53 activity is antagonized by NF-kappa B signaling. Dmp1 is a Myb-like transcription factor that activates the Arf-p53 pathway. The Dmp1 promoter was activated by a classical NF-kappa B activator tumor necrosis factor a but repressed by treatment of cells with non classical NF-kappa B activators anthracyclins and UV-C. p65 and other subsets of NF-kappa B proteins were bound to the Dmp1 promoter following anthracyclin/UV-C treatment of rodent. broblasts. This resulted in the downregulation of Dmp1 mRNA and protein. Repression of the Dmp1 transcription by anthracyclins depended on the unique NF-kappa B site on the promoter. Downregulation of p65 significantly attenuated the repression of the Dmp1 promoter by anthracyclins/UV-C. The amount of Dmp1 bound to the Arf promoter decreased significantly upon anthracyclin treatment this in turn downregulated the Arf levels. Repression of the Arf promoter by p65 or anthracyclins depended on Dmp1 which was significantly attenuated in Dmp1(-/-) cells. Both Dmp1(-/-) and Arf(-/-) cells showed resistance to anthracyclin-induced cell death compared to wild-type cells non-immortalized p65-knockdown cells were much more sensitive. Thus the Dmp1-Arf pathway is repressed by p65 in response to genotoxic stress which implicates a novel mechanism of p53 inactivation by NF-kappa B.	Wake Forest Univ Hlth Sci, Dept Pathol, Winston Salem, NC USA; Wake Forest Univ Hlth Sci, Dept Canc Biol, Winston Salem, NC USA	Wake Forest University; Wake Forest University School of Medicine; Wake Forest University; Wake Forest University School of Medicine	Inoue, K (corresponding author), Wake Forest Univ Hlth Sci, Dept Pathol & Canc Biol, 2102 Gray Bldg, Med Ctr Blvd, Winston Salem, NC 27157 USA.	kinoue@wfubmc.edu	Choudhary, Mayur/AAU-3497-2021	Choudhary, Mayur/0000-0001-8056-011X	NCI NIH HHS [5R01CA106314, R01 CA106314-03, R01 CA106314-02, R01 CA106314, P30 CA012197, CA12197-31] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA106314, P30CA012197] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; DeVita V. T., 2005, CANC PRINCIPLES PRAC; Gallagher S, 2005, CELL CYCLE, V4, P465, DOI 10.4161/cc.4.3.1526; Gapuzan MER, 2005, ONCOGENE, V24, P6574, DOI 10.1038/sj.onc.1208809; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Huang DB, 2005, STRUCTURE, V13, P1365, DOI 10.1016/j.str.2005.06.018; Inoue K, 1999, P NATL ACAD SCI USA, V96, P3993, DOI 10.1073/pnas.96.7.3993; Inoue K, 2001, GENE DEV, V15, P2934, DOI 10.1101/gad.929901; Inoue K, 2000, GENE DEV, V14, P1797; INOUE K, 2007, ONCOGENE        0122; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kurz EU, 2004, J BIOL CHEM, V279, P53272, DOI 10.1074/jbc.M406879200; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Mallakin A, 2006, ONCOGENE, V25, P7703, DOI 10.1038/sj.onc.1209750; Perkins ND, 2004, TRENDS CELL BIOL, V14, P64, DOI 10.1016/j.tcb.2003.12.004; Rocha S, 2003, MOL CELL BIOL, V23, P4713, DOI 10.1128/MCB.23.13.4713-4727.2003; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Saccani S, 2003, MOL CELL, V11, P1563, DOI 10.1016/S1097-2765(03)00227-2; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Sreeramaneni R, 2005, MOL CELL BIOL, V25, P220, DOI 10.1128/MCB.25.1.220-232.2005; Tergaonkar V, 2002, CANCER CELL, V1, P493, DOI 10.1016/S1535-6108(02)00068-5; Watts TH, 2005, ANNU REV IMMUNOL, V23, P23, DOI 10.1146/annurev.immunol.23.021704.115839; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Yoshimura A, 2006, CANCER SCI, V97, P439, DOI 10.1111/j.1349-7006.2006.00197.x	28	25	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 22	2007	26	53					7457	7466		10.1038/sj.onc.1210568	http://dx.doi.org/10.1038/sj.onc.1210568			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DA	17546045	Green Accepted			2022-12-17	WOS:000251282000007
J	Carbone, M; Albelda, SM; Broaddus, VC; Flores, RM; Hillerdal, G; Jaurand, MC; Jaerheim, KK; Pass, HI; Robinson, B; Tsao, A				Carbone, M.; Albelda, S. M.; Broaddus, V. C.; Flores, R. M.; Hillerdal, G.; Jaurand, M-C; Jaerheim, K. K.; Pass, H. I.; Robinson, B.; Tsao, A.			Eighth international mesothelioma interest group	ONCOGENE			English	Review						mesothelioma; asbestos; SV40; gene-environment	PLEURAL MESOTHELIOMA; ASBESTOS EXPOSURE; IN-VITRO; SV40; MODEL; TRANSFORMATION; EXPRESSION; MURINE; CELLS; RISK	The eighth International Mesothelioma Interest Group (IMIG) meeting was held in Chicago, IL, United States, in 19-22 October 2006 to discuss mesothelioma -the cancer often linked to asbestos exposure. It is a very aggressive malignancy with a median survival of less than 1 year from diagnosis. Millions of people have been exposed worldwide to asbestos, especially during the second half of the twentieth century when asbestos use increased significantly. The tons of asbestos utilized in the past remain a health hazard for current and future generations because asbestos is difficult to be disposed off. This makes asbestos and mesothelioma research a public health issue in addition to a medical problem. Moreover, the very high costs of asbestos litigation have a signi. cant impact on the whole economy. In the United States, up until 2001, defendant companies had paid 54 billion dollars in claims and estimated future liabilities ranged from 145 to 210 billion. Therefore, asbestos research is of great interest to a large audience that includes patients, millions of asbestos-exposed individuals, scientists, physicians, public health officials, politicians, unions of asbestos workers, lawyers and the public at large. During the past few years, there has been signi. cant progress in understanding the process of mineral fiber carcinogenesis and mesothelioma pathogenesis. With improved understanding of the pathogenesis of mesothelioma, new diagnostic, preventive and therapeutic options are being developed. A total of 247 papers were presented at the IMIG: the abstracts of these presentations were published in Lung Cancer, Supplement 1, October 2006. Here, experts in different disciplines critically review some of the most exciting presentations of the IMIG meeting. The result is a comprehensive review of the research field of asbestos carcinogenesis and mesothelioma, and of the progress that has been made in recent years in both basic and clinical sciences.	Univ Hawaii, Canc Res Ctr, Honolulu, HI 96813 USA; Univ Penn, Med Ctr, Thorac Oncol Res Lab, Philadelphia, PA 19104 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA USA; Mem Sloan Kettering Canc Ctr, Dept Surg, Thorac Serv, New York, NY USA; Karolonska Univ Hosp, Dept Pulm Med, Stockholm, Sweden; INSERM, U674, Fdn Jean Dausset CEPH, IFR105, Paris, France; Univ Paris 07, Paris, France; Canc Registry Norway, Oslo, Norway; NYU, Sch Med, Dept Cardiothorac Surg, New York, NY USA; Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia; Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA	Cancer Research Center of Hawaii; University of Hawaii System; University of Pennsylvania; University of California System; University of California San Francisco; Memorial Sloan Kettering Cancer Center; Karolinska Institutet; Karolinska University Hospital; Foundation Jean Dausset-CEPH; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; University of Oslo; New York University; University of Western Australia; University of Texas System; UTMD Anderson Cancer Center	Carbone, M (corresponding author), Univ Hawaii, Canc Res Ctr, 651 Ilalo St,BSB Room 231, Honolulu, HI 96813 USA.	mcarbone@crch.hawaii.edu	JAURAND, MARIE-CLAUDE/S-3538-2017; Robinson, Bruce/N-1900-2014	JAURAND, MARIE-CLAUDE/0000-0002-0915-6728; Pass, Harvey/0000-0003-3222-3471; Kjaerheim, Kristina/0000-0003-0691-3735				Altomare DA, 2005, CANCER RES, V65, P8090, DOI 10.1158/0008-5472.CAN-05-2312; BOOKCHIN D, 2004, VIRUS VACCINE, P287; Broaddus VC, 2005, J BIOL CHEM, V280, P12486, DOI 10.1074/jbc.M408190200; Cacciotti P, 2005, CANCER RES, V65, P5256, DOI 10.1158/0008-5472.CAN-05-0127; Carbone M, 2007, NAT REV CANCER, V7, P147, DOI 10.1038/nrc2068; Cristaudo A, 2005, CANCER RES, V65, P3049, DOI 10.1158/0008-5472.CAN-04-2219; Cutrone R, 2005, CANCER RES, V65, P10273, DOI 10.1158/0008-5472.CAN-05-2028; Gazdar AF, 2002, NAT REV CANCER, V2, P957, DOI 10.1038/nrc947; Gordon GJ, 2005, CLIN CANCER RES, V11, P4406, DOI 10.1158/1078-0432.CCR-04-2181; Kim KL, 2005, AM J RESP CELL MOL, V33, P541, DOI 10.1165/rcmb.2004-0355OC; Kroczynska B, 2006, P NATL ACAD SCI USA, V103, P14128, DOI 10.1073/pnas.0604544103; LAGNESE JA, 2005, MALIGNANT MESOTHELIO, P821; Lecomte C, 2005, CELL CYCLE, V4, P1862, DOI 10.4161/cc.4.12.2300; Lopez-Rios F, 2004, LANCET, V364, P1157, DOI 10.1016/S0140-6736(04)17102-X; Lopez-Rios F, 2006, CANCER RES, V66, P2970, DOI 10.1158/0008-5472.CAN-05-3907; Mazieres J, 2005, INT J CANCER, V117, P326, DOI 10.1002/ijc.21160; Pass HI, 2005, NEW ENGL J MED, V353, P1564, DOI 10.1056/NEJMoa051185; Pietruska JR, 2007, CANCER RES, V67, P3637, DOI 10.1158/0008-5472.CAN-05-3727; Robinson BWS, 2003, LANCET, V362, P1612, DOI 10.1016/S0140-6736(03)14794-0; Robinson C, 2006, CANCER RES, V66, P10786, DOI 10.1158/0008-5472.CAN-05-4668; Shoemaker AR, 2006, CANCER RES, V66, P8731, DOI 10.1158/0008-5472.CAN-06-0367; Testa JR, 1998, CANCER RES, V58, P4505; Yang HN, 2006, P NATL ACAD SCI USA, V103, P10397, DOI 10.1073/pnas.0604008103	23	25	25	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2007	26	49					6959	6967		10.1038/sj.onc.1210515	http://dx.doi.org/10.1038/sj.onc.1210515			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223YN	17496929				2022-12-17	WOS:000250412200001
J	Yang, L; Lin, C; Sun, SY; Zhao, S; Liu, ZR				Yang, L.; Lin, C.; Sun, S-Y; Zhao, S.; Liu, Z-R			A double tyrosine phosphorylation of P68 RNA helicase confers resistance to TRAIL-induced apoptosis	ONCOGENE			English	Article						P68 RNA helicase; TRAIL; phosphorylation; XAF1; caspase; DEAD box; PDGF autocrine	MALIGNANT GLIOMA-CELLS; LIGAND TRAIL; CANCER CELLS; MECHANISMS; EXPRESSION; GROWTH; DEATH; XAF1; XIAP; IDENTIFICATION	Tumor necrosis factor- related apoptosis- inducing ligand ( TRAIL) is a promising anticancer agent with the capability of inducing apoptosis specifically in tumor cells. However, cancer cells of many cancer types developed TRAIL resistance, limiting the applications of TRAIL in cancer therapies. We show here that p68 acquires a double tyrosine phosphorylation at Y593 and Y595 in TRAIL- resistant T98G glioblastoma cells. The double phosphorylations are induced by platelet- derived growth factor autocrine loop. The double phosphorylation mediates resistance to TRAIL- induced apoptosis. Our data suggest that the phosphorylated p68 protects the cells from programmed cell death by preventing procaspase- 8 from proteolytic cleavage. The double- phosphorylated p68 may also confer apoptosis resistance by upregulation of X- chromosome- linked inhibitor apoptosis protein- associated factor 1. In addition, exogenous expression of p68 mutant that carries mutations at the phosphorylation sites ( Y593/595F) dramatically sensitizes TRAIL- resistant cells to TRAIL- induced apoptosis, suggesting a potential therapeutic strategy to overcome TRAIL resistance.	Georgia State Univ, Dept Biol, Atlanta, GA 30303 USA; Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA	University System of Georgia; Georgia State University; Emory University	Liu, ZR (corresponding author), Georgia State Univ, Dept Biol, Univ Plaza, Atlanta, GA 30303 USA.	biozrl@langate.gsu.edu	Yang, Liuqing/B-7935-2011		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063874] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM063874] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aggarwal BB, 2004, VITAM HORM, V67, P453; Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009; Bockbrader KM, 2005, ONCOGENE, V24, P7381, DOI 10.1038/sj.onc.1208888; Bouralexis S, 2005, APOPTOSIS, V10, P35, DOI 10.1007/s10495-005-6060-0; Causevic M, 2001, ONCOGENE, V20, P7734, DOI 10.1038/sj.onc.1204976; Clarke N, 2005, CELL CYCLE, V4, P914, DOI 10.4161/cc.4.7.1822; CRAWFORD L, 1982, J VIROL, V42, P612, DOI 10.1128/JVI.42.2.612-620.1982; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Fong WG, 2000, GENOMICS, V70, P113, DOI 10.1006/geno.2000.6364; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Grotzer MA, 2000, ONCOGENE, V19, P4604, DOI 10.1038/sj.onc.1203816; Hao CH, 2001, CANCER RES, V61, P1162; Holcik M, 2001, APOPTOSIS, V6, P253, DOI 10.1023/A:1011379307472; Hwang RF, 2003, CLIN CANCER RES, V9, P6534; Kim Y, 2003, MOL CELLS, V15, P283; LANE DP, 1980, NATURE, V288, P167, DOI 10.1038/288167a0; Leaman DW, 2002, J BIOL CHEM, V277, P28504, DOI 10.1074/jbc.M204851200; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Liston P, 2001, NAT CELL BIOL, V3, P128, DOI 10.1038/35055027; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; Ng KCP, 2004, J INVEST DERMATOL, V123, P1127, DOI 10.1111/j.0022-202X.2004.23467.x; Nicol SM, 2000, EXP CELL RES, V257, P272, DOI 10.1006/excr.2000.4886; Potapova O, 1996, CANCER RES, V56, P280; Roth W, 2004, VITAM HORM, V67, P189; Soldani C, 2002, APOPTOSIS, V7, P321, DOI 10.1023/A:1016119328968; Stevenson RJ, 1998, J PATHOL, V184, P351, DOI 10.1002/(SICI)1096-9896(199804)184:4<351::AID-PATH1235>3.0.CO;2-C; Takeuchi H, 2004, BRIT J CANCER, V90, P1069, DOI 10.1038/sj.bjc.6601605; Thorburn A, 2004, CELL SIGNAL, V16, P139, DOI 10.1016/j.cellsig.2003.08.007; Van Geelen CMM, 2004, DRUG RESIST UPDATE, V7, P345, DOI 10.1016/j.drup.2004.11.002; Wang J, 2000, J CELL SCI, V113, P753; Yagita H, 2004, CANCER SCI, V95, P777, DOI 10.1111/j.1349-7006.2004.tb02181.x; Yang LQ, 2006, CELL, V127, P139, DOI 10.1016/j.cell.2006.08.036; Yang LQ, 2005, MOL CANCER RES, V3, P355, DOI 10.1158/1541-7786.MCR-05-0022; Yang XZ, 2003, CANCER RES, V63, P1122; Zhang LD, 2005, CANCER GENE THER, V12, P228, DOI 10.1038/sj.cgt.7700792	35	25	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2007	26	41					6082	6092		10.1038/sj.onc.1210427	http://dx.doi.org/10.1038/sj.onc.1210427			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	207US	17384675				2022-12-17	WOS:000249277200011
J	Singh, MK; Nicolas, E; Gherraby, W; Dadke, D; Lessin, S; Golemis, EA				Singh, M. K.; Nicolas, E.; Gherraby, W.; Dadke, D.; Lessin, S.; Golemis, E. A.			HEI10 negatively regulates cell invasion by inhibiting cyclin B/Cdk1 and other promotility proteins	ONCOGENE			English	Article						hEI10; Cdk1; cyclin B; migration; invasion; cell cycle	FOCAL ADHESION KINASE; TYROSINE PHOSPHORYLATION; NEUROFIBROMATOSIS TYPE-2; MIGRATION; CANCER; GENE; IDENTIFICATION; PROGRESSION; NF2/MERLIN; EXPRESSION	Human enhancer of invasion, clone 10 ( HEI10) (CCNB1IP1) was. rst described as a RING-finger family ubiquitin ligase that regulates cell cycle by interacting with cyclin B and promoting its degradation. Subsequently, other studies suggested specific upregulation of HEI10 in metastatic melanoma and demonstrated direct interaction between HEI10 and the tumor suppressor Merlin, encoded by the neurofibromatosis 2 gene. These and other results led us to hypothesize that HEI10 also influences the processes of cell migration and metastasis. We here show that cells with depleted HEI10 both migrate more rapidly and invade more effectively than control cells. HEI10 depletion post-transcriptionally increases the expression of a group of promotility regulatory proteins including p130Cas, paxillin, Cdk1 and cyclin B2, but excluding Merlin. Among these, only inhibition of Cdk1/ cyclin B activity specifically reversed the motility and invasion of HEI10-depleted cells. Finally, HEI10 is abundantly transcribed in many human tissues, and particularly abundant in some tumor cell lines, suggesting that it may be commonly involved in coordinating cell cycle with cell migration and invasion.	Fox Chase Canc Ctr, Inst Canc Res, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Golemis, EA (corresponding author), Fox Chase Canc Ctr, Inst Canc Res, W406,333 Cottman Ave, Philadelphia, PA 19111 USA.	ea_golemis@fccc.edu	Singh, Mahendra K./K-6267-2019	Golemis, Erica/0000-0003-3618-3673	NCI NIH HHS [P30 CA006927-44, P30 CA006927, CA-06927, R01 CA063366, R01 CA063366-12, R01 CA63366] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927, R01CA063366] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bouton AH, 1997, HYBRIDOMA, V16, P403, DOI 10.1089/hyb.1997.16.403; Brabek J, 2005, MOL CANCER RES, V3, P307, DOI 10.1158/1541-7786.MCR-05-0015; Draviam VM, 2001, J CELL BIOL, V152, P945, DOI 10.1083/jcb.152.5.945; Evans DGR, 2000, J MED GENET, V37, P897, DOI 10.1136/jmg.37.12.897; Fesik SW, 2005, NAT REV CANCER, V5, P876, DOI 10.1038/nrc1736; Gronholm M, 2006, ONCOGENE, V25, P4389, DOI 10.1038/sj.onc.1209475; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hirokawa Y, 2004, CANCER J, V10, P20, DOI 10.1097/00130404-200401000-00006; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; James MF, 2004, J CELL SCI, V117, P2951, DOI 10.1242/jcs.01156; Juliano R, 2003, NAT CELL BIOL, V5, P589, DOI 10.1038/ncb0703-589; Kaempchen K, 2003, HUM MOL GENET, V12, P1211, DOI 10.1093/hmg/ddg146; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Manes T, 2003, J CELL BIOL, V161, P817, DOI 10.1083/jcb.200212172; Mine N, 2001, JPN J CANCER RES, V92, P135, DOI 10.1111/j.1349-7006.2001.tb01075.x; Nymark P, 2006, CANCER RES, V66, P5737, DOI 10.1158/0008-5472.CAN-06-0199; Poulikakos PI, 2006, ONCOGENE, V25, P5960, DOI 10.1038/sj.onc.1209587; Rual JF, 2005, NATURE, V437, P1173, DOI 10.1038/nature04209; Ruest PJ, 2000, CELL GROWTH DIFFER, V11, P41; Schwikowski B, 2000, NAT BIOTECHNOL, V18, P1257, DOI 10.1038/82360; Smith AP, 2004, CANCER BIOL THER, V3, P104, DOI 10.4161/cbt.3.1.661; Toby GG, 2003, MOL CELL BIOL, V23, P2109, DOI 10.1128/MCB.23.6.2109-2122.2003; Wade R, 2006, BIOCHEM J, V393, P565, DOI 10.1042/BJ20051241; Worthylake RA, 2003, J BIOL CHEM, V278, P13578, DOI 10.1074/jbc.M211584200; Xiao GH, 2005, MOL CELL BIOL, V25, P2384, DOI 10.1128/MCB.25.6.2384-2394.2005; Zhao ZS, 2000, MOL CELL BIOL, V20, P6354, DOI 10.1128/MCB.20.17.6354-6363.2000	26	25	26	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2007	26	33					4825	4832		10.1038/sj.onc.1210282	http://dx.doi.org/10.1038/sj.onc.1210282			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	191ZL	17297447	Green Accepted			2022-12-17	WOS:000248170400007
J	Hatch, T; Derijck, AAHA; Black, PD; van der Heijden, GW; de Boer, P; Dubrova, YE				Hatch, T.; Derijck, A. A. H. A.; Black, P. D.; van der Heijden, G. W.; de Boer, P.; Dubrova, Y. E.			Maternal effects of the scid mutation on radiation-induced transgenerational instability in mice	ONCOGENE			English	Article						radiation; transgenerational instability; maternal effects; scid; NHEJ; mouse	DEPENDENT PROTEIN-KINASE; DNA-REPAIR; CATALYTIC SUBUNIT; GENOME STABILITY; GERM-LINE; DAMAGE; SPERM; RATES; DEFICIENCY; EXPRESSION	The results of a number of recent studies show that mutation rates in the offspring of irradiated parents are substantially elevated, however, the effect of parental genotype on transgenerational instability remains poorly understood. Here, we have analysed the mutation frequency at an expanded simple tandem repeat (ESTR) locus in the germline and bone marrow of the first-generation male offspring of control and irradiated male mice. The frequency of ESTR mutation was studied in the offspring of two reciprocal matings male scid x female BALB/c and male BALB/c x female scid, which were compared with that in BALB/c mice. In the offspring of the BALB/c x BALB/c and male scid x female BALB/c matings, which were conceived after paternal sperm irradiation, the frequency of ESTR mutation was significantly elevated in both tissues. In contrast, ESTR mutation frequency was only slightly elevated in the offspring of male BALB/c x female scid mating conceived after paternal irradiation. The results of this study suggest that the oocytes of scid females are unable to fully support the repair of double-strand breaks induced in paternal sperm which may in turn result in the elimination of cells/embryos containing high levels of DNA damage, thus partially preventing the manifestation of genomic instability.	Univ Leicester, Dept Genet, Leicester LE1 7RH, Leics, England; Radboud Univ Nijmegen, Med Ctr, Dept Obstet & Gynaecol, Nijmegen, Netherlands	University of Leicester; Radboud University Nijmegen	Dubrova, YE (corresponding author), Univ Leicester, Dept Genet, Univ Rd, Leicester LE1 7RH, Leics, England.	yed2@le.ac.uk	Dubrova, Yuri/ABA-7148-2020; van der Heijden, Godfried/ABC-5623-2021	van der Heijden, Godfried/0000-0001-5894-7027; Dubrova, Yuri/0000-0001-5281-7539	MRC [G0300477, G9806740] Funding Source: UKRI; Medical Research Council [G9806740, G0300477] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Ahmadi A, 1999, J EXP ZOOL, V284, P696, DOI 10.1002/(SICI)1097-010X(19991101)284:6&lt;696::AID-JEZ11&gt;3.0.CO;2-E; Allen C, 2002, P NATL ACAD SCI USA, V99, P3758, DOI 10.1073/pnas.052545899; Barber R, 2002, P NATL ACAD SCI USA, V99, P6877, DOI 10.1073/pnas.102015399; Barber RC, 2006, ONCOGENE, V25, P7336, DOI 10.1038/sj.onc.1209723; Barber RC, 2004, MUTAT RES-FUND MOL M, V554, P287, DOI 10.1016/j.mrfmmm.2004.05.003; Barton TS, 2005, P NATL ACAD SCI USA, V102, P7865, DOI 10.1073/pnas.0501200102; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; Blunt T, 1996, P NATL ACAD SCI USA, V93, P10285, DOI 10.1073/pnas.93.19.10285; Derijck AAHA, 2006, DNA REPAIR, V5, P959, DOI 10.1016/j.dnarep.2006.05.043; Dubrova YE, 1998, P NATL ACAD SCI USA, V95, P6251, DOI 10.1073/pnas.95.11.6251; Dubrova YE, 2000, NATURE, V405, P37, DOI 10.1038/35011135; Festing MF, 1996, GENETIC VARIANTS STR, P1537; Fiorenza MT, 2001, DEV BIOL, V233, P214, DOI 10.1006/dbio.2001.0199; GENEROSO WM, 1979, P NATL ACAD SCI USA, V76, P435, DOI 10.1073/pnas.76.1.435; Harrouk W, 2000, MUTAT RES-DNA REPAIR, V461, P229, DOI 10.1016/S0921-8777(00)00053-7; Jimenez GS, 1999, NATURE, V400, P81, DOI 10.1038/21913; Marchetti Francesco, 2005, Birth Defects Res C Embryo Today, V75, P112, DOI 10.1002/bdrc.20040; MATSUDA Y, 1989, MUTAT RES, V210, P35, DOI 10.1016/0027-5107(89)90042-0; Mohrenweiser HW, 2003, MUTAT RES-FUND MOL M, V526, P93, DOI 10.1016/S0027-5107(03)00049-6; Okayasu R, 2000, CANCER RES, V60, P4342; Olsen Ann-Karin, 2005, Toxicol Appl Pharmacol, V207, P521, DOI 10.1016/j.taap.2005.01.060; Rassoulzadegan M, 2006, NATURE, V441, P469, DOI 10.1038/nature04674; Rothkamm K, 2003, MOL CELL BIOL, V23, P5706, DOI 10.1128/MCB.23.16.5706-5715.2003; Rousseaux S, 2005, GENE, V345, P139, DOI 10.1016/j.gene.2004.12.004; SEARLE AG, 1974, ADV RADIAT BIOL, V4, P131; Shimura T, 2002, MOL CELL BIOL, V22, P2220, DOI 10.1128/MCB.22.7.2220-2228.2002; Wallace M, 2001, ONCOGENE, V20, P3597, DOI 10.1038/sj.onc.1204496; Yauk CL, 2002, MUTAT RES-FUND MOL M, V500, P147, DOI 10.1016/S0027-5107(02)00005-2; Yu YJ, 2001, CANCER RES, V61, P1820; Zeng FY, 2004, DEV BIOL, V272, P483, DOI 10.1016/j.ydbio.2004.05.018; Zhang SL, 1998, P NATL ACAD SCI USA, V95, P2429, DOI 10.1073/pnas.95.5.2429; Zheng NJ, 2000, ENVIRON MOL MUTAGEN, V36, P134, DOI 10.1002/1098-2280(2000)36:2<134::AID-EM8>3.0.CO;2-D	32	25	25	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2007	26	32					4720	4724		10.1038/sj.onc.1210253	http://dx.doi.org/10.1038/sj.onc.1210253			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	190DJ	17237807	Green Submitted			2022-12-17	WOS:000248037900012
J	Li, B; Smith, CC; Laing, JM; Gober, MD; Liu, L; Aurelian, L				Li, B.; Smith, C. C.; Laing, J. M.; Gober, M. D.; Liu, L.; Aurelian, L.			Overload of the heat-shock protein H11/HspB8 triggers melanoma cell apoptosis through activation of transforming growth factor-beta-activated kinase 1	ONCOGENE			English	Article						H11/HspB8; heat shock protein; melanoma; apoptosis/growth arrest; TAK1; beta-catenin	CHAPERONE-LIKE ACTIVITY; PROSTATE-CANCER CELLS; TRANSCRIPTION FACTOR; DNA METHYLATION; BETA-CATENIN; RIBONUCLEOTIDE REDUCTASE; MALIGNANT-MELANOMA; EXPRESSION; KINASE; PATHWAY	Molecular therapeutics is a recognized promising approach for melanoma, but relevant target genes remain elusive. We report that overload of the recently cloned H11/HspB8 induces apoptosis in 55% of examined melanoma cultures. Apoptosis was determined by activation of caspases-9 and -3 and terminal deoxynucleotidyl-transferase-mediated dUTP nick end labeling (TUNEL), and was not seen in normal melanocytes. It was associated with H11/HspB8 complexation with transforming growth factor-beta-activated kinase (TAK) 1 and activation of TAK1 and p38 mitogen activated protein 3 kinases. TAK1 was not bound, nor activated by the H11/HspB8 mutant W51C, which has dominant antiapoptotic activity. beta-Catenin was phosphorylated by activated TAK1, inhibiting its nuclear accumulation and mictophthalmia-associated transcription factor and cyclin dependent kinase 2 expression. The dominant-negative TAK1 mutant K63W inhibited beta-catenin phosphorylation and caspase activation. The data indicate that H11/HspB8 overload causes melanoma growth arrest and apoptosis through TAK1 activation and suggest that H11/HspB8 is a promising molecular therapy target.	Univ Maryland, Virol Immunol Labs, Sch Med, Dept Pharmacol, Baltimore, MD 21201 USA; Univ Maryland, Dept Expt Therapeut, Sch Med, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Aurelian, L (corresponding author), Univ Maryland, Virol Immunol Labs, Sch Med, Dept Pharmacol, Room 4-023,655 W Baltimore St, Baltimore, MD 21201 USA.	laurelia@umaryland.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR053512, R01AR042647] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007263] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR053512, AR42647, R01 AR042647, R01 AR053512-01A2] Funding Source: Medline; NIEHS NIH HHS [T32 ES007263, ES07263] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aurelian L, 2005, CURR TOP MICROBIOL, V289, P79; Chabaud S, 2003, FEBS LETT, V545, P213, DOI 10.1016/S0014-5793(03)00547-7; Chae HD, 2004, ONCOGENE, V23, P4084, DOI 10.1038/sj.onc.1207482; Chowdary TK, 2004, BIOCHEM J, V381, P379, DOI 10.1042/BJ20031958; Ciocca DR, 2005, CELL STRESS CHAPERON, V10, P86, DOI 10.1379/CSC-99r.1; Cox AD, 2003, ONCOGENE, V22, P8999, DOI 10.1038/sj.onc.1207111; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Diao LR, 2005, EXP CELL RES, V308, P196, DOI 10.1016/j.yexcr.2005.04.016; Du JY, 2004, CANCER CELL, V6, P565, DOI 10.1016/j.ccr.2004.10.014; Edlund S, 2003, MOL BIOL CELL, V14, P529, DOI 10.1091/mbc.02-03-0037; Fink D, 2001, MELANOMA RES, V11, P385, DOI 10.1097/00008390-200108000-00009; Furuta J, 2004, CANCER SCI, V95, P962, DOI 10.1111/j.1349-7006.2004.tb03184.x; Gallagher WM, 2005, CARCINOGENESIS, V26, P1856, DOI 10.1093/carcin/bgi152; Gober MD, 2005, FRONT BIOSCI-LANDMRK, V10, P2788, DOI 10.2741/1736; Gober MD, 2003, J BIOL CHEM, V278, P37600, DOI 10.1074/jbc.M303834200; Hase M, 2005, BIOCHEM J, V388, P475, DOI 10.1042/BJ20041314; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Ivanov VN, 2001, ONCOGENE, V20, P2243, DOI 10.1038/sj.onc.1204314; Karpf AR, 2004, MOL PHARMACOL, V65, P18, DOI 10.1124/mol.65.1.18; Kishimoto K, 2000, J BIOL CHEM, V275, P7359, DOI 10.1074/jbc.275.10.7359; Margolin KA, 2004, CANCER-AM CANCER SOC, V101, P435, DOI 10.1002/cncr.20402; Park CS, 2004, J BIOL CHEM, V279, P19592, DOI 10.1074/jbc.M314208200; Perez-Stable C, 2006, CANCER LETT, V231, P49, DOI 10.1016/j.canlet.2005.01.018; Reu FJ, 2006, CANCER RES, V66, P2785, DOI 10.1158/0008-5472.CAN-05-2303; Saito H, 2003, PIGM CELL RES, V16, P261, DOI 10.1034/j.1600-0749.2003.00039.x; Sharma BK, 2006, DERMATOLOGY, V213, P192, DOI 10.1159/000095035; Singhirunnusorn P, 2005, J BIOL CHEM, V280, P7359, DOI 10.1074/jbc.M407537200; Smith CC, 2000, J BIOL CHEM, V275, P25690, DOI 10.1074/jbc.M002140200; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Sun XK, 2004, J BIOL CHEM, V279, P2394, DOI 10.1074/jbc.M311324200; Tsao H, 2005, DERMATOL CLIN, V23, P323, DOI 10.1016/j.det.2004.09.005; Van der Velden PA, 2003, INT J CANCER, V106, P472, DOI 10.1002/ijc.11262; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wang TH, 2006, ONCOGENE, V25, P4857, DOI 10.1038/sj.onc.1209498; Widlund HR, 2002, J CELL BIOL, V158, P1079, DOI 10.1083/jcb.200202049; Yu R, 2000, J BIOL CHEM, V275, P39907, DOI 10.1074/jbc.M004037200; Zendman AJW, 2002, INT J CANCER, V97, P195, DOI 10.1002/ijc.1584	37	25	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2007	26	24					3521	3531		10.1038/sj.onc.1210145	http://dx.doi.org/10.1038/sj.onc.1210145			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172JC	17173073	Green Accepted			2022-12-17	WOS:000246799200008
J	Ma, Y; Cress, WD				Ma, Y.; Cress, W. D.			Transcriptional upregulation of p57 (Kip2) by the cyclin-dependent kinase inhibitor BMS-387032 is E2F dependent and serves as a negative feedback loop limiting cytotoxicity	ONCOGENE			English	Article						CDK; CDKN1C; E2F; BMS-387032; SNS-032; apoptosis	FLAVOPIRIDOL-INDUCED APOPTOSIS; S-PHASE; POTENTIAL MEDIATOR; GENE-EXPRESSION; P57(KIP2); ACTIVATION; PROMOTER; PROTEIN; CELLS; P21(WAF1/CIP1)	In spite of the fact that cyclin-dependent kinase (cdk) inhibiting drugs are potent transcriptional repressors, we discover that p57 (Kip2, CDKN1C) transcription is significantly upregulated by three small molecule cdk inhibitors, including BMS-387032. Treatment of MDAMB231 breast cancer cells with BMS-387032 led to a stabilization of the E2F1 protein that was accompanied by significant increases in the p57 mRNA and protein. This increase did not occur in an E2F1-deficient cell line. An E2F1-estrogen receptor fusion protein activated the endogenous p57 promoter in response to hydroxytamoxifen treatment in the presence of cycloheximide. Luciferase constructs driven by the p57 promoter verified that upregulation of p57 mRNA byBMS-38 7032 is transcriptional and dependent on E2F-binding sites in the promoter. Expression of exogenous p57 significantly decreased the fraction of cells in S phase. Furthermore, p57-deficient MDA-MB-231 cell lines were significantly more sensitive to BMS-387032-induced apoptosis than controls. The results presented in this manuscript demonstrate that small molecule cdk inhibitors transcriptionally activate p57 dependent upon E2F1 and that this activation in turn serves to limit E2F1's death-inducing activity.	Univ S Florida, Coll Med, H Lee Moffit Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA	State University System of Florida; University of South Florida	Cress, WD (corresponding author), Univ S Florida, Coll Med, H Lee Moffit Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.	cressd@moffitt.usf.edu			NCI NIH HHS [R01 CA090489-05, CA90489-01, R01 CA090489-04, R01 CA090489] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090489] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Afshari CA, 1996, CELL GROWTH DIFFER, V7, P979; Alheim K, 2003, J MOL ENDOCRINOL, V30, P359, DOI 10.1677/jme.0.0300359; Balint E, 2002, P NATL ACAD SCI USA, V99, P3529, DOI 10.1073/pnas.062491899; Brideau AD, 1998, J VIROL, V72, P4560, DOI 10.1128/JVI.72.6.4560-4570.1998; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; CRESS WD, 1994, J VIROL, V68, P4212, DOI 10.1128/JVI.68.7.4213-4219.1994; Delavaine L, 1999, ONCOGENE, V18, P5381, DOI 10.1038/sj.onc.1202923; Devgan V, 2005, GENE DEV, V19, P1485, DOI 10.1101/gad.341405; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gartel AL, 1998, ONCOGENE, V17, P3463, DOI 10.1038/sj.onc.1202240; Gartel AL, 2000, ONCOGENE, V19, P961, DOI 10.1038/sj.onc.1203411; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; Gonzalez S, 2005, CANCER RES, V65, P2186, DOI 10.1158/0008-5472.CAN-04-3047; HARPER JW, 1993, CELL, V75, P805; Hiyama H, 1997, ONCOGENE, V14, P2533, DOI 10.1038/sj.onc.1201080; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Jackson JF, 2002, MOLEC METH PLAN ANAL, V21, P1; Jackson RJ, 2003, CANCER RES, V63, P3021; Jiang J, 2003, CANCER RES, V63, P7410; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1995, ONCOGENE, V11, P1685; Kalejta RF, 1999, EXP CELL RES, V248, P322, DOI 10.1006/excr.1999.4427; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; Lam LT, 2001, GENOME BIOL, V2; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Lu X, 2004, MOL CANCER THER, V3, P861; Ma YH, 2004, CANCER BIOL THER, V3, P1262, DOI 10.4161/cbt.3.12.1239; Ma YH, 2002, ARCH BIOCHEM BIOPHYS, V399, P212, DOI 10.1006/abbi.2002.2761; Ma YH, 2003, J BIOL CHEM, V278, P16770, DOI 10.1074/jbc.M212702200; Ma YH, 2003, MOL CANCER THER, V2, P73; Matranga CB, 2002, CANCER RES, V62, P1707; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Merlo P, 2005, J BIOL CHEM, V280, P30354, DOI 10.1074/jbc.M500635200; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Samuelsson MKR, 2002, BIOCHEM BIOPH RES CO, V296, P702, DOI 10.1016/S0006-291X(02)00912-9; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; Shapiro GI, 2006, J CLIN ONCOL, V24, P1770, DOI 10.1200/JCO.2005.03.7689; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Stewart MC, 2004, J BONE MINER RES, V19, P123, DOI 10.1359/JBMR.0301209; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Wang CG, 2005, J BIOL CHEM, V280, P12339, DOI 10.1074/jbc.C400536200; ZHU LG, 1995, MOL CELL BIOL, V15, P3552	50	25	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	24					3532	3540		10.1038/sj.onc.1210143	http://dx.doi.org/10.1038/sj.onc.1210143			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172JC	17173074	Green Accepted			2022-12-17	WOS:000246799200009
J	Saintigny, Y; Delacote, F; Boucher, D; Averbeck, D; Lopez, BS				Saintigny, Y.; Delacote, F.; Boucher, D.; Averbeck, D.; Lopez, B. S.			XRCC4 in G1 suppresses homologous recombination in S/G2, in G1 checkpoint-defective cells	ONCOGENE			English	Article						double strand break; non homologous end joining; homologous recombination; cell cycle; mammalian cell	DOUBLE-STRAND BREAKS; DNA-LIGASE-IV; MAMMALIAN RAD51; V(D)J RECOMBINATION; INDUCED REPLICATION; GENOMIC STABILITY; REPAIR PATHWAYS; BACKUP PATHWAYS; NUCLEAR FOCI; S-PHASE	Non-homologous end joining (NHEJ) and homologous recombination (HR) are two pathways that can compete or cooperate for DNA double-strand break (DSB) repair. NHEJ was previously shown to act throughout the cell cycle whereas HR is restricted to late S/G2. Paradoxically, we show here that defect in XRCC4 (NHEJ) leads to over-stimulation of HR when cells were irradiated in G1, not in G2. However, XRCC4 defect did not modify the strict cell cycle regulation for HR (i.e. in S/G2) as attested by (i) the formation of Rad51 foci in late S/G2 whatever the XRCC4 status, and (ii) the fact that neither Rad51 foci nor HR (gene conversion plus single-strand annealing) events induced by ionizing radiation were detected when cells were maintained blocked in G1. Finally, both gamma-H2AX analysis and pulse field gel electrophoresis showed that following irradiation in G1, some DSBs reached S/G2 in NHEJ-defective cells. Taken together, our results show that when cells are defective in G1/S arrest, DSB produced in G1 and left unrepaired by XRCC4 can be processed by HR but in late S/G2.	CEA, CNRS, UMR 217, F-92265 Fontenay Aux Roses, France; Ctr Univ, Inst Curie, CNRS, UMR 2027,Sect Rech, F-91405 Orsay, France	CEA; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Lopez, BS (corresponding author), CEA, CNRS, UMR 217, 18 Route Panorama,BP6, F-92265 Fontenay Aux Roses, France.	bernard.lopez@cea.fr	Saintigny, Yannick/C-2697-2008; Lopez, Bernard S/O-7308-2017	Saintigny, Yannick/0000-0002-3839-3562; Lopez, Bernard S/0000-0001-5088-0155; Boucher, Didier/0000-0002-7964-0881				Aladjem MI, 1998, CURR BIOL, V8, P145, DOI 10.1016/S0960-9822(98)70061-2; Allen C, 2002, P NATL ACAD SCI USA, V99, P3758, DOI 10.1073/pnas.052545899; AMOR M, 1988, P NATL ACAD SCI USA, V85, P1600, DOI 10.1073/pnas.85.5.1600; Aten JA, 2004, SCIENCE, V303, P92, DOI 10.1126/science.1088845; Audebert M, 2004, J BIOL CHEM, V279, P55117, DOI 10.1074/jbc.M404524200; Ausubel F., 1999, CURRENT PROTOCOLS MO; BELMAAZA A, 1990, NUCLEIC ACIDS RES, V18, P6385, DOI 10.1093/nar/18.21.6385; BELMAAZA A, 1994, MUTAT RES, V314, P199, DOI 10.1016/0921-8777(94)90065-5; Bertrand P, 2004, TRENDS GENET, V20, P235, DOI 10.1016/j.tig.2004.04.003; Bertrand P, 2003, ONCOGENE, V22, P7587, DOI 10.1038/sj.onc.1206998; Boucher D, 2004, CAN J PHYSIOL PHARM, V82, P125, DOI 10.1139/Y04-006; BROUILLETTE S, 1987, MOL CELL BIOL, V7, P2248, DOI 10.1128/MCB.7.6.2248; CHEONG N, 1994, MUTAT RES, V314, P77, DOI 10.1016/0921-8777(94)90063-9; Cohen PE, 2001, BIOESSAYS, V23, P996, DOI 10.1002/bies.1145; Delacote F, 2002, NUCLEIC ACIDS RES, V30, P3454, DOI 10.1093/nar/gkf452; Difilippantonio MJ, 2002, J EXP MED, V196, P469, DOI 10.1084/jem.20020851; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; Esashi F, 2005, NATURE, V434, P598, DOI 10.1038/nature03404; FABRE F, 1984, MOL GEN GENET, V195, P139, DOI 10.1007/BF00332736; Ferguson DO, 2000, P NATL ACAD SCI USA, V97, P6630, DOI 10.1073/pnas.110152897; Ferguson DO, 2000, COLD SPRING HARB SYM, V65, P395, DOI 10.1101/sqb.2000.65.395; Guirouilh-Barbat J, 2004, MOL CELL, V14, P611, DOI 10.1016/j.molcel.2004.05.008; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Hinz JM, 2005, DNA REPAIR, V4, P782, DOI 10.1016/j.dnarep.2005.03.005; Ira G, 2004, NATURE, V431, P1011, DOI 10.1038/nature02964; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; JEGGO PA, 1990, MUTAT RES, V239, P1, DOI 10.1016/0165-1110(90)90028-A; JEGGO PA, 1995, BIOESSAYS, V17, P949, DOI 10.1002/bies.950171108; Johnson RD, 2000, EMBO J, V19, P3398, DOI 10.1093/emboj/19.13.3398; Jung D, 2004, CELL, V116, P299, DOI 10.1016/S0092-8674(04)00039-X; KADYK LC, 1992, GENETICS, V132, P387; Kim JS, 2005, J CELL BIOL, V170, P341, DOI 10.1083/jcb.200411083; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; Kraus E, 2001, P NATL ACAD SCI USA, V98, P8255, DOI 10.1073/pnas.151008198; Lambert S, 2000, EMBO J, V19, P3090, DOI 10.1093/emboj/19.12.3090; Lee SE, 1997, MOL CELL BIOL, V17, P1425, DOI 10.1128/MCB.17.3.1425; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; Malkova A, 2005, MOL CELL BIOL, V25, P933, DOI 10.1128/MCB.25.3.933-944.2005; Mills KD, 2004, GENE DEV, V18, P1283, DOI 10.1101/gad.1204304; Pierce AJ, 2001, GENE DEV, V15, P3237, DOI 10.1101/gad.946401; Purandare SM, 1997, GENOME RES, V7, P773, DOI 10.1101/gr.7.8.773; Raderschall E, 1999, P NATL ACAD SCI USA, V96, P1921, DOI 10.1073/pnas.96.5.1921; Redon C, 2002, CURR OPIN GENET DEV, V12, P162, DOI 10.1016/S0959-437X(02)00282-4; Richardson C, 2000, NATURE, V405, P697, DOI 10.1038/35015097; Richardson C, 2000, MOL CELL BIOL, V20, P9068, DOI 10.1128/MCB.20.23.9068-9075.2000; Rodrigue A, 2006, EMBO J, V25, P222, DOI 10.1038/sj.emboj.7600914; Rothkamm K, 2003, MOL CELL BIOL, V23, P5706, DOI 10.1128/MCB.23.16.5706-5715.2003; Rothstein R, 2000, GENE DEV, V14, P1; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; Saleh-Gohari N, 2004, NUCLEIC ACIDS RES, V32, P3683, DOI 10.1093/nar/gkh703; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; STAMATO TD, 1988, RADIAT RES, V115, P325, DOI 10.2307/3577168; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Tashiro S, 2000, J CELL BIOL, V150, P283, DOI 10.1083/jcb.150.2.283; Vanasse GJ, 1999, J CLIN INVEST, V103, P1669, DOI 10.1172/JCI6658; Wang HC, 2005, CANCER RES, V65, P4020, DOI 10.1158/0008-5472.CAN-04-3055; Wang HC, 2001, NUCLEIC ACIDS RES, V29, P1653, DOI 10.1093/nar/29.8.1653; Wang HC, 2003, NUCLEIC ACIDS RES, V31, P5377, DOI 10.1093/nar/gkg728; Yuan SSF, 2003, MUTAT RES-FUND MOL M, V525, P85, DOI 10.1016/S0027-5107(03)00009-5; Zhu CM, 2002, CELL, V109, P811, DOI 10.1016/S0092-8674(02)00770-5	63	25	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 26	2007	26	19					2769	2780		10.1038/sj.onc.1210075	http://dx.doi.org/10.1038/sj.onc.1210075			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CP	17057732	Green Published			2022-12-17	WOS:000246210600011
J	Spraggon, L; Dudnakova, T; Slight, J; Lustig-Yariv, O; Cotterell, J; Hastie, N; Miles, C				Spraggon, L.; Dudnakova, T.; Slight, J.; Lustig-Yariv, O.; Cotterell, J.; Hastie, N.; Miles, C.			hnRNP-U directly interacts with WT1 and modulates WT1 transcriptional activation	ONCOGENE			English	Article						hnRNP-U; WT1; zinc fingers; Wilms' tumour	WILMS-TUMOR GENE; RNA-POLYMERASE-II; SUPPRESSOR GENE; PROTEIN WT1; EXPRESSION; BINDING; RIBONUCLEOPROTEIN; INHIBITION; MUTATIONS; RECEPTOR	The Wilms' tumour suppressor gene, WT1, encodes a zinc-finger protein that is mutated in Wilms' tumours and highly expressed in a wide variety of other malignancies. WT1 is a transcription factor that is likely to have additional, post-transcriptional, regulatory roles, although the molecular mechanisms by which WT1 acts remain poorly understood. We have combined genetic and biochemical approaches to show, that endogenous WT1 binds to heterogeneous nuclear ribonuclear protein U (hnRNP-U), that this interaction does not require any other proteins or nucleic acids, involves the zinc-fingers of WT1 and the middle domain of hnRNP-U, and that hnRNP-U can modulate WT1 transcriptional activation of a bona. de WT1 target gene. These findings increase our knowledge of how WT1 exerts its transcriptional regulatory role and suggests that hnRNP-U may be a candidate Wilms' tumour gene at 1q44.	Western Gen Hosp, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Newcastle Upon Tyne, Inst Human Genet, Int Ctr Life, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Columbia Univ, Coll Phys & Surg, New York, NY USA	University of Edinburgh; Newcastle University - UK; Columbia University	Hastie, N (corresponding author), Western Gen Hosp, MRC, Human Genet Unit, Crew Rd, Edinburgh EH4 2XU, Midlothian, Scotland.	nick.hastie@hgu.mrc.ac.uk	Spraggon, Lee/E-5900-2012	Dudnakova, Tatyana/0000-0002-8388-8871	Medical Research Council [MC_U127527180] Funding Source: Medline; MRC [MC_U127527180] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ARMSTRONG JF, 1993, MECH DEVELOP, V40, P85, DOI 10.1016/0925-4773(93)90090-K; Barbaux S, 1997, NAT GENET, V17, P467, DOI 10.1038/ng1297-467; Bergmann L, 1997, LEUKEMIA LYMPHOMA, V25, P435, DOI 10.3109/10428199709039030; BRESLOW N, 1988, CANCER RES, V48, P1653; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; Caricasole A, 1996, P NATL ACAD SCI USA, V93, P7562, DOI 10.1073/pnas.93.15.7562; Carpenter B, 2004, MOL CELL BIOL, V24, P537, DOI 10.1128/MCB.24.2.537-549.2004; Challen G, 2005, PHYSIOL GENOMICS, V23, P159, DOI 10.1152/physiolgenomics.00043.2005; Davies RC, 1998, GENE DEV, V12, P3217, DOI 10.1101/gad.12.20.3217; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; Hammes A, 2001, CELL, V106, P319, DOI 10.1016/S0092-8674(01)00453-6; HASTIE ND, 1994, ANNU REV GENET, V28, P523; Heilbronn R, 2003, NUCLEIC ACIDS RES, V31, P6206, DOI 10.1093/nar/gkg827; Kanai Y, 2004, NEURON, V43, P513, DOI 10.1016/j.neuron.2004.07.022; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; Kim MK, 1999, MOL CELL BIOL, V19, P6833; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Kukalev A, 2005, NAT STRUCT MOL BIOL, V12, P238, DOI 10.1038/nsmb904; Ladomery MR, 1999, J BIOL CHEM, V274, P36520, DOI 10.1074/jbc.274.51.36520; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; Lee SB, 1999, CELL, V98, P663, DOI 10.1016/S0092-8674(00)80053-7; Lee TH, 2002, J BIOL CHEM, V277, P44826, DOI 10.1074/jbc.M205667200; Little M, 1999, BIOESSAYS, V21, P191, DOI 10.1002/(SICI)1521-1878(199903)21:3<191::AID-BIES3>3.3.CO;2-#; Loeb DM, 2001, CANCER RES, V61, P921; Miles CG, 2003, MOL CELL BIOL, V23, P2608, DOI 10.1128/MCB.23.7.2608-2613.2003; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; Natoli TA, 2002, MOL CELL BIOL, V22, P4433, DOI 10.1128/MCB.22.12.4433-4438.2002; Niksic M, 2004, HUM MOL GENET, V13, P463, DOI 10.1093/hmg/ddh040; Oji Y, 2004, NEOPLASMA, V51, P17; Oji Y, 2003, CANCER SCI, V94, P712, DOI 10.1111/j.1349-7006.2003.tb01507.x; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; REDDY JC, 1995, J BIOL CHEM, V270, P29976; Rivera MN, 2005, NAT REV CANCER, V5, P699, DOI 10.1038/nrc1696; Roberts SGE, 2005, CURR OPIN GENET DEV, V15, P542, DOI 10.1016/j.gde.2005.08.004; RODECK U, 1994, INT J CANCER, V59, P78, DOI 10.1002/ijc.2910590116; ROMIG H, 1992, EMBO J, V11, P3431, DOI 10.1002/j.1460-2075.1992.tb05422.x; SCHAFER V, 1997, PFLANZENBAUWISS, V1, P133; Sim EUH, 2002, ONCOGENE, V21, P2948, DOI 10.1038/sj.onc.1205373; Wagner N, 2005, GENE DEV, V19, P2631, DOI 10.1101/gad.346405; Wagner N, 2004, J AM SOC NEPHROL, V15, P3044, DOI 10.1097/01.ASN.0000146687.99058.25; Wilhelm D, 2002, GENE DEV, V16, P1839, DOI 10.1101/gad.220102; Williams RD, 2004, GENE CHROMOSOME CANC, V41, P65, DOI 10.1002/gcc.20060; Yamagami T, 1996, BLOOD, V87, P2878, DOI 10.1182/blood.V87.7.2878.bloodjournal8772878; Zapata-Benavides P, 2002, BIOCHEM BIOPH RES CO, V295, P784, DOI 10.1016/S0006-291X(02)00751-9	44	25	28	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 1	2007	26	10					1484	1491		10.1038/sj.onc.1209922	http://dx.doi.org/10.1038/sj.onc.1209922			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DV	16924231				2022-12-17	WOS:000244558800013
J	Castellano, E; De las Rivas, J; Guerrero, C; Santos, E				Castellano, E.; De Las Rivas, J.; Guerrero, C.; Santos, E.			Transcriptional networks of knockout cell lines identify functional specificities of H-Ras and N-Ras: significant involvement of N-Ras in biotic and defense responses	ONCOGENE			English	Article						H-Ras; N-Ras; microarray; genomics; transcriptome; cluster analysis; differential gene expression	K-RAS; PLASMA-MEMBRANE; DIFFERENTIAL ACTIVATION; INTERFERON-ALPHA; GENE-EXPRESSION; PROTEIN-KINASE; MOUSE; TRANSFORMATION; GROWTH; RECEPTOR	We characterized differential gene expression profiles of fibroblast cell lines harboring single or double-homozygous null mutations in H-ras and N-ras. Whereas the expression level of the individual H-, N- and K-ras genes appeared unaffected by the presence or absence of the other ras loci, significant differences were observed between the expression profiles of cells missing N-ras and/or H-ras. Absence of N-ras produced much stronger effects than absence of H-ras over the pro. le of the cellular transcriptome. N-ras(-/-) and H-ras(-/-). broblasts displayed rather antagonistic expression profiles and the transcriptome of H-ras(-/-) cells was significantly closer to that of wild-type. broblasts than to that of N- ras(-/-) cells. Classifying all differentially expressed genes into functional categories suggested specific roles for H-Ras and N-Ras. It was particularly strikingin N-ras(-/-) cells the upregulation of a remarkable number of immunity-related genes, as well as of several loci involved in apoptosis. Reverse-phase protein array assays demonstrated in the same N- ras(-/-) cells the overexpression and nuclear migration of tyrosine phosphorylated signal transducer and activator of transcription 1 (Stat1) which was concomitant with transcriptional activation mediated by interferon-stimulated response elements. Significantly enhanced numbers of apoptotic cells were also detected in cultures of N-ras(-/-) cells. Our data support the notion that different Ras isoforms play functionally distinct cellular roles and indicate that N-Ras is significantly involved in immune modulation/host defense and apoptotic responses.	Univ Salamanca, Ctr Invest Canc, CSIC, USAL,Inst Biol Mol & Celular Canc, Salamanca 37007, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Santos, E (corresponding author), Univ Salamanca, Ctr Invest Canc, CSIC, USAL,Inst Biol Mol & Celular Canc, Salamanca 37007, Spain.	esantos@usal.es	Guerrero, Carmen/F-1776-2010; 2007, Secribsal/A-1556-2012; Sánchez, Esther Castellano/AAA-8087-2020; De Las Rivas, Javier/G-5936-2014	Guerrero, Carmen/0000-0002-8747-6831; Sánchez, Esther Castellano/0000-0002-8449-4081; De Las Rivas, Javier/0000-0002-0984-9946				Barash Y, 2004, BIOINFORMATICS, V20, P839, DOI 10.1093/bioinformatics/btg487; BEADLING C, 1994, EMBO J, V13, P5605, DOI 10.1002/j.1460-2075.1994.tb06898.x; Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166-4328(01)00297-2; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; BOS JL, 1989, CANCER RES, V49, P4682; Brem R, 2001, ONCOGENE, V20, P2854, DOI 10.1038/sj.onc.1204403; Clyde-Smith J, 2000, J BIOL CHEM, V275, P32260, DOI 10.1074/jbc.M006087200; Colicelli John, 2004, Sci STKE, V2004, pRE13, DOI 10.1126/stke.2502004re13; Croonquist PA, 2003, BLOOD, V102, P2581, DOI 10.1182/blood-2003-04-1227; DAVIES SA, 1989, BIOCHIM BIOPHYS ACTA, V1013, P173, DOI 10.1016/0167-4889(89)90046-3; Dumaz N, 2005, FEBS J, V272, P3491, DOI 10.1111/j.1742-4658.2005.04763.x; Ehrhardt A, 2004, MOL CELL BIOL, V24, P6311, DOI 10.1128/MCB.24.14.6311-6323.2004; Eskandarpour M, 2005, INT J CANCER, V115, P65, DOI 10.1002/ijc.20873; Espina V, 2003, PROTEOMICS, V3, P2091, DOI 10.1002/pmic.200300592; Esteban LM, 2001, MOL CELL BIOL, V21, P1444, DOI 10.1128/MCB.21.5.1444-1452.2001; Hamilton M, 1998, J BIOL CHEM, V273, P28155, DOI 10.1074/jbc.273.43.28155; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; Herrmann PC, 2003, PROTEOMICS, V3, P1801, DOI 10.1002/pmic.200300461; Ihrie RA, 2005, CELL, V120, P843, DOI 10.1016/j.cell.2005.01.008; Improta T, 1997, CYTOKINE, V9, P383, DOI 10.1006/cyto.1996.0180; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Jones MK, 1998, J BIOL CHEM, V273, P1782, DOI 10.1074/jbc.273.3.1782; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; Koera K, 1997, ONCOGENE, V15, P1151, DOI 10.1038/sj.onc.1201284; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Liao JH, 2003, J BIOL CHEM, V278, P31871, DOI 10.1074/jbc.M301931200; MAHER J, 1995, ONCOGENE, V11, P1639; Matallanas D, 2006, MOL CELL BIOL, V26, P100, DOI 10.1128/MCB.26.1.100-116.2006; Murtagh F., 1985, COMPSTAT LECT, V4; Ohnami S, 2003, BIOCHEM BIOPH RES CO, V309, P798, DOI 10.1016/j.bbrc.2003.08.073; Oliva JL, 2004, J BIOL CHEM, V279, P33480, DOI 10.1074/jbc.M404058200; Perez de Castro I, 2004, MOL CELL BIOL, V24, P3485, DOI 10.1128/MCB.24.8.3485-3496.2004; Perez de Castro I, 2003, CANCER RES, V63, P1615; Petricoin EF, 1997, NATURE, V390, P629, DOI 10.1038/37648; PINEDA JA, 1994, COGNITIVE BRAIN RES, V2, P1, DOI 10.1016/0926-6410(94)90015-9; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Plowman SJ, 2005, BBA-MOL CELL RES, V1746, P274, DOI 10.1016/j.bbamcr.2005.06.004; Plowman SJ, 2003, MOL CELL BIOL, V23, P9245, DOI 10.1128/MCB.23.24.9245-9250.2003; Potenza N, 2005, EMBO REP, V6, P432, DOI 10.1038/sj.embor.7400397; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; Rocks O, 2005, SCIENCE, V307, P1746, DOI 10.1126/science.1105654; Rojas Jose M., 2002, Current Genomics, V3, P295, DOI 10.2174/1389202023350381; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Ruiz-Vela A, 2005, EMBO REP, V6, P379, DOI 10.1038/sj.embor.7400375; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Sweet-Cordero A, 2005, NAT GENET, V37, P48, DOI 10.1038/ng1490; Takahashi C, 2006, NAT GENET, V38, P118, DOI 10.1038/ng1703; Townsend PA, 2004, J BIOL CHEM, V279, P5811, DOI 10.1074/jbc.M302637200; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; Vasseur Sophie, 2003, Mol Cancer, V2, P19, DOI 10.1186/1476-4598-2-19; Voice JK, 1999, J BIOL CHEM, V274, P17164, DOI 10.1074/jbc.274.24.17164; Walsh AB, 2001, J BIOL CHEM, V276, P15609, DOI 10.1074/jbc.M010573200; Wolfman JC, 2002, MOL CELL BIOL, V22, P1589, DOI 10.1128/MCB.22.5.1589-1606.2002; Wulfkuhle JD, 2003, PROTEOMICS, V3, P2085, DOI 10.1002/pmic.200300591; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	61	25	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2007	26	6					917	933		10.1038/sj.onc.1209845	http://dx.doi.org/10.1038/sj.onc.1209845			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134DT	16909116				2022-12-17	WOS:000244063800012
J	Filomenko, R; Prevotat, L; Rebe, C; Cortier, M; Jeannin, JF; Solary, E; Bettaieb, A				Filomenko, R.; Prevotat, L.; Rebe, C.; Cortier, M.; Jeannin, J-F; Solary, E.; Bettaieb, A.			Caspase-10 involvement in cytotoxic drug-induced apoptosis of tumor cells	ONCOGENE			English	Article						caspase-10; apoptosis; cytotoxic drug; etoposide; acute leukemia	CHEMOTHERAPY-INDUCED APOPTOSIS; ACUTE MYELOID-LEUKEMIA; COLON-CANCER CELLS; CYTOCHROME-C; MITOCHONDRIAL PATHWAYS; INACTIVATING MUTATIONS; SIGNALING PATHWAYS; ARSENIC TRIOXIDE; DEATH RECEPTOR; ACTIVATION	Anticancer drugs can induce tumor cell death by caspase-dependent apoptosis. The observation that procaspase-10 expression decreased in leukemic cells from acute myeloblastic leukemia patients at first relapse led us to explore the role of caspase-10 in cytotoxic drug-induced apoptosis. We show that caspase-10 is activated in etoposide-treated cells in a dose- and time-dependent manner. A caspase-10 peptide inhibitor, a caspase-10 dominant-negative mutant or a small interfering RNA (siRNA)-mediated downregulation of the enzyme negatively interfere with drug-induced cell death and caspase-2, -3, -8 and -9 activation. The extrinsic pathway to apoptosis is not involved in drug-induced caspase-10 activation that occurs downstream of Bax redistribution to mitochondria and cytochrome c release from this organelle. siRNA-mediated downregulation of Apaf-1 prevents etoposide-mediated activation of caspase-10. In a cell-free assay, cytochrome c and dATP treatment of cell extracts after immunodepletion of either caspase-3 or caspase-9 indicates that caspase-10 is activated downstream of caspase-9. Then, caspase-10 is involved in a feedback amplification loop that amplifies caspase-9 and -3 activities. Altogether, these data indicate an active role for caspase-10 in cytotoxic drug-induced tumor cell death, downstream of the mitochondria.	Ecole Prat Hautes Etud, IFR 100, Fac Med, INSERM,U517, F-21079 Dijon, France; CHU Bocage, Clin Hematol Unit, Dijon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; CHU Dijon Bourgogne	Bettaieb, A (corresponding author), Ecole Prat Hautes Etud, IFR 100, Fac Med, INSERM,U517, 7 Blvd Jeanne Arc, F-21079 Dijon, France.	ali.bettaieb@u-bourgogne.fr	REBE, Cédric/AAD-4316-2019	REBE, Cédric/0000-0001-8831-145X; Bettaieb, Ali/0000-0002-6018-9592; Solary, Eric/0000-0002-8629-1341				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Cain K, 2000, J BIOL CHEM, V275, P6067, DOI 10.1074/jbc.275.9.6067; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Decaudin D, 1998, INT J ONCOL, V12, P141; Del Poeta G, 2003, BLOOD, V101, P2125, DOI 10.1182/blood-2002-06-1714; Delmas D, 2003, J BIOL CHEM, V278, P41482, DOI 10.1074/jbc.M304896200; Dubrez L, 1996, EMBO J, V15, P5504, DOI 10.1002/j.1460-2075.1996.tb00935.x; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Estrov Z, 1998, BLOOD, V92, P3090, DOI 10.1182/blood.V92.9.3090; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Fujita E, 2001, CELL DEATH DIFFER, V8, P335, DOI 10.1038/sj.cdd.4400824; Fulda S, 2001, ONCOGENE, V20, P1063, DOI 10.1038/sj.onc.1204141; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Harada K, 2002, CANCER RES, V62, P5897; HIDDEMANN W, 1991, ANN HEMATOL, V62, P119, DOI 10.1007/BF01702925; Hill MM, 2004, EMBO J, V23, P2134, DOI 10.1038/sj.emboj.7600210; KAMESAKI S, 1993, CANCER RES, V53, P4251; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Lacour S, 2001, CANCER RES, V61, P1645; Laurent G, 2001, BLOOD, V98, P913, DOI 10.1182/blood.V98.4.913; Li J, 2002, J BIOL CHEM, V277, P49504, DOI 10.1074/jbc.M207836200; Marsden VS, 2003, ANNU REV IMMUNOL, V21, P71, DOI 10.1146/annurev.immunol.21.120601.141029; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Millet A, 2002, GASTROENTEROLOGY, V123, P235, DOI 10.1053/gast.2002.34310; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Park SJ, 2004, J BIOL CHEM, V279, P51057, DOI 10.1074/jbc.M406543200; Park WS, 2002, ONCOGENE, V21, P2919, DOI 10.1038/sj.onc.1205394; Perkins C, 1998, CANCER RES, V58, P4561; Reed JC, 1997, SEMIN HEMATOL, V34, P9; Reed JC, 2003, GENOME RES, V13, P1376, DOI 10.1101/gr.1053803; Rikhof B, 2003, CANCER BIOL THER, V2, P707; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schmitt E, 1999, DRUG RESIST UPDATE, V2, P21, DOI 10.1054/drup.1999.0065; Shin MS, 2002, BLOOD, V99, P4094, DOI 10.1182/blood.V99.11.4094; Shin MS, 2002, ONCOGENE, V21, P4129, DOI 10.1038/sj.onc.1205527; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Sordet O, 2001, BLOOD, V97, P3931, DOI 10.1182/blood.V97.12.3931; Svingen PA, 2000, BLOOD, V96, P3922, DOI 10.1182/blood.V96.12.3922.h8003922_3922_3931; Tamm I, 2000, CLIN CANCER RES, V6, P1796; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Wang L, 2001, P NATL ACAD SCI USA, V98, P13884, DOI 10.1073/pnas.241358198; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	51	25	26	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2006	25	58					7635	7645		10.1038/sj.onc.1209733	http://dx.doi.org/10.1038/sj.onc.1209733			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114GU	16767158				2022-12-17	WOS:000242655500008
J	Darbro, BW; Lee, KM; Nguyen, NK; Domann, FE; Klingelhutz, AJ				Darbro, B. W.; Lee, K. M.; Nguyen, N. K.; Domann, F. E.; Klingelhutz, A. J.			Methylation of the p16(INK4a) promoter region in telomerase immortalized human keratinocytes co-culturedwith feeder cells	ONCOGENE			English	Article						hTERT; CDKN2A; senescence; epigenetic; Rb; telomeres	MAMMARY EPITHELIAL-CELLS; HUMAN UROEPITHELIAL CELLS; HUMAN ORAL KERATINOCYTES; DNA METHYLATION; PROGNOSTIC-SIGNIFICANCE; P16 EXPRESSION; HUMAN CANCER; REPLICATIVE SENESCENCE; GROWTH-CONDITIONS; P16/PRB PATHWAY	Human keratinocytes grown in co-culture with fibroblast feeder cells have an extended in vitro lifespan and delayed accumulation of the tumor suppressor protein p16(INK4a) when compared to the same cells grown on tissue culture plastic alone. Previous studies have indicated that human keratinocytes can be immortalized by telomerase activity alone when grown in co-culture with feeder cells, suggesting that loss of the p16(INK4a)/Rb pathway is not required for immortalization. Using two independent human keratinocyte cell strains, we found that exogenous telomerase expression and co-culture with feeder cells results in efficient extension of lifespan without an apparent crisis. However, when these cells were transferred from the co-culture environment to plastic alone they experienced only a brief period of slowed growth before continuing to proliferate indefinitely. Examination of immortal cell lines demonstrated p16(INK4a) promoter methylation had occurred in both the absence and presence of feeder cells. Reintroduction of p16INK4a into immortal cell lines resulted in rapid growth arrest. Our results suggest that p16(INK4a)/Rb-induced telomere-independent senescence, although delayed in the presence of feeders, still provides a proliferation barrier to human keratinocytes in this culture system and that extended culture of telomerase-transduced keratinocytes on feeders can lead to the methylation of p16(INK4a).	Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA; Univ Iowa, Holden Canc Ctr, Iowa City, IA 52242 USA; Univ Iowa, Interdisciplinary Program Mol Biol, Iowa City, IA 52242 USA; Univ Iowa, Med Scientist Training Program, Iowa City, IA 52242 USA; Univ Iowa, Dept Radiat Oncol, Iowa City, IA 52242 USA; Univ Iowa, Free Rad & Radiat Biol Program, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa; University of Iowa; University of Iowa; University of Iowa	Klingelhutz, AJ (corresponding author), Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA.	al-klingelhutz@uiowa.edu	Klingelhutz, Aloysius/L-9081-2018	Klingelhutz, Aloysius/0000-0003-4258-5046; Darbro, Benjamin/0000-0001-9279-356X; Domann, Frederick/0000-0002-0489-2179	NATIONAL CANCER INSTITUTE [R01CA073612] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007638] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018265] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA73612, R01 CA073612] Funding Source: Medline; NHLBI NIH HHS [T32 HL07638, T32 HL007638] Funding Source: Medline; NIA NIH HHS [R01 AG18265, R01 AG018265] Funding Source: Medline; NIGMS NIH HHS [T32 GM07337, T32 GM007337] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baek JH, 2003, INT J MOL MED, V12, P319; BLANTON RA, 1991, AM J PATHOL, V138, P673; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Brenner AJ, 1998, ONCOGENE, V17, P199, DOI 10.1038/sj.onc.1201919; Chakravarti A, 2003, J CLIN ONCOL, V21, P3328, DOI 10.1200/JCO.2003.12.151; Cody DT, 1999, ORAL ONCOL, V35, P516, DOI 10.1016/S1368-8375(99)00026-3; Curtis CD, 2005, METH MOLEC MED, V103, P123; Darbro BW, 2005, J INVEST DERMATOL, V125, P499, DOI 10.1111/j.0022-202X.2005.23844.x; Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151; DER CJ, 1986, MOL CELL BIOL, V6, P3291, DOI 10.1128/MCB.6.9.3291; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; Esteller M, 2001, J CLIN ONCOL, V19, P299, DOI 10.1200/JCO.2001.19.2.299; Farwell DG, 2000, AM J PATHOL, V156, P1537, DOI 10.1016/S0002-9440(10)65025-0; Foster SA, 1996, ONCOGENE, V12, P1773; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; Fu BJ, 2003, CANCER RES, V63, P7815; Govindarajan B, 2002, MOL MED, V8, P1; Groeger AM, 1999, J THORAC CARDIOV SUR, V118, P529, DOI 10.1016/S0022-5223(99)70192-3; Harada H, 2003, MOL CANCER RES, V1, P729; Herbert BS, 2002, ONCOGENE, V21, P7897, DOI 10.1038/sj.onc.1205902; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Jacobs JJL, 2004, CURR BIOL, V14, P2302, DOI 10.1016/j.cub.2004.12.025; Jarmalaite S, 2003, INT J CANCER, V106, P913, DOI 10.1002/ijc.11322; Jarrard DF, 1999, CANCER RES, V59, P2957; Jung A, 2001, AM J PATHOL, V159, P1613, DOI 10.1016/S0002-9440(10)63007-6; Kang MK, 2004, J CELL PHYSIOL, V199, P364, DOI 10.1002/jcp.10410; Kang MK, 2003, EXP CELL RES, V287, P272, DOI 10.1016/S0014-4827(03)00061-2; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Klingelhutz AJ, 2005, VIROLOGY, V340, P237, DOI 10.1016/j.virol.2005.06.027; Korkolopoulou P, 2001, EUR UROL, V39, P167, DOI 10.1159/000052432; Lewis A, 2004, NAT GENET, V36, P1291, DOI 10.1038/ng1468; Liggett WH, 1998, J CLIN ONCOL, V16, P1197, DOI 10.1200/JCO.1998.16.3.1197; Liu LM, 2005, INT J ONCOL, V26, P275; Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774; Natarajan E, 2003, AM J PATHOL, V163, P477, DOI 10.1016/S0002-9440(10)63677-2; Nilsson K, 2004, MODERN PATHOL, V17, P1464, DOI 10.1038/modpathol.3800220; Noble JR, 2004, ONCOGENE, V23, P3116, DOI 10.1038/sj.onc.1207440; Partridge M, 2005, CANCER METAST REV, V24, P71, DOI 10.1007/s10555-005-5048-0; Paz MF, 2003, CANCER RES, V63, P1114; Puthenveettil JA, 1999, ADV EXP MED BIOL, V462, P83; Ramirez RD, 2003, ONCOGENE, V22, P433, DOI 10.1038/sj.onc.1206046; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; REZNIKOFF CA, 1987, J CELL PHYSIOL, V131, P285, DOI 10.1002/jcp.1041310302; Reznikoff CA, 1996, CANCER RES, V56, P2886; Rheinwald JG, 2002, MOL CELL BIOL, V22, P5157, DOI 10.1128/MCB.22.14.5157-5172.2002; Rocco JW, 2001, EXP CELL RES, V264, P42, DOI 10.1006/excr.2000.5149; Romanenko A, 2002, DIAGN MOL PATHOL, V11, P163, DOI 10.1097/00019606-200209000-00007; Sandhu C, 2000, CANCER RES, V60, P2616; Sharpless NE, 2005, MUTAT RES-FUND MOL M, V576, P22, DOI 10.1016/j.mrfmmm.2004.08.021; Stampfer MR, 2003, CANCER LETT, V194, P199, DOI 10.1016/S0304-3835(02)00707-3; Stampfer MR, 2001, P NATL ACAD SCI USA, V98, P4498, DOI 10.1073/pnas.071483998; Svensson S, 2003, CANCER RES, V63, P1737; Taylor LM, 2004, J BIOL CHEM, V279, P43634, DOI 10.1074/jbc.M402388200; Thiagalingam S, 2003, ANN NY ACAD SCI, V983, P84, DOI 10.1111/j.1749-6632.2003.tb05964.x; Timmermann S, 1998, ONCOGENE, V17, P3445, DOI 10.1038/sj.onc.1202244; Tsihlias J, 1999, ANNU REV MED, V50, P401; Tsutsui T, 2002, CARCINOGENESIS, V23, P2111, DOI 10.1093/carcin/23.12.2111; Wang J, 2000, NATURE, V405, P755, DOI 10.1038/35015674; Wege H, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng003; Weinberger PM, 2004, CLIN CANCER RES, V10, P5684, DOI 10.1158/1078-0432.CCR-04-0448; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; Wong DJ, 1997, CANCER RES, V57, P2619; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; Zhao W, 2005, J BIOCHEM, V137, P431, DOI 10.1093/jb/mvi048; Zohn IE, 1998, MOL CELL BIOL, V18, P1225, DOI 10.1128/MCB.18.3.1225; Zongaro S, 2005, CANCER RES, V65, P11411, DOI 10.1158/0008-5472.CAN-05-1140	66	25	28	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2006	25	56					7421	7433		10.1038/sj.onc.1209729	http://dx.doi.org/10.1038/sj.onc.1209729			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110ZE	16767161	Green Accepted			2022-12-17	WOS:000242419100011
J	Davies, GC; Ryan, PE; Rahman, L; Zajac-Kaye, M; Lipkowitz, S				Davies, G. C.; Ryan, P. E.; Rahman, L.; Zajac-Kaye, M.; Lipkowitz, S.			EGFRvIII undergoes activation-dependent downregulation mediated by the Cbl proteins	ONCOGENE			English	Article						EGFRvIII; Cbl proteins; ubiquitin; cancer	EPIDERMAL-GROWTH-FACTOR; MUTANT EGF-RECEPTOR; CONFERS ENHANCED TUMORIGENICITY; HUMAN GLIOBLASTOMA CELLS; TYROSINE PHOSPHORYLATION; MONOCLONAL-ANTIBODIES; KINASE INHIBITORS; RING FINGER; CANCER; EXPRESSION	The overexpression or mutation of tyrosine kinases (TKs), such as the epidermal growth factor receptor (EGFR), can lead to the development of cancer. The most common mutation of the EGFR in glioblastomas is the deletion of exons 2-7 known as the EGFRvIII. This mutant receptor cannot bind EGF but, instead, is constitutively active. The Cbl family of ubiquitin ligases (Cbl, Cbl-b, and Cbl-c) targets the activated EGFR for degradation. As the EGFRvIII is transforming, we investigated whether it could be downregulated by the Cbl proteins. The overexpression of all three Cbl proteins resulted in the ubiquitination and degradation of the EGFRvIII. As with the wild-type EGFR, the TK-binding domain and the RING finger of Cbl-b are sufficient for the downregulation of the EGFRvIII. Also, we found that Cbl-b is recruited to the EGFRvIII and inhibits the transformation of NIH 3T3 cells by the EGFRvIII. Mutation of the Cbl-binding site (Y1045F) in the EGFRvIII inhibits its ubiquitination and downregulation by Cbl-b and enhances its ability to transform. Furthermore, the EGFR TK inhibitor, AG 1478, prevents the downregulation of the EGFRvIII by the Cbl proteins and antagonizes the ability of an immunotoxin directed against the EGFRvIII to kill cells expressing this receptor. In conclusion, the EGFRvIII does not transform by escaping regulation by Cbl proteins and this activation-induced downregulation of the EGFRvIII has an important role in mediating the toxicity of anti-EGFRvIII immunotoxins.	NCI, LCMB, CCR, NIH, Bethesda, MD 20892 USA; George Washington Univ, Inst Biomed Sci, Washington, DC USA; NCI, Mol Therapeut Program, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); George Washington University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lipkowitz, S (corresponding author), NCI, LCMB, CCR, NIH, Bldg 37,Rm 2066,37 Convent Dr, Bethesda, MD 20892 USA.	LipkowiS@mail.nih.gov			Intramural NIH HHS [Z99 CA999999] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01SC007263] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abulrob A, 2004, ONCOGENE, V23, P6967, DOI 10.1038/sj.onc.1207911; Antonyak MA, 1998, J BIOL CHEM, V273, P2817, DOI 10.1074/jbc.273.5.2817; BATRA SK, 1995, CELL GROWTH DIFFER, V6, P1251; Beers R, 2000, CLIN CANCER RES, V6, P2835; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Damstrup L, 2002, INT J CANCER, V97, P7, DOI 10.1002/ijc.1572; Duan L, 2003, J BIOL CHEM, V278, P28950, DOI 10.1074/jbc.M304474200; EKSTRAND AJ, 1994, ONCOGENE, V9, P2313; Ettenberg S A, 1999, Mol Cell Biol Res Commun, V2, P111, DOI 10.1006/mcbr.1999.0157; Ettenberg SA, 1999, ONCOGENE, V18, P1855, DOI 10.1038/sj.onc.1202499; Ettenberg SA, 2001, J BIOL CHEM, V276, P27677, DOI 10.1074/jbc.M102641200; Fernandes H, 2001, J BIOL CHEM, V276, P5375, DOI 10.1074/jbc.M005599200; GARCIA DP, 1993, CANCER RES, V53, P3217; Han YC, 1996, CANCER RES, V56, P3859; Heimberger AB, 2005, CLIN CANCER RES, V11, P1462, DOI 10.1158/1078-0432.CCR-04-1737; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Jiang XJ, 2003, MOL BIOL CELL, V14, P858, DOI 10.1091/mbc.E02-08-0532; Johns TG, 2003, P NATL ACAD SCI USA, V100, P15871, DOI 10.1073/pnas.2036503100; Keane MM, 1996, CANCER RES, V56, P4791; Keane MM, 1999, ONCOGENE, V18, P3365, DOI 10.1038/sj.onc.1202753; Kuan CT, 2000, INT J CANCER, V88, P962, DOI 10.1002/1097-0215(20001215)88:6<962::AID-IJC20>3.0.CO;2-U; Kuan CT, 2001, ENDOCR-RELAT CANCER, V8, P83, DOI 10.1677/erc.0.0080083; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Luwor RB, 2004, ONCOGENE, V23, P6095, DOI 10.1038/sj.onc.1207870; Mancini A, 2002, J BIOL CHEM, V277, P14635, DOI 10.1074/jbc.M109214200; Mellinghoff IK, 2005, NEW ENGL J MED, V353, P2012, DOI 10.1056/NEJMoa051918; Montgomery RB, 2002, INT J CANCER, V101, P111, DOI 10.1002/ijc.10560; MOSCATELLO DK, 1995, CANCER RES, V55, P5536; Moscatello DK, 1996, ONCOGENE, V13, P85; Nagane M, 1996, CANCER RES, V56, P5079; Nau MM, 2003, GENE, V308, P103, DOI 10.1016/S0378-1119(03)00471-2; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; O'Rourke DM, 1998, ONCOGENE, V16, P1197, DOI 10.1038/sj.onc.1201635; PASTAN I, 1992, ANNU REV BIOCHEM, V61, P331, DOI 10.1146/annurev.bi.61.070192.001555; Pedersen MW, 2004, INT J CANCER, V108, P643, DOI 10.1002/ijc.11566; Pedersen MW, 2001, ANN ONCOL, V12, P745, DOI 10.1023/A:1011177318162; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Peschard P, 2003, CANCER CELL, V3, P519, DOI 10.1016/S1535-6108(03)00136-3; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; REIST CJ, 1995, CANCER RES, V55, P4375; Schmidt MHH, 2003, P NATL ACAD SCI USA, V100, P6505, DOI 10.1073/pnas.1031790100; Shinojima N, 2003, CANCER RES, V63, P6962; Tang CK, 2000, CANCER RES, V60, P3081; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Waterman H, 1999, EMBO J, V18, P3348, DOI 10.1093/emboj/18.12.3348; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303; WIKSTRAND CJ, 1995, CANCER RES, V55, P3140; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707	49	25	28	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 19	2006	25	49					6497	6509		10.1038/sj.onc.1209662	http://dx.doi.org/10.1038/sj.onc.1209662			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	096RS	16702950	Green Accepted			2022-12-17	WOS:000241395100006
J	Castro, P; Soares, P; Gusmao, L; Seruca, R; Sobrinho-Simoes, M				Castro, P.; Soares, P.; Gusmao, L.; Seruca, R.; Sobrinho-Simoes, M.			H-RAS 81 polymorphism is significantly associated with aneuploidy in follicular tumors of the thyroid	ONCOGENE			English	Article						aneuploidy; RAS mutations; H-RAS polymorphism; H-RAS splicing	SPORADIC COLORECTAL ADENOMAS; GENOMIC INSTABILITY; PROTO-ONCOGENE; DNA ANEUPLOIDY; BRAF MUTATIONS; P21 PROTEIN; CELL-CYCLE; CANCER; CARCINOMA; ACTIVATION	Follicular thyroid tumors are often aneuploid. It was advanced that chromosomal instability is closely associated to RAS mutations, but such association remains unproven. H-RAS can be alternatively spliced in two different proteins, p21 and p19, the former being the active protein. In order to investigate the relationship between RAS mutational status and ploidy in thyroid tumors, we analysed RAS genes in a series of 99 follicular lesions (14 nodular goiters, 70 follicular adenomas and 15 follicular carcinomas), eight thyroid carcinoma cell lines and a control group of 102 blood donors, correlating the presence of RAS mutations with the ploidy of the tumors and evaluating the two spliced forms of H-RAS. Overall, 20% of the follicular tumors harbored RAS mutations and 62% of the patients with follicular tumors (and 51% of blood donors) harbored the H-RA S 81T -> C polymorphism. The presence of RAS mutations was not associated with aneuploidy. The H-RAS polymorphism did not seem to confer a higher propensity for neoplastic transformation as it was also found in hyperplastic lesions, but was strongly associated with aneuploidy (P < 0.0001). The presence of the H-RAS 81T -> C polymorphism was associated with significantly higher amounts of total H-RAS mRNA expression, higher amounts of p21 isoform and a higher fraction of neoplastic cells in S phase. Our results suggest that the H-RAS 81T -> C polymorphism may induce aneuploidy through overexpression of the active p21 isoform of H-RAS.	IPATIMUP, P-4200465 Oporto, Portugal; Fac Med Porto, Dept Pathol, Oporto, Portugal	Universidade do Porto	Sobrinho-Simoes, M (corresponding author), IPATIMUP, Rua Dr Roberto Frias S-N, P-4200465 Oporto, Portugal.	ssimoes@ipatimup.pt	Castro, Patricia/J-8537-2013; Sobrinho-Simões, Manuel/J-8290-2013; Gusmão, Leonor/L-8931-2019; Gusmao, Leonor/B-3122-2013; seruca, raquel/F-8187-2011; Soares, Paula/B-6054-2008	Gusmão, Leonor/0000-0003-0432-6481; Gusmao, Leonor/0000-0003-0432-6481; Soares, Paula/0000-0001-9607-6998; Castro, Patricia/0000-0001-9588-9065; Sobrinho-Simoes, Manuel/0000-0003-1613-1235; Seruca, Raquel/0000-0002-8851-4166				BOS JL, 1989, CANCER RES, V49, P4682; Castro P, 2005, J PATHOL, V206, P305, DOI 10.1002/path.1772; Castro P, 2001, VIRCHOWS ARCH, V438, P336, DOI 10.1007/s004280000354; Codony C, 2001, ONCOGENE, V20, P3683, DOI 10.1038/sj.onc.1204473; COHEN JB, 1993, MOL CELL BIOL, V13, P2666, DOI 10.1128/MCB.13.5.2666; COHEN JB, 1989, CELL, V58, P461, DOI 10.1016/0092-8674(89)90427-3; Coleman ML, 2004, NAT REV MOL CELL BIO, V5, P355, DOI 10.1038/nrm1365; CUSICK EL, 1991, BRIT J SURG, V78, P94, DOI 10.1002/bjs.1800780129; DEITCH AD, 1982, J HISTOCHEM CYTOCHEM, V30, P967, DOI 10.1177/30.9.6182188; DeLellis RA, 2004, PATHOLOGY GENETICS T; DENKO N, 1995, SOMAT CELL MOLEC GEN, V21, P241, DOI 10.1007/BF02255779; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; Esapa CT, 1999, CLIN ENDOCRINOL, V50, P529, DOI 10.1046/j.1365-2265.1999.00704.x; Fagin JA, 2002, MOL ENDOCRINOL, V16, P903, DOI 10.1210/me.16.5.903; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; Giaretti W, 2004, CELL ONCOL, V26, P301; GIARETTI W, 1995, GASTROENTEROLOGY, V108, P1040, DOI 10.1016/0016-5085(95)90201-5; Giaretti W, 1998, AM J PATHOL, V153, P1201, DOI 10.1016/S0002-9440(10)65664-7; Guil S, 2003, CANCER RES, V63, P5178; Guil S, 2003, MOL CELL BIOL, V23, P2927, DOI 10.1128/MCB.23.8.2927-2941.2003; HARA H, 1994, SURGERY, V116, P1010; HOSTETTER AL, 1988, AM J CLIN PATHOL, V89, P760, DOI 10.1093/ajcp/89.6.760; Huang MY, 1997, ONCOL RES, V9, P611; Illmer T, 2005, CLIN CANCER RES, V11, P3217, DOI 10.1158/1078-0432.CCR-04-2232; JOENSUU H, 1988, AM J CLIN PATHOL, V89, P35, DOI 10.1093/ajcp/89.1.35; JOHANNESSEN JV, 1982, AM J CLIN PATHOL, V77, P20; Johne A, 2003, CANCER EPIDEM BIOMAR, V12, P68; Kimura ET, 2003, CANCER RES, V63, P1454; KRONTIRIS TG, 1993, NEW ENGL J MED, V329, P517, DOI 10.1056/NEJM199308193290801; LIWO A, 1994, J PROTEIN CHEM, V13, P237, DOI 10.1007/BF01891982; Mammas IN, 2004, GYNECOL ONCOL, V92, P941, DOI 10.1016/j.ygyno.2003.11.040; Mascaux C, 2005, BRIT J CANCER, V92, P131, DOI 10.1038/sj.bjc.6602258; MONACO R, 1995, J PROTEIN CHEM, V14, P457, DOI 10.1007/BF01888140; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; Nikiforova MN, 2003, J CLIN ENDOCR METAB, V88, P2318, DOI 10.1210/jc.2002-021907; NOONAN T, 1991, J MED CHEM, V34, P1302, DOI 10.1021/jm00108a010; Pastinen T, 2004, SCIENCE, V306, P647, DOI 10.1126/science.1101659; PULCIANI S, 1985, MOL CELL BIOL, V5, P2836, DOI 10.1128/MCB.5.10.2836; Rosai J, 1993, TUMORS THYROID GLAND; Saavedra HI, 2000, ONCOGENE, V19, P3948, DOI 10.1038/sj.onc.1203723; SCHELFHOUT LJDM, 1990, INT J CANCER, V45, P16, DOI 10.1002/ijc.2910450105; Schneider S., 2000, ARLEQUIN SOFTWARE PO, V2, P2496; Soares P, 2003, ONCOGENE, V22, P4578, DOI 10.1038/sj.onc.1206706; Sugg SL, 1999, SURGERY, V125, P46, DOI 10.1016/S0039-6060(99)70287-4; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; Wang B, 1997, ANTICANCER RES, V17, P4387	46	25	27	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2006	25	33					4620	4627		10.1038/sj.onc.1209491	http://dx.doi.org/10.1038/sj.onc.1209491			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	069OG	16532025				2022-12-17	WOS:000239457500012
J	Pantic, M; Zimmermann, S; El Daly, H; Opitz, OG; Popp, S; Boukamp, P; Martens, UM				Pantic, M.; Zimmermann, S.; El Daly, H.; Opitz, O. G.; Popp, S.; Boukamp, P.; Martens, U. M.			Telomere dysfunction and loss of p53 cooperate in defective mitotic segregation of chromosomes in cancer cells	ONCOGENE			English	Article						telomere dysfunction; Q-FISH; telomerase inhibition; chromosomal instability; hyperdiploidy	SPINDLE CHECKPOINT; INSTABILITY; ANEUPLOIDY; INACTIVATION; PROGRESSION; CARCINOMA; DAMAGE; REQUIREMENT; CENTROSOME; MUTATIONS	Aneuploidy is a fundamental principle of many cancer cells and is mostly related to defects in mitotic segregation of chromosomes. Many solid tumors as well as some preneoplastic lesions have been shown to contain polyploid chromosome numbers. The exact mechanisms behind whole-genome duplications are not known but have been linked to compromised mitotic checkpoint genes. We now report that the telomere checkpoint plays a key role for polyploidy in colon cancer cells. Telomerase suppression by a dominant-negative mutant of hTERT and consecutive telomere dysfunction in wild-type HCT116 colon cancer cells resulted in only minor stable chromosomal alterations. However, higher ploidy levels with up to 350 chromosomes were found when the cell-cycle checkpoint proteins p53 or p21 were absent. These findings indicate that telomere dysfunction in the absence of cell-cycle control may explain the high frequency of alterations in chromosome numbers found in many solid tumors.	Univ Freiburg, Med Ctr, Dept Hematol Oncol, D-79106 Freiburg, Germany; Univ Freiburg, Med Ctr, Dept Gastroenterol, Freiburg, Germany; German Canc Res Ctr, D-6900 Heidelberg, Germany	University of Freiburg; University of Freiburg; Helmholtz Association; German Cancer Research Center (DKFZ)	Martens, UM (corresponding author), Univ Freiburg, Med Ctr, Dept Hematol Oncol, Hugstetterstr 55, D-79106 Freiburg, Germany.	uwe.martens@uniklinik-freiburg.de						Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Bharadwaj R, 2004, ONCOGENE, V23, P2016, DOI 10.1038/sj.onc.1207374; Borel F, 2002, P NATL ACAD SCI USA, V99, P9819, DOI 10.1073/pnas.152205299; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Bunz F, 2002, CANCER RES, V62, P1129; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Daniels MJ, 2004, SCIENCE, V306, P876, DOI 10.1126/science.1102574; DELANGE T, 1995, TELOMERES, P265; Edgar BA, 2001, CELL, V105, P297, DOI 10.1016/S0092-8674(01)00334-8; El-Daly H, 2005, BLOOD, V105, P1742, DOI 10.1182/blood-2003-12-4322; Feldser DM, 2003, NAT REV CANCER, V3, P623, DOI 10.1038/nrc1142; Fernandez-Capetillo O, 2004, NAT GENET, V36, P672, DOI 10.1038/ng0704-672; Filatov L, 1998, ONCOGENE, V16, P1825, DOI 10.1038/sj.onc.1201711; Fukasawa K, 2002, ONCOGENE, V21, P6140, DOI 10.1038/sj.onc.1205771; Gisselsson D, 2005, SEMIN CANCER BIOL, V15, P13, DOI 10.1016/j.semcancer.2004.09.002; Gisselsson D, 2000, P NATL ACAD SCI USA, V97, P5357, DOI 10.1073/pnas.090013497; Gordon KE, 2003, CANCER RES, V63, P458; Hanks S, 2004, NAT GENET, V36, P1159, DOI 10.1038/ng1449; Hansemann D., 1890, ARCH PATHOL ANAT PH, V119, P299, DOI DOI 10.1007/BF01882039; Hede K, 2005, J NATL CANCER I, V97, P87, DOI 10.1093/jnci/97.2.87; Herbig U, 2004, MOL CELL, V14, P501, DOI 10.1016/S1097-2765(04)00256-4; Jallepalli PV, 2001, NAT REV CANCER, V1, P109, DOI 10.1038/35101065; Maser RS, 2002, SCIENCE, V297, P565, DOI 10.1126/science.297.5581.565; Murnane JP, 2004, BIOESSAYS, V26, P1164, DOI 10.1002/bies.20125; O'Sullivan JN, 2002, NAT GENET, V32, P280, DOI 10.1038/ng989; Pantic M, 2005, INT J ONCOL, V26, P1227; Popp S, 2000, J INVEST DERMATOL, V115, P1095, DOI 10.1046/j.1523-1747.2000.00173.x; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Rudolph KL, 2001, NAT GENET, V28, P155, DOI 10.1038/88871; Saunders WS, 2000, P NATL ACAD SCI USA, V97, P303, DOI 10.1073/pnas.97.1.303; Sen S, 2000, CURR OPIN ONCOL, V12, P82, DOI 10.1097/00001622-200001000-00014; Shichiri M, 2002, CANCER RES, V62, P13; Smogorzewska A, 2002, EMBO J, V21, P4338, DOI 10.1093/emboj/cdf433; Stewenius Y, 2005, P NATL ACAD SCI USA, V102, P5541, DOI 10.1073/pnas.0408454102; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang RH, 2004, P NATL ACAD SCI USA, V101, P17108, DOI 10.1073/pnas.0407585101; Wright WE, 2000, NAT MED, V6, P849, DOI 10.1038/78592; Zimmermann S, 2004, STEM CELLS, V22, P741, DOI 10.1634/stemcells.22-5-741	40	25	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2006	25	32					4413	4420		10.1038/sj.onc.1209486	http://dx.doi.org/10.1038/sj.onc.1209486			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	067TR	16547498				2022-12-17	WOS:000239326000004
J	Belloni, L; Moretti, F; Merlo, P; Damalas, A; Costanzo, A; Blandino, G; Levrero, M				Belloni, L.; Moretti, F.; Merlo, P.; Damalas, A.; Costanzo, A.; Blandino, G.; Levrero, M.			DNp73 alpha protects myogenic cells from apoptosis	ONCOGENE			English	Article						p73; DNp73; myogenic differentiation; apoptosis	P73 EXPRESSION; DNA-DAMAGE; DIFFERENTIATION; P53; ACETYLATION; FAMILY; ROLES; GENE	The P73 gene is transcribed from two promoters, P1 and P2, that direct the expression of multiple transactivation competent (TA) and dominant negative (DN) isoforms. TAp73 transcription factors mediate cell cycle arrest and/or apoptosis in response to DNA damage and are involved in developmental processes. P73 mRNA levels increase and the P1p73 promoter is upregulated during myogenic differentiation of C2C12 skeletal muscle satellite cells. The DNp73 proteins act as trans-repressors of p53- and p73-dependent transcription, and possess both antiapoptotic and pro-proliferative potential. Here, we show that DNp73 alpha is expressed in proliferating C2C12 myoblasts, rapidly accumulates in differentiating myocytes and remains elevated in C2C12 myotubes. By combining transactivation assays and chromatin immunoprecipitation analysis, we could show that the upregulation of the P2p73 promoter during myogenic differentiation is mediated by the coordinated recruitment and activity of MyoD and p53/p73. Abrogation of DNp73 expression by specific siRNA led to a strong potentiation of the spontaneous apoptosis of C2C12 myoblasts induced to differentiate. Finally, unlike TAp73 that contributes to DNA damage-induced apoptosis of myotubes, endogenous DNp73 mediates the relative resistance of differentiated myotubes to DNA damage. Altogether, our findings identify DNp73 alpha as an important target in designing strategies aimed at the potentiation of the regenerative potential of skeletal satellite cells.	Univ Roma La Sapienza, Lab Gene Express, Fdn Andrea Cesalpino, Ist Tumori Regina Elena,CRS, I-00158 Rome, Italy; Univ Roma La Sapienza, Dept Internal Med, I-00158 Rome, Italy; Regina Elena Inst Canc Res, Rome Oncogenom Ctr, Rome, Italy; Regina Elena Inst Canc Res, Dept Expt Oncol, Rome, Italy; Univ Roma Tor Vergata, Dept Dermatol, Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Sapienza University Rome; Sapienza University Rome; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Rome Tor Vergata	Levrero, M (corresponding author), Univ Roma La Sapienza, Lab Gene Express, Fdn Andrea Cesalpino, Ist Tumori Regina Elena,CRS, Via Messi Oro 156, I-00158 Rome, Italy.	levmax@tin.it	Costanzo, Antonio/GZG-2433-2022; Blandino, Giovanni/B-1137-2013; Belloni, Laura/S-1432-2019; Merlo, Paola/K-5330-2014; Costanzo, Antonio/D-3896-2012; Levrero, Massimo/G-5680-2016	Costanzo, Antonio/0000-0001-9697-2557; Blandino, Giovanni/0000-0002-6970-2241; Merlo, Paola/0000-0003-0105-7044; Levrero, Massimo/0000-0002-4978-0875	Telethon [E.1325, GGP030358] Funding Source: Medline	Telethon(Fondazione Telethon)		Billon N, 2004, DEVELOPMENT, V131, P1211, DOI 10.1242/dev.01035; Cerone MA, 2000, CELL DEATH DIFFER, V7, P506, DOI 10.1038/sj.cdd.4400676; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; De Laurenzi V, 2000, BIOCHEM BIOPH RES CO, V273, P342, DOI 10.1006/bbrc.2000.2932; De Laurenzi V, 2000, J BIOL CHEM, V275, P15226, DOI 10.1074/jbc.275.20.15226; Fontemaggi G, 2002, J BIOL CHEM, V277, P43359, DOI 10.1074/jbc.M205573200; Fontemaggi G, 2001, MOL CELL BIOL, V21, P8461, DOI 10.1128/MCB.21.24.8461-8470.2001; HALEVY O, 1993, BIOCHEM BIOPH RES CO, V192, P714, DOI 10.1006/bbrc.1993.1473; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Kartasheva NN, 2002, ONCOGENE, V21, P4715, DOI 10.1038/sj.onc.1205584; Latella L, 2004, MOL CELL BIOL, V24, P6350, DOI 10.1128/MCB.24.14.6350-6361.2004; Levrero M, 2000, J CELL SCI, V113, P1661; Li CY, 2005, J BIOL CHEM, V280, P2159, DOI 10.1074/jbc.M411194200; Liu G, 2004, MOL CELL BIOL, V24, P487, DOI 10.1128/MCB.24.2.487-501.2004; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Porrello A, 2000, J CELL BIOL, V151, P1295, DOI 10.1083/jcb.151.6.1295; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Pozniak CD, 2002, J NEUROSCI, V22, P9800; Puri PL, 2002, NAT GENET, V32, P585, DOI 10.1038/ng1023; Rentzsch F, 2003, GENE, V323, P19, DOI 10.1016/j.gene.2003.10.002; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Tschan MP, 2000, BIOCHEM BIOPH RES CO, V277, P62, DOI 10.1006/bbrc.2000.3627; Vossio S, 2002, ONCOGENE, V21, P3796, DOI 10.1038/sj.onc.1205465; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607	28	25	25	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2006	25	25					3606	3612		10.1038/sj.onc.1209321	http://dx.doi.org/10.1038/sj.onc.1209321			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KC	16652159				2022-12-17	WOS:000238448200013
J	Stabach, PR; Thiyagarajan, MM; Woodfield, GW; Weigel, RJ				Stabach, PR; Thiyagarajan, MM; Woodfield, GW; Weigel, RJ			AP2 alpha alters the transcriptional activity and stability of p53	ONCOGENE			English	Article						AP2 alpha; AP-2; p53; transcription; stability; p21	INVASIVE BREAST-CANCER; APOPTOTIC CELL-DEATH; FACTOR AP-2; GENE PROMOTER; ESTROGEN-RECEPTOR; MAMMARY-CARCINOMA; EPITHELIAL-CELLS; DOWN-REGULATION; RETINOIC ACID; BINDING-SITE	AP2 alpha and p53 form nuclear complexes that establish a functional partnership, which regulates the expression of certain genes involved in cell growth and metastasis. The growth effects of AP2 alpha are mediated through p21(WAF1/CIP1) and the ability for AP2 alpha to coactivate p21 requires p53. Herein, we have localized the AP2-binding region of p53 to amino acids 305-375. Analysis of 26 distinct p53 alleles established a correlation between AP2a binding and transcriptional coactivation. The L350P point mutation was the only nonbinding allele that retained normal transcriptional activity by reporter assay. Although both wild-type and L350P alleles facilitated binding of AP2 alpha to the p21 promoter, the L350P allele was significantly reduced in its ability to induce the endogenous p21 gene, demonstrating a striking difference in activity comparing reporter assays with activation of endogenous p53 target genes. Interestingly, expression of AP2 in the absence of radiation repressed p53-mediated induction of p21 and this effect was explained by a reduction in p53 stability induced by AP2 alpha overexpression. We conclude that AP2 alpha has competing effects on p53 activity through coactivation and decreased stability. These findings may provide a mechanism to account for the discrepancies reported for the association between AP2 and p21 expression in tumor tissue.	Univ Iowa, Dept Surg, Iowa City, IA 52242 USA; Thomas Jefferson Univ, Dept Surg, Philadelphia, PA 19107 USA	University of Iowa; Jefferson University	Weigel, RJ (corresponding author), Univ Iowa, Dept Surg, 200 Hawkins Dr,Room 1516 JCP, Iowa City, IA 52242 USA.	Ronald-Weigel@uiowa.edu		Weigel, Ronald/0000-0002-9249-0793	NCI NIH HHS [R01 CA77350] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077350] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anttila MA, 2000, BRIT J CANCER, V82, P1974; ASTROM A, 1992, J BIOL CHEM, V267, P25251; Auman HJ, 2002, DEVELOPMENT, V129, P2733; Baldi A, 2001, J CELL BIOCHEM, V83, P364, DOI 10.1002/jcb.1235; Bar-Eli M, 2001, PIGM CELL RES, V14, P78, DOI 10.1034/j.1600-0749.2001.140202.x; Bar-Eli M, 1999, CANCER METAST REV, V18, P377, DOI 10.1023/A:1006377309524; Batsche E, 1998, MOL CELL BIOL, V18, P3647, DOI 10.1128/MCB.18.7.3647; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; Bosher JM, 1996, ONCOGENE, V13, P1701; Brokx RD, 2003, J BIOL CHEM, V278, P2327, DOI 10.1074/jbc.M208528200; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Buschmann T, 2001, J BIOL CHEM, V276, P13852, DOI 10.1074/jbc.M007955200; Chene P, 2001, ONCOGENE, V20, P2611, DOI 10.1038/sj.onc.1204373; DECONINCK EC, 1995, MOL CELL BIOL, V15, P2191; Doerksen LF, 1996, NUCLEIC ACIDS RES, V24, P2849, DOI 10.1093/nar/24.14.2849; Feng WG, 2003, MOL CELL NEUROSCI, V24, P460, DOI 10.1016/S1044-7431(03)00209-4; Gee JMW, 1999, J PATHOL, V189, P514, DOI 10.1002/(SICI)1096-9896(199912)189:4<514::AID-PATH463>3.0.CO;2-9; Gershenwald JE, 2001, ONCOGENE, V20, P3363, DOI 10.1038/sj.onc.1204450; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hilger-Eversheim K, 2000, GENE, V260, P1, DOI 10.1016/S0378-1119(00)00454-6; Jiang JG, 2000, BIOCHEM BIOPH RES CO, V272, P882, DOI 10.1006/bbrc.2000.2848; Karjalainen JM, 1998, J CLIN ONCOL, V16, P3584, DOI 10.1200/JCO.1998.16.11.3584; Katsel PL, 2001, J BIOL CHEM, V276, P752, DOI 10.1074/jbc.M007553200; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kim HS, 2001, J NEUROCHEM, V76, P280, DOI 10.1046/j.1471-4159.2001.00044.x; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Leung KM, 2002, CANCER RES, V62, P4890; Lipponen P, 2000, EUR UROL, V37, P573, DOI 10.1159/000020195; Marreiros A, 2005, ONCOGENE, V24, P637, DOI 10.1038/sj.onc.1208216; McPherson LA, 1999, NUCLEIC ACIDS RES, V27, P4040, DOI 10.1093/nar/27.20.4040; McPherson LA, 1997, P NATL ACAD SCI USA, V94, P4342, DOI 10.1073/pnas.94.9.4342; McPherson LA, 2002, J BIOL CHEM, V277, P45028, DOI 10.1074/jbc.M208924200; Mertens PR, 2002, J BIOL CHEM, V277, P24875, DOI 10.1074/jbc.M200445200; Modugno M, 2002, ONCOGENE, V21, P7478, DOI 10.1038/sj.onc.1205957; Moser M, 1997, GENE DEV, V11, P1938, DOI 10.1101/gad.11.15.1938; MOSER M, 1995, DEVELOPMENT, V121, P2779; Nottoli T, 1998, P NATL ACAD SCI USA, V95, P13714, DOI 10.1073/pnas.95.23.13714; OuladAbdelghani M, 1996, EXP CELL RES, V225, P338, DOI 10.1006/excr.1996.0184; Pellikainen MJ, 2003, J CLIN PATHOL, V56, P214, DOI 10.1136/jcp.56.3.214; REN Y, 2001, J BIOL CHEM, V13, P13; Ropponen KM, 2001, J CLIN PATHOL, V54, P533, DOI 10.1136/jcp.54.7.533; Ropponen KM, 1999, BRIT J CANCER, V81, P133, DOI 10.1038/sj.bjc.6690662; Terui T, 2003, CANCER RES, V63, P8948; Vega FM, 2004, MOL CELL BIOL, V24, P10366, DOI 10.1128/MCB.24.23.10366-10380.2004; Wajapeyee N, 2003, J BIOL CHEM, V278, P52093, DOI 10.1074/jbc.M305624200; Wang YH, 2003, J BIOL CHEM, V278, P25568, DOI 10.1074/jbc.M212574200; West-Mays JA, 1999, DEV BIOL, V206, P46, DOI 10.1006/dbio.1998.9132; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Wulf GM, 2002, J BIOL CHEM, V277, P47976, DOI 10.1074/jbc.C200538200; Xu Y, 2003, CELL DEATH DIFFER, V10, P1213, DOI 10.1038/sj.cdd.4401292; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhang J, 2003, DEV BIOL, V256, P127, DOI 10.1016/S0012-1606(02)00119-7; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0; Zhao F, 2001, J BIOL CHEM, V276, P40755, DOI 10.1074/jbc.M106284200	54	25	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	15					2148	2159		10.1038/sj.onc.1209250	http://dx.doi.org/10.1038/sj.onc.1209250			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029RD	16288208				2022-12-17	WOS:000236581200002
J	Ohtsuka, T; Liu, XF; Koga, Y; Kitajima, Y; Nakafusa, Y; Ha, CW; Lee, SW; Miyazaki, K				Ohtsuka, T; Liu, XF; Koga, Y; Kitajima, Y; Nakafusa, Y; Ha, CW; Lee, SW; Miyazaki, K			Methylation-induced silencing of ASC and the effect of expressed ASC on p53-mediated chemosensitivity in colorectal cancer	ONCOGENE			English	Article						ASC; p53; methylation; chemosensitivity; colorectal cancer	RECRUITMENT DOMAIN PROTEIN; APOPTOTIC RESPONSE; HUMAN BREAST; P53; GENE; CELLS; BAX; ACTIVATION; MUTATIONS; ASC/TMS1	Tumor suppressor p53 is known to play a crucial role in chemosensitivity in colorectal cancer. We previously demonstrated that an apoptosis-associated speck-like protein, ASC, is a p53-target gene which regulates p53-Bax mitochondrial apoptotic pathway. ASC is also known to be a target of methylation-induced gene silencing. An inactivation of ASC might thus cause resistance to chemotherapy, and if this is the case, then the expression of ASC would restore the chemosensitivity. The aim of this study was to clarify this hypothesis. ASC was methylated in 25% of all resected specimens in patients with colorectal cancer; however, ASC methylation did not always correspond to a lack of ASC protein. When expressed in colon cancer cells, in which ASC is absent due to methylation, ASC was found to enhance the chemosensitivity in a p53-dependent manner. In p53-null cells, ASC increased the p53-mediated cell death induced by p53-expressing adenovirus infection. Our data suggest that the methylation-induced silencing of ASC might cause resistance to p53-mediated chemosensitivity in colorectal cancer. The gene introduction of ASC may thus restore such chemosensitivity, and this modality may therefore be a useful new treatment strategy for colorectal cancer.	Saga Univ, Fac Med, Dept Surg, Saga 8498501, Japan; Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Orthoped Surg, Seoul, South Korea; Massachusetts Gen Hosp, Cutaneuos Biol Res Ctr, Charlestown, MA USA; Harvard Univ, Sch Med, Charlestown, MA USA	Saga University; Sungkyunkwan University (SKKU); Samsung Medical Center; Harvard University; Massachusetts General Hospital; Harvard University	Ohtsuka, T (corresponding author), Saga Univ, Fac Med, Dept Surg, Saga 8498501, Japan.	ootsuka4@cc.saga-u.ac.jp	Ha, C/GZL-9046-2022	HA, Chul-Won/0000-0001-5123-6513	NCI NIH HHS [CA80058-06, CA078356-05] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078356] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Conway KE, 2000, CANCER RES, V60, P6236; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Guan X, 2003, INT J CANCER, V107, P202, DOI 10.1002/ijc.11376; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hwang PM, 2001, NAT MED, V7, P1111, DOI 10.1038/nm1001-1111; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Mariathasan S, 2004, NATURE, V430, P213, DOI 10.1038/nature02664; Masumoto J, 1999, J BIOL CHEM, V274, P33835, DOI 10.1074/jbc.274.48.33835; MIYASHITA T, 1995, CELL, V80, P293; Moriai R, 2002, ANTICANCER RES, V22, P4163; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Ohtsuka T, 2004, NAT CELL BIOL, V6, P121, DOI 10.1038/ncb1087; SCARPA A, 1993, AM J PATHOL, V142, P1534; Stehlik C, 2002, J EXP MED, V196, P1605, DOI 10.1084/jem.20021552; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Yokoyama T, 2003, CANCER LETT, V202, P101, DOI 10.1016/j.canlet.2003.08.027; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	21	25	30	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2006	25	12					1807	1811		10.1038/sj.onc.1209204	http://dx.doi.org/10.1038/sj.onc.1209204			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	021VJ	16331272				2022-12-17	WOS:000236013700012
J	Muhlisch, J; Schwering, A; Grotzer, M; Vince, GH; Roggendorf, W; Hagemann, C; Sorensen, N; Rickert, CH; Osada, N; Jurgens, H; Fruhwald, MC				Muhlisch, J; Schwering, A; Grotzer, M; Vince, GH; Roggendorf, W; Hagemann, C; Sorensen, N; Rickert, CH; Osada, N; Jurgens, H; Fruhwald, MC			Epigenetic repression of RASSF1A but not CASP8 in supratentorial PNET (sPNET) and atypical teratoid/rhabdoit tumors (AT/RT) of childhood	ONCOGENE			English	Article						brain tumors; epigenetics; methylation; childhood; sPNET; AT/ RT	COMPARATIVE GENOMIC HYBRIDIZATION; PRIMITIVE NEUROECTODERMAL TUMORS; CENTRAL-NERVOUS-SYSTEM; ABERRANT PROMOTER METHYLATION; MOLECULAR ANALYSIS; PEDIATRIC TUMORS; SUPPRESSOR GENE; EXPRESSION; HYPERMETHYLATION; MEDULLOBLASTOMAS	Supratentorial primitive neuroectodermal tumors (sPNET) and atypical teratoid/rhabdoid tumors (AT/RT) of the CNS represent a biological and clinical enigma, despite advances in both molecular techniques and clinical management for these two rare embryonal brain tumors of childhood. Epigenetic changes hold great potential as possible disease mechanisms and may be manipulated therapeutically. We thus studied aberrant methylation of the genes RASSF1A and CASP8 and its consequence on expression in cell lines and primary tumors using a combination of semiquantitative methylation specific PCR (MSP), bisulfite sequencing and RT-PCR. In all, 17 samples of autopsy-derived normal appearing brain served as controls. Opposed to control tissues 19/24 sPNET and 4/6 AT/RT demonstrated aberrant methylation for the RASSF1A promoter region. Treatment of cell lines using 5-Aza-2'-deoxycytidine (5AZA) alone or in combination with trichostatin A (TSA) succeeded in re-establishing expression of RASSF1A in cell lines derived from a renal rhabdoid, an AT/RT and a medulloblastoma. A 5'-CpG-rich region of CASP8 was methylated in normal tissues and in tumors. However, CASP8 showed inconsistent expression patterns in normal and tumor tissues. Our results indicate that aberrant methylation of the RASSF1A promoter region maybe of importance in the origin and progression of sPNET and AT/RT while the analysed 5'-CpG rich region of the CASP8 gene does not seem to play an important role in these tumors. Further studies of epigenetic changes in these rare tumors are warranted as their biology remains obscure and treatment efforts have been rather unsuccessfull.	Univ Munster, Childrens Hosp, Dept Paediat Haematol & Oncol, D-48149 Munster, Germany; Univ Zurich, Childrens Hosp, Zurich, Switzerland; Univ Hosp Wuerzburg, Dept Neurosurg, Wurzburg, Germany; Univ Hosp Wuerzburg, Inst Neuropathol, Wurzburg, Germany; Univ Hosp Munster, Inst Neuropathol & Pathol, Munster, Germany; Univ Munster, Dept Med Informat & Biomath, Munster, Germany	University of Munster; University Children's Hospital Zurich; University of Zurich; University of Wurzburg; University of Wurzburg; University of Munster; University of Munster	Fruhwald, MC (corresponding author), Univ Munster, Childrens Hosp, Dept Paediat Haematol & Oncol, Albert Schweitzer Str 33, D-48149 Munster, Germany.	fruhwald@uni-muenster.de	Hagemann, Carsten/AAC-8037-2019	Grotzer, Michael/0000-0002-1154-2732; Vince, Giles/0000-0002-0222-8733				Agathanggelou A, 2005, CANCER RES, V65, P3497, DOI 10.1158/0008-5472.CAN-04-4088; Banelli B, 2002, NAT MED, V8, P1333, DOI 10.1038/nm1202-1333; Bayani J, 2000, J NEUROSURG, V93, P437, DOI 10.3171/jns.2000.93.3.0437; Biegel JA, 2002, CLIN CANCER RES, V8, P3461; BIEGEL JA, 1992, GENE CHROMOSOME CANC, V5, P104, DOI 10.1002/gcc.2870050203; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Fruhwald MC, 2001, GENE CHROMOSOME CANC, V30, P38; Fruhwald MC, 2004, CLIN CANCER RES, V10, P2997, DOI 10.1158/1078-0432.CCR-03-0083; Fruhwald MC, 2002, MOL GENET METAB, V75, P1, DOI 10.1006/mgme.2001.3265; Fruhwald MC, 2001, ONCOGENE, V20, P5033, DOI 10.1038/sj.onc.1204613; Fruhwald MC, 2000, J MED GENET, V37, P501, DOI 10.1136/jmg.37.7.501; Grotzer MA, 2000, J CLIN ONCOL, V18, P1027, DOI 10.1200/JCO.2000.18.5.1027; Harada K, 2002, CANCER RES, V62, P5897; Harada K, 2002, ONCOGENE, V21, P4345, DOI 10.1038/sj.onc.1205446; KELLY WK, 2005, J CLIN ONCOL, V16, P16; Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215, DOI 10.1093/jnen/61.3.215; Kortmann RD, 2000, INT J RADIAT ONCOL, V46, P269, DOI 10.1016/S0360-3016(99)00369-7; Lindsey JC, 2004, CARCINOGENESIS, V25, P661, DOI 10.1093/carcin/bgh055; Lusher ME, 2002, CANCER RES, V62, P5906; Melnick AM, 2005, J CLIN ONCOL, V23, P3957, DOI 10.1200/JCO.2005.14.498; Packer RJ, 2002, J PEDIAT HEMATOL ONC, V24, P337, DOI 10.1097/00043426-200206000-00004; Pingoud-Meier C, 2003, CLIN CANCER RES, V9, P6401; Rickert CH, 2004, CHILD NERV SYST, V20, P221, DOI 10.1007/s00381-003-0909-8; Russo C, 1999, CANCER, V86, P331, DOI 10.1002/(SICI)1097-0142(19990715)86:2<331::AID-CNCR18>3.0.CO;2-#; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Scheurlen WG, 1998, J CLIN ONCOL, V16, P2478, DOI 10.1200/JCO.1998.16.7.2478; Sevenet N, 1999, HUM MOL GENET, V8, P2359, DOI 10.1093/hmg/8.13.2359; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Zhang F, 2002, GENE CHROMOSOME CANC, V34, P398, DOI 10.1002/gcc.10078; Zuzak TJ, 2002, EUR J CANCER, V38, P83, DOI 10.1016/S0959-8049(01)00355-0	31	25	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	7					1111	1117		10.1038/sj.onc.1209137	http://dx.doi.org/10.1038/sj.onc.1209137			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	012SX	16186793				2022-12-17	WOS:000235361000015
J	Cesaire, R; Oliere, S; Sharif-Askari, E; Loignon, M; Lezin, A; Olindo, S; Panelatti, G; Kazanji, M; Aloyz, R; Panasci, L; Bell, JC; Hiscott, J				Cesaire, R; Oliere, S; Sharif-Askari, E; Loignon, M; Lezin, A; Olindo, S; Panelatti, G; Kazanji, M; Aloyz, R; Panasci, L; Bell, JC; Hiscott, J			Oncolytic activity of vesicular stomatitis virus in primary adult T-cell leukemia	ONCOGENE			English	Article						ATL; HTLV-1; HAM/TSP; VSV; apoptosis; oncolysis	CHRONIC LYMPHOCYTIC-LEUKEMIA; MATRIX PROTEIN; SIGNALING PATHWAYS; ANTIVIRAL DEFENSE; DNA FRAGMENTATION; INNATE IMMUNITY; IN-VIVO; APOPTOSIS; CANCER; INDUCTION	Treatments for hematological malignancies have improved considerably over the past decade, but the growing therapeutic arsenal has not benefited adult T-cell leukemia (ATL) patients. Oncolytic viruses such as vesicular stomatitis virus (VSV) have recently emerged as a potential treatment of solid tumors and leukemias in vitro and in vivo. In the current study, we investigated the ability of VSV to lyse primary human T-lymphotropic virus type 1 (HTLV-1)- infected T-lymphocytes from patients with ATL. Ex vivo primary ATL cells were permissive for VSV and underwent rapid oncolysis in a time-dependent manner. Importantly, VSV infection showed neither viral replication nor oncolysis in HTLV1- infected, nonleukemic cells from patients with HTLV-1associated myelopathy/ tropical spastic paraparesis (HAM/TSP), and in naive CD4+ T- lymphocytes from normal individuals or in ex vivo cell samples from patients with chronic lymphocytic leukemia (CLL). Interestingly, activation of primary CD4+ T- lymphocytes with antiCD3/ CD28 monoclonal antibody, and specifically with anti-CD3, was sufficient to induce limited viral replication and oncolysis. However, at a similar level of T- cell activation, VSV replication was increased fourfold in ATL cells compared to activated CD4+ T- lymphocytes, emphasizing the concept that VSV targets genetic defects unique to tumor cells to facilitate its replication. In conclusion, our findings provide the first essential information for the development of a VSV-based treatment for ATL.	McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada; CHU Ft France, Lab Virol Immunol, Martinique, France; CHU Ft de France, INSERM, UMR433, Martinique, France; McGill Univ, Dept Microbiol, Montreal, PQ H3A 2T5, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 2T5, Canada; CHU Ft de France, Neurol Serv, Martinique, France; CHU Ft de France, Serv Med Interne, Martinique, France; Inst Pasteur, Retrovirus Lab, Cayenne, French Guiana; Univ Ottawa, Ottawa Reg Canc Ctr, Ottawa, ON, Canada	Lady Davis Institute; McGill University; CHU Martinique; CHU Martinique; Institut National de la Sante et de la Recherche Medicale (Inserm); McGill University; McGill University; CHU Martinique; CHU Martinique; University of Ottawa; Ottawa Hospital Research Institute	Hiscott, J (corresponding author), McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Mol Oncol Grp, Room 526,3755 Cote Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada.	john.hiscott@mcgill.ca	Aloyz, Raquel S/N-6606-2013	Aloyz, Raquel S/0000-0002-6812-497X				Balachandran S, 2004, CANCER CELL, V5, P51, DOI 10.1016/S1535-6108(03)00330-1; Balachandran S, 2001, J VIROL, V75, P3474, DOI 10.1128/JVI.75.7.3474-3479.2001; Balachandran S, 2000, IUBMB LIFE, V50, P135, DOI 10.1080/15216540050212169; Bazarbachi A, 2004, LANCET ONCOL, V5, P664, DOI 10.1016/S1470-2045(04)01608-0; BELKOWSKI LS, 1987, J VIROL, V61, P653, DOI 10.1128/JVI.61.3.653-660.1987; Bell J. C., 2002, Current Gene Therapy, V2, P243, DOI 10.2174/1566523024605582; Caligaris-Cappio F, 2003, BRIT J HAEMATOL, V123, P380, DOI 10.1046/j.1365-2141.2003.04679.x; Cavrois M, 1996, ONCOGENE, V12, P2419; Chiocca EA, 2002, NAT REV CANCER, V2, P938, DOI 10.1038/nrc948; Desforges M, 2002, VIROLOGY, V295, P63, DOI 10.1006/viro.2001.1329; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Eastman A, 1999, SEMIN ONCOL, V26, P7; Ebert O, 2003, CANCER RES, V63, P3605; Fernandez M, 2002, J VIROL, V76, P895, DOI 10.1128/JVI.76.2.895-904.2002; Franchini G, 2003, ADV CANCER RES, V89, P69, DOI 10.1016/S0065-230X(03)01003-0; Gadaleta P, 2002, VIRUS RES, V86, P87, DOI 10.1016/S0168-1702(02)00049-7; GESSAIN A, 1985, LANCET, V2, P407; Grigera PR, 1996, J VIROL, V70, P8492, DOI 10.1128/JVI.70.12.8492-8501.1996; Gromeier M, 2001, CURR OPIN MOL THER, V3, P503; Hawkins LK, 2002, LANCET ONCOL, V3, P17, DOI 10.1016/S1470-2045(01)00618-0; HINUMA Y, 1982, INT J CANCER, V29, P631, DOI 10.1002/ijc.2910290606; Hobbs JA, 2003, HUM IMMUNOL, V64, P82, DOI 10.1016/S0198-8859(02)00702-4; Hobbs JA, 2001, VIRUS RES, V80, P53, DOI 10.1016/S0168-1702(01)00350-1; Huang TG, 2003, MOL THER, V8, P434, DOI 10.1016/S1525-0016(03)00204-1; Kirn D, 2001, NAT MED, V7, P781, DOI 10.1038/89901; Kopecky SA, 2003, J VIROL, V77, P5524, DOI 10.1128/JVI.77.9.5524-5528.2003; Kopecky SA, 2001, J VIROL, V75, P12169, DOI 10.1128/JVI.75.24.12169-12181.2001; Lichty BD, 2004, HUM GENE THER, V15, P821, DOI 10.1089/1043034041839208; LINGE C, 1995, CANCER RES, V55, P4099; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; Matin SF, 2001, CANCER RES, V61, P2261; Matsuoka M, 2003, ONCOGENE, V22, P5131, DOI 10.1038/sj.onc.1206551; Meinhardt G, 1999, J MOL MED-JMM, V77, P282, DOI 10.1007/s001090050351; Mortreux F, 2003, LEUKEMIA, V17, P26, DOI 10.1038/sj.leu.2402777; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; Nguyen JT, 2003, P NATL ACAD SCI USA, V100, P7533, DOI 10.1073/pnas.1031631100; Norman KL, 2001, CYTOKINE GROWTH F R, V12, P271, DOI 10.1016/S1359-6101(00)00024-1; Obuchi M, 2003, J VIROL, V77, P8843, DOI 10.1128/JVI.77.16.8843-8856.2003; OSAME M, 1986, LANCET, V1, P1031; Satoh M, 2002, ONCOGENE, V21, P2466, DOI 10.1038/sj.onc.1205329; Sharif-Askari E, 2001, EMBO J, V20, P3101, DOI 10.1093/emboj/20.12.3101; SHIMOYAMA M, 1991, BRIT J HAEMATOL, V79, P428, DOI 10.1111/j.1365-2141.1991.tb08051.x; Steele TA, 2000, P SOC EXP BIOL MED, V223, P118, DOI 10.1046/j.1525-1373.2000.22317.x; Stojdl DF, 2003, CANCER CELL, V4, P263, DOI 10.1016/S1535-6108(03)00241-1; Stojdl DF, 2000, NAT MED, V6, P821, DOI 10.1038/77558; Sun WH, 1998, BLOOD, V91, P570, DOI 10.1182/blood.V91.2.570.570_570_576; Takaoka A, 2003, NATURE, V424, P516, DOI 10.1038/nature01850; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; Wolf BB, 1999, J BIOL CHEM, V274, P30651, DOI 10.1074/jbc.274.43.30651; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Wu JT, 2001, B MATH BIOL, V63, P731, DOI 10.1006/bulm.2001.0245; Yasunaga JI, 2003, INT J HEMATOL, V78, P312, DOI 10.1007/BF02983555; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475	56	25	28	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					349	358		10.1038/sj.onc.1209055	http://dx.doi.org/10.1038/sj.onc.1209055			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY	16186807				2022-12-17	WOS:000234714100003
J	Xiao, H; Goodrich, DW				Xiao, H; Goodrich, DW			The retinoblastoma tumor suppressor protein is required for efficient processing and repair of trapped topoisomerase II-DNA-cleavable complexes	ONCOGENE			English	Article						retinoblastoma tumor suppressor gene; topoisomerase II; etoposide; DNA damage; DNA repair	DOUBLE-STRAND BREAKS; E2F TARGET GENES; DAMAGE RESPONSE; LIGASE ACTIVITY; RB PROTEIN; FAMILIAL RETINOBLASTOMA; INCOMPLETE PENETRANCE; GENOMIC INSTABILITY; BRCA1; BETA	Type II topoisomerases (TOP2) introduce transient double-stranded DNA breaks through a covalent TOP2 DNA intermediate. Anticancer agents like etoposide kill cells by trapping covalent TOP2-DNA cleavable complexes. Pathways influencing the repair of cleavable complexes are expected to be major determinants of therapeutic response to etoposide. Rb1 is required to enforce cell cycle checkpoints in response to DNA damage, but evidence for a direct role in the processing and repair of DNA lesions is lacking. We observe that degradation of trapped TOP2-cleavable complexes, liberation of DNA strand breaks, and repair of those breaks occurs more efficiently in cells expressing Rb1 protein (pRb). Cells lacking pRb are more sensitive to etoposide-induced cytotoxicity. Rb1-mediated processing and repair of TOP2-cleavable complexes is genetically separable from its ability to bind E2F and enforce DNA damage-induced cell cycle checkpoints. Rb1 protein binds both TOP2 and BRCA1 in intact cells, and pRb is required for association between TOP2 and BRCA1. These results suggest that pRb facilitates processing and repair of TOP2-cleavable complexes by recruiting proteins like BRCA1 to the damaged site. The functional status of pRb, therefore, may influence sensitivity to etoposide by facilitating the repair of trapped TOP2-DNA complexes as well as by enforcing cell cycle checkpoints.	Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Goodrich, DW (corresponding author), Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Elm & Carlton St, Buffalo, NY 14263 USA.	david.goodrich@roswellpark.org			NCI NIH HHS [R01 CA070292, R01 CA070292-07, CA70292] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070292] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi N, 2003, J BIOL CHEM, V278, P35897, DOI 10.1074/jbc.M306500200; Adachi N, 2004, BIOCHEM BIOPH RES CO, V318, P856, DOI 10.1016/j.bbrc.2004.04.099; Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; Bhat UG, 1999, P NATL ACAD SCI USA, V96, P7859, DOI 10.1073/pnas.96.14.7859; Bosco EE, 2004, NUCLEIC ACIDS RES, V32, P25, DOI 10.1093/nar/gkg919; Bracken AP, 2004, TRENDS BIOCHEM SCI, V29, P409, DOI 10.1016/j.tibs.2004.06.006; Brugarolas J, 1999, P NATL ACAD SCI USA, V96, P1002, DOI 10.1073/pnas.96.3.1002; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; Cortes F, 2003, MUTAT RES-REV MUTAT, V543, P59, DOI 10.1016/S1383-5742(02)00070-4; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Doostzadeh-Cizeron J, 1999, MOL BIOL CELL, V10, P3251, DOI 10.1091/mbc.10.10.3251; Fan SJ, 2001, ONCOGENE, V20, P4827, DOI 10.1038/sj.onc.1204666; GOVONI M, 1995, BIOCHEM BIOPH RES CO, V213, P282, DOI 10.1006/bbrc.1995.2127; Harbour JW, 2001, ARCH OPHTHALMOL-CHIC, V119, P1699; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Harrington EA, 1998, P NATL ACAD SCI USA, V95, P11945, DOI 10.1073/pnas.95.20.11945; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jasin M, 2002, ONCOGENE, V21, P8981, DOI 10.1038/sj.onc.1206176; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; Lee EY, 2002, CANCER CELL, V2, P463, DOI 10.1016/S1535-6108(02)00207-6; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; Mao Y, 2001, J BIOL CHEM, V276, P40652, DOI 10.1074/jbc.M104009200; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; Motoyama N, 2004, CURR OPIN GENET DEV, V14, P11, DOI 10.1016/j.gde.2003.12.003; Naderi S, 2002, CELL CYCLE, V1, P193, DOI 10.4161/cc.1.3.125; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Niimi A, 2001, CHROMOSOMA, V110, P102, DOI 10.1007/s004120100140; Otterson GA, 1997, P NATL ACAD SCI USA, V94, P12036, DOI 10.1073/pnas.94.22.12036; Otterson GA, 1999, AM J HUM GENET, V65, P1040, DOI 10.1086/302581; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Stevens C, 2004, DNA REPAIR, V3, P1071, DOI 10.1016/j.dnarep.2004.03.034; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Tsutsui K, 2001, J BIOL CHEM, V276, P5769, DOI 10.1074/jbc.M008517200; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Whitaker LL, 1998, MOL CELL BIOL, V18, P4032, DOI 10.1128/MCB.18.7.4032; WOESSNER RD, 1991, CELL GROWTH DIFFER, V2, P209; Xia Y, 2003, J BIOL CHEM, V278, P5255, DOI 10.1074/jbc.M204591200; Xiao H, 2003, P NATL ACAD SCI USA, V100, P3239, DOI 10.1073/pnas.0736401100; Yamamoto Y, 1998, ONCOL REP, V5, P447; Yang X, 2000, SCIENCE, V287, P131, DOI 10.1126/science.287.5450.131; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Zhong Q, 2002, J BIOL CHEM, V277, P28641, DOI 10.1074/jbc.M200748200; Zhong Q, 2002, CANCER RES, V62, P3966; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	51	25	25	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2005	24	55					8105	8113		10.1038/sj.onc.1208958	http://dx.doi.org/10.1038/sj.onc.1208958			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	991JL	16091739	Green Accepted			2022-12-17	WOS:000233809400003
J	Starczynowski, DT; Reynolds, JG; Gilmore, TD				Starczynowski, DT; Reynolds, JG; Gilmore, TD			Mutations of tumor necrosis factor alpha-responsive serine residues within the C-terminal transactivation domain of human transcription factor REL enhance its in vitro transforming ability	ONCOGENE			English	Article						c-Rel; Rel; NF-kappa B; malignant transformation; lymphoma; tumor necrosis factor	NF-KAPPA-B; MANGANESE SUPEROXIDE-DISMUTASE; CHICKEN SPLEEN-CELLS; V-REL; UP-REGULATION; DNA-BINDING; LINE RC-K8; LYMPHOMA; PROTEIN; ACTIVATION	The human c-rel gene (REL), encoding an NF-KB transcription factor, is amplifi. ed or mutated in several human B-cell lymphomas and can transform chicken lymphoid cells in vitro. We have previously shown that certain deletions of C-terminal transactivation sequences enhance REL's transforming ability in chicken spleen cells. In this report, we have analysed the effect of single amino-acid changes at select serine residues in the C-terminal transactivation domain on REL's transforming ability. Mutation of either of two TNF alpha-inducible serine residues (Ser460 and Ser471) to nonphosphorylatable residues (alanine, asparagine, phenylalanine) made REL more effi. cient at transforming chicken spleen cells in vitro. In contrast, mutation of Ser471 to a phosphorylation mimetic aspartate residue impaired REL's transforming ability, even though it increased REL's inherent transactivation ability as a GAL4-fusion protein. Alanine mutations of several other serine residues within the transactivation domain did not substantially affect REL's transforming ability. Transactivation by GAL4-REL fusion proteins containing either transformation enhancing or nonenhancing mutations at serine residues was generally similar to wild-type GAL4-REL. However, more transforming mutants with mutations at either Ser460 or Ser471 differed from wild-type REL in their ability to transactivate certain KB-site reporter genes. In particular, the SOD2 promoter, encoding manganese superoxide dismutase, was activated less strongly by the more transforming REL mutant REL-S471N transient assays, but REL-S471N-transformed chicken spleen cells had increased levels of MnSOD protein as compared to wild- type REL-transformed cells. Taken together, our results show that mutations of certain serine residues can enhance REL's transforming ability in vitro and suggest that these mutations increase REL-mediated transformation by altering REL's ability to modulate the expression of select target genes. Furthermore, phosphorylation of Ser471 may be involved in REL-mediated modulation of transformation-specific target gene expression. Lastly, these results suggest that similar mutations in the REL transactivation domain contribute to the development of certain human B-cell lymphomas.	Boston Univ, Dept Biol, Boston, MA 02215 USA	Boston University	Gilmore, TD (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.	gilmore@bu.edu			NATIONAL CANCER INSTITUTE [R01CA047763, R29CA047763] Funding Source: NIH RePORTER; NCI NIH HHS [CA47763] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; Abid MR, 2004, J BIOL CHEM, V279, P44030, DOI 10.1074/jbc.M408285200; Barth TFE, 2003, BLOOD, V101, P3681, DOI 10.1182/blood-2002-08-2577; Bash J, 1997, MOL CELL BIOL, V17, P6526, DOI 10.1128/MCB.17.11.6526; Bernard D, 2002, ONCOGENE, V21, P4392, DOI 10.1038/sj.onc.1205536; Bernard D, 2001, CANCER RES, V61, P2656; Chen EY, 1998, BIOCHEM BIOPH RES CO, V249, P728, DOI 10.1006/bbrc.1998.9224; Epinat JC, 2000, ONCOGENE, V19, P599, DOI 10.1038/sj.onc.1203376; Fan YJ, 2004, ONCOGENE, V23, P1030, DOI 10.1038/sj.onc.1207221; FEUERHAKE F, 2005, IN PRESS BLOOD; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; Gilmore TD, 2004, ONCOGENE, V23, P2275, DOI 10.1038/sj.onc.1207410; GILMORE TD, 1995, DNA PROVIRUS, P109; Gilmore TD, 2001, ONCOGENE, V20, P7098, DOI 10.1038/sj.onc.1204898; Hansen GM, 2000, GENOME RES, V10, P237, DOI 10.1101/gr.10.2.237; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hrdlickova R, 2001, MOL CELL BIOL, V21, P6369; HRDLICKOVA R, 1994, J VIROL, V68, P2371; Huguet C, 1999, APOPTOSIS, V4, P31, DOI 10.1023/A:1009678015249; Iwai K, 2005, FEBS LETT, V579, P141, DOI 10.1016/j.febslet.2004.11.060; KABRUN N, 1990, MOL CELL BIOL, V10, P4788, DOI 10.1128/MCB.10.9.4788; Kalaitzidis D, 2002, ONCOGENE, V21, P8759, DOI 10.1038/sj.onc.1206033; Kalaitzidis D, 2002, GENE CHROMOSOME CANC, V34, P129, DOI 10.1002/gcc.10051; Kralova J, 1998, MOL CELL BIOL, V18, P2997, DOI 10.1128/MCB.18.5.2997; Kralova J, 2002, J VIROL, V76, P11960, DOI 10.1128/JVI.76.23.11960-11970.2002; Lawrence T, 2005, NATURE, V434, P1138, DOI 10.1038/nature03491; Leung TH, 2004, CELL, V118, P453, DOI 10.1016/j.cell.2004.08.007; LU D, 1991, ONCOGENE, V6, P1235; Martin AG, 2000, J BIOL CHEM, V275, P24383, DOI 10.1074/jbc.M909396199; Martin AG, 2001, J BIOL CHEM, V276, P15840, DOI 10.1074/jbc.M011313200; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; Rayet B, 2003, MOL CELL BIOL, V23, P1520, DOI 10.1128/MCB.23.5.1520-1533.2003; Sachdev S, 1998, MOL CELL BIOL, V18, P5445, DOI 10.1128/MCB.18.9.5445; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SCHATZLE JD, 1995, J VIROL, V69, P5383, DOI 10.1128/JVI.69.9.5383-5390.1995; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SmithSorensen B, 1996, J BIOL CHEM, V271, P5513, DOI 10.1074/jbc.271.10.5513; Starczynowski DT, 2003, ONCOGENE, V22, P6928, DOI 10.1038/sj.onc.1206801; Wang Y, 2001, BBA-MOL CELL RES, V1538, P260, DOI 10.1016/S0167-4889(01)00077-5; Yu SH, 2004, J MOL MED, V82, P621, DOI 10.1007/s00109-004-0559-7	42	25	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2005	24	49					7355	7368		10.1038/sj.onc.1208902	http://dx.doi.org/10.1038/sj.onc.1208902			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982FA	16027730				2022-12-17	WOS:000233142100012
J	Casanovas, O; Hager, JH; Chun, MGH; Hanahan, D				Casanovas, O; Hager, JH; Chun, MGH; Hanahan, D			Incomplete inhibition of the Rb tumor suppressor pathway in the context of inactivated p53 is sufficient for pancreatic islet tumorigenesis	ONCOGENE			English	Article						oncogenesis; retinoblastoma protein ( Rb); tumor suppressor genes; transgenic mice; RIP-Tag2	CERVICAL CARCINOMAS; INSULIN; INTERMEDIATE; EXPRESSION; MUTATION; CELLS; MICE	Here, we describe the surprising residual capability of the Rb pathway to negatively regulate proliferation and tumorigenesis in a SV40 large T antigen (Tag)-driven mouse model of pancreatic islet carcinogenesis. Heterogeneous Tag expression during all progression stages suggested that a threshold level of the T antigen oncoprotein might be deterministic for beta-cell hyperproliferation and led us to hypothesize that Tag might not be fully inhibiting the tumor suppressor activity of Rb. Moreover, genomic pro. ling of these tumors by array CGH pointed to regions of loss on chromosomes 6 and 14, where the Rb pathway inhibitor p27 and Rb itself, respectively, reside. Indeed, genetic ablation of the p27(Kip1) or Rb genes accentuated Tag-induced tumorigenesis, with loss of Rb in particular broadly enhancing multiple parameters of tumorigenesis including the frequency and growth rates of premalignant lesions, of nascent solid tumors, and of invasive carcinomas. The data indicate that attenuation rather than complete inactivation of Rb tumor suppressor gene function, in the context of p53 inhibition, is sufficient to initiate tumorigenesis in this model of islet cell cancer, with the demonstrable possibility that subsequent losses of Rb or its regulators can enhance malignant progression. The results may be relevant to human papillomavirus (HPV)-induced cervical neoplasias where E7 oncogene expression levels or activity (in the case of intermediate/low-risk HPV subtypes) incompletely inhibits Rb tumor suppressor functions, as well as to other neoplasias where initiating oncogenic or tumor suppressor events reduce but do not abrogate Rb function.	Univ Calif San Francisco, Ctr Diabet, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Hanahan, D (corresponding author), Univ Calif San Francisco, Ctr Diabet, Dept Biochem & Biophys, 513 Parnassus Ave,HSW-1090, San Francisco, CA 94143 USA.	dh@biochem.ucsf.edu	Casanovas, Oriol/L-5210-2014	Casanovas, Oriol/0000-0002-4298-3995				BADER JL, 1980, LANCET, V2, P582; Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929; BROWNSTEIN S, 1984, ARCH OPHTHALMOL-CHIC, V102, P257, DOI 10.1001/archopht.1984.01040030207028; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; EFRAT S, 1987, EMBO J, V6, P2699, DOI 10.1002/j.1460-2075.1987.tb02562.x; Ferguson KL, 2002, EMBO J, V21, P3337, DOI 10.1093/emboj/cdf338; Gannon M, 2000, GENESIS, V26, P139, DOI 10.1002/(SICI)1526-968X(200002)26:2<139::AID-GENE12>3.0.CO;2-7; Giannoudis A, 2000, CANCER, V89, P1300, DOI 10.1002/1097-0142(20000915)89:6<1300::AID-CNCR15>3.0.CO;2-U; Hager JH, 2004, CANCER RES, V64, P2406, DOI 10.1158/0008-5472.CAN-03-3522; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; Hashizume H, 2000, AM J PATHOL, V156, P1363, DOI 10.1016/S0002-9440(10)65006-7; Herzig M, 1999, BIOL CHEM, V380, P203, DOI 10.1515/BC.1999.028; Hodgson G, 2001, NAT GENET, V29, P459, DOI 10.1038/ng771; Inoue M, 2002, CANCER CELL, V1, P193, DOI 10.1016/S1535-6108(02)00031-4; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Kim HJ, 2001, EUR J OBSTET GYN R B, V98, P213, DOI 10.1016/S0301-2115(01)00309-8; LO KW, 1992, ANTICANCER RES, V12, P1989; Lopez T, 2002, CANCER CELL, V1, P339, DOI 10.1016/S1535-6108(02)00055-7; Marino S, 2000, GENE DEV, V14, P994; Nakagawa S, 1999, BRIT J CANCER, V79, P1139, DOI 10.1038/sj.bjc.6690181; Peters MG, 2004, ONCOL REP, V12, P1143; Pipas JM, 2001, SEMIN CANCER BIOL, V11, P23, DOI 10.1006/scbi.2000.0343; PIPELEERS DG, 1992, DIABETES, V41, P777, DOI 10.2337/diabetes.41.7.777; Saenz-Robles MT, 2001, ONCOGENE, V20, P7899, DOI 10.1038/sj.onc.1204936; SANG BC, 1992, P NATL ACAD SCI USA, V89, P8063, DOI 10.1073/pnas.89.17.8063; Weir GC, 2001, DIABETES, V50, pS154, DOI 10.2337/diabetes.50.2007.S154	26	25	26	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2005	24	44					6597	6604		10.1038/sj.onc.1208823	http://dx.doi.org/10.1038/sj.onc.1208823			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	971FL	16007165				2022-12-17	WOS:000232367800001
J	Liu, TC; Kirn, D				Liu, TC; Kirn, D			Viruses with deletions in antiapoptotic genes as potential oncolytic agents	ONCOGENE			English	Review						oncolytic; virus; cancer; apoptosis; virology; gene therapy	E1B 19-KILODALTON PROTEIN; NECROSIS-FACTOR-ALPHA; APOPTOTIC CELL-DEATH; TYPE-1 US11 PROTEIN; INFLUENZA-A VIRUS; INFECTED-CELLS; DL1520 ONYX-015; HOST-RANGE; IN-VIVO; ADENOVIRUS PROTEINS	Replication-selective oncolytic viruses have emerged as a new treatment platform for cancers. However, selectivity and potency need to be improved before virotherapy can become a standard treatment modality. In addition, mechanisms that can be incorporated to enable targeting a broad range of cancer types are highly desirable. Cancer cells are well known to have multiple blocks in apoptosis pathways. On the other hand, viruses have evolved to express numerous antiapoptotic genes to antagonize apoptosis induced upon infection. Viruses with deletions in antiapoptotic genes can therefore be complemented by antiapoptotic genetic changes in cancer cells for efficient replication and oncolysis. In this review, we summarize the recent development of this concept, the potential obstacles, and future directions for optimization.	Harvard Univ, Sch Med, Cambridge, MA 02138 USA; Massachusetts Gen Hosp, Mol Neurosurg Lab, Boston, MA 02114 USA; Univ Oxford, Dept Clin Pharmacol, Oxford OX1 2JD, England; Jennnerex Biotherapeut Inc, Mountain View, CA USA	Harvard University; Harvard University; Massachusetts General Hospital; University of Oxford	Liu, TC (corresponding author), Harvard Univ, Sch Med, Cambridge, MA 02138 USA.	tachiangliu@yahoo.com; dkirn@jennerex.com		Liu, Ta-Chiang/0000-0002-2800-9360				Alcami A, 1999, J GEN VIROL, V80, P949, DOI 10.1099/0022-1317-80-4-949; ALCAMI A, 1995, J VIROL, V69, P4633; Alcami A, 2000, J VIROL, V74, P11230, DOI 10.1128/JVI.74.23.11230-11239.2000; BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; Beattie E, 1996, VIRUS GENES, V12, P89, DOI 10.1007/BF00370005; Bennett JJ, 2002, CANCER GENE THER, V9, P935, DOI 10.1038/sj.cgt.7700510; Bergmann M, 2001, CANCER RES, V61, P8188; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; Burgert HG, 2002, CURR TOP MICROBIOL, V269, P273; CANALE VC, 1967, J PEDIATR-US, V70, P891, DOI 10.1016/S0022-3476(67)80262-2; CARROLL K, 1993, J BIOL CHEM, V268, P12837; Cascallo M, 2003, CANCER RES, V63, P5544; Cassady KA, 2002, J VIROL, V76, P2029, DOI 10.1128/jvi.76.5.2029-2035.2002; Chen P, 1998, J BIOL CHEM, V273, P5815, DOI 10.1074/jbc.273.10.5815; Cheng EHY, 1997, P NATL ACAD SCI USA, V94, P690, DOI 10.1073/pnas.94.2.690; CHINNADURAI G, 1979, J VIROL, V32, P623, DOI 10.1128/JVI.32.2.623-628.1979; Chinnadurai G, 1998, SEMIN VIROL, V8, P399, DOI 10.1006/smvy.1997.0139; CHIOU SK, 1994, J VIROL, V68, P6553, DOI 10.1128/JVI.68.10.6553-6566.1994; Coffey MC, 1998, SCIENCE, V282, P1332, DOI 10.1126/science.282.5392.1332; COLAMONICI OR, 1995, J BIOL CHEM, V270, P15974, DOI 10.1074/jbc.270.27.15974; Coultas L, 2003, SEMIN CANCER BIOL, V13, P115, DOI 10.1016/S1044-579X(02)00129-3; DAVIES MV, 1993, J VIROL, V67, P1688, DOI 10.1128/JVI.67.3.1688-1692.1993; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; Gomez-Manzano C, 2004, ONCOGENE, V23, P1821, DOI 10.1038/sj.onc.1207321; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hagglund R, 2004, J VIROL, V78, P2169, DOI 10.1128/JVI.78.5.2169-2178.2004; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; Hallden G, 2003, MOL THER, V8, P412, DOI 10.1016/S1525-0016(03)00199-0; Heise C, 2000, NAT MED, V6, P1134, DOI 10.1038/80474; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; Katze MG, 2002, NAT REV IMMUNOL, V2, P675, DOI 10.1038/nri888; KATZE MG, 1987, EMBO J, V6, P689, DOI 10.1002/j.1460-2075.1987.tb04809.x; Kettle S, 1997, J GEN VIROL, V78, P677, DOI 10.1099/0022-1317-78-3-677; KETTLE S, 1995, VIROLOGY, V206, P136, DOI 10.1016/S0042-6822(95)80028-X; Kim J, 2002, CANCER GENE THER, V9, P725, DOI 10.1038/sj.cgt.7700494; Kirn D, 2001, NAT MED, V7, P781, DOI 10.1038/89901; Kirn D, 2001, EXPERT OPIN BIOL TH, V1, P525, DOI 10.1517/14712598.1.3.525; Kirn D, 2000, ONCOGENE, V19, P6660, DOI 10.1038/sj.onc.1204094; Kirn D, 2001, GENE THER, V8, P89, DOI 10.1038/sj.gt.3301377; Krajcsi P, 1996, J VIROL, V70, P4904, DOI 10.1128/JVI.70.8.4904-4913.1996; Langland JO, 2002, VIROLOGY, V299, P133, DOI 10.1006/viro.2002.1479; Legrand FA, 2004, J VIROL, V78, P2770, DOI 10.1128/JVI.78.6.2770-2779.2004; Leib DA, 1999, J EXP MED, V189, P663, DOI 10.1084/jem.189.4.663; Leppard KN, 1999, J GEN VIROL, V80, P997, DOI 10.1099/0022-1317-80-4-997; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu TC, 2004, MOL THER, V9, P786, DOI 10.1016/j.ymthe.2004.03.017; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LORENCE RM, 1988, J NATL CANCER I, V80, P1305, DOI 10.1093/jnci/80.16.1305; MARTUZA RL, 1991, SCIENCE, V252, P854, DOI 10.1126/science.1851332; McNees AL, 2002, VIRUS RES, V88, P87, DOI 10.1016/S0168-1702(02)00122-3; MINETA T, 1995, NAT MED, V1, P938, DOI 10.1038/nm0995-938; Moise AR, 2002, J VIROL, V76, P1578, DOI 10.1128/JVI.76.4.1578-1587.2002; MOSS B, 1977, J VIROL, V23, P234, DOI 10.1128/JVI.23.2.234-239.1977; Mossman KL, 2002, J VIROL, V76, P1995, DOI 10.1128/JVI.76.4.1995-1998.2002; Muster T, 2004, INT J CANCER, V110, P15, DOI 10.1002/ijc.20078; Najarro P, 2001, J VIROL, V75, P3185, DOI 10.1128/JVI.75.7.3185-3196.2001; Nava VE, 1997, J VIROL, V71, P4118, DOI 10.1128/JVI.71.5.4118-4122.1997; Ozoren N, 2003, SEMIN CANCER BIOL, V13, P135, DOI 10.1016/S1044-579X(02)00131-1; Peters GA, 2002, J VIROL, V76, P11054, DOI 10.1128/JVI.76.21.11054-11064.2002; Poppers J, 2000, J VIROL, V74, P11215, DOI 10.1128/JVI.74.23.11215-11221.2000; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Ries SJ, 2000, NAT MED, V6, P1128, DOI 10.1038/80466; Roth W, 2002, NAT MED, V8, P216, DOI 10.1038/nm0302-216; Russell SJ, 2002, CANCER GENE THER, V9, P961, DOI 10.1038/sj.cgt.7700535; Sauthoff H, 2000, HUM GENE THER, V11, P379, DOI 10.1089/10430340050015851; Shen YQ, 2001, J VIROL, V75, P4297, DOI 10.1128/JVI.75.9.4297-4307.2001; SMITH GL, 1989, J GEN VIROL, V70, P2333, DOI 10.1099/0022-1317-70-9-2333; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Stojdl DF, 2000, NAT MED, V6, P821, DOI 10.1038/77558; TARODI B, 1994, VIROLOGY, V201, P404, DOI 10.1006/viro.1994.1309; TELLING GC, 1994, J VIROL, V68, P541, DOI 10.1128/JVI.68.1.541-547.1994; Todo T, 2000, MOL THER, V2, P588, DOI 10.1006/mthe.2000.0200; Tollefson AE, 2001, J VIROL, V75, P8875, DOI 10.1128/JVI.75.19.8875-8887.2001; Verardi PH, 2001, J VIROL, V75, P11, DOI 10.1128/JVI.75.1.11-18.2001; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang YH, 2003, NAT BIOTECHNOL, V21, P1328, DOI 10.1038/nbt887; WHITE E, 1990, MOL CELL BIOL, V10, P120, DOI 10.1128/MCB.10.1.120; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WHITE E, 1984, J VIROL, V52, P410, DOI 10.1128/JVI.52.2.410-419.1984; Wickham TJ, 2003, NAT MED, V9, P135, DOI 10.1038/nm0103-135; YANG J, 1997, SCIENCE, V275, P1132; Zhirnov OP, 2002, J VIROL, V76, P1617, DOI 10.1128/JVI.76.4.1617-1625.2002	90	25	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 8	2005	24	40					6069	6079		10.1038/sj.onc.1208734	http://dx.doi.org/10.1038/sj.onc.1208734			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	962GD	16155595	Bronze			2022-12-17	WOS:000231718100001
J	Weinmann, M; Belka, C; Guner, D; Goecke, B; Muller, I; Bamberg, M; Jendrossek, V				Weinmann, M; Belka, C; Guner, D; Goecke, B; Muller, I; Bamberg, M; Jendrossek, V			Array-based comparative gene expression analysis of tumor cells with increased apoptosis resistance after hypoxic selection	ONCOGENE			English	Article						hypoxia; apoptosis resistance; mitochondria; gene expression pattern; microarray analysis	NF-KAPPA-B; PATHWAY; DEATH; ACTIVATION; CANCER; STRESS; INVOLVEMENT; SENSITIVITY; MYOCARDIUM; INDUCTION	Tumor hypoxia is an adverse prognostic factor. In a recent study, we could demonstrate that cyclic hypoxia selects for hypoxia-tolerant tumor cells, which are cross-resistant to other stimuli of mitochondrial death pathways. In contrast, sensitivity of the cells to death-receptor ligands was mainly not affected. The aim of the present study was to further elucidate cellular changes induced by cyclic hypoxia and to identify alterations in gene expression pattern upon hypoxic selection by means of DNA-microarray analysis. Our data reveal that cyclic hypoxia resulted in the selection of cells with resistance to doxorubicine and radiation. Furthermore, hypoxic selection was accompanied by constitutive changes of the gene expression pattern with downregulation of 156 and upregulation of 82 genes. Most of the differentially regulated genes were involved in cellular responses to hypoxia and reoxygenation. While many of the genes that were downregulated upon hypoxic selection represent genes that are usually upregulated by acute hypoxia, the genes that were upregulated represent genes that are involved in stress resistance and anti-apoptotic signalling. Most importantly, hypoxic selection was not associated with changes of single apoptosis relevant genes, but with alterations in gene expression levels of a wide variety of genes indicating a more complex adaptation process.	Univ Tubingen, Dept Radiat Oncol, D-72076 Tubingen, Germany; Humboldt Univ, Med Ctr, Charite, Dept Hematol Oncol & Tumor Immunol, Berlin, Germany	Eberhard Karls University of Tubingen; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Jendrossek, V (corresponding author), Univ Tubingen, Dept Radiat Oncol, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.	verena.jendrossek@uni-tuebingen.de	Jendrossek, Verena/AAH-4967-2019	Jendrossek, Verena/0000-0003-1058-2107				Arlt A, 2003, ONCOGENE, V22, P3343, DOI 10.1038/sj.onc.1206524; Baltathakis L, 2001, J CELL BIOCHEM, V83, P281, DOI 10.1002/jcb.1231; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Bode JG, 1999, J BIOL CHEM, V274, P30222, DOI 10.1074/jbc.274.42.30222; Chandrasekar B, 2003, BIOCHEM BIOPH RES CO, V303, P1152, DOI 10.1016/S0006-291X(03)00496-0; Collard CD, 1997, CIRCULATION, V96, P326; Comerford KM, 2002, CANCER RES, V62, P3387; DiIlio C, 1996, BBA-MOL CELL RES, V1312, P125, DOI 10.1016/0167-4889(96)00029-8; Dong Z, 2004, J BIOL CHEM, V279, P9215, DOI 10.1074/jbc.M312225200; Fan CG, 2003, J BIOL CHEM, V278, P2072, DOI 10.1074/jbc.M206718200; Fujise K, 2000, J BIOL CHEM, V275, P39458, DOI 10.1074/jbc.M006626200; Garrido C, 2003, CELL CYCLE, V2, P579, DOI 10.4161/cc.2.6.521; GORDON L, 1990, LIFE SCI, V47, P601, DOI 10.1016/0024-3205(90)90571-8; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRAY LH, 1953, BRIT J RADIOL, V26, P638, DOI 10.1259/0007-1285-26-312-638; Gruber C, 2004, BIOCHEM PHARMACOL, V67, P1859, DOI 10.1016/j.bcp.2004.01.026; Guo GZ, 2003, MOL CELL BIOL, V23, P2362, DOI 10.1128/MCB.23.7.2362-2378.2003; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hockel M, 1999, CANCER RES, V59, P4525; Ichinose F, 2002, J CLIN INVEST, V109, P1493, DOI 10.1172/JCI200214294; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Kacimi R, 1998, CIRC RES, V82, P576, DOI 10.1161/01.RES.82.5.576; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; Kojima T, 2001, THROMB HAEMOSTASIS, V85, P793; Konduri SD, 2003, INT J ONCOL, V22, P1277; Kuperstein F, 2001, J NEUROCHEM, V76, P758, DOI 10.1046/j.1471-4159.2001.00037.x; Lenaz G, 2002, ANN NY ACAD SCI, V959, P199, DOI 10.1111/j.1749-6632.2002.tb02094.x; Leonard MO, 2003, J BIOL CHEM, V278, P40296, DOI 10.1074/jbc.M302560200; Liu GY, 2003, NUCLEIC ACIDS RES, V31, P82, DOI 10.1093/nar/gkg121; Luders J, 2000, J BIOL CHEM, V275, P14817, DOI 10.1074/jbc.275.20.14817; Magnusson KP, 1998, ONCOGENE, V17, P2333, DOI 10.1038/sj.onc.1202149; Matsui H, 1999, CARDIOVASC RES, V42, P104, DOI 10.1016/S0008-6363(98)00285-5; MEHLER MF, 1992, P NATL ACAD SCI USA, V89, P2461, DOI 10.1073/pnas.89.6.2461; MOCHIZUKI S, 1987, BASIC RES CARDIOL, V82, P45; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; Reisdorph R, 1998, BIOCHEM BIOPH RES CO, V249, P709, DOI 10.1006/bbrc.1998.9216; Rockwell S, 2001, Novartis Found Symp, V240, P133; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Seta K, 2002, ANN NY ACAD SCI, V971, P379, DOI 10.1111/j.1749-6632.2002.tb04500.x; Synnestvedt K, 2002, J CLIN INVEST, V110, P993, DOI 10.1172/JCI200215337; Townsend PA, 2003, CANCER RES, V63, P4150; Weinmann M, 2004, INT J RADIAT ONCOL, V58, P386, DOI 10.1016/j.ijrobp.2003.09.052; Weinmann M, 2004, FASEB J, V18, P1906, DOI 10.1096/fj.04-1918fje; Weinmann M, 2004, ONCOGENE, V23, P3757, DOI 10.1038/sj.onc.1207481; Weinmann Martin, 2003, Curr Med Chem Anticancer Agents, V3, P364, DOI 10.2174/1568011033482350	45	25	26	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	38					5914	5922		10.1038/sj.onc.1208748	http://dx.doi.org/10.1038/sj.onc.1208748			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960KW	15897868				2022-12-17	WOS:000231590400014
J	Azran, I; Jeang, KT; Aboud, M				Azran, I; Jeang, KT; Aboud, M			High levels of cytoplasmic HTLV-1 Tax mutant proteins retain a Tax-NF-kappa B-CBP ternary complex in the cytoplasm	ONCOGENE			English	Article						HTLV-1; Tax; cytoplasmic Tax mutants; NF-kappa B; CBP; PKAc	T-CELL LEUKEMIA; VIRUS TYPE-I; LONG TERMINAL REPEAT; CREB BINDING-PROTEIN; TRANSCRIPTIONAL ACTIVATION; TYPE-1 TAX; TRANSACTIVATOR TAX; COACTIVATOR CBP; IKK-ALPHA; NUCLEAR TRANSLOCATION	The oncogenic potential of HTLV- 1 Tax protein is partially ascribed to its capacity to activate NF-kappa B. The current view is that Tax acts first in the cytoplasm to dissociate NF-kappa B factors from the I kappa B proteins and enable their nuclear translocation, then Tax links p65( RelA), within the nucleus, to CBP/p300 and P/ CAF, which are essential for its optimal transcriptional activity. Our present study challenges the paradigm that Tax-p65( RelA)-CBP/p300 assembly occurs in the nucleus. Using Tax mutants defective for nuclear localization we show that at low levels these mutants induce the nuclear translocation of NF-kappa B factors but not their transcriptional activity, whereas at high levels they trap CBP and free p65( RelA) in the cytoplasm and block, thereby, their transcriptional function. In contrast, wildtype (w.t.) Tax strongly stimulated NF-kappa B-dependent gene expression in all tested experimental settings. These data suggest that the Tax-p65( RelA)-CBP ternary complex is established in the cytoplasm rather than in the nucleus. When this complex is formed with w.t. Tax, the entire moiety translocates into the nucleus and exerts high transcriptional activity. However, if the complex is formed with the cytoplasmic Tax mutants, the resulting moiety is retained in the cytoplasm and is, therefore, devoid of transcriptional activity.	Ben Gurion Univ Negev, Fac Hlth Sci, Canc Res Ctr, Dept Microbiol & Immunol, IL-84105 Beer Sheva, Israel; NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA	Ben Gurion University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Aboud, M (corresponding author), Ben Gurion Univ Negev, Fac Hlth Sci, Canc Res Ctr, Dept Microbiol & Immunol, IL-84105 Beer Sheva, Israel.	aboud@bgu.ac.il	Jeang, Kuan-Teh/A-2424-2008		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000547, ZIAAI000547] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ariumi Y, 2000, ONCOGENE, V19, P1491, DOI 10.1038/sj.onc.1203450; Azran Inbal, 2004, Retrovirology, V1, P20; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; Bex F, 1997, J VIROL, V71, P3484, DOI 10.1128/JVI.71.5.3484-3497.1997; Bex F, 1998, METHODS, V16, P83, DOI 10.1006/meth.1998.0646; Bex F, 1998, MOL CELL BIOL, V18, P2392, DOI 10.1128/MCB.18.4.2392; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; Catley MC, 2004, J BIOL CHEM, V279, P18457, DOI 10.1074/jbc.M400765200; Chan HM, 2001, J CELL SCI, V114, P2363; Chen LF, 2003, J MOL MED, V81, P549, DOI 10.1007/s00109-003-0469-0; Chu ZL, 1998, J BIOL CHEM, V273, P15891, DOI 10.1074/jbc.273.26.15891; Duran A, 2003, EMBO J, V22, P3910, DOI 10.1093/emboj/cdg370; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; GITLIN SD, 1991, J VIROL, V65, P2612, DOI 10.1128/JVI.65.5.2612-2621.1991; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; Harrod R, 2000, J BIOL CHEM, V275, P11852, DOI 10.1074/jbc.275.16.11852; HIRAI H, 1994, P NATL ACAD SCI USA, V91, P3584, DOI 10.1073/pnas.91.9.3584; HIRAI H, 1992, ONCOGENE, V7, P1737; Iha H, 2003, ONCOGENE, V22, P8912, DOI 10.1038/sj.onc.1207058; Inoue M, 1998, JPN J CANCER RES, V89, P53, DOI 10.1111/j.1349-7006.1998.tb00479.x; Jeang KT, 2004, J BIOL CHEM, V279, P31991, DOI 10.1074/jbc.R400009200; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Jeang KT, 2001, CYTOKINE GROWTH F R, V12, P207, DOI 10.1016/S1359-6101(00)00028-9; Jiang H, 1999, MOL CELL BIOL, V19, P8136; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Li XH, 2001, J BIOL CHEM, V276, P4494, DOI 10.1074/jbc.M008353200; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Low KG, 1997, J VIROL, V71, P1956, DOI 10.1128/JVI.71.3.1956-1962.1997; Majone F, 2000, J BIOL CHEM, V275, P32906, DOI 10.1074/jbc.C000538200; MAJONE F, 1993, VIROLOGY, V193, P456, DOI 10.1006/viro.1993.1145; Marriott SJ, 2002, J BIOMED SCI, V9, P292, DOI 10.1159/000064998; Matsuoka M, 2003, ONCOGENE, V22, P5131, DOI 10.1038/sj.onc.1206551; Miyake H, 1999, VIROLOGY, V253, P155, DOI 10.1006/viro.1998.9500; Mori N, 2001, BLOOD, V97, P2137, DOI 10.1182/blood.V97.7.2137; MorVaknin N, 1997, VIROLOGY, V232, P337, DOI 10.1006/viro.1997.8566; MURAKAMI T, 1995, VIROLOGY, V206, P1066, DOI 10.1006/viro.1995.1029; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Neuveut C, 2002, FRONT BIOSCI-LANDMRK, V7, pD157, DOI 10.2741/neuveut; Nicot C, 2000, ONCOGENE, V19, P2155, DOI 10.1038/sj.onc.1203536; Nicot C, 1998, J VIROL, V72, P6777, DOI 10.1128/JVI.72.8.6777-6784.1998; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Petropoulos L, 1996, VIROLOGY, V225, P52, DOI 10.1006/viro.1996.0574; SEIKI M, 1986, EMBO J, V5, P561, DOI 10.1002/j.1460-2075.1986.tb04247.x; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUZUKI T, 1994, ONCOGENE, V9, P3099; Suzuki T, 1999, ONCOGENE, V18, P4137, DOI 10.1038/sj.onc.1202766; SUZUKI T, 1995, ONCOGENE, V10, P1199; SUZUKI T, 1993, ONCOGENE, V8, P2391; Tabakin-Fix Y, 2004, BIOCHEM BIOPH RES CO, V318, P1052, DOI 10.1016/j.bbrc.2004.04.137; Torgeman A, 2001, VIROLOGY, V281, P10, DOI 10.1006/viro.2000.0779; Torgeman A, 2001, EXP CELL RES, V271, P169, DOI 10.1006/excr.2001.5363; Turgeman H, 1998, FEBS LETT, V428, P183, DOI 10.1016/S0014-5793(98)00513-4; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; Van Orden K, 2000, GENE EXPRESSION, V9, P29; Van Orden K, 1999, ONCOGENE, V18, P3766, DOI 10.1038/sj.onc.1202703; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Wang TL, 2002, INT IMMUNOPHARMACOL, V2, P1509, DOI 10.1016/S1567-5769(02)00058-9; Whiteside ST, 1997, SEMIN CANCER BIOL, V8, P75, DOI 10.1006/scbi.1997.0058; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yasunaga JI, 2003, INT J HEMATOL, V78, P312, DOI 10.1007/BF02983555; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Yoshida M, 1997, LEUKEMIA, V11, P14, DOI 10.1038/sj.leu.2400545; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; YOSHIZAWA H, 1994, J ADHES SCI TECHNOL, V8, P1; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	78	25	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2005	24	28					4521	4530		10.1038/sj.onc.1208645	http://dx.doi.org/10.1038/sj.onc.1208645			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	940PT	15806143				2022-12-17	WOS:000230157100005
J	Wang, L; Dai, W; Lu, L				Wang, L; Dai, W; Lu, L			Ultraviolet irradiation-induced K+ channel activity involving p53 activation in corneal epithelial cells	ONCOGENE			English	Article						gene expression; Kv channel blocker; DNA damage; apoptosis	DNA-DAMAGE CHECKPOINT; MOLECULAR EPIDEMIOLOGY; SIGNALING PATHWAYS; GENOMIC STABILITY; LEUKEMIA-CELLS; SKIN TUMORS; APOPTOSIS; KINASE; CARCINOGENESIS; ATM	Recent studies from our lab found that ultraviolet (UV) irradiation induces a voltage-gated potassium (Kv) channel activation and subsequently activates JNK signaling pathway resulting in apoptosis. The present study in rabbit corneal epithelial (RCE) cells is to investigate mechanisms of UV irradiation-induced Kv channel activity involving p53 activation in parallel to DNA damage-induced signaling pathway. UV irradiation-induced signaling events were characterized by measurements of JNK activation and further downstream p53 phosphorylation. UV irradiation elicited an early response in the cell membrane through activation of Kv channels to activate the JNK signaling pathway and p53 phosphorylation. Exposure of RCE cells to UV irradiation within a few min resulted in JNK and p53 activations that were markedly inhibited by suppression of Kv channel activity. However, suppression of Kv channel activity failed to prevent p53 activation induced by extended DNA damages through prolonging UV exposure time ( more than 15 min). In addition, caffeine inhibited UV-induced activation of SEK, an upstream MAPK kinase of JNK, resulting in suppression of both Kv channel-involved and DNA damage-induced p53 activation. Our results indicate in these cells that UV irradiation induces earlier and later intracellular events that link to activation of JNK and p53. The early event in response to UV irradiation is initiated by activating Kv channels in the cell membrane, and the later event is predominated by UV irradiation-caused DNA damage.	Univ Calif Los Angeles, Sch Med, Harbor UCLA Med Ctr, Div Mol Med, Torrance, CA 90502 USA; New York Med Coll, Dept Med, Valhalla, NY 10595 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; New York Medical College	Lu, L (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Harbor UCLA Med Ctr, Dept Med,Div Mol Med, 1124 W Carson St,C-2, Torrance, CA 90502 USA.	lluou@ucla.edu		Dai, Wei/0000-0003-0169-8327	NCI NIH HHS [R01 CA074229, CA 79229] Funding Source: Medline; NEI NIH HHS [R01 EY012953, EY12953, R01 EY015281, EY15282] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074229] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY015281, R01EY012953] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ABRAHAMS PJ, 1995, MUTAT RES-DNA REPAIR, V336, P169, DOI 10.1016/0921-8777(94)00049-C; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Asher G, 2001, P NATL ACAD SCI USA, V98, P1188, DOI 10.1073/pnas.021558898; Blaise R, 2001, LEUKEMIA LYMPHOMA, V42, P1173, DOI 10.3109/10428190109097742; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; CHERNOVA OB, 1995, TRENDS BIOCHEM SCI, V20, P431, DOI 10.1016/S0968-0004(00)89094-5; Colman MS, 2000, MUTAT RES-REV MUTAT, V462, P179, DOI 10.1016/S1383-5742(00)00035-1; Costanzo V, 2003, MOL CELL, V11, P203, DOI 10.1016/S1097-2765(02)00799-2; Cross JV, 2004, BIOCHEM J, V381, P675, DOI 10.1042/BJ20040591; Dodson GE, 2004, J BIOL CHEM, V279, P34010, DOI 10.1074/jbc.C400242200; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Gentiletti F, 2002, ONCOGENE, V21, P867, DOI 10.1038/sj.onc.1205137; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; Goodarzi Aaron A, 2003, Prog Cell Cycle Res, V5, P393; Haupt S, 2003, J CELL SCI, V116, P4077, DOI 10.1242/jcs.00739; Hofseth LJ, 2004, CHEST, V125, p83S, DOI 10.1378/chest.125.5_suppl.83S-a; Hussain SP, 2000, P NATL ACAD SCI USA, V97, P12770, DOI 10.1073/pnas.220416097; Hussain SP, 1998, CANCER RES, V58, P4023; Irarrazabal CE, 2004, P NATL ACAD SCI USA, V101, P8809, DOI 10.1073/pnas.0403062101; Ito K, 2003, J CELL PHYSIOL, V196, P276, DOI 10.1002/jcp.10289; Kastan MB, 2004, BIOMED PHARMACOTHER, V58, P72, DOI 10.1016/S0753-3322(03)00045-3; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Kwan R, 2001, MOL CELL BIOL, V21, P7183, DOI 10.1128/MCB.21.21.7183-7190.2001; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lieber JG, 2004, BLOOD, V103, P852, DOI 10.1182/blood-2003-04-1030; Lu L, 2003, INVEST OPHTH VIS SCI, V44, P5102, DOI 10.1167/iovs.03-0591; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Medina D, 2002, ENVIRON MOL MUTAGEN, V39, P178, DOI 10.1002/em.10064; Melnikova VO, 2003, ONCOGENE, V22, P5958, DOI 10.1038/sj.onc.1206595; Nishikawa T, 2003, CANCER LETT, V194, P45, DOI 10.1016/S0304-3835(03)00057-0; Pluquet O, 2003, J BIOL CHEM, V278, P11879, DOI 10.1074/jbc.M207396200; Ringvold A, 1998, ACTA OPHTHALMOL SCAN, V76, P149, DOI 10.1034/j.1600-0420.1998.760205.x; Roderick C, 2003, J MEMBRANE BIOL, V196, P41, DOI 10.1007/s00232-003-0623-1; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Shirai N, 2002, CARCINOGENESIS, V23, P1541, DOI 10.1093/carcin/23.9.1541; Smirnova IS, 2001, CELL BIOL INT, V25, P1101, DOI 10.1006/cbir.2001.0709; Sogame N, 2003, P NATL ACAD SCI USA, V100, P4696, DOI 10.1073/pnas.0736384100; Tang Zhong-Hui, 2003, Ai Zheng, V22, P1057; Tominaga K, 1999, J BIOL CHEM, V274, P31463, DOI 10.1074/jbc.274.44.31463; VANKRANEN HJ, 1995, CARCINOGENESIS, V16, P1141; Wang L, 2004, INVEST OPHTH VIS SCI, V45, P1796, DOI 10.1167/iovs.03-1056; Wang L, 2003, INVEST OPHTH VIS SCI, V44, P5095, DOI 10.1167/iovs.03-0590; Wang L, 1999, J BIOL CHEM, V274, P3678, DOI 10.1074/jbc.274.6.3678; Wang LD, 1998, WORLD J GASTROENTERO, V4, P287, DOI 10.3748/wjg.v4.i4.287; Wang XW, 1999, ANTICANCER RES, V19, P4759; Wu GS, 2004, CANCER BIOL THER, V3, P156, DOI 10.4161/cbt.3.2.614; Xie SQ, 2001, J BIOL CHEM, V276, P43305, DOI 10.1074/jbc.M106050200; Xie SQ, 2001, J BIOL CHEM, V276, P36194, DOI 10.1074/jbc.M104157200; Xie SQ, 2002, CELL CYCLE, V1, P424, DOI 10.4161/cc.1.6.271; Xu DZ, 1999, BLOOD, V94, P139, DOI 10.1182/blood.V94.1.139.413k11_139_145; Yang L, 2004, WORLD J GASTROENTERO, V10, P155; Ye RQ, 2001, J BIOL CHEM, V276, P4828, DOI 10.1074/jbc.M004894200; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Ziegler A, 1996, PHOTOCHEM PHOTOBIOL, V63, P432, DOI 10.1111/j.1751-1097.1996.tb03064.x	56	25	25	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					3020	3027		10.1038/sj.onc.1208547	http://dx.doi.org/10.1038/sj.onc.1208547			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15750624	Green Accepted			2022-12-17	WOS:000228649500011
J	Jun, JI; Chung, CW; Lee, HJ; Pyo, JO; Lee, KN; Kim, NS; Kim, YS; Yoo, HS; Lee, TH; Kim, E; Jung, YK				Jun, JI; Chung, CW; Lee, HJ; Pyo, JO; Lee, KN; Kim, NS; Kim, YS; Yoo, HS; Lee, TH; Kim, E; Jung, YK			Role of FLASH in caspase-8-mediated activation of NF-kappa B: dominant-negative function of FLASH mutant in NF-kappa B signaling pathway	ONCOGENE			English	Article						caspase-8; FLASH; NF-kappa B; siRNA; dominant negative	TUMOR-NECROSIS-FACTOR; TNF RECEPTOR; CELL-DEATH; INTERFERING MUTANT; IKK-ALPHA; APOPTOSIS; PROTEIN; INDUCTION; TRANSDUCTION; FADD	Caspase-8 is the most receptor-proximal, upstream caspase in the caspase cascade and plays a key role in cell death triggered by various death receptors. Here, we addressed the role of endogenous caspase-8 in tumor necrosis factor (TNF)-alpha-induced activation of NF-kappaB. Direct targeting of caspase-8 with siRNA and antisense (AS) approaches abolished TNF-alpha-induced activation of NF-kappaB in NIH3T3, HeLa, and HEK293 cells as determined with luciferase reporter gene and cell fractionation assays. Reconstitution of caspase-8-deficient C33A cells with processing-defective (P/D) mutant of caspase-8 sensitized the cells to TNF-alpha for NF-kappaB activation. In contrast to wild-type caspase-8, death effector domain mutant replacing Asp73 with Ala (caspase-8 (D73A)) failed to activate NF-kappaB and to bind FLICE-associated huge protein ( FLASH) in vitro and in vivo. Instead, caspase-8 (D73A) mutant bound to caspase-8 and blocked NF-kappaB activation triggered by TNF-alpha and caspase-8. In addition, expression of an NF-kappaB-activating domain-deletion mutant of FLASH or transfection of FLASH AS oligonucleotides abolished TNF-alpha and caspase-8, but not phorbol 12-myristate 13-acetate, - induced activation of NF-kappaB. Further, immunoprecipitation assays showed that caspase-8 formed triple complex with TRAF2 and FLASH. Taken together, these results suggest that endogenous caspase-8 mediates TNF-alpha-induced activation of NF-kappaB via FLASH.	Gwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea; Korea Res Inst Biosci & Biotechnol, Taejon 305600, South Korea; Yonsei Univ, Dept Biol, Seoul 120749, South Korea; PaiChai Univ, Dept Life Sci, Taejon 302735, South Korea	Gwangju Institute of Science & Technology (GIST); Korea Research Institute of Bioscience & Biotechnology (KRIBB); Yonsei University; Pai Chai University	Jung, YK (corresponding author), Gwangju Inst Sci & Technol, Dept Life Sci, 1 Oryong Dong, Kwangju 500712, South Korea.	ykjung@kjist.ac.kr	Lee, Ho-June/D-8855-2014	Lee, Ho-June/0000-0002-7019-2533				Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Chaudhary PM, 2000, ONCOGENE, V19, P4451, DOI 10.1038/sj.onc.1203812; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Choi C, 2002, MOL CELL BIOL, V22, P724, DOI 10.1128/MCB.22.3.724-736.2002; Choi YH, 2001, J BIOL CHEM, V276, P25073, DOI 10.1074/jbc.M102941200; Chun HJ, 2002, NATURE, V419, P395, DOI 10.1038/nature01063; Chung CW, 2001, NEUROBIOL DIS, V8, P162, DOI 10.1006/nbdi.2000.0335; Grell M, 1999, EMBO J, V18, P3034, DOI 10.1093/emboj/18.11.3034; Guiet C, 2002, CELL DEATH DIFFER, V9, P138, DOI 10.1038/sj/cdd/4400947; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu WH, 2000, J BIOL CHEM, V275, P10838, DOI 10.1074/jbc.275.15.10838; Imai Y, 1999, NATURE, V398, P777, DOI 10.1038/19709; Inohara N, 2000, J BIOL CHEM, V275, P27823; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; Ito Y, 2001, MOL PHARMACOL, V59, P1094, DOI 10.1124/mol.59.5.1094; Kim IK, 2000, BIOCHEM BIOPH RES CO, V277, P311, DOI 10.1006/bbrc.2000.3673; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; Newton K, 2001, CURR BIOL, V11, P273, DOI 10.1016/S0960-9822(01)00067-7; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Shikama Y, 2003, EUR J IMMUNOL, V33, P1998, DOI 10.1002/eji.200324013; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	43	25	27	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					688	696		10.1038/sj.onc.1208186	http://dx.doi.org/10.1038/sj.onc.1208186			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15592525				2022-12-17	WOS:000226420400016
J	Liu, JJ; Maller, JL				Liu, JJ; Maller, JL			Xenopus Polo-like kinase Plx1: a multifunctional mitotic kinase	ONCOGENE			English	Article						Polo-like kinase; Plx1; Xenopus; mitosis; cell cycle	ANAPHASE-PROMOTING COMPLEX; PEPTIDYL-PROLYL ISOMERASE; SACCHAROMYCES-CEREVISIAE CDC5; SISTER-CHROMATID COHESION; CELL-CYCLE; PROTEIN-KINASE; FISSION YEAST; EGG EXTRACTS; BOX DOMAIN; SUBCELLULAR-LOCALIZATION	The Xenopus Polo-like kinase Plx1 plays multiple roles in mitosis. Accumulating evidence shows that Plx1 is the trigger kinase for the G(2)/M transition that phosphorylates and activates the phosphatase Cdc25C, which subsequently dephosphorylates Cdc2/cyclin B and initiates a positive feedback loop between Cdc25C and Cdc2/cyclin B. Recent findings indicate that Plx1 itself is also in a positive feedback loop. It phosphorylates and activates the protein kinase xPlkk1, which itself then phosphorylates and further activates Plx1. Plx1 functions on the centrosome to promote bipolar spindle formation. Plx1 associates with the anaphase-promoting complex/cyclosome (APC/C) and is required to activate the APC/C for degradation of mitotic regulators required for sister chromatid separation and exit from mitosis. Plx1 is also required for cytokinesis and is localized on the midbody of the contractile ring. All known functions of Plx1 require not only its kinase activity but also an intact polo box domain in the C-terminus.	Univ Colorado, Sch Med, Howard Hughes Med Inst, Denver, CO 80262 USA; Univ Colorado, Sch Med, Dept Pharmacol, Denver, CO 80262 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Maller, JL (corresponding author), Univ Colorado, Sch Med, Howard Hughes Med Inst, Denver, CO 80262 USA.	jim.maller@uchsc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026743] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26743-24] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrieu A, 1998, J CELL SCI, V111, P1751; Alexandru G, 2001, CELL, V105, P459, DOI 10.1016/S0092-8674(01)00362-2; Avides MD, 2001, NAT CELL BIOL, V3, P421, DOI 10.1038/35070110; Bahler J, 1998, J CELL BIOL, V143, P1603, DOI 10.1083/jcb.143.6.1603; Bin OY, 1999, ONCOGENE, V18, P6029, DOI 10.1038/sj.onc.1202983; Brassac T, 2000, ONCOGENE, V19, P3782, DOI 10.1038/sj.onc.1203724; Carmena M, 1998, J CELL BIOL, V143, P659, DOI 10.1083/jcb.143.3.659; Cheng KY, 2003, EMBO J, V22, P5757, DOI 10.1093/emboj/cdg558; Crenshaw DG, 1998, EMBO J, V17, P1315, DOI 10.1093/emboj/17.5.1315; Descombes P, 1998, EMBO J, V17, P1328, DOI 10.1093/emboj/17.5.1328; Donaldson MM, 2001, J CELL BIOL, V153, P663, DOI 10.1083/jcb.153.4.663; Duncan PI, 2001, EXP CELL RES, V270, P78, DOI 10.1006/excr.2001.5333; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; Erikson E, 2004, J BIOL CHEM, V279, P32219, DOI 10.1074/jbc.M403840200; Golan A, 2002, J BIOL CHEM, V277, P15552, DOI 10.1074/jbc.M111476200; Gonzalez C, 1998, CHROMOSOMA, V107, P452, DOI 10.1007/s004120050329; GONZALEZ C, 1990, J CELL SCI, V96, P605; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; Hauf S, 2001, SCIENCE, V293, P1320, DOI 10.1126/science.1061376; Hornig NCD, 2004, EMBO J, V23, P3144, DOI 10.1038/sj.emboj.7600303; Hsu JY, 2002, NAT CELL BIOL, V4, P358, DOI 10.1038/ncb785; IZUMI T, 1995, MOL BIOL CELL, V6, P215, DOI 10.1091/mbc.6.2.215; IZUMI T, 1991, MOL CELL BIOL, V11, P3860, DOI 10.1128/MCB.11.8.3860; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; Jackman M, 2003, NAT CELL BIOL, V5, P143, DOI 10.1038/ncb918; Jang YJ, 2002, J BIOL CHEM, V277, P44115, DOI 10.1074/jbc.M202172200; Jang YJ, 2002, P NATL ACAD SCI USA, V99, P1984, DOI 10.1073/pnas.042689299; Kang DM, 2002, J CELL BIOL, V156, P249, DOI 10.1083/jcb.200108016; Karaiskou A, 2004, DEVELOPMENT, V131, P1543, DOI 10.1242/dev.01050; Kelm O, 2002, J BIOL CHEM, V277, P25247, DOI 10.1074/jbc.M202855200; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Lee KS, 1998, P NATL ACAD SCI USA, V95, P9301, DOI 10.1073/pnas.95.16.9301; Lee KS, 1997, MOL CELL BIOL, V17, P3408, DOI 10.1128/MCB.17.6.3408; Leung GC, 2002, NAT STRUCT BIOL, V9, P719, DOI 10.1038/nsb848; LI JK, 1995, MOL BIOL CELL, V6, P1111, DOI 10.1091/mbc.6.9.1111; Lindon C, 2004, J CELL BIOL, V164, P233, DOI 10.1083/jcb.200309035; Liu JJ, 2004, J BIOL CHEM, V279, P21367, DOI 10.1074/jbc.M400482200; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8672, DOI 10.1073/pnas.132269599; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; Lorca T, 1998, EMBO J, V17, P3565, DOI 10.1093/emboj/17.13.3565; Losada A, 2002, GENE DEV, V16, P3004, DOI 10.1101/gad.249202; Losada A, 1998, GENE DEV, V12, P1986, DOI 10.1101/gad.12.13.1986; Losada A, 2000, J CELL BIOL, V150, P405, DOI 10.1083/jcb.150.3.405; Lowery DM, 2004, CELL CYCLE, V3, P128; Lu KP, 1996, NATURE, V380, P544; May KM, 2002, J CELL BIOL, V156, P23, DOI 10.1083/jcb.200106150; Moshe Y, 2004, P NATL ACAD SCI USA, V101, P7937, DOI 10.1073/pnas.0402442101; OHKURA H, 1995, GENE DEV, V9, P1059, DOI 10.1101/gad.9.9.1059; Perdiguero E, 2003, EMBO J, V22, P5746, DOI 10.1093/emboj/cdg559; Peter M, 2002, EMBO REP, V3, P551, DOI 10.1093/embo-reports/kvf111; Qian YW, 1999, MOL CELL BIOL, V19, P8625; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Qian YW, 1998, SCIENCE, V282, P1701, DOI 10.1126/science.282.5394.1701; Qian YW, 2001, MOL BIOL CELL, V12, P1791, DOI 10.1091/mbc.12.6.1791; Reimann JDR, 2001, CELL, V105, P645, DOI 10.1016/S0092-8674(01)00361-0; Reimann JDR, 2001, GENE DEV, V15, P3278, DOI 10.1101/gad.945701; Reynolds N, 2003, J CELL SCI, V116, P1377, DOI 10.1242/jcs.00314; Rudner AD, 2000, J CELL BIOL, V149, P1377, DOI 10.1083/jcb.149.7.1377; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; Shen MH, 1998, GENE DEV, V12, P706, DOI 10.1101/gad.12.5.706; Sigrist SJ, 1997, CELL, V90, P671, DOI 10.1016/S0092-8674(00)80528-0; Simizu S, 2000, NAT CELL BIOL, V2, P852, DOI 10.1038/35041102; Song SG, 2001, J CELL BIOL, V152, P451, DOI 10.1083/jcb.152.3.451; Sumara I, 2000, J CELL BIOL, V151, P749, DOI 10.1083/jcb.151.4.749; Sumara I, 2002, MOL CELL, V9, P515, DOI 10.1016/S1097-2765(02)00473-2; SUNKEL CE, 1988, J CELL SCI, V89, P25; Tavares AAM, 1996, EMBO J, V15, P4873, DOI 10.1002/j.1460-2075.1996.tb00868.x; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; Uhlmann F, 1998, CURR BIOL, V8, P1095, DOI 10.1016/S0960-9822(98)70463-4; Uhlmann F, 2001, CURR OPIN CELL BIOL, V13, P754, DOI 10.1016/S0955-0674(00)00279-9; Uhlmann F, 2004, EXP CELL RES, V296, P80, DOI 10.1016/j.yexcr.2004.03.005; Waizenegger IC, 2000, CELL, V103, P399, DOI 10.1016/S0092-8674(00)00132-X; Wakefield JG, 2001, J CELL BIOL, V153, P637, DOI 10.1083/jcb.153.4.637; Walsh S, 2003, MOL CANCER RES, V1, P280; Wind M, 2002, PROTEOMICS, V2, P1516, DOI 10.1002/1615-9861(200211)2:11<1516::AID-PROT1516>3.0.CO;2-Y; Yoo HY, 2004, CELL, V117, P575, DOI 10.1016/S0092-8674(04)00417-9; Yuan JP, 2002, ONCOGENE, V21, P8282, DOI 10.1038/sj.onc.1206011; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X	82	25	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2005	24	2					238	247		10.1038/sj.onc.1208220	http://dx.doi.org/10.1038/sj.onc.1208220			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	885UR	15640839				2022-12-17	WOS:000226183100004
J	Bhonde, MR; Hanski, ML; Magrini, R; Moorthy, D; Muller, A; Sausville, EA; Kohno, K; Wiegand, P; Daniel, PT; Zeitz, M; Hanski, C				Bhonde, MR; Hanski, ML; Magrini, R; Moorthy, D; Muller, A; Sausville, EA; Kohno, K; Wiegand, P; Daniel, PT; Zeitz, M; Hanski, C			The broad-range cyclin-dependent kinase inhibitor UCN-01 induces apoptosis in colon carcinoma cells through transcriptional suppression of the Bcl-x(L) protein	ONCOGENE			English	Article						colon carcinoma; chemotherapy; UCN-01; apoptosis; cell cycle arrest	LUNG-CANCER CELLS; 7-HYDROXYSTAUROSPORINE UCN-01; SELECTIVE INHIBITOR; ANTITUMOR-ACTIVITY; UP-REGULATION; CONSTITUTIVE ACTIVATION; CHECKPOINT FUNCTION; GROWTH-INHIBITION; LEUKEMIA-CELLS; BCL-X	The broad-range cyclin-dependent kinase inhibitor 7-hydroxystaurosporine (UCN-01) is known to induce both a G1 cell cycle arrest and apoptosis. The mechanism of UCN-01-induced apoptosis is largely unknown. We analysed the mechanism of cytotoxicity of UCN-01 in four established colon carcinoma cell lines. The cell lines SW48 and LS513 responded to UCN-01 treatment by undergoing apoptosis in a concentration-dependent manner while the cell lines HT-29 and WiDr were completely resistant. Apoptosis in LS513 and SW48 cell lines was concomitant with the suppression of Bcl-x(L) on mRNA and protein level. In contrast, in the apoptosis-resistant cell lines, Bcl-x(L) expression was not affected by UCN-01. Stable overexpression of the Bcl-x(L) protein abrogated UCN-01-triggered apoptosis, but only partially restored growth, indicating that both cell cycle arrest and apoptosis exert the anticancer effect in a coordinated manner. The inhibition of Akt phosphorylation did not correlate with the apoptotic phenotype. UCN-01 inhibited the activating STAT3 phosphorylations on Ser727 and, notably, on Tyr705, but STAT3 did not contribute to Bcl-x(L) expression in colon carcinoma cells. Moreover, we show for the first time that UCN-01 induces apoptosis by suppression of Bcl-x(L) expression. The inhibition of this pathway is a new aspect of cytotoxic and modulatory potential of UCN-01.	Charite Univ Med Berlin, Dept Gastroenterol, D-12200 Berlin, Germany; Dept Clin & Mol Oncol, Berlin, Germany; NCI, Rockville, MD USA; Univ Occupat & Environm Hlth, Sch Med, Kitakyushu, Fukuoka 807, Japan; Inst Forens Med, Ulm, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Occupational & Environmental Health - Japan	Hanski, C (corresponding author), Charite Univ Med Berlin, Dept Gastroenterol, Campus Benjamin Franklin,Hindenburgdamm 30, D-12200 Berlin, Germany.	christoph.hanski@charite.de	Moorthy, Dhatchana/AAD-7680-2019	Moorthy, Dhatchana/0000-0002-0071-4762				Abe S, 2000, JPN J CANCER RES, V91, P1192, DOI 10.1111/j.1349-7006.2000.tb00904.x; Ahn JW, 2003, J BIOL CHEM, V278, P20480, DOI 10.1074/jbc.M213185200; Akinaga S, 2000, ANTI-CANCER DRUG DES, V15, P43; AKINAGA S, 1993, CANCER CHEMOTH PHARM, V32, P183, DOI 10.1007/BF00685833; AKINAGA S, 1991, CANCER RES, V51, P4888; Akiyama T, 1999, ANTI-CANCER DRUG, V10, P67, DOI 10.1097/00001813-199901000-00009; Akiyama T, 1999, JPN J CANCER RES, V90, P1364, DOI 10.1111/j.1349-7006.1999.tb00721.x; Alas S, 2003, CLIN CANCER RES, V9, P316; Amundson SA, 2000, CANCER RES, V60, P6101; Bredel M, 1999, J NEURO-ONCOL, V41, P9, DOI 10.1023/A:1006047025425; Bunch RT, 1996, CLIN CANCER RES, V2, P791; Burke WM, 2001, ONCOGENE, V20, P7925, DOI 10.1038/sj.onc.1204990; Byrd JC, 2001, EXP HEMATOL, V29, P703, DOI 10.1016/S0301-472X(01)00649-X; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chan UPF, 2003, ANTI-CANCER DRUG, V14, P761, DOI 10.1097/01.cad.0000094782.62385.7a; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; COSSET FL, 1995, J VIROL, V69, P7430, DOI 10.1128/JVI.69.12.7430-7436.1995; Dai Y, 2001, CANCER RES, V61, P5106; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; Fan SJ, 1997, ONCOGENE, V14, P2127, DOI 10.1038/sj.onc.1201052; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Grad JM, 2000, CURR OPIN ONCOL, V12, P543, DOI 10.1097/00001622-200011000-00006; HANSKI C, 1992, INT J CANCER, V50, P924, DOI 10.1002/ijc.2910500618; Hirose Y, 2001, CANCER RES, V61, P5843; Husain A, 1997, CLIN CANCER RES, V3, P2089; Kato K, 2000, BBA-GENE STRUCT EXPR, V1493, P91, DOI 10.1016/S0167-4781(00)00168-8; Kawakami K, 1996, BIOCHEM BIOPH RES CO, V219, P778, DOI 10.1006/bbrc.1996.0310; Koh Junichi, 2002, Breast Cancer, V9, P50, DOI 10.1007/BF02967547; Kruger EA, 1999, INVAS METAST, V18, P209, DOI 10.1159/000024514; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Leong PL, 2003, P NATL ACAD SCI USA, V100, P4138, DOI 10.1073/pnas.0534764100; Mack PC, 1999, CLIN CANCER RES, V5, P2596; Mora LB, 2002, CANCER RES, V62, P6659; Nieves-Neira W, 1999, INT J CANCER, V82, P396, DOI 10.1002/(SICI)1097-0215(19990730)82:3<396::AID-IJC13>3.0.CO;2-Z; O'Connor P M, 1996, Prog Cell Cycle Res, V2, P165; Patel V, 2002, CLIN CANCER RES, V8, P3549; Plowright EE, 2000, BLOOD, V95, P992, DOI 10.1182/blood.V95.3.992.003k29_992_998; POWELL SN, 1995, CANCER RES, V55, P1643; Sato S, 2002, ONCOGENE, V21, P1727, DOI 10.1038/sj.onc.1205225; SEYNAEVE CM, 1993, CANCER RES, V53, P2081; Shao RG, 1997, EXP CELL RES, V234, P388, DOI 10.1006/excr.1997.3650; Sugiyama K, 1999, CANCER RES, V59, P4406; TAKAHASHI I, 1987, J ANTIBIOT, V40, P1782, DOI 10.7164/antibiotics.40.1782; Usuda J, 2000, INT J CANCER, V85, P275, DOI 10.1002/(SICI)1097-0215(20000115)85:2<275::AID-IJC20>3.0.CO;2-5; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; WANG QZ, 1995, CELL GROWTH DIFFER, V6, P927; Wei LH, 2003, ONCOGENE, V22, P1517, DOI 10.1038/sj.onc.1206226; Yamit-Hezi E, 2000, J BIOL CHEM, V275, P18180, DOI 10.1074/jbc.275.24.18180; Yu Q, 2002, CANCER RES, V62, P5743	51	25	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					148	156		10.1038/sj.onc.1207842	http://dx.doi.org/10.1038/sj.onc.1207842			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15467762				2022-12-17	WOS:000226125800017
J	Ekberg, J; Landberg, G; Holm, C; Richter, J; Wolgemuth, DJ; Persson, JL				Ekberg, J; Landberg, G; Holm, C; Richter, J; Wolgemuth, DJ; Persson, JL			Regulation of the cyclin A1 protein is associated with its differential subcellular localization in hematopoietic and leukemic cells	ONCOGENE			English	Article						cyclin A1; AML; subcellular localization; CDK1; RAR alpha	ACUTE PROMYELOCYTIC LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; ACUTE MYELOID-LEUKEMIA; PML-RAR-ALPHA; FUSION PROTEINS; ENDOPLASMIC-RETICULUM; TRANSCRIPTION FACTORS; NUCLEAR-LOCALIZATION; DEPENDENT KINASES; HUMAN CANCER	An important role of the cell cycle regulatory protein cyclin A1 in the development of acute myeloid leukemia (AML) was previously demonstrated in a transgenic mouse model. We have now turned our attention to study specific aspects of the activity and subcellular distribution of cyclin A1 using bone marrow samples from normal donors and patients with AML, as well as leukemic cell lines. We show that the localization of cyclin A1 in normal hematopoietic cells is nuclear, whereas in leukemic cells from AML patients and cell lines, it is predominantly cytoplasmic. In leukemic cell lines treated with all-trans retinoic acid (ATRA), cyclin A1 localized to the nucleus. Further, there was a direct interaction between cyclin A1 and cyclin-dependent kinase 1, as well as a major ATRA receptor, RARalpha, in ATRA-treated cells but not in untreated leukemic cells. Our results indicate that the altered intracellular distribution of cyclin A1 in leukemic cells correlates with the status of the leukemic phenotype.	Lund Univ, Univ Hosp, Dept Lab Med, Div Pathol, S-20502 Malmo, Sweden; BMC, Div Mol Med & Gene Therapy, S-22184 Lund, Sweden; Columbia Univ, Med Ctr, Ctr Reprod Sci, Dept Genet & Dev, New York, NY 10032 USA; Columbia Univ, Med Ctr, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Columbia Univ, Med Ctr, Ctr Reprod Sci, Dept Obstet & Gynecol, New York, NY 10032 USA	Lund University; Skane University Hospital; Columbia University; Columbia University; Columbia University	Persson, JL (corresponding author), Lund Univ, Univ Hosp, Dept Lab Med, Div Pathol, S-20502 Malmo, Sweden.	jenny.persson@pat.mas.lu.se		Persson, Jenny/0000-0001-7682-7678	NATIONAL CANCER INSTITUTE [T32CA009363, R21CA095362] Funding Source: NIH RePORTER; NCI NIH HHS [CA09363, CA95362] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amanullah A, 2000, BLOOD, V96, P475; Barseguian K, 2002, P NATL ACAD SCI USA, V99, P15434, DOI 10.1073/pnas.242588499; Berasain C, 1998, ONCOGENE, V16, P1277, DOI 10.1038/sj.onc.1201893; Dao MA, 1999, LEUKEMIA, V13, P1473, DOI 10.1038/sj.leu.2401537; Dimberg A, 2002, BLOOD, V99, P2199, DOI 10.1182/blood.V99.6.2199; Faderl S, 2000, CANCER, V89, P1976, DOI 10.1002/1097-0142(20001101)89:9<1976::AID-CNCR14>3.3.CO;2-E; Faivre J, 2002, ONCOGENE, V21, P1493, DOI 10.1038/sj.onc.1205215; Faretta M, 2001, SEMIN HEMATOL, V38, P42, DOI 10.1053/shem.2001.20866; Furukawa Y, 1997, Hum Cell, V10, P159; Furukawa Y, 1998, Hum Cell, V11, P81; He LZ, 1999, ONCOGENE, V18, P5278, DOI 10.1038/sj.onc.1203088; Iida H, 1997, BLOOD, V90, P3707, DOI 10.1182/blood.V90.9.3707; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Kramer A, 1998, LEUKEMIA, V12, P893, DOI 10.1038/sj.leu.2401051; Liao C, 2004, INT J CANCER, V108, P654, DOI 10.1002/ijc.11573; Liao C, 2001, P NATL ACAD SCI USA, V98, P6853, DOI 10.1073/pnas.121540098; Liu D, 2000, DEV BIOL, V224, P388, DOI 10.1006/dbio.2000.9776; Liu D, 1998, NAT GENET, V20, P377, DOI 10.1038/3855; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; MARIDOR G, 1993, J CELL SCI, V106, P535; Moore JD, 2003, SCIENCE, V300, P987, DOI 10.1126/science.1081418; Muller C, 2000, BLOOD, V96, P3894, DOI 10.1182/blood.V96.12.3894.h8003894_3894_3899; Palmqvist R, 2000, AM J PATHOL, V157, P1947, DOI 10.1016/S0002-9440(10)64833-X; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Singh SP, 1998, CANCER RES, V58, P1730; Stein GS, 2000, J CELL SCI, V113, P2527; Sweeney C, 1996, DEVELOPMENT, V122, P53; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Tenen DG, 2003, NAT REV CANCER, V3, P89, DOI 10.1038/nrc989; Volm M, 1997, INT J CANCER, V74, P508, DOI 10.1002/(SICI)1097-0215(19971021)74:5<508::AID-IJC5>3.0.CO;2-7; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Yang J, 1999, TRENDS CELL BIOL, V9, P207, DOI 10.1016/S0962-8924(99)01577-9; Yang R, 1997, CANCER RES, V57, P913; Yang R, 1999, BLOOD, V93, P2067; Yaroslavskiy B, 1999, BLOOD, V93, P2907; Yaroslavskiy B, 2001, J CELL BIOCHEM, V83, P380, DOI 10.1002/jcb.1243; Zhu J, 1999, P NATL ACAD SCI USA, V96, P14807, DOI 10.1073/pnas.96.26.14807	40	25	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2004	23	56					9082	9089		10.1038/sj.onc.1208090	http://dx.doi.org/10.1038/sj.onc.1208090			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15489899	Green Published			2022-12-17	WOS:000225492800009
J	Ohashi, Y; Ueda, M; Kawase, T; Kawakami, Y; Toda, M				Ohashi, Y; Ueda, M; Kawase, T; Kawakami, Y; Toda, M			Identification of an epigenetically silenced gene, RFX1, in human glioma cells using restriction landmark genomic scanning	ONCOGENE			English	Article						glioma; RLGS; RFX1; methylation; epigenetics	HUMAN PROSTATE-CANCER; DNA-BINDING; CPG ISLANDS; EXPRESSION; METHYLATION; PROTEIN; HYPERMETHYLATION; INACTIVATION; PROGRESSION; SEQUENCES	To identify the CpG islands differentially methylated in human glioma, we performed restriction landmark genomic scanning with a CpG methylation-sensitive enzyme. We found 12 spots, the intensity of which was entirely lost or decreased in both the human glioma tissues examined as compared with that in matched normal lymphocytes, indicating aberrant methylation of these CpG islands in gliomas. The expression of RFX1, one of the genes associated with the methylated CpG islands, was frequently decreased in human glioma cell lines and tissues. We also demonstrated that the isolated CpG island located in the seventh intron of the RFX1 gene had enhancer activity and was hypermethylated in all of the glioma tissues and cell lines analysed, but not in normal brains or lymphocytes. Treatment of glioma cells with a demethylating agent, 5-azacytidine, resulted in the expression of RFX1, indicating that the silencing of the RFX1 gene may be attributable to its methylation. RFX1 has been implicated in transcriptional downregulation of the proto-oncogene c-myc. By expression of the RFX1 gene, the cellular proliferative activity of glioma cells was suppressed. Taken together, these results suggest that the RFX1 gene may be epigenetically silenced in human gliomas and involved in glioma tumorigenesis.	Keio Univ, Sch Med, Neuroimmunol Res Grp, Shinjuku Ku, Tokyo 1608582, Japan; Keio Univ, Sch Med, Inst Adv Med Res, Div Cellular Signaling, Tokyo, Japan; Keio Univ, Sch Med, Dept Surg, Tokyo 160, Japan; Keio Univ, Sch Med, Dept Neurosurg, Shinjuku Ku, Tokyo 1608582, Japan	Keio University; Keio University; Keio University; Keio University	Toda, M (corresponding author), Keio Univ, Sch Med, Neuroimmunol Res Grp, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	todam@sc.itc.keio.ac.jp	Kawakami, Yutaka/E-7429-2013; Toda, Masahiro/L-2268-2013; nakamura, asuka/S-7235-2016	Kawakami, Yutaka/0000-0003-4836-2855; 				BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; Chen L, 2000, J BIOL CHEM, V275, P32227, DOI 10.1074/jbc.M002645200; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Emery P, 1996, NUCLEIC ACIDS RES, V24, P803, DOI 10.1093/nar/24.5.803; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; FULTS D, 1992, CANCER RES, V52, P674; Gajiwala KS, 2000, NATURE, V403, P916, DOI 10.1038/35002634; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; HATADA I, 1991, P NATL ACAD SCI USA, V88, P9523, DOI 10.1073/pnas.88.21.9523; HUMPHREY PA, 1988, CANCER RES, V48, P2231; Itano O, 2000, ONCOGENE, V19, P1676, DOI 10.1038/sj.onc.1203459; Katan-Khaykovich Y, 2001, EUR J BIOCHEM, V268, P3108, DOI 10.1046/j.1432-1327.2001.02211.x; LINDSAY S, 1987, NATURE, V327, P336, DOI 10.1038/327336a0; Maegawa S, 2001, MOL CARCINOGEN, V31, P1, DOI 10.1002/mc.1034; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; Melki JR, 1999, CANCER RES, V59, P3730; Nakamura M, 2001, LAB INVEST, V81, P77, DOI 10.1038/labinvest.3780213; Rasheed B K, 1999, Curr Opin Oncol, V11, P162; Saito Y, 2001, HEPATOLOGY, V33, P561, DOI 10.1053/jhep.2001.22507; Sekita N, 2001, JPN J CANCER RES, V92, P947, DOI 10.1111/j.1349-7006.2001.tb01185.x; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; SIEGRIST CA, 1993, MOL CELL BIOL, V13, P6375, DOI 10.1128/MCB.13.10.6375; Smiraglia DJ, 1999, GENOMICS, V58, P254, DOI 10.1006/geno.1999.5840; Umezawa A, 1997, MOL CELL BIOL, V17, P4885, DOI 10.1128/MCB.17.9.4885; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Yamada KM, 2001, J CELL SCI, V114, P2375; Zardo G, 2002, NAT GENET, V32, P453, DOI 10.1038/ng1007	28	25	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2004	23	47					7772	7779		10.1038/sj.onc.1208058	http://dx.doi.org/10.1038/sj.onc.1208058			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	860GX	15334059				2022-12-17	WOS:000224331600003
J	Nishikawa, T; Munshi, A; Story, MD; Ismail, S; Stevens, C; Chada, S; Meyn, RE				Nishikawa, T; Munshi, A; Story, MD; Ismail, S; Stevens, C; Chada, S; Meyn, RE			Adenoviral-mediated mda-7 expression suppresses DNA repair capacity and radiosensitizes non-small-cell lung cancer cells	ONCOGENE			English	Article						adenovirus; mda-7; radiation; lung cancer; DNA repair; nonhomologous end-joining	DIFFERENTIATION-ASSOCIATED GENE-7; DEPENDENT-PROTEIN-KINASE; DOUBLE-STRAND BREAKS; MELANOMA DIFFERENTIATION; LIGASE-IV; CATALYTIC SUBUNIT; CRYSTAL-STRUCTURE; RADIATION; APOPTOSIS; GROWTH	The melanoma differentiation-associated gene-7 (mda-7) was identified by virtue of its enhanced expression in human melanoma cells induced into terminal differentiation. Enforced expression of mda-7 in human cancer cell lines of diverse origins results in the suppression of growth and induction of apoptosis. We have shown that adenoviral-mediated mda-7 (Ad-mda7) radiosensitizes non-small-cell lung cancer (NSCLC) cells by enhancing the apoptotic pathway. To identify the mechanism of this radiosensitization, we examined the level of proteins involved in the nonhomologous end-joining (NHEJ) pathway of DNA double-strand break (DSB) repair. Western blot analysis indicated that the expression of NHEJ pathway components Ku70, XRCC4, and DNA ligase IV was downregulated in NSCLC cells - A549 with Ad-mda7 treatment. No such change was observed in normal human CCD16 fibroblasts previously shown not to be radiosensitized by Ad-mda7. The biological significance of these changes of expression of proteins critical for repair of radiation-induced DSBs was confirmed via the analysis of DSB rejoining kinetics using pulsed field gel electrophoresis and assessment of host cell reactivation capacity following Ad-mda7 treatment. Based on these results, we hypothesize that Ad-mda7 sensitizes NSCLC cells to ionizing radiation by suppressing the activity of NHEJ, a pathway essential for repair of radiation-induced DSBs.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Unit 66, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA; Introgen Therapeut Inc, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Meyn, RE (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Unit 66, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rmeyn@mdanderson.org	Story, Michael/AAX-2864-2021	Story, Michael/0000-0001-6522-4169	NATIONAL CANCER INSTITUTE [P01CA078778, P30CA016672, P01CA006294, R41CA088421] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA16672, R41 CA88421, P01 CA78778, P01 CA06294] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLALUNISTURNER MJ, 1993, RADIAT RES, V134, P349, DOI 10.2307/3578196; Blumberg H, 2001, CELL, V104, P9, DOI 10.1016/S0092-8674(01)00187-8; Bryans M, 1999, MUTAT RES-DNA REPAIR, V433, P53, DOI 10.1016/S0921-8777(98)00063-9; Collis SJ, 2003, CANCER RES, V63, P1550; Critchlow SE, 1998, TRENDS BIOCHEM SCI, V23, P394, DOI 10.1016/S0968-0004(98)01284-5; EADY JJ, 1992, BRIT J CANCER, V66, P113, DOI 10.1038/bjc.1992.226; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Gu YS, 1997, P NATL ACAD SCI USA, V94, P8076, DOI 10.1073/pnas.94.15.8076; Haber JE, 2000, TRENDS GENET, V16, P259, DOI 10.1016/S0168-9525(00)02022-9; Hopfner KP, 2002, CURR OPIN STRUC BIOL, V12, P115, DOI 10.1016/S0959-440X(02)00297-X; Huang EY, 2001, ONCOGENE, V20, P7051, DOI 10.1038/sj.onc.1204897; Jeggo PA, 1998, RADIAT RES, V150, pS80, DOI 10.2307/3579810; Jiang HP, 1995, ONCOGENE, V11, P2477; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P9160, DOI 10.1073/pnas.93.17.9160; Junop MS, 2000, EMBO J, V19, P5962, DOI 10.1093/emboj/19.22.5962; Kawabe S, 2002, MOL THER, V6, P637, DOI 10.1006/mthe.2002.0714; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kurimasa A, 1999, MOL CELL BIOL, V19, P3877; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Li GC, 2003, CANCER RES, V63, P3268; Lieber MR, 1999, GENES CELLS, V4, P77, DOI 10.1046/j.1365-2443.1999.00245.x; McDonald E, 1996, CANCER RES, V56, P2250; Mhashilkar AM, 2001, MOL MED, V7, P271, DOI 10.1007/BF03401847; Olive PL, 1998, RADIAT RES, V150, pS42, DOI 10.2307/3579807; Omori S, 2002, DNA REPAIR, V1, P299, DOI 10.1016/S1568-7864(02)00006-X; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Pataer A, 2002, CANCER RES, V62, P2239; Peng YL, 2002, CANCER RES, V62, P6400; RAINBOW AJ, 1972, RADIAT RES, V50, P319, DOI 10.2307/3573492; RAINBOW AJ, 1974, RADIAT RES, V60, P155, DOI 10.2307/3574013; Riballo E, 1999, CURR BIOL, V9, P699, DOI 10.1016/S0960-9822(99)80311-X; Sado K, 2001, J BIOL CHEM, V276, P9742, DOI 10.1074/jbc.M010530200; Saeki T, 2002, ONCOGENE, V21, P4558, DOI 10.1038/sj.onc.1205553; Saeki T, 2000, GENE THER, V7, P2051, DOI 10.1038/sj.gt.3301330; Sarkar D, 2002, P NATL ACAD SCI USA, V99, P10054, DOI 10.1073/pnas.152327199; Sibanda BL, 2001, NAT STRUCT BIOL, V8, P1015, DOI 10.1038/nsb725; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; STORY MD, 1994, INT J RADIAT BIOL, V65, P523, DOI 10.1080/09553009414550611; Su ZZ, 2003, ONCOGENE, V22, P1164, DOI 10.1038/sj.onc.1206062; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000	40	25	36	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2004	23	42					7125	7131		10.1038/sj.onc.1207917	http://dx.doi.org/10.1038/sj.onc.1207917			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	854EX	15273727				2022-12-17	WOS:000223885100013
J	Bakhanashvili, M; Novitsky, E; Lilling, G; Rahav, G				Bakhanashvili, M; Novitsky, E; Lilling, G; Rahav, G			P53 in cytoplasm may enhance the accuracy of DNA synthesis by human immunodeficiency virus type 1 reverse transcriptase	ONCOGENE			English	Article							ESCHERICHIA-COLI; POLYMERASE-ALPHA; MUTATION-RATE; IN-VITRO; FIDELITY; PROTEIN; EXPRESSION; CELLS; REPLICATION; EXTENSION	The tumor suppressor protein p53 displays 3'-->5' exonuclease activity and can provide a proofreading function for DNA polymerases. Reverse transcriptase (RT) of human immunodeficiency virus (HIV)-1 is responsible for the conversion of the viral genomic ssRNA into the proviral DNA in the cytoplasm. The relatively low fidelity of HIV-1 RT was implicated as a dominant factor contributing to the genetic variability of the virus. The lack of intrinsic 3'-->5' exonuclease activity, the formation of 3'-mispaired DNA and the subsequent extension of this DNA were shown to be determinants for the low fidelity of HIV-1 RT. It was of interest to analyse whether the cytoplasmic proteins may affect the accuracy of DNA synthesis by RT. We investigated the fidelity of DNA synthesis by HIV-1 RT with and without exonucleolytic proofreading provided by cytoplasmic fraction of LCC2 cells expressing high level of wild-type functional p53. Two basic features related to fidelity of DNA synthesis were studied: the misinsertion and mispair extension. The misincorporation of noncomplementary deoxynucleotides into nascent DNA and subsequent mispair extension by HIV-1 RT were substantially decreased in the presence of cytoplasmic fraction of LCC2 cells with both RNA/DNA and DNA/DNA template-primers with the same target sequence. The mispair extension frequencies obtained with the HIV-1 RT in the presence of cytoplasmic fraction of LCC2 cells were significantly lower (about 2.8-15-fold) than those detected with the purified enzyme. In addition, the productive interaction between polymerization ( by HIV-1 RT) and exonuclease ( by p53 in cytoplasm) activities was observed; p53 preferentially hydrolyses mispaired 3'-termini, permitting subsequent extension of the correctly paired 3'-terminus by HIV-1 RT. The data suggest that p53 in cytoplasm may affect the accuracy of DNA replication and the mutation spectra of HIV-1 RT by acting as an external proofreader. Furthermore, the decrease in error-prone DNA synthesis with RT in the presence of external exonuclease, provided by cytoplasmic p53, may partially account for lower mutation rate of HIV-1 observed in vivo.	Chaim Sheba Med Ctr, Infect Dis Unit, IL-52621 Tel Hashomer, Israel; Chaim Sheba Med Ctr, Dept Med C, IL-52621 Tel Hashomer, Israel; Chaim Sheba Med Ctr, Lab Expt Chemotherapy, IL-52621 Tel Hashomer, Israel; Bar Ilan Univ, Fac Life Sci, Ramat Gan, Israel	Chaim Sheba Medical Center; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Bar Ilan University	Bakhanashvili, M (corresponding author), Chaim Sheba Med Ctr, Infect Dis Unit, IL-52621 Tel Hashomer, Israel.	bakhanus@yahoo.com						Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; Bakhanashvili M, 1996, ARCH BIOCHEM BIOPHYS, V334, P89, DOI 10.1006/abbi.1996.0433; BAKHANASHVILI M, 1992, FEBS LETT, V306, P151, DOI 10.1016/0014-5793(92)80988-S; BAKHANASHVILI M, 1992, BIOCHEMISTRY-US, V31, P9393, DOI 10.1021/bi00154a010; Bakhanashvili M, 2001, EUR J BIOCHEM, V268, P2047, DOI 10.1046/j.1432-1327.2001.02075.x; BAKHANASHVILI M, 1993, BIOCHEMISTRY-US, V32, P7559, DOI 10.1021/bi00080a030; Bakhanashvili M, 2001, ONCOGENE, V20, P7635, DOI 10.1038/sj.onc.1204956; Bouhamdan M, 1996, J VIROL, V70, P697, DOI 10.1128/JVI.70.2.697-704.1996; CLARK PK, 1990, AIDS RES HUM RETROV, V6, P753, DOI 10.1089/aid.1990.6.753; COFFIN JM, 1986, CELL, V46, P1, DOI 10.1016/0092-8674(86)90851-2; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.bi.60.070191.002401; Genini D, 2001, FASEB J, V15, P5; Gila L, 2003, ONCOGENE, V22, P233, DOI 10.1038/sj.onc.1206111; Goodman MF, 1998, GENETICS, V148, P1475; GRAND RJA, 1994, VIROLOGY, V203, P229, DOI 10.1006/viro.1994.1480; HIZI A, 1988, P NATL ACAD SCI USA, V85, P1218, DOI 10.1073/pnas.85.4.1218; HOWLEY PM, 1991, CANCER RES, V51, pS5019; Huang P, 1998, ONCOGENE, V17, P261, DOI 10.1038/sj.onc.1201946; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; KATZ RA, 1990, ANNU REV GENET, V24, P409, DOI 10.1146/annurev.ge.24.120190.002205; KUNKEL TA, 1988, CELL, V53, P837, DOI 10.1016/S0092-8674(88)90189-4; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; MANSKY LM, 1995, J VIROL, V69, P5087, DOI 10.1128/JVI.69.8.5087-5094.1995; Mansky LM, 1996, VIROLOGY, V222, P391, DOI 10.1006/viro.1996.0436; Mansky LM, 1997, TRENDS GENET, V13, P134, DOI 10.1016/S0168-9525(97)01062-7; Melle C, 2002, NUCLEIC ACIDS RES, V30, P1493, DOI 10.1093/nar/30.7.1493; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; Menendez-Arias L, 2002, PROG NUCLEIC ACID RE, V71, P91, DOI 10.1016/S0079-6603(02)71042-8; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; Nermut MV, 2003, J VIROL, V77, P8196, DOI 10.1128/JVI.77.15.8196-8206.2003; Offer H, 2001, ONCOGENE, V20, P581, DOI 10.1038/sj.onc.1204120; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PERRINO FW, 1989, P NATL ACAD SCI USA, V86, P8343, DOI 10.1073/pnas.86.21.8343; Prives C, 1999, J PATHOL, V187, P112; Shaheen F, 1996, J VIROL, V70, P3392, DOI 10.1128/JVI.70.6.3392-3400.1996; Shakked Z, 2002, ONCOGENE, V21, P5117, DOI 10.1038/sj.onc.1205667; Shevelev IV, 2002, NAT REV MOL CELL BIO, V3, P364, DOI 10.1038/nrm804; Skalski V, 2000, ONCOGENE, V19, P3321, DOI 10.1038/sj.onc.1203649; Sluis-Cremer N, 2000, CELL MOL LIFE SCI, V57, P1408, DOI 10.1007/PL00000626; Soussi T, 2000, ANN NY ACAD SCI, V910, P121; Svarovskaia ES, 2003, FRONT BIOSCI-LANDMRK, V8, pD117, DOI 10.2741/957; SZEKELY L, 1995, ONCOGENE, V10, P1869; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; Zhang H, 1996, J VIROL, V70, P2809, DOI 10.1128/JVI.70.5.2809-2824.1996	44	25	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2004	23	41					6890	6899		10.1038/sj.onc.1207846	http://dx.doi.org/10.1038/sj.onc.1207846			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	852JD	15286711				2022-12-17	WOS:000223750700006
J	Pawar, SA; Szentirmay, MN; Hermeking, H; Sawadogo, M				Pawar, SA; Szentirmay, MN; Hermeking, H; Sawadogo, M			Evidence for a cancer-specific switch at the CDK4 promoter with loss of control by both USF and c-Myc	ONCOGENE			English	Article						USF; c-Myc; CDK4; breast cancer; promoter; transcription activation; E box; dominant-negative mutants; mammary epithelial cells	TRANSCRIPTION FACTOR USF; DNA-BINDING; ACTIVATES TRANSCRIPTION; DEPENDENT KINASES; PROTEIN; CELLS; GENE; EXPRESSION; PROLIFERATION; UPSTREAM	USF and c-Myc are basic helix-loop-helix transcription factors with similar DNA-binding specificities, but antagonistic effects on cellular transformation. In order to determine how these opposite functions correlate with the transcriptional activities of the two factors on particular downstream targets, we investigated the roles of USF and c-Myc in expression of CDK4, a known direct target of cMyc. Overexpression of either c-Myc or USF2, but not USF1, stimulated the expression of CDK4 promoter-driven reporter genes in the non-tumorigenic mammary epithelial MCF-10A cells. Dominant-negative mutants specific to either Myc or USF family proteins inhibited reporter gene activity as well as endogenous CDK4 expression, demonstrating involvement of both USF and Myc in CDK4 transcriptional control. In contrast, in two different breast cancer cell lines where USF is transcriptionally inactive and c-Myc is overexpressed, CDK4 promoter activity was no longer responsive to either transcription factor. Accordingly, chromatin immunoprecipitation revealed significantly lower levels of both USF and c-Myc bound to the endogenous CDK4 promoter in breast cancer cells than in MCF-10A cells, with a concomitant decrease in associated histone H3 acetylation. These results suggest that a major switch in the transcriptional control of CDK4 occurs during breast carcinogenesis, with likely alteration of cell cycle regulation.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Max Planck Inst Biochem, D-82152 Martinsried, Germany	University of Texas System; UTMD Anderson Cancer Center; Max Planck Society	Sawadogo, M (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, 1515 Holcombe Blvd, Houston, TX 77030 USA.	msawadog@mdanderson.org	Pawar, Snehalata/ABD-4557-2020	Pawar, Snehalata/0000-0003-3992-2494	NATIONAL CANCER INSTITUTE [P30CA016672, R01CA079578] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, CA79578] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		An HX, 1999, AM J PATHOL, V154, P113, DOI 10.1016/S0002-9440(10)65257-1; Athanikar JN, 1998, P NATL ACAD SCI USA, V95, P4935, DOI 10.1073/pnas.95.9.4935; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENDALL AJ, 1994, NUCLEIC ACIDS RES, V22, P2801, DOI 10.1093/nar/22.14.2801; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; Dang CV, 1999, MOL CELL BIOL, V19, P1; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; FISHER DE, 1991, GENE DEV, V5, P2342, DOI 10.1101/gad.5.12a.2342; Hadsell DL, 2003, MOL ENDOCRINOL, V17, P2251, DOI 10.1210/me.2002-0031; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HARPER JW, 1993, CELL, V75, P805; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Hurlin PJ, 2003, EMBO J, V22, P4584, DOI 10.1093/emboj/cdg442; Ismail PM, 1999, ONCOGENE, V18, P5582, DOI 10.1038/sj.onc.1202932; Ito, 1996, Breast Cancer, V3, P93, DOI 10.1007/BF02966969; KIRSCHBAUM BJ, 1992, MOL CELL BIOL, V12, P5094, DOI 10.1128/MCB.12.11.5094; Krylov D, 1997, P NATL ACAD SCI USA, V94, P12274, DOI 10.1073/pnas.94.23.12274; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; Lazarov M, 2002, NAT MED, V8, P1105, DOI 10.1038/nm779; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; Luo X, 1996, MOL CELL BIOL, V16, P1367; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; PERSSON H, 1985, MOL CELL BIOL, V5, P2903, DOI 10.1128/MCB.5.11.2903; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Qyang YB, 1999, MOL CELL BIOL, V19, P1508; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; Rodriguez-Puebla ML, 2002, AM J PATHOL, V161, P405, DOI 10.1016/S0002-9440(10)64196-X; Sasano H, 1997, ANTICANCER RES, V17, P3685; SAWADOGO M, 1988, J BIOL CHEM, V263, P11994; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sirito M, 1998, P NATL ACAD SCI USA, V95, P3758, DOI 10.1073/pnas.95.7.3758; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Sotillo R, 2001, EMBO J, V20, P6637, DOI 10.1093/emboj/20.23.6637; Swanson HI, 1999, NUCLEIC ACIDS RES, V27, P3205, DOI 10.1093/nar/27.15.3205; Szentirmay MN, 2003, J BIOL CHEM, V278, P37231, DOI 10.1074/jbc.M305791200; Tsutsui T, 1999, MOL CELL BIOL, V19, P7011; VANDYKE MW, 1992, GENE, V111, P99, DOI 10.1016/0378-1119(92)90608-R; Weissman JDJ, 2000, J BIOL CHEM, V275, P10160, DOI 10.1074/jbc.275.14.10160; YASUMOTO KI, 1994, MOL CELL BIOL, V14, P8058, DOI 10.1128/MCB.14.12.8058; Zou XH, 2002, GENE DEV, V16, P2923, DOI 10.1101/gad.1033002	45	25	27	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6125	6135		10.1038/sj.onc.1207806	http://dx.doi.org/10.1038/sj.onc.1207806			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15208653				2022-12-17	WOS:000223261000012
J	Meyer, RD; Singh, A; Majnoun, F; Latz, C; Lashkari, K; Rahimi, N				Meyer, RD; Singh, A; Majnoun, F; Latz, C; Lashkari, K; Rahimi, N			Substitution of C-terminus of VEGFR-2 with VEGFR-1 promotes VEGFR-1 activation and endothelial cell proliferation	ONCOGENE			English	Article						VEGFR-1; VEGFR-2; angiogenesis; tyrosine kinase activation; tyrosine phosphorylation; endothelial cells	GROWTH-FACTOR RECEPTOR; TYROSINE KINASE; SIGNAL-TRANSDUCTION; CARBOXYL-TERMINUS; FLT-1 VEGFR-1; KDR; DOMAIN; PHOSPHORYLATION; ANGIOGENESIS; NEUROPILIN-1	VEGFR-1 is devoid of ligand-dependent tyrosine autophosphorylation and its activation is not associated with proliferation of endothelial cells. The molecular mechanism responsible for this characteristic of VEGFR-1 is not known. In this study, we show that VEGFR-1 is devoid of ligand-dependent downregulation and failed to stimulate intracellular calcium release, cell migration and angiogenesis in vitro. To understand the molecular mechanisms responsible for the poor tyrosine autophosphorylation of VEGFR-1, we have either deleted the carboxyl terminus of VEGFR-1 or exchanged it with the carboxyl terminus of VEGFR-2. The deletion of carboxyl terminus of VEGFR-1 did not reverse its defective ligand-dependent autophosphorylation. The carboxyl terminus-swapped VEGFR-1, however, displayed ligand-dependent autophosphorylation, downregulation and also conveyed strong mitogenic responses. Thus, the carboxyl tail of VEGFR-1 restrains the ligand-dependent kinase activation and. downregulation of VEGFR-1 and its ability to convey the angiogenic responses in endothelial cells.	Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Harvard Univ, Sch Med, Dept Ophthalmol, Schepens Eye Res Inst, Boston, MA 02114 USA	Boston University; Boston University; Harvard University; Harvard Medical School; Schepens Eye Research Institute	Rahimi, N (corresponding author), Boston Univ, Sch Med, Dept Ophthalmol, 715 Albany St,Room 921L, Boston, MA 02118 USA.	nrahimi@bu.edu	Latz, Catharina/AAM-9079-2020	Rahimi, Nader/0000-0002-6745-1725; Lashkari, Kameran/0000-0003-3855-0246	NEI NIH HHS [EY 0137061, EY 012997, R03 EY013706, R01 EY012997] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012997, R03EY013706] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALIMANDI M, 1995, ONCOGENE, V10, P1813; Athanassiades A, 1998, PLACENTA, V19, P465, DOI 10.1016/S0143-4004(98)91039-6; Autiero M, 2003, NAT MED, V9, P936, DOI 10.1038/nm884; Breier G, 2000, ADV EXP MED BIOL, V476, P57; CHOU YH, 1991, P NATL ACAD SCI USA, V88, P4897, DOI 10.1073/pnas.88.11.4897; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fong GH, 1999, DEVELOPMENT, V126, P3015; Gille H, 2001, J BIOL CHEM, V276, P3222, DOI 10.1074/jbc.M002016200; Gille H, 2000, EMBO J, V19, P4064, DOI 10.1093/emboj/19.15.4064; Gruenberg J, 2001, NAT REV MOL CELL BIO, V2, P721, DOI 10.1038/35096054; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; Kanno S, 2000, ONCOGENE, V19, P2138, DOI 10.1038/sj.onc.1203533; Kearney JB, 2002, BLOOD, V99, P2397, DOI 10.1182/blood.V99.7.2397; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Klepeis VE, 2001, J CELL SCI, V114, P4185; Korff T, 1999, J CELL SCI, V112, P3249; Lee P, 2002, P NATL ACAD SCI USA, V99, P10470, DOI 10.1073/pnas.162366299; LI W, 1991, CELL REGUL, V2, P641, DOI 10.1091/mbc.2.8.641; Mashiba S, 1999, BIOCHEM BIOPH RES CO, V258, P674, DOI 10.1006/bbrc.1999.0611; Meyer RD, 2004, J BIOL CHEM, V279, P735, DOI 10.1074/jbc.M305575200; Meyer RD, 2003, J BIOL CHEM, V278, P16347, DOI 10.1074/jbc.M300259200; Meyer RD, 2002, J BIOL CHEM, V277, P27081, DOI 10.1074/jbc.M110544200; MOSSIE K, 1995, ONCOGENE, V11, P2179; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Neufeld G, 1996, CANCER METAST REV, V15, P153, DOI 10.1007/BF00437467; Niu XL, 2002, J BIOL CHEM, V277, P31768, DOI 10.1074/jbc.M203995200; Parks AL, 2000, DEVELOPMENT, V127, P1373; Rahimi N, 2000, J BIOL CHEM, V275, P16986, DOI 10.1074/jbc.M000528200; SEEDORF K, 1992, MOL CELL BIOL, V12, P4347, DOI 10.1128/MCB.12.10.4347; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shibuya M, 2001, CELL STRUCT FUNCT, V26, P25, DOI 10.1247/csf.26.25; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Suarez S, 2001, J CELL SCI, V114, P1229; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WALTON GM, 1990, J BIOL CHEM, V265, P1750; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Zeng HY, 2003, J BIOL CHEM, V278, P20738, DOI 10.1074/jbc.M209712200	45	25	25	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2004	23	32					5523	5531		10.1038/sj.onc.1207712	http://dx.doi.org/10.1038/sj.onc.1207712			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15107818	Green Accepted			2022-12-17	WOS:000222588400012
J	Thomas-Mudge, RJ; Okada-Ban, M; Vandenbroucke, F; Vincent-Salomon, A; Girault, JM; Thiery, JP; Jouanneau, J				Thomas-Mudge, RJ; Okada-Ban, M; Vandenbroucke, F; Vincent-Salomon, A; Girault, JM; Thiery, JP; Jouanneau, J			Nuclear FGF-2 facilitates cell survival in vitro and during establishment of metastases	ONCOGENE			English	Article						nuclear FGF-2; metastases; apoptosis; survival	FIBROBLAST-GROWTH-FACTOR; GREEN FLUORESCENT PROTEIN; BLADDER-CARCINOMA CELLS; KINASE-C-DELTA; CANCER CELLS; REGULATES BCL-2; MELANOMA-CELLS; TUMOR-CELLS; FACTOR BFGF; EXPRESSION	Nuclear-targeted high molecular weight 24 kDa fibroblast growth factor 2 (FGF-2) may induce specific cell functions through intracrine mechanisms. The role of nuclear FGF-2 on the metastatic potential of carcinoma cells was examined by conditional FGF-2 expression, which demonstrated that spontaneous metastasis in nude mice is a direct consequence of its expression. The lung colonizing capacities of fluorescent nuclear FGF-2-expressing cells following intravenous injection was also investigated. All cells reaching the lung extravasated as soon as 5 min following injection with similar in vivo behavior during the first 24 h. However, after 2 days, dramatic differences were observed between the FGF-2 and parental cells: most control cells underwent apoptosis, while the FGF-2-producing cells instigated a survival program and proliferated. Therefore, sustained apoptosis in vivo prevents growth of metastatic foci, while nuclear FGF-2 induction of a survival program is responsible for growth of the lung metastases. In vitro serum deprivation assays also established that 24 kDa FGF-2 expression improves carcinoma cell survival. This study provides both in vitro and in vivo evidence that the role of the nuclear 24kDa FGF-2 isoform in carcinoma is the promotion of cell survival, thereby defining its association with poor prognosis in some human carcinomas.	Inst Curie, Div Res, CNRS, UMR 144, F-75248 Paris 05, France; Inst Curie, Div Med, Dept Biol, F-75248 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Jouanneau, J (corresponding author), Inst Curie, Div Res, CNRS, UMR 144, F-75248 Paris 05, France.	Jacqueline.Jounneau@curie.fr	Thiery, Jean Paul/M-9387-2019; Thiery, Jean Paul/H-1550-2011	Thiery, Jean Paul/0000-0003-0478-5020; Mudge, Rachel/0000-0002-5727-3240				Al-Mehdi AB, 2000, NAT MED, V6, P100, DOI 10.1038/71429; Arnaud E, 1999, MOL CELL BIOL, V19, P505; Boelaert K, 2003, J CLIN ENDOCR METAB, V88, P2341, DOI 10.1210/jc.2002-021113; Bold RJ, 2001, CANCER-AM CANCER SOC, V92, P1122, DOI 10.1002/1097-0142(20010901)92:5<1122::AID-CNCR1429>3.0.CO;2-H; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; Cameron MD, 2000, CANCER RES, V60, P2541; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Delrieu I, 2000, FEBS LETT, V468, P6, DOI 10.1016/S0014-5793(00)01189-3; Farina KL, 1998, CANCER RES, V58, P2528; Fukui S, 2003, CANCER, V97, P3061, DOI 10.1002/cncr.11450; Fukui S, 2002, J NEURO-ONCOL, V57, P221, DOI 10.1023/A:1015763725104; Funato N, 1997, BIOCHEM BIOPH RES CO, V240, P21, DOI 10.1006/bbrc.1997.7588; Gaubert F, 2001, J BIOL CHEM, V276, P1545, DOI 10.1074/jbc.M001184200; Giavazzi R, 2001, CANCER RES, V61, P309; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gualandris A, 1999, J CELL PHYSIOL, V181, P273, DOI 10.1002/(SICI)1097-4652(199911)181:2<273::AID-JCP9>3.0.CO;2-#; Hajihosseini MK, 1999, MOL CELL NEUROSCI, V14, P468, DOI 10.1006/mcne.1999.0800; Karsan A, 1997, AM J PATHOL, V151, P1775; Konig A, 1997, LEUKEMIA, V11, P258, DOI 10.1038/sj.leu.2400556; KOOP S, 1995, CANCER RES, V55, P2520; Luzzi KJ, 1998, AM J PATHOL, V153, P865, DOI 10.1016/S0002-9440(10)65628-3; Maloof P, 1999, BREAST CANCER RES TR, V56, P153; Miyake H, 1999, BRIT J CANCER, V79, P1651, DOI 10.1038/sj.bjc.6690264; Naumov GN, 1999, J CELL SCI, V112, P1835; Okada-Ban M, 1999, ONCOGENE, V18, P6719, DOI 10.1038/sj.onc.1203092; Okada-Ban M, 2000, INT J BIOCHEM CELL B, V32, P263, DOI 10.1016/S1357-2725(99)00133-8; Pardo OE, 2002, J BIOL CHEM, V277, P12040, DOI 10.1074/jbc.M109006200; Pardo OE, 2003, MOL CELL BIOL, V23, P7600, DOI 10.1128/MCB.23.21.7600-7610.2003; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Rosini P, 2002, PROSTATE, V53, P310, DOI 10.1002/pros.10164; SAVAGNER P, 1994, MOL BIOL CELL, V5, P851, DOI 10.1091/mbc.5.8.851; Sun CP, 2001, J CELL PHYSIOL, V186, P457, DOI 10.1002/1097-4652(2000)9999:999<000::AID-JCP1044>3.0.CO;2-2; Takaoka A, 1997, ONCOGENE, V14, P2971, DOI 10.1038/sj.onc.1201147; TOYOSHIMA K, 1971, JNCI-J NATL CANCER I, V47, P979; Van den Berghe L, 2000, MOL ENDOCRINOL, V14, P1709, DOI 10.1210/me.14.11.1709; Wert MM, 2000, BIOCHEM J, V352, P175, DOI 10.1042/0264-6021:3520175; Wieder R, 1997, GROWTH FACTORS, V15, P41, DOI 10.3109/08977199709002111; Wong CW, 2001, CANCER RES, V61, P333	38	25	26	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2004	23	27					4771	4779		10.1038/sj.onc.1207638	http://dx.doi.org/10.1038/sj.onc.1207638			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZX	15122340				2022-12-17	WOS:000221799200012
J	Schmitt, E; Paquet, C; Beauchemin, M; Bertrand, R				Schmitt, E; Paquet, C; Beauchemin, M; Bertrand, R			Bcl-xES, a BH4-and BH2-containing antiapoptotic protein, delays Bax oligomer formation and binds Apaf-1, blocking procaspase-9 activation	ONCOGENE			English	Review						Bcl-x; Bax; Apaf-1; caspase; apoptosis	INNER MITOCHONDRIAL-MEMBRANE; DEPENDENT ANION CHANNEL; PROGRAMMED CELL-DEATH; CYTOCHROME-C RELEASE; FAMILY-MEMBERS; X-L; PROMOTES APOPTOSIS; BH4 DOMAIN; CASPASE ACTIVATION; CONSERVED DOMAINS	Bcl-2 family members either negatively or positively regulate the apoptotic threshold of cells. Bcl-xES ( extra short), a novel Bcl-x member, possesses a unique combination of BH4 and BH2 domains as well as a COOH-terminal hydrophobic transmembrane anchor domain. Bcl-xES contains sequences of hydrophobic alpha-6 helices but lacks sequences of alpha-5 helices, suggesting that it does not have pore channel-forming activity but functions uniquely as a trapping protein. mRNA expression analysis by reverse transcriptase-polymerase chain reaction and RNase protection assay reveal that Bcl-xES is expressed in a variety of human cancer cell lines and human tumors, including bone marrow from patients with acute lymphoblastic leukemia. Bcl-xES expression is much less pronounced in some specimens of normal human tissues, including the breast, ovary, testis and lung. Stable, transfected human B lymphoma Namalwa variant cells expressing Bcl-xES were derived to investigate its role in apoptosis. Bcl-xES had a preventive effect on cell death induced by tumor necrosis factor-alpha and various concentrations of anticancer drugs, including camptothecin, etoposide and cisplatin. Its protective action on cell death was correlated with the inhibition of mitochondrial cytochrome c release and caspase activation. In a yeast two-hybrid system, Bcl-xES interacted with most Bcl-2 family members, including those containing only a BH3 domain, and with the Ced-4 homolog Apaf-1. Co-immunoprecipitation and gel filtration chromatography experiments suggest that Bcl-xES delays drug-induced apoptosis by disturbing the formation of Bax oligomers and preventing cytochrome c release, but also by interacting with Apaf-1 and inhibiting procaspase-9 activation, thus averting the apoptogenic proteolytic caspase cascade and cell death.	Univ Montreal, Notre Dame Hosp, Ctr Hosp, Ctr Rech, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Inst Canc Montreal, Montreal, PQ H2L 4M1, Canada	Universite de Montreal; Universite de Montreal	Bertrand, R (corresponding author), Univ Montreal, Notre Dame Hosp, Ctr Hosp, Ctr Rech, 1560 Sherbrooke St E,Room Y-5634, Montreal, PQ H2L 4M1, Canada.	richard.bertrand@umontreal.ca						Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; APTE SS, 1995, GENOMICS, V26, P592, DOI 10.1016/0888-7543(95)80180-T; Ban J, 1998, BIOCHEM BIOPH RES CO, V248, P147, DOI 10.1006/bbrc.1998.8907; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; BERTRAND R, 1991, CANCER RES, V51, P6280; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; Bottero V, 2001, J BIOL CHEM, V276, P21317, DOI 10.1074/jbc.M005850200; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Cain K, 1999, J BIOL CHEM, V274, P22686, DOI 10.1074/jbc.274.32.22686; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chaudhary D, 1998, J BIOL CHEM, V273, P17708, DOI 10.1074/jbc.273.28.17708; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Conus S, 2000, CELL DEATH DIFFER, V7, P947, DOI 10.1038/sj.cdd.4400729; de Moissac D, 1999, J BIOL CHEM, V274, P29505, DOI 10.1074/jbc.274.41.29505; Droin N, 2000, CANCER RES, V60, P7039; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Franke TF, 1997, NATURE, V390, P116, DOI 10.1038/36442; Garrido C, 1999, FASEB J, V13, P2061, DOI 10.1096/fasebj.13.14.2061; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Guo B, 2001, J BIOL CHEM, V276, P2780, DOI 10.1074/jbc.M005889200; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; Haraguchi M, 2000, J EXP MED, V191, P1709, DOI 10.1084/jem.191.10.1709; Hausmann G, 2000, J CELL BIOL, V149, P623, DOI 10.1083/jcb.149.3.623; He HL, 1998, J IMMUNOL, V161, P1169; Hsu SY, 1998, J BIOL CHEM, V273, P30139, DOI 10.1074/jbc.273.46.30139; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Huang DCS, 1998, EMBO J, V17, P1029, DOI 10.1093/emboj/17.4.1029; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; Inohara N, 1998, J BIOL CHEM, V273, P32479, DOI 10.1074/jbc.273.49.32479; Jia L, 2001, ONCOGENE, V20, P4817, DOI 10.1038/sj.onc.1204628; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Makin GWJ, 2001, EMBO J, V20, P6306, DOI 10.1093/emboj/20.22.6306; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Miyashita MUT, 2001, FEBS LETT, V509, P135, DOI 10.1016/S0014-5793(01)03145-3; Moriishi K, 1999, P NATL ACAD SCI USA, V96, P9683, DOI 10.1073/pnas.96.17.9683; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; Newmeyer DD, 2000, CELL DEATH DIFFER, V7, P402, DOI 10.1038/sj.cdd.4400665; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Parrish J, 2001, NATURE, V412, P90, DOI 10.1038/35083608; Pavlov EV, 2001, J CELL BIOL, V155, P725, DOI 10.1083/jcb.200107057; Qin HX, 1999, NATURE, V399, P549, DOI 10.1038/21124; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schmitt E, 1998, CELL DEATH DIFFER, V5, P506, DOI 10.1038/sj.cdd.4400376; Schmitt E, 1998, EXP CELL RES, V240, P107, DOI 10.1006/excr.1998.4003; Schmitt E, 2000, BIOCHEM BIOPH RES CO, V270, P868, DOI 10.1006/bbrc.2000.2537; Seshagiri S, 1997, CURR BIOL, V7, P455, DOI 10.1016/S0960-9822(06)00216-8; Shi B, 1999, BIOCHEM BIOPH RES CO, V254, P779, DOI 10.1006/bbrc.1998.0130; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Song QZ, 1999, EMBO J, V18, P167, DOI 10.1093/emboj/18.1.167; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Wu DY, 1997, J BIOL CHEM, V272, P21449, DOI 10.1074/jbc.272.34.21449; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang XF, 1997, IMMUNITY, V7, P629, DOI 10.1016/S1074-7613(00)80384-2; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zhang H, 1999, FEBS LETT, V448, P23, DOI 10.1016/S0014-5793(99)00335-X; Zhao YG, 2001, J BIOL CHEM, V276, P27432, DOI 10.1074/jbc.M102465200; Zhou M, 1998, J BIOL CHEM, V273, P11930, DOI 10.1074/jbc.273.19.11930; Zhou P, 1999, P NATL ACAD SCI USA, V96, P11265, DOI 10.1073/pnas.96.20.11265; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601; ZORATTI M, 1994, J BIOENERG BIOMEMBR, V26, P543, DOI 10.1007/BF00762739; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	103	25	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					3915	3931		10.1038/sj.onc.1207554	http://dx.doi.org/10.1038/sj.onc.1207554			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15048082				2022-12-17	WOS:000221382000004
J	Liu, H; Chen, B; Xiong, H; Huang, QH; Zhang, QH; Wang, ZG; Li, BL; Chen, Z; Chen, SJ				Liu, H; Chen, B; Xiong, H; Huang, QH; Zhang, QH; Wang, ZG; Li, BL; Chen, Z; Chen, SJ			Functional contribution of EEN to leukemogenic transformation by MLL-EEN fusion protein	ONCOGENE			English	Article						MLL-EEN; transcriptional factor; HoxA7; leukemogenesis	LEUKEMIA-CELL LINE; SYNAPTIC VESICLE ENDOCYTOSIS; CENTRAL-NERVOUS-SYSTEM; HOMOLOGY 3 DOMAIN; MYELOID PROGENITORS; DOWN-REGULATION; ANTISENSE OLIGODEOXYRIBONUCLEOTIDE; CHROMOSOMAL TRANSLOCATION; ONCOGENIC ACTIVATION; BINDING PARTNERS	The EEN (extra eleven nineteen) gene was originally cloned from a case of acute myeloid leukemia M5 subtype with translocation t (11;19)(q23; p13), in which EEN was fused with MLL. To explore the involvement of EEN in leukemogenesis caused by MLL-EEN, we studied the transformation potential of the MLL-EEN fusion protein. MLL-EEN had oncogenic features, while, as a control, MLLDelta, the truncated form of MLL lacking the EEN moiety, did not show any oncogenic potential. MLL-EEN exerted a dominant-negative effect over wild-type EEN in terms of subcellular localization. Normally, EEN was found in the cytoplasm, but the MLL-EEN fusion protein was located in the nucleus, and EEN could be delocalized by MLL-EEN. This interaction is via a coiled-coil dimerization domain of EEN, which is reserved in the fusion protein. In addition, MLL-EEN might act as a potential transcriptional factor with the MLL part providing the DNA-binding domain and the EEN part providing the transcription activation domain, though EEN seems to have no direct role in transcriptional regulation. As an aberrant transcriptional factor, MLL-EEN could transactivate the promoter of HoxA7, a potential target gene of MLL.	Shanghai Med Univ 2, Ruijin Hosp, Shanghai Inst Hematol, State Key Lab Med Gen, Shanghai 200025, Peoples R China; Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China; Chinese Natl Human Genome Ctr Shanghai, Shanghai 201203, Peoples R China	Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Chen, SJ (corresponding author), Shanghai Med Univ 2, Ruijin Hosp, Shanghai Inst Hematol, State Key Lab Med Gen, 197 Ruijin Rd 2, Shanghai 200025, Peoples R China.	sjchen@stn.sh.cn		Liu, Han/0000-0002-0022-1861				Akao Y, 1998, CANCER RES, V58, P3773; Ayton PM, 2003, GENE DEV, V17, P2298, DOI 10.1101/gad.1111603; Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; Birke M, 2002, NUCLEIC ACIDS RES, V30, P958, DOI 10.1093/nar/30.4.958; Butler LH, 1997, BLOOD, V89, P3361, DOI 10.1182/blood.V89.9.3361; Chan LC, 2002, BLOOD, V100, p199B; Chen Y, 2003, CELL, V115, P37, DOI 10.1016/S0092-8674(03)00726-8; Collins EC, 2002, TRENDS MOL MED, V8, P436, DOI 10.1016/S1471-4914(02)02397-3; COLLINS SJ, 1987, BLOOD, V70, P1233; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DiMartino JF, 2002, BLOOD, V99, P3780, DOI 10.1182/blood.V99.10.3780; DiMartino JF, 2000, BLOOD, V96, P3887, DOI 10.1182/blood.V96.12.3887.h8003887_3887_3893; Dobson CL, 2000, EMBO J, V19, P843, DOI 10.1093/emboj/19.5.843; Dorrie J, 1999, LEUKEMIA, V13, P1539, DOI 10.1038/sj.leu.2401479; Ernst P, 2002, CURR OPIN HEMATOL, V9, P282, DOI 10.1097/00062752-200207000-00004; Floyd S, 1998, TRENDS CELL BIOL, V8, P299, DOI 10.1016/S0962-8924(98)01316-6; Frank RC, 1999, ONCOGENE, V18, P1701, DOI 10.1038/sj.onc.1202459; Giachino C, 1997, GENOMICS, V41, P427, DOI 10.1006/geno.1997.4645; HAJRA A, 1995, P NATL ACAD SCI USA, V92, P1926, DOI 10.1073/pnas.92.6.1926; Hayashi Y, 2000, CANCER RES, V60, P1139; Hsu K, 2003, CANCER CELL, V4, P81, DOI 10.1016/S1535-6108(03)00192-2; Huret JL, 2001, LEUKEMIA, V15, P987, DOI 10.1038/sj.leu.2402135; Joh T, 1996, ONCOGENE, V13, P1945; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; Kawagoe H, 2001, LEUKEMIA, V15, P1743, DOI 10.1038/sj.leu.2402262; Kersey JH, 1998, LEUKEMIA, V12, P1561, DOI 10.1038/sj.leu.2401148; Kitada S, 2002, ONCOGENE, V21, P3459, DOI 10.1038/sj.onc.1205327; Kwon KB, 2002, EXP MOL MED, V34, P32, DOI 10.1038/emm.2002.5; Lanza C, 1996, GENE CHROMOSOME CANC, V15, P48, DOI 10.1002/(SICI)1098-2264(199601)15:1<48::AID-GCC7>3.0.CO;2-4; Lavau C, 2000, EMBO J, V19, P4655, DOI 10.1093/emboj/19.17.4655; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; Mahgoub N, 1998, GENE CHROMOSOME CANC, V21, P270, DOI 10.1002/(SICI)1098-2264(199803)21:3<270::AID-GCC14>3.0.CO;2-T; Martin ME, 2003, CANCER CELL, V4, P197, DOI 10.1016/S1535-6108(03)00214-9; Mayer BJ, 2001, J CELL SCI, V114, P1253; McPherson PS, 1999, CELL SIGNAL, V11, P229, DOI 10.1016/S0898-6568(98)00059-X; Mollinedo F, 1998, ANIMAL CELL CULTURE TECHNIQUES, P264; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; NAOE T, 1993, BLOOD, V82, P2260, DOI 10.1182/blood.V82.7.2260.bloodjournal8272260; Niitsu N, 2001, ONCOGENE, V20, P375, DOI 10.1038/sj.onc.1204081; Ormerod MG, 1998, LEUKEMIA, V12, P1013, DOI 10.1038/sj.leu.2401061; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; POCOCK CFE, 1995, BRIT J HAEMATOL, V90, P855, DOI 10.1111/j.1365-2141.1995.tb05207.x; Polak PE, 2003, MOL BIOL CELL, V14, P1517, DOI 10.1091/mbc.E02-07-0394; Reutens AT, 2002, INT J BIOCHEM CELL B, V34, P1173, DOI 10.1016/S1357-2725(02)00063-8; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; Ringstad N, 2001, J BIOL CHEM, V276, P40424, DOI 10.1074/jbc.M106338200; Rogaia D, 1997, CANCER RES, V57, P799; Rowley JD, 1998, ANNU REV GENET, V32, P495, DOI 10.1146/annurev.genet.32.1.495; Rubnitz JE, 1996, LEUKEMIA, V10, P74; SCHICHMAN SA, 1994, P NATL ACAD SCI USA, V91, P6236, DOI 10.1073/pnas.91.13.6236; Schreiner SA, 1999, LEUKEMIA, V13, P1525, DOI 10.1038/sj.leu.2401534; Simone F, 2001, BLOOD, V98, P201, DOI 10.1182/blood.V98.1.201; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; So CW, 1997, P NATL ACAD SCI USA, V94, P2563, DOI 10.1073/pnas.94.6.2563; So CW, 2003, CANCER CELL, V4, P99, DOI 10.1016/S1535-6108(03)00188-0; So CW, 2003, BLOOD, V101, P633, DOI 10.1182/blood-2002-06-1785; So CW, 2002, MOL CELL BIOL, V22, P6542, DOI 10.1128/MCB.22.18.6542-6552.2002; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; Trayner ID, 1998, LEUKEMIA RES, V22, P537, DOI 10.1016/S0145-2126(98)00041-1; YAM JW, 2003, BLOOD; Yano T, 1997, P NATL ACAD SCI USA, V94, P7286, DOI 10.1073/pnas.94.14.7286; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; Zeisig BB, 2003, LEUKEMIA, V17, P359, DOI 10.1038/sj.leu.2402804; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610	65	25	26	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3385	3394		10.1038/sj.onc.1207402	http://dx.doi.org/10.1038/sj.onc.1207402			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15077184				2022-12-17	WOS:000220975000013
J	Woo, CW; Lucarelli, E; Thiele, CJ				Woo, CW; Lucarelli, E; Thiele, CJ			NGF activation of TrkA decreases N-myc expression via MAPK path leading to a decrease in neuroblastoma cell number	ONCOGENE			English	Article						NGF; TrkA; N-myc; MAPK; neuroblastoma; cell cycle; p27; E2F	NERVE GROWTH-FACTOR; RETINOIC ACID; FACTOR RECEPTOR; NEURONAL DIFFERENTIATION; CYCLE ARREST; PC12 CELLS; FACTOR I; INDUCTION; PROTEINS; RAP1	In neuroblastoma (NB), expression of the TrkA receptor is correlated with good prognosis while N-myc amplification is correlated with poor prognosis. Decreased N-myc levels are key to controlling growth and inducing differentiation in NB cells. In this report, we detail mechanisms by which nerve growth factor (NGF) decreases N-myc levels in TrkA-transfected NB cells and its effect on NB cell proliferation. NGF induced a decrease in N-myc mRNA within 1 h of treatment that occurred in the presence of cycloheximide. The stability of N-myc mRNA was not affected by NGF, indicating a transcriptional control of N-myc mRNA by NGF. NGF but not brain-derived neurotrophic factor (BDNF) decreased N-myc levels demonstrating that p75 alone was not involved. The NGF-induced decrease in N-myc expression was blocked by the Trk tyrosine kinase (TK) antagonist K252a indicating that signals transduced by Trk TK downstream targets were involved. Pharmacologic inhibitors implicated the mitogen-activated protein kinase (MAPK) path. This was supported by the finding that expression of a constitutively activated component of the MAPK path, MAPK kinase (MEK), decreased N-myc levels. Alterations in the level of N-myc are known to alter NB cell cycle progression by affecting the levels of E2Fs and p27(kip1). Consistent with these findings, NGF decreased NB cell number and decreased cyclin E-dependent kinase activity via an increase in p27(kip1). Thus, our results indicate that the MAP kinase is selectively involved in the NGF-induced N-myc downregulation through a transcriptional mechanism. Furthermore, NGF affects the time required for 15N TrkA cells to complete a replication cycle by decreasing N-myc, E2Fs, cyclin E kinase activity and increasing p27(kip1) binding to cyclin E kinase.	NCI, Cell & Mol Biol Sect, Pediat Oncol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Thiele, CJ (corresponding author), NCI, Cell & Mol Biol Sect, Pediat Oncol Branch, NIH, Bldg 10 Rm 13N240,10 Ctr MSC-1928, Bethesda, MD 20892 USA.	thielec@mail.nih.gov	Lucarelli, Enrico/AAF-1612-2021; Enrico, Lucarelli/G-3588-2015	Lucarelli, Enrico/0000-0002-6681-6374; Enrico, Lucarelli/0000-0002-6681-6374				Adams MR, 2000, MOL CELL BIOL, V20, P3633, DOI 10.1128/MCB.20.10.3633-3639.2000; Amati B., 2001, BIOCHIM BIOPHYS ACTA, V1471, P135; AZAR CG, 1990, CELL GROWTH DIFFER, V1, P421; Beier R, 2000, EMBO J, V19, P5813, DOI 10.1093/emboj/19.21.5813; Berns K, 2000, ONCOGENE, V19, P4822, DOI 10.1038/sj.onc.1203879; Billon N, 1996, ONCOGENE, V13, P2047; Bogenmann E, 1998, ONCOGENE, V17, P2367, DOI 10.1038/sj.onc.1202160; BORRELLO MG, 1993, INT J CANCER, V54, P540, DOI 10.1002/ijc.2910540404; Bulseco DA, 2001, J CELL BIOCHEM, V81, P193, DOI 10.1002/1097-4644(20010401)81:1<193::AID-JCB1035>3.0.CO;2-B; Chambery D, 1999, CANCER RES, V59, P2898; CICCARONE V, 1989, CANCER RES, V49, P219; Dechant G, 2001, CELL TISSUE RES, V305, P229, DOI 10.1007/s004410100378; Decker SJ, 1995, J BIOL CHEM, V270, P30841, DOI 10.1074/jbc.270.52.30841; DOBASHI Y, 1995, J BIOL CHEM, V270, P23031, DOI 10.1074/jbc.270.39.23031; Fan LJ, 2001, CANCER RES, V61, P1073; HARTMAN DS, 1994, J NEUROCHEM, V63, P1261; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; Kao SC, 2001, J BIOL CHEM, V276, P18169, DOI 10.1074/jbc.M008870200; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Kihara-Negishi F, 2001, ONCOGENE, V20, P6039, DOI 10.1038/sj.onc.1204756; Kim BS, 1998, J BIOL CHEM, V273, P34543, DOI 10.1074/jbc.273.51.34543; KNUDSON AG, 1980, NEW ENGL J MED, V302, P1254, DOI 10.1056/NEJM198005293022210; KOGNER P, 1993, CANCER RES, V53, P2044; LAVENIUS E, 1995, CELL GROWTH DIFFER, V6, P727; LUCARELLI E, 1995, J BIOL CHEM, V270, P24725, DOI 10.1074/jbc.270.42.24725; Lutz W, 1996, ONCOGENE, V13, P803; MacNicol MC, 1999, J BIOL CHEM, V274, P13193, DOI 10.1074/jbc.274.19.13193; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MATSUMOTO K, 1995, CANCER RES, V55, P1798; Matsuo T, 1998, ONCOGENE, V16, P3337, DOI 10.1038/sj.onc.1201830; MATSUSHIMA H, 1993, MOL CELL BIOL, V13, P7447, DOI 10.1128/MCB.13.12.7447; Misawa A, 2003, INT J CANCER, V104, P233, DOI 10.1002/ijc.10914; Misawa A, 2000, CANCER RES, V60, P64; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; Nakamura M, 2003, CELL DEATH DIFFER, V10, P230, DOI 10.1038/sj.cdd.4401125; Ong SH, 2000, MOL CELL BIOL, V20, P979, DOI 10.1128/MCB.20.3.979-989.2000; Persengiev SP, 1999, MOL CELL BIOL, V19, P6048; Persengiev SP, 2001, ONCOGENE, V20, P5124, DOI 10.1038/sj.onc.1204663; POLUHA W, 1995, ONCOGENE, V10, P185; Poluha W, 1996, MOL CELL BIOL, V16, P1335; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; REYNOLDS CP, 1986, J NATL CANCER I, V76, P375; Santoni-Rugiu E, 2000, MOL CELL BIOL, V20, P3497, DOI 10.1128/MCB.20.10.3497-3509.2000; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; Strieder V, 2003, J BIOL CHEM, V278, P2983, DOI 10.1074/jbc.M207596200; Strieder V, 2002, CANCER LETT, V180, P107, DOI 10.1016/S0304-3835(02)00020-4; SUZUKI T, 1993, J NATL CANCER I, V85, P377, DOI 10.1093/jnci/85.5.377; THIELE CJ, 1988, ONCOGENE, V3, P281; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; Tsygankova OM, 2001, MOL CELL BIOL, V21, P1921, DOI 10.1128/MCB.21.6.1921-1929.2001; vanGrunsven LA, 1996, ONCOGENE, V12, P1347; Veenstra TD, 1997, BIOCHEM BIOPH RES CO, V235, P15, DOI 10.1006/bbrc.1997.6718; WADA RK, 1992, ONCOGENE, V7, P711; Wittrock J, 2002, ANTICANCER RES, V22, P4205; Wu CB, 2001, J NEUROSCI, V21, P5406, DOI 10.1523/JNEUROSCI.21-15-05406.2001; Yang SH, 2002, MOL CELL BIOL, V22, P5036, DOI 10.1128/MCB.22.14.5036-5046.2002; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zhang XH, 1999, ANTICANCER RES, V19, P1641	59	25	30	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2004	23	8					1522	1530		10.1038/sj.onc.1207267	http://dx.doi.org/10.1038/sj.onc.1207267			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778BP	14691455				2022-12-17	WOS:000189219500005
J	Izumiyama, K; Nakagawa, M; Yonezumi, M; Kasugai, Y; Suzuki, R; Suzuki, H; Tsuzuki, S; Hosokawa, Y; Asaka, M; Seto, M				Izumiyama, K; Nakagawa, M; Yonezumi, M; Kasugai, Y; Suzuki, R; Suzuki, H; Tsuzuki, S; Hosokawa, Y; Asaka, M; Seto, M			Stability and subcellular localization of API2-MALT1 chimeric protein involved in t(11;18) (q21;q21) MALT lymphoma	ONCOGENE			English	Article						MALT lymphoma; chromosome trans location; API2; MALT1; API2-MALT1	B-CELL LYMPHOMA; TISSUE LYMPHOMA; LOW-GRADE; GENE; APOPTOSIS; T(11-18)(Q21-Q21); INHIBITOR; FUSION; LIGASE; BCL10	t(11;18) (q21;q21) is a chromosomal aberration specific to low-grade mucosa-associated lymphoid tissue (MALT) lymphoma, and generates the chimeric product apoptosis inhibitor 2 (API2)-MALT1, which has been suggested to play an important role in MALT lymphomagenesis. However, little is known about the characteristics of API2, MALT1, and API2-MALT1 proteins. We therefore investigated the subcellular localization and stability of these products. API2 was localized in the nucleus and the cytoplasm, and MALT1 and API2-MALT1 in the cytoplasm only. Western blot analysis showed that the products of API2 and MALT1 were unstable, while the API2-MALT1 product was stable. The API2 deletion mutants at the end of the C-terminal and the MALT1 deletion mutants at the end of the N-terminal were stable compared with the full-length products. These results indicate that the domains responsible for protein instability are located in the end of the C-terminal of API2 and in that of the N-terminal of MALT1, and also that API2-MALT1 became stable because it lacks these domains. It has been suggested that NF-kappaB activation plays an important role in the tumorigenesis of MALT lymphoma. Our findings further suggest that the stabilized expression of API2-MALT1 products may continuously stimulate the NF-kappaB activating pathway, thus leading to MALT lymphomagenesis.	Aichi Canc Ctr, Res Inst, Div Mol Med, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Hokkaido Univ, Grad Sch Med, Dept Gastroenterol & Hematol, Sapporo, Hokkaido 0608638, Japan	Aichi Cancer Center; Hokkaido University	Seto, M (corresponding author), Aichi Canc Ctr, Res Inst, Div Mol Med, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.		Asaka, Masahiro/A-5948-2012	Tsuzuki, Shinobu/0000-0002-3209-3550; Kasugai, Yumiko/0000-0003-4764-4455; Suzuki, Ritsuro/0000-0002-5974-7614				Akagi T, 1999, ONCOGENE, V18, P5785, DOI 10.1038/sj.onc.1203018; Baens M, 2000, AM J PATHOL, V156, P1433, DOI 10.1016/S0002-9440(10)65012-2; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Dierlamm J, 1999, BLOOD, V93, P3601, DOI 10.1182/blood.V93.11.3601; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Hozak RR, 2000, MOL CELL BIOL, V20, P1877, DOI 10.1128/MCB.20.5.1877-1885.2000; Huang HK, 2000, J BIOL CHEM, V275, P26661; Inagaki H, 2001, AM J PATHOL, V158, P699, DOI 10.1016/S0002-9440(10)64012-6; Isaacson PG, 1999, SEMIN HEMATOL, V36, P139; ISAACSON PG, 1987, HISTOPATHOLOGY, V11, P445, DOI 10.1111/j.1365-2559.1987.tb02654.x; Kalla J, 2000, LEUKEMIA, V14, P1967, DOI 10.1038/sj.leu.2401918; KIYONO T, 1994, J VIROL, V68, P4656, DOI 10.1128/JVI.68.7.4656-4661.1994; Lucas PC, 2001, J BIOL CHEM, V276, P19012, DOI 10.1074/jbc.M009984200; McAllister-Lucas LM, 2001, J BIOL CHEM, V276, P30589, DOI 10.1074/jbc.M103824200; Morgan JA, 1999, CANCER RES, V59, P6205; Motegi M, 2000, AM J PATHOL, V156, P807, DOI 10.1016/S0002-9440(10)64948-6; Ott G, 1997, CANCER RES, V57, P3944; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Remstein ED, 2000, AM J PATHOL, V156, P1183, DOI 10.1016/S0002-9440(10)64988-7; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Suzuki H, 1999, BLOOD, V94, P3270, DOI 10.1182/blood.V94.9.3270.421a44b_3270_3271; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(00)00094-0; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yonezumi M, 2001, BRIT J HAEMATOL, V115, P588, DOI 10.1046/j.1365-2141.2001.03158.x; Zhang QG, 1999, NAT GENET, V22, P63, DOI 10.1038/8767	27	25	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 6	2003	22	50					8085	8092		10.1038/sj.onc.1207002	http://dx.doi.org/10.1038/sj.onc.1207002			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	740LG	14603249				2022-12-17	WOS:000186403400003
J	Kuga, H; Morisaki, T; Nakamura, K; Onishi, H; Noshiro, H; Uchiyama, A; Tanaka, M; Katano, M				Kuga, H; Morisaki, T; Nakamura, K; Onishi, H; Noshiro, H; Uchiyama, A; Tanaka, M; Katano, M			Interferon-gamma suppresses transforming growth factor-beta-induced invasion of gastric carcinoma cells through cross-talk of Smad pathway in a three-dimensional culture model	ONCOGENE			English	Article						TGF-beta; IFN-gamma; gastric carcinoma; three-dimensional culture; Smad	UROKINASE PLASMINOGEN-ACTIVATOR; BREAST-CANCER CELLS; TGF-BETA; IN-VITRO; GENE-EXPRESSION; NUCLEAR-LOCALIZATION; HUMAN-FIBROBLASTS; SKIN FIBROBLASTS; GLIOMA INVASION; COLLAGEN GELS	We reconstituted a three-dimensional gastric carcinoma model similar to invasive gastric carcinoma tissue. This model consists of a human gastric carcinoma cell line, GCTM-1, a human fibroblast cell line, TIG-1-20, and transforming growth factor-beta (TGF-beta)-containing type I collagen gel. Using this model, we were able to observe the growth of the two cell types, especially carcinoma cell invasive growth, in real time for more than 30 days. TGF-beta and TIG-1-20 were essential for GCTM-1 invasive growth and proliferation, respectively. TGF-beta induced the enhanced expression of matrix metalloproteinase 9 (MMP9) and urokinase-type plasminogen activator (uPA) in GCTM-1 at both the protein and enzymatic activity levels. The TGF-beta-induced invasion of GCTM-1 was inhibited by MMP9- or uPA-antisense (AS) oligonucleotide transfection to GCTM-1. When exogenous interferon-gamma (IFN-gamma) was added to this model, TGF-beta-dependent GCTM-1 invasion was significantly inhibited, concomitant with the decreased expression of MMP9 and uPA. The intracellular signal transduction of Smad was examined to analyse the mechanism of the inhibitory effect of IFN-gamma. TGF-beta accelerated the phosphorylation of Smad2/3 and nuclear translocation of the Smad2/3 Smad4 complex in GCTM-1, but these TGF-beta-induced effects were significantly inhibited by IFN-gamma-induced Smad7 expression. When GCTM-1 was cotransfected with AS oligonucleotide of Smad2 and Smad3, the TGF-beta-induced invasion of GCTM-1 disappeared. In addition, the inhibitory effect of IFN-gamma on TGF-beta-dependent GCTM-1 invasion vanished by the AS oligonucleotide of Smad7 transfection. These results indicate that IFN-gamma inhibits TGF-beta-dependent GCTM-1 invasion through cross-talk in the Smad pathway. IFN-gamma may be a new therapeutic tool for TGF-beta-expressed invasive carcinomas.	Kyushu Univ, Grad Sch Med Sci, Dept Canc Therapy & Res, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Clin Oncol & Surg, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University; Kyushu University	Katano, M (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Canc Therapy & Res, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.							ALBINI A, 1987, CANCER RES, V47, P3239; ALEXANDROW MG, 1995, CANCER RES, V55, P1452; ANKRAPP DP, 1993, CANCER RES, V53, P3399; [Anonymous], GENOME BIOL; ARNOLETTI JP, 1995, CANCER, V76, P998, DOI 10.1002/1097-0142(19950915)76:6<998::AID-CNCR2820760613>3.0.CO;2-0; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Bauman GS, 1999, INT J DEV NEUROSCI, V17, P643, DOI 10.1016/S0736-5748(99)00023-4; Bell HS, 1999, J NEUROSURG, V91, P989, DOI 10.3171/jns.1999.91.6.0989; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; Chen SJ, 2000, J CELL PHYSIOL, V183, P381, DOI 10.1002/(SICI)1097-4652(200006)183:3<381::AID-JCP11>3.0.CO;2-O; COFFEY RJ, 1988, CANCER RES, V48, P1596; DAVID M, 1995, PHARMACOL THERAPEUT, V65, P149, DOI 10.1016/0163-7258(94)00050-D; Dong CM, 2000, MOL CELL, V5, P27, DOI 10.1016/S1097-2765(00)80400-1; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Ellenrieder V, 2001, INT J CANCER, V93, P204, DOI 10.1002/ijc.1330; ELLIS MJC, 1994, BREAST CANCER RES TR, V31, P249, DOI 10.1007/BF00666158; Festuccia C, 2000, INT J CANCER, V85, P407, DOI 10.1002/(SICI)1097-0215(20000201)85:3<407::AID-IJC18>3.0.CO;2-8; Fink SP, 2001, CANCER RES, V61, P256; Funaba M, 2002, J BIOL CHEM, V277, P41361, DOI 10.1074/jbc.M204597200; Ghosh AK, 2001, J BIOL CHEM, V276, P11041, DOI 10.1074/jbc.M004709200; Giehl K, 2000, ONCOGENE, V19, P4531, DOI 10.1038/sj.onc.1203806; GURUJEYALAKSHMI G, 1995, EXP LUNG RES, V21, P791, DOI 10.3109/01902149509050842; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; HLATKY L, 1994, CANCER RES, V54, P6083; HOFLAND LJ, 1995, INT J CANCER, V60, P93, DOI 10.1002/ijc.2910600114; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; Inagaki Y, 2001, J CELL PHYSIOL, V187, P117, DOI 10.1002/1097-4652(2001)9999:9999<00::AID-JCP1059>3.0.CO;2-S; Itoh S, 2000, EUR J BIOCHEM, V267, P6954, DOI 10.1046/j.1432-1327.2000.01828.x; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; KESKIOJA J, 1988, J CELL BIOL, V106, P451, DOI 10.1083/jcb.106.2.451; Kikuchi S, 2000, HEPATO-GASTROENTEROL, V47, P1256; Kunz-Schughart LA, 2001, EXP CELL RES, V266, P74, DOI 10.1006/excr.2001.5210; Leivonen SK, 2002, J BIOL CHEM, V277, P46338, DOI 10.1074/jbc.M206535200; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LUND LR, 1995, BIOCHEM J, V310, P345, DOI 10.1042/bj3100345; Ma ZD, 2001, J IMMUNOL, V167, P5150, DOI 10.4049/jimmunol.167.9.5150; MAHARA K, 1994, BRIT J CANCER, V69, P777, DOI 10.1038/bjc.1994.147; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; Matrisian LM, 2001, CANCER RES, V61, P3844; Meier F, 2000, AM J PATHOL, V156, P193, DOI 10.1016/S0002-9440(10)64719-0; Montgomery E, 2001, AM J PATHOL, V158, P537, DOI 10.1016/S0002-9440(10)63995-8; Mori Y, 2000, EXP CELL RES, V258, P374, DOI 10.1006/excr.2000.4930; Morisaki T, 2000, ANTICANCER RES, V20, P3363; Morrissey D, 1999, CLIN EXP METASTAS, V17, P77; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; Nakamura M, 1998, BRIT J CANCER, V78, P1373, DOI 10.1038/bjc.1998.687; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; OVERALL CM, 1989, J BIOL CHEM, V264, P1860; Pasche B, 2001, J CELL PHYSIOL, V186, P153, DOI 10.1002/1097-4652(200002)186:2<153::AID-JCP1016>3.0.CO;2-J; Razandi M, 2003, J BIOL CHEM, V278, P2701, DOI 10.1074/jbc.M205692200; Rossi L, 2000, INT J CANCER, V85, P667, DOI 10.1002/(SICI)1097-0215(20000301)85:5<667::AID-IJC12>3.0.CO;2-1; Saito H, 1999, CANCER, V86, P1455, DOI 10.1002/(SICI)1097-0142(19991015)86:8<1455::AID-CNCR11>3.0.CO;2-L; Sandusky G, 2002, J BIOL CHEM, V277, P49815, DOI 10.1074/jbc.C200543200; Sehgal I, 1996, CANCER RES, V56, P3359; SHIPLEY GD, 1986, CANCER RES, V46, P2068; Shyu RY, 2000, J SURG ONCOL, V75, P122, DOI 10.1002/1096-9098(200010)75:2<122::AID-JSO9>3.0.CO;2-4; Sowa H, 2002, J BIOL CHEM, V277, P36024, DOI 10.1074/jbc.M206030200; Teti A, 1997, INT J CANCER, V72, P1013; TORREAMIONE G, 1990, P NATL ACAD SCI USA, V87, P1486, DOI 10.1073/pnas.87.4.1486; Tredget EE, 2000, J INTERF CYTOK RES, V20, P143, DOI 10.1089/107999000312540; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; URA H, 1991, CANCER RES, V51, P3550; Verrecchia F, 2003, J BIOL CHEM, V278, P1585, DOI 10.1074/jbc.M206927200; WELCH DR, 1990, P NATL ACAD SCI USA, V87, P7678, DOI 10.1073/pnas.87.19.7678; Yashiro M, 1996, BRIT J CANCER, V74, P1096, DOI 10.1038/bjc.1996.496; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366	66	25	31	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 30	2003	22	49					7838	7847		10.1038/sj.onc.1207046	http://dx.doi.org/10.1038/sj.onc.1207046			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586410				2022-12-17	WOS:000186240200014
J	Muntoni, A; Fleming, J; Gordon, KE; Hunter, K; McGregor, F; Parkinson, EK; Harrison, PR				Muntoni, A; Fleming, J; Gordon, KE; Hunter, K; McGregor, F; Parkinson, EK; Harrison, PR			Senescing oral dysplasias are not immortalized by ectopic expression of hTERT alone without other molecular changes, such as loss of INK4A and/or retinoic acid receptor-beta: but p53 mutations are not necessarily required	ONCOGENE			English	Article						head and neck cancer; preneoplasia; immortalization; RAR-beta; INK4A; telomerase	KERATINOCYTE SENESCENCE; REPLICATIVE SENESCENCE; P16(INK4A); TELOMERASE; INACTIVATION; ACQUISITION; PROTEINS	Our previous work showed that acquisition of immortality at the dysplasia stage of oral cancer progression was consistently associated with four changes: loss of retinoic acid receptor (RAR)-beta and p16(INK4A) expression, p53 mutations and activation of telomerase. One atypical dysplasia (D17) that underwent delayed senescence after an extended lifespan showed loss of RAR-beta and p16(INK4A)/ p14(ARF) expression, but retained functional wild-type p53 and telomerase was not activated. We now demonstrate that retroviral delivery of hTERT results in telomere lengthening and immortalization of D17 without loss of functional wild-type p53 activity. In contrast, the expression of hTERT in two other typical mortal dyplasia cultures (that retain RAR-beta and p16(INK4A) expression) does not extend their lifespan, even though telomeres are lengthened.	CRC Beatson Labs, Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute	Harrison, PR (corresponding author), CRC Beatson Labs, Beatson Inst Canc Res, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	p.r.harrison@beatson.gla.ac.uk	Hunter, Keith D/B-5670-2009; Hunter, Keith/M-9784-2019	Hunter, Keith/0000-0002-7873-0877				Campisi J, 2000, IN VIVO, V14, P183; Ghose A, 2001, CANCER RES, V61, P7479; Gordon KE, 2003, CANCER RES, V63, P458; Kresty LA, 2002, CANCER RES, V62, P5295; Lustig AJ, 1999, P NATL ACAD SCI USA, V96, P3339, DOI 10.1073/pnas.96.7.3339; McGregor F, 1997, CANCER RES, V57, P3886; McGregor F, 2002, CANCER RES, V62, P4757; Morris M, 2002, ONCOGENE, V21, P4277, DOI 10.1038/sj.onc.1205492; Munro J, 1999, CANCER RES, V59, P2516; Munro J, 2001, ONCOGENE, V20, P3541, DOI 10.1038/sj.onc.1204460; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Pandita TK, 2002, ONCOGENE, V21, P611, DOI 10.1038/sj.onc.1205060; Papadimitrakopoulou V, 1997, ONCOGENE, V14, P1799, DOI 10.1038/sj.onc.1201010; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; Rheinwald JG, 2002, MOL CELL BIOL, V22, P5157, DOI 10.1128/MCB.22.14.5157-5172.2002; RHEINWALD JG, 1981, CANCER RES, V41, P1657; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shay JW, 1997, J CELL PHYSIOL, V173, P266, DOI 10.1002/(SICI)1097-4652(199711)173:2<266::AID-JCP33>3.0.CO;2-B; Smogorzewska A, 2002, EMBO J, V21, P4338, DOI 10.1093/emboj/cdf433; Stewart SA, 2002, ONCOGENE, V21, P627, DOI 10.1038/sj.onc.1205062; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Webley K, 2000, MOL CELL BIOL, V20, P2803, DOI 10.1128/MCB.20.8.2803-2808.2000; Xu DW, 2000, ONCOGENE, V19, P5123, DOI 10.1038/sj.onc.1203890; XU XC, 1994, CANCER RES, V54, P3580	24	25	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2003	22	49					7804	7808		10.1038/sj.onc.1207085	http://dx.doi.org/10.1038/sj.onc.1207085			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586406				2022-12-17	WOS:000186240200010
J	Domon-Dell, C; Schneider, A; Moucadel, V; Guerin, E; Guenot, D; Aguillon, S; Duluc, I; Martin, E; Iovanna, J; Launay, JF; Duclos, B; Chenard, MP; Meyer, C; Oudet, P; Kedinger, M; Gaub, MP; Freund, JN				Domon-Dell, C; Schneider, A; Moucadel, V; Guerin, E; Guenot, D; Aguillon, S; Duluc, I; Martin, E; Iovanna, J; Launay, JF; Duclos, B; Chenard, MP; Meyer, C; Oudet, P; Kedinger, M; Gaub, MP; Freund, JN			Cdx1 homeobox gene during human colon cancer progression	ONCOGENE			English	Article						allelic imbalance; genomic rearrangement; gene expression; xenografts	DOWN-REGULATION; COLORECTAL-CANCER; EXPRESSION; CELLS; PATHWAYS	The Cdx1 homeobox gene encodes an intestine-specific transcription factor with a pro-oncogenic function in vitro. Here we have analysed the pattern of Cdx1 in human colon cancer progression. Cdx1 expression remains at a high level in the majority of the polyps and it is even overexpressed in more than one-third of the specimens, consistent with the fact that the gene is an intestine-specific target of oncogenic pathways. However, Cdx1 decreases in one-fifth of the polyps, which is reminiscent of the loss of expression previously reported in the majority of carcinomas. Allelic imbalance analysis demonstrates that the Cdx1 locus located on chromosome 5q is a major site of genomic rearrangement in colorectal cancers, and that the frequency of the rearrangements increases during polyps to carcinoma progression. Allelic imbalance at the Cdx1 locus occurs in relation to, although not invariably in association with, the rearrangements at the APC locus on the same chromosomal arm. Xenografts of primary human colon carcinomas indicate that the level of Cdx1 mRNA correlates with the intensity of allelic imbalance. Together, these data show that Cdx1 exhibits a complex pattern during colorectal cancer progression. Given that Cdx1 has a pro-oncogenic function in vitro, the maintenance of a high level of expression in polyps, and even its overexpression in one-third of the specimens, suggest that this homeobox gene may be an important factor in the process toward malignant transformation during the first steps of tumorigenesis.	INSERM, U381, F-67200 Strasbourg, France; INSERM, Ctr Rech, EMI 0116, F-13009 Marseille, France; Univ Strasbourg, Hop Hautepierre, F-67200 Strasbourg, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Freund, JN (corresponding author), INSERM, U381, 3 Ave Moliere, F-67200 Strasbourg, France.	jean-noel.freund@inserm.u-strasburg.fr	Freund, Jean-Noel/R-4383-2016; Domon-Dell, Claire/P-2368-2017; Duluc, Isabelle/O-1972-2017; DULUC, Isabelle/AAA-7062-2022; guenot, dominique/R-3355-2016; Guerin, Eric/R-3426-2016; Chenard, Marie-Pierre/O-2373-2016; Iovanna, Juan/M-9805-2017	Freund, Jean-Noel/0000-0002-0971-3774; Duluc, Isabelle/0000-0001-8396-6385; DULUC, Isabelle/0000-0001-8396-6385; guenot, dominique/0000-0003-2782-8425; Iovanna, Juan/0000-0003-1822-2237; GUERIN, ERIC/0000-0003-1388-2834; DOMON-DELL, Claire/0000-0002-8445-9593				BONNER CA, 1995, GENOMICS, V28, P206, DOI 10.1006/geno.1995.1132; Chung DC, 2000, GASTROENTEROLOGY, V119, P854, DOI 10.1053/gast.2000.16507; Domon-Dell C, 2002, FEBS LETT, V518, P83, DOI 10.1016/S0014-5793(02)02650-9; Freund JN, 1998, BIOCHEM CELL BIOL, V76, P957, DOI 10.1139/bcb-76-6-957; JAMES R, 1994, J BIOL CHEM, V269, P15229; Lickert H, 2000, DEVELOPMENT, V127, P3805; Lorentz O, 1999, ONCOGENE, V18, P87, DOI 10.1038/sj.onc.1202280; Lorentz O, 1997, J CELL BIOL, V139, P1553, DOI 10.1083/jcb.139.6.1553; Lynch J, 2000, J BIOL CHEM, V275, P4499, DOI 10.1074/jbc.275.6.4499; Mallo GV, 1997, INT J CANCER, V74, P35, DOI 10.1002/(SICI)1097-0215(19970220)74:1<35::AID-IJC7>3.0.CO;2-1; MAULBECKER CC, 1993, CELL GROWTH DIFFER, V4, P431; Moucadel V, 2002, BIOCHEM BIOPH RES CO, V297, P607, DOI 10.1016/S0006-291X(02)02250-7; Moucadel V, 2001, EUR J CELL BIOL, V80, P156, DOI 10.1078/0171-9335-00148; Oh EJ, 2002, INT J ONCOL, V20, P23; Ren P, 2000, AM J PATHOL, V156, P621, DOI 10.1016/S0002-9440(10)64766-9; Schneider A, 2000, CANCER RES, V60, P4617; Schneider A, 2000, AUST NZ J SURG, V70, P587, DOI 10.1046/j.1440-1622.2000.01904.x; Shih LM, 2001, P NATL ACAD SCI USA, V98, P2640, DOI 10.1073/pnas.051629398; Silberg DG, 2000, GASTROENTEROLOGY, V119, P961, DOI 10.1053/gast.2000.18142; Silberg DG, 1997, GASTROENTEROLOGY, V113, P478, DOI 10.1053/gast.1997.v113.pm9247467; Soubeyran P, 1999, GASTROENTEROLOGY, V117, P1326, DOI 10.1016/S0016-5085(99)70283-0; Soubeyran P, 2001, ONCOGENE, V20, P4180, DOI 10.1038/sj.onc.1204551; Subramanian V, 1998, DIFFERENTIATION, V64, P11, DOI 10.1046/j.1432-0436.1998.6410011.x; Suh ER, 2002, J BIOL CHEM, V277, P35795, DOI 10.1074/jbc.M205567200; Vider BZ, 1997, BIOCHEM BIOPH RES CO, V232, P742, DOI 10.1006/bbrc.1997.6364; Weber JC, 2001, ANN SURG, V234, P795, DOI 10.1097/00000658-200112000-00011	26	25	25	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	2003	22	39					7913	7921		10.1038/sj.onc.1206756	http://dx.doi.org/10.1038/sj.onc.1206756			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970739				2022-12-17	WOS:000185388200006
J	Habraken, Y; Jolois, O; Piette, J				Habraken, Y; Jolois, O; Piette, J			Differential involvement of the hMRE11/hRAD50/NBS1 complex, BRCA1 and MLH1 in NF-kappa B activation by camptothecin and X-ray	ONCOGENE			English	Article						NF-kappa B; double-strand breaks; BRCA1; NBS; ATLD; MMR	NIJMEGEN BREAKAGE SYNDROME; DNA MISMATCH REPAIR; ATM-DEPENDENT PHOSPHORYLATION; ATAXIA-TELANGIECTASIA; TOPOISOMERASE-I; MRE11 COMPLEX; DAMAGE; PROTEIN; KINASE; CANCER	Camptothecin (CPT) and X-ray (XR) generate double-strand breaks (DSB) that can be processed by homologous or nonhomologous recombination. We studied the participation of proteins involved in recombination pathways and cell cycle control in the signal transduction between DNA damage and NF-kappaB. Cells harbouring mutated NBS, hMRE11, BRCA1 or MLH1 were analysed. NBS- and hMRE11-deficient cells present a classical kinetic of NF-kappaB induction after camptothecin treatment. When DSB are generated by XR, NBS-deficient cells exhibit a delayed and strongly reduced level of NF-kappaB induction, whereas the hMRE11 mutated cells do not induce NF-kappaB at all. This indicates an important role of the hMRE11/hRAD50/NBS complex in the signal transduction initiated by XR. In HCC1937 cells that express a truncated version of BRCA1, XR induces a very rapid and transient NF-kappaB activation, whereas CPT leads to a delayed activation suggesting that BRCA1 modulates the transduction pathways in different manners after these two stresses. Finally, we found that a proficient MMR pathway is essential to the NF-kappaB activation after both CPT and XR. These results indicate that DSB originating from XR or CPT do not induce NF-kappaB in a unique way. MMR participates in both cascades, whereas the hMRE11/hRAD50/NBS trimer is specifically involved in the response elicited by XR.	Univ Liege, Inst Pathol B23, Lab Virol & Immunol, B-4000 Liege, Belgium; Univ Liege, Inst Anat L3, Ctr Immunol, Lab Human Histol, B-4020 Liege, Belgium	University of Liege; University of Liege	Habraken, Y (corresponding author), Univ Liege, Inst Pathol B23, Lab Virol & Immunol, B-4000 Liege, Belgium.	Yvette.Habraken@ulg.ac.be						AVEMANN K, 1988, MOL CELL BIOL, V8, P3026, DOI 10.1128/MCB.8.8.3026; Bharti AC, 2002, BIOCHEM PHARMACOL, V64, P883, DOI 10.1016/S0006-2952(02)01154-1; Brown KD, 2003, NAT GENET, V33, P80, DOI 10.1038/ng1052; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Cerosaletti KM, 2000, MUTAGENESIS, V15, P281, DOI 10.1093/mutage/15.3.281; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; Friedberg E.C., 2016, DNA REPAIR MUTAGENES, V33, P35; Furuta T, 2003, J BIOL CHEM, V278, P20303, DOI 10.1074/jbc.M300198200; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Giannini G, 2002, EMBO REP, V3, P248, DOI 10.1093/embo-reports/kvf044; Habraken Y, 2001, BIOCHEM PHARMACOL, V62, P603, DOI 10.1016/S0006-2952(01)00709-2; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; Huang TT, 2000, J BIOL CHEM, V275, P9501, DOI 10.1074/jbc.275.13.9501; Hur GM, 2003, GENE DEV, V17, P873, DOI 10.1101/gad.1062403; Jacob S, 2001, CANCER RES, V61, P6555; Jacob S, 2002, BIOCHIMIE, V84, P27, DOI 10.1016/S0300-9084(01)01362-1; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; KOI M, 1994, CANCER RES, V54, P4308; KRAAKMANVANDERZ.M, 1999, MUTAT RES, V434, P127; Li NX, 2001, J BIOL CHEM, V276, P8898, DOI 10.1074/jbc.M009809200; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Liu CY, 2002, P NATL ACAD SCI USA, V99, P14970, DOI 10.1073/pnas.182557199; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Paull TT, 2001, P NATL ACAD SCI USA, V98, P6086, DOI 10.1073/pnas.111125998; Petrini JHJ, 2000, CURR OPIN CELL BIOL, V12, P293, DOI 10.1016/S0955-0674(00)00091-0; Pichierri P, 2001, CARCINOGENESIS, V22, P1781, DOI 10.1093/carcin/22.11.1781; Piret B, 1996, NUCLEIC ACIDS RES, V24, P4242, DOI 10.1093/nar/24.21.4242; Piret B, 1999, ONCOGENE, V18, P2261, DOI 10.1038/sj.onc.1202541; Pommier Y, 1998, BBA-GENE STRUCT EXPR, V1400, P83, DOI 10.1016/S0167-4781(98)00129-8; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Thompson LH, 2002, MUTAT RES-FUND MOL M, V509, P49, DOI 10.1016/S0027-5107(02)00224-5; Vance JR, 2002, P NATL ACAD SCI USA, V99, P13669, DOI 10.1073/pnas.202242599; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Venkitaraman AR, 2001, J CELL SCI, V114, P3591; WU X, 2000, SCIENCE, V289, pA11; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Zhong Q, 2002, CANCER RES, V62, P3966; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	44	25	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					6090	6099		10.1038/sj.onc.1206893	http://dx.doi.org/10.1038/sj.onc.1206893			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955088				2022-12-17	WOS:000185137800018
J	Beniston, RG; Campo, MS				Beniston, RG; Campo, MS			Quercetin elevates p27(Kip1) and arrests both primary and HPV16 E6/E7 transformed human keratinocytes in G1	ONCOGENE			English	Article						HFK; HPV E6/E7; quercetin; cell cycle; p27(Kip1)	HUMAN-PAPILLOMAVIRUS DNA; CELL-CYCLE; GASTRIC-CANCER; BRACKEN FERN; E7; PROTEIN; PTAQUILOSIDE; DEGRADATION; APOPTOSIS; P53	Our previous work with primary bovine fibroblasts demonstrated that quercetin, a potent mutagen found in high levels in bracken fern (Pteridium aquilinum), arrested cells in G1 and G2/M, in correlation with p53 activation. The expression of bovine papillomavirus type 4 (BPV-4) E7 overcame this arrest and lead to the development of tumorigenic cells lines (Beniston et al., 2001). Given the possible link between papillomavirus infection, bracken fern in the diet and cancer of the upper gastrointestinal (GI) tract in humans, we investigated whether a similar situation would occur in human cells transformed by human papillomavirus type 16 (HPV-16) oncoproteins. Quercetin arrested primary human foreskin keratinocytes in G1. Arrest was linked to an elevation of the cyclin-dependent kinase inhibitor (cdki) p27(Kip1). Expression of the HPV16 E6 and E7 oncoproteins in transformed cells failed to abrogate cell cycle arrest. GI arrest in the transformed cells was also linked to an increase of p27(Kip1) with a concomitant reduction of cyctin E-associated kinase activity. This elevation of p27(Kip1) was due not only to increased protein half-life, but also to increased mRNA transcription.	Univ Glasgow, Sch Vet, Inst Comparat Med, Glasgow G61 1QH, Lanark, Scotland	University of Glasgow	Campo, MS (corresponding author), Univ Glasgow, Sch Vet, Inst Comparat Med, Garscube Estate, Glasgow G61 1QH, Lanark, Scotland.	s.campo@vet.gla.ac.uk						Alonso-Amelot ME, 2001, INT J CANCER, V91, P252, DOI 10.1002/1097-0215(200002)9999:9999&lt;::AID-IJC1028&gt;3.0.CO;2-; AlonsoAmelot ME, 1996, NATURE, V382, P587, DOI 10.1038/382587a0; Arber N, 2000, GASTROENTEROLOGY, V118, P1045, DOI 10.1016/S0016-5085(00)70357-X; Ashby ADM, 2001, J GEN VIROL, V82, P2353, DOI 10.1099/0022-1317-82-10-2353; Beniston RG, 2001, CARCINOGENESIS, V22, P1069, DOI 10.1093/carcin/22.7.1069; BJELDANES LF, 1977, SCIENCE, V197, P577, DOI 10.1126/science.327550; Boyer SN, 1996, CANCER RES, V56, P4620; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; CAIRNEY M, 1995, CARCINOGENESIS, V16, P1997, DOI 10.1093/carcin/16.8.1997; CAMPO MS, 1994, CARCINOGENESIS, V15, P1597, DOI 10.1093/carcin/15.8.1597; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Casagrande F, 2001, BIOCHEM PHARMACOL, V61, P1205, DOI 10.1016/S0006-2952(01)00583-4; Casson AG, 1997, INT J CANCER, V72, P739, DOI 10.1002/(SICI)1097-0215(19970904)72:5<739::AID-IJC6>3.0.CO;2-T; CHANG FJ, 1990, INT J CANCER, V45, P21, DOI 10.1002/ijc.2910450106; Choi JA, 2001, INT J ONCOL, V19, P837; CONRAD M, 1993, J VIROL, V67, P6170, DOI 10.1128/JVI.67.10.6170-6178.1993; COOPER K, 1995, J PATHOL, V175, P273, DOI 10.1002/path.1711750304; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; de Villiers EM, 1999, INT J CANCER, V81, P225, DOI 10.1002/(SICI)1097-0215(19990412)81:2&lt;225::AID-IJC10&gt;3.0.CO;2-0; Dell C, 2001, CELL MOL LIFE SCI, V58, P1923, DOI 10.1007/PL00000827; FAZAL F, 1990, CARCINOGENESIS, V11, P2005, DOI 10.1093/carcin/11.11.2005; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Galiana C, 1995, MOL CARCINOGEN, V14, P286, DOI 10.1002/mc.2940140409; GALPIN OP, 1990, BRIT J CANCER, V61, P737, DOI 10.1038/bjc.1990.165; Gillison ML, 2000, JNCI-J NATL CANCER I, V92, P709, DOI 10.1093/jnci/92.9.709; Hara T, 2001, J BIOL CHEM, V276, P48937, DOI 10.1074/jbc.M107274200; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Hirayama T., 1979, NUTR CANCER, V1, P67; HIRONO I, 1987, J NATL CANCER I, V79, P1143; ISHIDATE M, 1988, MUTAT RES, V195, P151, DOI 10.1016/0165-1110(88)90023-1; Iwashita K, 2000, BIOSCI BIOTECH BIOCH, V64, P1813, DOI 10.1271/bbb.64.1813; JACKSON ME, 1991, MOL CARCINOGEN, V4, P382, DOI 10.1002/mc.2940040510; JACKSON ME, 1995, DNA TUMOUR VIRUSES O; Jones DL, 1997, VIROLOGY, V239, P97, DOI 10.1006/viro.1997.8851; JONES DL, 1921, GENE DEV, P11; LIANG Y, 2002, NAT MED, V10, P1163; Lloyd RV, 1999, AM J PATHOL, V154, P313, DOI 10.1016/S0002-9440(10)65277-7; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Marliere CA, 2000, BRACKEN FERN TOXICIT, V4, P144; Martin LG, 1998, J VIROL, V72, P975, DOI 10.1128/JVI.72.2.975-985.1998; MATOBA M, 1987, MUTAGENESIS, V2, P419, DOI 10.1093/mutage/2.6.419; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Nakayama K, 2001, BIOCHEM BIOPH RES CO, V282, P853, DOI 10.1006/bbrc.2001.4627; NAKAYASU M, 1986, MUTAT RES, V174, P79, DOI 10.1016/0165-7992(86)90081-3; OELZE I, 1995, J VIROL, V69, P4489, DOI 10.1128/JVI.69.7.4489-4494.1995; PENNIE WD, 1992, VIROLOGY, V190, P861, DOI 10.1016/0042-6822(92)90926-G; Plaumann B, 1996, ONCOGENE, V13, P1605; Potter DM, 2000, BRIT J CANCER, V83, P914, DOI 10.1054/bjoc.2000.1368; Reinstein E, 2000, ONCOGENE, V19, P5944, DOI 10.1038/sj.onc.1203989; Rong Y, 2000, ANTICANCER RES, V20, P4339; Sano T, 2002, PATHOL INT, V52, P375, DOI 10.1046/j.1440-1827.2002.01359.x; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SORSDAHL K, 1994, CANCER DETECT PREV, V18, P179; STRAIGHT SW, 1995, J VIROL, V69, P3185, DOI 10.1128/JVI.69.5.3185-3192.1995; Suzuk L, 1996, CANCER-AM CANCER SOC, V78, P704; SUZUKI S, 1991, JPN J CANCER RES, V82, P1061, DOI 10.1111/j.1349-7006.1991.tb01757.x; Syrjanen KJ, 2002, J CLIN PATHOL, V55, P721, DOI 10.1136/jcp.55.10.721; TOGAWA K, 1994, GASTROENTEROLOGY, V107, P128, DOI 10.1016/0016-5085(94)90070-1; Vance KW, 1999, J BIOL CHEM, V274, P27839, DOI 10.1074/jbc.274.39.27839; VILLALOBOSSALAZ.J, 1995, BRACKEN ENV ISSUE, P102; Yamashita N, 2000, FREE RADICAL RES, V33, P623, DOI 10.1080/10715760000301141; Zehbe I, 1999, ONCOGENE, V18, P2201, DOI 10.1038/sj.onc.1202549; ZerfassThome K, 1996, ONCOGENE, V13, P2323; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	66	25	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2003	22	35					5504	5514		10.1038/sj.onc.1206848	http://dx.doi.org/10.1038/sj.onc.1206848			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934110	Green Accepted			2022-12-17	WOS:000184735000015
J	Willis, AC; Pipes, T; Zhu, JH; Chen, XB				Willis, AC; Pipes, T; Zhu, JH; Chen, XB			p73 can suppress the proliferation of cells that express mutant p53	ONCOGENE			English	Article						p73; p53; p21; cell cycle arrest; apoptosis	INDUCIBLE GENE-EXPRESSION; MAMMALIAN-CELLS; DNA-DAMAGE; TUMOR-SUPPRESSOR; CODON-72 POLYMORPHISM; CYCLE ARREST; HEPATOCELLULAR-CARCINOMA; FUNCTIONAL DOMAINS; CHROMOSOME 1P36.3; COLORECTAL-CANCER	Mutation of the p53 tumor suppressor gene is the most common genetic alteration in human cancer. p73, a member of the p53 family, has been found to exhibit activity similar to that of p53, including the ability to induce growth arrest and apoptosis. p53 and p73 have a high percentage of similarity at several domains, including the DNA binding domain. This domain in p53 is the location of missense mutations in many human cancers. Mutant p53, which cannot suppress cell proliferation, has been found to have a dominant-negative activity that inactivates wild-type p53. To determine the effects of mutant p53 on wild-type p73, we have established cell lines expressing both mutant p53 and wild-type p73 in a dual-inducible system. This system expresses mutant p53 in a tetracycline-repressible system and p73beta in an ecdysone-inducible system in a p53-null lung carcinoma parental cell tine. We have found that wild-type p73beta, in the presence of mutant p53, retains the ability to transactivate p21 and suppresses cell growth through induction of both cell cycle arrest and apoptosis. In addition, in cell lines expressing wild-type p53 and wild-type p73beta, we have found that these proteins cooperate to additively transactivate p21 and suppress cell proliferation.	Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama, UAB Comprehens Canc Ctr, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Chen, XB (corresponding author), MCLM 660,1530 3rd Ave S, Birmingham, AL 35242 USA.			Amara, Amy/0000-0003-0762-9656	NATIONAL CANCER INSTITUTE [R01CA081237] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA81237] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Almog N, 1997, BBA-REV CANCER, V1333, pF1, DOI 10.1016/S0304-419X(97)00012-7; Brachmann RK, 1996, P NATL ACAD SCI USA, V93, P4091, DOI 10.1073/pnas.93.9.4091; Brunner HG, 2002, J MED GENET, V39, P377, DOI 10.1136/jmg.39.6.377; Calhoun ES, 2002, CLIN CHEM, V48, P1218; Celli J, 1999, CELL, V99, P143, DOI 10.1016/S0092-8674(00)81646-3; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chen XB, 1999, MOL MED TODAY, V5, P387, DOI 10.1016/S1357-4310(99)01545-2; Chene P, 1998, J MOL BIOL, V281, P205, DOI 10.1006/jmbi.1998.1897; Chinery R, 1997, NAT MED, V3, P1233, DOI 10.1038/nm1197-1233; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Davison TS, 1999, J BIOL CHEM, V274, P18709, DOI 10.1074/jbc.274.26.18709; De Laurenzi V, 2000, BIOCHEM BIOPH RES CO, V273, P342, DOI 10.1006/bbrc.2000.2932; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Dohn M, 2001, ONCOGENE, V20, P6503, DOI 10.1038/sj.onc.1204816; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Harvey DM, 1998, CURR OPIN CHEM BIOL, V2, P512; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kovalev S, 1998, CELL GROWTH DIFFER, V9, P897; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levrero M, 2000, J CELL SCI, V113, P1661; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; McGregor JM, 2002, J INVEST DERMATOL, V119, P84, DOI 10.1046/j.1523-1747.2002.01655.x; Mihara M, 1999, BRIT J CANCER, V79, P164, DOI 10.1038/sj.bjc.6690027; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MIYASHITA T, 1995, CELL, V80, P293; Moll UM, 2001, BBA-REV CANCER, V1552, P47, DOI 10.1016/S0304-419X(01)00036-1; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Nicholls CD, 2002, J BIOL CHEM, V277, P12937, DOI 10.1074/jbc.M108815200; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Nomoto S, 1998, CANCER RES, V58, P1380; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Robles AI, 2001, CANCER RES, V61, P6660; ROLLEY N, 1995, ONCOGENE, V11, P763; Rossi FMV, 1998, CURR OPIN BIOTECH, V9, P451, DOI 10.1016/S0958-1669(98)80028-1; Saez E, 1997, CURR OPIN BIOTECH, V8, P608, DOI 10.1016/S0958-1669(97)80037-7; Sambrook J, 1989, MOL CLONING LAB MANU; Saranath D, 2002, GYNECOL ONCOL, V86, P157, DOI 10.1006/gyno.2002.6735; Sasaki Y, 2001, GENE THER, V8, P1401, DOI 10.1038/sj.gt.3301538; Shinoura N, 2000, CANCER LETT, V160, P67, DOI 10.1016/S0304-3835(00)00564-4; Sifakis S, 2001, CLIN GENET, V60, P165, DOI 10.1034/j.1399-0004.2001.600301.x; Soulitzis N, 2002, CANCER LETT, V179, P175, DOI 10.1016/S0304-3835(01)00867-9; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Sunahara M, 1998, INT J ONCOL, V13, P319; Tannapfel A, 1999, J NATL CANCER I, V91, P1154, DOI 10.1093/jnci/91.13.1154; Toruner GA, 2001, UROL RES, V29, P393; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yokomizo A, 1999, PROSTATE, V39, P94; Zhu JH, 2000, MOL CELL BIOL, V20, P5602, DOI 10.1128/MCB.20.15.5602-5618.2000; Zhu JH, 2000, J BIOL CHEM, V275, P39927, DOI 10.1074/jbc.M005676200; Zhu JH, 1998, CANCER RES, V58, P5061; Zhu KC, 1999, ONCOGENE, V18, P7740, DOI 10.1038/sj.onc.1203235	76	25	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 21	2003	22	35					5481	5495		10.1038/sj.onc.1206505	http://dx.doi.org/10.1038/sj.onc.1206505			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934108				2022-12-17	WOS:000184735000013
J	Pirkmaier, A; Dow, R; Ganiatsas, S; Waring, P; Warren, K; Thompson, A; Hendley, J; Germain, D				Pirkmaier, A; Dow, R; Ganiatsas, S; Waring, P; Warren, K; Thompson, A; Hendley, J; Germain, D			Alternative mammary oncogenic pathways are induced by D-type cyclins; MMTV-cyclin D3 transgenic mice develop squamous cell carcinoma	ONCOGENE			English	Article						MMTV; D-type cyclins; squamous differentiation	ESTROGEN-RECEPTOR; BREAST CANCERS; P27(KIP1); PROLIFERATION; ACTIVATION; GLAND; TRANSDIFFERENTIATION; DIFFERENTIATION; SEQUESTRATION; PROGRESSION	The three human D-type cyclins, cyclin D1, D2 and D3 share the ability to bind to and activate cdk4 and 6. MMTV-cyclin D1 transgenic mice develop mainly adenocarcinoma, while MMTV-cyclin D2 mice show a lack of alveologenesis during pregnancy and only develop carcinoma at low frequency. The effect of cyclin D3 overexpression in mammary glands remains hitherto unknown. We generated MMTV-cyclin D3 transgenic mice and report here that they develop exclusively squamous cell carcinoma. We show that although cyclin D3 transgene expression was detected early in puberty, postnatal development and mammary gland proliferation were normal in virgin animals. In contrast, multiparous mice develop multiple foci of abnormal growth that correspond to various stages of squamous metaplasia. Therefore, our results support a role for cyclin D3 in squamous differentiation. In addition, we found that p16 expression during involution is abolished, while p27 expression increased in MMTV-cyclin D3 mice, two modifications that have been reported in the other MMTV-D-type cyclin transgenic models. Our observations indicate that despite biochemical redundancy in vitro and in vivo, D-type cyclins promote distinct oncogenic pathways.	Peter MacCallum Canc Inst, Trescowthick Res Labs, Melbourne, Vic 3002, Australia; Peter MacCallum Canc Inst, Dept Pathol, Melbourne, Vic 3002, Australia; Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3010, Australia	Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; University of Melbourne	Germain, D (corresponding author), Peter MacCallum Canc Inst, Trescowthick Res Labs, St Andrews Pl, Melbourne, Vic 3002, Australia.							Bartkova J, 1998, ONCOGENE, V17, P1027, DOI 10.1038/sj.onc.1202016; Bartkova J, 1996, INT J CANCER, V65, P323, DOI 10.1002/(SICI)1097-0215(19960126)65:3<323::AID-IJC8>3.0.CO;2-1; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Ciemerych MA, 2002, GENE DEV, V16, P3277, DOI 10.1101/gad.1023602; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Evron E, 2001, CANCER RES, V61, P2782; Fantl V, 1999, DEV BIOL, V212, P1, DOI 10.1006/dbio.1999.9329; Gadd M, 2001, CANCER RES, V61, P8811; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Geng Y, 2001, P NATL ACAD SCI USA, V98, P194, DOI 10.1073/pnas.011522998; Hauser PJ, 1997, CELL GROWTH DIFFER, V8, P203; HUANG AL, 1981, CELL, V27, P245, DOI 10.1016/0092-8674(81)90408-6; Kong G, 2002, ONCOGENE, V21, P7214, DOI 10.1038/sj.onc.1205895; Miyoshi K, 2002, ONCOGENE, V21, P5548, DOI 10.1038/sj.onc.1205686; Miyoshi K, 2002, P NATL ACAD SCI USA, V99, P219, DOI 10.1073/pnas.012414099; Muraoka RS, 2001, J CELL BIOL, V153, P917, DOI 10.1083/jcb.153.5.917; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Sicinski P, 1997, J MAMMARY GLAND BIOL, V2, P335, DOI 10.1023/A:1026391128117; Signoretti S, 2002, J CLIN INVEST, V110, P633, DOI 10.1172/JCI200215795; Tong W, 2001, MOL CELL BIOL, V21, P1319, DOI 10.1128/MCB.21.4.1319-1328.2001; TOYASHIMA H, 1994, CELL, V78, P67; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Wong SCC, 2001, J PATHOL, V194, P35, DOI 10.1002/path.838; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6; Zwijsen RML, 1998, GENE DEV, V12, P3488, DOI 10.1101/gad.12.22.3488	31	25	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 10	2003	22	28					4425	4433		10.1038/sj.onc.1206488	http://dx.doi.org/10.1038/sj.onc.1206488			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698BZ	12853979				2022-12-17	WOS:000183978900012
J	Chamboredon, S; Briggs, J; Vial, E; Hurault, J; Galvagni, F; Oliviero, S; Bos, T; Castellazzi, M				Chamboredon, S; Briggs, J; Vial, E; Hurault, J; Galvagni, F; Oliviero, S; Bos, T; Castellazzi, M			v-Jun downregulates the SPARC target gene by binding to the proximal promoter indirectly through Sp1/3	ONCOGENE			English	Article						cell transformation; v-Jun; Sp1; Sp3; SPARC; primary chick embryo fibroblasts	CHICK-EMBRYO FIBROBLASTS; EXTRACELLULAR-MATRIX PROTEIN; C-JUN; TRANSCRIPTION FACTOR; NEOPLASTIC PROGRESSION; TRANSFORMING ACTIVITY; CELL-TRANSFORMATION; IN-VIVO; EXPRESSION; CANCER	Transformation of chick embryo fibroblasts by the v-Jun oncoprotein correlates with a downregulation of the extracellular matrix protein SPARC and repression of the corresponding mRNA. Repression of SPARC contributes to the oncogenic process by facilitating tumor development in vivo. A proximal promoter fragment, designated -124/+16, is responsible for high constitutive activity of the SPARC gene and is the target of repression by v-Jun. In this paper, using electrophoretic mobility shift and pull-down assays in vitro, and transient transfections and chromatin immunoprecipitation assays in Sp1/3-deficient Drosophila SL2 cells and in chick embryo fibroblasts, we show that (i) Sp1 and/or Sp3 is required for constitutive activation of SPARC transcription, by binding directly to the GGA-rich -92/-57 fragment; and (ii) v-Jun does not bind -124/+16 directly, but binds to the GGA-rich fragment indirectly, most likely through a physical interaction with Sp1/3. Moreover, a transactivation-proficient v-Jun derivative, designated v-Jun/cebp/glz, which cannot bind Jun DNA motifs anymore and cannot heterodimerize, is still capable of downregulating SPARC efficiently. Taken together, these data strongly suggest that v-Jun downregulates SPARC through the formation of a DNA-Sp1/3-v-Jun, chromatin-associated complex.	Ecole Normale Super Lyon, INSERM, U412, Unite Virol Humaine, F-69364 Lyon 07, France; Eastern Virginia Med Sch, Dept Microbiol & Mol Cell Biol, Norfolk, VA 23501 USA; Univ Siena, Dipartimento Biol Mol, I-53100 Siena, Italy	Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); Eastern Virginia Medical School; University of Siena	Castellazzi, M (corresponding author), Ecole Normale Super Lyon, INSERM, U412, Unite Virol Humaine, 46 Allee Italie, F-69364 Lyon 07, France.	marc.castellazzi@ens-lyon.fr	Galvagni, Federico/F-9186-2013; oliviero, salvatore/R-6657-2019	oliviero, salvatore/0000-0002-3405-765X				Acloque H, 2001, MECH DEVELOP, V103, P79, DOI 10.1016/S0925-4773(01)00336-7; Bader AG, 2001, ONCOGENE, V20, P7524, DOI 10.1038/sj.onc.1204938; Basso J, 2000, ONCOGENE, V19, P4876, DOI 10.1038/sj.onc.1203863; BELLAHCENE A, 1995, AM J PATHOL, V146, P95; Blaine SA, 2001, J BIOL CHEM, V276, P42737, DOI 10.1074/jbc.M107773200; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; Brekken RA, 2000, MATRIX BIOL, V19, P569, DOI 10.1016/S0945-053X(00)00105-0; Briggs J, 2002, ONCOGENE, V21, P7077, DOI 10.1038/sj.onc.1205857; CASTELLAZZI M, 1993, ONCOGENE, V8, P1149; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; Castro-Rivera E, 2001, J BIOL CHEM, V276, P30853, DOI 10.1074/jbc.M103339200; Chen BK, 2000, P NATL ACAD SCI USA, V97, P10406, DOI 10.1073/pnas.180321497; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Fu SL, 2000, ONCOGENE, V19, P3537, DOI 10.1038/sj.onc.1203691; Hartl M, 2001, P NATL ACAD SCI USA, V98, P13601, DOI 10.1073/pnas.241451198; HUGHES M, 1992, CELL GROWTH DIFFER, V3, P889; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Huguier S, 1998, MOL CELL BIOL, V18, P7020, DOI 10.1128/MCB.18.12.7020; Hussain S, 1998, CELL GROWTH DIFFER, V9, P677; Ihn H, 1997, J BIOL CHEM, V272, P24666, DOI 10.1074/jbc.272.39.24666; Jacob K, 1999, CANCER RES, V59, P4453; JOHNSON PF, 1993, MOL CELL BIOL, V13, P6919, DOI 10.1128/MCB.13.11.6919; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; Kockel L, 2001, ONCOGENE, V20, P2347, DOI 10.1038/sj.onc.1204300; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; Ledda F, 1997, J INVEST DERMATOL, V108, P210, DOI 10.1111/1523-1747.ep12334263; Melnikova IN, 2001, J BIOL CHEM, V276, P19040, DOI 10.1074/jbc.M010735200; METTOUCHI A, 1994, EMBO J, V13, P5668, DOI 10.1002/j.1460-2075.1994.tb06905.x; Mok SC, 1996, ONCOGENE, V12, P1895; OLIVIERO S, 1992, GENE DEV, V6, P1799, DOI 10.1101/gad.6.9.1799; Perez S, 2001, ONCOGENE, V20, P1135, DOI 10.1038/sj.onc.1204200; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Piu F, 2001, MOL CELL BIOL, V21, P3012, DOI 10.1128/MCB.21.9.3012-3024.2001; PORTE H, 1995, INT J CANCER, V64, P70, DOI 10.1002/ijc.2910640114; Rinehart-Kim J, 2000, INT J CANCER, V88, P180, DOI 10.1002/1097-0215(20001015)88:2<180::AID-IJC6>3.0.CO;2-H; Sambrook J., 1989, MOL CLONING LAB MANU; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SUCKOW M, 1993, EMBO J, V12, P1193, DOI 10.1002/j.1460-2075.1993.tb05760.x; Tone M, 2000, J IMMUNOL, V165, P286, DOI 10.4049/jimmunol.165.1.286; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDEL L, 1995, ONCOGENE, V10, P495; Vial E, 2000, ONCOGENE, V19, P1772, DOI 10.1038/sj.onc.1203493; Vial E, 2000, ONCOGENE, V19, P5020, DOI 10.1038/sj.onc.1203867; Vogt PK, 1999, CELL GROWTH DIFFER, V10, P777; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Wang CH, 2000, BIOCHEM BIOPH RES CO, V270, P303, DOI 10.1006/bbrc.2000.2422	50	25	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	2003	22	26					4047	4061		10.1038/sj.onc.1206713	http://dx.doi.org/10.1038/sj.onc.1206713			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821939				2022-12-17	WOS:000183707600008
J	Lewis, MD; Roberts, BJ				Lewis, MD; Roberts, BJ			Role of nuclear and cytoplasmic localization in the tumour-suppressor activity of the von Hippel-Lindau protein	ONCOGENE			English	Article						VHL; HIF-1 alpha; RCC	HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; REGULATE HIF; HYDROXYLATION; DEGRADATION; DISEASE; ALPHA; GENE; CELL; FIBRONECTIN; TRAFFICKING	Mutations in the von Hippel-Lindau (VHL) tumour-suppressor gene result in several forms of cancer. In the present study, we investigated the role of VHL subcellular localization in its antitumour properties. We generated renal cell carcinoma (RCC) lines stably expressing either exclusively nuclear (RCC/NLS-VHL), cytoplasmic (RCC/NES-VHL) or nucleo-cytoplasmic shuttling (RCC/DNES-VHL or RCC/VHL) forms of VHL and investigated several parameters linked to tumorigenesis and known to be dysregulated in VHL disease. Remarkably, although the expression of wild-type VHL is largely cytoplasmic, all of the antitumour properties of VHL tested could be reconstituted by expressing exclusively nuclear VHL.	Univ S Australia, Sch Pharmaceut Mol & Biomed Sci, Adelaide, SA 5000, Australia	University of South Australia	Roberts, BJ (corresponding author), Univ S Australia, Sch Pharmaceut Mol & Biomed Sci, Reid Bldg,Frome Rd, Adelaide, SA 5000, Australia.		Lewis, Martin/A-3881-2010; Lewis, Martin/A-8489-2008	Lewis, Martin/0000-0002-3332-3776				Berra E, 2001, EMBO REP, V2, P615, DOI 10.1093/embo-reports/kve130; Bonicalzi ME, 2001, J BIOL CHEM, V276, P1407, DOI 10.1074/jbc.M008295200; Clifford SC, 2001, ADV CANCER RES, V82, P85, DOI 10.1016/S0065-230X(01)82003-0; Clifford SC, 2001, HUM MOL GENET, V10, P1029, DOI 10.1093/hmg/10.10.1029; Davidowitz EJ, 2001, MOL CELL BIOL, V21, P865, DOI 10.1128/MCB.21.3.865-874.2001; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; Elson DA, 2001, GENE DEV, V15, P2520, DOI 10.1101/gad.914801; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Groulx I, 2002, MOL CELL BIOL, V22, P5319, DOI 10.1128/MCB.22.15.5319-5336.2002; Hoffman MA, 2001, HUM MOL GENET, V10, P1019, DOI 10.1093/hmg/10.10.1019; Huang JH, 2002, J BIOL CHEM, V277, P39792, DOI 10.1074/jbc.M206955200; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Ivan M, 2001, CURR OPIN GENET DEV, V11, P27, DOI 10.1016/S0959-437X(00)00152-0; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Koochekpour S, 1999, MOL CELL BIOL, V19, P5902; Lee S, 1996, P NATL ACAD SCI USA, V93, P1770, DOI 10.1073/pnas.93.5.1770; Lee S, 1999, MOL CELL BIOL, V19, P1486; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Pause A, 1998, P NATL ACAD SCI USA, V95, P993, DOI 10.1073/pnas.95.3.993; Roberts BJ, 1999, J BIOL CHEM, V274, P36351, DOI 10.1074/jbc.274.51.36351; Ruoslahti E, 1999, ADV CANCER RES, V76, P1, DOI 10.1016/S0065-230X(08)60772-1; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298	22	25	25	2	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 26	2003	22	26					3992	3997		10.1038/sj.onc.1206683	http://dx.doi.org/10.1038/sj.onc.1206683			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821933				2022-12-17	WOS:000183707600002
J	Maurer, P; T'Sas, F; Coutte, L; Callens, N; Brenner, C; Van Lint, C; de Launoit, Y; Baert, JL				Maurer, P; T'Sas, F; Coutte, L; Callens, N; Brenner, C; Van Lint, C; de Launoit, Y; Baert, JL			FEV acts as a transcriptional repressor through its DNA-binding ETS domain and alanine-rich domain	ONCOGENE			English	Article						Ets; transcription factor; repression	FAMILY MEMBER ERM; SIGNALING CASCADES; GENE-TRANSCRIPTION; FACTOR ER81; PEA3 GROUP; PROTEIN; TEL; CONTAINS; NET; TRANSACTIVATION	Although most Ets transcription factors have been characterized as transcriptional activators, some of them display repressor activity. Here we characterize an Ets-family member, the very specifically expressed human Fifth Ewing Variant (FEV), as a transcriptional repressor. We show that among a broad range of human cell lines, only Dami megakaryocytic cells express FEV. This nuclear protein binds to Ets-binding sites, such as that of the human ICAM-1 promoter. We used this promoter to demonstrate that FEV can repress both basal transcription and, even more strongly, ectopically Ets-activated transcription. We identified two domains responsible for FEV-mediated repression: the ETS domain, responsible for passive repression, and the carboxy-terminal alanine-rich domain, involved in active repression. In the Ets-independent LEXA system also, FEV acts as a transcriptional repressor via its alanine-rich carboxyterminal domain. The mechanism by which FEV actively represses transcription is currently unknown, since FEV-triggered repression is not reversed by the histone deacetylase inhibitor trichostatin A. We also showed that long-term overexpression of FEV proteins containing the alanine-rich domain prevents cell clones from growing, whereas clones expressing a truncated FEV protein lacking this domain develop like control cells. This confirms the importance of this domain in FEV-triggered repression.	Free Univ Brussels, Fac Med, Mol Virol Lab, B-1070 Brussels, Belgium; Univ Lille 1, Inst Pasteur, CNRS, UMR 8117,Inst Biol Lille, F-59021 Lille, France; Free Univ Brussels, Fac Sci, Inst Biol & Med Mol, Dept Mol Biol, B-6041 Gosselies, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille	de Launoit, Y (corresponding author), Free Univ Brussels, Fac Med, Mol Virol Lab, 808 Route Lennik,CP 614, B-1070 Brussels, Belgium.		callens, nathalie/P-2256-2016	callens, nathalie/0000-0002-7508-6596; coutte, laurent/0000-0002-0031-4742				Baert JL, 2002, J BIOL CHEM, V277, P1002, DOI 10.1074/jbc.M107139200; Baert JL, 1997, INT J CANCER, V70, P590, DOI 10.1002/(SICI)1097-0215(19970304)70:5<590::AID-IJC17>3.0.CO;2-H; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Briata P, 1997, FEBS LETT, V402, P131, DOI 10.1016/S0014-5793(96)01512-8; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; Courey AJ, 2001, GENE DEV, V15, P2786; Coutte L, 1999, ONCOGENE, V18, P6278, DOI 10.1038/sj.onc.1203020; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; de Launoit Y, 2000, ADV EXP MED BIOL, V480, P107; de Launoit Y, 1998, ONCOGENE, V16, P2065, DOI 10.1038/sj.onc.1201726; Defossez PA, 1997, NUCLEIC ACIDS RES, V25, P4455, DOI 10.1093/nar/25.22.4455; Ducret C, 2000, ONCOGENE, V19, P5063, DOI 10.1038/sj.onc.1203892; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; Fyodorov D, 1998, J NEUROBIOL, V34, P151, DOI 10.1002/(SICI)1097-4695(19980205)34:2<151::AID-NEU5>3.0.CO;2-1; Goodman FR, 1997, P NATL ACAD SCI USA, V94, P7458, DOI 10.1073/pnas.94.14.7458; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Guidez F, 2000, BLOOD, V96, P2557; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; Hendricks T, 1999, J NEUROSCI, V19, P10348; Janknecht R, 1996, ONCOGENE, V13, P1745; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; Laget MP, 1996, ONCOGENE, V12, P1325; Lemercier C, 2000, J BIOL CHEM, V275, P15594, DOI 10.1074/jbc.M908437199; Li RZ, 2000, ONCOGENE, V19, P745, DOI 10.1038/sj.onc.1203385; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; Maira SM, 1996, EMBO J, V15, P5849, DOI 10.1002/j.1460-2075.1996.tb00972.x; Maroulakou IG, 2000, ONCOGENE, V19, P6432, DOI 10.1038/sj.onc.1204039; Mavrothalassitis G, 2000, ONCOGENE, V19, P6524, DOI 10.1038/sj.onc.1204045; MONTE D, 1995, ONCOGENE, V11, P771; MONTE D, 1994, ONCOGENE, V9, P1397; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; Pfaar H, 2002, DEV GENES EVOL, V212, P43, DOI 10.1007/s00427-001-0208-x; RAYGALLET D, 1995, ONCOGENE, V11, P303; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; Xing XM, 2000, NAT MED, V6, P189, DOI 10.1038/72294; YEUNG KC, 1994, GENE DEV, V8, P2097, DOI 10.1101/gad.8.17.2097	40	25	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 22	2003	22	21					3319	3329		10.1038/sj.onc.1206572	http://dx.doi.org/10.1038/sj.onc.1206572			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681MM	12761502				2022-12-17	WOS:000183040000014
J	Sarna, MK; Ingley, E; Busfield, SJ; Cull, VS; Lepere, W; McCarthy, DJ; Wright, MJ; Palmer, GA; Chappell, D; Sayer, MS; Alexander, WS; Hilton, DJ; Starr, R; Watowich, SS; Bittorf, T; Klinken, SP; Tilbrook, PA				Sarna, MK; Ingley, E; Busfield, SJ; Cull, VS; Lepere, W; McCarthy, DJ; Wright, MJ; Palmer, GA; Chappell, D; Sayer, MS; Alexander, WS; Hilton, DJ; Starr, R; Watowich, SS; Bittorf, T; Klinken, SP; Tilbrook, PA			Differential regulation of SOCS genes in normal and transformed erythroid cells	ONCOGENE			English	Article							PHENYLHYDRAZINE-TREATED MICE; PROTEIN-TYROSINE KINASE; ERYTHROPOIETIN RECEPTOR; C-KIT; SIGNAL-TRANSDUCTION; PROGENITOR CELLS; IN-VIVO; ERYTHROLEUKEMIA DEVELOPMENT; TRANSLATIONAL REPRESSION; TRANSCRIPTION FACTOR	The SOCS family of genes are negative regulators of cytokine signalling with SOCS-1 displaying tumor suppressor activity. SOCS-1, CIS and SOCS-3 have been implicated in the regulation of red blood cell production. In this study, a detailed examination was conducted on the expression patterns of these three SOCS family members in normal erythroid progenitors and a panel of erythroleukemic cell lines. Unexpectedly, differences in SOCS gene expression were observed during maturation of normal red cell progenitors, viz changes to CIS were inversely related to the alterations of SOCS-1 and SOCS-3. Similarly, these SOCS genes were differentially expressed in transformed erythoid cells erythroleukemic cells immortalized at an immature stage of differentiation expressed SOCS-1 and SOCS-3 mRNA constitutively, whereas in more mature cell lines SOCS-1 and CIS were induced only after exposure to erythropoietin (Epo). Significantly, when ectopic expression of the tyrosine kinase Lyn was used to promote differentiation of immature cell lines, constitutive expression of SOCS-1 and SOCS-3 was completely suppressed. Modulation of intracellular signalling via mutated Epo receptors in mature erythroleukemic lines also highlighted different responses by the three SOCS family members. Close scrutiny of SOCS-1 revealed that, despite large increases in mRNA levels, the activity of the promoter did not alter after erythropoietin stimulation; in addition, erythroid cells from SOCS-1-/- mice displayed increased sensitivity to Epo. These observations indicate complex, stage-specific regulation of SOCS genes during normal erythroid maturation and in erythroleukemic cells.	Univ Western Australia, Royal Perth Hosp, Western Australian Inst Med Res, Lab Canc Med, Perth, WA 6009, Australia; Univ Western Australia, Med Res Ctr, Perth, WA 6009, Australia; Royal Perth Hosp, Western Australian Inst Med Res, Neurotrauma Lab, Perth, WA 6000, Australia; PO Box Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Melbourne, Vic, Australia; PO Box Royal Melbourne Hosp, Cooperat Res Ctr Cellular Growth Factors, Melbourne, Vic, Australia; Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; Univ Rostock, Inst Med Biochem, D-2500 Rostock 1, Germany	Royal Perth Hospital; University of Western Australia; University of Western Australia; Royal Perth Hospital; University of Western Australia; Royal Melbourne Hospital; Walter & Eliza Hall Institute; Royal Melbourne Hospital; University of Texas System; UTMD Anderson Cancer Center; University of Rostock	Klinken, SP (corresponding author), Western Australian Inst Med Res, Lab Canc Med, 6th Floor MRF Bldg,Rear,50 Murray St, Perth, WA 6000, Australia.	pklinken@waimr.uwa.edu.au	Fear, Vanessa/A-6876-2013; Fear, Vanessa S/AAF-9805-2020; Hilton, Douglas J/C-7250-2013; Sarna, Mohinder/Q-7834-2016; Sarna, Mohinder/AAO-9343-2020; Ingley, Evan/C-2401-2013; Sarna, Mohinder/GYR-3271-2022; Fear, Vanessa/O-5618-2019	Fear, Vanessa S/0000-0001-8363-6685; Hilton, Douglas J/0000-0002-7698-2392; Sarna, Mohinder/0000-0002-2448-1588; Sarna, Mohinder/0000-0002-2448-1588; Ingley, Evan/0000-0002-8112-9134; Watowich, Stephanie/0000-0003-1969-659X	NATIONAL CANCER INSTITUTE [R01CA022556, R01CA077447, R37CA022556] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA022556, R37 CA022556, R01 CA077447-03, CA-77447, CA-22556, R01 CA077447-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; BIEKER JJ, 1995, MOL CELL BIOL, V15, P852; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Brysha M, 2001, J BIOL CHEM, V276, P22086, DOI 10.1074/jbc.M102737200; BUSFIELD SJ, 1992, BLOOD, V80, P412; Cacalano NA, 2001, NAT CELL BIOL, V3, P460, DOI 10.1038/35074525; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Cohney SJ, 1999, MOL CELL BIOL, V19, P4980; Constantinescu SN, 1999, TRENDS ENDOCRIN MET, V10, P18, DOI 10.1016/S1043-2760(98)00101-5; COOPER MC, 1974, P NATL ACAD SCI USA, V71, P1677, DOI 10.1073/pnas.71.5.1677; CORY S, 1991, CELL GROWTH DIFFER, V2, P165; Cull V, 2000, ONCOGENE, V19, P953, DOI 10.1038/sj.onc.1203370; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; De Sepulveda P, 1999, EMBO J, V18, P904; DEJONG MO, 1995, BLOOD, V86, P4076, DOI 10.1182/blood.V86.11.4076.bloodjournal86114076; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Gregorieff A, 2000, J BIOL CHEM, V275, P21596, DOI 10.1074/jbc.M910087199; HAWLEY RG, 1994, GENE THER, V1, P136; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Hodges VM, 1999, BRIT J HAEMATOL, V106, P325, DOI 10.1046/j.1365-2141.1999.01535.x; IACOPETTA BJ, 1982, BIOCHIM BIOPHYS ACTA, V687, P204, DOI 10.1016/0005-2736(82)90547-8; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Klingmuller U, 1997, EUR J BIOCHEM, V249, P637, DOI 10.1111/j.1432-1033.1997.t01-1-00637.x; KLINKEN SP, 1988, P NATL ACAD SCI USA, V85, P8506, DOI 10.1073/pnas.85.22.8506; KLINKEN SP, 1990, LEUKEMIA, V4, P24; KOURY MJ, 1992, EUR J BIOCHEM, V210, P649, DOI 10.1111/j.1432-1033.1992.tb17466.x; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; LANDSCHULZ KT, 1989, BLOOD, V73, P1476; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; MARSHALL CJ, 1988, J CELL SCI, P157; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Metcalf D, 1999, LEUKEMIA, V13, P926, DOI 10.1038/sj.leu.2401440; METZ T, 1995, CELL, V82, P29, DOI 10.1016/0092-8674(95)90049-7; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MIURA O, 1994, BLOOD, V84, P1501; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; Ohya K, 1997, J BIOL CHEM, V272, P27178, DOI 10.1074/jbc.272.43.27178; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; Pircher TJ, 2001, J BIOL CHEM, V276, P8995, DOI 10.1074/jbc.M007473200; RAYNER JR, 1994, MOL CELL BIOL, V14, P880, DOI 10.1128/MCB.14.2.880; Roberts AW, 2001, P NATL ACAD SCI USA, V98, P9324, DOI 10.1073/pnas.161271798; Rottapel R, 2002, ONCOGENE, V21, P4351, DOI 10.1038/sj.onc.1205537; Saito H, 2000, J IMMUNOL, V164, P5833, DOI 10.4049/jimmunol.164.11.5833; Sasaki A, 2000, J BIOL CHEM, V275, P29338, DOI 10.1074/jbc.M003456200; Schluter G, 2000, BIOCHEM BIOPH RES CO, V268, P255, DOI 10.1006/bbrc.2000.2109; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Tilbrook PA, 1999, GROWTH FACTORS, V17, P25, DOI 10.3109/08977199909001060; Tilbrook PA, 1996, J BIOL CHEM, V271, P3453; Tilbrook PA, 1996, CELL GROWTH DIFFER, V7, P511; Tilbrook PA, 1997, EMBO J, V16, P1610, DOI 10.1093/emboj/16.7.1610; Tilbrook PA, 2001, ARCH BIOCHEM BIOPHYS, V396, P128, DOI 10.1006/abbi.2001.2577; Tilbrook PA, 2001, CANCER RES, V61, P2453; TROWBRIDGE IS, 1982, J CELL PHYSIOL, V112, P403, DOI 10.1002/jcp.1041120314; UOSHIMA N, 1995, BRIT J HAEMATOL, V91, P30, DOI 10.1111/j.1365-2141.1995.tb05240.x; Vannucchi AM, 2000, BLOOD, V95, P2559; Verdier F, 1998, J BIOL CHEM, V273, P28185, DOI 10.1074/jbc.273.43.28185; Verdier F, 1998, MOL CELL BIOL, V18, P5852, DOI 10.1128/MCB.18.10.5852; Waldmann V, 1996, PATHOL RES PRACT, V192, P883, DOI 10.1016/S0344-0338(96)80067-7; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071	66	25	26	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2003	22	21					3221	3230		10.1038/sj.onc.1206381	http://dx.doi.org/10.1038/sj.onc.1206381			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681MM	12761492	Green Accepted			2022-12-17	WOS:000183040000004
J	Dekoninck, A; Calomme, C; Nizet, S; de Launoit, Y; Burny, A; Ghysdael, J; Van Lint, C				Dekoninck, A; Calomme, C; Nizet, S; de Launoit, Y; Burny, A; Ghysdael, J; Van Lint, C			Identification and characterization of a PU.1/Spi-B binding site in the bovine leukemia virus long terminal repeat	ONCOGENE			English	Review						BLV; transcription; PU.1; spi-b	TRANSCRIPTION FACTOR PU.1; NF-KAPPA-B; PERIPHERAL-BLOOD LYMPHOCYTES; SPI-B; ETS-DOMAIN; IN-VIVO; REGULATORY ELEMENTS; PUTATIVE ONCOGENE; GENE-EXPRESSION; NUCLEAR-FACTOR	Bovine leukemia virus (BLV) is a B-lymphotropic oncogenic retrovirus whose transcriptional promoter is located in the viral 5' long terminal repeat (LTR). To date, no B-lymphocyte-specific cis-regulatory element has been identified in this region. Since ETS proteins are known to regulate transcription of numerous retroviruses, we searched for the presence in the BLV promoter region of binding sites for PU.1/Spi-1, a B-cell- and macrophage-specific ETS family member. In this report, nucleotide sequence analysis of the viral LTR identified a PUbox located at -95/-84 bp. We demonstrated by gel shift and supershift assays that PU.1 and the related Ets transcription factor Spi-B interacted specifically with this PUbox. A 2-bp mutation (GGAA --> CCAA) within this motif abrogated PU.1/Spi-B binding. This mutation caused a marked decrease in LTR-driven basal gene expression in transient transfection assays of B-lymphoid cell tines, but did not impair the responsiveness of the BLV promoter to the virus-encoded transactivator Tax(BLV). Moreover, ectopically expressed PU.1 and Spi-B proteins transactivated the BLV promoter in a PUbox-dependent manner. Taken together, our results provide the first demonstration of regulation of the BLV promoter by two B-cell-specific Ets transcription factors, PU.1 and Spi-B. The PU.1/Spi-B binding site identified here could play an important role in BLV replication and B-lymphoid tropism.	Free Univ Brussels, IBMM, Serv Chim Biol, Mol Virol Lab, B-6041 Gosselies, Belgium; Free Univ Brussels, Fac Med, Mol Virol Lab, B-1070 Brussels, Belgium; Univ Lille 1, CNRS, UMR 8117, Inst Biol Lille,Inst Pasteur Lille, F-59021 Lille, France; Ctr Univ Orsay, Inst Curie, CNRS, UMR 146, F-91405 Orsay, France	Universite Libre de Bruxelles; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Van Lint, C (corresponding author), Free Univ Brussels, IBMM, Serv Chim Biol, Mol Virol Lab, Rue Profs Jeener & Brachet 12, B-6041 Gosselies, Belgium.	cvlint@ulb.ac.be	GHYSDAEL, Jacques/F-3377-2013					Adam E, 1996, J VIROL, V70, P1990, DOI 10.1128/JVI.70.3.1990-1999.1996; ADAM E, 1994, J VIROL, V68, P5845, DOI 10.1128/JVI.68.9.5845-5853.1994; AIDA Y, 1989, AM J VET RES, V50, P1946; Aurrekoetxea-Hernandez K, 2000, J VIROL, V74, P4988, DOI 10.1128/JVI.74.11.4988-4998.2000; BLOOM JC, 1979, BLOOD, V53, P899; BLOOM JC, 1980, CANCER RES, V40, P2240; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKS PA, 1995, J VIROL, V69, P6005, DOI 10.1128/JVI.69.10.6005-6009.1995; Brooks PA, 1998, VIROLOGY, V243, P94, DOI 10.1006/viro.1998.9035; BURNY A, 1987, CANCER SURV, V6, P139; BURNY A, 1994, SYMP SOC GEN MICROBI, V51, P213; BURNY A, 1987, VIRAL ONCOLOGY, P231; Calomme C, 2002, J BIOL CHEM, V277, P8775, DOI 10.1074/jbc.M107441200; Carey JO, 1996, BLOOD, V87, P4316, DOI 10.1182/blood.V87.10.4316.bloodjournal87104316; CARVALHO M, 1993, J VIROL, V67, P6586, DOI 10.1128/JVI.67.11.6586-6595.1993; CARVALHO M, 1993, J VIROL, V67, P3885, DOI 10.1128/JVI.67.7.3885-3890.1993; CHEN HM, 1995, BLOOD, V85, P2918, DOI 10.1182/blood.V85.10.2918.bloodjournal85102918; CHEN HM, 1993, J BIOL CHEM, V268, P8230; CHEN HM, 1995, ONCOGENE, V11, P1549; CLARK NM, 1993, J VIROL, V67, P5522, DOI 10.1128/JVI.67.9.5522-5528.1993; Dahl R, 2002, EMBO J, V21, P2220, DOI 10.1093/emboj/21.9.2220; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DERSE D, 1987, J VIROL, V61, P2462, DOI 10.1128/JVI.61.8.2462-2471.1987; DERSE D, 1986, SCIENCE, V231, P1437, DOI 10.1126/science.3006241; DJILALI S, 1987, LEUKEMIA, V1, P777; EISENBEIS CF, 1993, MOL CELL BIOL, V13, P6452, DOI 10.1128/MCB.13.10.6452; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; ERSELIUS JR, 1990, J VIROL, V64, P1657, DOI 10.1128/JVI.64.4.1657-1666.1990; FEINMAN R, 1994, EMBO J, V13, P3852, DOI 10.1002/j.1460-2075.1994.tb06696.x; FERRER JF, 1979, J AM VET MED ASSOC, V175, P1281; Ford AM, 1996, P NATL ACAD SCI USA, V93, P10838, DOI 10.1073/pnas.93.20.10838; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; GITLIN SD, 1993, J VIROL, V67, P7307, DOI 10.1128/JVI.67.12.7307-7316.1993; GITLIN SD, 1991, J VIROL, V65, P5513, DOI 10.1128/JVI.65.10.5513-5523.1991; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; HENKEL G, 1994, P NATL ACAD SCI USA, V91, P7737, DOI 10.1073/pnas.91.16.7737; Heydemann A, 1996, MOL CELL BIOL, V16, P1676; Himmelmann A, 1996, BLOOD, V87, P1036, DOI 10.1182/blood.V87.3.1036.bloodjournal8731036; HOLZMEISTER J, 1993, BIOCHEM BIOPH RES CO, V197, P1229, DOI 10.1006/bbrc.1993.2608; HORVAI A, 1995, P NATL ACAD SCI USA, V92, P5391, DOI 10.1073/pnas.92.12.5391; HROMAS R, 1993, BLOOD, V82, P2998; Hu CJ, 2001, IMMUNITY, V15, P545, DOI 10.1016/S1074-7613(01)00219-9; Jeeninga RE, 2000, J VIROL, V74, P3740, DOI 10.1128/JVI.74.8.3740-3751.2000; JENSEN WA, 1992, J VIROL, V66, P4427, DOI 10.1128/JVI.66.7.4427-4433.1992; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KATOH I, 1989, EMBO J, V8, P497, DOI 10.1002/j.1460-2075.1989.tb03403.x; Kettmann R., 1994, The retroviridae: Volume 3, P39; Kiermer V, 1998, J VIROL, V72, P5526, DOI 10.1128/JVI.72.7.5526-5534.1998; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; Kihara-Negishi F, 2001, ONCOGENE, V20, P6039, DOI 10.1038/sj.onc.1204756; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; KOMINATO Y, 1995, MOL CELL BIOL, V15, P58; LAGARIAS DM, 1989, J VIROL, V63, P2099, DOI 10.1128/JVI.63.5.2099-2107.1989; LAUX G, 1994, EMBO J, V13, P5624, DOI 10.1002/j.1460-2075.1994.tb06900.x; LEIDEN JM, 1992, J VIROL, V66, P5890, DOI 10.1128/JVI.66.10.5890-5897.1992; Li SL, 1999, J BIOL CHEM, V274, P32453, DOI 10.1074/jbc.274.45.32453; Lodie TA, 1997, J IMMUNOL, V158, P1848; Lodie TA, 1998, J IMMUNOL, V161, P268; Lopez-Rovira T, 2000, J BIOL CHEM, V275, P28937, DOI 10.1074/jbc.M909923199; Maitra S, 2000, MOL CELL BIOL, V20, P1911, DOI 10.1128/MCB.20.6.1911-1922.2000; Mao C, 1996, ONCOGENE, V12, P863; Marecki S, 2000, CELL BIOCHEM BIOPHYS, V33, P127, DOI 10.1385/CBB:33:2:127; MARKOVITZ DM, 1992, J VIROL, V66, P5479, DOI 10.1128/JVI.66.9.5479-5484.1992; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; Muller S, 1996, ONCOGENE, V13, P1955; Myers GK, 1995, HUMAN RETROVIRUSES A; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; Niermann GL, 1997, VIROLOGY, V239, P249, DOI 10.1006/viro.1997.8868; Nikolajczyk BS, 1999, IMMUNITY, V11, P11, DOI 10.1016/S1074-7613(00)80077-1; Nuchprayoon I, 1997, BLOOD, V89, P4546, DOI 10.1182/blood.V89.12.4546; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PAUL R, 1991, J VIROL, V65, P464, DOI 10.1128/JVI.65.1.464-467.1991; PEREZ C, 1994, MOL CELL BIOL, V14, P5023, DOI 10.1128/MCB.14.8.5023; Pio F, 1996, J BIOL CHEM, V271, P23329, DOI 10.1074/jbc.271.38.23329; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; Posada R, 2000, AIDS RES HUM RETROV, V16, P1981, DOI 10.1089/088922200750054710; QUANG CT, 1995, ONCOGENE, V11, P1229; Rao S, 1999, J BIOL CHEM, V274, P34245, DOI 10.1074/jbc.274.48.34245; Rao S, 1999, J BIOL CHEM, V274, P11115, DOI 10.1074/jbc.274.16.11115; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; RAYGALLET D, 1995, ONCOGENE, V11, P303; ROSEN CA, 1986, J VIROL, V57, P738, DOI 10.1128/JVI.57.3.738-744.1986; ROSEN CA, 1985, SCIENCE, V227, P320, DOI 10.1126/science.2981432; ROSMARIN AG, 1995, P NATL ACAD SCI USA, V92, P801, DOI 10.1073/pnas.92.3.801; ROSMARIN AG, 1995, J BIOL CHEM, V270, P23627, DOI 10.1074/jbc.270.40.23627; SAGATA N, 1985, P NATL ACAD SCI USA, V82, P677, DOI 10.1073/pnas.82.3.677; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SEELER JS, 1993, VIROLOGY, V196, P442, DOI 10.1006/viro.1993.1500; SHIN MK, 1993, GENE DEV, V7, P2006, DOI 10.1101/gad.7.10.2006; Smith LT, 1996, BLOOD, V88, P1234, DOI 10.1182/blood.V88.4.1234.bloodjournal8841234; Smith MF, 1998, J BIOL CHEM, V273, P24272, DOI 10.1074/jbc.273.37.24272; Su GH, 1996, J EXP MED, V184, P203, DOI 10.1084/jem.184.1.203; TANIMURA A, 1993, J VIROL, V67, P5375, DOI 10.1128/JVI.67.9.5375-5382.1993; Tsukada J, 1997, BLOOD, V90, P3142, DOI 10.1182/blood.V90.8.3142; VANLINT C, 1994, J VIROL, V68, P2632, DOI 10.1128/JVI.68.4.2632-2648.1994; Verhoef K, 1999, J VIROL, V73, P1331, DOI 10.1128/JVI.73.2.1331-1340.1999; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WILLEMS L, 1993, J VIROL, V67, P1086, DOI 10.1128/JVI.67.2.1086-1089.1993; Willems L, 2000, AIDS RES HUM RETROV, V16, P1787, DOI 10.1089/08892220050193326; WILLEMS L, 1999, CURRENT TOP VIROL, V1, P139; Xiao JQ, 1998, J VIROL, V72, P5994, DOI 10.1128/JVI.72.7.5994-6003.1998; Yamamoto H, 1999, ONCOGENE, V18, P1495, DOI 10.1038/sj.onc.1202427; Yamamoto H, 2002, CELL GROWTH DIFFER, V13, P69; Yang ZY, 2000, J BIOL CHEM, V275, P21272, DOI 10.1074/jbc.M000145200; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	113	25	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2003	22	19					2882	2896		10.1038/sj.onc.1206392	http://dx.doi.org/10.1038/sj.onc.1206392			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	677TY	12771939				2022-12-17	WOS:000182824800003
J	Pajer, P; Pecenka, V; Karafiat, V; Kralova, J; Horejsi, Z; Dvorak, M				Pajer, P; Pecenka, V; Karafiat, V; Kralova, J; Horejsi, Z; Dvorak, M			The twist gene is a common target of retroviral integration and transcriptional deregulation in experimental nephroblastoma	ONCOGENE			English	Article						Twist gene; MAV retrovirus; common viral integration site; nephroblastoma	MYELOBLASTOSIS-ASSOCIATED VIRUS; SAETHRE-CHOTZEN-SYNDROME; PROTEIN; MUTATIONS; ONCOGENE; CANCER; CELLS; BHLH; NOV	The genes involved in the transformation of kidney blastema cells were searched for in avian nephroblastomas induced by the MAV2 retrovirus. The twist gene was identified as a common site of provirus integration in tumor cells. Twist was rearranged by the MAV2 provirus in three out of 76 independent nephroblastoma samples. The MAV2 integration sites were localized within 40 nucleotides of the twist 5'UTR region, right upstream from the ATG initiation codon. The integrated proviruses were deleted at their 5'ends. As a consequence, twist transcription became controlled by the retroviral 3'LTR promoter and was strongly upregulated, more than 200 times. In addition, 2-100 times elevated twist transcription was also detected in the majority of other nephroblastoma samples not containing MAV2 in the twist locus. We propose that chicken nephroblastoma originates from a single blastemic cell in which the MAV retrovirus, through its integration, has deregulated specific combinations of genes controlling proliferation and differentiation. The activation of the twist gene expression appears to contribute to tumorigenesis, as there is an in vivo positive selection of tumor cell clones containing the twist gene hyperactivated by MAV2 sequences inserted within the twist promoter.	Acad Sci Czech Republ, Inst Mol Genet, CR-16637 Prague 6, Czech Republic	Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences	Dvorak, M (corresponding author), Acad Sci Czech Republ, Inst Mol Genet, Flemingovo 2, CR-16637 Prague 6, Czech Republic.		Kralova, Jarmila/G-3834-2014; Dvořák, Michal/I-9939-2014; Dvorak, Michal/G-5861-2014; Pajer, Petr/G-5869-2014	Kralova, Jarmila/0000-0002-4735-8857; Licenikova Horejsi, Zuzana/0000-0002-9943-1649				Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Baskaran N, 1996, GENOME RES, V6, P633, DOI 10.1101/gr.6.7.633; BONISCHNETZLER M, 1985, J VIROL, V55, P213; Bourgeois P, 1998, HUM MOL GENET, V7, P945, DOI 10.1093/hmg/7.6.945; Castanon I, 2002, GENE, V287, P11, DOI 10.1016/S0378-1119(01)00893-9; COFFIN JM, 1997, RETROVIRUSES; COLLART KL, 1990, J VIROL, V64, P3541, DOI 10.1128/JVI.64.7.3541-3544.1990; Dome JS, 2002, CURR OPIN PEDIATR, V14, P5, DOI 10.1097/00008480-200202000-00002; ElGhouzzi V, 1997, NAT GENET, V15, P42; Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3; Howard TD, 1997, NAT GENET, V15, P36, DOI 10.1038/ng0197-36; ISHIGURO H, 1962, J NATL CANCER I, V29, P1; Joliot V, 1996, J VIROL, V70, P2576, DOI 10.1128/JVI.70.4.2576-2580.1996; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; Lee MS, 1999, J CELL BIOCHEM, V75, P566, DOI 10.1002/(SICI)1097-4644(19991215)75:4<566::AID-JCB3>3.0.CO;2-0; LI L, 1995, DEV BIOL, V172, P280, DOI 10.1006/dbio.1995.0023; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; PECENKA V, 1988, FOLIA BIOL-PRAGUE, V34, P147; PECENKA V, 1988, FOLIA BIOL-PRAGUE, V34, P215; PECENKA V, 1988, FOLIA BIOL-PRAGUE, V34, P129; Perbal B, 2001, J CLIN PATHOL-MOL PA, V54, P57, DOI 10.1136/mp.54.2.57; Plachy J, 1997, FOLIA BIOL-PRAGUE, V43, P133; ROBINSON HL, 1986, J VIROL, V57, P28, DOI 10.1128/JVI.57.1.28-36.1986; Scharnhorst V, 2001, GENE, V273, P141, DOI 10.1016/S0378-1119(01)00593-5; Spicer DB, 1996, SCIENCE, V272, P1476, DOI 10.1126/science.272.5267.1476; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; WESTAWAY D, 1986, EMBO J, V5, P301, DOI 10.1002/j.1460-2075.1986.tb04213.x	28	25	25	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 6	2003	22	5					665	673		10.1038/sj.onc.1206105	http://dx.doi.org/10.1038/sj.onc.1206105			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569359				2022-12-17	WOS:000180642100004
J	Waga, K; Nakamura, Y; Maki, K; Arai, H; Yamagata, T; Sasaki, K; Kurokawa, M; Hirai, H; Mitani, K				Waga, K; Nakamura, Y; Maki, K; Arai, H; Yamagata, T; Sasaki, K; Kurokawa, M; Hirai, H; Mitani, K			Leukemia-related transcription factor TEL accelerates differentiation of Friend erythroleukemia cells	ONCOGENE			English	Article						erythroid differentiation; FLI-1; MEL; TEL	LONG TERMINAL REPEAT; ERYTHROID-DIFFERENTIATION; MYELOID-LEUKEMIA; FUSION PROTEIN; HISTONE DEACETYLASE; CO-REPRESSORS; GENE; FLI-1; VIRUS; ACTIVATION	TEL belongs to a member of the ETS family transcription factors that represses transcription of target genes such as FLI-1. Although TEL is essential for establishing hematopoiesis in neonatal bone marrow, its role in erythroid lineage is not understood. To investigate a role for TEL in erythroid differentiation, we introduced TEL into mouse erythroleukemia (MEL) cells. Overexpressing wild-type-TEL in MEL cells enhanced differentiation induced by hexamethylene bisacetamide or dimethylsulfoxide, as judged by the increased levels of erythroid-specific delta-aminolevulinate synthase and beta-globin mRNAs. TEL bound to a corepressor mSin3A through the helix-loop-helix domain. A TEL mutant lacking this domain still bound to the ETS binding site, but lost its transrepressional effect. This mutant completely blocked erythroid differentiation in MEL cells. Moreover, it showed dominant-negative effects over TEL-mediated transcriptional repression and acceleration of erythroid differentiation. Endogenous TEL mRNA was found to increase during the first 3 days in differentiating MEL cells and drastically decrease thereafter. All these data suggest that TEL might play some role in erythroid cell differentiation.	Dokkyo Univ, Sch Med, Dept Hematol, Mibu, Tochigi 3210293, Japan; Univ Tokyo, Dept Hematol & Oncol, Grad Sch Med, Tokyo 1138655, Japan	Dokkyo Medical University; University of Tokyo	Mitani, K (corresponding author), Dokkyo Univ, Sch Med, Dept Hematol, 880 Kitakobayashi, Mibu, Tochigi 3210293, Japan.							Athanasiou M, 2000, LEUKEMIA, V14, P439, DOI 10.1038/sj.leu.2401689; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; Buijs A, 2000, MOL CELL BIOL, V20, P9281, DOI 10.1128/MCB.20.24.9281-9293.2000; Fenrick R, 2000, MOL CELL BIOL, V20, P5828, DOI 10.1128/MCB.20.16.5828-5839.2000; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; Gu XS, 2001, J BIOL CHEM, V276, P9421, DOI 10.1074/jbc.M010070200; Guidez F, 2000, BLOOD, V96, P2557; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; Kim CA, 2001, EMBO J, V20, P4173, DOI 10.1093/emboj/20.15.4173; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Kuno Y, 2001, BLOOD, V97, P1050, DOI 10.1182/blood.V97.4.1050; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; Maki K, 1999, BLOOD, V93, P3216, DOI 10.1182/blood.V93.10.3216.410k45_3216_3224; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; Martinez R, 2000, BLOOD, V96, p453A; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nicol R, 1998, J BIOL CHEM, V273, P3588, DOI 10.1074/jbc.273.6.3588; Pereira R, 1999, ONCOGENE, V18, P1597, DOI 10.1038/sj.onc.1202534; Poirel H, 1997, ONCOGENE, V14, P349, DOI 10.1038/sj.onc.1200829; Potter MD, 2000, BLOOD, V95, P3341, DOI 10.1182/blood.V95.11.3341.011k44_3341_3348; Spyropoulos DD, 2000, MOL CELL BIOL, V20, P5643, DOI 10.1128/MCB.20.15.5643-5652.2000; Starck J, 1999, MOL CELL BIOL, V19, P121; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; TANAKA T, 1994, J BIOL CHEM, V269, P24020; Turner J, 2001, BIOESSAYS, V23, P683, DOI 10.1002/bies.1097; Van Rompaey L, 2000, ONCOGENE, V19, P5244, DOI 10.1038/sj.onc.1203899; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392; Wang LL, 2001, ONCOGENE, V20, P3716, DOI 10.1038/sj.onc.1204479	40	25	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 9	2003	22	1					59	68		10.1038/sj.onc.1206072	http://dx.doi.org/10.1038/sj.onc.1206072			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	631KL	12527908				2022-12-17	WOS:000180166900007
J	Chadee, DN; Peltier, CP; Davie, JR				Chadee, DN; Peltier, CP; Davie, JR			Histone H1(S)-3 phosphorylation in Ha-ras oncogene-transformed mouse fibroblasts	ONCOGENE			English	Article						histone Hl; ras oncogene; Cdk2	NIH 3T3 CELLS; G1 PHASE; SER-10 PHOSPHORYLATION; MAMMALIAN-CELLS; GENE-EXPRESSION; H1; KINASE; PROGRESSION; CHROMATIN; CYCLE	Phosphorylation of linker histone H1(S)-3 (previously named H1b) and core histone H3 is elevated in mouse fibroblasts transformed with oncogenes or constitutively active mitogen-activated protein kinase (MAPK) kinase (MEK). H1(S)-3 phosphorylation is the only histone modification known to be dependent upon transcription and replication. Our results show that the increased amounts of phosphorylated H1(S)-3 in the oncogene Ha-ras-transformed mouse fibroblasts was a consequence of an elevated Cdk2 activity rather than the reduced activity of a H1 phosphatase, which our studies suggest is PP1. Induction of oncogenic ras expression results in an increase in H1(S)-3 and H3 phosphorylation. However, in contrast to the phosphorylation of H3, which occurred immediately following the onset of Ras expression, there was a lag of several hours before H1(S)-3 phosphorylation levels increased. We found that there was a transient increase in the levels of P21(cip1), which inhibited the HI kinase activity of Cdk2. Cdk2 activity and H1(S)-3 phosphorylated levels increased after p21(cip1) levels declined. Our studies suggest that persistent activation of the Ras-MAPK signal transduction pathway in oncogene-transformed cells results in deregulated activity of kinases phosphorylating H3 and H1(S)-3 associated with transcribed genes. The chromatin remodelling actions of these modified histones may result in aberrant gene expression.	Manitoba Inst Cell Biol, Winnipeg, MB R3E 0V9, Canada		Davie, JR (corresponding author), Manitoba Inst Cell Biol, 675 McDeermot Ave, Winnipeg, MB R3E 0V9, Canada.	Davie@cc.umanitoba.ca		Davie, James/0000-0002-0420-6888				Bottazzi ME, 1999, J CELL BIOL, V146, P1255, DOI 10.1083/jcb.146.6.1255; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Chadee DN, 1997, J BIOL CHEM, V272, P8113, DOI 10.1074/jbc.272.13.8113; CHADEE DN, 1995, J BIOL CHEM, V270, P20098, DOI 10.1074/jbc.270.34.20098; CRISSMAN HA, 1991, P NATL ACAD SCI USA, V88, P7580, DOI 10.1073/pnas.88.17.7580; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; GADBOIS DM, 1992, BIOCHEM BIOPH RES CO, V184, P80, DOI 10.1016/0006-291X(92)91160-R; GADBOIS DM, 1992, P NATL ACAD SCI USA, V89, P8626, DOI 10.1073/pnas.89.18.8626; HALIOTIS T, 1990, INT J CANCER, V45, P1177, DOI 10.1002/ijc.2910450631; Herrera RE, 1996, P NATL ACAD SCI USA, V93, P11510, DOI 10.1073/pnas.93.21.11510; Kivinen L, 1999, ONCOGENE, V18, P6252, DOI 10.1038/sj.onc.1203000; KRAEMER PM, 1993, EXP CELL RES, V207, P206, DOI 10.1006/excr.1993.1183; LAITINEN J, 1990, J CELL BIOL, V111, P9, DOI 10.1083/jcb.111.1.9; LAITINEN J, 1995, J CELL BIOCHEM, V57, P1, DOI 10.1002/jcb.240570102; Lee HL, 1998, EMBO J, V17, P1454, DOI 10.1093/emboj/17.5.1454; LENNOX RW, 1982, J BIOL CHEM, V257, P5183; LU MJ, 1994, CHROMOSOMA, V103, P111; Maharizi M, 1999, J OPTOELECTRON ADV M, V1, P65; MELLO MLS, 1994, ANAL QUANT CYTOL, V16, P113; Parseghian MH, 2000, CHROMOSOME RES, V8, P405, DOI 10.1023/A:1009262819961; Parseghian MH, 2001, BIOCHEM CELL BIOL, V79, P289; Paulson JR, 1996, J CELL SCI, V109, P1437; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; ROTH SY, 1992, TRENDS BIOCHEM SCI, V17, P93, DOI 10.1016/0968-0004(92)90243-3; Strelkov IS, 2002, CANCER RES, V62, P75; TAN KB, 1982, J BIOL CHEM, V257, P5337; Taylor WR, 1995, FEBS LETT, V377, P51, DOI 10.1016/0014-5793(95)01314-8; TUCK AB, 1991, J NATL CANCER I, V83, P485; WRIGHT JA, 1990, ANTICANCER RES, V10, P1247	29	25	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 5	2002	21	55					8397	8403		10.1038/sj.onc.1206029	http://dx.doi.org/10.1038/sj.onc.1206029			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	619MQ	12466960				2022-12-17	WOS:000179480100003
J	Dahm, K; Hubscher, U				Dahm, K; Hubscher, U			Colocalization of human Rad17 and PCNA in late S phase of the cell cycle upon replication block	ONCOGENE			English	Article						DNA replication checkpoint; hRad17; PCNA; hRad9; confocal microscopy	DNA-DAMAGE CHECKPOINT; FACTOR-C COMPLEX; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; IONIZING-RADIATION; NUCLEAR ANTIGEN; PROTEIN-KINASE; BUDDING YEAST; FISSION YEAST; SMALL-SUBUNIT	In response to replication block or DNA damage in S phase the DNA replication and DNA damage checkpoints are activated. The current model in human predicts, that a Rad17/Replication factor C (RF-C) complex might serve as a recruitment complex for the Rad9/Hus1/Rad1 complex to sites of replication block or DNA damage. In this study we have investigated the fate of the Rad17/RF-C complex after treatment of synchronized Hela cells with the replication inhibitor hydroxyurea. In hydroxyurea treated cells the RF-C p37 subunit became more resistant to extraction. Moreover, co-immunoprecipitation studies with extracts of hydroxyurea treated cells showed an interaction of RF-C p37 with Rad17 and of PCNA with Rad9 and RF-C p37. An enhanced colocalization of Rad17 and PCNA in late S phase after hydroxyurea treatment was observed. Our data suggested, that upon replication block a Rad17/RFC complex is recruited to sites of DNA lesions in late S phase, binds the Rad9/Hus1/Rad1 complex and enables it to interact with PCNA. An interaction of Rad17/RF-C with PCNA appears to be mediated by the small RF-C p37 subunit, suggesting that PCNA might provide communication between replication checkpoint control and DNA replication and repair.	Univ Zurich Irchel, Inst Vet Biochem & Mol Biol, CH-8057 Zurich, Switzerland	University of Zurich	Hubscher, U (corresponding author), Univ Zurich Irchel, Inst Vet Biochem & Mol Biol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.			Dahm, Kirsten/0000-0001-7194-6600				Bao SD, 2001, NATURE, V411, P969, DOI 10.1038/35082110; Bessho T, 2000, J BIOL CHEM, V275, P7451, DOI 10.1074/jbc.275.11.7451; BRAVO R, 1986, EXP CELL RES, V163, P287, DOI 10.1016/0014-4827(86)90059-5; BRAVO R, 1985, EMBO J, V4, P655, DOI 10.1002/j.1460-2075.1985.tb03679.x; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; Burtelow MA, 2001, J BIOL CHEM, V276, P25903, DOI 10.1074/jbc.M102946200; Chang MS, 1999, J BIOL CHEM, V274, P36544, DOI 10.1074/jbc.274.51.36544; Chen MJ, 2001, J BIOL CHEM, V276, P16580, DOI 10.1074/jbc.M008871200; Chen MS, 2001, GENE, V277, P145, DOI 10.1016/S0378-1119(01)00692-8; de la Torre-Ruiz MA, 1998, EMBO J, V17, P2687, DOI 10.1093/emboj/17.9.2687; Donaldson AD, 2001, CURR BIOL, V11, pR979, DOI 10.1016/S0960-9822(01)00579-6; FOX MH, 1991, J CELL SCI, V99, P247; Green CM, 2000, CURR BIOL, V10, P39, DOI 10.1016/S0960-9822(99)00263-8; Griffith JD, 2002, J BIOL CHEM, V277, P15233, DOI 10.1074/jbc.C200129200; Kai M, 2001, MOL CELL BIOL, V21, P3289, DOI 10.1128/MCB.21.10.3289-3301.2001; Komatsu K, 2000, ONCOGENE, V19, P5291, DOI 10.1038/sj.onc.1203901; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; Lindsey-Boltz LA, 2001, P NATL ACAD SCI USA, V98, P11236, DOI 10.1073/pnas.201373498; Loor G, 1997, NUCLEIC ACIDS RES, V25, P5041, DOI 10.1093/nar/25.24.5041; Lopes M, 2001, NATURE, V412, P557, DOI 10.1038/35087613; Mitchell A, 2001, NAT REV MOL CELL BIO, V2, P563, DOI 10.1038/35085000; Miura M, 1999, J RADIAT RES, V40, P1, DOI 10.1269/jrr.40.1; Mossi R, 1997, J BIOL CHEM, V272, P1769, DOI 10.1074/jbc.272.3.1769; Mossi R, 1998, EUR J BIOCHEM, V254, P209, DOI 10.1046/j.1432-1327.1998.254209.x; Naiki T, 2000, MOL CELL BIOL, V20, P5888, DOI 10.1128/MCB.20.16.5888-5896.2000; Noskov VN, 1998, MOL CELL BIOL, V18, P4914, DOI 10.1128/MCB.18.8.4914; Parker AE, 1998, J BIOL CHEM, V273, P18332, DOI 10.1074/jbc.273.29.18332; Rauen M, 2000, J BIOL CHEM, V275, P29767, DOI 10.1074/jbc.M005782200; Reynolds N, 1999, NUCLEIC ACIDS RES, V27, P462, DOI 10.1093/nar/27.2.462; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; SASAKI K, 1993, CYTOMETRY, V14, P876, DOI 10.1002/cyto.990140805; Schmidt SLG, 2001, J BIOL CHEM, V276, P34792, DOI 10.1074/jbc.M011671200; Shimada M, 1999, MOL BIOL CELL, V10, P3991, DOI 10.1091/mbc.10.12.3991; Shimomura T, 1998, MOL CELL BIOL, V18, P5485, DOI 10.1128/MCB.18.9.5485; Shirahige K, 1998, NATURE, V395, P618, DOI 10.1038/27007; Sugimoto K, 1996, P NATL ACAD SCI USA, V93, P7048, DOI 10.1073/pnas.93.14.7048; Sugimoto K, 1997, MOL CELL BIOL, V17, P5905, DOI 10.1128/MCB.17.10.5905; Tercero JA, 2001, NATURE, V412, P553, DOI 10.1038/35087607; Tsurimoto T., 1999, FRONT BIOSCI, V4, P849; Venclovas C, 2000, NUCLEIC ACIDS RES, V28, P2481, DOI 10.1093/nar/28.13.2481; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302	42	25	27	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 31	2002	21	50					7710	7719		10.1038/sj.onc.1205872	http://dx.doi.org/10.1038/sj.onc.1205872			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	606VW	12400013	Green Accepted			2022-12-17	WOS:000178756200010
J	De Falco, G; Neri, LM; De Falco, M; Bellan, C; Yu, ZL; De Luca, A; Leoncini, L; Giordano, A				De Falco, G; Neri, LM; De Falco, M; Bellan, C; Yu, ZL; De Luca, A; Leoncini, L; Giordano, A			Cdk9, a member of the cdc2-like family of kinases, binds to gp130, the receptor of the IL-6 family of cytokines	ONCOGENE			English	Article						signal transduction; cytokine receptors; kinases; phosphatases growth factors; AIDS; HIV	PERIPHERAL-BLOOD LYMPHOCYTES; PROMONOCYTIC CELL-LINES; TAT-ASSOCIATED KINASE; FACTOR P-TEFB; SIGNAL-TRANSDUCTION; PROTEIN-KINASES; HIV-1 TAT; IN-VITRO; INTERLEUKIN-6; TRANSCRIPTION	Cdk9 is a member of the Cdc2-like family of kinases. It binds to members of the family of cyclin T (T1, T2a and T2b) and to cyclin K. The Cdk9/cyclin T complex appears to be involved in regulating several physiological processes. In fact Cdk9 is the kinase of the P-TEFb complex, involved in basal transcription. Cdk9 has also been described as the kinase of the TAK complex, homologous to P-TEFb and involved in HIV replication. Here we show that Cdk9 interacts with gp130, the receptor of the Interleukin-6 (IL-6) family of cytokines,,which includes Leukemia Inhibitory Factor (LIF), Oncostatin NI (OSM), Ciliary Neurotrophic Factor (CNTF), Interleukin-11 (IL-11) and Cardiotrophin (CT-1). IL-6 is a key regulator of hematopoiesis, immunological responses and inflammation. In addition, IL-6 plays a major role in the endocrine and nervous systems. Signal transduction by gp130 is mediated by physical interaction of the cytoplasmic region of gp130 with cellular kinases and results in the transcriptional activation of cellular and viral genes. We found that Cdk9 interacts in vitro with the cytoplasmic region of gp130 and we succeded in reproducing this interaction in vivo. Cdk9 expression was found both in the nucleus and in the cytoplasm. The binding occurring between Cdk9 and gp130 increased upon IL-6 stimulation. We also observed that Cdk9 synergized with IL-6 in inducing the activation of an IL-6-responsive reporter plasmid. In summary, these results point to a previously undisclosed role for Cdk9 in signal transduction.	Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; Ist Anat & Istol Patol, I-53100 Siena, Italy; Univ Ferrara, Dipartimento Morfol & Embriol, Sez Anat Umana, I-44100 Ferrara, Italy; CNR, Ist Citomorfol Normale & Patol, IOR, I-40137 Bologna, Italy; Univ Naples Federico II, Dipartimento Biol Evolut & Comparata, Naples, Italy; Jefferson Med Coll, Philadelphia, PA 19107 USA; Univ Naples 2, Ist Anat Topog, Naples, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Ferrara; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Jefferson University; Universita della Campania Vanvitelli	Giordano, A (corresponding author), Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, BioLife Sci Bldg,Suite 333,1900 N 12th St, Philadelphia, PA 19122 USA.	giordano@temple.edu	Neri, Luca Maria/J-2462-2017; BELLAN, CRISTIANA/L-3903-2013; Giordano, Antonio/F-1927-2010; BELLAN, CRISTIANA/ABG-4750-2021; LEONCINI, Lorenzo/U-4413-2019; De Luca, Antonio/AAD-9562-2020; leoncini, lorenzo/P-8361-2018; Neri, Luca Maria/AAU-1772-2021	BELLAN, CRISTIANA/0000-0001-6119-9007; Giordano, Antonio/0000-0002-5959-016X; BELLAN, CRISTIANA/0000-0001-6119-9007; LEONCINI, Lorenzo/0000-0002-7457-300X; De Luca, Antonio/0000-0002-3905-6154; leoncini, lorenzo/0000-0002-7457-300X; Neri, Luca Maria/0000-0002-7924-1477				AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; Bagella L, 1998, J CELL PHYSIOL, V177, P206, DOI 10.1002/(SICI)1097-4652(199811)177:2<206::AID-JCP2>3.3.CO;2-W; BELLAN C, 2002, J CLIN PATHOL S1, V55, pA29; BOULTON TG, 1994, J BIOL CHEM, V269, P648; BULLRICH F, 1995, CANCER RES, V55, P1199; Chun TW, 1998, J EXP MED, V188, P83, DOI 10.1084/jem.188.1.83; De Falco G, 2000, ONCOGENE, V19, P373, DOI 10.1038/sj.onc.1203305; DEFALCO G, 2002, CANC BIOL THER, V1, P66; DeLuca A, 1997, J CELL PHYSIOL, V172, P265, DOI 10.1002/(SICI)1097-4652(199708)172:2<265::AID-JCP13>3.3.CO;2-C; Foskett SM, 2001, J VIROL, V75, P1220, DOI 10.1128/JVI.75.3.1220-1228.2001; Fu TJ, 1999, J BIOL CHEM, V274, P34527, DOI 10.1074/jbc.274.49.34527; Ghose R, 2001, J VIROL, V75, P11336, DOI 10.1128/JVI.75.23.11336-11343.2001; Giordano V, 1997, J IMMUNOL, V158, P4097; GRANA X, 1994, P NATL ACAD SCI USA, V91, P3834, DOI 10.1073/pnas.91.9.3834; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Herrmann CH, 1998, J VIROL, V72, P9881, DOI 10.1128/JVI.72.12.9881-9888.1998; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; MacLachlan TK, 1998, J CELL BIOCHEM, V71, P467, DOI 10.1002/(SICI)1097-4644(19981215)71:4<467::AID-JCB2>3.3.CO;2-7; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NAKAJIMA K, 1989, J IMMUNOL, V142, P531; Napolitano G, 2002, J CELL PHYSIOL, V192, P209, DOI 10.1002/jcp.10130; OFFIT K, 1993, GENE CHROMOSOME CANC, V7, P1, DOI 10.1002/gcc.2870070102; ORLOW I, 1994, CANCER RES, V54, P2848; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Simone C, 2002, ONCOGENE, V21, P4137, DOI 10.1038/sj.onc.1205493; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; TAGA T, 1992, FASEB J, V6, P3387, DOI 10.1096/fasebj.6.15.1334470; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; ULRICH A, 1990, CELL, V61, P203; von Laue S, 2000, J ENDOCRINOL, V165, P301, DOI 10.1677/joe.0.1650301; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Yang XZ, 1997, P NATL ACAD SCI USA, V94, P12331, DOI 10.1073/pnas.94.23.12331; Zhou Q, 1998, EMBO J, V17, P3681, DOI 10.1093/emboj/17.13.3681; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	38	25	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 24	2002	21	49					7464	7470		10.1038/sj.onc.1205967	http://dx.doi.org/10.1038/sj.onc.1205967			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386808				2022-12-17	WOS:000178618200001
J	Hamad, NM; Banik, SSR; Counter, CM				Hamad, NM; Banik, SSR; Counter, CM			Mutational analysis defines a minimum level of telomerase activity required for tumourigenic growth of human cells	ONCOGENE			English	Article						telomerase; hTERT; immortalization; transformation; tumourigenesis	HUMAN EPITHELIAL-CELLS; MALIGNANT HEMATOPOIETIC-CELLS; CATALYTIC SUBUNIT GENE; LIFE-SPAN; IMMORTAL CELLS; TUMOR-CELLS; CARCINOMA; CANCER; MAINTENANCE; PATTERNS	A hallmark of cancer cells is the ability to proliferate indefinitely. This acquisition of an immortal lifespan usually requires the activation of telomerase, the enzyme that elongates telomeres. Human telomerase is minimally composed of the reverse transcriptase subunit hTERT, and the RNA subunit hTR. While hTR is ubiquitously expressed in human cells, the hTERT subunit is generally transcriptionally repressed in most normal somatic cells, but is illegitimately activated to restore telomerase activity in cancer cells. Indeed, in the thousands of different human tumours assayed, 85% were scored positive for telomerase activity. However, the levels of telomerase activity detected in tumour samples can vary substantially and even some normal somatic cells have been found to have low levels of enzyme activity. As the functional significance of low levels of telomerase activity is unclear, we investigated whether there is a minimum level of telomerase activity required for tumourigenesis. Using mutants of hTERT that induce varying levels of telomerase activity, we show that there does indeed exist a threshold of activity required for the processes of immortalization, transformation and tumourigenesis. Thus, low levels of activity detected in certain somatic cells would not be expected to contribute to tumourigenesis, nor does the mere detection of telomerase in cancer cells necessarily signify an immortal lifespan.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA	Duke University; Duke University	Counter, CM (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA.			Counter, Christopher M/0000-0003-0748-3079	NATIONAL CANCER INSTITUTE [R01CA082481, R01CA094184] Funding Source: NIH RePORTER; NCI NIH HHS [CA82481, CA94184] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Armbruster BN, 2001, MOL CELL BIOL, V21, P7775, DOI 10.1128/MCB.21.22.7775-7786.2001; BANIK SSR, 2002, IN PRESS MOL CELL BI; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; Buchkovich KJ, 1996, MOL BIOL CELL, V7, P1443, DOI 10.1091/mbc.7.9.1443; CIFONE MA, 1980, P NATL ACAD SCI-BIOL, V77, P1039, DOI 10.1073/pnas.77.2.1039; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Farwell DG, 2000, AM J PATHOL, V156, P1537, DOI 10.1016/S0002-9440(10)65025-0; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Halvorsen TL, 1999, MOL CELL BIOL, V19, P1864; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Harley CB, 2002, ONCOGENE, V21, P494, DOI 10.1038/sj.onc.1205076; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Kolquist KA, 1998, NAT GENET, V19, P182, DOI 10.1038/554; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Norrback KF, 1997, EUR J CANCER, V33, P774, DOI 10.1016/S0959-8049(97)00059-2; Norrback KF, 1996, BLOOD, V88, P222; Ouellette MM, 1999, BIOCHEM BIOPH RES CO, V254, P795, DOI 10.1006/bbrc.1998.0114; Rich JN, 2001, CANCER RES, V61, P3556; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Stewart GS, 2001, J MEMBRANE BIOL, V180, P49, DOI 10.1007/s002320010058; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Yasumoto S, 1996, ONCOGENE, V13, P433; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723	36	25	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 10	2002	21	46					7121	7125		10.1038/sj.onc.1205860	http://dx.doi.org/10.1038/sj.onc.1205860			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	601AX	12370834				2022-12-17	WOS:000178424900015
J	Jackson-Grusby, L				Jackson-Grusby, L			Modeling cancer in mice	ONCOGENE			English	Article						embryonic stem cell; gene targeting; mouse model; recombinase; inducible transgene; microarray	EMBRYONIC STEM-CELLS; MULTIPLE INTESTINAL NEOPLASIA; SITE-SPECIFIC RECOMBINATION; TRANSGENIC MICE; MAMMALIAN-CELLS; GENE-EXPRESSION; CHROMOSOMAL TRANSLOCATION; DNA HYPOMETHYLATION; CRE-LOXP; APC GENE	The laboratory mouse is one of the most powerful tools for both gene discovery and validation in cancer genetics. Recent technological advances in engineering the mouse genome with chromosome translocations, latent alleles, and tissue-specific and temporally regulated mutations have provided more exacting models of human disease. The marriage of mouse tumor models with rapidly evolving methods to profile genetic and epigenetic alterations in tumors, and to finely map genetic modifier loci, will continue to provide insight into the key pathways leading to tumorigenesis. These discoveries hold great promise for identifying relevant drug targets for treating human cancer.	MIT, Whitehead Inst Biomed Res, Cambridge Ctr 9, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute	Jackson-Grusby, L (corresponding author), MIT, Whitehead Inst Biomed Res, Cambridge Ctr 9, Cambridge, MA 02142 USA.							ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Berns A, 1999, CANCER RES, V59, p1773S; BRINSTER RL, 1984, CELL, V37, P367, DOI 10.1016/0092-8674(84)90367-2; Buchholz F, 2000, EMBO REP, V1, P133, DOI 10.1093/embo-reports/kvd027; Buchholz F, 1998, NAT BIOTECHNOL, V16, P657, DOI 10.1038/nbt0798-657; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Collins EC, 2000, EMBO REP, V1, P127, DOI 10.1093/embo-reports/kvd021; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Cronin CA, 2001, GENE DEV, V15, P1506, DOI 10.1101/gad.892001; Dennis K, 2001, GENE DEV, V15, P2940, DOI 10.1101/gad.929101; Diaz V, 2001, J BIOL CHEM, V276, P16257, DOI 10.1074/jbc.M011725200; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Eads CA, 2000, CANCER RES, V60, P5021; Eads CA, 2002, CANCER RES, V62, P1296; Eggan K, 2002, NAT BIOTECHNOL, V20, P455, DOI 10.1038/nbt0502-455; Eggan K, 2001, P NATL ACAD SCI USA, V98, P6209, DOI 10.1073/pnas.101118898; Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Fisher GH, 2001, GENE DEV, V15, P3249, DOI 10.1101/gad.947701; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; Gallahan D, 1997, ONCOGENE, V14, P1883, DOI 10.1038/sj.onc.1201035; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; Giovannini M, 2000, GENE DEV, V14, P1617; GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; Hasan MT, 2001, GENESIS, V29, P116, DOI 10.1002/gene.1014; Ho SN, 1996, NATURE, V382, P822, DOI 10.1038/382822a0; Hodgson G, 2001, NAT GENET, V29, P459, DOI 10.1038/ng771; Holland EC, 1998, GENE DEV, V12, P3675, DOI 10.1101/gad.12.23.3675; Indra AK, 1999, NUCLEIC ACIDS RES, V27, P4324, DOI 10.1093/nar/27.22.4324; Iyer VR, 2001, NATURE, V409, P533, DOI 10.1038/35054095; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730; Jacoby RF, 1996, CANCER RES, V56, P710; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; LAKSO M, 1992, P NATL ACAD SCI USA, V89, P6232, DOI 10.1073/pnas.89.14.6232; Lei H, 1996, DEVELOPMENT, V122, P3195; Lewandoski M, 2001, NAT REV GENET, V2, P743, DOI 10.1038/35093537; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Liang GG, 2002, MOL CELL BIOL, V22, P480, DOI 10.1128/MCB.22.2.480-491.2002; Lindblad-Toh K, 2000, NAT BIOTECHNOL, V18, P1001, DOI 10.1038/79269; Lindblad-Toh K, 2000, NAT GENET, V24, P381, DOI 10.1038/74215; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LOGIE C, 1995, P NATL ACAD SCI USA, V92, P5940, DOI 10.1073/pnas.92.13.5940; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; MATTIONI T, 1994, METHOD CELL BIOL, V43, P335; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; McCreath KJ, 2000, NATURE, V405, P1066, DOI 10.1038/35016604; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; NAGY A, 1990, DEVELOPMENT, V110, P815; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; OGORMAN S, 1991, SCIENCE, V251, P1351, DOI 10.1126/science.1900642; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAMIREZSOLIS R, 1995, NATURE, V378, P720, DOI 10.1038/378720a0; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Ringrose L, 1997, EUR J BIOCHEM, V248, P903, DOI 10.1111/j.1432-1033.1997.00903.x; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; SAUER B, 1988, P NATL ACAD SCI USA, V85, P5166, DOI 10.1073/pnas.85.14.5166; Scheurle D, 2000, CANCER RES, V60, P4037; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SMITH AJH, 1995, NAT GENET, V9, P376, DOI 10.1038/ng0495-376; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; Strausberg RL, 2000, TRENDS GENET, V16, P103, DOI 10.1016/S0168-9525(99)01937-X; STRUHL K, 1983, NATURE, V305, P391, DOI 10.1038/305391a0; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Sweeney TJ, 1999, P NATL ACAD SCI USA, V96, P12044, DOI 10.1073/pnas.96.21.12044; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; Urlinger S, 2000, P NATL ACAD SCI USA, V97, P7963, DOI 10.1073/pnas.130192197; Wang XJ, 1999, P NATL ACAD SCI USA, V96, P8483, DOI 10.1073/pnas.96.15.8483; Wutz A, 2002, NAT GENET, V30, P167, DOI 10.1038/ng820; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5	93	25	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	2002	21	35					5504	5514		10.1038/sj.onc.1205603	http://dx.doi.org/10.1038/sj.onc.1205603			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579VC	12154411				2022-12-17	WOS:000177197700015
J	Parlanti, E; Fortini, P; Macpherson, P; Laval, J; Dogliotti, E				Parlanti, E; Fortini, P; Macpherson, P; Laval, J; Dogliotti, E			Base excision repair of adenine/8-oxoguanine mispairs by an aphidicolin-sensitive DNA polymerase in human cell extracts	ONCOGENE			English	Article						DNA repair; oxidative damage; mammalian cell extracts; base excision repair; 8oxo G/A mismatch	TRANSCRIPTION-COUPLED REPAIR; MISMATCH-CONTAINING DNA; RETRACTED ARTICLE. SEE; THYMINE DIMER BYPASS; COLI MUTY GENE; ESCHERICHIA-COLI; HUMAN HOMOLOG; SUBCELLULAR-LOCALIZATION; GLYCOSYLASE DETERMINES; SUBSTRATE-SPECIFICITY	Replication of DNA containing 8-oxo-7,8-dihydroguanine (8oxoG) can generate 8oxoG/A base pairs which, if uncorrected, lead to G-->T transversions. It is generally accepted that the repair of these promutagenic base pairs in human cells is initiated by the MutY DNA glycosylase homolog (hMYH). Here we provide biochemical evidence that human cell extracts perform base excision repair (BER) on both DNA strands of an 8oxoG/A mismatch. At early repair times the specificity of nucleotide incorporation indicates a preferential insertion of C opposite 8oxoG leading to the formation of 8oxoG/C pairs. This is followed by repair synthesis on the opposite DNA strand that is consistent with hOGG1-mediated correction of 8oxoG/C to G/C. Repair synthesis on either strand is completely inhibited by aphidicolin suggesting that a replicative DNA polymerase is involved in the gap filling. This is the first demonstration that repair of 8oxoG/A base pairs is by two BER events likely mediated by Poldelta/epsilon. We suggest that the Poldelta/epsilon-mediated BER is the general mode of repair when BER lesions are formed at replication forks.	Ist Super Sanita, Lab Comparat Toxicol & Ecotoxicol, I-00161 Rome, Italy; Canc Res UK, London Res Inst, Clare Hall Labs, S Mimms, Herts, England; Inst Gustave Roussy, Grp Reparat ADN, UMR 1772 CNRS, F-94805 Villejuif, France	Istituto Superiore di Sanita (ISS); Cancer Research UK; UNICANCER; Gustave Roussy	Dogliotti, E (corresponding author), Ist Super Sanita, Lab Comparat Toxicol & Ecotoxicol, Via Regina Elena 299, I-00161 Rome, Italy.	dogliott@iss.it	Fortini, Paola/K-1197-2018; Parlanti, Eleonora/AAC-5978-2021	Fortini, Paola/0000-0001-6206-8498; 				AU KG, 1989, P NATL ACAD SCI USA, V86, P8877, DOI 10.1073/pnas.86.22.8877; Boiteux S, 2000, ARCH BIOCHEM BIOPHYS, V377, P1, DOI 10.1006/abbi.2000.1773; Boiteux S, 1999, BIOCHIMIE, V81, P59, DOI 10.1016/S0300-9084(99)80039-X; Boldogh I, 2001, NUCLEIC ACIDS RES, V29, P2802, DOI 10.1093/nar/29.13.2802; Caldecott KW, 2001, BIOESSAYS, V23, P447, DOI 10.1002/bies.1063; Colussi C, 2002, CURR BIOL, V12, P912, DOI 10.1016/S0960-9822(02)00863-1; DeMott MS, 1998, J BIOL CHEM, V273, P27492, DOI 10.1074/jbc.273.42.27492; DeWeese TL, 1998, P NATL ACAD SCI USA, V95, P11915, DOI 10.1073/pnas.95.20.11915; Dianov G, 1998, J BIOL CHEM, V273, P33811, DOI 10.1074/jbc.273.50.33811; Dianov GL, 1999, J BIOL CHEM, V274, P13741, DOI 10.1074/jbc.274.20.13741; Dianov GL, 1999, BIOCHEMISTRY-US, V38, P11021, DOI 10.1021/bi9908890; DIZDAROGLU M, 1993, BIOCHEMISTRY-US, V32, P12105, DOI 10.1021/bi00096a022; Dogliotti E, 2001, PROG NUCLEIC ACID RE, V68, P3; Efrati E, 1999, J BIOL CHEM, V274, P15920, DOI 10.1074/jbc.274.22.15920; Einolf HJ, 2001, J BIOL CHEM, V276, P3764, DOI 10.1074/jbc.M006696200; Fortini P, 1999, J BIOL CHEM, V274, P15230, DOI 10.1074/jbc.274.21.15230; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Gary R, 1999, J BIOL CHEM, V274, P4354, DOI 10.1074/jbc.274.7.4354; Gerlach VL, 2001, J BIOL CHEM, V276, P92, DOI 10.1074/jbc.M004413200; Haracska L, 2000, NAT GENET, V25, P458, DOI 10.1038/78169; Laval J, 1998, MUTAT RES-FUND MOL M, V402, P93, DOI 10.1016/S0027-5107(97)00286-8; Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2; Leadon SA, 1997, CANCER RES, V57, P3784; Li XH, 2000, J BIOL CHEM, V275, P8448, DOI 10.1074/jbc.275.12.8448; Masutani C, 1999, EMBO J, V18, P3491, DOI 10.1093/emboj/18.12.3491; MCGOLDRICK JP, 1995, MOL CELL BIOL, V15, P989; MICHAELS ML, 1992, BIOCHEMISTRY-US, V31, P10964, DOI 10.1021/bi00160a004; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; NGHIEM Y, 1988, P NATL ACAD SCI USA, V85, P2709, DOI 10.1073/pnas.85.8.2709; Nilsen H, 2000, MOL CELL, V5, P1059, DOI 10.1016/S1097-2765(00)80271-3; Otterlei M, 1999, EMBO J, V18, P3834, DOI 10.1093/emboj/18.13.3834; Parker A, 2001, J BIOL CHEM, V276, P5547, DOI 10.1074/jbc.M008463200; Porello SL, 1998, BIOCHEMISTRY-US, V37, P14756, DOI 10.1021/bi981594+; Prasad R, 2000, J BIOL CHEM, V275, P4460, DOI 10.1074/jbc.275.6.4460; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Slupska MM, 1996, J BACTERIOL, V178, P3885, DOI 10.1128/jb.178.13.3885-3892.1996; Slupska MM, 1999, J BACTERIOL, V181, P6210, DOI 10.1128/JB.181.19.6210-6213.1999; Takao M, 1999, NUCLEIC ACIDS RES, V27, P3638, DOI 10.1093/nar/27.18.3638; Taylor RM, 2000, MOL CELL BIOL, V20, P735, DOI 10.1128/MCB.20.2.735-740.2000; TCHOU J, 1994, J BIOL CHEM, V269, P15318; Tissier A, 2000, GENE DEV, V14, P1642; Tom S, 2001, J BIOL CHEM, V276, P24817, DOI 10.1074/jbc.M101673200; WEISER T, 1991, J BIOL CHEM, V266, P10420; Yang HJ, 2001, NUCLEIC ACIDS RES, V29, P743, DOI 10.1093/nar/29.3.743; YEH YC, 1991, J BIOL CHEM, V266, P6480; Zhang YB, 2001, NUCLEIC ACIDS RES, V29, P928, DOI 10.1093/nar/29.4.928; Zharkov DO, 1998, BIOCHEMISTRY-US, V37, P12384, DOI 10.1021/bi981066y	50	25	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 8	2002	21	34					5204	5212		10.1038/sj.onc.1205561	http://dx.doi.org/10.1038/sj.onc.1205561			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579TL	12149642				2022-12-17	WOS:000177193900002
J	Frechet, M; Canitrot, Y; Bieth, A; Dogliotti, E; Cazaux, C; Hoffmann, JS				Frechet, M; Canitrot, Y; Bieth, A; Dogliotti, E; Cazaux, C; Hoffmann, JS			Deregulated DNA polymerase beta strengthens ionizing radiation-induced nucleotidic and chromosomal instabilities	ONCOGENE			English	Article						DNA polymerase beta; ionizing radiations; genetic instability; mutagenesis	STRAND-BREAK REPAIR; MUTATOR PHENOTYPE; SOMATIC MUTATIONS; CANCER-CELLS; OVEREXPRESSION; EXPRESSION; TUMORS; DAMAGE; GENE; SENSITIVITY	DNA polymerase beta (Pol beta) is an error-prone enzyme which has been found to be overexpressed in several human tumors. By using a couple of recombinant CHO cells differing only from the exogenous expression of Pol P, we showed here that cells overexpressing Pol beta are much more sensitive to IR treatments by increasing apoptosis. We also found that the surviving cells displayed an hypermutator phenotype which could be explained by different pathways involving Pol beta, such as (i) an increased capacity to incorporate into DNA the mutagenic dGTP analog, 8-oxo-dGTP, one of the most abundant purine-derived nucleotides exposed to gamma-irradiation, (ii) the induction of IR-induced DNA breaks and (iii) accumulation of chromosome aberrations induced by radiation. Alteration of Pol beta expression in irradiated cells thus appears to strengthen both cell death and genetic changes associated with a malignant phenotype. These data provide new insights into the cellular response to radiations and the associated carcinogenic consequences.	CNRS, IPBS, Grp Instabilite Genet & Canc, UMR 5089, F-31077 Toulouse, France; Ist Super Sanita, Lab Comparat Toxicol & Ecotoxicol, I-00161 Rome, Italy	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Istituto Superiore di Sanita (ISS)	Hoffmann, JS (corresponding author), CNRS, IPBS, Grp Instabilite Genet & Canc, UMR 5089, 205 Route Narbonne, F-31077 Toulouse, France.	cazaux@ipbs.fr; jseb@ipbs.fr	Hoffmann, Jean-Sebastien/O-9183-2014	Hoffmann, Jean-Sebastien/0000-0003-2222-354X				Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; Bergoglio V, 2001, ONCOGENE, V20, P6181, DOI 10.1038/sj.onc.1204743; Bouayadi K, 1997, CANCER RES, V57, P110; Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; CALSOU P, 1992, NUCLEIC ACIDS RES, V20, P6363, DOI 10.1093/nar/20.23.6363; Canitrot Y, 1999, FASEB J, V13, P1107, DOI 10.1096/fasebj.13.9.1107; Canitrot Y, 1998, P NATL ACAD SCI USA, V95, P12586, DOI 10.1073/pnas.95.21.12586; Canitrot Y, 2000, FASEB J, V14, P1765, DOI 10.1096/fj.99-1063com; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; CHANG WP, 1991, INT J RADIAT BIOL, V60, P483, DOI 10.1080/09553009114552331; COPELAND WC, 1992, J BIOL CHEM, V267, P21459; DEWEY WC, 1995, INT J RADIAT ONCOL, V33, P781, DOI 10.1016/0360-3016(95)00214-8; Dimitriadis EK, 1998, J BIOL CHEM, V273, P20540, DOI 10.1074/jbc.273.32.20540; GEDIK CM, 1992, INT J RADIAT BIOL, V62, P313, DOI 10.1080/09553009214552161; GOODHEAD DT, 1994, INT J RADIAT BIOL, V65, P7, DOI 10.1080/09553009414550021; Hendry JH, 1997, INT J RADIAT BIOL, V71, P709, DOI 10.1080/095530097143716; Hoffmann JS, 1996, P NATL ACAD SCI USA, V93, P13766, DOI 10.1073/pnas.93.24.13766; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KamathLoeb AS, 1997, J BIOL CHEM, V272, P5892, DOI 10.1074/jbc.272.9.5892; KUMAR A, 1990, J BIOL CHEM, V265, P2124; Little JB, 2000, CARCINOGENESIS, V21, P397, DOI 10.1093/carcin/21.3.397; Loeb KR, 2000, CARCINOGENESIS, V21, P379, DOI 10.1093/carcin/21.3.379; LOEB LA, 1991, CANCER RES, V51, P3075; Louat T, 2001, MOL PHARMACOL, V60, P553; MAHER VM, 1976, NATURE, V261, P593, DOI 10.1038/261593a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; PEINADO MA, 1992, P NATL ACAD SCI USA, V89, P10065, DOI 10.1073/pnas.89.21.10065; Petrini J H, 1997, Semin Immunol, V9, P181, DOI 10.1006/smim.1997.0067; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; SCANLON KJ, 1989, CANCER INVEST, V7, P581, DOI 10.3109/07357908909017533; Singleton BK, 1999, MOL CELL BIOL, V19, P3267; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Srivastava DK, 1999, CARCINOGENESIS, V20, P1049, DOI 10.1093/carcin/20.6.1049; THOMPSON LH, 1982, MUTAT RES, V95, P427, DOI 10.1016/0027-5107(82)90276-7; Vamvakas S, 1997, CRIT REV TOXICOL, V27, P155, DOI 10.3109/10408449709021617; VELD CWOH, 1994, CANCER RES, V54, P3001; WARD JF, 1995, RADIAT RES, V142, P362, DOI 10.2307/3579145; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; YANDELL DW, 1986, SOMAT CELL MOLEC GEN, V12, P255, DOI 10.1007/BF01570784; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	40	25	31	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2320	2327		10.1038/sj.onc.1205295	http://dx.doi.org/10.1038/sj.onc.1205295			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY	11948415				2022-12-17	WOS:000174635600004
J	De Maria, R; Maggiora, P; Biolatti, B; Prat, M; Comoglio, PM; Castagnaro, M; Di Renzo, MF				De Maria, R; Maggiora, P; Biolatti, B; Prat, M; Comoglio, PM; Castagnaro, M; Di Renzo, MF			Feline STK gene expression in mammary carcinomas	ONCOGENE			English	Article						tyrosine kinase receptors; mammary carcinomas; companion animals tumours	HEPATOCYTE GROWTH-FACTOR; TYROSINE KINASE; POSTSURGICAL PROGNOSIS; IMMUNOHISTOCHEMICAL ANALYSIS; ESTROGEN-RECEPTORS; MOLECULAR-CLONING; MET ONCOGENE; RON GENE; CYCLIN-A; OVEREXPRESSION	The human RON and its mouse homologue stk are members of the MET family of tyrosine kinase receptors. We have previously shown that the RON gene is over-expressed in human breast carcinomas. As cat mammary tumours have been proposed as a suitable model for aggressive human breast cancer, we identified the feline stk gene and studied its expression in cat mammary cancer. Feline stk sequences were found highly homologous to the stk and RON gene exons that encode the juxtamembrane and transmembrane domains of the stk and RON receptors. Feline stk-specific transcript was detected by RT - PCR in cat lung and in 7/8 feline mammary carcinomas and a synchronous skin metastasis examined. Western blot and immunohistochemical analyses were carried out with an antibody that recognized both the human RON and mouse stk receptors. This antibody specifically detected a 135 Kd feline protein and stained 10/34 mammary carcinoma archival samples. These data show that the pattern of expression and distribution of the stk protein in feline mammary cancer could be superimposed on that of the RON receptor in human breast cancer and suggest that these feline tumours are a suitable model to test innovative approaches to therapy of aggressive human breast carcinomas.	Univ Turin, Sch Med, Inst Canc Res & Treatment, Canc Genet Lab, I-10060 Turin, Italy; Univ Turin, Inst Canc Res & Treatment, Comparat Oncol Ctr, I-10060 Turin, Italy; Univ Turin, IRCC, Inst Canc Res & Treatment, Div Mol Oncol, I-10060 Turin, Italy; Univ Turin, Sch Vet Med, Dept Anim Pathol, Turin, Italy; Univ Novara, Sch Med, Dept Med Sci, Novara, Italy; Univ Padua, Sch Vet Med, Dept Publ Hlth Comparat Pathol & Vet Hyg, I-35100 Padua, Italy	University of Turin; University of Turin; IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; University of Turin; University of Eastern Piedmont Amedeo Avogadro; University of Padua	Di Renzo, MF (corresponding author), Univ Turin, Sch Med, Inst Canc Res & Treatment, Canc Genet Lab, SP 142,Km 3-95, I-10060 Turin, Italy.	mfdirenzo@ircc.unito.it	DI RENZO, Maria Flavia/B-6091-2012	DI RENZO, Maria Flavia/0000-0002-5093-3373; DE MARIA, RAFFAELLA/0000-0002-7028-2280; CASTAGNARO, Massimo/0000-0003-3311-7806; Comoglio, Paolo/0000-0002-7056-5328; BIOLATTI, Bartolomeo/0000-0003-3657-3954				Angeloni D, 2000, GENE CHROMOSOME CANC, V29, P147, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1015>3.3.CO;2-E; Castagnaro M, 1998, RES VET SCI, V64, P97, DOI 10.1016/S0034-5288(98)90002-9; Castagnaro M, 1998, RES VET SCI, V65, P223, DOI 10.1016/S0034-5288(98)90147-3; Castagnaro M, 1998, J COMP PATHOL, V119, P263, DOI 10.1016/S0021-9975(98)80049-2; de las Mulas JM, 2000, DOMEST ANIM ENDOCRIN, V18, P111, DOI 10.1016/S0739-7240(99)00067-3; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DIRENZO MF, 1995, CANCER RES, V55, P1129; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; HAMILTON JM, 1976, VET REC, V99, P477, DOI 10.1136/vr.99.24.477; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; IWAMA A, 1994, BLOOD, V83, P3160, DOI 10.1182/blood.V83.11.3160.bloodjournal83113160; JOHNSTON SD, 1984, AM J VET RES, V45, P379; Kobayashi Y, 2001, J VET MED SCI, V63, P211, DOI 10.1292/jvms.63.211; Kolibaba KS, 1997, BIOCHIM BIOPHYS ACTA, V1333, P217; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; Murakami Y, 2000, J VET MED SCI, V62, P783, DOI 10.1292/jvms.62.783; Murakami Y, 2000, J VET MED SCI, V62, P743, DOI 10.1292/jvms.62.743; Olivero M, 1999, INT J CANCER, V82, P640, DOI 10.1002/(SICI)1097-0215(19990827)82:5<640::AID-IJC4>3.0.CO;2-6; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; RONSIN C, 1993, ONCOGENE, V8, P1195; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; Santoro MM, 1998, ONCOGENE, V17, P741, DOI 10.1038/sj.onc.1201994; Tuck AB, 1996, AM J PATHOL, V148, P225; Waltz SE, 1998, ONCOGENE, V16, P27, DOI 10.1038/sj.onc.1201508; WEIJER K, 1972, J NATL CANCER I, V49, P1697, DOI 10.1093/jnci/49.6.1697	26	25	25	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1785	1790		10.1038/sj.onc.1205221	http://dx.doi.org/10.1038/sj.onc.1205221			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896610				2022-12-17	WOS:000174214200017
J	Amanullah, A; Liebermann, DA; Hoffman, B				Amanullah, A; Liebermann, DA; Hoffman, B			Deregulated c-Myc prematurely recruits both Type I and IICD95/Fas apoptotic pathways associated with terminal myeloid differentiation	ONCOGENE			English	Article						myeloid; c-myc; differentiation; apoptosis; CD95; Fas	DNA-REPLICATION ORIGIN; FAS-LIGAND; LEUKEMIA CELLS; DEATH DOMAIN; T-CELLS; GROWTH; EXPRESSION; GENE; PROTEASE; MICE	Previously we have reported that deregulated expression of c-myc in normal and leukemic myeloid cells blocked differentiation and, concomitantly, induced p53-independent apoptosis. Here, we show that this morbidity was due to premature recruitment of the Fas/CD95 cell death pathway which normally operates to induce apoptosis at the end of the terminal myeloid differentiation program. Analysis of the regulated components of this pathway revealed that IL6-mediated induction of differentiation resulted in rapid cell surface expression of CD95 receptor. Deregulated c-myc prevented the downregulation of CD95 ligand by maintaining its transcription, but caused premature downregulation of c-FLIP. First, the Type II (mitochondria-dependent, bcl-2-sensitive) and, then, the Type I (mitochondria-independent, bcl-2-insensitive) pathway were activated. Stable exogenous c-FLIP expression completely rescued the apoptotic phenotype. Furthermore, when the deregulated c-myc transgene was stably transduced into bone marrow cells from Fas(lpr/lpr) (CD95 receptor mutant) and Fas(gld/gld) (CD95 ligand mutant) mice, cell death was significantly suppressed relative to c-myc-transduced wild type bone marrow cells upon induction of differentiation. These data indicate that c-myc-mediated apoptosis associated with blocks in myeloid differentiation is dependent on the Fas/CD95 pathway. Our findings offer important new insights into understanding how deregulated c-myc alters normal blood cell homeostasis, and how additional mutations might promote leukemogenesis.	Temple Univ, Sch Med, Fels Inst Canc Res, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Liebermann, DA (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res, 3307 N Broad St, Philadelphia, PA 19140 USA.	lieberma@unix.temple.edu; hoffman@unix.temple.edu			NCI NIH HHS [R01CA81168] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081168] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amanullah A, 2000, ONCOGENE, V19, P2967, DOI 10.1038/sj.onc.1203638; ARIGA H, 1989, EMBO J, V8, P4273, DOI 10.1002/j.1460-2075.1989.tb08613.x; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Brunner T, 2000, J BIOL CHEM, V275, P9767, DOI 10.1074/jbc.275.13.9767; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Eilers M, 1999, MOL CELLS, V9, P1; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; Fecho K, 1998, CELL IMMUNOL, V188, P19, DOI 10.1006/cimm.1998.1339; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; Genestier L, 1999, J EXP MED, V189, P231, DOI 10.1084/jem.189.2.231; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; HANN SR, 1994, GENE DEV, V8, P2441, DOI 10.1101/gad.8.20.2441; Harwood FG, 2000, J BIOL CHEM, V275, P10023, DOI 10.1074/jbc.275.14.10023; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; HOFFMANLIEBERMANN B, 1991, ONCOGENE, V6, P903; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Kagaya S, 1997, MOL CELL BIOL, V17, P6736, DOI 10.1128/MCB.17.11.6736; Kasibhatla S, 2000, CURR BIOL, V10, P1205, DOI 10.1016/S0960-9822(00)00727-2; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LIEBERMANN DA, 1994, STEM CELLS, V12, P352, DOI 10.1002/stem.5530120402; METCALF D, 1991, SCIENCE, V254, P529, DOI 10.1126/science.1948028; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PELLICER A, 1978, CELL, V14, P133, DOI 10.1016/0092-8674(78)90308-2; Refaeli Y, 1998, IMMUNITY, V8, P615, DOI 10.1016/S1074-7613(00)80566-X; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; SELVAKUMARAN M, 1993, BLOOD, V81, P2257; SPENCER CA, 1991, ADV CANCER RES, V56, P1; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; TAIRA T, 1994, MOL CELL BIOL, V14, P6386, DOI 10.1128/MCB.14.9.6386; TILLY JL, 1993, J CELL PHYSIOL, V154, P519, DOI 10.1002/jcp.1041540310; Traver D, 1998, IMMUNITY, V9, P47, DOI 10.1016/S1074-7613(00)80587-7; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0	47	25	25	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1600	1610		10.1038/sj.onc.1205231	http://dx.doi.org/10.1038/sj.onc.1205231			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896589				2022-12-17	WOS:000173956800016
J	Paterson, IC; Davies, M; Stone, A; Huntley, S; Smith, E; Pring, M; Eveson, JW; Robinson, CM; Parkinson, EK; Prime, SS				Paterson, IC; Davies, M; Stone, A; Huntley, S; Smith, E; Pring, M; Eveson, JW; Robinson, CM; Parkinson, EK; Prime, SS			TGF-beta 1 acts as a tumor suppressor of human malignant keratinocytes independently of Smad 4 expression and ligand-induced G(1) arrest	ONCOGENE			English	Article						TGF-beta 1; keratinocytcs; Smad 4; tumor suppression	GROWTH-FACTOR-BETA; SQUAMOUS-CELL CARCINOMAS; TRANSFORMING GROWTH-FACTOR-BETA-1; FUNCTIONAL-CHARACTERIZATION; DOWN-REGULATION; GENE-MUTATIONS; RECEPTOR GENE; II RECEPTOR; SKIN TUMORS; HIGH-RISK	This study examined the role of TGF-beta1 in human keratinocyte malignancy. Two carcinoma-derived human oral keratinocyte cell lines, BICR 31 and H314, were selected on the basis of their known resistance to TGF-beta1-induced G(1) arrest, the presence of wild type TGF-beta cell surface receptors and normal Ras. Smad 4 protein was undetectable in both cell lines, but Smad 2 and Smad 3 were expressed at levels comparable with a fully TGF-beta responsive cell line, and treatment of the cells with TGF-beta1 resulted in the phosphorylation of Smad 2. Treatment with exogenous TGF-beta1 resulted in a failure to induce transcription from an artificial Smad-dependent promoter and a failure to down-regulate c-myc, but resulted in an up-regulation of AP-1 associated genes (Fra-1, JunB and fibronectin). Transient transfection of Smad 4 into BICR 31 restored TGF-beta1-induced growth inhibition and Smad-dependent transcriptional activation. Protracted treatment of cells with exogenous TGF-beta1 resulted in the attenuation of cell growth in vitro. To over-express TGF-beta1, both cell lines were transfected with latent TGF-beta1 cDNA; neutralization studies of conditioned media demonstrated that whilst the majority of the peptide was in the latent form, a small proportion was present as the active peptide. Cells that overexpressed endogenous TGF-beta1 grew more slowly in vitro compared to both the vector-only controls and cells that did not over-express the peptide. Orthotopic transplantation of cells that over-expressed endogenous TGF-beta1 to the floor of the mouth in athymic mice resulted in marked inhibition of primary tumor formation compared to controls. Expression of a dominant-negative TGF-beta1 type II receptor in cells that over-expressed endogenous TGF-beta1 resulted in enhanced cell growth in vitro and diminished the tumor suppressor effect of the ligand in vivo, indicating that the endogenous TGF-beta1 was acting in an autocrine capacity. The results demonstrate that over-expression of endogenous TGF-beta1 in human malignant oral keratinocytes leads to growth inhibition in vivo and tumor suppression in vitro by mechanisms that are independent of Small 4 expression and TGF-beta1-induced G(1) arrest.	Univ Bristol, Dept Oral & Dent Sci, Bristol BS1 2LY, Avon, England; CRC, Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland	University of Bristol; Beatson Institute	Paterson, IC (corresponding author), Bristol Dent Hosp & Sch, Div Oral Med Pathol & Microbiol, Lower Maudlin St, Bristol BS1 2LY, Avon, England.	ian.paterson@bristol.ac.uk	Paterson, Ian/G-8688-2011; Robinson, Max/R-5280-2018	Paterson, Ian/0000-0001-9156-401X; Pring, Miranda/0000-0003-4658-5772; Robinson, Max/0000-0003-4491-6865				Amendt C, 1998, ONCOGENE, V17, P25, DOI 10.1038/sj.onc.1202161; BURNS JE, 1993, BRIT J CANCER, V67, P1274, DOI 10.1038/bjc.1993.238; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Chen TP, 2001, INT J CANCER, V93, P653, DOI 10.1002/ijc.1381; CLARK LJ, 1993, BRIT J CANCER, V68, P617, DOI 10.1038/bjc.1993.396; CUI W, 1994, CANCER RES, V54, P5831; Davies M, 1997, INT J CANCER, V73, P68, DOI 10.1002/(SICI)1097-0215(19970926)73:1<68::AID-IJC12>3.0.CO;2-1; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; deWinter JP, 1997, ONCOGENE, V14, P1891, DOI 10.1038/sj.onc.1201017; Fink SP, 2001, CANCER RES, V61, P256; GARRIGUEANTAR L, 1995, CANCER RES, V55, P3982; GLICK AB, 1994, GENE DEV, V8, P2429, DOI 10.1101/gad.8.20.2429; GLICK AB, 1993, P NATL ACAD SCI USA, V90, P6076, DOI 10.1073/pnas.90.13.6076; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Howell M, 1999, DEV BIOL, V214, P354, DOI 10.1006/dbio.1999.9430; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kim SK, 1996, CANCER RES, V56, P2519; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Korchynskyi O, 1999, INT J CANCER, V82, P197, DOI 10.1002/(SICI)1097-0215(19990719)82:2<197::AID-IJC8>3.0.CO;2-V; LEDAI J, 1999, MOL CARCINOG, V26, P37; Malliri A, 1996, CELL GROWTH DIFFER, V7, P1291; Masuyama N, 1999, J BIOL CHEM, V274, P12163, DOI 10.1074/jbc.274.17.12163; PATERSON IC, 1995, BRIT J CANCER, V72, P922, DOI 10.1038/bjc.1995.434; Paterson IC, 2001, J PATHOL, V193, P458, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH822>3.0.CO;2-V; Petritsch C, 2000, GENE DEV, V14, P3093, DOI 10.1101/gad.854200; Pierreux CE, 2000, MOL CELL BIOL, V20, P9041, DOI 10.1128/MCB.20.23.9041-9054.2000; PRIME SS, 1994, INT J CANCER, V56, P406, DOI 10.1002/ijc.2910560320; Qing J, 2000, J BIOL CHEM, V275, P38802, DOI 10.1074/jbc.M004731200; Riggins GJ, 1997, CANCER RES, V57, P2578; Schutte M, 1996, CANCER RES, V56, P2527; Sirard C, 2000, J BIOL CHEM, V275, P2063, DOI 10.1074/jbc.275.3.2063; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Wang D, 1997, CARCINOGENESIS, V18, P2285, DOI 10.1093/carcin/18.11.2285; Wilentz RE, 2000, AM J PATHOL, V156, P37, DOI 10.1016/S0002-9440(10)64703-7; Wilentz RE, 2000, CANCER RES, V60, P2002; Wong C, 1999, MOL CELL BIOL, V19, P1821; Xu XL, 2000, ONCOGENE, V19, P1868, DOI 10.1038/sj.onc.1203504; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200; Yan W, 2000, ONCOL RES, V12, P157; YEUDALL WA, 1995, ORAL ONCOL, V31B, P136, DOI 10.1016/0964-1955(94)00030-8; YEUDALL WA, 1993, ORAL ONCOL, V29B, P63, DOI 10.1016/0964-1955(93)90012-4; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	45	25	29	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1616	1624		10.1038/sj.onc.1205217	http://dx.doi.org/10.1038/sj.onc.1205217			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896591				2022-12-17	WOS:000173956800018
J	Wu, YF; Renard, CA; Apiou, F; Huerre, M; Tiollais, P; Dutrillaux, B; Buendia, MA				Wu, YF; Renard, CA; Apiou, F; Huerre, M; Tiollais, P; Dutrillaux, B; Buendia, MA			Recurrent allelic deletions at mouse chromosomes 4 and 14 in Myc-induced liver tumors	ONCOGENE			English	Article						hepatocellular carcinoma; c-Myc; LOH; CGH; INK4A/ARF	BETA-CATENIN MUTATIONS; COPY NUMBER CHANGES; HEPATOCELLULAR-CARCINOMA; C-MYC; SUPPRESSOR GENE; TRANSGENIC MICE; HETEROZYGOSITY; VIRUS; FREQUENT; P53	Transgenic mice expressing the c-Myc oncogene driven by woodchuck hepatitis virus (WHV) regulatory sequences develop hepatocellular carcinoma with a high frequency. To investigate genetic lesions that cooperate with Myc in liver carcinogenesis, we conducted a genome-wide scan for loss of heterozygosity (LOH) and mutational analysis of beta-catenin in 37 hepatocellular adenomas and carcinomas from C57BL/6 x castaneus F1 transgenic mice. In a subset of these tumors, chromosome imbalances were examined by comparative genomic hybridization (CGH). Allelotyping with 99 microsatellite markers spanning all autosomes revealed allelic imbalances at one or more chromosomes in 83.8% of cases. The overall fractional allelic loss was rather low, with a mean index of 0.066. However, significant LOH rates involved chromosomes 4 (21.6% of tumors), 14, 9 and 1 (11 to 16%). Interstitial LOH on chromosome 4 was mapped at band C4-C7 that contains the INK4a/ARF and INK4b loci, and on chromosome 14 at band B - D including the RB locus. In man, the homologous chromosomal regions 9p21, 13q14 and 8p21 - 23 are frequently deleted in liver cancer. LOH at chromosomes 1 and 14, and beta-catenin mutations (12.5% of cases) were seen only in HCCs. All tumors examined were found to be aneuploid. CGH analysis of 10 representative cases revealed recurrent gains at chromosomes 16 and 19, but losses or deletions involving mostly chromosomes 4 and 14 generally prevailed over gains. Thus, Myc activation in the liver might select for inactivation of tumor suppressor genes on regions of chromosomes 4 and 14 in a context of low genomic instability. Myc transgenic mice provide a useful model for better defining crosstalks between oncogene and tumor suppressor pathways in liver tumorigenesis.	Inst Pasteur, Unite Recombinat & Express Genet, Dept Retrovirus, INSERM,U163, F-75724 Paris 15, France; Inst Pasteur, Unite Histopathol, F-75015 Paris, France; Inst Curie, CNRS, UMR 147, F-75231 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Cite	Buendia, MA (corresponding author), Inst Pasteur, Unite Recombinat & Express Genet, Dept Retrovirus, INSERM,U163, 28 Rue Dr Roux, F-75724 Paris 15, France.	mbuendia@pasteur.fr						Boige V, 1997, CANCER RES, V57, P1986; Bosch FX, 1997, LIVER CANCER, P13; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; DAVIS LM, 1994, CARCINOGENESIS, V15, P1637; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; DIETRICH WF, 1994, P NATL ACAD SCI USA, V91, P9451, DOI 10.1073/pnas.91.20.9451; DURO D, 1995, ONCOGENE, V11, P21; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; El-Serag HB, 1999, NEW ENGL J MED, V340, P745, DOI 10.1056/NEJM199903113401001; ETIEMBLE J, 1994, ONCOGENE, V9, P727; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; HEGI ME, 1994, CANCER RES, V54, P6257; HERZOG CR, 1994, CANCER RES, V54, P4007; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; Hsu HC, 2000, AM J PATHOL, V157, P763, DOI 10.1016/S0002-9440(10)64590-7; KALLIONIEMI OP, 1994, GENE CHROMOSOME CANC, V10, P231, DOI 10.1002/gcc.2870100403; Lander JK, 1997, J VIROL, V71, P3940, DOI 10.1128/JVI.71.5.3940-3952.1997; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Legoix P, 1999, ONCOGENE, V18, P4044, DOI 10.1038/sj.onc.1202800; Liew CT, 1999, ONCOGENE, V18, P789, DOI 10.1038/sj.onc.1202359; Liu P, 1997, HEPATOLOGY, V25, P874, DOI 10.1002/hep.510250415; Luttges J, 2001, AM J PATHOL, V158, P1677, DOI 10.1016/S0002-9440(10)64123-5; Marchio A, 1997, GENE CHROMOSOME CANC, V18, P59, DOI 10.1002/(SICI)1098-2264(199701)18:1<59::AID-GCC7>3.3.CO;2-N; Marchio AS, 2000, ONCOGENE, V19, P3733, DOI 10.1038/sj.onc.1203713; Matsuda Y, 1999, GASTROENTEROLOGY, V116, P394, DOI 10.1016/S0016-5085(99)70137-X; MURAKAMI Y, 1991, CANCER RES, V51, P5520; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; Ogawa K, 1999, CARCINOGENESIS, V20, P2083, DOI 10.1093/carcin/20.11.2083; Pelengaris S, 2000, CURR OPIN GENET DEV, V10, P100, DOI 10.1016/S0959-437X(99)00046-5; QUELLE DE, 1995, CELL, V83, P993; Renard CA, 2000, ONCOGENE, V19, P2678, DOI 10.1038/sj.onc.1203617; Ritland SR, 1997, CANCER RES, V57, P3520; Santoni-Rugiu E, 1998, CANCER RES, V58, P123; Sargent LM, 1999, AM J PATHOL, V154, P1047, DOI 10.1016/S0002-9440(10)65357-6; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Schafer DF, 1999, LANCET, V353, P1253, DOI 10.1016/S0140-6736(98)09148-X; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Serrano M, 2000, CARCINOGENESIS, V21, P865, DOI 10.1093/carcin/21.5.865; Shao CS, 2001, NAT GENET, V28, P169, DOI 10.1038/88897; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sheu JC, 1999, BRIT J CANCER, V80, P468, DOI 10.1038/sj.bjc.6690380; Shi YP, 1997, GENE CHROMOSOME CANC, V19, P104, DOI 10.1002/(SICI)1098-2264(199706)19:2<104::AID-GCC6>3.3.CO;2-S; Van Nhieu JT, 1999, AM J PATHOL, V155, P703, DOI 10.1016/S0002-9440(10)65168-1; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300	48	25	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1518	1526		10.1038/sj.onc.1205208	http://dx.doi.org/10.1038/sj.onc.1205208			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896580				2022-12-17	WOS:000173956800007
J	Westwood, G; Dibling, BC; Cuthbert-Heavens, D; Burchill, SA				Westwood, G; Dibling, BC; Cuthbert-Heavens, D; Burchill, SA			Basic fibroblast growth factor (bFGF)-induced cell death is mediated through a caspase-dependent and p53-independent cell death receptor pathway	ONCOGENE			English	Article						bFGF; cell death; caspase; Ewing's sarcoma	CYTOCHROME-C RELEASE; EWING TUMOR-CELLS; INDUCED APOPTOSIS; P53; MITOCHONDRIAL; PROTEIN; SARCOMA; MODULATION; BCL-2; BAX	The mechanism of bFGF-induced cell death in tumours of the Ewing's sarcoma family (ESFT) has been investigated. bFGF-induces phosphorylation of FGFr 1 and activation of Ras/ERK in ESFT cells that die when exposed to bFGF. Induction of cell death was associated with activation of both initiator (caspases-2, -8 and -10) and effector (caspases-3, -6 and -7) caspases. Moreover, the general caspase inhibitor Z-VAD-FMK protected cells from bFGF-induced cell death. After treatment with bFGF, a loss of mitochondrial transmembrane potential was accompanied by down-regulation of Bcl-2. However, the observed cell death was not associated with release of cytochrome c from the mitochondria. Furthermore, expression of wild-type p53 was not required for bFGF-induced cell death. These observations suggest that bFGF-induced cell death may be mediated through a cell death receptor mechanism, supported by up-regulation of the p75 neurotrophin receptor. bFGF-induced cell death was associated with up-regulation of p21 and p53, down-regulation of PCNA and cyclin A and a decrease in active pRb1, changes consistent with accumulation of cells in G1. These data demonstrate that bFGF-induced cell death is effected through a caspase-dependent and p53-independent mechanism, that may be mediated through a cell death receptor pathway.	Univ Leeds, St James Hosp, Imperial Canc Res Fund, Canc Med Res Unit,Candlelighters Childrens Canc R, Leeds LS9 7TF, W Yorkshire, England; Univ Leeds, St James Hosp, Imperial Canc Res Fund, Canc Med Res Unit,Mutat Detect Facil, Leeds LS9 7TF, W Yorkshire, England	Saint James's University Hospital; University of Leeds; Saint James's University Hospital; University of Leeds	Burchill, SA (corresponding author), Univ Leeds, St James Hosp, Imperial Canc Res Fund, Canc Med Res Unit,Candlelighters Childrens Canc R, Beckett St, Leeds LS9 7TF, W Yorkshire, England.			Heavens, Darren/0000-0001-5418-7868				Achenbach TV, 2000, J BIOL CHEM, V275, P32089, DOI 10.1074/jbc.M005267200; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; BARTEK J, 1990, ONCOGENE, V5, P893; BIEDLER JL, 1973, CANCER RES, V33, P2643; Bratton SB, 2000, EXP CELL RES, V256, P27, DOI 10.1006/excr.2000.4835; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Dobrowsky RT, 2000, J NEUROSCI RES, V61, P237, DOI 10.1002/1097-4547(20000801)61:3<237::AID-JNR1>3.0.CO;2-M; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Girnita L, 2000, ONCOGENE, V19, P4298, DOI 10.1038/sj.onc.1203755; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; ITOH N, 1993, J BIOL CHEM, V268, P10932; Javelaud D, 2000, ONCOGENE, V19, P61, DOI 10.1038/sj.onc.1203246; Johnson BW, 2000, J BIOL CHEM, V275, P31546, DOI 10.1074/jbc.M001363200; Johnson MR, 1998, ONCOGENE, V16, P2647, DOI 10.1038/sj.onc.1201789; Joy A, 1997, ONCOGENE, V14, P171, DOI 10.1038/sj.onc.1200823; Kontny HU, 1998, CANCER RES, V58, P5842; KOVAR H, 1993, ONCOGENE, V8, P2683; Kovar H, 2000, ONCOGENE, V19, P4096, DOI 10.1038/sj.onc.1203780; Koya RC, 2000, J BIOL CHEM, V275, P15343, DOI 10.1074/jbc.275.20.15343; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Kruidering M, 2000, IUBMB LIFE, V50, P85, DOI 10.1080/713803693; Kumar A, 2001, ONCOGENE, V20, P1010, DOI 10.1038/sj.onc.1204154; Kusaka K, 1998, CURR EYE RES, V17, P524, DOI 10.1076/ceyr.17.5.524.5196; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; OConnor PM, 1997, CANCER RES, V57, P4285; Ong SH, 2000, MOL CELL BIOL, V20, P979, DOI 10.1128/MCB.20.3.979-989.2000; Ono T, 2000, J BIOL CHEM, V275, P31145, DOI 10.1074/jbc.M003031200; OWENSCHAUB LB, 1995, CANCER LETT, V94, P1, DOI 10.1016/0304-3835(95)03834-J; Petronilli V, 2001, J BIOL CHEM, V276, P12030, DOI 10.1074/jbc.M010604200; Piotrowicz RS, 1997, J BIOL CHEM, V272, P7042, DOI 10.1074/jbc.272.11.7042; Qin ZH, 2001, J BIOL CHEM, V276, P8079, DOI 10.1074/jbc.M007028200; Radig K, 1998, PATHOL RES PRACT, V194, P157, DOI 10.1016/S0344-0338(98)80016-2; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Schneider P, 2000, Pharm Acta Helv, V74, P281, DOI 10.1016/S0031-6865(99)00038-2; Schuelke M, 2000, NAT BIOTECHNOL, V18, P233, DOI 10.1038/72708; SCHWEIGERER L, 1987, J CLIN INVEST, V80, P1516, DOI 10.1172/JCI113236; Smits VAJ, 2000, J BIOL CHEM, V275, P19375, DOI 10.1074/jbc.M001764200; Sturla LM, 2000, CANCER RES, V60, P6160; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Wang HS, 1997, CANCER RES, V57, P1750; Wang Q, 1998, EXP CELL RES, V238, P177, DOI 10.1006/excr.1997.3820; Wang X, 2001, J BIOL CHEM, V276, P33812, DOI 10.1074/jbc.M010548200; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484	49	25	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2002	21	5					809	824		10.1038/sj.onc.1205128	http://dx.doi.org/10.1038/sj.onc.1205128			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FB	11850809				2022-12-17	WOS:000173427000012
J	Cerni, C; Skrzypek, B; Popov, N; Sasgary, S; Schmidt, G; Larsson, LG; Luscher, B; Henriksson, M				Cerni, C; Skrzypek, B; Popov, N; Sasgary, S; Schmidt, G; Larsson, LG; Luscher, B; Henriksson, M			Repression of in vivo growth of Myc/Ras transformed tumor cells by Mad1	ONCOGENE			English	Article						Mad1ER; Myc; cell cycle; gene repression; telomerase activity; tumor growth	MYC ANTAGONIST MAD1; HISTONE DEACETYLASE ACTIVITY; C-MYC; TRANSCRIPTIONAL REPRESSION; TELOMERASE ACTIVITY; INDUCIBLE EXPRESSION; ESSENTIAL COFACTOR; HTERT GENE; IN-VIVO; N-COR	The Myc/Max/Mad network of transcriptional regulatory proteins plays an essential role in cell proliferation, growth, apoptosis, and differentiation. Whereas, Myc proteins affect cell cycle progression positively,, Mad proteins are negative regulators of cell proliferation. It has been shown in several in vitro systems that Mad proteins antagonize c-Myc functions. In this report we describe the inhibition of tumor cell outgrowth in vivo by Mad1 expression. Transformed cell lines were generated by co-transfection of c-myc, c-H-ras, and a chimeric mad1ER construct into primary rat embryo cells (MRMad1ER cells). Activation of Mad1 by 4-Hydroxy-Tamoxifen (OHT) resulted in abrogation of telomerase activity, reduced cloning efficiency, and decreased proportion of cells in S phase. Injection of MRMad1ER cells into syngenic rats induced aggressively growing tumors after a short latency period. This tumor growth was inhibited by OHT-treatment of animals, with the extent of inhibition correlating with the amount of OHT injected. No effect of OHT on tumor growth was observed with similarly transformed Myc/Ras cell lines which did not express Mad1ER. These data demonstrate that Mad1 is able to suppress Myc/Ras-mediated transformation under in vivo conditions.	Univ Vienna, Inst Canc Res, A-1090 Vienna, Austria; Karolinska Inst, Ctr Microbiol & Tumor Biol, SE-17177 Stockholm, Sweden; Swedish Univ Agr Sci, Uppsala Genet Ctr, Dept Plant Biol, SE-75007 Uppsala, Sweden; Rhein Westfal TH Aachen, Inst Biochem, Abt Biochem & Mol Biol, D-52074 Aachen, Germany	University of Vienna; Karolinska Institutet; Swedish University of Agricultural Sciences; RWTH Aachen University	Cerni, C (corresponding author), Univ Vienna, Inst Canc Res, Borschkegasse 8A, A-1090 Vienna, Austria.	Christa.Cerni@univie.ac.at; Marie.Henriksson@mtc.ki.se	Henriksson, Marie Arsenian/F-5010-2015; Larsson, Lars-Gunnar/D-9747-2012; Luscher, Bernhard/A-7330-2011	Arsenian Henriksson, Marie/0000-0001-6376-7792; Luscher, Bernhard/0000-0002-9622-8709				Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Amati B, 2001, BBA-REV CANCER, V1471, pM135, DOI 10.1016/S0304-419X(01)00020-8; Avilion AA, 1996, CANCER RES, V56, P645; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; Bazarov AV, 2001, CANCER RES, V61, P1178; Bejarano MT, 2000, EXP CELL RES, V260, P61, DOI 10.1006/excr.2000.4996; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Cerni C, 2000, MUTAT RES-REV MUTAT, V462, P31, DOI 10.1016/S1383-5742(99)00091-5; CERNI C, 1995, ONCOGENE, V11, P587; CERNI C, 1990, VIROLOGY, V177, P427, DOI 10.1016/0042-6822(90)90506-M; CHEN J, 1995, NAT MED, V1, P638, DOI 10.1038/nm0795-638; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Cong YS, 2000, J BIOL CHEM, V275, P35665, DOI 10.1074/jbc.C000637200; Cultraro CM, 1997, MOL CELL BIOL, V17, P2353, DOI 10.1128/MCB.17.5.2353; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; Eilers M, 1999, MOL CELLS, V9, P1; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; Falchetti ML, 1999, ONCOGENE, V18, P1515, DOI 10.1038/sj.onc.1202438; Foley KP, 1998, EMBO J, V17, P774, DOI 10.1093/emboj/17.3.774; Gehring S, 2000, J BIOL CHEM, V275, P10413, DOI 10.1074/jbc.275.14.10413; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; Gundimeda U, 1996, J BIOL CHEM, V271, P13504, DOI 10.1074/jbc.271.23.13504; Gunes C, 2000, CANCER RES, V60, P2116; Guo QM, 2000, CANCER RES, V60, P5922; Han S, 2000, CANCER-AM CANCER SOC, V88, P1623, DOI 10.1002/(SICI)1097-0142(20000401)88:7<1623::AID-CNCR17>3.0.CO;2-W; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hurlin PJ, 1999, EMBO J, V18, P7019, DOI 10.1093/emboj/18.24.7019; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KOSKINEN PJ, 1995, CELL GROWTH DIFFER, V6, P623; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Larcher F, 1996, CANCER RES, V56, P5391; LARSSON LG, 1994, ONCOGENE, V9, P1247; Lee TH, 2000, ONCOGENE, V19, P3766, DOI 10.1038/sj.onc.1203715; Luscher B, 1999, ONCOGENE, V18, P2955, DOI 10.1038/sj.onc.1202750; Luscher B, 2001, GENE, V277, P1, DOI 10.1016/S0378-1119(01)00697-7; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; Ngo CV, 2000, CELL GROWTH DIFFER, V11, P201; O'Hagan RC, 2000, NAT GENET, V24, P113, DOI 10.1038/72761; Oh S, 2000, ONCOGENE, V19, P1485, DOI 10.1038/sj.onc.1203439; Prasad GL, 1999, ONCOGENE, V18, P2027, DOI 10.1038/sj.onc.1202264; Pulverer B, 2000, J CELL PHYSIOL, V183, P399, DOI 10.1002/(SICI)1097-4652(200006)183:3<399::AID-JCP13>3.3.CO;2-Z; Queva C, 1999, CELL GROWTH DIFFER, V10, P785; Queva C, 1998, ONCOGENE, V16, P967, DOI 10.1038/sj.onc.1201611; RAK J, 1995, CANCER RES, V55, P4575; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; ROY B, 1995, CELL BIOL INT, V19, P307, DOI 10.1006/cbir.1995.1073; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Sommer A, 1997, CURR BIOL, V7, P357, DOI 10.1016/S0960-9822(06)00183-7; Treon SP, 1998, BLOOD, V92, P1749, DOI 10.1182/blood.V92.5.1749.417k38_1749_1757; Ulaner GA, 1998, CANCER RES, V58, P4168; VASTRIK I, 1995, J CELL BIOL, V128, P1197, DOI 10.1083/jcb.128.6.1197; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723	72	25	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2002	21	3					447	459		10.1038/sj.onc.1205107	http://dx.doi.org/10.1038/sj.onc.1205107			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821957				2022-12-17	WOS:000173311200013
J	Wu, CH; Rastegar, M; Gordon, J; Safa, AR				Wu, CH; Rastegar, M; Gordon, J; Safa, AR			beta(2)-microglobulin induces apoptosis in HL-60 human leukemia cell line and its multidrug resistant variants overexpressing MRP1 but lacking Bax or overexpressing P-glycoprotein	ONCOGENE			English	Article						multidrug resistance; beta(2)-microglobulin; caspases; apoptosis; leukemia	PERMEABILITY TRANSITION PORE; CLASS-I MOLECULES; CYTOCHROME-C RELEASE; POLY(ADP-RIBOSE) POLYMERASE; INDEPENDENT APOPTOSIS; MELANOMA-CELLS; DEATH PATHWAY; GENE; FAS; ACTIVATION	In this study, we examined whether exogenous beta (2)-microglobulin (beta M-2) can induce apoptosis in the drug sensitive HL-60 leukemia cell line and its drug resistant variants and investigated the molecular mechanism of beta (2)m-induced apoptosis. Our data revealed that beta (2)m is very significantly down-regulated in two multidrug resistant variants of the HL-60 cells: (a) the MRP1-bearing, Bax-deficient HL-60/ADR cell line, and (b) the P-glycoprotein (P-gp) overexpressing HL-60/VCR cell line. However, exogenous beta (2)m induced similar levels of apoptosis in HL-60 cells and these drug resistant variants. beta (2)m-induced apoptosis in HL-60 and HL-60/VCR cells was associated with decreased mitochondrial membrane potential (Delta psim) but did not affect Delta psim in HL-60/ADR cells. Surprisingly, cyclosporin A (CsA), a known inhibitor of the mitochondrial permeability transition (MPT) pore, inhibited beta (2)m-induced apoptosis in HL-60/ADR cells but not in HL-60 and HL-60/VCR cells, suggesting that the pro-apoptotic effect of beta (2)m in these cells is not through MPT pore formation. Furthermore, beta (2)m induced the release of cytochrome c and the apoptosis-inducing factor (AIF) from mitochondria in HL-60 and HL-60/VCR cells, but not in HL-60/ADR cells. Additionally, z-VAD-fmk, a general inhibitor of caspases which inhibited cytochrome c release in HL-60 and HL-60/VCR cells, had no effect on AIF release in any of these cell lines, but inhibited beta (2)m-induced apoptosis in all three cell lines. However, Western blot analysis revealed that caspases-1, -3, -6, -8, and -9 are not activated during beta (2)m-induced apoptosis in these cells. Therefore, beta (2)m-induces apoptosis through an unknown caspase-dependent mitochondrial pathway in HL-60 and HL-60/VCR cells and by a Bax-independent, non-mitochodrial, caspase-dependent pathway in HL-60/ADR cells.	Indiana Univ, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA; Indiana Univ, Ctr Canc, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Safa, AR (corresponding author), Indiana Univ, Dept Pharmacol & Toxicol, 1044 W Walnut R4-119, Indianapolis, IN 46202 USA.	asafa@iupui.edu	Rastegar, Mojgan/T-9394-2019	Rastegar, Mojgan/0000-0003-3619-6116; Gordon, John/0000-0002-9781-9842	NATIONAL CANCER INSTITUTE [R01CA080734] Funding Source: NIH RePORTER; NCI NIH HHS [CA 80734] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Benitez R, 1998, TISSUE ANTIGENS, V52, P520, DOI 10.1111/j.1399-0039.1998.tb03082.x; Bezombes C, 1998, FASEB J, V12, P101, DOI 10.1096/fasebj.12.1.101; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Castano E, 1999, BRIT J CANCER, V81, P294, DOI 10.1038/sj.bjc.6690690; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chen HL, 1996, INT J CANCER, V67, P756, DOI 10.1002/(SICI)1097-0215(19960917)67:6<756::AID-IJC2>3.0.CO;2-Q; CHEN LB, 1988, ANNU REV CELL BIOL, V4, P155, DOI 10.1146/annurev.cellbio.4.1.155; Christianson GJ, 1997, J IMMUNOL, V159, P4781; Chung TDK, 1998, CANCER GENE THER, V5, P344; Costantini P, 2000, J NATL CANCER I, V92, P1042, DOI 10.1093/jnci/92.13.1042; Creagh EM, 2000, EXP CELL RES, V257, P58, DOI 10.1006/excr.2000.4856; Decker P, 2000, J BIOL CHEM, V275, P9043, DOI 10.1074/jbc.275.12.9043; DIXON B, 1993, IMMUNOGENETICS, V38, P27, DOI 10.1007/BF00216387; DURSO CM, 1991, J CLIN INVEST, V87, P284, DOI 10.1172/JCI114984; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Ferri KF, 2001, BIOESSAYS, V23, P111, DOI 10.1002/1521-1878(200102)23:2<111::AID-BIES1016>3.0.CO;2-Y; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; FLEMING GF, 1992, CANCER CHEMOTH PHARM, V29, P445, DOI 10.1007/BF00684845; Fournel S, 2000, J IMMUNOL, V164, P6100, DOI 10.4049/jimmunol.164.12.6100; Genestier L, 1997, BLOOD, V90, P3629, DOI 10.1182/blood.V90.9.3629; Genestier L, 1998, J BIOL CHEM, V273, P5060, DOI 10.1074/jbc.273.9.5060; Genestier L, 1997, BLOOD, V90, P726, DOI 10.1182/blood.V90.2.726.726_726_735; GRAZIOLI L, 1994, J BIOL CHEM, V269, P22304; Gregoli PA, 1999, J CELL PHYSIOL, V178, P133, DOI 10.1002/(SICI)1097-4652(199902)178:2<133::AID-JCP2>3.3.CO;2-X; GUSSOW D, 1987, J IMMUNOL, V139, P3132; Halestrap AP, 1997, MOL CELL BIOCHEM, V174, P167, DOI 10.1023/A:1006879618176; Hicklin DJ, 1998, J CLIN INVEST, V101, P2720, DOI 10.1172/JCI498; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Johnstone RW, 2000, LEUKEMIA LYMPHOMA, V38, P1, DOI 10.3109/10428190009060314; Jones BE, 2000, J BIOL CHEM, V275, P705, DOI 10.1074/jbc.275.1.705; KAKLAMANIS L, 1995, CANCER RES, V55, P5191; Kollet O, 2000, BLOOD, V95, P3102, DOI 10.1182/blood.V95.10.3102.010k14_3102_3105; KRISHNAMACHARY N, 1994, ONCOL RES, V6, P119; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kunstle G, 1997, IMMUNOL LETT, V55, P5, DOI 10.1016/S0165-2478(96)02642-9; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MCGRATH T, 1989, BIOCHEM PHARMACOL, V38, P3611, DOI 10.1016/0006-2952(89)90134-2; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Mori M, 1999, BLOOD, V94, P2744; Mori M, 2001, CANCER RES, V61, P4414; Munker R, 1997, HEMATOL CELL THER, V39, P75, DOI 10.1007/s00282-997-0075-7; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; Ogretmen B, 1997, ONCOGENE, V14, P499, DOI 10.1038/sj.onc.1200855; Ogretmen B, 1998, BIOCHEMISTRY-US, V37, P11679, DOI 10.1021/bi980573c; Ogretmen B, 2000, BIOCHEMISTRY-US, V39, P194, DOI 10.1021/bi991943f; Oliver FJ, 1998, J BIOL CHEM, V273, P33533, DOI 10.1074/jbc.273.50.33533; Pallis M, 2000, BLOOD, V95, P2897, DOI 10.1182/blood.V95.9.2897.009k14_2897_2904; Parham P, 1996, SCIENCE, V272, P67, DOI 10.1126/science.272.5258.67; Pastorino JG, 1999, J BIOL CHEM, V274, P31734, DOI 10.1074/jbc.274.44.31734; Perkins C, 2000, BLOOD, V95, P1014, DOI 10.1182/blood.V95.3.1014.003k04_1014_1022; PLOEGH HL, 1981, CELL, V24, P287, DOI 10.1016/0092-8674(81)90318-4; Restifo NP, 1996, J NATL CANCER I, V88, P100, DOI 10.1093/jnci/88.2.100; RESTIFO NP, 1993, J EXP MED, V177, P265, DOI 10.1084/jem.177.2.265; Robertson JD, 2000, CRIT REV TOXICOL, V30, P609, DOI 10.1080/10408440008951122; Robinson LJ, 1997, BIOCHEMISTRY-US, V36, P11169, DOI 10.1021/bi9627830; Rodriguez I, 1996, J EXP MED, V184, P2067, DOI 10.1084/jem.184.5.2067; ROWLEY DR, 1995, CANCER RES, V55, P781; Ruefli AA, 2000, BLOOD, V95, P2378, DOI 10.1182/blood.V95.7.2378.007k10_2378_2385; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; Schotte P, 1999, FEBS LETT, V442, P117, DOI 10.1016/S0014-5793(98)01640-8; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Skov S, 1997, J CELL BIOL, V139, P1523, DOI 10.1083/jcb.139.6.1523; Skov S, 1997, J IMMUNOL, V158, P3189; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Slee EA, 2001, J BIOL CHEM, V276, P7320, DOI 10.1074/jbc.M008363200; Smyth MJ, 1998, P NATL ACAD SCI USA, V95, P7024, DOI 10.1073/pnas.95.12.7024; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Takagi M, 1999, LEUKEMIA, V13, P70, DOI 10.1038/sj.leu.2401247; Takeuchi T, 1996, INT J CANCER, V67, P709, DOI 10.1002/(SICI)1097-0215(19960904)67:5<709::AID-IJC20>3.0.CO;2-Z; Ten Hagen TLM, 2000, INT J CANCER, V87, P829, DOI 10.1002/1097-0215(20000915)87:6<829::AID-IJC12>3.0.CO;2-C; Vitale M, 1998, CANCER RES, V58, P737; WallenOhman M, 1997, INT IMMUNOL, V9, P599, DOI 10.1093/intimm/9.4.599; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Woodle ES, 1997, J IMMUNOL, V158, P2156; Yamamoto H, 2001, GASTROENTEROLOGY, V120, P1565, DOI 10.1053/gast.2001.24497	80	25	28	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 25	2001	20	48					7006	7020		10.1038/sj.onc.1204893	http://dx.doi.org/10.1038/sj.onc.1204893			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485DY	11704825				2022-12-17	WOS:000171739300004
J	Zhang, XG; Steiner, MS; Rinaldy, A; Lu, Y				Zhang, XG; Steiner, MS; Rinaldy, A; Lu, Y			Apoptosis induction in prostate cancer cells by a novel gene product, pHyde, involves caspase-3	ONCOGENE			English	Article						pHyde; apoptosis; caspase-3; prostate cancer	DNA FRAGMENTATION; MAMMALIAN HOMOLOG; DEATH; CLEAVAGE; PROTEASE; ACTIVATION; INHIBITOR; PATHWAYS; CED-3; LINES	A novel gene, pHyde, was recently cloned from Dunning rat prostate cancer cells. A recombinant adenovirus containing pHyde cDNA gene (AdpHyde) was generated to investigate the biological function of pHyde protein. AdpHyde inhibited the growth of human prostate cancer cells. Apoptosis was induced in AdpHyde transduced cells as demonstrated by DAPI (4', 6-diamino-2-phenylindole), TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP nick and labeling) staining, and flow cytometry assays. Apoptosis was also induced in human xenograft prostate cancer tumors growing in nude mice following treatment with AdpHyde. AdpHyde transduction resulted in a dose-dependent stimulation of caspase-3 activity in DU145 cells which was blocked by DEVD (succinyl-Asp-Glu-Val-Asp-aldehyde) and VAD (benzyloxycarbonyl - Val - Ala - Asp -fluoromethylketone), inhibitors specifically against caspase-3. Moreover, cancer cells that lacked expression of endogenous caspase-3 were not or barely inhibited by pHyde. These results taken together suggest that pHyde inhibits cancer growth by inducing apoptosis through a caspase-3 dependent pathway.	Univ Tennessee, Hlth Sci Ctr, Coll Med, Dept Urol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Lu, Y (corresponding author), Univ Tennessee, Hlth Sci Ctr, Coll Med, Dept Urol, 956 Court Ave, Memphis, TN 38163 USA.							Buckley CD, 1999, NATURE, V397, P534, DOI 10.1038/17409; CARTER HB, 1990, J UROLOGY, V143, P742, DOI 10.1016/S0022-5347(17)40078-4; Chang HY, 2000, MICROBIOL MOL BIOL R, V64, P821, DOI 10.1128/MMBR.64.4.821-846.2000; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; El Etreby MF, 1998, BREAST CANCER RES TR, V51, P149, DOI 10.1023/A:1006078032287; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; Green DR, 2000, NAT IMMUNOL, V1, P15, DOI 10.1038/76868; HYER ML, 2000, MOL THER, V1, pS322; JACKMAN J, 1998, CURRENT PROTOCOLS CE; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; Kadkol SS, 1998, PROSTATE, V34, P231, DOI 10.1002/(SICI)1097-0045(19980215)34:3<231::AID-PROS11>3.0.CO;2-F; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Lu Y, 1999, CANCER GENE THER, V6, P64, DOI 10.1038/sj.cgt.7700011; Lu Yi, 1995, Molecular and Cellular Differentiation, V3, P175; Mantzoros CS, 1997, BRIT J CANCER, V76, P1115, DOI 10.1038/bjc.1997.520; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; Okuma E, 2000, LEUKEMIA, V14, P612, DOI 10.1038/sj.leu.2401716; Oridate N, 1996, CLIN CANCER RES, V2, P855; Porter AG, 1997, BIOESSAYS, V19, P501, DOI 10.1002/bies.950190609; Rinaldy AR, 1999, DNA CELL BIOL, V18, P829, DOI 10.1089/104454999314827; Rokhlin OW, 1997, CANCER RES, V57, P1758; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; SANDBERG AA, 1992, HUM PATHOL, V23, P368, DOI 10.1016/0046-8177(92)90083-F; SCHULZEOSTHOFF K, 1994, J CELL BIOL, V127, P15, DOI 10.1083/jcb.127.1.15; Steiner MS, 2000, CANCER RES, V60, P4419; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Stennicke HR, 1998, BBA-PROTEIN STRUCT M, V1387, P17, DOI 10.1016/S0167-4838(98)00133-2; Talanian RV, 1997, J EXP MED, V186, P1323, DOI 10.1084/jem.186.8.1323; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Tseng CP, 1998, ENDOCRINOLOGY, V139, P3542, DOI 10.1210/en.139.8.3542; UCKER DS, 1992, MOL CELL BIOL, V12, P3060, DOI 10.1128/MCB.12.7.3060; WOLK A, 1998, J NATL CANCER I, V90, P876; Yang XH, 1998, J BIOL CHEM, V273, P34278, DOI 10.1074/jbc.273.51.34278; Zhang XW, 1999, ANTI-CANCER DRUG, V10, P569, DOI 10.1097/00001813-199907000-00009	40	25	45	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2001	20	42					5982	5990		10.1038/sj.onc.1204831	http://dx.doi.org/10.1038/sj.onc.1204831			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473QF	11593405				2022-12-17	WOS:000171056300005
J	Blanchette, P; Gilchrist, CA; Baker, RT; Gray, DA				Blanchette, P; Gilchrist, CA; Baker, RT; Gray, DA			Association of UNP, a ubiquitin-specific protease, with the pocket proteins pRb, p107 and p130	ONCOGENE			English	Article						ubiquitin; Ubp; deubiquitinating enzyme; retinoblastoma; pocket protein	RETINOBLASTOMA GENE-PRODUCT; RB-RELATED P107; CELL-CYCLE; REGULATED PROTEOLYSIS; MICE LACKING; C-MYC; PATHWAY; DEGRADATION; FAMILY; E2F	The murine Unp gene encodes a widely expressed ubiquitin-specific protease. The predicted sequence of the UNP protein features motifs common to viral oncoproteins through which these proteins interact with the retinoblastoma gene product pRb, as well as the related 'pocket proteins' p107 and p130. We have explored the possibility that UNP interacts with pocket proteins, and report here that such associations can be detected in vitro and in cells. Associations of UNP and pocket proteins are sensitive to site-directed mutations in a manner directly analogous to those documented in viral oncoproteins. We conclude that within cells UNP does physically associate with pRb, and can also associate with p107 and p130.	Ottawa Reg Canc Ctr, Ctr Canc Therapeut, Ottawa, ON K1H 1C4, Canada; Australian Natl Univ, John Curtin Sch Med Res, Mol Genet Grp, Canberra, ACT 2601, Australia	University of Ottawa; Ottawa Hospital Research Institute; Australian National University; John Curtin School of Medical Research	Gray, DA (corresponding author), Ottawa Reg Canc Ctr, Ctr Canc Therapeut, 503 Smyth Rd, Ottawa, ON K1H 1C4, Canada.		Gilchrist, Catherine/GPW-8606-2022; /U-3554-2018	Gilchrist, Catherine/0000-0002-7467-7933; /0000-0002-8634-4984				BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; Boyer SN, 1996, CANCER RES, V56, P4620; BUYSE IM, 1995, P NATL ACAD SCI USA, V92, P4467, DOI 10.1073/pnas.92.10.4467; Cadavid ALM, 2000, DEVELOPMENT, V127, P1727; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DeSalle LM, 2001, ONCOGENE, V20, P5538, DOI 10.1038/sj.onc.1204824; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FATTAEY AR, 1993, ONCOGENE, V8, P3149; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; GRAY DA, 1995, ONCOGENE, V10, P2179; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; GUPTA K, 1994, ONCOGENE, V9, P1729; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Hoyt MA, 1997, CELL, V91, P149, DOI 10.1016/S0092-8674(00)80396-7; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; LeCouter JE, 1998, DEVELOPMENT, V125, P4669; LeCouter JE, 1998, MOL CELL BIOL, V18, P7455, DOI 10.1128/MCB.18.12.7455; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Sala A, 1996, J BIOL CHEM, V271, P28738, DOI 10.1074/jbc.271.46.28738; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; Smith EJ, 1998, CELL GROWTH DIFFER, V9, P297; Voorhoeve PM, 1999, ONCOGENE, V18, P515, DOI 10.1038/sj.onc.1202316; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7	30	25	30	1	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 6	2001	20	39					5533	5537		10.1038/sj.onc.1204823	http://dx.doi.org/10.1038/sj.onc.1204823			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571651				2022-12-17	WOS:000170781100014
J	Siegrist, S; Feral, C; Chami, M; Solhonne, B; Mattei, MG; Rajpert-De Meyts, E; Guellaen, G; Bulle, F				Siegrist, S; Feral, C; Chami, M; Solhonne, B; Mattei, MG; Rajpert-De Meyts, E; Guellaen, G; Bulle, F			hH-Rev107, a class II tumor suppressor gene, is expressed by post-meiotic testicular germ cells and CIS cells but not by human testicular germ cell tumors	ONCOGENE			English	Article						hH-Rev107; tumor suppressor gene; spermatogenesis; carcinoma in situ; testicular germ cell tumors	CARCINOMA-IN-SITU; DOWN-REGULATION; HUMAN TESTIS; CANCER; IDENTIFICATION; HYBRIDIZATION; H-REV107; RNA; CHROMOSOME; CLONING	By systematic analysis of a human testis library, we have isolated the hH-Rev107-3 cDNA, identical to hH-Rev107-1 cDNA, which was previously described as a class II tumor suppressor gene. In this study, two transcripts (I and 0.8 kb) were detected by Northern blot in all human tissues, excepted in thymus. The strongest expression was found in testis, skeletal muscle and heart. These two mRNA are probably transcribed from only one gene that we mapped to the q12-q13 region of the chromosome 11. In human testis, hH-Rev107 gene expression was localized, by in situ hybridization, within the round spermatids. To investigate a possible role for hH-Rev107 protein in testicular malignant growth, we examined the expression of this gene in germ cell tumors. A strong hH-Rev107 gene expression was observed in normal testis as well as in samples with preinvasive carcinoma in situ but was completely absent in overt tumors, both seminomas and non-seminomas. By in situ hybridization, CIS was found hH-ReP107 positive and tumor negative. A semi-quantitative assessment of hH-Rev107 mRNA level in testicular germ cell tumors, by RT-PCR, exhibited a ninefold decrease in the gene expression. No gross structural aberrations of hH-Rev107 gene were detected in these human primary tumors. The results suggest that down-regulation of hH-Rev107 may be associated with invasive progression of testicular germ cell tumors.	Hop Henri Mondor, INSERM, U99, F-94010 Creteil, France; Fac Med Marseille, INSERM, U491, F-13385 Marseille, France; Univ Copenhagen, Rigshosp, Dept Growth & Reprod, DK-2100 Copenhagen, Denmark	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Rigshospitalet; University of Copenhagen	Bulle, F (corresponding author), Hop Henri Mondor, INSERM, U99, F-94010 Creteil, France.		Feral, Chloe C/O-5781-2016; Rajpert-De Meyts, Ewa/H-6526-2019; Bulle-Thomas, Frederique/L-2528-2017; Chami, Mounia/S-6471-2019; FERAL, Chloe/AAB-6111-2020	Feral, Chloe C/0000-0001-9756-2082; Rajpert-De Meyts, Ewa/0000-0002-5946-7559; Chami, Mounia/0000-0003-1498-7187; FERAL, Chloe/0000-0001-9756-2082				Bartkova J, 2000, INT J CANCER, V85, P370, DOI 10.1002/(SICI)1097-0215(20000201)85:3<370::AID-IJC13>3.0.CO;2-A; BOS JL, 1989, CANCER RES, V49, P4682; Braun RE, 1998, SEMIN CELL DEV BIOL, V9, P483, DOI 10.1006/scdb.1998.0226; Bulle F, 1996, ANN GENET-PARIS, V39, P139; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DiSepio D, 1998, P NATL ACAD SCI USA, V95, P14811, DOI 10.1073/pnas.95.25.14811; Duvic M, 2000, CLIN CANCER RES, V6, P3249; ERICKSON RP, 1990, TRENDS GENET, V6, P264, DOI 10.1016/0168-9525(90)90209-O; HAJNAL A, 1994, ONCOGENE, V9, P479; Hecht NB, 1998, BIOESSAYS, V20, P555, DOI 10.1002/(SICI)1521-1878(199807)20:7<555::AID-BIES6>3.3.CO;2-J; Huang SL, 2000, MOL CELL ENDOCRINOL, V159, P15, DOI 10.1016/S0303-7207(99)00207-5; Husmann K, 1998, ONCOGENE, V17, P1305, DOI 10.1038/sj.onc.1202060; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; Levy I, 1996, FEBS LETT, V382, P276, DOI 10.1016/0014-5793(96)00183-4; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; MOUL JW, 1992, GENE CHROMOSOME CANC, V5, P109, DOI 10.1002/gcc.2870050204; MULDER MP, 1989, ONCOGENE, V4, P1345; PAWLAK A, 1995, GENOMICS, V26, P151, DOI 10.1016/0888-7543(95)80096-5; PECKHAM M, 1988, ACTA ONCOL, V27, P439, DOI 10.3109/02841868809093570; Rajpert-De Meyts E, 1998, APMIS, V106, P198; RICHIE JP, 1993, CA-CANCER J CLIN, V43, P151, DOI 10.3322/canjclin.43.3.151; SACCONE S, 1992, P NATL ACAD SCI USA, V89, P4913, DOI 10.1073/pnas.89.11.4913; SCHMIDT B, 1995, J MOL MED, V73, P355; SCHMIDT EE, 1995, DEVELOPMENT, V121, P2373; Sers C, 1997, J CELL BIOL, V136, P935, DOI 10.1083/jcb.136.4.935; SHUIN T, 1994, CANCER, V73, P1721, DOI 10.1002/1097-0142(19940315)73:6<1721::AID-CNCR2820730628>3.0.CO;2-W; SKAKKEBAEK NE, 1972, LANCET, V2, P516; SKAKKEBAEK NE, 1987, INT J ANDROL, V10, P19, DOI 10.1111/j.1365-2605.1987.tb00161.x	28	25	27	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2001	20	37					5155	5163		10.1038/sj.onc.1204658	http://dx.doi.org/10.1038/sj.onc.1204658			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526504	Green Accepted, Green Submitted			2022-12-17	WOS:000170464000009
J	Dennis, JH; Budhram-Mahadeo, V; Latchman, DS				Dennis, JH; Budhram-Mahadeo, V; Latchman, DS			The Brn-3b POU family transcription factor regulates the cellular growth, proliferation, and anchorage dependence of MCF7 human breast cancer cells	ONCOGENE			English	Article						Brn-3; MCF7; stable cell line; breast cancer; transcription factor	MAMMARY-CARCINOMA CELLS; CENTRAL-NERVOUS-SYSTEM; ESTROGEN-RECEPTOR; AUTOREGULATORY ELEMENT; RESPONSE ELEMENT; FACTOR SECRETION; NEURONAL CELLS; RETINOIC ACID; EXPRESSION; ACTIVATION	The Brn-3b POU domain containing transcription factor is expressed in the developing sensory nervous system as well as in epithelial cells of the breast, cervix, and testes. Brn-3b functionally interacts with the estrogen receptor (ER) and in association with the ER, regulates transcription from estrogen responsive genes. In addition, Brn-3b expression is elevated in breast tumours compared to levels in normal mammary cells. To explore the role of Brn-3b in breast cancer, we established stable cell lines derived from the MCF7 human breast cancer cell line which had been transfected with Brn-3b sense or anti-sense constructs. The Brn-3b over-expressing cell Hues exhibited increased growth rate, reached confluence at a higher saturation density, had higher proliferative activity, and an enhanced ability to form colonies in soft agar when compared to the control empty vector transfected cells. Likewise, the Brn-3b anti-sense cell lines showed reduced cellular growth and proliferation, reached confluence at a lower density, and exhibited a decreased ability to form colonies in soft agar when compared to the vector controls. Five to ten per cent of the Brn-3b over-expressing cells exhibited a severely altered morphology characterized by reduced adherence to tissue culture plastic, increased cell size, and a vacuolar cell shape. These results thus further indicate a role for the Brn-3b transcription factor in regulating mammary cell growth and suggest that its elevation in breast cancer is of functional significance.	Inst Child Hlth, London WC1N 1EH, England	University of London; University College London	Latchman, DS (corresponding author), Inst Child Hlth, 30 Guilford St, London WC1N 1EH, England.							AWGULEWITSCH A, 1992, NATURE, V358, P341, DOI 10.1038/358341a0; BERGSON C, 1990, EMBO J, V9, P4287, DOI 10.1002/j.1460-2075.1990.tb07877.x; Budhram-Mahadeo V, 1999, ONCOGENE, V18, P6684, DOI 10.1038/sj.onc.1203072; Budhram-Mahadeo V, 1998, MOL CELL BIOL, V18, P1029, DOI 10.1128/MCB.18.2.1029; BUDHRAMMAHADEO V, 1995, J BIOL CHEM, V270, P2853, DOI 10.1074/jbc.270.6.2853; DICKSON RB, 1987, P NATL ACAD SCI USA, V84, P837, DOI 10.1073/pnas.84.3.837; DICKSON RB, 1987, ENDOCR REV, V8, P29, DOI 10.1210/edrv-8-1-29; Elledge RM, 1997, BRIT MED J, V314, P1843, DOI 10.1136/bmj.314.7098.1843; Endoh H, 1999, MOL CELL BIOL, V19, P5363; FUQUA SA, 1992, J NATL CANCER I, V84, P554, DOI 10.1093/jnci/84.8.554; FUQUA SAW, 1992, CANCER RES, V52, P483; GERRERO MR, 1993, P NATL ACAD SCI USA, V90, P10841, DOI 10.1073/pnas.90.22.10841; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Latchman DS, 1999, J CELL PHYSIOL, V179, P126; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; LIPPMAN ME, 1987, J LAB CLIN MED, V109, P230; Liu YZ, 1996, J MOL NEUROSCI, V7, P77, DOI 10.1007/BF02736850; LOU L, 1995, NUCLEIC ACIDS RES, V23, P3481, DOI 10.1093/nar/23.17.3481; MALICKI J, 1992, NATURE, V358, P345, DOI 10.1038/358345a0; MORRIS PJ, 1994, MOL CELL BIOL, V14, P6907, DOI 10.1128/MCB.14.10.6907; MURPHY LC, 1983, J CLIN ENDOCR METAB, V57, P373, DOI 10.1210/jcem-57-2-373; Ndisang D, 1999, J BIOL CHEM, V274, P28521, DOI 10.1074/jbc.274.40.28521; Packer AI, 1998, DEVELOPMENT, V125, P1991; POPPERL H, 1992, EMBO J, V11, P3673, DOI 10.1002/j.1460-2075.1992.tb05452.x; REDDEL RR, 1983, CANCER RES, V43, P4618; REDDEL RR, 1983, EUR J CANCER CLIN ON, V19, P1179, DOI 10.1016/0277-5379(83)90047-0; Smith MD, 1996, INT J CANCER, V67, P653; Smith MD, 1997, J BIOL CHEM, V272, P1382, DOI 10.1074/jbc.272.2.1382; SUTHERLAND RL, 1983, EUR J CANCER CLIN ON, V19, P615, DOI 10.1016/0277-5379(83)90177-3; SUTHERLAND RL, 1983, CANCER RES, V43, P3998; TAYLOR IW, 1983, CANCER RES, V43, P4007; THEIL T, 1993, NUCLEIC ACIDS RES, V21, P5921, DOI 10.1093/nar/21.25.5921; TURNER EE, 1994, NEURON, V12, P205, DOI 10.1016/0896-6273(94)90164-3; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0	34	25	28	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 16	2001	20	36					4961	4971		10.1038/sj.onc.1204491	http://dx.doi.org/10.1038/sj.onc.1204491			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526481				2022-12-17	WOS:000170439800006
J	Nanbru, C; Prats, AC; Droogmans, L; Defrance, P; Huez, G; Kruys, V				Nanbru, C; Prats, AC; Droogmans, L; Defrance, P; Huez, G; Kruys, V			Translation of the human c-myc P0 tricistronic mRNA involves two independent internal ribosome entry sites	ONCOGENE			English	Article						translation; IRES; proto-oncogene	FACTOR MESSENGER-RNA; TRACT-BINDING-PROTEIN; ALTERNATIVE TRANSLATION; GROWTH-FACTOR; POLIOVIRUS RNA; CELL-CYCLE; POLY(RC) BINDING-PROTEIN-2; INITIATION; TRANSCRIPTION; EXPRESSION	The human c-myc proto-oncogene is transcribed from four alternative promoters (P0, P1, P2, and P3) giving rise to mRNAs having 5 ' leader sequences of various length. The c-myc P0 mRNA contains three open reading frames (ORFs), the last one encoding c-Myc1 and c-Myc2 proteins generated by alternative translation initiated at CUG and AUG codons, The middle ORF (MYCHEX1) and the 5 ' ORF (ORF1) code for proteins 188 and 114 amino acids in length, respectively. We and others previously identified an internal ribosome entry site (IRES) in P0 and P2 c-myc mRNAs, promoting the cap-independent translation of c-Myc1 and c-Myc2, Here, we report the presence of a second IRES (named IRES1) promoting the cap-independent translation of MYCHEX1 in c-myc P0 mRNA, Using deletion analysis, we mapped an 80-nt region essential for IRES1 activity. c-myc P0 mRNA is thus the first eukaryotic polycistronic mRNA described for which translation initiation of two different open reading frames (MYCHEX1 and c-Myc1/c-Myc2) involves internal ribosome entry.	Free Univ Brussels, Inst Biol & Med Mol, Chim Biol Lab, B-6041 Gosselies, Belgium; CHU Rangueil, Inst Louis Bugnard, INSERM, Endocrinol & Commun Cellulaire U397, F-31403 Toulouse 04, France; Free Univ Brussels, Microbiol Lab, B-1070 Brussels, Belgium	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Libre de Bruxelles; Vrije Universiteit Brussel	Kruys, V (corresponding author), Free Univ Brussels, Inst Biol & Med Mol, Chim Biol Lab, Rue Profs Jeener & Brachet 12, B-6041 Gosselies, Belgium.		Prats, Anne-Catherine/E-5051-2016; Kruys, Veronique I/N-6613-2018	Prats, Anne-Catherine/0000-0002-5282-3776; Kruys, Veronique/0000-0002-3144-5403				Akiri G, 1998, ONCOGENE, V17, P227, DOI 10.1038/sj.onc.1202019; AUSUBEL FM, 1995, CURR PROTOC MOLEC BI, V31, P10; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; Bernstein J, 1997, J BIOL CHEM, V272, P9356; BLACKWOOD EM, 1994, MOL BIOL CELL, V5, P597, DOI 10.1091/mbc.5.5.597; Blyn LB, 1997, J VIROL, V71, P6243, DOI 10.1128/JVI.71.8.6243-6246.1997; Blyn LB, 1996, P NATL ACAD SCI USA, V93, P11115, DOI 10.1073/pnas.93.20.11115; Chappell SA, 2000, P NATL ACAD SCI USA, V97, P1536, DOI 10.1073/pnas.97.4.1536; CORCORAN LM, 1985, CELL, V40, P71, DOI 10.1016/0092-8674(85)90310-1; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; Creancier L, 2001, MOL CELL BIOL, V21, P1833, DOI 10.1128/MCB.21.5.1833-1840.2001; DEDIEU JF, 1988, ONCOGENE, V3, P523; EICK D, 1990, ONCOGENE, V5, P1397; GAZIN C, 1986, EMBO J, V5, P2241, DOI 10.1002/j.1460-2075.1986.tb04491.x; Gueydan C, 1996, MOL MED, V2, P479, DOI 10.1007/BF03401907; HANN SR, 1992, GENE DEV, V6, P1229, DOI 10.1101/gad.6.7.1229; HANN SR, 1994, GENE DEV, V8, P2441, DOI 10.1101/gad.8.20.2441; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HELLEN CUT, 1993, P NATL ACAD SCI USA, V90, P7642, DOI 10.1073/pnas.90.16.7642; Henis-Korenblit S, 2000, MOL CELL BIOL, V20, P496, DOI 10.1128/MCB.20.2.496-506.2000; Holcik M, 2000, MOL CELL BIOL, V20, P4648, DOI 10.1128/MCB.20.13.4648-4657.2000; Holcik M, 1999, NAT CELL BIOL, V1, P190, DOI 10.1038/11109; Hoover R G, 1995, Curr Top Microbiol Immunol, V194, P257; Huez I, 1998, MOL CELL BIOL, V18, P6178, DOI 10.1128/MCB.18.11.6178; Hunt SL, 1999, GENE DEV, V13, P437, DOI 10.1101/gad.13.4.437; JACKSON RJ, 1988, NATURE, V334, P292, DOI 10.1038/334292a0; Johannes G, 1998, RNA, V4, P1500, DOI 10.1017/S1355838298981080; Kaminski A, 1998, RNA, V4, P626, DOI 10.1017/S1355838298971898; KRUYS V, 1993, J EXP MED, V177, P1383, DOI 10.1084/jem.177.5.1383; Le SY, 1997, NUCLEIC ACIDS RES, V25, P362, DOI 10.1093/nar/25.2.362; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Nanbru C, 1997, J BIOL CHEM, V272, P32061, DOI 10.1074/jbc.272.51.32061; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PRATS AC, 1992, MOL CELL BIOL, V12, P4796, DOI 10.1128/MCB.12.10.4796; Pyronnet S, 2000, MOL CELL, V5, P607, DOI 10.1016/S1097-2765(00)80240-3; RAY D, 1989, ONCOGENE RES, V5, P73; Ryan KM, 1996, BIOCHEM J, V314, P713, DOI 10.1042/bj3140713; Sella O, 1999, MOL CELL BIOL, V19, P5429; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; Spotts GD, 1997, MOL CELL BIOL, V17, P1459, DOI 10.1128/MCB.17.3.1459; Stoneley M, 2000, MOL CELL BIOL, V20, P1162, DOI 10.1128/MCB.20.4.1162-1169.2000; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; Teerink H, 1995, BBA-GENE STRUCT EXPR, V1264, P403, DOI 10.1016/0167-4781(95)00185-9; VAGNER S, 1995, J BIOL CHEM, V270, P20376, DOI 10.1074/jbc.270.35.20376; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; Willis AE, 1999, INT J BIOCHEM CELL B, V31, P73, DOI 10.1016/S1357-2725(98)00133-2; Yang Q, 1997, NUCLEIC ACIDS RES, V25, P2800, DOI 10.1093/nar/25.14.2800	49	25	26	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 12	2001	20	31					4270	4280		10.1038/sj.onc.1204548	http://dx.doi.org/10.1038/sj.onc.1204548			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464293				2022-12-17	WOS:000169857200017
J	Polanowska, J; Fabbrizio, E; Le Cam, L; Trouche, D; Emiliani, S; Herrera, R; Sardet, C				Polanowska, J; Fabbrizio, E; Le Cam, L; Trouche, D; Emiliani, S; Herrera, R; Sardet, C			The periodic down regulation of Cyclin E gene expression from exit of mitosis to end of G(1) is controlled by a deacetylase- and E2F-associated bipartite repressor element	ONCOGENE			English	Article						cyclin E; E2F; promoter; transcriptional repression; cell cycle	PAPILLOMAVIRUS TYPE-16 E7; IN-VIVO STRUCTURE; CELL-CYCLE; HISTONE DEACETYLASE; TRANSCRIPTION FACTOR; S-PHASE; RETINOBLASTOMA PROTEIN; DNA-REPLICATION; E2F BINDING; PROMOTER	The expression of cyclin E and that of a few other bona fide cell cycle regulatory genes periodically oscillates every cycle in proliferating cells. Although numerous experiments have documented the role of E2F sites and E2F activities in the control of these genes as cells exit from Co to move through the initial G(1)/S phase transition, almost nothing is known on the role of E2Fs during the subsequent cell cycles. Here we show that a variant E2F-site that is part of the Cyclin E Repressor Module (CERM) (Le Cam et al,, 1999b) accounts for the periodic down regulation of the cyclin E promoter observed between the exit from mitosis until the mid/late G(1) phase in exponentially cycling cells. This cell cycle-dependent repression correlates with the periodic binding of an atypical G(1)-specific high molecular weight p107-E2F complex (Cyclin E Repressor Complex: CERC2) that differs in both size and DNA binding behaviors from known p107-E2F complexes. Notably, affinity purified CERC2 displays a TSA-sensitive histone deacetylase activity and, consistent with this, derepression of the cyclin E promoter by trichostatin A depends on the GERM element, Altogether, this shows that the cell cycle-dependent control of cyclin E promoter in cycling cells is embroiled in acetylation pathways via the GERM-like E2F element.	CNRS, IFR24, UMR 5535, Inst Genet Mol, F-34293 Montpellier 5, France; CNRS, UPR 1142, Inst Human Genet, F-34396 Montpellier, France; CNRS, IBCG, LBME, F-31062 Toulouse, France; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Baylor College of Medicine	Sardet, C (corresponding author), CNRS, IFR24, UMR 5535, Inst Genet Mol, 1919 Route Mende, F-34293 Montpellier 5, France.		Le Cam, Laurent/O-1408-2016; Polanowska, Jolanta/P-9117-2016; Trouche, Didier/B-2854-2008	Polanowska, Jolanta/0000-0001-7666-7010; LE CAM, Laurent/0000-0003-0325-878X; Trouche, Didier/0000-0003-1398-6481				ALITALO R, 1990, LEUKEMIA RES, V14, P501, DOI 10.1016/0145-2126(90)90002-Q; Bennett JD, 1996, ONCOGENE, V13, P1073; Botz J, 1996, MOL CELL BIOL, V16, P3401; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Campanero MR, 1999, MOL CELL BIOL, V19, P8442; Carmen AA, 1996, J BIOL CHEM, V271, P15837, DOI 10.1074/jbc.271.26.15837; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Donnellan R, 1999, FASEB J, V13, P773, DOI 10.1096/fasebj.13.8.773; Duronio RJ, 1998, MOL CELL BIOL, V18, P141, DOI 10.1128/MCB.18.1.141; DURONIO RJ, 1995, GENE DEV, V9, P1456, DOI 10.1101/gad.9.12.1456; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Emiliani S, 1998, P NATL ACAD SCI USA, V95, P2795, DOI 10.1073/pnas.95.6.2795; Fajas L, 2000, FEBS LETT, V471, P29, DOI 10.1016/S0014-5793(00)01363-6; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Geng Y, 1996, ONCOGENE, V12, P1173; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Hua XH, 1997, J CELL BIOL, V137, P183, DOI 10.1083/jcb.137.1.183; Huet X, 1996, MOL CELL BIOL, V16, P3789; Humbert PO, 2000, GENE DEV, V14, P690; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Keyomarsi K, 1997, Prog Cell Cycle Res, V3, P171; Kim YB, 1999, ONCOGENE, V18, P2461, DOI 10.1038/sj.onc.1202564; Krude T, 2000, J BIOL CHEM, V275, P13699, DOI 10.1074/jbc.275.18.13699; Krude T, 1997, CELL, V88, P109, DOI 10.1016/S0092-8674(00)81863-2; Le Cam L, 1999, BIOTECHNIQUES, V26, P840; Le Cam L, 1999, EMBO J, V18, P1878, DOI 10.1093/emboj/18.7.1878; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Li FZ, 1999, CANCER RES, V59, P3143; LUCIBELLO FC, 1995, EMBO J, V14, P132, DOI 10.1002/j.1460-2075.1995.tb06983.x; Ma TL, 2000, GENE DEV, V14, P2298, DOI 10.1101/gad.829500; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; Merrill GF, 1998, METHOD CELL BIOL, V57, P229; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Nicolas E, 2000, J BIOL CHEM, V275, P9797, DOI 10.1074/jbc.275.13.9797; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940; Sandor V, 2000, BRIT J CANCER, V83, P817, DOI 10.1054/bjoc.2000.1327; SARDET C, 1997, PROGR GENE EXPRESSIO, V2, P1; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; SPITKOVSKY D, 1994, J VIROL, V68, P2206, DOI 10.1128/JVI.68.4.2206-2214.1994; Stiegler P, 1998, CANCER RES, V58, P5049; Sudarsanam P, 2000, TRENDS GENET, V16, P345, DOI 10.1016/S0168-9525(00)02060-6; Takahashi Y, 2000, GENE DEV, V14, P804; Tommasi S, 1999, J BIOL CHEM, V274, P27829, DOI 10.1074/jbc.274.39.27829; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; Uchiumi T, 1997, J BIOL CHEM, V272, P9166; Vogt B, 1999, J GEN VIROL, V80, P2103, DOI 10.1099/0022-1317-80-8-2103; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Wells J, 1996, MOL CELL BIOL, V16, P634; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Wolffe AP, 2000, BIOCHEM SOC T, V28, P379, DOI 10.1042/0300-5127:0280379; ZERFASS K, 1995, J VIROL, V69, P6389, DOI 10.1128/JVI.69.10.6389-6399.1995; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zhao JY, 2000, GENE DEV, V14, P2283, DOI 10.1101/gad.827700; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x; ZWICKER J, 1997, TRENDS GENET, V1, P3; ZWICKER J, 1996, SCIENCE, V271, P5255	66	25	25	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 12	2001	20	31					4115	4127		10.1038/sj.onc.1204514	http://dx.doi.org/10.1038/sj.onc.1204514			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464278				2022-12-17	WOS:000169857200002
J	Gimm, O; Dziema, H; Brown, J; Cuong, HV; Hinze, R; Dralle, H; Mulligan, LM; Eng, C				Gimm, O; Dziema, H; Brown, J; Cuong, HV; Hinze, R; Dralle, H; Mulligan, LM; Eng, C			Over-representation of a germline variant in the gene encoding RET co-receptor GFR alpha-1 but not GFR alpha-2 or GFR alpha-3 in cases with sporadic medullary thyroid carcinoma	ONCOGENE			English	Article						MEN 2; RET; common low penetrance alleles; polymorphisms; thyroid	ENDOCRINE-NEOPLASIA TYPE-2B; TYROSINE KINASE; NEUROTROPHIC FACTOR; GDNF FAMILY; HIRSCHSPRUNG-DISEASE; FUNCTIONAL RECEPTOR; CODON-918 MUTATION; MICE LACKING; PROTOONCOGENE; PROTEIN	In contrast to the hereditary form of medullary thyroid carcinoma (MTC), little is known about the etiology of sporadic MTC, Somatic gain-of-function mutations in the RET proto-oncogene, encoding a receptor tyrosine kinase, are found in an average of 40% of sporadic MTC, We analysed 31 sporadic MTC for somatic and germline variants in GFRA1, GFRA2 and GFRA3 which encode the co-receptors of RET, Although there were no somatic mutations in any of the three genes, a sequence variant (-193C>G) in the 5'-UTR of GFRA1 was found in 15% of cases. Three patients were heterozygous (het); another three patients homozygous (hom) for the G variant. The G allele was not observed in 31 race-matched normal controls. Hence, the relative frequency of this variant in sporadic MTC cases and controls differed significantly (P<0.05). Since this variant lies in the 5' UTR, likely at the transcriptional start site, we analysed for differential expression of GFR<alpha>-1 at the transcript and protein levels. At the mRNA level, GFRA1 was over-expressed in tumors harboring the rare variant (P=0.06), The presence of the G polymorphic allele seemed to be associated with increased expression by immunostaining for GFR alpha -1. Interestingly, cytoplasmic staining was stronger in intensity for het patients and nuclear staining predominant in hom cases. In conclusion, mutation analysis of GFRA1, GFRA2 and GFRA3 revealed over-representation of a rare variant in GFRA1 (- 193C > G) in the germline of sporadic MTC cases. Our data suggest that the mechanism is related to over-expression of GFR alpha -1 and differential subcellular compartmentalization but the precise mechanism as to how it acts as a low penetrance susceptibility allele for the development of sporadic MTC remains to be elucidated.	Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Clin Canc Genet Program, Columbus, OH 43210 USA; Ohio State Univ, Dept Internal Med, Div Human Genet, Columbus, OH 43210 USA; Univ Halle Wittenberg, Inst Pathol, Halle, Germany; Queens Univ, Dept Pathol, Kingston, ON K7L 3NR, Canada; Queens Univ, Dept Paediat, Kingston, ON K7L 3NR, Canada; Univ Cambridge, Canc Res Campaign, Human Canc Genet Res Grp, Cambridge CB2 2QQ, England; Univ Halle Wittenberg, Dept Gen Surg, Halle, Germany	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Martin Luther University Halle Wittenberg; Queens University - Canada; Queens University - Canada; CRUK Cambridge Institute; University of Cambridge; Martin Luther University Halle Wittenberg	Eng, C (corresponding author), Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, 420 W 12th Ave,Suite 690 TMRF, Columbus, OH 43210 USA.		Dralle, Henning/ABD-4454-2020	Eng, Charis/0000-0002-3693-5145	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD039058] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA016058] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA16058] Funding Source: Medline; NICHD NIH HHS [1RO1HD39058-01] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; Angrist M, 1998, GENOMICS, V48, P354, DOI 10.1006/geno.1997.5191; Baloh RH, 2000, CURR OPIN NEUROBIOL, V10, P103, DOI 10.1016/S0959-4388(99)00048-3; Baloh RH, 1998, NEURON, V21, P1291, DOI 10.1016/S0896-6273(00)80649-2; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; Ceccherini I, 1999, AM J HUM GENET, V65, pA266; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; Eng C, 1996, CANCER RES, V56, P2167; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; Eng C, 1997, HUM MUTAT, V9, P97, DOI 10.1002/(SICI)1098-1004(1997)9:2<97::AID-HUMU1>3.3.CO;2-Q; Eng C, 1996, JAMA-J AM MED ASSOC, V276, P1575, DOI 10.1001/jama.276.19.1575; Enokido Y, 1998, CURR BIOL, V8, P1019, DOI 10.1016/S0960-9822(07)00422-8; Gimm O, 1999, ONCOGENE, V18, P1369, DOI 10.1038/sj.onc.1202418; Gimm O, 2000, HUM MOL GENET, V9, P1633, DOI 10.1093/hmg/9.11.1633; Gimm O, 1997, J CLIN ENDOCR METAB, V82, P3902, DOI 10.1210/jc.82.11.3902; Gimm O, 1999, BRIT J CANCER, V80, P383, DOI 10.1038/sj.bjc.6690367; Gimm O, 1999, J CLIN ENDOCR METAB, V84, P2784, DOI 10.1210/jc.84.8.2784; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Jing SQ, 1997, J BIOL CHEM, V272, P33111, DOI 10.1074/jbc.272.52.33111; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Jordanova A, 1997, HUM MUTAT, V10, P65, DOI 10.1002/(SICI)1098-1004(1997)10:1<65::AID-HUMU9>3.3.CO;2-9; Klein RD, 1997, NATURE, V387, P717, DOI 10.1038/42722; Kotzbauer PT, 1996, NATURE, V384, P467, DOI 10.1038/384467a0; Masure S, 1999, EUR J BIOCHEM, V266, P892, DOI 10.1046/j.1432-1327.1999.00925.x; Milbrandt J, 1998, NEURON, V20, P245, DOI 10.1016/S0896-6273(00)80453-5; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; Myers SM, 1999, J MED GENET, V36, P217; Naveilhan P, 1998, P NATL ACAD SCI USA, V95, P1295, DOI 10.1073/pnas.95.3.1295; ONOCHIE CI, 2000, IN PRESS J MED GENET; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; Sanicola M, 1997, P NATL ACAD SCI USA, V94, P6238, DOI 10.1073/pnas.94.12.6238; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; Thompson J, 1998, MOL CELL NEUROSCI, V11, P117, DOI 10.1006/mcne.1998.0682; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; Trupp M, 1998, MOL CELL NEUROSCI, V11, P47, DOI 10.1006/mcne.1998.0667	37	25	27	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 19	2001	20	17					2161	2170		10.1038/sj.onc.1204289	http://dx.doi.org/10.1038/sj.onc.1204289			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	422KH	11360200				2022-12-17	WOS:000168116700011
J	Weterman, MAJ; van Groningen, JJM; den Hartog, A; van Kessel, AG				Weterman, MAJ; van Groningen, JJM; den Hartog, A; van Kessel, AG			Transformation capacities of the papillary renal cell carcinoma-associated PRCCTFE3 and TFE3PRCC fusion genes	ONCOGENE			English	Article						renal cell carcinoma; TFE3; PRCC; malignant transformation; t(X;1)	HELIX-LOOP-HELIX; TRANSLOCATION X-1; TUMORS; SUBTYPE; ADENOCARCINOMA; CLASSIFICATION; ZIPPER; CHILD	A recurrent chromosomal abnormality associated with a subset of papillary renal cell carcinomas is t(X;1)(p11;q21). This translocation leads to the formation of two fusion genes, TFE3PRCC and the reciprocal product PRCCTFE3. Both fusion genes are expressed in t(X;1)-positive renal cell carcinomas and contain major parts of the coding regions of the parental transcription factor PRCC and TFE3 genes, respectively. To find out whether these fusion genes possess transforming capacity, we transfected NIH3T3 and rat-1 cells with the fusion products, either separately or combined, When using soft agar assays, we observed colony formation in all cases. NIH3T3 cells transfected with PRCCTFE3 or PRCCTFE3 together with TFE3PRCC yielded the highest colony forming capacities. Examination of other characteristics associated with malignant transformation, i.e., growth under low-serum conditions and formation of tumors in athymic nude mice, revealed that cells transfected nith PRCCTFE3 exhibited all these transformation-associated characteristics. Upon transfection of the fusion products into conditionally immortalized kidney cells, derived from the proximal tubules of an H-2Kb-tsA58 transgenic mouse, and consecutive incubation under non-permissive conditions, growth arrest was observed, followed by differentiation except for those cells transfected with PRCCTFE3, Therefore, we conclude that PRCCTFE3 may be the t(X;1)-associated fusion product that is most critical for the development of papillary renal cell carcinomas.	Univ Nijmegen, Med Ctr, Dept Human Genet 417, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	Weterman, MAJ (corresponding author), Univ Nijmegen, Med Ctr, Dept Human Genet 417, POB 9101, NL-6500 HB Nijmegen, Netherlands.		van Kessel, Ad Geurts/A-2810-2010					AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BECKMANN H, 1991, GENE DEV, V5, P1057, DOI 10.1101/gad.5.6.1057; Carcao MD, 1998, MED PEDIATR ONCOL, V31, P153, DOI 10.1002/(SICI)1096-911X(199809)31:3<153::AID-MPO5>3.0.CO;2-A; DEJONG B, 1986, CANCER GENET CYTOGEN, V21, P165, DOI 10.1016/0165-4608(86)90042-7; Desangles F, 1999, CANCER GENET CYTOGEN, V113, P141, DOI 10.1016/S0165-4608(98)00261-1; DIJKHUIZEN T, 1995, GENE CHROMOSOME CANC, V14, P43, DOI 10.1002/gcc.2870140108; HERNANDEZMARTI MJ, 1995, CANCER GENET CYTOGEN, V83, P82, DOI 10.1016/0165-4608(94)00184-7; KOVACS G, 1988, CYTOGENET CELL GENET, V48, P242, DOI 10.1159/000132637; MELONI AM, 1993, CANCER GENET CYTOGEN, V65, P1, DOI 10.1016/0165-4608(93)90050-V; Perot C, 1999, CANCER GENET CYTOGEN, V110, P54, DOI 10.1016/S0165-4608(98)00181-2; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; ROMAN C, 1992, MOL CELL BIOL, V12, P817, DOI 10.1128/MCB.12.2.817; Sidhar SK, 1996, HUM MOL GENET, V5, P1333, DOI 10.1093/hmg/5.9.1333; Sorensen PHB, 1996, SEMIN CANCER BIOL, V7, P3, DOI 10.1006/scbi.1996.0002; THOENES W, 1986, PATHOL RES PRACT, V181, P125, DOI 10.1016/S0344-0338(86)80001-2; Thompson AD, 1999, ONCOGENE, V18, P5506, DOI 10.1038/sj.onc.1202928; TONK V, 1995, CANCER GENET CYTOGEN, V81, P72, DOI 10.1016/S0165-4608(94)00195-2; VANDENBERG E, 1993, INT J CANCER, V55, P223, DOI 10.1002/ijc.2910550210; Weterman MAJ, 1996, P NATL ACAD SCI USA, V93, P15294, DOI 10.1073/pnas.93.26.15294; Weterman MAJ, 2000, ONCOGENE, V19, P69, DOI 10.1038/sj.onc.1203255; Weterman MAJ, 1996, HUM GENET, V98, P16, DOI 10.1007/s004390050153; Zent CS, 1996, P NATL ACAD SCI USA, V93, P1044, DOI 10.1073/pnas.93.3.1044	22	25	27	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 22	2001	20	12					1414	1424		10.1038/sj.onc.1204213	http://dx.doi.org/10.1038/sj.onc.1204213			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	413DT	11313885				2022-12-17	WOS:000167595200002
J	Baker, SJ; Sumerson, R; Reddy, CD; Berrebi, AS; Flynn, DC; Reddy, EP				Baker, SJ; Sumerson, R; Reddy, CD; Berrebi, AS; Flynn, DC; Reddy, EP			Characterization of an alternatively spliced AATYK mRNA: Expression pattern of AATYK in the brain and neuronal cells	ONCOGENE			English	Article						AATYK; alternative splicing; brain; neuron; differentiation; P19 cells	APOPTOSIS; KINASE; DEATH; ORGANIZATION; PROTEINS; GROWTH; SYSTEM	The AATYK gene encodes a tyrosine kinase whose expression is up-regulated during the apoptosis and differentiation of 32Dcl3 myelobalstic cells. Because high levels of AATYK mRNA have also been detected in the brain, and because these transcripts differ in size from that observed in the 32Dcl3 cell line, it was of interest to determine whether this gene encodes mRNAs that are alternatively spliced and whether these mRNAs are expressed in a tissue-specific manner. We have isolated a novel, alternatively spliced AATYK mRNA using cDNA library screening and RT-PCR, whose expression is readily detected in the brain but not myeloid cells. Western blot analysis revealed that the AATYK protein was expressed in virtually all regions of the adult rat brain in which neurons are present, including olfactory bulb, forebrain, cortex, midbrain, cerebellum and pens. Immunohistochemical labeling of adult brain sections showed the highest levels of AATYK expression in the cerebellum and olfactory bulb. Expression of AATYK was also up-regulated as a function of RA-induced neuronal differentiation of p19 embryonal carcinoma cells, supporting a role for this protein in mature neurons and neuronal differentiation.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Div Neurooncol, Philadelphia, PA 19104 USA; W Virginia Univ, Sch Med, Dept Otolaryngol, Morgantown, WV 26506 USA; W Virginia Univ, Sch Med, Dept Anat Head & Neck Surg, Morgantown, WV 26506 USA; W Virginia Univ, Sch Med, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; West Virginia University; West Virginia University; West Virginia University	Reddy, EP (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.		Reddy, E. Premkumar/F-6233-2011		NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009225] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES09225] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALTMAN J, 1975, J COMP NEUROL, V163, P427, DOI 10.1002/cne.901630404; Berrebi AS, 1998, NEUROSCIENCE, V83, P535, DOI 10.1016/S0306-4522(97)00407-7; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Dragovich T, 1998, ONCOGENE, V17, P3207, DOI 10.1038/sj.onc.1202587; Gaozza E, 1997, ONCOGENE, V15, P3127, DOI 10.1038/sj.onc.1201575; GORDON N, 1995, BRAIN DEV-JPN, V17, P73, DOI 10.1016/0387-7604(94)00109-B; HALPERN M, 1987, ANNU REV NEUROSCI, V10, P325, DOI 10.1146/annurev.ne.10.030187.001545; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mombaerts P, 1999, SCIENCE, V286, P707, DOI 10.1126/science.286.5440.707; Narayanan V, 1997, PEDIATR NEUROL, V16, P9, DOI 10.1016/S0887-8994(96)00257-3; Palay S.L., 1974, CEREBELLAR CORTEX CY; Raghunath M, 2000, MOL BRAIN RES, V77, P151, DOI 10.1016/S0169-328X(00)00048-6	14	25	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 1	2001	20	9					1015	1021		10.1038/sj.onc.1204209	http://dx.doi.org/10.1038/sj.onc.1204209			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406TW	11314039				2022-12-17	WOS:000167232100001
J	Ozbek, S; Peters, M; Breuhahn, K; Mann, A; Blessing, M; Fischer, M; Schirmacher, P; Mackiewicz, A; Rose-John, S				Ozbek, S; Peters, M; Breuhahn, K; Mann, A; Blessing, M; Fischer, M; Schirmacher, P; Mackiewicz, A; Rose-John, S			The designer cytokine hyper-IL-6 mediates growth inhibition and GM-CSF-dependent rejection of B16 melanoma cells	ONCOGENE			English	Article						designer cytokine; GM-CSF; interleukin-6; melanoma; soluble receptor; tumor rejection	SOLUBLE IL-6 RECEPTOR; COLONY-STIMULATING FACTOR; NECROSIS-FACTOR-ALPHA; HEMATOPOIETIC PROGENITOR CELLS; DOUBLE-TRANSGENIC MICE; TUMOR-CELLS; IN-VIVO; INTERLEUKIN-6 RECEPTOR; ANTITUMOR-ACTIVITY; GENE-TRANSFER	The low immunogenic B16 melanoma cell line was transfected with a mammalian expression vector containing the complementary DNA for a sIL-6R/IL-6 fusion protein, termed Hyper-IL-6 (H-IL-6), which was shown to have biological activities at 100-1000-fold lower concentrations than IL-6 in combination with sIL-6R. The secreted p84 glycoprotein was detected in the supernatant of transfected cells and was fully active on BAF3/gp130 cells, which respond to IL-6/sIL-6R but not to IL-6 alone. Administration of recombinant H-IL-6 to C57BL/6 mice resulted in a prolonged acute phase protein gene expression indicating long systemic persistence of the fusion protein. Transfected B16 cells (B16/ H-IL6 cells) showed morphological alterations in combination with a dramatic growth inhibition in vitro. Subcutaneous injection in C57BL/6 mice resulted in an almost complete rejection of B16/H-IL6 cells. This effect was partially abolished in FVB/BL/6 mice transgenic for a GM-CSF receptor antagonist, indicating a GM-CSF-deependent rejection of H-IL-6 transfected B16 cells. These results demonstrate that the anti-tumor effect of cytokines like IL-6 which are secreted by transfected melanoma cells at least in part depends on GM-CSF activity.	Univ Kiel, Inst Biochem, Dept Biochem, D-24098 Kiel, Germany; Univ Mainz, Dept Med, Sect Pathophysiol, D-55101 Mainz, Germany; Univ Cologne, Inst Pathol, D-5000 Cologne, Germany; Great Poland Canc Ctr, Dept Canc Immunol, Poznan, Poland	University of Kiel; Johannes Gutenberg University of Mainz; University of Cologne; Wielkopolskie Centrum Onkologii	Rose-John, S (corresponding author), Univ Kiel, Inst Biochem, Dept Biochem, Olshausenstr 40, D-24098 Kiel, Germany.		Rose-John, Stefan/A-7998-2010; Özbek, Suat/D-3701-2014	Rose-John, Stefan/0000-0002-7519-3279; Breuhahn, Kai/0000-0002-2462-1229; Ozbek, Suat/0000-0003-2569-3942				AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; ALTMANN SW, 1995, J BIOL CHEM, V270, P2233, DOI 10.1074/jbc.270.5.2233; Bernhard H, 2000, EXP HEMATOL, V28, P365, DOI 10.1016/S0301-472X(00)00126-0; BLANKENSTEIN T, 1991, J EXP MED, V173, P1047, DOI 10.1084/jem.173.5.1047; Blessing M, 1996, J CELL BIOL, V135, P227, DOI 10.1083/jcb.135.1.227; BRANDT SJ, 1990, J CLIN INVEST, V86, P592, DOI 10.1172/JCI114749; Chebath J, 1997, EUR CYTOKINE NETW, V8, P359; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; Englaro W, 1999, ONCOGENE, V18, P1553, DOI 10.1038/sj.onc.1202446; Fischer M, 1997, NAT BIOTECHNOL, V15, P142, DOI 10.1038/nbt0297-142; Ganapathi MK, 1996, CELL GROWTH DIFFER, V7, P923; GANSBACHER B, 1990, J EXP MED, V172, P1217, DOI 10.1084/jem.172.4.1217; GOUGH NM, 1984, NATURE, V309, P763, DOI 10.1038/309763a0; Greene AL, 1997, J INTERF CYTOK RES, V17, P727, DOI 10.1089/jir.1997.17.727; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; HERMANN E, 1989, CLIN EXP RHEUMATOL, V7, P411; HIRANO T, 1994, STEM CELLS, V12, P262, DOI 10.1002/stem.5530120303; HOGAN BF, 1986, MANIPULATING MOUSE M; KATZ A, 1993, J IMMUNOTHER, V13, P98, DOI 10.1097/00002371-199302000-00004; Klouche M, 1999, J IMMUNOL, V163, P4583; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Mackiewicz A, 1995, ANN NY ACAD SCI, V762, P361; MACKIEWICZ A, 1995, HUM GENE THER, V6, P805, DOI 10.1089/hum.1995.6.6-805; MACKIEWICZ A, 1995, CYTOKINE, V7, P142, DOI 10.1006/cyto.1995.1019; MCINTOSH JK, 1989, J IMMUNOL, V143, P162; MULE JJ, 1990, J EXP MED, V171, P629, DOI 10.1084/jem.171.3.629; MULE JJ, 1992, J IMMUNOL, V148, P2622; MULE JJ, 1992, RES IMMUNOL, V143, P777, DOI 10.1016/0923-2494(92)80023-E; MULLEN CA, 1992, CANCER RES, V52, P6020; Nawrocki S, 2000, IMMUNOL LETT, V74, P81, DOI 10.1016/S0165-2478(00)00253-4; NOVICK D, 1992, CYTOKINE, V4, P6, DOI 10.1016/1043-4666(92)90029-Q; Oh JW, 1997, ONCOGENE, V15, P569, DOI 10.1038/sj.onc.1201213; PARDOLL DM, 1995, ANNU REV IMMUNOL, V13, P399, DOI 10.1146/annurev.immunol.13.1.399; Peters M, 1996, IMMUNOL LETT, V54, P177, DOI 10.1016/S0165-2478(96)02669-7; Peters M, 1996, J EXP MED, V183, P1399, DOI 10.1084/jem.183.4.1399; Peters M, 1997, J EXP MED, V185, P755, DOI 10.1084/jem.185.4.755; Peters M, 1998, J IMMUNOL, V161, P3575; POLI G, 1990, J EXP MED, V172, P151, DOI 10.1084/jem.172.1.151; PORGADOR A, 1992, CANCER RES, V52, P3679; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; Schirmacher P, 1998, AM J PATHOL, V153, P639, DOI 10.1016/S0002-9440(10)65605-2; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; SUEMATSU S, 1992, P NATL ACAD SCI USA, V89, P232, DOI 10.1073/pnas.89.1.232; SUN WH, 1992, CANCER RES, V52, P5412; TEPPER RI, 1994, HUM GENE THER, V5, P153, DOI 10.1089/hum.1994.5.2-153; Wu TY, 1998, J INTERF CYTOK RES, V18, P829, DOI 10.1089/jir.1998.18.829	47	25	32	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 22	2001	20	8					972	979		10.1038/sj.onc.1204180	http://dx.doi.org/10.1038/sj.onc.1204180			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	404KP	11314032				2022-12-17	WOS:000167097000008
J	Vannucchi, S; Percario, ZA; Chiantore, MV; Matarrese, P; Chelbi-Alix, MK; Fagioli, M; Pelicci, PG; Malorni, W; Fiorucci, G; Romeo, G; Affabris, E				Vannucchi, S; Percario, ZA; Chiantore, MV; Matarrese, P; Chelbi-Alix, MK; Fagioli, M; Pelicci, PG; Malorni, W; Fiorucci, G; Romeo, G; Affabris, E			Interferon-beta induces S phase slowing via up-regulated expression of PML in squamous carcinoma cells	ONCOGENE			English	Article						interferon; all-trans retinoic acid; PML; cell cycle; squamous carcinoma cells	PROMYELOCYTIC LEUKEMIA PROTEIN; PRIMARY BILIARY-CIRRHOSIS; CREB BINDING-PROTEIN; LARGE T-ANTIGEN; RETINOIC ACID; NUCLEAR-BODIES; GROWTH-SUPPRESSOR; CDK-INHIBITOR; APL CELLS; TRANSCRIPTIONAL ACTIVATION	Type I Interferon (IFN) and all-trans retinoic acid (RA) inhibit cell proliferation of squamous carcinoma cell Lines (SCC), Examinations of growth-affected cell populations show that SCC lines ME-180 and SiHa treated with IFN-beta undergo a specific slower progression through the S phase that seems to trigger cellular death. In combination treatment RA potentiates IFN-beta effect in SCC ME-180 but not in SiHa cell line, partially resistant to RA antiproliferative action. RA added as single agent affects cell proliferation differently by inducing a slight GI accumulation. The IFN-beta-induced S phase lengthening parallels the increased expression of PML, a nuclear phosphoprotein specifically up-regulated at transcriptional level by IFN, whose overexpression induces cell growth inhibition and tumor suppression. We report that PML up-regulation may account for the alteration of cell cycle progression induced by IFN-beta in SCC by infecting cells with PML-PINCO recombinant retrovirus carrying the PML3 cDNA under the control of the 5' LTR. In fact PML overexpression reproduces the IFN-beta-induced S phase lengthening, These findings provide important insight into the mechanism of tumor suppressing function of PML and could allow PML to be included in the pathways responsible for IFN-induced cell growth suppression.	Univ Roma 3, Dept Biol, I-00146 Rome, Italy; Ist Super Sanita, Virol Lab, I-00161 Rome, Italy; Ist Super Sanita, Lab Ultrastruct, I-00161 Rome, Italy; Hop St Louis, CNRS, UPR 9051, F-75010 Paris, France; Univ Perugia, Monteluce Policlin, I-06100 Perugia, Italy; European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; CNR, Ist Tecnol Biomed, Rome, Italy	Roma Tre University; Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; University of Perugia; IRCCS European Institute of Oncology (IEO); Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR)	Affabris, E (corresponding author), Univ Roma 3, Dept Biol, Viale G Marconi 446, I-00146 Rome, Italy.		CHIANTORE, MARIA VINCENZA/C-2948-2016; Matarrese, Paola/A-4369-2014; Fiorucci, Gianna/B-3064-2013; Malorni, Walter/G-5874-2016; Romeo, Giovanna/AAB-2613-2019; Pelicci, Pier Giuseppe/AAL-6572-2020; romeo, giovanna/P-8348-2015	CHIANTORE, MARIA VINCENZA/0000-0001-5163-2698; matarrese, paola/0000-0001-5477-3752; malorni, walter/0000-0002-1223-7000; AFFABRIS, Elisabetta/0000-0001-5142-8144; romeo, giovanna/0000-0002-7638-1001				Alcalay M, 1998, MOL CELL BIOL, V18, P1084, DOI 10.1128/MCB.18.2.1084; Bloch DB, 1999, MOL CELL BIOL, V19, P4423; CHANG KS, 1995, BLOOD, V85, P3646, DOI 10.1182/blood.V85.12.3646.bloodjournal85123646; Chelbi-Alix MK, 1999, LEUKEMIA, V13, P1167, DOI 10.1038/sj.leu.2401469; Chelbi-Alix MK, 1998, J VIROL, V72, P1043, DOI 10.1128/JVI.72.2.1043-1051.1998; ChelbiAlix MK, 1995, LEUKEMIA, V9, P2027; Chew YP, 1998, ONCOGENE, V17, P2177, DOI 10.1038/sj.onc.1202443; DANIEL MT, 1993, BLOOD, V82, P1858; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2627, DOI 10.1073/pnas.96.6.2627; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Dyson N, 1999, CURR OPIN GENET DEV, V9, P11, DOI 10.1016/S0959-437X(99)80002-1; Everett RD, 1999, J CELL SCI, V112, P4581; Fagioli M, 1998, ONCOGENE, V16, P2905, DOI 10.1038/sj.onc.1201811; FAGIOLI M, 1992, ONCOGENE, V7, P1083; Giandomenico V, 1998, EUR CYTOKINE NETW, V9, P619; Giandomenico V, 1997, CELL GROWTH DIFFER, V8, P91; Gongora C, 1997, J BIOL CHEM, V272, P19457, DOI 10.1074/jbc.272.31.19457; Grignani F, 1998, CANCER RES, V58, P14; GULDNER HH, 1992, J IMMUNOL, V149, P4067; Hara E, 1996, MOL CELL BIOL, V16, P859; Hodges M, 1998, AM J HUM GENET, V63, P297, DOI 10.1086/301991; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Iwase S, 1997, J BIOL CHEM, V272, P12406, DOI 10.1074/jbc.272.19.12406; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; Kalemkerian G. P., 1996, APOPTOSIS, V1, P11; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; KOKEN MHM, 1995, ONCOGENE, V10, P1315; Kuniyasu H, 1997, CELL GROWTH DIFFER, V8, P47; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; LaMorte VJ, 1998, P NATL ACAD SCI USA, V95, P4991, DOI 10.1073/pnas.95.9.4991; LANCILLOTTI F, 1995, CANCER RES, V55, P3158; LAVAU C, 1995, ONCOGENE, V11, P871; Le XF, 1998, ONCOGENE, V16, P1839, DOI 10.1038/sj.onc.1201705; Lee HY, 1998, J CLIN INVEST, V101, P1012, DOI 10.1172/JCI1329; Lindner DJ, 1997, CLIN CANCER RES, V3, P931; Lippman SM, 1997, INT J CANCER, V70, P481, DOI 10.1002/(SICI)1097-0215(19970207)70:4<481::AID-IJC20>3.0.CO;2-H; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; Macleod K, 1999, CURR OPIN GENET DEV, V9, P31, DOI 10.1016/S0959-437X(99)80005-7; Matarrese P, 1998, INT J CANCER, V76, P531, DOI 10.1002/(SICI)1097-0215(19980518)76:4<531::AID-IJC15>3.0.CO;2-A; Matsuoka M, 1998, ONCOGENE, V16, P2075, DOI 10.1038/sj.onc.1201745; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; NasonBurchenal K, 1996, BLOOD, V88, P3926, DOI 10.1182/blood.V88.10.3926.bloodjournal88103926; Pelicano L, 1999, ONCOGENE, V18, P3944, DOI 10.1038/sj.onc.1202802; Pelicano L, 1997, ONCOGENE, V15, P2349, DOI 10.1038/sj.onc.1201410; Percario ZA, 1999, CELL GROWTH DIFFER, V10, P263; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Qin XQ, 1997, J INTERF CYTOK RES, V17, P355, DOI 10.1089/jir.1997.17.355; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; ROMEO G, 1996, RETINOIDS TODAY TOMO, V45, P32; Sangfelt O, 1999, ONCOGENE, V18, P2798, DOI 10.1038/sj.onc.1202609; Seeler JS, 1999, CURR OPIN GENET DEV, V9, P362, DOI 10.1016/S0959-437X(99)80054-9; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Stadler M, 1995, ONCOGENE, V11, P2565; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Subramaniam PS, 1998, ONCOGENE, V16, P1885, DOI 10.1038/sj.onc.1201712; SZOSTECKI C, 1990, J IMMUNOL, V145, P4338; Vallian S, 1998, ONCOGENE, V16, P2843, DOI 10.1038/sj.onc.1201837; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1	64	25	27	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 19	2000	19	44					5041	5053		10.1038/sj.onc.1203883	http://dx.doi.org/10.1038/sj.onc.1203883			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	365CD	11042692	Green Published			2022-12-17	WOS:000089930100001
J	Morgan, SE; Kim, R; Wang, PC; Bhat, UG; Kusumoto, H; Lu, TH; Beck, WT				Morgan, SE; Kim, R; Wang, PC; Bhat, UG; Kusumoto, H; Lu, TH; Beck, WT			Differences in mutant p53 protein stability and functional activity in teniposide-sensitive and -resistant human leukemic CEM cells	ONCOGENE			English	Article						mutant p53; protein stability; teniposide resistance; ionizing radiation	DNA TOPOISOMERASE-II; TUMOR-SUPPRESSOR P53; WILD-TYPE P53; IN-VIVO; GENE-EXPRESSION; UP-REGULATION; BAX GENE; MDM2; BINDING; BCL-2	We examined p53 protein stability and DNA damage-induced p53-dependent responses in a human leukemic CEM cell line and two teniposide-resistant sublines, CEM/VM-1 and CEM/VM-1-5 (similar to 40 and 400-fold resistant to teniposide, respectively). Although all cell lines contain the same p53 mutations at codons 175 (Arg-->His) and 248 (Arg-->Gln), the constitutive levels of p53 were progressively increased with the resistance of the cells to teniposide, By pulse-chase experiments, we found that the half-lives of mutant p53 protein were approximately 12, 17, and >30 h in CEM, CEM/VM-1, and CEM/VM-1-5 cells, respectively. The prolonged half-lives of p53 in these cells is consistent with the fact that the protein harbors the indicated mutations. Of note, however, is the fact that the increased p53 protein half-lives in the two drug-resistant cell lines corresponds to a proportional decrease in MDM2 protein levels but an increase in p53-MDM2 binding interactions. This suggests that MDM2-mediated p53 degradation may be altered in our leukemic cell lines. The DNA damage-induced p53 response is fully functional in the drug-sensitive CEM cells containing a mutant p53, but this pathway is attenuated in the drug-resistant cells. Specifically, while the mutant p53 was phosphorylated at serine-15 in response to ionizing radiation in all these cell lines, mutant p53 induction in response to teniposide or ionizing radiation and induction of the p53-target genes, p21 and GADD45 only occurred in the drug-sensitive CEM cells. As assessed by MTT cytotoxicity assay, CEM cells were also significantly more sensitive to ionizing radiation, compared to the drug-resistant cell lines, and this correlated with p53 induction. Collectively, these results suggest that changes in constitutive mutant p53 protein levels, p53-MDM2 binding interactions, and altered regulation of the DNA damage-inducible p53-dependent pathway may play a role in drug- and radiation-responsiveness in these cells.	Univ Illinois, Dept Mol Genet MC 669, Div Mol Pharmacol, Chicago, IL 60607 USA; Hiroshima Univ, Dept Surg Oncol, Minami Ku, Hiroshima 7348553, Japan; Fukuoka Dent Coll Hosp, Dept Gen Surg, Fukuoka 81401, Japan; St Jude Childrens Res Hosp, Dept Cell & Gene Therapy, Memphis, TN 38101 USA; Univ Illinois, Dept Pharmaceut & Pharmacodynam, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Hiroshima University; Fukuoka Dental College (FDC); St Jude Children's Research Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Beck, WT (corresponding author), Univ Illinois, Dept Mol Genet MC 669, Div Mol Pharmacol, 900 S Ashland Ave, Chicago, IL 60607 USA.				NATIONAL CANCER INSTITUTE [R01CA030103, R01CA040570] Funding Source: NIH RePORTER; NCI NIH HHS [CA30103, CA40570] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alarcon R, 1999, CANCER RES, V59, P6046; Arriola EL, 1999, ONCOGENE, V18, P1081, DOI 10.1038/sj.onc.1202391; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Boise L H, 1995, Curr Top Microbiol Immunol, V200, P107; BROWN R, 1993, INT J CANCER, V55, P678, DOI 10.1002/ijc.2910550428; BUGG BY, 1991, P NATL ACAD SCI USA, V88, P7654, DOI 10.1073/pnas.88.17.7654; CHEN M, 1993, CANCER RES, V53, P5946; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CRAIG RW, 1995, SEMIN CANCER BIOL, V6, P35, DOI 10.1006/scbi.1995.0005; DANKS MK, 1993, CANCER RES, V53, P1373; DANKS MK, 1988, BIOCHEMISTRY-US, V27, P8861, DOI 10.1021/bi00424a026; DANKS MK, 1987, CANCER RES, V47, P1297; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KIM RS, 1994, CANCER RES, V54, P4958; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kubbutat MHG, 1999, CELL GROWTH DIFFER, V10, P87; KWOK TT, 1994, CANCER RES, V54, P2834; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maki CG, 1996, CANCER RES, V56, P2649; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PARK DJ, 1994, ONCOGENE, V9, P1899; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; TISHLER RB, 1993, CANCER RES, V53, P2212; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; Wang QJ, 1998, CANCER RES, V58, P5762; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; ZHANG W, 1993, ONCOGENE, V8, P2555	51	25	26	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 12	2000	19	43					5010	5019		10.1038/sj.onc.1203865	http://dx.doi.org/10.1038/sj.onc.1203865			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363KF	11042688				2022-12-17	WOS:000089834300008
J	Berns, K; Martins, C; Dannenberg, JH; Berns, A; Riele, HT; Bernards, R				Berns, K; Martins, C; Dannenberg, JH; Berns, A; Riele, HT; Bernards, R			p27(kip1)-independent cell cycle regulation by MYC	ONCOGENE			English	Article						CDK-inhibitors; cell cycle; retinoblastoma protein; c-Myc oncogene	C-MYC; RESPONSIVE GENES; KINASE-ACTIVITY; PROTEIN; TUMORIGENESIS; EXPRESSION; E2F; IDENTIFICATION; SEQUESTRATION; INDUCTION	MYC transcription factors are potent stimulators of cell proliferation. It has been suggested that the CDK-inhibitor p27(kip1) is a critical G1 phase cell cycle target of c-MYC. We show here that mouse embryo fibroblasts deficient for both p27(kip1) and the related p21(cip1) are still responsive to stimulation by c-MYC and can be arrested in G1 by a dominant negative mutant of c-MYC. This growth arrest can be overruled by ectopic expression of E2F or adenovirus E1A, but not by a mutant of E1A defective for binding to retinoblastoma family proteins. We show that fibroblasts with a genetic disruption of all three retinoblastoma family members (pRb, p107 and p130) are unresponsive to a dominant negative c-MYC mutant. These data indicate that p27(kip1) is not the only rate limiting cell cycle target of c-MYC and suggest that regulation of E2F is also essential for c-MYC's mitogenic activity.	Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute	Bernards, R (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.			Bernards, Rene/0000-0001-8677-3423				BERNS A, 1994, COLD SPRING HARB SYM, V59, P435, DOI 10.1101/SQB.1994.059.01.049; Berns K, 2000, ONCOGENE, V19, P3330, DOI 10.1038/sj.onc.1203639; Berns K, 1997, ONCOGENE, V15, P1347, DOI 10.1038/sj.onc.1201280; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Hateboer G, 1996, J BIOL CHEM, V271, P25906, DOI 10.1074/jbc.271.42.25906; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Humbert PO, 2000, GENE DEV, V14, P690; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; Kanda T, 1998, CURR BIOL, V8, P377, DOI 10.1016/S0960-9822(98)70156-3; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Leone G, 1999, P NATL ACAD SCI USA, V96, P6626, DOI 10.1073/pnas.96.12.6626; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; Santoni-Rugiu E, 2000, MOL CELL BIOL, V20, P3497, DOI 10.1128/MCB.20.10.3497-3509.2000; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; ZHU LG, 1995, MOL CELL BIOL, V15, P3552	27	25	25	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 5	2000	19	42					4822	4827		10.1038/sj.onc.1203879	http://dx.doi.org/10.1038/sj.onc.1203879			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	362BB	11039898	Green Published			2022-12-17	WOS:000089757800003
J	Nikiforov, MA; Kotenko, I; Petrenko, O; Beavis, A; Valenick, L; Lemischka, I; Cole, MD				Nikiforov, MA; Kotenko, I; Petrenko, O; Beavis, A; Valenick, L; Lemischka, I; Cole, MD			Complementation of Myc-dependent cell proliferation by cDNA expression library screening	ONCOGENE			English	Article						c-myc; N-myc; myc-null fibroblasts; proliferation; cDNA library	C-MYC; GROWTH; COOPERATION; MECHANISM; ONCOGENES; TARGET	The targeted knockout of the c-myc gene from rat fibroblasts leads to a stable defect in cell proliferation. We used complex cDNA libraries expressed from retroviral vectors and an efficient sorting procedure to rapidly select for cDNAs that can restore the growth rate of c-myc deficient cells, All of the biologically active cDNAs contained either c-myc or N-myc, suggesting that no other cellular genes can effectively bypass the requirement for c-myc in fibroblast proliferation. This approach provides a powerful screening method for cell cycle changes in genetically defined systems.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Cole, MD (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.							ADAMS JM, 1992, CANCER SURV, V15, P119; CORVI R, 1995, CANCER RES, V55, P3471; Dang CV, 1999, EXP CELL RES, V253, P63, DOI 10.1006/excr.1999.4686; Dang CV, 1999, MOL CELL BIOL, V19, P1; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; Petrenko O, 1999, IMMUNITY, V10, P691, DOI 10.1016/S1074-7613(00)80068-0; SHICHIRI M, 1993, CELL GROWTH DIFFER, V4, P93; WESTON SA, 1990, J IMMUNOL METHODS, V133, P87, DOI 10.1016/0022-1759(90)90322-M; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	18	25	27	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 5	2000	19	42					4828	4831		10.1038/sj.onc.1203880	http://dx.doi.org/10.1038/sj.onc.1203880			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	362BB	11039899				2022-12-17	WOS:000089757800004
J	Verselis, SJ; Rheinwald, JG; Fraumeni, JF; Li, FP				Verselis, SJ; Rheinwald, JG; Fraumeni, JF; Li, FP			Novel p53 splice site mutations in three families with Li-Fraumeni syndrome	ONCOGENE			English	Article						p53; germline mutation; Li-Fraumeni syndrome; alternate splicing	CANCER-PRONE FAMILY; CELL-LINES; GENE; TP53; DATABASE; PATIENT; POLYMORPHISM; DEFICIENCY; PROTEIN; TUMORS	Germline mutations in the p53 tumor suppressor gene predispose to a variety of cancers in families with Li-Fraumeni syndrome. Most germline p53 mutations observed to date cause amino acid substitutions in the protein's central sequence-specific DNA binding domain. Outside this conserved core region, however, we found novel alterations in sequences that regulate precursor mRNA splicing in three Li-Fraumeni syndrome families. Two splice site mutations affected the consensus sequence at the splice donor sites of introns 1 and 9, and produced unstable variant transcripts in normal cells. A third mutation at the splice acceptor site of intron 9 generated splicing at a cryptic acceptor site in intron 9, These splice site alterations emphasize the need to examine both noncoding and untranslated regions of the p53 gene for germline mutations in Li-Fraumeni syndrome families.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Skin Dis Res Ctr, Boston, MA 02115 USA; NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Li, FP (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA.							Antonarakis SE, 1998, HUM MUTAT, V11, P1; ARA S, 1990, NUCLEIC ACIDS RES, V18, P4961, DOI 10.1093/nar/18.16.4961; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; Beroud C, 1998, NUCLEIC ACIDS RES, V26, P200, DOI 10.1093/nar/26.1.200; BIRCH JM, 1994, CANCER RES, V54, P1298; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Darling TN, 1998, J INVEST DERMATOL, V110, P165, DOI 10.1046/j.1523-1747.1998.00103.x; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; FELIX CA, 1993, ONCOGENE, V8, P1203; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; FREBOURG T, 1995, AM J HUM GENET, V56, P608; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; ISHIOKA C, 1995, ONCOGENE, V10, P1485; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; JOLLY KW, 1994, ONCOGENE, V9, P97; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Maquat LE, 1996, AM J HUM GENET, V59, P279; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.biochem.55.1.1119; Sedlacek Z, 1998, NUCLEIC ACIDS RES, V26, P214, DOI 10.1093/nar/26.1.214; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Soria JM, 1996, THROMB HAEMOSTASIS, V75, P870; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; Varley JM, 1998, BRIT J CANCER, V78, P1081, DOI 10.1038/bjc.1998.631; Varley JM, 1998, ONCOGENE, V16, P3291, DOI 10.1038/sj.onc.1201878; Varley JM, 1997, CANCER RES, V57, P3245; Varley JM, 1997, BRIT J CANCER, V76, P1, DOI 10.1038/bjc.1997.328; WARNEFORD SG, 1992, CELL GROWTH DIFFER, V3, P839; Wilson A, 1998, AM J HUM GENET, V63, P409, DOI 10.1086/301976	33	25	28	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 31	2000	19	37					4230	4235		10.1038/sj.onc.1203758	http://dx.doi.org/10.1038/sj.onc.1203758			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349FL	10980596				2022-12-17	WOS:000089032900005
J	Almog, N; Goldfinger, N; Rotter, V				Almog, N; Goldfinger, N; Rotter, V			p53-dependent apoptosis is regulated by a C-terminally alternatively spliced form of murine p53	ONCOGENE			English	Article						p53; alternative splicing; C-terminus	WILD-TYPE P53; NUCLEOTIDE EXCISION-REPAIR; TUMOR-SUPPRESSOR P53; CELL-CYCLE ARREST; DNA-BINDING; IONIZING-RADIATION; SINGLE STRANDS; MYELOID CELLS; MOUSE P53; DOMAIN	It is now well accepted that the p53 C-terminus plays a central role in controlling the activity of the wild-type molecule. In our previous studies, we observed that a C-terminally altered p53 protein (p53AS), generated by an alternative spliced p53 mRNA, induces an attenuated p53-dependent apoptosis, compared to that induced by the regularly spliced form (p53RS). In the present study we analysed the interrelationships between these two physiological variants of wild-type p53, and found that in cells co-expressing both forms, in contrast to the expected additive effect on the induction of apoptosis, p53AS inhibits apoptosis induced by p53RS, This inhibitory effect is specific for p53-dependent apoptosis and was not evident in a p53-independent apoptotic pathway induced by growth factor deprivation. Furthermore, the expression of p53AS in transiently transfected cells caused both inhibition of apoptosis and inhibition of the p53RS-dependent transactivation of a number of p53 target genes. These results suggest that expression of an alternatively spliced p53 form may serve as an additional level in controlling the complexity of p53 function by the C-terminal domain.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Rotter, V (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.							Almog N, 1997, MOL CELL BIOL, V17, P713, DOI 10.1128/MCB.17.2.713; Almog Nava, 1998, Biochimica et Biophysica Acta, V1378, pR43; ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Flaman JM, 1996, ONCOGENE, V12, P813; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HALL PA, 1997, CURR BIOL, V7, P144; HAN KA, 1992, NUCLEIC ACIDS RES, V20, P1979, DOI 10.1093/nar/20.8.1979; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Ko JL, 1996, GENE DEV, V10, P1054; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KULESZMARTIN MF, 1994, MOL CELL BIOL, V14, P1698, DOI 10.1128/MCB.14.3.1698; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; McMasters KM, 1996, ONCOGENE, V13, P1731; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; Miner Z, 1997, NUCLEIC ACIDS RES, V25, P1319, DOI 10.1093/nar/25.7.1319; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Muller-Tiemann BF, 1998, P NATL ACAD SCI USA, V95, P6079, DOI 10.1073/pnas.95.11.6079; Okorokov AL, 1997, EMBO J, V16, P6008, DOI 10.1093/emboj/16.19.6008; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Peled A, 1996, CANCER RES, V56, P2148; Peled A, 1996, EXP HEMATOL, V24, P728; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; Rehberger PA, 1997, CELL GROWTH DIFFER, V8, P851; ROTTGER J, 1994, COSPAR COLL, V5, P29; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; SHAULIAN E, 1995, ONCOGENE, V10, P671; Shaw P, 1996, ONCOGENE, V12, P921; Steegenga WT, 1996, J MOL BIOL, V263, P103, DOI 10.1006/jmbi.1996.0560; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; WILL K, 1995, NUCLEIC ACIDS RES, V23, P4023, DOI 10.1093/nar/23.20.4023; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WOLF D, 1985, MOL CELL BIOL, V5, P127, DOI 10.1128/MCB.5.1.127; WOLKOWICZ R, 1995, P NATL ACAD SCI USA, V92, P6842, DOI 10.1073/pnas.92.15.6842; Wolkowicz R, 1997, PATHOL BIOL, V45, P785; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; Wu Y, 1997, P NATL ACAD SCI USA, V94, P8982, DOI 10.1073/pnas.94.17.8982; WYLLIE AH, 1995, CURR OPIN GENET DEV, V5, P97, DOI 10.1016/S0959-437X(95)90060-8; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; Zhou XL, 1999, CANCER RES, V59, P843	74	25	28	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 13	2000	19	30					3395	3403		10.1038/sj.onc.1203673	http://dx.doi.org/10.1038/sj.onc.1203673			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QX	10918596				2022-12-17	WOS:000088198100007
J	Pan, Y; Haines, DS				Pan, Y; Haines, DS			Identification of a tumor-derived p53 mutant with novel transactivating selectivity	ONCOGENE			English	Article						p53; MDM2; p53 target genes	WILD-TYPE P53; CELL-CYCLE ARREST; DNA-BINDING SITE; GENE-EXPRESSION; P53-INDEPENDENT ROLE; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; TERMINAL DOMAIN; LEUKEMIC-CELLS; TARGET GENES	MDM2 is a p53-responsive molecule that when overexpressed, can alter growth control pathways via p53-dependent and independent mechanisms. We have identified a mutant p53 containing line that expresses high levels of transcripts that are regulated by the p53-responsive promoter of the MDM2 gene. Analysis of cloned product obtained from these tumor cells revealed that they harbor a mutant p53 protein (possessing an Arg to Gin substitution at codon 213) that is a potent transactivator of MDM2 expression. Consistent with this activity, the R213Q mutant was found to have the ability to interact with DIVA sequences located within the MDM2 promoter. In contrast to previously described tumor-derived p53 mutants which retain MDM2 transactivation function and possess partial growth suppressive activity, the R213Q mutant is severely compromised in its ability to induce p53-regulated transcripts that encode for proteins involved in cell-cycle arrest and apoptosis. The R213Q mutant can also be expressed at high levels in stably transfected cells and cells that harbor this mutant possess elevated levels of MDM2 protein. The R213Q mutant was also found to be able to up-regulate MDM2 during a genotoxic stress response. R213Q is the first described tumor-derived p53 mutant that is deficient at up-regulating both cell cycle arrest and apoptotic factors, but is highly proficient at inducing the growth-promoting molecule MDM2.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Haines, DS (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.				NCI NIH HHS [CA70165] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA070165] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Bull EK, 1998, ONCOGENE, V16, P2249, DOI 10.1038/sj.onc.1201757; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DubsPoterszman MC, 1995, ONCOGENE, V11, P2445; DUTHU A, 1992, ONCOGENE, V7, P2161; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LIN JY, 1995, ONCOGENE, V10, P2387; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; LUNA RMD, 1995, NATURE, V378, P203; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Marks DI, 1996, BRIT J HAEMATOL, V92, P890, DOI 10.1046/j.1365-2141.1996.439978.x; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Montagnoli A, 1996, CELL GROWTH DIFFER, V7, P1327; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Pan Y, 1999, CANCER RES, V59, P2064; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Roemer K, 1999, BIOL CHEM, V380, P879, DOI 10.1515/BC.1999.108; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; WALDMAN T, 1995, CANCER RES, V55, P5187; WANG Y, 1995, MOL CELL BIOL, V15, P2157; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Xiao G, 1998, ONCOGENE, V16, P1171, DOI 10.1038/sj.onc.1201631; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Yang XL, 1999, ONCOGENE, V18, P4546, DOI 10.1038/sj.onc.1202843; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; Zhu JH, 1999, ONCOGENE, V18, P2149, DOI 10.1038/sj.onc.1202533; Zhu JH, 1998, CANCER RES, V58, P5061	46	25	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2000	19	27					3095	3100		10.1038/sj.onc.1203663	http://dx.doi.org/10.1038/sj.onc.1203663			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329JM	10871862				2022-12-17	WOS:000087903900007
J	Sehgal, A; Briggs, J; Rinehart-Kim, J; Basso, J; Bos, TJ				Sehgal, A; Briggs, J; Rinehart-Kim, J; Basso, J; Bos, TJ			The chicken c-Jun 5 ' untranslated region directs translation by internal initiation	ONCOGENE			English	Article						c-Jun; translation; internal initiation; 5 ' UTR	RIBOSOME ENTRY SITE; CAP-DEPENDENT TRANSLATION; EUKARYOTIC MESSENGER-RNAS; NF-KAPPA-B; BINDING-PROTEIN; DNA-BINDING; GLUCOCORTICOID RECEPTOR; 5'-UNTRANSLATED REGION; TRANSCRIPTION FACTORS; SECONDARY STRUCTURE	The 5' untranslated region (UTR) of the chicken c-jun message is exceptionally GC rich and has the potential to form a complex and extremely stable secondary structure. Because stable RNA secondary structures can serve as obstacles to scanning ribosomes, their presence suggests inefficient translation or initiation through alternate mechanisms. We have examined the role of the c-jun 5' UTR with respect to its ability to influence translation both in vitro and in vivo. We find, using rabbit reticulocyte lysates, that the presence of the c-jun 5' UTR severely inhibits translation of both homologous and heterologous genes in vitro. Furthermore, translational inhibition correlates with the degree of secondary structure exhibited by the 5' UTR, Thus, in the rabbit reticulocyte lysate system, the c-jun 5' UTR likely impedes ribosome scanning resulting in inefficient translation. In contrast to our results in vitro, the c-jun 5' UTR does not inhibit translation in a variety of different cell lines suggesting that it may direct an alternate mechanism of translational initiation in vivo, To distinguish among the alternate mechanisms, we generated a series of bicistronic expression plasmids, Our results demonstrate that the downstream cistron, in the bicistronic gene, is expressed to a much higher level when directly preceded by the c-jun 5' UTR, In addition, inhibition of ribosome scanning on the bicistronic message, through insertion of a synthetic stable hairpin, inhibits translation of the first cistron but does not inhibit translation of the cistron downstream of the c-jun 5' UTR, These results are consistent with a model by which the c-jun message is translated through cap independent internal initiation.	Eastern Virginia Med Sch, Dept Microbiol & Mol Cell Biol, Norfolk, VA 23501 USA	Eastern Virginia Medical School	Bos, TJ (corresponding author), Eastern Virginia Med Sch, Dept Microbiol & Mol Cell Biol, POB 1980, Norfolk, VA 23501 USA.				NCI NIH HHS [R01 CA51982] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051982] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; AHARON T, 1993, MOL CELL BIOL, V13, P1971, DOI 10.1128/MCB.13.3.1971; Akiri G, 1998, ONCOGENE, V17, P227, DOI 10.1038/sj.onc.1202019; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; Belsham GJ, 1995, CURR TOP MICROBIOL, V203, P85; Belsham GJ, 1996, MICROBIOL REV, V60, P499, DOI 10.1128/MMBR.60.3.499-511.1996; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BORMAN AM, 1995, NUCLEIC ACIDS RES, V23, P3656, DOI 10.1093/nar/23.18.3656; Borman AM, 1997, NUCLEIC ACIDS RES, V25, P925, DOI 10.1093/nar/25.5.925; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BUKH A, 1990, J IMMUNOL, V144, P4835; Chihab R, 1998, MOL BRAIN RES, V63, P105, DOI 10.1016/S0169-328X(98)00266-6; Coldwell MJ, 2000, ONCOGENE, V19, P899, DOI 10.1038/sj.onc.1203407; CURATOLA AM, 1995, MOL CELL BIOL, V15, P6331; deQuinto SL, 1997, J VIROL, V71, P4171; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; Diamond DA, 1999, J BIOL CHEM, V274, P16959, DOI 10.1074/jbc.274.24.16959; DUTTON CM, 1993, NUCLEIC ACIDS RES, V21, P2953, DOI 10.1093/nar/21.12.2953; Feigenblum D, 1996, MOL CELL BIOL, V16, P5450; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; Gan WN, 1996, J BIOL CHEM, V271, P623, DOI 10.1074/jbc.271.2.623; Gilby KL, 1997, MOL BRAIN RES, V48, P87, DOI 10.1016/S0169-328X(97)00085-5; Gingras AC, 1997, VIROLOGY, V237, P182, DOI 10.1006/viro.1997.8757; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; Hadman M, 1996, ONCOGENE, V12, P135; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; Jackson RJ, 1995, RNA, V1, P985; Kim YK, 1999, J GEN VIROL, V80, P3159, DOI 10.1099/0022-1317-80-12-3159; Kolupaeva VG, 1998, J BIOL CHEM, V273, P18599, DOI 10.1074/jbc.273.29.18599; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; Latorre P, 1998, MOL CELL BIOL, V18, P5021, DOI 10.1128/MCB.18.9.5021; Le SY, 1997, NUCLEIC ACIDS RES, V25, P362, DOI 10.1093/nar/25.2.362; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; Martinez-Salas E, 1999, CURR OPIN BIOTECH, V10, P458, DOI 10.1016/S0958-1669(99)00010-5; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Nanbru C, 1997, J BIOL CHEM, V272, P32061, DOI 10.1074/jbc.272.51.32061; NISHIMURA T, 1988, ONCOGENE, V3, P659; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RUPEC RA, 1995, EUR J BIOCHEM, V234, P632, DOI 10.1111/j.1432-1033.1995.632_b.x; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; SARNOW P, 1989, P NATL ACAD SCI USA, V86, P5795, DOI 10.1073/pnas.86.15.5795; SAVANTBHONSALE S, 1992, GENE DEV, V6, P1927, DOI 10.1101/gad.6.10.1927; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; Sella O, 1999, MOL CELL BIOL, V19, P5429; Sickinger S, 1999, BIOL CHEM, V380, P1217, DOI 10.1515/BC.1999.154; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; Stoneley M, 2000, MOL CELL BIOL, V20, P1162, DOI 10.1128/MCB.20.4.1162-1169.2000; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; TOURAY M, 1991, ONCOGENE, V6, P1227; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; Yueh A, 1996, GENE DEV, V10, P1557, DOI 10.1101/gad.10.12.1557; Zuker M., 1999, V70, P11	69	25	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2000	19	24					2836	2845		10.1038/sj.onc.1203601	http://dx.doi.org/10.1038/sj.onc.1203601			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	320LX	10851087				2022-12-17	WOS:000087403600005
J	Hernandez-Munoz, I; Malumbres, M; Leonardi, P; Pellicer, A				Hernandez-Munoz, I; Malumbres, M; Leonardi, P; Pellicer, A			The Rgr oncogene (homologous to RalGDS) induces transformation and gene expression by activating Ras, Ral and Rho mediated pathways	ONCOGENE			English	Article						Rgr; oncogene; exchange factor; Ral; signal transduction	NUCLEOTIDE EXCHANGE FACTORS; TERNARY COMPLEX FACTORS; C-FOS PROMOTER; NIH 3T3 CELLS; DISSOCIATION STIMULATOR; INCREASING COMPLEXITY; SIGNAL-TRANSDUCTION; BINDING PROTEIN-1; MAMMALIAN-CELL; GTPASES	The effects of the 5'-truncated Rgr oncogene, previously shown specific guanine exchange factor for Ral in vitro, in stimulating proliferation, cell transformation and gene expression were investigated. We have established TetRgr cell lines in which expression of Rgr can be inhibited by the presence of tetracycline in the medium. Using this system, we show that Rgr overexpressing cells are morphologically transformed and grow in a disorganized manner. At the transcriptional level, Rgr enhances the activity of the serum response element and c-Jun. Rgr induces phosphorylation of ERKs, p38 and JNK kinases, and increases the levels of the GTP-bound forms of Ral and Ras. I:as activation could account for the broad spectra of effects displayed by Rgr. The important role of these pathways is confirmed by experiments in which the transcriptional activation events can be blocked by dominant negative versions of Ras, Ral and Rho. Among all the Rgr-induced pathways, the Ras-Raf-MEK-ERK cascade is essential for the transforming properties of Rgr. Additional analysis has shown that the activation of this pathway by Rgr is not due to a feed back mechanism mediated by the Grb2 adaptor protein.	NYU Med Ctr, Dept Pathol, New York, NY 10016 USA; NYU Med Ctr, Kaplan Canc Ctr, New York, NY 10016 USA	New York University; New York University	Pellicer, A (corresponding author), NYU Med Ctr, Dept Pathol, New York, NY 10016 USA.		Malumbres, Marcos/E-8834-2011; MARTINEZ, ANTONIO PELLICER/C-4832-2015; Holt, Janet E/B-2415-2013	Malumbres, Marcos/0000-0002-0829-6315; Pellicer, Angel/0000-0002-5062-0692	NATIONAL CANCER INSTITUTE [R37CA036327, R01CA050434, R01CA036327] Funding Source: NIH RePORTER; NCI NIH HHS [CA 36327, CA 50434] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Bos JL, 1997, BBA-REV CANCER, V1333, pM19, DOI 10.1016/S0304-419X(97)00015-2; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; CHARDIN P, 1989, NUCLEIC ACIDS RES, V17, P4380, DOI 10.1093/nar/17.11.4380; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAdamo DR, 1997, ONCOGENE, V14, P1295, DOI 10.1038/sj.onc.1200950; Day GJ, 1998, MOL CELL BIOL, V18, P7444, DOI 10.1128/MCB.18.12.7444; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Goi T, 1999, MOL CELL BIOL, V19, P1731; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Ikeda M, 1998, J BIOL CHEM, V273, P814, DOI 10.1074/jbc.273.2.814; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; Kerkhoff E, 1998, ONCOGENE, V16, P211, DOI 10.1038/sj.onc.1201520; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; Mangues R, 1998, CANCER RES, V58, P1253; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; Murai H, 1997, J BIOL CHEM, V272, P10483; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Sawamoto K, 1999, J CELL BIOL, V146, P361, DOI 10.1083/jcb.146.2.361; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Verheijen MHG, 1999, ONCOGENE, V18, P4435, DOI 10.1038/sj.onc.1202834; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WHITEHURST CE, 1995, J BIOL CHEM, V270, P5594, DOI 10.1074/jbc.270.10.5594; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; Wolthuis RMF, 1998, CURR BIOL, V8, P471, DOI 10.1016/S0960-9822(98)70183-6; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486, DOI 10.1128/MCB.18.5.2486; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Yamaguchi A, 1997, J BIOL CHEM, V272, P31230, DOI 10.1074/jbc.272.50.31230	53	25	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2000	19	23					2745	2757		10.1038/sj.onc.1203586	http://dx.doi.org/10.1038/sj.onc.1203586			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	319BE	10851075	Bronze			2022-12-17	WOS:000087318500003
J	Yasuda, M; Chinnadurai, G				Yasuda, M; Chinnadurai, G			Functional identification of the apoptosis effector BH3 domain in cellular protein BNIP1	ONCOGENE			English	Article						BNIP1; BH3 domain; apoptosis; heterodimerization	INTERACTING PROTEIN; E1B 19K; BCL-2; DEATH; DISTINCT; SEQUENCE; NIP3; BAK	BCL-2 family proteins play a central role in apoptosis regulation in mammals and in C. elegans. Mammalian cellular and viral anti-apoptosis proteins such as BCL-2 and E1B-19K interact with several cellular proteins. Some of these interacting proteins promote apoptosis and belong to the BCL-2 family. Certain BCL-2 family pro-apoptotic proteins such as BAX and BAK share extensive sequence homology with BCL-2. In contrast, certain pro-apoptotic proteins such as BIK and BID share a single death effector domain, BH3, with other BCL-2 family proteins. By mutational analysis, we show that one of the cellular proteins, BNIP1 (previously Nip-1), that interacts with BCL-2 family anti-apoptosis proteins is a 'BH3 alone' pro-apoptotic protein. Transient transfection of BNIP1 induces a moderate level of apoptosis, Deletions of the N-terminal 32 amino acid region and the C-terminal tl aas-membrane domain did not significantly affect pro-apoptotic activity. In contrast, deletions encompassing a region containing a motif similar to the BH3-domain abrogated the apoptotic activity. Substitution of BNIP1 BH3 domain for the corresponding sequence in BAX efficiently restored the apoptotic activity of BAX, establishing the functional identity of the BH3 domain of BNIP1. The N-terminal deletions of BNIP1 (that retain the BH3 domain) enhanced the level of interaction with BCL-X-L. Mutants containing the BH3 deletions were still able to heterodimerize with BCL-X-L while mutants lacking both the N-terminal region and the BH3 domain were unable to heterodimerize, suggesting that BNIP1 may bind to BCL-XL via two different binding motifs.	St Louis Univ, Med Ctr, Inst Mol Virol, St Louis, MO 63110 USA	Saint Louis University	Chinnadurai, G (corresponding author), St Louis Univ, Med Ctr, Inst Mol Virol, 3681 Pk Ave, St Louis, MO 63110 USA.				NCI NIH HHS [CA-73803, CA-33616, R01 CA033616] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073803, R01CA033616] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BOYD JM, 1995, ONCOGENE, V11, P1921; Chen G, 1997, J EXP MED, V186, P1975, DOI 10.1084/jem.186.12.1975; Chen G, 1999, J BIOL CHEM, V274, P7, DOI 10.1074/jbc.274.1.7; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Han J, 1996, MOL CELL BIOL, V16, P5857; Hunter JJ, 1996, J BIOL CHEM, V271, P8521, DOI 10.1074/jbc.271.15.8521; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Matsushima M, 1998, GENE CHROMOSOME CANC, V21, P230, DOI 10.1002/(SICI)1098-2264(199803)21:3<230::AID-GCC7>3.0.CO;2-0; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Simonian PL, 1997, ONCOGENE, V15, P1871, DOI 10.1038/sj.onc.1201350; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415; Yasuda M, 1999, CANCER RES, V59, P533; Yasuda M, 1998, ONCOGENE, V17, P2525, DOI 10.1038/sj.onc.1202467; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; Zhang H, 1999, FEBS LETT, V448, P23, DOI 10.1016/S0014-5793(99)00335-X	18	25	26	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 4	2000	19	19					2363	2367		10.1038/sj.onc.1203565	http://dx.doi.org/10.1038/sj.onc.1203565			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZR	10822388				2022-12-17	WOS:000086974300012
J	Ma, AH; Xia, L; Littman, SJ; Swinler, S; Lader, G; Polinkovsky, A; Olechnowicz, J; Kasturi, L; Lutterbaugh, J; Modrich, P; Veigl, ML; Markowitz, SD; Sedwick, WD				Ma, AH; Xia, L; Littman, SJ; Swinler, S; Lader, G; Polinkovsky, A; Olechnowicz, J; Kasturi, L; Lutterbaugh, J; Modrich, P; Veigl, ML; Markowitz, SD; Sedwick, WD			Somatic mutation of hPMS2 as a possible cause of sporadic human colon cancer with microsatellite instability	ONCOGENE			English	Article						mismatch repair; hPMS2; colon cancer; MNNG; HPRT	DNA MISMATCH REPAIR; NONPOLYPOSIS COLORECTAL-CANCER; CARCINOMA CELL-LINES; TUMOR-CELLS; NUCLEAR EXTRACTS; DEFICIENCY; DEFECTS; HYPERMUTABILITY; HETERODIMER; PHENOTYPES	Inactivation of DIVA-mismatch repair underlies the genesis of microsatellite unstable (MSI) colon cancers. hPMS2 is one of several genes encoding components of the DNA-mismatch repair complex, and germline hPMS2 mutations have been found in a fem kindreds with hereditary nonpolyposis colorectal carcinoma (HNPCC), in whom hereditary MSI colon cancers develop. Ho tr ever, mice bearing null hPMS2 genes do not develop colon cancers and hPMS2 mutations in sporadic human colon cancers have not been described, Here we report that in Vaco481 colon cancer the hPMS2 gene is inactivated by somatic mutations of both hPMS2 alleles, The cell line derived from this tumor is functionally deficient in DNA mismatch repair. This deficiency can be biochemically complemented by addition of a purified hMLH1-hPMS2 (hMutL alpha) complex, The hPMS2 deficient Vaco481 cancer cell line demonstrates microsatellite instability, an elevated HPRT gene mutation rate, and resistance to the cytotoxicity of the alkylator MNNG. We conclude that somatic inactivation of hPMS2 can play a role in development of sporadic MSI colon cancer expressing the full range of cancer phenotypes associated with inactivation of the mismatch repair system.	Case Western Reserve Univ, Ireland Canc Ctr, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; Howard Hughes Med Inst, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Environm Hlth Sci, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Dept Med, Durham, NC 27710 USA	Case Western Reserve University; University Hospitals of Cleveland; Case Western Reserve University; Howard Hughes Medical Institute; Case Western Reserve University; Case Western Reserve University; Duke University; Howard Hughes Medical Institute; Duke University	Markowitz, SD (corresponding author), Case Western Reserve Univ, Ireland Canc Ctr, Cleveland, OH 44106 USA.			Modrich, Paul/0000-0001-8708-9885	NCI NIH HHS [R01 CA67409, R01 CA 70788] Funding Source: Medline; NIGMS NIH HHS [R01 GM45190] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067409, R01CA070788] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045190] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; BRANCH P, 1995, CANCER RES, V55, P2304; DIETZ HC, 1993, SCIENCE, V259, P680, DOI 10.1126/science.8430317; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Eshleman JR, 1996, HUM MOL GENET, V5, P1489, DOI 10.1093/hmg/5.Supplement_1.1489; ESHLEMAN JR, 1995, ONCOGENE, V10, P33; FANG WH, 1993, J BIOL CHEM, V268, P11838; FISHEL R, 1995, CURR OPIN GENET DEV, V5, P382, DOI 10.1016/0959-437X(95)80055-7; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302; Hinz JM, 1999, CARCINOGENESIS, V20, P215, DOI 10.1093/carcin/20.2.215; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KOI M, 1994, CANCER RES, V54, P4308; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MARRA G, 1995, J NATL CANCER I, V87, P1114, DOI 10.1093/jnci/87.15.1114; Miyaki M, 1997, NAT GENET, V17, P271, DOI 10.1038/ng1197-271; Modrich P, 1997, J BIOL CHEM, V272, P24727, DOI 10.1074/jbc.272.40.24727; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; NICOLAIDES NC, 1995, GENOMICS, V30, P195, DOI 10.1006/geno.1995.9885; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; Risinger JI, 1996, NAT GENET, V14, P102, DOI 10.1038/ng0996-102; RISINGER JI, 1995, J BIOL CHEM, V270, P18183, DOI 10.1074/jbc.270.31.18183; Risinger JI, 1998, CANCER RES, V58, P2978; Umar A, 1997, CANCER RES, V57, P3949	35	25	25	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 27	2000	19	18					2249	2256		10.1038/sj.onc.1203568	http://dx.doi.org/10.1038/sj.onc.1203568			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZP	10822375				2022-12-17	WOS:000086974100010
J	Raouf, A; Li, V; Kola, I; Watson, DK; Seth, A				Raouf, A; Li, V; Kola, I; Watson, DK; Seth, A			The Ets1 proto-oncogene is upregulated by retinoic acid: characterization of a functional retinoic acid response element in the Ets1 promoter	ONCOGENE			English	Article						Ets1 promoter; retinoic acid; osteoblast; transcription factor	MURINE LEUKEMIA-VIRUS; C-MYC; C-ETS-1 PROTOONCOGENE; TRANSCRIPTION FACTORS; GENE-EXPRESSION; MESSENGER-RNA; CELL-LINES; GROWTH; DIFFERENTIATION; PROTEINS	The v-ets oncoprotein and its progenitor Ets1 belong to a family of transcription factors that are related by an 85 amino acid conserved DNA binding domain, the ets domain. Ets1 plays important role(s) in control of cell proliferation, differentiation and apoptosis. Abnormal expression of Ets1 could lead to disruption of these processes and contribute to development of malignancy, Retinoic acid (RA) inhibits proliferation, induces differentiation and regulates apoptosis in many different cell types. Here, we demonstrate that RA treatment increases the expression of Ets1 mRNA, but not that of Ets2, Elk1 or Fli1 in MC3T3-E1 cells. Ets1 induction is detectable after 4 h, can be maintained for at least 14 days, and is inhibited by Actinomycin D, which suggests that RA regulation of Ets1 occurs at the transcriptional level. The promoter region of Ets1 contains four retinoic acid response element (RARE) half sites located at -94, - 152, - 1765 and - 2252 from the translation start site. We show that RAR beta is expressed by MC3T3-E1 cells in the presence of RA and demonstrate that it binds to the - 94 RARE half site. Furthermore, RA induces transcription of Ets1 promoter-reporter constructs containing this RARE half site.	Univ Toronto, Dept Lab Med & Pathobiol, MRC Grp Periodontal Physiol, Toronto, ON, Canada; Sunnybrook & Womens Coll, Hlth Sci Ctr, Toronto, ON, Canada; Monash Univ, Mol Genet & Dev Grp, Melbourne, Vic 3004, Australia; Med Univ S Carolina, Hollings Canc Ctr, Ctr Mol & Struct Biol, Charleston, SC USA	University of Toronto; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Monash University; Medical University of South Carolina	Seth, A (corresponding author), Univ Toronto, Dept Lab Med & Pathobiol, MRC Grp Periodontal Physiol, Toronto, ON, Canada.		Kola, Ismail/C-5254-2013					BELLACOSA A, 1994, J VIROL, V68, P2320, DOI 10.1128/JVI.68.4.2320-2330.1994; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; Chen ZQ, 1997, CANCER RES, V57, P2013; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DAVIDOFF AN, 1994, ANTICANCER RES, V14, P1199; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Gilles F, 1996, EXP CELL RES, V222, P370, DOI 10.1006/excr.1996.0046; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HART AH, 1995, ONCOGENE, V10, P1423; HOOSEIN NM, 1988, CANCER LETT, V40, P219, DOI 10.1016/0304-3835(88)90014-6; Inoue A, 1996, BIOCHEM BIOPH RES CO, V228, P182, DOI 10.1006/bbrc.1996.1636; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JORCYK CL, 1991, ONCOGENE, V6, P523; Jorcyk CL, 1997, CELL MOL BIOL, V43, P211; KARPERIEN M, 1997, MOL ENDOCRINOL, V11, P1434; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; LAROSA GJ, 1988, MOL CELL BIOL, V8, P3906, DOI 10.1128/MCB.8.9.3906; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LINNEY E, 1992, CURR TOP DEV BIOL, V27, P309, DOI 10.1016/S0070-2153(08)60538-4; LOHNES D, 1994, DEVELOPMENT, V120, P2723; MAHADEVAN LC, 1991, NATURE, V349, P747, DOI 10.1038/349747c0; MAJERUS MA, 1992, NUCLEIC ACIDS RES, V20, P2699, DOI 10.1093/nar/20.11.2699; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; NILES RM, 1988, CANCER INVEST, V6, P39, DOI 10.3109/07357908809077027; OKA T, 1991, ONCOGENE, V6, P2077; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SETH A, 1990, ONCOGENE, V5, P1761; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; SUN WW, 1995, J VIROL, V69, P4941, DOI 10.1128/JVI.69.8.4941-4949.1995; SUVA LJ, 1994, MOL ENDOCRINOL, V8, P1507, DOI 10.1210/me.8.11.1507; SUVA LJ, 1991, MOL CELL BIOL, V11, P2503, DOI 10.1128/MCB.11.5.2503; SUZUKI H, 1995, P NATL ACAD SCI USA, V92, P4442, DOI 10.1073/pnas.92.10.4442; THIELE CJ, 1988, ONCOGENE, V3, P281; Wang DY, 1997, IN VITRO CELL DEV-AN, V33, P248; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WATSON D K, 1990, Critical Reviews in Oncogenesis, V1, P409	41	25	25	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 6	2000	19	15					1969	1974		10.1038/sj.onc.1203505	http://dx.doi.org/10.1038/sj.onc.1203505			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	303LX	10773887				2022-12-17	WOS:000086424300013
J	Yang, HS; Jiang, DH; Li, WH; Liang, JR; Gentry, LE; Brattain, MG				Yang, HS; Jiang, DH; Li, WH; Liang, JR; Gentry, LE; Brattain, MG			Defective cleavage of membrane bound TGF alpha leads to enhanced activation of the EGF receptor in malignant cells	ONCOGENE			English	Article						tethered TGF alpha; EGFR activation; phosphatase resistance	TRANSFORMING-GROWTH-FACTOR; PROTEIN TYROSINE PHOSPHATASES; HUMAN-COLON-CARCINOMA; TRANSGENIC MICE; MAMMALIAN-CELLS; FACTOR-BETA; EXPRESSION; PRECURSOR; NEOPLASIA; BREAST	Transforming growth factor alpha (TGF alpha) is widely expressed in malignant as well as normal cells and is involved in regulating cell growth and differentiation. Although processing of TGF alpha has been extensively studied in normal cells, there is little information regarding TGF alpha cleavage in malignant cells. Therefore, we compared the processing of TGF alpha in two human colon carcinoma cell lines. We found that there was a defective cleavage pattern for the TGF alpha precursor resulting in retention of partially processed TGF alpha on the cell surface of both the HCT116a2 alpha S3 and CBS4 alpha S2 cell lines. This raised the possibility that signaling from the resulting defective cleavage species could differ from that of soluble TGF alpha, The membrane-associated TGF alpha induced higher phosphorylation of EGFR on the cell surface of adjacent cells than equivalent levels of mature TGF alpha. The interaction of membrane bound TGF alpha precursor with the EGFR caused a slower internalization of activated EGFR relative to the internalization of the soluble TGF alpha/EGFR complexes. In addition, the tethered TGF alpha was resistant to the ability of protein-tyrosine phosphatases (PTPs) to reduce EGFR tyrosine phosphorylation, also contributing to higher activation of EGFR, The enhanced activation of EGFR by the tethered form of TGF alpha was reflected by higher activation of Grb2, SHC and Erk downstream mediators of EGF receptor signaling. The higher activation of EGFR by membrane tethered TGF alpha indicates that defective TGF alpha processing provides a mechanism whereby malignant cells can obtain a growth advantage over normal cells.	Univ Texas, Hlth Sci Ctr, Dept Surg, San Antonio, TX 78284 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA; Med Coll Ohio, Dept Biochem & Mol Biol, Toledo, OH 43699 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Brattain, MG (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Surg, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.		Liang, Carol Jiurong/AAI-4963-2021; Jiang, Dianhua/B-1421-2009	Jiang, Dianhua/0000-0002-4508-3829; Liang, Jiurong/0000-0001-5179-5016	NATIONAL CANCER INSTITUTE [R01CA034432, R01CA054807] Funding Source: NIH RePORTER; NCI NIH HHS [CA54807, CA34432] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Baselga J, 1996, J BIOL CHEM, V271, P3279, DOI 10.1074/jbc.271.6.3279; BATES SE, 1990, ENDOCRINOLOGY, V126, P596, DOI 10.1210/endo-126-1-596; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BRATTAIN MG, 1984, CANCER METAST REV, V3, P177, DOI 10.1007/BF00048384; BRINGMAN TS, 1987, CELL, V48, P429, DOI 10.1016/0092-8674(87)90194-2; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DERYNCK R, 1988, EMBO J, V7, P3737, DOI 10.1002/j.1460-2075.1988.tb03257.x; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GENTRY LE, 1987, MOL CELL BIOL, V7, P1585, DOI 10.1128/MCB.7.5.1585; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Howell GM, 1998, MOL CELL BIOL, V18, P303, DOI 10.1128/MCB.18.1.303; Howell GM, 1998, J BIOL CHEM, V273, P9214, DOI 10.1074/jbc.273.15.9214; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; Jiang DH, 1998, J BIOL CHEM, V273, P31471, DOI 10.1074/jbc.273.47.31471; Jiang DH, 1998, J CELL PHYSIOL, V175, P174, DOI 10.1002/(SICI)1097-4652(199805)175:2<174::AID-JCP7>3.3.CO;2-E; KHAZAIE K, 1993, CANCER METAST REV, V12, P255, DOI 10.1007/BF00665957; LEE DC, 1985, NATURE, V313, P489, DOI 10.1038/313489a0; LINSLEY PS, 1985, P NATL ACAD SCI USA, V82, P356, DOI 10.1073/pnas.82.2.356; LUETTEKE NC, 1988, BIOCHEMISTRY-US, V27, P6487, DOI 10.1021/bi00417a043; MARKOWITZ SD, 1990, J CLIN INVEST, V86, P356, DOI 10.1172/JCI114709; MARQUARDT H, 1982, J BIOL CHEM, V257, P5220; MARQUARDT H, 1984, SCIENCE, V223, P1079, DOI 10.1126/science.6320373; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MASUI H, 1993, J CELL BIOL, V120, P85, DOI 10.1083/jcb.120.1.85; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; Miyoshi E, 1997, J BIOL CHEM, V272, P14349, DOI 10.1074/jbc.272.22.14349; MUELLER SG, 1989, MOL ENDOCRINOL, V3, P976, DOI 10.1210/mend-3-6-976; Mulder K. M., 1989, CELL MOL BIOL COLON, P45; Nagane M, 1996, CANCER RES, V56, P5079; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; PANDIELLA A, 1991, J BIOL CHEM, V266, P5769; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; POT DA, 1992, BIOCHIM BIOPHYS ACTA, V1136, P35, DOI 10.1016/0167-4889(92)90082-M; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; RUFF E, 1986, BIOCHEM BIOPH RES CO, V138, P714, DOI 10.1016/S0006-291X(86)80555-1; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; Sorby M, 1996, J BIOL CHEM, V271, P10963; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; SUN LZ, 1994, J BIOL CHEM, V269, P26449; SUNADA H, 1990, J CELL PHYSIOL, V142, P284, DOI 10.1002/jcp.1041420210; TEIXIDO J, 1988, J BIOL CHEM, V263, P3924; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; ZIOBER BL, 1993, J BIOL CHEM, V268, P691	48	25	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 6	2000	19	15					1901	1914		10.1038/sj.onc.1203513	http://dx.doi.org/10.1038/sj.onc.1203513			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	303LX	10773880				2022-12-17	WOS:000086424300006
J	Dion, F; Mes-Masson, AM; Seymour, RJ; Provencher, D; Tonin, PN				Dion, F; Mes-Masson, AM; Seymour, RJ; Provencher, D; Tonin, PN			Allelotyping defines minimal imbalance at chromosomal region 17q25 in non-serous epithelial ovarian cancers	ONCOGENE			English	Article						ovary; cancer; chromosome 17q35; loss of heterozygosity; tumor suppressor	ALLELIC LOSS; P53 GENE; BREAST CARCINOMAS; NM23 EXPRESSION; TUMORS DISTAL; DELETION UNIT; FREQUENT LOSS; HUMAN GENOME; HETEROZYGOSITY; MUTATIONS	Allelic deletions of multiple chromosome 17q loci in sporadic ovarian cancer of epithelial origin suggest that inactivation of tumor suppressor gene(s) in these regions may be important for ovarian tumorigenesis, To further define the pattern of allelic imbalance in epithelial ovarian tumors of different histologies, a PCR-based assay was used to assess loss of heterozygosity (LOH) of polymorphic markers representative of TP53, BRCA1, NME1 and GH1, and region 17q23-25, LOH was observed for at Least one marker in 68% of malignant tumors (n=60) and in 18% tumors of borderline malignancy (n=11), but not in benign tumors (n=5). The highest frequency of LOH in malignant tumors (64%) was observed with D17S801 on 17q25, Ten of 39 malignant ovarian tumors displaying LOH of at least one 17q marker, displayed a LOH pattern enabling the determination of a minimal region of overlapping deletion defined by D17S795 and D17S801, One borderline tumor also displayed an interstitial LOH pattern that overlapped this 17q25 minimal region of deletion. The histologies of malignant tumors displaying a pattern indicative of interstitial 17q deletions were of the endometrioid, clear cell and mucinous epithelial types. As the minimal region of overlap defined by these tumors overlap regions deleted in malignant tumors of all histologic types, and in a tumor of borderline malignancy, the 17q25-tumor suppressor may be implicated in the development of all types of epithelial ovarian tumors.	Montreal Gen Hosp, Inst Res, Montreal, PQ H3G 1A4, Canada; Univ Montreal, Notre Dame Hosp, Ctr Hosp, Inst Canc Montreal, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Dept Med, Montreal, PQ H3C 3J2, Canada; Montreal Gen Hosp, Dept Obstet & Gynecol, Montreal, PQ H3G 1A4, Canada; Univ Montreal, Dept Obstet Gynecol, Montreal, PQ H3C 3J2, Canada; McGill Univ, Dept Human Genet, Montreal, PQ H3A 1B1, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 1B1, Canada	McGill University; Universite de Montreal; Universite de Montreal; McGill University; Universite de Montreal; McGill University; McGill University	Tonin, PN (corresponding author), Montreal Gen Hosp, Inst Res, Room L10-120,1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada.			Mes-Masson, Anne-Marie/0000-0002-6498-266X				BERCHUCK A, 1994, GYNECOL ONCOL, V52, P232, DOI 10.1006/gyno.1994.1037; BORROW J, 1991, GENOMICS, V10, P477, DOI 10.1016/0888-7543(91)90335-C; CORNELIS RS, 1993, ONCOGENE, V8, P781; CROPP CS, 1993, CANCER RES, V53, P5617; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; ECCLES DM, 1990, ONCOGENE, V5, P1599; ECCLES DM, 1992, BRIT J CANCER, V65, P40, DOI 10.1038/bjc.1992.8; FOULKES WD, 1993, INT J CANCER, V54, P220, DOI 10.1002/ijc.2910540210; GODWIN AK, 1994, AM J HUM GENET, V55, P666; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HAHN M, 1993, CLIN CHEM, V39, P549; Harlozinska A, 1996, INT J CANCER, V69, P415, DOI 10.1002/(SICI)1097-0215(19961021)69:5<415::AID-IJC11>3.0.CO;2-1; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; JACOBS IJ, 1993, CANCER RES, V53, P1218; Kalikin LM, 1999, GENOMICS, V57, P36, DOI 10.1006/geno.1998.5740; Kalikin LM, 1997, ONCOGENE, V14, P1991, DOI 10.1038/sj.onc.1201013; Kalikin LM, 1996, GENE CHROMOSOME CANC, V17, P64, DOI 10.1002/(SICI)1098-2264(199609)17:1<64::AID-GCC10>3.3.CO;2-1; Kelsell DP, 1996, HUM MOL GENET, V5, P857, DOI 10.1093/hmg/5.6.857; KUPRYJANCZYK J, 1993, P NATL ACAD SCI USA, V90, P4961, DOI 10.1073/pnas.90.11.4961; LEARY JA, 1995, INT J CANCER, V64, P189, DOI 10.1002/ijc.2910640308; LEE JH, 1990, CANCER RES, V50, P2724; LOUNIS H, 1994, EXP CELL RES, V215, P303, DOI 10.1006/excr.1994.1346; MANDAI M, 1995, BRIT J CANCER, V72, P691, DOI 10.1038/bjc.1995.395; MARKS JR, 1991, CANCER RES, V51, P2979; Merajver SD, 1995, CLIN CANCER RES, V1, P539; Mertens F, 1997, CANCER RES, V57, P2765; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MILNER BJ, 1993, CANCER RES, V53, P2128; OKAMOTO A, 1991, CANCER RES, V51, P5171; Papp J, 1996, BRIT J CANCER, V74, P1592, DOI 10.1038/bjc.1996.594; Phelan CM, 1998, CANCER RES, V58, P1004; PHILLIPS N, 1993, INT J CANCER, V54, P85, DOI 10.1002/ijc.2910540115; Phillips NJ, 1996, CANCER RES, V56, P606; PIERETTI M, 1995, HUM PATHOL, V26, P393, DOI 10.1016/0046-8177(95)90139-6; Plummer SJ, 1997, ONCOGENE, V14, P2339, DOI 10.1038/sj.onc.1201073; Plummer SJ, 1997, GENOMICS, V45, P140, DOI 10.1006/geno.1997.4906; Plummer SJ, 1997, GENE CHROMOSOME CANC, V20, P354; Risk JM, 1999, GENOMICS, V59, P234, DOI 10.1006/geno.1999.5857; RUSSELL SEH, 1990, ONCOGENE, V5, P1581; Sakamoto T, 1996, GYNECOL ONCOL, V63, P173, DOI 10.1006/gyno.1996.0302; SATO T, 1991, CANCER RES, V51, P5118; Scambia G, 1996, J CLIN ONCOL, V14, P334, DOI 10.1200/JCO.1996.14.2.334; Schneider J, 1996, ANTICANCER RES, V16, P1197; Schultz DC, 1996, CANCER RES, V56, P1997; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Tangir J, 1996, ONCOGENE, V12, P735; TAVASSOLI M, 1993, GENE CHROMOSOME CANC, V8, P195, DOI 10.1002/gcc.2870080310; TSAO SW, 1991, ANTICANCER RES, V11, P1975; VIEL A, 1995, CANCER RES, V55, P2645; von Brevern M, 1998, ONCOGENE, V17, P2101, DOI 10.1038/sj.onc.1202139; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; Wertheim I, 1996, ONCOGENE, V12, P2147; Wiper DW, 1998, GYNECOL ONCOL, V71, P77, DOI 10.1006/gyno.1998.5110; YANGFENG TL, 1993, INT J CANCER, V54, P546, DOI 10.1002/ijc.2910540405	54	25	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 9	2000	19	11					1466	1472		10.1038/sj.onc.1203463	http://dx.doi.org/10.1038/sj.onc.1203463			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295AD	10723138				2022-12-17	WOS:000085942700012
J	Todd, MC; Sclafani, RA; Langan, TA				Todd, MC; Sclafani, RA; Langan, TA			Ovarian cancer cells that coexpress endogenous Rb and p16 are insensitive to overexpression of functional p16 protein	ONCOGENE			English	Article						adenovirus; cell cycle; cyclin D1; ovarian tumors; p16; Rb	RETINOBLASTOMA PROTEIN; P16(INK4A) EXPRESSION; PRODUCT P16(INK4A); MOLECULAR ANALYSIS; HIGH-FREQUENCY; BREAST-CANCER; CYCLE ARREST; GENE-PRODUCT; TUMORS; LINES	Defects of the 'Rb/cyclin D1/p16 pathway' have been shown to play a critical role in the development of virtually all human malignancies assessed. To determine the contribution of G1 phase cell cycle defects to ovarian tumorigenesis, we have examined a panel of normal and tumor ovarian tissues and ovarian cancer cell lines for the expression of Rb, p16 and cyclin D1 proteins. Unlike most types of human cancer whose development involves the loss of either Rb or p16 expression, we observed the coexpression of Rb, p16 and cyclin D1 in 82% of ovarian cancer tissues and cell lines, Furthermore, the growth and cell cycle distribution profiles of three ovarian cancer cell lines (ES-2, PA-1 and NIH OVCAR-3) that coexpressed Rb and p16, were found to be unaffected by adenoviral-mediated overexpression of functional p16 protein, indicating the existence of a defect(s) downstream from p16 in these cells. By contrast overexpression of ectopic p16 in the one ovarian cancer cell line (SK-OV3) that expressed Rb but lacked p16 protein, resulted in a G1 growth arrest. These data suggest that defects of the 'Rb/cyclin D1/p16 pathway', other than the loss of Rb or p16, may play a major role in the development of ovarian cancer.	Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Todd, MC (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, 4200 E 9th Ave,Box B121, Denver, CO 80262 USA.			Sclafani, Robert/0000-0002-1100-6489				Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; CAMPBELL IG, 1995, INT J CANCER, V63, P222, DOI 10.1002/ijc.2910630213; CHENEVIXTRENCH G, 1994, AM J HUM GENET, V55, P143; Craig C, 1998, ONCOGENE, V16, P265, DOI 10.1038/sj.onc.1201493; Dong Y, 1997, INT J CANCER, V74, P57, DOI 10.1002/(SICI)1097-0215(19970220)74:1<57::AID-IJC10>3.0.CO;2-F; Fang XJ, 1998, ONCOGENE, V16, P1, DOI 10.1038/sj.onc.1201525; Gemma A, 1996, INT J CANCER, V68, P605, DOI 10.1002/(SICI)1097-0215(19961127)68:5<605::AID-IJC9>3.0.CO;2-2; Geradts J, 1996, AM J PATHOL, V149, P15; GERADTS J, 1995, CANCER RES, V55, P6006; GrayBablin J, 1996, P NATL ACAD SCI USA, V93, P15215, DOI 10.1073/pnas.93.26.15215; HE J, 1995, CANCER RES, V55, P4833; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hung WC, 1996, HUM PATHOL, V27, P1324, DOI 10.1016/S0046-8177(96)90345-7; JIN XM, 1995, CANCER RES, V55, P3250; Kanuma T, 1997, MOL CARCINOGEN, V18, P134, DOI 10.1002/(SICI)1098-2744(199703)18:3<134::AID-MC2>3.0.CO;2-F; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI SB, 1991, J NATL CANCER I, V83, P637, DOI 10.1093/jnci/83.9.637; LIU Y, 1994, INT J CANCER, V58, P663, DOI 10.1002/ijc.2910580508; Marchini S, 1997, BRIT J CANCER, V76, P146, DOI 10.1038/bjc.1997.355; McCluskey LL, 1999, GYNECOL ONCOL, V72, P87, DOI 10.1006/gyno.1998.5235; Milde-Langosch K, 1998, INT J CANCER, V79, P61, DOI 10.1002/(SICI)1097-0215(19980220)79:1<61::AID-IJC12>3.0.CO;2-K; Niemann TH, 1998, GYNECOL ONCOL, V69, P214, DOI 10.1006/gyno.1998.5015; OSBORNE RJ, 1994, BRIT J CANCER, V69, P429, DOI 10.1038/bjc.1994.79; OTTERSON GA, 1994, ONCOGENE, V9, P3375; Palmero I, 1996, CANCER SURV, V27, P351; RODABAUGH KJ, 1995, ONCOGENE, V11, P1249; Ryan A, 1998, GYNECOL ONCOL, V68, P14, DOI 10.1006/gyno.1997.4881; SAITO M, 1995, GENOMICS, V25, P130, DOI 10.1016/0888-7543(95)80118-6; Sakaguchi M, 1996, INT J CANCER, V65, P442, DOI 10.1002/(SICI)1097-0215(19960208)65:4<442::AID-IJC8>3.0.CO;2-X; SCHULTZ DC, 1995, CANCER RES, V55, P2150; Schuyer M, 1996, BRIT J CANCER, V74, P1069, DOI 10.1038/bjc.1996.491; Sclafani RA, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P123; Sellers WR, 1997, J CLIN ONCOL, V15, P3301, DOI 10.1200/JCO.1997.15.11.3301; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Shih YC, 1997, INT J CANCER, V70, P508, DOI 10.1002/(SICI)1097-0215(19970304)70:5<508::AID-IJC3>3.3.CO;2-6; Sui L, 1999, GYNECOL ONCOL, V73, P202, DOI 10.1006/gyno.1999.5373; TAYLOR RR, 1995, GYNECOL ONCOL, V58, P307, DOI 10.1006/gyno.1995.1235; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; Wolf JK, 1999, GYNECOL ONCOL, V73, P27, DOI 10.1006/gyno.1998.5259; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Worsley SD, 1997, GYNECOL ONCOL, V64, P189, DOI 10.1006/gyno.1996.4569; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	46	25	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2000	19	2					258	264		10.1038/sj.onc.1203289	http://dx.doi.org/10.1038/sj.onc.1203289			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10645004				2022-12-17	WOS:000084844400011
J	Summy, JM; Guappone, AC; Sudol, M; Flynn, DC				Summy, JM; Guappone, AC; Sudol, M; Flynn, DC			The SH3 and SH2 domains are capable of directing specificity in protein interactions between the non-receptor tyrosine kinases cSrc and cYes	ONCOGENE			English	Article						Src; Yes; SH3; SH2; tyrosine phosphorylation	HUMAN-COLON-CARCINOMA; SRC FAMILY KINASES; C-SRC; BINDING-SPECIFICITY; COMPLEX-FORMATION; GENE-PRODUCT; YES; ASSOCIATION; ACTIVATION; CELLS	The c-src and eyes proto-oncogenes encode 60 000 and 62 000 Dalton non-receptor tyrosine kinases of the Src family, pp60(c-src) and pp62(c-yes), respectively. These kinases are over 80% homologous outside of their unique amino termini, yet several studies suggest that differences exist in the regulation, activation, and function of cSrc and c Yes. The determinants of specificity in signaling between these proteins, however, remain unclear, In order to investigate the roles of the Src Homology (SH) 3 and 2 domains in mediating signaling specificity between cSrc and cYes, chimeras were created in which the SH3 and/or SH2 domains of cSrc or the fully activated variant Src(527F) were replaced by the corresponding domains of cYes. These constructs were used to assess the effects of the Yes SH3 and SH2 domains on the ability of Src to form stable complexes with and induce tyrosine phosphorylation of Src SH3 and SH2 domain binding partners in vivo. Both the Yes SH3 and SH2 domains were found to alter the capacity of Src to form stable associations with heterologous proteins. The Yes SH3 domain was unable to affinity absorb the Src SN3/SH2 binding partner AFAP-110 from COS-1 cell lysates, and chimeric constructs of Src(527F) containing the cYes SH3 domain were unable to efficiently coimmunoprecipitate with AFAP-110 from chicken embryo fibroblasts. Interactions with the Src SH2 domain binding partner pp130cas were unaffected, Additionally only chimeras containing the cYes SH2 domain were able to co-immunoprecipitate with an unidentified 87 kDa tyrosine-phosphorylated protein. These results indicate that the SH3 and SH2 domains are capable of directing specificity in substrate binding between Src and Yes, suggesting potential mechanisms for generating specificity in signaling between these two highly related non-receptor tyrosine kinases.	W Virginia Univ, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA; W Virginia Univ, Dept Microbiol & Immunol, Morgantown, WV 26506 USA; CUNY Mt Sinai Sch Med, Dept Biochem, New York, NY 10029 USA	West Virginia University; West Virginia University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Flynn, DC (corresponding author), W Virginia Univ, Mary Babb Randolph Canc Ctr, POB 9300, Morgantown, WV 26506 USA.				NCI NIH HHS [CA60731, CA45757, CA01605] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA060731, R29CA045757, R01CA060731] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRICKELL P M, 1992, Critical Reviews in Oncogenesis, V3, P401; CARTWRIGHT CA, 1994, J CLIN INVEST, V93, P509, DOI 10.1172/JCI117000; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; Erpel T, 1996, J BIOL CHEM, V271, P16807, DOI 10.1074/jbc.271.28.16807; Fuhrer DK, 1996, EXP HEMATOL, V24, P195; Fuhrer DK, 1996, BIOCHEM BIOPH RES CO, V224, P289, DOI 10.1006/bbrc.1996.1023; Guappone AC, 1998, MOL CARCINOGEN, V22, P110, DOI 10.1002/(SICI)1098-2744(199806)22:2<110::AID-MC6>3.0.CO;2-Q; Guappone AC, 1997, MOL CELL BIOCHEM, V175, P243, DOI 10.1023/A:1006840104666; GUAPPONE AC, 1996, METH CELL SCI, V18, P1; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KEFALAS P, 1995, INT J BIOCHEM CELL B, V27, P551, DOI 10.1016/1357-2725(95)00024-J; KITAMURA N, 1982, NATURE, V297, P205, DOI 10.1038/297205a0; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; Luton F, 1999, MOL CELL, V4, P627, DOI 10.1016/S1097-2765(00)80213-0; Marchetti D, 1998, ONCOGENE, V16, P3253, DOI 10.1038/sj.onc.1201877; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; PARK J, 1995, MOL CELL BIOL, V15, P2374; PARK JS, 1993, ONCOGENE, V8, P2627; PENA SV, 1995, GASTROENTEROLOGY, V108, P117, DOI 10.1016/0016-5085(95)90015-2; RICKLES RJ, 1995, P NATL ACAD SCI USA, V92, P10909, DOI 10.1073/pnas.92.24.10909; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SCHALLER MD, 1993, PROG NUCLEIC ACID RE, V44, P205, DOI 10.1016/S0079-6603(08)60221-4; Sicilia RJ, 1998, J BIOL CHEM, V273, P16756, DOI 10.1074/jbc.273.27.16756; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999; SUDOL M, 1994, ONCOGENE, V9, P2145; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182; SUDOL M, 1986, MOL CELL BIOL, V6, P2839, DOI 10.1128/MCB.6.8.2839; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tsygankova OM, 1998, J CELL BIOCHEM, V69, P63, DOI 10.1002/(SICI)1097-4644(19980401)69:1<63::AID-JCB7>3.0.CO;2-T; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WENG ZG, 1995, MOL CELL BIOL, V15, P5627; ZHAO YH, 1993, MOL CELL BIOL, V13, P7507, DOI 10.1128/MCB.13.12.7507; ZHAO YH, 1990, ONCOGENE, V5, P1629; ZHOU SY, 1995, TRENDS BIOCHEM SCI, V20, P470; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	45	25	25	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2000	19	1					155	160		10.1038/sj.onc.1203265	http://dx.doi.org/10.1038/sj.onc.1203265			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644991				2022-12-17	WOS:000084844300018
J	Rey, O; Lee, S; Park, NH				Rey, O; Lee, S; Park, NH			Impaired nucleotide excision repair in UV-irradiated human oral keratinocytes immortalized with type 16 human papillomavirus genome	ONCOGENE			English	Article						HPV; p53; oral cancer; DNA repair	TRANSCRIPTION-COUPLED REPAIR; HUMAN FIBROBLASTS; MOUSE CELLS; DNA-BINDING; P53; PROTEIN; E6; DEGRADATION; INTEGRITY; DEFICIENT	We previously reported that 'high risk' human papillomaviruses (HPV) induce genetic instability in human oral keratinocytes. To understand the mechanisms of HPV-induced genetic instability, we determined the nucleotide excision repair (NER) capacity of normal (NHOK) and human papillomavirus type-16 immortalized oral keratinocytes HOK-16B) by strand-specific removal of UV-induced cyclobutane pyrimidine diners (CPDs) from a 16 Kb fragment of the p53 gene. In NHOK the NER activity was initiated in both DNA strands immediately, although the process in the non-transcribed strand was notably slower than that of the transcribed strand. In HOK-16B cells the initiation of CPDs removal was delayed for at least 8h in both DNA strands, and the process was significantly slower than that in NHOK. UV-irradiation enhanced the p53 protein level more than 30-fold in NHOK(, but it did not significantly alter the protein level in the HOK-16B cells. UV-irradiation also increased the p21(WAF1/CIP1) protein level only in NHOK. These data indicate that 'high risk' HPV induces genetic instability by impairing NER capacity of cells. Impaired NER activity of HOK-16B cells may be implicated with their inability to enhance active p53 when challenged by genotoxic stress.	Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90095 USA; Inst Dent Res, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Park, NH (corresponding author), Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90095 USA.			Rey, Osvaldo/0000-0003-1575-9864	NIDCR NIH HHS [DE11229, DE10598] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE010598, P20DE010598, R01DE011229] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ABOUSSEKHRA A, 1994, CURR OPIN GENET DEV, V4, P212, DOI 10.1016/S0959-437X(05)80047-4; ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BAND V, 1993, EMBO J, V12, P1847, DOI 10.1002/j.1460-2075.1993.tb05833.x; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; COVERLEY D, 1992, NUCLEIC ACIDS RES, V20, P3873, DOI 10.1093/nar/20.15.3873; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; El-Deiry WS, 1998, CURR TOP MICROBIOL, V227, P121; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Ford JM, 1998, CANCER RES, V58, P599; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; FRITSCHE M, 1993, ONCOGENE, V8, P307; HUBBERT NL, 1992, J VIROL, V66, P6237, DOI 10.1128/JVI.66.10.6237-6241.1992; ISHIZAKI K, 1994, INT J CANCER, V58, P254, DOI 10.1002/ijc.2910580218; LI SL, 1992, ORAL ONCOL, V28B, P129, DOI 10.1016/0964-1955(92)90041-X; Liu X, 1997, ONCOGENE, V14, P2347, DOI 10.1038/sj.onc.1201078; PARK NH, 1991, CARCINOGENESIS, V12, P1627, DOI 10.1093/carcin/12.9.1627; REY O, 1992, J VIROL, V66, P5815, DOI 10.1128/JVI.66.10.5815-5824.1992; Rey O, 1999, ONCOGENE, V18, P827, DOI 10.1038/sj.onc.1202328; SANCAR A, 1993, PHOTOCHEM PHOTOBIOL, V57, P905, DOI 10.1111/j.1751-1097.1993.tb09233.x; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Shin KH, 1996, ONCOGENE, V12, P1089; TOMMASINO M, 1993, ONCOGENE, V8, P195; vanderHorst GTJ, 1997, CELL, V89, P425, DOI 10.1016/S0092-8674(00)80223-8; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666	29	25	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	1999	18	50					6997	7001		10.1038/sj.onc.1203180	http://dx.doi.org/10.1038/sj.onc.1203180			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597299				2022-12-17	WOS:000083901900005
J	Robertson, K; Hensey, C; Gautier, J				Robertson, K; Hensey, C; Gautier, J			Isolation and characterization of Xenopus ATM (X-ATM): expression, localization, and complex formation during oogenesis and early development	ONCOGENE			English	Article						xenopus; ATM; development; cell cycle; checkpoints	ATAXIA-TELANGIECTASIA GENE; DNA-DAMAGE; IONIZING-RADIATION; PROTEIN-KINASE; DEFICIENT MICE; BREAST-CANCER; P53 PROTEIN; C-ABL; LAEVIS; ACTIVATION	ATM, the gene product mutated in Ataxia Telangiectasia (A-T) encodes a 350-KDa protein involved in the regulation of several cellular responses to DNA breaks. We used a degenerate PCR-based strategy to isolate a partial clone of X-ATM, the Xenopus homologue of human ATM. Sequence analysis and confirmed that the clone was most closely related to human ATM. Xenopus ATM protein (X-ATM) is 85% identical to human ATM within the kinase domain and 71% identical over the carboxyl-terminal half of the protein. Polyclonal antibodies raised against recombinant Ii-ATM are highly specific for the ATM protein and recognize a single polypeptide of 370-kDa in oocytes, embryos, egg extracts and a,Xenopus cell line. We found that X-ATM, mas expressed maternally in eggs and as early as stage II pre-vitellogenic oocytes, and the protein and mRNA sere present at relatively constant levels throughout development. Subcellular fractionation showed that the protein mas nuclear in both the female and male germlines. The level of X-ATM protein did not change throughout the meiotic divisions or the synchronous mitotic cycles of cleavage stage embryos. In addition, we did not observe any change in the level or mobility of X-ATM protein following ii-irradiation of embryos. Finally, we also demonstrated that X-ATM was present in a high molecular weight complex of approximately 500 kDa containing the X-ATM protein and other, as yet unidentified component(s).	Columbia Univ Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Dermatol, New York, NY 10032 USA	Columbia University; Columbia University	Gautier, J (corresponding author), Columbia Univ Coll Phys & Surg, Dept Genet & Dev, 630 W 168th St, New York, NY 10032 USA.		Gautier, jean/A-2774-2008; Hensey, Carmel/L-7456-2013	Hensey, Carmel/0000-0003-3319-4094				Anderson JA, 1997, MOL BIOL CELL, V8, P1195, DOI 10.1091/mbc.8.7.1195; Athma P, 1996, CANCER GENET CYTOGEN, V92, P130, DOI 10.1016/S0165-4608(96)00328-7; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barlow C, 1998, DEVELOPMENT, V125, P4007; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; BODER E, 1970, PSYCHIAT NEUROL MED, V14, P8; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Brown KD, 1997, P NATL ACAD SCI USA, V94, P1840, DOI 10.1073/pnas.94.5.1840; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chen G, 1996, J BIOL CHEM, V271, P33693, DOI 10.1074/jbc.271.52.33693; Chen JD, 1998, CANCER RES, V58, P1376; Chen P, 1999, ONCOGENE, V18, P249, DOI 10.1038/sj.onc.1202257; Concannon P, 1997, HUM MUTAT, V10, P100, DOI 10.1002/(SICI)1098-1004(1997)10:2<100::AID-HUMU2>3.0.CO;2-O; COX LS, 1994, ONCOGENE, V9, P2951; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DREYER C, 1983, DEV BIOL, V100, P412, DOI 10.1016/0012-1606(83)90235-X; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; FORD CC, 1977, J EMBRYOL EXP MORPH, V37, P203; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; GAUTIER J, 1991, EMBO J, V10, P177, DOI 10.1002/j.1460-2075.1991.tb07934.x; Hendrickson M, 1996, P NATL ACAD SCI USA, V93, P12223, DOI 10.1073/pnas.93.22.12223; Hensey C, 1995, Prog Cell Cycle Res, V1, P149; Hensey C, 1997, MECH DEVELOP, V69, P183, DOI 10.1016/S0925-4773(97)00191-3; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; Hoekstra MF, 1997, CURR OPIN GENET DEV, V7, P170, DOI 10.1016/S0959-437X(97)80125-6; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Kumagai A, 1998, MOL BIOL CELL, V9, P345, DOI 10.1091/mbc.9.2.345; Kumagai A, 1998, J CELL BIOL, V142, P1559, DOI 10.1083/jcb.142.6.1559; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Lim DS, 1998, P NATL ACAD SCI USA, V95, P10146, DOI 10.1073/pnas.95.17.10146; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MEYN MS, 1995, CANCER RES, V55, P5991; Morgan SE, 1997, MOL CELL BIOL, V17, P2020, DOI 10.1128/MCB.17.4.2020; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Nakagawa K, 1999, MOL CELL BIOL, V19, P2828; PUDNEY M, 1973, EXPERIENTIA, V29, P466, DOI 10.1007/BF01926785; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Scott SP, 1998, BIOCHEM BIOPH RES CO, V245, P144, DOI 10.1006/bbrc.1998.8137; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Shiloh Yosef, 1998, Biochimica et Biophysica Acta, V1378, pR11, DOI 10.1016/S0304-419X(98)00020-1; Smilenov LB, 1997, ONCOGENE, V15, P2659, DOI 10.1038/sj.onc.1201449; SOUSSI T, 1987, ONCOGENE, V1, P71; Stankovic T, 1999, LANCET, V353, P26, DOI 10.1016/S0140-6736(98)10117-4; SWIFT M, 1990, CANCER GENET CYTOGEN, V46, P21, DOI 10.1016/0165-4608(90)90004-T; Taylor AMR, 1998, INT J RADIAT BIOL, V73, P365, DOI 10.1080/095530098142185; TCHANG F, 1993, DEV BIOL, V159, P163, DOI 10.1006/dbio.1993.1230; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; Walter J, 1998, MOL CELL, V1, P519, DOI 10.1016/S1097-2765(00)80052-0; WANG Y, 1995, ONCOGENE, V10, P779; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Yuille MAR, 1998, RECENT RES CANCER, V154, P156	57	25	25	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	1999	18	50					7070	7079		10.1038/sj.onc.1203194	http://dx.doi.org/10.1038/sj.onc.1203194			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597308				2022-12-17	WOS:000083901900014
J	Tamura, K; Rice, RL; Wipf, P; Lazo, JS				Tamura, K; Rice, RL; Wipf, P; Lazo, JS			Dual G1 and G2/M phase inhibition by SC-alpha alpha delta 9, a combinatorially derived Cdc25 phosphatase inhibitor	ONCOGENE			English	Article						Cdc25 phosphatase inhibitor; cell cycle arrest; Cdc2; Cdk2; Cdk4; tsFT210	CELL-CYCLE; SMALL-MOLECULE; C-MYC; TYROSINE PHOSPHATASE; PROTEIN-KINASE; PHOSPHORYLATION; ACTIVATION; MITOSIS; LIBRARY; OVEREXPRESSION	The Cdc25 dual specificity phosphatase family has a central role in controlling cell cycle progression and has been implicated in the etiology of cancer. One compound, 4-(benzyl-(2-[(2, 5-diphenyl-oxazole-4-carbonyl)-amino]-ethyl)-carbamoyl) -2-decanoylamino butyric acid (SC-alpha alpha delta 9), was previously identified as the most potent reported synthetic inhibitor of Cdc25 phosphatases in vitro. In the present study, we demonstrate that SC-alpha alpha delta 9 inhibited Cdc25-dependent cell cycle progression at both G1 and G2/M phase using tsFT210 cells, which express a temperature-sensitive Cdc2 mutant, SC-alpha alpha delta 9 blocked both G2/M transition and dephosphorylation of Cdc2 in a concentration-dependent manner. SC-alpha alpha delta 9 also enhanced tyrosine phosphorylation of both Cdk2 and Cdk4, and decreased Cdk4 kinase activity. Both of the kinases are potent regulators of G1 transition. Furthermore, closely related chemical analogs that lacked Cdc25 inhibitory activity failed to block cell cycle progression at both G1 and G2/M, and did not affect Cdc2 phosphorylation or Cdk4 kinase activity. SC-alpha alpha delta 9 did not alter p53, p21 or p16 levels, Our results support the hypothesis that the disruption in cell cycle transition caused by SC-alpha alpha delta 9 was due to intracellular Cdc25 inhibition. We propose that the SC-alpha alpha delta 9 pharmacophore could be useful in further clarifying the role of Cdc25 phosphatase-dependent pathways in checkpoint control, oncogenesis, and apoptosis.	Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15261 USA; Hiroshima Univ, Sch Med, Dept Internal Med 2, Minami Ku, Hiroshima 734, Japan	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Hiroshima University	Lazo, JS (corresponding author), Univ Pittsburgh, Dept Pharmacol, Biomed Sci Tower E-1340, Pittsburgh, PA 15261 USA.		Wipf, Peter/AAG-1771-2021	Wipf, Peter/0000-0001-7693-5863	NATIONAL CANCER INSTITUTE [P01CA078039, R01CA039745] Funding Source: NIH RePORTER; NCI NIH HHS [CA-78039, CA-39745] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARATTE B, 1992, ANTICANCER RES, V12, P873; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Garner-Hamrick PA, 1998, INT J CANCER, V76, P720, DOI 10.1002/(SICI)1097-0215(19980529)76:5<720::AID-IJC18>3.0.CO;2-7; Gasparotto D, 1997, CANCER RES, V57, P2366; Gunasekera SP, 1996, J AM CHEM SOC, V118, P8759, DOI 10.1021/ja961961+; HAMAGUCHI T, 1995, FEBS LETT, V372, P54, DOI 10.1016/0014-5793(95)00953-7; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hernandez S, 1998, CANCER RES, V58, P1762; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HORIGUCHI T, 1994, BIOCHEM PHARMACOL, V48, P2139, DOI 10.1016/0006-2952(94)90516-9; HUNTER T, 1994, CELL, V79, P537; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Jinno S, 1999, ONCOGENE, V18, P565, DOI 10.1038/sj.onc.1202347; Kakeya H, 1998, CANCER RES, V58, P704; Lammer C, 1998, J CELL SCI, V111, P2445; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; NAGATA A, 1991, NEW BIOL, V3, P959; Peng HR, 1998, J MED CHEM, V41, P4677, DOI 10.1021/jm980500r; Rice RL, 1997, BIOCHEMISTRY-US, V36, P15965, DOI 10.1021/bi971338h; RICE RL, 1998, P AM ASSOC CANC RES, V39, P1208; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; STRAUSFELD U, 1994, J BIOL CHEM, V269, P5989; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; Vogt A, 1998, J PHARMACOL EXP THER, V287, P806; Wipf P, 1997, BIOORGAN MED CHEM, V5, P165, DOI 10.1016/S0968-0896(96)00199-X; Wu WG, 1998, CANCER RES, V58, P4082	33	25	25	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					6989	6996		10.1038/sj.onc.1203179	http://dx.doi.org/10.1038/sj.onc.1203179			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597298				2022-12-17	WOS:000083901900004
J	Russell, A; Hendley, J; Germain, D				Russell, A; Hendley, J; Germain, D			Inhibitory effect of p21 in MCF-7 cells is overcome by its coordinated stabilization with D-type cyclins	ONCOGENE			English	Article						D-type cyclins; p21; SCF; Skp2; ubiquitin; proteolysis, breast cancer	HUMAN BREAST-CARCINOMA; SUBCELLULAR-LOCALIZATION; OVEREXPRESSION; PROTEOLYSIS; TRANSITION; G(1); DIFFERENTIATION; P21(WAF1/CIP1); ABUNDANCE; RECEPTORS	Coordinated accumulation of cyclin D1 and D3 is observed in 15% of primary breast cancers and in the breast cancer cell line MCF-7 this simultaneous overexpression is due to a defect in their ubiquitin-mediated proteolysis. The F-box protein Skp2 is a component of an SCF ubiquitin ligase complex and can associate with cyclin D1 and the cdk inhibitor p21 (Zhong-Kang ct al., 1998). We extend this observation and show that cyclin D3 can also associate with Skp2 suggesting that cyclins D1, D3 and p21 may share the same SCF complex. In agreement with this hypothesis we report here that in primary breast cancers and in MCF-7 cells where cyclins D1 and D3 are elevated the level of p21 is also elevated. Further, we demonstrate that the turnover of p21 protein is reduced in MCF-7 cells. We show that p21 is active as a cdk inhibitor in this cell line but that the presence of elevated levels of cyclin D3 titrates p21 away from cyclin D1-cdk4/6 complexes and cdk2 complexes resulting in increased kinase activities. Our results suggest that a defect in the SCF complex may occur in 15-20% of breast cancers and that the resulting coordinated elevation of cyclins D1 and D3 overcomes the inhibition of cell cycle progression by p21. We propose that in the context of cyclins D1 and D3 overexpression, p21 may promote cell cycle progression.	Peter MacCallum Canc Inst, Trescowthick Res Labs, Melbourne, Vic 3002, Australia; Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3052, Australia	Peter Maccallum Cancer Center; University of Melbourne	Germain, D (corresponding author), Peter MacCallum Canc Inst, Trescowthick Res Labs, St-Andrews Pl, Melbourne, Vic 3002, Australia.							ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; Bartkova J, 1998, ONCOGENE, V17, P1027, DOI 10.1038/sj.onc.1202016; Bartkova J, 1996, INT J CANCER, V65, P323, DOI 10.1002/(SICI)1097-0215(19960126)65:3<323::AID-IJC8>3.0.CO;2-1; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; GILLETT C, 1994, CANCER RES, V54, P1812; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Krek W, 1998, CURR OPIN GENET DEV, V8, P36, DOI 10.1016/S0959-437X(98)80059-2; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lukas J, 1996, MOL CELL BIOL, V16, P6917; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Rey MJ, 1998, J PATHOL, V184, P265, DOI 10.1002/(SICI)1096-9896(199803)184:3<265::AID-PATH8>3.0.CO;2-8; Russell A, 1999, ONCOGENE, V18, P1983, DOI 10.1038/sj.onc.1202511; SHEIKH MS, 1995, ONCOGENE, V11, P1899; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; ZHONGKANG Y, 1998, P NATL ACAD SCI USA, V95, P11324	23	25	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6454	6459		10.1038/sj.onc.1203030	http://dx.doi.org/10.1038/sj.onc.1203030			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597247				2022-12-17	WOS:000083709200007
J	Wong, KS; Li, YJ; Howard, J; Ben-David, Y				Wong, KS; Li, YJ; Howard, J; Ben-David, Y			Loss of p53 in F-MuLV induced-erythroleukemias accelerates the acquisition of mutational events that confers immortality and growth factor independence	ONCOGENE			English	Article						Friend leukemia; p53; Epo; immortalization; genetic instability	WILD-TYPE P53; MURINE LEUKEMIA-VIRUS; FRIEND-VIRUS; P53-DEFICIENT MICE; GENE AMPLIFICATION; TRANSGENIC MICE; ALLELIC LOSSES; CELL-LINES; MUTANT P53; C-MYC	Erythroleukemias induced by Friend Murine Leukemia Virus (F-MuLV) involve the insertional activation of the proto-oncogene Fli-1, and the inactivation of the p53 tumor suppressor gene. While the activation of Fli-1 is an early, primary transforming event, p53 mutations are correlated with the immortalization of erythroleukemic cells in culture. In this study we have further analysed the role of p53 loss in F-MuLV induced erythroleukemias by examining the progression of this disease in p53 deficient mice. We found that p53-/- mice succumb to the disease more rapidly than p53+/+ littermates. Additionally, of the 112 tumors generated, 19 gave rise to immortal cell lines, eight of which were derived from p53-/- mice, and ten of which were from p53+/- mice. The ability of these primary tumor cells to grow in culture was associated with the complete loss of wildtype p53 in these cell lines. However, cells from many of the tumors induced in p53-/- hosts did not survive in vitro. These results suggest that the loss of p53 does not directly immortalize tumor cells. Instead, we have evidence to suggest that the loss of p53 promotes the accumulation of mutations that are required for survival in culture and that are capable of accelerating tumor progression in vivo. Indeed, mutations causing expression of the growth factor gene erythropoietin (Epo), were detected in two of seven Epo-independent cell lines from p53 deficient primary erythroleukemias, Moreover, the mechanism of activation of the Epo gene in one of these two Epo-independent cell lines involved genomic rearrangement, that is a hallmark of genetic instability. We propose that, in F-MuLV induced-erythroleukemias, p53 loss may encourage the accumulation of further mutations, subsequently conferring a growth advantage and immortality to the transformed erythroblasts.	Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Canc Biol, Toronto, ON M4N 3M5, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Ben-David, Y (corresponding author), Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Canc Biol, 2075 Bayview Ave,Res Bldg,S Wing,S-218, Toronto, ON M4N 3M5, Canada.							BAKER SJ, 1990, CANCER RES, V50, P7717; BARTHOLOMEW C, 1991, MOL CELL BIOL, V11, P1820, DOI 10.1128/MCB.11.4.1820; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BENDAVID Y, 1992, MOL CELL BIOL, V12, P4449, DOI 10.1128/MCB.12.10.4449; BLOUNT PL, 1993, P NATL ACAD SCI USA, V90, P3221, DOI 10.1073/pnas.90.8.3221; BORDEREAUX D, 1987, J VIROL, V61, P4043, DOI 10.1128/JVI.61.12.4043-4045.1987; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHOW V, 1987, J VIROL, V61, P2777, DOI 10.1128/JVI.61.9.2777-2781.1987; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, MOL CARCINOGEN, V14, P16, DOI 10.1002/mc.2940140105; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; DREYFUS F, 1990, LEUKEMIA, V4, P590; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; HICKS GG, 1988, J VIROL, V62, P4752, DOI 10.1128/JVI.62.12.4752-4755.1988; Howard J, 1996, CELL GROWTH DIFFER, V7, P1651; HOWARD JC, 1993, ONCOGENE, V8, P2721; Howard JC, 1996, ONCOGENE, V12, P1405; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; KABAT D, 1990, CURR TOP MICROBIOL I, V148, P1; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAVIGUEUR A, 1991, ONCOGENE, V6, P2197; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LU SJ, 1994, P NATL ACAD SCI USA, V91, P8398, DOI 10.1073/pnas.91.18.8398; MCDONALD J, 1987, MOL CELL BIOL, V7, P365, DOI 10.1128/MCB.7.1.365; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MUCENSKI ML, 1988, MOL CELL BIOL, V8, P301, DOI 10.1128/MCB.8.1.301; OKAMOTO A, 1991, CANCER RES, V51, P5171; PURDIE CA, 1994, ONCOGENE, V9, P603; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SELTEN G, 1984, EMBO J, V3, P3215, DOI 10.1002/j.1460-2075.1984.tb02281.x; SHIBUYA T, 1983, P NATL ACAD SCI-BIOL, V80, P3721, DOI 10.1073/pnas.80.12.3721; SILVER J, 1986, J VIROL, V57, P526, DOI 10.1128/JVI.57.2.526-533.1986; TSAI S, 1994, GENE DEV, V8, P2831, DOI 10.1101/gad.8.23.2831; USHIJIMA T, 1995, MOL CARCINOGEN, V12, P23, DOI 10.1002/mc.2940120105; WILLIAMS AC, 1995, ONCOGENE, V11, P141; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	46	25	26	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 30	1999	18	40					5525	5534		10.1038/sj.onc.1202938	http://dx.doi.org/10.1038/sj.onc.1202938			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	241QU	10523829				2022-12-17	WOS:000082894700005
J	McClatchey, AI				McClatchey, AI			Modeling metastasis in the mouse	ONCOGENE			English	Article						metastasis; mouse model; invasion; RhoGTPase	IN-VIVO; INTEGRIN ALPHA-4-BETA-1; MALIGNANT PROGRESSION; INTESTINAL NEOPLASIA; CELL INTRAVASATION; CANCER INVASION; SUPPRESSOR GENE; MAJOR MODIFIER; MELANOMA-CELLS; PHAGE DISPLAY		Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Dept Pathol, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University	McClatchey, AI (corresponding author), Massachusetts Gen Hosp, Ctr Canc, Bldg 149,13th St, Charlestown, MA 02129 USA.							Arap Wadih, 1998, Current Opinion in Oncology, V10, P560, DOI 10.1097/00001622-199811000-00014; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462; BUCK CA, 1995, MOL BASIS CANC, P172; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Chishima T, 1997, CANCER RES, V57, P2042; Coussens LM, 1996, AM J PATHOL, V149, P1899; Crepaldi T, 1997, J CELL BIOL, V138, P423, DOI 10.1083/jcb.138.2.423; DARMIENTO J, 1995, MOL CELL BIOL, V15, P5732; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Gusella JF, 1999, BBA-REV CANCER, V1423, pM29, DOI 10.1016/S0304-419X(99)00005-0; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Keely P, 1998, TRENDS CELL BIOL, V8, P101, DOI 10.1016/S0962-8924(97)01219-1; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; KOOP S, 1995, CANCER RES, V55, P2520; Koop S, 1996, P NATL ACAD SCI USA, V93, P11080, DOI 10.1073/pnas.93.20.11080; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; Lee JH, 1996, JNCI-J NATL CANCER I, V88, P1731, DOI 10.1093/jnci/88.23.1731; Lifsted T, 1998, INT J CANCER, V77, P640, DOI 10.1002/(SICI)1097-0215(19980812)77:4<640::AID-IJC26>3.0.CO;2-8; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Marra M, 1999, NAT GENET, V21, P191, DOI 10.1038/5976; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Matsuura N, 1996, AM J PATHOL, V148, P55; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; Nakagawa S, 1998, DEVELOPMENT, V125, P2963; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; QIAN F, 1994, CELL, V77, P335, DOI 10.1016/0092-8674(94)90149-X; Quigley JP, 1998, CELL, V94, P281, DOI 10.1016/S0092-8674(00)81470-1; Rajotte D, 1998, J CLIN INVEST, V102, P430, DOI 10.1172/JCI3008; Rhodes M, 1998, GENOME RES, V8, P531, DOI 10.1101/gr.8.5.531; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; Ruoslahti E, 1999, ADV CANCER RES, V76, P1, DOI 10.1016/S0065-230X(08)60772-1; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Sainio M, 1997, J CELL SCI, V110, P2249; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SHERBET G, 1997, GENETICS CANC GENES; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cellbio.9.1.541; Taverna D, 1998, CANCER RES, V58, P848; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Twardowski Przemyslaw, 1997, Current Opinion in Oncology, V9, P584, DOI 10.1097/00001622-199711000-00015; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Wilson CL, 1997, P NATL ACAD SCI USA, V94, P1402, DOI 10.1073/pnas.94.4.1402; Yu Q, 1997, J EXP MED, V186, P1985, DOI 10.1084/jem.186.12.1985; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Zetter BR, 1998, ANNU REV MED, V49, P407, DOI 10.1146/annurev.med.49.1.407; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	62	25	25	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	1999	18	38					5334	5339		10.1038/sj.onc.1203086	http://dx.doi.org/10.1038/sj.onc.1203086			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	240CP	10498886				2022-12-17	WOS:000082808400012
J	Alper, O; Hacker, NF; Cho-Chung, YS				Alper, O; Hacker, NF; Cho-Chung, YS			Protein kinase A-I alpha subunit-directed antisense inhibition of ovarian cancer cell growth: crosstalk with tyrosine kinase signaling pathway	ONCOGENE			English	Article						protein kinase A; antisense; ovarian cancer; tyrosine kinase; EGF receptor	REGULATORY SUBUNIT; CAMP; EXPRESSION; DIFFERENTIATION; OLIGODEOXYNUCLEOTIDE; TRANSFORMATION; ACTIVATION; RECEPTOR; SITE; FIBROBLASTS	Expression of the RI alpha subunit of cAMP-dependent protein kinase type I is increased in human cancers in which an autocrine pathway for epidermal growth factor-related growth factors is activated. We have investigated the effect of sequence-specific inhibition of RI alpha gene expression on ovarian cancer cell growth. We report that RI alpha antisense treatment results in a reduction in RI alpha expression and protein kinase A type I, and inhibition of cell growth. The growth inhibition was accompanied by changes in cell morphology and appearance of apoptotic nuclei. In addition, EGF receptor, c-erbB-2 and c-erbB-3 levels were reduced, and the basal and EGF-stimulated mitogen-activated protein kinase activities were reduced. Protein kinase A type I and EGF receptor levels were also reduced in cells overexpressing EGF receptor antisense cDNA. These results suggest that the antisense depletion of RI alpha leads to blockade of both the serine-threonine kinase and the tyrosine kinase signaling pathways resulting in arrest of ovarian cancer cell growth.	NCI, Cellular Biochem Sect, Tumor Immunol & Biol Lab, NIH, Bethesda, MD 20892 USA; Royal Hosp Women, Gynaecol Canc Ctr, Randwick, NSW 2031, Australia	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Cho-Chung, YS (corresponding author), NCI, Cellular Biochem Sect, Tumor Immunol & Biol Lab, NIH, Bethesda, MD 20892 USA.			ALPER, OZGE/0000-0002-9067-3270; Hacker, Neville/0000-0002-1445-2302				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; Alper O., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P646; BEEBE SJ, 1986, ENZYMES, V17, P43; BUDILLON A, 1995, P NATL ACAD SCI USA, V92, P10634, DOI 10.1073/pnas.92.23.10634; CHEN JH, 1994, SCIENCE, V263, P1278, DOI 10.1126/science.8122111; ChoChung YS, 1997, ANTISENSE NUCLEIC A, V7, P217, DOI 10.1089/oli.1.1997.7.217; CHOCHUNG YS, 1989, CANCER INVEST, V7, P161, DOI 10.3109/07357908909038282; CHOCHUNG YS, 1990, CANCER RES, V50, P7093; ChoChung YS, 1996, ANTISENSE NUCLEIC A, V6, P237, DOI 10.1089/oli.1.1996.6.237; CIARDIELLO F, 1990, J BIOL CHEM, V265, P1016; Ciardiello F, 1998, BREAST CANCER RES TR, V47, P57, DOI 10.1023/A:1005909419828; COBB CE, 1987, J BIOL CHEM, V262, P16566; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Dean N, 1996, CANCER RES, V56, P3499; Guyton KZ, 1996, CANCER RES, V56, P3480; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LEVY FO, 1988, MOL ENDOCRINOL, V2, P1364, DOI 10.1210/mend-2-12-1364; LOHMANN SM, 1984, ADV CYCLIC NUCL PROT, V18, P63; MCKNIGHT GS, 1988, RECENT PROG HORM RES, V44, P307; METELEV V, 1994, BIOORG MED CHEM LETT, V4, P2929, DOI 10.1016/S0960-894X(01)80842-8; Monia BP, 1996, NAT MED, V2, P668, DOI 10.1038/nm0696-668; Nesterova M, 1996, EUR J BIOCHEM, V235, P486, DOI 10.1111/j.1432-1033.1996.00486.x; NESTEROVA M, 1995, NAT MED, V1, P528, DOI 10.1038/nm0695-528; OTTEN AD, 1991, J BIOL CHEM, V266, P23074; Pegues JC, 1997, CANCER LETT, V117, P73, DOI 10.1016/S0304-3835(97)00209-7; SCHWARTZ DA, 1985, J BIOL CHEM, V260, P6296; Srivastava RK, 1998, BREAST CANCER RES TR, V49, P97, DOI 10.1023/A:1005905723550; STEIN CA, 1995, NAT MED, V1, P1119, DOI 10.1038/nm1195-1119; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TORTORA G, 1991, P NATL ACAD SCI USA, V88, P2011, DOI 10.1073/pnas.88.5.2011; Tortora G, 1997, ONCOGENE, V14, P923, DOI 10.1038/sj.onc.1200906; TORTORA G, 1989, FEBS LETT, V242, P363, DOI 10.1016/0014-5793(89)80502-2; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; YOKOZAKI H, 1993, CANCER RES, V53, P868	35	25	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	1999	18	35					4999	5004		10.1038/sj.onc.1202830	http://dx.doi.org/10.1038/sj.onc.1202830			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231QQ	10490835				2022-12-17	WOS:000082321700013
J	Fu, XY; McGrath, S; Pasillas, M; Nakazawa, S; Kamps, MP				Fu, XY; McGrath, S; Pasillas, M; Nakazawa, S; Kamps, MP			EB-1, a tyrosine kinase signal transduction gene, is transcriptionally activated in the t(1;19) subset of pre-B ALL, which express oncoprotein E2a-Pbx1	ONCOGENE			English	Article						E2a-Pbx1; pre-B ALL; RDA; target genes	HUMAN PROTOONCOGENE PBX1; DNA-BINDING; MESSENGER-RNA; TRANSLOCATION PROTEIN; HOMEODOMAIN PROTEIN; TRANSGENIC MICE; CELL LEUKEMIA; FUSION; RECEPTOR; DOMAIN	The t(1;19) translocation of pre-B cell acute lymphocytic leukemia (ALL) produces E2a-Pbx1, a chimeric oncoprotein containing the transactivation domains of E2a joined to the homeodomain protein, Pbx1, E2a-Pbx1 causes T cell and myeloid leukemia in mice, blocks differentiation of cultured myeloid progenitors, and transforms fibroblasts through a mechanism accompanied by aberrant expression of tissue-specific and developmentally-regulated genes. Here we investigate whether aberrant gene expression also occurs specifically in the t(1;19)-containing subset of pre-B cell ALL in man. Two new genes, EB-1 and EB-2, as well as Caldesmon were transcriptionally activated in each of seven t(1;19) cell Lines. EB-1 expression was extremely low in marrow from patients having pre-B ALL not associated with the t(1;19), and elevated more than 100-fold in marrow from patients with pre-B ALL associated with the t(1;19), Normal EB-1 expression,vas strong in brain and testis, the same tissues exhibiting the highest levels of PBX1 expression. EB-1 encodes a signaling protein containing a phosphotyrosine binding domain homologous to that of dNumb developmental regulators and two SAM domains homologous to those in the C-terminal tail of Eph receptor tyrosine kinases. We conclude that aberrant expression of tissue-specific genes is a characteristic of t(1;19) pre-B ALL, as was previously found in fibroblasts transformed by E2a-Pbx1, Potentially, EB-1 overexpression could interfere with normal signaling controlling proliferation or differentiation.	Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA; Yamanashi Med Univ, Dept Pediat, Yamanashi 40938, Japan	University of California System; University of California San Diego; University of Yamanashi	Kamps, MP (corresponding author), Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA.				NATIONAL CANCER INSTITUTE [P01CA050528, R01CA056876] Funding Source: NIH RePORTER; NCI NIH HHS [2P01 CA50528, CA56876] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barr MM, 1996, MOL CELL BIOL, V16, P5597; BEJSOVEC A, 1993, DEVELOPMENT, V119, P501; CamposOrtega JA, 1996, NEURON, V17, P1, DOI 10.1016/S0896-6273(00)80274-3; CARROLL AJ, 1984, BLOOD, V63, P721; Chan SK, 1996, P NATL ACAD SCI USA, V93, P5223, DOI 10.1073/pnas.93.11.5223; Chang CP, 1996, MOL CELL BIOL, V16, P1734; CHARITE J, 1994, CELL, V78, P589, DOI 10.1016/0092-8674(94)90524-X; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DAVIES BR, 1993, ONCOGENE, V8, P999; de Lau WBM, 1998, ONCOGENE, V17, P503, DOI 10.1038/sj.onc.1201967; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; DESILVA R, 1994, CELL MOL BIOL RES, V40, P323; Feldman BJ, 1997, ONCOGENE, V15, P2735, DOI 10.1038/sj.onc.1201670; Fu XY, 1997, MOL CELL BIOL, V17, P1503, DOI 10.1128/MCB.17.3.1503; GREEN JA, 1990, CARCINOGENESIS, V11, P1175, DOI 10.1093/carcin/11.7.1175; Guo M, 1996, NEURON, V17, P27, DOI 10.1016/S0896-6273(00)80278-0; Hisano T, 1996, FEBS LETT, V397, P101, DOI 10.1016/S0014-5793(96)01150-7; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Inada T, 1997, BLOOD, V89, P2757, DOI 10.1182/blood.V89.8.2757; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; Kamps MP, 1996, ONCOGENE, V12, P19; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KAMPS MP, 1994, ONCOGENE, V9, P3159; KIYOKAWA E, 1994, CANCER RES, V54, P3645; Klampfer L, 1996, P NATL ACAD SCI USA, V93, P14059, DOI 10.1073/pnas.93.24.14059; Knoepfler PS, 1996, NUCLEIC ACIDS RES, V24, P2288, DOI 10.1093/nar/24.12.2288; LEBRUN DP, 1994, ONCOGENE, V9, P1641; Lee SB, 1997, NAT GENET, V17, P309, DOI 10.1038/ng1197-309; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; Lu QA, 1997, ONCOGENE, V14, P75, DOI 10.1038/sj.onc.1200799; Magni M, 1996, BLOOD, V87, P1097, DOI 10.1182/blood.V87.3.1097.bloodjournal8731097; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; McWhirter JR, 1997, DEVELOPMENT, V124, P3221; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; ROBERTS VJ, 1995, MECH DEVELOP, V51, P193, DOI 10.1016/0925-4773(95)00364-9; Sakane F, 1997, INT J BIOCHEM CELL B, V29, P1139, DOI 10.1016/S1357-2725(97)00037-X; Sakane F, 1996, J BIOL CHEM, V271, P8394, DOI 10.1074/jbc.271.14.8394; Schultz J, 1997, PROTEIN SCI, V6, P249; Sefton M, 1997, CELL TISSUE RES, V290, P243, DOI 10.1007/s004410050928; Smith KS, 1997, ONCOGENE, V14, P2917, DOI 10.1038/sj.onc.1201249; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; SURGUCHEVA I, 1995, CELL MOTIL CYTOSKEL, V32, P233, DOI 10.1002/cm.970320307; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; Thompson AD, 1996, ONCOGENE, V13, P2649; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; VOGLER LB, 1978, NEW ENGL J MED, V298, P872, DOI 10.1056/NEJM197804202981603; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611	54	25	26	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	1999	18	35					4920	4929		10.1038/sj.onc.1202874	http://dx.doi.org/10.1038/sj.onc.1202874			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231QQ	10490826				2022-12-17	WOS:000082321700004
J	Quesnel, S; Verselis, S; Portwine, C; Garber, J; White, M; Feunteun, J; Malkin, D; Li, FP				Quesnel, S; Verselis, S; Portwine, C; Garber, J; White, M; Feunteun, J; Malkin, D; Li, FP			p53 compound heterozygosity in a severely affected child with Li-Fraumeni Syndrome	ONCOGENE			English	Article						Li-Fraumeni Syndrome; p53; germline mutations; functional assays	WILD-TYPE P53; TUMOR-SUPPRESSOR P53; CYCLIN-DEPENDENT KINASES; CANCER FAMILY SYNDROME; SOFT-TISSUE SARCOMA; GENE-MUTATIONS; CELL-LINES; GROWTH SUPPRESSION; ANTICANCER AGENTS; BREAST-CANCER	The Li-Fraumeni Syndrome (LFS) is a rare, dominantly inherited syndrome that features high risk of cancers in childhood and early adulthood. Affected families tend to develop bone and soft tissue sarcomas, breast cancers, brain tumors, leukemias, and adrenocortical carcinomas. In some kindreds, the genetic abnormality associated with this cancer phenotype is a heterozygous germline mutation in the p53 tumor suppressor gene. Recently, we identified one patient who presented in early childhood with multiple primary cancers and who harbored three germline p53 alterations (R156H and R267Q on the maternal allele and R290H on the paternal allele), To classify the biologic effects of these alterations, functional properties of each of the p53 mutants were examined using in vitro assays of cellular growth suppression and transcriptional activation. Each amino acid substitution conferred partial or complete loss of wild-type p53 function, but the child completed normal embryonic development. This observation has not been previously reported in a human, but is consistent with observations of normal embryogenesis in p53-deficient mice.	Hosp Sick Children, Div Oncol, Toronto, ON M5G 1X8, Canada; Dana Farber Canc Inst, Div Human Canc Genet, Boston, MA 02115 USA; Dana Farber Canc Inst, Div Populat Sci, Boston, MA 02115 USA; OncorMed Inc, Gaithersburg, MD 20877 USA; Inst Gustave Roussy, Mol Oncol Lab, F-75016 Villejuif, France	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; UNICANCER; Gustave Roussy	Malkin, D (corresponding author), Hosp Sick Children, Div Oncol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.		Portwine, Carol/AAS-4083-2021; Malkin, David/AAW-8715-2021; Feunteun, Jean/AAZ-1267-2020	Portwine, Carol/0000-0002-1314-8691; Feunteun, Jean/0000-0003-1212-9189				AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; Bian JH, 1997, P NATL ACAD SCI USA, V94, P14753, DOI 10.1073/pnas.94.26.14753; BIRCH JM, 1994, CANCER RES, V54, P1298; Brachmann RK, 1998, EMBO J, V17, P1847, DOI 10.1093/emboj/17.7.1847; CANNON JV, 1990, EMBO J, V9, P1595; COLES C, 1992, CANCER RES, V52, P5291; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Eeles RA, 1995, CANCER SURV, V25, P101; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; FREBOURG T, 1995, AM J HUM GENET, V56, P608; FREBOURG T, 1992, P NATL ACAD SCI USA, V89, P6413, DOI 10.1073/pnas.89.14.6413; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GARBER JE, 1990, CANCER-AM CANCER SOC, V66, P2432, DOI 10.1002/1097-0142(19901201)66:11<2432::AID-CNCR2820661132>3.0.CO;2-C; HARPER JW, 1993, CELL, V75, P805; HARTLEY AL, 1989, CANCER GENET CYTOGEN, V42, P221, DOI 10.1016/0165-4608(89)90090-3; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HU GY, 1992, BRIT J HAEMATOL, V81, P489, DOI 10.1111/j.1365-2141.1992.tb02979.x; ISHIOKA C, 1995, ONCOGENE, V10, P1485; Ishioka C, 1997, BIOCHEM BIOPH RES CO, V232, P54, DOI 10.1006/bbrc.1997.6216; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Kawamura M, 1996, ONCOGENE, V12, P2361; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kim E, 1997, ONCOGENE, V15, P857, DOI 10.1038/sj.onc.1201412; Kleihues P, 1997, AM J PATHOL, V150, P1; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANG P, 1993, INT J ONCOL, V2, P347; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; LI FP, 1969, J NATL CANCER I, V43, P1365; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1998, GENETIC BASIS HUMAN, P393; MASHIYAMA S, 1991, ONCOGENE, V6, P1313; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; OConnor PM, 1997, CANCER RES, V57, P4285; OSBORNE RJ, 1991, CANCER RES, V51, P6194; PAULES RS, 1995, CANCER RES, V55, P1763; PENG HQ, 1993, CANCER RES, V53, P3574; PROSSER J, 1992, BRIT J CANCER, V65, P527, DOI 10.1038/bjc.1992.109; PURDIE CA, 1994, ONCOGENE, V9, P603; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STRONG LC, 1987, JNCI-J NATL CANCER I, V79, P1213; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; Varley JM, 1997, CANCER RES, V57, P3245; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WILLIAMS WR, 1985, FAM CANCER, P151; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	68	25	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 8	1999	18	27					3970	3978		10.1038/sj.onc.1202783	http://dx.doi.org/10.1038/sj.onc.1202783			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KU	10435620				2022-12-17	WOS:000081327800007
J	Rousseau, D; Cannella, D; Boulaire, J; Fitzgerald, P; Fotedar, A; Fotedar, R				Rousseau, D; Cannella, D; Boulaire, J; Fitzgerald, P; Fotedar, A; Fotedar, R			Growth inhibition by CDK-cyclin and PCNA binding domains of p21 occurs by distinct mechanisms and is regulated by ubiquitin-proteasome pathway	ONCOGENE			English	Article						p21(WAF1/Cip1); CDK; cell cycle; ubiquitination; proteasome; PCNA	DEPENDENT KINASE INHIBITOR; NUCLEOTIDE EXCISION-REPAIR; CELL NUCLEAR ANTIGEN; DNA-REPLICATION; RETINOBLASTOMA PROTEIN; POTENTIAL MEDIATOR; MAMMALIAN-CELLS; P21(CIP1); SUBUNIT; CLONING	The CDK inhibitor, p21(WAF1/Cip1) blocks cell cycle progression, In vitro, the N-terminus of p21 binds and inhibits CDK-cyclin kinase activity, whereas the C-terminus binds and inhibits PCNA (proliferating cell nuclear antigen) function, PCNA is essential for processivity of both DNA polymerase delta and epsilon. We have performed a detailed analysis of growth inhibition by the N- and C-terminal regions of p21, and determined whether the N- and C-terminal regions mediate this effect by different mechanisms. Expression of either the N- or the C-terminal region of p21 inhibits DNA synthesis and cell growth, but not as efficiently as full length p21, The effectiveness of the two p21 domains is dependent on their stability which is determined by the ubiquitin-proteasome pathway. The stabilization of the N- and C-terminal region of p21 increases their effectiveness as inhibitors of DNA synthesis to levels comparable to full length p21, Inhibition of DNA synthesis by the N-terminal region of p21 involves suppression of E2F activity, In contrast, inhibition by the C-terminal region of p21 is not accompanied by suppression of E2F activity, but is mediated via PCNA binding, The C-terminal region of p21 therefore inhibits cell growth by a mechanism distinct from that of the N-terminal region containing the CDK-cyclin inhibitory domain.	Inst Biol Struct J P Ebel, F-38027 Grenoble 1, France; Sidney Kimmel Canc Ctr, San Diego, CA 92121 USA	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Fotedar, R (corresponding author), Inst Biol Struct J P Ebel, F-38027 Grenoble 1, France.		Cannella, Dominique/F-4879-2019	Cannella, Dominique/0000-0002-1665-9833	NCI NIH HHS [CA74435] Funding Source: Medline; NIAID NIH HHS [AI31453] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074435] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031453] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams PD, 1996, MOL CELL BIOL, V16, P6623; Ball KL, 1997, CURR BIOL, V7, P71, DOI 10.1016/S0960-9822(06)00029-7; BRENOTBOSC F, 1995, CHROMOSOMA, V103, P517, DOI 10.1007/BF00355316; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; Chen IT, 1996, ONCOGENE, V12, P595; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Fotedar A, 1996, J BIOL CHEM, V271, P31627, DOI 10.1074/jbc.271.49.31627; FOTEDAR R, 1991, COLD SH Q B, V56, P325; FOTEDAR R, 1995, MOL CELL BIOL, V15, P932; Fotedar R, 1996, EMBO J, V15, P4423, DOI 10.1002/j.1460-2075.1996.tb00815.x; Fotedar R, 1996, ONCOGENE, V12, P2155; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOUBIN F, 1995, ONCOGENE, V10, P2281; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Li R, 1996, CURR BIOL, V6, P189, DOI 10.1016/S0960-9822(02)00452-9; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Lin JY, 1996, MOL CELL BIOL, V16, P1786; Lukas J, 1996, MOL CELL BIOL, V16, P1047; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Ogryzko VV, 1997, MOL CELL BIOL, V17, P4877, DOI 10.1128/MCB.17.8.4877; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; ROBERTS JM, 1994, COLD SPRING HARB SYM, V59, P31, DOI 10.1101/SQB.1994.059.01.006; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; Sasaki T, 1990, J Enzyme Inhib, V3, P195, DOI 10.3109/14756369009035837; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SHIVJI MKK, 1995, BIOCHEMISTRY-US, V34, P5011, DOI 10.1021/bi00015a012; Shiyanov P, 1996, MOL CELL BIOL, V16, P737; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	57	25	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	1999	18	21					3290	3302		10.1038/sj.onc.1202681	http://dx.doi.org/10.1038/sj.onc.1202681			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200DF	10359535				2022-12-17	WOS:000080523800012
J	Balasubramanian, S; Kim, KH; Ahmad, N; Mukhtar, H				Balasubramanian, S; Kim, KH; Ahmad, N; Mukhtar, H			Activation of telomerase and its association with G1-phase of the cell cycle during UVB-induced skin tumorigenesis in SKH-1 hairless mouse	ONCOGENE			English	Article						telomerase; cell cycle; cyclin; cyclin dependent kinase; cyclin dependent kinase inhibitor; skin carcinogenesis	HUMAN BREAST-CANCER; HEMATOPOIETIC-CELLS; IMMORTAL CELLS; CDK INHIBITOR; OVEREXPRESSION; DIFFERENTIATION; CARCINOGENESIS; AMPLIFICATION; PROGRESSION; P15(INK4B)	Telomerase is a ribonucleoprotein enzyme that adds hexanucleotide repeats TTAGGG to the ends of chromosomes, Telomerase activation is known to play a crucial role in cell-immortalization and carcinogenesis. Telomerase is shown to have a correlation with cell cycle progression, which is controlled by the regulation of cyclins, cyclin dependent kinases (cdks) and cyclin dependent kinase inhibitors (cdkis), Abnormal expression of these regulatory molecules may cause alterations in cell cycle with uncontrolled cell growth, a universal feature of neoplasia, Skin cancer is the most prevalent form of cancer in humans and the solar UV radiation is its major cause. Here, we investigated modulation in telomerase activity and protein expression of cell cycle regulatory molecules during the development of UVB-induced tumors in SKH-1 hairless mice, The mice were exposed to 180 mjoules/cm(2) UVB radiation, thrice weekly for 24 weeks. The animals were sacrificed at 4 week intervals and the studies were performed in epidermis, Telomerase activity was barely detectable in the epidermis of non-irradiated mouse. UVB exposure resulted in a progressive increase in telomerase activity starting from the 4th week of exposure. The increased telomerase activity either persisted or further increased with the increased exposure, In papillomas and carcinomas the enzyme activity was comparable and was 45-fold higher than in the epidermis of control mice. Western blot analysis showed an upregulation in the protein expression of cyclin D1 and cyclin E and their regulatory subunits cdk4 and cdk2 during the course of UVB exposure and in papillomas and carcinomas. The protein expression of cdk6 and ckis viz, p16/Ink4A, p21/Waf1 and p27/Kip1 did not show any significant change in WE exposed skin, but significant upregulation was observed both in papillomas and carcinomas. The results suggest that telomerase activation may be involved in UVB-induced tumorigenesis in mouse skin and that increased telomerase activity may be associated with G1 phase of the cell cycle.	Case Western Reserve Univ, Dept Dermatol, Cleveland, OH 44106 USA	Case Western Reserve University	Mukhtar, H (corresponding author), Case Western Reserve Univ, Dept Dermatol, 11100 Euclid Ave, Cleveland, OH 44106 USA.				NATIONAL CANCER INSTITUTE [P30CA043703, R01CA051802, P01CA048735] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA 43703, R01 CA 51802, P01 CA 48735] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balasubramanian S, 1998, BIOCHEM BIOPH RES CO, V243, P744, DOI 10.1006/bbrc.1998.8172; BEDNAREK A, 1995, CANCER RES, V55, P4566; Bednarek AK, 1997, MOL CARCINOGEN, V20, P329, DOI 10.1002/(SICI)1098-2744(199712)20:4<329::AID-MC1>3.0.CO;2-E; BIANCHI AB, 1993, ONCOGENE, V8, P1127; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CHADENEAU C, 1995, ONCOGENE, V11, P893; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DAS M, 1987, CANCER RES, V47, P760; Engelhardt M, 1997, BLOOD, V90, P182; GREIDER CW, 1991, CELL, V67, P645, DOI 10.1016/0092-8674(91)90058-7; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Holt SE, 1997, P NATL ACAD SCI USA, V94, P10687, DOI 10.1073/pnas.94.20.10687; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Katiyar SK, 1997, JNCI-J NATL CANCER I, V89, P556, DOI 10.1093/jnci/89.8.556; KAWAMATA N, 1995, CANCER RES, V55, P2266; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Landberg G, 1997, CANCER RES, V57, P549; LEACH FS, 1993, CANCER RES, V53, P1986; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LINARDOPOULOS S, 1995, CANCER RES, V55, P5168; Pandita TK, 1996, ONCOGENE, V13, P1423; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SGAMBATO A, 1995, CARCINOGENESIS, V16, P2193, DOI 10.1093/carcin/16.9.2193; Sharma HW, 1995, P NATL ACAD SCI USA, V92, P12343, DOI 10.1073/pnas.92.26.12343; Taylor RS, 1996, J INVEST DERMATOL, V106, P759, DOI 10.1111/1523-1747.ep12345811; Tron VA, 1996, AM J PATHOL, V149, P1139; Ueda M, 1997, CANCER RES, V57, P370; WHITAKER NJ, 1995, ONCOGENE, V11, P971; Yashima K, 1998, CLIN CANCER RES, V4, P229; Yasumoto S, 1996, ONCOGENE, V13, P433; Yoshimi N, 1996, MOL CARCINOGEN, V16, P1, DOI 10.1002/(SICI)1098-2744(199605)16:1<1::AID-MC1>3.0.CO;2-N; Zhang T, 1997, CANCER RES, V57, P169; ZHOU P, 1995, ONCOGENE, V11, P571	39	25	32	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	1999	18	6					1297	1302		10.1038/sj.onc.1202417	http://dx.doi.org/10.1038/sj.onc.1202417			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FW	10022811				2022-12-17	WOS:000078510900005
J	Grand, RJA; Parkhill, J; Szestak, T; Rookes, SM; Roberts, S; Gallimore, PH				Grand, RJA; Parkhill, J; Szestak, T; Rookes, SM; Roberts, S; Gallimore, PH			Definition of a major p53 binding site on Ad2E1B58K protein and a possible nuclear localization signal on the Ad12E1B54K protein	ONCOGENE			English	Article						p53; nuclear localization signal; Ad2E1B; Ad12E1B; p53-binding proteins	REGION-4 34-KILODALTON PROTEIN; ADENOVIRUS E1A PROTEINS; WILD-TYPE P53; TRANSFORMED-CELLS; 55-KILODALTON PROTEIN; MESSENGER-RNA; GENE-PRODUCTS; TUMOR-ANTIGEN; CELLULAR P53; RAT-CELLS	Previous studies have established that adenovirus 2/5 early region 1B (Ad E1B) 58K protein binds p53 strongly and co-localizes with it to cytoplasmic dense bodies whilst the homologous Ad12E1B54K protein binds only weakly and co-localizes primarily to the nucleus in Ad12E1 transformed cells. We have used these properties of the E1B proteins from different viral serotypes to map the p53 binding site on the Ad2/5 protein. A set of chimaeric genes was constructed containing different proportions of the Ad12 and Ad2E1B DNA, These, together with Ad12E1A and E1B19K DNA, were transfected into baby rat kidney cells and transformed lines isolated, From an examination of the properties of these Ad12/Ad2E1B fusion proteins in co-immunoprecipitation and subcellular localization experiments it has been concluded that the p53 binding site on Ad2E1B58K protein lies between amino acids 216 and 235 and that the homologous region on Ad12E1B54K protein also binds p53. In addition, a unique nuclear localization signal is located on Ad12E1B54K between residues 228 and 239, We suggest that primary structure differences in these regions of the Ad2 and Ad12E1B proteins are responsible for the different subcellular localizations in AdE1 transformants.	Univ Birmingham, CRC, Inst Canc Studies, Birmingham B15 2TA, W Midlands, England	University of Birmingham	Grand, RJA (corresponding author), Univ Birmingham, CRC, Inst Canc Studies, Birmingham B15 2TA, W Midlands, England.		Parkhill, Julian/G-4703-2011; Roberts, Sally/N-6143-2014	Parkhill, Julian/0000-0002-7069-5958; Roberts, Sally/0000-0003-4653-9442				BABISS LE, 1984, J VIROL, V50, P202, DOI 10.1128/JVI.50.1.202-212.1984; BABISS LE, 1985, MOL CELL BIOL, V5, P2552, DOI 10.1128/MCB.5.10.2552; BAYLEY ST, 1994, INT J ONCOL, V5, P425; BERNARDS R, 1982, VIROLOGY, V120, P422, DOI 10.1016/0042-6822(82)90042-3; BERNARDS R, 1984, BIOCHIM BIOPHYS ACTA, V783, P187, DOI 10.1016/0167-4781(84)90029-0; BOULANGER PA, 1991, BIOCHEM J, V275, P281, DOI 10.1042/bj2750281; BOYD JM, 1995, ONCOGENE, V11, P1921; BREIDING DE, 1988, VIROLOGY, V164, P390, DOI 10.1016/0042-6822(88)90552-1; BYRD PJ, 1988, VIROLOGY, V163, P156; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Dobbelstein M, 1997, EMBO J, V16, P4276, DOI 10.1093/emboj/16.14.4276; Gallimore PH, 1997, J VIROL, V71, P6629, DOI 10.1128/JVI.71.9.6629-6640.1997; GALLIMORE PH, 1985, CANCER RES, V45, P2670; GALLIMORE PH, 1985, VIRUSES CANCER, P125; Goodrum FD, 1996, J VIROL, V70, P6323, DOI 10.1128/JVI.70.9.6323-6335.1996; GRAND RJA, 1994, VIROLOGY, V203, P229, DOI 10.1006/viro.1994.1480; Grand RJA, 1996, VIROLOGY, V218, P23, DOI 10.1006/viro.1996.0162; GRAND RJA, 1993, VIROLOGY, V193, P579, DOI 10.1006/viro.1993.1166; HALBERT DN, 1985, J VIROL, V56, P250, DOI 10.1128/JVI.56.1.250-257.1985; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; LEPPARD KN, 1989, EMBO J, V8, P2329, DOI 10.1002/j.1460-2075.1989.tb08360.x; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; MAK I, 1988, VIROLOGY, V163, P201, DOI 10.1016/0042-6822(88)90248-6; MERRICK RM, 1991, J GEN VIROL, V72, P955, DOI 10.1099/0022-1317-72-4-955; MONTELL C, 1984, CELL, V36, P951, DOI 10.1016/0092-8674(84)90045-X; MORAN E, 1994, SEMIN VIROL, V5, P327, DOI 10.1006/smvy.1994.1037; ORNELLES DA, 1991, J VIROL, V65, P424, DOI 10.1128/JVI.65.1.424-429.1991; PARASKEVA C, 1982, J GEN VIROL, V58, P73, DOI 10.1099/0022-1317-58-1-73; PILDER S, 1986, MOL CELL BIOL, V6, P470, DOI 10.1128/MCB.6.2.470; Prochiantz A, 1996, CURR OPIN NEUROBIOL, V6, P629, DOI 10.1016/S0959-4388(96)80095-X; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SARNOW P, 1984, J VIROL, V49, P592; SPRENGEL J, 1995, CURR TOP MICROBIOL, V199, P11; VANDENELSEN P, 1983, VIROLOGY, V131, P242, DOI 10.1016/0042-6822(83)90549-4; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; ZAJDEL MEB, 1988, ONCOGENE, V2, P579; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084	43	25	25	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					955	965		10.1038/sj.onc.1202358	http://dx.doi.org/10.1038/sj.onc.1202358			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023671				2022-12-17	WOS:000078510600012
J	Cobellis, G; Missero, C; Di Lauro, R				Cobellis, G; Missero, C; Di Lauro, R			Concomitant activation of MEK-1 and Rac-1 increases the proliferative potential of thyroid epithelial cells, without affecting their differentiation	ONCOGENE			English	Article						thyroid; Rac; MEK; Ras; differentiation; transformation	MAP KINASE KINASE; ACTIN STRESS FIBERS; PROTEIN-KINASE; MAMMALIAN-CELLS; THYROGLOBULIN PROMOTER; SIGNAL-TRANSDUCTION; RAS TRANSFORMATION; CYCLE PROGRESSION; GENE-EXPRESSION; CDC42 GTPASES	Activating point mutations in the Ras oncogene occur in a large number of human tumors, especially of epithelial origin. In thyroid follicular cells, ectopic expression of oncogenic H-Ras results in growth factor-independent proliferation, loss of differentiation and tumor formation in nude mice. In fibroblasts concomitant activation of the MAP kinase cascade and the small GTPase Rac-1 leads to full malignant transformation. We have tested the effects of these key downstream mediators of Pas in thyroid epithelial cells, by stably expressing either a constitutively active form of MEK-1 (MEKDelta N3/S218E/S222D), a constitutively active form of Rac-1 (Val12-Rac), or both. While the activation of one molecule or the other results in a weak phenotype, concomitant activation of both MEK-1 and Rac-1 in thyroid cells leads to growth factor-independent proliferation, morphological transformation and anchorage-independent growth. However, in contrast to Pas-transformed thyroid cells, the ones expressing the constitutively active forms of MEK-1 and Rac-1 maintain their differentiate phenotype and fail to form tumors when injected into nude mice. Thus, in thyroid epithelial cells, concomitant activation of MEK-1 and Rac-1 can reproduce only a subset of the Ras-induced effects and is not sufficient to cause full malignant transformation. Significantly, Pas-mediated increased proliferation and loss of differentiation can be dissociated in these cells.	Staz Zool Anton Dohrn, I-80121 Naples, Italy	Stazione Zoologica Anton Dohrn di Napoli	Di Lauro, R (corresponding author), Staz Zool Anton Dohrn, I-80121 Naples, Italy.		Di Lauro, Roberto/A-2746-2012	Di Lauro, Roberto/0000-0001-9493-3036; Cobellis, Gilda/0000-0003-2687-2272; Missero, Caterina/0000-0003-0905-5123	Telethon [E.0406] Funding Source: Medline	Telethon(Fondazione Telethon)		AELST LV, 1993, P NATL ACAD SCI USA, V90, P6213; ALBLAS J, 1993, J BIOL CHEM, V268, P22235; AMBESIIMPIOMBAT.FS, 1982, COLD SPRING HARBOR C, V9, P483; AVVEDIMENTO VE, 1985, EUR J BIOCHEM, V149, P467, DOI 10.1111/j.1432-1033.1985.tb08948.x; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1989, CANCER RES, V49, P4682; Bosch E, 1997, ONCOGENE, V15, P1021, DOI 10.1038/sj.onc.1201270; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CIVITAREALE D, 1989, EMBO J, V8, P2537, DOI 10.1002/j.1460-2075.1989.tb08391.x; Clark G. J., 1993, GTPASES BIOL, DOI 10.1007/978-3-642-78267-1_18; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAMANTE G, 1994, BBA-GENE STRUCT EXPR, V1218, P255, DOI 10.1016/0167-4781(94)90176-7; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; FARID NR, 1994, ENDOCR REV, V15, P202, DOI 10.1210/er.15.2.202; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P5793, DOI 10.1128/MCB.12.12.5793; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KONG YF, 1995, MOL CELL BIOL, V15, P5205; KUPPERMAN E, 1993, MOL CELL BIOL, V13, P4477, DOI 10.1128/MCB.13.8.4477; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LANGECARTER CA, 1995, METH ENZIMOL, V255; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEMOINE NR, 1990, ONCOGENE, V5, P1833; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARIAIS R, 1993, CELL, V73, P391; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Mascia A, 1997, BBA-GENE STRUCT EXPR, V1354, P171, DOI 10.1016/S0167-4781(97)00127-9; Miller MJ, 1997, J BIOL CHEM, V272, P5600, DOI 10.1074/jbc.272.9.5600; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MISSERO C, 1997, IN PRESS MOL CELL EN; NAMBA H, 1990, MOL ENDOCRINOL, V4, P1474, DOI 10.1210/mend-4-10-1474; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Ramocki MB, 1997, MOL CELL BIOL, V17, P3547, DOI 10.1128/MCB.17.7.3547; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rochefort P, 1996, ONCOGENE, V12, P111; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SAUREZ HG, 1990, ONCOGENE, V5, P565; VASSART G, 1992, ENDOCR REV, V13, P596, DOI 10.1210/er.13.3.596; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE P, 1993, NATURE, V36, P352; WESTWICK JK, 1995, METH ENZIMOL; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; YAMAMOTO M, 1993, J BIOL CHEM, V268, P21509; Zannini M, 1997, EMBO J, V16, P3185, DOI 10.1093/emboj/16.11.3185; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	76	25	26	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 22	1998	17	16					2047	2057		10.1038/sj.onc.1202130	http://dx.doi.org/10.1038/sj.onc.1202130			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130VK	9798676				2022-12-17	WOS:000076540900004
J	Thate, C; Englert, C; Gessler, M				Thate, C; Englert, C; Gessler, M			Analysis of WT1 target gene expression in stably transfected cell lines	ONCOGENE			English	Article						Wilms' tumour; WT1; zinc finger protein; differential display PCR; CSF1	WILMS-TUMOR GENE-WT1; DENYS-DRASH-SYNDROME; GROWTH-FACTOR-A; PRODUCT; BINDING; DNA; TRANSCRIPTION; MUTATIONS; RECEPTOR; SEQUENCE	The Wilms' tumour suppressor gene WT1 encodes a zinc finger protein that is mutated in a subset of Wilms' tumours. Mutation screening and animal studies revealed essential roles during development and later function of the kidneys and the entire genitourinary system. Sequence similarity suggested a possible role for WT1 as a transcription factor. Indeed, sequence specific DNA binding and transcriptional activation or repression potential could be demonstrated in transient transfection assays with various reporter constructs. To identify endogenous WT1 target genes we established HEK293 cell lines expressing the different WT1 isoforms in a tetracycline dependent manner. Differential display PCR (ddPCR) was performed on RNA from stable WT1 transfected HEK293 cell lines and two other WT1 transfected lines (G401 and Saos-2), In an extended survey of several thousand ddPCR bands only few differences in intensity were seen and none of these could unambiguously be verified as being WT1 regulated by subsequent Northern blot analysis, In addition, almost none of the WT1 target genes identified to date in transient co-transfection assays could be confirmed by either ddPCR or Northern hybridization in the three stable transfected cell lines. Among the nine genes expressed, the only exceptions were CSF1 and to a lesser extent IGF1R being induced in Saos-2/G401 and HEK293 cells, respectively. At least two of the cell lines tested had previously shown clear biological effects though - either WT1 dependent apoptosis (Saos-2) or greatly reduced tumorigenicity (G401). This suggests that WT1 may regulate only a very small set of genes that escape the detection methods used or it may not act as a transcription factor that influences steady state levels of mRNA.	Univ Wurzburg, Theodor Boveri Inst Biowissensch, D-97074 Wurzburg, Germany; Forschungszentrum Karlsruhe, Inst Genet, D-76021 Karlsruhe, Germany	University of Wurzburg; Helmholtz Association; Karlsruhe Institute of Technology	Gessler, M (corresponding author), Univ Wurzburg, Theodor Boveri Inst Biowissensch, Hubland, D-97074 Wurzburg, Germany.			Thaete, Claudia/0000-0002-2739-5669; Gessler, Manfred/0000-0002-7915-6045; Englert, Christoph/0000-0002-5931-3189				Barbaux S, 1997, NAT GENET, V17, P467, DOI 10.1038/ng1297-467; BARBU V, 1989, NUCLEIC ACIDS RES, V17, P7115, DOI 10.1093/nar/17.17.7115; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; Caricasole A, 1996, P NATL ACAD SCI USA, V93, P7562, DOI 10.1073/pnas.93.15.7562; Charlieu JP, 1995, J CELL SCI, P95; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GERALD WL, 1995, P NATL ACAD SCI USA, V92, P1028, DOI 10.1073/pnas.92.4.1028; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GESSLER M, 1992, GENOMICS, V12, P807, DOI 10.1016/0888-7543(92)90313-H; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; KENT J, 1995, ONCOGENE, V11, P1781; Kikuchi H, 1998, J MED GENET, V35, P45, DOI 10.1136/jmg.35.1.45; Kim J, 1998, ONCOGENE, V16, P1021, DOI 10.1038/sj.onc.1201616; Klamt B, 1998, HUM MOL GENET, V7, P709, DOI 10.1093/hmg/7.4.709; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LANGERAK AW, 1995, GENE CHROMOSOME CANC, V12, P87, DOI 10.1002/gcc.2870120203; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; Lee SB, 1997, NAT GENET, V17, P309, DOI 10.1038/ng1197-309; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LINSKENS MHK, 1995, NUCLEIC ACIDS RES, V23, P3244, DOI 10.1093/nar/23.16.3244; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MCMASTER ML, 1995, CELL GROWTH DIFFER, V6, P1609; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; REDDY JC, 1995, J BIOL CHEM, V270, P29976; Reddy JC, 1996, BBA-REV CANCER, V1287, P1, DOI 10.1016/0304-419X(95)00014-7; Vicanek C, 1997, KIDNEY INT, V52, P614, DOI 10.1038/ki.1997.374; Wan JS, 1996, NAT BIOTECHNOL, V14, P1685, DOI 10.1038/nbt1296-1685; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; WANG ZY, 1992, J BIOL CHEM, V267, P21999	36	25	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	1998	17	10					1287	1294		10.1038/sj.onc.1202055	http://dx.doi.org/10.1038/sj.onc.1202055			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	117VL	9771972				2022-12-17	WOS:000075803300011
J	Scotet, E; Houssaint, E				Scotet, E; Houssaint, E			Exon III splicing switch of fibroblast growth factor (FGF) receptor-2 and -3 can be induced by FGF-1 or FGF-2	ONCOGENE			English	Article						fibroblast growth factor receptor; fibroblast growth factor; splicing switch; epithelio-mesenchymal conversion	LIGAND-BINDING; SIGNAL TRANSDUCTION; MESSENGER-RNA; CELLS; GENE; ACTIVATION; PROTEINS; FAMILY; TRANSLOCATION; TRANSCRIPTION	An essential feature of fibroblast growth factor receptors (FGFRs) is the existence of multiple possibilities of alternative splicing. One of these concerns sequences of the mRNA coding for the C-terminal half of Ig domain 3 which corresponds to a part of the ligand-binding site: two alternative exons, IIIb and IIIc, encode the C-terminal half of Ig domain 3. The IIIb/lIIc choice in the FGFR-2 and FGFR-3 is strictly tissue-specific, the IIIb exon being expressed exclusively in epithelial cells. We describe here a reversible switch from IIIb to IIIc for FGFR-2 and FGFR-3 under the influence of exogenous and endogenous FGF-1 or FGF-2. We observed that EGF-induced FGF receptor exon switching (i) occurred as early as Ih after exposure to FGF (ii) was receptor-mediated (iii) was dependent on cell confluency and showed a link with the cell cycle (iv) was correlated with a reversible loss of epithelial properties. These results support a role for FGF in the regulation of expression of alternatively spliced FGFR mRNA.	Inst Biol, INSERM, U463, F-44035 Nantes 01, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Houssaint, E (corresponding author), Inst Biol, INSERM, U463, 9 Quai Moncousu, F-44035 Nantes 01, France.		SCOTET, Emmanuel/L-2576-2015; SCOTET, Emmanuel/AAC-9971-2019	SCOTET, Emmanuel/0000-0001-8010-9556; SCOTET, Emmanuel/0000-0001-8010-9556				BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P979; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COWIN P, 1985, J CELL BIOL, V101, P1442, DOI 10.1083/jcb.101.4.1442; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; HALLEY C, 1988, NUCLEIC ACIDS RES, V16, P10913, DOI 10.1093/nar/16.22.10913; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; HOUSSAINT E, 1990, P NATL ACAD SCI USA, V87, P8180, DOI 10.1073/pnas.87.20.8180; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOUANNEAU J, 1991, P NATL ACAD SCI USA, V88, P2893, DOI 10.1073/pnas.88.7.2893; KIEFER P, 1995, MOL CELL BIOL, V15, P4364; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MIGDAL M, 1995, J CELL PHYSIOL, V162, P266, DOI 10.1002/jcp.1041620212; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; NAKANISHI Y, 1992, P NATL ACAD SCI USA, V89, P5216, DOI 10.1073/pnas.89.12.5216; Oliver L, 1992, GROWTH FACTORS, V7, P97, DOI 10.3109/08977199209046399; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; Prudovsky IA, 1996, J BIOL CHEM, V271, P14198, DOI 10.1074/jbc.271.24.14198; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; SAVAGNER P, 1994, MOL BIOL CELL, V5, P851, DOI 10.1091/mbc.5.8.851; SCOTET E, 1995, ONCOL REP, V2, P203; VAINIKKA S, 1992, EMBO J, V11, P4273, DOI 10.1002/j.1460-2075.1992.tb05526.x; VALLES AM, 1990, P NATL ACAD SCI USA, V87, P1124, DOI 10.1073/pnas.87.3.1124; Wennstrom S, 1991, GROWTH FACTORS, V4, DOI 10.3109/08977199109104816; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x; ZHAN X, 1992, BIOCHEM BIOPH RES CO, V188, P982, DOI 10.1016/0006-291X(92)91328-N	39	25	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 9	1998	17	1					67	76		10.1038/sj.onc.1201908	http://dx.doi.org/10.1038/sj.onc.1201908			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZY936	9671315				2022-12-17	WOS:000074677800008
J	Tibiletti, MG; Trubia, M; Ponti, E; Sessa, L; Acquati, F; Furlan, D; Bernasconi, B; Fichera, M; Mihalich, A; Ziegler, A; Volz, A; Facco, C; Riva, C; Cremonesi, L; Ferrari, M; Taramelli, R				Tibiletti, MG; Trubia, M; Ponti, E; Sessa, L; Acquati, F; Furlan, D; Bernasconi, B; Fichera, M; Mihalich, A; Ziegler, A; Volz, A; Facco, C; Riva, C; Cremonesi, L; Ferrari, M; Taramelli, R			Physical map of the D6S149-D6S193 region on chromosome 6q27 and its involvement in benign surface epithelial ovarian tumours	ONCOGENE			English	Article						chromosome 6q27; physical map; YAC clones; deletion; benign ovarian tumors	LOW-GRADE; LONG ARM; HETEROZYGOSITY; TUMORS; CARCINOMAS; DELETION	A detailed long range restriction map of the region defined by markers D6S149 and D6S193 on chromosome 6q27 has been constructed, This was achieved by YAC cloning and contig assembling of the same region, Seven YAC clones were found to span the almost 1000 Kb region flanked by the two markers which on the genetic map resulted to be 1.9 cM apart, With some of the characterized YAC clones we undertook a molecular cytogenetic analysis of 20 benign ovarian tumors, The rationale for this was the recent mapping to a region of chromosome 6q27, flanked by markers D6281 and D6S133, of a locus for the SV40-mediated immortalization of human cells (SEN6 gene), Noteworthy we found that the the D6S149-D6S193 region (comprised in the larger D6S281-D6S133 physical interval) was altered in all samples analysed adding support to the occurrence of a immortalization step in this type of tumors.	Hosp San Raffaele, Lab Genet Base, I-20132 Milan, Italy; Univ Pavia, Dipartimento Patol, Varese, Italy; Osped Circolo Varese, Serv Anat Patol, Varese, Italy; IRCCS, Milan, Italy; Free Univ Berlin, Inst Expt Onkol & Transplantat Med, D-1000 Berlin, Germany	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Pavia; Free University of Berlin	Taramelli, R (corresponding author), Hosp San Raffaele, Lab Genet Base, Via Olgettina 60, I-20132 Milan, Italy.		Fichera, Marco/K-9220-2016; FURLAN, DANIELA/AAB-8271-2022; RIVA, CRISTINA/K-5063-2016	Fichera, Marco/0000-0002-8225-6880; FURLAN, DANIELA/0000-0002-5958-5379; Mihalich, Alessandra/0000-0002-1835-8241; RIVA, CRISTINA/0000-0001-9884-038X				Banga SS, 1997, ONCOGENE, V14, P313, DOI 10.1038/sj.onc.1200842; Cooke IE, 1996, GENE CHROMOSOME CANC, V15, P223, DOI 10.1002/(SICI)1098-2264(199604)15:4<223::AID-GCC4>3.3.CO;2-4; DalCin P, 1996, GENE CHROMOSOME CANC, V16, P68, DOI 10.1002/(SICI)1098-2264(199605)16:1<68::AID-GCC10>3.0.CO;2-H; DALPRA L, 1986, HUM REPROD, V12, P103; DIETRICH CU, 1995, INT J CANCER, V60, P49, DOI 10.1002/ijc.2910600107; FOULKES WD, 1993, BRIT J CANCER, V67, P551, DOI 10.1038/bjc.1993.101; IWABUCHI H, 1995, CANCER RES, V55, P6172; Liao F, 1997, GENOMICS, V40, P175, DOI 10.1006/geno.1996.4544; LIU E, 1995, J NATL CANCER I, V87, P1099, DOI 10.1093/jnci/87.15.1099; Mitelman F, 1995, ISCN INT SYSTEM HUMA; ORPHANOS V, 1995, BRIT J CANCER, V71, P666, DOI 10.1038/bjc.1995.132; SAITO S, 1992, CANCER RES, V52, P5815; Saito S, 1996, CANCER RES, V56, P5586; SALAZAR H, 1997, J NATL CANC, V188, P1810; SANDHU AK, 1994, P NATL ACAD SCI USA, V91, P5498, DOI 10.1073/pnas.91.12.5498; SATO T, 1991, CANCER RES, V51, P5188; Tibiletti MG, 1996, CANCER RES, V56, P4493; Trubia M, 1997, GENOMICS, V42, P342, DOI 10.1006/geno.1997.4679; WAN MH, 1994, INT J ONCOL, V5, P1043; WOLF NG, 1996, J PATHOL, P511; ZHENG J, 1995, J NATL CANC, V1, P1146; ZHENG JP, 1991, CANCER RES, V51, P4045	22	25	26	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 26	1998	16	12					1639	1642		10.1038/sj.onc.1201654	http://dx.doi.org/10.1038/sj.onc.1201654			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZD962	9569033				2022-12-17	WOS:000072743200016
J	Crook, T; Parker, GA; Rozycka, M; Crossland, S; Allday, MJ				Crook, T; Parker, GA; Rozycka, M; Crossland, S; Allday, MJ			A transforming p53 mutant, which binds DNA, transactivates and induces apoptosis reveals a nuclear : cytoplasmic shuttling defect	ONCOGENE			English	Article						nuclear; cytoplasmic shuttling; mutant p53; transformation	CELL-CYCLE ARREST; WILD-TYPE P53; TUMOR-SUPPRESSOR GENE; HUMAN B-CELLS; TRANSCRIPTIONAL ACTIVATION; IMMUNOCHEMICAL ANALYSIS; MONOCLONAL-ANTIBODIES; BREAST-CANCER; PROTEIN; LOCALIZATION	The DG75 Burkitt lymphoma-derived human B cell line is heterozygous for p53, carrying wild type (WT) and mutant (Arg283His) alleles, The cells constitutively express high levels of both p53 proteins and also Mdm2, Arg283His transactivates the p21(Waf1), Mdm2, bar, cyclin G and IGF-BP3 promoters in transient transfection assays equally as well as, if not better than WT p53. It also suppresses the outgrowth of SAOS-2 cells and specifically binds DNA like wild type protein, However, in primary rodent fibroblasts Arg283His fails to suppress transformation by HPV16-E7 and (Ha-)ras and even has modest transforming activity when transfected alone with (Ha-)ras, When Arg283His is transiently transfected into SAOS-2 cells it efficiently induces apoptosis, so - unlike mutants such as Arg175Pro - its behaviour in transformation assays does not clearly correlate with loss of the apoptosis function, Immunofluorescence staining of both REF transformants and transiently transfected SAOS-2 revealed that this unusual mutant becomes excluded from the nucleus and produces striking cytoplasmic fluorescence, The best correlation with transformation, therefore, appears to be the lack of nuclear retention of Arg283His, Since this mutation does not map to any known nuclear localization signal and its presence seems to result in aberrant exclusion from the nucleus, then it may prove very useful in exploring mechanisms involved in the nuclear:cytoplasmic shuttling of p53.	St Marys Hosp, Imperial Coll, Sch Med, Dept Virol, London W2 1PG, England; St Marys Hosp, Imperial Coll, Sch Med, Ludwig Inst Canc Res, London W2 1PG, England; Inst Canc Res, Haddow Labs, Surrey SM2 5NG, England	Imperial College London; Imperial College London; Ludwig Institute for Cancer Research; University of London; Institute of Cancer Research - UK	Allday, MJ (corresponding author), St Marys Hosp, Imperial Coll, Sch Med, Dept Virol, Praed St, London W2 1PG, England.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLDAY MJ, 1995, EMBO J, V14, P4994, DOI 10.1002/j.1460-2075.1995.tb00182.x; ALLDAY MJ, 1995, EMBO J, V14, P1382, DOI 10.1002/j.1460-2075.1995.tb07124.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHO Y, 1994, SCIENCE, V265, P246; CROOK T, 1991, J VIROL, V65, P505, DOI 10.1128/JVI.65.1.505-510.1991; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DANG CV, 1989, J BIOL CHEM, V264, P18019; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; DUTHU A, 1992, ONCOGENE, V7, P2161; EDWARDS RH, 1994, J VIROL, V68, P1309, DOI 10.1128/JVI.68.3.1309-1315.1994; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; Flamini G, 1996, EUR J CANCER, V32A, P802, DOI 10.1016/0959-8049(95)00625-7; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; GANNON JV, 1991, NATURE, V349, P802; GIADANO G, 1991, P NATL ACAD SCI USA, V88, P5413; Goldman SC, 1996, AM J PATHOL, V148, P1381; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HORAK E, 1991, ONCOGENE, V6, P2277; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LANDERS JE, 1994, ONCOGENE, V9, P2745; Lenoir GM, 1987, ADV VIRAL ONCOL, V7, P173; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Middeler G, 1997, ONCOGENE, V14, P1407, DOI 10.1038/sj.onc.1200949; MIYASHITA T, 1995, CELL, V80, P293; Moll UM, 1996, MOL CELL BIOL, V16, P1126; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OCONNOR PM, 1993, CANCER RES, V53, P4776; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OLTAVI ZN, 1993, CELL, V74, P609; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; Parker GA, 1996, ONCOGENE, V13, P2541; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; ROTTER V, 1983, EMBO J, V2, P1041, DOI 10.1002/j.1460-2075.1983.tb01543.x; ROVINSKI B, 1988, ONCOGENE, V2, P445; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Runnebaum IB, 1996, GYNECOL ONCOL, V61, P266, DOI 10.1006/gyno.1996.0137; Sambrook J, 1989, MOL CLONING LAB MANU; SEPEHRNIA B, 1996, J BIOL CHEM, V271, P15081; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SUN Y, 1993, P NATL ACAD SCI USA, V90, P2827, DOI 10.1073/pnas.90.7.2827; TAKAHASHI K, 1994, ONCOGENE, V9, P183; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; ZHAN QM, 1994, ONCOGENE, V9, P3743; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x	75	25	25	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 19	1998	16	11					1429	1441		10.1038/sj.onc.1201699	http://dx.doi.org/10.1038/sj.onc.1201699			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC383	9525742	Bronze			2022-12-17	WOS:000072572400007
J	Habano, W; Sugai, T; Nakamura, S				Habano, W; Sugai, T; Nakamura, S			Mismatch repair deficiency leads to a unique mode of colorectal tumorigenesis characterized by intratumoral heterogeneity	ONCOGENE			English	Article						mismatch repair gene; intratumoral heterogeneity; subpopulation analysis	NONPOLYPOSIS COLON-CANCER; POLYMERASE CHAIN-REACTION; CRYPT-ISOLATION TECHNIQUE; IN-SITU HYBRIDIZATION; MICROSATELLITE INSTABILITY; ALLELE LOSS; GENOMIC INSTABILITY; REPLICATION ERRORS; DNA CONTENT; GENE	In order to determine the effects of mismatch repair (MMR) deficiencies in sporadic colorectal carcinomas, 45 such cancers were examined using a sensitive method called crypt isolation technique, Loss of heterozygosity (LOH) in the MSH2 or MLH1 gene was more frequently observed in replication error (RER) (+) carcinomas than in RER (-) carcinomas, which implied that loss of one normal allele could partly affect repair capacity, MSH2 gene defects at both alleles were observed in two carcinomas, which showed severe repair deficiencies, Interestingly, unlike the situation observed in the p53 gene, the MSH2 and MLH1 genes did not show complete LOH, Novel crypt isolation-based subpopulation (CISP) analysis demonstrated that at least two distinct carcinoma subpopulations existed in most carcinomas that showed incomplete LOH; one with and one without LOH, In one carcinoma that had germline mutation and somatic incomplete LOH of the MSH2 gene, the mutator phenotype was only observed in populations affected in both alleles, Thus, the MSH2 gene appears to possess the two hits mechanism of tumor suppressor genes, However, unlike the tumor suppressor genes, MMR gene defects lead to a unique mode of colorectal tumorigenesis characterized by intratumoral heterogeneity.	Iwate Med Univ, Sch Med, Cent Clin Lab, Div Pathol, Morioka, Iwate 020, Japan	Iwate Medical University	Nakamura, S (corresponding author), Iwate Med Univ, Sch Med, Cent Clin Lab, Div Pathol, 19-1 Uchimaru, Morioka, Iwate 020, Japan.							AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Bocker T, 1996, J PATHOL, V179, P15; BOLAND CR, 1995, NAT MED, V1, P902, DOI 10.1038/nm0995-902; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CAWKWELL L, 1993, BRIT J CANCER, V67, P1262, DOI 10.1038/bjc.1993.236; CAWKWELL L, 1994, BRIT J CANCER, V70, P813, DOI 10.1038/bjc.1994.404; ENDO Y, 1995, PATHOL INT, V45, P602, DOI 10.1111/j.1440-1827.1995.tb03509.x; Eshleman JR, 1996, HUM MOL GENET, V5, P1489, DOI 10.1093/hmg/5.Supplement_1.1489; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GRIFFITHS DFR, 1988, NATURE, V333, P461, DOI 10.1038/333461a0; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; Habano W, 1996, LAB INVEST, V74, P933; HAHN M, 1995, BIOTECHNIQUES, V18, P1040; HEMMINKI A, 1994, NAT GENET, V8, P405, DOI 10.1038/ng1294-405; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JACOBY RF, 1995, GASTROENTEROLOGY, V109, P73, DOI 10.1016/0016-5085(95)90270-8; KIM HG, 1994, AM J PATHOL, V145, P148; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kobayashi M, 1996, AM J PATHOL, V149, P1575; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LIU B, 1994, CANCER RES, V54, P4590; LOTHE RA, 1993, CANCER RES, V53, P5849; Lu SL, 1996, JPN J CANCER RES, V87, P279, DOI 10.1111/j.1349-7006.1996.tb00218.x; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Moslein G, 1996, HUM MOL GENET, V5, P1245, DOI 10.1093/hmg/5.9.1245; NAKAMURA S, 1994, GASTROENTEROLOGY, V106, P100, DOI 10.1016/S0016-5085(94)94651-5; NAKAMURA S, 1993, GUT, V34, P1240, DOI 10.1136/gut.34.9.1240; NAN HJ, 1995, HUM MOL GENET, V4, P237, DOI 10.1093/hmg/4.2.237; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PAN LX, 1995, HISTOPATHOLOGY, V26, P201, DOI 10.1111/j.1365-2559.1995.tb01434.x; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1995, CANCER RES, V55, P5548; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Risinger JI, 1996, NAT GENET, V14, P102, DOI 10.1038/ng0996-102; RUSCHOFF J, 1995, VIRCHOWS ARCH, V426, P215; SASAKI K, 1988, CANCER, V62, P2569, DOI 10.1002/1097-0142(19881215)62:12<2569::AID-CNCR2820621220>3.0.CO;2-0; SAUTER G, 1994, AM J PATHOL, V144, P756; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Tomlinson IPM, 1996, BRIT J CANCER, V74, P1514, DOI 10.1038/bjc.1996.582; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; Yoshida T, 1996, J SURG ONCOL, V63, P9; YOUNG J, 1995, GENE CHROMOSOME CANC, V12, P251, DOI 10.1002/gcc.2870120403	44	25	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 12	1998	16	10					1259	1265		10.1038/sj.onc.1201651	http://dx.doi.org/10.1038/sj.onc.1201651			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA978	9546427				2022-12-17	WOS:000072422000004
J	Ohtsubo, M; Gamou, S; Shimizu, N				Ohtsubo, M; Gamou, S; Shimizu, N			Antisense oligonucleotide of WAF1 gene prevents EGF-induced cell-cycle arrest in A431 cells	ONCOGENE			English	Article						antisense oligonucleotide; EGF receptor; cell cycle; cyclin-dependent kinase inhibitor; tyrosine phosphorylation	EPIDERMAL GROWTH-FACTOR; SQUAMOUS CARCINOMA-CELLS; HUMAN-TUMOR CELLS; FACTOR RECEPTOR; TYROSINE PHOSPHORYLATION; P53-INDEPENDENT PATHWAY; EXPRESSION; INHIBITION; ACTIVATION; INDUCTION	A431 cells hyperproduce EGF receptors and possess inactive p53 proteins, It has been suggested that a cyclin-dependent kinase (CDK) inhibitor p21/WAF1 plays a crucial role in the EGF-induced cell-cycle arrest of A431 cells, Here, we investigated the role of WAF1 gene transcription in the EGF-induced cell-cycle arrest by transfecting the 18-mer antisense oligonucleotide which corresponds to the 5' region of WAF1 gene (AS/WAF1). When A431 cells were treated with EGF, a cascade of responses were observed, including immediate hyperphosphorylation of EGF receptor on tyrosine residues, accumulation of WAF1 mRNA and p21/WAF1 protein, dephosphorylation of RE protein which is a substrate of CDK-cyclin, and cell-cycle arrest, In the presence of ASI WAF1, EGF induced the tyrosine-phosphorylation of EGF receptor, but WAF1 mRNA was reduced to a half; accumulation of p21/WAF1 protein and its downstream responses were no longer observed; A431 cells grew continuously, Thus, the transfection of antisense efficiently prevented A431 cells from the EGF-induced arrest, These observations suggest that p21/WAF1 protein is a major effector molecule of the EGF-mediated cell-cycle arrest of A431 cells.	Keio Univ, Sch Med, Dept Mol Biol, Shinjuku Ku, Tokyo 160, Japan	Keio University	Shimizu, N (corresponding author), Keio Univ, Sch Med, Dept Mol Biol, Shinjuku Ku, 35 Shinanomachi, Tokyo 160, Japan.							BARLOGIE B, 1976, CANCER RES, V36, P1176; BARNES DW, 1982, J CELL BIOL, V93, P1, DOI 10.1083/jcb.93.1.1; BEHZADIAN MA, 1985, CELL STRUCT FUNCT, V10, P219, DOI 10.1247/csf.10.219; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; ENNIS BW, 1989, MOL ENDOCRINOL, V3, P1830, DOI 10.1210/mend-3-11-1830; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; FAN Z, 1994, J BIOL CHEM, V269, P27595; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GAMOU S, 1988, CELL STRUCT FUNCT, V13, P25, DOI 10.1247/csf.13.25; GAMOU S, 1995, FEBS LETT, V357, P161, DOI 10.1016/0014-5793(94)01335-X; GAMOU S, 1984, MOL CELL ENDOCRINOL, V37, P205; GILL GN, 1985, SOMAT CELL MOLEC GEN, V11, P309, DOI 10.1007/BF01534689; GILL GN, 1981, NATURE, V293, P305, DOI 10.1038/293305a0; Gulli LF, 1996, CELL GROWTH DIFFER, V7, P173; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; HARPER JW, 1993, CELL, V75, P805; HIRAI M, 1990, CELL SIGNAL, V2, P245, DOI 10.1016/0898-6568(90)90052-C; HIRAI M, 1990, CELL STRUCT FUNCT, V15, P191, DOI 10.1247/csf.15.191; HIRAI M, 1988, J CELL BIOL, V107, P791, DOI 10.1083/jcb.107.2.791; HUNTERS J, 1986, FEBS LETT, V206, P319, DOI 10.1016/0014-5793(86)81004-3; Jakus J, 1996, ONCOGENE, V12, P2369; KWOK TT, 1994, CANCER RES, V54, P2834; MICHIELI P, 1994, CANCER RES, V54, P3391; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; RUSSO T, 1995, J BIOL CHEM, V270, P29386, DOI 10.1074/jbc.270.49.29386; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; YAMADA H, 1989, EXP CELL RES, V184, P90, DOI 10.1016/0014-4827(89)90367-4; YAMAMOTO T, 1986, CANCER RES, V46, P414	33	25	26	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 12	1998	16	6					797	802		10.1038/sj.onc.1201588	http://dx.doi.org/10.1038/sj.onc.1201588			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YW403	9488044				2022-12-17	WOS:000071931800012
J	Feldman, BJ; Reid, TR; Cleary, ML				Feldman, BJ; Reid, TR; Cleary, ML			Pim1 cooperates with E2a-Pbx1 to facilitate the progression of thymic lymphomas in transgenic mice	ONCOGENE			English	Article						E2a-Pbx1; Pim1; lymphomagenesis; retroviral mutagenesis; progression	E-MU-MYC; PRE-B; DNA-BINDING; BONE-MARROW; C-MYC; LEUKEMIA; E2A; FUSION; PROTEINS; PBX1	Mice transgenic for the leukemia oncogene E2A-PBX1 invariably develop lethal, high-grade T-cell lymphomas by 5 months of age. In this study, retroviral insertional mutagenesis was employed to identify oncogenes that cooperate with the E2A-PBX1 transgene in lymphomagenesis. Neonatal retroviral infection substantially reduced length of survival due to accelerated development of lymphomas (81 versus 130 days). The Pim1 gene was targeted by retroviral insertions in 48% of accelerated lymphomas whereas less than 5% contained activated c-Myc and none contained activated Pim2. However, Pim1 DNA rearrangements were frequently sub-stoichiometric and not present at all sites of involvement in an otherwise monoclonal lymphoma indicating that Pim1 activation occurred late in the course of lymphomagenesis. Tumor subpopulations containing activated Pim1 alleles displayed a substantial growth advantage over Pim1 negative cells following serial transfer to secondary, syngeneic recipients. Cooperative interactions were observed in intercrossed Pim1 and E2A-PBX1 transgenic mice in which all double transgenic progeny developed lethal, diffuse T lineage lymphomas by 3 months of age, whereas only 13% of E2A-PBX1 and none of Pim1 single transgenic intercross progeny developed lymphomas by 1 year, Tumors from double transgenic mice were monoclonal providing evidence that additional genetic events were required for transformation, Therefore, Pim1 and E2a-Pbx1 cooperate in T lineage lymphomagenesis but they are not sufficient and the role of Pim1 is more likely to be associated with tumor progression.	STANFORD UNIV,MED CTR,DEPT PATHOL,STANFORD,CA 94305	Stanford University					NATIONAL CANCER INSTITUTE [R01CA042971, R37CA042971] Funding Source: NIH RePORTER; NCI NIH HHS [CA42971] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acton D, 1992, Curr Top Microbiol Immunol, V182, P293; ADAMS JM, 1992, CANCER SURV, V15, P119; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BERNS A, 1994, COLD SPRING HARB SYM, V59, P435, DOI 10.1101/SQB.1994.059.01.049; BERNS A, 1991, J CELL BIOCHEM, V47, P130, DOI 10.1002/jcb.240470206; BREUER M, 1989, NATURE, V340, P61, DOI 10.1038/340061a0; BREUER M, 1991, CANCER RES, V51, P958; Buckley AR, 1996, CELL GROWTH DIFFER, V7, P1713; Chang CP, 1997, MOL CELL BIOL, V17, P81, DOI 10.1128/MCB.17.1.81; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; CUYPERS HT, 1984, CELL, V37, P141; CUYPERS HTM, 1986, J VIROL, V60, P230, DOI 10.1128/JVI.60.1.230-241.1986; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; DOMEN J, 1993, LEUKEMIA, V7, pS108; DOMEN J, 1993, BLOOD, V82, P1445; DOMEN J, 1993, J EXP MED, V178, P1665, DOI 10.1084/jem.178.5.1665; Giordano V, 1997, J IMMUNOL, V158, P4097; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HOOVER D, 1991, J BIOL CHEM, V266, P14018; HUNGER SP, 1991, BLOOD, V77, P687; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Jonkers J, 1997, EMBO J, V16, P441, DOI 10.1093/emboj/16.3.441; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; KAMPS MP, 1994, ONCOGENE, V9, P3159; LEBRUN DP, 1994, ONCOGENE, V9, P1641; Liang H, 1996, ARCH BIOCHEM BIOPHYS, V330, P259, DOI 10.1006/abbi.1996.0251; LILLY M, 1992, ONCOGENE, V7, P727; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; MONICA K, 1994, MOL CELL BIOL, V14, P8304, DOI 10.1128/MCB.14.12.8304; MULI AL, 1996, EMBO J, V15, P2425; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; OFarrell AM, 1996, BLOOD, V87, P3655, DOI 10.1182/blood.V87.9.3655.bloodjournal8793655; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; Smith KS, 1997, ONCOGENE, V14, P2917, DOI 10.1038/sj.onc.1201249; SORENSEN IK, 1966, CARCINOGENESIS, V17, P2221; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; VANDERLUGT NMT, 1995, EMBO J, V14, P2536, DOI 10.1002/j.1460-2075.1995.tb07251.x; VANDERPUTTEN H, 1981, CELL, V24, P729, DOI 10.1016/0092-8674(81)90099-4; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	45	25	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 27	1997	15	22					2735	2742		10.1038/sj.onc.1201670	http://dx.doi.org/10.1038/sj.onc.1201670			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YH468	9401000				2022-12-17	WOS:A1997YH46800011
J	Linke, SP; Harris, MP; Neugebauer, SE; Clarkin, KC; Shepard, HM; Maneval, DC; Wahl, GM				Linke, SP; Harris, MP; Neugebauer, SE; Clarkin, KC; Shepard, HM; Maneval, DC; Wahl, GM			p53-mediated accumulation of hypophosphorylated pRb after the G(1) restriction point fails to halt cell cycle progression	ONCOGENE			English	Article						p53; pRb; restriction point; DNA damage; Glarrest	RETINOBLASTOMA GENE-PRODUCT; TUMOR-SUPPRESSOR GENE; HUMAN PAPILLOMAVIRUS TYPE-16; WILD-TYPE P53; DNA-BINDING; G1 PHASE; TRANSCRIPTIONAL ACTIVITY; SV40-TRANSFORMED CELLS; SUSCEPTIBILITY GENE; DEPENDENT KINASES	This study analyses whether the inability of p53 to induce G(1) arrest after the restriction point relates to an inability to modulate pRb phosphorylation. Transient p53 overexpression in normal human diploid fibroblasts and p53-deficient cancer cells led to increased levels of the cyclin-dependent kinase inhibitor p21(Cip1/Waf1/Sdi1) and an accumulation of hypophosphorylated pRb in cells growing asynchronously and in cells synchronized in late G(1) or M. Similarly, gamma-irradiation of asynchronous, late-G(1), or S phase fibroblasts led to an increase in hypophosphorylated pRb. Experiments with fibroblasts expressing the HPV16 E6 protein indicated that accumulation of hypophosphorylated pRb required functional p53. Progression into and through S phase was not altered by the presence of hypophosphorylated pRb in late G(1), consistent with the failure of p53 to mediate G(1) arrest in cells that are past the restriction point. These data indicate that accumulation of hypophosphorylated pRb has significantly different effects on cell cycle progression in early G(1) versus late G(1) or S phase.	SALK INST BIOL STUDIES, GENE EXPRESS LAB, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; CANJI INC, SAN DIEGO, CA 92121 USA	Salk Institute; University of California System; University of California San Diego				Linke, Steven/0000-0001-8584-4947				ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Di Leonardo A, 1997, CANCER RES, V57, P1013; DI LEONARDO A, 1993, COLD SPRING HARB SYM, V58, P655, DOI 10.1101/SQB.1993.058.01.073; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ETSCHEID BG, 1994, VIROLOGY, V205, P583, DOI 10.1006/viro.1994.1684; FAGAN R, 1994, CELL, V78, P799, DOI 10.1016/S0092-8674(94)90522-3; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HALBERT CL, 1992, J VIROL, V66, P2125, DOI 10.1128/JVI.66.4.2125-2134.1992; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Harris MP, 1996, CANCER GENE THER, V3, P121; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hecker D, 1996, ONCOGENE, V12, P953; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jones SN, 1996, P NATL ACAD SCI USA, V93, P14106, DOI 10.1073/pnas.93.24.14106; KASTAN MB, 1991, CANCER RES, V51, P6304; KHANNA KK, 1993, ONCOGENE, V8, P3307; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; LALANDE M, 1990, EXP CELL RES, V186, P332, DOI 10.1016/0014-4827(90)90313-Y; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LECHNER MS, 1994, J VIROL, V68, P4262, DOI 10.1128/JVI.68.7.4262-4273.1994; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Linke SP, 1997, CANCER RES, V57, P1171; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; McMasters KM, 1996, ONCOGENE, V13, P1731; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MOSCA PJ, 1992, MOL CELL BIOL, V12, P4375, DOI 10.1128/MCB.12.10.4375; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; OTTERSON GA, 1994, ONCOGENE, V9, P3375; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; RIEDER CL, 1992, J CELL SCI, V102, P387; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WEN SF, 1994, J IMMUNOL METHODS, V169, P231, DOI 10.1016/0022-1759(94)90267-4; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WILLS KN, 1995, CANCER GENE THER, V2, P191; WILLS KN, 1994, HUM GENE THER, V5, P1079, DOI 10.1089/hum.1994.5.9-1079; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	76	25	25	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	1997	15	3					337	345		10.1038/sj.onc.1201200	http://dx.doi.org/10.1038/sj.onc.1201200			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK999	9233768				2022-12-17	WOS:A1997XK99900010
J	Montano, X				Montano, X			p53 associates with trk tyrosine kinase	ONCOGENE			English	Article						trk and p53 association; PC12 differentiation; phosphorylation	NERVE GROWTH-FACTOR; AFFINITY NGF RECEPTOR; WILD-TYPE P53; DNA-REPLICATION; CELL-CYCLE; NEURONAL DIFFERENTIATION; SV40-TRANSFORMED CELLS; NEUROTROPHIN RECEPTORS; PROTOONCOGENE PRODUCT; TRANSFORMED-CELLS	The p53 tumor suppressor gene encodes a phosphoprotein which when overexpressed can induce growth arrest at the G1 and G2/M phases of the cell cycle, promote differentiation and apoptosis. This paper demonstrates that p53 can associate with trk tyrosine kinase. Expression of a murine temperature-sensitive (ts) p53 mutant in PC12 cells overexpressing trk (a model system to analyse cellular differentiation and signal transduction induced by NGF) induces morphological changes in the absence of NGF stimulation at 32 degrees C but not at 37 degrees C. In cells differentiated by p53, trk, but not EGFr, was hyperphosphorylated on tyrosine. Furthermore trk was not phosphorylated when expressed in Saos-2 cells (human osteosarcoma cells that lack expression of both endogenous trk and p53) at either temperature. However, transfection of ts p53 into these cells induces trk phosphorylation at 32 degrees C in the absence of NGF stimulation. Association of trk and p53 can be detected in NIH3T3 and PC12 cells co-expressing trk and the ts p53 mutant, in NIH3T3 and PC12 cells transfected with trk alone, and in untransfected PC12 cells, showing that overexpressed and/or endogenous trk associates with endogenous, low levels of p53. These data suggest a novel function for p53 which involves the stimulation of signal transduction pathways (mediating morphological properties of cells), possibly through association with and hyperphosphorylation of trk.	IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	Cancer Research UK								ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BARBACID M, 1993, ONCOGENE, V8, P2033; BARBACID M, 1993, TRK FAMILY NEUROTROP; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BASU T, 1994, ONCOGENE, V9, P3483; BERG MM, 1992, J BIOL CHEM, V267, P13; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; COFFER AI, 1994, BIOCHIM BIOPHYS ACTA, V1119, P11; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GANNON JV, 1991, NATURE, V349, P802; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GREEN SH, 1986, J BIOL CHEM, V261, P5316; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HALEGOUA S, 1991, CURR TOP MICROBIOL, V165, P119; HANTZOPOULOS PA, 1994, NEURON, V13, P187, DOI 10.1016/0896-6273(94)90469-3; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; Harlow E LD, 1988, ANTIBODIES LAB MANUA; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; Knippschild U, 1996, ONCOGENE, V12, P1755; KNUSEL B, 1992, J NEUROCHEM, V59, P715, DOI 10.1111/j.1471-4159.1992.tb09427.x; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lane DP, 1996, ONCOGENE, V12, P2461; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LOEB DM, 1992, NEURON, V9, P1053, DOI 10.1016/0896-6273(92)90065-L; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NYE SH, 1992, MOL BIOL CELL, V3, P677, DOI 10.1091/mbc.3.6.677; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; POSSENTI R, 1989, EMBO J, V8, P2217, DOI 10.1002/j.1460-2075.1989.tb08345.x; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; SATHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605; SEHGAL PB, 1993, ONCOGENE, V8, P3417; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; STEPHENS RM, 1994, NEURON, V1, P1; TAPLEY P, 1992, ONCOGENE, V7, P371; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; WOLF DE, 1995, J BIOL CHEM, V270, P2133, DOI 10.1074/jbc.270.5.2133; YAN GZ, 1995, J NEUROSCI, V15, P6200; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZERRAHN J, 1992, ONCOGENE, V7, P1371	78	25	28	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	1997	15	3					245	256		10.1038/sj.onc.1201215	http://dx.doi.org/10.1038/sj.onc.1201215			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK999	9233759				2022-12-17	WOS:A1997XK99900001
J	Worpenberg, S; Burk, O; Klempnauer, KH				Worpenberg, S; Burk, O; Klempnauer, KH			The chicken adenosine receptor 2B gene is regulated by v-myb	ONCOGENE			English	Article						v-myb; oncogene; target gene; differential display; A2b adenosine receptor	C-MYB; CELL-LINES; MIM-1 GENE; MYELOMONOCYTIC CELLS; DIFFERENTIAL DISPLAY; DIFFERENT MECHANISMS; TRANS-ACTIVATION; NF-M; EXPRESSION; ONCOGENE	The retroviral oncogene v-myb is a mutated and truncated version of the c-myb proto-oncogene and encodes a transcription factor (v-Myb) that specifically transforms myelomonocytic cells. v-Myb is thought to transform myelomonocytic cells by affecting the expression of specific target genes, most of which as yet remain unknown. To identify novel v-Myb regulated genes we have employed 'differential display', using a myelomonocytic chicken cell line that expresses a conditional version of v-Myb. Here me describe the identification of the gene encoding the A2b adenosine receptor, a member of the seven transmembrane receptor superfamily, as a v-Myb target gene. Our results provide the first evidence that v-Myb directly regulates a gene encoding a membrane receptor and establish a link between Myb function and adenosine receptor signaling.	MAX PLANCK INST IMMUNBIOL,HANS SPEMANN LAB,D-79108 FREIBURG,GERMANY; UNIV FREIBURG,KINDERKLIN,D-79106 FREIBURG,GERMANY	Max Planck Society; University of Freiburg								AKIYAMA Y, 1974, BIKEN J, V17, P105; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOUMA MG, 1994, J IMMUNOL, V153, P4159; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; CHEN LC, 1983, MOL CELL BIOL, V3, P1077, DOI 10.1128/MCB.3.6.1077; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DESBIENS X, 1991, DEVELOPMENT, V111, P699; EPPELL BA, 1989, J IMMUNOL, V143, P4141; FRAMPTON J, 1993, EMBO J, V12, P1333, DOI 10.1002/j.1460-2075.1993.tb05778.x; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; GRISHAM MB, 1989, AM J PHYSIOL, V257, pH1334, DOI 10.1152/ajpheart.1989.257.5.H1334; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; JURGENSEN CH, 1990, J IMMUNOL, V144, P653; KATZ S, 1993, EMBO J, V12, P1321, DOI 10.1002/j.1460-2075.1993.tb05777.x; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; LEONARD MW, 1993, DEVELOPMENT, V119, P519; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; MARQUARDT DL, 1984, J IMMUNOL, V133, P932; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; Mink S, 1996, MOL CELL BIOL, V16, P1316; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; PARMELY MJ, 1993, J IMMUNOL, V151, P389; PLAZA S, 1995, ONCOGENE, V10, P329; QUEVA C, 1992, DEVELOPMENT, V114, P125; SALMON JE, 1993, J IMMUNOL, V151, P2775; Sitzmann J, 1995, ONCOGENE, V11, P2273; STERNECK E, 1992, J BIOL CHEM, V267, P6451; STILES GL, 1992, J BIOL CHEM, V267, P6451; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; THIELE CJ, 1987, J CLIN INVEST, V80, P804, DOI 10.1172/JCI113137; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TRUEB B, 1988, NUCLEIC ACIDS RES, V16, P4723, DOI 10.1093/nar/16.10.4723; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	48	25	26	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 10	1997	15	2					213	221		10.1038/sj.onc.1201179	http://dx.doi.org/10.1038/sj.onc.1201179			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK372	9244356				2022-12-17	WOS:A1997XK37200009
J	Nehyba, J; Hrdlickova, R; Bose, HR				Nehyba, J; Hrdlickova, R; Bose, HR			Differences in kappa B DNA-binding properties of v-Rel and c-Rel are the result of oncogenic mutations in three distinct functional regions of the Rel protein	ONCOGENE			English	Article						v-Rel; c-Rel; DNA binding; oncogene; NF-kappa B	CHICKEN SPLEEN-CELLS; VIRUS STRAIN-T; RETICULOENDOTHELIOSIS VIRUS; TRANSCRIPTIONAL ACTIVATION; CYTOPLASMIC RETENTION; EMBRYO FIBROBLASTS; AMINO-ACIDS; RECOGNITION SEQUENCE; GENE-EXPRESSION; HOMOLOGY DOMAIN	The oncogene v-rel of Reticuloendotheliosis virus, strain T, is derived from an avian c-rel proto-oncogene, c-rel encodes a member of the Rel/NF-kappa B family of transcription factors, The highly oncogenic v-Rel differs from c-Rel which has low transforming potential by the acquisition of numerous mutations, In this manuscript, we demonstrate that the oncogenic mutations in v-Rel directly alter the ability of this protein to bind to DNA, Electrophoretic mobility shift analysis with Rel proteins synthesized in vitro as well as isolated from nuclei of Rel expressing cells showed that three mutation clusters, present in the N-terminus, the center and the C-terminus of v-Rel, altered three different aspects of DNA binding, In contrast, the oncogenic C-terminal deletion of 118 amino acids present in v-Rel had almost no influence on its DNA binding. The N-terminal mutation cluster altered the kappa B DNA-binding specificity of the v-Rel oncoprotein relative to c-Rel. The mutation Met-20-->Thr was found to be principally responsible for this alteration, The second mutation cluster was responsible for increased binding of v-Rel to all the KB sites examined presumably because it stabilized v-Rel homodimers, This alteration in DNA binding was mapped to the group of two mutations within the cluster, In contrast, the third mutation cluster in the C-terminus of v-Rel destabilized the binding of v-Rel to all of the kappa B sites examined, This is the first indication that regions outside the Rel Homology Region can participate in the control of binding of the c-Rel protein to DNA, The three mutation clusters examined contributed to the tumorigenic potential of v-Rel with the relative strength decreasing with their position from the N-terminus to the C-terminus, These results suggest that the oncogenic mutations in v-Rel cooperate and enable v-Rel to form nuclear complexes with aberrant DNA-binding properties that may directly alter gene expression and DNA replication resulting in the transformation of the cell.	UNIV TEXAS, DEPT MICROBIOL, AUSTIN, TX 78712 USA; UNIV TEXAS, CELL RES INST, AUSTIN, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin					NATIONAL CANCER INSTITUTE [R01CA033192] Funding Source: NIH RePORTER; NCI NIH HHS [CA33192] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; BABA TW, 1985, VIROLOGY, V144, P139, DOI 10.1016/0042-6822(85)90312-5; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BALTIMORE D, 1995, NATURE, V373, P287, DOI 10.1038/373287a0; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BHAT GV, 1990, ONCOGENE, V5, P625; BOEHMELT G, 1992, EMBO J, V11, P4641, DOI 10.1002/j.1460-2075.1992.tb05566.x; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BREITMAN ML, 1980, VIROLOGY, V100, P450, DOI 10.1016/0042-6822(80)90535-8; BRESSLER P, 1993, J VIROL, V67, P288, DOI 10.1128/JVI.67.1.288-293.1993; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CAPOBIANCO AJ, 1991, ONCOGENE, V6, P2203; Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN HW, 1993, MOL CELL BIOL, V13, P2366, DOI 10.1128/MCB.13.4.2366; CHEN ISY, 1982, CELL, V31, P111, DOI 10.1016/0092-8674(82)90410-X; Chytil M, 1996, CURR OPIN STRUC BIOL, V6, P91, DOI 10.1016/S0959-440X(96)80100-X; COLEMAN TA, 1993, MOL CELL BIOL, V13, P3850, DOI 10.1128/MCB.13.7.3850; DIEHL JA, 1993, MOL CELL BIOL, V13, P1769, DOI 10.1128/MCB.13.3.1769; DOBRZANSKI P, 1993, MOL CELL BIOL, V13, P1572, DOI 10.1128/MCB.13.3.1572; DOERRE S, 1993, P NATL ACAD SCI USA, V90, P1023, DOI 10.1073/pnas.90.3.1023; ERNST MK, 1995, MOL CELL BIOL, V15, P872; FILARDO EJ, 1994, VIROLOGY, V202, P116, DOI 10.1006/viro.1994.1328; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; GANCHI PA, 1993, MOL CELL BIOL, V13, P7826, DOI 10.1128/MCB.13.12.7826; GARSON K, 1990, VIROLOGY, V177, P106, DOI 10.1016/0042-6822(90)90464-3; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GILMORE TD, 1995, FRONTIERS MOL BIOL E, P1204; GILMORE TD, 1995, DNA PROVIRUS H TEMIN, P105; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HANNINK M, 1990, ONCOGENE, V5, P1843; HOELZER JD, 1979, VIROLOGY, V93, P20, DOI 10.1016/0042-6822(79)90272-1; HRDLICKOVA R, 1995, J VIROL, V69, P403; HRDLICKOVA R, 1995, J VIROL, V69, P3369; HRDLICKOVA R, 1994, J VIROL, V68, P308; HRDLICKOVA R, 1994, J VIROL, V68, P2371; IKEDA T, 1993, GENE, V133, P237, DOI 10.1016/0378-1119(93)90645-J; ISHIKAWA H, 1993, ONCOGENE, V8, P2889; KABRUN N, 1991, P NATL ACAD SCI USA, V88, P1783, DOI 10.1073/pnas.88.5.1783; KABRUN N, 1990, MOL CELL BIOL, V10, P4788, DOI 10.1128/MCB.10.9.4788; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KOCHEL T, 1992, ONCOGENE, V7, P567; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KRALOVA J, 1994, J VIROL, V68, P2073, DOI 10.1128/JVI.68.4.2073-2083.1994; KROEMER G, 1990, IMMUNOGENETICS, V31, P405, DOI 10.1007/BF02115020; KUMAR S, 1993, P NATL ACAD SCI USA, V90, P8962, DOI 10.1073/pnas.90.19.8962; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; LEWIS RB, 1981, CELL, V25, P421, DOI 10.1016/0092-8674(81)90060-X; LIPTAY S, 1994, MOL CELL BIOL, V14, P7695, DOI 10.1128/MCB.14.12.7695; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; LU D, 1991, ONCOGENE, V6, P1235; MOORE BE, 1988, VIROLOGY, V162, P377, DOI 10.1016/0042-6822(88)90478-3; MORRISON LE, 1992, ONCOGENE, V7, P1137; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; MOSIALOS G, 1993, ONCOGENE, V8, P721; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; NEHYBA J, 1994, J VIROL, V68, P2039, DOI 10.1128/JVI.68.4.2039-2050.1994; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; OHMORI Y, 1994, J BIOL CHEM, V269, P17684; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; ROBINSON FR, 1974, AVIAN DIS, V18, P278, DOI 10.2307/1589142; ROMERO P, 1995, J VIROL, V69, P301, DOI 10.1128/JVI.69.1.301-307.1995; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SARKAR S, 1993, ONCOGENE, V8, P2245; SCHATZLE JD, 1995, J VIROL, V69, P5383, DOI 10.1128/JVI.69.9.5383-5390.1995; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIF S, 1994, J VIROL, V68, P7131, DOI 10.1128/JVI.68.11.7131-7138.1994; SIF S, 1993, J VIROL, V67, P7612, DOI 10.1128/JVI.67.12.7612-7617.1993; STOKER AW, 1987, J GEN VIROL, V68, P2481, DOI 10.1099/0022-1317-68-9-2481; SYLLA BS, 1986, MOL CELL BIOL, V6, P4709, DOI 10.1128/MCB.6.12.4709; TOLEDANO MB, 1993, MOL CELL BIOL, V13, P852, DOI 10.1128/MCB.13.2.852; TONY Y, 1995, CURR BIOL, V5, P1; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WHITE DW, 1993, J VIROL, V67, P6876, DOI 10.1128/JVI.67.11.6876-6881.1993; WHITE DW, 1995, ONCOGENE, V10, P857; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; XU X, 1993, MOL CELL BIOL, V13, P6733, DOI 10.1128/MCB.13.11.6733; Zhang GQ, 1996, ONCOGENE, V12, P1153; ZHANG GQ, 1995, MOL CELL BIOL, V15, P1806	93	25	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	1997	14	24					2881	2897		10.1038/sj.onc.1201150	http://dx.doi.org/10.1038/sj.onc.1201150			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XF555	9205096				2022-12-17	WOS:A1997XF55500003
J	Zatsepina, O; Braspenning, J; Robberson, D; Hajibagheri, MAN; Blight, KJ; Ely, S; Hibma, M; Spitkovsky, D; Trendelenburg, M; Crawford, L; Tommasino, M				Zatsepina, O; Braspenning, J; Robberson, D; Hajibagheri, MAN; Blight, KJ; Ely, S; Hibma, M; Spitkovsky, D; Trendelenburg, M; Crawford, L; Tommasino, M			The human papillomavirus type 16 E7 protein is associated with the nucleolus in mammalian and yeast cells	ONCOGENE			English	Article						HPV; E7 protein; cellular localisation; nucleolus; mammalian and yeast cells	RETINOBLASTOMA GENE-PRODUCT; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; TRANSCRIPTION FACTOR; NUCLEAR; E2F; LOCALIZATION; E7-PROTEIN; SEQUENCES; THIAMINE	In this study we show, by immunofluorescence and electron microscopy immune-gold labelling, that the major transforming protein of Human Papillomavirus type 16 E7 is associated with the nucleolus of cells derived from the HPV16-positive cervical carcinoma line CaSki. The E7 nucleolar staining appeared to be cell cycle dependent, being considerably reduced in the G(2) phase. The total level of the protein in the cell, however, remained constant during all phases, We also show that the cellular protein Rb1, which is targeted by E7, is localised in the nucleus and nucleolus in CaSki cells. Thus, it is possible that the presence of E7 in the nucleolus correlates with a hypothetical function(s) of Rb1 in this particular intranuclear compartment. The nucleolar localisation of HPV16 E7 protein was also observed in the fission yeast Schizosaccharomyces pombe, suggesting that a targeting mechanism of HPV16 E7 protein into the nucleolus is common to both mammalian and yeast systems, Nucleolar localisation of HPV16 E7 protein may be independent from Rb1 since no Rb1 related proteins have been identified in fission yeast.	DEUTSCH KREBSFORSCHUNGSZENTRUM, ANGEW TUMORVIROL, D-69120 HEIDELBERG, GERMANY; IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND; DEUTSCH KREBSFORSCHUNGSZENTRUM, BIOMED STRUKTURFORSCH, D-69120 HEIDELBERG, GERMANY; ST MARYS HOSP, SCH MED, WRIGHT FLEMING INST, DEPT MED MICROBIOL, LONDON W2 1PG, ENGLAND; UNIV OTAGO, DEPT MICROBIOL, HRC VIRUS RES UNIT, DUNEDIN, NEW ZEALAND	Helmholtz Association; German Cancer Research Center (DKFZ); Cancer Research UK; Helmholtz Association; German Cancer Research Center (DKFZ); Imperial College London; University of Otago			Zatsepina, Olga/O-8753-2015; Spitkovsky, Dimitry/ABA-1605-2020	Zatsepina, Olga/0000-0001-5114-1127; 				BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CICCOLINI F, 1994, ONCOGENE, V9, P2633; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; COCHRANE AW, 1990, J VIROL, V64, P881, DOI 10.1128/JVI.64.2.881-885.1990; DANG CV, 1989, J BIOL CHEM, V264, P18019; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DEFEOJONES D, 1993, J VIROL, V67, P716, DOI 10.1128/JVI.67.2.716-725.1993; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; GREENFIELD I, 1991, P NATL ACAD SCI USA, V88, P11217, DOI 10.1073/pnas.88.24.11217; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; HU TH, 1995, INT J ONCOL, V6, P167; JEWERS RJ, 1992, J VIROL, V66, P1329, DOI 10.1128/JVI.66.3.1329-1335.1992; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; MANSUR CP, 1993, BIOCHIM BIOPHYS ACTA, V1155, P323, DOI 10.1016/0304-419X(93)90013-3; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MORENO S, 1991, METHOD ENZYMOL, V194, P795; PHELPS WC, 1991, J VIROL, V65, P6922, DOI 10.1128/JVI.65.12.6922-6930.1991; SATO H, 1989, VIROLOGY, V170, P311, DOI 10.1016/0042-6822(89)90386-3; SCHEER U, 1994, CURR OPIN CELL BIOL, V6, P354, DOI 10.1016/0955-0674(94)90026-4; SCHMIDTZACHMANN MS, 1993, J CELL SCI, V105, P799; SCHMITT A, 1994, J VIROL, V68, P7051, DOI 10.1128/JVI.68.11.7051-7059.1994; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SMOTKIN D, 1987, J VIROL, V61, P1686, DOI 10.1128/JVI.61.5.1686-1689.1987; TOMMASINO M, 1993, ONCOGENE, V8, P195; TOMMASINO M, 1995, BIOESSAYS, V17, P509, DOI 10.1002/bies.950170607; TOMMASINO M, 1990, GENE, V93, P265, DOI 10.1016/0378-1119(90)90234-I; TOMMASINO M, 1991, CURR GENET, V20, P63, DOI 10.1007/BF00312766; TOMMASINO M, 1992, GENE, V111, P93, DOI 10.1016/0378-1119(92)90607-Q	34	25	27	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	1997	14	10					1137	1145		10.1038/sj.onc.1200946	http://dx.doi.org/10.1038/sj.onc.1200946			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121762				2022-12-17	WOS:A1997WM78200002
J	Shu, JY; Hitomi, M; Stacey, D				Shu, JY; Hitomi, M; Stacey, D			Activation of JNK/SAPK pathway is not directly inhibitory for cell cycle progression in NIH3T3 cells	ONCOGENE			English	Article						JNK; SAPK; kinase; cell cycle; growth inhibition; c-jun	NERVE GROWTH-FACTOR; PROTEIN-KINASE ACTIVATION; SIGNAL-TRANSDUCTION PATHWAYS; DNA-DAMAGING AGENTS; C-JUN; TYROSINE KINASE; PC12 CELLS; TRANSCRIPTION FACTOR; RAS ACTIVITY; MITOGEN	In this study the induction of stress activated protein kinase (SAPK) activity by protein synthesis inhibitors was shown not to inhibit cellular proliferation. Anisomycin induced strong SAPK activity at non-inhibitory concentrations for either protein or DNA synthesis, while the other two inhibitors, emetine and cycloheximide, blocked cell cycle progression without strong SAPK induction. With all three inhibitors, the induction of SAPK activity was always accompanied by protein synthesis inhibition to some extent. Stimulation of mRNA expression of the genes c-jun, c-fos and c-myc correlated well with SAPK induction, but not with cell cycle inhibition. With concentrations of each inhibitor able to block DNA synthesis, no induction of message for the cyclin dependent kinase inhibitor waf-1 was observed;,while induction of gadd45 message indicated that the cells might be responding to growth-arrest or DNA damage. The inability of microinjected E2F/DP1 transcription factor proteins to overcome the inhibition of DNA synthesis induced by protein synthesis inhibitors indicate that blockage of an early event in cell cycle progression had occurred. These results indicate that the SAPK induction by protein synthesis inhibitors has no proliferative consequences.	CLEVELAND CLIN FDN,RES INST,DEPT MOL BIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation					NCI NIH HHS [CA53496] Funding Source: Medline; NIGMS NIH HHS [GM52271] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053496] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BERNSTEIN LR, 1994, J BIOL CHEM, V269, P9401; BIRD TA, 1994, J BIOL CHEM, V269, P31836; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; Cano E, 1996, ONCOGENE, V12, P805; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CONRAD KE, 1994, MOL CELL BIOL, V14, P1553, DOI 10.1128/MCB.14.3.1553; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; CREUZET C, 1995, J NEUROCHEM, V64, P1541; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DOBROWOLSKI S, 1994, MOL CELL BIOL, V14, P5441, DOI 10.1128/MCB.14.8.5441; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; ENGLARO W, 1995, J BIOL CHEM, V270, P24315, DOI 10.1074/jbc.270.41.24315; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Franklin CC, 1995, ONCOGENE, V11, P2365; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; Graves LM, 1996, J BIOL CHEM, V271, P505, DOI 10.1074/jbc.271.1.505; HARPER JW, 1993, CELL, V75, P805; Heasley LE, 1996, MOL CELL BIOL, V16, P648; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; Hitomi M, 1996, J BIOL CHEM, V271, P9376, DOI 10.1074/jbc.271.16.9376; HOWE PH, 1993, J BIOL CHEM, V268, P21448; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; KRACHT M, 1994, J EXP MED, V180, P2017, DOI 10.1084/jem.180.6.2017; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; KYRIAKIS JM, 1991, J BIOL CHEM, V266, P10043; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; Latinis KM, 1996, BLOOD, V87, P871, DOI 10.1182/blood.V87.3.871.bloodjournal873871; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LUBINUS M, 1994, J BIOL CHEM, V269, P9822; MAHADEVAN LC, 1991, NATURE, V349, P747, DOI 10.1038/349747c0; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PERALDI P, 1993, ENDOCRINOLOGY, V132, P2578, DOI 10.1210/en.132.6.2578; POMBO CM, 1994, J BIOL CHEM, V269, P26546; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; ROSSOW PW, 1979, P NATL ACAD SCI USA, V76, P4446, DOI 10.1073/pnas.76.9.4446; SA G, 1995, J BIOL CHEM, V270, P2360, DOI 10.1074/jbc.270.5.2360; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SHU JY, 1994, CELL IMMUNOL, V159, P170, DOI 10.1006/cimm.1994.1305; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; XU SC, 1995, P NATL ACAD SCI USA, V92, P6808, DOI 10.1073/pnas.92.15.6808; YAN MH, 1994, NATURE, V372, P798; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; ZHENG CF, 1993, J BIOL CHEM, V268, P23933; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	74	25	25	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2421	2430						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957084				2022-12-17	WOS:A1996VX10800015
J	BaierBitterlich, G; Baier, G; Fuchs, D; Bock, G; Hausen, A; Utermann, G; Pavelka, M; Wachter, H				BaierBitterlich, G; Baier, G; Fuchs, D; Bock, G; Hausen, A; Utermann, G; Pavelka, M; Wachter, H			Role of 7,8-dihydroneopterin in T-cell apoptosis and HTLV-1 transcription in vitro	ONCOGENE			English	Article						HTLV infection; apoptosis; neopterin; 7,8-dihydroneopterin; HTLV LTR; reactive oxygen intermediates	VIRUS TYPE-I; NF-KAPPA-B; LUMINOL-DEPENDENT CHEMILUMINESCENCE; INTERFERON-GAMMA; OXIDATIVE STRESS; REACTIVE OXYGEN; TRANSACTIVATOR TAX; HIV-INFECTION; NEOPTERIN; LEUKEMIA	Adult T-cell leukemia is associated with high levels of neopterin, released in large amounts from human macrophages upon stimulation with interferon-gamma. Recent data suggested a potential role of neopterin-derivatives in oxygen radical-mediated processes, and evidence accumulates that oxidative stress is involved in the pathogenesis of viral diseases. We now report that increased concentrations of 7,8-dihydroneopterin may lead to enhanced apoptosis and disturbance of the redox-balance of human leukemic Jurkat T cells. Additionally, we demonstrate that 7,8-dihydroneopterin and hydrogen peroxide activate the type 1 human T-cell leukemia virus (HTLV-1) long terminal repeat (LTR). Furthermore, we found that the activity of the HTLV-1 transactivator protein Tax is amplified by an elevated concentration of 7,8-dihydroneopterin. Tax did not significantly augment 7,8-dihydroneopterin mediated apoptosis. Based on our data we propose that 7,8-dihydroneopterin may be involved in the progression to higher stages of HTLV-1 associated disease.	UNIV INNSBRUCK, LUDWIG BOLTZMANN INST AIDS RES, A-6020 INNSBRUCK, AUSTRIA; UNIV INNSBRUCK, INST MED BIOL & HUMAN GENET, A-6020 INNSBRUCK, AUSTRIA; UNIV INNSBRUCK, INST EXPT PATHOL, A-6020 INNSBRUCK, AUSTRIA; UNIV INNSBRUCK, INST HISTOL & EMBRYOL, A-6020 INNSBRUCK, AUSTRIA	Ludwig Boltzmann Institute; University of Innsbruck; University of Innsbruck; University of Innsbruck; University of Innsbruck	BaierBitterlich, G (corresponding author), UNIV INNSBRUCK, INST MED CHEM & BIOCHEM, FRITZ PREGL STR 3, A-6020 INNSBRUCK, AUSTRIA.		Fuchs, Dietmar/AAL-8011-2021; Baier, Gottfried/E-8755-2012	Fuchs, Dietmar/0000-0003-1627-9563; Baier, Gottfried/0000-0002-2085-8325				BAIERBITTERELIC.G, IN PRESS AIDS RES HU; BAIERBITTERLICH G, 1995, FEBS LETT, V364, P234, DOI 10.1016/0014-5793(95)00403-V; BAIERBITTERLICH G, 1994, ONCOGENE, V9, P319; BAIERBITTERLICH G, IN PRESS AIDS RES HU; BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; BILLIAU A, 1990, BIOCHEM PHARMACOL, V40, P1433, DOI 10.1016/0006-2952(90)90437-P; BITTERLICH G, 1988, IMMUNOBIOLOGY, V176, P228, DOI 10.1016/S0171-2985(88)80055-X; CHLICHLIA K, 1995, ONCOGENE, V10, P269; CRAWFORD D, 1988, ONCOGENE, V3, P27; DAEFLER S, 1991, MOL F ONCOLOGY, P229; DATTA R, 1992, BIOCHEMISTRY-US, V31, P8300, DOI 10.1021/bi00150a025; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FORREST VJ, 1994, FREE RADICAL BIO MED, V16, P675, DOI 10.1016/0891-5849(94)90182-1; FUCHS D, 1988, IMMUNOL TODAY, V9, P150, DOI 10.1016/0167-5699(88)91203-0; FUCHS D, 1989, CLIN CHEM, V35, P2305; FUCHS D, 1994, IMMUNOL TODAY, V15, P496, DOI 10.1016/0167-5699(94)90197-X; FUJII N, 1992, MICROBIOL IMMUNOL, V36, P425, DOI 10.1111/j.1348-0421.1992.tb02041.x; FUJISAWA J, 1989, J VIROL, V63, P3234, DOI 10.1128/JVI.63.8.3234-3239.1989; GREEN PL, 1990, FASEB J, V4, P169, DOI 10.1096/fasebj.4.2.2404818; GREENSPAN HC, 1994, IMMUNOL TODAY, V15, P209, DOI 10.1016/0167-5699(94)90245-3; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HUBER C, 1984, J EXP MED, V160, P310, DOI 10.1084/jem.160.1.310; KLEBANOFF SJ, 1992, INFLAMMATION BASIC P; MERL S, 1984, BLOOD, V64, P967; MEYER M, 1994, CHEM-BIOL INTERACT, V91, P91, DOI 10.1016/0009-2797(94)90029-9; MURR C, 1994, FEBS LETT, V338, P223, DOI 10.1016/0014-5793(94)80369-2; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POMERANTZ RJ, 1990, J EXP MED, V172, P253, DOI 10.1084/jem.172.1.253; REIBNEGGER G, 1995, FREE RADICAL BIO MED, V18, P515, DOI 10.1016/0891-5849(94)00164-F; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J VIROL, V66, P6288, DOI 10.1128/JVI.66.11.6288-6293.1992; SGONC R, 1994, TRENDS GENET, V10, P41, DOI 10.1016/0168-9525(94)90140-6; SGONC R, 1994, INT ARCH ALLERGY IMM, V105, P327, DOI 10.1159/000236777; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; TAN TH, 1989, J VIROL, V63, P3761, DOI 10.1128/JVI.63.9.3761-3768.1989; UBERALL F, 1994, FEBS LETT, V352, P11, DOI 10.1016/0014-5793(94)00899-X; WACHTER H, 1989, ADV CLIN CHEM, V27, P81, DOI 10.1016/S0065-2423(08)60182-1; WACHTER H, 1979, H-S Z PHYSIOL CHEM, V360, P1957; Wachter H, 1992, NEOPTERIN BIOCH METH, V10, P289; WEISS G, 1993, FEBS LETT, V321, P89, DOI 10.1016/0014-5793(93)80627-7; WERNER ER, 1989, BIOCHEM J, V262, P861, DOI 10.1042/bj2620861; WERNER ER, 1990, J BIOL CHEM, V265, P3189; WESTENDORP MO, 1995, EMBO J, V14, P546, DOI 10.1002/j.1460-2075.1995.tb07030.x; WONGSTAAL F, 1985, NATURE, V317, P395, DOI 10.1038/317395a0; YODOI J, 1992, IMMUNOL TODAY, V13, P405, DOI 10.1016/0167-5699(92)90091-K; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; YOUNG HA, 1990, PHARMACOL THERAPEUT, V45, P137, DOI 10.1016/0163-7258(90)90012-Q	50	25	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	1996	13	10					2281	2285						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950996				2022-12-17	WOS:A1996VV14500026
J	Kim, YW; Wang, HY; Sures, I; Lammers, R; Martell, KJ; Ullrich, A				Kim, YW; Wang, HY; Sures, I; Lammers, R; Martell, KJ; Ullrich, A			Characterization of the PEST family protein tyrosine phosphatase BDP1	ONCOGENE			English	Article						protein tyrosine phosphatase; PEST sequence; growth factor receptor phosphatase	CHROMOSOMAL LOCALIZATION; HUMAN-PLACENTA; GENE; CLONING; SEQUENCES; REGION; CELLS; CAP	Using a polymerase chain reaction (PCR) amplication strategy, we identified a novel protein tyrosine phosphatase (PTPase) designated Brain Derived Phosphatase (BDP1). The full length sequence encoded an open reading frame of 459 amino acids with no transmembrane domain and had a calculated molecular weight of 50 kDa. The predicted amino acid sequence contained a PEST motif and accordingly, BDP1 shared the greatest homology with members of the PTP-PEST family. When transiently expressed in 293 cells BDP1 hydrolyzed p-Nitrophenylphosphate, confirming it as a functional protein tyrosine phosphatase. Northern blot analysis indicated that BDP1 was expressed not only in brain, but also in colon and several different tumor-derived cell lines. Furthermore, BDP1 was found to differentially dephosphorylate autophosphorylated tyrosine kinases which are known to be overexpressed in tumor tissues.	MAX PLANCK INST BIOCHEM,DEPT MOL BIOL,D-82152 MARTINSRIED,GERMANY	Max Planck Society			Wang, Hongyang/B-1340-2010					BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; BROWNSHIMER S, 1990, P NATL ACAD SCI USA, V87, P5148, DOI 10.1073/pnas.87.13.5148; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; FIELD J, 1990, CELL, V61, P319, DOI 10.1016/0092-8674(90)90812-S; KAPPES D, 1988, ANNU REV BIOCHEM, V57, P991, DOI 10.1146/annurev.bi.57.070188.005015; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAFORGIA S, 1991, P NATL ACAD SCI USA, V88, P5036, DOI 10.1073/pnas.88.11.5036; LOGAN J, 1987, P NATL ACAD SCI USA, V84, P8306, DOI 10.1073/pnas.84.23.8306; MALISSEN M, 1983, SCIENCE, V221, P750, DOI 10.1126/science.6410508; MARTELL KJ, 1994, GENOMICS, V22, P462, DOI 10.1006/geno.1994.1411; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MATVIW H, 1992, MOL CELL BIOL, V12, P5033, DOI 10.1128/MCB.12.11.5033; MCLAUGHLIN S, 1993, J BIOL CHEM, V268, P6839; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SCHLESSINGER J, 1992, CELL, V9, P383; SELICOF A, 1993, J BIOL CHEM, V268, P13448; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; TAKEKAWA M, 1994, FEBS LETT, V339, P222, DOI 10.1016/0014-5793(94)80420-6; TAKEKAWA M, 1992, BIOCHEM BIOPH RES CO, V189, P1223, DOI 10.1016/0006-291X(92)92335-U; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WILKS M, 1994, J HOSP INFECT, V28, P231, DOI 10.1016/0195-6701(94)90105-8; YANG Q, 1993, J BIOL CHEM, V268, P6622; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624	26	25	32	1	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2275	2279						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950995				2022-12-17	WOS:A1996VV14500025
J	Lee, SH; Fujita, N; Mashima, T; Tsuruo, T				Lee, SH; Fujita, N; Mashima, T; Tsuruo, T			Interleukin-7 inhibits apoptosis of mouse malignant T-lymphoma cells by both suppressing the CPP32-like protease activation and inducing the Bcl-2 expression	ONCOGENE			English	Article						interleukin-7; Bcl-2; ICE-family proteases; apoptosis; T-lymphoma	NODE STROMAL CELLS; DEATH GENE CED-3; GROWTH-FACTOR; HEMATOPOIETIC-CELLS; IL-1-BETA-CONVERTING ENZYME; MONOCLONAL-ANTIBODIES; MURINE INTERLEUKIN-7; ICE/CED-3 PROTEASE; CONVERTING-ENZYME; MAMMALIAN HOMOLOG	Mouse malignant T-lymphoma CS-21 cells grow in vitro in the presence of CA-12 lymph node stromal cells, but they undergo apoptotic cell death when separated from CA-12 stromal cells. In the course of examining the nursing effects of CA-12 stromal cells, we found that these cells provided some soluble factors that suppressed CS-21 cell apoptosis. We recently found that cysteine was an antiapoptotic soluble factor. In this report, we identify interleukin-7 (IL-7) as another antiapoptotic soluble factor secreted by CA-12 stromal cells. Although the activity of CPP32-like protease was increased in induction of CS-21 cell apoptosis, the addition of IL-7 suppressed the activity. The expression of Bcl-2 protein was down-regulated when CS-21 cells were cultured alone, but the addition of IL-7 recovered the expression of Bcl-2. These results indicate that CA-12 stromal cells inhibit CS-21 cell apoptosis by producing IL-7, which leads to the suppression of CPP32-like protease activation and the expression of Bcl-2 protein.	UNIV TOKYO,INST MOL & CELLULAR BIOSCI,BIOMED RES LAB,BUNKYO KU,TOKYO 113,JAPAN; JAPANESE FDN CANC RES,CTR CANC CHEMOTHERAPY,TOSHIMA KU,TOKYO 170,JAPAN	University of Tokyo; Japanese Foundation for Cancer Research			Fujita, Naoya/A-7349-2010	Fujita, Naoya/0000-0002-9631-9264; Lee, Sang-Han/0000-0002-2343-7315				BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BORZILLO GV, 1992, ONCOGENE, V7, P869; Boulakia CA, 1996, ONCOGENE, V12, P529; CARSON WE, 1994, P NATL ACAD SCI USA, V91, P7553, DOI 10.1073/pnas.91.16.7553; CHAZEN GD, 1989, P NATL ACAD SCI USA, V86, P5923, DOI 10.1073/pnas.86.15.5923; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FUJITA N, 1993, CANCER RES, V53, P5022; FUJITA N, 1995, CELL GROWTH DIFFER, V6, P355; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; GOODWIN RG, 1989, P NATL ACAD SCI USA, V86, P302, DOI 10.1073/pnas.86.1.302; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; HANAOKA K, 1995, CANCER RES, V55, P2186; HERNANDEZCASELLES T, 1995, HUM IMMUNOL, V43, P181, DOI 10.1016/0198-8859(94)00168-P; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KATAOKA S, 1993, EXP CELL RES, V207, P271, DOI 10.1006/excr.1993.1193; KERR JFR, 1974, J CELL SCI, V14, P571; KINOSHITA T, 1995, ONCOGENE, V10, P2207; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LEE SH, 1995, BIOCHEM BIOPH RES CO, V213, P837, DOI 10.1006/bbrc.1995.2205; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MASHIMA T, 1995, BIOCHEM BIOPH RES CO, V209, P907, DOI 10.1006/bbrc.1995.1584; Mashima T, 1995, BIOCHEM BIOPH RES CO, V217, P1185, DOI 10.1006/bbrc.1995.2894; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; Monney L, 1996, BIOCHEM BIOPH RES CO, V221, P340, DOI 10.1006/bbrc.1996.0597; NAMEN AE, 1988, NATURE, V333, P571, DOI 10.1038/333571a0; NAMEN AE, 1988, J EXP MED, V167, P988, DOI 10.1084/jem.167.3.988; NEITO MA, 1989, J IMMUNOL, V143, P4166; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OGAWA M, 1988, EMBO J, V7, P1337, DOI 10.1002/j.1460-2075.1988.tb02949.x; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RENAULD JC, 1995, BLOOD, V85, P1300, DOI 10.1182/blood.V85.5.1300.bloodjournal8551300; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; SAKATA T, 1990, J LEUKOCYTE BIOL, V48, P205, DOI 10.1002/jlb.48.3.205; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; Shimizu S, 1996, ONCOGENE, V12, P2251; SQUIER MKT, 1995, J LEUKOCYTE BIOL, V57, P2, DOI 10.1002/jlb.57.1.2; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; SUDO T, 1989, J EXP MED, V170, P333, DOI 10.1084/jem.170.1.333; SUDO T, 1993, P NATL ACAD SCI USA, V90, P9125, DOI 10.1073/pnas.90.19.9125; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; TSURUO T, 1988, CLIN EXP METASTAS, V6, P141, DOI 10.1007/BF01784845; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; YAMAGUCHI Y, 1991, BLOOD, V78, P2542	58	25	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2131	2139						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950980				2022-12-17	WOS:A1996VV14500010
J	Qian, XL; ORourke, DM; Zhao, HZ; Greene, MI				Qian, XL; ORourke, DM; Zhao, HZ; Greene, MI			Inhibition of p185(neu) kinase activity and cellular transformation by co-expression of a truncated neu protein	ONCOGENE			English	Article						ErbB receptors; neu ectodomain; trans inhibition	EPIDERMAL GROWTH-FACTOR; FACTOR RECEPTOR FAMILY; MONOCLONAL-ANTIBODIES; DOWN-MODULATION; ERBB-2 ONCOGENE; POINT MUTATION; DEFICIENT NEU; EGF RECEPTOR; HUMAN-BREAST; 3T3 CELLS	The rat nea oncogene product encodes a 185 kDa receptor tyrosine kinase which is constitutively activated as a result of a single amino acid substitution (Va1664-->Glu) within the transmembrane region. In this study, we show that the transforming activity of oncogenic p185(neu) (also termed Tneu) can be inhibited by co-expression of a truncated nea protein with a large cytoplasmic deletion (termed T691stop) which includes the tyrosine kinase domain. In cell lines co-expressing full-length and truncated nea proteins, we observed codimerization between full-length p185(neu) and truncated T691 stop, resulting in the formation of a kinase-inactive heteromeric complex. Phenotypic analysis of several different clones showed that the degree of inhibition of transformation in vitro and tumorigenicity in vivo was related to the ratio of full-length and truncated p185 proteins co-expressed in cells. These results provide evidence that expression of kinase-deficient nea proteins leads to co-dimerization that results in suppression of kinase activation and oncogenicity of associated p185(neu)-activated receptors. The mutant nea protein mediates inhibition in both transfected fibroblasts expressing oncogenic p185(neu) and mammalian cancer cells derived from a rat primary neuroglioblastoma expressing oncogenic p185(neu). This truncated peptide may be important for the design of future therapies directed against erbB family oncoproteins.	UNIV PENN,SCH MED,DIV NEUROSURG,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,CTR RECEPTOR BIOL,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania			O'Rourke, Donald/AAC-3376-2021	O'Rourke, Donald/0000-0002-8479-7314				AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BEERLI RR, 1994, J BIOL CHEM, V269, P23931; BROWN VI, 1994, DNA CELL BIOL, V13, P193, DOI 10.1089/dna.1994.13.193; BUCHDUNGER E, 1994, P NATL ACAD SCI USA, V91, P2334, DOI 10.1073/pnas.91.6.2334; CAMPOSGONZALEZ R, 1992, J BIOL CHEM, V267, P14535; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; CHAZIN VR, 1992, ONCOGENE, V7, P1859; CHOU CK, 1987, J BIOL CHEM, V262, P1842; COLOMER R, 1994, BRIT J CANCER, V70, P819, DOI 10.1038/bjc.1994.405; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; DOBASHI K, 1989, DNA-J MOLEC CELL BIO, V8, P723, DOI 10.1089/dna.1989.8.723; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; DREBIN JA, 1984, NATURE, V312, P545, DOI 10.1038/312545a0; FARNSWORTH C, 1991, MOL CELL BIOL, V11, P4832; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GULLICK WJ, 1991, BRIT MED BULL, V47, P87, DOI 10.1093/oxfordjournals.bmb.a072464; HACK N, 1993, J BIOL CHEM, V268, P26441; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LEMOINE NR, 1991, BRIT J CANCER, V64, P79, DOI 10.1038/bjc.1991.243; LEVEA CM, 1993, RECEPTOR, V3, P293; LOFTS FJ, 1993, ONCOGENE, V8, P2813; MESSERLE K, 1994, MOL CELL ENDOCRINOL, V105, P1, DOI 10.1016/0303-7207(94)90029-9; MYERS JN, 1992, RECEPTOR, V2, P1; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; QIAN XL, 1995, ONCOGENE, V10, P211; QIAN XL, 1994, ONCOGENE, V9, P1507; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; QIAN XL, 1992, P NATL ACAD SCI USA, V89, P1330, DOI 10.1073/pnas.89.4.1330; SAMANTA A, 1995, DNA CELL BIOL, V14, P921, DOI 10.1089/dna.1995.14.921; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCHUBERT D, 1974, NATURE, V249, P224, DOI 10.1038/249224a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; WEINER DB, 1989, ONCOGENE, V4, P1175; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WILLUMSEN BM, 1991, MOL CELL BIOL, V11, P6026, DOI 10.1128/MCB.11.12.6026; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0	48	25	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2149	2157						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950982				2022-12-17	WOS:A1996VV14500012
J	Mangeney, M; Schmitt, JR; Leverrier, Y; Thomas, J; Marvel, J; Brun, G; Gillet, G				Mangeney, M; Schmitt, JR; Leverrier, Y; Thomas, J; Marvel, J; Brun, G; Gillet, G			The product of the v-src-inducible gene nr-13 is a potent anti-apoptotic factor	ONCOGENE			English	Article						v-src; apoptosis; cell transformation	QUAIL NEURORETINAL CELLS; BONE-MARROW CELLS; B-CELLS; DEATH; BCL-2; VIRUS; PROTEIN; TRANSFORMATION; INDUCTION; ONCOGENES	Tumorigenesis can be induced either by activating cell proliferation or by inhibiting metabolic pathways regulating programmed cell death (apoptosis). There is evidence suggesting that p60(v-src) and other tyrosine kinases protect cells against apoptosis. This effect could contribute to cell transformation by the Rous sarcoma virus, Mechanism of cell death inhibition by p60(v-src) remains Largely unknown, We have recently reported that in avian cells p60(v-src) activates the expression of nr-13, a bcl-2-related gene, In this paper, we demonstrate, using the bone marrow derived cell line Baf-3 as an experimental model, that the product of this avian gene (nr-13) is a potent anti-apoptotic factor, In addition, we report that, in quail neuroretinal cells, nr-13 expression is activated upon infection by the Rous sarcoma virus (RSV) but not by other oncogenic retroviruses like FSV or MH2, suggesting that nr-13 is a specific target of v-src. Activation of nr-13 expression may be a key step in cellular transformation by v-src.	ECOLE NORMALE SUPER LYON,UMR 49 CNRS,BIOL CELLULAIRE & MOL LAB,IMMUNOL CELLULAIRE GRP,F-69364 LYON 07,FRANCE; ECOLE NORMALE SUPER LYON,UMR 49 CNRS,BIOL CELLULAIRE & MOL LAB,BIOL REGULAT CELLULAIRES RES GRP,F-69364 LYON 07,FRANCE	Ecole Normale Superieure de Lyon (ENS de LYON); Ecole Normale Superieure de Lyon (ENS de LYON)			marvel, jacqueline/H-8638-2014; LEVERRIER, Yann/M-3767-2014; gillet, germain/A-9095-2013	marvel, jacqueline/0000-0001-6241-459X; LEVERRIER, Yann/0000-0002-4227-5446; Mangeney, Marianne/0000-0002-9102-191X; Thomas, Joelle/0000-0002-0461-6131; GILLET, Germain/0000-0002-1514-327X				BECHADE C, 1985, NATURE, V316, P559, DOI 10.1038/316559a0; BRICKELL P M, 1992, Critical Reviews in Oncogenesis, V3, P401; CALOTHY G, 1980, COLD SPRING HARB SYM, V44, P983, DOI 10.1101/SQB.1980.044.01.106; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHEN J, 1994, J BIOL CHEM, V269, P7957; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GILLET G, 1995, EMBO J, V14, P1372, DOI 10.1002/j.1460-2075.1995.tb07123.x; GILLET G, 1993, ONCOGENE, V8, P565; GOTTSCHALK AR, 1994, P NATL ACAD SCI USA, V91, P7350, DOI 10.1073/pnas.91.15.7350; HAECKER G, 1994, TRENDS BIOCHEM SCI, V19, P99, DOI 10.1016/0968-0004(94)90197-X; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; MARVEL J, 1994, ONCOGENE, V9, P1117; MICHEL D, 1989, ONCOGENE RES, V4, P127; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NEILAN JG, 1993, J VIROL, V67, P4391, DOI 10.1128/JVI.67.7.4391-4394.1993; PEARSON GR, 1987, VIROLOGY, V160, P151, DOI 10.1016/0042-6822(87)90055-9; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; VAUX D, 1992, SCIENCE, V258, P1195; WIERDERRECHT G, 1993, ANN NY ACAD SCI, V696, P9; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5	33	25	25	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 3	1996	13	7					1441	1446						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875982				2022-12-17	WOS:A1996VL38400009
